{"meta":{"query_hash":"c0ea6a3cf2ea","filters":{"topic":"Multiple Myeloma Research and Treatments"},"cohort_total":2397,"direct_labels_cover":1,"predictions_cover":2397,"exported":2397,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c0ea6a3cf2ea","api":"https://metacan.xera.ac/api/v1/cohort?topic=Multiple+Myeloma+Research+and+Treatments"},"results":[{"id":"W1019948147","doi":"10.1182/blood.v124.21.5995.5995","title":"Retrospective Observational Study on Multiple Myeloma Cases Admitted to Kfsh – Dammam Between 1st of June 2006 till the End of December 2013","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Population; Autologous stem-cell transplantation; Retrospective cohort study; Transplantation; Observational study; Surgery; Internal medicine; Pediatrics","score_opus":0.07513266327263778,"score_gpt":0.33595189247673685,"score_spread":0.26081922920409906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1019948147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965264,0.00004026469,0.000015122389,0.0006150222,0.00004841901,0.0013679344,0.00028269127,0.000021724993,0.0010824164],"genre_scores_gemma":[0.99828994,0.000004225159,0.00037179363,0.000066348,0.00017911186,0.00008865479,0.00010423844,0.000024258676,0.00087144074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818426,0.00013816851,0.00036475863,0.0003019509,0.0007341138,0.00027672827],"domain_scores_gemma":[0.9979289,0.0008445352,0.00013892513,0.00053804123,0.00035779036,0.00019178704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029651108,0.00017724332,0.0004462625,0.0001241601,0.0000801828,0.000008332144,0.00015627246,0.000059222726,0.0001390856],"category_scores_gemma":[0.0016875375,0.00011535694,0.000095476506,0.00031962158,0.00009512512,0.000043427146,0.00008402595,0.00014995816,0.000056494482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003613359,0.0026769699,0.99142325,0.000023982839,0.00057676114,0.000033227112,0.00029620578,0.000005308385,0.002491529,0.000043980643,0.0011700554,0.0008973837],"study_design_scores_gemma":[0.006997293,0.0027250107,0.9694809,0.00006257217,0.00024228347,0.000008873716,0.00013680766,0.000030115561,0.019464705,0.000031888267,0.000730218,0.00008936217],"about_ca_topic_score_codex":0.00096436596,"about_ca_topic_score_gemma":0.001121532,"teacher_disagreement_score":0.021942388,"about_ca_system_score_codex":0.000042549847,"about_ca_system_score_gemma":0.00008495552,"threshold_uncertainty_score":0.47041196},"labels":[],"label_agreement":null},{"id":"W114597356","doi":"10.1182/blood.v122.21.408.408","title":"Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Internal medicine; Tolerability; Clinical endpoint; Dexamethasone; Neutropenia; Phases of clinical research; Population; Bortezomib; Ixazomib; Oncology; Multiple myeloma; Surgery; Adverse effect; Randomized controlled trial; Clinical trial; Toxicity; Carfilzomib","score_opus":0.05765599266490275,"score_gpt":0.33625866345399785,"score_spread":0.2786026707890951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W114597356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919756,0.0025951932,0.000099014534,0.000086777734,0.00013095216,0.004831339,0.00010142559,0.00012744656,0.000052239622],"genre_scores_gemma":[0.9957194,0.0007105799,0.0015493965,0.000041768155,0.00019465006,0.0007497181,0.0005590717,0.00014476482,0.00033066614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929721,0.0010234215,0.0015197375,0.0017875789,0.0010023495,0.0016948555],"domain_scores_gemma":[0.9955748,0.0011283509,0.0004196071,0.0015357793,0.00022772244,0.001113796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083615136,0.0010974647,0.002551616,0.001809831,0.00021957369,0.00022277496,0.0004334611,0.00035958877,0.0003441322],"category_scores_gemma":[0.00062685396,0.0009706222,0.00040218435,0.0017079624,0.00033293598,0.00035521464,0.00035577637,0.0007977216,0.00012442522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005222779,0.039384246,0.91899395,0.00017939923,0.004008117,0.005895711,0.00087900274,0.00006950071,0.008839643,0.0000018096284,0.000004690218,0.01652113],"study_design_scores_gemma":[0.14499725,0.0047434447,0.8394787,0.00026176352,0.0022567955,0.00010522822,0.00022992623,0.0011277605,0.0061329277,0.0000074997274,0.0000023823743,0.00065637694],"about_ca_topic_score_codex":0.009662566,"about_ca_topic_score_gemma":0.030364525,"teacher_disagreement_score":0.13977447,"about_ca_system_score_codex":0.00062285573,"about_ca_system_score_gemma":0.0003418085,"threshold_uncertainty_score":0.99927443},"labels":[],"label_agreement":null},{"id":"W1166382464","doi":"10.1038/bmt.2015.190","title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","year":2015,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"U.S. Navy; National Center for Advancing Translational Sciences; Health Resources and Services Administration; Allos Therapeutics; Kiadis Pharma; National Cancer Institute; Medac; Actinium Pharmaceuticals; National Heart, Lung, and Blood Institute; Blue Cross and Blue Shield Association; National Institute of Allergy and Infectious Diseases; Celgene; WellPoint; U.S. Department of Health and Human Services; Ariad Pharmaceuticals; Amgen; Office of Naval Research; Chimerix; U.S. Department of Defense","keywords":"Medicine; Multiple myeloma; Internal medicine; Transplantation; Chemotherapy; Confidence interval; Hematopoietic stem cell transplantation; Gastroenterology; Mobilization; Hematology; Progenitor cell; Haematopoiesis; Bone marrow; Surgery; Stem cell","score_opus":0.014234063918833391,"score_gpt":0.2607045470292905,"score_spread":0.24647048311045713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1166382464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696449,0.00012307569,0.027230818,0.0004255144,0.000020923331,0.002154517,0.0001928543,0.00007107535,0.00013634583],"genre_scores_gemma":[0.9970092,0.0001329158,0.0007679966,0.000109705215,0.00001591666,0.0002339234,0.0016445094,0.000030068364,0.00005574781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983547,0.00013032976,0.0004109091,0.00032544453,0.00047188747,0.00030677882],"domain_scores_gemma":[0.9989166,0.00010190593,0.000106140316,0.00018953085,0.00029385113,0.00039194207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021091332,0.00021429597,0.0003934999,0.0003117793,0.000039601193,0.000013249904,0.00004974135,0.00009109196,0.00001961541],"category_scores_gemma":[0.00004456786,0.00017863348,0.000061047176,0.00042580717,0.000053293687,0.00014616309,0.00000173216,0.00008932115,0.000016116544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053703107,0.0010684325,0.8670971,0.00075460883,0.00007698073,0.0008954308,0.0018293522,0.002294834,0.06984904,0.000056329613,0.00002524185,0.0023495485],"study_design_scores_gemma":[0.04150366,0.0012848178,0.86692786,0.00034965744,0.00030280533,0.00011579516,0.00011964185,0.007260817,0.08186312,0.000042244228,0.00001603238,0.00021356768],"about_ca_topic_score_codex":0.00028285934,"about_ca_topic_score_gemma":0.00035040927,"teacher_disagreement_score":0.02736434,"about_ca_system_score_codex":0.00015626186,"about_ca_system_score_gemma":0.00017997899,"threshold_uncertainty_score":0.7284462},"labels":[],"label_agreement":null},{"id":"W1187218857","doi":"10.1016/j.blre.2015.08.004","title":"Monoclonal antibodies — A new era in the treatment of multiple myeloma","year":2015,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministry of Health Mexico","keywords":"Daratumumab; Monoclonal antibody; Multiple myeloma; Denosumab; Medicine; Clinical trial; Oncology; Antibody; Cancer research; Pharmacology; Internal medicine; Immunology; Osteoporosis","score_opus":0.19668837020682414,"score_gpt":0.42489458235441,"score_spread":0.22820621214758588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1187218857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017819992,0.9915696,0.0000011666962,0.00006788627,0.00006983772,0.0069030495,0.00008619443,0.000016751264,0.0011073648],"genre_scores_gemma":[0.000010258475,0.9948498,0.0019587653,0.000028627157,0.0003923503,0.00076670933,0.000464469,0.0000504788,0.0014785589],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964638,0.00067660917,0.0013069855,0.0005158958,0.0005505184,0.0004862155],"domain_scores_gemma":[0.9976761,0.00034144,0.0004947982,0.0010998363,0.00007592888,0.0003119504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064135157,0.00066327746,0.0044871364,0.00029027433,0.000042843963,0.000023571502,0.0003337899,0.00022672878,0.000104409606],"category_scores_gemma":[0.0003379499,0.0003003563,0.0012917875,0.000567344,0.00008737012,0.000043348045,0.000045271085,0.00030767868,0.0003201484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039094593,0.0018919635,0.00077028736,0.01205382,0.00058681093,0.00035320251,0.00041696877,1.881517e-8,6.0942654e-7,0.000008339374,0.0021785947,0.9817003],"study_design_scores_gemma":[0.0035361522,0.0012600237,0.00025951114,0.015150323,0.0030330715,0.0003234568,0.000021108894,0.0000019001179,0.000003901402,0.000006389377,0.9762022,0.00020198409],"about_ca_topic_score_codex":0.00032926866,"about_ca_topic_score_gemma":0.00013768944,"teacher_disagreement_score":0.9814983,"about_ca_system_score_codex":0.00017173118,"about_ca_system_score_gemma":0.0010237443,"threshold_uncertainty_score":0.99994487},"labels":[],"label_agreement":null},{"id":"W1500575208","doi":"10.14740/jocmr2210w","title":"Immunoglobulin D Multiple Myeloma With Rapidly Progressing Renal Failure","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Serum protein electrophoresis; Immunoglobulin D; Immunofixation; Bone marrow; Gastroenterology; Internal medicine; Dialysis; Pathology; Urology; Antibody; Immunology; Monoclonal; B cell","score_opus":0.2938519778596939,"score_gpt":0.5312999539092876,"score_spread":0.23744797604959372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1500575208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492463,0.00542674,0.00036020816,0.03653422,0.00033766642,0.0010747385,0.0000041290987,0.000037836555,0.0069781747],"genre_scores_gemma":[0.9835104,0.0004713886,0.011365951,0.00018012439,0.0035844364,0.000016576623,0.000012363026,0.000050657833,0.00080815103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99050343,0.001356314,0.0020063312,0.00039491738,0.004805029,0.00093397306],"domain_scores_gemma":[0.9882806,0.003362696,0.000624744,0.0006129676,0.0045732595,0.0025457335],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01611334,0.00026451025,0.0014319664,0.00072316406,0.00016408929,0.000054412678,0.0004671655,0.00025938894,0.00021586566],"category_scores_gemma":[0.021611076,0.00013793829,0.00027250947,0.0010284248,0.0015590992,0.00026006286,0.00015571197,0.0030949428,0.000093924355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033163995,0.0019433683,0.53362185,0.00017479152,0.0012067242,0.010934183,0.00042431604,0.0000085291185,0.0014739155,0.000037626025,0.050110754,0.36689997],"study_design_scores_gemma":[0.1296663,0.09299073,0.4504464,0.008930313,0.0005125434,0.009143888,0.0042606303,0.0015669167,0.0032870201,0.0006894517,0.29800755,0.00049826346],"about_ca_topic_score_codex":0.000074815274,"about_ca_topic_score_gemma":0.000032584467,"teacher_disagreement_score":0.3664017,"about_ca_system_score_codex":0.00023231383,"about_ca_system_score_gemma":0.0028980481,"threshold_uncertainty_score":0.99920493},"labels":[],"label_agreement":null},{"id":"W1507518844","doi":"10.14694/edbook_am.2015.35.e504","title":"Multiple Myeloma: From Front-Line to Relapsed Therapies","year":2015,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Ixazomib; Lenalidomide; Thalidomide; Medicine; Carfilzomib; Multiple myeloma; Bortezomib; Oncology; Internal medicine; Proteasome inhibitor; Refractory (planetary science); Pharmacology; Biology","score_opus":0.21686139164684204,"score_gpt":0.531727034602765,"score_spread":0.314865642955923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507518844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044136262,0.9774246,0.000047265872,0.016325435,0.0005500164,0.0019432615,0.00044073022,0.0000434137,0.0027838743],"genre_scores_gemma":[0.000098777804,0.9186809,0.05058153,0.0053319805,0.001967635,0.0005151622,0.0017868843,0.00007590589,0.020961234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99501324,0.000721348,0.0021685748,0.00087035785,0.0007450163,0.00048146065],"domain_scores_gemma":[0.9855405,0.010441291,0.0014225519,0.0007793101,0.00070913293,0.0011072011],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011526837,0.0004940454,0.0051784874,0.0000965995,0.00008346426,0.0000098668925,0.0004250356,0.00058317,0.0015074646],"category_scores_gemma":[0.0028365508,0.0003669244,0.002186495,0.0003013179,0.001460818,0.00006258921,0.00018464116,0.0010704235,0.0009926802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032680618,0.0020283586,0.00286484,0.00043632078,0.0024225528,0.0000065246372,0.00033176536,2.4722138e-7,6.5170957e-7,0.000013418197,0.15823601,0.83333254],"study_design_scores_gemma":[0.0025782962,0.0027045684,0.0085535925,0.0011685072,0.0011464804,0.000010680279,0.00033770647,0.000013743617,4.8732556e-7,0.00009802567,0.9831205,0.00026739234],"about_ca_topic_score_codex":0.0007466792,"about_ca_topic_score_gemma":0.000037847087,"teacher_disagreement_score":0.8330651,"about_ca_system_score_codex":0.0007921086,"about_ca_system_score_gemma":0.013189516,"threshold_uncertainty_score":0.9998783},"labels":[],"label_agreement":null},{"id":"W1514929400","doi":"10.1002/ajh.23868","title":"A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","year":2014,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute; Janssen Scientific Affairs; Leukemia and Lymphoma Society","keywords":"Medicine; Bortezomib; Internal medicine; Multiple myeloma; Gastroenterology; Neutropenia; Placebo; Dexamethasone; Refractory (planetary science); Discontinuation; Febrile neutropenia; Oncology; Toxicity; Pathology","score_opus":0.0191206186390491,"score_gpt":0.31776368782950626,"score_spread":0.29864306919045713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1514929400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964672,0.00020176334,0.00009002452,0.0001843931,0.00011099916,0.002812223,0.0000084314015,0.000013314744,0.000111697576],"genre_scores_gemma":[0.99844605,0.000083476625,0.0011947111,0.00004641766,0.000041871514,0.00010594439,0.00001393583,0.000045023044,0.000022587506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99601346,0.00087544287,0.001488641,0.00038207218,0.00070657395,0.00053381635],"domain_scores_gemma":[0.994571,0.0024812745,0.0016220099,0.00042416033,0.00047761356,0.00042395093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010953255,0.00037527658,0.003949831,0.00075144885,0.0000715457,0.000016173779,0.00018985954,0.000093515315,0.000054192984],"category_scores_gemma":[0.0016469373,0.00022059967,0.0002064545,0.00041835252,0.0006804059,0.00016384777,0.00006276562,0.00052406546,0.000004023971],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8365354,0.010148515,0.14138602,0.000045856563,0.0022432262,0.0007139295,0.00062053197,0.000006240042,0.00006242277,0.00001335159,0.000029272485,0.008195267],"study_design_scores_gemma":[0.93263954,0.045434378,0.018144285,0.00015503503,0.00082162063,0.00033061818,0.0015780645,0.0005133652,0.00016626477,0.0000062105023,0.000026797297,0.00018381557],"about_ca_topic_score_codex":0.000285836,"about_ca_topic_score_gemma":0.00024799423,"teacher_disagreement_score":0.12324174,"about_ca_system_score_codex":0.00009478705,"about_ca_system_score_gemma":0.000281901,"threshold_uncertainty_score":0.89957935},"labels":[],"label_agreement":null},{"id":"W1515761395","doi":"10.1038/sj.bmt.1704288","title":"Autologous stem cell transplantation in multiple myeloma patients &lt;60 vs ⩾60 years of age","year":2003,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Centers for Disease Control and Prevention","keywords":"Medicine; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Transplantation; Confidence interval; Surgery; Chemotherapy; Multivariate analysis; Gastroenterology","score_opus":0.03651392167722986,"score_gpt":0.29507896588428084,"score_spread":0.25856504420705095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1515761395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18205772,0.8058317,0.00022694991,0.000012671615,0.00040916642,0.006890169,0.0023964783,0.00013663643,0.002038545],"genre_scores_gemma":[0.09736573,0.89283454,0.0006868023,0.000016176622,0.000027992031,0.00028413525,0.008237334,0.00010344203,0.00044385585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961159,0.0004837797,0.0013157153,0.0006884529,0.00080248347,0.0005936696],"domain_scores_gemma":[0.9984098,0.00036632793,0.0004647176,0.00041197307,0.00010671026,0.00024049002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030475884,0.00057290983,0.0019451162,0.0008407345,0.00005978142,0.000023735724,0.00016502882,0.00054286415,0.00006259751],"category_scores_gemma":[0.000019737889,0.0005442765,0.0004929029,0.0006038307,0.00009381076,0.0001457073,0.000008792462,0.00047886168,0.000096027274],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015482346,0.0010674295,0.004494518,0.06946573,0.0002424429,0.008963588,0.0009429821,0.000010017753,0.00010648949,0.0000104718865,0.00005138145,0.9130967],"study_design_scores_gemma":[0.06954736,0.0046893302,0.6790906,0.07030924,0.01320314,0.0017037573,0.00014722357,0.00025355778,0.0016345176,0.000051006067,0.15585414,0.0035161346],"about_ca_topic_score_codex":0.00017572368,"about_ca_topic_score_gemma":0.00029801758,"teacher_disagreement_score":0.9095806,"about_ca_system_score_codex":0.00028356034,"about_ca_system_score_gemma":0.00033473547,"threshold_uncertainty_score":0.9997009},"labels":[],"label_agreement":null},{"id":"W1522355061","doi":"10.1007/s00262-002-0357-4","title":"Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody","year":2003,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Mastocytoma; Vinblastine; Cytotoxic T cell; Paclitaxel; Cancer research; CD3; Cytotoxicity; In vitro; Immunology; Biology; Tumor cells; Chemistry; Medicine; Chemotherapy; CD8; Immune system; Internal medicine; Biochemistry","score_opus":0.017310360743286776,"score_gpt":0.28743186376468083,"score_spread":0.27012150302139404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1522355061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706602,0.025732057,0.00021722968,0.00094406464,0.00016383035,0.0019373382,0.00022236846,0.000080968006,0.00004191081],"genre_scores_gemma":[0.9894743,0.0070852856,0.0009791745,0.0007016226,0.00003720634,0.00042713518,0.00004765466,0.00011327723,0.0011343417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970066,0.00029104127,0.0004999472,0.0008808488,0.00038916818,0.00093239424],"domain_scores_gemma":[0.99818105,0.0003285747,0.00019055516,0.0008294523,0.00016276454,0.00030763086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002990718,0.00058647443,0.0007770832,0.00023731013,0.0005240985,0.000114186485,0.000264412,0.00020218898,0.00027141263],"category_scores_gemma":[0.000050333325,0.00034811368,0.00007133036,0.0005213201,0.00041547455,0.00013631645,0.00007953745,0.00034829156,0.000019427598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011622077,0.00023783138,0.0028865766,0.000047420664,0.0005769396,0.00009773,0.0012278059,0.0000085281,0.9774236,0.0000042501892,0.0020335587,0.003833675],"study_design_scores_gemma":[0.010896675,0.004349333,0.016909337,0.0005187877,0.00005628893,0.00013758475,0.0011815617,0.000011632438,0.952581,0.0000072652956,0.01291271,0.00043784003],"about_ca_topic_score_codex":0.00037424255,"about_ca_topic_score_gemma":0.000043311567,"teacher_disagreement_score":0.024842624,"about_ca_system_score_codex":0.00034297502,"about_ca_system_score_gemma":0.00032374501,"threshold_uncertainty_score":0.99989706},"labels":[],"label_agreement":null},{"id":"W1539780911","doi":"10.1007/s10637-006-9022-7","title":"A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Adverse effect; Rash; Internal medicine; Multiple myeloma; Nausea; Vomiting; Clinical endpoint; Anemia; Gastroenterology; Phases of clinical research; Diarrhea; Pharmacokinetics; Pharmacology; Clinical trial; Oncology","score_opus":0.01286201718875107,"score_gpt":0.26738986107407725,"score_spread":0.2545278438853262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1539780911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977262,0.00009997521,0.0000071146637,0.0002399181,0.000023685167,0.0016318667,0.0000849953,0.000022004471,0.000164266],"genre_scores_gemma":[0.99737775,0.0000018354598,0.0018642619,0.00004889603,0.00006511096,0.00007274972,0.0002973583,0.00002983476,0.0002422132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978259,0.000098496996,0.00053169415,0.00039693483,0.0008563783,0.0002905873],"domain_scores_gemma":[0.99863774,0.00020991873,0.00025262352,0.00022744614,0.00038351744,0.0002887688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014853297,0.00024196816,0.0004628978,0.00038554682,0.00009187735,0.000010586527,0.0000745528,0.000082736995,0.000021766742],"category_scores_gemma":[0.00034921677,0.00019819879,0.000042032534,0.0006943088,0.00025492985,0.00019479197,0.00006794954,0.00022655587,0.0000031299096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005150647,0.012776423,0.9682695,0.000098073775,0.00018219372,0.00003989549,0.0025249247,0.00005629569,0.007539871,0.000081345555,0.00047473767,0.0028060896],"study_design_scores_gemma":[0.07189522,0.008838983,0.899248,0.0002726273,0.000080963335,0.00000444276,0.00026079416,0.00044934422,0.018398575,0.00036318076,0.00003055421,0.00015730136],"about_ca_topic_score_codex":0.0031326946,"about_ca_topic_score_gemma":0.00044081768,"teacher_disagreement_score":0.069021486,"about_ca_system_score_codex":0.00017202704,"about_ca_system_score_gemma":0.00055990816,"threshold_uncertainty_score":0.8082312},"labels":[],"label_agreement":null},{"id":"W1556966617","doi":"10.1016/j.ymthe.2004.06.969","title":"1024. Dual Targeted Vector for Multiple Myeloma Tumors and its Associated Angiogenesis","year":2004,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Angiogenesis; Dual (grammatical number); Vector (molecular biology); Cancer research; Medicine; Biology; Immunology; Gene; Genetics; Recombinant DNA","score_opus":0.02463654307980015,"score_gpt":0.28971834616604863,"score_spread":0.2650818030862485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556966617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270046,0.0043663117,0.00040140023,0.00080974854,0.00004485207,0.0014064964,0.00011890105,0.00010277976,0.00004906647],"genre_scores_gemma":[0.9974061,0.00016232171,0.0011764923,0.00040031446,0.000047659847,0.00022242835,0.0003048439,0.000063350206,0.00021647694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986385,0.000052126044,0.00018486296,0.00035015834,0.00031050312,0.0004638631],"domain_scores_gemma":[0.99924195,0.000066573666,0.00005499593,0.00020461329,0.00016003389,0.0002718554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001287516,0.00022010788,0.00031698676,0.00012261658,0.00012497162,0.000027812031,0.00006284084,0.00010884923,0.000046913407],"category_scores_gemma":[0.00026909972,0.00018338881,0.00018089211,0.00021392827,0.000038010916,0.0000476527,0.000021912601,0.00007987844,0.000025576412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017009933,0.0007873475,0.015038451,0.00004353722,0.0011660083,0.00079296774,0.00027182925,0.000023543167,0.9678591,0.00017097525,0.000067454224,0.012077799],"study_design_scores_gemma":[0.022528064,0.0014821634,0.24253275,0.00006478208,0.000061953324,0.00004807101,0.000031164986,0.0005394057,0.73118013,0.0001926976,0.0010876496,0.00025114906],"about_ca_topic_score_codex":0.00007609829,"about_ca_topic_score_gemma":0.00001780347,"teacher_disagreement_score":0.23667893,"about_ca_system_score_codex":0.0001254468,"about_ca_system_score_gemma":0.00011752027,"threshold_uncertainty_score":0.74783784},"labels":[],"label_agreement":null},{"id":"W1572717899","doi":"10.1111/j.1600-0609.2011.01629.x","title":"Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?","year":2011,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Karyotype; Cytogenetics; Biology; Chromosome; Multiple myeloma; Genetics; Leukemia; Somatic evolution in cancer; Plasma cell leukemia; Cancer research; Cancer; Pathology; Immunology; Gene; Medicine","score_opus":0.0699727070098944,"score_gpt":0.2965551187885002,"score_spread":0.22658241177860583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1572717899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830017,0.009010727,0.00009253399,0.0006526815,0.00028133532,0.00018614801,0.000020504638,0.000014067761,0.0067403154],"genre_scores_gemma":[0.99131,0.005761983,0.0016459133,0.00014464397,0.00007890799,0.000003338945,0.0000357068,0.00003901933,0.0009805015],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975099,0.00075531384,0.0008057797,0.00021796672,0.00023137622,0.00047965668],"domain_scores_gemma":[0.9987514,0.00015266016,0.0003936126,0.00018884534,0.000213796,0.00029966177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006065403,0.00021785415,0.0006432675,0.0003263899,0.000059514117,0.000024470328,0.00024437753,0.00009408914,0.00071378367],"category_scores_gemma":[0.0001782706,0.00017227835,0.00017041272,0.00009672014,0.00024177319,0.00019187349,0.00009296868,0.00051319523,0.0003086619],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012873698,0.0057528974,0.6174003,0.0017214057,0.002690008,0.22858298,0.010241021,0.000040324296,0.064318836,0.0038456365,0.018617509,0.033915382],"study_design_scores_gemma":[0.1033406,0.020313106,0.16141415,0.0034598701,0.0007894639,0.122869655,0.00848395,0.00088130654,0.49674487,0.0016274642,0.078392535,0.0016830212],"about_ca_topic_score_codex":0.00001166373,"about_ca_topic_score_gemma":0.00001137103,"teacher_disagreement_score":0.45598614,"about_ca_system_score_codex":0.0001280405,"about_ca_system_score_gemma":0.00026050763,"threshold_uncertainty_score":0.7815431},"labels":[],"label_agreement":null},{"id":"W1576118523","doi":"10.1111/j.1600-0609.2011.01602.x","title":"Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients","year":2011,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Alberta","funders":"","keywords":"Carfilzomib; Multiple myeloma; Oncology; Variation (astronomy); Alkaline phosphatase; Medicine; Internal medicine; Chemistry; Lenalidomide; Biochemistry; Enzyme","score_opus":0.04353107053041077,"score_gpt":0.26935986516702304,"score_spread":0.22582879463661226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1576118523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987272,0.00016215508,0.000031795993,0.00015492711,0.00006522649,0.0004236406,0.000047673337,0.000013157196,0.00037423667],"genre_scores_gemma":[0.99851173,0.000054025648,0.00104785,0.000062117986,0.000028228436,0.000007638914,0.000040276063,0.000040648672,0.00020746792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976076,0.0008923418,0.00063017866,0.00020829025,0.0003022564,0.00035937218],"domain_scores_gemma":[0.9985658,0.00016243305,0.00045565845,0.00024052798,0.00030555594,0.00027001664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005454899,0.00020681931,0.00058014266,0.00036259447,0.00007337008,0.000010294575,0.00011901553,0.000044462966,0.00019665703],"category_scores_gemma":[0.0007527745,0.00014130409,0.00009927276,0.00020887524,0.00007542864,0.00012627922,0.000036583195,0.00020254836,0.0001066109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053513538,0.0045388364,0.8425303,0.000034912086,0.00085610483,0.09030312,0.004629501,0.000006542194,0.0011910304,0.000008223971,0.00012177643,0.0022660908],"study_design_scores_gemma":[0.029173598,0.0076609887,0.95131135,0.00029206733,0.00014558027,0.0021279927,0.000114400325,0.000062264815,0.008798631,0.0000039514175,0.00019101996,0.00011817338],"about_ca_topic_score_codex":0.00006797302,"about_ca_topic_score_gemma":0.000045069835,"teacher_disagreement_score":0.10878101,"about_ca_system_score_codex":0.0002781396,"about_ca_system_score_gemma":0.00013177947,"threshold_uncertainty_score":0.57622135},"labels":[],"label_agreement":null},{"id":"W1583671024","doi":"10.3747/co.v13i5.106","title":"Bortezomib in Multiple Myeloma and Lymphoma: A Systematic Review and Clinical Practice Guideline","year":2006,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Bortezomib; Randomized controlled trial; Guideline; Multiple myeloma; Internal medicine; Systematic review; MEDLINE; Cochrane Library; CINAHL; Intensive care medicine; Clinical trial; Oncology; Family medicine; Pathology; Nursing","score_opus":0.23680926186736578,"score_gpt":0.5478911944469366,"score_spread":0.3110819325795708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1583671024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011119998,0.9908307,0.000016387656,0.00047279306,0.00030458253,0.007697612,0.000068959234,0.00003687645,0.00056096894],"genre_scores_gemma":[0.0000056021604,0.9959296,0.0017621531,0.00032398655,0.00024386593,0.0009156195,0.0006138534,0.00005540598,0.0001499199],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931357,0.0020201989,0.003088213,0.00085715967,0.00035593487,0.0005428037],"domain_scores_gemma":[0.99417484,0.0034034443,0.0010594751,0.0006244068,0.00028521178,0.00045261974],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028499542,0.0005712809,0.0066535235,0.00031795274,0.000060954684,0.00002430546,0.00016404827,0.0005091611,0.000020763478],"category_scores_gemma":[0.011201061,0.00038765985,0.0003955881,0.00035637442,0.00023526375,0.00009056285,0.00025992823,0.00069820264,0.00008005482],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031949636,0.0009996973,0.0003562908,0.48360088,0.00029927265,0.0004891661,0.000004007653,1.6490729e-9,3.9438057e-9,0.000008593768,0.0039090733,0.51030105],"study_design_scores_gemma":[0.0035878143,0.0004483466,0.00019713756,0.25353143,0.010124904,0.0019438204,0.000009217895,0.000041080315,5.1783915e-9,0.000003221634,0.72991306,0.00019996379],"about_ca_topic_score_codex":0.00007217114,"about_ca_topic_score_gemma":0.00010477708,"teacher_disagreement_score":0.726004,"about_ca_system_score_codex":0.0006109143,"about_ca_system_score_gemma":0.0010628741,"threshold_uncertainty_score":0.99985754},"labels":[],"label_agreement":null},{"id":"W1584461023","doi":"10.1096/fasebj.29.1_supplement.926.9","title":"Whole Genome Sequence of Multiple Myeloma‐Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types","year":2015,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Biology; Exome sequencing; Stromal cell; Exome; Bone marrow; Haplotype; Phenotype; Plasma cell; Cancer research; Gene; Genetics; Monoclonal; Antibody; Immunology; Monoclonal antibody; Allele","score_opus":0.06713510123377567,"score_gpt":0.30992853641887,"score_spread":0.24279343518509436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1584461023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527705,0.0018184873,0.000096757256,0.0009644256,0.00010879251,0.0006626879,0.0008027426,0.000021968543,0.0002470621],"genre_scores_gemma":[0.99665564,0.00019750104,0.0006669283,0.00007706664,0.00020820381,0.000018932244,0.00011306826,0.000034918394,0.002027716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976024,0.00031732593,0.0004861998,0.00021011414,0.00090198044,0.0004819928],"domain_scores_gemma":[0.997558,0.00036486913,0.00032712767,0.0006320079,0.0004089847,0.0007090039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009791314,0.00023561803,0.00038916362,0.00013404056,0.00020643922,0.00003966907,0.00047823618,0.000061203435,0.0000878336],"category_scores_gemma":[0.0007116084,0.00012243573,0.00019333612,0.00025354096,0.00047172466,0.00015539576,0.00011647854,0.0004793125,0.00006378248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002385318,0.00071113027,0.11564753,0.00013984756,0.00028113625,0.00022600438,0.0017275916,0.00060253096,0.87505203,0.000028244094,0.00048085547,0.002717746],"study_design_scores_gemma":[0.032262143,0.0035333321,0.42462388,0.00061764574,0.0009492822,0.0004708234,0.007769855,0.014785084,0.5054192,0.0009128144,0.007848051,0.0008079206],"about_ca_topic_score_codex":0.00024073107,"about_ca_topic_score_gemma":0.00008647782,"teacher_disagreement_score":0.36963287,"about_ca_system_score_codex":0.00014876387,"about_ca_system_score_gemma":0.00075481663,"threshold_uncertainty_score":0.4992784},"labels":[],"label_agreement":null},{"id":"W1587685635","doi":"10.1111/j.1538-7836.2011.04215.x","title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis","year":2011,"lang":"en","type":"review","venue":"Journal of Thrombosis and Haemostasis","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Venous thromboembolism; Meta-analysis; Oncology; Internal medicine; Intensive care medicine; Thrombosis","score_opus":0.21867988468701718,"score_gpt":0.3990875863740474,"score_spread":0.18040770168703021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1587685635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058700526,0.99083155,0.0000058992555,0.00005790669,0.00002119838,0.0030687472,0.00011678661,0.000006169601,0.000021690843],"genre_scores_gemma":[0.014592446,0.98436624,0.0006703582,0.00009488442,0.000016656868,0.00012726423,0.00003513698,0.00007432419,0.000022719574],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954493,0.00077890017,0.0023005465,0.0004310531,0.0006283259,0.00041187232],"domain_scores_gemma":[0.99483067,0.0010270355,0.0027394402,0.0005896544,0.00050588755,0.00030731654],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0011549054,0.00071963656,0.014670262,0.0010184057,0.000106306856,0.000054803397,0.00026291842,0.0002245464,0.00015522215],"category_scores_gemma":[0.00038014498,0.00034944608,0.0017106064,0.0009362432,0.00020579208,0.00024341667,0.00010118694,0.00049036084,0.0000021580743],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051738735,0.0013147536,0.0018416826,0.58975023,0.3905745,0.00010691048,0.0003734863,3.4887833e-7,6.006956e-7,0.00000589327,0.000038449798,0.015475725],"study_design_scores_gemma":[0.0066607725,0.0026779152,0.0067563136,0.16350701,0.81873775,0.00029226602,0.00012070509,0.0000031493034,0.000018616289,0.000012231546,0.0007664563,0.0004468146],"about_ca_topic_score_codex":0.00018770773,"about_ca_topic_score_gemma":0.00012903794,"teacher_disagreement_score":0.42816323,"about_ca_system_score_codex":0.00015786848,"about_ca_system_score_gemma":0.00051365746,"threshold_uncertainty_score":0.999958},"labels":[],"label_agreement":null},{"id":"W1594796613","doi":"","title":"Surgical management of extramedullary cutaneous plasmacytoma in a Golden Retriever bitch","year":2009,"lang":"en","type":"article","venue":"Indian Journal of Veterinary Surgery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Labrador Retriever; Plasmacytoma; Extramedullary plasmacytoma; Pathology; General surgery; Dermatology; Multiple myeloma; Internal medicine","score_opus":0.04233460563422774,"score_gpt":0.32479753231158814,"score_spread":0.2824629266773604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1594796613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975038,0.00089006854,0.0000030413937,0.00050320436,0.00015176642,0.00019774603,0.00000857278,0.000008644959,0.0007331477],"genre_scores_gemma":[0.99786514,0.0010527396,0.0007297129,0.000047132104,0.00009885002,0.0000019958102,0.0000078631,0.00001565831,0.00018088051],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9978577,0.00012568437,0.0008102212,0.00016621024,0.00063412695,0.000406087],"domain_scores_gemma":[0.9987285,0.00030710295,0.0002793597,0.000227494,0.00009893462,0.00035861292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051236735,0.00017440821,0.0006495158,0.00072766084,0.00002467319,0.000014227993,0.00013229535,0.00010051227,0.00017900973],"category_scores_gemma":[0.00006591074,0.0001429779,0.00030688665,0.0004540957,0.00006635608,0.00014300048,0.00003317239,0.00034244164,0.000014299889],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008590416,0.001013864,0.14330229,0.00024438172,0.00030752723,0.73502654,0.0001862804,0.000005158676,0.0007885921,0.000005963626,0.0005043082,0.110024676],"study_design_scores_gemma":[0.005860782,0.0064750747,0.77284443,0.002909997,0.00008893303,0.20534857,0.0002909522,0.000035621473,0.0020030385,0.0001171362,0.0037600629,0.00026543223],"about_ca_topic_score_codex":0.000008596589,"about_ca_topic_score_gemma":5.3171215e-7,"teacher_disagreement_score":0.6295421,"about_ca_system_score_codex":0.00014832479,"about_ca_system_score_gemma":0.00018127469,"threshold_uncertainty_score":0.583047},"labels":[],"label_agreement":null},{"id":"W1601075921","doi":"10.1111/j.0022-202x.2005.23830.x","title":"Thalidomide Enhances the Anti-Tumor Activity of Standard Chemotherapy in a Human Melanoma Xenotransplatation Model","year":2005,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Thalidomide; Dacarbazine; Melanoma; Medicine; Chemotherapy; Pharmacology; Cancer research; Oncology; Internal medicine; Multiple myeloma","score_opus":0.037105298978990786,"score_gpt":0.34077687491129105,"score_spread":0.30367157593230026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1601075921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082404,0.00020964205,0.0009499753,0.0075323554,0.000015208736,0.00024774278,0.000012719322,0.0000038314906,0.00020447609],"genre_scores_gemma":[0.9965155,0.00009627907,0.0029753817,0.00034345838,0.000035245033,0.000007059652,0.0000027749825,0.000010226408,0.000014083037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987123,0.00020616161,0.00046303845,0.00010307101,0.00031888427,0.00019653351],"domain_scores_gemma":[0.99892396,0.00016953277,0.00043949342,0.0001231109,0.00022936387,0.00011452246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027972393,0.00012210602,0.0005217222,0.00018759722,0.000055852925,0.000007159042,0.00012085343,0.00005588006,0.000025742858],"category_scores_gemma":[0.00014857193,0.000074682444,0.000102528575,0.00015292408,0.00046900782,0.0001986111,0.000010806075,0.00031468226,0.000001641694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014916989,0.00031808438,0.030739253,0.00009888983,0.0003069497,0.00031301464,0.0027813457,0.00049394584,0.96087104,0.00063912885,0.00018412471,0.0017625152],"study_design_scores_gemma":[0.0048927795,0.0003185508,0.07128699,0.00012567053,0.0000385105,0.0005347683,0.00012818325,0.004628477,0.916275,0.0016732338,0.000044809618,0.000052999567],"about_ca_topic_score_codex":0.00003165718,"about_ca_topic_score_gemma":0.00008701574,"teacher_disagreement_score":0.04459602,"about_ca_system_score_codex":0.000095004085,"about_ca_system_score_gemma":0.00030747877,"threshold_uncertainty_score":0.30454618},"labels":[],"label_agreement":null},{"id":"W1602346905","doi":"10.1212/wnl.82.10_supplement.p7.013","title":"Polyneuropathy in Multiple Myeloma Patients Correlate with the Presence of Autoantibodies (P7.013)","year":2014,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Polyneuropathy; Medicine; Multiple myeloma; Autoantibody; Internal medicine; Oncology; Immunology; Antibody","score_opus":0.012821219035668243,"score_gpt":0.24734516913998714,"score_spread":0.2345239501043189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1602346905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668914,0.000041629046,0.000031493757,0.0016333845,0.00009473716,0.00049630017,0.00000670547,0.00002715332,0.0009794818],"genre_scores_gemma":[0.99909437,0.000022964276,0.000060334492,0.0006077564,0.000025992627,0.00003132594,0.000013086367,0.000020541018,0.00012360311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998598,0.0002801567,0.00019693398,0.00028300186,0.00028073334,0.00036116556],"domain_scores_gemma":[0.9987524,0.00057667895,0.00009008349,0.0003875154,0.00010116115,0.00009216198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013264493,0.00014063357,0.00027906676,0.00012029407,0.00005708606,0.000005293106,0.00015255855,0.00006708231,0.000022842567],"category_scores_gemma":[0.0005747087,0.00008005469,0.000042292904,0.00017964428,0.0002903976,0.000041745898,0.00008898214,0.00031333588,0.00003851502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027475718,0.00030887668,0.9891975,0.00002505074,0.000027910643,0.00011782559,0.00018026671,0.000040857994,0.0010727495,0.00006185623,0.00011910337,0.006100444],"study_design_scores_gemma":[0.004283539,0.0039949813,0.98387665,0.000016986665,0.000019828634,0.000037719597,0.000004569433,0.0056258156,0.00059148134,0.000017206696,0.0014746621,0.00005654173],"about_ca_topic_score_codex":0.0002531528,"about_ca_topic_score_gemma":0.0002729922,"teacher_disagreement_score":0.006043902,"about_ca_system_score_codex":0.0000076084234,"about_ca_system_score_gemma":0.000035261564,"threshold_uncertainty_score":0.32645354},"labels":[],"label_agreement":null},{"id":"W1616213856","doi":"10.1111/j.1365-2141.2010.08262.x","title":"Development of target‐specific treatments in multiple myeloma","year":2010,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Thalidomide; Bortezomib; Multiple myeloma; Arsenic trioxide; Cancer research; Lenalidomide; Medicine; Histone deacetylase; Protein kinase B; Pharmacology; Panobinostat; Monoclonal antibody; Immunology; Biology; Apoptosis; Histone; Signal transduction; Antibody; Cell biology","score_opus":0.07596536851419747,"score_gpt":0.3565687772379315,"score_spread":0.280603408723734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1616213856","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026144687,0.97229266,0.000031252053,0.000014238311,0.00031628867,0.00086335756,0.000044687724,0.000008280668,0.00028452137],"genre_scores_gemma":[0.0013530528,0.96709657,0.031054104,0.0000062603403,0.00009425666,0.000053957287,0.000121097466,0.0000650658,0.00015565525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959724,0.00024675185,0.0023443562,0.00033330676,0.00054956815,0.00055359886],"domain_scores_gemma":[0.99747723,0.00031076034,0.0012716592,0.0002865802,0.00029242988,0.00036136585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050146,0.00039698978,0.004408692,0.0008310393,0.000070864306,0.000021210471,0.00033037248,0.0005796855,0.00029489075],"category_scores_gemma":[0.0004028119,0.00034529553,0.00067644246,0.00032967216,0.00018114726,0.00008304126,0.000094876494,0.0012137146,0.000064222186],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011789468,0.0010004673,0.0008218738,0.0045352164,0.0007567933,0.08503179,0.000066520064,4.6574044e-8,0.000011047596,0.000008480163,0.0002612115,0.9073886],"study_design_scores_gemma":[0.0042624664,0.00021718051,0.0015681323,0.021213315,0.0003148132,0.22445816,0.000028970162,0.0000011880289,0.00009958813,0.000017767565,0.7476232,0.00019521322],"about_ca_topic_score_codex":0.000027489556,"about_ca_topic_score_gemma":0.00015120878,"teacher_disagreement_score":0.9071934,"about_ca_system_score_codex":0.00027829842,"about_ca_system_score_gemma":0.0015076199,"threshold_uncertainty_score":0.9998999},"labels":[],"label_agreement":null},{"id":"W1693098294","doi":"","title":"Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biology; Immunoglobulin class switching; Isotype; Antibody; Genetics; Immunology; Immunoglobulin heavy chain; clone (Java method); Complementarity determining region; Molecular biology; Gene; B cell; Immunoglobulin light chain; Monoclonal antibody","score_opus":0.029596691691860272,"score_gpt":0.24480194861887572,"score_spread":0.21520525692701545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1693098294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943132,0.0033630102,0.000010829235,0.00077317096,0.000084969935,0.0012416085,0.000027420712,0.000008698213,0.00017712763],"genre_scores_gemma":[0.9992893,0.00030998606,0.00014477964,0.000031572526,0.0000384736,0.00008755938,0.0000077324785,0.000009402887,0.000081215374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982123,0.0002177777,0.0005117783,0.0002572818,0.0004987097,0.00030217174],"domain_scores_gemma":[0.99848,0.00046289156,0.00022906183,0.0004656847,0.00023937771,0.00012297479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004462602,0.00015241152,0.0004219363,0.00013323386,0.00016199706,0.000004786644,0.00027957707,0.00013868535,0.00002524439],"category_scores_gemma":[0.0010403326,0.00008920727,0.00015443024,0.00041769983,0.00059612695,0.00008675676,0.00051110797,0.00028039224,0.0000030998724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011875697,0.00074277836,0.9051793,0.00010249955,0.00016909427,0.000010127076,0.0013175128,0.0000030847123,0.0013273405,0.00010286641,0.00002002875,0.089837804],"study_design_scores_gemma":[0.0036337622,0.0001614816,0.98911405,0.00004587953,0.00007915647,0.000009461467,0.00025338822,0.00059043535,0.0058661853,0.00014150032,0.000033593846,0.000071099166],"about_ca_topic_score_codex":0.005167149,"about_ca_topic_score_gemma":0.0019118213,"teacher_disagreement_score":0.0897667,"about_ca_system_score_codex":0.00016823904,"about_ca_system_score_gemma":0.000068116526,"threshold_uncertainty_score":0.7811218},"labels":[],"label_agreement":null},{"id":"W1730503696","doi":"10.3747/co.2007.107","title":"Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The National Cancer Institute of Canada Clinical Trials Group MY.11 Trial","year":2007,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Melphalan; Tolerability; Oncology; Internal medicine; Clinical trial; Prednisone; Randomized controlled trial; Cancer; Surgery; Adverse effect","score_opus":0.3644684821070608,"score_gpt":0.5368155580575764,"score_spread":0.17234707595051563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1730503696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272114,0.00063846225,0.000062578336,0.0014901054,0.0015195429,0.002889896,0.0004608291,0.000003928031,0.00021349385],"genre_scores_gemma":[0.99771136,0.00055194955,0.00015691701,0.00009444075,0.0007961144,0.00044771883,0.00021324854,0.0000077229015,0.000020519452],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964633,0.0009139768,0.0014133927,0.0002317848,0.00067281746,0.00030474315],"domain_scores_gemma":[0.99222875,0.00660963,0.00051421963,0.0002122636,0.0002795724,0.00015555465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038071352,0.00015116825,0.0009123637,0.00015387643,0.000048363156,0.0000026653242,0.00017180716,0.00010087691,0.0001205874],"category_scores_gemma":[0.0046936693,0.00007922905,0.00021709203,0.00027107954,0.00021335136,0.00003410917,0.000024341996,0.00014848934,0.0000014400086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14012618,0.01652417,0.22765872,0.00013584708,0.00086408656,0.00019427386,0.002126838,0.00009013614,0.000723157,0.00045701303,0.017589016,0.59351057],"study_design_scores_gemma":[0.20649444,0.0077395793,0.53815824,0.00015548815,0.000256334,0.000011784947,0.0006056258,0.00016223606,0.0023853353,0.000048511363,0.24386315,0.00011925537],"about_ca_topic_score_codex":0.07993438,"about_ca_topic_score_gemma":0.6466938,"teacher_disagreement_score":0.5933913,"about_ca_system_score_codex":0.0007673839,"about_ca_system_score_gemma":0.0022006899,"threshold_uncertainty_score":0.9261924},"labels":[],"label_agreement":null},{"id":"W1782227983","doi":"10.1186/1471-2407-6-118","title":"Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study","year":2006,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surgical oncology; Multiple myeloma; Radiation therapy; Internal medicine; Chemotherapy; Multivariate analysis; Retrospective cohort study; Oncology; Plasmacytoma; Proportional hazards model; Surgery; Radiology","score_opus":0.031693465004921303,"score_gpt":0.3289340679808081,"score_spread":0.2972406029758868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1782227983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952622,0.0020786505,0.0000020717252,0.00011819973,0.00021119196,0.002011342,0.00006897522,0.000019683426,0.0002277015],"genre_scores_gemma":[0.9982022,0.00004438287,0.00006554808,0.000036425485,0.00022298661,0.0005312819,0.000014164534,0.000023796727,0.000859205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985431,0.000096779695,0.00028884536,0.0002536407,0.00040018145,0.00041745955],"domain_scores_gemma":[0.99934286,0.0001351343,0.000081783386,0.00028287395,0.00007489257,0.00008246974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084320214,0.0001629731,0.00030475468,0.00006479064,0.000059424932,0.000008285905,0.00010513076,0.000047908772,0.00021997436],"category_scores_gemma":[0.00007009911,0.00009714647,0.00010317612,0.00030928792,0.00006692733,0.0000363064,0.000078990975,0.00017055991,0.000004258598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006312688,0.0007800105,0.995591,0.000105121304,0.000089781315,0.000050924213,0.0003143751,0.00065564294,0.00013548012,0.0000024927895,0.000909276,0.00073463825],"study_design_scores_gemma":[0.005430136,0.00013257936,0.99183136,0.00037839374,0.00009499447,0.0000020966074,0.00026591477,0.00086848397,0.00063721143,0.000009526958,0.0002644648,0.0000848165],"about_ca_topic_score_codex":0.027845062,"about_ca_topic_score_gemma":0.090986975,"teacher_disagreement_score":0.06314191,"about_ca_system_score_codex":0.00027213234,"about_ca_system_score_gemma":0.00031486087,"threshold_uncertainty_score":0.9786286},"labels":[],"label_agreement":null},{"id":"W1797900320","doi":"10.1182/blood-2015-05-644039","title":"Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Bundesministerium für Bildung und Forschung; Medical Research Council; Center for Translational Molecular Medicine; Stem Cell Network; SkylineDx; European Hematology Association","keywords":"Multiple myeloma; Oncology; Internal medicine; Medicine; Gene expression profiling; Gene expression; Computational biology; Gene; Bioinformatics; Biology; Genetics","score_opus":0.023125850120937947,"score_gpt":0.24890553924254932,"score_spread":0.22577968912161137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1797900320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984759,0.00016820642,0.00029167676,0.00014997397,0.00007352084,0.00036278536,0.0001034078,0.000027649456,0.00034684877],"genre_scores_gemma":[0.99859995,0.000032138756,0.0011309175,0.000018027991,0.00008676333,0.00003295515,0.000048974678,0.0000088225415,0.00004143933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991796,0.000073558156,0.00013408743,0.00015359618,0.00036122662,0.000097926815],"domain_scores_gemma":[0.99940294,0.0001562744,0.00006741181,0.00016336156,0.00008705382,0.00012295789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028753048,0.00007552145,0.0001419977,0.00007139131,0.000050672974,0.000015086808,0.00004280852,0.00003374696,0.000004132828],"category_scores_gemma":[0.00026658247,0.00004398777,0.000022340573,0.000039103037,0.00006594845,0.00003834948,0.00004229097,0.000078746314,0.0000021030971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003275773,0.00056194677,0.96882993,0.00015646692,0.00021256684,0.00005917214,0.00035929235,0.000056934103,0.022819875,0.0000681816,0.0001198673,0.0034799792],"study_design_scores_gemma":[0.09159778,0.0007065433,0.5773373,0.00068410084,0.00022915287,0.000054952674,0.0005290449,0.11195621,0.21672407,0.000032707892,0.00006260289,0.00008551557],"about_ca_topic_score_codex":0.00018799471,"about_ca_topic_score_gemma":0.0000036782617,"teacher_disagreement_score":0.39149264,"about_ca_system_score_codex":0.000028911762,"about_ca_system_score_gemma":0.00003954493,"threshold_uncertainty_score":0.17937692},"labels":[],"label_agreement":null},{"id":"W1798388355","doi":"10.1200/jco.2007.25.18_suppl.18500","title":"Retrospective review of DPACE therapy for aggressive, refractory multiple myeloma (MM)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Thalidomide; Neutropenia; Regimen; Salvage therapy; Surgery; Internal medicine; Etoposide; Refractory (planetary science); Febrile neutropenia; Lenalidomide; Multiple myeloma; Bortezomib; Gastroenterology; Cyclophosphamide; Progressive disease; Chemotherapy","score_opus":0.1624343293685952,"score_gpt":0.5268634708977441,"score_spread":0.3644291415291489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1798388355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9188943,0.063899375,0.00096364535,0.007217986,0.0013133262,0.0017823017,0.0000310218,0.000015294683,0.0058827675],"genre_scores_gemma":[0.88769174,0.09650819,0.011764686,0.002357391,0.001182019,0.000010165519,0.000008145569,0.000025541474,0.0004521345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99609226,0.00031089148,0.0024649533,0.00020515425,0.00058236567,0.00034434785],"domain_scores_gemma":[0.9885976,0.005016855,0.0037434315,0.00027930143,0.0018171915,0.000545651],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006553267,0.00015271088,0.00195817,0.00015024719,0.00004061407,0.0000027657568,0.00018113444,0.00031776345,0.0001844564],"category_scores_gemma":[0.03062604,0.000096153926,0.0009000284,0.00017431933,0.0002556019,0.00008865267,0.000033305154,0.0007940971,0.000009673516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027189853,0.0041192006,0.26242864,0.0006987282,0.001201077,0.0012511894,0.000053348424,1.5745263e-7,0.0010702213,0.000053818992,0.013004093,0.6889297],"study_design_scores_gemma":[0.023263466,0.033033866,0.7738837,0.0029253913,0.000205379,0.00027681876,0.000046405912,0.0000136644,0.0013910711,0.00017824963,0.16469231,0.0000896481],"about_ca_topic_score_codex":0.000011131962,"about_ca_topic_score_gemma":0.000020020565,"teacher_disagreement_score":0.68884003,"about_ca_system_score_codex":0.0002611408,"about_ca_system_score_gemma":0.0012920828,"threshold_uncertainty_score":0.9775394},"labels":[],"label_agreement":null},{"id":"W1798928306","doi":"10.1046/j.1365-2141.2003.03929.x","title":"Novel therapies for multiple myeloma","year":2002,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Public Health Service","keywords":"Stromal cell; Cancer research; Bortezomib; Multiple myeloma; Tumor microenvironment; Growth factor; Medicine; Extracellular matrix; Bone marrow; Immunology; Biology; Cell biology; Internal medicine; Receptor","score_opus":0.10477212268443684,"score_gpt":0.3753771102808782,"score_spread":0.27060498759644136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1798928306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015858658,0.99708295,0.0006794863,0.000115460076,0.00034272092,0.0012319685,0.00019301582,0.00001779436,0.00017803439],"genre_scores_gemma":[0.00016339564,0.98985523,0.008548737,0.000050178827,0.0003905606,0.000101893354,0.000077918034,0.000089367066,0.0007227048],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746794,0.00013402005,0.0012228069,0.0002805954,0.00035885326,0.00053576246],"domain_scores_gemma":[0.9972713,0.0008386819,0.00087968615,0.00023461266,0.00044570267,0.00033002283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033034172,0.00034265735,0.003758493,0.00038330737,0.00011559353,0.000053815656,0.0002909876,0.00042638063,0.0002413838],"category_scores_gemma":[0.0010909822,0.00028715935,0.0013781261,0.00016484674,0.0001585666,0.00008187694,0.000050087092,0.0006682284,0.000046992485],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008844385,0.00050339627,0.000027988435,0.010502049,0.0018329462,0.029751953,0.000019716908,3.7147196e-8,0.0000016114068,0.000029239785,0.006025725,0.9512169],"study_design_scores_gemma":[0.0028215048,0.0003683383,0.00002962318,0.011821733,0.0007752985,0.41013518,0.000011540484,0.000006839323,0.000001916578,0.000019256337,0.573887,0.00012178825],"about_ca_topic_score_codex":0.000024791943,"about_ca_topic_score_gemma":0.000029837158,"teacher_disagreement_score":0.9510951,"about_ca_system_score_codex":0.00011952986,"about_ca_system_score_gemma":0.0003798027,"threshold_uncertainty_score":0.99995804},"labels":[],"label_agreement":null},{"id":"W18153787","doi":"10.1016/s0301-472x(01)00682-8","title":"Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma","year":2001,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Autocrine signalling; Paracrine signalling; Cytokine; clone (Java method); Biology; CD40; Molecular biology; Flow cytometry; Receptor; Immunology; Cell biology; Cytotoxic T cell; In vitro","score_opus":0.024572200729001518,"score_gpt":0.31229174639029145,"score_spread":0.28771954566128993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W18153787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945217,0.0038533919,0.000024703799,0.000067021974,0.00009156889,0.00044726307,0.000013131337,0.000027050311,0.00095420564],"genre_scores_gemma":[0.9980361,0.000087185246,0.0015183537,0.000037183672,0.000018323444,0.00006207527,0.000051996027,0.000022255312,0.00016656796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987159,0.00008118685,0.00033923172,0.00032527864,0.00018283716,0.000355564],"domain_scores_gemma":[0.999387,0.00013002552,0.00008334928,0.00020079609,0.000021554853,0.00017725526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007692188,0.00016736232,0.00042287548,0.00013741023,0.000057621575,0.0000051367583,0.00006122255,0.0001293228,0.0002722724],"category_scores_gemma":[0.000051168776,0.00014647076,0.00005169054,0.0001352343,0.00015148394,0.00007223557,0.000089631816,0.00013333665,0.000025398196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005421676,0.00060805964,0.30387512,0.00005236189,0.000020861697,0.0002075503,0.0005156751,5.826651e-7,0.6917197,0.00013664328,0.00042951497,0.0018917841],"study_design_scores_gemma":[0.0042905235,0.00034244635,0.011858611,0.00011565677,0.0000050897834,0.00028547732,0.00087259646,0.00034724496,0.9809954,0.000016528258,0.00076194183,0.00010847158],"about_ca_topic_score_codex":0.00017039718,"about_ca_topic_score_gemma":0.000010380896,"teacher_disagreement_score":0.2920165,"about_ca_system_score_codex":0.00008058542,"about_ca_system_score_gemma":0.000024572442,"threshold_uncertainty_score":0.5972904},"labels":[],"label_agreement":null},{"id":"W1819391273","doi":"10.1016/j.tranon.2015.09.001","title":"Changes in Nuclear Orientation Patterns of Chromosome 11 during Mouse Plasmacytoma Development","year":2015,"lang":"en","type":"article","venue":"Translational Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Chromosome; Chromosomal translocation; Biology; Orientation (vector space); Karyotype; Genetics; Molecular biology; Gene","score_opus":0.06453299657681746,"score_gpt":0.3457701063470392,"score_spread":0.28123710977022176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819391273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979978,0.000016133905,0.000025810261,0.0011836631,0.000047325222,0.00029733844,0.000018571029,0.000018062121,0.00039529262],"genre_scores_gemma":[0.99708265,0.000008895598,0.0024196608,0.00003797293,0.00005154855,0.00003179571,0.00014205844,0.000012020271,0.0002133834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991465,0.000044728866,0.00021184872,0.00014222498,0.0002835555,0.00017110757],"domain_scores_gemma":[0.9996202,0.00005058447,0.00004861971,0.00006798285,0.00008119949,0.00013139345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112589136,0.000077725046,0.0001977658,0.00018307487,0.000022253327,0.0000022795355,0.000039990664,0.0000681996,0.0001929559],"category_scores_gemma":[0.000023570954,0.000063552485,0.000022002185,0.000098048025,0.000028153556,0.000052843836,0.000010660536,0.00007458243,0.000034138156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002487913,0.00086727063,0.9630717,0.00013941372,0.00009543705,0.00019732965,0.0057213427,0.00008517184,0.015675595,0.00026137198,0.000022212636,0.011375219],"study_design_scores_gemma":[0.011129435,0.0006115376,0.96123165,0.000040307856,0.0000143216575,0.00006314696,0.00025205855,0.00030323135,0.023227517,0.000024557532,0.0030275513,0.00007466171],"about_ca_topic_score_codex":0.0000743668,"about_ca_topic_score_gemma":0.0025435048,"teacher_disagreement_score":0.011300556,"about_ca_system_score_codex":0.00022261677,"about_ca_system_score_gemma":0.00029788358,"threshold_uncertainty_score":0.25915954},"labels":[],"label_agreement":null},{"id":"W1863671141","doi":"10.1158/1538-7445.am2014-2563","title":"Abstract 2563: Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Daratumumab; Serum protein electrophoresis; Monoclonal antibody; Immunofixation; Medicine; Multiple myeloma; Antibody; Monoclonal; Immunology; Internal medicine","score_opus":0.17600398529680306,"score_gpt":0.5321469711729264,"score_spread":0.35614298587612336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1863671141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970475,0.00008920594,0.0005616061,0.0005492645,0.000047232126,0.001435251,0.000040965944,0.00001370642,0.00021526353],"genre_scores_gemma":[0.9873878,0.00008776611,0.012048723,0.000025763859,0.00006561623,0.0001972955,0.000051960724,0.000030793344,0.000104303304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994445,0.0017242515,0.001329316,0.0006967918,0.001198472,0.0006061228],"domain_scores_gemma":[0.99616724,0.0015679919,0.0002317568,0.0006236137,0.0007998969,0.0006094893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012285193,0.00021074552,0.00075614237,0.00047638908,0.00012125131,0.00003330842,0.00029373675,0.00018239307,0.00009686318],"category_scores_gemma":[0.0024427513,0.00016105907,0.00007646056,0.00049265404,0.00054384733,0.00015923535,0.00025373432,0.0008994859,0.000009758823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021121616,0.0009034238,0.75967973,0.00020197067,0.0001656387,0.000045330347,0.000251178,0.000011372536,0.08260898,0.000020725547,0.0000116633155,0.13497837],"study_design_scores_gemma":[0.006767088,0.00414615,0.9639808,0.0011775891,0.000011483683,0.000003703992,0.00014330419,0.002598767,0.020779615,0.000017009119,0.00023250993,0.00014196477],"about_ca_topic_score_codex":0.00073839154,"about_ca_topic_score_gemma":0.0017473528,"teacher_disagreement_score":0.20430109,"about_ca_system_score_codex":0.0002372501,"about_ca_system_score_gemma":0.0022291539,"threshold_uncertainty_score":0.6567798},"labels":[],"label_agreement":null},{"id":"W1916555325","doi":"10.3109/10428194.2015.1085534","title":"Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Calgary Laboratory Services; Baker Hughes (Canada)","funders":"","keywords":"Bortezomib; Medicine; Melphalan; Multiple myeloma; Oncology; Stem cell; Autologous stem-cell transplantation; Internal medicine; Chemotherapy; Surgery; Biology","score_opus":0.02112626161931841,"score_gpt":0.2377327960704628,"score_spread":0.2166065344511444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916555325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895853,0.0016097401,0.00010527712,0.0034473531,0.00009122088,0.002555049,0.0023567826,0.00011191241,0.0001374108],"genre_scores_gemma":[0.98649865,0.00028093575,0.0006882819,0.009233042,0.00025184487,0.00029776798,0.002086696,0.00017334624,0.000489461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953401,0.00080724654,0.00083208526,0.0011882614,0.00075855234,0.0010737672],"domain_scores_gemma":[0.9920337,0.0055739083,0.0006746369,0.00074182067,0.00043764073,0.00053825596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007034906,0.0009969207,0.001610245,0.00036843776,0.00064882846,0.0001884746,0.00026027163,0.0007686204,0.000007704731],"category_scores_gemma":[0.0002738353,0.0006892079,0.00019130138,0.00026089046,0.0010857127,0.0002585962,0.000170041,0.0003792038,0.0000033733384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14031489,0.002574016,0.5491839,0.01613862,0.007285703,0.008864384,0.008715168,0.00006238085,0.008573071,0.00009465533,0.12243049,0.1357627],"study_design_scores_gemma":[0.1117885,0.007474603,0.83026814,0.00273494,0.002279145,0.0018511906,0.0007755721,0.005904392,0.003751086,0.0001957591,0.031318862,0.0016578047],"about_ca_topic_score_codex":0.0019878733,"about_ca_topic_score_gemma":0.00027679326,"teacher_disagreement_score":0.2810842,"about_ca_system_score_codex":0.0024952763,"about_ca_system_score_gemma":0.0032700927,"threshold_uncertainty_score":0.9995559},"labels":[],"label_agreement":null},{"id":"W1921751791","doi":"10.1111/bjh.13596","title":"Therapeutic targeting of N‐cadherin is an effective treatment for multiple myeloma","year":2015,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Royal Adelaide Hospital; Cancer Australia; Leukaemia Foundation; Multiple Myeloma Research Foundation","keywords":"Cadherin; Stromal cell; Bone marrow; Medicine; Multiple myeloma; Extravasation; Small hairpin RNA; Homing (biology); Cancer research; Pathogenesis; Pathology; Internal medicine; Cell culture; Cell; Chemistry; Biology; Gene knockdown","score_opus":0.0663614294524306,"score_gpt":0.3575109046384235,"score_spread":0.2911494751859929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1921751791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923553,0.005484213,0.00080765586,0.00026633267,0.00014444618,0.0007761265,0.00004040787,0.000010856275,0.00011467903],"genre_scores_gemma":[0.993711,0.00019872759,0.0057155876,0.000076568176,0.00012179955,0.00004812399,0.000019131989,0.000026507701,0.00008255351],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9985759,0.00018340923,0.00049863616,0.00016830137,0.00025407126,0.0003196754],"domain_scores_gemma":[0.99828666,0.00029647344,0.00031118948,0.00012951395,0.0006152745,0.00036087047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039163002,0.0001391186,0.0007964462,0.00012838093,0.00005490982,0.0000151392,0.00010092856,0.0001041512,0.00004209077],"category_scores_gemma":[0.0005083019,0.00011897196,0.00022769967,0.0000853601,0.000108328146,0.00011675125,0.000018326064,0.00012972279,0.000005964752],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010706395,0.0043844637,0.19144964,0.00044948334,0.0032550856,0.03394486,0.0027853837,0.000021314148,0.012879762,0.00013043892,0.0030958436,0.73689735],"study_design_scores_gemma":[0.11221928,0.05598238,0.20332605,0.0013779576,0.0013306921,0.34205836,0.0041668527,0.0041606864,0.2585001,0.002912056,0.013299441,0.00066614384],"about_ca_topic_score_codex":0.0002344212,"about_ca_topic_score_gemma":0.000072811075,"teacher_disagreement_score":0.7362312,"about_ca_system_score_codex":0.00013879329,"about_ca_system_score_gemma":0.00020623412,"threshold_uncertainty_score":0.4851536},"labels":[],"label_agreement":null},{"id":"W1944400929","doi":"10.1016/j.clml.2015.05.007","title":"Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Lenalidomide; Internal medicine; Multiple myeloma; Clinical endpoint; Randomized controlled trial; Refractory (planetary science); Bortezomib; Oncology; Surgery","score_opus":0.047607298519740625,"score_gpt":0.3588236787743686,"score_spread":0.311216380254628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944400929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989181,0.0008966381,0.000009594175,0.00086576585,0.0001161709,0.008707957,0.000037025435,0.00005580798,0.0001300762],"genre_scores_gemma":[0.99701166,0.00006755871,0.0012607947,0.0006710794,0.000108122564,0.0005222472,0.00012716146,0.00006421873,0.00016714107],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895399,0.0040149568,0.003479714,0.0010283337,0.0010524392,0.0008846557],"domain_scores_gemma":[0.9881696,0.008319411,0.0010760291,0.0007902216,0.00028558794,0.0013591254],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010520088,0.0005564298,0.0034285893,0.0004281162,0.000120316465,0.000056437686,0.00028319887,0.00044219915,0.000025384561],"category_scores_gemma":[0.024408827,0.0003537197,0.00028147866,0.00078666094,0.00084987836,0.00020216638,0.00021573683,0.00064125634,0.00002696503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77268606,0.0028741662,0.07947816,0.000106896965,0.00034270537,0.00014745502,0.001396176,0.000004500574,0.00014124451,0.000009485929,0.00010495865,0.14270818],"study_design_scores_gemma":[0.5539096,0.00408814,0.43993494,0.0002201678,0.000057859444,0.000011398356,0.00017259689,0.0013050105,0.000020420732,0.000041965563,0.000036118985,0.0002017803],"about_ca_topic_score_codex":0.0020391408,"about_ca_topic_score_gemma":0.00028098514,"teacher_disagreement_score":0.3604568,"about_ca_system_score_codex":0.0006768205,"about_ca_system_score_gemma":0.0021845624,"threshold_uncertainty_score":0.99989146},"labels":[],"label_agreement":null},{"id":"W1946820278","doi":"10.1111/bjh.13790","title":"Myeloma impairs mature osteoblast function but causes early expansion of osteo‐progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model","year":2015,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University College London; Leukaemia and Lymphoma Research; Leukemia and Lymphoma Research; Cancer Research UK; National Institute for Health and Care Research; Organisation Canadienne des Physiciens Médicaux","keywords":"Osteoblast; Progenitor cell; Osteoclast; Bone resorption; Bone remodeling; Resorption; Cell biology; Stromal cell; Medicine; Biology; Pathology; Cancer research; Internal medicine; Stem cell; In vitro; Receptor; Genetics","score_opus":0.03064421872906813,"score_gpt":0.283161634324778,"score_spread":0.25251741559570984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946820278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365383,0.0053436784,0.00004233445,0.0004493351,0.000101436286,0.0003667186,0.00001815004,0.000006483739,0.000018013534],"genre_scores_gemma":[0.9982528,0.00046902022,0.0010272381,0.000070300004,0.0001035302,0.000022492326,0.000018255525,0.000017400118,0.000018947445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99826354,0.0003439496,0.0005158479,0.00019713056,0.00036252462,0.0003169925],"domain_scores_gemma":[0.99903226,0.00009928451,0.00030350656,0.00015520347,0.00023726972,0.00017248701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050239766,0.0001498944,0.00068657426,0.0003234587,0.00004017516,0.000016732296,0.00011018392,0.00022050043,0.000009711049],"category_scores_gemma":[0.00023141892,0.00011146938,0.00006996841,0.00017607513,0.00015992072,0.00015831049,0.00006888815,0.00044582953,0.0000017160609],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0146583095,0.0016110068,0.27000278,0.0007389076,0.00024559887,0.07935565,0.004907835,0.0001361912,0.602121,0.00002472293,0.0019574587,0.024240548],"study_design_scores_gemma":[0.021214478,0.005988906,0.5831835,0.002134827,0.0001486344,0.25763822,0.005652744,0.00088558026,0.12166788,0.0011122182,0.00006401253,0.00030896807],"about_ca_topic_score_codex":0.00032887782,"about_ca_topic_score_gemma":0.0006334289,"teacher_disagreement_score":0.4804531,"about_ca_system_score_codex":0.00004976289,"about_ca_system_score_gemma":0.00017475331,"threshold_uncertainty_score":0.45455894},"labels":[],"label_agreement":null},{"id":"W1958630149","doi":"10.1309/xbj9-cpdm-hb52-05a3","title":"Clinical Pathology Rounds","year":2000,"lang":"en","type":"article","venue":"Laboratory Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"","keywords":"Medicine; Pathology","score_opus":0.04802276519995069,"score_gpt":0.40321742514211056,"score_spread":0.3551946599421599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958630149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523267,0.0014925932,0.000016957963,0.00445454,0.00025988405,0.00031688978,0.00001740356,0.00012751229,0.040987495],"genre_scores_gemma":[0.9826271,0.0012053365,0.0006154683,0.004287291,0.0012488372,0.00003092986,0.0000875651,0.00002942877,0.009868044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830484,0.0001894269,0.00041610445,0.0003442484,0.00037769106,0.0003677009],"domain_scores_gemma":[0.99862003,0.00015633421,0.000041549487,0.00049666653,0.00016429834,0.0005211232],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00062464294,0.00015764132,0.0004843582,0.000088686764,0.00006956121,0.000004539775,0.00009221987,0.00014464917,0.012433615],"category_scores_gemma":[0.00040423384,0.00010579367,0.00006178782,0.00036313967,0.00040909494,0.000057548517,0.000015701375,0.0003385443,0.0012443308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015283268,0.00085322605,0.5913173,0.00007957311,0.00028467088,0.0070471945,0.00024218354,5.4429825e-7,0.0019237871,0.00037758393,0.048301194,0.34804443],"study_design_scores_gemma":[0.009525441,0.0021896467,0.5837794,0.00011264054,0.00011617117,0.00016703563,0.00006990013,0.00006741333,0.00016621554,0.00009830478,0.40358582,0.000122036945],"about_ca_topic_score_codex":0.000027868184,"about_ca_topic_score_gemma":0.00000972788,"teacher_disagreement_score":0.35528463,"about_ca_system_score_codex":0.000049930695,"about_ca_system_score_gemma":0.00017820811,"threshold_uncertainty_score":0.9995333},"labels":[],"label_agreement":null},{"id":"W1963479853","doi":"10.1016/j.clinbiochem.2012.11.015","title":"Measurement uncertainty for serum free light chain assays: Estimation and implication on result interpretation","year":2012,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"","keywords":"Interpretation (philosophy); Immunoglobulin light chain; Estimation; Statistics; Computational biology; Computer science; Econometrics; Mathematics; Medicine; Biology; Economics; Immunology","score_opus":0.0779701312048182,"score_gpt":0.4061351070333309,"score_spread":0.3281649758285127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963479853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987046,0.0005216167,0.0024349557,0.0070791002,0.00015382074,0.0010275921,0.00008440419,0.00006933883,0.0015831916],"genre_scores_gemma":[0.99716574,0.000034301625,0.0018208453,0.00020453485,0.0002900168,0.00013842632,0.00017866527,0.000012237627,0.00015523497],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987662,0.000043446867,0.00036512385,0.00028511134,0.0002990536,0.00024105106],"domain_scores_gemma":[0.99874395,0.00023359891,0.000110088826,0.00040771882,0.00019728304,0.00030738252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011122125,0.00011932622,0.00019114192,0.000026268559,0.000063894244,0.000016170048,0.00006789493,0.00016413575,0.000013218011],"category_scores_gemma":[0.00545233,0.00009412139,0.00008903671,0.00005363171,0.000054504333,0.000047937312,0.00003737984,0.00015173403,0.000017612945],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077355765,0.003215241,0.10252103,0.0012221901,0.00064935454,0.000005250687,0.00024994178,0.000011843925,0.15826073,0.0003230042,0.019323278,0.7064825],"study_design_scores_gemma":[0.015668677,0.0018740745,0.31162703,0.0009177853,0.00031755707,0.0000234626,0.00014783502,0.025118954,0.63979393,0.0010078505,0.0030854,0.00041745487],"about_ca_topic_score_codex":0.0000051589795,"about_ca_topic_score_gemma":0.0000011074048,"teacher_disagreement_score":0.7060651,"about_ca_system_score_codex":0.00016227065,"about_ca_system_score_gemma":0.000069479116,"threshold_uncertainty_score":0.6527342},"labels":[],"label_agreement":null},{"id":"W1963783366","doi":"10.1182/blood-2002-02-0608","title":"Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Fibroblast growth factor receptor 3; Cancer research; Multiple myeloma; Biology; Dexamethasone; Cell culture; Fibroblast growth factor; Molecular biology; Receptor; Internal medicine; Endocrinology; Medicine; Immunology","score_opus":0.030370515430819752,"score_gpt":0.26194596787865154,"score_spread":0.2315754524478318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963783366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914409,0.00035656057,0.0000045188754,0.00046690783,0.00004137847,0.0005127919,0.00021135974,0.000044943834,0.006920673],"genre_scores_gemma":[0.99179167,0.000113149894,0.00070886343,0.000053117266,0.00005159279,0.000022950411,0.000025607711,0.000027310993,0.007205768],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983764,0.00015368985,0.0002637203,0.00026510473,0.0005936028,0.00034746772],"domain_scores_gemma":[0.99888283,0.00015850127,0.00016344001,0.00041403022,0.00018814433,0.00019307208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008946599,0.00017224603,0.00031713353,0.000060480274,0.0001097434,0.000012497666,0.00016684271,0.00012231202,0.0011583044],"category_scores_gemma":[0.0009192899,0.00011013864,0.00016344928,0.00028804605,0.00011797425,0.00005746258,0.000074622454,0.00019081858,0.0000657836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034929658,0.0027465853,0.12098799,0.0001951508,0.0005991405,0.00002924727,0.00039611355,2.2295359e-7,0.86764216,0.00006141353,0.005838359,0.0011542955],"study_design_scores_gemma":[0.010031131,0.00042714123,0.27830577,0.00094903575,0.000110178924,0.0000072130115,0.00004471111,0.000028913599,0.7088303,0.000027672922,0.0010930583,0.00014485941],"about_ca_topic_score_codex":0.00004656963,"about_ca_topic_score_gemma":0.000029784556,"teacher_disagreement_score":0.15881188,"about_ca_system_score_codex":0.0000814817,"about_ca_system_score_gemma":0.000059629383,"threshold_uncertainty_score":0.9997548},"labels":[],"label_agreement":null},{"id":"W1963910097","doi":"10.1111/bjh.12414","title":"Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","year":2013,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Etoposide; Multiple myeloma; Chemotherapy; Cyclophosphamide; Dexamethasone; Bortezomib; Radiation therapy; Internal medicine; Oncology; Surgery; Gastroenterology","score_opus":0.013725923017352431,"score_gpt":0.24364246069732953,"score_spread":0.2299165376799771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963910097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961601,0.0017644513,0.0003367307,0.0007714217,0.00011081107,0.0007725761,0.000016264914,0.000024639816,0.000043036664],"genre_scores_gemma":[0.99839354,0.00032097189,0.0008630722,0.00013944895,0.00010699601,0.000031540512,0.00003706354,0.000042687123,0.00006467309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803966,0.00017390132,0.00051452685,0.0002485454,0.00047402908,0.0005493152],"domain_scores_gemma":[0.99858576,0.000075716016,0.00032904296,0.0001847914,0.00033239686,0.00049226504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019301251,0.00022365479,0.00074899127,0.00013183754,0.0001519262,0.00009543176,0.00013424654,0.00010656822,0.00006921836],"category_scores_gemma":[0.000042896838,0.00017303177,0.00007530982,0.00010885044,0.00023153618,0.0001895686,0.00003363752,0.00033839716,0.0000028677464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012125678,0.0004996096,0.9197899,0.00033372265,0.0013377151,0.0331291,0.0004150876,0.000007883587,0.0005095986,0.000029074212,0.00030084985,0.04243491],"study_design_scores_gemma":[0.012011527,0.0011438519,0.885049,0.0005442881,0.00011432116,0.09965663,0.0004628843,0.0001880693,0.00063137646,0.0000034455272,0.000046755045,0.0001478983],"about_ca_topic_score_codex":0.0011544229,"about_ca_topic_score_gemma":0.00085874397,"teacher_disagreement_score":0.06652752,"about_ca_system_score_codex":0.00021023076,"about_ca_system_score_gemma":0.00028132048,"threshold_uncertainty_score":0.7056031},"labels":[],"label_agreement":null},{"id":"W1964493075","doi":"10.1159/000089873","title":"Different breakage-prone regions on chromosome 1 detected in t(11;14)-positive mantle cell lymphoma cell lines and multiple myeloma cell lines are associated with different tumor progession-related mechanisms","year":2006,"lang":"en","type":"article","venue":"Cytogenetic and Genome Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital","funders":"","keywords":"Mantle cell lymphoma; Biology; Lymphoma; Cell culture; Multiple myeloma; Chromosome; Cancer research; Genetics; Gene; Immunology","score_opus":0.02650725047157312,"score_gpt":0.2754986661339554,"score_spread":0.24899141566238228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964493075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993508,0.0024648383,0.000033114065,0.00030374754,0.000029195095,0.0028998978,0.00021998203,0.00007013685,0.00047110446],"genre_scores_gemma":[0.99369895,0.0005595763,0.00015803208,0.000021042531,0.000075850505,0.00033603745,0.0004696521,0.000108562046,0.0045722905],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953654,0.00054158614,0.00054619653,0.0010833414,0.0011410031,0.0013224947],"domain_scores_gemma":[0.9975462,0.0006402813,0.00018177555,0.00052126736,0.00044941105,0.00066108856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034337596,0.00058496796,0.00081462046,0.0007167144,0.0005162115,0.00011414647,0.00021207143,0.0002896726,0.00007387646],"category_scores_gemma":[0.00012216342,0.00040039004,0.000091099544,0.0007489241,0.00039258882,0.000053368538,0.00029717054,0.0005350698,0.000028623603],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028426843,0.00938112,0.28079993,0.0008408852,0.000220297,0.003120731,0.0005453044,0.00003680346,0.69970757,0.000022259224,0.00009688883,0.002385529],"study_design_scores_gemma":[0.013480384,0.0021857081,0.69775885,0.0005440512,0.00007017382,0.000055180633,0.00033193218,0.001285779,0.2838052,0.00012641688,0.000022033242,0.00033428776],"about_ca_topic_score_codex":0.00040717874,"about_ca_topic_score_gemma":0.00082575757,"teacher_disagreement_score":0.41695893,"about_ca_system_score_codex":0.00040698083,"about_ca_system_score_gemma":0.00019651628,"threshold_uncertainty_score":0.9998448},"labels":[],"label_agreement":null},{"id":"W1964522660","doi":"10.1182/blood-2008-10-184226","title":"Induction of angiogenesis by normal and malignant plasma cells","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Heidelberg; Stem Cell Network","keywords":"Angiogenesis; Cancer research; Medicine; Pathology; Internal medicine","score_opus":0.01437517581320826,"score_gpt":0.25424823677407676,"score_spread":0.2398730609608685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964522660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832755,0.000458401,0.000004867158,0.00014060548,0.000014154668,0.00014489406,0.00002151887,0.000011788907,0.00087624457],"genre_scores_gemma":[0.99880314,0.00014690608,0.00058280636,0.0000238806,0.000030733103,0.0000033589968,0.000019676527,0.0000044322746,0.00038508305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99951917,0.000012117273,0.00009044183,0.00010653303,0.00013843151,0.00013328507],"domain_scores_gemma":[0.99973637,0.00001122373,0.000024829187,0.00009607952,0.000027789589,0.00010368112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038939124,0.000058934864,0.00011431194,0.0000517085,0.000023142527,0.0000040273776,0.000019947014,0.00003938198,0.00003204681],"category_scores_gemma":[0.000011304512,0.000045488203,0.000030833973,0.000068961,0.000021897127,0.000031130836,0.000008455114,0.000030624473,0.000008866703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016970445,0.0010869345,0.049428172,0.0000345441,0.00012942962,0.00007027765,0.000069264526,2.0565815e-7,0.918591,0.000012408655,0.00067470066,0.029733343],"study_design_scores_gemma":[0.0037248842,0.0006789133,0.12933663,0.000021905458,0.0000942932,0.000052984087,0.000020341857,0.000016729997,0.86572665,0.000007801719,0.00027946677,0.0000394377],"about_ca_topic_score_codex":0.00004692695,"about_ca_topic_score_gemma":0.0000019408174,"teacher_disagreement_score":0.079908445,"about_ca_system_score_codex":0.000005925951,"about_ca_system_score_gemma":0.000018040364,"threshold_uncertainty_score":0.18549551},"labels":[],"label_agreement":null},{"id":"W1965225830","doi":"10.2165/00003495-200060020-00003","title":"Potential Novel Uses of Thalidomide","year":2000,"lang":"en","type":"review","venue":"Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Thalidomide; Medicine; Erythema nodosum; Multiple myeloma; Rheumatoid arthritis; Pyoderma gangrenosum; Dermatology; Cancer; Disease; Immunology; Internal medicine","score_opus":0.06488550715583498,"score_gpt":0.383350522487704,"score_spread":0.31846501533186905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965225830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008117694,0.98989975,0.0000074758073,0.000019759334,0.00007688501,0.00082760135,0.0002594837,0.000027340466,0.008800515],"genre_scores_gemma":[0.0002226965,0.9944274,0.0003760446,0.000016537024,0.00020261365,0.00005881175,0.00048370555,0.000048492213,0.0041637323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998521,0.00005379819,0.0004201802,0.000281225,0.00042889544,0.00029491747],"domain_scores_gemma":[0.9990791,0.00009792951,0.00014336326,0.00043941333,0.00005066098,0.00018955328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010058955,0.00027080107,0.0014914129,0.0002170623,0.000029092063,0.000010745645,0.00014197831,0.00018415543,0.0009050483],"category_scores_gemma":[0.000051377392,0.00018205546,0.00062831177,0.00018332413,0.000076365985,0.000028087787,0.000048768605,0.0002417473,0.00040286206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006541279,0.0002964481,0.000011020748,0.009487251,0.0005508665,0.00012509215,0.000023482242,8.713547e-8,0.0000020557995,0.00001951139,0.00058398466,0.9888348],"study_design_scores_gemma":[0.001503879,0.00008619009,0.000034518827,0.007334107,0.001085589,0.00015293303,0.0000073958104,0.0000034073598,0.000015278856,0.0000051593033,0.98964727,0.00012425907],"about_ca_topic_score_codex":0.00013870138,"about_ca_topic_score_gemma":0.0000011978998,"teacher_disagreement_score":0.9890633,"about_ca_system_score_codex":0.00007299556,"about_ca_system_score_gemma":0.0004094811,"threshold_uncertainty_score":0.9909644},"labels":[],"label_agreement":null},{"id":"W1965354201","doi":"10.1016/j.clml.2012.08.008","title":"Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Regimen; Multiple myeloma; Induction therapy; Salvage therapy; Oncology; Internal medicine; Induction chemotherapy; Maintenance therapy; Transplantation; Surgery; Urology; Overall survival; Chemotherapy","score_opus":0.140409532724376,"score_gpt":0.40292710964915174,"score_spread":0.26251757692477573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965354201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568987,0.000099075245,0.00021066009,0.0012498982,0.0002587764,0.0016791801,0.00074783975,0.000042486477,0.000022233557],"genre_scores_gemma":[0.9975601,0.000055393964,0.0011479933,0.0007225004,0.00012202995,0.00014151046,0.00015111403,0.000041192376,0.00005818555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99527735,0.0014679495,0.0013882304,0.0005172543,0.00077675586,0.0005724787],"domain_scores_gemma":[0.9928454,0.0052254265,0.00043565087,0.00078810606,0.00022616463,0.00047926477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041188314,0.00036631216,0.0011152719,0.00027942334,0.00012254223,0.00001813693,0.00023213364,0.00032328203,0.00006189685],"category_scores_gemma":[0.0033661607,0.00021278721,0.00037768204,0.00032559634,0.0005072543,0.00018223262,0.00006625379,0.00028204083,0.0000106746875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041078206,0.0018746423,0.7832063,0.00014021953,0.00020018741,0.0000108259,0.00038334855,0.000007794415,0.07819837,0.000013128601,0.000020692538,0.09486631],"study_design_scores_gemma":[0.020755883,0.0014296402,0.9206009,0.0002389982,0.000065599175,0.000010155735,0.00013480133,0.0005516663,0.055850506,0.0000036048748,0.00015550744,0.00020273113],"about_ca_topic_score_codex":0.0009846354,"about_ca_topic_score_gemma":0.00034022503,"teacher_disagreement_score":0.13739464,"about_ca_system_score_codex":0.0003972452,"about_ca_system_score_gemma":0.0005957337,"threshold_uncertainty_score":0.8677211},"labels":[],"label_agreement":null},{"id":"W1965512539","doi":"10.1089/thy.2011.0201","title":"Solitary Extramedullary Plasmacytomas of the Thyroid in Hashimoto's Thyroiditis","year":2012,"lang":"en","type":"letter","venue":"Thyroid","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Thyroiditis; Thyroid; Plasmacytoma; Nodule (geology); Pathology; Internal medicine; Multiple myeloma","score_opus":0.028894181820374676,"score_gpt":0.28424105549378115,"score_spread":0.25534687367340647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965512539","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35745823,0.02955824,0.000012588691,0.55948913,0.0017965041,0.006128222,0.0012832885,0.00025819708,0.044015586],"genre_scores_gemma":[0.7479106,0.0018601064,0.001038331,0.22257106,0.0069667953,0.00050976634,0.0019754842,0.00043321622,0.016734645],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951457,0.00043574875,0.00082678435,0.0006574673,0.0014995461,0.0014347461],"domain_scores_gemma":[0.9970765,0.00046876233,0.00033123133,0.00170213,0.00014054813,0.00028081445],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004298688,0.00068846217,0.0011895306,0.0004619095,0.00011904967,0.000025907388,0.0007462785,0.0010577074,0.00053875346],"category_scores_gemma":[0.0002861196,0.0004624966,0.00060463516,0.0005170146,0.00048782944,0.00015512924,0.00038280967,0.0035301023,0.00033446745],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003681485,0.00047684935,0.026414707,0.00065807905,0.00044080828,0.0024137136,0.00034106427,0.0000011805703,0.004426972,0.000022143551,0.9623318,0.0021045387],"study_design_scores_gemma":[0.015414711,0.0018450943,0.25627032,0.0019373607,0.0009049304,0.0020224315,0.0002162442,0.00016031062,0.020271858,0.00092648243,0.6985133,0.0015168987],"about_ca_topic_score_codex":0.00082775066,"about_ca_topic_score_gemma":0.000116574825,"teacher_disagreement_score":0.39045236,"about_ca_system_score_codex":0.0004150144,"about_ca_system_score_gemma":0.00055426225,"threshold_uncertainty_score":0.9997827},"labels":[],"label_agreement":null},{"id":"W1966657674","doi":"10.1182/blood-2008-02-142430","title":"A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"clone (Java method); Melphalan; Stromal cell; Bone marrow; Multiple myeloma; Bortezomib; Stem cell; Haematopoiesis; Cancer research; Biology; Immunology; Molecular biology; Cell biology","score_opus":0.1386837415988641,"score_gpt":0.3978047145033722,"score_spread":0.2591209729045081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966657674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977219,0.00023360888,0.0002936257,0.00013635447,0.000009469432,0.0013557741,0.00006157058,0.000023994586,0.00016371564],"genre_scores_gemma":[0.9955824,0.000027522268,0.003820298,0.0000646113,0.000047995847,0.00017644347,0.00003961846,0.000024004989,0.00021712943],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989421,0.000044247343,0.00017888832,0.00018587922,0.00038283312,0.0002660831],"domain_scores_gemma":[0.9987635,0.00054624456,0.000067646186,0.00032557404,0.00018759276,0.00010941642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023086733,0.00013857271,0.0002233264,0.000060902952,0.00015829381,0.0000037883487,0.00008550446,0.000053964002,0.0000334251],"category_scores_gemma":[0.00039972784,0.000071398266,0.00024080329,0.00009380679,0.00007637888,0.000027757465,0.000021115045,0.00011432363,0.000006663227],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017455801,0.011173148,0.66270304,0.00008280215,0.0033036931,0.00013705045,0.001674991,0.016253399,0.24854672,0.00015168072,0.0010224996,0.03749519],"study_design_scores_gemma":[0.016831117,0.004416277,0.34493563,0.000051263214,0.000043470234,0.00007186129,0.000004432995,0.60733855,0.025955008,0.00027426862,0.0000027979304,0.00007533247],"about_ca_topic_score_codex":0.00026074,"about_ca_topic_score_gemma":0.000024447389,"teacher_disagreement_score":0.59108514,"about_ca_system_score_codex":0.000036205438,"about_ca_system_score_gemma":0.0003794214,"threshold_uncertainty_score":0.29115367},"labels":[],"label_agreement":null},{"id":"W1967736686","doi":"10.5114/aoms.2010.14459","title":"Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis","year":2010,"lang":"en","type":"article","venue":"Archives of Medical Science","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Medicine Hat College","funders":"","keywords":"Mesenchymal stem cell; Apoptosis; Stem cell; Cell biology; Osteoblast; Cancer research; Medicine; Chemistry; In vitro; Biology; Biochemistry","score_opus":0.01665142452266618,"score_gpt":0.2827695013977302,"score_spread":0.26611807687506406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967736686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776495,0.000028542916,0.00024576942,0.00060037343,0.00018496127,0.0004170317,0.000016485854,0.000016483174,0.0007254168],"genre_scores_gemma":[0.99849296,0.00006739131,0.0012491746,0.00003232728,0.000045754678,0.0000113441665,0.0000045198335,0.000009995535,0.00008651628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99665606,0.00007078904,0.00040982204,0.00043237215,0.001961304,0.00046964467],"domain_scores_gemma":[0.9980697,0.00045627623,0.00015101956,0.00034232967,0.000074075215,0.0009066246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655426,0.0001631801,0.0003642403,0.00028325987,0.00011239133,0.000017154665,0.00039963247,0.00010088429,0.00018953139],"category_scores_gemma":[0.000265323,0.00011617707,0.00010002988,0.00034836878,0.0015752985,0.00013022198,0.00027766512,0.00035934604,0.000010336221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010032129,0.00020197425,0.005811137,0.00009026096,0.000023445742,0.0000075397425,0.0005261178,9.950142e-8,0.7776934,0.00007294707,0.0000037667253,0.21546899],"study_design_scores_gemma":[0.0018131065,0.0005784581,0.14563325,0.00013668975,0.000030481886,0.000019985973,0.00009348953,0.0025669276,0.8489362,0.0000880566,0.00001978149,0.00008356225],"about_ca_topic_score_codex":0.00015370984,"about_ca_topic_score_gemma":0.00006817961,"teacher_disagreement_score":0.21538542,"about_ca_system_score_codex":0.0000134311495,"about_ca_system_score_gemma":0.00034557504,"threshold_uncertainty_score":0.58042526},"labels":[],"label_agreement":null},{"id":"W1968618374","doi":"10.1007/s10637-015-0230-x","title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Pharmaceuticals International; Takeda Oncology","keywords":"Ixazomib; Medicine; Rash; Pharmacodynamics; Multiple myeloma; Pharmacokinetics; Adverse effect; Internal medicine; Proteasome inhibitor; Pharmacology; Gastroenterology; Oncology; Carfilzomib","score_opus":0.07539078866375962,"score_gpt":0.36400187646837306,"score_spread":0.2886110878046134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968618374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634075,0.000077951954,0.00001794298,0.001150928,0.00006966718,0.0018682645,0.00002657443,0.00004716993,0.00040074362],"genre_scores_gemma":[0.9897766,0.0000018663908,0.008850298,0.00024516077,0.00012861095,0.00027374917,0.0002868918,0.000023775196,0.00041304366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974112,0.00013507158,0.00059374294,0.00042807686,0.0011064222,0.00032550996],"domain_scores_gemma":[0.99805677,0.00010940169,0.00018796588,0.0003226822,0.00037224576,0.0009509204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003904837,0.00023490808,0.0004410842,0.00033779355,0.000055950084,0.000023540164,0.0001609097,0.00009237502,0.000044552868],"category_scores_gemma":[0.0009327977,0.00020223764,0.000051145165,0.0005589144,0.00025173524,0.0004639695,0.00006846458,0.00019278158,0.000039027607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020479474,0.014187469,0.9074607,0.00020506176,0.0002061347,0.0003862795,0.013745108,0.0008258672,0.05223007,0.0029619718,0.0024432524,0.0033001595],"study_design_scores_gemma":[0.15922022,0.015568794,0.63144964,0.0010183188,0.00014082709,0.00022896737,0.0109708505,0.008607889,0.11045126,0.060792122,0.00060678885,0.0009443527],"about_ca_topic_score_codex":0.0005677428,"about_ca_topic_score_gemma":0.00009423977,"teacher_disagreement_score":0.27601105,"about_ca_system_score_codex":0.00019303625,"about_ca_system_score_gemma":0.0022484313,"threshold_uncertainty_score":0.8247012},"labels":[],"label_agreement":null},{"id":"W1969110349","doi":"10.1016/j.critrevonc.2013.04.003","title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","year":2013,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Monoclonal antibody; Multiple myeloma; Immune system; Haematopoiesis; Immunology; Receptor; Biology; Autoimmunity; Cancer research; Antibody; Medicine; Cell biology; Stem cell; Genetics","score_opus":0.1524543527778546,"score_gpt":0.44352341900849934,"score_spread":0.29106906623064477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969110349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031553977,0.987062,0.00004836384,0.0019072656,0.00043281473,0.008675594,0.000039064253,0.00005383993,0.0014655418],"genre_scores_gemma":[0.0011135852,0.9830011,0.006363093,0.00093419506,0.000120527075,0.0075096856,0.00045355794,0.00013549654,0.0003687186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882933,0.0036539226,0.0042758896,0.0015432952,0.0004521517,0.0017814519],"domain_scores_gemma":[0.9922926,0.005062725,0.0005199832,0.001357885,0.00025521906,0.00051159185],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0022536723,0.0011141475,0.009834872,0.0015027416,0.00008124706,0.0000316586,0.0006627213,0.0021526422,0.0017570137],"category_scores_gemma":[0.01066193,0.0008443154,0.0009143619,0.0016684224,0.00086074707,0.00017432169,0.00033600343,0.0025004558,0.0027620427],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020244607,0.002155134,0.0062457,0.025858581,0.00017424911,0.0011355879,0.0002039233,4.723797e-8,0.000028870374,0.0035489812,0.0029791305,0.9574674],"study_design_scores_gemma":[0.004254589,0.00063193374,0.0017667831,0.040002704,0.0002617544,0.00038681785,0.00008274335,0.00014661704,0.000013944145,0.001576192,0.95026946,0.000606435],"about_ca_topic_score_codex":0.0002020011,"about_ca_topic_score_gemma":0.0003520205,"teacher_disagreement_score":0.9568609,"about_ca_system_score_codex":0.0019006287,"about_ca_system_score_gemma":0.0015770191,"threshold_uncertainty_score":0.9998008},"labels":[],"label_agreement":null},{"id":"W1969284011","doi":"10.1007/s00277-013-1959-y","title":"A rare IgM multiple myeloma with aberrant PAX5 expression mimicking lymphoplasmacytic lymphoma","year":2013,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Lymphoplasmacytic Lymphoma; Hematology; Multiple myeloma; PAX5; Lymphoma; Medicine; Pathology; Waldenstrom macroglobulinemia; Cancer research; Internal medicine; Immunology; B cell; Antibody","score_opus":0.056094194248893364,"score_gpt":0.3149534791100926,"score_spread":0.25885928486119925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969284011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.687463,0.004163631,0.00006705034,0.3026077,0.0002650516,0.0024621552,0.00019388941,0.00019147247,0.0025860944],"genre_scores_gemma":[0.8618476,0.00053631474,0.0020171092,0.1309683,0.0005551212,0.00049842364,0.0014302847,0.00021700394,0.0019298393],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958101,0.00024775462,0.00081175676,0.0009123166,0.0008999825,0.0013180937],"domain_scores_gemma":[0.9967112,0.0007665696,0.00057467923,0.0011739562,0.00044695073,0.0003266548],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012127602,0.0007361286,0.0019494004,0.00058897847,0.00013733807,0.000031680345,0.00038461763,0.0011373315,0.00046041622],"category_scores_gemma":[0.0003289563,0.0005069282,0.0003866774,0.00024272344,0.00039595988,0.0001349484,0.00019061081,0.00067714124,0.00030227748],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001662814,0.0004538485,0.04207347,0.0032794804,0.0012171825,0.017815476,0.00025666005,0.0000014382392,0.0022852328,0.000015703159,0.92516667,0.0057720323],"study_design_scores_gemma":[0.037462715,0.00431734,0.026530499,0.013455447,0.0008377176,0.029139273,0.00029959582,0.0013262772,0.500231,0.00035160544,0.3836954,0.002353136],"about_ca_topic_score_codex":0.00047032855,"about_ca_topic_score_gemma":0.000040112704,"teacher_disagreement_score":0.5414713,"about_ca_system_score_codex":0.00006446803,"about_ca_system_score_gemma":0.00054129545,"threshold_uncertainty_score":0.9997382},"labels":[],"label_agreement":null},{"id":"W1969524425","doi":"10.1586/17474086.2014.873699","title":"The emerging role of carfilzomib combination therapy in the management of multiple myeloma","year":2014,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Proteasome inhibitor; Multiple myeloma; Pharmacology; Oncology; Refractory (planetary science); Clinical trial; Internal medicine; Biology","score_opus":0.038215541105202006,"score_gpt":0.40029644227368966,"score_spread":0.3620809011684877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969524425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007303985,0.99458444,0.000006934079,0.00033117188,0.000059018235,0.0035220124,0.0000058254363,0.0000061309474,0.0014114437],"genre_scores_gemma":[0.0012843559,0.9972848,0.00028078744,0.00007672999,0.000020357798,0.00085988845,0.00009314983,0.00002751118,0.00007238296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966951,0.0008153667,0.0014061276,0.00027150885,0.00048926007,0.00032261753],"domain_scores_gemma":[0.9971481,0.00082293147,0.0008741779,0.0009443977,0.00016509024,0.000045302837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012266956,0.00030392435,0.0027778805,0.0001601953,0.000054282253,0.0000034813963,0.00053243723,0.00012937264,0.000044346947],"category_scores_gemma":[0.00019745687,0.0001391592,0.00061244733,0.0004079593,0.00018904149,0.000022706765,0.00011058721,0.00022495548,0.000010106718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032800253,0.0002963887,0.00010201382,0.12788507,0.0005615378,0.000029635057,0.00014129937,7.969573e-9,0.0000018707303,0.0063767442,0.00044186314,0.86413074],"study_design_scores_gemma":[0.0012142601,0.00025545587,0.000121809535,0.09372468,0.00022291813,0.000117946365,0.00021442997,0.000008733115,0.000072041,0.000064491585,0.90388703,0.000096218835],"about_ca_topic_score_codex":0.00007833582,"about_ca_topic_score_gemma":0.000007525552,"teacher_disagreement_score":0.9034451,"about_ca_system_score_codex":0.000046442474,"about_ca_system_score_gemma":0.000090796806,"threshold_uncertainty_score":0.5674747},"labels":[],"label_agreement":null},{"id":"W1969767395","doi":"10.1038/ncpneph0229","title":"Does plasmapheresis have a role in the management of myeloma cast nephropathy?","year":2006,"lang":"en","type":"article","venue":"Nature Clinical Practice Nephrology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Plasmapheresis; Paraproteins; Medicine; Multiple myeloma; Nephropathy; Intensive care medicine; Dialysis; Urology; Nephrotoxicity; Renal function; Internal medicine; Immunology; Kidney; Endocrinology; Monoclonal","score_opus":0.02031326408671732,"score_gpt":0.3846263231680701,"score_spread":0.3643130590813528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969767395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9054598,0.0019640075,0.000025015077,0.03173308,0.0003581085,0.0015292763,0.000025673717,0.000041267336,0.05886375],"genre_scores_gemma":[0.98583335,0.00043522488,0.0064218948,0.0061003985,0.0004465569,0.0000720264,0.000042655516,0.00002183945,0.0006260829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670976,0.0008717354,0.00082481344,0.00049921963,0.00060568604,0.0004887519],"domain_scores_gemma":[0.994619,0.0040942375,0.000313633,0.00066882663,0.00019089368,0.00011342167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016791772,0.00021301502,0.0005266986,0.0001259792,0.00007179851,0.000019000574,0.00029852163,0.00064433436,0.00017490315],"category_scores_gemma":[0.0012585681,0.000106353364,0.00021269456,0.00031267566,0.00032241296,0.00015035646,0.00012632004,0.0018373674,0.00007917151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048483867,0.023022013,0.49900976,0.0007120572,0.003991573,0.035097163,0.00066387584,0.000037104124,0.0013343426,0.024270378,0.04329531,0.32008255],"study_design_scores_gemma":[0.005604736,0.0009706475,0.73886687,0.000045680823,0.0004074432,0.0002446267,0.0011789933,0.00017533796,0.00007960509,0.0011532288,0.2511632,0.000109604494],"about_ca_topic_score_codex":0.00038946164,"about_ca_topic_score_gemma":0.0007944945,"teacher_disagreement_score":0.31997293,"about_ca_system_score_codex":0.00005264662,"about_ca_system_score_gemma":0.00008911792,"threshold_uncertainty_score":0.79825497},"labels":[],"label_agreement":null},{"id":"W1969934340","doi":"10.1007/s00277-004-0944-x","title":"IgD multiple myeloma?a clinical profile and outcome with chemotherapy and autologous stem cell transplantation","year":2004,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Autologous stem-cell transplantation; Chemotherapy; Internal medicine; Hematology; Transplantation; Oncology; Bone marrow; Hematopoietic stem cell transplantation; Gastroenterology; Surgery","score_opus":0.08139372406923957,"score_gpt":0.38818219888648675,"score_spread":0.3067884748172472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969934340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546564,0.0008441929,0.00019916472,0.0025572046,0.000018249382,0.0005137961,0.000021965261,0.00003161134,0.00034815946],"genre_scores_gemma":[0.9955976,0.00093314477,0.0029383479,0.00037910245,0.00001253887,0.000025193365,0.000027741806,0.000016022816,0.00007030062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890345,0.000055986,0.00036394404,0.00027308773,0.00013981036,0.00026374057],"domain_scores_gemma":[0.9992834,0.00019225226,0.00010928147,0.00016579464,0.0000691498,0.00018013263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014687715,0.00013895945,0.0005301431,0.00008414557,0.000044206598,0.00000532414,0.00004048734,0.00013284352,0.000014912177],"category_scores_gemma":[0.00002261076,0.00009665442,0.000050048984,0.000066142304,0.0002622365,0.00005041775,0.0000124469125,0.00013336727,0.0000075192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023656986,0.00047759112,0.9748713,0.00061406323,0.00016901057,0.00054585864,0.00037140475,9.209961e-7,0.00086127676,0.00037282443,0.000038143007,0.019311933],"study_design_scores_gemma":[0.0117939785,0.0024780612,0.8950615,0.00010081497,0.00006117059,0.0014800916,0.00014293453,0.000078728524,0.08844578,0.00013904921,0.000093579016,0.00012433216],"about_ca_topic_score_codex":0.00006793806,"about_ca_topic_score_gemma":0.00004056106,"teacher_disagreement_score":0.0875845,"about_ca_system_score_codex":0.0000041190265,"about_ca_system_score_gemma":0.00006797509,"threshold_uncertainty_score":0.39414528},"labels":[],"label_agreement":null},{"id":"W1970521173","doi":"10.1182/blood-2014-05-578732","title":"The Tao of myeloma","year":2014,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Multiple myeloma; Plasma cell; Proteasome; Malignancy; Hematologic malignancy; Cancer research; Carfilzomib; Proteasome inhibitor; Disease; Lenalidomide; Plasma cell neoplasm; Cancer; Biology; Medicine; Computational biology; Immunology; Internal medicine; Cell biology; Plasmacytoma","score_opus":0.051527146080962635,"score_gpt":0.3698060043597938,"score_spread":0.3182788582788312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970521173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028721715,0.9900979,0.0000015856509,0.000026376072,0.000052185074,0.00078268105,0.000022956248,0.000017884913,0.008969724],"genre_scores_gemma":[0.00007582486,0.9964545,0.00011604045,0.0000064710775,0.00019396255,0.00010820646,0.00007145704,0.000033239696,0.0029403155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987422,0.00011145752,0.00035751404,0.00019104463,0.00032869753,0.00026908913],"domain_scores_gemma":[0.9986176,0.00038114164,0.00017426714,0.0006189049,0.00006595145,0.00014214705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022583995,0.00019756892,0.0011050199,0.00007078781,0.00006820272,0.000011445726,0.00018890294,0.00013583532,0.000050786097],"category_scores_gemma":[0.00029774907,0.00009360157,0.000447977,0.00014233007,0.00009014847,0.000008588025,0.00006725909,0.00022278426,0.00026192045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000089850455,0.00022508355,0.00009876308,0.010031272,0.00086523336,0.000055714758,0.000003635793,6.4874767e-10,4.6457038e-7,0.00010967762,0.000474137,0.98812705],"study_design_scores_gemma":[0.0011677913,0.0002118997,0.00018693565,0.005379437,0.001668966,0.00012905395,0.0000017101279,3.503633e-7,0.00001366104,0.000008838841,0.9911627,0.00006862126],"about_ca_topic_score_codex":0.0000140790935,"about_ca_topic_score_gemma":0.0000045575116,"teacher_disagreement_score":0.9906886,"about_ca_system_score_codex":0.000019594927,"about_ca_system_score_gemma":0.0002623684,"threshold_uncertainty_score":0.38169613},"labels":[],"label_agreement":null},{"id":"W1971164768","doi":"10.1159/000350165","title":"Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus","year":2013,"lang":"en","type":"article","venue":"Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Manitoba; Toronto Western Hospital; University of Toronto; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Lupus Research Alliance; University of California, San Francisco; Canadian Arthritis Network; National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Arthritis Society; Johns Hopkins University","keywords":"Medicine; Lymphoma; Multiple myeloma; Myeloid; Chronic lymphocytic leukemia; Leukemia; Myeloid leukemia; Population; B cell; Internal medicine; Immunology; Plasmacytoma; Antibody","score_opus":0.027922033729696833,"score_gpt":0.31661436765216266,"score_spread":0.28869233392246585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971164768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130774,0.00046359043,0.000019842724,0.0010475934,0.00017481411,0.00090877415,0.0000019915194,0.000048236965,0.016027424],"genre_scores_gemma":[0.99585813,0.00008426971,0.00078845426,0.00022611248,0.000049085003,0.00048178597,0.000015536903,0.000014501749,0.0024821425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986809,0.000071515606,0.0002948583,0.00026810146,0.00018367445,0.0005009473],"domain_scores_gemma":[0.999228,0.00016386354,0.00005768929,0.00025094423,0.000078562705,0.00022093239],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013276322,0.00014543762,0.00053860625,0.00014833837,0.00003838667,0.00001207767,0.00009996071,0.00020944123,0.0006281978],"category_scores_gemma":[0.00012907067,0.00010068498,0.00007262661,0.0001649294,0.000112916605,0.000056541998,0.000073671035,0.00011709152,0.0020889924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041642433,0.0020777632,0.943849,0.00034279915,0.000118179596,0.006414357,0.000435908,0.0000015153004,0.011683075,0.000822998,0.008666209,0.02517172],"study_design_scores_gemma":[0.03657437,0.0060894666,0.85316104,0.00074873416,0.000090139176,0.08015651,0.002695681,0.0022997803,0.0059766797,0.001385424,0.010290735,0.000531417],"about_ca_topic_score_codex":0.00031468066,"about_ca_topic_score_gemma":0.000064603046,"teacher_disagreement_score":0.090688,"about_ca_system_score_codex":0.0003666545,"about_ca_system_score_gemma":0.000211014,"threshold_uncertainty_score":0.998688},"labels":[],"label_agreement":null},{"id":"W1971311217","doi":"10.5489/cuaj.2531","title":"AN EXTRAMEDULLARY PLASMACYTOMA LOCATED IN THE TESTICLE: A CASE REPORT AND REVIEW OF THE LITERATURE","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Multiple myeloma; Orchiectomy; Head and neck; Radiation therapy; Bone marrow; Chemotherapy; Testicle; Pathology; Radiology; Surgery; Anatomy; Internal medicine","score_opus":0.029757392054664794,"score_gpt":0.3036138181395795,"score_spread":0.2738564260849147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971311217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708113,0.005518145,0.0000013745776,0.023056535,0.00004345133,0.00029205976,0.000025381365,0.0000036739716,0.00024809112],"genre_scores_gemma":[0.99602383,0.00051728805,0.0000619868,0.0032580337,0.00007001309,0.00000683582,0.000015599735,0.0000035510413,0.000042843203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986637,0.00042770806,0.00024975854,0.000097643104,0.00034032727,0.00022083908],"domain_scores_gemma":[0.99869,0.00017167635,0.00015335863,0.00014586895,0.0003207656,0.00051834976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015068827,0.000069007845,0.00015805993,0.000061252795,0.0000923415,0.00004346336,0.00008788579,0.00009525169,0.00003085823],"category_scores_gemma":[0.0063006924,0.000032571523,0.000041566593,0.00033702748,0.000032229415,0.000058652262,0.000008410865,0.00049011305,0.0000014124495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003334908,0.00006935697,0.91360563,0.00005438747,0.00003108771,0.08089275,0.0002673251,0.0000016005298,0.0000074414743,0.000017428163,0.0028483544,0.0021713153],"study_design_scores_gemma":[0.00087348814,0.00032460474,0.77740914,0.0005046842,0.000048050097,0.21835124,0.00016211608,0.0002006448,0.0000059885265,0.00016266994,0.0019148783,0.000042474763],"about_ca_topic_score_codex":0.0011768334,"about_ca_topic_score_gemma":0.0015409542,"teacher_disagreement_score":0.13745849,"about_ca_system_score_codex":0.0003239391,"about_ca_system_score_gemma":0.00066604937,"threshold_uncertainty_score":0.7542972},"labels":[],"label_agreement":null},{"id":"W1971494282","doi":"10.1136/jcp.2007.049585","title":"Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Immunohistochemistry; Multiple myeloma; Oncology; Clinical significance; Internal medicine; Pathology; Genetic marker; Medicine; Biology; Gene; Genetics","score_opus":0.1362531466435693,"score_gpt":0.48237356552529415,"score_spread":0.34612041888172485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971494282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10044743,0.8973223,0.000012313809,0.00010599117,0.00036968302,0.00095598336,0.000014421667,0.0000083796085,0.0007634853],"genre_scores_gemma":[0.013714137,0.98354346,0.0019122001,0.000103638944,0.0004152048,0.000028197026,0.000050671628,0.00004853359,0.00018397125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99476874,0.00070244377,0.0032972358,0.0003943089,0.000376055,0.00046122604],"domain_scores_gemma":[0.9933789,0.004096839,0.001450316,0.00032475215,0.0001310757,0.00061815337],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002821716,0.00034384537,0.0032667974,0.0013330057,0.00005042747,0.000014670377,0.0002320236,0.0009642551,0.00008852678],"category_scores_gemma":[0.0105675245,0.00024269146,0.0008437745,0.00044205703,0.0005425528,0.00005235448,0.00012738496,0.0025061432,0.0000726388],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007646419,0.00070257735,0.07526835,0.0014465451,0.0004519004,0.008853996,0.000027423712,3.976096e-8,0.000008561782,0.000014122271,0.00020406439,0.9122578],"study_design_scores_gemma":[0.009166828,0.0038515502,0.30138436,0.008149953,0.001928113,0.017835736,0.000048875536,0.000006749923,0.0000016803301,0.00010316095,0.6571463,0.00037672895],"about_ca_topic_score_codex":0.000005937097,"about_ca_topic_score_gemma":0.0000073608694,"teacher_disagreement_score":0.911881,"about_ca_system_score_codex":0.0002217809,"about_ca_system_score_gemma":0.0014309463,"threshold_uncertainty_score":0.99979514},"labels":[],"label_agreement":null},{"id":"W1972733729","doi":"10.1016/j.bbmt.2007.12.195","title":"186: Bortezomib Added to High-Dose Cyclophosphamide During Stem Cell Mobilization is Safe and Provides Effective Disease Control in Chemotherapy-Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Cyclophosphamide; Refractory (planetary science); Chemotherapy; Oncology; Disease control; Internal medicine; Cancer research; Virology","score_opus":0.007232027675752443,"score_gpt":0.23531855336165763,"score_spread":0.22808652568590518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972733729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663734,0.0011480235,0.00011871394,0.000148856,0.000021680597,0.0016819837,0.0002041608,0.000021601687,0.000017663122],"genre_scores_gemma":[0.996858,0.0023726923,0.00023737413,0.00012003991,0.000023406255,0.00017338913,0.00014939552,0.000015140356,0.000050560717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990425,0.00009582685,0.00023689764,0.0003233443,0.00008970065,0.00021172597],"domain_scores_gemma":[0.99939525,0.00017659552,0.000069255795,0.00010537822,0.00005300495,0.00020048633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007926496,0.00016194594,0.00030654756,0.00015521183,0.000074580086,0.000003911347,0.000030632815,0.00009351627,0.000010452657],"category_scores_gemma":[0.000018201434,0.0001374952,0.00003690693,0.000094996976,0.00011006511,0.000080690894,0.000005932131,0.00007783452,0.0000015403833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072458456,0.00032687015,0.554083,0.00047826028,0.00009027726,0.00008281055,0.0009682868,0.0000045476318,0.43152454,0.0000031289956,0.0000026146024,0.0051898547],"study_design_scores_gemma":[0.019116875,0.0006735247,0.81737125,0.00013282034,0.00012126111,0.000026736014,0.00003840497,0.00011963413,0.16227372,0.000012237073,0.0000123252585,0.000101190875],"about_ca_topic_score_codex":0.00025336805,"about_ca_topic_score_gemma":0.000068935624,"teacher_disagreement_score":0.2692508,"about_ca_system_score_codex":0.000021315116,"about_ca_system_score_gemma":0.00005398409,"threshold_uncertainty_score":0.56068915},"labels":[],"label_agreement":null},{"id":"W1973352088","doi":"10.1371/journal.pone.0079939","title":"Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Nod; Multiple myeloma; Bone marrow; Cancer research; Flow cytometry; Medicine; Bortezomib; In vivo; Pathology; Immunology; Biology","score_opus":0.06011690687346713,"score_gpt":0.3054381265979354,"score_spread":0.24532121972446827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973352088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699694,0.00013450767,0.000050634913,0.00011397286,0.000021051172,0.0023303996,0.00002980829,0.000020700327,0.00030196784],"genre_scores_gemma":[0.9908533,0.000044609485,0.00834943,0.000024722778,0.00006229534,0.00034449808,0.00005747846,0.000026867312,0.0002367785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982535,0.000058890597,0.00055597146,0.00029064572,0.00048528882,0.00035570684],"domain_scores_gemma":[0.9988632,0.00027828527,0.00017107361,0.00026472047,0.00032763605,0.00009505318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003169999,0.00019621706,0.000457851,0.00015531744,0.00018813708,0.000047164838,0.00012892182,0.00009793428,0.0001244833],"category_scores_gemma":[0.00013891306,0.00014681503,0.00005532772,0.00018771713,0.00017898699,0.0002177683,0.00007564519,0.00015814732,0.000007677651],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036903587,0.0016348311,0.057614066,0.0008950737,0.0005162685,0.0000027922981,0.0023414565,0.0000047275894,0.93407357,0.00010992602,0.000035970752,0.0024022858],"study_design_scores_gemma":[0.003524285,0.0010068596,0.23625852,0.00036877545,0.000118357624,0.0000025025067,0.0014833987,0.0013604664,0.75549734,0.0002452488,0.000008287259,0.00012596516],"about_ca_topic_score_codex":0.0012531034,"about_ca_topic_score_gemma":0.0023155073,"teacher_disagreement_score":0.17864445,"about_ca_system_score_codex":0.00009894823,"about_ca_system_score_gemma":0.00025789114,"threshold_uncertainty_score":0.5986943},"labels":[],"label_agreement":null},{"id":"W1973423007","doi":"10.1159/000325966","title":"Cytopathology of Extramedullary Plasmacytoma of the Bladder","year":2006,"lang":"en","type":"article","venue":"Acta Cytologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Cytopathology; Plasmacytoma; Pathology; Extramedullary plasmacytoma; Blastomyces; Multiple myeloma; Cytology; Blastomycosis; Internal medicine","score_opus":0.017185492125527994,"score_gpt":0.27407279933390327,"score_spread":0.25688730720837527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973423007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845142,0.00020036112,0.000010051803,0.0009925031,0.00004729488,0.00031470534,0.000023404646,0.00002083822,0.013876691],"genre_scores_gemma":[0.99833643,0.00003169528,0.0008833893,0.0000781986,0.00003479647,0.000015834403,0.000015643944,0.000008408413,0.00059562706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898463,0.0000869357,0.00026351074,0.00017154703,0.00024872852,0.00024464808],"domain_scores_gemma":[0.99916697,0.0001669382,0.0001272732,0.00040173164,0.00008599117,0.0000511121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009728611,0.00010766367,0.00031313067,0.000059268725,0.00004340139,0.0000022900128,0.00016829756,0.00011231358,0.00027167244],"category_scores_gemma":[0.00021586644,0.000057984216,0.00013557199,0.00017240428,0.000333176,0.000022628737,0.00009347304,0.00014220469,0.000012249739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006019094,0.00087928784,0.74042773,0.00007329467,0.00011726483,0.00031000574,0.000052403127,0.0000025484367,0.2511724,0.0010366725,0.002453972,0.0028725243],"study_design_scores_gemma":[0.0014771696,0.00041893084,0.8673554,0.000024430157,0.000055724955,0.0003035811,0.00003287366,0.000034755154,0.12847294,0.00049802155,0.0012760363,0.00005012599],"about_ca_topic_score_codex":0.00010498362,"about_ca_topic_score_gemma":0.000023752102,"teacher_disagreement_score":0.12692767,"about_ca_system_score_codex":0.000021268279,"about_ca_system_score_gemma":0.00007908582,"threshold_uncertainty_score":0.29746228},"labels":[],"label_agreement":null},{"id":"W1974411638","doi":"10.1016/j.bbmt.2011.05.009","title":"Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation","year":2011,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Immunoglobulin light chain; Transplantation; Stem cell; Oncology; Cancer research; Internal medicine; Immunology; Genetics; Antibody; Biology","score_opus":0.01673536284212932,"score_gpt":0.22782392199875703,"score_spread":0.21108855915662772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974411638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977292,0.00029074278,0.0007466703,0.000026280744,0.000035394696,0.0004677208,0.00021553788,0.000019430892,0.0004690368],"genre_scores_gemma":[0.99672276,0.0010640235,0.001694709,0.000007776574,0.000008911309,0.000013942597,0.0004482029,0.000012403252,0.0000272579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915373,0.00008066747,0.00026683198,0.00022735671,0.000099084056,0.00017229709],"domain_scores_gemma":[0.9994708,0.00013402833,0.00012570216,0.00009269194,0.0000851587,0.00009167761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008333327,0.00014012083,0.0002751255,0.00013771749,0.000071179296,0.0000030317342,0.00003455336,0.000108998735,0.000010786867],"category_scores_gemma":[0.000004088144,0.000108718596,0.000032613956,0.000065752516,0.0001361775,0.00006804477,0.000004558469,0.0000688162,7.7370447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002238098,0.00033182767,0.8746698,0.00074860366,0.00021089654,0.000020855548,0.0022730266,7.054984e-7,0.11553308,0.00018551917,5.776616e-7,0.0037870228],"study_design_scores_gemma":[0.008101164,0.0016890394,0.91887826,0.00008364078,0.0005550274,0.00004810022,0.000161283,0.00001922411,0.07032522,0.000038778937,0.0000027356878,0.000097536235],"about_ca_topic_score_codex":0.00013086933,"about_ca_topic_score_gemma":0.0005536012,"teacher_disagreement_score":0.04520786,"about_ca_system_score_codex":0.000006342377,"about_ca_system_score_gemma":0.000077157056,"threshold_uncertainty_score":0.44334158},"labels":[],"label_agreement":null},{"id":"W1974511383","doi":"10.1016/j.leukres.2010.05.002","title":"Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Bortezomib; Multiple myeloma; Internal medicine; Refractory (planetary science); Medicine; Fluorescence in situ hybridization; Cytogenetics; Oncology; Adverse effect; Gastroenterology; Biology; Chromosome","score_opus":0.030969004063272687,"score_gpt":0.3650718684054194,"score_spread":0.3341028643421467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974511383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968643,0.000021792523,0.000002438574,0.0000102928425,0.00001412725,0.0022849706,0.00010906942,0.000026748998,0.0006662705],"genre_scores_gemma":[0.99848616,0.000030802483,0.00060262444,0.0000027838169,0.000030269235,0.000115859264,0.00020057648,0.00007781872,0.0004531275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959997,0.00042757162,0.00045965982,0.00050702394,0.0016868046,0.000919228],"domain_scores_gemma":[0.9963297,0.0011360303,0.00015628427,0.000998982,0.00086619385,0.00051278365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008346107,0.00033000624,0.0007729693,0.00083822553,0.00008188011,0.000010876909,0.0002642678,0.00025823398,0.00021864363],"category_scores_gemma":[0.0013514209,0.00017599639,0.00013870842,0.0013098471,0.0005909477,0.00011736092,0.00010500889,0.0012226602,0.000024239807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068099976,0.0010315789,0.9006935,0.00025422493,0.00040273237,0.00042361353,0.00014730741,0.000036642192,0.02200573,0.0000013341877,0.00007435172,0.006829041],"study_design_scores_gemma":[0.041279707,0.02749948,0.8910885,0.00031203436,0.000053717275,0.000012684954,0.000035045126,0.0005532675,0.038990095,8.8271895e-7,0.000028018756,0.00014659908],"about_ca_topic_score_codex":0.0037025379,"about_ca_topic_score_gemma":0.0017132517,"teacher_disagreement_score":0.026820265,"about_ca_system_score_codex":0.0010105717,"about_ca_system_score_gemma":0.00192695,"threshold_uncertainty_score":0.7176925},"labels":[],"label_agreement":null},{"id":"W1975076850","doi":"10.1016/j.jmir.2012.03.031","title":"A Literature Review to Evaluate How Anxiety Levels of Multiple Myeloma Patients with Bone Metastases Fluctuate Compared to Patients with Bone Metastases from Other Cancers","year":2012,"lang":"en","type":"review","venue":"Journal of medical imaging and radiation sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Michener Institute; University of Toronto","funders":"","keywords":"Multiple myeloma; Medicine; Bone pain; Anxiety; Cancer; Prostate cancer; Bone metastasis; Oncology; Breast cancer; Internal medicine; Radiology","score_opus":0.0576734318894082,"score_gpt":0.37375376892621154,"score_spread":0.3160803370368033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975076850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016828613,0.9785451,0.00020477737,0.0016849285,0.00019121532,0.001363355,0.0011655159,0.000008628698,0.000007816339],"genre_scores_gemma":[0.02515479,0.9684775,0.005126389,0.0007213202,0.0002332403,0.000041541556,0.00019360632,0.000033160308,0.000018444078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936417,0.0005256134,0.00095200184,0.00045052808,0.0039535915,0.00047658134],"domain_scores_gemma":[0.9958138,0.00049400213,0.0012036017,0.0002609816,0.00093384425,0.0012937614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021019725,0.00044190302,0.0022372636,0.0006143704,0.0001560991,0.00013305315,0.00031722037,0.00008075646,0.00014625944],"category_scores_gemma":[0.0013790288,0.00021200167,0.00023564298,0.0012031681,0.00033488896,0.00046984406,0.000083142055,0.00043184287,0.000004324343],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022647632,0.00027142427,0.028343685,0.0034548372,0.00059250183,0.00004481774,0.00023804537,0.0000022365493,0.0000011093855,4.685354e-7,0.0017089243,0.9651155],"study_design_scores_gemma":[0.013190568,0.0017983884,0.09189796,0.2224713,0.0071691913,0.00027937678,0.00020095297,0.00026608937,0.000019907975,0.0000037066827,0.6619235,0.0007790509],"about_ca_topic_score_codex":0.00013841203,"about_ca_topic_score_gemma":0.000034316156,"teacher_disagreement_score":0.9643364,"about_ca_system_score_codex":0.00019038243,"about_ca_system_score_gemma":0.0010904514,"threshold_uncertainty_score":0.86451775},"labels":[],"label_agreement":null},{"id":"W1975136159","doi":"10.1182/blood-2009-11-252072","title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institutes of Health","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Venous thrombosis; Thrombosis; Hazard ratio; Internal medicine; Gastroenterology; Multiple myeloma; Population; Macroglobulinemia; Confidence interval; Monoclonal; Immunology; Monoclonal antibody; Antibody","score_opus":0.021975873521951683,"score_gpt":0.2930616481460501,"score_spread":0.27108577462409844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975136159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99899423,0.00003588721,0.0000023323341,0.00004347693,0.000038324182,0.0008119741,0.000035464436,0.000014487816,0.000023794799],"genre_scores_gemma":[0.9989347,0.0000032861187,0.00091029814,0.000009556761,0.000047789526,0.00004563269,0.000030220517,0.000012604367,0.0000059420177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914783,0.000041522107,0.00020489795,0.00023749191,0.00019125051,0.0001770205],"domain_scores_gemma":[0.99945784,0.00014479081,0.00005456743,0.0001839233,0.000036483172,0.00012239747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001155747,0.0001126491,0.00028528692,0.00011310503,0.00004006011,0.000013216148,0.000036793535,0.00005339041,0.00001799625],"category_scores_gemma":[0.00015905157,0.00009605025,0.000024305697,0.00009512584,0.00004886264,0.00003894816,0.000022857776,0.00011797429,9.396785e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003800947,0.003405413,0.9206408,0.000049341932,0.000054322423,0.000080534344,0.00022059897,6.1959827e-7,0.0738854,0.0000025742486,5.493488e-7,0.001279742],"study_design_scores_gemma":[0.016181307,0.0011473043,0.9752971,0.000027252794,0.00007674778,0.00001049244,0.00006653404,0.0006513126,0.006448141,0.000018390947,0.0000019629365,0.00007348996],"about_ca_topic_score_codex":0.0009479196,"about_ca_topic_score_gemma":0.0014482083,"teacher_disagreement_score":0.06743727,"about_ca_system_score_codex":0.000010937379,"about_ca_system_score_gemma":0.000065333246,"threshold_uncertainty_score":0.39168155},"labels":[],"label_agreement":null},{"id":"W1975511462","doi":"10.1016/j.bbmt.2014.11.124","title":"Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study","year":2015,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Busulfan; Internal medicine; Proportional hazards model; Hematopoietic stem cell transplantation; Transplantation; Hematopoietic cell; Retrospective cohort study; Multivariate analysis; Oncology; Gastroenterology; Haematopoiesis; Stem cell","score_opus":0.03855524417234216,"score_gpt":0.32996570864188074,"score_spread":0.29141046446953855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975511462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712586,0.000337807,0.00031547406,0.0001988676,0.00012771177,0.0017858391,0.00004523296,0.000017894907,0.00004532617],"genre_scores_gemma":[0.99773824,0.00092401204,0.0009565793,0.00007822304,0.000060322673,0.000115306895,0.000093883435,0.000013959564,0.000019448207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983011,0.0003088628,0.0005658471,0.0003557688,0.0001936036,0.0002748471],"domain_scores_gemma":[0.99920315,0.0002597628,0.000097955235,0.0001720879,0.00006861569,0.00019842027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068841584,0.00018125931,0.00040603406,0.00017299273,0.000050729843,0.00000994606,0.00009798978,0.00012128543,0.0000039292686],"category_scores_gemma":[0.000052408803,0.00011851456,0.0000732867,0.00014437543,0.000065282744,0.00005166,0.000013297357,0.00018698208,0.0000048978814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020352225,0.0019911216,0.97734004,0.00022450228,0.0001703318,0.0001934975,0.008420769,0.000011497131,0.0073418156,0.0000032586242,0.000002169123,0.0022657707],"study_design_scores_gemma":[0.017463418,0.0049209646,0.97239345,0.000027433154,0.00095075136,0.0000412167,0.001922135,0.000022255677,0.002130644,0.000008751069,0.0000028031252,0.00011617098],"about_ca_topic_score_codex":0.00023319403,"about_ca_topic_score_gemma":0.00041969997,"teacher_disagreement_score":0.015428196,"about_ca_system_score_codex":0.000013531654,"about_ca_system_score_gemma":0.00008771452,"threshold_uncertainty_score":0.48328835},"labels":[],"label_agreement":null},{"id":"W1975539073","doi":"10.3816/clml.2011.n.005","title":"Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Regimen; Adverse effect; Oncology; Refractory (planetary science); Thalidomide; Population","score_opus":0.04915552958730707,"score_gpt":0.33045641490591665,"score_spread":0.2813008853186096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975539073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953876,0.00008502495,0.00007800522,0.000037664733,0.00013617947,0.0038763096,0.000049333034,0.00006303476,0.00028681936],"genre_scores_gemma":[0.9977863,0.000045084125,0.0016489277,0.000044064254,0.000038939,0.00012911718,0.00015639701,0.00006557361,0.000085590815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964906,0.00024059249,0.0014917365,0.00068921305,0.0005074461,0.0005804193],"domain_scores_gemma":[0.993456,0.004737094,0.0005166253,0.00055714155,0.00028785702,0.0004452753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052536675,0.0004296209,0.0013387995,0.00034284414,0.000077769444,0.0000053088943,0.00019066349,0.00036932103,0.00001772773],"category_scores_gemma":[0.0044407067,0.00031123203,0.00026430155,0.0004038128,0.0005146549,0.00012774054,0.00009064866,0.0002591221,0.000009137316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026427016,0.0028340386,0.8940939,0.0007077264,0.00040195658,0.00022627023,0.00036681723,0.0000032467565,0.001006268,0.0001944686,0.000010377996,0.07372792],"study_design_scores_gemma":[0.061384857,0.010511782,0.9115741,0.0008135078,0.0002874024,0.000019571868,0.0000794613,0.0009114323,0.01409836,0.000048890193,0.000025121275,0.00024548458],"about_ca_topic_score_codex":0.00030912232,"about_ca_topic_score_gemma":0.00008016731,"teacher_disagreement_score":0.07348243,"about_ca_system_score_codex":0.00037727586,"about_ca_system_score_gemma":0.00047034683,"threshold_uncertainty_score":0.99993396},"labels":[],"label_agreement":null},{"id":"W1976379188","doi":"10.1111/j.1365-2141.2007.06750.x","title":"Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma","year":2007,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Multiple myeloma; Fluorescence in situ hybridization; Chromosome; Biology; Internal medicine; Overall survival; Multivariate analysis; Medicine; Pathology; Gene; Genetics","score_opus":0.011883053470565716,"score_gpt":0.2629970046912819,"score_spread":0.25111395122071617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976379188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977394,0.0005060422,0.00074388995,0.00022871167,0.000081485734,0.0005097716,0.000017572052,0.0000098586315,0.00016327303],"genre_scores_gemma":[0.995554,0.000051107192,0.0040594446,0.00017361864,0.000051764768,0.000007677568,0.000025409034,0.000025459936,0.000051570867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816376,0.00005230159,0.00059465365,0.00019266503,0.0005044059,0.00049224176],"domain_scores_gemma":[0.99867886,0.00020070233,0.00025482828,0.00012059508,0.00046271476,0.00028229345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039670634,0.00014059145,0.00055640686,0.00031625936,0.000054033797,0.000021822749,0.00009901083,0.00012389055,0.0001499491],"category_scores_gemma":[0.0006460132,0.00012456201,0.000089829446,0.00025025735,0.00011239805,0.0001468073,0.00003141029,0.0003806091,0.000018753726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023650464,0.0014696565,0.94013226,0.00008571613,0.0001711776,0.035198286,0.00006358913,8.0903675e-7,0.00014559367,0.000006703333,0.00029960487,0.020061536],"study_design_scores_gemma":[0.016006703,0.0011194438,0.9245955,0.0007537067,0.000051775954,0.056642506,0.00004029638,0.00005558048,0.00032722874,0.000015532907,0.0002916825,0.00010007216],"about_ca_topic_score_codex":0.00011066461,"about_ca_topic_score_gemma":0.0003828389,"teacher_disagreement_score":0.02144422,"about_ca_system_score_codex":0.00012454914,"about_ca_system_score_gemma":0.00014625443,"threshold_uncertainty_score":0.5079491},"labels":[],"label_agreement":null},{"id":"W1977036406","doi":"10.1182/blood-2007-05-088666","title":"A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Ubiquitin; Transactivation; Biology; Ectopic expression; Cyclin D1; Cell culture; Cell cycle; Cell biology; Cyclin; Protein degradation; Cyclin D; Mdm2; Ubiquitin ligase; Molecular biology; Cell; Gene expression; Biochemistry; Genetics; Gene","score_opus":0.03408757011683462,"score_gpt":0.31812853618380676,"score_spread":0.28404096606697216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977036406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629253,0.0005680675,0.0014919464,0.00011201564,0.000038407157,0.00092754903,0.00003396838,0.000063494525,0.00047202207],"genre_scores_gemma":[0.9937805,0.000028765917,0.0049760775,0.000017806173,0.00009692262,0.000037198726,0.0006500918,0.000023895072,0.00038876486],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983828,0.00011280434,0.0003817346,0.00032858498,0.00040558598,0.00038847057],"domain_scores_gemma":[0.99908876,0.00013598312,0.00019511962,0.0002761415,0.00015671577,0.00014727775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043689643,0.00017233669,0.00030108372,0.00010487786,0.00008359233,0.000017594139,0.000091449794,0.00018169309,0.00008905665],"category_scores_gemma":[0.00041144184,0.00014016715,0.00008691396,0.00018015788,0.000118271164,0.00023318508,0.000081496044,0.00013587126,0.000012306723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000996408,0.00051830214,0.061210956,0.00008969976,0.00010214654,0.000012743162,0.00012305463,1.2846637e-7,0.9316922,0.00013114828,0.000067882895,0.005055319],"study_design_scores_gemma":[0.005135496,0.00016939742,0.105944015,0.00023135784,0.00010341301,0.00006411304,0.000065206565,0.00004912111,0.88776344,0.000309008,0.00006492263,0.000100533274],"about_ca_topic_score_codex":0.00029584047,"about_ca_topic_score_gemma":0.000009538189,"teacher_disagreement_score":0.04473306,"about_ca_system_score_codex":0.00004858582,"about_ca_system_score_gemma":0.000055817065,"threshold_uncertainty_score":0.571585},"labels":[],"label_agreement":null},{"id":"W1977204472","doi":"10.4103/0378-6323.19732","title":"Thalidomide: Current status","year":2006,"lang":"en","type":"article","venue":"Indian Journal of Dermatology Venereology and Leprology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thalidomide; Current (fluid); Medicine; Internal medicine; Multiple myeloma; Engineering; Electrical engineering","score_opus":0.015356084386498681,"score_gpt":0.3065127537582657,"score_spread":0.29115666937176704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977204472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98084384,0.01204586,0.00011739731,0.0056530624,0.00036300946,0.00014607816,0.000005380811,0.000011517955,0.0008138637],"genre_scores_gemma":[0.9982636,0.00062718475,0.00055864564,0.00025261915,0.00020994153,0.00000732049,0.000018375084,0.000012130673,0.00005020817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834895,0.00027872814,0.00050991756,0.0001872522,0.00012060588,0.0005545649],"domain_scores_gemma":[0.9989395,0.00019839338,0.00027684885,0.00015807085,0.0001563434,0.0002708387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014857814,0.00016023622,0.0006120172,0.00042696184,0.000091425965,0.0000062668023,0.00009037808,0.00025445837,0.000120246186],"category_scores_gemma":[0.00013119727,0.0001221427,0.00010898121,0.000103347964,0.00059114065,0.0000702832,0.00004334636,0.00057373545,0.000030315014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011011022,0.00026456537,0.9652572,0.000055415112,0.00020503649,0.015195539,0.00011927958,0.000002609235,0.0002648831,0.0018254298,0.0011652343,0.014543668],"study_design_scores_gemma":[0.011602001,0.000866091,0.67136115,0.000044902612,0.00021155439,0.2675542,0.00008062717,0.00003253653,0.0020636595,0.008762914,0.03725385,0.00016650988],"about_ca_topic_score_codex":0.000031491203,"about_ca_topic_score_gemma":0.0000372029,"teacher_disagreement_score":0.29389608,"about_ca_system_score_codex":0.0000373373,"about_ca_system_score_gemma":0.00030987785,"threshold_uncertainty_score":0.4980834},"labels":[],"label_agreement":null},{"id":"W1977303037","doi":"10.3747/co.21.1798","title":"Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations","year":2014,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Thalidomide; Regimen; Internal medicine; Oncology; Dexamethasone; Adverse effect; Transplantation; Hazard ratio; Lenalidomide; Confidence interval","score_opus":0.35565185207843014,"score_gpt":0.5517728959629759,"score_spread":0.1961210438845457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977303037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000620974,0.9909581,0.000011420344,0.00023516567,0.0004141747,0.007919495,0.00004983848,0.000036299356,0.00036929466],"genre_scores_gemma":[0.00004983817,0.9974019,0.00022820396,0.00018097376,0.00017877597,0.0014483802,0.00035855075,0.00004048299,0.000112901624],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99462664,0.0018867038,0.0021747556,0.0006421218,0.00022881974,0.00044098689],"domain_scores_gemma":[0.9943821,0.0037859331,0.00060556654,0.00064562756,0.00014714578,0.00043361622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015032425,0.00043850168,0.0072423033,0.0002882029,0.00007100932,0.000018712073,0.000116172916,0.00042640226,0.0001158365],"category_scores_gemma":[0.008213127,0.0002950279,0.0005529255,0.00021271151,0.00022640906,0.000035176636,0.000140881,0.0010536935,0.00034197565],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006293138,0.0005554211,0.00070952176,0.7402997,0.00033511818,0.00016547569,0.000006122012,2.2993267e-9,3.3175684e-9,0.00005500846,0.0019379962,0.25592935],"study_design_scores_gemma":[0.002005842,0.0003751825,0.00017544549,0.4309286,0.0076571032,0.0006181674,0.0000033490546,0.000028235449,7.463988e-9,0.000016554368,0.55801,0.00018157194],"about_ca_topic_score_codex":0.0000089610685,"about_ca_topic_score_gemma":0.00011715863,"teacher_disagreement_score":0.55607194,"about_ca_system_score_codex":0.00040443504,"about_ca_system_score_gemma":0.0010801089,"threshold_uncertainty_score":0.9999502},"labels":[],"label_agreement":null},{"id":"W1977487021","doi":"10.3747/co.20.1055","title":"Randomized Clinical Trial of Zoledronic Acid in Multiple Myeloma Patients Undergoing High-Dose Chemotherapy and Stem-Cell Transplantation","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Zoledronic acid; Multiple myeloma; Internal medicine; Bisphosphonate; Autologous stem-cell transplantation; Regimen; Population; Dexamethasone; Transplantation; Gastroenterology; Randomized controlled trial; Chemotherapy; Surgery; Oncology; Osteoporosis","score_opus":0.09703479790358198,"score_gpt":0.40859043801214306,"score_spread":0.31155564010856107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977487021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947738,0.0006292546,0.000117799995,0.00021163277,0.0005155127,0.0035515982,0.000010479155,0.000017292337,0.00017261792],"genre_scores_gemma":[0.9942687,0.0047955415,0.0003325786,0.000033670323,0.00008975517,0.00029916386,0.00012156672,0.000016923692,0.000042089763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975856,0.00075159903,0.00082096434,0.00030527753,0.00023179963,0.0003047438],"domain_scores_gemma":[0.9976342,0.001667011,0.0002355133,0.00016892607,0.000109806715,0.00018457108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069900247,0.00016518986,0.0009288907,0.00016907664,0.000032307784,0.000008308323,0.0000696677,0.00016144995,0.00009627619],"category_scores_gemma":[0.00024101633,0.00012510606,0.00014871,0.00010503446,0.00021270248,0.00009020635,0.000023597944,0.0002671082,0.00003182166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4582809,0.0038837264,0.17765915,0.00025739506,0.00010050993,0.0000111805975,0.00032172722,6.476344e-7,0.00019542138,0.000013735261,0.000055923792,0.3592197],"study_design_scores_gemma":[0.82043153,0.002606762,0.17494975,0.0000921023,0.00008357575,0.0000028659642,0.000042838758,0.0008266263,0.0006799385,0.00007147002,0.00013064654,0.00008188305],"about_ca_topic_score_codex":0.00008811733,"about_ca_topic_score_gemma":0.00009653049,"teacher_disagreement_score":0.36215064,"about_ca_system_score_codex":0.00013115694,"about_ca_system_score_gemma":0.00023777028,"threshold_uncertainty_score":0.5101677},"labels":[],"label_agreement":null},{"id":"W1977865587","doi":"10.2217/fon.10.105","title":"The Potential of Immunomodulatory Drugs in the Treatment of Solid Tumors","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Solid tumor; Intensive care medicine; Oncology; Pharmacology; Internal medicine; Cancer","score_opus":0.02649924056177988,"score_gpt":0.38462041893369553,"score_spread":0.35812117837191565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977865587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027016504,0.9929841,3.2831466e-7,0.00032866295,0.00059996126,0.0019479604,0.00008692034,0.000006394215,0.0013440207],"genre_scores_gemma":[0.0023916294,0.9958476,0.00007431249,0.0000153395,0.00078132574,0.0003235626,0.00014940755,0.000028999599,0.00038784975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977933,0.00052494014,0.0007252089,0.00025256092,0.00033196513,0.00037201933],"domain_scores_gemma":[0.99806976,0.0005138139,0.000467141,0.000784819,0.00008620813,0.00007826147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041358423,0.00030956956,0.0018898138,0.00016924125,0.00008005248,0.000004652078,0.00035431742,0.000484258,0.00005989314],"category_scores_gemma":[0.000045466335,0.00012614335,0.0006531037,0.00021640271,0.00032299725,0.000013641704,0.000039336937,0.00057474873,0.0000246628],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022032094,0.0011179713,0.000028474236,0.0011070292,0.00044869518,0.00021749857,0.00039529195,5.3756285e-8,0.000013355462,0.0000936114,0.0002215614,0.9961361],"study_design_scores_gemma":[0.00203959,0.002800766,0.0016992743,0.00065728155,0.0006716332,0.0002596124,0.00034006964,0.00000193714,0.000011473898,0.000018071152,0.99142253,0.000077749646],"about_ca_topic_score_codex":0.00011566666,"about_ca_topic_score_gemma":0.00015275026,"teacher_disagreement_score":0.9960584,"about_ca_system_score_codex":0.0003216358,"about_ca_system_score_gemma":0.0012644381,"threshold_uncertainty_score":0.5143976},"labels":[],"label_agreement":null},{"id":"W1978070566","doi":"10.1016/j.yebeh.2014.03.020","title":"Nitric oxide mediates the anticonvulsant effects of thalidomide on pentylenetetrazole-induced clonic seizures in mice","year":2014,"lang":"en","type":"article","venue":"Epilepsy & Behavior","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire en Santé Mentale de Québec","funders":"","keywords":"Thalidomide; Anticonvulsant; Nitric oxide; Pharmacology; Epilepsy; Molsidomine; Medicine; Sedative; Chemistry; Internal medicine","score_opus":0.019604390894998755,"score_gpt":0.30859275123112107,"score_spread":0.2889883603361223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978070566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739736,0.00041000464,0.0000024879898,0.00024458853,0.00014087913,0.0014669521,0.00000867337,0.000036771457,0.00029229835],"genre_scores_gemma":[0.99896586,0.00015835048,0.000091449416,0.00018901884,0.00009620922,0.0002898835,0.000033922457,0.000039407987,0.00013587729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976802,0.0003082505,0.0004182103,0.000368077,0.00060557923,0.0006197021],"domain_scores_gemma":[0.99777716,0.0011951259,0.00013579498,0.00056214805,0.000074542775,0.00025523923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000417779,0.00026780172,0.00052561663,0.00029926628,0.00007814859,0.00001893704,0.00025403808,0.00012079071,0.00006141161],"category_scores_gemma":[0.00076697423,0.0001687603,0.00017164844,0.00034546547,0.00010470566,0.000055208184,0.00006564094,0.00042642895,0.0001241253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005406491,0.0015703257,0.6236503,0.00014752164,0.00007762668,0.00061811117,0.00018811306,0.0000026051732,0.35184893,0.000076058095,0.00014873172,0.021131005],"study_design_scores_gemma":[0.004186404,0.0006099385,0.70633304,0.00019648575,0.00016019017,0.000034180044,0.00004375021,0.00007052145,0.2881939,0.000013272388,0.000052596195,0.000105734674],"about_ca_topic_score_codex":0.0008930479,"about_ca_topic_score_gemma":0.000100204226,"teacher_disagreement_score":0.08268269,"about_ca_system_score_codex":0.00011696106,"about_ca_system_score_gemma":0.00010497842,"threshold_uncertainty_score":0.68818456},"labels":[],"label_agreement":null},{"id":"W1978987454","doi":"10.1016/j.bbmt.2011.12.243","title":"Presenting Features of Multiple Myeloma in Patients Under the Age of 50 in Newfoundland and Labrador","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Multiple myeloma; Stage (stratigraphy); Hematologic malignancy; Malignancy; Internal medicine; Gastroenterology; Surgery; Pediatrics","score_opus":0.01621251741827924,"score_gpt":0.27225360708629637,"score_spread":0.25604108966801714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978987454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985986,0.00089653867,0.000008029657,0.00004910065,0.000018195537,0.00028387926,0.00003820469,0.0000019211723,0.00010556768],"genre_scores_gemma":[0.9991411,0.0004639212,0.00021971186,0.000009686859,0.000009592827,0.0000070924343,0.00013302789,0.0000035976118,0.000012292867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994732,0.000073077295,0.00017731689,0.00008153231,0.00006517973,0.0001296922],"domain_scores_gemma":[0.999669,0.00016708137,0.00005829932,0.00005547659,0.000020707845,0.000029412073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013218069,0.00006103144,0.00017687785,0.00009696829,0.000014117774,0.0000012389972,0.000023871045,0.000062235726,0.0000030348258],"category_scores_gemma":[0.000024442772,0.000039634684,0.00001763382,0.00005988142,0.00012367396,0.00004432124,0.0000078225885,0.00005934223,7.2380956e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006955515,0.0002692832,0.9323229,0.0002814809,0.000059673912,0.0000024864244,0.0010126121,4.3236523e-7,0.062731266,0.00008960768,7.8172565e-7,0.0025338936],"study_design_scores_gemma":[0.0061398474,0.00021495885,0.98242944,0.0000796972,0.00006809108,0.0000073948554,0.000105527935,0.0000056486556,0.0108739985,0.000041346357,0.0000044026233,0.00002963146],"about_ca_topic_score_codex":0.0018912797,"about_ca_topic_score_gemma":0.0020942718,"teacher_disagreement_score":0.051857267,"about_ca_system_score_codex":0.0000040542463,"about_ca_system_score_gemma":0.000010499776,"threshold_uncertainty_score":0.28590617},"labels":[],"label_agreement":null},{"id":"W1980168719","doi":"10.1111/bjh.13004","title":"Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma","year":2014,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Mayo Clinic","keywords":"Bortezomib; Multiple myeloma; Medicine; Dexamethasone; Cyclophosphamide; Induction therapy; Oncology; Internal medicine; Chemotherapy","score_opus":0.018039258852553048,"score_gpt":0.26081894217098844,"score_spread":0.24277968331843539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980168719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860613,0.0018809517,0.00014226332,0.010618539,0.000223449,0.000987422,0.000029139936,0.000018157341,0.00003882416],"genre_scores_gemma":[0.98148364,0.0016530501,0.0013658492,0.014361625,0.0005510188,0.000048775997,0.0003200312,0.00013342357,0.00008258028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965608,0.0006452761,0.0007909692,0.00044523086,0.0008665604,0.00069118],"domain_scores_gemma":[0.9974321,0.00061763177,0.00077998004,0.000303836,0.0005822836,0.00028413284],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00042870452,0.00044610427,0.001809396,0.0004901214,0.00011913901,0.00008246615,0.00020037242,0.00066408777,0.000055156037],"category_scores_gemma":[0.00037045858,0.00035053398,0.00012387612,0.00024264668,0.00037363148,0.00020746296,0.00004193095,0.0029586197,0.0000046579253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045262934,0.0005388777,0.7698908,0.00024974343,0.00073735934,0.15176521,0.000064489,0.000001307527,0.0000036044567,3.4689762e-7,0.0069392975,0.06528266],"study_design_scores_gemma":[0.037165735,0.004442699,0.88679725,0.0017421173,0.00014706317,0.06781542,0.000020651898,0.0000028299603,0.00005172525,0.0000118222315,0.0015097405,0.00029296847],"about_ca_topic_score_codex":0.00080843945,"about_ca_topic_score_gemma":0.0008314071,"teacher_disagreement_score":0.11690642,"about_ca_system_score_codex":0.00014654077,"about_ca_system_score_gemma":0.0002906515,"threshold_uncertainty_score":0.9998947},"labels":[],"label_agreement":null},{"id":"W1980756031","doi":"10.1016/j.bbmt.2008.07.007","title":"Comparison of Twin and Autologous Transplants for Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"Medicine; Multiple myeloma; Transplantation; Proportional hazards model; Internal medicine; Confounding; Surgery; Confidence interval; Relative risk; Cumulative incidence; Histocompatibility; Oncology; Multivariate analysis; Melphalan; Human leukocyte antigen; Immunology; Antigen","score_opus":0.0463828855340538,"score_gpt":0.33444951563072134,"score_spread":0.28806663009666755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980756031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690336,0.0013637762,0.00078467984,0.000076762335,0.00002512423,0.0004539051,0.0003040177,0.000014260006,0.00007408993],"genre_scores_gemma":[0.9943204,0.0018027165,0.0034440744,0.000011398269,0.000014031133,0.000024861758,0.00035376096,0.0000066696784,0.000022086604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993403,0.000034619356,0.00024472913,0.0001675829,0.000062871644,0.00014988368],"domain_scores_gemma":[0.9995274,0.0002134211,0.000070062015,0.000063669286,0.000049785067,0.00007564924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006868642,0.00009713448,0.00035787982,0.00009152716,0.000059119084,9.216236e-7,0.000026012207,0.00010941381,0.0000053848007],"category_scores_gemma":[0.000021074722,0.00007838175,0.00004517944,0.000039020702,0.00023631523,0.00002800247,0.0000027224432,0.000048736205,2.8149913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001746254,0.00022856296,0.63595545,0.00061048387,0.00017350497,0.000017807955,0.0008009663,4.2788585e-7,0.35417923,0.00006902219,0.000006933709,0.006211352],"study_design_scores_gemma":[0.009607442,0.0018678983,0.6331278,0.00008575056,0.0003792748,0.00035844452,0.000057871952,0.00031328134,0.3540285,0.000054279233,0.000043450887,0.00007599466],"about_ca_topic_score_codex":0.000074070085,"about_ca_topic_score_gemma":0.000049365924,"teacher_disagreement_score":0.007861188,"about_ca_system_score_codex":0.0000022546405,"about_ca_system_score_gemma":0.000031557818,"threshold_uncertainty_score":0.3196315},"labels":[],"label_agreement":null},{"id":"W1981102741","doi":"10.1111/j.1365-2141.2004.04814.x","title":"Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Multiple Myeloma Research Foundation","keywords":"Fibroblast growth factor receptor 3; Molecular biology; Cancer research; Multiple myeloma; Biology; Cell culture; Chromosomal translocation; Tyrosine kinase; Fibroblast growth factor receptor; Fibroblast growth factor; Signal transduction; Receptor; Cell biology; Immunology; Biochemistry","score_opus":0.06970726264567276,"score_gpt":0.369823338292175,"score_spread":0.3001160756465022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981102741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855305,0.009557382,0.00007335518,0.0012152323,0.00014434604,0.00033412498,0.000025429632,0.0000101930145,0.00008687916],"genre_scores_gemma":[0.9929051,0.002138006,0.0046823816,0.00011503616,0.00007079437,0.000010944448,0.0000062227086,0.000022174876,0.00004936585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786115,0.00020459908,0.000976737,0.00019742802,0.00038465383,0.00037541625],"domain_scores_gemma":[0.9983311,0.00046137397,0.00037431988,0.0001292543,0.00048381978,0.00022013222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003121449,0.00015450137,0.001102368,0.00023909751,0.000048666647,0.000011275099,0.00015942017,0.00015028838,0.0001895116],"category_scores_gemma":[0.002861608,0.00013659958,0.00023508588,0.00018695738,0.00033581408,0.00012645684,0.000059269976,0.00046124007,0.000033322554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009207033,0.007600302,0.7446892,0.002094856,0.0051998356,0.1520167,0.0030239015,0.000051292882,0.024447002,0.0008319657,0.001599479,0.0492384],"study_design_scores_gemma":[0.04661111,0.008513383,0.64031225,0.0068703694,0.00017414993,0.21960042,0.001686887,0.00003261855,0.06619375,0.009039272,0.0005544828,0.00041129882],"about_ca_topic_score_codex":0.00018488965,"about_ca_topic_score_gemma":0.00019566242,"teacher_disagreement_score":0.10437699,"about_ca_system_score_codex":0.00012353924,"about_ca_system_score_gemma":0.00036273507,"threshold_uncertainty_score":0.55703694},"labels":[],"label_agreement":null},{"id":"W1981161460","doi":"10.1016/j.leukres.2009.01.010","title":"p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Research; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Intramedullary rod; Multiple myeloma; Bone marrow; Medicine; Pathology; Medullary cavity; Proliferation index; Plasmacytoma; Immunohistochemistry; Internal medicine; Anatomy","score_opus":0.09732688832183028,"score_gpt":0.4157256430816742,"score_spread":0.3183987547598439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981161460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266297,0.0001924405,0.000018811956,0.0010870544,0.000014473483,0.0011918987,0.000019186145,0.00009009276,0.0047230613],"genre_scores_gemma":[0.99683857,0.00007247283,0.0016141037,0.0001131136,0.000066757835,0.000029980825,0.0001346173,0.000039177085,0.0010911828],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961923,0.0002573418,0.00031560622,0.00043692597,0.002015584,0.0007822856],"domain_scores_gemma":[0.9977831,0.00040148763,0.00009778584,0.00054823497,0.0007741348,0.00039526128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008227453,0.00019032137,0.00037836994,0.0004115053,0.00023857935,0.000045820998,0.00020399332,0.00022696397,0.00029070448],"category_scores_gemma":[0.0011283354,0.00013630178,0.000096317504,0.0009361603,0.00024220545,0.0001712662,0.0000751467,0.00070819823,0.00009675275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014685131,0.0032143453,0.34517455,0.0003478794,0.00072734884,0.0021319122,0.0022387416,0.00004878818,0.13116565,0.00044771878,0.009212678,0.49060524],"study_design_scores_gemma":[0.010886932,0.0051618232,0.92595565,0.0010043096,0.000043141583,0.00006104872,0.00023655644,0.02139848,0.03341566,0.00024513103,0.001380251,0.00021103868],"about_ca_topic_score_codex":0.00014550793,"about_ca_topic_score_gemma":0.000022229404,"teacher_disagreement_score":0.58078104,"about_ca_system_score_codex":0.0009174683,"about_ca_system_score_gemma":0.00065107533,"threshold_uncertainty_score":0.55582255},"labels":[],"label_agreement":null},{"id":"W1982055936","doi":"10.1038/leu.2010.62","title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","year":2010,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Multiple myeloma; Internal medicine; Proportional hazards model; Oncology; N-terminal telopeptide; Bone disease; Anemia; Prognostic variable; Multivariate analysis; Surgery; Osteoporosis","score_opus":0.012762669748116708,"score_gpt":0.2628066936860707,"score_spread":0.250044023937954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982055936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972067,0.00003147725,0.00017990217,0.00023430542,0.000044690183,0.0018426495,0.00014104311,0.00003746306,0.0002817702],"genre_scores_gemma":[0.9952689,0.0000023970413,0.0033881129,0.00003912664,0.000044626257,0.0005620816,0.00049480755,0.000026462614,0.00017349653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989549,0.000019728705,0.00016652115,0.00030100727,0.0002297333,0.00032811565],"domain_scores_gemma":[0.99885786,0.00032255746,0.000042232572,0.00028911507,0.00012413046,0.00036411177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083302046,0.00014598023,0.00021174629,0.000099884426,0.000096281496,0.000025503718,0.00005716379,0.000053755244,0.000023073813],"category_scores_gemma":[0.0005799787,0.00010981893,0.000032809246,0.00013257132,0.00011335906,0.00007745763,0.00003781195,0.00018089524,0.000012849117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008489031,0.00033700562,0.9920764,0.00012832656,0.00004196092,0.000022057837,0.000029561186,0.0000032598439,0.00029918106,0.00031784465,0.0000439366,0.0058515947],"study_design_scores_gemma":[0.011839283,0.00031750364,0.9833192,0.00006986433,0.000065902976,0.000003971137,0.000012782554,0.0036754159,0.00004167481,0.00010928372,0.0004314516,0.00011364743],"about_ca_topic_score_codex":0.00011534162,"about_ca_topic_score_gemma":0.00033333874,"teacher_disagreement_score":0.01099038,"about_ca_system_score_codex":0.00010700144,"about_ca_system_score_gemma":0.00026150848,"threshold_uncertainty_score":0.4478286},"labels":[],"label_agreement":null},{"id":"W1982141093","doi":"10.14740/jmc.v5i12.1979","title":"Mania in a Patient With Multiple Myeloma After Using Bortezomib","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Mania; Regimen; Thalidomide; Dexamethasone; Internal medicine; Adverse effect; Proteasome inhibitor; Oncology; Carfilzomib; Autologous stem-cell transplantation; Lenalidomide; Vincristine; Chemotherapy; Bipolar disorder; Cyclophosphamide","score_opus":0.028156310400136518,"score_gpt":0.31785850544863403,"score_spread":0.28970219504849754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982141093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761695,0.00040737135,0.00034347022,0.0013107158,0.000064099666,0.00014512343,0.0000028338952,0.000005148186,0.0001042872],"genre_scores_gemma":[0.99647933,0.000055397377,0.002697469,0.0004901066,0.00023804349,0.0000054350944,0.000001873889,0.000015127415,0.000017204298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761087,0.00010351015,0.0004084454,0.00011697093,0.0014832562,0.0002769751],"domain_scores_gemma":[0.99866885,0.00030810706,0.00013708601,0.00013241947,0.00013850832,0.0006150055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043353863,0.000118686374,0.0003560714,0.00020807431,0.000026074662,0.000015247963,0.00007918965,0.000086907836,0.00041026162],"category_scores_gemma":[0.0013441049,0.00006840534,0.0000832516,0.00013900766,0.00008439419,0.00008199071,0.000037280905,0.0003750519,0.000008423159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071652774,0.001129186,0.78173256,0.00014040065,0.0001724369,0.103320256,0.00025958286,0.000012092949,0.00030107386,0.0000067102583,0.00059465435,0.105165765],"study_design_scores_gemma":[0.025844853,0.009020174,0.86070704,0.003391655,0.00019059498,0.07275104,0.000571219,0.014803467,0.0018941112,0.00003356221,0.010524715,0.00026758434],"about_ca_topic_score_codex":0.00019136694,"about_ca_topic_score_gemma":0.00022365357,"teacher_disagreement_score":0.104898185,"about_ca_system_score_codex":0.000120532575,"about_ca_system_score_gemma":0.00029235962,"threshold_uncertainty_score":0.4492077},"labels":[],"label_agreement":null},{"id":"W1982556802","doi":"10.1016/j.neuroscience.2009.07.006","title":"Thalidomide inhibition of vascular remodeling and inflammatory reactivity in the quinolinic acid–injected rat striatum","year":2009,"lang":"en","type":"article","venue":"Neuroscience","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Astrogliosis; Quinolinic acid; Gliosis; Glial fibrillary acidic protein; Neuroprotection; Striatum; Astrocyte; Endocrinology; Pathology; Internal medicine; Biology; Central nervous system; Medicine; Biochemistry; Dopamine","score_opus":0.03995949820781159,"score_gpt":0.31434589262644796,"score_spread":0.2743863944186364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982556802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99878496,0.00010332887,0.00007953312,0.0003576007,0.00004260544,0.00037501007,0.0000017915785,0.000015372323,0.00023980619],"genre_scores_gemma":[0.99940217,0.00017586788,0.00009077044,0.0002897301,0.000020046085,0.000005660404,0.0000022546296,0.0000034135471,0.0000100770985],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988227,0.00014268149,0.00017744591,0.00024292884,0.000407983,0.00020630042],"domain_scores_gemma":[0.9994911,0.000076427394,0.00005940207,0.00026167172,0.000042302312,0.00006910134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004988966,0.000081677324,0.00015050507,0.00011476751,0.00006422899,0.000019941035,0.00007711786,0.00003823385,0.0000013756608],"category_scores_gemma":[0.0007091395,0.00005429418,0.000039306,0.00033547851,0.00011392869,0.00016972818,0.000024994635,0.00019789032,0.0000011141444],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018510659,0.0001980116,0.032389887,0.000020592059,0.0000012945372,0.00010163788,0.00022582068,0.000019044459,0.95649487,0.000075187076,0.00001063219,0.0102779465],"study_design_scores_gemma":[0.0019588058,0.00040126508,0.92305005,0.0000749979,0.000011279143,0.000047851714,0.00005320272,0.004306382,0.06974975,0.00023342682,0.000059731996,0.000053256645],"about_ca_topic_score_codex":0.000039564013,"about_ca_topic_score_gemma":0.000011743874,"teacher_disagreement_score":0.89066017,"about_ca_system_score_codex":0.000025371764,"about_ca_system_score_gemma":0.000089349356,"threshold_uncertainty_score":0.22140525},"labels":[],"label_agreement":null},{"id":"W1982866386","doi":"10.1182/blood-2004-05-1976","title":"Population dynamics and clonal dominance in tumors?","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Biology; Population; Evolutionary biology; Genetics; Demography","score_opus":0.01193816177904058,"score_gpt":0.2834473483126253,"score_spread":0.27150918653358475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982866386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99881536,0.00018175392,0.000022067536,0.00026678666,0.0000085475685,0.0001644178,0.000005627368,0.000010276461,0.0005251651],"genre_scores_gemma":[0.99826586,0.00003255154,0.0014740878,0.000023540877,0.000023659737,0.000010687768,0.000051787672,0.0000053174654,0.00011251838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995869,0.000006924179,0.000077238125,0.00010350301,0.00010387241,0.00012160463],"domain_scores_gemma":[0.99983203,0.000010357373,0.000013599524,0.000070806294,0.000011107364,0.00006211271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004165874,0.000046921094,0.00009416929,0.00005063759,0.000019077634,0.000005592948,0.000014605981,0.00002456008,0.000007210552],"category_scores_gemma":[0.000043207107,0.000039450533,0.000013317674,0.000069698224,0.000016153663,0.000034035846,0.000012236188,0.00006018337,0.000008479894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008965952,0.00043783992,0.9919972,0.00002729516,0.000014038078,0.00033372128,0.000035768997,0.000004038463,0.00025438334,0.0012882682,0.0000010065421,0.005516791],"study_design_scores_gemma":[0.008590041,0.00012519062,0.9894212,0.00007107871,0.00001238563,0.00010333883,0.000011284236,0.00026064657,0.0007200109,0.00064728945,0.0000037684138,0.00003377615],"about_ca_topic_score_codex":0.00055849494,"about_ca_topic_score_gemma":0.0005580083,"teacher_disagreement_score":0.008500381,"about_ca_system_score_codex":0.00005336508,"about_ca_system_score_gemma":0.00002687187,"threshold_uncertainty_score":0.1608746},"labels":[],"label_agreement":null},{"id":"W1984089719","doi":"10.1016/j.jecm.2014.01.005","title":"Multiple Osteolytic Lesions with a Non-Traumatic Spinal Compression Fracture: A Case Report of Nonsecretory Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Mesenchymal stem cell; In vivo; Scaffold; In vitro; Calcium; Biomedical engineering; Regeneration (biology); Cell culture; Medicine; Cell biology; Pathology; Biology; Biochemistry; Internal medicine; Biotechnology","score_opus":0.0758956360756188,"score_gpt":0.43085825120585586,"score_spread":0.3549626151302371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984089719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993948,0.0012606749,0.0021729926,0.0010416099,0.00037209177,0.0007290937,0.0000048782085,0.000018345243,0.00045234166],"genre_scores_gemma":[0.99175423,0.00004790774,0.006739259,0.00043705862,0.0008269091,0.000026277123,0.000020011375,0.00004714313,0.00010117241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952009,0.00031447184,0.0023901744,0.0003881958,0.0012821543,0.00042411033],"domain_scores_gemma":[0.99435276,0.0018573828,0.0015134302,0.00064436387,0.0004884148,0.0011436596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015746676,0.00036216053,0.0016103593,0.0003007171,0.00015275451,0.0000102303375,0.00021073915,0.00020081516,0.00036520846],"category_scores_gemma":[0.00395396,0.00020635508,0.00038757815,0.00023793025,0.0008411244,0.00015364157,0.000090149035,0.0008747568,0.000012622198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03885987,0.011143451,0.49409828,0.00069307664,0.0019989647,0.2662634,0.0023846154,0.000032251566,0.15294395,0.00000957041,0.0046301084,0.02694247],"study_design_scores_gemma":[0.089181915,0.07577437,0.45605493,0.010815713,0.0011654485,0.2790579,0.0062112864,0.0077569913,0.07125159,0.000025260784,0.0021597731,0.0005448235],"about_ca_topic_score_codex":0.00028069143,"about_ca_topic_score_gemma":0.00002942866,"teacher_disagreement_score":0.08169236,"about_ca_system_score_codex":0.00013340153,"about_ca_system_score_gemma":0.00029270945,"threshold_uncertainty_score":0.8414916},"labels":[],"label_agreement":null},{"id":"W1984362058","doi":"10.1182/blood.v98.9.2791","title":"Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Isotype; Immunology; Peripheral blood mononuclear cell; Antibody; clone (Java method); Biology; Bone marrow; Molecular biology; Medicine; Monoclonal antibody; Gene","score_opus":0.055722715834416986,"score_gpt":0.30931302988990567,"score_spread":0.2535903140554887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984362058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912064,0.0025581399,0.0010494732,0.0012968604,0.00020753218,0.0025331306,0.00001573906,0.00014157168,0.000991118],"genre_scores_gemma":[0.9937412,0.00027963438,0.0029903678,0.00024064977,0.00025605012,0.00030212136,0.000037550242,0.000083086255,0.0020693433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726635,0.00015376169,0.00041538046,0.00064141466,0.00076780276,0.00075526256],"domain_scores_gemma":[0.99728173,0.0008572132,0.00019795225,0.0008707854,0.00030183647,0.0004904608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066649937,0.0003822728,0.00048455037,0.00011912084,0.00043109918,0.00009806139,0.00032972504,0.00013923293,0.00006841794],"category_scores_gemma":[0.0005048724,0.00022657849,0.00027638205,0.0003955361,0.00011752017,0.00017672258,0.000088767854,0.0004011314,0.00010472129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04449249,0.007084044,0.7898067,0.0011050515,0.009430254,0.0031072432,0.003823909,0.00038763322,0.103104144,0.0005719482,0.0010002339,0.036086354],"study_design_scores_gemma":[0.054209284,0.010924463,0.8557988,0.0027043326,0.006423889,0.0019826838,0.002002614,0.013239252,0.047656905,0.00024420605,0.0034912005,0.0013224031],"about_ca_topic_score_codex":0.00041174632,"about_ca_topic_score_gemma":0.00026629193,"teacher_disagreement_score":0.06599207,"about_ca_system_score_codex":0.00009688752,"about_ca_system_score_gemma":0.00038758584,"threshold_uncertainty_score":0.9239602},"labels":[],"label_agreement":null},{"id":"W1985864219","doi":"10.1056/nejmoa1411321","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1324,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Oncology; Proteasome inhibitor; Internal medicine; Pharmacology","score_opus":0.03364004799786217,"score_gpt":0.3132240272849626,"score_spread":0.27958397928710044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985864219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734291,0.002726479,0.009509334,0.012323681,0.00042099998,0.0005288944,0.000006472829,0.00001928259,0.0010357761],"genre_scores_gemma":[0.98275983,0.00043075008,0.0114998175,0.00047688215,0.0037196183,0.000005929191,0.000014391031,0.000028199922,0.0010645742],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99832875,0.00012390852,0.00053412205,0.00018255052,0.0005113841,0.00031927502],"domain_scores_gemma":[0.996837,0.0015773484,0.00025844155,0.00019738727,0.00034450155,0.0007852956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014951122,0.0001881153,0.0007267118,0.00026208904,0.000077817465,0.000011869092,0.0000947878,0.00008337878,0.00009231476],"category_scores_gemma":[0.0054048244,0.00011293129,0.000104838015,0.0001278976,0.000143915,0.00008673148,0.000022303895,0.0002989073,0.000003691597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014384543,0.00015753368,0.086497575,0.00020765034,0.0005395822,0.00025225047,0.00076992135,0.000007458058,0.022891508,0.00024404687,0.013501537,0.8605464],"study_design_scores_gemma":[0.6074893,0.01493446,0.13348155,0.0011736525,0.0008444079,0.004492134,0.00026791554,0.0026209555,0.0066676233,0.002121712,0.22563857,0.00026775172],"about_ca_topic_score_codex":0.00012066849,"about_ca_topic_score_gemma":0.000048801536,"teacher_disagreement_score":0.86027867,"about_ca_system_score_codex":0.000053176944,"about_ca_system_score_gemma":0.00014351013,"threshold_uncertainty_score":0.64704704},"labels":[],"label_agreement":null},{"id":"W1985896548","doi":"10.1016/j.bbmt.2009.11.007","title":"Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Multiple myeloma; Hematopoietic cell; Hematopoietic stem cell transplantation; Transplantation; Oncology; Haematopoiesis; Internal medicine; Stem cell; Genetics","score_opus":0.013824366150316396,"score_gpt":0.282907607291786,"score_spread":0.2690832411414696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985896548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963208,0.0008495528,0.0015795917,0.00034847765,0.000022272086,0.0005661374,0.00019121982,0.000017497703,0.00010446924],"genre_scores_gemma":[0.9926706,0.0022828449,0.0046100197,0.000036841786,0.0000087295,0.000019322746,0.00032490696,0.000005945884,0.00004081635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99931264,0.00003529629,0.00024739193,0.00018299211,0.00006814264,0.00015351479],"domain_scores_gemma":[0.99948496,0.00023147183,0.00008588942,0.00007324672,0.000053464202,0.00007099163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000970096,0.0001141785,0.00034501601,0.000102926846,0.000042110867,0.0000024512635,0.00002756626,0.00011062609,0.000004415014],"category_scores_gemma":[0.000019464178,0.000089714216,0.000056542187,0.00004315348,0.00010191925,0.000041912685,0.0000016922392,0.000044643733,3.0379704e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018190435,0.00031982907,0.37078768,0.0013023039,0.00014520953,0.000021815806,0.0008929787,8.4471816e-7,0.60815895,0.00033742908,0.00000428279,0.016209662],"study_design_scores_gemma":[0.008371366,0.0015683309,0.6739748,0.00006163234,0.0005584019,0.00013554184,0.00005192517,0.0000641825,0.31478673,0.00034313806,0.000009072832,0.00007486766],"about_ca_topic_score_codex":0.000030293751,"about_ca_topic_score_gemma":0.00001999135,"teacher_disagreement_score":0.30318713,"about_ca_system_score_codex":0.0000027326432,"about_ca_system_score_gemma":0.00002448134,"threshold_uncertainty_score":0.36584395},"labels":[],"label_agreement":null},{"id":"W1985932235","doi":"10.1016/j.jval.2014.03.446","title":"A Canadian Cost Impact Analysis Comparing Maintenance Therapy with Bortezomib Versus Lenalidomide in Multiple Myeloma Patients Ineligible for Stem Cell Transplant","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Ottawa Hospital; Thames Valley Children's Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Bortezomib; Medicine; Internal medicine; Adverse effect; Oncology; Pharmacist; Pharmacy; Family medicine","score_opus":0.06781060032788233,"score_gpt":0.32664158267949694,"score_spread":0.2588309823516146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985932235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962916,0.00020810176,0.00035526353,0.0003775794,0.000048740785,0.002331574,0.00019009502,0.000018572215,0.00017849986],"genre_scores_gemma":[0.99835336,0.00024097679,0.00056870136,0.00015431253,0.000027120232,0.00021525784,0.00037202172,0.000032664946,0.00003557592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975712,0.00020238252,0.00048052732,0.00041259587,0.00031189903,0.0010214304],"domain_scores_gemma":[0.99822026,0.00046796928,0.00012490593,0.00033380234,0.000096106945,0.0007569317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006372434,0.00023854223,0.00073215726,0.00084108446,0.00010894242,0.000024352563,0.00012409678,0.000069472306,0.000010211552],"category_scores_gemma":[0.00005165141,0.00017232627,0.00013653409,0.00084348134,0.00003206127,0.00007003018,0.0000075547896,0.00021980348,0.0000059452727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008664043,0.00034544902,0.97278076,0.00014002153,0.00022716384,0.000032493856,0.0006854544,0.010730202,0.000012362672,0.000010824733,0.000053907857,0.006317325],"study_design_scores_gemma":[0.040794443,0.0018127149,0.79371136,0.00032043096,0.000044127213,0.0000022712463,0.0001083477,0.16255604,0.00015601823,0.0000050495737,0.0003282179,0.00016099584],"about_ca_topic_score_codex":0.65316015,"about_ca_topic_score_gemma":0.5360967,"teacher_disagreement_score":0.1790694,"about_ca_system_score_codex":0.0018188155,"about_ca_system_score_gemma":0.00096569065,"threshold_uncertainty_score":0.7027261},"labels":[],"label_agreement":null},{"id":"W1987310290","doi":"10.1038/bmt.2014.226","title":"Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure","year":2014,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Dialysis; Mucositis; Septic shock; Neutropenia; Surgery; Toxicity; Sepsis","score_opus":0.013444959480999427,"score_gpt":0.2542282640166661,"score_spread":0.24078330453566665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987310290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815536,0.000020283893,0.0008106062,0.000073273455,0.000012885745,0.00065697276,0.000086276326,0.000026635798,0.00015773447],"genre_scores_gemma":[0.9984478,0.00002749444,0.0009162074,0.000017766992,0.000015337877,0.00003138841,0.0005076844,0.000013779313,0.000022543909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858844,0.0001306384,0.0003031633,0.0002931365,0.00044960313,0.00023499226],"domain_scores_gemma":[0.99935406,0.00014408723,0.00009379741,0.00019165143,0.00007840817,0.00013797692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021928143,0.00015602424,0.00035620696,0.00016623638,0.00004879016,0.000010603955,0.000042531377,0.00008303365,0.000019947864],"category_scores_gemma":[0.00007322,0.000118929696,0.000047072248,0.00015764157,0.00008962849,0.00009105998,0.000008950238,0.00012565972,0.0000035789221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031971368,0.0007020921,0.97334117,0.00025482246,0.000114071234,0.00007909029,0.0003338193,0.000045725432,0.010692799,0.00001857778,0.0000035666308,0.011217106],"study_design_scores_gemma":[0.016276058,0.00056389533,0.968852,0.00013788202,0.00016924877,0.00001810025,0.000014235021,0.0009204581,0.012919765,0.000016939885,0.0000059793742,0.00010547625],"about_ca_topic_score_codex":0.00048922235,"about_ca_topic_score_gemma":0.0034689,"teacher_disagreement_score":0.0130789215,"about_ca_system_score_codex":0.00004409597,"about_ca_system_score_gemma":0.00004035408,"threshold_uncertainty_score":0.48498124},"labels":[],"label_agreement":null},{"id":"W1987679177","doi":"10.1038/ki.2008.117","title":"Plasma exchange for myeloma kidney: cast(s) away?","year":2008,"lang":"en","type":"letter","venue":"Kidney International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Multiple myeloma; Randomized controlled trial; Restitution; Medicine; Plasma Cell Myeloma; Kidney; Biopsy; Immunoglobulin light chain; Internal medicine; Urology; Immunology; Antibody; Political science","score_opus":0.0468093382501845,"score_gpt":0.3218478309436561,"score_spread":0.2750384926934716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987679177","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053883775,0.00010142624,0.00023724503,0.947458,0.0030870182,0.001712798,0.0082432525,0.00015987617,0.038461532],"genre_scores_gemma":[0.0011691375,0.0003574013,0.0048101223,0.7478672,0.01770867,0.0010581166,0.043555815,0.0001922948,0.1832812],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966142,0.00004844539,0.00046275204,0.0007589669,0.0013512096,0.00076443463],"domain_scores_gemma":[0.99764156,0.00021262627,0.00020126751,0.0005133597,0.0005340408,0.0008971377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011083034,0.0005134576,0.0005999172,0.00058833236,0.00015505604,0.00007065655,0.0004659512,0.0007417573,0.004203544],"category_scores_gemma":[0.0016242604,0.00045447698,0.00051284954,0.000120150995,0.00014477818,0.00012555353,0.00014463221,0.0011499837,0.0009979532],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040398288,0.00016753063,0.0011721848,0.00041117423,0.0015050642,0.0035396193,0.00008869783,1.1773977e-7,0.000079261576,0.00002797733,0.9876378,0.0049665724],"study_design_scores_gemma":[0.0072910865,0.00031710987,0.0007346186,0.00040377583,0.00014599203,0.0011600988,0.0000053777194,0.000792898,0.0005619374,0.000058801885,0.988178,0.0003502599],"about_ca_topic_score_codex":0.000115733485,"about_ca_topic_score_gemma":0.000005244293,"teacher_disagreement_score":0.19959077,"about_ca_system_score_codex":0.0006187831,"about_ca_system_score_gemma":0.0012742651,"threshold_uncertainty_score":0.99979067},"labels":[],"label_agreement":null},{"id":"W1988183285","doi":"10.1038/bmt.2013.12","title":"Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT","year":2013,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Hematopoietic cell; Haematopoiesis; Hematopoietic stem cell transplantation; Oncology; Internal medicine; Surgery; Transplantation; Stem cell","score_opus":0.020900110168864196,"score_gpt":0.27614675185037507,"score_spread":0.2552466416815109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988183285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9505386,0.0008260322,0.0011313981,0.034597836,0.00033396657,0.010911304,0.0006740213,0.00041250183,0.0005743372],"genre_scores_gemma":[0.9366526,0.00048471836,0.009501272,0.022837557,0.0006231101,0.0063658403,0.019695496,0.00047655698,0.003362837],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99468344,0.00030595914,0.0009498497,0.0014532431,0.0012528093,0.0013547235],"domain_scores_gemma":[0.9973627,0.00049666653,0.0003887112,0.0010154268,0.0002251214,0.00051140715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018242319,0.0011572235,0.0016458775,0.00056138285,0.00039966786,0.00015583709,0.00022082978,0.0009442515,0.00015624988],"category_scores_gemma":[0.00005615399,0.00087042194,0.0007199451,0.0002872675,0.00014159056,0.00029106234,0.000018500703,0.00069232984,0.00018885433],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07130627,0.013696215,0.09966363,0.045116525,0.030211829,0.30550647,0.038435556,0.0004359167,0.0654372,0.00023567711,0.1928031,0.1371516],"study_design_scores_gemma":[0.32473,0.14905846,0.07168952,0.028358035,0.043274757,0.08240676,0.0030714944,0.012699311,0.15980855,0.0018948624,0.10752589,0.015482375],"about_ca_topic_score_codex":0.0009348352,"about_ca_topic_score_gemma":0.0003192252,"teacher_disagreement_score":0.25342372,"about_ca_system_score_codex":0.0006103997,"about_ca_system_score_gemma":0.0005460215,"threshold_uncertainty_score":0.9993746},"labels":[],"label_agreement":null},{"id":"W1988669425","doi":"10.2174/156800912802429337","title":"Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD44; Integrin; Extracellular matrix; Cell biology; Cell adhesion molecule; Cell adhesion; Fibronectin; Chemistry; Laminin; Adhesion; Cancer research; Biology; Cell; Biochemistry","score_opus":0.11710704615758474,"score_gpt":0.4100367581634505,"score_spread":0.2929297120058657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988669425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006751259,0.99603057,0.000008850233,0.000020637766,0.0005036665,0.0022984024,0.00018163671,0.000043745702,0.00023737698],"genre_scores_gemma":[0.024096882,0.97366685,0.00008033166,0.000009442976,0.00035477625,0.00080127147,0.00071631855,0.00010808256,0.00016605336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964362,0.0003344209,0.0009857629,0.00063996145,0.00068227184,0.00092143274],"domain_scores_gemma":[0.99820834,0.00024268811,0.0005106678,0.00048024007,0.00015467049,0.00040336873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034254295,0.0006747801,0.0021656393,0.00049370347,0.0000702632,0.000018792458,0.00028383697,0.00022731573,0.0004904177],"category_scores_gemma":[0.00012258382,0.00049524556,0.0005592665,0.0004970111,0.00011392339,0.000116007024,0.00013955921,0.000806556,0.00015430525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115017254,0.00066971564,0.0036395865,0.026901383,0.00034236326,0.000053203672,0.00014020663,0.000003703915,0.000025409512,0.000033209624,0.0002231311,0.96785307],"study_design_scores_gemma":[0.0026917858,0.00015936006,0.0016311273,0.030397452,0.0012038609,0.000019962261,0.0000610623,0.00023095905,0.00026190095,0.000032285465,0.9627145,0.00059573055],"about_ca_topic_score_codex":0.00043909682,"about_ca_topic_score_gemma":0.000072328716,"teacher_disagreement_score":0.9672573,"about_ca_system_score_codex":0.00054570765,"about_ca_system_score_gemma":0.001109597,"threshold_uncertainty_score":0.9997499},"labels":[],"label_agreement":null},{"id":"W1989740966","doi":"10.1111/j.1365-2141.2008.07573.x","title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":308,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Medicine; Bortezomib; Peripheral neuropathy; Multiple myeloma; Internal medicine; Guideline; Surgery; Gastroenterology; Oncology; Diabetes mellitus; Pathology; Endocrinology","score_opus":0.030424365386935357,"score_gpt":0.361632983993509,"score_spread":0.33120861860657363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989740966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976618,0.0005980214,0.00012813974,0.0004492089,0.000035459685,0.0010382809,0.000017969958,0.0000045694546,0.00006652959],"genre_scores_gemma":[0.9986946,0.000104626255,0.0010575881,0.000055250974,0.00004187535,0.000009117995,0.000021415895,0.000009861143,0.0000056484723],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99703836,0.00057006057,0.0014819122,0.00018392557,0.00043889717,0.0002868437],"domain_scores_gemma":[0.99824977,0.0002681076,0.0007303227,0.00028269805,0.00035240233,0.000116687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012643539,0.00014495516,0.0010150999,0.00027429906,0.000030869505,0.00001097399,0.00020748316,0.00009528508,0.000044327146],"category_scores_gemma":[0.0013177714,0.00010119422,0.00022691209,0.00039503525,0.00015550072,0.00011227504,0.000013820916,0.00038978408,5.8301276e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.525521,0.02940449,0.19602494,0.00050456944,0.00077144935,0.119610354,0.00362699,0.00044617846,0.017944548,0.000062099054,0.001974946,0.104108445],"study_design_scores_gemma":[0.38184232,0.014973159,0.5334686,0.0008189531,0.00015316036,0.06270134,0.00048827913,0.004678361,0.0005592283,0.00017266576,0.000010232956,0.0001337247],"about_ca_topic_score_codex":0.00062200316,"about_ca_topic_score_gemma":0.00026161675,"teacher_disagreement_score":0.33744365,"about_ca_system_score_codex":0.00013316848,"about_ca_system_score_gemma":0.00041624205,"threshold_uncertainty_score":0.41265807},"labels":[],"label_agreement":null},{"id":"W1989751264","doi":"10.1053/j.seminhematol.2010.11.002","title":"Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance","year":2011,"lang":"en","type":"review","venue":"Seminars in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Medicine; Thalidomide; Lenalidomide; Thrombosis; Dexamethasone; Internal medicine; Venous thrombosis; Hematology; Oncology; Immunology; Monoclonal; Gastroenterology; Monoclonal antibody; Antibody","score_opus":0.08532530873158833,"score_gpt":0.358380231891562,"score_spread":0.27305492315997365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989751264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15116735,0.84594244,0.0000016929431,0.000010234159,0.00006935305,0.0024391427,0.00013248749,0.000018753051,0.00021856229],"genre_scores_gemma":[0.062140558,0.93591565,0.0008939705,0.0000056187046,0.000013343666,0.00061053166,0.00010418473,0.00005433639,0.00026178334],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966559,0.00045147137,0.001193668,0.00082361896,0.00022000453,0.00065535115],"domain_scores_gemma":[0.9976093,0.0011626205,0.00034636015,0.00055370707,0.00009159993,0.00023640365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004772589,0.0005028764,0.00320612,0.000612095,0.000023758488,0.000004736273,0.00023245676,0.0004957867,0.000070908165],"category_scores_gemma":[0.0010145016,0.00041430234,0.0002142617,0.0004530669,0.00031495825,0.000066001274,0.00018046128,0.0005926303,0.000026687705],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078976335,0.0012026525,0.102269635,0.051170293,0.00019276433,0.0020198326,0.0005628188,1.9744608e-7,0.000028468969,0.00011285902,0.000033107804,0.8416176],"study_design_scores_gemma":[0.054698598,0.01372474,0.16549572,0.39571106,0.003834705,0.028117107,0.0009834252,0.003009314,0.009649101,0.004889935,0.3122321,0.0076541887],"about_ca_topic_score_codex":0.00017310951,"about_ca_topic_score_gemma":0.00044034192,"teacher_disagreement_score":0.8339634,"about_ca_system_score_codex":0.00023285078,"about_ca_system_score_gemma":0.00052631326,"threshold_uncertainty_score":0.9998309},"labels":[],"label_agreement":null},{"id":"W1989803279","doi":"10.1038/sj.leu.2405087","title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Renal function; Internal medicine; Creatinine; Adverse effect; Proteasome inhibitor; Urology; Phases of clinical research; Gastroenterology; Toxicity; Surgery","score_opus":0.019329333024487288,"score_gpt":0.2877653199784997,"score_spread":0.2684359869540124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989803279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979819,0.0000520283,0.0000026352354,0.00008238896,0.00001106374,0.0013780722,0.00013951474,0.000012174507,0.00034022823],"genre_scores_gemma":[0.9994405,0.000029613946,0.00012968735,0.00003927303,0.000031098607,0.000018107437,0.00020379988,0.000011623711,0.00009628494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876195,0.00008005784,0.00028818444,0.00025304052,0.0004048602,0.00021188433],"domain_scores_gemma":[0.9991538,0.00022882022,0.00007725385,0.00035978557,0.00005545076,0.00012487128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013599225,0.0001246504,0.00025158675,0.000051796364,0.00007803566,0.000005059023,0.00007460754,0.00003502475,0.00002235538],"category_scores_gemma":[0.00013935652,0.000067631205,0.000023758139,0.00016633086,0.000108419285,0.000045254303,0.000047935115,0.00017090126,0.0000063558196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04159952,0.0027169005,0.9445051,0.000005904545,0.00020576987,0.00025420435,0.0023063961,0.0000067273454,0.00004953379,8.228761e-7,0.00026995546,0.008079195],"study_design_scores_gemma":[0.12829691,0.0032555752,0.8678113,0.00007466373,0.000042456893,0.0000036083695,0.00010990844,0.000090743684,0.00014476078,0.0000018990171,0.00011436597,0.00005380502],"about_ca_topic_score_codex":0.0016741544,"about_ca_topic_score_gemma":0.00012766468,"teacher_disagreement_score":0.086697385,"about_ca_system_score_codex":0.00018687334,"about_ca_system_score_gemma":0.00018143606,"threshold_uncertainty_score":0.27579206},"labels":[],"label_agreement":null},{"id":"W1990009253","doi":"10.1200/jco.2005.05.023","title":"Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fluorescence in situ hybridization; Gene expression profiling; Multiple myeloma; Cytogenetics; Pharmacogenomics; Chromosomal translocation; Computational biology; Bioinformatics; Gene; Gene expression; Genetics; Chromosome; Internal medicine; Biology; Pharmacology","score_opus":0.28515556573907846,"score_gpt":0.5364317676440781,"score_spread":0.2512762019049996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990009253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012401067,0.9861003,0.000041388827,0.00013679419,0.00017873677,0.00095691567,0.000010617494,0.000003931743,0.00017021596],"genre_scores_gemma":[0.006841295,0.9761422,0.015990758,0.00006204139,0.00082157645,0.000018478928,0.000006287255,0.000030547828,0.000086793734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956297,0.0007453402,0.0026956168,0.00027384298,0.00040153472,0.0002539399],"domain_scores_gemma":[0.9926341,0.0038662693,0.0024733923,0.0002031578,0.00031971105,0.0005033802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018111548,0.00024983275,0.003821683,0.00018021233,0.000032215616,0.000008429218,0.00013645914,0.0006368458,0.000027545295],"category_scores_gemma":[0.0021434608,0.0001459174,0.00046513614,0.00010469818,0.00034817794,0.000031155636,0.000092345035,0.0010961671,0.000003544253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005717462,0.0006842145,0.007274753,0.0032156492,0.000638967,0.000410168,0.0000135482705,2.0198345e-7,0.00005733699,0.000005232693,0.00003039295,0.9870978],"study_design_scores_gemma":[0.007467487,0.01751072,0.021671228,0.011361019,0.0051667956,0.002400338,0.000024762716,0.00006259966,0.00013089938,0.00008095506,0.93387586,0.00024731024],"about_ca_topic_score_codex":0.0000012544997,"about_ca_topic_score_gemma":0.0000013895958,"teacher_disagreement_score":0.9868505,"about_ca_system_score_codex":0.00007800068,"about_ca_system_score_gemma":0.0021872176,"threshold_uncertainty_score":0.5950339},"labels":[],"label_agreement":null},{"id":"W1990527483","doi":"10.1016/j.bbmt.2008.06.019","title":"Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Stem Cell Network; Ottawa Hospital","funders":"Ottawa Hospital Foundation; Canadian Blood Services; University of Ottawa","keywords":"Medicine; Toxicity; Transplantation; Comorbidity; Multiple myeloma; Hematopoietic stem cell transplantation; Internal medicine; Surgery; Oncology","score_opus":0.02791075948765629,"score_gpt":0.2954047845913669,"score_spread":0.26749402510371056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990527483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941337,0.0003555246,0.0033586086,0.000052617008,0.000081203674,0.0011734028,0.00060112117,0.000038609065,0.00020521117],"genre_scores_gemma":[0.9941272,0.002022856,0.0024111723,0.000009078264,0.00001011136,0.00007313888,0.0013175057,0.00001458784,0.000014323751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983123,0.00017449501,0.0006868864,0.00035110457,0.00018612585,0.00028908905],"domain_scores_gemma":[0.99895394,0.0005390674,0.00019618767,0.00012793517,0.00008098941,0.00010188002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033486294,0.0001983544,0.0005438814,0.00020058472,0.00011860069,0.0000028480404,0.00006460267,0.00022537787,0.000011880914],"category_scores_gemma":[0.000013330087,0.0001818749,0.00014525058,0.00015101985,0.00016833049,0.00010535074,0.0000039956294,0.00016679711,3.7511685e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014645306,0.0005771045,0.7273977,0.0024284823,0.00019132103,0.00015186926,0.0030065859,0.000011571563,0.26290327,0.000050170704,0.0000011556658,0.0018162527],"study_design_scores_gemma":[0.012340523,0.0007735722,0.7255284,0.00022056623,0.0006015302,0.0003048099,0.0002022379,0.0016781503,0.25815856,0.00006743456,0.0000013076881,0.00012288897],"about_ca_topic_score_codex":0.00030619669,"about_ca_topic_score_gemma":0.00027821236,"teacher_disagreement_score":0.010875993,"about_ca_system_score_codex":0.000014041468,"about_ca_system_score_gemma":0.00014465001,"threshold_uncertainty_score":0.74166435},"labels":[],"label_agreement":null},{"id":"W1991354959","doi":"10.1016/j.bbmt.2011.10.044","title":"Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival","year":2011,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Salvage therapy; Melphalan; Multiple myeloma; Autologous stem-cell transplantation; Regimen; Surgery; Progression-free survival; Oncology; Internal medicine; Transplantation; Overall survival; Chemotherapy","score_opus":0.02878744057369,"score_gpt":0.30122878834750977,"score_spread":0.2724413477738198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991354959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634314,0.00090006774,0.00016866527,0.00005209462,0.00006116053,0.0010976866,0.0006580852,0.000036091948,0.0006830237],"genre_scores_gemma":[0.9948421,0.0030466616,0.0013054322,0.000039862516,0.000028610948,0.000087567096,0.00056574855,0.000018437278,0.00006557445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989849,0.00009585833,0.00023827808,0.00031180383,0.00011121807,0.00025796596],"domain_scores_gemma":[0.9992798,0.0002782803,0.000098920915,0.000144157,0.000057205,0.00014162381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016889036,0.00020244933,0.000330533,0.0001270289,0.00008645502,0.000006659938,0.000059725913,0.0001769946,0.000049249047],"category_scores_gemma":[0.00000830095,0.00013973983,0.00008551321,0.00004109125,0.00012670082,0.00007283819,0.0000047534154,0.00009384383,0.0000014856836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033760052,0.0011701045,0.36262614,0.0014028945,0.00066688785,0.00016856274,0.0034130244,4.7169803e-7,0.5312723,0.00042110754,0.000026171188,0.065072276],"study_design_scores_gemma":[0.02062348,0.007370439,0.6452946,0.00009775469,0.0002692828,0.00016730255,0.000057598576,0.000042583113,0.32550392,0.0004014574,0.000022704198,0.00014889064],"about_ca_topic_score_codex":0.00010857452,"about_ca_topic_score_gemma":0.00006553586,"teacher_disagreement_score":0.28266844,"about_ca_system_score_codex":0.0000079411375,"about_ca_system_score_gemma":0.000055927383,"threshold_uncertainty_score":0.56984246},"labels":[],"label_agreement":null},{"id":"W1992419413","doi":"10.1038/leu.2009.301","title":"FES kinases are required for oncogenic FLT3 signaling","year":2010,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Fondation de France; Ligue Contre le Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Kinase; Receptor tyrosine kinase; Cancer research; Haematopoiesis; Biology; Fms-Like Tyrosine Kinase 3; Myeloid leukemia; Tyrosine kinase; Cell; Cell cycle; Cell biology; Signal transduction; Mutation; Stem cell; Genetics; Gene","score_opus":0.04264703591099411,"score_gpt":0.3336378850491636,"score_spread":0.29099084913816947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992419413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969827,0.00016004423,0.00008688235,0.00041324343,0.00018583334,0.00059017964,0.000037739537,0.00008775289,0.001455641],"genre_scores_gemma":[0.9924465,0.000013050784,0.0043811505,0.00017421204,0.00046908198,0.0001298981,0.000094807205,0.000029430814,0.0022618782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898434,0.000014751463,0.00015928803,0.00024771027,0.00022801897,0.00036587773],"domain_scores_gemma":[0.99910223,0.00018325672,0.000057085294,0.0003053362,0.000112202615,0.00023986989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012176514,0.00012993737,0.0002262183,0.000075949814,0.00012136815,0.000025179783,0.000090754715,0.000106403786,0.0002123445],"category_scores_gemma":[0.00050132436,0.00010193295,0.00013794978,0.000093772775,0.00005775979,0.00005813368,0.000030167512,0.000203144,0.00012755554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012980762,0.00021534001,0.07756101,0.00029054104,0.00032384341,0.00044992636,0.00016069376,0.0000032918508,0.84186304,0.00038483422,0.004857521,0.07259188],"study_design_scores_gemma":[0.017674182,0.0011397504,0.13152823,0.00033012388,0.00030540777,0.00019698164,0.00030226365,0.0022146516,0.804142,0.0022551902,0.039429095,0.0004821519],"about_ca_topic_score_codex":0.000120073906,"about_ca_topic_score_gemma":0.00010750802,"teacher_disagreement_score":0.07210972,"about_ca_system_score_codex":0.00018980254,"about_ca_system_score_gemma":0.00029662045,"threshold_uncertainty_score":0.4156705},"labels":[],"label_agreement":null},{"id":"W1992979998","doi":"10.1111/bjh.12325","title":"D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma","year":2013,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Medicine; Salvage therapy; Internal medicine; Regimen; Etoposide; Multiple myeloma; Surgery; Refractory (planetary science); Hematopoietic stem cell transplantation; Dexamethasone; Cohort; Autologous stem-cell transplantation; Transplantation; Oncology; Chemotherapy","score_opus":0.02862974617409571,"score_gpt":0.31976015781796086,"score_spread":0.29113041164386516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992979998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856213,0.011079118,0.00021593919,0.00077898975,0.0002967323,0.0012352098,0.000032017673,0.000031678752,0.0007090244],"genre_scores_gemma":[0.9865559,0.004744713,0.0047745076,0.0006998425,0.00032234137,0.0001428067,0.000029716382,0.000064573294,0.0026656056],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9977685,0.00017749856,0.0006814652,0.00027132404,0.00043724207,0.000663964],"domain_scores_gemma":[0.9962309,0.0013998253,0.0007323481,0.00023614679,0.00085283414,0.000547941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002794253,0.0002282434,0.00095446134,0.00023229452,0.00017069573,0.00008282474,0.00024176504,0.00023270282,0.00052504614],"category_scores_gemma":[0.0051234104,0.00018114744,0.00032433323,0.0001423015,0.00021280163,0.00029542902,0.00004720588,0.00047194157,0.00017855372],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030187469,0.0027142644,0.04145301,0.00040019688,0.0024727678,0.24489985,0.00067482935,0.0000020724976,0.010296477,0.00009084567,0.25075498,0.44322196],"study_design_scores_gemma":[0.03778083,0.008552089,0.14553073,0.0015096738,0.00017269133,0.70453185,0.0012804592,0.000207298,0.016558673,0.0013089394,0.08235123,0.00021552457],"about_ca_topic_score_codex":0.00024333574,"about_ca_topic_score_gemma":0.000087454115,"teacher_disagreement_score":0.459632,"about_ca_system_score_codex":0.00008583041,"about_ca_system_score_gemma":0.0004241892,"threshold_uncertainty_score":0.7386978},"labels":[],"label_agreement":null},{"id":"W1994684879","doi":"10.1002/cmdc.201000326","title":"Thalidomide Derivatives for the Treatment of Neuroinflammation","year":2010,"lang":"en","type":"article","venue":"ChemMedChem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Thalidomide; Experimental autoimmune encephalomyelitis; Medicine; Multiple sclerosis; Pharmacology; Drug; Immunology; Multiple myeloma","score_opus":0.05025797420761865,"score_gpt":0.34303825667168575,"score_spread":0.2927802824640671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994684879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958294,0.00011492782,0.00016163957,0.0016014068,0.00007418142,0.00087083766,0.000010515682,0.000019247058,0.0013178545],"genre_scores_gemma":[0.9968253,0.00009886061,0.0017278773,0.000016990552,0.00016170468,0.00021586145,0.00003765724,0.000012559452,0.00090321124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99947494,0.000006148768,0.0001254246,0.00011699979,0.00012502627,0.00015143005],"domain_scores_gemma":[0.9991683,0.00035212183,0.000050911178,0.00026844238,0.000085083986,0.00007518913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058890808,0.00008778855,0.00014896752,0.000027710334,0.00005596801,0.0000067810033,0.00005224793,0.00003838561,0.00007322502],"category_scores_gemma":[0.00020236833,0.000047366524,0.00010679265,0.000048004265,0.00009674986,0.000027902242,0.000007260734,0.000049241946,0.000009666331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049478124,0.00043700865,0.008857157,0.000057313744,0.00018780616,0.0000063142516,0.00067873235,4.88223e-7,0.8965137,0.0002865972,0.00023872133,0.09224136],"study_design_scores_gemma":[0.0030634294,0.00037290514,0.042642314,0.0000066466773,0.000056399753,0.000010441554,0.000060604,0.00050611363,0.945181,0.00013234002,0.007933142,0.000034657252],"about_ca_topic_score_codex":0.000020699048,"about_ca_topic_score_gemma":0.000018050341,"teacher_disagreement_score":0.0922067,"about_ca_system_score_codex":0.000023111079,"about_ca_system_score_gemma":0.000050224455,"threshold_uncertainty_score":0.19315508},"labels":[],"label_agreement":null},{"id":"W1995560549","doi":"10.1182/blood-2006-10-047951","title":"Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Care Ontario; Eli Lilly and Company","keywords":"Bortezomib; Melphalan; Bone marrow; Multiple myeloma; Cytotoxicity; Cancer research; Dexamethasone; Pharmacology; Medicine; Biology; Immunology; Internal medicine; In vitro; Genetics","score_opus":0.0854462178360637,"score_gpt":0.3807883635765643,"score_spread":0.2953421457405006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995560549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955198,0.0019698674,0.000003674404,0.0003839785,0.00013951526,0.00083955564,0.000014583243,0.00002797571,0.0011010492],"genre_scores_gemma":[0.9983102,0.00015391823,0.0006907055,0.00008075588,0.0001832,0.000037920356,0.0000061929827,0.000018775645,0.0005183364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982232,0.00008892811,0.00051213166,0.00027132648,0.00048644573,0.00041795734],"domain_scores_gemma":[0.9983869,0.0007785817,0.000100886515,0.00045029557,0.00014132474,0.0001420084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006386078,0.00015550968,0.0003973851,0.000104669736,0.000064858,0.0000055111914,0.00014449912,0.00011197171,0.00002456033],"category_scores_gemma":[0.002467741,0.00009382432,0.00015496988,0.00031559556,0.00024473827,0.000042925563,0.00015966428,0.0002779285,0.000036956084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004864823,0.0019179444,0.97493285,0.00011311874,0.00031512917,0.00018422863,0.0004398322,4.3473284e-7,0.0077137016,0.00002841166,0.0002195827,0.0136482855],"study_design_scores_gemma":[0.011184006,0.00041944342,0.9033827,0.00027706168,0.00009679581,0.000028520453,0.00041653635,0.000021685824,0.083586924,0.00006936255,0.00043513626,0.00008178453],"about_ca_topic_score_codex":0.00009804952,"about_ca_topic_score_gemma":0.0006265955,"teacher_disagreement_score":0.075873226,"about_ca_system_score_codex":0.000065215594,"about_ca_system_score_gemma":0.00012790093,"threshold_uncertainty_score":0.38260445},"labels":[],"label_agreement":null},{"id":"W1995576598","doi":"10.1038/sj.leu.2404800","title":"Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution","year":2007,"lang":"en","type":"letter","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Multiple myeloma; Medicine; Somatic evolution in cancer; Hematology; Oncology; Immunology; Internal medicine; Cancer research; Biology; Cancer","score_opus":0.12111152545305151,"score_gpt":0.38385046946697643,"score_spread":0.26273894401392495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995576598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.935057,0.012374432,0.0008666684,0.043881778,0.0003467613,0.0069547812,0.00015610237,0.000043742286,0.00031872204],"genre_scores_gemma":[0.98187834,0.00021799674,0.001538383,0.013286121,0.001184662,0.00062093185,0.0007348384,0.000049255596,0.00048947043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973728,0.00014998465,0.00042682764,0.0004543824,0.0011525226,0.00044348682],"domain_scores_gemma":[0.99505913,0.0038482423,0.00017244853,0.0003249174,0.0004988527,0.000096408934],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011851544,0.00023698084,0.0004576263,0.00041608568,0.000045354565,0.0000119071465,0.000090476686,0.0005524257,0.000045456167],"category_scores_gemma":[0.01002694,0.00021050636,0.00011180067,0.00019626395,0.00012592322,0.00009759412,0.000044106215,0.00066752185,0.000014155591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022506183,0.0001796851,0.6082123,0.0048204246,0.0003905443,0.00074317906,0.00025840054,0.000078254234,0.0011491085,0.000019419136,0.301486,0.080412105],"study_design_scores_gemma":[0.011447072,0.00062178174,0.9588221,0.003413203,0.000538035,0.00006828307,0.000020783571,0.015843792,0.00068976893,0.00039315713,0.007886967,0.00025509213],"about_ca_topic_score_codex":0.0007522074,"about_ca_topic_score_gemma":0.00028475857,"teacher_disagreement_score":0.35060978,"about_ca_system_score_codex":0.0023472249,"about_ca_system_score_gemma":0.0011548868,"threshold_uncertainty_score":0.998312},"labels":[],"label_agreement":null},{"id":"W1995938443","doi":"10.1111/apt.13181","title":"Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease","year":2015,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Thalidomide; Medicine; Discontinuation; Adverse effect; Internal medicine; Ulcerative colitis; Randomized controlled trial; Inflammatory bowel disease; Gastroenterology; Cochrane Library; Crohn's disease; Meta-analysis; Placebo; Disease; Pathology; Alternative medicine","score_opus":0.10748600083664463,"score_gpt":0.43582567701576763,"score_spread":0.328339676179123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995938443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023168781,0.9831442,0.0000030622505,0.00036174493,0.00026932432,0.014949295,0.00096770475,0.000045265748,0.000027662616],"genre_scores_gemma":[0.00004254906,0.99152875,0.00017122515,0.0017129811,0.00020609348,0.0038387585,0.0019587236,0.000111076166,0.00042986116],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99627054,0.0007932694,0.0013596226,0.0006007363,0.0004111232,0.0005647228],"domain_scores_gemma":[0.9967226,0.00081152876,0.0009822234,0.0006245268,0.00021344655,0.00064570474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005345033,0.0007941927,0.0042569693,0.0002808478,0.00009559565,0.000013489445,0.0002316673,0.00020754122,0.000068749694],"category_scores_gemma":[0.000005377471,0.0005231153,0.00088406925,0.00014533997,0.00028531614,0.00007305356,0.00008411177,0.00014399068,0.000029272689],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009399604,0.0012094065,0.00026605165,0.90278316,0.07480855,0.0003804586,0.000101720274,1.9621766e-7,0.000022967093,0.000007839708,0.00085416617,0.018625502],"study_design_scores_gemma":[0.010476477,0.0022859338,0.00002379385,0.18343692,0.50597596,0.0002423983,0.000047701993,0.000061714425,0.00014569814,0.000041955846,0.29666987,0.0005915722],"about_ca_topic_score_codex":0.000020854312,"about_ca_topic_score_gemma":0.0000030435608,"teacher_disagreement_score":0.7193463,"about_ca_system_score_codex":0.0005988114,"about_ca_system_score_gemma":0.00080038613,"threshold_uncertainty_score":0.99972206},"labels":[],"label_agreement":null},{"id":"W1996608580","doi":"10.1016/j.humpath.2011.07.013","title":"Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib","year":2011,"lang":"en","type":"article","venue":"Human Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Bortezomib; Cancer research; Multiple myeloma; Biology; Cyclin D1; Immunohistochemistry; Fluorescence in situ hybridization; Cyclin D; Molecular biology; Medicine; Cell cycle; Internal medicine; Cancer; Immunology; Biochemistry","score_opus":0.05103582742285989,"score_gpt":0.2958866043885326,"score_spread":0.2448507769656727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996608580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963199,0.000017667131,0.000049223712,0.000011828215,0.000047914138,0.0019894445,0.0001713065,0.00022546503,0.0011672667],"genre_scores_gemma":[0.9932031,0.0000055241844,0.0044066925,0.00011686753,0.000069184214,0.0002546005,0.0011650778,0.00013256309,0.000646357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975779,0.00018323498,0.00042666114,0.00072994037,0.00036905226,0.000713221],"domain_scores_gemma":[0.99796015,0.000087414286,0.00022703229,0.0008480767,0.00030770453,0.0005695928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016085223,0.00040159433,0.00058268517,0.0002849718,0.00033421227,0.000011556507,0.00019405482,0.00025964502,0.0003958152],"category_scores_gemma":[0.0001411511,0.0002683367,0.00010219295,0.00013020015,0.00033617954,0.00027142363,0.00006895488,0.00033398185,0.000074136246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013239834,0.004549505,0.97287846,0.000087239365,0.00012384435,0.0017273105,0.0011303233,6.373445e-7,0.004446264,0.00003397838,0.00013893614,0.0016436713],"study_design_scores_gemma":[0.035534844,0.016203947,0.9451049,0.00012070827,0.000194795,0.00005703311,0.0002386622,0.000068903595,0.0016082675,0.000018410634,0.0005583924,0.00029112445],"about_ca_topic_score_codex":0.00010586214,"about_ca_topic_score_gemma":0.00016466218,"teacher_disagreement_score":0.027773542,"about_ca_system_score_codex":0.000116294315,"about_ca_system_score_gemma":0.000059822523,"threshold_uncertainty_score":0.9999769},"labels":[],"label_agreement":null},{"id":"W1997095405","doi":"10.1038/bmt.2008.318","title":"Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma","year":2008,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Ottawa Hospital; University of Ottawa","funders":"Canadian Blood Services","keywords":"Medicine; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Bone marrow; Oncology; Transplantation; Autologous stem-cell transplantation; Internal medicine; Haematopoiesis; Immunology; Stem cell","score_opus":0.025723260291014037,"score_gpt":0.2817840047250371,"score_spread":0.2560607444340231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997095405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408555,0.000086219225,0.0021889696,0.00010284607,0.00030115675,0.0024001962,0.00041675137,0.00013077098,0.00028754698],"genre_scores_gemma":[0.9909695,0.0005184516,0.0062778997,0.00010784245,0.000078792975,0.00046818508,0.0005654414,0.00008385373,0.000930027],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966466,0.0001729852,0.0008379019,0.00072727713,0.0007187102,0.0008965571],"domain_scores_gemma":[0.99783677,0.0011821196,0.00017769731,0.0002983595,0.0001743798,0.00033068177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005134409,0.00046769623,0.00080314145,0.00040290208,0.0003271593,0.000039685274,0.00017539378,0.00025630867,0.000031828116],"category_scores_gemma":[0.00023443995,0.00037088877,0.00027726873,0.00043718255,0.00009709676,0.0003412595,0.000013033641,0.00023785925,0.00003598418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061493237,0.0020700856,0.25627655,0.0030193282,0.00032930035,0.042787954,0.010848972,0.00038806786,0.60711485,0.000016753922,0.00009138395,0.01556353],"study_design_scores_gemma":[0.05844413,0.0019753806,0.66291857,0.0010827201,0.00037553895,0.001104196,0.00041115997,0.006403698,0.26646513,0.000008143234,0.00014878856,0.0006625621],"about_ca_topic_score_codex":0.0008486057,"about_ca_topic_score_gemma":0.0018348912,"teacher_disagreement_score":0.40664202,"about_ca_system_score_codex":0.00024218365,"about_ca_system_score_gemma":0.00046327684,"threshold_uncertainty_score":0.9998743},"labels":[],"label_agreement":null},{"id":"W1998297722","doi":"10.1111/j.1365-2141.2008.07409.x","title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program","year":2008,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Neutropenia; Refractory (planetary science); Discontinuation; Internal medicine; Adverse effect; Gastroenterology; Progressive disease; Peripheral neuropathy; Surgery; Toxicity; Chemotherapy; Endocrinology","score_opus":0.03682708077172939,"score_gpt":0.3573689208051373,"score_spread":0.3205418400334079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998297722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971184,0.00016862754,0.00009683376,0.0003418451,0.00007276825,0.001976234,0.00016792967,0.00003391431,0.000023419101],"genre_scores_gemma":[0.9832666,0.000107282875,0.016193429,0.000097962016,0.000033230983,0.00008630593,0.000044151617,0.000043885255,0.00012714478],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99601233,0.0008672127,0.0012200831,0.00044355448,0.0007910706,0.00066573784],"domain_scores_gemma":[0.99647623,0.00069804315,0.000811182,0.00037657074,0.0010042614,0.00063373323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000907905,0.0003091929,0.0016065709,0.0003408412,0.00010645109,0.000036863607,0.00031960243,0.00018236277,0.00004975035],"category_scores_gemma":[0.0042624483,0.00020618529,0.00009667409,0.00090405415,0.00037008768,0.00036439943,0.00008754931,0.00048451108,0.000004417522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5152639,0.005612306,0.34403744,0.00007725646,0.0003577929,0.11731515,0.00015405464,0.000007356769,0.000094814764,5.7221297e-7,0.000537017,0.016542314],"study_design_scores_gemma":[0.15016882,0.03077304,0.75084674,0.0015017468,0.00011912943,0.064891644,0.000105985506,0.000030401534,0.0011166551,0.0000029836144,0.00023063897,0.00021221329],"about_ca_topic_score_codex":0.00082635396,"about_ca_topic_score_gemma":0.0031889314,"teacher_disagreement_score":0.4068093,"about_ca_system_score_codex":0.00028473933,"about_ca_system_score_gemma":0.0014155797,"threshold_uncertainty_score":0.8407992},"labels":[],"label_agreement":null},{"id":"W1998463059","doi":"10.1053/j.seminoncol.2013.07.006","title":"Initial Treatment of Transplant Candidates With Multiple Myeloma","year":2013,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Thalidomide; Bortezomib; Autologous stem-cell transplantation; Oncology; Internal medicine; Toxicity; Transplantation; Surgery","score_opus":0.06313384381745932,"score_gpt":0.40425614925885506,"score_spread":0.34112230544139577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998463059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049288333,0.9878572,0.0000022843863,0.0000405323,0.00008465209,0.003062018,0.00028445292,0.000024441177,0.0037155438],"genre_scores_gemma":[0.0035847137,0.991897,0.0011838129,0.000009832129,0.00009319402,0.0012725353,0.0010561602,0.00006444041,0.00083833403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977042,0.0002548933,0.00069676305,0.00049508637,0.00027181525,0.00057720824],"domain_scores_gemma":[0.9980653,0.0008907547,0.00027366754,0.00044033822,0.000066335044,0.00026360643],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000107377855,0.00051312667,0.0030792535,0.0004992861,0.000034003075,0.0000062589515,0.00014733127,0.0005211542,0.00030387338],"category_scores_gemma":[0.00005304509,0.00030361966,0.00030243152,0.0003047964,0.0002648171,0.000036389665,0.000027258702,0.00029053105,0.000110339955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076806796,0.001597418,0.0057731792,0.004770001,0.0007521622,0.004301802,0.00031076753,1.6429523e-7,0.000004770732,0.0000075307903,0.00013084755,0.9815833],"study_design_scores_gemma":[0.0073078694,0.012487351,0.00032769074,0.014584156,0.001272638,0.0017218115,0.00006599461,0.000021829821,0.0001307295,0.000005150286,0.9618007,0.00027407138],"about_ca_topic_score_codex":0.0007140261,"about_ca_topic_score_gemma":0.0010235163,"teacher_disagreement_score":0.98130924,"about_ca_system_score_codex":0.0011283985,"about_ca_system_score_gemma":0.0014693432,"threshold_uncertainty_score":0.9999416},"labels":[],"label_agreement":null},{"id":"W1998776005","doi":"10.1155/2012/621958","title":"Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus","year":2012,"lang":"en","type":"article","venue":"Advances in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Celgene","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Neutropenia; Adverse effect; Thalidomide; Internal medicine; Oncology; Toxicity","score_opus":0.2843666199379395,"score_gpt":0.38077731469141446,"score_spread":0.09641069475347497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998776005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861663,0.0022410112,0.00014991833,0.00956895,0.00011694055,0.0010066613,0.000019971949,0.0000095252835,0.0007207143],"genre_scores_gemma":[0.9816684,0.00007650191,0.017774738,0.00025551452,0.000025608182,0.00013901346,0.000010262184,0.000010982774,0.000038975395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862146,0.00017594938,0.00029291867,0.00017673192,0.00014050164,0.00059240975],"domain_scores_gemma":[0.9979001,0.0014275516,0.000050733597,0.0002781605,0.000029344903,0.0003140521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025564228,0.00011055705,0.00035163155,0.0002497043,0.00003207051,0.0000038537087,0.00006641482,0.000080031066,0.000029828963],"category_scores_gemma":[0.002882202,0.0000743253,0.00003553569,0.0002849232,0.00016672061,0.00012872057,0.000040570903,0.00020858149,0.000042519685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055164826,0.00026365675,0.98886925,0.00006222429,0.000026528107,0.00033785493,0.0004017192,0.00009638864,0.000020896105,0.0055773216,0.00026887626,0.0035236503],"study_design_scores_gemma":[0.009498124,0.00044379372,0.83384186,0.00030916213,0.00006020061,0.00350502,0.0017567534,0.0056324457,0.0061310697,0.0003795098,0.13806546,0.00037663116],"about_ca_topic_score_codex":0.019111345,"about_ca_topic_score_gemma":0.3042665,"teacher_disagreement_score":0.28515518,"about_ca_system_score_codex":0.00012351404,"about_ca_system_score_gemma":0.00020564093,"threshold_uncertainty_score":0.9874205},"labels":[],"label_agreement":null},{"id":"W2000069677","doi":"10.1038/leu.2009.147","title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":360,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Placebo; Multiple myeloma; Internal medicine; Gastroenterology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Pathology","score_opus":0.04957727320909769,"score_gpt":0.3301043192462646,"score_spread":0.28052704603716694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000069677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970112,0.0002867045,0.00003831524,0.00022184639,0.00014435295,0.0018519972,0.00021051703,0.000036964324,0.00019811511],"genre_scores_gemma":[0.9978054,0.00013829922,0.00042044593,0.0003059165,0.00014662332,0.00004228795,0.00047924407,0.000039000144,0.00062276627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671495,0.00054218026,0.0008209063,0.00054862647,0.0008621254,0.00051120174],"domain_scores_gemma":[0.99600935,0.0024822906,0.00037454296,0.00070193666,0.0001316461,0.0003002284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008720608,0.00037596095,0.0012345512,0.00017103022,0.00009904275,0.000035533554,0.00019838412,0.00020075284,0.00017176752],"category_scores_gemma":[0.00230197,0.00020504811,0.00016010577,0.00024051941,0.00013724918,0.00015489358,0.000050737184,0.00050561276,0.000012601739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24067588,0.0018182136,0.64471257,0.00005963315,0.0007315143,0.00063969934,0.00088848814,0.000015489548,0.005571169,0.000018561548,0.0005741532,0.10429463],"study_design_scores_gemma":[0.19282138,0.0040634032,0.7981959,0.000484238,0.00017132093,0.0000034863267,0.000043238422,0.00016348,0.003727319,0.000026729309,0.00011029067,0.00018922254],"about_ca_topic_score_codex":0.0017848676,"about_ca_topic_score_gemma":0.0012390476,"teacher_disagreement_score":0.15348333,"about_ca_system_score_codex":0.000771089,"about_ca_system_score_gemma":0.00049515016,"threshold_uncertainty_score":0.8361619},"labels":[],"label_agreement":null},{"id":"W2000114835","doi":"10.1038/bmt.2009.107","title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Internal medicine; Chemotherapy; Hematology; Plasma cell leukemia; Adverse effect; Progression-free survival; Gastroenterology; Monoclonal gammopathy; Pathology; Monoclonal; Immunology; Monoclonal antibody; Antibody","score_opus":0.023291595308413723,"score_gpt":0.2768272757070758,"score_spread":0.2535356803986621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000114835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958347,0.000022496433,0.0007516241,0.00027827907,0.000011394253,0.0023265234,0.0007425705,0.00002705652,0.000005376915],"genre_scores_gemma":[0.9982774,0.000025346062,0.0006349359,0.00005088029,0.00001015944,0.00011057226,0.00083956786,0.000021912598,0.000029220395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987767,0.000055796845,0.00025677198,0.00024991887,0.00040151767,0.00025933847],"domain_scores_gemma":[0.99916613,0.000192264,0.00017932177,0.0001605316,0.00018509667,0.00011663559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009463912,0.00018105957,0.0002972398,0.00012544495,0.00009141337,0.000013043408,0.000050407652,0.00007352861,0.000011245928],"category_scores_gemma":[0.000065523534,0.000112297435,0.000037815225,0.00015818472,0.000052513533,0.00013772516,0.0000023021753,0.00012471451,4.929938e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071171266,0.0010489759,0.9870992,0.00009416002,0.00013599129,0.000041446656,0.0005594851,0.000113588074,0.00024263129,0.000007301122,0.000001364915,0.0035387764],"study_design_scores_gemma":[0.027503977,0.0020048672,0.9686244,0.0002604359,0.00016150203,0.000005082774,0.00023640541,0.0007451493,0.0003332781,0.0000062193512,0.0000013899312,0.000117283555],"about_ca_topic_score_codex":0.00013923833,"about_ca_topic_score_gemma":0.0037051952,"teacher_disagreement_score":0.02038685,"about_ca_system_score_codex":0.00008429588,"about_ca_system_score_gemma":0.000047833382,"threshold_uncertainty_score":0.45793566},"labels":[],"label_agreement":null},{"id":"W2000423695","doi":"10.3747/co.v14i2.148","title":"Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The NCIC CTG MY.11 Trial","year":2007,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Melphalan; Oncology; Internal medicine; Pharmacology","score_opus":0.14350009505488706,"score_gpt":0.44170573839104244,"score_spread":0.2982056433361554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000423695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939536,0.0008316711,0.0000992779,0.0010971361,0.00048494997,0.0030131722,0.00008274095,0.000012090742,0.00042537978],"genre_scores_gemma":[0.99833494,0.00036231233,0.00020238594,0.0000577651,0.00039864366,0.00042052878,0.00017440683,0.000012685798,0.000036340003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980024,0.00034628267,0.0005712453,0.00024993412,0.00040668802,0.0004234405],"domain_scores_gemma":[0.99684846,0.0022781654,0.000182111,0.00041721316,0.00012156294,0.00015248034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007675739,0.00017996946,0.0005297842,0.00022434435,0.00005994576,0.000004964961,0.00018740288,0.00009745105,0.00013443182],"category_scores_gemma":[0.0006465431,0.00009274642,0.00017578492,0.0003329114,0.00016436816,0.000030690044,0.00002967283,0.0001449322,0.000029923694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.095591545,0.017738627,0.12944196,0.000100331876,0.00026924835,0.0005040103,0.008878922,0.000014494678,0.0016111762,0.00017315465,0.0035246895,0.74215186],"study_design_scores_gemma":[0.23762934,0.020967921,0.54834545,0.00014754497,0.0002568058,0.000058368652,0.0030244545,0.00015336135,0.011353639,0.00006990353,0.17781639,0.00017685506],"about_ca_topic_score_codex":0.00052755704,"about_ca_topic_score_gemma":0.0032586025,"teacher_disagreement_score":0.741975,"about_ca_system_score_codex":0.0004106154,"about_ca_system_score_gemma":0.00024061606,"threshold_uncertainty_score":0.3782089},"labels":[],"label_agreement":null},{"id":"W2000668568","doi":"10.1309/ajcphc85dgaxzdbe","title":"p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide","year":2012,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Lenalidomide; Immunohistochemistry; Multiple myeloma; Fluorescence in situ hybridization; Internal medicine; Refractory (planetary science); Oncology; Medicine; Pathology; Biology; Gene","score_opus":0.033244997166144485,"score_gpt":0.3466991318335039,"score_spread":0.31345413466735944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000668568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849755,0.00006685864,0.00048132765,0.0001195555,0.00008176596,0.00064340996,0.0000298293,0.0000299992,0.00004970324],"genre_scores_gemma":[0.9837885,0.000077469755,0.015491026,0.00025688967,0.00020407674,0.00001947885,0.000058006575,0.00006644777,0.00003812533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973502,0.00041474798,0.0009213585,0.00033585817,0.00044889678,0.00052890717],"domain_scores_gemma":[0.99601704,0.0010668816,0.0011474026,0.00030718136,0.0005140825,0.0009474246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006945839,0.0002840271,0.0011022202,0.00016487138,0.000119782184,0.0000104296105,0.00011077575,0.00014783269,0.000023438415],"category_scores_gemma":[0.00094058394,0.00015300397,0.00013016736,0.00014528651,0.0009366844,0.0003794166,0.000033252396,0.00059740676,0.000005308933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056547273,0.0020777066,0.9118214,0.000025501637,0.00025338167,0.00038388468,0.00023245664,0.000008590875,0.00025915756,0.000002155492,0.000044716013,0.028343763],"study_design_scores_gemma":[0.03171489,0.05399391,0.91152143,0.00022107878,0.00041291688,0.00084778015,0.0004819705,0.00011020564,0.00008615463,0.0000029899627,0.0004278166,0.00017884182],"about_ca_topic_score_codex":0.000019794763,"about_ca_topic_score_gemma":0.000009940645,"teacher_disagreement_score":0.051916204,"about_ca_system_score_codex":0.00006295502,"about_ca_system_score_gemma":0.000111054294,"threshold_uncertainty_score":0.62393206},"labels":[],"label_agreement":null},{"id":"W2000781567","doi":"10.1016/j.jpba.2008.09.053","title":"Elucidation of potential bortezomib response markers in mutliple myeloma patients","year":2008,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Chemistry; Bortezomib; Multiple myeloma; Pharmacology; Cancer research; Internal medicine","score_opus":0.025429374027873746,"score_gpt":0.33968300626675757,"score_spread":0.3142536322388838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000781567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99784845,0.00023318181,0.00039255744,0.001312894,0.000039444567,0.00011081759,0.000019000563,0.0000033942013,0.00004028001],"genre_scores_gemma":[0.99851644,0.0005503588,0.00066526857,0.000097926306,0.00006659965,0.0000015522284,0.00002669342,0.00000562232,0.0000695678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997706,0.00022717833,0.0007192237,0.00015362984,0.00094962574,0.00024432264],"domain_scores_gemma":[0.99869347,0.00017792839,0.00019923059,0.000078106306,0.00025134423,0.0005999458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007679111,0.00011575159,0.00055037416,0.00096369075,0.000046145567,0.000006050362,0.00007993033,0.0000929727,0.00042781155],"category_scores_gemma":[0.0005079073,0.00007533868,0.00029875003,0.0011279883,0.00033159868,0.000092496906,0.000045767953,0.00028110002,0.0000035479065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028950876,0.0034003872,0.8735105,0.0000873545,0.0032183176,0.002113335,0.0001410956,0.0000067875176,0.028480746,0.0000028384,0.00054801133,0.059539776],"study_design_scores_gemma":[0.008140754,0.0010563979,0.981109,0.000040316012,0.0011299337,0.00014144409,0.00004285571,0.0050007766,0.0022146665,0.000010510579,0.0010451601,0.000068147005],"about_ca_topic_score_codex":0.000030033261,"about_ca_topic_score_gemma":0.0000025703239,"teacher_disagreement_score":0.107598566,"about_ca_system_score_codex":0.00007103365,"about_ca_system_score_gemma":0.0001349877,"threshold_uncertainty_score":0.46842366},"labels":[],"label_agreement":null},{"id":"W2001476066","doi":"10.1007/s11060-007-9513-1","title":"Tyrosine kinase expression in pediatric high grade astrocytoma","year":2008,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"PTEN; Tyrosine kinase; Medicine; Astrocytoma; Kinase; Receptor tyrosine kinase; Oncology; Internal medicine; Cancer research; Receptor; Biology; Glioma; Signal transduction; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.04532044771162644,"score_gpt":0.3373773372971633,"score_spread":0.2920568895855369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001476066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963398,0.00049461256,0.00003645116,0.0022795943,0.0003242192,0.00019671144,0.0000031272657,0.000010695538,0.00031481593],"genre_scores_gemma":[0.99349815,0.0018310668,0.0036514886,0.00030919313,0.0005907688,0.0000065684094,0.0000040514687,0.000019521087,0.00008919054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982852,0.00021714882,0.0005368529,0.00016424056,0.00044110382,0.00035549916],"domain_scores_gemma":[0.9986637,0.0003343094,0.00030454222,0.00016101461,0.00015055765,0.00038584147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019358355,0.0001411556,0.0005125645,0.0005327506,0.000060831295,0.0000050918134,0.00012822659,0.00012440715,0.00009855556],"category_scores_gemma":[0.00049179455,0.000101854,0.00012863753,0.00029557507,0.00006550651,0.00012245381,0.000058817008,0.00063503534,0.00003248038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007594666,0.0038744875,0.56321347,0.00007037721,0.00005318497,0.11639872,0.000307344,0.000047899393,0.2857783,0.000008460377,0.012764264,0.009888806],"study_design_scores_gemma":[0.019014087,0.0106265405,0.91508,0.0000458543,0.00007155241,0.0143125355,0.000038002174,0.0000669739,0.030306617,0.000034931847,0.010306446,0.00009644337],"about_ca_topic_score_codex":0.0000121303065,"about_ca_topic_score_gemma":0.0000076019346,"teacher_disagreement_score":0.35186654,"about_ca_system_score_codex":0.00029048006,"about_ca_system_score_gemma":0.00051282847,"threshold_uncertainty_score":0.41534856},"labels":[],"label_agreement":null},{"id":"W2002125254","doi":"10.1136/gut.2004.057976","title":"The lighter side of myeloma: an easily overlooked diagnosis","year":2005,"lang":"en","type":"article","venue":"Gut","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.02725591982289195,"score_gpt":0.3202149519849468,"score_spread":0.2929590321620549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002125254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98347735,0.0008561635,0.0000057777493,0.002825739,0.00004084961,0.0003156301,0.000011227498,0.000029534178,0.012437696],"genre_scores_gemma":[0.9952792,0.00028398752,0.00065041415,0.00019979745,0.00020482307,0.0000712009,0.000014579372,0.000013474166,0.0032825482],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990841,0.000041951604,0.00016436457,0.00014669636,0.00030270827,0.00026016502],"domain_scores_gemma":[0.9991795,0.00014930118,0.00003925002,0.00038117042,0.000071181465,0.00017958849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118135984,0.00009023175,0.00015172068,0.000042258558,0.00009110763,0.000014684591,0.000100826146,0.000042006253,0.00014458295],"category_scores_gemma":[0.00013812918,0.00005170798,0.00007505478,0.000079257064,0.00007467539,0.000078025674,0.00003368064,0.00008791379,0.00024606648],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006677231,0.000904202,0.4752463,0.00004142797,0.0002954241,0.00012575086,0.0004825642,0.00000239727,0.0072310423,0.00072982506,0.00807242,0.5062009],"study_design_scores_gemma":[0.0022266537,0.000428095,0.89397067,0.000038513223,0.000046390665,0.000012183571,0.000059047983,0.00022193321,0.024584686,0.00008015812,0.07826276,0.00006891666],"about_ca_topic_score_codex":0.00013824222,"about_ca_topic_score_gemma":0.00019158665,"teacher_disagreement_score":0.506132,"about_ca_system_score_codex":0.00004776086,"about_ca_system_score_gemma":0.0000565273,"threshold_uncertainty_score":0.3162769},"labels":[],"label_agreement":null},{"id":"W2002253776","doi":"10.4021/cr105e","title":"Bortezomib-induced Severe Congestive Heart Failure","year":2010,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Bortezomib; Heart failure; Ejection fraction; Cardiology; Internal medicine; Cardiomyopathy; Proteasome inhibitor; Cardiotoxicity; Multiple myeloma; Chemotherapy","score_opus":0.08624539336017022,"score_gpt":0.4193820406318487,"score_spread":0.33313664727167847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002253776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745764,0.00011872869,0.0000075301427,0.0051040403,0.00022091033,0.00096247083,0.000028092301,0.000078841455,0.018902963],"genre_scores_gemma":[0.9960476,0.000021520305,0.00072103884,0.0001222705,0.0006965253,0.00020421138,0.00007643386,0.00003372225,0.0020766617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710286,0.00045738835,0.00018797483,0.00056837336,0.0006251154,0.0010583163],"domain_scores_gemma":[0.9970682,0.0006261427,0.000019435174,0.0007943492,0.0008362359,0.000655588],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013499206,0.0001798861,0.0006259159,0.00031973634,0.00028933166,0.000031034884,0.00021188322,0.00040627108,0.00044797867],"category_scores_gemma":[0.0019802987,0.00013980936,0.00018125855,0.00040125262,0.00060352706,0.00007032491,0.0002010688,0.002284409,0.0014772542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007859632,0.00012191341,0.6991298,0.000049963466,0.0005980491,0.0017652992,0.0000921766,0.0000013232373,0.2460988,0.0007472515,0.044733178,0.0058762897],"study_design_scores_gemma":[0.0050775805,0.001456728,0.8902921,0.0000366991,0.0000519455,0.0034159406,0.00040016463,0.0000991796,0.013766945,0.0005097014,0.08464781,0.00024521796],"about_ca_topic_score_codex":0.000087590895,"about_ca_topic_score_gemma":0.000059161302,"teacher_disagreement_score":0.23233186,"about_ca_system_score_codex":0.00009798286,"about_ca_system_score_gemma":0.0006029351,"threshold_uncertainty_score":0.9993002},"labels":[],"label_agreement":null},{"id":"W2002605588","doi":"10.1182/blood-2008-12-193458","title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; BC Cancer Agency; University of Calgary; Vancouver General Hospital","funders":"","keywords":"Lenalidomide; Internal medicine; Hazard ratio; Multiple myeloma; Dexamethasone; Medicine; Gastroenterology; Regimen; Refractory (planetary science); Adverse effect; Oncology; Surgery; Biology; Confidence interval","score_opus":0.009374690451090184,"score_gpt":0.2552826968188061,"score_spread":0.24590800636771593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002605588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984412,0.00006749751,0.000010629512,0.000009110372,0.0000036208696,0.001343298,0.000029039124,0.000025410578,0.00007015786],"genre_scores_gemma":[0.998172,0.000033894183,0.001579591,0.000015428926,0.000009056378,0.000035511057,0.00008688483,0.000024665687,0.000043010125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982748,0.00016682429,0.0003687055,0.00029864826,0.0005685604,0.00032244943],"domain_scores_gemma":[0.9986684,0.00029050338,0.00021843729,0.0004023836,0.00025156548,0.00016875289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016921165,0.00023927147,0.00057650165,0.00024411343,0.000028057775,0.0000031866882,0.000092467395,0.00011165847,0.000013534133],"category_scores_gemma":[0.00046166359,0.00014148011,0.000055523018,0.0004776828,0.0001140812,0.000092182294,0.00001760098,0.00017347319,0.0000042430293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037826207,0.0018365147,0.9430672,0.0001591103,0.00023675889,0.00020847715,0.00010559608,0.0005199952,0.0125819305,5.474317e-7,0.0000022338888,0.0034554054],"study_design_scores_gemma":[0.06633096,0.017250033,0.76114297,0.0005009499,0.0002518806,0.0000115442745,0.000012117414,0.000071405186,0.1543165,5.229891e-7,0.0000045788515,0.00010656673],"about_ca_topic_score_codex":0.0002679216,"about_ca_topic_score_gemma":0.0001261394,"teacher_disagreement_score":0.18192428,"about_ca_system_score_codex":0.00010030661,"about_ca_system_score_gemma":0.00017161423,"threshold_uncertainty_score":0.57693917},"labels":[],"label_agreement":null},{"id":"W2002628697","doi":"10.4021//jmc.v2i3.156","title":"Non-Secretory Myeloma or Light Chain-Producing Multiple Myeloma: A Case Report","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Immunoglobulin light chain; Immunofixation; Serum protein electrophoresis; Pathology; Bone marrow; Urine; Monoclonal; Antibody; Monoclonal antibody; Internal medicine; Immunology","score_opus":0.07489674003513982,"score_gpt":0.34452937786554516,"score_spread":0.26963263783040536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002628697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377173,0.0011035829,0.00024892777,0.002683866,0.0006123382,0.0004071708,0.000008247239,0.000037288897,0.0011268349],"genre_scores_gemma":[0.9931595,0.0002480802,0.0031341193,0.0004159679,0.0016372898,0.00001749532,0.000008879468,0.000046821828,0.001331855],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.995422,0.00011831763,0.0011685126,0.00037243543,0.0023148023,0.0006039205],"domain_scores_gemma":[0.99595755,0.0004974181,0.0005486272,0.00055045215,0.00054372096,0.0019022543],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019383933,0.00029313256,0.00079638837,0.00039366126,0.00017391614,0.000025637752,0.00025667687,0.00025911175,0.0033798697],"category_scores_gemma":[0.009730987,0.00017603196,0.000340661,0.00031108153,0.00019017694,0.00020161804,0.00013904092,0.0008851039,0.00005826761],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029259769,0.00087976234,0.037048034,0.00019768416,0.00040108603,0.92210984,0.00093558704,1.1732582e-7,0.0004349624,0.000003829967,0.009969858,0.025093239],"study_design_scores_gemma":[0.00670718,0.0026773792,0.04191191,0.00081382843,0.0002202637,0.9306807,0.0010845072,0.00024651331,0.008430624,0.000011547881,0.007023324,0.00019222016],"about_ca_topic_score_codex":0.00062553503,"about_ca_topic_score_gemma":0.0002668218,"teacher_disagreement_score":0.024901018,"about_ca_system_score_codex":0.00019690795,"about_ca_system_score_gemma":0.0014319945,"threshold_uncertainty_score":0.9986105},"labels":[],"label_agreement":null},{"id":"W2002857087","doi":"10.1053/j.seminhematol.2012.05.004","title":"The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies","year":2012,"lang":"en","type":"article","venue":"Seminars in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Carfilzomib; Bortezomib; Refractory (planetary science); Panobinostat; Thalidomide; Vorinostat; Oncology; Multiple myeloma; Proteasome inhibitor; Combination therapy; Internal medicine; Ixazomib; Pharmacology; Histone deacetylase","score_opus":0.03592587437793413,"score_gpt":0.34443080829094325,"score_spread":0.3085049339130091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002857087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666503,0.031177217,0.00006597496,0.000570543,0.00023030878,0.0010019717,0.000020055679,0.000015697575,0.00026794008],"genre_scores_gemma":[0.9906413,0.0072844913,0.0014358306,0.000029154247,0.00009820138,0.00026352642,0.000030520237,0.000021012691,0.00019595074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988801,0.00004821366,0.00027313508,0.0001899861,0.0001330871,0.00047551256],"domain_scores_gemma":[0.99884415,0.0006257248,0.000097754906,0.00025926312,0.000049937207,0.00012320232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020667067,0.0001719187,0.00036966018,0.0000988687,0.000117725474,0.000008072425,0.00007088639,0.00012813113,0.000014207143],"category_scores_gemma":[0.000084140855,0.00010310489,0.00007747565,0.000094529336,0.00015806012,0.00009125316,0.000029116933,0.00010381129,0.0000022343563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027260655,0.0017661046,0.7863462,0.0001688278,0.00037265982,0.000040177252,0.0028950397,0.0000016569828,0.0046525495,0.0057328013,0.00050381327,0.19479407],"study_design_scores_gemma":[0.049479816,0.005626763,0.7375013,0.00049346033,0.0001635408,0.00094464514,0.024278764,0.0014504243,0.03793864,0.0012679312,0.14032346,0.00053123],"about_ca_topic_score_codex":0.000047955436,"about_ca_topic_score_gemma":0.000089890484,"teacher_disagreement_score":0.19426285,"about_ca_system_score_codex":0.00007611425,"about_ca_system_score_gemma":0.00007827643,"threshold_uncertainty_score":0.42044953},"labels":[],"label_agreement":null},{"id":"W2003202645","doi":"10.1016/j.leukres.2014.02.009","title":"Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival","year":2014,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Ministry of Science and Technology of the People's Republic of China","keywords":"Multiple myeloma; Polyclonal antibodies; Medicine; Monoclonal; Internal medicine; Gastroenterology; Bone marrow; Monoclonal gammopathy of undetermined significance; Clinical significance; Bortezomib; Thalidomide; Immunology; Pathology; Oncology; Antibody; Monoclonal antibody","score_opus":0.04705372373716442,"score_gpt":0.3359393037555853,"score_spread":0.28888558001842085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003202645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976003,0.00022391803,0.000033695,0.00018759756,0.00007314201,0.0009767493,0.00032361262,0.00004151751,0.0005394612],"genre_scores_gemma":[0.99700767,0.00016675553,0.00077402155,0.00003520521,0.00014765648,0.000075566175,0.00018713527,0.000042476044,0.0015635291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955307,0.00078746193,0.0004272561,0.0006964273,0.0015780191,0.0009801013],"domain_scores_gemma":[0.99618715,0.001888778,0.00009851152,0.0005969084,0.0006821499,0.0005464838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016594019,0.00028714127,0.00064229395,0.00033907683,0.0003364527,0.00007812004,0.00027631398,0.00026536887,0.00013828918],"category_scores_gemma":[0.002774834,0.00018509374,0.00012337793,0.00043213836,0.0009910234,0.00013779195,0.00035754137,0.0010276858,0.00005294591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004979007,0.00043497185,0.9713684,0.00021062852,0.0002226584,0.000054759286,0.00018130349,0.0000017424228,0.0020526305,0.000100777346,0.00033867938,0.020054445],"study_design_scores_gemma":[0.0113975415,0.002409095,0.9800932,0.00017214926,0.00003696012,0.000015749638,0.0001958385,0.0004244988,0.0047151037,0.00013908451,0.00022435971,0.00017643374],"about_ca_topic_score_codex":0.0017479635,"about_ca_topic_score_gemma":0.0008884887,"teacher_disagreement_score":0.01987801,"about_ca_system_score_codex":0.00026523092,"about_ca_system_score_gemma":0.000422232,"threshold_uncertainty_score":0.75479037},"labels":[],"label_agreement":null},{"id":"W2003656303","doi":"10.1016/j.bbmt.2013.01.004","title":"Salvage Second Hematopoietic Cell Transplantation in Myeloma","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Terumo BCT; Health Resources and Services Administration; National Institutes of Health; Swedish Orphan Biovitrum; Otsuka America; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; U.S. Navy; Osiris Therapeutics; Celgene; HistoGenetics; Teva Pharmaceutical Industries; WellPoint; Merck; GlaxoSmithKline; Leukemia and Lymphoma Society; Be The Match Foundation; Ariad Pharmaceuticals; Otsuka America Pharmaceutical; Amgen; Sanofi; U.S. Department of Defense; Genentech; CellGenix; Seattle Genetics; U.S. Department of Health and Human Services; National Marrow Donor Program","keywords":"Medicine; Multiple myeloma; Transplantation; Surgery; Salvage therapy; Progression-free survival; Hematopoietic stem cell transplantation; Progressive disease; Hematopoietic cell; Retrospective cohort study; Internal medicine; Overall survival; Haematopoiesis; Chemotherapy; Stem cell","score_opus":0.010905995331608064,"score_gpt":0.2525937452193226,"score_spread":0.24168774988771452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003656303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668753,0.00060710125,0.0001237462,0.0001588311,0.000026921192,0.0005096815,0.000058660793,0.000017045624,0.0018104751],"genre_scores_gemma":[0.9969465,0.0015546023,0.0008683496,0.0000504062,0.000014850679,0.00005584583,0.00037174975,0.000008947072,0.00012873048],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99922127,0.00005980381,0.00024590365,0.00019810618,0.00007820623,0.00019671171],"domain_scores_gemma":[0.99965894,0.000084112995,0.000049440798,0.000082388884,0.000035498782,0.00008963005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082732106,0.00011357943,0.00022700656,0.00016119904,0.000027380083,0.000005443488,0.000033765107,0.000115759154,0.00025948195],"category_scores_gemma":[0.00000454369,0.000094411946,0.000039822153,0.000085229636,0.000085361455,0.000088063665,0.0000027353224,0.00009026158,0.000016224114],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031534216,0.00023801916,0.24727406,0.0012527179,0.000055851393,0.00008683604,0.00084636203,3.5684133e-7,0.745489,0.00012805987,0.000012480912,0.0043009194],"study_design_scores_gemma":[0.006535056,0.0005425947,0.6615192,0.00010940049,0.00017244802,0.00022062227,0.00009508273,0.000026626289,0.33030003,0.00036090717,0.000018035473,0.00009996523],"about_ca_topic_score_codex":0.00019122171,"about_ca_topic_score_gemma":0.0001413311,"teacher_disagreement_score":0.41518897,"about_ca_system_score_codex":0.0000058120254,"about_ca_system_score_gemma":0.000029842204,"threshold_uncertainty_score":0.38500074},"labels":[],"label_agreement":null},{"id":"W2004114140","doi":"10.3129/i06-067","title":"Orbital and muscle involvement in multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunoglobulin light chain; Multiple myeloma; Plasmacytoma; Medicine; Magnetic resonance imaging; Pathology; Extramedullary plasmacytoma; Computed tomography; Kappa; Antibody; Orbit (dynamics); Radiology; Internal medicine; Immunology","score_opus":0.036501544531816754,"score_gpt":0.28698110104252017,"score_spread":0.2504795565107034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004114140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916906,0.0011969479,0.000002600747,0.00047127708,0.00010533306,0.00015044848,0.000010661073,0.0000013354909,0.006370807],"genre_scores_gemma":[0.9988657,0.0000033209872,0.0005881219,0.000019808207,0.00009855096,0.0000039044703,0.000010076201,0.000011251672,0.000399231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990465,0.00004922148,0.0003042453,0.00011595656,0.000117756485,0.00036633218],"domain_scores_gemma":[0.9991048,0.0000673294,0.00007571492,0.00009972092,0.00009562754,0.0005567937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018571272,0.000095878735,0.00025972567,0.00044402908,0.000051138217,0.000014241727,0.00006531205,0.000075287615,0.0004129926],"category_scores_gemma":[0.00014823485,0.00008156492,0.000050756098,0.0001301083,0.00013227588,0.00006549999,0.0000109596085,0.0001939691,0.000010645095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008076711,0.00006645436,0.8788057,0.000017334876,0.000029891595,0.11906191,0.00006682767,0.000005980087,0.00050516817,0.000066315864,0.00027742877,0.0010162293],"study_design_scores_gemma":[0.0027512258,0.00056776556,0.9210374,0.000041691408,0.000011717727,0.07438272,0.00010661089,0.000055082117,0.00023948848,0.00029520938,0.00045229876,0.000058822534],"about_ca_topic_score_codex":0.029882425,"about_ca_topic_score_gemma":0.0072941217,"teacher_disagreement_score":0.044679184,"about_ca_system_score_codex":0.00020723042,"about_ca_system_score_gemma":0.0007335815,"threshold_uncertainty_score":0.9765777},"labels":[],"label_agreement":null},{"id":"W2004959870","doi":"10.1093/annonc/mdi818","title":"ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine","score_opus":0.2574790015634335,"score_gpt":0.4988641872042931,"score_spread":0.2413851856408596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004959870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966013,0.0007713277,0.000028769917,0.030977458,0.0001320179,0.0009576012,0.00018910864,0.000017763092,0.0009129168],"genre_scores_gemma":[0.98476744,0.0055162883,0.0078940615,0.0005436812,0.00015695501,0.00031910665,0.00014595258,0.000014351379,0.00064216234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987027,0.0001132014,0.0005719993,0.00024157895,0.00009446854,0.00027605443],"domain_scores_gemma":[0.99719596,0.0019092849,0.0001917197,0.00022632522,0.00025055656,0.00022617825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035158862,0.0001261804,0.00061216176,0.000118806594,0.00005057834,0.000002714044,0.000059074915,0.00015235745,0.000097225464],"category_scores_gemma":[0.0008511758,0.00009840236,0.00022706548,0.00007394519,0.00017516065,0.00005210821,0.000036269368,0.00006857682,0.000010309465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018364842,0.0026985947,0.29180062,0.000039223443,0.0005316384,0.000007682954,0.00019367918,4.22809e-7,0.00016391656,0.0000778252,0.025305979,0.67734396],"study_design_scores_gemma":[0.028480893,0.0253335,0.2369483,0.00007657739,0.00023349693,0.000022957309,0.00018745309,0.00057187147,0.02213084,0.0001245365,0.6857676,0.000121982],"about_ca_topic_score_codex":0.00013754667,"about_ca_topic_score_gemma":0.00044764325,"teacher_disagreement_score":0.67722195,"about_ca_system_score_codex":0.000044750614,"about_ca_system_score_gemma":0.0002099707,"threshold_uncertainty_score":0.40127316},"labels":[],"label_agreement":null},{"id":"W2005090809","doi":"10.1016/j.bbmt.2014.07.013","title":"Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Terumo BCT; Health Resources and Services Administration; Medac; Swedish Orphan Biovitrum; Incyte; Genentech; Seattle Genetics; University of Utah; Blue Cross and Blue Shield Association; Kiadis Pharma; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Takeda Oncology; University of Minnesota; National Marrow Donor Program; St. Baldrick's Foundation; Health Research; U.S. Navy; Osiris Therapeutics; Merck; GlaxoSmithKline; Texas Instruments; Leukemia and Lymphoma Society; Be The Match Foundation; Allos Therapeutics; Actinium Pharmaceuticals; Ariad Pharmaceuticals; Otsuka America Pharmaceutical; Amgen; WellPoint; National Institute of Allergy and Infectious Diseases; Roswell Park Cancer Institute; Onyx Pharmaceuticals; U.S. Department of Defense; Sanofi","keywords":"Medicine; Multiple myeloma; Cohort; Hematopoietic cell; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Multivariate analysis; Oncology; Demography; Gerontology; Haematopoiesis; Stem cell","score_opus":0.006925289993602052,"score_gpt":0.23251242440256956,"score_spread":0.2255871344089675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005090809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968396,0.00017091492,0.0017542028,0.00014264173,0.00003559617,0.0003968075,0.0003574342,0.000033198834,0.000269616],"genre_scores_gemma":[0.9935428,0.00047422774,0.0028909203,0.000076415905,0.000029187264,0.00002409529,0.0029336477,0.000013128059,0.00001556709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913317,0.00005930163,0.00020288487,0.00027543804,0.00013124302,0.00019794797],"domain_scores_gemma":[0.9994775,0.00013418237,0.00007859585,0.000111694535,0.00008846501,0.000109554145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005765264,0.00015411942,0.0002788723,0.000096189164,0.00006522891,0.000005188164,0.000040632916,0.0001346775,0.000041416],"category_scores_gemma":[0.0000093147,0.0001128891,0.000039455022,0.000061060055,0.0001369634,0.00006627787,0.0000031373077,0.00007922109,0.000003520336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030793797,0.0003966448,0.91470516,0.00034532463,0.0004698875,0.00003945895,0.00087113533,0.0000025963125,0.044593845,0.00026527914,0.0000042506736,0.03522706],"study_design_scores_gemma":[0.011280561,0.0014676253,0.9428813,0.00013556272,0.0008014816,0.0000335651,0.000021806178,0.0000623339,0.04296895,0.0002070697,0.000022159595,0.00011760483],"about_ca_topic_score_codex":0.00018010764,"about_ca_topic_score_gemma":0.00014154965,"teacher_disagreement_score":0.035109453,"about_ca_system_score_codex":0.000005854014,"about_ca_system_score_gemma":0.000022774577,"threshold_uncertainty_score":0.4603484},"labels":[],"label_agreement":null},{"id":"W2005128772","doi":"10.1160/th13-02-0140","title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","year":2013,"lang":"en","type":"article","venue":"Thrombosis and Haemostasis","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Medicine; Pulmonary embolism; Observational study; Internal medicine; Incidence (geometry); Low molecular weight heparin; Aspirin; Risk assessment; Venous thromboembolism; Prospective cohort study; Risk factor; Venous thrombosis; Thrombosis; Intensive care medicine; Surgery","score_opus":0.04946867830323342,"score_gpt":0.3000515710931263,"score_spread":0.2505828927898929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005128772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595714,0.00007490778,0.0000070043743,0.0000457986,0.0000148773515,0.0035687436,0.00025780255,0.00003562626,0.000038118782],"genre_scores_gemma":[0.99839014,0.00004110565,0.0010755784,0.000041650612,0.000011792096,0.0001611027,0.00020926057,0.000050828254,0.000018545035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997734,0.00012408246,0.00043561065,0.0004944916,0.0006671552,0.0005446778],"domain_scores_gemma":[0.9984,0.00020582038,0.00018605734,0.00045109648,0.00041893206,0.000338107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014913561,0.0003575513,0.0008992724,0.0003485971,0.00016722002,0.000038501115,0.00011490984,0.00006574176,0.00016015228],"category_scores_gemma":[0.000112091664,0.00023046548,0.00005837078,0.00064084365,0.000088141256,0.00025131102,0.00009161968,0.00018505569,0.000015537787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010571644,0.007966339,0.9763255,0.00005185331,0.00078257837,0.000009508733,0.004673499,0.0000095984,0.000106828666,0.0000015965996,0.000025363464,0.008990143],"study_design_scores_gemma":[0.018243931,0.004457871,0.97354096,0.00013147829,0.00030013322,7.8224963e-7,0.0019348154,0.00032198674,0.000817657,0.0000018480433,0.000012143088,0.0002363982],"about_ca_topic_score_codex":0.008200544,"about_ca_topic_score_gemma":0.00062012166,"teacher_disagreement_score":0.017186766,"about_ca_system_score_codex":0.00013661807,"about_ca_system_score_gemma":0.000081364204,"threshold_uncertainty_score":0.9984039},"labels":[],"label_agreement":null},{"id":"W2005204505","doi":"10.1177/1078155214533367","title":"Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site","year":2014,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Tolerability; Dosing; Subcutaneous injection; Anesthesia; Route of administration; Multiple myeloma; Adverse effect; Pharmacology; Internal medicine","score_opus":0.0622537412032568,"score_gpt":0.4347714572492852,"score_spread":0.37251771604602835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005204505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380034,0.00014907801,0.0012057441,0.0025673192,0.0002922405,0.0002882859,0.000010530098,0.0000064037167,0.0016800403],"genre_scores_gemma":[0.98870075,0.00014532047,0.010579505,0.00019007796,0.00028310137,0.000002297454,0.000006240772,0.0000143579055,0.00007832967],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975208,0.00068821205,0.00091064617,0.0001540563,0.0005121377,0.00021416193],"domain_scores_gemma":[0.9959391,0.0008901718,0.0015892339,0.00017707223,0.0011818478,0.00022258837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017571535,0.00013047105,0.0005652233,0.00021100308,0.000058901518,0.0000095435,0.000090051486,0.000099325145,0.00026287374],"category_scores_gemma":[0.0027276475,0.00010967645,0.00016657093,0.00017239488,0.00013175956,0.00051388226,0.000030614432,0.000578736,0.000009473978],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0823749,0.00930896,0.25180522,0.0005470858,0.0018382655,0.0020889163,0.0015239241,0.0006015452,0.5068638,0.000022327196,0.00081975135,0.14220534],"study_design_scores_gemma":[0.06805747,0.079016656,0.1733832,0.00048071594,0.008452006,0.16043967,0.0020183625,0.04924692,0.18243945,0.00041036104,0.27538404,0.00067115837],"about_ca_topic_score_codex":0.00020110441,"about_ca_topic_score_gemma":0.000013320836,"teacher_disagreement_score":0.32442433,"about_ca_system_score_codex":0.00037976584,"about_ca_system_score_gemma":0.0010919578,"threshold_uncertainty_score":0.4472476},"labels":[],"label_agreement":null},{"id":"W2005532233","doi":"10.1080/1042819021000040125","title":"Intra-cerebral Relapse Following Prolonged Remission after Autologous Stem Cell Transplantation for Multiple Myeloma","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Complication; Stem cell; Pathophysiology; Central nervous system; Oncology; Internal medicine; Surgery; Biology","score_opus":0.015530059102037147,"score_gpt":0.2456129782174663,"score_spread":0.23008291911542916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005532233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910608,0.002919721,0.00036054157,0.0002096998,0.00045438996,0.0023033984,0.00012260869,0.00037770884,0.0021911233],"genre_scores_gemma":[0.9894115,0.0006165395,0.0030478307,0.00049082015,0.0003449734,0.0008969991,0.00029579128,0.00015836993,0.004737223],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956046,0.00017766426,0.0008471313,0.0012500548,0.0007634897,0.0013570695],"domain_scores_gemma":[0.9974461,0.00048318034,0.00022820386,0.00072559516,0.00019582374,0.00092107395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003301793,0.0007697358,0.0009566718,0.00036636082,0.00053943536,0.00013872511,0.00024906712,0.0006678937,0.00011432237],"category_scores_gemma":[0.00015683648,0.000661269,0.00053119776,0.00040809973,0.00018292508,0.00043662818,0.00007933936,0.00019635523,0.00012186358],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011744647,0.0008512821,0.1021257,0.0018861723,0.0006746117,0.0043277587,0.0050471,0.000023173718,0.015069888,0.00004617429,0.0034971277,0.85470635],"study_design_scores_gemma":[0.12670738,0.0030278435,0.6813932,0.0013056048,0.0015836265,0.0024362572,0.000787498,0.0760792,0.08385596,0.00016015115,0.020651655,0.0020116286],"about_ca_topic_score_codex":0.000280569,"about_ca_topic_score_gemma":0.00006160272,"teacher_disagreement_score":0.85269475,"about_ca_system_score_codex":0.0036215798,"about_ca_system_score_gemma":0.00079921825,"threshold_uncertainty_score":0.99958384},"labels":[],"label_agreement":null},{"id":"W2005981818","doi":"10.1016/j.clml.2013.12.015","title":"Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma","year":2014,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Deutsche Forschungsgemeinschaft; National Cancer Institute; Celgene; Amgen; American Society of Hematology","keywords":"Thalidomide; Medicine; Lenalidomide; Multiple myeloma; Pomalidomide; Oncology; Teniposide; Clinical trial; Bortezomib; Internal medicine; Cyclophosphamide; Melphalan; Pharmacology; Prednisone; Chemotherapy; Etoposide","score_opus":0.2745757903204223,"score_gpt":0.5036168554340602,"score_spread":0.22904106511363792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005981818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47867358,0.51436013,0.000020765468,0.00011657814,0.0007524979,0.0051172916,0.00026410093,0.000090604175,0.000604446],"genre_scores_gemma":[0.18390968,0.8127165,0.00074858015,0.00012240246,0.0009966774,0.0004326899,0.00042776825,0.00020234718,0.00044337078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97230595,0.011081353,0.011241582,0.0025674817,0.001259735,0.0015439035],"domain_scores_gemma":[0.9591464,0.03301345,0.003679907,0.0021626642,0.0002575263,0.001740042],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.024131928,0.0014987449,0.017440228,0.0011765532,0.00017012462,0.00007135824,0.0007688385,0.0027778838,0.00015949912],"category_scores_gemma":[0.048297472,0.0011547691,0.0038620932,0.0011533069,0.00145018,0.00021626939,0.0010043508,0.0020440621,0.00016167513],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003939034,0.0067653526,0.012090787,0.008164853,0.00096011907,0.0008614726,0.000067095854,2.0241659e-7,0.00001455147,0.000021928328,0.00043664547,0.96667796],"study_design_scores_gemma":[0.08686087,0.007707328,0.26812726,0.03152999,0.0025943092,0.00026689313,0.00004221057,0.0010772959,0.000065077846,0.00009316303,0.6001364,0.0014992161],"about_ca_topic_score_codex":0.0004595842,"about_ca_topic_score_gemma":0.00021447577,"teacher_disagreement_score":0.9651787,"about_ca_system_score_codex":0.0023290534,"about_ca_system_score_gemma":0.0044923355,"threshold_uncertainty_score":0.9997762},"labels":[],"label_agreement":null},{"id":"W2006347360","doi":"10.1016/j.jval.2013.08.597","title":"A Prospective Time and Motion Analysis Comparing Intravenous (IV) Vesus Subcutaneous (SC) Bortezomib in Patients with Multiple Myeloma (MM)","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Premedication; Vial; Clinical trial; Surgery; Internal medicine","score_opus":0.017021210463844503,"score_gpt":0.2620738018861646,"score_spread":0.24505259142232008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006347360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969321,0.00015539974,0.000027358145,0.0002028041,0.000016697399,0.0024652143,0.000018043836,0.000036885423,0.00014549977],"genre_scores_gemma":[0.99852747,0.000035195786,0.0010589221,0.000043031865,0.000020588956,0.00009981071,0.00015180832,0.000023938957,0.000039206865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979585,0.00018103735,0.00042922044,0.0004535113,0.00039653337,0.0005812184],"domain_scores_gemma":[0.9989819,0.0001644583,0.00012500801,0.00027164194,0.000114630704,0.00034233936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002417961,0.00019256384,0.00063117896,0.000602929,0.000083544575,0.000033057437,0.000060368726,0.000069370784,0.000039818307],"category_scores_gemma":[0.0001528342,0.00015794727,0.000043087544,0.0008469108,0.0000666519,0.00011066926,0.000039086095,0.0002770196,0.000044372788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001030147,0.0008758839,0.98142856,0.00009295764,0.00021782766,0.00009371231,0.0009440429,0.0014645396,0.000017356977,0.000007105075,0.0000043504083,0.013823539],"study_design_scores_gemma":[0.0062192823,0.0015482833,0.8661572,0.0001670603,0.000044651893,0.000013577969,0.000053692867,0.12563026,0.000019207473,0.000037477555,0.0000017161988,0.0001076338],"about_ca_topic_score_codex":0.04308112,"about_ca_topic_score_gemma":0.0013421575,"teacher_disagreement_score":0.12416572,"about_ca_system_score_codex":0.00070631714,"about_ca_system_score_gemma":0.0001464449,"threshold_uncertainty_score":0.9632911},"labels":[],"label_agreement":null},{"id":"W2006498624","doi":"10.1592/phco.21.15.1175.33890","title":"Impact of Age and Gender on the Pharmacokinetics of Gemtuzumab Ozogamicin","year":2001,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gemtuzumab ozogamicin; Calicheamicin; Medicine; Pharmacokinetics; Internal medicine; Pediatrics; Myeloid leukemia; CD33","score_opus":0.0718844350974778,"score_gpt":0.42120010313754924,"score_spread":0.3493156680400714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006498624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879077,0.009555179,0.000012141885,0.0013516269,0.00012213981,0.0006272354,0.000014213311,0.00000799865,0.00040177547],"genre_scores_gemma":[0.9355095,0.06273392,0.000024339295,0.0012471903,0.0002570101,0.000006801924,0.0000017717291,0.00003155359,0.0001879103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979039,0.000660549,0.0005732896,0.0001475824,0.00038963824,0.00032502934],"domain_scores_gemma":[0.9981616,0.0007171167,0.0005196192,0.00018115918,0.00022189187,0.00019861976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011476803,0.00027314812,0.00055284664,0.00024767083,0.00019799598,0.000010979672,0.00027707385,0.0000538574,0.001658943],"category_scores_gemma":[0.000010894602,0.00012944722,0.0002441802,0.00017319732,0.0006075714,0.00008334317,0.000032878168,0.00056143035,0.0000017341705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015566008,0.0012089107,0.026254423,0.000038826238,0.0031871006,0.00020494581,0.0031033326,0.000053087595,0.9285686,0.000050169987,0.0057839444,0.015980624],"study_design_scores_gemma":[0.07574251,0.011121257,0.23932941,0.00012108434,0.0014890811,0.0017940932,0.00051152933,0.0008428601,0.6603872,0.0019268707,0.0062916465,0.00044244446],"about_ca_topic_score_codex":0.00004132921,"about_ca_topic_score_gemma":0.0000012687032,"teacher_disagreement_score":0.2681814,"about_ca_system_score_codex":0.000053319134,"about_ca_system_score_gemma":0.00010078246,"threshold_uncertainty_score":0.9992537},"labels":[],"label_agreement":null},{"id":"W2007047214","doi":"10.1111/j.1365-2141.2005.05849.x","title":"Lack of CD27 in myeloma delineates different presentation and outcome","year":2005,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Presentation (obstetrics); Plasma cell; Overall survival; Gastroenterology; Pathology; Surgery","score_opus":0.061643159301632916,"score_gpt":0.37949167654108673,"score_spread":0.31784851723945384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007047214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946635,0.0034238035,0.000064058746,0.0015156103,0.000037005357,0.00014518555,0.000005604252,0.0000031515349,0.00014208276],"genre_scores_gemma":[0.997316,0.0008378112,0.0016058355,0.00006968804,0.000056151526,0.0000029239643,0.000005629968,0.000007907909,0.0000980637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988486,0.00008310955,0.0006141123,0.000087348046,0.00019591243,0.00017089988],"domain_scores_gemma":[0.9993664,0.00011238299,0.00019066292,0.00006132788,0.00014638533,0.000122854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001619866,0.00007141936,0.0005176481,0.00017329806,0.0000171893,0.000009877971,0.000051197567,0.000060665287,0.00008406383],"category_scores_gemma":[0.0003104755,0.00006264886,0.00006458398,0.000061498984,0.000080777136,0.00008651676,0.000026390158,0.00017475916,0.0000033132894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038153387,0.00041662433,0.9152541,0.00014380761,0.00010923031,0.011202388,0.0000931369,0.000007107006,0.0007300072,0.000058514128,0.00039369916,0.07120984],"study_design_scores_gemma":[0.0057910285,0.00035223566,0.91057897,0.00027880803,0.00004643305,0.07853651,0.000106781226,0.00041473645,0.0035459124,0.0001294683,0.0001679299,0.000051168507],"about_ca_topic_score_codex":0.00010875608,"about_ca_topic_score_gemma":0.00046002906,"teacher_disagreement_score":0.07115867,"about_ca_system_score_codex":0.000031637508,"about_ca_system_score_gemma":0.000033594035,"threshold_uncertainty_score":0.25547466},"labels":[],"label_agreement":null},{"id":"W2007502238","doi":"10.1159/000205622","title":"Nonsecretory Myeloma: A Study on Hypoimmunoglobulinemia","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Arthritis Society","keywords":"Multiple myeloma; Polyclonal antibodies; Antibody; Medicine; Immunology; In vitro; Biology; Internal medicine; Genetics","score_opus":0.04568402998435911,"score_gpt":0.33865184189494163,"score_spread":0.2929678119105825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007502238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97345793,0.00017683338,0.000005201084,0.0028458005,0.000054248536,0.001167409,0.0000056978424,0.00020721111,0.02207969],"genre_scores_gemma":[0.99762005,0.000025992447,0.00046621528,0.00097794,0.000052947813,0.000061398096,0.000028301509,0.000013683176,0.000753482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825305,0.000105917,0.00027917113,0.00042285008,0.00046888037,0.00047010556],"domain_scores_gemma":[0.99877393,0.00015462637,0.000069433205,0.0006698837,0.000077252116,0.0002548604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016691656,0.00024561596,0.00052165095,0.00013934067,0.00015731844,0.000026517466,0.00018196668,0.000116664996,0.00033641714],"category_scores_gemma":[0.00040123344,0.0001631272,0.00012748456,0.00022561931,0.000060621554,0.00005370307,0.00004619715,0.00031125784,0.00060786906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022653362,0.04329053,0.63695407,0.00015350187,0.00193042,0.06186303,0.0025170913,0.0000026927428,0.034390863,0.0020001428,0.05282109,0.1414232],"study_design_scores_gemma":[0.004956115,0.007859606,0.98204297,0.000058724974,0.00007357783,0.0005744577,0.00036875976,0.000030728028,0.0014560021,0.00016454617,0.0022383423,0.00017616438],"about_ca_topic_score_codex":0.000018749875,"about_ca_topic_score_gemma":0.0000035314033,"teacher_disagreement_score":0.3450889,"about_ca_system_score_codex":0.00008750982,"about_ca_system_score_gemma":0.000082338054,"threshold_uncertainty_score":0.781313},"labels":[],"label_agreement":null},{"id":"W2007778917","doi":"10.1182/blood-2013-07-510941","title":"Transplants for the elderly in myeloma","year":2013,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Multiple myeloma; Medicine; Lenalidomide; Internal medicine; Oncology","score_opus":0.033832379600919636,"score_gpt":0.2917235550615796,"score_spread":0.25789117546066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007778917","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.118305154,0.003932691,0.00007498314,0.86436355,0.0003443529,0.007964468,0.00066116644,0.000106318475,0.0042472933],"genre_scores_gemma":[0.29581818,0.0026398737,0.0032141302,0.5983869,0.015851766,0.010198484,0.0061794613,0.0005736234,0.06713759],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984365,0.00004380337,0.00023026584,0.00032815247,0.0003803421,0.00058094785],"domain_scores_gemma":[0.99888,0.00046961452,0.0000498856,0.0004576021,0.000060249407,0.00008259906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010072889,0.00024931107,0.00038821375,0.00013841942,0.00006484261,0.00003418428,0.0002101624,0.0004328986,0.00024161187],"category_scores_gemma":[0.00006183391,0.00014481443,0.00018647687,0.00009212635,0.000054471053,0.000032893113,0.000015651009,0.0008931512,0.00021440179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021305976,0.0008003418,0.0100445375,0.0011036457,0.0013748587,0.0038824235,0.00016237458,1.15946364e-7,0.0002452176,0.000005014535,0.9400043,0.042164147],"study_design_scores_gemma":[0.028128954,0.0016760466,0.057845194,0.0006699785,0.0010478377,0.00036397073,0.000025010719,0.000059773756,0.0016675637,0.00012720433,0.90801394,0.0003745032],"about_ca_topic_score_codex":0.00027097642,"about_ca_topic_score_gemma":0.00006646064,"teacher_disagreement_score":0.2659767,"about_ca_system_score_codex":0.00003098327,"about_ca_system_score_gemma":0.00012665827,"threshold_uncertainty_score":0.5905361},"labels":[],"label_agreement":null},{"id":"W2007886942","doi":"10.2165/00063030-200013040-00004","title":"Use of Thalidomide in Dermatological Indications","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Thalidomide; Medicine; Adverse effect; Immunology; Pharmacology; Drug; Disease; Internal medicine; Multiple myeloma","score_opus":0.07712116623729452,"score_gpt":0.3360419291086052,"score_spread":0.25892076287131066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007886942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506825,0.0000935002,0.0000028308627,0.00079267815,0.000005696573,0.00021265916,0.000016180089,0.000015060901,0.0037931597],"genre_scores_gemma":[0.9978416,0.00012934401,0.0010427895,0.0001043079,0.000007814808,0.000020142606,0.000036178004,0.0000036497004,0.00081416254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946326,0.000032117583,0.00013977627,0.00009774783,0.00012954017,0.00013758196],"domain_scores_gemma":[0.99965334,0.000072486655,0.00001748213,0.00015279248,0.000017035354,0.00008684253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004058333,0.000049482733,0.00013276745,0.00008636543,0.000017189564,0.000004627775,0.000036793856,0.000044324875,0.0010526292],"category_scores_gemma":[0.00007997454,0.000035586396,0.000036717607,0.0001549359,0.00006269548,0.000040998737,0.000009894226,0.00006239244,0.00020121552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002725813,0.00055832235,0.96743876,0.00002135501,0.000034284127,0.00014126206,0.00014891084,0.0000010815761,0.0010833842,0.00026251187,0.0007218084,0.029315718],"study_design_scores_gemma":[0.00163615,0.00005314669,0.98108864,0.000033712207,0.000010772004,0.0000419839,0.000021768348,0.00010400456,0.0063099046,0.00005166621,0.01060881,0.00003942905],"about_ca_topic_score_codex":0.00020792028,"about_ca_topic_score_gemma":0.0000165417,"teacher_disagreement_score":0.029276287,"about_ca_system_score_codex":0.00002250302,"about_ca_system_score_gemma":0.00004281127,"threshold_uncertainty_score":0.9998605},"labels":[],"label_agreement":null},{"id":"W2008576749","doi":"10.1007/s11899-013-0183-0","title":"Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy","year":2013,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Multiple myeloma; Medicine; Bortezomib; Hematology; Internal medicine; Malignancy; Hematologic malignancy; Intensive care medicine; Clinical trial; Oncology","score_opus":0.07505719191943697,"score_gpt":0.3537867960608366,"score_spread":0.2787296041413996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008576749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03408786,0.9592628,0.0000129475375,0.000031557534,0.00053568423,0.005632632,0.0000844117,0.000112231195,0.00023990039],"genre_scores_gemma":[0.05713697,0.9387055,0.0003013249,0.000009726957,0.000108485845,0.0030083545,0.0005240897,0.0000828691,0.00012265482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99481946,0.00053300173,0.0016707795,0.0012066289,0.0006878591,0.0010822735],"domain_scores_gemma":[0.99510276,0.0011090221,0.0017223245,0.0014812885,0.00019054401,0.00039404636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043437802,0.0010859942,0.0025810897,0.00016557777,0.0007536434,0.00019110422,0.00023265778,0.00033686103,0.000121390214],"category_scores_gemma":[0.0007535279,0.0004464371,0.0007199268,0.000290532,0.00033466137,0.00009646829,0.00036195866,0.0007776644,0.000107172265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015444562,0.00041947947,0.016735978,0.003337613,0.00055508444,0.0018986401,0.00010839118,0.0000011769596,7.3618224e-8,0.00012243842,0.0003756648,0.97643],"study_design_scores_gemma":[0.003094836,0.0026121016,0.0060263346,0.023287302,0.007043271,0.021737315,0.00029257778,0.00021067087,0.000041658393,0.0002454713,0.93396604,0.0014424109],"about_ca_topic_score_codex":0.00012846637,"about_ca_topic_score_gemma":0.000014073413,"teacher_disagreement_score":0.9749876,"about_ca_system_score_codex":0.00027757254,"about_ca_system_score_gemma":0.00054987066,"threshold_uncertainty_score":0.9997987},"labels":[],"label_agreement":null},{"id":"W2008959642","doi":"10.1046/j.1365-2141.2000.02093.x","title":"A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma","year":2000,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Melphalan; Multiple myeloma; Dexamethasone; Medicine; Monoclonal antibody; Autologous stem-cell transplantation; Regimen; Monoclonal; Combination therapy; Transplantation; Internal medicine; Pharmacology; Immunology; Oncology; Antibody","score_opus":0.018043425714160972,"score_gpt":0.3049105630567748,"score_spread":0.2868671373426138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008959642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735755,0.0014714386,0.000032349715,0.00063511403,0.000038673606,0.00038744838,0.00004378462,0.000010234892,0.000023436469],"genre_scores_gemma":[0.9939597,0.0008204421,0.005031304,0.000040122057,0.000018691326,0.000009440217,0.00004792968,0.0000239297,0.000048391834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979191,0.000449576,0.00069921376,0.00023890044,0.00035271823,0.0003405271],"domain_scores_gemma":[0.9983822,0.0006533212,0.0003356915,0.00013947632,0.0002879625,0.00020136738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052599865,0.00017981233,0.0010165944,0.00039510027,0.000059354006,0.000024229712,0.00012338665,0.00010115249,0.00018240129],"category_scores_gemma":[0.00045023902,0.00016082457,0.00006557662,0.00025420781,0.00029172158,0.00021636607,0.00003404301,0.00035756163,0.0000035371943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060501948,0.0030879555,0.5233951,0.00039068167,0.000781922,0.14314629,0.00045265528,0.00006250322,0.13948661,0.00010704059,0.00006536077,0.12852192],"study_design_scores_gemma":[0.02361308,0.0027130349,0.8708298,0.0010060277,0.000052370702,0.086938195,0.00012490965,0.00024318049,0.014179408,0.00013468285,0.000045983026,0.000119309225],"about_ca_topic_score_codex":0.0008075311,"about_ca_topic_score_gemma":0.00030783648,"teacher_disagreement_score":0.3474347,"about_ca_system_score_codex":0.00006109843,"about_ca_system_score_gemma":0.00014560984,"threshold_uncertainty_score":0.6558235},"labels":[],"label_agreement":null},{"id":"W2009120840","doi":"10.1371/journal.pone.0064927","title":"Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; University of Manitoba; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Cancer Foundation","keywords":"clone (Java method); Biology; Monoclonal; Dominance (genetics); Multiple myeloma; Chronic lymphocytic leukemia; Polymerase chain reaction; Genetics; Somatic evolution in cancer; Monoclonal gammopathy of undetermined significance; Molecular biology; B cell; Immunology; Leukemia; Antibody; Monoclonal antibody; Gene","score_opus":0.028943053206743855,"score_gpt":0.2324205583031874,"score_spread":0.20347750509644352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009120840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975119,0.00011058964,0.000004142656,0.00010211712,0.000012876189,0.0015450536,0.00007499124,0.000041031828,0.0005972766],"genre_scores_gemma":[0.99748504,0.00003758841,0.0017591841,0.000028810935,0.000012494272,0.00015813751,0.00024884936,0.00001843799,0.0002514465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829006,0.0000534659,0.00031745702,0.00028463418,0.00067314703,0.0003812066],"domain_scores_gemma":[0.99885297,0.00011347137,0.00010764017,0.00035031664,0.00034073222,0.00023487263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005639063,0.00018103159,0.00041425353,0.00017989089,0.000032325708,0.000011275831,0.000103930666,0.00008394842,0.0003435568],"category_scores_gemma":[0.00015411196,0.00013065261,0.000039834085,0.00026519253,0.00008782892,0.00013425286,0.000045468598,0.00020106237,0.00021620041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007267384,0.009977766,0.9565829,0.00022636686,0.00023671325,0.000027844873,0.00015395116,5.874752e-7,0.030963166,0.0000026598746,0.000053742548,0.0010475763],"study_design_scores_gemma":[0.012994754,0.0011840618,0.8107496,0.00042471403,0.00007133858,5.324958e-7,0.000041949057,0.00033372993,0.17406724,0.000012125312,0.0000029634873,0.00011697519],"about_ca_topic_score_codex":0.0009333606,"about_ca_topic_score_gemma":0.00005083953,"teacher_disagreement_score":0.14583328,"about_ca_system_score_codex":0.000090897505,"about_ca_system_score_gemma":0.00007934381,"threshold_uncertainty_score":0.53278583},"labels":[],"label_agreement":null},{"id":"W2010131582","doi":"10.1055/s-2002-31574","title":"Recurrent Anterior Skull Base Plasmocytoma","year":2002,"lang":"en","type":"article","venue":"Skull base","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Paranasal sinuses; Skull; Surgery; Radiation therapy; Nasal cavity; Nose; Plasmacytoma; Anatomy; Multiple myeloma","score_opus":0.04952238194411124,"score_gpt":0.30847511852612675,"score_spread":0.2589527365820155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010131582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829492,0.0015683059,0.000031190564,0.0024476512,0.00028435976,0.0007241357,0.00013390998,0.00016024386,0.011701027],"genre_scores_gemma":[0.99094987,0.0003451226,0.0015268297,0.00067114295,0.00022027481,0.000080079255,0.0000779789,0.000041087893,0.0060876235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981169,0.000081193,0.00029150618,0.00043134956,0.00049064984,0.00058840954],"domain_scores_gemma":[0.99850416,0.00009312935,0.000060310136,0.0005659574,0.00013128578,0.0006451337],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014267342,0.0002456621,0.00034488697,0.0002098669,0.00011678547,0.000035732246,0.00012138524,0.00008840724,0.007089895],"category_scores_gemma":[0.00041571396,0.00019529124,0.00016905087,0.0002449296,0.0000889687,0.00010787926,0.000080595266,0.000273577,0.0034074953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045127906,0.0067109806,0.07510235,0.0007730028,0.00070345233,0.026728554,0.0009397328,0.0000033398746,0.018161856,0.00013849081,0.15750591,0.70871955],"study_design_scores_gemma":[0.10033222,0.016582783,0.2336006,0.0034711775,0.000942338,0.0044070664,0.0008187624,0.06817025,0.19277258,0.00026241093,0.3757075,0.0029322957],"about_ca_topic_score_codex":0.00008289254,"about_ca_topic_score_gemma":0.000039444432,"teacher_disagreement_score":0.70578724,"about_ca_system_score_codex":0.0001644061,"about_ca_system_score_gemma":0.000054295033,"threshold_uncertainty_score":0.99736845},"labels":[],"label_agreement":null},{"id":"W2010567185","doi":"10.3324/haematol.2010.022210","title":"CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Multiple myeloma; Internal medicine; Oncology; Expression (computer science); Overall survival; Medicine; Adverse effect; Cancer research","score_opus":0.01226226489713932,"score_gpt":0.24420793155145465,"score_spread":0.23194566665431532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010567185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981081,0.000013189472,0.0000108589775,0.000053793556,0.000040846688,0.0010001542,0.00008419467,0.00006402898,0.00062485714],"genre_scores_gemma":[0.99648976,0.000012251028,0.0032146026,0.000071978466,0.000009196415,0.00003467492,0.0000890974,0.000031971256,0.000046462177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981824,0.00010329603,0.00028071346,0.00051038637,0.00056204107,0.00036111794],"domain_scores_gemma":[0.99870956,0.00010578189,0.00017771732,0.00044403505,0.0002170892,0.00034583296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010916754,0.00026061016,0.00053512026,0.00016853963,0.00011167433,0.000010938685,0.00011838831,0.00023735102,0.0003674304],"category_scores_gemma":[0.00015623754,0.00015198083,0.000035657184,0.00023481353,0.0003217073,0.00024766772,0.000110627196,0.0004225225,0.000017338858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012714961,0.0011749354,0.9758252,0.00008703792,0.0000640792,0.00029303398,0.001618736,0.0000018379291,0.0070931707,0.000007597622,0.00016957492,0.0009498625],"study_design_scores_gemma":[0.01585904,0.0031884727,0.95320284,0.00045445375,0.000046276462,0.0000437238,0.0007764142,0.0015214207,0.024610795,0.000012159405,0.000105021725,0.00017935569],"about_ca_topic_score_codex":0.00014979126,"about_ca_topic_score_gemma":0.000073869815,"teacher_disagreement_score":0.022622306,"about_ca_system_score_codex":0.0000262242,"about_ca_system_score_gemma":0.00006094289,"threshold_uncertainty_score":0.61975986},"labels":[],"label_agreement":null},{"id":"W2010604023","doi":"10.3747/co.v17i5.618","title":"Radiotherapy for Multiple Myeloma with Skin Involvement","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Multiple myeloma; Radiation therapy; Dermatology; Pathology; Surgery; Internal medicine","score_opus":0.09431004407181977,"score_gpt":0.42140758942519885,"score_spread":0.3270975453533791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010604023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909451,0.0006124892,0.0026405095,0.0020149623,0.00084433024,0.0021835808,0.000036990525,0.0000720748,0.000649968],"genre_scores_gemma":[0.97817945,0.00016060323,0.019235585,0.00019377135,0.00066245097,0.0008980731,0.00021840655,0.000038619823,0.00041305932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880654,0.000034078425,0.00018681814,0.00032025168,0.00021195496,0.00044038592],"domain_scores_gemma":[0.9989214,0.0002317039,0.000067526635,0.00030911659,0.0001678685,0.00030237235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001746175,0.00016819107,0.00033075872,0.000118834505,0.0000952584,0.0000122202255,0.000102689315,0.000104515384,0.00025032472],"category_scores_gemma":[0.00011559157,0.000114590875,0.000093950606,0.00010302797,0.00014572921,0.000042250675,0.000025043091,0.00030656852,0.00003258494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002957607,0.0023549914,0.29767585,0.0001456943,0.00029780145,0.000053823012,0.0003384175,8.589821e-7,0.014688221,0.00043279913,0.0046296413,0.6764243],"study_design_scores_gemma":[0.023306187,0.0045997095,0.12967819,0.000039396156,0.00007676585,0.000086057946,0.000081642655,0.002165357,0.007367744,0.00009380898,0.83232915,0.00017599808],"about_ca_topic_score_codex":0.00002328553,"about_ca_topic_score_gemma":0.00047341076,"teacher_disagreement_score":0.8276995,"about_ca_system_score_codex":0.00018137848,"about_ca_system_score_gemma":0.0003112209,"threshold_uncertainty_score":0.46728805},"labels":[],"label_agreement":null},{"id":"W2011478815","doi":"10.1158/0008-5472.can-08-3467","title":"Loss of the SMRT/NCoR2 Corepressor Correlates with JAG2 Overexpression in Multiple Myeloma","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Leukemia and Lymphoma Society; Multiple Myeloma Research Foundation","keywords":"Corepressor; Biology; Notch signaling pathway; Histone; Cancer research; Epigenetics; Carcinogenesis; Molecular biology; Genetics; Gene; Cell biology; Nuclear receptor; Transcription factor","score_opus":0.0693210404117872,"score_gpt":0.39363005011921515,"score_spread":0.32430900970742793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011478815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438566,0.0007456062,0.0000052516825,0.0014489011,0.000032347132,0.0012383875,0.0000316009,0.00001893983,0.002093307],"genre_scores_gemma":[0.99756753,0.00023497388,0.000092815055,0.00006447544,0.000068757094,0.00015008397,0.000011568676,0.00002171419,0.001788079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972498,0.00021606595,0.00024963295,0.00038639366,0.0012359389,0.0006621958],"domain_scores_gemma":[0.9983204,0.0003345608,0.00006562703,0.00068672124,0.00036413755,0.00022856926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042752104,0.00015484904,0.00030869077,0.00022771266,0.00015415714,0.000020919044,0.000311484,0.00010683716,0.00026615558],"category_scores_gemma":[0.0004786735,0.00008507338,0.00007487955,0.00082396355,0.00040493594,0.00009478294,0.00013369585,0.0007209604,0.000023862349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050459923,0.0005920513,0.8408782,0.00013742602,0.000063816886,0.00021931002,0.00045611462,0.00010969685,0.13531174,0.00010718243,0.0011851201,0.015893377],"study_design_scores_gemma":[0.0061004995,0.00073229184,0.8154682,0.001974749,0.000010211423,0.000024713314,0.00014139152,0.00071673136,0.17402978,0.00021780032,0.00048708275,0.000096566044],"about_ca_topic_score_codex":0.0012826581,"about_ca_topic_score_gemma":0.0002797262,"teacher_disagreement_score":0.038718045,"about_ca_system_score_codex":0.00029610138,"about_ca_system_score_gemma":0.0004699022,"threshold_uncertainty_score":0.34691918},"labels":[],"label_agreement":null},{"id":"W2011644923","doi":"10.1200/jco.2005.17.129","title":"Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Multiple Myeloma Research Foundation","keywords":"Medicine; Dexamethasone; Vincristine; Internal medicine; Thalidomide; Chemotherapy; Oncology; Multiple myeloma; Salvage therapy; Prednisone; Melphalan; Gastroenterology; Cyclophosphamide","score_opus":0.08755274972010224,"score_gpt":0.45320424101853135,"score_spread":0.3656514912984291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011644923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060465,0.0011420456,0.000071977345,0.01678578,0.00031530092,0.0006073801,0.000024927433,0.000013530746,0.0004344046],"genre_scores_gemma":[0.98110163,0.004584203,0.008185509,0.0038677962,0.00086312415,0.00001615749,0.000012597165,0.000029503753,0.0013394569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432284,0.0011225272,0.0032216494,0.00038775644,0.0005101163,0.00043512866],"domain_scores_gemma":[0.9904358,0.0063274256,0.0014545075,0.00025773433,0.00030852633,0.0012160315],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004497835,0.000234309,0.0021319059,0.0001511603,0.00006047119,0.000016696627,0.00012807116,0.00035210463,0.00008889731],"category_scores_gemma":[0.011344735,0.0001638673,0.00060707936,0.00012006702,0.00035615586,0.0001881823,0.00007204322,0.0013564747,0.000018958946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026024029,0.0032172066,0.67907053,0.000027824495,0.00045399126,0.0017495363,0.00007291088,3.5578643e-7,0.00018862466,0.0000034555762,0.0011436138,0.2880479],"study_design_scores_gemma":[0.039606903,0.0027549218,0.8851249,0.000146665,0.000137365,0.00005109925,0.000051127423,0.00022881039,0.00003209643,0.00002821489,0.07171437,0.00012351692],"about_ca_topic_score_codex":0.000009958716,"about_ca_topic_score_gemma":0.000104977255,"teacher_disagreement_score":0.2879244,"about_ca_system_score_codex":0.00022308774,"about_ca_system_score_gemma":0.00077649334,"threshold_uncertainty_score":0.9969831},"labels":[],"label_agreement":null},{"id":"W2011692714","doi":"10.1016/j.bbmt.2008.07.011","title":"Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation","year":2008,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; U.S. Department of Health and Human Services; U.S. Department of Defense","keywords":"Medicine; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Oncology; Hypoalbuminemia; Cumulative incidence; Transplantation; Hematopoietic stem cell transplantation; Cohort; Surgery; Gastroenterology","score_opus":0.019426819381838933,"score_gpt":0.25611533478013127,"score_spread":0.23668851539829233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011692714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705344,0.0017869788,0.00012304295,0.00006328778,0.000039603423,0.0004355459,0.00019682317,0.000026789055,0.0002745137],"genre_scores_gemma":[0.9943119,0.0043944125,0.00075414515,0.000043927346,0.000011262685,0.00005749676,0.00030289084,0.000011131444,0.00011282599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900657,0.00010902944,0.00028751075,0.00027173813,0.00009137012,0.00023380431],"domain_scores_gemma":[0.99948996,0.00020254219,0.00006303518,0.00009539282,0.000033734705,0.00011534731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010389078,0.00016294746,0.00038243915,0.0001989443,0.0000634324,0.0000029894695,0.0000326322,0.00015483948,0.000018899269],"category_scores_gemma":[0.0000044537037,0.00013627385,0.00004706395,0.000066662884,0.00023777323,0.00007935608,0.000004929826,0.000122474,0.000002762218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019417516,0.00022239535,0.87226945,0.00057796825,0.00008571689,0.00051500543,0.0013297774,0.0000010793411,0.12152188,0.000015417103,0.0000023429823,0.0015172114],"study_design_scores_gemma":[0.008141737,0.0005736506,0.9482628,0.000081548234,0.00020084981,0.0006598127,0.00010986757,0.00011536231,0.041696344,0.000015338901,0.000019490737,0.00012321286],"about_ca_topic_score_codex":0.000264965,"about_ca_topic_score_gemma":0.00030829827,"teacher_disagreement_score":0.07982554,"about_ca_system_score_codex":0.000014132237,"about_ca_system_score_gemma":0.00005735244,"threshold_uncertainty_score":0.55570865},"labels":[],"label_agreement":null},{"id":"W2012126452","doi":"10.1016/j.cca.2007.07.008","title":"Tachykinins and Hematopoiesis","year":2007,"lang":"en","type":"review","venue":"Clinica Chimica Acta","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stem Cell Network","keywords":"Haematopoiesis; Bone marrow; Medicine; Hematopoietic stem cell; Myeloproliferative Disorders; Immunology; Leukemia; Tachykinin receptor; Stem cell; Receptor; Cancer research; Internal medicine; Biology; Substance P; Cell biology; Neuropeptide","score_opus":0.18515396094249476,"score_gpt":0.4716964056720775,"score_spread":0.28654244472958273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012126452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017566454,0.9870538,8.9213347e-7,0.00023914622,0.00014390235,0.0013286307,0.00010082523,0.00009785597,0.010859253],"genre_scores_gemma":[0.00023118149,0.99525183,0.00096016563,0.00016455016,0.0004030184,0.00007975733,0.00038275673,0.00010299977,0.002423713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997172,0.00012503404,0.0009921744,0.00074062473,0.0003871115,0.00058303657],"domain_scores_gemma":[0.99653643,0.0014424585,0.00032224704,0.00093847007,0.00006666555,0.000693715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005055582,0.00051348226,0.0026949688,0.0003317996,0.00010383239,0.00004297685,0.00023656206,0.0006133193,0.00042486103],"category_scores_gemma":[0.0010278506,0.0003538493,0.0007319489,0.0002899445,0.00025001392,0.00004691175,0.00024925463,0.00090562284,0.00032530644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007988775,0.00040444665,0.00018276482,0.013560274,0.0009669858,0.0002860619,0.000019700647,1.288997e-10,0.0000010865173,0.000034193068,0.005276943,0.97918767],"study_design_scores_gemma":[0.0011631278,0.00027101298,0.00038556202,0.008387127,0.0014307449,0.00050526584,0.000006808302,0.0000016999328,0.0000019496097,0.000015196092,0.98757124,0.00026024051],"about_ca_topic_score_codex":0.0000069023877,"about_ca_topic_score_gemma":0.0000054349834,"teacher_disagreement_score":0.9822943,"about_ca_system_score_codex":0.000103016144,"about_ca_system_score_gemma":0.00046805694,"threshold_uncertainty_score":0.99989134},"labels":[],"label_agreement":null},{"id":"W2012182672","doi":"10.1016/j.ccr.2008.01.007","title":"AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies","year":2008,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; Multiple Myeloma Research Foundation","keywords":"Germinal center; Transgene; Multiple myeloma; Cancer research; Genetically modified mouse; Biology; Center (category theory); Genetics; Immunology; Gene; B cell; Chemistry; Antibody","score_opus":0.05248662879118331,"score_gpt":0.2977271731314316,"score_spread":0.24524054434024828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012182672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794006,0.0002333908,0.00018960812,0.000097344855,0.000019023444,0.00043182194,0.0006384127,0.000010062537,0.00044027186],"genre_scores_gemma":[0.99785084,0.00032323896,0.0005552745,0.00007692346,0.00002803128,0.0001057679,0.00019014103,0.000016739614,0.0008530542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883515,0.000028450087,0.0002963851,0.00020277564,0.00040745785,0.00022976568],"domain_scores_gemma":[0.99938935,0.000045338056,0.000103111415,0.00015170645,0.00020498478,0.000105491774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005279174,0.00013005835,0.00028274272,0.00013167105,0.000031964628,0.0000021171104,0.00007153085,0.00007513658,0.00021113161],"category_scores_gemma":[0.000024346627,0.00011321332,0.00008596026,0.00009619387,0.000106953616,0.00013234226,0.000017991915,0.000105086765,0.000003499349],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014444216,0.00096019317,0.08848848,0.000254211,0.00006102078,0.00003200255,0.0014394497,0.0008290737,0.9057256,0.000008139024,0.000052877203,0.00070453656],"study_design_scores_gemma":[0.006629029,0.0002388993,0.098342,0.000102440266,0.000017519538,0.0000095463565,0.00019512507,0.0028991296,0.89145434,0.000013375009,0.000015451133,0.00008314114],"about_ca_topic_score_codex":0.0011381523,"about_ca_topic_score_gemma":0.00028478337,"teacher_disagreement_score":0.014271245,"about_ca_system_score_codex":0.00020220235,"about_ca_system_score_gemma":0.00038167008,"threshold_uncertainty_score":0.46167052},"labels":[],"label_agreement":null},{"id":"W2012198451","doi":"10.1097/rlu.0b013e3182a75c95","title":"Solitary Extramedullary Plasmacytoma of the Parotid Gland Imaged With 18F-FDG PET/CT","year":2013,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Plasmacytoma; Parotid gland; Multiple myeloma; Biopsy; Radiology; Nuclear medicine; Pathology; Internal medicine","score_opus":0.03793568959850487,"score_gpt":0.34495419890875584,"score_spread":0.307018509310251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012198451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772126,0.00021435393,0.0000034288687,0.014574865,0.00020824294,0.0011394102,0.0000095662135,0.000062059546,0.006575474],"genre_scores_gemma":[0.9950848,0.00024123145,0.0010920139,0.0021451782,0.00037074334,0.000024078674,0.00002397762,0.00005359942,0.0009643605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973623,0.00025118332,0.0007563134,0.00040858705,0.0007628134,0.0004587637],"domain_scores_gemma":[0.9972825,0.0008307694,0.00018834064,0.0008625843,0.00022327382,0.00061250443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056612137,0.00024247298,0.0007701201,0.00007279069,0.00012040052,0.0000096106105,0.0002948941,0.000028848555,0.0029583266],"category_scores_gemma":[0.001656543,0.0001140177,0.00019871729,0.0002507707,0.0015389334,0.00008723118,0.00013790009,0.0007129601,0.00038307963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025633662,0.0015093151,0.89878684,0.00033416325,0.0008532786,0.0032929527,0.0001622342,0.0000010361158,0.0012813285,0.000112139336,0.07538867,0.015714664],"study_design_scores_gemma":[0.013868578,0.0037226384,0.97077006,0.00075973646,0.00027778745,0.0019528959,0.0005023623,0.0007440433,0.00019506858,0.00016681678,0.006886258,0.0001537633],"about_ca_topic_score_codex":0.00047661457,"about_ca_topic_score_gemma":0.000024243562,"teacher_disagreement_score":0.0719832,"about_ca_system_score_codex":0.000039764374,"about_ca_system_score_gemma":0.0001400797,"threshold_uncertainty_score":0.9979531},"labels":[],"label_agreement":null},{"id":"W2012684467","doi":"10.1080/10428190600909578","title":"A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Collège de Maisonneuve","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Adverse effect; Internal medicine; Lymphoproliferative disorders; Gastroenterology; Phases of clinical research; Toxicity; Surgery; Lymphoma","score_opus":0.025166442700866824,"score_gpt":0.3165357937164136,"score_spread":0.2913693510155468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012684467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943941,0.0005396449,0.00006963743,0.000063373605,0.000268197,0.003449232,0.000100359895,0.00019036236,0.00092508586],"genre_scores_gemma":[0.9935418,0.00025462906,0.0013153107,0.00035817234,0.0002478973,0.0003343141,0.00013937702,0.00016601894,0.0036425064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9930884,0.00031938578,0.0019736763,0.001514597,0.0013664002,0.001737522],"domain_scores_gemma":[0.9954046,0.0012984787,0.00055438967,0.001207899,0.00038990134,0.0011447056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009887551,0.0010649243,0.0018852479,0.0011717594,0.00047819005,0.00007020154,0.0004239385,0.0005893333,0.00024643607],"category_scores_gemma":[0.0011950772,0.00075965043,0.00028156713,0.0014477394,0.0004453887,0.00041366633,0.00039931783,0.00030260088,0.00004303468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18212433,0.030553112,0.20503742,0.0006345891,0.0013760567,0.014611303,0.016800178,0.000026062722,0.017925609,0.000032278025,0.0005270307,0.53035206],"study_design_scores_gemma":[0.4540248,0.03398791,0.45434672,0.00080718537,0.00046399538,0.0011628105,0.011821663,0.016695013,0.022400199,0.000016662,0.0031442633,0.0011288022],"about_ca_topic_score_codex":0.0044050673,"about_ca_topic_score_gemma":0.005893018,"teacher_disagreement_score":0.52922326,"about_ca_system_score_codex":0.007770954,"about_ca_system_score_gemma":0.003913635,"threshold_uncertainty_score":0.99948543},"labels":[],"label_agreement":null},{"id":"W2013259362","doi":"10.1093/ndt/gfs569","title":"Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice","year":2013,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Kidney disease; Inflammation; Thalidomide; Context (archaeology); Uremia; Proinflammatory cytokine; Systemic inflammation; Blockade; Pharmacology; Internal medicine; Immunology; Receptor","score_opus":0.014755724906505355,"score_gpt":0.2722323070026919,"score_spread":0.25747658209618657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013259362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969723,0.000038801245,0.0001244705,0.0013515529,0.000018138922,0.00087869796,0.0000066369143,0.000036637328,0.0005727387],"genre_scores_gemma":[0.9980734,0.00019071093,0.00053842476,0.00015347959,0.000053612708,0.0004095248,0.0005195282,0.000016393502,0.000044901586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861366,0.00017574691,0.00034176724,0.00029601305,0.00023869303,0.0003341246],"domain_scores_gemma":[0.9993659,0.00023183196,0.000070706075,0.00015426413,0.00008129306,0.00009600519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013558957,0.0001629848,0.0003403841,0.0005116829,0.000032250286,0.000019639647,0.00006787414,0.00016426493,0.00022874052],"category_scores_gemma":[0.0000404808,0.00012861434,0.00004633156,0.00043109,0.000047202313,0.0003163101,0.000004979354,0.00021956656,0.0001122613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027551532,0.00018384545,0.6671236,0.00013221467,0.0001601889,0.00047770477,0.0016322093,0.0002599902,0.32127002,0.000025621248,0.000026810567,0.005952617],"study_design_scores_gemma":[0.009196353,0.0002695002,0.9176767,0.000067507855,0.0001559641,0.0000805372,0.00009462678,0.0013183356,0.07094849,0.000066943256,0.000016132468,0.00010891992],"about_ca_topic_score_codex":0.003083086,"about_ca_topic_score_gemma":0.009951831,"teacher_disagreement_score":0.25055307,"about_ca_system_score_codex":0.00008704305,"about_ca_system_score_gemma":0.000080521604,"threshold_uncertainty_score":0.5553355},"labels":[],"label_agreement":null},{"id":"W2013425043","doi":"10.1080/10428190500272549","title":"Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Melphalan; Multiple myeloma; Medicine; Chemotherapy; Bone marrow; Autologous stem-cell transplantation; Oncology; Internal medicine; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.020627777997041352,"score_gpt":0.26245457438802133,"score_spread":0.24182679639097998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013425043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949647,0.0020727124,0.000051366555,0.00007418721,0.000027414284,0.0024371033,0.000079146106,0.0001681242,0.00012522063],"genre_scores_gemma":[0.996545,0.00043753276,0.002032414,0.0001205876,0.00006698327,0.00037314172,0.0000997017,0.000111581925,0.00021306078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618214,0.00024975848,0.00082542276,0.0010872801,0.00073890935,0.00091647875],"domain_scores_gemma":[0.9973396,0.0010782235,0.00030290967,0.0006207116,0.00013811013,0.00052043656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002970117,0.0007378838,0.0012310375,0.00049915264,0.0002679872,0.000055947366,0.00020463516,0.0003080577,0.00001914369],"category_scores_gemma":[0.000071756986,0.00055096636,0.00010702962,0.0005853314,0.00033658295,0.00024144005,0.000073304785,0.00016962244,0.000006689586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013522564,0.0023693421,0.7646216,0.00062515127,0.00022047981,0.004792203,0.0024987916,0.00022988365,0.02434755,0.0000049421396,0.000029115945,0.18673839],"study_design_scores_gemma":[0.08538923,0.0031664537,0.78857833,0.001064827,0.00024890006,0.0008965489,0.0008366129,0.017599083,0.10157774,0.0000050210515,0.00011780951,0.0005194507],"about_ca_topic_score_codex":0.003057455,"about_ca_topic_score_gemma":0.0008845097,"teacher_disagreement_score":0.18621893,"about_ca_system_score_codex":0.0025170313,"about_ca_system_score_gemma":0.0014263374,"threshold_uncertainty_score":0.99969417},"labels":[],"label_agreement":null},{"id":"W2013806710","doi":"10.1038/bmt.2014.288","title":"CyBorD induction therapy in clinical practice","year":2015,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Induction therapy; Intensive care medicine; Internal medicine; Chemotherapy","score_opus":0.10722113685979368,"score_gpt":0.4122045735199078,"score_spread":0.3049834366601141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013806710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897873,0.00027963915,0.0003450482,0.002019469,0.00016874973,0.00052135775,0.000007703125,0.000044153312,0.0068266005],"genre_scores_gemma":[0.99386734,0.00165521,0.0035568818,0.0002782741,0.00013037508,0.000040045885,0.00022105585,0.000013282291,0.00023752676],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987439,0.00019457964,0.00032210464,0.0002010661,0.00036346313,0.00017489103],"domain_scores_gemma":[0.9993578,0.00012962923,0.00005898649,0.00013460011,0.00013159041,0.00018735316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074866257,0.00009036131,0.0001713978,0.0001262645,0.000022288315,0.000013981453,0.000028529388,0.0000957943,0.000026448457],"category_scores_gemma":[0.000246519,0.0000752534,0.000048346872,0.00019123522,0.000032789707,0.0002463136,0.0000026998616,0.0002065288,0.00009064586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026244426,0.0022092806,0.4579012,0.00010040093,0.00017576334,0.002752339,0.002025682,0.000020525653,0.0048694005,0.00025741124,0.00109953,0.502344],"study_design_scores_gemma":[0.018668525,0.0015118653,0.96962816,0.000076130455,0.00007030884,0.0006096789,0.00035596732,0.00026980767,0.0021958943,0.00016226359,0.0063240137,0.00012739497],"about_ca_topic_score_codex":0.00039545464,"about_ca_topic_score_gemma":0.00010734338,"teacher_disagreement_score":0.5117269,"about_ca_system_score_codex":0.00007477553,"about_ca_system_score_gemma":0.00016800368,"threshold_uncertainty_score":0.30687448},"labels":[],"label_agreement":null},{"id":"W2014089652","doi":"10.1111/j.1365-2141.2004.04996.x","title":"Correlation of <i>TACC3, FGFR3, MMSET</i> and <i>p21</i> expression with the t(4;14)(p16·3;q32) in multiple myeloma","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Chromosomal translocation; Multiple myeloma; Breakpoint; Gene; Polymerase chain reaction; Gene expression; Fusion gene; Medicine; Biology; Cancer research; Internal medicine; Genetics","score_opus":0.013295273796492525,"score_gpt":0.25969547780080554,"score_spread":0.246400204004313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014089652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934865,0.003671148,0.0009913208,0.0012303179,0.0000625455,0.00033335824,0.000010663554,0.0000066866023,0.00020741561],"genre_scores_gemma":[0.99713933,0.0006271367,0.0019888806,0.00013242911,0.000036402158,0.000008808696,0.0000102254635,0.000016984131,0.00003980115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985974,0.0001293898,0.00048415086,0.00015683853,0.0003657159,0.00026651408],"domain_scores_gemma":[0.9989033,0.00023478521,0.00033999662,0.00014145354,0.00022651463,0.00015396206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031848863,0.0001235287,0.00055403204,0.00015569308,0.00008999586,0.00001938097,0.00010828014,0.000109147026,0.00002660073],"category_scores_gemma":[0.00030214648,0.00008588572,0.000073134885,0.00018092175,0.00025560166,0.00016978143,0.000044266122,0.00040999806,0.0000037558736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007901186,0.0021893468,0.7911143,0.00058092806,0.00048979215,0.10959376,0.0016905206,0.00071979023,0.020445846,0.000269134,0.0038300809,0.061175328],"study_design_scores_gemma":[0.04072737,0.0025028747,0.51551735,0.0037049262,0.00018852318,0.40644574,0.0012178086,0.0002724414,0.027391993,0.0006020924,0.0011761814,0.0002527046],"about_ca_topic_score_codex":0.00036169976,"about_ca_topic_score_gemma":0.0007060943,"teacher_disagreement_score":0.29685196,"about_ca_system_score_codex":0.000048514426,"about_ca_system_score_gemma":0.00016280838,"threshold_uncertainty_score":0.3502318},"labels":[],"label_agreement":null},{"id":"W2014717400","doi":"10.1046/j.1365-2141.2001.02962.x","title":"Henry Bence Jones – physician, chemist, scientist and biographer: A man for all seasons","year":2001,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Chemist; Bence Jones protein; Medicine; Chemistry; Immunology; Organic chemistry","score_opus":0.022731071670530404,"score_gpt":0.3205165059369347,"score_spread":0.2977854342664043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014717400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877525,0.00861063,0.00048576744,0.0021320253,0.00010187738,0.00026667918,0.000030924835,0.000011542897,0.00060805015],"genre_scores_gemma":[0.99295366,0.0020776056,0.00403147,0.00039840114,0.00012186852,0.0000149668485,0.000016672879,0.000016098078,0.000369232],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99898,0.000032421874,0.00023928417,0.00017582896,0.00021801972,0.00035447668],"domain_scores_gemma":[0.99911356,0.00009004661,0.00015245406,0.00009947012,0.00025135206,0.0002931185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001886165,0.000100785124,0.00044167085,0.00012588469,0.00012289407,0.00005011343,0.00010225561,0.00006269944,0.000036902464],"category_scores_gemma":[0.00016565756,0.00009859574,0.00015609403,0.00016109526,0.00026421878,0.00010424683,0.000026320206,0.00014800981,0.000003796852],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026581993,0.002773591,0.32107294,0.0011604928,0.0023458952,0.25406367,0.00024183163,0.000001426941,0.01969846,0.00092845596,0.09498382,0.3000712],"study_design_scores_gemma":[0.012727085,0.0011963767,0.10963889,0.0011599752,0.00039462108,0.81800586,0.0003405574,0.00021217667,0.004741485,0.0016482393,0.049656745,0.0002779861],"about_ca_topic_score_codex":0.000051876406,"about_ca_topic_score_gemma":0.00008219812,"teacher_disagreement_score":0.5639422,"about_ca_system_score_codex":0.000020958307,"about_ca_system_score_gemma":0.00007642152,"threshold_uncertainty_score":0.40206176},"labels":[],"label_agreement":null},{"id":"W2015003025","doi":"10.1038/leu.2009.26","title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Dexamethasone; Cyclophosphamide; Bortezomib; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Gastroenterology; Surgery; Toxicity; Phases of clinical research; Chemotherapy","score_opus":0.060046710051175414,"score_gpt":0.39750959534053243,"score_spread":0.33746288528935703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015003025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945288,0.00041869018,0.00016058848,0.0014277702,0.00026353198,0.0030551204,0.000036599333,0.00007353099,0.000035381676],"genre_scores_gemma":[0.992181,0.00027013101,0.0057793376,0.00038428683,0.00042416656,0.00029689513,0.00013967669,0.000028565397,0.0004959198],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975767,0.00029799898,0.00071593333,0.00058734405,0.00029031013,0.0005316758],"domain_scores_gemma":[0.9969276,0.002039902,0.0001456929,0.00037223808,0.000103987215,0.00041054134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013644476,0.00025636298,0.0006688042,0.00023577298,0.0001605526,0.000034518678,0.00009053325,0.00029278887,0.0000309156],"category_scores_gemma":[0.0067219855,0.00021627579,0.000150249,0.0003245208,0.00012061626,0.00016344419,0.000043020606,0.00041293073,0.0000106502075],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6140288,0.002409073,0.021756379,0.000025959744,0.00011032696,0.00055925624,0.00021445265,0.000005900174,0.0054670284,0.000029232737,0.0010855163,0.35430804],"study_design_scores_gemma":[0.48272493,0.01652889,0.4913576,0.0000866316,0.000080816775,0.000027559214,0.00006739226,0.0019826626,0.0047646854,0.00030612785,0.0018723704,0.00020032153],"about_ca_topic_score_codex":0.00042429386,"about_ca_topic_score_gemma":0.00009663782,"teacher_disagreement_score":0.46960124,"about_ca_system_score_codex":0.00045103004,"about_ca_system_score_gemma":0.00058557926,"threshold_uncertainty_score":0.8819471},"labels":[],"label_agreement":null},{"id":"W2015401139","doi":"10.1097/mnh.0000000000000101","title":"Plasmapheresis in cast nephropathy","year":2015,"lang":"en","type":"review","venue":"Current Opinion in Nephrology & Hypertension","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Plasmapheresis; Medicine; Multiple myeloma; Nephropathy; Nephrotoxicity; Intensive care medicine; Extracorporeal; Chemotherapy; Urology; Renal function; Complication; Kidney; Internal medicine; Oncology; Surgery; Immunology; Endocrinology","score_opus":0.23363916924280476,"score_gpt":0.4325610489396763,"score_spread":0.19892187969687153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015401139","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010480925,0.99341565,0.0000020786717,0.00016985198,0.00290912,0.0021965287,0.000055746797,0.00005887294,0.00014404644],"genre_scores_gemma":[0.00015415285,0.9971547,0.000116775394,0.000073529874,0.00060684455,0.0003983034,0.001350102,0.000089863766,0.00005574498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99575675,0.0006594579,0.0010997985,0.0010124554,0.0005535324,0.0009179842],"domain_scores_gemma":[0.9980535,0.00028908116,0.00025796765,0.0007642925,0.00018127395,0.0004538827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053637376,0.0007067462,0.0030941234,0.0013171977,0.00005639527,0.000019062558,0.0002615778,0.00079232693,0.00013180022],"category_scores_gemma":[0.0002892994,0.00053275557,0.00041607933,0.00092026155,0.00018951514,0.00009498115,0.00027462174,0.0014941086,0.0007202351],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003165006,0.0009653632,0.0012784086,0.009131431,0.00010218663,0.0005612665,0.000041100404,9.2094183e-7,0.0000019586844,0.000017955967,0.018363265,0.9692196],"study_design_scores_gemma":[0.0043413155,0.00041799573,0.0013331483,0.018159628,0.000217299,0.0011046324,0.000018787458,0.00017038756,2.3147548e-7,0.000026946227,0.9738628,0.0003468294],"about_ca_topic_score_codex":0.0001171238,"about_ca_topic_score_gemma":0.00005589218,"teacher_disagreement_score":0.9688728,"about_ca_system_score_codex":0.00062801974,"about_ca_system_score_gemma":0.0010432244,"threshold_uncertainty_score":0.9997124},"labels":[],"label_agreement":null},{"id":"W2015577159","doi":"10.1038/bcj.2012.47","title":"Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Receptor tyrosine kinase; Cancer research; KRAS; Somatic cell; Signal transduction; ERBB3; Germline mutation; Mutation; Multiple myeloma; Genetics; Gene; Cell biology; Immunology","score_opus":0.014892732451273484,"score_gpt":0.27513573417818304,"score_spread":0.26024300172690956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015577159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682743,0.01144139,0.0000587286,0.0008201751,0.000049731458,0.00069003395,0.000077896395,0.000025363517,0.000009235104],"genre_scores_gemma":[0.99432075,0.001651647,0.0034116989,0.00018661482,0.00009448556,0.00016986151,0.00003729857,0.000035831235,0.00009180568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985074,0.00010934373,0.0003459827,0.0002842138,0.0003251561,0.00042792308],"domain_scores_gemma":[0.99891025,0.00018990962,0.000119546465,0.00013761895,0.00013403656,0.00050863833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001125176,0.00021951573,0.0003322095,0.00019623904,0.00021665468,0.00012425668,0.000063824016,0.000086592074,0.0005192545],"category_scores_gemma":[0.00024008736,0.00017618538,0.000061144674,0.00015775803,0.00008678588,0.0001724201,0.00004366512,0.00029230316,0.00001977206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019851953,0.00070576294,0.3479345,0.00018040878,0.00037275784,0.00030229735,0.0007239542,0.000026969394,0.6157781,5.3590776e-7,0.0008643318,0.03291183],"study_design_scores_gemma":[0.03367476,0.0013989006,0.33834428,0.0016847879,0.00041269624,0.0014522986,0.00056096487,0.019958386,0.60150826,0.00015662856,0.0002711586,0.0005768515],"about_ca_topic_score_codex":0.0007889593,"about_ca_topic_score_gemma":0.00014362957,"teacher_disagreement_score":0.03347624,"about_ca_system_score_codex":0.00008499035,"about_ca_system_score_gemma":0.00010714678,"threshold_uncertainty_score":0.7184631},"labels":[],"label_agreement":null},{"id":"W2015701553","doi":"10.1111/j.1365-2141.2007.06649.x","title":"Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous <i>P53</i> deletion and poor survival for multiple myeloma","year":2007,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Research; Cancer Research Society","keywords":"Immunohistochemistry; Fluorescence in situ hybridization; Multiple myeloma; Biology; Nuclear protein; Cancer research; Pathology; Internal medicine; Gene; Medicine; Transcription factor; Immunology; Genetics","score_opus":0.010967042469762468,"score_gpt":0.2638467855076395,"score_spread":0.252879743037877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015701553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955071,0.0022573194,0.0010381121,0.00025926135,0.000053030824,0.00069692096,0.00007656432,0.00003092103,0.00008076533],"genre_scores_gemma":[0.996653,0.000106961365,0.0027754307,0.00009105634,0.000050203635,0.000021110445,0.000056760473,0.000048117396,0.00019734155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981873,0.00008047669,0.0005740141,0.00025198876,0.00040898568,0.0004972191],"domain_scores_gemma":[0.99834067,0.00024708352,0.00043663225,0.000125189,0.0005307738,0.00031963058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005167011,0.00018870163,0.0006850924,0.00009110698,0.00020415938,0.000036181118,0.000110132256,0.0002441781,0.00005533192],"category_scores_gemma":[0.0009277118,0.0001726608,0.00012088277,0.0001090275,0.00017768155,0.00010187281,0.000034772474,0.00039363065,0.0000019215458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075319824,0.00095823884,0.0035765741,0.00025760717,0.00052111247,0.021390079,0.0001343119,3.1406907e-7,0.9466941,0.0000018030617,0.0057513765,0.013182534],"study_design_scores_gemma":[0.039705314,0.0029016961,0.020361578,0.0032129749,0.00028393173,0.19041349,0.0004978432,0.00030308237,0.7399727,0.000055620072,0.0018181362,0.00047361708],"about_ca_topic_score_codex":0.0001009273,"about_ca_topic_score_gemma":0.00005413283,"teacher_disagreement_score":0.20672135,"about_ca_system_score_codex":0.0001348463,"about_ca_system_score_gemma":0.000101793965,"threshold_uncertainty_score":0.7040903},"labels":[],"label_agreement":null},{"id":"W2015880063","doi":"10.1038/leu.2009.174","title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","year":2009,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":878,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Saint John Regional Hospital; Dalhousie University","funders":"National Cancer Institute; National Institute on Aging","keywords":"Multiple myeloma; Chromosomal translocation; Biology; Cancer research; Hematology; Cytogenetics; Comparative genomic hybridization; Gene expression profiling; Gene; Oncology; Genetics; Chromosome; Immunology; Gene expression; Medicine","score_opus":0.0645365481067835,"score_gpt":0.36010654349522536,"score_spread":0.29556999538844186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015880063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041983843,0.9849616,0.0001191466,0.00016183738,0.00021305264,0.0021789488,0.00004678159,0.000090412155,0.01218621],"genre_scores_gemma":[0.0010733684,0.9928744,0.00218033,0.00017283148,0.00030693208,0.0002675434,0.0023441012,0.00009326918,0.00068724086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963749,0.00021952725,0.001210513,0.00073230016,0.0009852722,0.00047749875],"domain_scores_gemma":[0.9975725,0.00021789176,0.000742404,0.0009641485,0.00020645601,0.00029661285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039308873,0.0005798784,0.0022716257,0.00042492143,0.0000595679,0.000029918214,0.00052308344,0.00041156876,0.00023069701],"category_scores_gemma":[0.0005226615,0.00045077573,0.0009739947,0.00063231355,0.00009168199,0.00008162195,0.00012201212,0.00068022805,0.00026053318],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045910354,0.00014926255,0.00012214667,0.023997819,0.00059213856,0.00047462087,0.0000072964117,1.02391354e-7,0.000058018002,0.00022079474,0.0012991537,0.9730327],"study_design_scores_gemma":[0.0011344542,0.00011949002,0.0012416103,0.094519585,0.0011770293,0.0002743683,0.000002392767,0.000060593367,0.000025475947,0.000013884595,0.9011445,0.00028660477],"about_ca_topic_score_codex":0.000021158003,"about_ca_topic_score_gemma":0.000003915982,"teacher_disagreement_score":0.97274613,"about_ca_system_score_codex":0.0015507538,"about_ca_system_score_gemma":0.00066407915,"threshold_uncertainty_score":0.9997944},"labels":[],"label_agreement":null},{"id":"W2016355237","doi":"10.3109/10428194.2012.719614","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Bortezomib; Multiple myeloma; Neutropenia; Internal medicine; Dexamethasone; Oncology; Adverse effect; Thalidomide; Gastroenterology; Surgery; Toxicity","score_opus":0.03254678982639751,"score_gpt":0.2968636568573042,"score_spread":0.2643168670309067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016355237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985036,0.00931591,0.00024399212,0.0002491876,0.00035851388,0.0027120986,0.00023306887,0.00040825485,0.0014429771],"genre_scores_gemma":[0.9815932,0.0029374843,0.0074301423,0.000934063,0.0007439862,0.00074970705,0.00045467544,0.00025647928,0.004900268],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99415016,0.00027853256,0.0011006512,0.001348435,0.0008815115,0.0022406857],"domain_scores_gemma":[0.99427724,0.001843094,0.0003938143,0.0010679816,0.00030252433,0.0021153174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008687001,0.0010982448,0.0015795821,0.0005247075,0.0006918942,0.0001580203,0.000298811,0.00086085923,0.00015268088],"category_scores_gemma":[0.0015035016,0.0008552386,0.00037756094,0.00062593486,0.000583295,0.00079422694,0.0002708319,0.00027353366,0.0000785409],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034704607,0.001498599,0.24899457,0.001521844,0.0020014008,0.0008127046,0.00205469,0.000004739608,0.028346673,0.00038604403,0.008955358,0.6707188],"study_design_scores_gemma":[0.11147511,0.002762108,0.7686092,0.00080894196,0.0011625604,0.0034708485,0.00082828704,0.0068793753,0.037373748,0.00012550272,0.06494646,0.0015578462],"about_ca_topic_score_codex":0.0015361967,"about_ca_topic_score_gemma":0.00013811461,"teacher_disagreement_score":0.6691609,"about_ca_system_score_codex":0.0053927363,"about_ca_system_score_gemma":0.0025276544,"threshold_uncertainty_score":0.9993898},"labels":[],"label_agreement":null},{"id":"W2016660563","doi":"10.1016/j.carj.2011.12.010","title":"Abdominal Extraosseous Lesions of Multiple Myeloma: Imaging Findings","year":2012,"lang":"en","type":"review","venue":"Canadian Association of Radiologists Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Anemia; Radiology; Radiography; Bone marrow; Overall survival; Incidence (geometry); Pathology; Surgery; Internal medicine","score_opus":0.06142454503656104,"score_gpt":0.3457353179461251,"score_spread":0.2843107729095641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016660563","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006685191,0.9964647,0.000046226047,0.00020986349,0.00042222973,0.0006370559,0.0004618476,0.000012330122,0.0010772024],"genre_scores_gemma":[0.030689342,0.96630347,0.0010219122,0.00002651198,0.000478346,0.00002146463,0.00023920125,0.000051715426,0.0011680363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967664,0.00039807454,0.0011263733,0.00024512154,0.0005646282,0.00089940743],"domain_scores_gemma":[0.99578756,0.0007716394,0.0014307378,0.00028755242,0.00047799776,0.0012444826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014597166,0.0003611681,0.002003731,0.0010467165,0.00021240326,0.000031084663,0.00028954906,0.00044903575,0.0002959809],"category_scores_gemma":[0.002850042,0.00028812143,0.0008953137,0.00034826683,0.00014257689,0.00011496715,0.000028592061,0.0009868128,0.000045765595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032111286,0.00009981933,0.06874959,0.0021410089,0.0011001503,0.0004596405,0.00007956893,5.478194e-7,0.000007524048,0.000025340796,0.0055685258,0.9217362],"study_design_scores_gemma":[0.0022813461,0.00017120421,0.033935178,0.004933108,0.0021799256,0.003923065,0.000058877624,0.000026099178,0.000008645545,0.000017351447,0.9521353,0.00032985338],"about_ca_topic_score_codex":0.0035456843,"about_ca_topic_score_gemma":0.0041110124,"teacher_disagreement_score":0.9465668,"about_ca_system_score_codex":0.004412308,"about_ca_system_score_gemma":0.003796358,"threshold_uncertainty_score":0.9999571},"labels":[],"label_agreement":null},{"id":"W2017037856","doi":"10.1038/sj.bmt.1705206","title":"Sequential, cycling maintenance therapy for post transplant multiple myeloma","year":2005,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Regimen; Neutropenia; Lenalidomide; Melphalan; Maintenance therapy; Prednisone; Surgery; Internal medicine; Transplantation; Chemotherapy","score_opus":0.02966645762156557,"score_gpt":0.3020948166036607,"score_spread":0.27242835898209516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017037856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97741586,0.0005026092,0.016162954,0.0025061087,0.00010708189,0.0018869326,0.000624314,0.00015345817,0.0006407049],"genre_scores_gemma":[0.9847938,0.0018052959,0.009781151,0.0004900068,0.00023100093,0.00027203656,0.0019185088,0.00004940505,0.0006588049],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983499,0.00004721646,0.00036988175,0.00038448372,0.00034471066,0.0005038082],"domain_scores_gemma":[0.9991789,0.0001699275,0.000071873525,0.00021103649,0.00015669015,0.00021158898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002162822,0.00023668498,0.000304847,0.00015718448,0.00017606326,0.000034173947,0.000077512734,0.00011168202,0.00011340344],"category_scores_gemma":[0.000029362458,0.00019690926,0.0002125055,0.0001178883,0.000055082983,0.00019879616,0.0000028430775,0.00013831671,0.00006217633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025116524,0.000908559,0.041134883,0.0006970584,0.00042719056,0.000514238,0.0019676483,0.00016017361,0.7637407,0.0002742295,0.00043109292,0.1646277],"study_design_scores_gemma":[0.06990508,0.0023615095,0.37816575,0.0008591148,0.0005417499,0.0015430149,0.00021381048,0.016526982,0.51541,0.00014173485,0.013399447,0.00093181455],"about_ca_topic_score_codex":0.00012916545,"about_ca_topic_score_gemma":0.00037234274,"teacher_disagreement_score":0.3370309,"about_ca_system_score_codex":0.00009579665,"about_ca_system_score_gemma":0.00010378901,"threshold_uncertainty_score":0.8029727},"labels":[],"label_agreement":null},{"id":"W2017564455","doi":"10.2165/00019053-200119080-00006","title":"Incremental Cost Analysis of Ambulatory Clinic and Home-Based Intravenous Therapy for Patients with Multiple Myeloma","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; University of Toronto","funders":"","keywords":"Medicine; Ambulatory; Multiple myeloma; Cancer; Physical therapy; Emergency medicine; Surgery; Internal medicine","score_opus":0.030471698388158434,"score_gpt":0.33638224249804316,"score_spread":0.3059105441098847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017564455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767464,0.00015006741,0.00016363256,0.00007213474,0.00003973284,0.0014750719,0.00032733192,0.000019032183,0.00007833735],"genre_scores_gemma":[0.9975414,0.0004017022,0.00097526464,0.00037260947,0.000035900222,0.00012032113,0.00049596187,0.000027606824,0.000029176625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989963,0.000028138656,0.00030832703,0.00028013837,0.00011724532,0.0002698486],"domain_scores_gemma":[0.9990896,0.00024018495,0.00014568759,0.00018972831,0.000108949454,0.0002258808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015231685,0.00016294322,0.00045256322,0.00028998914,0.00006737346,0.0000141442415,0.00006809978,0.0000360819,0.00027772528],"category_scores_gemma":[0.000019905958,0.0001334966,0.00013004406,0.00016533799,0.00009790274,0.000073294934,0.000018237888,0.000079679354,0.0000069650587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008698903,0.0010652988,0.93457955,0.000031426112,0.0026747044,0.000007543965,0.000050856714,0.00006018979,0.0005468923,0.000001430283,0.0000637857,0.052219402],"study_design_scores_gemma":[0.031451177,0.0012393423,0.9386516,0.000010952621,0.0007665842,0.0000015879527,0.000030370396,0.022330008,0.004012627,0.0000029993787,0.0013593654,0.00014335169],"about_ca_topic_score_codex":0.00007824816,"about_ca_topic_score_gemma":0.000050626986,"teacher_disagreement_score":0.05207605,"about_ca_system_score_codex":0.00012309913,"about_ca_system_score_gemma":0.000096242424,"threshold_uncertainty_score":0.54438335},"labels":[],"label_agreement":null},{"id":"W2018810266","doi":"10.1016/s0008-4182(04)80150-9","title":"Orbital extramedullary plasmacytoma leading to exenteration","year":2004,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Extramedullary plasmacytoma; Plasmacytoma; Medicine; Radiology; Multiple myeloma; Internal medicine","score_opus":0.04068121962012327,"score_gpt":0.33206880649019677,"score_spread":0.2913875868700735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018810266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889959,0.00022541234,0.00009653687,0.001753921,0.00033823578,0.00017022717,0.000009465653,0.0000027240546,0.008407557],"genre_scores_gemma":[0.99626005,0.0000010668814,0.0027711934,0.00007683015,0.00018628992,0.0000036458525,0.00000899055,0.000015236427,0.00067668327],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9990409,0.000031409872,0.00027300487,0.00011530006,0.00015588275,0.00038351808],"domain_scores_gemma":[0.9982001,0.000031661344,0.000068862726,0.000117449585,0.00017329387,0.0014086103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013484065,0.000101227495,0.00025298633,0.00048954994,0.00008506098,0.000026622674,0.00010134686,0.00007485426,0.00072527275],"category_scores_gemma":[0.0003101338,0.00008793071,0.000087819855,0.00015951478,0.000058831036,0.000096583215,0.000007943617,0.00021762957,0.00016175785],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007313941,0.00015697507,0.2612378,0.000043884927,0.00031470958,0.72659755,0.00088841614,0.00035988237,0.005131346,0.0004460733,0.0012341464,0.0028578304],"study_design_scores_gemma":[0.003513777,0.0031752167,0.13284126,0.00017372528,0.000040253097,0.8530637,0.00015493609,0.000010073137,0.005910863,0.00038827385,0.000607436,0.00012049202],"about_ca_topic_score_codex":0.0015981827,"about_ca_topic_score_gemma":0.00034848257,"teacher_disagreement_score":0.12839653,"about_ca_system_score_codex":0.00047050227,"about_ca_system_score_gemma":0.0015600525,"threshold_uncertainty_score":0.79412276},"labels":[],"label_agreement":null},{"id":"W2019023281","doi":"10.1002/ajh.23220","title":"No association between cigarette smoking and incidence of plasma cell myeloma: A meta‐analysis of 17 observational studies","year":2012,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Incidence (geometry); Internal medicine; Plasma Cell Myeloma; Observational study; Bone marrow; Meta-analysis; Oncology; Pathology","score_opus":0.18598639532587363,"score_gpt":0.4185439652328027,"score_spread":0.23255756990692905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019023281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028611112,0.97082436,0.000019382784,0.000114878276,0.00004466981,0.00022280002,0.000088456385,0.000003140024,0.0000711706],"genre_scores_gemma":[0.09078318,0.9073257,0.0015920403,0.000025004772,0.00007931416,0.000016802607,0.000053860043,0.000021354634,0.00010274504],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967319,0.0004978212,0.001524096,0.00019426168,0.00074682984,0.0003051408],"domain_scores_gemma":[0.9898093,0.0036087248,0.00518509,0.00020945049,0.0010064367,0.00018104953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010983442,0.0002833708,0.0076938346,0.0008754073,0.00003953462,0.0000045626525,0.00016836407,0.00014767113,0.00006253136],"category_scores_gemma":[0.000868021,0.00018954492,0.001345249,0.0008544834,0.00031364348,0.00009384914,0.00009610736,0.00044516695,0.0000016899476],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086031716,0.00018987857,0.21800096,0.006478772,0.688792,0.000114959665,0.0002514374,9.846223e-7,0.0000030452816,0.00003135006,0.00017189933,0.08587868],"study_design_scores_gemma":[0.00092868076,0.0011486625,0.020993993,0.0017750169,0.9487299,0.00041161716,0.00019324868,0.000008955976,0.00007668646,0.0000135933415,0.025497371,0.00022230986],"about_ca_topic_score_codex":0.000042921853,"about_ca_topic_score_gemma":0.000009465243,"teacher_disagreement_score":0.25993785,"about_ca_system_score_codex":0.00022024286,"about_ca_system_score_gemma":0.00040179995,"threshold_uncertainty_score":0.77294177},"labels":[],"label_agreement":null},{"id":"W2020428172","doi":"10.1111/bjh.13100","title":"Phase I‐<scp>II</scp> trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma","year":2014,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Celgene","keywords":"Medicine; Lenalidomide; Prednisone; Refractory (planetary science); Cyclophosphamide; Internal medicine; Regimen; Multiple myeloma; Surgery; Gastroenterology; Chemotherapy","score_opus":0.018161703457920467,"score_gpt":0.28916118427606546,"score_spread":0.270999480818145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020428172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401665,0.0041875443,0.00020327706,0.00011159332,0.000108634966,0.0012576643,0.00007986726,0.000004990741,0.000029788445],"genre_scores_gemma":[0.9955913,0.002222702,0.0019371257,0.000020264188,0.000053453794,0.00004095686,0.000022890186,0.000022864819,0.00008847783],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984328,0.00014688571,0.00065949064,0.00018270985,0.00030643123,0.00027168417],"domain_scores_gemma":[0.9971907,0.0014061454,0.0006260976,0.00016936548,0.0004031788,0.00020448402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032573854,0.00016358141,0.00097254047,0.000111902125,0.0001266712,0.000013159043,0.00008017944,0.00010292891,0.0000048058255],"category_scores_gemma":[0.0012320997,0.0001072647,0.00013362868,0.000073850875,0.00036428706,0.00009285661,0.000021991435,0.000121678335,2.307304e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24247071,0.0243666,0.2142536,0.00076103583,0.004221422,0.0029332084,0.0013824446,0.00000802053,0.0011976983,0.00009052639,0.0016744513,0.50664026],"study_design_scores_gemma":[0.74050856,0.08286479,0.14878914,0.0005395299,0.0009245558,0.007489505,0.00022151152,0.0003205119,0.010459978,0.00015066599,0.0076330155,0.0000982433],"about_ca_topic_score_codex":0.00014632517,"about_ca_topic_score_gemma":0.00009326551,"teacher_disagreement_score":0.506542,"about_ca_system_score_codex":0.000036338242,"about_ca_system_score_gemma":0.00010440068,"threshold_uncertainty_score":0.43741274},"labels":[],"label_agreement":null},{"id":"W2020431842","doi":"10.1016/j.clml.2012.08.003","title":"An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Beatrice Hunter Cancer Research Institute; Saint John Regional Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Multiple myeloma; Bortezomib; Lenalidomide; Internal medicine; Thalidomide; Refractory (planetary science); Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Anemia; Oncology; Surgery; Clinical trial; Gastroenterology","score_opus":0.09475273562003522,"score_gpt":0.37707119894691077,"score_spread":0.28231846332687555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020431842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335605,0.00037239183,0.000011028413,0.0000618213,0.00040004178,0.0047282954,0.00013964006,0.0001247785,0.00080596865],"genre_scores_gemma":[0.99610424,0.000047265577,0.002124692,0.00028938305,0.00029175097,0.00024037246,0.00042816464,0.00019072344,0.00028343595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923425,0.00096178096,0.0022840765,0.001487654,0.0013779476,0.0015460507],"domain_scores_gemma":[0.9938057,0.0010987835,0.00078535767,0.0018401345,0.0004899743,0.0019800416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016863159,0.00087142695,0.002014186,0.00044397032,0.00035572913,0.00011397199,0.00078085356,0.0004214865,0.00012271339],"category_scores_gemma":[0.0018240912,0.0006932717,0.00013913629,0.0007916698,0.000742705,0.0010707155,0.0008524708,0.0006386352,0.000055026943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028384982,0.16652094,0.5206991,0.00010691405,0.00043276165,0.00027721253,0.00061074796,0.0000010294708,0.0029651138,0.00000919063,0.00014939676,0.27984262],"study_design_scores_gemma":[0.1478761,0.11864545,0.7302318,0.0003707744,0.00024010388,0.000023659506,0.00032657286,0.00025264718,0.0010856476,0.000010594547,0.00041333697,0.00052330364],"about_ca_topic_score_codex":0.00073872297,"about_ca_topic_score_gemma":0.0003684796,"teacher_disagreement_score":0.27931932,"about_ca_system_score_codex":0.0017454431,"about_ca_system_score_gemma":0.0009343886,"threshold_uncertainty_score":0.99955183},"labels":[],"label_agreement":null},{"id":"W2020670863","doi":"10.4021//jmc.v3i6.855","title":"Isolated Abducens Nerve Palsy in Multiple Myeloma With Hyperviscosity of the Serum","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hyperviscosity; Abducens nerve; Multiple myeloma; Palsy; Magnetic resonance imaging; Pathological; Cerebrospinal fluid; Lesion; Pathology; Radiology; Surgery; Internal medicine; Blood viscosity","score_opus":0.050001452758994896,"score_gpt":0.32337428586272476,"score_spread":0.27337283310372984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020670863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937513,0.0013829796,0.000041375817,0.0044227373,0.000124062,0.0001842349,0.000010288481,0.0000042442966,0.0000788116],"genre_scores_gemma":[0.9989957,0.0001719277,0.00031735227,0.0002134563,0.00023069886,0.0000022832414,0.0000018341434,0.000011775183,0.00005493451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975175,0.0001747519,0.00044670093,0.00007914018,0.0014385913,0.00034326388],"domain_scores_gemma":[0.99839646,0.00043012304,0.00022716269,0.00019570877,0.00017255478,0.0005780137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079477055,0.00011752503,0.0004050804,0.00011349712,0.00004571743,0.0000060458124,0.00018354316,0.00010898894,0.00034351158],"category_scores_gemma":[0.0016296079,0.000054571065,0.00013687891,0.00027626855,0.00016152574,0.00011564898,0.00007253891,0.00053137616,0.000005622697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013001512,0.00103923,0.98019665,0.000094839175,0.00014800765,0.0018897912,0.00020407817,0.000001606199,0.00059693994,0.0000059368526,0.0005906888,0.013932091],"study_design_scores_gemma":[0.0060927374,0.0010255632,0.9795367,0.00083620695,0.00008930249,0.00687664,0.00032120157,0.00051348394,0.0039468617,0.000005078955,0.0006944853,0.00006175098],"about_ca_topic_score_codex":0.0002706208,"about_ca_topic_score_gemma":0.00020628731,"teacher_disagreement_score":0.013870341,"about_ca_system_score_codex":0.00007704059,"about_ca_system_score_gemma":0.00033346473,"threshold_uncertainty_score":0.3761211},"labels":[],"label_agreement":null},{"id":"W2020793885","doi":"10.1097/00002371-200201000-00008","title":"CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications","year":2002,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"CD20; Rituximab; Medicine; Multiple myeloma; Lymphoma; Immunology; Bone marrow; Chronic lymphocytic leukemia; Monoclonal; Chemoimmunotherapy; Internal medicine; Leukemia; Monoclonal antibody; Antibody","score_opus":0.024551432524570784,"score_gpt":0.2738442964361995,"score_spread":0.24929286391162872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020793885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170554,0.0061767832,0.00020189784,0.00084943656,0.000023169612,0.00087768934,0.0000092884275,0.00002488546,0.00013130864],"genre_scores_gemma":[0.99426293,0.0016757227,0.003410438,0.00044264505,0.00003804143,0.00004909491,0.0000058743135,0.000023735034,0.000091528986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989107,0.00009257638,0.00038120447,0.00014325038,0.0002524418,0.00021980079],"domain_scores_gemma":[0.99903107,0.00020611243,0.00019294911,0.00019476205,0.00026901095,0.000106084786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001340734,0.00015626814,0.00034352829,0.00026731082,0.00010014284,0.000031841144,0.000060295297,0.000069535105,0.00033481413],"category_scores_gemma":[0.000034750432,0.000098507786,0.000063539024,0.00023618511,0.000105496096,0.00009299508,0.0000061331925,0.00023315393,0.000008855724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013418746,0.0014497298,0.91674244,0.0000118034495,0.00045857875,0.00003337414,0.0003786784,0.000006830186,0.0046427264,0.000031270924,0.00009158876,0.07481111],"study_design_scores_gemma":[0.0199715,0.0018564394,0.974934,0.00007642495,0.000023216697,0.0001054301,0.000044160144,0.00026287657,0.0005688002,0.00016250994,0.0018820029,0.00011268697],"about_ca_topic_score_codex":0.000016334609,"about_ca_topic_score_gemma":0.000017609202,"teacher_disagreement_score":0.07469842,"about_ca_system_score_codex":0.00008430926,"about_ca_system_score_gemma":0.000048146456,"threshold_uncertainty_score":0.4017031},"labels":[],"label_agreement":null},{"id":"W2021954218","doi":"10.1056/nejmoa070596","title":"Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1235,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Oncology","score_opus":0.03906187277418626,"score_gpt":0.33035837478507923,"score_spread":0.29129650201089297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021954218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760192,0.0020101,0.01536174,0.004920918,0.00036028266,0.0006454967,0.0000070697315,0.000015217296,0.00066000014],"genre_scores_gemma":[0.9841912,0.00041535863,0.011417471,0.00051619066,0.0027642318,0.000005244777,0.000036590158,0.000030504647,0.00062325166],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99763864,0.00008028501,0.000877442,0.0001953153,0.00067769206,0.00053063687],"domain_scores_gemma":[0.99659437,0.0017228995,0.000351819,0.00021661821,0.00031739858,0.0007968952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015926795,0.0002100679,0.0008383851,0.0006003605,0.000051136376,0.000006918709,0.00014792512,0.00008047536,0.000126404],"category_scores_gemma":[0.0040969234,0.00013395438,0.00014114795,0.00047640907,0.00013660219,0.000096463074,0.000020710293,0.00049096014,0.00000795993],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03302303,0.00028444396,0.26816943,0.00010512856,0.00032490498,0.0031568345,0.0018417039,0.000077365126,0.0049258666,0.00001279244,0.004216364,0.68386215],"study_design_scores_gemma":[0.45161185,0.008415214,0.4454495,0.0007123812,0.0002833011,0.0018408373,0.00081555627,0.0009038259,0.0020432342,0.00015768631,0.08755132,0.00021530515],"about_ca_topic_score_codex":0.00044398653,"about_ca_topic_score_gemma":0.0016358169,"teacher_disagreement_score":0.68364686,"about_ca_system_score_codex":0.0002659187,"about_ca_system_score_gemma":0.00037493912,"threshold_uncertainty_score":0.5462501},"labels":[],"label_agreement":null},{"id":"W2022846389","doi":"10.1159/000166684","title":"Renal Transplantation in Light-Chain Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"American Journal of Nephrology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Kidney transplantation; Kidney; Cadaveric spasm; Intensive care medicine; Urology; Surgery; Internal medicine","score_opus":0.019284759719526867,"score_gpt":0.28576326773920285,"score_spread":0.266478508019676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022846389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614525,0.00016061324,0.00041489344,0.002689148,0.000039950315,0.00012897105,0.0000031991663,0.000007851565,0.00041012422],"genre_scores_gemma":[0.99532694,0.0006250789,0.0029613073,0.00084894005,0.00014426334,0.000005248834,0.000006861002,0.000013013991,0.00006833931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876416,0.00015650778,0.00039298082,0.00012522656,0.0002601604,0.0003009429],"domain_scores_gemma":[0.9991818,0.00017268753,0.0002113661,0.000114592214,0.00010560156,0.0002139518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017174189,0.00011040829,0.000429107,0.00038774815,0.000043119726,0.0000026105706,0.00008402575,0.000043535303,0.00006234437],"category_scores_gemma":[0.00008318377,0.00008489933,0.000107688276,0.00028124687,0.00023382828,0.000074816424,0.000008415777,0.00029401545,0.000021099335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015762119,0.0008034653,0.7449873,0.00002522994,0.00040181563,0.029024547,0.002905448,0.00006897639,0.10146685,0.0000326276,0.0011111847,0.1034104],"study_design_scores_gemma":[0.0075547798,0.004770634,0.9633239,0.000039293052,0.00004471866,0.01599568,0.000151745,0.00023411668,0.0028727714,0.00003542097,0.00489389,0.00008307869],"about_ca_topic_score_codex":0.00018232537,"about_ca_topic_score_gemma":0.000116675146,"teacher_disagreement_score":0.21833654,"about_ca_system_score_codex":0.000076413125,"about_ca_system_score_gemma":0.00017824072,"threshold_uncertainty_score":0.3462094},"labels":[],"label_agreement":null},{"id":"W2024971109","doi":"10.1016/j.ijrobp.2005.06.039","title":"Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients","year":2005,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Radiation therapy; Chemotherapy; Multivariate analysis; Cancer; Plasmacytoma; Internal medicine; Surgery; Radiology; Oncology","score_opus":0.020957809842254867,"score_gpt":0.3561254426836296,"score_spread":0.33516763284137474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024971109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978461,0.00021260559,0.000087754364,0.00094363355,0.00036149065,0.0004093992,0.00010595092,0.0000053506838,0.00002767069],"genre_scores_gemma":[0.9981269,0.00031394337,0.0008212721,0.00016646707,0.00047213584,0.000017227254,0.00005304341,0.0000143185825,0.0000146779175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998365,0.00018295537,0.0007713421,0.00016129314,0.0003195441,0.00019989484],"domain_scores_gemma":[0.99816257,0.00031402762,0.0007267207,0.00010244516,0.00058940984,0.00010481036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002218788,0.00014915451,0.00054739066,0.00018503712,0.000023913883,0.00000540813,0.00017633606,0.00011034718,0.000043551347],"category_scores_gemma":[0.0001671883,0.00011609516,0.00010951649,0.00009243571,0.00006970009,0.00015474542,0.00007501675,0.00028566702,0.0000019191314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010651125,0.0026005362,0.92293346,0.000016029366,0.00085892883,0.00003642817,0.0010097891,0.0006164305,0.00010640269,0.000048200112,0.000100681274,0.07060799],"study_design_scores_gemma":[0.024473784,0.0016985179,0.97097623,0.00011254348,0.00009059593,0.000013562057,0.0002687482,0.0014490056,0.0002777445,0.000107610664,0.00045804738,0.000073578],"about_ca_topic_score_codex":0.0002312482,"about_ca_topic_score_gemma":0.0005241966,"teacher_disagreement_score":0.070534416,"about_ca_system_score_codex":0.00037639786,"about_ca_system_score_gemma":0.00018044257,"threshold_uncertainty_score":0.4734223},"labels":[],"label_agreement":null},{"id":"W2025196053","doi":"10.1038/sj.bmt.1703253","title":"Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect","year":2001,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Chemotherapy; Surgery; Statistical significance; Allotransplantation; Transplantation; Gastroenterology; Confidence interval; Graft-versus-host disease","score_opus":0.10278321365952423,"score_gpt":0.3888093239543939,"score_spread":0.2860261102948697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025196053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003034699,0.96387535,0.008096603,0.00014701688,0.00071895384,0.019779148,0.0038177923,0.00034812992,0.00018229421],"genre_scores_gemma":[0.010682475,0.95336837,0.0019386079,0.00003223148,0.0003190043,0.007908792,0.024773812,0.00026431752,0.0007124182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951396,0.0004983825,0.0012326903,0.0012174665,0.00080538116,0.001106452],"domain_scores_gemma":[0.99278253,0.0053981054,0.0005676296,0.0005151836,0.00032170568,0.00041485747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009781219,0.0010685222,0.002521279,0.0006167622,0.0003218735,0.00008996743,0.00026398318,0.00085288746,0.00010931232],"category_scores_gemma":[0.0006587095,0.0008842463,0.001674154,0.0006537013,0.000097697506,0.0002989853,0.000010716283,0.0003977293,0.00007369087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017414484,0.0003763688,0.00077188347,0.079069145,0.0021255284,0.00054357265,0.00032034685,0.000004773993,0.00022746672,0.00001336892,0.00018915614,0.8989439],"study_design_scores_gemma":[0.23836923,0.027846888,0.035748973,0.13835862,0.13434926,0.003620303,0.00013471539,0.0022615225,0.003075454,0.0001530671,0.40863743,0.0074445247],"about_ca_topic_score_codex":0.00012546954,"about_ca_topic_score_gemma":0.00084144936,"teacher_disagreement_score":0.8914994,"about_ca_system_score_codex":0.0005274792,"about_ca_system_score_gemma":0.0005345409,"threshold_uncertainty_score":0.9993608},"labels":[],"label_agreement":null},{"id":"W2025250975","doi":"10.1007/s00277-008-0559-8","title":"Hepatotoxicity as a rare but serious side effect of Thalidomide","year":2008,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Thalidomide; Hematology; Medicine; Internal medicine; Intensive care medicine; Pharmacology; Multiple myeloma","score_opus":0.05088394232195603,"score_gpt":0.3612637248419146,"score_spread":0.31037978251995857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025250975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84598887,0.003391479,0.000002801658,0.1444811,0.00010985279,0.001414995,0.00022056968,0.0000500406,0.0043402864],"genre_scores_gemma":[0.8905677,0.0016658674,0.000121731246,0.10498932,0.0003565375,0.00016904909,0.00073004205,0.00009444883,0.0013052693],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968608,0.00047841057,0.0007208578,0.0005054167,0.000679063,0.0007554283],"domain_scores_gemma":[0.99712485,0.0011161915,0.00047431092,0.0008418904,0.00025271208,0.00019001872],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019522873,0.00047381417,0.002507072,0.0004098059,0.000051593823,0.0000040182886,0.00026727514,0.0010456783,0.0002067855],"category_scores_gemma":[0.0010251014,0.00035439685,0.00064750464,0.00016826513,0.00043645562,0.000040289462,0.00013116957,0.0010497568,0.00014909478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035374456,0.0003550043,0.054487836,0.0068447553,0.0026879173,0.060860954,0.00010316687,3.7797923e-7,0.0025506385,0.000030206302,0.8666746,0.0018671162],"study_design_scores_gemma":[0.006488167,0.005900558,0.0031465022,0.0011596476,0.0003096133,0.01691152,0.000011182499,0.000017785556,0.91255224,0.00022332527,0.052866936,0.0004125486],"about_ca_topic_score_codex":0.0011263179,"about_ca_topic_score_gemma":0.00001284854,"teacher_disagreement_score":0.9100016,"about_ca_system_score_codex":0.000019182062,"about_ca_system_score_gemma":0.00031011458,"threshold_uncertainty_score":0.9998908},"labels":[],"label_agreement":null},{"id":"W2025348939","doi":"10.1002/cncr.25139","title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function","year":2010,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Dexamethasone; Refractory (planetary science); Renal function; Impaired renal function; Internal medicine; Oncology; Urology","score_opus":0.017855631796236008,"score_gpt":0.28394716220730976,"score_spread":0.26609153041107375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025348939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983732,0.0005332762,0.000014094574,0.00016821623,0.00008348051,0.0007162132,0.000022501412,0.000013115793,0.00007587249],"genre_scores_gemma":[0.9989607,0.00028050458,0.0002691681,0.000034171793,0.00005312258,0.00007517125,0.00001891175,0.00001697295,0.00029128665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990575,0.000054425,0.00019996232,0.00021802448,0.00024212692,0.00022800098],"domain_scores_gemma":[0.9989438,0.00048109295,0.00008874933,0.0002236892,0.00011024641,0.0001524269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019481496,0.00012070235,0.00022805181,0.00006632753,0.0000977879,0.000010502808,0.000041449915,0.00007309551,0.000054670694],"category_scores_gemma":[0.00047189224,0.000062830535,0.000021222175,0.00013655992,0.0002105983,0.000055586203,0.00003265651,0.00026760617,0.0000013686108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056089837,0.00020332591,0.7613106,0.000057667974,0.00016366586,0.000018049617,0.00027210708,0.0000053274703,0.00805947,0.000008473064,0.00009218672,0.17371933],"study_design_scores_gemma":[0.029225584,0.00090504374,0.966458,0.00014622316,0.000050007264,0.00000431357,0.000046174653,0.0003484771,0.0010848963,0.0000053400886,0.0016554749,0.00007042002],"about_ca_topic_score_codex":0.0004609843,"about_ca_topic_score_gemma":0.0027279456,"teacher_disagreement_score":0.20514749,"about_ca_system_score_codex":0.00009757746,"about_ca_system_score_gemma":0.00018923065,"threshold_uncertainty_score":0.25621548},"labels":[],"label_agreement":null},{"id":"W2025533780","doi":"10.1111/ejh.12491","title":"Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation","year":2014,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation; Celgene","keywords":"Medicine; Refractory (planetary science); Internal medicine; Multiple myeloma; Gastroenterology; Clinical endpoint; Adverse effect; Chromosomal translocation; Dexamethasone; Clinical trial; Surgery; Biology","score_opus":0.029760721526495826,"score_gpt":0.311031236984917,"score_spread":0.2812705154584212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025533780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982443,0.000029082466,0.00046755478,0.00008778298,0.00004982869,0.00076565094,0.0000039898823,0.000012197218,0.00033961248],"genre_scores_gemma":[0.9978446,0.0000085893325,0.00190923,0.000040561186,0.000037454498,0.000005772877,0.000012051955,0.000050703115,0.000091045265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971849,0.0009934906,0.0007946264,0.00022440657,0.0005186769,0.00028394695],"domain_scores_gemma":[0.99817896,0.00024290277,0.00059934787,0.0003181063,0.00042997868,0.00023071567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068449334,0.00020601679,0.00086321175,0.0003851226,0.000046990535,0.000008849286,0.0001641307,0.00003383333,0.00007183653],"category_scores_gemma":[0.00045408163,0.00010459754,0.000045840094,0.0002620851,0.00013055463,0.00013920417,0.000019144025,0.00036159996,0.000011629984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10272968,0.012330272,0.8508988,0.0001238813,0.00041194895,0.007232039,0.002134569,0.000012564567,0.00021096965,0.0000028369882,0.00006163513,0.0238508],"study_design_scores_gemma":[0.2229108,0.12150124,0.6496,0.0007766026,0.00022886856,0.0021614851,0.001194573,0.0002524713,0.0007392824,0.0000012170931,0.00044244807,0.00019095483],"about_ca_topic_score_codex":0.000017577364,"about_ca_topic_score_gemma":0.00024879663,"teacher_disagreement_score":0.20129876,"about_ca_system_score_codex":0.00004377321,"about_ca_system_score_gemma":0.00016427635,"threshold_uncertainty_score":0.42653638},"labels":[],"label_agreement":null},{"id":"W2027774332","doi":"10.1111/j.1365-2141.2009.07728.x","title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University Health Network; Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Discontinuation; Dexamethasone; Internal medicine; Multiple myeloma; Adverse effect; Thalidomide; Refractory (planetary science); Gastroenterology; Surgery","score_opus":0.03021112419302469,"score_gpt":0.31823097306370635,"score_spread":0.28801984887068166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027774332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573106,0.0022826432,0.00043752548,0.0006443878,0.00007921308,0.00038947733,0.0000060105285,0.000021100805,0.00040861446],"genre_scores_gemma":[0.991525,0.0008815451,0.0068984954,0.000303131,0.00006833558,0.0000128001475,0.0000074445547,0.000021869933,0.00028137257],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99758524,0.0002515791,0.0008307929,0.00027683625,0.00050998456,0.0005455969],"domain_scores_gemma":[0.99834174,0.00042371775,0.00035161612,0.0002323058,0.00026636355,0.00038423343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041567374,0.00019681922,0.0010582795,0.00029698564,0.00009343252,0.000030350788,0.00019629503,0.00016154777,0.00024340338],"category_scores_gemma":[0.001502321,0.00015343321,0.00012158402,0.0003161366,0.00020229578,0.00019838636,0.000027676599,0.00063412957,0.000011319669],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05118662,0.0016335323,0.080615364,0.00010252398,0.0002868691,0.70530516,0.0013888995,0.00003996122,0.0040345653,0.000039513776,0.0007435131,0.15462348],"study_design_scores_gemma":[0.045207467,0.004299832,0.36445165,0.0017245725,0.00006833209,0.57617915,0.0011229744,0.00023950498,0.005366721,0.00008015348,0.0010051833,0.00025446477],"about_ca_topic_score_codex":0.00020632845,"about_ca_topic_score_gemma":0.00078217196,"teacher_disagreement_score":0.28383628,"about_ca_system_score_codex":0.00026048243,"about_ca_system_score_gemma":0.0005213931,"threshold_uncertainty_score":0.6256825},"labels":[],"label_agreement":null},{"id":"W2028283135","doi":"10.1016/j.bbmt.2014.08.007","title":"Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"Otsuka America; Celgene; Merck; Sanofi; Novartis; Spectrum Pharmaceuticals; Amgen","keywords":"Medicine; Transplantation; Multiple myeloma; Bortezomib; Busulfan; Regimen; Pharmacokinetics; Surgery; Toxicity; Urology; Internal medicine; Hematopoietic stem cell transplantation","score_opus":0.006396758255028212,"score_gpt":0.2345020117538441,"score_spread":0.22810525349881589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028283135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728125,0.0003302019,0.0005488853,0.000055786913,0.000024266517,0.0012231193,0.00042852163,0.00002318545,0.00008479381],"genre_scores_gemma":[0.99356765,0.00047788292,0.0040644594,0.000018076087,0.000018308838,0.000048534264,0.0017548798,0.000017519951,0.000032701777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989431,0.00009426097,0.0003217429,0.00032300493,0.0001039274,0.00021397098],"domain_scores_gemma":[0.99891,0.000573368,0.00018630875,0.000092244336,0.00011403738,0.00012406062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014756806,0.00017396497,0.00036624074,0.0001336021,0.00012446211,0.000007373128,0.000029978464,0.00014253761,0.000007121476],"category_scores_gemma":[0.000058918875,0.00014097376,0.000037896538,0.00006299602,0.0002055505,0.00008658929,0.0000047898143,0.0000785298,2.1630574e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021357445,0.00092948735,0.6729608,0.0037362564,0.0008764357,0.00002649235,0.0018970434,0.0000036475703,0.2894254,0.00025632489,0.0000032302733,0.008527428],"study_design_scores_gemma":[0.06326956,0.0074576177,0.79535407,0.00030951633,0.0016698736,0.00013587881,0.00008630054,0.0001567106,0.1312596,0.000095030664,0.000021031454,0.00018480359],"about_ca_topic_score_codex":0.00004749872,"about_ca_topic_score_gemma":0.00010381387,"teacher_disagreement_score":0.15816578,"about_ca_system_score_codex":0.0000054550196,"about_ca_system_score_gemma":0.000068010915,"threshold_uncertainty_score":0.5748743},"labels":[],"label_agreement":null},{"id":"W2029045196","doi":"10.1111/bjh.13176","title":"Thalidomide‐prednisone maintenance following autologous stem cell transplant for <scp>M</scp>ultiple <scp>M</scp>yeloma: effect on thrombin generation and procoagulant markers in <scp>NCIC CTG MY</scp>.10","year":2014,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Hôpital Maisonneuve-Rosemont; Queen's University; London Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Celgene; Amgen; National Cancer Institute; National Institutes of Health; Cancer Research Institute","keywords":"Medicine; Thalidomide; Prednisone; Internal medicine; Autologous stem-cell transplantation; Gastroenterology; Multiple myeloma; Incidence (geometry); Oncology; Surgery","score_opus":0.01678841548025037,"score_gpt":0.2652000940276421,"score_spread":0.24841167854739174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029045196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957515,0.0049272943,0.0015016522,0.00014116662,0.0005423471,0.0023013945,0.00009445518,0.000064881315,0.0008516867],"genre_scores_gemma":[0.9949137,0.0008102617,0.002085821,0.00017851991,0.00023306783,0.0002452009,0.00012265953,0.000109919674,0.0013008451],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9947518,0.0009255815,0.0013523106,0.0007943308,0.00075563096,0.0014203128],"domain_scores_gemma":[0.99276924,0.005269057,0.0006968943,0.0003573733,0.00028036907,0.0006270358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002141335,0.0005803694,0.002149165,0.00054565095,0.0003110705,0.00014680029,0.00034200647,0.0004900231,0.0000063385505],"category_scores_gemma":[0.0033723053,0.00052973116,0.0005224829,0.0002954434,0.0002314323,0.00028530273,0.000066855806,0.0008291677,0.000027894957],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040046875,0.007616415,0.26484627,0.010820753,0.0060933847,0.28428805,0.0088793915,0.0007126314,0.15157455,0.0008567995,0.15963823,0.100668855],"study_design_scores_gemma":[0.13603836,0.02660608,0.2063358,0.009777976,0.0021786436,0.38612238,0.0042801816,0.025804173,0.18904944,0.0008316575,0.012443116,0.00053221674],"about_ca_topic_score_codex":0.00014961636,"about_ca_topic_score_gemma":0.00040438204,"teacher_disagreement_score":0.14719512,"about_ca_system_score_codex":0.00024084526,"about_ca_system_score_gemma":0.0002747526,"threshold_uncertainty_score":0.99971545},"labels":[],"label_agreement":null},{"id":"W2029121719","doi":"10.1016/j.clinbiochem.2012.10.030","title":"Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation","year":2012,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Immunofixation; Monoclonal; Low resolution; Agarose; Artificial intelligence; Digital image; Monoclonal antibody; High resolution; Computer science; Medicine; Antibody; Chemistry; Image (mathematics); Image processing; Chromatography; Immunology; Geography","score_opus":0.074330256710185,"score_gpt":0.4177998276640114,"score_spread":0.3434695709538264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029121719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997815,0.00060795696,0.0005318864,0.000113357855,0.000048372327,0.0003993798,0.0003731271,0.0000067532287,0.00010413165],"genre_scores_gemma":[0.99671644,0.00011824608,0.00019158077,0.0000054672214,0.0000788527,0.00003951865,0.0026886156,0.000007004377,0.00015428185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989431,0.00003172852,0.00046897004,0.00013608768,0.00031502117,0.00010508671],"domain_scores_gemma":[0.9988276,0.00012968396,0.00026107387,0.00017315909,0.0005274827,0.000081012164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010112069,0.00006603409,0.0001701745,0.000019464373,0.000021870714,0.000009653784,0.000035991434,0.00009560387,0.0000205905],"category_scores_gemma":[0.0014744858,0.00005862022,0.00007469924,0.000050969473,0.00011393775,0.00013067432,0.000020330292,0.0000481793,0.000002318296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023242933,0.0005032118,0.11776874,0.000095208445,0.00010305168,3.251304e-8,0.000013228886,3.357415e-8,0.8322153,0.000002443465,0.00009386,0.048972443],"study_design_scores_gemma":[0.0016695284,0.00008860517,0.36409357,0.00002901383,0.0001521315,0.0000019265408,0.00001680519,0.00037666602,0.6334644,0.000029434383,0.000043691565,0.000034206718],"about_ca_topic_score_codex":0.0000026068653,"about_ca_topic_score_gemma":1.3709525e-8,"teacher_disagreement_score":0.24632482,"about_ca_system_score_codex":0.00003768798,"about_ca_system_score_gemma":0.00009327906,"threshold_uncertainty_score":0.2390463},"labels":[],"label_agreement":null},{"id":"W2030969865","doi":"10.3747/co.v17i4.644","title":"Access to Thalidomide for the Treatment of Multiple Myeloma in Canada: Physician Behaviours and Ethical Implications","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Thalidomide; Medicine; Multiple myeloma; Expanded access; Family medicine; Malignancy; Disease; Intensive care medicine; Internal medicine","score_opus":0.16478227575431534,"score_gpt":0.47154988787125335,"score_spread":0.30676761211693804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030969865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98418915,0.0002445641,0.00006124889,0.013247909,0.0002648626,0.0017506001,0.00016535369,0.0000054993916,0.00007078004],"genre_scores_gemma":[0.99827373,0.00012199764,0.0002637439,0.0002457013,0.00009325805,0.0009247943,0.000056833785,0.000009372791,0.0000105950285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999208,0.000036633995,0.00018877773,0.0002012197,0.000105725674,0.00025965588],"domain_scores_gemma":[0.9985546,0.0008584247,0.000050932722,0.00024500635,0.00010039988,0.00019063642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008705069,0.000102420374,0.0002758815,0.00006633708,0.00006802593,0.0000071109744,0.000112242626,0.000076933975,0.000011775494],"category_scores_gemma":[0.00017369716,0.00006456695,0.00004757437,0.00011334955,0.000087740234,0.000015934918,0.000037388745,0.00021820313,0.0000011012957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029948849,0.0005821951,0.6050406,0.000014597835,0.00003690306,0.0000052488062,0.00018009119,0.0000014546572,0.001282787,0.00013968174,0.0006296325,0.3917873],"study_design_scores_gemma":[0.004043883,0.00068090763,0.9680987,0.000012981471,0.00007065227,0.000008145929,0.00008738971,0.00031154638,0.0023539795,0.000047264934,0.024232237,0.0000523275],"about_ca_topic_score_codex":0.20659137,"about_ca_topic_score_gemma":0.91542566,"teacher_disagreement_score":0.7088343,"about_ca_system_score_codex":0.0004208106,"about_ca_system_score_gemma":0.0010146332,"threshold_uncertainty_score":0.798692},"labels":[],"label_agreement":null},{"id":"W2031141630","doi":"10.1038/bmt.2009.335","title":"Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan","year":2009,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Single-nucleotide polymorphism; Medicine; Melphalan; XRCC1; Genotyping; Oncology; Mucositis; Internal medicine; Haplotype; Pharmacogenetics; Genotype; Multiple myeloma; Genetics; Toxicity; Biology; Gene","score_opus":0.02085842810874624,"score_gpt":0.26143230608313495,"score_spread":0.2405738779743887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031141630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997943,0.000059585065,0.00015071205,0.00034765663,0.00004779312,0.00087229843,0.000070770286,0.00008804536,0.00042017264],"genre_scores_gemma":[0.9969097,0.000060720864,0.001476525,0.00016150338,0.000027250655,0.00004418282,0.0010756591,0.000029570012,0.00021490591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980951,0.00010822808,0.00042041545,0.0003553479,0.0005578805,0.00046303592],"domain_scores_gemma":[0.9992758,0.00011858608,0.00010803338,0.00020239824,0.00009070961,0.00020448086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014400366,0.00023625368,0.0003662959,0.00028927752,0.000086955886,0.000025322888,0.00006739671,0.00011307985,0.00004343611],"category_scores_gemma":[0.000105647814,0.00019429451,0.00006249047,0.00035126662,0.000035840236,0.00014227527,0.0000044348017,0.00019189465,0.000029520499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002072717,0.0007192633,0.9701456,0.000044853754,0.000058867234,0.0008663039,0.00034565388,0.00003289791,0.0044042696,0.0000073181727,0.000012271914,0.021290002],"study_design_scores_gemma":[0.018100902,0.0008932192,0.97841644,0.00025848733,0.00010957394,0.000039261457,0.000015273736,0.00045972227,0.0014788705,0.000033735658,0.0000037136774,0.00019079303],"about_ca_topic_score_codex":0.00048104307,"about_ca_topic_score_gemma":0.0013595023,"teacher_disagreement_score":0.02109921,"about_ca_system_score_codex":0.00020964978,"about_ca_system_score_gemma":0.000058730246,"threshold_uncertainty_score":0.79231},"labels":[],"label_agreement":null},{"id":"W2031541413","doi":"10.4021/jmc.v4i10.1470","title":"A Multiple Myeloma Patient Presenting with Multiple Hepatic Masses","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Plasma cell neoplasm; Multiple myeloma; Common bile duct; Plasma cell; Radiology; Porta hepatis; Pathology; Biopsy; Jaundice; Internal medicine","score_opus":0.030436060364253743,"score_gpt":0.30921792270410864,"score_spread":0.2787818623398549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031541413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423134,0.000638863,0.00022173714,0.0040505715,0.000104886225,0.0004977406,0.000005354178,0.000022654485,0.00022687201],"genre_scores_gemma":[0.99406713,0.00017452886,0.0048629665,0.0003563694,0.00032316506,0.000035172357,0.000008326133,0.000027500608,0.00014485852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612796,0.00012546263,0.000617245,0.00017715545,0.0024994728,0.00045268456],"domain_scores_gemma":[0.99649394,0.0013315323,0.00030985803,0.00022214817,0.0005051809,0.0011373687],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031709776,0.00019447306,0.0005034693,0.00020191722,0.00009819134,0.000059615053,0.00017402194,0.00011206625,0.0015976143],"category_scores_gemma":[0.0057972283,0.0001092509,0.0001674385,0.00019300077,0.00015199676,0.00023822446,0.0000868424,0.0004963096,0.00007612073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007296382,0.0010622042,0.9259891,0.00020493333,0.00039800085,0.0126043195,0.00022065072,0.000004987647,0.00050545734,0.0000026996258,0.007144529,0.051133472],"study_design_scores_gemma":[0.021926105,0.008564576,0.89097995,0.0021172736,0.00033631365,0.030546917,0.0020686488,0.018300137,0.011062554,0.00005715707,0.013632172,0.00040822456],"about_ca_topic_score_codex":0.000650244,"about_ca_topic_score_gemma":0.00010234151,"teacher_disagreement_score":0.050725248,"about_ca_system_score_codex":0.000093381626,"about_ca_system_score_gemma":0.00042653608,"threshold_uncertainty_score":0.9993151},"labels":[],"label_agreement":null},{"id":"W2031621781","doi":"10.1179/joc.2011.23.6.326","title":"Thalidomide: An Old Drug with New Action","year":2011,"lang":"en","type":"review","venue":"Journal of Chemotherapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Thalidomide; Immune system; Medicine; Drug; Tuberculosis; Cancer; Mode of action; Immunology; Drug action; Pathogenesis; Pharmacology; Biology; Pathology; Multiple myeloma; Internal medicine","score_opus":0.1237648748996664,"score_gpt":0.4159307699631318,"score_spread":0.29216589506346535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031621781","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069739495,0.9976795,0.000058994978,0.00015081289,0.00012798648,0.0005348773,0.0000035631135,0.000015147103,0.0007317318],"genre_scores_gemma":[0.00004759915,0.9901472,0.0020092656,0.0001248366,0.0011488746,0.000005497891,0.000016627611,0.00008856384,0.006411591],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984419,0.00008638287,0.0005490006,0.00018648413,0.0004756125,0.00026063705],"domain_scores_gemma":[0.99802965,0.000059113976,0.0008022588,0.00035360432,0.00017564606,0.0005797528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027493067,0.00033561513,0.00162576,0.00031188063,0.00003424297,0.000034776578,0.00019704086,0.00016669935,0.0007124475],"category_scores_gemma":[0.00002198879,0.00017852378,0.0005052284,0.00018585086,0.00003870325,0.00019599723,0.000007938606,0.00063532306,0.000036588866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009849466,0.0003288138,0.00014339044,0.0017429247,0.0012790725,0.00022068959,0.00011692075,2.8255181e-8,0.0000051760567,0.000005965439,0.0030348494,0.9921372],"study_design_scores_gemma":[0.005151099,0.0013607352,0.0001942717,0.008036328,0.0008087526,0.0031324252,0.000015302505,5.2335866e-7,0.00013809076,0.00005038806,0.98095334,0.00015875844],"about_ca_topic_score_codex":0.00006486116,"about_ca_topic_score_gemma":0.000014172204,"teacher_disagreement_score":0.99197847,"about_ca_system_score_codex":0.00021717325,"about_ca_system_score_gemma":0.0010864121,"threshold_uncertainty_score":0.7800801},"labels":[],"label_agreement":null},{"id":"W2032027314","doi":"10.1016/j.cancergencyto.2004.05.004","title":"Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization","year":2005,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; Plasma cell leukemia; Fluorescence in situ hybridization; Interphase; Chromosomal translocation; Multiple myeloma; Comparative genomic hybridization; Molecular biology; Immunofluorescence; In situ hybridization; Bone marrow; Cytogenetics; Genome instability; Plasma cell; Cancer research; Genetics; Antibody; Chromosome; Immunology; DNA; Gene; DNA damage; Gene expression","score_opus":0.019516625018509235,"score_gpt":0.2968173238776432,"score_spread":0.27730069885913394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032027314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922208,0.0060917265,0.00017293659,0.00031517504,0.000044259938,0.00043717283,0.00006209108,0.000010093623,0.0006457056],"genre_scores_gemma":[0.9824944,0.01391247,0.002664756,0.00014692123,0.0000852854,0.00007352915,0.00007862875,0.000025436708,0.00051857845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886376,0.00002877835,0.00028886166,0.00031308096,0.00017497242,0.00033057673],"domain_scores_gemma":[0.9994732,0.000022478667,0.000045804103,0.00020298244,0.000053616888,0.00020192435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061078965,0.00016366996,0.00019538212,0.00014391135,0.000043782333,0.00003176684,0.00008153947,0.0000837987,0.000059460624],"category_scores_gemma":[0.000014081678,0.00016318662,0.00002780248,0.00018623551,0.000070784045,0.00002922735,0.00005503146,0.0001507584,0.000012823633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017773217,0.00028450513,0.38639358,0.00006652975,0.00002596822,0.00004409426,0.0005738244,0.0028386484,0.4977805,0.000005357546,0.0013265745,0.1104827],"study_design_scores_gemma":[0.007892765,0.00039687805,0.21919252,0.00012751372,0.000060422404,0.000021269394,0.00013428862,0.073827446,0.68009716,0.000021345659,0.017876431,0.00035192375],"about_ca_topic_score_codex":0.00013610377,"about_ca_topic_score_gemma":0.0026751582,"teacher_disagreement_score":0.1823167,"about_ca_system_score_codex":0.00050539704,"about_ca_system_score_gemma":0.00032743067,"threshold_uncertainty_score":0.66545576},"labels":[],"label_agreement":null},{"id":"W2032055037","doi":"10.1080/10428190802064941","title":"Treatment of relapsed and refractory myeloma","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Dalhousie University; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Saskatchewan; London Health Sciences Centre; St. Paul's Hospital; Centre hospitalier universitaire de Québec; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Bortezomib; Refractory (planetary science); Salvage therapy; Oncology; Internal medicine; Clinical trial; Pomalidomide; Malignancy; Chemotherapy; Intensive care medicine; Biology","score_opus":0.037678915989462464,"score_gpt":0.3176391694733303,"score_spread":0.2799602534838679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032055037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038882416,0.95405835,0.0000032232804,0.000021424237,0.00021727078,0.0022784178,0.00025605274,0.00017584069,0.004106979],"genre_scores_gemma":[0.005913731,0.9867751,0.0005886963,0.000054726777,0.00041513628,0.00047310037,0.0007767948,0.0002727112,0.0047299964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940798,0.00034397826,0.0016770962,0.0016886715,0.0009621359,0.0012482726],"domain_scores_gemma":[0.9953789,0.00080061576,0.00083967776,0.00151154,0.0001949046,0.001274334],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00013823654,0.0017079632,0.0052692755,0.00089366984,0.0003820431,0.00007275722,0.00030605993,0.0013842696,0.00007597707],"category_scores_gemma":[0.00017047545,0.0012577162,0.0011482418,0.00067974837,0.00090066984,0.00020824796,0.00023472353,0.00021321341,0.00011719947],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00061404787,0.0006091143,0.00043338555,0.00814992,0.0017996614,0.0032768848,0.0003261995,1.0958056e-7,0.000016793243,0.000083571445,0.0007728689,0.9839174],"study_design_scores_gemma":[0.022588642,0.002883552,0.0052519157,0.006384677,0.002266886,0.013691528,0.000068693764,0.00010181283,0.00008908901,0.000023140485,0.94569856,0.0009514862],"about_ca_topic_score_codex":0.0013338677,"about_ca_topic_score_gemma":0.000024888306,"teacher_disagreement_score":0.98296595,"about_ca_system_score_codex":0.011625549,"about_ca_system_score_gemma":0.009159661,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W2032535873","doi":"10.1007/s12185-010-0691-9","title":"Overexpression of PAX5 induces apoptosis in multiple myeloma cells","year":2010,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Multiple myeloma; Hematology; Apoptosis; PAX5; Cancer research; Internal medicine; Medicine; Oncology; Biology; Gene; Transcription factor; Genetics","score_opus":0.02528437172684648,"score_gpt":0.333839093380864,"score_spread":0.3085547216540175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032535873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978096,0.00007600913,0.000036562924,0.0008714302,0.00057149667,0.00009364612,0.000009244748,0.0000034776676,0.0005285557],"genre_scores_gemma":[0.9968667,0.00005045454,0.0028566683,0.000054566615,0.00010926164,0.000003251723,0.000005717105,0.000008454918,0.000044909393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987408,0.000042361426,0.00050891517,0.000098381584,0.00046065013,0.00014890486],"domain_scores_gemma":[0.99877304,0.0002682444,0.0003206423,0.00010894624,0.00041756852,0.00011153868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018534217,0.00008698638,0.00032531412,0.0004245884,0.00001245925,0.0000071114614,0.000222069,0.00010931287,0.0003038639],"category_scores_gemma":[0.0004982135,0.00006370328,0.00011275707,0.00007136877,0.0000828526,0.00010676345,0.000059552804,0.00037487305,0.00001419775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008834475,0.00046768782,0.25605705,0.000024684157,0.0001692659,0.0002820328,0.00012912868,0.0000030970966,0.73613673,0.00035562622,0.00031599955,0.0051752287],"study_design_scores_gemma":[0.004272331,0.00023896639,0.1097612,0.00025366264,0.0000127419,0.0011166821,0.000081272505,0.0001245745,0.88330233,0.00035037516,0.00043696637,0.00004891058],"about_ca_topic_score_codex":0.000059711438,"about_ca_topic_score_gemma":0.000029858016,"teacher_disagreement_score":0.14716558,"about_ca_system_score_codex":0.000036467358,"about_ca_system_score_gemma":0.00012732131,"threshold_uncertainty_score":0.33270967},"labels":[],"label_agreement":null},{"id":"W2033671580","doi":"10.1002/ajh.20246","title":"Megakaryocyte‐like giant myeloma cells","year":2004,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Library science; Citation; Medicine; Medical laboratory; Family medicine; Pathology; Computer science","score_opus":0.013793857266544172,"score_gpt":0.29687643815796017,"score_spread":0.28308258089141597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033671580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234635,0.0007672127,0.0010740928,0.004435838,0.00020964255,0.00014779397,0.0000033548938,0.000017374321,0.0009983145],"genre_scores_gemma":[0.98180544,0.0001926259,0.017139459,0.0006279419,0.00009015825,0.0000032327912,0.0000023327216,0.00002112763,0.00011770334],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985502,0.00007084791,0.0004586325,0.00015209834,0.00036079335,0.00040744408],"domain_scores_gemma":[0.9986718,0.00010206897,0.0003546511,0.00022828099,0.00020387818,0.00043930634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015976751,0.00015219473,0.00072837766,0.00026298937,0.000051172174,0.000008885243,0.00014740098,0.00004441369,0.00013798918],"category_scores_gemma":[0.00008306783,0.00010698288,0.00020484992,0.00025346165,0.0003923557,0.00007144705,0.00003485126,0.0003106451,0.00015033383],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015647467,0.0067349277,0.1257543,0.00044541658,0.006524398,0.13851655,0.0033793997,0.0002178451,0.1966011,0.008797991,0.014876525,0.48250407],"study_design_scores_gemma":[0.041522104,0.035628352,0.1419518,0.00096023653,0.0009157777,0.23727797,0.004400442,0.00010561231,0.5066838,0.003270731,0.026350955,0.0009322234],"about_ca_topic_score_codex":0.00008364563,"about_ca_topic_score_gemma":0.0000098864675,"teacher_disagreement_score":0.48157185,"about_ca_system_score_codex":0.000134485,"about_ca_system_score_gemma":0.00041325216,"threshold_uncertainty_score":0.4362635},"labels":[],"label_agreement":null},{"id":"W2033722427","doi":"10.1016/j.jval.2012.08.304","title":"PCN6 Lenalidomide Versus Bortezomib for Treatment of Relapsed/Refractory Multiple Myeloma (MM): A Number Needed to Treat (NNT) Analysis","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Number needed to treat; Lenalidomide; Bortezomib; Multiple myeloma; Thalidomide; Refractory (planetary science); Clinical trial; Internal medicine; Oncology; Confidence interval; Relative risk","score_opus":0.10816854373297373,"score_gpt":0.39398734399835283,"score_spread":0.2858188002653791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033722427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361664,0.0011383083,0.00022006642,0.0013209694,0.00021685242,0.0026396664,0.00021130824,0.000048555892,0.0005876312],"genre_scores_gemma":[0.99093777,0.0004418411,0.0065081315,0.00017484627,0.00023532289,0.0005115953,0.00026348908,0.000051297156,0.00087571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969322,0.0002634177,0.0007938714,0.00044996943,0.00047141628,0.0010891183],"domain_scores_gemma":[0.996758,0.0011767229,0.0002169256,0.00066271384,0.00012668659,0.0010589779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056978536,0.00032992693,0.0011582869,0.00064241874,0.00011133397,0.000011775644,0.00010334317,0.00013773696,0.00015203384],"category_scores_gemma":[0.00054746674,0.0002609129,0.0004588652,0.0010076487,0.000052310108,0.0001268567,0.00003088003,0.00009592014,0.0000890577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030045558,0.0068549216,0.9030348,0.0006857492,0.0025286868,0.00006005922,0.0054964777,0.00079399906,0.0013195227,0.00017846734,0.001672987,0.047328744],"study_design_scores_gemma":[0.14583741,0.019321382,0.7589076,0.0005268551,0.0026598503,0.000043953423,0.003381565,0.013303105,0.020511873,0.000054556633,0.03450805,0.00094377145],"about_ca_topic_score_codex":0.03323161,"about_ca_topic_score_gemma":0.0008256662,"teacher_disagreement_score":0.14412719,"about_ca_system_score_codex":0.0017448331,"about_ca_system_score_gemma":0.0004659078,"threshold_uncertainty_score":0.9999843},"labels":[],"label_agreement":null},{"id":"W2034022870","doi":"10.1038/bmt.2011.192","title":"Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma","year":2011,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Public Health Service","keywords":"Medicine; Multiple myeloma; Internal medicine; Transplantation; Proportional hazards model; Incidence (geometry); Relative risk; Hematopoietic stem cell transplantation; Gastroenterology; Graft-versus-host disease; Confidence interval; Oncology; Immunology","score_opus":0.017611218687331866,"score_gpt":0.28256875822111593,"score_spread":0.2649575395337841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034022870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712926,0.00019271072,0.0007864321,0.000058414178,0.00008155832,0.0010560572,0.00034413338,0.000033537814,0.00031788403],"genre_scores_gemma":[0.9972818,0.0009813518,0.00064273545,0.000023814891,0.000032888587,0.00017394894,0.0007731255,0.000023204757,0.000067117915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989425,0.000094552175,0.00023692878,0.00029948007,0.00020271886,0.00022384967],"domain_scores_gemma":[0.9994261,0.00017993446,0.00007057018,0.00011765909,0.00007444055,0.00013127457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002619549,0.00018286693,0.0003303072,0.0001478249,0.00008309098,0.00000992857,0.000024060462,0.000100111465,0.00004430015],"category_scores_gemma":[0.000015446274,0.0001523564,0.000075958575,0.00006795517,0.00009891296,0.00011106973,0.0000034897334,0.000097340875,0.0000028396016],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13149466,0.00036323225,0.19481231,0.007870129,0.0015450111,0.0017395928,0.004318543,0.0000041037497,0.60558933,0.00033055144,0.000026612519,0.051905937],"study_design_scores_gemma":[0.008108134,0.003787862,0.6343625,0.0002232293,0.0010645653,0.00032968904,0.000014108235,0.000119579825,0.35182473,0.00004465854,0.0000034301634,0.00011748136],"about_ca_topic_score_codex":0.000053189626,"about_ca_topic_score_gemma":0.000056285604,"teacher_disagreement_score":0.43955025,"about_ca_system_score_codex":0.00004509774,"about_ca_system_score_gemma":0.000037635615,"threshold_uncertainty_score":0.62129134},"labels":[],"label_agreement":null},{"id":"W2034266037","doi":"10.1038/leu.2014.255","title":"Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"","keywords":"Bortezomib; MARCKS; Gene knockdown; Cancer research; Drug resistance; Proteasome; Biology; Kinome; Proteasome inhibitor; Multiple myeloma; Pharmacology; Cell culture; Phosphorylation; Medicine; Immunology; Cell biology; Protein kinase C","score_opus":0.03353693951535806,"score_gpt":0.3167081932484534,"score_spread":0.2831712537330953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034266037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968539,0.0005442989,0.00020130836,0.00020613801,0.000044652326,0.00041026136,0.000014171132,0.00003086375,0.0016943908],"genre_scores_gemma":[0.99618375,0.0001779266,0.0028427092,0.000049569575,0.000052287127,0.000030805568,0.000014987685,0.000020926782,0.00062703894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844784,0.00012744412,0.0003271492,0.00038285798,0.0003464046,0.00036829562],"domain_scores_gemma":[0.9986467,0.0006891212,0.00011868724,0.00028949603,0.00006406674,0.00019194122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046783529,0.00017510646,0.00049900875,0.00010869423,0.00005650516,0.000015635584,0.000102006714,0.000103507045,0.000021495918],"category_scores_gemma":[0.0008492205,0.0001453575,0.00006900352,0.00016893608,0.00015127372,0.0001902799,0.00010340509,0.00032330342,0.0000061483956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029380862,0.00056597515,0.8957292,0.00076184614,0.00015484563,0.00012231422,0.0007307474,0.00019550759,0.057174113,0.00036827332,0.00056124676,0.040697854],"study_design_scores_gemma":[0.009077127,0.00016469622,0.86429584,0.00046562668,0.00003513833,0.0000061425185,0.000080949765,0.057439394,0.066977695,0.00073599775,0.0004879314,0.00023344737],"about_ca_topic_score_codex":0.0007783017,"about_ca_topic_score_gemma":0.00033620678,"teacher_disagreement_score":0.057243887,"about_ca_system_score_codex":0.00019588055,"about_ca_system_score_gemma":0.00017961541,"threshold_uncertainty_score":0.5927506},"labels":[],"label_agreement":null},{"id":"W2034363241","doi":"10.1002/ajh.1106","title":"An unusual presentation of extramedullary plasmacytoma occurring sequentially in the testis, subcutaneous tissue, and heart","year":2001,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Plasmacytoma; Medicine; Presentation (obstetrics); Subcutaneous tissue; Soft tissue; Pathology; Nasal cavity; Extramedullary plasmacytoma; Anatomy; Radiology; Multiple myeloma; Internal medicine","score_opus":0.020835054313758636,"score_gpt":0.35760829905816316,"score_spread":0.3367732447444045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034363241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982227,0.0006099665,0.00012617317,0.00073568174,0.00002821098,0.00016601068,0.0000025126174,0.000004349192,0.000104369574],"genre_scores_gemma":[0.9968688,0.00016417558,0.0027574264,0.00015508418,0.00003510596,0.0000029586,0.0000035419787,0.0000086650825,0.0000042605266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988097,0.00023208684,0.00037119762,0.000107201755,0.00026684784,0.0002129756],"domain_scores_gemma":[0.9990628,0.0003422145,0.00022825552,0.00013478144,0.00009813569,0.00013382272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023104098,0.00008983006,0.00040382752,0.00020553324,0.000029481836,0.000009703227,0.00010198122,0.000029352972,0.00002375701],"category_scores_gemma":[0.00015342316,0.00006054282,0.000037417452,0.00022592806,0.00031253873,0.00008234632,0.000014192554,0.00019875319,0.0000018224116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017274276,0.0005131438,0.92274463,0.00004591063,0.000106321844,0.012538947,0.0008744074,0.000016886312,0.01080929,0.00011798207,0.00007915834,0.05042587],"study_design_scores_gemma":[0.00430394,0.014873584,0.59586835,0.00020369623,0.0001351195,0.36784366,0.0039815987,0.00069048896,0.011004207,0.00026409802,0.0006873543,0.00014391597],"about_ca_topic_score_codex":0.00027447782,"about_ca_topic_score_gemma":0.00007458686,"teacher_disagreement_score":0.35530472,"about_ca_system_score_codex":0.000023119392,"about_ca_system_score_gemma":0.00012330624,"threshold_uncertainty_score":0.24688646},"labels":[],"label_agreement":null},{"id":"W2034628751","doi":"10.1118/1.3476196","title":"Sci-Fri PM: Delivery - 08: Total Marrow Irradiation Using Helical Tomotherapy in Treating a Multiple Myeloma Patient: A Case Study","year":2010,"lang":"en","type":"article","venue":"Medical Physics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Carleton University; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Tomotherapy; Medicine; Radiation treatment planning; Multiple myeloma; Nuclear medicine; Total body irradiation; Dosimetry; Radiation therapy; Medical physics; Radiology; Surgery; Chemotherapy; Internal medicine","score_opus":0.03017369874234128,"score_gpt":0.3254055943946175,"score_spread":0.29523189565227625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034628751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806494,0.0000482311,0.00022054379,0.00016862419,0.0001703889,0.0011290859,0.000015678925,0.000061444116,0.000121059],"genre_scores_gemma":[0.9982103,0.0000051502698,0.0008922639,0.00016457416,0.00053291436,0.0000874467,0.00003864015,0.000042616997,0.000026053185],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973138,0.0001411464,0.00042236675,0.00045893618,0.0011195154,0.00054426026],"domain_scores_gemma":[0.9984975,0.00031788505,0.000087090186,0.00037122663,0.00010929126,0.00061702897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030839577,0.00025329506,0.00043373456,0.00013355487,0.00017846195,0.000036273465,0.00009540002,0.00016800746,0.00023534315],"category_scores_gemma":[0.00066247024,0.00020697301,0.000118418284,0.0004362178,0.00013950678,0.00015803329,0.00008489344,0.000735586,0.000040624356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005455158,0.005065593,0.4663162,0.0000535981,0.00016746375,0.017784998,0.0037356098,0.000016866004,0.0042277803,0.00000568329,0.000041941603,0.5020388],"study_design_scores_gemma":[0.07577721,0.0072686644,0.3918169,0.00072301616,0.00037428556,0.01014238,0.007969694,0.4946999,0.009300268,0.00020528739,0.0002575158,0.0014648762],"about_ca_topic_score_codex":0.0028066635,"about_ca_topic_score_gemma":0.0013670885,"teacher_disagreement_score":0.5005739,"about_ca_system_score_codex":0.00018010366,"about_ca_system_score_gemma":0.00030975137,"threshold_uncertainty_score":0.8440114},"labels":[],"label_agreement":null},{"id":"W2035790980","doi":"10.1002/ajh.23194","title":"In multiple myeloma, bone‐marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival","year":2012,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; China Scholarship Council","keywords":"Chromosomal translocation; Bone marrow; Fluorescence in situ hybridization; CD20; Multiple myeloma; Pathology; Biology; Abnormality; Chromosome abnormality; Peripheral blood mononuclear cell; Lymphocyte; Immunology; Karyotype; Medicine; Lymphoma; Chromosome; Genetics; Gene","score_opus":0.018378740826383563,"score_gpt":0.281875947007928,"score_spread":0.26349720618154443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035790980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947416,0.001722971,0.000021198994,0.002017088,0.0006191792,0.00028256536,0.000014008398,0.000025044927,0.0005563078],"genre_scores_gemma":[0.99751985,0.0002341411,0.0012755466,0.00035101463,0.00037487908,0.000025152483,0.0000047097697,0.000037680857,0.00017705349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969696,0.00045598415,0.0008081195,0.00020087526,0.0005627707,0.0010026717],"domain_scores_gemma":[0.9971922,0.0013069871,0.00055902614,0.0003022845,0.00015372086,0.00048575734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071399537,0.0002869381,0.001100575,0.00033967302,0.00013128995,0.00002180461,0.00027530923,0.00009516849,0.00020694453],"category_scores_gemma":[0.0006442097,0.00018536566,0.00023322988,0.00032178825,0.00081417867,0.00029530158,0.000101868005,0.0005083988,0.00010274249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029183843,0.0007237115,0.97527736,0.00009275132,0.00061874156,0.004321617,0.0022763668,0.00002140687,0.0049311277,0.00048248144,0.00064713566,0.00768893],"study_design_scores_gemma":[0.025279187,0.008500942,0.61971,0.0006535259,0.0005433081,0.11458009,0.019311005,0.002357557,0.19842623,0.0001927862,0.009541634,0.0009036855],"about_ca_topic_score_codex":0.0010014903,"about_ca_topic_score_gemma":0.000101736776,"teacher_disagreement_score":0.35556728,"about_ca_system_score_codex":0.00026009497,"about_ca_system_score_gemma":0.0004600818,"threshold_uncertainty_score":0.7558992},"labels":[],"label_agreement":null},{"id":"W2035901454","doi":"10.1016/j.leukres.2013.09.025","title":"Genomic aberrations in anaplastic multiple myeloma: High frequency of 1q21(CKS1B) amplifications","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Biology; Hematology; Gene duplication; Chromosome instability; Cytogenetics; Cancer research; Molecular biology; Pathology; Medicine; Internal medicine; Genetics; Gene; Chromosome","score_opus":0.06511811730914109,"score_gpt":0.3531914296015694,"score_spread":0.28807331229242833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035901454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906745,0.0002349885,0.00016198737,0.0010195287,0.00004709713,0.00180352,0.00005301762,0.000040387313,0.005964969],"genre_scores_gemma":[0.992361,0.00010811405,0.00373095,0.000024947049,0.000084906074,0.0008393015,0.00018324515,0.000036918198,0.0026306033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702746,0.00025069757,0.00052423554,0.00046405988,0.0008868413,0.0008466802],"domain_scores_gemma":[0.9970621,0.00097270194,0.00006522044,0.0007980577,0.0006891751,0.0004127419],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005241553,0.00017587077,0.00036248864,0.0009206702,0.00020258401,0.00005080465,0.0003026287,0.0001585667,0.0012455754],"category_scores_gemma":[0.0015426308,0.00015264218,0.00008610218,0.0011928062,0.00036068907,0.00019140675,0.0001302897,0.0007355832,0.0015249554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029373955,0.0010586011,0.6854144,0.00029670942,0.00021369937,0.00015437863,0.0007125881,0.0001758173,0.2908561,0.004440027,0.0051015434,0.01128245],"study_design_scores_gemma":[0.0038232543,0.00032722403,0.98361665,0.000094510375,0.000012933609,0.000017206388,0.000302024,0.0053732637,0.004530583,0.0015785247,0.00020160196,0.00012221893],"about_ca_topic_score_codex":0.01866769,"about_ca_topic_score_gemma":0.002606355,"teacher_disagreement_score":0.2982023,"about_ca_system_score_codex":0.0014621429,"about_ca_system_score_gemma":0.0013636111,"threshold_uncertainty_score":0.9996674},"labels":[],"label_agreement":null},{"id":"W2036291732","doi":"10.1111/j.1365-2141.2005.05493.x","title":"The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system","year":2005,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cerebrospinal fluid; Multiple myeloma; Central nervous system; Medicine; Pathology; Cancer research; Immunology; Internal medicine","score_opus":0.01725287106537729,"score_gpt":0.2623310306521224,"score_spread":0.2450781595867451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036291732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928294,0.0040593534,0.000026520382,0.0020307275,0.00018426104,0.0004904591,0.00003057203,0.0000050158033,0.00034370157],"genre_scores_gemma":[0.99816525,0.0010734363,0.0004030829,0.00015856758,0.000112421905,0.0000118073585,0.0000020053783,0.000016591066,0.000056829253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714255,0.00047166037,0.0009842496,0.00017013526,0.0006947478,0.0005366499],"domain_scores_gemma":[0.997672,0.0010401598,0.00056621444,0.00033203783,0.0002591725,0.00013042032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009399572,0.00016134536,0.00063788064,0.00010491944,0.00019618141,0.00003792465,0.0005495495,0.00010199625,0.000026756281],"category_scores_gemma":[0.00041067836,0.00008744413,0.0002452561,0.00019273943,0.0003631284,0.00007801269,0.00006398307,0.00047786577,0.000009555618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016100924,0.005959268,0.41727307,0.0040706457,0.003315788,0.16023646,0.012560604,0.0013530129,0.049743507,0.011750858,0.035377678,0.28225818],"study_design_scores_gemma":[0.011786832,0.0025723903,0.66218776,0.0065581896,0.0001986824,0.23827334,0.008656681,0.010014645,0.05657158,0.0001330174,0.0027588736,0.00028798726],"about_ca_topic_score_codex":0.0005433018,"about_ca_topic_score_gemma":0.0007808994,"teacher_disagreement_score":0.2819702,"about_ca_system_score_codex":0.000109021144,"about_ca_system_score_gemma":0.0002018546,"threshold_uncertainty_score":0.3565868},"labels":[],"label_agreement":null},{"id":"W2036416375","doi":"10.1182/blood-2008-01-129221","title":"Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunoglobulin class switching; Biology; Isotype; Molecular biology; Progenitor cell; Population; Antibody; Cancer research; Immunology; Genetics; B cell; Stem cell; Medicine; Monoclonal antibody","score_opus":0.028511240658133218,"score_gpt":0.2795348627438814,"score_spread":0.2510236220857482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036416375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975626,0.00039263917,0.00035481466,0.0003252043,0.000024214765,0.00096179877,0.000040293624,0.000041841628,0.00029662874],"genre_scores_gemma":[0.9970597,0.000038725215,0.002097982,0.000061776846,0.000053723907,0.00019323273,0.0003239987,0.000024527651,0.00014634247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808204,0.00013855057,0.00042887835,0.00039046042,0.0005997742,0.00036028126],"domain_scores_gemma":[0.9986026,0.00036436727,0.00018203004,0.00051425985,0.00021441143,0.00012230338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002410063,0.00021063662,0.0005150039,0.00044589277,0.00014441699,0.000018309664,0.00014301084,0.000094170384,0.00005489457],"category_scores_gemma":[0.00026920316,0.00013413731,0.00017678786,0.0017114015,0.000084321386,0.00010350897,0.000027369133,0.0002192944,0.000021245494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005859061,0.0032298854,0.9710194,0.000038593298,0.0025212471,0.00040891013,0.0018080991,0.00009987943,0.018420687,0.000012071165,0.000021039952,0.0018342969],"study_design_scores_gemma":[0.0073900553,0.0007599282,0.96850115,0.00009997192,0.0020307824,0.000075103875,0.0005726157,0.002970768,0.017321218,0.000042420073,0.000094956304,0.00014103524],"about_ca_topic_score_codex":0.0016117921,"about_ca_topic_score_gemma":0.0027023982,"teacher_disagreement_score":0.006804149,"about_ca_system_score_codex":0.000100221536,"about_ca_system_score_gemma":0.00018592975,"threshold_uncertainty_score":0.5469961},"labels":[],"label_agreement":null},{"id":"W2036582278","doi":"10.1038/sj.bmt.1704868","title":"Outcome of unrelated transplants in patients with multiple myeloma","year":2005,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; U.S. Public Health Service","keywords":"Medicine; Multiple myeloma; Cumulative incidence; Incidence (geometry); Surgery; Internal medicine; Multivariate analysis; Hematopoietic stem cell transplantation; Melphalan; Transplantation","score_opus":0.01482861410777176,"score_gpt":0.26394612375306875,"score_spread":0.249117509645297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036582278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978197,0.00004340724,0.00026382523,0.00016170273,0.000019873296,0.0007902908,0.00016565272,0.00003845777,0.0006970967],"genre_scores_gemma":[0.99617255,0.000051855215,0.0026900617,0.000036916917,0.000013651156,0.000030035362,0.0008409109,0.000024403176,0.00013964431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853176,0.00005091066,0.0004374997,0.00023540297,0.00045622094,0.00028823406],"domain_scores_gemma":[0.9994699,0.00007556655,0.00007332852,0.00016619862,0.00008494044,0.00013007635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011554722,0.0001708478,0.00032790386,0.0002649071,0.000031375374,0.0000056808885,0.000050078663,0.0000929542,0.000089014175],"category_scores_gemma":[0.000016026363,0.00013292528,0.000060242317,0.00025456017,0.00004777238,0.00015884517,0.0000026532014,0.00015359113,0.000031066043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007438869,0.0007363355,0.98063207,0.00029057488,0.0000770412,0.00012473408,0.00042692586,0.00009686672,0.0018816129,0.000018183116,0.000005246569,0.008271542],"study_design_scores_gemma":[0.022915114,0.00046001986,0.96870047,0.00022737148,0.00010843637,0.000021896474,0.000014667223,0.00052908267,0.00687176,0.000004613221,0.000024423585,0.00012216544],"about_ca_topic_score_codex":0.0001755173,"about_ca_topic_score_gemma":0.0009332437,"teacher_disagreement_score":0.0154762445,"about_ca_system_score_codex":0.000075739554,"about_ca_system_score_gemma":0.000049683156,"threshold_uncertainty_score":0.5420536},"labels":[],"label_agreement":null},{"id":"W2039051971","doi":"10.1016/j.bbmt.2012.12.006","title":"Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Freiwillige Akademische Gesellschaft","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Neutropenia; Outpatient clinic; Surgery; Internal medicine; Emergency medicine; Chemotherapy","score_opus":0.013276520669792072,"score_gpt":0.2536250980040495,"score_spread":0.2403485773342574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039051971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977479,0.00043173245,0.00037738006,0.000007492559,0.000029194756,0.0010488903,0.00025457516,0.000008917229,0.000093940514],"genre_scores_gemma":[0.99815214,0.000750797,0.0003765073,0.000004540528,0.000005204894,0.000035055455,0.0006630253,0.000008362347,0.0000043929394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991164,0.00017985108,0.00023812454,0.00016508267,0.000101265985,0.00019926063],"domain_scores_gemma":[0.9994432,0.00024673657,0.00008944715,0.0000690722,0.00005991152,0.00009163461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020143877,0.0001218124,0.00030454615,0.00013306749,0.000029089346,0.00000146134,0.000021926811,0.00010867514,0.000003211109],"category_scores_gemma":[0.000005318128,0.000090786954,0.000022713371,0.000075689815,0.00012129787,0.000084733925,0.0000037960212,0.0000731303,3.5981537e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011716557,0.00073430757,0.94538844,0.0014992486,0.000093313975,0.000007037947,0.0009145712,0.0000029656776,0.026434515,0.000044000735,9.7727224e-8,0.013164972],"study_design_scores_gemma":[0.016056992,0.0017848434,0.91025054,0.00019408503,0.00025567177,0.000019104116,0.000047068752,0.000016484933,0.07129333,0.0000040137106,0.000003496906,0.00007435778],"about_ca_topic_score_codex":0.00012373259,"about_ca_topic_score_gemma":0.00005282376,"teacher_disagreement_score":0.044858817,"about_ca_system_score_codex":0.000012300578,"about_ca_system_score_gemma":0.000023283514,"threshold_uncertainty_score":0.37021846},"labels":[],"label_agreement":null},{"id":"W2039423492","doi":"10.1016/j.bbmt.2013.04.027","title":"Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute","keywords":"Medicine; Multiple myeloma; Lymphoma; Internal medicine; Chemotherapy; Transplantation; Oncology; Population; Hematopoietic cell; Cancer; Cohort; Surgery; Haematopoiesis; Stem cell","score_opus":0.015267296051342538,"score_gpt":0.2514185642682885,"score_spread":0.236151268216946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039423492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99877906,0.00029056997,0.000036185327,0.00004384442,0.000016178665,0.0006085689,0.00021288285,0.000004250871,0.000008446551],"genre_scores_gemma":[0.997293,0.0014858061,0.0007952275,0.0000043631053,0.0000048292577,0.000110081084,0.00029143147,0.000009021518,0.0000062643767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884534,0.00012467928,0.00045597545,0.0002535766,0.00009029196,0.00023016747],"domain_scores_gemma":[0.999502,0.00021230875,0.00011309967,0.00007248849,0.000030169324,0.0000699561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015896565,0.00013983049,0.00044525848,0.00041316074,0.000016497646,0.0000051379166,0.00002441586,0.000089521425,0.000006456217],"category_scores_gemma":[0.000015287493,0.00012143089,0.000034344175,0.00013880881,0.00016686323,0.00008294142,0.0000069032944,0.000051572773,5.7581964e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032072377,0.00037749668,0.6826526,0.0012294805,0.000040387036,0.000080139005,0.0022863182,0.0000034713576,0.29758507,0.0000037486489,4.5546916e-8,0.012534005],"study_design_scores_gemma":[0.009969511,0.0008422132,0.95709944,0.00018427784,0.000112525115,0.000038727612,0.00029459267,0.00014120637,0.031214269,0.000011820292,5.79045e-7,0.00009085189],"about_ca_topic_score_codex":0.0039761583,"about_ca_topic_score_gemma":0.0059825554,"teacher_disagreement_score":0.27444685,"about_ca_system_score_codex":0.000017447099,"about_ca_system_score_gemma":0.00002864092,"threshold_uncertainty_score":0.6010788},"labels":[],"label_agreement":null},{"id":"W2039479173","doi":"10.1111/j.1365-2133.1989.tb07782.x","title":"Epithelioid cell histiocytoma: a new entity","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Epithelioid cell; Lesion; Pathology; Nodule (geology); Immunohistochemistry; Medicine; CD34; Factor XIIIa; Fibrocyte; Biology; Stem cell","score_opus":0.010809810883076877,"score_gpt":0.26034062528872665,"score_spread":0.24953081440564978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039479173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811082,0.01006081,0.001172551,0.0015996736,0.00017009616,0.00014813279,0.0000100210145,0.000019114112,0.005711412],"genre_scores_gemma":[0.9942565,0.00041996798,0.0029335455,0.00010899528,0.0002523195,0.0000014252972,0.000011269889,0.000013784864,0.002002178],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9988279,0.00007413864,0.00042016883,0.000107862936,0.0002770761,0.00029289545],"domain_scores_gemma":[0.99920654,0.000053250104,0.0001871344,0.00009834832,0.00018477983,0.00026994303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067386674,0.00008939581,0.00037702938,0.00015319654,0.00006403281,0.000031264986,0.00009994034,0.000085734406,0.00032503047],"category_scores_gemma":[0.0000954971,0.00009115722,0.00016428609,0.0001106893,0.00006885061,0.00009841834,0.000025759635,0.00027344152,0.00009366683],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010228311,0.0021926037,0.33661056,0.0002124158,0.00030619864,0.24994919,0.000048687314,0.000004050943,0.009586923,0.0001839181,0.3124706,0.087412074],"study_design_scores_gemma":[0.013411678,0.00029239318,0.37694147,0.0001780234,0.00014570066,0.554361,0.000023003273,0.000038482332,0.022222571,0.0010382233,0.031215023,0.00013241851],"about_ca_topic_score_codex":0.0008439372,"about_ca_topic_score_gemma":0.00015706947,"teacher_disagreement_score":0.30441183,"about_ca_system_score_codex":0.000077765835,"about_ca_system_score_gemma":0.00032927204,"threshold_uncertainty_score":0.37172836},"labels":[],"label_agreement":null},{"id":"W2039735377","doi":"10.1002/ajh.22090","title":"Myeloma ASH 2010 highlights","year":2011,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.03226952994917358,"score_gpt":0.30281670643244657,"score_spread":0.270547176483273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039735377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99169904,0.00041871401,0.00025174755,0.0017191818,0.00022449439,0.00010249008,0.0000016568733,0.0000151162485,0.005567588],"genre_scores_gemma":[0.98858714,0.00013211407,0.010565403,0.00024263807,0.00008161344,0.0000029844516,0.0000015231195,0.000015852891,0.00037072264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883026,0.00008770986,0.0003855577,0.00012189827,0.00025102057,0.00032357694],"domain_scores_gemma":[0.99876463,0.000087780376,0.0003428505,0.00021297229,0.00022086385,0.00037091365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014222096,0.000121265315,0.000605589,0.0002444252,0.00003922163,0.0000039881015,0.00014012985,0.00004162375,0.0005997195],"category_scores_gemma":[0.00011093788,0.00008093181,0.00015421804,0.00017733424,0.00035682047,0.000066357235,0.000030190766,0.00023525892,0.00018500617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065384754,0.0023065228,0.75187033,0.00009391152,0.002502602,0.02799793,0.0023784908,2.2643901e-7,0.0049736663,0.009260045,0.016796408,0.1752814],"study_design_scores_gemma":[0.007271871,0.01377286,0.8335663,0.00019586977,0.00035014583,0.070940085,0.0011740491,0.000020267074,0.05727079,0.001330868,0.013799898,0.0003069842],"about_ca_topic_score_codex":0.00008665583,"about_ca_topic_score_gemma":0.000009114289,"teacher_disagreement_score":0.17497443,"about_ca_system_score_codex":0.00003693306,"about_ca_system_score_gemma":0.00016245354,"threshold_uncertainty_score":0.6566508},"labels":[],"label_agreement":null},{"id":"W2040097291","doi":"10.1212/01.wnl.0000131766.90137.df","title":"Thalidomide neuropathy","year":2004,"lang":"en","type":"letter","venue":"Neurology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Thalidomide; Medicine; Internal medicine; Multiple myeloma","score_opus":0.03037780713997236,"score_gpt":0.2955193157012949,"score_spread":0.26514150856132257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040097291","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031375203,0.00020703087,0.00000795527,0.957385,0.00053802104,0.00065255776,0.00004467745,0.00014811908,0.009641427],"genre_scores_gemma":[0.019167025,0.00011589726,0.000067777386,0.97362816,0.003498186,0.00007261132,0.0006466015,0.00010998514,0.002693771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780566,0.00019160511,0.00023824349,0.00063061866,0.00041313015,0.0007207665],"domain_scores_gemma":[0.99885106,0.00015787207,0.00008278073,0.00068433903,0.00006721941,0.00015673522],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000054205633,0.00032883385,0.0005758623,0.00025066512,0.000054606877,0.00001586663,0.00018539421,0.00083827495,0.00058438606],"category_scores_gemma":[0.00014879442,0.00026651027,0.00021899103,0.000109003544,0.00015107688,0.000022689148,0.00009792809,0.003082913,0.0016372086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008748164,0.000099967576,0.0034027442,0.00016336533,0.00014378643,0.13620134,0.000011755601,0.0000013363824,0.00014216377,0.000012755669,0.8573067,0.0016392644],"study_design_scores_gemma":[0.0032761248,0.0026608258,0.011980757,0.000015309004,0.00011669621,0.003735193,1.2505211e-7,0.00001088628,0.00010248753,0.0002379988,0.97771627,0.00014732326],"about_ca_topic_score_codex":0.0001998977,"about_ca_topic_score_gemma":0.000007873101,"teacher_disagreement_score":0.13246614,"about_ca_system_score_codex":0.00004655111,"about_ca_system_score_gemma":0.00026261888,"threshold_uncertainty_score":0.9999787},"labels":[],"label_agreement":null},{"id":"W2040229955","doi":"10.1007/s10577-005-5264-z","title":"Rearrangements of the telomeric region of mouse chromosome 11 in Pre-B ABL/MYC cells revealed by mBANDing, spectral karyotyping, and fluorescence in-situ hybridization with a subtelomeric probe","year":2004,"lang":"en","type":"article","venue":"Chromosome Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Biology; Fluorescence in situ hybridization; Chromosomal translocation; ABL; Karyotype; Molecular biology; Carcinogenesis; Chromosome; Philadelphia chromosome; Subtelomere; Genetics; Gene; Tyrosine kinase","score_opus":0.029546276303946895,"score_gpt":0.3051052892818519,"score_spread":0.27555901297790497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040229955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959215,0.0007679521,0.000025502679,0.00030046157,0.00002225038,0.0026400895,0.000017830836,0.000018100058,0.00028632276],"genre_scores_gemma":[0.9967645,0.0017331947,0.00047247382,0.000008217395,0.000029829785,0.00016157658,0.000039602033,0.000046504374,0.00074411766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99640346,0.00031008042,0.0005468357,0.0005902562,0.0013086884,0.000840672],"domain_scores_gemma":[0.998542,0.00011963366,0.00019065358,0.000647476,0.00026178587,0.0002384368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072493224,0.0002534538,0.0005811343,0.0007147513,0.00010944351,0.000027684744,0.00032067506,0.00011262524,0.00002990508],"category_scores_gemma":[0.0002645134,0.00017683435,0.00006532075,0.0024956192,0.0007331892,0.00023031356,0.00018628083,0.0005451228,0.000006605262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000773515,0.0011207311,0.41138512,0.00095163606,0.000057311896,0.00023189504,0.0009769724,0.000020081972,0.58374053,0.00003769925,0.00011751734,0.0005870202],"study_design_scores_gemma":[0.008668914,0.0015403134,0.406886,0.0018698418,0.000020828673,0.000116383475,0.00019522081,0.00006851908,0.58034396,0.000079917736,0.00003735705,0.00017275606],"about_ca_topic_score_codex":0.0024143925,"about_ca_topic_score_gemma":0.00059179816,"teacher_disagreement_score":0.0078954,"about_ca_system_score_codex":0.0006278795,"about_ca_system_score_gemma":0.0004944048,"threshold_uncertainty_score":0.7211095},"labels":[],"label_agreement":null},{"id":"W2042662562","doi":"10.1182/blood-2010-08-299396","title":"Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"U.S. Public Health Service; National Cancer Institute; National Heart, Lung, and Blood Institute; Abramson Cancer Center; University of Calgary","keywords":"Multiple myeloma; Medicine; Immunotherapy; Vaccination; Adoptive cell transfer; Antigen; Cancer research; Immunology; Oncology; T cell; Immune system","score_opus":0.018650406776871246,"score_gpt":0.2757860889345335,"score_spread":0.25713568215766225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042662562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829954,0.00016803503,0.00018796686,0.00023393559,0.00002604467,0.00087579695,0.000034992383,0.000007224402,0.000166449],"genre_scores_gemma":[0.999102,0.000066767185,0.00062734896,0.000058314516,0.000021882692,0.000054855976,0.000014449135,0.000015367159,0.000039016344],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994295,0.00004137516,0.00011463027,0.00014271942,0.00014646076,0.00012530206],"domain_scores_gemma":[0.9995447,0.00015570226,0.00002558548,0.0001292445,0.00009970813,0.000045051333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021022448,0.00009249993,0.00014258566,0.000073191666,0.000066035784,0.000016441783,0.000030254383,0.00004089806,0.000058710644],"category_scores_gemma":[0.000035235065,0.000060301743,0.000039921975,0.000059458045,0.000034612283,0.000051931976,0.0000076100937,0.00008451614,7.0301957e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00204317,0.002036127,0.3812644,0.00017011292,0.0003372745,0.000011554909,0.0010524312,1.5433659e-7,0.5864259,0.00030359582,0.000010397735,0.0263449],"study_design_scores_gemma":[0.006992121,0.0005978928,0.65882444,0.000028024748,0.000058851198,0.0000110376795,0.000049231076,0.00043432857,0.3328621,0.000057912122,0.000033883323,0.00005015562],"about_ca_topic_score_codex":0.000054714637,"about_ca_topic_score_gemma":0.000038990784,"teacher_disagreement_score":0.27756006,"about_ca_system_score_codex":0.000007766093,"about_ca_system_score_gemma":0.000027388209,"threshold_uncertainty_score":0.24590337},"labels":[],"label_agreement":null},{"id":"W2042928846","doi":"10.1016/j.bbmt.2005.11.359","title":"Second autologous stem cell transplantation as salvage therapy in patients with relapsed multiple myeloma: Improved outcomes in patients with longer disease free interval after first autologous stem cell transplantation","year":2006,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Salvage therapy; Transplantation; Surgery; Autologous stem-cell transplantation; Internal medicine; Etoposide; Regimen; Median follow-up; Oncology; Gastroenterology; Chemotherapy","score_opus":0.005199179762191544,"score_gpt":0.2051591539843734,"score_spread":0.19995997422218187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042928846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583215,0.00027519235,0.00012766843,0.00006025006,0.00006494446,0.0021535836,0.0013612717,0.000051695046,0.00007326547],"genre_scores_gemma":[0.995736,0.00031823985,0.0003898274,0.000049583454,0.000012197714,0.0002237243,0.0031451115,0.0000451739,0.00008016672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977236,0.0002086167,0.0006478173,0.00063280825,0.00029364205,0.00049355655],"domain_scores_gemma":[0.99899805,0.00021267922,0.00023170265,0.00026833205,0.00011862127,0.00017063736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012664328,0.00043728802,0.0006406419,0.0004076898,0.00007805703,0.000017779072,0.0001211682,0.00025759244,0.000032362437],"category_scores_gemma":[0.0000028776126,0.00031777288,0.00008990124,0.00019365265,0.0001820734,0.00025148247,0.000007285394,0.0002486441,0.0000031348966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044717737,0.002395451,0.94478077,0.0012568627,0.00013075487,0.00033165707,0.0014442482,0.000015906136,0.0022670934,0.000004000393,0.000001814189,0.0026537133],"study_design_scores_gemma":[0.060158815,0.0041824435,0.92531204,0.00023866477,0.00039595435,0.00001109339,0.000050338636,0.00004818744,0.009277462,0.000014430398,0.0000025135673,0.0003080572],"about_ca_topic_score_codex":0.00042087998,"about_ca_topic_score_gemma":0.0034910396,"teacher_disagreement_score":0.019468721,"about_ca_system_score_codex":0.000050997467,"about_ca_system_score_gemma":0.00009346676,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W2043263033","doi":"10.1016/j.leukres.2011.07.030","title":"Analysis of chromosome 12p deletion in plasma cell dyscrasias","year":2011,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Plasma cell leukemia; Plasma cell; Immunofluorescence; Biology; Pathology; Monoclonal; Molecular biology; Medicine; Internal medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.11919883259301393,"score_gpt":0.3748475671737794,"score_spread":0.2556487345807654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043263033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96788263,0.00016842019,0.000016192027,0.00009012413,0.00001547683,0.0004902424,0.000017691982,0.00001904774,0.031300172],"genre_scores_gemma":[0.9964016,0.00022956633,0.0010961855,0.000014582532,0.000028983575,0.00008058067,0.00007837282,0.000019807527,0.0020503327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972053,0.00025045354,0.00036789972,0.00037662423,0.0011286554,0.0006710363],"domain_scores_gemma":[0.99845976,0.00021789441,0.00005030905,0.00054761936,0.00042751088,0.00029688657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010871929,0.00012749921,0.00044478697,0.0020088812,0.00006107451,0.000011193753,0.00020915759,0.00014606248,0.0013205974],"category_scores_gemma":[0.00037906374,0.000105636835,0.00016113812,0.0029604062,0.00019508314,0.00008202316,0.00011975069,0.0005509843,0.000231444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027161806,0.001368014,0.90813464,0.00035310033,0.0013242954,0.0016312348,0.0022166034,0.00004942097,0.05255582,0.00034921966,0.00069047755,0.028611],"study_design_scores_gemma":[0.0047722775,0.00085830456,0.8561086,0.00009041677,0.00019224545,0.000010587691,0.00038755403,0.015811004,0.121127516,0.00008869742,0.00043651747,0.00011626649],"about_ca_topic_score_codex":0.0049149017,"about_ca_topic_score_gemma":0.00075420155,"teacher_disagreement_score":0.068571694,"about_ca_system_score_codex":0.0011468016,"about_ca_system_score_gemma":0.0006860674,"threshold_uncertainty_score":0.9995923},"labels":[],"label_agreement":null},{"id":"W2043759160","doi":"10.1111/j.1365-2141.2006.06405.x","title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","year":2006,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health; Windsor Regional Hospital; BC Cancer Agency; St. John’s Health Sciences Centre; Royal Victoria Hospital; Moncton Hospital; Humber River Regional Hospital; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Dexamethasone; Medicine; Prednisone; Melphalan; Induction therapy; Multiple myeloma; Internal medicine; Oncology; Maintenance therapy; Chemotherapy","score_opus":0.06670175160755294,"score_gpt":0.33168352285355823,"score_spread":0.2649817712460053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043759160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899784,0.007565316,0.00039301906,0.0006134193,0.000070283975,0.0012881628,0.000008547726,0.000018068702,0.0000648103],"genre_scores_gemma":[0.98559636,0.0044354154,0.009445923,0.00009820446,0.00007507678,0.000064536136,0.000024118186,0.00003978531,0.000220552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971727,0.00045587795,0.0010716743,0.0003133634,0.00054242584,0.00044396857],"domain_scores_gemma":[0.99750054,0.0008084878,0.0007986974,0.00019325841,0.0005118506,0.00018717289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007484893,0.0002521473,0.0014931149,0.00033885695,0.000093774586,0.000037924117,0.0001377634,0.00021072179,0.00014604266],"category_scores_gemma":[0.0010742176,0.00017542191,0.000110815585,0.0004688789,0.00032770928,0.0002558925,0.000022407614,0.00047380652,0.0000028672678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2242934,0.0034242962,0.49021086,0.00021147463,0.0007715448,0.023942549,0.0007858768,0.000041403386,0.014845432,0.000052902462,0.00046747093,0.24095279],"study_design_scores_gemma":[0.18572095,0.00844631,0.6429376,0.0012928181,0.00009452472,0.12784891,0.0009737207,0.00059136853,0.031183437,0.00029226608,0.00036785004,0.00025026203],"about_ca_topic_score_codex":0.003160865,"about_ca_topic_score_gemma":0.0023329766,"teacher_disagreement_score":0.24070252,"about_ca_system_score_codex":0.00010316724,"about_ca_system_score_gemma":0.00043454225,"threshold_uncertainty_score":0.7153498},"labels":[],"label_agreement":null},{"id":"W2044636425","doi":"10.1111/j.1600-0609.2009.01257.x","title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Celgene","keywords":"Lenalidomide; Salvage therapy; Dexamethasone; Refractory (planetary science); Multiple myeloma; Medicine; Oncology; Internal medicine; Thalidomide; Chemotherapy","score_opus":0.050451942893496096,"score_gpt":0.30919838829429025,"score_spread":0.25874644540079417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044636425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967211,0.00053151575,0.000024655674,0.001735828,0.000039199767,0.0005673575,0.0000017000441,0.000014911078,0.0003637511],"genre_scores_gemma":[0.9972895,0.0003178057,0.0017678727,0.00027348573,0.000020201756,0.0000048548854,0.000012286292,0.000046140074,0.00026790262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683976,0.0011218563,0.0008821027,0.00028945733,0.00041358246,0.00045323416],"domain_scores_gemma":[0.99830186,0.0005852908,0.0004556453,0.00026861572,0.00017613487,0.00021247781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009390756,0.0002606594,0.0009120556,0.00078230747,0.000050729333,0.000025569054,0.00016973012,0.00007679437,0.00008809113],"category_scores_gemma":[0.0007186443,0.00015793706,0.00005923945,0.00044184082,0.00010203166,0.0002693266,0.000031103198,0.00077594817,0.000054750773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055579633,0.0020981939,0.8182455,0.000038109945,0.00011112765,0.11641855,0.0015991679,0.00016750387,0.0015719102,0.000019467449,0.00020114282,0.003949726],"study_design_scores_gemma":[0.056452595,0.011611582,0.9179518,0.00094578654,0.000023281455,0.0083869,0.00014937884,0.0003890766,0.0029124285,0.0000084090925,0.0009939333,0.00017483253],"about_ca_topic_score_codex":0.000058308808,"about_ca_topic_score_gemma":0.0017133023,"teacher_disagreement_score":0.108031645,"about_ca_system_score_codex":0.00029852585,"about_ca_system_score_gemma":0.00013164568,"threshold_uncertainty_score":0.64404863},"labels":[],"label_agreement":null},{"id":"W2045638842","doi":"10.1155/2013/293150","title":"Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review","year":2013,"lang":"en","type":"review","venue":"Case Reports in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunoglobulin D; Plasma Cell Myeloma; Plasma cell; Medicine; Bone marrow; Antibody; Lymphoma; Pathology; Monoclonal; B cell; Multiple myeloma; Immunohistochemistry; Immunology; Cancer research; Monoclonal antibody","score_opus":0.052550388347477425,"score_gpt":0.3878513173706717,"score_spread":0.33530092902319425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045638842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014286848,0.98185855,5.42571e-7,0.000057271885,0.00011231902,0.0030343514,0.00004956716,0.000024089351,0.00057647214],"genre_scores_gemma":[0.0019611663,0.99534935,0.00098875,0.000028991437,0.000052475618,0.00061554904,0.0003986032,0.00005842098,0.0005466689],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9958897,0.0002630749,0.0020893018,0.0009702111,0.0003036209,0.000484094],"domain_scores_gemma":[0.9963117,0.0008360245,0.0012566894,0.000948989,0.00022519124,0.00042135446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005971247,0.00058568356,0.0042507355,0.00050241395,0.000051578674,0.000021751108,0.0000436858,0.00048005863,0.00009999026],"category_scores_gemma":[0.0017718264,0.00040469915,0.00031280314,0.00045405107,0.00030324046,0.00007415551,0.00020528767,0.00067381305,0.000005705884],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011408602,0.00013813114,0.0011092351,0.17361985,0.0001554048,0.70307684,0.000024563209,2.8090636e-9,5.8522215e-7,0.000030579726,0.00055609836,0.1212773],"study_design_scores_gemma":[0.000550487,0.00013125625,0.000011945763,0.08309571,0.0008015065,0.7379588,0.000008165993,0.000002408387,0.000012551295,0.000020360789,0.1772179,0.00018894498],"about_ca_topic_score_codex":0.00016198742,"about_ca_topic_score_gemma":0.000048018694,"teacher_disagreement_score":0.1766618,"about_ca_system_score_codex":0.0000923858,"about_ca_system_score_gemma":0.00066227495,"threshold_uncertainty_score":0.9998405},"labels":[],"label_agreement":null},{"id":"W2045667534","doi":"10.3109/10428194.2014.1003057","title":"Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Multivariate analysis; Oncology; Lymphocyte; Surrogate endpoint; Overall survival; Gastroenterology; Stem cell; Surgery; Urology","score_opus":0.016522998800905204,"score_gpt":0.2301193305084677,"score_spread":0.21359633170756248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045667534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258155,0.0007305808,0.00023167128,0.000032480155,0.00015351403,0.0031385222,0.0008582531,0.00025746168,0.0020159686],"genre_scores_gemma":[0.9949809,0.0001479154,0.0012119013,0.00014161604,0.00012641701,0.00046535887,0.0010368362,0.00019651449,0.0016925974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949966,0.00014840404,0.0008695892,0.0011805026,0.0014568459,0.0013480376],"domain_scores_gemma":[0.9960437,0.00047618788,0.00046821317,0.0008605388,0.00081691967,0.0013344658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027599954,0.0009504799,0.0014776874,0.00033715894,0.00025719142,0.000094128765,0.00032875783,0.00045905483,0.000019751129],"category_scores_gemma":[0.000056908233,0.00067433715,0.00023676967,0.00041966324,0.0004982081,0.00034579367,0.00008774047,0.00011163011,0.00002742691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11661455,0.0053224047,0.7619575,0.0018982677,0.0027154768,0.0020194955,0.0033750862,0.00027927183,0.003482494,0.00015710118,0.0011165977,0.10106174],"study_design_scores_gemma":[0.23833457,0.0172898,0.69570756,0.0008982329,0.0012105263,0.00079813204,0.0005461039,0.010707299,0.026639864,0.00003894655,0.006574448,0.0012545356],"about_ca_topic_score_codex":0.003113497,"about_ca_topic_score_gemma":0.0002494862,"teacher_disagreement_score":0.12172002,"about_ca_system_score_codex":0.0068656965,"about_ca_system_score_gemma":0.005344775,"threshold_uncertainty_score":0.9995708},"labels":[],"label_agreement":null},{"id":"W2045782311","doi":"10.4021//jmc.v2i4.236","title":"Coexistence of Extramedullary Plasmacytoma and Fungus Balls in the Paranasal Sinuses: Report a Case","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Paranasal sinuses; Extramedullary plasmacytoma; Plasmacytoma; Sinusitis; Head and neck; Plasma cell neoplasm; Radiology; Surgery; Multiple myeloma; Internal medicine","score_opus":0.10882744028749304,"score_gpt":0.37269515165529044,"score_spread":0.2638677113677974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045782311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962698,0.0019195769,0.000019156505,0.0011154402,0.00006326679,0.00016743307,0.0000049348014,0.0000030038905,0.0004373826],"genre_scores_gemma":[0.99828285,0.00052768824,0.0008048005,0.00024214617,0.00010502895,0.0000037836305,0.0000015680278,0.0000067966844,0.000025350779],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99768317,0.0001512262,0.0006166827,0.000109414344,0.0012401283,0.00019938595],"domain_scores_gemma":[0.9982427,0.0007827762,0.0002453663,0.00018115238,0.00013695227,0.0004111004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013881219,0.00010007945,0.0003606356,0.00013158884,0.00003218863,0.000008796129,0.00013379354,0.000093001465,0.00027822284],"category_scores_gemma":[0.0032822397,0.00005300631,0.00009201443,0.00014247831,0.00028881046,0.000073139694,0.000037404054,0.0004076895,0.000001635227],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011586094,0.0006495875,0.1275639,0.000097519944,0.000097400014,0.8591307,0.0010025225,6.191122e-8,0.00004396086,0.00001996896,0.0008261021,0.0094097],"study_design_scores_gemma":[0.0036888588,0.0019457556,0.112181604,0.0004914233,0.00010252001,0.8778718,0.002511713,0.00009056359,0.0005416176,0.0000503576,0.00047064695,0.000053118914],"about_ca_topic_score_codex":0.00072426547,"about_ca_topic_score_gemma":0.00024270856,"teacher_disagreement_score":0.018741155,"about_ca_system_score_codex":0.000027693353,"about_ca_system_score_gemma":0.0003952826,"threshold_uncertainty_score":0.39293846},"labels":[],"label_agreement":null},{"id":"W2047025080","doi":"10.1016/j.bbmt.2008.10.018","title":"Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Occupational Cancer Research Centre","funders":"","keywords":"Plerixafor; Medicine; Pharmacodynamics; Granulocyte colony-stimulating factor; CXCR4 antagonist; Multiple myeloma; Pharmacokinetics; Lymphoma; Internal medicine; Oncology; Pharmacology; Chemotherapy; CXCR4","score_opus":0.006926854741713075,"score_gpt":0.25829606283346895,"score_spread":0.2513692080917559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047025080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99897224,0.00032407773,0.00006234276,0.00005859512,0.000011497284,0.00039338603,0.00012338313,0.0000056364465,0.000048816986],"genre_scores_gemma":[0.996561,0.0019050325,0.0012631968,0.000031728916,0.000007600882,0.000004285904,0.00021691967,0.000005600598,0.000004634578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942136,0.000027135997,0.00018084915,0.00016142175,0.00007292494,0.00013631428],"domain_scores_gemma":[0.99971396,0.00005655967,0.000061341176,0.00004745562,0.000044572815,0.00007613929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057543864,0.000104455634,0.00022858843,0.000119388584,0.000020575322,0.000002231293,0.000020431902,0.000060358325,0.0000030512722],"category_scores_gemma":[0.0000067938995,0.000079833946,0.000013365791,0.00006572396,0.00012440879,0.00004397298,0.000004523427,0.000040505227,7.4729e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003242467,0.00038356846,0.7991719,0.00024308104,0.00009246124,0.000015288902,0.00024358634,0.0000010832557,0.14912055,0.000014058742,8.715483e-7,0.047471043],"study_design_scores_gemma":[0.02562324,0.0019753964,0.9286705,0.000091863585,0.00022006112,0.000023880333,0.000017647135,0.0006247677,0.04265823,0.000020962,0.000005202242,0.00006825022],"about_ca_topic_score_codex":0.00004995297,"about_ca_topic_score_gemma":0.000029388153,"teacher_disagreement_score":0.12949856,"about_ca_system_score_codex":0.0000041269873,"about_ca_system_score_gemma":0.00001927996,"threshold_uncertainty_score":0.3255534},"labels":[],"label_agreement":null},{"id":"W2048293097","doi":"10.3324/haematol.2014.112557","title":"Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma","year":2014,"lang":"en","type":"letter","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Vancouver General Hospital","funders":"Erasmus Medisch Centrum; King's College London; University of Alberta; Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Multiple myeloma; Refractory (planetary science); Internal medicine; Oncology; Quality of life (healthcare); Lenalidomide","score_opus":0.1214802133070783,"score_gpt":0.3563383526192474,"score_spread":0.2348581393121691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048293097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8995694,0.0036481805,0.000025569581,0.09101031,0.00064222515,0.0044098063,0.00047909096,0.00010336817,0.00011204972],"genre_scores_gemma":[0.9715612,0.0009933084,0.004085286,0.020625751,0.0005254647,0.0003816957,0.0014326089,0.00012501283,0.00026969644],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98799,0.004884328,0.00316007,0.0012916208,0.0015218068,0.0011521648],"domain_scores_gemma":[0.9741691,0.020642478,0.0024825472,0.0019595101,0.00025784568,0.00048853917],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0027793108,0.0008969902,0.005237701,0.00042158758,0.00016631807,0.000029361023,0.00066252175,0.0019055392,0.00042344254],"category_scores_gemma":[0.020966828,0.00054961705,0.0005372541,0.0006428209,0.0010041863,0.00007948965,0.0003362693,0.003020977,0.000050343035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87051713,0.0028973164,0.01244624,0.003331734,0.0033962647,0.0046918164,0.0011651207,0.000013106418,0.0006069644,0.00010011045,0.0894315,0.011402689],"study_design_scores_gemma":[0.82443,0.014714605,0.13996336,0.0035257626,0.00080695504,0.00021624583,0.0005239732,0.0006186472,0.0008860882,0.0005098617,0.012359789,0.0014447207],"about_ca_topic_score_codex":0.023706013,"about_ca_topic_score_gemma":0.0016231044,"teacher_disagreement_score":0.12751712,"about_ca_system_score_codex":0.00046528166,"about_ca_system_score_gemma":0.0012539313,"threshold_uncertainty_score":0.99969554},"labels":[],"label_agreement":null},{"id":"W2048483323","doi":"10.1182/blood-2014-12-615187","title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":762,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Lenalidomide; Oncology; Intensive care medicine","score_opus":0.03792475166351981,"score_gpt":0.317462271230351,"score_spread":0.27953751956683115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048483323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605067,0.00011542181,0.000036976744,0.00012106064,0.00034627476,0.0004968883,0.000016692466,0.000062192004,0.01275381],"genre_scores_gemma":[0.9964403,0.000052837528,0.0023735364,0.000027564623,0.00031045504,0.000073932315,0.0003952033,0.000025377605,0.00030082263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979644,0.00010027244,0.00037908836,0.00040416338,0.00080310967,0.00034896648],"domain_scores_gemma":[0.99897444,0.00006173993,0.00010866014,0.00029426577,0.00016411596,0.0003967764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004524403,0.00018039637,0.00028123386,0.00027321695,0.000050523573,0.00007758874,0.00011642988,0.00009044287,0.000032999546],"category_scores_gemma":[0.00026561425,0.0001565745,0.000041317624,0.00019414557,0.000055103188,0.00028173465,0.00010979975,0.00019239716,0.0000054272205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022136803,0.0017533833,0.9733465,0.000022269001,0.0001555828,0.0017970767,0.00023427044,7.55944e-7,0.00011831304,0.00012295209,0.000037232658,0.022190304],"study_design_scores_gemma":[0.012557113,0.0014355645,0.9841553,0.00007934207,0.00005899885,0.00023292315,0.00032874855,0.00016593255,0.00013578935,0.00010509878,0.0006097093,0.00013546819],"about_ca_topic_score_codex":0.0001686924,"about_ca_topic_score_gemma":0.00014818786,"teacher_disagreement_score":0.022054838,"about_ca_system_score_codex":0.00014702149,"about_ca_system_score_gemma":0.00017248355,"threshold_uncertainty_score":0.6384923},"labels":[],"label_agreement":null},{"id":"W2049874438","doi":"10.1038/leu.2013.225","title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; U.S. Public Health Service; National Institutes of Health; Institut National Du Cancer","keywords":"Internal medicine; Multiple myeloma; Multivariate analysis; Univariate analysis; Medicine; Oncology; Gastroenterology","score_opus":0.014070746508805087,"score_gpt":0.24729362050359605,"score_spread":0.23322287399479097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049874438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967891,0.000011969461,0.0000080412465,0.00021747123,0.0000721146,0.0023217571,0.000012578166,0.00001392175,0.00055307185],"genre_scores_gemma":[0.99910754,0.0000070246538,0.00003551528,0.00018052055,0.000020391853,0.00035613246,0.00002673446,0.000019673585,0.0002464419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821335,0.00008947142,0.00024910798,0.0002798546,0.0008373974,0.00033083034],"domain_scores_gemma":[0.9989883,0.000083866944,0.00014004474,0.00046877208,0.00021411697,0.000104944185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004211983,0.00017520107,0.00018734748,0.00008612461,0.00009826707,0.000023640998,0.00019791404,0.000079357815,0.000084004954],"category_scores_gemma":[0.00020403643,0.000081200225,0.00005842428,0.00028518928,0.00011262918,0.00011964773,0.000076162585,0.00025799722,0.000055102868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002677214,0.00034920085,0.99076,0.00003044368,0.000032563625,0.000006326426,0.0019258681,0.0000020161342,0.00006184273,0.000009563068,0.00018494559,0.0063694613],"study_design_scores_gemma":[0.004677793,0.0006447612,0.99220914,0.00024078767,0.000017771517,0.0000029910773,0.00017483176,0.00015911159,0.0017318961,0.000019639121,0.000043298263,0.000077970835],"about_ca_topic_score_codex":0.0017579442,"about_ca_topic_score_gemma":0.00020728068,"teacher_disagreement_score":0.0062914905,"about_ca_system_score_codex":0.00055476255,"about_ca_system_score_gemma":0.00013344407,"threshold_uncertainty_score":0.3311249},"labels":[],"label_agreement":null},{"id":"W2050149294","doi":"10.1007/s12185-013-1461-2","title":"Plasma cell leukaemia and HIV co-infection: profile of patients and experience at Universitas Academic Hospital in Bloemfontein, South Africa","year":2013,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hematology; Internal medicine; Human immunodeficiency virus (HIV); Bone marrow; Malignancy; Retrospective cohort study; Gastroenterology; Pediatrics; Surgery; Immunology","score_opus":0.013285591118588846,"score_gpt":0.2790826297585904,"score_spread":0.26579703864000154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050149294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985389,0.0002337936,0.000011996755,0.0002802349,0.00009106572,0.00016696805,0.000015899606,0.000002682157,0.0006584408],"genre_scores_gemma":[0.9994312,0.00009831051,0.00026192926,0.000014666055,0.000020261929,0.0000049783785,0.000009470801,0.0000048849033,0.00015429985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991994,0.000028349577,0.00027806035,0.00010342423,0.00026523706,0.00012554904],"domain_scores_gemma":[0.9992801,0.00006558567,0.00021729572,0.00004201722,0.0002799622,0.00011501846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004838313,0.00007635516,0.00021263375,0.00022504313,0.000020159629,0.0000057067205,0.00007618123,0.000073445844,0.00028051937],"category_scores_gemma":[0.0000936597,0.00006098177,0.000034189987,0.00004203685,0.00012514899,0.00015855514,0.00007150863,0.00017747919,0.000018396522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003670876,0.00016831669,0.9944257,0.00002369365,0.00006334393,0.00017885111,0.0025148937,6.533283e-7,0.0009012094,0.000039237104,0.0008802355,0.00043677908],"study_design_scores_gemma":[0.0109981615,0.0010944781,0.95590293,0.00016499405,0.000032019158,0.0008704893,0.0019382646,0.0003834361,0.0277754,0.00008374151,0.0006473634,0.00010873613],"about_ca_topic_score_codex":0.000020179783,"about_ca_topic_score_gemma":0.0000018875519,"teacher_disagreement_score":0.038522784,"about_ca_system_score_codex":0.000120310906,"about_ca_system_score_gemma":0.000052557516,"threshold_uncertainty_score":0.30714902},"labels":[],"label_agreement":null},{"id":"W2051019115","doi":"10.1182/blood-2008-07-170464","title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Heidelberg; Stem Cell Network","keywords":"Autocrine signalling; Hepatocyte growth factor; Growth factor; Biology; Receptor; Cell culture; Internal medicine; Cancer research; Endocrinology; Medicine; Biochemistry; Genetics","score_opus":0.010729174263471728,"score_gpt":0.26284594594201427,"score_spread":0.2521167716785425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051019115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117976,0.0059561273,0.000003956844,0.00070626003,0.000022482303,0.0015644324,0.00006961069,0.000006840595,0.00049051346],"genre_scores_gemma":[0.9983431,0.0005949468,0.00038611132,0.000019307427,0.0000464993,0.00006687451,0.0000036208785,0.000009680758,0.00052986934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909604,0.00007637264,0.00023908909,0.00013099631,0.00028532534,0.00017217943],"domain_scores_gemma":[0.9983951,0.00088333513,0.00017543197,0.00027279125,0.00021818574,0.00005519877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014823303,0.00010041861,0.00022642325,0.000022778531,0.00009461171,0.000006136519,0.0001583287,0.00004642286,0.000011882586],"category_scores_gemma":[0.0016514063,0.000039323095,0.000102309554,0.00010102005,0.00015088772,0.000028292814,0.0000449326,0.00008121546,0.0000014337148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034750786,0.0012660738,0.043916136,0.00044556602,0.00015140678,0.0000018638901,0.000982735,2.3689722e-7,0.9272351,0.00050372817,0.00011955856,0.021902507],"study_design_scores_gemma":[0.0071860235,0.0007209961,0.06945408,0.00025773942,0.00011482978,0.000004274241,0.00011092923,0.000033122127,0.9211319,0.00066170184,0.00028837932,0.000035989826],"about_ca_topic_score_codex":0.0000164478,"about_ca_topic_score_gemma":0.0000047417716,"teacher_disagreement_score":0.025537945,"about_ca_system_score_codex":0.000005048404,"about_ca_system_score_gemma":0.00007188402,"threshold_uncertainty_score":0.1977007},"labels":[],"label_agreement":null},{"id":"W2051100871","doi":"10.1038/leusup.2013.4","title":"Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation","year":2013,"lang":"en","type":"review","venue":"Leukemia Supplements","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Celgene","keywords":"Bortezomib; Medicine; Thalidomide; Multiple myeloma; Lenalidomide; Dexamethasone; Regimen; Oncology; Maintenance therapy; Autologous stem-cell transplantation; Transplantation; Internal medicine; Cyclophosphamide; Surgery; Chemotherapy","score_opus":0.045305924193648706,"score_gpt":0.35126087339167766,"score_spread":0.30595494919802896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051100871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061699296,0.8593312,0.01257088,0.0001438483,0.00084230927,0.095335394,0.024925381,0.00040981878,0.0002712328],"genre_scores_gemma":[0.00042726987,0.8448888,0.07880676,0.000092895454,0.00017152807,0.018704014,0.05535272,0.00027926423,0.0012767473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962391,0.0000695764,0.00095016346,0.0008835151,0.0007667112,0.0010908917],"domain_scores_gemma":[0.997004,0.0011357437,0.0004325591,0.0005938272,0.00039192862,0.00044195482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001591499,0.00085685524,0.0021852187,0.00039912434,0.00026287822,0.00010342422,0.00029211264,0.00033165433,0.0001943757],"category_scores_gemma":[0.00021693326,0.00056932087,0.0007598242,0.0002197611,0.000049572125,0.00023538168,0.000047718644,0.0002629542,0.00008134766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012178243,0.00069563393,0.026460078,0.0398918,0.00288958,0.00005117406,0.00016741498,0.000006339122,9.1570456e-7,0.000014673639,0.0065457765,0.92205876],"study_design_scores_gemma":[0.05323659,0.0019547695,0.0024380663,0.0068519264,0.003880206,0.000010356716,0.00003374641,0.00022803071,0.000036432055,0.000012985334,0.9305494,0.00076752924],"about_ca_topic_score_codex":0.0002560217,"about_ca_topic_score_gemma":0.00010608593,"teacher_disagreement_score":0.9240036,"about_ca_system_score_codex":0.0011944459,"about_ca_system_score_gemma":0.0008122197,"threshold_uncertainty_score":0.9996758},"labels":[],"label_agreement":null},{"id":"W2051165614","doi":"10.1182/blood-2012-06-430645","title":"Darwinian evolution and tiding clones in multiple myeloma","year":2012,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Darwinism; Biology; Genetics; Cancer research; Computational biology; Evolutionary biology; Immunology","score_opus":0.035603067959147125,"score_gpt":0.28251217205177775,"score_spread":0.24690910409263062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051165614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88451797,0.0071223523,0.000015031143,0.10317785,0.00028598856,0.0015481588,0.00012711094,0.00012710453,0.0030784127],"genre_scores_gemma":[0.97918886,0.00015241108,0.0008036992,0.0151344035,0.0026790113,0.00011241643,0.0006011603,0.00007172341,0.0012563077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823505,0.00008943761,0.00024891528,0.0003847505,0.00039438353,0.00064745545],"domain_scores_gemma":[0.9992084,0.00016038262,0.00007228284,0.00033932945,0.000045223907,0.0001743994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015350235,0.00027577215,0.0004447472,0.0003563204,0.000074715615,0.00002503176,0.00007705917,0.0005181661,0.000083601415],"category_scores_gemma":[0.00020217805,0.00023356189,0.000081223836,0.00014977393,0.000074662974,0.00009259584,0.00008250499,0.00096847815,0.00012126115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107517124,0.00053263124,0.9444326,0.00065150816,0.00032825244,0.0029011522,0.00017264644,4.3429818e-8,0.001103626,0.000006551698,0.044666287,0.0050971904],"study_design_scores_gemma":[0.011696971,0.00027297635,0.8639056,0.0005934181,0.00037244445,0.0005344005,0.00003619762,0.00005364177,0.0008810618,0.000041042036,0.12125674,0.00035552343],"about_ca_topic_score_codex":0.00039611387,"about_ca_topic_score_gemma":0.000076982855,"teacher_disagreement_score":0.09467088,"about_ca_system_score_codex":0.00011247749,"about_ca_system_score_gemma":0.000093401606,"threshold_uncertainty_score":0.95243776},"labels":[],"label_agreement":null},{"id":"W2052229400","doi":"10.1111/j.1365-2141.2006.06237.x","title":"Significant increase of <i>CKS1B</i> amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence <i>in situ</i> hybridisation","year":2006,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Cancer Research Society","keywords":"Monoclonal gammopathy of undetermined significance; Plasma cell dyscrasia; Multiple myeloma; Fluorescence in situ hybridization; Plasma cell neoplasm; Plasma cell; Plasma cell leukemia; Pathology; Molecular biology; Monoclonal; Medicine; Cancer research; Plasmacytoma; Biology; Monoclonal antibody; Internal medicine; Immunology; Antibody; Immunoglobulin light chain; Genetics","score_opus":0.008814553048158688,"score_gpt":0.2486277847795551,"score_spread":0.2398132317313964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052229400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997227,0.000791231,0.0008822996,0.00013241799,0.000045182805,0.0005190108,0.00025292562,0.000009005959,0.00014094275],"genre_scores_gemma":[0.9953296,0.00020247235,0.0041955076,0.000037774396,0.000029162919,0.000017410373,0.0001415668,0.000020597,0.000025861245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763966,0.00021999085,0.0011347542,0.00031101416,0.00038856413,0.0003060303],"domain_scores_gemma":[0.9980781,0.000482897,0.00064284983,0.00017649712,0.00033345766,0.00028620803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029829793,0.00018713111,0.0007964549,0.00024361536,0.000040402363,0.000022563036,0.00016376015,0.00011969626,0.000022566828],"category_scores_gemma":[0.0004428261,0.0002004726,0.000100689744,0.00023425394,0.000248479,0.00015152243,0.000039226823,0.0002508654,0.0000047003196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032116044,0.0010146793,0.11234073,0.00013223293,0.000054192256,0.0075283796,0.00008102487,0.000018205126,0.86616474,0.000014480682,0.00077376986,0.008665936],"study_design_scores_gemma":[0.0076250527,0.00088014384,0.111316666,0.0006434346,0.000088164146,0.008075487,0.00017100053,0.000843831,0.8699839,0.00016122607,0.000050455412,0.00016062385],"about_ca_topic_score_codex":0.006410452,"about_ca_topic_score_gemma":0.0008249064,"teacher_disagreement_score":0.008505313,"about_ca_system_score_codex":0.00011433367,"about_ca_system_score_gemma":0.00033734794,"threshold_uncertainty_score":0.9690728},"labels":[],"label_agreement":null},{"id":"W2052603677","doi":"10.1080/10428190500080595","title":"N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Case Western Reserve University","keywords":"Protein kinase B; Apoptosis; Multiple myeloma; Cancer research; Kinase; Cell biology; Biology; Immunology; Biochemistry","score_opus":0.017821172388109048,"score_gpt":0.25637748407831695,"score_spread":0.2385563116902079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052603677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912665,0.0017840066,0.000035003522,0.00044882263,0.00028857274,0.0014175277,0.00009315192,0.00033287148,0.00433353],"genre_scores_gemma":[0.9909219,0.0009571759,0.0028993308,0.0013030146,0.00068121456,0.00027858597,0.00025428992,0.00019700053,0.002507477],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99362934,0.00019752952,0.0013033439,0.0016733075,0.0011755148,0.0020209628],"domain_scores_gemma":[0.9964064,0.0004527201,0.0003122762,0.001194037,0.00022201419,0.0014125768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005505443,0.001077061,0.0013763994,0.00095951784,0.00045482707,0.00019123452,0.00041313985,0.00068485114,0.00024272721],"category_scores_gemma":[0.00034701973,0.0009965022,0.00035962954,0.0012344517,0.00037595426,0.00066240533,0.0004168817,0.00037740983,0.00045364667],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031259267,0.0013707114,0.10094754,0.0005766892,0.00039067856,0.0017108385,0.0017385992,0.00022530723,0.118736885,0.00022220668,0.0029935534,0.7679611],"study_design_scores_gemma":[0.062683515,0.0008130288,0.35760784,0.0009079665,0.00022439106,0.00079355325,0.0006761549,0.017020691,0.5289597,0.00008155562,0.02877713,0.0014544543],"about_ca_topic_score_codex":0.0044515184,"about_ca_topic_score_gemma":0.00084422634,"teacher_disagreement_score":0.7665066,"about_ca_system_score_codex":0.010355762,"about_ca_system_score_gemma":0.0027187602,"threshold_uncertainty_score":0.99924856},"labels":[],"label_agreement":null},{"id":"W2052645281","doi":"10.1016/j.ccr.2013.08.009","title":"Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bortezomib; Proteasome inhibitor; Multiple myeloma; Endoplasmic reticulum; Proteasome; Cancer research; Plasma cell; Progenitor cell; Unfolded protein response; Biology; Antibody; Immunology; Cell biology; Stem cell","score_opus":0.017084614979331916,"score_gpt":0.2672179697081689,"score_spread":0.250133354728837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052645281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905697,0.0037604705,0.0000064781098,0.00047839,0.00013218651,0.0028849482,0.00007337455,0.000047297217,0.0020471448],"genre_scores_gemma":[0.99085224,0.0005433704,0.0009903834,0.000268373,0.00013891885,0.0016006912,0.00001274398,0.000045594592,0.005547687],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99819005,0.0000932265,0.00028804198,0.00048609055,0.00036178323,0.0005808317],"domain_scores_gemma":[0.9988855,0.00020934606,0.00010341218,0.00030058573,0.00013013075,0.0003710204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010561133,0.00026434477,0.00037528455,0.00009880545,0.00008046235,0.00004383819,0.000102834754,0.000080789214,0.0004785034],"category_scores_gemma":[0.00006674402,0.00020709957,0.000053935764,0.00020789875,0.00016022856,0.00023800028,0.00006212007,0.0002649046,0.00015955373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047381604,0.0013855331,0.3876332,0.0022217026,0.00035659934,0.0006089192,0.0069963927,0.000019752995,0.56271124,0.000027575332,0.004576533,0.028724402],"study_design_scores_gemma":[0.011076445,0.0003814753,0.51849145,0.00047264088,0.000044145356,0.0000058662886,0.0003028563,0.0013078812,0.46377212,0.00027348244,0.0035296776,0.00034193898],"about_ca_topic_score_codex":0.0015107386,"about_ca_topic_score_gemma":0.0027478656,"teacher_disagreement_score":0.13085827,"about_ca_system_score_codex":0.00034222225,"about_ca_system_score_gemma":0.00020919152,"threshold_uncertainty_score":0.84452754},"labels":[],"label_agreement":null},{"id":"W2053633180","doi":"10.1111/j.1365-2141.2004.04867.x","title":"The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Multiple myeloma; Medicine; Stem cell; Autologous stem-cell transplantation; Oncology; Internal medicine; Hematology; Biology","score_opus":0.013867100637654962,"score_gpt":0.2478277717385602,"score_spread":0.23396067110090524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053633180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960463,0.00167612,0.000034289755,0.0014227856,0.00008964399,0.0004223687,0.00002160422,0.000014944032,0.00027194453],"genre_scores_gemma":[0.99871397,0.00076126837,0.00021741509,0.00014868837,0.000015829364,0.000016529002,0.000011670083,0.000024169807,0.00009046885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807835,0.0001711033,0.0005767358,0.00017894668,0.00047492978,0.0005199237],"domain_scores_gemma":[0.99878114,0.00031022396,0.00032680336,0.00008643724,0.00029287723,0.00020252758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029354866,0.00015059284,0.0005908502,0.00014035076,0.00017316612,0.000046782894,0.00016160219,0.00013349419,0.00001612243],"category_scores_gemma":[0.00012060652,0.000107176056,0.00011990594,0.00021678855,0.00014819547,0.0000999204,0.000019888601,0.0004657714,0.000009742645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019995903,0.0027013777,0.6801942,0.0001947593,0.00090942904,0.2714495,0.0009240394,0.00002261889,0.00007324943,0.000057026158,0.00076913566,0.040705085],"study_design_scores_gemma":[0.035675094,0.004616516,0.78613394,0.0034789902,0.00026946788,0.16274838,0.00046141012,0.00003774032,0.005929459,0.00027135146,0.00012979307,0.00024786833],"about_ca_topic_score_codex":0.0000992531,"about_ca_topic_score_gemma":0.0014374657,"teacher_disagreement_score":0.10870111,"about_ca_system_score_codex":0.00022076606,"about_ca_system_score_gemma":0.00043545416,"threshold_uncertainty_score":0.43705127},"labels":[],"label_agreement":null},{"id":"W2053730391","doi":"10.1016/j.bbmt.2005.11.366","title":"A comparison of molecular prognostic tests in multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Multiple myeloma; Stage (stratigraphy); Karyotype; Fluorescence in situ hybridization; Internal medicine; Oncology; Bone marrow; Transplantation; Survival analysis; Pathology; Gastroenterology; Chromosome; Biology; Genetics; Gene","score_opus":0.021868567541295382,"score_gpt":0.3111329225677635,"score_spread":0.2892643550264681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053730391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980877,0.0010897298,0.00013681274,0.000054724384,0.0000108270915,0.00033909135,0.00004067472,0.000008549316,0.00023187997],"genre_scores_gemma":[0.99813414,0.00010171614,0.0014263272,0.000005079326,0.0000076253073,0.00001899356,0.00029349915,0.000004867469,0.000007745267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939686,0.000043560452,0.0002373919,0.00012736351,0.00006929796,0.00012554936],"domain_scores_gemma":[0.99969476,0.000115855844,0.000059289196,0.000059317197,0.00003687213,0.000033923603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060739992,0.00007267293,0.00023878866,0.000121817255,0.000012895817,0.0000011719507,0.000023183318,0.00007241833,0.0000053357894],"category_scores_gemma":[0.000029671724,0.00006052988,0.000029566787,0.00008361523,0.00010067052,0.00001901321,0.0000034646937,0.000050857398,6.494641e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024840463,0.00032266552,0.5453733,0.00020255039,0.000028672275,0.000029191862,0.000061363186,0.000002495558,0.45194283,0.00009065191,9.774825e-7,0.0016968865],"study_design_scores_gemma":[0.0035993524,0.00051455904,0.6651602,0.000086837055,0.00010712583,0.000024843539,0.000016172853,0.00012195283,0.3302248,0.000106296255,0.0000033554488,0.000034497596],"about_ca_topic_score_codex":0.00038667818,"about_ca_topic_score_gemma":0.00030241866,"teacher_disagreement_score":0.12171803,"about_ca_system_score_codex":0.0000034799273,"about_ca_system_score_gemma":0.000025697864,"threshold_uncertainty_score":0.24683368},"labels":[],"label_agreement":null},{"id":"W2054752816","doi":"10.1007/s10067-010-1417-3","title":"Early onset multiple myeloma in a patient with systemic lupus erythematosus: a case report and literature review","year":2010,"lang":"en","type":"review","venue":"Clinical Rheumatology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Dyscrasia; Multiple myeloma; Rheumatology; Plasma cell; Internal medicine; Pathogenesis; Dermatology; Immunology","score_opus":0.04960167155678659,"score_gpt":0.39530395850052075,"score_spread":0.34570228694373417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054752816","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0890075,0.90587944,0.0000024717451,0.00011334991,0.00035916924,0.0044035106,0.00011402066,0.000061819585,0.000058733356],"genre_scores_gemma":[0.004322043,0.9931124,0.00062737655,0.00009410127,0.000030844003,0.0009926087,0.0005268431,0.00010166026,0.0001921562],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9934105,0.0010206589,0.0031447606,0.0013218343,0.0003736519,0.0007285498],"domain_scores_gemma":[0.99332625,0.0029829247,0.0011758622,0.0014671021,0.00025777624,0.0007900809],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011606567,0.0007554225,0.006422413,0.00035695775,0.00007907197,0.000043367283,0.00018417931,0.0013531484,0.00003343736],"category_scores_gemma":[0.006352102,0.00045216174,0.00061544945,0.00055624946,0.00043500419,0.00006888078,0.00021932393,0.0027653808,0.000098563796],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020058836,0.00031900196,0.037905548,0.08360269,0.00031568352,0.54218453,0.000054186057,1.4027128e-9,5.7447576e-9,0.0000070103038,0.00035924537,0.33505154],"study_design_scores_gemma":[0.002245991,0.000635384,0.00011732971,0.24250522,0.00051861315,0.6371069,0.000012052757,0.0000032880998,1.7851827e-8,0.0000037005948,0.11661886,0.00023264329],"about_ca_topic_score_codex":0.000098104596,"about_ca_topic_score_gemma":0.00022894236,"teacher_disagreement_score":0.33481887,"about_ca_system_score_codex":0.00009690743,"about_ca_system_score_gemma":0.00087017147,"threshold_uncertainty_score":0.9999433},"labels":[],"label_agreement":null},{"id":"W2057046426","doi":"10.1097/01.cco.0000152978.32304.37","title":"Stem cell transplantation in multiple myeloma (0, 1, or 2)","year":2005,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Transplantation; Multiple myeloma; Context (archaeology); Bortezomib; Autologous stem-cell transplantation; Stem cell; Melphalan; Allotransplantation; Surgery; Oncology; Internal medicine; Biology","score_opus":0.2539251233572543,"score_gpt":0.4836763924712552,"score_spread":0.2297512691140009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057046426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000112691836,0.99384534,0.000020542404,0.00006442975,0.0022924265,0.0028324444,0.00013281847,0.00003827724,0.000661012],"genre_scores_gemma":[0.00016309792,0.9960071,0.00022457284,0.000008573226,0.0005906857,0.0009542274,0.00168584,0.00005298017,0.0003129306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968287,0.00053430884,0.0010696113,0.00063504814,0.0003162805,0.00061608164],"domain_scores_gemma":[0.9982756,0.0008332831,0.0002692285,0.0003297843,0.00004656423,0.00024556922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032792482,0.00044905732,0.0019372349,0.00093933643,0.00003698147,0.000012131359,0.00020233956,0.0005431546,0.00024796522],"category_scores_gemma":[0.000043821175,0.00032700272,0.00027704015,0.0005918505,0.00007309845,0.000073697614,0.000050809027,0.0009881086,0.00038522514],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004686904,0.0013358637,0.0012845307,0.031510312,0.0000349885,0.0001906838,0.00017592625,0.0000012920452,2.0667464e-7,0.000008882442,0.00064666383,0.96434194],"study_design_scores_gemma":[0.0067056096,0.00062566035,0.0015574438,0.016908411,0.000116435236,0.00022156576,0.00003235457,0.00007683222,0.0000010717278,0.0000017880753,0.9735047,0.00024812535],"about_ca_topic_score_codex":0.000034894434,"about_ca_topic_score_gemma":0.00020257734,"teacher_disagreement_score":0.972858,"about_ca_system_score_codex":0.0014991385,"about_ca_system_score_gemma":0.0015423964,"threshold_uncertainty_score":0.9999182},"labels":[],"label_agreement":null},{"id":"W2057527782","doi":"10.3109/10428194.2010.524325","title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Lenalidomide; Thalidomide; Dexamethasone; Multiple myeloma; Bortezomib; Refractory (planetary science); Medicine; Internal medicine; Oncology; Chromosome abnormality; Population; Gastroenterology; Chromosome; Biology; Karyotype; Genetics","score_opus":0.025848618773021297,"score_gpt":0.2825363406879408,"score_spread":0.2566877219149195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057527782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976263,0.00013662386,0.000009664422,0.000043887114,0.00004095631,0.0012319643,0.00026633855,0.00006503682,0.00057924504],"genre_scores_gemma":[0.9980793,0.00011275635,0.0007936519,0.000082381484,0.00006637176,0.00012580708,0.00018230791,0.00009479574,0.00046263437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703276,0.00016703046,0.00077424507,0.0006223329,0.00072991656,0.00067370763],"domain_scores_gemma":[0.99649036,0.0013093532,0.000530855,0.00085613056,0.00035534447,0.0004579395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033496218,0.0006174467,0.0010380918,0.00037030494,0.00038653563,0.000060858827,0.00022875979,0.00028412367,0.00014140399],"category_scores_gemma":[0.0004221568,0.00031716324,0.00017629462,0.0004314253,0.00090220745,0.00029410474,0.0001311054,0.000256998,0.000007425788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016072938,0.0005627481,0.9487098,0.00020308892,0.0010583334,0.00012906244,0.000895221,0.000021054933,0.017760942,0.00010272604,0.00006611598,0.014418012],"study_design_scores_gemma":[0.036949307,0.0040119207,0.94849813,0.0002671779,0.00031109064,0.00022300289,0.00029914698,0.0009738071,0.007976849,0.0000137453135,0.00012243443,0.00035337673],"about_ca_topic_score_codex":0.004491833,"about_ca_topic_score_gemma":0.0006931248,"teacher_disagreement_score":0.02087637,"about_ca_system_score_codex":0.0018977174,"about_ca_system_score_gemma":0.0018900824,"threshold_uncertainty_score":0.99992806},"labels":[],"label_agreement":null},{"id":"W2057614149","doi":"10.1007/s00256-008-0607-4","title":"Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)","year":2008,"lang":"en","type":"article","venue":"Skeletal Radiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Radiology; Skeletal survey; Nuclear medicine; Gold standard (test); Biopsy; Magnetic resonance imaging; Bone marrow; Stage (stratigraphy); Confidence interval; Pathology; Internal medicine","score_opus":0.02337308461063404,"score_gpt":0.29397397709547957,"score_spread":0.27060089248484553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057614149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622893,0.0010242916,0.0009986451,0.00010479606,0.00010215526,0.0010426884,0.00046413686,0.00001831992,0.000016032644],"genre_scores_gemma":[0.9982045,0.00036055627,0.00005960679,0.000006398284,0.000040839343,0.00005513327,0.0012284907,0.000020313671,0.000024129118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976299,0.00066925574,0.00056575687,0.0003637182,0.0004109458,0.00036044314],"domain_scores_gemma":[0.99751526,0.0012918462,0.00036468083,0.00043613106,0.00020972839,0.00018232943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004694207,0.0002443074,0.00059513765,0.00020885491,0.00010635522,0.000004206317,0.0001353136,0.000107707856,0.000011672849],"category_scores_gemma":[0.0015963226,0.00016618233,0.00012395655,0.00045217582,0.0007245412,0.00014149385,0.000049559272,0.00029981925,0.0000067417172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02055641,0.0014232667,0.87593347,0.0004980631,0.00041418112,0.0005021474,0.0003315463,0.00016258276,0.06928881,0.00007374521,0.00006398482,0.030751815],"study_design_scores_gemma":[0.010458528,0.0024511835,0.9793112,0.000108157175,0.00010491969,0.00023376728,0.00008380759,0.002562578,0.0044644848,0.000013933819,0.00007809995,0.00012933521],"about_ca_topic_score_codex":0.0007864372,"about_ca_topic_score_gemma":0.0002851033,"teacher_disagreement_score":0.10337776,"about_ca_system_score_codex":0.00010832798,"about_ca_system_score_gemma":0.00023561637,"threshold_uncertainty_score":0.6776719},"labels":[],"label_agreement":null},{"id":"W2058574039","doi":"10.1097/cej.0000000000000001","title":"Alcohol drinking and multiple myeloma risk – a systematic review and meta-analysis of the dose–risk relationship","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer Prevention","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Meta-analysis; Medicine; Relative risk; Confidence interval; Cohort study; Alcohol; Internal medicine; Random effects model; Cohort; Demography; Biology","score_opus":0.12702624815080285,"score_gpt":0.4032075620483606,"score_spread":0.27618131389755773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058574039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021151923,0.99731356,0.00021925989,0.00006355168,0.000037532085,0.001971949,0.000052999523,0.0000049518776,0.00012468445],"genre_scores_gemma":[0.016197506,0.9826957,0.00030236406,0.000022421254,0.000050749026,0.000033210385,0.000014849365,0.000040218096,0.000642957],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99093777,0.006284574,0.001796684,0.00024894188,0.0005717799,0.00016024461],"domain_scores_gemma":[0.9937508,0.00053673115,0.0047632908,0.00051302125,0.0002703178,0.00016583498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048240656,0.0003065,0.0046894657,0.00040635368,0.00013288754,0.00003600915,0.00020868627,0.000052390184,0.00007316379],"category_scores_gemma":[0.00184804,0.00015152249,0.0027848375,0.00061282655,0.00007468652,0.00008809732,0.00009355591,0.00061733427,0.0000038936846],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045300836,0.00008521474,0.004929496,0.5580752,0.31690437,0.00003552579,0.0000779316,0.0000070347096,3.4566006e-7,0.000009623383,0.00006647636,0.1197635],"study_design_scores_gemma":[0.00070723373,0.00017468997,0.0125563815,0.091546156,0.88781476,0.00010912427,0.0000049870637,0.000023689994,3.4485385e-7,0.000010244684,0.0069471863,0.00010519304],"about_ca_topic_score_codex":0.000021270513,"about_ca_topic_score_gemma":0.000044081768,"teacher_disagreement_score":0.5709104,"about_ca_system_score_codex":0.000087557586,"about_ca_system_score_gemma":0.00012200211,"threshold_uncertainty_score":0.6178908},"labels":[],"label_agreement":null},{"id":"W2059075557","doi":"10.1038/nrclinonc.2014.200","title":"Current treatment landscape for relapsed and/or refractory multiple myeloma","year":2014,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Medicine; Multiple myeloma; Carfilzomib; Refractory (planetary science); Lenalidomide; Bortezomib; Oncology; Internal medicine; Regimen; Ixazomib; Disease; Thalidomide; Clinical trial","score_opus":0.2542302185574246,"score_gpt":0.5603429840524028,"score_spread":0.3061127654949782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059075557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000080402,0.9860203,0.000030384621,0.00032896906,0.0016577216,0.011131211,0.00018804817,0.00007870339,0.0005565787],"genre_scores_gemma":[0.000008336415,0.98625004,0.004053332,0.00034117833,0.0028326104,0.003255548,0.0013741626,0.00013099592,0.0017537742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991831,0.0021544164,0.003282143,0.0015311693,0.00035219354,0.00084909337],"domain_scores_gemma":[0.9829309,0.012904932,0.0016249783,0.0012076756,0.00022366704,0.0011078394],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0028363545,0.0010426366,0.011277598,0.00029620115,0.0001471555,0.000025746565,0.00032701093,0.0034954925,0.00017857066],"category_scores_gemma":[0.014615855,0.00052388204,0.003068074,0.0003119757,0.00024641736,0.00005021519,0.00015818019,0.00311655,0.00041085688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011423407,0.0019461394,0.00031676513,0.030007979,0.0008418986,0.00012997932,0.0000068665154,2.6326854e-9,4.493798e-8,0.000030562267,0.017015599,0.94856185],"study_design_scores_gemma":[0.010370071,0.012918352,0.00020686454,0.017672349,0.0050765383,0.00021562111,0.0000017789416,0.000023249699,8.647896e-8,0.00000999577,0.9530908,0.00041432882],"about_ca_topic_score_codex":0.0000038166463,"about_ca_topic_score_gemma":0.000082885526,"teacher_disagreement_score":0.9481475,"about_ca_system_score_codex":0.0007192547,"about_ca_system_score_gemma":0.002097644,"threshold_uncertainty_score":0.9997213},"labels":[],"label_agreement":null},{"id":"W2059288982","doi":"10.1080/1059924x.2012.632339","title":"Multiple Myeloma and Exposure to Pesticides: A Canadian Case-Control Study","year":2011,"lang":"en","type":"article","venue":"Journal of Agromedicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Cancer Care Ontario; University of Toronto; BC Cancer Agency; University of British Columbia; University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Medicine; Odds ratio; Environmental health; Confidence interval; Incidence (geometry); Confounding; Pesticide; Population; Demography; Toxicology; Internal medicine; Biology","score_opus":0.03434310791470651,"score_gpt":0.2907712101614821,"score_spread":0.2564281022467756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059288982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967825,0.00043233033,0.0001160997,0.0011224385,0.00014020996,0.00084977463,0.000018492772,0.000009370835,0.0005288201],"genre_scores_gemma":[0.9975017,0.000019431189,0.0013815323,0.00051956216,0.00031889448,0.000010807024,0.000001232277,0.000021488611,0.000225369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998371,0.00008195204,0.0004993844,0.0001762403,0.0004630654,0.00040834956],"domain_scores_gemma":[0.99715286,0.0001786606,0.00013217701,0.00022118022,0.0003684713,0.0019466603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006224277,0.00018071868,0.00056014484,0.00065969373,0.000097533455,0.000012892829,0.00009288972,0.000059961898,0.0003974525],"category_scores_gemma":[0.0009884788,0.00011653709,0.00007020404,0.00024458053,0.000064162974,0.00009179137,0.000020725458,0.000307768,0.000020733676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014557014,0.0005366936,0.8609132,0.000034216766,0.000627581,0.11016609,0.004740668,0.0000010908942,0.0006295863,0.0000032369283,0.0006268863,0.020265043],"study_design_scores_gemma":[0.013101958,0.014771355,0.9401498,0.00016497007,0.00039146986,0.027659224,0.0033136988,0.000045904442,0.00006398649,0.0000118468315,0.0002362277,0.000089601344],"about_ca_topic_score_codex":0.024450287,"about_ca_topic_score_gemma":0.03680357,"teacher_disagreement_score":0.08250686,"about_ca_system_score_codex":0.000154854,"about_ca_system_score_gemma":0.00036225538,"threshold_uncertainty_score":0.982046},"labels":[],"label_agreement":null},{"id":"W2060632341","doi":"10.1016/j.bbmt.2013.08.002","title":"Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Health Resources and Services Administration; IC Design Education Center; Astellas Pharma; Eisai; Genentech; CellGenix; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; StemCyte; BioMarin Pharmaceutical; U.S. Navy; Celgene; Osiris Therapeutics; WellPoint; HistoGenetics; Teva Pharmaceutical Industries; Otsuka America; Pfizer; Biogen; AABB; U.S. Department of Defense; Sanofi; Amgen; Blue Cross and Blue Shield Association; U.S. Department of Health and Human Services; Astellas Pharma US; National Cancer Institute; Gilead Sciences","keywords":"Medicine; Multiple myeloma; Lenalidomide; Cohort; Thalidomide; Bortezomib; Internal medicine; Transplantation; Multivariate analysis; Autologous stem-cell transplantation; Hematopoietic stem cell transplantation; Oncology; Surgery","score_opus":0.030813796347625523,"score_gpt":0.31653909705108474,"score_spread":0.2857253007034592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060632341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808615,0.0006231182,0.0002596873,0.00019295696,0.000020968324,0.0006102189,0.000108740285,0.00001258184,0.00008559229],"genre_scores_gemma":[0.9942128,0.003949405,0.0010976725,0.000023444296,0.00000654851,0.000092019676,0.0005712071,0.000007781353,0.000039129405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993242,0.00004813194,0.00025014536,0.00017390921,0.00006377699,0.0001398537],"domain_scores_gemma":[0.9995766,0.00017932503,0.00007235579,0.000059872065,0.000059627127,0.00005218856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008206506,0.00010432025,0.00027391122,0.00025138728,0.000027105962,0.00000361892,0.000024179297,0.00011599192,0.000021094862],"category_scores_gemma":[0.0000168565,0.0000800674,0.00004253222,0.00008556049,0.00010275005,0.00008073834,0.0000017442335,0.000039881805,4.83634e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011690004,0.00017363986,0.7156196,0.00021581975,0.00012302684,0.000004824842,0.00088585645,3.496614e-7,0.16455302,0.00015675812,0.0000011697739,0.117096916],"study_design_scores_gemma":[0.009989788,0.0013695322,0.91293544,0.000040543142,0.00011731767,0.000035505287,0.00004167437,0.00014660672,0.075006686,0.00025086413,0.0000067573214,0.000059309874],"about_ca_topic_score_codex":0.0007423557,"about_ca_topic_score_gemma":0.00016246822,"teacher_disagreement_score":0.1973158,"about_ca_system_score_codex":0.0000033788726,"about_ca_system_score_gemma":0.00001796083,"threshold_uncertainty_score":0.3265054},"labels":[],"label_agreement":null},{"id":"W2060709908","doi":"10.1016/j.jval.2012.08.1727","title":"PSY4 Lenalidomide or Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma (MM): A Comparative Effectiveness Analysis Using Indirect Statistical Techniques","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Lenalidomide; Refractory (planetary science); Bortezomib; Internal medicine; Randomization; Clinical trial; Randomized controlled trial; Multiple myeloma; Surgery; Oncology","score_opus":0.17379470947664805,"score_gpt":0.4471904382956076,"score_spread":0.27339572881895957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060709908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98010075,0.0027253183,0.012339384,0.00010178139,0.0000766801,0.0042364877,0.00034554367,0.000040088376,0.000033978675],"genre_scores_gemma":[0.97953165,0.0005342164,0.019073779,0.000029758714,0.00009830165,0.0005647154,0.000109158704,0.000024668429,0.000033729888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997318,0.00083263573,0.00056866364,0.00030183772,0.00034634068,0.0006325015],"domain_scores_gemma":[0.9932413,0.0057342295,0.00023295669,0.00037491522,0.00010971481,0.00030685344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011938207,0.00024041723,0.0010733576,0.00042033775,0.00016713649,0.000010499869,0.000078004465,0.00008987966,0.000033910612],"category_scores_gemma":[0.00037694807,0.00013643266,0.00021204694,0.0006874186,0.00014573013,0.00008398309,0.000018422028,0.00014270624,0.0000028073516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017911034,0.0064324844,0.9069903,0.0009554979,0.004063624,0.00004663359,0.005118451,0.0007987849,0.0014241722,0.0002199787,0.0000676809,0.05597137],"study_design_scores_gemma":[0.011499004,0.0068914886,0.892131,0.00043294035,0.0010939135,0.000028644743,0.00064703065,0.062280335,0.022631025,0.000053320364,0.0020788873,0.00023246526],"about_ca_topic_score_codex":0.008910425,"about_ca_topic_score_gemma":0.00040997888,"teacher_disagreement_score":0.06148155,"about_ca_system_score_codex":0.0011628057,"about_ca_system_score_gemma":0.0005177721,"threshold_uncertainty_score":0.9976893},"labels":[],"label_agreement":null},{"id":"W2061196972","doi":"10.1182/blood-2005-01-0033","title":"Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immunohistochemistry; Multiple myeloma; Immunocytochemistry; Isotype; Pathology; Fibroblast growth factor receptor 3; Biology; Chromosomal translocation; Immunoglobulin A; Fluorescence in situ hybridization; Antibody; Medicine; Internal medicine; Fibroblast growth factor; Monoclonal antibody; Receptor; Immunology; Immunoglobulin G","score_opus":0.03258036829058847,"score_gpt":0.3066833460329813,"score_spread":0.27410297774239284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061196972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934442,0.0030364261,0.00000637241,0.00026549207,0.000025803216,0.00045456315,0.000019985586,0.00006112822,0.0026860514],"genre_scores_gemma":[0.99646163,0.00028845394,0.001902711,0.000055410466,0.00012766183,0.000088832225,0.00006738027,0.000022936485,0.0009849955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986901,0.000031020605,0.00025238417,0.0003368853,0.00030298976,0.00038658705],"domain_scores_gemma":[0.9992299,0.00008568923,0.000050329025,0.0003242673,0.000049400784,0.00026039215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011366306,0.00017946176,0.0002583346,0.000093410235,0.00007925844,0.000020947045,0.00008351221,0.00012393024,0.0001282683],"category_scores_gemma":[0.00026425623,0.00014559977,0.000050176033,0.000113030015,0.00007498069,0.00011610469,0.00008256384,0.0002399577,0.000050030165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006060709,0.0016280292,0.19099492,0.00013228925,0.0000826893,0.0004157594,0.00036009596,0.0000019437193,0.78583014,0.000001925367,0.00044364773,0.019502517],"study_design_scores_gemma":[0.025924647,0.00026585074,0.42475602,0.00044895196,0.00006344253,0.0002576194,0.00008532104,0.0005239634,0.545789,0.000011307117,0.001680106,0.00019373983],"about_ca_topic_score_codex":0.00005938695,"about_ca_topic_score_gemma":0.00002042833,"teacher_disagreement_score":0.24004109,"about_ca_system_score_codex":0.000061869476,"about_ca_system_score_gemma":0.000080889884,"threshold_uncertainty_score":0.5937386},"labels":[],"label_agreement":null},{"id":"W2061232800","doi":"10.1158/1940-6207.prev-11-b115","title":"Abstract B115: A pooled analysis of smoking and alcohol drinking and risk of multiple myeloma in the International Multiple Myeloma Consortium","year":2011,"lang":"en","type":"article","venue":"Cancer Prevention Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Confidence interval; Odds ratio; Multiple myeloma; Internal medicine; Population; Case-control study; Logistic regression; Monoclonal gammopathy of undetermined significance; Demography; Environmental health; Immunology; Monoclonal; Antibody","score_opus":0.11600429789178039,"score_gpt":0.4051530871789828,"score_spread":0.2891487892872024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061232800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996907,0.0010417217,0.000052945546,0.00011316237,0.000032583128,0.00079277216,0.00005974172,0.000008549053,0.0009915438],"genre_scores_gemma":[0.99767405,0.0015249923,0.00038040668,0.000010484314,0.000029249382,0.00018503825,0.00004449151,0.000013037963,0.00013826178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756324,0.00034059223,0.00047137804,0.00035894025,0.0009225082,0.00034335846],"domain_scores_gemma":[0.99831665,0.00063261786,0.00020107916,0.00032494153,0.00040069065,0.00012402653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022534435,0.0001291903,0.00037861543,0.00096104294,0.00010655066,0.000027373848,0.00021541523,0.0000903748,0.00041388866],"category_scores_gemma":[0.000917342,0.00009579544,0.00013947186,0.0008487709,0.0003267335,0.00012813757,0.00016094172,0.0004169988,0.0000013682693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008266763,0.00034684513,0.939206,0.00010024474,0.002634279,0.000037653048,0.0016820298,0.000010513201,0.007100369,0.0000490656,0.000022276592,0.047984075],"study_design_scores_gemma":[0.0036231228,0.00016120165,0.9813397,0.00024066934,0.000493429,0.0000050693584,0.0010501168,0.004858038,0.007952768,0.00014685263,0.00005880175,0.00007025746],"about_ca_topic_score_codex":0.0058592353,"about_ca_topic_score_gemma":0.006155715,"teacher_disagreement_score":0.047913816,"about_ca_system_score_codex":0.000100122816,"about_ca_system_score_gemma":0.00014614077,"threshold_uncertainty_score":0.88574505},"labels":[],"label_agreement":null},{"id":"W2061620261","doi":"10.1021/jm3017255","title":"Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"STAT protein; STAT3; Chemistry; stat; Small molecule; Cancer research; Intracellular; Proto-oncogene tyrosine-protein kinase Src; Multiple myeloma; Transcription factor; Activator (genetics); In vitro; SH2 domain; Cell biology; Phosphorylation; Biochemistry; Biology; Gene; Immunology","score_opus":0.023561336714864333,"score_gpt":0.2549266967580899,"score_spread":0.23136536004322555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061620261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996404,0.00018003536,0.0013103186,0.001090315,0.000015445185,0.000683354,0.000004732959,0.000011289302,0.00030051987],"genre_scores_gemma":[0.9961965,0.00003063771,0.0034067975,0.00006360812,0.00017178814,0.000028171582,0.000019943249,0.00003012734,0.000052426047],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980437,0.000072606716,0.00060571916,0.00023309166,0.0006970876,0.00034778606],"domain_scores_gemma":[0.9985637,0.00009101846,0.00046482237,0.00012533978,0.0003688723,0.00038626065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003445098,0.00023897405,0.0005190454,0.00014562617,0.00008295468,0.00002080429,0.000091237904,0.00016720903,0.00014439],"category_scores_gemma":[0.00015671122,0.00016686058,0.00011121827,0.00017766892,0.00022615388,0.00022026993,0.000011515932,0.0005803865,8.114236e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021983364,0.00045181238,0.005530399,0.0008594829,0.0003421049,0.0002830477,0.0007902893,0.000004261115,0.97731274,4.3417907e-7,0.000028378365,0.012198731],"study_design_scores_gemma":[0.0112724155,0.001209812,0.01704077,0.0023108902,0.00010922138,0.0008016983,0.0019821955,0.00033535974,0.9647515,0.000026354051,0.000019940595,0.00013983823],"about_ca_topic_score_codex":0.000059545226,"about_ca_topic_score_gemma":0.0000028618313,"teacher_disagreement_score":0.012561219,"about_ca_system_score_codex":0.00015809642,"about_ca_system_score_gemma":0.0003058024,"threshold_uncertainty_score":0.68043774},"labels":[],"label_agreement":null},{"id":"W2061621007","doi":"10.1016/s1098-3015(10)74332-1","title":"PCN81 COST EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS IN CANADA","year":2009,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bortezomib; Multiple myeloma; Oncology; Internal medicine; Medicine","score_opus":0.0321674714575426,"score_gpt":0.32276034153599403,"score_spread":0.2905928700784514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061621007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710447,0.0003428474,0.0000047515487,0.00018731628,0.00003289692,0.0021511149,0.00008004283,0.000009129767,0.000087412205],"genre_scores_gemma":[0.9991924,0.00021444961,0.00009369821,0.00012117999,0.0000063830144,0.000063205596,0.00028798613,0.000012021385,0.000008650277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971896,0.00061319943,0.0007164897,0.00036763342,0.00046798092,0.000645123],"domain_scores_gemma":[0.9986559,0.00048192055,0.00015162518,0.0003257577,0.00008915867,0.00029563005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006323863,0.00018090736,0.0009082073,0.0009703115,0.000025360261,0.0000044086178,0.00009415322,0.00006378023,0.000019732935],"category_scores_gemma":[0.0005021705,0.00016047494,0.000072528055,0.0024092982,0.000021598675,0.000051713087,0.000019325498,0.00023240093,0.000001993641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009795922,0.0008780049,0.9622897,0.00022058937,0.00012407338,0.00017899711,0.00023640708,0.0070913997,0.000022088998,0.000006549546,0.000010924504,0.027961662],"study_design_scores_gemma":[0.009080059,0.0005877912,0.9530235,0.00052539987,0.000041122126,0.0000010656807,0.000049531867,0.036372513,0.00020199802,0.000009415073,0.00001658302,0.00009102781],"about_ca_topic_score_codex":0.98619807,"about_ca_topic_score_gemma":0.95807743,"teacher_disagreement_score":0.029281111,"about_ca_system_score_codex":0.0037865925,"about_ca_system_score_gemma":0.0022154276,"threshold_uncertainty_score":0.9901808},"labels":[],"label_agreement":null},{"id":"W2061913370","doi":"10.1259/bjr/77207966","title":"Pulmonary and nodal multiple myeloma mimicking lymphoma","year":2006,"lang":"en","type":"article","venue":"British Journal of Radiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Lymphoma; Bone marrow; Plasmacytoma; Pathology; Malignancy; Lymph; Radiology; Internal medicine","score_opus":0.012304001366964207,"score_gpt":0.25384193949076056,"score_spread":0.24153793812379634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061913370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859383,0.011824118,0.00011860163,0.00031665518,0.00013641344,0.0001282453,0.000013026693,0.000012860616,0.0015117591],"genre_scores_gemma":[0.99563414,0.0009759899,0.002424088,0.00009926063,0.00054257456,0.0000030457272,0.000018883473,0.000018215453,0.0002838192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883455,0.000102250815,0.0003775496,0.00015769244,0.00019623946,0.00033173597],"domain_scores_gemma":[0.9992436,0.00017184523,0.00015290409,0.000085559186,0.00014183349,0.00020422079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023672893,0.00010870861,0.00039875423,0.00014476858,0.000099873745,0.000027831446,0.00007920991,0.00010458003,0.000053174826],"category_scores_gemma":[0.00023104316,0.00010641214,0.000113083624,0.000080990154,0.00017071549,0.00010129915,0.00003377719,0.00017682658,0.000007043109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080718356,0.00040966747,0.62449306,0.00004756687,0.00019513787,0.05052962,0.00002107371,0.000006152754,0.012070498,0.00003231264,0.0044718524,0.30691588],"study_design_scores_gemma":[0.003547083,0.00027551685,0.59811646,0.00009691878,0.000031837564,0.39578864,0.000022389931,0.00022765451,0.00040065806,0.00012510651,0.0013115513,0.00005617766],"about_ca_topic_score_codex":0.00042427925,"about_ca_topic_score_gemma":0.000051553972,"teacher_disagreement_score":0.34525904,"about_ca_system_score_codex":0.00008348095,"about_ca_system_score_gemma":0.00010278702,"threshold_uncertainty_score":0.43393612},"labels":[],"label_agreement":null},{"id":"W2062867383","doi":"10.1200/jco.2009.22.0392","title":"Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chromosomal translocation; Multiple myeloma; Complete remission; Internal medicine; Oncology; Chemotherapy; Genetics; Gene","score_opus":0.17420673631041428,"score_gpt":0.5012384800363613,"score_spread":0.327031743725947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062867383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005804544,0.99052185,0.00003242473,0.0006452399,0.0003194331,0.0012484716,0.0000069880266,0.000010460026,0.0014105701],"genre_scores_gemma":[0.0069350344,0.98824394,0.0038751382,0.0001858887,0.0004947781,0.000017804285,0.000034704884,0.000037247504,0.00017547724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99335974,0.0011292561,0.0040432885,0.00034360428,0.0007370141,0.00038711404],"domain_scores_gemma":[0.9928292,0.0031273991,0.0025690615,0.00031252834,0.00040740825,0.00075442385],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019999838,0.00034729156,0.0053569833,0.00045033568,0.00003140615,0.000009805579,0.000199393,0.00096332096,0.000073870404],"category_scores_gemma":[0.0041209944,0.00018968793,0.0010144595,0.00033003118,0.00011127592,0.00007108994,0.000023319837,0.0023377358,0.000030862895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005781228,0.0026766334,0.00024113896,0.0009965932,0.00038632326,0.094057895,0.000037175923,0.0000016836005,4.9504416e-7,0.0000015954256,0.00028686668,0.89553237],"study_design_scores_gemma":[0.009313491,0.027615817,0.0018244815,0.017890578,0.0008902821,0.044775274,0.0000185565,0.000026760054,0.0000011184703,0.000013855753,0.89747113,0.0001586262],"about_ca_topic_score_codex":0.000020562513,"about_ca_topic_score_gemma":0.00014866638,"teacher_disagreement_score":0.8971843,"about_ca_system_score_codex":0.00069519505,"about_ca_system_score_gemma":0.005536844,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2063028475","doi":"10.14740/jmc.v5i3.1674","title":"Endosonography-Guided Diagnosis of Mediastinal Involvement of Plasma Cell Dyscrasia in a Patient","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasma cell dyscrasia; Dyscrasia; Plasma cell; Lesion; Biopsy; Radiology; Pathology; Antibody; Immunoglobulin light chain; Immunology","score_opus":0.04499538173015401,"score_gpt":0.3253149739599115,"score_spread":0.2803195922297575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063028475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747837,0.0006814401,0.00004383992,0.001254837,0.000109719076,0.00019507167,0.000010956914,0.0000028207269,0.00022292277],"genre_scores_gemma":[0.9975138,0.00090456416,0.001306478,0.00012011664,0.00011975572,0.000014686113,0.0000051667607,0.000009892883,0.00000554084],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99632543,0.00017372727,0.0010032824,0.0001143387,0.0021316372,0.00025158538],"domain_scores_gemma":[0.99742657,0.0010795793,0.0004868283,0.00015018848,0.00026445687,0.0005924043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000860517,0.00012890225,0.0005979849,0.00045620237,0.00001558572,0.000003966663,0.00015739982,0.000096647826,0.00050955825],"category_scores_gemma":[0.0025726766,0.000085948355,0.00022229513,0.00025224674,0.00017081892,0.000050227343,0.000060263024,0.00032261014,0.0000023523282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001483903,0.0042055137,0.8984802,0.00071606576,0.00021384224,0.0037703246,0.0007266599,0.00000815957,0.0014235445,0.000020794718,0.0060164835,0.08293452],"study_design_scores_gemma":[0.05655605,0.036572292,0.40326902,0.008319302,0.0005764865,0.0046359287,0.003496339,0.0027198282,0.4725376,0.00019315403,0.010728027,0.00039593846],"about_ca_topic_score_codex":0.00035007388,"about_ca_topic_score_gemma":0.00008728206,"teacher_disagreement_score":0.49521115,"about_ca_system_score_codex":0.00006787117,"about_ca_system_score_gemma":0.0003439726,"threshold_uncertainty_score":0.5579305},"labels":[],"label_agreement":null},{"id":"W2064300367","doi":"10.1038/sj.bmt.1705131","title":"Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation","year":2005,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Multiple myeloma; Medicine; Stem cell; Transplantation; Autologous stem-cell transplantation; Oncology; Internal medicine; Immunology; Genetics; Biology","score_opus":0.01272838917331728,"score_gpt":0.2412562163791693,"score_spread":0.22852782720585202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064300367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935705,0.00047074122,0.0018008306,0.00014127127,0.00015812075,0.0011432348,0.002003276,0.0001562708,0.0005557236],"genre_scores_gemma":[0.98999375,0.002845935,0.003393908,0.000096122916,0.00015502017,0.0001291126,0.0026261245,0.00006120911,0.000698797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723005,0.00014033137,0.00065772294,0.00064098986,0.00080361875,0.00052726356],"domain_scores_gemma":[0.9986841,0.00026247188,0.00021668522,0.00036487047,0.00017198117,0.00029987452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013462566,0.00037066132,0.00045015806,0.00026648623,0.00025620539,0.00008715255,0.00012982037,0.00021239233,0.00020940557],"category_scores_gemma":[0.00001390795,0.00034701946,0.00019048095,0.00019574269,0.00006925294,0.00032190443,0.000010085857,0.0002675428,0.00035845334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055445256,0.0007165645,0.75731504,0.000537678,0.00023632552,0.00046345772,0.0038310161,0.0005164422,0.019751193,0.000009400533,0.0001358628,0.21094252],"study_design_scores_gemma":[0.010775496,0.00030145625,0.91133267,0.00016844572,0.0006166525,0.00004546837,0.00007691925,0.0024737613,0.07373493,0.000038054324,0.00014223167,0.00029391184],"about_ca_topic_score_codex":0.0010068135,"about_ca_topic_score_gemma":0.0013875796,"teacher_disagreement_score":0.21064861,"about_ca_system_score_codex":0.00015346361,"about_ca_system_score_gemma":0.0000616351,"threshold_uncertainty_score":0.9998982},"labels":[],"label_agreement":null},{"id":"W2064338630","doi":"10.1182/blood-2014-06-581611","title":"Oral therapy for multiple myeloma: ixazomib arriving soon","year":2014,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Ixazomib; Multiple myeloma; Medicine; Internal medicine; Oncology; Intensive care medicine; Lenalidomide; Carfilzomib","score_opus":0.05015570316181866,"score_gpt":0.31302725835172684,"score_spread":0.2628715551899082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064338630","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24562846,0.004554886,0.0014280499,0.72368145,0.0014094934,0.014621588,0.0008540366,0.0009986229,0.0068234163],"genre_scores_gemma":[0.28354025,0.000559,0.014961469,0.64831316,0.021721294,0.0027394153,0.007504358,0.00071026455,0.019950803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726784,0.000104533174,0.00036247107,0.0007024558,0.00060641835,0.0009562539],"domain_scores_gemma":[0.9981017,0.00054490485,0.0001578083,0.00078501296,0.00018664557,0.00022394514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024076788,0.0005054231,0.00086058583,0.00023781162,0.00016766321,0.000067830755,0.0002559227,0.00074510474,0.00018835005],"category_scores_gemma":[0.00037419173,0.00038701246,0.0004711825,0.00010657481,0.000083286985,0.000053204683,0.000056180837,0.0010048705,0.00020299798],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006017424,0.00096602086,0.028613381,0.0007118432,0.001992261,0.0013173984,0.000074379524,2.396338e-7,0.0018591582,0.000004031202,0.93870205,0.025157504],"study_design_scores_gemma":[0.030739442,0.0013550959,0.007847062,0.00025895544,0.0003901447,0.00016655726,0.0000065668864,0.00016929948,0.0060304073,0.00007329639,0.9525296,0.0004335494],"about_ca_topic_score_codex":0.000106421685,"about_ca_topic_score_gemma":0.000021559643,"teacher_disagreement_score":0.0753683,"about_ca_system_score_codex":0.00007172003,"about_ca_system_score_gemma":0.00019382167,"threshold_uncertainty_score":0.9998582},"labels":[],"label_agreement":null},{"id":"W2065318007","doi":"10.3111/13696998.2011.653511","title":"Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Medical Research Council","keywords":"Medicine; Zoledronic acid; Multiple myeloma; Incidence (geometry); Internal medicine; Cost effectiveness; Adverse effect; Oncology","score_opus":0.09017863653723394,"score_gpt":0.3739058121697349,"score_spread":0.28372717563250094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065318007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713225,0.0034515967,0.0018898882,0.0050230124,0.000752002,0.0015178119,0.00018598657,0.000017425595,0.000030003712],"genre_scores_gemma":[0.9969846,0.00064907945,0.00066378043,0.00031426756,0.0011747119,0.00008680888,0.00007825518,0.000044270884,0.0000042528704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720764,0.0004877857,0.00087407825,0.00022226135,0.00058358145,0.00062466366],"domain_scores_gemma":[0.9941356,0.003270803,0.00066911,0.0003715576,0.0005390799,0.0010138226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028416396,0.00024572798,0.0009577197,0.00020183256,0.00013839387,0.000024714545,0.00043876882,0.00029571194,0.000079034675],"category_scores_gemma":[0.0028490985,0.00016063724,0.0004312999,0.00016929496,0.00020910219,0.00019005996,0.00009740995,0.0007407101,0.000015086274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07253187,0.0055330223,0.7894772,0.0041551,0.012651121,0.0007488594,0.007544115,0.00043948455,0.0021931576,0.029536871,0.0024785409,0.072710656],"study_design_scores_gemma":[0.1459879,0.008331329,0.71105474,0.008304262,0.0018240869,0.0020225209,0.02212016,0.03534463,0.039243672,0.00082114595,0.024026584,0.00091893895],"about_ca_topic_score_codex":0.0015392149,"about_ca_topic_score_gemma":0.0002479552,"teacher_disagreement_score":0.078422435,"about_ca_system_score_codex":0.001955937,"about_ca_system_score_gemma":0.0013996313,"threshold_uncertainty_score":0.6550597},"labels":[],"label_agreement":null},{"id":"W2065628269","doi":"10.1080/10428190600822128","title":"Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma","year":2006,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs","keywords":"Chromosomal translocation; Multiple myeloma; Mechanism (biology); Outcome (game theory); Chromosome; Disease; Oncology; Biology; Medicine; Genetics; Internal medicine; Immunology; Gene","score_opus":0.020844550676225513,"score_gpt":0.29712161442013624,"score_spread":0.2762770637439107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065628269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01865467,0.9753114,0.000012685572,0.0000885861,0.0006549406,0.003080912,0.00033898544,0.00043649122,0.0014213496],"genre_scores_gemma":[0.0036968887,0.98454195,0.00078886776,0.00027207722,0.0012196494,0.0006971808,0.0013752837,0.0005433052,0.006864776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99021274,0.00045665985,0.002136863,0.0028738638,0.0017881385,0.002531732],"domain_scores_gemma":[0.9937387,0.0012070915,0.0010154641,0.0019702783,0.0003547468,0.0017137286],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007304692,0.0024309359,0.005303662,0.001244017,0.00085351215,0.0017198615,0.00077671633,0.0021361343,0.00014470656],"category_scores_gemma":[0.00037803507,0.0020419012,0.001281097,0.001195746,0.001227619,0.0009318715,0.00082325895,0.0006848793,0.0005153337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033445633,0.0002923177,0.0014375458,0.012524905,0.0012893506,0.0030349637,0.0002644329,0.000001004971,0.000010068014,0.000093444614,0.0049387757,0.97577876],"study_design_scores_gemma":[0.017394546,0.00042133118,0.008798888,0.032645322,0.002499335,0.0044220705,0.00022130812,0.0005461749,0.000025590647,0.00007448358,0.93121684,0.0017341097],"about_ca_topic_score_codex":0.0025973953,"about_ca_topic_score_gemma":0.00019428,"teacher_disagreement_score":0.9740446,"about_ca_system_score_codex":0.009675984,"about_ca_system_score_gemma":0.008177089,"threshold_uncertainty_score":0.99931645},"labels":[],"label_agreement":null},{"id":"W2065884408","doi":"10.1016/j.clinbiochem.2012.03.018","title":"Performance evaluation of the Helena V8 capillary electrophoresis system","year":2012,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Capillary electrophoresis; Agarose gel electrophoresis; Serum protein electrophoresis; Monoclonal; Immunofixation; Agarose; Chromatography; Medicine; Molecular biology; Monoclonal antibody; Chemistry; Antibody; Immunology; Biology; Biochemistry","score_opus":0.07108688122175807,"score_gpt":0.38984939132563895,"score_spread":0.3187625101038809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065884408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929597,0.0018268496,6.4014995e-7,0.00012355487,0.0001320474,0.00038567523,0.0000062042373,0.000016738592,0.0045486265],"genre_scores_gemma":[0.99898374,0.00017010984,0.00006473524,0.00003551816,0.00034412715,0.000043130574,0.00002267828,0.000009399642,0.0003265803],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998497,0.000114162925,0.00034704956,0.00016131804,0.0006163708,0.00026408365],"domain_scores_gemma":[0.9988403,0.000117609656,0.000111939495,0.0005017419,0.00022858242,0.00019987766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122732,0.00009143757,0.00021164694,0.00001290107,0.000054143984,0.0000031012166,0.00011184541,0.00013471156,0.00007451029],"category_scores_gemma":[0.0008480037,0.000054696302,0.00016384131,0.00012293328,0.00012957795,0.000024094381,0.000056949848,0.00019658098,0.000044823784],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025608047,0.00042055562,0.9024049,0.00038152686,0.00017859432,0.0000014958384,0.000014203573,4.4261253e-7,0.069126315,0.000003877491,0.0010968371,0.026115138],"study_design_scores_gemma":[0.0014935316,0.00009593205,0.46706665,0.00015975104,0.00020333852,0.000025926605,0.000040105395,0.0010020091,0.52967095,8.395226e-7,0.00018973314,0.00005127074],"about_ca_topic_score_codex":0.0000061970877,"about_ca_topic_score_gemma":1.9154915e-7,"teacher_disagreement_score":0.46054462,"about_ca_system_score_codex":0.00014767588,"about_ca_system_score_gemma":0.00026324054,"threshold_uncertainty_score":0.22304504},"labels":[],"label_agreement":null},{"id":"W2066244997","doi":"10.1158/1535-7163.pms-b17","title":"Abstract B17: Dexamethasone synthetic lethal screens uncover two potential combination therapies for the treatment of multiple myeloma","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University","funders":"","keywords":"Dexamethasone; Cancer research; Multiple myeloma; Programmed cell death; Apoptosis; Glucocorticoid receptor; Medicine; Pharmacology; Biology; Glucocorticoid; Immunology; Internal medicine","score_opus":0.041579972672195674,"score_gpt":0.33072438364142387,"score_spread":0.2891444109692282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066244997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96953064,0.016717607,0.007871999,0.0024391871,0.0001737311,0.0029759419,0.00009712744,0.00004045984,0.0001533066],"genre_scores_gemma":[0.99495256,0.002269949,0.0012328079,0.00028151486,0.00008823051,0.0008466424,0.000054529006,0.000059137623,0.00021462936],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984817,0.000068775385,0.00028473433,0.00029271806,0.00046267395,0.0004093961],"domain_scores_gemma":[0.9986232,0.000315075,0.00013400814,0.00049118657,0.00032461633,0.0001119379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011043337,0.00026628803,0.00034996396,0.00008756753,0.00014314223,0.000042223186,0.00013974986,0.00009014196,0.000248763],"category_scores_gemma":[0.000021599253,0.000165776,0.00030512523,0.00014011974,0.00019082864,0.00007354774,0.00001669313,0.00009887583,0.000018536988],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010842449,0.0017407747,0.011887716,0.00009692834,0.0030295441,0.000037677266,0.000619245,0.0003660686,0.3453623,0.00015045817,0.00003043721,0.6355946],"study_design_scores_gemma":[0.031270277,0.00407956,0.2984568,0.00016338426,0.0017135524,0.000039002138,0.0005773832,0.029830301,0.6166107,0.0011847066,0.015538816,0.0005355355],"about_ca_topic_score_codex":0.001456512,"about_ca_topic_score_gemma":0.000090155314,"teacher_disagreement_score":0.63505906,"about_ca_system_score_codex":0.00021510648,"about_ca_system_score_gemma":0.00012699467,"threshold_uncertainty_score":0.6760149},"labels":[],"label_agreement":null},{"id":"W2066650468","doi":"10.5339/qfarf.2012.aesnp12","title":"Identification and characterization of inhibitors of G protein-coupled receptor kinase 6 (GRK6) as potential therapeutics for multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Qatar Foundation Annual Research Forum Volume 2012 Issue 1","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"G protein-coupled receptor kinase; Kinome; Kinase; Beta adrenergic receptor kinase; Protein kinase domain; Gene silencing; Biology; Cell biology; Cancer research; Chemistry; Pharmacology; G protein-coupled receptor; Signal transduction; Biochemistry; Gene","score_opus":0.03675391295082804,"score_gpt":0.36072040571498615,"score_spread":0.3239664927641581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066650468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908601,0.00033641618,0.0027365226,0.0018308966,0.00020694843,0.0035920013,0.00035934983,0.000031314878,0.000046460307],"genre_scores_gemma":[0.98909044,0.00016116255,0.0008857584,0.000021859276,0.00032275962,0.0003543686,0.0021101339,0.000048045265,0.0070054685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99702376,0.00025433503,0.0006076205,0.00032962675,0.001083107,0.0007015465],"domain_scores_gemma":[0.997036,0.00015610685,0.00028339785,0.0004131815,0.0017626239,0.00034868572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018608616,0.00018905416,0.00034018146,0.00047856558,0.00026076252,0.00005267585,0.00014486836,0.00017167437,0.0005828546],"category_scores_gemma":[0.0010993611,0.00017331459,0.00010220656,0.0004190698,0.000349378,0.0010631273,0.00011567279,0.00021747041,0.00023722701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002175031,0.0008502034,0.026939258,0.0004511959,0.00016666314,0.0000011580717,0.0009323055,3.7701236e-7,0.884938,0.0003037284,0.00050688896,0.0827352],"study_design_scores_gemma":[0.007234268,0.0026816314,0.19126461,0.00030581118,0.00013440286,0.00001579237,0.0027190144,0.011695111,0.63437515,0.00019221813,0.14900717,0.00037478431],"about_ca_topic_score_codex":0.00026357567,"about_ca_topic_score_gemma":0.000020577481,"teacher_disagreement_score":0.25056282,"about_ca_system_score_codex":0.00014117015,"about_ca_system_score_gemma":0.00021719921,"threshold_uncertainty_score":0.70675635},"labels":[],"label_agreement":null},{"id":"W2066937098","doi":"10.1016/j.bbmt.2007.04.006","title":"Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma","year":2007,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; American Society of Hematology","keywords":"Medicine; Melphalan; Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Surgery; Cohort; Internal medicine; Total body irradiation; Median follow-up; Hematopoietic stem cell transplantation; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.030983839157873314,"score_gpt":0.31194727828335916,"score_spread":0.2809634391254858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066937098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985021,0.0006540543,0.012723889,0.000036979694,0.00005648887,0.0008913928,0.00043021917,0.00001892581,0.00016702998],"genre_scores_gemma":[0.9951381,0.0011194131,0.0026133992,0.00001927677,0.00003068686,0.000030334353,0.0009507595,0.000014395861,0.00008362579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988642,0.000046908448,0.00046689314,0.00024680415,0.00011735937,0.00025786765],"domain_scores_gemma":[0.9991089,0.00038988513,0.00016480261,0.00010355569,0.00012141669,0.00011141256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002841249,0.00015656356,0.0003645479,0.00018966256,0.0000531226,0.0000024735632,0.00005078572,0.00016271192,0.000010638151],"category_scores_gemma":[0.000009581716,0.00012967318,0.00010826454,0.000086029635,0.00014348752,0.000058211033,0.0000036609877,0.000068704474,9.830453e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026529285,0.00018422125,0.5585806,0.0013379997,0.00016458644,0.000029389692,0.00045047287,7.4407484e-7,0.42347327,0.00005923537,5.1920114e-7,0.013066069],"study_design_scores_gemma":[0.0061576623,0.00085856183,0.54272425,0.000060224167,0.0004651484,0.00005304949,0.000045972574,0.000011422665,0.44953188,0.000019703271,0.0000033520605,0.00006876251],"about_ca_topic_score_codex":0.00005222048,"about_ca_topic_score_gemma":0.00019352212,"teacher_disagreement_score":0.02605863,"about_ca_system_score_codex":0.000009616336,"about_ca_system_score_gemma":0.000033717468,"threshold_uncertainty_score":0.5287919},"labels":[],"label_agreement":null},{"id":"W2067320607","doi":"10.1016/s1658-3876(08)50065-3","title":"Cyclin D1 positive plasma cell myeloma","year":2008,"lang":"en","type":"letter","venue":"Hematology/Oncology and Stem Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Hamilton General Hospital; University of Alberta Hospital; Alberta Hospital Edmonton; University Health Network","funders":"","keywords":"Cyclin D1; Multiple myeloma; Plasma Cell Myeloma; Cancer research; Plasma cell; Cell biology; Chemistry; Medicine; Internal medicine; Biology; Cell cycle; Cancer","score_opus":0.033013270098028825,"score_gpt":0.29931132990877485,"score_spread":0.266298059810746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067320607","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6021047,0.028619962,0.000036059948,0.28964508,0.0014399007,0.0043757,0.000255055,0.00033195876,0.073191576],"genre_scores_gemma":[0.2760921,0.056037914,0.002117253,0.5639389,0.0030302405,0.0011032196,0.0025431071,0.00048516502,0.09465209],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957495,0.00072582817,0.00071230397,0.001143949,0.00044114224,0.0012272923],"domain_scores_gemma":[0.99710673,0.0012616146,0.00039442486,0.00068883866,0.00018368916,0.00036467792],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00021486019,0.000831103,0.002061018,0.00042515507,0.0003875115,0.000022233437,0.00027333281,0.0032956603,0.00042903508],"category_scores_gemma":[0.000010861747,0.0006532928,0.000369545,0.00018549246,0.0007555108,0.00006572601,0.00011107802,0.0028987452,0.0006277092],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034642841,0.0011248902,0.008319911,0.0006033815,0.0010567234,0.06263839,0.001164425,2.0873296e-7,0.0013031134,0.000027357417,0.8997437,0.020553647],"study_design_scores_gemma":[0.016253578,0.004676453,0.0023068688,0.00014912829,0.00020415425,0.011211738,0.00017945628,0.000059866554,0.028367218,0.00008396386,0.9358086,0.0006989548],"about_ca_topic_score_codex":0.000038016628,"about_ca_topic_score_gemma":0.0000105074,"teacher_disagreement_score":0.3260126,"about_ca_system_score_codex":0.00026453062,"about_ca_system_score_gemma":0.00068212044,"threshold_uncertainty_score":0.9995918},"labels":[],"label_agreement":null},{"id":"W2067456806","doi":"10.1002/ajh.1062","title":"Thalidomide‐associated hepatitis: A case report","year":2001,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Thalidomide; Medicine; Plasmacytosis; Multiple myeloma; Pomalidomide; Hepatitis; Aplastic anemia; Immunology; Internal medicine; Gastroenterology; Dermatology; Bone marrow","score_opus":0.022045487208967048,"score_gpt":0.3384723653067485,"score_spread":0.31642687809778147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067456806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586135,0.00035508175,0.00021855687,0.0019486388,0.000092140865,0.00011292112,0.00000270634,0.000015855916,0.0013927612],"genre_scores_gemma":[0.9976581,0.00020486036,0.0014907884,0.00025768531,0.00006545989,0.0000048156026,0.0000061506103,0.000016300235,0.00029586107],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99857056,0.00014251262,0.0005542944,0.00013028544,0.00027459374,0.0003277538],"domain_scores_gemma":[0.9983099,0.00020106645,0.000623122,0.000201229,0.00033182258,0.00033287142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031722325,0.00011599171,0.00070242933,0.00020616777,0.00005580573,0.000008083336,0.00006620664,0.000041832976,0.00020917311],"category_scores_gemma":[0.00093797664,0.00008547983,0.00017279544,0.00028899542,0.00024133701,0.00005988514,0.000022888818,0.00024467142,0.000029157542],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003362892,0.00021450191,0.416784,0.0000044256635,0.00033839737,0.57500726,0.00006547896,3.8551138e-7,0.00004273776,0.000030116427,0.0006464363,0.0065300097],"study_design_scores_gemma":[0.0023632476,0.0016814173,0.039110176,0.00006168689,0.000112730326,0.95481694,0.00039338804,0.00004051925,0.00027222815,0.00009061806,0.0009920814,0.00006498906],"about_ca_topic_score_codex":0.00086379447,"about_ca_topic_score_gemma":0.00014557071,"teacher_disagreement_score":0.37980968,"about_ca_system_score_codex":0.000105616986,"about_ca_system_score_gemma":0.00022555333,"threshold_uncertainty_score":0.34857664},"labels":[],"label_agreement":null},{"id":"W2067704026","doi":"10.1179/1607845413y.0000000082","title":"Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction","year":2013,"lang":"en","type":"article","venue":"Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Autologous stem-cell transplantation; Oncology; Internal medicine; Retrospective cohort study; Surgery","score_opus":0.035826327344949296,"score_gpt":0.3081526433898972,"score_spread":0.2723263160449479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067704026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979313,0.000038893162,0.00006524166,0.00049116625,0.00012199665,0.0010885522,0.000027281632,0.000019459285,0.00021608056],"genre_scores_gemma":[0.99892664,0.0000015429264,0.00048319256,0.000095808464,0.0000060665843,0.00027692906,0.00006679202,0.000013911925,0.00012912016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986639,0.00018525722,0.0004092426,0.00022726487,0.00020856639,0.0003057717],"domain_scores_gemma":[0.9991589,0.00023057708,0.00007521871,0.00023954619,0.00012461394,0.00017115376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013667317,0.00012970282,0.00040383733,0.00032797555,0.000022068323,0.000005528333,0.000054706805,0.00011162156,0.00031169437],"category_scores_gemma":[0.000035382378,0.00011017586,0.00005112758,0.00018695646,0.000050149723,0.000064321146,0.000014054276,0.00011801557,0.00034018865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024932295,0.0006798166,0.96950626,0.00018862894,0.00003507689,0.00010011418,0.00028434573,0.0000072530274,0.0032931569,0.000016907323,0.00014852606,0.0008076143],"study_design_scores_gemma":[0.014232459,0.0009584178,0.9338814,0.00007715326,0.00003173247,0.000010393646,0.000110176705,0.000279628,0.05021809,0.0000053970916,0.00010087484,0.000094251125],"about_ca_topic_score_codex":0.00025936178,"about_ca_topic_score_gemma":0.0001006375,"teacher_disagreement_score":0.04692493,"about_ca_system_score_codex":0.00010308487,"about_ca_system_score_gemma":0.00007489949,"threshold_uncertainty_score":0.44928414},"labels":[],"label_agreement":null},{"id":"W2067725825","doi":"10.1016/j.bbmt.2014.12.028","title":"New Cancers after Autotransplantations for Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Terumo BCT; Genentech; Health Resources and Services Administration; Medac; Swedish Orphan Biovitrum; Otsuka America; Incyte; Allos Therapeutics; Ariad Pharmaceuticals; Actinium Pharmaceuticals; Blue Cross and Blue Shield Association; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Chimerix; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Takeda Oncology; University of Minnesota; Amgen; Otsuka America Pharmaceutical; Teva Pharmaceutical Industries; HistoGenetics; WellPoint; U.S. Navy; Osiris Therapeutics; Celgene; Health Research; Onyx Pharmaceuticals; U.S. Department of Defense; Sanofi; Be The Match Foundation; GlaxoSmithKline","keywords":"Medicine; Incidence (geometry); Multiple myeloma; Cohort; Internal medicine; Confidence interval; Cumulative incidence; Population; Cancer; Relative risk; Oncology","score_opus":0.014159541418843236,"score_gpt":0.279854081265248,"score_spread":0.2656945398464048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067725825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710954,0.000437601,0.026863758,0.0003115057,0.00007087263,0.00055174006,0.00031778266,0.00003065911,0.00032069368],"genre_scores_gemma":[0.9851216,0.0006270244,0.0133133745,0.00006947951,0.00006805113,0.00009034382,0.0005490306,0.000009960795,0.00015112979],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999365,0.000031057018,0.00017088583,0.00019106345,0.000062141626,0.00017986652],"domain_scores_gemma":[0.9995156,0.00018316381,0.000040464933,0.0000827546,0.000047118287,0.00013091894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007696395,0.000101843136,0.00019650336,0.000089524845,0.000048992857,0.000003925934,0.000029066618,0.00008959205,0.000033215918],"category_scores_gemma":[0.000022629927,0.00008410827,0.00006082294,0.00004850828,0.0000672047,0.000041957468,0.0000020650937,0.000045923258,0.000001994143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058908327,0.00014632905,0.4438674,0.0012459783,0.0005853582,0.000018970832,0.00095082656,0.0000068491113,0.47449476,0.001376981,0.00008508494,0.071330644],"study_design_scores_gemma":[0.029597769,0.0030844097,0.7214007,0.0003055716,0.0019153756,0.00020326013,0.00005132761,0.0010546416,0.23896284,0.0011068594,0.002012317,0.00030496524],"about_ca_topic_score_codex":0.0003415092,"about_ca_topic_score_gemma":0.0004271352,"teacher_disagreement_score":0.27753326,"about_ca_system_score_codex":0.00000759513,"about_ca_system_score_gemma":0.00008473075,"threshold_uncertainty_score":0.3429836},"labels":[],"label_agreement":null},{"id":"W2067815150","doi":"10.1002/cncr.21666","title":"Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)","year":2006,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Doxorubicin; Vincristine; Dexamethasone; Refractory (planetary science); Urology; Chemotherapy; Toxicity; Internal medicine; Surgery; Pharmacology; Gastroenterology; Cyclophosphamide; Biology","score_opus":0.02670968218884696,"score_gpt":0.32508559488360983,"score_spread":0.2983759126947629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067815150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968556,0.000493877,0.000017914637,0.00004778207,0.000086871616,0.0022177394,0.000051219067,0.000031311025,0.000197677],"genre_scores_gemma":[0.998731,0.00006146664,0.00055462617,0.000017627404,0.00005247266,0.00027117002,0.000117886535,0.000050294624,0.00014344735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976551,0.00013567525,0.0005071311,0.0005427165,0.0006924883,0.0004668757],"domain_scores_gemma":[0.99867517,0.00028279432,0.00023548891,0.00036107143,0.0002816476,0.00016383674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002618035,0.00030715537,0.00068545336,0.00043701316,0.000072176445,0.000017906497,0.00009421751,0.00009111201,0.0000730902],"category_scores_gemma":[0.00020094408,0.0002150978,0.000026293545,0.00069439755,0.0001360713,0.00021093377,0.000053545078,0.00030884196,0.0000019836643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067015454,0.010391044,0.8996248,0.00013511431,0.0001584634,0.00024632984,0.00069989957,0.000044277986,0.0007048444,0.0000034107281,0.00007572766,0.02090062],"study_design_scores_gemma":[0.20985405,0.010432823,0.7763252,0.00047875752,0.000107006206,0.0000025487245,0.0005742273,0.000385769,0.0015300235,0.0000023524574,0.00010554442,0.00020168818],"about_ca_topic_score_codex":0.01011993,"about_ca_topic_score_gemma":0.023120172,"teacher_disagreement_score":0.1428386,"about_ca_system_score_codex":0.00051539915,"about_ca_system_score_gemma":0.0002226532,"threshold_uncertainty_score":0.99647176},"labels":[],"label_agreement":null},{"id":"W2068045978","doi":"10.1038/leu.2013.152","title":"Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Onyx Pharmaceuticals","keywords":"Carfilzomib; Internal medicine; Cytogenetics; Oncology; Medicine; Refractory (planetary science); Multiple myeloma; Fluorescence in situ hybridization; Confidence interval; Population; Gastroenterology; Biology; Lenalidomide; Genetics","score_opus":0.020091692711695797,"score_gpt":0.2568875595864741,"score_spread":0.23679586687477827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068045978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964939,0.0001678598,0.0000019152078,0.00013958568,0.00003948155,0.003011703,0.00002188064,0.00002407177,0.0000996258],"genre_scores_gemma":[0.9985911,0.00013040395,0.0005947142,0.000064140164,0.00002424422,0.00031662956,0.000043798766,0.000036356938,0.00019861288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979525,0.00029065317,0.00035490436,0.0004794021,0.00046404716,0.00045846295],"domain_scores_gemma":[0.9987006,0.00043254014,0.00011164222,0.00049538276,0.000061652834,0.00019814356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017080107,0.00031971483,0.0004858518,0.00019422175,0.000121101286,0.00006758374,0.00009738183,0.00009655732,0.000020150645],"category_scores_gemma":[0.00023557119,0.00017781857,0.000035325727,0.00020679485,0.00009424868,0.000115285664,0.00007378007,0.0002816039,0.0000145827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004952961,0.0017253704,0.9565837,0.00001973051,0.00017265377,0.00014826853,0.0029907434,0.000010337528,0.00011530678,6.605511e-7,0.00001991811,0.03771805],"study_design_scores_gemma":[0.02726969,0.0048851045,0.96575874,0.000060440165,0.00009754134,0.000006365958,0.0013280846,0.00019702586,0.00015904453,0.000010260848,0.000061031933,0.00016669977],"about_ca_topic_score_codex":0.009151811,"about_ca_topic_score_gemma":0.0045310613,"teacher_disagreement_score":0.037551347,"about_ca_system_score_codex":0.0009653463,"about_ca_system_score_gemma":0.000101144535,"threshold_uncertainty_score":0.99744636},"labels":[],"label_agreement":null},{"id":"W2069502026","doi":"10.1038/nm1010-1084","title":"Peering into the aftermath: The inhospitable host?","year":2010,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Bench to bedside; Immunology; Metastasis; Clinical trial; Disease; Cancer research; Cancer; Internal medicine","score_opus":0.007863316072763802,"score_gpt":0.3134034992042964,"score_spread":0.3055401831315326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069502026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8957809,0.0040881434,0.000018642382,0.08769196,0.0009803553,0.0006682838,0.000002324867,0.000069696755,0.0106996875],"genre_scores_gemma":[0.9916312,0.0001467956,0.00034269883,0.0032794233,0.001367599,0.00006725888,0.000022022354,0.000023395256,0.0031196133],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984542,0.000037875117,0.00018077063,0.00022377224,0.00073592324,0.00036745073],"domain_scores_gemma":[0.9986095,0.00024046627,0.00004669194,0.0007308626,0.00016273384,0.00020977845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005935373,0.00017487998,0.0002361915,0.00007529078,0.0002728657,0.000020369793,0.00029179605,0.00020233674,0.0005003926],"category_scores_gemma":[0.0012751241,0.00006589826,0.00006607075,0.00031909865,0.0003566553,0.000057687736,0.000095725794,0.0021466797,0.0000964983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001299176,0.0005687534,0.23210782,0.00036755847,0.0009772348,0.0011537183,0.016659323,0.0000011120496,0.45256612,0.00693938,0.113791,0.1735688],"study_design_scores_gemma":[0.0041326056,0.00047814872,0.47407484,0.00018354318,0.00016884797,0.00030253173,0.00064112485,0.0003162965,0.011105781,0.000402786,0.50805086,0.00014262815],"about_ca_topic_score_codex":0.0003307029,"about_ca_topic_score_gemma":0.00021705288,"teacher_disagreement_score":0.44146034,"about_ca_system_score_codex":0.000038178998,"about_ca_system_score_gemma":0.00007646527,"threshold_uncertainty_score":0.93263745},"labels":[],"label_agreement":null},{"id":"W2069827448","doi":"10.1182/blood-2004-04-1363","title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Multiple myeloma; Fluorescence in situ hybridization; Autologous stem-cell transplantation; Transplantation; Biology; Internal medicine; Beta-2 microglobulin; Chemotherapy; Stem cell; Oncology; Cancer research; Pathology; Immunology; Medicine; Gastroenterology; Gene","score_opus":0.011639351976677976,"score_gpt":0.23818833088007194,"score_spread":0.22654897890339395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069827448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940432,0.000043204316,0.003163438,0.0000203458,0.000029416675,0.002353738,0.00025685268,0.00008341248,0.0000064482074],"genre_scores_gemma":[0.9914687,0.000018428775,0.0067355293,0.000016590344,0.000015939413,0.00020222906,0.0014949623,0.00003459068,0.00001302129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863863,0.000043853808,0.00023729562,0.00037650767,0.00034641815,0.00035731256],"domain_scores_gemma":[0.9993902,0.00006438704,0.000077890036,0.00016518153,0.00012962817,0.00017270354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047455724,0.00018756719,0.00020775832,0.00013321938,0.00009632645,0.000015834774,0.00006262548,0.00008757815,0.0000041453004],"category_scores_gemma":[0.000043956537,0.00015856355,0.000058029527,0.0002053097,0.000020997079,0.00021425022,0.0000063658035,0.00009053889,0.000007161948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001185894,0.00272701,0.827612,0.00019649278,0.0000902558,0.00015667359,0.0009578956,0.000035899797,0.15898466,3.6145155e-7,0.0000016271758,0.008051255],"study_design_scores_gemma":[0.023071384,0.0015097267,0.6343979,0.000104268336,0.00014742935,0.0000080990285,0.000035039917,0.00029514224,0.34030494,0.0000018193264,0.0000021670148,0.000122057994],"about_ca_topic_score_codex":0.000085111096,"about_ca_topic_score_gemma":0.00014763084,"teacher_disagreement_score":0.19321404,"about_ca_system_score_codex":0.000113011156,"about_ca_system_score_gemma":0.00010846826,"threshold_uncertainty_score":0.6466034},"labels":[],"label_agreement":null},{"id":"W2070481877","doi":"10.1159/000206984","title":"Identical Twin Marrow Transplantation in Multiple Myeloma","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Misericordia Community Hospital","funders":"CYTED Ciencia y Tecnología para el Desarrollo","keywords":"Medicine; Melphalan; Multiple myeloma; Cyclophosphamide; Prednisone; Asymptomatic; Bone marrow; Total body irradiation; Exacerbation; Chemotherapy; Transplantation; Surgery; Pathology; Internal medicine","score_opus":0.03859330116210157,"score_gpt":0.3179083093178544,"score_spread":0.27931500815575283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070481877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914262,0.00010886137,0.00008488687,0.0036159952,0.00003183979,0.00052714534,0.0000072249895,0.00008793006,0.004109887],"genre_scores_gemma":[0.9973887,0.00013558869,0.0017420334,0.00041175063,0.000024753159,0.000031869404,0.00008614586,0.000008547927,0.00017056527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998603,0.000075815566,0.0003054543,0.00029622897,0.00030379178,0.00041572034],"domain_scores_gemma":[0.9993363,0.00016141981,0.00004088652,0.00022995679,0.000036714482,0.00019469266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014403847,0.00015539279,0.0003581899,0.00015998953,0.000059772166,0.000021255335,0.00010138204,0.00013125097,0.00026658375],"category_scores_gemma":[0.00032380936,0.00011515497,0.00008773178,0.00022311477,0.000056661873,0.00011155482,0.000012392432,0.00020486598,0.00017466208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048589334,0.0023361174,0.8774802,0.00025490992,0.00011243694,0.021861132,0.0006483526,0.000002900293,0.0475464,0.0017040643,0.0016402596,0.04155427],"study_design_scores_gemma":[0.004417641,0.0005396434,0.98267424,0.00010075732,0.00003351726,0.0009666548,0.000053725373,0.0006815642,0.009387264,0.0006982552,0.00032054173,0.00012621624],"about_ca_topic_score_codex":0.000045244855,"about_ca_topic_score_gemma":0.00007651015,"teacher_disagreement_score":0.105193995,"about_ca_system_score_codex":0.000057570996,"about_ca_system_score_gemma":0.000039980234,"threshold_uncertainty_score":0.46958834},"labels":[],"label_agreement":null},{"id":"W2071149898","doi":"10.1002/gcc.22049","title":"Differential nuclear organization of translocation‐prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma","year":2013,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Chromosomal translocation; Multiple myeloma; Gene; Differential (mechanical device); Biology; Cancer research; Medicine; Molecular biology; Pathology; Immunology; Genetics; Physics","score_opus":0.011122615583370951,"score_gpt":0.23709907292349452,"score_spread":0.22597645734012356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071149898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747694,0.0009433047,0.0000572874,0.00016835037,0.00006970667,0.001085652,0.0001395237,0.000025567022,0.000033684253],"genre_scores_gemma":[0.9968641,0.0017752608,0.0003746726,0.00005611458,0.000080348014,0.00010934512,0.000375003,0.000055614815,0.0003095879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985214,0.000039838036,0.00028663693,0.00038931708,0.00044436482,0.00031843007],"domain_scores_gemma":[0.999051,0.000027530139,0.00011967379,0.0002503467,0.00034954053,0.00020193495],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000019835881,0.00024886365,0.00046391465,0.00010145501,0.000088032,0.000039887662,0.00009262663,0.000084780535,0.0033628952],"category_scores_gemma":[0.00000600044,0.00015052302,0.00002802224,0.00031244627,0.00012603987,0.00014911781,0.00003367518,0.00007469108,0.000021714442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001635612,0.00097521127,0.86616063,0.00029609018,0.0004818423,0.000031351643,0.0013062168,0.000048777085,0.055968758,0.0000072643743,0.00019624672,0.072891995],"study_design_scores_gemma":[0.012781149,0.0008358055,0.8360343,0.00045962865,0.00015125649,0.000006314821,0.00030154455,0.00029891613,0.14837468,0.0000063998073,0.0004888908,0.00026112725],"about_ca_topic_score_codex":0.0048934366,"about_ca_topic_score_gemma":0.0019777974,"teacher_disagreement_score":0.09240592,"about_ca_system_score_codex":0.00011059162,"about_ca_system_score_gemma":0.00018003327,"threshold_uncertainty_score":0.99754816},"labels":[],"label_agreement":null},{"id":"W2072018052","doi":"10.1111/j.1365-2141.2004.05207.x","title":"A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Incidence (geometry); Population; Epidemiology; Multiple myeloma; Cancer registry; Demography; Clinical trial; Pediatrics; Internal medicine; Environmental health","score_opus":0.042833296858364185,"score_gpt":0.3484106212694448,"score_spread":0.3055773244110806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072018052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935992,0.0007680492,0.000056190096,0.0050131665,0.000035090627,0.0005104682,0.000003238099,0.000002121631,0.000012476369],"genre_scores_gemma":[0.9989654,0.00011645316,0.0006172917,0.0002601097,0.000018495051,0.000009103427,0.000004567651,0.000006184707,0.0000023925957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985518,0.00022417954,0.00055368204,0.000117912066,0.00037243322,0.00018000565],"domain_scores_gemma":[0.99923646,0.00018001809,0.00020561636,0.00006879665,0.00020270784,0.00010641565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080631796,0.00006684389,0.000446815,0.00026145088,0.000039838957,0.000009172363,0.00007897672,0.000032577776,0.000003542208],"category_scores_gemma":[0.00089137995,0.000056998626,0.000027206115,0.0003552963,0.000029512144,0.00006786437,0.00004337823,0.00020572476,0.0000010352667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060550985,0.00054484454,0.9860469,0.00005945256,0.000030380736,0.007870803,0.00104965,0.00009753367,0.00003008731,0.000076698234,0.000020721523,0.0035674288],"study_design_scores_gemma":[0.0065029683,0.0006864399,0.9518962,0.00055459625,0.000005327732,0.038852334,0.0008619734,0.000060282604,0.000018181854,0.0005243304,0.00000295304,0.00003443126],"about_ca_topic_score_codex":0.014877303,"about_ca_topic_score_gemma":0.10899626,"teacher_disagreement_score":0.09411895,"about_ca_system_score_codex":0.00015699971,"about_ca_system_score_gemma":0.0002708037,"threshold_uncertainty_score":0.9916827},"labels":[],"label_agreement":null},{"id":"W2072135692","doi":"10.1046/j.1365-2141.2002.03407.x","title":"Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma","year":2002,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Positron emission tomography; Medicine; Occult; Multiple myeloma; Magnetic resonance imaging; Deoxyglucose; Radiology; Nuclear medicine; Plasmacytoma; Transplantation; Pathology; Internal medicine","score_opus":0.019733550068863362,"score_gpt":0.27477393162081304,"score_spread":0.2550403815519497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072135692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750088,0.022179788,0.0012742751,0.00084332906,0.00012991925,0.00050351775,0.000022409007,0.000008713948,0.000029285025],"genre_scores_gemma":[0.99816865,0.0010040565,0.0006178936,0.000060514212,0.00006500225,0.000024717283,0.0000056869944,0.000016253756,0.000037251844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986684,0.00011234148,0.0005152395,0.00014321128,0.0002636287,0.00029719368],"domain_scores_gemma":[0.99875975,0.00036814107,0.0002466426,0.00014072978,0.00025930806,0.00022543933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026869125,0.000107701206,0.00041609397,0.0002575708,0.000114442155,0.000018637369,0.00012371496,0.000054710003,0.00004754293],"category_scores_gemma":[0.00084245537,0.00008501985,0.00026298114,0.00019618757,0.00012449897,0.0001192796,0.000027843884,0.00024609212,0.0000021595886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036204937,0.0013974339,0.45376518,0.00041191955,0.0003314544,0.024423817,0.00022024485,0.000019041001,0.0326887,0.000011052789,0.0012603366,0.48185033],"study_design_scores_gemma":[0.017954662,0.0008399991,0.8541409,0.0014940439,0.00035507706,0.06654283,0.0002780249,0.021859968,0.03442277,0.00026529914,0.0016410922,0.00020535759],"about_ca_topic_score_codex":0.00014231644,"about_ca_topic_score_gemma":0.0000861679,"teacher_disagreement_score":0.48164496,"about_ca_system_score_codex":0.000049661427,"about_ca_system_score_gemma":0.00003935512,"threshold_uncertainty_score":0.3467009},"labels":[],"label_agreement":null},{"id":"W2073121786","doi":"10.1002/gcc.21959","title":"Differential positioning and close spatial proximity of translocation‐prone genes in nonmalignant B‐cells from multiple myeloma patients","year":2012,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; Alberta Cancer Foundation; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Chromosomal translocation; Biology; Multiple myeloma; Locus (genetics); Gene; Population; Genetics; Cancer research; Immunology; Medicine","score_opus":0.015761802605652502,"score_gpt":0.267471784169444,"score_spread":0.2517099815637915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073121786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865517,0.01228984,0.000089443274,0.0000624712,0.00013249472,0.00059135025,0.00025875133,0.000010223824,0.000013713181],"genre_scores_gemma":[0.9942957,0.0047304463,0.0004057421,0.000020838459,0.00020393009,0.000121819074,0.00017413631,0.0000173387,0.000030012587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892515,0.00004268185,0.00024466065,0.00024530443,0.00023495188,0.00030724742],"domain_scores_gemma":[0.9995001,0.00003930544,0.00007169791,0.00013463892,0.00006221995,0.00019201485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042003507,0.00015980494,0.0003117768,0.00007309324,0.00007070509,0.000013580758,0.000037497128,0.000076319295,0.00017127434],"category_scores_gemma":[0.00000789652,0.00012613756,0.000042228774,0.00007483605,0.00008662135,0.00013757966,0.000041470863,0.000068598354,0.0000017449845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029684103,0.00036680253,0.6406764,0.00010604308,0.00008436547,0.0000032048526,0.000543521,0.0000013926535,0.09560326,0.000003013575,0.0000034703069,0.2623117],"study_design_scores_gemma":[0.0043967543,0.00014047776,0.74617684,0.00015100269,0.00005838477,0.0000019817192,0.000052617506,0.000513271,0.2483183,0.000010378106,0.00007923438,0.000100786056],"about_ca_topic_score_codex":0.003624919,"about_ca_topic_score_gemma":0.0007432118,"teacher_disagreement_score":0.26221094,"about_ca_system_score_codex":0.00005468761,"about_ca_system_score_gemma":0.000050402887,"threshold_uncertainty_score":0.54798174},"labels":[],"label_agreement":null},{"id":"W2073718048","doi":"10.1016/s0753-3322(01)00143-3","title":"Myeloma: what have we learned?","year":2001,"lang":"en","type":"review","venue":"Biomedicine & Pharmacotherapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immune system; Biology; Flow cytometry; Myeloid; Cancer research; Haematopoiesis; Multiple myeloma; Immunology; Cell biology; Stem cell","score_opus":0.16465999138351176,"score_gpt":0.47470020466937884,"score_spread":0.31004021328586706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073718048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013671962,0.9906822,0.000035289442,0.0025444247,0.0009780464,0.0033704622,0.000063089334,0.00026910857,0.002043745],"genre_scores_gemma":[0.000008508634,0.97184473,0.00022192344,0.0010094334,0.0031435667,0.00049857306,0.0009869863,0.0003076044,0.021978678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948911,0.00031108313,0.001112972,0.001162462,0.0012884878,0.0012338631],"domain_scores_gemma":[0.9968948,0.0002881665,0.000430928,0.0010005148,0.00017099937,0.0012145947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00046301298,0.0011945523,0.0035836091,0.0012718277,0.0001669622,0.00012807791,0.0004901731,0.00052472204,0.0063749533],"category_scores_gemma":[0.00004264355,0.00078372797,0.0011057829,0.001236471,0.0003761099,0.00027837278,0.00008797795,0.0010920565,0.001521408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002926287,0.00062983856,0.000033166252,0.008981561,0.0020358583,0.0023295288,0.000091599264,1.6593901e-8,0.000092354516,0.0000041688177,0.020194286,0.965315],"study_design_scores_gemma":[0.007976055,0.000907144,0.000013979584,0.025455259,0.0018633443,0.0012553653,0.00007177352,0.000017201297,0.000056885518,0.000011470496,0.9618339,0.0005376004],"about_ca_topic_score_codex":0.00006478116,"about_ca_topic_score_gemma":0.0000035965736,"teacher_disagreement_score":0.9647774,"about_ca_system_score_codex":0.00055809447,"about_ca_system_score_gemma":0.0007860707,"threshold_uncertainty_score":0.99946135},"labels":[],"label_agreement":null},{"id":"W2074789428","doi":"10.1016/j.clon.2013.11.022","title":"Bortezomib in Multiple Myeloma: A Practice Guideline","year":2013,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Sunnybrook Health Science Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"Cancer Care Ontario","keywords":"Medicine; Bortezomib; Multiple myeloma; Guideline; Internal medicine; Oncology; Cochrane Library; Proteasome inhibitor; Adverse effect; Transplantation; Sorafenib; Intensive care medicine; Hematology; Meta-analysis; Pathology","score_opus":0.14201219086985734,"score_gpt":0.499882040844831,"score_spread":0.3578698499749737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074789428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87182873,0.0004697582,0.00025105473,0.06391398,0.000579397,0.0021872043,0.000007437026,0.000109072826,0.060653348],"genre_scores_gemma":[0.941768,0.00030220492,0.04507697,0.010360747,0.00051967846,0.00023634925,0.00006823143,0.000026039703,0.0016418146],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997001,0.00048637026,0.0012794117,0.00044987915,0.00026147085,0.00052190153],"domain_scores_gemma":[0.9941604,0.0042039095,0.00020671819,0.0004490551,0.00040637702,0.00057350844],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014264456,0.00015811578,0.0007280481,0.00012444273,0.000042904383,0.000013068241,0.00013732609,0.00036968573,0.0012479512],"category_scores_gemma":[0.021174682,0.000119275115,0.00017104509,0.00022723518,0.00023593812,0.00017545656,0.00012965994,0.00070715294,0.0031155685],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001828925,0.005070121,0.43723485,0.0000180447,0.00019941604,0.0019535732,0.000050526614,0.0000024265908,0.0002780346,0.00008340601,0.070546344,0.48273435],"study_design_scores_gemma":[0.014224532,0.002756904,0.5467358,0.00002161749,0.000057055502,0.00013914489,0.00016217763,0.0030928159,0.000035326957,0.00015918422,0.43251207,0.00010334765],"about_ca_topic_score_codex":0.0010390342,"about_ca_topic_score_gemma":0.00031102714,"teacher_disagreement_score":0.482631,"about_ca_system_score_codex":0.00024034342,"about_ca_system_score_gemma":0.0006324189,"threshold_uncertainty_score":0.999665},"labels":[],"label_agreement":null},{"id":"W2074995740","doi":"10.1038/bmt.2014.237","title":"Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents","year":2014,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Multivariate analysis; Oncology; Proportional hazards model; Lenalidomide; Surgery","score_opus":0.028362813387897822,"score_gpt":0.27690534367638353,"score_spread":0.24854253028848572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074995740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992616,0.00005045331,0.0047608404,0.00035692696,0.000066203844,0.0012020142,0.000650495,0.000015334572,0.0002817323],"genre_scores_gemma":[0.9961062,0.000023935692,0.003102674,0.000075187956,0.000043062537,0.00019366683,0.000285472,0.000022352444,0.0001474228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985755,0.00008872879,0.0004054798,0.00021975626,0.0004632449,0.00024725965],"domain_scores_gemma":[0.99911344,0.0003538638,0.00011053629,0.0002415096,0.000106340056,0.00007432383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038706255,0.00014384964,0.00030910812,0.000119713215,0.00003257618,0.000009895077,0.00008808196,0.0000879945,0.000038445658],"category_scores_gemma":[0.00010617078,0.00010471165,0.00013095525,0.00016605663,0.00006484056,0.0000923537,0.000006301338,0.00012048928,0.000004097837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021246506,0.0031561374,0.735189,0.0025797146,0.00031680506,0.00008864149,0.012870181,0.000016402339,0.21396478,0.00014436156,0.00015557157,0.010271895],"study_design_scores_gemma":[0.015949264,0.0009839913,0.9600061,0.00032551555,0.00017361867,0.00001857424,0.00007517085,0.0039010262,0.018333022,0.000037107075,0.00010498017,0.00009160016],"about_ca_topic_score_codex":0.00046912013,"about_ca_topic_score_gemma":0.0003390554,"teacher_disagreement_score":0.22481711,"about_ca_system_score_codex":0.00003353546,"about_ca_system_score_gemma":0.00004630507,"threshold_uncertainty_score":0.4270017},"labels":[],"label_agreement":null},{"id":"W2075175917","doi":"10.1182/blood-2002-06-1675","title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Chromosomal translocation; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Fibroblast growth factor receptor 3; Biology; Bone marrow; Hazard ratio; Breakpoint; Internal medicine; Exon; Medicine; Molecular biology; Gastroenterology; Pathology; Immunology; Antibody; Monoclonal; Monoclonal antibody; Receptor; Fibroblast growth factor; Genetics; Gene","score_opus":0.038379939079467,"score_gpt":0.31034755893236465,"score_spread":0.27196761985289764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075175917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967003,0.00026064683,0.000022279248,0.000043056545,0.000056993165,0.0010124837,0.00007166217,0.000035776324,0.0017968361],"genre_scores_gemma":[0.99677026,0.000029695684,0.0024402726,0.000048300753,0.000041694228,0.00009014439,0.000027425122,0.0000302361,0.0005219683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824417,0.00015068612,0.00030482045,0.00040999133,0.00046503975,0.00042530306],"domain_scores_gemma":[0.99883753,0.0001801074,0.00009031439,0.00043646025,0.0001418083,0.0003137598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012059795,0.00020770727,0.0003685641,0.00023776207,0.000058205664,0.000007777892,0.00009884446,0.000118380536,0.0006965213],"category_scores_gemma":[0.0009733635,0.00016478951,0.00010352015,0.0002860654,0.00008271669,0.00019349104,0.000037428734,0.0002114498,0.00007920923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044553785,0.004541153,0.909397,0.00009737612,0.00012644188,0.00047671018,0.0015597185,0.0000012431672,0.082316436,0.000026887517,0.00010972242,0.0009017557],"study_design_scores_gemma":[0.012880121,0.0008311071,0.5779034,0.0001606493,0.00006282578,0.00003260157,0.00039628329,0.00005593686,0.40705493,0.00007155816,0.00041641647,0.0001342003],"about_ca_topic_score_codex":0.00017781435,"about_ca_topic_score_gemma":0.00008936556,"teacher_disagreement_score":0.33149365,"about_ca_system_score_codex":0.00006148838,"about_ca_system_score_gemma":0.00016240167,"threshold_uncertainty_score":0.762642},"labels":[],"label_agreement":null},{"id":"W2075520012","doi":"10.1182/blood-2008-09-178350","title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Krebshilfe; Universität Heidelberg; Stem Cell Network","keywords":"Aurora inhibitor; Multiple myeloma; Cancer research; Aurora kinase; Chromosome instability; Biology; Fluorescence in situ hybridization; Gene expression profiling; Tissue microarray; Cell cycle; Medicine; Internal medicine; Cancer; Gene expression; Immunology; Genetics; Gene","score_opus":0.033893588809122834,"score_gpt":0.3000409426158555,"score_spread":0.26614735380673266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075520012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974726,0.00046057208,0.00010307547,0.00010951645,0.000016138765,0.0011872855,0.00023074236,0.00003451524,0.00038556423],"genre_scores_gemma":[0.9948635,0.0001607648,0.004432313,0.000010871016,0.0000579945,0.00007092688,0.00026094852,0.000013710072,0.0001289826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900943,0.000033324195,0.00029113726,0.0002025711,0.00022890161,0.00023466333],"domain_scores_gemma":[0.99911654,0.00014498293,0.00016138087,0.00026836738,0.00017678096,0.00013197317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055027223,0.00014531195,0.00038205486,0.00013817333,0.000045666555,0.0000038554904,0.000033162472,0.00006604346,0.000031668176],"category_scores_gemma":[0.00025751386,0.00011004898,0.00018687181,0.00014326068,0.000047899553,0.000041893614,0.00000706525,0.00003381681,0.000005387391],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079204235,0.027906643,0.26198533,0.00029301943,0.0013216228,0.0002165329,0.00080321863,0.000011785442,0.498888,0.00016264652,0.00018719293,0.20030358],"study_design_scores_gemma":[0.027393285,0.0088194,0.28199694,0.00008215788,0.00039895315,0.000012113607,0.000070545306,0.0002833,0.68053526,0.00013195956,0.00020211266,0.00007396597],"about_ca_topic_score_codex":0.00017311789,"about_ca_topic_score_gemma":0.00003633326,"teacher_disagreement_score":0.20022961,"about_ca_system_score_codex":0.000039940238,"about_ca_system_score_gemma":0.000071659015,"threshold_uncertainty_score":0.44876674},"labels":[],"label_agreement":null},{"id":"W2075891452","doi":"10.3109/10428194.2011.608449","title":"Genomic stratification of multiple myeloma treated with novel agents","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Multiple myeloma; Stratification (seeds); Risk stratification; Computational biology; Medicine; Biology; Oncology; Internal medicine; Cancer research; Bioinformatics","score_opus":0.054621532574841286,"score_gpt":0.30317847664759484,"score_spread":0.24855694407275356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075891452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11237502,0.878248,0.0000775024,0.0000066571206,0.0001232677,0.003846025,0.0007600459,0.00023535403,0.0043281447],"genre_scores_gemma":[0.06391617,0.92846847,0.001541394,0.000052215175,0.00021695935,0.0006446518,0.0023954494,0.00033798238,0.0024267077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437624,0.0002129952,0.0016961918,0.001673316,0.00083159114,0.0012096376],"domain_scores_gemma":[0.9954223,0.0003772157,0.001179625,0.0017003742,0.0003394876,0.0009809872],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00029905047,0.001552423,0.0038004962,0.00084376615,0.00028632255,0.000097823366,0.0005758442,0.0010994012,0.00015594775],"category_scores_gemma":[0.00012889279,0.0011295634,0.0007680983,0.00091358554,0.0006055031,0.00023731448,0.0002265516,0.00027819656,0.00014362448],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011131119,0.000683957,0.0032653217,0.0116143795,0.002290481,0.00044018315,0.00020691198,0.0000010786649,0.0001975127,0.00019166613,0.00028181454,0.97971356],"study_design_scores_gemma":[0.047067504,0.002545302,0.1089882,0.022489652,0.0082881935,0.005705988,0.00019211095,0.0012759991,0.0010400155,0.000029361257,0.79987466,0.0025030063],"about_ca_topic_score_codex":0.0028628604,"about_ca_topic_score_gemma":0.00011643354,"teacher_disagreement_score":0.9772106,"about_ca_system_score_codex":0.006990098,"about_ca_system_score_gemma":0.007785958,"threshold_uncertainty_score":0.9997224},"labels":[],"label_agreement":null},{"id":"W2076039316","doi":"10.2165/00129785-200505010-00003","title":"Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma","year":2005,"lang":"en","type":"review","venue":"American Journal of PharmacoGenomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Kinome; Pharmacogenomics; Multiple myeloma; Disease; Bone marrow; Medicine; Computational biology; Bioinformatics; Oncology; Biology; Internal medicine; Gene; Genetics","score_opus":0.07745639155557346,"score_gpt":0.40906025264307083,"score_spread":0.3316038610874974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076039316","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042906754,0.9544552,0.0000394236,0.000040226532,0.00015172656,0.0021889713,0.00011909847,0.000011540053,0.000087057386],"genre_scores_gemma":[0.019394198,0.9614522,0.017985713,0.00007649332,0.00077310955,0.00012469808,0.00003109929,0.00014203624,0.000020458243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964346,0.000198531,0.0017066377,0.0005119598,0.00034301085,0.00080525037],"domain_scores_gemma":[0.99645406,0.0010708194,0.0014903144,0.00021140577,0.00022317888,0.0005502258],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006933232,0.00062344596,0.0028288965,0.0011163864,0.00006974748,0.000041187548,0.00034119943,0.00010824293,0.00001579202],"category_scores_gemma":[0.00034749453,0.0005269001,0.00042563892,0.0007651479,0.00028702352,0.00019130117,0.000109838045,0.00088770944,0.000007202514],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007016183,0.0003281558,0.006637807,0.0030143887,0.00029847925,0.0006427003,0.00010838231,0.000041169784,0.00035030645,0.0000011313907,0.000017769475,0.9878581],"study_design_scores_gemma":[0.014881818,0.002339334,0.0012859735,0.008232323,0.0017774208,0.0037828966,0.00015566891,0.0023905502,0.00025301505,0.00001979386,0.9640436,0.0008375825],"about_ca_topic_score_codex":0.000017224207,"about_ca_topic_score_gemma":0.00002672984,"teacher_disagreement_score":0.9870205,"about_ca_system_score_codex":0.0009401902,"about_ca_system_score_gemma":0.0011277326,"threshold_uncertainty_score":0.99971825},"labels":[],"label_agreement":null},{"id":"W2077343517","doi":"10.4065/80.12.1578","title":"Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation","year":2005,"lang":"en","type":"article","venue":"Mayo Clinic Proceedings","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prednisone; Regimen; Surgery; Multiple myeloma; Tolerability; Cyclophosphamide; Autologous stem-cell transplantation; Transplantation; Internal medicine; Salvage therapy; Chemotherapy; Adverse effect","score_opus":0.020887720494187485,"score_gpt":0.30532536285424433,"score_spread":0.28443764236005686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077343517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944496,0.0006675412,0.0000883813,0.00041553797,0.000096763404,0.003474736,0.00010635602,0.00016617372,0.0005348671],"genre_scores_gemma":[0.99193794,0.00071301364,0.0022144155,0.00018681327,0.00011898344,0.0011280575,0.00013820159,0.00006300341,0.0034995843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997845,0.000044873075,0.00048820022,0.0007946684,0.00025134755,0.0005759336],"domain_scores_gemma":[0.998713,0.00030441702,0.00016334857,0.00015075176,0.00018162417,0.0004868172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003684191,0.00039697776,0.0005925221,0.00015285911,0.00017764524,0.00009063063,0.00007712537,0.00022087837,0.000054949123],"category_scores_gemma":[0.00004498029,0.00031774203,0.00010861736,0.00012665143,0.00014863184,0.00033574968,0.0000276517,0.00018029808,0.00003826408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021295263,0.0015709706,0.73818606,0.0008673429,0.0003924135,0.00021207485,0.0046695564,0.0000022047166,0.007639581,0.000014157016,0.00031651335,0.22483386],"study_design_scores_gemma":[0.04781504,0.0097696725,0.86453825,0.00023160997,0.000684508,0.0002617982,0.00047919183,0.0145200705,0.056074943,0.00005104546,0.0050602905,0.00051360007],"about_ca_topic_score_codex":0.00010378539,"about_ca_topic_score_gemma":0.000062843756,"teacher_disagreement_score":0.22432026,"about_ca_system_score_codex":0.00018715256,"about_ca_system_score_gemma":0.000059714286,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W2077682572","doi":"10.1038/leu.2013.172","title":"Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institute on Aging","keywords":"Nuclear export signal; Biology; Monoclonal gammopathy of undetermined significance; Cell cycle; Molecular biology; Cancer research; RNA interference; Nuclear protein; Gene expression; Apoptosis; Cell nucleus; Gene; RNA; Monoclonal antibody; Transcription factor; Monoclonal; Genetics; Antibody","score_opus":0.0668419449408269,"score_gpt":0.3649538393636502,"score_spread":0.2981118944228233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077682572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956933,0.0007506338,0.000037309124,0.0009142809,0.0001883287,0.0014354148,0.000013557003,0.00010763305,0.00085949525],"genre_scores_gemma":[0.9957173,0.000076454264,0.0023834347,0.0006141145,0.00027699288,0.00019266756,0.000041482712,0.000074317104,0.0006232667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715793,0.00023306074,0.00050578924,0.0005673943,0.00066331855,0.0008725204],"domain_scores_gemma":[0.9979506,0.00067254296,0.0000841613,0.00049469486,0.0004559921,0.00034197356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034291227,0.00033912584,0.0005614184,0.00023496588,0.0003449832,0.00010200144,0.0002130547,0.0001710471,0.00043720682],"category_scores_gemma":[0.0030129217,0.00023525843,0.00015200835,0.0005461556,0.00044462612,0.00033109318,0.0002455437,0.00061861385,0.00079340924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015517019,0.0010269964,0.7187224,0.0005660588,0.001963811,0.0042556575,0.011633675,0.00010351215,0.2474685,0.0001479147,0.010872098,0.0016876665],"study_design_scores_gemma":[0.0076535996,0.00067104865,0.9355469,0.0004355982,0.00018815414,0.00035025843,0.0071159406,0.007646446,0.036359075,0.0013104243,0.0021768776,0.00054568995],"about_ca_topic_score_codex":0.0015940757,"about_ca_topic_score_gemma":0.000058757265,"teacher_disagreement_score":0.21682449,"about_ca_system_score_codex":0.0016608344,"about_ca_system_score_gemma":0.00043371352,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W2077769986","doi":"10.1016/j.cellsig.2004.10.004","title":"The survival of IL-6-dependent myeloma cells critically relies on their capability to transit the G1 to S phase interval of the cell cycle","year":2004,"lang":"en","type":"article","venue":"Cellular Signalling","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"","keywords":"MAPK/ERK pathway; Cell biology; Apoptosis; Cell cycle; Biology; STAT protein; Kinase; Signal transduction; Cell growth; Cancer research; STAT3; Biochemistry","score_opus":0.023950594128669813,"score_gpt":0.287348940402089,"score_spread":0.26339834627341924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077769986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860129,0.00030716605,0.0076775504,0.0036970926,0.00019344197,0.0013573294,0.000075809745,0.000021174092,0.0006575683],"genre_scores_gemma":[0.9990934,0.00003477083,0.00027975938,0.00023959143,0.00008499495,0.000041965515,0.000005434718,0.0000332863,0.00018676341],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99758184,0.00026216454,0.0005172225,0.000356177,0.0008051869,0.0004774007],"domain_scores_gemma":[0.99772215,0.0007923485,0.00008018459,0.00082237256,0.00031441968,0.00026853266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097570586,0.00023797456,0.0003835865,0.000058106194,0.0002711539,0.000033624034,0.00055327074,0.000072999144,0.000049945796],"category_scores_gemma":[0.00033467155,0.00011165224,0.00032268267,0.00025399233,0.00025626374,0.00003040903,0.00011928826,0.00034599632,0.00003941209],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014934315,0.0011917946,0.00020536828,0.0001359669,0.00013845517,0.000038735045,0.0031000224,0.0040202276,0.98492414,0.0002891262,0.00001773056,0.004444988],"study_design_scores_gemma":[0.0023433606,0.0012696594,0.0007811267,0.0002214548,0.00007937753,0.0000022599204,0.0014225461,0.0003602119,0.99258864,0.00046395397,0.00035842633,0.00010897331],"about_ca_topic_score_codex":0.00016568857,"about_ca_topic_score_gemma":0.000116841285,"teacher_disagreement_score":0.013080566,"about_ca_system_score_codex":0.00012228038,"about_ca_system_score_gemma":0.00016977513,"threshold_uncertainty_score":0.45530462},"labels":[],"label_agreement":null},{"id":"W2077914150","doi":"10.1007/s40618-013-0027-8","title":"The effect of steroid pulse therapy on carbohydrate metabolism in multiple myeloma patients: a randomized crossover observational clinical study","year":2014,"lang":"en","type":"article","venue":"Journal of Endocrinological Investigation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"European Social Fund; European Commission; Magyar Diabetes Társaság; Semmelweis Egyetem; American Diabetes Association","keywords":"Dexamethasone; Crossover study; Internal medicine; Medicine; Endocrinology; Glucocorticoid; Carbohydrate metabolism; Gastroenterology; Diabetes mellitus; Placebo; Pathology","score_opus":0.08913928597437333,"score_gpt":0.3664419937593725,"score_spread":0.27730270778499916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077914150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732417,0.00017115274,0.000017559249,0.00069536566,0.00022883418,0.0014818243,0.0000039550227,0.000008448307,0.00006868898],"genre_scores_gemma":[0.9991252,0.00017216097,0.00018548717,0.00020585457,0.00019122958,0.00007214523,0.000012352263,0.00001104844,0.000024525873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99479014,0.0026134695,0.0013439452,0.00020055068,0.00077546306,0.00027643912],"domain_scores_gemma":[0.99259996,0.0058636763,0.00071257405,0.00023015466,0.00040207093,0.00019154641],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0023702343,0.00019334006,0.0009913302,0.00015831071,0.000096988224,0.00003546941,0.00017959073,0.00008201648,0.00001669219],"category_scores_gemma":[0.014118275,0.00008829311,0.00030633836,0.00023824211,0.0004395993,0.00013472805,0.00004089623,0.00052803964,0.000005177426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1240474,0.0007539318,0.85564625,0.000009873147,0.00033639066,0.00003400188,0.0000940968,0.00006670716,0.0009216263,0.00014642047,0.000034557965,0.017908748],"study_design_scores_gemma":[0.21699764,0.006285295,0.7719716,0.000047222602,0.00006639449,0.0000047453955,0.000011807838,0.00072501437,0.003301612,0.00043768118,0.00009632934,0.000054651417],"about_ca_topic_score_codex":0.000043932054,"about_ca_topic_score_gemma":0.000012841949,"teacher_disagreement_score":0.09295024,"about_ca_system_score_codex":0.000062574756,"about_ca_system_score_gemma":0.000067709894,"threshold_uncertainty_score":0.9941862},"labels":[],"label_agreement":null},{"id":"W2079513879","doi":"10.1182/blood-2010-06-292243","title":"Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"National Cancer Institute; Terry Fox Foundation; Alberta Cancer Foundation; Multiple Myeloma Research Foundation; Georgia Cancer Coalition","keywords":"Integrin; Bortezomib; Homing (biology); Focal adhesion; Cell biology; Fibronectin; Cancer research; Cell adhesion; Cell adhesion molecule; Cell migration; Biology; Gene silencing; Transplantation; Cell; Chemistry; Immunology; Signal transduction; Multiple myeloma; Extracellular matrix; Medicine; Internal medicine","score_opus":0.03439741748884629,"score_gpt":0.2509290326101518,"score_spread":0.21653161512130553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079513879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976616,0.00029191628,0.000033480293,0.00005706857,0.000021285176,0.0004042651,0.0000128874135,0.00003473484,0.0014827916],"genre_scores_gemma":[0.9961381,0.00014472292,0.0031696088,0.000019254465,0.00002816698,0.00002074601,0.00013109791,0.000014127749,0.0003341728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914247,0.00004630676,0.00023138296,0.00019749007,0.00022450527,0.00015785269],"domain_scores_gemma":[0.99928564,0.000087633256,0.000082849016,0.00022316349,0.00016037773,0.00016031988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010747769,0.00010762844,0.00018398654,0.00013109336,0.00004320383,0.000004976763,0.00004327797,0.00008487624,0.00015471061],"category_scores_gemma":[0.0003004224,0.000081964026,0.000041977553,0.0001458595,0.000058715592,0.000079736186,0.000035958514,0.00008432203,0.000039516686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032213953,0.0009911032,0.72908634,0.000102294245,0.000054401462,0.000023940336,0.0006836428,6.381234e-8,0.26616246,0.00001710731,0.0001395256,0.0024169993],"study_design_scores_gemma":[0.004008015,0.0003580172,0.58868533,0.00005404737,0.00005228183,0.000012419376,0.00007564645,0.00015594595,0.40641907,0.000043140608,0.00009174912,0.00004434506],"about_ca_topic_score_codex":0.0004882745,"about_ca_topic_score_gemma":0.00021981752,"teacher_disagreement_score":0.14040099,"about_ca_system_score_codex":0.000012873509,"about_ca_system_score_gemma":0.0000444305,"threshold_uncertainty_score":0.3342396},"labels":[],"label_agreement":null},{"id":"W2079620495","doi":"10.1016/j.carj.2012.08.002","title":"Extramedullary Multiple Myeloma in the Head and Neck: A Pictorial Essay","year":2013,"lang":"en","type":"review","venue":"Canadian Association of Radiologists Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Head and neck; Multiple myeloma; Radiology; Surgery; Internal medicine","score_opus":0.05204749029345573,"score_gpt":0.34203127213230966,"score_spread":0.2899837818388539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079620495","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029942608,0.9936443,0.000003590841,0.0006329231,0.00047629554,0.0012266289,0.00016966328,0.00000651274,0.0008458421],"genre_scores_gemma":[0.0052962215,0.9926227,0.00028583765,0.00010311383,0.0008700535,0.000071501134,0.00019360647,0.000026658829,0.0005303219],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709255,0.0008458741,0.0007276159,0.00023842235,0.00046546783,0.0006300774],"domain_scores_gemma":[0.99727935,0.00097284536,0.0006927384,0.00024069165,0.00018776857,0.0006266009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013998769,0.0002935556,0.0013349386,0.0005513489,0.00015542941,0.000097275886,0.0002619335,0.0005650058,0.000118913325],"category_scores_gemma":[0.0033729195,0.00018109422,0.00032284454,0.00029601384,0.00009248509,0.00008673259,0.000018051367,0.0012127451,0.000024618399],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027045762,0.0000708953,0.07153002,0.001002026,0.0005690932,0.00069095334,0.00023622974,2.4762278e-7,3.2639264e-7,0.00004791791,0.012607961,0.9132173],"study_design_scores_gemma":[0.0024947647,0.0002728314,0.06426415,0.002480634,0.00027084292,0.0014381618,0.00005474639,0.000012454052,1.09333186e-7,0.000052804167,0.92849165,0.00016687234],"about_ca_topic_score_codex":0.009603974,"about_ca_topic_score_gemma":0.03708577,"teacher_disagreement_score":0.91588366,"about_ca_system_score_codex":0.0035360353,"about_ca_system_score_gemma":0.0036519454,"threshold_uncertainty_score":0.99699116},"labels":[],"label_agreement":null},{"id":"W2080047675","doi":"10.2217/ahe.11.61","title":"Lenalidomide: From Relapsed/Refractory Multiple Myeloma to Upfront Therapy","year":2011,"lang":"en","type":"article","venue":"Aging Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Alberta Hospital","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Oncology; Dexamethasone; Refractory (planetary science); Internal medicine; Maintenance therapy; Bortezomib; Chemotherapy","score_opus":0.10050324903326728,"score_gpt":0.35154117354012115,"score_spread":0.25103792450685386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080047675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98972017,0.0025406983,0.0005047784,0.003546334,0.00026411936,0.0010826095,0.000047276815,0.00019004624,0.002103968],"genre_scores_gemma":[0.98349917,0.00061297003,0.00998413,0.0046678823,0.00022459232,0.00007222242,0.000090354326,0.000050533028,0.00079816993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979756,0.00014204184,0.0003392264,0.00045873725,0.00039975718,0.0006846418],"domain_scores_gemma":[0.99817866,0.0001496152,0.00009168274,0.0005938369,0.00008079564,0.0009054253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032720703,0.0002137474,0.00040920742,0.00016394937,0.00018110192,0.000016354048,0.00014373269,0.0000674981,0.0006029967],"category_scores_gemma":[0.00014566592,0.00016829943,0.000099236204,0.00016762399,0.000040399915,0.000093680734,0.0000549638,0.00028253964,0.00071063946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024634684,0.0010685992,0.55627674,0.00006303548,0.00032475893,0.00032249757,0.0082802735,7.8064335e-7,0.002576737,0.00005034727,0.011852889,0.41671988],"study_design_scores_gemma":[0.007524902,0.0013299343,0.9514638,0.00020512512,0.000011627202,0.000013833868,0.0002712341,0.00011152226,0.0044019534,0.00012126104,0.034359865,0.00018490719],"about_ca_topic_score_codex":0.018570337,"about_ca_topic_score_gemma":0.00057796837,"teacher_disagreement_score":0.41653496,"about_ca_system_score_codex":0.00032587157,"about_ca_system_score_gemma":0.00037791848,"threshold_uncertainty_score":0.9879651},"labels":[],"label_agreement":null},{"id":"W2081434852","doi":"10.1016/j.leukres.2013.06.020","title":"t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Multiple myeloma; Bortezomib; Cohort; Internal medicine; CD20; Incidence (geometry); Medicine; Plasma cell leukemia; Population; Oncology; Immunology; Gastroenterology; Lymphoma","score_opus":0.06183816214560683,"score_gpt":0.32980931248744055,"score_spread":0.2679711503418337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081434852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942372,0.0005322257,0.000027126309,0.00083387655,0.00013470468,0.0022158797,0.00012751862,0.00020472435,0.001686741],"genre_scores_gemma":[0.98011434,0.000118245196,0.00040168522,0.000082223225,0.00016174778,0.0006042485,0.0008567703,0.000085739375,0.017575005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99404514,0.00058173167,0.00058934564,0.0008159764,0.002082169,0.0018856092],"domain_scores_gemma":[0.99548644,0.0012016182,0.00014934958,0.0010512647,0.0013718781,0.0007394642],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009645765,0.00046520372,0.0008138101,0.00038254962,0.00069509115,0.00022323933,0.0005571492,0.00042025468,0.0016040222],"category_scores_gemma":[0.0051768934,0.000306892,0.00018998233,0.00087712175,0.00067084323,0.00024283417,0.0005661593,0.0019608098,0.0018458209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022241878,0.00095097173,0.9696213,0.00011543957,0.00065281754,0.0013802191,0.0001472294,0.0000010335145,0.0098989485,0.00013659529,0.0021518252,0.012719436],"study_design_scores_gemma":[0.0072980872,0.001289684,0.9876652,0.00016241093,0.000058521757,0.00008514186,0.00016409352,0.0005480827,0.0010742552,0.00007769779,0.001259256,0.0003175636],"about_ca_topic_score_codex":0.0055322414,"about_ca_topic_score_gemma":0.00045768562,"teacher_disagreement_score":0.01804391,"about_ca_system_score_codex":0.0027566864,"about_ca_system_score_gemma":0.0008473005,"threshold_uncertainty_score":0.9999383},"labels":[],"label_agreement":null},{"id":"W2082863510","doi":"10.1111/j.1365-2141.2012.09232.x","title":"An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib","year":2012,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Onyx Pharmaceuticals; Exelixis; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Carfilzomib; Medicine; Bortezomib; Nausea; Refractory (planetary science); Proteasome inhibitor; Adverse effect; Multiple myeloma; Internal medicine; Regimen; Phases of clinical research; Oncology; Clinical trial; Surgery","score_opus":0.04593809647162775,"score_gpt":0.33000503209728976,"score_spread":0.284066935625662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082863510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651355,0.00107154,0.000013579104,0.000034276814,0.00003897535,0.0021633937,0.000046401063,0.000014089483,0.00010421561],"genre_scores_gemma":[0.9983135,0.00009727148,0.0012657403,0.00004434099,0.000041774038,0.000044782362,0.000057159108,0.00006671128,0.00006871683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967397,0.00054516835,0.0010086849,0.0003691786,0.00064491277,0.00069237844],"domain_scores_gemma":[0.9973976,0.00019471232,0.0007497709,0.0003600993,0.00059742446,0.00070041866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048017304,0.00031491634,0.001538935,0.00036145526,0.00011272455,0.00006803144,0.00028512656,0.00015119888,0.00006767943],"category_scores_gemma":[0.0003530142,0.00023374385,0.000041007548,0.00026506014,0.00022678534,0.00072582375,0.00010333015,0.00044696764,0.000001452249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027984045,0.06932086,0.8501759,0.0001228172,0.00073048077,0.021977598,0.0012487059,0.0000014286552,0.0006407889,0.0000010088065,0.000121389305,0.02767495],"study_design_scores_gemma":[0.14049602,0.10660033,0.72686094,0.0014838306,0.00047005,0.020828672,0.0015803146,0.00003965203,0.0012663638,0.0000017632943,0.00009249482,0.00027959564],"about_ca_topic_score_codex":0.0009906247,"about_ca_topic_score_gemma":0.0024836035,"teacher_disagreement_score":0.123315014,"about_ca_system_score_codex":0.00021907578,"about_ca_system_score_gemma":0.00019515882,"threshold_uncertainty_score":0.9531797},"labels":[],"label_agreement":null},{"id":"W2083365324","doi":"10.1182/blood-2012-03-414359","title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Alberta; University of Calgary; University of Toronto","funders":"National Cancer Institute","keywords":"Carfilzomib; Bortezomib; Medicine; Multiple myeloma; Nausea; Proteasome inhibitor; Refractory (planetary science); Internal medicine; Adverse effect; Cohort; Clinical endpoint; Oncology; Surgery; Gastroenterology; Clinical trial","score_opus":0.06713614919153943,"score_gpt":0.33827399089045646,"score_spread":0.271137841698917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083365324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559236,0.00030909848,0.0000051799875,0.00002215845,0.00007948281,0.0034594727,0.00010030206,0.000048609938,0.0003833255],"genre_scores_gemma":[0.99777806,0.000019610326,0.0014414883,0.000051890576,0.00007754861,0.0002001538,0.00022136125,0.00007817519,0.00013170441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970594,0.0002790746,0.0005874318,0.0005917274,0.00072726497,0.00075508264],"domain_scores_gemma":[0.997807,0.00019323285,0.00026013592,0.00077117764,0.00024615283,0.0007222699],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003257446,0.0003874175,0.00074954255,0.0003065002,0.00012495324,0.000052562253,0.00027346707,0.00013023734,0.000090237016],"category_scores_gemma":[0.00034140746,0.00027391152,0.000029180035,0.0004056817,0.00012305017,0.0005911626,0.00020879535,0.0002902472,0.000011625928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009041026,0.25638416,0.7029325,0.00007519215,0.00045938208,0.00028855458,0.0026091048,4.367743e-7,0.017051937,0.0000020380955,0.000034076547,0.011121628],"study_design_scores_gemma":[0.22559416,0.074341185,0.6876617,0.00024624442,0.00047833277,0.000028783283,0.0018274627,0.00006850564,0.009176645,0.0000018394109,0.00022162384,0.0003535286],"about_ca_topic_score_codex":0.0008272829,"about_ca_topic_score_gemma":0.00059652363,"teacher_disagreement_score":0.21655314,"about_ca_system_score_codex":0.00017306168,"about_ca_system_score_gemma":0.0001397571,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W2083572039","doi":"10.1158/1538-7445.am2012-lb-499","title":"Abstract LB-499: Malignancy-sustaining characteristics of cancer-associated plasma: role of systemic cytokines in maintaining tumor latency","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cytokine; Malignancy; Multiple myeloma; Cancer; Internal medicine; Disease; Oncology; Immunology","score_opus":0.057754898910380326,"score_gpt":0.3924109688898448,"score_spread":0.33465606997946445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083572039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252343,0.0052466816,6.417272e-7,0.00011014391,0.00010029828,0.0008426461,0.0002270516,0.000023214809,0.0009258744],"genre_scores_gemma":[0.9976694,0.0013624748,0.00003771305,0.000008199555,0.00018300992,0.00038787271,0.00004833555,0.00005081855,0.0002521819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648255,0.00019925625,0.0006906338,0.0003031221,0.0010600686,0.0012643505],"domain_scores_gemma":[0.9978578,0.00038706727,0.00026988308,0.0003392611,0.0007869829,0.0003589944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015862066,0.0002056217,0.0007308505,0.0005888841,0.000091132424,0.000015326674,0.00023235516,0.00013334441,0.00036294962],"category_scores_gemma":[0.000941757,0.00017745228,0.000099032855,0.00084820244,0.00020046743,0.00015529171,0.00014604098,0.0006322338,0.000016060561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008902848,0.00042655997,0.83738005,0.00086747966,0.00020743223,0.00014484928,0.0015048255,0.000013460951,0.14758281,0.00011334389,0.00003863356,0.010830287],"study_design_scores_gemma":[0.0032096056,0.00027814644,0.92859906,0.004261282,0.000041812204,0.000015234083,0.0032247126,0.00028836698,0.059816256,0.000036467383,0.00007587834,0.00015317817],"about_ca_topic_score_codex":0.008665064,"about_ca_topic_score_gemma":0.00038329232,"teacher_disagreement_score":0.09121904,"about_ca_system_score_codex":0.0012023054,"about_ca_system_score_gemma":0.0011629844,"threshold_uncertainty_score":0.9979363},"labels":[],"label_agreement":null},{"id":"W2084420820","doi":"10.1007/s00520-015-2680-2","title":"Exercise compliance among patients with multiple myeloma undergoing chemotherapy: a retrospective study","year":2015,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Pain medicine; Multiple myeloma; Chemotherapy; Nursing research; Compliance (psychology); Retrospective cohort study; Internal medicine; Intensive care medicine; Oncology; Physical therapy; Emergency medicine; Nursing; Anesthesiology; Anesthesia","score_opus":0.038658530350095026,"score_gpt":0.3395678507722017,"score_spread":0.30090932042210666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084420820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950136,0.000492762,0.000010388043,0.000079054655,0.000109350876,0.0028144827,0.00010213286,0.000054894914,0.0013233281],"genre_scores_gemma":[0.99850225,0.000060298167,0.00022635337,0.00007370752,0.000053976193,0.00062859326,0.00009971433,0.000055216853,0.00029990025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785715,0.000058388418,0.00026870024,0.0005714993,0.00073997414,0.0005042921],"domain_scores_gemma":[0.99815613,0.000042636624,0.00012776838,0.00035526048,0.0009498662,0.0003683639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010550516,0.00026986076,0.0004931865,0.00015744884,0.00006542423,0.000024984816,0.00010705417,0.000066318826,0.00014648112],"category_scores_gemma":[0.00015905515,0.0002058205,0.00005871528,0.0004308758,0.00013847093,0.00021623202,0.00005612809,0.00025918277,0.000022616296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035427848,0.0009610727,0.97792625,0.000077879464,0.0001756187,0.00028443194,0.0071330443,0.000012578664,0.0000050058607,8.1500764e-7,0.00022970917,0.009650805],"study_design_scores_gemma":[0.022622025,0.0024165474,0.963825,0.0007064554,0.00005691044,0.0000011099884,0.009657737,0.00005907341,0.00034725518,0.000009384684,0.00008953916,0.00020896911],"about_ca_topic_score_codex":0.0019778966,"about_ca_topic_score_gemma":0.012166598,"teacher_disagreement_score":0.01907924,"about_ca_system_score_codex":0.0018150528,"about_ca_system_score_gemma":0.00061338214,"threshold_uncertainty_score":0.83931166},"labels":[],"label_agreement":null},{"id":"W2084542540","doi":"10.1182/blood-2009-06-229658","title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Melphalan; Bortezomib; Multiple myeloma; Regimen; Autologous stem-cell transplantation; Internal medicine; Transplantation; Surgery; Oncology","score_opus":0.006386028454849118,"score_gpt":0.2424116482619217,"score_spread":0.23602561980707257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084542540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815035,0.00005807828,0.000013449999,0.00007605369,0.000028732447,0.0015203058,0.00005476545,0.000027832455,0.000070455244],"genre_scores_gemma":[0.9995433,0.000009242916,0.00017187564,0.000041865882,0.000023833027,0.000058134217,0.000099937264,0.000017382657,0.000034427743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872285,0.00010633977,0.0002803913,0.00027229617,0.0003393991,0.00027870238],"domain_scores_gemma":[0.9993667,0.00006043773,0.00012012887,0.00024352902,0.00007797298,0.00013121156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011045441,0.00017606994,0.0003228289,0.00013494508,0.00009200683,0.00001386912,0.000090234134,0.000065044536,0.0000121355515],"category_scores_gemma":[0.000020237196,0.00011593191,0.000034004723,0.00025293118,0.000056228553,0.00009274642,0.000017911574,0.00017190755,0.0000026224363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033404585,0.011964553,0.9673577,0.00008310564,0.00017543913,0.00058463326,0.008135957,0.00000845201,0.0017100921,0.000003253475,0.0000037883747,0.0066325595],"study_design_scores_gemma":[0.094990775,0.008131882,0.889341,0.0001479412,0.00017821057,0.000056989888,0.0009441911,0.0000910312,0.006018123,0.000013377653,9.896662e-7,0.000085471765],"about_ca_topic_score_codex":0.00037712842,"about_ca_topic_score_gemma":0.000377707,"teacher_disagreement_score":0.09165032,"about_ca_system_score_codex":0.000051617022,"about_ca_system_score_gemma":0.00007538003,"threshold_uncertainty_score":0.4727566},"labels":[],"label_agreement":null},{"id":"W2085190236","doi":"10.1111/j.1365-2141.2004.05199.x","title":"Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Biology; Chromosomal translocation; Pathology; Immunoglobulin heavy chain; Central nervous system; Immunofluorescence; Chromosome 13; Interphase; Immunoglobulin light chain; Cancer research; Molecular biology; Antibody; Chromosome; Genetics; Immunology; Gene; Medicine; Endocrinology","score_opus":0.015568707168997865,"score_gpt":0.2584159840179656,"score_spread":0.24284727684896776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085190236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916598,0.006040802,0.00070072815,0.000517196,0.00038247276,0.00035288936,0.00006176782,0.000033526685,0.00025081672],"genre_scores_gemma":[0.9917085,0.0005203896,0.007418657,0.00005111004,0.0001893053,0.0000116533665,0.00003293635,0.00003330786,0.000034142962],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99750197,0.00015193093,0.0010037211,0.00021517779,0.0005059897,0.0006212067],"domain_scores_gemma":[0.9980838,0.00014331909,0.00050638727,0.00022567615,0.00057174877,0.0004691277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002353324,0.00018342392,0.0010126893,0.00028274377,0.00014561016,0.00002857726,0.00022348294,0.00017980336,0.00011476142],"category_scores_gemma":[0.0006720608,0.00018270526,0.00028746141,0.00024610988,0.00023243505,0.0001941755,0.00005413517,0.00045203074,0.000025522451],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090052444,0.003325274,0.24083258,0.003236593,0.0025580355,0.6611275,0.00067270745,0.00031491445,0.05293812,0.010613661,0.0013191587,0.022160945],"study_design_scores_gemma":[0.012807667,0.00096987217,0.3098903,0.003440262,0.00028992546,0.65945953,0.0004666453,0.00007770906,0.011568369,0.0007312038,0.00008037019,0.00021815037],"about_ca_topic_score_codex":0.0025045038,"about_ca_topic_score_gemma":0.0006864447,"teacher_disagreement_score":0.06905771,"about_ca_system_score_codex":0.00033578323,"about_ca_system_score_gemma":0.0005448145,"threshold_uncertainty_score":0.74505043},"labels":[],"label_agreement":null},{"id":"W2086061986","doi":"10.1038/leu.2013.350","title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","year":2013,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"National Cancer Institute","keywords":"Daratumumab; Lenalidomide; Medicine; Multiple myeloma; Combination therapy; Cancer research; Panobinostat; Pharmacology; Histone deacetylase; Immunology; Biology; Histone","score_opus":0.08683142709177934,"score_gpt":0.3427305704482578,"score_spread":0.25589914335647845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086061986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012502181,0.97989786,0.0016057972,0.00036571507,0.0007683939,0.0038020713,0.00008760274,0.000055770597,0.00091461325],"genre_scores_gemma":[0.01835936,0.9709096,0.00763092,0.00006189375,0.00044642098,0.00035231205,0.0009970973,0.00008077182,0.0011616083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731773,0.00009881006,0.0009426127,0.0006172389,0.0006518263,0.0003717889],"domain_scores_gemma":[0.9980356,0.0006729973,0.0005058069,0.0005451404,0.000055513334,0.00018490768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042421097,0.00039711254,0.001223927,0.00036491267,0.00004108691,0.00005364937,0.00031843915,0.0003737457,0.0001798885],"category_scores_gemma":[0.00036110473,0.0002655809,0.00023048071,0.00036458042,0.00005621555,0.00012761005,0.00024737287,0.0007613311,0.000042013173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010700176,0.000085879095,0.0028939077,0.0007006409,0.00030614054,0.00038092706,0.00016149112,6.4162396e-7,0.00019501065,0.00008434146,0.0006782489,0.99440575],"study_design_scores_gemma":[0.015185731,0.00024382902,0.0654145,0.046484448,0.0007524159,0.0013546613,0.00047006935,0.0019575756,0.0002592198,0.0013651412,0.8655798,0.0009326347],"about_ca_topic_score_codex":0.017909072,"about_ca_topic_score_gemma":0.0027778326,"teacher_disagreement_score":0.9934731,"about_ca_system_score_codex":0.0012825198,"about_ca_system_score_gemma":0.000756759,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W2086847066","doi":"10.2214/ajr.183.4.1830929","title":"Spectrum of Imaging Findings in Abdominal Extraosseous Myeloma","year":2004,"lang":"en","type":"article","venue":"American Journal of Roentgenology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hamilton General Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Abdomen; Radiology; Pathology; Internal medicine","score_opus":0.00973744621608047,"score_gpt":0.2919674497424318,"score_spread":0.2822300035263513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086847066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486816,0.0005545201,0.0005792637,0.0034810011,0.00007399729,0.000113508264,0.0000026663838,0.000005089901,0.00032180606],"genre_scores_gemma":[0.99538815,0.00022621141,0.0041568847,0.00012209264,0.000064320455,0.0000018718878,0.0000015041302,0.000015448559,0.000023519657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985595,0.000060918366,0.00053099776,0.00013960735,0.00028993728,0.0004190653],"domain_scores_gemma":[0.9991505,0.000063927924,0.00032975947,0.0001600064,0.00010226224,0.00019350034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021467198,0.00012556455,0.00059358287,0.00058676116,0.000023237826,0.0000047600374,0.00014985059,0.000025222022,0.00008929179],"category_scores_gemma":[0.00014010115,0.0001019785,0.00014751748,0.00034870204,0.00044843077,0.00006870711,0.000033958382,0.00031483028,0.0000127471885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038433138,0.0009072599,0.8082875,0.00003959537,0.00036821855,0.010790854,0.0009150122,0.00013171528,0.0450204,0.0002018705,0.000041170555,0.12945308],"study_design_scores_gemma":[0.010418139,0.0060211495,0.937446,0.00021497422,0.00009763331,0.013089208,0.0015708344,0.000038694132,0.029955298,0.0008295408,0.00019864256,0.000119886696],"about_ca_topic_score_codex":0.00032727505,"about_ca_topic_score_gemma":0.00006801973,"teacher_disagreement_score":0.1293332,"about_ca_system_score_codex":0.0002552051,"about_ca_system_score_gemma":0.00030506903,"threshold_uncertainty_score":0.41585624},"labels":[],"label_agreement":null},{"id":"W2088123597","doi":"10.1182/blood-2004-10-3913","title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":289,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; MAPK/ERK pathway; Fibroblast growth factor receptor 3; Tyrosine kinase; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Biology; Cytotoxic T cell; Kinase; Molecular biology; Fibroblast growth factor; Cell biology; Signal transduction; Receptor; In vitro; Cancer; Biochemistry","score_opus":0.024645446219068407,"score_gpt":0.28353234773862024,"score_spread":0.25888690151955185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088123597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232936,0.0020072344,0.0013642296,0.00086971576,0.00018265663,0.0026496886,0.00045254987,0.000069948284,0.00007462578],"genre_scores_gemma":[0.9870285,0.00018101695,0.011168884,0.000045568817,0.00040836787,0.00041167912,0.00023087044,0.000046380243,0.00047874253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835443,0.00001661868,0.00036083366,0.00036459925,0.00041836378,0.00048515433],"domain_scores_gemma":[0.9987045,0.00020606138,0.00010640483,0.00050227455,0.00023766472,0.00024312598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010186387,0.0002705146,0.00040910675,0.00011652107,0.00019160625,0.000020074756,0.000117876385,0.00011601519,0.000041337968],"category_scores_gemma":[0.00030473922,0.00016350619,0.0003240846,0.00019846292,0.00013098476,0.00006077689,0.000039149087,0.00009144216,0.000024718169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055928114,0.03156974,0.025075195,0.00030292387,0.002966481,0.00040551496,0.00075756374,0.00021778651,0.9111145,0.0002066795,0.00015661599,0.021634165],"study_design_scores_gemma":[0.11698185,0.0055264733,0.14381474,0.00014958448,0.0010602636,0.00012952673,0.00015761673,0.0010887509,0.7284619,0.00005597202,0.0023314932,0.00024181444],"about_ca_topic_score_codex":0.0005312993,"about_ca_topic_score_gemma":0.00018303344,"teacher_disagreement_score":0.18265261,"about_ca_system_score_codex":0.00011733319,"about_ca_system_score_gemma":0.00021752164,"threshold_uncertainty_score":0.6667589},"labels":[],"label_agreement":null},{"id":"W2088189626","doi":"10.1016/j.jval.2014.03.449","title":"A Canadian Cost Analysis Comparing the Use of Bortezomib or Lenalidomide as Maintenance Therapies in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thames Valley Children's Centre; Ottawa Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Lenalidomide; Bortezomib; Multiple myeloma; Medicine; Internal medicine; Oncology; Autologous stem-cell transplantation; Pharmacist; Adverse effect; Pharmacy; Family medicine","score_opus":0.10385737084964787,"score_gpt":0.3223793400241688,"score_spread":0.21852196917452094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088189626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995909,0.0001919795,0.00032110207,0.0010818753,0.00004312807,0.0022264142,0.0001709067,0.000012909745,0.000042730182],"genre_scores_gemma":[0.99798733,0.00026702945,0.00086385943,0.0003936037,0.000013358379,0.00019229054,0.00011408843,0.000020337227,0.00014809574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977522,0.00035364187,0.0006088821,0.00030104912,0.00026631326,0.0007179514],"domain_scores_gemma":[0.9978474,0.0011948051,0.00016577933,0.00035897316,0.00009802261,0.0003350337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071916345,0.00017055964,0.0006766284,0.00054180034,0.00011817933,0.000019705747,0.00014709396,0.00006775121,0.000010268092],"category_scores_gemma":[0.00020711693,0.000105603096,0.00012329509,0.00061729975,0.000060315695,0.000058242815,0.000013275556,0.000182382,0.000004473966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019459641,0.0002698073,0.97952926,0.00029267572,0.00018087083,0.00002707343,0.0022448576,0.0065379213,0.000019202636,0.00006263888,0.00010000689,0.008789726],"study_design_scores_gemma":[0.008242638,0.0006682119,0.77778405,0.00039425396,0.00006914723,0.0000049465652,0.000264804,0.21020363,0.00026754325,0.000022511673,0.0019690802,0.00010917258],"about_ca_topic_score_codex":0.67822206,"about_ca_topic_score_gemma":0.5973074,"teacher_disagreement_score":0.20366572,"about_ca_system_score_codex":0.00061932264,"about_ca_system_score_gemma":0.00075096765,"threshold_uncertainty_score":0.4306369},"labels":[],"label_agreement":null},{"id":"W2089311432","doi":"10.1182/blood-2012-05-425934","title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":655,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; University of Toronto","funders":"National Cancer Institute; Jewish General Hospital; Onyx Pharmaceuticals; University of Alberta; Wake Forest University","keywords":"Carfilzomib; Multiple myeloma; Refractory (planetary science); Medicine; Pomalidomide; Lenalidomide; Oncology; Internal medicine; Materials science","score_opus":0.02848352810245834,"score_gpt":0.2876643652637208,"score_spread":0.25918083716126245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089311432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778324,0.00032956636,0.0000016293106,0.000013856846,0.00003781768,0.0015086812,0.000027895754,0.00002418741,0.00027310022],"genre_scores_gemma":[0.9993278,0.000010550824,0.00035717714,0.000016584952,0.000042606458,0.000071817136,0.00005913069,0.000031216314,0.00008311165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983955,0.00010611775,0.00030147188,0.00027023623,0.00049185945,0.0004348309],"domain_scores_gemma":[0.9990034,0.00009617886,0.000105724284,0.00036390763,0.00009086614,0.00033993475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015879769,0.00019546972,0.00038811192,0.00019218794,0.00004892073,0.0000089095,0.000060915605,0.00006577609,0.000033416894],"category_scores_gemma":[0.00018637809,0.00014037188,0.00003349422,0.00020800094,0.00006127597,0.00013921887,0.0000633877,0.00016666057,0.000008485644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025849496,0.07736052,0.9093176,0.000064017135,0.00030630542,0.00008857243,0.002005789,1.9012164e-7,0.0029652927,6.982081e-7,0.000020563655,0.005285488],"study_design_scores_gemma":[0.12359687,0.0112273805,0.86002165,0.00008932954,0.00020147479,0.0000073566766,0.0005779993,0.000009177719,0.004022155,6.271312e-7,0.00012666837,0.00011930115],"about_ca_topic_score_codex":0.0002396821,"about_ca_topic_score_gemma":0.00012521412,"teacher_disagreement_score":0.12101192,"about_ca_system_score_codex":0.00006708079,"about_ca_system_score_gemma":0.000043895587,"threshold_uncertainty_score":0.57241994},"labels":[],"label_agreement":null},{"id":"W2089410776","doi":"10.1016/s0093-7754(01)90035-1","title":"Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Québec Metro High Tech Park (Canada)","funders":"","keywords":"Medicine; Angiogenesis; Vascular endothelial growth factor; In vivo; Lewis lung carcinoma; Pharmacology; Matrigel; Neovascularization; Blood vessel; Thalidomide; Basic fibroblast growth factor; Cancer research; Bone marrow; Matrix metalloproteinase inhibitor; Matrix metalloproteinase; Cancer; Immunology; Internal medicine; Growth factor; Multiple myeloma; Receptor; Biology; VEGF receptors; Metastasis","score_opus":0.24415275304753292,"score_gpt":0.5670275841619712,"score_spread":0.32287483111443827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089410776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034280878,0.9900725,0.000008198091,0.00011933177,0.0012153425,0.0035492852,0.000110371344,0.00004335872,0.0014535398],"genre_scores_gemma":[0.00023826076,0.99413764,0.0014185115,0.00016810461,0.0008043695,0.00053167704,0.00088207895,0.000070768954,0.001748588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99054724,0.0034165608,0.003536238,0.0010360944,0.00048495494,0.000978905],"domain_scores_gemma":[0.9905229,0.0074936193,0.000869709,0.00055848283,0.00010233707,0.0004529029],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007792004,0.00061543094,0.006601638,0.001349673,0.000057873152,0.000018144783,0.00032928414,0.0011325593,0.0007724775],"category_scores_gemma":[0.0060712323,0.000471832,0.0016320397,0.001096451,0.0002475926,0.00007350744,0.00021810754,0.002207405,0.00024266697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002067945,0.0027497495,0.0018179595,0.0016330375,0.0006974627,0.015738701,0.00007155487,5.548223e-7,0.0000010734394,0.000007192642,0.0048670033,0.97034776],"study_design_scores_gemma":[0.02855702,0.0011804122,0.00014068068,0.012982481,0.0008353468,0.0016783148,0.00007019504,0.00009983643,6.77443e-7,0.000016303655,0.9541194,0.00031936733],"about_ca_topic_score_codex":0.00020069502,"about_ca_topic_score_gemma":0.000474462,"teacher_disagreement_score":0.9700284,"about_ca_system_score_codex":0.0015407195,"about_ca_system_score_gemma":0.0027817881,"threshold_uncertainty_score":0.9997733},"labels":[],"label_agreement":null},{"id":"W2089902119","doi":"10.1111/j.1365-2141.2006.06325.x","title":"Multiple myeloma patients with <i>CKS1B</i> gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation","year":2006,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"Cancer Research Society","keywords":"Multiple myeloma; Gastroenterology; Fluorescence in situ hybridization; Internal medicine; Transplantation; Autologous stem-cell transplantation; Medicine; Bone marrow; Beta-2 microglobulin; Pathology; Biology; Oncology; Immunology; Chromosome; Gene","score_opus":0.011202216900912006,"score_gpt":0.251527055066778,"score_spread":0.24032483816586603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089902119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585605,0.0008375514,0.001675096,0.00027712522,0.00013369077,0.0006668938,0.00015629394,0.000030242616,0.00036707125],"genre_scores_gemma":[0.9949982,0.00013468432,0.0041495916,0.00007538598,0.000085715394,0.000026450203,0.00037566503,0.000038009486,0.00011629549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767387,0.00019771617,0.00069544575,0.00027930466,0.00071645255,0.00043723042],"domain_scores_gemma":[0.99811697,0.00015567685,0.00044167836,0.00023768337,0.0008219893,0.00022600302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021414929,0.00020370235,0.0006349496,0.00019886774,0.00014563499,0.00005202816,0.00018921973,0.00016103566,0.00004043293],"category_scores_gemma":[0.00004556121,0.00017163201,0.00013790253,0.00012277246,0.00014569069,0.00019902187,0.000024582163,0.0003142214,0.000013136779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050704223,0.002350723,0.8571279,0.0003235913,0.00025298444,0.06861195,0.00015168844,0.000016454773,0.0024739308,0.000022221706,0.001141101,0.062457036],"study_design_scores_gemma":[0.014467488,0.001448634,0.9115669,0.00035795322,0.00023053467,0.06117533,0.00008876955,0.00006465228,0.0101786535,0.00005898486,0.00017333285,0.00018875363],"about_ca_topic_score_codex":0.00021777525,"about_ca_topic_score_gemma":0.00049478986,"teacher_disagreement_score":0.062268283,"about_ca_system_score_codex":0.000081111495,"about_ca_system_score_gemma":0.00016817031,"threshold_uncertainty_score":0.699895},"labels":[],"label_agreement":null},{"id":"W2090826831","doi":"10.1038/onc.2009.257","title":"Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis","year":2009,"lang":"en","type":"article","venue":"Oncogene","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stem Cell Network","keywords":"Multiple myeloma; Biology; Angiogenesis; Cancer research; Bone morphogenetic protein 6; Plasma cell; Bone morphogenetic protein; Internal medicine; Bone morphogenetic protein 7; Immunology; Medicine","score_opus":0.02498370135479834,"score_gpt":0.26742035934862596,"score_spread":0.24243665799382763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090826831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975915,0.0005832322,0.00008255639,0.00009434464,0.0000073320907,0.0013383807,0.0001747203,0.000015559815,0.00011240668],"genre_scores_gemma":[0.99694294,0.000050048453,0.0026454134,0.000014242106,0.000022617165,0.00005593615,0.000084164625,0.00001726231,0.00016735194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873984,0.00003577852,0.00034928235,0.0002714947,0.00033465205,0.000268967],"domain_scores_gemma":[0.999324,0.000056011064,0.00016104113,0.00014344102,0.00012125515,0.00019422019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012929058,0.00017628323,0.00037104907,0.000120292156,0.000049273454,0.00001238955,0.00003276657,0.000089660854,0.000021150116],"category_scores_gemma":[0.00009994407,0.00013801098,0.000062749525,0.0001500763,0.00007297088,0.000081611004,0.000034461194,0.000060142145,7.602742e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048162843,0.0006335777,0.02361833,0.00021038455,0.00009813538,0.00002805487,0.00021092824,0.000003337973,0.9700381,0.0000068129543,0.000028445394,0.0046422235],"study_design_scores_gemma":[0.004411379,0.0010417538,0.015512211,0.0001944813,0.000107073494,0.000035573143,0.00007247353,0.0012714155,0.9772151,0.0000032694984,0.00002707993,0.00010815477],"about_ca_topic_score_codex":0.00008186074,"about_ca_topic_score_gemma":0.000011805269,"teacher_disagreement_score":0.008106118,"about_ca_system_score_codex":0.000029514355,"about_ca_system_score_gemma":0.000087030785,"threshold_uncertainty_score":0.5627924},"labels":[],"label_agreement":null},{"id":"W2091346949","doi":"10.1056/nejmct0805626","title":"Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma","year":2009,"lang":"en","type":"review","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Hematopoietic stem cell transplantation; Transplantation; Autologous stem-cell transplantation; Stem cell; Chemotherapy; Oncology; Haematopoiesis; Internal medicine; Surgery","score_opus":0.058305781294826504,"score_gpt":0.3589522255501487,"score_spread":0.3006464442553222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091346949","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022065702,0.9948588,0.0015974195,0.000805539,0.00045359624,0.001492642,0.000035837857,0.000024376775,0.00051112636],"genre_scores_gemma":[0.0014713127,0.99154425,0.0014798199,0.000098817385,0.0033924067,0.000020408037,0.00021710867,0.00006193629,0.001713933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684674,0.00020290946,0.0014190611,0.0002888338,0.00078648975,0.00045599183],"domain_scores_gemma":[0.9964497,0.001261985,0.00093377737,0.00029279757,0.00029018216,0.00077153964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085217034,0.0004899191,0.0031041796,0.0006090184,0.0000756869,0.000014672488,0.00023304022,0.00030012237,0.00009785084],"category_scores_gemma":[0.00023639711,0.00027889336,0.00063386053,0.00024859834,0.00008369416,0.00007109779,0.0000095385585,0.00070021837,0.000018238923],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011164554,0.00017785987,0.000035297373,0.015452497,0.00042860507,0.0019480179,0.00032850818,7.6513993e-7,0.00001142353,0.0000112507505,0.0037508626,0.97673845],"study_design_scores_gemma":[0.06945813,0.0053951493,0.00012183685,0.026725486,0.0051129656,0.0154815065,0.0000393177,0.00001585356,0.000027933767,0.000081566126,0.8773319,0.00020832146],"about_ca_topic_score_codex":0.000020538831,"about_ca_topic_score_gemma":0.000011189245,"teacher_disagreement_score":0.97653013,"about_ca_system_score_codex":0.00017669651,"about_ca_system_score_gemma":0.0009373752,"threshold_uncertainty_score":0.9999663},"labels":[],"label_agreement":null},{"id":"W2091773528","doi":"10.1182/blood-2013-11-538835","title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of Alberta; University of Calgary; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Celgene","keywords":"Medicine; Pomalidomide; Lenalidomide; Neutropenia; Multiple myeloma; Internal medicine; Bortezomib; Population; Dexamethasone; Surgery; Febrile neutropenia; Thalidomide; Randomized controlled trial; Phases of clinical research; Chemotherapy","score_opus":0.01876082933216229,"score_gpt":0.3065881242718411,"score_spread":0.28782729493967885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091773528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566394,0.00021240603,0.000052583182,0.00016846371,0.000019599836,0.0036654428,0.000004936363,0.00004284851,0.00016980055],"genre_scores_gemma":[0.99734753,0.000046648256,0.0017510189,0.000052306474,0.000027837015,0.0004844825,0.000042084026,0.000034193683,0.00021391218],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99754924,0.00076076784,0.0004686818,0.0004292591,0.00042410873,0.00036793866],"domain_scores_gemma":[0.99777126,0.0014693638,0.00012277639,0.00033878806,0.000078870886,0.00021896146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014560091,0.00023163263,0.0009338212,0.00041271353,0.000050334493,0.000024794404,0.000069067755,0.000086871354,0.000033003616],"category_scores_gemma":[0.0029212008,0.00015159446,0.000046485577,0.00038751535,0.00012335756,0.000100291705,0.000044082342,0.0002845214,0.000010740534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5040025,0.047234014,0.4265726,0.00014968644,0.00049432076,0.0025187782,0.0018645684,0.0000033313033,0.004959366,0.000014928509,0.000009935663,0.012175966],"study_design_scores_gemma":[0.7993569,0.0041204374,0.19184946,0.00020142425,0.00018498595,0.000056392255,0.00031921637,0.0019832284,0.001753527,0.000022613156,0.000011406148,0.0001404074],"about_ca_topic_score_codex":0.0008289237,"about_ca_topic_score_gemma":0.0018425074,"teacher_disagreement_score":0.2953544,"about_ca_system_score_codex":0.00006978695,"about_ca_system_score_gemma":0.00010280065,"threshold_uncertainty_score":0.61818427},"labels":[],"label_agreement":null},{"id":"W2092060407","doi":"10.4021/wjon688w","title":"Transient Plasmacytosis With Trisomy of Chromosome 8 in a Patient With Multiple Myeloma: A Case Report","year":2013,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Plasmacytosis; Trisomy; Plasma cell leukemia; Multiple myeloma; Medicine; Bone marrow; Plasma cell; Chromosome; Aneuploidy; Pathology; Karyotype; Chromosome 13; Cancer research; Immunology; Biology; Gene; Genetics","score_opus":0.020327897470262472,"score_gpt":0.2988539821097619,"score_spread":0.2785260846394994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092060407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959051,0.00018530825,0.000056435914,0.0013934945,0.00005004556,0.0007942043,0.0000053242347,0.000005800244,0.001604288],"genre_scores_gemma":[0.9924156,0.000027315285,0.007160952,0.00006919522,0.00005033058,0.00006488007,0.00000448347,0.00002089005,0.00018634382],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99804926,0.00012342814,0.0008251419,0.00018676,0.00046049216,0.00035491816],"domain_scores_gemma":[0.9980958,0.00028173215,0.0005956215,0.0002160928,0.0004545796,0.00035616223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024190893,0.00017334611,0.00077740994,0.000638327,0.00003547788,0.000007434592,0.00007238728,0.000061634986,0.00025118096],"category_scores_gemma":[0.00011414194,0.000101689475,0.00010576728,0.0004919909,0.00015996752,0.0001289993,0.000019261288,0.00032813908,0.0000067527017],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008274693,0.003190805,0.22295709,0.00009695791,0.0006147926,0.70204127,0.0013543932,0.00009217455,0.0034992178,0.000004142225,0.00053129776,0.057343192],"study_design_scores_gemma":[0.039049022,0.026625872,0.1537086,0.0005827729,0.00028095228,0.7615893,0.001285763,0.00032253165,0.00959469,0.0000097540415,0.0067555252,0.0001952357],"about_ca_topic_score_codex":0.0006877214,"about_ca_topic_score_gemma":0.0035634981,"teacher_disagreement_score":0.06924848,"about_ca_system_score_codex":0.0003756641,"about_ca_system_score_gemma":0.00071074045,"threshold_uncertainty_score":0.41467765},"labels":[],"label_agreement":null},{"id":"W2093514907","doi":"10.1080/1042819031000067918","title":"Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma","year":2003,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Thalidomide; Discontinuation; Medicine; Multiple myeloma; Toxicity; Internal medicine; Gastroenterology; Retrospective cohort study","score_opus":0.0664127587477917,"score_gpt":0.3197220966819115,"score_spread":0.2533093379341198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093514907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39041427,0.60392225,0.000004076247,0.000038293787,0.0004953695,0.0027517872,0.00019528755,0.00020538687,0.0019732995],"genre_scores_gemma":[0.18957849,0.80290616,0.0003692954,0.00029155056,0.00040711142,0.0007278703,0.00083542854,0.00036886527,0.0045152465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901141,0.0010576317,0.002349383,0.0027239549,0.0012417373,0.0025131889],"domain_scores_gemma":[0.9933341,0.001909366,0.0008899004,0.001855102,0.00018981473,0.0018216852],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008795096,0.0024138424,0.006085051,0.0013147447,0.0006410774,0.0005201113,0.000764904,0.0017837248,0.00016257678],"category_scores_gemma":[0.0004951051,0.0019510885,0.00085040316,0.0013622784,0.0012372256,0.00037393798,0.0006398163,0.0008292434,0.00023675672],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027320925,0.0011066035,0.0100340415,0.012174394,0.0014354126,0.004924709,0.00046552703,0.0000045289203,0.000058674577,0.00012461747,0.0023820393,0.96455735],"study_design_scores_gemma":[0.09875655,0.0010713043,0.118548244,0.022839949,0.0022813994,0.003520748,0.0002576343,0.0007740037,0.00017263915,0.000092135015,0.74891716,0.0027682083],"about_ca_topic_score_codex":0.0035742864,"about_ca_topic_score_gemma":0.0006193763,"teacher_disagreement_score":0.96178913,"about_ca_system_score_codex":0.01076538,"about_ca_system_score_gemma":0.0070498213,"threshold_uncertainty_score":0.9995122},"labels":[],"label_agreement":null},{"id":"W2093748969","doi":"10.1097/iop.0b013e31802c7e6e","title":"Solitary Osseous Plasmacytoma of the Orbit With Amyloidosis","year":2007,"lang":"en","type":"article","venue":"Ophthalmic Plastic and Reconstructive Surgery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Plasmacytoma; Orbit (dynamics); Multiple myeloma; Pathology; Amyloidosis; Biopsy; Lesion; Radiology; Internal medicine","score_opus":0.017175908691413333,"score_gpt":0.254282948802376,"score_spread":0.23710704011096267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093748969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99483323,0.00021765738,0.00006624714,0.000043680946,0.00027677102,0.00026734744,0.000044559845,0.000016590158,0.0042338986],"genre_scores_gemma":[0.9990479,0.00005039302,0.00054101937,0.00001532901,0.000061717925,0.00000839923,0.000008248434,0.000018239956,0.00024877515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871653,0.00004317186,0.00028740257,0.00026908756,0.00030526298,0.000378545],"domain_scores_gemma":[0.9972262,0.0021020325,0.00012387343,0.00021425408,0.0001137604,0.00021992458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022756407,0.00018127573,0.00041983096,0.0001779178,0.00012685609,0.000007949155,0.000056794586,0.00008062964,0.00010137249],"category_scores_gemma":[0.00034608803,0.00010007199,0.00012118054,0.00025891862,0.0006956355,0.00006230104,0.000047581107,0.0002005726,0.00000805024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001768967,0.00011905206,0.97879416,0.00012232644,0.00038775965,0.00065399247,0.00007371435,0.0000012631574,0.0012866951,0.000043092135,0.00006927886,0.016679693],"study_design_scores_gemma":[0.0012492408,0.00020607356,0.97477144,0.00036373507,0.000111632886,0.010910059,0.0005246599,0.00006449357,0.011542832,0.00008950277,0.00003597728,0.00013033648],"about_ca_topic_score_codex":0.00010680848,"about_ca_topic_score_gemma":0.000020342763,"teacher_disagreement_score":0.016549356,"about_ca_system_score_codex":0.000059681268,"about_ca_system_score_gemma":0.0002541244,"threshold_uncertainty_score":0.40808174},"labels":[],"label_agreement":null},{"id":"W2094611598","doi":"10.1182/blood-2014-03-559963","title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Multiple myeloma; Pharmacokinetics; Medicine; Lenalidomide; Safety profile; Protein kinase B; Cancer research; Pharmacology; Oncology; Internal medicine; Adverse effect; Chemistry; Signal transduction","score_opus":0.04141649061552355,"score_gpt":0.33802430690756835,"score_spread":0.2966078162920448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094611598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957197,0.00029524567,0.000097985765,0.0013923752,0.00013551679,0.0007069454,0.000026418304,0.000040984334,0.0015848748],"genre_scores_gemma":[0.9977163,0.00038305728,0.0006523323,0.00012081368,0.00034551974,0.00003669054,0.000012623845,0.000026993042,0.0007056489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981966,0.0001875466,0.0003503457,0.00039016549,0.00036954653,0.0005057713],"domain_scores_gemma":[0.9980114,0.0010886189,0.00007078149,0.0004027007,0.00007501849,0.000351458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008987093,0.00018606668,0.0003437204,0.00007063116,0.00019366652,0.00004830946,0.0001363735,0.000117192394,0.00002808461],"category_scores_gemma":[0.0014314905,0.00012204554,0.0000933994,0.00014587861,0.00021036465,0.00007897394,0.00017022008,0.0004385284,0.000033815697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019438615,0.0035151278,0.85362935,0.00006196655,0.00027993266,0.00006846604,0.000053568212,0.0000016542067,0.04057223,0.000046577734,0.00036879128,0.09945849],"study_design_scores_gemma":[0.031964585,0.0007638189,0.9072706,0.0000759196,0.00013004235,0.00003734619,0.000029436273,0.0057227863,0.04192781,0.000039081493,0.011871073,0.00016750857],"about_ca_topic_score_codex":0.00024920664,"about_ca_topic_score_gemma":0.00092733966,"teacher_disagreement_score":0.09929099,"about_ca_system_score_codex":0.000034479257,"about_ca_system_score_gemma":0.00009041684,"threshold_uncertainty_score":0.49768725},"labels":[],"label_agreement":null},{"id":"W2094704437","doi":"10.1007/s00280-007-0442-7","title":"O6-benzylguanine and BCNU in multiple myeloma: a phase II trial","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Carmustine; Medicine; Multiple myeloma; Neutropenia; Internal medicine; Chemotherapy; Bone marrow; Toxicity; Oncology; Gastroenterology; Regimen; Pharmacology; Etoposide","score_opus":0.04729938861380173,"score_gpt":0.412195691664822,"score_spread":0.3648963030510203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094704437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185216,0.0043183053,0.000038911898,0.0020274555,0.00025165622,0.0010653985,0.000020040934,0.000029695133,0.00039638724],"genre_scores_gemma":[0.9923513,0.0037540675,0.00021510496,0.0023481569,0.0005303545,0.00012882092,0.00001714719,0.000022396718,0.00063267176],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988361,0.000039658255,0.00023904355,0.0003255467,0.00011960243,0.00044006968],"domain_scores_gemma":[0.9993699,0.00015783934,0.000051151874,0.00008938997,0.000038459104,0.0002932564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027492,0.00017488706,0.00035132174,0.00016087967,0.00011038157,0.000007327104,0.00004566823,0.00011785573,0.0010791068],"category_scores_gemma":[0.00002040506,0.00014621159,0.000039931565,0.00017171416,0.00016729819,0.000057387653,0.000034809338,0.00023237028,0.0000026574503],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21287332,0.002392398,0.030052781,0.000118030686,0.0003671024,0.0004541223,0.0012965412,6.719004e-7,0.3077685,0.00002042891,0.0020863877,0.4425697],"study_design_scores_gemma":[0.6668898,0.0055734683,0.02132101,0.000044369855,0.000095528136,0.00007582242,0.000101076745,0.0010814414,0.24853855,0.00005967604,0.055969767,0.0002495139],"about_ca_topic_score_codex":0.00014180112,"about_ca_topic_score_gemma":0.00016045396,"teacher_disagreement_score":0.45401645,"about_ca_system_score_codex":0.00009324704,"about_ca_system_score_gemma":0.00009497362,"threshold_uncertainty_score":0.99983406},"labels":[],"label_agreement":null},{"id":"W2095225241","doi":"10.3109/10428190309178811","title":"Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Hamilton Health Sciences; Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario; McMaster University","funders":"Hamilton Health Sciences","keywords":"Melphalan; Medicine; Prednisone; Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Internal medicine; Cost effectiveness; Surgery; Oncology","score_opus":0.022135308889808858,"score_gpt":0.2778753257788484,"score_spread":0.2557400168890395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095225241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533916,0.00039666242,0.00018735876,0.000010668389,0.000046603694,0.0027489415,0.00014236353,0.000053052747,0.00107519],"genre_scores_gemma":[0.99800205,0.00016981339,0.00092334737,0.00007186787,0.00001750621,0.00037454214,0.0003058611,0.00006318001,0.000071805945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970608,0.00033058703,0.0005341075,0.0007663617,0.0006064374,0.0007017364],"domain_scores_gemma":[0.9982169,0.00043935355,0.00013883189,0.0003938501,0.00021689617,0.0005941289],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035438503,0.00048768643,0.0008767469,0.00040722432,0.00012983702,0.000052362873,0.000112402966,0.00021959633,0.000020243788],"category_scores_gemma":[0.00012223869,0.00039824014,0.000075370706,0.00056300184,0.00021266205,0.00029700834,0.000036723624,0.000092095244,0.0000090340345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015016923,0.00079186325,0.923858,0.0010665108,0.00029994114,0.00041089716,0.0010361901,0.00017608919,0.0045214947,0.00028908177,0.000016569635,0.052516453],"study_design_scores_gemma":[0.065824136,0.0011514392,0.9157846,0.0006912379,0.00014497386,0.00023110828,0.00028317093,0.0011877384,0.0141291525,0.000051033338,0.0001587649,0.000362627],"about_ca_topic_score_codex":0.0019431207,"about_ca_topic_score_gemma":0.00036658443,"teacher_disagreement_score":0.052153826,"about_ca_system_score_codex":0.002137247,"about_ca_system_score_gemma":0.0011767983,"threshold_uncertainty_score":0.99984694},"labels":[],"label_agreement":null},{"id":"W2096302737","doi":"10.1177/1947601910382897","title":"Duplication of Subcytoband 11E2 of Chromosome 11 Is Regularly Associated with Accelerated Tumor Development in v-abl/myc-Induced Mouse Plasmacytomas","year":2010,"lang":"en","type":"article","venue":"Genes & Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Medical Research Council","keywords":"Gene duplication; Chromosomal translocation; Biology; Synteny; ABL; Karyotype; Trisomy; Chromosome; Genetics; Molecular biology; Cancer research; Gene; Receptor","score_opus":0.041314786719386605,"score_gpt":0.3122120156886266,"score_spread":0.27089722896924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096302737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987313,0.00019471528,0.0000031759755,0.00016649708,0.000039843842,0.0007056729,0.000053902593,0.000025609108,0.000079284124],"genre_scores_gemma":[0.99853295,0.000057444606,0.00039146727,0.0000458035,0.000030496298,0.00023569386,0.000115923925,0.00003063733,0.0005595754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848443,0.000032475047,0.00037773358,0.00030676785,0.00046860302,0.00032999957],"domain_scores_gemma":[0.99882984,0.000042076896,0.00022699281,0.0003267581,0.00042633063,0.00014800107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016228706,0.00017946903,0.0004106267,0.0001876538,0.00004476602,0.000011081342,0.000121763085,0.00010075694,0.00028240003],"category_scores_gemma":[0.00007192072,0.00013950418,0.000040667997,0.00048154662,0.000068086854,0.000092071605,0.00003529477,0.00016363108,0.0000071386607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041977942,0.00027571252,0.43888718,0.00007016149,0.00016494474,0.00002442119,0.000325897,0.0000030750016,0.55582464,0.00000365449,0.000048837202,0.003951671],"study_design_scores_gemma":[0.0030270135,0.00012703898,0.43986163,0.000102011094,0.000026686737,0.0000062776667,0.000022547714,0.00009515437,0.5565015,0.0000018061241,0.00015209593,0.00007622909],"about_ca_topic_score_codex":0.0019357912,"about_ca_topic_score_gemma":0.01112771,"teacher_disagreement_score":0.009191919,"about_ca_system_score_codex":0.00023185283,"about_ca_system_score_gemma":0.00083485246,"threshold_uncertainty_score":0.62095237},"labels":[],"label_agreement":null},{"id":"W2096672426","doi":"10.1200/jco.2014.57.9961","title":"Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Takeda Oncology; National Institutes of Health; National University Health System; Gachon University; Tel Aviv University; Ostravská Univerzita v Ostravě; Universidad de Salamanca; Eli Lilly and Company; National Taiwan University Hospital; Keio University; Northwestern University; York University; Nagoya City University; Cedars-Sinai Medical Center; University of Arkansas for Medical Sciences; Ankara Universitesi; National Taiwan University; National and Kapodistrian University of Athens; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; University of Alberta; Queen Mary University of London; Universität Wien; Emory University; Gil Medical Center, Gachon University; Universität Heidelberg; Celgene","keywords":"Medicine; Multiple myeloma; Magnetic resonance imaging; Radiology; Plasmacytoma; Bone marrow; Asymptomatic; Pathology; Internal medicine","score_opus":0.0815232574213156,"score_gpt":0.42783843505911334,"score_spread":0.34631517763779773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096672426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459183,0.0017066676,0.000008764554,0.0012095214,0.000078499324,0.00047826947,0.000010039562,0.0000015468628,0.0019148416],"genre_scores_gemma":[0.9923275,0.00015756582,0.007270427,0.0001410728,0.00004106545,0.0000073997826,0.000003041,0.0000075708904,0.000044338056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969376,0.0004201473,0.001611971,0.00011778211,0.00070570124,0.00020681633],"domain_scores_gemma":[0.99714446,0.00094926526,0.0009328279,0.00020092842,0.0005712749,0.00020126524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002551737,0.000092129,0.0007145176,0.00010512844,0.000011526569,0.0000027085005,0.00015927247,0.00005400964,0.00001984398],"category_scores_gemma":[0.0007493055,0.000048532776,0.00011693656,0.00014867606,0.00023727055,0.000033299104,0.000054031876,0.00031126608,0.0000030369856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010670006,0.0030339253,0.75148576,0.000034520148,0.00009981681,0.0006256988,0.00020168978,0.000008172702,0.00000976989,0.000026608399,0.0003537882,0.23345023],"study_design_scores_gemma":[0.03137743,0.010450162,0.9464243,0.00017649143,0.00013342987,0.00002907048,0.0012292161,0.0002095938,0.000030471281,0.0001333724,0.009768306,0.000038126615],"about_ca_topic_score_codex":0.0000587847,"about_ca_topic_score_gemma":0.0000556512,"teacher_disagreement_score":0.2334121,"about_ca_system_score_codex":0.000103389626,"about_ca_system_score_gemma":0.0005079899,"threshold_uncertainty_score":0.19791092},"labels":[],"label_agreement":null},{"id":"W2096844711","doi":"10.1158/1078-0432.ccr-06-0957","title":"CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Fibroblast growth factor receptor 3; Receptor tyrosine kinase; In vivo; Cancer research; Medicine; Fibroblast growth factor; Fibroblast growth factor receptor; Multiple myeloma; Receptor; Tyrosine-kinase inhibitor; Pathology; Biology; Internal medicine; Cancer","score_opus":0.18414792516677891,"score_gpt":0.4696726158016773,"score_spread":0.2855246906348984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096844711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936784,0.0005634943,0.000095210184,0.00236451,0.0000819236,0.0017231577,0.00010808638,0.00005937891,0.0013258238],"genre_scores_gemma":[0.9911733,0.00048642032,0.0038862613,0.00021709099,0.000355223,0.00045897783,0.00008108,0.00007463603,0.003267005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941879,0.0006489735,0.0012230858,0.001099535,0.0013349885,0.0015055375],"domain_scores_gemma":[0.9969315,0.0013593915,0.000110594694,0.00053775654,0.00048125224,0.00057951926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014174988,0.0003315342,0.00081758975,0.00064685644,0.00017334112,0.000087832435,0.00041589938,0.00041138864,0.0004914864],"category_scores_gemma":[0.0023275034,0.00028105068,0.00020596194,0.0012453562,0.00041067816,0.00018576627,0.00031752372,0.0019473712,0.00022069826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036764601,0.0016040514,0.944821,0.0002621733,0.00006941662,0.00036946457,0.00040946377,0.00014143549,0.012641645,0.000025014204,0.003624071,0.032355778],"study_design_scores_gemma":[0.017732637,0.00050962,0.94216466,0.0010489767,0.000009842842,0.000006621431,0.000080683654,0.026526796,0.009615167,0.00022881424,0.0017199937,0.00035617233],"about_ca_topic_score_codex":0.008240698,"about_ca_topic_score_gemma":0.011437025,"teacher_disagreement_score":0.031999607,"about_ca_system_score_codex":0.00078819005,"about_ca_system_score_gemma":0.0016454832,"threshold_uncertainty_score":0.9999642},"labels":[],"label_agreement":null},{"id":"W2097014087","doi":"10.1016/j.bbmt.2012.11.186","title":"Safety and Efficacy From Intravenous Busulfan with PK-Directed Dosed Adjustment and Bortezomib Conditioning Regimen in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Multiple myeloma; Busulfan; Bortezomib; Regimen; Hematopoietic stem cell transplantation; Transplantation; Surgery; Urology; Pharmacokinetics; Progressive disease; Dosing; Autologous stem-cell transplantation; Internal medicine; Chemotherapy","score_opus":0.007199685666502442,"score_gpt":0.21594244971316354,"score_spread":0.2087427640466611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097014087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748707,0.0007383328,0.00012364723,0.00006684905,0.000024683968,0.0011800061,0.00023498012,0.000042425694,0.000101977355],"genre_scores_gemma":[0.9956705,0.0013786996,0.0013132415,0.00002885067,0.000010631622,0.00005566297,0.0015060409,0.000016878666,0.000019505245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987428,0.00014219581,0.00036605904,0.00038159438,0.00011325109,0.00025406585],"domain_scores_gemma":[0.99912286,0.00043334923,0.00013987841,0.000099626224,0.000062233295,0.0001420593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007685928,0.00020503502,0.0004042699,0.00016313173,0.00009401856,0.000013315276,0.000031171876,0.00015898122,0.000030275787],"category_scores_gemma":[0.00000845916,0.00016726043,0.000022949005,0.00009166628,0.00016919365,0.0000960399,0.00000631166,0.00013329582,0.0000012805662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008605542,0.0010611268,0.7523008,0.0018966416,0.00064202875,0.00022773523,0.009322458,0.000011616466,0.19624062,0.000054821958,0.0000043285513,0.029632252],"study_design_scores_gemma":[0.032391988,0.0017618713,0.9405812,0.00039903412,0.0004100813,0.00011401457,0.00031056957,0.00031223358,0.023503402,0.00005389814,0.0000014712832,0.00016025297],"about_ca_topic_score_codex":0.00048729108,"about_ca_topic_score_gemma":0.0007336803,"teacher_disagreement_score":0.18828036,"about_ca_system_score_codex":0.000021526044,"about_ca_system_score_gemma":0.000054441945,"threshold_uncertainty_score":0.6820682},"labels":[],"label_agreement":null},{"id":"W2097603292","doi":"10.1200/jco.2011.35.9182","title":"Reply to S.M. Sorscher et al","year":2011,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.36529295829556274,"score_gpt":0.5584976683180847,"score_spread":0.19320471002252193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097603292","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3911512,0.008397292,0.0007021139,0.47377753,0.016619623,0.00060612377,0.00001855518,0.00001550575,0.10871206],"genre_scores_gemma":[0.58706063,0.009508582,0.064804874,0.3010094,0.005690534,0.000011713207,0.000003757665,0.00007699761,0.031833503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936008,0.0017688845,0.0030038543,0.00029436804,0.0006490906,0.00068300485],"domain_scores_gemma":[0.9920019,0.0032392761,0.0012599275,0.00036465633,0.000782606,0.0023516356],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00984821,0.00020724471,0.0017585924,0.00019632156,0.00004054219,0.000011207011,0.00031357876,0.00044584234,0.005260723],"category_scores_gemma":[0.01986739,0.00014908427,0.00079234614,0.0001984006,0.00034875635,0.00019102648,0.0001521675,0.002116069,0.0021157488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01149037,0.006281934,0.13089328,0.000025345766,0.0013028848,0.011451906,0.000461579,0.0000015565012,0.000043494118,0.0006142109,0.40070486,0.4367286],"study_design_scores_gemma":[0.007842997,0.029129947,0.31366768,0.00021622804,0.00024850428,0.00064641464,0.00012057618,0.000027105505,0.00008067989,0.00035500046,0.64758337,0.000081494814],"about_ca_topic_score_codex":0.00042079427,"about_ca_topic_score_gemma":0.00007852031,"teacher_disagreement_score":0.4366471,"about_ca_system_score_codex":0.00029745468,"about_ca_system_score_gemma":0.0038812626,"threshold_uncertainty_score":0.9986612},"labels":[],"label_agreement":null},{"id":"W2097752354","doi":"10.1080/10428190310001638832","title":"Detection of Chromosome 13q Deletions and IgH Translocations in Patients with Multiple Myeloma by FISH: Comparison with Karyotype Analysis","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Karyotype; Chromosomal translocation; Multiple myeloma; Fish <Actinopterygii>; Biology; Genetics; Chromosome; Chromosome analysis; Cytogenetics; Molecular biology; Gene; Immunology; Fishery","score_opus":0.0070428659838574215,"score_gpt":0.22985836820092523,"score_spread":0.2228155022170678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097752354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969836,0.0004363805,0.0011041634,0.00010931048,0.000022061868,0.00091684115,0.0001763984,0.00007374521,0.00017748373],"genre_scores_gemma":[0.9977083,0.00016163192,0.001058512,0.00009885649,0.000024671974,0.00014611716,0.0006767274,0.000054286833,0.00007089388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735916,0.000079184836,0.000597065,0.00072278123,0.0006478141,0.00059397094],"domain_scores_gemma":[0.99844676,0.00015112452,0.00021579998,0.0004920944,0.00024130878,0.0004529062],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001166656,0.0004530222,0.00090226,0.0006529245,0.0002767724,0.00005216967,0.00012641409,0.0002184283,0.000015761334],"category_scores_gemma":[0.000050841685,0.00035396786,0.000116546835,0.0016345542,0.0004169191,0.00027848978,0.000041477168,0.00013153515,0.0000051666793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036008265,0.0011631127,0.9301936,0.00018479962,0.0013319238,0.000066890156,0.0008104028,0.00060115213,0.0028011585,0.000026545627,0.000029222389,0.059190355],"study_design_scores_gemma":[0.041673157,0.001704473,0.938986,0.00020171517,0.0008965936,0.000064352316,0.00020116291,0.004033297,0.011673676,0.000015702595,0.00019339449,0.00035644465],"about_ca_topic_score_codex":0.0062075155,"about_ca_topic_score_gemma":0.0056717275,"teacher_disagreement_score":0.05883391,"about_ca_system_score_codex":0.0026531897,"about_ca_system_score_gemma":0.0010147914,"threshold_uncertainty_score":0.9998912},"labels":[],"label_agreement":null},{"id":"W2098341589","doi":"10.1007/s00259-009-1199-5","title":"Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma","year":2009,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"","keywords":"Medicine; Somatostatin receptor; Multiple myeloma; Plasmacytoma; Scintigraphy; Radiography; Somatostatin; Immunohistochemistry; Pathology; Internal medicine; Radiology; Nuclear medicine; Gastroenterology","score_opus":0.01113139021116028,"score_gpt":0.24742062039074733,"score_spread":0.23628923017958706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098341589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936892,0.00055677077,0.0001708005,0.0047939373,0.000035057663,0.0003237868,0.0000049991404,0.000015401307,0.00041003752],"genre_scores_gemma":[0.9901487,0.00007423437,0.007576387,0.0020685648,0.00007450004,7.400963e-7,0.000008537678,0.000042216747,0.0000060706648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985633,0.0001518824,0.0004137619,0.00020396244,0.00035829234,0.0003088183],"domain_scores_gemma":[0.9990747,0.00009943051,0.00020908019,0.00012123664,0.00020678263,0.0002887682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005293054,0.00018972321,0.0003593584,0.0004287546,0.00010940838,0.000037469894,0.000072635696,0.000014865695,0.000010850553],"category_scores_gemma":[0.0004043657,0.00013180808,0.000057691006,0.00014969274,0.00014496436,0.00017287127,0.000026487058,0.0002389689,8.42961e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063797818,0.00038486157,0.79556155,0.00029570388,0.00030810817,0.0031067543,0.005837884,0.0000030445192,0.031836797,0.00004109665,0.0032891093,0.15295531],"study_design_scores_gemma":[0.03231783,0.0060476023,0.94111735,0.0016790066,0.0001528249,0.00048482014,0.002406411,0.00047030422,0.0021198194,0.00001749516,0.012945833,0.00024073114],"about_ca_topic_score_codex":0.000009220399,"about_ca_topic_score_gemma":0.0000017247052,"teacher_disagreement_score":0.15271458,"about_ca_system_score_codex":0.000027639933,"about_ca_system_score_gemma":0.000025442609,"threshold_uncertainty_score":0.53749776},"labels":[],"label_agreement":null},{"id":"W2099334882","doi":"10.1016/j.leukres.2006.08.002","title":"Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Cancer Research Society","keywords":"Bortezomib; Multiple myeloma; Internal medicine; Fluorescence in situ hybridization; Refractory (planetary science); Medicine; Gastroenterology; Salvage therapy; Oncology; Cytogenetics; Chemotherapy; Biology; Chromosome","score_opus":0.06428577554715627,"score_gpt":0.36019112052934144,"score_spread":0.2959053449821852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099334882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178934,0.0022817717,0.0000057561065,0.00048423198,0.000042000815,0.0012295416,0.000060523238,0.000040428713,0.0040664086],"genre_scores_gemma":[0.990617,0.0006061671,0.00037700348,0.00007348635,0.00012478308,0.00021591606,0.00005311101,0.000059745646,0.007872807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945251,0.0009883229,0.0006654078,0.0005739541,0.0021028644,0.0011443802],"domain_scores_gemma":[0.99681735,0.0013968475,0.00009207986,0.0008988556,0.0004936719,0.0003011829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026663635,0.00026697776,0.0005220728,0.0011852003,0.00015060727,0.000040770836,0.00034385905,0.0002878496,0.0005232289],"category_scores_gemma":[0.000661671,0.00022402698,0.00017164218,0.00092126685,0.00044976463,0.00010416753,0.00017685935,0.0010127582,0.00017408765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035828017,0.0013688544,0.78715104,0.00019905159,0.00016425058,0.0017622577,0.0012883116,0.00006219505,0.15331197,0.00014345495,0.0030587842,0.015661791],"study_design_scores_gemma":[0.014813233,0.0014852013,0.84627765,0.00016002305,0.0000069097764,0.000052299347,0.00052882114,0.0007380101,0.13097072,0.00031878735,0.0044756737,0.00017265082],"about_ca_topic_score_codex":0.010889919,"about_ca_topic_score_gemma":0.00080788817,"teacher_disagreement_score":0.05912662,"about_ca_system_score_codex":0.0017471809,"about_ca_system_score_gemma":0.0019161128,"threshold_uncertainty_score":0.99569666},"labels":[],"label_agreement":null},{"id":"W2099844273","doi":"10.1186/2050-7771-2-10","title":"Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment","year":2014,"lang":"en","type":"review","venue":"Biomarker Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"Cancer Research Society","keywords":"Stromal cell; Multiple myeloma; Bone marrow; Microvesicles; microRNA; Context (archaeology); Tumor microenvironment; Cancer research; Medicine; Secretion; Biology; Immunology; Gene; Tumor cells; Genetics; Internal medicine","score_opus":0.17010171074703978,"score_gpt":0.4199784393830314,"score_spread":0.24987672863599164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099844273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085730065,0.9899886,0.000009301388,0.00035233764,0.00012261688,0.005114544,0.00009571186,0.000053063384,0.003406515],"genre_scores_gemma":[0.00052565156,0.9706781,0.0012716117,0.000034516983,0.0003525669,0.00063779263,0.0010117026,0.00023671513,0.025251351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99114734,0.0013640057,0.0012904432,0.0015674324,0.00218499,0.002445772],"domain_scores_gemma":[0.9953981,0.00104719,0.00021452525,0.0016742666,0.00012603053,0.0015398562],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0030548628,0.0009012683,0.0028567144,0.0023559837,0.00027987926,0.0001376444,0.0007012917,0.0007958762,0.0018608635],"category_scores_gemma":[0.0009580762,0.0006911424,0.0009125639,0.0014369794,0.00054522895,0.000104138766,0.0007375537,0.0019820353,0.004612753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006195757,0.0005896593,0.0026715249,0.01458157,0.00056131167,0.0013737428,0.000037136615,3.329678e-8,0.00037279594,0.000003715704,0.026154425,0.9530345],"study_design_scores_gemma":[0.0045881383,0.00044328565,0.0053706286,0.01279989,0.00019884341,0.0004127354,0.0000317277,0.000053562206,0.00008704382,0.000007815633,0.9755026,0.0005037227],"about_ca_topic_score_codex":0.001101394,"about_ca_topic_score_gemma":0.00018212071,"teacher_disagreement_score":0.9525308,"about_ca_system_score_codex":0.0022140353,"about_ca_system_score_gemma":0.001829114,"threshold_uncertainty_score":0.999554},"labels":[],"label_agreement":null},{"id":"W2100738529","doi":"10.1200/jco.2012.47.7901","title":"International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Cilag; Celgene; Takeda Oncology; Onyx Pharmaceuticals; Pfizer; Amgen","keywords":"Medicine; Multiple myeloma; Zoledronic acid; Spinal cord compression; Bone disease; Magnetic resonance imaging; Disease; Radiography; Radiology; Bisphosphonate; Surgery; Internal medicine; Osteoporosis; Spinal cord","score_opus":0.18317516296498768,"score_gpt":0.4766221856333922,"score_spread":0.2934470226684045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100738529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9073236,0.0013624647,0.0010812248,0.083815314,0.0028613044,0.0018476227,0.000041929292,0.00001796423,0.0016485933],"genre_scores_gemma":[0.9853856,0.003091155,0.009316773,0.00035964657,0.00086148066,0.000101653255,0.00004644638,0.000017668333,0.00081959064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971485,0.00022989837,0.001873693,0.00016769202,0.00033732777,0.00024286605],"domain_scores_gemma":[0.9906099,0.0069181104,0.0011997032,0.00022434877,0.0005617934,0.0004861518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009679433,0.00013597579,0.00081457355,0.00014336403,0.000088912915,0.00001587423,0.00018094748,0.00015895873,0.0006945811],"category_scores_gemma":[0.0034115643,0.00007414536,0.00075010565,0.00011309849,0.00019393036,0.00011397317,0.00003411855,0.0002962735,0.000029307217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046264455,0.005088266,0.16227292,0.000010493972,0.0017432132,0.00014152218,0.000108080196,0.00000967774,0.0001376213,0.0001227091,0.003970309,0.82176876],"study_design_scores_gemma":[0.0201649,0.009205356,0.65198636,0.000086279186,0.00048445264,0.000093583665,0.00015216733,0.0043711653,0.00004570383,0.00048177448,0.31286,0.00006826099],"about_ca_topic_score_codex":0.000042492287,"about_ca_topic_score_gemma":0.00002418003,"teacher_disagreement_score":0.8217005,"about_ca_system_score_codex":0.00023899015,"about_ca_system_score_gemma":0.00045414266,"threshold_uncertainty_score":0.76051754},"labels":[],"label_agreement":null},{"id":"W2101035019","doi":"10.1038/nature09837","title":"Initial genome sequencing and analysis of multiple myeloma","year":2011,"lang":"en","type":"article","venue":"Nature","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1439,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Multiple Myeloma Research Foundation; National Human Genome Research Institute; National Institute on Aging; Leukaemia and Lymphoma Research; Broad Institute","keywords":"Biology; Multiple myeloma; Gene; Genome; Genetics; Massive parallel sequencing; Mutation; Cancer; Somatic cell; DNA sequencing; Germline mutation; Cancer research; Cancer genome sequencing; Computational biology; Whole genome sequencing; Immunology","score_opus":0.046157222363353526,"score_gpt":0.3260179922858882,"score_spread":0.27986076992253467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101035019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384373,0.0008920147,0.000031188196,0.000039798397,0.000022724518,0.00016419093,0.00006504317,0.00001949221,0.0049218014],"genre_scores_gemma":[0.99687403,0.000040490682,0.0026751475,0.00012210678,0.00003303409,0.0000059430245,0.00010151844,0.00000851116,0.00013920545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929047,0.000022803893,0.0001260978,0.00017240936,0.00021881193,0.0001693978],"domain_scores_gemma":[0.99946976,0.000048627648,0.0000417341,0.00019323285,0.00010563881,0.00014100506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000848708,0.000086392014,0.00026715785,0.00030875788,0.00003333615,0.0000040169302,0.000048614722,0.0003529822,0.00026677933],"category_scores_gemma":[0.00016912284,0.000064961365,0.000093530325,0.00043473538,0.0000584113,0.000044814282,0.000036344627,0.00054032856,0.0000056544795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008276968,0.00017773498,0.94218904,0.000104709805,0.0037862016,0.00051407854,0.0017785644,0.0000014773841,0.037726525,0.0001811945,0.00003994241,0.012672862],"study_design_scores_gemma":[0.0012799152,0.000157492,0.98493433,0.00001485186,0.0006477449,0.000017810677,0.000107697466,0.0008364614,0.01175352,0.00002912705,0.00016307368,0.00005795663],"about_ca_topic_score_codex":0.00015012451,"about_ca_topic_score_gemma":0.00007835877,"teacher_disagreement_score":0.042745337,"about_ca_system_score_codex":0.00004470722,"about_ca_system_score_gemma":0.00005484262,"threshold_uncertainty_score":0.29210466},"labels":[],"label_agreement":null},{"id":"W2101141932","doi":"10.1182/blood-2012-03-417253","title":"Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; American Cancer Society","keywords":"Multiple myeloma; Medicine; Monoclonal gammopathy of undetermined significance; Internal medicine; Biomarker; Odds ratio; Cohort; Immunology; Oncology; Gastroenterology; Monoclonal; Antibody; Biology; Monoclonal antibody","score_opus":0.01878017910811322,"score_gpt":0.26407504714871344,"score_spread":0.24529486804060022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101141932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948776,0.002726012,0.000017299439,0.00015050174,0.000096819305,0.0016856433,0.00021384997,0.000043346416,0.00018892332],"genre_scores_gemma":[0.997209,0.001471767,0.0008508516,0.00006493991,0.000102498954,0.00013422717,0.00011630662,0.00003520664,0.000015199219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767137,0.00032140367,0.0005406654,0.00041199,0.00050499797,0.0005495539],"domain_scores_gemma":[0.99764407,0.0012399044,0.00022488847,0.00041957616,0.00014653643,0.00032500413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006025901,0.0003083485,0.00048734233,0.00030478032,0.0001243762,0.000035728346,0.00013870896,0.00018492177,0.000025821477],"category_scores_gemma":[0.001575873,0.0002192079,0.000090619855,0.00035873934,0.00033049608,0.00026750498,0.00012986103,0.00027946796,0.000007842532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006382668,0.0015492241,0.9810341,0.00015715837,0.00057906966,0.000034490637,0.0020371834,3.4897653e-7,0.0036649478,0.000012856406,0.00006441912,0.010227926],"study_design_scores_gemma":[0.012946682,0.00050893245,0.968681,0.00011772634,0.00030640082,0.00009246066,0.0005793488,0.00060186663,0.01583834,0.000024143299,0.00011761481,0.00018551484],"about_ca_topic_score_codex":0.0011330735,"about_ca_topic_score_gemma":0.0003583018,"teacher_disagreement_score":0.012353139,"about_ca_system_score_codex":0.000052720356,"about_ca_system_score_gemma":0.00005840409,"threshold_uncertainty_score":0.8939039},"labels":[],"label_agreement":null},{"id":"W2101753284","doi":"10.1186/1752-1947-1-84","title":"An unusual presentation of multiple myeloma: a case report","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Polyarthritis; Pathology; Serum protein electrophoresis; Arthritis; Amyloidosis; Rheumatoid arthritis; Biopsy; Dermatology; Immunology; Monoclonal; Antibody","score_opus":0.039104036867773966,"score_gpt":0.40321033876408846,"score_spread":0.3641063018963145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101753284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957506,0.00035188164,0.0024028532,0.00039873435,0.0003456009,0.0003011841,0.0000034165312,0.000015144958,0.00043060782],"genre_scores_gemma":[0.9967573,0.00003098376,0.0024107057,0.00004727053,0.00061420014,0.0000028165884,0.000019797322,0.000021438198,0.000095434145],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9946939,0.000108299275,0.0018730427,0.00022941343,0.0027436067,0.00035175483],"domain_scores_gemma":[0.9955627,0.00038650195,0.001225428,0.00042622501,0.00080750434,0.0015916978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052480823,0.0001562566,0.0005446025,0.00036471765,0.00007393362,0.000014554201,0.000053819705,0.00021745062,0.0002576926],"category_scores_gemma":[0.0064342446,0.000110375266,0.00023708939,0.0002689132,0.00015982521,0.00020529765,0.000039644812,0.00051762746,0.0000015338429],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006754899,0.0010735356,0.08802752,0.00009682538,0.00022034763,0.87366027,0.000222023,0.0000024406309,0.0009866701,0.0000039642177,0.0003411007,0.034689844],"study_design_scores_gemma":[0.0029748178,0.0011602384,0.029073328,0.00016736775,0.00017377887,0.9552221,0.0008087813,0.00036904606,0.009416851,0.000025604222,0.00052949204,0.00007861352],"about_ca_topic_score_codex":0.0008443742,"about_ca_topic_score_gemma":0.00034077678,"teacher_disagreement_score":0.08156184,"about_ca_system_score_codex":0.00013238486,"about_ca_system_score_gemma":0.00087806245,"threshold_uncertainty_score":0.77028567},"labels":[],"label_agreement":null},{"id":"W2102246371","doi":"10.3747/co.20.1252","title":"Lenalidomide in Multiple Myeloma—A Practice Guideline","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Northeast Cancer Centre; Health Sciences North; Windsor Regional Hospital; McMaster University","funders":"National Heart, Lung, and Blood Institute; Ontario Ministry of Health and Long-Term Care","keywords":"Lenalidomide; Medicine; Multiple myeloma; Internal medicine; Guideline; Oncology; Cochrane Library; Intensive care medicine; Thalidomide; MEDLINE; Hematology; Dexamethasone; Meta-analysis; Pathology","score_opus":0.14730006100607526,"score_gpt":0.4636655057375172,"score_spread":0.3163654447314419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102246371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93221253,0.0046224548,0.00067436445,0.029687986,0.0011640291,0.003157629,0.00001800759,0.0001445602,0.02831846],"genre_scores_gemma":[0.9853555,0.0005821505,0.011392221,0.0011033709,0.00037769132,0.00047314703,0.00017609123,0.00002889007,0.0005109332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805206,0.0002605715,0.00051536324,0.00034522734,0.00029034863,0.0005364557],"domain_scores_gemma":[0.99821705,0.00063666276,0.000116382005,0.0003202888,0.00037883912,0.00033080034],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00046162857,0.00017345126,0.00040473492,0.00022728344,0.00005095397,0.000017234282,0.00011569175,0.000119037824,0.0011604109],"category_scores_gemma":[0.0029907788,0.00013716065,0.00008379468,0.00024197357,0.00009902328,0.00021514216,0.00010119565,0.0004234065,0.001932921],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010474997,0.003466168,0.23977353,0.000081090264,0.00011526715,0.00044827265,0.00024497925,0.0000065292606,0.002780434,0.00015319155,0.07849773,0.6733853],"study_design_scores_gemma":[0.012199736,0.00069625006,0.110076346,0.00006859154,0.000049814298,0.00020613626,0.0003272225,0.004042661,0.00052992406,0.00015773412,0.87149906,0.00014650442],"about_ca_topic_score_codex":0.0005694419,"about_ca_topic_score_gemma":0.00015850765,"teacher_disagreement_score":0.79300135,"about_ca_system_score_codex":0.0004651923,"about_ca_system_score_gemma":0.0003028807,"threshold_uncertainty_score":0.99975264},"labels":[],"label_agreement":null},{"id":"W2102630035","doi":"10.1182/asheducation-2005.1.353","title":"An Update of the Management of Multiple Myeloma: The Changing Landscape","year":2005,"lang":"en","type":"article","venue":"Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Bortezomib; Clinical trial; Disease; Malignancy; Transplantation; Bioinformatics; Oncology; Immunology; Internal medicine; Biology","score_opus":0.018100369798882587,"score_gpt":0.3012004844753362,"score_spread":0.28310011467645363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102630035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945391,0.000540145,0.000093025905,0.0022138811,0.000042788546,0.00042918738,0.00000748498,0.0000151146905,0.002119306],"genre_scores_gemma":[0.99825394,0.00006307281,0.0012565935,0.000121949226,0.000027119895,0.000029554196,0.0000104934925,0.000009080452,0.00022818697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992267,0.00005576365,0.00018022672,0.00012204995,0.00017765911,0.00023760422],"domain_scores_gemma":[0.99931717,0.00004969868,0.000076128905,0.00046491926,0.00004228185,0.000049810587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014300497,0.000076486765,0.0002060946,0.000065349086,0.00006228547,0.0000021232022,0.00016237874,0.000038271224,0.00014362314],"category_scores_gemma":[0.0000148551735,0.000037677495,0.000068359965,0.00017163134,0.000099518635,0.000025574569,0.0000894224,0.00007432075,0.00002831967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009638772,0.0017280411,0.8713614,0.0011304386,0.0015334834,0.00022416959,0.0025024705,0.000072822055,0.0035924504,0.03466015,0.0016173576,0.080613345],"study_design_scores_gemma":[0.013221986,0.00049492024,0.7533667,0.00046852158,0.00046430298,0.00084597804,0.0040926854,0.019166335,0.1949806,0.00038680484,0.012266901,0.000244232],"about_ca_topic_score_codex":0.000011158653,"about_ca_topic_score_gemma":0.000031710297,"teacher_disagreement_score":0.19138815,"about_ca_system_score_codex":0.000011076539,"about_ca_system_score_gemma":0.000017180137,"threshold_uncertainty_score":0.15725727},"labels":[],"label_agreement":null},{"id":"W2102750142","doi":"10.1182/blood-2002-01-0008","title":"A molecular compendium of genes expressed in multiple myeloma","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Biology; Gene; Expressed sequence tag; Microarray; Genetics; Computational biology; Complementary DNA; Gene expression","score_opus":0.03476847430627687,"score_gpt":0.2740630524604476,"score_spread":0.2392945781541707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102750142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490494,0.0016313284,0.000016666276,0.000120274686,0.000014855029,0.0003623887,0.000020250125,0.000023355193,0.0029059537],"genre_scores_gemma":[0.9981617,0.0001061525,0.0014510523,0.000030935556,0.000021161492,0.000040469793,0.000018653374,0.000015729562,0.00015417338],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990785,0.000039809962,0.0001903544,0.0001814339,0.00025972186,0.00025019457],"domain_scores_gemma":[0.9994555,0.00005812574,0.000036688063,0.00028110447,0.000042844935,0.00012573038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004965527,0.000102176535,0.00024169408,0.00013689656,0.00001820306,0.000004973893,0.00007758975,0.0000504917,0.00027130992],"category_scores_gemma":[0.0000916609,0.00008729283,0.00007022508,0.00015840406,0.00004704451,0.00003008682,0.000038754162,0.00008270682,0.00006568582],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012593345,0.0033129726,0.54764575,0.00012294011,0.00016643241,0.0013767981,0.00018574686,0.000007081555,0.44041768,0.00003194728,0.00007225115,0.006534455],"study_design_scores_gemma":[0.016816169,0.00033239071,0.26555714,0.00009758784,0.000059094054,0.000047302932,0.000046441768,0.0018436152,0.71458757,0.000019718507,0.00049284153,0.000100152836],"about_ca_topic_score_codex":0.00011920452,"about_ca_topic_score_gemma":0.000024905545,"teacher_disagreement_score":0.2820886,"about_ca_system_score_codex":0.000013589812,"about_ca_system_score_gemma":0.000016186068,"threshold_uncertainty_score":0.35596982},"labels":[],"label_agreement":null},{"id":"W2102915129","doi":"10.1016/j.mehy.2008.02.014","title":"Proteasome inhibition as a novel therapy in treating rheumatoid arthritis","year":2008,"lang":"en","type":"article","venue":"Medical Hypotheses","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Pannus; Medicine; Rheumatoid arthritis; Apoptosis; Cancer research; Proteasome; In vivo; Proteasome inhibitor; Multiple myeloma; Immunology; Biology; Cell biology","score_opus":0.05521311205147472,"score_gpt":0.30948806830784914,"score_spread":0.2542749562563744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102915129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910786,0.0016280848,0.00011063591,0.0017258791,0.000027068001,0.0008576671,0.000008428786,0.00008175865,0.004481879],"genre_scores_gemma":[0.9892779,0.008346475,0.0009825258,0.000550319,0.00009979352,0.0003151972,0.000027961101,0.000027136974,0.00037269024],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976166,0.00013238599,0.00042374944,0.0002888236,0.0011279116,0.00041055732],"domain_scores_gemma":[0.9987274,0.0005118077,0.00006416177,0.00019899962,0.000055909088,0.00044176096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006431231,0.00017024198,0.0005038771,0.00019295617,0.00010556223,0.000013544195,0.00007238797,0.0001404223,0.001761065],"category_scores_gemma":[0.0058372016,0.00011820102,0.000119038494,0.0002603364,0.00022136362,0.00009078067,0.000033465385,0.0003254802,0.00021501264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009227926,0.003057018,0.26135853,0.00005489861,0.00014527052,0.0061244587,0.0009997851,5.1936513e-7,0.006757487,0.00023052792,0.00041812455,0.7199306],"study_design_scores_gemma":[0.061460666,0.004989035,0.8269245,0.0066143316,0.000013765976,0.01269194,0.00066609523,0.0014328904,0.06325188,0.0013714504,0.019787181,0.0007962336],"about_ca_topic_score_codex":0.000816777,"about_ca_topic_score_gemma":0.000090522735,"teacher_disagreement_score":0.7191344,"about_ca_system_score_codex":0.000085855034,"about_ca_system_score_gemma":0.00039230898,"threshold_uncertainty_score":0.99915147},"labels":[],"label_agreement":null},{"id":"W2103289668","doi":"10.18632/oncotarget.1497","title":"Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms","year":2013,"lang":"en","type":"review","venue":"Oncotarget","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"Ministry of Science and Technology of the People's Republic of China; Cancer Research Society","keywords":"Multiple myeloma; Hematology; Medicine; Drug resistance; Oncology; Cancer; Pomalidomide; Cancer research; Internal medicine; Bortezomib; Biology; Genetics","score_opus":0.05141101826830751,"score_gpt":0.3533042468832884,"score_spread":0.30189322861498086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103289668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016804878,0.9927437,0.00002156162,0.00044308582,0.00011556297,0.0025693625,0.000067260364,0.00006210132,0.0022969132],"genre_scores_gemma":[0.00094781595,0.9733643,0.0075055324,0.00015262126,0.00009008225,0.0003013249,0.00046589514,0.00012165905,0.017050775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972104,0.00017080884,0.00056845584,0.00081796106,0.000546749,0.0006856149],"domain_scores_gemma":[0.9981896,0.00037476624,0.00016684236,0.000575425,0.00005632771,0.0006370133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022263985,0.000623467,0.0018897222,0.00035856006,0.000077506986,0.000060587503,0.00020866164,0.00033678967,0.00030778788],"category_scores_gemma":[0.0003954433,0.00047363655,0.00027765648,0.000360116,0.000085477,0.00008171238,0.00011659668,0.00067776453,0.0006935867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068897515,0.0020546152,0.0031838934,0.040431853,0.0017318069,0.011105905,0.0008136711,8.472662e-7,0.00029947626,0.006833023,0.09164491,0.841211],"study_design_scores_gemma":[0.0034714015,0.00018601475,0.00054050423,0.013777546,0.00022275835,0.000034308916,0.000011747014,0.000010219599,0.000093388415,0.00047032145,0.98075783,0.00042394205],"about_ca_topic_score_codex":0.0002857468,"about_ca_topic_score_gemma":0.00020470524,"teacher_disagreement_score":0.88911295,"about_ca_system_score_codex":0.00039944882,"about_ca_system_score_gemma":0.0004960653,"threshold_uncertainty_score":0.99977154},"labels":[],"label_agreement":null},{"id":"W2104096033","doi":"10.1186/1756-8722-3-13","title":"Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Mass spectrometry; Hematology; Malignancy; Computational biology; Proteomics; Biomarker discovery; Disease; Internal medicine; Oncology; Bioinformatics; Cancer research; Biology; Chemistry; Biochemistry; Chromatography; Gene","score_opus":0.06230023267059034,"score_gpt":0.4045304902953145,"score_spread":0.3422302576247242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104096033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012028721,0.97652066,0.01283626,0.0029986678,0.0007125719,0.005061888,0.000026664513,0.000036020952,0.00060438924],"genre_scores_gemma":[0.010511736,0.8753086,0.11241056,0.00022916384,0.00035895733,0.0009184833,0.000018751827,0.00013987583,0.00010391308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605066,0.000448985,0.0018092386,0.00042182798,0.00049335853,0.0007759635],"domain_scores_gemma":[0.9942344,0.0021262225,0.002221215,0.0007344925,0.00034352462,0.00034014625],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011452392,0.00050599466,0.0046804864,0.0023043,0.00015862625,0.000010848707,0.00076106994,0.0012510453,0.000118033444],"category_scores_gemma":[0.0023125901,0.00030204386,0.00082893413,0.0011537474,0.0006019435,0.000057659166,0.0001584926,0.00289581,0.000047497753],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00212995,0.0014884165,0.006181403,0.015788328,0.0034027498,0.00898676,0.00008700933,0.0000054207344,0.0054523395,0.004169489,0.0008352033,0.95147294],"study_design_scores_gemma":[0.00556543,0.005284044,0.000069562906,0.009097787,0.0020350558,0.030210266,0.0003326689,0.00003459301,0.0020547733,0.0010199511,0.94393295,0.0003628912],"about_ca_topic_score_codex":0.0000042180486,"about_ca_topic_score_gemma":0.000025646532,"teacher_disagreement_score":0.95111006,"about_ca_system_score_codex":0.0012348416,"about_ca_system_score_gemma":0.002634236,"threshold_uncertainty_score":0.9999432},"labels":[],"label_agreement":null},{"id":"W2104559544","doi":"10.13055/ojhmt_5_1_1.140304","title":"Ocular crystal deposition leading to a diagnosis of multiple myeloma: a report of 2 cases and review of the literature","year":2014,"lang":"en","type":"article","venue":"Open Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Multiple myeloma; Medicine; Bortezomib; Cornea; Visual acuity; Pathology; Dermatology; Ophthalmology; Internal medicine","score_opus":0.026198595022556857,"score_gpt":0.34411876832071603,"score_spread":0.3179201732981592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104559544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760099,0.020996181,0.000076450924,0.0020949296,0.000039978142,0.0005658836,0.00001135145,9.2755255e-7,0.00020438072],"genre_scores_gemma":[0.9947172,0.0019583998,0.0031235141,0.00013265002,0.000016059152,0.000013198523,0.0000047373424,0.000007399891,0.000026871228],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868286,0.00018615722,0.0006628809,0.00010423543,0.00024516258,0.00011873609],"domain_scores_gemma":[0.9981639,0.00039525467,0.00064124307,0.00024044458,0.0004430858,0.00011608928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056653726,0.0000859299,0.0007610804,0.00010012239,0.000031296775,0.0000075452413,0.00015175753,0.000050833765,0.000025030826],"category_scores_gemma":[0.0034620047,0.000049996976,0.00013427605,0.00018304927,0.00007529331,0.00008471584,0.00012315449,0.00012478036,4.5168687e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012487002,0.0007877938,0.9404656,0.014281436,0.0007329734,0.006974138,0.0006753379,0.0000016271763,0.020602252,0.00038425502,0.0030929681,0.010752872],"study_design_scores_gemma":[0.008876936,0.004899573,0.1291121,0.11996356,0.00094970653,0.275614,0.0002754279,0.000045407196,0.45564342,0.00018996542,0.004211926,0.00021801695],"about_ca_topic_score_codex":0.000043499538,"about_ca_topic_score_gemma":0.00002148759,"teacher_disagreement_score":0.81135356,"about_ca_system_score_codex":0.0000183122,"about_ca_system_score_gemma":0.00009160978,"threshold_uncertainty_score":0.41445932},"labels":[],"label_agreement":null},{"id":"W2105407688","doi":"10.3816/clm.2005.n.034","title":"Evolving Role of Stem Cell Transplantation in Multiple Myeloma","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Thalidomide; Melphalan; Multiple myeloma; Oncology; Transplantation; Internal medicine; Lenalidomide; Bortezomib; Prednisone; Hematopoietic stem cell transplantation; Surgery","score_opus":0.08757526195142284,"score_gpt":0.394048972723216,"score_spread":0.30647371077179314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105407688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017952025,0.9753283,0.0000099645895,0.000021479822,0.00023048827,0.0025112487,0.00026943427,0.0001007622,0.0035762845],"genre_scores_gemma":[0.04550906,0.9507443,0.0012215073,0.00003999064,0.00051215757,0.00026278227,0.0007195469,0.00016905114,0.0008216212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99265534,0.00080861925,0.0034439778,0.0012207932,0.00090333936,0.0009679081],"domain_scores_gemma":[0.9941766,0.0028340244,0.00094349624,0.0011107315,0.00022028742,0.00071482203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010599544,0.0008642909,0.0044059055,0.00069430575,0.0000905099,0.000039390674,0.0005378397,0.0011808629,0.00023820064],"category_scores_gemma":[0.0002925809,0.000703685,0.0017831108,0.00079479587,0.00029824293,0.00018803036,0.00013826825,0.00069388514,0.0005896151],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048097872,0.0016721771,0.012053388,0.0114752455,0.00033426762,0.00073665596,0.00009192278,4.675402e-7,0.000008177344,0.000012246231,0.000103189166,0.9730313],"study_design_scores_gemma":[0.015745044,0.0013636802,0.22365709,0.02759549,0.0024225167,0.00062726694,0.00013928226,0.0005737055,0.00012968334,0.00002560561,0.7266606,0.0010600408],"about_ca_topic_score_codex":0.00012874504,"about_ca_topic_score_gemma":0.000101893485,"teacher_disagreement_score":0.9719712,"about_ca_system_score_codex":0.00058433606,"about_ca_system_score_gemma":0.0014574302,"threshold_uncertainty_score":0.9995414},"labels":[],"label_agreement":null},{"id":"W2105740844","doi":"10.3816/clml.2010.n.078","title":"Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; V Foundation for Cancer Research; American Cancer Society","keywords":"Medicine; Immunoglobulin D; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Internal medicine; Oncology; Myeloma protein; Bone marrow; Antibody; Immunology; B cell","score_opus":0.024492553527734683,"score_gpt":0.3122991664099886,"score_spread":0.28780661288225395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105740844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961996,0.000068688874,0.00007823035,0.000079664795,0.00027393052,0.0021121902,0.00010568345,0.00014220239,0.0009398167],"genre_scores_gemma":[0.9976037,0.00004263452,0.00149988,0.00009447894,0.000115201816,0.000103849685,0.00008662748,0.00008605608,0.0003675322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955561,0.0002652956,0.0014534168,0.0010578599,0.0009745625,0.00069275894],"domain_scores_gemma":[0.99591076,0.0015534182,0.00046686557,0.0009274089,0.00042789325,0.00071365334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062348833,0.0005234632,0.0013700825,0.00021678851,0.00024327588,0.000052413267,0.00027467162,0.00038043168,0.0000817516],"category_scores_gemma":[0.00039626495,0.0003932163,0.0002625194,0.00040414697,0.0006099739,0.00019893126,0.00013078263,0.00060681277,0.000055801145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003541727,0.002182,0.94210374,0.00036488136,0.00038263752,0.0007155399,0.0007367787,0.0000012158628,0.00014920402,0.000059672762,0.000029010085,0.04973357],"study_design_scores_gemma":[0.03006519,0.004604958,0.96273404,0.00012920935,0.00043393625,0.00012464827,0.00050111907,0.00021504522,0.00073728146,0.00005571346,0.000040055464,0.0003588271],"about_ca_topic_score_codex":0.00015459028,"about_ca_topic_score_gemma":0.00058148644,"teacher_disagreement_score":0.049374744,"about_ca_system_score_codex":0.00036552906,"about_ca_system_score_gemma":0.0006994943,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W2105763895","doi":"10.1158/1078-0432.ccr-10-3097","title":"Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134","year":2011,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Receptor; Multiple myeloma; Growth factor; Growth inhibition; Insulin-like growth factor; In vivo; Bone marrow; Cell culture; Apoptosis; Biology; Fibroblast growth factor receptor 3; Pharmacology; Internal medicine; Fibroblast growth factor; Immunology; Medicine; Biochemistry","score_opus":0.1895705407986632,"score_gpt":0.4392424509220034,"score_spread":0.24967191012334022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105763895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966932,0.00022204281,0.00015711134,0.0010969206,0.000292758,0.0010399683,0.00021104337,0.000022103517,0.00026487157],"genre_scores_gemma":[0.99764997,0.001166961,0.00040945664,0.0001193842,0.00020389711,0.00009639735,0.00002945153,0.000034362223,0.00029014295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703264,0.00052917644,0.00044048188,0.00050245074,0.0009861805,0.0005090903],"domain_scores_gemma":[0.9978742,0.00036049203,0.00013442503,0.0005174191,0.00069826026,0.00041520086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010608663,0.0001665995,0.0004291502,0.00010557551,0.00015071292,0.00002233928,0.00024889794,0.00021447013,0.00048721983],"category_scores_gemma":[0.0016888714,0.00010908789,0.00015295816,0.0005372824,0.0007587257,0.00013910785,0.00036388132,0.00094419514,0.000027045295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031672788,0.0015240314,0.57125807,0.00023827174,0.00024508688,0.000027331163,0.0002995691,5.107501e-8,0.37544465,0.00008846195,0.00020199982,0.047505222],"study_design_scores_gemma":[0.0025468506,0.0006884976,0.7843035,0.00014353565,0.000017327578,0.0000027718554,0.000015311472,0.00009548059,0.21070284,0.00003442311,0.0013634904,0.00008596506],"about_ca_topic_score_codex":0.0006890312,"about_ca_topic_score_gemma":0.000023921251,"teacher_disagreement_score":0.21304546,"about_ca_system_score_codex":0.00011633429,"about_ca_system_score_gemma":0.00050249277,"threshold_uncertainty_score":0.5334715},"labels":[],"label_agreement":null},{"id":"W2106379961","doi":"10.3816/clm.2008.n.051","title":"Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment","year":2008,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Doxorubicin; Internal medicine; Renal function; Chemotherapy; Materials science","score_opus":0.030798670057492043,"score_gpt":0.3048801949785689,"score_spread":0.27408152492107685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106379961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964678,0.00021158469,0.000013341949,0.00019902964,0.00019892857,0.0024133807,0.000039964318,0.00013527912,0.00032065966],"genre_scores_gemma":[0.9974542,0.00022693611,0.00071645255,0.00027478964,0.00018384229,0.00011071996,0.00035881455,0.00008893031,0.0005852719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946576,0.0004882252,0.0016926398,0.0012011797,0.0009272443,0.0010331108],"domain_scores_gemma":[0.99653935,0.0012902803,0.00032422636,0.0007655474,0.00022757289,0.0008530326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006980709,0.0005716755,0.0012797321,0.0004697544,0.00022972528,0.000027977367,0.00018982723,0.00050856295,0.00015365853],"category_scores_gemma":[0.0013623128,0.00040262126,0.00017907092,0.00082118285,0.00052405824,0.00023220509,0.00018134747,0.00063281215,0.00010107396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119654484,0.00520286,0.7860438,0.00005408254,0.00024032602,0.002627407,0.00020168202,0.0000130846,0.000089981375,0.00000394635,0.00021096018,0.085657366],"study_design_scores_gemma":[0.12949337,0.010905318,0.8566469,0.0004023163,0.000090553374,0.0001848893,0.000047307825,0.001040971,0.00006639273,0.00000564644,0.00074404746,0.00037226317],"about_ca_topic_score_codex":0.00035884953,"about_ca_topic_score_gemma":0.00048152122,"teacher_disagreement_score":0.085285105,"about_ca_system_score_codex":0.0009587273,"about_ca_system_score_gemma":0.000958304,"threshold_uncertainty_score":0.9998426},"labels":[],"label_agreement":null},{"id":"W2106860974","doi":"10.3109/10428194.2011.601475","title":"Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Incidence (geometry); Confidence interval; Demography; Ethnic group; Medicine; Standardized rate; Etiology; Population; Plasma cell neoplasm; Ethnic chinese; Epidemiology; Multiple myeloma; Internal medicine; Plasmacytoma","score_opus":0.013042410612530931,"score_gpt":0.23766761615937296,"score_spread":0.22462520554684204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106860974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568033,0.00036104734,0.000020874062,0.00002986882,0.00019787412,0.0011575412,0.0006429847,0.00009173462,0.0018177362],"genre_scores_gemma":[0.994495,0.00030989072,0.002025068,0.0004913897,0.00007890232,0.00014493082,0.00020476163,0.00011272785,0.0021373415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540967,0.00022346526,0.0010185377,0.0012466279,0.0009113033,0.0011904191],"domain_scores_gemma":[0.99707925,0.000508834,0.00021768833,0.0008865745,0.00027204357,0.0010355832],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005762034,0.0005620717,0.0012949008,0.00033795182,0.00019547385,0.00017271482,0.0004870781,0.00049383263,0.0011042466],"category_scores_gemma":[0.0005402947,0.00065989874,0.00024956596,0.001045442,0.00031084262,0.00026847408,0.00038605093,0.00020032481,0.0002411772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027692278,0.0007051974,0.9637494,0.00017811984,0.00020562213,0.0031142028,0.0027577286,0.00000230313,0.002645656,0.0000028494903,0.0034956017,0.020374063],"study_design_scores_gemma":[0.027102025,0.0008357419,0.9639221,0.0005770271,0.000087552115,0.0003243515,0.00031881532,0.0012177968,0.0042248806,0.00015592585,0.0006602898,0.0005735077],"about_ca_topic_score_codex":0.5410566,"about_ca_topic_score_gemma":0.114563085,"teacher_disagreement_score":0.42649347,"about_ca_system_score_codex":0.0038241353,"about_ca_system_score_gemma":0.0026141144,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W2107103889","doi":"10.2174/156800909789760393","title":"Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy","year":2009,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Comprehensive Cancer Network","keywords":"Multiple myeloma; Medicine; Bone disease; Disease; Current (fluid); Intensive care medicine; Bioinformatics; Osteoporosis; Internal medicine; Biology; Engineering","score_opus":0.16611818676336448,"score_gpt":0.37562812197963663,"score_spread":0.20950993521627215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107103889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035662958,0.98453164,0.000074108706,0.0024127176,0.0023172658,0.008117751,0.0018714155,0.00024774147,0.00007074102],"genre_scores_gemma":[0.0022229978,0.98782164,0.00029720186,0.00012278363,0.0010124695,0.004612209,0.0032263976,0.00022019958,0.00046412268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937734,0.00036714954,0.0011885996,0.0018057977,0.001341507,0.0015235435],"domain_scores_gemma":[0.9955438,0.0004167237,0.00040225775,0.0014893373,0.00017518364,0.001972706],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00039542184,0.0014490952,0.0027744754,0.00053124863,0.00043552634,0.00013694829,0.0008528505,0.0001805983,0.0004564276],"category_scores_gemma":[0.00025569834,0.0008907869,0.0011930682,0.0011043899,0.00011202372,0.0001225487,0.00035602576,0.0015706297,0.0006810061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003234513,0.00093097857,0.0004299562,0.0030933702,0.0009103858,0.00010046551,0.0006235029,0.000044213237,6.1978295e-7,0.000032484164,0.0067503843,0.9867602],"study_design_scores_gemma":[0.0019151884,0.000092071314,0.0031812743,0.019012125,0.0007273949,0.000005484567,0.000021238477,0.0003357101,0.000023603106,0.00011973949,0.97369444,0.0008717243],"about_ca_topic_score_codex":0.0002078936,"about_ca_topic_score_gemma":0.00004978796,"teacher_disagreement_score":0.9858885,"about_ca_system_score_codex":0.0010086356,"about_ca_system_score_gemma":0.0011274259,"threshold_uncertainty_score":0.9998259},"labels":[],"label_agreement":null},{"id":"W2107249625","doi":"10.1634/theoncologist.2012-0384","title":"Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Research Manitoba; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Otsuka Canada Pharmaceutical; Otsuka Pharmaceutical","keywords":"Medicine; Melphalan; Multiple myeloma; Busulfan; Lenalidomide; Thalidomide; Bortezomib; Regimen; Oncology; Conditioning regimen; Transplantation; Internal medicine; Surgery; Hematopoietic stem cell transplantation","score_opus":0.11800804324453118,"score_gpt":0.4107763555520448,"score_spread":0.2927683123075136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107249625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002662849,0.98977184,0.0001703329,0.00037038815,0.00008389918,0.007390093,0.00046963847,0.000052363102,0.0014251671],"genre_scores_gemma":[0.0024178843,0.9907308,0.0025060605,0.000062900675,0.00016772868,0.0012336319,0.0012064544,0.00005794301,0.0016165918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830395,0.00020692323,0.00054201926,0.0003444439,0.00023238413,0.0003703058],"domain_scores_gemma":[0.9948552,0.0038548445,0.0004253608,0.000538514,0.00015580097,0.00017025105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044298585,0.0003238828,0.0015467696,0.000117409734,0.00021584715,0.000022371587,0.00019262727,0.00025009995,0.00011299628],"category_scores_gemma":[0.0012917055,0.00017466926,0.00032733887,0.00015826026,0.0005621293,0.000024918518,0.000071936025,0.0002952113,0.00004935093],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056668004,0.00026030204,0.000062945415,0.008158258,0.0005480467,0.000024606841,0.000020946647,0.0000014294648,0.000008372835,0.00012401344,0.002331247,0.98789316],"study_design_scores_gemma":[0.007394303,0.0012995644,0.0014515395,0.0059044296,0.0014557202,0.00005554513,0.000025642732,0.00015799435,0.000033287066,0.000022057251,0.98200965,0.00019024142],"about_ca_topic_score_codex":0.00012327463,"about_ca_topic_score_gemma":0.00002169456,"teacher_disagreement_score":0.9877029,"about_ca_system_score_codex":0.00022951582,"about_ca_system_score_gemma":0.00054458535,"threshold_uncertainty_score":0.7122806},"labels":[],"label_agreement":null},{"id":"W2108234041","doi":"10.1111/j.1542-4758.2010.00481.x","title":"Role of plasmapheresis in the management of myeloma kidney: A systematic review","year":2010,"lang":"en","type":"review","venue":"Hemodialysis International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmapheresis; Dialysis; Randomized controlled trial; Nephrology; Observational study; Intensive care medicine; Multiple myeloma; Internal medicine; Renal function; Hemodialysis; Surgery; Immunology","score_opus":0.03210564936925508,"score_gpt":0.3507774212457769,"score_spread":0.3186717718765218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108234041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001980016,0.9821662,0.000003885218,0.000110608795,0.00005362546,0.0028271354,0.00014926847,0.0000064835226,0.0146630285],"genre_scores_gemma":[0.00034609798,0.99702346,0.0006257513,0.00007418446,0.00003905378,0.00088307174,0.0005078835,0.000022647682,0.00047783187],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968759,0.00026761563,0.0012766147,0.0002842225,0.0011166524,0.00017900822],"domain_scores_gemma":[0.99800926,0.0002789904,0.00071417843,0.0007381839,0.00016579959,0.00009355745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080759916,0.00026889282,0.0023792728,0.00040830247,0.000016535774,0.000011777119,0.00066514267,0.00013826853,0.00045435596],"category_scores_gemma":[0.00035698552,0.00015220152,0.00095298985,0.00050148263,0.000062811305,0.00003393035,0.00011453097,0.00031171937,0.00006980876],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018934457,0.00035732298,0.000043489454,0.8306304,0.003378941,0.00006597065,0.00003333431,3.9497937e-8,0.0000014195118,0.0006522247,0.00020046053,0.16461743],"study_design_scores_gemma":[0.0007518962,0.000040347324,0.00008077452,0.7960549,0.00940332,0.00008846566,0.00005073682,0.000030420373,0.00000878851,0.000041641415,0.19331767,0.00013103981],"about_ca_topic_score_codex":0.000028014012,"about_ca_topic_score_gemma":0.0000107164105,"teacher_disagreement_score":0.1931172,"about_ca_system_score_codex":0.00011630585,"about_ca_system_score_gemma":0.00017740479,"threshold_uncertainty_score":0.62065977},"labels":[],"label_agreement":null},{"id":"W2108495564","doi":"10.3324/haematol.2010.030296","title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Heidelberg; Deutsche Forschungsgemeinschaft; Stem Cell Network","keywords":"Multiple myeloma; Beta-2 microglobulin; Internal medicine; Oncology; Cancer research; Medicine; Chemotherapy; Proliferation index; Hematology; Bone marrow; Biology; Immunohistochemistry","score_opus":0.040330963112175724,"score_gpt":0.3031161525604666,"score_spread":0.2627851894482909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108495564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548465,0.00029667767,0.00014366677,0.0005116176,0.000038109152,0.0032656975,0.00016570002,0.0000469017,0.000046951907],"genre_scores_gemma":[0.99170625,0.00019369589,0.0070211473,0.000037630645,0.00003119323,0.0007106111,0.00009780585,0.0000151956365,0.00018648284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987167,0.000060177845,0.00021898074,0.00039875362,0.0001870287,0.00041832172],"domain_scores_gemma":[0.9991787,0.0002574776,0.000077127996,0.00014693383,0.00006371256,0.00027606272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000857098,0.0002081226,0.00041655707,0.000104197476,0.00013992612,0.000039282128,0.000035064382,0.0001553479,0.0001307579],"category_scores_gemma":[0.0006287023,0.00013660786,0.000060364597,0.00006892905,0.00010438473,0.00006465499,0.000027169353,0.00017204066,0.0000059163485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00139091,0.0005133096,0.9853867,0.000089630375,0.00012146307,0.00016716316,0.0010186802,1.5225977e-7,0.0017345324,0.00014402258,0.000027767905,0.0094056185],"study_design_scores_gemma":[0.012186631,0.0014627088,0.97176915,0.0000341788,0.0000714059,0.0002614455,0.00014522846,0.006467138,0.0058654053,0.00018526193,0.0014093891,0.00014207848],"about_ca_topic_score_codex":0.00018110083,"about_ca_topic_score_gemma":0.0006879955,"teacher_disagreement_score":0.013617621,"about_ca_system_score_codex":0.00005320734,"about_ca_system_score_gemma":0.00008741628,"threshold_uncertainty_score":0.5570707},"labels":[],"label_agreement":null},{"id":"W2108780838","doi":"","title":"Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"CD34; Progenitor cell; Bone marrow; Haematopoiesis; Multiple myeloma; Biology; Immunology; Cancer research; Stem cell; Cell biology","score_opus":0.01915964775763226,"score_gpt":0.23060320256051597,"score_spread":0.2114435548028837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108780838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836733,0.00075863337,0.000055812798,0.0030765526,0.00027259512,0.0077915466,0.000054675445,0.00025107106,0.004065817],"genre_scores_gemma":[0.97886884,0.000032695374,0.0018018428,0.0007647219,0.00013815681,0.006949956,0.00004680898,0.00012150021,0.011275497],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99554396,0.0001157791,0.0005597539,0.0009160448,0.0009466897,0.0019177926],"domain_scores_gemma":[0.9966847,0.00013566653,0.00011065988,0.0010707427,0.00031068522,0.0016875643],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003180527,0.0005618514,0.00079381117,0.00047398434,0.00028007693,0.00015820778,0.0004148537,0.00017455392,0.00037896866],"category_scores_gemma":[0.00015636353,0.00044479527,0.0001870048,0.0012595485,0.00012024583,0.00014170853,0.00022405146,0.00038421032,0.0022286682],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017524457,0.019470762,0.25645718,0.0031640977,0.0043880953,0.0045635495,0.008833568,0.0005241771,0.027850503,0.00018828726,0.072048254,0.58498704],"study_design_scores_gemma":[0.020347182,0.004243033,0.7890683,0.00047504395,0.00061430427,0.0005674237,0.00057666795,0.00062743487,0.14221382,0.00003369359,0.039464362,0.0017687266],"about_ca_topic_score_codex":0.00012964313,"about_ca_topic_score_gemma":0.000042450236,"teacher_disagreement_score":0.58321834,"about_ca_system_score_codex":0.00047239565,"about_ca_system_score_gemma":0.00008324184,"threshold_uncertainty_score":0.9998004},"labels":[],"label_agreement":null},{"id":"W2109029992","doi":"10.1016/j.cancergen.2015.03.003","title":"Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment","year":2015,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Scheme for Promotion of Academic and Research Collaboration; U.S. Food and Drug Administration; Ministry of Health, British Columbia","keywords":"Lenalidomide; microRNA; Myelodysplastic syndromes; Thalidomide; Transcriptome; Cancer research; CD34; Gene expression profiling; Stem cell; Bone marrow; Haematopoiesis; Medicine; Oncology; Multiple myeloma; Bioinformatics; Internal medicine; Gene expression; Biology; Gene; Genetics","score_opus":0.04418644303145426,"score_gpt":0.3029944905317684,"score_spread":0.25880804750031416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109029992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957134,0.003035511,0.000015703974,0.0004416244,0.00005623466,0.0005671237,0.000059080467,0.0000066340285,0.000104662475],"genre_scores_gemma":[0.9981627,0.00056842517,0.00025568414,0.000112202935,0.00001859789,0.00006828169,0.000010538022,0.000020129219,0.0007834791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900603,0.00006457835,0.00018530292,0.00020503784,0.00029157606,0.0002474818],"domain_scores_gemma":[0.9993139,0.000062029925,0.00008273106,0.00023887918,0.000116456446,0.00018602968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072973526,0.00014971684,0.00028482164,0.000058143232,0.000032082404,0.000008716915,0.00006464211,0.000068121444,0.00002547511],"category_scores_gemma":[0.00005248778,0.00008055765,0.000036376827,0.00014965334,0.00010663931,0.000019783722,0.000050569,0.00008447993,0.0000028869413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014029732,0.00039989242,0.9768345,0.000074809126,0.00030484205,0.00019062635,0.0019994965,0.0002610129,0.014139436,9.2504536e-7,0.00066277874,0.0037287166],"study_design_scores_gemma":[0.019425303,0.0013857122,0.864838,0.0009511159,0.000235868,0.00011611089,0.0001494574,0.0015055669,0.110661946,0.00003281425,0.0005438421,0.000154251],"about_ca_topic_score_codex":0.00043677175,"about_ca_topic_score_gemma":0.0007539234,"teacher_disagreement_score":0.11199648,"about_ca_system_score_codex":0.0004366432,"about_ca_system_score_gemma":0.00035299675,"threshold_uncertainty_score":0.32850456},"labels":[],"label_agreement":null},{"id":"W2109396389","doi":"10.1158/0008-5472.can-04-2263","title":"The FLT3 Internal Tandem Duplication Mutation Prevents Apoptosis in Interleukin-3-Deprived BaF3 Cells Due to Protein Kinase A and Ribosomal S6 Kinase 1–Mediated BAD Phosphorylation at Serine 112","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"National Cancer Institute","keywords":"Ribosomal s6 kinase; Cyclin-dependent kinase 9; Mitogen-activated protein kinase kinase; MAP kinase kinase kinase; MAP2K7; Cyclin-dependent kinase 2; Protein kinase B; Cyclin-dependent kinase 4; MAPK/ERK pathway; ASK1; c-Raf; Kinase; Protein kinase A; Biology; Cancer research; Phosphorylation; Molecular biology; Cell biology; P70-S6 Kinase 1","score_opus":0.03250012436646472,"score_gpt":0.3618831588247091,"score_spread":0.3293830344582444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109396389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914502,0.00086125557,0.00009372603,0.004041167,0.0000466603,0.0032919946,0.00003534124,0.000033332293,0.0001463141],"genre_scores_gemma":[0.9942904,0.0005778208,0.00031716822,0.00006483228,0.00015650566,0.002197707,0.000094440256,0.000037751317,0.0022633795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971779,0.0003142874,0.0003865119,0.000547125,0.0008857684,0.00068842573],"domain_scores_gemma":[0.99847364,0.0002429666,0.00007807813,0.00039389406,0.00035145157,0.00045994835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009335643,0.00019924712,0.00024875987,0.00034047986,0.00027771562,0.000091088594,0.00020999023,0.000106432475,0.00021630595],"category_scores_gemma":[0.00048478314,0.00015209414,0.000051748015,0.0006169463,0.00015687701,0.00021894323,0.0002737023,0.0004775948,0.00018675318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050376644,0.0004630324,0.044983797,0.00012418511,0.000121181714,0.00015089446,0.0010160522,0.000059630616,0.7060463,0.000029023795,0.0005396602,0.24142858],"study_design_scores_gemma":[0.0057929046,0.0006743263,0.22148164,0.00051419414,0.000016541235,0.000014913324,0.00018584555,0.0048842863,0.7606643,0.000051730247,0.005539066,0.0001802378],"about_ca_topic_score_codex":0.0015773794,"about_ca_topic_score_gemma":0.0027429627,"teacher_disagreement_score":0.24124834,"about_ca_system_score_codex":0.0018131139,"about_ca_system_score_gemma":0.00024239733,"threshold_uncertainty_score":0.6202219},"labels":[],"label_agreement":null},{"id":"W2110103407","doi":"10.5430/jhm.v3n1p1","title":"Plasmacytoma cases with unfamiliar clinical features","year":2013,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Plasmacytoma; Medicine; Plasma cell; Multiple myeloma; Malignancy; Plasma cell neoplasm; Radiation therapy; Radiology; Pathology; Internal medicine","score_opus":0.05429718021663344,"score_gpt":0.3501806019323399,"score_spread":0.2958834217157065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110103407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559337,0.0011330615,0.000055894736,0.0016004496,0.000080489845,0.00030974098,0.0000037867253,0.00002691632,0.0011962927],"genre_scores_gemma":[0.99117464,0.00026703428,0.007452149,0.00042802107,0.0001316905,0.000012272277,0.000002475067,0.0000126930145,0.00051903777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814457,0.00011193703,0.00063529244,0.00017336251,0.0005704453,0.00036439506],"domain_scores_gemma":[0.9978434,0.00072039384,0.00028619153,0.00019143874,0.0004937008,0.00046489382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002616091,0.00018428487,0.0007569351,0.00011138712,0.00007346952,0.00004457324,0.0001446828,0.00013746056,0.0004157596],"category_scores_gemma":[0.0011725688,0.000085825195,0.0002555487,0.00014982492,0.00030208423,0.00016529595,0.000047127505,0.00042398972,0.0001227593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027281474,0.0015263004,0.9244354,0.00014419765,0.0006319478,0.029253507,0.00005846304,0.0000024695523,0.001485738,0.0011319686,0.030809915,0.007791968],"study_design_scores_gemma":[0.004123615,0.0063914177,0.93445486,0.0003564328,0.00012338786,0.04748944,0.0003236375,0.00001535317,0.00481196,0.00050313585,0.001271365,0.00013542105],"about_ca_topic_score_codex":0.000030004936,"about_ca_topic_score_gemma":0.000008502473,"teacher_disagreement_score":0.02953855,"about_ca_system_score_codex":0.0000350255,"about_ca_system_score_gemma":0.00015714552,"threshold_uncertainty_score":0.4552276},"labels":[],"label_agreement":null},{"id":"W2110394393","doi":"10.5430/jhm.v1n1p15","title":"Rheumatic manifestations of hematologic malignancies: Correlation with","year":2011,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Gastroenterology; Rheumatoid factor; Rheumatoid arthritis; Odds ratio; Bone marrow; Lymphoma; Anti-nuclear antibody; Immunology; Autoantibody; Antibody","score_opus":0.06071243447242331,"score_gpt":0.29004361239004917,"score_spread":0.22933117791762586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110394393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99060947,0.0006668974,0.0052322554,0.00015035269,0.000054101238,0.00031881148,0.000005358641,0.000023599896,0.0029391642],"genre_scores_gemma":[0.96912795,0.00014496871,0.030513152,0.00004437856,0.000010790753,0.000012971905,0.0000038082785,0.000012138393,0.0001298082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981014,0.00008172767,0.0008212052,0.0001441398,0.0005579341,0.00029355497],"domain_scores_gemma":[0.997992,0.00026109666,0.00071176025,0.00020494989,0.0006247837,0.0002054435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029144264,0.00018356564,0.00074233365,0.00022251923,0.00006866949,0.00000965542,0.00014472996,0.000109415516,0.00041508372],"category_scores_gemma":[0.00058462855,0.00009990911,0.00018710413,0.00026825196,0.00027718095,0.00017875068,0.00003256133,0.00020488059,0.000027646429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030469983,0.0028020255,0.94123685,0.0013665879,0.00077725085,0.012841577,0.0022658252,0.00002490194,0.0063620755,0.027671006,0.0005991486,0.0010057595],"study_design_scores_gemma":[0.0059776497,0.00838027,0.8782253,0.0026631698,0.00050142023,0.060929973,0.0035091962,0.00026180872,0.031385474,0.0077748154,0.000083427294,0.00030747618],"about_ca_topic_score_codex":0.000014685903,"about_ca_topic_score_gemma":0.0000039851557,"teacher_disagreement_score":0.06301153,"about_ca_system_score_codex":0.000047192472,"about_ca_system_score_gemma":0.0001738961,"threshold_uncertainty_score":0.45448756},"labels":[],"label_agreement":null},{"id":"W2111068724","doi":"10.1096/fj.10-178814","title":"Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)‐dependent, reactive oxygen species (ROS)‐mediated mechanism","year":2011,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Reactive oxygen species; In vivo; Chemistry; Embryo; Prostaglandin; Biochemistry; Limb bud; Cell biology; Biology; Genetics","score_opus":0.06683925312489072,"score_gpt":0.2981978179757043,"score_spread":0.2313585648508136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111068724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934028,0.003400163,0.0000986293,0.00037855975,0.0001300379,0.00239284,0.00005043065,0.000018534374,0.00012800556],"genre_scores_gemma":[0.9965888,0.0014351192,0.00038198265,0.000047914815,0.00016243853,0.00015594422,0.000017331164,0.000029741028,0.001180726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977721,0.00035833902,0.00043355438,0.0003483181,0.00058088044,0.00050681265],"domain_scores_gemma":[0.99810237,0.0006364789,0.00033440182,0.00030801343,0.00032437663,0.00029436318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014216532,0.00026696172,0.00054585387,0.00026319694,0.00020661832,0.000039951457,0.00021756697,0.0001096436,0.000041441166],"category_scores_gemma":[0.004477949,0.00015572444,0.00012823426,0.00030744344,0.00011149835,0.00027727726,0.00008715253,0.0005241214,0.00001103744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006297108,0.00047387503,0.0054067,0.00055932475,0.00043755118,0.0008876112,0.004561914,6.431676e-7,0.98071325,0.00014695644,0.0000580752,0.00045699588],"study_design_scores_gemma":[0.0077341003,0.001532794,0.039893858,0.0012285014,0.00037900725,0.00082853786,0.00053810846,0.00034652886,0.94654286,0.00081063923,0.000006819602,0.0001582732],"about_ca_topic_score_codex":0.00010376603,"about_ca_topic_score_gemma":0.000038506652,"teacher_disagreement_score":0.034487158,"about_ca_system_score_codex":0.0001531588,"about_ca_system_score_gemma":0.00024226024,"threshold_uncertainty_score":0.63502586},"labels":[],"label_agreement":null},{"id":"W2112328159","doi":"10.1191/096120301677213822","title":"Update on therapy — thalidomide in the treatment of lupus","year":2001,"lang":"en","type":"review","venue":"Lupus","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Thalidomide; Medicine; Discontinuation; Systemic lupus erythematosus; Refractory (planetary science); Dermatology; Cutaneous Lupus Erythematosus; Side effect (computer science); Pregnancy; Lupus erythematosus; Surgery; Internal medicine; Multiple myeloma; Disease; Immunology; Antibody","score_opus":0.11927719897348085,"score_gpt":0.40909266503307384,"score_spread":0.28981546605959296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112328159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001079254,0.990752,4.3920937e-7,0.00014575422,0.0006739829,0.002770795,0.000052193394,0.000017635071,0.0045079426],"genre_scores_gemma":[0.00014334462,0.9906119,0.000035529138,0.000081917235,0.00018223285,0.00050486455,0.00036816605,0.00004757603,0.008024437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979496,0.00032138804,0.00046850808,0.00037232766,0.00047365087,0.0004144988],"domain_scores_gemma":[0.9984507,0.00036288894,0.00016982129,0.00087074394,0.00002945999,0.00011641213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016820616,0.00044353967,0.0016483848,0.0002757993,0.000039583494,0.000018610626,0.00022346569,0.00019154458,0.00024263767],"category_scores_gemma":[0.000027701157,0.00019815033,0.000624625,0.00042915196,0.00006607384,0.00002095793,0.0000129814825,0.00022351426,0.0002986774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033225346,0.0017870717,0.0011903227,0.000837171,0.00047648247,0.0012143538,0.00016168927,1.2503054e-7,2.0493152e-7,0.000047913436,0.0013542497,0.9925982],"study_design_scores_gemma":[0.0045243604,0.0019696895,0.00006734579,0.002728409,0.0002843284,0.0007076588,0.000021799795,0.0000015394561,0.000007885576,0.00002460921,0.9895346,0.00012777431],"about_ca_topic_score_codex":0.00018108105,"about_ca_topic_score_gemma":0.00007707239,"teacher_disagreement_score":0.9924704,"about_ca_system_score_codex":0.00034260386,"about_ca_system_score_gemma":0.00017491756,"threshold_uncertainty_score":0.8080336},"labels":[],"label_agreement":null},{"id":"W2112474467","doi":"10.1200/jco.2007.15.9319","title":"Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"American Society of Clinical Oncology; Pfizer","keywords":"Medicine; Pharmacokinetics; Tolerability; Pharmacodynamics; Dexamethasone; Internal medicine; Pharmacology; Endocrinology; Adverse effect","score_opus":0.08983225290521596,"score_gpt":0.4622123649232952,"score_spread":0.37238011201807925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112474467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790245,0.00014937235,0.0000054240363,0.00036388513,0.0005247623,0.000948081,0.000029470768,0.0000059252047,0.000070645176],"genre_scores_gemma":[0.99838614,0.0006321025,0.0005142218,0.00017371261,0.00020501198,0.0000045791817,0.000010612393,0.00002385754,0.00004975059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964421,0.00064164103,0.0016794839,0.00026523983,0.0006544133,0.00031714287],"domain_scores_gemma":[0.9964187,0.0011387113,0.0010985001,0.00019135256,0.0007332165,0.00041947956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063783367,0.00021203043,0.0012953312,0.00020883598,0.00007397179,0.000004539398,0.00022554479,0.0001553625,0.0000951882],"category_scores_gemma":[0.0016262236,0.000116182404,0.00017746349,0.00036384093,0.0003421781,0.00013070811,0.00009979128,0.0009954037,0.0000057508933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023182573,0.028307706,0.92252344,0.000030824813,0.00065098325,0.00049885176,0.00025418476,0.000007858701,0.002166103,4.6329762e-7,0.00014332178,0.022233661],"study_design_scores_gemma":[0.10574392,0.034168564,0.858384,0.00006656277,0.00019103532,0.00007661793,0.00006508034,0.0004369483,0.00040545294,0.0000024412868,0.0003701621,0.000089178015],"about_ca_topic_score_codex":0.000063740954,"about_ca_topic_score_gemma":0.000030577135,"teacher_disagreement_score":0.08256135,"about_ca_system_score_codex":0.00010833128,"about_ca_system_score_gemma":0.00079262623,"threshold_uncertainty_score":0.4737781},"labels":[],"label_agreement":null},{"id":"W2112637662","doi":"10.1038/bmt.2013.187","title":"Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation","year":2013,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Allos Therapeutics","keywords":"Medicine; Hazard ratio; Internal medicine; Cohort; Transplantation; Confidence interval; Multiple myeloma; Surgery; Proportional hazards model; Gastroenterology","score_opus":0.018340604140483652,"score_gpt":0.2652772921070485,"score_spread":0.24693668796656482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112637662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785404,0.00054966315,0.012460051,0.00067326037,0.00034749697,0.0048640105,0.0014999779,0.00039258422,0.00067255826],"genre_scores_gemma":[0.98370314,0.0013096958,0.007609726,0.00043040104,0.00014675004,0.0017234494,0.004047336,0.000119097705,0.00091042346],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962328,0.00015553668,0.0009063605,0.0009704203,0.00064147206,0.0010934225],"domain_scores_gemma":[0.998125,0.00035250612,0.00017881938,0.00044983748,0.0003465268,0.00054726977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030737466,0.0006404081,0.0008814717,0.00042469267,0.00032675627,0.000107616004,0.0001671973,0.000419896,0.0007097636],"category_scores_gemma":[0.00003699321,0.00058612233,0.00044916375,0.00027937506,0.000149169,0.0005561912,0.0000068877152,0.0003443426,0.0001758091],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07060405,0.00174232,0.17016934,0.013517591,0.0017066875,0.005741994,0.008339377,0.00013042698,0.6847828,0.00008829682,0.001117357,0.04205975],"study_design_scores_gemma":[0.019995095,0.0012794455,0.86480445,0.0012356081,0.0016681401,0.005501956,0.000081474784,0.0063764993,0.097469516,0.00023307092,0.00042727488,0.00092746754],"about_ca_topic_score_codex":0.0002732379,"about_ca_topic_score_gemma":0.0008774506,"teacher_disagreement_score":0.6946351,"about_ca_system_score_codex":0.00017823544,"about_ca_system_score_gemma":0.00020159617,"threshold_uncertainty_score":0.999659},"labels":[],"label_agreement":null},{"id":"W2113262521","doi":"10.3109/10428194.2011.576791","title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Tianjin Science and Technology Program; Natural Science Foundation of Tianjin City; National Natural Science Foundation of China; Peking Union Medical College; Academy of Medical Sciences","keywords":"Bortezomib; Stromal cell; Multiple myeloma; Bone marrow; microRNA; Cancer research; Transfection; Apoptosis; Vascular endothelial growth factor; Medicine; Immunology; Chemistry; Biology; Cell culture; VEGF receptors","score_opus":0.020943145627392513,"score_gpt":0.2422504560969769,"score_spread":0.22130731046958438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113262521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917232,0.001413357,0.00017751943,0.00007166376,0.00048937567,0.0019810041,0.0005116905,0.00041466503,0.003217521],"genre_scores_gemma":[0.9884216,0.0004055153,0.0074149272,0.00044719275,0.00041455904,0.0004147124,0.0005554349,0.00026781764,0.0016582233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930302,0.000384435,0.0012503546,0.0020074495,0.0013011742,0.002026419],"domain_scores_gemma":[0.99568236,0.00028043514,0.0005547761,0.0015528575,0.00022814347,0.0017014579],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003764432,0.0013180824,0.00158683,0.00045590036,0.0007312686,0.0002763375,0.0006081999,0.0010398407,0.00067800394],"category_scores_gemma":[0.000101728125,0.0011487327,0.00049211894,0.00054881384,0.00044576658,0.0006580416,0.0005290031,0.00042352284,0.00030256153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033383658,0.0006491248,0.004409452,0.00019407085,0.00043012534,0.00086378737,0.0011917902,8.959253e-7,0.89912385,0.000008171999,0.008003741,0.081786595],"study_design_scores_gemma":[0.02506758,0.0008809221,0.042856272,0.00071362004,0.00036861334,0.00028415857,0.0004898461,0.0010181363,0.92363155,0.00008706968,0.0035511218,0.0010511075],"about_ca_topic_score_codex":0.0074681016,"about_ca_topic_score_gemma":0.00005039305,"teacher_disagreement_score":0.08073549,"about_ca_system_score_codex":0.0045004166,"about_ca_system_score_gemma":0.002355627,"threshold_uncertainty_score":0.9999571},"labels":[],"label_agreement":null},{"id":"W2113716960","doi":"10.1007/s00280-010-1283-3","title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Pharmacodynamics; Bortezomib; Dosing; Medicine; Multiple myeloma; Pharmacology; Toxicity; Proteasome inhibitor; Internal medicine","score_opus":0.01165579831940681,"score_gpt":0.33695038874226746,"score_spread":0.32529459042286063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113716960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776006,0.00039087597,0.0000020878392,0.00013217118,0.00014073667,0.0014483486,0.000038648774,0.000012776781,0.00007429773],"genre_scores_gemma":[0.9988017,0.0005955818,0.0001361136,0.00019950833,0.000053515327,0.00013007256,0.000012242142,0.000026479322,0.000044775854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988901,0.0000687087,0.00028856224,0.000305425,0.0001869341,0.00026025783],"domain_scores_gemma":[0.99933934,0.00012310546,0.0001348269,0.000121533434,0.00011796688,0.00016322931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001061271,0.00019017268,0.00045426234,0.00018343783,0.00003519555,0.0000031961558,0.000073093106,0.000055137985,0.00045545085],"category_scores_gemma":[0.000007986262,0.00014476829,0.000025808433,0.00020340957,0.00023596869,0.00006194653,0.000029706307,0.00029510475,3.6804593e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007052567,0.0017600278,0.6711757,0.000118380485,0.00035136638,0.000016582084,0.0006352944,0.0000062040476,0.280908,9.796461e-7,0.000028430773,0.037946463],"study_design_scores_gemma":[0.09634776,0.0017339973,0.7804666,0.000029603892,0.00018185936,0.000004751525,0.00006637616,0.0010480622,0.11983823,0.00000525534,0.00016237209,0.00011511089],"about_ca_topic_score_codex":0.00036971018,"about_ca_topic_score_gemma":0.00023966431,"teacher_disagreement_score":0.16106975,"about_ca_system_score_codex":0.000026127744,"about_ca_system_score_gemma":0.00007730915,"threshold_uncertainty_score":0.59034795},"labels":[],"label_agreement":null},{"id":"W2114277323","doi":"10.1182/blood-2005-11-4449","title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma","year":2006,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Multiple myeloma; Bortezomib; Transplantation; Medicine; Donor lymphocyte infusion; Thalidomide; Lymphocyte; Stem cell; Lenalidomide; Immunology; Graft-versus-host disease; Internal medicine; Biology","score_opus":0.03035046726206052,"score_gpt":0.27442106844006625,"score_spread":0.24407060117800572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114277323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944274,0.00007059377,0.00002993581,0.0015386663,0.00009618987,0.0025364053,0.00080988306,0.00002305681,0.00046788264],"genre_scores_gemma":[0.99379826,0.0000687794,0.00123546,0.0027445585,0.00009249043,0.00021028152,0.0008779486,0.0000857253,0.0008864791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966427,0.0002473555,0.0007227776,0.0008111121,0.000811859,0.00076417794],"domain_scores_gemma":[0.99841994,0.00058112916,0.00028402978,0.00043200282,0.00009336469,0.00018955141],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037719824,0.0004999875,0.0010199795,0.0018724214,0.00009609694,0.000030844796,0.00017330975,0.00055967,0.000010166384],"category_scores_gemma":[0.00009778763,0.00047829852,0.00020148356,0.00086520857,0.00004542336,0.00018757912,0.00011158971,0.0006696395,0.0000074415234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041517178,0.002920331,0.91483694,0.0010640441,0.00038787912,0.0025029057,0.0010921588,0.00005599178,0.06949808,4.042686e-7,0.0008334853,0.002656054],"study_design_scores_gemma":[0.045137823,0.00046737742,0.90508807,0.0012588217,0.000322959,0.000010977677,0.00002920847,0.00019774685,0.0465656,0.0000012950784,0.00054408435,0.00037606945],"about_ca_topic_score_codex":0.0016984435,"about_ca_topic_score_gemma":0.0009365242,"teacher_disagreement_score":0.040986106,"about_ca_system_score_codex":0.00045669905,"about_ca_system_score_gemma":0.0002688619,"threshold_uncertainty_score":0.9997669},"labels":[],"label_agreement":null},{"id":"W2114908650","doi":"10.3324/haematol.2011.054254","title":"Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model","year":2012,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; CRIS Cancer Foundation; University of Toronto; Ontario Institute for Cancer Research; University Health Network","keywords":"Clonogenic assay; Cytotoxicity; Cancer research; Multiple myeloma; Lymphokine-activated killer cell; Bone marrow; Biology; Natural killer cell; Immunology; Progenitor cell; Cell culture; Stem cell; Interleukin 21; T cell; In vitro; Cell biology; Immune system","score_opus":0.03143935893418044,"score_gpt":0.2802471565983891,"score_spread":0.24880779766420869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114908650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411404,0.0030717065,0.00007081036,0.00028199842,0.0002009623,0.001722761,0.000046591525,0.00015099498,0.00034013225],"genre_scores_gemma":[0.9880443,0.0008069572,0.008487329,0.0002378042,0.00008577513,0.00030021253,0.00019859946,0.000053466898,0.0017855231],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969202,0.00016047563,0.00059421535,0.0006407477,0.00047120926,0.0012131149],"domain_scores_gemma":[0.9979302,0.00018216622,0.00014731065,0.0005528526,0.00011255978,0.0010748666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002389052,0.0005245681,0.00080350676,0.0003225576,0.00015693098,0.000049427847,0.0001901144,0.00026544774,0.00014508255],"category_scores_gemma":[0.00023812531,0.0003728194,0.00021562411,0.00024988342,0.00017359435,0.00019841241,0.00028037647,0.00038821867,0.00013896196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067734746,0.0123908995,0.7164525,0.0013939333,0.0006812457,0.0009869118,0.0022361611,0.00007639042,0.24490039,0.00028076966,0.0026947588,0.011132586],"study_design_scores_gemma":[0.024039429,0.0011582663,0.2566133,0.00032822764,0.00037703587,0.00044053607,0.0004363875,0.034443807,0.6776495,0.000080829646,0.0030986331,0.0013340267],"about_ca_topic_score_codex":0.00014889901,"about_ca_topic_score_gemma":0.00018194404,"teacher_disagreement_score":0.45983917,"about_ca_system_score_codex":0.00014373631,"about_ca_system_score_gemma":0.00012612704,"threshold_uncertainty_score":0.9998724},"labels":[],"label_agreement":null},{"id":"W2115476164","doi":"10.3129/i09-182","title":"Vitritis and retinal vasculitis as presenting signs of monoclonal gammopathy of unknown significance with progression to multiple myeloma","year":2010,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Monoclonal gammopathy; Medicine; Multiple myeloma; Pathology; Paraproteinemias; Retinal vasculitis; Monoclonal; Vasculitis; Dermatology; Immunology; Monoclonal antibody; Antibody; Disease","score_opus":0.02525844929257511,"score_gpt":0.30095658434233424,"score_spread":0.27569813504975915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115476164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694071,0.0011275769,0.000016479693,0.026297364,0.00022263493,0.00091145065,0.00022224423,0.000003187879,0.0017919568],"genre_scores_gemma":[0.9909251,0.000018638559,0.0063826055,0.0011078938,0.0007762179,0.000032581152,0.000080128935,0.00006664173,0.00061019056],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997152,0.00023779209,0.0007911813,0.00040222995,0.00064774655,0.0007690776],"domain_scores_gemma":[0.99632245,0.00039497955,0.0007562248,0.00037740715,0.0009818152,0.0011671297],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00038677925,0.0003529378,0.0011738946,0.00086053787,0.00009939658,0.000024856907,0.00031627392,0.00080757815,0.00056714163],"category_scores_gemma":[0.0009323039,0.00027993723,0.00021171433,0.00027486504,0.0006132563,0.000081705635,0.00004691848,0.0023227881,0.000004583554],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019460778,0.00016766376,0.47743365,0.0013271619,0.0010772897,0.4793015,0.0005561617,0.0000052250534,0.010123425,0.000011396765,0.021855228,0.0061952285],"study_design_scores_gemma":[0.008915018,0.019102803,0.25108787,0.0043267496,0.0006391053,0.6535205,0.00016566805,0.00003548037,0.022776892,0.00018906908,0.03849614,0.0007446632],"about_ca_topic_score_codex":0.008187646,"about_ca_topic_score_gemma":0.000560549,"teacher_disagreement_score":0.22634576,"about_ca_system_score_codex":0.00013736075,"about_ca_system_score_gemma":0.003198723,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2117384590","doi":"10.1158/1078-0432.ccr-04-2346","title":"The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01–Induced Apoptosis in Human Multiple Myeloma Cells","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Farnesyltransferase; Protein kinase B; Apoptosis; Cancer research; Signal transduction; Farnesyltransferase inhibitor; STAT3; Biology; Chemistry; Cell biology; Biochemistry","score_opus":0.18401171325008112,"score_gpt":0.49324428906053913,"score_spread":0.30923257581045804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117384590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866749,0.0011687832,0.000004844135,0.008831529,0.00026204195,0.0018025225,0.00003932505,0.000064445485,0.0011516128],"genre_scores_gemma":[0.9927191,0.0024001943,0.00014332627,0.0002499111,0.001283699,0.0006615062,0.000035958357,0.00006829369,0.0024379888],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937594,0.0010498381,0.0010894975,0.00087627536,0.0016373699,0.0015876497],"domain_scores_gemma":[0.9947916,0.002839431,0.000072218514,0.0009152366,0.00048898725,0.00089252164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040251655,0.00029519212,0.0006087547,0.00033056474,0.00077248906,0.00016010606,0.0005505776,0.00031466602,0.0006219034],"category_scores_gemma":[0.0016203847,0.00019717438,0.00035203338,0.00085839763,0.00071453856,0.00015495162,0.00024520326,0.0021294316,0.00046788578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058537875,0.0036244793,0.31820276,0.00019192007,0.00046503393,0.00027786675,0.0003435527,0.000019892625,0.19308877,0.00011814447,0.009946943,0.46786687],"study_design_scores_gemma":[0.026023624,0.0029835775,0.4089119,0.00056600873,0.00007616834,0.000009918195,0.00061763666,0.0020818082,0.5026648,0.00022277575,0.05525532,0.0005864075],"about_ca_topic_score_codex":0.0025411474,"about_ca_topic_score_gemma":0.0049118567,"teacher_disagreement_score":0.46728045,"about_ca_system_score_codex":0.0005174503,"about_ca_system_score_gemma":0.0006320519,"threshold_uncertainty_score":0.9251439},"labels":[],"label_agreement":null},{"id":"W2117588879","doi":"10.1186/1477-7819-1-12","title":"Solitary Plasmacytoma of the Parotid Gland with Crystalline Inclusions: A Case Report","year":2003,"lang":"en","type":"article","venue":"World Journal of Surgical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Medicine; Parotid gland; Plasmacytoma; Pathology; Extramedullary plasmacytoma; Salivary gland; Presentation (obstetrics); Surgical oncology; Radiology; Multiple myeloma; Internal medicine","score_opus":0.02698614875730248,"score_gpt":0.3364984914084065,"score_spread":0.309512342651104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117588879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97520113,0.0006046136,0.00002517341,0.0042220796,0.00011147675,0.00030914473,0.0000060339894,0.0000050600183,0.01951527],"genre_scores_gemma":[0.9962082,0.00020704493,0.0020297638,0.00011601944,0.00010162402,0.0000054718375,0.000002460959,0.000011863279,0.001317537],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9981048,0.0003200072,0.000695534,0.00013049689,0.00047832655,0.00027083996],"domain_scores_gemma":[0.9979988,0.00061022886,0.00047373807,0.00023706406,0.00033847717,0.0003417181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008089876,0.00012776695,0.000581072,0.00018024302,0.00010821994,0.000004164503,0.000093482435,0.00006727362,0.0003527019],"category_scores_gemma":[0.00025551065,0.00006051441,0.00019473159,0.00034756833,0.00025820447,0.00004937732,0.00006659313,0.00047797448,0.0000025683555],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004448091,0.0013913027,0.13466968,0.00004038622,0.00046017053,0.85412145,0.000109740395,0.00003988265,0.00015036264,0.00025215902,0.0009937348,0.0033230658],"study_design_scores_gemma":[0.010869615,0.0022064184,0.0112269055,0.00016784048,0.00016413972,0.7680059,0.000121964425,0.000027917406,0.000636556,0.00015379954,0.20635529,0.00006363763],"about_ca_topic_score_codex":0.000055218556,"about_ca_topic_score_gemma":0.00042965304,"teacher_disagreement_score":0.20536156,"about_ca_system_score_codex":0.00018884212,"about_ca_system_score_gemma":0.0008690684,"threshold_uncertainty_score":0.38618383},"labels":[],"label_agreement":null},{"id":"W2118067068","doi":"10.1016/j.beha.2005.02.003","title":"Gene expression profiling and multiple myeloma","year":2005,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gene expression profiling; Multiple myeloma; Computational biology; Biology; Gene expression; Gene; Profiling (computer programming); Bioinformatics; Cancer research; Genetics; Immunology; Computer science","score_opus":0.3913591458890733,"score_gpt":0.5953547236227015,"score_spread":0.2039955777336282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118067068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074473507,0.9894028,0.000025859616,0.0012382936,0.000238768,0.0049022525,0.00006494213,0.00010469796,0.0032776517],"genre_scores_gemma":[0.0002896868,0.97066057,0.025248364,0.00010934157,0.0010876422,0.00062984286,0.00037371862,0.00017380838,0.0014270435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9846785,0.0072671184,0.002420307,0.0019817846,0.0018115779,0.0018406978],"domain_scores_gemma":[0.96117795,0.033506904,0.0007371778,0.0016885624,0.0011578208,0.0017315748],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008540024,0.0007424039,0.0046157795,0.0008491223,0.000514188,0.00015385324,0.00059594965,0.0018265704,0.00027825884],"category_scores_gemma":[0.07420401,0.00053197227,0.0007514653,0.0007586073,0.001409289,0.0004505633,0.0014014257,0.0060205357,0.0030632503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010697305,0.0033182406,0.0010038752,0.008863492,0.000726528,0.010448395,0.000021153039,3.2863184e-8,0.0000068244635,0.0001185543,0.0014558057,0.9729674],"study_design_scores_gemma":[0.0031262648,0.0021034223,0.00002745948,0.008209116,0.001060922,0.01271923,0.00011799933,0.000057281995,0.000048902617,0.000028398737,0.97212106,0.00037996462],"about_ca_topic_score_codex":0.00009117567,"about_ca_topic_score_gemma":0.00002313022,"teacher_disagreement_score":0.9725874,"about_ca_system_score_codex":0.00028612246,"about_ca_system_score_gemma":0.002557251,"threshold_uncertainty_score":0.9997132},"labels":[],"label_agreement":null},{"id":"W2118080692","doi":"10.1155/2013/812605","title":"Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Advances in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Multiple myeloma; Lymphoproliferative disorders; Medicine; Oncology; Internal medicine; Cancer research; Lymphoma","score_opus":0.014843230051432704,"score_gpt":0.3186864341167135,"score_spread":0.30384320406528076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118080692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98788965,0.009164586,0.000018524634,0.0009989038,0.000023613024,0.0010140311,0.0000033055796,0.000006228251,0.0008811836],"genre_scores_gemma":[0.9913363,0.007560262,0.00064816093,0.00006336856,0.000008955485,0.00033573233,0.000009291146,0.0000066754483,0.00003128927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912333,0.00010399888,0.00023195994,0.00019056328,0.00010566513,0.00024445797],"domain_scores_gemma":[0.9991008,0.00060351484,0.00004746813,0.00017704841,0.000023977052,0.000047178382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056615045,0.00011661294,0.0003485392,0.000120522396,0.000024537208,0.000004098093,0.00005415395,0.0000475555,0.000037430593],"category_scores_gemma":[0.0001235391,0.000066618624,0.00003499618,0.0001445889,0.0001993601,0.00011521983,0.000012513012,0.00005040647,0.000011818285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027265635,0.0006243953,0.94396144,0.000053447435,0.000026322614,0.00006564996,0.0013901695,0.000009485059,0.00010381248,0.0007807538,0.0000063707125,0.05270552],"study_design_scores_gemma":[0.018413456,0.0021061525,0.95753425,0.00011259124,0.00002373855,0.00032624847,0.0028302532,0.002327782,0.006487748,0.0068208054,0.0028618535,0.0001551411],"about_ca_topic_score_codex":0.0005857853,"about_ca_topic_score_gemma":0.0021124734,"teacher_disagreement_score":0.052550375,"about_ca_system_score_codex":0.000052051793,"about_ca_system_score_gemma":0.00002788834,"threshold_uncertainty_score":0.27166286},"labels":[],"label_agreement":null},{"id":"W2120775216","doi":"10.1158/1078-0432.ccr-05-0577","title":"Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Medicine; Rituximab; Lymphoma; Pharmacology; In vivo; Immunology; Thalidomide; Cytokine; Biology","score_opus":0.1365087731726329,"score_gpt":0.48959190980645084,"score_spread":0.35308313663381796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120775216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167645,0.0030077319,0.00002311218,0.0025884502,0.000081193946,0.0015321998,0.000087673274,0.00006496043,0.00093822513],"genre_scores_gemma":[0.9835662,0.0047528013,0.00054761785,0.00022907763,0.00016237477,0.00042417072,0.000020917783,0.0000633449,0.010233465],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950006,0.00065193995,0.00078067614,0.0010423383,0.0012284372,0.0012960123],"domain_scores_gemma":[0.99681044,0.000997742,0.00010925476,0.0009967816,0.00045175618,0.0006340584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029678177,0.00032510032,0.0009143996,0.0003713957,0.00032097226,0.00010002233,0.00039181404,0.00022673464,0.00015672533],"category_scores_gemma":[0.0010994029,0.0002509518,0.0001841547,0.00064298726,0.00083166064,0.0003111974,0.0005476024,0.0012733609,0.00020763763],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07692573,0.17873263,0.06343898,0.0010548026,0.0007849802,0.0011028406,0.0015023103,0.00015388642,0.009798602,0.00019986829,0.006478847,0.6598265],"study_design_scores_gemma":[0.42605665,0.0037380375,0.29697433,0.0012653302,0.00010526495,0.0000994738,0.00051762443,0.24195707,0.021400185,0.0002483225,0.006454437,0.0011832519],"about_ca_topic_score_codex":0.0021619464,"about_ca_topic_score_gemma":0.0015598137,"teacher_disagreement_score":0.65864325,"about_ca_system_score_codex":0.0010545007,"about_ca_system_score_gemma":0.0019263616,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W2121100873","doi":"10.6000/1929-2279.2012.01.01.02","title":"Extramedullary Plasmacytoma of the Lung - Rather a Disseminated than a Localized Disease? - A Case Report of a Primary Pulmonary Plasmacytoma Showing Distinct Signs of Systemic Spread","year":2012,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pathology; Plasmacytoma; Multiple myeloma; Plasma cell; Medicine; Dyscrasia; Bone marrow; Plasma cell dyscrasia; Lymph; Extramedullary plasmacytoma; Lung; Immunoglobulin light chain; Antibody; Immunology; Internal medicine","score_opus":0.051901982301074644,"score_gpt":0.3852463800381134,"score_spread":0.3333443977370388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121100873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96734774,0.030509112,0.000040347502,0.00033509915,0.00013358459,0.0011307948,0.0002554334,0.000010077161,0.00023780689],"genre_scores_gemma":[0.9981389,0.00097649905,0.00020229192,0.0000081432545,0.00019533552,0.00007935766,0.000030214447,0.00005704633,0.0003122353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943782,0.0007266771,0.0014175877,0.00026265468,0.0024152088,0.0007996372],"domain_scores_gemma":[0.9951097,0.0010205616,0.0010617597,0.0007116113,0.0012978904,0.0007984921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002546236,0.00028119577,0.0010507992,0.00053476146,0.00013961495,0.000021908922,0.00045100285,0.000116342024,0.00019697314],"category_scores_gemma":[0.0016662851,0.0001681011,0.0005905743,0.000876747,0.0006605388,0.00033992776,0.00029566087,0.0007656287,0.0000014690048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013908523,0.001776056,0.77432853,0.003760261,0.0017953236,0.05847342,0.00082424935,0.00001913266,0.14080964,0.000015917769,0.0013447998,0.00294416],"study_design_scores_gemma":[0.012658144,0.0019416064,0.47273397,0.024535397,0.002101287,0.16643304,0.0033753794,0.0026083114,0.31232947,0.00010732126,0.00062086526,0.0005552084],"about_ca_topic_score_codex":0.0010114762,"about_ca_topic_score_gemma":0.00006012226,"teacher_disagreement_score":0.30159456,"about_ca_system_score_codex":0.00059712946,"about_ca_system_score_gemma":0.0018969541,"threshold_uncertainty_score":0.6854964},"labels":[],"label_agreement":null},{"id":"W2121399230","doi":"10.3324/haematol.11644","title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Thalidomide; Dexamethasone; Internal medicine; Vincristine; Complete response; Adverse effect; Melphalan; Multiple myeloma; Randomized controlled trial; Gastroenterology; Chemotherapy; Induction chemotherapy; Urology; Cyclophosphamide","score_opus":0.029433587298597613,"score_gpt":0.3032299416468039,"score_spread":0.27379635434820626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121399230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960208,0.00092283374,0.0000030186925,0.0009438339,0.000039184262,0.001943605,0.0000164853,0.00006026644,0.00004997277],"genre_scores_gemma":[0.9983387,0.0006088511,0.0001442729,0.00014863489,0.00004607038,0.0005023588,0.000051219627,0.000022503886,0.00013740383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746764,0.00083386747,0.00042463184,0.00044232636,0.00021910015,0.000612445],"domain_scores_gemma":[0.9982439,0.0010316981,0.0000906117,0.0003857783,0.000045883582,0.00020210422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001173839,0.00029867212,0.0005377147,0.00026520246,0.0001011524,0.00003342924,0.00007899139,0.00018118495,0.00008514963],"category_scores_gemma":[0.00065966166,0.00015936785,0.000080247024,0.0003693127,0.0001945095,0.000106800784,0.000051684456,0.00020464486,0.000029334296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08341423,0.0011938536,0.8770288,0.00002053573,0.00011854225,0.0063217427,0.00088746834,0.0000023376836,0.0013252398,0.000029413584,0.000011572145,0.029646268],"study_design_scores_gemma":[0.014924808,0.0025279713,0.9712399,0.00011344568,0.00003257968,0.00044972808,0.00029441455,0.00008375784,0.009857447,0.00009408624,0.00025396614,0.0001278966],"about_ca_topic_score_codex":0.0030494265,"about_ca_topic_score_gemma":0.006714441,"teacher_disagreement_score":0.094211094,"about_ca_system_score_codex":0.00025989272,"about_ca_system_score_gemma":0.00010777335,"threshold_uncertainty_score":0.6498832},"labels":[],"label_agreement":null},{"id":"W2121793416","doi":"10.2217/cer.12.69","title":"Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents","year":2012,"lang":"en","type":"review","venue":"Journal of Comparative Effectiveness Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Multiple myeloma; Incidence (geometry); Internal medicine; Bone disease; Randomized controlled trial; Surgery; Oncology; Osteoporosis","score_opus":0.24757855998991143,"score_gpt":0.5136934388489022,"score_spread":0.26611487885899077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121793416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57914853,0.41361013,0.000015075016,0.0000054923025,0.00007628938,0.0070497864,0.000040200433,0.000007122093,0.00004738511],"genre_scores_gemma":[0.8013272,0.19772989,0.000084634026,0.0000013598138,0.00007993534,0.0004823038,0.00016555043,0.0000728433,0.0000562629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9625345,0.027973164,0.0043074037,0.0006669163,0.0034672443,0.0010507941],"domain_scores_gemma":[0.9657369,0.0268634,0.0035998083,0.00064285443,0.0022832581,0.0008737285],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03271902,0.00078677526,0.012857976,0.0035197756,0.00014130169,0.00007155595,0.00038555247,0.00035988927,0.0002031236],"category_scores_gemma":[0.021682067,0.0004834324,0.001540294,0.0023074837,0.00071472843,0.0006224678,0.00027917768,0.002687591,0.00005089076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40242168,0.0077864686,0.48025966,0.022050016,0.007637517,0.0057617603,0.0007088016,0.00012854248,0.000112537826,0.000013356214,0.000034856588,0.0730848],"study_design_scores_gemma":[0.23138812,0.0016253982,0.6959299,0.06732467,0.0018810779,0.000121707555,0.000028798248,0.00047560394,0.00012934109,0.000089397574,0.0005329582,0.00047307153],"about_ca_topic_score_codex":0.0004061509,"about_ca_topic_score_gemma":0.000029601862,"teacher_disagreement_score":0.22217871,"about_ca_system_score_codex":0.0016383464,"about_ca_system_score_gemma":0.0026433717,"threshold_uncertainty_score":0.99976176},"labels":[],"label_agreement":null},{"id":"W2122021478","doi":"10.1182/blood-2005-09-3869","title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":370,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"","keywords":"Medicine; Melphalan; Transplantation; Autologous stem-cell transplantation; Multiple myeloma; Surgery; Internal medicine; Regimen; Vincristine; Clinical trial; Stem cell; Cyclophosphamide; Chemotherapy; Biology","score_opus":0.015402233590398533,"score_gpt":0.26716109181650316,"score_spread":0.2517588582261046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122021478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031657,0.00070719107,0.0005816655,0.00006367233,0.00015826109,0.0069151707,0.00048576816,0.00021856395,0.0005531241],"genre_scores_gemma":[0.9950643,0.0002600391,0.002391032,0.000012357991,0.00010225632,0.0007626742,0.0009067978,0.00009377463,0.00040673057],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952637,0.0006440171,0.0013051252,0.00091547065,0.00091024494,0.00096143084],"domain_scores_gemma":[0.9977233,0.000633287,0.00067906664,0.00047652848,0.00019113644,0.0002967237],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005431049,0.0006132061,0.0014245913,0.00043608926,0.00020233447,0.000049244936,0.0002482867,0.00046612526,0.00001942203],"category_scores_gemma":[0.000020749672,0.000510094,0.00027202666,0.00067191274,0.00015021466,0.0001851158,0.000015643032,0.000581901,0.00001746437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28896576,0.013297972,0.5881867,0.00072084053,0.00052770186,0.0012256334,0.0033280118,0.0003141338,0.100144915,0.000015557118,0.000070171554,0.0032026526],"study_design_scores_gemma":[0.40833226,0.0069310013,0.26568535,0.00014917548,0.0012374789,0.00009095064,0.00041411017,0.0003499952,0.3164395,0.000017715529,0.000010660283,0.00034179597],"about_ca_topic_score_codex":0.0029520239,"about_ca_topic_score_gemma":0.0030074487,"teacher_disagreement_score":0.3225013,"about_ca_system_score_codex":0.0003027277,"about_ca_system_score_gemma":0.0004771034,"threshold_uncertainty_score":0.99973506},"labels":[],"label_agreement":null},{"id":"W2122440892","doi":"10.1517/14712598.2013.814637","title":"Genomic instability in multiple myeloma: mechanisms and therapeutic implications","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage Medical Research Clinic; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Genome instability; Biology; Chromosome instability; Epigenetics; Comparative genomic hybridization; Multiple myeloma; Somatic evolution in cancer; Genetics; Homologous recombination; Computational biology; Genome; Gene; Cancer research; DNA damage; DNA; Chromosome; Immunology","score_opus":0.26650271805668735,"score_gpt":0.4271962167632671,"score_spread":0.16069349870657973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122440892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014738839,0.9937815,0.000041681385,0.00038501844,0.00012896625,0.0038661328,0.000049096023,0.000083008264,0.00019068627],"genre_scores_gemma":[0.0051093423,0.99081457,0.0008038253,0.0004448072,0.00013324193,0.002251575,0.00038218335,0.000043406515,0.000017039767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974666,0.00046944333,0.000567283,0.00084451446,0.00017385738,0.00047828286],"domain_scores_gemma":[0.99827284,0.00062725524,0.00014185539,0.0006344784,0.0000465904,0.00027699617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002524785,0.0005249408,0.0014623159,0.0002170316,0.00012862975,0.000034628654,0.000225129,0.00056047534,0.00037822122],"category_scores_gemma":[0.00010585509,0.00028562412,0.00032671788,0.00024154049,0.00019266672,0.000027510092,0.00008719144,0.00048721136,0.00016911575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015052341,0.0006337622,0.0006657556,0.0000842828,0.00013663585,0.00000416542,0.000034696506,2.6410081e-8,0.00025708,0.00067790353,0.000032807104,0.9973224],"study_design_scores_gemma":[0.0021423076,0.0012375608,0.021856936,0.00072051055,0.0000017095002,0.000035390884,0.000018374416,0.00001244728,0.000019633455,0.0008057536,0.97285277,0.0002966044],"about_ca_topic_score_codex":0.00005836402,"about_ca_topic_score_gemma":0.0000020974849,"teacher_disagreement_score":0.9970257,"about_ca_system_score_codex":0.000276776,"about_ca_system_score_gemma":0.000124977,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W2123159083","doi":"10.1182/blood-2012-09-452375","title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital","funders":"Agence Nationale de la Recherche; Celgene; American Society of Hematology","keywords":"Pomalidomide; Lenalidomide; Bortezomib; Multiple myeloma; Dexamethasone; Medicine; Refractory (planetary science); Thalidomide; Oncology; Salvage therapy; Internal medicine; Pharmacology; Chemotherapy; Materials science","score_opus":0.010772124904402184,"score_gpt":0.2453502164545257,"score_spread":0.23457809155012352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123159083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449223,0.0023362976,0.000025606869,0.0005518206,0.00011230054,0.001698527,0.00006380601,0.00007634172,0.00064308353],"genre_scores_gemma":[0.9964617,0.00093725236,0.0009257738,0.00043426192,0.0001852276,0.0002568799,0.000071741255,0.000069141606,0.0006580259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973707,0.00016979587,0.0005327208,0.00075718184,0.00041583643,0.0007537494],"domain_scores_gemma":[0.9980986,0.00045141412,0.00014501347,0.00045109622,0.00020402594,0.0006498157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021176871,0.00045821635,0.0008515613,0.00039218055,0.00012189521,0.000090248075,0.00012965029,0.00025360662,0.00082618964],"category_scores_gemma":[0.0004236561,0.0003853039,0.00009869583,0.0004388379,0.00023800916,0.0004261525,0.00018828787,0.00051721226,0.0002895746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008720486,0.006904829,0.72526497,0.00060515234,0.0019026623,0.0030803054,0.007192738,0.0000046153577,0.19849528,0.000008108201,0.0030129428,0.044807907],"study_design_scores_gemma":[0.06796651,0.00092011434,0.87045246,0.00035520626,0.00013314855,0.00028449923,0.0010458741,0.0027712744,0.055245947,0.000049794806,0.00034605328,0.00042909032],"about_ca_topic_score_codex":0.0037880924,"about_ca_topic_score_gemma":0.00033284945,"teacher_disagreement_score":0.14518751,"about_ca_system_score_codex":0.00014337346,"about_ca_system_score_gemma":0.00016467764,"threshold_uncertainty_score":0.99985987},"labels":[],"label_agreement":null},{"id":"W2125211913","doi":"10.1158/0008-5472.can-06-1098","title":"A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Cyclin-dependent kinase 6; Cancer research; Multiple myeloma; Bone marrow; Palbociclib; Biology; Cyclin; Cell cycle; Cyclin D; Cell cycle checkpoint; Apoptosis; Cyclin D1; Cancer; Medicine; Immunology; Internal medicine; Biochemistry","score_opus":0.041712005282019564,"score_gpt":0.32537681740634117,"score_spread":0.2836648121243216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125211913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949977,0.0012705032,0.000030199524,0.00035080742,0.000048573063,0.0015314776,0.00035006384,0.000016507978,0.0014041701],"genre_scores_gemma":[0.9976096,0.0005938586,0.00031582857,0.000039832248,0.00011596021,0.00031797643,0.00018420491,0.000042116222,0.000780632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970162,0.00020166082,0.0003922783,0.0005941291,0.001080263,0.0007154648],"domain_scores_gemma":[0.9988296,0.00014538362,0.00010088259,0.0002854427,0.00034722756,0.0002914358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005263943,0.00021565639,0.00039189626,0.00048402432,0.0000964652,0.000044028056,0.00014728152,0.000107763735,0.00007691867],"category_scores_gemma":[0.00007256669,0.00019118651,0.000062215775,0.00055646786,0.00028909527,0.00014299291,0.00019175996,0.00060944876,0.000016213591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020128617,0.001543315,0.011618843,0.00035168903,0.000058294976,0.0005605847,0.0001105783,0.000002660467,0.9783438,0.000025881358,0.00077137025,0.0046001403],"study_design_scores_gemma":[0.0058642193,0.00046750842,0.20414683,0.00043635038,0.000012505871,0.000012488408,0.00011583637,0.00001553554,0.78859925,0.000120362456,0.000074707394,0.0001343906],"about_ca_topic_score_codex":0.006267535,"about_ca_topic_score_gemma":0.00052968186,"teacher_disagreement_score":0.192528,"about_ca_system_score_codex":0.0007276315,"about_ca_system_score_gemma":0.00047877547,"threshold_uncertainty_score":0.947468},"labels":[],"label_agreement":null},{"id":"W2125877270","doi":"10.1158/1078-0432.ccr-11-3007","title":"A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Adverse effect; Tolerability; Dosing; Multiple myeloma; Pharmacokinetics; Proteasome inhibitor; Pharmacology; Refractory (planetary science); Internal medicine; Oncology; Gastroenterology","score_opus":0.2172473456305167,"score_gpt":0.4730811051271257,"score_spread":0.255833759496609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125877270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260247,0.00026888002,0.0000017320165,0.000182095,0.00021312268,0.0064953133,0.00011430857,0.000017978546,0.000104089355],"genre_scores_gemma":[0.99825525,0.00004035207,0.00012544189,0.000040095798,0.00023112439,0.0006483167,0.000015250851,0.00005871248,0.0005854784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927383,0.0022433645,0.0012143987,0.0005840836,0.0022133817,0.0010064902],"domain_scores_gemma":[0.9941313,0.0028898618,0.00037036798,0.00095026474,0.0010451438,0.0006130363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031298345,0.00027723072,0.00090999255,0.00033343,0.00016982225,0.000020170073,0.00037578802,0.00020427497,0.00022670707],"category_scores_gemma":[0.007001357,0.00014006671,0.00015140597,0.0012827007,0.00095964846,0.00019217546,0.0003826765,0.0008559823,0.000011716962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08381479,0.049966518,0.8167045,0.00022390242,0.00035225842,0.000080568454,0.0018349574,5.941423e-7,0.0014750261,8.745345e-7,0.00027949692,0.045266494],"study_design_scores_gemma":[0.09018154,0.030360319,0.87067723,0.0009683006,0.00008362891,0.000002556637,0.0016459808,0.000050179075,0.0052678552,0.0000013535115,0.0006077599,0.0001533239],"about_ca_topic_score_codex":0.001774498,"about_ca_topic_score_gemma":0.0013371481,"teacher_disagreement_score":0.05397269,"about_ca_system_score_codex":0.0007863671,"about_ca_system_score_gemma":0.0017270357,"threshold_uncertainty_score":0.8381784},"labels":[],"label_agreement":null},{"id":"W2126117617","doi":"10.1002/jcb.22499","title":"Promiscuity of translocation partners in multiple myeloma","year":2010,"lang":"en","type":"review","venue":"Journal of Cellular Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chromosomal translocation; Biology; Somatic hypermutation; Genetics; Immunoglobulin class switching; Promiscuity; Cytidine deaminase; Gene; Antibody; B cell","score_opus":0.05829492575624223,"score_gpt":0.37038966820958996,"score_spread":0.31209474245334773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126117617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020788314,0.97822523,0.00004088436,0.000029157198,0.00008171952,0.00050093676,0.000025379513,0.000004466201,0.00030389405],"genre_scores_gemma":[0.057115495,0.9414069,0.0007422981,0.000002586548,0.00024370958,0.000016369755,0.00014544575,0.000037141763,0.00029001752],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976776,0.00007981314,0.0012063264,0.00021314918,0.0005624979,0.0002606186],"domain_scores_gemma":[0.9980312,0.00011805018,0.00093741587,0.00037810605,0.00024637947,0.0002888573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056012656,0.00029497192,0.0016742955,0.0002461696,0.000020179546,0.000010770439,0.00023913736,0.00054036244,0.00006770507],"category_scores_gemma":[0.00047040544,0.00021123476,0.0007530845,0.00026250712,0.0001196874,0.0000397627,0.000024711795,0.0011045188,0.0000061364212],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021064682,0.00076213013,0.00038134505,0.026927298,0.0004010433,0.00059780286,0.000042179254,1.9554156e-7,0.0623817,0.0000010150019,0.00007740809,0.90821725],"study_design_scores_gemma":[0.0078041027,0.00052840554,0.0001662355,0.045419052,0.0016606029,0.0015181019,0.00006185285,0.0000316449,0.61303043,0.000018051363,0.32925284,0.0005087115],"about_ca_topic_score_codex":0.0000073876613,"about_ca_topic_score_gemma":0.000003143258,"teacher_disagreement_score":0.9077085,"about_ca_system_score_codex":0.0001722353,"about_ca_system_score_gemma":0.0013786611,"threshold_uncertainty_score":0.86139035},"labels":[],"label_agreement":null},{"id":"W2126528859","doi":"10.1016/j.blre.2007.07.001","title":"Management of multiple myeloma: The changing landscape","year":2007,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenalidomide; Multiple myeloma; Thalidomide; Bortezomib; Disease; Medicine; Autologous stem-cell transplantation; Transplantation; Oncology; Intensive care medicine; Internal medicine","score_opus":0.11194781566832096,"score_gpt":0.39383607449139946,"score_spread":0.2818882588230785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126528859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069893654,0.98580587,0.000024448422,0.000018694473,0.000110658075,0.0056485925,0.000029037634,0.00003065906,0.008325076],"genre_scores_gemma":[0.000015319425,0.9937565,0.0015017156,0.00003343289,0.0002482379,0.0006119613,0.00023462107,0.00006464861,0.0035335775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971146,0.00023595551,0.0010909579,0.00044340655,0.0004989602,0.00061610306],"domain_scores_gemma":[0.99786663,0.00022288525,0.00052684627,0.0011301242,0.000058149097,0.00019535261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013998694,0.0004918532,0.0026749687,0.0003571784,0.00010630411,0.000016212238,0.00036494253,0.00017778405,0.00024177112],"category_scores_gemma":[0.00010896376,0.00023528705,0.0012007088,0.0009178627,0.000069916314,0.000025766263,0.00023606124,0.00039921224,0.0004832355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011063139,0.0002639953,0.000056651974,0.079138964,0.0011921347,0.000376456,0.000035214347,7.568525e-9,1.1838607e-7,0.000037965383,0.0004811196,0.9184063],"study_design_scores_gemma":[0.0011307481,0.00009655481,0.000048882972,0.05095667,0.0052450304,0.00020223598,0.000033343153,0.0000021186308,0.0000037640614,9.725766e-7,0.9421112,0.00016847528],"about_ca_topic_score_codex":0.0000060546995,"about_ca_topic_score_gemma":0.0000028686184,"teacher_disagreement_score":0.94163007,"about_ca_system_score_codex":0.000042648757,"about_ca_system_score_gemma":0.0000765509,"threshold_uncertainty_score":0.9594727},"labels":[],"label_agreement":null},{"id":"W2127143739","doi":"10.1182/blood.v99.3.731","title":"Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Melphalan; Total body irradiation; Medicine; Transplantation; Conditioning; Surgery; Stem cell; Peripheral Blood Stem Cells; Peripheral blood; Hematopoietic stem cell transplantation; Chemotherapy; Internal medicine; Cyclophosphamide; Biology","score_opus":0.014935343163142592,"score_gpt":0.2591304528636316,"score_spread":0.24419510970048902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127143739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952488,0.0003977203,0.00015781204,0.000055790915,0.00008570844,0.0036625946,0.00025479478,0.00002225254,0.00011453968],"genre_scores_gemma":[0.9981316,0.00008562856,0.0003668703,0.000015278058,0.00007684081,0.0003730793,0.0008097127,0.00003286228,0.00010816216],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99727064,0.00035689882,0.0009140129,0.00043037615,0.0006500242,0.00037801694],"domain_scores_gemma":[0.99792176,0.00084690936,0.00054607575,0.00030319055,0.00021510001,0.00016695732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032933868,0.00031277552,0.0014309067,0.00042103292,0.00013785629,0.000028948156,0.00012038795,0.00014564935,0.000116369396],"category_scores_gemma":[0.00016550325,0.00022395456,0.00033754547,0.00067874725,0.0001712751,0.00015742051,0.000022836986,0.00019852539,0.0000016808727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32675385,0.0055907625,0.653945,0.00028457545,0.003394917,0.000042993004,0.0070855366,0.00043995725,0.0017613011,0.000010052708,0.000028547236,0.0006624932],"study_design_scores_gemma":[0.5838262,0.001930649,0.3884641,0.000118618955,0.0029656007,0.0000061788014,0.0003670304,0.018800236,0.0033776355,0.0000029888174,0.0000015445133,0.00013925454],"about_ca_topic_score_codex":0.000689636,"about_ca_topic_score_gemma":0.0004149266,"teacher_disagreement_score":0.26548094,"about_ca_system_score_codex":0.00008086859,"about_ca_system_score_gemma":0.000083847415,"threshold_uncertainty_score":0.91326016},"labels":[],"label_agreement":null},{"id":"W2129108344","doi":"10.5737/1181912x183141145","title":"Multiple myeloma: The patient’s perspective","year":2008,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Multiple myeloma; Psychosocial; Perspective (graphical); Malignancy; Qualitative research; Medicine; Survivorship curve; Family medicine; Psychology; Internal medicine; Cancer; Psychiatry; Sociology; Computer science","score_opus":0.03991493443262042,"score_gpt":0.33190750735563024,"score_spread":0.29199257292300984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129108344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8570334,0.004077519,0.00010005268,0.06051248,0.0011375068,0.0006407504,0.000024898542,0.000033990924,0.07643945],"genre_scores_gemma":[0.9964695,0.00018028241,0.00073376787,0.0013284425,0.00043276921,0.000011106653,0.000007145264,0.000021273718,0.0008157063],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851674,0.00016278529,0.00019993262,0.00017931686,0.00026369604,0.0006775591],"domain_scores_gemma":[0.99792385,0.00014841233,0.00007921004,0.00020322029,0.00034935557,0.0012959698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001533761,0.00013673387,0.00023546112,0.00028601,0.0012307243,0.000022991408,0.00013034182,0.00012588993,0.00032413012],"category_scores_gemma":[0.0004911537,0.000090994545,0.00012760931,0.00019780958,0.00053110206,0.00007569149,0.000008203378,0.00074420945,0.00013077924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012930773,0.00099798,0.17969276,0.000006985163,0.0007946696,0.0405131,0.026483888,0.000016634045,0.00054549647,0.0007648446,0.32803378,0.42085677],"study_design_scores_gemma":[0.008830476,0.0034444698,0.69669825,0.0003421565,0.00018694841,0.09734977,0.012899785,0.00085714017,0.00043226656,0.0008983509,0.17775829,0.00030211665],"about_ca_topic_score_codex":0.007080429,"about_ca_topic_score_gemma":0.014231328,"teacher_disagreement_score":0.51700544,"about_ca_system_score_codex":0.007832222,"about_ca_system_score_gemma":0.0066145523,"threshold_uncertainty_score":0.9995315},"labels":[],"label_agreement":null},{"id":"W2129689945","doi":"","title":"Diagnostiek bij multipel myeloom: de rol van beeldvorming, chromosomenanalyse en multiparameterflowcytometrie.","year":2011,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Philosophy","score_opus":0.04773744428266548,"score_gpt":0.30053267083266527,"score_spread":0.2527952265499998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129689945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98254365,0.007814622,0.0021040526,0.00011038077,0.0004227731,0.0015072061,0.0026692662,0.00023420218,0.0025938603],"genre_scores_gemma":[0.9701341,0.011422659,0.011118644,0.00034040015,0.0010666321,0.0001226037,0.004033758,0.00018310137,0.001578152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99217606,0.0011171532,0.0011292293,0.0020773085,0.0009790035,0.0025212695],"domain_scores_gemma":[0.9911276,0.0033971344,0.0004549285,0.0032379252,0.00011810845,0.0016643222],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019333205,0.001119036,0.0013974413,0.00082026736,0.0007722785,0.00027682498,0.0025270574,0.00038866772,0.0006983668],"category_scores_gemma":[0.0007183989,0.00094957225,0.00024282913,0.0011622971,0.0004621051,0.00088752975,0.0026830782,0.001241704,0.0008156996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021787274,0.0019656534,0.8410287,0.0019715051,0.0034891174,0.0032842825,0.025230912,0.00014197834,0.0015148027,0.000015859663,0.0009330218,0.11824544],"study_design_scores_gemma":[0.006271409,0.0011456002,0.5300976,0.0031732803,0.0018677458,0.000311567,0.003331332,0.44777235,0.0008819806,0.00015503996,0.0038953798,0.0010966962],"about_ca_topic_score_codex":0.0128113525,"about_ca_topic_score_gemma":0.0031300439,"teacher_disagreement_score":0.44763038,"about_ca_system_score_codex":0.00022486494,"about_ca_system_score_gemma":0.00029313087,"threshold_uncertainty_score":0.9999623},"labels":[],"label_agreement":null},{"id":"W2130548892","doi":"10.1002/ajh.21781","title":"Necrosis following skull base irradiation and stem cell transplant for multiple myeloma","year":2010,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Multiple myeloma; Skull; Necrosis; Medicine; Stem cell; Pathology; Immunology; Surgery; Biology","score_opus":0.014132465732123279,"score_gpt":0.28194197702822843,"score_spread":0.26780951129610514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130548892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970566,0.00020692075,0.0011525877,0.0010568467,0.00017334145,0.00025866262,0.000016671556,0.000009407923,0.0000689775],"genre_scores_gemma":[0.98921865,0.00006511985,0.010430974,0.00013816233,0.00006060243,0.000014156491,0.000008290748,0.000019251896,0.00004480729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989984,0.000050757248,0.0003484663,0.00014616232,0.00017082787,0.0002853605],"domain_scores_gemma":[0.9987163,0.00048681407,0.00025547287,0.00012910739,0.00009818317,0.00031413056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022609935,0.00012298931,0.0005306825,0.00017576227,0.00007651023,0.000012438501,0.00006935241,0.000052140753,0.00001394469],"category_scores_gemma":[0.00007421779,0.00009312832,0.00018353129,0.000097550896,0.00012877546,0.00007759614,0.000009163057,0.0002372599,0.00000392826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030243588,0.00055255,0.7087587,0.0001969668,0.00056028186,0.0013559625,0.0014644287,0.0000029871837,0.11831012,0.00013351835,0.00037170656,0.16526839],"study_design_scores_gemma":[0.06222318,0.020996157,0.6029433,0.00052437006,0.0019612925,0.029337062,0.0048386836,0.00956807,0.25709683,0.00043851172,0.009076526,0.0009960214],"about_ca_topic_score_codex":0.00004820009,"about_ca_topic_score_gemma":0.000037303005,"teacher_disagreement_score":0.16427238,"about_ca_system_score_codex":0.000021609903,"about_ca_system_score_gemma":0.00011206438,"threshold_uncertainty_score":0.37976626},"labels":[],"label_agreement":null},{"id":"W2131389179","doi":"10.5430/jhm.v3n2p8","title":"Retrospective study of quantitative free light chain levels in random urine of patients with multiple myeloma","year":2013,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Urine; Multiple myeloma; Immunofixation; Medicine; Immunoglobulin light chain; Kappa; Internal medicine; Urology; Gastroenterology; Antibody; Immunology; Monoclonal; Mathematics","score_opus":0.02888790914050887,"score_gpt":0.28721423303969895,"score_spread":0.2583263238991901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131389179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978938,0.0002815057,0.00008701739,0.00021821652,0.000030074976,0.0012887482,0.000022037537,0.000006348691,0.00017221637],"genre_scores_gemma":[0.99691534,0.00001528605,0.0029649662,0.00001274055,0.000011654941,0.000033850643,0.0000020224095,0.000012300883,0.000031862568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975229,0.00019066904,0.0009595923,0.00018666023,0.000847795,0.00029238517],"domain_scores_gemma":[0.99733347,0.00034840513,0.0007294785,0.00025315097,0.0011751114,0.00016038495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003451489,0.00020042912,0.0012824339,0.00031105828,0.000033749322,0.000009140676,0.00020075969,0.00007953618,0.00014727494],"category_scores_gemma":[0.0023462116,0.00010568737,0.00013587056,0.0003624016,0.00016137745,0.00018167839,0.00008943431,0.00026010312,0.000004152939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004633877,0.0054238816,0.9849423,0.00012183401,0.0003564244,0.00036337975,0.0012464703,0.0000062136137,0.0024412568,0.00024185602,0.000071555565,0.0001509547],"study_design_scores_gemma":[0.031832695,0.011724963,0.946461,0.0003986075,0.00006024451,0.000050113176,0.002215683,0.000032628144,0.006728423,0.00040076327,0.0000042349125,0.000090641246],"about_ca_topic_score_codex":0.0001087962,"about_ca_topic_score_gemma":0.000078703364,"teacher_disagreement_score":0.03848129,"about_ca_system_score_codex":0.000079646525,"about_ca_system_score_gemma":0.000086894084,"threshold_uncertainty_score":0.4309806},"labels":[],"label_agreement":null},{"id":"W2132171352","doi":"10.1182/blood-2003-04-1165","title":"Gene expression profiling illuminates myeloma biology","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gene expression profiling; Biology; Gene expression; Multiple myeloma; Genetics; Computational biology; Gene; Immunology","score_opus":0.026573726648077542,"score_gpt":0.3066200462234915,"score_spread":0.2800463195754139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132171352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901821,0.0010185911,0.000066544104,0.000056252306,0.000049219798,0.00032888065,0.000008538278,0.000057118978,0.008232731],"genre_scores_gemma":[0.9814616,0.00006629271,0.017578969,0.00004021866,0.00006166305,0.000051438037,0.00005820847,0.000015915997,0.0006656941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991502,0.00006386531,0.00012475811,0.00022959769,0.00012191094,0.00030966994],"domain_scores_gemma":[0.99946636,0.000047336223,0.000028266453,0.00023079272,0.000057010162,0.00017024124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010348191,0.000106181215,0.00016746558,0.00007560963,0.00007278632,0.0000073898377,0.000046004978,0.000077742,0.00022901609],"category_scores_gemma":[0.0002806955,0.00007591329,0.000054107313,0.00009659137,0.000051867082,0.00002947567,0.000023874689,0.00009864401,0.0001520427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004928077,0.000635608,0.26635778,0.00003223469,0.000082470215,0.00019046143,0.000038403545,9.135425e-8,0.7293659,0.00024972355,0.00004005456,0.002957995],"study_design_scores_gemma":[0.004179853,0.0003003533,0.016204018,0.00003178068,0.000045215773,0.0001349166,0.000040090083,0.000006963634,0.9778533,0.00017260984,0.00095838954,0.00007253429],"about_ca_topic_score_codex":0.000007566893,"about_ca_topic_score_gemma":7.747838e-7,"teacher_disagreement_score":0.25015375,"about_ca_system_score_codex":0.000015331141,"about_ca_system_score_gemma":0.00006391595,"threshold_uncertainty_score":0.3095654},"labels":[],"label_agreement":null},{"id":"W2132482558","doi":"10.1016/j.canep.2012.05.002","title":"Risk factors for multiple myeloma: A hospital-based case–control study in Northwest China","year":2012,"lang":"en","type":"article","venue":"Cancer Epidemiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Multiple myeloma; China; Internal medicine","score_opus":0.05969676128073725,"score_gpt":0.3873009498798731,"score_spread":0.32760418859913587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132482558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047285,0.0023869867,0.0010779586,0.0008572568,0.0004970477,0.0037988902,0.00083202304,0.00005651157,0.00002046693],"genre_scores_gemma":[0.99624985,0.00004846897,0.00075659197,0.00025023514,0.00037892128,0.0021076826,0.000110986985,0.000043108095,0.00005413473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969507,0.00071363105,0.0005730769,0.0004859895,0.00011534518,0.0011612978],"domain_scores_gemma":[0.99431396,0.004403946,0.00022223113,0.00044796334,0.00008392402,0.0005280067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014403105,0.00030945954,0.0010477134,0.00020652854,0.00014625845,0.000003725373,0.00010352991,0.00017634733,0.0001418306],"category_scores_gemma":[0.0060459794,0.00022458991,0.00021876438,0.00016922367,0.00011850539,0.00009143032,0.000029207358,0.0003531995,0.000020967029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008613621,0.001522645,0.9879527,0.000057164387,0.00039489774,0.00024887687,0.00062646775,0.00021042208,0.000010186064,0.000008852782,0.00025728828,0.007849099],"study_design_scores_gemma":[0.015325913,0.0016337106,0.97646755,0.000024110546,0.00023333343,0.000023734648,0.00032764123,0.005154317,0.000041859585,0.000026742273,0.00055256375,0.00018849752],"about_ca_topic_score_codex":0.02145041,"about_ca_topic_score_gemma":0.011295357,"teacher_disagreement_score":0.014464551,"about_ca_system_score_codex":0.00041062324,"about_ca_system_score_gemma":0.00016244651,"threshold_uncertainty_score":0.9850658},"labels":[],"label_agreement":null},{"id":"W2132959953","doi":"10.1080/10428194310001593193","title":"The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression","year":2004,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"RANKL; Osteoclast; Bone resorption; RANK Ligand; Osteoprotegerin; Osteolysis; Multiple myeloma; Cancer research; Stromal cell; Receptor; Chemistry; Internal medicine; Medicine; Bone remodeling; Endocrinology; Activator (genetics)","score_opus":0.02358573838970978,"score_gpt":0.2861738569402019,"score_spread":0.26258811855049213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132959953","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5627789,0.4340749,0.0000071476875,0.0000788885,0.0001680898,0.002386628,0.00037636023,0.00005535687,0.00007375409],"genre_scores_gemma":[0.24790616,0.7503146,0.00053112354,0.000097273594,0.00016294928,0.00025488343,0.00019154644,0.0001970254,0.00034442684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942007,0.0005069803,0.0019383207,0.0013465214,0.0009108981,0.0010965436],"domain_scores_gemma":[0.9953614,0.0013188064,0.0009969366,0.0012461426,0.00023939417,0.0008373127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006514678,0.0011919084,0.0038360297,0.0008440976,0.0003765347,0.000109343346,0.00043973688,0.0010618743,0.0000682932],"category_scores_gemma":[0.0006660615,0.00081475195,0.00061532826,0.00097308005,0.0005703021,0.00026510257,0.00047673617,0.00035964308,0.00005394445],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040988326,0.00031942723,0.0004736485,0.013752715,0.00056559534,0.00034069817,0.0010218645,0.0000013027516,0.00981249,0.0000688936,0.0006502992,0.96889424],"study_design_scores_gemma":[0.087298505,0.0026143657,0.07526921,0.094323605,0.0016278184,0.0014850743,0.00070174003,0.0002552922,0.060546,0.00020568259,0.673073,0.002599728],"about_ca_topic_score_codex":0.0036296449,"about_ca_topic_score_gemma":0.00008372964,"teacher_disagreement_score":0.9662945,"about_ca_system_score_codex":0.0053612734,"about_ca_system_score_gemma":0.0036091157,"threshold_uncertainty_score":0.99943036},"labels":[],"label_agreement":null},{"id":"W2133389067","doi":"10.1200/jco.2007.14.2372","title":"Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Prednisone; Regimen; Cyclophosphamide; Refractory (planetary science); Internal medicine; Multiple myeloma; Gastroenterology; Surgery; Urology; Chemotherapy","score_opus":0.15452083648870732,"score_gpt":0.4762083366351059,"score_spread":0.3216875001463986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133389067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963984,0.001168649,0.000011329732,0.0010864127,0.00036776892,0.00051418424,0.00000867876,0.000005662475,0.0004389101],"genre_scores_gemma":[0.9916919,0.004195606,0.0032981262,0.00017368853,0.00035080904,0.0000069193625,0.000004139568,0.000014997036,0.00026384703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963727,0.00045362933,0.0022521724,0.00022428541,0.000416071,0.00028111285],"domain_scores_gemma":[0.9953342,0.0025561054,0.001102184,0.00018003955,0.00023803148,0.00058945344],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021593592,0.00015155584,0.0017915152,0.00020731505,0.000061198916,0.0000030603107,0.000089743684,0.00037989035,0.00003960343],"category_scores_gemma":[0.008755589,0.00010753356,0.00022330866,0.00013408184,0.0005337418,0.00010659929,0.00008956161,0.0008893945,0.000001916042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52721673,0.016407639,0.21589847,0.000047898506,0.00046149563,0.005963204,0.0003683095,0.0000023766395,0.0008127522,0.000008803468,0.00084509014,0.23196723],"study_design_scores_gemma":[0.49876675,0.09237756,0.4007994,0.00008444028,0.00012104113,0.00063517527,0.00006147782,0.0003969882,0.00016052817,0.00005365581,0.0064698784,0.00007311055],"about_ca_topic_score_codex":0.00010935748,"about_ca_topic_score_gemma":0.00010254839,"teacher_disagreement_score":0.2318941,"about_ca_system_score_codex":0.00013642335,"about_ca_system_score_gemma":0.0015446411,"threshold_uncertainty_score":0.9995941},"labels":[],"label_agreement":null},{"id":"W2134812257","doi":"10.1039/c1md00260k","title":"Inhibitory effect of bortezomib on human multiple myeloma cells when combined with epigallocatechin-gallate (EGCG) analogs","year":2011,"lang":"en","type":"article","venue":"MedChemComm","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; U.S. Food and Drug Administration; Hong Kong Polytechnic University","keywords":"Bortezomib; Gallate; Multiple myeloma; Epigallocatechin gallate; Chemistry; Inhibitory postsynaptic potential; Cancer research; Pharmacology; Biochemistry; Medicine; Internal medicine; Polyphenol; Nuclear chemistry; Antioxidant","score_opus":0.03562589046420497,"score_gpt":0.2846581664059509,"score_spread":0.2490322759417459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134812257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837587,0.00007053526,0.000023821183,0.000094429364,0.000073115545,0.0012670129,0.000020585241,0.00013124855,0.014560557],"genre_scores_gemma":[0.9974356,0.0000120015775,0.0011375035,0.000086814085,0.000061365936,0.000107136104,0.00010701765,0.00007446121,0.0009780751],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763066,0.00020352301,0.00042748684,0.0004825291,0.0006695602,0.00058622425],"domain_scores_gemma":[0.99809307,0.00025420194,0.0001825173,0.0008900733,0.0001335927,0.0004465261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045698663,0.00041966647,0.00081981235,0.00028697104,0.00013826578,0.000012805668,0.00026110254,0.00016900926,0.00039462183],"category_scores_gemma":[0.00010391057,0.0002798435,0.00019116244,0.00021099581,0.00027628482,0.000080821614,0.00010118431,0.0004419796,0.00015790743],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016476734,0.0025871643,0.67134655,0.0008441545,0.001381793,0.001223684,0.0016187228,0.0000022334318,0.29357162,0.00015720272,0.0021913967,0.008598711],"study_design_scores_gemma":[0.013092853,0.010250579,0.16582966,0.0002780028,0.00017102303,0.000019060668,0.00003342946,0.00008776774,0.8096877,0.00007775189,0.00023796022,0.00023424244],"about_ca_topic_score_codex":0.0007510374,"about_ca_topic_score_gemma":0.00019793917,"teacher_disagreement_score":0.516116,"about_ca_system_score_codex":0.00012552136,"about_ca_system_score_gemma":0.00007783439,"threshold_uncertainty_score":0.99996537},"labels":[],"label_agreement":null},{"id":"W2134846586","doi":"10.1186/1471-2407-13-319","title":"Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study","year":2013,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Multiple myeloma; Surgical oncology; Qualitative research; Physical activity; MEDLINE; Internal medicine; Oncology; Physical therapy","score_opus":0.03670496666629902,"score_gpt":0.34115850988300167,"score_spread":0.30445354321670265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134846586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141264,0.0002240999,0.000014078052,0.00014285016,0.00003307275,0.0078325765,0.00024798137,0.00004091855,0.000051802235],"genre_scores_gemma":[0.99243295,0.000042424937,0.0015197059,0.00009514064,0.00003057524,0.004925857,0.00008317413,0.000041223295,0.00082895806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985602,0.000067340545,0.00018709734,0.00044695206,0.00033386613,0.00040453696],"domain_scores_gemma":[0.9982758,0.0001641349,0.00004947345,0.00023129278,0.00048499493,0.00079429056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084213934,0.00021801415,0.00036357454,0.00012248024,0.0001561881,0.000037164205,0.000058752914,0.000046100886,0.0003206073],"category_scores_gemma":[0.0003066446,0.00014765965,0.000044001248,0.00019427817,0.00004998423,0.00011917379,0.00003598401,0.00006770827,0.000030452224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004467378,0.00049965794,0.9449084,0.000068582725,0.00021225396,0.0000027641108,0.020553278,0.0000069939524,0.0000938535,0.0000010031735,0.00079797214,0.02838786],"study_design_scores_gemma":[0.019367943,0.0021988717,0.9634789,0.00021326457,0.00014286012,4.4730848e-7,0.013923157,0.00018122756,0.00017776713,0.0000028951927,0.00013779808,0.00017486274],"about_ca_topic_score_codex":0.0036510588,"about_ca_topic_score_gemma":0.0030084301,"teacher_disagreement_score":0.028212998,"about_ca_system_score_codex":0.00018189664,"about_ca_system_score_gemma":0.00015437446,"threshold_uncertainty_score":0.6021386},"labels":[],"label_agreement":null},{"id":"W2135395701","doi":"10.1093/annonc/11.suppl_1.s107","title":"Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Medical Research Council; Genentech; International Myeloma Foundation","keywords":"Medicine; CD20; Plasma cell; Rituximab; Antigen; Multiple myeloma; Immunology; Macroglobulinemia; Antibody; Plasma cell leukemia; Cancer research","score_opus":0.052945559003264336,"score_gpt":0.39305950612971663,"score_spread":0.34011394712645227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135395701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936079,0.0024611882,0.0000063458747,0.0007391118,0.000029871904,0.00061237684,0.00015423176,0.000015544449,0.0023734348],"genre_scores_gemma":[0.98565775,0.013337926,0.00033807644,0.0000511801,0.000030509174,0.000023953788,0.00020874513,0.000018657873,0.0003332071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99862576,0.00014878045,0.0004506228,0.00025016014,0.00022482823,0.00029987912],"domain_scores_gemma":[0.99884444,0.0002736357,0.00021906967,0.00022382909,0.0003062263,0.0001328198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012535311,0.00017598788,0.00074716855,0.00018870659,0.00004136234,0.0000019731203,0.00005725189,0.00018669285,0.00028453485],"category_scores_gemma":[0.00008410647,0.00013770725,0.000118105294,0.00026345064,0.00032135457,0.00006578055,0.00001084001,0.00007787779,0.0000081954895],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042271847,0.0026404737,0.114578635,0.000045043194,0.0009284613,0.000037193004,0.00090489816,9.058797e-7,0.4417002,0.000008517991,0.00033922875,0.4345893],"study_design_scores_gemma":[0.009507646,0.020780047,0.5293503,0.000036626032,0.00005469428,0.00007083982,0.00014173768,0.00011556538,0.4278379,0.00003209105,0.011979662,0.000092927876],"about_ca_topic_score_codex":0.00092249736,"about_ca_topic_score_gemma":0.000041839714,"teacher_disagreement_score":0.43449634,"about_ca_system_score_codex":0.000054868564,"about_ca_system_score_gemma":0.0001968919,"threshold_uncertainty_score":0.56155384},"labels":[],"label_agreement":null},{"id":"W2135430006","doi":"10.1158/1078-0432.ccr-04-1106","title":"Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Hamilton Regional Laboratory Medicine Program; Ontario Institute for Cancer Research; McGill University; Université de Montréal; Western University; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Nova Scotia Cancer Centre; University Health Network","funders":"","keywords":"Thalidomide; Medicine; Prednisone; Maintenance therapy; Multiple myeloma; Tolerability; Discontinuation; Surgery; Clinical endpoint; Melphalan; Internal medicine; Randomized controlled trial; Gastroenterology; Adverse effect; Chemotherapy","score_opus":0.13535450184085993,"score_gpt":0.47176959708396127,"score_spread":0.3364150952431013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135430006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855895,0.0023348816,0.00025133553,0.0014560813,0.00015931609,0.009072533,0.0009941016,0.00002113052,0.00012113203],"genre_scores_gemma":[0.9885966,0.00688233,0.0012074282,0.000058404512,0.00019077807,0.002284713,0.00004949826,0.000039377297,0.00069083314],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953584,0.00081087404,0.0015599756,0.0006733362,0.00085614884,0.0007412572],"domain_scores_gemma":[0.9930332,0.004977808,0.00028438243,0.0005569607,0.00070800725,0.00043967855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005015266,0.00024054683,0.0015515636,0.00020858266,0.00011524837,0.000014863405,0.00021458368,0.00024153794,0.000040573395],"category_scores_gemma":[0.0015146935,0.00015677242,0.0005463308,0.00022127906,0.0013749874,0.000070223934,0.00009434802,0.00052292994,0.0000030549045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9399756,0.006840011,0.0014166664,0.00039994574,0.00049550604,0.000107470536,0.0009928572,0.00000366527,0.0031689447,0.000013651856,0.0001336215,0.04645202],"study_design_scores_gemma":[0.94333917,0.016455881,0.0029503254,0.00052970526,0.00011454021,0.00000502949,0.000098546385,0.00078457507,0.03491944,0.00010656879,0.0005718784,0.000124336],"about_ca_topic_score_codex":0.00081530784,"about_ca_topic_score_gemma":0.00015788307,"teacher_disagreement_score":0.046327684,"about_ca_system_score_codex":0.00010975998,"about_ca_system_score_gemma":0.00068979076,"threshold_uncertainty_score":0.6392994},"labels":[],"label_agreement":null},{"id":"W2135893584","doi":"10.1016/j.leukres.2011.07.016","title":"Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma","year":2011,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"Alberta Heritage Foundation for Medical Research; Alberta Cancer Foundation","keywords":"Multiple myeloma; PLK1; Cancer research; Bone marrow; Centrosome; Medicine; Plasma Cell Myeloma; Internal medicine; Cell cycle; Cancer","score_opus":0.10407348632317467,"score_gpt":0.3334838629593509,"score_spread":0.22941037663617622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135893584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960263,0.00060313503,0.000051827265,0.000079519436,0.00001962207,0.0015162589,0.000015612324,0.000030395213,0.0016573594],"genre_scores_gemma":[0.99746656,0.00013824634,0.0015300765,0.000040636834,0.00002673858,0.00032727153,0.000030198842,0.00003294453,0.00040735086],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974567,0.00037711725,0.00033381145,0.0004707433,0.00067250273,0.00068911695],"domain_scores_gemma":[0.9984234,0.00043566455,0.00005954449,0.00043467927,0.00031001563,0.000336721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007188212,0.00017598047,0.00030202552,0.000509268,0.00010828634,0.000010460588,0.00012691076,0.00014821933,0.00014365549],"category_scores_gemma":[0.0006540067,0.00014285836,0.000058564045,0.0005818365,0.0004517014,0.0000753686,0.00015883779,0.00055161177,0.000045177338],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003174597,0.00081898004,0.45715916,0.00046243702,0.000058706453,0.0012833001,0.0016633434,0.0000026050375,0.5249281,0.00011565171,0.00009363003,0.010239517],"study_design_scores_gemma":[0.006014746,0.00093716395,0.5621909,0.00046139956,0.000015114027,0.000023823084,0.0006787368,0.001128879,0.4280486,0.0003014454,0.00006833154,0.00013085859],"about_ca_topic_score_codex":0.0020267658,"about_ca_topic_score_gemma":0.00031421386,"teacher_disagreement_score":0.10503175,"about_ca_system_score_codex":0.00038811442,"about_ca_system_score_gemma":0.00055672217,"threshold_uncertainty_score":0.5825595},"labels":[],"label_agreement":null},{"id":"W2136508030","doi":"10.3109/10428194.2014.915544","title":"Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Neutropenia; Dexamethasone; Granulocyte colony-stimulating factor; Multiple myeloma; Internal medicine; Refractory (planetary science); Absolute neutrophil count; Gastroenterology; Febrile neutropenia; Toxicity; Surgery; Chemotherapy","score_opus":0.016324495911819753,"score_gpt":0.25568155543578397,"score_spread":0.23935705952396422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136508030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935185,0.00012089322,0.00060833985,0.000053858203,0.00008477506,0.004490163,0.000115092495,0.0002135287,0.00079485023],"genre_scores_gemma":[0.9883612,0.000083129635,0.007576631,0.00037451624,0.000109472116,0.0008889826,0.00045858184,0.0002151212,0.0019323789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99492055,0.00025521638,0.0009374326,0.001469687,0.00097536005,0.0014417592],"domain_scores_gemma":[0.99659175,0.00090246944,0.00041837135,0.0009699715,0.00032490928,0.000792528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003413661,0.0009931814,0.0014786369,0.000601172,0.0003999688,0.00015841443,0.00033898972,0.00035504703,0.000052443236],"category_scores_gemma":[0.00026503752,0.0006592007,0.00019527858,0.00066396466,0.00033342815,0.00039133115,0.00019788767,0.00021364287,0.000026984797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089013815,0.00076969416,0.52577096,0.0006705653,0.0010352584,0.000791723,0.00048808052,0.0002285576,0.00047071965,0.000041353607,0.00015422552,0.38056505],"study_design_scores_gemma":[0.174399,0.0055633113,0.79043245,0.0008778311,0.0003788047,0.000108527514,0.00016264903,0.023756262,0.0012170312,0.000008354519,0.00237325,0.00072249613],"about_ca_topic_score_codex":0.0014493106,"about_ca_topic_score_gemma":0.0007184037,"teacher_disagreement_score":0.37984255,"about_ca_system_score_codex":0.008500445,"about_ca_system_score_gemma":0.0010981318,"threshold_uncertainty_score":0.9995859},"labels":[],"label_agreement":null},{"id":"W2136541422","doi":"10.1016/s1470-2045(13)70380-2","title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":799,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical endpoint; Bortezomib; Population; Thalidomide; Progressive disease; Clinical trial; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy","score_opus":0.08314179518883183,"score_gpt":0.37908462025288053,"score_spread":0.2959428250640487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136541422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790796,0.00041982348,0.00021164303,0.0024101676,0.000621192,0.016491434,0.00019868699,0.0001022131,0.00046521847],"genre_scores_gemma":[0.9681648,0.0002829813,0.023841418,0.0007101689,0.0007880835,0.0047636456,0.0005446757,0.000110326386,0.00079388765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957555,0.0009451378,0.0007030018,0.0008387118,0.0005533803,0.0012042847],"domain_scores_gemma":[0.9912619,0.0061507057,0.00047567487,0.0010704839,0.00041189103,0.00062937115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014325252,0.00053278287,0.002065135,0.00017679659,0.00039569417,0.00012191742,0.000582161,0.00033792236,0.00030414134],"category_scores_gemma":[0.0036781013,0.0003268925,0.00010754036,0.00032106193,0.00056940474,0.00036107883,0.00034283605,0.0006251469,0.0001077757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9197107,0.0059189573,0.0011369856,0.00011179763,0.0011793218,0.00014667738,0.00036059134,0.0000031673915,0.0024949748,0.00004369903,0.0044143163,0.0644788],"study_design_scores_gemma":[0.9480376,0.03400479,0.0086432,0.000101165526,0.0005582949,0.000031060266,0.00012600255,0.0010994432,0.00059999956,0.00011892035,0.0063177077,0.00036180654],"about_ca_topic_score_codex":0.0012482923,"about_ca_topic_score_gemma":0.00036216233,"teacher_disagreement_score":0.06411699,"about_ca_system_score_codex":0.0006013755,"about_ca_system_score_gemma":0.00065676705,"threshold_uncertainty_score":0.99991834},"labels":[],"label_agreement":null},{"id":"W2137040543","doi":"10.1182/blood-2007-03-081018","title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Internal medicine; Transplantation; Creatinine; Multivariate analysis; Adverse effect; Stage (stratigraphy); Surgery; Young adult","score_opus":0.020908658863440212,"score_gpt":0.2568256700594882,"score_spread":0.235917011196048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137040543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987232,0.00008913809,0.0000023424936,0.000082576866,0.00005157344,0.00048785654,0.00018457457,0.000018497765,0.00036020664],"genre_scores_gemma":[0.997481,0.000029420233,0.00046703027,0.00010928379,0.00006806378,0.00003487083,0.0015127078,0.000029677409,0.0002679574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788165,0.00011039215,0.00027102014,0.0004256681,0.0009877965,0.00032345665],"domain_scores_gemma":[0.99904406,0.00011988235,0.0001242859,0.00043061795,0.00012013953,0.00016103266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011540897,0.00020816173,0.0004113425,0.00028581455,0.000081303064,0.000041941188,0.00024835463,0.000089682595,0.00011522791],"category_scores_gemma":[0.00007215707,0.00013783015,0.000094121526,0.00042221125,0.00014604696,0.00019077514,0.00013202989,0.00020210491,0.0000037115067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008932206,0.001889856,0.9910122,0.000006863386,0.0020807397,0.0001855026,0.0010383022,0.000004452421,0.00013564706,0.0000016578672,0.000111698144,0.0026398555],"study_design_scores_gemma":[0.008361263,0.00038457537,0.990008,0.00007167335,0.00053221674,0.0000028209104,0.00011802187,0.0000843348,0.00021182175,0.0000055098403,0.000093448645,0.00012633471],"about_ca_topic_score_codex":0.001921063,"about_ca_topic_score_gemma":0.0020048895,"teacher_disagreement_score":0.0074680424,"about_ca_system_score_codex":0.000046526682,"about_ca_system_score_gemma":0.000029228868,"threshold_uncertainty_score":0.56205505},"labels":[],"label_agreement":null},{"id":"W2137055964","doi":"10.1097/moh.0b013e32832e3154","title":"Recent trends in the management of newly diagnosed multiple myeloma","year":2009,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Melphalan; Prednisone; Internal medicine; Oncology; Autologous stem-cell transplantation; Lenalidomide; Clinical trial; Transplantation; Intensive care medicine","score_opus":0.1764396153643693,"score_gpt":0.4546185029737315,"score_spread":0.2781788876093622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137055964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005704084,0.9959678,0.0000069222165,0.00026766726,0.0010271734,0.0019956334,0.000036672598,0.000019862207,0.0006212409],"genre_scores_gemma":[0.00025634325,0.9973094,0.0001997551,0.000010035333,0.000097476244,0.00080692815,0.0012570625,0.000028810804,0.0000342135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966449,0.000506377,0.001218097,0.0005775278,0.00046004623,0.0005930475],"domain_scores_gemma":[0.99823827,0.00047792768,0.00034579722,0.0007648843,0.00004870872,0.00012442528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004056931,0.00045131575,0.0021259103,0.0010775567,0.00003032523,0.0000101618225,0.00041947415,0.00027021082,0.0001459655],"category_scores_gemma":[0.000092126465,0.00028747247,0.00038756154,0.0013002388,0.00009591535,0.000033420114,0.00011688907,0.0006708067,0.000057626454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009094446,0.0014221995,0.0019282985,0.023932833,0.00014666162,0.0002370101,0.00009609114,2.6074392e-7,6.9140356e-9,0.00074750825,0.0017429664,0.9696552],"study_design_scores_gemma":[0.0040735337,0.00021457758,0.008052474,0.03222216,0.00016570507,0.00022703096,0.000054218755,0.00002472037,4.524812e-7,0.00004335894,0.9547278,0.00019394755],"about_ca_topic_score_codex":0.000023636057,"about_ca_topic_score_gemma":0.00002344009,"teacher_disagreement_score":0.96946126,"about_ca_system_score_codex":0.000253267,"about_ca_system_score_gemma":0.00012559042,"threshold_uncertainty_score":0.99995774},"labels":[],"label_agreement":null},{"id":"W2137310532","doi":"10.1371/journal.pone.0058504","title":"The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Indiana Clinical and Translational Sciences Institute; Canadian Institutes of Health Research; National Institutes of Health; University of Alberta; National Center for Advancing Translational Sciences; Purdue University","keywords":"Cytokine; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Malignancy; Medicine; Interleukin 6; Immunology; Bone marrow; Monoclonal; Internal medicine; Monoclonal antibody; Antibody","score_opus":0.0526773085017002,"score_gpt":0.24775841929033512,"score_spread":0.19508111078863494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137310532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994185,0.0007614566,0.000004101588,0.0024412659,0.000018062414,0.0017010862,0.00002069691,0.000033612265,0.000834755],"genre_scores_gemma":[0.99529564,0.000748775,0.00038932433,0.0001745967,0.000108978646,0.0005580986,0.00004332215,0.000027063626,0.0026541944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830955,0.00007092402,0.00028280498,0.0002709706,0.00060207414,0.00046368898],"domain_scores_gemma":[0.9990147,0.00015894219,0.000053660842,0.0005098046,0.00004171065,0.00022118994],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012441436,0.00015863798,0.00027987067,0.00007462165,0.00011939925,0.000036933405,0.00013707914,0.00005928931,0.00083469163],"category_scores_gemma":[0.000099708835,0.00010189947,0.00005962007,0.000083206054,0.000076322365,0.000074658994,0.00008254885,0.00019986267,0.0029682864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003940918,0.003608797,0.587526,0.00033222124,0.0008123189,0.00013722958,0.0007424593,0.0000011628113,0.39643392,0.00001723895,0.0010257093,0.00896882],"study_design_scores_gemma":[0.00900522,0.00062760647,0.82859975,0.0007461634,0.00014633466,0.000054094315,0.0004126618,0.012135478,0.14725849,0.00006678735,0.0006884812,0.00025892886],"about_ca_topic_score_codex":0.00034126913,"about_ca_topic_score_gemma":0.000026250964,"teacher_disagreement_score":0.24917541,"about_ca_system_score_codex":0.00022580469,"about_ca_system_score_gemma":0.000031056854,"threshold_uncertainty_score":0.99780804},"labels":[],"label_agreement":null},{"id":"W2138135185","doi":"10.1354/vp.08-vp-0266-r-cr","title":"Rectal Plasmacytoma with Intracellular Hemosiderin in a Dog","year":2009,"lang":"en","type":"article","venue":"Veterinary Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Hemosiderin; Pathology; Plasmacytoma; Immunohistochemistry; Histiocyte; Staining; Cytology; Medicine; Anatomy; Biology; Multiple myeloma; Internal medicine","score_opus":0.03312823503844631,"score_gpt":0.3175277930037218,"score_spread":0.2843995579652755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138135185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958307,0.00017629143,0.000053626944,0.0007520802,0.000034257646,0.00037217143,0.000004662177,0.00006305464,0.0027131147],"genre_scores_gemma":[0.9944399,0.000041467894,0.004846702,0.00022853182,0.00004210687,0.000038234746,0.000030154506,0.000014915592,0.00031797984],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988575,0.00009254391,0.00016906182,0.000320658,0.00014579389,0.00041443334],"domain_scores_gemma":[0.999486,0.000038078557,0.000030417323,0.00027100113,0.000024111494,0.0001503618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010548853,0.00015566223,0.0002882,0.00020968092,0.00003404096,0.000008209416,0.00006635463,0.00009286274,0.00010796913],"category_scores_gemma":[0.000038755366,0.00011851327,0.000039022194,0.00020661997,0.00007779375,0.000058170554,0.00003208812,0.0002253736,0.00009313518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008367467,0.0013980543,0.098851874,0.000070014634,0.000057879544,0.3532956,0.00046393994,0.000007910253,0.45616922,0.00009235935,0.00011615004,0.08110956],"study_design_scores_gemma":[0.010510673,0.030977635,0.8859985,0.00012710119,0.000026176212,0.052194946,0.00008371999,0.00048715645,0.016993264,0.00014509278,0.0021967813,0.0002589504],"about_ca_topic_score_codex":0.000018350402,"about_ca_topic_score_gemma":0.000010124456,"teacher_disagreement_score":0.7871466,"about_ca_system_score_codex":0.0000643546,"about_ca_system_score_gemma":0.0000560125,"threshold_uncertainty_score":0.4832831},"labels":[],"label_agreement":null},{"id":"W2138179458","doi":"10.1378/chest.06-2360","title":"Risk of Thrombosis With Lenalidomide and Its Prevention With Aspirin","year":2007,"lang":"en","type":"review","venue":"CHEST Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"","keywords":"Medicine; Lenalidomide; Aspirin; Warfarin; Multiple myeloma; Venous thrombosis; Thalidomide; Randomized controlled trial; Pomalidomide; Thrombosis; Regimen; Intensive care medicine; Internal medicine; Surgery","score_opus":0.1407604775316684,"score_gpt":0.4208586923801468,"score_spread":0.2800982148484784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138179458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062349974,0.9921074,0.00017860565,0.000015263638,0.000021925462,0.0007392132,0.000020043164,0.000008853715,0.00067373243],"genre_scores_gemma":[0.0012181211,0.9958428,0.0021831433,0.00000387053,0.00018063672,0.000017267448,0.00003301295,0.000047324138,0.00047382936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833727,0.0001410159,0.00045451906,0.00022545297,0.0005321467,0.00030962008],"domain_scores_gemma":[0.9984526,0.0001333343,0.00064236805,0.00018921106,0.00020795976,0.00037451173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000581031,0.00030005322,0.0013046091,0.00028964353,0.00009538108,0.000031264317,0.000085875625,0.00015183764,0.000089449735],"category_scores_gemma":[0.00008897228,0.00015270032,0.00021945797,0.00023516823,0.000091297276,0.00008797639,0.000027985601,0.0007834001,0.000013427656],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038121475,0.0002800101,0.0056637586,0.018448263,0.0029456418,0.00044196242,0.000038426067,2.1319062e-7,0.000002330379,0.0000060228717,0.000040491017,0.9717517],"study_design_scores_gemma":[0.015227078,0.007987367,0.035149433,0.16021918,0.017055087,0.017251985,0.00009665482,0.000010163478,0.0002282043,0.000039951366,0.74605656,0.00067836035],"about_ca_topic_score_codex":0.000011725222,"about_ca_topic_score_gemma":0.000017714256,"teacher_disagreement_score":0.9710733,"about_ca_system_score_codex":0.00013428966,"about_ca_system_score_gemma":0.0005667394,"threshold_uncertainty_score":0.62269384},"labels":[],"label_agreement":null},{"id":"W2138777076","doi":"10.1158/1078-0432.ccr-06-0719","title":"The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells <i>In vitro</i> and <i>In vivo</i>","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Thalidomide; Apoptosis; In vivo; In vitro; Leukemia; Immunology; Cell culture; Biology; Cancer research; Medicine; Multiple myeloma; Biochemistry","score_opus":0.04908071187165018,"score_gpt":0.38682727263138134,"score_spread":0.33774656075973114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138777076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385625,0.0025735875,0.0000018602891,0.0016442345,0.00010674653,0.0010451213,0.00007083222,0.000015888902,0.0006854511],"genre_scores_gemma":[0.9914425,0.00738976,0.000096755095,0.00018256328,0.00029562486,0.00031365364,0.000019158368,0.000038379683,0.00022162579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954161,0.000820636,0.00089017925,0.00080930174,0.00088308833,0.001180707],"domain_scores_gemma":[0.9945635,0.004426521,0.000088072375,0.0003585728,0.00015218846,0.0004111402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033758814,0.00026026892,0.0006640728,0.000426658,0.00022227028,0.00013991258,0.00027082156,0.00024310203,0.000017681177],"category_scores_gemma":[0.00084801426,0.00018110187,0.000096437114,0.0010152917,0.00080770743,0.00013241901,0.00027105288,0.0013631628,0.000012808036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01111978,0.003544961,0.8653678,0.00028412518,0.00029986634,0.0012327981,0.00027288205,0.000034860055,0.09779941,0.00011219594,0.0018557751,0.018075487],"study_design_scores_gemma":[0.048121754,0.0008087733,0.77563965,0.00092065334,0.00008058923,0.000022741475,0.00034107477,0.0011433881,0.1703216,0.0016406741,0.00052358327,0.0004355407],"about_ca_topic_score_codex":0.012549593,"about_ca_topic_score_gemma":0.005112453,"teacher_disagreement_score":0.08972823,"about_ca_system_score_codex":0.00056851754,"about_ca_system_score_gemma":0.00083238736,"threshold_uncertainty_score":0.99402595},"labels":[],"label_agreement":null},{"id":"W2138902352","doi":"10.1158/1055-9965.epi-14-1145","title":"A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium","year":2014,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Saskatchewan; Saskatchewan Health; Saskatchewan Health Authority; Public Health Ontario; University of British Columbia; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; World Health Organization","keywords":"Medicine; Multiple myeloma; Confounding; Odds ratio; Confidence interval; Internal medicine; Logistic regression; Risk factor; Population; Cigarette smoking; Demography; Oncology; Environmental health","score_opus":0.04168250592237924,"score_gpt":0.3478018087358764,"score_spread":0.3061193028134972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138902352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897594,0.0038763424,0.0042222943,0.0016779806,0.00025369567,0.00053202733,0.0003426468,0.000025543175,0.00009355631],"genre_scores_gemma":[0.99572796,0.0013375912,0.001822068,0.00020418622,0.00010389664,0.000112149995,0.00059609005,0.000016816808,0.00007923952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968941,0.0011193407,0.0008671234,0.00051316037,0.00027573347,0.00033054812],"domain_scores_gemma":[0.99364585,0.0046257004,0.0008583307,0.00049085007,0.00022615565,0.00015312212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023106511,0.00021468716,0.0008909815,0.00029549032,0.00010426266,0.000006162443,0.00021524979,0.00020502665,0.0002442232],"category_scores_gemma":[0.0056883073,0.00015210087,0.00043925593,0.00037353908,0.00047736472,0.00007726941,0.00013000831,0.00021847866,0.0000017204316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012627961,0.00010164186,0.8962064,0.000026414686,0.025621444,0.0000023852147,0.00010814935,0.00005222025,0.0036655662,0.000036794405,0.0004654928,0.07245074],"study_design_scores_gemma":[0.003504888,0.00015067411,0.93436235,0.00018274008,0.0062719253,0.000002193174,0.00009571897,0.051942877,0.0024326642,0.0004826105,0.00046529187,0.00010605516],"about_ca_topic_score_codex":0.005231894,"about_ca_topic_score_gemma":0.0030667116,"teacher_disagreement_score":0.07234468,"about_ca_system_score_codex":0.00011500939,"about_ca_system_score_gemma":0.000083379666,"threshold_uncertainty_score":0.79090935},"labels":[],"label_agreement":null},{"id":"W2139026714","doi":"10.3324/haematol.11168","title":"Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial","year":2007,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Cyclophosphamide; Internal medicine; Total body irradiation; Regimen; Chemotherapy; Randomized controlled trial; Surgery; Oncology","score_opus":0.06266984780719237,"score_gpt":0.3249320796119417,"score_spread":0.26226223180474934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139026714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409705,0.00022750837,0.000095703464,0.00017779139,0.0002526135,0.004116983,0.000044289063,0.000055902983,0.0009321616],"genre_scores_gemma":[0.9984769,0.000045267705,0.0003484789,0.00004804835,0.000058108446,0.00031089567,0.00014376715,0.000029831888,0.00053869677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726564,0.00029567516,0.0006625444,0.0005365165,0.0005610821,0.0006785598],"domain_scores_gemma":[0.9980128,0.0007171734,0.0002692409,0.0005595528,0.00017411668,0.00026715844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034048292,0.00041835356,0.0011185465,0.00021379013,0.00015589457,0.00002161145,0.00023870454,0.0001733813,0.00014539127],"category_scores_gemma":[0.00037498737,0.0002075694,0.00022226272,0.0005403687,0.000484914,0.00009586599,0.00011318157,0.0002968524,0.00003279834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13023335,0.0027698562,0.85578406,0.00008539207,0.00056538417,0.002548349,0.0027237711,0.0000040300583,0.0011708499,0.000102350234,0.000061267245,0.003951356],"study_design_scores_gemma":[0.14467849,0.0051721497,0.8313649,0.00029165993,0.00012749706,0.00017800015,0.0007902069,0.00014165956,0.017003415,0.00001604424,0.00003963054,0.0001963423],"about_ca_topic_score_codex":0.00040936176,"about_ca_topic_score_gemma":0.0079005575,"teacher_disagreement_score":0.024419148,"about_ca_system_score_codex":0.00034666064,"about_ca_system_score_gemma":0.00018135988,"threshold_uncertainty_score":0.8464435},"labels":[],"label_agreement":null},{"id":"W2139199450","doi":"10.3109/10428194.2010.548535","title":"Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Saint John Regional Hospital; University of Calgary; University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Multiple myeloma; Medicine; Oncology; Cancer research; Internal medicine","score_opus":0.04494350580488436,"score_gpt":0.28597660667642627,"score_spread":0.2410331008715419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139199450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933173,0.0036913496,0.00029949428,0.00009746487,0.000043878485,0.0019136771,0.00012606793,0.00006677444,0.00044398004],"genre_scores_gemma":[0.9908982,0.001134799,0.00684625,0.00015964716,0.000048967773,0.0005952567,0.00009580777,0.000059618127,0.00016143975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779016,0.00008452694,0.0005641147,0.00070901436,0.00023119463,0.00062097143],"domain_scores_gemma":[0.99822116,0.00056401524,0.00019555855,0.0004582627,0.00016572424,0.00039526008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000226574,0.0003885419,0.0006320469,0.00026737966,0.00021170564,0.00003285689,0.00013891801,0.00027592378,0.000010974316],"category_scores_gemma":[0.00022543706,0.00032492357,0.00008796096,0.00029374158,0.00043538545,0.00018670532,0.00012221225,0.00008246755,0.0000023379623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023980327,0.00048742522,0.6546285,0.0006308311,0.00019055605,0.000056237393,0.0018972808,0.0000012418099,0.13795047,0.00041710865,0.0001142422,0.20122807],"study_design_scores_gemma":[0.019399889,0.00063647254,0.9177849,0.0002705533,0.0001462627,0.00017235994,0.00034415966,0.0025213654,0.05687658,0.00082667737,0.0007198589,0.00030089717],"about_ca_topic_score_codex":0.0008622562,"about_ca_topic_score_gemma":0.000102232305,"teacher_disagreement_score":0.2631564,"about_ca_system_score_codex":0.0007732772,"about_ca_system_score_gemma":0.0009265763,"threshold_uncertainty_score":0.9999203},"labels":[],"label_agreement":null},{"id":"W2139230560","doi":"10.1158/0008-5472.can-05-2159","title":"Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Cyclin D; Cyclin-dependent kinase; Cyclin-dependent kinase 6; Cyclin D1; Cancer research; Cyclin D3; Retinoblastoma protein; Cyclin B; Cyclin A2; Cyclin A; Cyclin E; Cyclin D2; Biology; Cyclin; Cell biology; Cell cycle; Cancer; Genetics","score_opus":0.042170720834725055,"score_gpt":0.3512264233061662,"score_spread":0.30905570247144115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139230560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880922,0.0027601258,0.000038993207,0.0028332032,0.00008440491,0.005318023,0.00009847931,0.00013445418,0.00064014265],"genre_scores_gemma":[0.99256295,0.000946043,0.0015032724,0.000077200006,0.0005365005,0.0015343098,0.00009087474,0.00014943862,0.0025993863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99269915,0.0008655685,0.0009908959,0.0016546987,0.0019668383,0.0018228423],"domain_scores_gemma":[0.99643004,0.0009276573,0.00024532038,0.0008700699,0.00043602305,0.0010909127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020085583,0.0006403465,0.0008666306,0.001083992,0.00062226295,0.00024186863,0.00036362335,0.00042831793,0.0002844601],"category_scores_gemma":[0.001313162,0.0005801384,0.00013090494,0.0007729559,0.000628662,0.00057765393,0.0007890378,0.0016588166,0.00008957657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063934065,0.002001098,0.17013863,0.001140983,0.0001933654,0.0015673776,0.0024160738,0.0002069492,0.6661579,0.000036324207,0.00009967652,0.14964822],"study_design_scores_gemma":[0.01665301,0.0015218362,0.268994,0.0014423158,0.00005587369,0.00006874804,0.0016944658,0.009029572,0.6989202,0.0004469688,0.0004848184,0.00068821915],"about_ca_topic_score_codex":0.0023742765,"about_ca_topic_score_gemma":0.0037354226,"teacher_disagreement_score":0.14896,"about_ca_system_score_codex":0.0012183441,"about_ca_system_score_gemma":0.0005823777,"threshold_uncertainty_score":0.999665},"labels":[],"label_agreement":null},{"id":"W2140439585","doi":"10.1177/104063870001200318","title":"Extramedullary Plasmacytoma in a Horse with Ptyalism and Dysphagia","year":2000,"lang":"en","type":"article","venue":"Journal of Veterinary Diagnostic Investigation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Prince Edward Island","funders":"","keywords":"Pathology; Plasmacytoma; Medicine; Meninges; Bence Jones protein; Pericardium; Horse; Lymphoma; Anatomy; Multiple myeloma; Biology; Internal medicine; Antibody; Immunoglobulin light chain","score_opus":0.025808875302117004,"score_gpt":0.2930331651430816,"score_spread":0.2672242898409646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140439585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978529,0.00078573695,0.000012344176,0.00083862565,0.00003282963,0.00026259263,0.0000036226656,0.000008275934,0.00020306553],"genre_scores_gemma":[0.99473894,0.0009044587,0.0039638616,0.00019487928,0.000082557046,0.000012866915,0.000010308975,0.000014875484,0.00007728288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989373,0.000090657275,0.00032763343,0.0001247672,0.00032519936,0.00019440618],"domain_scores_gemma":[0.99898505,0.00041330964,0.00010935718,0.000103376515,0.0000812222,0.00030769897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021519442,0.00012434332,0.00024630403,0.00020622044,0.000039080813,0.000024790095,0.000047834343,0.00005903339,0.00015382095],"category_scores_gemma":[0.00044480237,0.00009074255,0.000031678093,0.00017441431,0.00014422038,0.00024097697,0.000011206022,0.00024186437,0.000013244758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068666153,0.0008085579,0.7897796,0.00037408416,0.00030063876,0.045370277,0.0020054232,0.00021298413,0.0076920292,0.000054081058,0.00062140444,0.1459143],"study_design_scores_gemma":[0.006579079,0.007449647,0.96816725,0.0010616691,0.0000867851,0.013928259,0.00008568267,0.00050772517,0.0011602358,0.00038554668,0.00047425082,0.00011384587],"about_ca_topic_score_codex":0.000047955105,"about_ca_topic_score_gemma":0.000007656258,"teacher_disagreement_score":0.17838767,"about_ca_system_score_codex":0.00008809974,"about_ca_system_score_gemma":0.00016520584,"threshold_uncertainty_score":0.37003738},"labels":[],"label_agreement":null},{"id":"W2140486815","doi":"10.3109/10428194.2013.873537","title":"Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Oncology; Multivariate analysis; Overall survival; Progression-free survival; clone (Java method); Stem cell; Monoclonal; Monoclonal antibody; Immunology; Antibody; Biology","score_opus":0.008659674165426144,"score_gpt":0.23120845890660932,"score_spread":0.22254878474118317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140486815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600977,0.00092386827,0.0000087832295,0.0001014518,0.00012032296,0.0015682426,0.00027001303,0.0001112518,0.00088632444],"genre_scores_gemma":[0.99806315,0.00019720866,0.0005018247,0.00014954279,0.000105643805,0.00030590498,0.000247976,0.00011281225,0.00031592042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554795,0.00021551471,0.0006373276,0.0011844337,0.0011243252,0.0012904608],"domain_scores_gemma":[0.99738395,0.0005216316,0.00018217534,0.0006584958,0.00016321226,0.0010905439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002433999,0.00091077597,0.0011070131,0.00038870756,0.00024538464,0.00021021099,0.00022061165,0.00043818503,0.00007613816],"category_scores_gemma":[0.000036845588,0.00061903597,0.00014974766,0.00027500055,0.00043424574,0.00041948634,0.00020445324,0.00024139104,0.000024296316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012038062,0.0009882846,0.8850537,0.00026317965,0.0002463342,0.0008611924,0.00057631114,0.000010959826,0.00046621705,0.000021627442,0.00013137651,0.09934277],"study_design_scores_gemma":[0.06026497,0.0032008025,0.9303409,0.00046471797,0.00011484824,0.00024941948,0.000110653746,0.0034158938,0.00104603,0.000051189225,0.000110066365,0.0006305489],"about_ca_topic_score_codex":0.0024205132,"about_ca_topic_score_gemma":0.0002523343,"teacher_disagreement_score":0.09871222,"about_ca_system_score_codex":0.002596634,"about_ca_system_score_gemma":0.0010203571,"threshold_uncertainty_score":0.9996261},"labels":[],"label_agreement":null},{"id":"W2141013094","doi":"10.1111/j.1542-4758.2011.00587.x","title":"Impact of free light chain hemodialysis in myeloma cast nephropathy: A case–control study","year":2011,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hemodialysis; Multiple myeloma; Nephropathy; Dialysis; Renal function; Surgery; Urology; Internal medicine","score_opus":0.030941270579925743,"score_gpt":0.3169801530986236,"score_spread":0.28603888251869786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141013094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258995,0.000070170936,0.00029090108,0.00014577589,0.00010372352,0.00083820627,0.00025155678,0.000032169733,0.0056775394],"genre_scores_gemma":[0.9985006,0.000011953417,0.0007676228,0.000037711015,0.00018433019,0.00014269854,0.000049358197,0.00003193029,0.00027379877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973879,0.00022297952,0.0006865531,0.00048652437,0.00080984307,0.00040620568],"domain_scores_gemma":[0.99825084,0.00014349075,0.0002132263,0.0007404227,0.0003855952,0.0002664065],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005642224,0.00028658632,0.00071688456,0.0010872544,0.000055769186,0.000024600005,0.0003430235,0.00010103877,0.0027519711],"category_scores_gemma":[0.00058809895,0.00022803398,0.0005496589,0.00057959947,0.000070108836,0.00017156653,0.00013933644,0.00022447483,0.00006683685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020714884,0.0039691916,0.9571428,0.000012224589,0.003616998,0.009967366,0.0030830472,0.000034734112,0.0021147553,0.000037328296,0.0001250396,0.017825076],"study_design_scores_gemma":[0.014735438,0.0010007669,0.9738828,0.00003134939,0.0004698511,0.0006935354,0.000489289,0.007103079,0.0012950439,0.000093194496,0.000018345278,0.0001873301],"about_ca_topic_score_codex":0.0050289384,"about_ca_topic_score_gemma":0.0019284121,"teacher_disagreement_score":0.017637746,"about_ca_system_score_codex":0.00047645913,"about_ca_system_score_gemma":0.00020776993,"threshold_uncertainty_score":0.99815965},"labels":[],"label_agreement":null},{"id":"W2141105112","doi":"10.1056/nejmoa1402551","title":"Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":786,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Dexamethasone; Multiple myeloma; Prednisone; Melphalan; Oncology; Internal medicine; Hematopoietic stem cell transplantation; Transplantation","score_opus":0.013964611025678756,"score_gpt":0.26763884653941267,"score_spread":0.2536742355137339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141105112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944189,0.0006646049,0.00063623756,0.0031142829,0.00007136667,0.00018477645,0.0000018362824,0.0000059544773,0.0009020145],"genre_scores_gemma":[0.99697584,0.0003806929,0.0015373018,0.00023854608,0.0006913544,0.000001300484,0.000010853548,0.00001535952,0.00014873226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998556,0.00010363665,0.0003859184,0.00013346793,0.0005706477,0.00025029818],"domain_scores_gemma":[0.998753,0.00033258102,0.0001400121,0.00012084029,0.00015026866,0.0005032591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006965143,0.00014918101,0.0005413112,0.00032829688,0.000026466945,0.0000068939025,0.00006406015,0.00004712605,0.00008530486],"category_scores_gemma":[0.0003883544,0.00007889169,0.000029696455,0.0001745674,0.00009646134,0.000087272914,0.000008364132,0.00030233053,0.0000024723474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068495716,0.00013621539,0.7945098,0.000057499994,0.0001059967,0.00033187008,0.00048333732,0.000004815511,0.0005018713,0.000027836175,0.00034238142,0.19664878],"study_design_scores_gemma":[0.21557246,0.0045141964,0.77274257,0.0010266982,0.00014598448,0.00070567586,0.00003805678,0.00008458544,0.0003823976,0.00017572822,0.004530109,0.00008151152],"about_ca_topic_score_codex":0.00019342001,"about_ca_topic_score_gemma":0.00012839507,"teacher_disagreement_score":0.20872289,"about_ca_system_score_codex":0.000038911447,"about_ca_system_score_gemma":0.00009526834,"threshold_uncertainty_score":0.32171097},"labels":[],"label_agreement":null},{"id":"W2142098084","doi":"10.1111/bjh.13825","title":"From <scp>CLL</scp> to Multiple Myeloma ‐ Spleen Tyrosine Kinase (<scp>SYK</scp>) influences multiple myeloma cell survival and migration","year":2015,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Syk; Cancer research; CD38; CXCR4; Multiple myeloma; Downregulation and upregulation; Chronic lymphocytic leukemia; Medicine; Chemistry; Immunology; Tyrosine kinase; Leukemia; Receptor; Biology; Chemokine; Stem cell; Cell biology; Immune system; Internal medicine; CD34","score_opus":0.028114109119932396,"score_gpt":0.2817599126208232,"score_spread":0.25364580350089083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142098084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95907664,0.013491871,0.00017100683,0.02269161,0.0014620897,0.0013467852,0.0011903434,0.00008329058,0.00048633313],"genre_scores_gemma":[0.91070706,0.004190449,0.015262866,0.04611491,0.0126965605,0.00023219865,0.0040662955,0.00056335225,0.0061662993],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926379,0.00088077574,0.0019331722,0.0011044572,0.0018871564,0.0015565912],"domain_scores_gemma":[0.9913442,0.0035828764,0.0013628943,0.0006816383,0.001632372,0.0013959978],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00085768197,0.0009359765,0.0030340368,0.0011583641,0.00029816263,0.00037089677,0.0007403426,0.0015309385,0.000050786435],"category_scores_gemma":[0.008219411,0.00093255227,0.0005077693,0.000571766,0.00047539524,0.0004769485,0.00037313846,0.002947961,0.00021218494],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017223277,0.00042641594,0.089705996,0.0005030334,0.00081088097,0.1446619,0.00062609377,0.000008510507,0.0021585335,0.0000016352121,0.7558938,0.0050309594],"study_design_scores_gemma":[0.020229854,0.002608818,0.14369924,0.0027700292,0.0010934129,0.09592083,0.001455579,0.00037311122,0.008681189,0.00030062773,0.7224431,0.00042420803],"about_ca_topic_score_codex":0.004183298,"about_ca_topic_score_gemma":0.0027186337,"teacher_disagreement_score":0.053993244,"about_ca_system_score_codex":0.0002915101,"about_ca_system_score_gemma":0.00080782315,"threshold_uncertainty_score":0.9997653},"labels":[],"label_agreement":null},{"id":"W2142708329","doi":"10.1007/s00330-014-3458-5","title":"The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken","year":2014,"lang":"en","type":"article","venue":"European Radiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"Dietmar Hopp Stiftung","keywords":"Medicine; Multiple myeloma; Renal function; Monoclonal gammopathy of undetermined significance; Radiology; Kidney disease; Magnetic resonance imaging; Plasma cell; Hematology; Monoclonal; Neuroradiology; Adverse effect; Internal medicine; Kidney; Urology; Monoclonal antibody; Neurology","score_opus":0.009267728000227194,"score_gpt":0.2571991943799735,"score_spread":0.24793146637974633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142708329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126846,0.000042436346,0.000078832345,0.00019285743,0.00005751243,0.00082931283,0.000019999507,0.000018701929,0.0074919034],"genre_scores_gemma":[0.998761,0.000042047726,0.00019403461,0.00003550622,0.0000729208,0.00003713542,0.0002652171,0.000028173918,0.0005639731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839854,0.0005412922,0.00022217588,0.0003173401,0.00023757,0.00028309025],"domain_scores_gemma":[0.99915487,0.00014305161,0.00016142594,0.00033382713,0.00006502901,0.00014178624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028126326,0.00017294932,0.0002219486,0.000087302156,0.00014386872,0.000017563065,0.00011671386,0.000045505494,0.000045245808],"category_scores_gemma":[0.0000897035,0.000099132005,0.000044985885,0.00007809934,0.00020219912,0.00004835864,0.00006125673,0.0001901265,0.00014454826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011551424,0.00063264125,0.9699885,0.000021489981,0.00010996084,0.00001018739,0.00007508165,0.0003247285,0.0012957623,0.00007394674,0.0010335251,0.014882722],"study_design_scores_gemma":[0.008675351,0.005654657,0.9784609,0.000036917678,0.000028883,0.0000078333405,0.000012172963,0.0024814042,0.00028525628,0.0000591897,0.004206489,0.00009096421],"about_ca_topic_score_codex":0.00019732305,"about_ca_topic_score_gemma":0.00008607161,"teacher_disagreement_score":0.014791758,"about_ca_system_score_codex":0.00007993702,"about_ca_system_score_gemma":0.000052456435,"threshold_uncertainty_score":0.4042486},"labels":[],"label_agreement":null},{"id":"W2145167393","doi":"10.1158/0008-5472.850.65.3","title":"Receptor for Hyaluronan-Mediated Motility Correlates with Centrosome Abnormalities in Multiple Myeloma and Maintains Mitotic Integrity","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Fondation pour la Recherche Médicale","keywords":"Centrosome; Motility; Multiple myeloma; Mitosis; Biology; Cell biology; Cancer research; Cancer; Immunology; Genetics; Cell cycle","score_opus":0.07405062333954149,"score_gpt":0.3745876947268252,"score_spread":0.3005370713872837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145167393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251854,0.0015873192,0.000036176774,0.0030993803,0.000049862963,0.0021848879,0.00028965485,0.00004722025,0.00018692584],"genre_scores_gemma":[0.995245,0.00056654273,0.001148917,0.00007654358,0.00019382384,0.0009070594,0.00017386499,0.00004019897,0.0016480404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971392,0.00022757586,0.00029396178,0.0005333003,0.0007053413,0.0011006031],"domain_scores_gemma":[0.9975532,0.0011207702,0.00003949441,0.00033402533,0.0004585829,0.00049390295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009354803,0.00021442826,0.00039271355,0.00034163563,0.00021445223,0.000057278445,0.00014801952,0.00014303498,0.00032164488],"category_scores_gemma":[0.0012373524,0.00015789075,0.000056916928,0.00043470497,0.00057109375,0.00019140774,0.00010380777,0.0008638913,0.00005113122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00563872,0.00055946625,0.95514804,0.00046332192,0.0001539725,0.00006855671,0.0008916763,0.000018819472,0.0043466534,0.00017022666,0.0008900459,0.031650525],"study_design_scores_gemma":[0.018857712,0.0023103268,0.9442228,0.000643169,0.000032939675,0.000031170337,0.0019314677,0.009786437,0.010595295,0.00014859825,0.011151638,0.00028843124],"about_ca_topic_score_codex":0.0018102285,"about_ca_topic_score_gemma":0.0043589766,"teacher_disagreement_score":0.03136209,"about_ca_system_score_codex":0.0009452497,"about_ca_system_score_gemma":0.00059074117,"threshold_uncertainty_score":0.6438598},"labels":[],"label_agreement":null},{"id":"W2146185798","doi":"10.3324/haematol.2009.015917","title":"Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Complete response; Dexamethasone; Multiple myeloma; Refractory (planetary science); Adverse effect; Internal medicine; Progressive disease; Surgery; Chemotherapy; Materials science","score_opus":0.0662267828043679,"score_gpt":0.375866646101104,"score_spread":0.3096398632967361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146185798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680424,0.0000059238923,0.000029629466,0.001096528,0.00005954717,0.0017680883,0.00010545766,0.00006877463,0.00006183938],"genre_scores_gemma":[0.9898026,0.0000022999313,0.008696597,0.0008347682,0.000011490481,0.00013550786,0.000059134825,0.00003748951,0.00042011624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625814,0.00083011034,0.000990953,0.00062648766,0.0007119495,0.00058238755],"domain_scores_gemma":[0.99357796,0.004336001,0.00044142012,0.0008234562,0.00039105563,0.00043009166],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017144344,0.0003298937,0.0015503571,0.00022891154,0.00007670811,0.000016286875,0.00021397458,0.0003526994,0.0002458835],"category_scores_gemma":[0.01538218,0.00017199708,0.00015591361,0.00038476088,0.00032299347,0.00009704478,0.00011009777,0.00075141457,0.000035421202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13208336,0.0021078542,0.861692,0.000037693764,0.0003998291,0.0003492804,0.00020310038,2.2698207e-7,0.0014816688,0.0000021987007,0.000103627644,0.0015391309],"study_design_scores_gemma":[0.03879621,0.0055001965,0.9533721,0.0001443989,0.00006300391,0.00001056987,0.00006913742,0.000040396306,0.0016798277,0.0000065504983,0.00009583777,0.00022178188],"about_ca_topic_score_codex":0.00033274878,"about_ca_topic_score_gemma":0.0019159549,"teacher_disagreement_score":0.09328714,"about_ca_system_score_codex":0.00012978147,"about_ca_system_score_gemma":0.0003345487,"threshold_uncertainty_score":0.9929117},"labels":[],"label_agreement":null},{"id":"W2147486721","doi":"10.1002/cncr.27745","title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Bortezomib; Bevacizumab; Multiple myeloma; Clinical endpoint; Internal medicine; Hazard ratio; Refractory (planetary science); Adverse effect; Placebo; Gastroenterology; Proteasome inhibitor; Phases of clinical research; Progressive disease; Oncology; Surgery; Randomized controlled trial; Confidence interval; Clinical trial; Chemotherapy; Pathology","score_opus":0.06845420894354572,"score_gpt":0.3886860045544843,"score_spread":0.3202317956109386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147486721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927371,0.0034395275,0.0000033610868,0.00010549675,0.00035778197,0.002451484,0.00034788344,0.00003543713,0.00052192586],"genre_scores_gemma":[0.9976214,0.00072334526,0.00024580612,0.000034930577,0.00022399853,0.00047059142,0.00013474909,0.000038225986,0.0005069306],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975539,0.0003026483,0.0007065321,0.00043934744,0.0004782422,0.0005193708],"domain_scores_gemma":[0.99717283,0.0015209723,0.00024072776,0.00053348526,0.000115484516,0.00041647072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005704871,0.0002697805,0.0010560318,0.00020833436,0.000057873513,0.000012229844,0.00009366301,0.00013088004,0.0002693414],"category_scores_gemma":[0.0021445875,0.00018811073,0.00010345214,0.0002675,0.0001543992,0.00015513632,0.00007607601,0.0002942234,0.000012583096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9062298,0.0046802503,0.04396568,0.000045935136,0.0009561162,0.00023742588,0.004887119,0.000002151549,0.0017621113,0.0000023420762,0.00049623393,0.03673486],"study_design_scores_gemma":[0.8768673,0.0017438408,0.116111666,0.00016261278,0.0003901986,0.0000041853323,0.0013266146,0.00071687566,0.0014519981,0.0000037055306,0.0010386567,0.00018235526],"about_ca_topic_score_codex":0.008213732,"about_ca_topic_score_gemma":0.0030095717,"teacher_disagreement_score":0.07214599,"about_ca_system_score_codex":0.00029314047,"about_ca_system_score_gemma":0.00023932359,"threshold_uncertainty_score":0.9983907},"labels":[],"label_agreement":null},{"id":"W2147495729","doi":"10.1016/j.clml.2013.07.003","title":"Multiple Myeloma International Staging System: “Staging” or Simply “Aging” System?","year":2013,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Cedars-Sinai Medical Center","keywords":"Staging system; Medicine; Multiple myeloma; Comorbidity; Malignancy; Hematologic malignancy; Oncology; Internal medicine; TNM staging system; Cancer","score_opus":0.11293239350661946,"score_gpt":0.41674017536947283,"score_spread":0.3038077818628534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147495729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032842935,0.958493,0.00041002876,0.00030404134,0.0069704056,0.009920573,0.0011302294,0.0024821407,0.017005285],"genre_scores_gemma":[0.01388642,0.9598894,0.0038275297,0.0003224063,0.0053499257,0.0020897978,0.0028098559,0.00075902,0.01106564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847305,0.0014681359,0.005729498,0.0031366167,0.0025117404,0.002423528],"domain_scores_gemma":[0.98644626,0.0046790694,0.002259044,0.0030956406,0.0009752906,0.0025447165],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022269385,0.0023009721,0.007802446,0.0011952015,0.0005625534,0.0006266092,0.0021307538,0.0019137838,0.0006398328],"category_scores_gemma":[0.0032697197,0.0016236724,0.003316008,0.0011433717,0.0006817219,0.0005253527,0.0013408721,0.0017680761,0.007845593],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00051934534,0.00039763606,0.0032668598,0.03965222,0.003791211,0.006696686,0.000038963597,0.0000010186158,0.0000015726844,0.0003047788,0.0066428822,0.93868685],"study_design_scores_gemma":[0.00934718,0.0006109958,0.013669761,0.054660883,0.002881493,0.0029454522,0.0003597435,0.0030074401,0.000008061402,0.000004366823,0.9109928,0.0015118354],"about_ca_topic_score_codex":0.0008291219,"about_ca_topic_score_gemma":0.000028625118,"teacher_disagreement_score":0.937175,"about_ca_system_score_codex":0.012362321,"about_ca_system_score_gemma":0.0077726953,"threshold_uncertainty_score":0.99938196},"labels":[],"label_agreement":null},{"id":"W2148565111","doi":"10.1186/1756-8722-4-37","title":"Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells","year":2011,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Peking Union Medical College; National Natural Science Foundation of China","keywords":"Stromal cell; Transfection; microRNA; Bone marrow; Cancer research; Hematology; Multiple myeloma; Cytotoxic T cell; Cell growth; Interleukin; Cell culture; Medicine; Biology; Immunology; Molecular biology; In vitro; Cytokine; Gene; Biochemistry","score_opus":0.022857659148931384,"score_gpt":0.3252212007589212,"score_spread":0.3023635416099898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148565111","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4402998,0.044772226,0.00037717327,0.4863647,0.005030589,0.0018975972,0.00010039742,0.0000802935,0.021077227],"genre_scores_gemma":[0.64624983,0.0066464115,0.031400483,0.2643713,0.006234063,0.0003287055,0.00054482627,0.00056434376,0.043660074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99467283,0.001020884,0.001840535,0.00061697955,0.000697957,0.0011508347],"domain_scores_gemma":[0.9955969,0.0012282865,0.0019190281,0.0005381489,0.0003885893,0.00032904887],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006687381,0.00061598315,0.002842841,0.0009890498,0.000100938916,0.00002703543,0.0006853454,0.0017226244,0.0010168466],"category_scores_gemma":[0.0002931821,0.0004609387,0.0004973877,0.00021061431,0.0005414215,0.00021379493,0.00018477326,0.004522976,0.00011031382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021815135,0.0006899024,0.002046291,0.0006059946,0.00042269283,0.04002933,0.00058682385,5.831529e-8,0.027061038,0.0000071909867,0.924604,0.0017651696],"study_design_scores_gemma":[0.0059977737,0.0010018005,0.00029313655,0.002393022,0.00023850134,0.0054259007,0.00015949243,0.0000014143465,0.22198564,0.00039126026,0.7617871,0.00032493068],"about_ca_topic_score_codex":0.000051644092,"about_ca_topic_score_gemma":0.0002592915,"teacher_disagreement_score":0.2219934,"about_ca_system_score_codex":0.0010160247,"about_ca_system_score_gemma":0.0010164448,"threshold_uncertainty_score":0.99989635},"labels":[],"label_agreement":null},{"id":"W2149219110","doi":"10.1016/s0360-3016(00)01572-8","title":"Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome","year":2001,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Plasmacytoma; Radiation therapy; Biopsy; Chemotherapy; Soft tissue; Internal medicine; Radiology; Surgery; Oncology","score_opus":0.030378476094695208,"score_gpt":0.38342496552797556,"score_spread":0.3530464894332804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149219110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633527,0.00017693386,0.00058900355,0.0012314633,0.0002230992,0.0002782153,0.00008759171,0.000025918709,0.0010525148],"genre_scores_gemma":[0.9962302,0.0002739161,0.001869872,0.00050649553,0.00088038866,0.000008844866,0.000079357866,0.000032413875,0.00011854387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825007,0.0001861724,0.0006740643,0.00019809263,0.00040972338,0.0002818957],"domain_scores_gemma":[0.9974583,0.0007135788,0.0008018321,0.00017571628,0.00062272185,0.00022784309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028401357,0.00023110336,0.0006480952,0.00023156102,0.000044774853,0.000012515142,0.00025976758,0.00012559013,0.00024293017],"category_scores_gemma":[0.00031738312,0.00015116483,0.00035464816,0.00019904714,0.00018616843,0.00017034648,0.000020877278,0.00038712125,0.00001979046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009142306,0.0012246019,0.9351622,0.0000061139076,0.0024766598,0.00068615266,0.00010234098,0.0005700069,0.0037824519,0.00034941477,0.00048352624,0.046014234],"study_design_scores_gemma":[0.031941883,0.01925298,0.9335581,0.00011441326,0.00020555465,0.0022977234,0.000055834058,0.0030248042,0.0044998582,0.0007339153,0.0040897788,0.00022513303],"about_ca_topic_score_codex":0.000096541895,"about_ca_topic_score_gemma":0.000005133469,"teacher_disagreement_score":0.0457891,"about_ca_system_score_codex":0.0013056175,"about_ca_system_score_gemma":0.00062398,"threshold_uncertainty_score":0.6164323},"labels":[],"label_agreement":null},{"id":"W2149247660","doi":"10.4021/jocmr2009.05.1240","title":"An Extraosseous Plasmacytoma of the Nasopharynx","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Biopsy; Radiation therapy; Refractory (planetary science); Extramedullary plasmacytoma; Surgery; Radiology; Internal medicine; Multiple myeloma","score_opus":0.30027226775485594,"score_gpt":0.6026075512796468,"score_spread":0.3023352835247909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149247660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96956205,0.0011354425,0.000023206567,0.022109928,0.0003217792,0.00042468886,0.0000026059613,0.000007393692,0.0064129108],"genre_scores_gemma":[0.99554825,0.00092091644,0.00054241635,0.00036099798,0.0019095733,0.0000017061601,0.0000015666498,0.0000139915865,0.0007005883],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9931636,0.0011552115,0.0017901729,0.0002178493,0.0031736237,0.0004995698],"domain_scores_gemma":[0.99320555,0.0027594375,0.00048353514,0.0006907764,0.001851249,0.0010094636],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009714401,0.00013803353,0.00097335136,0.00037427372,0.000113960574,0.000011327775,0.000654047,0.0001629601,0.00037282394],"category_scores_gemma":[0.014593317,0.00006447055,0.0003748026,0.0007080221,0.0009386896,0.00012505411,0.000055463363,0.0020457658,0.000020955786],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014072901,0.0055809985,0.42168444,0.00016976586,0.0005711817,0.0034852694,0.00038651619,0.000006694536,0.017258575,0.00055889104,0.025032695,0.5111921],"study_design_scores_gemma":[0.013156974,0.02874396,0.94232494,0.0010247641,0.00011408799,0.0011116461,0.00023392333,0.00038932054,0.005366881,0.001975462,0.0054884134,0.00006963079],"about_ca_topic_score_codex":0.000029769077,"about_ca_topic_score_gemma":0.000005184126,"teacher_disagreement_score":0.5206405,"about_ca_system_score_codex":0.00007067383,"about_ca_system_score_gemma":0.00097137893,"threshold_uncertainty_score":0.9937072},"labels":[],"label_agreement":null},{"id":"W2149319188","doi":"10.14740/wjon855w","title":"Significance of Fractionated Administration of Thalidomide Combined With γ-Ray Irradiation in Terms of Local Tumor Response and Lung Metastasis","year":2014,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Thalidomide; Population; Metastasis; Lung; Pharmacology; Pathology; Internal medicine; Cancer","score_opus":0.01814022751728267,"score_gpt":0.3314051200722358,"score_spread":0.31326489255495316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149319188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976916,0.000077016964,0.0007721346,0.0008745142,0.000030560364,0.00021882671,0.000007240281,0.0000014413093,0.00032670714],"genre_scores_gemma":[0.9974609,0.00002354047,0.00241207,0.00002609812,0.000015917385,0.000005020701,0.000004847948,0.0000060475127,0.00004557343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862057,0.00040771673,0.00054134906,0.000079539015,0.0002487047,0.00010209838],"domain_scores_gemma":[0.9981088,0.0007953642,0.00071199844,0.000086646425,0.0002068998,0.00009029182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009619921,0.000071781724,0.0004895181,0.00041865223,0.00001258714,0.0000018827569,0.00004323333,0.000033828273,0.000039846764],"category_scores_gemma":[0.00035461414,0.00005101003,0.00004209026,0.00023504195,0.00016825928,0.00007429669,0.000007700864,0.00015758093,2.3896672e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28731585,0.0025785933,0.4938964,0.00037437887,0.0007934525,0.00066117034,0.0004073715,0.00059724454,0.16962574,0.00040831938,0.00018904428,0.04315243],"study_design_scores_gemma":[0.011846412,0.010831053,0.9306259,0.00017569895,0.00014130295,0.00021540807,0.000120217985,0.001253003,0.04437877,0.00008063649,0.0002905122,0.000041054504],"about_ca_topic_score_codex":0.000046004283,"about_ca_topic_score_gemma":0.00026596282,"teacher_disagreement_score":0.43672952,"about_ca_system_score_codex":0.00013691213,"about_ca_system_score_gemma":0.00034518875,"threshold_uncertainty_score":0.20801286},"labels":[],"label_agreement":null},{"id":"W2149388503","doi":"10.1016/j.ctrv.2008.02.003","title":"A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma","year":2008,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Sudbury Regional Hospital; McMaster University Medical Centre; Princess Margaret Cancer Centre; Queen's University; McMaster University; Cancer Care Ontario; St. Michael's Hospital","funders":"Cancer Care Ontario; Canadian Institutes of Health Research; American Society of Hematology","keywords":"Thalidomide; Medicine; Multiple myeloma; Internal medicine; Meta-analysis; Relative risk; Randomized controlled trial; Transplantation; Surgery; Oncology; Confidence interval","score_opus":0.1545901539710433,"score_gpt":0.39731009047903815,"score_spread":0.24271993650799484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149388503","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006221063,0.95161194,0.000021066675,0.000024581279,0.00001845164,0.04682463,0.0014055034,0.000032706568,0.000054874887],"genre_scores_gemma":[0.0000051323227,0.9491001,0.0011897065,0.0000773398,0.00003131807,0.045158293,0.0031565994,0.00011169279,0.001169842],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99427444,0.0008228821,0.0025813142,0.001111698,0.00059728516,0.00061239506],"domain_scores_gemma":[0.9941714,0.0008312554,0.0024222764,0.0016216707,0.00046895465,0.00048446652],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00036765402,0.0013835441,0.024791634,0.00051552313,0.00011802528,0.000023235518,0.00021910704,0.00021027663,0.00021037884],"category_scores_gemma":[0.00038705915,0.000611715,0.0073920162,0.0013268199,0.00013638679,0.00008198608,0.000049747523,0.00014677331,0.000025674688],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070138216,0.00047754974,0.00047288236,0.63434297,0.26594272,0.000023292529,0.00002078232,2.8672122e-8,8.164438e-9,6.238204e-7,0.00011891922,0.09853008],"study_design_scores_gemma":[0.0020986784,0.0008456973,0.000022061919,0.28128025,0.5507438,0.000027544696,7.923516e-7,0.0000015124203,8.4525493e-7,1.9356776e-7,0.16472341,0.00025517246],"about_ca_topic_score_codex":0.00026881028,"about_ca_topic_score_gemma":0.00012522069,"teacher_disagreement_score":0.35306272,"about_ca_system_score_codex":0.00080005435,"about_ca_system_score_gemma":0.00057512266,"threshold_uncertainty_score":0.9998915},"labels":[],"label_agreement":null},{"id":"W2149971257","doi":"10.1093/toxsci/kfr086","title":"Fluorothalidomide: A Characterization of Maternal and Developmental Toxicity in Rabbits and Mice","year":2011,"lang":"en","type":"article","venue":"Toxicological Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"In vivo; Toxicant; Thalidomide; Teratology; Chemistry; In vitro; Stereoselectivity; Toxicity; Embryo; Developmental toxicity; Fetus; Pharmacology; Biology; Biochemistry; Cell biology; Genetics; Pregnancy; Immunology","score_opus":0.08671642583999181,"score_gpt":0.31528092527519985,"score_spread":0.22856449943520804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149971257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783474,0.000032849744,0.0000095009045,0.00007925347,0.000010568951,0.00021947372,0.0000035816452,0.0000074654504,0.0018025615],"genre_scores_gemma":[0.997324,0.00007365609,0.002471523,0.000060808674,0.000005539061,0.000011817625,0.0000012924987,0.000001240929,0.000050157123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937505,0.000036322963,0.0001260283,0.0001631413,0.00014645066,0.00015300067],"domain_scores_gemma":[0.99979836,0.000038274993,0.00003124886,0.000022342372,0.000013315333,0.00009647248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023796776,0.000056287685,0.00013394418,0.0000601257,0.00004602021,0.000009925604,0.000045369292,0.00003982955,0.00023530003],"category_scores_gemma":[0.00009757224,0.000034783014,0.000008793609,0.00012920369,0.0003332825,0.00008564761,0.000059983988,0.000041593285,0.0000034615857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012980266,0.000102718055,0.6777273,0.0000115511775,0.0000039331712,0.000027171307,0.0001635807,1.00317346e-8,0.3077945,0.00009621709,5.666083e-7,0.013942656],"study_design_scores_gemma":[0.0006181978,0.0004201371,0.84834033,0.000021731521,0.000002443752,0.000045810248,0.0000429172,0.000076762975,0.15029773,0.00009547123,0.000008513117,0.000029928402],"about_ca_topic_score_codex":0.000074508265,"about_ca_topic_score_gemma":0.0000299007,"teacher_disagreement_score":0.17061307,"about_ca_system_score_codex":0.000019513864,"about_ca_system_score_gemma":0.000033679316,"threshold_uncertainty_score":0.25763702},"labels":[],"label_agreement":null},{"id":"W2151148995","doi":"10.1093/toxsci/kfr084","title":"Resistance of CD-1 and ogg1 DNA Repair–Deficient Mice to Thalidomide and Hydrolysis Product Embryopathies in Embryo Culture","year":2011,"lang":"en","type":"article","venue":"Toxicological Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"In vivo; Embryo; Biology; Teratology; DNA damage; DNA glycosylase; DNA repair; DNA; Andrology; Molecular biology; Biochemistry; Genetics; Pregnancy; Fetus; Medicine","score_opus":0.06023019725178601,"score_gpt":0.3155890571778988,"score_spread":0.2553588599261128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151148995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063754,0.0015586509,0.0000021435364,0.000638878,0.000022478238,0.0005019401,0.00000634162,0.000030054473,0.006601958],"genre_scores_gemma":[0.99404573,0.00017792147,0.004702186,0.00015473942,0.000016165432,0.000039158123,8.8011035e-7,0.0000028184438,0.0008604077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846894,0.00010424824,0.00022928412,0.00050439965,0.00035787377,0.00033527135],"domain_scores_gemma":[0.99942756,0.00009430378,0.00005600625,0.00015147,0.000049613594,0.00022105596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007966881,0.00012319678,0.00031397014,0.00013075274,0.00012430112,0.000017772212,0.000121369165,0.000058928395,0.00006037359],"category_scores_gemma":[0.00086084683,0.00007042974,0.00004215874,0.0005804624,0.0006621766,0.00008167909,0.00012717745,0.000105135936,0.0000053050667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021725085,0.0016412867,0.6580648,0.00026394427,0.000067976456,0.0004412022,0.005891548,0.000005988898,0.32296756,0.0023644813,0.00070358306,0.005415121],"study_design_scores_gemma":[0.0008163015,0.0015968039,0.96476287,0.00009698461,0.000024771236,0.000027103477,0.0006988149,0.00007676088,0.03103053,0.00048692327,0.0002674466,0.00011469119],"about_ca_topic_score_codex":0.00012658017,"about_ca_topic_score_gemma":0.00036206032,"teacher_disagreement_score":0.30669808,"about_ca_system_score_codex":0.000032271408,"about_ca_system_score_gemma":0.000046915833,"threshold_uncertainty_score":0.28720415},"labels":[],"label_agreement":null},{"id":"W2151599813","doi":"10.3109/10428194.2012.661854","title":"Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; CpG site; DNA methylation; Multiple myeloma; Disease; Medicine; Stage (stratigraphy); Gene silencing; Internal medicine; Cancer research; Epigenetics; Oncology; Immunology; Gastroenterology; Biology; Gene; Gene expression; Genetics","score_opus":0.020197574919612844,"score_gpt":0.275966272670074,"score_spread":0.2557686977504612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151599813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417,0.0025165372,0.0007004849,0.00019232735,0.00021577445,0.0011323891,0.00007349589,0.000120458884,0.00087853207],"genre_scores_gemma":[0.99695385,0.000307324,0.0009286114,0.00017796444,0.00026759697,0.00039960726,0.00027845,0.000100401965,0.00058620627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966918,0.00021303864,0.00075201486,0.000668053,0.0006772185,0.0009978419],"domain_scores_gemma":[0.9972003,0.0005358206,0.00034883834,0.0007608952,0.00021015658,0.0009439684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003536832,0.0005210624,0.0007122318,0.00049729244,0.000258702,0.000051212788,0.00019924711,0.0002601363,0.000104008635],"category_scores_gemma":[0.00029745945,0.00041381957,0.00020447363,0.00057610264,0.0002918685,0.00068205514,0.00012680396,0.000192205,0.000034042274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006193462,0.0013404314,0.8140175,0.00035905055,0.0005084565,0.00017864263,0.0012456644,0.00008662454,0.014612069,0.00035808585,0.00020330456,0.1608967],"study_design_scores_gemma":[0.023349166,0.00040349047,0.96238095,0.00036734872,0.00033960555,0.00027653782,0.00039013522,0.0071758954,0.0024478803,0.00010111245,0.0023829748,0.0003848779],"about_ca_topic_score_codex":0.0010419345,"about_ca_topic_score_gemma":0.000071621624,"teacher_disagreement_score":0.16051182,"about_ca_system_score_codex":0.003539282,"about_ca_system_score_gemma":0.0018922907,"threshold_uncertainty_score":0.9998314},"labels":[],"label_agreement":null},{"id":"W2152124092","doi":"10.1200/jco.2013.48.7934","title":"International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Onyx Pharmaceuticals; National University Health System; Nagoya City University; Gil Medical Center, Gachon University; Genentech; Sahlgrenska Universitetssjukhuset; Università degli Studi di Pavia; Keio University; Cedars-Sinai Medical Center; Weill Cornell Medical College; Abbott Laboratories; Queen Mary University of London; University of Pittsburgh; Ankara Universitesi; University of Arkansas for Medical Sciences; Array BioPharma; Tel Aviv University; Gachon University; York University; Northwestern University; Emory University; American Society of Clinical Oncology; Universität Wien; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; National and Kapodistrian University of Athens; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Daiichi-Sankyo; Takeda Oncology; Massachusetts General Hospital; Sanofi; Amgen","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Transplantation; Adverse effect; Lenalidomide; Disease; Anemia; Autologous stem-cell transplantation; Concomitant; Internal medicine; Surgery","score_opus":0.13404119822155605,"score_gpt":0.4758519201022766,"score_spread":0.3418107218807206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152124092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033876333,0.922648,0.009571438,0.0012592336,0.0034604094,0.022602145,0.004447453,0.000035816247,0.00209917],"genre_scores_gemma":[0.029177662,0.9605842,0.008793362,0.000060270268,0.00027339958,0.00028657622,0.0005481403,0.00005032787,0.00022602083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958103,0.0003582326,0.0027304653,0.00034532585,0.00042834913,0.00032734463],"domain_scores_gemma":[0.9896354,0.0055093807,0.0036538176,0.00020276707,0.0007852373,0.00021339199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013774537,0.00034117358,0.00298638,0.00024190701,0.00009200837,0.000020611784,0.00019983626,0.0003079281,0.000015361213],"category_scores_gemma":[0.0001396436,0.00017340427,0.00080279977,0.00008306872,0.00022613058,0.00003915123,0.00003473046,0.0003329147,0.0000012181642],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019575594,0.0007614676,0.004021038,0.006469491,0.005743888,0.00015687662,0.00013175826,0.0000015530363,1.7937451e-7,0.000040999785,0.0002316047,0.96286553],"study_design_scores_gemma":[0.033848394,0.035893362,0.00919635,0.0028899224,0.009665203,0.00009304732,0.0002390722,0.000015536438,0.000010299879,0.000012569713,0.9079782,0.0001580814],"about_ca_topic_score_codex":0.000005673255,"about_ca_topic_score_gemma":0.000025796731,"teacher_disagreement_score":0.96270746,"about_ca_system_score_codex":0.0004769188,"about_ca_system_score_gemma":0.00089472294,"threshold_uncertainty_score":0.70712215},"labels":[],"label_agreement":null},{"id":"W2152557467","doi":"10.1182/blood-2003-11-4079","title":"RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Cancer Institute; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Gene isoform; Biology; Molecular biology; Immunology; Genetics; Gene","score_opus":0.015869188758726824,"score_gpt":0.2667017309133481,"score_spread":0.25083254215462125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152557467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957818,0.0028558352,0.00001656356,0.00036138642,0.000033035227,0.0005884875,0.00007071494,0.0000403489,0.00025182503],"genre_scores_gemma":[0.99811894,0.0007685707,0.0007226638,0.000049558897,0.00007968793,0.000072336414,0.00005695586,0.00001867014,0.00011261886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988351,0.000030909476,0.00016498631,0.00033394885,0.0002897232,0.00034532085],"domain_scores_gemma":[0.9991235,0.00008479744,0.000059102134,0.00019989318,0.000036198235,0.0004965209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008646899,0.00016087046,0.00023820625,0.000098701814,0.00008375664,0.00002292488,0.00004943929,0.000061041326,0.000018228824],"category_scores_gemma":[0.00044547458,0.00012215292,0.000032632604,0.0000983286,0.00010633082,0.000117517026,0.000093243725,0.00014221302,0.000008838339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009295068,0.00095720985,0.98230225,0.00013662208,0.00006297156,0.0018885378,0.00018384629,0.0000017690978,0.00923057,0.000017959774,0.00002041231,0.004268357],"study_design_scores_gemma":[0.025721924,0.00029828475,0.96273106,0.0005934066,0.000060036928,0.00006753894,0.00007708192,0.00020303475,0.009909335,0.00015638045,0.00006608133,0.00011582849],"about_ca_topic_score_codex":0.00012668672,"about_ca_topic_score_gemma":0.000073974385,"teacher_disagreement_score":0.024792418,"about_ca_system_score_codex":0.000033904504,"about_ca_system_score_gemma":0.00009552581,"threshold_uncertainty_score":0.49812517},"labels":[],"label_agreement":null},{"id":"W2153356756","doi":"10.1016/s0301-472x(01)00788-3","title":"Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice","year":2002,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Plasma cell; Biology; Bone marrow; CD19; Antibody; CD20; B-1 cell; Immune system; Molecular biology; Plasma cell leukemia; B cell; Immunology; Cancer research; T cell; Antigen-presenting cell","score_opus":0.029202903967748065,"score_gpt":0.30963735416339205,"score_spread":0.280434450195644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153356756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917954,0.002497891,0.00002028545,0.0007859916,0.0003415414,0.0010147843,0.000023135926,0.000093095616,0.003427869],"genre_scores_gemma":[0.9932168,0.00004053959,0.0024775262,0.0006952496,0.000095130395,0.00020770071,0.000030136556,0.00006118317,0.0031757157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969425,0.00013351192,0.0006287116,0.000757142,0.0005238127,0.0010143239],"domain_scores_gemma":[0.99853075,0.00015990596,0.00009615758,0.00047406103,0.000053764044,0.0006853481],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011707159,0.00038823878,0.0007614822,0.00039547888,0.00010355247,0.000031590087,0.00028000455,0.00023911374,0.0035054432],"category_scores_gemma":[0.00005834445,0.00036548622,0.00018615766,0.0003803464,0.00018435948,0.000107067775,0.00024582833,0.00035939083,0.010136921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001456994,0.0033935485,0.025390375,0.00016907004,0.00022165212,0.010514131,0.001701915,0.0000064220153,0.93682224,0.00128418,0.01802817,0.0010113205],"study_design_scores_gemma":[0.005675819,0.00071803026,0.009696774,0.00013034222,0.000023006305,0.0012804185,0.00075156544,0.0011166326,0.9791658,0.000017224287,0.0011123425,0.00031203177],"about_ca_topic_score_codex":0.00009403156,"about_ca_topic_score_gemma":0.000082387,"teacher_disagreement_score":0.04234359,"about_ca_system_score_codex":0.0005308979,"about_ca_system_score_gemma":0.00006188563,"threshold_uncertainty_score":0.9998797},"labels":[],"label_agreement":null},{"id":"W2153614907","doi":"10.1016/j.bbmt.2015.09.016","title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Dalhousie University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Cancer Research UK","keywords":"Medicine; Transplantation; Multiple myeloma; Salvage therapy; Clinical trial; Bone marrow; Oncology; Surgery; Hematopoietic stem cell transplantation; Hematopoietic cell; Internal medicine; Stem cell; Haematopoiesis; Chemotherapy","score_opus":0.05658823077037342,"score_gpt":0.3092763270803547,"score_spread":0.25268809630998124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153614907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446636,0.0011534347,0.0005714598,0.000363151,0.00009698768,0.001553615,0.0016126327,0.00004629144,0.00013605198],"genre_scores_gemma":[0.9619775,0.028817603,0.006637289,0.00011446705,0.00007762229,0.000049772156,0.0022460143,0.000060492363,0.000019249821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948264,0.0012381007,0.0018272907,0.001011305,0.00052804395,0.0005688988],"domain_scores_gemma":[0.9965961,0.0015116999,0.00090858265,0.00024727042,0.00028887755,0.00044747576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021000893,0.0006294588,0.0015111208,0.00026224402,0.00016153151,0.000041479045,0.00015588674,0.000373226,0.00000915358],"category_scores_gemma":[0.0000551318,0.0005375707,0.00021478349,0.00030092295,0.0013246292,0.00018801657,0.000017673161,0.00047856578,3.5348847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01423442,0.0014546182,0.85751843,0.003182688,0.0017757851,0.00018296752,0.0062862607,0.000011822521,0.11095735,0.00013447003,0.000017783439,0.0042434186],"study_design_scores_gemma":[0.09153474,0.006796723,0.85890007,0.0023636199,0.008378901,0.0009767909,0.0009667317,0.00040793436,0.028731149,0.0001717404,0.00001040483,0.0007612219],"about_ca_topic_score_codex":0.00023347721,"about_ca_topic_score_gemma":0.0003654221,"teacher_disagreement_score":0.0822262,"about_ca_system_score_codex":0.000012972347,"about_ca_system_score_gemma":0.00014188512,"threshold_uncertainty_score":0.9997076},"labels":[],"label_agreement":null},{"id":"W2153616582","doi":"10.3324/haematol.2013.090142","title":"High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib","year":2014,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Università degli Studi del Piemonte Orientale; Fondazione Umberto Veronesi; Università di Catania","keywords":"IRF4; Multiple myeloma; Bortezomib; XBP1; Transcription factor; Cancer research; Bone marrow; Monoclonal antibody; Antibody; Interferon regulatory factors; Medicine; Molecular biology; Immunology; Internal medicine; Biology; Gene","score_opus":0.028084629137060443,"score_gpt":0.27910227334030424,"score_spread":0.2510176442032438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153616582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769425,0.00002206688,0.0000361231,0.00033954583,0.000019645538,0.0007207596,0.000027316257,0.00004842861,0.0010918409],"genre_scores_gemma":[0.9956668,0.000006879602,0.0034878145,0.0003556172,0.00001244035,0.0001059517,0.0001037796,0.00002325612,0.0002374473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982163,0.00013050191,0.00044075365,0.00038270347,0.00042090437,0.00040888553],"domain_scores_gemma":[0.9988615,0.00018940476,0.00015146327,0.0004518863,0.00012330864,0.0002224184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012682135,0.00023338772,0.00070987,0.0001847163,0.000051160783,0.0000089309215,0.00011405383,0.00014551799,0.00052446086],"category_scores_gemma":[0.0003632152,0.00013385856,0.00008689902,0.00021532248,0.00011160852,0.00006864401,0.000072558934,0.00016818664,0.000073501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019103758,0.00075977127,0.9915092,0.0001291138,0.000057648464,0.00021581005,0.00007038079,4.996395e-7,0.0008271834,0.000013307806,0.0005327773,0.0039739516],"study_design_scores_gemma":[0.0101321805,0.0008898943,0.96736103,0.00022238035,0.000033092343,0.00002514486,0.000017749682,0.00025793086,0.02058261,0.000030505153,0.0003138591,0.00013363361],"about_ca_topic_score_codex":0.0002528678,"about_ca_topic_score_gemma":0.0000344933,"teacher_disagreement_score":0.024148162,"about_ca_system_score_codex":0.000051556774,"about_ca_system_score_gemma":0.000023974231,"threshold_uncertainty_score":0.57424784},"labels":[],"label_agreement":null},{"id":"W2154167873","doi":"10.1111/j.1556-4029.2008.00841.x","title":"Sudden Unexpected Death Due to a Previously Undiagnosed Plasma Cell Dyscrasia","year":2008,"lang":"en","type":"article","venue":"Journal of Forensic Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Plasma cell dyscrasia; Dyscrasia; Forensic pathology; Autopsy; Sudden death; Coroner; Medicine; Pathology; Plasma cell; Amyloidosis; Antibody; Poison control; Immunology; Internal medicine; Immunoglobulin light chain; Bone marrow; Injury prevention; Medical emergency","score_opus":0.05622089681648631,"score_gpt":0.3269242232459845,"score_spread":0.27070332642949824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154167873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942666,0.00035542744,0.00006637753,0.0011981428,0.00019237425,0.0002982249,0.0000025589961,0.0000145764225,0.0036056854],"genre_scores_gemma":[0.9865326,0.000117909505,0.01243075,0.00016949208,0.00019501668,0.000004903621,0.0000012457313,0.000008825867,0.00053922576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787074,0.0000548972,0.00037988718,0.0001970831,0.0010543858,0.0004429799],"domain_scores_gemma":[0.9985516,0.00021529924,0.00019457332,0.00015297794,0.0003041394,0.0005813832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004136586,0.00013791576,0.0003863546,0.00041365382,0.00023794251,0.000036694266,0.0002457527,0.000045515804,0.000111867834],"category_scores_gemma":[0.0005564659,0.00008659487,0.00014910765,0.00066403375,0.00026116066,0.00018429958,0.00004069998,0.00017459279,0.00006853471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017888596,0.0015221589,0.86997664,0.000089620415,0.00035428395,0.026648864,0.0041916035,0.00015329335,0.019167753,0.00015603699,0.041911762,0.03403912],"study_design_scores_gemma":[0.00781649,0.009623355,0.8689335,0.0004284186,0.00013608877,0.013842402,0.0010859235,0.0005806476,0.094751164,0.00031752628,0.002205619,0.0002788716],"about_ca_topic_score_codex":0.00010318614,"about_ca_topic_score_gemma":0.00004965945,"teacher_disagreement_score":0.07558341,"about_ca_system_score_codex":0.00013157049,"about_ca_system_score_gemma":0.00081725867,"threshold_uncertainty_score":0.35312364},"labels":[],"label_agreement":null},{"id":"W2154196037","doi":"10.1586/14737140.2014.868776","title":"Getting to the root of the problem: the causes of relapse in multiple myeloma","year":2014,"lang":"en","type":"editorial","venue":"Expert Review of Anticancer Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Proteasome; Multiple myeloma; Progenitor cell; Context (archaeology); Cancer research; Bortezomib; Proteasome inhibitor; Disease; Oncology; Immunology; Stem cell; Internal medicine; Biology; Cell biology","score_opus":0.026374022464082093,"score_gpt":0.36237249898833906,"score_spread":0.33599847652425696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154196037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016984163,0.8150422,0.000037156144,0.023845082,0.12895997,0.013713117,0.00024420352,0.0000330288,0.0011410913],"genre_scores_gemma":[0.056513466,0.7693888,0.0010393935,0.0021450168,0.16833507,0.0013548003,0.00009027033,0.00017275619,0.00096045557],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960296,0.00059685326,0.0010625852,0.00038642765,0.001528941,0.00039559035],"domain_scores_gemma":[0.9954005,0.0017676739,0.00070264674,0.0015009738,0.0005404528,0.00008773748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001548423,0.00036196844,0.0013690888,0.00008701974,0.00009471408,0.000009585881,0.0009034819,0.00019474867,0.00010653397],"category_scores_gemma":[0.0021528823,0.00014111186,0.0004701911,0.0005411024,0.0003568678,0.00003389078,0.00016444716,0.00062295824,0.0000067541164],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009095935,0.00045143103,0.0052913455,0.0067105666,0.00066999346,0.0000069314024,0.0020990712,0.0000025541592,0.0030171324,0.00003532694,0.8722361,0.10857],"study_design_scores_gemma":[0.0020545188,0.00047991797,0.0048330757,0.026577812,0.00007172248,0.0000025341405,0.00006799945,0.0000092506225,0.006469634,0.000015980635,0.9592738,0.0001437546],"about_ca_topic_score_codex":0.001782667,"about_ca_topic_score_gemma":0.00058778684,"teacher_disagreement_score":0.10842625,"about_ca_system_score_codex":0.000109417684,"about_ca_system_score_gemma":0.00061830645,"threshold_uncertainty_score":0.5754374},"labels":[],"label_agreement":null},{"id":"W2154279907","doi":"10.1259/bjr/37953406","title":"Gastric recurrence of a primary colon plasmacytoma: staging and evaluating response to therapy with 18F-FDG PET/CT","year":2011,"lang":"en","type":"article","venue":"British Journal of Radiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre; Brandon Regional Health Authority","funders":"","keywords":"Medicine; Plasmacytoma; Stomach; Radiology; Positron emission tomography; Adenocarcinoma; Mesentery; Lesion; Nuclear medicine; Multiple myeloma; Pathology; Internal medicine; Cancer","score_opus":0.06189976065318658,"score_gpt":0.3289318808558419,"score_spread":0.2670321202026553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154279907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550885,0.0037223669,0.0000729925,0.00013304364,0.000046222296,0.00031981192,0.000012602984,0.000005915702,0.00017817228],"genre_scores_gemma":[0.98250735,0.0013107674,0.015986864,0.00009251093,0.0000341875,0.000008604221,0.00000218543,0.000013506277,0.000044037202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847704,0.0004429988,0.0003542077,0.00016287288,0.00028613314,0.0002767482],"domain_scores_gemma":[0.9987432,0.00035986825,0.0002467507,0.00010474756,0.0002903505,0.00025511364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011228245,0.00010276387,0.00046406192,0.00023546217,0.000060471484,0.000010501119,0.000101043624,0.000010812786,0.000048812082],"category_scores_gemma":[0.0007082261,0.000086415945,0.000050390714,0.00018356305,0.00014761949,0.00007981195,0.000029834453,0.0002658199,0.0000015395264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08218868,0.00067493727,0.46680441,0.00010442219,0.0006308078,0.0716883,0.0008325721,0.0000071015234,0.028294025,0.0000046043865,0.0011128807,0.34765726],"study_design_scores_gemma":[0.007265048,0.010600731,0.6386242,0.00043264712,0.00003768358,0.34154335,0.0001180818,0.000031429732,0.0012046734,0.000017496906,0.00006386223,0.00006081724],"about_ca_topic_score_codex":0.000106221385,"about_ca_topic_score_gemma":0.00001190282,"teacher_disagreement_score":0.34759644,"about_ca_system_score_codex":0.000093756695,"about_ca_system_score_gemma":0.00042470862,"threshold_uncertainty_score":0.352394},"labels":[],"label_agreement":null},{"id":"W2154684620","doi":"10.1002/hed.20821","title":"Solitary extramedullary plasmacytoma of the head and neck—Long‐term outcome analysis of 68 cases","year":2008,"lang":"en","type":"article","venue":"Head & Neck","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plasma cell neoplasm; Extramedullary plasmacytoma; Head and neck; Plasmacytoma; Radiation therapy; Multiple myeloma; Surgery; Retrospective cohort study; Overall survival; Radiology; Internal medicine","score_opus":0.07746718557681408,"score_gpt":0.36513685716360106,"score_spread":0.28766967158678697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154684620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701387,0.001584908,0.0000059143526,0.00036420932,0.000040563355,0.00037294737,0.000106444655,0.000019873223,0.0004912751],"genre_scores_gemma":[0.99849594,0.00025811282,0.00034217755,0.00013436019,0.000033792865,0.000014942089,0.000052930773,0.000016886845,0.0006508503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984244,0.0000722311,0.0004314044,0.00025544717,0.00048542095,0.00033108896],"domain_scores_gemma":[0.9987704,0.00021665393,0.00010863584,0.0005659097,0.00010416763,0.00023424166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008921571,0.0001751788,0.0006654549,0.00025321968,0.00010907382,0.0000045066395,0.00011576701,0.00007693378,0.00018451952],"category_scores_gemma":[0.00020259123,0.00011247099,0.0003029989,0.0005606248,0.0002997074,0.000060444745,0.000093256174,0.00016577815,0.000010072338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005292875,0.00045683837,0.99296016,0.00019015583,0.0010993704,0.0009751409,0.00028966425,0.0000060416114,0.0009251912,0.000008976559,0.00017201166,0.0023871644],"study_design_scores_gemma":[0.002644093,0.0004914293,0.991889,0.00012532581,0.00067279465,0.00053463323,0.00004261508,0.00052827847,0.0028917734,0.0000050417907,0.00009224279,0.00008279351],"about_ca_topic_score_codex":0.0015176153,"about_ca_topic_score_gemma":0.000602973,"teacher_disagreement_score":0.002304371,"about_ca_system_score_codex":0.000050399944,"about_ca_system_score_gemma":0.00012097525,"threshold_uncertainty_score":0.45864338},"labels":[],"label_agreement":null},{"id":"W2156928661","doi":"10.1093/jnci/dju067","title":"Multiple Myeloma in the Very Old: An IASIA Conference Report","year":2014,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Center for Research Resources","keywords":"Medicine; Multidisciplinary approach; Population; Gerontology; Clinical trial; Geriatric oncology; Geriatrics; Family medicine; Alternative medicine; Multiple myeloma; Cancer; Psychiatry; Internal medicine; Pathology","score_opus":0.09690484745468034,"score_gpt":0.38970168337352556,"score_spread":0.2927968359188452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156928661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898095,0.00010005506,0.000095246614,0.0061596725,0.00079547474,0.00025641362,0.000016416374,0.000005228179,0.0035905337],"genre_scores_gemma":[0.9967144,0.000045948855,0.00048805005,0.0012372718,0.0009339275,0.000019354575,0.000010148636,0.0000070722613,0.0005438317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789673,0.00012771302,0.00039440923,0.00012295492,0.0012837078,0.00017451159],"domain_scores_gemma":[0.9986154,0.00012882054,0.00028355647,0.00019167004,0.0006711678,0.0001094219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010597744,0.00010389986,0.00019771734,0.00012934399,0.00012398137,0.00003916217,0.00034158767,0.000050913768,0.00005311701],"category_scores_gemma":[0.0014545101,0.00005234854,0.00011957355,0.00023069297,0.000121606936,0.00031846054,0.00003449093,0.00038186074,0.0000063177035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026228763,0.0013346724,0.9098457,0.00011275747,0.00058299705,0.001502422,0.0019468886,0.0027060148,0.008491747,0.0093198335,0.012126991,0.049407076],"study_design_scores_gemma":[0.0033908365,0.0001918494,0.952908,0.00017898541,0.000045013523,0.0020849216,0.000060351664,0.0018925284,0.0012245638,0.0010965576,0.03685058,0.000075823235],"about_ca_topic_score_codex":0.00032575143,"about_ca_topic_score_gemma":0.0009887012,"teacher_disagreement_score":0.04933125,"about_ca_system_score_codex":0.00031436217,"about_ca_system_score_gemma":0.00088441174,"threshold_uncertainty_score":0.21347114},"labels":[],"label_agreement":null},{"id":"W2157251410","doi":"10.1080/146532401317248090","title":"A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood","year":2001,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Stemcell Technologies","funders":"","keywords":"Leukapheresis; Multiple myeloma; CD38; Progenitor cell; Daratumumab; Transplantation; CD19; Immunology; Molecular biology; CD20; Bone marrow; Cancer research; Stem cell; Biology; Chemistry; Antibody; CD34; Medicine; Internal medicine; Cell biology; Bortezomib","score_opus":0.03783949523185337,"score_gpt":0.3121517557515661,"score_spread":0.27431226051971275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157251410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970399,0.00025101454,0.0009655509,0.00012414965,0.000037233276,0.0010293333,0.000056472203,0.000067440604,0.00042891936],"genre_scores_gemma":[0.9923178,0.000537155,0.0049478775,0.00020909352,0.00021496048,0.00015158737,0.000064655775,0.00004688187,0.0015100124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988642,0.000051255618,0.00019451618,0.00033603437,0.00020224837,0.0003517959],"domain_scores_gemma":[0.99919623,0.0002755886,0.00006917176,0.00014926761,0.00012132963,0.00018840334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069642236,0.0001786442,0.0002577686,0.00008052613,0.00015714997,0.000045054883,0.00005236437,0.000090017544,0.0006578524],"category_scores_gemma":[0.000078504025,0.00013238372,0.00007698724,0.0001339061,0.00004614945,0.000082084654,0.000010199332,0.00009759787,0.000019879344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010714145,0.0015033506,0.48818716,0.000078494646,0.0010099986,0.00008965858,0.00060348085,0.000009615532,0.08449262,0.000029770574,0.0011057208,0.41217598],"study_design_scores_gemma":[0.0496663,0.0074314475,0.62672853,0.00019514299,0.00026095266,0.000034233,0.00039663154,0.0025490853,0.30288893,0.0006912676,0.008660065,0.00049737503],"about_ca_topic_score_codex":0.00058195373,"about_ca_topic_score_gemma":0.00043119912,"teacher_disagreement_score":0.4116786,"about_ca_system_score_codex":0.000057784255,"about_ca_system_score_gemma":0.00007990938,"threshold_uncertainty_score":0.7203022},"labels":[],"label_agreement":null},{"id":"W2158801842","doi":"10.1186/1476-4598-11-78","title":"In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Alberta Cancer Foundation","keywords":"Multiple myeloma; Biology; Overall survival; Immunology; Progression-free survival; Event (particle physics); Oncology; Internal medicine; Cancer research; Medicine","score_opus":0.025052326104388154,"score_gpt":0.28909551721262966,"score_spread":0.2640431911082415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158801842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620533,0.00061155,0.0005472429,0.00021275264,0.00018127555,0.0015321384,0.0005014016,0.000011343788,0.00019695681],"genre_scores_gemma":[0.9984318,0.00011674753,0.00041020225,0.00008557069,0.0000630418,0.00034408414,0.00009337503,0.000036644004,0.0004185536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825907,0.00008727231,0.00024997015,0.00024825527,0.0006086777,0.00054676435],"domain_scores_gemma":[0.9989151,0.000069959046,0.000083396604,0.0006061122,0.00009935455,0.00022608336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012221203,0.00023689693,0.00033472906,0.00008808683,0.00004845108,0.000007470238,0.00017061549,0.00007425374,0.00009349437],"category_scores_gemma":[0.000027910815,0.00013400624,0.00010116152,0.0001963857,0.00008932935,0.00009722406,0.00005068787,0.00013162447,0.000012716712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001834029,0.0013675299,0.9801303,0.00009562527,0.00044045498,0.00007409016,0.0008278233,0.00012629047,0.011675783,0.000009278839,0.00014697322,0.0032717912],"study_design_scores_gemma":[0.010640407,0.00057624106,0.87782943,0.00015045033,0.00013935896,0.0000024189692,0.000023273142,0.00023602536,0.10985392,0.000004207117,0.0004276184,0.000116619485],"about_ca_topic_score_codex":0.0029634656,"about_ca_topic_score_gemma":0.0014340932,"teacher_disagreement_score":0.102300875,"about_ca_system_score_codex":0.00028696976,"about_ca_system_score_gemma":0.00017339666,"threshold_uncertainty_score":0.5464616},"labels":[],"label_agreement":null},{"id":"W2159528874","doi":"10.1038/leu.2009.61","title":"Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Concordance; Staging system; Multiple myeloma; Univariate analysis; Oncology; Univariate; Progression-free survival; Internal medicine; Proportional hazards model; Overall survival; Transplantation; Multivariate analysis; Multivariate statistics; Cancer","score_opus":0.02316841703921429,"score_gpt":0.2838815156990666,"score_spread":0.2607130986598523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159528874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434394,0.00013129448,0.00030133536,0.002237925,0.00028985803,0.0013676225,0.000074300515,0.00013470463,0.0011190259],"genre_scores_gemma":[0.9987171,0.000009665857,0.00026047803,0.00053974526,0.00011959664,0.00009577031,0.00007848287,0.000026011116,0.00015311172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756014,0.00014563941,0.00051479606,0.0004170616,0.0007834434,0.00057894527],"domain_scores_gemma":[0.99885523,0.00029951913,0.00009779868,0.00045643514,0.00010010469,0.00019091967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003526722,0.00025426774,0.0003925577,0.0001964229,0.0003012486,0.00011535044,0.00039543048,0.00008098492,0.00001566841],"category_scores_gemma":[0.00010884207,0.00015044297,0.00011319075,0.00028720318,0.000039096845,0.000103691506,0.000065212946,0.00038222838,0.00009400808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070524187,0.00012849594,0.98122364,0.00023602974,0.00015306036,0.0003381582,0.005864057,0.00049469835,0.00058540615,0.00014724229,0.00048289113,0.009641051],"study_design_scores_gemma":[0.0054516434,0.00029357034,0.9114803,0.0013551327,0.000055685643,0.00005755838,0.0040461994,0.07478875,0.0016330986,0.0000026167388,0.0006648622,0.0001705586],"about_ca_topic_score_codex":0.0010368852,"about_ca_topic_score_gemma":0.00048456786,"teacher_disagreement_score":0.07429405,"about_ca_system_score_codex":0.0024402945,"about_ca_system_score_gemma":0.000269476,"threshold_uncertainty_score":0.6381285},"labels":[],"label_agreement":null},{"id":"W2159589701","doi":"10.1002/cyto.b.20523","title":"Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stem Cell Network","keywords":"Multiple myeloma; CD38; Flow cytometry; Bone marrow; CD20; Pathology; Immunoglobulin light chain; Medicine; CD19; CD44; Immunophenotyping; Nuclear medicine; Plasma cell; Chemistry; Internal medicine; Antibody; Cell; Immunohistochemistry; Immunology; Biology; CD34","score_opus":0.06784175963986644,"score_gpt":0.3745718434586575,"score_spread":0.3067300838187911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159589701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208343,0.00030562302,0.0011744223,0.00008385464,0.002126647,0.0020312604,0.0003611312,0.0002464191,0.0015872064],"genre_scores_gemma":[0.9544264,0.00025769867,0.043315966,0.00015197188,0.00085545995,0.00015192183,0.00019900243,0.00016604301,0.0004755231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99046814,0.00048173076,0.0033162918,0.0017980852,0.0020401066,0.0018956359],"domain_scores_gemma":[0.9841568,0.010894006,0.0007711974,0.0017055561,0.0006544786,0.0018179513],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0035824904,0.0008946202,0.0025920959,0.0061940956,0.00019973327,0.00009108275,0.0008594093,0.0013056435,0.00089235173],"category_scores_gemma":[0.028877415,0.00078919315,0.0010153094,0.01217127,0.0010027605,0.0003696986,0.00054867903,0.003698614,0.001152876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024801989,0.004228825,0.8799842,0.0005333979,0.0004434432,0.0008862733,0.00003581425,0.00004383302,0.067679,0.000016319467,0.00031554553,0.043353148],"study_design_scores_gemma":[0.018932547,0.0019302445,0.80654496,0.0003515364,0.0002368313,0.00022874626,0.00014483332,0.029373908,0.14017071,0.00002760148,0.0012746773,0.00078341825],"about_ca_topic_score_codex":0.000073164854,"about_ca_topic_score_gemma":0.00006021171,"teacher_disagreement_score":0.07343925,"about_ca_system_score_codex":0.00024036858,"about_ca_system_score_gemma":0.0005735818,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W2160300160","doi":"10.1182/blood-2004-09-3704","title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; University of Alberta","keywords":"Biology; Breakpoint; Exon; Molecular biology; Alternative splicing; Nucleolus; Gene; Chromosomal translocation; Genetics; Cytoplasm","score_opus":0.018690058764591268,"score_gpt":0.27234382125712975,"score_spread":0.25365376249253846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160300160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966538,0.00030522607,0.000016797074,0.00051844225,0.00006192869,0.0008063409,0.00080247683,0.000044682907,0.00079029135],"genre_scores_gemma":[0.99720967,0.00006255902,0.0011442513,0.00025888093,0.00024521237,0.000051722473,0.00081346964,0.00003362404,0.00018058869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813306,0.00012167044,0.00036062562,0.00034938942,0.0006224331,0.00041281155],"domain_scores_gemma":[0.9986964,0.0003473816,0.00015580138,0.00040548996,0.00018956517,0.000205354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010983148,0.00023721247,0.00035885177,0.000062866115,0.00012546736,0.000026494848,0.00018446428,0.00010498882,0.00019060302],"category_scores_gemma":[0.00025275027,0.00015074038,0.00015705025,0.00012008348,0.00008941114,0.00018271765,0.00006052366,0.00023923923,0.000059612048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012601365,0.0045332746,0.5322802,0.00006816305,0.0009168601,0.00006567756,0.00255583,0.0000014688312,0.41042754,0.000016470693,0.00054922525,0.04732515],"study_design_scores_gemma":[0.0150762815,0.00046329186,0.6751674,0.00040923347,0.00021248213,0.000006801646,0.00006735688,0.00017068091,0.30570483,0.000011650242,0.002570915,0.00013905924],"about_ca_topic_score_codex":0.00050063257,"about_ca_topic_score_gemma":0.00005651502,"teacher_disagreement_score":0.1428872,"about_ca_system_score_codex":0.000052669446,"about_ca_system_score_gemma":0.00005913102,"threshold_uncertainty_score":0.6147014},"labels":[],"label_agreement":null},{"id":"W2161134408","doi":"10.1158/1078-0432.ccr-06-1526","title":"The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Multiple myeloma; Dexamethasone; Melphalan; Apoptosis; Cancer research; Medicine; Cell culture; Bone marrow; Pharmacology; Progenitor cell; Internal medicine; Stem cell; Chemistry; Biology; Biochemistry","score_opus":0.15956877610764686,"score_gpt":0.47939545742552253,"score_spread":0.31982668131787567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161134408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110234,0.0037378343,0.000103784056,0.001659184,0.00009154562,0.0025333008,0.000021276963,0.00005912727,0.0006915914],"genre_scores_gemma":[0.99657536,0.0014047163,0.00021548198,0.00003977946,0.00050568546,0.0002636786,0.0000066369607,0.00005047958,0.0009382002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949799,0.0010576418,0.0004568524,0.0008068892,0.001515968,0.0011827467],"domain_scores_gemma":[0.9917017,0.0062728887,0.000091238115,0.00058818,0.00039523336,0.00095073384],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.008823052,0.0002792415,0.00062710536,0.00017111443,0.0008145848,0.00021801978,0.00019631372,0.00023497801,0.00003028647],"category_scores_gemma":[0.0027391913,0.0001536917,0.00009281877,0.000536612,0.0027684977,0.00011371894,0.0002498035,0.0015820256,0.000018046228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03195798,0.000523709,0.49206054,0.00036086174,0.00048898585,0.0014296977,0.00007711854,2.0547442e-7,0.05157544,0.00007927193,0.000641621,0.4208046],"study_design_scores_gemma":[0.011094709,0.007252476,0.9441125,0.00048264422,0.000092690236,0.000045191824,0.00009163445,0.00034022643,0.03351325,0.00005153303,0.00268599,0.0002372001],"about_ca_topic_score_codex":0.0021215007,"about_ca_topic_score_gemma":0.0033779524,"teacher_disagreement_score":0.45205194,"about_ca_system_score_codex":0.00017840725,"about_ca_system_score_gemma":0.0006214828,"threshold_uncertainty_score":0.9999454},"labels":[],"label_agreement":null},{"id":"W2161371113","doi":"10.1503/cmaj.1031990","title":"Erythematous groin plaque in a patient with multiple myeloma","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Groin; Medicine; Multiple myeloma; Cyclophosphamide; Presentation (obstetrics); Lesion; Physical examination; Chemotherapy; Surgery; Medical history; Internal medicine","score_opus":0.007920609250154993,"score_gpt":0.23979006123795696,"score_spread":0.23186945198780196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161371113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761351,0.00013132693,0.00006217822,0.021467403,0.000099052464,0.00029164925,0.000014950706,0.000015486698,0.0017829002],"genre_scores_gemma":[0.99645126,0.000054010747,0.00053839484,0.0025712568,0.0002363646,0.000020963711,0.000014684509,0.000018874447,0.00009421575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972956,0.00007848381,0.00033529484,0.00016321214,0.0014832576,0.0006441251],"domain_scores_gemma":[0.99711126,0.00008777674,0.00010993202,0.0001036912,0.00022025718,0.0023670953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004652326,0.0001298073,0.000257239,0.00031870155,0.00013789395,0.00004352146,0.00008835019,0.00021795895,0.0006680797],"category_scores_gemma":[0.001385893,0.00009639118,0.0000655149,0.0002976321,0.00003448228,0.000091795024,0.000010002593,0.0008424844,0.00015926818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027803372,0.00038726136,0.8919492,0.00002541148,0.0002701695,0.05855429,0.0010632576,0.000045905483,0.000030928568,0.0001449154,0.0051140673,0.04213661],"study_design_scores_gemma":[0.03510413,0.001654128,0.885293,0.001395682,0.000054454405,0.035980035,0.0015827313,0.0005345564,0.00044218227,0.00045633625,0.03707387,0.0004288601],"about_ca_topic_score_codex":0.010388651,"about_ca_topic_score_gemma":0.20288326,"teacher_disagreement_score":0.1924946,"about_ca_system_score_codex":0.002970305,"about_ca_system_score_gemma":0.004838817,"threshold_uncertainty_score":0.9962013},"labels":[],"label_agreement":null},{"id":"W2162771614","doi":"10.1093/annonc/mdx096","title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":872,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Cilag; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; European Society for Medical Oncology; Bristol-Myers Squibb","keywords":"Medicine; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Asymptomatic; Stage (stratigraphy); Incidence (geometry); Scopus; Internal medicine; MEDLINE; Monoclonal; Immunology","score_opus":0.4685253170586109,"score_gpt":0.5882108824589835,"score_spread":0.11968556540037256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162771614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87437737,0.00258799,0.00005096207,0.116163835,0.0005580933,0.0017327666,0.00012411694,0.000029698633,0.004375142],"genre_scores_gemma":[0.9548633,0.015585336,0.023734838,0.0030210905,0.00055639533,0.00053587375,0.00006484766,0.000027547741,0.0016107673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998346,0.00011609579,0.00062449917,0.0003702764,0.00016746379,0.00037570455],"domain_scores_gemma":[0.9944699,0.0025598665,0.00043203443,0.0005965131,0.0016092276,0.00033247386],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00091716304,0.00017662418,0.0007184487,0.0000699017,0.00024852986,0.000023627455,0.00014056188,0.0002115843,0.000029535318],"category_scores_gemma":[0.033564,0.00012710913,0.0002484419,0.000025653046,0.00029821426,0.00016329503,0.00010131665,0.00009912005,0.000019383575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038786277,0.0016832788,0.29184344,0.000042143827,0.0007871089,0.00015323605,0.000069425354,1.9176423e-7,0.00005303856,0.00009750508,0.041213457,0.66017854],"study_design_scores_gemma":[0.01890836,0.014523738,0.2553948,0.000051583887,0.00027094528,0.000069301044,0.00012445376,0.00019863082,0.0026238495,0.00014776658,0.7075855,0.000101091675],"about_ca_topic_score_codex":0.0007733858,"about_ca_topic_score_gemma":0.00041579994,"teacher_disagreement_score":0.66637206,"about_ca_system_score_codex":0.000040512605,"about_ca_system_score_gemma":0.00035367341,"threshold_uncertainty_score":0.9745767},"labels":[],"label_agreement":null},{"id":"W2163150086","doi":"10.1084/jem.20051611","title":"Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow","year":2005,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Bone marrow; Plasma cell; Biology; Secretion; Antigen; Antibody; Cell biology; Immunology; Cancer research; Molecular biology; Endocrinology","score_opus":0.05261063459534111,"score_gpt":0.358363324244672,"score_spread":0.3057526896493309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163150086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97854924,0.0050420794,0.000065922446,0.014637967,0.00013202195,0.0007541361,0.000008669863,0.0000033971548,0.0008065769],"genre_scores_gemma":[0.9966418,0.00050218194,0.0007013958,0.0010475966,0.0004464915,0.00001657763,0.0000041033654,0.000016984037,0.00062282744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981183,0.00012517069,0.00065577903,0.00010213976,0.0006867645,0.0003118852],"domain_scores_gemma":[0.9986295,0.00044032524,0.00035049717,0.00028665035,0.00014813639,0.00014485355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012073594,0.0001571736,0.00047662592,0.00015717889,0.000058856484,0.000004472347,0.00027583988,0.000046041816,0.00028624243],"category_scores_gemma":[0.0001839287,0.00006868156,0.00012606468,0.0001797797,0.00031696362,0.00008813789,0.000032644337,0.00023296998,0.000008380068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011001744,0.001261405,0.0013948438,0.00007397239,0.00026813202,0.00030427217,0.0183273,0.000007594535,0.93739474,0.000039923398,0.023427535,0.0064985524],"study_design_scores_gemma":[0.026240118,0.007469623,0.006349779,0.0009207337,0.00019179695,0.0015192224,0.016691756,0.000700904,0.9371681,0.000051567084,0.0025916956,0.000104662984],"about_ca_topic_score_codex":0.000055153185,"about_ca_topic_score_gemma":0.000012961656,"teacher_disagreement_score":0.02083584,"about_ca_system_score_codex":0.00014559746,"about_ca_system_score_gemma":0.00007281909,"threshold_uncertainty_score":0.31341538},"labels":[],"label_agreement":null},{"id":"W2163320846","doi":"10.1182/blood-2005-06-2573","title":"Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Melphalan; Medicine; Transplantation; Multiple myeloma; Regimen; Autologous stem-cell transplantation; Population; Internal medicine; Surgery; Oncology; Urology; Gastroenterology","score_opus":0.01433486973002101,"score_gpt":0.2742035298222019,"score_spread":0.2598686600921809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163320846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95326537,0.000057322206,0.000045792054,0.00016957757,0.000010568979,0.04574641,0.00008615721,0.000026635644,0.00059216825],"genre_scores_gemma":[0.97983265,0.00004613328,0.0020826175,0.000014617649,0.00004480152,0.017687062,0.000013005662,0.000014243976,0.0002648607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984263,0.0003241703,0.00040748945,0.00026954486,0.0002848575,0.00028764262],"domain_scores_gemma":[0.99901515,0.0004335664,0.0001730677,0.00020855875,0.00007233643,0.00009732255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054461294,0.00015539162,0.00044595165,0.000089095214,0.000075806296,0.000010965897,0.00007799245,0.000100960424,0.000007644182],"category_scores_gemma":[0.00020448385,0.00009530669,0.000090412555,0.0001638457,0.00013611346,0.0000578187,0.000022255594,0.00023263693,0.0000040362215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1521812,0.0027636155,0.82383525,0.00035608822,0.00025117415,0.00023476449,0.0029703546,0.000050731072,0.0058087916,0.000032072236,0.000017838438,0.011498137],"study_design_scores_gemma":[0.40326858,0.00027942742,0.50319415,0.00010360876,0.00016259596,0.00007520559,0.000039967377,0.0004655976,0.0922892,0.000044146756,0.00001696295,0.00006054657],"about_ca_topic_score_codex":0.00040199715,"about_ca_topic_score_gemma":0.000647711,"teacher_disagreement_score":0.32064107,"about_ca_system_score_codex":0.0000718476,"about_ca_system_score_gemma":0.00016694964,"threshold_uncertainty_score":0.38864943},"labels":[],"label_agreement":null},{"id":"W2163375473","doi":"10.1158/1078-0432.ccr-14-1437","title":"miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"","keywords":"Multiple myeloma; Cancer research; Clonogenic assay; Apoptosis; microRNA; Transfection; Viability assay; In vivo; Plasma cell leukemia; Biology; Cell culture; Immunology; Gene; Genetics","score_opus":0.2832308845321098,"score_gpt":0.5013554029379498,"score_spread":0.21812451840583996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163375473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901917,0.0049808784,0.0000039111674,0.002834036,0.00014283323,0.0011384164,0.00010727832,0.000037219517,0.0005637094],"genre_scores_gemma":[0.99635005,0.0015512429,0.000456041,0.00016595039,0.00030225504,0.00031448476,0.00006899495,0.00004516633,0.00074582716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950864,0.0009144418,0.0007288027,0.0009249416,0.0012156429,0.0011297914],"domain_scores_gemma":[0.9953906,0.00199127,0.00007675137,0.00043928064,0.0005040599,0.0015980575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043711336,0.00024704004,0.00067996216,0.0002519177,0.00020248332,0.00009267993,0.00023974614,0.00028859708,0.00012808917],"category_scores_gemma":[0.0069574197,0.00020203738,0.00008364635,0.0005213824,0.00085543585,0.00018294324,0.0005172861,0.0015692239,0.00004562533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029897795,0.0007508973,0.9405604,0.00018489869,0.00012223302,0.00012357533,0.00041314747,6.7373793e-7,0.008150703,0.000010598658,0.024912037,0.021781027],"study_design_scores_gemma":[0.031849146,0.0029445195,0.87713736,0.000525552,0.000066901135,0.000031776144,0.0017278511,0.0027432328,0.04861922,0.00036204766,0.033369016,0.0006234021],"about_ca_topic_score_codex":0.0066299187,"about_ca_topic_score_gemma":0.0006645758,"teacher_disagreement_score":0.0634231,"about_ca_system_score_codex":0.0003118934,"about_ca_system_score_gemma":0.0005909811,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W2164147551","doi":"10.1200/jco.2005.10.126","title":"Phenotypic Heterogeneity in Multiple Myeloma Families","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Creighton University; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; University of Nebraska Medical Center; Nebraska Department of Health and Human Services","keywords":"Medicine; Proband; Multiple myeloma; Family history; Family aggregation; Population; Observational study; Family studies; Genetics; Pathology; Internal medicine; Mutation; Biology; Gene","score_opus":0.18286004531166014,"score_gpt":0.4861984207155332,"score_spread":0.3033383754038731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164147551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910233,0.0006282911,0.000057420326,0.0047641695,0.00033266112,0.00018913805,0.0000025906406,0.000008184571,0.0029942633],"genre_scores_gemma":[0.98720473,0.0007783928,0.009527984,0.0011554221,0.0011243564,0.000004252199,0.0000024793367,0.000012363101,0.00019004905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688244,0.00039518953,0.0018464377,0.00016989301,0.00038339547,0.00032265694],"domain_scores_gemma":[0.99661136,0.001866433,0.0005920321,0.00018930799,0.00024228978,0.00049855124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002054128,0.00012173007,0.0011594801,0.00021112508,0.000030222052,0.000006177026,0.00014818671,0.00028138247,0.00015185885],"category_scores_gemma":[0.005500299,0.00008276199,0.00040439315,0.00014213589,0.00017786336,0.00012714059,0.0000553776,0.0008781989,0.00012438752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036716028,0.0019387439,0.55230325,0.000010411947,0.0001618911,0.000756286,0.00004053257,0.000021687918,0.00020238216,0.000012623281,0.0005059955,0.44037455],"study_design_scores_gemma":[0.016744884,0.004848434,0.91527426,0.000047115005,0.000059450504,0.000255211,0.000058926093,0.00070887164,0.00052429765,0.00005962076,0.061356667,0.000062278334],"about_ca_topic_score_codex":0.000039159033,"about_ca_topic_score_gemma":0.00086294033,"teacher_disagreement_score":0.4403123,"about_ca_system_score_codex":0.00024269409,"about_ca_system_score_gemma":0.00090320973,"threshold_uncertainty_score":0.6584769},"labels":[],"label_agreement":null},{"id":"W2164239756","doi":"10.2174/156800912802429292","title":"Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Stromal cell; Multiple myeloma; Syngenic; In vivo; Cancer research; Bone marrow; Tumor microenvironment; Medicine; Biology; Immunology; Tumor cells","score_opus":0.32725508467932346,"score_gpt":0.44190329542170326,"score_spread":0.1146482107423798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164239756","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002426074,0.99289757,0.0010516832,0.00006683099,0.00046955663,0.004888745,0.00030472514,0.000022559037,0.000055736775],"genre_scores_gemma":[0.0047026193,0.98966867,0.0011538841,0.000017094375,0.0003090489,0.0024719955,0.0009201568,0.000085732354,0.0006707905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972474,0.00004893872,0.00091155956,0.00043208688,0.0006812569,0.0006787835],"domain_scores_gemma":[0.9984798,0.00039038394,0.00031662747,0.0003726534,0.000113840935,0.0003267278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003307953,0.00051016826,0.0012871356,0.00026787576,0.00012833574,0.00001602713,0.000318564,0.00014891828,0.00023910406],"category_scores_gemma":[0.000031956053,0.00031256795,0.00051010255,0.000259035,0.000061663704,0.00014321273,0.000060631297,0.00041462117,0.000034293906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002250096,0.00040669463,0.00046736174,0.009295558,0.0008311376,0.0000014212521,0.0016583063,0.000023526974,5.665183e-7,0.00007170559,0.00031471025,0.986704],"study_design_scores_gemma":[0.003765169,0.000030511434,0.00070800254,0.005773851,0.0008415593,0.000003996906,0.000028533914,0.0014972279,0.00006170089,0.00012883705,0.9868537,0.00030686997],"about_ca_topic_score_codex":0.00013669868,"about_ca_topic_score_gemma":0.0004586316,"teacher_disagreement_score":0.986539,"about_ca_system_score_codex":0.0005004402,"about_ca_system_score_gemma":0.002937815,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W2164257516","doi":"10.3109/10428194.2014.893304","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Bortezomib; Plasma cell leukemia; Dexamethasone; Medicine; Multiple myeloma; Pharmacology; Leukemia; Oncology; Internal medicine","score_opus":0.024237332105817144,"score_gpt":0.2679509948797453,"score_spread":0.24371366277392814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164257516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9216449,0.033307616,0.00030148734,0.029248394,0.0009377358,0.007905803,0.0014797221,0.00034931093,0.004825035],"genre_scores_gemma":[0.590307,0.09813689,0.011121201,0.21261908,0.016014269,0.0069569037,0.008165172,0.0022085842,0.054470923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99211925,0.0003898838,0.0017409053,0.0022172828,0.0013493182,0.0021833363],"domain_scores_gemma":[0.99117655,0.0044234665,0.0010455978,0.0020786182,0.00040495902,0.0008708319],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006319774,0.0020505493,0.0032844488,0.00069318735,0.0007617257,0.00023366488,0.00068960356,0.0024191525,0.00013976968],"category_scores_gemma":[0.0002341051,0.0014251057,0.0011415316,0.00045244495,0.001317938,0.0002328166,0.00024593883,0.0007234651,0.000058663678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0060292818,0.00051529845,0.0025592898,0.0050094663,0.0040557054,0.0021453775,0.0011385549,0.000021325213,0.0019508518,0.00005661749,0.40758142,0.5689368],"study_design_scores_gemma":[0.072719395,0.0038931125,0.01186033,0.0006408634,0.0034934191,0.0022535995,0.0002452536,0.0084323,0.016600892,0.00015080691,0.8783102,0.0013997942],"about_ca_topic_score_codex":0.00416234,"about_ca_topic_score_gemma":0.00013572298,"teacher_disagreement_score":0.567537,"about_ca_system_score_codex":0.013349751,"about_ca_system_score_gemma":0.0086532105,"threshold_uncertainty_score":0.99922365},"labels":[],"label_agreement":null},{"id":"W2164667231","doi":"10.3324/haematol.2014.120121","title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Vancouver General Hospital; University of Calgary; Hôpital Notre-Dame; London Health Sciences Centre","funders":"Celgene","keywords":"Thalidomide; Lenalidomide; Medicine; Melphalan; Prednisone; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Surgery; Gastroenterology","score_opus":0.11451472248451337,"score_gpt":0.3505249363184556,"score_spread":0.23601021383394222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164667231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908274,0.0008671063,0.000018698856,0.0025662673,0.00016311514,0.005020028,0.000044388617,0.00007213355,0.00042085288],"genre_scores_gemma":[0.99752134,0.00006793462,0.0012270395,0.0003245847,0.000026608164,0.000557265,0.00021041586,0.000039119433,0.000025712581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99455446,0.0013139643,0.0014890169,0.000609764,0.0011789984,0.00085381605],"domain_scores_gemma":[0.9946414,0.003175741,0.00062891253,0.0008294825,0.00021380736,0.00051066204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020897042,0.00041268737,0.0018170234,0.000325054,0.00010845153,0.00003288472,0.00040109866,0.0002438865,0.000043039778],"category_scores_gemma":[0.0077409977,0.00024165939,0.00016359809,0.0008897132,0.0002688808,0.00015323864,0.00011713284,0.0005121717,0.00005659657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34102625,0.0028976377,0.6508899,0.00023824134,0.0002051749,0.000628488,0.0022031995,0.00015542032,0.0000014906783,0.00012458723,0.0005628499,0.0010667868],"study_design_scores_gemma":[0.41327423,0.0035323533,0.5811116,0.00032384644,0.000032509324,0.000016222672,0.0010042101,0.00029624574,0.000039553863,0.000052585256,0.00011130759,0.00020532317],"about_ca_topic_score_codex":0.008699695,"about_ca_topic_score_gemma":0.008236278,"teacher_disagreement_score":0.07224796,"about_ca_system_score_codex":0.00040595434,"about_ca_system_score_gemma":0.0007361203,"threshold_uncertainty_score":0.99790144},"labels":[],"label_agreement":null},{"id":"W2165718641","doi":"10.1016/j.beha.2005.01.005","title":"Stem-cell transplantation in multiple myeloma","year":2005,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; Transplantation; Medicine; Stem cell; Oncology; Cancer research; Internal medicine; Biology; Genetics","score_opus":0.39000194679186034,"score_gpt":0.5783709416445553,"score_spread":0.18836899485269493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165718641","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008655766,0.98181653,0.000023779046,0.0012932374,0.00025012493,0.00514427,0.00009173455,0.00007190636,0.010442818],"genre_scores_gemma":[0.0009783764,0.99189544,0.0020242902,0.00011526973,0.00048810436,0.0011031392,0.0005163222,0.00015689626,0.0027221842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9815091,0.009960204,0.0030788654,0.0016880828,0.0018631128,0.0019006557],"domain_scores_gemma":[0.95723873,0.038807828,0.0006707847,0.0013898667,0.00078549725,0.0011072838],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009211568,0.0006966178,0.0046098228,0.0014429425,0.00024053728,0.00009937999,0.000727923,0.0018479767,0.00037450844],"category_scores_gemma":[0.008771627,0.00054863165,0.0009409597,0.0014295845,0.0008871817,0.0004742625,0.00031405746,0.0067317104,0.0077556768],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016675437,0.0071334033,0.0011543488,0.016224487,0.00039076275,0.02828841,0.0000658038,1.638625e-7,2.9245675e-7,0.00012683649,0.00089521677,0.94405276],"study_design_scores_gemma":[0.005650995,0.002228638,0.00014686442,0.0080614695,0.0010881323,0.0073678875,0.00019660687,0.00005534163,0.0000023927942,0.0000149183825,0.9748149,0.00037184427],"about_ca_topic_score_codex":0.00043763468,"about_ca_topic_score_gemma":0.00059411576,"teacher_disagreement_score":0.9739197,"about_ca_system_score_codex":0.0005536078,"about_ca_system_score_gemma":0.0035563512,"threshold_uncertainty_score":0.9996965},"labels":[],"label_agreement":null},{"id":"W2166459466","doi":"10.1016/j.bmcl.2008.11.118","title":"Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application","year":2008,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Thalidomide; Angiogenesis; Chemistry; In vivo; In vitro; Multiple sclerosis; Pharmacology; Cell culture; Cancer research; Biochemistry; Immunology; Multiple myeloma; Medicine; Biology","score_opus":0.12927677899697254,"score_gpt":0.32602847978575317,"score_spread":0.19675170078878063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166459466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884463,0.0005482944,0.0056868293,0.004251484,0.000033013173,0.00084359356,0.000054188455,0.00005890172,0.00007738575],"genre_scores_gemma":[0.9949688,0.00016879642,0.0031578364,0.00037992498,0.00039689726,0.00012972305,0.0006442118,0.000021691034,0.00013213912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984894,0.00002517601,0.0003604862,0.00037232146,0.0004313784,0.00032126435],"domain_scores_gemma":[0.9987404,0.0002603064,0.00018179655,0.0003618569,0.00013492038,0.00032071574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018581265,0.0001909016,0.0003649984,0.000053683616,0.00011901388,0.000003512835,0.00015548685,0.00012459925,0.00015676192],"category_scores_gemma":[0.00096227095,0.00014877763,0.00015099208,0.00021921785,0.00027047622,0.00003767731,0.00003915598,0.00014106026,0.000018493605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087788736,0.00022082898,0.055723183,0.00012364972,0.0001421488,0.000018725923,0.0001546423,0.0000015992347,0.93378913,0.0000013190598,0.0054190303,0.003527837],"study_design_scores_gemma":[0.005977106,0.0003448498,0.2962062,0.00012628853,0.00016490131,0.00017596128,0.00012316233,0.00042752587,0.6957695,0.000015797625,0.00052758824,0.00014115911],"about_ca_topic_score_codex":0.0001347607,"about_ca_topic_score_gemma":0.0000017126589,"teacher_disagreement_score":0.24048302,"about_ca_system_score_codex":0.00013387206,"about_ca_system_score_gemma":0.00023780858,"threshold_uncertainty_score":0.60669756},"labels":[],"label_agreement":null},{"id":"W2166508172","doi":"10.1158/0008-5472.can-03-2876","title":"Genetics and Cytogenetics of Multiple Myeloma","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":686,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Biology; Chromosomal translocation; Cytogenetics; Genetics; Immunology; Cancer research; Chromosome; Monoclonal; Gene; Antibody; Monoclonal antibody","score_opus":0.12736509049962977,"score_gpt":0.4379651948271182,"score_spread":0.3106001043274884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166508172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256986,0.005278893,0.00004936747,0.0006897859,0.000027596898,0.0005605203,0.000037369082,0.0000140874245,0.00077254],"genre_scores_gemma":[0.9934749,0.003989311,0.0018836848,0.000027661667,0.00009405545,0.00008530555,0.0000103374105,0.000023731314,0.00041101978],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835575,0.000053023752,0.00016868697,0.00025423706,0.000707662,0.00046066026],"domain_scores_gemma":[0.9988071,0.0001121145,0.000023317805,0.0003192566,0.0004005172,0.00033772035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026981859,0.000096024414,0.00020459574,0.00020630636,0.00009561707,0.000014933502,0.00010145552,0.00007314138,0.000098435776],"category_scores_gemma":[0.00021959309,0.00007900144,0.00004123311,0.00033279863,0.0003911027,0.000024630575,0.00013253483,0.0002485394,0.000025201498],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008794961,0.0003846095,0.568272,0.00043127986,0.00021688077,0.00021254724,0.0005141473,0.00007097453,0.34571078,0.0002789676,0.00024852864,0.08277982],"study_design_scores_gemma":[0.006378264,0.0009021883,0.37557715,0.00019475538,0.0000238427,0.00003582412,0.00015765584,0.00010278707,0.61314934,0.00051116693,0.0028684852,0.00009851956],"about_ca_topic_score_codex":0.0005929182,"about_ca_topic_score_gemma":0.00018140975,"teacher_disagreement_score":0.26743856,"about_ca_system_score_codex":0.00017443292,"about_ca_system_score_gemma":0.00048996124,"threshold_uncertainty_score":0.32215852},"labels":[],"label_agreement":null},{"id":"W2167269948","doi":"10.4212/cjhp.v53i4.749","title":"Stability of Ketorolac Tromethamine in IV Solutions and Waste Reduction","year":2000,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"College of Science and Health","keywords":"Ketorolac Tromethamine; Ketorolac; Chemistry; Chromatography; Anesthesia; Medicine; Analgesic","score_opus":0.03967663406116424,"score_gpt":0.3085595303208489,"score_spread":0.26888289625968465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167269948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927743,0.0015802669,9.5247793e-7,0.0046335314,0.0000935234,0.00022244327,0.000022104387,0.0000015114599,0.00067134475],"genre_scores_gemma":[0.9994237,0.00024384409,0.00006866488,0.000020258847,0.000106445514,0.0000023886814,0.0000026853231,0.0000067811307,0.00012526388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991614,0.00008317243,0.0002653961,0.0000729342,0.00017518837,0.000241868],"domain_scores_gemma":[0.99921334,0.000036210262,0.00007198562,0.00011155341,0.000118221906,0.00044870042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004535305,0.000072086754,0.00018318361,0.00015265896,0.00008804627,0.000012102961,0.00007559614,0.000017771552,0.0006933488],"category_scores_gemma":[0.000098611694,0.000048910133,0.00006121567,0.00017825869,0.00020427498,0.00013554556,0.0000056547806,0.00024372264,0.000003718381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003025338,0.001170573,0.65063506,0.00019973154,0.0008637951,0.0011700655,0.0087374905,0.00009294811,0.01915312,0.00012545922,0.00299615,0.31183028],"study_design_scores_gemma":[0.01772571,0.0033042678,0.9487023,0.00027943155,0.000302611,0.0011193777,0.0017086804,0.0009957483,0.019861361,0.00078627904,0.004960907,0.0002533463],"about_ca_topic_score_codex":0.017311117,"about_ca_topic_score_gemma":0.006922971,"teacher_disagreement_score":0.31157696,"about_ca_system_score_codex":0.00021335932,"about_ca_system_score_gemma":0.0006391389,"threshold_uncertainty_score":0.9892327},"labels":[],"label_agreement":null},{"id":"W2167599439","doi":"10.1354/vp.37-4-364","title":"Multiple Myeloma in Cats: Variable Presentation with Different Immunoglobulin Isotypes in Two Cats","year":2000,"lang":"en","type":"article","venue":"Veterinary Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Multiple myeloma; CATS; Bone marrow; Medicine; Proteinuria; Chemotherapy; Pathology; Antibody; Serum protein electrophoresis; Myeloma protein; Plasma cell; Globulin; Monoclonal; Immunology; Kidney; Monoclonal antibody; Internal medicine","score_opus":0.02828849164384992,"score_gpt":0.32524426984049976,"score_spread":0.2969557781966498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167599439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669415,0.00032261046,0.000032738473,0.00015890862,0.000048948303,0.000728917,0.000023000817,0.00004138547,0.0019493168],"genre_scores_gemma":[0.99639696,0.00015666946,0.0019126906,0.000083044,0.00003920566,0.00025372213,0.00019121853,0.00002739918,0.0009390749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983614,0.0002352803,0.00029377692,0.00041660792,0.00018588417,0.0005070175],"domain_scores_gemma":[0.99933726,0.000115948234,0.00004035092,0.00035943257,0.000031033134,0.00011597693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001251824,0.00020966111,0.00037985662,0.00027132954,0.000048611477,0.00001245813,0.00010407022,0.00008400537,0.00064590096],"category_scores_gemma":[0.000043525542,0.00016146127,0.000034307915,0.000310727,0.000095544776,0.00010700079,0.00005012552,0.00024629393,0.00011188919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008446199,0.0014356183,0.89651245,0.00009536778,0.00005370916,0.013148765,0.0007426485,0.00016981033,0.038713023,0.000019262345,0.000027164975,0.040635966],"study_design_scores_gemma":[0.010513457,0.0027835628,0.98192143,0.00012177142,0.000016119187,0.0016000645,0.00008722936,0.0012779101,0.00097073795,0.00004869082,0.0005070785,0.00015191824],"about_ca_topic_score_codex":0.0017915897,"about_ca_topic_score_gemma":0.00060388236,"teacher_disagreement_score":0.08540899,"about_ca_system_score_codex":0.000149517,"about_ca_system_score_gemma":0.00006822312,"threshold_uncertainty_score":0.70721626},"labels":[],"label_agreement":null},{"id":"W2167992370","doi":"10.1016/j.clml.2012.08.009","title":"Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Saint John Regional Hospital; University of Toronto; Western University; University of Calgary; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Dalhousie University; London Health Sciences Centre; McMaster University; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Celgene","keywords":"Lenalidomide; Multiple myeloma; Melphalan; Medicine; Prednisone; Internal medicine; Oncology","score_opus":0.04623544334153758,"score_gpt":0.368569340505802,"score_spread":0.3223338971642644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167992370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666286,0.00051723333,0.0005579976,0.00021900628,0.0006861437,0.009995479,0.00033561717,0.00039011586,0.00063555175],"genre_scores_gemma":[0.9866011,0.000066837376,0.0048844963,0.00045530204,0.001821365,0.0016807466,0.0018025952,0.00024470314,0.0024428295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99264693,0.00046018398,0.0019718325,0.0013504158,0.0012722705,0.0022983758],"domain_scores_gemma":[0.99309826,0.0016649503,0.0006975612,0.0014286388,0.0007388845,0.002371718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013317355,0.0009725064,0.0021698796,0.0002783275,0.00062833505,0.00009468028,0.00045780552,0.0006880931,0.00023426874],"category_scores_gemma":[0.0031883286,0.0006936915,0.0008349049,0.0005158659,0.00058193336,0.0006683639,0.0002910154,0.0004366822,0.0002303909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32695064,0.011010037,0.34343088,0.00022063374,0.0016768402,0.000110063214,0.00044824107,0.000002396631,0.00008983268,0.000041475887,0.002661641,0.31335732],"study_design_scores_gemma":[0.46759415,0.01417012,0.5084291,0.00030991642,0.0008612108,0.000054798125,0.000046371795,0.0011352999,0.00061233324,0.00001674786,0.006213978,0.0005559969],"about_ca_topic_score_codex":0.00020192735,"about_ca_topic_score_gemma":0.000060371134,"teacher_disagreement_score":0.31280133,"about_ca_system_score_codex":0.0019123274,"about_ca_system_score_gemma":0.002036557,"threshold_uncertainty_score":0.9995514},"labels":[],"label_agreement":null},{"id":"W2168505715","doi":"10.1369/jhc.2008.952200","title":"Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance","year":2008,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Plasmacytosis; Fibronectin; Laminin; Extracellular matrix; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Pathology; Plasma cell; Bone marrow; Medicine; Chemistry; Immunology; Monoclonal; Monoclonal antibody; Biology; Antibody; Cell biology","score_opus":0.02776017317036652,"score_gpt":0.2705849107189656,"score_spread":0.2428247375485991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168505715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965765,0.0028763027,0.000025711908,0.000054834974,0.000014084843,0.00019641157,0.00003395093,0.000004649427,0.0002175891],"genre_scores_gemma":[0.9959145,0.0004463769,0.0032423679,0.00000675938,0.00006386795,0.000009095807,0.000009735812,0.000017052,0.000290226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983928,0.00002723705,0.00069412164,0.0002636756,0.00039291164,0.00022921633],"domain_scores_gemma":[0.9984978,0.00021313221,0.0005329039,0.00021772204,0.00021339164,0.00032504508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016856754,0.0002109821,0.00064168416,0.00009058786,0.000057934012,0.000005704544,0.00009111488,0.00015036117,0.00002452406],"category_scores_gemma":[0.00040311104,0.00018778928,0.000085754495,0.0001115563,0.0004388082,0.000073427625,0.00007491399,0.00027822694,1.17672926e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020787504,0.00022058631,0.122678116,0.0008158018,0.00004590598,0.00034092017,0.00026787806,0.000002083623,0.872811,1.5367445e-7,0.00014690674,0.00059189164],"study_design_scores_gemma":[0.0056308894,0.0003467317,0.09047256,0.0006413793,0.000044004402,0.0024168715,0.00023836503,0.00017761593,0.89986044,0.0000121449775,0.000037171918,0.00012180539],"about_ca_topic_score_codex":0.0000258443,"about_ca_topic_score_gemma":0.0000024271471,"teacher_disagreement_score":0.032205563,"about_ca_system_score_codex":0.00011949906,"about_ca_system_score_gemma":0.00027948705,"threshold_uncertainty_score":0.7657825},"labels":[],"label_agreement":null},{"id":"W2169096446","doi":"10.3109/10428191003661860","title":"Multiple myeloma may include microvessel endothelial cells of malignant origin","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Paracrine signalling; Progenitor cell; Biology; Autocrine signalling; Pathology; Population; Bone marrow; Malignancy; Pericyte; Cancer research; Neovascularization; Endothelium; Cancer cell; Cancer; Angiogenesis; Stem cell; Endothelial stem cell; Immunology; Medicine; Cell biology; Cell culture; Genetics; Gene; Receptor","score_opus":0.029841449146530356,"score_gpt":0.3123519019111376,"score_spread":0.28251045276460723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169096446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063270554,0.9262341,0.000024997802,0.00003094769,0.001074244,0.0037946068,0.0020855512,0.00028605113,0.0031989003],"genre_scores_gemma":[0.012338797,0.9756647,0.0024573207,0.00016910792,0.0010123758,0.00058014016,0.00124257,0.0004874342,0.0060475743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99123245,0.00043846833,0.0025182248,0.0022054457,0.001510261,0.0020951263],"domain_scores_gemma":[0.99311286,0.0012707004,0.0013578627,0.002288146,0.00036892193,0.001601483],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006725356,0.0022160532,0.0059253047,0.0011590783,0.0004398831,0.0001821711,0.0010643826,0.0023150176,0.00022464727],"category_scores_gemma":[0.00036305343,0.0017185479,0.0017910517,0.0009856604,0.0009820582,0.00027241855,0.0007992849,0.00075414823,0.0004956798],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007316618,0.00055812375,0.00050766784,0.01805346,0.0012842305,0.0019350237,0.00018623474,4.7972895e-7,0.004536043,0.00016866604,0.0016352806,0.97040313],"study_design_scores_gemma":[0.018838737,0.00058371486,0.0011982011,0.010638703,0.0024475085,0.0034358238,0.0000614675,0.00019309112,0.01091413,0.000035761168,0.9502227,0.00143018],"about_ca_topic_score_codex":0.0027395638,"about_ca_topic_score_gemma":0.00014135036,"teacher_disagreement_score":0.9689729,"about_ca_system_score_codex":0.007017675,"about_ca_system_score_gemma":0.014234438,"threshold_uncertainty_score":0.99905795},"labels":[],"label_agreement":null},{"id":"W2169210165","doi":"10.1182/blood-2012-09-451872","title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Juravinski Cancer Centre; BC Cancer Agency; Dr. H. Bliss Murphy Cancer Centre; Hôpital de l'Enfant-Jésus; McGill University; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Saint John Regional Hospital; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute","keywords":"Medicine; Prednisone; Thalidomide; Hazard ratio; Surgery; Multiple myeloma; Internal medicine; Maintenance therapy; Transplantation; Randomized controlled trial; Autologous stem-cell transplantation; Clinical endpoint; Confidence interval; Chemotherapy","score_opus":0.06801261865729823,"score_gpt":0.4037691003261362,"score_spread":0.335756481668838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169210165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977345,0.0002349904,0.00001418359,0.0004333643,0.000083620565,0.008994492,0.00022917092,0.0000043322075,0.00023240403],"genre_scores_gemma":[0.9967808,0.00016480732,0.00047196794,0.00012342267,0.00011590602,0.0021753858,0.000048908565,0.000016346274,0.000102436075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955528,0.0012160421,0.0014425684,0.00028201946,0.0012420504,0.00026452547],"domain_scores_gemma":[0.9957648,0.0023232456,0.00094835623,0.0002525659,0.00053694047,0.00017409612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003306558,0.000210697,0.0017955664,0.00010066051,0.000036447193,0.000015138934,0.00011475122,0.00007414498,0.00024307115],"category_scores_gemma":[0.0038861432,0.00009865539,0.00015654524,0.00020366971,0.00037912925,0.00012843536,0.00002823732,0.00015433051,3.340596e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9622773,0.005075852,0.028755946,0.00007294097,0.0020183264,0.0000063532916,0.00010440053,0.0000016851274,0.000080350634,0.000063365755,0.000056045443,0.0014874369],"study_design_scores_gemma":[0.91169685,0.0047480497,0.08253253,0.00023253442,0.00021296303,8.6262565e-7,0.000029369272,0.000021364198,0.00030994622,0.000064939515,0.00005700263,0.00009360505],"about_ca_topic_score_codex":0.095783696,"about_ca_topic_score_gemma":0.027970476,"teacher_disagreement_score":0.06781322,"about_ca_system_score_codex":0.00006390342,"about_ca_system_score_gemma":0.0026063065,"threshold_uncertainty_score":0.98976654},"labels":[],"label_agreement":null},{"id":"W2169395626","doi":"10.3109/10428194.2010.531409","title":"Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (&lt;12 months)","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Hospital and Health Sciences Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Thalidomide; Bortezomib; Multiple myeloma; Internal medicine; Cohort; Oncology; Population; Autologous stem-cell transplantation; Surgery","score_opus":0.010861604291262782,"score_gpt":0.23001383547196608,"score_spread":0.2191522311807033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169395626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940742,0.0002492433,0.00027510012,0.000051162617,0.0003407709,0.0018679217,0.0025416685,0.00019134497,0.00040854764],"genre_scores_gemma":[0.9941694,0.00025134246,0.0030543874,0.00011556129,0.00015515031,0.0002686004,0.001286073,0.00021746874,0.00048197422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944734,0.00014228703,0.0008972012,0.0014137498,0.0016896124,0.0013837799],"domain_scores_gemma":[0.9954444,0.0005312097,0.00057848793,0.0012466938,0.00040955064,0.0017896446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033940186,0.001049857,0.0012733679,0.00035282524,0.000551189,0.0001189071,0.00043917488,0.00044853255,0.000055139066],"category_scores_gemma":[0.00030011658,0.0007544112,0.0002487292,0.0005169179,0.0006669858,0.0005114906,0.00019748493,0.00039227697,0.000023648934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020971658,0.0019213554,0.9114928,0.0003678407,0.0010513726,0.0006603463,0.00078090944,0.000016674172,0.022730622,0.000117755386,0.0002374396,0.039651208],"study_design_scores_gemma":[0.0829513,0.002034874,0.9019502,0.00046676898,0.0008640128,0.000077373355,0.00009996515,0.0025471258,0.0075534414,0.000028892931,0.00060818007,0.00081790745],"about_ca_topic_score_codex":0.01063625,"about_ca_topic_score_gemma":0.0014241209,"teacher_disagreement_score":0.061979644,"about_ca_system_score_codex":0.0017356172,"about_ca_system_score_gemma":0.0023676152,"threshold_uncertainty_score":0.9994907},"labels":[],"label_agreement":null},{"id":"W2171411430","doi":"10.4137/cmo.s615","title":"Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist during Treatment with Rituximab","year":2008,"lang":"en","type":"article","venue":"Clinical medicine Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"CD20; Rituximab; CD19; B cell; Multiple myeloma; Immunology; Plasma cell; clone (Java method); Medicine; Antibody; Biology","score_opus":0.11183339817943623,"score_gpt":0.3866858537468932,"score_spread":0.27485245556745697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171411430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900848,0.00075718353,0.00006714933,0.0034074783,0.00029727578,0.0011544181,0.000024175926,0.00009478273,0.004112697],"genre_scores_gemma":[0.9901311,0.0020470023,0.005563785,0.00038519298,0.0005396272,0.000111820016,0.00010141631,0.000056224715,0.001063831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963162,0.00037838615,0.0011291424,0.0007761303,0.00064651447,0.00075365754],"domain_scores_gemma":[0.9953787,0.0022668184,0.00039695756,0.0007517804,0.00030848835,0.00089730916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044931725,0.00044292182,0.0020300443,0.00024728244,0.00024465425,0.000003458157,0.00023790651,0.0004048804,0.00057383656],"category_scores_gemma":[0.0010864264,0.00027164267,0.0003116926,0.00030714204,0.0021719378,0.000067636254,0.00012227774,0.00052346924,0.00016399885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022829743,0.0081812,0.9139422,0.00021314278,0.001193685,0.004269525,0.00083053514,0.0000026333314,0.011340872,0.000032768494,0.000598998,0.036564708],"study_design_scores_gemma":[0.077195905,0.032094907,0.8707152,0.0002841069,0.00059549767,0.00082692347,0.00030611712,0.00017673608,0.010956259,0.000029273522,0.0065517575,0.0002672923],"about_ca_topic_score_codex":0.0003778294,"about_ca_topic_score_gemma":0.000324123,"teacher_disagreement_score":0.05436616,"about_ca_system_score_codex":0.00048773247,"about_ca_system_score_gemma":0.00078072224,"threshold_uncertainty_score":0.9999736},"labels":[],"label_agreement":null},{"id":"W2171529195","doi":"10.1158/1055-9965.epi-13-0334","title":"A Pooled Analysis of Alcohol Consumption and Risk of Multiple Myeloma in the International Multiple Myeloma Consortium","year":2013,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Multiple myeloma; Medicine; Confidence interval; Alcohol; Alcohol consumption; Logistic regression; Internal medicine; Demography; Case-control study; Proportional hazards model; Incidence (geometry); Environmental health; Oncology; Biology","score_opus":0.06816619433829421,"score_gpt":0.38198889195838703,"score_spread":0.31382269762009285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171529195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936349,0.002981433,0.00057969836,0.0012206829,0.00011006331,0.0012578131,0.00011522767,0.000014610409,0.000085603584],"genre_scores_gemma":[0.99444413,0.002741748,0.0017810093,0.000116605246,0.000028822638,0.00044779765,0.0003463962,0.000010490931,0.0000830086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711275,0.001045651,0.00088915764,0.00040887782,0.00022626018,0.00031732573],"domain_scores_gemma":[0.9964023,0.002276055,0.0006437075,0.000355946,0.000209694,0.00011228894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019221018,0.00018429817,0.00073684653,0.00058366155,0.00005445869,0.000006266308,0.00017159159,0.00017635926,0.00041664156],"category_scores_gemma":[0.002564596,0.00013052371,0.00030567532,0.00042992318,0.00043669532,0.00012528816,0.00006832227,0.00018342653,0.000009538099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008848789,0.00024602757,0.948909,0.000071042894,0.007920439,0.00000462642,0.00015479885,0.000038031878,0.007451731,0.000033779103,0.00041247773,0.033873204],"study_design_scores_gemma":[0.004121115,0.00015913922,0.9589036,0.00013042866,0.0019917963,0.000007130799,0.00018373525,0.03290238,0.0010821999,0.00035351102,0.0000748689,0.00009008807],"about_ca_topic_score_codex":0.005339089,"about_ca_topic_score_gemma":0.0031513143,"teacher_disagreement_score":0.033783115,"about_ca_system_score_codex":0.000120066856,"about_ca_system_score_gemma":0.00007663441,"threshold_uncertainty_score":0.80711406},"labels":[],"label_agreement":null},{"id":"W2172122039","doi":"10.1200/jco.2008.18.3087","title":"Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research","funders":"National Institute of Neurological Disorders and Stroke; National Eye Institute; Takeda Oncology; Celgene","keywords":"Medicine; Bortezomib; Multiple myeloma; Polyneuropathy; Peripheral neuropathy; Internal medicine; Surgery; Oncology; Gastroenterology","score_opus":0.05753808831090486,"score_gpt":0.3811943247090732,"score_spread":0.3236562363981684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172122039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656665,0.00019101547,0.00020634985,0.0024324793,0.000077828205,0.0004429383,0.0000052104238,0.0000073616325,0.00007017054],"genre_scores_gemma":[0.99805975,0.0003677464,0.0010053715,0.00043184822,0.00006511437,0.0000023262066,0.000010106565,0.000014366507,0.000043365864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708545,0.0009755376,0.0012434031,0.00020973099,0.0002718771,0.00021397173],"domain_scores_gemma":[0.9973177,0.0011344312,0.00075436215,0.00014863575,0.0002740117,0.00037090608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011378686,0.00014266568,0.0008826179,0.00019907884,0.000032006596,0.000011845079,0.000059701164,0.00015472599,0.000008928803],"category_scores_gemma":[0.0038456083,0.000099417695,0.0001008261,0.00019663815,0.0001873295,0.00010645592,0.000027020675,0.00047893485,7.8304754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06518052,0.004271807,0.6448014,0.000024484996,0.00013381951,0.006459406,0.00033290402,0.000029030629,0.12507011,0.000009793034,0.00001227761,0.15367447],"study_design_scores_gemma":[0.018576292,0.033421166,0.94421595,0.00012659641,0.0001497947,0.00083872885,0.000022312237,0.0014376296,0.0006355015,0.0000067213155,0.0005014855,0.000067789144],"about_ca_topic_score_codex":0.000008607211,"about_ca_topic_score_gemma":0.000013218186,"teacher_disagreement_score":0.2994146,"about_ca_system_score_codex":0.00007447685,"about_ca_system_score_gemma":0.00046580573,"threshold_uncertainty_score":0.460383},"labels":[],"label_agreement":null},{"id":"W2174938993","doi":"10.3324/haematol.2015.125864","title":"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Lenalidomide; Medicine; Internal medicine; Thalidomide; Refractory (planetary science); Multiple myeloma; Tolerability; Oncology; Gastroenterology; Adverse effect; Biology","score_opus":0.12101848918118802,"score_gpt":0.3982900003491797,"score_spread":0.2772715111679917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174938993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370164,0.00080088194,0.000016665732,0.00005353562,0.00010627725,0.0050775656,0.00004525266,0.00005255008,0.0001456445],"genre_scores_gemma":[0.9975103,0.00011905835,0.001821256,0.0000057766997,0.000017451366,0.00039412998,0.000045315435,0.000046694782,0.00004001441],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932887,0.0032296607,0.0012864298,0.0007563398,0.00070844416,0.0007304279],"domain_scores_gemma":[0.9902246,0.0077133896,0.00050897506,0.00079099275,0.0001781575,0.0005839027],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030086313,0.00058340706,0.0035812703,0.0008885887,0.000056803518,0.000019984991,0.00019977898,0.00023208585,0.00004034241],"category_scores_gemma":[0.009772493,0.0003896847,0.00032897887,0.0006511734,0.00042627918,0.00010531185,0.0001524974,0.00039393973,0.000012765685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69027466,0.013346421,0.28446618,0.00006983807,0.0007737429,0.002737547,0.0024096158,0.00019900873,0.001983945,0.000011162787,0.000005535966,0.0037223392],"study_design_scores_gemma":[0.58414996,0.01713908,0.39201197,0.0002408161,0.00019027617,0.000055391276,0.0011893623,0.002481338,0.0023208314,0.000015733309,0.0000016466438,0.00020359043],"about_ca_topic_score_codex":0.0073629636,"about_ca_topic_score_gemma":0.0019929502,"teacher_disagreement_score":0.10754579,"about_ca_system_score_codex":0.0010697158,"about_ca_system_score_gemma":0.0006663607,"threshold_uncertainty_score":0.9998555},"labels":[],"label_agreement":null},{"id":"W2187343014","doi":"10.1016/s2352-3026(15)00197-0","title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"AbbVie Biotherapeutics; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Thalidomide; Clinical trial","score_opus":0.11369672653323207,"score_gpt":0.37215393679621306,"score_spread":0.25845721026298096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187343014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148124,0.00013137363,0.000067302346,0.0026345227,0.000034843302,0.005340327,0.00007841082,0.000027305243,0.00020467152],"genre_scores_gemma":[0.9981137,0.00001628532,0.00081489293,0.00015707087,0.000031501382,0.00036741327,0.00043432356,0.000026004258,0.000038819875],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715656,0.0009968039,0.00049755344,0.00046507982,0.00045387328,0.00043009987],"domain_scores_gemma":[0.997297,0.0015325933,0.00024198866,0.0006145177,0.00016883822,0.00014510147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001398663,0.00024632845,0.0010068399,0.00012348485,0.00012206314,0.00005756608,0.00029279655,0.00008596364,0.0000077564055],"category_scores_gemma":[0.0013231273,0.00012071763,0.000014818566,0.00038456506,0.00023008655,0.0002068052,0.00013425626,0.00041064303,0.00001124583],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45022562,0.012773151,0.5274171,0.0000163512,0.000185446,0.0005486017,0.0028923962,0.0000134965885,0.00003118163,0.00004375922,0.00026918165,0.0055836593],"study_design_scores_gemma":[0.67172056,0.0050938874,0.3198141,0.000113098205,0.00009527765,0.00004213724,0.0005661527,0.002184971,0.000085042666,0.00013034626,0.000043673826,0.000110719346],"about_ca_topic_score_codex":0.0022107828,"about_ca_topic_score_gemma":0.0042669615,"teacher_disagreement_score":0.22149497,"about_ca_system_score_codex":0.00014152925,"about_ca_system_score_gemma":0.00017729295,"threshold_uncertainty_score":0.4922722},"labels":[],"label_agreement":null},{"id":"W2190417520","doi":"10.1182/blood.v124.21.3392.3392","title":"Bone Marrow Stromal Cells Induce Bortezomib Resistance Partly through a Transcriptome Modulation in Multiple Myeloma Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Bortezomib; Stromal cell; Cancer research; Bone marrow; Cell culture; Tetherin; Biology; Proteasome inhibitor; Molecular biology; Multiple myeloma; Immunology; Chemistry","score_opus":0.027129184832613385,"score_gpt":0.26814926877661127,"score_spread":0.24102008394399788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190417520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499285,0.00029851362,0.00030881015,0.00033821896,0.000114844326,0.00090730836,0.00005816276,0.00008246907,0.0028988218],"genre_scores_gemma":[0.9925872,0.000055402976,0.0052729617,0.00011925418,0.00019713599,0.00011000158,0.00009317981,0.000049295286,0.0015155354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761075,0.00015940004,0.00045026792,0.0005418813,0.00057224033,0.00066543906],"domain_scores_gemma":[0.9988831,0.00013682563,0.00009823176,0.0005374659,0.00008526149,0.00025909755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002773202,0.00027764024,0.00047966113,0.00015613488,0.00009948654,0.000036264428,0.00012864592,0.00017338496,0.00007982202],"category_scores_gemma":[0.00010748118,0.0002549809,0.0001335021,0.00034173607,0.00008167083,0.00021018706,0.00002868533,0.0003108223,0.00010549785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010329073,0.0023873372,0.058794707,0.00024113484,0.000155884,0.00042439875,0.0007608167,0.000040549618,0.9333205,0.00010837519,0.00048984704,0.0022435086],"study_design_scores_gemma":[0.034073394,0.0007402368,0.3178837,0.00032353905,0.00017525924,0.000027260676,0.00016488628,0.0031370907,0.63851506,0.00030663644,0.0042040236,0.0004489096],"about_ca_topic_score_codex":0.00022112865,"about_ca_topic_score_gemma":0.0005666194,"teacher_disagreement_score":0.29480547,"about_ca_system_score_codex":0.00008191239,"about_ca_system_score_gemma":0.00008900243,"threshold_uncertainty_score":0.9999902},"labels":[],"label_agreement":null},{"id":"W2191867422","doi":"10.3324/haematol.2015.133629","title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Thalidomide; Internal medicine; Prednisone; Melphalan; Renal function; Urology; Gastroenterology; Surgery","score_opus":0.09147771662842669,"score_gpt":0.3836690187173586,"score_spread":0.2921913020889319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191867422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859937,0.00013384657,0.000012986641,0.0004286235,0.00002038763,0.013048508,0.00009294349,0.000016945807,0.00025210256],"genre_scores_gemma":[0.9971665,0.00006789438,0.0006955885,0.00005577009,0.000013900265,0.0018317994,0.00012067788,0.000020483003,0.000027392247],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99712145,0.0006011237,0.0006596169,0.0004481873,0.0006870257,0.00048260644],"domain_scores_gemma":[0.9976046,0.0013122025,0.0002443621,0.0004242378,0.00011480784,0.00029977201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011753677,0.00040641337,0.0019138164,0.0002707871,0.000060067912,0.00005061593,0.00020617695,0.000102125,0.000018682187],"category_scores_gemma":[0.0005588778,0.00015636152,0.00012099603,0.00034208797,0.00021985348,0.0001154244,0.00003928441,0.00017549095,0.0000048300426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7369293,0.017027082,0.24290688,0.000024122039,0.00046609028,0.00082107773,0.001080496,0.000019007775,0.000002164952,0.000010684849,0.00006740763,0.00064571796],"study_design_scores_gemma":[0.90311366,0.062460717,0.033179294,0.00023627581,0.00020635579,0.000074179836,0.0001565412,0.0002785891,0.00008475041,0.000033218093,0.000018199058,0.00015820157],"about_ca_topic_score_codex":0.0027884985,"about_ca_topic_score_gemma":0.0015759451,"teacher_disagreement_score":0.20972759,"about_ca_system_score_codex":0.00029593872,"about_ca_system_score_gemma":0.00040109022,"threshold_uncertainty_score":0.6376238},"labels":[],"label_agreement":null},{"id":"W2193716145","doi":"10.1016/s1470-2045(15)00464-7","title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":849,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Cilag; Onyx Pharmaceuticals; Amgen; Takeda Oncology; Spectrum Pharmaceuticals; Array BioPharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Refractory (planetary science); Population; Tolerability; Interim analysis; Oncology; Surgery; Clinical trial; Adverse effect","score_opus":0.17996979241503736,"score_gpt":0.430217007053223,"score_spread":0.25024721463818567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2193716145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98729885,0.0005953084,0.000081875536,0.00092031056,0.00022804893,0.010107491,0.00016189637,0.00006632349,0.00053988723],"genre_scores_gemma":[0.98487,0.00019668363,0.012556703,0.00028904655,0.00024072385,0.001199077,0.00014712497,0.00006606619,0.00043457438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968764,0.00076083466,0.00043599843,0.000698146,0.00044074815,0.0007878339],"domain_scores_gemma":[0.994006,0.003943342,0.00027305644,0.0007137231,0.00040713107,0.0006567886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001539815,0.00039321335,0.0013671273,0.000116290066,0.000272709,0.00007722509,0.00033131687,0.00017965205,0.000034688666],"category_scores_gemma":[0.0038049726,0.0002168784,0.000037551927,0.00022871282,0.00035889063,0.00020772433,0.00033244304,0.00042364356,0.00001037668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7683562,0.0099084135,0.10727012,0.00008900758,0.0014364038,0.00032568077,0.0030035276,0.0000013070622,0.00016548904,0.000009595526,0.0016008117,0.107833415],"study_design_scores_gemma":[0.887664,0.048803218,0.047909793,0.000060037662,0.0008842844,0.000048255697,0.0027042273,0.0014238436,0.000083997315,0.00001817139,0.010111257,0.00028892187],"about_ca_topic_score_codex":0.0004368147,"about_ca_topic_score_gemma":0.0017666958,"teacher_disagreement_score":0.119307764,"about_ca_system_score_codex":0.00034654897,"about_ca_system_score_gemma":0.00053738407,"threshold_uncertainty_score":0.8844044},"labels":[],"label_agreement":null},{"id":"W2198348523","doi":"10.1016/j.clml.2015.07.180","title":"Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; Deep sequencing; DNA sequencing; Cell-free fetal DNA; Mutation; Genome; Medicine; Biology; Computational biology; Gene; Cancer research; Genetics; Prenatal diagnosis","score_opus":0.07559077949666501,"score_gpt":0.33915242373242827,"score_spread":0.2635616442357632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198348523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993927,0.0006151787,0.00030030124,0.0002016695,0.00021042068,0.0009816737,0.00016952539,0.00007019344,0.0035240229],"genre_scores_gemma":[0.9922936,0.00013649651,0.006389703,0.00012576496,0.00015804132,0.00022261775,0.00030806818,0.00007565658,0.00029003725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99519867,0.00037608363,0.001874598,0.0007733523,0.001008986,0.0007683324],"domain_scores_gemma":[0.99361753,0.003152336,0.0007135624,0.001010885,0.000677542,0.0008281115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010416781,0.00040126118,0.0012275609,0.00035203437,0.000119251745,0.000024991372,0.000433355,0.00044772538,0.00011568729],"category_scores_gemma":[0.008037499,0.00038326636,0.00044525554,0.0008314146,0.0005272706,0.00030151752,0.00026726245,0.00036906282,0.00007903188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000959371,0.0011953161,0.8370013,0.00034405987,0.0003081351,0.00079995475,0.0007414617,0.0002567586,0.0073601273,0.000054333148,0.0015916033,0.14938754],"study_design_scores_gemma":[0.023861539,0.0014588068,0.8492759,0.0005502028,0.0002201935,0.00014792,0.0018884978,0.012839698,0.10808152,0.0007339477,0.0005004733,0.00044130188],"about_ca_topic_score_codex":0.00220088,"about_ca_topic_score_gemma":0.0003935616,"teacher_disagreement_score":0.14894624,"about_ca_system_score_codex":0.002248976,"about_ca_system_score_gemma":0.0028442661,"threshold_uncertainty_score":0.9998619},"labels":[],"label_agreement":null},{"id":"W2201190784","doi":"10.1056/nejmoa1505654","title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1320,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Progression-free survival; Oncology; Neutropenia; Hazard ratio; Bortezomib; Dexamethasone; Confidence interval; Chemotherapy","score_opus":0.09997258122392107,"score_gpt":0.365146460681726,"score_spread":0.26517387945780496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201190784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96888304,0.0075622895,0.0020405706,0.016693441,0.0011493951,0.00113022,0.000012051532,0.00004606634,0.0024829276],"genre_scores_gemma":[0.98395854,0.0011566668,0.0049107284,0.00065336714,0.005014172,0.000009883514,0.000027906357,0.000040960538,0.004227799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792725,0.000103167025,0.00059588236,0.00016985486,0.0008546905,0.000349141],"domain_scores_gemma":[0.99685854,0.00075267686,0.0003061753,0.0002551719,0.0006706616,0.0011567802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011928645,0.00020454454,0.0006724884,0.0002827792,0.0000567035,0.000010434303,0.00015416941,0.000097288466,0.00024263976],"category_scores_gemma":[0.0039944155,0.00010359442,0.00012500647,0.00018467277,0.000102476995,0.00012768485,0.000015729496,0.00035419952,0.000013063941],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0830343,0.0004923183,0.02071968,0.000055674387,0.00060995313,0.0014759388,0.0015421121,0.000006224208,0.005746967,0.000031723463,0.08036742,0.8059177],"study_design_scores_gemma":[0.40706044,0.028428007,0.01776447,0.00042211945,0.00015192771,0.0023779983,0.00042224687,0.00021121591,0.0016883992,0.00037934046,0.5409642,0.00012961164],"about_ca_topic_score_codex":0.000114334696,"about_ca_topic_score_gemma":0.000046149187,"teacher_disagreement_score":0.8057881,"about_ca_system_score_codex":0.00018841003,"about_ca_system_score_gemma":0.0010544753,"threshold_uncertainty_score":0.4781977},"labels":[],"label_agreement":null},{"id":"W220323948","doi":"10.1182/blood.v95.5.1869.005k09_1869_1871","title":"Germline CDKN2A mutation implicated in predisposition to multiple myeloma","year":2000,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CDKN2A; Loss of heterozygosity; Cancer research; Multiple myeloma; Germline mutation; Germline; Plasmacytoma; Biology; Allele; Mutation; Genetics; Immunology; Cancer; Gene","score_opus":0.015717171284957806,"score_gpt":0.2968261956724675,"score_spread":0.2811090243875097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W220323948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962406,0.00006673579,0.000034072622,0.00063711725,0.0000124366325,0.0008879345,0.000038063565,0.000079506375,0.0020035228],"genre_scores_gemma":[0.99693465,0.000020640204,0.0014368857,0.00016327797,0.00008222263,0.00017270345,0.00037168508,0.00001895059,0.000798995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896306,0.00003408536,0.00020820956,0.00026476887,0.0002256639,0.00030421795],"domain_scores_gemma":[0.9994258,0.000042439384,0.00001900222,0.00022595565,0.00005316167,0.00023361038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007879241,0.00011354559,0.00016899158,0.00015672248,0.00004206974,0.00001496487,0.00005274776,0.00006402615,0.0005405132],"category_scores_gemma":[0.000080457015,0.00010045307,0.000045676694,0.00033394285,0.000015985717,0.00006876452,0.000014034529,0.000100143705,0.0005675254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029020612,0.0059004324,0.5983267,0.00010843198,0.00022698776,0.0017377717,0.00071353186,0.00009211531,0.12440084,0.00001818557,0.00043795453,0.26513502],"study_design_scores_gemma":[0.01018576,0.00053223973,0.95597804,0.00006754632,0.000045353827,0.00013786677,0.000015619198,0.00097290345,0.031499065,0.000027543168,0.00044396432,0.000094106],"about_ca_topic_score_codex":0.0002486942,"about_ca_topic_score_gemma":0.00014261472,"teacher_disagreement_score":0.35765135,"about_ca_system_score_codex":0.000057248453,"about_ca_system_score_gemma":0.000041942654,"threshold_uncertainty_score":0.729458},"labels":[],"label_agreement":null},{"id":"W2208379272","doi":"10.1186/2051-1426-3-s2-p160","title":"Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Pembrolizumab; Dexamethasone; Medicine; Multiple myeloma; Oncology; Internal medicine; Cancer research; Pharmacology; Immunotherapy; Cancer","score_opus":0.04112271902787046,"score_gpt":0.3538140881746188,"score_spread":0.31269136914674833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208379272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852431,0.010167612,0.0016701688,0.0009174238,0.00024168914,0.0016347728,0.000055845558,0.000015214986,0.000054187305],"genre_scores_gemma":[0.9900669,0.0025202658,0.0056603197,0.00016235303,0.00015402687,0.0003236448,0.00002813849,0.00007162382,0.0010127573],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982783,0.000075911856,0.0004947622,0.0002386267,0.00048888905,0.0004234619],"domain_scores_gemma":[0.99817806,0.00040000177,0.00034533822,0.00021191023,0.00061166217,0.00025300714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006854989,0.00022823364,0.00056362955,0.00031919387,0.000115537885,0.00004041002,0.000113641676,0.00012116385,0.000036423175],"category_scores_gemma":[0.00030111131,0.00016588756,0.00014730664,0.00016965339,0.00012832614,0.00027069956,0.0000140493485,0.0002877748,0.0000011395446],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27546117,0.002219861,0.14391103,0.00058135553,0.0018241075,0.00009069261,0.0026392057,0.00024895137,0.076158606,0.0000910377,0.0018930957,0.49488088],"study_design_scores_gemma":[0.5021905,0.021157483,0.37380394,0.0021441448,0.00028842984,0.00043981106,0.0010106143,0.007554189,0.052251596,0.0020047477,0.03644019,0.00071436114],"about_ca_topic_score_codex":0.00039499084,"about_ca_topic_score_gemma":0.00033549085,"teacher_disagreement_score":0.49416652,"about_ca_system_score_codex":0.00051424466,"about_ca_system_score_gemma":0.00066939095,"threshold_uncertainty_score":0.6764698},"labels":[],"label_agreement":null},{"id":"W2208450330","doi":"10.1007/s12308-015-0264-1","title":"Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow","year":2015,"lang":"en","type":"article","venue":"Journal of Hematopathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immunohistochemistry; Immunophenotyping; Flow cytometry; Pathology; Bone marrow; Fluorescence in situ hybridization; Plasma Cell Myeloma; Hematology; Multiple myeloma; Fish <Actinopterygii>; Medicine; Biology; Internal medicine; Molecular biology","score_opus":0.05160213006285378,"score_gpt":0.3743128266298163,"score_spread":0.3227106965669625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208450330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820924,0.0010001321,0.000043436932,0.0002561662,0.00008458516,0.00013127376,0.000011571803,0.0000016585345,0.00026194134],"genre_scores_gemma":[0.99628633,0.0002207484,0.00339941,0.000015363825,0.00004191453,0.0000036564063,0.000004342868,0.0000064093483,0.00002180234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775326,0.00037123813,0.0011374467,0.00016314331,0.00035274288,0.00022214455],"domain_scores_gemma":[0.9984121,0.00045842098,0.00046017213,0.00030423986,0.000221225,0.0001438958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029826052,0.0001175992,0.0010157726,0.00050878606,0.0000125848255,0.0000039231777,0.0001660763,0.00017418196,0.000020206313],"category_scores_gemma":[0.0011316143,0.00007993761,0.00020988628,0.0005483166,0.0002800273,0.000045187422,0.00007043921,0.00053476956,7.920386e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013658168,0.0008456436,0.977888,0.00010428401,0.000117325566,0.002556334,0.00046489,0.00001356305,0.015316819,7.553486e-7,0.00008177349,0.0012447833],"study_design_scores_gemma":[0.0064810934,0.00089351815,0.96636826,0.00008052549,0.00026790868,0.0031121701,0.0011142986,0.0007771814,0.020783897,0.00004998919,0.000015425227,0.000055725763],"about_ca_topic_score_codex":0.0000734635,"about_ca_topic_score_gemma":0.000021476138,"teacher_disagreement_score":0.011519746,"about_ca_system_score_codex":0.000058594,"about_ca_system_score_gemma":0.0001809518,"threshold_uncertainty_score":0.32597607},"labels":[],"label_agreement":null},{"id":"W2211641938","doi":"10.1016/s0140-6736(15)00384-0","title":"Clonal heterogeneity in plasma cell myeloma","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Plasma cell; Plasma Cell Myeloma; Computational biology; Medicine; Cancer research; Biology; Immunology","score_opus":0.10039221605767926,"score_gpt":0.3468898680029793,"score_spread":0.24649765194530002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211641938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762014,0.0002129077,0.0000045020515,0.0028092708,0.00005329812,0.00022023934,0.000016360005,0.000027851835,0.02045417],"genre_scores_gemma":[0.9979598,0.000029668183,0.0004933323,0.00035040602,0.0003516924,0.0000232867,0.00002262971,0.000009002046,0.0007601873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991591,0.000066781155,0.00009565279,0.00012367847,0.0002570427,0.00029774845],"domain_scores_gemma":[0.99940586,0.000048076832,0.000019547455,0.00033718708,0.000030382995,0.00015893255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027045887,0.00007700452,0.00021899458,0.00003424611,0.000025023748,0.000012287259,0.00012991684,0.00003379228,0.00004435788],"category_scores_gemma":[0.00007614572,0.000044476954,0.00003364198,0.0001000031,0.000046199944,0.00002754465,0.000053782875,0.00015861895,0.00038867292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024757492,0.00035690021,0.9574708,0.000052424948,0.00006265001,0.00050840975,0.0004705143,0.000020925989,0.0025350528,0.00012541714,0.027001627,0.008919575],"study_design_scores_gemma":[0.016136426,0.00039934248,0.90991604,0.00003957022,0.000021019856,0.0001031836,0.00010839738,0.0019053807,0.03188152,0.00040048425,0.03897382,0.00011483855],"about_ca_topic_score_codex":0.000114705734,"about_ca_topic_score_gemma":0.00015300175,"teacher_disagreement_score":0.04755474,"about_ca_system_score_codex":0.00008384543,"about_ca_system_score_gemma":0.000090530746,"threshold_uncertainty_score":0.49957338},"labels":[],"label_agreement":null},{"id":"W2215699720","doi":"10.1200/jco.2015.33.15_suppl.8508","title":"ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Bortezomib; Discontinuation; Interim analysis; Refractory (planetary science); Tolerability; Phases of clinical research; Progression-free survival; Gastroenterology; Neutropenia; Oncology; Surgery; Toxicity; Adverse effect; Randomized controlled trial; Chemotherapy","score_opus":0.19891199795524195,"score_gpt":0.49089901292909666,"score_spread":0.2919870149738547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2215699720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922737,0.00033941705,0.00011111973,0.00047293105,0.0003841248,0.0043641184,0.000012313291,0.000015077509,0.002027189],"genre_scores_gemma":[0.99131155,0.00016852407,0.007205997,0.0003136684,0.00023438137,0.00014226307,0.000018448096,0.000069651156,0.00053552125],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98870575,0.003415419,0.004793334,0.00061005907,0.0017814549,0.00069398317],"domain_scores_gemma":[0.9857099,0.00597557,0.004169148,0.00068674464,0.002003934,0.0014546717],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010651864,0.00047404022,0.0059446846,0.00056495017,0.00006923966,0.000035360183,0.0006646511,0.00044438645,0.000105758445],"category_scores_gemma":[0.012755571,0.00027322947,0.0003063248,0.0005232677,0.00068339385,0.00048490157,0.00027842444,0.0019210037,0.000021078045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5486248,0.07437428,0.31947914,0.000024548004,0.0020890431,0.0020944655,0.00076110946,0.000011304955,0.000016203156,0.0000055314067,0.00030890372,0.052210692],"study_design_scores_gemma":[0.7732262,0.13228711,0.089863084,0.00040372665,0.000922161,0.00016979178,0.00129223,0.00024853708,0.000044703855,0.000031350723,0.0012925144,0.00021858464],"about_ca_topic_score_codex":0.0010315278,"about_ca_topic_score_gemma":0.0012022723,"teacher_disagreement_score":0.22961603,"about_ca_system_score_codex":0.00072221627,"about_ca_system_score_gemma":0.0046335203,"threshold_uncertainty_score":0.999972},"labels":[],"label_agreement":null},{"id":"W2216303864","doi":"10.1038/leu.2015.356","title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","year":2015,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of Alberta","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Transplantation; Disease; Oncology; Internal medicine; Intensive care medicine; Autologous stem-cell transplantation","score_opus":0.08944497331140153,"score_gpt":0.36289546223945596,"score_spread":0.27345048892805446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216303864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002694066,0.9646622,0.00005304,0.00025744777,0.0010440999,0.0027519246,0.00019530093,0.0000501837,0.030716395],"genre_scores_gemma":[0.0036335646,0.98614043,0.00375914,0.000021978141,0.00015929335,0.00024784158,0.0007327816,0.00006293059,0.005242022],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975465,0.00014618288,0.0008359912,0.0003716438,0.0008118264,0.0002878769],"domain_scores_gemma":[0.99802744,0.00021443935,0.00061141216,0.00083156215,0.00016651589,0.0001486219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041735746,0.00031586463,0.0011109809,0.00024295224,0.000064695094,0.000015586447,0.00061945064,0.00020878842,0.00010448726],"category_scores_gemma":[0.00013915211,0.00020212922,0.00057305157,0.0005009936,0.00011208922,0.000048051956,0.00047221058,0.00044446182,0.000056533783],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006972965,0.00015777706,0.00056143384,0.005010401,0.0015246384,0.00007050076,0.000043290973,7.5097444e-7,0.000002574817,0.0004470734,0.0034594275,0.9886524],"study_design_scores_gemma":[0.0024652998,0.00007569901,0.0010801785,0.0192288,0.0009179011,0.00005043527,0.000060110786,0.000067581226,0.000016130334,0.00004531342,0.9758472,0.00014539101],"about_ca_topic_score_codex":0.000063468615,"about_ca_topic_score_gemma":0.000017934246,"teacher_disagreement_score":0.98850703,"about_ca_system_score_codex":0.0013482736,"about_ca_system_score_gemma":0.00050673005,"threshold_uncertainty_score":0.82425904},"labels":[],"label_agreement":null},{"id":"W2216707999","doi":"10.3109/10428194.2014.974043","title":"The risk of secondary primary malignancies after therapy for multiple myeloma","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Context (archaeology); Malignancy; Incidence (geometry); Disease; Oncology; Maintenance therapy; Internal medicine; Hematologic malignancy; Cancer; Intensive care medicine; Chemotherapy","score_opus":0.028808453546756495,"score_gpt":0.30089248121573137,"score_spread":0.2720840276689749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216707999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027863212,0.9632012,0.000022294162,0.000027153517,0.00041534647,0.0051584453,0.0016408548,0.00014247057,0.001528995],"genre_scores_gemma":[0.0036128708,0.98638827,0.0009545567,0.00019279617,0.00059964095,0.0032311217,0.0010586757,0.00032164343,0.0036404443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99352264,0.0005426235,0.001802217,0.001401714,0.0011892365,0.0015415818],"domain_scores_gemma":[0.9929837,0.0025027008,0.0011572798,0.0018215291,0.0006156462,0.0009191586],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001316678,0.0015226724,0.004089642,0.00044599496,0.0006212487,0.00018754856,0.00073237193,0.0011164799,0.00004257504],"category_scores_gemma":[0.00055784563,0.0009186662,0.001756989,0.00059494335,0.0009507832,0.00023060541,0.0003962762,0.00037182836,0.00006901572],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031947533,0.00021558697,0.0011345036,0.0103987,0.0023691773,0.00025844923,0.00020843183,3.1507412e-7,0.000009662242,0.000041799103,0.0042661685,0.9779025],"study_design_scores_gemma":[0.02301249,0.0010690896,0.015804527,0.0049303565,0.001936375,0.000874547,0.000110550085,0.00014366882,0.00009511913,0.00017290146,0.9509984,0.0008519726],"about_ca_topic_score_codex":0.0006144787,"about_ca_topic_score_gemma":0.00007832634,"teacher_disagreement_score":0.9770505,"about_ca_system_score_codex":0.007225386,"about_ca_system_score_gemma":0.017710784,"threshold_uncertainty_score":0.9997522},"labels":[],"label_agreement":null},{"id":"W2223829934","doi":"10.1002/ajmg.a.20226","title":"Novel mutation in the gene encoding c‐Abl‐binding protein SH3BP2 causes cherubism","year":2003,"lang":"en","type":"article","venue":"American Journal of Medical Genetics Part A","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cherubism; Exon; Transversion; Mutation; Genetics; Gene; Biology; Peptide sequence; Transition (genetics); Amino acid; Molecular biology; Giant cell","score_opus":0.05266574435093125,"score_gpt":0.3541115227457367,"score_spread":0.30144577839480546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223829934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956133,0.00048207777,0.0010772034,0.0020336912,0.000071628885,0.000296375,0.0000020506764,0.0000046450396,0.00041903867],"genre_scores_gemma":[0.9931737,0.00044613724,0.005748183,0.00034994536,0.00017424626,0.000019288178,0.000003773243,0.000016662256,0.00006803895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970562,0.00025670102,0.00051466137,0.00014555814,0.0016618224,0.00036507472],"domain_scores_gemma":[0.99880356,0.00022188913,0.00026411793,0.0001771956,0.0001219364,0.000411287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016893838,0.0001343814,0.00034581692,0.0001750302,0.000063710504,0.000027541413,0.00022173954,0.00006109777,0.00012699586],"category_scores_gemma":[0.0016453095,0.000083697094,0.00009927162,0.00042819098,0.00025603935,0.000037680675,0.000022089234,0.000525541,0.000013033528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014582417,0.0060331803,0.31142238,0.00024281588,0.0016944176,0.020381246,0.012217481,0.00019298977,0.2031178,0.00074114086,0.0015110135,0.4409873],"study_design_scores_gemma":[0.079652414,0.034743253,0.36626863,0.0067710853,0.0014549177,0.061832763,0.044443853,0.0062901736,0.30931506,0.0011725592,0.08572125,0.0023340534],"about_ca_topic_score_codex":0.000047093938,"about_ca_topic_score_gemma":0.000015934915,"teacher_disagreement_score":0.43865323,"about_ca_system_score_codex":0.00009704509,"about_ca_system_score_gemma":0.00055690366,"threshold_uncertainty_score":0.34130687},"labels":[],"label_agreement":null},{"id":"W2224822623","doi":"","title":"Extramedullary plasmacytoma in the lung of a Doberman pinscher dog.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Histopathology; Plasmacytoma; Extramedullary plasmacytoma; Lung; Medicine; Pathology; Multiple myeloma; Internal medicine","score_opus":0.026220780887577868,"score_gpt":0.28753246315685,"score_spread":0.26131168226927215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224822623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97938544,0.0003612933,0.000015739384,0.0009984762,0.00003533655,0.0009773837,0.0000033826857,0.00001636911,0.018206568],"genre_scores_gemma":[0.99820983,0.000038573045,0.00011365037,0.00026391426,0.00007375035,0.0008387602,0.000012656875,0.000010527687,0.00043833893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893314,0.00010917226,0.00016407958,0.00013739394,0.0003209366,0.00033528844],"domain_scores_gemma":[0.9993611,0.00016344526,0.00003619969,0.00029153182,0.000028158458,0.0001195837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047402136,0.000084368774,0.00017172328,0.00009976177,0.000022677477,0.000009981586,0.000120509045,0.000046538084,0.00003551754],"category_scores_gemma":[0.00026225546,0.00005026562,0.00005840327,0.00018165745,0.000059990154,0.000039440354,0.000027391523,0.00015137476,0.000014244019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039458295,0.0005986907,0.73897135,0.00017586011,0.00011913227,0.00015944996,0.00045572207,0.0000016744841,0.00012167363,0.00039810542,0.0028578797,0.2557459],"study_design_scores_gemma":[0.0028122412,0.00004993933,0.9900525,0.000018040371,0.000024207488,0.00003572285,0.000038654187,0.00044661405,0.00090967544,0.00006778332,0.0054993527,0.000045244054],"about_ca_topic_score_codex":0.00013518946,"about_ca_topic_score_gemma":0.000041847008,"teacher_disagreement_score":0.25570062,"about_ca_system_score_codex":0.000044264318,"about_ca_system_score_gemma":0.000023292225,"threshold_uncertainty_score":0.20497724},"labels":[],"label_agreement":null},{"id":"W2226640202","doi":"10.3109/10428194.2015.1128542","title":"Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Skin biopsy; Biopsy; Infiltration (HVAC); Immunohistochemistry; Pathology; Retrospective cohort study; Internal medicine","score_opus":0.02067668219786432,"score_gpt":0.2621880326709159,"score_spread":0.24151135047305158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226640202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633855,0.00026138223,0.00007413267,0.000048286583,0.00019147866,0.0022584717,0.00014889815,0.000103671824,0.00057513063],"genre_scores_gemma":[0.9979338,0.00022507587,0.0005519721,0.00011732649,0.00009645628,0.00032088108,0.00008537805,0.00006951213,0.0005996111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564,0.0001821843,0.001007066,0.0010017469,0.0012116835,0.0009573586],"domain_scores_gemma":[0.9976939,0.00026903817,0.0002969711,0.0007639185,0.00039136212,0.00058481493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026102422,0.0006583328,0.0010884772,0.00058881956,0.00027516112,0.00003768145,0.00028280652,0.0002952964,0.00007213036],"category_scores_gemma":[0.00056478276,0.0004412387,0.00020343415,0.00059545407,0.00045416033,0.00029807418,0.00030821745,0.000119260476,0.00006678237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025895266,0.004351259,0.8893927,0.00011892402,0.00039091107,0.0010306081,0.0016674437,0.000008912221,0.0032434457,0.00008953584,0.00009679745,0.09701993],"study_design_scores_gemma":[0.094459765,0.0027720488,0.8959623,0.00042209748,0.0001182725,0.00024282897,0.00078443676,0.0013451918,0.0030273665,0.000058531605,0.00038374626,0.00042344772],"about_ca_topic_score_codex":0.006043948,"about_ca_topic_score_gemma":0.002106369,"teacher_disagreement_score":0.09659649,"about_ca_system_score_codex":0.012260817,"about_ca_system_score_gemma":0.0020645335,"threshold_uncertainty_score":0.99980396},"labels":[],"label_agreement":null},{"id":"W2229483068","doi":"10.1016/s0140-6736(15)01120-4","title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Royal Victoria Hospital; University of British Columbia; Hôpital Maisonneuve-Rosemont; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Refractory (planetary science); Internal medicine; Clinical endpoint; Clinical trial; Phases of clinical research; Surrogate endpoint; Proteasome inhibitor; Surgery; Gastroenterology; Oncology; Lenalidomide","score_opus":0.07518314198563648,"score_gpt":0.37071873012083767,"score_spread":0.2955355881352012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229483068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925457,0.00011487589,0.000025708508,0.0010083633,0.0000885045,0.004940249,0.0001713659,0.000057042653,0.0010481833],"genre_scores_gemma":[0.996903,0.00017353182,0.000415787,0.00022792815,0.0004317747,0.00062141113,0.00015150428,0.00005021349,0.0010248543],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980188,0.00030836128,0.0002990088,0.00041913154,0.00038312664,0.00057154126],"domain_scores_gemma":[0.9982082,0.00032788815,0.00011966829,0.0010225077,0.00007856903,0.00024313653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030784335,0.0002849491,0.00079268595,0.00009618726,0.00014378708,0.00006983925,0.0004215923,0.00007558703,0.00023494172],"category_scores_gemma":[0.00013676472,0.00011649476,0.000041854506,0.00016410313,0.00013478273,0.000321075,0.000052201718,0.00013212742,0.000083464045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78988975,0.007909521,0.05646346,0.0000064281307,0.00029117757,0.00006931845,0.00020362857,2.2033836e-7,0.0012453331,0.0000130496555,0.00056060223,0.14334749],"study_design_scores_gemma":[0.91380066,0.017830562,0.060399506,0.000088131615,0.000053269756,0.0000029355763,0.000016572892,0.00006424351,0.00093613873,0.000031355747,0.0066160904,0.0001605629],"about_ca_topic_score_codex":0.0002608416,"about_ca_topic_score_gemma":0.0003393115,"teacher_disagreement_score":0.14318691,"about_ca_system_score_codex":0.00027026824,"about_ca_system_score_gemma":0.00015500434,"threshold_uncertainty_score":0.47505185},"labels":[],"label_agreement":null},{"id":"W2231200204","doi":"10.1182/blood.v124.21.3460.3460","title":"Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Discontinuation; Clinical endpoint; Multiple myeloma; Surrogate endpoint; Family medicine; Internal medicine; Oncology; Medical physics","score_opus":0.10680282608917449,"score_gpt":0.45167109004951544,"score_spread":0.344868263960341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231200204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050707,0.000009928422,0.0038658397,0.0026182262,0.000064609536,0.0028424163,0.0000038685225,0.000009629899,0.000078398414],"genre_scores_gemma":[0.9975578,0.0000038118362,0.0014016378,0.00013663074,0.000057130394,0.00081587903,0.000013713845,0.000008891413,0.000004501728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738675,0.0007252622,0.0011146978,0.0002740557,0.0003891184,0.000110109555],"domain_scores_gemma":[0.9960365,0.0025912027,0.00092254305,0.00031621626,0.00008735721,0.000046138866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011505197,0.0000942946,0.00028349963,0.000084802814,0.00011930854,0.00004267261,0.00012373732,0.000052682968,0.0000037177426],"category_scores_gemma":[0.007863731,0.000053691187,0.00006134683,0.00010006829,0.00008576704,0.000051081814,0.000079416975,0.0001593191,2.0339677e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002964161,0.0013939039,0.9567564,0.0000276472,0.000069478636,0.0000030445788,0.0009354476,0.000003178007,0.001729029,0.00020429706,0.0000050955696,0.03590831],"study_design_scores_gemma":[0.0060760975,0.00090157473,0.9342273,0.00016017426,0.00006479476,0.0000069739876,0.0006876935,0.056831572,0.00081562303,0.000141595,0.000042383508,0.000044229608],"about_ca_topic_score_codex":0.000037343067,"about_ca_topic_score_gemma":0.00015089088,"teacher_disagreement_score":0.056828395,"about_ca_system_score_codex":0.00005785943,"about_ca_system_score_gemma":0.0000909588,"threshold_uncertainty_score":0.9414188},"labels":[],"label_agreement":null},{"id":"W2234721586","doi":"10.1182/blood.v122.21.2939.2939","title":"Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Multiple myeloma; Internal medicine; Dexamethasone; Quality of life (healthcare); Randomized controlled trial; Surgery","score_opus":0.031077756836230323,"score_gpt":0.3190235386957008,"score_spread":0.2879457818594705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234721586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97994125,0.0019485472,0.000031915235,0.0005629649,0.0004392457,0.016634924,0.00017016694,0.00015549053,0.00011549614],"genre_scores_gemma":[0.99171257,0.00031363487,0.0041123284,0.00030262876,0.00014798163,0.002174434,0.0006767322,0.00015791148,0.00040177908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98526645,0.0049817553,0.0049078017,0.0014116362,0.0017059356,0.0017264106],"domain_scores_gemma":[0.9885365,0.0060644927,0.0019450742,0.0015086374,0.00053989596,0.0014054298],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0053979624,0.0009655895,0.005435437,0.0012855133,0.00016256442,0.00006536823,0.00048757036,0.00070942007,0.00041629252],"category_scores_gemma":[0.02659924,0.0008016501,0.00080136687,0.0013730472,0.00051634095,0.0004246685,0.0002510561,0.0013517276,0.00012582418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9013763,0.029908264,0.02924294,0.0005897047,0.0013666552,0.00018109976,0.0012458652,0.000021320346,0.022583663,0.000018223725,0.0001092288,0.013356703],"study_design_scores_gemma":[0.86458033,0.004324848,0.12187318,0.0004334018,0.00021942714,0.0000065873774,0.00018798193,0.0014317394,0.006241032,0.00014157788,0.000011625611,0.0005482782],"about_ca_topic_score_codex":0.035243414,"about_ca_topic_score_gemma":0.0012589758,"teacher_disagreement_score":0.09263024,"about_ca_system_score_codex":0.0007254178,"about_ca_system_score_gemma":0.0017140068,"threshold_uncertainty_score":0.9994434},"labels":[],"label_agreement":null},{"id":"W2236205422","doi":"10.1200/jco.2006.24.18_suppl.6091","title":"Gemcitabine-related thrombocytosis: Does it increase the risk of thrombosis?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thrombocytosis; Medicine; Gemcitabine; Internal medicine; Gastroenterology; Antimetabolite; Chemotherapy; Malignancy; Cancer; Surgery; Platelet","score_opus":0.08832522565417754,"score_gpt":0.4604334897423903,"score_spread":0.37210826408821274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236205422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783499,0.0005510466,0.000025614578,0.0117951585,0.00050361187,0.0002845927,0.000016087524,0.000008959018,0.008465006],"genre_scores_gemma":[0.9951886,0.0018868396,0.0012054377,0.0005190871,0.0007088515,0.000004900535,0.0000051190987,0.00001638611,0.00046479277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950629,0.0011230186,0.0027186424,0.00017293527,0.0006204041,0.0003020976],"domain_scores_gemma":[0.9916318,0.00486336,0.002234439,0.0003338929,0.0006048478,0.0003316297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004452507,0.00015658763,0.0015541157,0.00012181557,0.00008098942,0.000008816142,0.00025972957,0.00034859992,0.0005021227],"category_scores_gemma":[0.006913588,0.00006680745,0.0008348372,0.00021166992,0.0005702791,0.0001024766,0.00007922748,0.001205469,0.00004449963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038433436,0.0052114483,0.9518306,0.000038505525,0.0026916778,0.0005042374,0.00008972331,0.000025348325,0.00069277803,0.00030674908,0.011953561,0.022812014],"study_design_scores_gemma":[0.01265427,0.006351617,0.9657939,0.00010469155,0.0012020317,0.0001523143,0.0001818302,0.00013351643,0.00040075602,0.0022589487,0.010698625,0.00006746771],"about_ca_topic_score_codex":0.0007051688,"about_ca_topic_score_gemma":0.00033454527,"teacher_disagreement_score":0.022744546,"about_ca_system_score_codex":0.00010964794,"about_ca_system_score_gemma":0.0010769871,"threshold_uncertainty_score":0.827671},"labels":[],"label_agreement":null},{"id":"W2237949876","doi":"10.1016/j.clml.2015.07.216","title":"IMiDs induced Ikaros-dependent downregulation of MYC in myeloma is mediated through the repression of the 3’ IGH enhancer activity and the NURD complex repositioning","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Psychological repression; Enhancer; Downregulation and upregulation; Cancer research; Mechanism (biology); Cell biology; Chemistry; Transcription factor; Biology; Genetics; Gene expression; Gene; Physics","score_opus":0.09292985716171397,"score_gpt":0.3854794540345133,"score_spread":0.2925495968727993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2237949876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925939,0.00031411272,0.000047084806,0.00316022,0.00017794708,0.0013236006,0.000026948905,0.000030164745,0.0023260403],"genre_scores_gemma":[0.99871016,0.00012849594,0.00028052778,0.00037957248,0.00015306166,0.00008949885,0.00003056819,0.000029614584,0.00019848521],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954359,0.0012315372,0.0012653935,0.00058098783,0.0010859455,0.00040022685],"domain_scores_gemma":[0.9952296,0.0021444322,0.00079185906,0.0012583479,0.00036841922,0.00020735619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019964809,0.00028957025,0.000879335,0.000069127236,0.00022383919,0.00003452375,0.00039531433,0.00033079396,0.000052082487],"category_scores_gemma":[0.0029125896,0.00013880811,0.00030276316,0.00053029717,0.0012470623,0.00020172191,0.0004306711,0.00043613245,0.000010899073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030404245,0.0017666081,0.23721808,0.0002941022,0.0012699789,0.00016170226,0.0142471865,0.000092953764,0.14939938,0.0015158938,0.0016953152,0.56193453],"study_design_scores_gemma":[0.01403509,0.00033413252,0.94004816,0.00035829024,0.00013075088,0.00006891496,0.0003938988,0.0044714264,0.03899946,0.00094516744,0.00008586419,0.00012883323],"about_ca_topic_score_codex":0.0024765886,"about_ca_topic_score_gemma":0.00014518588,"teacher_disagreement_score":0.7028301,"about_ca_system_score_codex":0.0005422486,"about_ca_system_score_gemma":0.00087799464,"threshold_uncertainty_score":0.566043},"labels":[],"label_agreement":null},{"id":"W2242232812","doi":"10.1200/jco.2006.24.18_suppl.7506","title":"Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Thrombosis; Internal medicine; Gastroenterology; Venous thrombosis; Pulmonary embolism; Adverse effect; Placebo; Population; Surgery","score_opus":0.07507461435833444,"score_gpt":0.4346187648664301,"score_spread":0.35954415050809563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242232812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964754,0.000211155,0.00022383415,0.0016953511,0.000030393521,0.00022022512,0.0000034758903,0.0000029462403,0.0011372069],"genre_scores_gemma":[0.9837424,0.00055725325,0.01547867,0.000080355414,0.00009474863,0.0000031110462,0.0000036025097,0.000010190935,0.000029638642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975949,0.0006081204,0.0011214674,0.0001304421,0.000380417,0.00016466243],"domain_scores_gemma":[0.99546534,0.0026942084,0.001166189,0.00011055812,0.00037074988,0.0001929784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024811563,0.0000978687,0.0010969964,0.00017110599,0.000021443308,0.0000044445787,0.00005306691,0.00015348964,0.000041758984],"category_scores_gemma":[0.0018063613,0.000054122924,0.00009552232,0.00017732618,0.0003960176,0.00007895552,0.000018559867,0.0005602695,0.0000014107972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014082814,0.00325642,0.9568428,0.00003052908,0.00035284378,0.00042497047,0.000024836589,0.000009979075,0.00018885966,0.000050996634,0.00014251347,0.024592457],"study_design_scores_gemma":[0.040788162,0.023219641,0.93401843,0.00017027477,0.00031725297,0.00019725732,0.000084060935,0.0001063366,0.00043356855,0.00029906983,0.00031781266,0.000048130947],"about_ca_topic_score_codex":0.0014985254,"about_ca_topic_score_gemma":0.0011574074,"teacher_disagreement_score":0.026705347,"about_ca_system_score_codex":0.000087284745,"about_ca_system_score_gemma":0.0006817044,"threshold_uncertainty_score":0.24341235},"labels":[],"label_agreement":null},{"id":"W2247004227","doi":"10.1200/jco.2009.27.15_suppl.8517","title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Bortezomib; Regimen; Thalidomide; Internal medicine; Pharmacology; Gastroenterology","score_opus":0.13401828864569137,"score_gpt":0.48564311807315114,"score_spread":0.35162482942745976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247004227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290645,0.0005679432,0.000037462392,0.003985466,0.00065459183,0.0009671753,0.000036275633,0.00001491557,0.0008296938],"genre_scores_gemma":[0.9928522,0.0009904098,0.0038967526,0.00054805673,0.0015546586,0.000009026845,0.000026737915,0.000022580813,0.00009954659],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99228525,0.0009328032,0.0049870694,0.00043017798,0.00078352116,0.0005811971],"domain_scores_gemma":[0.98838174,0.0074134353,0.0023444798,0.00033842382,0.000565554,0.0009563428],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004990066,0.0003091238,0.0029370708,0.000548586,0.000073845724,0.000014516687,0.00023483376,0.00067439146,0.00005124441],"category_scores_gemma":[0.032335438,0.00022761498,0.00057615945,0.0004324291,0.00037224006,0.00025482624,0.00009225392,0.001592747,0.0000062575423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6387614,0.019270655,0.0101606175,0.000021617527,0.00044050606,0.007492026,0.00023668588,0.0000108299855,0.0027762672,0.000011253766,0.0007549334,0.3200632],"study_design_scores_gemma":[0.7043479,0.13204695,0.1551389,0.00023413828,0.0003502057,0.00042291722,0.000100307436,0.00072819,0.0034899472,0.00018046418,0.0027914064,0.00016865274],"about_ca_topic_score_codex":0.00027420316,"about_ca_topic_score_gemma":0.00032832593,"teacher_disagreement_score":0.31989455,"about_ca_system_score_codex":0.00018420554,"about_ca_system_score_gemma":0.0018247517,"threshold_uncertainty_score":0.9758156},"labels":[],"label_agreement":null},{"id":"W2249012585","doi":"10.1200/jco.2007.25.18_suppl.8003","title":"Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom’s macroglobulinemia at well-tolerated doses","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Macroglobulinemia; Multiple myeloma; Proteasome inhibitor; Internal medicine; Waldenstrom macroglobulinemia; Oncology; Progressive disease; Dosing; Adverse effect; Gastroenterology; Pharmacology; Lymphoma; Chemotherapy","score_opus":0.2234053623912945,"score_gpt":0.5196783874375903,"score_spread":0.2962730250462958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249012585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623764,0.0011647894,0.000019074203,0.00114286,0.00017342187,0.0005925886,0.0000093283525,0.0000060107736,0.0006543047],"genre_scores_gemma":[0.99652547,0.00048298683,0.002462867,0.00019857792,0.00013988215,0.000009105721,0.000009758633,0.0000120835675,0.00015929287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99407595,0.0012653628,0.0030708627,0.0002816159,0.0008369733,0.00046923553],"domain_scores_gemma":[0.99146396,0.005924673,0.0011123464,0.00018529304,0.00085247407,0.00046128273],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012529458,0.00018173149,0.0016540157,0.0004434738,0.0000384954,0.000006606956,0.00012456393,0.00049428875,0.00024035599],"category_scores_gemma":[0.02020689,0.00012650425,0.00022476607,0.00033945878,0.0003949462,0.00009991114,0.00009776351,0.00074826146,0.000010605067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0668936,0.005855544,0.8404814,0.000067687244,0.0001714633,0.008499221,0.00019940005,0.000014717143,0.007971744,0.000022823882,0.00033130377,0.069491126],"study_design_scores_gemma":[0.07861572,0.0119325435,0.89888084,0.00024886322,0.0001700863,0.0013332099,0.00051202363,0.0017639707,0.0052553494,0.00010516125,0.0010818299,0.00010042121],"about_ca_topic_score_codex":0.000099879064,"about_ca_topic_score_gemma":0.0009805192,"teacher_disagreement_score":0.0693907,"about_ca_system_score_codex":0.00050667336,"about_ca_system_score_gemma":0.0013254755,"threshold_uncertainty_score":0.98804635},"labels":[],"label_agreement":null},{"id":"W2249015683","doi":"10.1182/blood.v114.22.743.743","title":"Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Internal medicine; Multiple myeloma; Population; Univariate analysis; Multivariate analysis; Hematology; Oncology; Stage (stratigraphy); Progression-free survival; Cytogenetics; Medicine; Biology; Overall survival; Genetics; Chromosome","score_opus":0.02051526905891881,"score_gpt":0.3193394394229631,"score_spread":0.2988241703640443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249015683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992342,0.00009255315,0.0000012306956,0.000045160134,0.000004947751,0.0002170056,0.00019098695,0.0000043455193,0.00020956788],"genre_scores_gemma":[0.99956954,0.00013550697,0.00013239712,0.000026797998,0.0000102363365,0.0000022170311,0.000105475236,0.000006059522,0.000011768455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990733,0.000052431755,0.00022249496,0.00018413152,0.0002913582,0.00017626517],"domain_scores_gemma":[0.99935275,0.00005174326,0.00006813038,0.0002902259,0.0000718064,0.00016533956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009960418,0.00010935723,0.0003871669,0.00029347814,0.00001356009,0.00000522257,0.000051277213,0.00005065021,0.000021694654],"category_scores_gemma":[0.000110568435,0.00008321746,0.000090028734,0.0002487977,0.000036673533,0.000031510335,0.00002783984,0.00006453432,2.0172511e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004113472,0.0032355257,0.9875772,0.000018393031,0.0008155093,0.000023778628,0.00013740336,0.000016758242,0.0012786576,0.000010242176,0.000013536941,0.006461676],"study_design_scores_gemma":[0.009347742,0.004505772,0.9828572,0.000029369829,0.0005419589,0.0000010575149,0.000011015127,0.00024562943,0.0023553097,0.000044577577,0.0000017886624,0.000058537356],"about_ca_topic_score_codex":0.00047999393,"about_ca_topic_score_gemma":0.00034958083,"teacher_disagreement_score":0.008936396,"about_ca_system_score_codex":0.000024622956,"about_ca_system_score_gemma":0.000036117108,"threshold_uncertainty_score":0.33935097},"labels":[],"label_agreement":null},{"id":"W2254400861","doi":"10.1200/jco.2015.33.18_suppl.lba8512","title":"Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Neutropenia; Pomalidomide; Population; Refractory (planetary science); Nausea; Gastroenterology; Clinical endpoint; Adverse effect; Carfilzomib; Multiple myeloma; Phases of clinical research; Surgery; Lenalidomide; Clinical trial; Chemotherapy","score_opus":0.23382234559224524,"score_gpt":0.5029430214787639,"score_spread":0.26912067588651867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254400861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972486,0.00041056125,0.000013060766,0.000378979,0.00034668884,0.001334729,0.000010960735,0.0000075156836,0.0002489303],"genre_scores_gemma":[0.99695575,0.0003407628,0.0019817518,0.0001342288,0.00028044265,0.000017213595,0.000007509793,0.00003398349,0.0002483797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99482226,0.0005988742,0.0029096806,0.00028393848,0.0010435123,0.00034174847],"domain_scores_gemma":[0.9937434,0.0013062145,0.0023497932,0.00042907332,0.0015925767,0.0005789128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022097349,0.00024713314,0.0022590305,0.00037162774,0.000044579752,0.0000058004816,0.00028631746,0.00030632032,0.000097684286],"category_scores_gemma":[0.0019312686,0.0001360269,0.0002466184,0.00036033004,0.00026226195,0.00020692796,0.00006445282,0.0008494111,0.000003694526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27060616,0.08668393,0.4664149,0.000017703784,0.0007486548,0.00040747138,0.000781256,0.000013349996,0.000106884894,7.851802e-7,0.00033860424,0.17388032],"study_design_scores_gemma":[0.29903257,0.28654668,0.4085755,0.00009664093,0.00008708244,0.000016971257,0.0004106607,0.00007646403,0.00036178404,0.0000069409043,0.0047023348,0.00008633796],"about_ca_topic_score_codex":0.00016801302,"about_ca_topic_score_gemma":0.00045999303,"teacher_disagreement_score":0.19986276,"about_ca_system_score_codex":0.00018997694,"about_ca_system_score_gemma":0.0021580022,"threshold_uncertainty_score":0.55470157},"labels":[],"label_agreement":null},{"id":"W2258102812","doi":"10.1016/j.clml.2015.07.549","title":"Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the upfront therapy of transplant ineligible patients with multiple myeloma","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Multiple myeloma; Melphalan; Regimen; Dexamethasone; Prednisone; Medicine; Cyclophosphamide; Oncology; Internal medicine; Surgery; Chemotherapy","score_opus":0.05295383253533732,"score_gpt":0.33134190167031297,"score_spread":0.27838806913497566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258102812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920827,0.0030116509,0.00086211466,0.0004153399,0.00023761063,0.0027656194,0.000215952,0.00008345968,0.00032551386],"genre_scores_gemma":[0.9918007,0.0016727025,0.004981049,0.0004808565,0.00020305722,0.00031495705,0.00021650874,0.00009087497,0.00023928135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637103,0.00018187534,0.0010984952,0.0007644327,0.0008355621,0.00074861886],"domain_scores_gemma":[0.99453324,0.0026544249,0.0003328871,0.0008847123,0.00070859434,0.0008861147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010438228,0.00047805108,0.0010924742,0.00012120549,0.00018628623,0.000044047647,0.00033866445,0.00030588606,0.000024998884],"category_scores_gemma":[0.001191913,0.0002729544,0.00031090179,0.0003408372,0.0007320664,0.00016428364,0.000087614,0.0002493568,0.000018962144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014669908,0.0005915762,0.5839267,0.000048791295,0.00055797125,0.00004440454,0.00016584435,0.0000068194117,0.000056017678,0.000037835453,0.0007157092,0.39917842],"study_design_scores_gemma":[0.049110048,0.0037616906,0.93369037,0.00016139362,0.0001985544,0.000036655216,0.0001001508,0.0021256118,0.0013586448,0.00012675599,0.009036862,0.00029326067],"about_ca_topic_score_codex":0.000549917,"about_ca_topic_score_gemma":0.00009958935,"teacher_disagreement_score":0.39888516,"about_ca_system_score_codex":0.0003379829,"about_ca_system_score_gemma":0.0012446983,"threshold_uncertainty_score":0.9999723},"labels":[],"label_agreement":null},{"id":"W2259949595","doi":"10.1016/j.revmed.2015.12.025","title":"Myélome multiple et thrombose veineuse. Quelle thromboprophylaxie faut-il proposer ?","year":2016,"lang":"fr","type":"article","venue":"La Revue de Médecine Interne","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Gynecology","score_opus":0.024813410486303186,"score_gpt":0.3142249541612004,"score_spread":0.2894115436748972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259949595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91699827,0.009470606,0.0024914749,0.050877493,0.0025120748,0.002019063,0.00048040174,0.00030516775,0.014845455],"genre_scores_gemma":[0.8899564,0.0028800599,0.0020697995,0.00045628758,0.0018269107,0.00017496668,0.00007940021,0.00021166723,0.10234452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947644,0.00066750316,0.00091584906,0.0011309574,0.00069832243,0.0018229702],"domain_scores_gemma":[0.9954469,0.0014414776,0.000267409,0.0014335011,0.00030447572,0.0011062217],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00096220156,0.00078824593,0.001175701,0.0003368969,0.00012392583,0.00012597477,0.00064527825,0.00051220204,0.004853642],"category_scores_gemma":[0.0024999457,0.00054755376,0.0004832765,0.00042987926,0.0005968544,0.00039458965,0.00053927104,0.00082284125,0.006013113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001642988,0.005218385,0.7298155,0.0014660078,0.0015792473,0.00589855,0.0008997381,0.0000069906523,0.14113697,0.009874966,0.013024229,0.08943646],"study_design_scores_gemma":[0.023976002,0.0036851305,0.8158885,0.0074430113,0.0003602634,0.0014186573,0.00016697755,0.0013488588,0.034301374,0.002214859,0.10830013,0.000896207],"about_ca_topic_score_codex":0.0019871125,"about_ca_topic_score_gemma":0.00080926187,"teacher_disagreement_score":0.106835596,"about_ca_system_score_codex":0.0010975117,"about_ca_system_score_gemma":0.0005459077,"threshold_uncertainty_score":0.9996976},"labels":[],"label_agreement":null},{"id":"W2264688301","doi":"10.3324/haematol.2015.134049","title":"Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study","year":2015,"lang":"en","type":"letter","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Population; Melphalan; Cohort; Oncology; Transplantation; Malignancy; Myelodysplastic syndromes; Cancer; Bone marrow","score_opus":0.05383425820085901,"score_gpt":0.30255229735905703,"score_spread":0.248718039158198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264688301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803243,0.00009041673,0.0000065441627,0.011179637,0.00029794252,0.0059519736,0.00026666795,0.00014345108,0.0017390325],"genre_scores_gemma":[0.95897967,0.000004843956,0.00052527356,0.031046622,0.00023759983,0.0011861301,0.005711439,0.00010442705,0.0022040154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460953,0.00060698355,0.0009604113,0.0011201281,0.0016743195,0.0010286338],"domain_scores_gemma":[0.99707687,0.0006218516,0.0003406024,0.000926389,0.00073804526,0.00029624294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058797403,0.00070634903,0.0019866049,0.0005797129,0.0001421999,0.00006250243,0.00035422356,0.0009031773,0.00077671354],"category_scores_gemma":[0.0019244748,0.00053558423,0.00017582189,0.00062983565,0.00009415969,0.000085846325,0.00016475642,0.0013526811,0.00034165112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034836825,0.00093898625,0.83187455,0.00033322288,0.00024170184,0.007448686,0.00010355678,0.0000014330923,4.4316496e-7,0.0000010370507,0.15844764,0.00026035155],"study_design_scores_gemma":[0.008743224,0.0008186238,0.96232516,0.00029761624,0.000103337174,0.000033846234,0.00007140741,0.00013836987,0.00001210657,0.000025016703,0.026956925,0.00047435315],"about_ca_topic_score_codex":0.0014190862,"about_ca_topic_score_gemma":0.002188409,"teacher_disagreement_score":0.13149072,"about_ca_system_score_codex":0.0006863765,"about_ca_system_score_gemma":0.00064630166,"threshold_uncertainty_score":0.99970955},"labels":[],"label_agreement":null},{"id":"W2266244964","doi":"10.1182/blood.v124.21.3448.3448","title":"Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Internal medicine; Clinical endpoint; Lenalidomide; Interim analysis; Gastroenterology; Urology; Pharmacology; Oncology; Randomized controlled trial","score_opus":0.03416027449591645,"score_gpt":0.2806213074109411,"score_spread":0.24646103291502464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266244964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931769,0.00013678134,0.000077601515,0.00013584323,0.00009592875,0.003956514,0.000042752625,0.00011538301,0.00226231],"genre_scores_gemma":[0.9960339,0.000052710937,0.0022342487,0.000030796593,0.00022064056,0.00023984583,0.00035078096,0.00008492483,0.00075214944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950937,0.00079562096,0.0012465849,0.00080083736,0.0011870371,0.00087619934],"domain_scores_gemma":[0.9959846,0.0018661742,0.00057529006,0.0008184853,0.0003066055,0.00044881616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015278301,0.00053929526,0.002633333,0.00046261083,0.000106890664,0.00004239378,0.00023040904,0.00023492852,0.000042016978],"category_scores_gemma":[0.002355477,0.00033151664,0.00023304342,0.00054605823,0.00032815346,0.00018292214,0.00008467162,0.0006391891,0.000013428112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95175886,0.0035806207,0.03751762,0.00016638251,0.0012645442,0.0012926089,0.0004944093,0.00007371801,0.0033465088,0.00001960097,0.000038714792,0.0004464209],"study_design_scores_gemma":[0.8993089,0.008488666,0.0776524,0.0007762716,0.00068468996,0.00015027066,0.00007421141,0.0049447655,0.007495129,0.000007137663,0.000063632404,0.0003538821],"about_ca_topic_score_codex":0.0035318353,"about_ca_topic_score_gemma":0.0067335884,"teacher_disagreement_score":0.052449916,"about_ca_system_score_codex":0.00015034135,"about_ca_system_score_gemma":0.0007707923,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W2269258645","doi":"10.1182/blood.v122.21.5386.5386","title":"Description Of The Hematological Toxicity Of Different Regimens Using Bortezomib In Multiple Myeloma (CyborD, Vel-Dex and VMP)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Bortezomib; Melphalan; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Neutropenia; Cyclophosphamide; Gastroenterology; Prednisone; Oncology; Surgery; Chemotherapy","score_opus":0.05241896176627964,"score_gpt":0.27902178575121,"score_spread":0.22660282398493037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269258645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99878824,0.00019307234,0.000022751541,0.00012816938,0.000020312451,0.00070034823,0.00000909372,0.0000092891805,0.00012872276],"genre_scores_gemma":[0.9990294,0.00003311275,0.00082549773,0.000017327295,0.000013418081,0.000024704827,0.0000048537368,0.000008367942,0.000043317224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990236,0.00008066706,0.00026922778,0.00017500768,0.00023848015,0.00021303062],"domain_scores_gemma":[0.9993967,0.0000901776,0.000096062424,0.00024751722,0.00007296629,0.00009660487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007791759,0.00011313143,0.00032632757,0.0000685166,0.000037858823,0.000007133931,0.00006730447,0.00008024705,0.000038992614],"category_scores_gemma":[0.00025215125,0.000064787484,0.00006531324,0.000123662,0.00014033256,0.00005344298,0.00008711313,0.00011862286,0.0000019635022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008274181,0.0010473967,0.7779081,0.000088427325,0.00005839024,0.000011917259,0.00010694848,5.8128234e-7,0.22001036,0.000030749936,0.000009517308,0.0006448611],"study_design_scores_gemma":[0.0045501683,0.00017914169,0.8113936,0.00014189225,0.00005143159,0.00004557357,0.00009456509,0.0011934049,0.18219395,0.000108319386,0.0000023456332,0.000045604826],"about_ca_topic_score_codex":0.00048273368,"about_ca_topic_score_gemma":0.00012282663,"teacher_disagreement_score":0.037816413,"about_ca_system_score_codex":0.000029549876,"about_ca_system_score_gemma":0.00003081539,"threshold_uncertainty_score":0.26419568},"labels":[],"label_agreement":null},{"id":"W2269305268","doi":"10.1200/jco.2006.24.18_suppl.7604","title":"Effect of complete response pre- and post- autologous stem cell transplantation in multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Surgery; Oncology; Stem cell; Urology","score_opus":0.062212870772762045,"score_gpt":0.42869730620342866,"score_spread":0.3664844354306666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269305268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789953,0.00036867437,0.000041078885,0.0008553317,0.00013517831,0.00037576514,0.000019481693,0.0000050944986,0.00029983808],"genre_scores_gemma":[0.9984825,0.00018674892,0.0009687882,0.00009307929,0.00010138483,0.0000044311046,0.000007706006,0.0000098555965,0.00014546367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587405,0.0019316458,0.0015582492,0.00014472687,0.0002843339,0.00020699605],"domain_scores_gemma":[0.98734915,0.011440134,0.00071611383,0.00010789181,0.00018489221,0.00020180127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040566344,0.00011331558,0.0011555413,0.00021448804,0.000022617658,0.0000037866514,0.00007545532,0.00024731667,0.000014940914],"category_scores_gemma":[0.0011321896,0.00007529432,0.00021406493,0.000096987686,0.00018572343,0.000063436266,0.000017061117,0.0005037642,0.0000047422254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18702179,0.001200953,0.6290362,0.00023480228,0.000099230696,0.0032304379,0.00011331519,0.000026105356,0.024865245,0.000004878189,0.00007362672,0.1540934],"study_design_scores_gemma":[0.02624316,0.041633014,0.92607635,0.0000983023,0.00015557244,0.00046871835,0.000020107549,0.00039979146,0.004448279,0.000016676628,0.00039264833,0.000047378933],"about_ca_topic_score_codex":0.00015923814,"about_ca_topic_score_gemma":0.00012935816,"teacher_disagreement_score":0.29704013,"about_ca_system_score_codex":0.00008135054,"about_ca_system_score_gemma":0.00044039238,"threshold_uncertainty_score":0.30704132},"labels":[],"label_agreement":null},{"id":"W2272567705","doi":"10.1093/annonc/mdv563","title":"Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Prospective cohort study; Internal medicine","score_opus":0.10137213430937522,"score_gpt":0.38299706551908197,"score_spread":0.2816249312097068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272567705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922196,0.00005678036,0.0000040722543,0.00055725157,0.000031741693,0.005587314,0.0006788595,0.000007690863,0.0008566662],"genre_scores_gemma":[0.99911046,0.000011334843,0.00016989747,0.00004763878,0.000013061453,0.00034563305,0.0002442367,0.00001305776,0.000044672128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982189,0.00017438852,0.00058891246,0.00035903614,0.0004236728,0.00023508497],"domain_scores_gemma":[0.99791914,0.00019537582,0.00044310404,0.00023090826,0.0010104857,0.00020099709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025713083,0.00017845766,0.00067486486,0.00014941514,0.000021368567,0.0000062554163,0.000071430346,0.000107901564,0.000007142546],"category_scores_gemma":[0.00034082934,0.00014344623,0.000044835546,0.00022098426,0.00024013086,0.0001348219,0.00004456374,0.00012078827,0.0000012771196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046459753,0.023102313,0.9143981,0.00006691004,0.00039118945,0.00006268392,0.006349656,3.7432946e-7,0.00024316621,0.0000015155441,0.0014490983,0.0074752793],"study_design_scores_gemma":[0.04370117,0.12854707,0.80384946,0.00009377075,0.00004864463,0.000010309641,0.0015041301,0.00006626067,0.021849422,0.000014463129,0.0002183043,0.00009697198],"about_ca_topic_score_codex":0.00019419786,"about_ca_topic_score_gemma":0.00057385094,"teacher_disagreement_score":0.110548586,"about_ca_system_score_codex":0.00010696934,"about_ca_system_score_gemma":0.00035756818,"threshold_uncertainty_score":0.58495677},"labels":[],"label_agreement":null},{"id":"W2278895774","doi":"10.1182/blood.v122.21.5398.5398","title":"Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Bortezomib; Thalidomide; Plasma cell leukemia; Dexamethasone; Multiple myeloma; Internal medicine; Gastroenterology; Melphalan; Neutropenia; Toxicity; Oncology","score_opus":0.02664593212057632,"score_gpt":0.27908132835494825,"score_spread":0.25243539623437194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278895774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902239,0.005460282,0.000037769023,0.000589065,0.000038745737,0.002081008,0.00007412125,0.000025073487,0.001470069],"genre_scores_gemma":[0.990717,0.0024967983,0.0036465349,0.000065925866,0.00012382495,0.0005728547,0.000043355216,0.00003178186,0.002301943],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887717,0.000036715228,0.00025568876,0.0002670234,0.0002059193,0.00035751238],"domain_scores_gemma":[0.99855477,0.00068444293,0.000086404645,0.00035453806,0.0000991804,0.00022067285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010526216,0.0001966946,0.00037642042,0.000072247836,0.000102752856,0.000021305,0.00008062951,0.000087328706,0.00024298379],"category_scores_gemma":[0.00006781952,0.00011294206,0.00014814244,0.00008020143,0.00012359206,0.000064296124,0.000025590096,0.00009268955,0.000036241494],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027480233,0.011938736,0.21117356,0.0013018177,0.0048264917,0.00018173532,0.0020837148,0.0000054516154,0.18582155,0.00011718681,0.006658549,0.5731432],"study_design_scores_gemma":[0.06154656,0.0050408295,0.20342827,0.00007255629,0.0014358422,0.00013048289,0.00046109373,0.0008900158,0.7137274,0.00014453352,0.012885598,0.00023680419],"about_ca_topic_score_codex":0.00051838707,"about_ca_topic_score_gemma":0.000038859464,"teacher_disagreement_score":0.5729064,"about_ca_system_score_codex":0.000052711996,"about_ca_system_score_gemma":0.00015160927,"threshold_uncertainty_score":0.46056437},"labels":[],"label_agreement":null},{"id":"W2280981145","doi":"10.1182/blood.v122.21.5403.5403","title":"Implementing Cybord As First-Line Therapy For Transplant-Eligible Multiple Myeloma Patients : A Single-Center Preliminary Comparaison","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Multiple myeloma; Regimen; Single Center; Lenalidomide; Surgery; Autologous stem-cell transplantation; Internal medicine; Median follow-up; Chemotherapy","score_opus":0.041184436500048945,"score_gpt":0.30488826471424446,"score_spread":0.2637038282141955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280981145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355507,0.00030105177,0.00019067232,0.00051101623,0.00007031966,0.0041902266,0.0001839948,0.00010716932,0.00089046615],"genre_scores_gemma":[0.9950038,0.00009565753,0.0020193243,0.00025860275,0.00014791706,0.001059027,0.0010407781,0.00005972973,0.0003151567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997788,0.000038576465,0.00041450292,0.00043640565,0.00040234032,0.00092017034],"domain_scores_gemma":[0.99875087,0.00023854827,0.0001049685,0.00033855977,0.00024466738,0.000322393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111279915,0.0002911406,0.0003942008,0.00014012288,0.00027405107,0.000061022263,0.00014787761,0.00009286366,0.0003826901],"category_scores_gemma":[0.000085655454,0.00022936074,0.00020386642,0.00013223013,0.000042206608,0.0001607009,0.00005242241,0.00012950397,0.00018836095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023310226,0.010958147,0.94585145,0.0002018035,0.0005565138,0.0000369043,0.00047760908,8.153783e-7,0.004084674,0.000008405505,0.0009139539,0.034578692],"study_design_scores_gemma":[0.1262421,0.016523248,0.76515293,0.00040633042,0.0002865409,0.00009469219,0.0001221602,0.0017600979,0.069266714,0.000145639,0.019453632,0.00054593856],"about_ca_topic_score_codex":0.0002986164,"about_ca_topic_score_gemma":0.00010041865,"teacher_disagreement_score":0.18069854,"about_ca_system_score_codex":0.000045131503,"about_ca_system_score_gemma":0.000044388416,"threshold_uncertainty_score":0.93530595},"labels":[],"label_agreement":null},{"id":"W2281277401","doi":"10.1158/0008-5472.can-15-2406","title":"Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institutes of Health","keywords":"Medicine; Adiponectin; Overweight; Multiple myeloma; Internal medicine; Quartile; Body mass index; Obesity; Population; Confidence interval; Cancer; Insulin resistance; Environmental health","score_opus":0.0788986461537108,"score_gpt":0.3767806936737487,"score_spread":0.29788204752003794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281277401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722826,0.0007967857,0.000015352645,0.0003834614,0.000015848109,0.00086339074,0.00040697824,0.000021633414,0.00026830836],"genre_scores_gemma":[0.9987087,0.0003322784,0.0001052504,0.0000122840565,0.000048531743,0.00019541831,0.000008775834,0.000036785852,0.00055192143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969784,0.00044813257,0.00028574403,0.00044448403,0.0010929095,0.0007503272],"domain_scores_gemma":[0.99717104,0.0015655834,0.00014032444,0.0003352009,0.000471857,0.00031599827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013483096,0.00016336663,0.00042369493,0.00046129923,0.00013294333,0.000022339007,0.00012339285,0.00012362325,0.0002902834],"category_scores_gemma":[0.0042322595,0.0000987172,0.00004352734,0.0007402912,0.00033016197,0.00013398784,0.00012958334,0.0004391316,0.000012170179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047870135,0.00026507457,0.9301427,0.00012603057,0.00025580142,0.00020286739,0.00037712738,0.0000025120903,0.035785966,0.000008208332,0.0000722906,0.032282747],"study_design_scores_gemma":[0.008527398,0.0004199507,0.9418162,0.0023609747,0.00002108598,0.000010922151,0.00017928376,0.000108685526,0.04632967,0.00007639157,0.000039714345,0.00010971793],"about_ca_topic_score_codex":0.0014297117,"about_ca_topic_score_gemma":0.0025885364,"teacher_disagreement_score":0.03217303,"about_ca_system_score_codex":0.00051992765,"about_ca_system_score_gemma":0.000410117,"threshold_uncertainty_score":0.50667155},"labels":[],"label_agreement":null},{"id":"W2286499359","doi":"10.1016/j.clml.2015.07.339","title":"Continuous Lenalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and Renal Impairment in the First Trial","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Thalidomide; Melphalan; Internal medicine; Prednisone; Dialysis; Oncology; Surgery; Gastroenterology","score_opus":0.04745924129519422,"score_gpt":0.3306398906729909,"score_spread":0.28318064937779663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286499359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913945,0.0010330433,0.00005043073,0.0008767657,0.00015237466,0.0063121547,0.00010823618,0.000027145468,0.000045338424],"genre_scores_gemma":[0.99628234,0.00055448094,0.0012389778,0.00032174517,0.0003274574,0.0010330459,0.00010689474,0.000046520014,0.000088519686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996657,0.00034230846,0.0010400079,0.00066103466,0.0006753698,0.00062423816],"domain_scores_gemma":[0.9909191,0.0072397445,0.00034469622,0.00072674354,0.00026930493,0.0005004149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012467975,0.0004279589,0.0010549582,0.000111511894,0.00019056561,0.00006956601,0.0002340685,0.00021648195,0.000007891533],"category_scores_gemma":[0.0018635874,0.00020729717,0.00025782312,0.00024983144,0.0007322493,0.0001077568,0.000081143924,0.00015296669,0.0000057666975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17820291,0.003284022,0.46379602,0.00005439188,0.00045456947,0.00019572611,0.0009451981,0.000008519453,0.000006068558,0.00001562197,0.00048135893,0.3525556],"study_design_scores_gemma":[0.29012692,0.015756061,0.68850654,0.0001111629,0.00026248104,0.000020959398,0.00031729726,0.0011218808,0.000098758,0.000038425456,0.003484048,0.00015549826],"about_ca_topic_score_codex":0.00075650006,"about_ca_topic_score_gemma":0.00077947543,"teacher_disagreement_score":0.3524001,"about_ca_system_score_codex":0.00058671535,"about_ca_system_score_gemma":0.00073253043,"threshold_uncertainty_score":0.8453333},"labels":[],"label_agreement":null},{"id":"W2286812527","doi":"10.1182/blood.v122.21.3396.3396","title":"Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Hazard ratio; Oncology; Proportional hazards model; Cohort; Multivariate analysis; Single Center; Median follow-up; Progression-free survival; Surgery; Overall survival; Confidence interval","score_opus":0.028791436224282343,"score_gpt":0.2744883921870438,"score_spread":0.24569695596276145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286812527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974685,0.00006722335,0.000016124803,0.00016946036,0.00004477794,0.0015702195,0.00027138906,0.0000059374347,0.0003863799],"genre_scores_gemma":[0.9983988,0.0000051443867,0.0008985199,0.00007445906,0.000035011446,0.00028887158,0.000043097923,0.00001652622,0.00023958323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885833,0.000036498717,0.00027348535,0.00016344384,0.00042555472,0.00024268629],"domain_scores_gemma":[0.999239,0.0001229584,0.00007998232,0.0002921266,0.00018132979,0.00008456579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012353167,0.00010555809,0.0002389223,0.00006603997,0.000017434697,0.00000920765,0.000111954905,0.00006008504,0.00014026261],"category_scores_gemma":[0.00020425432,0.000066469416,0.00010276863,0.00012543962,0.000049958504,0.00007049423,0.000036080026,0.00010063871,0.000015176251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053822057,0.008589964,0.9848527,0.00016350932,0.00023830439,0.000008150446,0.0013718372,6.8238194e-8,0.0026093246,0.0000049375694,0.00033105406,0.0012919455],"study_design_scores_gemma":[0.020056013,0.0014990801,0.9729084,0.00013000381,0.000104968836,0.0000013979397,0.000054853983,0.000048297243,0.0050505153,0.000023519679,0.00007267141,0.000050272374],"about_ca_topic_score_codex":0.00063167553,"about_ca_topic_score_gemma":0.000031536372,"teacher_disagreement_score":0.019517792,"about_ca_system_score_codex":0.000017127468,"about_ca_system_score_gemma":0.000039776434,"threshold_uncertainty_score":0.27105442},"labels":[],"label_agreement":null},{"id":"W2290370781","doi":"10.1182/blood.v124.21.3458.3458","title":"Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Multiple myeloma; Progression-free survival; Melphalan; Clinical endpoint; Gastroenterology; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.04400510173070445,"score_gpt":0.3413703157451652,"score_spread":0.29736521401446075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290370781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558437,0.000020480356,0.0000040134364,0.0005948651,0.00015022539,0.0014829691,0.0018129349,0.000038261223,0.0003118967],"genre_scores_gemma":[0.99905753,0.000027204582,0.00007468063,0.00006926958,0.00012679525,0.0000726442,0.0004638689,0.000029615005,0.00007838992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965809,0.0008794822,0.00078690273,0.00045943612,0.00080083613,0.0004924143],"domain_scores_gemma":[0.98985535,0.008741514,0.00020822647,0.00085099076,0.00010706776,0.00023686072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309165,0.00029706402,0.00075909874,0.00014929828,0.00009718634,0.000023355342,0.00025719972,0.00014294943,0.000035227964],"category_scores_gemma":[0.007215588,0.00017155509,0.00035690752,0.0002408427,0.00008437025,0.00006291266,0.0000420026,0.00027508667,0.000046316036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28564167,0.005179401,0.7067604,0.000012824217,0.00029473347,0.000043864038,0.00060427596,0.000008799936,0.00022201374,0.0000029154285,0.00008673513,0.0011423819],"study_design_scores_gemma":[0.29245743,0.0030483566,0.70269525,0.000100699566,0.000069361995,4.409355e-7,0.000022916587,0.00005034115,0.0013461997,0.0000100221605,0.00008785997,0.00011114372],"about_ca_topic_score_codex":0.014649942,"about_ca_topic_score_gemma":0.004136619,"teacher_disagreement_score":0.010513322,"about_ca_system_score_codex":0.00009726698,"about_ca_system_score_gemma":0.0001628384,"threshold_uncertainty_score":0.9919116},"labels":[],"label_agreement":null},{"id":"W2290979025","doi":"10.1016/j.thromres.2016.03.006","title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review","year":2016,"lang":"en","type":"review","venue":"Thrombosis Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Venous thromboembolism; Thalidomide; Surgery; Thrombosis","score_opus":0.16211921737364837,"score_gpt":0.4347705680913401,"score_spread":0.27265135071769175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290979025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053532445,0.97466445,0.0000012825901,0.00009592082,0.000030895055,0.022755537,0.00025485925,0.00010288944,0.0015588562],"genre_scores_gemma":[0.0013446965,0.98919123,0.00008848411,0.000039674553,0.00008464592,0.0068607694,0.00065216486,0.0002802082,0.0014581183],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9874355,0.0033160867,0.0019805892,0.0015698996,0.003621391,0.002076498],"domain_scores_gemma":[0.9924243,0.0025185314,0.0004950218,0.0024553747,0.0012595869,0.0008471518],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027546573,0.0011262855,0.008383721,0.0019040677,0.0002770516,0.00010598956,0.00088940526,0.0005433385,0.00066176214],"category_scores_gemma":[0.0039691473,0.0005678085,0.00085651944,0.0033001462,0.00058843143,0.00021421662,0.00043641933,0.0016618839,0.0034150726],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016185001,0.0011862859,0.0026513995,0.90988404,0.0016865619,0.00036420717,0.000026486536,4.7293365e-9,0.0000023382427,0.000008675202,0.00069047837,0.0833377],"study_design_scores_gemma":[0.004574055,0.0017545098,0.002116156,0.96685,0.0015026121,0.00006233094,0.000012811844,0.000002468829,0.000009512489,0.0000058403193,0.022534655,0.00057507015],"about_ca_topic_score_codex":0.00045403853,"about_ca_topic_score_gemma":0.00012614095,"teacher_disagreement_score":0.08276263,"about_ca_system_score_codex":0.002300722,"about_ca_system_score_gemma":0.0013076256,"threshold_uncertainty_score":0.99967736},"labels":[],"label_agreement":null},{"id":"W2291176625","doi":"10.1158/1535-7163.mct-15-0730","title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Venetoclax; Multiple myeloma; Bortezomib; Cancer research; Bcl-xL; Lenalidomide; Medicine; Pharmacology; Biology; Leukemia; Apoptosis; Immunology; Programmed cell death; Chronic lymphocytic leukemia; Genetics","score_opus":0.05085372977947655,"score_gpt":0.3446252469714147,"score_spread":0.29377151719193817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291176625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889454,0.0034097044,0.0018963291,0.003294719,0.00007429583,0.0020101673,0.00018308342,0.000038734623,0.00014756432],"genre_scores_gemma":[0.9965779,0.0009420507,0.0006395005,0.0007512691,0.000050893326,0.0006091215,0.000009765876,0.00004224913,0.00037721253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978141,0.00038962826,0.00031514623,0.0004559638,0.0005171629,0.00050796306],"domain_scores_gemma":[0.9988443,0.00028821427,0.000090864494,0.00036193224,0.00017424824,0.00024038588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003700398,0.00025195372,0.00036277025,0.00014374459,0.000112999856,0.000017837001,0.00019211399,0.00013836344,0.000050207873],"category_scores_gemma":[0.00009257448,0.00013686102,0.00008222678,0.00031724034,0.00019606644,0.000076250784,0.00013153513,0.0002168082,0.000008895876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013356276,0.00026021167,0.010489531,0.000041299143,0.00025651263,0.00013152395,0.0007045269,0.00017007378,0.93771106,0.000013032439,0.0001872851,0.03667867],"study_design_scores_gemma":[0.010217612,0.0012726269,0.047980227,0.00039113665,0.00013537926,0.000024067427,0.00010053314,0.0065126163,0.9279104,0.00016059815,0.0050722645,0.00022257665],"about_ca_topic_score_codex":0.00011004788,"about_ca_topic_score_gemma":0.00004856081,"teacher_disagreement_score":0.037490696,"about_ca_system_score_codex":0.00044189522,"about_ca_system_score_gemma":0.00041106733,"threshold_uncertainty_score":0.5581031},"labels":[],"label_agreement":null},{"id":"W2295624617","doi":"10.1002/ajh.24351","title":"Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice","year":2016,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Medicine; Retrospective cohort study; Central nervous system; Clinical Practice; Intensive care medicine; Oncology; Internal medicine; Family medicine","score_opus":0.025557997983065527,"score_gpt":0.3449735239218295,"score_spread":0.319415525938764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295624617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977887,0.00015262204,0.000600156,0.00041625075,0.00023787917,0.000688996,0.000033852415,0.00001010319,0.00007139506],"genre_scores_gemma":[0.99671227,0.000070983115,0.0030272796,0.00007492466,0.00005493711,0.000019678757,0.000006741889,0.00001714539,0.000016046044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964323,0.000646636,0.0014275077,0.00030487866,0.0007324036,0.00045626526],"domain_scores_gemma":[0.9966439,0.0006946689,0.0012626821,0.00026398775,0.00076383166,0.0003709125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065921654,0.00020551746,0.0011954377,0.000255538,0.000053794523,0.000005743599,0.00018328588,0.00006756103,0.000015070889],"category_scores_gemma":[0.0026352173,0.000120976896,0.00017196432,0.000280787,0.00047692476,0.00018431831,0.00007757999,0.00033556024,0.000009541809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00411747,0.009905272,0.9674785,0.00003672379,0.0007320056,0.0011849815,0.0004941077,0.0000023176765,0.00018496496,0.00007096075,0.00029571002,0.015496954],"study_design_scores_gemma":[0.025574002,0.01305693,0.9546252,0.00027903132,0.00013918726,0.00074185955,0.0050067166,0.00008229148,0.00019492369,0.000002909247,0.0001928913,0.00010406764],"about_ca_topic_score_codex":0.0007259763,"about_ca_topic_score_gemma":0.00018935754,"teacher_disagreement_score":0.021456532,"about_ca_system_score_codex":0.00058074686,"about_ca_system_score_gemma":0.00036842018,"threshold_uncertainty_score":0.49332947},"labels":[],"label_agreement":null},{"id":"W2296026603","doi":"10.1200/jco.2009.27.15_suppl.8597","title":"A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Refractory (planetary science); Internal medicine; Proteasome inhibitor; Lenalidomide; Oncology; Gastroenterology; Pharmacology","score_opus":0.29832626792209627,"score_gpt":0.5394487551109878,"score_spread":0.2411224871888915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296026603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272424,0.00036383737,0.000024710143,0.004267273,0.0005464268,0.00062689936,0.0000031072614,0.000006595504,0.0014369261],"genre_scores_gemma":[0.9958917,0.00041576783,0.002205726,0.0006368616,0.0007792706,0.0000044319336,0.0000034408208,0.000008796204,0.0000540225],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941022,0.0013267825,0.0035961103,0.00021616135,0.00048993557,0.00026882382],"domain_scores_gemma":[0.9820162,0.01473994,0.0020925663,0.00023348017,0.00051071023,0.0004070932],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008934711,0.00013903655,0.0014969538,0.00018048167,0.000051202434,0.000009183331,0.00016943665,0.000402911,0.00002607654],"category_scores_gemma":[0.053441767,0.00008218956,0.00037152474,0.00022777375,0.00036228672,0.00009814376,0.00004260412,0.0016060761,0.00000474699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11499598,0.016898546,0.1818444,0.000011716637,0.00016621572,0.0006848355,0.000060389728,0.0000015023616,0.00029477585,0.000041249154,0.00042516482,0.6845752],"study_design_scores_gemma":[0.29531616,0.08572406,0.6131395,0.000096574884,0.00013679767,0.00014135455,0.000059217757,0.0012659824,0.000028660343,0.00034341664,0.0036967918,0.000051449344],"about_ca_topic_score_codex":0.000026213767,"about_ca_topic_score_gemma":0.000030164614,"teacher_disagreement_score":0.68452376,"about_ca_system_score_codex":0.00009882839,"about_ca_system_score_gemma":0.001273934,"threshold_uncertainty_score":0.9545315},"labels":[],"label_agreement":null},{"id":"W2297463033","doi":"10.1172/jci.insight.84738","title":"Identification of human plasma cells with a lamprey monoclonal antibody","year":2016,"lang":"en","type":"article","venue":"JCI Insight","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Winship Cancer Institute; Hospital for Sick Children; University of Toronto; National Cancer Institute; National Institutes of Health; King's College London; Emory University","keywords":"Lamprey; CD38; Monoclonal antibody; Epitope; Antigen; Immunology; Antibody; Biology; Chemistry; Cell biology; Stem cell","score_opus":0.025972924445755014,"score_gpt":0.3216608443801227,"score_spread":0.2956879199343677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2297463033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952493,0.00003258371,0.000220856,0.00021216739,0.00003224413,0.00031718073,0.000023194376,0.000026924572,0.0038855765],"genre_scores_gemma":[0.9936946,0.000031996817,0.00022673029,0.00001302724,0.0000504065,0.000021658303,0.000033709646,0.000014858744,0.005912999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990857,0.000025979034,0.00020304078,0.0001929731,0.00031908494,0.00017320502],"domain_scores_gemma":[0.99932915,0.00004843737,0.00008665713,0.00029047605,0.00012571449,0.00011957004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000647723,0.0000944659,0.00017445625,0.000111201545,0.00004794161,0.000009122279,0.00006539828,0.000045776615,0.00019239313],"category_scores_gemma":[0.000024552304,0.0000494739,0.000044583674,0.0001081176,0.00008994299,0.000088962464,0.00002174132,0.000051052,0.00014777717],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032765916,0.00034016315,0.05022172,0.000044953238,0.000110599845,0.00007020606,0.00013841652,2.636966e-7,0.9451568,0.00027761274,0.00024324803,0.0030683605],"study_design_scores_gemma":[0.0035948358,0.00062795327,0.15770991,0.00012081854,0.00003779324,0.000015288437,0.000013768896,0.000054651995,0.8362639,0.000045497927,0.0014469707,0.00006861584],"about_ca_topic_score_codex":0.00004075234,"about_ca_topic_score_gemma":0.000021468351,"teacher_disagreement_score":0.1088929,"about_ca_system_score_codex":0.000044818735,"about_ca_system_score_gemma":0.00006173502,"threshold_uncertainty_score":0.21065699},"labels":[],"label_agreement":null},{"id":"W2299207322","doi":"10.1016/j.clml.2015.07.324","title":"Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone for Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the First Trial: Impact of Age","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Alberta Cancer Foundation; Royal Victoria Hospital","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Hazard ratio; Thalidomide; Prednisone; Internal medicine; Melphalan; Oncology; Randomized controlled trial; Gastroenterology; Surgery; Confidence interval","score_opus":0.05105834596086928,"score_gpt":0.34641336190987404,"score_spread":0.29535501594900476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299207322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928601,0.00030848477,0.000067701476,0.0002010514,0.00007817468,0.006002999,0.00026378199,0.00005464077,0.0001631044],"genre_scores_gemma":[0.99611944,0.00024249872,0.001853575,0.00015697404,0.00018700669,0.00084645307,0.00041431817,0.000087583314,0.0000921287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996042,0.00033818383,0.0011758986,0.0008191197,0.0007561921,0.000868616],"domain_scores_gemma":[0.99341315,0.0042464905,0.00039918028,0.00083371904,0.00034436453,0.0007631134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009594138,0.00061326567,0.0016447076,0.00021688094,0.00012426317,0.00007057993,0.00029263375,0.00028716607,0.000010202449],"category_scores_gemma":[0.0011108429,0.00031255904,0.00043806902,0.00044149623,0.00055849424,0.00017815016,0.00004269275,0.00020199256,0.000010472717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25488105,0.003276519,0.6235626,0.00009044432,0.00068988185,0.0009801271,0.00071947154,0.000021810498,0.00001503206,0.0000059448435,0.00024643636,0.1155107],"study_design_scores_gemma":[0.3227519,0.026645869,0.6485217,0.000313764,0.0003130963,0.000052960324,0.00013724738,0.00048372868,0.00011725497,0.000023935803,0.00039829014,0.00024018886],"about_ca_topic_score_codex":0.0027127047,"about_ca_topic_score_gemma":0.0017342907,"teacher_disagreement_score":0.11527052,"about_ca_system_score_codex":0.0010046862,"about_ca_system_score_gemma":0.0016531224,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W2300100795","doi":"10.1200/jco.2009.27.15_suppl.e19532","title":"Snk/Plk2 CpG methylation in patients with multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; CpG site; Medicine; DNA methylation; Population; CDKN2B; Molecular biology; Cancer research; Internal medicine; Cancer; Biology; CDKN2A; Gene; Genetics; Gene expression","score_opus":0.09568431572473651,"score_gpt":0.4643688400629813,"score_spread":0.3686845243382448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300100795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939726,0.00007378052,0.00014231139,0.0031489257,0.00019258149,0.00030416748,0.0000022915922,0.0000065825675,0.0021567324],"genre_scores_gemma":[0.9929189,0.000055206383,0.0057776035,0.0008283155,0.000293188,0.0000027567494,0.000009488208,0.000009112562,0.000105442545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972351,0.0003460075,0.0014499984,0.00016135516,0.00053868926,0.00026884433],"domain_scores_gemma":[0.99689376,0.0012650697,0.00077718095,0.00015895367,0.00047865705,0.00042636183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001520034,0.00011757812,0.0009908413,0.00021853263,0.000025930323,0.000006746173,0.00010130652,0.00024292294,0.00010779559],"category_scores_gemma":[0.0042973123,0.00007118405,0.00020667074,0.0001964828,0.00008099686,0.00015221919,0.000016604625,0.0007738624,0.000025817537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01105949,0.0028782205,0.6707494,0.000004415319,0.00010818934,0.00041137874,0.000023561968,0.000008616136,0.000022139398,0.000017264987,0.000276733,0.31444058],"study_design_scores_gemma":[0.033327438,0.027699964,0.93442047,0.00006672544,0.00007541952,0.000026988164,0.000016487164,0.00015460992,0.00005883987,0.00021690107,0.0038761431,0.00006003738],"about_ca_topic_score_codex":0.00001476673,"about_ca_topic_score_gemma":0.000048831953,"teacher_disagreement_score":0.31438056,"about_ca_system_score_codex":0.00019647567,"about_ca_system_score_gemma":0.0006861765,"threshold_uncertainty_score":0.5144595},"labels":[],"label_agreement":null},{"id":"W2300177903","doi":"10.1111/bjh.14038","title":"Increased microcirculation detected by dynamic contrast‐enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"Dietmar Hopp Stiftung; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Asymptomatic; Magnetic resonance imaging; Multiple myeloma; Hazard ratio; Radiology; Bone marrow; Nuclear medicine; Dynamic contrast; Clinical significance; Univariate analysis; Internal medicine; Multivariate analysis; Confidence interval; Monoclonal; Monoclonal antibody","score_opus":0.006446553114684086,"score_gpt":0.25826079424191345,"score_spread":0.2518142411272294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300177903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98358613,0.013788788,0.0015270113,0.0004378047,0.00004385544,0.00051839364,0.000047609887,0.000012878516,0.000037527727],"genre_scores_gemma":[0.9978973,0.0005331639,0.0013990459,0.000060682283,0.000012390011,0.00002444468,0.0000072977205,0.000023126875,0.00004252264],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797046,0.00022770793,0.00085494877,0.0002199043,0.00033504007,0.0003919314],"domain_scores_gemma":[0.9984243,0.00045510425,0.00042907536,0.00014606475,0.00037720014,0.0001682827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027138364,0.00014569837,0.00070645584,0.00022982949,0.000036050318,0.000013945299,0.00013682933,0.00008495397,0.00014741562],"category_scores_gemma":[0.0010995927,0.00012644651,0.00010507605,0.00022931692,0.00021910343,0.00013660769,0.000021219477,0.00017891546,0.000010006944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006207553,0.0003709515,0.17039622,0.00019703608,0.000059222595,0.008229288,0.00007311568,2.1141705e-7,0.59028137,0.0000030291467,0.00023820355,0.22953059],"study_design_scores_gemma":[0.011415097,0.00045557896,0.85744387,0.0033207878,0.00007926397,0.036761258,0.000047135043,0.0004758809,0.08959733,0.00023823419,0.000029008535,0.000136563],"about_ca_topic_score_codex":0.00015409912,"about_ca_topic_score_gemma":0.00010795103,"teacher_disagreement_score":0.68704766,"about_ca_system_score_codex":0.00014852728,"about_ca_system_score_gemma":0.00022621194,"threshold_uncertainty_score":0.5156339},"labels":[],"label_agreement":null},{"id":"W2300531214","doi":"10.1182/blood.v116.21.2956.2956","title":"Incidence of Plasma Cell Myeloma In Ethnic Chinese In British Columbia, a 30-Year Survey From 1975–2004","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Demography; Incidence (geometry); Population; Ethnic group; Census; Cancer registry; Medicine; Plasma Cell Myeloma; Poisson regression; Multiple myeloma; Geography; Internal medicine","score_opus":0.01727314790618624,"score_gpt":0.28387087946687944,"score_spread":0.2665977315606932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300531214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802023,0.0003346883,6.233128e-7,0.000015246065,0.00006840647,0.0005160202,0.0002320337,0.00001721703,0.0007955554],"genre_scores_gemma":[0.99854815,0.00009605107,0.00060360954,0.000020012927,0.00005150197,0.000044539847,0.00014109611,0.000024856352,0.0004701552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983679,0.00013508489,0.00036578826,0.000351776,0.00039920537,0.00038024565],"domain_scores_gemma":[0.9988871,0.0003440145,0.00007750514,0.00039211157,0.00009021715,0.00020903113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004461369,0.00011628861,0.0004190899,0.00010773147,0.000023510533,0.000033674158,0.00018166563,0.00017024278,0.0007904169],"category_scores_gemma":[0.00094776787,0.00015247318,0.000060994153,0.0004996392,0.00009487538,0.000078529854,0.00009073055,0.0005196361,0.00008890219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009144113,0.0018277363,0.9707741,0.000049540624,0.000034374054,0.0009546121,0.00013563692,5.19205e-7,0.022963043,1.5694464e-7,0.00006687407,0.0031019277],"study_design_scores_gemma":[0.013409915,0.00021327064,0.9815542,0.00015329232,0.000018087698,0.000030333005,0.000026848014,0.00008100846,0.004327661,0.00005811384,0.000012822015,0.00011441043],"about_ca_topic_score_codex":0.41389778,"about_ca_topic_score_gemma":0.8992146,"teacher_disagreement_score":0.48531684,"about_ca_system_score_codex":0.00003257329,"about_ca_system_score_gemma":0.00026333946,"threshold_uncertainty_score":0.8654511},"labels":[],"label_agreement":null},{"id":"W2300957547","doi":"10.1182/blood.v122.21.5529.5529","title":"Second Autologous Stem Cell Transplant As Salvage Therapy For Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Salvage therapy; Lenalidomide; Multiple myeloma; Surgery; Bortezomib; Thalidomide; Transplantation; Internal medicine; Median follow-up; Chemotherapy; Oncology","score_opus":0.021871443546456665,"score_gpt":0.2687739272912105,"score_spread":0.24690248374475385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300957547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914861,0.0009612762,0.00005981888,0.0002783309,0.00006231033,0.0023299071,0.00011365949,0.00011630109,0.004592342],"genre_scores_gemma":[0.99144393,0.00012965835,0.0011698755,0.00028463622,0.000102822494,0.0006263833,0.000114682014,0.000043086355,0.006084903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986828,0.000039128856,0.00021398124,0.0003270794,0.00022840778,0.0005085833],"domain_scores_gemma":[0.99901044,0.00021618711,0.000047325335,0.00032993648,0.00008740839,0.00030872633],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008093216,0.00020226245,0.00031086666,0.00008419245,0.00010555414,0.00003375444,0.00011528702,0.000118298994,0.0010503656],"category_scores_gemma":[0.000013050878,0.00014722567,0.00016163505,0.0000750583,0.00004464106,0.00007799059,0.000013317661,0.00013354288,0.0005697152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025369015,0.009193992,0.24785292,0.000879857,0.0018806253,0.0012271248,0.0026349328,0.0000011037342,0.50688493,0.00010110215,0.006068247,0.22073823],"study_design_scores_gemma":[0.042498864,0.0031086686,0.34294468,0.000060558767,0.00014497431,0.00025673784,0.00017023402,0.0004056302,0.59969765,0.00011396952,0.010297731,0.0003002946],"about_ca_topic_score_codex":0.000110855275,"about_ca_topic_score_gemma":0.000032073123,"teacher_disagreement_score":0.22043794,"about_ca_system_score_codex":0.000022261433,"about_ca_system_score_gemma":0.000098984725,"threshold_uncertainty_score":0.9998628},"labels":[],"label_agreement":null},{"id":"W2301325588","doi":"10.1182/blood.v122.21.3145.3145","title":"Abnormalities Of FAM46C, AHCYL1, CDC14A and CDKN2C Genes Located At Chromosome 1p Detected By QM-FISH Identifies Deletion Of 1p32.3 Covered CDKN2C Is An Independent Adverse Prognostic Marker In Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Chromosome; Locus (genetics); Gene; Biology; Genetics; Molecular biology","score_opus":0.01682184609377475,"score_gpt":0.24346923579602278,"score_spread":0.22664738970224804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301325588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648374,0.0011887783,0.0000083978875,0.000066632114,0.00004239569,0.0017172747,0.0003487461,0.000053724332,0.00009030367],"genre_scores_gemma":[0.9978879,0.0004883825,0.00021666352,0.00004140441,0.000028620894,0.0002371329,0.000512195,0.00004414085,0.000543575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742687,0.00018524838,0.00068646227,0.00048442264,0.0006818664,0.0005351374],"domain_scores_gemma":[0.9983674,0.00023107378,0.00025003802,0.0004447976,0.00040273814,0.0003038992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022106277,0.000316192,0.0005941882,0.00031895284,0.00008822137,0.000029314171,0.00015110508,0.00021194399,0.0005180503],"category_scores_gemma":[0.0003841605,0.00028090706,0.00009734754,0.00031555514,0.00027181618,0.0003817378,0.00016424253,0.00017162791,0.000032139855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006413201,0.0014240752,0.73972946,0.00056628016,0.00038208766,0.00008657036,0.0005866605,0.0000026313035,0.25461072,0.0000011988385,0.00019113928,0.001777846],"study_design_scores_gemma":[0.009777323,0.0006147588,0.6837298,0.00021133244,0.00015236894,0.0000625241,0.00054292334,0.0007656046,0.30391338,0.000015881018,0.000037316844,0.00017672508],"about_ca_topic_score_codex":0.0030164716,"about_ca_topic_score_gemma":0.0012509559,"teacher_disagreement_score":0.05599962,"about_ca_system_score_codex":0.00009383287,"about_ca_system_score_gemma":0.00011074929,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W2301842411","doi":"10.1016/j.clml.2015.07.298","title":"A single centre retrospective analysis of diagnostic fluorescence in situ hybridisation reveals distinct groups of cytogenetic abnormalities, which affect early survival of new myeloma diagnosis","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Multivariate analysis; Fish <Actinopterygii>; Internal medicine; Oncology; Biology; Multivariate statistics; Affect (linguistics); Medicine; Pathology; Genetics; Gene; Chromosome; Psychology","score_opus":0.061943823010377916,"score_gpt":0.3387572941521385,"score_spread":0.2768134711417606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301842411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685585,0.0006086532,0.00007029864,0.00012213986,0.00019027016,0.001068315,0.00025679605,0.000041650335,0.00078604213],"genre_scores_gemma":[0.99817985,0.0002512317,0.00078118674,0.000018690156,0.00018182836,0.000053914882,0.00034204344,0.000053528776,0.00013773248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935688,0.00095281145,0.0023836496,0.0008902309,0.0014575648,0.00074696494],"domain_scores_gemma":[0.9901641,0.0058037266,0.0010275323,0.0010896049,0.0009999737,0.00091505604],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017892357,0.00046984895,0.0024617622,0.0006845347,0.00004628362,0.000024173954,0.00042075847,0.00034662374,0.00008823686],"category_scores_gemma":[0.023926541,0.00042406312,0.0007257078,0.0029219422,0.00053547707,0.00020115901,0.0002467601,0.00026798467,0.000020693476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018749194,0.0014206916,0.9324846,0.00021760035,0.0015223023,0.00022277827,0.00075597496,0.00003259233,0.0014123775,0.00014274029,0.00020010692,0.05971328],"study_design_scores_gemma":[0.008032766,0.002420636,0.9753942,0.0006805049,0.0016433285,0.000010440309,0.00024935632,0.0005146965,0.010378025,0.0003624111,0.0000147749215,0.00029886016],"about_ca_topic_score_codex":0.0038445655,"about_ca_topic_score_gemma":0.0035298422,"teacher_disagreement_score":0.059414424,"about_ca_system_score_codex":0.0016271624,"about_ca_system_score_gemma":0.0016934394,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W2308400377","doi":"10.1016/j.clml.2015.07.338","title":"Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Cryopreservation; Medicine; Stem cell; Autologous stem-cell transplantation; Multiple myeloma; Transplantation; Autologous blood; Surgery; Oncology; Internal medicine; Biology","score_opus":0.05442501528796141,"score_gpt":0.3211895658432269,"score_spread":0.2667645505552655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308400377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922035,0.0005391329,0.00023842673,0.0001372025,0.0009989209,0.00426794,0.0003642895,0.00040776198,0.00084282615],"genre_scores_gemma":[0.9935064,0.00018684058,0.002092103,0.00030299436,0.00031949993,0.00060711615,0.0008273565,0.00019467538,0.001963018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918679,0.00086638867,0.002572871,0.0017430395,0.001198831,0.0017509661],"domain_scores_gemma":[0.99311185,0.0025916565,0.0006710215,0.0013529521,0.00062042754,0.0016521211],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015088832,0.000887239,0.0018659108,0.00047196442,0.00024435436,0.000111855355,0.00074209605,0.0011530778,0.000043109103],"category_scores_gemma":[0.00050300406,0.00079175015,0.00078025984,0.000605506,0.0004140716,0.00032606858,0.00021215939,0.00065892213,0.00033824373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009156208,0.0026743915,0.63795567,0.0006576736,0.0003496432,0.0027439527,0.0005044737,0.00004095718,0.0011517453,0.000011915704,0.00093380985,0.3438196],"study_design_scores_gemma":[0.069032885,0.0038880769,0.9028697,0.00036067315,0.0005138414,0.00012619914,0.00014855791,0.003396038,0.018624503,0.000046123412,0.00031524734,0.00067815493],"about_ca_topic_score_codex":0.00027197797,"about_ca_topic_score_gemma":0.0003178038,"teacher_disagreement_score":0.3431414,"about_ca_system_score_codex":0.0014065125,"about_ca_system_score_gemma":0.0020419967,"threshold_uncertainty_score":0.99945337},"labels":[],"label_agreement":null},{"id":"W2308972734","doi":"10.1182/blood.v124.21.81.81","title":"Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Royal Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Clinical endpoint; Thalidomide; Interim analysis; Multiple myeloma; Melphalan; Adverse effect; Gastroenterology; Prednisone; Dexamethasone; Surgery; Randomized controlled trial","score_opus":0.011535121424371865,"score_gpt":0.26795987437220153,"score_spread":0.2564247529478297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308972734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968158,0.00007907338,0.000005468305,0.0002124051,0.00004229474,0.0026746297,0.000015787482,0.000022249684,0.0001322722],"genre_scores_gemma":[0.999395,0.00006323434,0.00021952362,0.000063122185,0.000054458465,0.00011203133,0.000025090185,0.000031139483,0.000036396945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981235,0.00038456215,0.00033353845,0.00037214492,0.000430872,0.0003553845],"domain_scores_gemma":[0.9938722,0.0053730984,0.0001262292,0.00040368756,0.000039982686,0.00018477763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007509769,0.00026597144,0.00067273306,0.00013418413,0.000118505224,0.00002772077,0.0000985109,0.00008592444,0.00000871554],"category_scores_gemma":[0.0035168685,0.00014177895,0.00006733539,0.00016267555,0.0001621782,0.00005702838,0.00007681852,0.00023422064,0.0000047791236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09156178,0.002032052,0.8629148,0.00017890778,0.00026357506,0.00008116221,0.00030662323,0.0000065456406,0.000118596974,0.000002668213,0.000011463686,0.042521834],"study_design_scores_gemma":[0.3284364,0.007707783,0.66087574,0.00033396218,0.00013834881,0.0000032121588,0.000009408036,0.00007680816,0.0022844034,0.000001647976,0.000041579846,0.000090713016],"about_ca_topic_score_codex":0.0003393977,"about_ca_topic_score_gemma":0.00044471127,"teacher_disagreement_score":0.23687463,"about_ca_system_score_codex":0.000035727284,"about_ca_system_score_gemma":0.00002688689,"threshold_uncertainty_score":0.5781577},"labels":[],"label_agreement":null},{"id":"W2312406641","doi":"10.1182/blood-2014-02-555755","title":"Jumping translocations and high-risk myeloma","year":2014,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Multiple myeloma; Chromosomal translocation; Mechanism (biology); Disease; Biology; Genetics; Bioinformatics; Immunology; Medicine; Gene; Internal medicine","score_opus":0.02362528862622432,"score_gpt":0.27731315877534934,"score_spread":0.253687870149125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312406641","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.178378,0.0026604165,0.0005270245,0.8106541,0.00020971613,0.0017862772,0.00031679482,0.0002696923,0.0051979837],"genre_scores_gemma":[0.6008842,0.0018845166,0.006164217,0.36795822,0.008961047,0.00042658314,0.0034832468,0.00025859696,0.00997939],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998527,0.00009122086,0.00020503548,0.00041249298,0.00036635413,0.0003979166],"domain_scores_gemma":[0.99906415,0.0001695161,0.00007496327,0.0004535258,0.00007530464,0.00016252625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099284,0.00024819665,0.00041488983,0.0001910771,0.00013552871,0.00003718981,0.00008792861,0.0004071661,0.00011518003],"category_scores_gemma":[0.00009826901,0.00020209141,0.00010463437,0.00010046237,0.000089038294,0.00003081748,0.000024028677,0.0010138481,0.00015931272],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010014162,0.000768318,0.05997892,0.001892811,0.0035068702,0.004132637,0.0002629478,3.4311347e-7,0.0004080053,0.00004911274,0.8663691,0.06253077],"study_design_scores_gemma":[0.016620563,0.0008966265,0.12067008,0.0006480514,0.003389301,0.0007793408,0.000012823415,0.00009127438,0.001782295,0.0003018293,0.8542501,0.00055775786],"about_ca_topic_score_codex":0.00034607,"about_ca_topic_score_gemma":0.000022133889,"teacher_disagreement_score":0.4426959,"about_ca_system_score_codex":0.00002230116,"about_ca_system_score_gemma":0.00009514496,"threshold_uncertainty_score":0.82410485},"labels":[],"label_agreement":null},{"id":"W2313380772","doi":"10.1182/blood-2016-01-689547","title":"Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; White blood cell; Hemoglobin; Cyclin D1; Exertion; Internal medicine; Pathology; Gastroenterology; Cancer; Cell cycle","score_opus":0.012824190253998221,"score_gpt":0.2519222492665129,"score_spread":0.23909805901251469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313380772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642026,0.00017044533,0.00004608884,0.00036987828,0.00003198731,0.00030877008,0.00001628669,0.00005405083,0.0025822527],"genre_scores_gemma":[0.9943077,0.00015038908,0.0023158074,0.000054688066,0.00006066158,0.000045857072,0.000009401397,0.000025617703,0.0030298599],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989438,0.000040862444,0.0001302329,0.0003174515,0.00022300093,0.0003446466],"domain_scores_gemma":[0.9991824,0.00015561735,0.000043117383,0.00027877587,0.00004179318,0.0002982683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059700655,0.00015109079,0.00022062297,0.00008900701,0.00006457351,0.000010204044,0.000055735993,0.00008147674,0.00018308911],"category_scores_gemma":[0.000058815374,0.00007638799,0.000030806434,0.00006786587,0.00011904187,0.000058778183,0.000058645775,0.000064259664,0.00019249368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012158395,0.00093956926,0.36491904,0.00007298346,0.00011245149,0.0018486113,0.00007867633,1.2181084e-7,0.6171042,0.000009770034,0.0003848893,0.013313902],"study_design_scores_gemma":[0.03906006,0.0012482539,0.13294362,0.00021480853,0.0001349786,0.0012228619,0.000034582947,0.000022212987,0.823967,0.000029510866,0.0009787873,0.00014334409],"about_ca_topic_score_codex":0.00002011967,"about_ca_topic_score_gemma":0.000008391215,"teacher_disagreement_score":0.23197542,"about_ca_system_score_codex":0.000034003544,"about_ca_system_score_gemma":0.00010058601,"threshold_uncertainty_score":0.31150118},"labels":[],"label_agreement":null},{"id":"W2314865208","doi":"10.5414/cn107064","title":"Plasmapheresis in myeloma cast nephropathy","year":2012,"lang":"en","type":"article","venue":"Clinical Nephrology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Plasmapheresis; Medicine; Nephropathy; Multiple myeloma; Chemotherapy; Dexamethasone; Urology; Clinical trial; Intensive care medicine; Internal medicine; Surgery; Endocrinology; Immunology","score_opus":0.08057494572286476,"score_gpt":0.40587345350896303,"score_spread":0.32529850778609826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314865208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907683,0.0005424028,0.00002163065,0.002227063,0.0003331887,0.00039691222,0.000007160115,0.000051673993,0.0056516845],"genre_scores_gemma":[0.99294746,0.00018010999,0.0013723198,0.004021514,0.00072697515,0.000048414455,0.000028073693,0.000025193505,0.0006499608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771017,0.00032688744,0.0005951932,0.00032116388,0.00019869511,0.00084790296],"domain_scores_gemma":[0.9980163,0.00081123447,0.00006942462,0.00041112804,0.000047480797,0.00064443675],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006984385,0.00016998233,0.0005533487,0.00013865784,0.00004513785,0.000006419714,0.00011335429,0.0003254442,0.0012166727],"category_scores_gemma":[0.00086443784,0.00013490042,0.00018087743,0.00022682686,0.00031449768,0.00009355398,0.000110773704,0.00052571396,0.0018483942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014277912,0.0012644314,0.9448297,0.000017095947,0.00010074647,0.0004572563,0.00006325827,3.4208185e-7,0.00033986155,0.00022673701,0.004876502,0.04639625],"study_design_scores_gemma":[0.0048858635,0.00067557325,0.93325895,0.0000141621695,0.000041554762,0.0001806801,0.00003962698,0.000122691,0.00007733881,0.00008447432,0.060519148,0.00009993926],"about_ca_topic_score_codex":0.00007987473,"about_ca_topic_score_gemma":0.00014022463,"teacher_disagreement_score":0.055642646,"about_ca_system_score_codex":0.00006170358,"about_ca_system_score_gemma":0.00010417449,"threshold_uncertainty_score":0.9996964},"labels":[],"label_agreement":null},{"id":"W2317418659","doi":"10.1038/sj.bmt.1703765","title":"Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets","year":2002,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Amgen (Canada); Hamilton Health Sciences; Toronto General Hospital; Research Manitoba; Princess Margaret Cancer Centre; Ottawa Hospital; Alberta Cancer Foundation; Robarts Clinical Trials; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre","funders":"","keywords":"Leukapheresis; Filgrastim; Medicine; Granulocyte colony-stimulating factor; Apheresis; Multiple myeloma; Cyclophosphamide; CD34; Immunology; Internal medicine; Surgery; Stem cell; Chemotherapy; Biology; Platelet","score_opus":0.016331165514991853,"score_gpt":0.24593296930493377,"score_spread":0.2296018037899419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317418659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977385,0.00041295178,0.00076917355,0.00003802227,0.000014017611,0.00062984845,0.0002929832,0.000014150406,0.000090351525],"genre_scores_gemma":[0.9767938,0.00016902226,0.022459462,0.000022658249,0.000006100593,0.00008127635,0.00035344067,0.00001820315,0.0000960164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988788,0.000042194075,0.00026131325,0.00029325552,0.00028464085,0.00023983174],"domain_scores_gemma":[0.99945223,0.0001392555,0.000080632,0.00011801961,0.00009069298,0.00011916316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113590744,0.0001660722,0.00038044827,0.0003376846,0.000044284963,0.000025296858,0.000027899841,0.00007274245,0.00007752922],"category_scores_gemma":[0.000032639986,0.00013787627,0.00006584487,0.00036497304,0.000094997646,0.00013485397,0.0000049555606,0.000075797776,0.0000011265038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032119898,0.00028148407,0.9864726,0.0002897281,0.0006964706,0.00006704915,0.0005169687,0.00011085844,0.0002669005,0.0000012144891,0.00001664355,0.008068082],"study_design_scores_gemma":[0.009598464,0.00042189725,0.9679567,0.0001394235,0.0014368675,0.000008630986,0.000023552822,0.019944984,0.00031627153,0.0000047721596,0.000009825651,0.00013857981],"about_ca_topic_score_codex":0.00020853101,"about_ca_topic_score_gemma":0.00063533965,"teacher_disagreement_score":0.02169029,"about_ca_system_score_codex":0.00003237065,"about_ca_system_score_gemma":0.000016872646,"threshold_uncertainty_score":0.5622431},"labels":[],"label_agreement":null},{"id":"W2317757653","doi":"10.1097/01.cot.0000446194.82745.c5","title":"Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thalidomide; Bortezomib; Medicine; Lenalidomide; Multiple myeloma; Melphalan; Oncology; Bendamustine; Internal medicine; Carfilzomib; Pharmacology; Lymphoma; Rituximab","score_opus":0.02555260835734464,"score_gpt":0.3352360972157081,"score_spread":0.30968348885836344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317757653","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44285288,0.00017920445,0.00029272158,0.004388285,0.00016863042,0.0004276142,0.000006025263,0.00016270053,0.5515219],"genre_scores_gemma":[0.9641773,0.000019288253,0.0049459874,0.00059207674,0.00018803499,0.000044235814,0.000040528805,0.000015421932,0.029977106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991357,0.000083737315,0.0001256648,0.00020082916,0.0001515809,0.00030249235],"domain_scores_gemma":[0.99914694,0.00029441368,0.000032376385,0.00024386171,0.000057988906,0.00022440331],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016430524,0.000099805875,0.000253782,0.00007981609,0.000073621464,0.0000065143886,0.00006614721,0.00011126384,0.0012883698],"category_scores_gemma":[0.00043847272,0.00007502907,0.000069728914,0.000079247715,0.000101451886,0.00003361918,0.000043629345,0.00013508038,0.0020670998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008412845,0.0008683167,0.37715787,0.000043413682,0.00026741176,0.00034334362,0.00014278301,0.000002108178,0.0071919034,0.0012685364,0.05685883,0.5550142],"study_design_scores_gemma":[0.0062731635,0.0018477633,0.33530352,0.000019348818,0.00005549015,0.00016815063,0.000034122408,0.0028757963,0.0051262095,0.00029747363,0.6478918,0.00010716125],"about_ca_topic_score_codex":0.000039117123,"about_ca_topic_score_gemma":0.000028284752,"teacher_disagreement_score":0.591033,"about_ca_system_score_codex":0.00009546552,"about_ca_system_score_gemma":0.000108677064,"threshold_uncertainty_score":0.9996246},"labels":[],"label_agreement":null},{"id":"W2318116115","doi":"10.1097/00003072-200211000-00028","title":"Serendipitous Diagnosis of Multiple Myeloma During Sestamibi Myocardial Perfusion Imaging","year":2002,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège de Maisonneuve; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Myocardial perfusion imaging; Multiple myeloma; Technetium Tc 99m Sestamibi; Technetium (99mTc) sestamibi; Perfusion; Appropriateness criteria; Perfusion scanning; Nuclear medicine; Radiology; Internal medicine","score_opus":0.054429044685136915,"score_gpt":0.34763237183081813,"score_spread":0.2932033271456812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318116115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883384,0.0010256602,0.0000043229174,0.0050191297,0.000454305,0.0005261204,0.000016228978,0.0001333474,0.004482475],"genre_scores_gemma":[0.994246,0.0029652254,0.00044002626,0.0006624036,0.0011783761,0.0000173145,0.000026397049,0.00007069591,0.00039357645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703085,0.00018565777,0.00096666755,0.00054422836,0.0007472098,0.0005253811],"domain_scores_gemma":[0.99740285,0.00086205296,0.00019739661,0.00065405626,0.00018863578,0.0006950188],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046997835,0.00026545906,0.00092256564,0.0002065293,0.00015507374,0.000009172397,0.00018535739,0.00015054645,0.004216676],"category_scores_gemma":[0.0034633027,0.0001960891,0.00032429528,0.00029268287,0.00063609215,0.00009368828,0.00017505343,0.0005305984,0.000415821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075153494,0.000993216,0.8484729,0.00015967977,0.00018449793,0.0008391652,0.00037685875,9.699683e-7,0.0030944992,0.000012389143,0.010813391,0.13430092],"study_design_scores_gemma":[0.014786908,0.00142938,0.9651913,0.0006991861,0.00024366556,0.00012161401,0.00032177533,0.0042983727,0.00036028083,0.000012979893,0.012348533,0.0001860087],"about_ca_topic_score_codex":0.0001444015,"about_ca_topic_score_gemma":0.0000070247506,"teacher_disagreement_score":0.13411492,"about_ca_system_score_codex":0.00008007978,"about_ca_system_score_gemma":0.000023364553,"threshold_uncertainty_score":0.9966936},"labels":[],"label_agreement":null},{"id":"W2318215694","doi":"10.1038/bmt.2015.319","title":"Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation","year":2015,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Multiple myeloma; Fludarabine; Cumulative incidence; Transplantation; Cyclophosphamide; Incidence (geometry); Surgery; Internal medicine; Melphalan; Hematopoietic stem cell transplantation; Regimen; Oncology; Chemotherapy","score_opus":0.03383905961693549,"score_gpt":0.2802437855526472,"score_spread":0.24640472593571167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318215694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498767,0.000112534544,0.048043117,0.00002394693,0.000022811311,0.0014407034,0.00021915327,0.00004511123,0.00021591231],"genre_scores_gemma":[0.9756328,0.00006700188,0.022044094,0.000019946212,0.000020337104,0.000057950674,0.0020536755,0.00004390835,0.000060275514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807155,0.00009266158,0.00041982305,0.00042547638,0.0006300511,0.00036045242],"domain_scores_gemma":[0.9989304,0.00007641564,0.0002008726,0.00019578262,0.00030568536,0.0002908734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001892716,0.0003037139,0.00054316805,0.00023089227,0.000097599856,0.000022206079,0.00005770064,0.00012350584,0.000008312445],"category_scores_gemma":[0.000017587401,0.00021597202,0.000049464074,0.00024847235,0.00015564985,0.0002748779,0.0000068448894,0.00015530619,0.0000022674951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011026329,0.0005178031,0.98134804,0.00081627816,0.00028437912,0.00029030986,0.001673896,0.00046739893,0.0015427647,0.0000045279494,0.0000011500473,0.0020270967],"study_design_scores_gemma":[0.023011228,0.0014207526,0.9667618,0.0002369475,0.0006863303,0.0002474684,0.00012729915,0.0044759903,0.0027928946,0.0000060734155,8.3405973e-7,0.00023233112],"about_ca_topic_score_codex":0.00035012106,"about_ca_topic_score_gemma":0.00046232404,"teacher_disagreement_score":0.025999025,"about_ca_system_score_codex":0.00011534153,"about_ca_system_score_gemma":0.00016118103,"threshold_uncertainty_score":0.88070834},"labels":[],"label_agreement":null},{"id":"W2318763430","doi":"10.1097/pai.0000000000000089","title":"Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma","year":2014,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Cyclin D1; Cyclin; Multiple myeloma; Cyclin D3; Immunohistochemistry; Plasma Cell Myeloma; Cyclin D2; Cancer research; Gene expression; Pathology; Biology; Medicine; Cell cycle; Oncology; Molecular biology; Cancer; Gene; Immunology; Internal medicine; Genetics","score_opus":0.010069442296597382,"score_gpt":0.25485515050311963,"score_spread":0.24478570820652226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318763430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738019,0.0002297486,0.017584665,0.00010388485,0.00007879398,0.00630917,0.00007054107,0.00014872068,0.0016725938],"genre_scores_gemma":[0.9659144,0.00001701378,0.02485528,0.00012155098,0.000058564416,0.0054581515,0.0020134049,0.0001790554,0.0013825388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956362,0.00010415586,0.00095796364,0.0014696746,0.00061271375,0.0012192572],"domain_scores_gemma":[0.997123,0.00016652061,0.00061035325,0.001475319,0.0002101009,0.0004147073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004337682,0.0007136492,0.00092464616,0.00019387373,0.00019994339,0.00003520578,0.00038651717,0.0005669596,0.00015811001],"category_scores_gemma":[0.00036469108,0.0006134358,0.00021085222,0.0002709344,0.00025689902,0.00006382978,0.00023397175,0.00075404806,0.00003516248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061807167,0.0012678797,0.0032998892,0.0007414336,0.0001565618,0.00094203255,0.00011464534,0.000035322693,0.9855956,0.0000044918443,0.00022943522,0.0014320193],"study_design_scores_gemma":[0.016251424,0.0010210352,0.0056222957,0.0007434165,0.00018673888,0.00058027636,0.000088270564,0.0006128183,0.97413915,0.000016472926,0.00017417458,0.0005639297],"about_ca_topic_score_codex":0.00006853298,"about_ca_topic_score_gemma":0.0000010549353,"teacher_disagreement_score":0.011456424,"about_ca_system_score_codex":0.0004208021,"about_ca_system_score_gemma":0.00034578773,"threshold_uncertainty_score":0.9996317},"labels":[],"label_agreement":null},{"id":"W2321034066","doi":"10.1097/01.cot.0000416570.49020.3e","title":"Best of ASCO 2012","year":2012,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Multiple myeloma; Tolerability; Internal medicine; Thalidomide; Oncology; Plasma cell leukemia; Dexamethasone; Adverse effect","score_opus":0.04620166454705379,"score_gpt":0.38370188311524955,"score_spread":0.3375002185681958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321034066","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4483303,0.0036974167,0.000014433111,0.0011613976,0.00015757773,0.00025915378,0.00000842221,0.000022313086,0.546349],"genre_scores_gemma":[0.9416642,0.000091514215,0.0021879976,0.000085474996,0.00015525453,0.000018058725,0.000013408656,0.000008259995,0.05577581],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993521,0.00003997747,0.00010902338,0.00007218123,0.00015653625,0.000270212],"domain_scores_gemma":[0.9994489,0.00010194662,0.00003709105,0.00014995107,0.000068915084,0.00019317682],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016989865,0.00006142436,0.0002095524,0.000047226324,0.000022753673,0.0000010146665,0.000038348706,0.00008416764,0.0031582506],"category_scores_gemma":[0.00010942687,0.000044796365,0.000050181163,0.000059025133,0.000095231306,0.00007120782,0.00003195433,0.00008386684,0.0012720119],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006036539,0.0033845233,0.7753875,0.00007785758,0.00043389213,0.00008427327,0.00041649016,2.0485909e-7,0.008024265,0.0011986779,0.07630791,0.13408072],"study_design_scores_gemma":[0.0045257346,0.0020909798,0.37952152,0.000041282092,0.00017894099,0.00017904658,0.00013528661,0.000023572098,0.0142705,0.00007179308,0.59886855,0.00009281367],"about_ca_topic_score_codex":0.0000663791,"about_ca_topic_score_gemma":0.000009519297,"teacher_disagreement_score":0.5225606,"about_ca_system_score_codex":0.00011432866,"about_ca_system_score_gemma":0.00020083548,"threshold_uncertainty_score":0.99950564},"labels":[],"label_agreement":null},{"id":"W2321435906","doi":"10.1038/sj.bmt.1702574","title":"Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma","year":2000,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Multiple myeloma; Cyclophosphamide; Regimen; Internal medicine; Bone marrow; Surgery; Oncology; Chemotherapy","score_opus":0.012661267718615123,"score_gpt":0.23798933836262828,"score_spread":0.22532807064401317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321435906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801964,0.00013652176,0.000015163229,0.00024579783,0.00001994331,0.001161689,0.00006140676,0.00003263249,0.00030721564],"genre_scores_gemma":[0.9983279,0.00038394134,0.0003639854,0.00014065357,0.000017482125,0.00016259521,0.00043949336,0.000023694483,0.00014025804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886495,0.000078220764,0.00018875867,0.00027889668,0.00031918593,0.00027000395],"domain_scores_gemma":[0.99955237,0.00006006623,0.000027670909,0.0001314866,0.000099655925,0.00012877194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007571527,0.00016628469,0.00024008809,0.000127353,0.000042640844,0.000018246335,0.00002581747,0.00006641138,0.00018869554],"category_scores_gemma":[0.00001643429,0.00012117861,0.000031049516,0.00014302364,0.00006146879,0.00013384385,0.0000025430834,0.0001335871,0.00001791155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03582517,0.0002714992,0.90992475,0.000068911446,0.00006860988,0.000350221,0.0009309194,0.0000018686804,0.0008773486,0.0000011952981,0.000003655984,0.051675875],"study_design_scores_gemma":[0.02108495,0.0007285464,0.9766448,0.00011908227,0.000034769106,0.000022790633,0.000041308962,0.00012483608,0.0010276077,0.000005790672,0.000043282147,0.00012223379],"about_ca_topic_score_codex":0.0001810294,"about_ca_topic_score_gemma":0.00045954858,"teacher_disagreement_score":0.066720076,"about_ca_system_score_codex":0.000029255272,"about_ca_system_score_gemma":0.000033971402,"threshold_uncertainty_score":0.49415204},"labels":[],"label_agreement":null},{"id":"W2322178907","doi":"10.6000/1927-7229.2012.01.01.15","title":"Decrease in Bilateral Corneal Deposits After Bortezomib/ Dexamethasone Chemotherapy in Monoclonal Gammopathy: Case Report","year":2012,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Monoclonal gammopathy; Dexamethasone; Photophobia; Chemotherapy; Paraproteinemia; Bortezomib; Pathology; Quadrant (abdomen); Monoclonal; Multiple myeloma; Dermatology; Ophthalmology; Surgery; Radiology; Monoclonal antibody; Internal medicine; Immunology","score_opus":0.0386903860387065,"score_gpt":0.37803108146408615,"score_spread":0.33934069542537965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322178907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662113,0.0005672192,0.00008387488,0.001702126,0.000121761965,0.00022925787,0.0000029151006,0.0000048993816,0.0006668039],"genre_scores_gemma":[0.9948072,0.00008411719,0.003988074,0.00057833485,0.0003588432,0.000011465141,0.0000062516597,0.000020449823,0.00014525179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754536,0.00022294342,0.0010141414,0.00018846938,0.00038671517,0.00064235047],"domain_scores_gemma":[0.9979171,0.00033188774,0.00026061575,0.0001895185,0.00017281855,0.00112804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012779421,0.0001837147,0.0008094288,0.0005445684,0.000019487548,0.00001261036,0.00007343014,0.00022088549,0.00034982673],"category_scores_gemma":[0.00084009045,0.00013383318,0.00021147235,0.00034541605,0.00011557423,0.0001967489,0.000036285976,0.0006779301,0.000014490746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053833895,0.0017496963,0.57092756,0.000011066722,0.00012350499,0.41364723,0.00011825653,0.0000031800137,0.00013916282,0.000010274492,0.00008972325,0.007796947],"study_design_scores_gemma":[0.008163397,0.0014663923,0.7124724,0.00005767311,0.0001127731,0.2752864,0.000038276314,0.0013476226,0.0003188326,0.00003462346,0.00060836505,0.00009325914],"about_ca_topic_score_codex":0.00029176334,"about_ca_topic_score_gemma":0.00043378625,"teacher_disagreement_score":0.1415448,"about_ca_system_score_codex":0.0007851254,"about_ca_system_score_gemma":0.0007257542,"threshold_uncertainty_score":0.54575586},"labels":[],"label_agreement":null},{"id":"W2323533441","doi":"10.1016/j.bbmt.2011.12.173","title":"Impact of Graft CD34 Cell Dose on Chronic Graft-Versus-Host Disease (cGVHD) and Predictive Values of CD3 Cell Dose and Day 56 Chimerism on Survival in Nonmyeloablative (Nma) Allogeneic Hematopoietic Stem Cell Transplant (HSCT)","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Gastroenterology; Tacrolimus; Internal medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; CD34; Transplantation; Fludarabine; Incidence (geometry); Surgery; Immunology; Urology; Stem cell; Chemotherapy; Cyclophosphamide","score_opus":0.017986818943350868,"score_gpt":0.2866421812693845,"score_spread":0.26865536232603365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323533441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233216,0.0051105814,0.000026731808,0.000021951859,0.000068916685,0.0008546139,0.0013139364,0.000010869568,0.00026021808],"genre_scores_gemma":[0.99082315,0.008557357,0.000046897607,0.0000046191353,0.000038478236,0.000030467005,0.00045377915,0.000021328482,0.000023900388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983184,0.00030190148,0.00040631395,0.00037293983,0.00020850067,0.000391954],"domain_scores_gemma":[0.9988251,0.0004341597,0.00019751012,0.000175093,0.00004885904,0.00031929542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002800998,0.000307912,0.0005995915,0.0002623383,0.000053158452,0.000003980705,0.000061538376,0.00017346766,0.000014613176],"category_scores_gemma":[0.000006699806,0.00023221521,0.00013334877,0.00011739385,0.00035208324,0.000097760225,0.000012002025,0.00017552929,0.0000010657519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01671313,0.002051133,0.54009306,0.0022641658,0.0005052678,0.00006016244,0.0060679046,0.000018991755,0.43155456,0.00003360552,0.0000024449075,0.0006355841],"study_design_scores_gemma":[0.01816985,0.008679012,0.7827737,0.00039475385,0.0010535903,0.0000125474835,0.00026248506,0.00008271071,0.188353,0.000030013638,8.6701e-7,0.00018748082],"about_ca_topic_score_codex":0.00020970557,"about_ca_topic_score_gemma":0.000045579276,"teacher_disagreement_score":0.24320157,"about_ca_system_score_codex":0.00003235101,"about_ca_system_score_gemma":0.0001180022,"threshold_uncertainty_score":0.9469462},"labels":[],"label_agreement":null},{"id":"W2325022302","doi":"10.1038/sj.bmt.1702685","title":"Donor leukocyte infusions for multiple myeloma","year":2000,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Chemotherapy; Pancytopenia; Gastroenterology; Bone marrow; Surgery","score_opus":0.02418148290300916,"score_gpt":0.2891789194168167,"score_spread":0.2649974365138076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325022302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912585,0.00013972561,0.0012120313,0.000660587,0.00005159562,0.0013156005,0.00021979312,0.00011769265,0.0050244816],"genre_scores_gemma":[0.9865159,0.00067872327,0.005463368,0.00018089694,0.00010054417,0.00030109475,0.0014534388,0.000029073479,0.0052769687],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886996,0.00003119641,0.00024454694,0.00026516788,0.00025017044,0.0003389616],"domain_scores_gemma":[0.9993437,0.0001563538,0.000030160563,0.00019117242,0.00006837873,0.00021027097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010473162,0.00015448635,0.00021626611,0.00011394418,0.0001715659,0.000022051756,0.000049097438,0.00008444747,0.00087387586],"category_scores_gemma":[0.000032381857,0.00013357807,0.00013398254,0.00013458234,0.000040209074,0.00011785331,0.0000029502382,0.00009253357,0.000212637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02732022,0.0011890144,0.09243829,0.0014087431,0.0004492014,0.00087329245,0.0016864126,0.00015463757,0.19864139,0.00031193625,0.0028849894,0.6726419],"study_design_scores_gemma":[0.03659679,0.0013423086,0.84049165,0.00034763134,0.000562551,0.00063769537,0.00008520181,0.009499366,0.07519716,0.0002553297,0.03448158,0.00050274876],"about_ca_topic_score_codex":0.0001628871,"about_ca_topic_score_gemma":0.00024251088,"teacher_disagreement_score":0.7480534,"about_ca_system_score_codex":0.0000612906,"about_ca_system_score_gemma":0.000083938154,"threshold_uncertainty_score":0.9568328},"labels":[],"label_agreement":null},{"id":"W2329055621","doi":"10.3899/jrheum.111054","title":"Prevalence of Monoclonal Gammopathy Among Patients with Psoriatic Arthritis","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"Canadian Arthritis Network; Krembil Foundation; University of Toronto; Arthritis Society","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Gammopathy; Monoclonal gammopathy; Monoclonal; Internal medicine; Serum protein electrophoresis; Psoriatic arthritis; Gastroenterology; Arthritis; Monoclonal antibody; Immunology; Antibody","score_opus":0.011682189443132594,"score_gpt":0.25677176657109896,"score_spread":0.24508957712796636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329055621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710757,0.002260709,0.00010180717,0.00011236907,0.000120667726,0.00019141268,0.0000063046496,0.000003488078,0.00009569463],"genre_scores_gemma":[0.99790853,0.0014445875,0.0005748999,0.000012241376,0.000011471219,0.0000026714997,0.0000016105236,0.000010286209,0.00003367623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873805,0.00016595414,0.00038346555,0.000048642924,0.00038847653,0.00027543132],"domain_scores_gemma":[0.998743,0.00023777556,0.0004107742,0.00017258125,0.00024972847,0.00018615717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004175085,0.000094279836,0.0003517487,0.000095665826,0.000040315397,0.0000023212158,0.00012334617,0.000042988162,0.0001293175],"category_scores_gemma":[0.00023094637,0.000048207607,0.00006312472,0.00008404057,0.00020243441,0.00013347683,0.000028763703,0.00019937466,0.00001044203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012168336,0.000386381,0.9917857,0.00011456492,0.00022805353,0.000008320873,0.0004293541,0.0000021502935,0.000017929771,0.00004772763,0.00014214504,0.0056208163],"study_design_scores_gemma":[0.0042440705,0.0011103497,0.9920524,0.0003929281,0.00012407752,0.0015772776,0.00006450035,0.000022507777,0.00029941802,0.00004959199,0.000021326096,0.000041572366],"about_ca_topic_score_codex":0.000083730505,"about_ca_topic_score_gemma":0.000009053368,"teacher_disagreement_score":0.005579244,"about_ca_system_score_codex":0.00002933689,"about_ca_system_score_gemma":0.000081572914,"threshold_uncertainty_score":0.19658493},"labels":[],"label_agreement":null},{"id":"W2329368040","doi":"10.6004/jnccn.2007.0016","title":"Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma","year":2007,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Celgene","keywords":"Medicine; Multiple myeloma; Thalidomide; Bortezomib; Autologous stem-cell transplantation; Lenalidomide; Oncology; Transplantation; Internal medicine; Surgery","score_opus":0.08784823920259621,"score_gpt":0.3916811902525102,"score_spread":0.303832951049914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329368040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013690452,0.99694693,0.0000071857626,0.00020817814,0.00020498448,0.00075374555,0.00019637181,0.0000014707431,0.0003120639],"genre_scores_gemma":[0.026816145,0.9719038,0.00013342906,0.0001780845,0.0008248338,0.000026182164,0.000047249174,0.000020371313,0.000049880204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680644,0.00038792274,0.0010220844,0.00012564154,0.0014495646,0.00020835878],"domain_scores_gemma":[0.9963401,0.0009533484,0.0012753991,0.00015729692,0.0011648879,0.00010896534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004901577,0.00020931345,0.0010553139,0.0002520843,0.00005099436,0.0000071735863,0.000293472,0.00010349686,0.00004316577],"category_scores_gemma":[0.0001327674,0.000105997264,0.00073458307,0.0006326312,0.00011102159,0.000050310064,0.000027999478,0.00056269066,0.0000012234901],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043364344,0.0007996793,0.004270362,0.020301592,0.002431762,0.0004280181,0.00044590977,0.0026279306,0.00009699477,0.0008350291,0.0042497874,0.9591765],"study_design_scores_gemma":[0.003980154,0.0003701321,0.102396496,0.05209614,0.0022461468,0.0007121466,0.00009021438,0.00013854516,0.000033970096,0.0013762843,0.8363116,0.00024818906],"about_ca_topic_score_codex":0.000016353551,"about_ca_topic_score_gemma":0.00001770333,"teacher_disagreement_score":0.9589283,"about_ca_system_score_codex":0.0002736777,"about_ca_system_score_gemma":0.0012173567,"threshold_uncertainty_score":0.4322443},"labels":[],"label_agreement":null},{"id":"W2331392729","doi":"10.1097/icb.0000000000000071","title":"AN OTHERWISE HEALTHY YOUNG MAN PRESENTS WITH BILATERAL CRVO AS THE FIRST SIGN OF HYPERVISCOSITY SYNDROME IN THE SETTING OF NEW MULTIPLE MYELOMA","year":2014,"lang":"en","type":"article","venue":"Retinal Cases & Brief Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Hyperviscosity syndrome; Central retinal vein occlusion; Bortezomib; Multiple myeloma; Cyclophosphamide; Hyperviscosity; Etiology; Lenalidomide; Surgery; Internal medicine; Retinal; Ophthalmology; Chemotherapy; Macular edema; Blood viscosity","score_opus":0.02223781028651577,"score_gpt":0.30144304648743564,"score_spread":0.27920523620091986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331392729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965401,0.00017644666,0.000024373585,0.0013008728,0.00003088313,0.0012300204,0.000009963457,0.0000234314,0.00066390116],"genre_scores_gemma":[0.99912304,0.000016210837,0.00028195936,0.0002546587,0.00007278061,0.00003997452,0.00004176125,0.000032943295,0.0001366452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733984,0.00028601883,0.0006144266,0.0004180719,0.00088768377,0.00045393794],"domain_scores_gemma":[0.99782413,0.00038958553,0.0004465247,0.0009643558,0.00013759185,0.0002378148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010128908,0.00022992796,0.00047234865,0.00010567952,0.00016397792,0.00003291244,0.00018878214,0.00007217603,0.00005345657],"category_scores_gemma":[0.00050611503,0.00012318471,0.00011286716,0.00030986962,0.00016622567,0.00012229127,0.000060552848,0.0002589316,0.000002923375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019939456,0.00049533125,0.9820604,0.00026139154,0.00007367145,0.010224986,0.0011923658,0.00003415579,0.00034017474,0.000009551491,0.0001206194,0.0031934523],"study_design_scores_gemma":[0.0017369587,0.003643075,0.95798093,0.00040129226,0.00008539176,0.033492647,0.00027642425,0.0006771516,0.0010209754,0.000043796827,0.0005224333,0.00011890666],"about_ca_topic_score_codex":0.022724178,"about_ca_topic_score_gemma":0.0028969836,"teacher_disagreement_score":0.024079407,"about_ca_system_score_codex":0.000063433,"about_ca_system_score_gemma":0.00024019807,"threshold_uncertainty_score":0.9837836},"labels":[],"label_agreement":null},{"id":"W2331817699","doi":"10.1038/sj.bmt.1702771","title":"Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes","year":2001,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Internal medicine; Total body irradiation; Autologous stem-cell transplantation; Transplantation; Surgery; Etoposide; Gastroenterology; Hematopoietic stem cell transplantation; Regimen; Chemotherapy; Cyclophosphamide","score_opus":0.01903151413538369,"score_gpt":0.2668742684296369,"score_spread":0.24784275429425323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331817699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615693,0.00026586774,0.00046483014,0.00039884067,0.00013498109,0.000977621,0.0011939877,0.00015579992,0.00025113707],"genre_scores_gemma":[0.988466,0.005187411,0.000074058975,0.000045113688,0.000033734705,0.00012623124,0.0051814127,0.000034852063,0.0008511343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983732,0.00011820586,0.0003626107,0.00037634454,0.00040298782,0.00036664418],"domain_scores_gemma":[0.9990388,0.00023135597,0.00011396259,0.00015696688,0.000055798886,0.00040312865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000078252735,0.00030584072,0.0004384376,0.00017600646,0.00023139885,0.00004927462,0.00003877278,0.00010737046,0.000033354805],"category_scores_gemma":[0.0000149311345,0.0002530223,0.00017444884,0.00015424343,0.000041152838,0.00021055301,0.0000033478368,0.000104492756,0.000011802024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001370998,0.0004736089,0.976427,0.00014237921,0.00034150065,0.0034853714,0.0017292,0.000006418198,0.0010073347,0.00000805468,0.0000075602507,0.015000578],"study_design_scores_gemma":[0.0069760866,0.0005671956,0.9892078,0.00010530265,0.0011586138,0.00008502091,0.00012545112,0.0006061408,0.00090741605,0.000011260967,0.000049963448,0.00019976364],"about_ca_topic_score_codex":0.00023013407,"about_ca_topic_score_gemma":0.000086482294,"teacher_disagreement_score":0.014800814,"about_ca_system_score_codex":0.00024940027,"about_ca_system_score_gemma":0.00012421135,"threshold_uncertainty_score":0.9999922},"labels":[],"label_agreement":null},{"id":"W2332763467","doi":"10.1016/j.clml.2015.07.588","title":"A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Dexamethasone; Pharmacology; Multiple myeloma; Insulin-like growth factor; Medicine; Refractory (planetary science); Clinical trial; Proteasome inhibitor; Receptor; Internal medicine; Oncology; Growth factor; Biology","score_opus":0.07643165159987207,"score_gpt":0.3600412260199811,"score_spread":0.28360957442010903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332763467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919453,0.0010743858,0.00008442123,0.0006942205,0.00053671934,0.0052210526,0.0002862568,0.000046004774,0.000111619214],"genre_scores_gemma":[0.99605405,0.0008619186,0.0015397439,0.00010812462,0.00043314326,0.0005405859,0.00013777701,0.000077762525,0.00024687048],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954707,0.000621714,0.001683251,0.000751069,0.00088387704,0.00058939966],"domain_scores_gemma":[0.9914727,0.0055370866,0.000819765,0.00095296965,0.00068083976,0.00053661386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011599094,0.0005008015,0.001368693,0.00020613025,0.00015533193,0.000034174886,0.00031730256,0.00045343876,0.000019284838],"category_scores_gemma":[0.0053260797,0.00027380462,0.00046799707,0.0005763058,0.0009429808,0.0001826729,0.0001105838,0.00030320443,0.00000920889],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23104772,0.014001933,0.086187124,0.0001427342,0.0007575459,0.00005833979,0.0012535348,0.000002795509,0.0015386639,0.00009253433,0.0003841631,0.6645329],"study_design_scores_gemma":[0.46963832,0.037271984,0.47236928,0.00030697792,0.00032945754,0.000027568009,0.00039726085,0.0020983864,0.012901843,0.00011636593,0.004264821,0.00027773567],"about_ca_topic_score_codex":0.0005708738,"about_ca_topic_score_gemma":0.00024177265,"teacher_disagreement_score":0.6642552,"about_ca_system_score_codex":0.0012017577,"about_ca_system_score_gemma":0.002392843,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W2335826388","doi":"10.3324/haematol.2015.137083","title":"Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Refractory (planetary science); Lenalidomide; Multiple myeloma; Creatinine; Internal medicine; Urology; Gastroenterology; Materials science","score_opus":0.052192227517079505,"score_gpt":0.35049796612858714,"score_spread":0.2983057386115076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335826388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970041,0.00047702526,0.000043293418,0.00012825783,0.000059146554,0.0020893132,0.000092868235,0.000046230758,0.00005979727],"genre_scores_gemma":[0.99730015,0.00043138524,0.0017642049,0.000020330202,0.000017078542,0.00026737564,0.000053409414,0.000033693235,0.000112345355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953314,0.0008256442,0.001415399,0.0008917892,0.00081564573,0.0007201257],"domain_scores_gemma":[0.99478596,0.0030575024,0.0006081203,0.0009803604,0.00016642325,0.00040165146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001136753,0.00045539188,0.002289797,0.00159444,0.000063448264,0.00001220936,0.00024861222,0.00029369985,0.0005073211],"category_scores_gemma":[0.002802926,0.0002700529,0.00022147536,0.0017689683,0.00036350897,0.00019777381,0.00022091535,0.00036027253,0.00000811557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24621618,0.04017391,0.5966774,0.00033764294,0.004991922,0.010074462,0.002871206,0.000037162547,0.058001127,0.000025797131,0.00007326098,0.040519904],"study_design_scores_gemma":[0.20608456,0.01666036,0.7645317,0.0005497833,0.001179959,0.000055307224,0.0018513643,0.00074465416,0.0079248035,0.00001801765,0.000040841613,0.0003586977],"about_ca_topic_score_codex":0.0027357785,"about_ca_topic_score_gemma":0.004567581,"teacher_disagreement_score":0.16785422,"about_ca_system_score_codex":0.00037260412,"about_ca_system_score_gemma":0.00022663185,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W2336872381","doi":"10.3324/haematol.2014.117077","title":"Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone","year":2015,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Discontinuation; Multiple myeloma; Gastroenterology; Surgery; Oncology; Biology","score_opus":0.05052684580106229,"score_gpt":0.2953094141086336,"score_spread":0.2447825683075713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336872381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977414,0.000935117,0.000025377652,0.000047246936,0.000016361302,0.0009938312,0.000054936067,0.00005259949,0.00013312174],"genre_scores_gemma":[0.9964265,0.00036716083,0.00280313,0.000029100718,0.00001332735,0.000041033014,0.00010548473,0.000039290644,0.00017497774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981192,0.00018392934,0.00032347863,0.00050467683,0.0004782772,0.0003904477],"domain_scores_gemma":[0.9980614,0.00044013534,0.00020828485,0.0003824708,0.00030564208,0.0006020521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018510423,0.00032828402,0.0008035602,0.00014597364,0.00008623362,0.000026101983,0.00006939431,0.00017509086,0.000026917778],"category_scores_gemma":[0.00052731344,0.00017989476,0.000026326832,0.00018450372,0.0005679932,0.000112210284,0.000104878,0.00019784359,0.0000032316304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022485448,0.00079996197,0.96901137,0.00027653904,0.00028519076,0.0013327287,0.00021033072,3.6366723e-7,0.00048463602,0.0000053896915,0.00001797301,0.0050900932],"study_design_scores_gemma":[0.024747683,0.0067960466,0.9651556,0.00028101375,0.00019151843,0.0003245059,0.00015256905,0.000040602343,0.0020425878,0.000005388726,0.000044588545,0.00021787248],"about_ca_topic_score_codex":0.000079752266,"about_ca_topic_score_gemma":0.00021608887,"teacher_disagreement_score":0.0059960843,"about_ca_system_score_codex":0.00005094036,"about_ca_system_score_gemma":0.00013139853,"threshold_uncertainty_score":0.73358953},"labels":[],"label_agreement":null},{"id":"W2338464704","doi":"10.1182/blood.v122.21.3085.3085","title":"Bone Marrow Microenvironment Affects The Pathogenesis Of Multiple Myeloma Through Downregulation Of Alternative Splicing Factor Fox2 In Myeloma Cells","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"RNA splicing; Alternative splicing; Stromal cell; Splicing factor; Downregulation and upregulation; Cancer research; Biology; Exon; Gene expression; Cell culture; Molecular biology; Bone marrow; RNA; Gene; Immunology; Genetics","score_opus":0.018447345420321,"score_gpt":0.2535769200385018,"score_spread":0.2351295746181808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338464704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972957,0.00046059777,0.00007890206,0.00016836503,0.000030213843,0.0016830467,0.00006278763,0.000012290666,0.00020812916],"genre_scores_gemma":[0.9970738,0.00014564247,0.0023605921,0.000030135037,0.000048042577,0.00012762436,0.00003115719,0.000027813414,0.00015519047],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984045,0.00013230383,0.00036908142,0.00029157635,0.0004572237,0.00034534055],"domain_scores_gemma":[0.99890715,0.00028035932,0.00021834538,0.00043807816,0.000060754996,0.000095311254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012185085,0.00020442379,0.00041292456,0.000111496905,0.000046141133,0.000009692111,0.00012437995,0.00007880592,0.00018122623],"category_scores_gemma":[0.00008180335,0.00013721132,0.00013212259,0.00018320123,0.00012578182,0.000114968294,0.00009198697,0.00011449149,0.000037120906],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012051398,0.0009169001,0.15784322,0.0001362856,0.00017518601,0.000037256486,0.0010433437,0.000029146222,0.8315336,0.000008553862,0.00001904608,0.008136907],"study_design_scores_gemma":[0.0033565538,0.00021349813,0.52277094,0.000100177036,0.000047146037,0.000008399611,0.00014105035,0.0003126294,0.47295344,0.000023781655,0.000013626212,0.00005877805],"about_ca_topic_score_codex":0.0010212312,"about_ca_topic_score_gemma":0.00009233775,"teacher_disagreement_score":0.3649277,"about_ca_system_score_codex":0.00007086548,"about_ca_system_score_gemma":0.000034929544,"threshold_uncertainty_score":0.5595315},"labels":[],"label_agreement":null},{"id":"W2339372094","doi":"10.1016/j.jcjo.2015.10.017","title":"Neuro-ophthalmic presentations of clival plasmacytoma","year":2016,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Multiple myeloma; Internal medicine","score_opus":0.054963330726107845,"score_gpt":0.3366043662521183,"score_spread":0.2816410355260105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339372094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49191523,0.0011376251,0.000012314858,0.43800026,0.0021728892,0.00080402085,0.00074755057,0.0000067920455,0.06520333],"genre_scores_gemma":[0.9741989,0.000019479643,0.00028662695,0.009940023,0.0032259566,0.000012605371,0.00012402287,0.00009285865,0.0120995715],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9974119,0.00026558855,0.0007979007,0.00026781808,0.0004542016,0.0008026127],"domain_scores_gemma":[0.9967468,0.00063519564,0.0006217523,0.00045404574,0.00061257114,0.0009296812],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018506356,0.00030358447,0.00093551376,0.0012631156,0.00008092877,0.00001734959,0.00042722674,0.0006147286,0.0048246905],"category_scores_gemma":[0.00076795754,0.00022698323,0.00043170547,0.00018568375,0.00045922818,0.000087059874,0.000027379088,0.0014698991,0.00010857725],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014804729,0.000023615918,0.08044336,0.00013982173,0.0005386716,0.4328508,0.00003597648,6.6612324e-7,0.00009937894,0.000009296952,0.4854255,0.00028484952],"study_design_scores_gemma":[0.003333932,0.0021636935,0.05335272,0.00028600788,0.0003055501,0.7742871,0.000018972964,0.0000044929616,0.00044096046,0.00032682522,0.16526233,0.00021743387],"about_ca_topic_score_codex":0.0020842892,"about_ca_topic_score_gemma":0.00003707604,"teacher_disagreement_score":0.48228365,"about_ca_system_score_codex":0.00018817662,"about_ca_system_score_gemma":0.0046021943,"threshold_uncertainty_score":0.99608505},"labels":[],"label_agreement":null},{"id":"W2339584422","doi":"10.1200/jco.2009.27.15_suppl.e19535","title":"A retrospective chart review study of relapsed or refractory multiple myeloma (MM) patients (Pts): A look into historical treatment (Tx) patterns","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Internal medicine; Oncology; Prednisone; Multiple myeloma; Bortezomib; Refractory (planetary science); Surgery","score_opus":0.14024492262626512,"score_gpt":0.4711736823009262,"score_spread":0.33092875967466107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339584422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165636,0.0021428412,0.000016911104,0.0034425638,0.00063581223,0.001655673,0.000010123869,0.000015433921,0.00042429462],"genre_scores_gemma":[0.9871924,0.009495963,0.0008417634,0.0011250786,0.0005650296,0.0000289012,0.000011904567,0.000024403127,0.00071457913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935081,0.0010639109,0.0035462987,0.00042616716,0.0010569552,0.00039857827],"domain_scores_gemma":[0.9935613,0.0014384893,0.0025200837,0.0005160755,0.0011379103,0.0008261354],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017269491,0.0003113467,0.003213193,0.00023746783,0.00007076446,0.000005660737,0.00024106116,0.00033192922,0.00027813957],"category_scores_gemma":[0.009526195,0.00018115727,0.00077404815,0.00025257553,0.00008868949,0.00014114766,0.000057277208,0.00097094284,0.000029814555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016423324,0.046309683,0.6242769,0.000109123546,0.00087132363,0.0020715673,0.00039381027,1.8803382e-7,0.0000316151,0.0000012412967,0.004069974,0.30544126],"study_design_scores_gemma":[0.037751965,0.22702527,0.7158356,0.00068322633,0.00067945465,0.000071570925,0.000115775394,0.000011857271,0.00001883465,0.00002150572,0.017676862,0.000108129745],"about_ca_topic_score_codex":0.00019357547,"about_ca_topic_score_gemma":0.00029846368,"teacher_disagreement_score":0.30533314,"about_ca_system_score_codex":0.0036214157,"about_ca_system_score_gemma":0.0013497006,"threshold_uncertainty_score":0.99881697},"labels":[],"label_agreement":null},{"id":"W2340216483","doi":"10.1182/blood.v124.21.4714.4714","title":"Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; Stromal cell; Gene knockdown; Alternative splicing; Cell biology; Molecular biology; Small hairpin RNA; Cell culture; RNA splicing; Podosome; Cancer research; Cell adhesion; Cell; Exon; RNA; Cytoskeleton; Gene; Genetics","score_opus":0.01595184215941961,"score_gpt":0.2614747376178033,"score_spread":0.2455228954583837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340216483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776125,0.0001785154,0.00009795495,0.00013080964,0.000022695951,0.0011354659,0.000010791203,0.00001764738,0.00064488663],"genre_scores_gemma":[0.9948492,0.000050367114,0.0041791084,0.000012796312,0.00006428459,0.000069144226,0.000045963956,0.000027259719,0.00070188235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844444,0.000105074476,0.00035952742,0.00031921413,0.00042013868,0.00035158367],"domain_scores_gemma":[0.9993373,0.000054241977,0.000170453,0.00030820078,0.000029583449,0.00010018537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002497217,0.0001783524,0.00034222024,0.00015903647,0.000047378868,0.0000058398464,0.00008182876,0.000073087154,0.000062361934],"category_scores_gemma":[0.000058710564,0.00015279868,0.00008152834,0.00015828446,0.000054918248,0.00012560125,0.00006999445,0.00012610236,0.000043308377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002010328,0.0008773978,0.04030564,0.00017052486,0.00011565086,0.000036154917,0.0002856854,0.000026359408,0.9533718,0.000054090262,0.0000053727385,0.0045502954],"study_design_scores_gemma":[0.0067528603,0.00035577817,0.17404436,0.0004996647,0.000053681477,0.000013176059,0.00003921357,0.0002982707,0.8175079,0.00028293717,0.00005204484,0.00010010535],"about_ca_topic_score_codex":0.0002235532,"about_ca_topic_score_gemma":0.00002896586,"teacher_disagreement_score":0.13586389,"about_ca_system_score_codex":0.00010892366,"about_ca_system_score_gemma":0.000022102455,"threshold_uncertainty_score":0.6230949},"labels":[],"label_agreement":null},{"id":"W2340844015","doi":"10.1371/journal.pone.0127828","title":"Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Musculoskeletal Research Center, Washington University in St. Louis; National Institute on Aging; National Institutes of Health","keywords":"Monoclonal gammopathy of undetermined significance; Biology; Multiple myeloma; Exome sequencing; Stromal cell; Haplotype; Exome; Bone marrow; Plasma cell; Phenotype; Genetics; Cancer research; Gene; Monoclonal; Antibody; Immunology; Genotype; Monoclonal antibody","score_opus":0.11507520937882552,"score_gpt":0.29928180585935243,"score_spread":0.1842065964805269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340844015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946267,0.0012929573,0.000015985283,0.00051705475,0.000025276717,0.0013393302,0.0017428156,0.000060472983,0.00037942993],"genre_scores_gemma":[0.99403226,0.00013045975,0.002671832,0.000053064676,0.000096414864,0.000106166866,0.0005799515,0.000048283513,0.002281592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975603,0.00015064473,0.0004313192,0.00036725617,0.0010190486,0.00047138552],"domain_scores_gemma":[0.99756294,0.00029863918,0.00019615697,0.00082150515,0.0004598316,0.0006608975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003508429,0.00025402947,0.0005425208,0.00014227237,0.00007493464,0.000016959895,0.00031185558,0.00008359196,0.00008690809],"category_scores_gemma":[0.0010238843,0.00017701094,0.00011638181,0.00029404112,0.00035712976,0.00013795501,0.00013355537,0.00023689437,0.00012820115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014147012,0.0042671645,0.17633407,0.0007063924,0.00041275253,0.00007437636,0.0007972785,0.000028498027,0.8154149,0.00001958172,0.000086525295,0.00044378472],"study_design_scores_gemma":[0.014536073,0.0019875385,0.21946964,0.0005945997,0.000744351,0.0000046473133,0.0011426305,0.008318021,0.7517447,0.00014175521,0.0008300098,0.00048604762],"about_ca_topic_score_codex":0.0004205089,"about_ca_topic_score_gemma":0.00015319182,"teacher_disagreement_score":0.06367019,"about_ca_system_score_codex":0.0001313621,"about_ca_system_score_gemma":0.000474744,"threshold_uncertainty_score":0.72182965},"labels":[],"label_agreement":null},{"id":"W2341490834","doi":"10.1371/journal.pone.0140463","title":"Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"Kidney Foundation of Canada; Canadian Institutes of Health Research; Canadian Society of Nephrology; Université Laval","keywords":"Multiple myeloma; Materials science; Immunoglobulin light chain; Medicine; Internal medicine; Immunology","score_opus":0.029259137699182314,"score_gpt":0.23979429995045762,"score_spread":0.2105351622512753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341490834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973568,0.00008862934,0.00004342626,0.00016196167,0.000021505131,0.0019851292,0.00004399061,0.000029932144,0.000268637],"genre_scores_gemma":[0.9973048,0.000006547183,0.0021080382,0.0000143595325,0.00004206473,0.00019564011,0.00023329524,0.00004459881,0.000050630402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977526,0.00028795667,0.0003107125,0.0003939285,0.0008485526,0.000406235],"domain_scores_gemma":[0.998737,0.00011227274,0.000076678865,0.00051900814,0.0002885323,0.00026652424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032451237,0.00023745975,0.00068434805,0.00034316533,0.000030136953,0.000015671098,0.00010576786,0.0000866588,0.000027446955],"category_scores_gemma":[0.00023194819,0.00017029888,0.000028129596,0.0004957074,0.000071355615,0.00020852212,0.000056080007,0.00019400963,0.000008908624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023289781,0.0064778714,0.9086271,0.000538558,0.00032487078,0.00017924515,0.0009719222,0.000020535965,0.05893226,0.000011967701,0.0000052741843,0.00062061974],"study_design_scores_gemma":[0.028733049,0.0034297486,0.79740715,0.0020232904,0.000091593756,0.0000029989858,0.0000668767,0.00020513628,0.16788542,0.000011943328,5.205362e-7,0.00014226438],"about_ca_topic_score_codex":0.0021869,"about_ca_topic_score_gemma":0.0007695229,"teacher_disagreement_score":0.11121994,"about_ca_system_score_codex":0.00040077104,"about_ca_system_score_gemma":0.00026912554,"threshold_uncertainty_score":0.69445866},"labels":[],"label_agreement":null},{"id":"W2342410120","doi":"10.1182/blood.v122.21.1735.1735","title":"Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Autologous stem-cell transplantation; Regimen; Oncology; Internal medicine; Transplantation; Clinical trial; Progression-free survival; Surgery; Chemotherapy","score_opus":0.022281077438896686,"score_gpt":0.25776500038183753,"score_spread":0.23548392294294085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342410120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951239,0.0000782487,0.0000026463372,0.00007208502,0.000037327474,0.0044267867,0.0000842853,0.000014138557,0.0001605507],"genre_scores_gemma":[0.99876374,0.000099826,0.00020569525,0.000019509149,0.000007126037,0.0005838659,0.00024086778,0.000016637594,0.00006273765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981757,0.00015276646,0.00054556393,0.00036258734,0.0003100568,0.00045331803],"domain_scores_gemma":[0.9992393,0.00010347815,0.00008812012,0.00025383628,0.00009690321,0.00021832927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009590556,0.00020443508,0.00044744296,0.00030661962,0.000021337451,0.0000071024724,0.000069552305,0.0000917967,0.00006082344],"category_scores_gemma":[0.000047302277,0.00017142612,0.000039460734,0.00043451914,0.000020005185,0.00009901795,0.000013898539,0.00013033104,0.000014838245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006438666,0.003036605,0.90906096,0.00013135385,0.000040630748,0.0001833028,0.001053019,0.000024160003,0.0008570127,1.6029449e-7,0.000011543356,0.0849574],"study_design_scores_gemma":[0.023534296,0.00078474416,0.94792706,0.0001467732,0.00004834846,0.000007831571,0.00025186336,0.00044708242,0.026730109,0.0000016332158,0.00001210067,0.00010816604],"about_ca_topic_score_codex":0.91170484,"about_ca_topic_score_gemma":0.9486583,"teacher_disagreement_score":0.08484923,"about_ca_system_score_codex":0.00092241884,"about_ca_system_score_gemma":0.00078684493,"threshold_uncertainty_score":0.69905543},"labels":[],"label_agreement":null},{"id":"W2343386476","doi":"10.1056/nejmoa1516282","title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1054,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Hotel Dieu Hospital","funders":"Takeda Oncology","keywords":"Lenalidomide; Ixazomib; Medicine; Multiple myeloma; Dexamethasone; Oncology; Internal medicine; Dermatology; Pharmacology; Carfilzomib","score_opus":0.05120611506231794,"score_gpt":0.3360375626803982,"score_spread":0.28483144761808027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343386476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96096003,0.0028194436,0.00915232,0.02589359,0.00033323056,0.00047855472,0.000012943053,0.000016214703,0.00033364407],"genre_scores_gemma":[0.9855336,0.0009452556,0.008655086,0.00031994501,0.0027195292,0.0000057864663,0.0000047854537,0.000025347532,0.0017906707],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984388,0.00008184713,0.00049378315,0.00017288169,0.0004804825,0.00033225692],"domain_scores_gemma":[0.99704105,0.0014682519,0.0002234458,0.00016955541,0.00032681227,0.00077090395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010780597,0.00017780658,0.0006475345,0.0002496955,0.000058076093,0.000008547043,0.00009032714,0.00007108964,0.00021603584],"category_scores_gemma":[0.0038123121,0.000081976956,0.000098914315,0.00010398888,0.00017806288,0.0001240628,0.000024435707,0.0001611782,0.000005827524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010833017,0.000096092794,0.09096467,0.00006314233,0.00036672427,0.00035829688,0.00021265353,3.0487726e-7,0.03989277,0.00008061927,0.009126024,0.8480057],"study_design_scores_gemma":[0.62434155,0.010984986,0.16912422,0.0017185817,0.00061493943,0.0052532395,0.00016128764,0.0001483198,0.013017662,0.002010656,0.17239302,0.00023154146],"about_ca_topic_score_codex":0.0000752414,"about_ca_topic_score_gemma":0.000051102263,"teacher_disagreement_score":0.84777415,"about_ca_system_score_codex":0.00006968217,"about_ca_system_score_gemma":0.00018765645,"threshold_uncertainty_score":0.4563969},"labels":[],"label_agreement":null},{"id":"W2343681268","doi":"10.1038/onc.2016.116","title":"MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents","year":2016,"lang":"en","type":"article","venue":"Oncogene","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; National Cancer Institute; Celgene; Samuel Waxman Cancer Research Foundation; Foundation for the National Institutes of Health","keywords":"Biology; DNA damage; Histone; DNA repair; Homologous recombination; Chromatin; Molecular biology; DNA repair protein XRCC4; Cell biology; DNA; DNA methylation; Non-homologous end joining; Cancer research; Cell cycle; Cell; Gene expression; Gene; Nucleotide excision repair; Genetics","score_opus":0.04377347108432479,"score_gpt":0.36169508345842305,"score_spread":0.3179216123740983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343681268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148273,0.00013315513,0.00010181781,0.0018026026,0.000050741357,0.00070628576,0.000032321048,0.00009508022,0.005595245],"genre_scores_gemma":[0.9781019,0.000054013555,0.0036389385,0.0012145855,0.00013388014,0.000116416355,0.000016355909,0.000038327897,0.016685557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998206,0.00009894912,0.00025368168,0.00050928834,0.00039819014,0.000533866],"domain_scores_gemma":[0.9984995,0.00008367698,0.00003754135,0.00060580706,0.00007090535,0.0007025689],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032993118,0.0001883081,0.0003147847,0.00024367971,0.00006309766,0.000017388464,0.00016354464,0.00006193053,0.00034620299],"category_scores_gemma":[0.00030191115,0.00013222844,0.00007134099,0.0003927949,0.000036183927,0.00012625489,0.000064616324,0.000071332885,0.0008706105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019093103,0.0004943476,0.051565163,0.000060086313,0.00009388029,0.0005466595,0.0004372277,7.185224e-7,0.89461553,0.00002393272,0.0020552396,0.048197877],"study_design_scores_gemma":[0.00614372,0.0011960332,0.23198232,0.0008975731,0.000046997084,0.00001616502,0.00010506749,0.000033995457,0.70070654,0.000066575114,0.058423303,0.00038173294],"about_ca_topic_score_codex":0.00015864453,"about_ca_topic_score_gemma":0.0019142625,"teacher_disagreement_score":0.19390903,"about_ca_system_score_codex":0.0003827548,"about_ca_system_score_gemma":0.00012236577,"threshold_uncertainty_score":0.9999073},"labels":[],"label_agreement":null},{"id":"W2344741804","doi":"10.1080/10428194.2016.1177772","title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","year":2016,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Celgene","keywords":"Lenalidomide; Multiple myeloma; Medicine; Thalidomide; Oncology; Internal medicine; Autologous stem-cell transplantation; Bortezomib; Melphalan; Transplantation; Progression-free survival; Meta-analysis; Surgery; Chemotherapy","score_opus":0.033855129194133374,"score_gpt":0.30208937127960067,"score_spread":0.2682342420854673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344741804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017852881,0.975114,0.00017567708,0.000015738202,0.00005515863,0.01602083,0.0066990466,0.000078964826,0.000055279343],"genre_scores_gemma":[0.002091062,0.9786516,0.0010570964,0.0001354553,0.00006117536,0.0073315967,0.008359158,0.00021100369,0.002101881],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99409485,0.00044523543,0.0021246665,0.0015641218,0.0007076147,0.0010635328],"domain_scores_gemma":[0.9935698,0.0024190983,0.0016394504,0.0011150003,0.00070192,0.0005547463],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005125261,0.0015856026,0.01127696,0.00083589635,0.00031005777,0.00012275537,0.00029819345,0.0007396879,0.000019335384],"category_scores_gemma":[0.00008873851,0.000865113,0.0030160428,0.0015310862,0.00016583194,0.00024054084,0.00006514062,0.000102733575,0.000008366675],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014873667,0.00034327633,0.00028707308,0.61472714,0.20809777,0.0000831543,0.00013813123,0.0000021263027,0.000001752036,0.000021004418,0.00024665985,0.17456454],"study_design_scores_gemma":[0.026349721,0.0014855282,0.0009806304,0.13653095,0.8191066,0.00018890444,0.00001296598,0.00019223355,0.000044500648,0.000005318683,0.014220624,0.0008820618],"about_ca_topic_score_codex":0.00008677837,"about_ca_topic_score_gemma":0.000029596278,"teacher_disagreement_score":0.61100876,"about_ca_system_score_codex":0.0025635746,"about_ca_system_score_gemma":0.001596363,"threshold_uncertainty_score":0.9996892},"labels":[],"label_agreement":null},{"id":"W2345460629","doi":"10.1016/j.clml.2015.07.606","title":"A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Clarithromycin; Medicine; Multiple myeloma; Internal medicine; Oncology; Progressive disease; Disease; Pharmacology","score_opus":0.021835613811933528,"score_gpt":0.2889869361719164,"score_spread":0.26715132235998285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345460629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976265,0.00013829024,0.00001290416,0.00015493753,0.000036868052,0.0014796602,0.0004613473,0.000021378206,0.000068156645],"genre_scores_gemma":[0.9983353,0.000006657962,0.0012007328,0.000046952293,0.000042529762,0.000045155837,0.00019613391,0.000038566475,0.0000879778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961936,0.00044325454,0.0011813578,0.0006825316,0.0010321728,0.0004671163],"domain_scores_gemma":[0.99627274,0.0006349823,0.00070558337,0.0008069198,0.0008380555,0.0007417226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049796415,0.00032305447,0.0013927101,0.00043333924,0.000058232974,0.0000144542555,0.00023064179,0.00019700722,0.00006396873],"category_scores_gemma":[0.0035172354,0.00022100637,0.00035670862,0.0014878071,0.0006349419,0.00015309709,0.0002194277,0.00020901131,0.000006551745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014377873,0.0018460002,0.9633373,0.000121594916,0.0014329941,0.000074640375,0.00038780167,0.00007747589,0.00079620635,0.000010102776,0.000036957706,0.017501075],"study_design_scores_gemma":[0.02008457,0.0012834717,0.96966714,0.0007651976,0.001086495,0.00000259072,0.00013108856,0.0013538062,0.0053932015,0.0000338212,0.0000072958715,0.00019130921],"about_ca_topic_score_codex":0.00030172113,"about_ca_topic_score_gemma":0.00017800402,"teacher_disagreement_score":0.017309764,"about_ca_system_score_codex":0.0009514286,"about_ca_system_score_gemma":0.0007176652,"threshold_uncertainty_score":0.9012378},"labels":[],"label_agreement":null},{"id":"W2346242965","doi":"10.2147/ceor.s104195","title":"Cost-effectiveness of bortezomib for multiple myeloma: a systematic review","year":2016,"lang":"en","type":"review","venue":"ClinicoEconomics and Outcomes Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Thalidomide; Lenalidomide; Cost effectiveness; Melphalan; Internal medicine; Oncology","score_opus":0.3310564834221789,"score_gpt":0.560687487546833,"score_spread":0.22963100412465404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346242965","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005280172,0.9698036,0.00003299305,0.00009439546,0.00013266734,0.028781474,0.0008450636,0.000019702873,0.00023730981],"genre_scores_gemma":[0.00011698011,0.9898115,0.00020080598,0.000046411416,0.00007817456,0.008001998,0.00029630688,0.000116860174,0.0013309879],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9944742,0.0013108791,0.0020918471,0.0008829225,0.00040106341,0.00083913445],"domain_scores_gemma":[0.9712209,0.02577631,0.0006252524,0.0012610591,0.00058913406,0.0005273445],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008616997,0.0005363105,0.00791758,0.000582984,0.00014681483,0.000048835012,0.00043707245,0.00041835543,0.00005264249],"category_scores_gemma":[0.009803297,0.00031098793,0.0015448933,0.00021711842,0.00036254356,0.00007819619,0.00034577257,0.0005818749,0.00016379493],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001337845,0.00015670541,0.0005765875,0.7167809,0.0013358754,0.000015113579,0.000004250833,4.227531e-9,1.6124623e-7,0.00014866404,0.00012947804,0.28071845],"study_design_scores_gemma":[0.0047378154,0.0006481762,0.00046656988,0.8115968,0.002016767,0.00005442531,0.0000135918635,0.000025118085,0.0000029302996,0.000106925596,0.18000796,0.00032293165],"about_ca_topic_score_codex":0.000018153329,"about_ca_topic_score_gemma":0.000008191802,"teacher_disagreement_score":0.28039554,"about_ca_system_score_codex":0.00046669258,"about_ca_system_score_gemma":0.0011313892,"threshold_uncertainty_score":0.9999342},"labels":[],"label_agreement":null},{"id":"W2346817266","doi":"10.1016/j.clml.2016.04.012","title":"Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Prednisone; Cyclophosphamide; Tolerability; Dexamethasone; Regimen; Internal medicine; Multiple myeloma; Refractory (planetary science); Gastroenterology; Peripheral neuropathy; Surgery; Chemotherapy; Adverse effect; Endocrinology","score_opus":0.05131108994435344,"score_gpt":0.344220347304109,"score_spread":0.29290925735975554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346817266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991696,0.0036831857,0.00053735595,0.00108185,0.0001312314,0.002477367,0.00016184794,0.00008449485,0.00014667158],"genre_scores_gemma":[0.9783629,0.010917704,0.0066441223,0.00016058427,0.00026867603,0.00048791367,0.000029728199,0.0000880637,0.003040313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968117,0.0001752847,0.00097040425,0.00089788495,0.00045908985,0.00068565225],"domain_scores_gemma":[0.9881351,0.009606814,0.00036675882,0.00095780427,0.00025637203,0.0006771786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005668084,0.0004813686,0.0011377936,0.000104979714,0.00024773608,0.000033294535,0.00017595211,0.0003249666,0.000058546833],"category_scores_gemma":[0.0019515383,0.00020573621,0.00025695332,0.00021309212,0.001280379,0.00015272835,0.000083899664,0.000106236,0.0000142123245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0251583,0.0007741332,0.22627507,0.00008849658,0.00091406953,0.00019444955,0.00013416974,2.557025e-7,0.0014721957,0.000044605786,0.0002513593,0.74469286],"study_design_scores_gemma":[0.048772722,0.013538251,0.9077841,0.00032781146,0.0005388907,0.00022139137,0.00011782215,0.00041755495,0.0045658736,0.00007588389,0.023372184,0.0002675153],"about_ca_topic_score_codex":0.00022505486,"about_ca_topic_score_gemma":0.00019983691,"teacher_disagreement_score":0.74442536,"about_ca_system_score_codex":0.00060392206,"about_ca_system_score_gemma":0.00094068114,"threshold_uncertainty_score":0.838968},"labels":[],"label_agreement":null},{"id":"W2352795241","doi":"10.1182/blood.v122.21.130.130","title":"A Transgenic Model Of Multiple Myeloma Bone Disease Shows Profound Mesenchymal Stem Cell Impairment","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Genetically modified mouse; Apposition; Osteoclast; Transgene; Bone disease; Mesenchymal stem cell; Pathology; Osteolysis; Multiple myeloma; Osteoblast; Bone mineral; Biology; Immunology; Internal medicine; Osteoporosis; Medicine; Anatomy; Surgery; In vitro; Genetics; Receptor","score_opus":0.027330745517966923,"score_gpt":0.26134452595986196,"score_spread":0.23401378044189503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2352795241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956174,0.0006720102,0.00016654024,0.0002585046,0.000023194792,0.0022631611,0.00012324622,0.000062817424,0.00081311783],"genre_scores_gemma":[0.9936051,0.00004734073,0.0018807845,0.000043986733,0.000050588777,0.00045977894,0.000055542485,0.000038676288,0.003818236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980847,0.000051973628,0.00036715355,0.00036452946,0.00059611397,0.0005354944],"domain_scores_gemma":[0.9984587,0.00005791619,0.00007779938,0.0005107865,0.00015036894,0.00074445555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010495268,0.00023504437,0.00038677442,0.0001241176,0.000068747126,0.000020586363,0.00011737119,0.000071970244,0.00029720447],"category_scores_gemma":[0.000021603428,0.00017965937,0.00023800346,0.00013192081,0.000081156206,0.0001276161,0.000053031596,0.000147601,0.00014833434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024512364,0.026648764,0.48763153,0.0024995496,0.0011968011,0.00052659394,0.001664029,0.0002079045,0.46242753,0.00006886517,0.00088381773,0.013793393],"study_design_scores_gemma":[0.065419905,0.003210583,0.4452686,0.00035750362,0.001574135,0.000060994673,0.0005490108,0.13874231,0.3436234,0.0003054712,0.00011744149,0.00077061635],"about_ca_topic_score_codex":0.00013116059,"about_ca_topic_score_gemma":0.000022349846,"teacher_disagreement_score":0.13853441,"about_ca_system_score_codex":0.000050712224,"about_ca_system_score_gemma":0.00028949126,"threshold_uncertainty_score":0.73262966},"labels":[],"label_agreement":null},{"id":"W23628980","doi":"10.1634/theoncologist.2012-0384","title":"Возвращение к истокам","year":2011,"lang":"en","type":"article","venue":"Методология и история психологии","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Otsuka Canada Pharmaceutical","keywords":"Computer science","score_opus":0.11125204592255501,"score_gpt":0.3362291736385359,"score_spread":0.22497712771598088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23628980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6837082,0.00078274973,0.00043545954,0.0005339312,0.00047080856,0.0012594955,0.000042635704,0.00063169864,0.31213504],"genre_scores_gemma":[0.9810493,0.00013617738,0.0062076855,0.0006140488,0.0003039343,0.000111917376,0.00008209164,0.00009760555,0.011397215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997029,0.0000890644,0.00046405953,0.0006667994,0.0007302767,0.0010207786],"domain_scores_gemma":[0.99771583,0.000075114636,0.00010505731,0.0010063567,0.0002241508,0.00087349553],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027349565,0.0004144837,0.00056918996,0.0003285334,0.00019700741,0.000037429036,0.0002945163,0.00021632724,0.00469874],"category_scores_gemma":[0.0002185571,0.00033671065,0.00031579542,0.00048058177,0.00021860225,0.00022198811,0.00016025171,0.0004525756,0.0038311644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005255457,0.0062913536,0.76399046,0.00063073094,0.0020483427,0.006923496,0.0038265185,0.0000017203746,0.015157183,0.012218527,0.036015276,0.14764094],"study_design_scores_gemma":[0.010915048,0.0021448142,0.88646936,0.00025703438,0.00036221466,0.000921986,0.00045868594,0.00037885868,0.04246982,0.0022325006,0.052488383,0.00090130727],"about_ca_topic_score_codex":0.0005160998,"about_ca_topic_score_gemma":0.00005075475,"teacher_disagreement_score":0.30073783,"about_ca_system_score_codex":0.00016890478,"about_ca_system_score_gemma":0.00024545906,"threshold_uncertainty_score":0.9999085},"labels":[],"label_agreement":null},{"id":"W2366481835","doi":"10.1111/bjh.14125","title":"A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis","year":2016,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Takeda Oncology","keywords":"Ixazomib; Medicine; Multiple myeloma; Renal function; Pharmacokinetics; Urology; End stage renal disease; Adverse effect; Internal medicine; Gastroenterology; Pharmacology; Proteasome inhibitor; Hemodialysis; Carfilzomib","score_opus":0.019561755818772963,"score_gpt":0.3082482007602953,"score_spread":0.28868644494152235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2366481835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982251,0.00043597078,0.000115183015,0.00019152017,0.000032317887,0.0008236329,0.0001608479,0.000007211179,0.000008234199],"genre_scores_gemma":[0.99855995,0.00042394354,0.00084317685,0.000027966513,0.000030297717,0.000015988686,0.000013262729,0.000023992103,0.00006142762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977235,0.00027242955,0.0007944684,0.00029713105,0.0005184454,0.00039401665],"domain_scores_gemma":[0.9983963,0.00022955322,0.00039497836,0.00016488545,0.00027160326,0.00054271513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003608882,0.00020392163,0.0009059998,0.000307836,0.00008091137,0.000022854989,0.00010010325,0.000058514917,0.00013228404],"category_scores_gemma":[0.00038403904,0.00013455341,0.000070077396,0.00016869293,0.00023714647,0.00020837644,0.00010986029,0.0002155407,7.095215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043323282,0.006816638,0.8057331,0.00015504741,0.00070777093,0.053467453,0.00028174065,0.000006083233,0.0003261593,0.0000016221279,0.000088353816,0.089092754],"study_design_scores_gemma":[0.15796302,0.007238457,0.8229841,0.0010986412,0.00042026423,0.00929147,0.00022521192,0.00015217799,0.00035400616,0.000010544461,0.00009037904,0.00017170276],"about_ca_topic_score_codex":0.00015224653,"about_ca_topic_score_gemma":0.00058097887,"teacher_disagreement_score":0.114639744,"about_ca_system_score_codex":0.00009566955,"about_ca_system_score_gemma":0.00018256911,"threshold_uncertainty_score":0.5486929},"labels":[],"label_agreement":null},{"id":"W2366488966","doi":"10.1136/vetreccr-2016-000304","title":"Multiple myeloma in a dog: a typical presentation with an atypical serum protein electrophoretogram","year":2016,"lang":"en","type":"article","venue":"Veterinary Record Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Serum protein electrophoresis; Multiple myeloma; Pathology; Histopathology; Proteinuria; Osteolysis; Bence Jones protein; Bone marrow; Biopsy; Urinalysis; Anatomy; Radiology; Internal medicine; Immunoglobulin light chain; Urinary system; Kidney; Antibody; Monoclonal","score_opus":0.03516597473196256,"score_gpt":0.3264659316347718,"score_spread":0.2912999569028092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2366488966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738204,0.00004185797,0.00022458039,0.00025464056,0.000050704544,0.0017683936,0.000009935569,0.00011428189,0.00015358164],"genre_scores_gemma":[0.9937356,0.000019183093,0.0049829166,0.00001988119,0.00010812684,0.00057684677,0.000036424004,0.000049056558,0.00047196035],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9977266,0.00017525803,0.00045232015,0.0006599345,0.0003897594,0.00059612066],"domain_scores_gemma":[0.99860275,0.00007515987,0.00012964368,0.0006135182,0.000106207044,0.0004727201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020381388,0.00025307765,0.00035944168,0.00021642685,0.000076583165,0.000029432078,0.000039181054,0.00013381429,0.00021512526],"category_scores_gemma":[0.0001958818,0.00015270498,0.00008159355,0.00029412544,0.00010695529,0.0002430975,0.000057939924,0.00020426295,0.000023761051],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013108608,0.0006686909,0.2872316,0.00005784103,0.00006318189,0.5311543,0.000039655795,1.7173943e-7,0.039725408,0.0000032525654,0.000017946993,0.12792939],"study_design_scores_gemma":[0.0055845696,0.020975182,0.50193846,0.00039462605,0.000039860104,0.46176317,0.00006708897,0.00046463768,0.0062737563,0.00010359128,0.0020725299,0.00032253884],"about_ca_topic_score_codex":0.00037592073,"about_ca_topic_score_gemma":0.00046511163,"teacher_disagreement_score":0.21470687,"about_ca_system_score_codex":0.00022968551,"about_ca_system_score_gemma":0.00019567313,"threshold_uncertainty_score":0.6227128},"labels":[],"label_agreement":null},{"id":"W2371874718","doi":"","title":"The Effect of Yi-Shen-Huo-Xue Yin(YSHXY)Plus Arsenic Trioxide on Multiple Myeloma Lytic Bone Disease","year":2009,"lang":"en","type":"article","venue":"Liaoning zhongyi zazhi","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; RANKL; Osteoprotegerin; Multiple myeloma; Internal medicine; Bone pain; Arsenic trioxide; Bone remodeling; Bone resorption; N-terminal telopeptide; Endocrinology; Bone disease; Alkaline phosphatase; Osteoporosis; Osteocalcin; Activator (genetics); Receptor; Arsenic; Biochemistry; Chemistry","score_opus":0.013283438862624288,"score_gpt":0.29447713602558306,"score_spread":0.2811936971629588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2371874718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202836,0.0015182669,0.00005162187,0.0018313361,0.0002447644,0.001650627,0.000035857876,0.00017473623,0.0024644178],"genre_scores_gemma":[0.9934978,0.0001543651,0.00025540122,0.00022228228,0.0002785062,0.00010439004,0.0000717524,0.000060161048,0.005355381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654114,0.0002991639,0.00058437116,0.00061499985,0.0009942298,0.00096610934],"domain_scores_gemma":[0.9957758,0.0019799063,0.00020984346,0.0011577978,0.0001092286,0.00076741166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058947306,0.00047097923,0.0007640791,0.00023442294,0.0004113647,0.00007628681,0.00029522047,0.00013141693,0.000064948814],"category_scores_gemma":[0.00340922,0.00029879579,0.00045645068,0.0004527941,0.00019804004,0.00010946389,0.00008178751,0.0005354593,0.00030208295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054554835,0.0023414013,0.52817917,0.0010644097,0.0018369727,0.007176155,0.0012393653,0.00095971185,0.047163375,0.0010719668,0.008251548,0.34616107],"study_design_scores_gemma":[0.026379552,0.007890972,0.90259093,0.0015033622,0.0005822893,0.0001047365,0.00009499384,0.014222388,0.040588595,0.0002498401,0.005195261,0.0005971085],"about_ca_topic_score_codex":0.000113612616,"about_ca_topic_score_gemma":0.000026878619,"teacher_disagreement_score":0.3744117,"about_ca_system_score_codex":0.00033626892,"about_ca_system_score_gemma":0.0002572936,"threshold_uncertainty_score":0.9999464},"labels":[],"label_agreement":null},{"id":"W2377143140","doi":"10.1080/10428194.2016.1180685","title":"Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Lenalidomide; Randomization; Multiple myeloma; Internal medicine; Refractory (planetary science); Gastroenterology; Phases of clinical research; Randomized controlled trial; Progressive disease; Surgery; Clinical trial; Chemotherapy","score_opus":0.018214258481873274,"score_gpt":0.2731410443367429,"score_spread":0.2549267858548696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2377143140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249035,0.00050424377,0.000033724307,0.00015949598,0.0000787813,0.0064112083,0.00008462374,0.000057357145,0.00018022611],"genre_scores_gemma":[0.99801534,0.00024443195,0.000380257,0.000077804856,0.00008937397,0.00063061964,0.00011456093,0.00008839565,0.00035922608],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321204,0.0025345418,0.0013116933,0.001024038,0.0010692733,0.00084842485],"domain_scores_gemma":[0.9889561,0.009001662,0.0005607471,0.00081078924,0.0001903352,0.0004803431],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028603396,0.0007258201,0.0020262187,0.0007380535,0.00023099013,0.0000796133,0.00022108144,0.00044682386,0.000019522322],"category_scores_gemma":[0.0032731118,0.00038333194,0.00016242494,0.0008069505,0.0011849141,0.0004159129,0.00010250199,0.00023418436,0.0000034511113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85542494,0.0012462229,0.119510725,0.00008393068,0.00028662506,0.0005393638,0.0010559086,0.000002640648,0.0004364966,0.000049097383,0.000022269065,0.021341754],"study_design_scores_gemma":[0.62279856,0.004795893,0.37032005,0.00044159,0.00024509418,0.0000771528,0.0002493104,0.00038718848,0.0003055019,0.000029217921,0.00004746093,0.00030300455],"about_ca_topic_score_codex":0.0022780555,"about_ca_topic_score_gemma":0.00050865964,"teacher_disagreement_score":0.2508093,"about_ca_system_score_codex":0.0029102634,"about_ca_system_score_gemma":0.0024548692,"threshold_uncertainty_score":0.99986184},"labels":[],"label_agreement":null},{"id":"W2400894217","doi":"10.1182/blood.v126.23.727.727","title":"Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Ixazomib; Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Progression-free survival; Oncology; Internal medicine; Proteasome inhibitor; Pegfilgrastim; Miltefosine; Pharmacology; Febrile neutropenia; Neutropenia; Overall survival; Carfilzomib; Chemotherapy; Immunology","score_opus":0.05309745008142338,"score_gpt":0.3334005016023233,"score_spread":0.28030305152089996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400894217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991762,0.00011910218,0.000055229077,0.00044544012,0.000046973702,0.007356996,0.00012780033,0.00006606012,0.000020393192],"genre_scores_gemma":[0.98980063,0.000008296461,0.007776378,0.00005205446,0.0001365947,0.0016808728,0.0003705455,0.000067831774,0.000106804844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966999,0.00048387342,0.0004749221,0.00067515334,0.0011731032,0.0004930294],"domain_scores_gemma":[0.99742645,0.0005328992,0.00025495482,0.00053601677,0.00059885223,0.0006508554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011996251,0.00038431986,0.0005312453,0.00023604109,0.00023019544,0.00009777791,0.00018526346,0.00011655381,0.000008435347],"category_scores_gemma":[0.0019235121,0.00020782874,0.000034549437,0.00035327292,0.0003383557,0.00045901912,0.00010742132,0.00033702553,0.0000014276192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03847482,0.025474634,0.9138755,0.00013166934,0.00036487114,0.00024438044,0.0019222451,0.0000031324093,0.0010579089,0.000020682732,0.00008632951,0.018343836],"study_design_scores_gemma":[0.33494088,0.053600784,0.60233206,0.00039616082,0.0004056385,0.00006653415,0.0023812896,0.0020431248,0.0031309412,0.00013548207,0.00013207473,0.00043502645],"about_ca_topic_score_codex":0.0002091289,"about_ca_topic_score_gemma":0.001290431,"teacher_disagreement_score":0.31154343,"about_ca_system_score_codex":0.00010863908,"about_ca_system_score_gemma":0.00055342534,"threshold_uncertainty_score":0.847501},"labels":[],"label_agreement":null},{"id":"W2402003835","doi":"10.1182/blood-2016-03-705210","title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Refractory (planetary science); Carfilzomib; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Pomalidomide; Bortezomib","score_opus":0.028289681126676833,"score_gpt":0.32043252700161345,"score_spread":0.2921428458749366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402003835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982246,0.00009560217,0.000013081418,0.00008024874,0.00003906839,0.0011076614,0.000049394253,0.000049893915,0.000340409],"genre_scores_gemma":[0.9979445,0.000106068466,0.001161345,0.000032373224,0.000042473883,0.00003405095,0.00004636015,0.00004357381,0.00058926176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804395,0.00016293529,0.0005450769,0.00041692864,0.00045440145,0.00037667694],"domain_scores_gemma":[0.99821216,0.00061403244,0.00015697014,0.00059182424,0.00016803243,0.00025701144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018876647,0.00020827314,0.00053199433,0.00017072895,0.0000355781,0.0000060076613,0.000119176315,0.00015310518,0.00014342465],"category_scores_gemma":[0.0007184711,0.00010257495,0.00010025455,0.00027347065,0.00015549357,0.00009692564,0.000030585423,0.00018488432,0.000042255757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027286505,0.009637159,0.91349417,0.000028798479,0.0003774024,0.00014821358,0.000061807696,9.888685e-8,0.0009439565,0.0000017558574,0.000054937875,0.047965206],"study_design_scores_gemma":[0.13658059,0.006671669,0.8517203,0.00041845837,0.00007119969,0.000004020893,0.0000065264067,0.0000065561917,0.0041466653,0.0000020649557,0.0002591473,0.000112830305],"about_ca_topic_score_codex":0.00007386773,"about_ca_topic_score_gemma":0.00009035294,"teacher_disagreement_score":0.10929409,"about_ca_system_score_codex":0.000064568696,"about_ca_system_score_gemma":0.00019767553,"threshold_uncertainty_score":0.41828853},"labels":[],"label_agreement":null},{"id":"W2402661058","doi":"10.1158/1078-0432.ccr-15-1790","title":"The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Cancer Institute; Wellcome Trust","keywords":"Multiple myeloma; Epigenetics; Medicine; Genetics; Biology; Cancer research; Oncology; Computational biology; Internal medicine; Gene","score_opus":0.26439112371027307,"score_gpt":0.5900468396188847,"score_spread":0.32565571590861164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402661058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014884,0.0014391601,0.000021490965,0.006785415,0.000080727674,0.0007381708,0.000036669197,0.000008735832,0.0007407958],"genre_scores_gemma":[0.98684835,0.011231695,0.00005731482,0.000019883639,0.00023100393,0.00009958946,0.0000028491654,0.00001831864,0.0014909781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651,0.0009201986,0.0008284044,0.000407848,0.0006820667,0.00065146066],"domain_scores_gemma":[0.9907172,0.007886841,0.000075491895,0.00052920246,0.00027600664,0.0005152614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044904193,0.000109835375,0.00040650347,0.00015693303,0.00013059677,0.000022124495,0.00019957022,0.00014535974,0.00031986524],"category_scores_gemma":[0.005409927,0.00004981627,0.00024603325,0.00039553075,0.0017481842,0.000047886468,0.00016962638,0.00063491194,0.000070817274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015736369,0.00031331662,0.75746834,0.000012915501,0.00016480383,0.00005165074,0.000017979532,5.7251367e-7,0.00015181069,0.000085523025,0.0004283691,0.23973106],"study_design_scores_gemma":[0.0050149714,0.0020287079,0.9897846,0.00013972317,0.0000181886,0.0000050390536,0.000028054184,0.00023106232,0.00024044495,0.001902157,0.0005522694,0.000054771837],"about_ca_topic_score_codex":0.001286084,"about_ca_topic_score_gemma":0.0014018143,"teacher_disagreement_score":0.2396763,"about_ca_system_score_codex":0.00021228901,"about_ca_system_score_gemma":0.001100142,"threshold_uncertainty_score":0.6476579},"labels":[],"label_agreement":null},{"id":"W2402933581","doi":"10.1002/cncr.30026","title":"Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Hazard ratio; Clinical endpoint; Interim analysis; Refractory (planetary science); Oncology; Randomized controlled trial; Surgery; Gastroenterology; Confidence interval","score_opus":0.03908266839749894,"score_gpt":0.2993876865394823,"score_spread":0.26030501814198337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402933581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994651,0.00016452103,0.00005134016,0.0002487119,0.00019032304,0.003920745,0.00019596332,0.00006081578,0.0005165617],"genre_scores_gemma":[0.9968723,0.00011876599,0.00042447654,0.000034933513,0.00016038219,0.00041577555,0.00019474528,0.00006734329,0.0017112762],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962648,0.0003440524,0.0009887972,0.0006703679,0.0010205313,0.000711429],"domain_scores_gemma":[0.9971856,0.0009274307,0.0005082977,0.0005881542,0.00043554223,0.00035501542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000560016,0.00042216337,0.0019093675,0.0003020591,0.00007185642,0.000019422781,0.00017153528,0.00016904487,0.00018530319],"category_scores_gemma":[0.00097538927,0.00020743995,0.0001662976,0.00036184274,0.00034358317,0.0002246572,0.000065572895,0.0003261596,0.000011001367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81656754,0.0008965226,0.17732894,0.000068509566,0.0007398361,0.00021961243,0.0002313831,0.000029438886,0.00064377656,0.0000041678877,0.00017232027,0.0030979484],"study_design_scores_gemma":[0.7079899,0.0031160132,0.2857614,0.0010408099,0.00019122171,0.0000040189116,0.000018810952,0.00045268444,0.0010546317,0.0000023998168,0.0001469946,0.00022116995],"about_ca_topic_score_codex":0.0028720414,"about_ca_topic_score_gemma":0.0042111054,"teacher_disagreement_score":0.10857768,"about_ca_system_score_codex":0.0006683506,"about_ca_system_score_gemma":0.000988555,"threshold_uncertainty_score":0.84591556},"labels":[],"label_agreement":null},{"id":"W2409070542","doi":"10.1080/10428194.2016.1177181","title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Clinical trial; Urology; Renal function; Refractory (planetary science); Creatinine; Dosing; Surgery; Lenalidomide; Gastroenterology","score_opus":0.034032644198169676,"score_gpt":0.3138947330508331,"score_spread":0.2798620888526634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409070542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960508,0.00094806805,0.0003704603,0.00009872345,0.000092561204,0.0019029712,0.00028670626,0.000091702546,0.00015801255],"genre_scores_gemma":[0.9966307,0.0007181789,0.0015068552,0.00020564716,0.00011476275,0.00018692178,0.00021362418,0.00010338304,0.00031987327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99267,0.0011168064,0.0024081254,0.001478773,0.0011635853,0.0011626992],"domain_scores_gemma":[0.9929114,0.0035100551,0.00097510475,0.0011054381,0.00037307793,0.001124945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002743719,0.000838792,0.003449233,0.0012551843,0.00019754446,0.00008224562,0.0002827621,0.0006249066,0.000112969414],"category_scores_gemma":[0.0020689147,0.0005212768,0.00062334654,0.0011375434,0.00076314504,0.00045155745,0.00026907225,0.00021040108,0.00001993801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046495635,0.0011097908,0.7118794,0.00013521529,0.0052575185,0.0004367518,0.000262922,0.00004969442,0.0013928043,0.000031564232,0.00007501043,0.23287371],"study_design_scores_gemma":[0.15938456,0.0021869368,0.8173243,0.00062088843,0.0028044411,0.00004311616,0.000060974533,0.015709301,0.0012032324,0.00007482703,0.00008501813,0.0005024382],"about_ca_topic_score_codex":0.0019596312,"about_ca_topic_score_gemma":0.0010025325,"teacher_disagreement_score":0.23237127,"about_ca_system_score_codex":0.0043002767,"about_ca_system_score_gemma":0.002959663,"threshold_uncertainty_score":0.99972385},"labels":[],"label_agreement":null},{"id":"W2409224885","doi":"10.1182/blood.v122.21.3198.3198","title":"MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (&gt; 65 Years of Age)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Lenalidomide","score_opus":0.018021240543051906,"score_gpt":0.2833395327326576,"score_spread":0.2653182921896057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409224885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212825,0.00020856557,0.00006298741,0.000072975075,0.0001013654,0.007127438,0.00021543392,0.000045565725,0.00003742772],"genre_scores_gemma":[0.99394757,0.00004187287,0.004596498,0.00005400449,0.000054741522,0.000715594,0.0003503838,0.00012035122,0.00011896133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99536467,0.00036602092,0.0013044839,0.00087257935,0.0012234419,0.0008687965],"domain_scores_gemma":[0.9966045,0.00096900784,0.00060413446,0.00086698943,0.00058603846,0.00036934737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000601448,0.0005250923,0.001371936,0.0009752091,0.000076182056,0.00003747296,0.0003333256,0.00030244674,0.00011206372],"category_scores_gemma":[0.0011242633,0.00048442182,0.00018022944,0.0009249869,0.00018596706,0.00033832502,0.00012521606,0.00047386164,0.000023468609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018299773,0.10850934,0.75673056,0.0005433618,0.00092894206,0.0005019926,0.0040314007,0.00007222346,0.020559078,0.000020821797,0.000095699754,0.08970681],"study_design_scores_gemma":[0.21679772,0.021070179,0.7423052,0.00043682888,0.00030134816,0.000006924598,0.0006598416,0.0007642002,0.017165678,0.00010165961,0.000021776541,0.0003686313],"about_ca_topic_score_codex":0.007950933,"about_ca_topic_score_gemma":0.0027965168,"teacher_disagreement_score":0.19849794,"about_ca_system_score_codex":0.00023686762,"about_ca_system_score_gemma":0.0002803928,"threshold_uncertainty_score":0.99976075},"labels":[],"label_agreement":null},{"id":"W2409580646","doi":"10.1016/j.bbmt.2015.11.848","title":"Bortezomib Consolidation after Allogeneic Nonmyeloablative Transplantation to Improve Outcome in Poor Prognosis Multiple Myeloma Patients: A Preliminary Safety Report","year":2016,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Hematopoietic stem cell transplantation; Internal medicine; Incidence (geometry); Oncology; Transplantation","score_opus":0.013323334151377611,"score_gpt":0.2776179521704551,"score_spread":0.2642946180190775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409580646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950477,0.000097388016,0.0016096785,0.00062294595,0.00007201655,0.0016747717,0.00075832644,0.00002708952,0.00009007237],"genre_scores_gemma":[0.99572533,0.00059326534,0.0021031226,0.00007970085,0.000026558602,0.00036802387,0.0010231861,0.000017494423,0.00006329205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998302,0.00011904945,0.0006519058,0.00046049076,0.00016503883,0.0003015268],"domain_scores_gemma":[0.99916285,0.0002338643,0.00015691161,0.00013306031,0.00015522217,0.00015807955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023156048,0.00020667182,0.00037499116,0.0002812486,0.0000450145,0.000005118594,0.000048206577,0.00017389584,0.000030258405],"category_scores_gemma":[0.00011889499,0.00014489712,0.00007276953,0.00013849861,0.00011545544,0.00015579653,0.0000104412775,0.00007586276,0.0000060999214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009812911,0.00038090823,0.7650856,0.00028492164,0.00014265215,0.00022183023,0.0004679789,5.117201e-7,0.20352626,0.0000135837245,0.0000017603887,0.020061111],"study_design_scores_gemma":[0.010914177,0.0018907706,0.86825424,0.00024495425,0.00033261467,0.00012146762,0.000027562655,0.000014364418,0.11800093,0.000025841056,0.000025620571,0.00014742496],"about_ca_topic_score_codex":0.00014292289,"about_ca_topic_score_gemma":0.000245087,"teacher_disagreement_score":0.1031687,"about_ca_system_score_codex":0.0000382845,"about_ca_system_score_gemma":0.0000632651,"threshold_uncertainty_score":0.59087324},"labels":[],"label_agreement":null},{"id":"W2410851753","doi":"10.1016/j.clml.2016.06.001","title":"Revised International Staging System Applied to Real World Multiple Myeloma Patients","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services","funders":"","keywords":"Medicine; Multiple myeloma; Staging system; Real world data; Oncology; Internal medicine; Cancer; Data science","score_opus":0.03628137295759545,"score_gpt":0.3403525894437358,"score_spread":0.3040712164861404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410851753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067953,0.000020463878,0.00039052533,0.0013102327,0.0011110668,0.0018042672,0.00016320733,0.00047570193,0.034045007],"genre_scores_gemma":[0.9878152,0.000075975695,0.0030276862,0.00078835845,0.0011448163,0.00030385022,0.00021106306,0.00012242504,0.0065106493],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994282,0.00023049577,0.00170185,0.0013384873,0.0013440562,0.001103133],"domain_scores_gemma":[0.9948667,0.0014189014,0.000369253,0.001209356,0.0005360969,0.0015996451],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008793737,0.00055780396,0.0011103958,0.00049819844,0.00021939867,0.00009494838,0.00065004255,0.00028053095,0.0003008681],"category_scores_gemma":[0.001784572,0.00038483113,0.0004837389,0.00057631,0.00024882282,0.00020642737,0.0004951716,0.00023999123,0.0030767838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029969388,0.00032448093,0.4819785,0.00007421347,0.0003085327,0.00023212149,0.000038811835,7.944719e-7,0.0007602341,0.00053687836,0.003635567,0.50911295],"study_design_scores_gemma":[0.020173699,0.0004509847,0.9521636,0.0008419245,0.00009500627,0.000015717347,0.000040990137,0.00029484858,0.001081672,0.000034083507,0.0243847,0.00042278558],"about_ca_topic_score_codex":0.00021849314,"about_ca_topic_score_gemma":0.000078569006,"teacher_disagreement_score":0.5086901,"about_ca_system_score_codex":0.0040265336,"about_ca_system_score_gemma":0.0008069777,"threshold_uncertainty_score":0.99986035},"labels":[],"label_agreement":null},{"id":"W2411574854","doi":"10.1016/j.clml.2016.06.006","title":"Vaccination in Multiple Myeloma: Review of Current Literature","year":2016,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Aurora Research Institute","keywords":"Multiple myeloma; Vaccination; Medicine; Current (fluid); Virology; Immunology; Engineering","score_opus":0.10768974702617448,"score_gpt":0.445554923738294,"score_spread":0.33786517671211946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411574854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017909546,0.9927259,0.000015204852,0.00012868369,0.00083260913,0.004185835,0.0004354016,0.00009920171,0.0013980819],"genre_scores_gemma":[0.0002967658,0.99498385,0.0003081882,0.00016903834,0.0009226016,0.0006175331,0.0017829086,0.00017062167,0.0007485064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990211,0.0013529232,0.004632241,0.0015840231,0.001179419,0.0010403695],"domain_scores_gemma":[0.99182385,0.003085645,0.0016598263,0.0019056837,0.00068162597,0.00084335264],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021170166,0.0011454722,0.0066469987,0.00079038145,0.00008210422,0.000041190557,0.00075521035,0.0012607438,0.0004667462],"category_scores_gemma":[0.007963673,0.0007361319,0.0027483758,0.0015911933,0.00023523283,0.00022957775,0.00041436398,0.0011425392,0.00089468947],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018784207,0.00059191167,0.000968661,0.1802324,0.00034484643,0.0005345293,0.000009703972,6.654602e-9,3.5243312e-7,0.00007322771,0.0034542936,0.8136022],"study_design_scores_gemma":[0.0040041204,0.0002875171,0.04280297,0.3778717,0.00058022933,0.00018294448,0.0000010025583,0.000008067513,0.0000024759465,0.000041196126,0.5738353,0.00038247398],"about_ca_topic_score_codex":0.000014924722,"about_ca_topic_score_gemma":0.000010641098,"teacher_disagreement_score":0.8132197,"about_ca_system_score_codex":0.00280384,"about_ca_system_score_gemma":0.0047076703,"threshold_uncertainty_score":0.99988323},"labels":[],"label_agreement":null},{"id":"W2413126406","doi":"","title":"Bortezomib (millennium pharmaceuticals).","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Oncology; Proteasome inhibitor; Internal medicine; Clinical trial","score_opus":0.11384659509225226,"score_gpt":0.3206849202111406,"score_spread":0.20683832511888833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413126406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53786707,0.011296907,0.000065307264,0.013952316,0.00045785075,0.0042124805,0.00003612542,0.00044542388,0.43166655],"genre_scores_gemma":[0.9827742,0.0008912769,0.00017213149,0.00063007,0.00018036008,0.0011540847,0.000009833425,0.00001792022,0.014170119],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99878484,0.00002688365,0.0001328005,0.00020449664,0.0002994974,0.0005514727],"domain_scores_gemma":[0.999101,0.00004582443,0.000018261695,0.00023314462,0.000042445514,0.00055934966],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011111048,0.00010343037,0.00016617612,0.0000840281,0.000052009822,0.000016782005,0.00006250192,0.000047498128,0.0013303956],"category_scores_gemma":[0.0001475611,0.00007904142,0.00007951289,0.00014371503,0.00005560963,0.000052003208,0.000032418302,0.00014594865,0.0006903108],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017242908,0.00057663216,0.055910412,0.000042594456,0.00020877284,0.00043709,0.00003333927,2.4725236e-7,0.00009622486,0.000068628826,0.04046198,0.90199167],"study_design_scores_gemma":[0.005598145,0.000057818113,0.71242213,0.000006815447,0.000084479565,0.000103899445,0.000012663037,0.0010100027,0.0035674542,0.000020205607,0.27699095,0.00012544781],"about_ca_topic_score_codex":0.000011238158,"about_ca_topic_score_gemma":0.000001303363,"teacher_disagreement_score":0.9018662,"about_ca_system_score_codex":0.000073613315,"about_ca_system_score_gemma":0.0000073192778,"threshold_uncertainty_score":0.9995825},"labels":[],"label_agreement":null},{"id":"W2415182610","doi":"10.18632/oncotarget.9901","title":"Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"Région Normandie; Université de Caen Normandie","keywords":"Cyclin D1; Stromal cell; Cancer research; Cell biology; Cyclin D; Biology; Cyclin; Cell cycle; Cell; Biochemistry","score_opus":0.010213233495224551,"score_gpt":0.2672335443945042,"score_spread":0.2570203108992796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415182610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98202384,0.0053914106,0.000050949795,0.008614439,0.00010706499,0.0005849998,0.000046275618,0.000031898773,0.0031491225],"genre_scores_gemma":[0.9819078,0.0034128604,0.0016463642,0.00021861952,0.00010732677,0.000055917437,0.00001750286,0.00001881202,0.012614825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983697,0.00014895378,0.00030290635,0.00032661622,0.00034183255,0.00050997175],"domain_scores_gemma":[0.99878263,0.0005054036,0.00009405441,0.00031158674,0.00009430449,0.00021201195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003732877,0.00016389888,0.00028590774,0.00008122827,0.00012947666,0.000029955629,0.00009094523,0.000056237866,0.00011423059],"category_scores_gemma":[0.00018142552,0.00008213896,0.00005125326,0.00016309899,0.0001267366,0.00010970155,0.000035190922,0.00012852173,0.000079999605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015036156,0.00023672853,0.871949,0.00007971578,0.000048661364,0.00017623746,0.0008752805,0.0000012604373,0.10231996,0.00010180018,0.020352049,0.002355678],"study_design_scores_gemma":[0.014073439,0.00022139873,0.6921668,0.0004678844,0.000049994185,0.000005116552,0.00043959657,0.00016594985,0.07403804,0.0012754716,0.21682082,0.00027551188],"about_ca_topic_score_codex":0.00029303413,"about_ca_topic_score_gemma":0.0027772079,"teacher_disagreement_score":0.19646877,"about_ca_system_score_codex":0.00011127438,"about_ca_system_score_gemma":0.000110207155,"threshold_uncertainty_score":0.33495298},"labels":[],"label_agreement":null},{"id":"W2416181174","doi":"10.1182/blood.v122.21.686.686","title":"Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Tolerability; Clinical endpoint; Internal medicine; Dexamethasone; Phases of clinical research; Neutropenia; Bortezomib; Refractory (planetary science); Progressive disease; Population; Multiple myeloma; Surgery; Urology; Oncology; Randomized controlled trial; Adverse effect; Clinical trial; Toxicity; Chemotherapy","score_opus":0.025200036811512953,"score_gpt":0.3113322676816826,"score_spread":0.28613223087016965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416181174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942428,0.0021340032,0.00003858847,0.00020046944,0.000042221174,0.003118576,0.00014299696,0.000058955662,0.00002137415],"genre_scores_gemma":[0.994941,0.000121906196,0.0042285873,0.00006964749,0.000012449135,0.00034178692,0.00009915286,0.00007249846,0.00011300489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948796,0.0010581352,0.001406627,0.0008402526,0.0010650425,0.00075033266],"domain_scores_gemma":[0.99503595,0.002464722,0.00061057525,0.0010909506,0.0003170308,0.00048074996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010215839,0.00057070743,0.0022490278,0.0013510168,0.00011279367,0.000046650162,0.0002622028,0.00019233298,0.00015098287],"category_scores_gemma":[0.0019065803,0.00045279998,0.00032597038,0.0013836375,0.00031443575,0.00022460091,0.00023531601,0.00043884755,0.000011653795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013261536,0.024563784,0.856949,0.00011693378,0.006565166,0.00022505793,0.0037211545,0.00002698967,0.07699059,0.0000017926635,0.000037788257,0.01754022],"study_design_scores_gemma":[0.07856643,0.004866109,0.8823212,0.00016394042,0.0018142036,0.000010200676,0.0021599662,0.0014093521,0.028336033,0.000008119588,0.000021854756,0.00032259483],"about_ca_topic_score_codex":0.007116224,"about_ca_topic_score_gemma":0.0015755307,"teacher_disagreement_score":0.0653049,"about_ca_system_score_codex":0.00014553005,"about_ca_system_score_gemma":0.00018206354,"threshold_uncertainty_score":0.9997924},"labels":[],"label_agreement":null},{"id":"W2419591865","doi":"10.1385/1-59259-916-8:121","title":"Identification of Clonotypic IgH VDJ Sequences in Multiple Myeloma","year":2005,"lang":"en","type":"article","venue":"Humana Press eBooks","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biology; Immunoglobulin heavy chain; Primer (cosmetics); clone (Java method); Molecular biology; Polymerase chain reaction; Antibody; Genetics; Gene; Chemistry","score_opus":0.08398065201499769,"score_gpt":0.3372013059359252,"score_spread":0.2532206539209275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419591865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837183,0.0014960653,0.000054883014,0.00006978106,0.00005582025,0.0007181305,0.00001652248,0.000047351106,0.013823171],"genre_scores_gemma":[0.9941271,0.00008624939,0.00043397144,0.000027742299,0.000086473585,0.00010041346,0.000023771929,0.0000149221305,0.0050993473],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987449,0.00005646514,0.00039091372,0.00024713186,0.00030406498,0.00025649503],"domain_scores_gemma":[0.9992933,0.00006595592,0.00010660327,0.00035308945,0.00007955146,0.00010145932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017507467,0.00011843168,0.00022907961,0.00016432386,0.000053196003,0.000017521601,0.00012772213,0.000066399654,0.000046889505],"category_scores_gemma":[0.000087349574,0.00010192343,0.00006483284,0.000030415551,0.00012236026,0.00007561492,0.000043141874,0.00012654159,0.00003031998],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014734702,0.0011011459,0.052524466,0.00068964757,0.0003968285,0.00023451321,0.0038599323,0.00015383019,0.13855554,0.008331219,0.0007485556,0.79193085],"study_design_scores_gemma":[0.0073136385,0.00030477828,0.40228733,0.00024269258,0.000086352826,0.000023654016,0.00012762667,0.0064230287,0.5666151,0.0003943776,0.015911624,0.00026982333],"about_ca_topic_score_codex":0.0006794344,"about_ca_topic_score_gemma":0.00072605617,"teacher_disagreement_score":0.791661,"about_ca_system_score_codex":0.00008151611,"about_ca_system_score_gemma":0.000049806295,"threshold_uncertainty_score":0.4156317},"labels":[],"label_agreement":null},{"id":"W2428221660","doi":"10.1017/cjn.2016.193","title":"P.091 Intracerebral hemorrhage secondary to multiple myeloma: a systematic review","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Systems, Applications & Products in Data Processing (Canada); Toronto Public Health","funders":"","keywords":"Medicine; Hematoma; Intracerebral hemorrhage; Spontaneous intracerebral hemorrhage; Multiple myeloma; Abnormality; Radiology; Craniotomy; Surgery; Glasgow Coma Scale; Internal medicine","score_opus":0.05964671384836752,"score_gpt":0.3383217966446311,"score_spread":0.2786750827962636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2428221660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012844849,0.9797415,0.000013635408,0.0029443142,0.00079730374,0.0021779432,0.000108988526,0.00002932139,0.0013421584],"genre_scores_gemma":[0.009564635,0.9830913,0.0015695838,0.0049851662,0.0004887549,0.0000594683,0.0000026912592,0.000048442056,0.00018993487],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9894511,0.002633111,0.0026849646,0.0010565578,0.0016679574,0.0025062927],"domain_scores_gemma":[0.9881609,0.0018902319,0.0019973223,0.00048160853,0.0007775762,0.0066923564],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.00666108,0.00094463717,0.004383056,0.0023033842,0.0021155044,0.0007018972,0.003231754,0.00044975916,0.000662492],"category_scores_gemma":[0.014884015,0.0004789725,0.0013949265,0.0023575209,0.004121437,0.00076112855,0.00019165163,0.0026097705,0.00010700265],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024075502,0.00023809308,0.017861338,0.26932988,0.0006152915,0.1721452,0.00020913739,0.000015216323,0.0000019613246,0.00018534696,0.0067234146,0.5324344],"study_design_scores_gemma":[0.0012264814,0.11311315,0.0013690247,0.30636415,0.0025888067,0.41137898,0.00006932168,0.00007320784,0.0000042923443,0.00080941943,0.16161925,0.0013839361],"about_ca_topic_score_codex":0.00038481748,"about_ca_topic_score_gemma":0.01285233,"teacher_disagreement_score":0.53105044,"about_ca_system_score_codex":0.0009843538,"about_ca_system_score_gemma":0.014907243,"threshold_uncertainty_score":0.9997662},"labels":[],"label_agreement":null},{"id":"W2460697893","doi":"10.1182/blood.v122.21.3353.3353","title":"High Progression-Free Survival At 10 Years After Tandem Autologous/Nonmyeloablative Allogeneic Transplants For Multiple Myeloma In a Cohort Of 93 Patients: Impact Of Disease Remission Status At Transplant and Chronic Graft-Versus-Host Disease","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Immunosuppression; Transplantation; Progression-free survival; Hematopoietic stem cell transplantation; Fludarabine; Cohort; Regimen; Multiple myeloma; Cyclophosphamide; Surgery; Proportional hazards model; Oncology; Graft-versus-host disease; Chemotherapy","score_opus":0.011905659776299784,"score_gpt":0.2801296716959936,"score_spread":0.26822401191969386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460697893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910874,0.0016217572,0.0000043234236,0.00004213677,0.000048268146,0.0032984798,0.0038601863,0.000025754714,0.000011700705],"genre_scores_gemma":[0.99704164,0.0006804324,0.0002717406,0.000004151111,0.000028697283,0.00058433414,0.0012428407,0.00004497737,0.00010119992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976057,0.00012314176,0.0004883617,0.00051392935,0.0006007281,0.0006681333],"domain_scores_gemma":[0.9979088,0.0003340189,0.00017039473,0.00045804217,0.00016483825,0.000963914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012999166,0.0003236338,0.0006179769,0.00018046392,0.00006762347,0.000008834447,0.00012684331,0.00012226675,0.00033905072],"category_scores_gemma":[0.0002652135,0.00023571953,0.00023515304,0.00015503072,0.00020907065,0.0001252239,0.00008908945,0.000109465094,0.000006923721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03138781,0.0020988737,0.957384,0.00052642095,0.00062344497,0.00018907891,0.00025161312,0.0000043808236,0.0052814013,9.922826e-7,0.000037119196,0.0022148897],"study_design_scores_gemma":[0.041770115,0.0021947585,0.9517674,0.0006219524,0.000539459,0.000002358976,0.000009386666,0.00032548368,0.0025338118,0.00001634466,0.000016540342,0.00020243313],"about_ca_topic_score_codex":0.0003769863,"about_ca_topic_score_gemma":0.00039416287,"teacher_disagreement_score":0.010382305,"about_ca_system_score_codex":0.0003403509,"about_ca_system_score_gemma":0.0003482421,"threshold_uncertainty_score":0.96123636},"labels":[],"label_agreement":null},{"id":"W2461345736","doi":"10.1182/blood.v114.22.2872.2872","title":"Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (&lt;12 months).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Thalidomide; Cohort; Internal medicine; Bortezomib; Autologous stem-cell transplantation; Oncology; Transplantation; Surgery","score_opus":0.009810796874228304,"score_gpt":0.23123278838826913,"score_spread":0.22142199151404082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461345736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661446,0.00014811003,0.000009173911,0.00030368424,0.000058489022,0.0014252999,0.00067777437,0.000098017255,0.0006649749],"genre_scores_gemma":[0.9962955,0.000033831995,0.0020086612,0.00026344613,0.00006468592,0.00007022624,0.00066291564,0.000057577523,0.0005431573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970127,0.0001357554,0.00043912587,0.00064645696,0.0009960033,0.00076996617],"domain_scores_gemma":[0.9980525,0.00013618376,0.00013436789,0.00067343377,0.00023908091,0.00076446164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020876234,0.00040177227,0.0005737828,0.00029461898,0.00013328751,0.000049295784,0.00020857809,0.00017268794,0.00009421375],"category_scores_gemma":[0.0007234975,0.0003113681,0.00009560885,0.00045779682,0.000048942526,0.0001904062,0.00007532343,0.00036079713,0.00017871463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045434632,0.013507293,0.97588986,0.000018898056,0.00029881808,0.00034087515,0.0001930085,0.0000037482944,0.0008995814,0.000027929891,0.0006166348,0.0036598807],"study_design_scores_gemma":[0.04736507,0.009268612,0.9415732,0.00016574842,0.0002337456,0.000009666087,0.000029206309,0.000004001174,0.0009227418,0.000017666709,0.00011608104,0.00029426924],"about_ca_topic_score_codex":0.0050504236,"about_ca_topic_score_gemma":0.0008438203,"teacher_disagreement_score":0.04282161,"about_ca_system_score_codex":0.00011736612,"about_ca_system_score_gemma":0.00012117292,"threshold_uncertainty_score":0.99993384},"labels":[],"label_agreement":null},{"id":"W2462737759","doi":"10.1111/bjh.14199","title":"Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium","year":2016,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Public Health Ontario; Toronto Public Health; University of Saskatchewan; Saskatchewan Health Authority","funders":"National Cancer Institute; National Institutes of Health; Fondation de France; University of Alabama; National Institute of Environmental Health Sciences; American Cancer Society; University of Southern California; Brown University","keywords":"Medicine; Odds ratio; Family history; Multiple myeloma; Relative risk; Confidence interval; Internal medicine; Etiology; First-degree relatives; Oncology; Cancer; Demography; Family aggregation; Disease","score_opus":0.051699426396183724,"score_gpt":0.3146568069504227,"score_spread":0.26295738055423895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462737759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015344859,0.9800159,0.00003205207,0.0003051018,0.0014667645,0.0007792403,0.0013882136,0.000017880704,0.0006500321],"genre_scores_gemma":[0.013614446,0.98409414,0.0007029505,0.0001449611,0.00042960982,0.00004547638,0.00018065769,0.00007457228,0.00071316276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532825,0.0005160034,0.0023006478,0.00052894844,0.000819544,0.0005066147],"domain_scores_gemma":[0.9924785,0.0037138131,0.002253737,0.00050995225,0.0006583833,0.00038565334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007032205,0.00046011453,0.0033364536,0.0003264242,0.00008260267,0.0000376198,0.0007067018,0.0004507005,0.00017521474],"category_scores_gemma":[0.0042061596,0.00031569766,0.000781726,0.00012061003,0.00088198116,0.00014681203,0.00025762012,0.0006883189,0.000036154343],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012069892,0.00022522536,0.0010697983,0.002106579,0.0027616525,0.03537647,0.00017482453,1.5413899e-7,0.000033380013,0.000022377179,0.029149348,0.9278732],"study_design_scores_gemma":[0.00946492,0.0002856228,0.0023534717,0.036183048,0.00091509335,0.13327569,0.00012513319,0.000024299463,0.000019910043,0.000043889984,0.8170407,0.00026822006],"about_ca_topic_score_codex":0.0016354976,"about_ca_topic_score_gemma":0.0005097976,"teacher_disagreement_score":0.927605,"about_ca_system_score_codex":0.0012450072,"about_ca_system_score_gemma":0.0031034069,"threshold_uncertainty_score":0.9999295},"labels":[],"label_agreement":null},{"id":"W2466110078","doi":"10.1182/blood.v106.11.1572.1572","title":"Studies of the Bcl Inhibitor GX15-070 in Multiple Myeloma Demonstrate Substantial Pre-Clinical Activity.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Apoptosis; Cytotoxicity; Cytotoxic T cell; Biology; Bcl-2 family; Viability assay; Cell culture; Cancer research; Molecular biology; Programmed cell death; In vitro; Biochemistry; Genetics","score_opus":0.07985099789310943,"score_gpt":0.3775488828657138,"score_spread":0.2976978849726044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466110078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996838,0.0010574585,0.0000026800683,0.00072824955,0.000110986075,0.00071708334,0.000022362814,0.000026250744,0.00049695955],"genre_scores_gemma":[0.99826646,0.00029879384,0.00061091885,0.000040088693,0.00030538742,0.000037951228,0.0000036525776,0.000018130666,0.00041861704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983083,0.00019371818,0.00043578245,0.00029183773,0.00041193774,0.00035842333],"domain_scores_gemma":[0.99881876,0.00042647042,0.00012077684,0.0003937691,0.000102391044,0.00013782449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036983937,0.00016533468,0.00045022758,0.00008208078,0.000073295865,0.000008623402,0.00013379536,0.00011257367,0.00003546502],"category_scores_gemma":[0.00092350104,0.0001043262,0.00017916157,0.00025236697,0.00031164667,0.00008864529,0.00011960116,0.0003316213,0.000030063562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008665806,0.0035336588,0.934747,0.000075800235,0.00049216766,0.00008825941,0.00031711775,0.0000024479432,0.022797486,0.0000072545427,0.00016569151,0.036906537],"study_design_scores_gemma":[0.012329498,0.00036964234,0.8289518,0.00016355276,0.00012419,0.000024926876,0.00009773947,0.00018256977,0.15739088,0.000012340674,0.00026842844,0.00008447621],"about_ca_topic_score_codex":0.00007224844,"about_ca_topic_score_gemma":0.0011894517,"teacher_disagreement_score":0.1345934,"about_ca_system_score_codex":0.000044135202,"about_ca_system_score_gemma":0.00018053039,"threshold_uncertainty_score":0.4254299},"labels":[],"label_agreement":null},{"id":"W2468676672","doi":"10.1182/blood.v122.21.532.532","title":"Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Multiple myeloma; Interim analysis; Exome; Oncology; Internal medicine; Bioinformatics; Exome sequencing; Genetics; Biology; Gene","score_opus":0.10274117346414163,"score_gpt":0.3879965017064567,"score_spread":0.2852553282423151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468676672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648434,0.00010406574,0.000004844587,0.00025234921,0.0000506204,0.0030148188,0.000009667251,0.000014014938,0.0000653084],"genre_scores_gemma":[0.9989181,0.0000074741274,0.0006189371,0.000037647478,0.000025880123,0.00025886734,0.000007955733,0.000014444924,0.00011068238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813706,0.00031018292,0.0007055089,0.00031789244,0.00026851773,0.00026085362],"domain_scores_gemma":[0.9984547,0.0006299079,0.00014914942,0.00054289965,0.00008154656,0.00014179702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052834133,0.00015602406,0.0007400349,0.0002749518,0.00007902331,0.00002887074,0.0001692782,0.000062782536,0.00007267811],"category_scores_gemma":[0.0012221193,0.00009396017,0.00021660824,0.0005382017,0.00008686355,0.0000518567,0.00028358385,0.00024482544,0.000019707943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019750667,0.003401269,0.98827565,0.00001639693,0.0029735041,0.000018384484,0.00054619374,0.0000029133255,0.0007047633,0.0000031319373,0.0000091544725,0.0020735688],"study_design_scores_gemma":[0.046882916,0.0013561237,0.9495063,0.000038746315,0.0011037542,0.000002397,0.0005933487,0.00033102464,0.000100673955,0.0000068898016,0.0000027377341,0.00007509721],"about_ca_topic_score_codex":0.0025076526,"about_ca_topic_score_gemma":0.0013956407,"teacher_disagreement_score":0.04490785,"about_ca_system_score_codex":0.000038040518,"about_ca_system_score_gemma":0.00005994407,"threshold_uncertainty_score":0.38315845},"labels":[],"label_agreement":null},{"id":"W2469018277","doi":"10.1182/blood-2016-03-704379","title":"Anaplastic variant of plasma cell myeloma with Dutcher bodies","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple myeloma; Plasma cell; Plasma Cell Myeloma; Plasma cell leukemia; Plasmacytoma; Medicine; Cancer research; Pathology; Internal medicine","score_opus":0.015116557880913123,"score_gpt":0.2464288482005438,"score_spread":0.2313122903196307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469018277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901435,0.000095429066,0.000083221144,0.00020569807,0.000017018989,0.00022607321,0.000027278153,0.000028808316,0.009172996],"genre_scores_gemma":[0.9946685,0.0000431336,0.0021410068,0.000010677926,0.000045215085,0.000021381196,0.0000037378163,0.000017808423,0.0030485652],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914587,0.00002132115,0.0001313677,0.00017718923,0.00027211328,0.00025215928],"domain_scores_gemma":[0.9993074,0.00016188768,0.000047776888,0.00024041136,0.00008059699,0.00016195727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050174713,0.00011277648,0.00021300103,0.000073817995,0.000027711463,0.000004614191,0.00005534165,0.000042819767,0.0002721971],"category_scores_gemma":[0.00009800063,0.000054928616,0.000042782074,0.000065229884,0.00008710102,0.000039597795,0.000027708924,0.00004838001,0.00012311233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005051389,0.0060027665,0.67554843,0.000582423,0.0018082546,0.004513128,0.0005565416,9.655894e-7,0.282875,0.00024806836,0.0006737099,0.022139305],"study_design_scores_gemma":[0.031011006,0.0038634504,0.32914403,0.0003724385,0.00041171312,0.0003066774,0.000074502794,0.000026406207,0.6335633,0.00006280204,0.0009980771,0.00016561344],"about_ca_topic_score_codex":0.000043593707,"about_ca_topic_score_gemma":0.000060466118,"teacher_disagreement_score":0.35068828,"about_ca_system_score_codex":0.000018529003,"about_ca_system_score_gemma":0.00011107879,"threshold_uncertainty_score":0.29803672},"labels":[],"label_agreement":null},{"id":"W2471073614","doi":"10.1182/blood.v126.23.731.731","title":"Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Carfilzomib; Dexamethasone; Multiple myeloma; Medicine; Oncology; Pomalidomide; Internal medicine; Subgroup analysis; Thalidomide; Confidence interval","score_opus":0.02159025863719672,"score_gpt":0.2805427240642102,"score_spread":0.2589524654270135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471073614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951429,0.0012458665,0.00009081961,0.00007065056,0.000015722417,0.002878446,0.00049423054,0.000028282255,0.00003310428],"genre_scores_gemma":[0.99691784,0.00015923996,0.0023917076,0.00006074119,0.00003259824,0.000102794365,0.00026884247,0.000052024236,0.000014204363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959929,0.000945265,0.00064893527,0.00086223107,0.00094185234,0.000608821],"domain_scores_gemma":[0.9956107,0.0023134204,0.00032423917,0.0008226623,0.00026537682,0.00066357973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010657308,0.00046080965,0.0011453702,0.00044998972,0.00016681723,0.00006153749,0.00013916485,0.00013057776,0.000024770563],"category_scores_gemma":[0.001976355,0.00029225452,0.000094486204,0.0009497299,0.0003367205,0.00011161824,0.00013879673,0.00040948,0.0000021514431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04806212,0.0075819697,0.93190736,0.0000381584,0.0027165718,0.0001415255,0.0014727064,0.00008935316,0.00021813455,9.682736e-7,0.0000064274964,0.007764707],"study_design_scores_gemma":[0.22427954,0.0070189694,0.76171726,0.00011255283,0.003395265,0.0000022553302,0.00086832297,0.0014912239,0.000878014,0.000005815317,0.000015336414,0.00021543422],"about_ca_topic_score_codex":0.0061396826,"about_ca_topic_score_gemma":0.001990399,"teacher_disagreement_score":0.1762174,"about_ca_system_score_codex":0.000088969944,"about_ca_system_score_gemma":0.00017382132,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W2472197357","doi":"10.1182/blood-2016-06-716902","title":"A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma","year":2016,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital; Queen's University; London Health Sciences Centre; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of New Brunswick; Dalhousie University; Saint John Regional Hospital; Vancouver General Hospital; University of Calgary","funders":"","keywords":"Medicine; Maintenance therapy; Melphalan; Multiple myeloma; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Chemotherapy; Cancer; Lenalidomide; Intensive care medicine","score_opus":0.14671447241158198,"score_gpt":0.42923783083892075,"score_spread":0.2825233584273388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472197357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6175518,0.0054546525,0.00005694439,0.3295023,0.0023735003,0.02280285,0.021594383,0.000045839894,0.00061770505],"genre_scores_gemma":[0.8324011,0.0065735565,0.0010066385,0.123756394,0.016953832,0.0050705653,0.001788035,0.00028042487,0.012169465],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99550104,0.0008599497,0.0015517661,0.0005957641,0.0007568619,0.0007346214],"domain_scores_gemma":[0.99476755,0.002473704,0.001043184,0.00094590697,0.00047547178,0.00029417453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00189068,0.00036960994,0.0024194838,0.0005230741,0.0001009952,0.000015017311,0.00048722388,0.0006587326,0.00080028083],"category_scores_gemma":[0.0022737337,0.00018952056,0.0024971021,0.0005289355,0.00030956924,0.00002089813,0.000045503315,0.0005304886,0.0000059081517],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10121269,0.0023324036,0.08825414,0.00052969716,0.09960628,0.00026555074,0.00010290936,0.0000015377226,0.003424322,0.000003919423,0.5688068,0.13545975],"study_design_scores_gemma":[0.37142152,0.0022180018,0.026712073,0.00038220693,0.018255627,0.000004207306,0.0000043630757,0.00010622217,0.0056225406,0.00002195722,0.5749523,0.00029897573],"about_ca_topic_score_codex":0.025893893,"about_ca_topic_score_gemma":0.0672063,"teacher_disagreement_score":0.27020884,"about_ca_system_score_codex":0.00014771028,"about_ca_system_score_gemma":0.0019990737,"threshold_uncertainty_score":0.9805928},"labels":[],"label_agreement":null},{"id":"W2472478074","doi":"10.1182/blood.v110.11.2730.2730","title":"Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Bortezomib; Transplantation; Lenalidomide; Surgery; Melphalan; Gastroenterology","score_opus":0.01174926590662012,"score_gpt":0.24795790738812115,"score_spread":0.23620864148150103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472478074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510896,0.00026011313,0.0007821296,0.000035087585,0.00006940756,0.0032996447,0.00015810887,0.000061978004,0.00022454628],"genre_scores_gemma":[0.99645096,0.000046796802,0.002722697,0.000022632481,0.000024877925,0.00009554333,0.00036118226,0.00006715702,0.00020813731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977102,0.0001013801,0.00063668314,0.00042916444,0.0005529608,0.00056957296],"domain_scores_gemma":[0.99860525,0.00035518163,0.0003187869,0.00032282865,0.00019720197,0.00020076278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042183223,0.00029424543,0.0004938909,0.0003227535,0.00010107013,0.000015652959,0.000115510295,0.00016294161,0.000007895079],"category_scores_gemma":[0.000032831213,0.00022427262,0.00008811465,0.00027896176,0.0000757714,0.00016779001,0.000017030196,0.00028258143,0.0000037127336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432041,0.005403934,0.94339937,0.00039279403,0.00031066572,0.00018737424,0.001771952,0.00001876092,0.022319356,0.000032676187,0.0000030071924,0.016728071],"study_design_scores_gemma":[0.06773437,0.0048827906,0.62483793,0.00043833963,0.00045125635,0.000016319793,0.00048804612,0.0010297173,0.29985383,0.000030616382,0.000016542717,0.00022026271],"about_ca_topic_score_codex":0.0006436332,"about_ca_topic_score_gemma":0.0013636996,"teacher_disagreement_score":0.31856143,"about_ca_system_score_codex":0.000099351935,"about_ca_system_score_gemma":0.00012260061,"threshold_uncertainty_score":0.9145572},"labels":[],"label_agreement":null},{"id":"W2473454213","doi":"10.1182/blood.v122.21.1854.1854","title":"High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Hazard ratio; Medicine; Multiple myeloma; Internal medicine; Cohort; Oncology; Gene signature; Gastroenterology; Confidence interval; Gene expression; Gene; Biology; Genetics","score_opus":0.020987598677551653,"score_gpt":0.2844865496153304,"score_spread":0.2634989509377787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473454213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511874,0.0009034086,0.000002813121,0.00024445838,0.00009213444,0.003320203,0.00017521143,0.000086110274,0.00005693746],"genre_scores_gemma":[0.99751884,0.00005372681,0.00023940284,0.00009287009,0.00017276286,0.0007777208,0.00021365659,0.000047287063,0.0008837412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759555,0.0003662927,0.00034489165,0.0005423536,0.0005925647,0.00055831915],"domain_scores_gemma":[0.99823225,0.00031906,0.00013962005,0.00081592286,0.00018154272,0.00031161855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025835496,0.00029146398,0.00042131668,0.00013588522,0.00022519723,0.000110695226,0.00027535428,0.00014233994,0.00044074157],"category_scores_gemma":[0.000514608,0.0001813165,0.000092594644,0.00032075564,0.0000767519,0.00019862667,0.00010929419,0.00051305315,0.0002568227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027544828,0.0070725596,0.9514906,0.000029293878,0.00043264494,0.0013181345,0.0005271143,0.000003403079,0.032298632,0.0000014287896,0.0015522254,0.004998543],"study_design_scores_gemma":[0.017904405,0.0010966524,0.94648415,0.00003877751,0.00022585195,0.00006440251,0.0015750409,0.00020374233,0.032152586,0.000024066387,0.00005059398,0.0001797373],"about_ca_topic_score_codex":0.0093947,"about_ca_topic_score_gemma":0.003825637,"teacher_disagreement_score":0.017628957,"about_ca_system_score_codex":0.000054491236,"about_ca_system_score_gemma":0.00005944477,"threshold_uncertainty_score":0.9972018},"labels":[],"label_agreement":null},{"id":"W2473614468","doi":"10.1182/blood.v126.23.1982.1982","title":"Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTMÂ chain (HLC) Normalization","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; University of British Columbia; McGill University; Saint John Regional Hospital; Saskatchewan Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Lenalidomide; Busulfan; Multiple myeloma; Maintenance therapy; Internal medicine; Urology; Thalidomide; Surgery; Oncology; Transplantation; Hematopoietic stem cell transplantation; Chemotherapy","score_opus":0.06906379413577311,"score_gpt":0.3158552214971248,"score_spread":0.24679142736135168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473614468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933749,0.00016581196,0.0000614475,0.0002583566,0.00007140847,0.0053171497,0.0006893607,0.000021692207,0.000039868082],"genre_scores_gemma":[0.99724716,0.000009338276,0.0007260832,0.00005406679,0.0001131834,0.00077190576,0.0009961327,0.000041450523,0.000040672192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954768,0.000744484,0.00071055174,0.0006791991,0.0014332904,0.0009556991],"domain_scores_gemma":[0.9968376,0.0005913296,0.0002660724,0.00024506034,0.0012233062,0.000836592],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024814762,0.00031893645,0.0005549655,0.000424315,0.00048774996,0.00006144463,0.000116958974,0.00010151083,0.0000051627526],"category_scores_gemma":[0.000646862,0.0002835426,0.000037189715,0.0005520689,0.00014480963,0.00021162159,0.000047775884,0.00029908167,2.8599962e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05126662,0.0026458346,0.9393993,0.00042602114,0.00032718875,0.00017946496,0.0017843203,0.0011489968,0.00056863524,0.00003281385,0.00010885285,0.002111965],"study_design_scores_gemma":[0.19449542,0.0054274695,0.7777106,0.0005484863,0.00022270312,0.0000057083353,0.0026968913,0.01464155,0.0038763566,0.00003994195,0.00001990425,0.00031497303],"about_ca_topic_score_codex":0.32044342,"about_ca_topic_score_gemma":0.88685304,"teacher_disagreement_score":0.5664096,"about_ca_system_score_codex":0.0006663291,"about_ca_system_score_gemma":0.004898741,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W2475561659","doi":"10.1182/blood.v124.21.2019.2019","title":"Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Univariate analysis; Internal medicine; Autologous stem-cell transplantation; Retrospective cohort study; Surgery; Stage (stratigraphy); Survival analysis; Transplantation; Disease; Multivariate analysis","score_opus":0.01840966357043382,"score_gpt":0.26834290251098697,"score_spread":0.24993323894055314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475561659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896103,0.00020013234,0.000018124621,0.000030544234,0.00002670958,0.00042882774,0.00014893421,0.000014232167,0.00017145113],"genre_scores_gemma":[0.99928755,0.00017569895,0.00021090484,0.000009208122,0.00003882804,0.000027065817,0.0001362011,0.000015515678,0.000099005265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913645,0.000048511716,0.0002396911,0.00017995722,0.0002107467,0.00018463751],"domain_scores_gemma":[0.99908644,0.00012397884,0.000107193286,0.00029764452,0.00008347656,0.0003012717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046596197,0.00013053694,0.0003288894,0.000077093915,0.000027585755,0.0000047110366,0.000033611726,0.00003464677,0.000033312244],"category_scores_gemma":[0.00020002737,0.000095834854,0.00007588807,0.00006101276,0.00009272334,0.000026999782,0.00003466523,0.000034657995,0.00000541896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048481923,0.0023025954,0.92193854,0.00020484444,0.00026935263,0.00008715618,0.00011903877,5.3291824e-8,0.0034338383,0.000011842644,0.0000017684124,0.071146145],"study_design_scores_gemma":[0.0063641733,0.0014761002,0.96981674,0.000107229476,0.0002941087,0.000009656922,0.0000091333395,0.00008139078,0.02173812,0.0000047342382,0.000033022407,0.00006560512],"about_ca_topic_score_codex":0.00013900027,"about_ca_topic_score_gemma":0.00005512213,"teacher_disagreement_score":0.07108054,"about_ca_system_score_codex":0.000015053135,"about_ca_system_score_gemma":0.000045106928,"threshold_uncertainty_score":0.3908032},"labels":[],"label_agreement":null},{"id":"W2476275359","doi":"10.1158/1538-7445.am2016-ct034","title":"Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Tolerability; Immunogenicity; Pharmacology; Cancer research; Monoclonal antibody; Immunology; Internal medicine; Oncology; Adverse effect","score_opus":0.06872917316155,"score_gpt":0.40331119292844075,"score_spread":0.3345820197668907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2476275359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956678,0.00047127565,0.000008288249,0.00016059841,0.000031741165,0.0033102124,0.00019039848,0.00006605806,0.000093612456],"genre_scores_gemma":[0.9987076,0.00005967627,0.00038545835,0.000033320895,0.000035445297,0.0004921647,0.000024480874,0.00006659622,0.00019528897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961375,0.00033640998,0.00057850865,0.00078539696,0.0011806845,0.0009815078],"domain_scores_gemma":[0.9975692,0.00056218024,0.00016149801,0.0005307124,0.00068821106,0.00048818474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074245286,0.00031560488,0.000664117,0.00068576046,0.00019718551,0.000050565613,0.00021164495,0.00012384854,0.00024175091],"category_scores_gemma":[0.00079980824,0.00019493874,0.00005085727,0.00069970364,0.0003193604,0.00017631172,0.00021412742,0.0004159497,0.000022015323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009676285,0.003207575,0.627841,0.00018718353,0.00018602493,0.0003385793,0.0011104622,0.0000018197053,0.34882486,0.0000010784652,0.00008378917,0.0085413065],"study_design_scores_gemma":[0.041582767,0.004588621,0.90317553,0.0024135907,0.000029899245,0.0000106977495,0.0009699625,0.000050645856,0.0466278,0.0000042142256,0.00028892886,0.00025731628],"about_ca_topic_score_codex":0.0025539263,"about_ca_topic_score_gemma":0.0005747893,"teacher_disagreement_score":0.30219707,"about_ca_system_score_codex":0.00045738695,"about_ca_system_score_gemma":0.000339074,"threshold_uncertainty_score":0.79493713},"labels":[],"label_agreement":null},{"id":"W2478932238","doi":"10.1182/blood-2016-03-707596","title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Onyx Pharmaceuticals; Agence Nationale de la Recherche; National Cancer Institute; Celgene; Amgen","keywords":"Carfilzomib; Multiple myeloma; Internal medicine; Oncology; Medicine; Overall survival; Progression-free survival; Cytogenetics; Lenalidomide; Biology; Genetics; Chromosome","score_opus":0.016309791118099017,"score_gpt":0.26684108587892624,"score_spread":0.25053129476082725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478932238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978659,0.00012286971,0.0000073528754,0.00032789382,0.00009418652,0.0010303993,0.00022847862,0.000029833578,0.00029309568],"genre_scores_gemma":[0.9989201,0.00011154162,0.0005128117,0.000012277743,0.00007393374,0.000121781275,0.00002598445,0.00002553224,0.00019603466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817497,0.00016084718,0.0003347894,0.00030184863,0.0006214814,0.00040603924],"domain_scores_gemma":[0.9983003,0.0005282951,0.00014763408,0.00069819984,0.00016145526,0.00016407829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028573873,0.00017194697,0.00032530245,0.000106022984,0.0000731191,0.000009217794,0.00026197368,0.00008131791,0.000044625955],"category_scores_gemma":[0.0016460132,0.00007760259,0.00009360148,0.0001984209,0.0001721142,0.00006835987,0.00015729906,0.00014021168,0.000029238252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006149632,0.0018722033,0.9124592,0.0000383928,0.0001646692,0.000040450876,0.0001062518,9.527691e-8,0.012203081,0.000032227403,0.00008460771,0.07238385],"study_design_scores_gemma":[0.026439877,0.0008350542,0.92088133,0.00015216664,0.000081611164,0.000002232769,0.000053801894,0.000009754657,0.051242724,0.00013036364,0.00008229672,0.00008877437],"about_ca_topic_score_codex":0.0010506632,"about_ca_topic_score_gemma":0.00062714075,"teacher_disagreement_score":0.07229508,"about_ca_system_score_codex":0.00002875359,"about_ca_system_score_gemma":0.000106611915,"threshold_uncertainty_score":0.31645417},"labels":[],"label_agreement":null},{"id":"W2479223216","doi":"10.1182/blood.v126.23.5322.5322","title":"Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Oncology","score_opus":0.05029673230955647,"score_gpt":0.3072337228935889,"score_spread":0.25693699058403247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479223216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407375,0.00045824895,0.000043907217,0.00024925784,0.000093647206,0.0032090906,0.00031976547,0.000107614534,0.0014447024],"genre_scores_gemma":[0.9978178,0.000065502405,0.00057757687,0.0002345297,0.00016388309,0.00042237848,0.000412128,0.000069866444,0.000236335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962871,0.0007612533,0.00056659733,0.00064585975,0.00093018514,0.0008089886],"domain_scores_gemma":[0.9974454,0.00070499495,0.00018571457,0.0008885868,0.00027122346,0.0005040517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001022989,0.0004207975,0.0005852561,0.00022882839,0.0001981177,0.00009242698,0.00044419017,0.000158751,0.00006075282],"category_scores_gemma":[0.0019095561,0.00029168907,0.00013470571,0.0006281913,0.00013495322,0.00018082687,0.00018459592,0.0006225225,0.00030700656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011808657,0.013460917,0.9628655,0.000032505992,0.0007364607,0.0013223976,0.010900113,0.000012068177,0.0027577765,0.0000029606174,0.0017045756,0.005023868],"study_design_scores_gemma":[0.07794567,0.003847956,0.86743265,0.00008318447,0.00052362785,0.00013513076,0.018212548,0.0017743066,0.026667222,0.00006438915,0.0027773546,0.00053592457],"about_ca_topic_score_codex":0.001197549,"about_ca_topic_score_gemma":0.0010103284,"teacher_disagreement_score":0.09543281,"about_ca_system_score_codex":0.00019396313,"about_ca_system_score_gemma":0.00031339272,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W2479809460","doi":"10.1182/blood.v122.21.3147.3147","title":"Multiclonality In Multiple Myeloma: A Retrospective Analysis Of Clonal Progression and Selection","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Plasma cell dyscrasia; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Medicine; Internal medicine; Serum protein electrophoresis; Plasma cell neoplasm; Dyscrasia; Monoclonal; Plasmacytoma; Oncology; Plasma cell; Immunology; Monoclonal antibody; Antibody; Immunoglobulin light chain","score_opus":0.018942612498810563,"score_gpt":0.3087086977262808,"score_spread":0.2897660852274702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479809460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988631,0.00014281762,0.00001790279,0.00009613402,0.0000057466596,0.00061407406,0.000014886475,0.000019910734,0.00022543332],"genre_scores_gemma":[0.99700326,0.000022094633,0.002743343,0.000009765007,0.000018245759,0.000099854566,0.000036084566,0.000007420658,0.000059951217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989616,0.00006140799,0.00021506452,0.0002534043,0.000299923,0.00020856396],"domain_scores_gemma":[0.999447,0.00007943391,0.00006617434,0.00010714516,0.00016859263,0.0001316373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014356918,0.00009947989,0.0003324183,0.00032335502,0.00003926384,0.000010674382,0.000029475124,0.000066420755,0.00012885919],"category_scores_gemma":[0.0002736611,0.000076065495,0.000079241254,0.0007667053,0.00007312427,0.00008007745,0.00003398704,0.00012400925,0.0000066917196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013439285,0.00148563,0.96508837,0.000037213376,0.00084529654,0.00001771335,0.00012547334,0.00000173851,0.026826175,0.000017608481,0.000005830505,0.0054145562],"study_design_scores_gemma":[0.0055750813,0.00031492815,0.96916264,0.00003594819,0.00047022637,0.000010767506,0.000033730157,0.009991044,0.014304659,0.000039120798,0.000004079193,0.000057791818],"about_ca_topic_score_codex":0.0010118111,"about_ca_topic_score_gemma":0.00049002137,"teacher_disagreement_score":0.012521516,"about_ca_system_score_codex":0.000054749602,"about_ca_system_score_gemma":0.000039125902,"threshold_uncertainty_score":0.3101861},"labels":[],"label_agreement":null},{"id":"W2480827570","doi":"10.1136/bcr-2016-215521","title":"Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma","year":2016,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Thalidomide; Medicine; Multiple myeloma; Lenalidomide; Prednisone; Dermatology; Surgery; Internal medicine","score_opus":0.07600421501281093,"score_gpt":0.36111738755979106,"score_spread":0.2851131725469801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480827570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948211,0.00010122183,0.00078136404,0.00060019374,0.000061850435,0.0034390537,0.0000783599,0.00003860828,0.00007825208],"genre_scores_gemma":[0.99514264,0.00008401961,0.0008031156,0.000020248535,0.00006144593,0.0008588106,0.00009964631,0.00002792556,0.002902155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986416,0.00005506115,0.00041289642,0.00028711182,0.00033462804,0.00026868266],"domain_scores_gemma":[0.9972836,0.0013941017,0.00035548507,0.00055681553,0.00026821392,0.00014182503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002759926,0.00015996578,0.00030326724,0.00006491191,0.000120712255,0.000015098367,0.000015952546,0.000055922595,0.000042131014],"category_scores_gemma":[0.0012550367,0.00006683188,0.0001530078,0.000103688675,0.00009068784,0.000100956044,0.000009425423,0.000022963468,0.000003297109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036948975,0.0016169384,0.58688223,0.000047334324,0.0020284485,0.27710223,0.00037970758,0.00000814452,0.0077497587,0.0000096705035,0.0007737522,0.1197069],"study_design_scores_gemma":[0.032765213,0.0071747443,0.6269852,0.000674667,0.0013380911,0.19213942,0.0004203987,0.0009925006,0.12887968,0.000062335705,0.00819687,0.00037089994],"about_ca_topic_score_codex":0.0006922621,"about_ca_topic_score_gemma":0.00069024105,"teacher_disagreement_score":0.12112992,"about_ca_system_score_codex":0.0003018039,"about_ca_system_score_gemma":0.00016642032,"threshold_uncertainty_score":0.27253252},"labels":[],"label_agreement":null},{"id":"W2486629951","doi":"10.1016/s1470-2045(16)30206-6","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2995,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Bone marrow; Myeloma protein; Clinical trial; Disease; Oncology; Monoclonal; Internal medicine; Monoclonal antibody; Immunology; Antibody","score_opus":0.18498453553729838,"score_gpt":0.47315065993772726,"score_spread":0.2881661244004289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486629951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01412162,0.96139175,0.000045813922,0.014862262,0.0009585162,0.005429416,0.0014962993,0.00008896026,0.0016053616],"genre_scores_gemma":[0.013467692,0.97596234,0.0050115963,0.0002617118,0.0020302013,0.001880135,0.0004590807,0.00008205197,0.000845173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961369,0.001536417,0.0006693133,0.0006260934,0.00032479045,0.0007064535],"domain_scores_gemma":[0.99205893,0.006709743,0.00030407836,0.0005457985,0.00008561104,0.00029582737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021337345,0.00040678272,0.0018704394,0.00031590305,0.00013359974,0.000047488447,0.00036150703,0.00028564798,0.00012416841],"category_scores_gemma":[0.0018515522,0.0002344533,0.00022903844,0.00013002945,0.00036102778,0.00003178114,0.00029896875,0.0005151417,0.000026549902],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023493724,0.0003069696,0.0032239594,0.0022672915,0.0005630242,0.0018249976,0.00007575133,3.1896562e-8,0.00004428211,0.00023419263,0.00292003,0.96504575],"study_design_scores_gemma":[0.0096286945,0.0007584005,0.043472875,0.0051850956,0.00033504853,0.00033920567,0.00003231898,0.00008015893,9.2287826e-7,0.00010176696,0.93984616,0.00021937524],"about_ca_topic_score_codex":0.00001475625,"about_ca_topic_score_gemma":0.000060488397,"teacher_disagreement_score":0.96482635,"about_ca_system_score_codex":0.00083439413,"about_ca_system_score_gemma":0.0010635423,"threshold_uncertainty_score":0.9560728},"labels":[],"label_agreement":null},{"id":"W2488182585","doi":"10.1182/blood.v116.21.39.39","title":"A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; London Health Sciences Centre; McGill University Health Centre; Hôpital Maisonneuve-Rosemont; Université de Montréal; Queen Elizabeth II Health Sciences Centre; University of Alberta; Saint John Regional Hospital; Saskatchewan Cancer Agency; Victoria Hospital; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Thalidomide; Lenalidomide; Internal medicine; Prednisone; Multiple myeloma; Clinical endpoint; Maintenance therapy; Transplantation; Autologous stem-cell transplantation; Randomized controlled trial; Surgery; Clinical trial; Oncology; Chemotherapy","score_opus":0.013811884603905358,"score_gpt":0.27841976064123836,"score_spread":0.264607876037333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488182585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910313,0.00015729225,0.000029942119,0.000075460914,0.00016594387,0.008188722,0.000042325235,0.000031346408,0.0002776826],"genre_scores_gemma":[0.9985272,0.000118189324,0.00031403813,0.00002371653,0.0000803923,0.0005837451,0.00008654546,0.000030213829,0.00023594391],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99778473,0.00036893488,0.0005650288,0.00035505625,0.00054471736,0.00038153934],"domain_scores_gemma":[0.9983074,0.00086750387,0.00023893158,0.0003502279,0.00008868044,0.00014726135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008483947,0.00025256342,0.0008858777,0.00013358593,0.00010065372,0.000027354505,0.00012701102,0.00013352439,0.00003765582],"category_scores_gemma":[0.00021557599,0.00013789869,0.00021411476,0.00017458409,0.00017796682,0.00010387813,0.00001682988,0.00029096156,0.0000042171937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9754101,0.004852103,0.006817531,0.000046591726,0.0004901489,0.00013967724,0.0013198366,6.8585274e-7,0.0028703513,0.0000065371523,0.0000050373574,0.008041414],"study_design_scores_gemma":[0.9663871,0.0053258175,0.00980222,0.00009119507,0.0004286558,0.000015508662,0.00009757774,0.00015065553,0.017534446,0.000016793394,0.00001917457,0.0001308569],"about_ca_topic_score_codex":0.00031402035,"about_ca_topic_score_gemma":0.00013697492,"teacher_disagreement_score":0.014664094,"about_ca_system_score_codex":0.000018828467,"about_ca_system_score_gemma":0.0001784243,"threshold_uncertainty_score":0.5623346},"labels":[],"label_agreement":null},{"id":"W2488510469","doi":"10.1182/blood.v110.11.412.412","title":"Prolonged Overall Survival with Lenalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dexamethasone; Medicine; Lenalidomide; Thalidomide; Placebo; Refractory (planetary science); Multiple myeloma; Internal medicine; Corticosteroid; Phases of clinical research; Gastroenterology; Urology; Surgery; Chemotherapy","score_opus":0.02657669359127127,"score_gpt":0.27442810623955693,"score_spread":0.24785141264828567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488510469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954514,0.00017362364,0.0003902044,0.00008730571,0.000040290903,0.0030061472,0.000046865658,0.00015504276,0.0006491052],"genre_scores_gemma":[0.97730523,0.000018141218,0.021296209,0.00009620652,0.00008857445,0.00015467395,0.00034728853,0.00013770847,0.0005559922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99543554,0.00023787738,0.0005887161,0.00090996514,0.0015649857,0.0012628963],"domain_scores_gemma":[0.9968843,0.00081935374,0.00028947587,0.0008669185,0.0004333477,0.00070661836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076790806,0.00060606044,0.0011599768,0.00044415705,0.00015069768,0.000047199068,0.00022627984,0.00020559442,0.00010497531],"category_scores_gemma":[0.00045112133,0.0003558339,0.000074695294,0.00082326634,0.00030077435,0.00027479406,0.00007606121,0.00073896284,0.00003246831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13191168,0.0060590045,0.8551809,0.00013290638,0.0010397703,0.002660305,0.00044348463,0.000030195313,0.0007331201,0.0000032587827,0.000023515102,0.001781819],"study_design_scores_gemma":[0.18020497,0.0077830222,0.805907,0.00049249025,0.0003396877,0.00009063783,0.00017270302,0.000092190334,0.0043533905,0.0000019868512,0.00013345802,0.0004284354],"about_ca_topic_score_codex":0.0011783601,"about_ca_topic_score_gemma":0.009973891,"teacher_disagreement_score":0.049273916,"about_ca_system_score_codex":0.00037044514,"about_ca_system_score_gemma":0.0005881947,"threshold_uncertainty_score":0.9998894},"labels":[],"label_agreement":null},{"id":"W2490755617","doi":"10.1182/blood.v126.23.4227.4227","title":"Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Ixazomib; Medicine; Urology; Hemodialysis; Pharmacokinetics; Dosing; Cmax; Multiple myeloma; Dialysis; Renal function; Pharmacology; Internal medicine; Pharmacodynamics; End stage renal disease; Surgery; Proteasome inhibitor; Carfilzomib","score_opus":0.03441198321908557,"score_gpt":0.2973784338222597,"score_spread":0.26296645060317414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2490755617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532306,0.00009958699,0.0000041499798,0.00014820797,0.00004762102,0.0039737,0.00030819842,0.000035877994,0.000059615944],"genre_scores_gemma":[0.9983514,0.000009759007,0.00052538473,0.000060368144,0.000111133704,0.0004113176,0.00017715147,0.000045662742,0.00030783194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964927,0.00040245193,0.0006401399,0.0005966293,0.0013716468,0.000496447],"domain_scores_gemma":[0.99789345,0.00014585568,0.00028407216,0.00051308004,0.00026979353,0.00089372875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044776153,0.0003683028,0.0005245597,0.0002470819,0.00015303779,0.00003142815,0.00018598464,0.000073006515,0.00008754616],"category_scores_gemma":[0.00061917864,0.00022309535,0.00009051017,0.0005112789,0.00023905361,0.00021367866,0.00023494448,0.00037644865,0.0000048530355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025366263,0.04034251,0.9228432,0.00019172321,0.0006406491,0.00057544356,0.0016506532,0.00012555449,0.0028906465,0.0000017887481,0.0000848845,0.0052866666],"study_design_scores_gemma":[0.28386804,0.008899544,0.6974599,0.000505136,0.00071112154,0.000034492834,0.00047635022,0.0014607417,0.006031395,0.000013453832,0.00020108726,0.0003387591],"about_ca_topic_score_codex":0.00024060695,"about_ca_topic_score_gemma":0.00034391895,"teacher_disagreement_score":0.25850177,"about_ca_system_score_codex":0.0002646209,"about_ca_system_score_gemma":0.00078333955,"threshold_uncertainty_score":0.9097565},"labels":[],"label_agreement":null},{"id":"W2494811759","doi":"10.1182/blood.v110.11.950.950","title":"Effect of the Percent Decrease in Monoclonal Protein with Induction Therapy on the Outcome after Autologous Stem Cell Transplantation in Patients with IgG and IgA Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Gastroenterology; Thalidomide; Transplantation; Dexamethasone; Creatinine; Beta-2 microglobulin; Bortezomib; Surgery; Urology; Oncology","score_opus":0.01083629602466205,"score_gpt":0.24550617452989026,"score_spread":0.23466987850522822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494811759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972453,0.000051224106,0.000003396398,0.00006964974,0.00000851765,0.0025654885,0.0000138943105,0.000007883366,0.000034619305],"genre_scores_gemma":[0.99966276,0.000006848031,0.000070651455,0.000031984622,0.000007943931,0.00017562101,0.000014659937,0.000013803445,0.00001575323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989307,0.00016945906,0.00017585044,0.00018548571,0.00033338374,0.00020514849],"domain_scores_gemma":[0.9995095,0.00014703542,0.00005826536,0.000177838,0.000031137442,0.0000762172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030452255,0.00014054119,0.00017826578,0.00009515456,0.000036163823,0.0000066961516,0.00004700666,0.000053596483,0.0000068217278],"category_scores_gemma":[0.000018750825,0.00005815009,0.000026287964,0.00016066321,0.0000674206,0.00003910648,0.000007528746,0.00018805217,9.208594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01716938,0.0011080356,0.96945506,0.00009423827,0.00003745567,0.00007980539,0.0005791473,0.000003062877,0.0011458594,0.0000012646949,1.2191154e-7,0.010326536],"study_design_scores_gemma":[0.020167274,0.002964233,0.90313417,0.00016410384,0.000036925827,0.000009850295,0.00003169308,0.000016970771,0.07341742,8.731292e-7,9.601546e-7,0.00005551899],"about_ca_topic_score_codex":0.00025602913,"about_ca_topic_score_gemma":0.00045754557,"teacher_disagreement_score":0.07227156,"about_ca_system_score_codex":0.000043321645,"about_ca_system_score_gemma":0.00003757287,"threshold_uncertainty_score":0.23712918},"labels":[],"label_agreement":null},{"id":"W2496924072","doi":"","title":"Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Bortezomib; Multiple myeloma; Maintenance therapy; Medicine; Oncology; Internal medicine; Adverse effect; Autologous stem-cell transplantation; Chemotherapy","score_opus":0.02610538797153506,"score_gpt":0.2343623779707795,"score_spread":0.20825698999924444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2496924072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307,0.00008200282,0.0005543725,0.0006997857,0.00006283085,0.00407283,0.0007680055,0.0000612854,0.0006288752],"genre_scores_gemma":[0.9956513,0.000056553294,0.00028795234,0.000121004574,0.000033784294,0.0027399322,0.00037038673,0.000047636226,0.00069144164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976633,0.000051062216,0.0002461964,0.00049684127,0.00039055862,0.0011520035],"domain_scores_gemma":[0.9978442,0.00038454428,0.00010927982,0.00041531347,0.00033241935,0.00091421977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015217514,0.00029125717,0.00056247425,0.000369112,0.00017653021,0.000037602586,0.00016755456,0.0000803935,0.000022790375],"category_scores_gemma":[0.000040356586,0.00015330946,0.00014749212,0.00038327102,0.000104507104,0.00012322096,0.000009802058,0.00010243549,0.000010168432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028153596,0.00025878867,0.857827,0.000025659396,0.0019969507,0.00012455015,0.000091501344,0.000010207942,0.000021699008,0.0000052742275,0.00012932633,0.11135544],"study_design_scores_gemma":[0.048083175,0.0007648375,0.948039,0.000049626284,0.0005217052,0.0000047897365,0.000052558804,0.00021307702,0.0009304133,8.0764613e-7,0.0011101153,0.0002298858],"about_ca_topic_score_codex":0.018052202,"about_ca_topic_score_gemma":0.19448112,"teacher_disagreement_score":0.17642891,"about_ca_system_score_codex":0.00063496374,"about_ca_system_score_gemma":0.0002562269,"threshold_uncertainty_score":0.98848665},"labels":[],"label_agreement":null},{"id":"W2499395398","doi":"10.17925/eoh.2007.0.2.32","title":"Treatment of Multiple Myeloma Patients Who Have Received at Least One Prior Therapy","year":2007,"lang":"en","type":"article","venue":"European Oncology & Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine","score_opus":0.054319180231085354,"score_gpt":0.33647497275216726,"score_spread":0.2821557925210819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2499395398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95975435,0.0006471404,0.00004833815,0.0006322579,0.00017757974,0.0014587916,0.000032933138,0.00007862415,0.037169978],"genre_scores_gemma":[0.99306834,0.0007481521,0.0016133598,0.00025168754,0.00012540245,0.000033993623,0.00021956292,0.00008385316,0.003855632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676967,0.0006554292,0.0007901929,0.0006099673,0.00033090755,0.0008438493],"domain_scores_gemma":[0.99762493,0.0006132987,0.00036158058,0.0006406634,0.00030585413,0.0004536843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003577468,0.00036896646,0.001243629,0.0003162224,0.00018731283,0.000005514632,0.00019101915,0.00020563886,0.00043852418],"category_scores_gemma":[0.00029016688,0.00028815493,0.00024383572,0.00016184822,0.00051672716,0.000050417144,0.00013031314,0.0001863909,0.0007146704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008721914,0.0054234704,0.74886537,0.000041197938,0.0007243421,0.0047034295,0.0014122964,7.8099316e-7,0.0038678194,0.00003053335,0.0005789614,0.22562988],"study_design_scores_gemma":[0.02864871,0.010832359,0.8837017,0.000047869373,0.000098081015,0.000705208,0.00012652934,0.000047629434,0.019540656,0.0000066194775,0.056054357,0.00019027607],"about_ca_topic_score_codex":0.000094158946,"about_ca_topic_score_gemma":0.00037757892,"teacher_disagreement_score":0.22543961,"about_ca_system_score_codex":0.0006810492,"about_ca_system_score_gemma":0.00015000351,"threshold_uncertainty_score":0.9999571},"labels":[],"label_agreement":null},{"id":"W2501425081","doi":"10.1182/blood.v124.21.302.302","title":"Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Regimen; Neutropenia; Multiple myeloma; Clinical endpoint; Internal medicine; Progressive disease; Phases of clinical research; Adverse effect; Gastroenterology; Dosing; Urology; Oncology; Toxicity; Chemotherapy; Clinical trial","score_opus":0.02640005774996663,"score_gpt":0.2912116139478415,"score_spread":0.2648115561978749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501425081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969818,0.000063424835,0.00006148547,0.000078349185,0.000010679411,0.0026813461,0.000032297903,0.000011064362,0.00007953242],"genre_scores_gemma":[0.9988263,0.000008892582,0.000782854,0.000014820991,0.0000127946205,0.00021717604,0.00007247263,0.000021036953,0.000043603704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985812,0.00014129012,0.0003177497,0.00030224904,0.00040139304,0.0002561697],"domain_scores_gemma":[0.9984126,0.0008862484,0.00014394982,0.0003150551,0.00015459918,0.00008755114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047990892,0.00015760543,0.00033011808,0.00018844167,0.00006238699,0.000012082519,0.00007666616,0.0000491885,0.0000016292149],"category_scores_gemma":[0.0007093937,0.0000903467,0.000020779002,0.00023105377,0.00008123896,0.0000907923,0.00002819676,0.00017258365,7.243736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037157323,0.031024775,0.9138171,0.00006920178,0.0002032301,0.000027413671,0.00097647397,0.000009992813,0.00013050101,0.00000940273,0.000010867827,0.016563699],"study_design_scores_gemma":[0.3161948,0.016683977,0.66524404,0.00012188531,0.000105561856,0.000002981287,0.00028021476,0.0005919829,0.00066072453,0.000007658764,0.000035999063,0.000070166716],"about_ca_topic_score_codex":0.0004765338,"about_ca_topic_score_gemma":0.001638416,"teacher_disagreement_score":0.2790375,"about_ca_system_score_codex":0.000048430677,"about_ca_system_score_gemma":0.00006694757,"threshold_uncertainty_score":0.36842316},"labels":[],"label_agreement":null},{"id":"W2502727669","doi":"10.1182/blood.v122.21.416.416","title":"Multiple Myeloma (MM) In Older (&gt;70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cohort; Multiple myeloma; Transplantation; Melphalan; Internal medicine; Hematopoietic stem cell transplantation; Surgery","score_opus":0.009803410104956507,"score_gpt":0.22317020891648995,"score_spread":0.21336679881153345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2502727669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968889,0.00009077395,0.000017884462,0.000072006565,0.00005919004,0.001877514,0.00022213339,0.00007356922,0.0006980547],"genre_scores_gemma":[0.99580055,0.000033556727,0.0015930142,0.000101995756,0.00003270379,0.00023953083,0.0019920024,0.00005355181,0.00015308667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978706,0.00006138794,0.00038801058,0.0004958233,0.00063295447,0.0005512292],"domain_scores_gemma":[0.9988636,0.00012450876,0.000107805914,0.00038466987,0.00021662432,0.00030280382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042538122,0.00030676142,0.00044973777,0.00017541133,0.0000801286,0.000041744934,0.00013476361,0.00014430034,0.0004956928],"category_scores_gemma":[0.00003317902,0.00023844144,0.00007820517,0.00021149003,0.000062709,0.00022541621,0.000031407453,0.00021209789,0.00043966967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005073307,0.0049393014,0.9910539,0.0001322547,0.00014383462,0.00013103889,0.000985525,0.000008735184,0.00093061564,0.0000016632359,0.0001453999,0.0010203954],"study_design_scores_gemma":[0.038484927,0.0005885685,0.95038456,0.00019397307,0.00018575534,0.0000055547484,0.000098463366,0.0002159162,0.0095539875,0.000028352968,0.000028586284,0.00023138103],"about_ca_topic_score_codex":0.001303822,"about_ca_topic_score_gemma":0.00033636153,"teacher_disagreement_score":0.04066937,"about_ca_system_score_codex":0.00008500908,"about_ca_system_score_gemma":0.000060510047,"threshold_uncertainty_score":0.97233593},"labels":[],"label_agreement":null},{"id":"W2504016118","doi":"10.1182/blood.v108.11.3570.3570","title":"A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma.","year":2006,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital; McMaster University Medical Centre; Princess Margaret Cancer Centre; Cancer Care Ontario; McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Thalidomide; Medicine; Multiple myeloma; Internal medicine; Number needed to treat; Adverse effect; Number needed to harm; Regimen; Relative risk; Cochrane Library; Meta-analysis; Oncology; Randomized controlled trial; Confidence interval","score_opus":0.04622355380127601,"score_gpt":0.32367140770596814,"score_spread":0.2774478539046921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504016118","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040054394,0.98885983,8.696905e-7,0.0000077074765,0.0000023929072,0.010140476,0.00045291035,0.000021668393,0.000113598166],"genre_scores_gemma":[0.0008381867,0.99537855,0.0002116235,0.000024659976,0.0000044157496,0.0013874653,0.0016881375,0.0000597429,0.00040724102],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962099,0.0005943072,0.001546341,0.0006029425,0.0006436171,0.0004028562],"domain_scores_gemma":[0.99725777,0.0004511337,0.00089941116,0.0009641477,0.00022391621,0.00020362808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004422874,0.0006207838,0.013900205,0.0008385841,0.000027307371,0.000018000479,0.00016597097,0.00017739488,0.00008186078],"category_scores_gemma":[0.00045401763,0.00031734403,0.0016665324,0.0017336743,0.00006752233,0.000047792324,0.000067441244,0.00023477692,0.00001198864],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021432432,0.0010994861,0.005200348,0.67843693,0.3146024,0.000090064445,0.000007844785,9.902744e-8,7.272151e-9,8.781211e-7,0.000008512786,0.0005319803],"study_design_scores_gemma":[0.0037441403,0.0002677862,0.0018408835,0.09048571,0.9031038,0.000018416225,0.0000012533638,0.0000017814932,4.620908e-7,2.7029105e-7,0.00032571523,0.00020974493],"about_ca_topic_score_codex":0.00033584927,"about_ca_topic_score_gemma":0.00024708596,"teacher_disagreement_score":0.58850145,"about_ca_system_score_codex":0.00007596429,"about_ca_system_score_gemma":0.0001630915,"threshold_uncertainty_score":0.9999279},"labels":[],"label_agreement":null},{"id":"W2505446618","doi":"10.1016/j.bbmt.2016.07.007","title":"Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis","year":2016,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Office of Naval Research; Onyx Pharmaceuticals; Health Resources and Services Administration; Otsuka Pharmaceutical; Miltenyi Biotec; Incyte; Telomere Diagnostics; Sunesis; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Therakos; Sigma-Tau Pharmaceuticals; Chimerix; Medical College of Wisconsin; Takeda Oncology; University of Minnesota; Spectrum Pharmaceuticals; National Marrow Donor Program; St. Baldrick's Foundation; Genentech; Seattle Genetics; Pharmacyclics; Health Research; National Cancer Institute; Gilead Sciences; Leukemia and Lymphoma Society; Genzyme; Alexion Pharmaceuticals; Jazz Pharmaceuticals; Be The Match Foundation; Otsuka America Pharmaceutical; Amgen; National Institute of Allergy and Infectious Diseases; Roswell Park Cancer Institute; Fred Hutchinson Cancer Research Center; Celgene; Gamida Cell; WellPoint; Sanofi","keywords":"Medicine; Multiple myeloma; Internal medicine; Bortezomib; Confidence interval; Oncology; Fluorescence in situ hybridization; Transplantation; Chromosome; Gene","score_opus":0.009011483660965018,"score_gpt":0.25021918598580223,"score_spread":0.2412077023248372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505446618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951873,0.00015968809,0.0016249815,0.0002677318,0.000029341147,0.0005245876,0.002152961,0.00002967711,0.000023732917],"genre_scores_gemma":[0.99458,0.0026235357,0.001750984,0.000023214941,0.00001713002,0.00005425178,0.0008851167,0.000014565316,0.000051254272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985256,0.00016861034,0.0003824347,0.00041143387,0.00017289736,0.00033899597],"domain_scores_gemma":[0.99892455,0.00043922258,0.00016620105,0.00021549728,0.00009636914,0.00015818415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019447351,0.00023271047,0.0007078661,0.0004763152,0.00007344886,0.0000057059497,0.00007494413,0.00014855503,0.000041283463],"category_scores_gemma":[0.000035600464,0.00013067911,0.000112845584,0.0002674395,0.0002083476,0.00008184963,0.000007070477,0.00012749183,0.0000053453327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039435904,0.00043165573,0.8999112,0.00011835673,0.002619547,0.0001427386,0.00036451741,0.0000056680315,0.08792032,0.00003024684,6.941758e-7,0.0045114346],"study_design_scores_gemma":[0.021849904,0.0013930036,0.94494635,0.00012240765,0.0040346673,0.00003869226,0.000042861735,0.00004994727,0.027329175,0.000035913126,0.000002212202,0.00015487676],"about_ca_topic_score_codex":0.008154798,"about_ca_topic_score_gemma":0.014389827,"teacher_disagreement_score":0.060591146,"about_ca_system_score_codex":0.000015416139,"about_ca_system_score_gemma":0.000054588567,"threshold_uncertainty_score":0.99845},"labels":[],"label_agreement":null},{"id":"W2506579659","doi":"10.1158/1538-7445.am2016-lb-091","title":"Abstract LB-091: Inhibition of Siglec-15 prevents bone loss in a mouse model of multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alethia Biotherapeutics (Canada)","funders":"","keywords":"Bortezomib; Multiple myeloma; Bone marrow; Medicine; Femur; Tibia; Bone disease; Osteoporosis; Internal medicine; Pathology; Anatomy; Surgery","score_opus":0.10278785322535819,"score_gpt":0.40310140440589864,"score_spread":0.3003135511805405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2506579659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970619,0.00044364666,0.00006833553,0.0005067556,0.000016740705,0.001055487,0.00033596126,0.000015668991,0.0004954691],"genre_scores_gemma":[0.9958387,0.00074131304,0.00024481505,0.000010140468,0.00004764884,0.0003034148,0.000022046741,0.00003528534,0.0027566112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971465,0.0001250687,0.00047646114,0.00037436577,0.0012166651,0.00066094723],"domain_scores_gemma":[0.99833316,0.0003124078,0.000099027624,0.00047225552,0.0004983577,0.0002847693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078901334,0.00014912784,0.00041090092,0.00056206447,0.000044718057,0.0000068746,0.00014124667,0.00012846265,0.00036096983],"category_scores_gemma":[0.0006235582,0.00010345073,0.000103197744,0.00041437877,0.0003520978,0.00016317313,0.00013563964,0.00030827694,0.00003870703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002553301,0.0008443858,0.082094535,0.0004927449,0.00007296188,0.00008631824,0.0002151584,0.000050421426,0.8917902,0.00003173871,0.00029841045,0.021469796],"study_design_scores_gemma":[0.0090561835,0.00037689798,0.067534335,0.0011575309,0.0000071249497,0.0000031873542,0.000053538944,0.0007489831,0.92057383,0.00033656842,0.000049895036,0.00010193036],"about_ca_topic_score_codex":0.0015307929,"about_ca_topic_score_gemma":0.00059177197,"teacher_disagreement_score":0.028783599,"about_ca_system_score_codex":0.00048808954,"about_ca_system_score_gemma":0.0006486649,"threshold_uncertainty_score":0.42185983},"labels":[],"label_agreement":null},{"id":"W2507507842","doi":"10.1182/blood.v122.21.4441.4441","title":"A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Cancer research; STAT3; Angiogenesis; In vivo; Apoptosis; Biology; Chemistry; Multiple myeloma; Molecular biology; Immunology; Biochemistry","score_opus":0.033686052717683164,"score_gpt":0.28622486167558153,"score_spread":0.2525388089578984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507507842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976058,0.00015795465,0.00027388518,0.00015609046,0.00001511993,0.0014782618,0.000057100715,0.000027282324,0.0002285002],"genre_scores_gemma":[0.99551576,0.00013418905,0.0040418175,0.000023972743,0.000027856675,0.00015296732,0.000011860097,0.000035249708,0.000056314977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979544,0.00012145409,0.00052487553,0.00053374114,0.00034448222,0.0005210473],"domain_scores_gemma":[0.99872476,0.00033777952,0.0001452754,0.00032502558,0.00012248983,0.00034469887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029684248,0.00026784293,0.00067040493,0.00022789901,0.000029186993,0.000028571276,0.00010490124,0.0001618831,0.000022432594],"category_scores_gemma":[0.00019421181,0.00020209374,0.000070284,0.0002734793,0.00022274118,0.00020311323,0.0000897634,0.0003684958,0.000003992009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006586278,0.005263752,0.5907671,0.00012915807,0.00016421605,0.00029689603,0.00020825221,0.000056655572,0.40105724,0.00001033026,0.000009856246,0.0013779212],"study_design_scores_gemma":[0.019413587,0.0010759948,0.7836559,0.00026883392,0.000062531384,0.00004762334,0.00011786701,0.020072548,0.17506717,0.000036332447,0.0000012073444,0.00018042087],"about_ca_topic_score_codex":0.0061597447,"about_ca_topic_score_gemma":0.002017062,"teacher_disagreement_score":0.22599006,"about_ca_system_score_codex":0.000034763354,"about_ca_system_score_gemma":0.00026951075,"threshold_uncertainty_score":0.93117326},"labels":[],"label_agreement":null},{"id":"W2507902340","doi":"10.3390/ijms17091506","title":"Development of Novel Immunotherapies for Multiple Myeloma","year":2016,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Midwest Athletes Against Childhood Cancer","keywords":"Immunotherapy; Medicine; Multiple myeloma; Malignancy; Hematologic malignancy; Clinical trial; Monoclonal antibody; Oncology; Bone marrow; Immunology; Internal medicine; Cancer; Antibody","score_opus":0.10234335970524282,"score_gpt":0.4226175989837152,"score_spread":0.3202742392784724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507902340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011193411,0.9845611,0.013163293,0.000121979894,0.00042997827,0.00039955214,0.000052454146,0.000003611944,0.00014867925],"genre_scores_gemma":[0.0016903483,0.895621,0.10235316,0.000025224059,0.00014660487,0.000027183316,0.000012648714,0.000019179704,0.00010463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764305,0.000029425026,0.00084185996,0.00017047196,0.0011314577,0.00018373519],"domain_scores_gemma":[0.9979285,0.0002683919,0.0008596177,0.000104105726,0.00074292516,0.00009644712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064052735,0.00017916171,0.00073765795,0.0005619026,0.00005121536,0.00003577455,0.0006614223,0.00007616241,0.000035218265],"category_scores_gemma":[0.00038543195,0.00009949699,0.0005534585,0.00012585758,0.00019409403,0.00009345631,0.000072042356,0.00010166052,0.0000051772877],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096867894,0.00021407797,0.000021350128,0.00051233155,0.0013845217,0.000055570927,0.00007149169,5.0273206e-7,0.0016883133,0.000139822,0.000016949054,0.99579823],"study_design_scores_gemma":[0.0031587272,0.00039463726,0.00007801958,0.017776873,0.00015926239,0.00058858114,0.000042046817,0.00001940671,0.0036781656,0.000041219708,0.97391254,0.00015052178],"about_ca_topic_score_codex":0.000002122317,"about_ca_topic_score_gemma":0.0000012570677,"teacher_disagreement_score":0.99564767,"about_ca_system_score_codex":0.00015983953,"about_ca_system_score_gemma":0.0016790036,"threshold_uncertainty_score":0.40573695},"labels":[],"label_agreement":null},{"id":"W2508655644","doi":"10.1158/1055-9965.epi-15-1193","title":"A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci","year":2016,"lang":"en","type":"review","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Cancer Institute; National Center for Chronic Disease Prevention and Health Promotion; National Human Genome Research Institute","keywords":"Multiple myeloma; Biology; Genome-wide association study; Genetics; Single-nucleotide polymorphism; Genetic association; SNP; Gene; Genotype; Immunology","score_opus":0.475409906171085,"score_gpt":0.4810187686094133,"score_spread":0.00560886243832831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508655644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055030215,0.9937676,0.0026450625,0.00043596968,0.00011789164,0.0013275453,0.0009811638,0.000032068394,0.00014239304],"genre_scores_gemma":[0.010661411,0.98380584,0.001503389,0.00002116468,0.000071856375,0.0007671318,0.0019328762,0.0000454167,0.0011908921],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99175245,0.0048967283,0.0016931731,0.0009497337,0.00023075534,0.00047718536],"domain_scores_gemma":[0.9950546,0.0022566475,0.0017501402,0.00052601815,0.00016997942,0.00024259294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028749167,0.0004837,0.0043356926,0.0014348889,0.00013979891,0.000008700874,0.00015098586,0.0003059383,0.00038860465],"category_scores_gemma":[0.0018187858,0.00032101796,0.002600205,0.0011873083,0.0005472618,0.00013374264,0.0001195604,0.00035874016,0.000018770716],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029481045,0.00024418294,0.10532008,0.0022585348,0.34707448,0.000042882097,0.00006215654,0.000016629705,0.0000035434948,0.00014503983,0.0010247825,0.5435129],"study_design_scores_gemma":[0.0016027552,0.00016470678,0.53117007,0.0023528917,0.41973224,0.000026924288,0.00006222031,0.00021138047,0.0000010759745,0.001771737,0.042497825,0.0004061716],"about_ca_topic_score_codex":0.00092384673,"about_ca_topic_score_gemma":0.0018190389,"teacher_disagreement_score":0.54310673,"about_ca_system_score_codex":0.00033437682,"about_ca_system_score_gemma":0.00028697253,"threshold_uncertainty_score":0.9999242},"labels":[],"label_agreement":null},{"id":"W2510788806","doi":"10.1182/blood.v110.11.1482.1482","title":"Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Zoledronic acid; Oncology; Bone pain; Population; Univariate analysis; Bone remodeling; Spinal cord compression; Cancer; Bone disease; Surgery; Osteoporosis; Multivariate analysis","score_opus":0.008242888841877996,"score_gpt":0.2609110036232772,"score_spread":0.25266811478139917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510788806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700654,0.00008325694,0.00009150465,0.000029509147,0.000056542274,0.002133809,0.000039653954,0.000062742954,0.0004964277],"genre_scores_gemma":[0.9967856,0.0000065996114,0.002324656,0.000024798126,0.000027572874,0.00010565815,0.00034655642,0.000039597788,0.0003389795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984166,0.000019007293,0.00029091738,0.00031619275,0.00039927947,0.0005579871],"domain_scores_gemma":[0.9991419,0.00013830059,0.0000699628,0.0002562564,0.00013001537,0.00026361083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018250436,0.00018005798,0.00026540464,0.00019516029,0.000057139096,0.000003699297,0.000076505705,0.000095042,0.000029070088],"category_scores_gemma":[0.0002617898,0.00013376081,0.00007239653,0.00027259585,0.000037898993,0.00009187305,0.000025891792,0.0001432771,0.000022915672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019735585,0.003007421,0.98245126,0.00005501279,0.00027487506,0.000044335397,0.000077723045,0.0000029759915,0.00026288952,0.000006715188,0.000010506053,0.011832729],"study_design_scores_gemma":[0.06291535,0.0018711723,0.93184173,0.00011858263,0.00008751266,0.0000040903633,0.000023385535,0.000038499926,0.0027284834,0.000015558944,0.00023511639,0.00012050425],"about_ca_topic_score_codex":0.00002376757,"about_ca_topic_score_gemma":0.00010016227,"teacher_disagreement_score":0.06094179,"about_ca_system_score_codex":0.000076291326,"about_ca_system_score_gemma":0.00006118728,"threshold_uncertainty_score":0.54546076},"labels":[],"label_agreement":null},{"id":"W2511121889","doi":"10.1182/blood.v110.11.189.189","title":"Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Lenalidomide; Medicine; Neutropenia; Tolerability; Multiple myeloma; Adverse effect; Melphalan; Febrile neutropenia; Internal medicine; Phases of clinical research; Toxicity; Surgery; Oncology; Gastroenterology","score_opus":0.07021945872571524,"score_gpt":0.33511903297076184,"score_spread":0.2648995742450466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511121889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929553,0.0002980851,0.00036636757,0.00008403617,0.00005360563,0.0046226755,0.0014286041,0.00006802809,0.00012328575],"genre_scores_gemma":[0.9910642,0.000007155101,0.0055686524,0.000063581625,0.00024096158,0.00010536135,0.0027790845,0.000049440117,0.0001215975],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975549,0.00009004276,0.00055378536,0.00056563586,0.0006159223,0.00061969104],"domain_scores_gemma":[0.99610645,0.0017857059,0.00028505953,0.001172188,0.00036124792,0.00028935994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067214493,0.00028737384,0.00056933303,0.00008296029,0.0002628073,0.000023973898,0.00041234976,0.00010145686,0.000050820407],"category_scores_gemma":[0.0029385358,0.00016681908,0.00009049787,0.00032122602,0.00012241649,0.00013886248,0.00022499758,0.00016245445,0.000006457026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11592283,0.028506657,0.815989,0.0002119356,0.0022526311,0.00022911296,0.0009491554,0.0000030587444,0.0057900995,0.000004734785,0.0009178952,0.029222867],"study_design_scores_gemma":[0.7291009,0.009168444,0.2142861,0.00047883188,0.0015632088,0.0000147830415,0.00015202996,0.0011481015,0.043426298,0.000011512582,0.00038227686,0.00026755297],"about_ca_topic_score_codex":0.0015908027,"about_ca_topic_score_gemma":0.0013523636,"teacher_disagreement_score":0.613178,"about_ca_system_score_codex":0.00006866264,"about_ca_system_score_gemma":0.00026145988,"threshold_uncertainty_score":0.68026847},"labels":[],"label_agreement":null},{"id":"W2511176690","doi":"10.1016/j.clml.2016.08.010","title":"Myelomatous Involvement of the Central Nervous System","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Central nervous system; Multiple myeloma; Cerebrospinal fluid; Odds ratio; Magnetic resonance imaging; Confidence interval; Complication; Bone marrow; Cohort; Plasma cell; Internal medicine; Pathology; Gastroenterology; Radiology","score_opus":0.03741777232020433,"score_gpt":0.3179641029791642,"score_spread":0.2805463306589599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511176690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991946,0.00027823204,0.00011661385,0.0011596477,0.0008679981,0.0010821625,0.00006840673,0.00016856336,0.00431241],"genre_scores_gemma":[0.9961688,0.00012684957,0.00044988355,0.00036374468,0.0004952056,0.00007543495,0.000013667386,0.000060747374,0.002245678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99554574,0.00038437618,0.0014256653,0.00067922636,0.0010058301,0.00095913],"domain_scores_gemma":[0.9962572,0.00076609035,0.0004251443,0.0014963606,0.0002766707,0.0007785474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066328177,0.00037305232,0.0009148842,0.00009906109,0.00017362986,0.000023300601,0.0005713236,0.0003218019,0.0001413026],"category_scores_gemma":[0.00094784907,0.0001823769,0.00080657634,0.00036201187,0.00070316193,0.0001060001,0.0003806348,0.0001692231,0.00035473783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009177642,0.00036603314,0.34125507,0.00023461832,0.0004308712,0.00032781065,0.000048664355,7.663259e-7,0.0026965362,0.0014699347,0.0021054957,0.6501464],"study_design_scores_gemma":[0.0085610915,0.00055767194,0.9750032,0.0009207586,0.00016967644,0.00021654714,0.000090477464,0.00018433352,0.008331556,0.000107383064,0.0056515853,0.00020571971],"about_ca_topic_score_codex":0.00027951927,"about_ca_topic_score_gemma":0.000036463876,"teacher_disagreement_score":0.6499407,"about_ca_system_score_codex":0.0018512979,"about_ca_system_score_gemma":0.0016580118,"threshold_uncertainty_score":0.7437114},"labels":[],"label_agreement":null},{"id":"W2511905967","doi":"10.1182/blood.v124.21.2109.2109","title":"Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pomalidomide; Lenalidomide; Carfilzomib; Medicine; Internal medicine; Regimen; Discontinuation; Refractory (planetary science); Bortezomib; Population; Multiple myeloma; Dexamethasone; Daratumumab; Phases of clinical research; Gastroenterology; Oncology; Pharmacology; Toxicity; Biology","score_opus":0.060879720459982356,"score_gpt":0.3409894979192949,"score_spread":0.28010977745931254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511905967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98386896,0.000093926166,0.000017987159,0.000043400625,0.000055769386,0.015573361,0.00022582762,0.00007999613,0.000040753315],"genre_scores_gemma":[0.99638385,0.000025696347,0.0014739963,0.00003611918,0.0001326581,0.001361936,0.000087504224,0.00014191122,0.0003563228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99182624,0.0021714098,0.001217532,0.0015856654,0.0017923147,0.0014068664],"domain_scores_gemma":[0.99415755,0.0021660551,0.0004221956,0.0010005119,0.0013564855,0.00089719536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001901327,0.000781245,0.001725496,0.001092808,0.00037005387,0.00010310569,0.00025768226,0.00025273443,0.000026892249],"category_scores_gemma":[0.0054752976,0.00052177144,0.000102877886,0.000907617,0.0006756075,0.00039653783,0.0005426899,0.0009909292,0.000016090622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061119854,0.166875,0.7495644,0.00030389518,0.0011379741,0.0017605871,0.0070942235,5.5420355e-7,0.007948302,8.217255e-7,0.000016895912,0.0041774646],"study_design_scores_gemma":[0.38994807,0.046634383,0.5339448,0.00036247267,0.0002925046,0.000066025146,0.014277862,0.00040534924,0.013662714,9.712477e-7,0.000017381026,0.00038749023],"about_ca_topic_score_codex":0.0027790267,"about_ca_topic_score_gemma":0.0053325235,"teacher_disagreement_score":0.32882822,"about_ca_system_score_codex":0.00022326787,"about_ca_system_score_gemma":0.00038243056,"threshold_uncertainty_score":0.9997234},"labels":[],"label_agreement":null},{"id":"W2513223133","doi":"10.1182/blood.v108.11.3550.3550","title":"Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Internal medicine; Prednisone; Multiple myeloma; Regimen; Gastroenterology; Dexamethasone; Neutropenia; Refractory (planetary science); Creatinine; Surgery; Chemotherapy","score_opus":0.011800895330646,"score_gpt":0.24100791513177228,"score_spread":0.2292070198011263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513223133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995779,0.0003777819,0.000016961456,0.00009321415,0.00004519733,0.00093277096,0.000032810916,0.00007608014,0.002646181],"genre_scores_gemma":[0.9975055,0.000024016113,0.0010192171,0.00007564343,0.00009253022,0.0000956623,0.00027133696,0.000050259103,0.0008658425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979625,0.00007007589,0.00038218847,0.00041801325,0.0005778622,0.0005894059],"domain_scores_gemma":[0.9989577,0.00013653883,0.00009910565,0.00043870913,0.0001389248,0.0002290156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009839495,0.0002553792,0.0003807976,0.00022641094,0.00007074714,0.000027461301,0.00010472319,0.000112579066,0.00009053359],"category_scores_gemma":[0.00013566593,0.0001901561,0.00008029533,0.00026991632,0.000084336236,0.00015328448,0.000042723237,0.00028772067,0.00012122772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013722773,0.0052514547,0.9841161,0.000056298555,0.0001193936,0.0005477335,0.000043023778,0.0000038568905,0.0017566216,0.000009896778,0.00020459799,0.0065187807],"study_design_scores_gemma":[0.049391445,0.0017828996,0.9435183,0.00016670417,0.00011287739,0.000024376706,0.000020797122,0.000033422795,0.0038749077,0.000021879096,0.00086455187,0.0001878486],"about_ca_topic_score_codex":0.00065034215,"about_ca_topic_score_gemma":0.0007755027,"teacher_disagreement_score":0.048019167,"about_ca_system_score_codex":0.000106156884,"about_ca_system_score_gemma":0.00011468074,"threshold_uncertainty_score":0.7754341},"labels":[],"label_agreement":null},{"id":"W2514555365","doi":"10.1200/jco.2012.30.15_suppl.tps8112","title":"ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Internal medicine; Refractory (planetary science); Multiple myeloma; Progression-free survival; Phases of clinical research; Gastroenterology; Tolerability; Urology; Surgery; Oncology; Clinical trial; Chemotherapy; Adverse effect","score_opus":0.2741734888740753,"score_gpt":0.5310445704647311,"score_spread":0.2568710815906558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514555365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892591,0.0009659859,0.00026941832,0.0013810962,0.0011341202,0.0046157953,0.00001835755,0.000020286945,0.0023358355],"genre_scores_gemma":[0.97059023,0.0014443803,0.022985995,0.00061082677,0.0012457407,0.0002163055,0.000016514967,0.00008071726,0.0028092742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866103,0.0041047917,0.0063331015,0.00052725745,0.0013664135,0.0010581511],"domain_scores_gemma":[0.9715715,0.02028654,0.004968037,0.0007163151,0.00085657503,0.0016010008],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018278131,0.0005206557,0.0075298375,0.00059018703,0.00009457235,0.000034094784,0.0006922432,0.0008186312,0.0012166097],"category_scores_gemma":[0.03545598,0.00027094496,0.0006685187,0.0005941749,0.0009809415,0.00054681586,0.00025517071,0.002296145,0.000038274247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8084455,0.038403556,0.015085003,0.0000765054,0.0024359962,0.0024335175,0.00043549092,0.0000016022784,0.00033807463,0.00003168189,0.00065055164,0.1316625],"study_design_scores_gemma":[0.90462375,0.07760609,0.004782674,0.00066914305,0.001184596,0.0008831638,0.00040146397,0.0004034977,0.00034650083,0.000034409222,0.008787827,0.00027690752],"about_ca_topic_score_codex":0.0006389987,"about_ca_topic_score_gemma":0.00062684255,"teacher_disagreement_score":0.1313856,"about_ca_system_score_codex":0.0006557284,"about_ca_system_score_gemma":0.0066214628,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W2515657367","doi":"10.1080/10428194.2016.1204657","title":"Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Follicular lymphoma; Lymphoma; Dermatology; Oncology; Internal medicine","score_opus":0.014584976461774424,"score_gpt":0.2546905278786067,"score_spread":0.24010555141683226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515657367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613703,0.012169581,0.00005110244,0.018938117,0.00094945775,0.0033226665,0.00047713748,0.00035514837,0.0023664725],"genre_scores_gemma":[0.904293,0.0154839605,0.0005486921,0.035211336,0.00988523,0.002265605,0.001388324,0.0009730756,0.029950794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899904,0.0005639536,0.0018744658,0.002311909,0.0024377457,0.0028215244],"domain_scores_gemma":[0.9936518,0.0014712847,0.00086362,0.0028200985,0.00032119072,0.00087201607],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00040015535,0.0022169221,0.0033613457,0.00084091193,0.00096176664,0.00025423942,0.0008813568,0.0020188617,0.00021423245],"category_scores_gemma":[0.00023878098,0.0013663383,0.0026913602,0.0007252202,0.0009334922,0.00034842978,0.00033073337,0.00035313482,0.00028328536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007476324,0.0014169872,0.017334705,0.005088924,0.025353631,0.07929614,0.0024176904,0.000021945787,0.008741436,0.00014756666,0.120957956,0.7317467],"study_design_scores_gemma":[0.10347604,0.0020126256,0.064979136,0.0029175833,0.0040129106,0.0059361863,0.0002029822,0.0004591784,0.017507836,0.00022390462,0.7962252,0.0020464114],"about_ca_topic_score_codex":0.003987126,"about_ca_topic_score_gemma":0.00008275888,"teacher_disagreement_score":0.72970027,"about_ca_system_score_codex":0.025967868,"about_ca_system_score_gemma":0.0064012343,"threshold_uncertainty_score":0.9992767},"labels":[],"label_agreement":null},{"id":"W2518324907","doi":"10.1182/blood.v114.22.430.430","title":"Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Proteasome inhibitor; Medicine; Bortezomib; Discontinuation; Adverse effect; Internal medicine; Multiple myeloma; Peripheral neuropathy; Refractory (planetary science); Oncology; Pharmacology; Endocrinology","score_opus":0.02275757229499013,"score_gpt":0.275534983373577,"score_spread":0.25277741107858687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518324907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444115,0.00024969582,0.00011610504,0.00045815957,0.00007896248,0.00401257,0.00018207886,0.00020811927,0.0002531384],"genre_scores_gemma":[0.9917837,0.000010578272,0.0040847682,0.0008186311,0.00031015323,0.00057890586,0.00013866846,0.00008396583,0.0021906728],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973969,0.00012233101,0.00036386083,0.00065629353,0.00064602535,0.00081458513],"domain_scores_gemma":[0.99814695,0.0004618313,0.0001700284,0.0004616695,0.00029022846,0.00046928783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028471331,0.0004116517,0.0006454912,0.0001500319,0.00021867611,0.00005591895,0.00014836254,0.0002301014,0.00004461688],"category_scores_gemma":[0.0024616339,0.00027797755,0.0002016272,0.00033518142,0.000091565984,0.00015561003,0.00003374952,0.00041898745,0.000020256413],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04444795,0.03161778,0.16253133,0.0010255502,0.0027705233,0.0055361553,0.0022353323,0.0000027518263,0.7162824,0.00002574559,0.0023061663,0.031218275],"study_design_scores_gemma":[0.16274647,0.04056012,0.674269,0.0013184451,0.0010812962,0.00046002274,0.00009820782,0.0020511034,0.11340818,0.000016176791,0.0031290874,0.0008618728],"about_ca_topic_score_codex":0.0000363518,"about_ca_topic_score_gemma":0.00004815382,"teacher_disagreement_score":0.6028743,"about_ca_system_score_codex":0.00016410895,"about_ca_system_score_gemma":0.00041912537,"threshold_uncertainty_score":0.9999672},"labels":[],"label_agreement":null},{"id":"W2518878080","doi":"10.1182/blood.v126.23.3031.3031","title":"Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Neutropenia; Internal medicine; Dexamethasone; Multiple myeloma; Surgery; Refractory (planetary science); Population; Urology; Gastroenterology; Toxicity","score_opus":0.019148678171921084,"score_gpt":0.2665810931258431,"score_spread":0.24743241495392201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518878080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981712,0.0001188851,0.00012954156,0.000039857885,0.000015402476,0.0011507929,0.00007333084,0.000042894444,0.00025810537],"genre_scores_gemma":[0.9939948,0.000010154301,0.00524498,0.000042215404,0.000024788878,0.00010729176,0.0003059338,0.000049525912,0.00022034602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971745,0.00017009978,0.0004631696,0.0005291397,0.0010986157,0.00056447415],"domain_scores_gemma":[0.99797326,0.00011811474,0.00023611842,0.0006531617,0.00043169645,0.0005876215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034167824,0.0003337482,0.0009746451,0.0007003108,0.00004793987,0.000022672419,0.00013576371,0.00010986715,0.000045649158],"category_scores_gemma":[0.00017873608,0.00021942753,0.00012445822,0.0009568549,0.0001415891,0.00017218664,0.00006873318,0.00027057383,0.00001528593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035846572,0.005948676,0.95101887,0.000059366575,0.0037948336,0.00035760258,0.00067331735,0.0014287882,0.00023735517,0.0000015601576,0.000015720407,0.0006173651],"study_design_scores_gemma":[0.09819751,0.005665163,0.8841084,0.00021398305,0.0019275241,0.000010396167,0.00011597659,0.0064638653,0.003057405,0.000003099686,0.000010762455,0.00022590076],"about_ca_topic_score_codex":0.00084884575,"about_ca_topic_score_gemma":0.0009918496,"teacher_disagreement_score":0.06691043,"about_ca_system_score_codex":0.0002729634,"about_ca_system_score_gemma":0.00051781425,"threshold_uncertainty_score":0.89479953},"labels":[],"label_agreement":null},{"id":"W2519777424","doi":"10.1182/blood.v126.23.368.368","title":"Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Boréal","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; Digital polymerase chain reaction; KRAS; Exome; Exome sequencing; DNA; Cell-free fetal DNA; Molecular biology; Liquid biopsy; Multiple myeloma; Cancer research; Biology; Mutation; Polymerase chain reaction; Cancer; Medicine; Genetics; Gene; Immunology","score_opus":0.1273705593362092,"score_gpt":0.36233882179121224,"score_spread":0.23496826245500305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519777424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980416,0.00015494447,0.00037617437,0.00015425216,0.00003661822,0.0009651802,0.000038300765,0.000007693152,0.00022520254],"genre_scores_gemma":[0.9984534,0.0000017085622,0.0011435971,0.000008426532,0.00008789976,0.00012950554,0.00014765926,0.000008403947,0.000019426265],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99876416,0.00006778578,0.00020794675,0.00009427386,0.0007668715,0.000098974895],"domain_scores_gemma":[0.9983844,0.00025805846,0.00013777277,0.00012472096,0.0010378455,0.00005717434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001106697,0.00005581347,0.00012393652,0.000051883948,0.000034415625,0.000004187268,0.00003983626,0.000027871063,0.000022762622],"category_scores_gemma":[0.002262461,0.00003819319,0.000058042642,0.0000809464,0.000031615993,0.000050262188,0.000011650774,0.000032559143,0.0000033790711],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007381253,0.0021002754,0.42786035,0.00026011467,0.0012155322,0.000007882853,0.0025385055,0.00030755423,0.4336463,0.0001693881,0.00007302993,0.13108295],"study_design_scores_gemma":[0.011623749,0.00025903518,0.8262964,0.000042587024,0.00050930347,0.000019521049,0.00027263843,0.05273549,0.10796977,0.00022260858,0.000014344425,0.000034547444],"about_ca_topic_score_codex":0.000048173923,"about_ca_topic_score_gemma":0.0000108948125,"teacher_disagreement_score":0.39843607,"about_ca_system_score_codex":0.000037363337,"about_ca_system_score_gemma":0.0002951457,"threshold_uncertainty_score":0.27085406},"labels":[],"label_agreement":null},{"id":"W2521137575","doi":"10.1200/jco.2013.31.15_suppl.8528","title":"Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Neutropenia; Internal medicine; Clinical endpoint; Febrile neutropenia; Discontinuation; Surgery; Multiple myeloma; Oncology; Clinical trial; Chemotherapy","score_opus":0.13740891986873646,"score_gpt":0.4642725011870012,"score_spread":0.32686358131826476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521137575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488086,0.0013209948,0.000075312935,0.0009945622,0.0010429638,0.0012036435,0.00002860848,0.000016919113,0.00043615728],"genre_scores_gemma":[0.9776167,0.0017771686,0.019425368,0.00023107346,0.00064399635,0.000039066043,0.000020671705,0.00007921202,0.00016673755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99000436,0.002047041,0.0050885896,0.0005945831,0.0011461816,0.0011192427],"domain_scores_gemma":[0.9792314,0.014824758,0.0027137734,0.0007905764,0.000947202,0.0014922563],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0047480115,0.00052960194,0.0038676092,0.0009981703,0.000048195954,0.00002491045,0.00056627946,0.0011453935,0.0008123199],"category_scores_gemma":[0.028534526,0.00039332375,0.0011340203,0.000835762,0.00065202004,0.0003108631,0.000243643,0.0028539412,0.00014219913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081799075,0.009658995,0.7109084,0.000110713794,0.0014692926,0.0053193206,0.00028674776,0.0013274691,0.007857421,0.000013316081,0.0010759473,0.18017332],"study_design_scores_gemma":[0.12085909,0.027491009,0.84617174,0.0003522282,0.00023184916,0.00022307764,0.00019303027,0.0024756473,0.001126112,0.00018869319,0.00041519635,0.00027232806],"about_ca_topic_score_codex":0.0039494387,"about_ca_topic_score_gemma":0.0017803464,"teacher_disagreement_score":0.17990099,"about_ca_system_score_codex":0.001975547,"about_ca_system_score_gemma":0.005299896,"threshold_uncertainty_score":0.9998519},"labels":[],"label_agreement":null},{"id":"W2521802479","doi":"10.1200/jco.2013.31.15_suppl.8583","title":"Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Population; Quality of life (healthcare); Multiple myeloma; Internal medicine; Lenalidomide; Environmental health","score_opus":0.12958121648736118,"score_gpt":0.45786709637234085,"score_spread":0.3282858798849797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521802479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960256,0.000341488,0.00005406505,0.0009077215,0.00042104736,0.0020053764,0.000024476547,0.0000063023876,0.00021387902],"genre_scores_gemma":[0.9913078,0.00036798956,0.0070836437,0.000731605,0.00021326491,0.00008824952,0.000017732033,0.000031890708,0.00015784826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99235195,0.0012769086,0.004730034,0.0003986691,0.0006777397,0.0005646999],"domain_scores_gemma":[0.98591626,0.009463455,0.002559586,0.00034483915,0.0008429354,0.00087292766],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054422515,0.00026560636,0.002829541,0.00041917182,0.00003794791,0.000012394204,0.00022919636,0.0005907547,0.00011819278],"category_scores_gemma":[0.042288374,0.00019590542,0.00043845185,0.00024381155,0.00027875174,0.00022588402,0.00013551903,0.0010799611,0.000011900129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043831848,0.0073068,0.81942,0.00019120771,0.00040869636,0.00010729137,0.00018144508,0.000010096405,0.0018424442,0.0000065256413,0.00040445823,0.12628922],"study_design_scores_gemma":[0.15114322,0.011775885,0.83451396,0.00017202507,0.000057547848,0.000005978829,0.00016700322,0.0012087061,0.00017118015,0.00022792158,0.00042750066,0.00012909173],"about_ca_topic_score_codex":0.0009849643,"about_ca_topic_score_gemma":0.00076139503,"teacher_disagreement_score":0.12616013,"about_ca_system_score_codex":0.0005277768,"about_ca_system_score_gemma":0.0018146723,"threshold_uncertainty_score":0.9657788},"labels":[],"label_agreement":null},{"id":"W2521999181","doi":"10.1182/blood.v112.11.1723.1723","title":"Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Regimen; Multiple myeloma; Internal medicine; Cyclophosphamide; Prednisone; Gastroenterology; Surgery; Bortezomib; Transplantation; Chemotherapy","score_opus":0.030984845810534366,"score_gpt":0.2908620072020939,"score_spread":0.25987716139155953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521999181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943962,0.0020502368,0.000014384688,0.00006474552,0.000036369904,0.0031719725,0.00020724171,0.000015826143,0.00004301578],"genre_scores_gemma":[0.9954827,0.0022683963,0.0015560945,0.000010382555,0.00004500902,0.00023702663,0.00010114953,0.000026483372,0.0002727485],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987644,0.000044054446,0.0003402386,0.0002731521,0.00032129415,0.0002568446],"domain_scores_gemma":[0.9987454,0.00041432912,0.0001819154,0.0003252942,0.00016290195,0.00017018752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009622073,0.00020239597,0.0005076481,0.00007372665,0.00017974188,0.0000042464244,0.00005157829,0.00007056254,0.000010938053],"category_scores_gemma":[0.00018340799,0.00011118258,0.00009291266,0.00009928082,0.0002854234,0.00006404576,0.000021801461,0.00005737709,4.322128e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39594933,0.06742818,0.47004098,0.0002523112,0.0027053591,0.00008263853,0.0017566477,0.0000017588465,0.0024313894,0.0000087014305,0.00013706076,0.05920565],"study_design_scores_gemma":[0.68352294,0.064772144,0.22953044,0.000067153815,0.0007336785,0.000015823363,0.000050019804,0.00009050344,0.019672586,0.0000069607977,0.0014244741,0.00011328709],"about_ca_topic_score_codex":0.0002004919,"about_ca_topic_score_gemma":0.00003738411,"teacher_disagreement_score":0.2875736,"about_ca_system_score_codex":0.000029219385,"about_ca_system_score_gemma":0.00010397213,"threshold_uncertainty_score":0.4533894},"labels":[],"label_agreement":null},{"id":"W2522592085","doi":"10.1182/blood.v126.23.4322.4322","title":"Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Busulfan; Medicine; Dosing; Hematopoietic stem cell transplantation; Transplantation; Pharmacokinetics; Therapeutic drug monitoring; Cohort; Regimen; Internal medicine; Bioequivalence; Clinical trial; Surgery; Pharmacology","score_opus":0.040410476004269856,"score_gpt":0.28631602559276365,"score_spread":0.24590554958849378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522592085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446446,0.0040502045,0.000054964115,0.000070063375,0.000057464273,0.00029111787,0.0000051689512,0.00002172276,0.0009848386],"genre_scores_gemma":[0.99819535,0.00056617736,0.0008314643,0.000009185944,0.00005949391,0.000029473687,0.000007644955,0.000016603715,0.0002846352],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990668,0.000047718073,0.00020818044,0.00015857558,0.00030117662,0.00021752721],"domain_scores_gemma":[0.9994941,0.000054127828,0.00004636383,0.00019458497,0.00006248198,0.00014835768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012202045,0.00009971533,0.00021610092,0.00008643041,0.000016802614,0.0000059907907,0.0000688303,0.000037130012,0.000006900054],"category_scores_gemma":[0.0000065421546,0.00008360424,0.00003730347,0.00019505613,0.000028192555,0.00004063338,0.000008625963,0.00010617609,0.000020365263],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089876784,0.004398409,0.8662871,0.0015867633,0.0002466814,0.0020655005,0.01468473,0.000082646424,0.06541732,0.000045551627,0.000019478444,0.044267017],"study_design_scores_gemma":[0.015959604,0.00064591505,0.3001395,0.00034648756,0.00021349467,0.00024471333,0.0013312395,0.00010074474,0.68066627,0.000118516604,0.00006512975,0.00016843787],"about_ca_topic_score_codex":0.000089876274,"about_ca_topic_score_gemma":0.0000113620945,"teacher_disagreement_score":0.6152489,"about_ca_system_score_codex":0.000038593855,"about_ca_system_score_gemma":0.000111343856,"threshold_uncertainty_score":0.3409282},"labels":[],"label_agreement":null},{"id":"W2523288082","doi":"10.1182/blood.v112.11.867.867","title":"Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Regimen; Lenalidomide; Dexamethasone; Internal medicine; Transplantation; Oncology; Gastroenterology; Surgery","score_opus":0.03800804186316246,"score_gpt":0.31367291580299683,"score_spread":0.27566487393983435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523288082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791056,0.0002515227,0.00000448254,0.00012784833,0.000017687966,0.0012086259,0.000064898726,0.000016777314,0.00039760856],"genre_scores_gemma":[0.9978534,0.000487647,0.0010048873,0.0000125638735,0.000024866818,0.00007589209,0.0003501977,0.000021864738,0.00016870558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981715,0.00020050326,0.0005248515,0.00032913638,0.0004825734,0.00029141718],"domain_scores_gemma":[0.9987331,0.00033935858,0.00018921561,0.00052354566,0.00011560953,0.00009917926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021724301,0.00020269467,0.00047486238,0.0003024442,0.00004626979,0.000004802835,0.00014043825,0.00009491803,0.000012192219],"category_scores_gemma":[0.00014771668,0.00011478394,0.00007263632,0.00036782373,0.00016248584,0.00013323758,0.00001727605,0.00013554693,0.0000025679308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031968206,0.037513915,0.9013895,0.000095304604,0.00022425923,0.0034313886,0.0065476466,0.000011142598,0.014214835,0.000008896439,0.000025431045,0.004569495],"study_design_scores_gemma":[0.05529873,0.030419221,0.8776723,0.00021906754,0.00007660519,0.00023424103,0.00046932665,0.0005281251,0.034904342,0.0000049245527,0.000077263365,0.00009583788],"about_ca_topic_score_codex":0.0017055287,"about_ca_topic_score_gemma":0.0010711865,"teacher_disagreement_score":0.023717165,"about_ca_system_score_codex":0.00010342281,"about_ca_system_score_gemma":0.0002340136,"threshold_uncertainty_score":0.46807534},"labels":[],"label_agreement":null},{"id":"W2523490165","doi":"10.1200/jco.2013.31.15_suppl.8510","title":"MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Thalidomide; Clinical endpoint; Neutropenia; Internal medicine; Dexamethasone; Phases of clinical research; Surgery; Population; Multiple myeloma; Gastroenterology; Randomized controlled trial; Toxicity","score_opus":0.18168473715271388,"score_gpt":0.4888007598015487,"score_spread":0.3071160226488348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523490165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874722,0.0010476647,0.00017460198,0.0012934412,0.0021723814,0.0073696217,0.00002638555,0.000030028776,0.0004137165],"genre_scores_gemma":[0.97677964,0.0010033257,0.019977078,0.0005224827,0.0006533363,0.00036047833,0.00002743827,0.00010482547,0.0005714191],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9821253,0.0059349756,0.008135602,0.00094915286,0.0016513536,0.0012036633],"domain_scores_gemma":[0.9552854,0.034623887,0.0053787837,0.0011858757,0.0016052255,0.001920857],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0124360565,0.0007333059,0.008160774,0.0009132959,0.0001375753,0.00007969446,0.0012366647,0.0009252912,0.00075236155],"category_scores_gemma":[0.048713233,0.00053168985,0.00090786594,0.0007298329,0.000965849,0.00073652697,0.0007304186,0.0031936292,0.00013236766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.720593,0.09657062,0.015983593,0.00008748903,0.0035841272,0.0047858167,0.00075152016,0.00005536697,0.002591672,0.000011803579,0.00079408096,0.15419091],"study_design_scores_gemma":[0.89602566,0.050959226,0.042342838,0.00040214875,0.0012725865,0.00014581344,0.0015712611,0.005739306,0.000499825,0.000073569034,0.00058693974,0.0003808149],"about_ca_topic_score_codex":0.0060449964,"about_ca_topic_score_gemma":0.0018253302,"teacher_disagreement_score":0.17543268,"about_ca_system_score_codex":0.0010509087,"about_ca_system_score_gemma":0.003189441,"threshold_uncertainty_score":0.9997135},"labels":[],"label_agreement":null},{"id":"W2523786227","doi":"10.1182/blood.v116.21.1954.1954","title":"Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Tolerability; Proteasome inhibitor; Neutropenia; Bortezomib; Medicine; Adverse effect; Internal medicine; Pharmacology; Multiple myeloma; Toxicity","score_opus":0.01912431446018829,"score_gpt":0.3009066052993577,"score_spread":0.2817822908391694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523786227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983965,0.0005783252,0.0000036582687,0.000050117378,0.000019900848,0.00055661815,0.00030421882,0.00001828301,0.00007236006],"genre_scores_gemma":[0.9977997,0.00017322287,0.0015399246,0.000021141526,0.000026790669,0.000030433222,0.00026427253,0.000017835295,0.00012670983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866325,0.00006461793,0.000315493,0.00036148445,0.00032798268,0.0002671553],"domain_scores_gemma":[0.99882185,0.0003328948,0.000116263414,0.00033677282,0.00018199174,0.00021022519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014383774,0.00018909184,0.00064245163,0.00029318393,0.00006826196,0.000010028643,0.000055863686,0.000089976325,0.000081320555],"category_scores_gemma":[0.0005913865,0.00011908046,0.000056193327,0.00038558553,0.00018136743,0.00009346639,0.00007715002,0.00023591965,0.0000019838856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006456325,0.0031215989,0.97316295,0.00006057892,0.0039765066,0.00015085658,0.0006812317,2.164976e-7,0.0053969384,0.00000351591,0.000009752014,0.006979523],"study_design_scores_gemma":[0.06451027,0.0015027897,0.92783743,0.000065853856,0.0017974665,0.000002054287,0.00032482672,0.00008832656,0.0036546618,0.000006993835,0.000094811054,0.000114535294],"about_ca_topic_score_codex":0.0007941386,"about_ca_topic_score_gemma":0.002700911,"teacher_disagreement_score":0.058053948,"about_ca_system_score_codex":0.000022739845,"about_ca_system_score_gemma":0.00005900627,"threshold_uncertainty_score":0.48559603},"labels":[],"label_agreement":null},{"id":"W2523798870","doi":"10.1007/978-3-319-40320-5_10","title":"Treatment of Relapsed/Refractory Multiple Myeloma","year":2016,"lang":"en","type":"review","venue":"Cancer treatment and research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Pomalidomide; Thalidomide; Carfilzomib; Bortezomib; Lenalidomide; Medicine; Multiple myeloma; Pharmacology; Refractory (planetary science); Oncology; Internal medicine; Biology","score_opus":0.20129800098045472,"score_gpt":0.4787035238320829,"score_spread":0.27740552285162823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523798870","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014219015,0.99099046,6.745652e-7,0.00016543016,0.00014856315,0.0038653258,0.0006748955,0.000046500372,0.0026862766],"genre_scores_gemma":[0.0017125418,0.9616502,0.00005815163,0.0000021059209,0.0005228982,0.002869536,0.0002859563,0.00012156282,0.032777082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597734,0.0004818474,0.0006780084,0.0009980353,0.00078658067,0.0010782023],"domain_scores_gemma":[0.9963564,0.0013600944,0.00020878906,0.00096549914,0.0003393098,0.00076988136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021166523,0.0007539826,0.0027496258,0.00092105253,0.0002705,0.000039221908,0.00017081593,0.00049975456,0.0005738736],"category_scores_gemma":[0.00011405891,0.0003703386,0.0007951057,0.0005088631,0.00064299844,0.00007915138,0.000080783604,0.00028477443,0.00032117055],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005572438,0.0017395704,0.0023064367,0.005110218,0.002849276,0.00045818798,0.00015610733,1.1423408e-8,0.000024358125,0.00002590141,0.00022910323,0.9865436],"study_design_scores_gemma":[0.008504589,0.0073729507,0.00040129767,0.010150372,0.0009691904,0.00009616369,0.00003394358,0.000002862395,0.0002547175,0.000012842319,0.971928,0.00027308826],"about_ca_topic_score_codex":0.00083366147,"about_ca_topic_score_gemma":0.00007822434,"teacher_disagreement_score":0.9862705,"about_ca_system_score_codex":0.0029220833,"about_ca_system_score_gemma":0.0021284933,"threshold_uncertainty_score":0.99987483},"labels":[],"label_agreement":null},{"id":"W2524341612","doi":"10.1200/jco.2015.33.15_suppl.tps8613","title":"The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Multicenter study; Randomized controlled trial","score_opus":0.15953253754496918,"score_gpt":0.47876826623604535,"score_spread":0.3192357286910762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524341612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967792,0.00010610062,0.000008697515,0.00044987226,0.00046623338,0.002004236,0.0000059429103,0.000006267271,0.00017342021],"genre_scores_gemma":[0.99867564,0.000024312398,0.0009072419,0.0000973416,0.00016082577,0.000027532607,0.000004674382,0.000022027358,0.00008037455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486923,0.0010874615,0.0023252163,0.00025830558,0.0010796767,0.000380102],"domain_scores_gemma":[0.99373704,0.002676739,0.0014620025,0.00038426137,0.0010923377,0.00064762234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028254576,0.00019711681,0.0013983165,0.00016764626,0.00005460402,0.000012223169,0.000267875,0.0001318475,0.000019986815],"category_scores_gemma":[0.0072220857,0.00010018765,0.00017571865,0.00022434976,0.00017877198,0.00012391074,0.00010591929,0.00072925276,0.000010277932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08570146,0.087795034,0.6927427,0.000008235733,0.0005802841,0.001036565,0.00077113655,0.000034302866,0.000012750227,2.2384546e-7,0.00015121062,0.13116607],"study_design_scores_gemma":[0.16838051,0.17977615,0.6460096,0.000052575284,0.00018667185,0.000011412124,0.003594642,0.00013258554,0.0000143767265,0.0000026195958,0.0017766624,0.00006219434],"about_ca_topic_score_codex":0.000068873174,"about_ca_topic_score_gemma":0.00088144664,"teacher_disagreement_score":0.13110389,"about_ca_system_score_codex":0.000291299,"about_ca_system_score_gemma":0.0007514542,"threshold_uncertainty_score":0.8646033},"labels":[],"label_agreement":null},{"id":"W2524550612","doi":"10.1182/blood.v126.23.2086.2086","title":"Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Adverse effect; Neutropenia; Internal medicine; Bortezomib; Thalidomide; Oncology; Surgery; Chemotherapy","score_opus":0.08459238000182355,"score_gpt":0.3872454119856169,"score_spread":0.30265303198379334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524550612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903104,0.000035657155,0.0000063590196,0.000047476566,0.0001227951,0.0012482705,0.0000892222,0.00004118763,0.0080986805],"genre_scores_gemma":[0.99808806,0.000018986058,0.0010268233,0.00001970793,0.00012403136,0.0002458455,0.00019870356,0.00001732702,0.00026050903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814254,0.00011847954,0.0002910841,0.0003692924,0.00084262324,0.00023600682],"domain_scores_gemma":[0.9987322,0.00012500909,0.00011853929,0.00044908008,0.00019398105,0.00038118658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011562127,0.00020290115,0.00032052523,0.00013954671,0.000045165438,0.00002862567,0.00015004013,0.000042426793,0.00007002412],"category_scores_gemma":[0.00017243868,0.00012866972,0.00007543579,0.0001003775,0.000039736755,0.00014086581,0.00005574058,0.00008954709,0.000017591763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003146177,0.019229993,0.9617184,0.000011230596,0.00082731684,0.00008263575,0.0007564938,0.000018526684,0.00037141627,0.0000163942,0.0000081695025,0.016644843],"study_design_scores_gemma":[0.01915384,0.02201952,0.95227176,0.00005263712,0.00018547813,0.000007486634,0.0009295223,0.0005959281,0.0038722774,0.000009729497,0.00079581945,0.00010598914],"about_ca_topic_score_codex":0.0013314228,"about_ca_topic_score_gemma":0.00064890477,"teacher_disagreement_score":0.018839223,"about_ca_system_score_codex":0.00017519832,"about_ca_system_score_gemma":0.00020070212,"threshold_uncertainty_score":0.5246999},"labels":[],"label_agreement":null},{"id":"W2525525075","doi":"10.1182/blood.v120.21.lba-6.lba-6","title":"Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Thalidomide; Internal medicine; Population; Dexamethasone; Refractory (planetary science); Progression-free survival; Interim analysis; Phases of clinical research; Bortezomib; Surgery; Multiple myeloma; Intention-to-treat analysis; Neutropenia; Gastroenterology; Randomized controlled trial; Clinical trial; Chemotherapy","score_opus":0.03688351435222334,"score_gpt":0.3623769974216015,"score_spread":0.3254934830693782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525525075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908754,0.000980816,0.00002504939,0.000109741515,0.000089188215,0.0074769114,0.000028897191,0.00003888423,0.00037510772],"genre_scores_gemma":[0.99615735,0.00017341982,0.0026825638,0.000019145671,0.000039573548,0.00072462065,0.00007852336,0.000050040075,0.00007474774],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962089,0.001235923,0.0006085662,0.0005268959,0.0007148254,0.00070488645],"domain_scores_gemma":[0.99770164,0.0010770861,0.00021032564,0.00046773197,0.00010834546,0.0004348739],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024776452,0.00036711522,0.0010556497,0.00033522496,0.000087011744,0.000089549445,0.00022942871,0.00011500489,0.000025844603],"category_scores_gemma":[0.0011371553,0.0002569554,0.00004559597,0.00031092254,0.0001887265,0.0004723927,0.00023784996,0.00044970724,0.000006909765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16952878,0.10657355,0.7137665,0.00010910324,0.0003328507,0.0010001014,0.00074327557,4.103155e-7,0.004059408,0.000051806037,0.0000042067477,0.0038299991],"study_design_scores_gemma":[0.81032634,0.0031111455,0.1822441,0.00041003074,0.00023592149,0.000028098333,0.0012452767,0.00055946613,0.0015687061,0.000029662848,0.000004361644,0.00023688797],"about_ca_topic_score_codex":0.0010724086,"about_ca_topic_score_gemma":0.0007183296,"teacher_disagreement_score":0.64079756,"about_ca_system_score_codex":0.00010617906,"about_ca_system_score_gemma":0.00016650402,"threshold_uncertainty_score":0.99998826},"labels":[],"label_agreement":null},{"id":"W2525709004","doi":"10.1182/blood.v124.21.1326.1326","title":"Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Transplantation; Surgery","score_opus":0.018483521177799583,"score_gpt":0.26934786888148005,"score_spread":0.2508643477036805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525709004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961875,0.00013339873,0.000026883672,0.0003507461,0.000013933919,0.0010615363,0.000061858416,0.000099179066,0.002064942],"genre_scores_gemma":[0.9962717,0.000024193845,0.00063874933,0.00018101028,0.00008761336,0.00020390969,0.0008576467,0.00007010805,0.0016650232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976383,0.00019749708,0.00033627867,0.0005743613,0.0006188669,0.00063469145],"domain_scores_gemma":[0.9985531,0.00020618546,0.0001421639,0.0005395107,0.00014228838,0.0004167496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012614907,0.00036680096,0.0005839868,0.0003170836,0.00011168876,0.000037574846,0.000095254254,0.00011963798,0.0001307402],"category_scores_gemma":[0.00012810816,0.00023842699,0.00007784633,0.0004353882,0.00008167542,0.000103816084,0.000030191026,0.00015347716,0.000051095565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053962353,0.004038524,0.9083372,0.000045096414,0.00026915476,0.00026036898,0.00038362105,0.000016277383,0.00007083022,0.000009587924,0.0001490898,0.08102402],"study_design_scores_gemma":[0.102563255,0.009501886,0.8812059,0.00029399266,0.00019391828,0.00002257529,0.000051809653,0.0006882735,0.00203572,0.0000031344146,0.0031970954,0.00024241665],"about_ca_topic_score_codex":0.0013636743,"about_ca_topic_score_gemma":0.0017507925,"teacher_disagreement_score":0.097167015,"about_ca_system_score_codex":0.00024055874,"about_ca_system_score_gemma":0.00012018604,"threshold_uncertainty_score":0.97227705},"labels":[],"label_agreement":null},{"id":"W2526225966","doi":"10.1182/blood.v126.23.505.505","title":"Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Tolerability; Pembrolizumab; Dexamethasone; Internal medicine; Multiple myeloma; Oncology; Clinical endpoint; Phases of clinical research; Neutropenia; Gastroenterology; Surgery; Adverse effect; Clinical trial; Toxicity; Immunotherapy; Cancer","score_opus":0.035525364555547764,"score_gpt":0.29419090445438484,"score_spread":0.25866553989883706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526225966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662644,0.00073190645,0.00021482006,0.00033120706,0.000043857603,0.0015039913,0.000028524752,0.00006029381,0.00045897812],"genre_scores_gemma":[0.9939395,0.000062657695,0.004868637,0.000073554045,0.00007044859,0.00025973882,0.00013537052,0.000048056372,0.000542004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983939,0.00008884639,0.00026100702,0.00039394907,0.000419368,0.00044296432],"domain_scores_gemma":[0.9985924,0.00037416836,0.00008813123,0.0003098543,0.00021728751,0.00041815246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003655882,0.0002185814,0.00038894184,0.00024031974,0.00006541288,0.000031241132,0.00007778368,0.0001248212,0.000011149214],"category_scores_gemma":[0.00092631474,0.00017027135,0.000052668212,0.00021009617,0.00010307435,0.0001756444,0.000045698613,0.00021341651,0.000021112055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038053457,0.010926066,0.8862179,0.0006632591,0.0007388525,0.001262637,0.0016793677,0.000022641801,0.013868974,0.00022873985,0.0006251428,0.045712978],"study_design_scores_gemma":[0.34428295,0.007463283,0.61841846,0.00046551603,0.00031145688,0.00031931134,0.00045921528,0.0033038545,0.022837238,0.0004494585,0.0012600129,0.0004292398],"about_ca_topic_score_codex":0.000281322,"about_ca_topic_score_gemma":0.00034324083,"teacher_disagreement_score":0.3062295,"about_ca_system_score_codex":0.00012757958,"about_ca_system_score_gemma":0.0002810167,"threshold_uncertainty_score":0.6943464},"labels":[],"label_agreement":null},{"id":"W2526983807","doi":"10.1200/jco.2013.31.15_suppl.8527","title":"Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Neutropenia; Dexamethasone; Clinical endpoint; Internal medicine; Population; Urology; Adverse effect; Surgery; Gastroenterology; Toxicity; Clinical trial","score_opus":0.07336388582057025,"score_gpt":0.39894167578969064,"score_spread":0.3255777899691204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526983807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959648,0.0003740847,0.00039374235,0.00096626166,0.0006159919,0.0013509346,0.000056639372,0.00002242118,0.00025512482],"genre_scores_gemma":[0.97781056,0.00053582,0.020478372,0.00038977622,0.00032333445,0.000071981915,0.00009144413,0.0000711307,0.00022756887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897158,0.0019756795,0.004740929,0.00076376187,0.0017499267,0.0010538863],"domain_scores_gemma":[0.98344827,0.008884888,0.0035949766,0.0008447681,0.0016726018,0.0015544991],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038010466,0.0005870598,0.0046083224,0.0014181957,0.000098576544,0.000037659196,0.00049534155,0.00079299737,0.0009177057],"category_scores_gemma":[0.008015175,0.00040404778,0.0011671573,0.001265315,0.0006223793,0.00043072843,0.00021554162,0.0021346668,0.00008189354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2195318,0.020294327,0.5914579,0.00011469618,0.013390099,0.0029023208,0.00040315854,0.0059141396,0.00077130395,0.000015581243,0.0009153256,0.14428936],"study_design_scores_gemma":[0.13645355,0.03504102,0.8070778,0.00023113182,0.0027164684,0.000038010592,0.00018437428,0.017077154,0.00041313338,0.000063113934,0.00038187427,0.0003223196],"about_ca_topic_score_codex":0.0018007397,"about_ca_topic_score_gemma":0.0017394476,"teacher_disagreement_score":0.21561997,"about_ca_system_score_codex":0.0015150626,"about_ca_system_score_gemma":0.0028417315,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W2528329272","doi":"10.1056/nejmoa1607751","title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1434,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Otsuka Pharmaceutical; Celgene; Bristol-Myers Squibb; Incyte; Chugai Pharmaceutical; Spectrum Pharmaceuticals; Amgen","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine","score_opus":0.04367413013929703,"score_gpt":0.3284536669106923,"score_spread":0.2847795367713952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528329272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536383,0.004640772,0.011390484,0.028619261,0.00040951953,0.00054436136,0.000014849832,0.000017852155,0.0007245772],"genre_scores_gemma":[0.98747724,0.0010665443,0.0062588016,0.0002473345,0.0030408723,0.0000054951975,0.000004580656,0.000023262925,0.001875853],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985124,0.00006990427,0.0004725831,0.00016721568,0.00047184344,0.00030604834],"domain_scores_gemma":[0.9970791,0.0014791196,0.00022076652,0.00017253603,0.000325562,0.0007229149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090889935,0.00016785253,0.00058758777,0.00024054982,0.00006818615,0.000008188234,0.00008626969,0.000066408815,0.00017570396],"category_scores_gemma":[0.0035963948,0.0000771272,0.00008991148,0.000102204016,0.00017707732,0.00011846911,0.000022387625,0.00015914891,0.0000051307024],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010522789,0.00009490341,0.065867,0.00007340157,0.0003634861,0.00040241028,0.00025274017,2.681433e-7,0.046804957,0.0001186985,0.010425046,0.8650743],"study_design_scores_gemma":[0.6016331,0.011072545,0.1419497,0.002080658,0.0005554264,0.0060873344,0.00015955455,0.00011825219,0.014581659,0.0019172402,0.21961765,0.0002269159],"about_ca_topic_score_codex":0.000047499307,"about_ca_topic_score_gemma":0.000038104918,"teacher_disagreement_score":0.86484736,"about_ca_system_score_codex":0.00006457628,"about_ca_system_score_gemma":0.00016568394,"threshold_uncertainty_score":0.430548},"labels":[],"label_agreement":null},{"id":"W2529026236","doi":"10.1002/ijc.30461","title":"Distinct and shared three‐dimensional chromosome organization patterns in lymphocytes, monoclonal gammopathy of undetermined significance and multiple myeloma","year":2016,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canada Foundation for Innovation; CancerCare Manitoba Foundation; Cancer Research Society","keywords":"Chromosomal translocation; Interphase; Multiple myeloma; Biology; Fluorescence in situ hybridization; Chromosome; Karyotype; Monoclonal gammopathy of undetermined significance; Genetics; Molecular biology; Monoclonal; Immunology; Monoclonal antibody; Gene; Antibody","score_opus":0.01837308863999435,"score_gpt":0.2990285177846939,"score_spread":0.28065542914469954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529026236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997337,0.0008703941,0.0002981002,0.0010100049,0.00015412674,0.00013671708,0.00017954562,0.0000041434037,0.000009973384],"genre_scores_gemma":[0.9989461,0.00041142284,0.00033453357,0.000048732127,0.00017436364,0.0000051719585,0.00001476311,0.000014830048,0.000050109902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987618,0.000026299433,0.00039481508,0.00015382563,0.00052926375,0.00013403026],"domain_scores_gemma":[0.9987488,0.00019900278,0.00026001438,0.00006909728,0.0005855386,0.00013756838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011500808,0.00011227108,0.0002454485,0.00020196078,0.000017957347,0.00001677504,0.000100548044,0.00004447429,0.0002644832],"category_scores_gemma":[0.000278865,0.00007344288,0.000038665155,0.00008383786,0.00008571445,0.00019397766,0.000059019872,0.00006955274,0.0000014108895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011063438,0.000115449526,0.9072374,0.000027219585,0.0001967038,0.00028125566,0.00006299061,0.000006003439,0.047994014,0.00001571756,0.000023836501,0.042933032],"study_design_scores_gemma":[0.008210033,0.0002090617,0.96978414,0.0007137033,0.000029750288,0.00027290758,0.000010447498,0.0007057162,0.019831454,0.00009081873,0.00006979616,0.00007219671],"about_ca_topic_score_codex":0.000298393,"about_ca_topic_score_gemma":0.00049063377,"teacher_disagreement_score":0.06254668,"about_ca_system_score_codex":0.00031133302,"about_ca_system_score_gemma":0.00027695257,"threshold_uncertainty_score":0.29949138},"labels":[],"label_agreement":null},{"id":"W2529603678","doi":"10.1200/jco.2012.30.15_suppl.8013","title":"Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Dosing; Urology; Multiple myeloma; Internal medicine; Clinical endpoint; Gastroenterology; Pharmacology; Clinical trial","score_opus":0.20799719870669567,"score_gpt":0.5220809802286622,"score_spread":0.3140837815219666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529603678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658144,0.000270848,0.0002073761,0.0007723327,0.0004109421,0.0013676872,0.000015744647,0.0000031197735,0.00037051184],"genre_scores_gemma":[0.9930047,0.00035118574,0.006064111,0.000034519268,0.00035387534,0.00003889576,0.00001682691,0.000014627851,0.00012129274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967116,0.00034953735,0.0021675548,0.000119947195,0.00036752815,0.0002838096],"domain_scores_gemma":[0.993814,0.003419986,0.0017547916,0.00017446741,0.00046910057,0.00036767047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002134543,0.00013026554,0.0017318715,0.00022434842,0.000017687344,0.0000018339931,0.00007626452,0.00024440652,0.00003248371],"category_scores_gemma":[0.0033145784,0.00007784494,0.00042421807,0.00014333779,0.00016575068,0.0001207804,0.000012001782,0.00018731502,0.000002108553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5311758,0.05290615,0.19433105,0.000049742623,0.00084639154,0.00012306678,0.0002015578,0.0000036992262,0.00064515765,0.000086644235,0.00012539931,0.21950535],"study_design_scores_gemma":[0.6449415,0.22162667,0.12393166,0.00008348483,0.00040319952,0.000060688042,0.00008021334,0.00039209682,0.0028602341,0.00008261617,0.0054802443,0.00005735985],"about_ca_topic_score_codex":0.000045450925,"about_ca_topic_score_gemma":0.00005774695,"teacher_disagreement_score":0.219448,"about_ca_system_score_codex":0.0002714948,"about_ca_system_score_gemma":0.0011211938,"threshold_uncertainty_score":0.39680994},"labels":[],"label_agreement":null},{"id":"W2530661236","doi":"10.1182/blood.v120.21.576.576","title":"BP-2-047, a Novel Small-Molecule Inhibitor of Stat3 Is Active in Myeloma Pre-Clinical Models: Rationale for Treatment of Stat3-Dependent Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Cancer research; STAT3; Angiogenesis; Biology; In vivo; Cell culture; Phosphorylation; Immunology; Cell biology; Genetics","score_opus":0.10551439926021645,"score_gpt":0.36199295120694613,"score_spread":0.2564785519467297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530661236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930564,0.00072033855,0.0012688695,0.00014243093,0.00008184585,0.0031145697,0.0012225088,0.000023358814,0.00036963742],"genre_scores_gemma":[0.9874843,0.00018149699,0.010407151,0.000048087404,0.0001852336,0.00064658216,0.00029080122,0.000049697413,0.00070667267],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974314,0.00009697526,0.000863701,0.00044205404,0.0005459217,0.00061996304],"domain_scores_gemma":[0.99790007,0.00064936985,0.00028486238,0.00046165375,0.00030789874,0.0003961285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030420863,0.00030052362,0.00078717567,0.0002254323,0.000049548267,0.000009063564,0.00011678659,0.00017817527,0.00007425346],"category_scores_gemma":[0.00030676957,0.0002455621,0.00030861868,0.0001825388,0.00012160453,0.00018597636,0.000067913395,0.00010919176,0.000010434699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023025908,0.1194107,0.64443916,0.0010281804,0.005368635,0.000112824586,0.015092482,0.00009276008,0.14197885,0.00046494344,0.00032966692,0.048655882],"study_design_scores_gemma":[0.07201931,0.0062492224,0.27168408,0.00020246174,0.0005426846,0.000030115414,0.0008246383,0.0048504886,0.64283085,0.00010034214,0.00035401728,0.0003117931],"about_ca_topic_score_codex":0.00044361132,"about_ca_topic_score_gemma":0.0003438436,"teacher_disagreement_score":0.500852,"about_ca_system_score_codex":0.00017023264,"about_ca_system_score_gemma":0.0004144199,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W2531356683","doi":"10.1182/blood.v108.11.3533.3533","title":"Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Pharmacodynamics; Bortezomib; Volume of distribution; Pharmacology; Multiple myeloma; Distribution (mathematics); Internal medicine","score_opus":0.009579060015435492,"score_gpt":0.2762750528402685,"score_spread":0.266695992824833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531356683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977056,0.0001982996,0.0000038527132,0.000013008252,0.000023404255,0.0015856494,0.00006570506,0.000021673115,0.00038280868],"genre_scores_gemma":[0.9992259,0.00002240957,0.00048759943,0.000009662705,0.000026445052,0.000052944033,0.000077450386,0.00003075916,0.00006682536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837327,0.00008253844,0.00043061987,0.00030463227,0.0005050353,0.00030389815],"domain_scores_gemma":[0.99919784,0.00011111883,0.00015712889,0.00024996337,0.00015937176,0.00012458646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107137894,0.0002022946,0.00045220836,0.00024658715,0.000032613247,0.0000068547665,0.00008537545,0.00003809299,0.000029243585],"category_scores_gemma":[0.00004171748,0.00015566905,0.00003931916,0.00032076173,0.00009440985,0.00007043565,0.0000587328,0.00015367761,0.0000018069567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021425849,0.016415838,0.96874774,0.00013872689,0.00033111128,0.00014505979,0.00020196752,0.00003745696,0.009427087,0.0000034448576,0.00001242525,0.0023965791],"study_design_scores_gemma":[0.11441386,0.0024092188,0.86834013,0.0000875965,0.0003733085,0.000006966984,0.00009070076,0.0007385533,0.013411608,0.000006933657,0.000007901215,0.00011319522],"about_ca_topic_score_codex":0.0012572703,"about_ca_topic_score_gemma":0.0004676664,"teacher_disagreement_score":0.11227127,"about_ca_system_score_codex":0.000027763,"about_ca_system_score_gemma":0.000055487762,"threshold_uncertainty_score":0.63479996},"labels":[],"label_agreement":null},{"id":"W2531760402","doi":"10.1182/blood.v106.11.229.229","title":"Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Public Health; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Bendamustine; Medicine; Rituximab; Internal medicine; Population; Refractory (planetary science); Gastroenterology; Salvage therapy; Progressive disease; Neutropenia; Oncology; Chemotherapy; Surgery; Lymphoma; Biology","score_opus":0.017716380277482582,"score_gpt":0.2854540597887837,"score_spread":0.2677376795113011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531760402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930337,0.00043623443,0.000001242913,0.00012955595,0.00007416351,0.0036688766,0.0025050952,0.000041434785,0.0001096866],"genre_scores_gemma":[0.9974157,0.0001045981,0.0008370772,0.000038837694,0.00010265699,0.00019679416,0.0010561788,0.00007837944,0.00016973879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952408,0.00057123625,0.0012855306,0.0012283938,0.000895029,0.0007790097],"domain_scores_gemma":[0.9969645,0.0008258835,0.0005079329,0.0009063651,0.0003112414,0.00048407447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005534904,0.00068760687,0.0011511229,0.00072223984,0.00013435294,0.000036226003,0.00017225213,0.00019725887,0.00003491653],"category_scores_gemma":[0.0006061509,0.0005125243,0.000108412096,0.00041492216,0.00016987926,0.00028078523,0.00018818039,0.00029190147,0.000018384226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30088964,0.2865058,0.3679406,0.000041289495,0.0008131845,0.0011242386,0.01075562,0.00001530657,0.0043206895,7.508443e-8,0.000039061495,0.027554506],"study_design_scores_gemma":[0.3642315,0.034406483,0.57848364,0.00032653887,0.00027945387,0.000002576423,0.0007315733,0.000094681796,0.020998966,5.793363e-7,0.0001833022,0.00026071703],"about_ca_topic_score_codex":0.0050242497,"about_ca_topic_score_gemma":0.002632255,"teacher_disagreement_score":0.2520993,"about_ca_system_score_codex":0.00097430224,"about_ca_system_score_gemma":0.0003770718,"threshold_uncertainty_score":0.9997326},"labels":[],"label_agreement":null},{"id":"W2532841680","doi":"10.1158/1078-0432.ccr-16-0184","title":"New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma","year":2016,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SAIT Polytechnic","funders":"","keywords":"Multiple myeloma; Medicine; Immunotherapy; Cancer; Oncology; Immunology; Internal medicine","score_opus":0.262883191333897,"score_gpt":0.5140105323390389,"score_spread":0.25112734100514195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532841680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006636939,0.970881,0.00037702668,0.00032358474,0.0002536586,0.013940787,0.0006988317,0.00013809616,0.006750106],"genre_scores_gemma":[0.004534943,0.9782991,0.0032019697,0.000097213764,0.000998126,0.004072444,0.0005326117,0.0003671771,0.0078964345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891771,0.0011700703,0.002031413,0.0023713543,0.0028741246,0.0023759513],"domain_scores_gemma":[0.99019814,0.004435339,0.0003438632,0.0020145646,0.0009310439,0.0020770682],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021463397,0.0011065055,0.004066732,0.0013490814,0.00027745598,0.00024870754,0.0012080887,0.0010125003,0.00062734296],"category_scores_gemma":[0.002490719,0.00064282643,0.00087067724,0.00214856,0.0006488708,0.0002903015,0.00053427054,0.0028979848,0.0011139411],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007032399,0.0032014716,0.025485687,0.0044314885,0.00077611813,0.00014875326,0.00011523527,0.0000011056097,0.00000479432,0.00006174569,0.0020985343,0.9566427],"study_design_scores_gemma":[0.039850462,0.005086477,0.05621523,0.02519001,0.00023334831,0.00002937332,0.00012536686,0.000020688141,0.000008153566,0.000061274215,0.87212515,0.0010544775],"about_ca_topic_score_codex":0.005034265,"about_ca_topic_score_gemma":0.0009890348,"teacher_disagreement_score":0.95558816,"about_ca_system_score_codex":0.0017459824,"about_ca_system_score_gemma":0.009037091,"threshold_uncertainty_score":0.99966383},"labels":[],"label_agreement":null},{"id":"W2533046947","doi":"10.1182/blood.v114.22.1827.1827","title":"Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Cytogenetics; Multiple myeloma; Lenalidomide; Bortezomib; Refractory (planetary science); Internal medicine; Proteasome inhibitor; Medicine; Oncology; Fluorescence in situ hybridization; Biology; Chromosome; Genetics","score_opus":0.009380696814739794,"score_gpt":0.2380721969716121,"score_spread":0.2286915001568723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533046947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988436,0.00015414473,0.0000011443559,0.000027246413,0.0000020371856,0.00066388154,0.00002855782,0.000023745122,0.0002556153],"genre_scores_gemma":[0.99864674,0.000045736153,0.0011102617,0.000037491223,0.000008661936,0.000015602796,0.000055444416,0.000018401954,0.00006168434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988189,0.000038864706,0.00021456176,0.00027632725,0.00036252724,0.00028883188],"domain_scores_gemma":[0.99918884,0.000054858647,0.00008493322,0.00030652402,0.00017227452,0.00019259569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049831397,0.00017876037,0.00032114872,0.00015578754,0.00003355882,0.000007538859,0.0000588301,0.00007666974,0.000005785234],"category_scores_gemma":[0.00008938289,0.00011847769,0.00002044984,0.0002649318,0.000098994715,0.00007262109,0.000017249122,0.00014269286,0.0000028988431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027820785,0.002014152,0.9880943,0.000038641534,0.00011949337,0.00016318665,0.00013062052,0.000027406053,0.0037643446,0.0000018479891,0.000003173988,0.0028607713],"study_design_scores_gemma":[0.034115862,0.005604411,0.9394202,0.00021360982,0.00011050258,0.000013173639,0.000018800272,0.000019942785,0.020345887,0.0000029922344,0.000019659545,0.00011491737],"about_ca_topic_score_codex":0.00017167063,"about_ca_topic_score_gemma":0.00010429215,"teacher_disagreement_score":0.048674043,"about_ca_system_score_codex":0.000035088535,"about_ca_system_score_gemma":0.00008276364,"threshold_uncertainty_score":0.48313802},"labels":[],"label_agreement":null},{"id":"W2533157543","doi":"10.1182/blood.v114.22.132.132","title":"Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Regimen; Bortezomib; Internal medicine; Thalidomide; Melphalan; Transplantation; Phases of clinical research; Gastroenterology; Oncology; Urology; Chemotherapy","score_opus":0.02599818394216666,"score_gpt":0.3137119133069846,"score_spread":0.287713729364818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533157543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950527,0.001038009,0.000008931704,0.0007491009,0.00005700414,0.0021140727,0.00017789048,0.000092436305,0.0007098626],"genre_scores_gemma":[0.99645376,0.0003125843,0.002087466,0.00011702306,0.00013083358,0.000053653966,0.0004967139,0.000033296186,0.00031464716],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99699664,0.00019573556,0.0009556442,0.00063547795,0.0005485104,0.000668019],"domain_scores_gemma":[0.99808896,0.00041243,0.00025076367,0.00057998154,0.00020124775,0.00046660047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005427669,0.00035848902,0.0009209673,0.00045715942,0.00010613471,0.000025986752,0.0001494143,0.00023357067,0.00005585225],"category_scores_gemma":[0.0019116454,0.00029896174,0.00014469726,0.0007020565,0.00012914531,0.00016338498,0.00007568779,0.00035972934,0.000012567352],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4801135,0.06322706,0.032965872,0.00013748978,0.0011911689,0.0059087244,0.0014940684,0.000008760192,0.29304537,0.000034632034,0.0016006915,0.120272644],"study_design_scores_gemma":[0.7500491,0.011820707,0.09688521,0.00020753275,0.00032269457,0.00008954415,0.00009224394,0.0005616477,0.13920984,0.00003949786,0.000464891,0.00025708246],"about_ca_topic_score_codex":0.00082924304,"about_ca_topic_score_gemma":0.00024255016,"teacher_disagreement_score":0.26993558,"about_ca_system_score_codex":0.000054460943,"about_ca_system_score_gemma":0.00020658594,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W2534579778","doi":"10.1017/cjn.2016.395","title":"PC3 - 216 Presentation of Intradural Extramedullary Plasmacytoma with Intratumoral Hemorrhage: Case Report and Review of Literature","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Plasmacytoma; Medicine; Meningioma; Differential diagnosis; Multiple myeloma; POEMS syndrome; Radiology; Sarcoma; Pathology; Polyneuropathy","score_opus":0.030877869775196947,"score_gpt":0.30676486265305875,"score_spread":0.2758869928778618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534579778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851126,0.0082389405,0.000016241724,0.0058123483,0.00014226153,0.00025025284,0.000024291756,0.0000055002365,0.0003975745],"genre_scores_gemma":[0.99271727,0.003481173,0.0030250873,0.00065423886,0.000090096684,0.0000024415474,6.868788e-7,0.0000071184045,0.000021901778],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9967642,0.00052399235,0.000871582,0.00036401383,0.00077937904,0.0006968539],"domain_scores_gemma":[0.9961455,0.00047207493,0.0008825377,0.00014950315,0.000777723,0.0015727014],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0022263215,0.00022829817,0.0005889195,0.00060162327,0.0005102226,0.00011999904,0.00046259377,0.00010095366,0.000088482404],"category_scores_gemma":[0.0030380678,0.000107995445,0.00013468874,0.0009790303,0.0055967746,0.0007322994,0.000036310023,0.00056499604,2.9087965e-7],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034778565,0.000039666345,0.5478292,0.00024380849,0.000026222531,0.44033214,0.00011193133,0.000008237769,0.00023676493,0.00009694522,0.00016888669,0.010558396],"study_design_scores_gemma":[0.00070194167,0.04683035,0.08602114,0.0013387117,0.00007229416,0.8630948,0.000077116776,0.00010756003,0.0008382526,0.0007132751,0.000086807224,0.00011773893],"about_ca_topic_score_codex":0.0006601762,"about_ca_topic_score_gemma":0.008660914,"teacher_disagreement_score":0.4618081,"about_ca_system_score_codex":0.00010368318,"about_ca_system_score_gemma":0.0028373655,"threshold_uncertainty_score":0.9971094},"labels":[],"label_agreement":null},{"id":"W2534684017","doi":"10.1017/cjn.2016.319","title":"Unusual Cause of Sphenoidal Sinus Mass: Extramedullary Plasmacytoma","year":2016,"lang":"fr","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Plasmacytoma; Medicine; Internal medicine; Multiple myeloma","score_opus":0.052485399628149305,"score_gpt":0.3090626684831599,"score_spread":0.2565772688550106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534684017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96355516,0.014705158,0.00008833292,0.0146954665,0.0034587858,0.00031654234,0.00013995438,0.000015405934,0.0030251706],"genre_scores_gemma":[0.9906087,0.0037375034,0.0028810517,0.0011762251,0.0010621948,0.0000031776206,4.6529104e-7,0.00002779804,0.00050289446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9899786,0.0021221451,0.0017942104,0.00083177973,0.0019408982,0.0033323846],"domain_scores_gemma":[0.98854935,0.0023523143,0.0014021064,0.00030575573,0.0010789792,0.00631147],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["sts"],"category_scores_codex":[0.0055887527,0.0006363865,0.0011589087,0.0016726,0.0019999258,0.0004729793,0.0025412983,0.00048048992,0.0014040768],"category_scores_gemma":[0.008116772,0.00036584004,0.00056179235,0.001878052,0.023384616,0.0015576287,0.000117920186,0.0016322588,0.000033587552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006543828,0.00016062811,0.8616046,0.00004933936,0.00014797681,0.086596906,0.00028181926,0.0003862232,0.0006971356,0.0014184415,0.0013727436,0.046629835],"study_design_scores_gemma":[0.0040165414,0.29615298,0.4600776,0.0011851911,0.00045772595,0.20251961,0.0006942454,0.0012938723,0.0032316158,0.020240454,0.009208412,0.000921731],"about_ca_topic_score_codex":0.0032979923,"about_ca_topic_score_gemma":0.051123314,"teacher_disagreement_score":0.40152696,"about_ca_system_score_codex":0.00089652307,"about_ca_system_score_gemma":0.013922306,"threshold_uncertainty_score":0.99987936},"labels":[],"label_agreement":null},{"id":"W2534814303","doi":"10.1182/blood.v114.22.603.603","title":"Comparative Whole Transcriptome Shotgun Sequencing (WTSS) of Myeloma at Diagnosis and at Drug-Resistant Relapse.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; Genome British Columbia; Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Multiple myeloma; Transcriptome; Population; Drug resistance; Bone marrow; Biology; Panobinostat; Carfilzomib; Cancer research; Medicine; Oncology; Internal medicine; Immunology; Gene; Gene expression; Genetics; Bortezomib","score_opus":0.0408339993105416,"score_gpt":0.3039775867542676,"score_spread":0.263143587443726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534814303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906106,0.0037499138,0.000002302618,0.0007420165,0.0000218025,0.0005764998,0.00010253162,0.000041766096,0.004152562],"genre_scores_gemma":[0.99692893,0.0003181594,0.00048851967,0.000108499,0.000038088776,0.00004742587,0.00006648117,0.000014688837,0.0019892366],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99849516,0.00007039361,0.00029921162,0.00034146055,0.00041921213,0.00037453487],"domain_scores_gemma":[0.9990998,0.0001289184,0.00007660157,0.00029296035,0.00008664517,0.00031509847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012780708,0.00020414083,0.00051682116,0.00012413478,0.00014701443,0.000012289544,0.00007732703,0.00006924342,0.00014961514],"category_scores_gemma":[0.00004390262,0.00016377901,0.00011393849,0.00018264413,0.00012936097,0.00007894106,0.000040208863,0.00012992231,0.000045572833],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016906175,0.0017656832,0.20066349,0.00024801798,0.0007102674,0.00088122726,0.005162263,0.000003195957,0.78442127,0.00010187748,0.0020333063,0.0023187795],"study_design_scores_gemma":[0.011227473,0.0014134325,0.51967525,0.0003412335,0.00042240947,0.000121050434,0.00037711125,0.00007465771,0.46386343,0.00007536574,0.0022001062,0.00020848462],"about_ca_topic_score_codex":0.00008282319,"about_ca_topic_score_gemma":0.00019046589,"teacher_disagreement_score":0.32055786,"about_ca_system_score_codex":0.00018040193,"about_ca_system_score_gemma":0.00006536705,"threshold_uncertainty_score":0.6678714},"labels":[],"label_agreement":null},{"id":"W2535110757","doi":"10.1182/blood.v110.11.1499.1499","title":"Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; N-terminal telopeptide; Internal medicine; Multiple myeloma; Univariate analysis; Oncology; Creatinine; Gastroenterology; Proportional hazards model; Performance status; Cancer; Urology; Multivariate analysis; Alkaline phosphatase","score_opus":0.018165537692736898,"score_gpt":0.2698278280753894,"score_spread":0.25166229038265253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535110757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974079,0.00008201136,0.0000111611835,0.000007689321,0.000027020265,0.0009988826,0.000060193684,0.000020549187,0.001384557],"genre_scores_gemma":[0.9957868,0.000009377953,0.0038986912,0.000007750045,0.000012836686,0.000011342267,0.000088215165,0.00003465118,0.0001503231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983766,0.000057913796,0.00036787547,0.00026809418,0.000554233,0.00037527096],"domain_scores_gemma":[0.9987025,0.00019034336,0.00016963502,0.00034995325,0.000380587,0.00020697247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002457988,0.00018721638,0.00047082605,0.00021872454,0.000029263028,0.0000028925529,0.00009586656,0.0000745906,0.000047744892],"category_scores_gemma":[0.00024003578,0.00013301421,0.00003755458,0.0005876309,0.00011271764,0.000073425996,0.000043685657,0.00010911172,0.0000071680656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016696298,0.0039908774,0.9624279,0.00012186663,0.00033081466,0.00038592893,0.00016307425,0.000013956988,0.01305889,0.0000038313447,0.0000028357988,0.0028036956],"study_design_scores_gemma":[0.03683877,0.005003807,0.91280407,0.00033111044,0.00010490599,0.000015708372,0.00009623392,0.000017976618,0.044652015,0.0000016625261,0.000011909465,0.000121859644],"about_ca_topic_score_codex":0.00021635406,"about_ca_topic_score_gemma":0.0001682999,"teacher_disagreement_score":0.049623888,"about_ca_system_score_codex":0.00005147122,"about_ca_system_score_gemma":0.00024847712,"threshold_uncertainty_score":0.54241616},"labels":[],"label_agreement":null},{"id":"W2537965676","doi":"10.1182/blood.v116.21.1938.1938","title":"Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Internal medicine; Bortezomib; Regimen; Multiple myeloma; Proteasome inhibitor; Adverse effect; Clinical endpoint; Refractory (planetary science); Gastroenterology; Oncology; Clinical trial; Biology","score_opus":0.011277986536664912,"score_gpt":0.24021254727957647,"score_spread":0.22893456074291155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537965676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987069,0.000022260736,0.0000015738055,0.00021039715,0.00012896719,0.0006384172,0.00009158844,0.000047934675,0.00015197396],"genre_scores_gemma":[0.99821955,0.000011204267,0.0009988907,0.00007863331,0.00008616704,0.00006411244,0.000077497556,0.000043426997,0.00042054628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821305,0.0003539173,0.00022643835,0.00037840984,0.00038040167,0.00044777044],"domain_scores_gemma":[0.9988206,0.00023362742,0.000083943174,0.00043921097,0.00011727555,0.000305339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037567646,0.00019745431,0.0002774038,0.0001814511,0.00007023928,0.000025250227,0.000107113316,0.00008057887,0.00008956557],"category_scores_gemma":[0.0008145486,0.00014247293,0.000048570735,0.00023214369,0.000072809875,0.00006882043,0.00006386754,0.00038806026,0.0001252978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012547561,0.004454141,0.9355194,0.000021995576,0.00010956438,0.0017225347,0.00022546116,0.0000015145289,0.042449065,0.0000042555084,0.000075823424,0.0028687096],"study_design_scores_gemma":[0.025250718,0.0036162562,0.94288653,0.00004052019,0.00009443821,0.000026905618,0.00001983987,0.000016411177,0.02751645,0.000009960539,0.000391637,0.00013030584],"about_ca_topic_score_codex":0.00075786794,"about_ca_topic_score_gemma":0.00044302567,"teacher_disagreement_score":0.014932615,"about_ca_system_score_codex":0.000042052965,"about_ca_system_score_gemma":0.00013567974,"threshold_uncertainty_score":0.58098775},"labels":[],"label_agreement":null},{"id":"W2538114067","doi":"10.1182/blood.v124.21.4756.4756","title":"Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Transplantation; Multiple myeloma; Internal medicine; Surgery; Regimen; Single Center; Retrospective cohort study; Oncology","score_opus":0.049612190374744784,"score_gpt":0.3069341689529689,"score_spread":0.2573219785782241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538114067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988475,0.00007732292,0.00015638012,0.00017429693,0.000013785483,0.00035384702,0.000025637495,0.00000746117,0.0003437615],"genre_scores_gemma":[0.99858636,0.000032618525,0.0012263989,0.00007133678,0.000016325552,0.000015662792,0.000022917431,0.0000073839105,0.000021010232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990812,0.000052116906,0.0002569118,0.00014877401,0.00028723764,0.00017379163],"domain_scores_gemma":[0.99945027,0.00018662174,0.00006269486,0.00018108459,0.000050011797,0.00006935015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001265302,0.00009151102,0.00021774518,0.000050273367,0.000029101837,0.0000059022364,0.00008063345,0.000042409843,0.000021892109],"category_scores_gemma":[0.00016735849,0.000060659455,0.000041910207,0.00014452191,0.000079375095,0.000041376938,0.000013063058,0.00008975757,0.0000012917957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014474848,0.0016014616,0.9699508,0.0001279321,0.000046701913,0.000040140705,0.0041290093,0.0000013791239,0.02139435,0.000029424062,0.0000037594616,0.0025303198],"study_design_scores_gemma":[0.014183383,0.00029295738,0.9535636,0.00012906462,0.00006598067,0.000043628446,0.0005524666,0.00079635065,0.030262507,0.0000058847068,0.000047367343,0.00005680901],"about_ca_topic_score_codex":0.00015338819,"about_ca_topic_score_gemma":0.0001866592,"teacher_disagreement_score":0.016387174,"about_ca_system_score_codex":0.000008688321,"about_ca_system_score_gemma":0.00001604064,"threshold_uncertainty_score":0.24736208},"labels":[],"label_agreement":null},{"id":"W2539244465","doi":"10.1182/blood.v126.23.2960.2960","title":"A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of New Brunswick; Dalhousie University; Saint John Regional Hospital; Vancouver General Hospital; University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; Thalidomide; Single-nucleotide polymorphism; Progression-free survival; Lenalidomide; Multiple myeloma; Cereblon; Pomalidomide; Genotype; Biology; Genetics; Overall survival","score_opus":0.0958585646357947,"score_gpt":0.3364908829677887,"score_spread":0.24063231833199397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539244465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137515,0.0023785175,0.0000136764775,0.00012119851,0.00040527628,0.0054094917,0.00019679715,0.000062344036,0.000037543003],"genre_scores_gemma":[0.9984751,0.000078031226,0.00059168314,0.000054575106,0.0003016465,0.0003245797,0.000035874746,0.00005255653,0.00008597211],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738735,0.0002583785,0.0007646603,0.00055016356,0.00054691616,0.00049255206],"domain_scores_gemma":[0.99812645,0.0007431745,0.00026446042,0.00039028376,0.00012323303,0.00035239937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005804618,0.00028221525,0.0006950404,0.000064458414,0.00017523329,0.00003659479,0.00024103471,0.00011374324,0.000008071266],"category_scores_gemma":[0.000101210855,0.00018539547,0.00029270156,0.00013794543,0.00010875182,0.000059210022,0.00007424012,0.000219078,0.0000025170993],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035810966,0.014413809,0.91270244,0.00005053543,0.0015637863,0.00020931354,0.0023278398,0.000004446246,0.017577391,3.2452576e-7,0.00006647296,0.015272683],"study_design_scores_gemma":[0.48898128,0.013433479,0.45244122,0.00029354874,0.0017206797,0.000040789622,0.0013347259,0.0020543241,0.03916011,0.000018931045,0.0002365518,0.00028437813],"about_ca_topic_score_codex":0.00031961306,"about_ca_topic_score_gemma":0.00013963651,"teacher_disagreement_score":0.46026123,"about_ca_system_score_codex":0.000043537017,"about_ca_system_score_gemma":0.00017559418,"threshold_uncertainty_score":0.7560208},"labels":[],"label_agreement":null},{"id":"W2540991648","doi":"10.1007/978-3-319-42615-0_6","title":"Plasmacytoma and Multiple Myeloma","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Plasmacytoma; Medicine; Internal medicine","score_opus":0.03244354598608889,"score_gpt":0.28456025973478505,"score_spread":0.25211671374869615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540991648","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022519792,0.0005967333,0.0000231246,0.00066004385,0.00006744763,0.0007006709,0.00010754679,0.0001269828,0.99546546],"genre_scores_gemma":[0.0719981,0.00061627274,0.0006435894,0.00015307509,0.00023300647,0.000011028592,0.00006364123,0.000077862154,0.9262034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858826,0.000006860492,0.00022231879,0.0004548367,0.00039445426,0.00033326523],"domain_scores_gemma":[0.9987705,0.00019651813,0.000062066014,0.00040529564,0.0000927158,0.00047291545],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000055023516,0.0003417032,0.00047998162,0.00019253434,0.00006691917,0.000020302698,0.00006548253,0.0002876882,0.0037456446],"category_scores_gemma":[0.00007545024,0.00020799822,0.00013166807,0.000010468811,0.00016122173,0.000044942597,0.00011815459,0.00022199421,0.0018177532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030815445,0.00018658112,0.02206345,0.0006506966,0.0027077757,0.005738043,0.00007119388,2.4114229e-8,0.0016380695,0.113604054,0.025106624,0.8251519],"study_design_scores_gemma":[0.01510901,0.0012649416,0.014731723,0.0011659915,0.00031805882,0.000992689,0.000008634603,0.00010990148,0.0023436858,0.0056840214,0.9575249,0.0007464385],"about_ca_topic_score_codex":0.000013704049,"about_ca_topic_score_gemma":0.000035214856,"teacher_disagreement_score":0.9324183,"about_ca_system_score_codex":0.000095654184,"about_ca_system_score_gemma":0.00010689978,"threshold_uncertainty_score":0.9989594},"labels":[],"label_agreement":null},{"id":"W2544036771","doi":"10.1182/blood.v122.21.1988.1988","title":"FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Carfilzomib; Proteasome; Proteasome inhibitor; Pharmacology; In vivo; Pharmacokinetics; IC50; Bioavailability; Multiple myeloma; Cytotoxicity; Cell culture; Chemistry; Biology; In vitro; Biochemistry; Immunology","score_opus":0.03172782629800786,"score_gpt":0.30545610336298623,"score_spread":0.2737282770649784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544036771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565715,0.00026988503,0.0000064350193,0.0008426944,0.000021620783,0.0028513435,0.00004894023,0.00003100589,0.0002709181],"genre_scores_gemma":[0.99458635,0.00008868409,0.0038270243,0.00019378946,0.0000797548,0.00042170257,0.000018706152,0.000035643974,0.0007483647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983838,0.000040265826,0.00029440693,0.00045534328,0.00030739536,0.00051873975],"domain_scores_gemma":[0.99912304,0.00013031258,0.00006843535,0.00028021526,0.00006097523,0.00033704742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015341211,0.00022817701,0.00039275413,0.00016526387,0.000032217104,0.000052331932,0.00009344484,0.00011267251,0.00025832222],"category_scores_gemma":[0.000113193986,0.0001588376,0.00004296142,0.0002045482,0.00011533083,0.00014748129,0.00009537044,0.00033677893,0.00006176346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023176065,0.006892851,0.31496754,0.00018256229,0.0001641209,0.0001473896,0.00018696871,4.3293792e-7,0.67239726,9.0506364e-7,0.00018533008,0.0025570302],"study_design_scores_gemma":[0.06729207,0.0012901457,0.32551575,0.00028152906,0.00012700968,0.000073900635,0.000048986087,0.0023335759,0.6023246,0.0000057524703,0.00044346653,0.0002631951],"about_ca_topic_score_codex":0.0005444472,"about_ca_topic_score_gemma":0.000074952324,"teacher_disagreement_score":0.07007263,"about_ca_system_score_codex":0.000039914037,"about_ca_system_score_gemma":0.00013017734,"threshold_uncertainty_score":0.64772093},"labels":[],"label_agreement":null},{"id":"W2546416649","doi":"10.1182/blood.v112.11.1731.1731","title":"The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; BC Cancer Agency; Calgary Laboratory Services; Leukemia & Lymphoma Society of Canada; University of Calgary","funders":"","keywords":"Lenalidomide; Thalidomide; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Refractory (planetary science); Bortezomib; Gastroenterology; Surgery; Oncology; Biology","score_opus":0.06803620130697113,"score_gpt":0.33292646163777834,"score_spread":0.2648902603308072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546416649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979524,0.00045044196,0.000002746694,0.00016411484,0.000010996185,0.0009631337,0.000041975738,0.000011747927,0.0004024474],"genre_scores_gemma":[0.99790776,0.00081123406,0.00043938687,0.000015048526,0.000019255878,0.0000888452,0.000009707837,0.000026436488,0.0006823221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985788,0.00016002305,0.00033763042,0.00019808997,0.00039407535,0.00033137915],"domain_scores_gemma":[0.9972088,0.0017680269,0.00016229712,0.00064510235,0.00009489665,0.000120905104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019098971,0.00021681242,0.000490367,0.000100461366,0.000104233724,0.0000047462427,0.00013723876,0.00006400969,0.000037930025],"category_scores_gemma":[0.00052856136,0.00007581113,0.0001807887,0.00024137844,0.00026223986,0.000017136304,0.000027401322,0.00014627125,0.000007589914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077453707,0.0026671775,0.9785621,0.000014553678,0.001673856,0.00033035318,0.0006791651,0.000084041116,0.0052940664,0.000007885775,0.0000307546,0.00291064],"study_design_scores_gemma":[0.029008003,0.010676849,0.9040361,0.000079654186,0.00015271231,0.000083826075,0.00019937361,0.00017731189,0.055442203,0.0000059338813,0.000053308653,0.000084717125],"about_ca_topic_score_codex":0.001660028,"about_ca_topic_score_gemma":0.0006520348,"teacher_disagreement_score":0.07452603,"about_ca_system_score_codex":0.00024320873,"about_ca_system_score_gemma":0.0006209175,"threshold_uncertainty_score":0.30914882},"labels":[],"label_agreement":null},{"id":"W2546846989","doi":"10.1182/blood.v106.11.3414.3414","title":"Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Cohort; Creatinine; Multiple myeloma; Gastroenterology; Surgery","score_opus":0.03904975464525355,"score_gpt":0.3506064399552149,"score_spread":0.31155668530996133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546846989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976136,0.00023742454,5.054097e-7,0.00015063047,0.00015277028,0.001505065,0.000058809146,0.000033524564,0.0002476639],"genre_scores_gemma":[0.99814737,0.000052174546,0.0009257817,0.00020457273,0.00010307881,0.00009059603,0.00018589625,0.000046417976,0.00024410678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968281,0.00024566066,0.0009065325,0.00063861633,0.00065252354,0.00072860846],"domain_scores_gemma":[0.998724,0.00024982102,0.000116828305,0.00041206565,0.00006417413,0.00043313022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045216497,0.00029048082,0.000751435,0.00052929437,0.00003690148,0.000042627096,0.00018614325,0.00024551828,0.000032421478],"category_scores_gemma":[0.0010363054,0.00027111685,0.00010555765,0.0004360544,0.00007289024,0.00017659506,0.00019570628,0.00066319125,0.000121210585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013081884,0.0064010737,0.9682219,0.00003229296,0.00006874919,0.00020532939,0.0013772144,0.0000047112126,0.00004800816,9.352679e-7,0.00032799735,0.022003597],"study_design_scores_gemma":[0.036523063,0.0007398017,0.9617397,0.00016903222,0.000038542177,0.0000045115185,0.00010908986,0.00008803531,0.00011842328,0.0000034100904,0.00024784703,0.00021852784],"about_ca_topic_score_codex":0.0017961416,"about_ca_topic_score_gemma":0.016261123,"teacher_disagreement_score":0.035214875,"about_ca_system_score_codex":0.00019336167,"about_ca_system_score_gemma":0.00005692412,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W2547612211","doi":"10.1182/blood.v104.11.783.783","title":"Sequencing the Multiple Myeloma Kinome: Absence of Mutation in Known Malignancy-Associated Kinases.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Kinome; Biology; Receptor tyrosine kinase; Genetics; Cancer research; Tyrosine kinase; Kinase; Mutation; CDKN2A; Exon; Bruton's tyrosine kinase; Gene; Signal transduction","score_opus":0.025871643028557753,"score_gpt":0.2799492332638534,"score_spread":0.25407759023529564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547612211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978957,0.0004848736,0.000025740805,0.00024982108,0.000029159632,0.00055858673,0.000019342588,0.000031477724,0.000705285],"genre_scores_gemma":[0.99920744,0.000047613947,0.00046234837,0.000045372482,0.000026761718,0.000053241532,0.000047527115,0.000014980391,0.00009473211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988411,0.000054060783,0.00026791752,0.00019823697,0.0003357239,0.00030297856],"domain_scores_gemma":[0.99931955,0.00014490196,0.000098941884,0.0002457747,0.00010613876,0.000084674095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020505388,0.000117051066,0.00021557034,0.00011706174,0.00005937665,0.000010105223,0.00009788652,0.000067178014,0.000029179937],"category_scores_gemma":[0.0006668784,0.00008167355,0.00007167336,0.00040002266,0.00007829265,0.00006827432,0.00003290443,0.00014515224,0.000027559134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002566278,0.002964119,0.84557974,0.00016912675,0.00036781142,0.0023837774,0.002297092,0.00026884608,0.13527806,0.0003464479,0.000016309814,0.010072064],"study_design_scores_gemma":[0.01198835,0.00031876122,0.8279375,0.00039848732,0.00005358769,0.00006630523,0.00026802672,0.00020862154,0.1583975,0.00026859835,0.000009757931,0.00008451163],"about_ca_topic_score_codex":0.0017990129,"about_ca_topic_score_gemma":0.0008805332,"teacher_disagreement_score":0.02311944,"about_ca_system_score_codex":0.00019497954,"about_ca_system_score_gemma":0.00027560763,"threshold_uncertainty_score":0.33305508},"labels":[],"label_agreement":null},{"id":"W2549408839","doi":"10.14740/jocmr2802w","title":"Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Serum protein electrophoresis; Immunoglobulin light chain; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal; Immunofixation; Medicine; Urine; False positive rate; Monoclonal gammopathy; Myeloma protein; Nephelometry; Monoclonal antibody; Bence Jones protein; Molecular biology; Pathology; Internal medicine; Antibody; Immunology; Biology","score_opus":0.09789331941531842,"score_gpt":0.4413671626483566,"score_spread":0.3434738432330382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549408839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650894,0.00020428558,0.00035361442,0.032432795,0.00017604243,0.0013764313,0.00003143246,0.000005789391,0.00033025842],"genre_scores_gemma":[0.99591744,0.00090916926,0.0011163364,0.00017766753,0.00088465237,0.000049759896,0.000008025148,0.000030494333,0.0009064514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947306,0.0010547423,0.0014411864,0.0003667298,0.001666406,0.0007403693],"domain_scores_gemma":[0.98888063,0.00690304,0.0003802535,0.00038597515,0.0023518177,0.0010982729],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013321349,0.00021673556,0.0010375797,0.00074978743,0.00014985522,0.000023923843,0.00027760695,0.00018032597,0.00014555753],"category_scores_gemma":[0.024872195,0.00009974937,0.00010302668,0.0004391495,0.0005888202,0.00033061532,0.000096316144,0.0010093257,0.000013998498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016190594,0.0005949198,0.9075895,0.000109679946,0.00023740412,0.0001809257,0.00013189291,0.000001001299,0.00022406946,0.00013016937,0.001973383,0.07263646],"study_design_scores_gemma":[0.050063834,0.01883469,0.9257957,0.0015993122,0.00004821608,0.000022939274,0.00008458806,0.00032623246,0.0010989752,0.0006847886,0.0013350254,0.00010572141],"about_ca_topic_score_codex":0.00015365458,"about_ca_topic_score_gemma":0.0003792383,"teacher_disagreement_score":0.07253074,"about_ca_system_score_codex":0.00020564103,"about_ca_system_score_gemma":0.0010741341,"threshold_uncertainty_score":0.9833417},"labels":[],"label_agreement":null},{"id":"W2549580878","doi":"10.1182/blood.v126.23.28.28","title":"Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Daratumumab; Clinical trial; Biology","score_opus":0.031839832501048354,"score_gpt":0.31030300562441016,"score_spread":0.2784631731233618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549580878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226606,0.00019807332,0.000022552696,0.000050752315,0.000031509833,0.007005534,0.000031100713,0.000024453388,0.00036998838],"genre_scores_gemma":[0.9980771,0.00003854838,0.001229539,0.000019535324,0.000008669693,0.00026402023,0.00020210056,0.000049703667,0.000110812165],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969588,0.0006073689,0.00066114066,0.0005427439,0.0008172769,0.00041266473],"domain_scores_gemma":[0.9981458,0.00045660467,0.00027256433,0.0004827143,0.0003074167,0.00033485572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011456237,0.0003125402,0.0011811692,0.00040942556,0.000055351862,0.00004142123,0.000189876,0.00009695848,0.000016300643],"category_scores_gemma":[0.0008724448,0.00021342156,0.000031899985,0.00056230277,0.00016156866,0.00031142886,0.0001489291,0.00031470804,0.0000075832722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4661323,0.06745853,0.45947042,0.000040220933,0.00058125023,0.00019522832,0.0017056509,0.0000026882742,0.000033082535,0.000025070349,0.000010997416,0.0043445486],"study_design_scores_gemma":[0.7393625,0.011585261,0.24721141,0.00024776807,0.0002805815,0.000006941484,0.0008569473,0.00009287457,0.00016124934,0.000011569774,0.000015184141,0.0001677415],"about_ca_topic_score_codex":0.0016330159,"about_ca_topic_score_gemma":0.0009105732,"teacher_disagreement_score":0.27323014,"about_ca_system_score_codex":0.0001731394,"about_ca_system_score_gemma":0.00027806518,"threshold_uncertainty_score":0.87030786},"labels":[],"label_agreement":null},{"id":"W2550260109","doi":"10.1182/blood.v108.11.241.241","title":"A Novel Transgenic Mouse Model of Multiple Myeloma Reliably Predicts Drug Response.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Multiple myeloma; Somatic hypermutation; Paraproteinemia; Plasma cell; Immunology; Germinal center; Carfilzomib; Monoclonal; Biology; Genetically modified mouse; Cancer research; Monoclonal antibody; Antibody; Transgene; B cell; Bortezomib; Genetics","score_opus":0.023922140323694125,"score_gpt":0.2625121457514105,"score_spread":0.23859000542771638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550260109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962979,0.00023122372,0.0009180514,0.0002776025,0.00001981892,0.0007027685,0.00036365527,0.00010779804,0.001081207],"genre_scores_gemma":[0.9810594,0.000029187691,0.010475942,0.000037901846,0.0000664736,0.000071462266,0.00008545732,0.000046627338,0.008127562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982074,0.00005302808,0.00038260684,0.00033871052,0.0005697624,0.00044848386],"domain_scores_gemma":[0.9988688,0.00017334313,0.00007780853,0.00050638494,0.00014772001,0.00022592765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000264479,0.0002044712,0.00036240145,0.00019094603,0.00006773287,0.000010579205,0.00013732299,0.00010118031,0.000031407082],"category_scores_gemma":[0.00022249471,0.00017201343,0.00018471172,0.00020026151,0.00009817538,0.00007707063,0.000035071036,0.00017274398,0.000030518848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048340885,0.0046714083,0.032242645,0.00014475634,0.00025630568,0.000038389404,0.00024544442,0.00042763277,0.9562044,0.00004486725,0.00053679664,0.00035322274],"study_design_scores_gemma":[0.03460236,0.00058618345,0.09777464,0.000120104385,0.00031070775,0.000036273,0.00004423262,0.018919978,0.84713644,0.00006491442,0.00020067417,0.000203497],"about_ca_topic_score_codex":0.0005682302,"about_ca_topic_score_gemma":0.0001498207,"teacher_disagreement_score":0.10906801,"about_ca_system_score_codex":0.000042841853,"about_ca_system_score_gemma":0.00027485026,"threshold_uncertainty_score":0.7014504},"labels":[],"label_agreement":null},{"id":"W2550414527","doi":"10.1093/annonc/mdw606","title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"Italfarmaco; Ministero della Salute; Prothena; Celgene; Takeda Oncology; Gilead Sciences; Sanofi; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Melphalan; Bortezomib; Thalidomide; Oncology; Hematology; Transplantation; Incidence (geometry); Surgery; Intensive care medicine","score_opus":0.3007739062417689,"score_gpt":0.4743367711595702,"score_spread":0.17356286491780126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550414527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052180197,0.98821,2.489348e-7,0.00035343686,0.00008147531,0.0013261058,0.00036460606,0.000019770641,0.00442634],"genre_scores_gemma":[0.00073351903,0.9972176,0.0003257028,0.00031269516,0.00010138501,0.00015125897,0.00019562899,0.00004708008,0.0009151549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99727815,0.00052159483,0.0008505094,0.0005329596,0.0002381991,0.00057859306],"domain_scores_gemma":[0.9974215,0.0011473487,0.0003988049,0.0004949947,0.00018659986,0.0003507268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006167552,0.00039691574,0.0030258372,0.00043353697,0.000039207673,0.000007815582,0.0001575333,0.0005266281,0.0003541546],"category_scores_gemma":[0.00040712088,0.00026210267,0.00029013323,0.0001944505,0.00039058263,0.00005923154,0.00016169749,0.00032661256,0.00006670695],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022052282,0.00050961704,0.0008023389,0.018227065,0.000340122,0.0011199507,0.000041652824,4.299818e-9,0.000019126477,0.000100786885,0.0014057494,0.9772131],"study_design_scores_gemma":[0.002908184,0.0023876473,0.008536857,0.0101947915,0.00015708571,0.0004544932,0.000014184748,0.0000010659448,0.000022088241,0.00009020005,0.9750211,0.00021227682],"about_ca_topic_score_codex":0.00007160741,"about_ca_topic_score_gemma":0.00029852477,"teacher_disagreement_score":0.9770008,"about_ca_system_score_codex":0.00013842515,"about_ca_system_score_gemma":0.0013173419,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W2550531387","doi":"10.1182/blood.v124.21.647.647","title":"Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Epithelial–mesenchymal transition; Multiple myeloma; Mesenchymal stem cell; Microarray analysis techniques; Cancer research; Biology; Microarray; Gene signature; Downregulation and upregulation; Gene expression; Oncology; Gene; Medicine; Immunology; Pathology; Genetics","score_opus":0.02590204199985138,"score_gpt":0.3117922808917032,"score_spread":0.28589023889185183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550531387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656523,0.00006949958,0.030687777,0.0004055911,0.00007693778,0.0028583643,0.00017488126,0.00003981316,0.000034873],"genre_scores_gemma":[0.9936211,0.0000063915845,0.004965871,0.000088278815,0.000087988876,0.00056438893,0.0005139898,0.000031331474,0.00012067754],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982621,0.00013741205,0.00051100686,0.00038102348,0.00032989783,0.00037855378],"domain_scores_gemma":[0.998958,0.0001361968,0.00014255928,0.00030113914,0.00026949678,0.00019263431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084348343,0.00016685323,0.0003291114,0.00025797597,0.000059499398,0.000027060882,0.00010993593,0.00010138757,0.000010914303],"category_scores_gemma":[0.00025887863,0.00014964888,0.00016336206,0.00022401703,0.00004660542,0.00015931964,0.00002214253,0.0001001596,0.000013652448],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023742612,0.008052585,0.01477015,0.00039832745,0.00026847757,0.000009557516,0.0013483102,0.000016856246,0.85440993,0.0002025713,0.000005432135,0.11814356],"study_design_scores_gemma":[0.02394909,0.003841556,0.608847,0.0003063232,0.00023743772,0.00002660714,0.00020776274,0.008715164,0.35307336,0.0005104015,0.00009058437,0.00019471833],"about_ca_topic_score_codex":0.0001944348,"about_ca_topic_score_gemma":0.00026713312,"teacher_disagreement_score":0.5940769,"about_ca_system_score_codex":0.000056589062,"about_ca_system_score_gemma":0.000035542747,"threshold_uncertainty_score":0.6102504},"labels":[],"label_agreement":null},{"id":"W2550582210","doi":"10.1182/blood.v120.21.4029.4029","title":"A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Adverse effect; Internal medicine; Antibody; Toxicity; Multiple myeloma; Gastroenterology; Oncology; Immunology","score_opus":0.016703943797388352,"score_gpt":0.3009600301493398,"score_spread":0.28425608635195143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550582210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975548,0.00009827991,0.000006354474,0.000012072788,0.000029545728,0.0018562572,0.00036302183,0.0000097800075,0.000069920294],"genre_scores_gemma":[0.99919355,0.000033044274,0.0006116124,0.000005765394,0.000026044487,0.000017551025,0.00005343028,0.000029101104,0.000029872523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981338,0.0002123719,0.00053476164,0.00022884058,0.0005644758,0.00032576622],"domain_scores_gemma":[0.99855894,0.00034210566,0.0003675908,0.00028399986,0.00027862293,0.00016871747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015200306,0.00021428124,0.0005334205,0.00015041626,0.000054378605,0.000004163286,0.000107948465,0.00006731462,0.000049837916],"category_scores_gemma":[0.0005037657,0.00012249837,0.00005729945,0.00038127849,0.00015933135,0.00013651053,0.00012297464,0.00020497774,7.136046e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009462858,0.02569709,0.90349954,0.0002852214,0.0004947536,0.000007682559,0.0034269362,5.7962905e-7,0.054660834,0.0000012180112,0.0000037835223,0.002459471],"study_design_scores_gemma":[0.070287995,0.007633719,0.82978773,0.00054909295,0.00020473923,0.0000032076891,0.0005589922,0.000030638563,0.09084212,2.8671244e-7,0.0000046359764,0.000096852265],"about_ca_topic_score_codex":0.00022303853,"about_ca_topic_score_gemma":0.00004309073,"teacher_disagreement_score":0.07371185,"about_ca_system_score_codex":0.000035660698,"about_ca_system_score_gemma":0.000081616425,"threshold_uncertainty_score":0.49953386},"labels":[],"label_agreement":null},{"id":"W2550950130","doi":"10.1182/blood.v114.22.2876.2876","title":"Infectious Complications in Advanced Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide (Revlimid +/- Corticosteroids).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Neutropenia; Thalidomide; Multiple myeloma; Internal medicine; Surgery; Chemotherapy","score_opus":0.014501217070552748,"score_gpt":0.2675675724735097,"score_spread":0.25306635540295697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550950130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509436,0.00017896853,0.00002140317,0.0001734265,0.000017594437,0.0013010317,0.0000294199,0.00013624365,0.0030475447],"genre_scores_gemma":[0.99833745,0.00007879921,0.00064200675,0.00025361992,0.00002472689,0.00014292914,0.0003093041,0.000030118541,0.0001810726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836224,0.000068354166,0.00035033654,0.00040893623,0.00034580694,0.0004643502],"domain_scores_gemma":[0.9987921,0.00012210473,0.00011453206,0.00048609867,0.00019155616,0.00029362558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056239303,0.00024291714,0.0003660261,0.00024476927,0.00010348186,0.00002020236,0.00009164284,0.00008797384,0.00003014955],"category_scores_gemma":[0.0002183636,0.00018928738,0.0000695481,0.00039040417,0.00005990411,0.00015660505,0.000021685773,0.0002583946,0.00008867199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011042919,0.0066539585,0.9600151,0.00002090717,0.00011725819,0.00017051876,0.00007795897,0.000009845205,0.0066107605,0.00000809588,0.000036813617,0.02517445],"study_design_scores_gemma":[0.043732744,0.003113494,0.946853,0.00015844333,0.00010431511,0.000052359475,0.000017519453,0.00007544202,0.0054239673,0.00001590828,0.0002800521,0.0001727735],"about_ca_topic_score_codex":0.00011285132,"about_ca_topic_score_gemma":0.00020746022,"teacher_disagreement_score":0.042628452,"about_ca_system_score_codex":0.00014906176,"about_ca_system_score_gemma":0.00008087004,"threshold_uncertainty_score":0.77189153},"labels":[],"label_agreement":null},{"id":"W2552110041","doi":"10.1182/blood.v124.21.2112.2112","title":"Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Renal function; Internal medicine; Thalidomide; Melphalan; Urology; Creatinine; Dialysis; Surgery; Gastroenterology","score_opus":0.01653517012503599,"score_gpt":0.2859744430745613,"score_spread":0.26943927294952535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552110041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634695,0.00007649453,0.0000055238265,0.00017677394,0.000044411823,0.0029149821,0.00025799623,0.000033475153,0.00014337436],"genre_scores_gemma":[0.99824554,0.000085107786,0.0006869502,0.00003884225,0.00009573163,0.00049256074,0.0001794124,0.000049995826,0.00012583246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971321,0.00022057716,0.00066521345,0.00064241927,0.0006776008,0.00066207984],"domain_scores_gemma":[0.9974508,0.0010496418,0.0002321784,0.000652287,0.000114581904,0.000500459],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031034416,0.0004902558,0.00092733675,0.0003394035,0.00007178923,0.00003069848,0.00009377785,0.00013433734,0.00004137182],"category_scores_gemma":[0.00084753643,0.00028948285,0.00026699746,0.0002216539,0.00012413925,0.0000986609,0.000060627703,0.00018012484,0.000019443047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21930243,0.014575539,0.7547827,0.000053014453,0.0007899396,0.0003811734,0.000477791,0.00003298065,0.00007794544,6.2558405e-7,0.000040845098,0.00948506],"study_design_scores_gemma":[0.3705019,0.023525761,0.6038279,0.0002682523,0.000179532,0.000007658623,0.000015986961,0.00014674365,0.0013395313,0.0000031926456,0.000026016554,0.00015749874],"about_ca_topic_score_codex":0.0024459793,"about_ca_topic_score_gemma":0.0018729621,"teacher_disagreement_score":0.15119949,"about_ca_system_score_codex":0.0003326736,"about_ca_system_score_gemma":0.00016898473,"threshold_uncertainty_score":0.9999557},"labels":[],"label_agreement":null},{"id":"W2552176673","doi":"10.1182/blood.v120.21.4055.4055","title":"A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Internal medicine; Clinical endpoint; Chromosomal translocation; Phases of clinical research; Gastroenterology; Tyrosine-kinase inhibitor; Regimen; Oncology; Clinical trial; Cancer; Biology","score_opus":0.05020356072462877,"score_gpt":0.3489929799330997,"score_spread":0.2987894192084709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552176673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909228,0.00009413438,0.000046468638,0.000022444921,0.000042971646,0.0086086085,0.00005843649,0.000040550924,0.00016359494],"genre_scores_gemma":[0.99478674,0.000018002009,0.0037612387,0.000040053845,0.000044086064,0.0008006404,0.00016341617,0.000074666386,0.00031116334],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99717844,0.00031069445,0.0006268389,0.00046598585,0.00080003217,0.0006179873],"domain_scores_gemma":[0.9980552,0.0003249041,0.00028286557,0.0006228005,0.00029930877,0.00041491992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004684207,0.00036251094,0.0009646305,0.00026070038,0.000095279276,0.00003245887,0.00023353192,0.00009977777,0.00010100459],"category_scores_gemma":[0.00035094286,0.00019717234,0.00003568859,0.0004711743,0.000092871735,0.00049198425,0.00006165343,0.0002854366,0.000015385653],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24260062,0.1837014,0.5647795,0.0001026324,0.0006184786,0.00009399978,0.0021628996,3.5439942e-7,0.000519357,2.7136693e-7,0.0000083949935,0.0054120813],"study_design_scores_gemma":[0.75531584,0.029560454,0.21003199,0.0004834172,0.00053562934,0.000016680742,0.0010636529,0.00019161435,0.0025185694,1.2110935e-7,0.000054725042,0.00022727878],"about_ca_topic_score_codex":0.00080836035,"about_ca_topic_score_gemma":0.0023310948,"teacher_disagreement_score":0.5127152,"about_ca_system_score_codex":0.00008121025,"about_ca_system_score_gemma":0.00024330935,"threshold_uncertainty_score":0.8040455},"labels":[],"label_agreement":null},{"id":"W2552255104","doi":"10.1182/blood.v108.11.3557.3557","title":"Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Thalidomide; Gastroenterology; Fluorescence in situ hybridization; Refractory (planetary science); Progressive disease; Oncology; Surgery; Chemotherapy; Chromosome; Biology","score_opus":0.020678194487749005,"score_gpt":0.26935233987854346,"score_spread":0.24867414539079447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552255104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595225,0.0013825686,0.000007957334,0.000399073,0.0000327868,0.0014619168,0.0000914386,0.00003510084,0.0006369268],"genre_scores_gemma":[0.9984874,0.00015585113,0.0003961059,0.0000335179,0.00008548436,0.00019216155,0.0002056061,0.000022835424,0.0004210032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853,0.0000838114,0.00040097328,0.00030019315,0.00034886086,0.00033619508],"domain_scores_gemma":[0.99935734,0.00017506252,0.00010290393,0.00016650929,0.00008576178,0.00011243348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018406195,0.00017550049,0.00045839004,0.00017056573,0.00004252083,0.00001898822,0.000058767,0.00010947098,0.000058168636],"category_scores_gemma":[0.00024406238,0.00014278972,0.00008393027,0.00018472111,0.000103915474,0.00009175573,0.000038466656,0.00011844297,0.000011458687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012160764,0.007182588,0.79583126,0.00028270084,0.0003142934,0.00021157511,0.00006917123,8.8683896e-7,0.17693493,0.000045158748,0.001979665,0.0049870284],"study_design_scores_gemma":[0.3106772,0.0015202035,0.42738995,0.0002285095,0.00021108428,0.000057928348,0.00004463297,0.00023901058,0.2582921,0.00008120925,0.0010466713,0.00021149732],"about_ca_topic_score_codex":0.0018140186,"about_ca_topic_score_gemma":0.00032753643,"teacher_disagreement_score":0.3684413,"about_ca_system_score_codex":0.000043063155,"about_ca_system_score_gemma":0.00008120322,"threshold_uncertainty_score":0.58227956},"labels":[],"label_agreement":null},{"id":"W2552262126","doi":"10.1182/blood.v118.21.4121.4121","title":"Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Stem cell; Medicine; Oncology; Internal medicine; Cancer research; Biology","score_opus":0.0228822897816177,"score_gpt":0.2250548619356589,"score_spread":0.20217257215404122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552262126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621487,0.00011898194,0.000089634486,0.0000034762736,0.00003066603,0.001799637,0.00060106453,0.00005736095,0.0010842961],"genre_scores_gemma":[0.9977493,0.000014000701,0.0015675251,0.000007716385,0.000015305577,0.00011142648,0.00018126027,0.000048933194,0.0003045309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981282,0.000045803143,0.000373322,0.0003940763,0.0005623561,0.0004962528],"domain_scores_gemma":[0.9986401,0.00012916492,0.00023599627,0.00037722898,0.00035934136,0.00025817472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005263174,0.0002792039,0.00055596186,0.0001061663,0.000058730664,0.000007734038,0.00013950693,0.00009951085,0.000049500868],"category_scores_gemma":[0.000018953944,0.00018934465,0.000095027775,0.00015047994,0.00018755563,0.000102300655,0.00002040302,0.000058378122,0.000003880829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018698376,0.01725342,0.9390735,0.0005149067,0.0006999055,0.00019018345,0.005801786,0.0000024691587,0.016624724,0.000009123177,0.0000063770476,0.0011252428],"study_design_scores_gemma":[0.056800734,0.013204301,0.4976304,0.0004297623,0.0005208772,0.000027428365,0.00031483336,0.00014308389,0.430625,0.0000024625874,0.00006809558,0.00023304508],"about_ca_topic_score_codex":0.0006329134,"about_ca_topic_score_gemma":0.00016238797,"teacher_disagreement_score":0.44144312,"about_ca_system_score_codex":0.000084582534,"about_ca_system_score_gemma":0.00017372194,"threshold_uncertainty_score":0.77212507},"labels":[],"label_agreement":null},{"id":"W2552542954","doi":"10.1182/blood.v116.21.1962.1962","title":"Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Pharmacokinetics; Adverse effect; Phases of clinical research; Refractory (planetary science); Cohort; Toxicity; Chemotherapy; Cancer; Tolerability; Nausea; Gastroenterology; Surgery; Oncology; Pharmacology","score_opus":0.010735552580372445,"score_gpt":0.29714161753965307,"score_spread":0.2864060649592806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552542954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955759,0.00007962341,0.000057048514,0.000039068545,0.000019041641,0.0036986773,0.00040084322,0.00008247855,0.00004732051],"genre_scores_gemma":[0.99642295,0.000007053554,0.0007217134,0.000022209002,0.000038428145,0.0001728643,0.002486425,0.00006888411,0.00005949098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600613,0.00030715836,0.0008315388,0.0010496894,0.0011843995,0.0006210667],"domain_scores_gemma":[0.99673903,0.000703081,0.00035999395,0.0012996453,0.00042272903,0.00047553974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001872935,0.00055750756,0.0016431505,0.0016508338,0.00012815552,0.000044453715,0.00028598597,0.0001973854,0.0002953826],"category_scores_gemma":[0.0002814806,0.00041812667,0.00044504373,0.004271286,0.00014568692,0.00016201564,0.00008443221,0.0004853052,0.000016823025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037495576,0.09067986,0.82279086,0.000013241952,0.037881013,0.00044455638,0.0033858325,0.00019417913,0.0034340983,5.583027e-7,0.0000021574278,0.0036780795],"study_design_scores_gemma":[0.15262501,0.013438003,0.80279815,0.000049049228,0.019289244,0.0000017918876,0.0002459387,0.0025039478,0.008758061,0.0000015094355,0.0000019423499,0.00028732704],"about_ca_topic_score_codex":0.014463837,"about_ca_topic_score_gemma":0.0069663986,"teacher_disagreement_score":0.11512944,"about_ca_system_score_codex":0.000093271505,"about_ca_system_score_gemma":0.00014857951,"threshold_uncertainty_score":0.999827},"labels":[],"label_agreement":null},{"id":"W2552620919","doi":"10.1182/blood.v114.22.302.302","title":"Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Medicine; Tolerability; Proteasome inhibitor; Multiple myeloma; Internal medicine; Phases of clinical research; Refractory (planetary science); Adverse effect; Clinical endpoint; Pharmacology; Oncology; Gastroenterology; Clinical trial; Biology","score_opus":0.04407682764474058,"score_gpt":0.3293003965449342,"score_spread":0.2852235689001936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552620919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995005,0.00003383536,4.2388513e-7,0.000027394797,0.00004134948,0.0040757973,0.00023967859,0.000029434867,0.00054708694],"genre_scores_gemma":[0.9981521,0.000013559956,0.0005647814,0.00004294863,0.00001828505,0.0000580605,0.0009774738,0.000045671575,0.0001271475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611443,0.0003309761,0.0012005565,0.00074813084,0.0009979223,0.000607979],"domain_scores_gemma":[0.9976449,0.00008623747,0.0005403032,0.0008874548,0.00048760345,0.00035348276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038245812,0.0003835708,0.0009610595,0.0005866257,0.00009427867,0.000024902882,0.00038347923,0.00014501889,0.000038088427],"category_scores_gemma":[0.0004653519,0.00028563142,0.000038114933,0.0009244296,0.000075339245,0.00040450052,0.00018796761,0.00034715858,0.0000036756276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057725526,0.29799896,0.61146003,0.0000517883,0.00037473015,0.0005542057,0.0035684034,0.0000071379122,0.0025966996,0.0000010791556,0.00008420663,0.025577256],"study_design_scores_gemma":[0.27674365,0.09958197,0.61888725,0.00037666658,0.00015584652,0.0000017571438,0.00045744318,0.00003348234,0.0035405399,0.0000024795509,0.000025324402,0.00019362655],"about_ca_topic_score_codex":0.0018951289,"about_ca_topic_score_gemma":0.0023374122,"teacher_disagreement_score":0.21901812,"about_ca_system_score_codex":0.00023892785,"about_ca_system_score_gemma":0.00028851323,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W2552675878","doi":"10.1182/blood.v110.11.2498.2498","title":"The Multiple Myeloma Research Consortium Genomics Initiative.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Genomics; Comparative genomic hybridization; Computational biology; Genome; Human genome; Biology; DNA sequencing; Genetics; Gene","score_opus":0.09746773302003374,"score_gpt":0.3785845686649132,"score_spread":0.28111683564487944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552675878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685899,0.0010380123,0.00006118111,0.0009999376,0.00007342148,0.0008080492,0.000015763275,0.000057171797,0.028356543],"genre_scores_gemma":[0.9968818,0.00021352094,0.00082506397,0.00010637062,0.00026615988,0.00004425144,0.000024957548,0.000028141572,0.0016097333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978307,0.00012909698,0.00026191634,0.00026506762,0.00066199736,0.0008512174],"domain_scores_gemma":[0.99733734,0.0014183391,0.000041661133,0.00048096108,0.0003599466,0.00036176553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017889092,0.0001247985,0.0001701271,0.00014597585,0.0005719139,0.000052174626,0.0001776158,0.00008548073,0.00005812505],"category_scores_gemma":[0.0015217308,0.00007986303,0.000079997386,0.0003265298,0.00036055784,0.0000471446,0.0001213543,0.00045154057,0.00041699279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002546054,0.0030229902,0.8614515,0.00008357622,0.0011225312,0.0030702562,0.0012071712,4.442093e-7,0.05357364,0.0018320208,0.003763919,0.068325885],"study_design_scores_gemma":[0.01139105,0.00074821856,0.79352784,0.00004155988,0.00007067055,0.00020273191,0.0012864742,0.000082108694,0.14254561,0.00038188236,0.04957221,0.0001496169],"about_ca_topic_score_codex":0.000074405696,"about_ca_topic_score_gemma":0.00031929833,"teacher_disagreement_score":0.08897197,"about_ca_system_score_codex":0.00010955762,"about_ca_system_score_gemma":0.00028764305,"threshold_uncertainty_score":0.5359738},"labels":[],"label_agreement":null},{"id":"W2552676814","doi":"10.1182/blood.v106.11.5144.5144","title":"Salvage Thalidomide Improves Survival of Relapsed Multiple Myeloma Patients When Compared to Other Salvage Chemotherapies: A Retrospective Analysis.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Thalidomide; Medicine; Salvage therapy; Melphalan; Surgery; Multiple myeloma; Regimen; Lenalidomide; Internal medicine; Retrospective cohort study; Prednisone; Refractory (planetary science); Chemotherapy regimen; Chemotherapy; Dexamethasone; Oncology","score_opus":0.01682169155940251,"score_gpt":0.2758087390662176,"score_spread":0.2589870475068151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552676814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947467,0.00014258386,0.00017979225,0.00032538985,0.00004617913,0.0012272029,0.00024398816,0.00009360769,0.0029945544],"genre_scores_gemma":[0.9920472,0.00001101901,0.006289036,0.00027193173,0.00014807089,0.00008087528,0.000133614,0.00006366963,0.0009546192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974227,0.00011890016,0.00053197617,0.0005741335,0.0007941854,0.0005581322],"domain_scores_gemma":[0.9981768,0.00017052543,0.00019721735,0.00075087644,0.00031191183,0.0003926357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002649239,0.00032481828,0.00095145486,0.00043121204,0.000083845465,0.00002872661,0.00022382625,0.00012021167,0.00039284353],"category_scores_gemma":[0.0003262001,0.0002654878,0.00038165646,0.00068161293,0.00009693164,0.00011245072,0.00009221914,0.00019582751,0.000099681965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013058564,0.0036621853,0.95229197,0.0000493206,0.004979466,0.000021920076,0.0016377413,0.0000075595185,0.033740357,0.000023779943,0.0003518838,0.0019279915],"study_design_scores_gemma":[0.022748947,0.00068429194,0.92551,0.000052793683,0.00091369014,0.0000017766118,0.00021413532,0.0003943707,0.048359815,0.000021956348,0.0008698649,0.00022837671],"about_ca_topic_score_codex":0.00058396347,"about_ca_topic_score_gemma":0.00085385406,"teacher_disagreement_score":0.026781961,"about_ca_system_score_codex":0.00015856492,"about_ca_system_score_gemma":0.00007116204,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2552678756","doi":"10.1182/blood.v110.11.547.547","title":"A Unique Pre-Clinical Model Providing Access to a Drug Resistant Population within the Multiple Myeloma Stem Cell Niche in a Novel 3-D Culture System for Bone Marrow.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Bone marrow; Stromal cell; Haematopoiesis; Stem cell; Biology; clone (Java method); Progenitor cell; Tumor microenvironment; Population; Cancer research; Immunology; Cell biology; Pathology; Medicine; Immune system","score_opus":0.06046261450685329,"score_gpt":0.3585497915231922,"score_spread":0.2980871770163389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552678756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887557,0.00019552142,0.004629986,0.00038250993,0.0000653342,0.0053626867,0.00007594259,0.00009401093,0.00031841226],"genre_scores_gemma":[0.98653215,0.0000040792524,0.010869517,0.00014427207,0.00012982462,0.00050495396,0.00006868478,0.000048524056,0.0016979686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975458,0.0001161975,0.00080799946,0.00052762905,0.0004765866,0.00052582676],"domain_scores_gemma":[0.9983861,0.00040214258,0.00021307592,0.00050162576,0.00016049884,0.00033657753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019459854,0.00024279009,0.00045436318,0.00016500786,0.00016301361,0.00008247258,0.00025822668,0.00017720336,0.0000010082188],"category_scores_gemma":[0.00035467048,0.00015505665,0.00015231666,0.000378845,0.000028908742,0.00014100643,0.00013514208,0.00035193315,0.0000042660786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024334699,0.007845433,0.8339331,0.0037584892,0.00056382956,0.000563016,0.011039931,0.0015498874,0.110757805,0.000734944,0.00081203633,0.0041067917],"study_design_scores_gemma":[0.06434528,0.0018891724,0.5999595,0.0027639747,0.00071820157,0.00016179978,0.0036924977,0.18863864,0.13650633,0.00010445633,0.00036646595,0.0008537121],"about_ca_topic_score_codex":0.0006035259,"about_ca_topic_score_gemma":0.0033925776,"teacher_disagreement_score":0.23397367,"about_ca_system_score_codex":0.00027454816,"about_ca_system_score_gemma":0.000264561,"threshold_uncertainty_score":0.63230264},"labels":[],"label_agreement":null},{"id":"W2552737980","doi":"10.1182/blood.v126.23.1789.1789","title":"Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cereblon; Lenalidomide; Biology; Transcriptome; Gene expression; Gene; Gene expression profiling; Pomalidomide; Genetics; Multiple myeloma; Computational biology; Cancer research; Molecular biology; Ubiquitin ligase; Immunology; Ubiquitin","score_opus":0.041941598536092514,"score_gpt":0.2928726285631699,"score_spread":0.2509310300270774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552737980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965176,0.00025844207,0.000014020755,0.00049852865,0.000014777964,0.0010391033,0.00003808064,0.000039487808,0.0015799862],"genre_scores_gemma":[0.9924546,0.000007692826,0.00492155,0.00015014752,0.000033636763,0.00028570156,0.000062714535,0.000028603206,0.0020553644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983244,0.00009140394,0.00024241523,0.00036581972,0.0005185987,0.00045735124],"domain_scores_gemma":[0.9990447,0.000090039815,0.000053766755,0.0003145477,0.00012376692,0.00037315922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030032243,0.00016185941,0.0003322363,0.00022032642,0.000030381763,0.000016415055,0.000096262265,0.000088146655,0.000037284983],"category_scores_gemma":[0.000817541,0.00012025567,0.000030924584,0.00049272523,0.000024069168,0.000077037934,0.000057308163,0.00017945966,0.0000720951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033528127,0.002030534,0.93808794,0.000035157533,0.00007445763,0.0018234359,0.0011510421,0.0000044754834,0.051605135,0.0000017747469,0.0014656248,0.00036761502],"study_design_scores_gemma":[0.038913473,0.00051958294,0.5333388,0.00084880675,0.000028091774,0.000017985816,0.00019930289,0.00009749464,0.42551607,0.000026278185,0.00031712087,0.00017701475],"about_ca_topic_score_codex":0.00028246306,"about_ca_topic_score_gemma":0.0023359966,"teacher_disagreement_score":0.40474916,"about_ca_system_score_codex":0.00019792958,"about_ca_system_score_gemma":0.0002309331,"threshold_uncertainty_score":0.49038836},"labels":[],"label_agreement":null},{"id":"W2552855124","doi":"10.1182/blood.v126.23.730.730","title":"Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Melphalan; Population; Clinical endpoint; Oncology; Surgery; Randomized controlled trial","score_opus":0.030789792210626134,"score_gpt":0.2931294713694757,"score_spread":0.2623396791588496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552855124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966494,0.00008301849,0.000011981814,0.000055550045,0.000016811415,0.002739423,0.00028194906,0.000022170276,0.00013968638],"genre_scores_gemma":[0.9989892,0.000032116368,0.00051816774,0.000028703402,0.000034153803,0.0001293278,0.00019645502,0.000042619096,0.000029225053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767226,0.0001575013,0.00049384724,0.00032109613,0.0008902414,0.0004650501],"domain_scores_gemma":[0.998013,0.00068766094,0.00023197936,0.0005423732,0.0002638137,0.00026112937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025031177,0.0003446462,0.0009171186,0.00024082349,0.000039101535,0.000016073745,0.00020619809,0.00010293498,0.000017283537],"category_scores_gemma":[0.0003508441,0.00016821102,0.00017437879,0.0004298799,0.00014488626,0.000053117776,0.000018128983,0.00019067859,0.0000068545905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14911018,0.0071906834,0.840482,0.00005966638,0.00088882144,0.0004206073,0.00092273497,0.00024434162,0.00011975704,0.0000010006853,0.00002396286,0.00053623517],"study_design_scores_gemma":[0.35060984,0.012740147,0.63019204,0.00020461467,0.00035292437,0.000013007114,0.00009070176,0.000060689446,0.0056100492,0.0000013120562,0.0000042165825,0.00012044548],"about_ca_topic_score_codex":0.0031987382,"about_ca_topic_score_gemma":0.0013800677,"teacher_disagreement_score":0.21028996,"about_ca_system_score_codex":0.00009657991,"about_ca_system_score_gemma":0.00035679943,"threshold_uncertainty_score":0.6859446},"labels":[],"label_agreement":null},{"id":"W2553077423","doi":"10.1182/blood.v116.21.138.138","title":"Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"STAT3; Angiogenesis; Cell biology; Chemistry; Biology; SH2 domain; Cancer research; Phosphopeptide; Phosphorylation; Tyrosine phosphorylation","score_opus":0.06712066682499301,"score_gpt":0.37671051634063724,"score_spread":0.3095898495156442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553077423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977071,0.00042854907,0.000021191974,0.00008548193,0.00016804042,0.0005997558,0.00013788816,0.000039152088,0.0008127827],"genre_scores_gemma":[0.9970237,0.00015246778,0.002455891,0.000010169737,0.00016535712,0.000023754978,0.000015332223,0.000025988711,0.00012733358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822354,0.000087945235,0.0005205243,0.00036875802,0.0004294258,0.000369802],"domain_scores_gemma":[0.99823827,0.0005235264,0.00023282881,0.00043662122,0.00033496716,0.00023377615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043977922,0.00021396362,0.00079449377,0.000118899145,0.00005830895,0.000009615215,0.00012723632,0.00015457105,0.00004029957],"category_scores_gemma":[0.0011356713,0.00016357584,0.00022558834,0.00023080164,0.0005156332,0.00006755267,0.000108777924,0.00037257886,0.0000066066764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069177337,0.005290995,0.31409788,0.00021621371,0.0012110067,0.00009034659,0.0001242244,1.2312302e-7,0.6757203,0.000017217799,0.00004299166,0.002496925],"study_design_scores_gemma":[0.0069275084,0.00091717334,0.38940296,0.0000981305,0.00027560536,0.000023925826,0.000049172086,0.000032173833,0.6021556,0.0000051599113,0.000026161973,0.00008642189],"about_ca_topic_score_codex":0.00017376842,"about_ca_topic_score_gemma":0.00035650088,"teacher_disagreement_score":0.07530507,"about_ca_system_score_codex":0.00001026774,"about_ca_system_score_gemma":0.00029483647,"threshold_uncertainty_score":0.6670429},"labels":[],"label_agreement":null},{"id":"W2553143951","doi":"10.1182/blood.v116.21.3031.3031","title":"Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Tolerability; Medicine; Bortezomib; Proteasome inhibitor; Peripheral neuropathy; Adverse effect; Internal medicine; Multiple myeloma; Clinical trial; Thalidomide; Lenalidomide; Pharmacology; Oncology; Endocrinology","score_opus":0.014051712405646682,"score_gpt":0.28277856389058453,"score_spread":0.26872685148493786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553143951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569887,0.000025577965,0.0000015645007,0.0001148831,0.00003782104,0.0025642787,0.0015437135,0.000006802392,0.0000064985506],"genre_scores_gemma":[0.9995895,0.0000062700406,0.00018898654,0.000011869092,0.00004265559,0.000049994556,0.00008429625,0.000015925945,0.000010487742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793434,0.00026969213,0.0006585797,0.0003637867,0.0005391765,0.00023439772],"domain_scores_gemma":[0.9978717,0.00060168153,0.0003923,0.00071313814,0.00027160437,0.00014956617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007226253,0.00020665568,0.0006971053,0.00018220457,0.00005654476,0.000010699937,0.0001259136,0.00008895479,0.000012666185],"category_scores_gemma":[0.0029940319,0.000088682784,0.00015616952,0.0005859845,0.00040187463,0.00007197806,0.00008276436,0.00034956037,6.350553e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16741185,0.010814973,0.7046532,0.00007695484,0.0007591516,0.00000660702,0.0008433008,0.000004106099,0.11343424,5.317218e-7,0.0000021716135,0.001992898],"study_design_scores_gemma":[0.23809917,0.0034170747,0.73590225,0.000053356187,0.00067617244,0.0000017168563,0.00003334034,0.00065173814,0.021092676,5.1309434e-7,0.000006361382,0.00006565627],"about_ca_topic_score_codex":0.0010966205,"about_ca_topic_score_gemma":0.0008507536,"teacher_disagreement_score":0.092341565,"about_ca_system_score_codex":0.000021482514,"about_ca_system_score_gemma":0.00016521869,"threshold_uncertainty_score":0.3616379},"labels":[],"label_agreement":null},{"id":"W2553612058","doi":"10.1182/blood.v104.11.1414.1414","title":"VDJ-Switch Region Analysis in Multiple Myeloma Patients Reveals Homogeneity and Long-Term Stability of Switch Junctions, and Ongoing Mutation Upstream of Switch Mu.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunoglobulin class switching; V(D)J recombination; Biology; Recombination; Molecular biology; Immunoglobulin heavy chain; Antibody; Genetics; Gene; B cell","score_opus":0.0246147609555835,"score_gpt":0.2775926377406795,"score_spread":0.252977876785096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553612058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983747,0.00037939587,0.00018555406,0.00006437737,0.000021454773,0.0008688825,0.000046852958,0.000019141078,0.000039658673],"genre_scores_gemma":[0.998803,0.00019718506,0.00073511485,0.000008306075,0.000016451293,0.000039484203,0.00016901232,0.000016363796,0.000015072089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981737,0.000103657905,0.0005734402,0.00044870115,0.0004155972,0.0002849131],"domain_scores_gemma":[0.99873066,0.00013484262,0.0002414818,0.00042082462,0.0002788315,0.00019333039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029647228,0.00019943331,0.00059235387,0.0004373448,0.000078751975,0.000012784053,0.00006159384,0.0001196202,0.000013440697],"category_scores_gemma":[0.0004683095,0.00017300238,0.00011867522,0.00076028076,0.00012439801,0.00014004332,0.00006769019,0.00014157269,0.000001172341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041619944,0.0028353974,0.98241585,0.00039365064,0.0006323263,0.00005701425,0.0004933773,0.000007019481,0.004570388,0.000004293071,0.000001029132,0.008173444],"study_design_scores_gemma":[0.012455968,0.000572949,0.94617194,0.00017852057,0.0007907124,0.000020995109,0.00013026863,0.00006300113,0.03944103,0.000062308776,3.7636943e-7,0.00011194563],"about_ca_topic_score_codex":0.0016824102,"about_ca_topic_score_gemma":0.0027241341,"teacher_disagreement_score":0.036243938,"about_ca_system_score_codex":0.000096093936,"about_ca_system_score_gemma":0.00009361959,"threshold_uncertainty_score":0.70548326},"labels":[],"label_agreement":null},{"id":"W2553643169","doi":"10.1182/blood.v124.21.4706.4706","title":"Initial Results of an Ex Vivo Microfluidic Cis-Coculture Csra to Predict Response for Myeloma Patients","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bortezomib; Multiple myeloma; Ex vivo; In vivo; Tumor microenvironment; Cancer research; In vitro; Cancer; Cell culture; Proteasome inhibitor; Immunology; Medicine; Chemistry; Biology; Internal medicine; Tumor cells; Biochemistry","score_opus":0.018259453241484765,"score_gpt":0.30537341731362627,"score_spread":0.2871139640721415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553643169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616265,0.00007332518,0.00007628078,0.00028010525,0.00008551462,0.0014682052,0.00094014464,0.000052699514,0.0008610746],"genre_scores_gemma":[0.99639094,0.000010164681,0.0019466664,0.00020182475,0.00025010615,0.000104677,0.00039138342,0.000035679925,0.00066853996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981455,0.00018178778,0.0003892233,0.00040466915,0.00045780608,0.00042097276],"domain_scores_gemma":[0.9982654,0.00025972383,0.00009152581,0.00053209544,0.0003719551,0.00047928773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047495318,0.00019540548,0.0003522862,0.0001758634,0.00008084726,0.000018007284,0.00016457088,0.00013650715,0.000028626762],"category_scores_gemma":[0.002170176,0.00015157252,0.000118087286,0.000185218,0.000056846307,0.00008304116,0.000060484428,0.000108444816,0.000031289514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21511008,0.014323786,0.0557064,0.00054417114,0.001031737,0.0001960606,0.003000332,0.0000012768226,0.6187986,0.000040390176,0.029627059,0.061620094],"study_design_scores_gemma":[0.0557116,0.016305206,0.25953612,0.00020822824,0.00023444815,0.00002334964,0.00007196772,0.00004474782,0.64180475,0.00003890057,0.025811898,0.00020879191],"about_ca_topic_score_codex":0.00004998623,"about_ca_topic_score_gemma":0.000012903777,"teacher_disagreement_score":0.2038297,"about_ca_system_score_codex":0.0000343876,"about_ca_system_score_gemma":0.00011225226,"threshold_uncertainty_score":0.6180948},"labels":[],"label_agreement":null},{"id":"W2553684168","doi":"10.1002/cam4.799","title":"Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Dexamethasone; Cumulative incidence; Concomitant; Regimen; Incidence (geometry); Gastroenterology; Refractory (planetary science); Cumulative dose; Oncology; Surgery; Cohort","score_opus":0.021225628743226522,"score_gpt":0.2826656687584357,"score_spread":0.26144004001520915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553684168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830163,0.0057015135,0.000010521375,0.0066824667,0.0003715358,0.0010785278,0.000060872706,0.000068031346,0.0030102236],"genre_scores_gemma":[0.9884641,0.0018801613,0.00007841648,0.00094985607,0.00053310615,0.00036560078,0.00004037701,0.000055435226,0.0076329177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727863,0.00016304826,0.0005324707,0.00053128577,0.0007895182,0.00070506544],"domain_scores_gemma":[0.9979546,0.00063394627,0.00017997882,0.0006853966,0.00020381005,0.00034225607],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044796243,0.0003194345,0.0006246668,0.00026143642,0.00014467044,0.000008201186,0.00023777719,0.00012591858,0.0013191204],"category_scores_gemma":[0.00093145086,0.00015192623,0.000095458214,0.00036141547,0.00051611185,0.00015445604,0.00012410305,0.00039856386,0.00007171494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029162103,0.00029654277,0.81707114,0.00031796758,0.00021426548,0.0003124525,0.0007720433,7.7319254e-7,0.056478888,0.000012008668,0.0049898983,0.11661779],"study_design_scores_gemma":[0.03244102,0.0005507249,0.9451275,0.0017957819,0.00006178867,0.000023548097,0.00015919302,0.0000073289275,0.0062223966,0.00003598376,0.0133956205,0.00017910726],"about_ca_topic_score_codex":0.00060274487,"about_ca_topic_score_gemma":0.00023315835,"teacher_disagreement_score":0.12805635,"about_ca_system_score_codex":0.0010137553,"about_ca_system_score_gemma":0.00034534233,"threshold_uncertainty_score":0.9995938},"labels":[],"label_agreement":null},{"id":"W2553842621","doi":"10.1182/blood.v110.11.3597.3597","title":"Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Internal medicine; Refractory (planetary science); Gastroenterology; Oncology; Urology; Biology","score_opus":0.036015507475953355,"score_gpt":0.28671566278572924,"score_spread":0.2507001553097759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553842621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368566,0.0004304763,0.0000019000167,0.0017162861,0.00007416691,0.0019100601,0.0003989745,0.00001882625,0.0017636416],"genre_scores_gemma":[0.9983375,0.00006458265,0.00030369425,0.00025997218,0.00006319835,0.00006887394,0.00007180649,0.000024767867,0.0008055743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979025,0.00010451379,0.00053579075,0.00035168458,0.00048136103,0.0006241262],"domain_scores_gemma":[0.99854594,0.00042914963,0.00012529276,0.00032722126,0.00014380865,0.00042860175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007307432,0.00020504963,0.0004211481,0.00023513754,0.00013775397,0.000028468356,0.0001519181,0.00016215525,0.000017574675],"category_scores_gemma":[0.001601673,0.00013903146,0.00010592547,0.0002847645,0.00018247832,0.000066524124,0.0000616835,0.00023978653,0.000007880127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0653979,0.0038483946,0.8633664,0.00021560813,0.0009412421,0.00081690925,0.0007369893,0.0000011326458,0.042513654,0.000079359816,0.004783398,0.017298969],"study_design_scores_gemma":[0.24766313,0.0006533595,0.5190819,0.00018285218,0.00017158291,0.000053459473,0.00015200442,0.000091387345,0.22853722,0.000015519925,0.0032078722,0.0001897507],"about_ca_topic_score_codex":0.20262389,"about_ca_topic_score_gemma":0.44440112,"teacher_disagreement_score":0.34428456,"about_ca_system_score_codex":0.00014186557,"about_ca_system_score_gemma":0.00053087244,"threshold_uncertainty_score":0.8026859},"labels":[],"label_agreement":null},{"id":"W2553893461","doi":"10.1182/blood.v116.21.5031.5031","title":"A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Adverse effect; Refractory (planetary science); Surgery; Gastroenterology; Biology","score_opus":0.010980151753230805,"score_gpt":0.2828969533631146,"score_spread":0.2719168016098838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553893461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943746,0.000030628362,0.00002241264,0.00009068521,0.000099948695,0.0049863886,0.000081848935,0.000030247442,0.00028325059],"genre_scores_gemma":[0.9967945,0.000013471869,0.002003461,0.00002184132,0.00004568633,0.0003329211,0.00064766145,0.000046218945,0.000094239185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742144,0.00021291348,0.00068507897,0.00045780372,0.00074507185,0.00047769563],"domain_scores_gemma":[0.9985043,0.00032144025,0.00029341053,0.00041837752,0.000228126,0.0002343494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005026732,0.00031734625,0.0009917791,0.00045978514,0.00007867237,0.000021510543,0.00013340868,0.00016812669,0.00007249312],"category_scores_gemma":[0.00055656297,0.0002160401,0.0001390228,0.0003336223,0.00029623866,0.00020369886,0.000047942744,0.00059168646,0.0000058089686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64047194,0.045507062,0.30611846,0.00006576796,0.00029766725,0.00018988183,0.0005066034,6.859063e-7,0.0039240224,0.000012087326,0.0000049339496,0.0029008621],"study_design_scores_gemma":[0.73467845,0.007819486,0.2535131,0.00019398186,0.00017968005,0.000006476705,0.000038421862,0.00062159175,0.002751732,0.000007126321,0.00003111542,0.00015883666],"about_ca_topic_score_codex":0.0005411405,"about_ca_topic_score_gemma":0.00092493655,"teacher_disagreement_score":0.09420648,"about_ca_system_score_codex":0.000059687278,"about_ca_system_score_gemma":0.0002635322,"threshold_uncertainty_score":0.880986},"labels":[],"label_agreement":null},{"id":"W2554005559","doi":"10.1182/blood.v116.21.5034.5034","title":"Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Neutropenia; Medicine; Lenalidomide; Dexamethasone; Febrile neutropenia; Internal medicine; Absolute neutrophil count; Refractory (planetary science); Gastroenterology; Surgery; Chemotherapy","score_opus":0.015002457150749576,"score_gpt":0.2386497411046597,"score_spread":0.22364728395391012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554005559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998352,0.00005707686,0.0000045674865,0.000049949685,0.000019453915,0.0011529018,0.000037528436,0.00006238305,0.00026417398],"genre_scores_gemma":[0.9953642,0.000019468864,0.0037942529,0.000057861183,0.000037899754,0.00008328333,0.00013429766,0.000061072766,0.00044766898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827653,0.00007564771,0.00023029154,0.0004882921,0.00043437033,0.00049486867],"domain_scores_gemma":[0.9985854,0.00024455698,0.000088637804,0.0004908698,0.00017730742,0.0004132397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011183244,0.00029078187,0.00044636938,0.00022099928,0.000085619155,0.000061739185,0.00008633967,0.0001326315,0.000059971488],"category_scores_gemma":[0.0002796889,0.00018380434,0.00003504024,0.00027646607,0.00017698396,0.0003094324,0.00005378746,0.00052221573,0.000024712388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007659991,0.0022381821,0.9822214,0.000036085003,0.00026627208,0.000603876,0.00009724392,0.0000012256819,0.0043731644,0.0000047500475,0.000019869341,0.0024778876],"study_design_scores_gemma":[0.082825325,0.0021753726,0.908995,0.00011748585,0.00018277546,0.000056559176,0.000021648344,0.000059809114,0.0051303166,0.0000013546443,0.00023688696,0.00019751755],"about_ca_topic_score_codex":0.0012043973,"about_ca_topic_score_gemma":0.0030256321,"teacher_disagreement_score":0.07516533,"about_ca_system_score_codex":0.000052235275,"about_ca_system_score_gemma":0.00013861357,"threshold_uncertainty_score":0.74953234},"labels":[],"label_agreement":null},{"id":"W2554059528","doi":"10.1038/leu.2016.325","title":"Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Chinese Academy of Medical Sciences; Chinese Academy of Sciences; Academy of Medical Sciences","keywords":"Cancer research; Bortezomib; microRNA; Gene silencing; Epigenetics; Chromosome instability; Biology; Ectopic expression; Multiple myeloma; DNA methylation; Transfection; Cell culture; Apoptosis; Gene expression; Immunology; Chromosome; Gene; Genetics","score_opus":0.016305459054739496,"score_gpt":0.2615476411607951,"score_spread":0.2452421821060556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554059528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966504,0.0018533512,0.000021604666,0.00031952068,0.00003422298,0.00045902305,0.0000429208,0.000029719617,0.0005892211],"genre_scores_gemma":[0.9976312,0.00017160778,0.001420326,0.000025536605,0.000039248676,0.00004399895,0.000017572846,0.00002158799,0.00062891404],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99825054,0.00011602266,0.00041516378,0.00042520507,0.00034440847,0.0004486595],"domain_scores_gemma":[0.9988202,0.00046768374,0.00010968804,0.00030532372,0.00007813028,0.00021900954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033201,0.00018301909,0.00037482567,0.000104181614,0.0000700895,0.000009762393,0.00010413148,0.0000969228,0.00007510284],"category_scores_gemma":[0.0009867081,0.00012709635,0.00005164367,0.00019965904,0.00021796412,0.0001229435,0.000085189255,0.00016366718,0.000010993274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038645745,0.000098748445,0.41365483,0.00023162237,0.00003360318,0.000070158094,0.0006805561,5.040437e-7,0.57256365,0.000009422631,0.00030523704,0.011965211],"study_design_scores_gemma":[0.0053684646,0.00009814989,0.55947524,0.0005365598,0.000014982966,0.0000057926745,0.00024279134,0.00013869665,0.4334913,0.0000932825,0.00038466655,0.00015006127],"about_ca_topic_score_codex":0.0006529786,"about_ca_topic_score_gemma":0.00056357577,"teacher_disagreement_score":0.14582042,"about_ca_system_score_codex":0.0005937967,"about_ca_system_score_gemma":0.0002652599,"threshold_uncertainty_score":0.51828384},"labels":[],"label_agreement":null},{"id":"W2554088166","doi":"10.1182/blood.v114.22.2822.2822","title":"High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of Calgary; University of Alberta","funders":"","keywords":"Multiple myeloma; Tissue microarray; Immunohistochemistry; Biology; Malignancy; Pathology; Medicine; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.014685023646101764,"score_gpt":0.24293257550759256,"score_spread":0.2282475518614908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554088166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923727,0.00009083859,0.000022014978,0.00057061604,0.000054013846,0.00558222,0.00048181342,0.00028897682,0.0005368176],"genre_scores_gemma":[0.9936524,0.00001457652,0.0011443938,0.0002734447,0.00009743548,0.0006134704,0.001926472,0.00014293042,0.0021348605],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99355906,0.00064688135,0.0008232464,0.0013022156,0.0021676202,0.0015009742],"domain_scores_gemma":[0.99668795,0.00021111415,0.0006337949,0.0009715004,0.00069654244,0.00079909863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005455852,0.0008900508,0.0013566378,0.00035596872,0.00030221327,0.00014452686,0.0003626978,0.00055232673,0.0004087717],"category_scores_gemma":[0.0008673213,0.0006295089,0.00018850737,0.00068245345,0.00011072328,0.00047921282,0.00013725545,0.0008162979,0.000028981975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017598191,0.03445993,0.43557733,0.00020329186,0.0015667658,0.0017178489,0.0009482332,0.0000056848357,0.50381404,0.00003304996,0.0017630378,0.0023126001],"study_design_scores_gemma":[0.05844429,0.0054697217,0.598106,0.0033221336,0.00018142218,0.000004125546,0.00003367569,0.000090147034,0.33352524,0.00010744354,0.00005108094,0.0006646499],"about_ca_topic_score_codex":0.0018265011,"about_ca_topic_score_gemma":0.00044155994,"teacher_disagreement_score":0.17028879,"about_ca_system_score_codex":0.0005214597,"about_ca_system_score_gemma":0.00047314577,"threshold_uncertainty_score":0.9996156},"labels":[],"label_agreement":null},{"id":"W2554514455","doi":"10.1182/blood.v124.21.3990.3990","title":"First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; Saint John Regional Hospital; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Melphalan; Multiple myeloma; Maintenance therapy; Busulfan; Bortezomib; Minimal residual disease; Internal medicine; Regimen; Progressive disease; Plerixafor; Oncology; Autologous stem-cell transplantation; Surgery; Bone marrow; Urology; Transplantation; Chemotherapy; Hematopoietic stem cell transplantation; CXCR4","score_opus":0.0489398456507827,"score_gpt":0.3201919338570257,"score_spread":0.271252088206243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554514455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995749,0.00001608884,0.00001407321,0.0010156429,0.00005684275,0.0025431404,0.00024645013,0.0000071884124,0.0003515749],"genre_scores_gemma":[0.99923503,0.0000010026514,0.00021842348,0.00004725927,0.00012771484,0.00016396293,0.00014476442,0.000019440298,0.000042395586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584866,0.0006779632,0.0006318155,0.00048646188,0.0018320085,0.000523099],"domain_scores_gemma":[0.9967555,0.0007540085,0.000374905,0.0005986667,0.0010485043,0.00046842362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026969172,0.00020038012,0.0004853275,0.00019444247,0.00039941425,0.00001540043,0.00015085745,0.000058702255,0.000036500707],"category_scores_gemma":[0.002982875,0.00013995478,0.00006616175,0.00051277986,0.00034241498,0.00005119992,0.000048594866,0.00031113054,1.474075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03979884,0.0039123264,0.9533918,0.00027995193,0.0004147553,0.00020366156,0.00012838226,0.00074698543,0.0004837809,0.000088009045,0.00037662973,0.0001748711],"study_design_scores_gemma":[0.066255085,0.0025222395,0.924343,0.0004546027,0.00015844965,0.000007888793,0.00032455352,0.0008413308,0.0049068164,0.000046380377,0.000028485772,0.000111192036],"about_ca_topic_score_codex":0.5482177,"about_ca_topic_score_gemma":0.8999126,"teacher_disagreement_score":0.35169485,"about_ca_system_score_codex":0.00041527642,"about_ca_system_score_gemma":0.006469782,"threshold_uncertainty_score":0.9991626},"labels":[],"label_agreement":null},{"id":"W2554665350","doi":"10.1182/blood.v118.21.987.987","title":"A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; microRNA; Multiple myeloma; Oncology; Internal medicine; Biology; Cancer research; Gene expression profiling; Cohort; Medicine; Gene expression; Bioinformatics; Gene; Genetics","score_opus":0.059242968423758834,"score_gpt":0.2827313778567519,"score_spread":0.22348840943299306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554665350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972241,0.000087140725,0.00011157757,0.00007682202,0.00005478485,0.0019871504,0.0003185919,0.000018863557,0.00012098224],"genre_scores_gemma":[0.9975676,0.000026939415,0.0017964928,0.000034111672,0.000036538044,0.00035640917,0.000027900433,0.000018557663,0.00013546676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989057,0.00010772652,0.00026173162,0.00020291851,0.0002591463,0.00026274446],"domain_scores_gemma":[0.99885464,0.00045793844,0.00007696851,0.00033091736,0.00013800689,0.00014155888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000384435,0.000108052634,0.00019334668,0.00016108398,0.00006860571,0.0000046977757,0.000103000726,0.000055068336,0.00003267291],"category_scores_gemma":[0.0019225831,0.00006949707,0.00009108621,0.00017456454,0.000045283876,0.000043303877,0.00004375936,0.00010058208,0.000017992767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018624876,0.0017780364,0.96689284,0.000039562612,0.00018343236,0.000016122493,0.00101398,0.0000012058089,0.0037557955,0.0000032285186,0.000142405,0.0075485054],"study_design_scores_gemma":[0.020996237,0.0017536207,0.93672776,0.00010070092,0.00013019876,0.000003796775,0.00009411792,0.00019079664,0.039624162,0.000027455852,0.0003042599,0.000046892837],"about_ca_topic_score_codex":0.0006314673,"about_ca_topic_score_gemma":0.00021516318,"teacher_disagreement_score":0.03586837,"about_ca_system_score_codex":0.00003800392,"about_ca_system_score_gemma":0.00007052345,"threshold_uncertainty_score":0.28340083},"labels":[],"label_agreement":null},{"id":"W2554778782","doi":"","title":"Clinical Relevance of Trace Bands on Serum Electrophoresis in Patients Without a History of Gammopathy.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Dyscrasia; Plasma cell dyscrasia; Serum protein electrophoresis; Medicine; Multiple myeloma; Immunofixation; Monoclonal gammopathy of undetermined significance; Macroglobulinemia; Myeloma protein; Cryoglobulins; Gammopathy; Plasmacytoma; Pathology; Plasma cell; Waldenstrom macroglobulinemia; Gastroenterology; Internal medicine; Antibody; Immunology; Lymphoma; Monoclonal; Immunoglobulin light chain","score_opus":0.06378525435508846,"score_gpt":0.3094715409543268,"score_spread":0.2456862865992383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554778782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442786,0.00076363893,0.0000020353198,0.00009148809,0.00013129081,0.0007918289,0.000010819035,0.000010848723,0.0037702068],"genre_scores_gemma":[0.99712956,0.000116950534,0.00016333025,0.000035166064,0.000033342603,0.00021595291,0.000009090371,0.000015788855,0.002280801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984092,0.00012580906,0.0004231336,0.0002194653,0.00049068505,0.00033168457],"domain_scores_gemma":[0.99898416,0.000117873795,0.00014050129,0.0002941834,0.00016166632,0.00030160477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005722042,0.000101853606,0.00041436043,0.00014861117,0.0000045735896,0.0000011002046,0.000082428705,0.00007738735,0.000009566197],"category_scores_gemma":[0.0015957442,0.000080857346,0.000084112755,0.00013479555,0.000098045195,0.000037563696,0.00002134918,0.00018504816,0.00000664032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044886167,0.0012761676,0.8390129,0.000045479326,0.000044855424,0.000018874627,0.00009143475,7.211118e-7,0.000017835739,0.000004507958,0.0012988359,0.15369977],"study_design_scores_gemma":[0.009386358,0.001030599,0.985679,0.000041219504,0.000025125055,9.435216e-7,0.000009241388,0.000033770182,0.0009328074,0.000017359578,0.00278766,0.000055957553],"about_ca_topic_score_codex":0.000076569326,"about_ca_topic_score_gemma":0.000032235283,"teacher_disagreement_score":0.15364382,"about_ca_system_score_codex":0.0005153631,"about_ca_system_score_gemma":0.0002238189,"threshold_uncertainty_score":0.3297267},"labels":[],"label_agreement":null},{"id":"W2554797011","doi":"10.1182/blood.v110.11.449.449","title":"A Tissue Microarray Classification in Multiple Myeloma (MM) Predicts Survival Post Autologous Stem Cell Transplant (ASCT).","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; Tissue microarray; Proportional hazards model; Multiple myeloma; Univariate analysis; Immunohistochemistry; Pathology; Multivariate analysis","score_opus":0.03051540818010379,"score_gpt":0.27904577169476963,"score_spread":0.24853036351466584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554797011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938636,0.000568998,0.00031456994,0.00029235063,0.00013169226,0.0010596521,0.00012673205,0.00012356527,0.0035188464],"genre_scores_gemma":[0.99753314,0.00008224971,0.00085773005,0.00006261471,0.00011696797,0.00004877731,0.00030979922,0.000040226485,0.0009484885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781543,0.000098915894,0.0004451675,0.00047168258,0.00046431366,0.0007044976],"domain_scores_gemma":[0.99877286,0.0002441071,0.00008345725,0.00041493902,0.00010854552,0.00037610563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045813248,0.00024386936,0.00037900134,0.00028608632,0.00008937109,0.0000213761,0.00015201514,0.00021249575,0.000061190185],"category_scores_gemma":[0.00004720906,0.00020949832,0.00008390249,0.00029442474,0.000083224375,0.00007645871,0.000023886,0.00030448483,0.00019262717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012504053,0.0034322832,0.4781362,0.00022911737,0.00013122079,0.0026146956,0.0012121203,9.489374e-7,0.4773678,0.000019952045,0.000057700356,0.035547536],"study_design_scores_gemma":[0.011272189,0.000584833,0.71746653,0.00008894714,0.000094363,0.00013072611,0.00031621163,0.000115863404,0.26916534,0.0000036227132,0.00061199605,0.00014940309],"about_ca_topic_score_codex":0.00041767178,"about_ca_topic_score_gemma":0.0011474914,"teacher_disagreement_score":0.23933028,"about_ca_system_score_codex":0.000104989864,"about_ca_system_score_gemma":0.00016076342,"threshold_uncertainty_score":0.8543094},"labels":[],"label_agreement":null},{"id":"W2554921082","doi":"10.1182/blood.v104.11.3464.3464","title":"A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Vascular endothelial growth factor; Angiogenesis; Pharmacology; Gastroenterology","score_opus":0.014658817334158268,"score_gpt":0.25519929410555714,"score_spread":0.24054047677139886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554921082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419993,0.0002379633,0.00001314135,0.00013039359,0.00012795531,0.0041991468,0.00095061545,0.000105924264,0.000034905213],"genre_scores_gemma":[0.9973176,0.00007242833,0.0015894456,0.00004652029,0.00018042569,0.00028416672,0.00032517122,0.00012246383,0.00006178215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956097,0.00025727742,0.0009057783,0.0010136206,0.0012781535,0.0009354898],"domain_scores_gemma":[0.9976007,0.00022666091,0.0003093732,0.0006474669,0.00047490222,0.0007409516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002029797,0.00067539216,0.0011547878,0.0005524247,0.00023988592,0.0000434679,0.00022598729,0.00023466256,0.00017818938],"category_scores_gemma":[0.0012163088,0.0005206663,0.00018632898,0.000649907,0.00021456351,0.00037086994,0.0002090018,0.00052244304,0.000029954375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008841959,0.075796396,0.8684636,0.0003337401,0.0010856182,0.0002816386,0.0034525902,0.000001025165,0.038766656,0.0000148692325,0.000038093738,0.0029238423],"study_design_scores_gemma":[0.30625823,0.035638887,0.53074855,0.00048627335,0.00032242393,0.00001187522,0.00039874073,0.000010547609,0.12547746,0.000012490985,0.00008410806,0.0005504222],"about_ca_topic_score_codex":0.0012493272,"about_ca_topic_score_gemma":0.0002559464,"teacher_disagreement_score":0.33771503,"about_ca_system_score_codex":0.00024177037,"about_ca_system_score_gemma":0.0002837201,"threshold_uncertainty_score":0.9997245},"labels":[],"label_agreement":null},{"id":"W2555050655","doi":"10.1182/blood.v106.11.1556.1556","title":"The Classical Illegitimate Switch Translocation Model Is Unable To Account for at Least Half of the Translocation Breakpoints from t(4;14)(p16;q32) Multiple Myeloma.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Breakpoint; Chromosomal translocation; Biology; Genetics; Derivative chromosome; Locus (genetics); Chromosome; Immunoglobulin class switching; Gene; Molecular biology; Chromosome 22; B cell","score_opus":0.02577253144406177,"score_gpt":0.2849630355202376,"score_spread":0.25919050407617583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555050655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95919085,0.00067355216,0.0058505,0.030040987,0.00007877651,0.0030212933,0.000557844,0.000056362576,0.0005298176],"genre_scores_gemma":[0.9930986,0.00013510881,0.0038166589,0.00036369145,0.00017220258,0.00048224226,0.00014486066,0.000044269334,0.0017423665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800426,0.00005036901,0.00044099224,0.00041264712,0.00061516085,0.00047657802],"domain_scores_gemma":[0.9984599,0.00025011593,0.000102518934,0.0006788129,0.00029135562,0.00021733309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002525662,0.00022767443,0.00031842428,0.000061032504,0.00039722386,0.000038718874,0.0002776029,0.00012519295,0.000050135634],"category_scores_gemma":[0.00014374402,0.00013651718,0.00023157992,0.000215318,0.00010847896,0.00013125443,0.000043422828,0.00014988256,0.000059919606],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013186163,0.009109346,0.021721993,0.00048720703,0.0028478852,0.000014337865,0.011609044,0.005443971,0.5240564,0.0010988661,0.012616695,0.39780813],"study_design_scores_gemma":[0.024941405,0.00045353637,0.03175589,0.00032900408,0.00056065765,0.000027934624,0.00025146405,0.29527208,0.6267802,0.0004884914,0.018791966,0.00034738024],"about_ca_topic_score_codex":0.0004083447,"about_ca_topic_score_gemma":0.0022504136,"teacher_disagreement_score":0.39746076,"about_ca_system_score_codex":0.00015072124,"about_ca_system_score_gemma":0.00021481332,"threshold_uncertainty_score":0.5567009},"labels":[],"label_agreement":null},{"id":"W2555159995","doi":"10.1182/blood.v114.22.3879.3879","title":"Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Cancer research; Medicine; PI3K/AKT/mTOR pathway; Multiple myeloma; Angiogenesis; In vivo; Dexamethasone; Population; Melphalan; PTEN; Paclitaxel; Cancer; Internal medicine; Pharmacology; Oncology; Chemistry; Biology; Apoptosis","score_opus":0.014277882728381123,"score_gpt":0.28028821199197446,"score_spread":0.26601032926359336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555159995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998061,0.00015455595,1.2433044e-7,0.000072436604,0.000014767792,0.0013764072,0.000045259334,0.000009693155,0.000265733],"genre_scores_gemma":[0.9997371,0.000010581349,0.00008967672,0.000016847005,0.000016706595,0.000018197885,0.000022276374,0.000010312391,0.000078338104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986793,0.00010376251,0.00033777778,0.00023915667,0.00045132267,0.00018871207],"domain_scores_gemma":[0.99913895,0.00007355803,0.00014820078,0.00043539572,0.00010696118,0.00009692177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013777806,0.00013063091,0.00028792507,0.0001220502,0.000034883506,0.000003827529,0.00007674528,0.000051203846,0.000003124013],"category_scores_gemma":[0.00023586414,0.000075733056,0.000032223288,0.000250689,0.00006602876,0.000059096412,0.0000442874,0.00016019565,7.0435095e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0391911,0.079030946,0.8471435,0.000094932846,0.00022656869,0.00023781178,0.002688529,5.4874437e-7,0.0041751745,0.0000024203641,0.00007974157,0.027128749],"study_design_scores_gemma":[0.105283014,0.03515467,0.85121197,0.00024074057,0.00014100382,0.0000032506075,0.0002987487,0.000005882454,0.0075850408,0.0000045870743,0.000013002666,0.000058103986],"about_ca_topic_score_codex":0.00010922278,"about_ca_topic_score_gemma":0.000033358963,"teacher_disagreement_score":0.06609191,"about_ca_system_score_codex":0.000020642243,"about_ca_system_score_gemma":0.00007060684,"threshold_uncertainty_score":0.30883044},"labels":[],"label_agreement":null},{"id":"W2555424733","doi":"10.1182/blood.v126.23.722.722","title":"Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; KRAS; Multiple myeloma; Interim analysis; Oncology; Internal medicine; Cohort; Medicine; Exome sequencing; Clinical trial; Biology; Mutation; Cancer; Genetics; Gene","score_opus":0.05618595741210662,"score_gpt":0.36633362297908895,"score_spread":0.3101476655669823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555424733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992454,0.000055052187,0.0001277291,0.000042206524,0.000009654399,0.00031738548,0.000033463723,0.0000065713157,0.00016250748],"genre_scores_gemma":[0.9997952,9.075089e-7,0.00009843989,0.0000049692517,0.0000052759524,0.000018833094,0.000059194113,0.0000052005103,0.000011985308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999231,0.00013076929,0.00022666743,0.00010882181,0.00023375872,0.000068980866],"domain_scores_gemma":[0.99929017,0.000050128154,0.00012073118,0.00028654266,0.00017644696,0.00007597686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024173273,0.000052009946,0.0001794566,0.000120831064,0.000032190837,0.000009545239,0.000064838445,0.000016297481,0.0000071601935],"category_scores_gemma":[0.0003946404,0.000035296955,0.000047123805,0.00040069182,0.000060462084,0.000040353087,0.00003762873,0.000045024914,6.3455764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005021904,0.002464113,0.9771169,0.000023585033,0.0014841504,0.000012512525,0.0025725658,0.000010133357,0.015560471,0.000029630932,0.0000012517382,0.00067448494],"study_design_scores_gemma":[0.0026094473,0.00049122894,0.9683256,0.000014518909,0.0024133143,0.0000032843657,0.0028987217,0.0018240572,0.021353772,0.00003617842,8.21093e-7,0.000029038461],"about_ca_topic_score_codex":0.00025220553,"about_ca_topic_score_gemma":0.00021972257,"teacher_disagreement_score":0.008791263,"about_ca_system_score_codex":0.0000113140095,"about_ca_system_score_gemma":0.000044555887,"threshold_uncertainty_score":0.1439368},"labels":[],"label_agreement":null},{"id":"W2555484425","doi":"10.1182/blood.v118.21.1875.1875","title":"Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Multiple myeloma; Medicine; Internal medicine; Refractory (planetary science); Fluorescence in situ hybridization; Oncology; Transplantation; Lenalidomide; Gastroenterology; Biology","score_opus":0.04537408221526898,"score_gpt":0.2718674968393186,"score_spread":0.22649341462404962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555484425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970489,0.00003460753,6.3118773e-7,0.0000344476,0.000017572735,0.0025704815,0.00010717755,0.000047519232,0.00013863097],"genre_scores_gemma":[0.9991151,0.000016023027,0.00020125727,0.000055256776,0.000018979757,0.00015635705,0.00006612302,0.000070210735,0.0003006922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975395,0.00048562023,0.00033344148,0.0005227961,0.0005675997,0.00055105024],"domain_scores_gemma":[0.9982229,0.00043864007,0.0001639575,0.0006739949,0.00017603893,0.00032447686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003642644,0.0003972474,0.00049217645,0.0002369867,0.00016139566,0.000043584296,0.00013413084,0.00009102292,0.00013004955],"category_scores_gemma":[0.0004890889,0.00019106081,0.00005188849,0.00037813303,0.0001330455,0.00008716952,0.000053535823,0.00030253583,0.000032070406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10664084,0.011081389,0.87578696,0.00001917484,0.00062196,0.0010193061,0.0014910992,8.1617634e-7,0.0023240244,4.2178732e-7,0.000011281774,0.0010027485],"study_design_scores_gemma":[0.037405796,0.03223515,0.9195157,0.00021640718,0.00030547738,0.000021018473,0.00058700563,0.000019383908,0.009451386,5.392068e-7,0.000023095814,0.00021904304],"about_ca_topic_score_codex":0.0005286345,"about_ca_topic_score_gemma":0.00023209772,"teacher_disagreement_score":0.06923504,"about_ca_system_score_codex":0.00018391613,"about_ca_system_score_gemma":0.00021697363,"threshold_uncertainty_score":0.77912337},"labels":[],"label_agreement":null},{"id":"W2555499891","doi":"10.1182/blood.v112.11.1688.1688","title":"HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM).","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Human leukocyte antigen; Haplotype; Immunology; Allele; Population; Medicine; Allele frequency; Linkage disequilibrium; Typing; Biology; Genetics; Antigen; Gene","score_opus":0.036371028711575,"score_gpt":0.27140737298833717,"score_spread":0.23503634427676218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555499891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997299,0.00026617263,0.00011989926,0.00023844051,0.00002148645,0.00045897515,0.00001599514,0.00001945967,0.0015605612],"genre_scores_gemma":[0.9925714,0.000039727267,0.0065959115,0.000035217596,0.00006861108,0.000049135277,0.000025777857,0.000009153509,0.0006050483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992548,0.000019721496,0.00016289117,0.00013683266,0.00025836175,0.00016736421],"domain_scores_gemma":[0.99956447,0.000061513834,0.000026136415,0.0001628458,0.000061356644,0.00012367232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007650106,0.00008198533,0.00013560808,0.00006191253,0.00014164903,0.000005677974,0.000048371632,0.000027689515,0.000033391527],"category_scores_gemma":[0.00006763981,0.00005235529,0.000026826381,0.000088763474,0.00006178525,0.000035140314,0.00004698202,0.000054563185,0.000032659947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001060723,0.0023044029,0.88077843,0.00022649382,0.0006842258,0.0002842886,0.014997749,0.0000044879507,0.054875087,0.000096493255,0.0010783327,0.043609273],"study_design_scores_gemma":[0.0028171209,0.00023442169,0.869538,0.000056509154,0.000032579854,0.000116347604,0.0002946865,0.000038755996,0.12473393,0.0000057516377,0.0020762195,0.000055639994],"about_ca_topic_score_codex":0.000022060816,"about_ca_topic_score_gemma":0.0000567401,"teacher_disagreement_score":0.06985884,"about_ca_system_score_codex":0.000016955299,"about_ca_system_score_gemma":0.0000763123,"threshold_uncertainty_score":0.21349868},"labels":[],"label_agreement":null},{"id":"W2555914769","doi":"10.1182/blood.v110.11.4757.4757","title":"Molecular Quantification of Pre-Treatment Bone Marrow Clonal Cells in Multiple Myeloma Is a Novel Predictive Indicator of Remission Length.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Medicine; Bone marrow; Plasmacytosis; Internal medicine; Prednisone; Thalidomide; Plasma cell; Monoclonal gammopathy of undetermined significance; Melphalan; Oncology; Pathology; Immunology; Gastroenterology; Antibody; Monoclonal","score_opus":0.023328859945617786,"score_gpt":0.29575386112002783,"score_spread":0.27242500117441004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555914769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997004,0.00051388366,0.00084941974,0.00007886323,0.000025238942,0.0010574802,0.00019541167,0.000019179266,0.00025654456],"genre_scores_gemma":[0.99554104,0.00009610523,0.0040339734,0.000013556429,0.000025285279,0.000043633074,0.00011562242,0.000022699542,0.00010810746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823284,0.000038526843,0.00051945145,0.00034702575,0.00054735923,0.00031480266],"domain_scores_gemma":[0.9988878,0.00014739808,0.00022734335,0.00039759677,0.00012215534,0.0002177383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029511785,0.00017691779,0.00038567706,0.0003207709,0.000028643959,0.0000035066346,0.0000818069,0.00014309255,0.000042601474],"category_scores_gemma":[0.00014585762,0.00014396306,0.00012499758,0.0002797094,0.00009869408,0.000047222195,0.000037756592,0.00011584378,0.000008249564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001736594,0.006292667,0.23026319,0.00012919602,0.00025657055,0.00009790246,0.0005537995,0.0000060835737,0.7567445,0.000015345646,0.00001327718,0.0038908669],"study_design_scores_gemma":[0.007995797,0.00081963366,0.38105395,0.00013188325,0.00009758956,0.000012806889,0.000071996794,0.0004320955,0.60925806,0.0000058203477,0.00006346389,0.000056877725],"about_ca_topic_score_codex":0.0003263239,"about_ca_topic_score_gemma":0.000032682045,"teacher_disagreement_score":0.15079078,"about_ca_system_score_codex":0.00011285254,"about_ca_system_score_gemma":0.0001784031,"threshold_uncertainty_score":0.5870643},"labels":[],"label_agreement":null},{"id":"W2555962573","doi":"10.1182/blood.v118.21.1810.1810","title":"Alternate Splicing Factor Fox2 Affects Growth and Survival of Multiple Myeloma Cells","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Exon; RNA splicing; Alternative splicing; Biology; Small hairpin RNA; Splicing factor; Cell growth; Molecular biology; Cell culture; Gene expression; Cancer research; Gene; Cell biology; Gene knockdown; RNA; Genetics","score_opus":0.03719988467604131,"score_gpt":0.27203678170868434,"score_spread":0.23483689703264304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555962573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953285,0.00018340386,0.00003371825,0.000015112796,0.00007126316,0.00039973174,0.000036191617,0.00003744907,0.0038946492],"genre_scores_gemma":[0.998104,0.00010714503,0.0015118434,0.0000144222595,0.000058259007,0.000012694834,0.000008793532,0.000024816016,0.00015807502],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989959,0.00004442078,0.0001495839,0.0002412334,0.0002606265,0.00030825182],"domain_scores_gemma":[0.9992827,0.00012449945,0.00006431607,0.00022593529,0.000051109484,0.00025139702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000073252544,0.00014952321,0.00029863443,0.000101530946,0.000040442348,0.000007664746,0.000074206626,0.00005848404,0.00007434778],"category_scores_gemma":[0.00010624218,0.00011647829,0.00006820252,0.00008469083,0.00006529956,0.00005933174,0.00007303005,0.00010418265,0.000020707572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022924475,0.00066871935,0.71761525,0.00021471438,0.00026833874,0.00024841976,0.00043871035,2.1188052e-8,0.27821186,0.000053571308,0.000006205322,0.0020449301],"study_design_scores_gemma":[0.005284877,0.00040810212,0.44606644,0.000056531717,0.00006837886,0.00002443342,0.000029390618,0.000032579323,0.5479358,0.000021350039,0.0000066869893,0.00006544711],"about_ca_topic_score_codex":0.00066794344,"about_ca_topic_score_gemma":0.000052548206,"teacher_disagreement_score":0.2715488,"about_ca_system_score_codex":0.000009023994,"about_ca_system_score_gemma":0.000031729047,"threshold_uncertainty_score":0.47498468},"labels":[],"label_agreement":null},{"id":"W2555978778","doi":"10.1182/blood.v120.21.4053.4053","title":"Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pomalidomide; Medicine; Tolerability; Internal medicine; Multiple myeloma; Lenalidomide; Bortezomib; Oncology; Adverse effect; Population; Expanded access; Surgery","score_opus":0.01879581665067745,"score_gpt":0.26038265894574447,"score_spread":0.24158684229506702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555978778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943215,0.0022243233,0.000014265249,0.00015657819,0.000011100618,0.003116933,0.000053700893,0.0000448264,0.000056777095],"genre_scores_gemma":[0.9938176,0.0014744732,0.0035961266,0.00008438806,0.00002177588,0.00041398496,0.00011150027,0.00009445088,0.00038565326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716836,0.0002730597,0.00046347769,0.000708146,0.0005989519,0.00078800623],"domain_scores_gemma":[0.9981123,0.0005098209,0.000244383,0.00042858097,0.00018014139,0.00052478095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029888208,0.00064390065,0.0010236909,0.00042287773,0.00017170532,0.00008385283,0.0000678055,0.00016314327,0.0000102367585],"category_scores_gemma":[0.00010402862,0.00035484173,0.000030812604,0.00025605955,0.0004308544,0.00053326384,0.000051546845,0.0002720676,8.2063536e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034413543,0.003863813,0.94499785,0.00014834155,0.0007929251,0.00031175133,0.003039118,0.0000027280462,0.00022349013,0.0000052196233,0.0000012752345,0.012199929],"study_design_scores_gemma":[0.15521562,0.011290819,0.8281508,0.00048819595,0.00029762735,0.00018047952,0.0007306497,0.00007257729,0.0031363564,0.000003740553,0.000037334397,0.00039576986],"about_ca_topic_score_codex":0.0014645634,"about_ca_topic_score_gemma":0.0040766164,"teacher_disagreement_score":0.12080208,"about_ca_system_score_codex":0.00017481088,"about_ca_system_score_gemma":0.00021103321,"threshold_uncertainty_score":0.9998903},"labels":[],"label_agreement":null},{"id":"W2556106714","doi":"10.1182/blood.v126.23.1121.1121","title":"Comparing the Efficacy of Aspirin or Low Molecular Weight Heparin or Vitamin K Antagonists in the Risk of Thromboembolic Events in Patients with Multiple Myeloma Treated with Lenalidomide-Based Therapy","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Surgery; Oncology; Intensive care medicine","score_opus":0.027133644205496344,"score_gpt":0.2784189445408723,"score_spread":0.25128530033537594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556106714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973646,0.000103075305,0.000018146178,0.000055313958,0.000009383567,0.0023183334,0.000032568234,0.0000163034,0.00008230227],"genre_scores_gemma":[0.9992569,0.000027038519,0.00038135095,0.00004259821,0.000013254291,0.00013022011,0.00009706372,0.000039506667,0.0000120363175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739426,0.00052531244,0.00046118908,0.00033239194,0.00086304365,0.00042380733],"domain_scores_gemma":[0.9983461,0.00038778235,0.00026047276,0.0006839766,0.0001829481,0.00013873933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004783223,0.00029919308,0.0006898558,0.00020634464,0.000051624407,0.000011334596,0.00031475825,0.00007371414,0.000012150763],"category_scores_gemma":[0.00022870334,0.00011837128,0.00007962878,0.00077528873,0.00019085535,0.00006303713,0.00004021257,0.00026351094,0.0000037932134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02474226,0.009304743,0.96272975,0.00006995027,0.00045467285,0.00019092759,0.00062168186,0.00018266196,0.00056911475,0.0000027365627,0.000004991898,0.0011265347],"study_design_scores_gemma":[0.102942705,0.003337467,0.8569104,0.00040478632,0.00015560245,0.000009219802,0.0001102638,0.0005319986,0.035460375,0.0000025683025,0.000009027075,0.00012559493],"about_ca_topic_score_codex":0.0024327897,"about_ca_topic_score_gemma":0.0018072501,"teacher_disagreement_score":0.10581934,"about_ca_system_score_codex":0.000069068454,"about_ca_system_score_gemma":0.00034078144,"threshold_uncertainty_score":0.48270407},"labels":[],"label_agreement":null},{"id":"W2556470338","doi":"10.1182/blood.v108.11.368.368","title":"A Chemical Biology Screen Identifies Glucocorticoids as Inhibitors of C-Maf and C-Maf-Dependent Transactivation of Cyclin D2.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Transactivation; Cyclin D2; Cyclin D1; Cyclin; Biology; Cancer research; Cyclin D3; Molecular biology; Cell cycle; Cell; Biochemistry; Transcription factor; Gene","score_opus":0.01181211805639537,"score_gpt":0.2817117927313165,"score_spread":0.26989967467492115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556470338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981983,0.0004481393,0.00008889035,0.00011327738,0.000018966313,0.00034007986,0.000036030735,0.000017061473,0.0007393016],"genre_scores_gemma":[0.99914825,0.00004727173,0.0004761553,0.000007920609,0.00006343525,0.000018080324,0.00008605792,0.000011287122,0.00014153848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990243,0.0000346247,0.00033830505,0.00019602854,0.00022662293,0.00018015338],"domain_scores_gemma":[0.9994931,0.0000832436,0.00009534823,0.000157751,0.00008884595,0.00008167517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010186576,0.00010477527,0.00028833293,0.00012260208,0.000020405027,0.0000051677557,0.00004517699,0.00010203129,0.00005388839],"category_scores_gemma":[0.00010353442,0.000085005,0.00006948887,0.000110321555,0.00015618067,0.00004763177,0.000021591575,0.00009025506,0.000004760489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030194264,0.0010890479,0.1571454,0.0001038734,0.00017043712,0.000025233308,0.00006637346,3.500396e-7,0.83587956,0.0001477158,0.000010314853,0.0050597796],"study_design_scores_gemma":[0.006142217,0.00033168212,0.102443404,0.00007109115,0.00014858403,0.00003272469,0.000045558667,0.000015308635,0.89000034,0.00069732603,0.000013822992,0.00005791218],"about_ca_topic_score_codex":0.0016290286,"about_ca_topic_score_gemma":0.000044187316,"teacher_disagreement_score":0.054701988,"about_ca_system_score_codex":0.000013810263,"about_ca_system_score_gemma":0.000053647735,"threshold_uncertainty_score":0.34664032},"labels":[],"label_agreement":null},{"id":"W2556710404","doi":"10.1182/blood.v118.21.813.813","title":"Final Results From the Bortezomib-naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Tolerability; Medicine; Multiple myeloma; Regimen; Refractory (planetary science); Proteasome inhibitor; Internal medicine; Clinical endpoint; Oncology; Cohort; Progression-free survival; Surgery; Adverse effect; Overall survival; Clinical trial","score_opus":0.06477484060319613,"score_gpt":0.29062869432444255,"score_spread":0.22585385372124642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556710404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978122,0.00013289518,0.0000016335691,0.000015291833,0.00002587151,0.0013901467,0.0002692041,0.000011472156,0.0003412631],"genre_scores_gemma":[0.99927616,0.000022154496,0.0004211704,0.000016395572,0.000023963441,0.000043176806,0.00012074027,0.000019642597,0.000056618326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832654,0.00015659034,0.00045257478,0.00033332442,0.00048822933,0.00024273964],"domain_scores_gemma":[0.9987736,0.00021546312,0.00023377276,0.00050245377,0.0001357075,0.0001390513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001917425,0.00017500915,0.00040316654,0.0001030542,0.000042468964,0.000005203079,0.0001202491,0.00005963039,0.000043751417],"category_scores_gemma":[0.00030846885,0.000095402436,0.00004115249,0.0001899561,0.00011394452,0.00006618917,0.00007040076,0.00018338145,0.0000024717813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044009168,0.055040088,0.883593,0.000039862884,0.0007403702,0.00037060416,0.010376072,1.6806482e-7,0.0010207134,0.0000017845676,0.00004389946,0.004764236],"study_design_scores_gemma":[0.1310741,0.021461898,0.8433659,0.0002260677,0.00033608067,0.000002735236,0.001380437,0.0000067729898,0.0020371056,0.00000596776,0.000019893734,0.00008301928],"about_ca_topic_score_codex":0.004657253,"about_ca_topic_score_gemma":0.0010083177,"teacher_disagreement_score":0.08706493,"about_ca_system_score_codex":0.00003712109,"about_ca_system_score_gemma":0.000082667946,"threshold_uncertainty_score":0.70404047},"labels":[],"label_agreement":null},{"id":"W2556836548","doi":"10.1182/blood.v104.11.75.75","title":"Altered Kinetics and Localization of MMSET Variants Suggests That RE-IIBP Overexpression Is a Unifying Event in t(4;14)(p16;q32) Multiple Myeloma.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Breakpoint; Chromosomal translocation; Exon; Biology; Locus (genetics); Genetics; Gene; Alternative splicing; Gene duplication; RNA splicing; Molecular biology; RNA","score_opus":0.03245402061892937,"score_gpt":0.3058172494883735,"score_spread":0.27336322886944414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556836548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746805,0.0005164593,0.0007872748,0.00017520481,0.000038077997,0.00066774763,0.00006449405,0.000026895506,0.00025582087],"genre_scores_gemma":[0.99750715,0.00030327644,0.0018078277,0.00008776096,0.000051330873,0.000024654968,0.00012390409,0.000028004371,0.00006609072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984655,0.00006835357,0.00032666308,0.00034154335,0.00045765363,0.00034031607],"domain_scores_gemma":[0.9991616,0.00008021355,0.00011923199,0.00034285616,0.000086920285,0.00020915859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014296862,0.00018799318,0.00032944808,0.00020406018,0.000051930656,0.000017996897,0.000077549965,0.0001301845,0.00005892331],"category_scores_gemma":[0.00023707078,0.00015872343,0.00006509315,0.00023587797,0.000063600004,0.00010352984,0.00009537773,0.0001442884,0.000007884932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009501207,0.003630087,0.9311539,0.00055388705,0.00024848196,0.0003117182,0.0017476421,0.0002940758,0.057261914,0.00002956843,0.00011973214,0.0036988612],"study_design_scores_gemma":[0.032859225,0.0009054649,0.71578234,0.0018621784,0.00014146406,0.00006662731,0.00020986986,0.0022608773,0.24527912,0.00029542606,0.00012841992,0.00020898847],"about_ca_topic_score_codex":0.0005254687,"about_ca_topic_score_gemma":0.00019768656,"teacher_disagreement_score":0.21537156,"about_ca_system_score_codex":0.000073321266,"about_ca_system_score_gemma":0.00008499186,"threshold_uncertainty_score":0.64725536},"labels":[],"label_agreement":null},{"id":"W2556974834","doi":"10.1182/blood.v118.21.303.303","title":"A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Regimen; Multiple myeloma; Premedication; Internal medicine; Phases of clinical research; Pharmacology; Gastroenterology; Chemotherapy; Surgery","score_opus":0.023982915378325333,"score_gpt":0.2728240151189493,"score_spread":0.248841099740624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556974834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978558,0.00007012186,0.0000048077954,0.000005857335,0.000007446318,0.001857637,0.000010213981,0.000016410408,0.00017173083],"genre_scores_gemma":[0.99894655,0.000010113289,0.00083278446,0.000008004902,0.0000043305495,0.00011313842,0.000035585967,0.000027094267,0.000022399468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858063,0.00012391285,0.00029594594,0.0003157412,0.000414101,0.00026964085],"domain_scores_gemma":[0.99921936,0.00010724646,0.000119786186,0.00028437492,0.00012476195,0.0001444727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018137296,0.00017777379,0.00038818782,0.00035031306,0.000028127803,0.0000062797653,0.00006187884,0.000056529854,0.000019539017],"category_scores_gemma":[0.00014551583,0.00012452569,0.00001709345,0.00033055813,0.00008016048,0.00014989832,0.00003596048,0.00019740716,0.0000026722976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015388181,0.077902384,0.89736617,0.00007367274,0.00018919024,0.00034773702,0.0025517105,5.70376e-7,0.00032620537,0.000003057174,8.459461e-7,0.005850273],"study_design_scores_gemma":[0.25026467,0.018979266,0.72768736,0.00019248282,0.00008400233,0.0000058278074,0.000514217,0.000047665744,0.0021269086,0.000005003829,0.0000011231659,0.00009148497],"about_ca_topic_score_codex":0.0011392669,"about_ca_topic_score_gemma":0.0012875911,"teacher_disagreement_score":0.23487648,"about_ca_system_score_codex":0.00006244087,"about_ca_system_score_gemma":0.000088917375,"threshold_uncertainty_score":0.507801},"labels":[],"label_agreement":null},{"id":"W2556978135","doi":"10.1182/blood.v126.23.4261.4261","title":"In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Cohort; Bortezomib; Regimen; Internal medicine; Oncology; Progression-free survival; Refractory (planetary science); Maintenance therapy; Overall survival; Chemotherapy","score_opus":0.041236579819620964,"score_gpt":0.3169666778374186,"score_spread":0.27573009801779763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556978135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963361,0.00008961813,0.000013466832,0.0010834446,0.000038955033,0.0015789958,0.000043353564,0.00003125473,0.000784834],"genre_scores_gemma":[0.993836,0.000012447692,0.0052377926,0.0002422004,0.00009340912,0.00032829275,0.00004512812,0.00002676317,0.00017797905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979007,0.00014710549,0.00027743887,0.00046127284,0.0007763354,0.0004371339],"domain_scores_gemma":[0.99880016,0.00021559275,0.00006677839,0.0005205393,0.00007796321,0.00031897653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050414423,0.00020175302,0.00031791034,0.00016648593,0.00006704611,0.000053981195,0.00020441004,0.00006961557,0.0000127498715],"category_scores_gemma":[0.00065352564,0.00012427625,0.000027070826,0.0003816656,0.00006715227,0.00017259114,0.0001351835,0.00025846544,0.000008845172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012674374,0.0012386973,0.98501647,0.000015464093,0.000059777303,0.0010114879,0.0075967903,0.0000018259957,0.003181393,0.000015351827,0.00013782311,0.00045751102],"study_design_scores_gemma":[0.026236147,0.0009194956,0.96938413,0.000367261,0.00003513124,0.000024066976,0.0011937784,0.00013757683,0.0014185326,0.000024041325,0.000121727426,0.00013811298],"about_ca_topic_score_codex":0.0068872757,"about_ca_topic_score_gemma":0.012752449,"teacher_disagreement_score":0.02496871,"about_ca_system_score_codex":0.00008413047,"about_ca_system_score_gemma":0.000116715564,"threshold_uncertainty_score":0.99972594},"labels":[],"label_agreement":null},{"id":"W2557392219","doi":"10.1182/blood.v126.23.4213.4213","title":"Prima-1Met Combined with Bortezomib Has Synergistic Anti-Myeloma Activity By Modulation of Apoptosis and Cell Cycle Regulating Genes","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Bortezomib; Multiple myeloma; In vivo; Cytotoxicity; Housekeeping gene; Biology; Apoptosis; Cancer research; Cell culture; Gene expression; Pharmacology; Chemistry; Gene; Immunology; In vitro; Biochemistry; Genetics","score_opus":0.02752699093899491,"score_gpt":0.2632618762589371,"score_spread":0.2357348853199422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557392219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983252,0.0002296608,0.00024470783,0.00012467772,0.000014556868,0.0004292491,0.00002815976,0.000037106944,0.0005666483],"genre_scores_gemma":[0.99704796,0.000017495959,0.002641484,0.0000071864238,0.000027802505,0.000020187688,0.00007047177,0.000023578554,0.00014381528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998927,0.000057023557,0.0001624776,0.00025127476,0.00037232463,0.0002299071],"domain_scores_gemma":[0.99917465,0.00006689787,0.00011880649,0.00025921586,0.00013719435,0.00024325671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013680654,0.00014687543,0.0003242655,0.00007602312,0.00007328214,0.00002405674,0.000044371765,0.00006200997,0.0000072869775],"category_scores_gemma":[0.000084712774,0.000112611815,0.00003131004,0.00015197542,0.00010950658,0.00009925689,0.000041469015,0.00007638684,0.0000025791735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010182529,0.0020991839,0.3496486,0.00025741744,0.0003040151,0.000024953471,0.00017143815,0.000050726954,0.6362037,0.000012078526,0.00011943814,0.010090216],"study_design_scores_gemma":[0.013600058,0.0011914088,0.3329226,0.000073617615,0.00025384984,0.000015430958,0.00005221112,0.005537649,0.6461778,0.00003105725,0.000017700895,0.00012659395],"about_ca_topic_score_codex":0.00031825222,"about_ca_topic_score_gemma":0.000010347378,"teacher_disagreement_score":0.016725987,"about_ca_system_score_codex":0.000029462797,"about_ca_system_score_gemma":0.000106712,"threshold_uncertainty_score":0.45921767},"labels":[],"label_agreement":null},{"id":"W2557413597","doi":"10.1182/blood.v106.11.3487.3487","title":"Molecular Quantitation of Minimal Residual Disease in Multiple Myeloma Patients Achieving Complete Remission after Treatment with Revlimid or Velcade.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lenalidomide; Minimal residual disease; Multiple myeloma; Bortezomib; Thalidomide; Medicine; Proteasome inhibitor; Cancer research; Molecular biology; Oncology; Internal medicine; Biology; Bone marrow","score_opus":0.03274675511642622,"score_gpt":0.29304314996062786,"score_spread":0.26029639484420164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557413597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982107,0.0004456267,0.000025027743,0.00024412603,0.0000087612225,0.00087136537,0.00009688877,0.000021734433,0.00007573029],"genre_scores_gemma":[0.9949166,0.00006791444,0.00447849,0.000037742302,0.00003844021,0.000120066536,0.0002282583,0.000029318917,0.00008317843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985315,0.00008723583,0.0003163289,0.00032123362,0.0004320446,0.0003116532],"domain_scores_gemma":[0.9991371,0.000094396935,0.00009098285,0.0002898452,0.00009736216,0.00029028245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067272704,0.00019594414,0.00029953034,0.0001781546,0.00004197518,0.00001069395,0.000052525556,0.000052170737,0.000046267425],"category_scores_gemma":[0.00019658224,0.00012659607,0.000065027394,0.0001794209,0.00005555288,0.00009906204,0.000032232725,0.00008440875,0.000012138095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013127187,0.004304932,0.9659869,0.00012460671,0.00014981153,0.00070582295,0.0002404844,0.00004299715,0.0071168,0.0000034028988,0.0000069711996,0.008190062],"study_design_scores_gemma":[0.021870157,0.0029260283,0.96107876,0.0004696778,0.00021251944,0.0000071151658,0.000037696933,0.0011573575,0.011917071,9.60319e-7,0.00019382066,0.0001288458],"about_ca_topic_score_codex":0.00007870408,"about_ca_topic_score_gemma":0.00020037752,"teacher_disagreement_score":0.0087429695,"about_ca_system_score_codex":0.00010909762,"about_ca_system_score_gemma":0.00012905529,"threshold_uncertainty_score":0.5162438},"labels":[],"label_agreement":null},{"id":"W2557468307","doi":"10.1182/blood.v120.21.1863.1863","title":"Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Oncology; Adverse effect; Refractory (planetary science); Proteasome inhibitor; Dexamethasone; Hematology; Surgery","score_opus":0.03913274468234272,"score_gpt":0.2819730903136505,"score_spread":0.24284034563130774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557468307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99797064,0.00085171446,0.0000022538961,0.000053555596,0.000007237941,0.0007500857,0.00010289145,0.0000047784292,0.00025681424],"genre_scores_gemma":[0.99929094,0.00001946296,0.0004991361,0.0000132263585,0.0000063844245,0.00002693536,0.00004809065,0.000010241868,0.00008557361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880695,0.000088981804,0.00028868127,0.00016275747,0.0004172731,0.00023535003],"domain_scores_gemma":[0.99903876,0.00017526439,0.00013290586,0.00043874225,0.000085058055,0.00012925516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016841409,0.00013362718,0.0007278777,0.00016770004,0.000029924598,0.0000026015675,0.000062600324,0.000042283038,0.00008334919],"category_scores_gemma":[0.00011187791,0.00006459418,0.00025346634,0.0005462742,0.00008551828,0.00004607262,0.00005468478,0.000072497656,0.0000013690441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007539736,0.003771112,0.91651046,0.000024827543,0.07804969,0.0000030063268,0.00023866366,0.0000034258808,0.00009882992,0.000008886682,0.0000022969311,0.0005348305],"study_design_scores_gemma":[0.012914269,0.0003513712,0.8887261,0.000010598958,0.09370397,9.620725e-7,0.000020438241,0.000015892701,0.0041934536,7.1433254e-7,0.000015774145,0.000046410718],"about_ca_topic_score_codex":0.0002275092,"about_ca_topic_score_gemma":0.00012229051,"teacher_disagreement_score":0.027784318,"about_ca_system_score_codex":0.000026191728,"about_ca_system_score_gemma":0.00003072848,"threshold_uncertainty_score":0.2634074},"labels":[],"label_agreement":null},{"id":"W2557893350","doi":"10.1182/blood.v110.11.4777.4777","title":"Spontaneous Tumoural Regression in a Patient with t(4;14) Translocation Multiple Myeloma. A Case Report.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Serum protein electrophoresis; Bone marrow; Bence Jones protein; Gastroenterology; Proteinuria; Internal medicine; Beta-2 microglobulin; Pathology; Chemotherapy; Urology; Immunology; Antibody; Monoclonal; Immunoglobulin light chain; Monoclonal antibody; Kidney","score_opus":0.016141757091846797,"score_gpt":0.2818803929631768,"score_spread":0.26573863587133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557893350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997542,0.00030275952,0.000119157856,0.00013925892,0.000030899428,0.00087448786,0.000007228111,0.000058262765,0.00092589407],"genre_scores_gemma":[0.9967699,0.000012576716,0.0027680567,0.00003344167,0.00004729457,0.000048559406,0.00008655785,0.000025792271,0.00020780214],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9984215,0.00004010496,0.00035522215,0.00033188867,0.00042700375,0.00042429563],"domain_scores_gemma":[0.9990802,0.00010422389,0.0000912388,0.00033243417,0.000109842345,0.00028206152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025040278,0.00017291165,0.00024545428,0.00020338323,0.000074225856,0.0000124418775,0.0000366821,0.00007714651,0.000032553602],"category_scores_gemma":[0.00020182457,0.000116344774,0.000053627766,0.00027340258,0.000043108063,0.000063444175,0.000014601119,0.00020257497,0.000014695432],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020906972,0.0015602907,0.06760467,0.00004110873,0.0000611531,0.8930092,0.0006949682,0.000002630546,0.0039982563,0.0000023303699,0.0000123684495,0.030922333],"study_design_scores_gemma":[0.012846862,0.0011885065,0.07420823,0.0003434053,0.00007347595,0.8721657,0.00048142156,0.00019548176,0.03822129,0.000004950414,0.00012352022,0.00014719629],"about_ca_topic_score_codex":0.00088224787,"about_ca_topic_score_gemma":0.005189837,"teacher_disagreement_score":0.034223035,"about_ca_system_score_codex":0.000097257085,"about_ca_system_score_gemma":0.000114194074,"threshold_uncertainty_score":0.47444022},"labels":[],"label_agreement":null},{"id":"W2557971489","doi":"10.1182/blood.v108.11.3029.3029","title":"Fludarabine-Busulfan Conditioning and In Vivo T-Cell Depletion with Reduced Dose of ATG Followed by Allografting Induces Durable Responses in Patients with Advanced Multiple Myeloma with No Grade III-IV aGvHD.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Thymoglobulin; Busulfan; Fludarabine; Multiple myeloma; Surgery; Gastroenterology; Internal medicine; Regimen; Folinic acid; Melphalan; Transplantation; Plasma cell leukemia; Urology; Chemotherapy; Cyclophosphamide; Hematopoietic stem cell transplantation; Kidney transplantation","score_opus":0.007054677525832847,"score_gpt":0.23079158084238416,"score_spread":0.2237369033165513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557971489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979817,0.00019474095,0.0000073849556,0.000056437682,0.000009869558,0.0013256165,0.000053280895,0.00003953939,0.00033139615],"genre_scores_gemma":[0.9959652,0.000023268702,0.0032733595,0.000016889653,0.000015047959,0.00016229079,0.000287069,0.00004605669,0.0002108265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980151,0.000118102675,0.00038808084,0.00047862265,0.00051065086,0.0004894276],"domain_scores_gemma":[0.99902624,0.00018892248,0.00021711412,0.00024943473,0.00017493204,0.00014335239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016448714,0.000286012,0.00047678757,0.0003253757,0.000104131665,0.000026896605,0.00007213927,0.00009195541,0.000013028526],"category_scores_gemma":[0.00011183599,0.00020474335,0.000029088076,0.0005112841,0.00014673204,0.00023915248,0.000027358805,0.00022295573,0.0000012198868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010697889,0.0021770787,0.75970227,0.00008986524,0.000076424265,0.0001457849,0.00013347315,0.00003268508,0.22675882,9.35239e-7,0.000024074447,0.0001606894],"study_design_scores_gemma":[0.064084694,0.0026569583,0.7644139,0.00060097495,0.00007929511,0.000016809228,0.00015080228,0.000050299903,0.16772203,0.0000024213077,0.000018319915,0.00020352047],"about_ca_topic_score_codex":0.0012309287,"about_ca_topic_score_gemma":0.0013596897,"teacher_disagreement_score":0.05903679,"about_ca_system_score_codex":0.000068590394,"about_ca_system_score_gemma":0.00012554701,"threshold_uncertainty_score":0.83491915},"labels":[],"label_agreement":null},{"id":"W2558057034","doi":"10.1182/blood.v108.11.3554.3554","title":"Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Neutropenia; Multiple myeloma; Refractory (planetary science); Progression-free survival; Autologous stem-cell transplantation; Gastroenterology; Phases of clinical research; Toxicity; Oncology; Surgery; Chemotherapy","score_opus":0.024475023768014963,"score_gpt":0.3249339793342329,"score_spread":0.30045895556621793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558057034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264044,0.00028657573,0.000409745,0.00011360781,0.000028277913,0.006164776,0.0002008738,0.000073640695,0.00008205755],"genre_scores_gemma":[0.9935943,0.00010708708,0.0040336936,0.000040206512,0.00006593323,0.00061165873,0.0011653121,0.000074464144,0.00030737746],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937601,0.0018496787,0.0018660044,0.0010151896,0.00089422,0.00061479444],"domain_scores_gemma":[0.99443126,0.0037302575,0.0006432835,0.000507874,0.00020441487,0.00048291674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032373173,0.0005117437,0.002792725,0.0008339472,0.000095866795,0.000064334956,0.00015789988,0.00030639465,0.000064398126],"category_scores_gemma":[0.00056104583,0.00029982705,0.0002861435,0.0010462863,0.0001715102,0.00020294293,0.000038296534,0.0005301858,0.000021880085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6855879,0.0257306,0.2229427,0.00011790641,0.001912387,0.00104569,0.00064277527,0.000020374493,0.021242574,5.757085e-7,0.00003573115,0.040720783],"study_design_scores_gemma":[0.81577605,0.006279712,0.14667022,0.0006154801,0.0033013287,0.000005474685,0.000094853705,0.005960736,0.02087994,0.0000049038454,0.000024735149,0.00038656633],"about_ca_topic_score_codex":0.001797916,"about_ca_topic_score_gemma":0.002268832,"teacher_disagreement_score":0.13018815,"about_ca_system_score_codex":0.00012173927,"about_ca_system_score_gemma":0.00022973705,"threshold_uncertainty_score":0.9999454},"labels":[],"label_agreement":null},{"id":"W2558240189","doi":"10.1182/blood.v108.11.5102.5102","title":"Quantitative Detection Using SYBR Green of Residual Disease in Myeloma Patients Treated with Revlimid or Velcade.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Minimal residual disease; clone (Java method); Multiple myeloma; TaqMan; Lenalidomide; Melting curve analysis; Gene rearrangement; Biology; Medicine; Polymerase chain reaction; Cancer research; Immunology; Gene; Leukemia; Genetics","score_opus":0.03352409807380212,"score_gpt":0.30068276354716295,"score_spread":0.2671586654733608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558240189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990239,0.000119622164,0.000026639207,0.000022015194,0.0000075851112,0.0006028073,0.000052981784,0.00002356038,0.00012089801],"genre_scores_gemma":[0.99895394,0.000009202776,0.0007002834,0.0000068171325,0.00002990453,0.000025935607,0.00009715013,0.000021943522,0.00015481179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889153,0.000075671975,0.00023167784,0.00022643604,0.00032958822,0.00024509098],"domain_scores_gemma":[0.99940735,0.00006144925,0.000089181456,0.00017056604,0.00014105829,0.00013041242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005979619,0.00013531663,0.00023786977,0.00022048972,0.000044562512,0.0000067249466,0.000039980696,0.00004614448,0.000017108596],"category_scores_gemma":[0.0001150574,0.00009065329,0.000035332243,0.00037679393,0.00006833075,0.00008346903,0.000019036015,0.000092191265,0.000004063233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073523507,0.00212112,0.98512197,0.00012797411,0.00011818421,0.00047960458,0.0000432489,0.000027661305,0.0037325048,0.0000065704066,0.000002346539,0.000866487],"study_design_scores_gemma":[0.012631107,0.0018949851,0.9579848,0.0002444272,0.0002308998,0.000008939481,0.000030256168,0.0010510708,0.025820393,0.000008911104,0.0000037808709,0.0000904078],"about_ca_topic_score_codex":0.0044672517,"about_ca_topic_score_gemma":0.00093348685,"teacher_disagreement_score":0.027137125,"about_ca_system_score_codex":0.00006710941,"about_ca_system_score_gemma":0.00010163737,"threshold_uncertainty_score":0.67531776},"labels":[],"label_agreement":null},{"id":"W2558398014","doi":"10.1182/blood.v118.21.5136.5136","title":"CYBOR-D Induction Therapy In Clinical Practice","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Internal medicine; Bortezomib; Surgery; Maintenance therapy; Clinical trial; Cyclophosphamide; Multiple myeloma; Chemotherapy","score_opus":0.16078938800462997,"score_gpt":0.42137277113476673,"score_spread":0.26058338313013674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558398014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725773,0.00028648772,0.0000050609456,0.00027899575,0.0000713263,0.00029065917,9.695426e-7,0.000026198964,0.026463013],"genre_scores_gemma":[0.99442625,0.0006462753,0.0043005426,0.00022449403,0.00014190727,0.000025350762,0.000006882511,0.000009727287,0.00021854824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921983,0.000099005854,0.00019390302,0.00015852792,0.00016743649,0.00016126572],"domain_scores_gemma":[0.99950254,0.00008502241,0.00004014545,0.00019451299,0.00006314811,0.000114616574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035519307,0.000060618728,0.0001271504,0.000064323875,0.00001835948,0.0000045351953,0.000038342292,0.00007286533,0.00018028263],"category_scores_gemma":[0.00058845425,0.00004489666,0.000037403028,0.00011802746,0.000032997697,0.00009791757,0.00001370074,0.00020744088,0.00016420898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013227919,0.008650642,0.81211865,0.000007948136,0.0002511682,0.0008556125,0.00038288123,1.1177366e-8,0.00080460875,0.000118622855,0.000157644,0.17532942],"study_design_scores_gemma":[0.009411072,0.0014362971,0.98105735,0.000016717528,0.000035298915,0.0001140072,0.00009406359,0.000003049271,0.004250484,0.00006753964,0.0034698253,0.00004430074],"about_ca_topic_score_codex":0.0003057493,"about_ca_topic_score_gemma":0.00001776114,"teacher_disagreement_score":0.17528512,"about_ca_system_score_codex":0.000012518676,"about_ca_system_score_gemma":0.00007350745,"threshold_uncertainty_score":0.2110629},"labels":[],"label_agreement":null},{"id":"W2558638322","doi":"10.1182/blood.v120.21.1867.1867","title":"Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Cyclophosphamide; Melphalan; Prednisone; Surgery; Oncology; Gastroenterology; Chemotherapy","score_opus":0.016737049798718855,"score_gpt":0.25496423057625867,"score_spread":0.23822718077753982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558638322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793273,0.00033383563,0.000017635643,0.00003814472,0.00019551624,0.0008922135,0.00008159341,0.00010899113,0.00039934542],"genre_scores_gemma":[0.99786365,0.000036792568,0.00095125154,0.00011698425,0.00009515175,0.00020413433,0.00013401567,0.00007767388,0.00052036566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969628,0.00014302757,0.0005662966,0.00059374486,0.0005908785,0.0011432801],"domain_scores_gemma":[0.998008,0.00048351055,0.00016221152,0.0005194129,0.00010397043,0.0007228834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015583295,0.00042643354,0.00058169116,0.00040609163,0.00018135966,0.000042789747,0.00014907055,0.00019218471,0.00026771342],"category_scores_gemma":[0.0008259723,0.00034479232,0.000110493485,0.00034471732,0.00019704679,0.0003597681,0.00013822428,0.0004718575,0.00009574204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034390707,0.004902273,0.96777976,0.0003538042,0.00029595298,0.0018487602,0.00094582245,0.0000039930005,0.019200563,0.0000029131236,0.000040009378,0.0011870929],"study_design_scores_gemma":[0.048985552,0.0015510531,0.928808,0.00070762436,0.000182841,0.0006835852,0.00016147886,0.00015151342,0.018105889,0.0000018041594,0.00028190066,0.00037877558],"about_ca_topic_score_codex":0.000069258684,"about_ca_topic_score_gemma":0.00005706296,"teacher_disagreement_score":0.04554648,"about_ca_system_score_codex":0.0005640401,"about_ca_system_score_gemma":0.00025686252,"threshold_uncertainty_score":0.9999004},"labels":[],"label_agreement":null},{"id":"W2558778524","doi":"10.1182/blood.v108.11.3432.3432","title":"Accumulation of Inherited and Acquired Mutations in Hyaluronan Synthase1 Gene May Contribute Oncogenesis in Multiple Myeloma and Waldenstrom’s Macroglobulinemia.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Intron; Biology; Macroglobulinemia; Exon; RNA splicing; Waldenstrom macroglobulinemia; Molecular biology; Bone marrow; Cancer research; Haematopoiesis; Gene; Germline; Mutation; Multiple myeloma; Stem cell; Genetics; Immunology; Lymphoma; RNA","score_opus":0.0381868998615135,"score_gpt":0.31499227700920823,"score_spread":0.2768053771476947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558778524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779373,0.0010260404,0.000028942044,0.00021744783,0.00001102668,0.0006765173,0.00016599354,0.000020746638,0.00005957218],"genre_scores_gemma":[0.9966654,0.00006260001,0.0027172472,0.00001718523,0.000031221694,0.000057144774,0.0003705822,0.000017109694,0.000061467035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879724,0.00007354288,0.0003733543,0.00027017583,0.00020780205,0.0002778968],"domain_scores_gemma":[0.9993817,0.00019433243,0.000078933495,0.0001567188,0.00007850906,0.00010978243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014078272,0.00014570939,0.00032963904,0.0002561421,0.000041743384,0.0000142581575,0.00003677994,0.00010149811,0.000014939465],"category_scores_gemma":[0.00020997188,0.0001367604,0.000033121054,0.0002869775,0.0000989074,0.00007458622,0.00004096899,0.00006314494,0.0000021982114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031107702,0.00081371324,0.87898684,0.00006943724,0.000054206503,0.00031733612,0.00007220406,0.00003100552,0.11081523,0.000010545364,0.000005390175,0.00851302],"study_design_scores_gemma":[0.017406093,0.00023274311,0.92907196,0.000098683304,0.000078892066,0.00007536967,0.000047289566,0.0029717044,0.049861737,0.000032828026,0.000028135953,0.000094577044],"about_ca_topic_score_codex":0.0020138305,"about_ca_topic_score_gemma":0.0015659188,"teacher_disagreement_score":0.06095349,"about_ca_system_score_codex":0.000050243703,"about_ca_system_score_gemma":0.00006471274,"threshold_uncertainty_score":0.5576927},"labels":[],"label_agreement":null},{"id":"W2558924416","doi":"10.1182/blood.v114.22.1853.1853","title":"Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Bortezomib; Internal medicine; Multiple myeloma; Dexamethasone; Gastroenterology; Refractory (planetary science); Neutropenia; Autologous stem-cell transplantation; Salvage therapy; Transplantation; Thalidomide; Surgery; Oncology; Chemotherapy","score_opus":0.09113696582219274,"score_gpt":0.31763674621006927,"score_spread":0.22649978038787652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558924416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979025,0.00068785826,0.00011075433,0.00016066858,0.00003832968,0.000845279,0.00005308089,0.000049583723,0.00015196203],"genre_scores_gemma":[0.990861,0.000113586575,0.008092733,0.0005782084,0.000058107416,0.00006760023,0.000052047722,0.000036470043,0.00014025376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997933,0.00010323789,0.00047987862,0.00041833273,0.00053129724,0.00053428323],"domain_scores_gemma":[0.99856985,0.00033645408,0.00013461805,0.00055776513,0.00013221461,0.00026913043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027119133,0.0002715301,0.00050487363,0.00035851318,0.00004008203,0.000022231001,0.00011685217,0.0001624471,0.000111220885],"category_scores_gemma":[0.0005442737,0.00022348911,0.00018764977,0.00034124375,0.0000759052,0.00014876436,0.000021880396,0.0003139629,0.000020868247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042348993,0.0065247733,0.76886165,0.00006120285,0.0002522509,0.0011368465,0.00026911945,0.00006317531,0.20676306,0.0000047592716,0.00005255205,0.011775717],"study_design_scores_gemma":[0.040386125,0.00095683214,0.8456944,0.00027202236,0.00007165853,0.000026260159,0.000027113423,0.0010609956,0.11095788,0.000010737075,0.00035310263,0.00018287233],"about_ca_topic_score_codex":0.000585552,"about_ca_topic_score_gemma":0.00012648125,"teacher_disagreement_score":0.095805176,"about_ca_system_score_codex":0.00017835268,"about_ca_system_score_gemma":0.00032422613,"threshold_uncertainty_score":0.9113622},"labels":[],"label_agreement":null},{"id":"W2559190882","doi":"10.1182/blood.v112.11.1671.1671","title":"Validation of a Novel Tissue Array Based Classification of Multiple Myeloma (MM).","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Cohort; Medicine; Multiple myeloma; Oncology; Internal medicine; Immunohistochemistry; Pathology; Tissue microarray; Immunoperoxidase; Immunology; Antibody; Monoclonal antibody","score_opus":0.06481948848454816,"score_gpt":0.3147652170580641,"score_spread":0.24994572857351594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559190882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950196,0.00006179994,0.002957533,0.000120657285,0.000020269536,0.0004521574,0.00004951533,0.000024080224,0.0012943844],"genre_scores_gemma":[0.9879322,0.000013022348,0.011584343,0.000011083017,0.000037564412,0.00003386854,0.00018121167,0.000013901385,0.00019277728],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990296,0.000028925544,0.00026375786,0.00016647387,0.0003625156,0.00014873191],"domain_scores_gemma":[0.9991517,0.00010615093,0.00013031243,0.00030636947,0.00020473675,0.00010070227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094498464,0.00009011253,0.00022319802,0.00013186845,0.00003881433,0.000002030789,0.00006106749,0.00006366159,0.000076366276],"category_scores_gemma":[0.0003066838,0.00007733983,0.00006279401,0.0001979774,0.000083983214,0.00004701406,0.000008863106,0.00006212279,0.000016578058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016971995,0.0026163678,0.2151196,0.00009958551,0.00007965093,0.000012095821,0.000097831784,0.0000044847166,0.7804542,0.000015981803,0.000031316642,0.0012991257],"study_design_scores_gemma":[0.006932636,0.00027850043,0.37128863,0.000042094536,0.000052892447,0.000018909774,0.000015810909,0.00045685112,0.6207713,0.0000018652454,0.000103991435,0.000036550744],"about_ca_topic_score_codex":0.00010167284,"about_ca_topic_score_gemma":0.0000062258036,"teacher_disagreement_score":0.15968297,"about_ca_system_score_codex":0.000019713827,"about_ca_system_score_gemma":0.00014414471,"threshold_uncertainty_score":0.31538266},"labels":[],"label_agreement":null},{"id":"W2559408837","doi":"10.1182/blood.v114.22.2841.2841","title":"Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"RNA splicing; Intron; Biology; Exon; Mutation; Monoclonal gammopathy of undetermined significance; Genetics; Molecular biology; Gene; Monoclonal; Monoclonal antibody; RNA; Antibody","score_opus":0.01753480009453971,"score_gpt":0.2729657599082055,"score_spread":0.25543095981366576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559408837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887866,0.000054904856,0.00003282208,0.00007681128,0.0000047141675,0.00051723595,0.000046583613,0.000005598759,0.00038267171],"genre_scores_gemma":[0.99836904,0.0000039152064,0.0014698352,0.000031796535,0.000012955743,0.000021103533,0.00006750524,0.000006141804,0.000017679467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915326,0.00004127527,0.00019740932,0.0001255623,0.0003240853,0.00015841181],"domain_scores_gemma":[0.9994843,0.00009087512,0.00007696027,0.00021201385,0.000079524514,0.000056326877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008736677,0.000082192426,0.00017958148,0.00009383204,0.000023916058,0.0000034755096,0.00007352927,0.000023072726,0.000015693231],"category_scores_gemma":[0.00006418546,0.000049475762,0.00003806391,0.00019549114,0.000053416738,0.000031437423,0.0000068337217,0.000068677735,0.0000016897171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008766553,0.0065793586,0.95664793,0.000066213106,0.00011802924,0.00019222044,0.0007089461,0.000024470826,0.013936247,0.00005888359,0.0000051567613,0.0207859],"study_design_scores_gemma":[0.007281925,0.002193706,0.9545044,0.00006993487,0.000103837265,0.0000074197956,0.00007924802,0.00009223464,0.035574477,0.000045418044,0.0000030104768,0.00004443516],"about_ca_topic_score_codex":0.00009826582,"about_ca_topic_score_gemma":0.000028013063,"teacher_disagreement_score":0.021638231,"about_ca_system_score_codex":0.0000148295385,"about_ca_system_score_gemma":0.00008206447,"threshold_uncertainty_score":0.2017563},"labels":[],"label_agreement":null},{"id":"W2559444424","doi":"10.1182/blood.v106.11.5192.5192","title":"The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Zoledronic acid; Pharmacokinetics; Multiple myeloma; Cmax; Renal function; Pharmacodynamics; Regimen; Urology; Surgery; Internal medicine","score_opus":0.005260010415583243,"score_gpt":0.24511728963827012,"score_spread":0.23985727922268688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559444424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980906,0.00077141763,0.0000076260517,0.00009200304,0.000037507394,0.00090244546,0.000011047058,0.000016670256,0.00007065599],"genre_scores_gemma":[0.9986518,0.0009614665,0.0001296012,0.000068178066,0.000046931524,0.000039284434,0.000035616184,0.000018984061,0.00004816325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989934,0.000083101964,0.00018203232,0.00021288078,0.000269297,0.00025926574],"domain_scores_gemma":[0.9993323,0.00023471592,0.00007401,0.00015289363,0.000064457614,0.00014161035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013329634,0.00015745361,0.000182497,0.00010325865,0.000091687856,0.00001528078,0.000042767322,0.00004594141,0.000004812143],"category_scores_gemma":[0.00009426407,0.00009552864,0.000022225293,0.00013509784,0.00008972289,0.00007020234,0.000049950464,0.00019284111,0.0000035940257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009589215,0.002395565,0.7686944,0.0002566215,0.0003449406,0.000045857516,0.00016594335,0.000029838735,0.07519441,0.000008741751,0.00003237518,0.14324209],"study_design_scores_gemma":[0.050321043,0.002508185,0.8921443,0.00017589859,0.00020961171,0.0000049153123,0.0000073795795,0.0029119658,0.051393524,0.000004647358,0.00022958191,0.00008894947],"about_ca_topic_score_codex":0.000016154854,"about_ca_topic_score_gemma":0.00006685888,"teacher_disagreement_score":0.14315313,"about_ca_system_score_codex":0.000035601137,"about_ca_system_score_gemma":0.00003512854,"threshold_uncertainty_score":0.38955447},"labels":[],"label_agreement":null},{"id":"W2559507418","doi":"10.1182/blood.v110.11.2740.2740","title":"Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Internal medicine; Population; Oncology; Gastroenterology; Proteasome inhibitor; Refractory (planetary science); Biology","score_opus":0.011713872575113204,"score_gpt":0.31308591590509854,"score_spread":0.30137204332998535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559507418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942328,0.00038771375,0.0000082541565,0.0002880078,0.000026822787,0.004569464,0.0002616764,0.00008538785,0.00013991422],"genre_scores_gemma":[0.9964802,0.000036004723,0.000932247,0.00008050352,0.00008403173,0.00046483925,0.00025080433,0.00007055883,0.0016007927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974231,0.0001707391,0.0005236001,0.0006296955,0.000556633,0.0006962224],"domain_scores_gemma":[0.9964817,0.0019264406,0.00015435272,0.0004999167,0.00011198369,0.0008256144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000826645,0.00036227968,0.000733922,0.00041229418,0.00009512157,0.000019760602,0.00012410326,0.00017036781,0.00014767375],"category_scores_gemma":[0.0022123007,0.00025481964,0.00012682652,0.000391291,0.00009174466,0.0000850071,0.00008713982,0.00022992064,0.00010795303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18021348,0.009076558,0.580992,0.0012455066,0.00047208712,0.0026710215,0.00022331093,0.000006577258,0.155081,0.0000035467315,0.0005246005,0.06949029],"study_design_scores_gemma":[0.053075045,0.02444215,0.5597183,0.0015150107,0.00038172377,0.0000135367545,0.00000985549,0.0009798663,0.35864824,0.0000020758998,0.0008848378,0.00032934351],"about_ca_topic_score_codex":0.00007289696,"about_ca_topic_score_gemma":0.000039037874,"teacher_disagreement_score":0.20356725,"about_ca_system_score_codex":0.000116191,"about_ca_system_score_gemma":0.00014091065,"threshold_uncertainty_score":0.9999904},"labels":[],"label_agreement":null},{"id":"W2559682469","doi":"10.1182/blood.v106.11.2556.2556","title":"A Phase I–II Trial of Bortezomib (Velcade) (Vc) and Oral Cyclophosphamide (CY) Plus Prednisone (P) for Relapsed/Refractory Multiple Myeloma (MM).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Thalidomide; Prednisone; Lenalidomide; Internal medicine; Gastroenterology; Regimen; Multiple myeloma; Melphalan; Cyclophosphamide; Refractory (planetary science); Surgery; Urology; Chemotherapy","score_opus":0.030952904249561767,"score_gpt":0.3238474744655238,"score_spread":0.29289457021596205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559682469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936693,0.0017885542,0.00011798733,0.00037993345,0.0001114965,0.0030092928,0.00027468774,0.000085346874,0.0005634219],"genre_scores_gemma":[0.9883374,0.00031734165,0.00823329,0.000082381994,0.00045300752,0.00035699195,0.00018321765,0.00005973165,0.0019766502],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99776787,0.00006055436,0.00058886345,0.00050340104,0.00047924975,0.00060006144],"domain_scores_gemma":[0.99839526,0.00031763897,0.00019818501,0.00046926347,0.0001560492,0.00046357454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031319456,0.00030496684,0.0007133485,0.00017681687,0.00018205494,0.000020047122,0.00013370188,0.0002116099,0.000079257174],"category_scores_gemma":[0.0008040105,0.0002585002,0.00021358495,0.00017048308,0.00016148797,0.00017603938,0.00010340748,0.00023790052,0.000014714648],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38428673,0.06974787,0.017549496,0.0008057249,0.003126948,0.00042989975,0.0019708322,0.000007792832,0.07683974,0.00014532465,0.0036554518,0.4414342],"study_design_scores_gemma":[0.8705214,0.023240983,0.010756362,0.00014882568,0.00074836344,0.000077139906,0.00009532504,0.0015652392,0.069432616,0.000044261244,0.023050006,0.00031945243],"about_ca_topic_score_codex":0.00013052663,"about_ca_topic_score_gemma":0.00009090391,"teacher_disagreement_score":0.4862347,"about_ca_system_score_codex":0.000094367635,"about_ca_system_score_gemma":0.00027370578,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W2559685064","doi":"10.1182/blood.v126.23.3034.3034","title":"Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Family medicine; Surgery","score_opus":0.26823362071252094,"score_gpt":0.44903554697545567,"score_spread":0.18080192626293473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559685064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711305,0.00005344478,0.000025676052,0.0005457752,0.00004384939,0.0012801591,0.00062106765,0.000011793976,0.00030516382],"genre_scores_gemma":[0.99026006,0.000010471108,0.004290079,0.00010431605,0.000080072445,0.00010102979,0.004979878,0.000018187988,0.00015587873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962516,0.0005030746,0.000981371,0.0006048886,0.001392635,0.00026642065],"domain_scores_gemma":[0.99535567,0.0024017117,0.0003751711,0.0009713923,0.0007139584,0.00018211213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017477621,0.00019308573,0.00057539105,0.00038075633,0.000049278093,0.00002847817,0.00045841173,0.00005566837,0.00010434847],"category_scores_gemma":[0.0048287204,0.00013047231,0.000117134936,0.0014594722,0.000100156074,0.00037849465,0.00031057443,0.00034168555,0.00002266104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029337173,0.034662396,0.95748585,0.000010107154,0.002945578,0.00014877503,0.00028274665,0.00008137417,0.000002319042,0.0000077689165,0.00044303125,0.0009963289],"study_design_scores_gemma":[0.037497595,0.0012362648,0.9492679,0.000098332275,0.001460833,0.0000012908497,0.0006138275,0.009495642,0.000007811325,0.000007986945,0.00020337566,0.00010908776],"about_ca_topic_score_codex":0.009430491,"about_ca_topic_score_gemma":0.040908396,"teacher_disagreement_score":0.03456388,"about_ca_system_score_codex":0.00010909927,"about_ca_system_score_gemma":0.00042408652,"threshold_uncertainty_score":0.9971658},"labels":[],"label_agreement":null},{"id":"W2560165448","doi":"10.1515/cclm-2016-1026","title":"Response to: Interference of daratumumab on the serum protein electrophoresis","year":2016,"lang":"en","type":"letter","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Daratumumab; Serum protein electrophoresis; Interference (communication); Electrophoresis; Gel electrophoresis of proteins; Chemistry; Chromatography; Computer science; Polyacrylamide gel electrophoresis; Medicine; Antibody; Biochemistry; Immunology; Monoclonal; Telecommunications; Monoclonal antibody","score_opus":0.049188185415225315,"score_gpt":0.3653151596814524,"score_spread":0.3161269742662271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560165448","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35755172,0.00054770405,0.000006347725,0.6387428,0.00011763131,0.00089499616,0.00029748637,0.000037385034,0.0018039385],"genre_scores_gemma":[0.5977977,0.000655926,0.00009113231,0.36677098,0.0077964542,0.0003779719,0.00016462662,0.00014188218,0.026203346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960375,0.00068362075,0.0009908215,0.00085948367,0.00080823863,0.000620358],"domain_scores_gemma":[0.9942123,0.0031113725,0.0003459059,0.0013063439,0.0005070017,0.0005170579],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019392897,0.00050515094,0.0011926488,0.000071457325,0.00011694971,0.000014338616,0.00043255076,0.00091085414,0.0012508462],"category_scores_gemma":[0.010498238,0.00025438168,0.00016503702,0.0003555653,0.0011303724,0.000027032915,0.00015049904,0.0027112316,0.00007320838],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011270416,0.00015791247,0.00091914606,0.0007835591,0.0004488246,0.0013186777,0.000051608902,1.0973209e-8,0.07854598,0.0000064234905,0.9030425,0.0034549292],"study_design_scores_gemma":[0.00511784,0.0048729377,0.0035206531,0.005741951,0.00023842328,0.00003170527,0.000059720576,0.0000028683596,0.0969538,0.00008066141,0.88301086,0.000368594],"about_ca_topic_score_codex":0.0000071423883,"about_ca_topic_score_gemma":8.264579e-7,"teacher_disagreement_score":0.27197182,"about_ca_system_score_codex":0.00011141513,"about_ca_system_score_gemma":0.00068652607,"threshold_uncertainty_score":0.9999908},"labels":[],"label_agreement":null},{"id":"W2560219832","doi":"10.1182/blood.v118.21.3983.3983","title":"Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Multiple myeloma; Internal medicine; Bortezomib; Disease; Oncology; Surgery; Gastroenterology","score_opus":0.02790396314340708,"score_gpt":0.23915716930922393,"score_spread":0.21125320616581683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560219832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717516,0.0002926174,0.000100966,0.00022799429,0.000071685725,0.0013671188,0.00006515413,0.00012099047,0.00057830935],"genre_scores_gemma":[0.9978512,0.0000831706,0.0011791703,0.00020083932,0.00013339763,0.000121230405,0.00016780726,0.000078196375,0.00018497182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767905,0.00010941547,0.00033087243,0.0005373437,0.0006136178,0.00072972034],"domain_scores_gemma":[0.99857324,0.000041880896,0.0001379817,0.00054428814,0.00012923032,0.0005734042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018089857,0.00038692728,0.00048576845,0.00012080005,0.00019070176,0.000050387953,0.00015820903,0.000112123766,0.00006674361],"category_scores_gemma":[0.00001913686,0.00026792742,0.00006726849,0.00017218225,0.00018809167,0.00011764877,0.00005444324,0.00022060718,0.000006577216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030508866,0.0019827073,0.9809693,0.0002920156,0.0018919425,0.0009389695,0.0038534142,0.0000024845215,0.0014217913,0.000051382034,0.00009782469,0.0054472974],"study_design_scores_gemma":[0.02540991,0.0021253377,0.95812756,0.000216884,0.00032193706,0.00024983345,0.0011441092,0.00038044833,0.011555497,0.0000018839743,0.00016593999,0.00030068046],"about_ca_topic_score_codex":0.0017724696,"about_ca_topic_score_gemma":0.0010886954,"teacher_disagreement_score":0.022841746,"about_ca_system_score_codex":0.00018792253,"about_ca_system_score_gemma":0.0002706651,"threshold_uncertainty_score":0.9999773},"labels":[],"label_agreement":null},{"id":"W2560581580","doi":"10.1182/blood.v112.11.1176.1176","title":"Graft-Versus-Host Disease (Gvhd) Prophylaxis with Tacrolimus and Mycophenolate Mofetil (MMF) in 131 Matched Sibling Nonmyeloablative (NMA) Transplant Recipients: Long-Term Follow-up Confirms Extremely Low Incidence of Acute (a) Gvhd, High Incidence of Extensive Chronic (c) Gvhd and Favorable Disease Outcome.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Mucositis; Tacrolimus; Internal medicine; Fludarabine; Gastroenterology; Regimen; Transplantation; Methotrexate; Surgery; Toxicity; Graft-versus-host disease; Cyclophosphamide; Chemotherapy","score_opus":0.02607188366044243,"score_gpt":0.2812328357312887,"score_spread":0.25516095207084627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560581580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936934,0.0032120217,0.00012764965,0.00010874278,0.000108695356,0.0021198066,0.0005528682,0.00004346017,0.000033320965],"genre_scores_gemma":[0.99615467,0.002507218,0.00073329575,0.000034564237,0.00003563366,0.00016295936,0.00013658073,0.00006759361,0.00016751072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621624,0.00015937135,0.0008199141,0.0009575784,0.0010323176,0.0008145943],"domain_scores_gemma":[0.9970431,0.00033880392,0.0004194549,0.0006930913,0.00050392986,0.0010016371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023883056,0.0005733782,0.0011323759,0.0004653203,0.00019573134,0.000033336084,0.00024678552,0.0001297077,0.00012747492],"category_scores_gemma":[0.00032581418,0.0004520247,0.00016711582,0.0007188219,0.00078304094,0.0004848207,0.00015674082,0.0004137015,0.000006842926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019193111,0.0012863053,0.95851004,0.0011456815,0.0010094322,0.011132136,0.0012877099,0.00002056212,0.0044488497,0.000010039908,0.0000014718385,0.0019546559],"study_design_scores_gemma":[0.037723683,0.0025105667,0.95133734,0.0009856562,0.0011182608,0.00011337818,0.00010430296,0.00024534308,0.0054193297,0.000041165375,4.5120947e-7,0.00040053076],"about_ca_topic_score_codex":0.0007723518,"about_ca_topic_score_gemma":0.00038755478,"teacher_disagreement_score":0.018530574,"about_ca_system_score_codex":0.0001874537,"about_ca_system_score_gemma":0.0008076504,"threshold_uncertainty_score":0.9997932},"labels":[],"label_agreement":null},{"id":"W2560706611","doi":"10.1182/blood.v108.11.3547.3547","title":"Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Placebo; Refractory (planetary science); Multiple myeloma; Internal medicine; Randomization; Phases of clinical research; Gastroenterology; Corticosteroid; Urology; Toxicity; Randomized controlled trial; Pathology; Biology","score_opus":0.03302685785422914,"score_gpt":0.2975950705888775,"score_spread":0.26456821273464837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560706611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99067134,0.0008584455,0.0009408503,0.00013650184,0.00012252401,0.004516853,0.0026347956,0.000108630324,0.000010060893],"genre_scores_gemma":[0.9738928,0.000084108164,0.0218782,0.00004235466,0.00014947604,0.00050079415,0.002859236,0.00009824446,0.0004947628],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9945679,0.00037456106,0.001702727,0.0012227593,0.0011906365,0.00094145734],"domain_scores_gemma":[0.9935203,0.0023280447,0.0010314081,0.0010597243,0.0014978402,0.000562687],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009773895,0.0007384452,0.0027995745,0.0010276483,0.00025731573,0.00004517006,0.00024042244,0.0002281754,0.00003071394],"category_scores_gemma":[0.0022381374,0.00052598154,0.00037404904,0.001435242,0.00041428406,0.00031424357,0.0001880819,0.00029669647,0.0000020271334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6358464,0.026892902,0.13767523,0.0012154353,0.034376115,0.00021776395,0.0012686658,0.00058496714,0.15188956,0.000028189146,0.000850074,0.009154744],"study_design_scores_gemma":[0.34400296,0.016627368,0.5963699,0.00034837594,0.009679467,0.000005889667,0.00038390924,0.0025095677,0.029351939,0.000030123436,0.00011261465,0.00057783275],"about_ca_topic_score_codex":0.00941641,"about_ca_topic_score_gemma":0.007966228,"teacher_disagreement_score":0.45869473,"about_ca_system_score_codex":0.00029700197,"about_ca_system_score_gemma":0.00038602395,"threshold_uncertainty_score":0.9997192},"labels":[],"label_agreement":null},{"id":"W2560711903","doi":"10.1182/blood.v104.11.4917.4917","title":"Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Prednisone; Cyclophosphamide; Multiple myeloma; Regimen; Surgery; Internal medicine; Transplantation; Autologous stem-cell transplantation; Gastroenterology; Chemotherapy","score_opus":0.012781175069763851,"score_gpt":0.26063540561940984,"score_spread":0.247854230549646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560711903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938068,0.0018719,0.00021408031,0.00012163221,0.000115275856,0.003338465,0.00015325125,0.00014027463,0.000238371],"genre_scores_gemma":[0.9967796,0.00033943346,0.0014593006,0.000047055488,0.000048052203,0.00051566435,0.00023762418,0.000055127297,0.0005181051],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814713,0.000090288544,0.00029774665,0.0006595395,0.00023629484,0.0005689803],"domain_scores_gemma":[0.9988191,0.00023906448,0.00007677602,0.00030055802,0.000053302327,0.00051120203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015828815,0.0003669602,0.0005603762,0.00011025316,0.00022939492,0.000053856715,0.00007034657,0.00014672587,0.00000698486],"category_scores_gemma":[0.000015684074,0.00028815732,0.00012761442,0.0000962165,0.00007400551,0.00012841956,0.000023474468,0.0001200969,0.000010169288],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0095361415,0.011801947,0.699117,0.00088444806,0.0037635893,0.007253517,0.008664622,0.00011263255,0.17586444,0.000063202424,0.000030001007,0.082908474],"study_design_scores_gemma":[0.1642825,0.014115005,0.2986678,0.0003739454,0.001569569,0.0005142481,0.0003178927,0.0020125746,0.5169015,0.00007482592,0.0006223584,0.0005477895],"about_ca_topic_score_codex":0.0004394989,"about_ca_topic_score_gemma":0.00011742011,"teacher_disagreement_score":0.4004492,"about_ca_system_score_codex":0.00012761533,"about_ca_system_score_gemma":0.00009080691,"threshold_uncertainty_score":0.9999571},"labels":[],"label_agreement":null},{"id":"W2561245808","doi":"10.1182/blood.v112.11.3667.3667","title":"Pre-Clinical Evaluation of a Small Molecule Inhibitor of CDK1 as Potential Therapy for MYC Expressing Mutiple Myeloma Tumors","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyclin-dependent kinase 6; Multiple myeloma; Cancer research; Cell cycle; Cyclin-dependent kinase 1; Cyclin-dependent kinase; Biology; Cyclin; Cell growth; Cell culture; Viability assay; Cancer; Immunology; Genetics","score_opus":0.08537788657400636,"score_gpt":0.3780388125341908,"score_spread":0.29266092596018445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561245808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674064,0.0008849379,0.00020202094,0.000051148254,0.00005598912,0.0015698068,0.000028245477,0.000020406673,0.00044678108],"genre_scores_gemma":[0.9955891,0.000087985,0.0037132595,0.000026390022,0.00019041574,0.00013817583,0.00007346713,0.000025588419,0.00015563697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981264,0.00016805486,0.00050275156,0.00027020994,0.00068309,0.00024953272],"domain_scores_gemma":[0.99870867,0.00013633061,0.00019769139,0.00031105572,0.0004922763,0.00015399452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059055054,0.00013256834,0.00038117103,0.00010063361,0.00006884578,0.0000051764123,0.00008871428,0.000098657496,0.00009288629],"category_scores_gemma":[0.0006976026,0.00010746274,0.00023226389,0.00010898801,0.00013927567,0.000045830373,0.000033818244,0.00009949853,0.000005658359],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009249434,0.015403836,0.18340634,0.0003620002,0.0017224634,0.00024383707,0.0014947864,0.000034490105,0.7024255,0.000020140547,0.00039647584,0.085240714],"study_design_scores_gemma":[0.036515176,0.0031184244,0.28366393,0.0001733909,0.0003175438,0.00010187728,0.00006265464,0.003141216,0.6726714,0.00009287198,0.000034981862,0.00010656459],"about_ca_topic_score_codex":0.000097893935,"about_ca_topic_score_gemma":0.0000048440734,"teacher_disagreement_score":0.10025758,"about_ca_system_score_codex":0.000020158124,"about_ca_system_score_gemma":0.0004935226,"threshold_uncertainty_score":0.43822035},"labels":[],"label_agreement":null},{"id":"W2562339195","doi":"10.3747/co.23.3288","title":"Treatment and Outcomes for Primary Cutaneous Extramedullary Plasmacytoma: A Case Series","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Multiple myeloma; Retrospective cohort study; Radiation therapy; Plasmacytoma; Surgery; Internal medicine; Disease; Confidence interval","score_opus":0.09363002803951026,"score_gpt":0.4171486328718106,"score_spread":0.3235186048323003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562339195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923311,0.001418265,0.000121335695,0.0036922432,0.00035784385,0.0012917839,0.00018277761,0.0000683227,0.00053635496],"genre_scores_gemma":[0.99319404,0.0016877353,0.0018859952,0.000060947033,0.00015851777,0.0005875624,0.000058906466,0.000026720145,0.0023395736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891853,0.000052044208,0.00020645751,0.00032672012,0.00009840759,0.00039784118],"domain_scores_gemma":[0.99872315,0.0006230714,0.00005395495,0.0002118912,0.000073941024,0.0003140031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050021285,0.00019966355,0.00046213163,0.000096040945,0.00010567108,0.0000093663275,0.000036312347,0.000092102884,0.0000609968],"category_scores_gemma":[0.00017370904,0.000106299914,0.00010540924,0.000039396873,0.00018529629,0.00006304206,0.000045945144,0.00006063932,0.0000299674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018663998,0.0010825016,0.21872336,0.0001338958,0.00024968284,0.01056812,0.0001415693,2.0763132e-8,0.00068649545,0.00012865638,0.0004794461,0.76593983],"study_design_scores_gemma":[0.050180238,0.02243185,0.050773866,0.00016579984,0.00072669436,0.26048636,0.00028586495,0.00007473327,0.0021758382,0.0006065358,0.6116099,0.00048235277],"about_ca_topic_score_codex":0.000013781099,"about_ca_topic_score_gemma":0.00007539006,"teacher_disagreement_score":0.7654575,"about_ca_system_score_codex":0.00054707786,"about_ca_system_score_gemma":0.00026909736,"threshold_uncertainty_score":0.43347847},"labels":[],"label_agreement":null},{"id":"W2562916116","doi":"10.1182/blood.v126.23.5361.5361","title":"Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Thalidomide; Lenalidomide; Multiple myeloma; Internal medicine; Bortezomib; Plasma cell leukemia; Oncology; Progression-free survival; Cancer; Surgery; Gastroenterology; Overall survival","score_opus":0.04444903979363133,"score_gpt":0.28795949045913716,"score_spread":0.24351045066550583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562916116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99905854,0.00018159559,0.000018899394,0.00004426912,0.000007774235,0.00060419214,0.000042208667,0.000013907689,0.000028626935],"genre_scores_gemma":[0.99897426,0.000009596201,0.00078362005,0.00001693817,0.000006982983,0.00004132533,0.000116561416,0.000012364619,0.000038364902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991252,0.00003308992,0.00014706353,0.00021475587,0.0003031684,0.00017671326],"domain_scores_gemma":[0.99946785,0.000037774873,0.00006345949,0.00011674219,0.00011386192,0.0002003124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049878698,0.000113197246,0.00017377004,0.000085395,0.000025427293,0.000010118528,0.00002824508,0.000043021377,0.000012245733],"category_scores_gemma":[0.00006777245,0.0000758634,0.000017507837,0.000091649825,0.000069224814,0.00005828403,0.000022502914,0.00005457606,6.4328174e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015547789,0.0049465573,0.9839604,0.00004461097,0.00004808194,0.00006773679,0.00050929876,3.0477077e-7,0.0048891935,0.0000017057906,0.0000028343165,0.0039744964],"study_design_scores_gemma":[0.05099002,0.0016630406,0.9176312,0.00033244753,0.000021846847,0.000009457902,0.00021267985,0.00025656048,0.028778868,0.0000010607082,0.00003121327,0.00007157759],"about_ca_topic_score_codex":0.000143827,"about_ca_topic_score_gemma":0.00007550076,"teacher_disagreement_score":0.066329174,"about_ca_system_score_codex":0.00002381214,"about_ca_system_score_gemma":0.000050482973,"threshold_uncertainty_score":0.30936196},"labels":[],"label_agreement":null},{"id":"W2563435628","doi":"10.1093/ajcp/138.suppl2.107","title":"Plasma Cell Enrichment in the Detection of Genetic Abnormalities in Plasma Cell Myeloma by Fluorescence In Situ Hybridization: A Single-Center Experience","year":2012,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fluorescence in situ hybridization; Plasma Cell Myeloma; Plasma cell; Multiple myeloma; In situ; In situ hybridization; Cell; Fluorescence; Pathology; Molecular biology; Biology; Medicine; Chemistry; Genetics; Immunology; Gene; Chromosome; Gene expression; Physics","score_opus":0.03782819384057896,"score_gpt":0.3432060913923016,"score_spread":0.3053778975517227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563435628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855775,0.00029721207,0.00016797661,0.0002206779,0.00016513717,0.00025782865,0.0000042446463,0.0000026988941,0.00032646756],"genre_scores_gemma":[0.99776524,0.00043859408,0.0014725479,0.00017039188,0.00009965388,0.000020917178,0.000003062193,0.000010934107,0.000018675471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965935,0.0010021942,0.001398678,0.00018392004,0.00039054986,0.00043116635],"domain_scores_gemma":[0.99795455,0.00090842316,0.0006587567,0.00020455621,0.0000893989,0.00018429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011724202,0.00014401946,0.0006348814,0.0002442753,0.000020865216,0.0000071299914,0.00020195663,0.00007478443,0.00001907761],"category_scores_gemma":[0.0005349759,0.000100705496,0.00011913159,0.00038889042,0.0005071509,0.0001237969,0.000046678924,0.00052100356,0.000006760366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00142398,0.0028967948,0.90450746,0.000025676281,0.0000103825305,0.00067191786,0.0035598802,0.0000129739,0.040935274,8.5349944e-7,0.000023279767,0.04593154],"study_design_scores_gemma":[0.0068019307,0.00521108,0.941155,0.000091419904,0.000021061798,0.0008657919,0.004728075,0.00014758766,0.040455133,0.0000063314014,0.00040624302,0.00011032688],"about_ca_topic_score_codex":0.00006549358,"about_ca_topic_score_gemma":0.000060475882,"teacher_disagreement_score":0.045821216,"about_ca_system_score_codex":0.000120014214,"about_ca_system_score_gemma":0.000116844916,"threshold_uncertainty_score":0.4106651},"labels":[],"label_agreement":null},{"id":"W2563483539","doi":"10.1182/blood.v106.11.2547.2547","title":"Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Adverse effect; Progressive disease; Surgery; Refractory (planetary science); Gastroenterology; Clinical trial; Chemotherapy","score_opus":0.019943816147831583,"score_gpt":0.2671768286086359,"score_spread":0.2472330124608043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563483539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965301,0.00036128133,0.000003282886,0.0008604217,0.000027332708,0.0013897205,0.00015113788,0.00006943991,0.00060726586],"genre_scores_gemma":[0.9932727,0.000026659114,0.005933798,0.000045497185,0.00006413144,0.00005476091,0.0001791046,0.000037749644,0.00038558347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977752,0.00019230433,0.0005950849,0.00042429662,0.00049487466,0.0005182153],"domain_scores_gemma":[0.9984235,0.0003986137,0.00016657168,0.00063640124,0.0001591205,0.0002157762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028083782,0.000277974,0.0006308291,0.00015383943,0.000088737965,0.00002333823,0.0002344334,0.0001234032,0.000052560674],"category_scores_gemma":[0.0005282952,0.00017060841,0.00011436406,0.0005485174,0.00030214316,0.000081934486,0.000058748974,0.00034355622,0.000022531987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017814543,0.011244067,0.79877526,0.00009811393,0.0011393409,0.00048770796,0.0015098538,0.00015603635,0.15387745,0.000028991106,0.00047463115,0.014394038],"study_design_scores_gemma":[0.08814713,0.000556681,0.7613952,0.00022708166,0.0002020644,0.00007163661,0.00019553542,0.0005379247,0.14816104,0.0000030933722,0.00035056405,0.00015201814],"about_ca_topic_score_codex":0.00071584637,"about_ca_topic_score_gemma":0.0020245526,"teacher_disagreement_score":0.070332594,"about_ca_system_score_codex":0.00005466383,"about_ca_system_score_gemma":0.00022180284,"threshold_uncertainty_score":0.6957209},"labels":[],"label_agreement":null},{"id":"W2563521219","doi":"10.1182/blood.v114.22.303.303","title":"PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Bortezomib; Clinical endpoint; Phases of clinical research; Refractory (planetary science); Internal medicine; Multiple myeloma; Proteasome inhibitor; Oncology; Pharmacology; Adverse effect; Gastroenterology; Clinical trial","score_opus":0.047830979505024226,"score_gpt":0.3235842274055434,"score_spread":0.27575324790051914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563521219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937177,0.00007531042,8.246486e-7,0.00014379591,0.000041688538,0.0048262416,0.0004846369,0.00008298646,0.0006268678],"genre_scores_gemma":[0.9963639,0.000020124487,0.00042852617,0.0001265318,0.00005692899,0.00008599067,0.0025331418,0.00005762761,0.00032725243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610364,0.00044207557,0.000926311,0.00090190064,0.000991703,0.00063438667],"domain_scores_gemma":[0.99719626,0.00020340887,0.00041300186,0.0014103842,0.00036810484,0.00040887026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043797144,0.0004459811,0.0008514282,0.0002128531,0.00028416995,0.000079829864,0.0005352955,0.00015039941,0.00009803065],"category_scores_gemma":[0.000440077,0.0002615623,0.00004360392,0.0007769118,0.000092160124,0.0003401081,0.00019043163,0.0004257326,0.000012457706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07541765,0.2410725,0.64494365,0.000013669217,0.001835566,0.0017451814,0.0034015812,0.0000057197076,0.008562979,0.0000015840606,0.0005718673,0.02242803],"study_design_scores_gemma":[0.238172,0.06352893,0.6924041,0.00024431682,0.0006304652,0.0000060670313,0.0005692276,0.000067632616,0.003994948,0.000003227399,0.00013177663,0.00024730002],"about_ca_topic_score_codex":0.0049972283,"about_ca_topic_score_gemma":0.0030469445,"teacher_disagreement_score":0.17754358,"about_ca_system_score_codex":0.00019751657,"about_ca_system_score_gemma":0.0002694104,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W2563947761","doi":"10.1182/blood.v116.21.1963.1963","title":"Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Neutropenia; Multiple myeloma; Absolute neutrophil count; Dexamethasone; Complete blood count; Internal medicine; Blood count; Platelet; Toxicity; Surgery; Gastroenterology","score_opus":0.02698907948293442,"score_gpt":0.26695772677026663,"score_spread":0.23996864728733222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563947761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978532,0.00003959571,7.0075885e-7,0.000064702734,0.000012964697,0.00044076124,0.000043713342,0.000011710622,0.0015326533],"genre_scores_gemma":[0.9988671,0.0000024433828,0.00084305595,0.00003481078,0.000011822205,0.000022750104,0.000022008859,0.00001355294,0.0001824638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892145,0.00002759826,0.00020358404,0.00018300868,0.00043629893,0.00022805553],"domain_scores_gemma":[0.9992037,0.0001335245,0.00010850088,0.0003262498,0.00014310027,0.00008493838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012408374,0.00010894193,0.00025430167,0.000049821127,0.00003444048,0.0000041959147,0.000082254504,0.000057686444,0.00015272372],"category_scores_gemma":[0.00016216551,0.000055754106,0.000027217915,0.00018236708,0.0001494307,0.000037654398,0.00004753911,0.00016652928,0.000016698066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090838043,0.0019526319,0.99336874,0.000054544333,0.0001812665,0.00008876444,0.00012187152,3.887315e-7,0.0025251608,0.000012346637,0.000030754247,0.00075512443],"study_design_scores_gemma":[0.013336902,0.0012504081,0.95693326,0.00012381405,0.00016141677,0.000032836266,0.000024486208,0.000030126683,0.028007807,0.000009726108,0.000019707468,0.00006951629],"about_ca_topic_score_codex":0.00012580119,"about_ca_topic_score_gemma":0.000060445578,"teacher_disagreement_score":0.036435515,"about_ca_system_score_codex":0.000009480089,"about_ca_system_score_gemma":0.00008679515,"threshold_uncertainty_score":0.22735865},"labels":[],"label_agreement":null},{"id":"W2563961844","doi":"10.1016/j.monrhu.2016.09.004","title":"L’os du myélome multiple : physiopathologie","year":2016,"lang":"fr","type":"article","venue":"Revue du Rhumatisme Monographies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Molecular biology; Gynecology; Biology","score_opus":0.03146147369337348,"score_gpt":0.2688370354392898,"score_spread":0.23737556174591629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563961844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8615409,0.09533905,0.0016562934,0.03152331,0.003455585,0.0021766766,0.0007740896,0.0005113946,0.0030226787],"genre_scores_gemma":[0.9167924,0.07043001,0.0020031857,0.00013229308,0.001974899,0.00033181996,0.00007206351,0.000114220595,0.00814911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956859,0.00041639578,0.0008076545,0.00089210866,0.00056429533,0.0016336631],"domain_scores_gemma":[0.9963174,0.001196524,0.0002867684,0.0011423539,0.00028859003,0.0007683997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00054934976,0.0006986504,0.0010475795,0.00086491293,0.00044760449,0.000102476224,0.00045638665,0.00036885907,0.0015980488],"category_scores_gemma":[0.0015345124,0.00049821445,0.00064785103,0.0009865905,0.0012445343,0.0005997492,0.00029370232,0.00034981116,0.003015566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041811864,0.0012345545,0.52172846,0.0011907532,0.0007532471,0.0024224985,0.0012246743,0.000004803324,0.008509,0.0024305363,0.015174754,0.44490862],"study_design_scores_gemma":[0.012897023,0.0018019816,0.8917342,0.008711286,0.0004916819,0.0007331796,0.00055550534,0.001385081,0.0037448534,0.0024004572,0.07448785,0.001056911],"about_ca_topic_score_codex":0.0003265483,"about_ca_topic_score_gemma":0.00012624808,"teacher_disagreement_score":0.4438517,"about_ca_system_score_codex":0.0002784066,"about_ca_system_score_gemma":0.00011686705,"threshold_uncertainty_score":0.999747},"labels":[],"label_agreement":null},{"id":"W2564171273","doi":"10.1182/blood.v112.11.3299.3299","title":"Tandem Autologous-Nonmyeloablative (NMA) Allogeneic(Allo) Transplant (Tx) in Newly Diagnosed Multiple Myeloma (MM) Leads to Improved Survival When Compared to Conventional Allogeneic Transplant","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Fleurimont; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Internal medicine; Fludarabine; Surgery; Bortezomib; Transplantation; Cyclophosphamide; Graft-versus-host disease; Oncology; Gastroenterology; Chemotherapy","score_opus":0.03943246113642086,"score_gpt":0.28376938112596095,"score_spread":0.2443369199895401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564171273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314785,0.00033706412,0.0007663084,0.001201077,0.00019984179,0.0029760792,0.00067592255,0.00017702028,0.00051884097],"genre_scores_gemma":[0.9907927,0.00015741584,0.0061206985,0.0004947953,0.00017572436,0.00060080015,0.0008527302,0.00008620886,0.0007189398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547756,0.00031035024,0.00086537877,0.0010838518,0.0009254844,0.0013373978],"domain_scores_gemma":[0.997409,0.00052002433,0.00011345671,0.0005719022,0.00020537333,0.0011802762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040181793,0.0006298412,0.0011695417,0.00051707984,0.0002624429,0.000030622046,0.00041038214,0.00028505744,0.0003454534],"category_scores_gemma":[0.0002132021,0.0005663636,0.0003449639,0.0005105213,0.0001758279,0.000121281606,0.000074342344,0.00043893888,0.00023900604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040207403,0.0031659515,0.87521344,0.000083151856,0.0007952827,0.006134716,0.0036154573,0.00015107717,0.105195954,0.000021730215,0.00023692488,0.0013655768],"study_design_scores_gemma":[0.035033517,0.0014938832,0.9252909,0.00025510482,0.00025101606,0.0005013222,0.0001355821,0.00074334105,0.034850363,0.000018086033,0.000833828,0.00059306825],"about_ca_topic_score_codex":0.0011581097,"about_ca_topic_score_gemma":0.006469714,"teacher_disagreement_score":0.07034559,"about_ca_system_score_codex":0.00022360448,"about_ca_system_score_gemma":0.00051499694,"threshold_uncertainty_score":0.9996788},"labels":[],"label_agreement":null},{"id":"W2564227909","doi":"10.1182/blood.v124.21.722.722","title":"Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Interim analysis; Exome; Medicine; Clinical trial; Oncology; Exome sequencing; Cancer research; Internal medicine; Biology; Genetics; Gene; Phenotype","score_opus":0.037333814764416856,"score_gpt":0.3341505778331718,"score_spread":0.29681676306875493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564227909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99861497,0.000031911237,0.0004143704,0.00016260736,0.000017839953,0.0006192358,0.00004258615,0.000009060942,0.000087437875],"genre_scores_gemma":[0.9995798,0.000009049472,0.00010879937,0.000011892462,0.000010182722,0.00003363766,0.00019393806,0.0000068235,0.000045897814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906325,0.000104422346,0.0002420308,0.00012670949,0.00037795963,0.000085652384],"domain_scores_gemma":[0.99915266,0.000053835436,0.00028885243,0.00024821892,0.00018463022,0.000071783084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028757105,0.00006456961,0.00020448158,0.00013192951,0.000042478558,0.000011156569,0.000057439796,0.000028095958,0.000008497567],"category_scores_gemma":[0.0005040936,0.000037978363,0.000068816866,0.00036887208,0.000065390464,0.000044566736,0.000034848043,0.00004376957,2.7035435e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008618059,0.0060834526,0.9393157,0.00011731129,0.0039052018,0.000003116331,0.00020268591,0.0000103619195,0.037524134,0.000042407675,0.00001151055,0.0041660722],"study_design_scores_gemma":[0.03649705,0.00040737638,0.9511363,0.00018295091,0.0032721716,3.4474564e-7,0.000018012068,0.002201353,0.0062418487,0.000006199882,0.000003682421,0.00003273118],"about_ca_topic_score_codex":0.000030949763,"about_ca_topic_score_gemma":0.000037134807,"teacher_disagreement_score":0.031282283,"about_ca_system_score_codex":0.000013712031,"about_ca_system_score_gemma":0.000037091817,"threshold_uncertainty_score":0.15487127},"labels":[],"label_agreement":null},{"id":"W2564582829","doi":"10.1182/blood.v116.21.3486.3486","title":"Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Transplantation; Splenectomy; Internal medicine; Gastroenterology; Bone marrow; Cumulative incidence; Stem cell; Total body irradiation; Hematopoietic stem cell transplantation; Surgery; Spleen; Chemotherapy; Cyclophosphamide; Biology","score_opus":0.010203386256106289,"score_gpt":0.25308053919838286,"score_spread":0.24287715294227658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564582829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978343,0.0006786018,0.000011652513,0.00010378485,0.00004239099,0.00046221056,0.000057426343,0.00003411534,0.00077549904],"genre_scores_gemma":[0.9981606,0.0004200911,0.000756339,0.000054626995,0.00004294996,0.00009850776,0.00007688739,0.000014197761,0.00037579043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990954,0.00002318304,0.00013071342,0.00021920455,0.00022635117,0.00030515136],"domain_scores_gemma":[0.999414,0.000036246573,0.000023527713,0.00019481884,0.000031628257,0.00029973473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006407615,0.00012379553,0.00015204422,0.000065978595,0.000043227814,0.000021074256,0.000030449979,0.000066183646,0.00017716183],"category_scores_gemma":[0.0000034986217,0.000095391675,0.000043559274,0.00005171482,0.000039374347,0.000040106195,0.000014383449,0.00014148917,0.00008342588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049386243,0.0015782323,0.88678366,0.00055204844,0.0002366458,0.0012109743,0.0014212617,1.6069905e-7,0.09888634,0.000034776327,0.00003646405,0.0087656],"study_design_scores_gemma":[0.010797605,0.00046932555,0.7558416,0.000037802292,0.0004095511,0.00025364294,0.00008963449,0.000007751512,0.23095569,0.00003015165,0.0009616123,0.00014562401],"about_ca_topic_score_codex":0.00005460563,"about_ca_topic_score_gemma":0.000086381646,"teacher_disagreement_score":0.13206935,"about_ca_system_score_codex":0.000010030482,"about_ca_system_score_gemma":0.00005071912,"threshold_uncertainty_score":0.38899598},"labels":[],"label_agreement":null},{"id":"W2565133281","doi":"10.1182/blood.v112.11.2767.2767","title":"Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Victoria Hospital; University of Calgary; Queen's University; McMaster University; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Multiple myeloma; Melphalan; Internal medicine; Toxicity; Phases of clinical research; Gastroenterology; Febrile neutropenia; Tolerability; Surgery; Adverse effect","score_opus":0.04342470690850933,"score_gpt":0.2986483750118101,"score_spread":0.25522366810330077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565133281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944277,0.00020141962,0.000045282544,0.00007977788,0.000045412267,0.0048110597,0.00013078217,0.000067191184,0.00019139262],"genre_scores_gemma":[0.9964603,0.000011244408,0.002143748,0.000034005727,0.00017149263,0.00043962424,0.0002683215,0.000049253955,0.000421969],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980346,0.00008465002,0.00042925382,0.0003598302,0.00055114966,0.00054049655],"domain_scores_gemma":[0.9980606,0.000604214,0.00021737597,0.00045917163,0.00042210252,0.000236556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019910756,0.00026323897,0.000527235,0.000105230036,0.00037916342,0.000011170873,0.00015626334,0.00008174739,0.0000328211],"category_scores_gemma":[0.0012636482,0.00014785498,0.00014396367,0.00030990085,0.00016807517,0.000077898396,0.00006214619,0.00013501954,0.0000063828975],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14778145,0.035589997,0.79283375,0.00041427804,0.0021951825,0.00049150817,0.002658125,0.000014309976,0.0026670913,0.000010458727,0.0007100218,0.014633836],"study_design_scores_gemma":[0.85837674,0.01822094,0.099211864,0.00028681563,0.0009228981,0.00010958364,0.00007578916,0.00067491765,0.021619357,0.000005696404,0.00026935287,0.00022601246],"about_ca_topic_score_codex":0.00036623754,"about_ca_topic_score_gemma":0.000093493494,"teacher_disagreement_score":0.7105953,"about_ca_system_score_codex":0.000060109105,"about_ca_system_score_gemma":0.00034000495,"threshold_uncertainty_score":0.6029351},"labels":[],"label_agreement":null},{"id":"W2565225713","doi":"10.3747/co.23.3298","title":"Risk Stratification, Treatment Selection, and Transplant Eligibility in Multiple Myeloma: A Qualitative Study of the Perspectives and Self-Reported Practices of Oncologists","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Comprehensive Cancer Network; National Cancer Institute; Celgene","keywords":"Medicine; Referral; Psychosocial; Psychological intervention; Family medicine; Transplantation; Multiple myeloma; Qualitative research; Nursing; Internal medicine; Psychiatry","score_opus":0.15998476521984767,"score_gpt":0.4975213548833564,"score_spread":0.33753658966350875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565225713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673325,0.0008802014,0.000021233744,0.00042113056,0.00004480037,0.0017770898,0.0000508042,0.000014499576,0.000057001595],"genre_scores_gemma":[0.99766624,0.0019334096,0.00017540806,8.302576e-7,0.000015636962,0.0001843273,0.0000043874743,0.000005626335,0.00001413249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977142,0.0010906308,0.00046303676,0.0003782871,0.00019063878,0.00016316425],"domain_scores_gemma":[0.99727637,0.0014591496,0.000671106,0.00021769087,0.0002926882,0.00008297386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063892547,0.0001372893,0.00041646813,0.00010708844,0.000074894066,0.0000035850292,0.000048857797,0.00006767373,0.000010425347],"category_scores_gemma":[0.0013679793,0.000068850386,0.0000403131,0.0002005654,0.00027522416,0.00007200577,0.000023155899,0.00011768758,4.5001113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012121226,0.01294706,0.8721748,0.00006065495,0.00047786516,0.000007819048,0.089753814,3.895643e-7,0.0019837297,0.00004178301,0.0000056736026,0.021334263],"study_design_scores_gemma":[0.010608225,0.0057729427,0.93579084,0.00004961202,0.0003329673,0.000030837982,0.04554503,0.0001046131,0.0014757244,0.00011918771,0.00011058723,0.000059456517],"about_ca_topic_score_codex":0.0012522473,"about_ca_topic_score_gemma":0.009540748,"teacher_disagreement_score":0.06361599,"about_ca_system_score_codex":0.00039335186,"about_ca_system_score_gemma":0.0003744037,"threshold_uncertainty_score":0.53239614},"labels":[],"label_agreement":null},{"id":"W2565322871","doi":"10.1182/blood.v126.23.3189.3189","title":"Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Melphalan; Bortezomib; Single Center; Internal medicine; Multiple myeloma; Regimen; Oncology; Surgery; Urology; Gastroenterology","score_opus":0.06284492650403548,"score_gpt":0.3152140233770871,"score_spread":0.25236909687305165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565322871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521804,0.000857356,0.00037822805,0.00052054244,0.0000883302,0.0016841891,0.0010057252,0.0000407355,0.00020684635],"genre_scores_gemma":[0.9937626,0.00007738894,0.0041783275,0.000048834012,0.00014625773,0.00030521274,0.0012583305,0.000025859388,0.0001971962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986607,0.00003442943,0.00033928073,0.00033641545,0.00030753098,0.00032166255],"domain_scores_gemma":[0.9986874,0.00030417542,0.000094396346,0.00038301936,0.00015186679,0.00037915542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011152548,0.00019373272,0.00043170978,0.000078315425,0.00009933014,0.000029610277,0.00006911674,0.00005650733,0.000022391754],"category_scores_gemma":[0.00008995772,0.00012236937,0.00010152195,0.00009113373,0.00006452482,0.000048827515,0.000017014856,0.000046437184,0.0000085224865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058538774,0.012508774,0.9154341,0.000104871746,0.003248419,0.0017085429,0.004652801,0.000025593414,0.04646446,0.000026341444,0.0015359949,0.008436222],"study_design_scores_gemma":[0.13659655,0.00704233,0.5561154,0.000387854,0.0020944919,0.00086765445,0.0009824064,0.0014390115,0.27921933,0.0001877973,0.014634498,0.00043270944],"about_ca_topic_score_codex":0.0024610697,"about_ca_topic_score_gemma":0.0005407962,"teacher_disagreement_score":0.35931873,"about_ca_system_score_codex":0.00007371469,"about_ca_system_score_gemma":0.00009554141,"threshold_uncertainty_score":0.4990078},"labels":[],"label_agreement":null},{"id":"W2565604933","doi":"10.1182/blood.v126.23.1846.1846","title":"Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Dexamethasone; Melphalan; Regimen; Oncology; Cyclophosphamide; Surgery; Gastroenterology; Chemotherapy","score_opus":0.053807694201940745,"score_gpt":0.32443622344406003,"score_spread":0.2706285292421193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565604933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937209,0.0017787438,0.0006040517,0.0004182784,0.000090646725,0.0018541241,0.000122564,0.00003634342,0.001374352],"genre_scores_gemma":[0.9957273,0.00041525587,0.0023138989,0.00003790067,0.00018029976,0.00037944497,0.000102018894,0.000029918538,0.00081396586],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987573,0.000021035337,0.00025667986,0.00024922666,0.00030872674,0.00040701067],"domain_scores_gemma":[0.9986778,0.00035320056,0.00007657562,0.0004431895,0.00016368057,0.00028557485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017099164,0.00018668381,0.00036965028,0.0000784565,0.000096590506,0.00001384232,0.00010008279,0.00006829258,0.000012498123],"category_scores_gemma":[0.00009149842,0.00010783349,0.00018671312,0.00011246631,0.000067227076,0.000040591298,0.000012517182,0.000056462803,0.000023014923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009556803,0.010408431,0.9008695,0.00023668657,0.004705029,0.00053660583,0.0067835157,0.00004719067,0.03187566,0.00013410005,0.0013691275,0.033477392],"study_design_scores_gemma":[0.14684674,0.025143223,0.22859782,0.00032457706,0.0027914334,0.0003219412,0.0018026929,0.006416833,0.5619273,0.00013751368,0.025234904,0.0004550041],"about_ca_topic_score_codex":0.0005808494,"about_ca_topic_score_gemma":0.0001515007,"teacher_disagreement_score":0.67227167,"about_ca_system_score_codex":0.00007338881,"about_ca_system_score_gemma":0.00022546003,"threshold_uncertainty_score":0.43973222},"labels":[],"label_agreement":null},{"id":"W2565658402","doi":"10.1182/blood.v114.22.949.949","title":"Integrin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fibronectin; Molecular biology; Small hairpin RNA; Stromal cell; Flow cytometry; Cell culture; Integrin; Cell adhesion; Bortezomib; Biology; MTT assay; Cell migration; Cell biology; Cancer research; Cell; Chemistry; Gene knockdown; Immunology; Multiple myeloma; Extracellular matrix; Biochemistry","score_opus":0.018340776049804147,"score_gpt":0.26590957784494856,"score_spread":0.24756880179514443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565658402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976161,0.00035221933,0.000039848943,0.00033584205,0.000022688833,0.00036789442,0.0000138813375,0.000038304766,0.0012131804],"genre_scores_gemma":[0.9979477,0.00014055295,0.0012342064,0.00002727993,0.00004795287,0.000007831665,0.00019379565,0.000008963069,0.00039173363],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999121,0.00005068815,0.0002110011,0.00018438458,0.00026870315,0.00016420857],"domain_scores_gemma":[0.99935585,0.0001122233,0.0000708845,0.00019090135,0.00013055737,0.00013956419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011705946,0.0001058559,0.0002014685,0.00011356058,0.000038178234,0.000008684642,0.000035039422,0.00007823231,0.000044180644],"category_scores_gemma":[0.00027717283,0.00008348925,0.000043857162,0.00015649057,0.0000324182,0.000067133755,0.000013195405,0.000085100546,0.00001955141],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036001837,0.0012371531,0.46176687,0.00006998201,0.00005244512,0.000025428071,0.00021031211,8.827239e-7,0.52443534,0.000028973798,0.00014844112,0.011664167],"study_design_scores_gemma":[0.005497229,0.0005569304,0.7459627,0.000047209687,0.000054477652,0.000008227396,0.000047735783,0.0005768074,0.24698831,0.000048354443,0.00015864897,0.000053395932],"about_ca_topic_score_codex":0.0001424406,"about_ca_topic_score_gemma":0.00010515564,"teacher_disagreement_score":0.28419578,"about_ca_system_score_codex":0.00001563448,"about_ca_system_score_gemma":0.000034444554,"threshold_uncertainty_score":0.3404593},"labels":[],"label_agreement":null},{"id":"W2565808132","doi":"10.1182/blood.v120.21.596.596","title":"Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A Cibmtr Analysis","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Population; Thalidomide; Hematopoietic cell; Bortezomib; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Oncology; Surgery; Stem cell; Haematopoiesis","score_opus":0.018723871920987786,"score_gpt":0.2797567782569659,"score_spread":0.2610329063359781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565808132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887735,0.0002643632,0.0000788122,0.00002448929,0.000004911225,0.00035968277,0.000024972585,0.0000046522982,0.00036078904],"genre_scores_gemma":[0.9989782,0.00008318098,0.0006515859,0.0000064163264,0.000001722851,0.00003698544,0.00020213556,0.0000057636225,0.00003402187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991442,0.00006411763,0.00023007969,0.00011812718,0.0002723251,0.00017112821],"domain_scores_gemma":[0.9996396,0.000056214343,0.000074945034,0.00015988393,0.000026684076,0.000042709722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013759911,0.000091013106,0.00026957176,0.0003817624,0.000013958066,0.0000027725087,0.00004320399,0.000032351672,0.000015457314],"category_scores_gemma":[0.000006271708,0.000054251686,0.00004492702,0.0005730985,0.000033907996,0.00005357446,0.000009594472,0.000045414134,5.016652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023584135,0.0028550113,0.9895894,0.00025860505,0.00039409738,0.000022264876,0.0018054806,0.000007313489,0.000021323855,0.000018442039,8.141786e-7,0.0047914316],"study_design_scores_gemma":[0.009613324,0.0001823643,0.9876986,0.00003804762,0.0010393044,0.0000018762544,0.00031512292,0.000106240164,0.00095709274,0.0000023304683,0.0000015883962,0.000044109463],"about_ca_topic_score_codex":0.00014643821,"about_ca_topic_score_gemma":0.00027515087,"teacher_disagreement_score":0.009377483,"about_ca_system_score_codex":0.000014331862,"about_ca_system_score_gemma":0.0000061598057,"threshold_uncertainty_score":0.22123195},"labels":[],"label_agreement":null},{"id":"W2566507382","doi":"10.1182/blood.v114.22.2865.2865","title":"Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Multiple myeloma; Medicine; Internal medicine; Refractory (planetary science); Proteasome inhibitor; Oncology; Retrospective cohort study; Gastroenterology; Biology","score_opus":0.026152302054536905,"score_gpt":0.30089545400844603,"score_spread":0.27474315195390914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566507382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615186,0.00027011006,0.0000073974625,0.0014908582,0.000029350178,0.0014959538,0.00030316025,0.00007664226,0.00017468895],"genre_scores_gemma":[0.9966171,0.00007019737,0.0008647711,0.00029788032,0.00007512869,0.00017148111,0.00029005788,0.000025058443,0.0015883294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812794,0.00013899161,0.00034644536,0.00043859833,0.00039967362,0.00054835004],"domain_scores_gemma":[0.99884105,0.00014573244,0.000070589056,0.00043312597,0.0001014464,0.00040805037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025439824,0.00024921345,0.00040478472,0.00030399798,0.000113850925,0.00003148566,0.00008609702,0.00011984149,0.00014677431],"category_scores_gemma":[0.000839243,0.0002152864,0.00010322783,0.0004966207,0.000014930991,0.00009314699,0.0000286988,0.000121328565,0.0003187138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044971693,0.038834155,0.4458344,0.000066424414,0.0013952854,0.01050494,0.0059648254,0.000098191216,0.429749,0.0000211941,0.00048652888,0.022073355],"study_design_scores_gemma":[0.032255933,0.0031235039,0.82586116,0.00014013356,0.00014164048,0.000039031638,0.00005152959,0.00029801755,0.13745113,0.000010427259,0.00045502116,0.00017249872],"about_ca_topic_score_codex":0.0009336812,"about_ca_topic_score_gemma":0.00026315692,"teacher_disagreement_score":0.38002673,"about_ca_system_score_codex":0.00052341097,"about_ca_system_score_gemma":0.00015228745,"threshold_uncertainty_score":0.87791246},"labels":[],"label_agreement":null},{"id":"W2566628598","doi":"10.1182/blood.v104.11.335.335","title":"Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Ontario Institute for Cancer Research; McGill University; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Nova Scotia Cancer Centre; London Health Sciences Centre","funders":"","keywords":"Thalidomide; Medicine; Tolerability; Prednisone; Multiple myeloma; Clinical endpoint; Melphalan; Maintenance therapy; Surgery; Internal medicine; Single Center; Randomized controlled trial; Adverse effect; Chemotherapy","score_opus":0.03109308781095624,"score_gpt":0.3064219060696922,"score_spread":0.27532881825873595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566628598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99108905,0.0010492249,0.0011530902,0.00015465089,0.00009426425,0.0056841117,0.00064644264,0.000037184258,0.000092012146],"genre_scores_gemma":[0.9925269,0.00052932964,0.006133571,0.000019651206,0.00004524401,0.0003632557,0.00011807364,0.00003191862,0.00023207716],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99803585,0.0001315588,0.0007486112,0.00037595507,0.000306743,0.00040128923],"domain_scores_gemma":[0.9985653,0.0005741008,0.00026504725,0.00031693204,0.00010467727,0.00017393532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006297981,0.00024258773,0.0011623175,0.00012741945,0.000086033084,0.000007811439,0.00010432263,0.00012332514,0.0000024745386],"category_scores_gemma":[0.00022997239,0.0001680257,0.0004953143,0.00009682708,0.00015122454,0.00006219983,0.000024398376,0.00010571143,7.113816e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9192143,0.020732468,0.00042987306,0.00021702763,0.0011455253,0.00014829352,0.002119782,0.0000032375704,0.049095146,0.000008061588,0.000009456768,0.0068768286],"study_design_scores_gemma":[0.7787634,0.0057222275,0.00019111458,0.0002638259,0.00034011624,0.000028803237,0.00008162947,0.0003581907,0.21409388,0.000016955073,0.000038026497,0.00010183778],"about_ca_topic_score_codex":0.000145615,"about_ca_topic_score_gemma":0.000024199155,"teacher_disagreement_score":0.16499873,"about_ca_system_score_codex":0.000022832462,"about_ca_system_score_gemma":0.00013499125,"threshold_uncertainty_score":0.68518895},"labels":[],"label_agreement":null},{"id":"W2566964764","doi":"10.1182/blood.v112.11.3706.3706","title":"A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Proteasome inhibitor; Multiple myeloma; Internal medicine; Lenalidomide; Refractory (planetary science); Neutropenia; Oncology; Pharmacology; Toxicity","score_opus":0.13052371614131603,"score_gpt":0.3844697312099192,"score_spread":0.25394601506860315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566964764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748206,0.00032838047,0.0000040438154,0.00013310784,0.00006458557,0.0010014789,0.0000105521485,0.000024121666,0.00095164677],"genre_scores_gemma":[0.99897397,0.000114213064,0.00057415024,0.000036967813,0.00012197771,0.000051136507,0.00002357919,0.000012808281,0.00009122019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985438,0.00019179565,0.0004999346,0.00023321858,0.00030953684,0.00022170128],"domain_scores_gemma":[0.99808496,0.0012646702,0.00014563483,0.00026338585,0.000104485334,0.00013683843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059231045,0.000113996786,0.00032869205,0.000102291844,0.00009400037,0.0000061271735,0.000072579955,0.00009792817,0.000014714785],"category_scores_gemma":[0.00390905,0.00007693039,0.0000742472,0.00021406065,0.00020830412,0.000047515987,0.000044626868,0.00030545497,0.000007996393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017269116,0.019779366,0.90741956,0.00004670929,0.00017336354,0.0005191212,0.00033134318,3.2652446e-7,0.0039335373,0.000020629284,0.0001008338,0.05040609],"study_design_scores_gemma":[0.38684154,0.0054123756,0.6049461,0.00006563203,0.00007977667,0.00010498556,0.0000488451,0.0009039021,0.0012706636,0.000024093672,0.0002359827,0.00006614591],"about_ca_topic_score_codex":0.00014268403,"about_ca_topic_score_gemma":0.000028638635,"teacher_disagreement_score":0.36957243,"about_ca_system_score_codex":0.000019994994,"about_ca_system_score_gemma":0.00016985544,"threshold_uncertainty_score":0.46797803},"labels":[],"label_agreement":null},{"id":"W2567624910","doi":"10.1182/blood.v114.22.616.616","title":"A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Regimen; Internal medicine; Cohort; Cyclophosphamide; Surgery; Toxicity; Gastroenterology; Chemotherapy","score_opus":0.054298635492380606,"score_gpt":0.4000287091053771,"score_spread":0.34573007361299646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567624910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958483,0.00040313814,0.000059265138,0.0017868942,0.00007251134,0.0017140775,0.000041894717,0.000028557015,0.00004539285],"genre_scores_gemma":[0.997798,0.000069813934,0.0016735154,0.00007793083,0.00013771802,0.00008942633,0.00004130071,0.00001819201,0.00009405338],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983339,0.00013564677,0.00047618084,0.00033711654,0.00032745893,0.0003897024],"domain_scores_gemma":[0.99831176,0.0010001063,0.00011454762,0.0002574035,0.0000900636,0.00022610961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042954323,0.00019443502,0.0006295475,0.00017272601,0.00008391536,0.000024342084,0.00010359663,0.00011900495,0.000016559188],"category_scores_gemma":[0.001025027,0.00016949137,0.00009667474,0.00022784898,0.00009613376,0.00008752092,0.000026971873,0.00015978228,0.0000016848516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82156765,0.029202033,0.0051554935,0.000060069855,0.00028377253,0.00024649483,0.0007379542,7.3950577e-7,0.08798768,0.000097255885,0.00023872568,0.05442214],"study_design_scores_gemma":[0.7395642,0.047624983,0.07779536,0.000119088836,0.00019453217,0.000007599418,0.0002835732,0.00052151375,0.133451,0.00006165794,0.00021807493,0.00015842081],"about_ca_topic_score_codex":0.00015595784,"about_ca_topic_score_gemma":0.00011384881,"teacher_disagreement_score":0.082003444,"about_ca_system_score_codex":0.000052408996,"about_ca_system_score_gemma":0.00017208433,"threshold_uncertainty_score":0.69116575},"labels":[],"label_agreement":null},{"id":"W2567835463","doi":"10.1182/blood.v116.21.4580.4580","title":"The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Cohort; Transplantation; Population; Internal medicine; Hematopoietic stem cell transplantation; Surgery; Donor lymphocyte infusion; Progression-free survival; Median follow-up; Oncology; Overall survival","score_opus":0.03746768730328527,"score_gpt":0.2549513480998074,"score_spread":0.21748366079652215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567835463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978205,0.000005854534,0.000010291804,0.000031157695,0.00001375839,0.0016934116,0.0003480592,0.0000108892,0.00006605947],"genre_scores_gemma":[0.9985969,0.000018889685,0.0007762856,0.0000056162075,0.000006187781,0.000069408445,0.00046631662,0.000023260167,0.000037099788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844927,0.00010907391,0.00045060724,0.00025918958,0.0004813354,0.00025053194],"domain_scores_gemma":[0.99878967,0.0003133648,0.00022476711,0.00026832655,0.00031457932,0.00008929767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023133002,0.00015817942,0.0002644917,0.00018644224,0.000037758968,0.000011607053,0.00008637893,0.00008888412,0.0000020247192],"category_scores_gemma":[0.00010408595,0.00009274159,0.00003118974,0.00034451668,0.00010093082,0.000112068934,0.000011008137,0.00020065173,0.0000010202308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020774899,0.0045860508,0.9252643,0.00011355416,0.000119332944,0.000113016526,0.0006317678,0.000058418933,0.04699198,0.000002310485,6.422757e-7,0.0013437422],"study_design_scores_gemma":[0.048524864,0.002128885,0.88865954,0.00016592036,0.00010823579,0.0000050658905,0.000060103757,0.00022162097,0.06004244,2.2927682e-7,0.0000026269952,0.00008045537],"about_ca_topic_score_codex":0.0012326587,"about_ca_topic_score_gemma":0.0056190565,"teacher_disagreement_score":0.036604736,"about_ca_system_score_codex":0.000022901257,"about_ca_system_score_gemma":0.00013814702,"threshold_uncertainty_score":0.37818924},"labels":[],"label_agreement":null},{"id":"W2568354557","doi":"10.1182/blood.v108.11.3536.3536","title":"A Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone for Relapsed/Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Neutropenia; Bortezomib; Internal medicine; Gastroenterology; Multiple myeloma; Cyclophosphamide; Lenalidomide; Thalidomide; Toxicity; Febrile neutropenia; Refractory (planetary science); Urology; Surgery; Chemotherapy","score_opus":0.02489002344502734,"score_gpt":0.3103489872472944,"score_spread":0.28545896380226704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568354557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951435,0.0011945415,0.00011109344,0.000108827146,0.000096175245,0.002397305,0.00023307226,0.000061149636,0.00065437896],"genre_scores_gemma":[0.99311423,0.00009069283,0.004370796,0.000022749882,0.00026779564,0.00027301608,0.00026184804,0.000038392805,0.0015604671],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984336,0.000038244492,0.00042314982,0.00035365633,0.0003364353,0.00041491864],"domain_scores_gemma":[0.99896026,0.00022085942,0.00013999663,0.00033408162,0.00012489529,0.00021990534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020149353,0.00020841265,0.0005205899,0.000120024015,0.00013294065,0.000013523966,0.000075066484,0.00013135285,0.00003074279],"category_scores_gemma":[0.00038063026,0.00017171477,0.00015512749,0.00012783347,0.00012112907,0.00008828798,0.000059984388,0.00012658964,0.0000047033936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5844186,0.10845627,0.07399164,0.0011232763,0.0024414149,0.0008348377,0.00067052327,0.0000072114212,0.12806417,0.0003587007,0.0057346444,0.0938987],"study_design_scores_gemma":[0.90459305,0.02063855,0.020756803,0.00009576113,0.00055745145,0.000045674667,0.00004160119,0.00065765704,0.04605447,0.00015884575,0.0061925994,0.00020753176],"about_ca_topic_score_codex":0.00044132664,"about_ca_topic_score_gemma":0.00010214202,"teacher_disagreement_score":0.32017443,"about_ca_system_score_codex":0.000047188423,"about_ca_system_score_gemma":0.00020826823,"threshold_uncertainty_score":0.7002325},"labels":[],"label_agreement":null},{"id":"W2568419443","doi":"10.1182/blood-2016-09-738021","title":"Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pathology; Bone marrow; Plasma cell; Plasma cell neoplasm; Medicine; Multiple myeloma; Biology; Plasmacytoma; Internal medicine","score_opus":0.018171598724125337,"score_gpt":0.2747689751313528,"score_spread":0.25659737640722746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568419443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98126006,0.000039383838,0.00004003374,0.0002304399,0.00008662789,0.00036601728,0.000026731028,0.00006503854,0.017885655],"genre_scores_gemma":[0.9924883,0.000050965766,0.0032779,0.000060544106,0.00011614828,0.000045254892,0.000034278793,0.00004095064,0.0038856377],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859256,0.000023097236,0.00015414612,0.00037709583,0.00030651342,0.00054657867],"domain_scores_gemma":[0.9986367,0.00008812489,0.00012554438,0.0007597335,0.00007096561,0.00031891404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064733875,0.00021465286,0.00034508182,0.00009619826,0.00038696555,0.00007905036,0.00023636465,0.00011246556,0.00010107924],"category_scores_gemma":[0.00009401348,0.00015473251,0.00006969295,0.000044901684,0.00018188903,0.00011109653,0.00011723156,0.00027148586,0.00044795295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003609692,0.0023132376,0.788998,0.0003171964,0.0030551734,0.03631208,0.00044351385,0.000037107795,0.15614201,0.00008704188,0.0014195555,0.0072653936],"study_design_scores_gemma":[0.06732783,0.0029097572,0.40918377,0.000287021,0.0018344162,0.00523263,0.00007285403,0.0017024643,0.508592,0.000039810187,0.0023252761,0.0004921537],"about_ca_topic_score_codex":0.00016417622,"about_ca_topic_score_gemma":0.00008230036,"teacher_disagreement_score":0.37981424,"about_ca_system_score_codex":0.00008879575,"about_ca_system_score_gemma":0.00033096745,"threshold_uncertainty_score":0.63098085},"labels":[],"label_agreement":null},{"id":"W2568914178","doi":"10.1182/blood.v114.22.2826.2826","title":"Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bortezomib; Internal medicine; Fluorescence in situ hybridization; Multiple myeloma; Medicine; Gastroenterology; Refractory (planetary science); Adverse effect; Oncology; Biology; Chromosome","score_opus":0.013155834312164931,"score_gpt":0.27787758362329773,"score_spread":0.2647217493111328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568914178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756473,0.00006222531,0.000006394616,0.0000066598964,0.000008818625,0.0014071543,0.0001629999,0.000053245516,0.0007277866],"genre_scores_gemma":[0.99918723,0.000014119751,0.0002115917,0.0000094365,0.00002062399,0.00005070812,0.000306844,0.000039456398,0.00015998067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980051,0.00012747152,0.00044658736,0.00034921637,0.00066063175,0.0004110203],"domain_scores_gemma":[0.9982288,0.00023987553,0.0003091477,0.00065832946,0.0002744633,0.0002893835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012618344,0.00034804907,0.00067896815,0.00027615132,0.00006374257,0.00000777264,0.000120537974,0.000106574946,0.000056872144],"category_scores_gemma":[0.00017437866,0.00020016046,0.00019376492,0.0003040431,0.00017560166,0.00011676575,0.000014755592,0.00017968217,0.00001347387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008267182,0.003481156,0.9836074,0.00011400935,0.00085783325,0.00007723975,0.0001118313,0.00004248806,0.001540583,0.0000029164623,0.000011336784,0.0018860264],"study_design_scores_gemma":[0.033132855,0.028037814,0.913868,0.00024548935,0.0004940449,0.00000991231,0.000020364443,0.00002472114,0.024000267,9.851755e-7,0.0000028381016,0.00016267558],"about_ca_topic_score_codex":0.0005086046,"about_ca_topic_score_gemma":0.000032515618,"teacher_disagreement_score":0.069739364,"about_ca_system_score_codex":0.00010433884,"about_ca_system_score_gemma":0.00010423248,"threshold_uncertainty_score":0.81623065},"labels":[],"label_agreement":null},{"id":"W2568959487","doi":"10.1182/blood.v110.11.953.953","title":"p53 Deletion Yields High Response Rates but Rapid Progression and Poor Overall Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Transplantation; Surgery; Chemotherapy; Stem cell; Oncology; Bortezomib; Progression-free survival; Plasma cell leukemia; Gastroenterology; Biology","score_opus":0.019399777953256613,"score_gpt":0.27700313114526975,"score_spread":0.25760335319201316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568959487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813557,0.0003727922,0.00012712902,0.00016126678,0.00008029855,0.0008594359,0.000036814494,0.00006478131,0.00016190659],"genre_scores_gemma":[0.9978805,0.00025398354,0.0013576254,0.000044375418,0.00003815916,0.000033391523,0.00017231147,0.000026716809,0.00019293358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982213,0.00022416167,0.00033766704,0.00035299372,0.00040513263,0.00045875943],"domain_scores_gemma":[0.9986143,0.0008258332,0.00008705824,0.00016074869,0.000089545385,0.00022253009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053458096,0.00019689304,0.00026975313,0.0002449721,0.00012221112,0.000027336897,0.0000579795,0.00016281437,0.000020591302],"category_scores_gemma":[0.00012794533,0.00016274866,0.000047271307,0.00015588047,0.000053375126,0.00011712031,0.000027121598,0.00019792176,0.000014428871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013680803,0.0019551385,0.9192905,0.00028942816,0.00007762984,0.0010763113,0.00043491067,0.000003099453,0.027990762,0.000012514442,0.000011550794,0.035177384],"study_design_scores_gemma":[0.023666594,0.0015668813,0.88920957,0.00020092182,0.00006641941,0.000039264727,0.0000983595,0.00011949435,0.08485354,0.000010728858,0.00003110544,0.00013713389],"about_ca_topic_score_codex":0.00014371876,"about_ca_topic_score_gemma":0.00026688335,"teacher_disagreement_score":0.05686278,"about_ca_system_score_codex":0.0000745701,"about_ca_system_score_gemma":0.00010398098,"threshold_uncertainty_score":0.66366976},"labels":[],"label_agreement":null},{"id":"W2569685357","doi":"10.1182/blood.v104.11.4890.4890","title":"t(11;14) Is Infrequent in Long-Term Myeloma Survivors.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Multiple myeloma; Fluorescence in situ hybridization; Chromosomal translocation; Internal medicine; Median follow-up; Progression-free survival; Medicine; Gastroenterology; Chemotherapy; Surgery; Biology; Chromosome; Gene; Genetics","score_opus":0.022830824758873648,"score_gpt":0.30244504997380117,"score_spread":0.2796142252149275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569685357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487585,0.000596534,0.000018789864,0.00083519885,0.000059402562,0.00050691684,0.000016555827,0.00005533968,0.0030354103],"genre_scores_gemma":[0.9981768,0.0001639252,0.00044926206,0.00025449952,0.0000926562,0.000053404758,0.000058955768,0.000024998157,0.00072548294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998586,0.000028360128,0.00023437596,0.00029594605,0.00039801642,0.0004572819],"domain_scores_gemma":[0.99922156,0.000028055636,0.000035896086,0.00037947996,0.000059336446,0.00027569346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115528244,0.00016564308,0.00026170272,0.0001834696,0.000042629257,0.000021502294,0.00010366774,0.00009358875,0.00031972348],"category_scores_gemma":[0.00007965241,0.00013675359,0.00008859677,0.00025452353,0.00005505722,0.00007613591,0.000054511806,0.00017366766,0.00036649863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007883367,0.0020138675,0.98903936,0.000091395596,0.00012080442,0.0025501214,0.00026926986,9.834632e-7,0.0016707486,0.00008508325,0.000041922736,0.004037604],"study_design_scores_gemma":[0.0149373235,0.00030348537,0.94964,0.00017984024,0.000055687688,0.00014343088,0.0000159904,0.000002377411,0.03428983,0.00013876123,0.00017323875,0.000120067874],"about_ca_topic_score_codex":0.0013929426,"about_ca_topic_score_gemma":0.0023747354,"teacher_disagreement_score":0.039399397,"about_ca_system_score_codex":0.000117839314,"about_ca_system_score_gemma":0.00017193862,"threshold_uncertainty_score":0.557665},"labels":[],"label_agreement":null},{"id":"W2571078417","doi":"10.1182/blood.v114.22.3855.3855","title":"Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Thalidomide; Pomalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Autologous stem-cell transplantation; Oncology; Refractory (planetary science); Combination therapy; Progressive disease; Maintenance therapy; Transplantation; Gastroenterology; Surgery; Chemotherapy","score_opus":0.019466180485118355,"score_gpt":0.26720748448673587,"score_spread":0.2477413040016175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571078417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695355,0.00025294872,0.00014467156,0.00023884806,0.0000270408,0.001642433,0.000016065775,0.00010761288,0.000616853],"genre_scores_gemma":[0.996286,0.000019396135,0.003054462,0.00024732473,0.000048710124,0.00009359851,0.000084416046,0.000057350455,0.0001087851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973817,0.0001778535,0.0002612102,0.00058542937,0.00089215196,0.00070164667],"domain_scores_gemma":[0.9984673,0.00031837553,0.00013359544,0.0006152921,0.00011658961,0.0003488033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026723248,0.00039529603,0.00065346994,0.00028740268,0.00012115003,0.0000411635,0.00014427582,0.0001407888,0.00003681252],"category_scores_gemma":[0.00018931329,0.0002586646,0.00014659237,0.00046416756,0.00007404567,0.00025285155,0.000017781602,0.00044408924,0.000018837092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022162024,0.006743634,0.94863266,0.000023385071,0.00042575455,0.00077570725,0.00012495782,0.000036813388,0.0028945603,0.0000017423152,0.000015308324,0.018163437],"study_design_scores_gemma":[0.14424205,0.0047384356,0.82795924,0.00026337625,0.000120798606,0.000007697375,0.00002061424,0.00013858394,0.022176148,0.000006131205,0.000065248634,0.000261712],"about_ca_topic_score_codex":0.0003012601,"about_ca_topic_score_gemma":0.00016980142,"teacher_disagreement_score":0.12208002,"about_ca_system_score_codex":0.00022594821,"about_ca_system_score_gemma":0.0004005857,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W2571301763","doi":"10.1182/blood.v114.22.1839.1839","title":"Extracellular Metabolite Biomarkers of Bortezomib Resistance in Multiple Myeloma Indicate Involvement of Unexpected Metabolic Pathways.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Bortezomib; Metabolite; Metabolomics; Extracellular; Metabolic pathway; Multiple myeloma; Proteasome inhibitor; Cell growth; Cell culture; Chemistry; Pharmacology; Biology; Proteasome; Cancer research; Biochemistry; Metabolism; Chromatography; Immunology","score_opus":0.02916951317365667,"score_gpt":0.2666788154445136,"score_spread":0.23750930227085693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571301763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641841,0.03387082,0.000031405238,0.00013670247,0.000024373674,0.0008777766,0.00009675007,0.00003609147,0.0007419979],"genre_scores_gemma":[0.9936799,0.00069880567,0.0051959837,0.000025026186,0.000026855438,0.00004793858,0.00013071667,0.000022361975,0.00017245863],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975626,0.00013460351,0.0007699852,0.00039729182,0.00064602215,0.0004894949],"domain_scores_gemma":[0.9986743,0.0000872123,0.00029665616,0.0005360198,0.00016006693,0.00024576407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038009995,0.00024689373,0.0007748697,0.0005606531,0.000036703368,0.000007430193,0.00017557241,0.000114305454,0.00004406423],"category_scores_gemma":[0.00028578,0.00021022113,0.00019477945,0.0009105946,0.00013442057,0.000088508634,0.00004119841,0.00016591222,0.0000072116122],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013208997,0.0050142207,0.26094025,0.00019362065,0.00096645614,0.00037365555,0.0006498393,8.59208e-7,0.72191447,0.0009303304,0.000025984573,0.00766939],"study_design_scores_gemma":[0.011006033,0.00021777842,0.60346097,0.000119870274,0.00021269928,0.0000039151005,0.000102222686,0.000037530535,0.38413423,0.00015173979,0.00044629356,0.000106747044],"about_ca_topic_score_codex":0.00020118098,"about_ca_topic_score_gemma":0.00014153177,"teacher_disagreement_score":0.34252068,"about_ca_system_score_codex":0.000033681717,"about_ca_system_score_gemma":0.00018172065,"threshold_uncertainty_score":0.8572569},"labels":[],"label_agreement":null},{"id":"W2571440990","doi":"10.1182/blood.v124.21.3421.3421","title":"The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Odds ratio; Genome-wide association study; Context (archaeology); Single-nucleotide polymorphism; Multiple myeloma; SNP; Internal medicine; Oncology; Genetic association; Biology; Medicine; Genotype; Genetics; Gene","score_opus":0.043361884258914046,"score_gpt":0.3270510127439485,"score_spread":0.28368912848503447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571440990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484545,0.0011718575,0.000048041726,0.00091610185,0.000090995825,0.00093275105,0.00007129887,0.000037423833,0.0018860688],"genre_scores_gemma":[0.99533904,0.0011786562,0.002532117,0.000033960463,0.00018770363,0.00015762965,0.00003824587,0.000033629953,0.0004990118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973314,0.00030774684,0.0004007772,0.00040687394,0.0009958221,0.0005574229],"domain_scores_gemma":[0.99662554,0.0018461854,0.00013181617,0.0005115853,0.0005829406,0.00030191557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012564599,0.00018195268,0.0002843705,0.0001801607,0.00037691384,0.000071263945,0.00028344788,0.00010913209,0.000037721155],"category_scores_gemma":[0.0035589042,0.00012343039,0.00009757475,0.00022317868,0.0005343804,0.000049613045,0.00027505847,0.00037623697,0.00004451296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046347454,0.00080712535,0.9104965,0.000052697404,0.00046024504,0.000029171493,0.00020905606,0.0000010402689,0.013541447,0.00010976994,0.0005051151,0.07332439],"study_design_scores_gemma":[0.011225122,0.00092221296,0.8732934,0.00008629446,0.00013397254,0.00006562603,0.0002789569,0.0055195154,0.09494835,0.00020429408,0.013186235,0.00013603397],"about_ca_topic_score_codex":0.00027734108,"about_ca_topic_score_gemma":0.0003581482,"teacher_disagreement_score":0.081406906,"about_ca_system_score_codex":0.000040399475,"about_ca_system_score_gemma":0.00012335839,"threshold_uncertainty_score":0.5033345},"labels":[],"label_agreement":null},{"id":"W2571509750","doi":"10.1007/s00277-016-2901-x","title":"Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma","year":2017,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Dexamethasone; Melphalan; Oncology; Prednisone; Hematology; Proteasome inhibitor; Cyclophosphamide; Chemotherapy","score_opus":0.11059568306063669,"score_gpt":0.40846087057661845,"score_spread":0.2978651875159818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571509750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900826,0.0021414384,0.00045475597,0.0044874195,0.0001010791,0.0013259287,0.00012423385,0.000013326188,0.0012692013],"genre_scores_gemma":[0.9966362,0.0019576012,0.000764047,0.000081568185,0.000051509614,0.0001981336,0.000044079956,0.00002007857,0.00024675138],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987389,0.000023005177,0.00037719318,0.00024458207,0.00017689129,0.000439435],"domain_scores_gemma":[0.9978843,0.000646499,0.00029890097,0.0008565873,0.00018236018,0.00013140525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015621918,0.0001777668,0.0007040919,0.000091257454,0.00025804917,0.000010536037,0.00021495095,0.0001045037,0.000022596652],"category_scores_gemma":[0.00020794536,0.00010660738,0.0002870198,0.000033564313,0.00027489164,0.000052854568,0.000025079544,0.000056301214,0.0000085344445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011852172,0.0027263942,0.9051181,0.0006984699,0.003878939,0.0004671821,0.0021907738,0.00001039994,0.026821293,0.0026868472,0.0021208962,0.041428547],"study_design_scores_gemma":[0.0109909605,0.0060590566,0.22481151,0.00023952051,0.00026305462,0.00021784117,0.0002500497,0.0018831006,0.750406,0.00030198964,0.004432826,0.0001440626],"about_ca_topic_score_codex":0.00081169046,"about_ca_topic_score_gemma":0.00021801646,"teacher_disagreement_score":0.7235847,"about_ca_system_score_codex":0.000011280679,"about_ca_system_score_gemma":0.00011437973,"threshold_uncertainty_score":0.4347323},"labels":[],"label_agreement":null},{"id":"W2572746867","doi":"10.1182/blood.v106.11.500.500","title":"Circulating B Lymphocytes from Patients with Multiple Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chromosomal translocation; Peripheral blood mononuclear cell; Multiple myeloma; Pathology; Bone marrow; Lymphocyte; Biology; Breakpoint; Molecular biology; Chromosome abnormality; Chromosome; Karyotype; Immunology; Medicine; Genetics; Gene","score_opus":0.011855052042191443,"score_gpt":0.23805096777404247,"score_spread":0.22619591573185102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572746867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976005,0.00066146645,0.00014522426,0.00034463615,0.000015292784,0.0005808817,0.00013650229,0.00008265102,0.0004328641],"genre_scores_gemma":[0.992072,0.000041823336,0.0070557897,0.000097324526,0.00013948332,0.00009054888,0.00039334415,0.000031969765,0.000077706536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987813,0.000032066193,0.00020343346,0.00032649335,0.0003416433,0.00031506133],"domain_scores_gemma":[0.99913853,0.00012549714,0.000050712148,0.00026988256,0.00013920985,0.00027619395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042788455,0.00017499218,0.00022642408,0.00009487824,0.000198527,0.000037843976,0.000058639307,0.00006668779,0.00013299812],"category_scores_gemma":[0.00008154932,0.00013822794,0.000047241705,0.00015631191,0.000075177835,0.00014608882,0.000021021548,0.00010635735,0.000058986872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013231976,0.0015665588,0.974015,0.00003231449,0.00037806766,0.00005356402,0.00034945193,0.000012514523,0.003592432,0.000012030974,0.000023532584,0.0198322],"study_design_scores_gemma":[0.021941453,0.00025048846,0.9667865,0.00011948987,0.00023905179,0.000031674346,0.00004390921,0.0011652973,0.008900878,0.00001104948,0.00035309652,0.0001570955],"about_ca_topic_score_codex":0.00035413174,"about_ca_topic_score_gemma":0.00030228414,"teacher_disagreement_score":0.021809133,"about_ca_system_score_codex":0.000066865694,"about_ca_system_score_gemma":0.000108894455,"threshold_uncertainty_score":0.5636772},"labels":[],"label_agreement":null},{"id":"W2573219103","doi":"10.1182/blood.v112.11.3323.3323","title":"Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Autologous stem-cell transplantation; Medicine; Transplantation; Immunoglobulin light chain; Monoclonal gammopathy of undetermined significance; Internal medicine; Monoclonal; Immunoglobulin D; Gastroenterology; Melphalan; Plasma cell; Kappa; Antibody; Monoclonal antibody; Immunology; B cell","score_opus":0.03372988955375703,"score_gpt":0.26828393581235965,"score_spread":0.23455404625860263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573219103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818766,0.00017539578,0.00000950701,0.00003816307,0.000007493762,0.0011675766,0.00017924322,0.000031845106,0.00020309129],"genre_scores_gemma":[0.99861044,0.000038966533,0.0009860449,0.000009345612,0.000009760614,0.00007089343,0.00019962608,0.000023967097,0.000050979852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819475,0.00016011897,0.00029752462,0.00029821598,0.00078804255,0.00026133016],"domain_scores_gemma":[0.99907875,0.0000534233,0.00010655107,0.0003073475,0.0003013855,0.00015256029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020708234,0.00019468156,0.0003377936,0.00019038522,0.00007729102,0.00000704634,0.00007927768,0.0000802821,0.000024790188],"category_scores_gemma":[0.000022253122,0.00013150538,0.00002852028,0.00021604421,0.00007145282,0.00013826179,0.00001399065,0.00012654447,0.0000029359776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001989521,0.0024366768,0.98748034,0.00008465531,0.00020172741,0.00025769285,0.0008477844,0.000024720954,0.0005797084,0.0000011808156,9.372791e-7,0.006095046],"study_design_scores_gemma":[0.049177025,0.0030089181,0.92805594,0.00007997274,0.00040881007,0.000096605145,0.000085391664,0.0011830658,0.017777245,0.0000019601089,9.924712e-7,0.00012409588],"about_ca_topic_score_codex":0.0003406922,"about_ca_topic_score_gemma":0.0005570755,"teacher_disagreement_score":0.059424434,"about_ca_system_score_codex":0.0000721257,"about_ca_system_score_gemma":0.00017330234,"threshold_uncertainty_score":0.5362634},"labels":[],"label_agreement":null},{"id":"W2573497597","doi":"10.1182/blood.v106.11.2561.2561","title":"Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hamilton Regional Laboratory Medicine Program; Queen's University; London Health Sciences Centre","funders":"","keywords":"Medicine; Thalidomide; Prednisone; Multiple myeloma; Internal medicine; Surgery; Maintenance therapy; Autologous stem-cell transplantation; Transplantation; Gastroenterology; Oncology; Chemotherapy","score_opus":0.016275738304112986,"score_gpt":0.24370058362956948,"score_spread":0.22742484532545648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573497597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533314,0.0007851242,0.00014263648,0.00039308358,0.000015342532,0.0022695453,0.0008247223,0.000091472684,0.0001449199],"genre_scores_gemma":[0.9940815,0.00013720854,0.004259483,0.00021729908,0.00005828234,0.0002079649,0.0001815684,0.00007262636,0.0007840884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980881,0.000043134096,0.00026431133,0.0005221698,0.0004101384,0.0006721471],"domain_scores_gemma":[0.9987337,0.00021688627,0.00011221247,0.00032676855,0.00027753355,0.00033291717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007060448,0.00037204725,0.0004820287,0.00011400094,0.00017327229,0.00004547893,0.00011430242,0.00011336291,0.00004735297],"category_scores_gemma":[0.000017130053,0.00021556205,0.00007604218,0.000119945515,0.00014196637,0.00015821529,0.000016582753,0.00016207258,0.000014859112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015038342,0.005015505,0.9219616,0.0002033272,0.0010396395,0.00015274067,0.0014213509,0.0000025643872,0.014768306,0.000009240776,0.00007708355,0.040310316],"study_design_scores_gemma":[0.08179899,0.00698874,0.8435046,0.00020016712,0.00020140104,0.000090084264,0.0001046668,0.00018174724,0.06603417,0.0000040674468,0.00055719726,0.00033416165],"about_ca_topic_score_codex":0.000092730195,"about_ca_topic_score_gemma":0.00013831025,"teacher_disagreement_score":0.07845698,"about_ca_system_score_codex":0.000042170595,"about_ca_system_score_gemma":0.00013481759,"threshold_uncertainty_score":0.87903655},"labels":[],"label_agreement":null},{"id":"W2573557015","doi":"10.1182/blood.v126.23.1853.1853","title":"Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McGill University; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Population; Neutropenia; Clinical endpoint; Discontinuation; Progressive disease; Oncology; Phases of clinical research; Multiple myeloma; Surgery; Adverse effect; Clinical trial; Chemotherapy","score_opus":0.07505917762754469,"score_gpt":0.35174125258759537,"score_spread":0.2766820749600507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573557015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494386,0.0014334772,0.00003016406,0.00027543004,0.0001252732,0.0029412247,0.000057710044,0.00006255404,0.00013031646],"genre_scores_gemma":[0.9934207,0.00009045325,0.0057983436,0.00015097181,0.00011183992,0.0001328505,0.0001433152,0.00007972498,0.000071794166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958653,0.0006952544,0.0012704093,0.0006972115,0.0007548928,0.00071692816],"domain_scores_gemma":[0.9963042,0.0019335046,0.00035723008,0.00059583946,0.0001243059,0.00068492565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002202657,0.00045020515,0.0012252324,0.0007445666,0.000068828886,0.00003440487,0.00019529455,0.00027241267,0.000058589416],"category_scores_gemma":[0.0060030306,0.0003578659,0.0002301297,0.0008813407,0.00023562943,0.00016617468,0.00008899278,0.00048022726,0.000006654478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5964127,0.02018533,0.15021305,0.00034604617,0.0014973228,0.0033060783,0.0017125767,0.000071576775,0.16946977,0.0000042205065,0.000047677186,0.056733638],"study_design_scores_gemma":[0.8814358,0.0070244353,0.028435532,0.0009724143,0.0001489233,0.000039189435,0.00032761728,0.0031685901,0.07791676,0.000031144027,0.00012905164,0.0003705154],"about_ca_topic_score_codex":0.00079948525,"about_ca_topic_score_gemma":0.0012670747,"teacher_disagreement_score":0.28502312,"about_ca_system_score_codex":0.00021534984,"about_ca_system_score_gemma":0.001164857,"threshold_uncertainty_score":0.99988735},"labels":[],"label_agreement":null},{"id":"W2574647756","doi":"10.1182/blood.v110.11.4952.4952","title":"Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Melphalan; Transplantation; Internal medicine; Multiple myeloma; Surgery; Gastroenterology; Autologous stem-cell transplantation; Creatinine; Hematopoietic stem cell transplantation","score_opus":0.019790775230668228,"score_gpt":0.2708152651092209,"score_spread":0.25102448987855264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574647756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484825,0.00013515232,0.00006282301,0.000019149855,0.00007158119,0.0007336814,0.000042799893,0.00006420327,0.0040223654],"genre_scores_gemma":[0.99838036,0.00005925115,0.00056623115,0.00006727698,0.000048038753,0.000027085109,0.0002535549,0.000026551907,0.00057165703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984316,0.00004744213,0.0003082003,0.00029969166,0.00040898967,0.0005040333],"domain_scores_gemma":[0.999292,0.00014600878,0.000056670735,0.00022752625,0.00004936289,0.00022843835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017816972,0.0001714947,0.00024981884,0.00021806278,0.000057880767,0.000013738463,0.00007805136,0.00012584857,0.00006418495],"category_scores_gemma":[0.00002695115,0.00014706657,0.00007887453,0.00021456213,0.000039627343,0.00007978783,0.000017941444,0.00018935637,0.00011092111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076011673,0.0027009605,0.9621047,0.00016847212,0.00006361627,0.0033015728,0.00066626415,0.0000013920231,0.0053239996,0.000006127009,0.000045638208,0.024857135],"study_design_scores_gemma":[0.021457879,0.00044740125,0.9258082,0.000063897314,0.00007758503,0.000026336782,0.0000543418,0.000052048137,0.051679876,0.0000072040893,0.00020478418,0.000120454926],"about_ca_topic_score_codex":0.00025903212,"about_ca_topic_score_gemma":0.0005358853,"teacher_disagreement_score":0.046355877,"about_ca_system_score_codex":0.000079794874,"about_ca_system_score_gemma":0.000046969086,"threshold_uncertainty_score":0.59972006},"labels":[],"label_agreement":null},{"id":"W2575449152","doi":"10.1182/blood.v110.11.5123.5123","title":"Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Internal medicine; Surgery; Cyclophosphamide; Autologous stem-cell transplantation; Gastroenterology; Chemotherapy","score_opus":0.015572496499151817,"score_gpt":0.24935596400898272,"score_spread":0.2337834675098309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575449152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743813,0.00009146383,0.0001534019,0.0002059297,0.00006537741,0.0017276503,0.00011424484,0.000108926084,0.00009488558],"genre_scores_gemma":[0.9973112,0.000023903569,0.001649714,0.00013204393,0.000030442267,0.000104487684,0.00014088409,0.00006805774,0.0005393053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725085,0.00020113772,0.00046434396,0.0005706826,0.00061652635,0.0008964279],"domain_scores_gemma":[0.9983891,0.0006469087,0.00008690735,0.00035336343,0.00012684477,0.00039687287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045239652,0.00036442044,0.00052304234,0.00032368052,0.00012891385,0.000051064573,0.00013629047,0.00018220286,0.000058144684],"category_scores_gemma":[0.000051108553,0.00023471315,0.000091112866,0.0002490238,0.00013356301,0.00012473941,0.00003951118,0.00030341,0.000043121992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02726306,0.003620726,0.95008343,0.00017816633,0.00029279504,0.003966555,0.0008789054,0.000007712011,0.011664049,0.000008507311,0.0000047859876,0.0020312867],"study_design_scores_gemma":[0.03270421,0.0019757398,0.8266078,0.00024829217,0.00016989476,0.00002722467,0.00024764644,0.000033050015,0.13770245,0.0000033182148,0.000032006457,0.00024834275],"about_ca_topic_score_codex":0.00031526544,"about_ca_topic_score_gemma":0.001964761,"teacher_disagreement_score":0.1260384,"about_ca_system_score_codex":0.00019114843,"about_ca_system_score_gemma":0.0002802866,"threshold_uncertainty_score":0.95713246},"labels":[],"label_agreement":null},{"id":"W2576428875","doi":"10.2217/ijh-2016-0014","title":"Management of Multiple Myeloma: The Impact of Ixazomib’s Approval in Canada","year":2016,"lang":"en","type":"article","venue":"International Journal of Hematologic Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; University of Kentucky; International Myeloma Foundation","keywords":"Medicine; Family medicine; Internship; Internal medicine; Medical education","score_opus":0.02964974679434092,"score_gpt":0.3644268375009572,"score_spread":0.3347770907066163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576428875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952439,0.0002113491,0.00012616909,0.0025544807,0.00020591487,0.00018867952,0.000019197016,0.0000014703868,0.001448856],"genre_scores_gemma":[0.9987302,0.00020651297,0.00093000114,0.00002558073,0.000034411423,0.0000066008774,0.0000018342151,0.000004892396,0.0000600134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985309,0.0000947279,0.00062885927,0.00008850516,0.00048141144,0.00017554566],"domain_scores_gemma":[0.9983864,0.00052783766,0.00050286856,0.00012214467,0.00038167392,0.000079094425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032465113,0.00009086266,0.00042564332,0.00016524037,0.000009491715,0.000002056769,0.00032313878,0.000045555596,0.00017723443],"category_scores_gemma":[0.00024869817,0.00003922577,0.00015930997,0.00008186719,0.00010662681,0.000051468152,0.000081049926,0.0001235658,0.0000026747557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00328972,0.00077721063,0.92493415,0.00003982044,0.0016937945,0.005913957,0.00007582163,0.000051725994,0.003237232,0.00063430145,0.0008780791,0.05847419],"study_design_scores_gemma":[0.010477118,0.0011593623,0.9765598,0.0003176606,0.000047180674,0.0030681952,0.00047653724,0.00018588148,0.006589222,0.00063597,0.0004260997,0.000056932677],"about_ca_topic_score_codex":0.062147427,"about_ca_topic_score_gemma":0.03731474,"teacher_disagreement_score":0.05841726,"about_ca_system_score_codex":0.0012616735,"about_ca_system_score_gemma":0.0013265018,"threshold_uncertainty_score":0.9802517},"labels":[],"label_agreement":null},{"id":"W2576909123","doi":"10.1182/blood.v104.11.4939.4939","title":"The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Zoledronic acid; Pharmacokinetics; Cmax; Multiple myeloma; Regimen; Renal function; Adverse effect; Pharmacodynamics; Internal medicine; Urology; Surgery","score_opus":0.005394093303611121,"score_gpt":0.24895226954896796,"score_spread":0.24355817624535683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576909123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985637,0.00041888328,0.0000062404292,0.000054134238,0.00002851729,0.00084758236,0.00001215058,0.00001591447,0.000052846448],"genre_scores_gemma":[0.99952054,0.00026131576,0.00007877421,0.000021980268,0.000026083171,0.000025124686,0.000041590458,0.000017586906,0.000007024701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998997,0.00014388273,0.00017140385,0.00021182442,0.00023906166,0.00023685428],"domain_scores_gemma":[0.9994104,0.00021087007,0.000070020695,0.00013388653,0.00004724556,0.00012756714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003097865,0.00015516194,0.00019952774,0.000106830215,0.000104666666,0.000016984495,0.000036310114,0.000039836515,0.0000035832784],"category_scores_gemma":[0.00013558396,0.0000895043,0.00002258827,0.00012530126,0.000107345935,0.00006140855,0.000046370908,0.00018242112,0.0000021384867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016379021,0.00052709196,0.91385746,0.00009300569,0.00018868528,0.00003376766,0.000053566266,0.00002978093,0.037635393,0.000003486175,0.000001461848,0.031197272],"study_design_scores_gemma":[0.06986811,0.004237856,0.86946887,0.0002134729,0.00018923107,0.000008770414,0.0000060586844,0.00041849035,0.05549378,0.000007464123,0.000015861659,0.000072049384],"about_ca_topic_score_codex":0.0001376223,"about_ca_topic_score_gemma":0.000067432775,"teacher_disagreement_score":0.05348909,"about_ca_system_score_codex":0.000048195394,"about_ca_system_score_gemma":0.000034758898,"threshold_uncertainty_score":0.3649879},"labels":[],"label_agreement":null},{"id":"W2577289848","doi":"10.1182/blood.v112.11.865.865","title":"Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Medicine; Multiple myeloma; Proteasome inhibitor; Population; Lenalidomide; Phases of clinical research; Internal medicine; Adverse effect; Gastroenterology; Toxicity","score_opus":0.0779266594997658,"score_gpt":0.3478634319597014,"score_spread":0.2699367724599356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577289848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949195,0.000042225827,7.0002204e-7,0.00002440988,0.00003006828,0.0025674105,0.00017276601,0.000025404759,0.0022175086],"genre_scores_gemma":[0.9986039,0.000008048985,0.0006693357,0.000019307437,0.000037490656,0.000073547526,0.000306103,0.000041473275,0.00024078607],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973244,0.00020214537,0.0006979069,0.0004948769,0.00082907063,0.00045159628],"domain_scores_gemma":[0.99823934,0.000082056154,0.00026775818,0.0007229839,0.0003892314,0.00029862608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023645378,0.00025394405,0.0006950218,0.00030622608,0.00013571892,0.000011769605,0.000306873,0.00009459999,0.000039682243],"category_scores_gemma":[0.00031642383,0.000195434,0.000029367684,0.00053025136,0.00015421856,0.00025972375,0.00023897116,0.00022761204,0.0000051761813],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055361126,0.52640575,0.39586148,0.000104046514,0.00084126944,0.0023553616,0.005951662,0.0000027791982,0.005234661,0.000007482255,0.00014647961,0.0077279187],"study_design_scores_gemma":[0.438069,0.17372963,0.36800417,0.0001870831,0.00023199669,0.000025969926,0.00054930424,0.000017251792,0.018940963,0.000004996499,0.000042945983,0.00019670524],"about_ca_topic_score_codex":0.0017779986,"about_ca_topic_score_gemma":0.0004858103,"teacher_disagreement_score":0.38270786,"about_ca_system_score_codex":0.00005728119,"about_ca_system_score_gemma":0.00024264911,"threshold_uncertainty_score":0.7969567},"labels":[],"label_agreement":null},{"id":"W2577435390","doi":"10.1182/blood.v122.21.1856.1856","title":"Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ion semiconductor sequencing; Genetics; Biology; SNP array; DNA sequencing; Computational biology; Deep sequencing; Bioinformatics; Single-nucleotide polymorphism; Gene; Genome; Genotype","score_opus":0.04256819058609661,"score_gpt":0.29376159585607914,"score_spread":0.2511934052699825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577435390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962939,0.00087764265,0.00012300073,0.00066901295,0.00005251938,0.0017235342,0.000010541283,0.000036312103,0.00021351672],"genre_scores_gemma":[0.99608403,0.000049726197,0.0031327466,0.00027490265,0.00010860754,0.00024287358,0.000012922558,0.000029290315,0.00006491867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998546,0.000075614815,0.00024146511,0.00033269473,0.00026603448,0.0005382066],"domain_scores_gemma":[0.99859625,0.000614608,0.00004476644,0.00034391796,0.000056864606,0.00034359976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015694594,0.0001865434,0.0002623566,0.00013312035,0.00013380483,0.00006165487,0.00010232891,0.000073246374,0.000080640406],"category_scores_gemma":[0.0014913507,0.00012374076,0.000047855814,0.00025436436,0.0000698376,0.00012067306,0.000099467354,0.0002096171,0.000099260855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012579009,0.0006285092,0.7544451,0.00013036755,0.00030254642,0.00078369945,0.0019198869,0.00006479536,0.21143226,0.000047517828,0.000059348447,0.030060219],"study_design_scores_gemma":[0.010243664,0.00050114637,0.9174831,0.0002057418,0.0001534231,0.00017414546,0.0005668162,0.017575564,0.052405555,0.0003455724,0.00007920532,0.00026609836],"about_ca_topic_score_codex":0.003927832,"about_ca_topic_score_gemma":0.0004914298,"teacher_disagreement_score":0.163038,"about_ca_system_score_codex":0.00011286944,"about_ca_system_score_gemma":0.000106238054,"threshold_uncertainty_score":0.59377337},"labels":[],"label_agreement":null},{"id":"W2577571378","doi":"10.1182/blood.v126.23.2321.2321","title":"Thromboprophylaxis in Multiple Myeloma Patients Treated with Lenalidomide - a Systematic Review","year":2015,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Randomized controlled trial; Thalidomide; Rivaroxaban; Surgery; Oncology; Warfarin","score_opus":0.060038938495165534,"score_gpt":0.33287393689190553,"score_spread":0.27283499839673997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577571378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007627045,0.9843502,3.2326992e-7,0.0000074187255,0.000021728263,0.014098091,0.00015455749,0.00007670148,0.0005282428],"genre_scores_gemma":[0.00042775797,0.9948043,0.00016308593,0.00003843752,0.000046220222,0.0026372029,0.0013274227,0.00013997492,0.0004155982],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956099,0.0005941475,0.0013164207,0.0007456172,0.0010690233,0.00066490215],"domain_scores_gemma":[0.9971538,0.00023817846,0.00056497165,0.001161027,0.0003716971,0.0005103323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004889824,0.00077504746,0.0064097517,0.00043512366,0.000051652176,0.000033593104,0.00028967712,0.00027961304,0.000046215304],"category_scores_gemma":[0.0010858948,0.00044367142,0.000509843,0.0010162693,0.000080073274,0.000084166946,0.00009741103,0.0005123395,0.00050306704],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006406207,0.0022269464,0.0034490372,0.9506107,0.0016796654,0.0010672469,0.00001554768,6.3258097e-9,7.7616946e-8,7.8867646e-7,0.00009029072,0.040795647],"study_design_scores_gemma":[0.011923649,0.001385252,0.00049943256,0.9594867,0.012083693,0.00032451504,0.00000492968,0.0000013294575,0.000002236382,9.933617e-7,0.013839417,0.00044784485],"about_ca_topic_score_codex":0.00016867834,"about_ca_topic_score_gemma":0.00005983588,"teacher_disagreement_score":0.0403478,"about_ca_system_score_codex":0.00039656984,"about_ca_system_score_gemma":0.0006822835,"threshold_uncertainty_score":0.9998015},"labels":[],"label_agreement":null},{"id":"W2577615809","doi":"10.1182/blood.v112.11.864.864","title":"Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Lenalidomide; Multiple myeloma; Refractory (planetary science); Proteasome inhibitor; Internal medicine; Thalidomide; Progressive disease; Phases of clinical research; Dexamethasone; Gastroenterology; Oncology; Pharmacology; Toxicity; Chemotherapy; Biology","score_opus":0.06796061892251935,"score_gpt":0.33243604603545795,"score_spread":0.2644754271129386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577615809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962691,0.00016371527,0.0000012892459,0.000048043687,0.000041854742,0.001842109,0.00031944434,0.00003997171,0.0012744534],"genre_scores_gemma":[0.9972885,0.000050713355,0.0017031747,0.00005022048,0.000057210404,0.000068422596,0.00053029635,0.000053308715,0.00019811725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974089,0.00019186028,0.00058932963,0.0006260269,0.000679053,0.00050478446],"domain_scores_gemma":[0.9982764,0.00015966827,0.00021974987,0.00064364023,0.0002588249,0.000441722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002420725,0.00030829656,0.0006494088,0.00027081007,0.00021596637,0.00002302109,0.00023324032,0.00013818296,0.000028401493],"category_scores_gemma":[0.000549447,0.00024168585,0.000026978763,0.0003555379,0.00025303537,0.000381489,0.0002520155,0.00031432498,0.0000058149817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05990254,0.22872148,0.6662097,0.0001318809,0.00072648184,0.0022124497,0.0036033408,0.0000012147834,0.015049406,0.0000046282476,0.00030246118,0.023134418],"study_design_scores_gemma":[0.39774644,0.067639165,0.51682407,0.00026208666,0.00017340978,0.000053313892,0.00018084193,0.000057766534,0.016387666,0.00000536205,0.000373186,0.0002967106],"about_ca_topic_score_codex":0.0008028706,"about_ca_topic_score_gemma":0.00049106445,"teacher_disagreement_score":0.3378439,"about_ca_system_score_codex":0.00007962702,"about_ca_system_score_gemma":0.00024049357,"threshold_uncertainty_score":0.9855663},"labels":[],"label_agreement":null},{"id":"W2578051459","doi":"10.1182/blood.v106.11.2568.2568","title":"Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; McGill University; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Population; Melphalan; Multiple myeloma; Randomization; Dexamethasone; Lenalidomide; Transplantation; Surgery; Randomized controlled trial","score_opus":0.02077457200410801,"score_gpt":0.30534009570836096,"score_spread":0.2845655237042529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578051459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638087,0.000306513,0.00000740799,0.00007847467,0.0000128933025,0.0019286287,0.0010897313,0.000036224515,0.00015924989],"genre_scores_gemma":[0.997125,0.000022560062,0.00041584807,0.0000885542,0.000018138973,0.00006612093,0.0014141267,0.000030628675,0.0008189695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726456,0.00047942516,0.0007436966,0.00037713192,0.0007395204,0.00039568567],"domain_scores_gemma":[0.99720854,0.0005958196,0.0004864028,0.00066663924,0.00079744076,0.00024515737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004406534,0.00029248788,0.0014009916,0.00029599952,0.00007262942,0.000014768888,0.00016997616,0.00011527395,0.00087448995],"category_scores_gemma":[0.001351282,0.00015456545,0.00023168795,0.001222672,0.00025012865,0.000115640505,0.00003974208,0.00013760474,0.000017968341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015272811,0.004812589,0.97367036,0.00002901852,0.013781213,0.000012781325,0.0005739718,0.0000072610164,0.003292743,0.0000036710048,0.0004729844,0.0018161252],"study_design_scores_gemma":[0.032016832,0.0009973642,0.92275226,0.000050238057,0.007666741,0.000002637652,0.000084647254,0.0006496908,0.03555256,6.7293223e-7,0.00008600817,0.0001403382],"about_ca_topic_score_codex":0.0009514072,"about_ca_topic_score_gemma":0.00027240824,"teacher_disagreement_score":0.050918095,"about_ca_system_score_codex":0.00005431066,"about_ca_system_score_gemma":0.00019415145,"threshold_uncertainty_score":0.9575052},"labels":[],"label_agreement":null},{"id":"W2578172276","doi":"10.1182/blood.v118.21.1876.1876","title":"Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Multiple myeloma; Medicine; Proteasome inhibitor; Internal medicine; Refractory (planetary science); Clinical trial; Renal function; Adverse effect; Phases of clinical research; Urology; Pharmacology; Oncology; Biology","score_opus":0.035636662927110256,"score_gpt":0.3026075490250956,"score_spread":0.26697088609798536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578172276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839985,0.00044951992,0.000019123128,0.000009262569,0.00001251092,0.0005482676,0.00044497746,0.000032659602,0.00008382783],"genre_scores_gemma":[0.9950785,0.00014708613,0.0029995856,0.000021350803,0.0000097932425,0.000025473879,0.001660497,0.00002370905,0.00003397629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986042,0.00013778913,0.00036304584,0.0003771258,0.00027448998,0.00024335414],"domain_scores_gemma":[0.9989405,0.00007191103,0.00013257252,0.0004077519,0.00025804076,0.0001892185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011663898,0.00021011011,0.0006457007,0.0003653296,0.000046139383,0.0000058895275,0.00007744075,0.00008319894,0.00018273013],"category_scores_gemma":[0.000083296414,0.000140541,0.00006167028,0.00060412416,0.00014151138,0.00013459807,0.000027490825,0.00015773797,0.0000022500067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012193121,0.007162366,0.96166646,0.000012521615,0.005697882,0.000088953806,0.0023781364,5.9215307e-7,0.0019802165,0.0000013546794,0.000008349581,0.00881007],"study_design_scores_gemma":[0.06355729,0.0028804569,0.92180246,0.0000536748,0.0010518119,6.059875e-7,0.00062017137,0.00022106832,0.009631299,0.000009310781,0.000043173844,0.00012868196],"about_ca_topic_score_codex":0.0026780493,"about_ca_topic_score_gemma":0.0017301477,"teacher_disagreement_score":0.05136417,"about_ca_system_score_codex":0.00005190111,"about_ca_system_score_gemma":0.000059217513,"threshold_uncertainty_score":0.57310957},"labels":[],"label_agreement":null},{"id":"W2578678001","doi":"10.1182/blood.v116.21.4036.4036","title":"Prognostic Relevance of Genomic Aberrations In Light Chain Only Multiple Myeloma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Multiple myeloma; Internal medicine; Gastroenterology; Fluorescence in situ hybridization; Medicine; Progression-free survival; Immunoglobulin light chain; Autologous stem-cell transplantation; Monoclonal; Confidence interval; Oncology; Plasma cell; Chemotherapy; Antibody; Biology; Monoclonal antibody; Immunology","score_opus":0.01468643369673203,"score_gpt":0.27305550158228953,"score_spread":0.2583690678855575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578678001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553806,0.00019911773,0.000009999173,0.0004463452,0.0000631888,0.00072803313,0.000020118783,0.000030077465,0.00296508],"genre_scores_gemma":[0.99502516,0.000031607513,0.0038710132,0.000024184312,0.00008236946,0.00007648214,0.000032490658,0.000019042636,0.00083767733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990416,0.000026159536,0.0002440965,0.00021302683,0.00020242594,0.00027268403],"domain_scores_gemma":[0.99922585,0.00016893113,0.000056105633,0.0003304934,0.00007484395,0.0001437873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011491153,0.00010948298,0.00021564217,0.00014887139,0.00003894879,0.000007493455,0.000087275046,0.00007882309,0.00009124358],"category_scores_gemma":[0.0008729777,0.00009234737,0.00005559161,0.00016942504,0.000053631582,0.00004642363,0.000033986642,0.00025389067,0.00009352226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007931845,0.0014562523,0.66733444,0.000056522083,0.00006190458,0.00012017837,0.00019717104,8.9555374e-7,0.32585323,0.00015001505,0.0000433133,0.0046467506],"study_design_scores_gemma":[0.006205331,0.0002634418,0.9483166,0.000062565225,0.00005072178,0.000073069525,0.00002696676,0.00037389892,0.043572158,0.00006268096,0.00091294345,0.00007965062],"about_ca_topic_score_codex":0.00011597897,"about_ca_topic_score_gemma":0.0020508158,"teacher_disagreement_score":0.28228107,"about_ca_system_score_codex":0.00001715751,"about_ca_system_score_gemma":0.00020157151,"threshold_uncertainty_score":0.37658164},"labels":[],"label_agreement":null},{"id":"W2579787262","doi":"10.1182/blood.v126.23.1772.1772","title":"Bone Marrow Stromal Cells Induce Bortezomib Resistance in Multiple Myeloma Cells through Downregulation of miRNA-101-3p Targeting Survivin","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Bortezomib; Stromal cell; Cancer research; Panobinostat; Bone marrow; Survivin; Downregulation and upregulation; Cell culture; Biology; Multiple myeloma; microRNA; Tetherin; Stem cell; Molecular biology; Immunology; Cell biology","score_opus":0.03844603199944534,"score_gpt":0.28120865730410355,"score_spread":0.2427626253046582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579787262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950233,0.0011266252,0.000054354914,0.00017166752,0.00010007606,0.00083059486,0.00008393846,0.00004848723,0.0025609236],"genre_scores_gemma":[0.9813776,0.0000468621,0.017262945,0.000022913822,0.00013196366,0.00004303864,0.00014406527,0.00004216442,0.000928438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973632,0.00020685571,0.00061340234,0.000457793,0.0007679074,0.00059083675],"domain_scores_gemma":[0.9985519,0.00020085988,0.00023048367,0.00047134148,0.00024802514,0.0002973651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006292837,0.00025961906,0.0005461512,0.00017031237,0.000059663307,0.000022120603,0.0001450966,0.00017216982,0.000059593745],"category_scores_gemma":[0.0003871917,0.0002372193,0.000107853164,0.000428221,0.00010489996,0.0002168675,0.00008485866,0.0002668269,0.000050183055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013028652,0.0023097794,0.2014483,0.00026077923,0.00017553556,0.000417451,0.0011827067,0.000033779357,0.79081976,0.000051695635,0.0013782409,0.0006190714],"study_design_scores_gemma":[0.018630985,0.00039429718,0.30234832,0.00025565526,0.00009432251,0.0000117838335,0.0004103592,0.00026808988,0.6762656,0.00013725791,0.0009359288,0.0002473863],"about_ca_topic_score_codex":0.00096783007,"about_ca_topic_score_gemma":0.001160562,"teacher_disagreement_score":0.11455416,"about_ca_system_score_codex":0.00012683631,"about_ca_system_score_gemma":0.00025471734,"threshold_uncertainty_score":0.9673523},"labels":[],"label_agreement":null},{"id":"W2579821503","doi":"10.1182/blood.v112.11.3315.3315","title":"Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Salvage therapy; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Maintenance therapy; Autologous stem-cell transplantation; Vincristine; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.03956711233836863,"score_gpt":0.273261040609517,"score_spread":0.23369392827114838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579821503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629617,0.00008661896,0.00004203076,0.00017001072,0.0001010628,0.0026959288,0.0005313162,0.00005286053,0.000024031844],"genre_scores_gemma":[0.9983197,0.00007594375,0.0006908921,0.000083236155,0.000055721477,0.0002588031,0.00017425237,0.00004516244,0.00029628348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978243,0.00016663155,0.0005151841,0.00043781247,0.00058699143,0.00046907662],"domain_scores_gemma":[0.9985184,0.00029981174,0.00015352378,0.0004353663,0.00033089172,0.0002619869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002793987,0.00026920956,0.0005675881,0.00030897663,0.000093285424,0.0000073388987,0.00013979615,0.00015193605,0.00001109866],"category_scores_gemma":[0.000114368224,0.00019510134,0.00010306064,0.00026259298,0.000068721965,0.00012236032,0.000022928185,0.00020157165,0.000009527327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061989978,0.0044671674,0.85443455,0.00015880975,0.00015887817,0.00015321671,0.0010420785,0.000004215838,0.07162942,2.9212126e-7,0.000020385703,0.0059410296],"study_design_scores_gemma":[0.038248353,0.0067358757,0.7616086,0.0000731962,0.000041677875,0.00002582641,0.000059611335,0.000011871702,0.19293153,4.7205796e-7,0.0001282173,0.0001347643],"about_ca_topic_score_codex":0.00025737044,"about_ca_topic_score_gemma":0.000105441584,"teacher_disagreement_score":0.12130211,"about_ca_system_score_codex":0.000098280834,"about_ca_system_score_gemma":0.00019218757,"threshold_uncertainty_score":0.7956002},"labels":[],"label_agreement":null},{"id":"W2580216323","doi":"10.1182/blood.v120.21.4052.4052","title":"Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Pomalidomide; Tolerability; Internal medicine; Population; Neutropenia; Surgery; Creatinine; Gastroenterology; Multiple myeloma; Adverse effect; Lenalidomide; Toxicity","score_opus":0.025041961596287986,"score_gpt":0.3076681686536303,"score_spread":0.2826262070573423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580216323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957307,0.00010704502,0.0000082709075,0.00005582527,0.000030283325,0.0038994425,0.00011137579,0.000031010877,0.00002603881],"genre_scores_gemma":[0.99573946,0.000018703222,0.003361015,0.000053709253,0.00002330347,0.00029933229,0.00042469052,0.000051527724,0.000028249433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967594,0.00027913667,0.0008420623,0.00071951404,0.0007323045,0.0006675638],"domain_scores_gemma":[0.99789226,0.00072917185,0.00027685188,0.0005674175,0.0001185954,0.00041572144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008968009,0.00035720546,0.0007224582,0.0003967116,0.000046395257,0.000029419227,0.00010466456,0.00013802024,0.0000063712496],"category_scores_gemma":[0.00054117554,0.00024270227,0.000035055862,0.00047505426,0.0001290716,0.0003304497,0.00007184416,0.00054584345,0.00000456907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059528604,0.058263563,0.8603389,0.000027455293,0.00031022396,0.00039754776,0.0013510084,0.000006635662,0.00016212392,7.367788e-7,0.000001622003,0.019611582],"study_design_scores_gemma":[0.30424133,0.01645942,0.67739516,0.0003086377,0.00012567829,0.0000029076261,0.0004816148,0.00012846696,0.00065742055,0.000003087539,0.000003476207,0.00019276775],"about_ca_topic_score_codex":0.0037135584,"about_ca_topic_score_gemma":0.0060231523,"teacher_disagreement_score":0.24471274,"about_ca_system_score_codex":0.00019896639,"about_ca_system_score_gemma":0.0001236974,"threshold_uncertainty_score":0.98971117},"labels":[],"label_agreement":null},{"id":"W2580547579","doi":"10.1182/blood.v118.21.3982.3982","title":"Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McGill University; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; McGill University Health Centre; Princess Margaret Cancer Centre; University of Manitoba; London Health Sciences Centre; CancerCare Manitoba; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Internal medicine; Surgery; Melphalan; Transplantation; Autologous stem-cell transplantation; Dexamethasone; Maintenance therapy; Lenalidomide; Gastroenterology; Chemotherapy","score_opus":0.03567060873495256,"score_gpt":0.2660870695991821,"score_spread":0.23041646086422954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580547579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375266,0.00006674062,0.0002525308,0.00006645327,0.00007124199,0.004054405,0.0005315856,0.000067946494,0.0011364415],"genre_scores_gemma":[0.99283093,0.000020697491,0.0048208213,0.00023664802,0.000064844535,0.0008874636,0.00094455516,0.000048262005,0.0001457954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836886,0.00006489466,0.00025333828,0.00035508192,0.00047926715,0.0004785758],"domain_scores_gemma":[0.998661,0.00018482753,0.00009947256,0.00020966867,0.00038592136,0.00045912087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013757762,0.0002280466,0.00029752494,0.00024168339,0.00017069986,0.00002202447,0.00010269894,0.000119965895,0.00007407413],"category_scores_gemma":[0.00004398586,0.00016993468,0.000103481354,0.00014801753,0.00005700204,0.00008779137,0.0000030975834,0.00010966508,0.000020496902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08596653,0.005130574,0.8929721,0.00012760781,0.0004769018,0.00023637795,0.0008341397,0.000006038648,0.00017281192,0.000014468119,0.00021137398,0.013851047],"study_design_scores_gemma":[0.32702833,0.0042662327,0.65709746,0.000047338017,0.0001776006,0.00000639888,0.000029456314,0.00025910584,0.010526285,0.000008994882,0.00036432184,0.00018849767],"about_ca_topic_score_codex":0.010163542,"about_ca_topic_score_gemma":0.024137545,"teacher_disagreement_score":0.2410618,"about_ca_system_score_codex":0.000109693945,"about_ca_system_score_gemma":0.0011389123,"threshold_uncertainty_score":0.9964279},"labels":[],"label_agreement":null},{"id":"W2581040141","doi":"10.1182/blood.v124.21.2075.2075","title":"Inherited Loss of Samsn1 Contributes to Increased Risk of MGUS and MM through Effects on Multiple Cell Types, Including B-Cells, Transformed Myeloma Cells, and Macrophages","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Biology; Plasma cell; Multiple myeloma; Plasma cell dyscrasia; Cancer research; Immunology; B cell; T cell; Molecular biology; Immune system; Monoclonal; Antibody; Immunoglobulin light chain; Monoclonal antibody","score_opus":0.011576200661810178,"score_gpt":0.257458820482916,"score_spread":0.24588261982110585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581040141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965467,0.0016205894,0.00012731456,0.00007406268,0.000038005986,0.0010772888,0.00021168892,0.000030343606,0.00027402013],"genre_scores_gemma":[0.9971102,0.0007485332,0.0018739422,0.0000787267,0.00004071129,0.000033596254,0.000038509985,0.000031917058,0.000043855962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985168,0.00019393457,0.0003113674,0.00033586987,0.00028929466,0.00035275082],"domain_scores_gemma":[0.99800813,0.0012338836,0.00011577688,0.00027668552,0.0001112622,0.0002542658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002698543,0.00023902416,0.00061227434,0.00014452559,0.000091082045,0.000013746166,0.000080236154,0.00012380141,0.000009065766],"category_scores_gemma":[0.00050141383,0.00018861571,0.00007198378,0.00021545238,0.00012589275,0.00004797661,0.0000624093,0.0001662683,0.0000067856763],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020178196,0.0016654867,0.219411,0.0014706759,0.0005278253,0.00008348144,0.00051159714,0.000003238057,0.766974,0.000017568509,0.00007657772,0.0072407676],"study_design_scores_gemma":[0.022055343,0.0018721317,0.16072822,0.00030264244,0.0003701715,0.000006976419,0.000037082824,0.00018744095,0.8140188,0.000043599488,0.00025681898,0.00012077729],"about_ca_topic_score_codex":0.0011824789,"about_ca_topic_score_gemma":0.00008553404,"teacher_disagreement_score":0.058682796,"about_ca_system_score_codex":0.000022932063,"about_ca_system_score_gemma":0.000042098483,"threshold_uncertainty_score":0.7691526},"labels":[],"label_agreement":null},{"id":"W2581122960","doi":"10.1182/blood.v104.11.943.943","title":"Outcome after Second Autologous Stem Cell Transplantation as Salvage Therapy in Patients with Relapsed Multiple Myeloma.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Salvage therapy; Surgery; Transplantation; Median follow-up; Internal medicine; Etoposide; Regimen; Autologous stem-cell transplantation; Gastroenterology; Chemotherapy","score_opus":0.012340145528378869,"score_gpt":0.24934638105985235,"score_spread":0.23700623553147349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581122960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770474,0.00015362779,0.000015053267,0.000060513932,0.0000333436,0.0011171359,0.000059400023,0.000061172395,0.00079502293],"genre_scores_gemma":[0.9984057,0.000027081394,0.00066288176,0.00017172279,0.000018209606,0.00013289321,0.00013890507,0.00003656789,0.00040602937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863094,0.000048433994,0.0002646694,0.0003196865,0.00036394334,0.00037233098],"domain_scores_gemma":[0.9994045,0.000049108952,0.00005355328,0.00026378303,0.000056431527,0.00017260965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007003827,0.00020282727,0.00028066026,0.00015664165,0.00004357221,0.000017064607,0.00006850032,0.00010531834,0.00014648275],"category_scores_gemma":[0.000007795156,0.00014416307,0.00006235535,0.00016492285,0.000040542356,0.000107214844,0.000008936867,0.00020550843,0.00013437228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003827933,0.0026000848,0.9873281,0.00011196405,0.00009377482,0.0011964948,0.0007940112,0.0000049045802,0.00070587476,0.0000026915902,0.0000016609062,0.003332508],"study_design_scores_gemma":[0.0674269,0.0019813313,0.9092118,0.000057073794,0.00005550899,0.000024063043,0.00003587397,0.000002673884,0.021025104,0.000011254246,0.000030506082,0.00013787074],"about_ca_topic_score_codex":0.000117521246,"about_ca_topic_score_gemma":0.00029246413,"teacher_disagreement_score":0.07811625,"about_ca_system_score_codex":0.000074826945,"about_ca_system_score_gemma":0.00009220724,"threshold_uncertainty_score":0.58787996},"labels":[],"label_agreement":null},{"id":"W2581159256","doi":"10.1182/blood.v116.21.986.986","title":"Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Regimen; Internal medicine; Adverse effect; Interim analysis; Premedication; Phases of clinical research; Nausea; Bortezomib; Oncology; Gastroenterology; Clinical trial; Surgery","score_opus":0.016248758170867097,"score_gpt":0.29246174735512265,"score_spread":0.2762129891842556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581159256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979249,0.000017312057,0.000004820374,0.00004588104,0.00001314882,0.0017815724,0.000028589908,0.00001577424,0.00016799454],"genre_scores_gemma":[0.9983005,0.0000030020024,0.0014658484,0.0000066375387,0.0000064838946,0.00008552735,0.00008081338,0.000021241993,0.000029973768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986251,0.00009279986,0.00033809626,0.00032327528,0.0003803709,0.00024034397],"domain_scores_gemma":[0.99913853,0.00017389374,0.000118896445,0.0003022105,0.00014123949,0.00012521574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030550084,0.0001594208,0.00036848045,0.00031741348,0.000025204314,0.000011572023,0.00006292143,0.00005909047,0.0000071388267],"category_scores_gemma":[0.000489824,0.00010884787,0.00001650804,0.00033181955,0.00009610911,0.00010922527,0.00004056114,0.00029797145,0.0000016416532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027014919,0.02797285,0.9355391,0.000043866716,0.00013962854,0.00020684984,0.0010281287,4.8640214e-7,0.0028643904,0.000003626925,0.000002024342,0.0051840795],"study_design_scores_gemma":[0.28490797,0.009835429,0.6996926,0.00012727207,0.00005932809,0.000008075311,0.00023536733,0.00008176755,0.0049669705,0.0000037626953,0.0000044768294,0.00007698318],"about_ca_topic_score_codex":0.0008599181,"about_ca_topic_score_gemma":0.0037762846,"teacher_disagreement_score":0.25789303,"about_ca_system_score_codex":0.000034502948,"about_ca_system_score_gemma":0.000083612205,"threshold_uncertainty_score":0.44386873},"labels":[],"label_agreement":null},{"id":"W2581357176","doi":"10.1182/blood.v126.23.371.371","title":"Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Exome sequencing; Somatic evolution in cancer; Multiple myeloma; Exome; Biology; Plasma cell leukemia; Genetic heterogeneity; CDKN2A; Cancer research; Neuroblastoma RAS viral oncogene homolog; Bone marrow; Mutation; Pathology; Cancer; Genetics; Immunology; Medicine; Phenotype; Gene; KRAS","score_opus":0.12111700236964291,"score_gpt":0.33999963766570507,"score_spread":0.21888263529606217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581357176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99890035,0.00030998202,0.00007977302,0.00003452297,0.0000067664128,0.0005747155,0.000075372445,0.0000046181217,0.000013879495],"genre_scores_gemma":[0.99852467,0.000017294758,0.0013887746,0.0000016653138,0.000018348948,0.000013395994,0.000024329991,0.0000091970605,0.000002349909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986586,0.00022942654,0.0004557808,0.000175399,0.00027191488,0.0002088951],"domain_scores_gemma":[0.99885064,0.00029128924,0.00029328995,0.00027887346,0.0001869788,0.00009893299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000712796,0.0001476992,0.0006124826,0.00020945657,0.000053055355,0.000008476445,0.00007258297,0.000048787067,0.0000030060116],"category_scores_gemma":[0.00033990343,0.00007195323,0.00022231622,0.0005533393,0.00032257018,0.000057655678,0.000042048076,0.00009493486,1.3543641e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005027883,0.00042826033,0.9257797,0.000049536477,0.0020898387,0.0000124780745,0.0022483345,0.0036522723,0.06480253,0.000008372932,7.383565e-8,0.0004258162],"study_design_scores_gemma":[0.010609969,0.00065212534,0.6873781,0.00008159025,0.0012540929,0.0000292498,0.00062584947,0.13117345,0.16809537,0.000032811276,1.4260824e-7,0.00006723376],"about_ca_topic_score_codex":0.03359137,"about_ca_topic_score_gemma":0.0019486545,"teacher_disagreement_score":0.23840158,"about_ca_system_score_codex":0.00019646414,"about_ca_system_score_gemma":0.00032964235,"threshold_uncertainty_score":0.972844},"labels":[],"label_agreement":null},{"id":"W2581712213","doi":"10.1182/blood.v112.11.4479.4479","title":"Snk/Plk2 Methylation Is a Frequent Event in Patients with Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; DNA methylation; Monoclonal gammopathy of undetermined significance; CpG site; Biology; Cancer research; Epigenetics; Molecular biology; Gene; Genetics; Gene expression; Monoclonal","score_opus":0.020006478693872613,"score_gpt":0.2686162346726264,"score_spread":0.2486097559787538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581712213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99816626,0.00010327503,0.0000392994,0.0001278605,0.000021168002,0.00084351934,0.000026896712,0.000035539884,0.0006361568],"genre_scores_gemma":[0.99775064,0.000027548305,0.0015637621,0.00010310694,0.000034358443,0.000079605044,0.00013615485,0.000022981185,0.0002818173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985954,0.00004522315,0.00021480188,0.00027903158,0.0005367567,0.0003287694],"domain_scores_gemma":[0.9993029,0.000047944286,0.000054881733,0.00028525942,0.00011352027,0.00019548125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007078138,0.00015197396,0.00023179343,0.00016450552,0.00007178868,0.000006463942,0.000057028123,0.0000633027,0.00017376892],"category_scores_gemma":[0.000098159944,0.00011061831,0.00005959662,0.00023401587,0.000044782755,0.000084794345,0.000028007664,0.00014049372,0.00013428341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047812975,0.0028765618,0.99194807,0.000025694055,0.00015792961,0.00023683596,0.00038877034,0.0000026257217,0.00035184,0.000003645879,0.00007769199,0.0034522216],"study_design_scores_gemma":[0.024186786,0.00088345364,0.9648191,0.00006927137,0.00005147069,0.000018301447,0.000016423968,0.000112284,0.009436655,0.000012606618,0.0002869876,0.000106695734],"about_ca_topic_score_codex":0.0003192192,"about_ca_topic_score_gemma":0.00008984763,"teacher_disagreement_score":0.027128989,"about_ca_system_score_codex":0.00009076022,"about_ca_system_score_gemma":0.00010072333,"threshold_uncertainty_score":0.4510884},"labels":[],"label_agreement":null},{"id":"W2581869914","doi":"10.1182/blood.v110.11.396.396","title":"Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Comparative genomic hybridization; Genomics; Computational biology; Copy-number variation; Gene expression profiling; Biology; Genetics; Multiple myeloma; Gene; Copy number analysis; Genome; Gene deletion; Gene expression; Immunology","score_opus":0.027231807226767712,"score_gpt":0.3099051586046558,"score_spread":0.28267335137788807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581869914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969215,0.0002683179,0.00047624498,0.000041058687,0.00001891706,0.0005038672,0.000015545147,0.000018249008,0.001736294],"genre_scores_gemma":[0.96749705,0.000044828244,0.032150365,0.000027678774,0.00005097788,0.000024742465,0.0000610423,0.000013802895,0.00012953907],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990744,0.000026714686,0.00024747208,0.0001937871,0.00020340412,0.0002542185],"domain_scores_gemma":[0.99938345,0.00017000447,0.00004598164,0.00018222789,0.00006191057,0.00015640743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019835745,0.000096707896,0.00018720984,0.000099262834,0.000052852924,0.000007906634,0.00003665509,0.000060062554,0.000049946997],"category_scores_gemma":[0.00021946168,0.0000794855,0.000032339074,0.00012375115,0.000044489552,0.000057794565,0.000031669424,0.00010046095,0.000015304495],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016649436,0.00046618265,0.6120087,0.00004126162,0.00002801697,0.00011333882,0.00016188585,7.010556e-7,0.38615668,0.000009347579,0.000008182595,0.000839206],"study_design_scores_gemma":[0.0052209753,0.00007752145,0.3277773,0.00006773256,0.00002144108,0.00003163415,0.00007162879,0.00006107491,0.66657126,0.000016162667,0.00003671951,0.000046524314],"about_ca_topic_score_codex":0.000081273814,"about_ca_topic_score_gemma":0.00007649078,"teacher_disagreement_score":0.28423142,"about_ca_system_score_codex":0.000022127611,"about_ca_system_score_gemma":0.000049891605,"threshold_uncertainty_score":0.32413247},"labels":[],"label_agreement":null},{"id":"W2582434768","doi":"10.1182/blood.v116.21.2981.2981","title":"Second Clones In Molecularly-Defined Biclonal Multiple Myeloma Are Derived From Unrelated B Cells, Can Be Present at High Frequency and Exhibit Chromosomal Abnormalities","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Isotype; Biology; Molecular biology; Immunoglobulin class switching; Monoclonal; Somatic hypermutation; Complementarity determining region; Immunoglobulin light chain; Genetics; Virology; Antibody; Monoclonal antibody; Gene; B cell","score_opus":0.013334391013900713,"score_gpt":0.23086424719896112,"score_spread":0.2175298561850604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582434768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996182,0.00087927544,0.0000018922849,0.0007198264,0.00013644264,0.00075590314,0.0009186283,0.00008313896,0.00032288855],"genre_scores_gemma":[0.9961755,0.000078808145,0.0020126274,0.00011380022,0.00016017849,0.00012132348,0.00074898184,0.00005282797,0.0005359311],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99780214,0.00010475108,0.00039490484,0.0005830028,0.00047903392,0.0006361796],"domain_scores_gemma":[0.9985802,0.00024598045,0.00011824321,0.00047103575,0.00011101104,0.00047350518],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009626263,0.00034834933,0.00049059436,0.0001860743,0.00015473072,0.00005303871,0.0001394616,0.0002706712,0.0012149642],"category_scores_gemma":[0.00015900937,0.00030417598,0.00009520628,0.00017502185,0.00020598437,0.00011758028,0.00018469425,0.0005044748,0.00003145152],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023056722,0.00064806745,0.49625853,0.00006627062,0.00027086562,0.0020133364,0.00035480584,5.688959e-7,0.4999625,0.000020550797,0.000037793827,0.00013613395],"study_design_scores_gemma":[0.011172051,0.0001707349,0.5864454,0.00006175655,0.00008727691,0.000099308665,0.00008153778,0.000072280585,0.4014502,0.00007692264,0.00009856158,0.00018398433],"about_ca_topic_score_codex":0.008468646,"about_ca_topic_score_gemma":0.02069864,"teacher_disagreement_score":0.09851231,"about_ca_system_score_codex":0.00006928895,"about_ca_system_score_gemma":0.00015337422,"threshold_uncertainty_score":0.99994105},"labels":[],"label_agreement":null},{"id":"W2582502952","doi":"10.1182/blood.v104.11.2479.2479","title":"Targeting FGFR3 in t(4;14) Mutiple Myeloma: Pre-Clinical Studies of PRO-001, a Novel Anti-FGFR3 Neutralizing Antibody.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chromosomal translocation; Cancer research; Biology; Antibody; Multiple myeloma; Molecular biology; Fibroblast growth factor receptor 3; Cyclin D1; Phage display; Receptor tyrosine kinase; Receptor; Cancer; Fibroblast growth factor; Gene; Genetics; Immunology; Cell cycle","score_opus":0.0834791114309878,"score_gpt":0.41368897569308216,"score_spread":0.33020986426209437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582502952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950046,0.0027963417,0.000039765564,0.00035740758,0.00012804978,0.0011109946,0.000031265303,0.00007061447,0.00046095],"genre_scores_gemma":[0.9924396,0.00080085866,0.0061434037,0.00006443519,0.00020026905,0.000055669727,0.00009263073,0.000040803923,0.00016228993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728644,0.00009183522,0.0008947867,0.00053180585,0.0005124017,0.00068275805],"domain_scores_gemma":[0.998683,0.00025107551,0.00020347955,0.00038999322,0.00023304755,0.00023941738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074967084,0.0002773529,0.00088533596,0.00023024311,0.00009674588,0.000016772192,0.00016427819,0.0001550233,0.000028285014],"category_scores_gemma":[0.001336642,0.00022297139,0.00017812362,0.0004192091,0.00024270818,0.00013578328,0.00016818591,0.00040608237,0.000031264823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050577987,0.011106909,0.8970138,0.00073325797,0.0010618416,0.0008102182,0.0010602291,0.000053998734,0.086138,0.00014892813,0.000083972875,0.0012830838],"study_design_scores_gemma":[0.045951627,0.0015890198,0.9179327,0.0010239662,0.0003163376,0.00010889693,0.00056137616,0.00011134418,0.03164957,0.00010972692,0.00034703303,0.00029840757],"about_ca_topic_score_codex":0.00043085386,"about_ca_topic_score_gemma":0.000099273406,"teacher_disagreement_score":0.05448843,"about_ca_system_score_codex":0.000067827226,"about_ca_system_score_gemma":0.00024748011,"threshold_uncertainty_score":0.9092509},"labels":[],"label_agreement":null},{"id":"W2582546462","doi":"10.1182/blood.v120.21.595.595","title":"Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Autologous stem-cell transplantation; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Medicine; clone (Java method); Monoclonal; Hazard ratio; Immunoglobulin light chain; Transplantation; Monoclonal antibody; Oncology; Isotype; Plasma cell; Progression-free survival; Malignancy; Internal medicine; Immunology; Antibody; Chemotherapy; Biology; Confidence interval","score_opus":0.013320627009963485,"score_gpt":0.25964524467942063,"score_spread":0.24632461766945715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582546462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982747,0.00035935853,0.000005359278,0.000038885602,0.000052300617,0.0006461354,0.00018107737,0.00003010103,0.00041211312],"genre_scores_gemma":[0.9990404,0.00003118044,0.0005536636,0.000014691586,0.00006260341,0.00006052088,0.00016595017,0.000029909987,0.0000410674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836254,0.00010034703,0.00019446817,0.0002962033,0.0005327235,0.00051372935],"domain_scores_gemma":[0.9991356,0.00018058403,0.00005623635,0.00020171233,0.000050705366,0.00037514977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015909367,0.00025308577,0.00032056024,0.00013744095,0.000060598613,0.000028690882,0.000050892322,0.000104124454,0.000024859537],"category_scores_gemma":[0.000017672046,0.00016398825,0.000042886888,0.00009022035,0.0000733294,0.00017472467,0.000036543785,0.00018024692,0.000004806318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077432743,0.003609766,0.98315156,0.00012832296,0.000116156174,0.00016456237,0.00034482652,0.0000013016893,0.00029392398,0.000005309169,0.000005397685,0.0044355947],"study_design_scores_gemma":[0.02944866,0.0023621204,0.9655126,0.00013254008,0.000105328225,0.000035671917,0.00002421099,0.000045110588,0.0021560122,0.0000044887424,0.00000811393,0.0001651813],"about_ca_topic_score_codex":0.000082456674,"about_ca_topic_score_gemma":0.00007389078,"teacher_disagreement_score":0.021705385,"about_ca_system_score_codex":0.000055614575,"about_ca_system_score_gemma":0.000049258535,"threshold_uncertainty_score":0.6687247},"labels":[],"label_agreement":null},{"id":"W2582570920","doi":"10.1182/blood.v120.21.931.931","title":"High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cereblon; Lenalidomide; Tissue microarray; Medicine; Multiple myeloma; Bone marrow; Dexamethasone; Oncology; Internal medicine; Cancer research; Immunohistochemistry; Biology; Ubiquitin ligase; Ubiquitin","score_opus":0.010698988344171174,"score_gpt":0.24075602917138492,"score_spread":0.23005704082721373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582570920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818814,0.00017349535,0.000004064627,0.00006700832,0.000013535686,0.0013710731,0.000017966953,0.000046277783,0.000118466756],"genre_scores_gemma":[0.9981594,0.0000100506295,0.0010693097,0.000011376397,0.000033920813,0.00018331812,0.000057761496,0.000037866404,0.00043699445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852276,0.00020433673,0.00018283984,0.00027752438,0.00032580202,0.00048675353],"domain_scores_gemma":[0.9991383,0.00011793442,0.000075231364,0.00025202121,0.0000863677,0.00033016875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022618087,0.0002206176,0.00031571055,0.00014861283,0.00006776673,0.000019459889,0.00004591573,0.000091313574,0.000031718122],"category_scores_gemma":[0.00014098166,0.00012866645,0.000021640835,0.00019250324,0.000077072735,0.00016773658,0.000041773477,0.0001858098,0.000010504038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030295186,0.002012147,0.9040632,0.000047610247,0.00011583256,0.000121868696,0.00018365982,1.859113e-7,0.06200305,0.0000027918293,0.000004172093,0.0011502717],"study_design_scores_gemma":[0.033858884,0.0024824578,0.7893746,0.0003983976,0.00007966413,0.000032523298,0.0000556367,0.000012102813,0.1735591,0.0000016985739,0.000014690053,0.00013025128],"about_ca_topic_score_codex":0.0003597106,"about_ca_topic_score_gemma":0.00006866496,"teacher_disagreement_score":0.114688635,"about_ca_system_score_codex":0.000049983253,"about_ca_system_score_gemma":0.00006460162,"threshold_uncertainty_score":0.5246865},"labels":[],"label_agreement":null},{"id":"W2582787413","doi":"10.1182/blood.v114.22.4892.4892","title":"Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Thalidomide; Multiple myeloma; Serum protein electrophoresis; Bortezomib; Gastroenterology; Refractory (planetary science); Lenalidomide; Univariate analysis; Oncology; Surgery; Immunology; Antibody; Monoclonal; Multivariate analysis; Monoclonal antibody","score_opus":0.058756396469428034,"score_gpt":0.34224736938640216,"score_spread":0.2834909729169741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582787413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945052,0.0024612914,0.0000017121853,0.00016481233,0.0000061461083,0.00255037,0.0000475213,0.000015984033,0.0002469224],"genre_scores_gemma":[0.99880946,0.00022402435,0.0003711585,0.000033920576,0.000014971478,0.00013319771,0.000033241937,0.000010664307,0.0003693743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983345,0.00024855873,0.0004555836,0.00037401877,0.00036480906,0.00022251815],"domain_scores_gemma":[0.9987444,0.00038849155,0.0001896381,0.00044826866,0.000100037665,0.0001291441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003278438,0.00020481592,0.00095996,0.0004813988,0.00004056514,0.0000038501544,0.00005610762,0.00007346828,0.00004013633],"category_scores_gemma":[0.0013247572,0.000140459,0.00015598687,0.0010727589,0.00003943144,0.000038541482,0.000016226502,0.0001569913,0.0000042215306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015738448,0.007887157,0.9755591,0.0004257784,0.0013562179,0.00036425987,0.00038629246,0.0000013975722,0.004400121,0.000023622526,0.00001015285,0.008012021],"study_design_scores_gemma":[0.019058688,0.0147787025,0.954762,0.0012653277,0.0020072674,0.0000063135058,0.000044217664,0.00005040042,0.00790901,0.000018460816,0.000007038784,0.00009261984],"about_ca_topic_score_codex":0.0001746876,"about_ca_topic_score_gemma":0.00022421035,"teacher_disagreement_score":0.020797182,"about_ca_system_score_codex":0.00021856843,"about_ca_system_score_gemma":0.00011990728,"threshold_uncertainty_score":0.5727752},"labels":[],"label_agreement":null},{"id":"W2584983278","doi":"10.1038/emm.2016.143","title":"Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease","year":2017,"lang":"en","type":"article","venue":"Experimental & Molecular Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"Health Canada; Generalitat de Catalunya","keywords":"Lenalidomide; Thalidomide; Pomalidomide; Medicine; Rheumatoid arthritis; Inflammatory bowel disease; Pharmacology; Immunology; Leflunomide; Multiple myeloma; Internal medicine; Disease","score_opus":0.012884651167790754,"score_gpt":0.3015734718313467,"score_spread":0.28868882066355595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584983278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9396167,0.057866313,0.000009124607,0.00032040785,0.00015062424,0.0013574915,0.00001400284,0.000016062202,0.0006492857],"genre_scores_gemma":[0.9986724,0.0007971008,0.00004258495,0.00015241031,0.00003428862,0.00017222554,0.000015312111,0.000051246334,0.0000624344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974634,0.0002707944,0.00061940536,0.0004282037,0.00083483936,0.00038332463],"domain_scores_gemma":[0.99806285,0.00009169237,0.0003282793,0.0011342948,0.000054648208,0.0003282486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042524535,0.00036947886,0.00076602877,0.0001663421,0.00018101178,0.00001817365,0.00035044018,0.00007618624,0.00007512834],"category_scores_gemma":[0.00014759248,0.00024527867,0.0002148878,0.00006543594,0.0012532478,0.0001949664,0.00031999603,0.00022898422,0.0000027907688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003886743,0.0003966612,0.03690931,0.00013139175,0.00023281551,0.00039780964,0.0010610858,0.000010343235,0.95506614,0.00045133536,0.000019745818,0.0014366386],"study_design_scores_gemma":[0.018448323,0.00068075606,0.14023124,0.0013868428,0.000029087163,0.00004723965,0.00054569566,0.0006365704,0.8377792,0.00005234944,0.000011654834,0.00015105674],"about_ca_topic_score_codex":0.0006993564,"about_ca_topic_score_gemma":0.0000069104467,"teacher_disagreement_score":0.11728693,"about_ca_system_score_codex":0.00013698294,"about_ca_system_score_gemma":0.000117657495,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W2585025605","doi":"10.1182/blood.v114.22.2397.2397","title":"BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CpG site; DNA methylation; Methylation; Epigenetics; Cancer research; Multiple myeloma; Biology; Bone marrow; Gene silencing; Molecular biology; Immunology; Genetics; Gene; Gene expression","score_opus":0.015491181669064177,"score_gpt":0.2760061180421629,"score_spread":0.26051493637309875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585025605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978589,0.00036405955,0.00008313697,0.00011368486,0.00015896178,0.0008107932,0.0000994149,0.00005690958,0.00045413247],"genre_scores_gemma":[0.99828285,0.000085686814,0.0008336926,0.000042003212,0.00010975409,0.000042645483,0.00041847516,0.00002496485,0.0001599571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979213,0.00012264818,0.00049086165,0.0003590212,0.0006122128,0.0004939684],"domain_scores_gemma":[0.9986772,0.00018149485,0.0001849503,0.00034449706,0.00019096867,0.00042089523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013499515,0.00020523043,0.00034997205,0.0003422813,0.000064275155,0.000016972086,0.00008725569,0.00009082594,0.00014198471],"category_scores_gemma":[0.00143476,0.00017697648,0.00014427277,0.00026940493,0.000043359738,0.00024395446,0.000041360752,0.00025669916,0.00002386955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024181958,0.006747983,0.9531103,0.00009459194,0.0001668763,0.00022421757,0.0003121044,0.000023059922,0.008261484,0.000009844198,0.00011125021,0.028520107],"study_design_scores_gemma":[0.02075383,0.0011845465,0.9725151,0.0002671748,0.00014870515,0.0000032855314,0.00007482509,0.0012504507,0.003259552,0.00005214853,0.00035928446,0.00013108963],"about_ca_topic_score_codex":0.00014331193,"about_ca_topic_score_gemma":0.00002282862,"teacher_disagreement_score":0.028389018,"about_ca_system_score_codex":0.000119020515,"about_ca_system_score_gemma":0.0001597713,"threshold_uncertainty_score":0.7216891},"labels":[],"label_agreement":null},{"id":"W2586168500","doi":"10.1182/blood.v110.11.2735.2735","title":"Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Internal medicine; Gastroenterology; Refractory (planetary science); Urology","score_opus":0.011025037036368276,"score_gpt":0.2648498630517679,"score_spread":0.25382482601539963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586168500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628925,0.00034236917,0.000026782714,0.00019783623,0.000033376095,0.0022506022,0.000109665394,0.000104764265,0.0006453565],"genre_scores_gemma":[0.99728674,0.000011662516,0.0010436958,0.00002368678,0.000054119624,0.00006968052,0.00017729096,0.0000634575,0.0012696966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742484,0.00010244285,0.000588099,0.00042633247,0.0008534701,0.00060479436],"domain_scores_gemma":[0.99826986,0.0001506112,0.00032426257,0.00056321005,0.00031616897,0.00037586302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034245403,0.00032457506,0.00068445015,0.00036971396,0.000106222506,0.000013190577,0.00013957825,0.00022950211,0.00009082985],"category_scores_gemma":[0.0003598918,0.00023170336,0.00018812978,0.0006824054,0.000047631205,0.00013683141,0.00005544157,0.0001271644,0.000031188956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003644849,0.009099251,0.7776343,0.00007714481,0.0020094388,0.0007336389,0.002327074,0.000002480509,0.19412492,0.0000014077306,0.00005282859,0.010292665],"study_design_scores_gemma":[0.026313767,0.008898926,0.5637405,0.0005158595,0.0004526693,0.0000142305325,0.00003932265,0.00013800486,0.39966372,0.0000015589983,0.00006980499,0.00015165302],"about_ca_topic_score_codex":0.00015272634,"about_ca_topic_score_gemma":0.00014909166,"teacher_disagreement_score":0.21389382,"about_ca_system_score_codex":0.00017885378,"about_ca_system_score_gemma":0.00017439765,"threshold_uncertainty_score":0.9448589},"labels":[],"label_agreement":null},{"id":"W2586268812","doi":"10.1182/blood.v110.11.3529.3529","title":"Effects of Integrin-Linked Kinase (ILK) Inhibitor QLT0267 on Multiple Myeloma Cells and Evaluation of ILK as a Therapeutic Target in Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrin-linked kinase; Cancer research; Protein kinase B; Multiple myeloma; Cell culture; Bone marrow; Medicine; Cancer; Biology; Cell cycle; Signal transduction; Immunology; Internal medicine; Cell biology","score_opus":0.02792794630012822,"score_gpt":0.3102332232520119,"score_spread":0.2823052769518837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586268812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518394,0.0014670502,0.000032375116,0.000052833875,0.00011183784,0.0025663308,0.000026225889,0.000033485125,0.0005259445],"genre_scores_gemma":[0.9983945,0.00008104134,0.001097586,0.00006043715,0.0000932885,0.000092671864,0.000051668736,0.000044318178,0.000084487736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970732,0.00027180123,0.0005941675,0.00046449996,0.0010844134,0.00051192526],"domain_scores_gemma":[0.9972933,0.0014744336,0.00020746012,0.00040659163,0.0003377513,0.00028046424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012543026,0.00030737693,0.000596765,0.0005031146,0.00005305012,0.000011145383,0.00011707039,0.00020802191,0.000052778545],"category_scores_gemma":[0.0015793592,0.00025014993,0.0001322273,0.00040170093,0.0001588841,0.00008478513,0.0000693686,0.0003204182,0.000028686294],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029416536,0.00531863,0.2196836,0.0006331006,0.00036530403,0.00026754732,0.0009585624,0.00001537874,0.7249625,0.000032230368,0.000014611162,0.04480691],"study_design_scores_gemma":[0.023678878,0.0013546845,0.41408607,0.00036046535,0.00020064914,0.000011423268,0.00013233325,0.0015966292,0.558349,0.00007246512,0.000041492694,0.00011588977],"about_ca_topic_score_codex":0.00039430236,"about_ca_topic_score_gemma":0.00025251124,"teacher_disagreement_score":0.19440247,"about_ca_system_score_codex":0.00012255368,"about_ca_system_score_gemma":0.00024134926,"threshold_uncertainty_score":0.99999505},"labels":[],"label_agreement":null},{"id":"W2586275027","doi":"10.1182/blood.v126.23.3806.3806","title":"AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Tyrosine kinase; Cancer research; Cytotoxic T cell; Monoclonal antibody; Receptor tyrosine kinase; Antibody-drug conjugate; Antibody; Biology; Medicine; In vitro; Immunology; Receptor; Internal medicine; Biochemistry","score_opus":0.047491707089885794,"score_gpt":0.32869511155459974,"score_spread":0.2812034044647139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586275027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590206,0.0016055675,0.000018695799,0.00026764304,0.00011923264,0.0015332185,0.0000946181,0.000114982206,0.00034395084],"genre_scores_gemma":[0.9968268,0.00018623467,0.0023750933,0.00015790589,0.00013002644,0.00005159477,0.000195494,0.000054133856,0.000022673454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707323,0.00015989666,0.0007661079,0.0007278947,0.0005717367,0.000701134],"domain_scores_gemma":[0.9979645,0.00035933615,0.00020486861,0.00043668563,0.00029309213,0.00074150064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040457965,0.00037115076,0.0007743768,0.00026884492,0.00013110296,0.00011617218,0.00012798411,0.00008843506,0.000034281737],"category_scores_gemma":[0.0006666834,0.00031478953,0.00011054554,0.0003829718,0.00030801335,0.0001771698,0.00014149357,0.00037783157,0.000099017074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004316006,0.0050712563,0.8787473,0.00008825724,0.00019064656,0.0013047466,0.0008148407,0.0000074329478,0.11234565,0.000019001804,0.00019719177,0.00078208366],"study_design_scores_gemma":[0.032612853,0.0009069364,0.91509694,0.0005014489,0.00014633629,0.00046444242,0.0004621528,0.0003121065,0.04852137,0.000019309751,0.00059204135,0.00036407253],"about_ca_topic_score_codex":0.00020736753,"about_ca_topic_score_gemma":0.00006103945,"teacher_disagreement_score":0.06382428,"about_ca_system_score_codex":0.000053856103,"about_ca_system_score_gemma":0.0002820215,"threshold_uncertainty_score":0.99993044},"labels":[],"label_agreement":null},{"id":"W2586319235","doi":"10.1182/blood.v108.11.2990.2990","title":"Predictors of Blood Transfusion Requirements in Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Platelet transfusion; Autologous stem-cell transplantation; Blood transfusion; Population; Univariate analysis; Hematopoietic stem cell transplantation; Surgery; Internal medicine; Multivariate analysis; Platelet","score_opus":0.01652051748870765,"score_gpt":0.2538974040890719,"score_spread":0.23737688660036427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586319235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708915,0.00014762564,0.00019780947,0.000018586252,0.00006955529,0.0016931978,0.00015597312,0.000044858887,0.0005832337],"genre_scores_gemma":[0.9979875,0.000100621815,0.0010710136,0.0000075699363,0.000040250157,0.00010566531,0.0005009485,0.000029378385,0.00015701962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998416,0.000052692467,0.0004632302,0.0003051576,0.00039578538,0.00036712445],"domain_scores_gemma":[0.99935186,0.00016879912,0.00010500842,0.00018310465,0.00009629238,0.00009491337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012341909,0.00017244257,0.00030448078,0.0002121466,0.00006159734,0.0000075237003,0.00007375277,0.000114081326,0.000010419531],"category_scores_gemma":[0.000021974836,0.00015406893,0.000110864356,0.00017548824,0.00003455315,0.00009481868,0.000009496786,0.00008694616,0.0000032122161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010595389,0.0050200773,0.96912575,0.00076768413,0.00014076909,0.00004690132,0.00023123552,0.000019344478,0.021244664,0.000008373057,0.00001356039,0.0023221208],"study_design_scores_gemma":[0.04344495,0.0015941523,0.7762461,0.00018640232,0.00042610161,0.0000051863367,0.00003555349,0.00011399803,0.17782275,0.000017106118,0.000010054758,0.00009768994],"about_ca_topic_score_codex":0.00023207725,"about_ca_topic_score_gemma":0.00043476757,"teacher_disagreement_score":0.19287968,"about_ca_system_score_codex":0.000039377737,"about_ca_system_score_gemma":0.000092031914,"threshold_uncertainty_score":0.62827486},"labels":[],"label_agreement":null},{"id":"W2586331836","doi":"10.1182/blood.v120.21.202.202","title":"A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Regimen; Population; Phases of clinical research; Internal medicine; Neutropenia; Gastroenterology; Urology; Pharmacology; Chemotherapy","score_opus":0.019072128144097235,"score_gpt":0.28473297022815425,"score_spread":0.265660842084057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586331836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710125,0.00015928932,0.000003686492,0.000028515895,0.000018840674,0.0024378556,0.000048442605,0.000030634303,0.00017145938],"genre_scores_gemma":[0.99882746,0.000023833785,0.0005802279,0.000014509148,0.000016065223,0.00013749818,0.00030414917,0.000043083888,0.000053171934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975819,0.00026414252,0.00053907215,0.00042116386,0.0006637239,0.00052998104],"domain_scores_gemma":[0.9986179,0.00023359698,0.00023048102,0.000428832,0.00019572709,0.0002934731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004672758,0.00027965257,0.00056003674,0.0004906898,0.000051980525,0.000014199887,0.00008882112,0.00010094479,0.000012920231],"category_scores_gemma":[0.00039584748,0.00020096498,0.000025599305,0.0006119767,0.00010099333,0.00032419874,0.00005990937,0.00032268264,0.000006452182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031521183,0.09847808,0.859466,0.00007996909,0.00028552304,0.00021617748,0.0024650912,0.0000035700834,0.0009169687,0.0000025189615,0.000013367972,0.006551562],"study_design_scores_gemma":[0.31579727,0.014708645,0.664834,0.00024608214,0.0001255486,0.000013447372,0.0006338432,0.000107691376,0.00337054,0.0000015022947,0.000016028074,0.00014539417],"about_ca_topic_score_codex":0.0010371008,"about_ca_topic_score_gemma":0.0011095221,"teacher_disagreement_score":0.2842761,"about_ca_system_score_codex":0.0001378766,"about_ca_system_score_gemma":0.000119729746,"threshold_uncertainty_score":0.8195114},"labels":[],"label_agreement":null},{"id":"W2586434177","doi":"10.1182/blood.v112.11.4332.4332","title":"Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Melphalan; Multiple myeloma; Internal medicine; Transplantation; Surgery; Population; Autologous stem-cell transplantation; Lymphoma; Gastroenterology; Total body irradiation; Chemotherapy; Cyclophosphamide","score_opus":0.048266432900576944,"score_gpt":0.3171237236990749,"score_spread":0.26885729079849796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586434177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99860865,0.000063578766,0.000009141017,0.00001254409,0.000024728388,0.00103091,0.00023941124,0.0000050691247,0.000005980017],"genre_scores_gemma":[0.99896765,0.00008768108,0.00081026315,0.0000071976856,0.000010846511,0.000027460044,0.000048625076,0.000012253943,0.000028006101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858975,0.00020286728,0.000545135,0.00019155079,0.00028235654,0.00018832397],"domain_scores_gemma":[0.99863994,0.00060248753,0.00025764995,0.0002948871,0.00013251313,0.00007249282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013574777,0.00012054876,0.0004580203,0.0001193389,0.000057945545,0.0000032504954,0.00009298972,0.00009920053,0.0000043853374],"category_scores_gemma":[0.00045806935,0.00006674006,0.00044152237,0.00040951083,0.00017356596,0.000046796038,0.000026084397,0.00006686023,8.3729034e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013279455,0.0033340277,0.9897123,0.00014942231,0.0015328899,0.000010673073,0.00059226755,0.0000515796,0.002020804,6.1643436e-7,0.000003016212,0.001264442],"study_design_scores_gemma":[0.02502985,0.0011788694,0.9525413,0.00006841689,0.0020914143,0.000011030319,0.000023421831,0.0013721047,0.01762945,0.0000015609884,7.7719915e-7,0.00005182969],"about_ca_topic_score_codex":0.0003565659,"about_ca_topic_score_gemma":0.0003351413,"teacher_disagreement_score":0.03717104,"about_ca_system_score_codex":0.000026192452,"about_ca_system_score_gemma":0.00025944063,"threshold_uncertainty_score":0.27215806},"labels":[],"label_agreement":null},{"id":"W2586573535","doi":"10.1182/blood.v126.23.4175.4175","title":"Ikaros-Dependent Downregulation of MYC with IMiDs in Myeloma (MM) Cells Is Mediated through the Depletion of the Acetylated Chromatin Reader BRD4 at Super-Enhancer Loci","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Enhancer; Biology; Downregulation and upregulation; BRD4; Molecular biology; Chromatin; KLF4; Cancer research; Transcription factor; Bromodomain; Histone; Gene; Genetics; SOX2","score_opus":0.02899555465763853,"score_gpt":0.27523507798788704,"score_spread":0.2462395233302485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586573535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652165,0.00043739149,0.000022032858,0.0010019745,0.000030179755,0.0010324979,0.000050873612,0.000021934502,0.000881482],"genre_scores_gemma":[0.9988059,0.00006751427,0.000287511,0.00007372075,0.000037587426,0.000053364543,0.000092263595,0.00002579971,0.00055634056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980181,0.00017140413,0.00039479285,0.00025120837,0.0008734975,0.0002909915],"domain_scores_gemma":[0.9988253,0.00010039105,0.00019101986,0.00054852816,0.00023900173,0.00009577107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027770564,0.00017900037,0.0003361049,0.00006132335,0.00005835698,0.000008689483,0.00016194885,0.00012810976,0.000191904],"category_scores_gemma":[0.00010435509,0.000090089656,0.000074247764,0.0004144821,0.00021178093,0.00009569173,0.0000929951,0.00016768867,0.000030149942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017683438,0.0018797803,0.22531505,0.00023528932,0.0006730727,0.000047965274,0.0106363,0.00011457295,0.7572243,0.00002290209,0.0011748384,0.00090755493],"study_design_scores_gemma":[0.00937195,0.00039933057,0.3347151,0.00016549033,0.0001314677,0.000029899049,0.00048166272,0.00030364215,0.65419286,0.000032286374,0.00009495884,0.00008134751],"about_ca_topic_score_codex":0.0010456998,"about_ca_topic_score_gemma":0.00059943734,"teacher_disagreement_score":0.10940004,"about_ca_system_score_codex":0.00013535518,"about_ca_system_score_gemma":0.00019308152,"threshold_uncertainty_score":0.36737496},"labels":[],"label_agreement":null},{"id":"W2586629413","doi":"10.1182/blood.v104.11.2417.2417","title":"t(4;14) Positive Multiple Myeloma Is Chemosensitive to Dexamethasone and/or Thalidomide but Not Alkylating Agents: Rapid Relapse and Not Primary Drug Resistance Explains Poor Outcomes.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Melphalan; Medicine; Internal medicine; Dexamethasone; Chemotherapy; Multiple myeloma; Vincristine; Autologous stem-cell transplantation; Oncology; Gastroenterology; Chemotherapy regimen; Surgery; Cyclophosphamide","score_opus":0.027376332065746967,"score_gpt":0.2867280161057858,"score_spread":0.25935168404003883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586629413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887664,0.0005004083,0.0000902982,0.00711447,0.000057525795,0.0017402286,0.0003721396,0.000103075894,0.0011452334],"genre_scores_gemma":[0.9641323,0.00025857837,0.025939524,0.0055383267,0.00009703581,0.00012205998,0.00009425588,0.00007663327,0.003741305],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970267,0.00013353038,0.0004892173,0.00088550453,0.0007126649,0.000752406],"domain_scores_gemma":[0.9975079,0.00087946374,0.00015796913,0.0004718581,0.00022999532,0.00075280014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042198843,0.00046409364,0.00083488284,0.00021655925,0.000323728,0.00007158031,0.00011220076,0.00014396934,0.000039559647],"category_scores_gemma":[0.0016741294,0.00036880447,0.00014152084,0.00028757678,0.00017857635,0.00021841435,0.0002433116,0.0003635073,0.00004323971],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041055366,0.0068573467,0.29621896,0.0015843139,0.0066638286,0.018461652,0.031223813,0.000006139615,0.547483,0.00018747145,0.0023287244,0.047929324],"study_design_scores_gemma":[0.036196437,0.00046410822,0.59195274,0.00058236223,0.00031679397,0.00021967806,0.00083864736,0.000022694194,0.36873782,0.000026106922,0.00021481042,0.00042783227],"about_ca_topic_score_codex":0.00048885524,"about_ca_topic_score_gemma":0.0003201182,"teacher_disagreement_score":0.29573375,"about_ca_system_score_codex":0.00023906176,"about_ca_system_score_gemma":0.00019000602,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W2587049046","doi":"10.1200/jco.2007.25.18_suppl.9056","title":"A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Thalidomide; Randomized controlled trial; Warfarin; Multiple myeloma; Chemoprophylaxis; Surgery","score_opus":0.08647644461623892,"score_gpt":0.46032977444641243,"score_spread":0.3738533298301735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587049046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1466175,0.84895104,0.0000067979545,0.0000151979175,0.00018265501,0.0041508637,0.000016860773,0.0000015652333,0.000057521385],"genre_scores_gemma":[0.1882003,0.81129044,0.00037099628,0.000024174937,0.000047888192,0.000032423726,0.0000038026087,0.000025899524,0.000004057351],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9880318,0.0046925503,0.005734816,0.00026432637,0.0010041277,0.00027234963],"domain_scores_gemma":[0.9726684,0.016749455,0.0086889,0.0005188044,0.0011498486,0.00022459084],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011710119,0.00031333853,0.012263887,0.00030315036,0.000022263195,0.0000028290717,0.00039761246,0.0005089249,0.000007852752],"category_scores_gemma":[0.031789754,0.00014396587,0.0009854925,0.0005533328,0.0004972484,0.000071032555,0.00016586561,0.0012826769,0.0000010075408],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016037596,0.0023617216,0.065479696,0.76244193,0.0014394849,0.00014270362,0.000037252918,2.1057312e-7,8.909359e-7,0.0000035979504,0.0000025873853,0.16648616],"study_design_scores_gemma":[0.004998507,0.010336398,0.29624096,0.6852023,0.0026737764,0.00016212491,0.000009173289,9.839792e-7,0.0000064071705,0.00000949625,0.0002802233,0.00007961915],"about_ca_topic_score_codex":0.000066419234,"about_ca_topic_score_gemma":0.00003307503,"teacher_disagreement_score":0.23076126,"about_ca_system_score_codex":0.00028471265,"about_ca_system_score_gemma":0.0024921244,"threshold_uncertainty_score":0.97636586},"labels":[],"label_agreement":null},{"id":"W2587347954","doi":"10.1182/blood.v120.21.1793.1793","title":"GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Thalidomide; Pomalidomide; Cancer research; Biomarker; Wnt signaling pathway; Multiple myeloma; Cereblon; Biology; Chemistry; Genetics; Immunology; Signal transduction; Gene","score_opus":0.08311589550309026,"score_gpt":0.40432308599183847,"score_spread":0.32120719048874824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587347954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990292,0.00011654358,0.000020461695,0.00021125522,0.000041813026,0.00042371015,0.000009891844,0.000010037287,0.0001370923],"genre_scores_gemma":[0.99942744,0.0000179912,0.00034562024,0.000008007668,0.00010450627,0.000019147543,0.000019617992,0.0000118630915,0.00004582629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980771,0.00072344986,0.0003750897,0.00024494945,0.00030029533,0.00027914444],"domain_scores_gemma":[0.9990285,0.00030489068,0.000100369165,0.00030342382,0.000037584712,0.00022524122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016762975,0.0000985074,0.00032946494,0.00020494757,0.000023736624,0.000011293989,0.00004733414,0.00012688384,0.000047142337],"category_scores_gemma":[0.0011133944,0.00008456205,0.000055630757,0.00015241197,0.000115152085,0.00019916685,0.00006809837,0.00015348375,0.0000051195207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024517158,0.004094543,0.8751807,0.000024407538,0.00006599756,0.000060102087,0.00020285376,4.650991e-7,0.084420785,0.000002514981,0.0000065524623,0.011423909],"study_design_scores_gemma":[0.016861958,0.0003868573,0.9469683,0.000057438057,0.000044766013,0.000022070919,0.000028553182,0.0010345526,0.034479413,0.000026829146,0.000028641496,0.000060628943],"about_ca_topic_score_codex":0.0026545322,"about_ca_topic_score_gemma":0.00068769103,"teacher_disagreement_score":0.07178757,"about_ca_system_score_codex":0.000022528922,"about_ca_system_score_gemma":0.00011184578,"threshold_uncertainty_score":0.40128762},"labels":[],"label_agreement":null},{"id":"W2587495422","doi":"10.1182/blood.v126.23.3176.3176","title":"Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Bortezomib; Oncology; Transplantation; Median follow-up; Regimen; Surgery; Chemotherapy","score_opus":0.01698268058370789,"score_gpt":0.24718602575450516,"score_spread":0.23020334517079727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587495422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952871,0.00050904916,0.00031828767,0.00015560482,0.000046229063,0.001618141,0.0015107848,0.00007867661,0.00047608122],"genre_scores_gemma":[0.9957411,0.00033704465,0.0018155955,0.00014976317,0.00007036383,0.00026573706,0.0009433832,0.000059849255,0.00061711756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824053,0.000081250495,0.0002577393,0.00040290502,0.0005411683,0.0004763931],"domain_scores_gemma":[0.9987087,0.00015084217,0.00013711792,0.00032029426,0.00025166525,0.00043132872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010620108,0.00026327465,0.0003495533,0.0000714682,0.000113251444,0.000035954014,0.00012641409,0.00013816117,0.00002821554],"category_scores_gemma":[0.000027861146,0.00019379018,0.00008416339,0.0001426601,0.000049766655,0.000070376984,0.000016995686,0.00014346982,0.0000409534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015599538,0.0030717973,0.95162666,0.00016244865,0.00049512315,0.00021209593,0.0015462223,0.0000089484965,0.00065809157,0.0000027204417,0.00378824,0.036867686],"study_design_scores_gemma":[0.09619193,0.010692586,0.74061716,0.00014477366,0.0015777422,0.00004308904,0.00048096167,0.0002992094,0.1461083,0.00006351003,0.0033408392,0.00043991493],"about_ca_topic_score_codex":0.00044053467,"about_ca_topic_score_gemma":0.00027155774,"teacher_disagreement_score":0.21100953,"about_ca_system_score_codex":0.000070591865,"about_ca_system_score_gemma":0.0001756944,"threshold_uncertainty_score":0.79025346},"labels":[],"label_agreement":null},{"id":"W2587621549","doi":"10.1182/blood.v116.21.1877.1877","title":"Incidence and Characteristics of Secondary Myelodysplastic Syndrome Developing During Lenalidomide-Based Regimens In Relapsed and/or Refractory Multiple Myeloma Patients","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Internal medicine; Melphalan; Cyclophosphamide; Oncology; Prednisone; Incidence (geometry); Surgery; Gastroenterology; Chemotherapy","score_opus":0.01179877410903639,"score_gpt":0.24880662209415666,"score_spread":0.23700784798512026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587621549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991603,0.000070516675,0.0000067319315,0.00005556221,0.00007021049,0.0005252232,0.00005011777,0.00002783405,0.00003349647],"genre_scores_gemma":[0.9969035,0.00004926462,0.002807439,0.00003484748,0.000022619477,0.00004082085,0.000049374627,0.00002976268,0.00006236227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849063,0.00005544519,0.00043807985,0.00035725924,0.0003051549,0.00035341203],"domain_scores_gemma":[0.99873567,0.00046809227,0.00016783712,0.00027269445,0.00012586296,0.00022985102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018108432,0.00020742069,0.00045117064,0.0002822748,0.000085670436,0.000017551241,0.00007714601,0.00013868455,0.000039533934],"category_scores_gemma":[0.0015279168,0.0001713527,0.00003368404,0.0001731007,0.00015610269,0.00010174293,0.00009562925,0.00042926666,0.000005329647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011305095,0.0005797358,0.95863944,0.00063492276,0.00007686586,0.00089036126,0.0001490734,1.0421234e-7,0.035391092,0.0000052698942,0.0000014676327,0.0025011478],"study_design_scores_gemma":[0.01964252,0.00055985665,0.96310735,0.0006242918,0.00006365491,0.00022131485,0.000023150378,0.00009803847,0.015473924,0.000006628481,0.000017614999,0.0001616416],"about_ca_topic_score_codex":0.0000724646,"about_ca_topic_score_gemma":0.00018084534,"teacher_disagreement_score":0.01991717,"about_ca_system_score_codex":0.00004906645,"about_ca_system_score_gemma":0.00031922112,"threshold_uncertainty_score":0.69875604},"labels":[],"label_agreement":null},{"id":"W2587780452","doi":"10.5114/dr.2016.63842","title":"Skin lesions caused by bortezomib targeted therapy of multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Dermatology Review","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Dermatology; Internal medicine","score_opus":0.03670174797203895,"score_gpt":0.3312882843176453,"score_spread":0.29458653634560633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587780452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49534717,0.4794501,0.0002748582,0.02080712,0.000104959414,0.0026923255,0.00020919484,0.000127029,0.0009872348],"genre_scores_gemma":[0.7641418,0.2337849,0.0002244772,0.0011961074,0.000013305761,0.00014072635,0.00010473252,0.00002338646,0.00037054825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841714,0.00021700135,0.00048176944,0.00027782167,0.00022487665,0.0003814203],"domain_scores_gemma":[0.9986669,0.00028845764,0.00014946958,0.0005184241,0.00014252539,0.00023424615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012208555,0.00019599237,0.00082303234,0.00008034213,0.00005467147,0.000002319215,0.00013773564,0.00011197575,0.0007406428],"category_scores_gemma":[0.0003812639,0.00010727072,0.00019615043,0.00020032549,0.00017304796,0.00005677952,0.000037918144,0.00010076822,0.00029626332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028817906,0.00093229255,0.28600693,0.0021200145,0.0008474137,0.0005839077,0.00005377132,8.106737e-9,0.05771737,0.000120556826,0.15544306,0.4958865],"study_design_scores_gemma":[0.015350346,0.0003869698,0.22387505,0.0050924295,0.0001848266,0.0010180429,0.000013024974,0.000021671067,0.15515366,0.00005309234,0.59849197,0.0003588998],"about_ca_topic_score_codex":0.000028555893,"about_ca_topic_score_gemma":0.0000094798725,"teacher_disagreement_score":0.49552763,"about_ca_system_score_codex":0.000033147375,"about_ca_system_score_gemma":0.00011819359,"threshold_uncertainty_score":0.8109519},"labels":[],"label_agreement":null},{"id":"W2587789435","doi":"10.1182/blood.v116.21.1090.1090","title":"Thromboprophylaxis In Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide and Lenalidomide: A Systematic Review and Meta-Analysis.","year":2010,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Internal medicine; Multiple myeloma; Population; Warfarin; Dexamethasone; Surgery","score_opus":0.07006178504004101,"score_gpt":0.32787614210384375,"score_spread":0.25781435706380273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587789435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004002814,0.9868536,0.0000017458825,0.000028344286,0.000010278836,0.008908486,0.00010345415,0.00003244959,0.00005884967],"genre_scores_gemma":[0.007051252,0.9903174,0.000408579,0.00010496395,0.00001606292,0.0016244835,0.00023308695,0.00010072693,0.00014343498],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959467,0.00068523013,0.0012701645,0.00093058776,0.00065050996,0.0005168182],"domain_scores_gemma":[0.99682915,0.0007971923,0.00071557,0.0011692246,0.0001726534,0.0003162316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075868977,0.0008725625,0.010610029,0.00063870376,0.000118401615,0.00008574541,0.00020705184,0.00031007515,0.00006979902],"category_scores_gemma":[0.0004997579,0.00045977574,0.0012548962,0.00084929616,0.00016748888,0.00012612862,0.000121511766,0.0007190993,0.0000159595],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052177165,0.0010123813,0.0029235017,0.7414549,0.2481467,0.00019743538,0.000043410822,2.9214954e-8,9.110794e-7,0.000004388035,0.0000029991195,0.0061611678],"study_design_scores_gemma":[0.009617868,0.00079250487,0.0024054633,0.058487386,0.9266337,0.00023483044,0.000010692746,0.000002337548,0.000004824111,0.0000060489733,0.0012292615,0.0005750474],"about_ca_topic_score_codex":0.00012766093,"about_ca_topic_score_gemma":0.0002884095,"teacher_disagreement_score":0.68296754,"about_ca_system_score_codex":0.0000738511,"about_ca_system_score_gemma":0.0002947521,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W2587835525","doi":"10.1182/blood.v114.22.3861.3861","title":"Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; University of Calgary; London Health Sciences Centre; CancerCare Manitoba; Dalhousie University; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Dexamethasone; Melphalan; Transplantation; Maintenance therapy; Surgery; Gastroenterology; Lenalidomide; Autologous stem-cell transplantation; Prednisone; Hematopoietic stem cell transplantation; Cyclophosphamide; Oncology; Chemotherapy","score_opus":0.015246605146950967,"score_gpt":0.2583392451055925,"score_spread":0.2430926399586415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587835525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948925,0.00019512628,0.001229757,0.00019989784,0.000031494863,0.002713277,0.00019641519,0.00011401303,0.00042756068],"genre_scores_gemma":[0.9925559,0.0000583981,0.00565768,0.00042153272,0.0000713068,0.0002438615,0.0006901142,0.000044661494,0.00025653746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983671,0.000045940644,0.00025292728,0.00039172822,0.00046965317,0.00047267173],"domain_scores_gemma":[0.998804,0.00018754244,0.00009269587,0.00034147673,0.00027012295,0.00030421597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084378145,0.000266724,0.00034170772,0.0001222139,0.00014197857,0.000033285785,0.00010615309,0.00009084183,0.000028905031],"category_scores_gemma":[0.0000205449,0.00018724446,0.00011918126,0.00016250298,0.000042403393,0.00009410175,0.0000033753186,0.00011469939,0.000019007455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008251255,0.006140548,0.94274205,0.00012877208,0.00021186082,0.00014867542,0.0002950741,0.000017026883,0.0016226765,0.0000040569785,0.00017722596,0.040260762],"study_design_scores_gemma":[0.11003211,0.0044342647,0.82612747,0.00009320026,0.00023531224,0.0000054083584,0.000026645703,0.00021486123,0.05810845,0.0000070421015,0.00050580665,0.00020943426],"about_ca_topic_score_codex":0.00003586834,"about_ca_topic_score_gemma":0.000041635096,"teacher_disagreement_score":0.1166146,"about_ca_system_score_codex":0.000033660206,"about_ca_system_score_gemma":0.00017505241,"threshold_uncertainty_score":0.7635607},"labels":[],"label_agreement":null},{"id":"W2587881875","doi":"10.1182/blood.v126.23.5351.5351","title":"Targeting Cancer Stem Cell Survival in Plasma Cell Leukemia with a Pan-BCL2 Inhibitor","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Plasma cell leukemia; Stem cell; Cancer research; Myeloid leukemia; Leukemia; Multiple myeloma; Plasma cell; Biology; Cancer stem cell; Bone marrow; CD34; Molecular biology; Immunology","score_opus":0.029672801228874408,"score_gpt":0.2736138966412132,"score_spread":0.2439410954123388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587881875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913969,0.0007918939,0.000005275962,0.00008293296,0.000076615936,0.00049514865,0.000023951057,0.000046419824,0.007080864],"genre_scores_gemma":[0.9964271,0.00005926117,0.00070829416,0.000025020092,0.00022118466,0.000098976896,0.000030268548,0.000036881716,0.002392985],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845827,0.00006956043,0.0001999813,0.00030396396,0.00049441744,0.0004738272],"domain_scores_gemma":[0.99920857,0.00005662503,0.00006023214,0.0002053683,0.000104812796,0.00036440114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019783419,0.0001786601,0.00029155557,0.00010068672,0.000036404315,0.000021622145,0.000079218946,0.00008039275,0.000034301902],"category_scores_gemma":[0.000022700175,0.00012862944,0.000036170433,0.00021792928,0.000044778077,0.0000683415,0.00004996302,0.00024553708,0.00009452979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013556371,0.0017846363,0.9705735,0.0002922102,0.0001295812,0.0019946776,0.0013234415,0.0001076515,0.01831788,0.000003437418,0.0010049184,0.003112451],"study_design_scores_gemma":[0.1471469,0.0036692414,0.098094426,0.0007097797,0.0004480175,0.00008353653,0.004882662,0.0036641026,0.7333892,0.000012510009,0.0070135123,0.00088611734],"about_ca_topic_score_codex":0.0017295027,"about_ca_topic_score_gemma":0.00064533844,"teacher_disagreement_score":0.872479,"about_ca_system_score_codex":0.00031072128,"about_ca_system_score_gemma":0.0008735941,"threshold_uncertainty_score":0.52453566},"labels":[],"label_agreement":null},{"id":"W2587935914","doi":"10.1182/blood.v114.22.2154.2154","title":"Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Leukapheresis; Autologous stem-cell transplantation; Transplantation; Cyclophosphamide; Surgery; CD34; Plerixafor; Stem cell; Regimen; Internal medicine; Mobilization; Chemotherapy; Urology; Oncology","score_opus":0.026747596890697077,"score_gpt":0.2519472397726218,"score_spread":0.2251996428819247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587935914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973661,0.00023282546,0.00019549555,0.000070239876,0.000057707824,0.0010172157,0.0003029846,0.000059678863,0.00069780013],"genre_scores_gemma":[0.9986911,0.00012994756,0.0004974146,0.000060212347,0.00004174502,0.00007124034,0.00009534419,0.000021725129,0.00039130423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981513,0.0001397552,0.00044082926,0.00037704565,0.0005094892,0.00038155197],"domain_scores_gemma":[0.99914783,0.000115636736,0.00011190787,0.00031949242,0.0001171215,0.00018798046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017477192,0.00021651191,0.00041423106,0.00020189688,0.000039554383,0.000012789563,0.00009409871,0.00017028314,0.00006041558],"category_scores_gemma":[0.000008060903,0.000189749,0.00011198837,0.0002554045,0.000051343784,0.000112404734,0.0000119895685,0.00017703068,0.000027650955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003017824,0.0051478576,0.87364405,0.0010350074,0.00008611656,0.00056163344,0.005238385,0.000028659812,0.09955298,0.0000073331043,0.000024304409,0.011655848],"study_design_scores_gemma":[0.010387855,0.0007378591,0.65335834,0.000092391194,0.00012902309,0.000018226821,0.00012534103,0.0008425487,0.33417594,0.000005974788,0.00001781582,0.00010867997],"about_ca_topic_score_codex":0.00017422457,"about_ca_topic_score_gemma":0.00015222076,"teacher_disagreement_score":0.23462296,"about_ca_system_score_codex":0.000066218796,"about_ca_system_score_gemma":0.00009812453,"threshold_uncertainty_score":0.77377397},"labels":[],"label_agreement":null},{"id":"W2588028995","doi":"10.1182/blood.v126.23.3004.3004","title":"Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Medicine; Dexamethasone; Lenalidomide; Bortezomib; In vivo; Bone marrow; Internal medicine; Cyclophosphamide; Oncology; Cancer research; Chemotherapy; Pathology; Biology","score_opus":0.06958297664270507,"score_gpt":0.3115760193165639,"score_spread":0.24199304267385885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588028995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567485,0.00015279996,0.00038044705,0.00017130437,0.00012432199,0.0020563616,0.00023187489,0.00013028042,0.0010777762],"genre_scores_gemma":[0.98815894,0.000046071,0.010698726,0.00017271243,0.000089636436,0.00030971508,0.00032107864,0.00007775949,0.0001253638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657696,0.0001195705,0.000528046,0.00081027026,0.0009715414,0.0009936221],"domain_scores_gemma":[0.9976629,0.00016999237,0.00014349593,0.0006878101,0.00043640533,0.0008994002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020912345,0.0005171677,0.0007516028,0.0002969897,0.00012175475,0.00004432524,0.000103229184,0.00020418837,0.00001457036],"category_scores_gemma":[0.0009613265,0.00041734675,0.00019752297,0.00038685504,0.0001235585,0.00023279853,0.00015751098,0.0002445136,0.000084724124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003396452,0.023251543,0.7971801,0.00009033897,0.0006581885,0.0011827076,0.0028322244,0.0006608366,0.0999206,0.000010459819,0.00010708388,0.07070947],"study_design_scores_gemma":[0.072104216,0.0032884886,0.65158325,0.00017675148,0.0002421044,0.00008315198,0.00026606032,0.068727575,0.20275094,0.00003425319,0.00018839454,0.0005548141],"about_ca_topic_score_codex":0.0023494288,"about_ca_topic_score_gemma":0.002461219,"teacher_disagreement_score":0.14559683,"about_ca_system_score_codex":0.0008064281,"about_ca_system_score_gemma":0.000731264,"threshold_uncertainty_score":0.99982786},"labels":[],"label_agreement":null},{"id":"W2588071773","doi":"10.1182/blood.v128.22.117.117","title":"A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fusion gene; Gene; Biology; DNA sequencing; Molecular biology; RNA; DNA; Genetics","score_opus":0.036764625624315574,"score_gpt":0.2900010109015289,"score_spread":0.2532363852772133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588071773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825746,0.00029073335,0.000026158832,0.0002144917,0.000018583341,0.00058861857,0.00011904928,0.0000264557,0.00045844872],"genre_scores_gemma":[0.997734,0.00018562152,0.00048854644,0.000012736633,0.000017613223,0.00007483793,0.00024201378,0.000023390583,0.0012212413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853456,0.00015125996,0.00024732575,0.00030641307,0.00045302452,0.00030743063],"domain_scores_gemma":[0.9989305,0.00021281985,0.00010032276,0.0003348762,0.00028983725,0.00013163002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002761483,0.00016798136,0.00031349235,0.00021934039,0.00005197767,0.000011957052,0.00006970684,0.00008675012,0.00033789274],"category_scores_gemma":[0.00030203455,0.00009595533,0.000031886393,0.00048190833,0.000058991263,0.00014755745,0.00003867741,0.00006146663,0.00004748965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001375863,0.0016873453,0.71150076,0.000045941477,0.0002375027,0.00010163601,0.00010804062,1.8383518e-7,0.28129444,0.0000036362762,0.00012422679,0.003520452],"study_design_scores_gemma":[0.012468135,0.0004580322,0.66830266,0.00021673649,0.00004788388,0.0000075728594,0.000033614117,0.0000060464026,0.31834275,0.000011556002,0.000035062734,0.00006996384],"about_ca_topic_score_codex":0.0024956334,"about_ca_topic_score_gemma":0.0035774002,"teacher_disagreement_score":0.04319809,"about_ca_system_score_codex":0.00008098635,"about_ca_system_score_gemma":0.00020851122,"threshold_uncertainty_score":0.39129448},"labels":[],"label_agreement":null},{"id":"W2588282992","doi":"10.1182/blood.v116.21.1968.1968","title":"Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; University of Calgary; Victoria Hospital; London Health Sciences Centre; Southlake Regional Health Center; Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; University of Alberta; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Internal medicine; Melphalan; Dexamethasone; Lenalidomide; Maintenance therapy; Surgery; Gastroenterology; Prednisone; Cyclophosphamide; Chemotherapy; Oncology","score_opus":0.011601866194161757,"score_gpt":0.2610627755224404,"score_spread":0.24946090932827863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588282992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367785,0.000034772347,0.0000026988284,0.00020090697,0.00014456474,0.0044820854,0.00009222692,0.000060107206,0.0013047898],"genre_scores_gemma":[0.9974147,0.0000065602007,0.0011845784,0.00019323122,0.00018706504,0.00062108453,0.00021368454,0.000059645132,0.000119432676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997915,0.00007160558,0.0002642893,0.0004924077,0.0005455133,0.00071116263],"domain_scores_gemma":[0.998299,0.00015106812,0.000078382276,0.0005099509,0.00023039851,0.000731196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001690579,0.00029156593,0.0004259083,0.0003493726,0.00012549217,0.000045300232,0.00014429084,0.00016534411,0.00017944482],"category_scores_gemma":[0.0004576516,0.0002076347,0.00009046768,0.00035245944,0.00011966783,0.00010245034,0.000014099313,0.0005119836,0.000049344846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03178411,0.0037295984,0.9577376,0.000010737437,0.00019811666,0.00041016605,0.00015584561,0.0000010580818,0.00028952572,0.0000053424474,0.000049566777,0.0056283306],"study_design_scores_gemma":[0.3269762,0.0020826734,0.6671049,0.000035133155,0.00003964015,0.0000032807313,0.000014165097,0.00006038475,0.0031220682,0.0000061911164,0.0003969031,0.00015844038],"about_ca_topic_score_codex":0.058325015,"about_ca_topic_score_gemma":0.41124466,"teacher_disagreement_score":0.35291964,"about_ca_system_score_codex":0.00013575422,"about_ca_system_score_gemma":0.0012679469,"threshold_uncertainty_score":0.94794565},"labels":[],"label_agreement":null},{"id":"W2588370718","doi":"10.1182/blood.v122.21.530.530","title":"RNA-Sequencing Of Paired Pre-Treatment and Relapse Samples Reveals Differentially Expressed Genes Associated With Lenalidomide Resistance In Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cereblon; Lenalidomide; Biology; Pomalidomide; Molecular biology; Exon; Multiple myeloma; Cancer research; Gene; Ubiquitin ligase; Immunology; Genetics; Ubiquitin","score_opus":0.03657468359301485,"score_gpt":0.258404923781669,"score_spread":0.22183024018865416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588370718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660224,0.0015423963,0.000022333465,0.000135975,0.000011573384,0.0013684938,0.000068395486,0.000049099166,0.00019951187],"genre_scores_gemma":[0.99457437,0.00035188606,0.0037402234,0.000014893365,0.000025274747,0.00032371993,0.00009018159,0.0000343466,0.0008451031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982594,0.00017370039,0.00041132895,0.00039602947,0.0003317129,0.00042779677],"domain_scores_gemma":[0.9986144,0.00044980954,0.00018510177,0.0003718678,0.00016164254,0.00021721341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014437194,0.00025391864,0.0005845079,0.0001500368,0.00007619695,0.000030209452,0.000082104336,0.00010195301,0.000048223865],"category_scores_gemma":[0.0005355679,0.00017479528,0.000069985974,0.00018162654,0.00012098154,0.00012061657,0.000042934153,0.000096692864,0.0000037357847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007379188,0.0010717256,0.63479435,0.00013361986,0.0005564797,0.00013650772,0.00055912405,0.0000020361492,0.36030465,0.000012205775,0.00002236585,0.0016690049],"study_design_scores_gemma":[0.019113624,0.0006204081,0.82239205,0.0007973539,0.00017937984,0.000008394438,0.00012430603,0.00006432347,0.15640591,0.00013787659,0.0000108617605,0.00014550576],"about_ca_topic_score_codex":0.0018030864,"about_ca_topic_score_gemma":0.0031686537,"teacher_disagreement_score":0.20389873,"about_ca_system_score_codex":0.00016120072,"about_ca_system_score_gemma":0.00014836139,"threshold_uncertainty_score":0.7127944},"labels":[],"label_agreement":null},{"id":"W2588557764","doi":"10.1182/blood.v120.21.4034.4034","title":"Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Pomalidomide; Daratumumab; Etoposide; Oncology; Melphalan; Internal medicine; Phases of clinical research; Lenalidomide; Chemotherapy","score_opus":0.13562963148249854,"score_gpt":0.40737554794224434,"score_spread":0.2717459164597458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588557764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970057,0.0012018307,0.0000032320324,0.00018444461,0.00013357229,0.001018958,0.000108103595,0.000014969023,0.00032917087],"genre_scores_gemma":[0.9988936,0.0002286579,0.00036792213,0.000016708495,0.00034708634,0.000042466978,0.00003454742,0.000012639223,0.000056343062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978494,0.00050566194,0.0006359918,0.00027461335,0.00032233476,0.00041202037],"domain_scores_gemma":[0.9984986,0.0006243638,0.00015156981,0.0003066188,0.00004329072,0.00037550868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022308975,0.00015592165,0.0007876966,0.00013957325,0.000040368654,0.0000058582946,0.000059244245,0.00017778079,0.00006899322],"category_scores_gemma":[0.0017718509,0.000119787896,0.000120477205,0.00018664768,0.0001186782,0.00013201479,0.0001047832,0.00027450226,0.000005686883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002347861,0.03368736,0.8415534,0.0001067032,0.00012713911,0.000047610727,0.0007394312,2.93261e-8,0.009332893,0.0000021799242,0.000037797774,0.11201758],"study_design_scores_gemma":[0.051342066,0.0015394372,0.91389924,0.00011947979,0.00013246559,0.000012235888,0.00022318943,0.000104840394,0.031977605,0.000007117244,0.0005580421,0.0000842548],"about_ca_topic_score_codex":0.00027534162,"about_ca_topic_score_gemma":0.00021960426,"teacher_disagreement_score":0.11193333,"about_ca_system_score_codex":0.000038493028,"about_ca_system_score_gemma":0.00009283698,"threshold_uncertainty_score":0.48848087},"labels":[],"label_agreement":null},{"id":"W2588865522","doi":"10.1182/blood.v118.21.634.634","title":"Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Neutropenia; Internal medicine; Clinical endpoint; Population; Phases of clinical research; Lenalidomide; Adverse effect; Dexamethasone; Febrile neutropenia; Regimen; Surgery; Gastroenterology; Randomized controlled trial; Clinical trial; Chemotherapy","score_opus":0.06689704075909599,"score_gpt":0.33766078471489747,"score_spread":0.2707637439558015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588865522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734194,0.00028220468,0.000008788487,0.000056874967,0.00001540357,0.011917076,0.00015532866,0.000029988192,0.00019238687],"genre_scores_gemma":[0.99507314,0.00039317936,0.0027746463,0.000029358353,0.000012066382,0.0010356405,0.00027501516,0.000074968804,0.0003320138],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99574155,0.0009406888,0.0010794245,0.00096395105,0.0007037963,0.0005705981],"domain_scores_gemma":[0.9969368,0.0010443003,0.00064773357,0.0006837797,0.00027971994,0.0004076898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012565904,0.0005787991,0.001982391,0.0005997587,0.00013595044,0.00006200966,0.0002066337,0.00016085824,0.000018483623],"category_scores_gemma":[0.0010211392,0.00035856402,0.000048721715,0.00041043284,0.0003372417,0.00056148844,0.0001930496,0.0002936458,0.0000014138948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6099193,0.08660563,0.280536,0.000093962226,0.0010195752,0.001101537,0.006920872,6.3186593e-7,0.00062762,0.0000011017801,0.0000037003758,0.013170075],"study_design_scores_gemma":[0.7166978,0.03303404,0.23061885,0.00069369806,0.00062927406,0.000030872226,0.0013393144,0.0002769523,0.016386766,0.000007268921,0.0000056858757,0.0002794507],"about_ca_topic_score_codex":0.007965598,"about_ca_topic_score_gemma":0.01042125,"teacher_disagreement_score":0.106778525,"about_ca_system_score_codex":0.00022810919,"about_ca_system_score_gemma":0.00028634715,"threshold_uncertainty_score":0.99988663},"labels":[],"label_agreement":null},{"id":"W2589057659","doi":"10.1182/blood.v104.11.1479.1479","title":"Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hotel Dieu Hospital","funders":"","keywords":"Medicine; Bortezomib; Hazard ratio; Dexamethasone; Internal medicine; Multiple myeloma; Clinical endpoint; Gastroenterology; Oncology; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.03250827096040593,"score_gpt":0.30562658840310425,"score_spread":0.2731183174426983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589057659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964582,0.00013698958,0.000011546375,0.00071458105,0.00007142906,0.0023747936,0.000017724858,0.000041003284,0.00017375936],"genre_scores_gemma":[0.99498034,0.0000058243254,0.004516275,0.000043477507,0.00005758258,0.0001402986,0.000017718277,0.00003113841,0.00020733303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782574,0.00010813148,0.0005660211,0.00045657106,0.0005998772,0.00044363414],"domain_scores_gemma":[0.99852085,0.00020853624,0.00010604336,0.0007805238,0.0001199396,0.00026413548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003936684,0.00022726262,0.0004988205,0.0001800212,0.00008941024,0.000016493428,0.00021205127,0.0000914068,0.000035553097],"category_scores_gemma":[0.0016543447,0.00015344616,0.00013626162,0.00065704156,0.00011324212,0.00004444947,0.00012882888,0.00029223438,0.000034420056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009964975,0.011865319,0.9475824,0.000041133768,0.00030398185,0.0048276954,0.0005892377,0.00009634857,0.031072784,0.000018374449,0.000013854194,0.002592336],"study_design_scores_gemma":[0.040916134,0.0012966539,0.9044977,0.00015088348,0.00017339956,0.00042799267,0.00031282016,0.000011502334,0.052038617,0.00002686749,0.00002330113,0.00012417026],"about_ca_topic_score_codex":0.0018142085,"about_ca_topic_score_gemma":0.0010340256,"teacher_disagreement_score":0.04308478,"about_ca_system_score_codex":0.000094024406,"about_ca_system_score_gemma":0.00043035127,"threshold_uncertainty_score":0.6257353},"labels":[],"label_agreement":null},{"id":"W2589058778","doi":"10.1182/blood.v108.11.5459.5459","title":"Combination High-Dose Cyclophosphamide and Bortezomib Is Safe and Effective for Stem Cell Harvesting in Chemotherapy Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Medicine; Bortezomib; Cyclophosphamide; Stem cell; Autologous stem-cell transplantation; Multiple myeloma; Melphalan; Surgery; Transplantation; Oncology; Internal medicine; Chemotherapy; Biology","score_opus":0.009514570107209444,"score_gpt":0.25420080630768255,"score_spread":0.2446862362004731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589058778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961078,0.0013451856,0.000043284468,0.00020595573,0.000023198829,0.0017377962,0.000031515527,0.000033792963,0.00047147533],"genre_scores_gemma":[0.996558,0.00014807578,0.0017788173,0.00010267144,0.00005406092,0.0001986047,0.00005711942,0.00003099636,0.0010716247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895626,0.000044214015,0.00020801346,0.00033608938,0.0001676129,0.00028778176],"domain_scores_gemma":[0.9991865,0.00040236,0.00007780669,0.00014859765,0.00006786512,0.00011687301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018133804,0.00016882172,0.0002810679,0.00011733204,0.00008750052,0.0000297722,0.00003274152,0.00009160799,0.000006240557],"category_scores_gemma":[0.000051002553,0.00015016686,0.000035257268,0.00010994628,0.000054905966,0.00010983562,0.000021651558,0.00011953083,0.000003094366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001030275,0.001856599,0.85811746,0.0003622018,0.0001013138,0.00009241552,0.00030329206,8.9924936e-7,0.037071325,0.00004521213,0.00012653848,0.10089249],"study_design_scores_gemma":[0.038259096,0.00066982093,0.8586515,0.00009455505,0.0000536842,0.000013629349,0.000040422397,0.00039952146,0.1010377,0.00013666278,0.000524231,0.00011915374],"about_ca_topic_score_codex":0.001160589,"about_ca_topic_score_gemma":0.00013930563,"teacher_disagreement_score":0.10077334,"about_ca_system_score_codex":0.000063351246,"about_ca_system_score_gemma":0.000036803853,"threshold_uncertainty_score":0.6123627},"labels":[],"label_agreement":null},{"id":"W2589446847","doi":"10.1182/blood.v108.11.3501.3501","title":"Diagnostic Evaluation of t[4;14] in Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Bone marrow; Flow cytometry; Biology; Gold standard (test); Pathology; Medicine; Molecular biology; Immunology; Internal medicine","score_opus":0.040885278424064725,"score_gpt":0.3205290946531306,"score_spread":0.27964381622906587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589446847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934579,0.0007874773,0.0000075333264,0.000078076584,0.000022796137,0.00066402124,0.000011107516,0.000015874402,0.004955229],"genre_scores_gemma":[0.99914217,0.000018846446,0.000449846,0.000008398945,0.000061440165,0.000097463686,0.0000830888,0.00001023256,0.00012849567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988377,0.00007317765,0.00020089316,0.00014776565,0.0005504014,0.00019003393],"domain_scores_gemma":[0.999268,0.00028632052,0.0000405502,0.00018631657,0.00016211043,0.000056687644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003304624,0.000076041826,0.00016476857,0.00013492402,0.00001870834,0.0000040631626,0.0000387287,0.000046137895,0.00012400161],"category_scores_gemma":[0.0013911154,0.00006424661,0.000044593315,0.0001847205,0.00003449544,0.00003693679,0.000017156392,0.00006738237,0.000044999193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059578815,0.0020555537,0.98222846,0.00004370058,0.00004303061,0.00008112213,0.00003269203,0.000031908734,0.0062466078,0.00003400861,0.00009238428,0.009050928],"study_design_scores_gemma":[0.015369577,0.00015070809,0.94849396,0.00008026567,0.00014989794,0.000013966963,0.000015695074,0.001253773,0.034138,0.00023450267,0.00005154338,0.000048127287],"about_ca_topic_score_codex":0.000703142,"about_ca_topic_score_gemma":0.0005519827,"teacher_disagreement_score":0.033734545,"about_ca_system_score_codex":0.000045373097,"about_ca_system_score_gemma":0.00011294445,"threshold_uncertainty_score":0.2619901},"labels":[],"label_agreement":null},{"id":"W2589997752","doi":"10.1182/blood.v112.11.1724.1724","title":"Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Gastroenterology; Internal medicine; Medicine; Lenalidomide; Transplantation; Concomitant; Beta-2 microglobulin; Median follow-up; Progression-free survival; Refractory (planetary science); Chemotherapy; Biology","score_opus":0.017301992136897554,"score_gpt":0.24472092671450177,"score_spread":0.2274189345776042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589997752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99864453,0.00033925724,0.0000018535101,0.000033976088,0.000008799633,0.00054134504,0.000018789708,0.000013156591,0.0003983083],"genre_scores_gemma":[0.9983704,0.00023637175,0.0010660549,0.000008306513,0.000015367876,0.0000398792,0.000059370985,0.000014678625,0.00018955558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991855,0.000029421724,0.00016124929,0.00019246506,0.00024054012,0.00019081247],"domain_scores_gemma":[0.9994837,0.00006210586,0.000047603407,0.00020136751,0.000071514456,0.00013370543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000020506335,0.000117465584,0.00024639265,0.000119600336,0.00004147238,0.0000021176,0.000023153254,0.00004967048,0.000021660995],"category_scores_gemma":[0.00005187179,0.00007862131,0.000030733998,0.000113816415,0.00008320683,0.000036340018,0.0000108752865,0.000050937062,0.0000079907695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012170953,0.005458276,0.98730475,0.000023409864,0.00013975713,0.00025386043,0.00025393022,3.477602e-7,0.0005061997,0.0000021868696,0.000008202646,0.0048319874],"study_design_scores_gemma":[0.0439978,0.00443946,0.9472989,0.000041373292,0.00005456023,0.00003282898,0.000018076045,0.000017581286,0.0037895902,0.0000016195197,0.00024505786,0.00006316269],"about_ca_topic_score_codex":0.00019220613,"about_ca_topic_score_gemma":0.00004342308,"teacher_disagreement_score":0.04278071,"about_ca_system_score_codex":0.000055226123,"about_ca_system_score_gemma":0.000065882276,"threshold_uncertainty_score":0.32060844},"labels":[],"label_agreement":null},{"id":"W2590011141","doi":"10.1182/blood.v108.11.5118.5118","title":"Safety and Efficacy of Bortezomib (VELCADE™) in 104 Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy: Impact of Cytogenetics on Response from a Canadian Cohort.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Proteasome inhibitor; Neutropenia; Gastroenterology; Progressive disease; Dexamethasone; Surgery; Oncology; Toxicity; Chemotherapy","score_opus":0.013976039929333913,"score_gpt":0.27634865128426556,"score_spread":0.2623726113549316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590011141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969329,0.0006799582,5.276565e-7,0.000040003724,0.0000070875562,0.0014083456,0.00083806284,0.000007126325,0.00008598822],"genre_scores_gemma":[0.99874234,0.0005188919,0.0002983772,0.0000130506705,0.000020324553,0.000016781762,0.00023039733,0.000035098346,0.00012475782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830174,0.00021267755,0.00048993825,0.00032908455,0.00035358156,0.00031299196],"domain_scores_gemma":[0.9982964,0.0006048237,0.0002447666,0.00038386308,0.00018959299,0.0002805782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019324134,0.00023426807,0.00063573115,0.00028423552,0.000044391047,0.0000051963793,0.00007243834,0.00011823734,0.0000309234],"category_scores_gemma":[0.00045446795,0.00015644479,0.000069566006,0.00017107038,0.0001812691,0.000034561745,0.00002996664,0.00014434355,6.612101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0693336,0.001721057,0.91491306,0.000033933586,0.00046681677,0.00007538765,0.0003743282,0.000023687393,0.008926585,2.2023309e-7,0.000015216608,0.004116134],"study_design_scores_gemma":[0.05311855,0.0049699508,0.92624044,0.00042371507,0.00012301074,0.000005833408,0.000022364356,0.00010764843,0.0148214465,0.0000015435872,0.00004536456,0.00012012687],"about_ca_topic_score_codex":0.09553504,"about_ca_topic_score_gemma":0.0973795,"teacher_disagreement_score":0.016215047,"about_ca_system_score_codex":0.00015834387,"about_ca_system_score_gemma":0.00043410063,"threshold_uncertainty_score":0.919091},"labels":[],"label_agreement":null},{"id":"W2590133597","doi":"10.1182/blood.v114.22.1866.1866","title":"Prolonged Use of Lenalidomide (≥12 Cycles) for Multiple Myeloma (MM) Is Frequently Affected by Dose-Limiting Thrombocytopenia but Is Associated with Improved Quality of Response and Survival.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Data monitoring committee; Refractory (planetary science); Surgery; Oncology; Randomized controlled trial; Biology","score_opus":0.06479940935999418,"score_gpt":0.32684519123499833,"score_spread":0.26204578187500416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590133597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955886,0.00019100604,0.000045113342,0.0004423833,0.000013180988,0.0023211306,0.001304228,0.000059456503,0.000034871922],"genre_scores_gemma":[0.9966901,0.00003187278,0.0025401528,0.0001489173,0.000020104653,0.00007650632,0.00019543157,0.00004026194,0.00025668406],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99734336,0.0004920961,0.00061444775,0.0004966232,0.00052505947,0.0005284233],"domain_scores_gemma":[0.9966557,0.0016900987,0.0004784837,0.0004733271,0.00044728201,0.00025508233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010360542,0.00030211848,0.0010061907,0.00012772692,0.00011509667,0.000033565695,0.000117070915,0.0001873444,0.000019903347],"category_scores_gemma":[0.003996859,0.00023488655,0.0001576023,0.00022823132,0.0001603866,0.00017295693,0.00004270173,0.00018801451,9.064906e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019036107,0.0021339108,0.22616412,0.00015300959,0.0010544816,0.000028177821,0.00043158943,1.6139747e-7,0.7493458,0.0000034443071,0.00009778738,0.001551443],"study_design_scores_gemma":[0.02978163,0.0021867172,0.5657181,0.00016905104,0.00025884373,0.00000814065,0.00007624995,0.00020569026,0.40143567,0.000011097496,0.00000938809,0.00013938174],"about_ca_topic_score_codex":0.000760816,"about_ca_topic_score_gemma":0.0002747298,"teacher_disagreement_score":0.3479101,"about_ca_system_score_codex":0.00006541506,"about_ca_system_score_gemma":0.00018737232,"threshold_uncertainty_score":0.95783955},"labels":[],"label_agreement":null},{"id":"W2590306790","doi":"10.1182/blood.v114.22.3409.3409","title":"Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (&lt;70 years).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Surgery; Transplantation; Multiple myeloma; Internal medicine; Gastroenterology","score_opus":0.016602091666397943,"score_gpt":0.24472882946800145,"score_spread":0.2281267378016035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590306790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955767,0.000104000486,0.000035852954,0.00010850738,0.00025091117,0.0013365579,0.0005598112,0.00014604823,0.0018816594],"genre_scores_gemma":[0.99575514,0.000116179384,0.00033308758,0.00019901879,0.00013800425,0.000039576553,0.001679306,0.00007207603,0.0016676264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965336,0.00018317613,0.0005433099,0.000713173,0.0011227089,0.0009040828],"domain_scores_gemma":[0.9984342,0.00012352718,0.00016670323,0.00053931284,0.00022094014,0.0005153233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001337694,0.00043909388,0.0005647302,0.00024227622,0.00013660028,0.00007661862,0.00023076951,0.00027869706,0.00009860189],"category_scores_gemma":[0.000032637643,0.00041153614,0.00023777623,0.000160449,0.00006799528,0.00022984445,0.000038206275,0.00035797872,0.00016845063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014255878,0.005010721,0.9464053,0.00011150471,0.00039730003,0.00090882095,0.0015137253,0.000004328258,0.0028949575,0.000012272199,0.0002865729,0.041028943],"study_design_scores_gemma":[0.022239061,0.0027280778,0.96705604,0.00009322713,0.00035998694,0.000019922074,0.000086878696,0.00007279957,0.0066874507,0.000027590188,0.00025146277,0.0003774804],"about_ca_topic_score_codex":0.0006510824,"about_ca_topic_score_gemma":0.00067407335,"teacher_disagreement_score":0.040651463,"about_ca_system_score_codex":0.00018780939,"about_ca_system_score_gemma":0.00017222058,"threshold_uncertainty_score":0.99983364},"labels":[],"label_agreement":null},{"id":"W2590572482","doi":"10.1186/s12885-017-3137-4","title":"High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Autologous stem-cell transplantation; Transplantation; Chemotherapy; Internal medicine; Outpatient clinic; Surgical oncology; Adverse effect; Surgery; Oncology","score_opus":0.021549173137358837,"score_gpt":0.2969497209229182,"score_spread":0.2754005477855594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590572482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893665,0.00008884656,0.000036646547,0.000045697754,0.00003892793,0.00068844954,0.0001019507,0.000011942874,0.000050884784],"genre_scores_gemma":[0.99816144,0.000077659526,0.0014868351,0.000023335562,0.000020726418,0.00007237218,0.00006305975,0.000017457312,0.00007713168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991801,0.00003327296,0.00015883634,0.00021785706,0.00021814686,0.00019183589],"domain_scores_gemma":[0.99939173,0.00003869985,0.00013721069,0.00025107863,0.00007821912,0.00010305608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000621783,0.00011110416,0.00021152881,0.00006531837,0.000081277045,0.000017558988,0.00006211553,0.00005075224,0.000021335123],"category_scores_gemma":[0.000008718009,0.0000815877,0.000019679288,0.0000311459,0.00006675664,0.00012603901,0.000011052959,0.00007534729,0.0000011020037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032564895,0.0003071905,0.91452575,0.00024636666,0.000020757625,0.000015698737,0.00095678924,0.000020679221,0.000525931,0.0000014651777,0.000004050916,0.08011884],"study_design_scores_gemma":[0.014870501,0.00070874626,0.9747107,0.00014864655,0.000025760122,0.0000010233061,0.00006760169,0.00072925206,0.008644209,0.0000020854313,0.000013160198,0.00007832079],"about_ca_topic_score_codex":0.0014711333,"about_ca_topic_score_gemma":0.0034479669,"teacher_disagreement_score":0.08004052,"about_ca_system_score_codex":0.00007276155,"about_ca_system_score_gemma":0.00008605798,"threshold_uncertainty_score":0.33270496},"labels":[],"label_agreement":null},{"id":"W2590983141","doi":"10.1182/blood.v118.21.811.811","title":"Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Bortezomib; Internal medicine; Multiple myeloma; Clinical endpoint; Panobinostat; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Surrogate endpoint; Gastroenterology; Adverse effect; Chemotherapy; Histone deacetylase","score_opus":0.019806327992397905,"score_gpt":0.2789102579825956,"score_spread":0.2591039299901977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590983141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939412,0.00005920338,0.00002052052,0.000018798504,0.00005061174,0.0042210873,0.00017587356,0.000028570852,0.0014841299],"genre_scores_gemma":[0.99802005,0.000025437086,0.001335453,0.00001089733,0.000017611306,0.00019660026,0.00032502736,0.000023323473,0.000045580684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976814,0.0002661537,0.00066389475,0.0003935885,0.0006084329,0.0003865499],"domain_scores_gemma":[0.99868584,0.0002573007,0.000289486,0.00039326955,0.00019059713,0.00018349245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004986001,0.0002407308,0.00083477667,0.00021607979,0.000028855799,0.000008227598,0.00010283236,0.000105370586,0.000021876533],"category_scores_gemma":[0.0007131969,0.0001590532,0.00008171134,0.0004381122,0.00015981864,0.00017232823,0.000033484852,0.00021283365,0.0000060946213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5851503,0.020103527,0.3926503,0.0000362221,0.00019681553,0.00025098055,0.0003206504,2.5337718e-7,0.000020609192,0.000017029104,0.000008679596,0.0012446089],"study_design_scores_gemma":[0.64015955,0.007035785,0.35149348,0.00016871109,0.00014092248,0.0000030031376,0.000041814015,0.00004310792,0.00078919274,0.000016236705,0.000008152352,0.00010006719],"about_ca_topic_score_codex":0.0012968953,"about_ca_topic_score_gemma":0.0008516806,"teacher_disagreement_score":0.0550092,"about_ca_system_score_codex":0.00010592136,"about_ca_system_score_gemma":0.00021588546,"threshold_uncertainty_score":0.64860016},"labels":[],"label_agreement":null},{"id":"W2590989844","doi":"10.14740/wjon1000w","title":"Hypoglossal Nerve Mononeuropathy as the First Presenting Symptom of Progressing Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hypoglossal nerve; Multiple myeloma; Skull; Plasmacytoma; Clivus; Pathology; Surgery; Internal medicine; Tongue","score_opus":0.04521887269094796,"score_gpt":0.3670016290731733,"score_spread":0.3217827563822253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590989844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809406,0.00072675187,0.000011803344,0.0080821365,0.0003889394,0.00036941262,0.0000031478035,0.000008824251,0.009468425],"genre_scores_gemma":[0.9970327,0.000076015785,0.0013705964,0.00010526115,0.0005330879,0.0000098251185,0.000001377054,0.00002347204,0.00084765354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981844,0.00016343161,0.00060613477,0.00016127918,0.0004950289,0.0003897644],"domain_scores_gemma":[0.9970849,0.00058951555,0.0012181142,0.0004978706,0.0003844542,0.00022515091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007132452,0.00015468984,0.00054447737,0.00021540998,0.00051601656,0.00007059053,0.0004831762,0.00006789722,0.00006812683],"category_scores_gemma":[0.0016232402,0.00009279697,0.00024741952,0.00010666021,0.00044803976,0.00019044119,0.00022004149,0.0005103508,0.000018791565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001693961,0.0007403346,0.8643259,0.00007373523,0.000428374,0.0047293366,0.0004997872,0.000011406979,0.0029141186,0.000062968684,0.00087788014,0.12364221],"study_design_scores_gemma":[0.0076149437,0.0020282513,0.93851465,0.0003282469,0.000218294,0.0026670443,0.0001268107,0.00085074414,0.006317278,0.00013437073,0.041102607,0.00009675422],"about_ca_topic_score_codex":0.00009784715,"about_ca_topic_score_gemma":0.00019954798,"teacher_disagreement_score":0.12354546,"about_ca_system_score_codex":0.00012858464,"about_ca_system_score_gemma":0.00040772845,"threshold_uncertainty_score":0.39688343},"labels":[],"label_agreement":null},{"id":"W2590996367","doi":"10.1182/blood.v106.11.3384.3384","title":"A High Throughput Seeking Myeloma Therapeutics Identifies Glucocorticoids as Inhibitors of c-Maf-Dependent Transactivation of Cyclin D2.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Transactivation; Luciferase; Cyclin; Cancer research; Cyclin D1; Biology; Transcription factor; Chemistry; Molecular biology; Cell cycle; Biochemistry; Cell; Gene; Transfection","score_opus":0.02162061704519746,"score_gpt":0.2997802515673962,"score_spread":0.2781596345221987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590996367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973555,0.00054326805,0.00046454967,0.00041091398,0.00006924457,0.00052928115,0.000019240357,0.00003997022,0.00056798937],"genre_scores_gemma":[0.9973124,0.00019714242,0.0018545164,0.00005599397,0.00015575746,0.000028097365,0.000030119572,0.00002853105,0.0003373904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822515,0.000059447277,0.000528582,0.00024331188,0.00067030906,0.00027318456],"domain_scores_gemma":[0.99909437,0.00010764452,0.00019346354,0.00032678136,0.00017749495,0.00010026793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017319627,0.00016945419,0.00038267157,0.00016409974,0.000052085208,0.00001347551,0.00009605603,0.00011077973,0.00013520992],"category_scores_gemma":[0.000064699176,0.00014037352,0.00014872999,0.00021274154,0.00010199999,0.00015021085,0.000024421273,0.00015769049,0.000023333958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067395484,0.003756315,0.055373706,0.0003103082,0.0013039268,0.000073377065,0.0018711182,0.00003109001,0.86628765,0.00023396949,0.00001033741,0.07007426],"study_design_scores_gemma":[0.0073832166,0.0005698658,0.073859684,0.00019183978,0.0003990297,0.000037041755,0.00024821673,0.000122078,0.91670746,0.00030140238,0.000076397984,0.000103775455],"about_ca_topic_score_codex":0.0003445699,"about_ca_topic_score_gemma":0.000071583025,"teacher_disagreement_score":0.06997049,"about_ca_system_score_codex":0.0000484627,"about_ca_system_score_gemma":0.00012453701,"threshold_uncertainty_score":0.5724266},"labels":[],"label_agreement":null},{"id":"W2591005764","doi":"10.1182/blood.v106.11.5086.5086","title":"Prognostic Relevance of CD56 Expression in Patients with Multiple Myeloma Treated with High-Dose Melphalan-Based Chemotherapy and Autologous Stem Cell Transplant.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Melphalan; Medicine; Multiple myeloma; Internal medicine; Chemotherapy; Gastroenterology; Bone marrow; Autologous stem-cell transplantation; Surgery; Oncology","score_opus":0.0075971534887974415,"score_gpt":0.22114338701166417,"score_spread":0.21354623352286672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591005764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981907,0.00024456336,0.00003627093,0.00006182719,0.0000039862753,0.001292625,0.000060998518,0.000050207724,0.000058802525],"genre_scores_gemma":[0.9945965,0.000035320107,0.005018361,0.00002626003,0.000012384293,0.00008720724,0.000115585244,0.000037110207,0.000071298105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868137,0.000055801964,0.00022747437,0.0003436698,0.00036245058,0.00032923883],"domain_scores_gemma":[0.9992278,0.00017133632,0.000096284944,0.0002539173,0.00008383915,0.000166771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051588562,0.00022426201,0.00038409003,0.00013482079,0.000038578306,0.000007639173,0.00006312328,0.000084461455,0.000016529273],"category_scores_gemma":[0.000011832919,0.00013987537,0.00002625841,0.00018598966,0.00008795437,0.0000672504,0.000006740149,0.00013099531,0.00000309438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007534935,0.004222293,0.9677023,0.000215226,0.00008475447,0.00016989675,0.0002572413,0.000032023316,0.007207936,3.9495566e-7,0.000003450973,0.012569544],"study_design_scores_gemma":[0.055558156,0.002548896,0.75419116,0.00048059874,0.00009303897,0.0000088956485,0.000015292666,0.00040662364,0.18657202,4.5708958e-7,0.00001080107,0.00011405126],"about_ca_topic_score_codex":0.00007709744,"about_ca_topic_score_gemma":0.000102298596,"teacher_disagreement_score":0.21351114,"about_ca_system_score_codex":0.00003136339,"about_ca_system_score_gemma":0.00007675173,"threshold_uncertainty_score":0.5703952},"labels":[],"label_agreement":null},{"id":"W2591612602","doi":"10.1182/blood.v118.21.3968.3968","title":"Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Regimen; Population; Thalidomide; Multiple myeloma; Dexamethasone; Oncology; Phases of clinical research; Gastroenterology; Chemotherapy","score_opus":0.027542022663080094,"score_gpt":0.2935291335301979,"score_spread":0.2659871108671178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591612602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979854,0.00023738563,0.000010410769,0.000024902802,0.000011486819,0.0015484813,0.00013340526,0.000016308102,0.000032190183],"genre_scores_gemma":[0.9988051,0.0002725159,0.000606019,0.000010873876,0.000006439956,0.00010823501,0.000035006742,0.00002232161,0.00013349511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981389,0.0003609684,0.00037310665,0.00045867346,0.0003904061,0.00027792013],"domain_scores_gemma":[0.9987576,0.00036720344,0.00021701962,0.00040384548,0.00010689244,0.00014744654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005876717,0.00021433563,0.000674156,0.00055614486,0.00007694179,0.000015417154,0.000080262755,0.00008486312,0.00003510441],"category_scores_gemma":[0.0008238376,0.00012126658,0.000044977984,0.0011198479,0.00020359199,0.00013865792,0.000090446636,0.00031367558,5.946661e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014274804,0.009494312,0.96744275,0.000063347965,0.0013225575,0.0004962316,0.003880714,0.000001022254,0.00091432914,0.000014214043,0.000001353091,0.0020943827],"study_design_scores_gemma":[0.09790661,0.005336552,0.8903255,0.00010893284,0.0012416218,0.000012702267,0.0016671851,0.0006936202,0.0025703562,0.000018274688,0.0000015236658,0.00011715941],"about_ca_topic_score_codex":0.0066836653,"about_ca_topic_score_gemma":0.023163777,"teacher_disagreement_score":0.08363181,"about_ca_system_score_codex":0.00010613312,"about_ca_system_score_gemma":0.00011705163,"threshold_uncertainty_score":0.9999309},"labels":[],"label_agreement":null},{"id":"W2592049596","doi":"10.1182/blood.v108.11.3551.3551","title":"Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Tolerability; Thalidomide; Population; Placebo; Refractory (planetary science); Clinical trial; Combination therapy; Multiple myeloma; Gastroenterology; Surgery; Adverse effect","score_opus":0.011774752614454983,"score_gpt":0.26231165148167435,"score_spread":0.25053689886721936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592049596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721295,0.00012713906,0.00001290417,0.00017214104,0.000014104522,0.0019043852,0.0000137061525,0.0000643532,0.00047833877],"genre_scores_gemma":[0.9948371,0.000011931874,0.003964569,0.000021249616,0.000028385864,0.00021047099,0.00014750527,0.00005605192,0.00072270684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980159,0.00014821794,0.00032135853,0.0004798479,0.0005740449,0.0004606769],"domain_scores_gemma":[0.9990331,0.00024003431,0.000107577616,0.0002668929,0.00014152285,0.00021087653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026152012,0.00025308167,0.00041649817,0.00034603127,0.00006138112,0.00003376305,0.00007439831,0.00011486835,0.00002609835],"category_scores_gemma":[0.00025394204,0.00015962472,0.000023324868,0.00045676422,0.00007439736,0.00018611585,0.00004792886,0.00024679035,0.000030836545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011890789,0.0070447233,0.9167841,0.00011136844,0.00007963484,0.0005098008,0.00015996522,0.0000030530286,0.009189267,0.000005447279,0.000042346208,0.054179475],"study_design_scores_gemma":[0.06874449,0.009454473,0.9134513,0.00058650697,0.00005699438,0.000021513766,0.000060512786,0.00020133478,0.007055477,0.000011557179,0.00014540328,0.00021043106],"about_ca_topic_score_codex":0.00089788693,"about_ca_topic_score_gemma":0.0026516085,"teacher_disagreement_score":0.056853704,"about_ca_system_score_codex":0.00012439473,"about_ca_system_score_gemma":0.00013669349,"threshold_uncertainty_score":0.6509307},"labels":[],"label_agreement":null},{"id":"W2593224771","doi":"10.1182/blood.v112.11.1702.1702","title":"Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Plasma cell leukemia; Fluorescence in situ hybridization; Transplantation; Biology; Plasma cell; Pathology; Stem cell; Bone marrow; Chromosome 13; Medicine; Internal medicine; Monoclonal; Immunology; Chromosome; Monoclonal antibody; Antibody; Gene; Genetics","score_opus":0.0187909325527553,"score_gpt":0.25285232032357596,"score_spread":0.23406138777082067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593224771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99859834,0.00032205696,0.0000052717105,0.00005278651,0.000016008336,0.0006689739,0.000168696,0.000028391965,0.00013949492],"genre_scores_gemma":[0.9992341,0.00024094696,0.00013433093,0.000014699379,0.000009998871,0.000034521046,0.00020187498,0.000021398806,0.00010816845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868506,0.0000864045,0.00023004091,0.0002687302,0.00044306432,0.0002866813],"domain_scores_gemma":[0.999226,0.00019843537,0.000099437944,0.000132655,0.000096392345,0.00024708576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006566512,0.00015558199,0.0003025451,0.00011269318,0.000091794216,0.0000068933027,0.000045900586,0.000066673856,0.000013691017],"category_scores_gemma":[0.000053546533,0.000115144954,0.000038285252,0.00018400732,0.000111872,0.00008272812,0.000014449848,0.00010422178,0.0000029108098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012918233,0.0028354123,0.9912316,0.0003260647,0.00012796058,0.0018598516,0.0006024394,0.0000018546733,0.0005849676,7.4956637e-7,0.0000051448287,0.001132096],"study_design_scores_gemma":[0.029057443,0.0009152831,0.9544867,0.00047950773,0.0001369861,0.000032732576,0.000035449084,0.00012732524,0.014617188,0.0000026536686,0.0000019571178,0.00010674138],"about_ca_topic_score_codex":0.00004072176,"about_ca_topic_score_gemma":0.00011687836,"teacher_disagreement_score":0.036744904,"about_ca_system_score_codex":0.00003951499,"about_ca_system_score_gemma":0.0001816384,"threshold_uncertainty_score":0.4695475},"labels":[],"label_agreement":null},{"id":"W2593360865","doi":"10.1182/blood.v128.22.4434.4434","title":"Multiple Myeloma Cancer Stem Cells: Immunophenotypic and Functional Characterization, Gene Expression Profiling and Therapeutic Targets","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD34; CD19; Stem cell; Flow cytometry; Cancer stem cell; Cancer research; Multiple myeloma; Bone marrow; CD20; Medicine; Molecular biology; Biology; Antibody; Immunology; Genetics","score_opus":0.02461289194391677,"score_gpt":0.25612523782062036,"score_spread":0.23151234587670358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593360865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994953,0.003635264,0.00053582905,0.00021648023,0.00007979589,0.00044745815,0.00006969981,0.000042179207,0.000020289306],"genre_scores_gemma":[0.9972813,0.0008792506,0.00062823284,0.00005772862,0.0001340671,0.00012617117,0.00004322545,0.00002284647,0.0008271662],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991184,0.000039622577,0.00014471637,0.00027719507,0.00019392918,0.00022616108],"domain_scores_gemma":[0.99950266,0.000063894324,0.000051658473,0.00015254258,0.00008287477,0.00014637045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006592321,0.00013317229,0.00016172882,0.00006053403,0.00013077841,0.0000186046,0.000026945467,0.000060967115,0.00013135107],"category_scores_gemma":[0.000013677444,0.00007986812,0.000023867817,0.000053357293,0.00006918834,0.000081132755,0.000045666595,0.0000595042,0.000015247894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026425513,0.00016141558,0.20934829,0.000043378415,0.000109975765,0.000012301439,0.000061271,7.749208e-8,0.7595718,0.0000068392105,0.000003851905,0.030416552],"study_design_scores_gemma":[0.004981716,0.00009270548,0.3778935,0.000085372885,0.000049741262,0.000018228373,0.000014442476,0.000048060265,0.6165304,0.000011863636,0.00020558202,0.00006836369],"about_ca_topic_score_codex":0.000009818025,"about_ca_topic_score_gemma":0.0000024019673,"teacher_disagreement_score":0.16854523,"about_ca_system_score_codex":0.000024757126,"about_ca_system_score_gemma":0.000059753595,"threshold_uncertainty_score":0.32569277},"labels":[],"label_agreement":null},{"id":"W2593439184","doi":"10.1182/blood.v124.21.1295.1295","title":"Targeting Patient at High Risk of Thrombocytopenia and Neutropenia with Cybord, Vel-Dex and VMP: Time to Decrease the Number of Blood Tests ?","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Neutropenia; Medicine; Bortezomib; McNemar's test; Retrospective cohort study; Internal medicine; Absolute neutrophil count; Complete blood count; Surgery; Multiple myeloma; Toxicity","score_opus":0.005989839501110271,"score_gpt":0.23969021144305458,"score_spread":0.23370037194194432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593439184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981652,0.00019891615,0.000002774993,0.00016247283,0.0000058423957,0.0006618243,0.000056632147,0.000013041634,0.00073327724],"genre_scores_gemma":[0.99647105,0.000061683895,0.003110299,0.000065065724,0.000029283663,0.000029389274,0.000021702128,0.000023533301,0.00018801012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998825,0.00011527546,0.00022703616,0.00026518916,0.00031507763,0.0002524327],"domain_scores_gemma":[0.99876326,0.00025820904,0.00013390149,0.00032245708,0.00013264215,0.00038951632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018871746,0.00016192417,0.00038264447,0.000038405928,0.00010271693,0.000013140098,0.00007405596,0.000041702813,0.00023890367],"category_scores_gemma":[0.00051941536,0.00009014891,0.000030024723,0.00012208936,0.00013328923,0.000040857212,0.00016260373,0.00009959306,0.000039115246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090103626,0.0009818372,0.96230906,0.00009905964,0.00056652224,0.000053557455,0.00036478613,0.0000030542371,0.03054114,0.000021159478,0.00013740094,0.0040213754],"study_design_scores_gemma":[0.012848861,0.0026456064,0.900751,0.00021675556,0.0012208701,0.00019407265,0.000051873154,0.000108356435,0.08135097,0.000027524678,0.0004187642,0.00016537671],"about_ca_topic_score_codex":0.00082466396,"about_ca_topic_score_gemma":0.000056205565,"teacher_disagreement_score":0.0615581,"about_ca_system_score_codex":0.000009110075,"about_ca_system_score_gemma":0.00005489991,"threshold_uncertainty_score":0.3676166},"labels":[],"label_agreement":null},{"id":"W2593443444","doi":"10.1182/blood.v128.22.194.194","title":"Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Interim analysis; Interquartile range; Cohort; Multiple myeloma; Exome sequencing; Univariate analysis; Clinical trial; Regimen; Bortezomib; Exome; Oncology; Surgery; Multivariate analysis; Mutation; Biology; Genetics","score_opus":0.029945130256521853,"score_gpt":0.3243466149619323,"score_spread":0.29440148470541044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593443444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898124,0.000070817485,0.00000830739,0.00022049536,0.000016877917,0.00059587025,0.0000691268,0.000010075224,0.000027209127],"genre_scores_gemma":[0.999805,0.000004996131,0.000059299913,0.000013273607,0.000005415898,0.000028856028,0.0000043794507,0.000011268133,0.000067522065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984439,0.0004662487,0.0003615205,0.00021157498,0.0003418089,0.00017493354],"domain_scores_gemma":[0.99879414,0.00032587437,0.00010370349,0.0005832388,0.00007469935,0.00011836706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005497519,0.00011361643,0.00044059675,0.0003393785,0.000023930139,0.000004299338,0.00014658317,0.000035298788,0.000018690738],"category_scores_gemma":[0.000710839,0.000058199366,0.000111582514,0.00048667964,0.00013283164,0.000046253204,0.00012914906,0.00007553614,8.145673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018200182,0.0031275698,0.9547672,0.00001929499,0.0015088898,0.0000795244,0.000991587,0.0000018034262,0.03727696,0.000002431602,0.0000021898275,0.00040247603],"study_design_scores_gemma":[0.010586745,0.00089874415,0.96269846,0.0000482965,0.0009939693,0.0000024647052,0.0006080611,0.00010062845,0.02400567,0.0000023462892,0.000005035029,0.000049568793],"about_ca_topic_score_codex":0.00043228522,"about_ca_topic_score_gemma":0.0008332193,"teacher_disagreement_score":0.013271293,"about_ca_system_score_codex":0.000027342605,"about_ca_system_score_gemma":0.000039327493,"threshold_uncertainty_score":0.23733012},"labels":[],"label_agreement":null},{"id":"W2593675088","doi":"10.1182/blood.v128.22.241.241","title":"Final Analysis of Overall Survival from the First Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Clinical endpoint; Multiple myeloma; Thalidomide; Internal medicine; Progression-free survival; Melphalan; Intention-to-treat analysis; Oncology; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.05529072315189045,"score_gpt":0.31385951154189523,"score_spread":0.2585687883900048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593675088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712485,0.00011388127,0.000024280867,0.0013224205,0.00004686344,0.00022224584,0.00015482583,0.000010587698,0.0009800318],"genre_scores_gemma":[0.9990375,0.000050328694,0.000082684135,0.00004299701,0.0001829937,0.000014839174,0.00003677914,0.0000054519096,0.0005464289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921525,0.000040015162,0.00014648147,0.0001386021,0.0003117512,0.00014792164],"domain_scores_gemma":[0.9990553,0.0004595015,0.000045155062,0.00032277123,0.000045657805,0.000071590024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011444402,0.00006782334,0.0002485882,0.00005750418,0.00003678484,0.0000057893694,0.00008800998,0.00003357026,0.0007715553],"category_scores_gemma":[0.00024115843,0.000029247529,0.00019596762,0.00017173616,0.0000483474,0.00002145873,0.00003276632,0.00004093293,0.000039033355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016339967,0.0015854283,0.96607995,0.000006218445,0.00884978,0.00007579463,0.00009242938,3.8507383e-7,0.0019942836,0.00010208876,0.00056615897,0.0043074926],"study_design_scores_gemma":[0.10523943,0.000413646,0.88755065,0.000025591233,0.0024873398,7.8992167e-7,0.000007791762,0.000019129582,0.0026428676,0.00004927741,0.0015227844,0.00004070559],"about_ca_topic_score_codex":0.0008471431,"about_ca_topic_score_gemma":0.0005050082,"teacher_disagreement_score":0.08889946,"about_ca_system_score_codex":0.000012984818,"about_ca_system_score_gemma":0.00004835804,"threshold_uncertainty_score":0.8447989},"labels":[],"label_agreement":null},{"id":"W2594151149","doi":"10.1182/blood.v108.11.367.367","title":"Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Cyclin D2; Cyclin D1; Transactivation; Cancer research; Biology; Cyclin B1; Cyclin D; Cyclin A; Cell cycle; Cyclin; Molecular biology; Biochemistry; Genetics; Gene expression; Cancer; Cyclin-dependent kinase 1; Gene","score_opus":0.021516807086795476,"score_gpt":0.2839931647472843,"score_spread":0.2624763576604888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594151149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977028,0.0001588116,0.00074266887,0.000398897,0.000018835624,0.00058321597,0.00009196204,0.000038337654,0.00026448513],"genre_scores_gemma":[0.99609184,0.000027319322,0.0035029275,0.000023359153,0.00013069596,0.000023629338,0.000050301278,0.000026579297,0.00012333808],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986557,0.000038414226,0.0002652975,0.0003319858,0.00042611995,0.00028251557],"domain_scores_gemma":[0.9992947,0.00012574441,0.00010791055,0.0002119178,0.000121653575,0.00013805096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011195619,0.0001760192,0.0003750887,0.00011556221,0.00005176518,0.000015309619,0.000044718377,0.00011661401,0.00005904122],"category_scores_gemma":[0.000048287395,0.00013259597,0.000070298855,0.00022761867,0.00013465554,0.00010473729,0.000013644554,0.0001753101,0.0000034259842],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021643788,0.004748751,0.2717668,0.00016320907,0.00032189363,0.000068816276,0.00010459519,0.0000017867591,0.7173448,0.000015254169,0.000057010257,0.00324268],"study_design_scores_gemma":[0.012735146,0.0007162984,0.5232205,0.00009198255,0.0001483869,0.000038915416,0.000008613803,0.00011128634,0.46278313,0.000006966607,0.000060711856,0.00007810339],"about_ca_topic_score_codex":0.00045558746,"about_ca_topic_score_gemma":0.00008176517,"teacher_disagreement_score":0.2545617,"about_ca_system_score_codex":0.000015983256,"about_ca_system_score_gemma":0.000106921354,"threshold_uncertainty_score":0.54071075},"labels":[],"label_agreement":null},{"id":"W2594418048","doi":"10.1182/blood.v124.21.1740.1740","title":"Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Mantle cell lymphoma; Bortezomib; Adverse effect; Oncology; Neutropenia; Phases of clinical research; Discontinuation; Rituximab; Carfilzomib; Surgery; Clinical trial; Multiple myeloma; Lymphoma; Chemotherapy","score_opus":0.04972315257606459,"score_gpt":0.32868254989258977,"score_spread":0.2789593973165252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594418048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978898,0.000019882775,4.90209e-7,0.00006116394,0.000019540388,0.0012630387,0.000041285948,0.000013757817,0.0006910366],"genre_scores_gemma":[0.9994169,0.00003028346,0.00018655644,0.00003281996,0.00000774345,0.000101411366,0.00008945885,0.00001907524,0.00011573649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983288,0.0004869862,0.00034025402,0.00025906897,0.0003247592,0.0002601302],"domain_scores_gemma":[0.9986275,0.0004934435,0.00029919035,0.0003757891,0.00010891355,0.000095202966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002461229,0.00019171779,0.000555475,0.00017198118,0.000072157265,0.000011668579,0.00008720489,0.00007967655,0.000017219978],"category_scores_gemma":[0.000234977,0.00013644833,0.000030138908,0.00015292373,0.0000515243,0.00008727865,0.00006236599,0.00017951398,0.000003086116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017993974,0.049830474,0.94428724,0.000050682316,0.00024480408,0.00024196156,0.0013031934,0.000002359346,0.000059210066,0.0000030147019,0.0000013234933,0.0021763218],"study_design_scores_gemma":[0.067472845,0.027540555,0.9035765,0.00004005953,0.00015164122,0.000024728197,0.00074096065,0.000051263254,0.00027265103,0.000009710328,0.000024285033,0.00009480428],"about_ca_topic_score_codex":0.017656246,"about_ca_topic_score_gemma":0.025413092,"teacher_disagreement_score":0.06567345,"about_ca_system_score_codex":0.00040252958,"about_ca_system_score_gemma":0.00013622698,"threshold_uncertainty_score":0.9923706},"labels":[],"label_agreement":null},{"id":"W2594442364","doi":"10.1182/blood.v128.22.675.675","title":"Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Lenalidomide; Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Dexamethasone; Oncology; Internal medicine","score_opus":0.03761855174225196,"score_gpt":0.30014886028019844,"score_spread":0.26253030853794646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594442364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610436,0.0004950209,0.00014536107,0.00013346238,0.000033236847,0.0022165107,0.00060708856,0.000032815537,0.0002321714],"genre_scores_gemma":[0.99612224,0.00095548347,0.002137293,0.000006541391,0.000051773848,0.00023987476,0.000102439364,0.000031225365,0.0003531261],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976326,0.00024610842,0.00070468744,0.0005134796,0.00046099751,0.0004420897],"domain_scores_gemma":[0.99786067,0.0010627435,0.0002964184,0.00040356928,0.00012103189,0.00025554898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028411447,0.00031555074,0.0008445547,0.00029666608,0.000042508862,0.000008901651,0.000090306115,0.00014095697,0.00001819431],"category_scores_gemma":[0.00014286612,0.0001885073,0.00012586969,0.00022234529,0.00018926231,0.000106435495,0.000018176137,0.00010151973,0.000003976831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69938874,0.013995745,0.02335728,0.00046179575,0.0007692593,0.0034130905,0.002755454,0.000010050853,0.09428513,0.000009034282,0.000015237714,0.16153917],"study_design_scores_gemma":[0.6263187,0.013900459,0.057340976,0.00038857642,0.0005178221,0.000107487685,0.00016219307,0.00011863975,0.3009685,0.0000073123174,0.000022346978,0.00014699982],"about_ca_topic_score_codex":0.0014655152,"about_ca_topic_score_gemma":0.0012128515,"teacher_disagreement_score":0.20668337,"about_ca_system_score_codex":0.00013626963,"about_ca_system_score_gemma":0.0004176544,"threshold_uncertainty_score":0.76871043},"labels":[],"label_agreement":null},{"id":"W2594482699","doi":"10.1182/blood.v128.22.4517.4517","title":"Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Daratumumab; Pomalidomide; Medicine; Lenalidomide; Carfilzomib; Internal medicine; Population; Hazard ratio; Multiple myeloma; Oncology; Proportional hazards model; Propensity score matching; Progression-free survival; Confidence interval; Chemotherapy","score_opus":0.015379544027113484,"score_gpt":0.2528049908430324,"score_spread":0.2374254468159189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594482699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965449,0.00037937087,0.0000079281535,0.00011907104,0.000011709845,0.0018198167,0.00089434005,0.000083950086,0.00013893549],"genre_scores_gemma":[0.99887836,0.000024546613,0.0004147088,0.000011469449,0.000010803318,0.0000986108,0.00041548858,0.00005970969,0.00008629711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758255,0.00019923865,0.0003421667,0.0005016944,0.00085779803,0.0005165463],"domain_scores_gemma":[0.99807256,0.00025509525,0.00024175966,0.0004382756,0.0007369158,0.00025539476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010707943,0.00037140085,0.0009301651,0.00020363579,0.000112171125,0.000023124978,0.00010810114,0.00012235365,0.00002035361],"category_scores_gemma":[0.00008845245,0.00019043381,0.000038408067,0.00038944598,0.00033274826,0.00014780594,0.000040222607,0.00020899624,0.0000016569436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03512642,0.0025699101,0.9575449,0.00011139745,0.0013280722,0.00012509085,0.0017801002,8.8040343e-7,0.0005455294,0.0000019272225,0.000030548195,0.00083517964],"study_design_scores_gemma":[0.08729582,0.012104918,0.8923191,0.0012339158,0.00030678592,0.0000056463878,0.0005011773,0.000011049512,0.0059313113,4.0194968e-7,0.000056251443,0.00023363734],"about_ca_topic_score_codex":0.00055545475,"about_ca_topic_score_gemma":0.0069665946,"teacher_disagreement_score":0.06522586,"about_ca_system_score_codex":0.00019699293,"about_ca_system_score_gemma":0.0002380193,"threshold_uncertainty_score":0.77656657},"labels":[],"label_agreement":null},{"id":"W2594668490","doi":"10.1182/blood.v116.21.452.452","title":"SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"In vivo; Stromal cell; Bone marrow; Multiple myeloma; In vitro; Cancer research; Pathology; Chemistry; Medicine; Immunology; Biology; Biochemistry","score_opus":0.032647133983738356,"score_gpt":0.2853032607522818,"score_spread":0.25265612676854343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594668490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954001,0.000056302564,0.002041316,0.0000863246,0.000067228015,0.001127301,0.00017689497,0.000029686069,0.0010148963],"genre_scores_gemma":[0.9547096,0.00001710464,0.044221696,0.00005780619,0.00006333497,0.0001579986,0.000035823457,0.0000307679,0.0007058698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987082,0.000013321782,0.0002833963,0.0003006141,0.00032287557,0.00037163158],"domain_scores_gemma":[0.99900234,0.0002201112,0.00006819603,0.00039098036,0.00012338192,0.00019497002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024228415,0.00015402469,0.00035337443,0.00018943996,0.000043233827,0.000008038867,0.00011508772,0.00013051298,0.00004528859],"category_scores_gemma":[0.00029095975,0.00012688716,0.00011696543,0.00013959866,0.00007182784,0.000073587194,0.00006348766,0.00019090304,0.000008633122],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005407479,0.0024204368,0.020945342,0.00022665162,0.000062487175,0.000023228144,0.00019698359,0.000020887574,0.97237766,0.000032536573,0.000107229505,0.0030458327],"study_design_scores_gemma":[0.020983765,0.00029558042,0.027898474,0.000108047294,0.00007872324,0.000018612287,0.000028043507,0.06578895,0.8844401,0.000047295864,0.00018381227,0.00012857502],"about_ca_topic_score_codex":0.00013895544,"about_ca_topic_score_gemma":0.0002437545,"teacher_disagreement_score":0.08793751,"about_ca_system_score_codex":0.000028434028,"about_ca_system_score_gemma":0.00026996506,"threshold_uncertainty_score":0.5174308},"labels":[],"label_agreement":null},{"id":"W2594744300","doi":"10.1182/blood.v126.23.4201.4201","title":"Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Multiple myeloma; Medicine; Regimen; Bortezomib; Internal medicine; Clinical trial; Surgery","score_opus":0.06316883351363833,"score_gpt":0.3488994633154714,"score_spread":0.28573062980183306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594744300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963965,0.000074797055,0.000018392999,0.00008467989,0.0002689812,0.00069809484,0.000026490428,0.000065758424,0.0023663514],"genre_scores_gemma":[0.9972931,0.0000044182766,0.0018864833,0.000057967205,0.0002572958,0.00013266534,0.00008552333,0.000032807293,0.0002497456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981014,0.00010989115,0.00035997102,0.00033739494,0.0007865832,0.0003047668],"domain_scores_gemma":[0.99878764,0.00009954828,0.0000907482,0.00044900333,0.00018858488,0.00038446896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030270804,0.0001913699,0.00035780715,0.0002109737,0.000039005412,0.00002880076,0.00019302465,0.00007688425,0.000105612264],"category_scores_gemma":[0.0004577201,0.00014972579,0.00010330537,0.00015085924,0.00006726295,0.00020329205,0.00014667356,0.00018402716,0.000058638438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014694491,0.007383055,0.98102874,0.000012820637,0.0006204975,0.0013699774,0.0011627296,5.72351e-7,0.0002111179,0.000017894841,0.000019627194,0.006703523],"study_design_scores_gemma":[0.024889862,0.0014891425,0.9712389,0.00004575343,0.00017354726,0.00005501405,0.000769991,0.0000806955,0.0008700081,0.000029879378,0.00023030881,0.00012687204],"about_ca_topic_score_codex":0.00016304672,"about_ca_topic_score_gemma":0.00022236364,"teacher_disagreement_score":0.023420412,"about_ca_system_score_codex":0.000055954893,"about_ca_system_score_gemma":0.00008610829,"threshold_uncertainty_score":0.61056405},"labels":[],"label_agreement":null},{"id":"W2594828897","doi":"10.1182/blood.v126.23.5573.5573","title":"Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier Universitaire Sainte-Justine; Centre Hospitalier Universitaire de Sherbrooke; McGill University; Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Proteasome inhibitor; Internal medicine; Adverse effect; Mantle cell lymphoma; Autologous stem-cell transplantation; Oncology; Population; Regimen; Surgery; Lymphoma","score_opus":0.03186814555242502,"score_gpt":0.2510077652511925,"score_spread":0.2191396196987675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594828897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990505,0.00005724194,0.0000069117573,0.0001253326,0.000017496579,0.0003608871,0.0000620748,0.000008277391,0.000311281],"genre_scores_gemma":[0.99882835,0.000014541962,0.00059727253,0.000020297783,0.000007634328,0.00000496276,0.000057086098,0.000009326302,0.00046052548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859905,0.00019219366,0.00025950946,0.0002654815,0.00035255463,0.00033120907],"domain_scores_gemma":[0.99916035,0.00016168538,0.0000714907,0.00024935714,0.0001253575,0.00023176239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022654503,0.0001310921,0.00047556614,0.0007766692,0.000018956598,0.000008784666,0.00010390699,0.000068238456,0.000008713802],"category_scores_gemma":[0.0011336849,0.00012673771,0.000068658395,0.0009133373,0.000035239256,0.00018357093,0.000058275156,0.00024711838,0.0000012202439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037406827,0.00065956794,0.99363065,0.000015616915,0.00047050166,0.0026614289,0.0010999158,0.00009354129,0.00021426145,0.000014397296,0.00008060472,0.00068542326],"study_design_scores_gemma":[0.011786667,0.00009007164,0.98213667,0.00009034402,0.0002381308,0.000002165431,0.0027986206,0.0021824532,0.0005281625,0.0000027915878,0.000044240525,0.00009968878],"about_ca_topic_score_codex":0.99002445,"about_ca_topic_score_gemma":0.9990356,"teacher_disagreement_score":0.011494008,"about_ca_system_score_codex":0.0008221153,"about_ca_system_score_gemma":0.0008251196,"threshold_uncertainty_score":0.5168214},"labels":[],"label_agreement":null},{"id":"W2595062990","doi":"10.1200/jco.2009.27.15_suppl.e19503","title":"Current treatment (Tx) patterns in relapsed or refractory multiple myeloma (MM): A retrospective chart review study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Refractory (planetary science); Internal medicine; Prednisone; Bortezomib; Multiple myeloma; Surgery; Cyclophosphamide; Oncology; Chemotherapy","score_opus":0.21476384551059627,"score_gpt":0.5339815459925386,"score_spread":0.3192177004819423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595062990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828283,0.0076495325,0.00000913716,0.0065582315,0.0006633593,0.0018080781,0.0000124722865,0.000015920987,0.0004549398],"genre_scores_gemma":[0.9579676,0.039377514,0.000329482,0.0012217439,0.00078592385,0.000036271555,0.0000082166725,0.000018473962,0.000254803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942044,0.0011859451,0.0030022594,0.00040588112,0.00073766225,0.00046382291],"domain_scores_gemma":[0.9953161,0.0016570104,0.001425394,0.00042404022,0.0004581051,0.0007193896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029592358,0.0002837912,0.0026948957,0.00026099643,0.00004846554,0.00000904772,0.0001992195,0.00022960317,0.00036892437],"category_scores_gemma":[0.008027275,0.00016126441,0.0006352811,0.00028157688,0.00007658616,0.00010679258,0.00004080248,0.001375266,0.000062153966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008668836,0.021456422,0.540019,0.00005468594,0.00031079727,0.005552421,0.00013107255,2.5023533e-7,0.000012509526,0.0000016223646,0.0011307218,0.42266166],"study_design_scores_gemma":[0.034205053,0.11221449,0.8307977,0.0013854015,0.00035767446,0.00023624975,0.00012437567,0.00003096893,0.0000113475035,0.000026334908,0.020501036,0.000109421744],"about_ca_topic_score_codex":0.000047497822,"about_ca_topic_score_gemma":0.00048141475,"teacher_disagreement_score":0.42255223,"about_ca_system_score_codex":0.0013644579,"about_ca_system_score_gemma":0.0017219532,"threshold_uncertainty_score":0.96099776},"labels":[],"label_agreement":null},{"id":"W2595109760","doi":"10.1200/jco.2012.30.15_suppl.8035","title":"Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Bortezomib; Internal medicine; Clinical endpoint; Thalidomide; Lenalidomide; Gastroenterology; Multiple myeloma; Proteasome inhibitor; Progressive disease; Clinical trial; Phases of clinical research; Surgery; Oncology; Disease","score_opus":0.18607810554596838,"score_gpt":0.5003545129570304,"score_spread":0.314276407411062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595109760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945478,0.00024676105,0.000007450768,0.0027940192,0.0012592352,0.0010315907,0.0000060411,0.0000048804977,0.00010223877],"genre_scores_gemma":[0.9958668,0.00011989143,0.0017821186,0.0014988375,0.0005225335,0.000021809352,0.0000032550645,0.000023495328,0.00016129886],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9945734,0.001587877,0.0024927973,0.00025352108,0.00050994207,0.0005824216],"domain_scores_gemma":[0.9944445,0.0032017394,0.00061175774,0.00024689638,0.00020397459,0.0012911259],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0065340614,0.00020303969,0.0015647019,0.000579691,0.00003275342,0.000015516121,0.00015150897,0.00032562125,0.00010009406],"category_scores_gemma":[0.017799,0.00013205923,0.00019664886,0.00031543965,0.00009106192,0.0001884323,0.0001290179,0.0008743036,0.000031409396],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48138165,0.006422255,0.4390783,0.000009205608,0.00012281815,0.0005135353,0.0005069759,0.000003047874,0.00045780375,0.0000011236307,0.00070387614,0.07079941],"study_design_scores_gemma":[0.11166956,0.049179353,0.8145486,0.00013847541,0.000048264792,0.00003539607,0.00014106181,0.000010112255,0.00012767976,0.0000065665554,0.023990043,0.00010487894],"about_ca_topic_score_codex":0.00013492553,"about_ca_topic_score_gemma":0.00020856857,"teacher_disagreement_score":0.3754703,"about_ca_system_score_codex":0.0008330815,"about_ca_system_score_gemma":0.0011585908,"threshold_uncertainty_score":0.9904745},"labels":[],"label_agreement":null},{"id":"W2595210719","doi":"10.1182/blood.v128.22.2061.2061","title":"Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"","keywords":"MARCKS; Bortezomib; Cytotoxicity; Apoptosis; Cytotoxic T cell; Cancer research; Cell culture; Proteasome inhibitor; Chemistry; Programmed cell death; Viability assay; Pharmacology; Phosphorylation; Molecular biology; Biology; Myristoylation; Multiple myeloma; Biochemistry; Immunology; In vitro","score_opus":0.00743718624176384,"score_gpt":0.24098958539730764,"score_spread":0.2335523991555438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595210719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963495,0.0002646825,0.00006292525,0.00017623937,0.00007069498,0.0013453839,0.00014194698,0.000109383174,0.0014792273],"genre_scores_gemma":[0.9948826,0.00006830117,0.0006666652,0.000032029373,0.00018803116,0.0002972406,0.000030268458,0.00005765845,0.0037772194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971739,0.00021851946,0.0004115573,0.00068169634,0.0006870437,0.0008272894],"domain_scores_gemma":[0.99785906,0.0008870721,0.00012216884,0.00059145835,0.00008259601,0.00045766137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003680485,0.00039927426,0.00063194724,0.00023153613,0.00012042562,0.000037291764,0.00018449486,0.00011026878,0.0001258944],"category_scores_gemma":[0.0004273398,0.00021993316,0.00012879129,0.00028299267,0.00023648095,0.0001408474,0.00009241482,0.0002479466,0.00020725054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034925307,0.0013304976,0.16956335,0.000283958,0.00024312406,0.0035415788,0.00008485305,8.2096153e-7,0.8199909,0.0000163382,0.0001846665,0.001267382],"study_design_scores_gemma":[0.017867109,0.0013168568,0.2579819,0.000812375,0.00013980328,0.000040578074,0.000027554595,0.00004300037,0.7214145,0.000013181618,0.00011150121,0.00023164572],"about_ca_topic_score_codex":0.00073083997,"about_ca_topic_score_gemma":0.0014710699,"teacher_disagreement_score":0.098576404,"about_ca_system_score_codex":0.0002042541,"about_ca_system_score_gemma":0.00021533052,"threshold_uncertainty_score":0.8968614},"labels":[],"label_agreement":null},{"id":"W2595228860","doi":"10.1182/blood.v126.23.4234.4234","title":"Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Dalhousie University; University Health Network; Jewish General Hospital; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Bortezomib; Internal medicine; Dexamethasone; Lenalidomide; Dosing; Multiple myeloma; Pharmacology; Refractory (planetary science); Carfilzomib; Oncology; Gastroenterology; Adverse effect; Urology; Biology","score_opus":0.026090857815357395,"score_gpt":0.278428074502276,"score_spread":0.2523372166869186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595228860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973942,0.00021458983,0.000018167872,0.0001858852,0.00004105556,0.0018708502,0.00008312006,0.000052654905,0.00013948971],"genre_scores_gemma":[0.99692047,0.00019114753,0.0024974255,0.000038833274,0.000051910793,0.00007031812,0.00014905179,0.000047933605,0.00003293194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733514,0.00038942014,0.00051872554,0.0006646735,0.00059435813,0.00049769186],"domain_scores_gemma":[0.99801034,0.00056948955,0.00021253103,0.00027804746,0.0003140327,0.00061553466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063403725,0.00033932523,0.0006805444,0.0002701544,0.000080236015,0.000048248476,0.000073478586,0.00026186893,0.0000070355386],"category_scores_gemma":[0.0012827964,0.00024961174,0.000036037745,0.00039604426,0.00026689193,0.00045040858,0.000081758284,0.0006896251,0.000007842026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012328128,0.008071305,0.96806985,0.00009405174,0.00016937596,0.00008693762,0.00029134587,4.57483e-7,0.0002369289,0.0000053898043,0.000013037245,0.0106331995],"study_design_scores_gemma":[0.08932968,0.006087082,0.9009957,0.00032851638,0.00007330785,0.000011682304,0.00015811659,0.00019698947,0.002527855,0.000012195308,0.000032798205,0.00024610583],"about_ca_topic_score_codex":0.00056120515,"about_ca_topic_score_gemma":0.0010712186,"teacher_disagreement_score":0.07700155,"about_ca_system_score_codex":0.00016174476,"about_ca_system_score_gemma":0.0004776739,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W2595388903","doi":"10.1007/s11899-017-0368-z","title":"Current Review on High-Risk Multiple Myeloma","year":2017,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Risk stratification; Disease; Intensive care medicine; Hematology; Internal medicine; Oncology; Risk assessment","score_opus":0.1741396546027891,"score_gpt":0.4409754810943322,"score_spread":0.26683582649154314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595388903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047085425,0.98592293,0.000014993346,0.00006615156,0.0035390232,0.008540868,0.00025910503,0.00031831342,0.0012915547],"genre_scores_gemma":[0.00023496561,0.99302894,0.00013444101,0.00002886779,0.00049711886,0.002606226,0.00269358,0.00016536957,0.0006104959],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908199,0.0006190381,0.0031002092,0.0024129732,0.0016026885,0.0014452435],"domain_scores_gemma":[0.9886177,0.0005041859,0.004748061,0.004726683,0.00038544767,0.0010178938],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001159309,0.0017613574,0.007892954,0.00051721605,0.00055541657,0.00011121782,0.0006567528,0.00056041655,0.00057427335],"category_scores_gemma":[0.0058332398,0.0011242277,0.0025135435,0.00039997586,0.0002681769,0.00012925733,0.00047018204,0.0021015415,0.0014335185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022124652,0.000967336,0.0028337091,0.20023698,0.00039832175,0.008741729,0.0000034850957,1.5970379e-8,2.2093518e-8,0.00007479423,0.0159522,0.7707693],"study_design_scores_gemma":[0.0006063133,0.0002160422,0.00029599294,0.3276452,0.0025699828,0.0051023606,5.1306966e-7,0.0000012804607,0.0000029839812,0.00012519457,0.66282487,0.0006092503],"about_ca_topic_score_codex":0.00003287918,"about_ca_topic_score_gemma":0.000005856988,"teacher_disagreement_score":0.77016,"about_ca_system_score_codex":0.00047899762,"about_ca_system_score_gemma":0.0013102193,"threshold_uncertainty_score":0.9995132},"labels":[],"label_agreement":null},{"id":"W2595594504","doi":"10.1200/jco.2012.30.15_suppl.tps8113","title":"ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Internal medicine; Phases of clinical research; Urology; Gastroenterology; Combination therapy; Oncology; Surgery; Chemotherapy","score_opus":0.20673582234737273,"score_gpt":0.5079667286859392,"score_spread":0.3012309063385664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595594504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032605,0.00078891317,0.00027373765,0.0007225187,0.00032925553,0.0054597557,0.000010838939,0.000016461434,0.0020724845],"genre_scores_gemma":[0.98134017,0.0007788417,0.015706135,0.00029277193,0.0005962119,0.0002011968,0.000017061946,0.000063964806,0.001003671],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99026614,0.0029506222,0.0043367026,0.0004262029,0.0010713458,0.00094900606],"domain_scores_gemma":[0.9833183,0.010201887,0.003769274,0.0005310721,0.0008323779,0.0013470479],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0117055895,0.00045014036,0.0066487673,0.00046758878,0.00006578619,0.000032640204,0.00047328844,0.00048843306,0.0003810959],"category_scores_gemma":[0.01173964,0.00022311856,0.0004068553,0.0006337294,0.00086427864,0.00049897644,0.00014746113,0.0013723361,0.000015680898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82905126,0.031025585,0.0732131,0.00007747637,0.0029409283,0.0022125186,0.00043895526,0.0000034234258,0.00012683118,0.000027018752,0.00015295568,0.06072995],"study_design_scores_gemma":[0.8915758,0.095585234,0.0068473513,0.0007472288,0.0015008737,0.0012879609,0.0002945315,0.0003089543,0.0004950284,0.00001548241,0.0011195292,0.00022200175],"about_ca_topic_score_codex":0.0010147623,"about_ca_topic_score_gemma":0.0012320915,"teacher_disagreement_score":0.06636575,"about_ca_system_score_codex":0.00042886563,"about_ca_system_score_gemma":0.0049732625,"threshold_uncertainty_score":0.9965849},"labels":[],"label_agreement":null},{"id":"W2595611953","doi":"10.1182/blood.v128.22.489.489","title":"Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; University of British Columbia","funders":"","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Internal medicine; Interim analysis; Clinical endpoint; Multiple myeloma; Refractory (planetary science); Gastroenterology; Intention-to-treat analysis; Oncology; Surgery; Randomized controlled trial; Biology","score_opus":0.03217945903125362,"score_gpt":0.29854864507836426,"score_spread":0.26636918604711063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595611953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537766,0.0005344084,0.0002213008,0.000094108866,0.000025681196,0.0031375464,0.000568191,0.000026526222,0.000014584702],"genre_scores_gemma":[0.98998463,0.0003088089,0.009087414,0.000019086356,0.000025549274,0.00020596298,0.0001943018,0.00005473708,0.00011952838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974847,0.00021250066,0.0007114018,0.00061747263,0.000571606,0.00040234873],"domain_scores_gemma":[0.995348,0.002608522,0.00049221574,0.0007216481,0.00046771063,0.0003619392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031183878,0.00040470666,0.0014277269,0.0006812509,0.00007489415,0.000011003556,0.00011539306,0.00014460381,0.000046561978],"category_scores_gemma":[0.0013489092,0.00021668912,0.0002234649,0.0007277434,0.00027828084,0.000092985865,0.000036521695,0.00007452821,6.621659e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20202705,0.007649857,0.6721599,0.000134597,0.008771218,0.000027390328,0.0003283685,0.000023424464,0.042828,0.0000015567069,0.000013141974,0.0660355],"study_design_scores_gemma":[0.1780142,0.02123603,0.62184626,0.00033893972,0.0027567395,0.0000010789745,0.000032828953,0.0001624267,0.17539884,6.15987e-7,0.00004230691,0.00016974985],"about_ca_topic_score_codex":0.0003737587,"about_ca_topic_score_gemma":0.0004239816,"teacher_disagreement_score":0.13257085,"about_ca_system_score_codex":0.00008927406,"about_ca_system_score_gemma":0.00017620604,"threshold_uncertainty_score":0.8836326},"labels":[],"label_agreement":null},{"id":"W2595668491","doi":"10.1182/blood.v104.11.4934.4934","title":"Thalidomide +/− Corticosteroids for the Treatment of Multiple Myeloma Patients ≥ 70 Years of Age.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Thalidomide; Prednisone; Gastroenterology; Internal medicine; Lenalidomide; Thrombocytosis; Multiple myeloma; Surgery; Platelet","score_opus":0.031009496680620266,"score_gpt":0.2960436096393507,"score_spread":0.2650341129587305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595668491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762386,0.0004367286,0.00006950802,0.00007358454,0.000053999658,0.0014919073,0.00012675182,0.0000131731495,0.000110512716],"genre_scores_gemma":[0.99787045,0.00021117461,0.001465692,0.000018036759,0.00004330523,0.00015021469,0.000079348276,0.000019899784,0.00014187912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990547,0.000017166449,0.00026491092,0.00016017057,0.00027229413,0.00023076416],"domain_scores_gemma":[0.99907875,0.00025516291,0.000100554185,0.00034973552,0.00011333024,0.000102453734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048112866,0.000114986186,0.00029490542,0.000059680857,0.000038405833,0.000005333628,0.00007961034,0.000046158464,0.000014738462],"category_scores_gemma":[0.00016795628,0.000072865405,0.00018485864,0.000092004346,0.00009461321,0.000025077587,0.000017244236,0.000031935604,0.00000842044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002624694,0.020310704,0.83927673,0.00018984788,0.002100754,0.00014057876,0.0016651433,0.000021049122,0.01749624,0.000068521396,0.000039273622,0.11606643],"study_design_scores_gemma":[0.04821529,0.0048713065,0.8007741,0.00006415689,0.00042698134,0.0000067775954,0.00006777314,0.000020372807,0.14480415,0.00006094628,0.00062510546,0.00006307767],"about_ca_topic_score_codex":0.00028822842,"about_ca_topic_score_gemma":0.000063900814,"teacher_disagreement_score":0.1273079,"about_ca_system_score_codex":0.000055076503,"about_ca_system_score_gemma":0.00007065631,"threshold_uncertainty_score":0.29713652},"labels":[],"label_agreement":null},{"id":"W2595753835","doi":"10.1182/blood.v124.21.2447.2447","title":"Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Internal medicine; Melphalan; Thalidomide; Transplantation; Mucositis; Regimen; Plerixafor; Cyclophosphamide; Chemotherapy; Surgery; Oncology; Clinical endpoint; Chemotherapy regimen; Gastroenterology; Randomized controlled trial","score_opus":0.008578086463383719,"score_gpt":0.2565454628737735,"score_spread":0.2479673764103898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595753835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911395,0.00003831225,0.0071997955,0.000283854,0.000005903357,0.0011830248,0.000045666937,0.000039187813,0.000064760105],"genre_scores_gemma":[0.9990983,0.000022660277,0.00033237858,0.0001026849,0.000018001327,0.00012549883,0.00026342357,0.000013604333,0.000023430104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917465,0.00007225505,0.00017769495,0.0001863902,0.00019731432,0.00019169241],"domain_scores_gemma":[0.9993882,0.00009237174,0.000046266327,0.00015452554,0.00013539504,0.0001832087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000995146,0.000104761544,0.0002362563,0.00013454912,0.000025797159,0.000005233825,0.00003307226,0.00004399277,0.000017220404],"category_scores_gemma":[0.0001476503,0.00007800627,0.00003347859,0.00020741118,0.000031055133,0.00004171891,0.0000020899222,0.00004494773,0.0000073841084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071339305,0.001261069,0.9573347,0.00007396577,0.00009576996,0.00007146157,0.00010536978,0.0001138738,0.02866024,0.00004514109,0.0000034412449,0.005101063],"study_design_scores_gemma":[0.03927844,0.0010450095,0.9072387,0.000111457324,0.00013752602,0.000012595717,0.000007641351,0.006257577,0.04580626,0.00001200333,0.000024372217,0.00006841461],"about_ca_topic_score_codex":0.00011981114,"about_ca_topic_score_gemma":0.00014343284,"teacher_disagreement_score":0.050095968,"about_ca_system_score_codex":0.000032657343,"about_ca_system_score_gemma":0.000046563433,"threshold_uncertainty_score":0.31810033},"labels":[],"label_agreement":null},{"id":"W2595917680","doi":"10.1182/blood.v128.22.2271.2271","title":"High-Risk Cytogenetics Multiple Myeloma: Impact of Consolidation and Maintenance","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Exact test; Internal medicine; Log-rank test; Oncology; Surgery; Survival analysis","score_opus":0.017593901825313108,"score_gpt":0.28892524358829946,"score_spread":0.27133134176298634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595917680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99882597,0.00020811298,0.00024167966,0.000088276814,0.000015719044,0.0002831947,0.00017965729,0.000018907209,0.00013849325],"genre_scores_gemma":[0.99692416,0.00060700974,0.0021733125,0.0000062299755,0.000042115294,0.000012937391,0.000015365711,0.000012931416,0.00020595436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992672,0.000035459674,0.00015577966,0.0001646957,0.00016103822,0.00021581752],"domain_scores_gemma":[0.99926656,0.00015670313,0.00007874792,0.00022162576,0.00011167466,0.00016471179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000828039,0.00009931375,0.00019803482,0.00006427752,0.000032464723,0.000005187585,0.000036760142,0.000048706686,0.000064862325],"category_scores_gemma":[0.00046325417,0.00005416483,0.00006321823,0.000067166024,0.00010571266,0.00003758315,0.000032328535,0.00004490761,0.00002377438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026142213,0.00034175056,0.9052766,0.000021367961,0.00027721483,0.000035165835,0.000027141637,4.300887e-7,0.07178026,0.000028812605,0.00007857806,0.02187127],"study_design_scores_gemma":[0.013242941,0.00079031417,0.8526289,0.000075293734,0.00011129095,0.000051234725,0.000007808058,0.000029586743,0.13288328,0.00008772057,0.000035977522,0.00005568692],"about_ca_topic_score_codex":0.00029609198,"about_ca_topic_score_gemma":0.00002827789,"teacher_disagreement_score":0.061103016,"about_ca_system_score_codex":0.000029307304,"about_ca_system_score_gemma":0.00007378644,"threshold_uncertainty_score":0.22087777},"labels":[],"label_agreement":null},{"id":"W2595988118","doi":"10.1182/blood.v128.22.4632.4632","title":"Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont; Université de Montréal; Leukemia & Lymphoma Society of Canada; University of British Columbia; McGill University Health Centre; Saint John Regional Hospital; Ottawa Hospital; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Minimal residual disease; Lenalidomide; Busulfan; Multiple myeloma; Internal medicine; Maintenance therapy; Autologous stem-cell transplantation; Oncology; Thalidomide; Surgery; Urology; Bone marrow; Transplantation; Hematopoietic stem cell transplantation; Chemotherapy","score_opus":0.045154314947404496,"score_gpt":0.3399590849051596,"score_spread":0.29480476995775506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595988118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938976,0.00032683287,0.000008259744,0.0013713656,0.00017681894,0.0022432217,0.0016072632,0.0000613145,0.0003072856],"genre_scores_gemma":[0.99564296,0.00008753801,0.00023424269,0.00007247884,0.00044060376,0.00022197311,0.00134227,0.00007179128,0.0018861716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935061,0.0011380628,0.0009970472,0.0009910192,0.0018884762,0.001479302],"domain_scores_gemma":[0.9964106,0.00079241314,0.0003248651,0.0007533526,0.00066995,0.0010488257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00219232,0.00043965204,0.000806024,0.0002600347,0.0006953191,0.00010223443,0.0003045942,0.00014359756,0.00012342936],"category_scores_gemma":[0.0014438701,0.00032496944,0.000076108205,0.0006354877,0.00024904267,0.0003054427,0.00044686112,0.00042158415,0.0000065584186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037579697,0.007243083,0.81753314,0.0003297985,0.0037811534,0.004775754,0.00081093435,0.0000157515,0.045253593,0.00014220315,0.079117924,0.0034169545],"study_design_scores_gemma":[0.17457433,0.0054155192,0.7948168,0.0015637194,0.00079792255,0.000043702017,0.0037536363,0.0003174985,0.016126784,0.00014322119,0.0016504382,0.00079641526],"about_ca_topic_score_codex":0.059739713,"about_ca_topic_score_gemma":0.13114505,"teacher_disagreement_score":0.13699463,"about_ca_system_score_codex":0.00041781488,"about_ca_system_score_gemma":0.0017170757,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W2596288557","doi":"10.1182/blood.v128.22.1151.1151","title":"Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Alberta","funders":"","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Oncology; Multiple myeloma; Internal medicine; Thalidomide; Refractory (planetary science); Carfilzomib; Biology","score_opus":0.029548182363770412,"score_gpt":0.2992962749890381,"score_spread":0.26974809262526767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596288557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777174,0.00066867797,0.000028698094,0.0001006226,0.000021140793,0.0011459804,0.0002126906,0.000016748882,0.00003370762],"genre_scores_gemma":[0.99477124,0.0003322833,0.004648339,0.00001599284,0.000016672679,0.000034375993,0.00005908953,0.00003583745,0.00008617296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976727,0.00021153415,0.0006961609,0.00049238116,0.0005634383,0.0003637942],"domain_scores_gemma":[0.9968276,0.0015672713,0.00036827815,0.00056093035,0.00038635166,0.00028954665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037449974,0.00028840554,0.0011744474,0.0009149765,0.000038709695,0.000007699149,0.00012671712,0.00013370774,0.00008390935],"category_scores_gemma":[0.0018745523,0.00016217298,0.00011410463,0.0012969907,0.0002799478,0.00009809239,0.00008904427,0.0001246214,0.0000013427682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08796631,0.003165445,0.79527617,0.0000895878,0.0042966185,0.00003916646,0.00041837132,0.0000040404466,0.0686279,0.0000031106558,0.00000907494,0.04010423],"study_design_scores_gemma":[0.123046316,0.0038232326,0.7867437,0.00032425442,0.0010963748,0.0000023088987,0.000075759745,0.000039512517,0.084661014,0.0000013609066,0.000038434082,0.00014772151],"about_ca_topic_score_codex":0.000596584,"about_ca_topic_score_gemma":0.0007779689,"teacher_disagreement_score":0.039956506,"about_ca_system_score_codex":0.00004641923,"about_ca_system_score_gemma":0.00015366805,"threshold_uncertainty_score":0.66132224},"labels":[],"label_agreement":null},{"id":"W2596564154","doi":"10.1200/jco.2006.24.18_suppl.7608","title":"Update of melphalan 280 mg/m<sup>2 </sup>plus amifostine cytoprotection before autologous stem cell transplantation as part of initial therapy in multiple myeloma patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Regimen; Internal medicine; Transplantation; Autologous stem-cell transplantation; Amifostine; Urology; Surgery; Clinical endpoint; AL amyloidosis; Gastroenterology; Toxicity; Clinical trial; Immunology","score_opus":0.07193456100702537,"score_gpt":0.41084819333757455,"score_spread":0.33891363233054916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596564154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975595,0.00013174307,0.00010562433,0.00044003048,0.00026655456,0.0006753839,0.000046996975,0.00000974493,0.0007644308],"genre_scores_gemma":[0.99788487,0.00054346264,0.00092279835,0.00010985058,0.0003669809,0.000013841742,0.00008132159,0.000020893292,0.000056001914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953225,0.0006995959,0.0028247647,0.00022325858,0.0006139529,0.00031589394],"domain_scores_gemma":[0.99631643,0.0009804341,0.0017272199,0.00017783919,0.000577567,0.00022052083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013798638,0.00018907378,0.0014307934,0.00031879116,0.00003716268,0.000004502136,0.00014876176,0.0004286319,0.000088128945],"category_scores_gemma":[0.00040189657,0.00013624835,0.0003760842,0.00022914805,0.00021767094,0.00013382005,0.000022030134,0.00070831284,0.000012001615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029078424,0.004713341,0.5639208,0.00012984182,0.00021904078,0.0008863816,0.00027967762,0.00034679472,0.0006184404,0.000012754705,0.00009228594,0.39970222],"study_design_scores_gemma":[0.045981996,0.029791093,0.9133377,0.00016762018,0.00014545706,0.00017434836,0.00009592498,0.001448144,0.0073651955,0.00018384625,0.00121267,0.000095971096],"about_ca_topic_score_codex":0.00046770027,"about_ca_topic_score_gemma":0.00030594663,"teacher_disagreement_score":0.39960623,"about_ca_system_score_codex":0.00018591246,"about_ca_system_score_gemma":0.00082282705,"threshold_uncertainty_score":0.55560464},"labels":[],"label_agreement":null},{"id":"W2597008783","doi":"10.1182/blood.v128.22.2306.2306","title":"Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Fludarabine; Transplantation; Internal medicine; Bortezomib; Cyclophosphamide; Multiple myeloma; Gastroenterology; Surgery; Oncology; Immunology; Chemotherapy","score_opus":0.013372511911879423,"score_gpt":0.25065262006571715,"score_spread":0.2372801081538377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597008783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752265,0.00008621079,0.00032284262,0.000088421395,0.000043731445,0.0012525977,0.000643943,0.000022692768,0.000016895887],"genre_scores_gemma":[0.9974772,0.00018270816,0.0018380614,0.000029254728,0.000017597065,0.00020418485,0.000079698526,0.000027291353,0.00014401328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980618,0.00034709836,0.00046137167,0.00039726184,0.00038182203,0.00035067566],"domain_scores_gemma":[0.9985269,0.00063304213,0.00016133563,0.00029967623,0.00019282926,0.00018627169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030355624,0.00021503668,0.0003820698,0.00030097598,0.00005873055,0.000012405026,0.000091179245,0.000097346696,0.000049207894],"category_scores_gemma":[0.00019828003,0.0001458265,0.000046526202,0.00024970283,0.000093721515,0.00016584004,0.000048233014,0.00010508954,0.000045200475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034019496,0.0006803177,0.8181529,0.000093494884,0.00008206346,0.00012076057,0.0011867179,0.0000027941733,0.14096123,0.0000035285082,0.000001766205,0.004694919],"study_design_scores_gemma":[0.020608384,0.0020679235,0.8854575,0.00032201162,0.00013645737,0.000013913388,0.000055519795,0.00002267761,0.09115485,0.000011814719,0.0000038931066,0.00014503121],"about_ca_topic_score_codex":0.00083006884,"about_ca_topic_score_gemma":0.00090630504,"teacher_disagreement_score":0.06730462,"about_ca_system_score_codex":0.000104033476,"about_ca_system_score_gemma":0.00011519514,"threshold_uncertainty_score":0.5946632},"labels":[],"label_agreement":null},{"id":"W2597108928","doi":"10.1182/blood.v116.21.985.985","title":"Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Thalidomide; Multiple myeloma; Bortezomib; Refractory (planetary science); Internal medicine; Clinical endpoint; Regimen; Phases of clinical research; Progression-free survival; Gastroenterology; Surgery; Oncology; Clinical trial; Chemotherapy","score_opus":0.04297886026335334,"score_gpt":0.3249800669720499,"score_spread":0.28200120670869655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597108928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607486,0.000054915246,5.0637703e-7,0.000024421557,0.000050382092,0.0026760278,0.00017070094,0.00002606114,0.0009221581],"genre_scores_gemma":[0.9981407,0.000012875287,0.0012831383,0.000015653268,0.00003565097,0.00008175883,0.0001990465,0.00005046119,0.00018073442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973902,0.00018944389,0.0006770535,0.0006201044,0.0006653063,0.0004578626],"domain_scores_gemma":[0.9978327,0.00020397354,0.00032676596,0.0009028568,0.00033824466,0.00039545997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042679583,0.0002912296,0.0007027619,0.00030410124,0.00008358188,0.000032315318,0.00029521057,0.00014452238,0.0000288389],"category_scores_gemma":[0.000782073,0.00022114071,0.000023906592,0.00038044076,0.000176722,0.0003186473,0.00022004005,0.00042571095,0.000003607541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023479987,0.22851595,0.6342414,0.00014297145,0.0004657965,0.00042428917,0.002616366,4.612633e-7,0.0956081,0.000005351205,0.000060934035,0.014438356],"study_design_scores_gemma":[0.3560098,0.06598724,0.5428457,0.00017845983,0.0002535323,0.000015044484,0.0009158024,0.00006334133,0.03331574,0.000006020468,0.00017660612,0.00023270262],"about_ca_topic_score_codex":0.0022890107,"about_ca_topic_score_gemma":0.0036390433,"teacher_disagreement_score":0.3325298,"about_ca_system_score_codex":0.000039606253,"about_ca_system_score_gemma":0.00015098965,"threshold_uncertainty_score":0.9017857},"labels":[],"label_agreement":null},{"id":"W2597273572","doi":"10.1111/ejh.12876","title":"Economic burden of relapsed or refractory multiple myeloma: Results from an international trial","year":2017,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Absenteeism; Medicine; Indirect costs; Quality of life (healthcare); Multiple myeloma; Multivariate analysis; Clinical trial; Physical therapy; Randomized controlled trial; Family medicine; Internal medicine; Nursing","score_opus":0.06516772725094637,"score_gpt":0.358220158953896,"score_spread":0.2930524317029496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597273572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004847,0.000059648497,0.000034769855,0.0014664677,0.0012098289,0.00020361508,0.00010955373,0.000009782107,0.0068578594],"genre_scores_gemma":[0.99582326,0.00013622221,0.0023659198,0.00002851522,0.0010666661,0.000001005297,0.000052265397,0.000030099978,0.0004960558],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99787647,0.00044781456,0.0009823503,0.000224292,0.00026202618,0.00020706811],"domain_scores_gemma":[0.99710923,0.0003417766,0.0013930099,0.0006823762,0.00019879277,0.00027483812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083325,0.00014474917,0.000628814,0.0001935008,0.000107962696,0.000040266717,0.00064195006,0.00005438922,0.0003298899],"category_scores_gemma":[0.0030035896,0.00010096638,0.0001715113,0.000014653928,0.0002095554,0.0003188146,0.00012934805,0.00031798438,0.00013343505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169382,0.0014947744,0.031250358,0.00004405131,0.002480943,0.07373958,0.0019062784,0.00003981065,0.006381158,0.00011389315,0.0053855386,0.060225405],"study_design_scores_gemma":[0.5661523,0.014695169,0.36071473,0.0005846761,0.00034470373,0.007576812,0.0005210479,0.0014146751,0.005773507,0.00010456146,0.04177063,0.0003472104],"about_ca_topic_score_codex":0.00016324948,"about_ca_topic_score_gemma":0.000054394324,"teacher_disagreement_score":0.32946438,"about_ca_system_score_codex":0.000076993114,"about_ca_system_score_gemma":0.0002410719,"threshold_uncertainty_score":0.41172898},"labels":[],"label_agreement":null},{"id":"W2597309066","doi":"10.1182/blood.v128.22.243.243","title":"Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Ixazomib; Placebo; Oncology; Progression-free survival; Clinical endpoint; Interim analysis; Proteasome inhibitor; Dexamethasone; Multiple myeloma; Randomized controlled trial; Carfilzomib; Pathology; Chemotherapy","score_opus":0.04594296410992498,"score_gpt":0.33523731177272736,"score_spread":0.2892943476628024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597309066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587345,0.0003447642,0.000008916572,0.0005342911,0.00019703263,0.002202609,0.00042203176,0.00008581482,0.0003310636],"genre_scores_gemma":[0.99799883,0.000036661102,0.00031324665,0.000029896128,0.0000847993,0.00028555212,0.00008153286,0.0000796614,0.001089794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949548,0.00068805757,0.00083720067,0.0008641814,0.0018646778,0.00079107756],"domain_scores_gemma":[0.9948599,0.0020995205,0.000568439,0.0016823345,0.00039138895,0.00039842143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011264636,0.0005162153,0.001170728,0.0006729802,0.00018002217,0.000031497137,0.0005640147,0.00027032933,0.00072574295],"category_scores_gemma":[0.00211131,0.0002582321,0.00039749162,0.0017636886,0.00022870374,0.00017048033,0.00038196304,0.000359701,0.000016628943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03246186,0.018092666,0.88529086,0.000033073895,0.008491252,0.00045502718,0.00047341335,0.000004745862,0.04794728,0.0000019709398,0.00030605533,0.0064417846],"study_design_scores_gemma":[0.21107247,0.0023946883,0.74577427,0.00068669894,0.003230695,0.000003499351,0.00027401253,0.0001793712,0.03597688,0.0000061043615,0.0000963507,0.00030495544],"about_ca_topic_score_codex":0.00043225568,"about_ca_topic_score_gemma":0.0018014067,"teacher_disagreement_score":0.17861061,"about_ca_system_score_codex":0.00025580724,"about_ca_system_score_gemma":0.00023029024,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W2597611793","doi":"","title":"Allogeneic Transplantation and Cell Therapy in Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Pharma Medica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Transplantation; Medicine; Hematopoietic cell; Immunology; Internal medicine; Biology; Stem cell","score_opus":0.04200966257882726,"score_gpt":0.3230637202176244,"score_spread":0.28105405763879715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597611793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950181,0.0010660196,0.000120785684,0.0022524772,0.0000519226,0.00040990507,0.0000185293,0.000031869127,0.0010303707],"genre_scores_gemma":[0.98762614,0.011317492,0.00027963612,0.0002700338,0.00007299846,0.00006684088,0.000022625176,0.000014471328,0.00032976162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990438,0.00005621175,0.00015067181,0.00020966076,0.00027540926,0.0002642039],"domain_scores_gemma":[0.9993951,0.00018085382,0.000024103954,0.00011129567,0.00002385579,0.00026483537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015655931,0.00010509921,0.00015438061,0.00011306686,0.00003328212,0.000004738979,0.0000488781,0.000046510355,0.00047563715],"category_scores_gemma":[0.00005162597,0.00006031188,0.000030337023,0.00008385884,0.00007917923,0.000066654844,0.000009686243,0.00007921777,0.00006424701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010485367,0.00024052989,0.31615925,0.000058826026,0.000039755367,0.00048100593,0.00033777967,5.5889604e-8,0.2698334,0.000002969648,0.00023997514,0.4115579],"study_design_scores_gemma":[0.033714365,0.0004102139,0.6807168,0.00013305343,0.000026599371,0.00010838255,0.000030377401,0.0001834201,0.27794966,0.000038220074,0.006563936,0.00012493889],"about_ca_topic_score_codex":0.000057741818,"about_ca_topic_score_gemma":0.000022303097,"teacher_disagreement_score":0.41143298,"about_ca_system_score_codex":0.000036788202,"about_ca_system_score_gemma":0.00006060883,"threshold_uncertainty_score":0.5207893},"labels":[],"label_agreement":null},{"id":"W2597630242","doi":"10.1200/jco.2013.31.15_suppl.8532","title":"Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Tolerability; Lenalidomide; Adverse effect; Regimen; Bortezomib; Population; Internal medicine; Multiple myeloma; Surgery","score_opus":0.07793697440587355,"score_gpt":0.42683275227097156,"score_spread":0.348895777865098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597630242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971987,0.0001708547,0.00018464438,0.00084769225,0.00012420927,0.0011317881,0.000012219318,0.000018392742,0.0003114925],"genre_scores_gemma":[0.98332036,0.00024296131,0.014517438,0.0006943094,0.00023143625,0.00004423573,0.000038627724,0.000050749975,0.0008599048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432224,0.0009691525,0.0024917522,0.0005577078,0.00097535603,0.00068379997],"domain_scores_gemma":[0.9923608,0.0031806235,0.0018136777,0.0005000756,0.0007996561,0.0013451879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021847766,0.00039814276,0.0031758295,0.0007148393,0.000116267925,0.00003741124,0.00024361705,0.00047794127,0.00036863153],"category_scores_gemma":[0.0044919807,0.00021491753,0.00035825456,0.00078968774,0.0005984275,0.00045141886,0.00012039118,0.0016240211,0.000024544817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0844324,0.013736734,0.7842155,0.000044493736,0.0027212424,0.0038634639,0.00021049184,0.000013177615,0.0002492489,0.0000017374836,0.00025554153,0.11025596],"study_design_scores_gemma":[0.13687025,0.080751106,0.77792156,0.00019294217,0.001272307,0.00015708912,0.00014869298,0.001015059,0.00008065808,0.000011679206,0.0013670955,0.00021158294],"about_ca_topic_score_codex":0.0004785579,"about_ca_topic_score_gemma":0.002145555,"teacher_disagreement_score":0.11004437,"about_ca_system_score_codex":0.00034766257,"about_ca_system_score_gemma":0.0011589442,"threshold_uncertainty_score":0.8764082},"labels":[],"label_agreement":null},{"id":"W2598509493","doi":"10.1182/blood.v128.22.5821.5821","title":"Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Salvage therapy; Autologous stem-cell transplantation; Regimen; Multiple myeloma; Thalidomide; Surgery; Internal medicine; Lenalidomide; Oncology; Cyclophosphamide; Transplantation; Median follow-up; Chemotherapy","score_opus":0.04255757704501884,"score_gpt":0.298766442566565,"score_spread":0.25620886552154615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598509493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544275,0.000085169726,0.0005860612,0.00021990358,0.000050345254,0.0022664648,0.0012311265,0.000018790732,0.00009939963],"genre_scores_gemma":[0.9970728,0.000101172634,0.0023649458,0.0000487873,0.000015774493,0.00012413926,0.00017252802,0.000029584337,0.00007026926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977809,0.00015064748,0.0009145884,0.0003087759,0.000520063,0.00032499785],"domain_scores_gemma":[0.99753004,0.0012103945,0.00046791468,0.00047537024,0.00024013975,0.00007614772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005656104,0.00019968521,0.0005152844,0.00017034037,0.00004231414,0.00000451329,0.00021065734,0.00012347313,0.000009290671],"category_scores_gemma":[0.0002961433,0.000113480324,0.00019748713,0.00021853093,0.00009150446,0.000077341545,0.000012423914,0.00012406714,0.0000015848864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012327273,0.008969233,0.8220988,0.0008017034,0.00025235815,0.00003054896,0.0019799063,0.000012510117,0.098792054,0.0000063400225,0.000034752575,0.05469451],"study_design_scores_gemma":[0.08657085,0.0015791545,0.7217604,0.00033808465,0.00010954841,0.000001843106,0.00006703682,0.00022472483,0.18922538,0.000002779187,0.000035640074,0.000084571926],"about_ca_topic_score_codex":0.00020178012,"about_ca_topic_score_gemma":0.0001037439,"teacher_disagreement_score":0.10033843,"about_ca_system_score_codex":0.000044720047,"about_ca_system_score_gemma":0.00011513252,"threshold_uncertainty_score":0.46275932},"labels":[],"label_agreement":null},{"id":"W2599153150","doi":"10.1200/jco.2009.27.15_suppl.8537","title":"PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Multiple myeloma; Clinical endpoint; Internal medicine; Phases of clinical research; Proteasome inhibitor; Adverse effect; Gastroenterology; Oncology; Chemotherapy; Clinical trial","score_opus":0.08971307137979027,"score_gpt":0.48656278221239757,"score_spread":0.3968497108326073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599153150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742943,0.000047456397,0.000008163249,0.000952242,0.00018354379,0.0010349705,0.0000054960515,0.00000817705,0.00033053328],"genre_scores_gemma":[0.99745333,0.000043415093,0.0016850207,0.0004811516,0.00021523396,0.0000046881564,0.000014792252,0.000017970196,0.00008440129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952528,0.0007956524,0.0024651515,0.0002995151,0.0007618579,0.00042504954],"domain_scores_gemma":[0.9961234,0.00067842816,0.0013735244,0.00037180664,0.0007454875,0.0007073701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001820104,0.00020815399,0.0017779828,0.0002663432,0.0000576119,0.00000791302,0.00023894971,0.00024056339,0.00009889587],"category_scores_gemma":[0.0023441985,0.00012824009,0.00024133814,0.00026592813,0.00013755108,0.00022668178,0.00006297099,0.0010669947,0.000009563197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11400838,0.14185038,0.5358757,0.00001111057,0.0004971214,0.002334408,0.000457011,0.000010520982,0.00003830682,0.000005583559,0.00020350136,0.20470798],"study_design_scores_gemma":[0.16583231,0.22519529,0.60761863,0.000065065906,0.00022008843,0.000013267971,0.0001975697,0.0000574529,0.000022122316,0.000009369141,0.0007034103,0.00006543923],"about_ca_topic_score_codex":0.000054129472,"about_ca_topic_score_gemma":0.00012069832,"teacher_disagreement_score":0.20464255,"about_ca_system_score_codex":0.00017194341,"about_ca_system_score_gemma":0.00064329244,"threshold_uncertainty_score":0.5229479},"labels":[],"label_agreement":null},{"id":"W2600008150","doi":"10.1200/jco.2012.30.15_suppl.8020","title":"A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Thalidomide; Multiple myeloma; Refractory (planetary science); Bortezomib; Internal medicine; Phases of clinical research; Progressive disease; Gastroenterology; Toxicity; Urology; Surgery; Chemotherapy","score_opus":0.08419696088202684,"score_gpt":0.44069445114764233,"score_spread":0.3564974902656155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600008150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742043,0.0004075282,0.000032266977,0.00020188978,0.00013784942,0.0016084394,0.0000048725356,0.0000057427937,0.00018095609],"genre_scores_gemma":[0.9963444,0.00015791557,0.0030957437,0.00011685094,0.0001646324,0.000028794253,0.000005421538,0.000027691882,0.00005858299],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946296,0.0016184247,0.0023218195,0.00022972078,0.000772399,0.00042799543],"domain_scores_gemma":[0.9903924,0.006139893,0.0018906515,0.00026556008,0.0005553287,0.0007561807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00518457,0.00023136473,0.0030496267,0.00032608391,0.0000534883,0.0000055171176,0.00011896991,0.00022494403,0.00005397059],"category_scores_gemma":[0.007682673,0.00012252739,0.00021100741,0.00022235718,0.00045489313,0.00027646637,0.000081360755,0.0010202593,0.0000027239287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46558276,0.037875067,0.4605108,0.00002451745,0.0009501607,0.00026316365,0.00048482735,0.000003244618,0.00002192962,0.0000018654459,0.000020902835,0.034260765],"study_design_scores_gemma":[0.5067334,0.06883399,0.4233057,0.00013202174,0.00041701246,0.00004129393,0.00025411544,0.00004228735,0.000024035842,0.0000039471674,0.00014630007,0.000065908105],"about_ca_topic_score_codex":0.00010860571,"about_ca_topic_score_gemma":0.00015259761,"teacher_disagreement_score":0.041150633,"about_ca_system_score_codex":0.00016858353,"about_ca_system_score_gemma":0.0008170378,"threshold_uncertainty_score":0.91974324},"labels":[],"label_agreement":null},{"id":"W2600310070","doi":"10.1200/jco.2014.32.15_suppl.e19568","title":"Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexamethasone (CyBor-P/D): Updated experience at Princess Margaret Cancer Centre (PMCC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Regimen; Prednisone; Discontinuation; Internal medicine; Dexamethasone; Multiple myeloma; Surgery; Gastroenterology; Cyclophosphamide; Urology; Chemotherapy","score_opus":0.08999254252035456,"score_gpt":0.42933988416640345,"score_spread":0.3393473416460489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600310070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935209,0.0011541866,0.00025661403,0.0025205405,0.0006689111,0.00095041515,0.00004813522,0.00003142709,0.0008488647],"genre_scores_gemma":[0.9827615,0.004029817,0.008386717,0.0002932788,0.00060925697,0.000058031128,0.00003768232,0.00006099482,0.0037626994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940058,0.00084095413,0.0027547881,0.0005884829,0.0010564369,0.00075355644],"domain_scores_gemma":[0.9908268,0.0036489232,0.002731621,0.00063238223,0.00088597037,0.0012743355],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010174718,0.00045171072,0.0030089524,0.00019429346,0.00013002938,0.000015232466,0.00036524786,0.00056138024,0.00094832666],"category_scores_gemma":[0.0029430815,0.00025655617,0.00049879396,0.0003385831,0.00073530845,0.00022843086,0.00012930633,0.00070242136,0.000027576578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13162686,0.0051359045,0.7034977,0.00009461474,0.0019301286,0.003207753,0.0009948352,0.00017365745,0.000737345,0.00001322377,0.001211416,0.15137653],"study_design_scores_gemma":[0.09357417,0.05036883,0.7302137,0.00039050315,0.0007986752,0.0006596736,0.0005624579,0.0022284305,0.004026056,0.000011154078,0.11684565,0.00032068207],"about_ca_topic_score_codex":0.00076976727,"about_ca_topic_score_gemma":0.0024633498,"teacher_disagreement_score":0.15105584,"about_ca_system_score_codex":0.0021211796,"about_ca_system_score_gemma":0.004135858,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W2601169542","doi":"10.14740/jh322e","title":"Multiple Myeloma-Induced Hyperammonemic Encephalopathy","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Hyperammonemia; Encephalopathy; Complication; Anemia; Gastroenterology; Pathology; Pediatrics; Internal medicine","score_opus":0.047018742157089885,"score_gpt":0.34494088249339167,"score_spread":0.29792214033630177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601169542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946788,0.00057545176,0.00005992823,0.0021176082,0.00034904998,0.00015964881,0.000002165977,0.00001053716,0.0020468335],"genre_scores_gemma":[0.9972295,0.000102812315,0.0021580388,0.00010069038,0.00019528443,0.00000449058,0.000001816491,0.000016194974,0.00019115812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998721,0.000050290222,0.0004255308,0.00013974874,0.00032765462,0.00033579953],"domain_scores_gemma":[0.9983037,0.00014003026,0.00048620376,0.00047364694,0.00027488542,0.00032153339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000256848,0.0001330782,0.0005778706,0.00017158523,0.00022635235,0.000035323876,0.00028821704,0.00012071839,0.00011737952],"category_scores_gemma":[0.0014969317,0.00009342627,0.00018941023,0.000034303044,0.00011944777,0.00016937293,0.000073246694,0.0003561859,0.00011034376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001367366,0.0005018156,0.8903777,0.00007794053,0.0003614711,0.010455355,0.00017693742,3.872895e-7,0.064094566,0.00032149957,0.0010111354,0.03125383],"study_design_scores_gemma":[0.013753469,0.0018330956,0.8448234,0.0002578909,0.0001583746,0.03470913,0.00019810906,0.00023770425,0.10057751,0.0005279303,0.0027409072,0.00018247092],"about_ca_topic_score_codex":0.000034221754,"about_ca_topic_score_gemma":0.000019719713,"teacher_disagreement_score":0.045554288,"about_ca_system_score_codex":0.00006281917,"about_ca_system_score_gemma":0.00022339777,"threshold_uncertainty_score":0.3809813},"labels":[],"label_agreement":null},{"id":"W2601654193","doi":"10.1182/blood.v126.23.5228.5228","title":"Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lenalidomide; Myelodysplastic syndromes; Neutropenia; Medicine; Bone marrow failure; Bone marrow; Thrombocytosis; Myeloid; Immunology; Internal medicine; Oncology; Stem cell; Cancer research; Haematopoiesis; Biology; Multiple myeloma; Chemotherapy; Genetics","score_opus":0.025241491959236792,"score_gpt":0.2763959753417481,"score_spread":0.2511544833825113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601654193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778557,0.00009242181,0.00017215496,0.00011688815,0.00004941651,0.0005365031,0.000030077868,0.000018031473,0.0011989349],"genre_scores_gemma":[0.9956314,0.000004255195,0.0035468377,0.000057172263,0.000009218459,0.000051344072,0.000026522908,0.000017409717,0.0006558716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869865,0.00004530034,0.00025231286,0.00021639727,0.0004905815,0.0002967344],"domain_scores_gemma":[0.9991138,0.000060418715,0.000046844532,0.00025600253,0.00014817034,0.00037477352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016628898,0.00011440173,0.00029078,0.00019706858,0.000015291826,0.000005690455,0.00009189308,0.000049943545,0.000027221033],"category_scores_gemma":[0.00056231185,0.00009549115,0.00004062993,0.00026053042,0.000021338692,0.000045247627,0.00005536384,0.00008467655,0.00011991835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006465958,0.011289341,0.95840526,0.0006536937,0.00066343066,0.004217426,0.0010311297,0.0000443665,0.012624002,0.001301438,0.0014953436,0.0018086173],"study_design_scores_gemma":[0.0369079,0.0024136987,0.9277198,0.0006164065,0.00014087939,0.00005766023,0.00012366856,0.000035397243,0.030264087,0.0012847809,0.0002273134,0.00020841073],"about_ca_topic_score_codex":0.00008678258,"about_ca_topic_score_gemma":0.00016443682,"teacher_disagreement_score":0.030685456,"about_ca_system_score_codex":0.00007425169,"about_ca_system_score_gemma":0.00013503479,"threshold_uncertainty_score":0.3894016},"labels":[],"label_agreement":null},{"id":"W2601657417","doi":"10.1200/jco.2007.25.18_suppl.13016","title":"Effect of ketoconazole administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib in patients with advanced solid tumors","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Bortezomib; Pharmacology; Ketoconazole; Adverse effect; Multiple myeloma; Pharmacodynamics; In vivo; CYP3A4; Internal medicine; Urology; Gastroenterology","score_opus":0.04048130438078471,"score_gpt":0.4824133161229638,"score_spread":0.44193201174217905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601657417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981302,0.00004725993,0.000029690958,0.0004463639,0.000114454946,0.0006267613,0.0000074912655,0.0000016217756,0.00059616426],"genre_scores_gemma":[0.9992107,0.00014587342,0.00036370885,0.00016885756,0.00008178241,0.0000037583338,0.0000044983917,0.000009329909,0.000011464393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751824,0.00033824754,0.0014384284,0.00010703933,0.00041568896,0.00018237084],"domain_scores_gemma":[0.9944669,0.003740449,0.001183054,0.00010197614,0.00029255945,0.00021506837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030756122,0.000109347115,0.0008895169,0.00012149088,0.000015675136,0.000001959118,0.000085859756,0.000099213496,0.000021969421],"category_scores_gemma":[0.0015636447,0.000056408488,0.000117841555,0.00012020045,0.00022018954,0.000047758404,0.000021178752,0.0005613433,7.2479014e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091784135,0.0026606447,0.67944354,0.000084386396,0.00028096233,0.00031023182,0.000033559496,0.00004153863,0.0008308536,0.000019605632,0.000035040484,0.22447549],"study_design_scores_gemma":[0.0355924,0.07870747,0.8673818,0.00017557984,0.00018288684,0.000029760102,0.000022588225,0.0004458654,0.017210845,0.000013366274,0.000191441,0.000045997363],"about_ca_topic_score_codex":0.000003644028,"about_ca_topic_score_gemma":0.000013803921,"teacher_disagreement_score":0.22442949,"about_ca_system_score_codex":0.00006604278,"about_ca_system_score_gemma":0.00038493882,"threshold_uncertainty_score":0.24387884},"labels":[],"label_agreement":null},{"id":"W2601767411","doi":"10.1200/jco.2013.31.15_suppl.8542","title":"Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Gastroenterology; Regimen; Internal medicine; Dexamethasone; Adverse effect; Cohort; Toxicity","score_opus":0.10781353209332806,"score_gpt":0.45022822690405334,"score_spread":0.3424146948107253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601767411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915513,0.00094572705,0.00002298498,0.0036888623,0.0006746336,0.0021272667,0.000054100918,0.00003196563,0.00090320845],"genre_scores_gemma":[0.9945594,0.0013041133,0.0013292271,0.00039217758,0.0006305554,0.000046264486,0.00006687275,0.00006952023,0.0016018418],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9886232,0.0020258543,0.00630186,0.00081173686,0.0012834482,0.0009538966],"domain_scores_gemma":[0.98722214,0.005906448,0.0034234012,0.00082261907,0.0012088168,0.0014165795],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0057749446,0.0005567247,0.0039065867,0.00075001526,0.00032647964,0.000026367723,0.0005336621,0.00087466644,0.0006015848],"category_scores_gemma":[0.01402659,0.00040449377,0.00056086545,0.00055062654,0.0006584647,0.0004644708,0.00064395164,0.0027890052,0.000046370245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20400079,0.09993516,0.21254465,0.0001557246,0.0035332819,0.008147084,0.0038531846,0.000041416697,0.0071549197,0.0000107063515,0.0041161776,0.4565069],"study_design_scores_gemma":[0.27329335,0.12709135,0.591578,0.00038486088,0.0005162389,0.00043402993,0.00070369715,0.000750922,0.0005117124,0.00004650809,0.0043919263,0.00029738],"about_ca_topic_score_codex":0.00093020656,"about_ca_topic_score_gemma":0.0011632032,"teacher_disagreement_score":0.45620954,"about_ca_system_score_codex":0.0009515789,"about_ca_system_score_gemma":0.0026931383,"threshold_uncertainty_score":0.9998407},"labels":[],"label_agreement":null},{"id":"W2603467063","doi":"10.1200/jco.2013.31.15_suppl.8588","title":"Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Vancouver General Hospital; Royal Victoria Regional Health Centre; University of Alberta; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Population; Adverse effect; Surgery; Internal medicine; Multiple myeloma","score_opus":0.09232298271356609,"score_gpt":0.4453981457106731,"score_spread":0.353075162997107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603467063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581,0.00032882104,0.000015862139,0.0012215438,0.00015060512,0.002332414,0.0000071495274,0.0000048279453,0.00012882505],"genre_scores_gemma":[0.9967476,0.0008070127,0.0016601951,0.0003625493,0.00018648525,0.000035669887,0.000009115709,0.000024850637,0.00016652852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942517,0.0016359285,0.0027571418,0.00033024146,0.0006193589,0.00040560658],"domain_scores_gemma":[0.9870774,0.010112074,0.0015954629,0.0003352626,0.00037484712,0.0005049098],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003769213,0.0002544019,0.0022256926,0.0003181075,0.00006732301,0.000015538462,0.00020692934,0.00037023402,0.00010760414],"category_scores_gemma":[0.0127201425,0.00012617272,0.00019237693,0.00027286293,0.0004992039,0.00018211339,0.000103748454,0.0012402325,0.000003939174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36399135,0.0138825625,0.4675708,0.00004083932,0.00024189804,0.000721135,0.0003124736,0.0000014654356,0.00016800953,9.649287e-7,0.00003459479,0.15303388],"study_design_scores_gemma":[0.3811002,0.052488178,0.5654769,0.00022041335,0.000120064105,0.00010047766,0.000080832186,0.00014710544,0.00003765443,0.0000066125544,0.00014746739,0.000074114134],"about_ca_topic_score_codex":0.00015112442,"about_ca_topic_score_gemma":0.0005519662,"teacher_disagreement_score":0.15295976,"about_ca_system_score_codex":0.00015796367,"about_ca_system_score_gemma":0.0008525766,"threshold_uncertainty_score":0.9955961},"labels":[],"label_agreement":null},{"id":"W2603632799","doi":"10.1200/jco.2012.30.15_suppl.8018","title":"Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Clinical endpoint; Multiple myeloma; Refractory (planetary science); Gastroenterology; Dexamethasone; Placebo; Randomized controlled trial; Urology; Surgery","score_opus":0.1848560529788988,"score_gpt":0.4819584062365803,"score_spread":0.29710235325768153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603632799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876737,0.0013336708,0.000091932154,0.0007363675,0.0017076067,0.004692522,0.000003976449,0.000030943993,0.0037293101],"genre_scores_gemma":[0.99564075,0.0003206499,0.0016946198,0.0001861266,0.0014206897,0.00022923149,0.000017834915,0.000058685437,0.00043141036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99060035,0.002017791,0.00460727,0.00046071492,0.0012493434,0.0010645451],"domain_scores_gemma":[0.9818522,0.0126044145,0.0027852762,0.0005479704,0.00063212233,0.0015780481],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012761456,0.00048808687,0.0071750665,0.0006000145,0.00017759686,0.00003067888,0.0003606383,0.000523541,0.00017450518],"category_scores_gemma":[0.009672919,0.0003011449,0.0009963296,0.0003660672,0.00046362987,0.0005345959,0.00018330789,0.0026158935,0.000053368036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8181522,0.056102198,0.10456665,0.000021517437,0.0043310635,0.0026224027,0.0006708241,0.000059287006,0.00004317921,0.00001014187,0.00035715458,0.013063419],"study_design_scores_gemma":[0.9151055,0.05787027,0.01951629,0.0001338533,0.0020518554,0.00024212539,0.00086180156,0.0020950735,0.00004193436,0.0000064961296,0.0018271105,0.0002476702],"about_ca_topic_score_codex":0.0002849975,"about_ca_topic_score_gemma":0.0010167619,"teacher_disagreement_score":0.096953355,"about_ca_system_score_codex":0.0008510621,"about_ca_system_score_gemma":0.0023888443,"threshold_uncertainty_score":0.9999441},"labels":[],"label_agreement":null},{"id":"W2604105114","doi":"10.1200/jco.2012.30.15_suppl.tps8114","title":"A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Dexamethasone; Bortezomib; Antibody-dependent cell-mediated cytotoxicity; Internal medicine; Refractory (planetary science); Phases of clinical research; Progression-free survival; Oncology; Gastroenterology; Urology; Multiple myeloma; Chemotherapy; Antibody; Monoclonal antibody; Immunology","score_opus":0.10603643779784919,"score_gpt":0.4578265074100374,"score_spread":0.35179006961218817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604105114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951695,0.00029196223,0.000078683755,0.00029346105,0.0003710044,0.0031132037,0.000014390436,0.000019989167,0.000647808],"genre_scores_gemma":[0.99282664,0.00024091311,0.0057192883,0.00023475032,0.0004168721,0.000098785546,0.00001708412,0.000075432086,0.00037021146],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903762,0.002473901,0.004233404,0.00046194743,0.0015888978,0.0008656647],"domain_scores_gemma":[0.9863663,0.00684334,0.0037256605,0.0006129936,0.0011594016,0.0012923505],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006965532,0.00048093573,0.005538216,0.00058380095,0.00010899416,0.000012064841,0.0003311546,0.00047624143,0.000272711],"category_scores_gemma":[0.011070641,0.00024758186,0.00047923625,0.0005393348,0.0006552646,0.0004689468,0.00014214126,0.0019184536,0.000014799846],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4279548,0.07153731,0.44940752,0.00003397573,0.001645702,0.00064168323,0.000729658,0.0000039556767,0.000022605487,0.0000019035625,0.00009868807,0.04792221],"study_design_scores_gemma":[0.51565814,0.15183412,0.32928428,0.00022869119,0.00088465185,0.00012628804,0.00055772736,0.00013251844,0.00004548153,0.0000034454542,0.0010864248,0.00015824397],"about_ca_topic_score_codex":0.00033123704,"about_ca_topic_score_gemma":0.0009091881,"teacher_disagreement_score":0.12012325,"about_ca_system_score_codex":0.00048352417,"about_ca_system_score_gemma":0.0024422419,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W2605270513","doi":"10.1038/leu.2017.111","title":"Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Alberta Cancer Foundation; University of Calgary","funders":"Celgene","keywords":"Medicine; Lenalidomide; Thalidomide; Internal medicine; Multiple myeloma; Melphalan; Randomized controlled trial; Dexamethasone; Gastroenterology; Prednisone; Surgery","score_opus":0.03900635522089815,"score_gpt":0.31998645323623537,"score_spread":0.2809800980153372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605270513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900355,0.00012850511,0.00007679013,0.001238716,0.000069603564,0.00704087,0.000048036512,0.000017079052,0.0013449389],"genre_scores_gemma":[0.9953291,0.00010275643,0.0011502136,0.00006372798,0.00013356036,0.0018437371,0.000062536375,0.000024784174,0.0012896127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99854505,0.00009920321,0.00035356107,0.00028573233,0.00034388984,0.0003725591],"domain_scores_gemma":[0.99622804,0.0025011848,0.00024208106,0.0008237813,0.000090542875,0.00011436787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054611143,0.00021373923,0.00085603254,0.00010698482,0.00024947387,0.000056215275,0.0002491544,0.000093398274,0.000024823572],"category_scores_gemma":[0.0018212858,0.00010753505,0.00027033087,0.00006277507,0.00026517248,0.00007568516,0.000025441777,0.00010241231,0.0000066505004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9606542,0.00045491767,0.022291742,0.00004816076,0.00040754073,0.00029774444,0.0010742979,0.00002494032,0.00008077933,0.00014241584,0.00020351411,0.014319752],"study_design_scores_gemma":[0.9413606,0.0032031504,0.050334513,0.00013941032,0.0002130068,0.000012951738,0.00027593144,0.0013277191,0.0014667516,0.00008454926,0.0014757501,0.00010565986],"about_ca_topic_score_codex":0.004336471,"about_ca_topic_score_gemma":0.0052079125,"teacher_disagreement_score":0.02804277,"about_ca_system_score_codex":0.00038263056,"about_ca_system_score_gemma":0.00032199145,"threshold_uncertainty_score":0.65554756},"labels":[],"label_agreement":null},{"id":"W2605893447","doi":"10.1016/j.clml.2017.03.075","title":"Evaluating the Role of Tregs in the Progression of Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Child and Family Research Institute","funders":"","keywords":"Multiple myeloma; Immunology; Treg cell; Compartment (ship); Medicine; Biology; T cell; Immune system","score_opus":0.11263952864315159,"score_gpt":0.4621159181353165,"score_spread":0.3494763894921649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605893447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885852,0.0008392469,0.0000041955786,0.0007853794,0.0001351038,0.0013778008,0.000021335103,0.000023686109,0.008228061],"genre_scores_gemma":[0.9978337,0.00012969055,0.0012664491,0.0001059042,0.00026199518,0.00015186916,0.000027246237,0.000034744153,0.00018838583],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99565613,0.00072673237,0.0013529068,0.0005233021,0.0011766155,0.0005642969],"domain_scores_gemma":[0.99353,0.002833917,0.0009185015,0.0022222595,0.00028563218,0.00020969145],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035119767,0.0002875053,0.0008258382,0.00010205877,0.00041269723,0.00005873766,0.0011704321,0.00027043995,0.000056890334],"category_scores_gemma":[0.008876164,0.00014713722,0.00047388228,0.00021116454,0.0011844344,0.00015393914,0.00037259018,0.0003830834,0.000045986544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014856056,0.00042872105,0.39204484,0.00005144321,0.000093672854,0.0000671301,0.00028537764,0.000002065193,0.002554466,0.00017768411,0.00005238955,0.6027566],"study_design_scores_gemma":[0.008335732,0.001866937,0.9704231,0.00048231156,0.00011427441,0.000056381738,0.0005518084,0.009313161,0.0072801583,0.0005450241,0.0009007597,0.0001303277],"about_ca_topic_score_codex":0.00057807314,"about_ca_topic_score_gemma":0.00012037374,"teacher_disagreement_score":0.60262626,"about_ca_system_score_codex":0.00017384351,"about_ca_system_score_gemma":0.0009730248,"threshold_uncertainty_score":0.9994725},"labels":[],"label_agreement":null},{"id":"W2606367272","doi":"10.1016/j.clml.2017.03.256","title":"Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Carfilzomib; Multiple myeloma; Medicine; Open label; Refractory (planetary science); Oncology; Phase (matter); Randomized controlled trial; Internal medicine; Lenalidomide; Materials science; Physics","score_opus":0.08929741469129712,"score_gpt":0.40360225369489794,"score_spread":0.31430483900360084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606367272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177897,0.00088890025,0.0000049054042,0.00036103604,0.00036346252,0.00394772,0.0006697082,0.00006829241,0.0019170282],"genre_scores_gemma":[0.99348044,0.0010432784,0.0028381918,0.0002892677,0.00018945256,0.00024868778,0.00090431725,0.0001064833,0.00089985365],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99276364,0.0009217124,0.0027125275,0.0016420584,0.00095556426,0.0010045078],"domain_scores_gemma":[0.99035543,0.0039679846,0.0016391781,0.0023058583,0.0008687785,0.0008627647],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021725479,0.000769822,0.0033062203,0.00027192337,0.00051271846,0.00020343975,0.0009936831,0.00052858266,0.00005109107],"category_scores_gemma":[0.015874261,0.0005429069,0.00027372033,0.00020990093,0.0024047315,0.00081796065,0.001349376,0.00060506514,0.00007310892],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4514314,0.004354679,0.21640596,0.00009228731,0.0017399666,0.0009602445,0.00038799006,6.617088e-7,0.00013215223,0.000019413117,0.0007025992,0.32377267],"study_design_scores_gemma":[0.48304832,0.0027510494,0.51068556,0.00064491376,0.00031434878,0.0000062942995,0.00016172514,0.0008708859,0.0004556533,0.00004635279,0.0007095591,0.00030532482],"about_ca_topic_score_codex":0.0036590125,"about_ca_topic_score_gemma":0.00073564926,"teacher_disagreement_score":0.32346734,"about_ca_system_score_codex":0.00083662407,"about_ca_system_score_gemma":0.00088953244,"threshold_uncertainty_score":0.9997023},"labels":[],"label_agreement":null},{"id":"W2606664616","doi":"10.1158/1078-0432.ccr-16-2895","title":"The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; International Myeloma Foundation; Multiple Myeloma Research Foundation; Foundation for the National Institutes of Health","keywords":"Medicine; Multiple myeloma; Minimal residual disease; Oncology; Disease; Bone marrow; Drug development; Internal medicine; Intensive care medicine; Immunology; Drug; Pharmacology","score_opus":0.16667201864935197,"score_gpt":0.5103978063235773,"score_spread":0.34372578767422535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606664616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832968,0.012686481,0.0000010914507,0.0024474373,0.00003415247,0.0011239735,0.000019153387,0.0000091918355,0.0003817341],"genre_scores_gemma":[0.9905954,0.007415898,0.00038959726,0.000004824595,0.000520516,0.0008298983,0.000009583477,0.000012894386,0.00022138434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981518,0.00024454846,0.000363556,0.00038153792,0.0004764867,0.0003820712],"domain_scores_gemma":[0.99778146,0.00108802,0.00009321899,0.00036532516,0.00025962907,0.0004123447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013459162,0.00010884001,0.00022419191,0.00009107269,0.00086185976,0.00008093004,0.00014300893,0.000050297014,0.000009912168],"category_scores_gemma":[0.0009859892,0.00006884236,0.00003293467,0.000144958,0.0005051602,0.00006336603,0.0001802962,0.00038804588,0.0000037621783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064690824,0.0002015138,0.4970432,0.000041041287,0.000031384734,0.000005338546,0.00007419731,1.627261e-7,0.000048479436,0.00011243041,0.000023960854,0.5017714],"study_design_scores_gemma":[0.0022289325,0.0002512696,0.95272267,0.00011733659,0.000022312846,0.0000021054955,0.00014552282,0.00044323722,0.0004867247,0.00036926166,0.04315437,0.0000562617],"about_ca_topic_score_codex":0.0006721546,"about_ca_topic_score_gemma":0.0012257728,"teacher_disagreement_score":0.5017151,"about_ca_system_score_codex":0.00017544036,"about_ca_system_score_gemma":0.00097352895,"threshold_uncertainty_score":0.66288155},"labels":[],"label_agreement":null},{"id":"W2607270289","doi":"10.1007/s00280-017-3287-8","title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Amgen","keywords":"Carfilzomib; Medicine; Multiple myeloma; Pharmacokinetics; End stage renal disease; Stage (stratigraphy); Oncology; Disease; Internal medicine; Intensive care medicine; Proteasome inhibitor","score_opus":0.05407738287008189,"score_gpt":0.3948468544672407,"score_spread":0.3407694715971588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607270289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958524,0.0007902375,0.0000049482082,0.0004056611,0.000070340684,0.0024883342,0.0002922414,0.00001258373,0.000083264946],"genre_scores_gemma":[0.9975277,0.0012980533,0.00018589807,0.0003990249,0.00006917432,0.00017073608,0.00006147029,0.00003627573,0.00025162185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985122,0.00013087549,0.00027720482,0.0005119113,0.00020000139,0.00036778278],"domain_scores_gemma":[0.9988048,0.0000844734,0.0001920207,0.00029090233,0.00011791976,0.0005098487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018810149,0.0002557486,0.0004962676,0.0001047104,0.00025102176,0.000055187444,0.00018869108,0.00006143682,0.00036338714],"category_scores_gemma":[0.000025042807,0.00020104501,0.000013100549,0.00007148693,0.00043576004,0.00027139278,0.00015445174,0.00020781635,2.6456064e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07258107,0.011206839,0.798467,0.00017001075,0.00049154356,0.0002267435,0.0009701958,0.0000018370931,0.037058376,0.00000402385,0.00007474993,0.07874764],"study_design_scores_gemma":[0.23062229,0.009212991,0.7402699,0.00006870278,0.00023967681,0.0000030798537,0.00009531422,0.0008003764,0.016826067,0.0000067261326,0.0016401868,0.00021466555],"about_ca_topic_score_codex":0.00038791032,"about_ca_topic_score_gemma":0.0001356097,"teacher_disagreement_score":0.15804122,"about_ca_system_score_codex":0.0000702947,"about_ca_system_score_gemma":0.0001279154,"threshold_uncertainty_score":0.81983775},"labels":[],"label_agreement":null},{"id":"W2607390287","doi":"10.1016/j.clml.2017.03.011","title":"Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS)","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Medicine; Melphalan; Multiple myeloma; Oncology; Internal medicine; Maintenance therapy; Autologous stem-cell transplantation; Placebo; Surgery; Chemotherapy; Pathology","score_opus":0.052263338673336115,"score_gpt":0.3196888583339865,"score_spread":0.2674255196606504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607390287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635816,0.00056553906,0.00008632453,0.00030170789,0.00022182986,0.0015179007,0.0003923041,0.000080174,0.00047606966],"genre_scores_gemma":[0.99677116,0.00027919168,0.0014490043,0.00020557512,0.00007294287,0.00018798382,0.00029353658,0.00010091021,0.00063968386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297976,0.00073438993,0.0020918355,0.0016039193,0.001329359,0.0012607228],"domain_scores_gemma":[0.99291635,0.0026594528,0.0010811123,0.0020756486,0.00030243772,0.0009650119],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015835935,0.0008430796,0.0045491825,0.00053200015,0.0003633188,0.00014256926,0.00076982676,0.0005090925,0.00008919983],"category_scores_gemma":[0.0008038077,0.00059454265,0.0020863244,0.00046121416,0.00067193544,0.000438951,0.00027718526,0.0004954504,0.00003262977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011885724,0.0016406241,0.861202,0.0001749612,0.04422234,0.00417117,0.00031373894,0.000070565875,0.00012992702,0.000060435235,0.00006483204,0.07606371],"study_design_scores_gemma":[0.0534978,0.0014337385,0.90434635,0.00014503293,0.036517728,0.000017270082,0.000070615824,0.0027443334,0.00057354127,0.000030078272,0.0001075986,0.0005158971],"about_ca_topic_score_codex":0.005070613,"about_ca_topic_score_gemma":0.0031223497,"teacher_disagreement_score":0.075547814,"about_ca_system_score_codex":0.00067599915,"about_ca_system_score_gemma":0.0007750429,"threshold_uncertainty_score":0.9996506},"labels":[],"label_agreement":null},{"id":"W2607449242","doi":"10.1016/j.clml.2017.03.122","title":"Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Oncology; Refractory (planetary science); CD38; Internal medicine; Monoclonal; Monoclonal antibody; Antibody; Immunology; Lenalidomide; Stem cell","score_opus":0.10248146687702306,"score_gpt":0.3935936168366012,"score_spread":0.2911121499595781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607449242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918199,0.0011472797,0.00021470212,0.00068578264,0.0010115491,0.0021802175,0.00017830801,0.0000871006,0.0026751282],"genre_scores_gemma":[0.99283004,0.00095511193,0.0016710318,0.00016997308,0.00077481376,0.0005974224,0.000103488164,0.0000810049,0.0028170943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99625784,0.0001421365,0.0011961864,0.00090605405,0.000623364,0.0008744031],"domain_scores_gemma":[0.9930969,0.002553558,0.0006878431,0.0026975984,0.00036114804,0.0006029912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041294008,0.0004920877,0.001086348,0.000094648276,0.0010564497,0.00013218776,0.00077121524,0.00036662823,0.000104327504],"category_scores_gemma":[0.0028614837,0.000306493,0.0009889369,0.00010240314,0.0014189592,0.000264528,0.0001829765,0.00017388834,0.000120738565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005754257,0.0038429247,0.21910608,0.00006419149,0.0006265289,0.00023857519,0.0005081776,0.0000010283663,0.0016245899,0.00007561166,0.001093418,0.76706463],"study_design_scores_gemma":[0.027859367,0.005578129,0.8472975,0.0001554573,0.00021484541,0.00009014673,0.00018875058,0.0014975087,0.006687982,0.00005816721,0.110107884,0.0002642807],"about_ca_topic_score_codex":0.00033779515,"about_ca_topic_score_gemma":0.00015263511,"teacher_disagreement_score":0.76680034,"about_ca_system_score_codex":0.0011734524,"about_ca_system_score_gemma":0.000693961,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2607944311","doi":"10.1038/leu.2017.122","title":"Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Lenalidomide; Medicine; Autologous stem-cell transplantation; Multiple myeloma; Oncology; Internal medicine; Dexamethasone; Bortezomib; Hazard ratio; Salvage therapy; Transplantation; Chemotherapy; Confidence interval","score_opus":0.019377839062738305,"score_gpt":0.2684230750100851,"score_spread":0.24904523594734682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607944311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972523,0.0004081299,0.0000047821536,0.00011723295,0.000054385448,0.000710175,0.00006972415,0.000021200678,0.0013620849],"genre_scores_gemma":[0.99857724,0.00015978733,0.0003115126,0.0000362086,0.000014071686,0.0000291983,0.000027609054,0.000023799605,0.00082058436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986297,0.000056811987,0.00031973777,0.00035440794,0.00025043217,0.000388895],"domain_scores_gemma":[0.9989412,0.00018876906,0.0001353124,0.00047611567,0.00004755642,0.0002110882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012724542,0.0002086418,0.00048332012,0.00011937851,0.00017857192,0.00003036563,0.000099318335,0.00014695732,0.000011633913],"category_scores_gemma":[0.000083705134,0.00016158313,0.000057392528,0.000039740644,0.00019717863,0.00012976576,0.00009341798,0.00022486069,0.0000060179336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002415142,0.00013789721,0.9602523,0.00025323732,0.00007255932,0.00047011502,0.0012721559,9.606562e-7,0.0004187232,0.0000082361175,0.000011732152,0.03468694],"study_design_scores_gemma":[0.020163897,0.00030484932,0.9767059,0.00030859344,0.00006679549,0.000017536611,0.00006893268,0.00022646163,0.0018882033,0.0000068746594,0.00011181793,0.00013011364],"about_ca_topic_score_codex":0.00061709876,"about_ca_topic_score_gemma":0.00021059092,"teacher_disagreement_score":0.03455683,"about_ca_system_score_codex":0.00019565366,"about_ca_system_score_gemma":0.00009157771,"threshold_uncertainty_score":0.6589169},"labels":[],"label_agreement":null},{"id":"W2608522660","doi":"10.1182/blood.v128.22.4528.4528","title":"Development of Second Primary Malignancies in Multiple Myeloma Patients Treated with Lenalidomide: An Alberta Perspective","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Children's Hospital; University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Internal medicine; Oncology; Thalidomide; Cancer; Transplantation","score_opus":0.019374747880028857,"score_gpt":0.2532059949176327,"score_spread":0.23383124703760383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608522660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965668,0.00005743785,0.0000050097074,0.000045864133,0.000007897208,0.0006590707,0.000035813067,0.000018887446,0.0026032515],"genre_scores_gemma":[0.99531865,0.000007251704,0.0032963715,0.000023627881,0.000014710041,0.00008849191,0.00006526333,0.000026189198,0.0011594505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863046,0.000051340445,0.0002851362,0.00034073633,0.000345053,0.0003472927],"domain_scores_gemma":[0.9990764,0.00012352562,0.00008832508,0.0002719455,0.0002469492,0.0001928075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000873299,0.00018764695,0.00034811505,0.00018069253,0.00004760563,0.0000067136134,0.00008503366,0.00006254381,0.00017206016],"category_scores_gemma":[0.00013643599,0.000105964136,0.000040502902,0.00017641274,0.0000944843,0.00014756618,0.000041417024,0.00006266609,0.00002626465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015551957,0.0032873633,0.94720066,0.000065752814,0.00030259104,0.000086350825,0.0014562358,4.8507758e-8,0.04018907,0.000021764943,0.0000103440725,0.0058246045],"study_design_scores_gemma":[0.026086336,0.00074409915,0.82500106,0.0002516184,0.000042539712,0.000012178089,0.00022891477,0.0000014917554,0.14737979,0.0000060487864,0.00012573155,0.000120193596],"about_ca_topic_score_codex":0.00042339732,"about_ca_topic_score_gemma":0.0044367025,"teacher_disagreement_score":0.12219962,"about_ca_system_score_codex":0.00021311607,"about_ca_system_score_gemma":0.00028593207,"threshold_uncertainty_score":0.4321092},"labels":[],"label_agreement":null},{"id":"W2609136251","doi":"10.15273/dmj.vol43no1.6872","title":"Clinical features and diagnosis of multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Dalhousie Medical Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.03460673128051547,"score_gpt":0.3578217673436689,"score_spread":0.32321503606315344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609136251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886788,0.0012436484,0.00032985685,0.008605211,0.00024076998,0.00018161409,0.000021426327,0.000024350307,0.0006743097],"genre_scores_gemma":[0.9903614,0.006726839,0.0013082433,0.00042339409,0.00067905197,0.000011928622,0.0000035722203,0.000020292407,0.00046530773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974879,0.000186575,0.00057892466,0.00022488873,0.001138258,0.0003834586],"domain_scores_gemma":[0.9966607,0.0013844279,0.00014290986,0.00021253142,0.00016454121,0.001434872],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010330611,0.00014389514,0.00047255348,0.00012901425,0.000089161804,0.000015417243,0.00015167134,0.00020434055,0.0012819325],"category_scores_gemma":[0.0070235096,0.000071227914,0.00018677182,0.00009829071,0.0005008152,0.00007826442,0.00011366235,0.00047547818,0.00003490335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035449455,0.00028750778,0.55987203,0.000020625273,0.00015384336,0.0009130251,0.000030729578,6.2677747e-9,0.00016869963,0.000016744343,0.0050823023,0.43309996],"study_design_scores_gemma":[0.009325203,0.00085025263,0.9741426,0.0005888362,0.0000732366,0.0029157032,0.000028475848,0.000021302567,0.0012371414,0.00011998708,0.010611274,0.00008595047],"about_ca_topic_score_codex":0.000021635118,"about_ca_topic_score_gemma":0.000026952011,"teacher_disagreement_score":0.433014,"about_ca_system_score_codex":0.000032159867,"about_ca_system_score_gemma":0.00030634424,"threshold_uncertainty_score":0.99963105},"labels":[],"label_agreement":null},{"id":"W2609900216","doi":"10.1182/blood.v128.22.2095.2095","title":"TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Trillium Therapeutics (Canada)","funders":"","keywords":"Pharmacology; Bioavailability; In vivo; ADME; Bromodomain; Oral administration; Pharmacokinetics; IC50; Chemistry; In vitro; Biology; Biochemistry; Epigenetics","score_opus":0.03026844614524714,"score_gpt":0.2984379529543976,"score_spread":0.26816950680915047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609900216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959507,0.0010172408,0.00016691923,0.00064648,0.000033883953,0.0017974683,0.0002645939,0.000032442895,0.00009027843],"genre_scores_gemma":[0.9918944,0.0003622267,0.0059030177,0.00003471569,0.00015814815,0.00028671508,0.000031133743,0.000037110138,0.0012924897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985172,0.00006508222,0.00028658018,0.0004021162,0.00026307846,0.00046591208],"domain_scores_gemma":[0.99877405,0.0002871937,0.000098126635,0.0004586668,0.000104113155,0.00027784385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019752017,0.00023721937,0.0003658132,0.000092306116,0.00019093479,0.00003838693,0.00009188083,0.000084571235,0.00006695316],"category_scores_gemma":[0.000058657006,0.00011506304,0.000108965345,0.00009885163,0.00020450926,0.00012617414,0.000027317354,0.00003871839,0.000010830598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037706743,0.0052195797,0.24643116,0.00021706305,0.0010896755,0.00028809425,0.0017975621,7.8468936e-8,0.6091308,0.000055699533,0.00028121294,0.13171838],"study_design_scores_gemma":[0.07537477,0.012894544,0.122331135,0.00042770206,0.00073077437,0.0003283872,0.00036913695,0.0002901706,0.7780476,0.00039644845,0.008454956,0.00035434763],"about_ca_topic_score_codex":0.00039102018,"about_ca_topic_score_gemma":0.0002819857,"teacher_disagreement_score":0.1689168,"about_ca_system_score_codex":0.00007524315,"about_ca_system_score_gemma":0.00016774965,"threshold_uncertainty_score":0.46921346},"labels":[],"label_agreement":null},{"id":"W2610875117","doi":"10.1182/blood.v128.22.2108.2108","title":"B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Multiple myeloma; Cancer research; IGHV@; Medicine; Immunology; Oncology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.01874606279069476,"score_gpt":0.272848247350366,"score_spread":0.25410218455967126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610875117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958741,0.00014170422,0.000029276667,0.0010221545,0.000043358505,0.0008455608,0.000048609112,0.00006176446,0.0019334904],"genre_scores_gemma":[0.99392253,0.000029291588,0.0010987873,0.00012250678,0.00006614441,0.00014936978,0.000008206921,0.000029507244,0.004573644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984811,0.00014171927,0.0002086857,0.00033586076,0.00034444165,0.0004881927],"domain_scores_gemma":[0.99864066,0.00041559868,0.000027236081,0.00042420535,0.00004891816,0.00044337098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035849994,0.00014953801,0.00021913949,0.00025182447,0.000038193288,0.000010186845,0.000112948626,0.00007877264,0.00020907777],"category_scores_gemma":[0.00096123834,0.000097957105,0.000070618305,0.00023536313,0.00004319248,0.00005378515,0.00007416605,0.00009137807,0.0005412467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015505126,0.0010786584,0.76640296,0.000042246993,0.0001005032,0.0014132122,0.00012103268,0.0000011221393,0.20035027,0.0000022524823,0.0018923859,0.013090231],"study_design_scores_gemma":[0.026646819,0.0013149463,0.8960658,0.0002166825,0.000034835262,0.000041054667,0.000031979274,0.00003580163,0.06899332,0.000009773387,0.0064845183,0.00012448468],"about_ca_topic_score_codex":0.000090980735,"about_ca_topic_score_gemma":0.00005343092,"teacher_disagreement_score":0.13135695,"about_ca_system_score_codex":0.00019938318,"about_ca_system_score_gemma":0.00026039104,"threshold_uncertainty_score":0.6956812},"labels":[],"label_agreement":null},{"id":"W2612511582","doi":"10.1182/blood.v128.22.4414.4414","title":"Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Multiple myeloma; Pomalidomide; Lenalidomide; Medicine; Bortezomib; Refractory (planetary science); Ixazomib; Proteasome inhibitor; Internal medicine; Natural history; Oncology; Carfilzomib; Thalidomide; Biology","score_opus":0.012614655181575684,"score_gpt":0.2627553543396567,"score_spread":0.250140699158081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612511582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948007,0.002296573,0.0000014908196,0.0001831597,0.00020253725,0.0020306553,0.00001204971,0.000052205112,0.00042064436],"genre_scores_gemma":[0.99432606,0.000023616807,0.00035439743,0.000058929923,0.00011387728,0.00017133704,0.000004401996,0.000035357287,0.0049120444],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99832034,0.00011294741,0.00034003117,0.00040240207,0.00048044077,0.00034381586],"domain_scores_gemma":[0.9988218,0.00010318201,0.00010210768,0.00051010115,0.0001579372,0.00030487656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023815036,0.00020806647,0.00037148717,0.00022728754,0.000036899044,0.0000061589462,0.00010117273,0.000070532216,0.00006962767],"category_scores_gemma":[0.00030141775,0.00013117344,0.000087338136,0.000084665546,0.00011736027,0.00013980236,0.00012814038,0.000150182,0.000051799663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029425425,0.008028245,0.35113865,0.00018543562,0.0009579052,0.00032466944,0.005245058,1.8200556e-8,0.59122103,0.000005499034,0.0012641596,0.038686763],"study_design_scores_gemma":[0.039243244,0.0035241714,0.9241045,0.000544703,0.00024127254,0.000030059673,0.00054893794,0.0000045433935,0.025515473,0.0000050816147,0.0059726136,0.00026537073],"about_ca_topic_score_codex":0.00014216476,"about_ca_topic_score_gemma":0.000017945213,"teacher_disagreement_score":0.57296586,"about_ca_system_score_codex":0.000338824,"about_ca_system_score_gemma":0.00020109859,"threshold_uncertainty_score":0.5349097},"labels":[],"label_agreement":null},{"id":"W2613963547","doi":"10.1038/ncomms15086","title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Cancer Society Research Institute; National Institutes of Health; Princess Margaret Cancer Foundation; Ontario Ministry of Research and Innovation; Multiple Myeloma Research Foundation","keywords":"Neuroblastoma RAS viral oncogene homolog; Bone marrow; Multiple myeloma; KRAS; Concordance; Medicine; Cancer research; Pathology; Oncology; Internal medicine; Cancer","score_opus":0.08456498827939549,"score_gpt":0.41331448601088683,"score_spread":0.3287494977314913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613963547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98321295,0.0006991417,0.00009186093,0.008193809,0.000051431736,0.0007056103,0.00011182705,0.00009196113,0.0068414006],"genre_scores_gemma":[0.9828807,0.00008840766,0.015303356,0.000515493,0.000079366284,0.00014091254,0.0005143172,0.000026875976,0.00045054167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983484,0.00017775789,0.00027370485,0.00039786551,0.00044655195,0.00035569706],"domain_scores_gemma":[0.9942658,0.00029067247,0.0002119256,0.0042550946,0.0005082152,0.00046831847],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00033295035,0.0002019055,0.00037900388,0.00034589102,0.0013123394,0.00020191811,0.0013621658,0.0001798634,0.00007393366],"category_scores_gemma":[0.0029156406,0.00017831192,0.00018160202,0.00045050858,0.00019635304,0.00032482677,0.000591921,0.0008214665,0.00014060481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023138913,0.0009362495,0.8524481,0.000029237463,0.0022272582,0.00038262835,0.0012272929,0.0000785427,0.10891633,0.0029318582,0.0002790165,0.030312074],"study_design_scores_gemma":[0.0014689245,0.00023543015,0.96168053,0.000083865336,0.0004907249,0.000060827457,0.00022339517,0.023787437,0.009172781,0.0003087119,0.0022397165,0.00024764432],"about_ca_topic_score_codex":0.0015430405,"about_ca_topic_score_gemma":0.005253472,"teacher_disagreement_score":0.10923241,"about_ca_system_score_codex":0.00018611288,"about_ca_system_score_gemma":0.00013738227,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W2614011808","doi":"10.1111/bjh.14733","title":"Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Takeda Pharmaceutical Company","keywords":"Medicine; Lenalidomide; Ixazomib; Nausea; Adverse effect; Multiple myeloma; Rash; Placebo; Internal medicine; Mucositis; Dexamethasone; Vomiting; Thalidomide; Gastroenterology; Surgery; Chemotherapy; Carfilzomib","score_opus":0.029417235466169988,"score_gpt":0.30637939824332555,"score_spread":0.2769621627771556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614011808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722046,0.0009524489,0.00006686321,0.00023377754,0.00014371259,0.00046559417,0.000022310289,0.000009142906,0.0008857092],"genre_scores_gemma":[0.9965659,0.0006519755,0.0022136914,0.000025767655,0.000028585291,0.000014682918,0.000013004476,0.00003068276,0.00045570967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769264,0.00022414692,0.00079221575,0.00023582732,0.0005972769,0.00045789903],"domain_scores_gemma":[0.9976658,0.00023715784,0.0011191851,0.00038359544,0.0003407488,0.00025351558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007393947,0.00018298005,0.0011018183,0.00026688055,0.00014133567,0.000011049026,0.0003461572,0.00015909328,0.00010315568],"category_scores_gemma":[0.001084616,0.00016771125,0.0001905624,0.000112152244,0.00026467757,0.00020524146,0.00011758727,0.00050017616,0.000011397475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063781114,0.0018432564,0.6293304,0.00034845888,0.0021706782,0.33738473,0.00015539484,0.00003934271,0.00025738668,0.00004910334,0.00025404448,0.021789087],"study_design_scores_gemma":[0.042167295,0.00094989006,0.922021,0.0042503127,0.00022583854,0.028893141,0.0003175533,0.00015529073,0.00068550365,0.000101484016,0.00008970243,0.0001430452],"about_ca_topic_score_codex":0.000419893,"about_ca_topic_score_gemma":0.00073600304,"teacher_disagreement_score":0.3084916,"about_ca_system_score_codex":0.00026026188,"about_ca_system_score_gemma":0.00020937875,"threshold_uncertainty_score":0.6839066},"labels":[],"label_agreement":null},{"id":"W2614781853","doi":"10.1111/ejh.12903","title":"Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis","year":2017,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Medicine; Neutropenia; Lenalidomide; Multiple myeloma; Dexamethasone; Internal medicine; Adverse effect; Bortezomib; Febrile neutropenia; Refractory (planetary science); Surgery; Toxicity; Gastroenterology","score_opus":0.019646255981155318,"score_gpt":0.291607620513063,"score_spread":0.27196136453190767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614781853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974564,0.00020620374,0.00038105823,0.000223914,0.00007652286,0.00042057058,0.0000044621634,0.000010256351,0.0012206538],"genre_scores_gemma":[0.9948658,0.0000807852,0.0047594286,0.00007135717,0.000029706842,0.0000038549797,0.000011338823,0.000035797788,0.000141975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759966,0.00056363706,0.0006879083,0.00030169034,0.00045148365,0.0003956086],"domain_scores_gemma":[0.99764925,0.00012658323,0.0011246518,0.0005726242,0.00019215657,0.00033471306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008502055,0.0002264805,0.00085671234,0.0007501409,0.00017384399,0.000037848557,0.00027166685,0.000041610994,0.00006528648],"category_scores_gemma":[0.0006519466,0.00016139551,0.00017949843,0.0001792941,0.00018599871,0.0002056336,0.000189306,0.00037265656,0.000022317372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008840354,0.0006418638,0.9132243,0.000107472704,0.0039134882,0.053382948,0.00036053508,0.000101224985,0.0000486691,0.000014791901,0.00004668104,0.019317668],"study_design_scores_gemma":[0.033281863,0.0010241176,0.96264017,0.00034444648,0.0012137431,0.0005143555,0.0001571106,0.000507934,0.000052143674,0.000004941631,0.00012505316,0.00013410485],"about_ca_topic_score_codex":0.000029030947,"about_ca_topic_score_gemma":0.00005757246,"teacher_disagreement_score":0.05286859,"about_ca_system_score_codex":0.00015010472,"about_ca_system_score_gemma":0.000063348816,"threshold_uncertainty_score":0.65815175},"labels":[],"label_agreement":null},{"id":"W2615579443","doi":"","title":"Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent.","year":2002,"lang":"en","type":"article","venue":"Research Portal (King's College London)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Thalidomide; Toxicity; Medicine; Multiple myeloma; Pomalidomide; Lenalidomide; Pharmacology; Internal medicine; Oncology","score_opus":0.10449544418016557,"score_gpt":0.3921677417737117,"score_spread":0.2876722975935462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615579443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99080265,0.0031540508,0.0000017021503,0.000456964,0.000041660805,0.0026472325,0.00028446308,0.000025982281,0.0025852807],"genre_scores_gemma":[0.9964389,0.0013739187,0.00029253794,0.000011134561,0.00005766483,0.00015601773,0.000035032703,0.0000353861,0.0015993946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958015,0.00040920958,0.0007813378,0.0006637587,0.00146427,0.0008798925],"domain_scores_gemma":[0.9974653,0.0008962551,0.00023208495,0.00052884757,0.00032186936,0.00055565336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000732084,0.00033489277,0.0011940819,0.00072959426,0.0001812077,0.00003362039,0.00016457542,0.00020146614,0.0002948039],"category_scores_gemma":[0.0007353519,0.0002671862,0.00011861397,0.00071374385,0.00060988986,0.0001609457,0.0002096936,0.00040033215,0.000011485262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003716472,0.0067091505,0.93848187,0.0006206343,0.00032636066,0.0021564225,0.0009350016,0.00000485021,0.032995053,0.00020002168,0.0003778219,0.013476342],"study_design_scores_gemma":[0.02208855,0.0045878747,0.7288015,0.00053584704,0.00007027026,0.00024859095,0.0012627478,0.0023234924,0.23958705,0.00004500435,0.00020153297,0.00024755794],"about_ca_topic_score_codex":0.0009597169,"about_ca_topic_score_gemma":0.001621848,"teacher_disagreement_score":0.2096804,"about_ca_system_score_codex":0.00021744949,"about_ca_system_score_gemma":0.00015265291,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W2615766380","doi":"10.1182/blood.v128.22.1148.1148","title":"First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Pharmacology; Immunology; Pharmacokinetics; Plasma cell; Transplantation; Cancer research; Internal medicine; Oncology","score_opus":0.01609402546199887,"score_gpt":0.2762876653695559,"score_spread":0.260193639907557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615766380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919158,0.00002352849,0.000005439395,0.00006975754,0.000054588036,0.007365783,0.0002853569,0.00017320621,0.00010649794],"genre_scores_gemma":[0.9970195,0.000009926769,0.00053565943,0.000026037114,0.00007967481,0.00026064427,0.0018576379,0.00009113308,0.00011973385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579865,0.00051495736,0.0009093335,0.0011666452,0.0009241428,0.0006862995],"domain_scores_gemma":[0.99779516,0.00026786028,0.0003230996,0.0008854329,0.00030821134,0.00042020995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050682924,0.0004943733,0.00065609906,0.00051292137,0.0002540987,0.0000869462,0.00020708678,0.00011739793,0.000025508314],"category_scores_gemma":[0.0002960553,0.00032245892,0.000045415738,0.00069594523,0.000059673206,0.00043707475,0.00010631225,0.0003160447,0.00003844773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013968185,0.0357084,0.92079693,0.000025251436,0.00027043239,0.00063836336,0.005105618,0.000031251115,0.022164848,8.1969326e-8,0.000022523105,0.0012681232],"study_design_scores_gemma":[0.11656972,0.0070379404,0.8691085,0.00068763265,0.000112444286,0.0000010780543,0.0013487078,0.0001426659,0.004585425,5.523949e-7,0.000033848515,0.00037151377],"about_ca_topic_score_codex":0.0029668303,"about_ca_topic_score_gemma":0.019355057,"teacher_disagreement_score":0.102601536,"about_ca_system_score_codex":0.00027827965,"about_ca_system_score_gemma":0.00011131629,"threshold_uncertainty_score":0.99992275},"labels":[],"label_agreement":null},{"id":"W2618328561","doi":"10.1182/blood.v128.22.4497.4497","title":"Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University Health Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Progressive disease; Internal medicine; Regimen; Multiple myeloma; Neutropenia; Population; Phases of clinical research; Clinical endpoint; Dexamethasone; Oncology; Surgery; Gastroenterology; Clinical trial; Chemotherapy","score_opus":0.052097136182529986,"score_gpt":0.34331889794625303,"score_spread":0.29122176176372305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618328561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955415,0.00069629465,0.000052798565,0.0003862317,0.00006935581,0.0030102152,0.00004920755,0.00013211454,0.00006228601],"genre_scores_gemma":[0.9959852,0.000068435416,0.00287732,0.00023651555,0.00012745406,0.00024722388,0.000036951507,0.00008885079,0.00033203422],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99649525,0.00054572587,0.00080328895,0.00080883066,0.00060016447,0.00074676215],"domain_scores_gemma":[0.99587154,0.0025579082,0.00020191916,0.00067317876,0.00009653191,0.00059890497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011453374,0.0004530773,0.00086906273,0.00038417138,0.0001888003,0.00004421658,0.00016789367,0.0001612557,0.00022260482],"category_scores_gemma":[0.0038338674,0.00027566866,0.00016294463,0.0004734869,0.0001544104,0.00017926155,0.00008579639,0.00037074648,0.000026069372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026670216,0.021080969,0.4978618,0.00011596917,0.0010316604,0.0041825245,0.0009773121,0.0000034899954,0.35763195,0.000001990121,0.000019685167,0.09042241],"study_design_scores_gemma":[0.5724087,0.00978039,0.32723334,0.0010763427,0.00024215663,0.00006128232,0.00033784486,0.00033124856,0.087903574,0.000015485482,0.00015171288,0.00045793861],"about_ca_topic_score_codex":0.00019985084,"about_ca_topic_score_gemma":0.00042443053,"teacher_disagreement_score":0.54573846,"about_ca_system_score_codex":0.00015618924,"about_ca_system_score_gemma":0.00045109037,"threshold_uncertainty_score":0.99996954},"labels":[],"label_agreement":null},{"id":"W2620016413","doi":"10.1111/bjh.14780","title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions","year":2017,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Amgen","keywords":"Multiple myeloma; Medicine; Intensive care medicine; Oncology; Internal medicine","score_opus":0.2364325585495828,"score_gpt":0.4665470139031241,"score_spread":0.23011445535354128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620016413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018338511,0.99331576,0.000025645484,0.00084408204,0.0002338094,0.0033769377,0.00026274976,0.000014110888,0.000093069575],"genre_scores_gemma":[0.00052565546,0.9949676,0.0028037403,0.000023140396,0.00015681045,0.0009991205,0.00023532477,0.00007744422,0.00021118035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970235,0.00028353097,0.0014755384,0.0004020093,0.00023694489,0.000578449],"domain_scores_gemma":[0.99605036,0.0011427494,0.0012767798,0.0006007831,0.00053584046,0.00039347186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043649922,0.0003784043,0.0037254628,0.00054948777,0.00024800407,0.00008480877,0.0004306447,0.0004329865,0.000045728266],"category_scores_gemma":[0.0016571918,0.0002954148,0.0010144737,0.00017516971,0.00020505201,0.00006980122,0.000054885535,0.00038084033,0.000021262278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003241172,0.0013229157,0.0017118738,0.0007508319,0.00091707025,0.014963967,0.00001778978,5.007545e-8,1.5406745e-7,0.000019466792,0.0014578061,0.97851396],"study_design_scores_gemma":[0.008586287,0.0011544303,0.003804236,0.013442567,0.0004799525,0.15711397,0.0000066568837,0.0000029101811,0.0000017502934,0.000104870094,0.8151387,0.00016366858],"about_ca_topic_score_codex":0.000025624999,"about_ca_topic_score_gemma":0.00027829516,"teacher_disagreement_score":0.9783503,"about_ca_system_score_codex":0.0004827038,"about_ca_system_score_gemma":0.0015762846,"threshold_uncertainty_score":0.9999498},"labels":[],"label_agreement":null},{"id":"W2621281002","doi":"10.1182/blood.v128.22.4526.4526","title":"Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Queen's University; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Neuroblastoma RAS viral oncogene homolog; Medicine; Protein kinase B; Multiple myeloma; Progressive disease; Oncology; Biomarker; Internal medicine; Clinical trial; PI3K/AKT/mTOR pathway; Lenalidomide; MEK inhibitor; Cancer research; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; MAPK/ERK pathway; Cancer; Disease; Biology; KRAS; Signal transduction","score_opus":0.04344315609987847,"score_gpt":0.36256081193825196,"score_spread":0.3191176558383735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621281002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093145,0.000044769964,0.000005053819,0.00056561717,0.0001897396,0.0067098187,0.001501907,0.0000162941,0.000035347766],"genre_scores_gemma":[0.99876004,0.000024515764,0.00029750014,0.000009764509,0.00016105112,0.00038275812,0.00010918931,0.00003393847,0.00022125896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960567,0.00072890095,0.001328809,0.0004944628,0.0010274946,0.00036363094],"domain_scores_gemma":[0.99698806,0.0006056307,0.00092115515,0.00092050363,0.00021949291,0.00034515647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054921414,0.00031014756,0.0009155135,0.00017332149,0.00011172443,0.000004724284,0.00026252712,0.00018206623,0.0002346464],"category_scores_gemma":[0.0013063401,0.00013942868,0.00051227695,0.0003831959,0.00065910746,0.000085311985,0.00027817907,0.00014901497,0.0000029135356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7438061,0.07424679,0.032770958,0.00011448763,0.0007545248,0.000053196374,0.00028960526,7.183481e-7,0.12117648,0.000004634283,0.00016231128,0.02662018],"study_design_scores_gemma":[0.7396483,0.05534356,0.022971814,0.0012169408,0.00070439,0.0000056699814,0.000021297545,0.00004343387,0.17946057,0.000006993758,0.0004410127,0.00013605795],"about_ca_topic_score_codex":0.00006271868,"about_ca_topic_score_gemma":0.00010420398,"teacher_disagreement_score":0.058284085,"about_ca_system_score_codex":0.00015623783,"about_ca_system_score_gemma":0.0007263427,"threshold_uncertainty_score":0.56857365},"labels":[],"label_agreement":null},{"id":"W2623186942","doi":"10.1111/vcp.12503","title":"A metastatic secretory gastric plasmacytoma with aberrant<scp>CD</scp>3 expression in a dog","year":2017,"lang":"en","type":"article","venue":"Veterinary Clinical Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; McMaster University; McMaster University Medical Centre","funders":"","keywords":"Plasmacytoma; Pathology; Multiple myeloma; Monoclonal; Medicine; Immunohistochemistry; Lethargy; Monoclonal antibody; Immunology; Internal medicine; Antibody","score_opus":0.13278469006324536,"score_gpt":0.4268275762403602,"score_spread":0.2940428861771148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623186942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964022,0.00017084497,0.00012295072,0.0002947009,0.00020563106,0.0006686119,0.000029680197,0.000057216428,0.0020481308],"genre_scores_gemma":[0.9897574,0.00019340013,0.008713749,0.00022460372,0.00012422915,0.00015626676,0.000041112078,0.000039968043,0.00074924564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970853,0.0005856259,0.00063316355,0.0006987077,0.00032509118,0.000672127],"domain_scores_gemma":[0.99699605,0.0010896198,0.00029028396,0.0010947785,0.00006867392,0.00046060965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007377075,0.0002770928,0.0008305935,0.00022776038,0.00020393002,0.000035459798,0.00032821175,0.00019709462,0.000081199956],"category_scores_gemma":[0.00217154,0.00019302187,0.00017281322,0.000104294435,0.00059019093,0.00016061417,0.00031165677,0.0006683749,0.0002149882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032770147,0.002113696,0.7995417,0.00020201167,0.00017747481,0.15081373,0.00022548529,0.000002373485,0.023739828,0.000008367741,0.0007759301,0.019122366],"study_design_scores_gemma":[0.013100112,0.0120319715,0.96714187,0.0002584861,0.000076315904,0.00448731,0.00008621362,0.0002500402,0.00028590192,0.00007927517,0.0021170685,0.00008544792],"about_ca_topic_score_codex":0.0000350887,"about_ca_topic_score_gemma":0.000029278171,"teacher_disagreement_score":0.16760013,"about_ca_system_score_codex":0.000062400664,"about_ca_system_score_gemma":0.00015975077,"threshold_uncertainty_score":0.78712034},"labels":[],"label_agreement":null},{"id":"W2624034585","doi":"10.1016/j.cancergen.2017.04.020","title":"Development of Consensus Recommendations for Genomic Testing of Plasma Cell Neoplasms for Diagnosis and Prognosis","year":2017,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Multiple myeloma; Plasma cell neoplasm; Plasma cell; Neuroblastoma RAS viral oncogene homolog; Biology; Plasma cell leukemia; Computational biology; Genetics; Bioinformatics; Cancer research; Oncology; Medicine; Mutation; Gene; Immunology; Plasmacytoma","score_opus":0.17064284122841397,"score_gpt":0.38702918956013177,"score_spread":0.2163863483317178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624034585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970662,0.000538055,0.00014285074,0.0004795189,0.00006602282,0.0012990113,0.00031235538,0.000004784412,0.000091191134],"genre_scores_gemma":[0.7252489,0.00035147672,0.27344593,0.000009395897,0.000027557373,0.00079984014,0.000022312806,0.000013105914,0.00008149786],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99937546,0.0000054849584,0.00023084275,0.00014804893,0.00007316635,0.00016701176],"domain_scores_gemma":[0.9990064,0.00029836548,0.00019673447,0.00016757235,0.00023781219,0.000093111994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008012893,0.00008158218,0.00019396604,0.000041757878,0.00017914607,0.000010991678,0.00006577386,0.000038020735,0.000008770974],"category_scores_gemma":[0.00023592837,0.00007405208,0.00003344127,0.000022017923,0.00007919326,0.000008666053,0.00004576164,0.00002700772,3.5888357e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018020676,0.0001514538,0.6160596,0.0007001942,0.00015423364,6.745175e-7,0.00039008894,0.00000840638,0.019543368,0.000003932036,0.0006124977,0.36219534],"study_design_scores_gemma":[0.0043925247,0.0004163329,0.18660182,0.00019909794,0.0001562,0.0000018203109,0.00010578622,0.002985315,0.7877219,0.000024281839,0.017305925,0.000089041525],"about_ca_topic_score_codex":0.000054191092,"about_ca_topic_score_gemma":0.00015925884,"teacher_disagreement_score":0.76817846,"about_ca_system_score_codex":0.00006383444,"about_ca_system_score_gemma":0.00035573792,"threshold_uncertainty_score":0.3019756},"labels":[],"label_agreement":null},{"id":"W2625253716","doi":"10.1038/leu.2017.138","title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Janssen Pharmaceuticals","keywords":"Multiple myeloma; Medicine; Internal medicine; Carfilzomib; Oncology; Proteasome inhibitor; Lenalidomide; Refractory (planetary science); Hematology; Natural history; Pomalidomide; Bortezomib; Biology","score_opus":0.01825545139266853,"score_gpt":0.293698689027516,"score_spread":0.27544323763484746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625253716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428177,0.0012649485,0.0000010451996,0.00014846053,0.0004378142,0.0020650842,0.000007706612,0.00004338324,0.0017498177],"genre_scores_gemma":[0.9901871,0.000016540731,0.00040389327,0.00009736788,0.0001558572,0.00014689677,0.00001015976,0.00003858518,0.008943603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982309,0.00008422496,0.0003477901,0.0004439914,0.0005202277,0.00037289454],"domain_scores_gemma":[0.99813855,0.000058691985,0.00021001708,0.0010979216,0.000162458,0.00033233472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002864379,0.00023800552,0.00044738114,0.00018684754,0.00015676137,0.000030328945,0.00023029718,0.000098168224,0.000049756858],"category_scores_gemma":[0.00047699537,0.0001924958,0.000100585756,0.000040157618,0.00020897617,0.0002440816,0.00026227417,0.00035462654,0.000051634775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008658757,0.0023809301,0.6440898,0.00059874094,0.0011823724,0.0009841169,0.018889593,0.0000010901753,0.20506631,0.000017566326,0.009565456,0.10856527],"study_design_scores_gemma":[0.01158385,0.0012518308,0.97461826,0.00027906595,0.00008262097,0.000012721,0.000548155,0.00015010902,0.0030361037,0.000004803076,0.0082323095,0.00020017705],"about_ca_topic_score_codex":0.0013494713,"about_ca_topic_score_gemma":0.000071419294,"teacher_disagreement_score":0.33052847,"about_ca_system_score_codex":0.0021516215,"about_ca_system_score_gemma":0.0005314268,"threshold_uncertainty_score":0.7849751},"labels":[],"label_agreement":null},{"id":"W2625781879","doi":"10.17576/mh.2017.1201.13","title":"A Rare Occurrence of Plasma Cell Myeloma with Biclonal Gammopathy","year":2017,"lang":"en","type":"article","venue":"Medicine & health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diagnostic Services Manitoba","funders":"","keywords":"Multiple myeloma; Plasma Cell Myeloma; Medicine; Gammopathy; Plasma cell; Monoclonal gammopathy; Internal medicine; Immunology; Antibody","score_opus":0.049980562682005396,"score_gpt":0.36202329509298625,"score_spread":0.31204273241098085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625781879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788324,0.00091111736,0.00008690102,0.011289026,0.00014380015,0.00082913676,0.00008311409,0.000039759063,0.0077847275],"genre_scores_gemma":[0.9970269,0.000283116,0.0010227442,0.00042534267,0.00020640618,0.000032886295,0.000107315864,0.000018060151,0.00087719364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977847,0.00006656413,0.00038712338,0.00036149088,0.0008361916,0.0005639313],"domain_scores_gemma":[0.99769133,0.00010327798,0.000384884,0.00088298426,0.00019853364,0.000738993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043586796,0.00021503515,0.00066773326,0.00016170724,0.00035811609,0.000010607567,0.00024957833,0.000054815733,0.0003269999],"category_scores_gemma":[0.0002962253,0.0001308455,0.00005351078,0.0001178283,0.0005512132,0.00008178106,0.0000658859,0.00029001254,0.000052270574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029754676,0.00079998106,0.82543963,0.0020420826,0.000093127346,0.0013452042,0.0017079363,9.751683e-7,0.0011251328,0.000078868,0.014539218,0.14985238],"study_design_scores_gemma":[0.018937076,0.010960254,0.9520468,0.0019281902,0.000077890945,0.00039321193,0.0004571184,0.00035831722,0.0040691784,0.000027584387,0.010556697,0.00018766415],"about_ca_topic_score_codex":0.0013387043,"about_ca_topic_score_gemma":0.00019814009,"teacher_disagreement_score":0.14966471,"about_ca_system_score_codex":0.00012363197,"about_ca_system_score_gemma":0.0010072616,"threshold_uncertainty_score":0.53357244},"labels":[],"label_agreement":null},{"id":"W2625828374","doi":"10.1016/j.tmrv.2017.05.007","title":"Interference of Anti-CD38 in Multiple Myeloma Patients","year":2017,"lang":"en","type":"article","venue":"Transfusion Medicine Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Multiple myeloma; CD38; Interference (communication); Medicine; Internal medicine; Computer science; Biology; Telecommunications; Genetics","score_opus":0.09695567060726674,"score_gpt":0.37250548533292066,"score_spread":0.27554981472565393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625828374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98992836,0.003501178,0.00013909423,0.00090166216,0.00016164902,0.0017700883,0.000009248827,0.000014785781,0.0035739525],"genre_scores_gemma":[0.90621185,0.09290606,0.00035520582,0.00008135518,0.00006765917,0.00005327811,0.00004119232,0.000016454174,0.0002669562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802333,0.00012253776,0.0007784856,0.0003396018,0.00042528534,0.00031074867],"domain_scores_gemma":[0.998386,0.00009688165,0.00024546913,0.0008901104,0.00013664123,0.00024488516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059297116,0.00022089992,0.0010564929,0.00021159284,0.00011796078,0.000007079546,0.00029434162,0.000080408594,0.00057185884],"category_scores_gemma":[0.0015961345,0.0001365879,0.00014346991,0.00014034825,0.0002862746,0.00011785419,0.00005139239,0.00025064373,0.00007707074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024223166,0.0003695813,0.7477899,0.00057407323,0.000018754201,0.000034934794,0.00028189356,6.219544e-8,0.008061231,0.000009465097,0.00033134117,0.24228653],"study_design_scores_gemma":[0.010379936,0.0008780367,0.97557396,0.0041110665,0.00006581928,0.00000774541,0.000035434026,0.00011091782,0.0025556358,0.000017722514,0.006158412,0.00010529448],"about_ca_topic_score_codex":0.001839674,"about_ca_topic_score_gemma":0.000769782,"teacher_disagreement_score":0.24218124,"about_ca_system_score_codex":0.00004914678,"about_ca_system_score_gemma":0.000049827606,"threshold_uncertainty_score":0.62614536},"labels":[],"label_agreement":null},{"id":"W2626414898","doi":"10.1186/s13045-017-0492-1","title":"Role of epigenetics-microRNA axis in drug resistance of multiple myeloma","year":2017,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"microRNA; Multiple myeloma; Epigenetics; Hematology; Drug resistance; Medicine; Internal medicine; Oncology; Drug; Cancer research; Bioinformatics; Pharmacology; Computational biology; Biology; Genetics; Gene","score_opus":0.0652217907511443,"score_gpt":0.4123141270484581,"score_spread":0.3470923362973138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626414898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007888647,0.98876065,0.0000051207858,0.00025834545,0.00024034076,0.00079342996,0.000043761516,0.0000040679024,0.0020056078],"genre_scores_gemma":[0.01809932,0.97715396,0.0039074584,0.00001341518,0.00010417379,0.000029620121,0.000020148154,0.000049331586,0.0006225787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99524885,0.00071729167,0.0027496128,0.00033047024,0.00041240934,0.000541358],"domain_scores_gemma":[0.9921748,0.001584987,0.0046526715,0.0007528506,0.00055803783,0.0002766494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010905123,0.00040851725,0.0069046565,0.0010243324,0.00005352234,0.0000049300093,0.0006883771,0.0007581735,0.00009349283],"category_scores_gemma":[0.0018586937,0.00030134854,0.000997119,0.00020656598,0.00061887904,0.00005867646,0.00017149073,0.0011129227,0.000021454725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002316736,0.0025771619,0.015104554,0.02641055,0.0028999215,0.007706994,0.00046152057,4.4710833e-7,0.00044426208,0.00029509354,0.001913394,0.93986934],"study_design_scores_gemma":[0.0050469064,0.0010989856,0.0021052256,0.014688319,0.0010866673,0.0054697944,0.000098253746,0.0000020925215,0.0010574155,0.00021046941,0.968952,0.000183863],"about_ca_topic_score_codex":0.0000743164,"about_ca_topic_score_gemma":0.0009390077,"teacher_disagreement_score":0.96703863,"about_ca_system_score_codex":0.00041401442,"about_ca_system_score_gemma":0.0028758538,"threshold_uncertainty_score":0.99994385},"labels":[],"label_agreement":null},{"id":"W2626685501","doi":"10.1016/j.transci.2017.06.002","title":"The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma","year":2017,"lang":"en","type":"article","venue":"Transfusion and Apheresis Science","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Medicine; Platelet; CD34; Multiple myeloma; Chemotherapy; Autologous stem-cell transplantation; Haematopoiesis; Platelet transfusion; Internal medicine; Urology; Stem cell; Surgery; Biology","score_opus":0.03383936634196988,"score_gpt":0.31001850001275805,"score_spread":0.27617913367078817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626685501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968362,0.0005819453,0.000024665085,0.0014622769,0.000057701105,0.0004803582,0.0000053529093,0.000014713582,0.00053681206],"genre_scores_gemma":[0.99571365,0.0032287517,0.0007357885,0.000037002577,0.0000108333,0.000012193715,0.0000016644519,0.000008367014,0.0002517683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872124,0.000050399947,0.00022038163,0.00036209173,0.0003552589,0.0002906435],"domain_scores_gemma":[0.9988739,0.00048156045,0.0000762528,0.00035679835,0.00003525234,0.0001762211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007454753,0.00012864341,0.00023236584,0.00011643325,0.0012839781,0.00012127948,0.00015415387,0.000076068136,0.000016862976],"category_scores_gemma":[0.00058982597,0.00008219388,0.00004169038,0.00017464791,0.00083252625,0.00027914817,0.000068269954,0.00015454771,0.0000011735907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010290506,0.00007093769,0.61806375,0.000048318943,0.00001672533,0.00006721069,0.00053830625,0.0000010084177,0.07808038,0.00019479897,0.000011203092,0.3018783],"study_design_scores_gemma":[0.00478198,0.00023519684,0.9841372,0.00019127192,0.000011936479,0.000023545637,0.00018230524,0.0010035824,0.008850784,0.00043182552,0.00006626097,0.000084134495],"about_ca_topic_score_codex":0.001073005,"about_ca_topic_score_gemma":0.0009103566,"teacher_disagreement_score":0.36607343,"about_ca_system_score_codex":0.000025178935,"about_ca_system_score_gemma":0.000081041544,"threshold_uncertainty_score":0.9875452},"labels":[],"label_agreement":null},{"id":"W2626839357","doi":"10.1002/oby.21894","title":"Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease","year":2017,"lang":"en","type":"article","venue":"Obesity","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Purdue University","keywords":"Adiponectin; Multiple myeloma; Medicine; Internal medicine; Disease; Oncology; Endocrinology; Obesity","score_opus":0.04078379006762668,"score_gpt":0.29909258979826325,"score_spread":0.2583087997306366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626839357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998177,0.00007994811,0.000029157762,0.00017334364,0.000029074432,0.0008663598,0.00020378825,0.000044447308,0.0003969032],"genre_scores_gemma":[0.99889255,0.0000037187451,0.0002442937,0.000021384933,0.00009546646,0.000030528197,0.0000906653,0.000025865202,0.0005955575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986826,0.000046864498,0.00013327913,0.000374519,0.0003949983,0.0003676926],"domain_scores_gemma":[0.99851555,0.000111769856,0.00010781465,0.0005008056,0.00013881622,0.0006252603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009413321,0.00018720387,0.00028794177,0.00005112277,0.0006193327,0.0000785865,0.00011616925,0.000056585322,0.000055668428],"category_scores_gemma":[0.0008752575,0.00013590009,0.000049631974,0.000034872803,0.00008055013,0.00020807178,0.0001414659,0.00015707097,0.000049336428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035268045,0.0002734899,0.988328,0.000114960494,0.00014854963,0.00010490128,0.00006596615,1.7309567e-7,0.00015245835,0.0000060009725,0.00001780406,0.010435057],"study_design_scores_gemma":[0.005760525,0.00019556221,0.9922888,0.00015840007,0.00013886011,0.0000022815043,0.000003942112,0.00032560842,0.00089946063,0.000022369662,0.000057250338,0.00014692596],"about_ca_topic_score_codex":0.000075165684,"about_ca_topic_score_gemma":0.000039096467,"teacher_disagreement_score":0.010288131,"about_ca_system_score_codex":0.00006466655,"about_ca_system_score_gemma":0.000058195215,"threshold_uncertainty_score":0.5541845},"labels":[],"label_agreement":null},{"id":"W2628084958","doi":"10.1182/blood.v128.22.4519.4519","title":"A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Bortezomib; Dexamethasone; Internal medicine; Multiple myeloma; Cyclophosphamide; Autologous stem-cell transplantation; Regimen; Transplantation; Induction chemotherapy; Surgery; Gastroenterology; Oncology; Chemotherapy","score_opus":0.021932576883592965,"score_gpt":0.2921746258348039,"score_spread":0.27024204895121096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2628084958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964265,0.0018020505,0.00011110389,0.00011965729,0.00004099502,0.0011527975,0.00014808154,0.00004062638,0.0001581796],"genre_scores_gemma":[0.9942194,0.0008473685,0.0046520988,0.00001912216,0.000023412647,0.00009816466,0.000058886028,0.000044166387,0.000037352715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977622,0.000095780764,0.00048749574,0.0005549715,0.00052541523,0.0005741388],"domain_scores_gemma":[0.9978063,0.001096226,0.00015759592,0.0003771895,0.0001294693,0.0004332365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019955025,0.00032840428,0.00082129735,0.0002468597,0.00006517674,0.000018537565,0.000098247605,0.00014596699,0.000031671236],"category_scores_gemma":[0.00040276692,0.00021049101,0.000058599875,0.00030333913,0.00025278263,0.00015481694,0.000054613058,0.00018369815,0.0000058606433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009536341,0.0027973475,0.94734025,0.0001389182,0.00040472546,0.00021636035,0.00045236817,8.9213194e-7,0.0036303105,0.000010141144,0.000017339813,0.035455022],"study_design_scores_gemma":[0.1107357,0.0026704266,0.8595549,0.00048397764,0.00028761794,0.000013554938,0.000095744035,0.000087557884,0.025773762,0.000009488938,0.00006939805,0.00021788769],"about_ca_topic_score_codex":0.0008088972,"about_ca_topic_score_gemma":0.0009426174,"teacher_disagreement_score":0.10119936,"about_ca_system_score_codex":0.00005294251,"about_ca_system_score_gemma":0.00011468852,"threshold_uncertainty_score":0.8583574},"labels":[],"label_agreement":null},{"id":"W2639253133","doi":"10.1182/blood.v128.22.4505.4505","title":"Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Bortezomib; Medicine; Thalidomide; Dexamethasone; Multiple myeloma; Regimen; Cyclophosphamide; Internal medicine; Autologous stem-cell transplantation; Lenalidomide; Gastroenterology; Oncology; Surgery; Chemotherapy","score_opus":0.037364715148987725,"score_gpt":0.31157889982393855,"score_spread":0.27421418467495084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2639253133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861354,0.0078083235,0.000708325,0.0014368524,0.00008289722,0.0034343817,0.00025116338,0.000056790854,0.00008582357],"genre_scores_gemma":[0.9786179,0.015968436,0.00404261,0.00009864592,0.00012657323,0.00071640266,0.000039570463,0.000052963533,0.00033687407],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980007,0.000091641385,0.00042916654,0.000574861,0.00036658734,0.00053708645],"domain_scores_gemma":[0.99739456,0.0013728383,0.00012954549,0.00051912654,0.0001594673,0.00042448248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002983457,0.00036691176,0.0006997713,0.00017077531,0.0001955525,0.000032885277,0.00011101644,0.00013245214,0.00004136076],"category_scores_gemma":[0.00019689059,0.00019180775,0.00015362869,0.00022113867,0.00020699955,0.00010238341,0.000023879857,0.00007591609,0.000008641287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01206306,0.0034396907,0.37735844,0.00009491249,0.002261674,0.00008431543,0.0015618317,0.000002111305,0.2223704,0.00006312516,0.00009569703,0.38060474],"study_design_scores_gemma":[0.051652946,0.0051486623,0.49079382,0.0001800246,0.00054296246,0.00018478255,0.00022447843,0.00008783612,0.44682527,0.00014359615,0.0039675515,0.0002480558],"about_ca_topic_score_codex":0.0009913053,"about_ca_topic_score_gemma":0.00022680323,"teacher_disagreement_score":0.38035667,"about_ca_system_score_codex":0.000071221475,"about_ca_system_score_gemma":0.00012272308,"threshold_uncertainty_score":0.7821693},"labels":[],"label_agreement":null},{"id":"W26452364","doi":"10.1016/j.clml.2015.07.347","title":"Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Melphalan; Multiple myeloma; Internal medicine; Bortezomib; Autologous stem-cell transplantation; Dexamethasone; Chemotherapy; Induction chemotherapy; Cancer; Surgery; Oncology","score_opus":0.09018790762246759,"score_gpt":0.392261338032704,"score_spread":0.30207343041023643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W26452364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956904,0.0006065536,0.000007620655,0.0004836686,0.0005278051,0.00093868107,0.00006763993,0.00007414179,0.0016034909],"genre_scores_gemma":[0.99631476,0.00017672872,0.00043032895,0.0004985575,0.00032847884,0.00014329326,0.000048882095,0.000063755404,0.0019951873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99530786,0.00037498615,0.0014934147,0.0007988909,0.0011386626,0.00088620355],"domain_scores_gemma":[0.99631786,0.0010429744,0.0003571807,0.0011127846,0.00033389297,0.00083528704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097418576,0.00039915575,0.0010240962,0.00016942239,0.00008473174,0.000044066528,0.0006516082,0.0003566588,0.00056903047],"category_scores_gemma":[0.00310716,0.00027869883,0.00037051074,0.0006574047,0.0008314299,0.00020204567,0.0004260365,0.0004070998,0.00027790572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014074642,0.00039437893,0.8103629,0.000051000676,0.00011713725,0.0004908284,0.00063004385,0.0000144696405,0.00006489425,0.00005036924,0.0021530709,0.18426348],"study_design_scores_gemma":[0.012060359,0.00030274803,0.9639221,0.00020949249,0.000054993645,0.00003231791,0.0005081198,0.0013226658,0.0004862129,0.00005065874,0.020787084,0.0002632576],"about_ca_topic_score_codex":0.001973011,"about_ca_topic_score_gemma":0.0016884296,"teacher_disagreement_score":0.18400022,"about_ca_system_score_codex":0.0012630561,"about_ca_system_score_gemma":0.0014245698,"threshold_uncertainty_score":0.9999665},"labels":[],"label_agreement":null},{"id":"W2703436965","doi":"10.1080/10428194.2017.1334125","title":"Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Celgene","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Quality of life (healthcare); Internal medicine; Confidence interval; Pediatrics; Oncology","score_opus":0.027634969815474822,"score_gpt":0.2933253349468921,"score_spread":0.2656903651314173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2703436965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487275,0.0025232416,0.000054303055,0.00025765784,0.00010717716,0.0015628622,0.00014718986,0.000093174625,0.00038167386],"genre_scores_gemma":[0.99600893,0.0019749613,0.0010019252,0.00024388352,0.00006492492,0.00012337866,0.0002797169,0.000100546815,0.00020170848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495095,0.00037012025,0.00148823,0.0011061386,0.00090629904,0.0011782746],"domain_scores_gemma":[0.9955639,0.0009140824,0.00095452706,0.0011886391,0.00021997234,0.0011588351],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088018476,0.0007040323,0.0018680878,0.00042727316,0.00060997845,0.00016286543,0.00038335536,0.00040528935,0.000035989022],"category_scores_gemma":[0.0010543369,0.0005737295,0.00018017355,0.00030684605,0.00068409124,0.00053240464,0.00019244089,0.00022856142,0.000011182749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00886758,0.0005114862,0.85751396,0.0008880871,0.00036869035,0.00040017036,0.00096934306,0.0000104364135,0.00043748738,0.000028769065,0.00004641306,0.1299576],"study_design_scores_gemma":[0.107834056,0.0006757394,0.88729393,0.0014623785,0.00009854324,0.00010963392,0.00010672692,0.0008392577,0.0010356375,0.000031897922,0.000027924678,0.00048424213],"about_ca_topic_score_codex":0.031679243,"about_ca_topic_score_gemma":0.0055614305,"teacher_disagreement_score":0.12947336,"about_ca_system_score_codex":0.0024853048,"about_ca_system_score_gemma":0.0027756114,"threshold_uncertainty_score":0.9996714},"labels":[],"label_agreement":null},{"id":"W2725206342","doi":"10.1182/blood.v128.22.3457.3457","title":"Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Bortezomib; Internal medicine; Lenalidomide; Surgery; Dexamethasone; Autologous stem-cell transplantation; Cyclophosphamide; Maintenance therapy; Median follow-up; Prednisone; Oncology; Chemotherapy","score_opus":0.0236939429228463,"score_gpt":0.2597571939518852,"score_spread":0.23606325102903888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725206342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775106,0.00045832348,0.00014402896,0.00023852976,0.000022997772,0.00071298215,0.00007415354,0.00008943286,0.0005084842],"genre_scores_gemma":[0.9965939,0.00007545297,0.0020488799,0.00003235621,0.000044224344,0.00007871073,0.000028948962,0.000034872122,0.0010626438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983096,0.00007479961,0.0002649948,0.00047849884,0.0003003576,0.00057171547],"domain_scores_gemma":[0.9990233,0.00025609072,0.00007468184,0.0002752254,0.00004450935,0.00032618231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007087316,0.00025914892,0.00041438747,0.00011721993,0.0000797501,0.000022293698,0.00008420559,0.000095861775,0.00004520533],"category_scores_gemma":[0.000046759927,0.00014918779,0.00004028261,0.000100655714,0.0001116585,0.00011296257,0.000025559539,0.00011256552,0.000020505518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019238256,0.0015278611,0.9216917,0.00007358462,0.000080016645,0.0017712612,0.0040131398,0.0000011862198,0.03755028,0.0000010751978,0.000008966394,0.031357083],"study_design_scores_gemma":[0.08938783,0.0035274646,0.6198542,0.0014275641,0.00020375819,0.00036707747,0.0020721562,0.0004702872,0.28201526,0.000003642913,0.00022232931,0.00044838994],"about_ca_topic_score_codex":0.0002619909,"about_ca_topic_score_gemma":0.0016412874,"teacher_disagreement_score":0.30183747,"about_ca_system_score_codex":0.000058875114,"about_ca_system_score_gemma":0.000069500704,"threshold_uncertainty_score":0.6083701},"labels":[],"label_agreement":null},{"id":"W2725714565","doi":"10.1016/j.clml.2017.06.020","title":"Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cohort; Multiple myeloma; Hazard ratio; Confidence interval","score_opus":0.032282119663963285,"score_gpt":0.33413161693560944,"score_spread":0.30184949727164617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725714565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973874,0.000045320896,0.00002455738,0.00006272155,0.000057784673,0.0020112684,0.00005358387,0.00002662397,0.000330742],"genre_scores_gemma":[0.9986813,0.000039129336,0.0007035795,0.00002148874,0.000037868536,0.00009854116,0.00031851177,0.000043322972,0.000056253815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699026,0.00020326069,0.0009047291,0.0006263479,0.0008890431,0.00038635187],"domain_scores_gemma":[0.99684215,0.0004676277,0.0007462562,0.00080711074,0.00074447994,0.00039238943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006429516,0.00028774753,0.0008286852,0.00020080802,0.0001487931,0.000048373462,0.00027339396,0.00024550117,0.000022992583],"category_scores_gemma":[0.0016256752,0.00020944964,0.00007829307,0.00015965392,0.0004529613,0.00047641387,0.0001400894,0.00019852705,0.000006963074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004909698,0.001783069,0.9132151,0.00018920352,0.00019865067,0.00009765225,0.000093235016,0.0000048127736,0.00015920121,0.000079223726,0.0000045665165,0.079265565],"study_design_scores_gemma":[0.02575205,0.0047585955,0.96307164,0.0004698756,0.00016983054,0.000013780224,0.000038592192,0.001831251,0.0036281322,0.000056396213,0.000009048383,0.00020079095],"about_ca_topic_score_codex":0.000239804,"about_ca_topic_score_gemma":0.000213137,"teacher_disagreement_score":0.07906477,"about_ca_system_score_codex":0.00029358396,"about_ca_system_score_gemma":0.00060873566,"threshold_uncertainty_score":0.85411084},"labels":[],"label_agreement":null},{"id":"W2726667285","doi":"10.1182/blood.v128.22.2137.2137","title":"Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Maintenance therapy; Thalidomide; Regimen; Internal medicine; Autologous stem-cell transplantation; Multiple myeloma; Oncology; Bortezomib; Transplantation; Surgery; Chemotherapy","score_opus":0.015900020236878122,"score_gpt":0.26684772706854054,"score_spread":0.2509477068316624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726667285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870265,0.00009938135,0.00001013846,0.00015380025,0.000015631542,0.00081668724,0.000081377846,0.000008826311,0.00011152071],"genre_scores_gemma":[0.99904555,0.00067315885,0.00007271902,0.000012523159,0.000014562964,0.00009451201,0.00002244223,0.000015162455,0.000049357135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879074,0.00015214713,0.0003395588,0.00022231843,0.0002398178,0.00025543358],"domain_scores_gemma":[0.9992644,0.00023517072,0.00015124204,0.00022988569,0.000064585016,0.000054698292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025075162,0.00013869576,0.00025227564,0.00020893921,0.000024346471,0.0000052131118,0.000069540525,0.000067082045,0.000012239932],"category_scores_gemma":[0.00002641591,0.00007296081,0.00006374356,0.00021134055,0.00006555196,0.00010207732,0.0000127263165,0.000112835274,0.0000017085662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015340315,0.0009466115,0.9307067,0.00012394122,0.000055994973,0.00008732295,0.0029707819,7.8170194e-7,0.0030684713,4.7638903e-7,0.000008688837,0.060496222],"study_design_scores_gemma":[0.017334322,0.001012099,0.9703874,0.00051123113,0.000028945615,0.0000128033,0.00014360395,0.00003763666,0.010449173,0.000008585662,0.000005352059,0.0000688617],"about_ca_topic_score_codex":0.0025785507,"about_ca_topic_score_gemma":0.0026272526,"teacher_disagreement_score":0.06042736,"about_ca_system_score_codex":0.00007319358,"about_ca_system_score_gemma":0.000040029096,"threshold_uncertainty_score":0.38980147},"labels":[],"label_agreement":null},{"id":"W2732548543","doi":"10.1111/bjh.14787","title":"Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Hazard ratio; Internal medicine; Multiple myeloma; Progression-free survival; Post-hoc analysis; Oncology; Interim analysis; Refractory (planetary science); Gastroenterology; Surgery; Chemotherapy; Randomized controlled trial; Confidence interval; Biology","score_opus":0.07180174197422885,"score_gpt":0.37094425773124934,"score_spread":0.2991425157570205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732548543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886025,0.008266667,0.00014452456,0.0009546297,0.00047361435,0.0009424997,0.00014004133,0.00003174447,0.0004437709],"genre_scores_gemma":[0.99084467,0.0025819975,0.0050628483,0.00013042774,0.00022340857,0.00006949802,0.000033080705,0.00007108247,0.0009829914],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9967931,0.0003452893,0.00087219285,0.00052886095,0.0007165252,0.0007440685],"domain_scores_gemma":[0.99457663,0.0023897057,0.0010254422,0.000490163,0.0007899368,0.00072813494],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010082845,0.00036743836,0.0016119061,0.0003378125,0.00073343766,0.0002560825,0.00043652646,0.0002874579,0.000025392274],"category_scores_gemma":[0.017049687,0.0002928939,0.0002977821,0.00009734171,0.00057265826,0.00038122627,0.00023911597,0.00063611334,0.0000057121706],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06769958,0.0050800657,0.17527393,0.0040135146,0.009964434,0.4149601,0.002024928,0.0000035054668,0.029923366,0.0011210807,0.049552854,0.24038264],"study_design_scores_gemma":[0.18233825,0.017784411,0.49362013,0.004945728,0.0016214459,0.27520025,0.0022328508,0.00033706112,0.016550515,0.0012756233,0.0035541814,0.00053955667],"about_ca_topic_score_codex":0.0004890104,"about_ca_topic_score_gemma":0.0006638705,"teacher_disagreement_score":0.3183462,"about_ca_system_score_codex":0.00013637672,"about_ca_system_score_gemma":0.00050340424,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W2734177594","doi":"10.14740/jocmr3049w","title":"Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Serum protein electrophoresis; Medicine; Kappa; Immunofixation; Immunoglobulin light chain; Plasma cell; Autologous stem-cell transplantation; Internal medicine; Plasma Cell Myeloma; Incidence (geometry); Gastroenterology; Immunology; Antibody; Monoclonal; Monoclonal antibody","score_opus":0.0988028322955729,"score_gpt":0.4502489363407043,"score_spread":0.3514461040451314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734177594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90852,0.00039612487,0.000032211097,0.08611739,0.000098054436,0.0033976284,0.00018236076,0.000008951401,0.0012473175],"genre_scores_gemma":[0.9951008,0.0008209215,0.0009894089,0.00008481365,0.0012748436,0.00035963507,0.00005207608,0.000046606125,0.001270915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99383694,0.00082775747,0.002160657,0.00057917874,0.0015486194,0.0010468436],"domain_scores_gemma":[0.9924294,0.001983743,0.00093192275,0.0011228217,0.0023190195,0.0012131049],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008265992,0.00032074473,0.0012140296,0.00072032894,0.0005114362,0.00008925258,0.0007026293,0.0003149072,0.000053740972],"category_scores_gemma":[0.027323443,0.000199123,0.00028564915,0.00023604766,0.0005800821,0.00024439965,0.00026686816,0.0013606211,0.000009715759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023573961,0.004384887,0.5747922,0.00034215863,0.00051701034,0.0005873822,0.0002934762,3.8499437e-7,0.011619223,0.000068395966,0.0033435686,0.38047734],"study_design_scores_gemma":[0.052151978,0.033629198,0.89471054,0.0009423387,0.000074388634,0.00006059626,0.000104104176,0.0001775599,0.011225797,0.00046027589,0.0063023157,0.00016090336],"about_ca_topic_score_codex":0.00036742954,"about_ca_topic_score_gemma":0.00046429498,"teacher_disagreement_score":0.38031644,"about_ca_system_score_codex":0.00041066614,"about_ca_system_score_gemma":0.0012396688,"threshold_uncertainty_score":0.9808698},"labels":[],"label_agreement":null},{"id":"W2734751871","doi":"10.1136/lupus-2017-000215.48","title":"48 Ixazomib, an oral proteasome inhibitor, reduces antibody production by depleting plasma cells in a t cell dependent antigen response model","year":2017,"lang":"en","type":"article","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ixazomib; Medicine; Antibody; Immunology; Plasma cell; ELISPOT; Immune system; Proteasome inhibitor; Multiple myeloma; T cell; Carfilzomib","score_opus":0.037268355415093504,"score_gpt":0.34680293702332315,"score_spread":0.30953458160822966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734751871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572986,0.000056575405,0.00005792747,0.0009656398,0.00015036348,0.001933295,0.000029501125,0.00008600666,0.0009908184],"genre_scores_gemma":[0.98626906,0.000077954435,0.004606057,0.000027739976,0.000117315416,0.00010964613,0.000073207295,0.000047207,0.0086718295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974185,0.00023522768,0.00036355978,0.0007253679,0.000612904,0.00064441067],"domain_scores_gemma":[0.99844784,0.00003432635,0.00016789294,0.000841906,0.00012704598,0.00038100054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010829193,0.00027069272,0.0003693493,0.00022968832,0.00039689013,0.00017221185,0.0002593431,0.00014535189,0.00005931223],"category_scores_gemma":[0.00048923073,0.00021800514,0.00006950305,0.00009067128,0.00011392664,0.000552285,0.00014260478,0.00032401894,0.00011421315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006211851,0.0012918588,0.055225924,0.00006250036,0.00003304173,0.00022329153,0.00031043089,0.0000812292,0.9324137,0.0000014596328,0.00081514433,0.0033296004],"study_design_scores_gemma":[0.0049209883,0.00051229395,0.031396665,0.00011177642,0.000019734596,0.00003248058,0.00022007432,0.02288395,0.9395014,0.0000173472,0.00015201826,0.00023128916],"about_ca_topic_score_codex":0.00087126746,"about_ca_topic_score_gemma":0.00021656799,"teacher_disagreement_score":0.023829259,"about_ca_system_score_codex":0.0001901131,"about_ca_system_score_gemma":0.00029622606,"threshold_uncertainty_score":0.88899916},"labels":[],"label_agreement":null},{"id":"W2740395975","doi":"10.3324/haematol.2017.170118","title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Takeda Oncology","keywords":"Ixazomib; Lenalidomide; Medicine; Multiple myeloma; Placebo; Internal medicine; Thalidomide; Dexamethasone; Population; Oncology; Carfilzomib; Pathology","score_opus":0.03835956097297118,"score_gpt":0.3196807159182124,"score_spread":0.28132115494524124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740395975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956052,0.00029935435,0.000009933191,0.00050994835,0.000038945695,0.0030548049,0.00008754183,0.00002924556,0.00036505456],"genre_scores_gemma":[0.9980601,0.00045076048,0.0011444417,0.00008137833,0.000018325722,0.00011135896,0.00003779413,0.000050676128,0.000045147048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996386,0.00061481475,0.0009128694,0.0006368098,0.0007499446,0.00069957186],"domain_scores_gemma":[0.9947994,0.002554984,0.00080708787,0.0013342381,0.00023590875,0.0002684259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001229312,0.00050568563,0.0015845955,0.00032747333,0.00020816948,0.000040969066,0.00046650213,0.000267844,0.0001847386],"category_scores_gemma":[0.0036359197,0.00026323425,0.00021999166,0.0002701,0.0007473209,0.0001991906,0.00018529716,0.0006471641,0.0000118187645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11347523,0.0029427437,0.86892414,0.0000885855,0.00038153032,0.00021796579,0.00041874973,0.000027919687,0.0009885065,0.00004556297,0.00008282147,0.012406216],"study_design_scores_gemma":[0.07330441,0.0053539267,0.91551095,0.0006844443,0.0000462969,0.00002661172,0.00006244531,0.00015186719,0.0045388727,0.000032306467,0.000054897904,0.00023297666],"about_ca_topic_score_codex":0.0014990276,"about_ca_topic_score_gemma":0.0002673493,"teacher_disagreement_score":0.04658678,"about_ca_system_score_codex":0.00017460696,"about_ca_system_score_gemma":0.0002199666,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W2740828344","doi":"10.1158/2326-6066.cir-17-0012","title":"Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Deutsche Forschungsgemeinschaft; Howard Hughes Medical Institute","keywords":"Biology; Phenotype; Antibody; Multiple myeloma; Bone marrow; Plasma cell; Lineage (genetic); Somatic cell; B cell; Immunology; Molecular biology; Genetics; Gene","score_opus":0.12933774684445906,"score_gpt":0.42897214913289894,"score_spread":0.29963440228843985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740828344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925811,0.00488329,0.0000046240507,0.00081923563,0.00015387915,0.0007075078,0.000050042177,0.0000138853475,0.00078638893],"genre_scores_gemma":[0.9973798,0.0010805028,0.00009285189,0.000010805924,0.00004583389,0.00021846336,0.000059221,0.000022264627,0.0010902674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790573,0.00024136639,0.00034911622,0.00041348944,0.00044342765,0.0006468629],"domain_scores_gemma":[0.9984284,0.00027880925,0.00011141219,0.0007250845,0.00028831567,0.00016796413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000690167,0.00016088123,0.0004962443,0.000368131,0.00036067708,0.000033870605,0.0002924684,0.00017324743,0.00022051018],"category_scores_gemma":[0.0008039762,0.00013179512,0.00005758761,0.0001459654,0.0014709055,0.00013257026,0.00054289604,0.00074009266,0.000032925782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004451492,0.0004613019,0.90795153,0.00013331675,0.00023058674,0.00048491388,0.00029144308,5.838005e-7,0.04686013,0.000038989954,0.00017244037,0.03892326],"study_design_scores_gemma":[0.008930198,0.00054014544,0.9662821,0.0004352117,0.000014569612,0.000050241335,0.00018005175,0.0009789338,0.02192629,0.000047136073,0.00052405824,0.000091008194],"about_ca_topic_score_codex":0.0028956996,"about_ca_topic_score_gemma":0.0009896787,"teacher_disagreement_score":0.058330618,"about_ca_system_score_codex":0.00022856737,"about_ca_system_score_gemma":0.00025897808,"threshold_uncertainty_score":0.54196125},"labels":[],"label_agreement":null},{"id":"W2742169549","doi":"10.1182/blood.v128.22.3318.3318","title":"An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Carfilzomib; Medicine; Pharmacokinetics; Hemodialysis; Cmax; Renal function; Urology; End stage renal disease; Multiple myeloma; Internal medicine; Gastroenterology; Proteasome inhibitor","score_opus":0.03127264767840359,"score_gpt":0.3132466429932698,"score_spread":0.2819739953148662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742169549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706495,0.00010109043,0.0000035238577,0.00006036101,0.000013663827,0.0022757186,0.00040920253,0.00000889987,0.00006256621],"genre_scores_gemma":[0.99950004,0.000029029969,0.0002118568,0.000017057886,0.0000129535465,0.00004648945,0.000030444433,0.000024035484,0.00012806834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984861,0.00017266376,0.00032097072,0.00033425225,0.0004232068,0.00026278303],"domain_scores_gemma":[0.9988263,0.00013174464,0.00014379334,0.00044625893,0.00013808368,0.00031381033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016143611,0.0001754767,0.00033490054,0.00009423954,0.000068346424,0.000015064241,0.00017372236,0.00003304072,0.0000375349],"category_scores_gemma":[0.00016542434,0.00009043884,0.000014500096,0.00017911251,0.00018421395,0.00014786262,0.00020711072,0.000093639814,3.9893118e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013712728,0.04782896,0.90508664,0.00008091611,0.00024316162,0.00010384157,0.00043556507,6.054281e-7,0.02424153,0.000006044996,0.0000059107397,0.008254113],"study_design_scores_gemma":[0.20262171,0.0102516115,0.77293235,0.00018705384,0.00025828957,0.0000020938571,0.00012580519,0.00004600423,0.013440686,0.0000033039685,0.00003693223,0.00009417292],"about_ca_topic_score_codex":0.00016887966,"about_ca_topic_score_gemma":0.00013116373,"teacher_disagreement_score":0.18890898,"about_ca_system_score_codex":0.000026336718,"about_ca_system_score_gemma":0.000084364445,"threshold_uncertainty_score":0.3687989},"labels":[],"label_agreement":null},{"id":"W2748238482","doi":"10.1016/j.clinbiochem.2017.08.013","title":"Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences","year":2017,"lang":"en","type":"review","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Immunofixation; Context (archaeology); Monoclonal antibody; Monoclonal; Computational biology; Computer science; Medicine; Immunology; Biology; Antibody","score_opus":0.2626376121444879,"score_gpt":0.46793117258519507,"score_spread":0.20529356044070718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748238482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07365677,0.92470896,0.0000035890714,0.000046750152,0.000019220395,0.0009777873,0.00016324979,0.000010220503,0.00041343155],"genre_scores_gemma":[0.020366967,0.9780737,0.000489929,0.00000527088,0.00005320644,0.000104245926,0.00043325528,0.000015305819,0.00045812412],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99858606,0.000052539905,0.00060894975,0.00044117527,0.00014689687,0.00016435959],"domain_scores_gemma":[0.9988334,0.00014477126,0.0004223703,0.0003661529,0.000066677414,0.00016658512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003416652,0.00022499684,0.0010379257,0.00004388949,0.00006558313,0.000039169223,0.00009446176,0.0003121904,0.000016348107],"category_scores_gemma":[0.00024750823,0.00016514331,0.00012406603,0.00004298908,0.00035363119,0.000028014594,0.0001959532,0.00030361084,0.0000036838958],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012544836,0.00019455962,0.00053512986,0.032135896,0.00057759904,0.000024898582,0.0000020873765,5.2074376e-11,0.00011401189,0.0000019960396,0.000027814367,0.96626055],"study_design_scores_gemma":[0.030156044,0.007470078,0.06869276,0.5380555,0.016521774,0.0011903589,0.00023483245,0.00004025091,0.021441676,0.0012876343,0.3119518,0.002957309],"about_ca_topic_score_codex":0.000016837126,"about_ca_topic_score_gemma":0.0000013198587,"teacher_disagreement_score":0.96330327,"about_ca_system_score_codex":0.000025445426,"about_ca_system_score_gemma":0.00007986603,"threshold_uncertainty_score":0.67343485},"labels":[],"label_agreement":null},{"id":"W2749746182","doi":"10.1016/s1470-2045(17)30578-8","title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Bortezomib; Medicine; Interim analysis; Multiple myeloma; Dexamethasone; Proteasome inhibitor; Tolerability; Internal medicine; Refractory (planetary science); Clinical trial; Oncology; Surgery; Adverse effect","score_opus":0.2558644524284098,"score_gpt":0.49781809117761694,"score_spread":0.2419536387492071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749746182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920183,0.000048265436,0.000015578187,0.0010271071,0.0004124186,0.0027856946,0.00025713348,0.000038471673,0.003397071],"genre_scores_gemma":[0.99573916,0.00019233716,0.0011914826,0.0002813523,0.0005518643,0.000355512,0.00035800683,0.00004002802,0.0012902657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959409,0.0015354583,0.00080725225,0.0006059749,0.00041629752,0.0006940891],"domain_scores_gemma":[0.9954241,0.0012098558,0.0006361769,0.0021952828,0.0001692113,0.00036537956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027521588,0.00031066564,0.0024086442,0.00033848346,0.0002767042,0.000097766424,0.0014431723,0.00026698425,0.0007839966],"category_scores_gemma":[0.0030020846,0.00017270984,0.00013839184,0.0002972493,0.00040531505,0.00033822912,0.00041417955,0.00054154475,0.000014583625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9226177,0.008086774,0.0058806534,0.000037317084,0.002242309,0.0013861432,0.00074412866,0.000006845998,0.0071369153,0.000034709003,0.0003214163,0.051505122],"study_design_scores_gemma":[0.89356005,0.024723459,0.06643164,0.00004897486,0.0011563214,0.000030783696,0.00026932498,0.009049005,0.0006584504,0.000038937276,0.0038134935,0.00021953501],"about_ca_topic_score_codex":0.00424354,"about_ca_topic_score_gemma":0.03634358,"teacher_disagreement_score":0.06055099,"about_ca_system_score_codex":0.00036651,"about_ca_system_score_gemma":0.00085414236,"threshold_uncertainty_score":0.98124063},"labels":[],"label_agreement":null},{"id":"W2750432438","doi":"10.1016/s0140-6736(17)31471-x","title":"Soft tissue plasmacytomas in multiple myeloma","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Toronto Western Hospital","funders":"","keywords":"Plasmacytoma; Medicine; Multiple myeloma; Bone marrow; Skull; Pathology; Biopsy; Soft tissue; Forehead; Population; Anatomy; Internal medicine","score_opus":0.08133065804952243,"score_gpt":0.3628796537313516,"score_spread":0.2815489956818292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750432438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690282,0.00016492716,0.000016245092,0.009606493,0.00008965256,0.00043893795,0.00002348173,0.00004748791,0.020584613],"genre_scores_gemma":[0.99584967,0.00006116617,0.00049281545,0.00023710752,0.0005164571,0.0000454705,0.000015271602,0.000014809839,0.0027672295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990764,0.000037538084,0.00011326362,0.00016831422,0.00021888987,0.0003855689],"domain_scores_gemma":[0.998634,0.00012054807,0.00005256266,0.0010646968,0.000025791393,0.00010242452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021692026,0.00010205619,0.00030549144,0.00003904765,0.00025287108,0.00006368199,0.0003726753,0.000044234574,0.00013824097],"category_scores_gemma":[0.0006586323,0.00006056231,0.000034718174,0.000038345905,0.00013347095,0.00007316222,0.000120590434,0.00020398454,0.00053365197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011234644,0.00013303464,0.9177079,0.000050544957,0.00006692201,0.0006289709,0.00023860467,0.0000025173479,0.0035970344,0.00018765834,0.006756635,0.0695067],"study_design_scores_gemma":[0.0070418552,0.00010821049,0.9516554,0.00006551743,0.000012099922,0.000043555618,0.000025135634,0.0009916755,0.008038352,0.0002507194,0.03169944,0.000068036024],"about_ca_topic_score_codex":0.00052340206,"about_ca_topic_score_gemma":0.0007537406,"teacher_disagreement_score":0.069438666,"about_ca_system_score_codex":0.000046197216,"about_ca_system_score_gemma":0.000044541684,"threshold_uncertainty_score":0.6859194},"labels":[],"label_agreement":null},{"id":"W2751006050","doi":"10.1182/blood.v128.22.5874.5874","title":"Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Single Center Experience","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Surgery; Internal medicine; Single Center; Melphalan; Autologous stem-cell transplantation; Stem cell; Median follow-up; Retrospective cohort study; Cohort; Oncology; Chemotherapy","score_opus":0.03554665423340628,"score_gpt":0.2839223300539518,"score_spread":0.2483756758205455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751006050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960238,0.00014675698,0.0020949973,0.00016516069,0.000052471227,0.0007229392,0.00013198641,0.00005310694,0.000608828],"genre_scores_gemma":[0.99619836,0.00007215836,0.0018426697,0.00005158819,0.00007554406,0.0002513698,0.000048838858,0.000021537533,0.0014379339],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905884,0.00002172918,0.00015084959,0.00025600087,0.0001905087,0.00032209355],"domain_scores_gemma":[0.99940896,0.00012846733,0.000034784825,0.00019222175,0.00006428467,0.00017129746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045251523,0.000116423915,0.00014614698,0.00005612104,0.00006219544,0.000010998407,0.00006520561,0.000052486754,0.000050934672],"category_scores_gemma":[0.000020557747,0.00007211184,0.00008747039,0.000052805593,0.00003817918,0.00007660995,0.000010689855,0.0000281195,0.00005875706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007294418,0.001955775,0.2636287,0.00014615945,0.00008066646,0.00012952858,0.00062253367,8.9621494e-8,0.7009577,0.000007351907,0.00006643796,0.031675592],"study_design_scores_gemma":[0.02577575,0.00077853893,0.06899608,0.000110821384,0.0000938155,0.00011087227,0.00009585139,0.000015596057,0.9018071,0.000008094255,0.0020854594,0.00012200533],"about_ca_topic_score_codex":0.0000096606955,"about_ca_topic_score_gemma":0.000020629957,"teacher_disagreement_score":0.2008494,"about_ca_system_score_codex":0.0000335581,"about_ca_system_score_gemma":0.000033259927,"threshold_uncertainty_score":0.29406357},"labels":[],"label_agreement":null},{"id":"W2751803734","doi":"","title":"Modeling bone marrow: A novel 3-D culture system for characterization of the multiple myeloma stem cell niche","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Bone marrow; Stem cell; In vivo; Multiple myeloma; Extracellular matrix; Cell culture; Biology; Cancer research; In vitro; Malignancy; Pathology; Immunology; Cell biology; Medicine; Genetics","score_opus":0.09413340389435801,"score_gpt":0.37733525524240585,"score_spread":0.2832018513480479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751803734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892911,0.0005557525,0.006503767,0.00029992926,0.00014083456,0.0025189454,0.0002231366,0.000033663528,0.00043287297],"genre_scores_gemma":[0.9946844,0.00008386639,0.00037117553,0.000024839444,0.00025202736,0.00038728787,0.000067569854,0.000041972926,0.004086842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756545,0.000077138786,0.00035599023,0.00034361606,0.00097498536,0.0006828224],"domain_scores_gemma":[0.9980879,0.00014776849,0.00007664986,0.00047852428,0.0009715737,0.00023757944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012436619,0.00014586696,0.0002909091,0.00018042402,0.00026772256,0.000026961092,0.0002258122,0.00014136717,0.000015632422],"category_scores_gemma":[0.00010942466,0.00009283147,0.00014481496,0.0005498401,0.000098697245,0.000075481774,0.000121420584,0.00037648858,0.000008813317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00166957,0.00020323138,0.0079296,0.0013040984,0.000074637624,0.000011903698,0.0005681644,0.00005899507,0.9822552,0.00006409682,0.00008640203,0.005774092],"study_design_scores_gemma":[0.00778503,0.0003323218,0.0139779085,0.0008326306,0.000052482505,0.000021595282,0.0013781352,0.05400859,0.9194247,0.0000045849206,0.0020343224,0.00014771786],"about_ca_topic_score_codex":0.00031384558,"about_ca_topic_score_gemma":0.00011805906,"teacher_disagreement_score":0.06283052,"about_ca_system_score_codex":0.0005542127,"about_ca_system_score_gemma":0.0003810235,"threshold_uncertainty_score":0.37855574},"labels":[],"label_agreement":null},{"id":"W2751915567","doi":"10.3747/co.24.3572","title":"Pomalidomide Desensitization in a Patient Hypersensitive to Immunomodulating Agents","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Pomalidomide; Medicine; Multiple myeloma; Lenalidomide; Efalizumab; Tolerability; Adverse effect; Desensitization (medicine); Internal medicine; Pharmacology; Rheumatoid arthritis; Etanercept","score_opus":0.17296252540076648,"score_gpt":0.463883020509007,"score_spread":0.2909204951082405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751915567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932734,0.0000995353,0.000088445246,0.00091087323,0.00044070705,0.00076797634,0.000009192556,0.000018401679,0.0043914746],"genre_scores_gemma":[0.9987506,0.00003435611,0.0008447851,0.00010797295,0.000088805806,0.00005304759,0.00005139027,0.000013527297,0.000055477547],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988873,0.00010045733,0.0002205626,0.00026487527,0.00018614967,0.00034064043],"domain_scores_gemma":[0.9991297,0.00006704868,0.00010570736,0.00034512155,0.0001476203,0.00020478046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014095075,0.000117006115,0.00028085063,0.00016708014,0.00017587337,0.000026784573,0.00006972705,0.00006210531,0.000037181755],"category_scores_gemma":[0.0009562007,0.000103712206,0.000053687276,0.00006786095,0.000059495294,0.00007295092,0.00014255059,0.00016487314,0.0001677595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008227792,0.0007251345,0.37671965,0.000031268377,0.00005391957,0.0013122958,0.0013641173,0.000022896418,0.0031999762,0.00005106695,0.000291757,0.61540514],"study_design_scores_gemma":[0.0045340443,0.00082310865,0.9809059,0.00019594624,0.000023883293,0.00010120498,0.00029527108,0.0032921412,0.0015688655,0.00003781841,0.008112489,0.00010936251],"about_ca_topic_score_codex":0.00020796001,"about_ca_topic_score_gemma":0.00015205226,"teacher_disagreement_score":0.61529577,"about_ca_system_score_codex":0.0005050518,"about_ca_system_score_gemma":0.00012852077,"threshold_uncertainty_score":0.4229261},"labels":[],"label_agreement":null},{"id":"W2752464581","doi":"10.1111/ejh.12961","title":"Post‐transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review","year":2017,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Internal medicine; Autologous stem-cell transplantation; Adverse effect; Maintenance therapy; Transplantation; Oncology; Surgery; Chemotherapy","score_opus":0.08682034022645548,"score_gpt":0.35746485631628944,"score_spread":0.270644516089834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752464581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019721434,0.9930107,0.00029759065,0.000941571,0.00040485262,0.0041106055,0.00013873099,0.000030046675,0.00086871645],"genre_scores_gemma":[0.0059670545,0.99142253,0.0007039197,0.00044744113,0.00017610629,0.00009932967,0.00017530726,0.00017564898,0.00083265756],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9881181,0.0046454677,0.0046816343,0.00067998545,0.0008104459,0.0010643351],"domain_scores_gemma":[0.9908196,0.0011281682,0.005218194,0.0013898544,0.00084151066,0.00060270086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004921565,0.00095139834,0.011134409,0.0009195803,0.00017948527,0.0000827297,0.0012130475,0.00021595399,0.00008268955],"category_scores_gemma":[0.0076579745,0.0006066056,0.0015918755,0.00027960475,0.00041046648,0.00025343988,0.0001800882,0.001699099,0.0006808266],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001275612,0.00024078062,0.00007409297,0.80060184,0.0015835469,0.17809623,0.00010178751,6.982781e-7,0.000004247084,0.00006167037,0.0017182071,0.016241286],"study_design_scores_gemma":[0.008270545,0.00052317063,0.000081370374,0.75418603,0.0038866815,0.16209328,0.000025747073,0.000015797157,0.0000051319475,0.0000061168084,0.07050185,0.00040429828],"about_ca_topic_score_codex":0.00003261697,"about_ca_topic_score_gemma":0.000049234775,"teacher_disagreement_score":0.06878364,"about_ca_system_score_codex":0.0006094761,"about_ca_system_score_gemma":0.0012719642,"threshold_uncertainty_score":0.99963856},"labels":[],"label_agreement":null},{"id":"W2752645248","doi":"10.14740/jocmr3109w","title":"Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunofixation; Medicine; Monoclonal antibody; Monoclonal; clone (Java method); Pathology; Kappa; Serum protein electrophoresis; Antibody; Immunology; Biology; DNA","score_opus":0.10736779386636848,"score_gpt":0.48223677345667587,"score_spread":0.3748689795903074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752645248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875382,0.0027201546,0.00003822927,0.008157688,0.00029615161,0.00071132736,0.00001756887,0.0000016920411,0.00051899574],"genre_scores_gemma":[0.9954855,0.0032141032,0.000035284087,0.00002466504,0.0005040736,0.00000724176,0.0000062670792,0.0000146184975,0.0007082387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448586,0.00067212444,0.0019491038,0.00022376743,0.0023621512,0.00030698522],"domain_scores_gemma":[0.9916228,0.0018378722,0.0017177892,0.0007546888,0.003796467,0.00027038623],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.0067659095,0.00014693345,0.0008783524,0.00017006148,0.0002567256,0.000024951236,0.0006329091,0.00015441445,0.0001240745],"category_scores_gemma":[0.017115837,0.00006845525,0.00018206859,0.0003303211,0.0027661554,0.00013145819,0.0001737871,0.0009996204,0.0000033884685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01206896,0.0014611721,0.8032487,0.00055947097,0.0010328942,0.000042011383,0.00058652944,0.0000018962629,0.16344683,0.00043051632,0.0020808883,0.015040137],"study_design_scores_gemma":[0.0064522577,0.0038100225,0.89695215,0.0010727233,0.00019210525,0.00011259189,0.00024945353,0.00010604818,0.09014495,0.00071308383,0.00014762722,0.000046972422],"about_ca_topic_score_codex":0.0005938965,"about_ca_topic_score_gemma":0.000019667523,"teacher_disagreement_score":0.09370348,"about_ca_system_score_codex":0.000058740065,"about_ca_system_score_gemma":0.00080613064,"threshold_uncertainty_score":0.9999477},"labels":[],"label_agreement":null},{"id":"W2754044603","doi":"10.1016/j.clinbiochem.2017.09.007","title":"Analytical sensitivity and diagnostic performance of serum protein electrophoresis on the HYDRAGEL 30 PROTEIN(E) β1-β2 Sebia Hydrasys system","year":2017,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Alberta Medical Association; Alberta Health; University of Alberta","funders":"","keywords":"Serum protein electrophoresis; Detection limit; Immunofixation; Gel electrophoresis of proteins; Chemistry; Molecular biology; Immunoglobulin M; Antibody; Immunoglobulin G; Chromatography; Monoclonal; Medicine; Polyacrylamide gel electrophoresis; Immunology; Monoclonal antibody; Biology; Biochemistry","score_opus":0.035603188545611286,"score_gpt":0.337628620434742,"score_spread":0.3020254318891307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754044603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549645,0.00008664671,0.000002453622,0.0015895622,0.00002331617,0.001042149,0.00005841705,0.00003269771,0.0016682991],"genre_scores_gemma":[0.9989227,0.000056479967,0.00006364878,0.000046309488,0.00021690011,0.00008416238,0.000012496532,0.000020869893,0.0005764413],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979802,0.00016245281,0.00047447006,0.00051670335,0.00045401353,0.0004121608],"domain_scores_gemma":[0.9970297,0.0009898264,0.0002534267,0.0012203361,0.00013670808,0.00036999863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010345408,0.00022905701,0.00052790117,0.000023514242,0.00031736106,0.00005297887,0.00019941812,0.00024077459,0.000044689667],"category_scores_gemma":[0.007807007,0.00014355822,0.00017693039,0.000058993024,0.0007370424,0.00003766709,0.00018124242,0.0005757241,0.00005283054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027819152,0.0017748859,0.7877078,0.003539064,0.0009231464,0.0013242594,0.000030537667,0.0000013114314,0.18122108,0.0001671455,0.0005282873,0.02000056],"study_design_scores_gemma":[0.0019930846,0.0010314194,0.36462045,0.0014352214,0.00012405665,0.000045465345,0.00003748972,0.0056715966,0.6248366,0.000007984073,0.00003255996,0.00016407663],"about_ca_topic_score_codex":0.00004466405,"about_ca_topic_score_gemma":0.0000023532336,"teacher_disagreement_score":0.4436155,"about_ca_system_score_codex":0.00007807838,"about_ca_system_score_gemma":0.00018439996,"threshold_uncertainty_score":0.93462807},"labels":[],"label_agreement":null},{"id":"W2754901779","doi":"10.1016/j.celrep.2017.08.062","title":"Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism","year":2017,"lang":"en","type":"article","venue":"Cell Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre","funders":"Medical Research Council; Canadian Institutes of Health Research; Deutsche Krebshilfe; Dietmar Hopp Stiftung; Heinz Nixdorf Stiftung; Myeloma UK; Deutsche Forschungsgemeinschaft; Rosetrees Trust; Cancer Research UK; Bloodwise; Wellcome Trust; Foundation Medicine; McGill University; Bundesministerium für Bildung und Forschung; Blood Cancer UK; Multiple Myeloma Research Foundation","keywords":"Enhancer; Genetics; Biology; Allele; Transcription factor; Carcinogenesis; Gene","score_opus":0.018241850976561926,"score_gpt":0.2943264266568501,"score_spread":0.27608457568028816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754901779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149084,0.00052082713,0.00009601673,0.0005181214,0.00027458867,0.0010211584,0.00006941317,0.00008205199,0.0059269834],"genre_scores_gemma":[0.9798295,0.00009432943,0.00074027374,0.00028429343,0.00020837097,0.00013608874,0.00042323527,0.000052911677,0.018230999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769104,0.00003647638,0.00040105885,0.000690422,0.0006329028,0.00054808456],"domain_scores_gemma":[0.9970675,0.00003840074,0.0002694817,0.0015248702,0.00014651258,0.0009532195],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014558903,0.00025014987,0.00032468757,0.00009711149,0.00044446418,0.00008069652,0.00015006341,0.00015111375,0.0010949604],"category_scores_gemma":[0.0002585908,0.0002159159,0.000104819585,0.00006456732,0.00009186609,0.00015482426,0.00015841989,0.00013106834,0.00045635842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042283032,0.0005039966,0.3160196,0.00005634673,0.00008348115,0.004755154,0.00033945675,0.0000014520602,0.64531356,1.3473488e-7,0.022960192,0.009543779],"study_design_scores_gemma":[0.0014794009,0.00044937155,0.4840177,0.000051005856,0.00006329282,0.000307776,0.000012326815,0.00036312526,0.5017944,0.000011068233,0.011263485,0.00018703418],"about_ca_topic_score_codex":0.0006704981,"about_ca_topic_score_gemma":0.00011690083,"teacher_disagreement_score":0.16799809,"about_ca_system_score_codex":0.00023498885,"about_ca_system_score_gemma":0.00011663825,"threshold_uncertainty_score":0.99981815},"labels":[],"label_agreement":null},{"id":"W2755035768","doi":"10.1007/s12288-017-0876-y","title":"Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India","year":2017,"lang":"en","type":"article","venue":"Indian Journal of Hematology and Blood Transfusion","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Plasma cell dyscrasia; Mucositis; Autologous stem-cell transplantation; Bortezomib; Internal medicine; Transplantation; Melphalan; Hematopoietic stem cell transplantation; Surgery; Gastroenterology; Chemotherapy; Immunoglobulin light chain; Immunology","score_opus":0.019672175982955863,"score_gpt":0.2689597547507975,"score_spread":0.2492875787678416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755035768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755806,0.0008012489,0.00039474914,0.00048285958,0.00017021346,0.00042917076,0.00009459029,0.00001067382,0.000058445206],"genre_scores_gemma":[0.9976602,0.0005264601,0.0016178257,0.00003476004,0.00006864351,0.000008984286,0.000037489823,0.000014665215,0.00003094816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885255,0.00006671367,0.00038235864,0.00021469101,0.00019195699,0.00029174238],"domain_scores_gemma":[0.998867,0.00026440105,0.00028115383,0.00019552701,0.00011918037,0.0002727648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011718824,0.00016151383,0.0004443087,0.00013334326,0.00043171996,0.00003793934,0.00015051618,0.00016644083,0.00002771904],"category_scores_gemma":[0.000047169873,0.00012357824,0.00013117057,0.00003366729,0.00016326539,0.00020443107,0.000010208525,0.00022253112,0.0000030990154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032575424,0.00078223564,0.93646014,0.0002731282,0.00021736982,0.0058116904,0.007962666,6.226964e-7,0.015321105,0.000009505165,0.000015430267,0.029888552],"study_design_scores_gemma":[0.014200416,0.0012455981,0.76508194,0.0002717703,0.0003650678,0.003343078,0.00074704067,0.000024741867,0.21445495,0.000051748848,0.00008167659,0.00013195295],"about_ca_topic_score_codex":0.000045927263,"about_ca_topic_score_gemma":0.00034918927,"teacher_disagreement_score":0.19913384,"about_ca_system_score_codex":0.000014460939,"about_ca_system_score_gemma":0.000086389504,"threshold_uncertainty_score":0.5039374},"labels":[],"label_agreement":null},{"id":"W2755976565","doi":"10.1182/blood.v128.22.4406.4406","title":"Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Inference; Bayesian network; Bayesian probability; Approximate Bayesian computation; Causal inference; Computational biology; Computer science; Set (abstract data type); Bayesian inference; Biology; Bioinformatics; Machine learning; Artificial intelligence; Statistics; Mathematics","score_opus":0.014132920736549004,"score_gpt":0.24572116729398305,"score_spread":0.23158824655743404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755976565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978123,0.00030505026,0.0009772544,0.00016989702,0.000021094913,0.00032647143,0.00009584006,0.000020541198,0.0002715689],"genre_scores_gemma":[0.9944387,0.0004155491,0.0045699463,0.000007677696,0.00003593041,0.000013460892,0.0000051769707,0.000016686683,0.0004968446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890035,0.00013292595,0.00022210932,0.0002074312,0.00025489094,0.00028230628],"domain_scores_gemma":[0.9987744,0.000500282,0.00010953005,0.0003227589,0.000098451004,0.0001945419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028451998,0.000113468624,0.00031488034,0.00008651002,0.000049683593,0.000003014934,0.00006262382,0.00007079314,0.00005406639],"category_scores_gemma":[0.00034466348,0.00007187645,0.000064948996,0.00012776983,0.0001440591,0.00007705873,0.000053329393,0.00006405072,0.0000060222214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007822599,0.0009784811,0.9372127,0.00011019007,0.00069448585,0.00015697672,0.00023310128,0.0000910268,0.037174895,0.00020766881,0.0002872328,0.015030656],"study_design_scores_gemma":[0.035206232,0.0016123967,0.8686185,0.00041213285,0.00038600358,0.000045972974,0.000068028465,0.0015272606,0.09000057,0.001815125,0.00015136745,0.0001564046],"about_ca_topic_score_codex":0.0003901056,"about_ca_topic_score_gemma":0.00004881533,"teacher_disagreement_score":0.06859418,"about_ca_system_score_codex":0.00001787944,"about_ca_system_score_gemma":0.0000808721,"threshold_uncertainty_score":0.29310367},"labels":[],"label_agreement":null},{"id":"W2756951306","doi":"10.1188/17.cjon.s5.7-18","title":"Distress, Fatigue, and Sexuality: Understanding and Treating Concerns and Symptoms in Patients With Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Clinical journal of oncology nursing","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Distress; Ambulatory; Psychiatry; Incidence (geometry); Cancer; Adjustment disorders; Clinical psychology; Anxiety; Internal medicine","score_opus":0.15560979707557496,"score_gpt":0.4677102027136038,"score_spread":0.3121004056380289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756951306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724364,0.0003349104,0.0002758088,0.001400798,0.00010986023,0.0002205271,0.0000072796283,0.000004006082,0.0004031801],"genre_scores_gemma":[0.9982728,0.0001803885,0.0013413233,0.000051003684,0.00012344313,0.000001208417,0.000004360635,0.000011741472,0.00001376235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986631,0.00016524568,0.0005246241,0.00020810675,0.00019931555,0.00023959322],"domain_scores_gemma":[0.9979439,0.0009525149,0.0005084476,0.00014665356,0.000092052316,0.00035644678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054922566,0.00012590217,0.0005900199,0.00008565038,0.00025321156,0.000064309526,0.00006327496,0.00013747273,0.000003588682],"category_scores_gemma":[0.0011089124,0.000086854394,0.000034301283,0.000029640492,0.0010828378,0.00020174289,0.00004698323,0.00041558713,1.261021e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001859275,0.00041063977,0.7283257,0.000022883005,0.00011666371,0.0002455418,0.0002489155,3.4882214e-7,0.0000065352647,0.000026847027,0.000015055613,0.26872155],"study_design_scores_gemma":[0.023609037,0.005223437,0.9683494,0.0010481572,0.00013578299,0.00012722079,0.0006635309,0.0005343303,0.0000063937655,0.00019311205,0.000032806656,0.0000768126],"about_ca_topic_score_codex":0.000020993673,"about_ca_topic_score_gemma":0.000045171142,"teacher_disagreement_score":0.26864475,"about_ca_system_score_codex":0.00023536265,"about_ca_system_score_gemma":0.00012980014,"threshold_uncertainty_score":0.39897612},"labels":[],"label_agreement":null},{"id":"W2757118435","doi":"10.1016/j.clinbiochem.2017.09.020","title":"Synoptic reporting for protein electrophoresis and immunofixation","year":2017,"lang":"en","type":"review","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Multiple myeloma; Serum protein electrophoresis; Immunoglobulin light chain; Immunofixation; Medicine; Myeloma protein; Monoclonal; Computational biology; Antibody; Immunology; Monoclonal antibody; Biology","score_opus":0.30808682354485817,"score_gpt":0.5446069564894378,"score_spread":0.23652013294457963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757118435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003134246,0.99414986,0.000008374981,0.0000607306,0.00004740548,0.0020598792,0.000039303082,0.00003255127,0.0004676434],"genre_scores_gemma":[0.0008947535,0.99087137,0.0015022972,0.000008163918,0.000490585,0.0006385216,0.00066322624,0.000046623056,0.0048844744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701506,0.000048161815,0.0017404871,0.0006690091,0.0001889478,0.00033832283],"domain_scores_gemma":[0.9961062,0.00033756197,0.0022455847,0.000886348,0.00014122212,0.00028310023],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010869103,0.00029154003,0.0018129585,0.000038919672,0.0001544963,0.00006230125,0.00014831271,0.00061214087,0.000016843605],"category_scores_gemma":[0.02210939,0.00021048838,0.0007386958,0.000044151573,0.00018484528,0.00002003533,0.00009505406,0.0004935279,0.000017689841],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098404686,0.00012654936,0.0001274056,0.027192635,0.00049537927,0.000100013174,6.034266e-7,2.4186605e-10,0.00024839575,0.0000015763717,0.00024219716,0.9713668],"study_design_scores_gemma":[0.002036919,0.0006441782,0.0001888798,0.02915698,0.0021053492,0.00030421343,0.0000029762125,0.000011435566,0.0017716164,0.000042880154,0.9633453,0.00038930937],"about_ca_topic_score_codex":0.000005299584,"about_ca_topic_score_gemma":1.9612645e-7,"teacher_disagreement_score":0.97097754,"about_ca_system_score_codex":0.00010371937,"about_ca_system_score_gemma":0.00078356866,"threshold_uncertainty_score":0.9861278},"labels":[],"label_agreement":null},{"id":"W2758550989","doi":"10.1200/jco.2017.35.15_suppl.8028","title":"Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Clinical endpoint; Discontinuation; Multiple myeloma; Dexamethasone; Gastroenterology; Oncology; Randomized controlled trial","score_opus":0.2201404032116821,"score_gpt":0.5047877075079944,"score_spread":0.2846473042963123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758550989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928982,0.00048787054,0.000048177593,0.0014254958,0.0014849963,0.0010634906,0.000019860285,0.000015212412,0.0025566488],"genre_scores_gemma":[0.9938047,0.0007304028,0.0030352375,0.0002110744,0.0007802265,0.000029028775,0.000005864611,0.000053107473,0.0013503663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99243647,0.0014224765,0.003755022,0.00050737493,0.0011894963,0.00068918767],"domain_scores_gemma":[0.988933,0.004501127,0.0037499468,0.0010838073,0.00076903345,0.0009630754],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006981675,0.0003481062,0.003244776,0.00046632864,0.00016156779,0.0000358597,0.0007536091,0.00061446364,0.00040920055],"category_scores_gemma":[0.028418195,0.00025958565,0.00094620156,0.00016590982,0.00054013124,0.0002759494,0.00027337688,0.0021102426,0.000077369456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14746244,0.03159454,0.41277134,0.00010572022,0.0022764564,0.018496878,0.0006624419,0.0000051931193,0.0009999304,0.000044037228,0.0019187578,0.38366225],"study_design_scores_gemma":[0.2536529,0.055499814,0.68141526,0.0002806526,0.0004814602,0.00027868757,0.0007520407,0.0003381272,0.0003258484,0.0001311786,0.006650845,0.00019315872],"about_ca_topic_score_codex":0.0006143568,"about_ca_topic_score_gemma":0.0012130496,"teacher_disagreement_score":0.38346907,"about_ca_system_score_codex":0.00061970373,"about_ca_system_score_gemma":0.0033868935,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W2762460731","doi":"10.24870/cjb.2017-a42","title":"Comparison of the modulation of FGFR signalling by thalidomide and its analogs lenalidomide and pomalidomide","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Biotechnology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Research (Canada)","funders":"","keywords":"Pomalidomide; Lenalidomide; Thalidomide; Signalling; Internal medicine; Oncology; Medicine; Multiple myeloma; Biology; Cell biology","score_opus":0.042350818001116265,"score_gpt":0.32915171011300015,"score_spread":0.28680089211188386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762460731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053234,0.0035991168,0.00007775678,0.005425924,0.00005960792,0.00018084799,0.00003406879,0.0000023676478,0.00008799673],"genre_scores_gemma":[0.9994546,0.0002124698,0.00022849708,0.000024607458,0.000022371665,9.621317e-7,0.0000020509215,0.00000909854,0.000045300356],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905497,0.00004909927,0.00040644806,0.000115091745,0.00015370655,0.00022066475],"domain_scores_gemma":[0.99863225,0.00006743714,0.00061383075,0.0002497433,0.00016147159,0.0002752819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027720007,0.000102646256,0.000460825,0.00028488648,0.0001901366,0.000018887376,0.00022485804,0.00020595326,0.000016348584],"category_scores_gemma":[0.0007646752,0.000071483184,0.00007022769,0.00007505692,0.00050734845,0.000081434795,0.00004113903,0.00029561724,4.3516417e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030652032,0.000048624883,0.5679387,0.00010420326,0.00033553262,0.000093583345,0.00018871606,0.000022305063,0.41292793,0.00083547237,0.0003083017,0.016890142],"study_design_scores_gemma":[0.004355485,0.00060158264,0.35022902,0.00034605517,0.0001502622,0.00042421315,0.0002451833,0.0021571536,0.6402897,0.00055175065,0.000554878,0.00009470778],"about_ca_topic_score_codex":0.003353834,"about_ca_topic_score_gemma":0.0042022453,"teacher_disagreement_score":0.22736177,"about_ca_system_score_codex":0.000061008912,"about_ca_system_score_gemma":0.00031897996,"threshold_uncertainty_score":0.50700164},"labels":[],"label_agreement":null},{"id":"W2762584070","doi":"10.1172/jci.insight.95367","title":"Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens","year":2017,"lang":"en","type":"article","venue":"JCI Insight","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Antigen; Immunology; Hepatitis C virus; Monoclonal gammopathy of undetermined significance; Virology; Virus; Immunoglobulin G; Antibody; Herpes simplex virus; Immune system; Helicobacter pylori; Medicine; Biology; Monoclonal antibody; Monoclonal","score_opus":0.030370368677288265,"score_gpt":0.3068475861859676,"score_spread":0.2764772175086793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762584070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857036,0.00071500347,0.000014664066,0.00052652817,0.00013067137,0.00048390304,0.000024497744,0.000042952903,0.012358179],"genre_scores_gemma":[0.998082,0.00024334615,0.0005281494,0.000112128706,0.00015218093,0.000040718372,0.00003531396,0.00002370975,0.0007824765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998792,0.000039299262,0.0001924332,0.00033556917,0.00025489042,0.00038582526],"domain_scores_gemma":[0.9989719,0.000083208695,0.0000753215,0.0005113657,0.00006668792,0.00029153752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011127837,0.00017567187,0.00029755462,0.00016404448,0.0002853156,0.000076815,0.00009957857,0.000112815826,0.000095410556],"category_scores_gemma":[0.00056650024,0.00013979344,0.00006319153,0.000059577396,0.00012762968,0.00017288269,0.00013686517,0.00022677866,0.00010432394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002684329,0.0003546111,0.95860445,0.000044551052,0.00007579819,0.0018833367,0.00031307372,0.0000011962102,0.006704964,0.00006975046,0.00023621178,0.031443592],"study_design_scores_gemma":[0.0058142957,0.0003174568,0.97966224,0.000055356897,0.000019670471,0.00012736127,0.000018948549,0.0011736385,0.0050888387,0.00013084729,0.0074568545,0.00013448675],"about_ca_topic_score_codex":0.0006426844,"about_ca_topic_score_gemma":0.00083652564,"teacher_disagreement_score":0.031309105,"about_ca_system_score_codex":0.00009541854,"about_ca_system_score_gemma":0.000079486636,"threshold_uncertainty_score":0.57006115},"labels":[],"label_agreement":null},{"id":"W2763779520","doi":"10.1182/blood.v108.11.5517.5517","title":"Ten-Year Overall Survival Analysis of Current Treatments of Relapsed or Refractory Multiple Myeloma in Canada.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Thalidomide; Multiple myeloma; Internal medicine; Interim analysis; Lenalidomide; Clinical trial; Oncology; Surgery","score_opus":0.027923415720154172,"score_gpt":0.29332471182485564,"score_spread":0.2654012961047015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763779520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979546,0.0005078673,0.0000035352775,0.000020923184,0.000049826125,0.00037122218,0.0002963055,0.000009765068,0.0007859336],"genre_scores_gemma":[0.99879587,0.0001118734,0.00025218917,0.0000044585026,0.00002832123,0.000024133495,0.0003477559,0.000016862985,0.00041852932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981923,0.00008572687,0.00049784314,0.00027295624,0.0006181768,0.00033298714],"domain_scores_gemma":[0.99897176,0.00020692777,0.00016796253,0.00039254528,0.0001185916,0.00014220459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103625694,0.00017319033,0.00068519264,0.0004098391,0.000021432568,0.0000032363848,0.000093757466,0.000053003692,0.00017392261],"category_scores_gemma":[0.00016083682,0.00012620208,0.00015722275,0.00071349175,0.000039957486,0.000041744945,0.00003466778,0.00012284052,0.0000033151111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094579265,0.0034041924,0.98835933,0.00007761406,0.0018393336,0.00023519149,0.000033873213,0.000027038612,0.002543597,0.0000152798,0.00009210374,0.0024266231],"study_design_scores_gemma":[0.015980426,0.00033077103,0.97411656,0.000076831435,0.0013500886,0.0000022434274,0.000052726125,0.0003510316,0.0074844756,0.0000050061917,0.00015642509,0.00009343628],"about_ca_topic_score_codex":0.7199624,"about_ca_topic_score_gemma":0.842624,"teacher_disagreement_score":0.12266158,"about_ca_system_score_codex":0.00032156924,"about_ca_system_score_gemma":0.0010273999,"threshold_uncertainty_score":0.5146372},"labels":[],"label_agreement":null},{"id":"W2764047877","doi":"10.1182/blood.v128.22.5675.5675","title":"Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple myeloma: a Meta Analysis of Individual Patient Data from Clinical Trials","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Carfilzomib; Medicine; Multiple myeloma; Lenalidomide; Bortezomib; Meta-analysis; Clinical trial; Oncology; Internal medicine; Thalidomide; Proteasome inhibitor; Cochrane Library; Intensive care medicine","score_opus":0.3327612388515309,"score_gpt":0.4480871288065761,"score_spread":0.11532588995504517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764047877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924785,0.0030862568,0.000005513263,0.0001167567,0.000015676667,0.0010238686,0.0032353522,0.0000051221027,0.00003294394],"genre_scores_gemma":[0.9972721,0.0013869108,0.00072388304,0.000013023228,0.00003136793,0.00004848318,0.00048421198,0.000009973977,0.00003007536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963157,0.0012484919,0.0012776334,0.00040264285,0.000556645,0.0001988645],"domain_scores_gemma":[0.98801154,0.0099794725,0.00054373255,0.001259689,0.00008347645,0.00012209012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001852186,0.00016803837,0.0019050572,0.00027748875,0.000019256297,0.000005330129,0.00026195563,0.00010886782,0.00015313823],"category_scores_gemma":[0.0042780307,0.00006718056,0.0005073387,0.00039185776,0.00019029267,0.00005981588,0.00011879156,0.000070620066,0.0000015615384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009410228,0.028005034,0.6792775,0.00004300706,0.20503229,0.00019331515,0.002205314,4.8773103e-7,0.0041907732,0.0000074569703,0.00008623155,0.07154842],"study_design_scores_gemma":[0.04362989,0.004140972,0.83730626,0.000036521862,0.10740384,0.0000018058365,0.00029146968,0.00003315088,0.00680371,0.000006344211,0.0002774793,0.00006853715],"about_ca_topic_score_codex":0.0011077512,"about_ca_topic_score_gemma":0.0005701146,"teacher_disagreement_score":0.15802884,"about_ca_system_score_codex":0.00001671702,"about_ca_system_score_gemma":0.00013523022,"threshold_uncertainty_score":0.5121511},"labels":[],"label_agreement":null},{"id":"W2765526403","doi":"10.3747/co.24.3574","title":"Short-Course Lenalidomide Plus Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma—A Single-Centre Pragmatic Study","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Amrita Vishwa Vidyapeetham University","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Progressive disease; Gastroenterology; Transplantation; Surgery; Chemotherapy","score_opus":0.16923202166380716,"score_gpt":0.44262442875935115,"score_spread":0.273392407095544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765526403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99129933,0.0016075626,0.00001997442,0.0010764236,0.0004945015,0.005000418,0.000039034396,0.000027642709,0.00043510366],"genre_scores_gemma":[0.9982539,0.0003775194,0.00029893126,0.000023155582,0.00021354554,0.0006033565,0.000083081504,0.00003076328,0.00011576065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969523,0.00067274563,0.0006337254,0.000511909,0.0005613902,0.0006679305],"domain_scores_gemma":[0.9964766,0.0014759747,0.00031079826,0.0013014341,0.0001644269,0.00027077846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056856906,0.00035796047,0.000998306,0.0001783472,0.00024429252,0.000051925956,0.0004511285,0.00012765263,0.00007952848],"category_scores_gemma":[0.0012048478,0.00022470526,0.00022151564,0.00015138437,0.00033458244,0.00011411132,0.00009653026,0.00027807133,0.000055237717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020572771,0.041132856,0.6146918,0.00010328972,0.00031755076,0.0014617251,0.0067599565,0.000013027053,0.00027275665,0.000007366758,0.00023053012,0.33295184],"study_design_scores_gemma":[0.053776257,0.007867063,0.92590356,0.00024437899,0.0005287959,0.000039306356,0.0050393813,0.0015363389,0.00057300087,0.000021995613,0.0042631957,0.00020671346],"about_ca_topic_score_codex":0.0004059221,"about_ca_topic_score_gemma":0.004692417,"teacher_disagreement_score":0.33274513,"about_ca_system_score_codex":0.0009050403,"about_ca_system_score_gemma":0.00044280896,"threshold_uncertainty_score":0.91632146},"labels":[],"label_agreement":null},{"id":"W2766219238","doi":"10.1016/j.clml.2017.10.009","title":"Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Multiple myeloma; Single Center; Medicine; Center (category theory); Stem cell; Oncology; Surgery; Internal medicine; Biology","score_opus":0.08481384470598866,"score_gpt":0.3450338676793674,"score_spread":0.26022002297337876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766219238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916597,0.0002713577,0.00021553457,0.0002947788,0.0011710224,0.002656208,0.00011927041,0.00027954066,0.00333257],"genre_scores_gemma":[0.992163,0.00013354735,0.0028810555,0.00057146227,0.0005278548,0.00046184167,0.00015130544,0.00017539607,0.002934534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426293,0.0002722367,0.001518902,0.0015387508,0.00089395995,0.0015132157],"domain_scores_gemma":[0.9930424,0.0020766815,0.00090010633,0.0022960696,0.000553319,0.001131434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005350071,0.0007173362,0.0012591853,0.0001787358,0.0012220142,0.0004261536,0.0009946551,0.0006663686,0.00006574846],"category_scores_gemma":[0.0022444346,0.00060302985,0.0008645259,0.0001519041,0.0008657004,0.00059468765,0.00047768053,0.00037372104,0.00033867484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040156986,0.002574793,0.52786326,0.0000884238,0.00020000602,0.0002635589,0.0003693966,5.780772e-7,0.001352748,0.000016417653,0.0005736474,0.46268147],"study_design_scores_gemma":[0.041951608,0.006243236,0.934216,0.00033199866,0.00008136023,0.00005404568,0.00012914234,0.00066537614,0.007123051,0.0000800634,0.008553384,0.00057072507],"about_ca_topic_score_codex":0.00013906103,"about_ca_topic_score_gemma":0.00007455252,"teacher_disagreement_score":0.46211076,"about_ca_system_score_codex":0.0015304494,"about_ca_system_score_gemma":0.0009005152,"threshold_uncertainty_score":0.99964213},"labels":[],"label_agreement":null},{"id":"W2766664918","doi":"10.1016/j.clinbiochem.2017.10.006","title":"Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis","year":2017,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Serum protein electrophoresis; Monoclonal gammopathy of undetermined significance; Monoclonal; Myeloma protein; Monoclonal antibody; Multiple myeloma; Albumin; Monoclonal gammopathy; Agarose gel electrophoresis; Medicine; Immunology; Internal medicine; Chemistry; Antibody; Biochemistry","score_opus":0.10016075869858702,"score_gpt":0.4151581053341483,"score_spread":0.3149973466355613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766664918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252135,0.00029339967,0.000008141489,0.0034860391,0.000032796717,0.001377898,0.00013317139,0.00007477015,0.0020724267],"genre_scores_gemma":[0.9904428,0.000038550854,0.0012871263,0.00036126634,0.00043080753,0.00067924056,0.00022641374,0.00003758348,0.0064962087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747807,0.00008519188,0.0005039095,0.00078597426,0.00050957943,0.0006372604],"domain_scores_gemma":[0.9972478,0.00010632918,0.00027809336,0.0014466686,0.00016462123,0.0007564912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004119435,0.000301431,0.0004934696,0.000029532053,0.00030417254,0.00009373516,0.00050555315,0.00043858023,0.00033936725],"category_scores_gemma":[0.0030044527,0.00024638724,0.00023986296,0.00005825975,0.0004285856,0.00006791687,0.00016414613,0.00062846876,0.0002668647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003258517,0.0014763769,0.06237252,0.0004197784,0.0002161055,0.00064345775,0.0000052559603,1.5358461e-8,0.89006376,0.000012709508,0.001676732,0.039854746],"study_design_scores_gemma":[0.0051678442,0.0011539775,0.042738542,0.00036830685,0.000056399902,0.000014496496,0.000003935759,0.00026314656,0.9476474,0.00009021251,0.0022344198,0.0002613116],"about_ca_topic_score_codex":0.0001843956,"about_ca_topic_score_gemma":0.0000042776783,"teacher_disagreement_score":0.057583623,"about_ca_system_score_codex":0.00011793706,"about_ca_system_score_gemma":0.0005114287,"threshold_uncertainty_score":0.99999887},"labels":[],"label_agreement":null},{"id":"W2766948867","doi":"10.1182/blood-2017-06-791228","title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ixazomib; Multiple myeloma; Progression-free survival; Refractory (planetary science); Medicine; Lenalidomide; Oncology; Internal medicine; Pomalidomide; Overall survival; Carfilzomib; Biology","score_opus":0.01918654123332542,"score_gpt":0.2931582333603844,"score_spread":0.27397169212705896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766948867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480367,0.00014225743,0.0000027158328,0.00032494104,0.0002331864,0.001388041,0.00010694958,0.00007394277,0.002924323],"genre_scores_gemma":[0.9977993,0.00011064112,0.0009244447,0.0000214761,0.00018147635,0.00020047453,0.00011225856,0.00004938245,0.0006005532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973944,0.00018323965,0.0003619747,0.00054253277,0.0008686229,0.000649223],"domain_scores_gemma":[0.9974393,0.00013254902,0.00029472215,0.0015716155,0.0001638085,0.00039798723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004874105,0.000269964,0.00045616046,0.0001689258,0.0003655908,0.00008907424,0.0005166465,0.00018890962,0.000096433054],"category_scores_gemma":[0.0022633988,0.00020410269,0.00010900285,0.00009457204,0.0001816811,0.0002309365,0.0003009141,0.0004933476,0.00016577696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007631091,0.00462917,0.94431484,0.00006623256,0.00018442226,0.00068535295,0.00011896145,1.1678704e-7,0.00038418148,0.000025368847,0.00024164189,0.048586592],"study_design_scores_gemma":[0.03460676,0.0015526423,0.9596325,0.00019116534,0.00012661368,0.0000062544304,0.000025941965,0.000016748423,0.0030883946,0.00020358732,0.00036414,0.00018524879],"about_ca_topic_score_codex":0.00075299974,"about_ca_topic_score_gemma":0.00035222873,"teacher_disagreement_score":0.04840134,"about_ca_system_score_codex":0.00007762636,"about_ca_system_score_gemma":0.00017973653,"threshold_uncertainty_score":0.8323066},"labels":[],"label_agreement":null},{"id":"W2767153221","doi":"10.1016/j.clinbiochem.2017.10.013","title":"Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group","year":2017,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Grand River Hospital; London Health Sciences Centre; Trillium Health Centre; University of Toronto; Memorial University of Newfoundland; University of Saskatchewan; Hamilton Regional Laboratory Medicine Program; Nova Scotia Health Authority; Saskatchewan Health Authority; Kingston General Hospital; Queen's University; St Joseph's Health Centre; Dr. Everett Chalmers Regional Hospital; University of Ottawa; Dalhousie University; Royal University Hospital; St. Michael's Hospital; Sunnybrook Health Science Centre; University of Alberta; Brampton Civic Hospital; McMaster University; Dr. Georges-L.-Dumont University Hospital Centre; University of British Columbia; Children's Hospital of Eastern Ontario; Ottawa Hospital","funders":"","keywords":"Standardization; Monoclonal gammopathy; Serum protein electrophoresis; Medicine; Monoclonal; Political science; Monoclonal antibody; Immunology; Law; Antibody","score_opus":0.17627868061733964,"score_gpt":0.4577775433337319,"score_spread":0.28149886271639224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767153221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871525,0.00022588838,0.000034918063,0.010626425,0.00013116542,0.0006759953,0.00021353854,0.000018933522,0.0009206337],"genre_scores_gemma":[0.9857896,0.00017867015,0.011064424,0.0003505946,0.0011106064,0.00014030469,0.0007055313,0.000024437912,0.000635823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678737,0.00005929444,0.001825137,0.0005878997,0.0002690734,0.0004712209],"domain_scores_gemma":[0.99556035,0.00073698966,0.0017022769,0.0011873019,0.00020441879,0.00060864096],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002529587,0.00017872301,0.00058912864,0.00000997176,0.000723776,0.00008325192,0.00041067548,0.00037067803,0.00007188822],"category_scores_gemma":[0.013606429,0.00012952526,0.0007504339,0.000051371633,0.0004841333,0.00003082135,0.00012353707,0.0006543942,0.0000045761244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071561715,0.0003698991,0.8807212,0.000094160234,0.0007196472,0.000042071722,0.000031346564,3.1325925e-8,0.024532694,0.000010204392,0.015592167,0.07717095],"study_design_scores_gemma":[0.009515266,0.00048867194,0.6597642,0.001153796,0.00042691725,0.000023097988,0.00015485652,0.0010144953,0.28764614,0.00057344226,0.038776133,0.00046300812],"about_ca_topic_score_codex":0.020651203,"about_ca_topic_score_gemma":0.011278184,"teacher_disagreement_score":0.26311344,"about_ca_system_score_codex":0.0001391721,"about_ca_system_score_gemma":0.0013244618,"threshold_uncertainty_score":0.9947024},"labels":[],"label_agreement":null},{"id":"W2769593282","doi":"10.1182/blood-2017-07-795047","title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary","funders":"National Cancer Institute; Celgene","keywords":"Multiple myeloma; Medicine; Internal medicine; Oncology; Progression-free survival; Overall survival; Surgery","score_opus":0.12058246848122686,"score_gpt":0.40384146286934536,"score_spread":0.2832589943881185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769593282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971474,0.00006212058,0.00003209502,0.0004121742,0.000076380195,0.0015218293,0.00039365163,0.000005341358,0.00034901677],"genre_scores_gemma":[0.99860275,0.00004207355,0.0003805449,0.0000059694303,0.0000556107,0.00025767196,0.0001254689,0.0000091495685,0.00052075094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987934,0.000057168494,0.00035796428,0.00020391117,0.00034667263,0.00024088613],"domain_scores_gemma":[0.99828166,0.0005609989,0.00021484368,0.00078409736,0.00008204801,0.00007634595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003057735,0.00014450446,0.00076920737,0.00020082774,0.0001240558,0.000016568982,0.0002164769,0.00005345998,0.000046230783],"category_scores_gemma":[0.0008290727,0.00008105117,0.00047688885,0.00009287029,0.00009272406,0.000040445513,0.000030162268,0.0000471039,0.0000023565328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036398698,0.01586112,0.9298707,0.00006329419,0.005853459,0.00006671471,0.0007821827,0.000003998908,0.0004350338,0.000028774055,0.000024236038,0.010611777],"study_design_scores_gemma":[0.3376709,0.004181255,0.6492098,0.000019461877,0.0029178767,0.0000013324934,0.00012132624,0.00073883595,0.004847403,0.000009444722,0.00022198945,0.000060381983],"about_ca_topic_score_codex":0.0016175687,"about_ca_topic_score_gemma":0.0048501506,"teacher_disagreement_score":0.3012722,"about_ca_system_score_codex":0.00003430481,"about_ca_system_score_gemma":0.0000860743,"threshold_uncertainty_score":0.33051708},"labels":[],"label_agreement":null},{"id":"W2769707874","doi":"10.15406/acp.2017.02.00026","title":"Case Study of Intracerebral Recurrence of Plasmablastic Myeloma with Achievement of Complete Response after Treatment with Lenalidomide","year":2017,"lang":"en","type":"article","venue":"Advances in Cytology & Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Complete response; Oncology; Internal medicine; Chemotherapy","score_opus":0.03727802666538156,"score_gpt":0.35132841482533983,"score_spread":0.3140503881599583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769707874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802977,0.00046960005,0.00011286191,0.00011701848,0.000048944563,0.0010710492,0.00007023576,0.0000068406166,0.00007367562],"genre_scores_gemma":[0.99600506,0.00014976994,0.0035190184,0.000010339338,0.00000955757,0.00025797886,0.0000071684826,0.000016371952,0.000024732975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979983,0.00044369578,0.0005233931,0.0004372083,0.00022069251,0.00037669446],"domain_scores_gemma":[0.9978018,0.00057992764,0.00052395154,0.0008356495,0.00016162843,0.00009705351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028240564,0.00024430008,0.0009713403,0.00025808963,0.000075630014,0.000002959946,0.00015751652,0.00008263136,0.00002452727],"category_scores_gemma":[0.00019070337,0.00015628543,0.000046635374,0.000104322724,0.00122912,0.00012667816,0.000093667484,0.00016812507,0.000002088577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07442382,0.002773127,0.85067254,0.00010628066,0.00026440932,0.056814693,0.0016632732,0.000055648543,0.0019844347,0.000022136706,2.9230958e-7,0.011219352],"study_design_scores_gemma":[0.028527308,0.06571693,0.8812298,0.00026829555,0.000284793,0.0130682085,0.0022855457,0.00008157009,0.008292268,0.000041783325,0.000041206273,0.000162282],"about_ca_topic_score_codex":0.00036434093,"about_ca_topic_score_gemma":0.008163914,"teacher_disagreement_score":0.0629438,"about_ca_system_score_codex":0.00008570505,"about_ca_system_score_gemma":0.00016482234,"threshold_uncertainty_score":0.6373135},"labels":[],"label_agreement":null},{"id":"W2770790219","doi":"10.1182/bloodadvances.2017011601","title":"CD86 regulates myeloma cell survival","year":2017,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Multiple myeloma; Cancer research; Downregulation and upregulation; Gene silencing; CD86; Signal transduction; CD28; Biology; Medicine; Cell biology; T cell; Immunology; Genetics; Gene; Immune system","score_opus":0.025556134169272066,"score_gpt":0.3246470050546573,"score_spread":0.2990908708853853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770790219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238079,0.0036394529,0.000008827077,0.0006386514,0.00021678004,0.0002990354,0.00001799494,0.000069432,0.07130193],"genre_scores_gemma":[0.9851949,0.00067508925,0.0020995187,0.00003116823,0.0002543273,0.000023943308,0.000021033058,0.000019446099,0.011680573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988836,0.000022205586,0.00013607994,0.00027715514,0.000328121,0.00035280836],"domain_scores_gemma":[0.99886125,0.000060359784,0.00009748642,0.0006811639,0.000073099414,0.00022664842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095148316,0.00014406817,0.00024933528,0.00004640779,0.0003731724,0.00007287117,0.0002053495,0.00004755503,0.00016013357],"category_scores_gemma":[0.00019063069,0.00010698723,0.00008522527,0.0000338204,0.0001487711,0.00025622934,0.00008681882,0.00010559754,0.00019326548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043226063,0.00093387556,0.8745295,0.00023207159,0.00022581368,0.0009983684,0.00007709006,0.0000018850402,0.020386763,0.00028446424,0.0003205788,0.10157738],"study_design_scores_gemma":[0.005868289,0.00045408538,0.76849115,0.00008968037,0.00011502577,0.000044116634,0.00006610434,0.000034478115,0.19034207,0.00047328844,0.033852093,0.00016962572],"about_ca_topic_score_codex":0.00005541191,"about_ca_topic_score_gemma":0.00005639229,"teacher_disagreement_score":0.1699553,"about_ca_system_score_codex":0.00001366882,"about_ca_system_score_gemma":0.00005379618,"threshold_uncertainty_score":0.43628126},"labels":[],"label_agreement":null},{"id":"W2771680190","doi":"10.1182/blood.v128.22.5676.5676","title":"High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Lenalidomide; Progression-free survival; Cyclophosphamide; Surgery; Regimen; Refractory (planetary science); Oncology; Chemotherapy","score_opus":0.018339538225723043,"score_gpt":0.27227082968242766,"score_spread":0.2539312914567046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771680190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645543,0.00023392215,0.000028433586,0.0014367517,0.00013022871,0.0010503978,0.00009832521,0.00008781577,0.00047869518],"genre_scores_gemma":[0.9962687,0.0001266277,0.0012744085,0.00046110523,0.0001257324,0.00018859607,0.000038142247,0.00006200527,0.0014546772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797237,0.000052142314,0.00033227677,0.0004910073,0.0005390653,0.0006131196],"domain_scores_gemma":[0.99860805,0.0002209405,0.00007028474,0.000538184,0.00013963164,0.0004229323],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013017005,0.00027059077,0.00037417264,0.00024022836,0.000053519714,0.000020187334,0.00016597568,0.00011323388,0.00021392132],"category_scores_gemma":[0.00057221844,0.00017155528,0.00009591565,0.0002584265,0.00006141288,0.00013634244,0.00010150953,0.00013720391,0.0009675031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018205309,0.005438212,0.87112916,0.000027791299,0.00027955076,0.00027127183,0.0006449368,2.8557363e-7,0.05752206,0.000038947972,0.00022288709,0.06260438],"study_design_scores_gemma":[0.03658278,0.0011061452,0.9361655,0.00021656604,0.00003669777,0.000010983408,0.000025909721,0.0000014511483,0.021334622,0.00004377749,0.004275936,0.00019961664],"about_ca_topic_score_codex":0.0012964422,"about_ca_topic_score_gemma":0.00028175936,"teacher_disagreement_score":0.06503637,"about_ca_system_score_codex":0.00014331896,"about_ca_system_score_gemma":0.00011800885,"threshold_uncertainty_score":0.99981034},"labels":[],"label_agreement":null},{"id":"W2772881286","doi":"10.1182/blood-2017-08-797886","title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Multiple myeloma; Medicine; Macroglobulinemia; Refractory (planetary science); Waldenstrom macroglobulinemia; Dexamethasone; Internal medicine; Oncology; Gastroenterology; Lymphoma; Biology","score_opus":0.025158198645819394,"score_gpt":0.3108131917688931,"score_spread":0.2856549931230737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772881286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978886,0.0006022179,0.0000030709587,0.00037648968,0.000027413676,0.0004880783,0.000052057723,0.000019091998,0.0005429348],"genre_scores_gemma":[0.9960398,0.00060059334,0.0025078885,0.000022139098,0.000065097774,0.000010194901,0.0000226178,0.000018514454,0.00071314286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989067,0.000039435203,0.0002892879,0.0002938788,0.00020658324,0.0002641726],"domain_scores_gemma":[0.99883664,0.0002472976,0.00012504507,0.00050528,0.00006173213,0.00022399504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017578964,0.00014781907,0.00037468743,0.000086840635,0.00012316095,0.000023353976,0.000098482364,0.00010567939,0.00004250438],"category_scores_gemma":[0.0014586309,0.000105889936,0.000038063416,0.000045893747,0.00018923281,0.000059331764,0.00012369374,0.00018694761,0.0000067255796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051707225,0.0013264051,0.9152636,0.00018131653,0.00019312587,0.0008858353,0.0002023106,2.8684337e-7,0.015641896,0.0000096796575,0.000044781216,0.061080046],"study_design_scores_gemma":[0.040635765,0.0006401561,0.9512058,0.00022122754,0.00009466415,0.00013467016,0.00004332728,0.0002635271,0.006067212,0.000006387441,0.00059433095,0.00009296852],"about_ca_topic_score_codex":0.00034907326,"about_ca_topic_score_gemma":0.0003607099,"teacher_disagreement_score":0.060987078,"about_ca_system_score_codex":0.000022171644,"about_ca_system_score_gemma":0.00009396028,"threshold_uncertainty_score":0.43180662},"labels":[],"label_agreement":null},{"id":"W2772890129","doi":"10.1634/theoncologist.2017-0103","title":"Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Hazard ratio; Population; Confidence interval; Propensity score matching; Oncology; Dexamethasone; Surgery; Lenalidomide; Environmental health","score_opus":0.13851089506331335,"score_gpt":0.4163297299963975,"score_spread":0.2778188349330841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772890129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448246,0.0015561965,0.00002812536,0.0006213064,0.000043824148,0.0019598957,0.000033426997,0.000015238563,0.001259554],"genre_scores_gemma":[0.99832755,0.00041313967,0.0009114629,0.00002744723,0.000042938293,0.00012664172,0.000023939083,0.00001361932,0.00011327907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825734,0.0004422253,0.0004288743,0.00025662495,0.00031266277,0.0003022533],"domain_scores_gemma":[0.9967702,0.0018217299,0.0004454132,0.00081341347,0.000067631,0.00008160212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005120262,0.00022848844,0.0009962607,0.0000967499,0.00032126607,0.0000393513,0.00034205185,0.00008721014,0.000015444055],"category_scores_gemma":[0.00024539648,0.000113194794,0.00011811683,0.00012123636,0.000849212,0.000061590654,0.000058987036,0.00019490287,0.0000054035518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045755647,0.014665331,0.69005674,0.00023091312,0.002000209,0.0004903029,0.09110261,0.00052711024,0.020815477,0.00019067124,0.00021467695,0.13395032],"study_design_scores_gemma":[0.029551098,0.0031276138,0.94578165,0.00012984521,0.0001346254,0.00002571596,0.0029770255,0.0030705337,0.01487927,0.000044484354,0.0001798284,0.00009831251],"about_ca_topic_score_codex":0.0049937833,"about_ca_topic_score_gemma":0.0034023714,"teacher_disagreement_score":0.2557249,"about_ca_system_score_codex":0.00024996354,"about_ca_system_score_gemma":0.00014254247,"threshold_uncertainty_score":0.754914},"labels":[],"label_agreement":null},{"id":"W2774700270","doi":"10.1038/leu.2017.331","title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Transplantation; Oncology; Population; Internal medicine; Multiple myeloma; Hematopoietic stem cell transplantation","score_opus":0.01723027951420258,"score_gpt":0.2772434045291609,"score_spread":0.2600131250149583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774700270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99697083,0.000072741546,0.0000431973,0.00028259165,0.000086358625,0.0015219457,0.00015361268,0.00009366368,0.0007750718],"genre_scores_gemma":[0.9921884,0.00002374633,0.00094856846,0.00011900293,0.00005145733,0.0002814746,0.00008601852,0.000056493715,0.0062448317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979471,0.000074213734,0.00039837763,0.00051558757,0.0004026138,0.00066211814],"domain_scores_gemma":[0.998467,0.0002480381,0.00016399751,0.0007328445,0.00006925567,0.00031883476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001157988,0.0003319431,0.00053540757,0.0001844627,0.00018799282,0.000109231216,0.00021933617,0.0002491353,0.00022140301],"category_scores_gemma":[0.00045265717,0.00026039474,0.00018177666,0.000056799894,0.00013404388,0.0002544738,0.00006282154,0.0003958407,0.0004479046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013336007,0.00022536617,0.9760346,0.00028100307,0.0000853893,0.0028879906,0.0009432847,9.3245524e-7,0.016504707,0.0000022530714,0.000040219995,0.0016606913],"study_design_scores_gemma":[0.010710844,0.00036540278,0.9771829,0.00019512368,0.00009752917,0.000070323455,0.000026531878,0.002725738,0.00832337,0.00003052842,0.000031074993,0.00024059779],"about_ca_topic_score_codex":0.0015070607,"about_ca_topic_score_gemma":0.0007910723,"teacher_disagreement_score":0.009377243,"about_ca_system_score_codex":0.00053250464,"about_ca_system_score_gemma":0.00028431424,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W2774761959","doi":"10.1182/blood.v130.suppl_1.5524.5524","title":"Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Surgery; Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Internal medicine","score_opus":0.05433498657521999,"score_gpt":0.38483227951047844,"score_spread":0.3304972929352584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774761959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968351,0.000055187174,0.000024449328,0.00028255215,0.00015171927,0.0016106492,0.00047734694,0.000051945823,0.00051105506],"genre_scores_gemma":[0.99820644,0.00019802395,0.0004160122,0.00023906282,0.000091409,0.00011301176,0.00029565953,0.000032555286,0.00040784007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986504,0.000064303094,0.00031298335,0.0003246736,0.00028389355,0.00036374768],"domain_scores_gemma":[0.9983268,0.0005056895,0.00016668637,0.0005764813,0.0001761054,0.00024825596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001796457,0.0002068982,0.00039935668,0.00006981776,0.00027638997,0.000053747186,0.00017243154,0.0001326101,0.000028365585],"category_scores_gemma":[0.00017881744,0.00012803337,0.00038341354,0.000019143643,0.00006554721,0.00009681957,0.000014216841,0.00014514379,0.00007264117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004068788,0.0039014146,0.90620536,0.0000442734,0.00040702405,0.00007528093,0.00009454807,3.7736731e-7,0.00033485657,0.0000031256536,0.00007300647,0.08479195],"study_design_scores_gemma":[0.043735113,0.007113177,0.941833,0.000029668146,0.00013014502,0.0000049675095,0.000015087125,0.00004009638,0.006883657,0.0000107136075,0.000089715984,0.00011461273],"about_ca_topic_score_codex":0.00012143083,"about_ca_topic_score_gemma":0.000027183849,"teacher_disagreement_score":0.08467734,"about_ca_system_score_codex":0.000028849088,"about_ca_system_score_gemma":0.00008758483,"threshold_uncertainty_score":0.5221049},"labels":[],"label_agreement":null},{"id":"W2781661609","doi":"10.1016/j.clml.2017.12.011","title":"A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis","year":2018,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Janssen Pharmaceuticals","keywords":"Lenalidomide; Medicine; Internal medicine; Daratumumab; Oncology; Carfilzomib; Ixazomib; Multiple myeloma; Hazard ratio; Subgroup analysis; Pomalidomide; Progression-free survival; Meta-analysis; Chemotherapy; Confidence interval","score_opus":0.21187975904621487,"score_gpt":0.4481643213528339,"score_spread":0.23628456230661904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781661609","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05890362,0.93647206,0.0000124298995,0.00003255232,0.000449188,0.00321905,0.00015677532,0.000067328816,0.00068697316],"genre_scores_gemma":[0.5309739,0.46540278,0.0011503327,0.00007995577,0.0006401705,0.00039666818,0.00038803666,0.00023359992,0.00073453947],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98500913,0.0031702248,0.0071326117,0.0017922058,0.0015534698,0.0013423265],"domain_scores_gemma":[0.98007303,0.00991035,0.0046454314,0.0041942084,0.0005544438,0.0006225192],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0037828442,0.0013372982,0.017135955,0.000829409,0.00022077764,0.000037447164,0.0015635439,0.0016591668,0.00027132803],"category_scores_gemma":[0.0055657215,0.0008297683,0.0146666635,0.0036663073,0.0015054899,0.00009579037,0.0007500837,0.0015317602,0.00012272097],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019097049,0.0024243286,0.07138459,0.0040718056,0.22348475,0.00020709667,0.00020521166,0.00005595941,0.0000022424983,0.00005174109,0.00091643113,0.69528615],"study_design_scores_gemma":[0.009414127,0.0017836819,0.534814,0.004709184,0.29513195,0.000050617236,0.000051594932,0.000664461,0.000015650712,0.000023988214,0.152576,0.0007647518],"about_ca_topic_score_codex":0.0005199301,"about_ca_topic_score_gemma":0.00030548885,"teacher_disagreement_score":0.69452137,"about_ca_system_score_codex":0.0018066774,"about_ca_system_score_gemma":0.0044670543,"threshold_uncertainty_score":0.99993783},"labels":[],"label_agreement":null},{"id":"W2781805276","doi":"10.1016/j.clml.2017.12.009","title":"Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center; Princess Margaret Cancer Centre","funders":"Celgene; Amgen","keywords":"Medicine; Bortezomib; Multiple myeloma; Hazard ratio; Autologous stem-cell transplantation; Single Center; Internal medicine; Stem cell; Transplantation; Oncology; Progression-free survival; Surgery; Confidence interval; Chemotherapy","score_opus":0.036924814555313594,"score_gpt":0.31338370039348784,"score_spread":0.27645888583817424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781805276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631876,0.00007611218,0.00027331893,0.00007064135,0.00011662204,0.0013802899,0.000078388235,0.00014513276,0.0015407255],"genre_scores_gemma":[0.99307144,0.000040946023,0.0055572838,0.00024357469,0.00017981489,0.00014769431,0.0002774161,0.0000865395,0.00039530126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961526,0.00024941593,0.0009619694,0.0010891696,0.0006807266,0.0008661612],"domain_scores_gemma":[0.9976825,0.0005162998,0.00031148677,0.00055639475,0.0003059084,0.0006273756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027546956,0.0005241613,0.0009223659,0.00021589866,0.00022501551,0.00007264278,0.00019560443,0.0003103734,0.000045952227],"category_scores_gemma":[0.00013615012,0.0003622275,0.00009924765,0.00035194049,0.00080013985,0.00031040618,0.000069385016,0.00027827444,0.00005602031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01754865,0.0010166565,0.74021167,0.00009391898,0.000094911746,0.00038974997,0.0010005744,0.0000016145111,0.00018242288,0.0000019358724,0.000027256789,0.23943062],"study_design_scores_gemma":[0.04308218,0.008082752,0.9429398,0.0005841875,0.000101245445,0.00020396957,0.000293912,0.001619939,0.0023476314,0.0000031903216,0.00034637598,0.00039477125],"about_ca_topic_score_codex":0.00018283384,"about_ca_topic_score_gemma":0.0007470174,"teacher_disagreement_score":0.23903584,"about_ca_system_score_codex":0.00059980707,"about_ca_system_score_gemma":0.00039851185,"threshold_uncertainty_score":0.999883},"labels":[],"label_agreement":null},{"id":"W2781915512","doi":"10.5114/pdia.2016.62463","title":"Skin dissemination of myeloma","year":2017,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Dermatology; Internal medicine","score_opus":0.011801324770437214,"score_gpt":0.3574091082781964,"score_spread":0.34560778350775917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781915512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848368,0.0036537126,0.00007206918,0.0015934762,0.0000777265,0.00014179127,0.0000026070936,0.0000074116942,0.009614377],"genre_scores_gemma":[0.9956366,0.0035260285,0.0005973397,0.000036259426,0.000011963514,0.000020265128,0.000009391756,0.0000044174276,0.0001577451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994116,0.000036967,0.0001607597,0.00015664361,0.000056238117,0.00017780646],"domain_scores_gemma":[0.99941856,0.00016877966,0.00009438787,0.00023506857,0.000032017335,0.00005119573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048360802,0.000072073184,0.00026117737,0.000092651026,0.000084742984,0.0000032597259,0.000086491644,0.00009210164,0.000041534317],"category_scores_gemma":[0.0003527181,0.000059273254,0.00002293492,0.000023113364,0.00042954425,0.00014167582,0.00006472341,0.00009351527,0.0000061421633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003344811,0.00012095998,0.8899072,0.00009468215,0.000036998154,0.00052401726,0.00011240767,5.081099e-7,0.0004936335,0.0042466326,0.000054685745,0.10407383],"study_design_scores_gemma":[0.0014987707,0.00011238018,0.98722297,0.00006877953,0.0000093634535,0.00076722185,0.000056733585,0.00017855575,0.005125268,0.0017026922,0.0032041897,0.00005308447],"about_ca_topic_score_codex":0.000017244003,"about_ca_topic_score_gemma":0.00023669132,"teacher_disagreement_score":0.104020745,"about_ca_system_score_codex":0.000008050723,"about_ca_system_score_gemma":0.000018699784,"threshold_uncertainty_score":0.24170932},"labels":[],"label_agreement":null},{"id":"W2782099884","doi":"10.1182/blood.v130.suppl_1.1812.1812","title":"Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Royal Victoria Hospital; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Internal medicine; Neutropenia; Multiple myeloma; Lenalidomide; Bortezomib; Clinical endpoint; Cohort; Adverse effect; Surgery; Population; Gastroenterology; Randomized controlled trial; Chemotherapy","score_opus":0.01574568132597968,"score_gpt":0.2580557407215349,"score_spread":0.24231005939555525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782099884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925933,0.000621853,0.000006215718,0.00017306971,0.000010370771,0.006432471,0.00004691701,0.00006684155,0.00004898152],"genre_scores_gemma":[0.9960622,0.000522528,0.0023837558,0.000046805486,0.00005154673,0.00045839231,0.00007166248,0.000113931485,0.00028913043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966683,0.0002909257,0.00054293324,0.0010399596,0.000634214,0.00082371506],"domain_scores_gemma":[0.99759215,0.00040116892,0.00038616726,0.0008609069,0.00018694926,0.0005726748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042894468,0.00063421007,0.001111457,0.00035335092,0.00038713805,0.00022570908,0.00017415459,0.00021549426,0.000014694935],"category_scores_gemma":[0.00060326664,0.0003676426,0.000043231197,0.00027018585,0.0006287656,0.00053011754,0.000126633,0.00054005755,0.0000037730126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.122246936,0.004873148,0.8425927,0.00023321474,0.0004478589,0.0010890283,0.00094395,0.0000016415879,0.0022048121,8.056427e-7,0.0000020223401,0.025363855],"study_design_scores_gemma":[0.22128887,0.008004996,0.76245284,0.0019173509,0.00014039401,0.0000996447,0.00010736783,0.00006671541,0.0054846327,0.0000010141733,0.00006726567,0.00036887944],"about_ca_topic_score_codex":0.00095715455,"about_ca_topic_score_gemma":0.004758258,"teacher_disagreement_score":0.099041946,"about_ca_system_score_codex":0.00014131796,"about_ca_system_score_gemma":0.0003803318,"threshold_uncertainty_score":0.9998776},"labels":[],"label_agreement":null},{"id":"W2782542268","doi":"10.1182/blood.v130.suppl_1.739.739","title":"Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Dexamethasone; Internal medicine; Interim analysis; Pomalidomide; Oncology; Multiple myeloma; Bortezomib; Clinical endpoint; Neutropenia; Ixazomib; Progression-free survival; Carfilzomib; Gastroenterology; Clinical trial; Chemotherapy","score_opus":0.04574990434246723,"score_gpt":0.3348571041925786,"score_spread":0.28910719985011135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782542268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488384,0.0028112223,0.000019324953,0.00038495712,0.00006509456,0.00095721526,0.0002141153,0.00004387014,0.000620353],"genre_scores_gemma":[0.99389607,0.0018857077,0.0035017626,0.000035847213,0.000058960537,0.00003557751,0.00016887856,0.000051773834,0.00036543194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681085,0.0003111624,0.0007576445,0.00088972884,0.0005640466,0.0006665883],"domain_scores_gemma":[0.9960205,0.0016104447,0.00044649956,0.00115117,0.00017423737,0.0005971559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009076099,0.00045712563,0.0014757172,0.0008245854,0.0003950361,0.00010836682,0.0002346387,0.0002946234,0.00015459044],"category_scores_gemma":[0.0041484185,0.0003597508,0.00015074463,0.0006089257,0.0006987426,0.0002517919,0.00033031128,0.00047966986,0.000005382288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07353045,0.0027008865,0.8269658,0.00028518884,0.00985682,0.001410376,0.0008051136,0.000008346322,0.033167373,0.000045616187,0.000091720794,0.05113231],"study_design_scores_gemma":[0.1194409,0.0013121831,0.8650502,0.0002229346,0.003410397,0.00006414633,0.00022925156,0.0011272022,0.008396016,0.000010672327,0.0004106154,0.000325488],"about_ca_topic_score_codex":0.0020500808,"about_ca_topic_score_gemma":0.003470706,"teacher_disagreement_score":0.05080682,"about_ca_system_score_codex":0.00008819549,"about_ca_system_score_gemma":0.00018835216,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W2783634626","doi":"10.14740/jh356w","title":"Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Pure red cell aplasia; Bone marrow; Dexamethasone; Aplasia; Plasma cell; Anemia; Internal medicine; Gastroenterology; Oncology; Cancer research","score_opus":0.038251464099323826,"score_gpt":0.3350023693515569,"score_spread":0.2967509052522331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783634626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997497,0.0006965446,0.00034089258,0.0004874619,0.000059558435,0.00026406077,0.000009404984,0.000013333702,0.0006317501],"genre_scores_gemma":[0.98875517,0.0001583542,0.010690134,0.000051289153,0.000085897984,0.0000032162802,0.00001264365,0.000021231175,0.00022207589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792343,0.00031651658,0.00087096536,0.0002049019,0.00035094176,0.00033326822],"domain_scores_gemma":[0.99731934,0.00062272296,0.00077124726,0.00021479909,0.0007498781,0.00032202897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007306865,0.00016263765,0.00093944586,0.00024085488,0.00006667254,0.0000070714636,0.00009294398,0.00024127198,0.00007528285],"category_scores_gemma":[0.0012695927,0.000107971886,0.00012953772,0.00016641722,0.00041619892,0.00008582223,0.000038836228,0.00035003168,0.000008295912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072490294,0.000970296,0.98100173,0.00006126304,0.000681162,0.000750332,0.00011868187,3.945606e-7,0.00455439,0.000017069182,0.0023516256,0.002244032],"study_design_scores_gemma":[0.025875585,0.010364634,0.9344068,0.00034631052,0.00048853643,0.003358449,0.00015663853,0.0015881183,0.022649888,0.000120583405,0.00051135157,0.0001330833],"about_ca_topic_score_codex":0.00007986234,"about_ca_topic_score_gemma":0.00014133444,"teacher_disagreement_score":0.046594903,"about_ca_system_score_codex":0.000072233815,"about_ca_system_score_gemma":0.00022259264,"threshold_uncertainty_score":0.44029656},"labels":[],"label_agreement":null},{"id":"W2785388766","doi":"10.1016/j.bbmt.2017.12.602","title":"Outpatient Autologous Stem Cell Transplants for Multiple Myeloma—Analysis of Safety and Outcomes in a Tertiary Care Centre","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Multiple myeloma; Neutropenia; Autologous stem-cell transplantation; Febrile neutropenia; Surgery; Chemotherapy regimen; Chemotherapy; Internal medicine","score_opus":0.011163363599188611,"score_gpt":0.2685911010741215,"score_spread":0.25742773747493286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785388766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693763,0.00069765473,0.00031055094,0.000077063305,0.0000279844,0.00061497744,0.0012817316,0.000009528356,0.00004288941],"genre_scores_gemma":[0.99763906,0.0007001683,0.00082633854,0.00002000712,0.000006869765,0.000016525375,0.00076067116,0.000006693952,0.000023691831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991078,0.00006553713,0.00033008523,0.00023475621,0.000073949544,0.00018787912],"domain_scores_gemma":[0.99944866,0.00021716843,0.00008697803,0.00009275372,0.000080680526,0.00007376728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008582051,0.00012326559,0.0004574798,0.0002804632,0.00003901837,0.0000018148579,0.00003378155,0.00012569415,0.0000070904985],"category_scores_gemma":[0.0000078954445,0.00009426938,0.000087311964,0.00010408848,0.00015350009,0.000028543274,0.0000050375625,0.000046836303,2.3941465e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002295989,0.00023210418,0.939079,0.0008311413,0.0008224293,0.000013036073,0.0041766833,0.0000016587144,0.040803988,0.00001635639,4.924625e-7,0.011727124],"study_design_scores_gemma":[0.008474918,0.000896053,0.9223807,0.000077895245,0.0022886142,0.000007918848,0.00044281813,0.00043150285,0.06490473,0.0000058911364,0.00000948957,0.00007946287],"about_ca_topic_score_codex":0.00024413923,"about_ca_topic_score_gemma":0.001486906,"teacher_disagreement_score":0.02410074,"about_ca_system_score_codex":0.000008725887,"about_ca_system_score_gemma":0.000028377604,"threshold_uncertainty_score":0.38441938},"labels":[],"label_agreement":null},{"id":"W2789930186","doi":"10.1016/j.bbmt.2017.12.226","title":"Bortezomib Consolidation after Frontline Auto-Allogeneic Transplant: Low Toxicity and Frequent Immunophenotypic Complete Responses in High-Risk or Young Myeloma Patients","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Minimal residual disease; Bortezomib; Multiple myeloma; Autologous stem-cell transplantation; Cyclophosphamide; Fludarabine; Transplantation; Surgery; Median follow-up; Oncology; Gastroenterology; Leukemia; Chemotherapy","score_opus":0.013251534081772808,"score_gpt":0.2612871234179773,"score_spread":0.24803558933620445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789930186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971523,0.0005380153,0.00031380937,0.00007396383,0.00007997113,0.0005911958,0.0012060343,0.000020628064,0.000024031657],"genre_scores_gemma":[0.9952528,0.00235484,0.0012469903,0.00005188503,0.000040128976,0.00004977466,0.0009658387,0.00001275308,0.000025002033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870133,0.00021967778,0.00037904896,0.0003242078,0.000118700504,0.00025704718],"domain_scores_gemma":[0.99944234,0.00012319305,0.000107480555,0.00013109185,0.0000932228,0.00010270069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019078318,0.00018135941,0.00035354155,0.00019973726,0.000085139436,0.000008348798,0.000044678418,0.00015674806,0.000059157555],"category_scores_gemma":[0.000039263716,0.00013778094,0.000034798915,0.00009071674,0.00032889636,0.00008105867,0.00000875895,0.0001124309,0.0000032586815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016211059,0.00040399146,0.8289334,0.00022902481,0.00020643424,0.00006520517,0.00076022843,1.6973219e-7,0.1473485,0.000033500302,0.000001554728,0.0058069397],"study_design_scores_gemma":[0.013012512,0.0022617835,0.94937605,0.00019306708,0.00035856827,0.00006460083,0.000021708911,0.00007321942,0.034400966,0.000100918616,0.000009321963,0.00012730686],"about_ca_topic_score_codex":0.0007188627,"about_ca_topic_score_gemma":0.0020209954,"teacher_disagreement_score":0.12044264,"about_ca_system_score_codex":0.000018105313,"about_ca_system_score_gemma":0.000060244205,"threshold_uncertainty_score":0.56185436},"labels":[],"label_agreement":null},{"id":"W2790257752","doi":"10.1111/cas.13550","title":"Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma","year":2018,"lang":"en","type":"article","venue":"Cancer Science","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Ministry of Health, Labour and Welfare","keywords":"Dexamethasone; Bortezomib; Thalidomide; Multiple myeloma; Refractory (planetary science); Medicine; Internal medicine; Lenalidomide; Oncology; Biology","score_opus":0.0825611048857459,"score_gpt":0.391696403772379,"score_spread":0.3091352988866331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790257752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845684,0.0012326727,0.0069669425,0.0012324278,0.0011990593,0.0025872523,0.00014215407,0.00020538102,0.0018656956],"genre_scores_gemma":[0.9618938,0.0002703372,0.029822445,0.0007917542,0.00078560965,0.000730736,0.000022181044,0.00005976314,0.0056233965],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957063,0.00007662071,0.0004574941,0.0011849934,0.0011898497,0.001384718],"domain_scores_gemma":[0.99601024,0.00079731026,0.00021367532,0.0010745,0.0009267677,0.0009775118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001246648,0.00037419642,0.000681801,0.00038258682,0.00073908153,0.00012471834,0.0006981391,0.00016095315,0.000568489],"category_scores_gemma":[0.004243233,0.00027013035,0.00016497298,0.0014286583,0.0020940958,0.00054941827,0.0002269123,0.0003149188,0.00014693708],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07111756,0.0012119068,0.089844696,0.0007897985,0.00078074104,0.00080231664,0.0055669667,0.0000952336,0.34024552,0.00045698637,0.01910409,0.4699842],"study_design_scores_gemma":[0.07716159,0.011525927,0.28113458,0.0011924158,0.00048633295,0.00032592757,0.0010217732,0.093111455,0.42901686,0.00027431786,0.103079095,0.0016697419],"about_ca_topic_score_codex":0.0010034502,"about_ca_topic_score_gemma":0.00092195306,"teacher_disagreement_score":0.46831444,"about_ca_system_score_codex":0.0018696701,"about_ca_system_score_gemma":0.004520874,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W2790538995","doi":"10.1007/s40266-018-0539-1","title":"Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?","year":2018,"lang":"en","type":"review","venue":"Drugs & Aging","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Cohort; Transplantation; Internal medicine; Intensive care medicine; Oncology","score_opus":0.03992087757190279,"score_gpt":0.3600835229687599,"score_spread":0.3201626453968571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790538995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017520913,0.9903347,0.000026072008,0.000058990747,0.00027018628,0.0062873545,0.00023761753,0.00008501256,0.0009480082],"genre_scores_gemma":[0.005069777,0.9864676,0.0016576309,0.000061263425,0.00056437135,0.0023790144,0.0017045008,0.000211113,0.0018847369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996309,0.00010466175,0.0007907392,0.0011241504,0.00056248385,0.0011090096],"domain_scores_gemma":[0.9976507,0.00057498715,0.00031570595,0.00087732874,0.00017487048,0.00040643467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036663373,0.0008202188,0.0020997606,0.0006222633,0.00016691054,0.00023348645,0.00031747614,0.00036480423,0.00006209368],"category_scores_gemma":[0.00020644531,0.00059414154,0.0008184898,0.00020410347,0.000078903206,0.00033637055,0.00017544634,0.00043094787,0.00024134092],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017583529,0.0008935731,0.0011957567,0.0067686355,0.000880858,0.00009488663,0.0029608984,1.2568495e-7,0.0000021221138,0.0000069180487,0.00013713713,0.9868833],"study_design_scores_gemma":[0.029124849,0.00048633618,0.001476486,0.1362489,0.0026013358,0.00018324553,0.0023762397,0.00061295053,0.000058955255,0.00005052653,0.8256525,0.0011276761],"about_ca_topic_score_codex":0.000657596,"about_ca_topic_score_gemma":0.00029491284,"teacher_disagreement_score":0.98575556,"about_ca_system_score_codex":0.0007680905,"about_ca_system_score_gemma":0.00036347136,"threshold_uncertainty_score":0.999651},"labels":[],"label_agreement":null},{"id":"W2790687822","doi":"10.1053/j.seminhematol.2018.03.002","title":"Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma","year":2018,"lang":"en","type":"review","venue":"Seminars in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Bone marrow; DNA; Somatic cell; Cell-free fetal DNA; DNA sequencing; Medicine; Circulating tumor DNA; Cancer research; Computational biology; Biology; Immunology; Internal medicine; Cancer; Gene; Genetics","score_opus":0.08299426955755611,"score_gpt":0.38579050127562864,"score_spread":0.3027962317180725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790687822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.055023078,0.9408494,0.000013473005,0.000052521944,0.0001923739,0.0035689995,0.00010113066,0.00005644819,0.00014256607],"genre_scores_gemma":[0.058365528,0.9313851,0.0058724442,0.000031884578,0.00047583884,0.0026632783,0.0006959345,0.0002241602,0.0002858365],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99587697,0.0003454781,0.0012669567,0.0010271757,0.0003176541,0.0011657688],"domain_scores_gemma":[0.9960143,0.002528363,0.0003823904,0.0005885562,0.00009368166,0.00039272112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070035824,0.00059017126,0.0026634077,0.00092861406,0.00011965323,0.000020281585,0.00027490698,0.00053877744,0.00004260683],"category_scores_gemma":[0.00647195,0.0005169099,0.00045745668,0.0005257209,0.00020238975,0.000060580547,0.00021155448,0.0006379367,0.00006283104],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011741318,0.0007020786,0.07000362,0.073763214,0.00032902515,0.015416283,0.00034504395,8.6980003e-7,0.000018288238,0.000073403935,0.00046322873,0.8377108],"study_design_scores_gemma":[0.0337503,0.0038660178,0.017657148,0.48899415,0.003868364,0.016607344,0.0010520831,0.006902059,0.00069771014,0.0011764934,0.42083904,0.0045892736],"about_ca_topic_score_codex":0.00007028297,"about_ca_topic_score_gemma":0.00026778004,"teacher_disagreement_score":0.83312154,"about_ca_system_score_codex":0.00046829932,"about_ca_system_score_gemma":0.0007377696,"threshold_uncertainty_score":0.99972826},"labels":[],"label_agreement":null},{"id":"W2792685463","doi":"10.31053/1853.0605.v74.n3.16895","title":"Infiltración pleural en la recaída de un mieloma múltiple","year":2017,"lang":"es","type":"article","venue":"Revista de la Facultad de Ciencias Médicas de Córdoba","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canarie","funders":"","keywords":"Medicine","score_opus":0.026345622477567866,"score_gpt":0.35772121255618977,"score_spread":0.3313755900786219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792685463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624623,0.0046655685,0.0012590742,0.0022237166,0.00009740496,0.0011734426,0.0004937922,0.00023607994,0.027388602],"genre_scores_gemma":[0.98219144,0.0048107742,0.007630419,0.00085431914,0.00077365775,0.00016905912,0.00013256492,0.00015260729,0.0032851754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915629,0.0021237924,0.0009210592,0.0011761519,0.0013324842,0.002883632],"domain_scores_gemma":[0.99239457,0.0022021965,0.00064887217,0.00201794,0.00033656065,0.0023998704],"candidate_categories":["metaresearch","metaepi_narrow","sts","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.004550473,0.000915391,0.0012535602,0.00036013153,0.0015383371,0.0022678205,0.0019604587,0.0010862844,0.0006392436],"category_scores_gemma":[0.015700005,0.000823797,0.0006829612,0.00047939652,0.0015023557,0.00053166953,0.0006709105,0.0018309384,0.0005542103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075700623,0.0011735734,0.82844484,0.0010039816,0.0009448118,0.012368619,0.0024825968,0.000026646556,0.020502018,0.0064512882,0.007897957,0.11794664],"study_design_scores_gemma":[0.005724291,0.0004852896,0.7931397,0.0012930542,0.0006138354,0.0030496756,0.0005084991,0.002926121,0.0055326796,0.00040318712,0.18555844,0.0007652521],"about_ca_topic_score_codex":0.00167449,"about_ca_topic_score_gemma":0.000040198312,"teacher_disagreement_score":0.17766048,"about_ca_system_score_codex":0.0022339514,"about_ca_system_score_gemma":0.0028747832,"threshold_uncertainty_score":0.9997615},"labels":[],"label_agreement":null},{"id":"W2793129204","doi":"10.1097/hs9.0000000000000033","title":"Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Medical education","score_opus":0.048800714674720316,"score_gpt":0.3674418180071542,"score_spread":0.3186411033324339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793129204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98357844,0.004882742,0.000014053303,0.0011791377,0.000037849582,0.00057341944,0.0000067160645,0.000006488551,0.0097211385],"genre_scores_gemma":[0.99353284,0.0018504036,0.0040622307,0.00004522201,0.000024434545,0.000034101642,0.000012018754,0.000010379416,0.00042839145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990996,0.00016830943,0.00023056625,0.00018944297,0.00014644917,0.00016563052],"domain_scores_gemma":[0.9990402,0.00050599594,0.000104305516,0.00020762134,0.0000713296,0.000070583206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022726918,0.000118486845,0.00024530478,0.00007163483,0.00005719128,0.000012675723,0.000049330032,0.000031811098,0.000040497536],"category_scores_gemma":[0.00015080239,0.00007704745,0.000022991182,0.0001458849,0.00035972538,0.00007085777,0.00005029034,0.000048826878,0.000005145138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015210247,0.0025836497,0.90853894,0.0023603188,0.0007740916,0.00048757688,0.01270615,2.3090163e-7,0.0021951348,0.015956808,0.00064406317,0.052232016],"study_design_scores_gemma":[0.0066854544,0.0013178444,0.95861447,0.0006906852,0.00025368558,0.002102121,0.019734154,0.00007114108,0.005725809,0.000326882,0.004343339,0.00013441907],"about_ca_topic_score_codex":0.00013435596,"about_ca_topic_score_gemma":0.00010348108,"teacher_disagreement_score":0.052097596,"about_ca_system_score_codex":0.000020281423,"about_ca_system_score_gemma":0.000023360688,"threshold_uncertainty_score":0.3141904},"labels":[],"label_agreement":null},{"id":"W2793606391","doi":"10.3390/cancers10060206","title":"Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model","year":2018,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions","keywords":"3D cell culture; Cell culture; Bortezomib; STAT3; Multiple myeloma; Cancer research; Bone marrow; Chemistry; Biology; Molecular biology; Cell biology; Immunology; Phosphorylation","score_opus":0.03374503899815378,"score_gpt":0.306431830275541,"score_spread":0.2726867912773872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793606391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963037,0.00008660286,0.00011904688,0.00009729631,0.000060218823,0.00056856533,0.00005617345,0.000012752246,0.002695679],"genre_scores_gemma":[0.99608463,0.000023133078,0.0034849339,0.00007959692,0.000025191559,0.00004197981,0.00003910319,0.000009060323,0.00021238378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990472,0.000027482574,0.00023448217,0.00022551959,0.00022111085,0.00024415998],"domain_scores_gemma":[0.99945116,0.000042352574,0.000077473065,0.00015681206,0.00016822945,0.000103981554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008730024,0.00011095631,0.00026441948,0.00020341262,0.00002639087,0.0000037840348,0.000041543288,0.00007696705,0.00012670388],"category_scores_gemma":[0.000090019246,0.00009414672,0.00003439931,0.0003348095,0.00033874754,0.000094501585,0.000020784595,0.00013316366,0.000011207894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011294354,0.00036486762,0.13698436,0.00028281607,0.00035343043,0.00031979536,0.002261872,0.0077032684,0.8044295,0.00080706604,0.002868621,0.03233008],"study_design_scores_gemma":[0.020688294,0.0007979689,0.08751988,0.0013571365,0.0000454045,0.000026829644,0.00051720464,0.26021197,0.62693065,0.0013159709,0.00024200992,0.00034670663],"about_ca_topic_score_codex":0.0018243721,"about_ca_topic_score_gemma":0.0026926992,"teacher_disagreement_score":0.2525087,"about_ca_system_score_codex":0.0011098118,"about_ca_system_score_gemma":0.0012369212,"threshold_uncertainty_score":0.38391918},"labels":[],"label_agreement":null},{"id":"W2794240753","doi":"10.1093/jcag/gwy008.035","title":"A34 DARATUMUMAB DOSE DEPENDENT LIVER INJURY","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Daratumumab; Medicine; Liver injury; Internal medicine; Antibody; Gastroenterology; Monoclonal antibody; Immunology","score_opus":0.01449601409063752,"score_gpt":0.27553428452219475,"score_spread":0.26103827043155725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794240753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900524,0.000018312167,0.000010898848,0.008272909,0.0005026705,0.0001393308,0.000036904737,0.0000020056982,0.0009645742],"genre_scores_gemma":[0.99721545,0.000020621153,0.00020211704,0.0010179863,0.0002806706,0.000001220623,0.000002012614,0.000007986487,0.0012519272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864525,0.00021358172,0.00033230337,0.00007359641,0.0004103304,0.00032494104],"domain_scores_gemma":[0.9982745,0.00003523991,0.0005616625,0.00015599567,0.00063741853,0.0003351958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005709414,0.00007671571,0.00025903663,0.00023263071,0.00011264997,0.000011428996,0.00017517521,0.00009092546,0.0002187917],"category_scores_gemma":[0.00048136027,0.000052721432,0.00015487608,0.000083888444,0.00008162013,0.0000573502,0.000029390683,0.00026888808,0.000025326965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011304765,0.000081976614,0.98167694,0.0000074317354,0.00040017738,0.00006287788,0.000109705805,0.0000010734992,0.00052565796,0.000016947795,0.015111876,0.0008748859],"study_design_scores_gemma":[0.0033523953,0.002523934,0.9892318,0.000039029917,0.00010849768,0.00021240942,0.000021918057,0.000041428444,0.0006859442,0.0000393468,0.0037181512,0.000025098803],"about_ca_topic_score_codex":0.00555007,"about_ca_topic_score_gemma":0.35284686,"teacher_disagreement_score":0.34729677,"about_ca_system_score_codex":0.0014663435,"about_ca_system_score_gemma":0.000537019,"threshold_uncertainty_score":0.83900833},"labels":[],"label_agreement":null},{"id":"W2794252378","doi":"10.14740/gr925w","title":"Autologous Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients With Multiple Myeloma and Hematopoietic Stem Cell Transplantation","year":2018,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Multiple myeloma; Graft-versus-host disease; Transplantation; Complication; Immunosuppression; Disease; Surgery; Gastroenterology; Internal medicine","score_opus":0.025608856149074818,"score_gpt":0.29710603576690864,"score_spread":0.2714971796178338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794252378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833715,0.000023799885,0.000049986935,0.00039799558,0.00003340662,0.0010007893,0.000059839283,0.000014104629,0.00008295099],"genre_scores_gemma":[0.99944735,0.000010085275,0.00031398147,0.000026119651,0.000023838584,0.00006133778,0.000031207728,0.00002014107,0.00006592184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975736,0.0004261195,0.00026207487,0.00037892943,0.00063967507,0.0007195713],"domain_scores_gemma":[0.998705,0.0002472163,0.000069015936,0.00036139993,0.00031235395,0.00030500657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035371105,0.00016303317,0.00027169098,0.00026254513,0.00013965247,0.000012908494,0.00017354003,0.00004507897,0.000034363016],"category_scores_gemma":[0.00008458955,0.00010373012,0.000051962586,0.00025153803,0.0010235189,0.00007322736,0.00008828785,0.0004220698,0.000013399027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033187855,0.0009201807,0.96437144,0.00019296486,0.000021028964,0.00017110528,0.00026895505,0.0000012500807,0.00046732885,0.000004432128,0.000023981662,0.00036949557],"study_design_scores_gemma":[0.014991698,0.005579044,0.9781626,0.00020115748,0.0000374124,0.00009159627,0.00012445907,0.00022078714,0.00053984224,0.000005546859,0.0000027321958,0.00004313456],"about_ca_topic_score_codex":0.00007035508,"about_ca_topic_score_gemma":0.00044153686,"teacher_disagreement_score":0.018196158,"about_ca_system_score_codex":0.00007993753,"about_ca_system_score_gemma":0.0001276434,"threshold_uncertainty_score":0.42299914},"labels":[],"label_agreement":null},{"id":"W2795058342","doi":"10.1182/blood.v130.suppl_1.2010.2010","title":"Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Retrospective cohort study; Surgery; Proportional hazards model; Cancer; Progression-free survival; Overall survival","score_opus":0.02020551344361357,"score_gpt":0.3067184191123035,"score_spread":0.2865129056686899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795058342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364024,0.0012207988,2.6711814e-7,0.00070577505,0.0001273321,0.0020327053,0.0008406577,0.00006537866,0.0013668354],"genre_scores_gemma":[0.9793228,0.016414443,0.00020207367,0.00007899794,0.00008613766,0.0002252209,0.000294714,0.00004962521,0.003325977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754405,0.00011872424,0.00047946148,0.00056188647,0.00073363364,0.0005622144],"domain_scores_gemma":[0.9973042,0.00015409046,0.0006146411,0.0011530888,0.00038909726,0.00038487848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015485211,0.00033183437,0.0010126414,0.00012024747,0.00033468768,0.00002838643,0.00030968362,0.00008832209,0.0004764078],"category_scores_gemma":[0.0011994761,0.00024809252,0.00023861855,0.00017047595,0.00016099362,0.00014020015,0.00023802498,0.00021524461,0.000068448484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040678424,0.0018815806,0.9863798,0.00045615452,0.0010447763,0.00019661877,0.00007933867,7.250883e-8,0.00009505942,0.000010801798,0.0009603189,0.00848872],"study_design_scores_gemma":[0.024036976,0.00032875562,0.9674086,0.0014714756,0.00081824634,0.000001523528,0.000004759887,0.00000960974,0.005266801,0.000007614811,0.00044865193,0.00019697448],"about_ca_topic_score_codex":0.017559716,"about_ca_topic_score_gemma":0.014134292,"teacher_disagreement_score":0.02363019,"about_ca_system_score_codex":0.00031358877,"about_ca_system_score_gemma":0.000106569154,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W2795765610","doi":"10.1186/s13045-018-0589-1","title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway","year":2018,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Clinical trial; Hematology; PD-L1; Oncology; Immune system; Immunotherapy; Bioinformatics; Cancer research; Pharmacology; Internal medicine; Immunology; Biology","score_opus":0.12021023957209341,"score_gpt":0.43454534948459955,"score_spread":0.3143351099125061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795765610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041489262,0.951891,0.00036314467,0.0006473889,0.0011173557,0.0028264988,0.00007214392,0.000033258857,0.0015599683],"genre_scores_gemma":[0.08268453,0.8942865,0.018615114,0.00052262476,0.0024514126,0.00045746338,0.00019503369,0.00024282225,0.00054450805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992732,0.00233994,0.0024067299,0.0007249301,0.00070508476,0.0010913084],"domain_scores_gemma":[0.99364847,0.0021417101,0.002087448,0.00075821776,0.0006075181,0.0007566219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018895761,0.0007380463,0.004652233,0.0010189369,0.00024399412,0.000037406408,0.0008962319,0.0010122549,0.00030499566],"category_scores_gemma":[0.0017876975,0.0004220363,0.0007350821,0.00049481564,0.00038800226,0.00022779581,0.00035272268,0.002194713,0.00015821264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038254573,0.0038071456,0.0044949125,0.0049634376,0.0022797317,0.03901923,0.0019713403,0.000081765065,0.00032773725,0.0003398655,0.0034046895,0.9354847],"study_design_scores_gemma":[0.010450981,0.016365964,0.002322455,0.016160721,0.0009248385,0.039168794,0.0010183905,0.0006649943,0.00081504014,0.0008184771,0.910504,0.0007853395],"about_ca_topic_score_codex":0.00008875379,"about_ca_topic_score_gemma":0.00027106825,"teacher_disagreement_score":0.93469936,"about_ca_system_score_codex":0.0009954324,"about_ca_system_score_gemma":0.0023242568,"threshold_uncertainty_score":0.99982315},"labels":[],"label_agreement":null},{"id":"W2796115040","doi":"10.1182/blood.v130.suppl_1.741.741","title":"Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Internal medicine; Plasma cell leukemia; Pharmacokinetics; Immunology; Pharmacology; Oncology; Gastroenterology; Cancer research","score_opus":0.01649827824944232,"score_gpt":0.2736216586074257,"score_spread":0.2571233803579834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796115040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964296,0.00023588352,0.0000035203027,0.000054809305,0.00002697724,0.0025506578,0.00032283465,0.00005395994,0.00032173737],"genre_scores_gemma":[0.99735534,0.00035315656,0.0007615571,0.000021215872,0.00004302072,0.00008261262,0.0009933108,0.00006907529,0.00032069007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728775,0.00034837652,0.0005516925,0.00077219476,0.00059053604,0.0004494527],"domain_scores_gemma":[0.9974797,0.00026196594,0.0005027494,0.0012095127,0.0002573916,0.00028868444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031443333,0.0003912101,0.0006391752,0.00023609943,0.00033657387,0.00010345771,0.00021854394,0.0001230729,0.0000116550145],"category_scores_gemma":[0.00022572189,0.00027410372,0.000043516306,0.00013724713,0.00022454932,0.0005482519,0.000065113,0.0002636156,0.0000065302315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10528787,0.012202395,0.8671985,0.00004299941,0.00041586478,0.0006326941,0.0018629525,0.00000982385,0.00924512,1.8475147e-7,0.000015790658,0.0030857718],"study_design_scores_gemma":[0.099866055,0.013200252,0.85841185,0.00034539495,0.00016943103,0.0000054494117,0.0007098217,0.0006074074,0.02639139,0.0000017195736,0.000038094917,0.00025313025],"about_ca_topic_score_codex":0.003121612,"about_ca_topic_score_gemma":0.0015910019,"teacher_disagreement_score":0.01714627,"about_ca_system_score_codex":0.000051059276,"about_ca_system_score_gemma":0.00013414699,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W2796394809","doi":"10.1200/jco.2012.30.15_suppl.e18562","title":"Number needed to treat (NNT) as a measure of drug benefit: Lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (MM).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Number needed to treat; Lenalidomide; Multiple myeloma; Bortezomib; Refractory (planetary science); Thalidomide; Internal medicine; Confidence interval; Oncology; Surgery; Relative risk","score_opus":0.17794682662387246,"score_gpt":0.48414149840327464,"score_spread":0.3061946717794022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796394809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991038,0.00094227085,0.00005352477,0.0024854443,0.0011509698,0.0010222726,0.00005992106,0.000010226632,0.0032373313],"genre_scores_gemma":[0.9898697,0.0006028752,0.0065642954,0.00027422758,0.0012961752,0.000049754784,0.00001719959,0.000044396973,0.0012813429],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99527246,0.00038706308,0.0027373275,0.00026012483,0.0007304328,0.0006126217],"domain_scores_gemma":[0.9875498,0.00777501,0.0017768022,0.00042137248,0.0010947462,0.0013822771],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021035715,0.00030013628,0.0026722522,0.00023207573,0.00005680039,0.0000056231,0.00020197894,0.00043436544,0.00028416468],"category_scores_gemma":[0.008658401,0.00019931237,0.0013275195,0.00019562984,0.00020227728,0.000186974,0.000049741226,0.0003270841,0.00006216017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27688405,0.022286212,0.31522557,0.00017135075,0.004027063,0.00035701474,0.0013824176,0.000020416253,0.0052992087,0.00014905121,0.0079713,0.36622632],"study_design_scores_gemma":[0.29288283,0.12797491,0.38100994,0.00049115845,0.0041836123,0.000525945,0.0020443422,0.0001045639,0.04179914,0.00020083807,0.14831628,0.00046645102],"about_ca_topic_score_codex":0.00042247534,"about_ca_topic_score_gemma":0.000180449,"teacher_disagreement_score":0.36575988,"about_ca_system_score_codex":0.00062213687,"about_ca_system_score_gemma":0.0014429503,"threshold_uncertainty_score":0.9996921},"labels":[],"label_agreement":null},{"id":"W2797283462","doi":"10.4158/accr-2017-0194","title":"Solitary Extramedullary Plasmacytoma of the Thyroid Gland Following Head and Neck External Beam Radiotherapy","year":2018,"lang":"en","type":"article","venue":"AACE Clinical Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Thyroid; Plasmacytoma; Radiation therapy; Biopsy; External beam radiotherapy; Cervical lymphadenopathy; Radiology; Pathology; Multiple myeloma; Internal medicine","score_opus":0.04666997034755675,"score_gpt":0.39959973734467513,"score_spread":0.35292976699711837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797283462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396294,0.004116435,0.000033542652,0.00042341565,0.0004773604,0.00057529827,0.0000065865497,0.000029943389,0.00037447168],"genre_scores_gemma":[0.99602455,0.000361165,0.0023040087,0.0003872968,0.000492061,0.000012782083,0.0000053915187,0.000027393813,0.00038537555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978108,0.00014150178,0.0008167134,0.00043917508,0.00044693658,0.0003448675],"domain_scores_gemma":[0.9980566,0.00048652606,0.0002384764,0.0007186675,0.00009969432,0.00040006952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087369455,0.0001786453,0.0005029293,0.00004581713,0.00015698743,0.00001786441,0.000053295265,0.00015088366,0.000068493326],"category_scores_gemma":[0.00092708983,0.00010998417,0.0003479681,0.00012500687,0.00043594436,0.0000742698,0.000100818965,0.00031189615,0.0000040705345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006780261,0.00038907328,0.86555994,0.000039773407,0.00030948734,0.12237221,0.00010153928,2.5406084e-7,0.001442988,0.000003419765,0.00056162337,0.008541692],"study_design_scores_gemma":[0.006537395,0.0031037945,0.7966169,0.00042117175,0.00023029307,0.18573603,0.00007334511,0.00048975,0.004272196,0.00023504184,0.0020938125,0.00019027319],"about_ca_topic_score_codex":0.00042716984,"about_ca_topic_score_gemma":0.000116576244,"teacher_disagreement_score":0.06894301,"about_ca_system_score_codex":0.000040934618,"about_ca_system_score_gemma":0.00021496201,"threshold_uncertainty_score":0.44850242},"labels":[],"label_agreement":null},{"id":"W2799641062","doi":"10.1002/ajh.25134","title":"Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma","year":2018,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"Museums Association","keywords":"Placebo; Lenalidomide; Medicine; Clinical endpoint; Internal medicine; Multiple myeloma; Ixazomib; Quality of life (healthcare); Hazard ratio; Dexamethasone; Surgery; Gastroenterology; Randomized controlled trial; Confidence interval; Carfilzomib; Pathology","score_opus":0.06886877488201884,"score_gpt":0.3831735620730968,"score_spread":0.3143047871910779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799641062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942932,0.0021732962,0.00012673398,0.0012931894,0.00046129824,0.0014918022,0.000063951215,0.000023562054,0.000072945535],"genre_scores_gemma":[0.9973853,0.0001599337,0.001929092,0.00024475908,0.00014081881,0.000035219422,0.000031717547,0.00005957457,0.000013542529],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9890684,0.0035159718,0.004752568,0.00056963525,0.0012836087,0.0008098366],"domain_scores_gemma":[0.98323256,0.0074074534,0.0064821406,0.0010582497,0.0011108333,0.0007087767],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031713208,0.00048431032,0.0035890618,0.00061979704,0.00014508907,0.000012861262,0.00046145654,0.00017810869,0.00034631192],"category_scores_gemma":[0.009469239,0.00033765932,0.00043449507,0.0011252789,0.001545008,0.00015681631,0.00018110886,0.0010855342,0.000011580676],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27909696,0.016840357,0.62624854,0.00012859653,0.007242234,0.0014918203,0.017160894,0.000052714386,0.006364469,0.000037354588,0.0009892656,0.044346772],"study_design_scores_gemma":[0.43030068,0.08398566,0.3972766,0.0010142947,0.00096294796,0.0011590457,0.072248586,0.0009554719,0.010963785,0.00013200474,0.00026143587,0.0007394841],"about_ca_topic_score_codex":0.016509535,"about_ca_topic_score_gemma":0.0015881561,"teacher_disagreement_score":0.22897194,"about_ca_system_score_codex":0.00028462458,"about_ca_system_score_gemma":0.001200631,"threshold_uncertainty_score":0.99990755},"labels":[],"label_agreement":null},{"id":"W2800995228","doi":"10.3238/arztebl.2017.0168","title":"Mental Disorders in People Affected by Thalidomide","year":2017,"lang":"de","type":"article","venue":"Deutsches Ärzteblatt international","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Psychosocial; Mental health; Psychiatry; Population; Thalidomide; Prevalence of mental disorders; Depression (economics); Comorbidity; Internal medicine","score_opus":0.01772282325554998,"score_gpt":0.3307857956680471,"score_spread":0.31306297241249714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800995228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95035213,0.0035763176,0.000051387866,0.011423395,0.0036102617,0.0012585878,0.001108107,0.000057661884,0.02856214],"genre_scores_gemma":[0.98685837,0.0032354866,0.00016138186,0.00014257488,0.00063029194,0.00012627624,0.0019993247,0.00006322665,0.006783055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969024,0.00012540746,0.00049178675,0.00068166794,0.0010387474,0.00075999316],"domain_scores_gemma":[0.9982565,0.00017777954,0.00030619826,0.0007598507,0.00010874614,0.0003908911],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003522391,0.00042842215,0.0005041592,0.0003054575,0.0004018437,0.0003937284,0.0009254794,0.00022521574,0.0022510092],"category_scores_gemma":[0.00077764445,0.000407152,0.00024105354,0.00009817498,0.0002864025,0.00048325458,0.00045805337,0.0005430697,0.0019823688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010034036,0.0018207658,0.9574459,0.000059483606,0.0016759014,0.00014888882,0.00078835787,0.0000036813715,0.0016419507,0.00027715752,0.012923512,0.02221097],"study_design_scores_gemma":[0.013193775,0.00025170672,0.91499025,0.0003315934,0.00012235987,0.000011166273,0.0002025511,0.0065943142,0.0023789736,0.0001492219,0.061385304,0.00038876513],"about_ca_topic_score_codex":0.0034602312,"about_ca_topic_score_gemma":0.0036707318,"teacher_disagreement_score":0.048461795,"about_ca_system_score_codex":0.0005896674,"about_ca_system_score_gemma":0.00018513703,"threshold_uncertainty_score":0.99983805},"labels":[],"label_agreement":null},{"id":"W2801072147","doi":"10.14740/jh380w","title":"A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Bone marrow; Plasma cell neoplasm; Neoplasm; Plasma cell; Biopsy; Pathology; Internal medicine; Plasmacytoma","score_opus":0.030319942122012174,"score_gpt":0.3206572170741972,"score_spread":0.29033727495218503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801072147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886525,0.00022571794,0.000029173727,0.00031961707,0.0000779381,0.0002855418,0.00003511367,0.0000066584917,0.00015500534],"genre_scores_gemma":[0.99686456,0.000011288469,0.0027742619,0.000043477965,0.00010895021,0.0000063724797,0.0000031903762,0.000020021707,0.00016787423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985684,0.00010346392,0.0005471325,0.00015606027,0.0002847941,0.00034012867],"domain_scores_gemma":[0.9985408,0.00023086598,0.000325863,0.00022682895,0.00041069445,0.00026494608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001644858,0.00015012259,0.0006826222,0.0004084346,0.000038551225,0.000008162524,0.000090640264,0.00012165024,0.00023949942],"category_scores_gemma":[0.0003748555,0.000098199846,0.000107197695,0.00023783931,0.00022190541,0.000107242435,0.000038800135,0.00031185176,0.000032033455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053561567,0.0005371719,0.9484632,0.00012234226,0.00019301541,0.04135337,0.0009444592,2.5869025e-7,0.0018649335,0.00002330092,0.00037124893,0.00077054143],"study_design_scores_gemma":[0.028000932,0.013892407,0.69177884,0.0010304264,0.00011986234,0.18796232,0.0014873229,0.00012136443,0.07494779,0.00006152765,0.00037034403,0.00022685096],"about_ca_topic_score_codex":0.00019602918,"about_ca_topic_score_gemma":0.00096825574,"teacher_disagreement_score":0.25668436,"about_ca_system_score_codex":0.00007072479,"about_ca_system_score_gemma":0.00026993902,"threshold_uncertainty_score":0.40044734},"labels":[],"label_agreement":null},{"id":"W2803388295","doi":"10.1200/edbk_200841","title":"Global Approaches in Myeloma: Critical Trials That May Change Practice","year":2018,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Clinical trial; Multiple myeloma; Medicine; Intensive care medicine; Clinical Practice; Transplantation; Family medicine; Internal medicine","score_opus":0.6743432344979641,"score_gpt":0.6407470193452658,"score_spread":0.03359621515269828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803388295","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027758717,0.931737,0.00001793137,0.051815234,0.00056139514,0.002412786,0.00018946963,0.000021250898,0.013217185],"genre_scores_gemma":[0.00022368101,0.9586209,0.028371437,0.0059509757,0.003173001,0.0011655808,0.00044358862,0.000040782037,0.0020100437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911537,0.0036002137,0.0029077304,0.0009262686,0.0008081845,0.00060390413],"domain_scores_gemma":[0.95018494,0.04580584,0.0022877562,0.00060075,0.00046178876,0.000658937],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.006844279,0.00047081997,0.0066331145,0.00009072816,0.00007596571,0.000014927815,0.00036273262,0.00080867554,0.0007444971],"category_scores_gemma":[0.030431066,0.0003482622,0.0027559763,0.0005498784,0.004232052,0.00018821633,0.00018553667,0.0009968145,0.00022867788],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040788596,0.0048477,0.0061418307,0.00243037,0.0015226073,0.000021753816,0.00012296747,9.8408774e-9,5.0706115e-9,0.00079265784,0.045080885,0.93863136],"study_design_scores_gemma":[0.0016763658,0.0020512794,0.014816415,0.0018899887,0.0021111937,0.00013832978,0.00051105564,0.0000056260874,6.6385326e-8,0.00013167746,0.9764372,0.0002307985],"about_ca_topic_score_codex":0.00033801346,"about_ca_topic_score_gemma":0.000018787492,"teacher_disagreement_score":0.9384005,"about_ca_system_score_codex":0.0011009531,"about_ca_system_score_gemma":0.011429418,"threshold_uncertainty_score":0.99989694},"labels":[],"label_agreement":null},{"id":"W2805341297","doi":"10.1016/s1470-2045(18)30354-1","title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Amgen","keywords":"Carfilzomib; Medicine; Dosing; Refractory (planetary science); Interim analysis; Interim; Multiple myeloma; Lenalidomide; Internal medicine; Oncology; Clinical trial; Materials science","score_opus":0.05709115066878615,"score_gpt":0.3817391800709356,"score_spread":0.32464802940214943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805341297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957838,0.000081175676,0.000023705674,0.0005790176,0.000117425225,0.0016914011,0.000076941506,0.00002960743,0.0016169065],"genre_scores_gemma":[0.99871624,0.000030827185,0.0006907875,0.00008395552,0.00016351277,0.000087677894,0.00007943975,0.000021438922,0.00012612998],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99739134,0.0007033726,0.00056158745,0.00047466945,0.00038992765,0.00047912117],"domain_scores_gemma":[0.99730384,0.0012295457,0.000341312,0.000698348,0.00026729275,0.0001596783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010914977,0.0002289043,0.0011425557,0.00032264518,0.00011349536,0.000015405976,0.00021494218,0.000104952494,0.000031897453],"category_scores_gemma":[0.0010185365,0.00013951183,0.00008446286,0.00071994244,0.00045006795,0.00009747558,0.00013220856,0.00035404533,0.000009249703],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6216363,0.0037792565,0.35087758,0.000031561158,0.0020978758,0.00013965848,0.004238474,0.0000037567513,0.000959187,0.0000028104578,0.00022242405,0.01601115],"study_design_scores_gemma":[0.4303021,0.025733875,0.5401656,0.000060885224,0.00082039903,0.0000033373672,0.0011668913,0.0005168282,0.00030623176,0.0000024478593,0.0008066337,0.000114728224],"about_ca_topic_score_codex":0.0013233575,"about_ca_topic_score_gemma":0.0037639863,"teacher_disagreement_score":0.19133414,"about_ca_system_score_codex":0.0002881306,"about_ca_system_score_gemma":0.00016634232,"threshold_uncertainty_score":0.56891274},"labels":[],"label_agreement":null},{"id":"W2806219610","doi":"10.1101/340877","title":"Multiple myeloma immunoglobulin λ translocations portend poor prognosis","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Multiple Myeloma Research Foundation; American Cancer Society","keywords":"Chromosomal translocation; Multiple myeloma; Enhancer; Malignancy; Antibody; Biology; Cancer research; Myeloma protein; Immunology; Transcription factor; Genetics; Gene","score_opus":0.026319421486586024,"score_gpt":0.2684751265829475,"score_spread":0.24215570509636145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806219610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898596,0.0023379077,0.00090075406,0.0014213029,0.00081479823,0.0036830478,0.0009753304,0.00080696674,0.00007394244],"genre_scores_gemma":[0.98069245,0.00045098332,0.016200993,0.0002155684,0.00083242543,0.0013136138,0.0000105286645,0.00023754648,0.00004590014],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9954188,0.0001616225,0.0008605327,0.0014863134,0.000945386,0.0011273706],"domain_scores_gemma":[0.99553126,0.00011622441,0.00036460778,0.001781216,0.0012903654,0.0009163108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051796774,0.0008553536,0.0010199654,0.0005328344,0.00034849174,0.0002086083,0.0005746878,0.00076570426,0.00038007536],"category_scores_gemma":[0.0005904186,0.00081940345,0.00045321867,0.0007135832,0.00036747524,0.00015927466,0.00037492998,0.0010542327,0.00070970104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010644954,0.0033384135,0.35045448,0.0020290334,0.0035263258,0.0012063665,0.000044222805,0.000008666618,0.6346106,0.00011847951,0.003489769,0.00010915495],"study_design_scores_gemma":[0.0035166447,0.00035119025,0.68886083,0.00091030425,0.0005818788,2.3471061e-7,0.000004863727,0.00093032105,0.29812512,0.0000014673985,0.005949372,0.0007678019],"about_ca_topic_score_codex":0.00027094732,"about_ca_topic_score_gemma":0.000014976731,"teacher_disagreement_score":0.33840632,"about_ca_system_score_codex":0.0005384959,"about_ca_system_score_gemma":0.0016840065,"threshold_uncertainty_score":0.9994257},"labels":[],"label_agreement":null},{"id":"W2808562501","doi":"10.1038/s41409-018-0261-y","title":"Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival","year":2018,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Melphalan; Medicine; Amifostine; Multiple myeloma; Internal medicine; Oncology; Autologous stem-cell transplantation; Transplantation; Chemotherapy; Hematopoietic stem cell transplantation; Surgery; Urology","score_opus":0.019221915732473546,"score_gpt":0.27954197952241544,"score_spread":0.2603200637899419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808562501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750057,0.00010411016,0.021285348,0.0003978059,0.00012216947,0.0025361653,0.00036530054,0.00013113242,0.000052252384],"genre_scores_gemma":[0.99196273,0.00017451195,0.0063232426,0.000024509665,0.00004793453,0.0002837634,0.0009508644,0.00006236527,0.00017004985],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977232,0.00013663238,0.00064214156,0.00057994155,0.0004557548,0.00046230914],"domain_scores_gemma":[0.998662,0.0003530425,0.00023134975,0.00024214886,0.00030500512,0.0002064536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033408875,0.00040758692,0.0007366276,0.0002828519,0.00024276327,0.00004047996,0.00008091236,0.00021850014,0.000027117763],"category_scores_gemma":[0.000018414581,0.00031928008,0.0001414801,0.000276177,0.00020742671,0.00021543665,0.0000053469603,0.00018154549,0.000005466349],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04790505,0.000640529,0.10759864,0.0046285684,0.00062124466,0.00025857083,0.005873012,0.000024663466,0.80670583,0.000066874876,0.000004491757,0.025672546],"study_design_scores_gemma":[0.026743496,0.0031468666,0.53254056,0.00026692188,0.00090686866,0.00022677072,0.00021337219,0.0041832533,0.43136755,0.00007872813,0.000006312321,0.00031926553],"about_ca_topic_score_codex":0.0008451356,"about_ca_topic_score_gemma":0.0013412106,"teacher_disagreement_score":0.42494196,"about_ca_system_score_codex":0.00006294157,"about_ca_system_score_gemma":0.000109926325,"threshold_uncertainty_score":0.9999259},"labels":[],"label_agreement":null},{"id":"W2808748371","doi":"10.1016/j.clml.2018.06.018","title":"Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Janssen Pharmaceuticals; Takeda Oncology","keywords":"Medicine; Multinational corporation; Multiple myeloma; Clinical Practice; Oncology; Internal medicine; Family medicine; Law","score_opus":0.08839271982467811,"score_gpt":0.45732599415284003,"score_spread":0.3689332743281619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808748371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97627884,0.00010170055,0.000025301584,0.0006319591,0.0006068428,0.0038447587,0.00018961508,0.00014149408,0.018179478],"genre_scores_gemma":[0.9844839,0.0001841922,0.008227562,0.00018021297,0.0012455058,0.00043314035,0.00027029405,0.000086529304,0.0048886663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99001735,0.0014685049,0.0043957476,0.0017314721,0.0014779902,0.0009089193],"domain_scores_gemma":[0.9883669,0.0066602896,0.0011648476,0.001438746,0.0015678508,0.00080133614],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004158187,0.00062122906,0.0017790234,0.0006177092,0.00021777929,0.000056924728,0.00043606354,0.00040630493,0.00024014796],"category_scores_gemma":[0.015625596,0.0005047767,0.000977092,0.0011376885,0.0011985505,0.00037273573,0.00033935157,0.0004878622,0.0005293978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023029536,0.018309807,0.69665796,0.000035250057,0.0010507025,0.0011292121,0.00031700093,0.0000018784324,0.000038199927,0.0001719986,0.0009519074,0.25830653],"study_design_scores_gemma":[0.071335636,0.016033057,0.90163565,0.00029423216,0.00030395767,0.00008362451,0.00045030846,0.0021593864,0.00041183762,0.00011674509,0.0068269665,0.00034861523],"about_ca_topic_score_codex":0.0035320153,"about_ca_topic_score_gemma":0.006376223,"teacher_disagreement_score":0.25795794,"about_ca_system_score_codex":0.0026776097,"about_ca_system_score_gemma":0.0027780656,"threshold_uncertainty_score":0.99974036},"labels":[],"label_agreement":null},{"id":"W2808865397","doi":"10.1212/wnl.90.15_supplement.p1.368","title":"Safety and efficacy of IV cladribine versus alemtuzumab in aggressive multiple sclerosis: a retrospective cohort study (P1.368)","year":2018,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Alemtuzumab; Medicine; Cladribine; Multiple sclerosis; Retrospective cohort study; Cohort; Internal medicine; Oncology; Psychiatry","score_opus":0.0381069125733202,"score_gpt":0.31145815067915966,"score_spread":0.27335123810583944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808865397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964064,0.00013059216,0.000004107428,0.00033773005,0.00018268831,0.0019057441,0.000027050344,0.000031705447,0.00097399286],"genre_scores_gemma":[0.99942756,0.00015595266,0.000056441935,0.00010733938,0.0001080237,0.000067218105,0.000019349953,0.000023890787,0.000034206212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981455,0.00022899026,0.00033987884,0.0005594965,0.00031700695,0.0004091018],"domain_scores_gemma":[0.99865425,0.0004283867,0.0001612567,0.000423647,0.0001641331,0.0001683265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022166064,0.00018732983,0.00058953016,0.00021925854,0.00007560481,0.0000058932783,0.00010005461,0.00012272135,0.00011524338],"category_scores_gemma":[0.0012516849,0.00015714833,0.00005214512,0.0002779225,0.0004050733,0.00004610953,0.00014734878,0.0003377365,0.000027821585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045755167,0.0012483376,0.94764763,0.000011560116,0.0002691019,0.00044467545,0.00048095058,0.0000013430528,0.0009285819,0.000016708922,0.000041694122,0.0031542482],"study_design_scores_gemma":[0.04127478,0.019416958,0.93808335,0.000029329387,0.00009002876,0.00003683839,0.000044223063,0.00046427723,0.0003969713,0.000009397853,0.000072260955,0.00008157119],"about_ca_topic_score_codex":0.00093054614,"about_ca_topic_score_gemma":0.0019550798,"teacher_disagreement_score":0.018168619,"about_ca_system_score_codex":0.00008580942,"about_ca_system_score_gemma":0.000074706695,"threshold_uncertainty_score":0.6408323},"labels":[],"label_agreement":null},{"id":"W2808959977","doi":"10.1093/neuonc/noy059.455","title":"MBRS-10. RISK STRATIFICATION OF MEDULLOBLASTOMA ON THE BASIS OF MOLECULAR SUBGROUPING; AN EXPERIENCE FROM A SINGLE TERTIARY CARE CENTER FROM A DEVELOPING COUNTRY","year":2018,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Medicine; Risk stratification; Single Center; Internal medicine; Pediatrics; Oncology; Pathology","score_opus":0.0309419376267085,"score_gpt":0.3223927517377767,"score_spread":0.2914508141110682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808959977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762404,0.00009221788,0.00028881396,0.0004596084,0.00012611429,0.00047459546,0.00020186913,0.000023601204,0.0007091591],"genre_scores_gemma":[0.99708813,0.000027646109,0.0018871408,0.0006198437,0.000099468154,0.00006314571,0.00019019029,0.000021585989,0.0000028733054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982695,0.00038386422,0.00034617813,0.00039098194,0.00036055426,0.00024890676],"domain_scores_gemma":[0.99831665,0.00049846544,0.00023440916,0.0005500449,0.00028129813,0.00011915579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008698153,0.00015804017,0.00030567,0.00008030084,0.000089558554,0.0000108327595,0.00021137785,0.00012743809,0.0002961038],"category_scores_gemma":[0.00046848546,0.0001130219,0.00006201251,0.00015176124,0.00033888358,0.00006730856,0.000063002306,0.0001733218,0.000023777453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010765094,0.00052874995,0.08332501,0.000018957084,0.0001112584,0.00009675652,0.005251587,9.3834313e-7,0.8859774,0.000042298932,0.00008983659,0.02348068],"study_design_scores_gemma":[0.00191683,0.0024824217,0.14799759,0.0000961649,0.000064609616,0.000008948892,0.0022001013,0.0003941851,0.8434219,0.00006148983,0.0012675772,0.000088227454],"about_ca_topic_score_codex":0.0012249735,"about_ca_topic_score_gemma":0.0005393555,"teacher_disagreement_score":0.06467257,"about_ca_system_score_codex":0.00018279394,"about_ca_system_score_gemma":0.00024905312,"threshold_uncertainty_score":0.46088994},"labels":[],"label_agreement":null},{"id":"W2809484902","doi":"10.1016/j.ijrobp.2018.05.009","title":"Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group","year":2018,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Radiation therapy; Lymphoma; Plasma cell neoplasm; Guideline; Plasmacytoma; Oncology; Internal medicine; Radiology; Pathology","score_opus":0.08653212989879262,"score_gpt":0.4258540694480942,"score_spread":0.33932193954930157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809484902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009379432,0.96742487,0.003569993,0.0062007136,0.008426072,0.0026547825,0.0020013505,0.00008233924,0.00026046275],"genre_scores_gemma":[0.0052531892,0.9650472,0.0057577863,0.0015332988,0.016660469,0.0002077502,0.0053434437,0.00011231134,0.0000845854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526525,0.00070473645,0.0021585573,0.0006876578,0.00069697795,0.00048684858],"domain_scores_gemma":[0.98962754,0.004741892,0.003045236,0.00038067508,0.0019013481,0.0003033304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014531142,0.00065168523,0.0018484254,0.00043097528,0.00025203757,0.00011215751,0.0010506161,0.00090114615,0.000089467845],"category_scores_gemma":[0.0026976322,0.00045027022,0.00094809773,0.00023117119,0.00041132007,0.00043869994,0.0001906865,0.0006168369,0.000055796274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016215784,0.00066076533,0.011197736,0.00008593886,0.004595638,0.000056005734,0.00022667495,0.0000070894885,0.00003632102,0.00063119904,0.012519208,0.96836185],"study_design_scores_gemma":[0.0172975,0.0024079755,0.004138642,0.0006686069,0.0007791613,0.000488337,0.000053625474,0.0032383553,0.00007144819,0.0024013869,0.9681166,0.00033839396],"about_ca_topic_score_codex":0.00013667124,"about_ca_topic_score_gemma":0.000031653377,"teacher_disagreement_score":0.9680235,"about_ca_system_score_codex":0.0026733228,"about_ca_system_score_gemma":0.0022684033,"threshold_uncertainty_score":0.9997949},"labels":[],"label_agreement":null},{"id":"W2810897454","doi":"10.7759/cureus.2881","title":"Acute Kidney Injury in a 31-year-old Male as a Consequence of Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Cureus","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina; Regina General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Acute kidney injury; Pleural effusion; Creatinine; Radiology; Lesion; Bruise; Biopsy; Hemothorax; Bone marrow; Pathology; Surgery; Internal medicine; Pneumothorax","score_opus":0.026534376843337294,"score_gpt":0.336261842696616,"score_spread":0.3097274658532787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810897454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844291,0.000073982555,0.00001196815,0.00055431994,0.000099433266,0.0005643276,0.00016112995,0.0000340022,0.014071689],"genre_scores_gemma":[0.9920457,0.00010707861,0.0018591873,0.00042136523,0.00010118145,0.000054275726,0.00005404776,0.000020036305,0.005337152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986932,0.00004226876,0.00025932566,0.0002933536,0.00031217837,0.00039961908],"domain_scores_gemma":[0.9988492,0.000054836793,0.00006691433,0.00047055195,0.00016778687,0.00039072454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013405806,0.00015225609,0.0003103756,0.00012851636,0.000041432562,0.000010292462,0.00015132395,0.00010464207,0.0010383099],"category_scores_gemma":[0.00087904895,0.0001270513,0.000075393065,0.0002792565,0.0003201116,0.00009213283,0.00009561868,0.00016028673,0.0005933171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004224324,0.0010196326,0.7221917,0.0001448522,0.00046789413,0.0030740977,0.000637227,6.321391e-8,0.2471395,0.000444963,0.015754644,0.0049011055],"study_design_scores_gemma":[0.018250452,0.005509298,0.5092416,0.0008042387,0.00018330752,0.0013378258,0.00022380329,0.0006741646,0.44306144,0.00073450705,0.019502755,0.00047664865],"about_ca_topic_score_codex":0.0011548803,"about_ca_topic_score_gemma":0.000090692236,"teacher_disagreement_score":0.21295014,"about_ca_system_score_codex":0.00013479563,"about_ca_system_score_gemma":0.00042131147,"threshold_uncertainty_score":0.9998749},"labels":[],"label_agreement":null},{"id":"W2810970248","doi":"10.3324/haematol.2017.185991","title":"A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"Takeda Oncology","keywords":"Ixazomib; Medicine; Melphalan; Prednisone; Multiple myeloma; Maintenance therapy; Internal medicine; Adverse effect; Surgery; Lenalidomide; Chemotherapy; Carfilzomib","score_opus":0.08065535250103235,"score_gpt":0.3476845975581068,"score_spread":0.2670292450570745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810970248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439824,0.00020104786,0.00036123773,0.0010725221,0.00021355324,0.0030059798,0.000066053726,0.00026987641,0.00041148596],"genre_scores_gemma":[0.9955547,0.00005679845,0.0027591016,0.00027258822,0.00011924804,0.0005163488,0.00043234034,0.000055646855,0.0002332606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960208,0.0003828724,0.00091204525,0.00094911736,0.00070632406,0.0010288672],"domain_scores_gemma":[0.9981769,0.0002792483,0.0002797658,0.00056086073,0.00018527695,0.00051794853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005707502,0.00050714856,0.0009783105,0.0003464924,0.0003727189,0.00007208395,0.00024597024,0.00027552203,0.00016424998],"category_scores_gemma":[0.0009529699,0.00039979123,0.00016390425,0.0006963434,0.0002705406,0.00030237588,0.00011349944,0.00042526127,0.000120812445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009119419,0.029484352,0.6853674,0.00021417446,0.0006368076,0.0042780396,0.00878144,0.000017544853,0.21788241,0.000039641647,0.0073008714,0.0368779],"study_design_scores_gemma":[0.2558529,0.048469745,0.4914957,0.0018004203,0.0007990853,0.0013440957,0.006000483,0.028449722,0.15981577,0.0004095495,0.003485723,0.002076812],"about_ca_topic_score_codex":0.0011682012,"about_ca_topic_score_gemma":0.0013766221,"teacher_disagreement_score":0.24673347,"about_ca_system_score_codex":0.00031037195,"about_ca_system_score_gemma":0.00011363393,"threshold_uncertainty_score":0.9998454},"labels":[],"label_agreement":null},{"id":"W2811051271","doi":"10.5045/br.2018.53.2.172","title":"Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Myeloid leukemia; Imatinib; Peripheral neuropathy; Nilotinib; Oncology; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.0759532459153459,"score_gpt":0.3850054139166126,"score_spread":0.30905216800126667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811051271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911706,0.0006488462,0.000048265374,0.0006779795,0.000048015852,0.002311404,0.000042465625,0.000100297584,0.0049521187],"genre_scores_gemma":[0.99115676,0.00022481091,0.000691669,0.00010344474,0.0007391943,0.00054343144,0.00011772395,0.00007987093,0.0063431147],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966399,0.00029243223,0.0002134209,0.0005087816,0.0011659702,0.0011794937],"domain_scores_gemma":[0.9974875,0.00041917386,0.000046744663,0.0005228191,0.0011247221,0.00039902775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010786029,0.00020413127,0.00032154378,0.00022979791,0.0005149419,0.00009033715,0.00023732966,0.00011762224,0.0004967006],"category_scores_gemma":[0.0008064662,0.00013561783,0.00010452724,0.0006034154,0.00055482105,0.0000884937,0.00007895425,0.00048903376,0.00012656162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030660387,0.008556119,0.2455619,0.00071733154,0.005521848,0.0025075518,0.00306067,0.000007936016,0.3756991,0.0006554587,0.024900325,0.30215138],"study_design_scores_gemma":[0.09794174,0.08783399,0.5676116,0.0007458493,0.00018220117,0.00028902065,0.00033917205,0.008267179,0.2085138,0.00032731603,0.027209613,0.0007385675],"about_ca_topic_score_codex":0.00014195211,"about_ca_topic_score_gemma":0.00014261236,"teacher_disagreement_score":0.32204965,"about_ca_system_score_codex":0.000491726,"about_ca_system_score_gemma":0.0015993513,"threshold_uncertainty_score":0.5530334},"labels":[],"label_agreement":null},{"id":"W2811073750","doi":"10.1111/ijlh.12882","title":"Recent advances in cytogenetic characterization of multiple myeloma","year":2018,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Dong-A University","keywords":"Multiple myeloma; Fluorescence in situ hybridization; Cytogenetics; Risk stratification; Bone marrow; Microarray; Medicine; Pathology; Oncology; Bioinformatics; Biology; Internal medicine; Computational biology; Gene; Genetics; Chromosome; Gene expression","score_opus":0.04402766022750909,"score_gpt":0.39272789162502386,"score_spread":0.34870023139751477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811073750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069391667,0.9914863,0.00004438327,0.0000925576,0.00085357716,0.0003504622,0.0001601602,0.0000051400284,0.00006821242],"genre_scores_gemma":[0.0021915387,0.99684566,0.00040142602,0.000035010944,0.00030585745,0.000019414072,0.00015303747,0.000030181749,0.000017854058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739426,0.00024118925,0.0013904251,0.00020122956,0.0005729982,0.0001999235],"domain_scores_gemma":[0.9962124,0.00020883471,0.001462485,0.00018447035,0.0017932837,0.00013852057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003119778,0.00023335111,0.001580798,0.0009178802,0.000012917113,0.00001003905,0.0003441994,0.00023107628,0.00019405055],"category_scores_gemma":[0.00073757453,0.00017597091,0.00023348894,0.00035127474,0.0001289942,0.00015911453,0.000064196916,0.00031716123,0.00003382692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005435797,0.0006079609,0.0114384405,0.0033197019,0.0008986776,0.0018712028,0.00005471069,2.7815773e-7,0.00022075625,0.00008187194,0.000066834735,0.980896],"study_design_scores_gemma":[0.001828885,0.00034926212,0.0012130054,0.010043613,0.00017900318,0.0016148936,0.00000994825,0.0000068271443,0.00072511646,0.000018034592,0.9838982,0.000113174705],"about_ca_topic_score_codex":9.4353305e-7,"about_ca_topic_score_gemma":0.0000116247875,"teacher_disagreement_score":0.9838314,"about_ca_system_score_codex":0.00026683277,"about_ca_system_score_gemma":0.0011177488,"threshold_uncertainty_score":0.71758854},"labels":[],"label_agreement":null},{"id":"W2859167663","doi":"10.1200/jop.18.00377","title":"Infusion Reactions With Monoclonal Antibody Therapy in Myeloma: Learning From Experience","year":2018,"lang":"en","type":"letter","venue":"Journal of Oncology Practice","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Monoclonal antibody; Multiple myeloma; Monoclonal antibody therapy; Monoclonal; Antibody therapy; Antibody; Oncology; Immunology","score_opus":0.0631624295680639,"score_gpt":0.4174068901456015,"score_spread":0.3542444605775376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2859167663","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5688317,0.0007753546,0.00014167155,0.42259687,0.0005184238,0.0004685062,0.000005701588,0.000018212826,0.0066435803],"genre_scores_gemma":[0.38085702,0.027140053,0.07192268,0.4840942,0.0269705,0.00013634772,0.00070955744,0.00032492512,0.0078447275],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967949,0.0008706275,0.0007031161,0.00031814212,0.0008916817,0.00042157524],"domain_scores_gemma":[0.99448127,0.0026166565,0.0015684131,0.00026979097,0.00088796666,0.00017589664],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007393275,0.00028062332,0.0007925207,0.0005238171,0.00014052384,0.00004286346,0.00021152403,0.00072854146,0.0005158517],"category_scores_gemma":[0.002258713,0.00018971773,0.00013352808,0.00028915278,0.00022999906,0.0006382462,0.00005586957,0.0054904795,0.00006622884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050945573,0.0047824574,0.1973485,0.00011358842,0.0042502824,0.2320693,0.006724103,0.00003370146,0.018970843,0.0000033042863,0.37424177,0.11051656],"study_design_scores_gemma":[0.0069037485,0.010845379,0.046534672,0.0003530832,0.00018527031,0.007772364,0.0007484122,0.000044105233,0.00023880372,0.0000107504975,0.9262124,0.00015102657],"about_ca_topic_score_codex":0.0006369428,"about_ca_topic_score_gemma":0.000030766383,"teacher_disagreement_score":0.5519706,"about_ca_system_score_codex":0.00067756744,"about_ca_system_score_gemma":0.00148853,"threshold_uncertainty_score":0.9968039},"labels":[],"label_agreement":null},{"id":"W2884857006","doi":"10.1097/brs.0000000000002777","title":"Solitary Plasmacytoma of Bone of the Spine","year":2018,"lang":"en","type":"article","venue":"Spine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Incidence (geometry); Proportional hazards model; Logistic regression; Population; Epidemiology; Survival analysis; Internal medicine; Multiple myeloma; Surgery; Plasmacytoma; Retrospective cohort study","score_opus":0.024383281828082734,"score_gpt":0.32180344402878525,"score_spread":0.2974201622007025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884857006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910739,0.0002910943,0.000024081948,0.0009534445,0.00008766569,0.0002897005,0.000017128372,0.000012473365,0.0072505223],"genre_scores_gemma":[0.9960608,0.000025893882,0.0014474613,0.00007492806,0.00015300512,0.0000058284627,0.000010851855,0.000010268005,0.0022109891],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991846,0.000019457008,0.00021188513,0.00011294082,0.0002901321,0.00018096867],"domain_scores_gemma":[0.99930227,0.0000071588534,0.00006957972,0.00038459388,0.00015172575,0.00008465316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000958724,0.00007803904,0.0002311045,0.000060822087,0.00003189829,0.0000011954595,0.00007923808,0.0000342044,0.00033537703],"category_scores_gemma":[0.00017570384,0.0000446506,0.000093412615,0.00019052158,0.00027369408,0.000022143588,0.00008084069,0.000071139795,0.000038251572],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012376868,0.0018922458,0.20174041,0.0009172081,0.0007923312,0.00016470064,0.00050175196,0.0000014011022,0.7314639,0.0018548182,0.0073187025,0.0521148],"study_design_scores_gemma":[0.0027613826,0.0011567331,0.69422764,0.00014666145,0.000041646552,0.000036197896,0.000023748726,0.00018964779,0.29994863,0.000094501134,0.0013350351,0.000038210823],"about_ca_topic_score_codex":0.00015847497,"about_ca_topic_score_gemma":0.000048258218,"teacher_disagreement_score":0.4924872,"about_ca_system_score_codex":0.0000223936,"about_ca_system_score_gemma":0.00008337273,"threshold_uncertainty_score":0.36721432},"labels":[],"label_agreement":null},{"id":"W2886598432","doi":"10.1186/s13643-018-0785-7","title":"Evidence-based guidelines for physiotherapy management of patients with multiple myeloma: study protocol","year":2018,"lang":"en","type":"article","venue":"Systematic Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University; Laurentian University; Health Sciences North","funders":"Northern Ontario Academic Medicine Association; Cancer Care Ontario","keywords":"Medicine; MEDLINE; CINAHL; Protocol (science); Cochrane Library; Critical appraisal; Guideline; Physical therapy; Systematic review; Inclusion and exclusion criteria; Randomized controlled trial; Alternative medicine; Surgery; Nursing; Psychological intervention; Pathology","score_opus":0.21032215759021528,"score_gpt":0.4714553971654293,"score_spread":0.261133239575214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886598432","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02593411,0.00040581802,0.0032396899,0.00009549194,0.00004662312,0.9701175,0.000011271289,0.00003472243,0.00011474777],"genre_scores_gemma":[0.16005328,0.000027474449,0.030328732,0.00012035178,0.00010143186,0.80880374,0.000015112452,0.000044462955,0.0005054109],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968831,0.0003834139,0.0013658643,0.00035873448,0.00074281066,0.0002661067],"domain_scores_gemma":[0.9966414,0.0002500825,0.0006738599,0.0009344045,0.001377628,0.00012261306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015159808,0.00027958603,0.001323748,0.000100569734,0.00008096694,0.000018945186,0.00018489675,0.000029977386,0.00006898143],"category_scores_gemma":[0.0009290319,0.00013038065,0.00020538537,0.00027677458,0.000059191665,0.00009055831,0.000028132288,0.00003674855,0.0000728702],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004928138,0.004915656,0.24966958,0.7119114,0.001568597,0.000014715323,0.00032255202,0.0000015126027,0.000109049666,0.000015174609,0.0031638371,0.02337981],"study_design_scores_gemma":[0.10094975,0.037113257,0.4016714,0.43362898,0.0020226012,0.000004500367,0.0008672478,0.0042026467,0.0018311922,0.00002743144,0.016798235,0.0008827425],"about_ca_topic_score_codex":0.00002049998,"about_ca_topic_score_gemma":0.000014952669,"teacher_disagreement_score":0.2782824,"about_ca_system_score_codex":0.00008024684,"about_ca_system_score_gemma":0.000060055838,"threshold_uncertainty_score":0.5316768},"labels":[],"label_agreement":null},{"id":"W2886628870","doi":"10.1182/blood-2018-05-852798","title":"Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; National Institute of General Medical Sciences; Henry and Marilyn Taub Foundation; Edward P. Evans Foundation; Howard Hughes Medical Institute","keywords":"Thalidomide; Lenalidomide; In vivo; Cereblon; Pharmacology; Multiple myeloma; Medicine; Cancer research; Chemistry; Immunology; Biology; Genetics; Biochemistry","score_opus":0.03244490506308645,"score_gpt":0.3242023924631409,"score_spread":0.29175748740005447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886628870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996379,0.000064067695,0.000015159661,0.001538605,0.000022218677,0.00074427284,0.00003272911,0.000013428009,0.0011905043],"genre_scores_gemma":[0.998047,0.00001079954,0.0005493558,0.00091186597,0.00005565068,0.00003302705,0.0000024494836,0.000011397311,0.00037843682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989461,0.00007995135,0.00014223353,0.00030167506,0.00019957608,0.0003304688],"domain_scores_gemma":[0.9993668,0.00011253456,0.000015724716,0.00014161576,0.00009412736,0.00026917618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023376547,0.00011668751,0.00022794631,0.000204953,0.000032342046,0.000016628268,0.000034037075,0.000044686836,0.000103156126],"category_scores_gemma":[0.00040735785,0.0000978452,0.00001975076,0.0002729566,0.000036855712,0.000040092767,0.00009058997,0.00008371605,0.00011744058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013195522,0.0021806913,0.42341754,0.00009586626,0.000128398,0.0014010399,0.0118861245,0.0000037703085,0.5571458,0.00008183793,0.00061540946,0.0017240057],"study_design_scores_gemma":[0.0056972895,0.0005958106,0.49011064,0.00015225008,0.000016470787,0.00004265625,0.00037274096,0.00023962987,0.5021426,0.0000046961723,0.00051833515,0.00010687175],"about_ca_topic_score_codex":0.00046156105,"about_ca_topic_score_gemma":0.0011593156,"teacher_disagreement_score":0.0666931,"about_ca_system_score_codex":0.000041585696,"about_ca_system_score_gemma":0.00006633045,"threshold_uncertainty_score":0.39900115},"labels":[],"label_agreement":null},{"id":"W2887009286","doi":"10.1158/1538-7445.am2018-3006","title":"Abstract 3006: Molecular characterization of baseline and serial multiple myeloma patients from the MMRF CoMMpass study","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exome; Multiple myeloma; Medicine; Cohort; Oncology; Cancer; Internal medicine; Malignancy; Interim analysis; Exome sequencing; Clinical trial; Gene; Genetics; Mutation; Biology","score_opus":0.061295271302341595,"score_gpt":0.38951777232327417,"score_spread":0.3282225010209326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887009286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693847,0.0000972133,0.000022102655,0.00061654404,0.0001027254,0.0017145732,0.00038129697,0.000015026619,0.000112069494],"genre_scores_gemma":[0.99882495,0.00008611242,0.00004144748,0.00006801536,0.0003780837,0.0001866096,0.00031089818,0.000026837539,0.00007706095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977416,0.00033011485,0.00025998184,0.00033194176,0.00095408055,0.0003822947],"domain_scores_gemma":[0.99803096,0.0003484769,0.00006697378,0.00046792655,0.0008793649,0.00020627378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007218376,0.00012949992,0.00024156815,0.000102905746,0.00021398811,0.000042477815,0.00018103298,0.000062308376,0.00049020053],"category_scores_gemma":[0.00062123674,0.00008532282,0.000037244205,0.00029868857,0.0003349205,0.00008573503,0.00018058944,0.0002841129,0.000035858386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023474684,0.0008843337,0.6981141,0.0000386217,0.00020830045,0.000032089556,0.0008200473,2.3529779e-7,0.27348298,0.0000027363153,0.00031137018,0.023757711],"study_design_scores_gemma":[0.0059013334,0.00093226874,0.9246195,0.00009128246,0.000026156114,4.7426985e-7,0.00022273215,0.0001875899,0.06720475,0.000010409552,0.00073874823,0.000064761356],"about_ca_topic_score_codex":0.0040809694,"about_ca_topic_score_gemma":0.00066744816,"teacher_disagreement_score":0.22650538,"about_ca_system_score_codex":0.00010454544,"about_ca_system_score_gemma":0.00018684176,"threshold_uncertainty_score":0.6169232},"labels":[],"label_agreement":null},{"id":"W2887662642","doi":"10.1158/1557-3265.hemmal17-ia06","title":"Abstract IA06: Intratumor heterogeneity and its role in therapeutic escape in multiple myeloma","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD38; Unfolded protein response; Biology; Plasma cell; Cancer research; Bortezomib; XBP1; Multiple myeloma; Bone marrow; Stem cell; Endoplasmic reticulum; Immunology; CD34; Cell biology","score_opus":0.2986004711141817,"score_gpt":0.5336421423536849,"score_spread":0.2350416712395032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887662642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912429,0.004226852,5.822255e-7,0.0021076389,0.00009553816,0.0010942786,0.000024677542,0.000016565877,0.001190959],"genre_scores_gemma":[0.99752694,0.0015487772,0.000027034963,0.00008479697,0.00023683364,0.00028961568,0.000007929307,0.000031077805,0.00024701166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966994,0.00036681557,0.00057772634,0.0006921792,0.0007438395,0.00092003384],"domain_scores_gemma":[0.99736124,0.0010119226,0.00008822507,0.0007649468,0.00021218004,0.0005614673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003035971,0.00018210085,0.00053104263,0.00026903528,0.0002797815,0.00013491057,0.0004063482,0.00022310723,0.00019497503],"category_scores_gemma":[0.002858333,0.00014527443,0.00010132688,0.00019499176,0.00050532277,0.00019482018,0.00033855604,0.0015396493,0.00012207893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022595786,0.00067572825,0.88248706,0.00009143187,0.00006139165,0.00049099524,0.000051849576,0.0000018499092,0.0025697497,0.000036395417,0.000039391627,0.111234576],"study_design_scores_gemma":[0.007539456,0.00038549298,0.98698455,0.0002473361,0.000007104283,0.000007708515,0.000068800065,0.0020208806,0.0019855544,0.00033406264,0.00029870844,0.00012033539],"about_ca_topic_score_codex":0.0029330284,"about_ca_topic_score_gemma":0.013309191,"teacher_disagreement_score":0.11111424,"about_ca_system_score_codex":0.00028155636,"about_ca_system_score_gemma":0.00055434793,"threshold_uncertainty_score":0.74268407},"labels":[],"label_agreement":null},{"id":"W2888841176","doi":"10.3390/jcm7090253","title":"Abducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial Plasmacytoma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston","keywords":"Medicine; Plasmacytoma; Clivus; Presentation (obstetrics); Abducens nerve; Multiple myeloma; Palsy; Lesion; Pathology; Anatomy; Radiology; Skull; Internal medicine","score_opus":0.1002144858853781,"score_gpt":0.47570955723266317,"score_spread":0.3754950713472851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888841176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924761,0.0002818972,0.00015396682,0.0039900285,0.00079770613,0.00031072574,0.0000076187243,0.000009275337,0.001972648],"genre_scores_gemma":[0.99181426,0.00045394103,0.0021859712,0.000326262,0.0050730007,0.0000023749533,0.000008191386,0.000018484627,0.000117510215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965289,0.0002535253,0.0018485998,0.00020003326,0.00090850703,0.00026040946],"domain_scores_gemma":[0.99514806,0.0021303135,0.00085522456,0.00021048024,0.000971036,0.00068486144],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015871539,0.00016350606,0.0010209286,0.00022423523,0.00005638474,0.000007706477,0.000123478,0.00016139999,0.00047497614],"category_scores_gemma":[0.01401888,0.00010181701,0.00018232016,0.00019063389,0.0009283981,0.0001392854,0.00005374642,0.00050801964,0.000023988712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025105331,0.0012053844,0.65195024,0.0002114033,0.00090105424,0.0026702953,0.00073987717,4.1812643e-7,0.006327244,0.00007400366,0.0031016155,0.30771312],"study_design_scores_gemma":[0.03219879,0.02270191,0.93229705,0.00082924595,0.00040988423,0.001924245,0.00034733216,0.000832757,0.0064311633,0.0004946347,0.0014355058,0.00009746532],"about_ca_topic_score_codex":0.000102165555,"about_ca_topic_score_gemma":0.000030691925,"teacher_disagreement_score":0.30761567,"about_ca_system_score_codex":0.000025434518,"about_ca_system_score_gemma":0.0002809494,"threshold_uncertainty_score":0.9942865},"labels":[],"label_agreement":null},{"id":"W2889097815","doi":"10.1016/j.clml.2018.07.155","title":"Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine; Milestone; Progression-free survival; Cancer research; Overall survival","score_opus":0.07937008621541364,"score_gpt":0.3886256237391009,"score_spread":0.3092555375236873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889097815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180394,0.00041814923,0.000014303262,0.00011697966,0.0016682573,0.0028635436,0.000088562825,0.00010067977,0.0029255848],"genre_scores_gemma":[0.9970708,0.00011237628,0.00061800133,0.00011815617,0.00049590896,0.00019008544,0.00004823418,0.00013075022,0.0012157126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914549,0.0013395939,0.0028963452,0.0013636616,0.0017512104,0.001194271],"domain_scores_gemma":[0.9914396,0.0034405256,0.0010634849,0.0025989807,0.00071132876,0.0007460797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020631396,0.00071862334,0.0021271799,0.00045590432,0.00024150964,0.000033249504,0.0010439077,0.0006398049,0.00046260012],"category_scores_gemma":[0.0072219134,0.0005294547,0.0009146687,0.0013497731,0.001525659,0.00018721572,0.0006497025,0.00079698773,0.00020294153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16276519,0.016439432,0.25331298,0.00026653626,0.0026812064,0.0009586857,0.0031606057,0.000007903982,0.0063195964,0.00018959334,0.0016006371,0.55229765],"study_design_scores_gemma":[0.2220444,0.01357011,0.75194895,0.00040685578,0.0004141516,0.000033590502,0.0023263923,0.0008015936,0.0069677946,0.000065028304,0.0010359467,0.00038517284],"about_ca_topic_score_codex":0.0020419394,"about_ca_topic_score_gemma":0.0012708042,"teacher_disagreement_score":0.5519125,"about_ca_system_score_codex":0.0019625998,"about_ca_system_score_gemma":0.0030824456,"threshold_uncertainty_score":0.9997157},"labels":[],"label_agreement":null},{"id":"W2889200524","doi":"10.1177/1744806918797042","title":"Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain","year":2018,"lang":"en","type":"article","venue":"Molecular Pain","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neuropathic pain; Bortezomib; Calcitonin gene-related peptide; Peripheral neuropathy; Nerve fiber; Sensory nerve; Internal medicine; Anesthesia; Pathology; Multiple myeloma; Sensory system; Neuroscience; Endocrinology; Psychology; Neuropeptide; Anatomy","score_opus":0.01641952736911186,"score_gpt":0.27560526247429096,"score_spread":0.2591857351051791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889200524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943421,0.000043174397,0.004458226,0.0002647698,0.00002909199,0.0007857412,0.000003136408,0.000032618565,0.0000411647],"genre_scores_gemma":[0.9960068,0.000030671443,0.0019799147,0.0017858872,0.00004590553,0.00003948205,0.00006144252,0.00003728752,0.00001262866],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9955456,0.0028525984,0.00036845042,0.00048662644,0.00038691875,0.0003597851],"domain_scores_gemma":[0.99885625,0.0002372687,0.00014074452,0.00034563514,0.00023140757,0.00018868431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017105063,0.00022397771,0.0004423232,0.00015441822,0.00006881992,0.000015854803,0.00009711443,0.00013041169,0.000016271122],"category_scores_gemma":[0.002069828,0.00016276435,0.00005347295,0.00035204762,0.00017143869,0.000040352897,0.00006800028,0.0002899928,0.0000033625217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044417367,0.0014829214,0.19533384,0.00016497826,0.00011752583,0.0013389596,0.00027629267,0.0000018207706,0.62865144,0.00014080782,0.000021933993,0.16802774],"study_design_scores_gemma":[0.009862426,0.0877412,0.8344301,0.00038646313,0.000098466386,0.00003404977,0.000061192186,0.010118211,0.05542081,0.0011208628,0.00018011236,0.0005461207],"about_ca_topic_score_codex":0.000072998715,"about_ca_topic_score_gemma":0.00005154284,"teacher_disagreement_score":0.63909626,"about_ca_system_score_codex":0.000053093056,"about_ca_system_score_gemma":0.000076524084,"threshold_uncertainty_score":0.6637338},"labels":[],"label_agreement":null},{"id":"W2890273388","doi":"10.1200/jco.2017.35.15_suppl.8027","title":"Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); McGill University Health Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Daratumumab; Progressive disease; Clinical endpoint; Multiple myeloma; Cohort; Population; Neutropenia; Bortezomib; Refractory (planetary science); Surgery; Dexamethasone; Oncology; Clinical trial; Chemotherapy","score_opus":0.11709354483459519,"score_gpt":0.4371151103498414,"score_spread":0.3200215655152462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890273388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484897,0.00056039507,0.0003263295,0.0014564379,0.00030583856,0.0011111472,0.0012937607,0.0000081540375,0.00008899641],"genre_scores_gemma":[0.99532723,0.00017517513,0.0034808381,0.0002371141,0.0001993482,0.0000770117,0.00012647892,0.000052356925,0.0003244349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919441,0.0014698544,0.003843677,0.00059173716,0.0014944872,0.0006561497],"domain_scores_gemma":[0.9847559,0.00596562,0.0051533272,0.001414038,0.001381409,0.0013297381],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003312798,0.0004912161,0.0042639063,0.00073573046,0.000103927996,0.00002527129,0.0006341395,0.00047876753,0.0003637386],"category_scores_gemma":[0.013533797,0.0003072627,0.0014106646,0.00032330593,0.00091025134,0.00030934563,0.0001407642,0.0008703055,0.0000057122847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20929734,0.018770529,0.71309936,0.000104195824,0.0051585576,0.001217558,0.000040860046,0.00011111283,0.0002927584,0.0000019293275,0.0001451262,0.05176066],"study_design_scores_gemma":[0.1556408,0.025709145,0.8117698,0.00040962544,0.0034589048,0.000004088351,0.000026660153,0.0013704594,0.00087213813,0.00001598881,0.00052126864,0.0002011205],"about_ca_topic_score_codex":0.00042743556,"about_ca_topic_score_gemma":0.0027782684,"teacher_disagreement_score":0.09867044,"about_ca_system_score_codex":0.000572766,"about_ca_system_score_gemma":0.0026674415,"threshold_uncertainty_score":0.99993795},"labels":[],"label_agreement":null},{"id":"W2890496731","doi":"10.1200/jco.2017.35.15_suppl.8015","title":"Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Pembrolizumab; Multiple myeloma; Oncology; Toxicity; Cancer; Immunotherapy","score_opus":0.29015573585746385,"score_gpt":0.5321339181034322,"score_spread":0.2419781822459684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890496731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075,0.0027865916,0.00036500685,0.0037287658,0.0007225938,0.0007930682,0.000024054658,0.000015439275,0.000814471],"genre_scores_gemma":[0.98595136,0.0025878637,0.009318282,0.00046818395,0.0008490191,0.000020498628,0.000011122917,0.000045949233,0.0007477415],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956395,0.0005698621,0.0021673858,0.00050327706,0.000535104,0.0005848707],"domain_scores_gemma":[0.9855246,0.009525188,0.0023354026,0.0006428223,0.0006551444,0.0013168433],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036056787,0.0003289727,0.002391423,0.0002934023,0.0004220276,0.00008652936,0.00033467868,0.00062054733,0.00007106955],"category_scores_gemma":[0.03268554,0.00022660963,0.0006148896,0.00007715138,0.0010573756,0.00037295412,0.00023430813,0.0010477786,0.00001372042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11592533,0.0029302987,0.11509424,0.00022062904,0.0028947191,0.002505576,0.00010366917,0.000005002177,0.0058118887,0.000029096453,0.0022741456,0.75220543],"study_design_scores_gemma":[0.13967243,0.011226462,0.8308418,0.00025235664,0.00093879213,0.00081918394,0.00006462383,0.0025582176,0.00034163703,0.00015901912,0.012927106,0.00019842097],"about_ca_topic_score_codex":0.00013094682,"about_ca_topic_score_gemma":0.00013054872,"teacher_disagreement_score":0.752007,"about_ca_system_score_codex":0.00023572547,"about_ca_system_score_gemma":0.0015964296,"threshold_uncertainty_score":0.97546256},"labels":[],"label_agreement":null},{"id":"W2890512508","doi":"10.1200/jco.2018.36.15_suppl.8040","title":"Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Dexamethasone; Oncology; Gastroenterology; Discontinuation","score_opus":0.17176960524995247,"score_gpt":0.5024723600516399,"score_spread":0.3307027548016874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890512508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524033,0.00055150787,0.000052918163,0.000472096,0.0011130783,0.0009933944,0.000014579614,0.000011981272,0.0015501183],"genre_scores_gemma":[0.99538594,0.00044523145,0.0027336904,0.00020835969,0.000695616,0.000019611674,0.00000566806,0.000042557356,0.00046329954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99091566,0.0018566434,0.005001022,0.00044902705,0.0011847178,0.0005929495],"domain_scores_gemma":[0.98789656,0.0060473024,0.0032868271,0.00065119733,0.0013553799,0.0007627326],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006141894,0.00031552234,0.0033112764,0.0006558334,0.00005723906,0.0000074758277,0.00044179143,0.0005553016,0.00059816404],"category_scores_gemma":[0.016471444,0.00023011786,0.00075338135,0.00049995066,0.00068766763,0.0001621297,0.00016341647,0.0015195295,0.000035768302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17576438,0.07465701,0.34863123,0.0001383711,0.0027405352,0.004930934,0.0017184792,0.000002709166,0.0062531168,0.000037950074,0.001537022,0.38358825],"study_design_scores_gemma":[0.21940246,0.17127353,0.59859794,0.0003421013,0.00062323624,0.0002550394,0.0017828058,0.00032663933,0.0029961418,0.00013558158,0.0040796157,0.00018491776],"about_ca_topic_score_codex":0.00050175824,"about_ca_topic_score_gemma":0.0010150364,"teacher_disagreement_score":0.38340333,"about_ca_system_score_codex":0.0003576158,"about_ca_system_score_gemma":0.0023362073,"threshold_uncertainty_score":0.99181324},"labels":[],"label_agreement":null},{"id":"W2890572331","doi":"10.1200/jco.2017.35.15_suppl.8033","title":"Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Lenalidomide; Internal medicine; Dexamethasone; Daratumumab; Carfilzomib; Adverse effect; Gastroenterology; Toxicity","score_opus":0.08499588755638966,"score_gpt":0.4329216199730279,"score_spread":0.34792573241663827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890572331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982679,0.00019705416,0.000036535508,0.0006607058,0.00011212105,0.0003502524,0.00003229555,0.000002961304,0.0003402085],"genre_scores_gemma":[0.9968183,0.00041610023,0.0024610583,0.0000774466,0.000064666914,0.0000023081147,0.000012541236,0.000016244845,0.00013134396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634403,0.00048300513,0.0020581477,0.00028962016,0.0005434374,0.00028176422],"domain_scores_gemma":[0.99157566,0.0039550574,0.0029164716,0.00050171086,0.0005543394,0.0004967754],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001847371,0.00018700826,0.0022994287,0.0005189204,0.00009637232,0.000011062511,0.00019132542,0.000329274,0.000049951122],"category_scores_gemma":[0.009205984,0.00011368016,0.00028926358,0.00024376268,0.0007518984,0.00015311914,0.00007316169,0.0007033799,7.5171505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06930542,0.0032743723,0.81523526,0.000056599423,0.0018048872,0.00074523623,0.00011121577,0.000011071497,0.00011401102,0.0000044744106,0.000048997983,0.10928843],"study_design_scores_gemma":[0.06413384,0.03344049,0.8989475,0.00022885915,0.0013176989,0.000026685364,0.000056143297,0.0005905924,0.0000758948,0.000003151477,0.0010938465,0.000085322965],"about_ca_topic_score_codex":0.00035121047,"about_ca_topic_score_gemma":0.00225094,"teacher_disagreement_score":0.10920311,"about_ca_system_score_codex":0.00015140571,"about_ca_system_score_gemma":0.00094826386,"threshold_uncertainty_score":0.9991399},"labels":[],"label_agreement":null},{"id":"W2890915407","doi":"10.1200/jco.2017.35.15_suppl.tps8052","title":"CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Nivolumab; Internal medicine; Pembrolizumab; Lenalidomide; Dexamethasone; Oncology; Refractory (planetary science); Progressive disease; Multiple myeloma; Immunotherapy; Chemotherapy; Cancer","score_opus":0.2646944539655388,"score_gpt":0.5483476067111028,"score_spread":0.283653152745564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890915407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938953,0.0004370958,0.00004454634,0.0014801316,0.0005222424,0.0016114197,0.00002403867,0.0000045743895,0.0019806742],"genre_scores_gemma":[0.99045146,0.0017194245,0.0072144927,0.00008725797,0.00021191011,0.000029902172,0.000009596902,0.000024208319,0.00025172456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931051,0.0019260454,0.0038029696,0.0002877963,0.00055919494,0.0003188787],"domain_scores_gemma":[0.9850574,0.008147089,0.0048134513,0.00062741555,0.00074742635,0.0006071887],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011587492,0.00020103187,0.0038715266,0.00032915885,0.00011811645,0.000034108245,0.00061563856,0.00043623286,0.00008240732],"category_scores_gemma":[0.051319413,0.00014502613,0.00030464228,0.0001013025,0.0012540244,0.00043829443,0.00027460902,0.00096083607,0.000003654359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8186882,0.034891695,0.014596632,0.000050897623,0.00074899604,0.00056259916,0.00011272448,0.0000011571124,0.0015747485,0.00020827734,0.0001113829,0.12845267],"study_design_scores_gemma":[0.8968255,0.04312288,0.055969484,0.0002248366,0.00040798806,0.00009418373,0.00007751113,0.0011685123,0.00054758566,0.00065459457,0.0008072532,0.00009968617],"about_ca_topic_score_codex":0.00058553484,"about_ca_topic_score_gemma":0.00037978828,"teacher_disagreement_score":0.128353,"about_ca_system_score_codex":0.00014600092,"about_ca_system_score_gemma":0.0017766404,"threshold_uncertainty_score":0.9566717},"labels":[],"label_agreement":null},{"id":"W2890977830","doi":"10.3324/haematol.2018.194282","title":"Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; University of British Columbia; University of Alberta; Queen Elizabeth II Health Sciences Centre; Université Laval; Dalhousie University","funders":"Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Yale University","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Hazard ratio; Multiple myeloma; Internal medicine; Oncology; Confidence interval; Gastroenterology","score_opus":0.06103873061989124,"score_gpt":0.341154983171765,"score_spread":0.2801162525518738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890977830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955787,0.0015452865,0.00013433072,0.00043937896,0.000076701384,0.0008643709,0.000093226845,0.00008542723,0.0011825633],"genre_scores_gemma":[0.9904757,0.000562291,0.008133018,0.00016393884,0.000041333366,0.00006844001,0.00014167436,0.000036646346,0.0003769275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965365,0.00044714025,0.000845135,0.0008777263,0.00055485714,0.00073867344],"domain_scores_gemma":[0.9965798,0.0016215913,0.00034855635,0.00072244764,0.0002635043,0.0004640696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007639809,0.00044121937,0.0018811128,0.000996228,0.00018986619,0.000038805967,0.00019001839,0.000350978,0.0005529944],"category_scores_gemma":[0.0027741704,0.00030639276,0.00018916193,0.0018597458,0.0009777272,0.00015176463,0.00024356964,0.0004176896,0.000026402608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20778868,0.0027691638,0.6884001,0.000763532,0.012582911,0.0071662785,0.0031298923,0.000025843534,0.045402132,0.0005845175,0.0023775126,0.029009474],"study_design_scores_gemma":[0.1186279,0.0068933913,0.79777163,0.0005640023,0.004828904,0.00080066477,0.002358753,0.01791076,0.046197984,0.00014535172,0.0027800545,0.0011206206],"about_ca_topic_score_codex":0.0011269832,"about_ca_topic_score_gemma":0.0033996294,"teacher_disagreement_score":0.10937154,"about_ca_system_score_codex":0.00018017708,"about_ca_system_score_gemma":0.00020587823,"threshold_uncertainty_score":0.99993885},"labels":[],"label_agreement":null},{"id":"W2891085289","doi":"10.1038/s41467-018-04989-w","title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","year":2018,"lang":"en","type":"review","venue":"Nature Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Heart, Lung, and Blood Institute; Medical Research Council; Hellenic Health Foundation; Mutuelle Générale de l'Education Nationale; Svenska Läkaresällskapet; Center for Translational Molecular Medicine; Deutsche Krebshilfe; Associazione Italiana per la Ricerca sul Cancro; Vetenskapsrådet; World Cancer Research Fund; Stavros Niarchos Foundation; National Cancer Institute; Knut och Alice Wallenbergs Stiftelse; Karolinska Institutet; Blood Cancer UK; Marcus och Amalia Wallenbergs minnesfond; Institut Gustave-Roussy; European Hematology Association; Stiftelsen för Strategisk Forskning; University of Leeds; Deutsche Forschungsgemeinschaft; National Institutes of Health; Heinz Nixdorf Stiftung; Rosetrees Trust; European Commission; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; Queensland University of Technology; University of Cambridge; Wellcome Trust; University of Southern California; Cancer Research UK; Ligue Contre le Cancer; Deutsches Krebsforschungszentrum; National Institute of General Medical Sciences; Deutsches Zentrum für Neurodegenerative Erkrankungen; Australian Prostate Cancer Research; National Cancer Research Institute; Lunds Universitet; Instituto de Salud Carlos III; Amgen; Centre International de Recherche sur le Cancer; Institut National de la Santé et de la Recherche Médicale; Multiple Myeloma Research Foundation; Case Western Reserve University; Cancer Research Institute","keywords":"Genome-wide association study; Epigenetics; Biology; Genetics; Genetic association; Biological pathway; Computational biology; microRNA; Gene expression profiling; Gene; Autophagy; Gene expression; Single-nucleotide polymorphism; Apoptosis; Genotype","score_opus":0.05148444152847069,"score_gpt":0.38163417227753427,"score_spread":0.33014973074906356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891085289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049926215,0.99044764,0.00021088355,0.00011130011,0.00009248391,0.0032846201,0.0006608736,0.00009261,0.00010699407],"genre_scores_gemma":[0.20709167,0.7809463,0.010519393,0.000031508556,0.000056424306,0.0003183352,0.0008433009,0.00006133199,0.0001317244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674684,0.00063913804,0.0010877891,0.00065407594,0.00052155496,0.0003506116],"domain_scores_gemma":[0.99192923,0.001263483,0.00073849823,0.0049492083,0.00074164814,0.00037794004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011255677,0.00042046877,0.001312692,0.0004960162,0.0004079348,0.000041030427,0.00095612707,0.00086873834,0.000019895317],"category_scores_gemma":[0.004757347,0.00035145637,0.00037841246,0.0007356019,0.00037588613,0.0001093746,0.00086177094,0.001535843,0.00008718882],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001479753,0.0009407147,0.011835737,0.010257351,0.0013799962,0.000006420546,0.0006258964,6.68539e-7,0.00097613735,0.0008013059,0.0016046388,0.97142315],"study_design_scores_gemma":[0.0028595307,0.00059135543,0.0895813,0.01057713,0.0035578168,0.000093466006,0.00027293037,0.000868183,0.0012461504,0.00041238364,0.88896257,0.0009771776],"about_ca_topic_score_codex":0.00015618367,"about_ca_topic_score_gemma":0.0013402005,"teacher_disagreement_score":0.970446,"about_ca_system_score_codex":0.00038798765,"about_ca_system_score_gemma":0.00040158068,"threshold_uncertainty_score":0.9998937},"labels":[],"label_agreement":null},{"id":"W2891531514","doi":"10.1200/jco.2017.35.15_suppl.8041","title":"Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Carfilzomib; Lenalidomide; Internal medicine; Neurotoxicity; Progression-free survival; Multiple myeloma; Bortezomib; Dexamethasone; Refractory (planetary science); Clinical endpoint; Gastroenterology; Oncology; Urology; Toxicity; Clinical trial; Chemotherapy","score_opus":0.15279300443406846,"score_gpt":0.4796246044408957,"score_spread":0.32683160000682726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891531514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834186,0.00013620779,0.0000043460836,0.00034535644,0.00016039942,0.000691638,0.000018022141,0.000004572443,0.0002976199],"genre_scores_gemma":[0.9987516,0.00023102631,0.0006491831,0.00009524913,0.0001514572,0.000011092696,0.000012904465,0.000024909597,0.00007258902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950281,0.001286573,0.0025361124,0.0003044455,0.0004924557,0.000352334],"domain_scores_gemma":[0.9936779,0.0021953827,0.0027858457,0.00034342232,0.0004685988,0.0005288086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027765483,0.0002447681,0.0029616968,0.00027514962,0.000076014534,0.000022989629,0.0001966342,0.00027290275,0.00004159803],"category_scores_gemma":[0.0066903858,0.00014028877,0.00020238772,0.00012889646,0.00060571294,0.00026626,0.000060198003,0.0010609382,0.0000017696573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18722796,0.00646545,0.7674901,0.000026866594,0.00029340104,0.0022902142,0.00015274878,0.0000062101176,0.00019151396,0.0000014357971,0.00007040535,0.035783667],"study_design_scores_gemma":[0.2075779,0.05534506,0.7355241,0.0002321405,0.00014872914,0.0000634446,0.0000823168,0.0003492958,0.00020271998,0.0000036153285,0.0003781314,0.000092542425],"about_ca_topic_score_codex":0.0004333126,"about_ca_topic_score_gemma":0.0010084015,"teacher_disagreement_score":0.04887961,"about_ca_system_score_codex":0.00019778043,"about_ca_system_score_gemma":0.0010070037,"threshold_uncertainty_score":0.80095},"labels":[],"label_agreement":null},{"id":"W2891692504","doi":"10.1200/jco.2016.34.15_suppl.8039","title":"Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Ixazomib; Multiple myeloma; Placebo; Internal medicine; Dexamethasone; Oncology; Refractory (planetary science); Carfilzomib; Pathology","score_opus":0.08530791326686953,"score_gpt":0.4407067113779121,"score_spread":0.3553987981110426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891692504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762,0.0001721105,0.000018467794,0.0009931175,0.00013861225,0.0008754651,0.000026903088,0.000005107594,0.00015024624],"genre_scores_gemma":[0.996264,0.001564486,0.0018227582,0.00012454181,0.0001222781,0.0000072797216,0.0000044304547,0.00003287038,0.000057379122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944895,0.0011933929,0.002851315,0.0003239151,0.0006925119,0.0004493826],"domain_scores_gemma":[0.9874473,0.009193787,0.0019800514,0.00033183204,0.00051082444,0.00053617486],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035230957,0.00027837703,0.0023541097,0.0004944184,0.00002298201,0.0000043425807,0.00020164154,0.00042185947,0.00015012494],"category_scores_gemma":[0.009090627,0.00013863861,0.00038359585,0.0002495137,0.00043726814,0.00017538336,0.000063265354,0.0009300587,0.000006307814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24365348,0.006331333,0.53377277,0.000017677563,0.00042095457,0.00022695669,0.00009185535,0.000013246178,0.00057091576,0.0000018131224,0.00009020123,0.21480878],"study_design_scores_gemma":[0.18797046,0.07082808,0.7395256,0.000580774,0.000057311543,0.000028942944,0.000017681126,0.00003255417,0.00039170368,0.000013769864,0.00045619032,0.00009692515],"about_ca_topic_score_codex":0.00024695497,"about_ca_topic_score_gemma":0.00025946245,"teacher_disagreement_score":0.21471184,"about_ca_system_score_codex":0.0004753313,"about_ca_system_score_gemma":0.0014782809,"threshold_uncertainty_score":0.99925625},"labels":[],"label_agreement":null},{"id":"W2891798328","doi":"10.1200/jco.2018.36.15_suppl.8000","title":"Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Carfilzomib; Internal medicine; Clinical endpoint; Lenalidomide; Regimen; Interim analysis; Multiple myeloma; Tolerability; Neutropenia; Dexamethasone; Gastroenterology; Adverse effect; Randomized controlled trial; Toxicity","score_opus":0.08809992328939925,"score_gpt":0.4424007583133508,"score_spread":0.35430083502395154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891798328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949231,0.00019934522,0.000026559372,0.001512639,0.000585706,0.0020881162,0.000022161343,0.000008649931,0.0006337117],"genre_scores_gemma":[0.99637043,0.00011374991,0.0025054582,0.00029538907,0.00042795108,0.000016192891,0.000006412648,0.000031409214,0.00023297337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913989,0.0030676231,0.0035917442,0.00042252455,0.0010682956,0.0004509509],"domain_scores_gemma":[0.9848087,0.009760358,0.0031103839,0.000544887,0.0012325812,0.00054312375],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0077846996,0.00028738385,0.0031754454,0.0002933787,0.000108760876,0.000016273007,0.0003083453,0.00035780133,0.00003241206],"category_scores_gemma":[0.02758004,0.00014920377,0.00041256048,0.0004048007,0.0013289349,0.00019901089,0.00016673742,0.0014299856,0.000004974367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60700685,0.00952931,0.34317312,0.00002023871,0.00081736705,0.0002816193,0.0007803494,0.0000023637708,0.000073442694,0.000001546658,0.00029753562,0.03801626],"study_design_scores_gemma":[0.48131928,0.048547413,0.4681053,0.00022005122,0.00040381873,0.000024252791,0.00027941083,0.00020660616,0.000081616105,0.000013926505,0.00071801967,0.00008032861],"about_ca_topic_score_codex":0.0003671212,"about_ca_topic_score_gemma":0.0005661684,"teacher_disagreement_score":0.12568758,"about_ca_system_score_codex":0.00035176225,"about_ca_system_score_gemma":0.001852191,"threshold_uncertainty_score":0.9806111},"labels":[],"label_agreement":null},{"id":"W2891801563","doi":"10.30699/mmlj17.2.2.132","title":"Serum Free Light-chain Assay for the Diagnosis, Management, and Prognosis of Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Modern Medical Laboratory Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Immunoglobulin light chain; Medicine; Heavy chain; Monoclonal; Clinical Practice; Intensive care medicine; Antibody; Immunology; Medical physics; Monoclonal antibody; Family medicine","score_opus":0.024109055615635498,"score_gpt":0.30347067538156314,"score_spread":0.27936161976592766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891801563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91146606,0.0123125445,0.030881817,0.03942892,0.0008107354,0.0034598878,0.00044146844,0.00010271679,0.0010958543],"genre_scores_gemma":[0.9933186,0.0011657354,0.0036089213,0.00072054367,0.0007122662,0.00023103628,0.0000061381456,0.000035836707,0.00020092902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975248,0.00016650686,0.00042098475,0.0002637004,0.001147499,0.0004765306],"domain_scores_gemma":[0.99766076,0.0005938676,0.00015261756,0.00037594113,0.0005007386,0.00071606477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001594631,0.00019065478,0.00033744558,0.00013703169,0.0003843123,0.0000496997,0.0003345787,0.0001457707,0.00031946824],"category_scores_gemma":[0.0020522296,0.000111035704,0.00010725668,0.00022113636,0.0003771069,0.00010090681,0.00017105695,0.00038424364,0.000008868963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001102328,0.00090280804,0.6584329,0.00036217849,0.0015751203,0.0004923893,0.00056046556,5.4818463e-7,0.00062865356,0.00035842817,0.035360396,0.3002238],"study_design_scores_gemma":[0.037642594,0.0039262353,0.7300255,0.0017098909,0.0010843751,0.0005147865,0.0008140469,0.036421858,0.028363312,0.0036052056,0.15530294,0.0005892961],"about_ca_topic_score_codex":0.000008085996,"about_ca_topic_score_gemma":0.00007075403,"teacher_disagreement_score":0.29963452,"about_ca_system_score_codex":0.00005850013,"about_ca_system_score_gemma":0.00024243449,"threshold_uncertainty_score":0.45279044},"labels":[],"label_agreement":null},{"id":"W2892110441","doi":"10.1200/jco.2016.34.15_suppl.8010","title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Pembrolizumab; Multiple myeloma; Internal medicine; Tolerability; Dexamethasone; Population; Refractory (planetary science); Adverse effect; Oncology; Toxicity; Cancer; Immunotherapy","score_opus":0.10145107000851554,"score_gpt":0.43749800026940094,"score_spread":0.3360469302608854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892110441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289834,0.0004450929,0.0017788522,0.0041170944,0.00009307951,0.00054165145,0.000013800298,0.000006378377,0.0001056983],"genre_scores_gemma":[0.9913832,0.0012829712,0.0066871056,0.00021459367,0.00017297134,0.000013466822,0.000008460369,0.000016630473,0.0002205861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970015,0.00051532325,0.001513293,0.00029678934,0.0003549021,0.00031813871],"domain_scores_gemma":[0.9867181,0.011282279,0.0009019094,0.00017878579,0.00040342196,0.0005154749],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028675585,0.0001695918,0.0015580184,0.00041690446,0.000057079462,0.00001117127,0.00008841258,0.00028401968,0.000040746043],"category_scores_gemma":[0.00908262,0.00009176492,0.00024073831,0.0002377326,0.00035541318,0.00018355771,0.000045364042,0.0004969942,0.0000026586292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11307969,0.0026040159,0.47710124,0.00004284334,0.0013748511,0.0005514331,0.00005677021,0.0000073753577,0.0005459137,0.00005133638,0.000102322934,0.40448222],"study_design_scores_gemma":[0.14986837,0.018431198,0.8265627,0.00018185523,0.0007475051,0.00019617255,0.000030171082,0.00059036503,0.000080908336,0.00012436564,0.0030969284,0.000089466776],"about_ca_topic_score_codex":0.000030747768,"about_ca_topic_score_gemma":0.00031993818,"teacher_disagreement_score":0.40439275,"about_ca_system_score_codex":0.00021797136,"about_ca_system_score_gemma":0.0007910024,"threshold_uncertainty_score":0.9992643},"labels":[],"label_agreement":null},{"id":"W2892222821","doi":"10.1200/jco.2017.35.15_suppl.tps8055","title":"A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Lenalidomide; Clinical endpoint; Internal medicine; Regimen; Dexamethasone; Population; Multiple myeloma; Cohort; Oncology; Phases of clinical research; Surgery; Chemotherapy; Clinical trial","score_opus":0.13688062233079704,"score_gpt":0.4809013942419234,"score_spread":0.34402077191112634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892222821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683267,0.000027947774,0.00010437841,0.000618833,0.00011641004,0.002042444,0.0000071641202,0.000007645969,0.00024250793],"genre_scores_gemma":[0.9945845,0.00005954346,0.004906662,0.000106951346,0.000104527644,0.000060310165,0.000008790185,0.000043199045,0.00012550586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945994,0.001054687,0.0022393372,0.0004253922,0.001201323,0.00047984213],"domain_scores_gemma":[0.99164426,0.0029891543,0.0031752645,0.0006284982,0.0010343473,0.00052847265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029623173,0.0003113822,0.0026051542,0.00044910307,0.00010372231,0.000032269916,0.00039038513,0.00025984237,0.00004736345],"category_scores_gemma":[0.007899335,0.00016660886,0.00013244984,0.00028647258,0.00048553717,0.0004527436,0.00008909961,0.0011741464,0.000004488357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20722127,0.05451841,0.65465546,0.000041291692,0.00056267425,0.004078636,0.00049325713,0.000034632896,0.000012848033,0.000001474529,0.000017213377,0.07836286],"study_design_scores_gemma":[0.29243246,0.1550477,0.5505934,0.00041970238,0.00021240825,0.000074432,0.00051465083,0.00047633145,0.000050751885,0.0000056326453,0.000068088455,0.00010448014],"about_ca_topic_score_codex":0.0012378572,"about_ca_topic_score_gemma":0.020916857,"teacher_disagreement_score":0.10406208,"about_ca_system_score_codex":0.00042530126,"about_ca_system_score_gemma":0.002616569,"threshold_uncertainty_score":0.99694884},"labels":[],"label_agreement":null},{"id":"W2892534902","doi":"10.3233/978-1-61499-896-9-160","title":"Finding Needles in the Haystack: Identifying Patients with Rare Subtype of Multiple Myeloma Supported by a Data Warehouse and Information Extraction","year":2018,"lang":"en","type":"article","venue":"Studies in health technology and informatics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Haystack; Multiple myeloma; Data warehouse; Warehouse; Extraction (chemistry); Data extraction; Medicine; Computer science; Database; Business; MEDLINE; World Wide Web; Internal medicine; Biology; Chemistry; Chromatography; Marketing","score_opus":0.08103195734588782,"score_gpt":0.39061849880514427,"score_spread":0.30958654145925646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892534902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754006,0.00074361044,0.00014069749,0.00057269493,0.000036738988,0.00080421293,0.00006981614,0.000025819732,0.00006633715],"genre_scores_gemma":[0.9959494,0.0019019286,0.0017377405,0.00015889996,0.0000049901587,0.000028165125,0.0002116065,0.000004065882,0.000003192678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988858,0.000030309404,0.00056384905,0.00008098517,0.00018995669,0.00024907038],"domain_scores_gemma":[0.999122,0.00015212632,0.00026885033,0.00028824632,0.00013475618,0.00003401701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049118383,0.000104155995,0.00025818232,0.00051039207,0.00018111746,0.000011566013,0.00010952999,0.00008760762,0.000001689766],"category_scores_gemma":[0.0007528432,0.00006588975,0.000005701918,0.0005224014,0.00036151675,0.00087679544,0.00016942597,0.00023093636,0.00000160093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000268373,0.00008013331,0.950975,0.001148995,0.00005722357,0.0000023423595,0.01342512,3.4855682e-7,0.0000024008152,0.000080521335,0.00048207946,0.033477455],"study_design_scores_gemma":[0.006324243,0.0016044755,0.911635,0.00088817975,0.000022908174,0.00004390987,0.0739833,0.00291614,0.00017193789,0.0000981577,0.0021928514,0.00011889184],"about_ca_topic_score_codex":0.00008812718,"about_ca_topic_score_gemma":0.00022062633,"teacher_disagreement_score":0.060558174,"about_ca_system_score_codex":0.00006025047,"about_ca_system_score_gemma":0.000065017906,"threshold_uncertainty_score":0.2686906},"labels":[],"label_agreement":null},{"id":"W2894767012","doi":"10.1016/j.cancergen.2018.07.002","title":"Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders","year":2018,"lang":"en","type":"review","venue":"Cancer Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Plasma cell neoplasm; Plasma cell leukemia; Fluorescence in situ hybridization; Biology; Copy-number variation; Plasma cell; Multiple myeloma; Copy number analysis; Karyotype; Comparative genomic hybridization; Cytogenetics; Oncology; Bioinformatics; Cancer research; Computational biology; Genetics; Medicine; Chromosome; Genome; Immunology; Plasmacytoma; Gene","score_opus":0.158159661908279,"score_gpt":0.4532366311074498,"score_spread":0.2950769691991708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894767012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018946303,0.973974,0.00036804986,0.00056439184,0.0004557525,0.0048836567,0.0006752212,0.000022245087,0.00011040256],"genre_scores_gemma":[0.005016387,0.9844282,0.006700463,0.00073517644,0.000698667,0.0015158603,0.0007097501,0.00013308915,0.00006240288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966161,0.00046158387,0.0009542311,0.0009161101,0.00044094195,0.00061099185],"domain_scores_gemma":[0.9947536,0.0024408074,0.0010320033,0.0009579615,0.000407712,0.0004079023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005297953,0.0006179233,0.0016058213,0.00006796135,0.00040311544,0.00021010432,0.00043996942,0.00029421586,0.00018795721],"category_scores_gemma":[0.0004663609,0.00045479677,0.00039340352,0.00030213394,0.00051154365,0.00022592532,0.00012566696,0.0005142157,0.00002082214],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000574684,0.00095161836,0.08393244,0.06525275,0.0024322388,0.00004745599,0.00039640485,0.00005674782,0.00007051823,0.0000091836355,0.0021328754,0.8441431],"study_design_scores_gemma":[0.0017048351,0.00045001763,0.0013704761,0.061941557,0.009309086,0.000019063435,0.00007836601,0.00019623962,0.0001410539,0.000015788199,0.92421854,0.0005549612],"about_ca_topic_score_codex":0.001520907,"about_ca_topic_score_gemma":0.0019831918,"teacher_disagreement_score":0.9220857,"about_ca_system_score_codex":0.0008020881,"about_ca_system_score_gemma":0.0028690274,"threshold_uncertainty_score":0.9997904},"labels":[],"label_agreement":null},{"id":"W2897038974","doi":"10.2196/cancer.9918","title":"Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study","year":2018,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pill; Family medicine; Medication adherence; Qualitative research; Phone; Demographics; Medical record; Adverse effect; Medical prescription; Nursing; Internal medicine","score_opus":0.046539164710991794,"score_gpt":0.3979057496364768,"score_spread":0.351366584925485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897038974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844724,0.00005495564,0.000025668955,0.000012376975,0.00002054064,0.0011256486,0.00029439837,0.0000057605853,0.000013387157],"genre_scores_gemma":[0.9989914,0.0000058284504,0.0008501509,0.000008480181,0.0000108281265,0.00009996,0.00001737422,0.000007532558,0.0000085048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889535,0.00012688692,0.00021905237,0.00021028485,0.0003895613,0.00015889436],"domain_scores_gemma":[0.99910784,0.00017925973,0.00013618899,0.00014351038,0.00029680497,0.00013639024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014832072,0.0001004763,0.00025980346,0.00012861373,0.000039734183,0.000002782151,0.000042780208,0.000032551317,0.00011581041],"category_scores_gemma":[0.00028909653,0.000072020106,0.000017810471,0.00023753429,0.00030554566,0.000089486835,0.000032418407,0.000057429974,8.291911e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015766431,0.00022684514,0.9480552,0.00010579273,0.0001314788,0.000002787565,0.046539415,0.0000014251664,0.00026658832,0.0000012292868,0.00000719791,0.0030853716],"study_design_scores_gemma":[0.0070753885,0.0012699331,0.9454339,0.00016032008,0.000038849903,1.6144952e-7,0.04497358,0.00036569673,0.00060010527,0.000005587678,0.000014840746,0.000061644416],"about_ca_topic_score_codex":0.009303938,"about_ca_topic_score_gemma":0.005588792,"teacher_disagreement_score":0.0054987455,"about_ca_system_score_codex":0.0001000837,"about_ca_system_score_gemma":0.00015723692,"threshold_uncertainty_score":0.9972932},"labels":[],"label_agreement":null},{"id":"W2897241170","doi":"10.1182/blood-2018-06-858852","title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Carfilzomib; Medicine; Refractory (planetary science); Oncology; Internal medicine; Pomalidomide; Lenalidomide; Biology","score_opus":0.02251411635390486,"score_gpt":0.28837410980690453,"score_spread":0.26585999345299965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897241170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721414,0.00016566887,0.0001420361,0.00010280443,0.000066262524,0.0018736995,0.00012212258,0.00008214138,0.00023111806],"genre_scores_gemma":[0.980551,0.000043213007,0.017271819,0.00014531893,0.00027533542,0.00020334736,0.00019034166,0.000060283997,0.0012593577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983959,0.00004237957,0.00024661756,0.00046111053,0.00036809448,0.00048586784],"domain_scores_gemma":[0.99830365,0.00035865922,0.00009542257,0.0004267102,0.00040546575,0.00041008394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522014,0.0002385237,0.0003753876,0.00011887391,0.00017039702,0.000027750377,0.00008489291,0.000117477786,0.000089375484],"category_scores_gemma":[0.0009292944,0.00014989701,0.00005590643,0.00017090954,0.00018804707,0.00011519136,0.000053652537,0.00014259896,0.00004163263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038160328,0.0074775983,0.8909952,0.00047256553,0.001337833,0.00028081553,0.000656144,2.2751682e-7,0.0037923928,0.000010510301,0.001446119,0.055370264],"study_design_scores_gemma":[0.13485333,0.013591834,0.83561105,0.00029959096,0.0005089711,0.00005532403,0.000097290496,0.00077733205,0.0084999995,0.00001371801,0.005351833,0.0003396925],"about_ca_topic_score_codex":0.00006303009,"about_ca_topic_score_gemma":0.00015765481,"teacher_disagreement_score":0.09669301,"about_ca_system_score_codex":0.000060424034,"about_ca_system_score_gemma":0.00024484945,"threshold_uncertainty_score":0.61126226},"labels":[],"label_agreement":null},{"id":"W2898644963","doi":"10.1182/blood-2018-99-114960","title":"Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pomalidomide; Lenalidomide; Atezolizumab; Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Cohort; Tolerability; Cancer; Adverse effect; Immunotherapy; Nivolumab","score_opus":0.02632864527307843,"score_gpt":0.3215447505745981,"score_spread":0.29521610530151965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898644963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423975,0.00001864244,0.00003438482,0.000065668326,0.00002391155,0.0051015527,0.00003222355,0.000078614416,0.00040523394],"genre_scores_gemma":[0.9969122,0.0000035695273,0.0017624845,0.000050218423,0.000054472806,0.0005150595,0.00012945132,0.0000894662,0.00048309524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968012,0.0002077587,0.00047705707,0.0007434341,0.0010195412,0.0007509892],"domain_scores_gemma":[0.9983097,0.00013725276,0.00018352542,0.0006344818,0.00041343388,0.00032165018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002546355,0.00045689236,0.00078988314,0.00053010933,0.00015323905,0.00006749343,0.00018229292,0.00009615445,0.0001258982],"category_scores_gemma":[0.00020722304,0.00023764934,0.00003218873,0.0011058142,0.00024203022,0.0003211817,0.00006705585,0.00032428183,0.000039584873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14493456,0.030423373,0.818175,0.00006428981,0.00042187708,0.0020850839,0.0013130889,0.0000011879644,0.00006441744,0.000002883202,0.000012938881,0.0025012896],"study_design_scores_gemma":[0.31983948,0.04543193,0.63122815,0.00042448542,0.00019082549,0.00009408779,0.0005886782,0.00021292838,0.0017022229,0.0000017613293,0.00002926427,0.00025621685],"about_ca_topic_score_codex":0.001045477,"about_ca_topic_score_gemma":0.026602902,"teacher_disagreement_score":0.18694688,"about_ca_system_score_codex":0.00022322882,"about_ca_system_score_gemma":0.0005025868,"threshold_uncertainty_score":0.9911591},"labels":[],"label_agreement":null},{"id":"W2898813536","doi":"10.1182/blood-2018-99-113585","title":"Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Chromosomal translocation; Lenalidomide; Internal medicine; Biology; Hazard ratio; Oncology; Immunology; Cancer research; Medicine; Genetics; Confidence interval; Gene","score_opus":0.031954615612353764,"score_gpt":0.3240272048402091,"score_spread":0.29207258922785534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898813536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995902,0.0014772022,0.000032474356,0.0006234663,0.000017347844,0.0006275141,0.00006874148,0.00004351112,0.0012077626],"genre_scores_gemma":[0.99546957,0.000105129075,0.0034706555,0.000091256516,0.000058006153,0.00007185879,0.000043926022,0.000024736812,0.0006648564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987786,0.000048934642,0.0002498484,0.00034725893,0.0002561624,0.00031918968],"domain_scores_gemma":[0.9992784,0.00010444843,0.000043262742,0.0002825484,0.00008930427,0.00020199238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015372357,0.00017046582,0.00028962418,0.0001383033,0.00015314638,0.00004186401,0.000069105234,0.00007013978,0.000035649846],"category_scores_gemma":[0.000119345765,0.00013169524,0.000028789062,0.00020736505,0.0002775485,0.00011236823,0.000026036389,0.00015277477,0.00003110524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079029135,0.0005591112,0.9871705,0.00011793628,0.00016168981,0.00020355085,0.0003742192,4.5814435e-8,0.009537307,0.00004428527,0.000039332834,0.0010017046],"study_design_scores_gemma":[0.014923904,0.0004038091,0.97839385,0.00013344591,0.0001110676,0.000101389414,0.00016620012,0.00003399844,0.0050713723,0.000034264558,0.00049196684,0.00013471363],"about_ca_topic_score_codex":0.0002107799,"about_ca_topic_score_gemma":0.0027101112,"teacher_disagreement_score":0.014133613,"about_ca_system_score_codex":0.000027562906,"about_ca_system_score_gemma":0.00007130388,"threshold_uncertainty_score":0.5370376},"labels":[],"label_agreement":null},{"id":"W2899110450","doi":"10.14740/jmc.v9i11.3179","title":"Localized Extramedullary Plasmacytoma: A Report of Two Cases","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Extramedullary plasmacytoma; Larynx; Plasma cell neoplasm; Presentation (obstetrics); Plasma cell; Rare disease; Laryngeal Neoplasm; Radiology; Surgery; Pathology; Disease; Multiple myeloma; Internal medicine","score_opus":0.06290517080570238,"score_gpt":0.4085059679571403,"score_spread":0.3456007971514379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899110450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937092,0.0013413148,0.00035838818,0.0034774414,0.00028323912,0.00015086835,0.000009669047,0.000012684789,0.00065716414],"genre_scores_gemma":[0.9951585,0.0003523156,0.0027975051,0.0003049266,0.0010964961,0.0000028528748,0.000007417995,0.000016423786,0.00026353996],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9961756,0.00011251838,0.0008801325,0.00014553334,0.0023919053,0.00029433973],"domain_scores_gemma":[0.996895,0.00084457337,0.0004274165,0.00025315053,0.0006234694,0.00095639523],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010477612,0.00014014004,0.00060112146,0.00022060846,0.000052630006,0.00001123227,0.00016658698,0.000119704484,0.0024372688],"category_scores_gemma":[0.008942682,0.00008834952,0.00024080098,0.0002083126,0.00052842806,0.00008086043,0.000066529734,0.00038000432,0.000023452621],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005753596,0.0019549245,0.09021123,0.00028534085,0.0007907375,0.8009334,0.00014201595,4.55167e-7,0.0012611109,0.000059977025,0.043923866,0.054683335],"study_design_scores_gemma":[0.019717604,0.009012959,0.013256178,0.0016522135,0.00041774282,0.88968456,0.0003483013,0.0005619243,0.028677506,0.0001495165,0.036355894,0.00016561065],"about_ca_topic_score_codex":0.00030814114,"about_ca_topic_score_gemma":0.00006432583,"teacher_disagreement_score":0.088751145,"about_ca_system_score_codex":0.000075183016,"about_ca_system_score_gemma":0.0011579578,"threshold_uncertainty_score":0.99940544},"labels":[],"label_agreement":null},{"id":"W2899267864","doi":"10.1182/blood-2018-99-118617","title":"Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; KRAS; Multiple myeloma; Oncology; Internal medicine; Exome; Medicine; Malignancy; Exome sequencing; Mutation; Cancer; Biology; Genetics; Gene; Colorectal cancer","score_opus":0.035692975071496,"score_gpt":0.33525018888877617,"score_spread":0.2995572138172802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899267864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984118,0.00025246225,0.00003501267,0.00008362831,0.00007069666,0.0007415303,0.000292759,0.000027397224,0.00008475405],"genre_scores_gemma":[0.99910814,0.000023461766,0.0004157942,0.000019064351,0.00013497332,0.000053974014,0.0002100379,0.000011383686,0.000023182594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844164,0.0002516133,0.0002672771,0.00025076282,0.00058569654,0.00020302973],"domain_scores_gemma":[0.9987405,0.00021372529,0.00016414151,0.0005705802,0.00021536244,0.00009569109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018870503,0.00012184886,0.00033815324,0.00011744669,0.0001836071,0.00003101954,0.0001371996,0.000038658665,0.00039086293],"category_scores_gemma":[0.00022870845,0.000067457666,0.0001347162,0.0004575774,0.00015654576,0.000037803144,0.0001330765,0.000108826476,0.000030649186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004705628,0.0038121762,0.9731297,0.000006956038,0.008527682,0.00003778563,0.0024271014,0.000001069442,0.0012798264,0.000005320717,0.00012753891,0.01017429],"study_design_scores_gemma":[0.0042619277,0.001621608,0.972933,0.000035871122,0.007170234,7.351762e-7,0.0009860873,0.00013203251,0.012677142,0.00005284918,0.00006713357,0.00006138827],"about_ca_topic_score_codex":0.011536756,"about_ca_topic_score_gemma":0.003530732,"teacher_disagreement_score":0.011397316,"about_ca_system_score_codex":0.00001900061,"about_ca_system_score_gemma":0.000048611757,"threshold_uncertainty_score":0.9950455},"labels":[],"label_agreement":null},{"id":"W2900305229","doi":"10.1093/neuonc/noy148.316","title":"DRES-09. IN VIVO FUNCTIONAL GENOMICS IDENTIFIES DRIVERS OF CHEMORESISTANCE IN MEDULLOBLASTOMA","year":2018,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Chemotherapy; Biology; Cancer research; Sonic hedgehog; Metastasis; Oncology; Cancer; Medicine; Internal medicine; Gene; Genetics","score_opus":0.02764333757226746,"score_gpt":0.31228911194245046,"score_spread":0.284645774370183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900305229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910953,0.000055153716,0.000013584543,0.0006756924,0.00031077146,0.00035205157,0.000017074775,0.000016710897,0.0074636606],"genre_scores_gemma":[0.998769,0.0000944822,0.00031128197,0.00023823026,0.00014250458,0.000037632202,0.000008386081,0.000016866636,0.00038162677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986362,0.00010763714,0.00032667202,0.0003150598,0.00026407378,0.0003503878],"domain_scores_gemma":[0.99914527,0.0002787689,0.00009435897,0.00023277651,0.00012247283,0.00012634683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018076538,0.0001268516,0.00036911128,0.00031458648,0.00003500318,0.000005521341,0.000109326815,0.0001276963,0.00064698316],"category_scores_gemma":[0.00036903718,0.00011970757,0.00006268943,0.0002827439,0.00037232367,0.00006771964,0.00007917375,0.00021989773,0.00007459695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028873798,0.000523256,0.1551484,0.000051170427,0.000048282975,0.0008373522,0.00048448102,0.000009144404,0.8320602,0.000083289415,0.0039602616,0.0039067506],"study_design_scores_gemma":[0.011594258,0.0022732595,0.460861,0.00006228533,0.00003485731,0.00014293505,0.0004939385,0.0006124521,0.49260923,0.00020573717,0.030959358,0.00015067407],"about_ca_topic_score_codex":0.00017297026,"about_ca_topic_score_gemma":0.0035947107,"teacher_disagreement_score":0.339451,"about_ca_system_score_codex":0.00046245998,"about_ca_system_score_gemma":0.00042000046,"threshold_uncertainty_score":0.70840114},"labels":[],"label_agreement":null},{"id":"W2901260218","doi":"10.1182/blood-2018-120737","title":"Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Daratumumab; Transplantation; Multiple myeloma; Melphalan; Surgery; Gastroenterology; Oncology","score_opus":0.029646445552999362,"score_gpt":0.3113519878671562,"score_spread":0.2817055423141568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901260218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074894,0.0007838225,0.00037492823,0.000086385546,0.00009040345,0.0075603174,0.00021419904,0.000048162532,0.00009283662],"genre_scores_gemma":[0.9927059,0.00020671515,0.0058932025,0.00003347248,0.00010694713,0.00076936244,0.00017079704,0.00007586021,0.00003776463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964647,0.00041178975,0.0008372958,0.0008270947,0.00070995366,0.00074915297],"domain_scores_gemma":[0.9954098,0.0029127812,0.0002886581,0.0005453211,0.00036948756,0.00047399383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009382963,0.00051754894,0.0018137271,0.0004873473,0.00018687248,0.00005138558,0.00016197118,0.00016288107,0.00002600033],"category_scores_gemma":[0.0015430708,0.0003784984,0.0001393945,0.00044044116,0.00051423477,0.00020858538,0.00007947701,0.00026807643,0.0000033494791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7484752,0.014172799,0.22415125,0.0002935965,0.0021353518,0.00024494127,0.003283503,0.000004534077,0.0014674012,0.0000068864156,0.000036197456,0.0057283384],"study_design_scores_gemma":[0.91492623,0.0155476425,0.05192847,0.00036298277,0.0016112102,0.00001932964,0.0007165691,0.0009556134,0.013531159,0.000016357902,0.000032374268,0.00035203435],"about_ca_topic_score_codex":0.001410491,"about_ca_topic_score_gemma":0.0021068165,"teacher_disagreement_score":0.17222278,"about_ca_system_score_codex":0.00008155557,"about_ca_system_score_gemma":0.00018876357,"threshold_uncertainty_score":0.9998667},"labels":[],"label_agreement":null},{"id":"W2901760736","doi":"10.1016/s1470-2045(18)30576-x","title":"Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute for Health and Care Research; GlaxoSmithKline; American Society of Hematology","keywords":"Conjugate; Antibody-drug conjugate; Multiple myeloma; Medicine; Refractory (planetary science); Antibody; Cancer research; Drug; Oncology; Antigen; Internal medicine; Pharmacology; Immunology; Monoclonal antibody; Materials science","score_opus":0.0496385688750652,"score_gpt":0.38452979460518505,"score_spread":0.33489122573011987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901760736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539006,0.00019843603,0.00011763141,0.0015664396,0.00016941347,0.0017158792,0.000018990453,0.00006168916,0.00076144177],"genre_scores_gemma":[0.9958239,0.00042904672,0.0019751396,0.0002910034,0.00088206405,0.00007897225,0.00018945467,0.000027591688,0.0003028283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980774,0.00048020657,0.0003609711,0.0003609073,0.00026543826,0.00045509537],"domain_scores_gemma":[0.99870163,0.0005136667,0.00020628232,0.00031593835,0.00012947439,0.00013302501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008918267,0.00019366885,0.0005353737,0.00013474263,0.0001945973,0.000027099617,0.0001009442,0.00013710397,0.00011200046],"category_scores_gemma":[0.0003816281,0.000106091284,0.000032293025,0.00023516186,0.0002674855,0.00012929527,0.000057678262,0.00035116586,0.000040820516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68203104,0.0019969696,0.034160886,0.00014090806,0.0001157652,0.0006250221,0.0026253131,0.000006773062,0.24832067,0.000015458989,0.0012388702,0.028722351],"study_design_scores_gemma":[0.74611235,0.025976142,0.15177397,0.00035935824,0.00016057843,0.00021530749,0.0010915603,0.029046722,0.025115265,0.00008702136,0.019612722,0.00044902568],"about_ca_topic_score_codex":0.00021912849,"about_ca_topic_score_gemma":0.00041468348,"teacher_disagreement_score":0.2232054,"about_ca_system_score_codex":0.00015835559,"about_ca_system_score_gemma":0.00027019373,"threshold_uncertainty_score":0.43262768},"labels":[],"label_agreement":null},{"id":"W2902348661","doi":"10.1182/blood-2018-06-860015","title":"Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Carfilzomib; Hazard ratio; Renal function; Multiple myeloma; Internal medicine; Confidence interval; Urology; Creatinine; Population; Dexamethasone; Gastroenterology; Subgroup analysis; Bortezomib","score_opus":0.008370298583563177,"score_gpt":0.24236132120059722,"score_spread":0.23399102261703406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902348661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989569,0.000060125,0.000017734217,0.000055484954,0.000008225162,0.00047144148,0.0000907924,0.00001807623,0.00032119718],"genre_scores_gemma":[0.9978192,0.000008373968,0.0018274223,0.000029418734,0.000036825357,0.00003102773,0.00016395652,0.00001734285,0.000066474444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986016,0.000049084676,0.0002611193,0.00033845287,0.00041603556,0.0003336903],"domain_scores_gemma":[0.99907947,0.00007499651,0.00008681538,0.00034574652,0.00019915921,0.00021384483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011543563,0.00016486367,0.0004931612,0.00049901294,0.000045863657,0.000012516006,0.00007036442,0.0000733366,0.00008107945],"category_scores_gemma":[0.00012898461,0.00011775173,0.000077414275,0.000864842,0.00017269875,0.00007257055,0.000052516334,0.00011069573,0.0000067040264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018999026,0.001383641,0.990764,0.00003527812,0.002064226,0.00006097365,0.00026592173,5.081246e-7,0.0011496583,0.0000076262936,0.000023943463,0.0023443135],"study_design_scores_gemma":[0.020771267,0.0018098069,0.9694571,0.000056775203,0.0012575234,0.000003922933,0.00003912927,0.0002940823,0.006140767,0.0000033989072,0.00006117653,0.000105087616],"about_ca_topic_score_codex":0.00055229664,"about_ca_topic_score_gemma":0.0032482774,"teacher_disagreement_score":0.021306945,"about_ca_system_score_codex":0.00003165294,"about_ca_system_score_gemma":0.000065854365,"threshold_uncertainty_score":0.48017764},"labels":[],"label_agreement":null},{"id":"W2902998154","doi":"10.1182/blood-2018-99-112697","title":"Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Internal medicine; Dexamethasone; Oncology; Gastroenterology","score_opus":0.06057921579186873,"score_gpt":0.3349619899212702,"score_spread":0.2743827741294015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902998154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953627,0.0014273104,0.000023145096,0.00017813932,0.00022539575,0.0023829087,0.000102862854,0.000036554913,0.0002610057],"genre_scores_gemma":[0.99722487,0.00016178725,0.0019782912,0.00002946276,0.00014785492,0.00009594381,0.00001742383,0.00006986333,0.0002745092],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643064,0.00040223103,0.00084002834,0.0007488481,0.0009157458,0.00066253514],"domain_scores_gemma":[0.99655265,0.0013028367,0.0003994724,0.0010840757,0.0002887786,0.00037218918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008907406,0.00044980628,0.0012049429,0.0003810626,0.0002009265,0.000028540357,0.0002972568,0.00022126258,0.000114096],"category_scores_gemma":[0.0029154217,0.00030061387,0.00014991258,0.0007493103,0.0006964325,0.00014818902,0.00033775522,0.00049374707,0.000008857995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22588456,0.020342326,0.57539463,0.0005924239,0.0044562826,0.0009649606,0.008284309,0.0000031531902,0.13403858,0.000029499892,0.00045469246,0.029554578],"study_design_scores_gemma":[0.5735987,0.017877283,0.31046635,0.0005836079,0.0013135076,0.00012473272,0.0038477632,0.0005795008,0.09090707,0.000051120867,0.00020490083,0.00044546108],"about_ca_topic_score_codex":0.0031032523,"about_ca_topic_score_gemma":0.013590184,"teacher_disagreement_score":0.34771416,"about_ca_system_score_codex":0.0001264746,"about_ca_system_score_gemma":0.00038549086,"threshold_uncertainty_score":0.9999446},"labels":[],"label_agreement":null},{"id":"W2903132660","doi":"10.1182/blood-2018-99-113504","title":"Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"MCL1; Cell culture; Apoptosis; Venetoclax; Stromal cell; Annexin A5; IC50; Programmed cell death; Molecular biology; Annexin; Chemistry; Cancer research; Medicine; Biology; Leukemia; Immunology; Biochemistry; Downregulation and upregulation; Genetics","score_opus":0.07668441025883248,"score_gpt":0.3614075094630266,"score_spread":0.2847230992041941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903132660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969731,0.000056442113,0.00004620168,0.00019590362,0.00007747601,0.0004970654,0.000036408397,0.000030593543,0.0020868203],"genre_scores_gemma":[0.99643636,0.000011541761,0.0028804543,0.00003419208,0.00030579005,0.00003310615,0.00001212714,0.000018274073,0.00026817553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987266,0.000046807723,0.00027145995,0.00029183875,0.00033175322,0.0003315237],"domain_scores_gemma":[0.9989921,0.00025359023,0.00006869608,0.00036176454,0.00012097466,0.00020286595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022540831,0.00012811356,0.00032736693,0.00012697892,0.000036662204,0.0000061424507,0.00008817118,0.000121667916,0.000115178904],"category_scores_gemma":[0.0009888258,0.00010374772,0.000095693336,0.00021137296,0.00020261665,0.00007015856,0.0000863771,0.00019389665,0.00006947427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012959964,0.010099517,0.797701,0.00008853287,0.00016490689,0.00007706181,0.00014636676,1.5632261e-7,0.17667654,0.000018058481,0.00010063884,0.013631208],"study_design_scores_gemma":[0.017404892,0.001063362,0.68371737,0.000107485306,0.000043548847,0.000021355962,0.000012955886,0.00040814432,0.29689053,0.00000930556,0.00024941727,0.000071619404],"about_ca_topic_score_codex":0.00026406956,"about_ca_topic_score_gemma":0.00033072638,"teacher_disagreement_score":0.12021398,"about_ca_system_score_codex":0.000031458054,"about_ca_system_score_gemma":0.0001395254,"threshold_uncertainty_score":0.4230709},"labels":[],"label_agreement":null},{"id":"W2903706649","doi":"10.3747/co.25.4188","title":"Incidence of Spinal Disease and Role of Spinal Radiotherapy in Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Multiple myeloma; Incidence (geometry); Radiation therapy; Disease; Spinal disease; Pathology; Internal medicine; Surgery; Lumbar","score_opus":0.08187249587261905,"score_gpt":0.43033239942894824,"score_spread":0.34845990355632916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903706649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99006814,0.00899018,0.00006526444,0.00018613291,0.000111848094,0.0004105398,0.0000145996455,0.000007906188,0.00014540182],"genre_scores_gemma":[0.9983428,0.0006648581,0.0007647525,0.000017652532,0.000146932,0.000031434894,0.000009554136,0.000008565851,0.000013412014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989681,0.00008515517,0.0002781986,0.00022158085,0.00020000197,0.00024696768],"domain_scores_gemma":[0.9992667,0.000063924526,0.00010346769,0.00019588905,0.00013182824,0.00023821613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015952793,0.000107899796,0.0003571936,0.00018635967,0.0000257054,0.0000022478262,0.000082254934,0.000053683656,0.00008742309],"category_scores_gemma":[0.00027052048,0.000089040965,0.000049544167,0.00015632281,0.00048536676,0.000047033383,0.000055993954,0.00012658487,0.0000068352406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057392744,0.0008173592,0.7033082,0.00015356147,0.000035689005,0.000044843255,0.00016820976,1.9495519e-7,0.01016143,0.00008306584,0.000033317767,0.27945483],"study_design_scores_gemma":[0.0055716387,0.005060498,0.9795246,0.00028885817,0.00003203506,0.000024255583,0.0000707264,0.001953228,0.0035829798,0.00016118895,0.0036645385,0.000065425505],"about_ca_topic_score_codex":0.00010446156,"about_ca_topic_score_gemma":0.00012205822,"teacher_disagreement_score":0.2793894,"about_ca_system_score_codex":0.00012269765,"about_ca_system_score_gemma":0.00028745734,"threshold_uncertainty_score":0.36309853},"labels":[],"label_agreement":null},{"id":"W2903833951","doi":"10.1016/j.clml.2018.12.007","title":"Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience","year":2018,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Medicine; Lenalidomide; Multiple myeloma; Cyclophosphamide; Single Center; Refractory (planetary science); Center (category theory); Oncology; Internal medicine; Chemotherapy","score_opus":0.04712718828424388,"score_gpt":0.3537560554148936,"score_spread":0.3066288671306497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903833951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39077225,0.6028127,0.000010237589,0.000022404745,0.00023240954,0.0051563927,0.0005429457,0.000041591993,0.0004090297],"genre_scores_gemma":[0.08478495,0.91242576,0.0007096333,0.00039772884,0.0001659811,0.0005566028,0.0007150438,0.00014096055,0.0001033696],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9924787,0.00071614597,0.0033365618,0.0014903194,0.0012265431,0.0007516864],"domain_scores_gemma":[0.99378306,0.001634995,0.0017114977,0.0013620255,0.00072498346,0.00078343676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008457327,0.0008950966,0.0048786975,0.00047267915,0.00007423044,0.000021850807,0.0003996072,0.00063775404,0.000119867625],"category_scores_gemma":[0.0051571648,0.0006394503,0.00071961066,0.0008236395,0.00081605196,0.0001838099,0.00030939942,0.0005343412,0.00007597432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004929451,0.0022713935,0.13920869,0.02705587,0.00050016283,0.00017922514,0.000083551044,5.3035585e-8,0.0000032033772,0.0000061732007,0.0007085012,0.82505375],"study_design_scores_gemma":[0.012672409,0.008727738,0.6865076,0.23069626,0.0005715643,0.000048209604,0.000011586669,0.000003289548,0.000035631245,0.000006051125,0.060231887,0.00048778087],"about_ca_topic_score_codex":0.000052879237,"about_ca_topic_score_gemma":0.000028508572,"teacher_disagreement_score":0.82456595,"about_ca_system_score_codex":0.0022121465,"about_ca_system_score_gemma":0.0010805733,"threshold_uncertainty_score":0.99960566},"labels":[],"label_agreement":null},{"id":"W2904685525","doi":"10.1016/j.bbmt.2018.12.141","title":"Revised International Staging System Is Predictive and Prognostic for Early Relapse (&lt;24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North; Science North","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Multiple myeloma; Stage (stratigraphy); Oncology; Cumulative incidence; Hematopoietic cell; Multivariate analysis; Transplantation; Overall survival; Hematopoietic stem cell transplantation; Single Center; Haematopoiesis; Stem cell","score_opus":0.013194137959614544,"score_gpt":0.2700705094641186,"score_spread":0.25687637150450404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904685525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817816,0.00048701413,0.013168816,0.00023006412,0.0001668255,0.0022334985,0.0018267586,0.000049098624,0.00005632275],"genre_scores_gemma":[0.9917171,0.00077470066,0.0057162344,0.000044748256,0.00012391212,0.0006778101,0.0008872293,0.000018411803,0.00003984517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989337,0.000054927994,0.00031135595,0.00035672312,0.00010890022,0.00023441605],"domain_scores_gemma":[0.9990246,0.00044709095,0.00011143126,0.00008690686,0.00022162255,0.00010830899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001635975,0.00016479321,0.00028952255,0.0001543968,0.00010189146,0.000014380685,0.000046742116,0.00014916986,0.0000064098945],"category_scores_gemma":[0.00007584591,0.00013888256,0.000069644906,0.00005186136,0.00018458578,0.00011235523,0.0000052466557,0.000059529906,9.028883e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031518806,0.00028373348,0.8546903,0.003920187,0.0011012196,0.000099238285,0.005671791,7.205899e-7,0.08485818,0.00022997966,0.000043544715,0.01758227],"study_design_scores_gemma":[0.03123826,0.005607836,0.89300567,0.0010523059,0.00203809,0.00020049248,0.0002574454,0.004776873,0.06133703,0.00013249803,0.00011491928,0.00023857738],"about_ca_topic_score_codex":0.000069521186,"about_ca_topic_score_gemma":0.00006449287,"teacher_disagreement_score":0.038315337,"about_ca_system_score_codex":0.000017111517,"about_ca_system_score_gemma":0.000047006055,"threshold_uncertainty_score":0.56634665},"labels":[],"label_agreement":null},{"id":"W2904768589","doi":"10.1182/blood-2018-99-113467","title":"Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Multiple myeloma; Lenalidomide; Oncology; AL amyloidosis; Phases of clinical research; Monoclonal gammopathy of undetermined significance; Clinical trial; Gastroenterology; Monoclonal; Immunology; Antibody; Monoclonal antibody","score_opus":0.01780307888727778,"score_gpt":0.2831513490794173,"score_spread":0.2653482701921395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904768589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962958,0.000052112366,0.000011669098,0.000032469223,0.000110826346,0.0022756981,0.0011258493,0.000054773955,0.000040820596],"genre_scores_gemma":[0.99858767,0.000057999463,0.0004498667,0.00003540674,0.00014390434,0.000077366094,0.0005564654,0.000054266908,0.00003703098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973911,0.0002965512,0.00059574115,0.0005787787,0.00065900123,0.00047884532],"domain_scores_gemma":[0.9979774,0.0003352814,0.00034590345,0.0009288731,0.00021567565,0.00019688431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024074194,0.0003131482,0.00051389704,0.00016175296,0.00018579315,0.00003298047,0.00028597124,0.00008840749,0.00010214355],"category_scores_gemma":[0.00042373204,0.00017185506,0.000056447785,0.00045729816,0.00018237215,0.00011476057,0.000107345426,0.00037065765,0.000028132818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045193344,0.01605729,0.91123194,0.0000067890546,0.0010717566,0.00016950793,0.003710566,0.0000033452145,0.00019084978,1.8112256e-7,0.000118461074,0.022245977],"study_design_scores_gemma":[0.20285504,0.012107841,0.77706665,0.00011155877,0.0002578645,0.0000014699852,0.0008103461,0.00023371393,0.006335578,0.0000033682718,0.00007321367,0.00014339105],"about_ca_topic_score_codex":0.011630367,"about_ca_topic_score_gemma":0.009716601,"teacher_disagreement_score":0.15766169,"about_ca_system_score_codex":0.00006678653,"about_ca_system_score_gemma":0.00010553138,"threshold_uncertainty_score":0.99495125},"labels":[],"label_agreement":null},{"id":"W2905416479","doi":"10.1002/hsr2.104","title":"Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice","year":2018,"lang":"en","type":"article","venue":"Health Science Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Takeda Oncology","keywords":"Bortezomib; Medicine; Multiple myeloma; Discontinuation; Refractory (planetary science); Internal medicine; Adverse effect; Dexamethasone; Lenalidomide; Surgery; Observational study; Prospective cohort study","score_opus":0.11497470099337953,"score_gpt":0.4948636398393963,"score_spread":0.37988893884601677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905416479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837281,0.00047731795,0.00005642695,0.00510747,0.0006092526,0.0029341546,0.0000066967687,0.00007987423,0.0070007225],"genre_scores_gemma":[0.968204,0.00089494,0.028558949,0.0009699911,0.0002546288,0.00014624663,0.000019696738,0.000020688682,0.0009308606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610084,0.00008923474,0.0010995609,0.0009790014,0.00083264586,0.00089869776],"domain_scores_gemma":[0.9965513,0.0006073679,0.00053479266,0.0007467266,0.0005111435,0.0010486706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059446455,0.00018289308,0.00050460786,0.00040422025,0.00044555002,0.0000461658,0.00008232672,0.00008147893,0.000019765574],"category_scores_gemma":[0.0056787124,0.00014215836,0.000069765774,0.0008210583,0.0008542985,0.00039436712,0.00008772232,0.0002577105,0.0000121842395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010443922,0.00083641254,0.90889543,0.00009082848,0.000025227466,0.001070763,0.00025633714,1.2827992e-7,0.00018436478,0.00006398577,0.0015718074,0.0859603],"study_design_scores_gemma":[0.0030938396,0.003142342,0.94999427,0.00019121553,0.000020856864,0.0006924266,0.00015127166,0.0007223362,0.00031903954,0.000086679094,0.041469175,0.00011657745],"about_ca_topic_score_codex":0.0021857584,"about_ca_topic_score_gemma":0.0017103751,"teacher_disagreement_score":0.08584372,"about_ca_system_score_codex":0.00074567756,"about_ca_system_score_gemma":0.003012001,"threshold_uncertainty_score":0.6798359},"labels":[],"label_agreement":null},{"id":"W2905442284","doi":"10.1182/blood-2018-99-117201","title":"Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; Royal Victoria Hospital; Dalhousie University; CancerCare Manitoba; Vancouver General Hospital; University of Calgary","funders":"","keywords":"Tolerability; Medicine; Daratumumab; Internal medicine; Carfilzomib; Neutropenia; Lenalidomide; Adverse effect; Refractory (planetary science); Gastroenterology; Phases of clinical research; Multiple myeloma; Oncology; Toxicity","score_opus":0.012893574554797959,"score_gpt":0.27032631820654307,"score_spread":0.2574327436517451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905442284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949212,0.00049403677,0.000004288909,0.000025734831,0.000012609712,0.0044292496,0.000056684246,0.000022031678,0.000034130524],"genre_scores_gemma":[0.9976908,0.000025345196,0.0019713768,0.000012174878,0.000026330496,0.00015562556,0.000023313198,0.00003926295,0.000055749195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769956,0.0002265109,0.0005486857,0.00058184034,0.00054925494,0.00039417768],"domain_scores_gemma":[0.99836713,0.0002302242,0.00021763954,0.0004972029,0.00036318006,0.0003245974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046780994,0.0002940382,0.00063557876,0.0004011496,0.00010249898,0.000023543835,0.00008192297,0.00007719502,0.0000030183987],"category_scores_gemma":[0.0005628612,0.00020267662,0.000020164893,0.00041836288,0.00030525684,0.00017423286,0.00011617481,0.00016107986,9.3492804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05492197,0.013512902,0.904572,0.00025257122,0.00044212147,0.000089330875,0.008933638,8.7144804e-7,0.008708919,5.054184e-7,0.0000061414003,0.008559014],"study_design_scores_gemma":[0.15554626,0.03735727,0.7750462,0.00058401853,0.00017871041,0.000019224079,0.001607696,0.000078211546,0.02937511,0.0000020082853,0.00001262136,0.00019261814],"about_ca_topic_score_codex":0.00044853508,"about_ca_topic_score_gemma":0.00063305005,"teacher_disagreement_score":0.12952577,"about_ca_system_score_codex":0.00003379451,"about_ca_system_score_gemma":0.00012246695,"threshold_uncertainty_score":0.82649124},"labels":[],"label_agreement":null},{"id":"W2905506084","doi":"10.1182/blood-2018-99-113177","title":"Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Internal medicine; Oncology; Minimal residual disease; Multiple myeloma; Dexamethasone; Bone marrow","score_opus":0.03312665798193124,"score_gpt":0.30586820979717566,"score_spread":0.2727415518152444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905506084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968373,0.0002770079,0.000039242677,0.00007234095,0.000013869293,0.002387072,0.0002350879,0.000024709223,0.00011337906],"genre_scores_gemma":[0.9978346,0.000023108601,0.001330713,0.000010947578,0.000025739822,0.00017550647,0.00045444389,0.000047239264,0.00009769613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529785,0.0009415987,0.0007573429,0.000716573,0.0017512398,0.0005354094],"domain_scores_gemma":[0.99632007,0.0006808635,0.00052397244,0.0005966035,0.0015021152,0.00037635613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013980021,0.00039726327,0.0011564874,0.0014930626,0.00009357358,0.000021552558,0.00012639146,0.00016124386,0.00007834966],"category_scores_gemma":[0.002859875,0.00028641627,0.00009190271,0.0023757364,0.00050585996,0.00026271743,0.0000747162,0.0002615345,0.0000014005284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054401983,0.006160926,0.92711085,0.00018787663,0.0022789293,0.0002745855,0.0013029242,0.0001335659,0.0014936049,0.0000047387634,0.000009709467,0.006640284],"study_design_scores_gemma":[0.12319801,0.005994881,0.8369842,0.00032206264,0.0050081485,0.0000070467713,0.000625124,0.021059044,0.006555841,0.0000075887,0.000002226471,0.0002358355],"about_ca_topic_score_codex":0.0035021,"about_ca_topic_score_gemma":0.021275777,"teacher_disagreement_score":0.09012668,"about_ca_system_score_codex":0.0007586195,"about_ca_system_score_gemma":0.0015004918,"threshold_uncertainty_score":0.9999588},"labels":[],"label_agreement":null},{"id":"W2905731813","doi":"10.1016/j.jval.2018.09.170","title":"PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBEC","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Takeda (Canada)","funders":"","keywords":"Ixazomib; Lenalidomide; Carfilzomib; Multiple myeloma; Medicine; Dexamethasone; Intensive care medicine; Oncology; Internal medicine","score_opus":0.04407377388686907,"score_gpt":0.3565733311433827,"score_spread":0.3124995572565136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905731813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966597,0.000500062,0.00012803452,0.00050220825,0.000005931129,0.0021227929,0.000061874794,0.000004175729,0.00001520092],"genre_scores_gemma":[0.99687237,0.00031200587,0.0025010812,0.000027969481,0.00001298553,0.00014967936,0.00010013754,0.0000119721035,0.000011773884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845976,0.00027565644,0.00041741165,0.00024476755,0.00028591102,0.00031651105],"domain_scores_gemma":[0.99848866,0.00083854445,0.00018976332,0.00027143263,0.000108687906,0.0001029065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066084915,0.00014576787,0.0006540544,0.00067619793,0.000030083665,0.000006873245,0.000054510365,0.00004559692,0.0000070106016],"category_scores_gemma":[0.00014072817,0.000077029574,0.000059363625,0.0010914494,0.0001381108,0.000059667575,0.0000061788087,0.0000655446,2.468384e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012249445,0.0018813094,0.9559809,0.00024897698,0.00037626503,0.000018099621,0.008113316,0.00062979467,0.00006076037,0.00004274727,0.0000037258733,0.020394677],"study_design_scores_gemma":[0.02495791,0.013112571,0.9064336,0.0004192884,0.000108983935,0.0000054866573,0.0009749035,0.053306952,0.0005920643,0.000021731923,0.0000100459665,0.000056463876],"about_ca_topic_score_codex":0.31364703,"about_ca_topic_score_gemma":0.24660146,"teacher_disagreement_score":0.06704557,"about_ca_system_score_codex":0.0004543261,"about_ca_system_score_gemma":0.0003703982,"threshold_uncertainty_score":0.7671461},"labels":[],"label_agreement":null},{"id":"W2905841490","doi":"10.1182/blood-2018-99-111920","title":"Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; McGill University Health Centre","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Daratumumab; Population; Multiple myeloma; Internal medicine; Regimen; Clinical endpoint; Cohort; Dexamethasone; Progressive disease; Surgery; Oncology; Clinical trial; Chemotherapy","score_opus":0.02318288688704756,"score_gpt":0.2923809173059088,"score_spread":0.26919803041886126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905841490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657065,0.0007614171,0.000029244931,0.00056122104,0.00007567563,0.0014055391,0.000072201394,0.00010621865,0.0004178584],"genre_scores_gemma":[0.98951966,0.00008321483,0.008197632,0.00024592492,0.0002813014,0.0004880633,0.00008365138,0.0000755603,0.0010249742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726427,0.00022894975,0.00048738482,0.00075539976,0.00047308693,0.00079088507],"domain_scores_gemma":[0.9979898,0.00045326535,0.000111488036,0.0007517591,0.00014845286,0.000545289],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026204914,0.00045953522,0.0006920472,0.00040301218,0.00014265467,0.00005465127,0.000118738106,0.00024640106,0.00048627213],"category_scores_gemma":[0.00058823475,0.000321923,0.00016356583,0.00039348193,0.0003113818,0.00012241407,0.00006928562,0.00027876362,0.00020954864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055481132,0.014410154,0.82622975,0.00035429344,0.0011226526,0.009995099,0.001210518,0.0000027644587,0.057096433,0.0000139015065,0.00028096733,0.033802364],"study_design_scores_gemma":[0.18167719,0.010315624,0.67328995,0.00084280217,0.00053018704,0.00036068785,0.00023872926,0.0008526544,0.12533735,0.00002923247,0.0058617466,0.0006638211],"about_ca_topic_score_codex":0.00051632244,"about_ca_topic_score_gemma":0.0039696624,"teacher_disagreement_score":0.15293975,"about_ca_system_score_codex":0.00028182633,"about_ca_system_score_gemma":0.0003912836,"threshold_uncertainty_score":0.9999233},"labels":[],"label_agreement":null},{"id":"W2906220152","doi":"10.1182/blood-2018-99-117824","title":"MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Western University; Saint John Regional Hospital; Hôtel-Dieu de Québec; University of Ottawa; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Alberta; University of New Brunswick; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Carfilzomib; Medicine; Dexamethasone; Cyclophosphamide; Internal medicine; Multiple myeloma; Oncology; Refractory (planetary science); Phases of clinical research; Progressive disease; Lenalidomide; Clinical trial; Gastroenterology; Pharmacology; Urology; Chemotherapy","score_opus":0.028921294288764245,"score_gpt":0.30297931295058567,"score_spread":0.27405801866182145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906220152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941535,0.0027432141,0.00000382287,0.00019064895,0.000052213232,0.002647701,0.00006869183,0.0000248875,0.00011532097],"genre_scores_gemma":[0.9975755,0.00029923732,0.0013270682,0.000033868702,0.000092329254,0.0004018772,0.000019905436,0.00003491511,0.00021528716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979632,0.00021708691,0.0004885593,0.00043144802,0.00049202034,0.0004077054],"domain_scores_gemma":[0.99850976,0.0003696971,0.00016333172,0.00066958816,0.00013650864,0.00015113411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023505083,0.00030346125,0.0007017722,0.00020253833,0.00012133734,0.00001596211,0.00013522129,0.00009326848,0.000067356064],"category_scores_gemma":[0.00016102003,0.00018501785,0.000101192825,0.00036260375,0.0003022481,0.000071497176,0.000062063256,0.000114137416,0.000005099402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025820848,0.226303,0.49037376,0.0001702484,0.00262994,0.0013836051,0.08831641,0.000001421126,0.034565188,0.000010331476,0.000029143932,0.1303961],"study_design_scores_gemma":[0.17140235,0.10544623,0.65130556,0.00014480435,0.0006956229,0.000056928628,0.0055175805,0.00007251913,0.06479404,0.000036615023,0.0003199618,0.00020782427],"about_ca_topic_score_codex":0.0022215839,"about_ca_topic_score_gemma":0.0018499345,"teacher_disagreement_score":0.16093175,"about_ca_system_score_codex":0.00009227672,"about_ca_system_score_gemma":0.0001077649,"threshold_uncertainty_score":0.7544809},"labels":[],"label_agreement":null},{"id":"W2906428280","doi":"10.1182/blood-2018-99-118691","title":"A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immune system; Biology; Multiple myeloma; Tumor microenvironment; Plasma cell; Pathogenesis; Monoclonal gammopathy of undetermined significance; Bone marrow; Cancer research; Transcriptome; Gene expression profiling; Immunology; Gene expression; Gene; Monoclonal; Monoclonal antibody; Antibody; Genetics","score_opus":0.014724086288724575,"score_gpt":0.2251622792467876,"score_spread":0.21043819295806304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906428280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980152,0.0010289608,0.0002921229,0.00008312057,0.0000041099465,0.0003836766,0.00014232236,0.000004827757,0.000045618657],"genre_scores_gemma":[0.9992089,0.00013607855,0.00039145956,0.000004959091,0.000010617724,0.000025314917,0.000021519732,0.000009562003,0.00019153532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990378,0.00006057649,0.00028601778,0.0001780879,0.00026283023,0.00017469317],"domain_scores_gemma":[0.9995726,0.000027892132,0.00006359611,0.00020260645,0.000030322119,0.0001029832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012555071,0.00010007437,0.00030115747,0.00022667834,0.000037063353,0.0000035191838,0.000058768175,0.000028247201,0.0000331279],"category_scores_gemma":[0.000010704543,0.00007100914,0.0001843083,0.00021838426,0.00026596963,0.000034253047,0.00001626325,0.000063626954,0.0000015415634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023176132,0.002237604,0.025633048,0.00012538116,0.00063372334,0.000004696686,0.0005800063,0.00022387487,0.96817905,0.000026405833,1.7645768e-7,0.000038398975],"study_design_scores_gemma":[0.013290628,0.00013614265,0.45097426,0.00003141878,0.0016670848,8.276792e-7,0.000053115913,0.01164993,0.5221307,0.000020466405,3.548398e-7,0.000045079913],"about_ca_topic_score_codex":0.00011191056,"about_ca_topic_score_gemma":0.000057953843,"teacher_disagreement_score":0.44604838,"about_ca_system_score_codex":0.000042819585,"about_ca_system_score_gemma":0.00004316577,"threshold_uncertainty_score":0.28956687},"labels":[],"label_agreement":null},{"id":"W2906981998","doi":"10.1182/blood-2018-99-111869","title":"Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Bortezomib; Dexamethasone; Lenalidomide; Medicine; Multiple myeloma; Internal medicine; Oncology; Subgroup analysis; Thalidomide; Confidence interval","score_opus":0.019588685657509066,"score_gpt":0.299463498173763,"score_spread":0.27987481251625396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906981998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991994,0.00027867517,0.00005503429,0.00014358197,0.0001701926,0.006131695,0.00081010256,0.00011131101,0.00030538664],"genre_scores_gemma":[0.99430835,0.000067643945,0.0026324845,0.00015267855,0.0002544929,0.00059271784,0.0010650788,0.00014594653,0.00078059995],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931832,0.00076935475,0.0016282116,0.0014648559,0.0015328686,0.0014215164],"domain_scores_gemma":[0.9944614,0.0008834086,0.00082404417,0.002189385,0.00078073674,0.0008610349],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079238875,0.0010419535,0.00255235,0.0013093096,0.0002846924,0.00008685724,0.00055716763,0.00040473568,0.0011277478],"category_scores_gemma":[0.0013636986,0.0006669636,0.00095293927,0.003667753,0.0007030246,0.00029874037,0.00021886303,0.00050675357,0.00006563313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33210835,0.049875792,0.58529973,0.00014717583,0.016670391,0.0007067243,0.000998213,0.00010187181,0.007499657,0.000007991297,0.000053033862,0.0065310565],"study_design_scores_gemma":[0.5110155,0.017144272,0.37662825,0.00028057233,0.0074493005,0.000025283263,0.00012163251,0.0026464465,0.08407742,0.000008521809,0.00006175802,0.0005410839],"about_ca_topic_score_codex":0.0030270573,"about_ca_topic_score_gemma":0.00415123,"teacher_disagreement_score":0.2086715,"about_ca_system_score_codex":0.00057793903,"about_ca_system_score_gemma":0.0008125878,"threshold_uncertainty_score":0.99978536},"labels":[],"label_agreement":null},{"id":"W2907519508","doi":"10.1182/blood-2018-99-117363","title":"Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; University Health Network; Ottawa Hospital; CancerCare Manitoba; Saint John Regional Hospital; Leukemia & Lymphoma Society of Canada; University of New Brunswick; Hôpital Maisonneuve-Rosemont; University of Calgary; Princess Margaret Cancer Centre; University of Ottawa; McGill University Health Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Bortezomib; Dexamethasone; Exact test; Internal medicine; Log-rank test; Regimen; Oncology; Survival analysis","score_opus":0.08947436621363755,"score_gpt":0.36217797116085987,"score_spread":0.27270360494722234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907519508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427384,0.0005211549,0.0002820028,0.0012661755,0.00007552009,0.0020234191,0.0012045441,0.000016324351,0.00033699567],"genre_scores_gemma":[0.9920958,0.00028940226,0.0052313474,0.00012891866,0.00037423012,0.00045025628,0.0009707302,0.000023336233,0.00043593772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974957,0.000110763525,0.00039353708,0.00041810333,0.0010578405,0.000524022],"domain_scores_gemma":[0.9961687,0.0023492028,0.00014169466,0.00042282138,0.00072481815,0.00019281352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007359448,0.00022287092,0.00040194477,0.00007939496,0.00066804804,0.00002949183,0.00013852218,0.000041193456,0.000023485947],"category_scores_gemma":[0.00039314633,0.00010264608,0.00007199541,0.00028544426,0.00043607206,0.00007366073,0.00003953273,0.00014376805,0.0000011786157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00459827,0.0011214342,0.98824507,0.000029664834,0.0022729093,0.00030434784,0.00050470425,0.000035992558,0.00013144652,0.00024184356,0.0014516829,0.001062641],"study_design_scores_gemma":[0.03481646,0.0014897417,0.9527583,0.00026373236,0.00057774264,0.000084561325,0.00020566466,0.0012649418,0.0023143457,0.000037545782,0.006032318,0.00015463213],"about_ca_topic_score_codex":0.42872465,"about_ca_topic_score_gemma":0.68456256,"teacher_disagreement_score":0.25583792,"about_ca_system_score_codex":0.00037738946,"about_ca_system_score_gemma":0.0021882022,"threshold_uncertainty_score":0.5750795},"labels":[],"label_agreement":null},{"id":"W2908013812","doi":"10.1182/blood-2018-99-111533","title":"Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Vancouver General Hospital; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Lenalidomide; Autologous stem-cell transplantation; Internal medicine; Oncology; Multiple myeloma; Population; Bortezomib; Surgery","score_opus":0.017135795948242282,"score_gpt":0.24143210044389063,"score_spread":0.22429630449564836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908013812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977307,0.000060017366,0.00003580299,0.000030343343,0.00005565064,0.0007771124,0.0012535055,0.000014154292,0.00004271212],"genre_scores_gemma":[0.9980333,0.00013158134,0.001018615,0.000022791362,0.000058817808,0.000017208866,0.00066691986,0.00002233598,0.000028461338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849087,0.00013250054,0.00048341707,0.0002623489,0.0003956426,0.00023522813],"domain_scores_gemma":[0.99899286,0.000113973234,0.0002606089,0.00034211483,0.00016904753,0.00012138509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002641253,0.00016501526,0.00040200268,0.00011616984,0.00006595669,0.000009464199,0.00010719013,0.00010588749,0.000012868408],"category_scores_gemma":[0.00009031292,0.00011545199,0.000048260295,0.00010318368,0.00010762203,0.00007212089,0.00001451622,0.00019267797,0.000003936701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015201579,0.005316774,0.97243345,0.00018345162,0.00013695509,0.00003626671,0.0039476156,0.0000010270253,0.012056464,0.000011785232,0.0000023626071,0.0043536997],"study_design_scores_gemma":[0.012175999,0.0025608384,0.9625862,0.00014780277,0.0002732803,0.000006761443,0.00017059491,0.0003791234,0.021590905,0.0000067328506,0.0000058669207,0.00009588437],"about_ca_topic_score_codex":0.002914934,"about_ca_topic_score_gemma":0.0013129044,"teacher_disagreement_score":0.010655841,"about_ca_system_score_codex":0.00002678073,"about_ca_system_score_gemma":0.000039966286,"threshold_uncertainty_score":0.47079957},"labels":[],"label_agreement":null},{"id":"W2908473823","doi":"10.1182/blood-2018-99-111554","title":"Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; McGill University Health Centre; University of Calgary","funders":"","keywords":"Pomalidomide; Daratumumab; Lenalidomide; Medicine; Multiple myeloma; Immunology; Immune system; Dexamethasone; Oncology; Internal medicine; Cancer research","score_opus":0.01639173408916918,"score_gpt":0.26744380952402597,"score_spread":0.2510520754348568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908473823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981476,0.00012833477,0.000013868625,0.000021857777,0.0000127782005,0.0012904516,0.000020151752,0.000035787776,0.00032915664],"genre_scores_gemma":[0.9946282,0.000027013979,0.004883568,0.00000992871,0.000018422206,0.000074622614,0.00015755468,0.000037154347,0.00016355369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985479,0.0001004479,0.00031408868,0.00033412094,0.00038847295,0.0003149652],"domain_scores_gemma":[0.9988753,0.0001621687,0.0001635059,0.0003193113,0.00033196574,0.00014769916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016016158,0.000203453,0.00041504484,0.00023938673,0.00007718604,0.000013571912,0.000062860054,0.00009074487,0.000022084678],"category_scores_gemma":[0.00033238836,0.00012566165,0.00002515796,0.00041720082,0.00022945688,0.0001447897,0.000036551617,0.00016908896,0.0000056385743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018074995,0.0047749346,0.9458362,0.0001593905,0.00026501878,0.00023036073,0.00028937598,3.1001056e-7,0.026062591,0.000006102752,0.0000024012452,0.0042983154],"study_design_scores_gemma":[0.07568302,0.009292391,0.73849016,0.0004989652,0.000118730975,0.000034889403,0.00009595782,0.00026025614,0.17539884,0.0000025560278,0.0000056485633,0.00011858311],"about_ca_topic_score_codex":0.00035775738,"about_ca_topic_score_gemma":0.00032687085,"teacher_disagreement_score":0.20734604,"about_ca_system_score_codex":0.00006242504,"about_ca_system_score_gemma":0.00013436154,"threshold_uncertainty_score":0.51243335},"labels":[],"label_agreement":null},{"id":"W2908650768","doi":"10.6004/jnccn.2018.7079","title":"Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology","score_opus":0.03695116062310916,"score_gpt":0.2964003712810561,"score_spread":0.25944921065794696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908650768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974635,0.0010967364,0.0000066145662,0.0004559785,0.00032303506,0.00056297705,0.00003318777,0.000003060591,0.000054909204],"genre_scores_gemma":[0.9978582,0.00014181956,0.0011663772,0.00047009936,0.00014278463,0.00001006799,0.00000941091,0.000017098111,0.00018412663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998119,0.00008655544,0.00040583342,0.00012786462,0.001035833,0.00022492424],"domain_scores_gemma":[0.9963516,0.00082026585,0.0004478172,0.00012254102,0.002155487,0.00010231076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079915655,0.00013711929,0.00037551887,0.00012476322,0.00004101972,0.000014866289,0.00015284056,0.00005356091,0.00009764435],"category_scores_gemma":[0.00023214151,0.00007903557,0.00013976538,0.000441075,0.00006655813,0.00017014515,0.000050222126,0.00029910257,0.0000044775798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038440835,0.0002496794,0.9516325,0.000036302532,0.0003308194,0.000015159775,0.00005948619,0.037344478,0.00022207823,0.000019102583,0.0030068785,0.00323942],"study_design_scores_gemma":[0.009324689,0.00063096173,0.9834658,0.0006942622,0.000039145743,0.000010378471,0.000020668955,0.0011876759,0.0004665252,0.000077127865,0.0040076445,0.000075118034],"about_ca_topic_score_codex":0.00014774992,"about_ca_topic_score_gemma":0.00010829662,"teacher_disagreement_score":0.0361568,"about_ca_system_score_codex":0.00027414178,"about_ca_system_score_gemma":0.00035289908,"threshold_uncertainty_score":0.3222977},"labels":[],"label_agreement":null},{"id":"W2909071270","doi":"10.1182/blood-2018-99-110140","title":"Economics of Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Cohort; Retrospective cohort study; Health care; Cancer; Pharmacy; Emergency medicine; Family medicine; Internal medicine","score_opus":0.027497074112993864,"score_gpt":0.2880651789637725,"score_spread":0.26056810485077864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909071270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876481,0.000076591394,0.000013746958,0.0000904097,0.000037689842,0.00018263138,0.000017340517,0.000021277707,0.011912172],"genre_scores_gemma":[0.9965883,0.00003387621,0.0025491267,0.000042285348,0.00017162853,0.000008837632,0.000015375013,0.000011314117,0.0005792558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948716,0.000010348882,0.00012795697,0.00012675369,0.00007748585,0.0001702727],"domain_scores_gemma":[0.9994841,0.0000410424,0.000034443157,0.00023924746,0.00007852681,0.0001226157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005292061,0.000064868014,0.00015167437,0.000058132664,0.000029768922,0.00000396809,0.00005154504,0.000038045433,0.0002056604],"category_scores_gemma":[0.000110429944,0.000052880667,0.000055190623,0.000057359754,0.000097353244,0.00002831623,0.00003170046,0.000041402665,0.00019893551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040215935,0.0015919729,0.95111686,0.000065138636,0.0004527714,0.00005522153,0.00016663199,1.7572073e-7,0.02187773,0.00024415375,0.00031699633,0.02371018],"study_design_scores_gemma":[0.010288192,0.0010589706,0.5686606,0.000034726225,0.000093858194,0.000059958777,0.00003422872,0.00027551476,0.41564214,0.000096442585,0.0036809323,0.00007440464],"about_ca_topic_score_codex":0.000054992248,"about_ca_topic_score_gemma":0.000043381595,"teacher_disagreement_score":0.3937644,"about_ca_system_score_codex":0.00001198427,"about_ca_system_score_gemma":0.000062629326,"threshold_uncertainty_score":0.25569797},"labels":[],"label_agreement":null},{"id":"W2910636995","doi":"10.3390/cancers11020248","title":"Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions","keywords":"CD38; Chemistry; IC50; Cell culture; Cancer research; Pharmacology; Molecular biology; Medicine; In vitro; Biology; Biochemistry; Cell biology; Stem cell; Genetics","score_opus":0.025549844186919093,"score_gpt":0.3065976148937081,"score_spread":0.28104777070678905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910636995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997321,0.0002683788,0.0000033499712,0.0006355572,0.00020941734,0.00089946034,0.000027384958,0.00002386758,0.00061160285],"genre_scores_gemma":[0.99919826,0.000073868236,0.000029251129,0.00036536664,0.00008651854,0.000041002684,0.000020789284,0.000020316616,0.00016465617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989721,0.0000510097,0.00017752693,0.00020968744,0.00031088217,0.00027879086],"domain_scores_gemma":[0.99926114,0.00011918114,0.00008266939,0.00033009256,0.00009557915,0.00011134896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111078756,0.000121668905,0.00020515804,0.000060255385,0.00007044148,0.00001745262,0.000078253746,0.000039886065,0.000044844328],"category_scores_gemma":[0.000059979375,0.000075723154,0.0000724245,0.00016778067,0.000081793216,0.000043710064,0.000019145291,0.00012753705,0.00003858784],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077113253,0.000077782475,0.037259903,0.00009399312,0.00023808464,0.000019234738,0.0010775471,0.00048364777,0.86654466,0.00009174139,0.0001522578,0.09319001],"study_design_scores_gemma":[0.0067323176,0.0013775879,0.16268198,0.00023697766,0.00007962079,0.0000033403778,0.0011983535,0.0037602845,0.8228335,0.00002735604,0.00090835185,0.00016035532],"about_ca_topic_score_codex":0.0003611265,"about_ca_topic_score_gemma":0.00009391916,"teacher_disagreement_score":0.12542208,"about_ca_system_score_codex":0.00058187055,"about_ca_system_score_gemma":0.0005971953,"threshold_uncertainty_score":0.30879006},"labels":[],"label_agreement":null},{"id":"W2910763590","doi":"10.1182/blood-2018-99-112313","title":"Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Fludarabine; Minimal residual disease; Bortezomib; Transplantation; Internal medicine; Autologous stem-cell transplantation; Oncology; Multiple myeloma; Bone marrow; Surgery; Cyclophosphamide; Chemotherapy","score_opus":0.018830946460843448,"score_gpt":0.29474875021054175,"score_spread":0.2759178037496983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910763590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677014,0.0002361154,0.00021436343,0.000025320958,0.00009290726,0.0015536807,0.0010477368,0.000021834245,0.000037912072],"genre_scores_gemma":[0.9939914,0.0004210608,0.0044628447,0.00001419913,0.00017415386,0.00011507153,0.00076654705,0.000026855034,0.000027863185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976375,0.00040298013,0.00049185404,0.0004057121,0.0007665908,0.0002953248],"domain_scores_gemma":[0.99866325,0.000137743,0.00024915955,0.00023784443,0.0004621525,0.00024986634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059072615,0.00019751856,0.00033705786,0.00036562566,0.00010192471,0.00001993641,0.000050491188,0.0001314031,0.00010665778],"category_scores_gemma":[0.0011966446,0.00015995427,0.00004932674,0.00032223813,0.00014460187,0.00024573802,0.000025127001,0.00016846071,0.0000067712213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013694877,0.0011168666,0.97522026,0.00012216758,0.00023919674,0.000098868164,0.00092973834,0.00001338392,0.00029410177,7.231638e-7,0.00001913272,0.008250697],"study_design_scores_gemma":[0.029605875,0.0016366079,0.94444877,0.00039034119,0.0018440814,0.0000104570245,0.000066366796,0.01751557,0.0043081106,0.000042204425,0.0000021345493,0.00012947813],"about_ca_topic_score_codex":0.0004178028,"about_ca_topic_score_gemma":0.0006688906,"teacher_disagreement_score":0.030771473,"about_ca_system_score_codex":0.00012539742,"about_ca_system_score_gemma":0.00024657737,"threshold_uncertainty_score":0.6522746},"labels":[],"label_agreement":null},{"id":"W2911780157","doi":"10.1097/rlu.0000000000002462","title":"Multiple Myeloma of Testes and Spermatic Cord on 18F-FDG PET/CT","year":2019,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North; Science North","funders":"","keywords":"Spermatic cord; Medicine; Histopathology; Scrotum; Multiple myeloma; Avidity; Pathology; Radiology; Internal medicine; Anatomy; Antibody","score_opus":0.06490931944747702,"score_gpt":0.38979650604620514,"score_spread":0.3248871865987281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911780157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98629534,0.0002127387,9.181928e-7,0.003751807,0.00023752058,0.00075042376,0.000010635977,0.00005563727,0.008684947],"genre_scores_gemma":[0.99597096,0.00037044793,0.0006182288,0.0016572095,0.00020887617,0.0000043981613,0.000028292225,0.00004328797,0.00109831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997861,0.00012366314,0.0007507622,0.00040445974,0.0005358205,0.0003242388],"domain_scores_gemma":[0.9965598,0.0020612276,0.00016673253,0.00058876077,0.00011169483,0.000511791],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00057083135,0.00020815768,0.0008931358,0.00013224034,0.000045128945,0.0000063639654,0.00013057761,0.000026954713,0.0016055304],"category_scores_gemma":[0.0035459215,0.0001350626,0.00012997638,0.00016307273,0.0005640199,0.00004964871,0.00009180235,0.00041417603,0.0009489461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036270886,0.0012346095,0.92467815,0.0006639257,0.00035864615,0.0017777942,0.000103452374,5.2126865e-7,0.0025402398,0.00039607318,0.0076596406,0.056959853],"study_design_scores_gemma":[0.017223869,0.012224064,0.9502125,0.0013180863,0.00016321214,0.0006049975,0.0004005898,0.002765988,0.00014771898,0.00012295455,0.014652243,0.0001638258],"about_ca_topic_score_codex":0.000060212435,"about_ca_topic_score_gemma":0.0000042499432,"teacher_disagreement_score":0.056796025,"about_ca_system_score_codex":0.000030810927,"about_ca_system_score_gemma":0.00004567332,"threshold_uncertainty_score":0.99982893},"labels":[],"label_agreement":null},{"id":"W2913119958","doi":"10.1016/bs.acc.2018.12.001","title":"Laboratory assessment of multiple myeloma","year":2019,"lang":"en","type":"review","venue":"Advances in clinical chemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Multiple myeloma; Immunoglobulin light chain; Serum protein electrophoresis; Medicine; Myeloma protein; Computational biology; Monoclonal; Antibody; Immunology; Monoclonal antibody; Biology","score_opus":0.12046626307825203,"score_gpt":0.5324718721095519,"score_spread":0.4120056090312999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913119958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004074126,0.990552,0.000006163911,0.000009138911,0.00019470046,0.00082613504,0.00022016391,0.000025404719,0.0077588796],"genre_scores_gemma":[0.0010184353,0.9953992,0.0018833837,0.000019138055,0.00024681422,0.00013146362,0.0003771652,0.00005330415,0.0008710955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965056,0.00015116372,0.0017501827,0.0006963939,0.0005065036,0.00039012087],"domain_scores_gemma":[0.99548197,0.0025115563,0.000641327,0.0009542913,0.00014252252,0.00026832873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064821023,0.00039044872,0.0030178041,0.0000653497,0.000016430504,0.000006928909,0.0003135202,0.0006015426,0.00021060188],"category_scores_gemma":[0.001878659,0.00029599396,0.00072926277,0.00035328593,0.00024070372,0.00008472483,0.00016584447,0.0012651295,0.000058931633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051919946,0.00075387897,0.045692734,0.0699735,0.00023335764,0.00017238224,0.0000013434693,6.832827e-7,0.0000046340565,0.0000036808653,0.000065862536,0.88304603],"study_design_scores_gemma":[0.0024412828,0.00016256506,0.0016799825,0.01797642,0.00038274293,0.000014621782,0.000007679965,0.0000338992,0.000049496233,0.000009218597,0.9769998,0.00024225998],"about_ca_topic_score_codex":0.0000031056243,"about_ca_topic_score_gemma":0.000002562452,"teacher_disagreement_score":0.97693396,"about_ca_system_score_codex":0.00022758286,"about_ca_system_score_gemma":0.0013977976,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W2913302924","doi":"10.1182/blood-2018-99-117531","title":"Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; TIGIT; Pomalidomide; CD38; Bone marrow; Immunotherapy; Biology; Cancer research; Immunology; Immune system; Antibody; Multiple myeloma; Monoclonal antibody; CD34; Stem cell; Lenalidomide","score_opus":0.012237757286525952,"score_gpt":0.2354026129571714,"score_spread":0.22316485567064545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913302924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969261,0.00026780897,0.0000025039087,0.0000136101435,0.000016998403,0.00062862644,0.000013760227,0.00001581281,0.002114752],"genre_scores_gemma":[0.99770564,0.000020541735,0.0020407564,0.000007173539,0.00004190434,0.000019787762,0.000059987586,0.000019434423,0.00008478855],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988613,0.000048161266,0.00031788912,0.00026900184,0.00028256734,0.000221079],"domain_scores_gemma":[0.99938095,0.000053648422,0.00015568094,0.00017735364,0.0001386545,0.000093730436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017211246,0.00014835614,0.00023062697,0.00015777923,0.00007765233,0.000026082707,0.000029133718,0.00007116487,0.000006436968],"category_scores_gemma":[0.00007662284,0.00011570696,0.000020076217,0.00017079331,0.0000980721,0.00011241864,0.00003343265,0.00008376508,0.0000019757197],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013549567,0.0010095354,0.538782,0.00030946004,0.000025270298,0.00001427855,0.00036109463,0.0000016529572,0.45720345,0.000007489805,0.000003118652,0.0009276531],"study_design_scores_gemma":[0.009360002,0.0029778616,0.36524525,0.00051562506,0.00004109271,0.000004687681,0.000107654334,0.0000992231,0.62154347,0.000017154594,0.000003394706,0.00008456466],"about_ca_topic_score_codex":0.00010354189,"about_ca_topic_score_gemma":0.000027492622,"teacher_disagreement_score":0.17353676,"about_ca_system_score_codex":0.00008223608,"about_ca_system_score_gemma":0.000059074875,"threshold_uncertainty_score":0.47183925},"labels":[],"label_agreement":null},{"id":"W2914157523","doi":"10.1038/s41375-018-0374-8","title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","year":2019,"lang":"en","type":"letter","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Emory University; U.S. Department of Health and Human Services","keywords":"Venetoclax; Multiple myeloma; Medicine; Oncology; Immunology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.06348571096583726,"score_gpt":0.3297354700999637,"score_spread":0.2662497591341264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914157523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95399046,0.00010109048,0.000037871192,0.04237746,0.0006060605,0.0018845294,0.00056204776,0.00006656347,0.000373895],"genre_scores_gemma":[0.935045,0.00004155669,0.0011428741,0.052306,0.0028600814,0.00011894641,0.0029640824,0.00012153908,0.005399944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555296,0.0011089385,0.00087484816,0.0007814476,0.0009907102,0.00069107424],"domain_scores_gemma":[0.99507135,0.0033991914,0.00028974816,0.00085125637,0.00022155221,0.00016689986],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001506705,0.00039981198,0.0011234873,0.0004249699,0.000045929755,0.000014008981,0.00012257186,0.0012213669,0.00009774354],"category_scores_gemma":[0.002725073,0.00034896383,0.0003896275,0.0002612885,0.00023529337,0.00005040334,0.00013708933,0.0030242847,0.00015551769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02116636,0.00015416808,0.64366865,0.0009852786,0.0006099112,0.010207966,0.0000615219,0.0001814888,0.0034952615,0.0000015863914,0.31653568,0.0029321497],"study_design_scores_gemma":[0.01045048,0.0011964246,0.94314706,0.0008141705,0.00013565955,0.00021385605,0.000019206545,0.008061323,0.0027752444,0.000010003128,0.032852,0.00032458158],"about_ca_topic_score_codex":0.0010527261,"about_ca_topic_score_gemma":0.00014740576,"teacher_disagreement_score":0.2994784,"about_ca_system_score_codex":0.002502621,"about_ca_system_score_gemma":0.00529088,"threshold_uncertainty_score":0.9998962},"labels":[],"label_agreement":null},{"id":"W2914429602","doi":"10.14740/jmc.v10i2.3223","title":"Utility of Fine Needle Aspiration for Diagnosis of Plasmacytoma","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Fine-needle aspiration; Sternum; Pathology; Biopsy; Radiology; Open biopsy; Rib cage; Bone marrow; Multiple myeloma; Surgery; Anatomy; Internal medicine","score_opus":0.07293397319353043,"score_gpt":0.3797797857474395,"score_spread":0.3068458125539091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914429602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685854,0.0005292586,0.00013614997,0.001886962,0.000108770735,0.00026677756,0.000033317643,0.0000024003828,0.00017784571],"genre_scores_gemma":[0.99877125,0.00012203377,0.0008137844,0.000062282874,0.00013718198,0.0000054816373,0.000008977459,0.0000060618077,0.00007292367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982022,0.000041907686,0.000508152,0.00006902519,0.001051979,0.00012672451],"domain_scores_gemma":[0.99797535,0.0010148238,0.00027863562,0.00011669109,0.00035437298,0.0002601343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056657125,0.00006655344,0.00040093032,0.00011460675,0.000012644999,0.000002818456,0.000088140245,0.00008178025,0.0017125896],"category_scores_gemma":[0.0036635804,0.000042877284,0.00018350908,0.00009298066,0.0000692173,0.000061022645,0.00002288591,0.00014083194,0.0000042672336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033207268,0.0013613952,0.8691476,0.0008034751,0.00027093472,0.0003274328,0.000073058276,0.0000015417825,0.00076620985,0.000053487915,0.007997436,0.11587668],"study_design_scores_gemma":[0.029572975,0.021922516,0.72669256,0.002050645,0.00040499924,0.0017436094,0.00042655822,0.005986045,0.20134212,0.00022141739,0.009496059,0.00014047966],"about_ca_topic_score_codex":0.0000746892,"about_ca_topic_score_gemma":0.00002456489,"teacher_disagreement_score":0.2005759,"about_ca_system_score_codex":0.000018831393,"about_ca_system_score_gemma":0.0003345733,"threshold_uncertainty_score":0.9992},"labels":[],"label_agreement":null},{"id":"W2916907431","doi":"10.1182/blood-2018-99-109523","title":"Enhancer Deregulation in Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Bromodomain; BRD4; Enhancer; Biology; Chromatin; Transcription factor; Enhancer RNAs; BET inhibitor; Promoter; Transcriptional regulation; Regulation of gene expression; Gene; Cancer research; Cell biology; Gene expression; Genetics; Histone","score_opus":0.02346340077979518,"score_gpt":0.3191593964861414,"score_spread":0.2956959957063462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916907431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857777,0.00010840749,0.00003136011,0.00021230502,0.0000265284,0.00019291765,0.0000013400246,0.000023369143,0.01362609],"genre_scores_gemma":[0.997726,0.000010477089,0.0010094702,0.0000519477,0.00018837619,0.000020198368,0.000012767734,0.000007599395,0.0009731343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946713,0.000014904614,0.0000837776,0.00012229549,0.00014293562,0.0001689801],"domain_scores_gemma":[0.99971104,0.000015552061,0.000013053342,0.00014031884,0.00004542422,0.00007461862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052612933,0.00005165766,0.000084687126,0.00007501643,0.00002512163,0.0000060514685,0.000025534027,0.000035281788,0.00042140836],"category_scores_gemma":[0.00005480616,0.000041367293,0.000021305541,0.00012558045,0.000038221446,0.00003640859,0.000014503415,0.00004505241,0.00034651873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002934492,0.0012535057,0.8733513,0.000036775724,0.000107276384,0.00019458533,0.0002942614,1.2511647e-7,0.05851276,0.00015260819,0.0003231901,0.065480165],"study_design_scores_gemma":[0.0044058454,0.0002594926,0.8520633,0.000037434886,0.00001854704,0.00002158824,0.000011325143,0.00008924873,0.14226314,0.000104551465,0.0006882668,0.000037229776],"about_ca_topic_score_codex":0.00005614069,"about_ca_topic_score_gemma":0.00014548839,"teacher_disagreement_score":0.08375038,"about_ca_system_score_codex":0.000022428832,"about_ca_system_score_gemma":0.00004105117,"threshold_uncertainty_score":0.4614126},"labels":[],"label_agreement":null},{"id":"W2919501631","doi":"10.1182/blood-2018-99-117482","title":"Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; T-cell receptor; Biology; T cell; Pomalidomide; CD8; Cytotoxic T cell; Antigen; Multiple myeloma; Immunology; Immune system; Molecular biology; Cancer research; Lenalidomide; Genetics","score_opus":0.030470224684984535,"score_gpt":0.27012999997290854,"score_spread":0.239659775287924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919501631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909727,0.00015247421,0.00005710195,0.000047873196,0.00014550697,0.000639883,0.000041467658,0.00003956521,0.007903458],"genre_scores_gemma":[0.9972582,0.000047172838,0.0014792029,0.000031540618,0.00017718184,0.000025976457,0.000121320336,0.000031317944,0.0008281234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980602,0.000090326845,0.0005483577,0.00043019303,0.0004921775,0.00037871342],"domain_scores_gemma":[0.9987745,0.00006419989,0.00021572583,0.0005236756,0.00029405009,0.00012781098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019663932,0.00017744067,0.00030650824,0.00013354537,0.00008953278,0.000020793377,0.00013891417,0.00011533727,0.0002165997],"category_scores_gemma":[0.00019136207,0.00015725965,0.000088956076,0.00035533472,0.00013759975,0.00017588874,0.000065618435,0.00015479636,0.00023355297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002831454,0.0048951386,0.2504885,0.00022958593,0.00004557089,0.000040289717,0.0016657284,4.847068e-7,0.7397727,0.000012633187,0.00032648508,0.0022397833],"study_design_scores_gemma":[0.00563444,0.000890439,0.100293376,0.0001140982,0.000050353603,0.0000039794627,0.00026918374,0.00004014169,0.8922704,0.000058251964,0.00025306444,0.0001223076],"about_ca_topic_score_codex":0.00024954556,"about_ca_topic_score_gemma":0.00007451725,"teacher_disagreement_score":0.1524977,"about_ca_system_score_codex":0.00023602441,"about_ca_system_score_gemma":0.0001088771,"threshold_uncertainty_score":0.64128625},"labels":[],"label_agreement":null},{"id":"W2921046872","doi":"10.1016/j.humpath.2019.03.002","title":"Fusion of ALK to the melanophilin gene MLPH in pediatric Spitz nevi","year":2019,"lang":"en","type":"article","venue":"Human Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Spitz nevus; ROS1; Anaplastic lymphoma kinase; Fusion gene; Biology; Fluorescence in situ hybridization; Exon; Cancer research; Pathology; Melanoma; Gene; Medicine; Cancer; Nevus; Genetics; Adenocarcinoma; Lung cancer","score_opus":0.02701664154590942,"score_gpt":0.32027927407223417,"score_spread":0.29326263252632473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921046872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959132,0.00038228292,0.00000568161,0.00064659386,0.000083743376,0.00068887556,0.0000075915427,0.000011653886,0.002260387],"genre_scores_gemma":[0.998256,0.00009938929,0.00022422188,0.00020925996,0.00013262023,0.0000316664,0.000032395557,0.0000124093085,0.0010020101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990138,0.00009736812,0.00021390666,0.0002272608,0.00018299064,0.00026466305],"domain_scores_gemma":[0.999358,0.00005394814,0.000046213925,0.00040869083,0.000045900477,0.00008722867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026787343,0.000092413844,0.0002507052,0.00021567386,0.000033956032,0.0000028534137,0.00012046047,0.000074845586,0.00041372515],"category_scores_gemma":[0.00007455672,0.000059098486,0.000051877654,0.0001900803,0.00003067213,0.00001650804,0.000105414736,0.00014984958,0.000601782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020798355,0.00028394247,0.9257012,0.0000676793,0.000013626357,0.00053322886,0.00069616316,0.00001150831,0.06846202,0.00022279195,0.0003768477,0.003422994],"study_design_scores_gemma":[0.0022214004,0.0009041272,0.993424,0.000013312801,0.00002126942,0.00006521981,0.00004692693,0.000021114623,0.002587133,0.0000967512,0.000545552,0.00005317494],"about_ca_topic_score_codex":0.00008200665,"about_ca_topic_score_gemma":0.00014503761,"teacher_disagreement_score":0.067722805,"about_ca_system_score_codex":0.000033706896,"about_ca_system_score_gemma":0.00004019499,"threshold_uncertainty_score":0.7734891},"labels":[],"label_agreement":null},{"id":"W2921247651","doi":"10.1182/blood.v130.suppl_1.4533.4533","title":"High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Transplantation; Minimal residual disease; Medicine; Population; Stem cell; Negativity effect; Oncology; Surgery; Internal medicine; Biology; Bone marrow; Genetics; Psychology","score_opus":0.039029666609865184,"score_gpt":0.3211773204419465,"score_spread":0.28214765383208135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921247651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936088,0.00007112559,0.00005220519,0.0009125206,0.000121931815,0.004744357,0.00044081692,0.00001635396,0.000031930693],"genre_scores_gemma":[0.9987963,0.000028402566,0.00008622592,0.000019820984,0.00015115966,0.00044930182,0.00039513252,0.000013432963,0.000060246395],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99846524,0.00033878066,0.00031603477,0.0002306459,0.00037184544,0.00027745983],"domain_scores_gemma":[0.99857336,0.00054290716,0.00024623878,0.00044375777,0.00009383336,0.000099888246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005773442,0.00014376128,0.00027051652,0.000054996177,0.00027152343,0.000044881057,0.00016746458,0.000061048086,0.000005057503],"category_scores_gemma":[0.00032077628,0.00008090422,0.00009503093,0.00004452058,0.00007870523,0.000114416325,0.00002132784,0.00012455512,6.9363716e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8285,0.014970591,0.1166559,0.0013805773,0.00061941537,0.0012428757,0.0066383365,0.0001615309,0.0016122594,0.00041432388,0.00015240394,0.02765181],"study_design_scores_gemma":[0.22987896,0.0034603633,0.7606404,0.000048634014,0.0005713519,0.0000037356945,0.00019836788,0.0013872805,0.003599176,0.000116285475,0.000013858858,0.000081583494],"about_ca_topic_score_codex":0.00077521533,"about_ca_topic_score_gemma":0.0002978048,"teacher_disagreement_score":0.6439845,"about_ca_system_score_codex":0.000043054028,"about_ca_system_score_gemma":0.00020918867,"threshold_uncertainty_score":0.32991785},"labels":[],"label_agreement":null},{"id":"W2922069978","doi":"10.1182/blood-2018-99-117571","title":"Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Thalidomide; Dexamethasone; Internal medicine; Cyclophosphamide; Autologous stem-cell transplantation; Lenalidomide; Oncology; Melphalan; Plasma cell leukemia; Hematopoietic stem cell transplantation; Progression-free survival; Transplantation; Surgery; Chemotherapy","score_opus":0.01675167144090109,"score_gpt":0.26230357450800973,"score_spread":0.24555190306710864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922069978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922956,0.0012230102,0.00012484849,0.00009044908,0.00015908535,0.0057527306,0.0001560197,0.000054278767,0.00014397546],"genre_scores_gemma":[0.99629956,0.0003980099,0.002641783,0.000023326906,0.000044886412,0.0003527049,0.00013851283,0.00008065707,0.00002056813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964218,0.00031635957,0.0007172375,0.00094652077,0.00068962475,0.00090842356],"domain_scores_gemma":[0.9958336,0.0021653452,0.0003778508,0.00054203405,0.00049753755,0.00058367517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076236675,0.0005463804,0.0010680095,0.0005313415,0.0004078454,0.000096681484,0.00018932739,0.00021563371,0.000007971034],"category_scores_gemma":[0.0005028509,0.00043473832,0.00007670574,0.0007256392,0.00042219678,0.0002670819,0.000077753,0.00037078044,0.0000022582071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01916745,0.002482713,0.9684189,0.00027879392,0.0007160237,0.00015438918,0.004226746,0.000009996131,0.00023131652,0.00002640471,0.0000087919425,0.0042785006],"study_design_scores_gemma":[0.15836576,0.006589319,0.82323796,0.0001617096,0.0011537725,0.000020525482,0.002486606,0.0016013817,0.006015169,0.000017872151,0.0000071836807,0.00034278005],"about_ca_topic_score_codex":0.034520745,"about_ca_topic_score_gemma":0.111369275,"teacher_disagreement_score":0.14518094,"about_ca_system_score_codex":0.00037228395,"about_ca_system_score_gemma":0.000331934,"threshold_uncertainty_score":0.99981046},"labels":[],"label_agreement":null},{"id":"W2923666301","doi":"10.1038/s41408-019-0196-6","title":"Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; National Institute for Health and Care Research; National Institutes of Health; American Society of Hematology; Cancer Research UK; National Cancer Institute; University College London; Celgene; University College London Hospitals NHS Foundation Trust; Sanofi; GlaxoSmithKline; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Internal medicine; Refractory (planetary science); Multiple myeloma; Interim analysis; Lenalidomide; Transplantation; Phases of clinical research; Clinical trial; Oncology; Gastroenterology; Surgery; Adverse effect; Biology","score_opus":0.02122107329605373,"score_gpt":0.35036038003859094,"score_spread":0.3291393067425372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923666301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957554,0.0019528967,0.000006100634,0.0002757844,0.00032902398,0.0012965895,0.00015031412,0.00003677527,0.00019712246],"genre_scores_gemma":[0.99680525,0.0019582596,0.00022965018,0.0002150479,0.00036688772,0.000022784641,0.00015251525,0.0000544095,0.00019521762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971724,0.0003538014,0.0005850344,0.000593145,0.000734115,0.0005614877],"domain_scores_gemma":[0.99823934,0.0002359313,0.00021375337,0.0004917064,0.00013038128,0.00068891206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005277405,0.00033808255,0.00065377646,0.00031289738,0.00020200967,0.00008865875,0.00017449797,0.00009896996,0.0007309141],"category_scores_gemma":[0.00011622639,0.00025624453,0.00009609563,0.00021100871,0.00006195488,0.0002863882,0.000074391384,0.00096790324,0.00007181878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021684848,0.01526343,0.8520634,0.000035200832,0.00067784224,0.0028922847,0.0017974754,0.00008845536,0.038723253,0.0000022735549,0.000086367036,0.06668517],"study_design_scores_gemma":[0.14476517,0.0050633196,0.8435265,0.00052527006,0.00023966465,0.000108206244,0.00093127164,0.0008136119,0.0026695416,0.000013346191,0.0010629434,0.0002811598],"about_ca_topic_score_codex":0.0012383226,"about_ca_topic_score_gemma":0.0005033737,"teacher_disagreement_score":0.12308031,"about_ca_system_score_codex":0.00019362361,"about_ca_system_score_gemma":0.00033082903,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W2925264218","doi":"10.1038/s41408-019-0200-1","title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Carfilzomib; Multiple myeloma; Intensive care medicine; Population; Clinical trial; Ixazomib; Internal medicine","score_opus":0.01894229791230373,"score_gpt":0.29470740091309067,"score_spread":0.27576510300078694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925264218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967177,0.0016219976,0.000011265447,0.00020597542,0.00007037598,0.0010224342,0.000038493243,0.000017346234,0.0002944337],"genre_scores_gemma":[0.99680555,0.0005728981,0.0018160973,0.00004818209,0.0001852295,0.00007163123,0.000024979303,0.000045228935,0.0004301849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834156,0.000052419928,0.00025350912,0.0002480626,0.00071549084,0.00038894726],"domain_scores_gemma":[0.9988592,0.000053284533,0.0002404438,0.00026088164,0.00030198423,0.0002841995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052114447,0.00024363709,0.0004551225,0.00014291136,0.00009730189,0.00003564965,0.00007298293,0.000048544265,0.00027893056],"category_scores_gemma":[0.00000992737,0.0001238939,0.000099767836,0.00013186914,0.00006364544,0.00010277895,0.000007385771,0.00016185369,0.00001302668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01865733,0.003106871,0.88176656,0.000032486365,0.0013638821,0.00019443274,0.00019547011,0.00004199845,0.0006135198,0.0000012054004,0.000025324149,0.09400091],"study_design_scores_gemma":[0.0897256,0.022606013,0.85807514,0.0006075067,0.00021977969,0.00012786307,0.000055980832,0.000084438325,0.026632907,0.000002273189,0.0017011012,0.00016141903],"about_ca_topic_score_codex":0.000107861844,"about_ca_topic_score_gemma":0.00004699497,"teacher_disagreement_score":0.0938395,"about_ca_system_score_codex":0.00020454283,"about_ca_system_score_gemma":0.00038743805,"threshold_uncertainty_score":0.50522465},"labels":[],"label_agreement":null},{"id":"W2925889262","doi":"10.14740/jh468","title":"Intracranial Involvement in Multiple Myeloma Presenting as a Cranial Nerve Palsy","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Complication; Dexamethasone; Pathology; Plasmacytoma; Monoclonal gammopathy of undetermined significance; Surgery; Radiology; Monoclonal; Internal medicine; Antibody","score_opus":0.026797333699849653,"score_gpt":0.3136927710656047,"score_spread":0.28689543736575507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925889262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964612,0.00055264664,0.000030192106,0.0012409496,0.0003332381,0.0004907784,0.0000020758162,0.000009577756,0.00087930285],"genre_scores_gemma":[0.9977201,0.00005378187,0.0016477414,0.00012208012,0.00019114515,0.000008852687,0.000005040311,0.000020000158,0.00023123188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979774,0.00014250712,0.0007562725,0.00018925662,0.00047829893,0.00045627332],"domain_scores_gemma":[0.99874514,0.00029369124,0.00031772078,0.00020709922,0.00019745322,0.0002389184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004470585,0.00015994768,0.00071092363,0.00037728687,0.000035723326,0.000017772269,0.0001523165,0.00013356605,0.0005646263],"category_scores_gemma":[0.0005676572,0.00011986013,0.00019100703,0.00018173121,0.00005516907,0.00013847329,0.00007821563,0.0004657192,0.0002258721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020136854,0.0007493639,0.9746539,0.00019236772,0.00023938392,0.0084227165,0.00040549444,0.000008524447,0.00963067,0.00024401986,0.00023723327,0.0032026197],"study_design_scores_gemma":[0.038686465,0.0034404069,0.9055503,0.00071298005,0.00013673754,0.025297433,0.001022725,0.0035255018,0.017602377,0.0013404131,0.002380601,0.00030403453],"about_ca_topic_score_codex":0.00014013902,"about_ca_topic_score_gemma":0.00014193593,"teacher_disagreement_score":0.06910359,"about_ca_system_score_codex":0.00011810201,"about_ca_system_score_gemma":0.00025507697,"threshold_uncertainty_score":0.6182262},"labels":[],"label_agreement":null},{"id":"W2928272073","doi":"10.1200/jco.18.02096","title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Multiple myeloma; Randomized controlled trial; Evidence-based medicine; Systematic review; MEDLINE; Intensive care medicine; Evidence-based practice; Family medicine; Quality of life (healthcare); Clinical trial; Oncology; Internal medicine; Alternative medicine; Nursing; Pathology","score_opus":0.20892787530049778,"score_gpt":0.5413060471164012,"score_spread":0.3323781718159034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928272073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97697175,0.0017792387,0.00012916363,0.013490269,0.0011411385,0.00066024443,0.000010056037,0.00000911314,0.005809056],"genre_scores_gemma":[0.9247008,0.005998571,0.06617981,0.0011561902,0.0012089616,0.000004742594,0.000008679785,0.000022969798,0.00071926607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9929564,0.0009404433,0.0048658224,0.0003082922,0.000610421,0.00031862836],"domain_scores_gemma":[0.9856548,0.009116032,0.002754642,0.00038473864,0.0012534991,0.00083634193],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0046660136,0.0001994559,0.0025586914,0.0001548401,0.000029388846,0.000008439392,0.000113451344,0.00045363398,0.00024828952],"category_scores_gemma":[0.023138775,0.00012114778,0.0007888899,0.000114216455,0.0003002549,0.0001734337,0.000078971214,0.0006783625,0.00009241917],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014111787,0.0093355,0.48398095,0.000035008437,0.0015878519,0.0016642464,0.00005543043,0.0000031708414,0.00038056474,0.00004231622,0.0028339932,0.4859692],"study_design_scores_gemma":[0.047387443,0.07581912,0.48731148,0.000073178904,0.00069928216,0.0015191233,0.00023673421,0.000673329,0.00028301898,0.00006279131,0.38583598,0.00009851284],"about_ca_topic_score_codex":0.00007763817,"about_ca_topic_score_gemma":0.000020768857,"teacher_disagreement_score":0.48587066,"about_ca_system_score_codex":0.00017394742,"about_ca_system_score_gemma":0.0018077743,"threshold_uncertainty_score":0.9850897},"labels":[],"label_agreement":null},{"id":"W2929422481","doi":"","title":"Pre-clinical studies of CHIR258, a small molecule inhibitor that targets FGFR3, for the treatment of t(4;14) multiple myeloma","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; Chromosomal translocation; Fibroblast growth factor receptor 3; Tyrosine kinase; Receptor tyrosine kinase; In vitro; Molecular biology; Biology; Cell culture; Tyrosine-kinase inhibitor; Multiple myeloma; Apoptosis; Kinase; Fibroblast growth factor; Receptor; Signal transduction; Cancer; Cell biology; Immunology; Biochemistry; Genetics; Gene","score_opus":0.28849269390962157,"score_gpt":0.5027094238483805,"score_spread":0.2142167299387589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929422481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675463,0.026294049,0.00009038124,0.0017820114,0.00017981822,0.003800275,0.00017137949,0.00002033627,0.0001154855],"genre_scores_gemma":[0.98078793,0.014285089,0.0009447449,0.000028207325,0.0003499532,0.0019436375,0.000029246505,0.000041727602,0.0015894477],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997297,0.00018276132,0.00050092017,0.00045957754,0.0008535883,0.00070613576],"domain_scores_gemma":[0.9960952,0.0018849095,0.00012436716,0.0006512696,0.000969067,0.00027523437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886786,0.0002166099,0.0006860046,0.00019217785,0.00021446828,0.00001305753,0.00023874118,0.0001144141,0.000055651904],"category_scores_gemma":[0.0012253709,0.00012366513,0.0003567485,0.00034230755,0.0008785468,0.0000429273,0.00010855439,0.00024448548,0.000011317278],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050286833,0.018358141,0.48096162,0.00371758,0.014906499,0.0004275269,0.016133113,0.00029575554,0.12074499,0.00041637145,0.0063888226,0.28736275],"study_design_scores_gemma":[0.031853445,0.013945045,0.18028565,0.00065899553,0.00026755437,0.000009383733,0.0014811647,0.00024020996,0.76157486,0.00032503484,0.0091505945,0.00020808069],"about_ca_topic_score_codex":0.0013842174,"about_ca_topic_score_gemma":0.0010639373,"teacher_disagreement_score":0.64082986,"about_ca_system_score_codex":0.00050275953,"about_ca_system_score_gemma":0.00077150995,"threshold_uncertainty_score":0.5042918},"labels":[],"label_agreement":null},{"id":"W2930942278","doi":"10.1002/cncr.32128","title":"Multiple myeloma epidemiology and patient geographic distribution in Canada: A population study","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Ottawa","funders":"Fonds de Recherche du Québec - Santé; Canadian Dermatology Foundation","keywords":"Incidence (geometry); Demography; Medicine; Metropolitan area; Epidemiology; Population; Distribution (mathematics); Cancer registry; Latitude; Geography; Environmental health; Internal medicine; Pathology","score_opus":0.027066304978395406,"score_gpt":0.31440131342554056,"score_spread":0.28733500844714516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930942278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758404,0.00093125907,0.0000026447765,0.00034322427,0.000096376796,0.00094959117,0.000061033483,0.0000074576405,0.000024359662],"genre_scores_gemma":[0.9994506,0.00007182937,0.000014974979,0.0001183847,0.000015892048,0.00013964217,0.0001570812,0.0000061524443,0.000025403244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991365,0.00008751525,0.00018597361,0.00021935182,0.00012555352,0.0002450918],"domain_scores_gemma":[0.99954695,0.00011638082,0.000044630335,0.00013700414,0.000035554982,0.0001194754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096882875,0.00008069141,0.00023410129,0.00004953969,0.000026651303,0.0000021171124,0.000020550415,0.000029767409,0.00007443043],"category_scores_gemma":[0.00016536379,0.000063512154,0.000018338485,0.000117850104,0.000013175529,0.000031338415,0.000023937708,0.000097069955,0.0000041041812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002017135,0.000083226056,0.9587816,0.00001972208,0.000036881345,0.000028132868,0.000050552873,0.000029939816,0.000027715112,0.0000075784073,0.000065947424,0.04066698],"study_design_scores_gemma":[0.0025576653,0.00024531613,0.9946016,0.0000365322,0.000012914122,0.0000036515255,0.00020655557,0.001915438,0.000018807072,0.00001366808,0.00033362524,0.000054195967],"about_ca_topic_score_codex":0.930403,"about_ca_topic_score_gemma":0.9184769,"teacher_disagreement_score":0.040612783,"about_ca_system_score_codex":0.00063646305,"about_ca_system_score_gemma":0.0002115397,"threshold_uncertainty_score":0.25899506},"labels":[],"label_agreement":null},{"id":"W2936254348","doi":"10.1007/s11136-017-1658-6","title":"Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study","year":2017,"lang":"en","type":"article","venue":"Pure Amsterdam UMC","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, Indiana University; Medical Center, University of Pittsburgh; Liaoning University of Traditional Chinese Medicine; Hospital for Sick Children; National Institute for Health and Care Research; Università degli Studi del Piemonte Orientale; Università degli Studi di Pavia; University of Toronto; Universiteit van Amsterdam; University of Bristol; University of Aberdeen; Universitat Pompeu Fabra; National Taiwan University; Karolinska Institutet; Institut National de la Santé et de la Recherche Médicale; Memorial Sloan-Kettering Cancer Center; Università degli Studi di Cagliari; University of Pittsburgh; Liaoning University; Universitair Medisch Centrum Groningen; Kræftens Bekæmpelse; Uniwersytet Jagielloński Collegium Medicum; University of Oxford; McMaster University; Marie Curie; Fondazione IRCCS Policlinico San Matteo","keywords":"Medicine; Lenalidomide; Thalidomide; Melphalan; Quality of life (healthcare); Multiple myeloma; Internal medicine; Physical therapy; Peripheral neuropathy; Maintenance therapy; Surgery; Chemotherapy","score_opus":0.04507230198138521,"score_gpt":0.3317179930119265,"score_spread":0.28664569103054127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936254348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925728,0.00015517122,0.0000070048436,0.00097065436,0.00009779347,0.0048787403,0.0006948748,0.000039092218,0.00058386486],"genre_scores_gemma":[0.99861705,0.00008816105,0.00011587375,0.00008230606,0.00003665924,0.0002161089,0.00020032284,0.00006637849,0.0005771398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99492085,0.0007082564,0.0017531367,0.00070966844,0.0011483463,0.00075976027],"domain_scores_gemma":[0.9952354,0.000660928,0.001455971,0.0018816725,0.00033572435,0.00043031716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010871788,0.0004825942,0.0017514299,0.00022974004,0.00030920532,0.000046934627,0.00066399836,0.00019468777,0.00003342316],"category_scores_gemma":[0.0014168826,0.00026470365,0.00022255916,0.00037707775,0.0003613974,0.0002070558,0.00019316471,0.0004217125,0.000014527149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062120374,0.0036453158,0.92655504,0.0003911886,0.0007800311,0.00021114662,0.0038551092,0.000041845014,0.0005060513,0.0000017352451,0.00018800612,0.0017041625],"study_design_scores_gemma":[0.10556646,0.0030807022,0.8870099,0.00087691547,0.00013315004,0.000010446451,0.00044641268,0.00023181125,0.0024017624,0.000005380111,0.00001628766,0.00022077997],"about_ca_topic_score_codex":0.04890272,"about_ca_topic_score_gemma":0.03259069,"teacher_disagreement_score":0.04344608,"about_ca_system_score_codex":0.00022684126,"about_ca_system_score_gemma":0.0005755604,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W2936956800","doi":"10.1182/blood.v130.suppl_1.3125.3125","title":"Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Carfilzomib; Medicine; Dexamethasone; Bortezomib; Population; Multiple myeloma; Internal medicine; Pharmacology; Hazard ratio; Peripheral blood mononuclear cell; Ixazomib; Gastroenterology; Urology; Confidence interval; Chemistry","score_opus":0.11287543437803774,"score_gpt":0.4464530792465211,"score_spread":0.3335776448684834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936956800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971585,0.000051943236,0.0000034885552,0.00024337145,0.0000078721905,0.0018460817,0.00003616009,0.000007945083,0.00064459443],"genre_scores_gemma":[0.99973255,0.0000049405735,0.000045751985,0.000004338678,0.000059088296,0.00011275764,0.000013591833,0.000006776396,0.00002018999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991005,0.000110476525,0.0001547086,0.0001747191,0.0002945679,0.00016501445],"domain_scores_gemma":[0.9992629,0.0000728041,0.000115712384,0.00043526312,0.000036351525,0.00007694768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033306328,0.00009280845,0.0003049565,0.000063464766,0.00014384337,0.00003272997,0.00008476956,0.00003943489,0.0000066847156],"category_scores_gemma":[0.00020098411,0.00005934317,0.000031675194,0.000044310258,0.00008613539,0.0000949478,0.000058977083,0.00017579464,0.0000026891528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029370651,0.008084001,0.96776885,0.000050476745,0.00012409127,0.00009650699,0.0010364658,2.0754273e-8,0.0055057486,0.0000033835142,0.000007834594,0.017028939],"study_design_scores_gemma":[0.024250688,0.0017866772,0.93908364,0.00004439089,0.00015665223,0.0000066022512,0.00041510086,0.000021442927,0.034157485,0.000020067631,0.00001192194,0.000045311874],"about_ca_topic_score_codex":0.00063624856,"about_ca_topic_score_gemma":0.00017783468,"teacher_disagreement_score":0.028685166,"about_ca_system_score_codex":0.000014012244,"about_ca_system_score_gemma":0.000042354,"threshold_uncertainty_score":0.24199443},"labels":[],"label_agreement":null},{"id":"W2937090388","doi":"10.1182/blood.v130.suppl_1.123.123","title":"Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Antibody-dependent cell-mediated cytotoxicity; Immunology; Biology; CD38; Bone marrow; Immune system; Cytotoxic T cell; Cancer research; Multiple myeloma; Antibody; Monoclonal antibody; CD34; Cell biology; Stem cell","score_opus":0.03623905010016729,"score_gpt":0.27122481486140737,"score_spread":0.23498576476124008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937090388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175066,0.0061381496,0.0000052161877,0.0004205023,0.000026759466,0.00092375575,0.000039786348,0.000027313548,0.0006678682],"genre_scores_gemma":[0.997731,0.00062333734,0.0008009061,0.000011740359,0.000034003537,0.000109756686,0.00006577763,0.000022969316,0.0006005424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988263,0.00007942513,0.0002153934,0.0003659872,0.00018121704,0.00033165608],"domain_scores_gemma":[0.99912786,0.00008586049,0.00010775268,0.0005020678,0.0000604987,0.0001159752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014319779,0.00020221614,0.00027233508,0.0000740679,0.00055190193,0.00008759751,0.00008553303,0.000088764034,0.0000029839332],"category_scores_gemma":[0.00022237113,0.00012741853,0.000041254967,0.00006030983,0.00022655388,0.00010162471,0.00011258837,0.00012099405,0.0000029991738],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019420274,0.0027224766,0.40721694,0.000075872056,0.00033858122,0.0003623762,0.00078352937,0.000005361808,0.5604394,0.000023689965,0.00003810066,0.026051635],"study_design_scores_gemma":[0.019031476,0.0016794299,0.57113236,0.00013719272,0.00014046712,0.00008347466,0.00021349758,0.006460492,0.40072766,0.000047692643,0.00018091283,0.0001653116],"about_ca_topic_score_codex":0.0023336993,"about_ca_topic_score_gemma":0.0004112685,"teacher_disagreement_score":0.16391546,"about_ca_system_score_codex":0.00006871448,"about_ca_system_score_gemma":0.000048921414,"threshold_uncertainty_score":0.5195977},"labels":[],"label_agreement":null},{"id":"W2939235761","doi":"10.1080/2162402x.2019.1599636","title":"Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells","year":2019,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"H2020 European Institute of Innovation and Technology; Instituto de Salud Carlos III; Worldwide Cancer Research","keywords":"Daratumumab; Antibody-dependent cell-mediated cytotoxicity; CD137; Cancer research; CD38; Medicine; Monoclonal antibody; Immunology; CD8; Multiple myeloma; Immunotherapy; Antibody; Immune system; Biology; Cell biology; CD34","score_opus":0.013188750396068554,"score_gpt":0.27480009527139615,"score_spread":0.2616113448753276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939235761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933282,0.00014332285,0.000051931853,0.00033188812,0.00014518217,0.0014532632,0.000015456479,0.000047923946,0.004482829],"genre_scores_gemma":[0.99849594,0.000041059287,0.00038394818,0.00007551644,0.000009802859,0.00008571269,0.000083648265,0.000030148512,0.0007942357],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981652,0.0001562036,0.00025825202,0.000539897,0.00028929178,0.000591154],"domain_scores_gemma":[0.9991332,0.000060169354,0.00010663106,0.00048020313,0.0001132494,0.00010652483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020399476,0.00024662647,0.0005625906,0.0006193258,0.00008043395,0.000023394387,0.00015265623,0.00016129161,0.00010442862],"category_scores_gemma":[0.000022676668,0.00019227159,0.000038163984,0.00066364714,0.00014009164,0.00014644106,0.0000804584,0.0003561121,0.00031210174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009195141,0.0037100012,0.33240804,0.00015452718,0.00029164477,0.0017320688,0.00065053324,0.0003094301,0.6315078,0.00039727698,0.0000363411,0.0196072],"study_design_scores_gemma":[0.028241932,0.004205762,0.92063785,0.000430061,0.00003234902,0.00021925372,0.0002214455,0.00027847363,0.044861637,0.000011365622,0.00060180586,0.00025808814],"about_ca_topic_score_codex":0.0022076322,"about_ca_topic_score_gemma":0.0022832707,"teacher_disagreement_score":0.5882298,"about_ca_system_score_codex":0.000884332,"about_ca_system_score_gemma":0.00038163856,"threshold_uncertainty_score":0.7840608},"labels":[],"label_agreement":null},{"id":"W294175278","doi":"10.1182/blood.v122.21.5610.5610","title":"First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Neutropenia; Adverse effect; Retrospective cohort study; Surgery; Proteasome inhibitor; Internal medicine; Toxicity","score_opus":0.014258937918007645,"score_gpt":0.2442562630735579,"score_spread":0.22999732515555027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W294175278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855405,0.000022897433,0.0000057868197,0.000077409466,0.000013231355,0.0003005626,0.000006692785,0.0000159946,0.0010033967],"genre_scores_gemma":[0.9977622,0.000022810837,0.0015053186,0.0000055428436,0.000011624525,0.0000037850207,0.0000053898816,0.0000061538403,0.00067719014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994516,0.000021032594,0.00008072837,0.00013190758,0.00014330952,0.00017144629],"domain_scores_gemma":[0.9996136,0.00005458528,0.000024581526,0.00017084528,0.00003208614,0.00010431736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029017827,0.000060767376,0.00012530948,0.00007309106,0.00003266791,0.000008272714,0.00006224948,0.000034168756,0.00011816272],"category_scores_gemma":[0.00012537988,0.000053891592,0.000036113583,0.0000732334,0.000044521974,0.00011710459,0.000040931114,0.0001048278,0.000041896845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077628094,0.0011280585,0.99471045,0.000022614522,0.00004327911,0.001205084,0.0012403859,5.7837093e-7,0.0010528574,0.00005907266,0.00007448886,0.00038549013],"study_design_scores_gemma":[0.0053413208,0.0006576979,0.9902088,0.000088494955,0.000028963474,0.00006644275,0.0013615778,0.00012484408,0.0016494503,0.000010675762,0.0003776148,0.000084088446],"about_ca_topic_score_codex":0.0037659497,"about_ca_topic_score_gemma":0.00015978565,"teacher_disagreement_score":0.0052636927,"about_ca_system_score_codex":0.000032457687,"about_ca_system_score_gemma":0.000030110925,"threshold_uncertainty_score":0.5693015},"labels":[],"label_agreement":null},{"id":"W2941943538","doi":"10.1186/s12885-019-5467-x","title":"Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Toronto Rehabilitation Institute; Toronto Public Health; St. Michael's Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Focus group; Qualitative research; Mood; Cognition; Multiple myeloma; Expectancy theory; Clinical psychology; Psychology; Nursing; Psychiatry; Internal medicine; Social psychology","score_opus":0.048116815011157964,"score_gpt":0.3628196405176985,"score_spread":0.31470282550654055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941943538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970098,0.00033830066,0.0000026972607,0.0000156415,0.00003566369,0.0019686515,0.000103952356,0.00001587153,0.0005094131],"genre_scores_gemma":[0.9978525,0.000053682084,0.0003359003,0.0000053948775,0.000015864876,0.00026981323,0.000040880182,0.000015498706,0.0014104473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988764,0.00011841227,0.00017181705,0.00029158438,0.00035655624,0.00018522031],"domain_scores_gemma":[0.9991643,0.00022412238,0.000099417746,0.00023733726,0.00015232952,0.00012248625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006365189,0.00015043085,0.00034107958,0.00007735312,0.00003208013,0.0000068786235,0.00003665668,0.000034840443,0.00018811064],"category_scores_gemma":[0.000046508332,0.00008748964,0.00003440725,0.000102848215,0.00006440263,0.00007239884,0.000023115761,0.00006041495,0.000014657626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046356707,0.0019148481,0.9722824,0.0000859428,0.00037568563,0.000004784458,0.013843055,0.0000013008374,0.000111935035,0.0000031336558,0.000015994085,0.006725235],"study_design_scores_gemma":[0.02187092,0.008087069,0.960959,0.00008229039,0.00010519695,4.357774e-7,0.008232312,0.00003670978,0.000343404,0.000004626527,0.00018957366,0.00008847196],"about_ca_topic_score_codex":0.0017754831,"about_ca_topic_score_gemma":0.0017144181,"teacher_disagreement_score":0.01723525,"about_ca_system_score_codex":0.00016043746,"about_ca_system_score_gemma":0.00020139318,"threshold_uncertainty_score":0.3567724},"labels":[],"label_agreement":null},{"id":"W2943115873","doi":"10.1016/j.clml.2019.04.014","title":"Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"American Society of Clinical Oncology; Janssen Biotech; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Medicine; Meta-analysis; Hazard ratio; Multiple myeloma; Internal medicine; Confidence interval; Incidence (geometry); Adverse effect","score_opus":0.2212138162500832,"score_gpt":0.4785600637822102,"score_spread":0.257346247532127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943115873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013156306,0.98620224,0.000013149015,0.00010562399,0.00010739705,0.011048258,0.00051508646,0.0000989937,0.0005936344],"genre_scores_gemma":[0.0019325543,0.99267703,0.00051093433,0.00045769056,0.00012943,0.0020810943,0.000824141,0.00013696856,0.0012501709],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98626,0.003165282,0.0056457366,0.0024448845,0.0014266785,0.0010573976],"domain_scores_gemma":[0.9898181,0.0038445217,0.0019925232,0.0028812762,0.0002658318,0.0011977652],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004980954,0.0015336974,0.026523307,0.0009815211,0.00013909469,0.00017069494,0.0006129316,0.0011592598,0.00036869777],"category_scores_gemma":[0.0023074818,0.0009633676,0.0057938397,0.002171116,0.00048642428,0.00021380489,0.0007182838,0.0010840467,0.00017005161],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029358636,0.00030686776,0.0061208797,0.6952391,0.18185186,0.000688773,0.0000060162483,1.14966404e-7,2.3201189e-8,0.000037838465,0.00019865934,0.11552047],"study_design_scores_gemma":[0.0018230887,0.00034667423,0.21812116,0.03442813,0.73911273,0.00023608313,0.0000050591825,0.00009136782,5.1721653e-8,0.00002142674,0.0051992554,0.00061497896],"about_ca_topic_score_codex":0.00029218697,"about_ca_topic_score_gemma":0.00009065809,"teacher_disagreement_score":0.660811,"about_ca_system_score_codex":0.001699419,"about_ca_system_score_gemma":0.0034362827,"threshold_uncertainty_score":0.99974114},"labels":[],"label_agreement":null},{"id":"W2944536895","doi":"10.1111/cge.13561","title":"Low‐depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution","year":2019,"lang":"en","type":"article","venue":"Clinical Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Associated Medical Services; Dalhousie University","funders":"Nova Scotia Health Research Foundation","keywords":"Fluorescence in situ hybridization; Fish <Actinopterygii>; Biology; Multiple myeloma; Genome; Malignancy; DNA sequencing; Whole genome sequencing; Computational biology; Genetics; Molecular biology; DNA; Gene; Immunology","score_opus":0.08284626564420658,"score_gpt":0.3794344399130444,"score_spread":0.29658817426883777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944536895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974186,0.00043998158,0.00008571436,0.00011911289,0.00011125453,0.0013793826,0.000014484468,0.000013729072,0.00041773898],"genre_scores_gemma":[0.9939887,0.0014377405,0.0040463526,0.00011425861,0.000075039825,0.000053632983,0.000110363944,0.000022281416,0.00015163796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820995,0.00015709775,0.0006554464,0.0003680221,0.00021094347,0.0003985438],"domain_scores_gemma":[0.9989258,0.000561043,0.000057656387,0.00022421077,0.00008193099,0.00014937697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006925321,0.0001406234,0.00037689344,0.00013381746,0.0000259565,0.000021300355,0.000062700026,0.0001538415,0.000024850977],"category_scores_gemma":[0.0008481205,0.0001299611,0.0000550595,0.00018415396,0.00010804595,0.00007082723,0.000063048254,0.00022960558,0.00003565617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088419724,0.00028800927,0.9856731,0.00019476614,0.000014871223,0.00005032041,0.00024716387,0.00019275829,0.0026683535,0.000023003755,0.00004373019,0.009719717],"study_design_scores_gemma":[0.010525504,0.0004800731,0.9578322,0.00044375568,0.00001138756,0.000008456658,0.000411777,0.019467536,0.010471015,0.000059340608,0.00015720549,0.00013175255],"about_ca_topic_score_codex":0.00023526092,"about_ca_topic_score_gemma":0.0028472356,"teacher_disagreement_score":0.027840912,"about_ca_system_score_codex":0.00023528983,"about_ca_system_score_gemma":0.00020385784,"threshold_uncertainty_score":0.529966},"labels":[],"label_agreement":null},{"id":"W2945852816","doi":"10.1016/s1470-2045(19)30152-4","title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Celgene","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Bortezomib; Medicine; Refractory (planetary science); Multiple myeloma; Open label; Oncology; Internal medicine; Thalidomide; Randomized controlled trial; Biology","score_opus":0.07880100858038529,"score_gpt":0.38267076028817626,"score_spread":0.30386975170779096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945852816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779234,0.00020226554,0.000096165284,0.0010302482,0.000095152485,0.019233564,0.00013907047,0.00008129615,0.0011988457],"genre_scores_gemma":[0.97982305,0.0002544149,0.012497858,0.0007517229,0.00029945045,0.0027328562,0.00039414738,0.000101689046,0.0031448342],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968541,0.0006150987,0.00052936515,0.00070916855,0.0003936116,0.0008986097],"domain_scores_gemma":[0.9950304,0.003007004,0.0004168356,0.00085208454,0.00031560482,0.00037808987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011828637,0.00043283644,0.0017900378,0.00012467198,0.00022366867,0.000080142694,0.00039290416,0.00021994974,0.00020000641],"category_scores_gemma":[0.0009904037,0.00020530724,0.00007162076,0.0002572597,0.00030215917,0.00022276727,0.00014388243,0.0003995273,0.00003175916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.938972,0.0044974564,0.024284596,0.0001406316,0.001215255,0.00018064793,0.00023407038,0.0000025634704,0.00066060585,0.00001741285,0.0014430622,0.028351672],"study_design_scores_gemma":[0.91049916,0.06807929,0.0052726814,0.00018141909,0.00065345643,0.00010213589,0.000082476276,0.0007664319,0.00039074704,0.000013174523,0.013679678,0.00027936877],"about_ca_topic_score_codex":0.0002095204,"about_ca_topic_score_gemma":0.00027300027,"teacher_disagreement_score":0.06358183,"about_ca_system_score_codex":0.00029393964,"about_ca_system_score_gemma":0.0006554853,"threshold_uncertainty_score":0.83721864},"labels":[],"label_agreement":null},{"id":"W2946447136","doi":"","title":"Autoimmune Neurological Disorder with Anti-Ma2/Ta Antibodies in a Pediatric Patient.","year":2018,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Medicine; Antibody; Dermatology; Pediatrics; Internal medicine; Immunology","score_opus":0.02095211425539256,"score_gpt":0.25649426474407516,"score_spread":0.2355421504886826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946447136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350214,0.00041755816,0.0000061556734,0.0008663825,0.00006570946,0.0010959471,0.0000048534616,0.00006510573,0.003976132],"genre_scores_gemma":[0.99844235,0.00018834637,0.0001585518,0.00017794405,0.00010727148,0.000559076,0.000019156434,0.00001750867,0.00032980423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998537,0.000060415405,0.00018222023,0.00030494996,0.00031258108,0.0006028058],"domain_scores_gemma":[0.99939173,0.00006246294,0.00004410108,0.00025569848,0.00007300072,0.00017298781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011326735,0.00014541374,0.00025892069,0.00018954017,0.000066908535,0.000020138095,0.00008041578,0.00006157842,0.000053539105],"category_scores_gemma":[0.00024152777,0.00009021012,0.000040830797,0.0003939913,0.00014582954,0.00007406999,0.000078005396,0.00017601076,0.000051186747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054462306,0.0005174015,0.92432684,0.0000250737,0.000030156492,0.00035402,0.00007704977,6.4414024e-7,0.0000074769796,0.000016892061,0.00013850638,0.07396133],"study_design_scores_gemma":[0.003191624,0.00069007603,0.9936033,0.0000053734175,0.000031457657,0.000037500784,0.000014193017,0.0001060752,0.00004445209,0.000015353344,0.0021692803,0.000091342365],"about_ca_topic_score_codex":0.00008652856,"about_ca_topic_score_gemma":0.00008824437,"teacher_disagreement_score":0.07386999,"about_ca_system_score_codex":0.000024207584,"about_ca_system_score_gemma":0.000036528636,"threshold_uncertainty_score":0.3678662},"labels":[],"label_agreement":null},{"id":"W2947217637","doi":"10.1186/s12885-019-5600-x","title":"Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Bristol-Myers Squibb Canada; MorphoSys; Celgene; Sanofi; Deutsches Krebsforschungszentrum; Bristol-Myers Squibb; Novartis Pharma; Roche; Chugai Pharmaceutical; Amgen","keywords":"Lenalidomide; Medicine; Multiple myeloma; Bortezomib; Maintenance therapy; Clinical endpoint; Internal medicine; Oncology; Dexamethasone; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.023882720257556857,"score_gpt":0.3073506523200687,"score_spread":0.28346793206251186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947217637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859604,0.000107196174,0.00011355838,0.00012641928,0.00014642307,0.013488429,0.000020261416,0.000005100203,0.000032184693],"genre_scores_gemma":[0.9984324,0.000055338365,0.00011775004,0.000040156472,0.00006586656,0.0012032855,0.000019474299,0.000016652984,0.000049106686],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977026,0.0008831491,0.00048498853,0.0002811182,0.00043348613,0.00021462975],"domain_scores_gemma":[0.9972108,0.002092563,0.0003209827,0.00024118338,0.000083271756,0.00005119581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009787129,0.000183282,0.0006492597,0.00015151888,0.000052765718,0.000017764043,0.00007583515,0.00006687895,0.000055817316],"category_scores_gemma":[0.0008278063,0.00008918451,0.00008202788,0.0002138152,0.00018311966,0.00012681763,0.000036155343,0.00017833969,0.0000011051374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93286395,0.00038518923,0.060211707,0.0000825318,0.0001319961,0.0000031735974,0.0005716036,0.00007777384,0.0007205334,0.000033790413,0.00001569689,0.004902052],"study_design_scores_gemma":[0.86781377,0.0021442352,0.12518705,0.0005887253,0.000085669286,0.0000010120439,0.000044578414,0.0019099741,0.002126427,0.000009747877,0.000011757885,0.00007707433],"about_ca_topic_score_codex":0.0006168954,"about_ca_topic_score_gemma":0.00045108987,"teacher_disagreement_score":0.065050215,"about_ca_system_score_codex":0.00016024984,"about_ca_system_score_gemma":0.00014753369,"threshold_uncertainty_score":0.36368388},"labels":[],"label_agreement":null},{"id":"W2947822050","doi":"10.1016/j.jgo.2019.05.014","title":"Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; University of Ottawa; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Observational study; Internal medicine; Multiple myeloma; Hazard ratio; Meta-analysis; Confidence interval; Randomized controlled trial; Odds ratio; Cochrane Library; Autologous stem-cell transplantation; Oncology","score_opus":0.05745312381832959,"score_gpt":0.3492808580954229,"score_spread":0.2918277342770933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947822050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004580439,0.9925415,0.00003141144,0.0001005319,0.000080307706,0.006551036,0.00012788441,0.0000099543395,0.00009935969],"genre_scores_gemma":[0.0027077273,0.9953048,0.00067092053,0.00012982567,0.000042962107,0.00035711663,0.00010143712,0.00006249219,0.00062268967],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933769,0.0018480797,0.0028951573,0.00053767243,0.0007614837,0.00058066787],"domain_scores_gemma":[0.993474,0.0020134905,0.0031110344,0.0005910311,0.00034706894,0.00046337122],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0013092072,0.0007190894,0.018666115,0.0016608662,0.00004640477,0.00003046458,0.00034515274,0.0004961366,0.0001539124],"category_scores_gemma":[0.00017101417,0.00036644682,0.0026726187,0.0014510637,0.00006800788,0.000106257554,0.00005962004,0.0009813114,0.00003988108],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029091755,0.0015781278,0.00084177946,0.8424677,0.12885185,0.009990755,0.00016685488,0.0000022251354,6.7728394e-8,5.33223e-7,0.0001788781,0.01563028],"study_design_scores_gemma":[0.0076470226,0.0029140403,0.0009865457,0.022749424,0.95517504,0.001463963,0.000026742513,0.0000068275385,1.7264934e-7,3.92755e-7,0.008712008,0.00031779293],"about_ca_topic_score_codex":0.00005096349,"about_ca_topic_score_gemma":0.00010094646,"teacher_disagreement_score":0.8263232,"about_ca_system_score_codex":0.00067489664,"about_ca_system_score_gemma":0.0011671177,"threshold_uncertainty_score":0.99987876},"labels":[],"label_agreement":null},{"id":"W2947874495","doi":"10.1056/nejmoa1817249","title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":987,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute; Incyte; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical; Amgen","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine","score_opus":0.03083090465145425,"score_gpt":0.32272611846995003,"score_spread":0.29189521381849576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947874495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984702,0.003959769,0.0007852026,0.0076974225,0.00033443107,0.0006218995,0.0000064525857,0.000013240094,0.0018795674],"genre_scores_gemma":[0.99107075,0.0005707598,0.002891176,0.00031203366,0.001753728,0.0000033423128,0.000020514524,0.000024594221,0.0033530823],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985092,0.0000696116,0.000452146,0.00017300824,0.00049586775,0.00030014338],"domain_scores_gemma":[0.9980557,0.00062658516,0.00022042877,0.00018503985,0.00030319957,0.0006090216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075126305,0.00017883412,0.00073390163,0.0002674288,0.00005011362,0.00001230232,0.00008378131,0.00007492172,0.00034660677],"category_scores_gemma":[0.00085603434,0.000104193605,0.0000861668,0.00015230806,0.00009418672,0.000094999545,0.000020677566,0.00027464528,0.000012404816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05121771,0.00023816756,0.12014094,0.0005190739,0.0017379721,0.0016032029,0.0017219879,0.00002376748,0.03700902,0.0004014504,0.01774562,0.76764107],"study_design_scores_gemma":[0.74671364,0.017697088,0.10588063,0.0018183347,0.0009580074,0.008747611,0.00049803825,0.001349428,0.006059785,0.0009654457,0.109037496,0.0002744842],"about_ca_topic_score_codex":0.00011756424,"about_ca_topic_score_gemma":0.000024105419,"teacher_disagreement_score":0.7673666,"about_ca_system_score_codex":0.000099262055,"about_ca_system_score_gemma":0.00027428134,"threshold_uncertainty_score":0.42488918},"labels":[],"label_agreement":null},{"id":"W2948354434","doi":"10.1373/clinchem.2018.299461","title":"Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry","year":2019,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Mass spectrometry; Chromatography; Chemistry; Monoclonal; Monoclonal antibody; Medicine; Antibody","score_opus":0.028522918759781992,"score_gpt":0.32346440737184273,"score_spread":0.29494148861206076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948354434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974022,0.00041298973,0.00002474812,0.00019401383,0.00008063353,0.00033501018,0.00009312873,0.000022106533,0.0014352003],"genre_scores_gemma":[0.9956895,0.0002578622,0.0004865952,0.000024060857,0.000070355694,0.000015302521,0.00006517281,0.000022063772,0.0033690792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806136,0.000049053364,0.00077917316,0.00037714586,0.000407249,0.00032599308],"domain_scores_gemma":[0.9983353,0.00044087257,0.00022929325,0.0007011325,0.00009707801,0.00019630037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036373857,0.00017371199,0.0006518802,0.00006522554,0.000014159981,0.000007162984,0.00017770089,0.0002475666,0.0005197344],"category_scores_gemma":[0.00096018804,0.0001505953,0.0002483761,0.00029125574,0.000096764976,0.00006326444,0.00009973835,0.00040815648,0.00002198891],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007829154,0.0006272566,0.44545886,0.00019206388,0.00015558876,0.000020982048,0.0000054638194,7.5416114e-7,0.55216795,6.1405865e-7,0.00012018475,0.00046736904],"study_design_scores_gemma":[0.0056693126,0.00041478468,0.23953892,0.00012595899,0.000042117637,0.0000061282267,0.000024373518,0.00077410054,0.75301605,0.000012728225,0.0002736305,0.000101868834],"about_ca_topic_score_codex":0.00009062668,"about_ca_topic_score_gemma":0.000004645512,"teacher_disagreement_score":0.20591994,"about_ca_system_score_codex":0.000119652985,"about_ca_system_score_gemma":0.00009629615,"threshold_uncertainty_score":0.6141098},"labels":[],"label_agreement":null},{"id":"W2949266517","doi":"10.1097/01.hs9.0000560668.77636.9b","title":"PF595 POMALIDOMIDE + BORTEZOMIB + LOW‐DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE‐PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Dexamethasone; Bortezomib; Internal medicine; Population; Refractory (planetary science); Multiple myeloma; Phases of clinical research; Oncology; Surgery; Clinical trial","score_opus":0.018447104509424005,"score_gpt":0.2828985369928948,"score_spread":0.2644514324834708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949266517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947609,0.00044652063,0.00004400835,0.000085811545,0.000059615817,0.004252481,0.0001937133,0.000025799503,0.00013118667],"genre_scores_gemma":[0.9970156,0.00006736797,0.0018398484,0.00007028863,0.000037871527,0.00018475775,0.00023016555,0.000060139893,0.0004939525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668294,0.00027589916,0.0008998054,0.0005778322,0.00102508,0.00053842476],"domain_scores_gemma":[0.99735767,0.00037381085,0.00046091064,0.0011560518,0.00042053475,0.0002309962],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036444928,0.0003955156,0.0014663227,0.00032718293,0.000041061317,0.000016296883,0.00024693945,0.00019829976,0.0016282802],"category_scores_gemma":[0.0002748414,0.00023996047,0.00048910076,0.0018500544,0.0001853254,0.00014153552,0.00009162814,0.00030904292,0.000015582411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28270623,0.0077539915,0.69397235,0.00014310301,0.003396748,0.0000381481,0.0002655059,0.00023579488,0.004440411,0.0000022957,0.000012214218,0.0070332],"study_design_scores_gemma":[0.3162293,0.004155325,0.6523708,0.00032859677,0.00086438307,0.0000013198355,0.00007607182,0.0022653274,0.023488894,0.0000024732383,0.000017677783,0.00019978534],"about_ca_topic_score_codex":0.0007052034,"about_ca_topic_score_gemma":0.0004699089,"teacher_disagreement_score":0.041601546,"about_ca_system_score_codex":0.00016074763,"about_ca_system_score_gemma":0.00022457483,"threshold_uncertainty_score":0.9992844},"labels":[],"label_agreement":null},{"id":"W2949446669","doi":"10.1182/blood-2019-126867","title":"Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Regimen; Chromosome abnormality; Cohort; Lenalidomide; Bortezomib; Stage (stratigraphy); Median follow-up; Oncology; Gastroenterology; Surgery; Karyotype; Chemotherapy; Chromosome; Biology","score_opus":0.01910243048310636,"score_gpt":0.2842938596114688,"score_spread":0.26519142912836247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949446669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971448,0.00001254821,0.000009913715,0.000031424934,0.0001916321,0.0018028466,0.000042050706,0.000055167904,0.00070961675],"genre_scores_gemma":[0.99756676,0.0000024410026,0.0016391195,0.000045451783,0.000059126258,0.00006525908,0.00023520076,0.000043424287,0.0003432343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978896,0.00007337479,0.0003429449,0.00044196093,0.00089081883,0.00036134967],"domain_scores_gemma":[0.9987227,0.0001190839,0.00014498783,0.0005579261,0.0002365271,0.000218794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013703208,0.00023935505,0.00042935894,0.0002007282,0.00005240967,0.000030092026,0.00023431882,0.000062600506,0.00023327158],"category_scores_gemma":[0.0001140776,0.00016454638,0.00009183998,0.00014802448,0.000047204292,0.00022546954,0.000120367265,0.00015476924,0.00006983845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011867873,0.015513261,0.9782361,0.000031487194,0.0010306214,0.00009065196,0.00047683003,0.0000015817401,0.0002222234,0.000008746032,0.0000042633565,0.0031974574],"study_design_scores_gemma":[0.045182727,0.001915837,0.9513742,0.00006780423,0.00017923047,0.0000024141693,0.00031812896,0.00013970002,0.0005361691,0.0000012670655,0.00013480175,0.00014774936],"about_ca_topic_score_codex":0.00012204566,"about_ca_topic_score_gemma":0.0002365781,"teacher_disagreement_score":0.04399594,"about_ca_system_score_codex":0.000049231083,"about_ca_system_score_gemma":0.00003336086,"threshold_uncertainty_score":0.67100066},"labels":[],"label_agreement":null},{"id":"W2949991172","doi":"10.1097/01.hs9.0000567032.31064.27","title":"PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Internal medicine; Melphalan; Prednisone; Progression-free survival; Surgery; Gastroenterology; Chemotherapy","score_opus":0.014403361998694684,"score_gpt":0.26546221435834677,"score_spread":0.2510588523596521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949991172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970607,0.00026551582,0.0000041418334,0.0004056229,0.00003970854,0.0016159514,0.0005103159,0.0000060250295,0.00009198168],"genre_scores_gemma":[0.99733645,0.00026121174,0.00003068178,0.0001837904,0.000017928085,0.00009467996,0.0020131497,0.000012053642,0.00005005604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983712,0.00020609364,0.00039572926,0.0002531295,0.00047940892,0.00029443178],"domain_scores_gemma":[0.99753356,0.0018542814,0.00009154897,0.00036620104,0.00005836059,0.00009607364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022434107,0.0001678758,0.00054241647,0.00015424647,0.000044957007,0.000017455295,0.00014985043,0.00005856633,0.00032258473],"category_scores_gemma":[0.00018232998,0.000089951565,0.00009471841,0.001158378,0.00007454893,0.000045699795,0.000021553824,0.00018263272,0.000003155508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044339582,0.0007953633,0.9504197,0.000051720115,0.0005444105,0.00013431998,0.0023724602,0.00022985699,0.000015410273,0.0000066389225,0.00021649747,0.0008739913],"study_design_scores_gemma":[0.24788786,0.00030545914,0.73341924,0.00007925761,0.0003406222,4.7076807e-7,0.0011646381,0.016101092,0.0001521176,0.000014126008,0.00044237805,0.00009271876],"about_ca_topic_score_codex":0.8897249,"about_ca_topic_score_gemma":0.94353074,"teacher_disagreement_score":0.2170005,"about_ca_system_score_codex":0.000085199,"about_ca_system_score_gemma":0.0001328699,"threshold_uncertainty_score":0.36681184},"labels":[],"label_agreement":null},{"id":"W2950269753","doi":"10.1097/01.hs9.0000560680.23378.f5","title":"PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Plerixafor; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Daratumumab; Transplantation; Surgery; Bortezomib; Oncology; CXCR4","score_opus":0.024670295667957722,"score_gpt":0.2923307548691387,"score_spread":0.267660459201181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950269753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926932,0.0005941908,0.00007260168,0.000058248697,0.00015966248,0.0038582361,0.00013446818,0.000087543915,0.0023418663],"genre_scores_gemma":[0.99751544,0.00043972867,0.0003663528,0.00005406475,0.000045195404,0.00021780464,0.0002320455,0.00007612684,0.0010532513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689525,0.00019402706,0.0006576535,0.0008344343,0.000698253,0.00072035386],"domain_scores_gemma":[0.9980833,0.0006996681,0.00014905205,0.00052097894,0.000110956375,0.00043602518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032809548,0.00045115204,0.00079106615,0.0002042845,0.00013876984,0.00007254967,0.00014962272,0.00020071892,0.00038898585],"category_scores_gemma":[0.00006131583,0.00038705944,0.00011517819,0.0004322496,0.00004951534,0.0003409107,0.00003486427,0.00045116586,0.00013598816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006026858,0.0047539226,0.94037616,0.0007096437,0.00014011702,0.0017142266,0.0051974473,0.00002489694,0.008369297,0.0000013289698,0.00013421227,0.032551907],"study_design_scores_gemma":[0.10694544,0.004199419,0.850735,0.0010146125,0.00024823053,0.00006721719,0.003946245,0.0015148597,0.03060257,0.0000049596706,0.00016925683,0.0005521806],"about_ca_topic_score_codex":0.0014336511,"about_ca_topic_score_gemma":0.0032446682,"teacher_disagreement_score":0.10091858,"about_ca_system_score_codex":0.00016643881,"about_ca_system_score_gemma":0.00012507784,"threshold_uncertainty_score":0.99985814},"labels":[],"label_agreement":null},{"id":"W2950296737","doi":"10.1097/01.hs9.0000563780.03390.ca","title":"PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; Dalhousie University; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Bortezomib; Oncology; Internal medicine; Maintenance therapy; Chemotherapy","score_opus":0.0944339017398557,"score_gpt":0.38919401619865,"score_spread":0.2947601144587943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950296737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921947,0.0002576532,0.000010431093,0.0013233079,0.000060904633,0.0013971863,0.0033056543,0.000017436016,0.001432732],"genre_scores_gemma":[0.9933221,0.00011400336,0.001737744,0.00027472508,0.000110161374,0.000054148328,0.0034939982,0.000045498895,0.00084764854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941339,0.00091813493,0.0007620436,0.0009362511,0.002028201,0.0012214712],"domain_scores_gemma":[0.99283063,0.0041162716,0.00028222258,0.0017384446,0.0005519996,0.0004804554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023861714,0.00035378765,0.0010983198,0.00039378775,0.00014940483,0.000054679003,0.0007963875,0.00009096882,0.00046845313],"category_scores_gemma":[0.0030094488,0.00023916384,0.00011243201,0.0032717232,0.00026755792,0.00053905445,0.0005568229,0.0008630039,0.000027081214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034899286,0.00037219838,0.9883671,0.000042097745,0.0013059512,0.00040933266,0.00037918924,0.0007768494,0.000690011,0.0001292422,0.0034888065,0.00054933975],"study_design_scores_gemma":[0.0059942575,0.00017278154,0.96147686,0.0005486856,0.0001358524,0.0000046566743,0.0015346841,0.029318986,0.00041945654,0.00006484713,0.00012190158,0.0002070361],"about_ca_topic_score_codex":0.8824545,"about_ca_topic_score_gemma":0.9938038,"teacher_disagreement_score":0.111349255,"about_ca_system_score_codex":0.0013898065,"about_ca_system_score_gemma":0.002754711,"threshold_uncertainty_score":0.97528183},"labels":[],"label_agreement":null},{"id":"W2950359233","doi":"10.3324/haematol.2019.217448","title":"Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies","year":2019,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Dexamethasone; Medicine; Lenalidomide; Internal medicine; Hazard ratio; Neutropenia; Bortezomib; Multiple myeloma; Progression-free survival; Confidence interval; Oncology; Gastroenterology; Surgery; Chemotherapy","score_opus":0.02860394486689076,"score_gpt":0.3202406490927045,"score_spread":0.2916367042258137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950359233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642867,0.0015639411,0.0000013697037,0.00018062125,0.00004592891,0.0015756902,0.000067442124,0.000018246901,0.00011809918],"genre_scores_gemma":[0.99939513,0.00009145527,0.0001864047,0.00005489819,0.0000036450128,0.00008752567,0.000027233895,0.0000130462495,0.00014063896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817574,0.00035509068,0.00044522344,0.0004199273,0.0003319986,0.00027202352],"domain_scores_gemma":[0.9980096,0.0008138458,0.0003750857,0.00048320755,0.00020467231,0.000113564594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020044835,0.00023033023,0.0012427055,0.00034813883,0.00007636758,0.000007780452,0.00008297532,0.00012740609,0.000046721827],"category_scores_gemma":[0.00074607786,0.00012261623,0.00012782383,0.00081941235,0.00034461022,0.000037913887,0.00010460589,0.00020284441,0.0000027512456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014169518,0.001958462,0.9628875,0.0010044381,0.0027835513,0.0017257978,0.0022189508,0.00004087749,0.009681999,0.000035218516,0.00014761927,0.0033460448],"study_design_scores_gemma":[0.02026547,0.0037414236,0.93590766,0.00078542286,0.00090241525,0.00004482837,0.0026377046,0.0036094177,0.03174491,0.0000098596265,0.00015293898,0.00019796506],"about_ca_topic_score_codex":0.00020677417,"about_ca_topic_score_gemma":0.0007474688,"teacher_disagreement_score":0.026979879,"about_ca_system_score_codex":0.0000983599,"about_ca_system_score_gemma":0.00005726762,"threshold_uncertainty_score":0.5000144},"labels":[],"label_agreement":null},{"id":"W2950618735","doi":"10.1182/blood-2019-122902","title":"A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Dexamethasone; Internal medicine; Bortezomib; Regimen; Oncology; Gastroenterology; Pharmacology; Multiple myeloma; Materials science","score_opus":0.028058839664640654,"score_gpt":0.3223427778076554,"score_spread":0.29428393814301473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950618735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964688,0.000942902,0.0000017057423,0.00004605163,0.000046846857,0.0017624381,0.000030969077,0.000035506873,0.00066481705],"genre_scores_gemma":[0.99838597,0.000089335284,0.0007865555,0.000028647966,0.000047514903,0.000071652474,0.00002869771,0.000034776396,0.00052683015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981468,0.00015209924,0.0004143469,0.00045125443,0.00045464543,0.00038088099],"domain_scores_gemma":[0.9986731,0.00031986157,0.00011183718,0.0005358459,0.00010967694,0.0002496797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003373239,0.00021238584,0.00057074736,0.00028999752,0.000033341283,0.000010430647,0.000099491386,0.000106731495,0.000099256285],"category_scores_gemma":[0.00045820823,0.00017344984,0.00006224623,0.0003091373,0.000056014404,0.00007030548,0.00009840865,0.00030595018,0.000047684796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022048368,0.04499726,0.8950919,0.00017832543,0.00038620122,0.00056914944,0.0015257801,0.0000011519394,0.04036758,0.0000037056388,0.000031154224,0.014642982],"study_design_scores_gemma":[0.32588533,0.015691461,0.6373712,0.00024303654,0.0003032194,0.00009334015,0.0025256805,0.00080620445,0.016401792,0.0000142768995,0.00039332386,0.00027113216],"about_ca_topic_score_codex":0.0008283861,"about_ca_topic_score_gemma":0.00044837245,"teacher_disagreement_score":0.3236805,"about_ca_system_score_codex":0.000044686643,"about_ca_system_score_gemma":0.000115954594,"threshold_uncertainty_score":0.7073079},"labels":[],"label_agreement":null},{"id":"W2950630840","doi":"10.1097/01.hs9.0000560636.62389.3a","title":"PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SAIT Polytechnic; Alberta Cancer Foundation; Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Tolerability; Lenalidomide; Medicine; Multiple myeloma; Refractory (planetary science); Dexamethasone; Internal medicine; Oncology; Bortezomib; Pharmacology; Phases of clinical research; Progressive disease; Adverse effect; Gastroenterology; Toxicity; Chemotherapy; Materials science","score_opus":0.01371024063456188,"score_gpt":0.2593603018621555,"score_spread":0.24565006122759359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950630840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568343,0.00039535973,0.000009518778,0.00012667877,0.000055974037,0.0014688502,0.000020767307,0.00006408257,0.0021753612],"genre_scores_gemma":[0.9888133,0.00005796659,0.0045216875,0.00015885309,0.00004147313,0.00003701565,0.00009913544,0.000059760554,0.006210809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807876,0.00008719853,0.00030668444,0.0005124953,0.0005090724,0.0005057963],"domain_scores_gemma":[0.9986251,0.0003168868,0.00009331997,0.00049180276,0.00014112153,0.00033176073],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016239016,0.00027369807,0.00050481054,0.00010396448,0.000050370774,0.000024202793,0.00008208946,0.00015497222,0.0012997966],"category_scores_gemma":[0.0003545302,0.00017600681,0.00004920731,0.00031083098,0.00007301068,0.0001799066,0.000071802824,0.00032717796,0.0002520761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009304892,0.0007439746,0.97269505,0.00019533279,0.000119906734,0.00024335008,0.00014136585,0.0000034455418,0.0004888348,0.000008501399,0.00034266146,0.015712678],"study_design_scores_gemma":[0.036821257,0.0022721798,0.95640796,0.0003725515,0.000039444436,0.000024166786,0.00021037295,0.0005779401,0.00063843315,0.000008056481,0.002396469,0.00023117405],"about_ca_topic_score_codex":0.00022558881,"about_ca_topic_score_gemma":0.00037499965,"teacher_disagreement_score":0.027516363,"about_ca_system_score_codex":0.00014061663,"about_ca_system_score_gemma":0.00015510459,"threshold_uncertainty_score":0.99961317},"labels":[],"label_agreement":null},{"id":"W2950880743","doi":"10.1097/01.hs9.0000560844.39623.aa","title":"PF640 MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION‐BASED “IDENTIFYING OUTCOMES IN REAL‐WORLD MULTIPLE MYELOMA” (INFORMM) STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Multiple myeloma; Lenalidomide; Medicine; Population; Bortezomib; Autologous stem-cell transplantation; Transplantation; Family medicine; Internal medicine; Environmental health","score_opus":0.045912224532869875,"score_gpt":0.3112283706097278,"score_spread":0.26531614607685794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950880743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910524,0.00017144272,0.0000032024673,0.0018288419,0.00033233658,0.0042731497,0.0007161249,0.0000512293,0.0015712657],"genre_scores_gemma":[0.9858081,0.00002188486,0.0009012563,0.00025059583,0.00010880118,0.00037211462,0.0016754719,0.00006436977,0.010797428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606276,0.00020756341,0.0009984485,0.00092033506,0.00096202735,0.0008488421],"domain_scores_gemma":[0.9953832,0.0023595353,0.00022242601,0.0015136251,0.00009297157,0.00042826723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026874425,0.00054454454,0.0010019718,0.00022039964,0.00016604437,0.00008061683,0.00036815688,0.00012995195,0.0010738495],"category_scores_gemma":[0.00057602156,0.0003674372,0.00016783297,0.000457952,0.00002110798,0.000195258,0.00014862245,0.0003305021,0.00075003755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025570437,0.0009871599,0.9865882,0.000020544103,0.00029596605,0.000417914,0.0017900168,0.00032955283,0.00006426407,0.0000020007597,0.0025050128,0.004442324],"study_design_scores_gemma":[0.02676487,0.0002895921,0.9641754,0.00024036443,0.000073005845,0.0000013096821,0.001765469,0.0042713135,0.0002940699,0.000008303895,0.0017782162,0.00033807638],"about_ca_topic_score_codex":0.99124855,"about_ca_topic_score_gemma":0.9989643,"teacher_disagreement_score":0.024207827,"about_ca_system_score_codex":0.0013502317,"about_ca_system_score_gemma":0.00070180214,"threshold_uncertainty_score":0.99987775},"labels":[],"label_agreement":null},{"id":"W2950944873","doi":"10.1097/01.hs9.0000563756.72895.a3","title":"PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW‐UP OF THE PHASE 2, RANDOMIZED ELOQUENT‐3 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Combination therapy; Ixazomib; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib","score_opus":0.025348177318384468,"score_gpt":0.31251581433105274,"score_spread":0.2871676370126683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950944873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865555,0.00097551564,0.000046889953,0.00020784723,0.00025351415,0.008808246,0.0015799701,0.000050314444,0.0015221795],"genre_scores_gemma":[0.98600763,0.000028533408,0.0017849042,0.0000787795,0.0001111356,0.0014417857,0.0004535557,0.00006202002,0.0100316275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970077,0.00038962622,0.0007398404,0.0006314882,0.0007323264,0.0004990094],"domain_scores_gemma":[0.99460864,0.003738374,0.00030661095,0.0008057432,0.0002610417,0.0002796034],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072318857,0.0003560147,0.0011073273,0.00007003103,0.00013375524,0.00002803131,0.00017104113,0.00015426832,0.002315227],"category_scores_gemma":[0.0029498222,0.0002244146,0.0004791973,0.00021750692,0.00023823371,0.00011728009,0.00013945751,0.00029095932,0.000068788584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9584505,0.005636859,0.01093331,0.00036215244,0.002246628,0.00015176472,0.0020335938,0.000008059997,0.0015316074,0.000079130514,0.0071397917,0.0114266],"study_design_scores_gemma":[0.94499725,0.0021030232,0.043532275,0.00039953765,0.0005126579,0.000043385324,0.0010181679,0.0010278949,0.0014678829,0.000050775423,0.0045865476,0.0002605917],"about_ca_topic_score_codex":0.00014963871,"about_ca_topic_score_gemma":0.000105137595,"teacher_disagreement_score":0.032598965,"about_ca_system_score_codex":0.00018410268,"about_ca_system_score_gemma":0.00033929592,"threshold_uncertainty_score":0.9985968},"labels":[],"label_agreement":null},{"id":"W2950984087","doi":"10.1097/01.hs9.0000563784.11014.52","title":"PS1377 IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT‐ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University; Hotel Dieu Hospital","funders":"","keywords":"Medicine; Daratumumab; Bortezomib; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Oncology","score_opus":0.03098393264413396,"score_gpt":0.3156171613640681,"score_spread":0.28463322871993413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950984087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033695,0.0005998895,0.000021751883,0.00012073405,0.000043471566,0.008371559,0.00021647755,0.000048822843,0.00024032162],"genre_scores_gemma":[0.99763346,0.00008878466,0.00085808925,0.00006885573,0.000012622379,0.00048360915,0.00030196575,0.000060105518,0.0004924872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996729,0.00024601797,0.001086329,0.0006900923,0.00059433974,0.0006542053],"domain_scores_gemma":[0.9977837,0.00059854,0.0003753782,0.0005343099,0.00021713058,0.000490948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005844389,0.00037939605,0.0012253738,0.0001349283,0.00009833571,0.000022599494,0.00011212567,0.00014233358,0.00013840973],"category_scores_gemma":[0.0002643642,0.0002737035,0.000107980515,0.00038953792,0.00007404907,0.0001340358,0.000041094525,0.00024079463,0.000010884267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014331524,0.0037202334,0.97093844,0.0011034753,0.0004830454,0.000064536565,0.0012554512,0.000016103833,0.0010174091,0.000009956775,0.0000855624,0.0069742682],"study_design_scores_gemma":[0.09036678,0.008446173,0.89629143,0.000428196,0.00007029693,0.000004767556,0.0014470874,0.00060390134,0.0020394037,0.0000073187243,0.000049738537,0.00024492908],"about_ca_topic_score_codex":0.013286757,"about_ca_topic_score_gemma":0.0058835163,"teacher_disagreement_score":0.07603525,"about_ca_system_score_codex":0.00018525268,"about_ca_system_score_gemma":0.00031565956,"threshold_uncertainty_score":0.9999715},"labels":[],"label_agreement":null},{"id":"W2951183316","doi":"10.1016/j.htct.2019.03.005","title":"The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience","year":2019,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Cyclophosphamide; Dexamethasone; Internal medicine; Regimen; Hematopoietic stem cell transplantation; Granulocyte colony-stimulating factor; Oncology; CD34; Surgery; Transplantation; Stem cell; Chemotherapy","score_opus":0.023044340847318556,"score_gpt":0.2951353711433874,"score_spread":0.27209103029606885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951183316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950736,0.002620293,0.000049424896,0.00014044128,0.00008396131,0.0012063325,0.0000030471222,0.000029412144,0.0007934975],"genre_scores_gemma":[0.9752907,0.023900688,0.000035735742,0.000036741298,0.000012550094,0.000075887634,0.0000076277097,0.000020559854,0.00061947166],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988633,0.00013134594,0.00024295483,0.00031541093,0.00021115245,0.00023587393],"domain_scores_gemma":[0.99923843,0.00020814103,0.000077394434,0.00027183877,0.00007969553,0.00012447734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013307268,0.00018964548,0.00033162796,0.00010348808,0.00022923684,0.000018722007,0.000056581328,0.00014499779,0.00021064634],"category_scores_gemma":[0.0000037105647,0.000109768145,0.00009835592,0.00021152328,0.00015956597,0.000057517584,0.0000089468,0.00015547023,0.000011172997],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009549454,0.0014814123,0.6038823,0.00016555436,0.00015976478,0.000017355089,0.010280274,0.0000101648475,0.32919043,0.00020856623,0.00014461076,0.044910084],"study_design_scores_gemma":[0.022167359,0.007117309,0.28173822,0.000103013794,0.000016674467,0.00028313234,0.0044037006,0.0013977309,0.6818085,0.00009974699,0.0006056058,0.00025900741],"about_ca_topic_score_codex":0.000099597535,"about_ca_topic_score_gemma":0.000009725113,"teacher_disagreement_score":0.35261807,"about_ca_system_score_codex":0.000029991195,"about_ca_system_score_gemma":0.000060017657,"threshold_uncertainty_score":0.4476215},"labels":[],"label_agreement":null},{"id":"W2951755260","doi":"10.1111/imj.14395","title":"A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience","year":2019,"lang":"en","type":"article","venue":"Internal Medicine Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Transplantation; Retrospective cohort study; Internal medicine; Lymphoma; Incidence (geometry); Multiple myeloma; Malignancy; Hematopoietic stem cell transplantation; Surgery; Cause of death; Disease","score_opus":0.02166662072741258,"score_gpt":0.31674486932826307,"score_spread":0.29507824860085047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951755260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976916,0.00034746694,0.000349158,0.00082222035,0.00006386727,0.00019833891,0.000021844588,0.000004534578,0.0005010253],"genre_scores_gemma":[0.99893916,0.00023729942,0.0002468593,0.000034940163,0.000022926912,0.0000029724686,0.000011132044,0.0000071432673,0.00049755105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984989,0.000079682715,0.00052322116,0.00016864008,0.0005584006,0.00017111644],"domain_scores_gemma":[0.9990122,0.00017638115,0.00032664734,0.00013564549,0.00019120584,0.00015796423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020374705,0.00011449253,0.0006006956,0.0008197175,0.000019565045,0.000004362763,0.000090553986,0.000055135788,0.00033284546],"category_scores_gemma":[0.000072357034,0.00007706636,0.00010871363,0.0004039468,0.00016320935,0.00007132944,0.000013633286,0.00026358388,0.0000022826798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005745086,0.00024605385,0.98471135,0.00006778768,0.0006760499,0.000120656674,0.008696208,0.0000066787597,0.0039050344,0.000026657915,0.00004185749,0.00092716044],"study_design_scores_gemma":[0.004612208,0.0008700094,0.9885959,0.0004895048,0.0005672206,0.0002450432,0.0026877103,0.00049634173,0.0013388142,0.000038872073,0.0000071362424,0.000051266077],"about_ca_topic_score_codex":0.0003151029,"about_ca_topic_score_gemma":0.00012755996,"teacher_disagreement_score":0.0060084974,"about_ca_system_score_codex":0.0001227706,"about_ca_system_score_gemma":0.00006426028,"threshold_uncertainty_score":0.36444244},"labels":[],"label_agreement":null},{"id":"W2952400570","doi":"10.1038/s41467-019-09555-6","title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; Winship Cancer Institute; Steadman Philippon Research Institute; Emory University; Multiple Myeloma Research Foundation; National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Chromosomal translocation; Multiple myeloma; Antibody; Enhancer; Myeloma protein; Biology; Breakpoint; Malignancy; Immunoglobulin heavy chain; Cancer research; Locus (genetics); Immunology; Genetics; Transcription factor; Gene","score_opus":0.02840580091148031,"score_gpt":0.33098266260958187,"score_spread":0.30257686169810155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952400570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85351604,0.024547795,0.00011272746,0.055728294,0.00037621392,0.0058365236,0.00040119892,0.00061496574,0.058866218],"genre_scores_gemma":[0.9804965,0.00080789253,0.014035785,0.00052100065,0.00004224961,0.00032606057,0.001278658,0.000038945305,0.0024528585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984985,0.0001153365,0.00032478952,0.0003070504,0.00038943833,0.00036489058],"domain_scores_gemma":[0.99681777,0.00035722036,0.00008495851,0.0021462103,0.00036807815,0.00022574041],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000184601,0.00020084923,0.00029754595,0.00019410369,0.00029252097,0.000041054387,0.00070650165,0.00030495095,0.00031969958],"category_scores_gemma":[0.00026897716,0.00017238312,0.00019077468,0.00045708212,0.00013977461,0.00014563749,0.00017214529,0.001101582,0.0008135978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039287374,0.00288372,0.91968983,0.00011744499,0.0008786291,0.000025142082,0.0005201366,0.000004682062,0.022247385,0.004295389,0.006539527,0.042405233],"study_design_scores_gemma":[0.0043715155,0.00026150854,0.84756285,0.00013464736,0.00017531107,0.00008623441,0.00026615875,0.0023785385,0.004514441,0.00006761718,0.13992092,0.00026026976],"about_ca_topic_score_codex":0.00012583972,"about_ca_topic_score_gemma":0.0005653646,"teacher_disagreement_score":0.13338138,"about_ca_system_score_codex":0.00012811054,"about_ca_system_score_gemma":0.00024090806,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W2952497968","doi":"10.1097/01.hs9.0000563764.80519.69","title":"PS1372 B‐CELL MATURATION ANTIGEN ANTIBODY‐DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Interim analysis; Pharmacokinetics; Antibody; Pharmacology; Immunology; Clinical trial","score_opus":0.045145304319847965,"score_gpt":0.3849031199403042,"score_spread":0.3397578156204562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952497968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138254,0.0033430785,0.000052086863,0.00016852864,0.00017291644,0.0029596596,0.0001803693,0.00010302164,0.0016378224],"genre_scores_gemma":[0.99592733,0.0006240415,0.0007885822,0.000103714745,0.0001630134,0.000057632897,0.00070316147,0.00007257874,0.0015599492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996765,0.00027463958,0.000698334,0.00090892334,0.0006983085,0.00065477163],"domain_scores_gemma":[0.9980865,0.0004979989,0.00021424158,0.0006525279,0.00013148967,0.00041721883],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002735479,0.00048730406,0.00085291074,0.00021512576,0.00013981627,0.00007801344,0.00018358298,0.00014104437,0.0023544498],"category_scores_gemma":[0.00014072073,0.00040649791,0.00013429754,0.0004363153,0.00009592107,0.00023917563,0.00014494195,0.00054676435,0.00043415715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019088995,0.009416797,0.5434835,0.00030048218,0.00066148466,0.0020025347,0.0017353949,0.00008746706,0.39547196,0.0000027747424,0.0008598333,0.026888773],"study_design_scores_gemma":[0.09877407,0.0021879869,0.8569275,0.00039880752,0.00033348097,0.000038197664,0.0014107751,0.009262945,0.02789759,0.000018476172,0.0022232938,0.00052687293],"about_ca_topic_score_codex":0.0015316457,"about_ca_topic_score_gemma":0.00037052223,"teacher_disagreement_score":0.36757436,"about_ca_system_score_codex":0.0001510029,"about_ca_system_score_gemma":0.00017656105,"threshold_uncertainty_score":0.9998387},"labels":[],"label_agreement":null},{"id":"W2952690147","doi":"10.1097/01.hs9.0000558800.37954.72","title":"S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Multiple myeloma; Autologous stem-cell transplantation; Hazard ratio; Lenalidomide; Clinical endpoint; Thalidomide; Bortezomib; Surgery; Oncology; Gastroenterology; Randomized controlled trial; Confidence interval","score_opus":0.044020976145244646,"score_gpt":0.3431851252762097,"score_spread":0.29916414913096506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952690147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840941,0.0011488383,0.000019967609,0.00017890487,0.00047418242,0.007053339,0.00026858816,0.00010666982,0.0066554397],"genre_scores_gemma":[0.99569225,0.00037051484,0.0006855091,0.000028824057,0.0001265759,0.0005678342,0.00038675382,0.000088190114,0.0020535463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99463123,0.00073117664,0.0015086534,0.0010268096,0.0011329749,0.00096914044],"domain_scores_gemma":[0.99461436,0.002954329,0.00038246086,0.001280876,0.0002261847,0.0005417767],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012499186,0.000595206,0.0023687717,0.00027520832,0.00010888966,0.00004288245,0.00030628487,0.00026713102,0.0009659888],"category_scores_gemma":[0.0015532577,0.0004625986,0.00040005537,0.00075286144,0.00017298531,0.00023835036,0.00008669929,0.0005835936,0.0002864766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9103877,0.01298712,0.05248932,0.0004458523,0.0014720411,0.004032203,0.004358251,0.000118854856,0.004648239,0.000022577147,0.0016883778,0.007349438],"study_design_scores_gemma":[0.9655581,0.0044440543,0.009126316,0.00067296624,0.00045624087,0.000040276598,0.0034330902,0.002306933,0.012326712,0.000010233957,0.0011839215,0.00044113863],"about_ca_topic_score_codex":0.0036267012,"about_ca_topic_score_gemma":0.004092028,"teacher_disagreement_score":0.055170394,"about_ca_system_score_codex":0.00022108553,"about_ca_system_score_gemma":0.0003292903,"threshold_uncertainty_score":0.99994725},"labels":[],"label_agreement":null},{"id":"W2952794489","doi":"10.1002/hon.232_2631","title":"QUALITY OF LIFE AND CAREGIVER BURDEN IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS UNDERGOING OUTPATIENT AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS INPATIENT TRANSPLANTATION","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Caregiver burden; Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Distress; Population; Physical therapy; Internal medicine; Clinical psychology; Disease; Nursing","score_opus":0.04702925078614812,"score_gpt":0.3144274004288685,"score_spread":0.2673981496427204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952794489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733657,0.0002732113,0.00006344651,0.00011453869,0.00011438627,0.0010762484,0.00004149738,0.000026457497,0.00095363904],"genre_scores_gemma":[0.9987288,0.00053604617,0.00046230847,0.00004647272,0.0000073534043,0.000050660045,0.00013798889,0.000011039977,0.000019322862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807256,0.0003347713,0.00057465467,0.00040446644,0.00029970036,0.00031386784],"domain_scores_gemma":[0.9979736,0.0013754,0.00020456457,0.00014059477,0.000093151546,0.00021267262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017448048,0.00018806852,0.00069023663,0.00015079371,0.000045855766,0.0000062960885,0.00005366149,0.000283478,0.000027263737],"category_scores_gemma":[0.00010077603,0.0001479062,0.00005759114,0.00011627343,0.00013852559,0.000079312325,0.00003326358,0.00013296638,0.000012725648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011584902,0.00084215397,0.9566183,0.0013693202,0.000060076818,0.00014714416,0.0032612267,0.000020865504,0.00037493432,0.00018788969,0.0000037416219,0.025529431],"study_design_scores_gemma":[0.036398344,0.0046746037,0.9560036,0.00008492982,0.000049777533,0.000033069005,0.0010417005,0.00063054374,0.0008899022,0.000024375946,0.000031162537,0.00013797553],"about_ca_topic_score_codex":0.00022308061,"about_ca_topic_score_gemma":0.0003539339,"teacher_disagreement_score":0.025391456,"about_ca_system_score_codex":0.00018285509,"about_ca_system_score_gemma":0.00014939986,"threshold_uncertainty_score":0.603144},"labels":[],"label_agreement":null},{"id":"W2952813810","doi":"10.1097/01.hs9.0000560808.16752.64","title":"PF631 HEALTH‐RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW‐DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; McGill University Health Centre; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Daratumumab; Multiple myeloma; Regimen; Internal medicine; Cohort; Clinical endpoint; Dexamethasone; Progressive disease; Oncology; Clinical trial; Chemotherapy","score_opus":0.020931311982442687,"score_gpt":0.28274938292954693,"score_spread":0.26181807094710424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952813810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398774,0.0012848827,0.000013117824,0.00024158238,0.000059567963,0.0033156818,0.00010006753,0.00007317993,0.0009241575],"genre_scores_gemma":[0.99473643,0.000056268105,0.0027714453,0.00014342504,0.000024050734,0.00024814674,0.00029979832,0.000101317004,0.0016191152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575806,0.00047952327,0.0010982429,0.0008081243,0.0010069248,0.00084914354],"domain_scores_gemma":[0.99698764,0.0004252781,0.00054582185,0.0010856794,0.00028214042,0.00067340955],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004067344,0.0005403597,0.001530164,0.00018715482,0.00007261836,0.000020072273,0.00013425031,0.00022051386,0.0009150933],"category_scores_gemma":[0.00025919668,0.00035232678,0.00017836844,0.0005530532,0.00017812647,0.0002334286,0.000058485923,0.0004074036,0.0001724319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06604247,0.0040689996,0.9221093,0.0005645542,0.0006789165,0.0001790021,0.0006804645,0.000050322025,0.00029632202,0.000012510885,0.000052669315,0.005264459],"study_design_scores_gemma":[0.09038335,0.007235938,0.8995047,0.00092151924,0.000058564234,0.0000097882075,0.00033693845,0.00010496049,0.0009499964,0.000006439216,0.00016308129,0.00032468536],"about_ca_topic_score_codex":0.0032719253,"about_ca_topic_score_gemma":0.002468798,"teacher_disagreement_score":0.024340887,"about_ca_system_score_codex":0.0008484815,"about_ca_system_score_gemma":0.0008367308,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W2952975510","doi":"10.1182/blood-2019-122765","title":"Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Clinical endpoint; Internal medicine; Adverse effect; Refractory (planetary science); Population; Phases of clinical research; Multiple myeloma; Gastroenterology; Randomized controlled trial; Lenalidomide; Clinical trial","score_opus":0.028028583787347874,"score_gpt":0.3247151012838969,"score_spread":0.29668651749654906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952975510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858386,0.0000456354,0.000004427898,0.000025407937,0.00019179784,0.010180728,0.000100925776,0.000037237067,0.0008299544],"genre_scores_gemma":[0.9982844,0.000030751995,0.00055155606,0.00001669017,0.00003564234,0.00029245974,0.00043539578,0.00005825882,0.0002948313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686795,0.00031853165,0.00077475543,0.0006427736,0.000870845,0.0005251257],"domain_scores_gemma":[0.997799,0.00042722686,0.00035740167,0.00080226356,0.00032774924,0.00028640186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044331866,0.00036209208,0.0013140952,0.00023761876,0.00011182954,0.000081075355,0.00032875236,0.0001543502,0.00016886937],"category_scores_gemma":[0.000437986,0.00026958738,0.00005910575,0.00043729428,0.00012204823,0.00027038483,0.0001722175,0.00040880134,0.000074587064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7876751,0.070144035,0.13516335,0.000116100986,0.0010046487,0.0019385034,0.0005932797,0.0000015861381,0.000488526,0.000003809521,0.000020236752,0.002850868],"study_design_scores_gemma":[0.8804671,0.06626969,0.050839502,0.00016283705,0.00051386055,0.000043682132,0.00030252998,0.00024783626,0.0008466926,0.0000021672413,0.000040205876,0.0002638774],"about_ca_topic_score_codex":0.00076930807,"about_ca_topic_score_gemma":0.0024927112,"teacher_disagreement_score":0.09279206,"about_ca_system_score_codex":0.00015326984,"about_ca_system_score_gemma":0.0006266383,"threshold_uncertainty_score":0.9999756},"labels":[],"label_agreement":null},{"id":"W2953676957","doi":"10.2217/cer-2019-0052","title":"Cost–effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China","year":2019,"lang":"en","type":"review","venue":"Journal of Comparative Effectiveness Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Cost effectiveness; Quality-adjusted life year; Transplantation; Bortezomib; Dexamethasone; Autologous stem-cell transplantation; China; Internal medicine; Oncology; Risk analysis (engineering)","score_opus":0.23850686821996936,"score_gpt":0.48982209004031313,"score_spread":0.25131522182034377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953676957","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39750376,0.5558798,0.009854261,0.000005790199,0.00038436768,0.035399903,0.00088222534,0.000011946449,0.00007797265],"genre_scores_gemma":[0.5073461,0.4869815,0.0008068012,0.0000015328915,0.00015685748,0.0039208597,0.00059492595,0.00013236154,0.000059038233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9873981,0.0072506666,0.0018151286,0.00075998466,0.0017221854,0.0010539547],"domain_scores_gemma":[0.9539292,0.04070357,0.0011974329,0.00048441262,0.0032529559,0.00043243932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008514439,0.0007623327,0.0060749366,0.002517216,0.00016640645,0.000070380986,0.00058718416,0.000474246,0.000009629278],"category_scores_gemma":[0.0010660456,0.0005594785,0.001441515,0.0014241522,0.00026110234,0.0003732093,0.000097086704,0.0014741819,0.000014836022],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14556701,0.0064254627,0.015132162,0.40990922,0.00285035,0.0003152257,0.0012669573,0.0017926346,0.00086388126,0.000043792883,0.00010177896,0.41573152],"study_design_scores_gemma":[0.29776457,0.033846356,0.3106767,0.2807076,0.0037453931,0.00018460643,0.000501351,0.0035471192,0.04765999,0.0002739097,0.019267863,0.001824535],"about_ca_topic_score_codex":0.00013285206,"about_ca_topic_score_gemma":0.000034929435,"teacher_disagreement_score":0.413907,"about_ca_system_score_codex":0.002332754,"about_ca_system_score_gemma":0.003058845,"threshold_uncertainty_score":0.99968565},"labels":[],"label_agreement":null},{"id":"W2953850267","doi":"10.1200/jco.2019.37.15_suppl.8035","title":"Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Lenalidomide; Population; Multiple myeloma; Clinical endpoint; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.04693400693711868,"score_gpt":0.402716890099325,"score_spread":0.3557828831622063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953850267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985333,0.00009435537,0.0000202714,0.00023389523,0.00004413088,0.0007951099,0.000017649612,0.000002310907,0.00025899085],"genre_scores_gemma":[0.9981193,0.0005326309,0.0012301303,0.00004056788,0.000023257011,0.000003845786,0.000016925142,0.000015768652,0.000017602912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972309,0.0004403749,0.001411318,0.00021925809,0.0004441364,0.00025400816],"domain_scores_gemma":[0.99426806,0.0041625113,0.0008891634,0.00016537537,0.00023350041,0.0002814095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013067613,0.00017221984,0.0015593894,0.00036085487,0.000014649605,0.000005064626,0.00008360358,0.00020723815,0.000022168757],"category_scores_gemma":[0.001240211,0.0001000084,0.00011362062,0.00023097137,0.00021739285,0.00012100794,0.000020936475,0.0006272085,0.0000013160018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14523675,0.005512189,0.8088286,0.000078999794,0.00030791384,0.0005949542,0.00020259504,0.00010074279,0.0001800123,0.000007561044,0.000013538206,0.038936175],"study_design_scores_gemma":[0.16069615,0.058820724,0.7792071,0.0006739878,0.00008528915,0.000045029847,0.000035438417,0.00018778023,0.00014111605,0.000014608812,0.000025103418,0.00006764853],"about_ca_topic_score_codex":0.00034610127,"about_ca_topic_score_gemma":0.0006196226,"teacher_disagreement_score":0.053308535,"about_ca_system_score_codex":0.00016235297,"about_ca_system_score_gemma":0.00051564653,"threshold_uncertainty_score":0.40782243},"labels":[],"label_agreement":null},{"id":"W2954105574","doi":"10.1016/j.jval.2019.04.357","title":"PCN236 COST-EFFECTIVENESS OF LENALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN THE CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BUT INELIGIBLE FOR STEM CELL TRANSPLANT THERAPY","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Quality-adjusted life year; Cost effectiveness; Cost-effectiveness analysis; Relative risk; Per capita; Cost–benefit analysis; Internal medicine; Confidence interval; Environmental health; Population; Risk analysis (engineering)","score_opus":0.041184977474890576,"score_gpt":0.32130413625237836,"score_spread":0.2801191587774878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954105574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860033,0.00081882975,0.00023958893,0.00015526963,0.00008146266,0.012434028,0.00021456579,0.000018325045,0.000034628414],"genre_scores_gemma":[0.99741626,0.0005166731,0.00062659883,0.00015745254,0.000028094893,0.0009863642,0.00019874163,0.000045409586,0.000024425448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969372,0.00089459436,0.0005369886,0.00042883537,0.0005657538,0.0006365983],"domain_scores_gemma":[0.995405,0.0036088075,0.00018743011,0.00048162258,0.00012361998,0.00019352658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015463657,0.00028590142,0.00079231383,0.00028307387,0.000057210953,0.000014519088,0.0002079045,0.00009603142,0.000009040086],"category_scores_gemma":[0.00008567101,0.00016110667,0.000108608125,0.0005787266,0.000056677127,0.00009887986,0.000016300059,0.00028393138,0.00000824741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028169673,0.0021246294,0.9484156,0.002409795,0.00006333082,0.00005005448,0.0024133096,0.005856299,0.0007006824,0.000011475903,0.000005988427,0.009779171],"study_design_scores_gemma":[0.08720881,0.0031786761,0.8958402,0.0011926967,0.000010359499,0.0000051981833,0.00022975604,0.009023464,0.0031000774,0.000025037245,0.000035341924,0.0001503565],"about_ca_topic_score_codex":0.011537192,"about_ca_topic_score_gemma":0.00043140186,"teacher_disagreement_score":0.05903913,"about_ca_system_score_codex":0.00037845233,"about_ca_system_score_gemma":0.00059407967,"threshold_uncertainty_score":0.99504507},"labels":[],"label_agreement":null},{"id":"W2954187556","doi":"10.1200/jco.2019.37.15_suppl.8005","title":"Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Population; Internal medicine; Adverse effect; Refractory (planetary science); Phases of clinical research; Daratumumab; Gastroenterology; Surgery; Clinical trial; Multiple myeloma; Lenalidomide","score_opus":0.08786617734048409,"score_gpt":0.44924676918679557,"score_spread":0.3613805918463115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954187556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939643,0.00004944746,0.0000059793397,0.00023334776,0.0006066916,0.0045431703,0.000018826013,0.0000033129327,0.0005749021],"genre_scores_gemma":[0.9989337,0.00018460533,0.0005830372,0.000047362046,0.00008253463,0.000017433436,0.000009968345,0.000021998201,0.00011936015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942349,0.0014749997,0.002898882,0.00031200168,0.00079101743,0.00028820123],"domain_scores_gemma":[0.9889086,0.0070557557,0.00257694,0.00044383568,0.0006907382,0.00032415558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002971888,0.00021905341,0.0027695016,0.00014794958,0.00006971785,0.000018317845,0.0003759035,0.00030012702,0.00006675114],"category_scores_gemma":[0.007070061,0.000120971636,0.00014997595,0.00027529773,0.00042954835,0.00016444363,0.00019554708,0.0010580817,0.0000037230907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75998014,0.038545255,0.15191735,0.000051145023,0.0008944697,0.00080933917,0.0003537973,0.000005144219,0.00011420237,0.0000032532178,0.000029120501,0.04729676],"study_design_scores_gemma":[0.5435831,0.1803714,0.27478525,0.00017865408,0.0003411538,0.000093681614,0.00019735965,0.00017512485,0.000039565042,0.0000030776469,0.00016221718,0.00006940493],"about_ca_topic_score_codex":0.00020695956,"about_ca_topic_score_gemma":0.0015875028,"teacher_disagreement_score":0.21639706,"about_ca_system_score_codex":0.00024009714,"about_ca_system_score_gemma":0.0025855058,"threshold_uncertainty_score":0.8464034},"labels":[],"label_agreement":null},{"id":"W2954483077","doi":"10.14283/jfa.2019.25","title":"Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review","year":2019,"lang":"en","type":"review","venue":"The Journal of Frailty & Aging","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Frailty Index; Usability; Operationalization; Disease; Internal medicine; Physical therapy; Intensive care medicine","score_opus":0.11853226734127195,"score_gpt":0.4149831246082071,"score_spread":0.2964508572669351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954483077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012535202,0.9845971,0.000031104708,0.00013406092,0.00012208184,0.0023826787,0.00004862424,0.000008944834,0.0001402112],"genre_scores_gemma":[0.020185215,0.97887367,0.00047364683,0.000083953215,0.000117733005,0.000023348812,0.00008255135,0.00007256446,0.00008730089],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9953826,0.0006535703,0.0018748826,0.00026180674,0.0013101259,0.0005170282],"domain_scores_gemma":[0.9947072,0.0015398319,0.0022899027,0.0007356652,0.00046259616,0.00026476342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010997299,0.0005283209,0.0041967146,0.00046424774,0.00006974741,0.000020993206,0.0006120029,0.00015634576,0.00009873783],"category_scores_gemma":[0.0009988624,0.00026386822,0.00061858137,0.0006659765,0.00014397484,0.00016575589,0.00014772943,0.0014446785,0.000038700335],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033764474,0.0007630417,0.15453187,0.040946398,0.00085819233,0.00014312769,0.00027331975,0.0000050903113,0.0000014595173,0.0000010280268,0.0012325121,0.8009063],"study_design_scores_gemma":[0.014309207,0.002008533,0.12640877,0.5545634,0.0057234447,0.0002158729,0.00008285274,0.000048585753,0.000015636064,0.0000055736186,0.29613286,0.0004852732],"about_ca_topic_score_codex":0.000226731,"about_ca_topic_score_gemma":0.00011452197,"teacher_disagreement_score":0.80042106,"about_ca_system_score_codex":0.00031105735,"about_ca_system_score_gemma":0.0007870739,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W2954836703","doi":"10.1200/jco.2019.37.15_suppl.8016","title":"Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Multiple myeloma; Lenalidomide; Internal medicine; Dexamethasone; Daratumumab; Health related quality of life; Visual analogue scale; Surgery; Disease","score_opus":0.1049742725139085,"score_gpt":0.43223732366070045,"score_spread":0.32726305114679194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954836703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935242,0.00049093814,0.00018531078,0.0025211768,0.0001874026,0.0029283615,0.00010960841,0.0000068975723,0.000046115183],"genre_scores_gemma":[0.9943387,0.00057247566,0.004439476,0.0002969758,0.00007567175,0.00006520433,0.00007645367,0.000029450423,0.00010558446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950547,0.0005021931,0.0031648846,0.00037080212,0.0004000377,0.00050739],"domain_scores_gemma":[0.9878789,0.008722505,0.0018389008,0.0002042205,0.00066001574,0.00069543323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032899375,0.00024866383,0.0024248473,0.0002529094,0.000052432933,0.000012070195,0.00010363348,0.00032902393,0.000018967183],"category_scores_gemma":[0.0044664145,0.00016387751,0.00025205148,0.00017077467,0.00019693565,0.0001397893,0.000036620986,0.00047272962,9.2758796e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2593577,0.0024324113,0.6956799,0.00061255094,0.00086461194,0.00006235644,0.00018482233,0.000011826319,0.00033896227,0.000016219108,0.00016238843,0.040276296],"study_design_scores_gemma":[0.28932607,0.06255938,0.6451938,0.00027769516,0.00018803607,0.000012586519,0.00039573247,0.0009131319,0.0003189164,0.000036819652,0.0006388545,0.00013892967],"about_ca_topic_score_codex":0.0007284596,"about_ca_topic_score_gemma":0.0011135779,"teacher_disagreement_score":0.060126968,"about_ca_system_score_codex":0.00021919455,"about_ca_system_score_gemma":0.0010982436,"threshold_uncertainty_score":0.6682731},"labels":[],"label_agreement":null},{"id":"W2955312833","doi":"10.1182/blood.v130.suppl_1.3107.3107","title":"Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Refractory (planetary science); Phases of clinical research; Proteasome inhibitor; Gastroenterology; Multiple myeloma; Lenalidomide; Oncology; Surgery; Clinical trial","score_opus":0.01985083109453835,"score_gpt":0.26899780093365966,"score_spread":0.24914696983912132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955312833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997799,0.0007014278,0.0000018294535,0.000096561394,0.000014273495,0.0007662221,0.00032085442,0.000016292717,0.00028355233],"genre_scores_gemma":[0.9983608,0.0004208283,0.0008803842,0.000011685525,0.000021354133,0.000009638205,0.00018549757,0.00002313598,0.000086667926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998702,0.00006150309,0.00029537702,0.00043486894,0.0002598291,0.00024645776],"domain_scores_gemma":[0.99875605,0.00024001556,0.00018144789,0.00053309824,0.00008256357,0.00020681472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010225168,0.00019602175,0.00040865355,0.00009666916,0.0001679757,0.000036201767,0.000072401584,0.000108894106,0.000005669924],"category_scores_gemma":[0.00043748773,0.00014328113,0.000021853593,0.000051492712,0.00023705025,0.00013365885,0.00006488272,0.0001821392,0.000001112797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03193473,0.0014949214,0.94620997,0.00003209628,0.00025845785,0.000114847106,0.00040825515,2.733571e-7,0.000910409,0.0000012588539,0.000008820925,0.018625952],"study_design_scores_gemma":[0.14280231,0.0018021117,0.8531592,0.00022920128,0.00008817294,0.000005685622,0.000021914051,0.000078315665,0.001632358,0.000005680252,0.00006499279,0.000110077155],"about_ca_topic_score_codex":0.0014043631,"about_ca_topic_score_gemma":0.0003995749,"teacher_disagreement_score":0.11086758,"about_ca_system_score_codex":0.00002461804,"about_ca_system_score_gemma":0.000053124662,"threshold_uncertainty_score":0.5842835},"labels":[],"label_agreement":null},{"id":"W2955507595","doi":"10.1007/s00280-019-03899-y","title":"Population pharmacokinetics of trabectedin in adolescent patients with cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Trabectedin; Pharmacokinetics; Medicine; Population pharmacokinetics; Population; Cancer; Oncology; Pharmacology; Internal medicine; Sarcoma; Pathology; Soft tissue sarcoma","score_opus":0.020476247915726567,"score_gpt":0.35171804403402446,"score_spread":0.3312417961182979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955507595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972037,0.0011819839,0.0000027200547,0.000515933,0.00015427527,0.0007973783,0.000033972236,0.0000092759155,0.00010075364],"genre_scores_gemma":[0.99569076,0.0030676192,0.00004952949,0.00084597175,0.0000679276,0.000074087424,0.000031574924,0.000016266684,0.00015623585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931026,0.00002925731,0.00014474196,0.00018554705,0.00013340102,0.00019680995],"domain_scores_gemma":[0.9996977,0.000021789365,0.00006245666,0.00005905974,0.000069960246,0.00008905406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000036144975,0.00010860206,0.00025269052,0.00008850383,0.000012401184,0.0000020903246,0.000033832457,0.00004992639,0.0018929999],"category_scores_gemma":[0.0000012546672,0.00008144478,0.000021399992,0.000144552,0.000041911222,0.000036709964,0.000007908813,0.00012812592,0.0000015218421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003714298,0.00040348794,0.91716534,0.00023450161,0.00014593954,0.0000037313773,0.00013736307,0.000036385733,0.033011254,0.0000016502732,0.00025747996,0.04488855],"study_design_scores_gemma":[0.020899247,0.0003414649,0.92144597,0.000102117185,0.000052095846,8.442558e-7,0.000006881918,0.00052705227,0.05520981,0.0000033683643,0.0013355062,0.0000756439],"about_ca_topic_score_codex":0.000382815,"about_ca_topic_score_gemma":0.000046663645,"teacher_disagreement_score":0.044812903,"about_ca_system_score_codex":0.00010515318,"about_ca_system_score_gemma":0.00006195566,"threshold_uncertainty_score":0.9990194},"labels":[],"label_agreement":null},{"id":"W2955655006","doi":"10.1200/jco.2019.37.15_suppl.8038","title":"Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Tolerability; Oncology; Gastroenterology; Multiple myeloma; Adverse effect","score_opus":0.0812774770851059,"score_gpt":0.4335409812033129,"score_spread":0.352263504118207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955655006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978571,0.0004965361,0.00005268347,0.0005318566,0.00013134032,0.0005408571,0.00005037613,0.0000045468114,0.0003347234],"genre_scores_gemma":[0.9944452,0.0012721112,0.0038967323,0.00017815318,0.00006432251,0.0000027679687,0.000021803968,0.00002045008,0.0000984771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943911,0.0015029468,0.0028397986,0.0003585339,0.00059169345,0.00031596713],"domain_scores_gemma":[0.9847887,0.011699807,0.0022348615,0.00041558142,0.00037058617,0.00049045804],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004163915,0.00021931226,0.0028910039,0.0009631536,0.00003310556,0.0000056564227,0.00015605542,0.00044954804,0.00031702642],"category_scores_gemma":[0.010138425,0.00014289378,0.00042439,0.0008077037,0.0003820512,0.00006127892,0.000068657726,0.001030788,0.000004522071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13367707,0.0030521997,0.7890071,0.0000620387,0.0023683046,0.0003972659,0.00006402004,0.00033785644,0.002090453,0.0000042960555,0.000054900138,0.068884484],"study_design_scores_gemma":[0.07176959,0.02220453,0.89316607,0.00020150367,0.0016936228,0.00003098993,0.0000719176,0.009528721,0.00049950305,0.000009054851,0.000723571,0.00010094738],"about_ca_topic_score_codex":0.00020486649,"about_ca_topic_score_gemma":0.00055408006,"teacher_disagreement_score":0.10415894,"about_ca_system_score_codex":0.00015301732,"about_ca_system_score_gemma":0.0009224062,"threshold_uncertainty_score":0.9981996},"labels":[],"label_agreement":null},{"id":"W2956031825","doi":"10.1200/jco.2019.37.15_suppl.8025","title":"A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; McGill University Health Centre; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Daratumumab; Internal medicine; Regimen; Population; Multiple myeloma; Tolerability; Cohort; Progressive disease; Quality of life (healthcare); Oncology; Surgery; Adverse effect; Disease; Nursing","score_opus":0.15176227673606202,"score_gpt":0.484319824326145,"score_spread":0.332557547590083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956031825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931001,0.0028088908,0.00002304567,0.0021605766,0.00046352518,0.00084250164,0.000058904996,0.000010991466,0.0005314804],"genre_scores_gemma":[0.99431306,0.001187546,0.0033002736,0.00046790595,0.0001324129,0.000020431049,0.00004145295,0.000038103095,0.000498839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98604125,0.003653473,0.008185814,0.0005012233,0.000984139,0.0006340798],"domain_scores_gemma":[0.9802266,0.011443024,0.0058428356,0.00074376893,0.00069581426,0.0010479705],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0076876944,0.00036182933,0.0069590523,0.0014305308,0.000035461995,0.000007703693,0.00028113418,0.0007082587,0.0006703249],"category_scores_gemma":[0.013436961,0.00025571446,0.0021056111,0.0013023155,0.00038039306,0.00016261246,0.00008920569,0.0012681795,0.00004765202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10579382,0.009205472,0.83167654,0.00017476086,0.009138828,0.000890516,0.0004329882,0.0001944575,0.0014191503,0.000020900297,0.00008482348,0.04096772],"study_design_scores_gemma":[0.079149805,0.018787771,0.89789325,0.00032325293,0.0012053185,0.000047834135,0.00024472,0.0010106687,0.00023244922,0.000042947348,0.00089899724,0.00016298292],"about_ca_topic_score_codex":0.002195903,"about_ca_topic_score_gemma":0.002676297,"teacher_disagreement_score":0.06621669,"about_ca_system_score_codex":0.00091753964,"about_ca_system_score_gemma":0.004201456,"threshold_uncertainty_score":0.9999895},"labels":[],"label_agreement":null},{"id":"W2956888684","doi":"10.1016/s2352-3026(19)30109-7","title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Merck Sharp and Dohme","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Interim analysis; Pembrolizumab; Adverse effect; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy","score_opus":0.07617864432414798,"score_gpt":0.37293546761854046,"score_spread":0.29675682329439246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956888684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827675,0.00037263855,0.00018128469,0.0013166579,0.00016247088,0.014321632,0.0002068293,0.00005855868,0.0006124033],"genre_scores_gemma":[0.99346006,0.00013692898,0.0027193043,0.00031905144,0.00018756805,0.0019091332,0.000325384,0.00005967223,0.0008829238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759126,0.0003133435,0.0004062384,0.0006032133,0.00028259432,0.00080332375],"domain_scores_gemma":[0.9966329,0.001913061,0.00023399325,0.0007801412,0.00017744751,0.0002624742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034824817,0.00038458456,0.0020383375,0.000111208494,0.00021882431,0.000073074385,0.0003230142,0.00014865803,0.00012297035],"category_scores_gemma":[0.0005575231,0.00020565583,0.00009418201,0.00014655116,0.00025645053,0.00014538936,0.00014829183,0.00018879956,0.00008381254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9577143,0.0022403586,0.027910914,0.00017520062,0.0009861686,0.00017893472,0.00039654475,0.0000017461435,0.0001985604,0.00029132096,0.000601546,0.009304404],"study_design_scores_gemma":[0.9773819,0.014162536,0.0027616867,0.0000934118,0.00045981008,0.0002759568,0.000078077195,0.0015705356,0.0007777246,0.00016170739,0.0020481704,0.00022850207],"about_ca_topic_score_codex":0.00023705488,"about_ca_topic_score_gemma":0.00011184105,"teacher_disagreement_score":0.025149226,"about_ca_system_score_codex":0.00016719363,"about_ca_system_score_gemma":0.00027290697,"threshold_uncertainty_score":0.83864015},"labels":[],"label_agreement":null},{"id":"W2957190798","doi":"10.1002/cyto.b.21837","title":"Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab","year":2019,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Calgary Laboratory Services","keywords":"Daratumumab; Bone marrow; Immunoglobulin light chain; Minimal residual disease; Immunophenotyping; Plasma cell; Population; Pathology; Plasma Cell Myeloma; Flow cytometry; CD38; Multiple myeloma; Hematopathology; Immunology; Medicine; Monoclonal antibody; Antibody; CD34; Biology; Stem cell","score_opus":0.026548378391552923,"score_gpt":0.34927949568013567,"score_spread":0.3227311172885827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957190798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486125,0.00014375157,0.000055132572,0.00020477724,0.00071876764,0.0019329914,0.00034452422,0.000053304408,0.0016854911],"genre_scores_gemma":[0.9978275,0.00028451442,0.0005399418,0.00008322804,0.00026121028,0.000095622985,0.0004659376,0.00007585638,0.0003662373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992907,0.00062993803,0.0023419454,0.0011142308,0.002120974,0.00088590564],"domain_scores_gemma":[0.9930536,0.0036153037,0.0007887208,0.0011567377,0.0003818533,0.0010037601],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001316617,0.0005283679,0.0015735046,0.001989505,0.00007930394,0.000032067892,0.00037838556,0.0004447986,0.0004949088],"category_scores_gemma":[0.0054451153,0.00045523926,0.00055089965,0.0022832092,0.00026317782,0.00020221337,0.00028790892,0.0009984326,0.00029909203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006899292,0.011298998,0.9751212,0.0008100002,0.00025351465,0.00045990298,0.000036672216,0.00004314647,0.0019229677,0.000036338013,0.0009758906,0.0021420766],"study_design_scores_gemma":[0.016587682,0.0065739993,0.96502787,0.0007067156,0.00018887072,0.000005640939,0.00012829345,0.0009359254,0.009178718,0.000021673675,0.00029813076,0.00034648424],"about_ca_topic_score_codex":0.000022719036,"about_ca_topic_score_gemma":0.0000068070726,"teacher_disagreement_score":0.010093334,"about_ca_system_score_codex":0.0003275025,"about_ca_system_score_gemma":0.0005900905,"threshold_uncertainty_score":0.99978995},"labels":[],"label_agreement":null},{"id":"W2958027909","doi":"10.1159/000500976","title":"The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors","year":2019,"lang":"en","type":"review","venue":"Acta Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Multiple myeloma; Gastrointestinal tract; Gut flora; Immunology; Proteasome inhibitor; Biology; Proteasome; Disease; Cancer; Medicine; Internal medicine; Genetics","score_opus":0.09614967771470653,"score_gpt":0.36751387145598857,"score_spread":0.27136419374128207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958027909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011771844,0.9816198,8.9681976e-8,0.0002798995,0.000086853426,0.005428401,0.000033829427,0.00005557174,0.00072371226],"genre_scores_gemma":[0.020331902,0.97733414,0.00009502687,0.000026857251,0.000060223643,0.0006262933,0.00016921687,0.000055330387,0.001301012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739826,0.00029771696,0.00068745867,0.00065901934,0.00027758896,0.0006799873],"domain_scores_gemma":[0.9979236,0.00075057097,0.00028753397,0.0007829614,0.00004783516,0.0002075071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034031502,0.0005158012,0.002114826,0.0002290288,0.00027550285,0.00008657963,0.00031616964,0.00048908714,0.00004103439],"category_scores_gemma":[0.0005666265,0.00025886708,0.0003276196,0.00030257538,0.00028057667,0.00005561409,0.00034055085,0.000799022,0.00021956144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010413174,0.00040362275,0.008096012,0.025028508,0.000562032,0.0015349499,0.000062205654,6.146543e-9,0.000079422694,0.0001639507,0.0024988966,0.96146625],"study_design_scores_gemma":[0.0015743736,0.00027807566,0.0029737477,0.0099005075,0.00026770885,0.0012175735,0.000027977834,0.0000027544693,0.000022223325,0.000026738378,0.9834098,0.00029849785],"about_ca_topic_score_codex":0.000073849944,"about_ca_topic_score_gemma":0.00008162619,"teacher_disagreement_score":0.9809109,"about_ca_system_score_codex":0.00015437072,"about_ca_system_score_gemma":0.00021109392,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W2958693056","doi":"10.1200/jco.2019.37.15_suppl.e19509","title":"Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Population; Bortezomib; Incidence (geometry); Internal medicine; Cohort; Regimen; Environmental health","score_opus":0.14077603666368246,"score_gpt":0.45669606844115956,"score_spread":0.3159200317774771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958693056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350375,0.000039700783,0.0000060322454,0.0032107737,0.0013710255,0.0014643301,0.00020619237,0.0000061050796,0.00019207003],"genre_scores_gemma":[0.9977203,0.000026703263,0.00096710597,0.00065338804,0.00031232496,0.000045308447,0.000087860884,0.000028038976,0.00015893899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224794,0.0010249385,0.0045706555,0.00044964973,0.0011926115,0.0005141948],"domain_scores_gemma":[0.96406955,0.032873742,0.0016465402,0.0006313015,0.0002731201,0.0005057405],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032046759,0.00028905665,0.0023556615,0.00035329317,0.000060716393,0.000022837754,0.00047241035,0.0002662927,0.00015054058],"category_scores_gemma":[0.016696753,0.00018938717,0.00055855705,0.0003475981,0.000058100904,0.00025419155,0.00015559702,0.001040315,0.000036495552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00854133,0.0021122731,0.97405785,0.000010193227,0.0008286864,0.0009987401,0.0005546767,0.00014378957,0.000018981065,0.0000011896016,0.00034507102,0.012387233],"study_design_scores_gemma":[0.03546056,0.002191307,0.96040416,0.0003342084,0.00020307743,0.0000010036214,0.00033850496,0.0005006607,0.00008057572,0.00003478898,0.0002944356,0.00015670646],"about_ca_topic_score_codex":0.97874904,"about_ca_topic_score_gemma":0.9922867,"teacher_disagreement_score":0.031848807,"about_ca_system_score_codex":0.00081359874,"about_ca_system_score_gemma":0.0032199349,"threshold_uncertainty_score":0.991586},"labels":[],"label_agreement":null},{"id":"W2960767893","doi":"10.3390/cells8070723","title":"Distinct Nuclear Organization of Telomeres and Centromeres in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Cells","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba; University of British Columbia","funders":"Cancer Research Society","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Telomere; Centromere; Biology; Bone marrow; Disease; Pathology; Medicine; Monoclonal; Monoclonal antibody; Genetics; Immunology; Chromosome; Antibody; DNA","score_opus":0.009655496808453698,"score_gpt":0.23456162304431197,"score_spread":0.22490612623585826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960767893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991279,0.00015208853,0.0000037214386,0.000031505388,0.000021196702,0.00039401278,0.000034947338,0.000007795219,0.00022680806],"genre_scores_gemma":[0.9991962,0.000115343486,0.0004735672,0.0000074837667,0.00000969634,0.0000013713255,0.000024167839,0.00001583483,0.00015637619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993052,0.000029654559,0.0001929415,0.00017926749,0.00014787409,0.00014510298],"domain_scores_gemma":[0.99950695,0.00012756542,0.00007570459,0.00013785494,0.00006308388,0.00008881174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057295067,0.00008913766,0.00025491722,0.0000961824,0.00001423456,0.0000059706535,0.000038445738,0.000042221465,0.00015022505],"category_scores_gemma":[0.00010133237,0.000074370524,0.000017246182,0.00015055377,0.00009541973,0.00004603582,0.000045238885,0.000055108147,0.000009882045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018430343,0.0001148232,0.6726653,0.00024131671,0.000020115998,0.000013999834,0.00019723667,0.000001391448,0.32337373,0.000014780618,0.000010952032,0.003162058],"study_design_scores_gemma":[0.0026512558,0.00024675042,0.8603272,0.00009029534,0.000014433254,0.0000058925316,0.00012900369,0.0012002969,0.13519388,0.000009864645,0.00007498667,0.000056176767],"about_ca_topic_score_codex":0.00013791984,"about_ca_topic_score_gemma":0.0000138021505,"teacher_disagreement_score":0.18817985,"about_ca_system_score_codex":0.000022794298,"about_ca_system_score_gemma":0.000033168948,"threshold_uncertainty_score":0.30327418},"labels":[],"label_agreement":null},{"id":"W2961430794","doi":"10.5281/zenodo.4768130","title":"Thalidomide – An Overview and the Species-Specific Teratogenicity","year":2019,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Queen's University","keywords":"Thalidomide; Cereblon; Medicine; Multiple myeloma; Drug; Intensive care medicine; Pharmacology; Internal medicine; Biology; Genetics","score_opus":0.07755816657523917,"score_gpt":0.28972826470335455,"score_spread":0.21217009812811538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961430794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8141335,0.0020121853,0.00015770907,0.0024977473,0.000092092734,0.0021590632,0.00017002235,0.00046110636,0.17831656],"genre_scores_gemma":[0.9937971,0.0015486806,0.00013537267,0.00027131572,0.0001259219,8.7978954e-8,0.0007301032,0.00054706546,0.0028443225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982678,0.00042388376,0.00018382439,0.00037092876,0.00042570973,0.00032785157],"domain_scores_gemma":[0.9987561,0.000048982514,0.000052652027,0.00061012205,0.00027411547,0.00025804646],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007289597,0.00013254627,0.00021949914,0.00011069364,0.0009679951,0.000495773,0.00037770628,0.000043386524,0.018359983],"category_scores_gemma":[0.00021812414,0.0000902991,0.00006560371,0.00028072757,0.00025935317,0.00018536337,0.00055327226,0.00024542064,0.006430238],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012146802,0.0020045757,0.0034505837,0.0008992399,0.0011595305,0.0004171686,0.0067414064,0.000020301555,0.04746432,0.16068439,0.18383436,0.58117735],"study_design_scores_gemma":[0.0061201137,0.00041997625,0.026056794,0.000043392436,0.000023237193,0.00035353302,0.00026764898,0.00037724455,0.00065013295,0.00018437351,0.96538764,0.000115911855],"about_ca_topic_score_codex":0.00002357519,"about_ca_topic_score_gemma":3.7406735e-7,"teacher_disagreement_score":0.78155327,"about_ca_system_score_codex":0.0000949708,"about_ca_system_score_gemma":0.000004469246,"threshold_uncertainty_score":0.9943434},"labels":[],"label_agreement":null},{"id":"W2962628474","doi":"10.1182/blood.v130.suppl_1.4537.4537","title":"Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Dialysis; Internal medicine; Bortezomib; Melphalan; Surgery; Retrospective cohort study; Autologous stem-cell transplantation","score_opus":0.03488918285128841,"score_gpt":0.3012494014383221,"score_spread":0.2663602185870337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962628474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99881816,0.000046087767,0.00004783129,0.000038059577,0.00001715066,0.0005005935,0.00020440496,0.00001873638,0.00030899583],"genre_scores_gemma":[0.9989545,0.000005176778,0.0008639792,0.000008272296,0.000016498152,0.000015235575,0.00010897286,0.000009650371,0.000017727965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987269,0.00005058224,0.00027993458,0.0002760297,0.00039281856,0.00027373046],"domain_scores_gemma":[0.9991765,0.00007716374,0.00013721095,0.00033779046,0.000067916444,0.00020342514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118374555,0.0001590872,0.0004538858,0.00011562289,0.00021417449,0.000023542108,0.0001482819,0.00006545177,0.000005594681],"category_scores_gemma":[0.000029265904,0.00011025475,0.00003522465,0.00005030492,0.00025402138,0.00014640359,0.000042273656,0.00016596186,0.000002582048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039635532,0.0057262927,0.98666364,0.000060680326,0.000105529994,0.00009007721,0.00042485955,0.000006556945,0.00039568858,0.00001723749,7.509163e-7,0.006112344],"study_design_scores_gemma":[0.025075028,0.0015509301,0.96300274,0.00008357117,0.0001014872,0.0000064761284,0.000024637373,0.0002982384,0.009740162,0.000004506982,0.000007223921,0.000104967694],"about_ca_topic_score_codex":0.00056417787,"about_ca_topic_score_gemma":0.0007422033,"teacher_disagreement_score":0.024678674,"about_ca_system_score_codex":0.00002952943,"about_ca_system_score_gemma":0.00012709772,"threshold_uncertainty_score":0.44960582},"labels":[],"label_agreement":null},{"id":"W2963547298","doi":"10.1182/blood.v130.suppl_1.3123.3123","title":"Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Observational study; Ixazomib; Multiple myeloma; Family medicine; Bortezomib; Oncology; Carfilzomib","score_opus":0.016773592280238402,"score_gpt":0.2749713511974358,"score_spread":0.25819775891719743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963547298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981771,0.000046858124,3.2677298e-7,0.00019737254,0.000021291935,0.0011572009,0.00028352637,0.000013017997,0.0001033126],"genre_scores_gemma":[0.99917305,0.00014382588,0.000066978784,0.00006934128,0.000013232815,0.000120795696,0.00015421327,0.000020488083,0.00023807808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987425,0.00006274265,0.00020106258,0.00032593342,0.00033652864,0.0003311849],"domain_scores_gemma":[0.99892473,0.00035649122,0.00010913138,0.0004491164,0.00004288051,0.00011763594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011071313,0.00021365676,0.00040139485,0.00008630215,0.00018846878,0.00009974931,0.00011076714,0.00010244992,0.000022245884],"category_scores_gemma":[0.0003727993,0.0001094151,0.000027251255,0.00004460308,0.00008565006,0.00015006035,0.00005360778,0.00014881605,0.00000524859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001348644,0.0025009608,0.9934118,0.000019771538,0.0003052543,0.0004189493,0.0011436634,7.492251e-8,0.000017575341,2.7998536e-7,0.0000073122446,0.0008257417],"study_design_scores_gemma":[0.058498483,0.0022299595,0.93845123,0.00017664173,0.00012984258,0.0000033036624,0.00010287792,0.000036713904,0.00019896596,0.00000281968,0.000058335234,0.00011083377],"about_ca_topic_score_codex":0.010945268,"about_ca_topic_score_gemma":0.014444655,"teacher_disagreement_score":0.05714984,"about_ca_system_score_codex":0.00011844845,"about_ca_system_score_gemma":0.00007253105,"threshold_uncertainty_score":0.99564093},"labels":[],"label_agreement":null},{"id":"W2964527614","doi":"10.1182/blood-2018-99-113026","title":"Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"MARCKS; Bortezomib; Cancer research; Proteasome inhibitor; Cytotoxic T cell; Pharmacology; Drug resistance; Carfilzomib; Medicine; Chemistry; Multiple myeloma; Biology; Molecular biology; Phosphorylation; Myristoylation; Immunology; Biochemistry; In vitro","score_opus":0.009708367469993708,"score_gpt":0.25451907581628086,"score_spread":0.24481070834628715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964527614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945471,0.00036709858,0.000046233115,0.00083995634,0.00003241991,0.0015602472,0.000077229284,0.00008692059,0.0024427688],"genre_scores_gemma":[0.993329,0.000028985572,0.0028590544,0.00025034262,0.00014658365,0.00035085337,0.00012652714,0.000052960113,0.0028557156],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979585,0.00012396008,0.00027564616,0.0005779157,0.0004555928,0.00060839404],"domain_scores_gemma":[0.99876416,0.00015677276,0.00005999289,0.000347911,0.00028892825,0.00038221275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026262895,0.0002823445,0.00037715957,0.00022988337,0.00015313408,0.00004790422,0.00008363452,0.00007020233,0.000051644663],"category_scores_gemma":[0.00033581458,0.00022008206,0.000048569826,0.0005727383,0.00016467374,0.00014311387,0.00006874519,0.00023181445,0.00021694513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01457979,0.0056046695,0.62278235,0.00044371834,0.00047744205,0.0027808477,0.0022826437,0.0000011064468,0.32381165,0.00005164783,0.022477506,0.0047066235],"study_design_scores_gemma":[0.023712095,0.0019979114,0.37997898,0.0010612581,0.000092133705,0.00006247357,0.00014729913,0.000043318745,0.5889803,0.000025327849,0.0035626863,0.00033618108],"about_ca_topic_score_codex":0.00037627833,"about_ca_topic_score_gemma":0.0042265565,"teacher_disagreement_score":0.2651687,"about_ca_system_score_codex":0.00014330707,"about_ca_system_score_gemma":0.00013122275,"threshold_uncertainty_score":0.89746857},"labels":[],"label_agreement":null},{"id":"W2964541799","doi":"10.1182/blood.v128.22.4506.4506","title":"IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Lenalidomide; Multiple myeloma; Bortezomib; Thalidomide; Medicine; Bone marrow; Internal medicine; Oncology; Cancer research; Immunology","score_opus":0.018945569644428065,"score_gpt":0.2451466673186635,"score_spread":0.22620109767423544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964541799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721974,0.000036592028,0.000008713187,0.00030172334,0.00001400819,0.0016124188,0.00015856043,0.00011271806,0.00053553696],"genre_scores_gemma":[0.99744356,0.000005711823,0.00028885296,0.000048718714,0.00004376415,0.00046926056,0.00012976967,0.00007315297,0.0014971998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975269,0.00023968727,0.00031220703,0.0005243819,0.00072460226,0.0006722488],"domain_scores_gemma":[0.99844265,0.0002877213,0.00019397006,0.00046834841,0.00024883254,0.000358467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014666007,0.00033321374,0.0005091413,0.00022575339,0.00010454262,0.00002044445,0.00012288243,0.00016066525,0.00012234075],"category_scores_gemma":[0.0007087753,0.00016713123,0.000072075236,0.0003369367,0.00012546792,0.00013984862,0.000054206463,0.0002616532,0.000058094825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003099226,0.0048567336,0.97036505,0.000026799913,0.00045429997,0.0009168135,0.000082185055,2.283532e-7,0.018403042,0.000001005967,0.00005949206,0.0017351375],"study_design_scores_gemma":[0.07342839,0.0017358992,0.89607567,0.0021570795,0.00011981098,0.0000079617585,0.000041340267,0.000005875585,0.026087021,0.0000042471206,0.00010131836,0.00023541684],"about_ca_topic_score_codex":0.00022006551,"about_ca_topic_score_gemma":0.0009514391,"teacher_disagreement_score":0.0742894,"about_ca_system_score_codex":0.00019130204,"about_ca_system_score_gemma":0.00013704173,"threshold_uncertainty_score":0.6815414},"labels":[],"label_agreement":null},{"id":"W2964823446","doi":"10.1182/blood.v130.suppl_1.3100.3100","title":"A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; University of Toronto; Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Phases of clinical research; Pomalidomide; Lenalidomide; Clinical endpoint; Carfilzomib; Multiple myeloma; Adverse effect; Oncology; Nausea; Neutropenia; Gastroenterology; Clinical trial; Toxicity","score_opus":0.02393189601697607,"score_gpt":0.3035758967366704,"score_spread":0.2796440007196943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964823446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298507,0.0001435614,0.0000034684467,0.0001282409,0.000035607594,0.0066091493,0.000023502613,0.000020395846,0.000051019462],"genre_scores_gemma":[0.999167,0.000010116265,0.00029134468,0.000026936823,0.00002511106,0.00036981562,0.000023428724,0.00003108724,0.00005515419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982568,0.00016290156,0.0003437353,0.00040654535,0.000535994,0.00029403972],"domain_scores_gemma":[0.9984341,0.00010697826,0.00019259444,0.0007641135,0.00024559733,0.00025659538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047522146,0.00021623849,0.00039253425,0.00019337125,0.0002595272,0.000071928705,0.00017195306,0.00005239975,0.0000027404103],"category_scores_gemma":[0.00063960603,0.00014058458,0.000027685703,0.00013238365,0.00010207554,0.00021065037,0.0001784036,0.00020445714,0.0000030743054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004560238,0.028079242,0.9405446,0.00010890964,0.00024735028,0.00004902448,0.005160492,4.0607085e-7,0.00476759,0.0000024023898,0.000024323657,0.016455391],"study_design_scores_gemma":[0.094672956,0.011272377,0.88730496,0.0002899559,0.00010523006,0.0000031133668,0.0006021345,0.000041861407,0.0055369707,0.0000030313224,0.000031761494,0.00013565205],"about_ca_topic_score_codex":0.0002060102,"about_ca_topic_score_gemma":0.00014705067,"teacher_disagreement_score":0.090112716,"about_ca_system_score_codex":0.000063064384,"about_ca_system_score_gemma":0.00010130914,"threshold_uncertainty_score":0.5732873},"labels":[],"label_agreement":null},{"id":"W2967712966","doi":"10.1007/s00432-019-02998-w","title":"Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow","year":2019,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Università di Bologna; Université de Toulouse; Cedars-Sinai Medical Center; University of Calgary; Roswell Park Cancer Institute","keywords":"Multiple myeloma; Medicine; Hematology; Minimal residual disease; Medical physics; Oncology; Internal medicine; Clinical trial; Bone marrow","score_opus":0.14239254305640345,"score_gpt":0.5303890216521774,"score_spread":0.3879964785957739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967712966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97435564,0.004127099,0.0000022037304,0.016448429,0.00030618242,0.00038005618,0.0000030420142,0.0000024085077,0.004374935],"genre_scores_gemma":[0.987925,0.0074727414,0.0003436309,0.00020259846,0.0004028416,0.0000074965765,7.5157635e-7,0.00001192081,0.0036330286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969324,0.0005365923,0.0010256988,0.00022565061,0.0008840652,0.0003955907],"domain_scores_gemma":[0.9950372,0.002771982,0.00050582056,0.0002829984,0.0009077733,0.00049423514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050432626,0.00009764071,0.00071063795,0.00012778299,0.00008424127,0.000016957007,0.0001756132,0.00016526441,0.00019791894],"category_scores_gemma":[0.003667902,0.00005268524,0.00018041865,0.00024896514,0.0006146208,0.0000794323,0.00024014794,0.0012420547,0.000004032377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003967092,0.00060872367,0.858858,0.000096658056,0.0005272614,0.0013897636,0.00009070938,0.000002056039,0.0011031748,0.000052177733,0.002797848,0.13050658],"study_design_scores_gemma":[0.01022025,0.01027627,0.9181496,0.0008591197,0.00014301958,0.002438049,0.00075581,0.0001341409,0.0014797931,0.00075304165,0.054693814,0.000097131044],"about_ca_topic_score_codex":0.00024954008,"about_ca_topic_score_gemma":0.00050752383,"teacher_disagreement_score":0.13040945,"about_ca_system_score_codex":0.000155952,"about_ca_system_score_gemma":0.0015602099,"threshold_uncertainty_score":0.5396179},"labels":[],"label_agreement":null},{"id":"W2967774833","doi":"10.1182/blood.v130.suppl_1.1261.1261","title":"FOXM1 Is Associated with Development of Therapeutic Resistance in Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Corporation; Business; Political science; Management; Finance; Economics","score_opus":0.04853608577264014,"score_gpt":0.30529568128767887,"score_spread":0.25675959551503874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967774833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514246,0.00033037295,0.000012737401,0.00020745189,0.000010557403,0.00036557514,0.000011258855,0.000015807043,0.0039037676],"genre_scores_gemma":[0.9953477,0.000014508075,0.0031627773,0.00003651484,0.000010277302,0.00004375489,0.000015872203,0.000016167809,0.0013524633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897707,0.000024727802,0.00019345827,0.00019644543,0.00033960067,0.00026870673],"domain_scores_gemma":[0.9991832,0.000065928536,0.00013315157,0.00042936782,0.000094531715,0.000093847775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015461301,0.00011262833,0.0002624865,0.00007162589,0.0001505643,0.000017343827,0.00013762372,0.00005622643,0.00003875733],"category_scores_gemma":[0.00023270506,0.000081574566,0.0000335991,0.00007096585,0.00008396412,0.00005517454,0.000038407852,0.00009872137,0.000013768345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049635995,0.0013345472,0.9869813,0.000055613044,0.0004825149,0.00022184731,0.00078879285,4.4493596e-8,0.0037635902,0.000016410895,0.000022009504,0.0058370177],"study_design_scores_gemma":[0.012527622,0.00013013455,0.92738557,0.00033178294,0.00004816309,0.000003241932,0.00003410146,0.000014271425,0.059117775,0.000034334837,0.00029540673,0.00007760594],"about_ca_topic_score_codex":0.000052483058,"about_ca_topic_score_gemma":0.00228245,"teacher_disagreement_score":0.059595693,"about_ca_system_score_codex":0.00005463174,"about_ca_system_score_gemma":0.00021339665,"threshold_uncertainty_score":0.3326514},"labels":[],"label_agreement":null},{"id":"W2968790042","doi":"10.1097/md.0000000000016711","title":"MiRNAs with prognostic significance in multiple myeloma","year":2019,"lang":"en","type":"review","venue":"Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Government of Jiangsu Province; Jiangsu Provincial Medical Youth Talent; Six Talent Peaks Project in Jiangsu Province; National Natural Science Foundation of China","keywords":"Medicine; Multiple myeloma; MEDLINE; Oncology; Internal medicine","score_opus":0.12287545041233204,"score_gpt":0.38369451099183643,"score_spread":0.2608190605795044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968790042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018735779,0.99063194,0.000023672956,0.0003559309,0.00015316096,0.005701097,0.000029085551,0.00007122841,0.002846544],"genre_scores_gemma":[0.0015810528,0.9916397,0.0004272638,0.00008108693,0.00038805415,0.0008171766,0.0006510456,0.0001257091,0.0042889244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664223,0.0001811413,0.0007377221,0.000813251,0.00088048103,0.00074514427],"domain_scores_gemma":[0.99741507,0.0009228764,0.00026086404,0.0008554764,0.00011998498,0.00042574666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035135823,0.0006513561,0.0032353874,0.00067218125,0.000043810473,0.000011018862,0.0002510739,0.00027650347,0.00041209548],"category_scores_gemma":[0.0009257848,0.00035127634,0.00019229106,0.0009486664,0.000285939,0.0000503768,0.0000616861,0.0008509466,0.0006793416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026238282,0.0003160001,0.014781691,0.037319772,0.00041102862,0.0029482653,0.000076584336,2.4323904e-7,0.0000030082815,0.000008985429,0.0010064453,0.9428656],"study_design_scores_gemma":[0.0064204936,0.0018498865,0.005717329,0.08114533,0.0012459018,0.00042180807,0.000035027388,0.000031191776,0.000002402807,0.0000031484112,0.9028086,0.00031888078],"about_ca_topic_score_codex":0.00030722813,"about_ca_topic_score_gemma":0.00015936054,"teacher_disagreement_score":0.9425467,"about_ca_system_score_codex":0.00038332384,"about_ca_system_score_gemma":0.0008437271,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W2970396729","doi":"10.3747/co.26.5565","title":"Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Impact; Dalhousie University; Vancouver General Hospital; University of British Columbia; Fluidigm (Canada); Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Clinical Oncology; Hematology; Internal medicine; Oncology; Family medicine; Multiple myeloma; Cytogenetics; Cancer","score_opus":0.07633175635008398,"score_gpt":0.42077496004207765,"score_spread":0.34444320369199366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970396729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900356,0.000859272,0.0000030524798,0.006148763,0.00043671238,0.0007391501,0.000589902,0.00001524106,0.0011722882],"genre_scores_gemma":[0.99642134,0.0018832763,0.000681076,0.0005078041,0.00022955997,0.000018224107,0.0001852609,0.000020316924,0.000053115244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662143,0.0015407806,0.0005980203,0.0004898211,0.00025628004,0.0004936656],"domain_scores_gemma":[0.99525434,0.0032574215,0.00056600804,0.00029367663,0.00032371827,0.00030485637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013602964,0.00018714296,0.0008845208,0.0001102628,0.000076850054,0.000006970994,0.00015402501,0.00021686134,0.000057793703],"category_scores_gemma":[0.0019923584,0.00013614896,0.00015416692,0.00020103624,0.00036163,0.000029797593,0.00011656255,0.000841838,0.00012027659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058149546,0.0006462901,0.91052693,0.000008425596,0.00028500988,0.000037300644,0.0019271295,0.0000050912618,0.00005341652,0.00012282562,0.0063882694,0.0794178],"study_design_scores_gemma":[0.0072187684,0.003093625,0.94716245,0.000046424033,0.00010354067,0.0000104615665,0.004518934,0.0005789816,0.00009669066,0.00008279505,0.036978032,0.000109309265],"about_ca_topic_score_codex":0.11790513,"about_ca_topic_score_gemma":0.10845139,"teacher_disagreement_score":0.079308495,"about_ca_system_score_codex":0.0013107568,"about_ca_system_score_gemma":0.0009513523,"threshold_uncertainty_score":0.90781707},"labels":[],"label_agreement":null},{"id":"W2970658501","doi":"10.1182/blood-2018-99-117819","title":"Monoclonal Gammopathy of Clinical Significance - a Single Center Experience","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Hematology; Internal medicine; Retrospective cohort study; Nomogram; Pediatrics; Oncology; Monoclonal; Immunology","score_opus":0.1009190964356573,"score_gpt":0.4012438631901661,"score_spread":0.3003247667545088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970658501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336845,0.00008876339,0.00005372528,0.00007973975,0.000087422064,0.00021806845,0.000016749482,0.000021634285,0.0060654595],"genre_scores_gemma":[0.9960184,0.00001855769,0.0030753373,0.000082989005,0.00034917967,0.00002252173,0.0000094125235,0.000010032574,0.0004135533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891114,0.00004486687,0.00030839923,0.00022951174,0.000276093,0.00022997324],"domain_scores_gemma":[0.99924123,0.00007166077,0.000070442875,0.00027790703,0.00013293518,0.00020580046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013007963,0.00008146045,0.00023938357,0.000036815687,0.000031681466,0.0000059094136,0.00008396155,0.000050734066,0.00028633396],"category_scores_gemma":[0.0002877414,0.000062142906,0.000097294454,0.00009578446,0.00028927985,0.000039655286,0.000041676267,0.00008455385,0.00010451852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005862001,0.0048663174,0.958503,0.000026864782,0.00010997561,0.00015028667,0.00034763297,1.3761411e-8,0.024638703,0.000022394059,0.00020924152,0.010539358],"study_design_scores_gemma":[0.014483906,0.0043260427,0.6861175,0.00013774421,0.00007866388,0.00012632318,0.00014748989,0.00009718257,0.28908145,0.00003790699,0.0052329344,0.0001328774],"about_ca_topic_score_codex":0.000038606395,"about_ca_topic_score_gemma":0.000009255727,"teacher_disagreement_score":0.27238554,"about_ca_system_score_codex":0.0000091290385,"about_ca_system_score_gemma":0.000082555955,"threshold_uncertainty_score":0.31351563},"labels":[],"label_agreement":null},{"id":"W2970820386","doi":"10.1097/01.cot.0000581680.26138.04","title":"Multiple Myeloma Treatment","year":2019,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lenalidomide; Daratumumab; Multiple myeloma; Internal medicine; Oncology; Disease; Clinical trial; Dexamethasone; Prednisone; Intensive care medicine","score_opus":0.02888721733491941,"score_gpt":0.34084024051580286,"score_spread":0.31195302318088347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970820386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76874816,0.0002716417,0.00000496861,0.0014192882,0.00013807164,0.0007215887,0.000011077898,0.00008164314,0.22860353],"genre_scores_gemma":[0.87515616,0.00008044933,0.0017167921,0.00021105069,0.00009051774,0.00007940176,0.000076249664,0.000018194856,0.12257117],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990084,0.00005443949,0.00014350319,0.0002739287,0.00016469341,0.0003550478],"domain_scores_gemma":[0.9991414,0.00021176573,0.00003823776,0.00034024622,0.000050028844,0.00021835243],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006924236,0.00014627245,0.0003566671,0.000096327385,0.00004977854,0.000007416298,0.000057997913,0.00012409255,0.0045204055],"category_scores_gemma":[0.000059476788,0.000101111116,0.00011498223,0.00008850058,0.000060162096,0.000043748933,0.0000338513,0.00009189461,0.008351696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012659465,0.0014660162,0.7578816,0.000027895238,0.00052186963,0.000675668,0.00020413825,0.0000030514855,0.008980749,0.00021101671,0.0071488707,0.22161321],"study_design_scores_gemma":[0.016250739,0.007980639,0.40031072,0.000028001627,0.00011020643,0.0002584512,0.00013942416,0.0011690595,0.012137072,0.0000682711,0.56138307,0.00016432427],"about_ca_topic_score_codex":0.00010619665,"about_ca_topic_score_gemma":0.00003838911,"teacher_disagreement_score":0.5542342,"about_ca_system_score_codex":0.00041992092,"about_ca_system_score_gemma":0.0002704581,"threshold_uncertainty_score":0.9963896},"labels":[],"label_agreement":null},{"id":"W2971739694","doi":"10.1016/j.bbmt.2019.08.023","title":"Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Food and Drug Administration; Ottawa Hospital; Celgene; Miltenyi Biotec; Leukemia and Lymphoma Society; National Cancer Institute; National Institutes of Health; International Myeloma Foundation; Ottawa Hospital Research Institute; Amgen; Multiple Myeloma Research Foundation","keywords":"Medicine; Multiple myeloma; Cumulative incidence; Transplantation; Internal medicine; Hematopoietic stem cell transplantation; Melphalan; Cohort; Surgery; Fludarabine; Oncology; Cyclophosphamide; Chemotherapy","score_opus":0.018867505372002165,"score_gpt":0.28277560102593285,"score_spread":0.2639080956539307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971739694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628377,0.00033835197,0.0007646331,0.00006798553,0.00007341044,0.0011241505,0.00116908,0.00003131356,0.00014733228],"genre_scores_gemma":[0.9975643,0.00037545254,0.000910673,0.000024072839,0.000016436403,0.0000814472,0.0008714841,0.00001711348,0.00013901705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988608,0.00007400426,0.0004494583,0.00027863603,0.00012247276,0.00021468125],"domain_scores_gemma":[0.9993744,0.00023299933,0.00016423286,0.00008501427,0.000074198244,0.00006914717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023972747,0.00014204952,0.0003137663,0.00019802882,0.000042422114,0.00001051688,0.000047716738,0.00012715424,0.0000108271115],"category_scores_gemma":[0.000010291131,0.00012433456,0.0000484192,0.00008636169,0.000037926162,0.000072048446,0.000005032005,0.0000814579,0.0000011648699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057095767,0.000108406566,0.7417892,0.0013056343,0.00014218292,0.000017691107,0.0006877798,0.0000044424396,0.254763,0.00026520767,5.696496e-7,0.0003449098],"study_design_scores_gemma":[0.014867384,0.0005241556,0.90313894,0.00021312213,0.00038592162,0.00006992797,0.00053261104,0.0014714636,0.078568034,0.000023239316,0.000029055129,0.00017616115],"about_ca_topic_score_codex":0.00017165496,"about_ca_topic_score_gemma":0.00022351385,"teacher_disagreement_score":0.17619498,"about_ca_system_score_codex":0.00002918144,"about_ca_system_score_gemma":0.00004829915,"threshold_uncertainty_score":0.50702167},"labels":[],"label_agreement":null},{"id":"W2971830193","doi":"10.1182/blood-2018-99-117930","title":"Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Multiple myeloma; Population; Internal medicine; Paraproteinemia; Hematology; Referral; Incidence (geometry); Cohort; Pediatrics; Monoclonal; Immunology; Family medicine; Monoclonal antibody","score_opus":0.031993882816636995,"score_gpt":0.2924877797108114,"score_spread":0.2604938968941744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971830193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898255,0.000048030706,0.000026371063,0.00006121317,0.0000394205,0.00023977466,0.000112023314,0.000015166384,0.00047544652],"genre_scores_gemma":[0.9989627,0.000038200982,0.00062504224,0.000049858096,0.00012714659,0.000017914504,0.00004404271,0.000011425056,0.00012366122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992478,0.000022684591,0.00017659216,0.00016955858,0.00019585874,0.0001875313],"domain_scores_gemma":[0.99947035,0.00003030647,0.00006451666,0.0001867481,0.00009648685,0.00015156833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004186664,0.00009226344,0.00018933904,0.00004869304,0.000033542514,0.000007482479,0.00003649056,0.000038099195,0.000089246016],"category_scores_gemma":[0.000059596914,0.00007265886,0.000031483996,0.00004622211,0.00009776749,0.000027208396,0.000038825983,0.000061160674,0.00001374533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046090363,0.00094166596,0.94223994,0.0001232872,0.0001372165,0.00020509263,0.0003237792,4.8972875e-9,0.03031,0.000020971696,0.00003603397,0.025201105],"study_design_scores_gemma":[0.0031831916,0.0022009052,0.92044115,0.00008728578,0.00008200975,0.000063785,0.000036916485,0.000083776424,0.07352065,0.000015413312,0.00021147588,0.00007346244],"about_ca_topic_score_codex":0.00006569471,"about_ca_topic_score_gemma":0.0000124746975,"teacher_disagreement_score":0.04321065,"about_ca_system_score_codex":0.000012590251,"about_ca_system_score_gemma":0.00004721384,"threshold_uncertainty_score":0.29629424},"labels":[],"label_agreement":null},{"id":"W2972016640","doi":"10.6004/jnccn.2019.7298","title":"Influence of Treating Facility, Provider Volume, and Patient-Sharing on Survival of Patients With Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Decile; Multiple myeloma; Hazard ratio; Cancer; Proportional hazards model; Internal medicine; Population; Community hospital; Cohort; Emergency medicine; Family medicine; Nursing; Confidence interval; Environmental health","score_opus":0.02461337907977604,"score_gpt":0.2907486100880378,"score_spread":0.26613523100826175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972016640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987872,0.00034351804,0.0000030731603,0.00012963523,0.000094884985,0.0004621963,0.00007958132,0.0000022788777,0.0000976221],"genre_scores_gemma":[0.9995048,0.000022256756,0.00020906262,0.0001259792,0.00006324388,0.0000052879145,0.0000057227803,0.000008484935,0.000055172175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821305,0.0000676583,0.00040182198,0.0001379722,0.0010189638,0.00016052292],"domain_scores_gemma":[0.9965582,0.0003469388,0.00060129917,0.000117062635,0.0022929884,0.00008352569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000839961,0.0001215766,0.0003530171,0.00007613501,0.000058219674,0.000007819426,0.00011405305,0.000037515656,0.000026279096],"category_scores_gemma":[0.00022310554,0.00007139861,0.00008738716,0.00019850713,0.000090613976,0.0001073168,0.00008568022,0.00020816839,0.0000012497163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023546498,0.00013345032,0.93029815,0.00010809253,0.00030205588,0.0000016722212,0.0001235868,0.06364459,0.00039952464,0.000011958613,0.00012394693,0.002498341],"study_design_scores_gemma":[0.0039593354,0.0009429908,0.9921947,0.0006867577,0.00004299658,0.0000050689073,0.000046505393,0.0012706575,0.0004601248,0.00004830973,0.00028374325,0.000058814217],"about_ca_topic_score_codex":0.00004204949,"about_ca_topic_score_gemma":0.000011698815,"teacher_disagreement_score":0.062373932,"about_ca_system_score_codex":0.00014199901,"about_ca_system_score_gemma":0.00016618302,"threshold_uncertainty_score":0.29115507},"labels":[],"label_agreement":null},{"id":"W2974693007","doi":"10.1182/blood.v130.suppl_1.3135.3135","title":"Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; University of Toronto; Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Medicine; Tolerability; Bortezomib; Dexamethasone; Combination therapy; Internal medicine; Lenalidomide; Ixazomib; Oncology; Pharmacology; Refractory (planetary science); Multiple myeloma; Carfilzomib; Adverse effect","score_opus":0.017489383093827988,"score_gpt":0.27008165047396276,"score_spread":0.2525922673801348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974693007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744487,0.00009828065,0.0000049492355,0.00071294454,0.00001752153,0.0015759632,0.000047701313,0.000039625138,0.00005814726],"genre_scores_gemma":[0.99696976,0.00004420012,0.0020446768,0.000051491515,0.000019746913,0.00018896224,0.00007277835,0.00005627445,0.0005520813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974857,0.00054122746,0.00031051328,0.000588107,0.00054769224,0.0005267415],"domain_scores_gemma":[0.99767935,0.00075512007,0.00026215115,0.00075919833,0.00026557167,0.00027860794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009598973,0.00032692644,0.0005188734,0.00045516834,0.00023431762,0.00011924239,0.00016560152,0.00013336694,0.000014542751],"category_scores_gemma":[0.0017135727,0.0002129798,0.000021603493,0.00026854902,0.0002733929,0.00048662184,0.00007073049,0.00039022556,0.000008044596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13804586,0.004141578,0.8493919,0.00007655814,0.00017640213,0.0011536604,0.00033523922,0.0000022401282,0.0037715374,0.0000025701713,0.00000952385,0.0028929578],"study_design_scores_gemma":[0.09359646,0.0068832384,0.8913304,0.00074452773,0.00008772708,0.000030959476,0.00014567729,0.00006543714,0.0068321563,0.000007452785,0.000033562723,0.00024240842],"about_ca_topic_score_codex":0.0013788227,"about_ca_topic_score_gemma":0.002179763,"teacher_disagreement_score":0.044449408,"about_ca_system_score_codex":0.00011877094,"about_ca_system_score_gemma":0.00042546753,"threshold_uncertainty_score":0.8685064},"labels":[],"label_agreement":null},{"id":"W2974882261","doi":"10.1097/txd.0000000000000937","title":"The Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients","year":2019,"lang":"en","type":"article","venue":"Transplantation Direct","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Hazard ratio; Transplantation; Internal medicine; Gastroenterology; Kidney transplantation; Immunosuppression; Pathology; Immunology; Confidence interval; Monoclonal; Monoclonal antibody","score_opus":0.017378471158357712,"score_gpt":0.28219400744582407,"score_spread":0.26481553628746635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974882261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949434,0.00016932993,0.00014380991,0.000081754464,0.000086164415,0.0006332065,0.00018108857,0.000012959794,0.0037483182],"genre_scores_gemma":[0.9987549,0.00056725537,0.00015782185,0.0000089884725,0.000009152701,0.00003249212,0.00010845062,0.000009533981,0.00035136176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998873,0.000090101756,0.00033481274,0.00016809803,0.00034436074,0.00018961342],"domain_scores_gemma":[0.9993544,0.00022613569,0.00008824322,0.00017573859,0.00006579336,0.00008964635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023777098,0.000097025455,0.00023340301,0.0001277191,0.000024423369,0.000003463963,0.00007867647,0.000046272246,0.00004858384],"category_scores_gemma":[0.000029680405,0.00006771062,0.00007819173,0.00022779437,0.00006122605,0.00005911079,0.0000022773309,0.00008240365,0.000015083551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056384834,0.00025535197,0.89982134,0.0004298016,0.00008493193,0.000039448205,0.00079750235,0.000052496034,0.08995399,0.000174426,0.000011924912,0.002740314],"study_design_scores_gemma":[0.0047510224,0.00037670386,0.91136885,0.00060368783,0.00006184434,0.000016172895,0.000055459357,0.001327335,0.08128386,0.000054870812,0.0000311727,0.0000689975],"about_ca_topic_score_codex":0.0006697794,"about_ca_topic_score_gemma":0.00016687784,"teacher_disagreement_score":0.011547542,"about_ca_system_score_codex":0.00010087247,"about_ca_system_score_gemma":0.0001926968,"threshold_uncertainty_score":0.27611592},"labels":[],"label_agreement":null},{"id":"W2977204914","doi":"10.1038/s41409-019-0697-8","title":"Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras","year":2019,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Mucositis; Autologous stem-cell transplantation; Bortezomib; Toxicity; Ixazomib; Dialysis; Surgery; Oncology; Population; Urology; Carfilzomib","score_opus":0.023562043713395268,"score_gpt":0.27678694547138233,"score_spread":0.25322490175798706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977204914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756676,0.000034666842,0.0006519686,0.000035447305,0.000041676263,0.00090561464,0.0004600058,0.000032794956,0.00027109057],"genre_scores_gemma":[0.9978768,0.000019765694,0.0007956212,0.000011890155,0.00001030663,0.000019515743,0.0012227406,0.00001560121,0.000027755912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982002,0.0001274618,0.00044428644,0.00035295,0.00057851116,0.0002966264],"domain_scores_gemma":[0.9992982,0.00017012203,0.000113123955,0.00016974588,0.00008045775,0.00016834207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001960712,0.00021136148,0.00056106417,0.0002340363,0.00007029868,0.000013025632,0.000069828304,0.000088984634,0.000017690034],"category_scores_gemma":[0.0000044990556,0.00016213243,0.00004643561,0.00018202915,0.000111942245,0.00020729583,0.0000070875562,0.00018773522,0.0000066361813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028327275,0.0015670336,0.98591983,0.00032659623,0.000064507745,0.00006829404,0.001219277,0.00019369487,0.0036092517,0.00004472295,4.2755607e-7,0.004153633],"study_design_scores_gemma":[0.019283261,0.0014935287,0.96995616,0.00013808551,0.00010501913,0.000012017864,0.00007180346,0.0016002402,0.0071722595,0.0000050383596,0.0000035187857,0.0001590621],"about_ca_topic_score_codex":0.00053879595,"about_ca_topic_score_gemma":0.001134299,"teacher_disagreement_score":0.016450534,"about_ca_system_score_codex":0.00007077323,"about_ca_system_score_gemma":0.000129498,"threshold_uncertainty_score":0.6611569},"labels":[],"label_agreement":null},{"id":"W2977283561","doi":"10.1182/blood.v114.22.1845.1845","title":"Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Multiple myeloma; Bone marrow; Proteasome; Proteasome inhibitor; Medicine; Peripheral blood mononuclear cell; Pharmacology; Cancer research; Internal medicine; Chemistry; In vitro; Biochemistry","score_opus":0.01535904812107852,"score_gpt":0.26540346366588624,"score_spread":0.2500444155448077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977283561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974488,0.00007739248,6.0446473e-7,0.00024922733,0.000047526,0.0016752147,0.000020288437,0.000018389326,0.0004625468],"genre_scores_gemma":[0.99923515,0.000008078765,0.00032090297,0.00008871585,0.000028206234,0.000084711595,0.00005994031,0.000014435385,0.00015984595],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99847454,0.00013182471,0.0004249672,0.0002488272,0.00043500724,0.0002848211],"domain_scores_gemma":[0.99937844,0.000047362602,0.00013698218,0.00028338374,0.000057281308,0.000096519834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018720831,0.00014994627,0.00029783606,0.0001698775,0.000040899005,0.0000101262385,0.00006354419,0.00008324613,0.000030830895],"category_scores_gemma":[0.00031893447,0.00010108404,0.00010379154,0.0003739366,0.000032510445,0.00009463863,0.000024215251,0.00023378669,0.000007535707],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002407332,0.006824077,0.2591094,0.00013338546,0.000054729462,0.0010540809,0.00059214776,0.000001818415,0.724758,0.000008900328,0.00003740609,0.0050186943],"study_design_scores_gemma":[0.014513181,0.0013384784,0.63005584,0.00037176983,0.000036851474,0.000008796498,0.00007386656,0.000018010198,0.3534499,0.000033902696,0.000020292167,0.00007907684],"about_ca_topic_score_codex":0.000066925684,"about_ca_topic_score_gemma":0.00021050108,"teacher_disagreement_score":0.37130812,"about_ca_system_score_codex":0.00011875741,"about_ca_system_score_gemma":0.00024603924,"threshold_uncertainty_score":0.41220877},"labels":[],"label_agreement":null},{"id":"W2978422592","doi":"10.1182/blood-2018-99-114274","title":"An Increased Number of Cybord Induction Cycles Does Not Increase Peri-Transplant Morbidity in Multiple Myeloma Patients","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Bortezomib; Autologous stem-cell transplantation; Busulfan; Internal medicine; Transplantation; Surgery; Hematopoietic stem cell transplantation; Oncology","score_opus":0.02380352254892753,"score_gpt":0.3019297641042701,"score_spread":0.27812624155534255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978422592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984618,0.000011482801,0.0000051488405,0.000028481398,0.00007438969,0.00056750333,0.0002762409,0.00004926671,0.00052571663],"genre_scores_gemma":[0.9982127,0.000032652693,0.0010579868,0.00004319594,0.0001933335,0.000052399042,0.0003556279,0.000027301934,0.000024788022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983028,0.00016211566,0.00034612787,0.0003618715,0.00046589674,0.000361177],"domain_scores_gemma":[0.9988605,0.00007902542,0.000092474605,0.00042267193,0.0002166061,0.000328733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019933206,0.00019652031,0.00033819865,0.00016140469,0.000085031985,0.000013833369,0.00011787712,0.00012901697,0.00026939248],"category_scores_gemma":[0.00024895804,0.00014192841,0.00007327799,0.00023113457,0.00019072008,0.00019242261,0.000032672833,0.00016860219,0.000058769743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001919794,0.005057425,0.9370939,0.00008122859,0.000108880864,0.00009591036,0.0003334439,1.2925342e-7,0.052044727,0.000009031703,0.000008184799,0.0032473388],"study_design_scores_gemma":[0.01103729,0.00053982856,0.78707516,0.00009878444,0.00008792374,0.0000220121,0.000058825208,0.00012597187,0.20079894,0.000018658333,0.00002308,0.00011351742],"about_ca_topic_score_codex":0.010742577,"about_ca_topic_score_gemma":0.0015559439,"teacher_disagreement_score":0.15001874,"about_ca_system_score_codex":0.00005145187,"about_ca_system_score_gemma":0.0001068596,"threshold_uncertainty_score":0.99584496},"labels":[],"label_agreement":null},{"id":"W2978425920","doi":"10.14309/00000434-201210001-01218","title":"Extramedullary Plasmacytoma of the Cecum: A Rare Cause of Iron Deficiency Anemia","year":2012,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Plasmacytoma; Anemia; Iron-deficiency anemia; Colonoscopy; Barium enema; Multiple myeloma; Ascending colon; Context (archaeology); Plasma cell neoplasm; Pathology; Surgery; Internal medicine; Colorectal cancer; Cancer","score_opus":0.018260769027590364,"score_gpt":0.2937008957866438,"score_spread":0.27544012675905344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978425920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781615,0.00045505032,0.000072249764,0.0012982516,0.000110909816,0.00015491963,0.000013303756,0.0000029180421,0.0000762355],"genre_scores_gemma":[0.9988683,0.00015749717,0.00056990434,0.00027394158,0.00009055203,0.0000025085035,0.0000011010729,0.000012888891,0.000023320676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998267,0.00036816372,0.00045968549,0.00007659523,0.0003949524,0.00043361384],"domain_scores_gemma":[0.99831545,0.00014521518,0.00085101044,0.00034943986,0.00015004189,0.00018886119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039288469,0.00012349126,0.0005266837,0.00011737811,0.000044759785,0.0000024407427,0.0003335548,0.000022798074,0.000049358132],"category_scores_gemma":[0.00014320602,0.000060067698,0.00020495897,0.00017545624,0.00093283755,0.000056064342,0.00009520717,0.0003248314,0.0000029752111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011162878,0.0004979539,0.97625095,0.000046922476,0.00012737271,0.00005967659,0.00062101666,0.000012777385,0.007891581,0.0000112886955,0.00025213952,0.0030654185],"study_design_scores_gemma":[0.002539472,0.011705161,0.97525984,0.000079328405,0.0002680354,0.0055622156,0.00086782366,0.000014025163,0.0036153411,0.00001527041,0.000040924435,0.000032562162],"about_ca_topic_score_codex":0.000058696747,"about_ca_topic_score_gemma":0.000011558678,"teacher_disagreement_score":0.011207207,"about_ca_system_score_codex":0.000058773243,"about_ca_system_score_gemma":0.00009286526,"threshold_uncertainty_score":0.3437079},"labels":[],"label_agreement":null},{"id":"W2978510275","doi":"10.1111/bjh.16213","title":"Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","year":2019,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University Health Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Lenalidomide; Pomalidomide; Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Thalidomide; Oncology; Adverse effect; Refractory (planetary science); Population; Surgery; Clinical trial","score_opus":0.015517708207336058,"score_gpt":0.2802767169421137,"score_spread":0.26475900873477765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978510275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923647,0.0053802812,0.00003009365,0.0007074538,0.00027848507,0.00088328077,0.000028648601,0.000023549685,0.00030348919],"genre_scores_gemma":[0.99416256,0.0008286289,0.0035494545,0.00020749071,0.00013261766,0.000059508082,0.000023682454,0.000060140483,0.00097591826],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99678737,0.0004335943,0.0010843527,0.00041157662,0.000532442,0.0007506509],"domain_scores_gemma":[0.99782914,0.00058659056,0.0004308587,0.00038472042,0.00028575235,0.0004829561],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048155824,0.0003226753,0.0015906019,0.00052049616,0.000054156968,0.000048628594,0.00019930105,0.00031085435,0.0009681592],"category_scores_gemma":[0.00075129524,0.0002931293,0.0004157142,0.000262405,0.00015436426,0.00021591851,0.000069803624,0.0006747066,0.00026578968],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02184726,0.0027283602,0.39485198,0.00038740443,0.0011212747,0.5307688,0.00059646444,0.00007430132,0.0068748915,0.000022486125,0.0013267379,0.039400034],"study_design_scores_gemma":[0.11870524,0.0048300633,0.45726007,0.0031343042,0.0003017279,0.40094775,0.00072365795,0.0005555393,0.0070805894,0.00016635387,0.0057236985,0.0005709905],"about_ca_topic_score_codex":0.00061091105,"about_ca_topic_score_gemma":0.0017933472,"teacher_disagreement_score":0.12982105,"about_ca_system_score_codex":0.0007204358,"about_ca_system_score_gemma":0.000583811,"threshold_uncertainty_score":0.9999521},"labels":[],"label_agreement":null},{"id":"W2978647547","doi":"10.1182/blood.v126.23.5384.5384","title":"Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"","keywords":"Pomalidomide; Lenalidomide; Bortezomib; Medicine; Multiple myeloma; Internal medicine; Dexamethasone; Oncology; Thalidomide; Surgery; Gastroenterology","score_opus":0.06323097932850842,"score_gpt":0.31696981247590034,"score_spread":0.25373883314739193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978647547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931521,0.0041274223,0.000047259622,0.00048276954,0.000059578066,0.0012644911,0.000036965743,0.000033255175,0.00079618185],"genre_scores_gemma":[0.9958736,0.00034724458,0.0022121095,0.000035902816,0.00013008135,0.00021232497,0.00003502949,0.000024812613,0.0011289096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990181,0.00004402109,0.00021172497,0.00022408663,0.0002264899,0.0002756103],"domain_scores_gemma":[0.9985259,0.0006345366,0.00008672441,0.00036208285,0.00014054877,0.00025019769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019573969,0.0001492361,0.00030814685,0.00006542545,0.000087956716,0.000012519197,0.00005628569,0.000066712724,0.000009273795],"category_scores_gemma":[0.00042831592,0.000087210574,0.0001008989,0.00007250306,0.00009529539,0.000045308523,0.000020072748,0.000054496842,0.0000068529116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017029226,0.009654269,0.8194701,0.00020956658,0.0043910425,0.00048615775,0.00783833,0.0000049237565,0.022544997,0.00038866207,0.0014113949,0.11657133],"study_design_scores_gemma":[0.28699306,0.0460391,0.43506187,0.0002993944,0.002938295,0.00043520372,0.004611053,0.002323216,0.13284343,0.000381811,0.08751949,0.00055408484],"about_ca_topic_score_codex":0.00022311306,"about_ca_topic_score_gemma":0.000058682577,"teacher_disagreement_score":0.38440824,"about_ca_system_score_codex":0.000068373294,"about_ca_system_score_gemma":0.00013312203,"threshold_uncertainty_score":0.3556344},"labels":[],"label_agreement":null},{"id":"W2979227727","doi":"10.1111/bjh.16214","title":"Pomalidomide in lenalidomide‐refractory multiple myeloma: Far from futile","year":2019,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pomalidomide; Lenalidomide; Multiple myeloma; Medicine; Oncology; Refractory (planetary science); Internal medicine; Biology","score_opus":0.024522558363938365,"score_gpt":0.2838409606787506,"score_spread":0.25931840231481224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979227727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85972106,0.025673062,0.0000603199,0.109812446,0.0018306493,0.0011504027,0.000556475,0.000040660438,0.0011549195],"genre_scores_gemma":[0.73814106,0.006966143,0.0034075975,0.23811808,0.007137369,0.00007852606,0.0017996184,0.00039927877,0.0039523025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99498135,0.0006772395,0.0017005992,0.0005993182,0.0010094839,0.0010320254],"domain_scores_gemma":[0.9960701,0.0015878229,0.0010762442,0.0005377371,0.00046149077,0.0002665904],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004758973,0.00050803117,0.002963409,0.0008195513,0.00007192002,0.000087302506,0.00054463383,0.0014600595,0.0012397794],"category_scores_gemma":[0.0015812924,0.0005134428,0.0007034866,0.00021070566,0.00024249402,0.00023143801,0.00015687663,0.0048499187,0.00042098243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080985925,0.00028275276,0.015703216,0.00026251137,0.00067866594,0.48261642,0.000039548842,0.0000014095923,0.00018090126,0.0000011753807,0.4926486,0.0067749466],"study_design_scores_gemma":[0.023696916,0.0007208477,0.032904632,0.0032998163,0.00038800505,0.31355816,0.00008735219,0.000069677204,0.00046374544,0.00021051026,0.62406707,0.0005332758],"about_ca_topic_score_codex":0.0024363312,"about_ca_topic_score_gemma":0.0006684791,"teacher_disagreement_score":0.16905825,"about_ca_system_score_codex":0.00040947276,"about_ca_system_score_gemma":0.00083369657,"threshold_uncertainty_score":0.99983627},"labels":[],"label_agreement":null},{"id":"W2979282408","doi":"10.1093/annonc/mdz251.039","title":"DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Refractory (planetary science); Phases of clinical research; Oncology; Open label study; Internal medicine; Safety profile; Clinical trial; Adverse effect; Immunotherapy; Cancer","score_opus":0.17193234766611384,"score_gpt":0.44411592859264654,"score_spread":0.2721835809265327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979282408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940851,0.000021115999,0.0000052315395,0.00055901415,0.0000463876,0.0044464683,0.00006392926,0.000010978903,0.00076178357],"genre_scores_gemma":[0.9991053,0.00003235558,0.00043072118,0.00011965546,0.000009944514,0.00007724523,0.00009011119,0.000032987737,0.000101732345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971699,0.000559187,0.0007858961,0.0005861224,0.00046578838,0.00043307678],"domain_scores_gemma":[0.9977809,0.00066159625,0.00043083576,0.00047361062,0.0003656229,0.00028740303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008042998,0.0002569438,0.001221688,0.00039241466,0.000052032065,0.000009955918,0.0002140699,0.00015887931,0.00003810132],"category_scores_gemma":[0.00043698866,0.00019537249,0.00003833056,0.00038413546,0.00016125888,0.0002491054,0.00031954277,0.0003759508,0.0000058356954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14485134,0.13466154,0.6203265,0.00006333755,0.0002136996,0.00013990613,0.0011951859,0.0000010479016,0.0002208464,0.0000040280784,0.000020711153,0.098301865],"study_design_scores_gemma":[0.163028,0.22675534,0.6086333,0.00019873322,0.00003824746,0.0000062738286,0.00050547876,0.00007733298,0.00048984867,0.000003466078,0.00015081596,0.00011317447],"about_ca_topic_score_codex":0.00060527906,"about_ca_topic_score_gemma":0.0026149477,"teacher_disagreement_score":0.09818869,"about_ca_system_score_codex":0.00016486108,"about_ca_system_score_gemma":0.00038491245,"threshold_uncertainty_score":0.79670584},"labels":[],"label_agreement":null},{"id":"W2979301166","doi":"10.1182/blood.v118.21.4111.4111","title":"Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Internal medicine; Progression-free survival; Hazard ratio; Cyclophosphamide; Autologous stem-cell transplantation; Proportional hazards model; Creatinine; Urology; Surgery; Gastroenterology; Oncology; Overall survival; Chemotherapy; Confidence interval","score_opus":0.02356297165650279,"score_gpt":0.23620530064740333,"score_spread":0.21264232899090055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979301166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976444,0.00031565028,0.000007581934,0.000058092526,0.00006924757,0.001269272,0.00048406748,0.00007153852,0.00008010312],"genre_scores_gemma":[0.9988947,0.000019524148,0.00072654855,0.000016389788,0.000027562,0.00012697012,0.000057108202,0.00005048459,0.000080698366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970471,0.00077523506,0.0003550027,0.00058285444,0.0006115336,0.0006282432],"domain_scores_gemma":[0.9984748,0.00048089353,0.00007353788,0.00046488165,0.00007770048,0.00042820696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058990286,0.00033944455,0.00051920477,0.00019683153,0.00010321981,0.000037196405,0.00011439526,0.00015909997,0.000034916913],"category_scores_gemma":[0.00009934633,0.00024788085,0.000053989505,0.00012254296,0.0002292328,0.00015962879,0.000115033174,0.00025237154,0.000006293703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1973287,0.0029300458,0.7906842,0.00010530978,0.00012026471,0.0014691899,0.0014177542,1.157144e-7,0.0049244617,0.0000010541775,0.0000022558595,0.0010166334],"study_design_scores_gemma":[0.04502124,0.007372159,0.9410436,0.0002793584,0.00015643629,0.000049080205,0.00009955478,0.00006340665,0.0056103547,0.0000024911367,0.000061724895,0.00024056724],"about_ca_topic_score_codex":0.00015151109,"about_ca_topic_score_gemma":0.00023526374,"teacher_disagreement_score":0.15230747,"about_ca_system_score_codex":0.00005227277,"about_ca_system_score_gemma":0.00013271533,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W2979307590","doi":"10.1182/blood.v128.22.2263.2263","title":"Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Bortezomib; Internal medicine; Progression-free survival; Lenalidomide; Oncology; Urology; Gastroenterology; Surgery; Chemotherapy","score_opus":0.012076879897014323,"score_gpt":0.2806665186982146,"score_spread":0.26858963880120024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979307590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667084,0.0002129514,0.00004669714,0.0002439762,0.00011069798,0.0016026264,0.0007060744,0.000056881483,0.00034925085],"genre_scores_gemma":[0.9973681,0.000062090614,0.0014823524,0.000027871245,0.00014390815,0.0002877371,0.0001221379,0.000056906938,0.00044892324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980458,0.00007461294,0.00022466,0.00046143238,0.00061973254,0.0005737797],"domain_scores_gemma":[0.9982141,0.00058162626,0.00008435942,0.00058663933,0.0001893833,0.00034389127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019381488,0.00030898003,0.00041000667,0.00010485593,0.00009535209,0.000038727212,0.000118552234,0.00010715494,0.000099819365],"category_scores_gemma":[0.00059084326,0.00014849752,0.0001453828,0.00007772017,0.000087763154,0.00015322155,0.00009951346,0.00010540151,0.000032261778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026135048,0.0026338976,0.9412578,0.000064073734,0.0006582443,0.0000843261,0.000020272648,1.5425059e-7,0.00040194317,0.0000068846807,0.00017940013,0.028557956],"study_design_scores_gemma":[0.056946453,0.007991614,0.9327136,0.00038953644,0.00013098672,0.000009066756,0.0000059418003,0.000007395182,0.0012628324,0.00007287722,0.00026821002,0.00020145056],"about_ca_topic_score_codex":0.00006128437,"about_ca_topic_score_gemma":0.000043147167,"teacher_disagreement_score":0.030811403,"about_ca_system_score_codex":0.00008952425,"about_ca_system_score_gemma":0.000116668234,"threshold_uncertainty_score":0.6055553},"labels":[],"label_agreement":null},{"id":"W2979350016","doi":"10.1182/blood.v114.22.4323.4323","title":"Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantion for Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Stem cell; Transplantation; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Cyclophosphamide; Melphalan; Median follow-up; Oncology; Surgery; Gastroenterology; Chemotherapy; Biology","score_opus":0.029549942311992778,"score_gpt":0.3096492217573308,"score_spread":0.280099279445338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979350016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938294,0.00042659108,0.0013665825,0.00038181627,0.00009161447,0.002213434,0.00021900212,0.0001146637,0.0013568952],"genre_scores_gemma":[0.99320847,0.00009160809,0.0053736945,0.0000690847,0.00021909874,0.0001230717,0.0005488743,0.000037171027,0.00032892873],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980368,0.00005588147,0.00031983264,0.00046840712,0.0005360312,0.00058305485],"domain_scores_gemma":[0.9987846,0.00019281881,0.0000638993,0.0004079894,0.0002360326,0.00031466817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026773804,0.0002702757,0.00038907648,0.00019878802,0.00019863521,0.000035202513,0.00016832855,0.00016276381,0.000015906238],"category_scores_gemma":[0.00005944315,0.0002133313,0.00021200787,0.00022115461,0.00003821212,0.00012631166,0.000025615494,0.00018086041,0.000021134845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040202956,0.005557165,0.37085405,0.00054577994,0.0005058213,0.0005187637,0.0006049328,0.000013107741,0.47702652,0.000030222425,0.0001578213,0.14016551],"study_design_scores_gemma":[0.020396331,0.0032177437,0.5531265,0.00031636367,0.0005138464,0.0000374238,0.00019780967,0.000989217,0.4206856,0.00004867768,0.00017148799,0.00029899302],"about_ca_topic_score_codex":0.00001977312,"about_ca_topic_score_gemma":0.00005051816,"teacher_disagreement_score":0.18227246,"about_ca_system_score_codex":0.000046379646,"about_ca_system_score_gemma":0.00010616076,"threshold_uncertainty_score":0.8699398},"labels":[],"label_agreement":null},{"id":"W2979356821","doi":"10.1182/blood.v120.21.3080.3080","title":"Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Multiple myeloma; Busulfan; Bortezomib; Regimen; Autologous stem-cell transplantation; Transplantation; Surgery; Internal medicine; Hematopoietic stem cell transplantation; Oncology","score_opus":0.01865443310180049,"score_gpt":0.25196456350417323,"score_spread":0.23331013040237275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979356821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973905,0.00033714765,0.00028777448,0.00003579293,0.000034078028,0.0009979943,0.0002977937,0.00004222807,0.00057666143],"genre_scores_gemma":[0.99271226,0.000035724977,0.0061737895,0.000026216383,0.0000278497,0.000048495003,0.0008216336,0.000036805923,0.0001171973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979417,0.0000961674,0.00063997286,0.0003900377,0.000452463,0.00047968928],"domain_scores_gemma":[0.9984162,0.0005665355,0.00033950212,0.00030414583,0.00009749581,0.00027612926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023233205,0.00025181146,0.00057880447,0.00019323143,0.000113316775,0.00001916819,0.00007448482,0.00013688406,0.000058448433],"category_scores_gemma":[0.00008294332,0.00021358396,0.00005810415,0.00022113808,0.00012740909,0.00013689806,0.000029450079,0.0002491287,0.0000050178287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035020113,0.005330567,0.9746275,0.0005184289,0.00052757683,0.0012350101,0.008264544,0.000013782694,0.0042457287,0.000021539474,0.000008849552,0.0017044434],"study_design_scores_gemma":[0.07145162,0.0009466096,0.9106643,0.00056561455,0.00039135403,0.0006541724,0.0005065621,0.000056816727,0.01453242,0.0000074568625,0.000024400477,0.00019864037],"about_ca_topic_score_codex":0.00022108438,"about_ca_topic_score_gemma":0.00025721107,"teacher_disagreement_score":0.06794961,"about_ca_system_score_codex":0.000073157695,"about_ca_system_score_gemma":0.00023992149,"threshold_uncertainty_score":0.87097013},"labels":[],"label_agreement":null},{"id":"W2979406515","doi":"10.1182/blood.v110.11.954.954","title":"Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients with Dialysis-Dependent Renal Failure Is Effective but Carries High Rates of Toxicity.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Neutropenia; Transplantation; Internal medicine; Dialysis; Hemodialysis; Surgery; Gastroenterology; Toxicity; Autologous stem-cell transplantation; Urology","score_opus":0.008605388553050658,"score_gpt":0.24092020208927659,"score_spread":0.23231481353622593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979406515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979402,0.00011396161,0.0001863906,0.000032940643,0.000023821722,0.0013002682,0.00022837771,0.000032869255,0.00014117188],"genre_scores_gemma":[0.99881655,0.000023349166,0.0006718716,0.00002070601,0.000030879604,0.000073889925,0.00021514438,0.000025582289,0.00012200392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816465,0.00010789531,0.00035692452,0.00036437862,0.00058383524,0.00042231215],"domain_scores_gemma":[0.99892795,0.00032276564,0.00013801374,0.00024136489,0.00018941595,0.00018048364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020248839,0.0002337322,0.00046743348,0.00027998528,0.0000697169,0.000013242879,0.000087917695,0.0001326475,0.00003350135],"category_scores_gemma":[0.000033314427,0.00017225291,0.000085782034,0.00028981385,0.00009331596,0.00010215989,0.000020442836,0.00019714993,0.000011914614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033220933,0.0020112803,0.9573684,0.00029535618,0.00040793294,0.0005575628,0.0018050174,0.000013625462,0.027657842,0.0000036731162,0.0000060361003,0.006551216],"study_design_scores_gemma":[0.013148507,0.00093890494,0.53920156,0.00008743374,0.00019947028,0.000010081712,0.00018053524,0.000013563107,0.44612637,0.0000034107518,0.0000033612594,0.00008682773],"about_ca_topic_score_codex":0.0010008812,"about_ca_topic_score_gemma":0.0023602773,"teacher_disagreement_score":0.41846853,"about_ca_system_score_codex":0.00008661325,"about_ca_system_score_gemma":0.00007789755,"threshold_uncertainty_score":0.70242697},"labels":[],"label_agreement":null},{"id":"W2979547422","doi":"10.1182/blood.v114.22.1217.1217","title":"Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Salvage therapy; Multiple myeloma; Surgery; Regimen; Internal medicine; Etoposide; Transplantation; Cyclophosphamide; Median follow-up; Autologous stem-cell transplantation; Oncology; Chemotherapy","score_opus":0.01067422038702937,"score_gpt":0.23469763147845232,"score_spread":0.22402341109142296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979547422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940919,0.00035104202,0.0000043375435,0.00010956943,0.000027010212,0.00118771,0.000052482053,0.000087985594,0.004087923],"genre_scores_gemma":[0.9982116,0.000070951384,0.00033564074,0.00026261416,0.000026976544,0.000039051974,0.0001505816,0.000030347106,0.00087221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830335,0.00007746709,0.00026309924,0.0003964088,0.0004331878,0.00052649266],"domain_scores_gemma":[0.9991551,0.00007864762,0.00006310428,0.00037957434,0.00006139187,0.00026218136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092437,0.00025171012,0.00038141117,0.000169736,0.00006700326,0.000019521745,0.00011763665,0.0001263046,0.00019329178],"category_scores_gemma":[0.000009148572,0.00017544186,0.00007756828,0.0002133879,0.000040766816,0.00008591288,0.0000084616195,0.00027654707,0.00010287662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042034835,0.007310264,0.95145845,0.00005045964,0.00018627677,0.0014592855,0.0009240061,0.0000016731427,0.003723427,0.000008091692,0.00007016218,0.030604439],"study_design_scores_gemma":[0.05442214,0.005345298,0.90876687,0.00008381626,0.000049491773,0.000030635892,0.000035365887,0.00002477765,0.030775245,0.000011608837,0.00027896406,0.00017579492],"about_ca_topic_score_codex":0.00004927539,"about_ca_topic_score_gemma":0.00008117196,"teacher_disagreement_score":0.050218657,"about_ca_system_score_codex":0.000051050727,"about_ca_system_score_gemma":0.00011410563,"threshold_uncertainty_score":0.71543115},"labels":[],"label_agreement":null},{"id":"W2979643211","doi":"10.1182/blood.v118.21.480.480","title":"Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Regimen; Vorinostat; Clinical endpoint; Internal medicine; Phases of clinical research; Dexamethasone; Oncology; Salvage therapy; Refractory (planetary science); Gastroenterology; Progressive disease; Clinical trial; Combination therapy; Pharmacology; Chemotherapy; Histone deacetylase","score_opus":0.04700091844040593,"score_gpt":0.3249367596965943,"score_spread":0.27793584125618837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979643211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952698,0.000021908616,0.0000055855076,0.000017834587,0.00005609995,0.003321963,0.00025140212,0.000023761777,0.0010316572],"genre_scores_gemma":[0.99904317,0.000006370274,0.00053237006,0.0000095642,0.000023649896,0.00013881558,0.00019638998,0.000015703527,0.000033953536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979316,0.0001751433,0.00057725166,0.00038379326,0.0005570137,0.00037517722],"domain_scores_gemma":[0.99909663,0.00009435432,0.00016381206,0.00035166988,0.00013739099,0.00015612665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031146285,0.00019810534,0.0004365274,0.00018558338,0.000029023806,0.000008618829,0.00011557139,0.000069031725,0.000020109734],"category_scores_gemma":[0.00047763548,0.00015463888,0.00005326604,0.00047180342,0.00005958033,0.0001357117,0.00005543583,0.00016974569,0.000007645923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15676878,0.069078095,0.7672181,0.000030867253,0.00012841327,0.0009538707,0.0010439308,2.344739e-7,0.00004485064,0.00001115602,0.000011320944,0.0047103674],"study_design_scores_gemma":[0.42705017,0.015650423,0.5560226,0.00006559171,0.00006508053,0.000003981868,0.00026335995,0.000049425777,0.0007396867,0.000009183074,0.00000597984,0.00007454725],"about_ca_topic_score_codex":0.0024066549,"about_ca_topic_score_gemma":0.0036387397,"teacher_disagreement_score":0.27028137,"about_ca_system_score_codex":0.00010585367,"about_ca_system_score_gemma":0.00014979983,"threshold_uncertainty_score":0.6305991},"labels":[],"label_agreement":null},{"id":"W2979671217","doi":"10.1182/blood.v114.22.2812.2812","title":"Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunophenotyping; Fluorescence in situ hybridization; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Pathology; Medicine; Bone marrow; Flow cytometry; Internal medicine; Biology; Monoclonal; Immunology; Monoclonal antibody; Antibody","score_opus":0.005562170629835833,"score_gpt":0.22689641794004728,"score_spread":0.22133424731021145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979671217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988127,0.0000897871,0.00006349851,0.000034108492,0.000012059693,0.00087397057,0.000026889304,0.000013325294,0.00007366116],"genre_scores_gemma":[0.99855834,0.000027214432,0.0010152002,0.000039442493,0.0000055090045,0.000012718162,0.0003202169,0.000012886236,0.000008482963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895793,0.00005292391,0.00025069717,0.00027800357,0.00023408944,0.0002263546],"domain_scores_gemma":[0.99943095,0.00005691773,0.00011117696,0.00016572989,0.00013793824,0.000097285825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007559471,0.0001523285,0.00026598742,0.00023045175,0.000033331366,0.000011558315,0.000042133743,0.00006145803,0.000005378003],"category_scores_gemma":[0.00015734,0.0001151479,0.0000112884345,0.00023835954,0.00010380075,0.00016089025,0.000027193011,0.00014342995,0.0000011811926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027293013,0.0024679487,0.9826588,0.000038508537,0.000036870948,0.000055571985,0.00037979873,0.0000053231024,0.0012714993,0.0000038544417,0.0000039656766,0.010348545],"study_design_scores_gemma":[0.035487577,0.002438836,0.9589352,0.00034333076,0.00004577957,0.000009221879,0.00003727467,0.00035972972,0.002230982,0.000007187923,0.000001957742,0.000102942766],"about_ca_topic_score_codex":0.00016073472,"about_ca_topic_score_gemma":0.00029290302,"teacher_disagreement_score":0.032758273,"about_ca_system_score_codex":0.00004299403,"about_ca_system_score_gemma":0.000041199724,"threshold_uncertainty_score":0.46955952},"labels":[],"label_agreement":null},{"id":"W2979673767","doi":"10.1182/blood.v116.21.783.783","title":"Cancer-Specific Nuclear Positioning of Translocation Prone Gene Loci In Non-Malignant B-Cells From Patients with Multiple Myeloma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"","keywords":"Chromosomal translocation; CD19; Biology; Molecular biology; CD34; Multiple myeloma; Cancer research; Immunoglobulin heavy chain; Antibody; Stem cell; Gene; Immunology; Genetics; Flow cytometry","score_opus":0.008865589308113335,"score_gpt":0.2335077814258115,"score_spread":0.22464219211769815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979673767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985458,0.00013159975,0.00004365508,0.00007775247,0.000044266188,0.00088285375,0.00014703938,0.000020286394,0.0001067441],"genre_scores_gemma":[0.9942225,0.00007184513,0.00521494,0.000020282672,0.00006490218,0.0000686902,0.00028709185,0.000033059005,0.000016655842],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988497,0.000023308896,0.00024354314,0.00027940102,0.00034857512,0.00025549828],"domain_scores_gemma":[0.99928707,0.00003930255,0.000083163446,0.0002697419,0.00018167587,0.00013903934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005980677,0.00013900855,0.00025430194,0.00010852748,0.000053494976,0.000012625586,0.0000791939,0.00008217181,0.00014556773],"category_scores_gemma":[0.000017387058,0.00010920965,0.00004129049,0.00018021064,0.00006634753,0.00008134917,0.000015103912,0.00019354488,0.00001923598],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006753954,0.0027184978,0.3995337,0.00003804244,0.00013508933,0.00004541425,0.0005713978,0.0000066351918,0.5833818,0.0000032902901,0.000014891298,0.012875873],"study_design_scores_gemma":[0.013893994,0.0003332278,0.62491953,0.00015348381,0.00004741111,0.0000019047013,0.000036845744,0.00022856757,0.36025903,0.0000036918698,0.00004063691,0.00008167233],"about_ca_topic_score_codex":0.0015599942,"about_ca_topic_score_gemma":0.0010022902,"teacher_disagreement_score":0.22538583,"about_ca_system_score_codex":0.00003589953,"about_ca_system_score_gemma":0.0000694333,"threshold_uncertainty_score":0.44534403},"labels":[],"label_agreement":null},{"id":"W2979691426","doi":"10.1182/blood.v108.11.3556.3556","title":"Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Thalidomide; Interim analysis; Data monitoring committee; Expanded access; Neutropenia; Refractory (planetary science); Oncology; Surgery; Clinical trial; Toxicity","score_opus":0.043862974235070865,"score_gpt":0.342573809831714,"score_spread":0.29871083559664313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979691426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931567,0.0006383267,0.00011214454,0.00014227729,0.00005419993,0.0045680767,0.000050795632,0.00021806548,0.0010594198],"genre_scores_gemma":[0.98347723,0.00007974116,0.01194851,0.00008835868,0.00024193722,0.0019013901,0.00029917556,0.00009712057,0.0018665198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972328,0.00010683175,0.00046595442,0.0006732879,0.00060459826,0.0009165573],"domain_scores_gemma":[0.9981521,0.00062723475,0.0001633398,0.0005760324,0.0001755204,0.00030580882],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003078091,0.00038311415,0.0006840048,0.00032378026,0.00011772202,0.00008781078,0.00023032648,0.00020783074,0.00011038716],"category_scores_gemma":[0.0005373315,0.0002583994,0.00014538455,0.00055321807,0.00012682837,0.00029435797,0.00008049301,0.00032920192,0.000018788087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046248384,0.015977224,0.8775164,0.0009910407,0.00096539466,0.0033655604,0.00030324538,0.000037444093,0.014652317,0.000038901904,0.0015220174,0.03838207],"study_design_scores_gemma":[0.15030865,0.004472398,0.78512895,0.0005804707,0.00041107502,0.00018720806,0.00010168502,0.0009405566,0.05426515,0.00006736895,0.0030140814,0.0005224038],"about_ca_topic_score_codex":0.0015460758,"about_ca_topic_score_gemma":0.0052418984,"teacher_disagreement_score":0.10406027,"about_ca_system_score_codex":0.0002252028,"about_ca_system_score_gemma":0.00053219235,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W2979704099","doi":"10.1182/blood.v118.21.2936.2936","title":"Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Bortezomib; Regimen; Multiple myeloma; Dexamethasone; Refractory (planetary science); Neutropenia; Oncology; Progression-free survival; Thalidomide; Toxicity; Gastroenterology; Surgery; Chemotherapy","score_opus":0.07568505293985034,"score_gpt":0.30700020220972785,"score_spread":0.2313151492698775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979704099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936352,0.0016763149,0.00014460605,0.00014543734,0.000078142984,0.002152418,0.00013029613,0.00019537419,0.0018422286],"genre_scores_gemma":[0.97464216,0.0005446118,0.021260945,0.00016093315,0.00014805689,0.0003878406,0.0001343486,0.000091199225,0.0026299094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977381,0.00010570851,0.00044366284,0.000636081,0.0003598115,0.0007166385],"domain_scores_gemma":[0.99793595,0.00054756977,0.0001397423,0.0005685335,0.0001990863,0.0006091371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003319598,0.00035792618,0.0006165928,0.0002136825,0.00017591166,0.000025186258,0.00013874912,0.0002470624,0.0003116361],"category_scores_gemma":[0.0013825357,0.00025902072,0.00016329088,0.00023558726,0.00016188924,0.00016560883,0.00007749619,0.00028457353,0.000048076483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0417428,0.010246747,0.7711442,0.001118944,0.003974803,0.0023328639,0.002285547,2.4075302e-7,0.08099984,0.00013846201,0.0029743952,0.083041124],"study_design_scores_gemma":[0.08613577,0.0066400953,0.68463016,0.00043162,0.0013452667,0.000547197,0.000291191,0.00033811637,0.21461812,0.00015341102,0.0042765583,0.0005925252],"about_ca_topic_score_codex":0.00035206228,"about_ca_topic_score_gemma":0.00015462923,"teacher_disagreement_score":0.13361828,"about_ca_system_score_codex":0.000068069,"about_ca_system_score_gemma":0.00021298105,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W2979726845","doi":"10.1182/blood.v128.22.994.994","title":"Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Hazard ratio; Melphalan; Internal medicine; Urology; Proportional hazards model; Renal function; Surgery; Creatinine; Lenalidomide; Confidence interval","score_opus":0.011511772549474096,"score_gpt":0.2590326137767893,"score_spread":0.2475208412273152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979726845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972182,0.00020551044,0.00017436966,0.00025751806,0.000027428616,0.00090743444,0.00009469128,0.00008106638,0.0010337647],"genre_scores_gemma":[0.9972569,0.00014081325,0.0014763144,0.0001389798,0.00002445837,0.00010305212,0.000046018296,0.000041271855,0.00077219657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807346,0.00007402344,0.00027860835,0.00049210835,0.00055072946,0.0005310638],"domain_scores_gemma":[0.99891263,0.0001635664,0.000088288274,0.00034659807,0.00012434184,0.00036454733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101515696,0.00029812742,0.0003901351,0.00014753982,0.00011011057,0.000026656564,0.00008610611,0.000114568196,0.00008634461],"category_scores_gemma":[0.00010417784,0.00016195048,0.000075401476,0.00009397031,0.00016085009,0.00014110959,0.00003401071,0.00012717053,0.00008822969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014728927,0.0027511716,0.9871492,0.0001597858,0.00015071403,0.0007334344,0.0008291655,3.4806482e-7,0.0016804686,0.000005869134,0.000012374614,0.0050546015],"study_design_scores_gemma":[0.029495928,0.0022719002,0.94341505,0.00030209258,0.00036271987,0.00018654758,0.00006807723,0.00002948164,0.023481667,0.000023846249,0.00012186124,0.00024084511],"about_ca_topic_score_codex":0.00006699614,"about_ca_topic_score_gemma":0.00009228675,"teacher_disagreement_score":0.04373414,"about_ca_system_score_codex":0.000044519715,"about_ca_system_score_gemma":0.00010703581,"threshold_uncertainty_score":0.6604149},"labels":[],"label_agreement":null},{"id":"W2979732157","doi":"10.1182/blood.v122.21.282.282","title":"Novel Targeting Of Phospho-Marcks Overcomes Drug Resistance and Induces Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; MARCKS; Multiple myeloma; Cancer research; Cell culture; Viability assay; Dexamethasone; MTT assay; Western blot; Drug resistance; Pharmacology; Lenalidomide; Molecular biology; Biology; Medicine; Kinase; Immunology; Internal medicine; Protein kinase C; Cell biology; Biochemistry","score_opus":0.039176749387891605,"score_gpt":0.3084121908889006,"score_spread":0.269235441501009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979732157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976469,0.0009083251,0.000037915433,0.00017105868,0.000019356414,0.00068051676,0.000038483748,0.000015238735,0.00048215038],"genre_scores_gemma":[0.99360114,0.00012646876,0.0060047708,0.0000146581815,0.000020685005,0.000048309255,0.000008480923,0.000017443172,0.00015802191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985896,0.00006198058,0.00039789575,0.0003073325,0.00034512303,0.00029806953],"domain_scores_gemma":[0.99874675,0.00053697167,0.00017501184,0.00026065158,0.00012725474,0.00015336818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030140686,0.00015047047,0.00053013075,0.0001096706,0.000031957636,0.000009781457,0.00009539935,0.0000700785,0.000030359779],"category_scores_gemma":[0.000695309,0.00012183977,0.00007340755,0.00017418343,0.00014759167,0.0002160686,0.000104891245,0.00021395087,0.0000023782611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044068106,0.003290846,0.64689606,0.00044715218,0.00017722542,0.000029427354,0.0003779276,0.000006030269,0.34584358,0.000032270622,0.00005543111,0.0024033694],"study_design_scores_gemma":[0.008269887,0.00010537454,0.71524894,0.00026834966,0.000038352162,0.0000046612204,0.00009698696,0.0015701308,0.2741766,0.000121513076,0.000009128733,0.00009010835],"about_ca_topic_score_codex":0.0015260048,"about_ca_topic_score_gemma":0.00018344386,"teacher_disagreement_score":0.07166698,"about_ca_system_score_codex":0.00001945516,"about_ca_system_score_gemma":0.00009769978,"threshold_uncertainty_score":0.49684817},"labels":[],"label_agreement":null},{"id":"W2979754366","doi":"10.1042/bio03205036","title":"Thalidomide and its analogues in prostate cancer therapy: A scientific update","year":2010,"lang":"en","type":"article","venue":"The Biochemist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thalidomide; Medicine; Multiple myeloma; Methemoglobinemia; Dermatology; Pharmacology; Internal medicine; Anesthesia","score_opus":0.026817130070158596,"score_gpt":0.3268435101923635,"score_spread":0.30002638012220495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979754366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350274,0.0034753056,5.064906e-8,0.0020232648,0.0000606653,0.00035116743,0.000029663881,0.000015887957,0.0005412621],"genre_scores_gemma":[0.9964422,0.0007892888,0.000024388612,0.000107880114,0.000058295722,0.00007653401,0.00005174603,0.000009193439,0.002440504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931955,0.000015747804,0.00008624093,0.00020061794,0.00016019875,0.00021766561],"domain_scores_gemma":[0.9995385,0.000024279752,0.000024345176,0.00022727188,0.000053637526,0.00013197844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022239686,0.00008665672,0.00010766629,0.000044952267,0.000100231715,0.00005197817,0.000082646446,0.000028079703,0.00009641294],"category_scores_gemma":[0.00007526615,0.000048160127,0.000022893555,0.0001603453,0.00018904965,0.000029687075,0.000039013612,0.0001612545,0.000024161454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005803834,0.00011627468,0.08946618,0.000042505308,0.00005394516,0.00004572083,0.00055285695,8.342726e-8,0.9001832,0.000034652334,0.00084096554,0.00808321],"study_design_scores_gemma":[0.0036519298,0.000054251348,0.057315543,0.000059085953,0.000013507857,0.00003318007,0.0000978263,0.00022047848,0.9289146,0.00014101565,0.009394186,0.000104417115],"about_ca_topic_score_codex":0.0001636891,"about_ca_topic_score_gemma":0.00018721799,"teacher_disagreement_score":0.032150634,"about_ca_system_score_codex":0.000018193172,"about_ca_system_score_gemma":0.00011249174,"threshold_uncertainty_score":0.1963913},"labels":[],"label_agreement":null},{"id":"W2979802032","doi":"10.1182/blood.v114.22.1813.1813","title":"Molecular Biclonality: Analysis of Clonotypic IgH VDJ Reveals the Frequent Occurrence of a Second Clone in Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Biology; Isotype; Molecular biology; Immunoglobulin heavy chain; Monoclonal; Antibody; Gene; Monoclonal antibody; Genetics","score_opus":0.028354871174469408,"score_gpt":0.3050883526976066,"score_spread":0.2767334815231372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979802032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968539,0.0015544273,0.000026104492,0.0003403272,0.000012752965,0.0005316416,0.00022986153,0.000011936455,0.00043906612],"genre_scores_gemma":[0.9990367,0.00006488477,0.0005486557,0.00014462075,0.000013016076,0.000025255229,0.0001207737,0.0000061188216,0.000039974966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982593,0.0001462858,0.0005190199,0.00028858805,0.00047287162,0.00031393883],"domain_scores_gemma":[0.9987272,0.00019920935,0.00017655507,0.0006165978,0.00014602454,0.0001344013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386883,0.00015771715,0.00061644125,0.00038475025,0.000031061372,0.000007037487,0.00018511523,0.000074976866,0.00015616682],"category_scores_gemma":[0.00035247105,0.00010813075,0.00026538078,0.0012933742,0.00011224726,0.00004004263,0.00003902573,0.00017754556,0.0000056619847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032978773,0.0025948165,0.8311128,0.0001098216,0.002146043,0.00023925562,0.00029624187,0.000036365935,0.15821515,0.00025569156,0.000035636454,0.004628401],"study_design_scores_gemma":[0.0042185998,0.0003913666,0.89902335,0.00007535408,0.0010306777,0.000008969724,0.000040457024,0.0003207123,0.09456888,0.0002006842,0.000038266367,0.00008270181],"about_ca_topic_score_codex":0.0002634576,"about_ca_topic_score_gemma":0.00024426417,"teacher_disagreement_score":0.067910545,"about_ca_system_score_codex":0.00003356692,"about_ca_system_score_gemma":0.000101014164,"threshold_uncertainty_score":0.4409444},"labels":[],"label_agreement":null},{"id":"W2979830663","doi":"10.1182/blood.v116.21.862.862","title":"Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Carfilzomib; Lenalidomide; Neutropenia; Medicine; Dexamethasone; Multiple myeloma; Toxicity; Refractory (planetary science); Internal medicine; Phases of clinical research; Pharmacology; Urology; Gastroenterology; Materials science","score_opus":0.0364600752379513,"score_gpt":0.3428658753765564,"score_spread":0.3064058001386051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979830663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968926,0.0001855886,0.0000051969996,0.0002063897,0.00017405592,0.0014173812,0.00023140504,0.000035244953,0.00085215963],"genre_scores_gemma":[0.9958764,0.00006978097,0.003235618,0.00003443285,0.00036926146,0.00011984173,0.00013229107,0.000028443166,0.00013395338],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980308,0.00010909706,0.0005815288,0.00042202845,0.000417871,0.0004386731],"domain_scores_gemma":[0.9982195,0.0007206079,0.0001427379,0.00043844615,0.00012275131,0.00035597984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005263129,0.00022272796,0.00058686547,0.00027597917,0.00007896509,0.000017630286,0.00011117961,0.00018947262,0.000065926324],"category_scores_gemma":[0.003956844,0.0001843473,0.000108220345,0.00027340668,0.00019150625,0.0001054886,0.000110157365,0.0004482243,0.000009477003],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46839187,0.03444765,0.090220764,0.00022946537,0.00076604425,0.00391537,0.0022578088,0.0000011637871,0.2752206,0.00005582508,0.00047926855,0.12401416],"study_design_scores_gemma":[0.814298,0.0050763343,0.04177518,0.00008410473,0.00017794913,0.0000739666,0.00009511397,0.00012963181,0.13745512,0.000030291812,0.00063387543,0.00017048056],"about_ca_topic_score_codex":0.0016296125,"about_ca_topic_score_gemma":0.0019193216,"teacher_disagreement_score":0.34590608,"about_ca_system_score_codex":0.000018818902,"about_ca_system_score_gemma":0.0002186712,"threshold_uncertainty_score":0.7517465},"labels":[],"label_agreement":null},{"id":"W2979857835","doi":"10.1182/blood.v118.21.4509.4509","title":"Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Busulfan; Melphalan; Multiple myeloma; Bortezomib; Mucositis; Hematopoietic stem cell transplantation; Regimen; Internal medicine; Transplantation; Oncology; Surgery; Chemotherapy","score_opus":0.02110035861322016,"score_gpt":0.24831750718497356,"score_spread":0.2272171485717534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979857835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968667,0.00015514782,0.0002824624,0.000015258773,0.000022764605,0.0011106447,0.00018296951,0.00003998536,0.0013240651],"genre_scores_gemma":[0.99293876,0.0000946465,0.006556214,0.00003287311,0.000009798899,0.00006105061,0.00020434869,0.00003640489,0.0000658853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983799,0.000083170016,0.0004741876,0.0003538944,0.00034177513,0.00036706065],"domain_scores_gemma":[0.9990681,0.00020424221,0.00022792726,0.00019864495,0.00011144286,0.0001896566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014603176,0.00022907698,0.00044103048,0.0002286173,0.00008290824,0.0000124656135,0.00007793558,0.00010883543,0.000059249374],"category_scores_gemma":[0.000022582815,0.00019714145,0.000043426884,0.00023044687,0.00013320889,0.00008592758,0.000024608455,0.00021391425,0.0000027129286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00768942,0.008210867,0.9348454,0.0021109753,0.00075271167,0.00086883205,0.023193603,0.00001971671,0.017963385,0.00006117801,0.000009897363,0.004274044],"study_design_scores_gemma":[0.10715859,0.0023741827,0.8021564,0.0006603492,0.000495459,0.00021308266,0.00077830424,0.00035341748,0.08555276,0.000015791931,0.000007925043,0.00023372158],"about_ca_topic_score_codex":0.00009582564,"about_ca_topic_score_gemma":0.00023348705,"teacher_disagreement_score":0.13268895,"about_ca_system_score_codex":0.000049173817,"about_ca_system_score_gemma":0.00016660435,"threshold_uncertainty_score":0.8039195},"labels":[],"label_agreement":null},{"id":"W2979863150","doi":"10.1182/blood.v116.21.5002.5002","title":"A Review of Multiple Myeloma Patients on Dialysis Treated with High Cutoff Hemodialysis","year":2010,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Dialysis; Hemodialysis; Bortezomib; Multiple myeloma; Urology; Surgery; Nephropathy; Internal medicine; Gastroenterology; Endocrinology","score_opus":0.02807284779152683,"score_gpt":0.30759914028755475,"score_spread":0.2795262924960279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979863150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042542773,0.99071676,8.015381e-7,0.00002089477,0.000037958158,0.0034308415,0.0005636301,0.00006626776,0.00090855267],"genre_scores_gemma":[0.0007998756,0.99273545,0.00055071677,0.000082892046,0.00013451451,0.0006722598,0.0045212964,0.00013115638,0.00037186831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963827,0.00028957633,0.0009998375,0.00081149716,0.0009702508,0.00054613734],"domain_scores_gemma":[0.99643004,0.00042840332,0.00073877315,0.0014755868,0.00046617535,0.0004610002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021952482,0.00077993097,0.0044316025,0.00055559457,0.00007913113,0.000017679988,0.00030018942,0.00040880337,0.00030275487],"category_scores_gemma":[0.0008652632,0.00045844325,0.0011817184,0.0011396818,0.00012271335,0.000047705475,0.00008475077,0.00067036547,0.00022879355],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015295387,0.0045455783,0.008711661,0.105909534,0.004173242,0.00018368466,0.0000072020307,1.6762375e-8,0.0000015640189,0.0000022220902,0.00021756686,0.87609476],"study_design_scores_gemma":[0.01346285,0.0024007352,0.0032206434,0.26706904,0.038101092,0.00005998247,0.0000013201511,0.0000013842904,0.0002250323,0.0000011096905,0.6748238,0.00063299475],"about_ca_topic_score_codex":0.00023721142,"about_ca_topic_score_gemma":0.000040848547,"teacher_disagreement_score":0.87546176,"about_ca_system_score_codex":0.00010308667,"about_ca_system_score_gemma":0.00040235516,"threshold_uncertainty_score":0.99978673},"labels":[],"label_agreement":null},{"id":"W2979865431","doi":"10.1182/blood-2018-99-117705","title":"Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Maintenance therapy; Internal medicine; Oncology; Bortezomib; Clinical endpoint; Autologous stem-cell transplantation; Progression-free survival; Surgery; Clinical trial; Chemotherapy","score_opus":0.04025280004998385,"score_gpt":0.3362893295632122,"score_spread":0.2960365295132284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979865431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960713,0.00016718364,0.00035174814,0.0010232031,0.00009564677,0.0018240705,0.00029023073,0.00005784307,0.000118774806],"genre_scores_gemma":[0.9838776,0.00003272051,0.015238135,0.0001116356,0.00026852434,0.00014045637,0.000054347383,0.000058150967,0.0002184164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766856,0.00012186966,0.0004026855,0.00058195856,0.00045874435,0.0007661891],"domain_scores_gemma":[0.9980123,0.0006747067,0.00017855491,0.0005171807,0.00026322837,0.0003540166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000547294,0.0003348298,0.0005516261,0.00022343567,0.00024586354,0.00005972898,0.0001540004,0.00014794816,0.000037978232],"category_scores_gemma":[0.0020086318,0.0002117133,0.00017019924,0.00018888182,0.00029877122,0.0001836438,0.000111617366,0.00020673829,0.000006626787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022995867,0.0021813565,0.8784621,0.00046466652,0.000529191,0.00055320887,0.0005492566,0.000017043672,0.09110434,0.000085493004,0.00046173553,0.0025957495],"study_design_scores_gemma":[0.13569474,0.0033433635,0.554493,0.0021087292,0.00029015486,0.00010624855,0.00012598927,0.017006233,0.2852112,0.0005234226,0.00053612306,0.0005607906],"about_ca_topic_score_codex":0.0012182277,"about_ca_topic_score_gemma":0.0016382191,"teacher_disagreement_score":0.3239691,"about_ca_system_score_codex":0.00019561741,"about_ca_system_score_gemma":0.00026010312,"threshold_uncertainty_score":0.8633418},"labels":[],"label_agreement":null},{"id":"W2979871905","doi":"10.1182/blood.v114.22.2793.2793","title":"“Longterm Survival (≥10 years) in Multiple Myeloma (MM) Is Associated with Longer Duration of Therapy and Improved Quality of Response to Novel agents”.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Surgery; Bortezomib; Median follow-up; Pediatrics; Overall survival","score_opus":0.06679748478643414,"score_gpt":0.33681122747382264,"score_spread":0.2700137426873885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979871905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988174,0.00006544689,0.000014255451,0.00025269671,0.000008890619,0.0006814047,0.000091188915,0.000012952264,0.000055806984],"genre_scores_gemma":[0.99894285,0.000020710015,0.0006250233,0.000078808516,0.000011748834,0.000014342777,0.000037417696,0.000011814413,0.00025731119],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987446,0.00014223381,0.000335371,0.00022379085,0.0003453733,0.00020864863],"domain_scores_gemma":[0.9991172,0.00022805537,0.0001337383,0.00024489796,0.00015170935,0.00012442473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059680577,0.00011938503,0.00037041382,0.00014870364,0.000019434858,0.0000081932585,0.00005640878,0.00007731883,0.00005615533],"category_scores_gemma":[0.0007213575,0.00009433661,0.000044563567,0.0002547391,0.00004453973,0.000054995293,0.000017623432,0.00008034311,0.000002755565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017186228,0.0036889983,0.40304625,0.000021576241,0.00024356891,0.00004711628,0.0013985276,4.3277836e-7,0.5676409,0.0000031852235,0.00001395653,0.006709282],"study_design_scores_gemma":[0.025174625,0.0018625042,0.9054151,0.00007122788,0.000023064817,0.0000032585301,0.0000786648,0.0000953242,0.0671841,0.0000030089736,0.000012363864,0.000076725926],"about_ca_topic_score_codex":0.00028116157,"about_ca_topic_score_gemma":0.00022451964,"teacher_disagreement_score":0.5023689,"about_ca_system_score_codex":0.000033991953,"about_ca_system_score_gemma":0.000085533204,"threshold_uncertainty_score":0.38469353},"labels":[],"label_agreement":null},{"id":"W2979878708","doi":"10.1016/j.clml.2019.09.619","title":"Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Tertiary care; Center (category theory); Multiple myeloma; Medicine; Stem cell; Surgery; Internal medicine; Chemistry; Biology","score_opus":0.02158837584531826,"score_gpt":0.32015317837497,"score_spread":0.29856480252965173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979878708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555445,0.00052313716,0.000077291275,0.00011627217,0.00021732961,0.0021163335,0.0009080573,0.000055518878,0.0004316212],"genre_scores_gemma":[0.9973126,0.00020986734,0.00088598445,0.00023409877,0.000033301272,0.00009837407,0.00063562655,0.000050084644,0.0005400362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959882,0.0002443569,0.0016259105,0.0009236071,0.0004885838,0.00072937994],"domain_scores_gemma":[0.9963541,0.0018855046,0.00031758507,0.0007678523,0.00020331412,0.0004716423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046390865,0.00042223936,0.001887581,0.00053397426,0.00007129385,0.000019339901,0.00023994918,0.00044335373,0.000053104388],"category_scores_gemma":[0.00017690052,0.00032876365,0.00084860297,0.00043481422,0.00020554122,0.00010811335,0.00012145807,0.00023412569,0.000037158272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038590904,0.00066312077,0.77045834,0.000462458,0.0011945618,0.00012872861,0.0006031606,0.000022319406,0.00015886486,0.000008362976,0.000017349896,0.22242364],"study_design_scores_gemma":[0.02520077,0.0010886886,0.9632401,0.00016901975,0.00092446024,0.000013330668,0.0004136642,0.0074973875,0.00071984174,0.000004716717,0.00045168298,0.00027632885],"about_ca_topic_score_codex":0.000248233,"about_ca_topic_score_gemma":0.00036668187,"teacher_disagreement_score":0.22214732,"about_ca_system_score_codex":0.000666944,"about_ca_system_score_gemma":0.00044340183,"threshold_uncertainty_score":0.99991643},"labels":[],"label_agreement":null},{"id":"W2979907850","doi":"10.1182/blood.v122.21.3111.3111","title":"A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Genome-wide association study; Biology; Single-nucleotide polymorphism; Population stratification; Genetics; Genetic association; Linkage disequilibrium; Imputation (statistics); Meta-analysis; SNP; Case-control study; Population; Genotype; Medicine; Gene; Internal medicine; Missing data","score_opus":0.08138664452300585,"score_gpt":0.32777504303364174,"score_spread":0.24638839851063588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979907850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918541,0.0072419327,0.0000028030793,0.000094980765,0.000005934163,0.00058762345,0.000111915644,0.000005182061,0.00009558351],"genre_scores_gemma":[0.9988081,0.0007112466,0.00020233289,0.000011964402,0.000006621925,0.00005701415,0.000019762048,0.000009476355,0.00017348296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982722,0.00037587207,0.00062331307,0.00020025944,0.00033706837,0.00019129591],"domain_scores_gemma":[0.9965147,0.0024884418,0.00041761357,0.0002254612,0.00029481426,0.000059013506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000756336,0.00012382689,0.0012824745,0.0005805715,0.000016732518,0.0000074141076,0.0000582542,0.000035785535,0.00005338775],"category_scores_gemma":[0.0052800598,0.00008947381,0.00027614107,0.00053604384,0.00007588339,0.00007715888,0.00005510788,0.000086758264,0.000004143899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009423755,0.0007213452,0.91053486,0.00010767853,0.081067845,0.00007632784,0.00087213825,0.000023528328,0.0063233613,0.0000018325376,0.0000095100495,0.00016731647],"study_design_scores_gemma":[0.0058365855,0.00021627238,0.9430575,0.000020224492,0.04337419,0.0000013184591,0.0005815531,0.00014394698,0.0066820094,0.000025241929,0.0000058267206,0.000055374974],"about_ca_topic_score_codex":0.0053421766,"about_ca_topic_score_gemma":0.0039211623,"teacher_disagreement_score":0.037693657,"about_ca_system_score_codex":0.000044059114,"about_ca_system_score_gemma":0.00002725733,"threshold_uncertainty_score":0.8075809},"labels":[],"label_agreement":null},{"id":"W2979923058","doi":"10.1182/blood.v108.11.3530.3530","title":"Preliminary Safety and Efficacy Results from an International Phase 3b Study for Expanded Access to Bortezomib in 624 Patients with Relapsed and/or Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Progressive disease; Adverse effect; Internal medicine; Proteasome inhibitor; Dexamethasone; Refractory (planetary science); Gastroenterology; Phases of clinical research; Surgery; Urology; Toxicity; Chemotherapy","score_opus":0.03056316464014592,"score_gpt":0.3498052333605649,"score_spread":0.319242068720419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979923058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536574,0.00003719944,0.00002841966,0.00015626726,0.000043454595,0.0034399608,0.0007847112,0.000040167375,0.000104089435],"genre_scores_gemma":[0.996339,0.00001560126,0.0014805757,0.000052034597,0.00010562937,0.0001953054,0.0016434113,0.000031270793,0.00013713255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982973,0.00006830946,0.00039192932,0.00058891857,0.00037199672,0.00028157988],"domain_scores_gemma":[0.99876,0.0004199893,0.00009428269,0.00033388764,0.00013274347,0.00025912005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016197258,0.00020346566,0.00031602776,0.00020002484,0.0000890129,0.00006376892,0.00013739275,0.00006726336,0.00001332853],"category_scores_gemma":[0.0005009648,0.00014473201,0.000024166742,0.00013088809,0.00003939352,0.00031294246,0.000106710075,0.00012703014,0.0000017111304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12346504,0.023454675,0.82971525,0.000015860585,0.00022349684,0.00021864695,0.00074700423,0.0000041063613,0.00026878857,7.4711767e-7,0.000060770035,0.021825625],"study_design_scores_gemma":[0.18848754,0.009257726,0.800853,0.00010070303,0.000109059794,0.000003832711,0.00013352832,0.00027582608,0.00042051836,0.0000039408374,0.00022340594,0.00013087559],"about_ca_topic_score_codex":0.0009671222,"about_ca_topic_score_gemma":0.0012588138,"teacher_disagreement_score":0.06502251,"about_ca_system_score_codex":0.000057276728,"about_ca_system_score_gemma":0.00006919486,"threshold_uncertainty_score":0.5902},"labels":[],"label_agreement":null},{"id":"W2979940690","doi":"10.1182/blood.v116.21.1942.1942","title":"Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Pomalidomide; Lenalidomide; Multiple myeloma; Bortezomib; Cytogenetics; Proteasome inhibitor; Internal medicine; Fluorescence in situ hybridization; Oncology; Medicine; Biology; Chromosome; Genetics","score_opus":0.01629366573959535,"score_gpt":0.2407367586772273,"score_spread":0.22444309293763196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979940690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984862,0.00015179791,0.0000019058454,0.000067059766,0.00002268934,0.00093319063,0.00020282103,0.000054355107,0.000079971935],"genre_scores_gemma":[0.99846107,0.000038973274,0.0008953209,0.00002934652,0.000023756687,0.00004957087,0.00019270579,0.00005268722,0.00025658376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983437,0.00013985595,0.00019989259,0.0004698105,0.0004397399,0.00040698095],"domain_scores_gemma":[0.9987864,0.00023534111,0.00010060085,0.00035574049,0.00015730984,0.00036461884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116377116,0.00028331415,0.00039923127,0.0001719198,0.000094084164,0.000037011814,0.000057615114,0.00014597736,0.000014061046],"category_scores_gemma":[0.00033112333,0.00019312378,0.000022273916,0.00021273193,0.00019305068,0.000067303816,0.00004779627,0.0003232248,0.0000031239656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007843378,0.0036905166,0.914206,0.00005504597,0.00020825195,0.00029414974,0.00012981561,1.0293992e-7,0.07179814,4.4233002e-7,0.000020970292,0.0017531393],"study_design_scores_gemma":[0.046322066,0.0034856165,0.9007972,0.0001237422,0.00015673033,0.000028367002,0.000056731882,0.000015293277,0.048681796,4.3004886e-7,0.00013335698,0.00019865483],"about_ca_topic_score_codex":0.00024703256,"about_ca_topic_score_gemma":0.0014415431,"teacher_disagreement_score":0.038478687,"about_ca_system_score_codex":0.000039242488,"about_ca_system_score_gemma":0.00006839172,"threshold_uncertainty_score":0.7875359},"labels":[],"label_agreement":null},{"id":"W2979965816","doi":"10.1182/blood.v106.11.3449.3449","title":"CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Cancer research; Bone marrow; In vivo; Multiple myeloma; Medicine; Tyrosine-kinase inhibitor; Pathology; Biology; Immunology; Cancer; Internal medicine","score_opus":0.06207645131023944,"score_gpt":0.34061328693648424,"score_spread":0.2785368356262448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979965816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486566,0.00050970254,0.00009868068,0.0007743186,0.0000235886,0.0008523795,0.000033727367,0.00005864972,0.0027833213],"genre_scores_gemma":[0.9641165,0.000110935376,0.033863135,0.00012099992,0.000112712216,0.00006577551,0.00006163903,0.000036542868,0.0015117364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786913,0.00007215029,0.0006370703,0.00041147933,0.00048642608,0.000523715],"domain_scores_gemma":[0.9987037,0.0002724598,0.00010358906,0.0004668333,0.00011237009,0.00034104174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031962048,0.0002184078,0.00056447723,0.00021016077,0.000040695923,0.00001057085,0.00014800068,0.00016319685,0.00010173539],"category_scores_gemma":[0.0011360851,0.00018327759,0.00015225743,0.00028350097,0.00009027808,0.000092407965,0.000104359126,0.00031569204,0.00012293742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004678224,0.029520728,0.76181954,0.0003356353,0.00082634203,0.0005242821,0.0011776441,0.0010045992,0.058823828,0.00010419131,0.00088417163,0.1403008],"study_design_scores_gemma":[0.09038207,0.0008156417,0.7943551,0.00036922333,0.0002501138,0.00009927825,0.000039450242,0.055265706,0.05679184,0.000061519066,0.0011693428,0.00040072543],"about_ca_topic_score_codex":0.000084626874,"about_ca_topic_score_gemma":0.00035099708,"teacher_disagreement_score":0.13990007,"about_ca_system_score_codex":0.000059251495,"about_ca_system_score_gemma":0.00036510365,"threshold_uncertainty_score":0.7473843},"labels":[],"label_agreement":null},{"id":"W2979979447","doi":"10.1182/blood.v116.21.1876.1876","title":"Characteristics of Patients Presenting with Secondary Myelodysplastic Syndrome During Treatment with Lenalidomide for Relapsed/Refractory Multiple Myeloma: 5q Deletions Can Be Observed","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Thalidomide; Internal medicine; Melphalan; Autologous stem-cell transplantation; Cyclophosphamide; Transplantation; Bortezomib; Surgery; Prednisone; Oncology; Gastroenterology; Chemotherapy","score_opus":0.020990196200028812,"score_gpt":0.24221128164855416,"score_spread":0.22122108544852534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979979447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968423,0.000029084607,0.0000251282,0.000077536024,0.00007567215,0.0018465052,0.00094067265,0.000065753244,0.00009735041],"genre_scores_gemma":[0.9939888,0.000021951331,0.0038210044,0.000013512848,0.000081311664,0.0004808769,0.0009706455,0.00008363083,0.0005382676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803525,0.00003978637,0.00042910632,0.00046156932,0.00044188075,0.000592426],"domain_scores_gemma":[0.9981298,0.00032263936,0.00027567914,0.00051447295,0.00038038366,0.0003770142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079115416,0.0003487921,0.0005961524,0.0001804687,0.00024904206,0.000029697067,0.00011931136,0.000121590696,0.00006934194],"category_scores_gemma":[0.00025705583,0.00024189615,0.00012724886,0.00016523423,0.00015518453,0.00012473259,0.00004687156,0.00030088835,0.0000037206098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026364652,0.0043761665,0.97005063,0.0005218791,0.0012276574,0.00044204204,0.00026062832,0.0000016106402,0.01967698,0.0000059809095,0.00000528943,0.0007946698],"study_design_scores_gemma":[0.04063808,0.0041526235,0.9287265,0.00014027358,0.0007727333,0.00019675911,0.00004503115,0.00008225769,0.024725761,0.000002371601,0.00028682832,0.00023077863],"about_ca_topic_score_codex":0.00019843814,"about_ca_topic_score_gemma":0.000763132,"teacher_disagreement_score":0.041324127,"about_ca_system_score_codex":0.000090528956,"about_ca_system_score_gemma":0.00034936165,"threshold_uncertainty_score":0.9864239},"labels":[],"label_agreement":null},{"id":"W2980002967","doi":"10.1182/blood.v128.22.2113.2113","title":"Ex Vivo Modeling of Multiple Myeloma Provides Basis for Studying Treatment Combinations and Immunotherapy","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunotherapy; Medicine; Ipilimumab; Pembrolizumab; Ex vivo; Cancer research; Tumor microenvironment; Nivolumab; Multiple myeloma; Immunology; In vivo; Immune system; Biology","score_opus":0.05339702392790718,"score_gpt":0.3135478860589719,"score_spread":0.2601508621310647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980002967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554306,0.00069831405,0.0017590572,0.00036734733,0.000015649422,0.0013302398,0.000085529544,0.000031486587,0.0001693135],"genre_scores_gemma":[0.9943718,0.00038589517,0.004489198,0.000011465201,0.000026162303,0.0002926502,0.000008116863,0.000021980033,0.00039275145],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921817,0.000024428662,0.00019315767,0.00020159001,0.00015148077,0.00021120334],"domain_scores_gemma":[0.9992166,0.00031211754,0.000046971738,0.00020704398,0.00012312092,0.000094133335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088354805,0.00012230325,0.00024626293,0.000101647325,0.000092575305,0.000010040443,0.000039776107,0.000038121245,0.000021673468],"category_scores_gemma":[0.00014152868,0.0000720574,0.00008369922,0.00005761326,0.000042563046,0.00006707495,0.000017314382,0.000019949386,0.000002323502],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013503148,0.009001482,0.48093152,0.00021175589,0.0022468,0.000026091951,0.0013297844,0.000007654747,0.2951253,0.0002691737,0.000019605704,0.2094805],"study_design_scores_gemma":[0.23529659,0.0134373475,0.12731099,0.0011741499,0.0011596202,0.00008552132,0.0012538141,0.03408221,0.583409,0.0013112263,0.0008779924,0.0006015425],"about_ca_topic_score_codex":0.00011865483,"about_ca_topic_score_gemma":0.000032142212,"teacher_disagreement_score":0.35362053,"about_ca_system_score_codex":0.000053339456,"about_ca_system_score_gemma":0.00006926863,"threshold_uncertainty_score":0.29384154},"labels":[],"label_agreement":null},{"id":"W2980053490","doi":"10.1182/blood.v116.21.4045.4045","title":"Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Chromosomal translocation; Bone marrow; Trisomy; Biology; Pathology; Chromosomal Deletion; Molecular biology; G banding; Trisomy 8; Karyotype; Multiple myeloma; Chromosome; Immunology; Medicine; Genetics; Gene","score_opus":0.010587794535055546,"score_gpt":0.25593362982723117,"score_spread":0.24534583529217563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980053490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950824,0.000164321,1.8814936e-7,0.000041591484,0.00005941937,0.00025693025,0.00003433159,0.000017408116,0.0043434477],"genre_scores_gemma":[0.99886227,0.000025421687,0.0005448901,0.000022367583,0.000055066354,0.000027179836,0.000058991387,0.000012224248,0.0003915788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991111,0.000020177784,0.00020236037,0.00013583971,0.000279266,0.00025122677],"domain_scores_gemma":[0.99948776,0.00004828145,0.00004416711,0.00021856326,0.000077820754,0.00012340666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008020278,0.00009399736,0.00021455355,0.00012014385,0.000021370553,0.0000060570073,0.000057808997,0.00006595088,0.00028213486],"category_scores_gemma":[0.0001704896,0.000075702534,0.000052777028,0.000108576045,0.00007562551,0.00006043917,0.00003913209,0.000118484975,0.000037596896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001550453,0.0019317953,0.97896075,0.00009380217,0.00005817027,0.00013839989,0.00013726299,6.5955035e-8,0.015600947,0.0000631047,0.000040392126,0.0028202513],"study_design_scores_gemma":[0.013606785,0.00036729683,0.8727943,0.000052761177,0.000032808497,0.000033097258,0.000032246633,0.000015495707,0.11275562,0.000032925745,0.00021454408,0.0000621183],"about_ca_topic_score_codex":0.00037431638,"about_ca_topic_score_gemma":0.00018899712,"teacher_disagreement_score":0.10616647,"about_ca_system_score_codex":0.000019326415,"about_ca_system_score_gemma":0.00010560129,"threshold_uncertainty_score":0.3089179},"labels":[],"label_agreement":null},{"id":"W2980074380","doi":"10.1182/blood.v128.22.2273.2273","title":"Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Melphalan; Bortezomib; Internal medicine; Regimen; Autologous stem-cell transplantation; Urology; Surgery; Oncology; Chemotherapy; Multiple myeloma","score_opus":0.02671847572376897,"score_gpt":0.30074199320638323,"score_spread":0.2740235174826143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980074380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975091,0.0002886417,0.00017931107,0.00041219112,0.00006216319,0.0010195782,0.00015958468,0.000023203413,0.00034618395],"genre_scores_gemma":[0.9980203,0.0003368773,0.00058145804,0.000023319702,0.00009547855,0.00019733593,0.00008673706,0.000017855138,0.00064065994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991687,0.000024182358,0.00017497812,0.00017016508,0.00021702464,0.0002449576],"domain_scores_gemma":[0.99881136,0.00064578874,0.00007281573,0.0002588817,0.00010575184,0.00010536851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005610957,0.00011412761,0.00019946332,0.000050940682,0.000112121255,0.0000088130555,0.000053477637,0.000037261354,0.00010214844],"category_scores_gemma":[0.00014019181,0.00005185639,0.00011788319,0.000055867422,0.000056730078,0.000044053286,0.000011359476,0.000019908297,0.000023144701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010485125,0.0076618153,0.8854295,0.00010253916,0.0026428998,0.000047067595,0.00032975888,0.000001227783,0.005317936,0.000697919,0.00032246028,0.09639836],"study_design_scores_gemma":[0.08124511,0.007118506,0.8253986,0.0002191499,0.0008176474,0.0000113560955,0.00007815609,0.000024997069,0.0825453,0.0003500586,0.0020647245,0.00012639028],"about_ca_topic_score_codex":0.00007752964,"about_ca_topic_score_gemma":0.00004600709,"teacher_disagreement_score":0.09627197,"about_ca_system_score_codex":0.00006858807,"about_ca_system_score_gemma":0.00008603739,"threshold_uncertainty_score":0.21146423},"labels":[],"label_agreement":null},{"id":"W2980094467","doi":"10.1182/blood.v122.21.1946.1946","title":"Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Bone marrow; Multiple myeloma; Fibrosis; Proportional hazards model; Incidence (geometry); Internal medicine; Gastroenterology; Survival analysis; Pathology; Stage (stratigraphy); Surgery; Biology","score_opus":0.019363241565154635,"score_gpt":0.2520494521895545,"score_spread":0.23268621062439987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980094467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576426,0.00008133158,0.000052882835,0.00022452605,0.000033693603,0.0035367922,0.00009673659,0.00005195172,0.00015785366],"genre_scores_gemma":[0.992808,0.000003953384,0.00554538,0.000032124117,0.0000663058,0.00046698813,0.00017962247,0.00004198045,0.0008556901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985587,0.000028489263,0.00021438148,0.00032206345,0.00036753743,0.00050882215],"domain_scores_gemma":[0.9989128,0.00022543369,0.000054816326,0.00027519485,0.0001597855,0.0003719589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042940137,0.00019644528,0.00033063386,0.00013162833,0.000048971306,0.000034939298,0.00007296451,0.00007542019,0.00023980248],"category_scores_gemma":[0.0004504338,0.00013612099,0.000069400405,0.000190728,0.00003074068,0.0001273248,0.00003474777,0.00010824737,0.00011574729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055073464,0.0019482808,0.98703325,0.00011450299,0.0001524337,0.000017247154,0.00009465099,2.8188177e-7,0.00075342634,0.000002398383,0.00021560192,0.009117188],"study_design_scores_gemma":[0.036069345,0.0016133507,0.9594429,0.0001261835,0.00007580602,0.0000024642682,0.000019990004,0.0000711204,0.002214561,0.000016364009,0.00020716783,0.00014073067],"about_ca_topic_score_codex":0.0006182483,"about_ca_topic_score_gemma":0.00025161618,"teacher_disagreement_score":0.03551861,"about_ca_system_score_codex":0.000045231063,"about_ca_system_score_gemma":0.00012934244,"threshold_uncertainty_score":0.5550853},"labels":[],"label_agreement":null},{"id":"W2980122607","doi":"10.1182/blood.v110.11.770.770","title":"Ex Vivo Graft Purging and Expansion of Autologous Mobilized Peripheral Blood Progenitor Cell (PBPC) Products from Patients with Multiple Myeloma (MM).","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ex vivo; Progenitor cell; Stem cell; Medicine; CD34; Transplantation; Bortezomib; Population; Bone marrow; Autologous stem-cell transplantation; Rituximab; Haematopoiesis; Cancer research; Immunology; Multiple myeloma; In vivo; Biology; Antibody; Internal medicine; Cell biology","score_opus":0.009498205135958917,"score_gpt":0.23854233297526226,"score_spread":0.22904412783930334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980122607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669,0.0008912299,0.000022529211,0.00003285236,0.00006584831,0.0019142342,0.00007913854,0.00009120207,0.00021297246],"genre_scores_gemma":[0.9882604,0.000030553034,0.011106938,0.000017089804,0.00012420968,0.0000589008,0.00014596782,0.000053600274,0.00020237113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977119,0.00006370407,0.00039413836,0.0006068192,0.00063230685,0.00059112016],"domain_scores_gemma":[0.99855614,0.0001363193,0.00016244511,0.00047750288,0.00031445813,0.0003531614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016991468,0.00030538073,0.0005078622,0.00015033239,0.00011353999,0.00002226841,0.00010525147,0.00012815667,0.00006609759],"category_scores_gemma":[0.00019626248,0.0002233377,0.000069997826,0.0002456306,0.00015783493,0.000117381074,0.00008567777,0.0001946002,0.000006793161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002083198,0.0042429892,0.81106067,0.00022898267,0.00038073014,0.00037740087,0.0006044985,5.26423e-7,0.17529574,8.082055e-7,0.000015637466,0.0057088095],"study_design_scores_gemma":[0.02778686,0.0014847998,0.48956606,0.00012262416,0.0003543691,0.000031318883,0.00013700679,0.00004546567,0.48022112,0.0000035534113,0.00008171435,0.00016511022],"about_ca_topic_score_codex":0.0003414081,"about_ca_topic_score_gemma":0.00007351458,"teacher_disagreement_score":0.32149464,"about_ca_system_score_codex":0.000033885688,"about_ca_system_score_gemma":0.00014657924,"threshold_uncertainty_score":0.9107447},"labels":[],"label_agreement":null},{"id":"W2980137220","doi":"10.1182/blood.v110.11.3601.3601","title":"A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Bortezomib; Internal medicine; Prednisone; Cyclophosphamide; Gastroenterology; Phases of clinical research; Surgery; Toxicity; Oncology; Chemotherapy","score_opus":0.025775856841918833,"score_gpt":0.3137336558421229,"score_spread":0.2879577990002041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980137220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939059,0.002764007,0.00041142324,0.00031098197,0.00013416304,0.0022156034,0.000024349321,0.00007813274,0.0001554377],"genre_scores_gemma":[0.9949189,0.00036128375,0.0035511453,0.00009403114,0.00027038966,0.000116492076,0.000019441353,0.00006122466,0.0006071245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971905,0.00035964596,0.00064683723,0.00051398703,0.0006839473,0.0006050905],"domain_scores_gemma":[0.9974633,0.00091190304,0.00031144812,0.0005493155,0.00025131166,0.0005127086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022423216,0.00035714475,0.0008759131,0.00034382922,0.00020463378,0.0000206779,0.00010352716,0.00024248425,0.000056603127],"category_scores_gemma":[0.0011666007,0.0002585661,0.00016159948,0.0004752243,0.00021867832,0.00015525309,0.000051524927,0.00051215827,0.0000021823068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55373657,0.013372275,0.0040869974,0.000030818195,0.0007990666,0.0002831973,0.000297096,6.1814696e-8,0.327988,0.000008018415,0.00003586096,0.099362],"study_design_scores_gemma":[0.7086519,0.064849466,0.08022101,0.000096881566,0.00043723543,0.00022646763,0.000100634505,0.000029455696,0.14347541,0.000030430332,0.0015993642,0.0002817471],"about_ca_topic_score_codex":0.00087595586,"about_ca_topic_score_gemma":0.000048278256,"teacher_disagreement_score":0.1845126,"about_ca_system_score_codex":0.00027653878,"about_ca_system_score_gemma":0.00032673115,"threshold_uncertainty_score":0.99998665},"labels":[],"label_agreement":null},{"id":"W2980151503","doi":"10.1182/blood.v128.22.2624.2624","title":"Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Internal medicine; Thalidomide; Pomalidomide; Incidence (geometry); Risk factor; Odds ratio; Concomitant; Surgery","score_opus":0.011960707307669004,"score_gpt":0.24445870463224875,"score_spread":0.23249799732457974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980151503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991683,0.00016451564,0.0000071935337,0.000008186859,0.000025431502,0.00048209613,0.000052487318,0.000018909272,0.00007288137],"genre_scores_gemma":[0.9994351,0.00015584372,0.00031790265,0.000004451934,0.000012281544,0.000013733544,0.000011898767,0.00002191788,0.000026856838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988247,0.00006377508,0.00021505583,0.0002600331,0.00034391487,0.0002925197],"domain_scores_gemma":[0.9991941,0.0001620602,0.00011458546,0.00029548156,0.000087895096,0.00014588387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010736874,0.00015070832,0.00035193822,0.00013833202,0.000051391435,0.0000063768066,0.000074923475,0.000062335865,0.000031518215],"category_scores_gemma":[0.0003540203,0.00008709057,0.000033891607,0.00012305545,0.00010941216,0.00012807653,0.0000662625,0.00010168752,0.0000075143175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002653747,0.0014843016,0.9841109,0.00003763877,0.00024042695,0.000029445619,0.00040131368,3.2378878e-7,0.0015409945,0.000001187766,0.0000025896009,0.011885495],"study_design_scores_gemma":[0.013418174,0.0009833183,0.97855675,0.0003455427,0.000086693064,0.0000034609243,0.000034717945,0.000008062538,0.00644759,0.000012645236,0.0000069798043,0.000096037744],"about_ca_topic_score_codex":0.0007155963,"about_ca_topic_score_gemma":0.000116332776,"teacher_disagreement_score":0.0131528,"about_ca_system_score_codex":0.00005072799,"about_ca_system_score_gemma":0.00006148533,"threshold_uncertainty_score":0.35514504},"labels":[],"label_agreement":null},{"id":"W2980154814","doi":"10.1182/blood.v112.11.735.735","title":"An Automated and Quantitative Protein Expression-Based Classification System to Identify High Risk Multiple Myeloma Patients","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Oncology; Autologous stem-cell transplantation; Internal medicine; Lenalidomide; Gene expression profiling; Transplantation; Tissue microarray; Immunohistochemistry; Bioinformatics; Cancer research; Gene expression; Biology","score_opus":0.034102122960087175,"score_gpt":0.33283503642319123,"score_spread":0.29873291346310404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980154814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690145,0.000040590043,0.00025593053,0.000046588088,0.00003454212,0.0020557619,0.00015722374,0.0004400953,0.000067789544],"genre_scores_gemma":[0.9863073,0.000003963811,0.012844555,0.000018387054,0.00003013668,0.00041864955,0.000309178,0.00003296424,0.000034823843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998242,0.00023007033,0.00028181126,0.00044797306,0.0004928782,0.00030522142],"domain_scores_gemma":[0.9986092,0.00011115772,0.00012908438,0.00041652308,0.0002759994,0.000458027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013542523,0.00018874035,0.00027218164,0.00019855934,0.00029345948,0.000029848634,0.000090497495,0.00009611477,0.000012735636],"category_scores_gemma":[0.0004568909,0.000149715,0.000043787637,0.00023309173,0.000065955064,0.0001282535,0.00002895594,0.00012453747,0.00010610106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083910255,0.002546587,0.84664094,0.00018268131,0.000118535194,0.0001303073,0.00038774786,0.000009869133,0.14800876,0.000030296573,0.000103867205,0.0010012952],"study_design_scores_gemma":[0.010539361,0.0012702039,0.88914007,0.0002670179,0.000065781285,0.0000092016135,0.0002002105,0.014073681,0.08428699,0.0000018784334,0.000013956301,0.00013162168],"about_ca_topic_score_codex":0.0004963966,"about_ca_topic_score_gemma":0.000023634624,"teacher_disagreement_score":0.063721776,"about_ca_system_score_codex":0.00007570333,"about_ca_system_score_gemma":0.00009498498,"threshold_uncertainty_score":0.61052},"labels":[],"label_agreement":null},{"id":"W2980239934","doi":"10.1016/j.clml.2019.09.618","title":"Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institutes of Health; Agency for Healthcare Research and Quality; National Cancer Institute; Institute of Translational Health Sciences, University of Washington; Centers for Medicare and Medicaid Services","keywords":"Lenalidomide; Multiple myeloma; Medicine; Internal medicine; Oncology","score_opus":0.02879022313772613,"score_gpt":0.33143374279881693,"score_spread":0.3026435196610908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980239934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916449,0.00023912807,0.000070647344,0.0005398647,0.00036484905,0.0037840914,0.00004264046,0.00020339967,0.0031104507],"genre_scores_gemma":[0.9898478,0.00011471606,0.0045447466,0.0017667718,0.0003485125,0.00048177553,0.00013972413,0.00013179211,0.0026241827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939483,0.00033132467,0.0014986766,0.0016631221,0.0011028451,0.001455742],"domain_scores_gemma":[0.9941085,0.0021727239,0.0002717511,0.0015460264,0.00032193243,0.0015790977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007859058,0.0006786096,0.0015217582,0.00039345789,0.00010608092,0.0000859844,0.0005679096,0.00048577305,0.0007585086],"category_scores_gemma":[0.0019630522,0.0005194365,0.00041214377,0.0009286493,0.00026529885,0.0002861764,0.0002988646,0.00056796503,0.0048244526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013775465,0.0007718876,0.57634556,0.00013944707,0.0001498513,0.002241523,0.00026249955,0.000024099652,0.00021062902,0.00002846012,0.0009623511,0.40508822],"study_design_scores_gemma":[0.058599163,0.003922181,0.92918867,0.0017248166,0.000062944295,0.00015220344,0.0003261939,0.0018079954,0.0011909867,0.000022202066,0.0024322968,0.0005703762],"about_ca_topic_score_codex":0.0016449969,"about_ca_topic_score_gemma":0.0012328377,"teacher_disagreement_score":0.40451783,"about_ca_system_score_codex":0.0012661696,"about_ca_system_score_gemma":0.0017056098,"threshold_uncertainty_score":0.9997257},"labels":[],"label_agreement":null},{"id":"W2980248458","doi":"10.1182/blood.v108.11.3548.3548","title":"Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Internal medicine; Prednisone; Gastroenterology; Multiple myeloma; Creatinine; Dexamethasone; Refractory (planetary science); Cyclophosphamide; Urology; Surgery; Chemotherapy","score_opus":0.028874828547414425,"score_gpt":0.2551794900175741,"score_spread":0.2263046614701597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980248458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980731,0.00016526543,0.000029216275,0.00007882356,0.00002921369,0.0010166139,0.0003398023,0.0000612986,0.00020666038],"genre_scores_gemma":[0.99544126,0.000020999114,0.0029085,0.00007054123,0.00005696073,0.000055634006,0.0005779909,0.00006180701,0.00080630503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974994,0.00015425724,0.0006920077,0.00043641584,0.0006605404,0.00055737724],"domain_scores_gemma":[0.99822485,0.00040625044,0.00022843386,0.00053594087,0.00037810596,0.00022643046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019040612,0.00031106293,0.0005944502,0.0003142171,0.000051238963,0.000018610219,0.00010160204,0.00013190456,0.0001963214],"category_scores_gemma":[0.00066747714,0.00023313679,0.000092776405,0.00045301951,0.00011501394,0.00016730142,0.00005995707,0.0002750196,0.000026280464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027278697,0.007169463,0.9725288,0.000109149325,0.00022012496,0.00031990843,0.000040775678,0.00003248655,0.013479271,0.000004877786,0.00012400435,0.00324324],"study_design_scores_gemma":[0.04340961,0.0015710834,0.91550946,0.00034668922,0.00018575035,0.000016849051,0.0000141621495,0.00046840485,0.038038608,0.0000044350877,0.00024149523,0.00019347528],"about_ca_topic_score_codex":0.0011757048,"about_ca_topic_score_gemma":0.00074976037,"teacher_disagreement_score":0.05701939,"about_ca_system_score_codex":0.00008655639,"about_ca_system_score_gemma":0.00015241765,"threshold_uncertainty_score":0.9507042},"labels":[],"label_agreement":null},{"id":"W2980298754","doi":"10.1182/blood.v110.11.3618.3618","title":"Bortezomib [VELCADE™], Pegylated Liposomal Doxorubicin [DOXIL/CAELYX®] and Dexamethasone in the Treatment of Previously Untreated Multiple Myeloma Patients: Impact on Quality-of-Life.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Quality of life (healthcare); Multiple myeloma; Cancer; Oncology; Gastroenterology; Surgery","score_opus":0.03760358170003624,"score_gpt":0.3455037861999114,"score_spread":0.30790020449987515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980298754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601716,0.0012294839,0.0000066655543,0.00008501742,0.000024596444,0.002033223,0.00013019529,0.000032536977,0.00044114172],"genre_scores_gemma":[0.99873835,0.00043819827,0.00036992732,0.000046318797,0.000049327497,0.000048920683,0.00022070334,0.00003500173,0.000053230313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970486,0.0003233589,0.0008621891,0.00042739857,0.0006872073,0.0006512308],"domain_scores_gemma":[0.99732393,0.0012587275,0.00029591584,0.00058257027,0.00018622473,0.00035265728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006428186,0.00038376465,0.00087251945,0.0003726872,0.00006904272,0.000015089078,0.00013945102,0.0001815061,0.00004594014],"category_scores_gemma":[0.00070678955,0.00021952421,0.00022424462,0.000589767,0.00017120667,0.00007179844,0.000027347915,0.00019307171,0.000009780178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006072672,0.013798836,0.9519076,0.00011964301,0.0008233719,0.00014006771,0.0020380204,0.0000043237196,0.0064936373,0.000019542915,0.000010869206,0.018571429],"study_design_scores_gemma":[0.03970975,0.010041247,0.91558915,0.00015500987,0.0002542832,0.00001818455,0.00029898246,0.0000618783,0.033665724,0.00001057839,0.00003746216,0.00015777232],"about_ca_topic_score_codex":0.003358722,"about_ca_topic_score_gemma":0.0005696676,"teacher_disagreement_score":0.03631846,"about_ca_system_score_codex":0.00015010401,"about_ca_system_score_gemma":0.00014841704,"threshold_uncertainty_score":0.89519376},"labels":[],"label_agreement":null},{"id":"W2980314982","doi":"10.1182/blood.v110.11.3326.3326","title":"Multiple Myeloma in Manitoba: A Population Based Study.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Transplantation; Multiple myeloma; Surgery; Cohort; Population; Incidence (geometry); Retrospective cohort study; Cohort study; Internal medicine","score_opus":0.03315161237594816,"score_gpt":0.312131879283865,"score_spread":0.27898026690791683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980314982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798423,0.000053858985,0.000047365345,0.000054221247,0.000032216718,0.0009829884,0.000003919716,0.000051968254,0.0007892074],"genre_scores_gemma":[0.9984811,0.000001043365,0.0011916996,0.000051125808,0.00007772451,0.0000374174,0.00006360443,0.000016759479,0.00007951443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998883,0.000038210284,0.00021344743,0.00021563424,0.0003306582,0.00031904152],"domain_scores_gemma":[0.9994316,0.000111625784,0.000030571548,0.00023467767,0.000040326322,0.00015119849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029979536,0.000106207735,0.00017529532,0.00023936472,0.000043461605,0.000010519898,0.000048065267,0.00005063365,0.000048028254],"category_scores_gemma":[0.0002137276,0.000089632726,0.00004488373,0.00025050386,0.000007972339,0.000043254662,0.00002003325,0.00012119356,0.0000625934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038415537,0.004286595,0.9852402,0.000021039956,0.000051294217,0.001205479,0.00006647659,0.0000015472017,0.00095055776,0.0000033601084,0.0000060708044,0.0077831848],"study_design_scores_gemma":[0.018431846,0.0004992531,0.9777654,0.00003322944,0.000045903354,0.000012897088,0.00024240608,0.00020585161,0.0026473477,0.000008154376,0.000035794867,0.00007195848],"about_ca_topic_score_codex":0.0020476098,"about_ca_topic_score_gemma":0.0124995075,"teacher_disagreement_score":0.018047692,"about_ca_system_score_codex":0.00008965976,"about_ca_system_score_gemma":0.000036998783,"threshold_uncertainty_score":0.6975019},"labels":[],"label_agreement":null},{"id":"W2980324440","doi":"10.1182/blood.v122.21.3093.3093","title":"Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Mesenchymal stem cell; Bone marrow; Stromal cell; Cancer research; Chemistry; Pathology; Cell biology; Biology; Medicine","score_opus":0.018325820125034416,"score_gpt":0.25072213554782347,"score_spread":0.23239631542278905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980324440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998107,0.0003272837,0.000089733214,0.000046014044,0.000014402876,0.0010927002,0.000054831293,0.000015214071,0.00025277823],"genre_scores_gemma":[0.9944766,0.000015850186,0.005145577,0.0000055837427,0.000013707379,0.00014862392,0.00005194691,0.000021050088,0.00012104076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998576,0.00006562722,0.00049509754,0.0002298729,0.00035541187,0.00027802412],"domain_scores_gemma":[0.9992681,0.00006104977,0.00012640622,0.00031103397,0.00012545954,0.000107951826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017369588,0.00013395632,0.00043795435,0.00034863444,0.000012702945,0.0000049614328,0.00007392351,0.00009496771,0.000022885808],"category_scores_gemma":[0.000088456414,0.00011673199,0.00007376235,0.00021708249,0.000030378864,0.0000802188,0.000049769227,0.000086562744,0.000019059424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003950898,0.00104294,0.23366848,0.00043874595,0.00006382739,0.00006180233,0.00016164781,0.0003645064,0.7598147,0.000003657241,0.0000025845595,0.0039820503],"study_design_scores_gemma":[0.011640988,0.000121221834,0.37346044,0.00023432149,0.000042294207,0.000028147833,0.00014436044,0.13907534,0.4751676,0.000008935233,4.920339e-7,0.000075878714],"about_ca_topic_score_codex":0.002700787,"about_ca_topic_score_gemma":0.00024640706,"teacher_disagreement_score":0.28464708,"about_ca_system_score_codex":0.0000976905,"about_ca_system_score_gemma":0.00008270262,"threshold_uncertainty_score":0.47601926},"labels":[],"label_agreement":null},{"id":"W2980380805","doi":"10.1182/blood.v120.21.323.323","title":"Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Lenalidomide; Bortezomib; Multiple myeloma; Biology; microRNA; Cancer research; Downregulation and upregulation; Molecular biology; Immunology; Gene; Genetics","score_opus":0.01852438703072472,"score_gpt":0.2730364971323385,"score_spread":0.2545121101016138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980380805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952117,0.002321008,0.000005323156,0.0001466677,0.000020469637,0.00050678704,0.000032301254,0.000015013573,0.0017407228],"genre_scores_gemma":[0.99479437,0.00006258838,0.0043435674,0.00006244079,0.0000638302,0.000046705183,0.000010008407,0.000017070892,0.00059944764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893093,0.000043025837,0.00021607369,0.00018062403,0.0002315026,0.0003978621],"domain_scores_gemma":[0.9992092,0.00011269428,0.000040697178,0.00025131356,0.000041243544,0.0003448261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016812429,0.00011614459,0.00027128612,0.00013531533,0.000027747617,0.000006337647,0.00005745092,0.000055308625,0.000039970673],"category_scores_gemma":[0.00016157953,0.00009813166,0.000041357354,0.00015518635,0.00004191174,0.00007093834,0.000052353415,0.00009113255,0.000042581712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073512597,0.001179041,0.6632969,0.000102119324,0.00008653454,0.00004213694,0.00050611637,5.29803e-7,0.33118573,0.0000354435,0.0002598927,0.0025704678],"study_design_scores_gemma":[0.007359209,0.00011692644,0.6069155,0.00010367699,0.000042491778,0.000010316842,0.00011286869,0.000015314428,0.3808399,0.000016839866,0.0043885605,0.00007839078],"about_ca_topic_score_codex":0.0001778833,"about_ca_topic_score_gemma":0.00034032774,"teacher_disagreement_score":0.056381375,"about_ca_system_score_codex":0.00002622361,"about_ca_system_score_gemma":0.000036816476,"threshold_uncertainty_score":0.4001693},"labels":[],"label_agreement":null},{"id":"W2980405084","doi":"10.1182/blood-2018-99-114907","title":"New Blood Based M-Protein Quantification Method 3,000 Times More Sensitive Than Standard SPEP","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Polyclonal antibodies; Protein sequencing; Peptide sequence; Biology; Antibody; Molecular biology; Immunology; Biochemistry; Gene","score_opus":0.03101908213188804,"score_gpt":0.34597890965560985,"score_spread":0.3149598275237218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980405084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94832516,0.0001978432,0.04012568,0.00200101,0.000072196104,0.0016102181,0.00021015512,0.0002178542,0.007239892],"genre_scores_gemma":[0.8793144,0.000006178346,0.116490945,0.00009936006,0.00039064846,0.000027989614,0.0001466386,0.000037969818,0.0034858182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982023,0.00015557327,0.00022390098,0.00044343734,0.0005706609,0.00040410654],"domain_scores_gemma":[0.99856746,0.000106641215,0.000082831844,0.0005470689,0.00030339413,0.0003925981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032990126,0.00021043773,0.00032541447,0.0001579286,0.00013893754,0.00004199779,0.000092639304,0.00011743989,0.00074155256],"category_scores_gemma":[0.0002987357,0.0001687204,0.0001148156,0.00027109555,0.000113118615,0.00007081491,0.000026359323,0.00017488908,0.00031232578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053712456,0.003830882,0.04857727,0.0002766418,0.0029589396,0.0017466939,0.0014333187,0.0000023780867,0.8563876,0.0016303285,0.0030869953,0.074697666],"study_design_scores_gemma":[0.011037663,0.0013916406,0.03354861,0.00014787469,0.0004765393,0.00006443101,0.00009498017,0.00044068595,0.9514554,0.00014984036,0.001027859,0.00016447454],"about_ca_topic_score_codex":0.00050587225,"about_ca_topic_score_gemma":0.000060202725,"teacher_disagreement_score":0.09506776,"about_ca_system_score_codex":0.000040167324,"about_ca_system_score_gemma":0.0003426131,"threshold_uncertainty_score":0.81194806},"labels":[],"label_agreement":null},{"id":"W2980405531","doi":"10.1016/j.clml.2019.09.531","title":"Clinical and prognostic impact of circulating plasma cells on peripheral blood smears in multiple myeloma at presentation and during follow-up","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Multiple myeloma; Plasma cell leukemia; Medicine; Peripheral blood; Proportional hazards model; Internal medicine; Multivariate analysis; Oncology; Single Center; Presentation (obstetrics); Gastroenterology; Surgery","score_opus":0.03751029044061064,"score_gpt":0.3497344506432094,"score_spread":0.31222416020259874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980405531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725145,0.00017568035,0.0000013835113,0.000041432777,0.0002727683,0.0017553926,0.000041028354,0.00006088302,0.0003999802],"genre_scores_gemma":[0.9981571,0.00023445416,0.00061986136,0.000042657543,0.00018569597,0.000052945477,0.00006533905,0.00007561087,0.00056637963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533695,0.00048259037,0.0016859494,0.0010943122,0.0006309525,0.00076922076],"domain_scores_gemma":[0.99524534,0.0028462387,0.00040596147,0.00062376633,0.00014149609,0.00073722535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087150984,0.0004522343,0.0012749973,0.00023697113,0.00013369031,0.000050405277,0.0001623961,0.00047620767,0.00011531768],"category_scores_gemma":[0.002264267,0.000375361,0.00049960957,0.00029872963,0.00050346146,0.000194673,0.000297812,0.00044752922,0.00007205437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005720416,0.00058841653,0.8874856,0.00027503466,0.00045906845,0.0005189368,0.00018933263,0.000044662345,0.009585758,0.000007734844,0.0000213271,0.0951037],"study_design_scores_gemma":[0.0398427,0.0029678047,0.9396128,0.0005480596,0.00015660019,0.0002184604,0.00007757231,0.01396533,0.002278979,0.000023227674,0.000011185393,0.00029727808],"about_ca_topic_score_codex":0.00038470223,"about_ca_topic_score_gemma":0.000111475696,"teacher_disagreement_score":0.094806425,"about_ca_system_score_codex":0.0005783952,"about_ca_system_score_gemma":0.0005610157,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2980562306","doi":"10.1016/j.clml.2019.09.375","title":"Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Daratumumab; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Quality of life (healthcare); Physical therapy","score_opus":0.02003324017375479,"score_gpt":0.29692993721462285,"score_spread":0.27689669704086806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980562306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942038,0.0003859444,0.0010261608,0.00011138388,0.0001354752,0.0038818927,0.00015974855,0.000046506477,0.00004906603],"genre_scores_gemma":[0.9854824,0.0002644049,0.013150867,0.000099205514,0.00009778893,0.0003681792,0.0003558147,0.000072637864,0.00010871043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967262,0.00024961814,0.0010536134,0.00089068915,0.00039945668,0.0006804202],"domain_scores_gemma":[0.9945527,0.0039291675,0.00032269311,0.00041303568,0.0003241587,0.00045830006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012542031,0.00040296454,0.0011099457,0.00030755295,0.00012152118,0.000029369456,0.00013297451,0.00033823898,0.0000104349465],"category_scores_gemma":[0.0014038775,0.00032112672,0.00021467125,0.00032429126,0.00033480694,0.00023356754,0.00005629543,0.00019993914,0.0000038652092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023476955,0.00044518485,0.68213314,0.00042151051,0.00030430563,0.00004367179,0.00023564616,0.000025958905,0.000451622,0.000033379896,0.000083975974,0.29234463],"study_design_scores_gemma":[0.07811169,0.0047377506,0.90045524,0.0009112095,0.00021865664,0.000044902037,0.00017933533,0.013634079,0.00081144506,0.000061958715,0.0004981012,0.0003356034],"about_ca_topic_score_codex":0.00038405013,"about_ca_topic_score_gemma":0.00018840736,"teacher_disagreement_score":0.29200903,"about_ca_system_score_codex":0.00036216,"about_ca_system_score_gemma":0.00043123402,"threshold_uncertainty_score":0.99992406},"labels":[],"label_agreement":null},{"id":"W2980591051","doi":"10.1182/blood.v118.21.5099.5099","title":"Discrepancies in Serum Free Light Chain Assays and Immunofixation for Response Evaluation and Prognostication in Plasma Cell Proliferative Disorders","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"B.C. Women's Hospital & Health Centre","funders":"","keywords":"Immunofixation; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Medicine; Serum protein electrophoresis; Context (archaeology); Internal medicine; Monoclonal; Plasma cell; Macroglobulinemia; Population; Plasma cell dyscrasia; Immunoglobulin light chain; Gastroenterology; Immunology; Antibody; Monoclonal antibody; Biology","score_opus":0.029206837937792895,"score_gpt":0.2917082573160104,"score_spread":0.2625014193782175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980591051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995187,0.00036558686,0.000038424943,0.0010431042,0.000010958206,0.0028839235,0.00002076658,0.000012253323,0.00043798832],"genre_scores_gemma":[0.99697894,0.00007430026,0.0018690362,0.0000073026476,0.000010532311,0.0009310969,0.000045687357,0.000010512281,0.00007258947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991003,0.0001760569,0.00016468433,0.00021278925,0.0001740731,0.000172058],"domain_scores_gemma":[0.9994979,0.00018247226,0.000050251187,0.0001397424,0.000074407995,0.000055241955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076502725,0.000092459,0.0001284133,0.00017355093,0.000045640452,0.000013282885,0.000029987094,0.0000565846,0.000006942431],"category_scores_gemma":[0.0012904278,0.00007557179,0.000014007171,0.000115420546,0.00003734051,0.00011838338,0.000027122453,0.00006488987,0.0000012227872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058534094,0.0017318364,0.9518541,0.00015386158,0.00005627339,0.000008642401,0.009137355,6.1924686e-7,0.02015049,0.00018163786,0.0000073683796,0.010864414],"study_design_scores_gemma":[0.016404483,0.0009202196,0.93526435,0.00007737775,0.00006698856,0.0000047953217,0.00057122245,0.0044201086,0.04121252,0.0009592708,0.000024503395,0.000074134674],"about_ca_topic_score_codex":0.00014545736,"about_ca_topic_score_gemma":0.0011771945,"teacher_disagreement_score":0.021062031,"about_ca_system_score_codex":0.00004689121,"about_ca_system_score_gemma":0.00010554778,"threshold_uncertainty_score":0.30817282},"labels":[],"label_agreement":null},{"id":"W2980592905","doi":"10.1016/j.clml.2019.09.162","title":"Mass cytometry reveals increase in marrow resident monocytes associated with response to daratumumab and pomalidomide","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Mass cytometry; Bone marrow; Immune system; Immunology; CD38; Monocyte; Medicine; Cancer research; Multiple myeloma; Biology; Antibody; Monoclonal antibody; CD34; Stem cell; Lenalidomide; Cell biology","score_opus":0.026794748634111715,"score_gpt":0.336731276792525,"score_spread":0.3099365281584133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980592905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454457,0.0003708812,0.00001437866,0.0010440005,0.000114161965,0.0018012791,0.000072958675,0.00012489872,0.0019128581],"genre_scores_gemma":[0.9912859,0.00009515314,0.0015121859,0.0010479279,0.00010679548,0.00012920938,0.00009454493,0.00009273032,0.0056355256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944405,0.0012482497,0.0012099401,0.0011754603,0.0009069624,0.0010188748],"domain_scores_gemma":[0.9928554,0.004183031,0.0002670804,0.0010596872,0.00024985085,0.0013849254],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032674007,0.0004927428,0.0013604172,0.0006355403,0.00010391491,0.00010503874,0.00030175468,0.00045437188,0.00018947978],"category_scores_gemma":[0.009460946,0.00039095053,0.00020522987,0.0011010895,0.00025799213,0.00021257634,0.00027047965,0.00045793277,0.0005675927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057627782,0.00034402742,0.89951515,0.0000747227,0.0003580966,0.004051788,0.000113634094,0.0000045258275,0.007754483,0.00004043603,0.0009826644,0.029132692],"study_design_scores_gemma":[0.024584472,0.0030208759,0.96843356,0.0008902304,0.00009874709,0.00015770552,0.0001385663,0.00036473988,0.0010605186,0.00016589812,0.0006761167,0.0004085895],"about_ca_topic_score_codex":0.00046124356,"about_ca_topic_score_gemma":0.00015411607,"teacher_disagreement_score":0.06891839,"about_ca_system_score_codex":0.0022890186,"about_ca_system_score_gemma":0.0013509117,"threshold_uncertainty_score":0.99985427},"labels":[],"label_agreement":null},{"id":"W2980665363","doi":"10.1182/blood-2018-99-116796","title":"Mechanical Loading Shows Anti-Myeloma Effects While Rescuing Bone Loss with Net Bone Formation in a Myeloma Bone Disease Murine Model","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Children's Hospital","funders":"","keywords":"Bone resorption; Medicine; Bone remodeling; Bone marrow; Multiple myeloma; Osteolysis; Bone disease; Resorption; In vivo; Pathology; Bone healing; Internal medicine; Osteoporosis; Anatomy; Surgery; Biology","score_opus":0.01951311393566581,"score_gpt":0.27192125542878354,"score_spread":0.25240814149311774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980665363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510133,0.00053307717,0.0016454359,0.0004287684,0.000042494645,0.0014306764,0.000039530678,0.00015387774,0.0006247881],"genre_scores_gemma":[0.99436295,0.000063520674,0.0044316724,0.00015918158,0.0002710404,0.00020064366,0.00016015761,0.00007013721,0.00028069582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99715054,0.000108129636,0.0004805913,0.00058239844,0.00079191977,0.0008864282],"domain_scores_gemma":[0.9982313,0.00010660869,0.00012924122,0.0006257146,0.00017053793,0.00073661463],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003412994,0.000364756,0.00063053146,0.00038676563,0.00018634196,0.00006455803,0.00012217724,0.00013086844,0.000059630474],"category_scores_gemma":[0.00029637388,0.00028798336,0.0001147768,0.00048465037,0.00013043518,0.0004227079,0.0001556172,0.00032952894,0.0000918452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028284578,0.02188223,0.1924426,0.006418942,0.0017066095,0.08692883,0.0031777832,0.00038675673,0.6106631,0.0024127646,0.0015427261,0.044153087],"study_design_scores_gemma":[0.08921818,0.0059231413,0.25743422,0.00479475,0.0012691203,0.0033064787,0.00016743195,0.2831267,0.352312,0.00082648883,0.00023446228,0.001386999],"about_ca_topic_score_codex":0.000070500726,"about_ca_topic_score_gemma":0.0002288781,"teacher_disagreement_score":0.28273997,"about_ca_system_score_codex":0.00014316168,"about_ca_system_score_gemma":0.00015143241,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W2980792813","doi":"10.1016/j.clml.2019.09.275","title":"Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Internal medicine; Medicine; Ixazomib; Multiple myeloma; Oncology; Hazard ratio; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib; Biology; Confidence interval","score_opus":0.03648884867608198,"score_gpt":0.3331541773261949,"score_spread":0.2966653286501129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980792813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915183,0.00056603923,0.000016608117,0.00020613598,0.00085208914,0.00490361,0.0008989419,0.000091168935,0.000947076],"genre_scores_gemma":[0.9914336,0.00005686596,0.0013370487,0.0003978729,0.0003743689,0.0008222996,0.00032347586,0.00011750594,0.005136961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947504,0.00056225894,0.0015598527,0.0012078076,0.0010464387,0.0008732825],"domain_scores_gemma":[0.99006945,0.0068212887,0.00051964354,0.001483611,0.00044165127,0.00066437566],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011352953,0.0005689502,0.0013602594,0.00019426667,0.00022577157,0.000052970252,0.00045927954,0.000462371,0.001590028],"category_scores_gemma":[0.0046915207,0.00039778367,0.00091345434,0.00041191862,0.0006164126,0.00019559039,0.00044153575,0.0004596397,0.0002681051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022341073,0.0033902442,0.70776045,0.00021106108,0.0014749672,0.00017994303,0.00030678598,0.0000019653219,0.00056669395,0.000112814065,0.0047535417,0.25890046],"study_design_scores_gemma":[0.062826835,0.0033937106,0.91988593,0.00032264888,0.0003957458,0.00008063506,0.00028899987,0.0003232831,0.00039126383,0.00009527112,0.011639183,0.00035648388],"about_ca_topic_score_codex":0.00015149925,"about_ca_topic_score_gemma":0.00008223379,"teacher_disagreement_score":0.25854397,"about_ca_system_score_codex":0.00073462294,"about_ca_system_score_gemma":0.0014232752,"threshold_uncertainty_score":0.9998474},"labels":[],"label_agreement":null},{"id":"W2980805176","doi":"10.1016/j.clml.2019.09.410","title":"Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Refractory (planetary science); Internal medicine; Adverse effect; Multiple myeloma; Oncology; Lenalidomide","score_opus":0.04796568004329691,"score_gpt":0.3345886507110818,"score_spread":0.28662297066778486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980805176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053466,0.00012158461,0.000017413515,0.00012933397,0.002196783,0.0050835954,0.00016454351,0.00023959068,0.0015125112],"genre_scores_gemma":[0.99239314,0.0002679707,0.001622708,0.00017997745,0.00047457384,0.0005156359,0.0007232534,0.00019838146,0.0036243366],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99342644,0.00045294687,0.0019211897,0.0017195839,0.0009339118,0.0015459249],"domain_scores_gemma":[0.9937488,0.0029767212,0.00053827267,0.001436523,0.00041018068,0.0008895293],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006152468,0.000842172,0.0017783161,0.0004094703,0.0003166497,0.00011974998,0.00032980138,0.00090519805,0.00041209316],"category_scores_gemma":[0.002260564,0.0006848664,0.00067842857,0.00052770873,0.00027465192,0.0003392051,0.00015491227,0.0005148726,0.000881044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06314322,0.0010701902,0.44092497,0.00009895201,0.0004589849,0.00072184217,0.00017279011,0.000007889321,0.00018571295,0.0000061686046,0.00035985588,0.49284944],"study_design_scores_gemma":[0.0883533,0.025986917,0.8765307,0.00033495892,0.00024334507,0.00011889739,0.000103304366,0.0018729952,0.0004509281,0.000021329364,0.0053731306,0.0006101618],"about_ca_topic_score_codex":0.0012147255,"about_ca_topic_score_gemma":0.0025104843,"teacher_disagreement_score":0.49223927,"about_ca_system_score_codex":0.00779667,"about_ca_system_score_gemma":0.001940459,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W2980929842","doi":"10.1016/j.clml.2019.09.414","title":"The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Saskatchewan; Université de Montréal; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Alberta; Canadian Council on International Law; Dalhousie University; University of British Columbia","funders":"","keywords":"Lenalidomide; Multiple myeloma; Oncology; Medicine; Maintenance therapy; Internal medicine; Chemotherapy","score_opus":0.017786836732838505,"score_gpt":0.31902921537140455,"score_spread":0.30124237863856607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980929842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445015,0.00009505039,0.0000015382158,0.00082000816,0.00008306039,0.0019144252,0.00013304078,0.000017648294,0.0024850806],"genre_scores_gemma":[0.99829316,0.000114316426,0.000114285416,0.0007981003,0.00008939892,0.000080440754,0.00012989675,0.000055038963,0.00032536473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961805,0.00039538954,0.0010794984,0.0005987818,0.00067376456,0.0010720893],"domain_scores_gemma":[0.99577117,0.0024215768,0.00026969842,0.00092542445,0.00018418679,0.00042794395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015991227,0.00039739304,0.00079388253,0.00024427864,0.00016421577,0.000058468046,0.000513981,0.00026515656,0.000109503664],"category_scores_gemma":[0.00057547115,0.00019389727,0.0003470503,0.0005652522,0.00030624462,0.00010637205,0.000029005854,0.00058467616,0.00009704526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008094569,0.00044810033,0.89006585,0.0000433192,0.00018392895,0.00024538094,0.0003461295,0.00007720017,0.00006905611,0.00003714475,0.0003693296,0.10001998],"study_design_scores_gemma":[0.026690457,0.002364651,0.9665916,0.0005206976,0.000018622692,0.00003042274,0.00009881421,0.0022797205,0.00035249162,0.00005999246,0.00078316574,0.0002093658],"about_ca_topic_score_codex":0.04286089,"about_ca_topic_score_gemma":0.15264869,"teacher_disagreement_score":0.10978779,"about_ca_system_score_codex":0.0018811856,"about_ca_system_score_gemma":0.002541651,"threshold_uncertainty_score":0.9635128},"labels":[],"label_agreement":null},{"id":"W2980945138","doi":"10.1039/c9nr06512a","title":"Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma","year":2019,"lang":"en","type":"article","venue":"Nanoscale","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Philippe Foundation; National Cancer Institute; Dana-Farber Cancer Institute; Multiple Myeloma Research Foundation","keywords":"Multiple myeloma; Antibody; Sensitivity (control systems); Tracking (education); Nanoparticle; Materials science; Nanotechnology; Cancer research; Medicine; Immunology; Engineering","score_opus":0.020955947492712783,"score_gpt":0.2915857961377416,"score_spread":0.2706298486450288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980945138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786234,0.0009795175,0.00015711618,0.000076260265,0.000057358735,0.00037730706,0.00002475849,0.000026621661,0.00043872098],"genre_scores_gemma":[0.9981119,0.000090969486,0.0016074977,0.000011300652,0.00003583964,0.0000045348133,0.000030423407,0.00001785676,0.00008966652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986143,0.00010385098,0.0003189757,0.00030604663,0.00029782543,0.0003590093],"domain_scores_gemma":[0.9988762,0.00047122492,0.00014380927,0.00020127467,0.00017723574,0.00013021342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042105024,0.00015342332,0.00043406844,0.00010486777,0.00007036775,0.000014689743,0.000047059715,0.000050216888,0.00003971889],"category_scores_gemma":[0.00038648807,0.00012592654,0.00008862021,0.00015466045,0.00016187005,0.00014230354,0.0000401811,0.000125913,0.000009074447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016092384,0.00012686173,0.48722374,0.00024646329,0.00003925036,0.000033636366,0.00017976295,0.00000221972,0.5075033,0.0000059838057,0.0000032314947,0.0044746827],"study_design_scores_gemma":[0.0012197744,0.00011572324,0.41671872,0.00020519854,0.000027574872,0.000026121232,0.00029119223,0.00078664103,0.5805185,0.0000074176564,0.000020425094,0.00006275048],"about_ca_topic_score_codex":0.0003641418,"about_ca_topic_score_gemma":0.00006403794,"teacher_disagreement_score":0.073015206,"about_ca_system_score_codex":0.000022985925,"about_ca_system_score_gemma":0.000052922333,"threshold_uncertainty_score":0.51351357},"labels":[],"label_agreement":null},{"id":"W2981119159","doi":"10.1016/j.clml.2019.09.572","title":"The Princess Margaret Cancer Centre Experience: Transitioning to GCSF Alone for Stem Cell Mobilization in Myeloma Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Plerixafor; Medicine; Regimen; Multiple myeloma; Apheresis; Mobilization; Cyclophosphamide; Surgery; Febrile neutropenia; Internal medicine; Oncology; Neutropenia; Chemotherapy; CXCR4","score_opus":0.028423449931071165,"score_gpt":0.3459116521429805,"score_spread":0.3174882022119093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981119159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360865,0.00025579607,0.0001488029,0.00077621144,0.00062622054,0.0037715458,0.000080599144,0.00007379695,0.0006583496],"genre_scores_gemma":[0.9949656,0.00022758805,0.0004815314,0.0006245459,0.00020149814,0.0007381008,0.00019183564,0.00007045458,0.0024988204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612355,0.00022826834,0.0011141072,0.0009031288,0.00070685474,0.0009240899],"domain_scores_gemma":[0.9971128,0.0009849898,0.00021544538,0.0007033242,0.0004001011,0.00058330595],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005831842,0.00035498178,0.00069306866,0.00013152962,0.00027187355,0.00009414823,0.0003711506,0.00028422152,0.0001312333],"category_scores_gemma":[0.00024654964,0.0002601351,0.00027900195,0.0005130484,0.00015783113,0.00020154579,0.00011953115,0.00021293499,0.00019764362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024414705,0.00040119406,0.5931508,0.00012691245,0.000059744227,0.000028314289,0.0007914571,0.00007264982,0.00026137792,0.000049836854,0.00047055172,0.4021457],"study_design_scores_gemma":[0.013068458,0.0007525388,0.96893114,0.00034310375,0.000044839995,0.000003786943,0.0007402047,0.0034264487,0.002937468,0.00003405747,0.0094291195,0.00028881442],"about_ca_topic_score_codex":0.00023477363,"about_ca_topic_score_gemma":0.0003248509,"teacher_disagreement_score":0.4018569,"about_ca_system_score_codex":0.0014331432,"about_ca_system_score_gemma":0.00090530945,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W2981157362","doi":"10.1016/j.clml.2019.09.022","title":"Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Hazard ratio; Internal medicine; Medicine; Interim analysis; Multiple myeloma; Oncology; Refractory (planetary science); Progression-free survival; Neutropenia; Confidence interval; Randomized controlled trial; Overall survival; Chemotherapy; Biology","score_opus":0.10961399750232273,"score_gpt":0.3883472726813034,"score_spread":0.2787332751789807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981157362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821738,0.0008441638,0.00024595635,0.0015347224,0.003391663,0.006610257,0.0018096892,0.00030687134,0.0030828821],"genre_scores_gemma":[0.97981936,0.00031150857,0.0026432986,0.0011765952,0.0036628754,0.0005917269,0.0027896625,0.00021381599,0.00879114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899926,0.001227619,0.0030394201,0.0022479277,0.001715682,0.0017767372],"domain_scores_gemma":[0.9730167,0.021407487,0.0009946942,0.002803771,0.00053371664,0.001243645],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003560306,0.000992566,0.0023080504,0.00018783966,0.00049755175,0.00021042931,0.0010701893,0.0009912169,0.0006081221],"category_scores_gemma":[0.012653143,0.0007010843,0.0017377988,0.00043527008,0.00067281624,0.0003690907,0.00043101824,0.001066466,0.0016862422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6086452,0.0027745606,0.007678479,0.00007524882,0.0016771543,0.0005515832,0.00030551336,0.000015502452,0.000980796,0.0002902406,0.013367408,0.3636383],"study_design_scores_gemma":[0.58214617,0.0076301508,0.32585979,0.000287553,0.00047713373,0.000045883724,0.00020984924,0.0042288,0.00054095476,0.0003198458,0.077590354,0.0006635129],"about_ca_topic_score_codex":0.002119316,"about_ca_topic_score_gemma":0.00018377716,"teacher_disagreement_score":0.36297482,"about_ca_system_score_codex":0.0027514107,"about_ca_system_score_gemma":0.0044295993,"threshold_uncertainty_score":0.999544},"labels":[],"label_agreement":null},{"id":"W2981166293","doi":"10.1016/j.clml.2019.09.033","title":"Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Locus (genetics); MCL1; Gene; Genetics; Cancer research; Biology; Medicine; Leukemia; Downregulation and upregulation","score_opus":0.020977209466760783,"score_gpt":0.31538119349890215,"score_spread":0.29440398403214135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981166293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664533,0.00016695997,0.00002373173,0.00021894151,0.00028608998,0.0017375264,0.00012507763,0.00002506797,0.00077128067],"genre_scores_gemma":[0.9975062,0.00009088982,0.0012657907,0.0003123579,0.00009792685,0.000074970914,0.00013417614,0.00004742483,0.00047027113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962648,0.00038844522,0.0013373025,0.0006597276,0.0008332931,0.00051641004],"domain_scores_gemma":[0.99691963,0.0010562282,0.00044613195,0.0008092159,0.00038687585,0.00038188923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007379032,0.000300979,0.0008623414,0.000150821,0.00006864235,0.000015826086,0.00027518603,0.0003074908,0.00010523014],"category_scores_gemma":[0.0014908729,0.00023008083,0.00023523567,0.0005761902,0.00032315898,0.0001321008,0.00022234273,0.00020982025,0.00016275873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003815843,0.00033955235,0.9238518,0.00022587586,0.000111953945,0.000058703998,0.00023467855,0.000041717336,0.0033579352,0.000053947053,0.00030028966,0.06760771],"study_design_scores_gemma":[0.013251253,0.0005830183,0.95649225,0.00051347614,0.000057861074,0.00001168723,0.000051665895,0.00070175616,0.027625678,0.00021920927,0.00030246025,0.00018969708],"about_ca_topic_score_codex":0.00028016092,"about_ca_topic_score_gemma":0.00021479174,"teacher_disagreement_score":0.06741801,"about_ca_system_score_codex":0.0010530138,"about_ca_system_score_gemma":0.0007665232,"threshold_uncertainty_score":0.9382424},"labels":[],"label_agreement":null},{"id":"W2981169884","doi":"10.1016/j.clml.2019.09.063","title":"Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Oncology; Internal medicine; Stem cell; Transplantation; Minimal residual disease; Bone marrow; Surgery","score_opus":0.015983547934228324,"score_gpt":0.297058285405214,"score_spread":0.28107473747098566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981169884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941813,0.00040815596,0.00015938972,0.00018456107,0.0007960825,0.0031287996,0.00046837213,0.00017864064,0.0004947248],"genre_scores_gemma":[0.9900932,0.0009634155,0.0011701979,0.00040733608,0.00018319766,0.00042745384,0.0008648354,0.00013263023,0.0057577714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932356,0.000857101,0.0019433837,0.0015817974,0.0009834835,0.001398628],"domain_scores_gemma":[0.996237,0.0010513983,0.0006344448,0.0010024172,0.00032611907,0.0007486543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010625633,0.000778052,0.0016802058,0.0002433319,0.0001648617,0.00009308205,0.00041937132,0.00076262973,0.00032864214],"category_scores_gemma":[0.00040314262,0.0005824942,0.00047918345,0.00058477855,0.00029041158,0.0004159605,0.0001372689,0.00067919696,0.00074205105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01340175,0.0012373223,0.8489008,0.00023299536,0.0002461699,0.0012149228,0.00016191347,0.0000059007116,0.00040694297,0.000007051646,0.0012476933,0.13293654],"study_design_scores_gemma":[0.03701372,0.0024584366,0.9553373,0.0003632898,0.0002727409,0.00005492651,0.00007735807,0.0011673514,0.0019120002,0.000072406634,0.0006739738,0.0005965088],"about_ca_topic_score_codex":0.0009272378,"about_ca_topic_score_gemma":0.001169786,"teacher_disagreement_score":0.13234003,"about_ca_system_score_codex":0.0018758138,"about_ca_system_score_gemma":0.0013056841,"threshold_uncertainty_score":0.99966264},"labels":[],"label_agreement":null},{"id":"W2981240392","doi":"10.1016/j.clml.2019.09.064","title":"Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant.","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Lenalidomide; Bortezomib; Medicine; Multiple myeloma; Maintenance therapy; Internal medicine; Regimen; Autologous stem-cell transplantation; Oncology; Transplantation; Progression-free survival; Surgery; Overall survival; Chemotherapy","score_opus":0.025264289345250025,"score_gpt":0.3063023602096018,"score_spread":0.28103807086435173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981240392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388766,0.00036692328,0.00006693393,0.00036411057,0.00008120291,0.0025244202,0.00013596578,0.00021372318,0.002359084],"genre_scores_gemma":[0.9906816,0.0022444401,0.0023482854,0.0008537878,0.00020709286,0.00022247287,0.00013372852,0.00017695145,0.003131627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457437,0.00052036875,0.001277354,0.0014847077,0.00085325,0.0012899584],"domain_scores_gemma":[0.9959831,0.0014555515,0.00045945108,0.00096833275,0.00029231585,0.0008412496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009610671,0.0008177996,0.001696295,0.00028982048,0.00015049858,0.000118128526,0.00036483083,0.0005178015,0.0003416151],"category_scores_gemma":[0.00031667104,0.00046185078,0.00021791163,0.00062528317,0.0007328188,0.00033625725,0.00008726521,0.00067819346,0.00020130316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07165425,0.0006583828,0.5407372,0.00012798261,0.00095882005,0.00574498,0.0001602276,0.00000869296,0.0011254232,0.00008164714,0.000097413125,0.378645],"study_design_scores_gemma":[0.070470944,0.010478149,0.9131411,0.0008707041,0.00020357111,0.0008989651,0.000120974844,0.0009438762,0.0013369763,0.00007447384,0.00084589724,0.0006144057],"about_ca_topic_score_codex":0.0021750305,"about_ca_topic_score_gemma":0.0009123741,"teacher_disagreement_score":0.3780306,"about_ca_system_score_codex":0.0006271943,"about_ca_system_score_gemma":0.0020668835,"threshold_uncertainty_score":0.99978334},"labels":[],"label_agreement":null},{"id":"W2981456572","doi":"10.1182/blood.v110.11.2475.2475","title":"Chromosome 1p21 Deletion Defines a Subgroup of Multiple Myeloma with Poor Clinical Outcomes Independent of del (13q), del(p53), t(4;14) or 1q21 Amplification.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Chromosome 13; Biology; Fluorescence in situ hybridization; Multiple myeloma; Pathogenesis; Internal medicine; Pathology; Molecular biology; Gene; Gastroenterology; Chromosome; Medicine; Immunology; Genetics","score_opus":0.05152371000253943,"score_gpt":0.34424255585638364,"score_spread":0.2927188458538442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981456572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631345,0.0003228428,0.0016903823,0.00018190235,0.00006652788,0.0010322351,0.00007717029,0.000057537032,0.00025796614],"genre_scores_gemma":[0.9874417,0.00014044745,0.011576904,0.000093579976,0.0001021107,0.00006172374,0.00016109904,0.000045874138,0.00037651256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969407,0.00009360022,0.0010573594,0.00047706396,0.00092140347,0.00050991564],"domain_scores_gemma":[0.997225,0.00079086504,0.00040540774,0.00062588946,0.0005646522,0.00038822842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007818891,0.0002834948,0.0007879044,0.00027630627,0.000079487865,0.000012014977,0.00020029515,0.00021652506,0.00012388555],"category_scores_gemma":[0.0011682546,0.00018454042,0.00023795114,0.0004171412,0.00024279012,0.00010457177,0.00007748217,0.0002600695,0.000040173825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030808966,0.004804004,0.9763492,0.00020785129,0.0008764061,0.00024244146,0.000090491274,0.0000018656261,0.0071886047,0.000106086176,0.00004814828,0.0070040417],"study_design_scores_gemma":[0.018827055,0.0019303899,0.947251,0.00017501095,0.00038301822,0.00015802939,0.00012089745,0.000073286086,0.030767696,0.000021547996,0.00012114412,0.00017092045],"about_ca_topic_score_codex":0.0006589771,"about_ca_topic_score_gemma":0.0010968718,"teacher_disagreement_score":0.029098159,"about_ca_system_score_codex":0.000056797257,"about_ca_system_score_gemma":0.00029487588,"threshold_uncertainty_score":0.75253403},"labels":[],"label_agreement":null},{"id":"W2981550333","doi":"10.1182/blood.v122.21.3189.3189","title":"Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Placebo; Dexamethasone; Refractory (planetary science); Phases of clinical research; Gastroenterology; Multiple myeloma; Randomization; Urology; Maintenance therapy; Pharmacology; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Pathology","score_opus":0.011842555344181405,"score_gpt":0.2628375749493714,"score_spread":0.25099501960519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981550333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798555,0.00038571097,0.000008793647,0.000040994037,0.000013635064,0.019333595,0.000018310535,0.000073284325,0.00027021038],"genre_scores_gemma":[0.9957136,0.000079865014,0.00072345196,0.000026349877,0.000020696283,0.002846673,0.00013692112,0.00007701479,0.00037542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99636513,0.0006284942,0.000954721,0.0006722654,0.0007512917,0.00062810344],"domain_scores_gemma":[0.9970717,0.0008973619,0.00045624407,0.00064518326,0.00046609796,0.00046344264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005341392,0.0005263771,0.0025172324,0.00042284772,0.00010357314,0.000041678642,0.0001300446,0.00013855714,0.000118268224],"category_scores_gemma":[0.00072929065,0.0003103416,0.00012167426,0.00043469633,0.00027042103,0.0001860839,0.00005976758,0.00034816161,0.000007850807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.589898,0.027118335,0.37723875,0.00007684653,0.0020562958,0.00024130772,0.0009514307,0.0000024588967,0.000530885,9.975104e-7,0.000017242113,0.0018674437],"study_design_scores_gemma":[0.8269449,0.020952063,0.14733842,0.0002693415,0.001438185,0.00002609714,0.0004899607,0.0013888117,0.0008944193,0.0000015456001,0.000004662178,0.00025161152],"about_ca_topic_score_codex":0.0025678105,"about_ca_topic_score_gemma":0.0007313453,"teacher_disagreement_score":0.23704688,"about_ca_system_score_codex":0.00007657633,"about_ca_system_score_gemma":0.00016170774,"threshold_uncertainty_score":0.99993485},"labels":[],"label_agreement":null},{"id":"W2981699389","doi":"10.1186/s12885-019-6151-x","title":"Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Survivin; Stromal cell; Cancer research; Downregulation and upregulation; microRNA; Multiple myeloma; Bone marrow; Bortezomib; Gene silencing; Apoptosis; Viability assay; Chemistry; Molecular biology; Biology; Immunology; Biochemistry","score_opus":0.01937092089926972,"score_gpt":0.28253737265134987,"score_spread":0.26316645175208014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981699389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934965,0.003921824,0.000009458051,0.00018657545,0.00022458007,0.00096348394,0.00010346366,0.000045877518,0.0010482513],"genre_scores_gemma":[0.98672956,0.00022350818,0.0038224217,0.0000465036,0.00009513371,0.0001214626,0.00007507207,0.000041468866,0.008844841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785775,0.00011877187,0.00046368464,0.00045519797,0.00057341735,0.00053120265],"domain_scores_gemma":[0.99868876,0.0003790508,0.00018655736,0.00043815366,0.0001077548,0.00019970047],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000230756,0.00022920915,0.00054206245,0.00022366046,0.00004576519,0.000014130467,0.00013056898,0.00010580579,0.00097505335],"category_scores_gemma":[0.00021343626,0.00018881923,0.00012473158,0.0003302302,0.000062670326,0.00010007979,0.00008405783,0.00023415963,0.00009685209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094117987,0.00016364272,0.59752727,0.000489209,0.00002539955,0.000046237994,0.00025551222,0.000019877967,0.39789623,0.0000041897847,0.0023778568,0.00025339995],"study_design_scores_gemma":[0.00941187,0.00007636836,0.6953511,0.0010556176,0.000021150723,0.0000015592237,0.00020736117,0.0006385495,0.2891782,0.000020557236,0.0038318557,0.00020580113],"about_ca_topic_score_codex":0.0013914099,"about_ca_topic_score_gemma":0.0035046495,"teacher_disagreement_score":0.10871804,"about_ca_system_score_codex":0.00028150406,"about_ca_system_score_gemma":0.00026384616,"threshold_uncertainty_score":0.9999382},"labels":[],"label_agreement":null},{"id":"W2983008416","doi":"10.1182/blood-2019-125454","title":"Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Checklist; Medicine; Multiple myeloma; MEDLINE; Systematic review; Cochrane Library; Cost effectiveness; Intensive care medicine; Family medicine; Meta-analysis; Internal medicine; Psychology; Risk analysis (engineering)","score_opus":0.19418998858158557,"score_gpt":0.424643867079468,"score_spread":0.23045387849788243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983008416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042471485,0.9742174,0.0000038483604,0.0000037156688,0.0000401893,0.024865199,0.00026146608,0.000007986698,0.00017549016],"genre_scores_gemma":[0.0015847966,0.99439865,0.000065845015,0.00000816219,0.000020293797,0.0034301772,0.00037582297,0.000043713706,0.000072548486],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99663824,0.0009895214,0.0010926492,0.00037049464,0.00059704325,0.0003120536],"domain_scores_gemma":[0.9959177,0.002129005,0.0006135906,0.0011353606,0.00011418209,0.00009019467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008544913,0.0004335473,0.005325931,0.000228043,0.000019215253,0.0000062779122,0.00029161165,0.00016290467,0.00001311399],"category_scores_gemma":[0.00059909903,0.00021734716,0.00096251484,0.00051978236,0.00005625811,0.000023836485,0.000035168887,0.00015262778,0.00005162683],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004043496,0.008865719,0.00042662956,0.9629126,0.0020397804,0.00011425969,0.00005480206,6.3920815e-8,0.0000023402476,0.0000057321136,0.000003826718,0.025533782],"study_design_scores_gemma":[0.01102962,0.0012717089,0.00093505875,0.9622516,0.017505357,0.00020623443,0.000013203841,0.0000054972534,0.000030502297,3.5654423e-7,0.006597131,0.00015374948],"about_ca_topic_score_codex":0.00011462098,"about_ca_topic_score_gemma":0.000011271648,"teacher_disagreement_score":0.025380034,"about_ca_system_score_codex":0.0001957602,"about_ca_system_score_gemma":0.00032902998,"threshold_uncertainty_score":0.88631594},"labels":[],"label_agreement":null},{"id":"W2983220476","doi":"10.1182/blood-2019-122637","title":"Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa; London Health Sciences Centre; Hôtel-Dieu de Québec; Saint John Regional Hospital; Princess Margaret Cancer Centre; University of New Brunswick; Université de Montréal; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Carfilzomib; Medicine; Clinical endpoint; Lenalidomide; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Cyclophosphamide; Progression-free survival; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.036434562548736296,"score_gpt":0.31399656386001135,"score_spread":0.27756200131127506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983220476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112827,0.0025662747,7.903034e-7,0.00030100704,0.000102417165,0.00563998,0.00016647067,0.000019484289,0.000075291864],"genre_scores_gemma":[0.9987155,0.0003279754,0.00043771838,0.000018104034,0.00007499452,0.00022258269,0.00007105668,0.000029309389,0.000102717735],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976338,0.0004241044,0.00049257075,0.00045947498,0.00066101935,0.00032902003],"domain_scores_gemma":[0.99733365,0.0013671599,0.00022546422,0.00087138545,0.00006815195,0.00013417548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041648067,0.0002841321,0.0007772544,0.000089422356,0.00011031579,0.00002326896,0.00019152368,0.0001013294,0.000026805908],"category_scores_gemma":[0.00037738058,0.00014674001,0.00008770579,0.00021535809,0.00013857326,0.00006903696,0.0001304157,0.00016258997,0.0000015520709],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10940019,0.13794374,0.6681316,0.000100490666,0.0017122655,0.00044653853,0.020320477,0.0000041214803,0.02200944,0.000021385711,0.000045690656,0.039864086],"study_design_scores_gemma":[0.5106487,0.059525244,0.41558483,0.00014777418,0.0005056321,0.00001068471,0.0023866626,0.00011479312,0.01079857,0.00007400326,0.00007620633,0.00012689554],"about_ca_topic_score_codex":0.00759399,"about_ca_topic_score_gemma":0.0015998834,"teacher_disagreement_score":0.4012485,"about_ca_system_score_codex":0.0000662082,"about_ca_system_score_gemma":0.00010059324,"threshold_uncertainty_score":0.99901456},"labels":[],"label_agreement":null},{"id":"W2983305723","doi":"10.1182/blood-2019-125810","title":"Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1st, 2nd or 3rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Saint John Regional Hospital; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; McGill University Health Centre; Hôpital Maisonneuve-Rosemont; University of New Brunswick; Leukemia & Lymphoma Society of Canada; University of British Columbia; University of Calgary; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Maintenance therapy; Oncology; Thalidomide; Pomalidomide; Internal medicine; Chemotherapy","score_opus":0.07187631093639534,"score_gpt":0.34969379855697524,"score_spread":0.2778174876205799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983305723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915573,0.00033460004,4.808702e-7,0.001142332,0.00011990521,0.0023367326,0.0020033482,0.000017802822,0.0024874883],"genre_scores_gemma":[0.99449605,0.00029828242,0.00054334715,0.000208172,0.00040924505,0.00030570253,0.0016219118,0.000048482765,0.0020688009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951453,0.00042510938,0.0007310009,0.00062559184,0.0022448958,0.0008280897],"domain_scores_gemma":[0.9957061,0.0019577446,0.0003078641,0.00084990205,0.0008996773,0.0002787221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007390641,0.0003309831,0.00058725185,0.00016127634,0.00018852728,0.000031074847,0.00025565646,0.00008207851,0.000425659],"category_scores_gemma":[0.0006652897,0.00017827172,0.00014119408,0.0006099942,0.00021815076,0.00008674814,0.000077332166,0.00027635708,0.000026913707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10570049,0.00810488,0.8407078,0.00014778262,0.0017054586,0.00051855505,0.00032825285,0.000078356774,0.00069253496,0.000050316085,0.006046921,0.035918698],"study_design_scores_gemma":[0.062747024,0.007829287,0.87305325,0.0018203439,0.0001452017,0.000006949915,0.000083777486,0.00075288804,0.036296148,0.000030400337,0.01696814,0.0002666078],"about_ca_topic_score_codex":0.108745374,"about_ca_topic_score_gemma":0.116323695,"teacher_disagreement_score":0.04295347,"about_ca_system_score_codex":0.00048997515,"about_ca_system_score_gemma":0.0028438026,"threshold_uncertainty_score":0.8998011},"labels":[],"label_agreement":null},{"id":"W2983319734","doi":"10.1182/blood.v110.11.946.946","title":"Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Salvage therapy; Surgery; Multiple myeloma; Internal medicine; Busulfan; Regimen; Transplantation; Median follow-up; Autologous stem-cell transplantation; Etoposide; Hematopoietic stem cell transplantation; Chemotherapy","score_opus":0.005948708127525622,"score_gpt":0.21454852766541835,"score_spread":0.20859981953789272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983319734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963339,0.0001588276,0.000011032346,0.000062347186,0.00006519946,0.0027760991,0.00036115735,0.000067302644,0.00016411775],"genre_scores_gemma":[0.9985308,0.000010662397,0.00030455814,0.0001728108,0.000020837926,0.00022182908,0.00030297844,0.00008786343,0.0003476526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970636,0.00009044909,0.00054657116,0.00068595994,0.0007122016,0.0009012576],"domain_scores_gemma":[0.9982294,0.00019382965,0.00013475122,0.0007578438,0.00012828482,0.00055591855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018658473,0.0004934066,0.0006658775,0.00036690125,0.00006742552,0.0000334502,0.0002381631,0.00015973215,0.0001824141],"category_scores_gemma":[0.00003823034,0.0003178147,0.00012777271,0.00028152988,0.00010987219,0.00020426775,0.000059993334,0.000437255,0.000034298406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032997664,0.012044924,0.94946223,0.00016457756,0.00030157124,0.0016701028,0.0011327495,0.0000010085693,0.000026125354,4.1287979e-7,0.000010829857,0.002187784],"study_design_scores_gemma":[0.11457743,0.004260099,0.879508,0.00023212633,0.000107361506,0.0000024866551,0.00005148709,0.000022919803,0.00088460924,0.0000023603784,0.000028970957,0.00032210775],"about_ca_topic_score_codex":0.00021484705,"about_ca_topic_score_gemma":0.0040118564,"teacher_disagreement_score":0.08157977,"about_ca_system_score_codex":0.0001660518,"about_ca_system_score_gemma":0.00013058409,"threshold_uncertainty_score":0.9999274},"labels":[],"label_agreement":null},{"id":"W2983600820","doi":"10.1182/blood-2019-126222","title":"Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Multiple myeloma; Minimal residual disease; Immunology; Bone marrow; Medicine; Peripheral blood mononuclear cell; Cancer; Cancer research; Immune system; Biology; Oncology; Internal medicine; In vitro","score_opus":0.0164877812982664,"score_gpt":0.28995978043999104,"score_spread":0.27347199914172465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983600820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937837,0.0007392564,0.000008100763,0.00081740855,0.00009563769,0.0016578971,0.000031871212,0.000050493385,0.0028156014],"genre_scores_gemma":[0.9909664,0.000039742947,0.0014810893,0.00009198042,0.000057784484,0.000097279844,0.00010756128,0.00002622802,0.007131935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984794,0.00008110573,0.00026475612,0.00036981894,0.00037701277,0.00042787642],"domain_scores_gemma":[0.99904436,0.000107846194,0.000052683332,0.00047646186,0.00010562947,0.00021300615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021048677,0.00014950642,0.0002939668,0.00018859231,0.000048192487,0.000023316643,0.000114641094,0.000058553916,0.000107575914],"category_scores_gemma":[0.00023874905,0.00013544339,0.00006884149,0.00027909316,0.000023759334,0.00010340088,0.000055665987,0.00014454791,0.0005779752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012065601,0.00078342634,0.81867766,0.00008769002,0.00016943531,0.00023406046,0.00054237625,0.000003928407,0.17651325,0.000046586454,0.00070033316,0.0010347042],"study_design_scores_gemma":[0.012906597,0.00010995952,0.88330024,0.00015951804,0.000022764743,0.000007705198,0.00008960273,0.000050373652,0.10078342,0.000023814515,0.0024233311,0.00012266875],"about_ca_topic_score_codex":0.0002039906,"about_ca_topic_score_gemma":0.00029345744,"teacher_disagreement_score":0.075729825,"about_ca_system_score_codex":0.0000947351,"about_ca_system_score_gemma":0.00011680574,"threshold_uncertainty_score":0.7428894},"labels":[],"label_agreement":null},{"id":"W2983609105","doi":"10.1097/01.cot.0000615272.66203.18","title":"Examining Facility &amp; Provider Influence on Multiple Myeloma Survival","year":2019,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Business; Internal medicine","score_opus":0.06086097539582779,"score_gpt":0.347162888753965,"score_spread":0.2863019133581372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983609105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93831,0.000057559097,0.000009653012,0.0005630097,0.00016068624,0.00079408125,0.000032596115,0.00009789615,0.059974518],"genre_scores_gemma":[0.96538645,0.000012143408,0.0008885453,0.0003335482,0.000055182583,0.00007321824,0.00010561308,0.000014917559,0.033130392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982837,0.00017606065,0.00023607849,0.0004682758,0.0003588108,0.00047711533],"domain_scores_gemma":[0.9980296,0.0010154448,0.00007113703,0.00051507785,0.000120360266,0.00024838626],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003243079,0.00019546473,0.00043798785,0.00011002902,0.00008252082,0.000015124806,0.00012148361,0.00018644544,0.0018732608],"category_scores_gemma":[0.0011318434,0.0001508806,0.0000719589,0.00012919924,0.00013362295,0.000097735436,0.00008990605,0.00032625534,0.00766878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012577848,0.00049321697,0.9496805,0.000067045105,0.00015501487,0.00013548743,0.00021493733,0.00002626278,0.008391938,0.000037449692,0.0015721597,0.037968222],"study_design_scores_gemma":[0.004952586,0.0018699307,0.9066646,0.000047580044,0.000028450715,0.000036773425,0.0001199616,0.00017116178,0.001654662,0.000026348083,0.08428216,0.00014577222],"about_ca_topic_score_codex":0.0001604863,"about_ca_topic_score_gemma":0.00010423676,"teacher_disagreement_score":0.08271,"about_ca_system_score_codex":0.0002651402,"about_ca_system_score_gemma":0.00031589367,"threshold_uncertainty_score":0.9990392},"labels":[],"label_agreement":null},{"id":"W2983728775","doi":"10.1182/blood-2019-128819","title":"Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Western University; Queen's University","funders":"","keywords":"Plerixafor; Medicine; Multiple myeloma; Autologous stem-cell transplantation; Regimen; Febrile neutropenia; Cyclophosphamide; Surgery; Oncology; Neutropenia; Transplantation; Internal medicine; Chemotherapy; CXCR4","score_opus":0.04005273014943504,"score_gpt":0.29195642878391476,"score_spread":0.2519036986344797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983728775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938846,0.0009091946,0.00044902725,0.00046030962,0.00014552787,0.0035179334,0.00029926037,0.00009758203,0.0002365585],"genre_scores_gemma":[0.9957294,0.00013499292,0.0026233424,0.000050535466,0.000048832597,0.00015832516,0.00055235106,0.00006987656,0.00063234917],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975258,0.000092021124,0.0007272854,0.00056730525,0.00045029056,0.0006372814],"domain_scores_gemma":[0.9982716,0.0003406094,0.00047699377,0.00041571085,0.00028142272,0.00021370673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016377571,0.0003309047,0.00081234524,0.00027644297,0.00009474953,0.000028013796,0.00014363506,0.00022407799,0.000062799176],"category_scores_gemma":[0.000084954954,0.00030648158,0.00018898539,0.0003655413,0.00006250286,0.00016762334,0.00002717813,0.00018700672,0.0000319003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004299287,0.005580021,0.8874806,0.003281879,0.00022712332,0.000098973294,0.0032271645,0.000602119,0.088516824,0.000026002288,0.00030098695,0.0063589867],"study_design_scores_gemma":[0.04185391,0.002275584,0.36845168,0.0016245592,0.00046281365,0.000043234148,0.0031585274,0.016557181,0.5637149,0.000039403716,0.001328171,0.00049000233],"about_ca_topic_score_codex":0.00015777619,"about_ca_topic_score_gemma":0.0005634003,"teacher_disagreement_score":0.51902896,"about_ca_system_score_codex":0.00018911228,"about_ca_system_score_gemma":0.0001598259,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2983745227","doi":"10.1182/blood-2019-126828","title":"Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cereblon; Pomalidomide; Lenalidomide; Multiple myeloma; Medicine; Oncology; Drug resistance; Cancer research; Internal medicine; Immunology; Biology; Genetics; Gene; Ubiquitin ligase; Ubiquitin","score_opus":0.014272729494892281,"score_gpt":0.24782498572619427,"score_spread":0.233552256231302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983745227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675786,0.00056170905,5.031212e-7,0.00010615129,0.000029491712,0.0008124212,0.000017692031,0.00002741424,0.0016867326],"genre_scores_gemma":[0.99896556,0.000121344834,0.00021761947,0.00006201039,0.00002569149,0.000033833454,0.000047915866,0.000021114161,0.00050492707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902284,0.00003773371,0.00014365416,0.0002651218,0.0002199173,0.00031071826],"domain_scores_gemma":[0.99954426,0.000021774342,0.000022454338,0.00020247734,0.0000385978,0.00017040718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040074403,0.00013127958,0.00022398055,0.00015304961,0.000021448077,0.0000121993635,0.000043256478,0.000072023424,0.00017406174],"category_scores_gemma":[0.000020430276,0.00010605458,0.000036026315,0.00015356141,0.0000248911,0.000040049,0.000019717596,0.00009826506,0.000116501746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001865039,0.0010048288,0.9806347,0.00008855754,0.00007683567,0.00012588772,0.00017524723,1.10593476e-7,0.007424796,0.0000025578936,0.000016480879,0.010263518],"study_design_scores_gemma":[0.017150097,0.0007105194,0.9732358,0.00008241969,0.000067574925,0.00002147599,0.000021694628,0.00006006256,0.008395327,0.000008560349,0.00015666102,0.00008979557],"about_ca_topic_score_codex":0.00024731384,"about_ca_topic_score_gemma":0.00010189856,"teacher_disagreement_score":0.016963592,"about_ca_system_score_codex":0.000027427417,"about_ca_system_score_gemma":0.000024361358,"threshold_uncertainty_score":0.432478},"labels":[],"label_agreement":null},{"id":"W2983814742","doi":"10.1182/blood-2019-127593","title":"Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Venetoclax; Carfilzomib; Bortezomib; Cancer research; Biology; Multiple myeloma; Somatic evolution in cancer; Oncology; Internal medicine; Medicine; Immunology; Leukemia; Cancer; Chronic lymphocytic leukemia","score_opus":0.019343761079217137,"score_gpt":0.285565816716774,"score_spread":0.26622205563755685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983814742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475116,0.0000853979,0.0000011883112,0.0001449111,0.0000630216,0.001096288,0.00007903995,0.0000115358,0.003767459],"genre_scores_gemma":[0.9981712,0.000024607974,0.0006590572,0.00012277094,0.000015643718,0.000063616004,0.00003431231,0.000017277149,0.0008915282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988782,0.00006061788,0.00021701641,0.00022500643,0.00036628067,0.00025289206],"domain_scores_gemma":[0.99922514,0.00015198877,0.000058797785,0.0003128892,0.000096085736,0.00015507745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009387207,0.00011226008,0.00021630546,0.00006939023,0.00004354351,0.000007856853,0.00009250871,0.00005191283,0.000052333267],"category_scores_gemma":[0.00027701873,0.00008026214,0.00004742992,0.00027809647,0.000060019738,0.000044697063,0.00006648894,0.00010832406,0.000074348914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021921637,0.0003414814,0.9954203,0.00007155011,0.00006950662,0.000013479668,0.00053697923,0.000010496575,0.0027303374,0.000019883151,0.00016308221,0.00040369297],"study_design_scores_gemma":[0.009317543,0.00011905271,0.981253,0.00015981632,0.000039756454,0.0000016831708,0.00012636614,0.000062846055,0.008220614,0.000031244013,0.00059465726,0.00007337708],"about_ca_topic_score_codex":0.00023287052,"about_ca_topic_score_gemma":0.000701719,"teacher_disagreement_score":0.014167251,"about_ca_system_score_codex":0.00007138125,"about_ca_system_score_gemma":0.00011993079,"threshold_uncertainty_score":0.3272995},"labels":[],"label_agreement":null},{"id":"W2983979814","doi":"10.1182/blood-2019-123652","title":"Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"CD8; Cytotoxic T cell; CD38; Tumor microenvironment; Bone marrow; Daratumumab; Cancer research; Medicine; T cell; Internal medicine; Immunology; Multiple myeloma; Immune system; Oncology; Biology; CD34; Bortezomib; Stem cell; In vitro","score_opus":0.019420840708481643,"score_gpt":0.28026496286632224,"score_spread":0.2608441221578406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983979814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978531,0.00007894924,4.934472e-7,0.0001309331,0.00001481208,0.0018006674,0.00008315531,0.000009717858,0.000028186667],"genre_scores_gemma":[0.99940246,0.00019200884,0.00012255796,0.000020625434,0.000005215148,0.000023546907,0.00015864662,0.00002326817,0.00005164279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982212,0.00035071015,0.0004901884,0.00035077747,0.00032449106,0.00026263052],"domain_scores_gemma":[0.9980367,0.0011544036,0.00032918472,0.00031848825,0.00004636555,0.000114850416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003598117,0.00021013367,0.0006540331,0.0001689334,0.000027866812,0.000009059764,0.00007393904,0.00011557981,0.0000125945],"category_scores_gemma":[0.00036751406,0.00012558962,0.00005631724,0.00023628192,0.0001651553,0.000048503025,0.0000373799,0.00019914542,0.0000021230737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024402847,0.012187752,0.9159784,0.000086009284,0.00028549283,0.00021760243,0.00026187138,0.0000040469295,0.0676771,0.0000015001659,0.0000016884909,0.00085826707],"study_design_scores_gemma":[0.064100415,0.003409574,0.900018,0.000487387,0.000160663,0.000019256979,0.00041583428,0.00075434474,0.030530103,0.0000016924496,0.000003246438,0.000099518475],"about_ca_topic_score_codex":0.0002558218,"about_ca_topic_score_gemma":0.0006415478,"teacher_disagreement_score":0.061660126,"about_ca_system_score_codex":0.0001383036,"about_ca_system_score_gemma":0.00011589786,"threshold_uncertainty_score":0.5121396},"labels":[],"label_agreement":null},{"id":"W2984217605","doi":"10.1182/blood-2019-131243","title":"Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Bone marrow; Epigenetics; Stromal cell; Multiple myeloma; Biology; Cancer research; Gene; Immunology; Genetics","score_opus":0.03152449185201439,"score_gpt":0.2724274557066791,"score_spread":0.2409029638546647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984217605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632644,0.034920774,0.000030117288,0.00007383685,0.0001241937,0.001466818,0.00006302031,0.0000132073155,0.000043619646],"genre_scores_gemma":[0.9951839,0.0010779576,0.003278634,0.0000065333916,0.00016763617,0.000074610536,0.000058810554,0.000026220563,0.00012573332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990221,0.00003204306,0.00022108795,0.00029128132,0.00015725209,0.00027620696],"domain_scores_gemma":[0.999501,0.000050486604,0.00008192998,0.00021894653,0.000043035383,0.00010461711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012453517,0.00015503979,0.0003248373,0.000089588946,0.000049813,0.000022743077,0.00005041871,0.000057370416,0.000021676506],"category_scores_gemma":[0.0000075340718,0.0001247495,0.00006585015,0.000044409564,0.00006585932,0.00004168998,0.000048022204,0.00009152318,0.000005055173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005410874,0.00062464474,0.101296045,0.0015959978,0.0004772145,0.0000066792268,0.00036756205,5.7071736e-7,0.85976326,0.00005306289,0.0000067625897,0.035267126],"study_design_scores_gemma":[0.014740802,0.0010942534,0.45667264,0.00012760003,0.00038942072,0.000050742183,0.00038556475,0.0005501921,0.5252052,0.00012698004,0.00046309707,0.00019351802],"about_ca_topic_score_codex":0.0000071219656,"about_ca_topic_score_gemma":0.0000024786068,"teacher_disagreement_score":0.35537657,"about_ca_system_score_codex":0.000012621059,"about_ca_system_score_gemma":0.00005093357,"threshold_uncertainty_score":0.50871366},"labels":[],"label_agreement":null},{"id":"W2984791646","doi":"10.1182/blood-2020-141087","title":"A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of New Brunswick; Thunder Bay Regional Research Institute; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Thunder Bay Regional Health Sciences Centre; University Health Network; Ottawa Hospital; CancerCare Manitoba; McGill University Health Centre; Juravinski Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Daratumumab; Dexamethasone; Internal medicine; Cyclophosphamide; Clinical endpoint; Regimen; Multiple myeloma; Progressive disease; Refractory (planetary science); Oncology; Surgery; Gastroenterology; Urology; Clinical trial; Chemotherapy; Biology","score_opus":0.03769247981951125,"score_gpt":0.3218313031854524,"score_spread":0.28413882336594115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984791646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917716,0.00029828143,0.0000065265644,0.00013685806,0.000011444776,0.007580238,0.00004783726,0.00003614501,0.000111098045],"genre_scores_gemma":[0.9951735,0.000056024754,0.004035659,0.00010481223,0.000016990061,0.00034427125,0.000061891544,0.0000615576,0.00014525234],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997363,0.0003824271,0.00055710616,0.0006866909,0.00059259025,0.0004182013],"domain_scores_gemma":[0.99820966,0.00040604232,0.00026585447,0.00040446175,0.00018466335,0.0005293251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043579878,0.00038370403,0.0016047109,0.00015329415,0.00013745972,0.000055574325,0.00018045574,0.000088020024,0.000031186428],"category_scores_gemma":[0.00087187055,0.00022659455,0.000028453385,0.00046551146,0.00027529756,0.0002879736,0.00029578814,0.00032227387,0.0000017948482],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48511636,0.018868452,0.49015096,0.000103337465,0.0007938153,0.0005102412,0.0018753815,4.2257523e-7,0.00040993319,8.336078e-7,0.000010399166,0.0021598758],"study_design_scores_gemma":[0.76795614,0.03074054,0.19843107,0.000296798,0.00057780143,0.000017603543,0.0006701393,0.0002701655,0.00080787885,0.0000016854545,0.000015311827,0.00021485987],"about_ca_topic_score_codex":0.0009812912,"about_ca_topic_score_gemma":0.0009036986,"teacher_disagreement_score":0.29171985,"about_ca_system_score_codex":0.0000329822,"about_ca_system_score_gemma":0.00020501217,"threshold_uncertainty_score":0.9240258},"labels":[],"label_agreement":null},{"id":"W2985072184","doi":"10.1182/blood-2019-129357","title":"Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Université de Montréal; Leukemia & Lymphoma Society of Canada; University of British Columbia; Saint John Regional Hospital; University of Ottawa; McGill University Health Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Melphalan; Multiple myeloma; Bortezomib; Busulfan; Medicine; Maintenance therapy; Oncology; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Chemotherapy","score_opus":0.02046326695381915,"score_gpt":0.27650298483389574,"score_spread":0.25603971788007657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985072184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959819,0.00006730455,0.000012366068,0.0006121499,0.000039694667,0.0026226968,0.00048350292,0.000016042517,0.00016436573],"genre_scores_gemma":[0.9987193,0.000006959443,0.00030453462,0.00011463967,0.000050519833,0.00017433606,0.00031289682,0.000022086806,0.00029475815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998628,0.00006866668,0.0002605616,0.00034814747,0.00038268615,0.0003119195],"domain_scores_gemma":[0.9987335,0.00028872295,0.0001375418,0.00021420566,0.00037739324,0.00024863513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028972796,0.00016504213,0.0002692852,0.0001572354,0.00018810338,0.00003086678,0.000075556796,0.000056177767,0.000016249189],"category_scores_gemma":[0.00048491597,0.00010814111,0.000038213377,0.00017049353,0.00010255366,0.00008543404,0.00002289863,0.00012438017,0.0000020528264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015934032,0.0009004335,0.99487954,0.00008410201,0.00044864637,0.000051662675,0.00018085909,0.000013379119,0.0011643518,0.000013151203,0.00017920468,0.0004912922],"study_design_scores_gemma":[0.075894855,0.0009930326,0.9183793,0.00019733745,0.00016798488,0.0000519984,0.00021464049,0.00030549377,0.0036302833,0.000007138833,0.00005434459,0.00010355787],"about_ca_topic_score_codex":0.012086208,"about_ca_topic_score_gemma":0.07212848,"teacher_disagreement_score":0.07650018,"about_ca_system_score_codex":0.00009068434,"about_ca_system_score_gemma":0.00044924713,"threshold_uncertainty_score":0.9944924},"labels":[],"label_agreement":null},{"id":"W2985424375","doi":"10.1182/blood-2019-125479","title":"Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University; London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; University of Ottawa; McGill University Health Centre; University of New Brunswick; Leukemia & Lymphoma Society of Canada; University of British Columbia; University of Calgary; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Lenalidomide; Carfilzomib; Medicine; Regimen; Multiple myeloma; Ixazomib; Bortezomib; Internal medicine; Thalidomide; Oncology; Surgery; Gastroenterology","score_opus":0.024710324022573435,"score_gpt":0.29131473213418857,"score_spread":0.2666044081116151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985424375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955863,0.00014165531,0.0000025447046,0.00011874907,0.000055068213,0.0013631654,0.000036816866,0.00004535781,0.0026503853],"genre_scores_gemma":[0.99783176,0.000011358721,0.0011691201,0.00003395316,0.00004325756,0.00007536844,0.00014659979,0.000029719457,0.0006588313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998634,0.00005161888,0.00023190299,0.00030366864,0.00044654214,0.00033227232],"domain_scores_gemma":[0.9989859,0.00014000403,0.00010841257,0.00045984946,0.00012157337,0.00018424718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042070904,0.00019060193,0.0003645786,0.00014145685,0.000045270303,0.000011748609,0.00005640201,0.00006762776,0.000103765764],"category_scores_gemma":[0.00007885364,0.00013206578,0.00015586973,0.00012505743,0.000048068323,0.00003638497,0.000014079372,0.000057739166,0.00019967894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017147278,0.01015063,0.9613425,0.00010090127,0.00030915727,0.0000952058,0.00008136774,0.0000045635306,0.0047365734,0.000011348386,0.000023841576,0.021429189],"study_design_scores_gemma":[0.07201205,0.010439337,0.622169,0.0002996016,0.00019898482,0.00000837963,0.000022063747,0.00042224964,0.29324448,0.0000055587057,0.0010298144,0.00014843777],"about_ca_topic_score_codex":0.000050957962,"about_ca_topic_score_gemma":0.0000043027044,"teacher_disagreement_score":0.33917347,"about_ca_system_score_codex":0.00009908758,"about_ca_system_score_gemma":0.00011926019,"threshold_uncertainty_score":0.5385486},"labels":[],"label_agreement":null},{"id":"W2985741206","doi":"10.1182/blood-2019-130251","title":"Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo","funders":"","keywords":"Medicine; Melphalan; Internal medicine; Serum protein electrophoresis; Multiple myeloma; Gastroenterology; Immunology; Monoclonal; Antibody","score_opus":0.01634477426913836,"score_gpt":0.27100696641800276,"score_spread":0.2546621921488644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985741206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628294,0.0001425771,0.0012974786,0.0001033805,0.00014561355,0.0014917573,0.00002373989,0.00010641533,0.00040607282],"genre_scores_gemma":[0.98173743,0.000002890565,0.01619143,0.00000944112,0.00021431434,0.00016640285,0.000018463219,0.00003567435,0.0016239303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988719,0.000026987713,0.00014494002,0.00027364717,0.00029549072,0.00038701444],"domain_scores_gemma":[0.99933356,0.000053017986,0.000046555313,0.00030124243,0.00008871428,0.00017692328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012631193,0.00013349058,0.00019926344,0.00018277962,0.00006845795,0.000025084108,0.00006171677,0.00009139775,0.000106665306],"category_scores_gemma":[0.00012936196,0.00011570182,0.000116726405,0.00022979367,0.000013138637,0.00006558535,0.000012371298,0.00015934947,0.00022308661],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048034525,0.00030064466,0.28168133,0.00011600374,0.00015891057,0.000039916562,0.000013451555,0.0000014575821,0.7157497,0.000005346991,0.0000028188201,0.0014500808],"study_design_scores_gemma":[0.010959731,0.0014717496,0.24566022,0.00007032564,0.00007012878,0.000004915371,0.000016334927,0.0002197603,0.7413157,0.000049206043,0.00007567809,0.0000862368],"about_ca_topic_score_codex":0.000063182975,"about_ca_topic_score_gemma":0.0000031676614,"teacher_disagreement_score":0.03602112,"about_ca_system_score_codex":0.00007868213,"about_ca_system_score_gemma":0.000064132284,"threshold_uncertainty_score":0.47181833},"labels":[],"label_agreement":null},{"id":"W2986233340","doi":"10.1016/s0140-6736(19)32684-4","title":"Incorporating isatuximab in the treatment of multiple myeloma","year":2019,"lang":"en","type":"letter","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Lenalidomide; Multiple myeloma; Dexamethasone; Internal medicine; Medicine; Refractory (planetary science); Oncology; Biology","score_opus":0.07339129836160638,"score_gpt":0.32806848887383705,"score_spread":0.2546771905122307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986233340","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18005577,0.0015289434,0.000004453326,0.8048465,0.00021519161,0.003112971,0.00032146115,0.00004183666,0.009872857],"genre_scores_gemma":[0.71846914,0.0007149951,0.0006771648,0.26503256,0.008781223,0.00043338415,0.0013859851,0.000092332746,0.0044131996],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802864,0.00030607733,0.00031890505,0.00028487074,0.00057360553,0.00048788378],"domain_scores_gemma":[0.9973669,0.0009956987,0.0001979946,0.0013625934,0.000051996893,0.000024800762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029813938,0.00028537525,0.00094851555,0.00010856815,0.000057986395,0.00002700112,0.00043152296,0.0002446411,0.000051325365],"category_scores_gemma":[0.00012901635,0.0001236911,0.00018847232,0.00020694283,0.00013175874,0.000027372436,0.000037709502,0.0007721539,0.00015817651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008857426,0.00063531054,0.13582124,0.00052713964,0.0005275456,0.0016431214,0.001769822,0.0000042124884,0.00021198456,0.000027502729,0.8425143,0.015432124],"study_design_scores_gemma":[0.01542729,0.0017787593,0.09328402,0.00038875436,0.00020123193,0.000110810135,0.00017919864,0.0005138503,0.0005644686,0.0002106189,0.887119,0.00022200907],"about_ca_topic_score_codex":0.000630957,"about_ca_topic_score_gemma":0.00011777318,"teacher_disagreement_score":0.53981394,"about_ca_system_score_codex":0.00017584846,"about_ca_system_score_gemma":0.0001412244,"threshold_uncertainty_score":0.5043977},"labels":[],"label_agreement":null},{"id":"W2986442725","doi":"10.1182/blood-2019-131981","title":"IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Venetoclax; Multiple myeloma; Chromatin; Cancer research; BRD4; Gene expression profiling; Biology; Gene; Computational biology; Gene expression; Epigenetics; Molecular biology; Genetics; Immunology; Leukemia; Bromodomain; Chronic lymphocytic leukemia","score_opus":0.015862646985682915,"score_gpt":0.26327378389975636,"score_spread":0.24741113691407346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986442725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056196,0.00055776694,0.00002016668,0.000064819134,0.000030148047,0.0011614005,0.00003376587,0.000018521849,0.007551452],"genre_scores_gemma":[0.9948281,0.00009764408,0.0030853322,0.000019176932,0.00002134469,0.00006359243,0.000029144547,0.000029529403,0.0018261013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982207,0.000059207647,0.00035120317,0.00033507284,0.00067351345,0.00036030688],"domain_scores_gemma":[0.9989039,0.00009145864,0.00014639615,0.00056576467,0.00014731979,0.00014521102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020063056,0.00017465626,0.00045926552,0.00018451919,0.000021903737,0.000004958495,0.00014793692,0.00008783603,0.00025458823],"category_scores_gemma":[0.00010309396,0.00013651914,0.00007684772,0.00027394714,0.00006237203,0.00006237374,0.00005783859,0.00015072514,0.00007421412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042281,0.0023076723,0.88015366,0.0010968139,0.0006108067,0.00095065247,0.00069424347,0.000007658807,0.10625384,0.0025822236,0.000023320576,0.0010910378],"study_design_scores_gemma":[0.035625312,0.0027368332,0.5274474,0.0012669397,0.00018883697,0.000059328675,0.000314357,0.00008473349,0.43075216,0.0010226419,0.00025557453,0.00024588115],"about_ca_topic_score_codex":0.000605712,"about_ca_topic_score_gemma":0.001002221,"teacher_disagreement_score":0.35270622,"about_ca_system_score_codex":0.00008905708,"about_ca_system_score_gemma":0.00028428802,"threshold_uncertainty_score":0.55670893},"labels":[],"label_agreement":null},{"id":"W2986907937","doi":"10.1182/blood-2019-126088","title":"Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Genome-wide association study; Single-nucleotide polymorphism; Imputation (statistics); Internal medicine; Haplotype; Oncology; Genetic association; Medicine; Multiple myeloma; Biology; Genetics; Genotype; Gene; Missing data","score_opus":0.022588753423883716,"score_gpt":0.280045564926497,"score_spread":0.2574568115026133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986907937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997117,0.00033732492,0.00006750596,0.00011735364,0.00007475985,0.0012658759,0.0005843313,0.000054099237,0.00038175634],"genre_scores_gemma":[0.9961185,0.0002307044,0.0010199295,0.000018857076,0.00025972823,0.00005650484,0.00019324306,0.000030019375,0.0020725022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998649,0.00009155279,0.00018998083,0.00031582714,0.00035037962,0.00040326413],"domain_scores_gemma":[0.998573,0.00070606725,0.00015203762,0.00024954288,0.000101269485,0.00021808808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037363992,0.00015121631,0.00033360653,0.00008189262,0.00011207979,0.00003083881,0.00005789303,0.00013009403,0.000056237906],"category_scores_gemma":[0.0009223677,0.0001258951,0.00012639297,0.0000794074,0.00001587581,0.00007411981,0.000046908055,0.00019395542,0.00010377905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024986308,0.00024254838,0.9900986,0.000062403866,0.0010819036,0.000005597117,0.000074152704,3.3070756e-7,0.0007111231,0.0000076276087,0.000111122274,0.0073547177],"study_design_scores_gemma":[0.02192473,0.0006629033,0.97302365,0.000033513832,0.0007534625,0.0000032852854,0.000022130973,0.00025587896,0.0021810825,0.0001292246,0.00089305115,0.00011708178],"about_ca_topic_score_codex":0.00060288707,"about_ca_topic_score_gemma":0.00013862667,"teacher_disagreement_score":0.021674866,"about_ca_system_score_codex":0.00007838093,"about_ca_system_score_gemma":0.00006668714,"threshold_uncertainty_score":0.5133853},"labels":[],"label_agreement":null},{"id":"W2987604528","doi":"10.1182/blood-2019-122261","title":"Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Polypharmacy; Multiple myeloma; Geriatric oncology; Prospective cohort study; Geriatrics; Activities of daily living; Physical therapy; Internal medicine; Cancer","score_opus":0.018296552407680286,"score_gpt":0.2864020806162066,"score_spread":0.2681055282085263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987604528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966584,0.0002304554,0.000007630283,0.00019751734,0.00003917708,0.0019078113,0.00002500197,0.00004088897,0.00089313],"genre_scores_gemma":[0.99677426,0.0002231444,0.0020968108,0.000059199272,0.00004583532,0.00018091657,0.00013258733,0.0000336256,0.00045360863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858975,0.00005338864,0.00016111866,0.00041906716,0.00035229183,0.00042436123],"domain_scores_gemma":[0.99910164,0.00024426024,0.00006325182,0.00031061645,0.000055447457,0.00022477219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006133115,0.00023426929,0.00035706157,0.00021477684,0.000054349377,0.000031598476,0.00004850942,0.00007712151,0.00014597834],"category_scores_gemma":[0.000034882265,0.00016001378,0.000037836457,0.00021754322,0.000027451606,0.00007984703,0.000046093613,0.0001071881,0.00003601619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003041,0.0031915647,0.981481,0.00009160677,0.00023088732,0.00018372756,0.00018363705,0.0000028104128,0.00026141558,0.000006065196,0.000010880724,0.0140522625],"study_design_scores_gemma":[0.06754478,0.0026756737,0.9278648,0.00013867872,0.00011287157,0.000009064479,0.000107359774,0.00012530183,0.0011320601,0.000004201884,0.00013690567,0.00014828998],"about_ca_topic_score_codex":0.00033372466,"about_ca_topic_score_gemma":0.0016114631,"teacher_disagreement_score":0.067240685,"about_ca_system_score_codex":0.000188324,"about_ca_system_score_gemma":0.00017855372,"threshold_uncertainty_score":0.6525172},"labels":[],"label_agreement":null},{"id":"W2987691693","doi":"10.1182/blood-2019-130733","title":"Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Autologous stem-cell transplantation; Multiple myeloma; Bortezomib; Internal medicine; Oncology; Salvage therapy; Surgery; Chemotherapy","score_opus":0.012340157504084022,"score_gpt":0.24139123968674592,"score_spread":0.2290510821826619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987691693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932233,0.0010283015,7.0482514e-7,0.00014215954,0.000017885372,0.0012843255,0.00010146993,0.000015523343,0.0041863355],"genre_scores_gemma":[0.99921316,0.00017882037,0.000045876637,0.00005991291,0.000009195839,0.00007497656,0.000054305197,0.000020697094,0.00034306519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986226,0.00013485488,0.00028320053,0.00027209,0.0003419877,0.00034526447],"domain_scores_gemma":[0.9993087,0.00011163229,0.00006475033,0.00041548302,0.000026780595,0.000072649425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010071432,0.00018123901,0.00036536096,0.00010635637,0.000020753258,0.00000774445,0.00013827306,0.000105007515,0.000067237306],"category_scores_gemma":[0.000003923158,0.00010702501,0.00010428125,0.00018237699,0.00002739698,0.000034709494,0.0000134078,0.00020713733,0.00007332097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062987936,0.005326553,0.9563849,0.00010662799,0.000118791875,0.00036028403,0.009114293,0.000004152817,0.0018858054,0.000008430184,0.0000049069054,0.026055377],"study_design_scores_gemma":[0.02812282,0.0019820717,0.9531546,0.00018026447,0.000097394746,0.000016348436,0.0002873856,0.0005472906,0.015421776,0.00005280866,0.000040339324,0.000096863914],"about_ca_topic_score_codex":0.0005702674,"about_ca_topic_score_gemma":0.00026029788,"teacher_disagreement_score":0.02749294,"about_ca_system_score_codex":0.00005961482,"about_ca_system_score_gemma":0.00008328423,"threshold_uncertainty_score":0.4364353},"labels":[],"label_agreement":null},{"id":"W2988051942","doi":"10.1182/blood-2019-126837","title":"The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Disease burden; Internal medicine; Incidence (geometry); Hematopoietic stem cell transplantation; Disease; Oncology","score_opus":0.010122058805244702,"score_gpt":0.26638751228712243,"score_spread":0.25626545348187774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988051942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384266,0.0012106762,0.00012297566,0.00007398431,0.00002189303,0.0023208088,0.0023707985,0.0000055721603,0.00003064281],"genre_scores_gemma":[0.9991444,0.00044301103,0.00015757763,0.0000055580726,0.000012804118,0.000050939063,0.00015643408,0.000008562704,0.000020751873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833393,0.00027680982,0.00048146423,0.00024318956,0.00045572218,0.00020888587],"domain_scores_gemma":[0.99842715,0.00052402617,0.0002956134,0.00048299256,0.00015148195,0.00011873902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050463836,0.00015225296,0.00047292348,0.00003604407,0.000096312855,0.000011794981,0.00016500763,0.000025375663,0.0000032926873],"category_scores_gemma":[0.000028042608,0.00007914698,0.00015386983,0.00047133357,0.0002387236,0.000068982175,0.0000294267,0.000053601685,1.2925761e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009013199,0.0012120502,0.98147047,0.0011962755,0.002423291,0.000011136699,0.0017112031,0.0006026544,0.0010740428,0.00014164654,9.65176e-7,0.0011430929],"study_design_scores_gemma":[0.028135043,0.000686258,0.94391423,0.00016768524,0.015926158,0.0000073682513,0.0012335213,0.004722703,0.004972275,0.00015179689,0.0000012528633,0.000081722144],"about_ca_topic_score_codex":0.0006182927,"about_ca_topic_score_gemma":0.0013883325,"teacher_disagreement_score":0.037556227,"about_ca_system_score_codex":0.000012156485,"about_ca_system_score_gemma":0.000089002984,"threshold_uncertainty_score":0.322752},"labels":[],"label_agreement":null},{"id":"W2988277843","doi":"10.1182/blood-2019-124349","title":"Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Pomalidomide; Bortezomib; Population; Dexamethasone; Internal medicine; Clinical endpoint; Multiple myeloma; Phases of clinical research; Surgery; Gastroenterology; Clinical trial","score_opus":0.009879637305894647,"score_gpt":0.23855475843797677,"score_spread":0.22867512113208213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988277843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453366,0.00070302124,0.000007786736,0.000033143384,0.000031212487,0.0041568656,0.00049828045,0.000014201226,0.000021802784],"genre_scores_gemma":[0.99889153,0.00015377933,0.0004428751,0.000033660122,0.000013397203,0.0001480476,0.00015569617,0.000046012727,0.00011499348],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738514,0.00025896277,0.0007479935,0.00048295478,0.00071271893,0.0004122414],"domain_scores_gemma":[0.9983834,0.00024788757,0.0003504058,0.0006363592,0.00017215159,0.00020978332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002253225,0.00034505615,0.0009391888,0.00021130852,0.000038419243,0.00001563023,0.00015451289,0.00013566317,0.00007715653],"category_scores_gemma":[0.000035498575,0.0002002275,0.00021676855,0.00042551977,0.00013619818,0.0000887876,0.000044964305,0.00021766525,0.0000024361123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26041377,0.017752936,0.6778297,0.0002753649,0.0011175316,0.0001692384,0.0015265773,0.000019845935,0.027354969,1.7408968e-7,0.000005973774,0.013533934],"study_design_scores_gemma":[0.49186844,0.007969355,0.22457469,0.00032511703,0.0005924334,0.0000041282096,0.00009702267,0.00034649178,0.27400833,5.493449e-7,0.000010514646,0.00020290623],"about_ca_topic_score_codex":0.0003338195,"about_ca_topic_score_gemma":0.00007606987,"teacher_disagreement_score":0.453255,"about_ca_system_score_codex":0.000049515245,"about_ca_system_score_gemma":0.00012319375,"threshold_uncertainty_score":0.81650406},"labels":[],"label_agreement":null},{"id":"W2988589642","doi":"10.1182/blood-2019-124191","title":"Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Progression-free survival; Meta-analysis; Multiple myeloma; Transplantation; Surrogate endpoint; Overall survival; Confidence interval","score_opus":0.13571165768311683,"score_gpt":0.377394655627346,"score_spread":0.24168299794422915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988589642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972489,0.0004880794,0.00000555812,0.0006952459,0.000044968136,0.00081564684,0.000047650057,0.000029251049,0.0006246987],"genre_scores_gemma":[0.9970801,0.000047616526,0.00006376001,0.00006151969,0.000056780034,0.00005991217,0.00008753875,0.000018051473,0.0025247624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982785,0.00020489926,0.00030130206,0.0002948975,0.00056506466,0.00035535582],"domain_scores_gemma":[0.9982422,0.0010664153,0.00012307767,0.0003560275,0.00007781334,0.00013448484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005084826,0.00019113571,0.00079275283,0.00011603999,0.00006710591,0.000049994273,0.00010614475,0.00010292745,0.00020231889],"category_scores_gemma":[0.00051197695,0.00010313933,0.00022781888,0.00015509222,0.000035768335,0.00008289533,0.00006916941,0.00020358161,0.00010257554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005250839,0.00031931323,0.98897165,0.00003119761,0.008330932,0.000043474414,0.00011827503,3.0278738e-7,0.001275327,0.0000070027013,0.000006960238,0.00084305124],"study_design_scores_gemma":[0.009343874,0.00015513091,0.9813893,0.000011436486,0.003711023,0.000004629463,0.000060209382,0.000014127526,0.0051625664,0.000016381304,0.000033014177,0.00009832947],"about_ca_topic_score_codex":0.00040630074,"about_ca_topic_score_gemma":0.0006074605,"teacher_disagreement_score":0.009291366,"about_ca_system_score_codex":0.000059206195,"about_ca_system_score_gemma":0.000048804566,"threshold_uncertainty_score":0.42059},"labels":[],"label_agreement":null},{"id":"W2988753938","doi":"10.14740/jmc3382","title":"Relapsing Cutaneous Multiple Myeloma Responding to Immunochemotherapy: A Rare Case Report","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Rash; Biopsy; Autologous stem-cell transplantation; Malignancy; Skin biopsy; Surgery; Dermatology; Radiology; Pathology; Internal medicine","score_opus":0.03049996182634801,"score_gpt":0.350888575993366,"score_spread":0.32038861416701797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988753938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105746,0.0010824541,0.00017439538,0.0063369763,0.0004368858,0.00038612678,0.000007237336,0.000024115165,0.000494331],"genre_scores_gemma":[0.9927704,0.0001607139,0.0031758754,0.0007867009,0.0004639394,0.000004141435,0.0000071745912,0.000036966045,0.0025941306],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99644554,0.00012538747,0.0007807705,0.00023585375,0.0019959165,0.00041652352],"domain_scores_gemma":[0.9968304,0.001025005,0.00029146933,0.00038512773,0.00032682248,0.0011411591],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011057202,0.00018697036,0.000574157,0.000677008,0.000096820935,0.000043712334,0.00017189152,0.00017568057,0.00196718],"category_scores_gemma":[0.0072693313,0.00013051975,0.0002538122,0.0004783186,0.00005805834,0.00011406368,0.00008357171,0.0006368734,0.00010657878],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040151267,0.00026378332,0.029308299,0.00008274173,0.00024470108,0.9178211,0.0002791718,0.0000027416052,0.0053107794,0.0000060485886,0.003539641,0.039125837],"study_design_scores_gemma":[0.0048691924,0.0021220392,0.0017161078,0.0012312036,0.00006204767,0.96348476,0.0007771528,0.00036586466,0.003522724,0.000009945079,0.021716807,0.0001221651],"about_ca_topic_score_codex":0.00012801816,"about_ca_topic_score_gemma":0.000018999099,"teacher_disagreement_score":0.04566362,"about_ca_system_score_codex":0.00025945948,"about_ca_system_score_gemma":0.00065204693,"threshold_uncertainty_score":0.9989452},"labels":[],"label_agreement":null},{"id":"W2988868939","doi":"10.1182/blood-2019-128769","title":"First Review of Multiple Myeloma Patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Abu dhabi; Medicine; Incidence (geometry); Multiple myeloma; Demography; Internal medicine; Pathology; Metropolitan area","score_opus":0.02189552262397528,"score_gpt":0.2940192232792801,"score_spread":0.27212370065530483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988868939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922406,0.0036063606,0.0000013431019,0.00059047056,0.000064313565,0.0012919361,0.000056503937,0.000034076802,0.002114373],"genre_scores_gemma":[0.9920717,0.006344064,0.00020994229,0.0005286018,0.000040800373,0.00006360646,0.00045253735,0.000026370131,0.00026239714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975666,0.000105711,0.0005554103,0.00034172097,0.001009079,0.00042149064],"domain_scores_gemma":[0.9984709,0.0003107779,0.00012267726,0.00049597805,0.0002376154,0.000362031],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037033457,0.0002079363,0.0006059548,0.0002606024,0.00003184701,0.00000721985,0.00021164256,0.00014958114,0.0016950942],"category_scores_gemma":[0.0018031265,0.00015909405,0.00013155614,0.00061959267,0.00007966131,0.00006896366,0.00013672563,0.00028275198,0.0002187059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001428027,0.0029083563,0.9902079,0.0040434846,0.00015608768,0.00013383529,0.00006069824,2.4079344e-7,0.00008014816,0.000009818709,0.00048681308,0.001769788],"study_design_scores_gemma":[0.020128537,0.00072755554,0.96071947,0.012743034,0.00010467207,0.000024054796,0.000020180789,0.00033407006,0.002261374,0.000013521965,0.0027556291,0.00016789766],"about_ca_topic_score_codex":0.0006098833,"about_ca_topic_score_gemma":0.00026629918,"teacher_disagreement_score":0.029488454,"about_ca_system_score_codex":0.00005175679,"about_ca_system_score_gemma":0.0001616048,"threshold_uncertainty_score":0.9992175},"labels":[],"label_agreement":null},{"id":"W2989077172","doi":"10.1182/blood-2019-123426","title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Daratumumab; Hazard ratio; Multiple myeloma; Transplantation; Oncology; Surgery; Confidence interval","score_opus":0.016260619452254294,"score_gpt":0.2651019646184587,"score_spread":0.2488413451662044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989077172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570733,0.0008130286,0.0001781258,0.00010525305,0.00004970975,0.0023974814,0.00056150503,0.000040524727,0.00014700927],"genre_scores_gemma":[0.9923289,0.00026053813,0.005880533,0.000041282972,0.000026646117,0.00015096024,0.0011656873,0.00006041548,0.00008503653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971304,0.00014917384,0.0006191164,0.00079012953,0.00060414325,0.00070702395],"domain_scores_gemma":[0.9973503,0.0012135194,0.00023011502,0.0005585324,0.00024704402,0.0004005023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038881495,0.00044099122,0.0013777113,0.0008971597,0.000091048736,0.000044270782,0.00015230494,0.00020154502,0.000078632074],"category_scores_gemma":[0.00033983582,0.00034733771,0.00017643986,0.0011525397,0.00017365879,0.00021094923,0.00006690031,0.00025959002,0.0000064592064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044307727,0.0014595218,0.94362146,0.0003014831,0.004955048,0.0001148017,0.0005794785,0.00009956436,0.0023208144,0.0000122480515,0.00003286713,0.0021949667],"study_design_scores_gemma":[0.22076568,0.002300617,0.75769645,0.00024822954,0.0039124344,0.000008896505,0.00020444674,0.003277801,0.011146661,0.000007633015,0.00008158599,0.00034955592],"about_ca_topic_score_codex":0.0012924501,"about_ca_topic_score_gemma":0.0019688876,"teacher_disagreement_score":0.18592502,"about_ca_system_score_codex":0.000095750154,"about_ca_system_score_gemma":0.00015496576,"threshold_uncertainty_score":0.99989784},"labels":[],"label_agreement":null},{"id":"W2989272704","doi":"10.1182/blood.v128.22.1184.1184","title":"Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Lenalidomide; Transplantation; Cohort; Surgery; Stem cell; Oncology; Internal medicine","score_opus":0.026623454237661694,"score_gpt":0.2763678617771729,"score_spread":0.2497444075395112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989272704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397695,0.00009151725,0.002196531,0.000051862087,0.000034878187,0.0016685957,0.0018318298,0.00004679744,0.0001010199],"genre_scores_gemma":[0.9943875,0.000047450514,0.0042994125,0.000030099674,0.000015123905,0.00037968723,0.0002643378,0.000030263485,0.00054613134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981346,0.000090640206,0.0005101188,0.00044810586,0.00032559808,0.0004909159],"domain_scores_gemma":[0.9987988,0.0003069976,0.00016053667,0.00033667235,0.00020108357,0.00019595027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016120252,0.00023206319,0.00068841496,0.0005041548,0.00005714618,0.000010106667,0.00012247128,0.00016167978,0.00010029772],"category_scores_gemma":[0.00006094543,0.00016453961,0.0002789582,0.00040735689,0.00008616951,0.00010618978,0.000019960302,0.00008862053,0.0000039486913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047600446,0.0066900626,0.8636521,0.0005311352,0.005421382,0.00024531974,0.0016512189,0.00020388718,0.07190796,0.000016292493,0.00005330848,0.044867277],"study_design_scores_gemma":[0.073895656,0.0018115981,0.75451964,0.00017879279,0.00527501,0.000023268247,0.00010654841,0.05147107,0.11233795,0.000018037981,0.000030587034,0.00033183827],"about_ca_topic_score_codex":0.00008092549,"about_ca_topic_score_gemma":0.0010628157,"teacher_disagreement_score":0.109132476,"about_ca_system_score_codex":0.00009826262,"about_ca_system_score_gemma":0.0001471985,"threshold_uncertainty_score":0.67097306},"labels":[],"label_agreement":null},{"id":"W2989326485","doi":"10.1182/blood-2019-129430","title":"Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of p53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"XIAP; Cancer research; Mdm2; Downregulation and upregulation; Multiple myeloma; Apoptosis; Inhibitor of apoptosis; Cancer; Oncogene; Bone marrow; Bortezomib; Biology; Cancer cell; Medicine; Immunology; Cell cycle; Programmed cell death; Caspase; Internal medicine","score_opus":0.013879027734276525,"score_gpt":0.2652097219441933,"score_spread":0.25133069420991677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989326485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975966,0.000113659575,0.000017596913,0.00014205152,0.000034660996,0.0017984961,0.0001225607,0.000028623794,0.00014572096],"genre_scores_gemma":[0.99890774,0.000016517526,0.00037813303,0.000041651936,0.000029360273,0.00006060761,0.0004468525,0.000025520229,0.000093617666],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983283,0.00016662954,0.00039384537,0.00032822374,0.00047871072,0.0003042333],"domain_scores_gemma":[0.9988555,0.00045286684,0.00018967953,0.00020783074,0.0001655717,0.00012858401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020980973,0.00019802486,0.0005533198,0.0001789883,0.000034845667,0.000009647557,0.00004723637,0.00017456815,0.000021537542],"category_scores_gemma":[0.0008824003,0.00016649526,0.000054476517,0.0004315506,0.000060636627,0.00018992306,0.000050089588,0.00014826733,0.000012662819],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003858303,0.0010616856,0.4152546,0.00015016829,0.00013385387,0.000009527445,0.0008033037,0.0000037054472,0.5817433,0.000011195616,0.000059978527,0.0003828567],"study_design_scores_gemma":[0.010930223,0.0008825682,0.49933997,0.0002538273,0.000030440311,0.0000019028591,0.00005718995,0.00021488269,0.48819292,0.00000853112,0.00001086977,0.00007668181],"about_ca_topic_score_codex":0.0003228192,"about_ca_topic_score_gemma":0.00007328639,"teacher_disagreement_score":0.09355038,"about_ca_system_score_codex":0.00007393038,"about_ca_system_score_gemma":0.00010189303,"threshold_uncertainty_score":0.678948},"labels":[],"label_agreement":null},{"id":"W2989404845","doi":"10.1182/blood-2019-128917","title":"Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"microRNA; SKP2; Bortezomib; Apoptosis; Cancer research; Multiple myeloma; Cell cycle; Drug resistance; Downregulation and upregulation; Cell cycle checkpoint; Medicine; Biology; Internal medicine; Gene; Ubiquitin; Genetics","score_opus":0.011484384534491441,"score_gpt":0.2529445803804797,"score_spread":0.24146019584598824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989404845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955576,0.0023759173,8.1011666e-7,0.00011778092,0.000024467921,0.0005695977,0.00006606341,0.000019735435,0.001268006],"genre_scores_gemma":[0.9978005,0.00024334776,0.001378516,0.000021149572,0.000023322811,0.00002428236,0.00004114877,0.00002260889,0.00044510377],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986354,0.0000591798,0.00028729494,0.00037783236,0.0003205717,0.00031970805],"domain_scores_gemma":[0.99913144,0.00024444188,0.000119288685,0.00028871605,0.000039085407,0.00017703221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013156427,0.00018297802,0.0003826747,0.000118276505,0.000058360652,0.000022271122,0.000067830566,0.000112833404,0.000036600166],"category_scores_gemma":[0.00010908553,0.00015015875,0.00004037821,0.00014407745,0.00007857679,0.00014512484,0.0000985411,0.00015885648,0.0000054696748],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002803512,0.0004780303,0.4897083,0.0003155241,0.00004123437,0.000005876176,0.00022696363,5.4853956e-7,0.50809187,0.0000061794167,0.00011784708,0.00072725007],"study_design_scores_gemma":[0.010983615,0.0001662519,0.5727555,0.0005551126,0.000033834185,0.0000029194016,0.00017758607,0.000109416666,0.41493255,0.000043996544,0.00011455154,0.00012466239],"about_ca_topic_score_codex":0.0004693826,"about_ca_topic_score_gemma":0.00009741645,"teacher_disagreement_score":0.09315935,"about_ca_system_score_codex":0.000023142307,"about_ca_system_score_gemma":0.000035247518,"threshold_uncertainty_score":0.6123296},"labels":[],"label_agreement":null},{"id":"W2989436630","doi":"10.1182/blood-2019-122501","title":"Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Subgroup analysis; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Confidence interval","score_opus":0.0251781818217981,"score_gpt":0.3245696725637161,"score_spread":0.299391490741918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989436630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991524,0.0000585915,0.000009026978,0.0000116580695,0.00012238105,0.007371832,0.00016947728,0.000025150477,0.0007078893],"genre_scores_gemma":[0.9982755,0.00004826357,0.00044602423,0.000007591446,0.00002528766,0.00023554069,0.0006685076,0.000049511767,0.00024373364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960959,0.00043110785,0.0011344312,0.0007123158,0.0011186844,0.00050756935],"domain_scores_gemma":[0.99689716,0.000714886,0.00063570373,0.0009845291,0.00048300112,0.00028470982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057581393,0.00039595057,0.0021890474,0.0006993201,0.00009305779,0.000052990334,0.00038403476,0.00018213135,0.00021713556],"category_scores_gemma":[0.00047086907,0.00029821714,0.00014774932,0.0014451548,0.00015854572,0.00023984184,0.00015970379,0.00035798483,0.000016806254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60126096,0.06955839,0.3172153,0.00013210686,0.0065900423,0.001089166,0.0008043184,0.000003789511,0.001979008,0.0000038676367,0.000007008698,0.0013560419],"study_design_scores_gemma":[0.78732926,0.06641691,0.13712929,0.00014037795,0.0046503446,0.000018490095,0.0003654703,0.0017926649,0.0018837918,0.0000010556313,0.000011800723,0.00026052934],"about_ca_topic_score_codex":0.0021569207,"about_ca_topic_score_gemma":0.0070766006,"teacher_disagreement_score":0.1860683,"about_ca_system_score_codex":0.00018154648,"about_ca_system_score_gemma":0.0005770496,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W2989629378","doi":"10.1182/blood-2019-123636","title":"Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Saskatchewan Cancer Agency; McGill University; Royal Victoria Hospital","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Melphalan; Bortezomib; Oncology; Autologous stem-cell transplantation; Progression-free survival; Thalidomide; Ixazomib; Hazard ratio; Daratumumab; Transplantation; Surgery; Chemotherapy; Carfilzomib; Confidence interval","score_opus":0.031122734644931028,"score_gpt":0.3019089109276732,"score_spread":0.27078617628274215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989629378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520224,0.000990579,0.000007772101,0.0001987055,0.000024163515,0.0024559859,0.0006421376,0.000011250201,0.00046714186],"genre_scores_gemma":[0.9983678,0.0003565735,0.00035572497,0.00004104733,0.000037170204,0.0002572274,0.0004992836,0.000016188207,0.00006900151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820656,0.00032392863,0.0003132687,0.0004398435,0.00030964412,0.00040674623],"domain_scores_gemma":[0.99675065,0.0021872441,0.00008713725,0.00059648766,0.000071501905,0.00030700417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035352216,0.00021178642,0.0006813544,0.00041123477,0.000053079984,0.000024732508,0.00010520999,0.00009922242,0.000041633673],"category_scores_gemma":[0.00037807104,0.00013590408,0.00017045747,0.00066311326,0.000066734625,0.000051655217,0.000015764139,0.00010477533,0.000019351539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029716836,0.0015618061,0.97980833,0.000026329546,0.0024977466,0.0008373355,0.0018319964,0.00006982716,0.0011407832,0.0000053016593,0.000007446389,0.009241433],"study_design_scores_gemma":[0.06596119,0.00088149245,0.92385197,0.000060865284,0.0012952894,0.000009440384,0.00040558403,0.0012466143,0.005806138,0.000009325571,0.00036293874,0.000109170884],"about_ca_topic_score_codex":0.5623028,"about_ca_topic_score_gemma":0.45276242,"teacher_disagreement_score":0.10954042,"about_ca_system_score_codex":0.00026915994,"about_ca_system_score_gemma":0.00032233156,"threshold_uncertainty_score":0.5572232},"labels":[],"label_agreement":null},{"id":"W2989825979","doi":"10.1001/jamaoncol.2019.5098","title":"<i>Listeria</i> Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy","year":2019,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Daratumumab; Listeria; Multiple myeloma; Listeria monocytogenes; Oncology; Internal medicine; MEDLINE; Bortezomib","score_opus":0.019006791030601954,"score_gpt":0.2983351776100454,"score_spread":0.2793283865794435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989825979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913629,0.000045638168,0.0000110436895,0.0009146531,0.0001640048,0.0018159566,0.000025516565,0.000055202257,0.005605048],"genre_scores_gemma":[0.99691844,0.0000106545995,0.0014159428,0.0009361411,0.000057446578,0.00009665284,0.00022499177,0.00003444212,0.000305272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979571,0.00026934108,0.00031824937,0.0005228251,0.0003813568,0.00055111054],"domain_scores_gemma":[0.99847865,0.0004046349,0.00011109522,0.0005886781,0.00020257379,0.00021437238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000342964,0.00022368951,0.00053556816,0.0001766955,0.00005724132,0.000025343243,0.00013744073,0.00022450801,0.00061760336],"category_scores_gemma":[0.00022626873,0.00015782543,0.000076186385,0.0002833838,0.00011211661,0.0001391515,0.000049645587,0.00037493245,0.00022050108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013093088,0.0018421792,0.91566205,0.000052113428,0.000057075897,0.00009724601,0.000139524,0.000009226432,0.0014385405,0.000003745506,0.00023835682,0.06736684],"study_design_scores_gemma":[0.045478087,0.005736723,0.9373704,0.000078531324,0.000009785413,0.0000045846123,0.000050521307,0.00045980318,0.0010764058,0.000006720847,0.009584305,0.00014411696],"about_ca_topic_score_codex":0.00035371364,"about_ca_topic_score_gemma":0.0012619213,"teacher_disagreement_score":0.067222714,"about_ca_system_score_codex":0.00060290267,"about_ca_system_score_gemma":0.0003886741,"threshold_uncertainty_score":0.6762324},"labels":[],"label_agreement":null},{"id":"W2990635370","doi":"10.1182/blood-2019-121672","title":"Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Cohort; Population; Thalidomide; Clinical trial; Bortezomib; Retrospective cohort study; Diagnosis code; Pediatrics; Internal medicine","score_opus":0.015836852575690806,"score_gpt":0.2602950482790833,"score_spread":0.24445819570339247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990635370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944351,0.000225433,0.0000035110722,0.00016026823,0.00005229272,0.0018437786,0.00018960502,0.000034818037,0.0030552365],"genre_scores_gemma":[0.9960365,0.0000824519,0.0015608777,0.000062760286,0.00004654533,0.00010355193,0.00043665298,0.000037616457,0.0016330382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809366,0.0000519466,0.00026671056,0.0004824276,0.00060956914,0.0004956545],"domain_scores_gemma":[0.9979472,0.00031854055,0.00011774277,0.00078483357,0.00019899517,0.00063267007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006942187,0.00024084629,0.00044047824,0.00019629468,0.000060771876,0.000019799125,0.00014160803,0.00008541538,0.0004969679],"category_scores_gemma":[0.00013571426,0.00017678551,0.00008653925,0.00027978903,0.0000719817,0.00010737551,0.000037967115,0.00015035034,0.00014994407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006064797,0.0013479358,0.99506867,0.000062103456,0.000842563,0.00038418945,0.00014730281,0.000002292628,0.00018748849,0.000004532648,0.00025007024,0.0010963889],"study_design_scores_gemma":[0.021363365,0.0006799058,0.97294056,0.0006974153,0.00036299916,0.0000037985553,0.000054543747,0.00003913678,0.0035903829,0.0000047507156,0.00010884461,0.00015430964],"about_ca_topic_score_codex":0.48487177,"about_ca_topic_score_gemma":0.3793254,"teacher_disagreement_score":0.10554638,"about_ca_system_score_codex":0.00028726517,"about_ca_system_score_gemma":0.0007433838,"threshold_uncertainty_score":0.72091043},"labels":[],"label_agreement":null},{"id":"W2990707530","doi":"10.1182/blood-2019-124407","title":"First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Venetoclax; Bortezomib; Tolerability; Internal medicine; Ven; Regimen; Oncology; Proteasome inhibitor; Lenalidomide; Dexamethasone; Carfilzomib; Combination therapy; Phases of clinical research; Multiple myeloma; Pharmacology; Clinical trial; Adverse effect; Leukemia; Chronic lymphocytic leukemia","score_opus":0.0109241296040956,"score_gpt":0.26254022716365166,"score_spread":0.25161609755955605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990707530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979174,0.00010187792,0.00000636835,0.00000893699,0.00000924895,0.0018218416,0.000055457807,0.000012387592,0.00006646979],"genre_scores_gemma":[0.99911886,0.000009588156,0.00046407268,0.0000059665726,0.000004979788,0.00007818066,0.00027283368,0.00002141713,0.000024090923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984496,0.00009903709,0.0002996717,0.00041658367,0.0004952679,0.0002398129],"domain_scores_gemma":[0.9990125,0.00020304396,0.00014064285,0.00040994846,0.00011037415,0.00012353252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012393242,0.00018284081,0.000564294,0.0005417096,0.00003110202,0.0000131621555,0.00007020678,0.00006819102,0.00003985688],"category_scores_gemma":[0.000077234894,0.00013353417,0.000031925545,0.0008629572,0.000044100798,0.0001313792,0.00003649242,0.00019807747,0.000003771615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061240555,0.020056512,0.9699119,0.000039623923,0.0012331206,0.00012429376,0.0011708714,0.000054281205,0.000083941966,8.1817103e-7,9.606898e-7,0.0011996357],"study_design_scores_gemma":[0.16061865,0.0095006265,0.8270046,0.00011548846,0.0005760766,7.6434054e-7,0.00041117176,0.0014262256,0.0002314257,0.000002006269,0.000004725135,0.00010824702],"about_ca_topic_score_codex":0.003984956,"about_ca_topic_score_gemma":0.010128103,"teacher_disagreement_score":0.15449458,"about_ca_system_score_codex":0.00011267689,"about_ca_system_score_gemma":0.00008942974,"threshold_uncertainty_score":0.60240877},"labels":[],"label_agreement":null},{"id":"W2991484933","doi":"10.1097/mnm.0000000000001113","title":"Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders","year":2019,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University Health Network; Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Organomegaly; Plasma cell; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Radiology; Nuclear medicine; Plasmacytoma; Retrospective cohort study; Polyneuropathy; Internal medicine; Monoclonal; Monoclonal antibody","score_opus":0.01955256992762253,"score_gpt":0.3091234988343773,"score_spread":0.28957092890675473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991484933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96580285,0.00016050572,0.0000011464083,0.0011574122,0.000010299985,0.001059309,0.000017957962,0.00001014978,0.03178037],"genre_scores_gemma":[0.9977696,0.0007458997,0.0011603921,0.000040512004,0.0000031874442,0.00002136782,0.00013496072,0.000020567444,0.00010349204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988832,0.00011101477,0.00027483737,0.00012797365,0.0004246453,0.00017834491],"domain_scores_gemma":[0.9978029,0.00017751943,0.00012721184,0.0017258463,0.000095575364,0.000070960275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019584273,0.00011775314,0.000272815,0.00014769832,0.00004814821,0.0000027877782,0.00054480217,0.000006956504,0.00034784447],"category_scores_gemma":[0.000022393442,0.000063669184,0.00006975428,0.0003759696,0.00025207663,0.000049126684,0.00014367743,0.0002114909,0.00004098819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065845443,0.003460816,0.9847555,0.00030106513,0.000387709,0.000021550573,0.0012538974,0.000018142475,0.00013796252,0.0006535646,0.0006637428,0.007687554],"study_design_scores_gemma":[0.007966081,0.0016290171,0.9859148,0.00030618976,0.00010913654,0.000007396421,0.0014712478,0.00060008874,0.000009661641,0.000025395539,0.0019048827,0.00005604924],"about_ca_topic_score_codex":0.0005599043,"about_ca_topic_score_gemma":0.00006151633,"teacher_disagreement_score":0.031966772,"about_ca_system_score_codex":0.00007394196,"about_ca_system_score_gemma":0.00004098343,"threshold_uncertainty_score":0.3808653},"labels":[],"label_agreement":null},{"id":"W2991977565","doi":"10.1182/blood.v106.11.2932.2932","title":"Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Etoposide; Autologous stem-cell transplantation; Chemotherapy; Melphalan; Transplantation; Surgery; Cyclophosphamide; Gastroenterology; Urology; Oncology","score_opus":0.019727672655474603,"score_gpt":0.2706630612648186,"score_spread":0.250935388609344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991977565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967548,0.000036260484,0.00035675292,0.00030958455,0.00019756508,0.0019179106,0.00029184902,0.00007590824,0.000059350714],"genre_scores_gemma":[0.99670225,0.00004544897,0.001903878,0.0001610469,0.00014095088,0.00016515514,0.0002428225,0.00004327169,0.00059519516],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840975,0.00006658638,0.0004098161,0.00037219367,0.00035684553,0.00038483832],"domain_scores_gemma":[0.9983497,0.0003828261,0.00021103186,0.00023881717,0.0005663554,0.0002512676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015214142,0.00023629752,0.0004275757,0.00016710661,0.0000962333,0.000016417263,0.00008742109,0.00011643374,0.0000412396],"category_scores_gemma":[0.00023853985,0.00015889066,0.00015013535,0.00012407066,0.00007119782,0.00014121682,0.000016405706,0.00013193543,0.0000070468373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028487602,0.015390538,0.3258837,0.0018493755,0.0016147872,0.00020507484,0.0048724962,0.0000087189555,0.29746574,0.000034074084,0.000109494424,0.3240784],"study_design_scores_gemma":[0.053627186,0.0029600868,0.2136623,0.00015165286,0.00032495736,0.000021802343,0.00077856105,0.0013563349,0.7267577,0.000007026598,0.0001473264,0.00020504721],"about_ca_topic_score_codex":0.00012697013,"about_ca_topic_score_gemma":0.00048892776,"teacher_disagreement_score":0.42929196,"about_ca_system_score_codex":0.00010112805,"about_ca_system_score_gemma":0.00024862113,"threshold_uncertainty_score":0.6479373},"labels":[],"label_agreement":null},{"id":"W2993477374","doi":"10.1136/bcr-2019-232233","title":"CD138-negative plasma cell myeloma: a diagnostic challenge and a unique entity","year":2019,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Plasma Cell Myeloma; Medicine; Plasma cell; Mantle cell lymphoma; Immunophenotyping; Pathology; Lymphoma; Multiple myeloma; Lymphoproliferative disorders; CD20; Cancer research; Flow cytometry; Immunology; Bone marrow","score_opus":0.024219653152592613,"score_gpt":0.31551249189217556,"score_spread":0.29129283873958295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993477374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98196644,0.0003294412,0.0000101639935,0.00033303426,0.00011789769,0.0022782711,0.000011405979,0.00006147142,0.014891864],"genre_scores_gemma":[0.99583364,0.00020737793,0.00052120956,0.000038319642,0.00007707132,0.00019562712,0.000029657103,0.000028462948,0.0030686343],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.998349,0.00008250097,0.00034974338,0.00048593577,0.00036617456,0.00036663987],"domain_scores_gemma":[0.9981934,0.00054736086,0.00016829469,0.00054047914,0.0001348233,0.0004156385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003201216,0.00020387252,0.00037740974,0.00012389821,0.000081499,0.000027535143,0.00001989181,0.000111984366,0.00035914168],"category_scores_gemma":[0.0010343025,0.0001647622,0.000090218724,0.0001256308,0.00007086223,0.000104826606,0.00009967312,0.00021230883,0.00016570343],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016542134,0.00047739447,0.09213946,0.0003820026,0.00014245026,0.89984566,0.00043596007,8.888445e-7,0.00047091016,0.000025044652,0.00032356475,0.005591241],"study_design_scores_gemma":[0.0067109214,0.0016121041,0.11185227,0.0004663606,0.00027298002,0.85526675,0.00068327045,0.0007631909,0.016811408,0.0004402993,0.0046330383,0.0004873982],"about_ca_topic_score_codex":0.0006640223,"about_ca_topic_score_gemma":0.00023305809,"teacher_disagreement_score":0.04457891,"about_ca_system_score_codex":0.00012132239,"about_ca_system_score_gemma":0.00024644082,"threshold_uncertainty_score":0.6718808},"labels":[],"label_agreement":null},{"id":"W2994201103","doi":"10.1182/blood.v106.11.3474.3474","title":"Hematologic Profiles in the Phase 3 APEX Trial.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Adverse effect; Internal medicine; Multiple myeloma; Anemia; Dexamethasone; Bortezomib; Phases of clinical research; Gastroenterology; Placebo; Refractory (planetary science); Clinical trial; Surgery; Toxicity; Pathology","score_opus":0.05441622732473057,"score_gpt":0.37136239892328415,"score_spread":0.3169461715985536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994201103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880845,0.00048091437,0.0000025832867,0.0022967656,0.000013513607,0.0010812258,0.0000050032772,0.000025611696,0.007285932],"genre_scores_gemma":[0.9983635,0.000038383354,0.00056800497,0.00024926188,0.0001646994,0.00019806817,0.000023439046,0.000005866492,0.00038880977],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992505,0.000064713364,0.00013422385,0.0001276949,0.00021174192,0.0002111756],"domain_scores_gemma":[0.99959207,0.000092229755,0.000021968046,0.00021584445,0.000016294762,0.00006160617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019013438,0.00007291895,0.00014806545,0.000055538418,0.000034760833,0.000012197875,0.00008176987,0.000037516555,0.00018634164],"category_scores_gemma":[0.00018379287,0.000038153332,0.000049258055,0.00012191812,0.000029625604,0.000030780426,0.00001441519,0.00011319071,0.00020714109],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.100880414,0.217671,0.26269302,0.0006656071,0.0015616055,0.0136571005,0.005168821,0.000002731446,0.024402538,0.004574398,0.020017566,0.3487052],"study_design_scores_gemma":[0.89987594,0.004181192,0.02478349,0.00009971232,0.00023150482,0.00066476775,0.00045093606,0.00023796296,0.04764998,0.00024367153,0.021376533,0.0002043226],"about_ca_topic_score_codex":0.000016697875,"about_ca_topic_score_gemma":0.00001618597,"teacher_disagreement_score":0.7989955,"about_ca_system_score_codex":0.00001305827,"about_ca_system_score_gemma":0.000045993183,"threshold_uncertainty_score":0.26624486},"labels":[],"label_agreement":null},{"id":"W2995934717","doi":"10.1016/s1470-2045(19)30788-0","title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":796,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Institute for Health and Care Research; Seattle Genetics; GlaxoSmithKline; U.S. Department of Veterans Affairs","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Multiple myeloma; Discontinuation; Toxicity; Phases of clinical research; Gastroenterology; Oncology; Surgery","score_opus":0.13348396835885917,"score_gpt":0.452415809330682,"score_spread":0.3189318409718228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995934717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739405,0.00021224761,0.0000599618,0.0030332715,0.00044117865,0.014781623,0.00014120099,0.00011386939,0.0072761723],"genre_scores_gemma":[0.98233926,0.00012009984,0.0025472913,0.0013065193,0.0006666297,0.0020880757,0.00019551253,0.00007420656,0.010662379],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967175,0.0007683425,0.0005537908,0.0006408391,0.00038194508,0.0009375958],"domain_scores_gemma":[0.9951255,0.0029768925,0.000262796,0.0011596489,0.0001828193,0.00029236518],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020201295,0.0003414265,0.0014971438,0.0001237246,0.00026102524,0.000059110902,0.0007875013,0.00016301348,0.0010452389],"category_scores_gemma":[0.0010886728,0.00019011334,0.00011135524,0.00024328,0.00013800137,0.00013805705,0.00036059742,0.0005302013,0.0006059409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.757389,0.027109876,0.039715745,0.00021782493,0.0020562322,0.0013086526,0.0017324876,0.000004224663,0.014622511,0.00016127198,0.019302985,0.13637915],"study_design_scores_gemma":[0.8422973,0.037394945,0.0085075665,0.000074395684,0.00041335294,0.00025021945,0.0009601491,0.0017731392,0.0008759734,0.000087758635,0.10708819,0.00027699806],"about_ca_topic_score_codex":0.000351167,"about_ca_topic_score_gemma":0.00062061724,"teacher_disagreement_score":0.13610215,"about_ca_system_score_codex":0.0003725667,"about_ca_system_score_gemma":0.0006026983,"threshold_uncertainty_score":0.9998679},"labels":[],"label_agreement":null},{"id":"W2999514175","doi":"10.1515/cclm-2019-1104","title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis","year":2020,"lang":"en","type":"article","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Serum protein electrophoresis; Gel electrophoresis of proteins; Electrophoresis; Detection limit; Chemistry; Chromatography; Molecular biology; Medicine; Immunology; Polyacrylamide gel electrophoresis; Biology; Biochemistry; Antibody; Enzyme","score_opus":0.08943109901205763,"score_gpt":0.40136077200491765,"score_spread":0.31192967299286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999514175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644154,0.0005392859,0.000037084843,0.0012408968,0.00003303986,0.001460404,0.00014819563,0.000045124107,0.00005444767],"genre_scores_gemma":[0.9985816,0.00022676343,0.0004983528,0.000103241386,0.00034237726,0.000064166954,0.000084877865,0.000039046845,0.00005957049],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969323,0.00028196166,0.001122175,0.0006782628,0.0005838312,0.00040146886],"domain_scores_gemma":[0.9975641,0.00028959283,0.0005547577,0.00037191412,0.00053449726,0.00068516843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000762182,0.0003417678,0.00085891347,0.000064596694,0.00010336531,0.000022508053,0.00020891996,0.0002214375,0.00021870679],"category_scores_gemma":[0.006536443,0.00026383196,0.000096088246,0.00038471672,0.00036531937,0.00022782547,0.000091258655,0.0006551532,0.0000016449852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021241452,0.0014559819,0.43451956,0.00077335874,0.00045743547,0.00006264418,0.00056786835,4.6541012e-7,0.5573084,0.0000047372614,0.00003540769,0.002690014],"study_design_scores_gemma":[0.017391551,0.0070200064,0.38990048,0.0012462563,0.00025948384,0.000006854317,0.003811811,0.0010583967,0.57856554,0.000014087765,0.00036043162,0.0003651325],"about_ca_topic_score_codex":0.000055587734,"about_ca_topic_score_gemma":0.000011329657,"teacher_disagreement_score":0.044619083,"about_ca_system_score_codex":0.000052784333,"about_ca_system_score_gemma":0.00027686713,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W2999610272","doi":"10.1515/cclm-2019-1105","title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins","year":2020,"lang":"en","type":"article","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Università degli Studi di Verona; Radboud Universitair Medisch Centrum; Università degli Studi di Padova; Radboud Universiteit; Royal College of Pathologists of Australasia; Fondazione IRCCS Policlinico San Matteo; ARUP Laboratories; University of Michigan; Sebia; NSW Health Pathology; University of Minnesota","keywords":"Serum protein electrophoresis; Detection limit; Capillary electrophoresis; Immunofixation; Chemistry; Coefficient of variation; Chromatography; Polyclonal antibodies; Analytical Chemistry (journal); Molecular biology; Monoclonal; Medicine; Antibody; Monoclonal antibody; Biology; Immunology","score_opus":0.05467622806748354,"score_gpt":0.3330464166299298,"score_spread":0.2783701885624462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999610272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978281,0.00025702862,0.000047377238,0.0004662733,0.00003054432,0.001226552,0.0000887088,0.000024889716,0.00003047467],"genre_scores_gemma":[0.99886197,0.00013201103,0.0004916508,0.00011611064,0.00020002219,0.00006684412,0.000054524262,0.000023591474,0.00005326014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981014,0.00012595768,0.0006469603,0.000534846,0.00036688565,0.0002239606],"domain_scores_gemma":[0.9983382,0.00011207108,0.00030110768,0.000266917,0.00046105363,0.00052062934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037236643,0.00023464888,0.0005867115,0.000035039484,0.00009244784,0.0000107168,0.000110679364,0.00014695957,0.00006652058],"category_scores_gemma":[0.0019947367,0.00016910303,0.000038412512,0.00019833239,0.00039156343,0.00012119547,0.000103370614,0.00039925316,4.152623e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083226785,0.0025211915,0.86322236,0.0007621248,0.0005099728,0.000045376935,0.00052923535,1.6061173e-7,0.10993982,0.0000012960329,0.000014085786,0.014131686],"study_design_scores_gemma":[0.059673678,0.015507683,0.78298235,0.001011953,0.00032874997,0.000004902068,0.0010447853,0.0004545187,0.13770556,0.0000066639636,0.0009582332,0.00032093455],"about_ca_topic_score_codex":0.000027014337,"about_ca_topic_score_gemma":0.000021605034,"teacher_disagreement_score":0.08024004,"about_ca_system_score_codex":0.000021198653,"about_ca_system_score_gemma":0.00010577205,"threshold_uncertainty_score":0.6895821},"labels":[],"label_agreement":null},{"id":"W3001655014","doi":"10.1158/1078-0432.ccr-19-1431","title":"First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"AbbVie","keywords":"Medicine; Neutropenia; Leukopenia; Pharmacokinetics; Adverse effect; Internal medicine; Gastroenterology; Toxicity","score_opus":0.13314455515717813,"score_gpt":0.4959936230890403,"score_spread":0.3628490679318622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001655014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962456,0.00029264353,0.0000019583604,0.000614257,0.000036195033,0.0026387093,0.000051673298,0.000025666644,0.00009328791],"genre_scores_gemma":[0.999055,0.00023306347,0.00012674961,0.00007971421,0.00013636136,0.00014949376,0.00011614953,0.00005186432,0.000051559156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949149,0.0010256353,0.0010396047,0.0009316887,0.0013155028,0.0007726671],"domain_scores_gemma":[0.9968766,0.0011448901,0.00016349745,0.00048240562,0.0005089247,0.0008237022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239678,0.00023794292,0.0008507204,0.00031753085,0.00017489797,0.00003529527,0.00026751027,0.00012512965,0.00017253784],"category_scores_gemma":[0.002260406,0.00018251303,0.00006404848,0.0007513813,0.00046754078,0.00022236978,0.00024513956,0.0014701211,0.000010250298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018747633,0.009855193,0.96083844,0.00026151232,0.00013089842,0.000476952,0.0018172323,0.000016788183,0.0006088563,0.0000024045316,0.00013757123,0.0071065323],"study_design_scores_gemma":[0.07054771,0.017405558,0.9079335,0.00032377138,0.000025721243,3.821089e-7,0.0011124176,0.0019379179,0.00023304968,0.0000089314735,0.00030852703,0.0001625321],"about_ca_topic_score_codex":0.0038402618,"about_ca_topic_score_gemma":0.003348028,"teacher_disagreement_score":0.052904937,"about_ca_system_score_codex":0.0001752712,"about_ca_system_score_gemma":0.0003223037,"threshold_uncertainty_score":0.74426657},"labels":[],"label_agreement":null},{"id":"W3002933537","doi":"10.1016/j.bbmt.2019.12.469","title":"Myeloma Patients Relapsing after First Line Treatment with Tandem Auto/Allo Transplant or Auto Transplant Only Have Similar Outcomes.","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Fludarabine; Melphalan; Multiple myeloma; Internal medicine; Hematopoietic stem cell transplantation; Cyclophosphamide; Cohort; Transplantation; Lenalidomide; Surgery; Gastroenterology; Oncology; Chemotherapy","score_opus":0.0229216091443527,"score_gpt":0.26660334016006026,"score_spread":0.24368173101570756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002933537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945335,0.00047809398,0.00089828786,0.0017222081,0.000047135705,0.0010128217,0.0010924381,0.000075618154,0.00013992691],"genre_scores_gemma":[0.99250454,0.0042723315,0.0011919171,0.00030482127,0.000045259367,0.000083293846,0.0014612408,0.00003449169,0.00010211912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982802,0.00008389063,0.00046358717,0.000515552,0.000245501,0.000411248],"domain_scores_gemma":[0.99914366,0.0001540609,0.00011253338,0.00015718199,0.000077416626,0.00035513673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000705956,0.00038438075,0.00067972665,0.000121856036,0.000119535514,0.000012431316,0.000069899186,0.0002155513,0.000098173674],"category_scores_gemma":[0.000010236948,0.00023350159,0.00013531145,0.00011206457,0.00017468134,0.00009689107,0.0000052159667,0.00015306736,0.0000049061023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014113067,0.00091245037,0.96296805,0.0006168501,0.0009827218,0.0010483974,0.0033693728,0.0000040579766,0.0075457804,0.00001432775,0.0000044313165,0.008420516],"study_design_scores_gemma":[0.042630203,0.019381942,0.9166948,0.0007880607,0.003542332,0.00037696896,0.00008345461,0.00057117955,0.014883137,0.0000146071025,0.0005626046,0.0004706796],"about_ca_topic_score_codex":0.00012200107,"about_ca_topic_score_gemma":0.0010681385,"teacher_disagreement_score":0.046273198,"about_ca_system_score_codex":0.00003263872,"about_ca_system_score_gemma":0.0001557012,"threshold_uncertainty_score":0.9521918},"labels":[],"label_agreement":null},{"id":"W3003488950","doi":"10.1016/j.clml.2020.01.017","title":"Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of British Columbia; Western University; University of Manitoba; London Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba; Memorial University of Newfoundland","funders":"Memorial University of Newfoundland; Queen's University; Centre Hospitalier Universitaire de Québec; Saskatchewan Cancer Agency","keywords":"Guideline; Multiple myeloma; Consensus conference; Medicine; Family medicine; Intensive care medicine; Pathology; Immunology; Internal medicine","score_opus":0.1785388692396007,"score_gpt":0.438239768301308,"score_spread":0.25970089906170735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003488950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018159907,0.92392343,0.0000020485284,0.043788146,0.0015957725,0.007910425,0.0019846503,0.000109464556,0.0025261252],"genre_scores_gemma":[0.022454554,0.97203326,0.0011190169,0.0010801738,0.00076260685,0.00069171545,0.00049779966,0.00024359999,0.0011172711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9830373,0.004598389,0.0070669935,0.0016642502,0.0020904455,0.0015426175],"domain_scores_gemma":[0.9570074,0.0346838,0.002501529,0.0027510629,0.0020522529,0.0010039454],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0052657924,0.0011689625,0.004742422,0.00028212013,0.0008467939,0.000059347112,0.0013428732,0.0010963099,0.00023734936],"category_scores_gemma":[0.046520475,0.00067987613,0.0016038809,0.0023466921,0.0032638174,0.00003407964,0.0013393726,0.002099451,0.00006129133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004970184,0.00025157974,0.004095435,0.0015853109,0.0018719741,0.00026792297,0.000024995798,0.000009700896,8.4852394e-7,0.00046105322,0.2370571,0.75387704],"study_design_scores_gemma":[0.00425441,0.00082274457,0.02390226,0.013053407,0.0014601613,0.00031822175,0.00021457755,0.00091376604,0.000020772155,0.00031869975,0.9541667,0.0005542872],"about_ca_topic_score_codex":0.039625976,"about_ca_topic_score_gemma":0.039846133,"teacher_disagreement_score":0.7533228,"about_ca_system_score_codex":0.001497515,"about_ca_system_score_gemma":0.017470155,"threshold_uncertainty_score":0.99956524},"labels":[],"label_agreement":null},{"id":"W3004303031","doi":"10.1038/s41375-020-0711-6","title":"Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Yale University","keywords":"Lenalidomide; Medicine; Internal medicine; Daratumumab; Dexamethasone; Multiple myeloma; Population; Gastroenterology; Refractory (planetary science); Oncology; Surgery","score_opus":0.06341334890599047,"score_gpt":0.35578240967606056,"score_spread":0.2923690607700701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004303031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913469,0.0015995427,0.00010268796,0.00044480138,0.000096523494,0.0051029595,0.00005833755,0.00005466019,0.0011936163],"genre_scores_gemma":[0.9963413,0.0001593793,0.0018930964,0.00029593942,0.00007855,0.00037800273,0.00006542215,0.000060216433,0.0007281235],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965183,0.00063631823,0.0008775212,0.00075897,0.00064437225,0.0005644972],"domain_scores_gemma":[0.9974411,0.0010016599,0.00025760717,0.00055002194,0.00013423609,0.0006153783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095813297,0.00039538543,0.0018598874,0.00024787072,0.00011240984,0.000059678096,0.00034263913,0.0001599966,0.00012976593],"category_scores_gemma":[0.0033661325,0.0003130571,0.00012763937,0.0005620002,0.00026786988,0.00022034558,0.00040876295,0.0005933168,0.00003325572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90057594,0.005241921,0.01792486,0.00034858525,0.0015001558,0.0031026178,0.007194368,0.000011528671,0.023073751,0.00006675298,0.0008346994,0.040124826],"study_design_scores_gemma":[0.9719147,0.0037682634,0.008041672,0.0001869162,0.0003279216,0.000037101465,0.0013000595,0.010319337,0.0035263232,0.000049164973,0.0002539573,0.0002745823],"about_ca_topic_score_codex":0.0021248544,"about_ca_topic_score_gemma":0.00039798394,"teacher_disagreement_score":0.071338765,"about_ca_system_score_codex":0.0005847837,"about_ca_system_score_gemma":0.0007967549,"threshold_uncertainty_score":0.99993217},"labels":[],"label_agreement":null},{"id":"W3004333995","doi":"10.14740/wjon1241","title":"Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone","year":2020,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Vanderbilt University Medical Center; Vanderbilt University","keywords":"Medicine; Bortezomib; Nelfinavir; Proteasome inhibitor; Multiple myeloma; Dexamethasone; Lenalidomide; Refractory (planetary science); Proteasome; Oncology; Pharmacology; Cancer research; Internal medicine; Immunology","score_opus":0.03871034861272023,"score_gpt":0.3169032622663106,"score_spread":0.2781929136535904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004333995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98684835,0.0014903713,0.00020296413,0.008873125,0.00009101683,0.0006018125,0.0000063376756,0.000025265866,0.0018607397],"genre_scores_gemma":[0.98506325,0.0001970437,0.012718142,0.0011621902,0.00050057174,0.00001582475,0.000004443395,0.00003753512,0.00030102034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980962,0.00017672694,0.0005248477,0.00026106954,0.00048630752,0.00045479723],"domain_scores_gemma":[0.99759716,0.00046142383,0.0004149641,0.00015963776,0.0002566569,0.0011101505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038984997,0.00022662188,0.00077514537,0.0002854479,0.00010188715,0.000026153883,0.000120998535,0.00010295533,0.00012204648],"category_scores_gemma":[0.0009352423,0.00015834789,0.00011166113,0.00034699973,0.00020367099,0.00022274099,0.00008275566,0.000819394,0.000018246405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026019942,0.0014323737,0.57814944,0.00025674404,0.0011817381,0.012709295,0.0012291869,0.000018313363,0.05354528,0.00008087449,0.003791868,0.3215849],"study_design_scores_gemma":[0.053798895,0.02839121,0.5076067,0.00060767593,0.0005249998,0.0053787995,0.0005733615,0.0007240764,0.009736204,0.000061642175,0.39214453,0.00045190493],"about_ca_topic_score_codex":0.00003483347,"about_ca_topic_score_gemma":0.00009938341,"teacher_disagreement_score":0.38835266,"about_ca_system_score_codex":0.00038324753,"about_ca_system_score_gemma":0.0009330441,"threshold_uncertainty_score":0.64572394},"labels":[],"label_agreement":null},{"id":"W3005289851","doi":"10.1038/s41375-020-0718-z","title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cilag; National Cancer Institute; Pharmacyclics; Chugai Pharmaceutical; Janssen Research and Development; National Institutes of Health; Glenmark Pharmaceuticals; Adaptive Biotechnologies; Array BioPharma; Yale University; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Winship Cancer Institute; Pfizer; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Foundation","keywords":"Clinical endpoint; Medicine; Dosing; Internal medicine; Multiple myeloma; Gastroenterology; Confidence interval; Phases of clinical research; Surgery; Clinical trial","score_opus":0.03634479394324643,"score_gpt":0.32998234699099743,"score_spread":0.293637553047751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005289851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98057634,0.000116868774,0.002263309,0.00013141584,0.00018703255,0.015957644,0.00056868256,0.00015595832,0.00004273275],"genre_scores_gemma":[0.9876127,0.00021601588,0.00850839,0.00043528524,0.00020084094,0.0021820683,0.0005083942,0.00015117285,0.00018513322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99644315,0.00038253845,0.00074212474,0.0009865039,0.0006560252,0.00078965945],"domain_scores_gemma":[0.9970429,0.00086405635,0.00043416634,0.00063182914,0.00027166042,0.00075536984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038389355,0.00057535956,0.0014297348,0.00014339061,0.00039163177,0.00019564011,0.0005203561,0.00012090975,0.00016088506],"category_scores_gemma":[0.0014896621,0.0003631,0.00015261708,0.0003300269,0.00016587347,0.00035509077,0.00028298976,0.0005107689,0.000067744506],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7024389,0.007071707,0.20410304,0.00011637021,0.0020806673,0.00025219514,0.0018648059,0.000011473725,0.00008692035,0.0000016992944,0.0005810393,0.08139121],"study_design_scores_gemma":[0.91981953,0.019641204,0.027994512,0.00015063585,0.0007747966,0.0000030602573,0.0005580549,0.029120672,0.000809122,0.0000060442712,0.00071911694,0.00040324728],"about_ca_topic_score_codex":0.0020043126,"about_ca_topic_score_gemma":0.0004302669,"teacher_disagreement_score":0.21738066,"about_ca_system_score_codex":0.00055807637,"about_ca_system_score_gemma":0.00033942677,"threshold_uncertainty_score":0.9998821},"labels":[],"label_agreement":null},{"id":"W3005555374","doi":"10.1097/01.hs9.0000563932.34778.38","title":"PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Carfilzomib; Internal medicine; Refractory (planetary science); Dexamethasone; Oncology; Phases of clinical research; Gastroenterology; Multiple myeloma; Lenalidomide; Adverse effect; Pharmacology; Chemotherapy","score_opus":0.029405700020044563,"score_gpt":0.32857225329266204,"score_spread":0.2991665532726175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005555374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412096,0.0017935343,0.000007965105,0.00006961879,0.00007725014,0.002121269,0.000027356185,0.000048370515,0.0017337041],"genre_scores_gemma":[0.9965364,0.00008902177,0.0012012161,0.00004741146,0.00005438057,0.00009369149,0.000031931595,0.000050670053,0.0018952782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777246,0.00016127453,0.0005053141,0.0005530216,0.00053589465,0.00047205682],"domain_scores_gemma":[0.9984003,0.00037024912,0.00014217556,0.00063290645,0.0001389726,0.00031544588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003133193,0.00028580864,0.0007348915,0.00015803045,0.00004347991,0.000013716917,0.00011373928,0.00015037518,0.0006747404],"category_scores_gemma":[0.0003878608,0.00023328545,0.00008535286,0.00037362167,0.00007225003,0.00009969294,0.00011353065,0.00038607983,0.000113742084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038461227,0.0132921375,0.91625726,0.00041307046,0.00035691317,0.0006340999,0.0020935163,0.000008882732,0.019507796,0.0000111574345,0.00027160943,0.04330744],"study_design_scores_gemma":[0.2562304,0.01582117,0.6924486,0.0007349451,0.000300903,0.00015148162,0.012652497,0.006854496,0.0112333605,0.000045370805,0.0028639329,0.0006628316],"about_ca_topic_score_codex":0.0010803503,"about_ca_topic_score_gemma":0.0011723618,"teacher_disagreement_score":0.25238428,"about_ca_system_score_codex":0.000114593524,"about_ca_system_score_gemma":0.00014899454,"threshold_uncertainty_score":0.95131046},"labels":[],"label_agreement":null},{"id":"W3005643883","doi":"10.1097/01.hs9.0000561572.20578.17","title":"S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Clinical endpoint; Neutropenia; Refractory (planetary science); Multiple myeloma; Population; Daratumumab; Phases of clinical research; Gastroenterology; Randomized controlled trial; Surgery; Lenalidomide; Clinical trial; Toxicity","score_opus":0.0321007392232158,"score_gpt":0.3338785845535127,"score_spread":0.3017778453302969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005643883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854378,0.000075244156,0.000009928961,0.000029152181,0.0002411254,0.011082599,0.00006729085,0.00004367646,0.0030131906],"genre_scores_gemma":[0.9969803,0.000023223562,0.00075003156,0.000017212504,0.000038421116,0.00034151407,0.00030795115,0.000071565984,0.0014697707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99657923,0.0003145501,0.00083777716,0.00070362556,0.0009900912,0.0005747319],"domain_scores_gemma":[0.9974426,0.00059664424,0.0003798118,0.00087422767,0.00038500415,0.00032172282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039922257,0.00041304293,0.0014977158,0.00013332824,0.00012436444,0.000079143494,0.00032058885,0.00019876278,0.00078522996],"category_scores_gemma":[0.0004924319,0.0003048829,0.000078640645,0.00049063005,0.00014285192,0.00029863056,0.00016915934,0.00048417095,0.00010457495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8285289,0.02744186,0.1311497,0.00022988999,0.00065341964,0.0019020393,0.0009234131,0.000005627941,0.00037269737,0.000007549454,0.000094792915,0.008690124],"study_design_scores_gemma":[0.87757677,0.06829334,0.05058559,0.0003231239,0.0002673282,0.00004402029,0.0012127551,0.0007639211,0.0004681584,0.000003817342,0.00011728934,0.0003439021],"about_ca_topic_score_codex":0.0013688115,"about_ca_topic_score_gemma":0.0069179507,"teacher_disagreement_score":0.0805641,"about_ca_system_score_codex":0.00035019993,"about_ca_system_score_gemma":0.00080805004,"threshold_uncertainty_score":0.99994034},"labels":[],"label_agreement":null},{"id":"W3005951838","doi":"10.1097/01.hs9.0000560716.15860.50","title":"PF607 MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012–03)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Multiple myeloma; Adverse effect; Melphalan; Maintenance therapy; Internal medicine; Oncology; Chemotherapy","score_opus":0.014678304737559142,"score_gpt":0.2619128628335819,"score_spread":0.24723455809602274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005951838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97628,0.00089937745,0.000055712855,0.001050438,0.00011544503,0.0017282281,0.000031264255,0.00010983973,0.019729745],"genre_scores_gemma":[0.9624432,0.0001030151,0.0031388162,0.0002521627,0.00010176573,0.00019297238,0.00007871988,0.000075415715,0.03361396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974231,0.0000737342,0.0003439945,0.0006394144,0.0005931726,0.0009265898],"domain_scores_gemma":[0.99831504,0.000250262,0.00009635146,0.0007528196,0.000154165,0.00043135099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015672087,0.00035913358,0.00060556433,0.00010670542,0.000062840125,0.000038489183,0.00018866002,0.00016801173,0.002291883],"category_scores_gemma":[0.00016396883,0.0002577487,0.0001224796,0.00042682947,0.00009438701,0.00025114286,0.000069179325,0.0004263762,0.0022022761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003217754,0.0007330727,0.9488749,0.00031148733,0.00020083235,0.0030303611,0.00036503424,0.00003458104,0.00303368,0.00012356917,0.00975544,0.030319316],"study_design_scores_gemma":[0.039640196,0.002802322,0.91898,0.0011036653,0.000061639126,0.00022593068,0.0014135403,0.0015036223,0.005165891,0.00005481111,0.028480701,0.0005676636],"about_ca_topic_score_codex":0.0013365198,"about_ca_topic_score_gemma":0.003904162,"teacher_disagreement_score":0.036422443,"about_ca_system_score_codex":0.00023925446,"about_ca_system_score_gemma":0.0002726686,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W3006286575","doi":"10.1002/hon.2723","title":"Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carfilzomib; Ibrutinib; Medicine; Dexamethasone; Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Lenalidomide; Leukemia; Materials science","score_opus":0.06631480899877269,"score_gpt":0.35118968776323356,"score_spread":0.2848748787644609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006286575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976181,0.000043092594,0.00005774191,0.0002513623,0.000011335374,0.0016534036,0.000047920686,0.000032824148,0.00028422097],"genre_scores_gemma":[0.9977885,0.0000056765743,0.001799947,0.00011269859,0.000007412089,0.000111591944,0.00014376671,0.000017400345,0.000013014826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973365,0.00039336053,0.0007299866,0.00053794775,0.0005896975,0.00041248376],"domain_scores_gemma":[0.9977365,0.00086216204,0.00039435615,0.00035737996,0.0002905045,0.00035908594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019061584,0.00026512207,0.0020294073,0.0003716269,0.00003672243,0.0000035299731,0.00016307957,0.00019337582,0.00028156178],"category_scores_gemma":[0.0007222465,0.00015794046,0.00013136174,0.001598396,0.00029835105,0.000053458454,0.00009804327,0.00038865977,0.000006821278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06776069,0.030930454,0.8942095,0.000096602176,0.00225868,0.0011767606,0.00097574806,0.00004037723,0.00023941003,0.000021900458,0.00002636183,0.0022634983],"study_design_scores_gemma":[0.09147003,0.095970094,0.80860233,0.000039363527,0.0011330544,0.000008841667,0.0007990496,0.0013965821,0.00039872923,0.0000024624705,0.000048940015,0.0001305125],"about_ca_topic_score_codex":0.00015444595,"about_ca_topic_score_gemma":0.00038796154,"teacher_disagreement_score":0.085607186,"about_ca_system_score_codex":0.00011098976,"about_ca_system_score_gemma":0.00020421723,"threshold_uncertainty_score":0.6440625},"labels":[],"label_agreement":null},{"id":"W3007563585","doi":"10.1159/000506174","title":"The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma","year":2020,"lang":"en","type":"letter","venue":"Acta Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Multiple myeloma; Lactate dehydrogenase; Internal medicine; Medicine; L-Lactate dehydrogenase; Oncology; Cancer research; Biology; Biochemistry; Enzyme","score_opus":0.027153307162524985,"score_gpt":0.2638303491537865,"score_spread":0.23667704199126152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007563585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60181224,0.0031376851,0.0000012764435,0.38995576,0.00011051032,0.0026888524,0.00037203878,0.00012533662,0.0017963231],"genre_scores_gemma":[0.9803394,0.0007683956,0.00032709484,0.016522106,0.0001879543,0.00026987537,0.0006890486,0.00007675052,0.00081933953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679446,0.00021565444,0.0008048909,0.0005889495,0.00086295325,0.0007330658],"domain_scores_gemma":[0.9952845,0.0026324175,0.0006427546,0.00097250205,0.00022658108,0.00024122228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014084349,0.00047719237,0.0012922395,0.00011970614,0.00027767933,0.000018580373,0.0005377874,0.00055054855,0.0001937569],"category_scores_gemma":[0.002946345,0.0002741091,0.00046528308,0.00028246135,0.0005506019,0.00004447242,0.00042593217,0.0010797484,0.00018243202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030690297,0.00051551836,0.15885259,0.0026324163,0.0022045618,0.016925057,0.00043020584,8.2479426e-7,0.004271816,0.000026756617,0.8093944,0.0016767964],"study_design_scores_gemma":[0.004975708,0.0022435028,0.022913972,0.0010019875,0.0008833189,0.0015225512,0.0001351289,0.0007418908,0.04266528,0.00036947962,0.92197716,0.00056999],"about_ca_topic_score_codex":0.00011333978,"about_ca_topic_score_gemma":0.00010219568,"teacher_disagreement_score":0.37852722,"about_ca_system_score_codex":0.00010418349,"about_ca_system_score_gemma":0.00018154073,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W3010273422","doi":"10.1111/ejh.13405","title":"c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma","year":2020,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SAIT Polytechnic","funders":"Agence Nationale de la Recherche","keywords":"Lenalidomide; Medicine; Internal medicine; Oncology; Multiple myeloma; Hazard ratio; Dexamethasone; Placebo; Ixazomib; Autologous stem-cell transplantation; Confidence interval; Pathology; Carfilzomib","score_opus":0.04591443661562897,"score_gpt":0.2880934337399425,"score_spread":0.24217899712431354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010273422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638575,0.0004069572,0.00020905379,0.0024847693,0.000033982644,0.00019085096,0.000057286572,0.000010539092,0.00022081565],"genre_scores_gemma":[0.9962812,0.0000309539,0.0032306414,0.00033203096,0.00006063575,0.0000014238549,0.000024245264,0.000025045534,0.000013830901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829197,0.00043662018,0.000585569,0.00018881557,0.00029187047,0.00020517372],"domain_scores_gemma":[0.9986231,0.00027773296,0.00047234946,0.00012609742,0.00017485333,0.00032589133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036527117,0.0001462111,0.00078460784,0.0001664936,0.0000287455,0.000011630873,0.00011146033,0.000043600954,0.0001323762],"category_scores_gemma":[0.0010971978,0.0001007706,0.0000627559,0.00015715417,0.00006950014,0.00008976101,0.000075565236,0.0003243243,0.000016915312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01255515,0.00056301896,0.92261744,0.00018387304,0.0005262972,0.027270377,0.0020445895,0.000039793293,0.026710244,0.00003794902,0.0011211527,0.0063301246],"study_design_scores_gemma":[0.009398283,0.0014826729,0.9761758,0.0009822954,0.00008954624,0.0005443079,0.00036659668,0.00005680576,0.010599718,0.000056940487,0.00014288894,0.00010417437],"about_ca_topic_score_codex":0.000017514865,"about_ca_topic_score_gemma":0.00003063837,"teacher_disagreement_score":0.05355834,"about_ca_system_score_codex":0.000037083315,"about_ca_system_score_gemma":0.000031936965,"threshold_uncertainty_score":0.41093057},"labels":[],"label_agreement":null},{"id":"W3010281084","doi":"10.3747/co.27.5789","title":"The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Bone marrow; Plasma cell neoplasm; Plasma cell; Neoplasm; Pathology; Skeletal survey; Cancer research; Internal medicine; Plasmacytoma","score_opus":0.09203084448299018,"score_gpt":0.40711992464071856,"score_spread":0.3150890801577284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010281084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94505507,0.0039755013,0.00039559972,0.04518156,0.00032438745,0.0012624041,0.000039111015,0.000039869898,0.0037265075],"genre_scores_gemma":[0.99869394,0.00012135211,0.00016611392,0.00054473913,0.00014149387,0.00005229388,0.0000269865,0.000013932892,0.00023914444],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99842834,0.00025652844,0.0003685856,0.0002792168,0.00025530075,0.00041203835],"domain_scores_gemma":[0.99836445,0.0009507714,0.000080901795,0.00020754647,0.00012921666,0.00026714295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005525825,0.00013645367,0.00039190712,0.00009968899,0.00007288015,0.0000122566935,0.00012929471,0.000053808013,0.00060926465],"category_scores_gemma":[0.0020642222,0.00009785037,0.00010283987,0.0002674144,0.00007275077,0.00005209452,0.00015459093,0.00028730702,0.00040344647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005520573,0.0004465451,0.3899618,0.00009909522,0.00004883178,0.00015383986,0.0011832233,0.0000015502644,0.0047594686,0.0000045105826,0.033038467,0.5697506],"study_design_scores_gemma":[0.014170136,0.0024590464,0.7237896,0.0003007557,0.000072644434,0.00004938029,0.0004721039,0.024141671,0.0071316236,0.000024321667,0.22709222,0.00029649638],"about_ca_topic_score_codex":0.00011012368,"about_ca_topic_score_gemma":0.000112254726,"teacher_disagreement_score":0.5694541,"about_ca_system_score_codex":0.00013515745,"about_ca_system_score_gemma":0.00018544799,"threshold_uncertainty_score":0.6671021},"labels":[],"label_agreement":null},{"id":"W3011089553","doi":"10.1200/jco.2013.31.15_suppl.8593","title":"Early versus late treatment for smoldering (asymptomatic) multiple myeloma: A systematic review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Multiple myeloma; Thalidomide; Randomized controlled trial; Internal medicine; Jadad scale; Lenalidomide; Population; MEDLINE; Oncology; Cochrane Library; Surgery","score_opus":0.19860095513282414,"score_gpt":0.48802110782073405,"score_spread":0.2894201526879099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011089553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833638,0.005523608,0.00023531762,0.0045063733,0.00091787043,0.004473829,0.000007299192,0.0000252436,0.0009466731],"genre_scores_gemma":[0.9822271,0.004407209,0.010559564,0.00075303763,0.0005573705,0.00039223765,0.00000749379,0.00003535707,0.0010606718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99569845,0.00042486287,0.0028593247,0.00020180424,0.0004171935,0.00039837154],"domain_scores_gemma":[0.9897292,0.0069264793,0.001609903,0.0003330469,0.00068802264,0.00071334245],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017696626,0.00021050559,0.0028029731,0.00011968315,0.0000603756,0.000020638363,0.00016869453,0.00022701,0.0001344178],"category_scores_gemma":[0.012400995,0.00012143287,0.0010070346,0.000106905034,0.000089922214,0.0001608857,0.00003648009,0.00032733777,0.00020688192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05423316,0.026552372,0.16202518,0.2723966,0.03767372,0.005516478,0.0010042257,0.0000249509,0.0012460763,0.00019395998,0.018554641,0.42057863],"study_design_scores_gemma":[0.2356831,0.23380399,0.40852186,0.09118234,0.013500249,0.0011532636,0.0003155389,0.006612074,0.00039068845,0.00044490115,0.007667675,0.00072432094],"about_ca_topic_score_codex":0.00006374834,"about_ca_topic_score_gemma":0.000018610046,"teacher_disagreement_score":0.4198543,"about_ca_system_score_codex":0.00038604744,"about_ca_system_score_gemma":0.0007187889,"threshold_uncertainty_score":0.995918},"labels":[],"label_agreement":null},{"id":"W3012328912","doi":"10.1182/blood.2019003807","title":"Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta; Hôpital du Sacré-Cœur de Montréal; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Clinical Science Research and Development; National Institutes of Health; University of Alberta; National Institute of Diabetes and Digestive and Kidney Diseases; Brigham and Women's Hospital; U.S. Department of Veterans Affairs","keywords":"Medicine; Renal function; Nephropathy; Acute kidney injury; Kidney disease; Renal biopsy; Biopsy; Urology; Retrospective cohort study; Internal medicine; Gastroenterology; Pathology; Diabetes mellitus; Endocrinology","score_opus":0.032103755660853675,"score_gpt":0.3161329453192187,"score_spread":0.28402918965836504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012328912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714774,0.00009774828,0.000005138972,0.0006780749,0.00004641277,0.0013621214,0.00004126837,0.000043105603,0.0005783693],"genre_scores_gemma":[0.9993551,0.00001652,0.00019231923,0.00013589895,0.00009599806,0.00006648462,0.000011869128,0.000018660015,0.00010719783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837345,0.0001522889,0.00041604822,0.00036966192,0.00040188737,0.0002866691],"domain_scores_gemma":[0.99927336,0.00005702073,0.00010336654,0.000260636,0.00008289942,0.0002227439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022504905,0.0001665157,0.00055141404,0.00011567162,0.0000270035,0.000007713256,0.00010506362,0.00006462198,0.000065740205],"category_scores_gemma":[0.0008623016,0.000117662836,0.000111003574,0.00025839717,0.000049646016,0.000046720383,0.00010148157,0.00025728287,0.000035291774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066239206,0.006415174,0.9842896,0.00003394599,0.00027395017,0.0022177575,0.0028723532,7.156825e-7,0.0030405573,0.0000030002345,0.00002290051,0.00016766432],"study_design_scores_gemma":[0.021713404,0.0045104944,0.969879,0.000041696192,0.00016779212,0.000011562904,0.0007419863,0.000108177795,0.002718336,0.0000032393934,0.00002517567,0.00007916591],"about_ca_topic_score_codex":0.000067815374,"about_ca_topic_score_gemma":0.00007781431,"teacher_disagreement_score":0.02105101,"about_ca_system_score_codex":0.000042612486,"about_ca_system_score_gemma":0.000065395674,"threshold_uncertainty_score":0.4798151},"labels":[],"label_agreement":null},{"id":"W3012570191","doi":"10.1016/s2352-3026(20)30070-3","title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Surgery; Clinical trial; Bortezomib","score_opus":0.08514856475611958,"score_gpt":0.35792034743549933,"score_spread":0.27277178267937974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012570191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880552,0.00009970782,0.000035390716,0.0020034015,0.0003508226,0.008337151,0.0000933162,0.000091386646,0.00093360926],"genre_scores_gemma":[0.99723184,0.00008559383,0.0010178611,0.00058532046,0.000262134,0.00043574566,0.00021570093,0.000065692206,0.00010008256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966985,0.0004838539,0.0006520591,0.00067187275,0.0005100529,0.0009836688],"domain_scores_gemma":[0.9971873,0.0011187895,0.0002735598,0.0008047686,0.00016581295,0.00044972985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031303737,0.00040354067,0.0020050744,0.00010164166,0.00023080574,0.00008381738,0.00068748195,0.00021928185,0.00024531432],"category_scores_gemma":[0.0017731554,0.0002453966,0.00007095658,0.0004429582,0.00028348507,0.0001597715,0.00032666486,0.0007823974,0.0001795095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96382713,0.004685221,0.013667307,0.00016813345,0.00043159563,0.008111784,0.0009775333,0.0000025646086,0.00011744396,0.000018040673,0.0008838661,0.007109374],"study_design_scores_gemma":[0.9666863,0.023045179,0.0058571445,0.00011517878,0.00023418946,0.00020913192,0.00014256685,0.0019488583,0.00015686842,0.0000070066567,0.0013053478,0.00029219623],"about_ca_topic_score_codex":0.00039022774,"about_ca_topic_score_gemma":0.0015652315,"teacher_disagreement_score":0.018359957,"about_ca_system_score_codex":0.00019395268,"about_ca_system_score_gemma":0.00043599657,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W3012669854","doi":"10.1093/jncics/pkz104","title":"A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor","year":2019,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Queen's University Belfast; Queen's University; Cancer Research UK","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Internal medicine; Prospective cohort study; Oncology; Multiple myeloma; Odds ratio; Angiogenesis; Biomarker; Immunology; Gastroenterology; Monoclonal; Antibody; Monoclonal antibody","score_opus":0.015041241044183428,"score_gpt":0.28723327922033753,"score_spread":0.2721920381761541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012669854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432635,0.0033645253,0.000001141974,0.000061987936,0.000040130384,0.00182946,0.00006478469,0.000015091314,0.00029653788],"genre_scores_gemma":[0.9987333,0.0008122236,0.00010446324,0.0000045411207,0.000040520845,0.00008415533,0.000002549356,0.000021679478,0.0001965891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988669,0.00004590152,0.0002205049,0.000363434,0.00027173958,0.00023152705],"domain_scores_gemma":[0.9993201,0.00012041732,0.00016371903,0.00018489939,0.00007731759,0.00013353466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000137596,0.00016202264,0.00043799847,0.00012494843,0.000049915277,0.000009554668,0.000037411235,0.000049077033,0.00006349062],"category_scores_gemma":[0.00012434556,0.00012924241,0.000041038435,0.0001866196,0.000060349492,0.00007458822,0.00008216695,0.00008753326,9.2852787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012069105,0.00026443554,0.9806519,0.00034849523,0.00079110055,0.000014315891,0.0013355551,0.000002809752,0.0058681634,0.0000068710137,0.0000055512955,0.009503897],"study_design_scores_gemma":[0.0073799654,0.001393212,0.9656568,0.000111764915,0.000246639,0.000019726589,0.00086920307,0.0018688997,0.022321844,0.00002349448,0.0000056568215,0.00010279201],"about_ca_topic_score_codex":0.0022513927,"about_ca_topic_score_gemma":0.0008345617,"teacher_disagreement_score":0.016453682,"about_ca_system_score_codex":0.00006364712,"about_ca_system_score_gemma":0.000057947258,"threshold_uncertainty_score":0.52703524},"labels":[],"label_agreement":null},{"id":"W3013023102","doi":"10.14740/wjon1245","title":"Recent Advances in the Management of Smoldering Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Internal medicine","score_opus":0.09049656707715129,"score_gpt":0.4231178853126563,"score_spread":0.332621318235505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013023102","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022860515,0.9909288,0.000013072696,0.0008947194,0.00023836002,0.0008499753,0.000006299412,0.0000034879972,0.007042412],"genre_scores_gemma":[0.0003044791,0.9969839,0.0022136138,0.000079968755,0.00019983746,0.000040456594,0.000010796932,0.00002285457,0.00014413596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753875,0.0003832744,0.0011244183,0.00017809468,0.0004833167,0.0002921466],"domain_scores_gemma":[0.9980805,0.0005238111,0.0009092928,0.0002282595,0.000104568426,0.00015357224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000663125,0.00023611124,0.0019627502,0.0004878821,0.000028674433,0.0000074693876,0.00037832474,0.00009217073,0.00011857572],"category_scores_gemma":[0.00010305931,0.00013077588,0.00042367962,0.0007106498,0.00007905724,0.00005991999,0.00009861346,0.00080840936,0.00001621416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028588375,0.00039064736,0.00021836252,0.0068449313,0.0007016143,0.0077225147,0.00008840665,0.0000014776106,3.1712892e-7,0.000048618436,0.0002982917,0.9833989],"study_design_scores_gemma":[0.0025423216,0.0010295939,0.0005267522,0.010409416,0.0008251842,0.0010422112,0.00014071407,0.0000035183696,0.0000013810549,0.000020261314,0.98338,0.00007862687],"about_ca_topic_score_codex":0.0000024138892,"about_ca_topic_score_gemma":0.000066037384,"teacher_disagreement_score":0.9833203,"about_ca_system_score_codex":0.00048002496,"about_ca_system_score_gemma":0.0004336268,"threshold_uncertainty_score":0.53328854},"labels":[],"label_agreement":null},{"id":"W3013575560","doi":"10.1158/1078-0432.ccr-19-1714","title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Blood Cancer UK; Cancer Research UK; Canadian Institute for Theoretical Astrophysics","keywords":"Immune system; CD8; Multiple myeloma; Bone marrow; Immunology; Medicine; FOXP3; IL-2 receptor; Cytotoxic T cell; T cell; Cancer research; Biology; In vitro","score_opus":0.07903201766159101,"score_gpt":0.37426237699981585,"score_spread":0.29523035933822483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013575560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571675,0.0001741347,0.000026074387,0.0019287369,0.00008634512,0.00169255,0.00008333307,0.000019855484,0.0002722049],"genre_scores_gemma":[0.99863374,0.00016303256,0.00032258208,0.00018905252,0.00014708552,0.0001744391,0.000024991441,0.000039208484,0.00030586668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995819,0.0006875376,0.00056423445,0.00063830626,0.0016614202,0.00062951626],"domain_scores_gemma":[0.99413425,0.0040556076,0.00015012517,0.00043325062,0.0006331745,0.0005936068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013810906,0.0002144565,0.00054201874,0.00010613612,0.00016988721,0.000042658055,0.00024393591,0.00013951586,0.0002383249],"category_scores_gemma":[0.001280654,0.00012434094,0.00007251502,0.0006642755,0.0011406259,0.00013660555,0.00021733492,0.0012347016,0.0000232643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015167292,0.0004592524,0.9738314,0.00018945344,0.00016164777,0.000108676824,0.00029709248,0.00013814798,0.0009419805,0.000010223593,0.0010561023,0.007638727],"study_design_scores_gemma":[0.015263503,0.0033463796,0.97632796,0.0002834932,0.00003243177,9.076401e-7,0.00021996199,0.00193459,0.0019023177,0.0000035477947,0.00055213436,0.00013275749],"about_ca_topic_score_codex":0.0008457238,"about_ca_topic_score_gemma":0.00075023074,"teacher_disagreement_score":0.0075059696,"about_ca_system_score_codex":0.00010136016,"about_ca_system_score_gemma":0.000818431,"threshold_uncertainty_score":0.53642327},"labels":[],"label_agreement":null},{"id":"W3013611021","doi":"10.21037/tcr.2020.03.36","title":"Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Translational Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Science and Technology Project of Nantong City","keywords":"Medicine; Meta-analysis; Internal medicine; Multiple myeloma; Cochrane Library; Odds ratio; Type 2 Diabetes Mellitus; Subgroup analysis; Diabetes mellitus; Study heterogeneity; Incidence (geometry); Endocrinology; Mathematics","score_opus":0.20465722082477103,"score_gpt":0.45315828010153925,"score_spread":0.24850105927676822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013611021","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017356542,0.98803705,0.0000045183324,0.0019031395,0.000011018543,0.006905944,0.0030252265,0.000017423976,0.000078311605],"genre_scores_gemma":[0.0024937275,0.99343365,0.00012647262,0.000084572755,0.00005771157,0.0027576494,0.00041924682,0.000050847622,0.00057613145],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99263495,0.002953161,0.0011385881,0.00065541355,0.0021184988,0.0004994127],"domain_scores_gemma":[0.9926372,0.004945563,0.00038322326,0.0007937346,0.00084720313,0.00039307115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030474297,0.00044581652,0.00650302,0.0004982281,0.00022523965,0.000046121106,0.00039589626,0.00016074248,0.0011821927],"category_scores_gemma":[0.0017642993,0.00018989289,0.0021884416,0.002472893,0.0003667404,0.00006563129,0.0000920718,0.0010123773,0.000050897146],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008863308,0.00008286073,0.00016415352,0.7263496,0.26232997,0.000023256565,0.000059520422,0.0000010684479,7.8642955e-7,0.000037292004,0.00007578858,0.010787103],"study_design_scores_gemma":[0.0005013201,0.0001321835,0.00016809067,0.018691275,0.94603413,0.0000060897764,0.000009910344,0.0001403141,0.000008668659,0.000037205686,0.034066822,0.00020399122],"about_ca_topic_score_codex":0.0011707429,"about_ca_topic_score_gemma":0.00042413388,"teacher_disagreement_score":0.7076583,"about_ca_system_score_codex":0.0001169622,"about_ca_system_score_gemma":0.0010433021,"threshold_uncertainty_score":0.9997309},"labels":[],"label_agreement":null},{"id":"W3014004858","doi":"10.14740/jmc3428","title":"Myelomatous Pleural Effusion: A Rare Involvement in Myeloma","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pleural effusion; Multiple myeloma; Incidence (geometry); Pleural fluid; Effusion; Chest pain; Internal medicine; Radiology; Pathology; Surgery","score_opus":0.0668239661220422,"score_gpt":0.34637358047866734,"score_spread":0.2795496143566252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014004858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9394495,0.001883605,0.000047611848,0.058071893,0.00011222475,0.00021139123,0.000005645417,0.000014753855,0.00020340833],"genre_scores_gemma":[0.9940283,0.0006653655,0.00060926523,0.0039404323,0.0006804147,0.0000055917826,0.000008531242,0.000015178755,0.00004694896],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9965978,0.00011326135,0.0006357035,0.00015283751,0.0021855962,0.0003147768],"domain_scores_gemma":[0.9979287,0.00028345195,0.00015452111,0.000116477415,0.00014025856,0.0013766148],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045753387,0.00014574583,0.0004993781,0.0001625485,0.00003787166,0.000019999326,0.00020010582,0.000117545605,0.0018255679],"category_scores_gemma":[0.002568458,0.00009520442,0.00017758309,0.00028855776,0.000084565254,0.00009237444,0.000109777524,0.0005984338,0.000048642185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006713023,0.0018185729,0.34427923,0.00082253024,0.00043421774,0.3566983,0.0017927113,0.0000059688505,0.0015535075,0.00006984872,0.069214895,0.21659717],"study_design_scores_gemma":[0.07799565,0.021365697,0.6909442,0.0056449473,0.00037423766,0.057601348,0.0067359344,0.008375429,0.009934139,0.00017792864,0.120095074,0.00075539877],"about_ca_topic_score_codex":0.00007042501,"about_ca_topic_score_gemma":0.00003699091,"teacher_disagreement_score":0.346665,"about_ca_system_score_codex":0.000116809984,"about_ca_system_score_gemma":0.0005901256,"threshold_uncertainty_score":0.9990869},"labels":[],"label_agreement":null},{"id":"W3014488763","doi":"10.1002/jha2.4","title":"Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Bortezomib; Medicine; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Placebo; Hazard ratio; Interim analysis; Adverse effect; Surgery; Gastroenterology; Oncology; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.017713981571373643,"score_gpt":0.27255795567471003,"score_spread":0.25484397410333637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014488763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860534,0.0003790717,0.00004580975,0.00019400194,0.000011990917,0.012925601,0.000039708044,0.00009056958,0.00025984985],"genre_scores_gemma":[0.9976381,0.000052619103,0.00089140417,0.000085150554,0.000032690943,0.0008258062,0.00017988784,0.000100227786,0.00019411066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99625915,0.0005633219,0.00079402793,0.0008215549,0.0009469695,0.0006149574],"domain_scores_gemma":[0.9972893,0.0007026774,0.00042944765,0.00056149147,0.00036609996,0.00065100857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004710201,0.0005939218,0.0025567403,0.00028269397,0.000109617235,0.00003691051,0.00014435915,0.00011533118,0.00007378933],"category_scores_gemma":[0.0006506631,0.00033456858,0.00010161416,0.00062734616,0.00036368478,0.00022234212,0.00006659671,0.0004640046,0.000005910652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5690397,0.005644873,0.41952178,0.00009954561,0.0013802486,0.0005294092,0.0018569716,0.000010818934,0.000057008878,0.0000017502368,0.000023878936,0.0018340086],"study_design_scores_gemma":[0.7714443,0.03996286,0.18437351,0.00028699395,0.00087223254,0.00001604902,0.0009487294,0.0015590618,0.00022943421,5.216477e-7,0.00002409271,0.00028218888],"about_ca_topic_score_codex":0.00062134425,"about_ca_topic_score_gemma":0.00061802333,"teacher_disagreement_score":0.23514827,"about_ca_system_score_codex":0.00012111572,"about_ca_system_score_gemma":0.00021718728,"threshold_uncertainty_score":0.99991065},"labels":[],"label_agreement":null},{"id":"W3015554102","doi":"10.1016/j.jval.2019.11.003","title":"Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Health Evaluation and Outcome Sciences","funders":"National Cancer Institute; Amgen","keywords":"Medicine; Credibility; Randomized controlled trial; Psychological intervention; Pharmacoeconomics; Checklist; Outcomes research; Meta-analysis; Relevance (law); Alternative medicine; Family medicine; Medical physics; Psychology; Intensive care medicine; Psychiatry; Internal medicine; Pathology","score_opus":0.5210599431721261,"score_gpt":0.5482646029242919,"score_spread":0.027204659752165794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015554102","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040966483,0.99525815,0.00087893184,0.00066153554,0.00013783346,0.0022942948,0.00065341574,0.000022864604,0.000052022282],"genre_scores_gemma":[0.00905855,0.9525027,0.037013568,0.000028021455,0.00018210801,0.00040364533,0.000741741,0.000059789716,0.000009822817],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99510163,0.0012632766,0.0021839978,0.0005218606,0.00039872777,0.0005304969],"domain_scores_gemma":[0.9845425,0.013659495,0.0007845056,0.0003794922,0.00019844044,0.0004355725],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018309213,0.0003485772,0.0062718913,0.0003600447,0.000081894126,0.000026263422,0.00018086292,0.00017103969,0.000054414835],"category_scores_gemma":[0.013978428,0.00025194316,0.0016706066,0.00071015273,0.00017872818,0.00006528359,0.00014531518,0.00051123183,0.0000018635982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035907043,0.0018011716,0.012948689,0.4918999,0.01955181,0.000056699286,0.00031474922,0.0000976221,9.966263e-7,0.0013177397,0.004402502,0.46724904],"study_design_scores_gemma":[0.008330068,0.0047838558,0.0066418382,0.1435049,0.04221664,0.00015845503,0.00039560467,0.017766481,0.000012861358,0.00015364763,0.7752034,0.0008322194],"about_ca_topic_score_codex":0.0016303719,"about_ca_topic_score_gemma":0.00012546846,"teacher_disagreement_score":0.77080095,"about_ca_system_score_codex":0.00011595409,"about_ca_system_score_gemma":0.0008701675,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W3016333719","doi":"10.1182/blood.v110.11.1505.1505","title":"Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Flow cytometry; Signal transduction; Biology; Cancer research; Cell culture; PI3K/AKT/mTOR pathway; Cell biology; Cytokine; Molecular biology; Immunology; Genetics","score_opus":0.019103842475807594,"score_gpt":0.2561482182932446,"score_spread":0.23704437581743698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016333719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163204,0.004136749,0.0023732241,0.000022508888,0.000053779586,0.0013905987,0.00015798233,0.00007113834,0.0001619828],"genre_scores_gemma":[0.84714407,0.000086968066,0.15199491,0.000054583958,0.00006604922,0.000042746364,0.00038687608,0.00004168255,0.00018208375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99786115,0.000054523676,0.00051344966,0.00043887398,0.00047198625,0.00066000636],"domain_scores_gemma":[0.99867463,0.0002658269,0.00017195469,0.0003494279,0.0001889247,0.00034924716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028669983,0.00027616156,0.00048182337,0.0001573726,0.000109797584,0.000022127566,0.00009327495,0.00015803307,0.0000451697],"category_scores_gemma":[0.00033333313,0.00022339042,0.00012014031,0.0003888701,0.00011283784,0.00007250454,0.00012236077,0.00022101706,0.000009155014],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012999892,0.003599068,0.47686112,0.00047228672,0.00043169438,0.00022805734,0.00013936289,0.000010600349,0.48657733,0.0000012085078,0.00015444885,0.03022483],"study_design_scores_gemma":[0.012221196,0.0008244571,0.16709682,0.00017396203,0.00015931846,0.000026818016,0.000072495146,0.0014404953,0.817604,0.000005874289,0.00017213417,0.00020244712],"about_ca_topic_score_codex":0.00020454623,"about_ca_topic_score_gemma":0.000023883053,"teacher_disagreement_score":0.33102664,"about_ca_system_score_codex":0.000039036582,"about_ca_system_score_gemma":0.000064599604,"threshold_uncertainty_score":0.9109597},"labels":[],"label_agreement":null},{"id":"W3016522843","doi":"10.1016/j.clml.2020.04.002","title":"KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; Bristol-Myers Squibb Canada; Seattle Genetics; Celgene; Sanofi; AbbVie; Bristol-Myers Squibb; GlycoMimetics","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Mobilization; Minimal residual disease; Transplantation; Stem cell; Oncology; Internal medicine; Genetics; Bone marrow","score_opus":0.033885022541965536,"score_gpt":0.30530949325010304,"score_spread":0.2714244707081375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016522843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907221,0.00012330101,0.0026310317,0.0011763405,0.00016372015,0.003869053,0.00081215735,0.00032418038,0.00017809309],"genre_scores_gemma":[0.9916467,0.00008193341,0.0028440256,0.00093969307,0.00042692674,0.0004465424,0.003029024,0.00013934202,0.00044578707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995463,0.00028448223,0.0011726747,0.00127907,0.00092959945,0.0008711611],"domain_scores_gemma":[0.9956615,0.0009918977,0.00037854924,0.00064688415,0.00053721585,0.00178395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032951185,0.00055902684,0.0009183955,0.00012658194,0.00030270562,0.000075682634,0.00030657896,0.00034517178,0.000057965695],"category_scores_gemma":[0.0006945987,0.00043228795,0.00038267166,0.00042330407,0.00035616648,0.00026738597,0.00006993072,0.00026730425,0.00014894921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025906868,0.001116363,0.67110664,0.00083800894,0.00027510163,0.0005988041,0.0004098829,0.00009441993,0.00020807436,0.000052518106,0.0011059041,0.29828742],"study_design_scores_gemma":[0.027832925,0.00502535,0.9539093,0.00017766528,0.00056834216,0.000010661103,0.0001092015,0.009480725,0.0011630519,0.000041894928,0.0012627697,0.0004181396],"about_ca_topic_score_codex":0.00004166257,"about_ca_topic_score_gemma":0.000035124463,"teacher_disagreement_score":0.2978693,"about_ca_system_score_codex":0.000566278,"about_ca_system_score_gemma":0.0015708571,"threshold_uncertainty_score":0.9998129},"labels":[],"label_agreement":null},{"id":"W3016922132","doi":"10.1182/blood.v130.suppl_1.1845.1845","title":"Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Carfilzomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Hazard ratio; Bortezomib; Clinical endpoint; Renal function; Creatinine; Adverse effect; Urology; Surgery; Confidence interval; Gastroenterology; Randomized controlled trial","score_opus":0.024720765597734652,"score_gpt":0.2989913116747137,"score_spread":0.27427054607697904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016922132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970453,0.0001994425,0.000016619582,0.000072953124,0.000012593663,0.0024113806,0.0002025528,0.000014744924,0.000024454339],"genre_scores_gemma":[0.9980259,0.000041718373,0.0016352924,0.0000129688615,0.000018691711,0.0001142986,0.000043118787,0.000037054673,0.00007097064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973954,0.00027459834,0.00054660277,0.0006210519,0.00067249854,0.00048987864],"domain_scores_gemma":[0.99745804,0.00049886154,0.00036499955,0.0011279616,0.00026023033,0.00028990113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047582935,0.00034735785,0.0011914715,0.00039383298,0.00027546898,0.000075125296,0.00026291807,0.00011761687,0.00003062796],"category_scores_gemma":[0.0014596911,0.00020286912,0.00013309947,0.0005771659,0.0004293824,0.00018999702,0.00027361733,0.00028001456,5.2071834e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013819289,0.009011898,0.9581169,0.00011123078,0.0040512322,0.0002462361,0.0018409534,0.000008116291,0.0045209145,0.0000018120408,0.0000019807576,0.008269449],"study_design_scores_gemma":[0.09493576,0.0036200078,0.8869079,0.00011774502,0.0032159765,0.000015424981,0.00042111002,0.0012257856,0.009356624,0.0000020320579,0.000005164218,0.00017649001],"about_ca_topic_score_codex":0.002216933,"about_ca_topic_score_gemma":0.007591407,"teacher_disagreement_score":0.081116475,"about_ca_system_score_codex":0.00004250454,"about_ca_system_score_gemma":0.00017212503,"threshold_uncertainty_score":0.8272763},"labels":[],"label_agreement":null},{"id":"W3017092769","doi":"10.1182/blood.v108.11.5081.5081","title":"Bortezomib Therapy Response Is Independent of Cytogenetic Abnormalities in Relapsed/Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Bortezomib; Multiple myeloma; Internal medicine; Fluorescence in situ hybridization; Gastroenterology; Cytogenetics; Refractory (planetary science); Biology; Medicine; Chromosome","score_opus":0.02416553443200218,"score_gpt":0.2830395228515201,"score_spread":0.2588739884195179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017092769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99482435,0.0028288786,0.0000035980568,0.00015658422,0.000034365985,0.0006044651,0.00006489119,0.000035550507,0.0014473285],"genre_scores_gemma":[0.99725556,0.00028330984,0.0004589695,0.00008686631,0.00007131211,0.000072528645,0.0000379154,0.000033245353,0.0017003048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980971,0.00018896183,0.00044185165,0.00030051148,0.00054759375,0.0004239622],"domain_scores_gemma":[0.99893165,0.00026832044,0.000102651524,0.0004623095,0.000100759906,0.00013429584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038101763,0.00019943021,0.0003685255,0.00032243202,0.00004501968,0.0000122430565,0.00012159725,0.00013793656,0.00023056373],"category_scores_gemma":[0.00013593896,0.00016633139,0.0001286867,0.00022904208,0.00010198423,0.000052532967,0.00004351261,0.00020722972,0.000042088326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062397197,0.0033777584,0.9043134,0.000052382067,0.0001686948,0.00057479047,0.0004977187,0.000005623258,0.0821621,0.0000176968,0.00016693817,0.0024231966],"study_design_scores_gemma":[0.020639593,0.0008407792,0.7915715,0.000069324626,0.00003133798,0.00005198246,0.00013642236,0.000032727323,0.18558775,0.000063122,0.0008615428,0.00011393109],"about_ca_topic_score_codex":0.0016056228,"about_ca_topic_score_gemma":0.00027219544,"teacher_disagreement_score":0.11274189,"about_ca_system_score_codex":0.000072283045,"about_ca_system_score_gemma":0.00023483128,"threshold_uncertainty_score":0.6782797},"labels":[],"label_agreement":null},{"id":"W3020567662","doi":"10.14740/gr1277","title":"First Reported Case of Extramedullary Plasmacytoma of the Appendix","year":2020,"lang":"en","type":"article","venue":"Gastroenterology Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of California, Irvine","keywords":"Appendix; Medicine; Plasmacytoma; Extramedullary plasmacytoma; General surgery; Radiology; Multiple myeloma; Internal medicine; Geology; Paleontology","score_opus":0.10772909909404366,"score_gpt":0.3807844550345941,"score_spread":0.27305535594055047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020567662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923345,0.00007606873,0.000026614674,0.006195378,0.000036610254,0.0007459363,0.000051568528,0.000015536489,0.00051782856],"genre_scores_gemma":[0.9992607,0.000033067332,0.0003491121,0.00013551593,0.0000516905,0.000037356334,0.000020487547,0.000017840164,0.000094186624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976513,0.00037328212,0.0004381637,0.00031874888,0.00062264665,0.00059586397],"domain_scores_gemma":[0.9984219,0.00021230648,0.0001223001,0.0005685531,0.0003328902,0.0003420511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056719495,0.00011831443,0.00038278924,0.00015248301,0.0001211184,0.0000051068737,0.00025601347,0.00008927356,0.00043217596],"category_scores_gemma":[0.00097395835,0.00007815109,0.00016045236,0.00039604033,0.0007690821,0.000032549488,0.00036884175,0.0006032081,0.00005039106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046741636,0.0004042865,0.9766462,0.0003307804,0.00038311683,0.009104245,0.00037859098,0.000011467439,0.004772544,0.000031419066,0.002743136,0.0005200931],"study_design_scores_gemma":[0.014023989,0.008296932,0.9095922,0.00026656632,0.00016944131,0.027995223,0.0013423642,0.005417655,0.031411767,0.00008179944,0.0012937177,0.00010830479],"about_ca_topic_score_codex":0.00028161795,"about_ca_topic_score_gemma":0.00024392115,"teacher_disagreement_score":0.067053914,"about_ca_system_score_codex":0.000043211392,"about_ca_system_score_gemma":0.00016460226,"threshold_uncertainty_score":0.47320238},"labels":[],"label_agreement":null},{"id":"W3021927596","doi":"10.3389/fonc.2020.00636","title":"Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities","year":2020,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Immune system; Immunotherapy; Stromal cell; Multiple myeloma; Immunology; Medicine; Bone marrow; Disease; Cancer research; Immunity; Biology; Internal medicine","score_opus":0.10997264487872302,"score_gpt":0.3503485907757205,"score_spread":0.24037594589699748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021927596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005937466,0.99529314,0.0009705828,0.000079884405,0.00022761287,0.0017749543,0.000017751787,0.000016859696,0.0010254502],"genre_scores_gemma":[0.020049093,0.96707475,0.012214575,0.000041582014,0.0000315299,0.00022771943,0.00020090965,0.000042738364,0.00011708642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976085,0.0007906155,0.00069386634,0.0003844687,0.0002152794,0.00030731648],"domain_scores_gemma":[0.9987826,0.000375924,0.00032270132,0.0002714669,0.0000678059,0.00017950867],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002341345,0.00035107267,0.0023345156,0.00079100224,0.00004699486,0.0000054092807,0.00015937543,0.00054019707,0.000020511698],"category_scores_gemma":[0.00010957884,0.0002862744,0.00015788905,0.00034829116,0.00024880553,0.000052853284,0.00014335844,0.0006394609,0.0000038621934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042599553,0.00038611554,0.00055377034,0.004023269,0.00026734345,0.0005245951,0.0012353407,7.511978e-7,0.000012391646,0.00014477948,0.000079734324,0.9923459],"study_design_scores_gemma":[0.011755907,0.0049617784,0.0030685235,0.0065950337,0.0011609275,0.00009304334,0.005012347,0.0036277683,0.0001529798,0.006023254,0.9568508,0.000697583],"about_ca_topic_score_codex":0.00031056345,"about_ca_topic_score_gemma":0.00024901982,"teacher_disagreement_score":0.9916483,"about_ca_system_score_codex":0.0008254393,"about_ca_system_score_gemma":0.001061444,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W3023266336","doi":"10.1038/s41375-020-0813-1","title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; McGill University Health Centre","funders":"Bristol-Myers Squibb","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Neutropenia; Dexamethasone; Oncology; Regimen; Refractory (planetary science); Febrile neutropenia; Surgery; Chemotherapy; Biology","score_opus":0.03163110271519153,"score_gpt":0.28793509524778443,"score_spread":0.2563039925325929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023266336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363077,0.0018467865,0.000021142667,0.0012458427,0.00004919582,0.0008948366,0.000038162263,0.00009056477,0.0021826765],"genre_scores_gemma":[0.9954644,0.00032375217,0.0020949773,0.0007956685,0.00016441879,0.0002344953,0.00006091224,0.00005340119,0.00080799975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793077,0.0001417996,0.00039021438,0.0006294255,0.0003508086,0.00055698835],"domain_scores_gemma":[0.9985542,0.00029274312,0.0000727459,0.0003773422,0.000050461815,0.0006525029],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012307541,0.0003392599,0.0005938108,0.00016266866,0.00007216307,0.000039190316,0.00008581504,0.0001790512,0.00020609015],"category_scores_gemma":[0.0004739887,0.00026665907,0.00012926565,0.00029997202,0.00011926855,0.00011690042,0.00008123246,0.00033865194,0.00018532191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021079311,0.0005282339,0.873936,0.00022229255,0.0004231018,0.0077405875,0.0022174541,0.000020716685,0.017882386,0.000035928948,0.0007747546,0.07513921],"study_design_scores_gemma":[0.050390787,0.0024949638,0.912408,0.00020296505,0.00013773725,0.00013676294,0.0002556203,0.00474727,0.013542502,0.000039366125,0.015229703,0.0004142976],"about_ca_topic_score_codex":0.00077746063,"about_ca_topic_score_gemma":0.00040081728,"teacher_disagreement_score":0.07472491,"about_ca_system_score_codex":0.0010913474,"about_ca_system_score_gemma":0.00033711485,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W3023905358","doi":"10.1038/s41408-020-0319-0","title":"The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Multiple myeloma; Bone marrow; Internal medicine; Cohort; Gastroenterology; Retrospective cohort study; Biopsy; Renal function; Pathology; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.014517996752799115,"score_gpt":0.24561186572125138,"score_spread":0.23109386896845227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023905358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593395,0.0007228455,0.000004991258,0.0018225446,0.000021859638,0.0011242449,0.00010463827,0.00001122553,0.00025368386],"genre_scores_gemma":[0.99867153,0.00011324945,0.00078603206,0.00011957052,0.000070261514,0.0001090659,0.000034949393,0.000040130348,0.00005523207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977845,0.000074657466,0.0003667019,0.00026203194,0.0010061825,0.0005059308],"domain_scores_gemma":[0.9988595,0.000034308203,0.00026311167,0.00018505653,0.00022949473,0.00042852364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010908715,0.00023449774,0.00034448976,0.000099849996,0.0001260788,0.00004463905,0.00016039678,0.000064892374,0.00009372669],"category_scores_gemma":[0.00004268523,0.00012609691,0.000074214215,0.0003017972,0.00011485935,0.00012582996,0.000052572675,0.0005033031,0.000003183629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009004161,0.0016852013,0.97681165,0.00006563549,0.00043430325,0.000060892165,0.00039759005,0.000020847781,0.0008701477,0.000003169232,0.00007837742,0.010568003],"study_design_scores_gemma":[0.05067732,0.006671833,0.926513,0.00042765058,0.00028218658,0.00001874765,0.00031377695,0.0002935277,0.011632005,0.00003000756,0.0028595182,0.00028043293],"about_ca_topic_score_codex":0.0002703516,"about_ca_topic_score_gemma":0.00026785838,"teacher_disagreement_score":0.05029868,"about_ca_system_score_codex":0.000096387506,"about_ca_system_score_gemma":0.00036879955,"threshold_uncertainty_score":0.51420826},"labels":[],"label_agreement":null},{"id":"W3024907887","doi":"10.1016/j.clml.2020.05.006","title":"A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Janssen Biotech; Roche Italia; Celgene; Bristol-Myers Squibb; Takeda Pharmaceutical Company; Takeda Canada; Novartis; Amgen","keywords":"Medicine; Lenalidomide; Refractory (planetary science); Authorization; Observational study; Internal medicine; Multiple myeloma; Oncology; Expanded access","score_opus":0.06524772035819815,"score_gpt":0.3229437420080261,"score_spread":0.25769602164982797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024907887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546075,0.000057597033,0.00035697586,0.00043208562,0.00006913557,0.002339341,0.00026916573,0.00019061781,0.000824317],"genre_scores_gemma":[0.99486774,0.000023527477,0.0013500679,0.00055218564,0.00024100872,0.00007482386,0.002406707,0.00014708603,0.0003368777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994165,0.000903835,0.0018020967,0.0011367357,0.0014237611,0.0005685862],"domain_scores_gemma":[0.99513555,0.0009261195,0.00080788764,0.00074114924,0.0015010164,0.0008883098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060716795,0.0005641314,0.0011406022,0.0001821255,0.0002515638,0.000053204618,0.00037497052,0.00019304644,0.00024749115],"category_scores_gemma":[0.0019345916,0.00040060916,0.00034893973,0.0008127399,0.00035315735,0.00036976102,0.00019856631,0.00039459096,0.00016820857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036725976,0.005282697,0.8879331,0.00013389812,0.001308962,0.0005297745,0.0003167239,0.000058715013,0.00016889344,0.000038223377,0.00032525393,0.0671778],"study_design_scores_gemma":[0.053601235,0.01945893,0.9231611,0.0003342611,0.000433067,0.000015496362,0.00029439386,0.0010217669,0.00013554019,0.0000029393907,0.0011725489,0.0003687101],"about_ca_topic_score_codex":0.00019180914,"about_ca_topic_score_gemma":0.00008657801,"teacher_disagreement_score":0.06680909,"about_ca_system_score_codex":0.00058155804,"about_ca_system_score_gemma":0.00088620174,"threshold_uncertainty_score":0.99984455},"labels":[],"label_agreement":null},{"id":"W3026687938","doi":"10.2991/chi.d.200502.001","title":"Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"Clinical Hematology International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Stem cell; Maintenance therapy; Transplantation; Intensive care medicine; Disease; Oncology; Malignancy; Chemotherapy; Internal medicine","score_opus":0.09566178335813888,"score_gpt":0.4328981237115701,"score_spread":0.3372363403534312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026687938","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006926287,0.9824371,0.0042282003,0.0019645419,0.0020408132,0.0044546556,0.002188963,0.00023094573,0.0017621729],"genre_scores_gemma":[0.0048216307,0.9846588,0.003416114,0.0004379189,0.0005017223,0.0009604051,0.004245154,0.00008902404,0.00086927036],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609965,0.00028561088,0.00174436,0.00094925414,0.00038744262,0.0005336721],"domain_scores_gemma":[0.9930403,0.0051110056,0.0006336085,0.00036247526,0.00043944773,0.0004131212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027905457,0.00053342164,0.0026013956,0.00021196141,0.00008995768,0.00005468528,0.00051102287,0.000815758,0.00015924913],"category_scores_gemma":[0.00078723347,0.00040743794,0.0013518424,0.000135071,0.00029000023,0.0001192084,0.00007975641,0.00082427263,0.00048400005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016516193,0.00073537,0.0011468667,0.011565108,0.001371454,0.0038790365,0.000060560953,5.5221415e-7,8.5186326e-7,0.0017627504,0.002913976,0.97491187],"study_design_scores_gemma":[0.010295607,0.0015049897,0.0017751826,0.0052524987,0.0015073082,0.0017059493,0.00015132982,0.00058266823,0.000017753913,0.00023649943,0.9764758,0.00049446156],"about_ca_topic_score_codex":0.000015983482,"about_ca_topic_score_gemma":0.000033035292,"teacher_disagreement_score":0.9744174,"about_ca_system_score_codex":0.00015434466,"about_ca_system_score_gemma":0.00096431514,"threshold_uncertainty_score":0.99983776},"labels":[],"label_agreement":null},{"id":"W3029230186","doi":"10.1200/jco.2020.38.15_suppl.8501","title":"Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Clinical endpoint; Surrogate endpoint; Randomization; Oncology; Phases of clinical research; Gastroenterology; Surgery; Randomized controlled trial; Clinical trial","score_opus":0.1266587915961721,"score_gpt":0.4381648612830087,"score_spread":0.3115060696868366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029230186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663145,0.0004386584,0.00009232621,0.010134716,0.00029247295,0.0021803838,0.000089986686,0.00001210757,0.00012790441],"genre_scores_gemma":[0.9913871,0.00017106367,0.006636965,0.001238167,0.00045078478,0.000036569825,0.000009407839,0.00004515483,0.00002477589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99393666,0.0010089088,0.0028242453,0.000608034,0.0010949614,0.00052717485],"domain_scores_gemma":[0.99097043,0.0051909797,0.0015153654,0.00045984908,0.00078298367,0.0010804152],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0028136028,0.000374577,0.002267363,0.00022928014,0.00008628155,0.000027466245,0.00031294767,0.00035499161,0.00004530559],"category_scores_gemma":[0.011174348,0.00022789408,0.00024417968,0.00052909675,0.0004971307,0.0002181941,0.00029680764,0.0014238929,0.0000044721974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34838587,0.007955791,0.49212813,0.000040843574,0.0011474469,0.00048741282,0.0015588241,0.0000029178864,0.00019578685,0.0000011061642,0.00017195259,0.14792392],"study_design_scores_gemma":[0.20663227,0.0854845,0.7048336,0.0001769586,0.0005070988,0.00001941134,0.00072436495,0.00015445787,0.0001077521,0.000009282678,0.001194118,0.00015614979],"about_ca_topic_score_codex":0.00033002146,"about_ca_topic_score_gemma":0.0021384733,"teacher_disagreement_score":0.21270551,"about_ca_system_score_codex":0.00015258827,"about_ca_system_score_gemma":0.001029209,"threshold_uncertainty_score":0.99715495},"labels":[],"label_agreement":null},{"id":"W3029536828","doi":"10.1200/jco.2020.38.15_suppl.tps8553","title":"Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Carfilzomib; Adverse effect; Internal medicine; Dexamethasone; Multiple myeloma; Population; Randomization; Oncology; Clinical trial; Lenalidomide","score_opus":0.05597045505588093,"score_gpt":0.40172916654421975,"score_spread":0.3457587114883388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029536828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928678,0.00023591453,0.00008177241,0.001304297,0.000111372734,0.0047705024,0.000027002327,0.000028195658,0.0005731391],"genre_scores_gemma":[0.9971726,0.00015506275,0.0015130168,0.0005125559,0.0003318504,0.00006689905,0.000043520413,0.000068138484,0.00013633903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99198365,0.0021543105,0.003320674,0.0006231488,0.0011706492,0.00074756495],"domain_scores_gemma":[0.9921896,0.002955652,0.0019888089,0.00039812594,0.0010165104,0.0014512871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022584002,0.00048982585,0.004597129,0.00028469265,0.00018544373,0.000035981608,0.00035364865,0.00033719445,0.000101627666],"category_scores_gemma":[0.0065914225,0.00027915952,0.00047708122,0.00037656902,0.0005123546,0.00022230527,0.0001378065,0.0021526744,0.000018680646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.503927,0.02656343,0.40320364,0.000034245495,0.0017996813,0.014044329,0.0012175653,0.000017287943,0.0000047879403,6.889742e-7,0.00011178351,0.04907556],"study_design_scores_gemma":[0.5803848,0.21704657,0.19834562,0.00020926989,0.0009714507,0.00023761259,0.00043547503,0.0015765581,0.000020362373,0.0000017953666,0.0005848246,0.00018567566],"about_ca_topic_score_codex":0.000208744,"about_ca_topic_score_gemma":0.000739209,"teacher_disagreement_score":0.20485802,"about_ca_system_score_codex":0.00034955828,"about_ca_system_score_gemma":0.001189943,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W3029657105","doi":"10.1200/jco.2020.38.15_suppl.8531","title":"Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cereblon; Bone marrow; Flow cytometry; Pharmacology; Internal medicine; Immunology; Ubiquitin ligase","score_opus":0.20102354672216266,"score_gpt":0.509867596448804,"score_spread":0.3088440497266413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029657105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611753,0.0001219795,0.00018321461,0.0019468743,0.0003067897,0.0011243701,0.000017738093,0.000015449592,0.00016603165],"genre_scores_gemma":[0.99663174,0.000190488,0.002262244,0.00037661,0.0004057465,0.000027292,0.000010729762,0.000031435167,0.000063690735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938652,0.0015005489,0.0031535195,0.0003929557,0.0006936251,0.00039414916],"domain_scores_gemma":[0.9937019,0.003445487,0.001639697,0.0001717513,0.0004377401,0.0006034222],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031081033,0.00023314604,0.0016829991,0.000548698,0.00004042573,0.000008905835,0.00020025254,0.00035328922,0.000097218],"category_scores_gemma":[0.0103782695,0.00018835772,0.00038022682,0.00068923517,0.00014776073,0.00020729756,0.00008197864,0.0017869921,0.0000190901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10633036,0.09549888,0.68217015,0.00006814417,0.00060388417,0.0023011921,0.0011387836,0.000094226525,0.037740596,0.0000036134363,0.00013345011,0.07391672],"study_design_scores_gemma":[0.20298177,0.03859775,0.7308723,0.00010720072,0.00020583381,0.00008668768,0.0005225774,0.02505854,0.0005809969,0.00001019229,0.00086399924,0.00011216976],"about_ca_topic_score_codex":0.00012878823,"about_ca_topic_score_gemma":0.0006522021,"teacher_disagreement_score":0.09665142,"about_ca_system_score_codex":0.0005420847,"about_ca_system_score_gemma":0.0019573711,"threshold_uncertainty_score":0.9979577},"labels":[],"label_agreement":null},{"id":"W3030047905","doi":"10.3747/co.27.5385","title":"Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Public Health; Ottawa Hospital","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Regimen; Dexamethasone; Cyclophosphamide; Cohort; Internal medicine; Transplantation; Autologous stem-cell transplantation; Surgery; Oncology; Gastroenterology; Chemotherapy","score_opus":0.06555459435177843,"score_gpt":0.3499365590084082,"score_spread":0.2843819646566298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030047905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211186,0.0010175927,0.0014831339,0.0013274329,0.00021166685,0.0028653962,0.00020932227,0.00016633536,0.0006072621],"genre_scores_gemma":[0.990669,0.00072152895,0.006001954,0.00039763987,0.00014622207,0.00048357257,0.0014603072,0.000089113244,0.00003064604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606717,0.000293256,0.00072809646,0.0010218279,0.000856456,0.001033187],"domain_scores_gemma":[0.99702376,0.0008654541,0.0002808428,0.00046641144,0.00037764807,0.0009859033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021863212,0.0005750893,0.0012739513,0.000313318,0.00013324231,0.000037444577,0.00027786964,0.00020982478,0.00024502494],"category_scores_gemma":[0.00037215053,0.00042992798,0.00012767293,0.0010672137,0.00031725917,0.00024075151,0.00006366126,0.0008082478,0.00013369774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018487478,0.0034454623,0.91720927,0.00035970958,0.0003098022,0.0013547655,0.0018072684,0.00019926015,0.00016496475,0.000013848721,0.00057178497,0.05607637],"study_design_scores_gemma":[0.07525696,0.005190974,0.9063869,0.00034888397,0.00029109497,0.000038993414,0.00033081803,0.002881226,0.0008975654,0.000009423783,0.00789096,0.0004761948],"about_ca_topic_score_codex":0.00045015584,"about_ca_topic_score_gemma":0.0011180039,"teacher_disagreement_score":0.056769483,"about_ca_system_score_codex":0.00048472508,"about_ca_system_score_gemma":0.0007072474,"threshold_uncertainty_score":0.9998152},"labels":[],"label_agreement":null},{"id":"W3030269889","doi":"10.1016/j.jgo.2020.05.004","title":"Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment","year":2020,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institute on Aging; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Quality of life (healthcare); Gerontology; Intensive care medicine; Pediatrics; Internal medicine; Nursing","score_opus":0.04665365086083584,"score_gpt":0.36039423912309076,"score_spread":0.3137405882622549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030269889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918495,0.0017295204,0.00017634469,0.0050929403,0.000090162655,0.00080721994,0.000013483764,0.000010400068,0.0002304268],"genre_scores_gemma":[0.98810023,0.0033675286,0.007867385,0.00022216894,0.00035417738,0.000030692372,0.000008840765,0.000022498278,0.000026454687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977351,0.00037123813,0.0008249413,0.00027173647,0.0004432909,0.00035372502],"domain_scores_gemma":[0.9969366,0.001289653,0.00080218434,0.00015279194,0.00022919918,0.00058955245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000430556,0.00022763984,0.0011599435,0.00039006962,0.00004402354,0.0000133435315,0.00009552001,0.00014446225,0.00009445307],"category_scores_gemma":[0.0006248041,0.0001517879,0.000119991826,0.000504329,0.000072691626,0.000098202196,0.000052521802,0.00026532443,0.0000024102078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015043519,0.0020825618,0.91514724,0.00046955756,0.0005338093,0.0013254979,0.001861169,0.000039078037,0.0011990123,0.000011679437,0.00013187203,0.062155016],"study_design_scores_gemma":[0.056582112,0.016714217,0.9236928,0.00011424155,0.0001832329,0.0001163535,0.0015447643,0.00026841968,0.00031366805,0.0000044071426,0.00034245368,0.00012332943],"about_ca_topic_score_codex":0.0003687103,"about_ca_topic_score_gemma":0.0013381151,"teacher_disagreement_score":0.062031686,"about_ca_system_score_codex":0.0005877494,"about_ca_system_score_gemma":0.0016727587,"threshold_uncertainty_score":0.61897314},"labels":[],"label_agreement":null},{"id":"W3030811423","doi":"10.1200/jco.2020.38.15_suppl.8536","title":"Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Neutropenia; Refractory (planetary science); Internal medicine; Gastroenterology; Febrile neutropenia; Multiple myeloma; Surgery; Toxicity","score_opus":0.09030549551261925,"score_gpt":0.384794551510006,"score_spread":0.2944890559973868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030811423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311215,0.00043850098,0.000018780864,0.0029748613,0.0005059173,0.0027888054,0.000051027626,0.000034470428,0.000075507334],"genre_scores_gemma":[0.99435604,0.00027191715,0.0027395415,0.0017631267,0.00063454546,0.000046591995,0.000021654594,0.00008746381,0.00007911432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99274665,0.0010642626,0.003128388,0.0009226027,0.001331581,0.00080652797],"domain_scores_gemma":[0.99387205,0.0015387709,0.0013657688,0.00043639285,0.0006211901,0.0021658482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020081704,0.0005906749,0.0026957777,0.00059955247,0.00016237595,0.00005789227,0.00032269885,0.00046803098,0.00007979075],"category_scores_gemma":[0.005432011,0.0004004103,0.00027794216,0.0004428858,0.00033601464,0.00044272322,0.0004632331,0.0020459366,0.00003414942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05352909,0.012791718,0.8268607,0.0001135574,0.0008716452,0.0034687067,0.001647068,0.000015144562,0.0011505488,7.84666e-7,0.0007802023,0.0987708],"study_design_scores_gemma":[0.035520773,0.088287376,0.8632829,0.0004523797,0.00022815526,0.00009802594,0.0008071794,0.00007126283,0.00012536753,0.000002897835,0.010766549,0.00035709102],"about_ca_topic_score_codex":0.00016647723,"about_ca_topic_score_gemma":0.000240972,"teacher_disagreement_score":0.098413706,"about_ca_system_score_codex":0.0006364467,"about_ca_system_score_gemma":0.0012671176,"threshold_uncertainty_score":0.9998448},"labels":[],"label_agreement":null},{"id":"W3030820428","doi":"10.1200/jco.2020.38.15_suppl.8511","title":"Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"AbbVie","keywords":"Daratumumab; Medicine; Venetoclax; Dexamethasone; Lenalidomide; Internal medicine; Bortezomib; Ven; Multiple myeloma; Refractory (planetary science); Adverse effect; Gastroenterology; Oncology; Pharmacology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.07932042657040811,"score_gpt":0.43214285257206797,"score_spread":0.35282242600165986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030820428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988792,0.000065194894,0.000023242646,0.00026819395,0.000028121107,0.0006655756,0.000012566044,0.000002764853,0.00005512166],"genre_scores_gemma":[0.9987721,0.00004157026,0.0010274805,0.00008349389,0.000018957579,0.000006309048,0.000032612646,0.000012132381,0.000005354837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996505,0.00062453956,0.0018744257,0.00023604692,0.00057612767,0.00018384149],"domain_scores_gemma":[0.9962921,0.0011098202,0.0015540415,0.00016887396,0.00055186637,0.0003232672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011458846,0.00013950549,0.0019360177,0.0005765269,0.00002121339,0.0000031472732,0.00010595824,0.0001668689,0.000027953787],"category_scores_gemma":[0.0020874697,0.000089740555,0.000116541494,0.0010845448,0.00017076606,0.00013144399,0.000052370073,0.0007048274,3.1819621e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074126646,0.025392974,0.8676503,0.000023675537,0.002354686,0.00046192907,0.00079572696,0.00016377553,0.000058227673,0.000001628284,0.000019370773,0.028951103],"study_design_scores_gemma":[0.12755708,0.14672157,0.72131574,0.000055970704,0.0009534344,0.000002817741,0.00038549624,0.0028723702,0.000024408942,0.000002087783,0.000057601283,0.000051421117],"about_ca_topic_score_codex":0.00020709941,"about_ca_topic_score_gemma":0.0012513846,"teacher_disagreement_score":0.14633451,"about_ca_system_score_codex":0.00016898004,"about_ca_system_score_gemma":0.00078020466,"threshold_uncertainty_score":0.36595136},"labels":[],"label_agreement":null},{"id":"W3031273809","doi":"10.1200/jco.2020.38.15_suppl.8519","title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Renal function; Internal medicine; Gastroenterology; Tolerability; Neutropenia; Anemia; Creatinine; Population; Urology; Surgery; Adverse effect; Toxicity","score_opus":0.09016006363210953,"score_gpt":0.3858816295409379,"score_spread":0.29572156590882837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031273809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935963,0.00023136768,0.000041016458,0.004748968,0.00020540137,0.00051814056,0.000017248603,0.000013555059,0.0006279702],"genre_scores_gemma":[0.99395937,0.00020688272,0.0036791228,0.001560188,0.00045993982,0.0000058685196,0.000019571129,0.000031038875,0.00007802255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960336,0.0005313595,0.0019061451,0.00035095646,0.000726762,0.00045119133],"domain_scores_gemma":[0.9955993,0.0016037113,0.0010608459,0.00018576243,0.00033547555,0.0012148503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001177513,0.00023494156,0.0014392185,0.00017471833,0.000050384795,0.000016466396,0.00015794122,0.0003263179,0.00015109958],"category_scores_gemma":[0.0034732,0.0001513391,0.0002447218,0.00020418418,0.0002419587,0.000175504,0.00011442334,0.0013285406,0.000027562435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03447106,0.005485079,0.845224,0.000042134536,0.0004215459,0.002438722,0.00014963212,0.0000050129393,0.00019786769,0.0000027911742,0.0012535516,0.110308595],"study_design_scores_gemma":[0.05576918,0.056865573,0.8741105,0.00016398185,0.0001680807,0.00010310574,0.00007841337,0.00014651676,0.00010399536,0.000012279599,0.012355078,0.00012328061],"about_ca_topic_score_codex":0.00003065373,"about_ca_topic_score_gemma":0.00007236687,"teacher_disagreement_score":0.11018531,"about_ca_system_score_codex":0.0002843616,"about_ca_system_score_gemma":0.0008588657,"threshold_uncertainty_score":0.617143},"labels":[],"label_agreement":null},{"id":"W3031419286","doi":"10.1200/jco.2020.38.15_suppl.e20532","title":"The impact of first-line therapy with novel agents in multiple myeloma patients age 80 and above: A systematic review.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Anemia; Adverse effect; Population; Retrospective cohort study; Randomized controlled trial; Surgery; Pediatrics","score_opus":0.21368511920464062,"score_gpt":0.49357388088968407,"score_spread":0.27988876168504345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031419286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945177,0.0053366283,0.000027177535,0.003617066,0.00005668082,0.0013941836,0.0000153833,0.0000030663034,0.00009805121],"genre_scores_gemma":[0.97862566,0.019993346,0.00035251994,0.0008718846,0.00010142726,0.000015383666,0.0000043498158,0.00001447348,0.000020986525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655247,0.00041704366,0.0021633322,0.0001536353,0.00047914404,0.00023438547],"domain_scores_gemma":[0.994044,0.0032628397,0.0015996359,0.0001965073,0.00041518718,0.00048183592],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0017945353,0.00015484699,0.001966144,0.00005900287,0.000040916144,0.000008344447,0.0001759681,0.00012557775,0.000020793184],"category_scores_gemma":[0.011513533,0.00006523476,0.00035906507,0.00020446679,0.00018778781,0.00006827667,0.00004742667,0.00056002237,0.0000030026883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013359415,0.0032790995,0.96260667,0.006605557,0.0012895772,0.0006602098,0.00016169777,0.000007771874,0.00002738955,0.00000188375,0.0005950737,0.01140566],"study_design_scores_gemma":[0.029013328,0.030442374,0.9305596,0.008473286,0.00020803131,0.000072964314,0.000030850897,0.0008097707,0.000010017999,0.000008743764,0.00031065225,0.000060399198],"about_ca_topic_score_codex":0.000050039594,"about_ca_topic_score_gemma":0.00007142508,"teacher_disagreement_score":0.032047085,"about_ca_system_score_codex":0.00010459276,"about_ca_system_score_gemma":0.0004517385,"threshold_uncertainty_score":0.9968129},"labels":[],"label_agreement":null},{"id":"W3031773775","doi":"10.1200/jco.2020.38.15_suppl.8541","title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Cytogenetics; Adverse effect; Nausea; Gastroenterology; Refractory (planetary science); Oncology; Lenalidomide; Surgery; Multiple myeloma","score_opus":0.08724952197433244,"score_gpt":0.3742772388134105,"score_spread":0.2870277168390781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031773775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995544,0.0003572191,0.00008097281,0.002895785,0.00028216187,0.00051394926,0.00004542039,0.000013128541,0.00026736013],"genre_scores_gemma":[0.99155915,0.0007464762,0.005949418,0.0011103599,0.0005140441,0.000005660145,0.000026621583,0.000040211657,0.000048062047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571335,0.000706343,0.0019920156,0.00039484166,0.00073304283,0.00046041387],"domain_scores_gemma":[0.9946337,0.002163973,0.0013520423,0.00023126366,0.0004035257,0.0012155484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001127877,0.00025982436,0.0015774849,0.00017744303,0.000060466133,0.000017384706,0.00018328604,0.000395752,0.00013027647],"category_scores_gemma":[0.005531071,0.00017225646,0.00023123661,0.0002112362,0.00028001485,0.00012225189,0.00013007244,0.0015163218,0.000034793888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021138659,0.0036106326,0.78755015,0.000034262237,0.00044106867,0.0014826041,0.00011269073,0.000012497821,0.00009961139,0.0000030658357,0.00049650244,0.18501823],"study_design_scores_gemma":[0.051916286,0.047890216,0.89139056,0.00011595119,0.00028774206,0.000060713526,0.00006785794,0.00015633854,0.00017132005,0.000023003706,0.0077781193,0.00014190069],"about_ca_topic_score_codex":0.000111340414,"about_ca_topic_score_gemma":0.00021823417,"teacher_disagreement_score":0.18487632,"about_ca_system_score_codex":0.00023869012,"about_ca_system_score_gemma":0.0007653797,"threshold_uncertainty_score":0.70244145},"labels":[],"label_agreement":null},{"id":"W3032362629","doi":"10.1200/jco.2020.38.15_suppl.e20516","title":"First-line CyborD treatment for graft ineligible multiple myeloma patients: Real-life efficacy and tolerability.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Regimen; Tolerability; Neutropenia; Internal medicine; Multiple myeloma; Surgery; Population; Anemia; Adverse effect; Chemotherapy","score_opus":0.2225687004561233,"score_gpt":0.48105982702739764,"score_spread":0.2584911265712744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032362629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971772,0.0002992566,0.00034322185,0.02579537,0.00029885137,0.0011245884,0.000039568007,0.00002015391,0.00030699428],"genre_scores_gemma":[0.9886026,0.002434593,0.0056379666,0.0019411885,0.0012052638,0.000032644573,0.000031449443,0.000026876574,0.00008744958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644214,0.00024559107,0.0022219683,0.00034959696,0.00036759913,0.00037310296],"domain_scores_gemma":[0.99124986,0.005311513,0.0009063115,0.00021102212,0.0006846164,0.0016366552],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0008661395,0.0002269247,0.0018589421,0.00009290549,0.00009129281,0.000015632191,0.00012790096,0.00029687776,0.00006701147],"category_scores_gemma":[0.01887701,0.0001450563,0.0004982753,0.00014272981,0.00019153471,0.00010723209,0.000068526315,0.0004164612,0.000017730867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03685606,0.007229383,0.7356587,0.000114911265,0.00094416615,0.0002549472,0.00021037055,0.00003546499,0.00004074443,0.00002809828,0.002305648,0.21632153],"study_design_scores_gemma":[0.077382,0.07770662,0.75320166,0.00006153921,0.0004136974,0.00002731901,0.000043093907,0.0021265375,0.00008276626,0.000075869364,0.088759944,0.00011896501],"about_ca_topic_score_codex":0.00007373958,"about_ca_topic_score_gemma":0.00010671168,"teacher_disagreement_score":0.21620256,"about_ca_system_score_codex":0.00021307812,"about_ca_system_score_gemma":0.0010406112,"threshold_uncertainty_score":0.9893874},"labels":[],"label_agreement":null},{"id":"W3032537564","doi":"10.1038/s41375-020-0855-4","title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Medicine; Internal medicine; Profiling (computer programming); Oncology; Immune system; Immunology; Computer science","score_opus":0.025229035277628615,"score_gpt":0.2772892025512971,"score_spread":0.2520601672736685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032537564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976499,0.0001934939,0.00034289763,0.00009397674,0.0000048451216,0.0009007204,0.000013526812,0.0000471323,0.00075349415],"genre_scores_gemma":[0.988934,0.00003274162,0.010550129,0.00008188674,0.000025868441,0.00004473139,0.00010532211,0.000037645677,0.00018771758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874395,0.000047551828,0.0002256686,0.00031596035,0.0003798828,0.00028696927],"domain_scores_gemma":[0.9991334,0.00006877197,0.000111590685,0.00021988346,0.00016903019,0.00029733658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055700504,0.0002054012,0.00049988757,0.00006166778,0.000062951236,0.000015454827,0.00006388338,0.000060097795,0.00005193886],"category_scores_gemma":[0.00012430246,0.00010954783,0.000030742744,0.00029966477,0.00014736765,0.00008871906,0.00004012256,0.00019022595,0.000007877859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026614804,0.00013392215,0.961835,0.0002934129,0.00041060537,0.00022542749,0.00040730005,0.000014048633,0.003915572,0.000007428098,0.000011046608,0.006131392],"study_design_scores_gemma":[0.06739308,0.0123831825,0.72659355,0.00057489186,0.0005507447,0.000100235986,0.00048203816,0.0130587695,0.17832553,0.0000034644804,0.0001444033,0.00039011968],"about_ca_topic_score_codex":0.00025570256,"about_ca_topic_score_gemma":0.000053741824,"teacher_disagreement_score":0.2352415,"about_ca_system_score_codex":0.00013883872,"about_ca_system_score_gemma":0.00025259797,"threshold_uncertainty_score":0.44672307},"labels":[],"label_agreement":null},{"id":"W3032742617","doi":"10.1016/s2352-3026(20)30081-8","title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Sirius; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lenalidomide","score_opus":0.14371685728919703,"score_gpt":0.3637452154296498,"score_spread":0.2200283581404528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032742617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98400044,0.0006720248,0.000023863444,0.012645067,0.00005134092,0.0018380892,0.00055470533,0.000066634784,0.00014781942],"genre_scores_gemma":[0.9968877,0.00023546861,0.00049316575,0.0015533688,0.00017646598,0.00009871561,0.0004472374,0.000033342127,0.00007452876],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99720836,0.00091907114,0.00058730633,0.00048597762,0.00031838182,0.00048092342],"domain_scores_gemma":[0.99637103,0.0024733024,0.00025767754,0.00062478567,0.00008543187,0.00018779836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053857977,0.00027063,0.0013872079,0.000050065657,0.00015137118,0.000030454297,0.00024146581,0.00014010302,0.00007883874],"category_scores_gemma":[0.0024897666,0.00011507366,0.00006178452,0.00027641267,0.00026341667,0.00007384466,0.000066154,0.00047744153,0.000031710304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49580628,0.0014103106,0.4631036,0.000082218554,0.0008630125,0.0020889135,0.0051193805,0.000006840308,0.00067496963,0.000031652013,0.009378064,0.021434756],"study_design_scores_gemma":[0.27509278,0.005623862,0.7106761,0.00020729839,0.0002272088,0.00009597184,0.00024500757,0.0013284379,0.0011942176,0.00008538656,0.0049557067,0.00026802195],"about_ca_topic_score_codex":0.00051286677,"about_ca_topic_score_gemma":0.00051917555,"teacher_disagreement_score":0.2475725,"about_ca_system_score_codex":0.000055974237,"about_ca_system_score_gemma":0.00014112583,"threshold_uncertainty_score":0.46925676},"labels":[],"label_agreement":null},{"id":"W3033703217","doi":"10.1016/j.clml.2020.05.027","title":"Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Bristol-Myers Squibb Canada; Array BioPharma; Celgene; Novartis; Merck","keywords":"Medicine; Multiple myeloma; Melphalan; Autologous stem-cell transplantation; Internal medicine; Transplantation; Surgery; Cohort; Progression-free survival; Stem cell; Oncology; Overall survival","score_opus":0.09837376150056121,"score_gpt":0.37212455258916083,"score_spread":0.2737507910885996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033703217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428076,0.0015175253,0.0012047857,0.0008977056,0.00013548306,0.0015140317,0.00013873329,0.000040706313,0.00027027796],"genre_scores_gemma":[0.9963655,0.00069742725,0.0021472187,0.00030863084,0.00016661962,0.00013474478,0.00012620955,0.000034428216,0.000019220623],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997014,0.00033452673,0.0012660975,0.0004691657,0.0004917498,0.00042445827],"domain_scores_gemma":[0.99610466,0.0027318269,0.00036215506,0.00039855746,0.00017786383,0.00022495838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006888716,0.0002619319,0.0008387918,0.00008103821,0.00007144524,0.000013932468,0.00034374476,0.0001977428,0.000026713715],"category_scores_gemma":[0.0003732793,0.00017930924,0.00044623864,0.00033531667,0.00028385883,0.00008782493,0.000040717718,0.00030436378,0.000017335806],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043573473,0.0005686689,0.09715726,0.0010452383,0.00011262652,0.00010115612,0.0029358454,0.00001222008,0.0026456453,0.000086263746,0.00022951279,0.8907482],"study_design_scores_gemma":[0.011987832,0.0017101815,0.9625877,0.00028703464,0.00016515667,0.00002583008,0.00058621715,0.009475849,0.011875825,0.00007506347,0.0010616316,0.00016169419],"about_ca_topic_score_codex":0.00006111817,"about_ca_topic_score_gemma":0.000023919181,"teacher_disagreement_score":0.8905865,"about_ca_system_score_codex":0.00014585374,"about_ca_system_score_gemma":0.00065021124,"threshold_uncertainty_score":0.7312018},"labels":[],"label_agreement":null},{"id":"W3034037943","doi":"10.1111/bjh.16793","title":"Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Myeloma UK; University of Leeds; National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Cancer Research Institute; Celgene; University of Birmingham; Cancer Research Institute","keywords":"Medicine; Multiple myeloma; Melphalan; Oncology; Stem cell; Internal medicine; Disease; Transplantation; Overall survival; Surgery; Biology","score_opus":0.011623310942427956,"score_gpt":0.22495124785147702,"score_spread":0.21332793690904905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034037943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106896,0.0041758334,0.00006152958,0.00324897,0.00006521251,0.0005869006,0.0007534839,0.000031931722,0.0000071941263],"genre_scores_gemma":[0.99680185,0.0023113186,0.00041303772,0.00023213003,0.00007394994,0.000033557135,0.000055758963,0.000049852704,0.000028546385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728215,0.0005431475,0.0006616405,0.00044483074,0.0005379087,0.00053035247],"domain_scores_gemma":[0.997302,0.0003836096,0.00027807514,0.00016063628,0.00019622837,0.0016794752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025194173,0.000287657,0.0010240441,0.00015656036,0.00008834283,0.00007868169,0.00012731335,0.00015848187,0.00006421065],"category_scores_gemma":[0.00033175832,0.00025322498,0.00009384964,0.0001608082,0.0003044382,0.00017034162,0.00007527244,0.0006201131,0.0000052645446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009894913,0.00030422237,0.67245746,0.00023685445,0.00033840354,0.31123066,0.00059709826,0.000012062942,0.00006822503,0.000014068579,0.00004251942,0.0048035407],"study_design_scores_gemma":[0.018836092,0.0015303954,0.97101736,0.00078038,0.0005829721,0.0061179856,0.00006573605,0.0006788816,0.00007610033,0.00008259099,0.000015399151,0.00021610834],"about_ca_topic_score_codex":0.0009134391,"about_ca_topic_score_gemma":0.0003804764,"teacher_disagreement_score":0.30511266,"about_ca_system_score_codex":0.000052555548,"about_ca_system_score_gemma":0.00033071538,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W3035482992","doi":"10.1182/blood.v130.suppl_1.3132.3132","title":"The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lenalidomide; Multiple myeloma; Bortezomib; Medicine; Oncology; Autologous stem-cell transplantation; Stem cell; Induction chemotherapy; Internal medicine; Thalidomide; Chemotherapy; Biology","score_opus":0.0451861496722879,"score_gpt":0.3158915809301914,"score_spread":0.2707054312579035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035482992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987522,0.00003782615,0.000008435377,0.0000522067,0.00000894953,0.00046548684,0.0005511029,0.00001133732,0.000112475],"genre_scores_gemma":[0.99921435,0.00014450795,0.00013651371,0.0000032157736,0.0000119010565,0.000013899621,0.0004073249,0.00001698843,0.000051271294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986301,0.00011849578,0.00031250934,0.00034263285,0.0003087528,0.00028751857],"domain_scores_gemma":[0.99804103,0.00015797337,0.00031572965,0.0012128752,0.00012790933,0.0001444595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030094417,0.00017430964,0.0005775875,0.00023027671,0.00013408723,0.00002638482,0.00029362884,0.000045314806,0.0000062790264],"category_scores_gemma":[0.00002718548,0.00009576612,0.00008510497,0.00030536077,0.00026611058,0.00012005752,0.000028061246,0.000116842275,2.4137003e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063917884,0.0015492785,0.9809931,0.000033672113,0.0015868964,0.000068588764,0.00012719788,0.00001847885,0.001113527,0.0000015123837,0.0000027322244,0.008113221],"study_design_scores_gemma":[0.0211439,0.0012068164,0.96270853,0.00006884858,0.0007963226,0.0000026612747,0.00005490472,0.005882713,0.008047332,5.3509666e-7,0.0000026602518,0.00008478794],"about_ca_topic_score_codex":0.0119804805,"about_ca_topic_score_gemma":0.022128005,"teacher_disagreement_score":0.018284589,"about_ca_system_score_codex":0.000045318317,"about_ca_system_score_gemma":0.00014057882,"threshold_uncertainty_score":0.9957156},"labels":[],"label_agreement":null},{"id":"W3036230532","doi":"10.1182/bloodadvances.2020001435","title":"Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; Cancer Council Victoria; Mayo Clinic; Medical Research Council; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; University of Utah; Utah State University; Huntsman Cancer Institute; Utah Department of Health; National Health and Medical Research Council","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal gammopathy; Medicine; Monoclonal; Paraproteinemias; Genetics; Internal medicine; Biology; Immunology; Monoclonal antibody; Antibody","score_opus":0.037700322618257225,"score_gpt":0.29661162675624286,"score_spread":0.25891130413798563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036230532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827625,0.015967892,0.00006100049,0.0002202576,0.000021540805,0.00055293774,0.0001294671,0.000025246056,0.0002591674],"genre_scores_gemma":[0.9925371,0.0016456958,0.005575514,0.000046601883,0.000050806124,0.000026698468,0.000022349735,0.000017488454,0.00007778993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889,0.00003868053,0.0002973261,0.00026620174,0.00029753652,0.00021028738],"domain_scores_gemma":[0.99917865,0.00015274328,0.00014310073,0.00013930236,0.00014436357,0.0002418499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044820405,0.0001447474,0.0003793543,0.0000474903,0.000026480004,0.0000045329084,0.00008604199,0.00004659451,0.000027404554],"category_scores_gemma":[0.00028869716,0.00012229112,0.00005962634,0.0001828922,0.00011662875,0.0000748406,0.000048753198,0.00008150424,0.0000038136584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016997478,0.0006296817,0.459355,0.0011992848,0.0002696649,0.00013911161,0.00046553148,0.000027155298,0.49780473,0.000037096725,0.000019595856,0.038353406],"study_design_scores_gemma":[0.0071070357,0.0023740397,0.17538363,0.00015947591,0.00015772278,0.00002775949,0.00012242494,0.005605988,0.8076812,0.000038730104,0.001192913,0.00014910648],"about_ca_topic_score_codex":0.000008263574,"about_ca_topic_score_gemma":0.000012241743,"teacher_disagreement_score":0.30987644,"about_ca_system_score_codex":0.0000066887783,"about_ca_system_score_gemma":0.000075734344,"threshold_uncertainty_score":0.49868876},"labels":[],"label_agreement":null},{"id":"W3036571224","doi":"10.1158/1557-3265.liqbiop20-ia11","title":"Abstract IA11: Clinical applications of liquid biopsy in multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Liquid biopsy; Genetic heterogeneity; Exome sequencing; Biopsy; Somatic evolution in cancer; Circulating tumor cell; Biology; Multiple myeloma; Tumour heterogeneity; Exome; Pathology; Medicine; Cancer; Gene; Genetics; Mutation; Immunology; Metastasis; Phenotype","score_opus":0.39895135993122754,"score_gpt":0.5661026930599158,"score_spread":0.16715133312868824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036571224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852352,0.0011106012,0.00006752334,0.009033345,0.00007880286,0.0019260121,0.0001059652,0.000047179896,0.0023953565],"genre_scores_gemma":[0.9949241,0.002112863,0.00087643665,0.00036424483,0.00084527256,0.00058346416,0.000050006278,0.000038643688,0.00020491984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952839,0.00051387236,0.0015565995,0.0007982883,0.0011170893,0.00073023816],"domain_scores_gemma":[0.99397343,0.003413828,0.00014751352,0.00066605734,0.0006220217,0.001177127],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00340978,0.00017108776,0.0007936302,0.00021955739,0.00009210981,0.00001902409,0.0004340493,0.00031554716,0.0010176226],"category_scores_gemma":[0.005991662,0.00014035605,0.00034810498,0.0011882972,0.0009953876,0.00007616718,0.00029148234,0.0018816132,0.0005200202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090751555,0.0019217785,0.85780627,0.00033353543,0.00017800485,0.0002370662,0.000083164814,0.0000032840283,0.0019077299,0.000068741414,0.0023873656,0.12599789],"study_design_scores_gemma":[0.007948838,0.0022587061,0.9662287,0.00017707318,0.00002303407,0.000003898045,0.00014192214,0.0005757466,0.0016068954,0.00006399042,0.020835549,0.00013562528],"about_ca_topic_score_codex":0.0008020202,"about_ca_topic_score_gemma":0.00021727795,"teacher_disagreement_score":0.12586226,"about_ca_system_score_codex":0.00012340624,"about_ca_system_score_gemma":0.0011501606,"threshold_uncertainty_score":0.9998956},"labels":[],"label_agreement":null},{"id":"W3037740879","doi":"10.1111/cts.12836","title":"Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Chinese University of Hong Kong","keywords":"Daratumumab; Lenalidomide; Internal medicine; Oncology; Proportional hazards model; Medicine; Progression-free survival; Refractory (planetary science); Multiple myeloma; Bortezomib; Dexamethasone; Overall survival; Biology","score_opus":0.042149088892030735,"score_gpt":0.3326439552413016,"score_spread":0.29049486634927085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037740879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957301,0.000042474727,0.00019130172,0.0026132488,0.000041308966,0.00072702824,0.00006650963,0.000030694555,0.0005573379],"genre_scores_gemma":[0.9967646,0.0000069432635,0.002952236,0.00010551756,0.000057311558,0.000020148576,0.000054330427,0.000009440875,0.00002946121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977304,0.000060483257,0.00035471152,0.00049787044,0.0010467274,0.00030985626],"domain_scores_gemma":[0.998748,0.0002481269,0.000058367983,0.00017400217,0.0001596781,0.00061179214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043221575,0.00012789639,0.00023940201,0.000066973604,0.00013838056,0.000032200132,0.00017764323,0.00007698124,0.000027431677],"category_scores_gemma":[0.0008001511,0.000084786036,0.00004541536,0.00046851105,0.00095091027,0.00027752525,0.000057022015,0.0003227055,0.000011600178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020602816,0.00053003593,0.9599136,0.00002278874,0.000016217138,0.000028158076,0.000077101475,0.0000027932117,0.000028258339,0.00027091155,0.0000036143344,0.037046224],"study_design_scores_gemma":[0.011583715,0.0016172156,0.9796701,0.00009635155,0.000011388101,7.1442605e-7,0.000008836129,0.006630351,0.000018881985,0.00019857661,0.00007000948,0.00009386052],"about_ca_topic_score_codex":0.000023002725,"about_ca_topic_score_gemma":0.00006036173,"teacher_disagreement_score":0.036952365,"about_ca_system_score_codex":0.00001979462,"about_ca_system_score_gemma":0.00030133378,"threshold_uncertainty_score":0.35036686},"labels":[],"label_agreement":null},{"id":"W3038047590","doi":"10.1016/j.clml.2020.06.015","title":"Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Bristol-Myers Squibb Canada; bluebird bio; Takeda Pharmaceutical Company; AbbVie; Celgene; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Internal medicine","score_opus":0.18091232221144657,"score_gpt":0.4590091025912288,"score_spread":0.27809678037978225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038047590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034525734,0.9913602,0.000022244412,0.000846463,0.00021983587,0.0043087527,0.0016897041,0.000052361287,0.0011551842],"genre_scores_gemma":[0.00073793094,0.9886833,0.0027489925,0.00018588142,0.0011726316,0.00027131982,0.005682453,0.0001174064,0.00040011518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914078,0.0016322035,0.0034206612,0.001697085,0.0011789904,0.0006632319],"domain_scores_gemma":[0.9867106,0.0072527453,0.0014322009,0.0036745162,0.0002897264,0.0006401869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010570866,0.00093167427,0.005696189,0.00028226193,0.000094469186,0.000046221354,0.0018777933,0.0005759854,0.00057581736],"category_scores_gemma":[0.007094577,0.0005702732,0.0017234237,0.0011148094,0.00040859092,0.00024130059,0.0006972867,0.0005850657,0.0001991314],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028041858,0.0010453613,0.0025799535,0.01061078,0.0016265105,0.0004345623,0.00063266535,9.658099e-8,0.0000015632451,0.000015176102,0.041549068,0.94122386],"study_design_scores_gemma":[0.0083283,0.0010478469,0.10785197,0.064261556,0.0029432212,0.00009938464,0.0006856682,0.00021779927,0.000005010654,0.000021672871,0.81405145,0.0004861002],"about_ca_topic_score_codex":0.002515697,"about_ca_topic_score_gemma":0.00016189567,"teacher_disagreement_score":0.9407377,"about_ca_system_score_codex":0.0008603817,"about_ca_system_score_gemma":0.007528213,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W3038249453","doi":"10.1177/1941874420937562","title":"Isolated Leptomeningeal Recurrence of Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"The Neurohospitalist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University","funders":"","keywords":"Medicine; Multiple myeloma; Pathology; Internal medicine","score_opus":0.0370787913495811,"score_gpt":0.29404742042028514,"score_spread":0.25696862907070406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038249453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902154,0.00018748015,0.00009006638,0.0069054426,0.0000873882,0.00053842505,0.000043294738,0.00007793839,0.0018545467],"genre_scores_gemma":[0.9988732,0.000044675715,0.00015428521,0.00059022964,0.00009446266,0.000019278572,0.00003221994,0.000022574508,0.00016908188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988202,0.00006666915,0.0002369704,0.00024759234,0.0003536697,0.00027489502],"domain_scores_gemma":[0.99910986,0.00013822725,0.000084858046,0.00032252562,0.0000991433,0.00024537358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007126217,0.0001424261,0.00025187808,0.000032582237,0.000082130806,0.000015546388,0.00021001144,0.00003773009,0.00011969991],"category_scores_gemma":[0.0005138413,0.00009153716,0.00010641084,0.00032862602,0.00017546,0.000057627352,0.00010198342,0.0002211678,0.000117222735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006602577,0.0010607013,0.80620724,0.00055892346,0.00062962977,0.001109683,0.0048332415,0.000024651075,0.09044517,0.0005318966,0.014001284,0.07399498],"study_design_scores_gemma":[0.0072339294,0.005457819,0.9190467,0.00013323817,0.00017425709,0.00010242296,0.00025788564,0.023118569,0.036701396,0.000072753974,0.0073826527,0.00031837894],"about_ca_topic_score_codex":0.000077441095,"about_ca_topic_score_gemma":0.0000031222148,"teacher_disagreement_score":0.11283943,"about_ca_system_score_codex":0.000018152496,"about_ca_system_score_gemma":0.000053357817,"threshold_uncertainty_score":0.3732777},"labels":[],"label_agreement":null},{"id":"W3038822856","doi":"10.1016/j.clml.2020.06.024","title":"Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Takeda Oncology; Amgen; Takeda Pharmaceuticals U.S.A.; British Microcirculation Society; Celgene","keywords":"Medicine; Bortezomib; Ixazomib; Internal medicine; Regimen; Multiple myeloma; Proteasome inhibitor; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Carfilzomib","score_opus":0.07255064007328885,"score_gpt":0.3545877338522112,"score_spread":0.2820370937789224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038822856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919617,0.00022218128,0.0003127967,0.0030686362,0.0001304777,0.0035802661,0.0003847747,0.00010981626,0.00022930569],"genre_scores_gemma":[0.9957329,0.000083314626,0.0008885265,0.0016436027,0.0002796225,0.0002855518,0.0009686571,0.00007372435,0.00004408705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942393,0.0005580034,0.0021277596,0.0014001693,0.0008446649,0.00083013595],"domain_scores_gemma":[0.9966769,0.0008137942,0.00029547274,0.00077354664,0.00020187555,0.0012384168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076858327,0.000501397,0.001496266,0.00024957905,0.00006715645,0.00003743769,0.00024701096,0.0005734831,0.00021277908],"category_scores_gemma":[0.0023173452,0.00047723632,0.0004434192,0.0009513091,0.0003241846,0.00029555833,0.00016469495,0.00055494654,0.00024672877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0112924315,0.0016376112,0.780507,0.00024857515,0.000114121765,0.001482891,0.00053994276,0.000016987033,0.023456799,0.0000070701444,0.00052564236,0.18017092],"study_design_scores_gemma":[0.025641613,0.001459438,0.951283,0.0005903174,0.00006360823,0.000021670374,0.00008396863,0.0027376474,0.017563513,0.00009072309,0.00009663466,0.00036789684],"about_ca_topic_score_codex":0.0010269122,"about_ca_topic_score_gemma":0.0006718417,"teacher_disagreement_score":0.17980303,"about_ca_system_score_codex":0.0016250168,"about_ca_system_score_gemma":0.0009491781,"threshold_uncertainty_score":0.99976796},"labels":[],"label_agreement":null},{"id":"W3041001077","doi":"10.1182/blood.v130.suppl_1.3462.3462","title":"Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lenalidomide; Tolerability; Discontinuation; Maintenance therapy; Regimen; Salvage therapy; Multiple myeloma; Internal medicine; Neutropenia; Surgery; Melphalan; Oncology; Adverse effect; Chemotherapy","score_opus":0.04049360258884416,"score_gpt":0.3047032085685599,"score_spread":0.26420960597971577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041001077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770457,0.00019775004,0.000002454583,0.00045811135,0.000025166624,0.0006117377,0.00004503697,0.000017307952,0.0009378763],"genre_scores_gemma":[0.9990283,0.0002311782,0.00042942635,0.000026139765,0.000030377018,0.000023584595,0.000015169479,0.000012901385,0.00020289519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878407,0.000052652937,0.00027007025,0.00032523085,0.0002255205,0.00034247208],"domain_scores_gemma":[0.998938,0.00016803459,0.00010078521,0.0005391247,0.00007960316,0.00017440098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014107968,0.00014775502,0.0003647398,0.00007857347,0.000115812574,0.000027660566,0.00014468419,0.000045671422,0.000039514194],"category_scores_gemma":[0.0003151118,0.00010952247,0.00007003113,0.000064349224,0.00027222856,0.00010015699,0.000037018024,0.000121132965,0.0000030745505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025946898,0.0027328902,0.9247675,0.000056524776,0.000061570696,0.0002972108,0.0018553311,2.1148423e-7,0.055582497,0.000015852098,0.0000036881477,0.01203203],"study_design_scores_gemma":[0.023392892,0.00034597307,0.90244687,0.00024693165,0.000018704515,0.00001912953,0.00012723455,0.000042176198,0.07321015,0.000010393571,0.00005360808,0.000085952124],"about_ca_topic_score_codex":0.0025924705,"about_ca_topic_score_gemma":0.0035073983,"teacher_disagreement_score":0.022320649,"about_ca_system_score_codex":0.000033704335,"about_ca_system_score_gemma":0.000058234902,"threshold_uncertainty_score":0.4466197},"labels":[],"label_agreement":null},{"id":"W3042425559","doi":"10.3747/co.27.5577","title":"Evaluation of a Routine Screening Program with Tuberculin Skin Testing on Rates of Detection of Latent Tuberculosis Infection and Prevention of Active Tuberculosis in Patients with Multiple Myeloma at a Canadian Cancer Centre","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tuberculin; Latent tuberculosis; Tuberculosis; Cohort; Retrospective cohort study; Internal medicine; Mycobacterium tuberculosis; Pathology","score_opus":0.1043383910954696,"score_gpt":0.3856847006123472,"score_spread":0.2813463095168776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042425559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718195,0.00015258459,0.000024324023,0.00009519885,0.000026597405,0.002416829,0.00006603882,0.000008986551,0.000027484812],"genre_scores_gemma":[0.9990327,0.000044478515,0.0005854921,0.0000033764613,0.000015790169,0.00018106992,0.00012081897,0.00001548334,8.084407e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824405,0.00030080136,0.00040606398,0.00028363467,0.00053784694,0.00022761407],"domain_scores_gemma":[0.9981043,0.0001320236,0.0003811134,0.00010479501,0.0011043672,0.00017344048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030090334,0.00016030009,0.0004611596,0.0002957079,0.000036853744,0.0000022918468,0.000029888533,0.00009054323,0.000018511711],"category_scores_gemma":[0.0005392612,0.00012358991,0.000049497394,0.00059006707,0.000102885904,0.00007747669,0.000028842414,0.0001575692,3.0698047e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002407189,0.0007306697,0.56880563,0.00026305998,0.0002130212,8.68043e-7,0.0005045834,0.00043449664,0.0010102033,2.6109038e-7,5.6847097e-7,0.42562944],"study_design_scores_gemma":[0.011095413,0.007211365,0.92509496,0.00088734966,0.00046601886,0.0000022217687,0.00010318004,0.02631274,0.028736614,0.000001910361,0.0000069605608,0.0000812808],"about_ca_topic_score_codex":0.032713432,"about_ca_topic_score_gemma":0.16460735,"teacher_disagreement_score":0.42554817,"about_ca_system_score_codex":0.00069271727,"about_ca_system_score_gemma":0.00038667204,"threshold_uncertainty_score":0.9737278},"labels":[],"label_agreement":null},{"id":"W3043145484","doi":"10.22541/au.159136816.67491836","title":"Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada); SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Thalidomide; Repurposing; Lenalidomide; Drug repositioning; Medicine; Pneumonia; Angiogenesis; Immunology; Immune system; Inflammation; Pharmacology; Biology; Cancer research; Multiple myeloma; Drug; Internal medicine","score_opus":0.19112690121913922,"score_gpt":0.4308300542973206,"score_spread":0.23970315307818135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043145484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902895,0.0023095452,0.002189622,0.0010386473,0.00008998892,0.0033160443,0.000074055955,0.000029000159,0.0006635993],"genre_scores_gemma":[0.9952021,0.0029997176,0.0011360238,0.00006211501,0.00004405106,0.00039013245,0.00006459804,0.000022627295,0.00007858669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989837,0.000063101455,0.00027677728,0.00031975508,0.00021801393,0.00013868698],"domain_scores_gemma":[0.99893546,0.0003568761,0.00018797327,0.00030476562,0.00016154458,0.000053364573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007393788,0.00020458226,0.00044887493,0.0001138102,0.000057615667,0.000012455433,0.00004946404,0.000108405366,0.0000096629155],"category_scores_gemma":[0.0002978448,0.00011976735,0.00020254214,0.000075910764,0.00006651798,0.000024651305,0.0000620877,0.000113660266,0.0000016175989],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005477437,0.00429925,0.0048583956,0.0029413255,0.0073609035,0.00006126204,0.002213684,0.00014050807,0.83296436,0.0016499548,0.00014518572,0.13788773],"study_design_scores_gemma":[0.003067977,0.0027256047,0.0051138084,0.00024131875,0.0005299841,0.000009084126,0.00011702255,0.0026337686,0.98443973,0.0005571174,0.0004844609,0.00008013252],"about_ca_topic_score_codex":0.00033052766,"about_ca_topic_score_gemma":0.00002383705,"teacher_disagreement_score":0.15147537,"about_ca_system_score_codex":0.00012062727,"about_ca_system_score_gemma":0.00010366972,"threshold_uncertainty_score":0.4883971},"labels":[],"label_agreement":null},{"id":"W3043437003","doi":"10.1111/bjh.16945","title":"Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Leeds; National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Cancer Research Institute; Celgene; University of Birmingham; Cancer Research Institute; Merck; Myeloma UK","keywords":"Medicine; Lenalidomide; Thalidomide; Multiple myeloma; Tolerability; Internal medicine; Discontinuation; Maintenance therapy; Cyclophosphamide; Dexamethasone; Oncology; Dosing; Surgery; Chemotherapy; Adverse effect","score_opus":0.02275721751476278,"score_gpt":0.28080097173672386,"score_spread":0.2580437542219611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043437003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953282,0.0014143862,0.00012135207,0.0006370802,0.00012810738,0.0021827845,0.00015299412,0.000009593713,0.00002549021],"genre_scores_gemma":[0.9966001,0.0008522776,0.0022279352,0.00009186988,0.0000880594,0.00003305283,0.00007004935,0.000029960607,0.000006729764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970222,0.00039860906,0.0012879834,0.00036076942,0.0004838523,0.00044656786],"domain_scores_gemma":[0.997765,0.00066439586,0.00076040596,0.00019602201,0.0003110134,0.00030317117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005508579,0.00022729374,0.001177598,0.00016265981,0.00015768119,0.00007270904,0.00029196564,0.00012715916,0.000014910339],"category_scores_gemma":[0.0012243678,0.00017008066,0.00009590897,0.00026723172,0.00022291132,0.00035789836,0.00010321311,0.00055905303,0.0000011411544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9400816,0.0024514543,0.011417207,0.00013580668,0.0007189075,0.018906653,0.003628743,0.00014394689,0.0023501557,0.0000040259138,0.00010806045,0.020053418],"study_design_scores_gemma":[0.9168784,0.0016115456,0.0702452,0.0016567115,0.00021778543,0.0035007598,0.0007037989,0.0017386292,0.0032502778,0.000011193006,0.000021704951,0.00016398112],"about_ca_topic_score_codex":0.0016431414,"about_ca_topic_score_gemma":0.00018826028,"teacher_disagreement_score":0.058827993,"about_ca_system_score_codex":0.000083271196,"about_ca_system_score_gemma":0.00023172243,"threshold_uncertainty_score":0.69356877},"labels":[],"label_agreement":null},{"id":"W3044064794","doi":"10.1016/j.rmcr.2020.101169","title":"Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia","year":2020,"lang":"en","type":"article","venue":"Respiratory Medicine Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Bortezomib; Diffuse alveolar hemorrhage; Bronchoalveolar lavage; Respiratory failure; Leukemia; Multiple myeloma; Plasma cell leukemia; Internal medicine; Gastroenterology; Lung; Oncology; Surgery","score_opus":0.04139765255771457,"score_gpt":0.2887289116128026,"score_spread":0.24733125905508804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044064794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266374,0.0007861593,0.000019975463,0.000773051,0.00009361394,0.0014332037,0.0000067323867,0.00012346337,0.0041000587],"genre_scores_gemma":[0.9968963,0.000017135711,0.00026768903,0.0022035372,0.00029909948,0.00013064961,0.00003751099,0.00007792485,0.00007014099],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.996395,0.00014688779,0.0009298274,0.0008503699,0.0010149799,0.00066291605],"domain_scores_gemma":[0.99718577,0.00012471757,0.00033304354,0.0007694313,0.0001826596,0.0014044051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036375085,0.0004281776,0.00083878887,0.00028577104,0.00010256386,0.000014872238,0.000055286324,0.00016395951,0.00023900523],"category_scores_gemma":[0.0007686509,0.0002929154,0.000104384664,0.0006464942,0.00013720266,0.00012273653,0.00007814979,0.000642474,0.000035025565],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096657884,0.0003479807,0.029539598,0.0003630486,0.000074302174,0.93757236,0.0009790953,0.000012209522,0.01877414,0.0000011751192,0.0009324852,0.0104370285],"study_design_scores_gemma":[0.07007832,0.029971447,0.024132833,0.0018149964,0.0009932216,0.65010446,0.0055289543,0.007067757,0.1558698,0.000011391912,0.052678943,0.0017478548],"about_ca_topic_score_codex":0.0004824416,"about_ca_topic_score_gemma":0.00013560244,"teacher_disagreement_score":0.28746787,"about_ca_system_score_codex":0.0005787405,"about_ca_system_score_gemma":0.0010254554,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W3044606577","doi":"10.1111/ejh.13496","title":"Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Ottawa Hospital; University of Ottawa; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Confidence interval; Hazard ratio; Adverse effect; Randomized controlled trial; Internal medicine; Multiple myeloma; Maintenance therapy; MEDLINE; Relative risk; Surgery; Chemotherapy","score_opus":0.056808534067040915,"score_gpt":0.3254934137450504,"score_spread":0.2686848796780095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044606577","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008200397,0.9960716,0.00012009401,0.00065047253,0.000017431345,0.0028871887,0.00005101068,0.000015927912,0.000104300525],"genre_scores_gemma":[0.0033258977,0.9950356,0.0009556338,0.00038015036,0.000025730755,0.00009728089,0.00004420749,0.00008605469,0.000049430637],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99383056,0.0027312413,0.0021051625,0.00046489618,0.00042282516,0.0004453089],"domain_scores_gemma":[0.9966669,0.0006771827,0.00149793,0.00046884685,0.00022976956,0.00045935568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011366382,0.000626662,0.01330272,0.0007969617,0.000039774703,0.000025994155,0.00036971454,0.00008249476,0.00007119112],"category_scores_gemma":[0.00044004244,0.00030907916,0.0016148719,0.0010607806,0.000118992866,0.00007552154,0.00004494296,0.000820673,0.00004464075],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005677547,0.00021928694,0.000086598884,0.6880198,0.14552915,0.15892571,0.00022389111,6.90288e-7,7.105233e-8,0.000006856636,0.00011855613,0.006301642],"study_design_scores_gemma":[0.007856142,0.0016109849,0.00005862381,0.2636398,0.65316826,0.05651256,0.000051759936,0.000016111826,7.4237755e-7,0.000001035355,0.016716782,0.00036721327],"about_ca_topic_score_codex":0.000015953985,"about_ca_topic_score_gemma":0.00005111473,"teacher_disagreement_score":0.5076391,"about_ca_system_score_codex":0.00006175065,"about_ca_system_score_gemma":0.00027342385,"threshold_uncertainty_score":0.9999361},"labels":[],"label_agreement":null},{"id":"W3046562558","doi":"10.1038/s41598-020-70026-w","title":"Synergistic drug combinations and machine learning for drug repurposing in chordoma","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health; Ministero dello Sviluppo Economico; Ontario Ministry of Economic Development and Innovation; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Novartis Pharma; Wellcome Trust; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Pfizer; Chordoma Foundation; Research Opportunities Initiative, University of North Carolina; Genome Canada","keywords":"Chordoma; Medicine; Drug repositioning; Repurposing; Palbociclib; PI3K/AKT/mTOR pathway; Drug; Pharmacology; Oncology; Cancer research; Cancer; Internal medicine; Biology; Signal transduction; Surgery","score_opus":0.034847664221890326,"score_gpt":0.3028092606433167,"score_spread":0.26796159642142636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046562558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994193,0.00075134507,0.00036450362,0.0024575943,0.00045889342,0.000958409,0.0000037148486,0.0000645573,0.00074795686],"genre_scores_gemma":[0.99386066,0.000010197355,0.0012910868,0.00004539403,0.000034345856,0.00006565855,0.0001666712,0.000016092012,0.004509897],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99844974,0.0000448284,0.00032881513,0.00056092395,0.00033887546,0.0002767917],"domain_scores_gemma":[0.9991484,0.00011040196,0.00010862545,0.00023624723,0.00011602763,0.00028029858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070928317,0.000105254025,0.00021532322,0.00016575062,0.00029716583,0.00013136654,0.000039049708,0.000023716682,0.000034817273],"category_scores_gemma":[0.0015498387,0.00009056471,0.000054773864,0.0003872093,0.00013250344,0.00009362086,0.00005856238,0.0001566704,0.0000051409047],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048595286,0.0010837747,0.8437865,0.0009925811,0.00018720537,0.008400461,0.005290557,0.0002624402,0.07535216,0.0007101541,0.014632732,0.048815493],"study_design_scores_gemma":[0.024878995,0.0010933973,0.20251988,0.0014171241,0.00049805746,0.0015866031,0.0016765877,0.35112986,0.11743858,0.0171349,0.2791909,0.00143513],"about_ca_topic_score_codex":0.0001240823,"about_ca_topic_score_gemma":0.000065135486,"teacher_disagreement_score":0.6412666,"about_ca_system_score_codex":0.000057304693,"about_ca_system_score_gemma":0.000112375164,"threshold_uncertainty_score":0.36931217},"labels":[],"label_agreement":null},{"id":"W3046566558","doi":"10.1182/blood.2020007522","title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Carfilzomib; Internal medicine; Multiple myeloma; Minimal residual disease; Neutropenia; Autologous stem-cell transplantation; Transplantation; Regimen; Surgery; Oncology; Clinical endpoint; Chemotherapy; Clinical trial; Leukemia","score_opus":0.03450849152160632,"score_gpt":0.2749467073629789,"score_spread":0.24043821584137257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046566558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954985,0.0014861576,0.00006116048,0.0015617643,0.000020728317,0.0007290966,0.000066342844,0.0000639614,0.00051228225],"genre_scores_gemma":[0.99665976,0.00047724327,0.0020534883,0.00045676812,0.000112730966,0.00008031275,0.000063942854,0.000029081193,0.00006667528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858254,0.000076396595,0.0002514549,0.00039101325,0.0002895655,0.0004090117],"domain_scores_gemma":[0.99892396,0.0003017981,0.000034825287,0.00018181102,0.000033617158,0.00052401214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010892931,0.00019443333,0.0004301304,0.00009626118,0.000046718847,0.000022809689,0.0000799556,0.00009178273,0.00007834346],"category_scores_gemma":[0.00039086127,0.00016059908,0.00007332679,0.00023876697,0.00006663068,0.00007132707,0.000038799986,0.00023931706,0.000046671845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003066656,0.0007969007,0.95444053,0.00027222454,0.00030812938,0.0067276377,0.0023047212,0.0000090419135,0.020384764,0.00001973936,0.00013906688,0.011530563],"study_design_scores_gemma":[0.10397363,0.0009296242,0.8498314,0.00020406152,0.00024926523,0.00019196328,0.00027028954,0.00287005,0.040448762,0.000016856904,0.0007390189,0.00027505396],"about_ca_topic_score_codex":0.00065159425,"about_ca_topic_score_gemma":0.00039457856,"teacher_disagreement_score":0.104609124,"about_ca_system_score_codex":0.000035319914,"about_ca_system_score_gemma":0.000119579745,"threshold_uncertainty_score":0.65490407},"labels":[],"label_agreement":null},{"id":"W3047919807","doi":"10.1136/jitc-2020-000915","title":"Discovery and validation of surface <i>N</i>-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; University of Toronto; Midwest Athletes Against Childhood Cancer","keywords":"Flow cytometry; Immunotherapy; Cell; Proteome; Medicine; Glycoprotein; Cell culture; Mass cytometry; Cancer research; Computational biology; Bioinformatics; Chemistry; Immunology; Biology; Molecular biology; Internal medicine; Cancer; Biochemistry","score_opus":0.02659038686089481,"score_gpt":0.3168505820342918,"score_spread":0.29026019517339696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047919807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626275,0.0347996,0.00046280609,0.0012245128,0.00008113338,0.00067061523,0.00010822255,0.000004171167,0.000021474549],"genre_scores_gemma":[0.9698471,0.027578479,0.0021752873,0.00022751716,0.000045759534,0.000020141955,0.000009567293,0.000025844956,0.00007033765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893016,0.000043080654,0.00042046493,0.0001504312,0.00027019938,0.00018565252],"domain_scores_gemma":[0.9993025,0.000103902945,0.00027966374,0.00009457575,0.00013844503,0.000080930826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013455738,0.00014152518,0.00039616294,0.000075959964,0.000055104407,0.000027480753,0.0000547736,0.00005333118,0.000050157134],"category_scores_gemma":[0.000036331778,0.00010631304,0.00010123781,0.00011180392,0.00007918259,0.0002089003,0.00001374455,0.00013288569,1.4070747e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012005217,0.00027409018,0.14307176,0.00032984454,0.000407385,0.000008167965,0.0026734087,0.0003671712,0.77855074,0.000007489497,0.0002013467,0.062103402],"study_design_scores_gemma":[0.016120845,0.0031702658,0.048232738,0.00033243597,0.000036617075,0.000013213921,0.0005186644,0.00023234777,0.9238521,0.00014853178,0.0071872887,0.00015497628],"about_ca_topic_score_codex":0.00057384436,"about_ca_topic_score_gemma":0.000024067447,"teacher_disagreement_score":0.14530134,"about_ca_system_score_codex":0.00006536469,"about_ca_system_score_gemma":0.00016111013,"threshold_uncertainty_score":0.433532},"labels":[],"label_agreement":null},{"id":"W3048777681","doi":"10.1016/j.oooo.2020.03.015","title":"MANDIBULAR PLASMACYTOMA PRESENTING WITH EXTENSIVE ROOT RESORPTION","year":2020,"lang":"en","type":"article","venue":"Oral Surgery Oral Medicine Oral Pathology and Oral Radiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Differential diagnosis; Plasmacytoma; Physical examination; Palpation; Multiple myeloma; Presentation (obstetrics); Central giant-cell granuloma; Dentistry; Lesion; Radiology; Pathology; Internal medicine","score_opus":0.05222960200745481,"score_gpt":0.3118254892583288,"score_spread":0.259595887250874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048777681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97648823,0.0015800056,0.00032858213,0.020013576,0.0002901649,0.00077617535,0.000023989514,0.00019676573,0.00030249628],"genre_scores_gemma":[0.99329394,0.00033915372,0.0015899178,0.0034503576,0.00047783,0.000068316214,0.00041342483,0.000066232344,0.00030084283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958388,0.00081622414,0.0006921805,0.0010684271,0.00043773025,0.0011465914],"domain_scores_gemma":[0.9975645,0.0005798071,0.00024554523,0.00038811142,0.000251581,0.0009704586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082269206,0.0005703384,0.0018769451,0.00034531497,0.00027893207,0.000019930292,0.0001495188,0.00042523452,0.00052827375],"category_scores_gemma":[0.0014664512,0.00037944893,0.00015727071,0.0005429608,0.0014553225,0.00022403427,0.00015179554,0.00078972225,0.00010830609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008557384,0.00016324763,0.9244766,0.00019011772,0.00034389936,0.029655645,0.00035136944,0.000009039981,0.0049520265,0.00016877645,0.013459314,0.017672574],"study_design_scores_gemma":[0.012054761,0.008421462,0.9428223,0.00023880365,0.0006732025,0.016876772,0.0003759697,0.0015632296,0.0014615816,0.00052353536,0.014248224,0.0007401968],"about_ca_topic_score_codex":0.00023567352,"about_ca_topic_score_gemma":0.00014785946,"teacher_disagreement_score":0.018345654,"about_ca_system_score_codex":0.00006845182,"about_ca_system_score_gemma":0.0001444504,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W3049668987","doi":"10.1515/cclm-2020-0981","title":"Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein","year":2020,"lang":"en","type":"article","venue":"Clinical Chemistry and Laboratory Medicine (CCLM)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Dental and Craniofacial Research; Canadian Institutes of Health Research; National Institutes of Health; University of Occupational and Environmental Health; University of Florida; Thermo Fisher Scientific; Japan Society for the Promotion of Science; Bio-Rad Laboratories","keywords":"Autoantibody; Antibody; Immunofluorescence; Molecular biology; Immunoassay; Anti-nuclear antibody; Western blot; Staining; Immunoprecipitation; Antigen; Immunohistochemistry; Chemistry; Biology; Pathology; Immunology; Medicine; Biochemistry","score_opus":0.054651088857062775,"score_gpt":0.3785792651301667,"score_spread":0.32392817627310394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049668987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98210233,0.007975245,0.0003368672,0.0058756648,0.00015399333,0.001112316,0.0009993026,0.00008473867,0.00135955],"genre_scores_gemma":[0.9950674,0.0036260742,0.00032505085,0.00021390522,0.00035552005,0.00005514438,0.00014151655,0.000015903748,0.00019947396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980646,0.000071636976,0.0007344645,0.00038479298,0.0005371945,0.00020731047],"domain_scores_gemma":[0.9975948,0.0006522582,0.00030112494,0.00024030317,0.0009115731,0.00029997397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008902156,0.00019901952,0.0006075499,0.00002440364,0.00010510194,0.000012621416,0.00013362562,0.00015323015,0.00007676321],"category_scores_gemma":[0.0064867726,0.00012584229,0.00006401841,0.000106331805,0.000856485,0.0000693257,0.00009881885,0.00035185917,3.4260165e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011840573,0.00088161416,0.11864104,0.0067894626,0.0022544963,0.00009372418,0.0016722011,0.0000024317117,0.76812893,0.00009144812,0.0057737753,0.083830304],"study_design_scores_gemma":[0.03147223,0.005480919,0.1725042,0.0034135922,0.001008674,0.000021058355,0.003346656,0.0076722973,0.5214894,0.00014816668,0.25281492,0.000627867],"about_ca_topic_score_codex":0.000031696945,"about_ca_topic_score_gemma":0.000009716007,"teacher_disagreement_score":0.24704115,"about_ca_system_score_codex":0.000042589647,"about_ca_system_score_gemma":0.00034176887,"threshold_uncertainty_score":0.77657413},"labels":[],"label_agreement":null},{"id":"W3080205612","doi":"10.1016/j.bbmt.2020.08.018","title":"The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; National Cancer Institute; Bristol-Myers Squibb Canada; AbbVie","keywords":"Medicine; Hematopoietic cell; Multiple myeloma; Transplantation; Disease; Haematopoiesis; Hematopoietic stem cell transplantation; Bone marrow transplantation; Bone transplantation; Oncology; Intensive care medicine; Internal medicine; Stem cell; Surgery","score_opus":0.013616727434958021,"score_gpt":0.27416248411255695,"score_spread":0.26054575667759894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080205612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014133,0.0019800689,0.0010184732,0.00034019718,0.000024731764,0.001572784,0.0049017263,0.000006943308,0.000013724865],"genre_scores_gemma":[0.994436,0.004283171,0.0004197205,0.000018360008,0.00001820419,0.000045948513,0.00076819106,0.000007836789,0.0000025215038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982401,0.00037719982,0.00063677394,0.00029925557,0.00024473606,0.00020189634],"domain_scores_gemma":[0.99852765,0.0005865361,0.0003780521,0.000219952,0.00015037598,0.00013745183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000433674,0.00018638113,0.00057963346,0.000047871643,0.000126081,0.000006837044,0.00013458119,0.000056491353,0.000002518952],"category_scores_gemma":[0.000046315196,0.00010743581,0.00014457767,0.0003961963,0.00062047713,0.00007570448,0.000013709887,0.00006754255,2.9617398e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0273028,0.00059667276,0.9233687,0.0032649494,0.0026600843,0.000015272988,0.0044496856,0.0003652187,0.035345834,0.00045064854,0.0000012128769,0.002178916],"study_design_scores_gemma":[0.027096815,0.0019321948,0.9111077,0.00022447572,0.026950829,0.000021182881,0.0010443127,0.0035359042,0.027408801,0.0005288231,0.0000019681636,0.00014699403],"about_ca_topic_score_codex":0.00066267885,"about_ca_topic_score_gemma":0.0014446519,"teacher_disagreement_score":0.024290746,"about_ca_system_score_codex":0.0000054990255,"about_ca_system_score_gemma":0.00007904524,"threshold_uncertainty_score":0.4381105},"labels":[],"label_agreement":null},{"id":"W3080206549","doi":"10.1182/blood.2020005199","title":"Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Deubiquitinating enzyme; Apoptosis; Transcription factor; Cancer research; Biology; Ubiquitin; Cell biology; Biochemistry; Gene","score_opus":0.04419274333353106,"score_gpt":0.3010571760965666,"score_spread":0.25686443276303556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080206549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815192,0.0045120753,0.00041549501,0.00992075,0.00006466433,0.0028986728,0.00013959943,0.000057070334,0.00047243302],"genre_scores_gemma":[0.9972708,0.00040317807,0.0011695802,0.0002115051,0.0003271631,0.00030522043,0.000044956836,0.000021586431,0.0002459617],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999064,0.000037437076,0.00019639892,0.00019477325,0.00023318964,0.00027417165],"domain_scores_gemma":[0.9987121,0.0007316911,0.000060923423,0.0002754411,0.00008292562,0.00013687578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009081492,0.00013300811,0.00022618972,0.000017940802,0.00017465054,0.000012859575,0.00012214415,0.00003710016,0.00007235052],"category_scores_gemma":[0.0004278394,0.000058964826,0.00018679789,0.0001250678,0.000077530385,0.000021520516,0.000025228088,0.000059406102,0.000029237528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004953421,0.010365727,0.6150897,0.0006074429,0.0077318517,0.00027127066,0.013783322,0.00009414567,0.10486086,0.00028594397,0.006672554,0.23528372],"study_design_scores_gemma":[0.07534768,0.015838098,0.20817302,0.000108687236,0.0025789319,0.00005542965,0.0034495054,0.028005235,0.4501868,0.000083204955,0.21575034,0.0004230782],"about_ca_topic_score_codex":0.00010939007,"about_ca_topic_score_gemma":0.000015151689,"teacher_disagreement_score":0.4069167,"about_ca_system_score_codex":0.00002154639,"about_ca_system_score_gemma":0.00006233788,"threshold_uncertainty_score":0.24045159},"labels":[],"label_agreement":null},{"id":"W3080219429","doi":"10.1007/s00432-020-03365-w","title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","year":2020,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Lenalidomide","score_opus":0.2644732653653533,"score_gpt":0.5179843896295361,"score_spread":0.25351112426418276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080219429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887778,0.00028858925,0.000009620464,0.0073358337,0.00078363385,0.0025389334,0.00007884185,0.000012412549,0.0001743146],"genre_scores_gemma":[0.98817015,0.008314627,0.00084486627,0.00031148235,0.0018356318,0.0001186676,0.000029830917,0.000036673355,0.00033804812],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99356806,0.001476709,0.0027373293,0.00060587237,0.00085435354,0.0007576704],"domain_scores_gemma":[0.98924893,0.0073787975,0.00076777674,0.0002566488,0.0010666966,0.0012811269],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037098858,0.00023465874,0.0015901893,0.0002498999,0.00018363127,0.000049259488,0.000173509,0.0005457408,0.000084796775],"category_scores_gemma":[0.014851409,0.00015579133,0.0003693517,0.0003183136,0.00045307822,0.00015072241,0.00008887481,0.001683156,0.000011519808],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46507782,0.002412191,0.23000199,0.00003419716,0.00039865533,0.0010292325,0.00014160757,9.1619546e-7,0.000017728666,7.260087e-7,0.0018127235,0.2990722],"study_design_scores_gemma":[0.25984782,0.2619033,0.45966053,0.00012480009,0.000118679294,0.00004669827,0.00009399589,0.00015854872,0.000037457106,0.00002069902,0.017890163,0.00009734442],"about_ca_topic_score_codex":0.0005760363,"about_ca_topic_score_gemma":0.0052232496,"teacher_disagreement_score":0.29897487,"about_ca_system_score_codex":0.0013189856,"about_ca_system_score_gemma":0.0027700576,"threshold_uncertainty_score":0.9934469},"labels":[],"label_agreement":null},{"id":"W3080496620","doi":"10.1002/jha2.77","title":"Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals","keywords":"Bortezomib; Multiple myeloma; Dosing; Thalidomide; Medicine; Dexamethasone; Matching (statistics); Internal medicine; Oncology; Pathology","score_opus":0.040852141848497864,"score_gpt":0.29436453962409775,"score_spread":0.25351239777559986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080496620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699545,0.00075625465,0.00022579177,0.00018614241,0.000010769641,0.0015302534,0.0001667444,0.000041347368,0.00008727366],"genre_scores_gemma":[0.99411094,0.000113803704,0.0054454235,0.000050055784,0.0000150480855,0.000028622982,0.00018294602,0.000045702487,0.0000074354434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781865,0.00016394941,0.0005427689,0.00048689032,0.00058978086,0.00039797643],"domain_scores_gemma":[0.99839866,0.00053280435,0.0002844856,0.00025604473,0.0001533037,0.0003746767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015231103,0.00033688525,0.0013033762,0.00019626119,0.000089612164,0.000024913927,0.00010488702,0.000108652544,0.000014728254],"category_scores_gemma":[0.00013111118,0.00024074492,0.000040903975,0.0003664471,0.0002308909,0.00013144682,0.000053270356,0.00031198288,0.0000018769408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035039935,0.0012459725,0.94949776,0.0005838032,0.00045512937,0.0001093244,0.0069734524,0.00033288114,0.0015597538,0.000015510936,0.000007351526,0.0041791084],"study_design_scores_gemma":[0.06487334,0.0016793283,0.9126522,0.0016098738,0.00019736023,0.00000746903,0.0012858075,0.0040640645,0.013398078,0.0000048682214,0.0000066825187,0.00022091188],"about_ca_topic_score_codex":0.0011032711,"about_ca_topic_score_gemma":0.0007680902,"teacher_disagreement_score":0.036845557,"about_ca_system_score_codex":0.00005045355,"about_ca_system_score_gemma":0.000102594844,"threshold_uncertainty_score":0.98172927},"labels":[],"label_agreement":null},{"id":"W3080672747","doi":"10.1016/j.clml.2020.08.008","title":"Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Takeda Canada; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Janssen Biotech; Roche; GlaxoSmithKline; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Multiple myeloma; Lenalidomide","score_opus":0.054986441452762595,"score_gpt":0.3589540105480418,"score_spread":0.3039675690952792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080672747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991883,0.000599151,0.00010293404,0.0015847798,0.00026080615,0.0013725798,0.00011381415,0.0004056378,0.0036773018],"genre_scores_gemma":[0.9908602,0.00034538037,0.0043028807,0.002166722,0.00094374415,0.00009725374,0.0007726888,0.00020046999,0.00031064873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926688,0.00059141906,0.001815619,0.0020127997,0.0013530706,0.001558292],"domain_scores_gemma":[0.9942867,0.0010720498,0.00041432475,0.0013783504,0.00034014994,0.0025083842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007528075,0.00087848026,0.0018619286,0.00033614202,0.00029615712,0.00012634773,0.0007092714,0.0007391777,0.00032572838],"category_scores_gemma":[0.0018622756,0.0007065025,0.00050037773,0.0011624908,0.00079973135,0.0005137013,0.00033725778,0.0011940877,0.000936229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011979852,0.0018990895,0.7124725,0.0001625893,0.00038104405,0.008696097,0.00028092484,0.00003931042,0.0032708626,0.00008020391,0.00093333883,0.2598042],"study_design_scores_gemma":[0.03292043,0.0063266573,0.93619573,0.00032270412,0.00014381547,0.0003398636,0.00019652947,0.013478308,0.001206579,0.000035629935,0.008113907,0.0007198197],"about_ca_topic_score_codex":0.00044539198,"about_ca_topic_score_gemma":0.00021513563,"teacher_disagreement_score":0.25908437,"about_ca_system_score_codex":0.0010716332,"about_ca_system_score_gemma":0.0024198005,"threshold_uncertainty_score":0.99984163},"labels":[],"label_agreement":null},{"id":"W3082666946","doi":"10.2217/fon-2020-0521","title":"Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Biotech; Celgene; Genentech; Amgen","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Clinical trial; Oncology; Internal medicine; Antigen; Population; Chimeric antigen receptor; Antibody; Antibody-drug conjugate; Drug; Immunology; Immunotherapy; Cancer research; Cancer; Pharmacology; Monoclonal antibody","score_opus":0.08867892424622806,"score_gpt":0.4105295756180951,"score_spread":0.3218506513718671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082666946","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023655653,0.9914352,9.3809587e-7,0.0010954185,0.00039265482,0.0035851237,0.00021196075,0.000035767534,0.003006344],"genre_scores_gemma":[0.00022846051,0.9949774,0.00063536083,0.00013461274,0.001309377,0.0007419532,0.00086376915,0.00006948122,0.0010395803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966696,0.00094162655,0.0008661803,0.0005867577,0.00040981322,0.00052605785],"domain_scores_gemma":[0.9969937,0.0015578965,0.00043189232,0.00072399096,0.00005910254,0.00023338651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002266674,0.0005612471,0.0032271883,0.0003036327,0.00006170027,0.000008924915,0.0003400524,0.0008031306,0.0003999658],"category_scores_gemma":[0.00024700156,0.00026094244,0.00065806863,0.0005979568,0.00012991273,0.000027829961,0.00005060642,0.000721372,0.00023960054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001648923,0.0025499251,0.00024202414,0.0038574962,0.0007049023,0.007901546,0.000763528,1.9734888e-8,0.0000022156273,0.000024649475,0.0023196489,0.9799851],"study_design_scores_gemma":[0.0072731487,0.011649943,0.0008651033,0.0016756436,0.0010979124,0.00084171194,0.00031174222,0.0000038818325,0.000003357674,0.0000024816054,0.97609645,0.00017862103],"about_ca_topic_score_codex":0.00011672967,"about_ca_topic_score_gemma":0.0006762699,"teacher_disagreement_score":0.9798065,"about_ca_system_score_codex":0.0011863912,"about_ca_system_score_gemma":0.001794567,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W3083020346","doi":"10.3389/fimmu.2020.02153","title":"Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells","year":2020,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; Peter MacCallum Cancer Centre; University of Melbourne","keywords":"Multiple myeloma; CD8; Cytotoxic T cell; Stem cell; Immunology; Biology; Cancer research; T cell; Immune system; Medicine; Cell biology; Internal medicine; In vitro","score_opus":0.01857904638328338,"score_gpt":0.26658376940901646,"score_spread":0.24800472302573306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083020346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97567,0.016756209,0.0031886825,0.0021801873,0.00050863094,0.001484519,0.000048827034,0.000042837866,0.00012015049],"genre_scores_gemma":[0.9807701,0.001186278,0.017097551,0.00012436078,0.00008102539,0.00024171262,0.00015010251,0.000019755702,0.0003291116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900043,0.00007309179,0.00021166683,0.00031735763,0.000085757594,0.0003116789],"domain_scores_gemma":[0.9996399,0.00008192378,0.000049057067,0.00011457081,0.000032375094,0.00008214541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062662446,0.00015533791,0.00041184717,0.00020644761,0.00004844449,0.000010694571,0.000049980234,0.000119359676,0.000026331149],"category_scores_gemma":[0.00011144279,0.00013114528,0.000070279944,0.00015008562,0.00010222304,0.00007455684,0.000031124917,0.00014169533,0.0000066077773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009036131,0.0006993341,0.78434485,0.00019970124,0.0011611704,0.0001374101,0.0024624555,0.000046914654,0.040684063,0.00028527275,0.0013926917,0.15955],"study_design_scores_gemma":[0.03535074,0.0016671628,0.8805212,0.00010258287,0.00013963849,0.000024842773,0.0014433849,0.012292039,0.035447877,0.00047039517,0.032295834,0.00024431857],"about_ca_topic_score_codex":0.000077340446,"about_ca_topic_score_gemma":0.000052858595,"teacher_disagreement_score":0.15930568,"about_ca_system_score_codex":0.00011634623,"about_ca_system_score_gemma":0.00006803918,"threshold_uncertainty_score":0.5347949},"labels":[],"label_agreement":null},{"id":"W3083246189","doi":"10.1038/s41375-020-01021-3","title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Celgene; Bristol-Myers Squibb","keywords":"Lenalidomide; Pomalidomide; Bortezomib; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Refractory (planetary science); Oncology; Thalidomide; Gastroenterology; Materials science","score_opus":0.03002251729832317,"score_gpt":0.2784020533142037,"score_spread":0.24837953601588053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083246189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911226,0.0012818945,0.00023360158,0.004544324,0.000022319397,0.0039386856,0.0003055791,0.00022135863,0.00033997704],"genre_scores_gemma":[0.9796828,0.00056262716,0.010369811,0.00095139723,0.000088048175,0.0009826852,0.00060779514,0.00013298776,0.006621824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726206,0.000074601114,0.00048254235,0.0009158393,0.00042076994,0.00084420457],"domain_scores_gemma":[0.9973404,0.000764771,0.00017928303,0.000507049,0.00012385068,0.0010846471],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012450886,0.00059703237,0.0010586113,0.0000938712,0.00034486558,0.00006504372,0.000133152,0.00019930773,0.00011373735],"category_scores_gemma":[0.0005091459,0.0003931913,0.00024108043,0.00022573523,0.00017794273,0.00014580885,0.000090568785,0.00017633867,0.000061597595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026900923,0.00054783595,0.92339027,0.0004362634,0.0023182086,0.0008229267,0.0011108563,0.00004801771,0.006509004,0.0000132588575,0.011149466,0.02675299],"study_design_scores_gemma":[0.30725282,0.023533445,0.37779552,0.00061593595,0.003250308,0.0006992633,0.0004674498,0.025600245,0.1359841,0.000019518207,0.12273519,0.0020462195],"about_ca_topic_score_codex":0.0008656276,"about_ca_topic_score_gemma":0.0004703956,"teacher_disagreement_score":0.54559475,"about_ca_system_score_codex":0.0015295421,"about_ca_system_score_gemma":0.0002897689,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W3083502363","doi":"10.1038/s41408-020-00357-4","title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Internal medicine; Multiple myeloma; Regimen; Hazard ratio; Clinical endpoint; Oncology; Adverse effect; Randomized controlled trial; Confidence interval","score_opus":0.10023944158936043,"score_gpt":0.37622240002227375,"score_spread":0.2759829584329133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083502363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98396355,0.005628549,0.00003911597,0.008340861,0.00014624874,0.0013419818,0.00013043953,0.000019220626,0.00039005172],"genre_scores_gemma":[0.995623,0.002309217,0.0003323585,0.00064566167,0.0007826367,0.00009530854,0.000023475202,0.000027030299,0.0001613138],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996747,0.0009383159,0.0007028774,0.00040077046,0.000760844,0.00045017042],"domain_scores_gemma":[0.99776775,0.0011173584,0.00023173596,0.00023331266,0.00011759344,0.0005322321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014536452,0.00025193466,0.0008650795,0.00007878869,0.0001780157,0.00013037623,0.00018604546,0.00006084463,0.00037225353],"category_scores_gemma":[0.001419674,0.0001487032,0.00016968814,0.00021416518,0.00012529442,0.00011603418,0.00008979256,0.000811171,0.000010057854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80655813,0.003736213,0.13421941,0.00003015385,0.004291557,0.0057042176,0.008488241,0.000030142915,0.001444546,0.000027066602,0.0017069805,0.033763323],"study_design_scores_gemma":[0.9235181,0.0012700958,0.07107956,0.00018510908,0.0008425472,0.00013501878,0.0011025107,0.00053800025,0.0004355516,0.000109861496,0.00061536755,0.00016823158],"about_ca_topic_score_codex":0.004713737,"about_ca_topic_score_gemma":0.0006499786,"teacher_disagreement_score":0.11696,"about_ca_system_score_codex":0.00010301464,"about_ca_system_score_gemma":0.00046953346,"threshold_uncertainty_score":0.71257913},"labels":[],"label_agreement":null},{"id":"W3084658128","doi":"10.2196/17850","title":"Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial","year":2020,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Positron emission tomography; Positron Emission Tomography-Computed Tomography; Nuclear medicine; Radiology; Tomography; Fluorodeoxyglucose; PET-CT; Prospective cohort study; Preclinical imaging; Computed tomography; Pathology","score_opus":0.12526949612098118,"score_gpt":0.5062780498640927,"score_spread":0.3810085537431116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084658128","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41945478,0.000014776574,0.000007727782,0.00015787056,0.00000385546,0.58004314,0.000042157124,0.000038361115,0.00023735159],"genre_scores_gemma":[0.5033907,3.128165e-7,0.00040450535,0.000007134104,0.0000688767,0.4960735,0.000013822035,0.000033971617,0.000007124424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914379,0.0020448524,0.0015900192,0.0010986765,0.0028206445,0.0010079076],"domain_scores_gemma":[0.9958073,0.0010194815,0.0005930854,0.0007989479,0.0012766336,0.0005045459],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002461417,0.00052746234,0.0014974413,0.0011229928,0.0002620267,0.000107764085,0.00073630747,0.000017341841,0.000048078564],"category_scores_gemma":[0.0012103115,0.00036387565,0.00035096687,0.0035562331,0.000903373,0.0003352107,0.00063311873,0.0016513211,0.0000028879763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16939932,0.02000477,0.7917393,0.0019482594,0.00031980625,0.0024381971,0.0023414926,0.000003878289,0.007815166,0.000027137083,0.00023703488,0.0037256363],"study_design_scores_gemma":[0.2336006,0.03637616,0.6409184,0.0036335404,0.000054740296,0.00026818807,0.004691338,0.0028135432,0.07672751,0.00019688862,0.0003124665,0.00040662155],"about_ca_topic_score_codex":0.00039565438,"about_ca_topic_score_gemma":0.00007018399,"teacher_disagreement_score":0.1508209,"about_ca_system_score_codex":0.00016273619,"about_ca_system_score_gemma":0.0005682831,"threshold_uncertainty_score":0.9998813},"labels":[],"label_agreement":null},{"id":"W3085568508","doi":"10.1016/j.htct.2020.07.007","title":"Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis","year":2020,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Autologous stem-cell transplantation; Cyclophosphamide; Dexamethasone; Internal medicine; Oncology; Adverse effect; Transplantation; Bortezomib; Retrospective cohort study; Single Center; Surgery; Chemotherapy","score_opus":0.027019900958503717,"score_gpt":0.2806866787613068,"score_spread":0.2536667778028031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085568508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894901,0.0042453865,0.0016220197,0.0016796703,0.00009739346,0.0022030917,0.0001288566,0.00013029066,0.00040321948],"genre_scores_gemma":[0.9735947,0.023585754,0.00084552716,0.0003333334,0.000037524434,0.0007854879,0.00019945507,0.00005429594,0.0005639239],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766564,0.00013676524,0.00048315502,0.00087129686,0.00030041306,0.000542738],"domain_scores_gemma":[0.998424,0.00052080024,0.000117572534,0.00031423065,0.0001051227,0.00051828707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000107967266,0.00044364162,0.0010540657,0.00019702461,0.00031116302,0.000023147792,0.000081299,0.00029852035,0.00059188274],"category_scores_gemma":[0.00001567641,0.00034131756,0.0005201078,0.00045826458,0.00015524605,0.00007229476,0.0000134933,0.00017544848,0.000051592287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20198143,0.0020403736,0.7252162,0.00062407483,0.003365879,0.0021005033,0.011908829,0.00003578503,0.03191917,0.00006940559,0.00008307707,0.02065526],"study_design_scores_gemma":[0.13949576,0.016723994,0.33877605,0.00006929169,0.003870883,0.00029368146,0.0009814331,0.003679633,0.49166802,0.000050233004,0.0035803441,0.0008106769],"about_ca_topic_score_codex":0.00019387223,"about_ca_topic_score_gemma":0.00057268166,"teacher_disagreement_score":0.45974883,"about_ca_system_score_codex":0.00020020675,"about_ca_system_score_gemma":0.00008584705,"threshold_uncertainty_score":0.99990386},"labels":[],"label_agreement":null},{"id":"W3085958492","doi":"10.1158/1078-0432.ccr-20-1781","title":"Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Bristol-Myers Squibb Canada","keywords":"Pomalidomide; Daratumumab; Multiple myeloma; Lenalidomide; Medicine; Immunology; Immune system; CD8; Cancer research; T cell; Oncology; Internal medicine","score_opus":0.15593329845042367,"score_gpt":0.4489423615434022,"score_spread":0.2930090630929786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085958492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950066,0.0009591535,0.0000116352585,0.001604359,0.000044389646,0.0016300057,0.000047509307,0.000047287536,0.0006490365],"genre_scores_gemma":[0.99795616,0.0006170487,0.00045137052,0.00021987189,0.00015851458,0.00020224882,0.00013957026,0.00005088334,0.00020432749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996161,0.00070028944,0.00060962304,0.0007853617,0.0010448784,0.0006988872],"domain_scores_gemma":[0.9966423,0.0014903975,0.000091880385,0.00040610597,0.0005804413,0.0007888943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010561895,0.00021732753,0.0005718465,0.00023164516,0.00016785196,0.000055714656,0.00016416279,0.00021576438,0.00022331065],"category_scores_gemma":[0.0032789947,0.0001597732,0.00007992667,0.0008724349,0.00050328136,0.00020462823,0.00018771368,0.0013378349,0.00008157266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015903298,0.0007092573,0.925104,0.00008786763,0.0001347889,0.00018689866,0.00013202343,0.000004702779,0.0002808841,0.000007577653,0.00037460303,0.057074085],"study_design_scores_gemma":[0.024244439,0.0033184583,0.96821046,0.00019209542,0.000024830022,0.0000018147045,0.00005809313,0.0014710447,0.000296733,0.000016004253,0.0020172228,0.00014880528],"about_ca_topic_score_codex":0.001342071,"about_ca_topic_score_gemma":0.00054263877,"teacher_disagreement_score":0.05692528,"about_ca_system_score_codex":0.00026603744,"about_ca_system_score_gemma":0.00038092467,"threshold_uncertainty_score":0.6515362},"labels":[],"label_agreement":null},{"id":"W3086814173","doi":"","title":"Lymphoma and Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Electronic Kharkiv National University Institutional Repository (Kharkiv National University)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Lymphoma; Medicine; Internal medicine","score_opus":0.014446079620934802,"score_gpt":0.23422136304392685,"score_spread":0.21977528342299205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086814173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7506467,0.00021553709,0.0009327128,0.0012756516,0.00026979533,0.0007487258,0.00026039156,0.00024369292,0.24540676],"genre_scores_gemma":[0.9794479,0.0001197254,0.0006288278,0.00022175792,0.00045301873,9.330133e-7,0.00035060314,0.000017914877,0.018759292],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966464,0.0001406441,0.00023468223,0.0007267392,0.0016444498,0.0006070986],"domain_scores_gemma":[0.99686354,0.00030631153,0.00015211887,0.00018308705,0.0020510096,0.00044392902],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00029474366,0.00031565293,0.00029264335,0.001140124,0.0018187785,0.000053397413,0.000308981,0.00021883966,0.00018269416],"category_scores_gemma":[0.00033773953,0.0003696288,0.00019612312,0.0010126785,0.0009927803,0.00080883276,0.00019902457,0.0002981778,0.0001613138],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008580541,0.002107154,0.06051378,0.00011973437,0.002327056,0.0026254656,0.00023314086,0.00018253866,0.016079862,0.8966135,0.0067714253,0.003845829],"study_design_scores_gemma":[0.014750809,0.0008397334,0.2206768,0.00011717909,0.00021816436,0.0018608444,0.0002982613,0.008394788,0.004806112,0.0012894784,0.7460354,0.00071242003],"about_ca_topic_score_codex":0.00012987715,"about_ca_topic_score_gemma":0.00010019983,"teacher_disagreement_score":0.895324,"about_ca_system_score_codex":0.0047705867,"about_ca_system_score_gemma":0.00534463,"threshold_uncertainty_score":0.99987555},"labels":[],"label_agreement":null},{"id":"W3087676245","doi":"10.1188/20.cjon.538-546","title":"Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids","year":2020,"lang":"en","type":"article","venue":"Clinical journal of oncology nursing","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Oncolytics Biotech; National Institute of Nursing Research; Sanofi","keywords":"Medicine; Multiple myeloma; Hematologic malignancy; Malignancy; African american; Epidemiology; Internal medicine; Cancer; Oncology; Family medicine; Ethnology","score_opus":0.07794708288865966,"score_gpt":0.4022651017253721,"score_spread":0.32431801883671246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087676245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823146,0.00012769464,0.0016419713,0.0147262635,0.00034132387,0.00037770794,0.0000030998267,0.000023436984,0.00044390242],"genre_scores_gemma":[0.98822725,0.00004599049,0.006357793,0.004298677,0.0010099474,0.000012738469,0.0000081437465,0.000030337646,0.000009094619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996747,0.0007531542,0.0010795994,0.00030985498,0.0006014673,0.0005089257],"domain_scores_gemma":[0.99502,0.0020313852,0.0013711017,0.00021565656,0.00038386445,0.0009780338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011949892,0.00021667998,0.00092665013,0.00009793262,0.0002238265,0.00004493883,0.0003093916,0.00010942102,0.000057528767],"category_scores_gemma":[0.0049141864,0.00012785873,0.00026979565,0.00040267128,0.0011760266,0.00016432829,0.000045501176,0.00095899455,0.000008511882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004621367,0.0010102863,0.54650193,0.000011949304,0.00023552975,0.00039859852,0.0050381385,0.0000034710476,0.00012754642,0.000002152827,0.00029850955,0.44175053],"study_design_scores_gemma":[0.012526335,0.029902369,0.91380596,0.0006817899,0.0002850105,0.0002010341,0.02786747,0.0026184558,0.00015088858,0.000009724894,0.0117163425,0.00023461781],"about_ca_topic_score_codex":0.000010509181,"about_ca_topic_score_gemma":0.0000032928149,"teacher_disagreement_score":0.4415159,"about_ca_system_score_codex":0.00031388985,"about_ca_system_score_gemma":0.00070708955,"threshold_uncertainty_score":0.5883095},"labels":[],"label_agreement":null},{"id":"W3088017015","doi":"10.1111/ctr.14099","title":"Newly diagnosed multiple myeloma patients treated with tandem auto‐allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only","year":2020,"lang":"en","type":"article","venue":"Clinical Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Cumulative incidence; Multiple myeloma; Cohort; Internal medicine; Incidence (geometry); Surgery; Stem cell; Transplantation; Graft-versus-host disease; Oncology","score_opus":0.04093305427565783,"score_gpt":0.2956933861562328,"score_spread":0.25476033188057495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088017015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930301,0.000018225988,0.0006017856,0.0006242089,0.00006813463,0.0029063069,0.0023959456,0.0001547525,0.00020059459],"genre_scores_gemma":[0.99219054,0.00019551722,0.0012090751,0.00087114907,0.000042860596,0.00008871138,0.0051192646,0.00010126347,0.00018161959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951656,0.0005297539,0.0013937934,0.0010489051,0.0011358906,0.0007260587],"domain_scores_gemma":[0.9965238,0.0012968638,0.00036513514,0.00043016727,0.0003541285,0.0010298954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022220044,0.0006546426,0.0016357676,0.00015683367,0.00017107485,0.000026188069,0.00026187353,0.00032976325,0.000102068036],"category_scores_gemma":[0.000047617024,0.0004514525,0.00034380378,0.0002784504,0.00021184132,0.00016202168,0.000017941311,0.00044023347,0.00009300113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039556228,0.0020396318,0.9505525,0.00039082125,0.00081927644,0.00089828396,0.002593643,0.00022670125,0.000702079,6.0732907e-7,0.00008829862,0.0021318982],"study_design_scores_gemma":[0.054212965,0.0069576665,0.9307547,0.0005076858,0.0010274472,0.000011978045,0.000031173386,0.0018531401,0.0041165454,8.2177e-7,0.00005813471,0.00046773948],"about_ca_topic_score_codex":0.0001955711,"about_ca_topic_score_gemma":0.0007145734,"teacher_disagreement_score":0.019797826,"about_ca_system_score_codex":0.0001449168,"about_ca_system_score_gemma":0.00017840193,"threshold_uncertainty_score":0.9997937},"labels":[],"label_agreement":null},{"id":"W3088063465","doi":"10.1016/j.exphem.2020.09.196","title":"Mechanisms of lenalidomide sensitivity and resistance","year":2020,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; Genome British Columbia; Leukemia and Lymphoma Society of Canada; Genome Canada","keywords":"Lenalidomide; Thalidomide; Multiple myeloma; clone (Java method); Medicine; Myelodysplastic syndromes; Drug resistance; Cancer; Cancer research; Biology; Immunology; Internal medicine; Bone marrow; Genetics","score_opus":0.058346849570927534,"score_gpt":0.39274291436573566,"score_spread":0.3343960647948081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088063465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034518675,0.9975746,0.000063191896,0.00006759278,0.000055560213,0.0008672114,0.000052763895,0.000029554076,0.0012549737],"genre_scores_gemma":[0.010003611,0.9859472,0.0035232115,0.000035822013,0.0000248436,0.00010483709,0.00009207766,0.00004390361,0.00022452054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984676,0.00022239446,0.00041444838,0.0004262499,0.00020906243,0.00026020195],"domain_scores_gemma":[0.99907714,0.00020707854,0.00018779791,0.00026342698,0.000026236348,0.00023832038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009510861,0.00030528786,0.0023338937,0.000104964696,0.00003977619,0.0000052126343,0.000052448024,0.00021220498,0.00008334831],"category_scores_gemma":[0.00007077797,0.00023535686,0.00025799766,0.00011671749,0.00017455067,0.000024658166,0.0001467926,0.00021602822,0.000056118115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022712925,0.0021680854,0.00008251985,0.12532414,0.004354564,0.027036615,0.0005481091,6.0295284e-9,0.0025299324,0.4016761,0.0025145453,0.4314941],"study_design_scores_gemma":[0.0048842346,0.0009983492,0.000015574213,0.017915696,0.0009936627,0.009227178,0.00026159015,0.000009533816,0.100697495,0.0004910399,0.863874,0.00063161063],"about_ca_topic_score_codex":0.000016932197,"about_ca_topic_score_gemma":0.000007615249,"teacher_disagreement_score":0.8613595,"about_ca_system_score_codex":0.00009356766,"about_ca_system_score_gemma":0.0001614588,"threshold_uncertainty_score":0.9597574},"labels":[],"label_agreement":null},{"id":"W3088817136","doi":"10.1093/ptj/pzaa180","title":"Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Practice Guidelines Endorsed by the Canadian Physiotherapy Association","year":2020,"lang":"en","type":"article","venue":"Physical Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University; Laurentian University; Health Sciences North","funders":"Northern Ontario Academic Medicine Association","keywords":"Medicine; Guideline; Physical therapy; Rehabilitation; MEDLINE; Systematic review; Evidence-based medicine; Family medicine; Alternative medicine; Pathology","score_opus":0.05459554117618551,"score_gpt":0.40782360417019875,"score_spread":0.3532280629940132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088817136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98124796,0.00034368385,0.0005589536,0.01473787,0.000054682994,0.002815359,0.00013995949,0.000044506418,0.000056999706],"genre_scores_gemma":[0.9946794,0.00039784526,0.0011466905,0.0026900636,0.00030308243,0.0002374054,0.00042781085,0.000031656662,0.00008602481],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987338,0.000116430805,0.00025123236,0.00028360545,0.00037793478,0.000236962],"domain_scores_gemma":[0.9981069,0.00053225673,0.00015628476,0.00014436789,0.0007782166,0.00028199155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023644122,0.00014621415,0.00026337302,0.00002168506,0.00018198423,0.000057095283,0.0000683758,0.000060480073,0.0000097348],"category_scores_gemma":[0.0013713113,0.00008508629,0.00011651467,0.00014545712,0.00004683207,0.00016670389,0.000009564212,0.00013280525,0.000007018376],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009527098,0.00287341,0.30434406,0.00005719853,0.0008081451,0.0000028824727,0.00085040624,0.000008762544,0.0011140526,0.000042545027,0.0194772,0.6608942],"study_design_scores_gemma":[0.07173633,0.010320243,0.72197014,0.00017900977,0.00032093597,0.0000012011882,0.00038320894,0.043523055,0.0038587262,0.00027425762,0.1469455,0.00048739376],"about_ca_topic_score_codex":0.0042927996,"about_ca_topic_score_gemma":0.0008604253,"teacher_disagreement_score":0.6604068,"about_ca_system_score_codex":0.000118398355,"about_ca_system_score_gemma":0.00008550559,"threshold_uncertainty_score":0.64894575},"labels":[],"label_agreement":null},{"id":"W3089211657","doi":"10.1002/cncr.33171","title":"Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Biotech; National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Daiichi Sankyo Company; Legend Biotech; Janssen Pharmaceuticals; Sanofi Genzyme; Daiichi Sankyo Europe; Takeda Oncology; Kite Pharma; Adaptive Biotechnologies; Health Resources and Services Administration; CytoSen Therapeutics; Atara Biotherapeutics; Daiichi-Sankyo; Biomedical Advanced Research and Development Authority; Astellas Pharma; Swedish Orphan Biovitrum; GlaxoSmithKline; Kiadis Pharma; Miltenyi Biotec; Omeros Corporation; bluebird bio; Actinium Pharmaceuticals; Seattle Genetics; Takeda Pharmaceuticals North America; Regeneron Pharmaceuticals; Chimerix; Medical College of Wisconsin; Merck Sharp and Dohme; Novartis; Johnson and Johnson; Millennium Challenge Corporation; Celgene; Medac; Jazz Pharmaceuticals; National Marrow Donor Program; National Cancer Institute; Genzyme; Terumo BCT; St. Baldrick's Foundation; Boston Children's Hospital; Merck; Kyowa Hakko Kirin; Sanofi; CSL Behring; Bristol-Myers Squibb; AstraZeneca; AbbVie; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation; Dana-Farber Cancer Institute; Incyte; Pfizer; Be The Match Foundation; HistoGenetics","keywords":"Medicine; Hazard ratio; Multiple myeloma; Internal medicine; Confidence interval; Transplantation; Hematopoietic stem cell transplantation; Melphalan; Proportional hazards model; Surgery; Gastroenterology; Oncology","score_opus":0.02826307758878465,"score_gpt":0.3019835015472888,"score_spread":0.27372042395850416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089211657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957438,0.00028684965,0.0020552147,0.000251509,0.00005470209,0.0007923663,0.00032275548,0.000037521517,0.00045526164],"genre_scores_gemma":[0.9975104,0.00019936265,0.0011770952,0.00019646231,0.00004334163,0.00015864935,0.00051980006,0.00002047821,0.000174445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989356,0.000027441112,0.00025477214,0.0002788876,0.00024980374,0.00025352012],"domain_scores_gemma":[0.9991881,0.0001927261,0.000092238326,0.00014743928,0.00017199983,0.00020746294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037480633,0.00013151637,0.00040453,0.00012311396,0.00005264264,0.00000934231,0.00006851887,0.00006574973,0.00023814873],"category_scores_gemma":[0.000116282295,0.00011236561,0.00021968808,0.0003535331,0.00003745902,0.000048573293,0.000010585086,0.0000716872,0.000019258412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028427546,0.0004398624,0.9536077,0.0028227917,0.0024440368,0.000119056,0.0025405562,0.000321841,0.011238467,0.000016941754,0.0006414546,0.022964533],"study_design_scores_gemma":[0.013198528,0.0017679913,0.9468045,0.00015208696,0.003159708,0.0000012525816,0.00010535832,0.012796841,0.021312162,0.000011391939,0.0004848849,0.00020528963],"about_ca_topic_score_codex":0.00010170158,"about_ca_topic_score_gemma":0.00019694053,"teacher_disagreement_score":0.022759244,"about_ca_system_score_codex":0.00008090489,"about_ca_system_score_gemma":0.00012416845,"threshold_uncertainty_score":0.4582137},"labels":[],"label_agreement":null},{"id":"W3090860704","doi":"10.1016/j.clml.2020.09.010","title":"Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Interquartile range; Disease burden; Internal medicine; Comorbidity; Epidemiology; Odds ratio; Malignancy; Logistic regression; Disease; Emergency medicine; Intensive care medicine","score_opus":0.034343741437501914,"score_gpt":0.31534074407744117,"score_spread":0.28099700263993926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090860704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382865,0.0004091176,0.000117825395,0.0010593378,0.00013141065,0.0023188377,0.00010930474,0.00026419692,0.0017613077],"genre_scores_gemma":[0.9937316,0.00038671042,0.003161415,0.00053928053,0.0008759547,0.00027488024,0.0002872557,0.00013866957,0.0006042227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99499696,0.00028122147,0.0015062925,0.0013322928,0.00088069856,0.0010025308],"domain_scores_gemma":[0.99456304,0.001510606,0.00048403995,0.0010861272,0.00039665063,0.0019595225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025574502,0.00071733416,0.0017202948,0.0001525458,0.00015799252,0.000047608322,0.0004115615,0.00046180075,0.00039071962],"category_scores_gemma":[0.0015036699,0.0005052478,0.00071932835,0.00063405506,0.0007830652,0.00021544128,0.00018576128,0.00031478496,0.0004008488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010444074,0.0007826307,0.45479977,0.00022095801,0.00096005114,0.0025210576,0.0011700345,0.000043773132,0.00022172318,0.000016348953,0.0008653544,0.5279542],"study_design_scores_gemma":[0.05382907,0.008332623,0.9197009,0.00065881154,0.00038840933,0.00007606154,0.0006070384,0.010072336,0.0031600294,0.0000072246744,0.0027173122,0.00045014016],"about_ca_topic_score_codex":0.0018570635,"about_ca_topic_score_gemma":0.00017497977,"teacher_disagreement_score":0.5275041,"about_ca_system_score_codex":0.0010568169,"about_ca_system_score_gemma":0.0018215505,"threshold_uncertainty_score":0.9997399},"labels":[],"label_agreement":null},{"id":"W3092183154","doi":"10.1038/s41375-020-01051-x","title":"Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Medicine; Disease; Risk stratification; Bone marrow; Monoclonal; Oncology; Immunology; Pathology; Internal medicine; Monoclonal antibody; Antibody","score_opus":0.07765431955879935,"score_gpt":0.3379218021911808,"score_spread":0.2602674826323814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092183154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0995844,0.8983559,0.000008105129,0.00002279855,0.000029857647,0.0017663608,0.0001394434,0.00001866182,0.000074491014],"genre_scores_gemma":[0.15079238,0.8478762,0.0005328012,0.000005820568,0.000065175016,0.00054291834,0.000087963796,0.000047436024,0.000049323535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801886,0.00009522627,0.0006570237,0.00054701313,0.00026368554,0.0004182177],"domain_scores_gemma":[0.99851173,0.0005846846,0.00029461808,0.0003011526,0.00002843784,0.00027937017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000097383505,0.00044717823,0.002228457,0.00041440115,0.000035632,0.000013069323,0.000087928776,0.00019602948,0.000014271345],"category_scores_gemma":[0.00012642892,0.00034718853,0.00023326787,0.00039068772,0.0001380359,0.00004856085,0.00008830929,0.00017395525,0.0000027931196],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014912074,0.0001482036,0.020236038,0.0093568545,0.0003390937,0.0007165891,0.00045453684,8.923013e-7,0.000032248343,0.000009016896,0.000002883088,0.9685545],"study_design_scores_gemma":[0.05420495,0.014548108,0.11569122,0.13602667,0.00758588,0.0013748845,0.00094027614,0.008903307,0.010647687,0.00010276601,0.6464961,0.0034781508],"about_ca_topic_score_codex":0.00043149252,"about_ca_topic_score_gemma":0.000077938064,"teacher_disagreement_score":0.9650764,"about_ca_system_score_codex":0.00071601843,"about_ca_system_score_gemma":0.0004415117,"threshold_uncertainty_score":0.999898},"labels":[],"label_agreement":null},{"id":"W3092332842","doi":"10.1002/cam4.3511","title":"Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients","year":2020,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Vancouver General Hospital; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Neutropenia; Thalidomide; Adverse effect; Gastroenterology; Dexamethasone; Population; Anemia; Multiple myeloma; Prednisone; Surgery; Chemotherapy","score_opus":0.022698137626127435,"score_gpt":0.2684075668851049,"score_spread":0.24570942925897749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092332842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366987,0.0010444901,0.00000918936,0.003112519,0.0000799548,0.0016332007,0.00020635389,0.000015484618,0.00022891056],"genre_scores_gemma":[0.997161,0.0011898282,0.00008153331,0.00083974755,0.00016556284,0.00012967778,0.00035477354,0.000033015338,0.000044896635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782795,0.00006918024,0.00052265805,0.00044217042,0.00063944166,0.00049858127],"domain_scores_gemma":[0.99813616,0.00020571951,0.00014966774,0.0002378707,0.000266214,0.001004374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014549462,0.00027165023,0.0009938836,0.00060274405,0.00005632954,0.000007587336,0.00011328187,0.00009636509,0.00035133873],"category_scores_gemma":[0.00046835208,0.00018652783,0.00006407699,0.0011263032,0.00021246429,0.00007759377,0.000016336022,0.0002276781,0.000004194114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04575787,0.00033238193,0.94507223,0.00025914374,0.00036738804,0.00021982056,0.001131401,0.000024189876,0.000039514038,0.0000015261975,0.0009839108,0.005810622],"study_design_scores_gemma":[0.25752077,0.0032216252,0.7368353,0.0006736255,0.0004306474,8.1910713e-7,0.00007157782,0.0001894992,0.00020354125,0.0000014764532,0.000704632,0.00014650049],"about_ca_topic_score_codex":0.20462215,"about_ca_topic_score_gemma":0.12550403,"teacher_disagreement_score":0.2117629,"about_ca_system_score_codex":0.00020554764,"about_ca_system_score_gemma":0.00038436672,"threshold_uncertainty_score":0.8904532},"labels":[],"label_agreement":null},{"id":"W3092945883","doi":"10.3390/ijms21207539","title":"Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"microRNA; Multiple myeloma; Malignancy; Medicine; Bone marrow; Disease; Cancer research; Hematological malignancy; Bioinformatics; Pathology; Oncology; Internal medicine; Biology; Gene","score_opus":0.04313766204380171,"score_gpt":0.3720477213928985,"score_spread":0.3289100593490968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092945883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019045075,0.97999024,0.000016437905,0.00020999325,0.00007082957,0.00041211318,0.00002495261,0.0000016166432,0.00022872485],"genre_scores_gemma":[0.084207796,0.9116551,0.0040578214,0.000012715417,0.000026397545,0.00002186224,0.0000053229824,0.000008354684,0.000004620153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997866,0.00008257451,0.000734691,0.00018936062,0.000993754,0.00013364217],"domain_scores_gemma":[0.9988,0.00012350199,0.00065707037,0.000073653195,0.00023114061,0.00011466086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003536143,0.00014960015,0.00078164646,0.0005504681,0.000012946687,0.000022659056,0.00046001544,0.000056031953,0.000015549704],"category_scores_gemma":[0.0001374057,0.00010448987,0.00028385286,0.00032232274,0.00020667035,0.00007478961,0.00016283605,0.00016040773,0.0000015792214],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060238803,0.00030254587,0.012991163,0.002030613,0.0009618285,0.0012795776,0.000060622388,0.000001747629,0.00020788614,0.00011800507,0.00001100111,0.9819748],"study_design_scores_gemma":[0.011184541,0.0046676905,0.053801116,0.17217262,0.002917921,0.0032284472,0.0010438379,0.0003439595,0.0235266,0.0006423957,0.7256539,0.0008169543],"about_ca_topic_score_codex":0.00003140943,"about_ca_topic_score_gemma":0.0000049045657,"teacher_disagreement_score":0.98115784,"about_ca_system_score_codex":0.00007231281,"about_ca_system_score_gemma":0.00024848286,"threshold_uncertainty_score":0.4260973},"labels":[],"label_agreement":null},{"id":"W3093120364","doi":"10.3324/haematol.2020.259093","title":"The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Dalhousie University; Saint John Regional Hospital; Princess Margaret Cancer Centre; Vancouver General Hospital; McGill University; CancerCare Manitoba; Ottawa Hospital; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"Dalhousie University; University of Alberta; Celgene; Sanofi; Amgen; Pfizer; McGill University","keywords":"Lenalidomide; Multiple myeloma; Medicine; Database; Oncology; Internal medicine; Computer science","score_opus":0.33194027255700204,"score_gpt":0.4670194784622977,"score_spread":0.13507920590529565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093120364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97859526,0.00024949678,0.000027981518,0.009854796,0.00002367248,0.0006415128,0.007188259,0.000019115427,0.0033999088],"genre_scores_gemma":[0.9950163,0.00020914999,0.00039947536,0.000118944015,0.0000641836,0.000022317796,0.004105324,0.000011599207,0.000052754986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654377,0.00078356423,0.00041894402,0.00046849917,0.0012617769,0.00052344304],"domain_scores_gemma":[0.9951481,0.0021843258,0.00016543487,0.0013659358,0.00060540024,0.00053077546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022401253,0.00014755856,0.0005935224,0.00023058131,0.00039243547,0.000048453614,0.0010955251,0.000049625294,0.0004068799],"category_scores_gemma":[0.00389918,0.00006841526,0.00017272212,0.0019245113,0.00074318855,0.00012239866,0.00035349972,0.00036307663,0.00002654182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024015137,0.00022620507,0.96618366,0.000028600343,0.0038202698,0.00044841453,0.0002634528,0.000024238518,0.00058894145,0.0082217045,0.016270446,0.0015225599],"study_design_scores_gemma":[0.0008984822,0.00030060293,0.9786303,0.000031552096,0.00025990268,0.000006010916,0.00042372156,0.018197877,0.000114468414,0.0002031282,0.0008651317,0.00006879549],"about_ca_topic_score_codex":0.61350375,"about_ca_topic_score_gemma":0.8946185,"teacher_disagreement_score":0.28111473,"about_ca_system_score_codex":0.0002200536,"about_ca_system_score_gemma":0.0011103668,"threshold_uncertainty_score":0.46679643},"labels":[],"label_agreement":null},{"id":"W3094310701","doi":"10.1016/j.jgo.2020.10.009","title":"Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study","year":2020,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Demography; Mortality rate; Population; Gerontology; Clinical trial; Internal medicine; Environmental health","score_opus":0.017150242398666013,"score_gpt":0.30196008080943154,"score_spread":0.2848098384107655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094310701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652725,0.00026848158,0.00003080872,0.0020865626,0.000048999318,0.0010064739,0.0000127458625,0.000009349488,0.000009342557],"genre_scores_gemma":[0.998823,0.0001224253,0.0006628979,0.00018267024,0.00010856758,0.0000511999,0.000011551398,0.000018019273,0.000019688427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865896,0.00016118944,0.00044927705,0.00021942792,0.00026647645,0.00024468053],"domain_scores_gemma":[0.9986745,0.0005412978,0.00024137381,0.00009567314,0.00009199186,0.00035516257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012854888,0.00019159549,0.00072427455,0.00024386038,0.000051934167,0.00002484231,0.000045820845,0.00007875268,0.000031888758],"category_scores_gemma":[0.00021741078,0.00011709966,0.000061533996,0.00015863449,0.00003651894,0.00013726116,0.000024744324,0.00018215906,9.2675407e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046021515,0.0017589873,0.9756468,0.00006927399,0.00026534247,0.003255706,0.0014919749,0.000018373123,0.0000050527988,4.3179554e-7,0.000014326387,0.012871566],"study_design_scores_gemma":[0.049172703,0.0102203805,0.93837637,0.0000602058,0.00022554734,0.00006320348,0.0012533173,0.0005103581,0.000007735793,0.0000011568388,0.000017551238,0.00009149712],"about_ca_topic_score_codex":0.005065369,"about_ca_topic_score_gemma":0.004871121,"teacher_disagreement_score":0.04457055,"about_ca_system_score_codex":0.00024505807,"about_ca_system_score_gemma":0.0001848626,"threshold_uncertainty_score":0.7657356},"labels":[],"label_agreement":null},{"id":"W3094760802","doi":"10.1182/blood-2020-140612","title":"Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Jewish General Hospital; CancerCare Manitoba","funders":"","keywords":"Multiple myeloma; Medicine; Monoclonal gammopathy of undetermined significance; Stage (stratigraphy); Asymptomatic; Internal medicine; Cohort; Oncology; Prospective cohort study; Surgery; Immunology; Monoclonal","score_opus":0.017747565847662444,"score_gpt":0.2808727619215524,"score_spread":0.26312519607388996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094760802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664074,0.0003026456,0.00059138145,0.00009702278,0.000015265068,0.002078316,0.0002185258,0.00004589159,0.000010186198],"genre_scores_gemma":[0.98416567,0.0000040754235,0.015553608,0.000014465907,0.000017367904,0.000093555296,0.00011022924,0.00003408119,0.0000069491207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974746,0.00006934055,0.00063013844,0.00056810427,0.0008318981,0.00042592466],"domain_scores_gemma":[0.99844676,0.00008869587,0.0003664583,0.00042788888,0.00041439966,0.00025581752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001537035,0.00027319597,0.0009321578,0.00073618436,0.00007129767,0.000010695604,0.00017218795,0.00014696317,0.00007013712],"category_scores_gemma":[0.00048384265,0.00020333068,0.0001344239,0.0022441123,0.00020381322,0.00009655307,0.00022864882,0.0002633868,0.0000025758243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013717677,0.0015303134,0.97444236,0.00024482602,0.0021986123,0.00013576678,0.00025907892,0.0008010873,0.0115431575,0.0000035679313,0.0000036334643,0.007465838],"study_design_scores_gemma":[0.008076656,0.001702613,0.7820844,0.00034997612,0.0011681439,0.000003942358,0.0001105933,0.0027202365,0.20361243,0.000006894453,0.0000039579163,0.00016012759],"about_ca_topic_score_codex":0.00048095084,"about_ca_topic_score_gemma":0.0006999807,"teacher_disagreement_score":0.19235793,"about_ca_system_score_codex":0.000056232613,"about_ca_system_score_gemma":0.00014636261,"threshold_uncertainty_score":0.8291584},"labels":[],"label_agreement":null},{"id":"W3094795635","doi":"10.1182/blood-2020-133869","title":"Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Nausea; Population; Depression (economics); Autologous stem-cell transplantation; Internal medicine; Physical therapy","score_opus":0.01073587474739432,"score_gpt":0.22392859511486665,"score_spread":0.21319272036747233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094795635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979482,0.000065200504,0.000030227018,0.00002302163,0.00001681282,0.0016403354,0.00014288547,0.00007066349,0.00006261423],"genre_scores_gemma":[0.9993869,6.285496e-7,0.00019325918,0.000044231845,0.000023518021,0.00014472619,0.00014702261,0.000033852706,0.000025835025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984981,0.00008437064,0.00028291187,0.00033518957,0.00052035425,0.00027906534],"domain_scores_gemma":[0.9991988,0.00008690014,0.00008765058,0.00024425078,0.00009029712,0.00029207778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043477234,0.00019973733,0.00038343045,0.000087748514,0.00004339309,0.0000086042555,0.00008027294,0.00006183545,0.00005682808],"category_scores_gemma":[0.00001235977,0.0001418192,0.00008695691,0.00018344987,0.000035472913,0.000049605154,0.000012564354,0.00013750658,0.000011529102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023237874,0.0058348402,0.98881626,0.00021656966,0.00031448118,0.0003650437,0.0011503703,0.00002342177,0.00014897891,1.1571364e-7,0.0000022722563,0.00080385513],"study_design_scores_gemma":[0.028219063,0.0038239718,0.9641505,0.00007346571,0.00044168226,0.0000012038186,0.00009984275,0.00042796275,0.002633423,1.14264246e-7,0.0000023582538,0.000126404],"about_ca_topic_score_codex":0.0002130534,"about_ca_topic_score_gemma":0.00014838458,"teacher_disagreement_score":0.025895275,"about_ca_system_score_codex":0.000026787751,"about_ca_system_score_gemma":0.00008172893,"threshold_uncertainty_score":0.57832193},"labels":[],"label_agreement":null},{"id":"W3094860080","doi":"10.1182/blood-2020-139689","title":"Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Toronto; University of New Brunswick; Université de Montréal; Hôpital Maisonneuve-Rosemont; Nova Scotia Health Authority; McGill University Health Centre; McMaster University; London Health Sciences Centre; University of Calgary; Princess Margaret Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; University Health Network; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Lenalidomide; Medicine; Bortezomib; Internal medicine; Multiple myeloma; Oncology; Regimen; Melphalan; Maintenance therapy; Autologous stem-cell transplantation; Dexamethasone; Transplantation; Surgery; Database; Chemotherapy","score_opus":0.05981702633613518,"score_gpt":0.30274829726377955,"score_spread":0.24293127092764438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094860080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98530495,0.00035196543,0.000001656023,0.010512227,0.000014333046,0.0014295855,0.002026383,0.000007310705,0.00035158516],"genre_scores_gemma":[0.996927,0.00049453543,0.00043705062,0.0014024497,0.00008255967,0.00006553886,0.0005526279,0.000025446478,0.000012749727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970162,0.0005855958,0.00034704842,0.00041859288,0.0010231725,0.0006093705],"domain_scores_gemma":[0.9980593,0.00060018856,0.000089024485,0.0007483946,0.00020292347,0.00030020444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008621827,0.00017499228,0.00027502395,0.000107602515,0.00017144028,0.000039748415,0.00044635846,0.00008287501,0.000043544707],"category_scores_gemma":[0.000911802,0.000089000736,0.000044838074,0.0009163267,0.00019948102,0.00005466147,0.00007573563,0.0008709569,0.000018580664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024412505,0.000802471,0.9851365,0.000010396217,0.0001880852,0.0003449259,0.004812947,0.0000025661013,0.00017436946,0.000018101673,0.0017047931,0.0043635797],"study_design_scores_gemma":[0.026267324,0.0011389294,0.9682392,0.00016415333,0.0000356105,0.000001886362,0.0010558253,0.00009136198,0.002110675,0.00005192848,0.0007513684,0.00009176466],"about_ca_topic_score_codex":0.5258651,"about_ca_topic_score_gemma":0.52225405,"teacher_disagreement_score":0.023826074,"about_ca_system_score_codex":0.00010356316,"about_ca_system_score_gemma":0.00047519535,"threshold_uncertainty_score":0.48646355},"labels":[],"label_agreement":null},{"id":"W3095013795","doi":"10.1182/blood-2020-134928","title":"Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Multiple myeloma; Medicine; Minimal residual disease; Internal medicine; Bortezomib; Oncology; Surgery; Negativity effect; Melphalan; Bone marrow; Psychology","score_opus":0.02447451623414271,"score_gpt":0.29380934530748526,"score_spread":0.26933482907334255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095013795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725807,0.0002722699,0.000024421393,0.0005912493,0.000006280823,0.0012814286,0.00045503073,0.000051496572,0.000059729617],"genre_scores_gemma":[0.9980356,0.00013450539,0.0007119339,0.00011451174,0.00003509582,0.000041612235,0.00086551934,0.00003516399,0.000026058648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972723,0.0003119963,0.00064299384,0.0007551815,0.0005248221,0.00049267407],"domain_scores_gemma":[0.99735725,0.0009784718,0.00017772849,0.00036999903,0.00017137948,0.000945146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020876403,0.00034521852,0.0010215954,0.00039738367,0.00008322937,0.00003066399,0.00010009641,0.00012415506,0.000024987034],"category_scores_gemma":[0.0009694745,0.00026418065,0.00016320763,0.0010870105,0.0002943021,0.000109191096,0.00006145515,0.0002568881,0.0000020927819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024293628,0.006238316,0.96246094,0.00023364207,0.0020156112,0.0017335555,0.00031112367,0.000017116956,0.00026599402,0.0000028767156,0.00004259309,0.00238461],"study_design_scores_gemma":[0.0851454,0.002797883,0.90112144,0.0001718082,0.0039200033,0.0000018898432,0.000095056275,0.004881923,0.0016354556,0.0000014646225,0.0000137250445,0.00021396314],"about_ca_topic_score_codex":0.0005320585,"about_ca_topic_score_gemma":0.00061921624,"teacher_disagreement_score":0.061339505,"about_ca_system_score_codex":0.000034133085,"about_ca_system_score_gemma":0.00023171028,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W3095134159","doi":"10.1182/blood-2020-135874","title":"Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pomalidomide; Daratumumab; Dexamethasone; Medicine; Internal medicine; Refractory (planetary science); Oncology; Multiple myeloma; Lenalidomide; Materials science","score_opus":0.027140993031851593,"score_gpt":0.2862342285527387,"score_spread":0.25909323552088714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095134159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176407,0.0019085583,0.000032072538,0.0001670799,0.000086629385,0.005555429,0.00012356111,0.00009562652,0.0002669742],"genre_scores_gemma":[0.9964581,0.000259625,0.0025237224,0.00008578671,0.000085597654,0.00026164847,0.00014217253,0.00011695125,0.000066411776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994779,0.0010109505,0.0010869385,0.0011512192,0.0011227932,0.0008491068],"domain_scores_gemma":[0.99499714,0.002643909,0.00045773239,0.0006743252,0.0002722418,0.00095464726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075939513,0.0007053267,0.0024691876,0.00041706103,0.00019529613,0.00006329682,0.00022269056,0.00024156623,0.00006292481],"category_scores_gemma":[0.0034929605,0.0005536451,0.00016784786,0.0006823151,0.000494854,0.00024415803,0.00024686338,0.0007434619,0.000012359953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7845679,0.0144131025,0.17868724,0.00030381896,0.0027174824,0.0042988425,0.0046650646,0.000010425709,0.003916136,0.000005278704,0.000028403098,0.0063862954],"study_design_scores_gemma":[0.9300741,0.023729347,0.036312245,0.0002153117,0.0016570537,0.0001745885,0.0016384289,0.00094726885,0.0047021727,0.0000063703237,0.00003905197,0.0005040654],"about_ca_topic_score_codex":0.0014271117,"about_ca_topic_score_gemma":0.0006893988,"teacher_disagreement_score":0.14550619,"about_ca_system_score_codex":0.00014995175,"about_ca_system_score_gemma":0.0002504709,"threshold_uncertainty_score":0.9996915},"labels":[],"label_agreement":null},{"id":"W3095177954","doi":"10.1182/blood-2020-134189","title":"Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; McGill University Health Centre","funders":"","keywords":"Pomalidomide; Daratumumab; Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Internal medicine; Oncology; Refractory (planetary science); Phases of clinical research; Thalidomide; Bortezomib; Surgery; Clinical trial","score_opus":0.0704919808063595,"score_gpt":0.35972674380776287,"score_spread":0.2892347630014034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095177954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917206,0.0009307109,0.0000064821756,0.0010185417,0.00011483256,0.004304451,0.0014100611,0.00011602378,0.00037828868],"genre_scores_gemma":[0.9910449,0.0002226796,0.004933157,0.0004639344,0.00032735534,0.00052601314,0.0021879,0.00008627827,0.00020777885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99600697,0.0005614702,0.0009323701,0.0013038527,0.00049100944,0.0007043196],"domain_scores_gemma":[0.9972379,0.0005030596,0.00022613177,0.00081205514,0.0001095926,0.001111239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032878367,0.0005359056,0.0010287915,0.00019454716,0.00013604347,0.00017746865,0.0003047928,0.0002523174,0.00016181792],"category_scores_gemma":[0.001194404,0.0004323491,0.000082057915,0.00036141445,0.00013342776,0.00041229397,0.0002550988,0.00040906857,0.00008275831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8848211,0.036812875,0.016090732,0.00003180909,0.0009692121,0.0062763467,0.0015667565,8.1268587e-7,0.034952376,0.0000024023977,0.00024826414,0.018227274],"study_design_scores_gemma":[0.928677,0.021281948,0.023424247,0.0001337448,0.0005380596,0.00002289374,0.00020586833,0.002049423,0.020384928,0.000009065046,0.002866199,0.00040661005],"about_ca_topic_score_codex":0.0034160698,"about_ca_topic_score_gemma":0.0013108201,"teacher_disagreement_score":0.043855872,"about_ca_system_score_codex":0.00018835206,"about_ca_system_score_gemma":0.00026503034,"threshold_uncertainty_score":0.99981284},"labels":[],"label_agreement":null},{"id":"W3095225774","doi":"10.1038/s41408-020-00375-2","title":"Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Lenalidomide; Internal medicine; Daratumumab; Medicine; Oncology; Hazard ratio; Population; Multiple myeloma; Confidence interval","score_opus":0.03944056650698583,"score_gpt":0.3211153016057787,"score_spread":0.28167473509879287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095225774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259723,0.015616567,0.000047872596,0.0011766065,0.00003873259,0.00020997788,0.000045627014,0.000009963447,0.0002573947],"genre_scores_gemma":[0.9950911,0.0035317442,0.00083966536,0.00025477383,0.00016544832,0.000017510101,0.000008552612,0.000021745,0.000069494956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981836,0.00014605657,0.0004937704,0.00028753775,0.0005186494,0.00037040454],"domain_scores_gemma":[0.9987982,0.000105827676,0.00020789634,0.00017758424,0.00013162446,0.0005788613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027698005,0.00018219803,0.00071453606,0.0005180159,0.0000748017,0.000029176781,0.00011133567,0.00008770283,0.000452995],"category_scores_gemma":[0.00022655993,0.00014673432,0.00020419553,0.0011838934,0.00010370102,0.000072002265,0.000053675358,0.0004912331,0.0000033695324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021032149,0.00049244345,0.93595856,0.000118107426,0.0050119944,0.0011643209,0.00084167236,0.00010187557,0.032725006,0.00000998285,0.00013172756,0.021341074],"study_design_scores_gemma":[0.017374882,0.0011021668,0.9666425,0.00017463163,0.0036848497,0.00020601998,0.00022053676,0.0011347862,0.008929801,0.000018132578,0.00034956346,0.00016212088],"about_ca_topic_score_codex":0.00034163438,"about_ca_topic_score_gemma":0.00035718252,"teacher_disagreement_score":0.03068393,"about_ca_system_score_codex":0.00009835474,"about_ca_system_score_gemma":0.00032392805,"threshold_uncertainty_score":0.59836525},"labels":[],"label_agreement":null},{"id":"W3095302273","doi":"10.1182/blood-2020-142984","title":"A Case of Pancoast Syndrome Caused By an Extramedullary Plasmacytoma in Relapsed Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Multiple myeloma; Plasmacytoma; Bortezomib; Bone marrow; Lenalidomide; Biopsy; Gastroenterology; Pathology; Surgery; Internal medicine","score_opus":0.03244839662762526,"score_gpt":0.28479863629645413,"score_spread":0.25235023966882886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095302273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818665,0.0002631099,0.000010182516,0.0003180634,0.000021544247,0.0007172078,0.0002016497,0.00007292598,0.0002086783],"genre_scores_gemma":[0.99845177,0.00002026134,0.0010661819,0.0001258017,0.000027119024,0.00005981729,0.00014034429,0.000041278065,0.00006744834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984033,0.00010377053,0.0003743966,0.00039671414,0.0003104248,0.0004113876],"domain_scores_gemma":[0.9987768,0.00013938607,0.000078024575,0.00034128097,0.000056107972,0.000608407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010441189,0.00020242794,0.0004690084,0.0001201983,0.00004342109,0.000011526847,0.00010672203,0.00012259661,0.0001373922],"category_scores_gemma":[0.00036001,0.00018041371,0.000086198605,0.00037069418,0.00007796762,0.00008049518,0.00005791834,0.0002706581,0.0000421763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001585862,0.006178269,0.6305048,0.000503947,0.0005051161,0.24437581,0.0017660143,0.000011812626,0.108865,0.000006603942,0.0004397627,0.005257044],"study_design_scores_gemma":[0.15250874,0.01450922,0.52552885,0.0005363337,0.00067091454,0.04163304,0.0020959673,0.016546937,0.24445798,0.000035115194,0.00054407545,0.0009328731],"about_ca_topic_score_codex":0.00047824366,"about_ca_topic_score_gemma":0.0003551962,"teacher_disagreement_score":0.20274277,"about_ca_system_score_codex":0.000032151962,"about_ca_system_score_gemma":0.00012953658,"threshold_uncertainty_score":0.7357058},"labels":[],"label_agreement":null},{"id":"W3095308393","doi":"10.3747/co.27.7149","title":"Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Impact; Dalhousie University; Fluidigm (Canada); Queen Elizabeth II Health Sciences Centre; University of Alberta; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; McGill University; Jewish General Hospital; McMaster University; Juravinski Hospital; Juravinski Cancer Centre","funders":"Janssen Canada","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Novelty; Intensive care medicine; Reactionary; Perspective (graphical); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Coronavirus; Disease; Risk management; Virology; Pathology; Infectious disease (medical specialty); Political science; Business; Artificial intelligence","score_opus":0.24400921670889741,"score_gpt":0.4585871826262155,"score_spread":0.2145779659173181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095308393","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43263483,0.002099003,0.00003045504,0.5609934,0.0002649862,0.0009861129,0.00011235004,0.00009098662,0.0027879311],"genre_scores_gemma":[0.99427307,0.0010290052,0.00007093634,0.0038638962,0.0005576777,0.000080975464,0.000035766632,0.000015526324,0.00007312917],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875164,0.00018479305,0.0001406813,0.00037781018,0.00015638543,0.00038871547],"domain_scores_gemma":[0.99820644,0.00042733748,0.000045444238,0.00017716554,0.00008949461,0.0010541453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011988337,0.00015091052,0.00024230864,0.00011929462,0.00058237446,0.000031458716,0.00006680238,0.0000866383,0.00024344295],"category_scores_gemma":[0.0010432358,0.00010645797,0.000056501627,0.00013769427,0.00015015817,0.000038010312,0.000055386477,0.00051714294,0.000051799998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015464758,0.00044407483,0.8430793,0.00027157034,0.00059971825,0.0020278273,0.024907012,0.000058633115,0.00092909025,0.017957702,0.011031834,0.09714671],"study_design_scores_gemma":[0.014571281,0.0011565906,0.3318196,0.00004370796,0.00019119028,0.0008290281,0.01885851,0.0029416555,0.00010775471,0.0021065855,0.6270208,0.00035333593],"about_ca_topic_score_codex":0.008047201,"about_ca_topic_score_gemma":0.077967696,"teacher_disagreement_score":0.6159889,"about_ca_system_score_codex":0.0015890856,"about_ca_system_score_gemma":0.0010963883,"threshold_uncertainty_score":0.9985583},"labels":[],"label_agreement":null},{"id":"W3095605271","doi":"10.1016/s1470-2045(20)30587-8","title":"BELLINI: a renaissance for an era of precision therapy in multiple myeloma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Genentech; Takeda Pharmaceuticals U.S.A.; Janssen Biotech; Celgene","keywords":"Venetoclax; Bortezomib; Multiple myeloma; Dexamethasone; Context (archaeology); Medicine; Oncology; Internal medicine; Cancer research; Chromosomal translocation; Biology; Leukemia; Chronic lymphocytic leukemia; Genetics; Gene","score_opus":0.1744093802438907,"score_gpt":0.4059269157998305,"score_spread":0.2315175355559398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095605271","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069300085,0.0016315461,0.00013399778,0.92253345,0.00029396938,0.004283626,0.00033739544,0.00006774768,0.0014181931],"genre_scores_gemma":[0.2911425,0.005023195,0.010942257,0.67633426,0.0115099065,0.001771691,0.0021341504,0.00018494968,0.000957123],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758524,0.000500427,0.0004707832,0.0004945209,0.000346114,0.00060290634],"domain_scores_gemma":[0.99698097,0.0017407675,0.00026133837,0.00077777106,0.00013947886,0.00009970023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004837922,0.00028050257,0.001364962,0.000098788725,0.00007066469,0.000009258433,0.0004806386,0.00055434735,0.00008528589],"category_scores_gemma":[0.00048957765,0.00017178454,0.00017654263,0.000200833,0.0002355888,0.000041722655,0.00007296994,0.0018120352,0.000029883671],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012754302,0.0004199422,0.006461841,0.0003675696,0.00029009808,0.0007382627,0.00075639423,0.00000426045,0.0015160594,0.000011380024,0.790931,0.1857489],"study_design_scores_gemma":[0.015551554,0.008027347,0.012510634,0.00022674595,0.00005029222,0.00004523229,0.000024815141,0.0010428096,0.0012253141,0.0007335389,0.9603951,0.00016658928],"about_ca_topic_score_codex":0.00019209439,"about_ca_topic_score_gemma":0.00022856538,"teacher_disagreement_score":0.2461992,"about_ca_system_score_codex":0.00016367996,"about_ca_system_score_gemma":0.00038164985,"threshold_uncertainty_score":0.7872492},"labels":[],"label_agreement":null},{"id":"W3095664040","doi":"10.1182/blood-2020-141088","title":"Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Bortezomib; Internal medicine; Comorbidity; Malignancy; Pediatrics","score_opus":0.06723516495288251,"score_gpt":0.32772629891777644,"score_spread":0.26049113396489393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095664040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99902624,0.00017496487,6.039476e-7,0.00031058135,0.000004881898,0.00038184502,0.00001126914,8.488696e-7,0.00008879033],"genre_scores_gemma":[0.9997406,0.00007402751,0.000043140513,0.000101596605,0.0000029197638,0.000008338345,0.000020248055,0.0000037020882,0.0000054274574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994197,0.000044416425,0.00017492191,0.00009096579,0.00018218382,0.0000878016],"domain_scores_gemma":[0.9996269,0.00018358618,0.000043953532,0.00007118489,0.000026451718,0.000047943955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038995484,0.000057866764,0.0002049197,0.000031864194,0.000011627762,0.0000024059623,0.00003456316,0.000020594809,0.000008314616],"category_scores_gemma":[0.0001979146,0.00003604571,0.000010331618,0.000107599466,0.000029703093,0.000019725734,0.000014902975,0.000050238144,1.5439016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001326574,0.00053079234,0.9918277,0.00004544252,0.000030957955,0.0000048849433,0.0015524231,6.48735e-7,0.00016853864,0.0000050047033,0.000014847332,0.005686099],"study_design_scores_gemma":[0.008623935,0.00034173357,0.9863309,0.000019837245,0.000010004568,4.4851143e-7,0.00022677719,0.0005004353,0.0038718951,0.000002078274,0.000046109693,0.00002583617],"about_ca_topic_score_codex":0.37546456,"about_ca_topic_score_gemma":0.71160245,"teacher_disagreement_score":0.3361379,"about_ca_system_score_codex":0.0000074252375,"about_ca_system_score_gemma":0.000057240853,"threshold_uncertainty_score":0.6286943},"labels":[],"label_agreement":null},{"id":"W3095670170","doi":"10.1182/blood-2020-142271","title":"Monoclonal Protein Response Trajectory and Survival in Newly Diagnosed Multiple Myeloma: A Retrospective Cohort Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"","keywords":"Multiple myeloma; Retrospective cohort study; Medicine; Cohort; Internal medicine; Bortezomib; Oncology; Trajectory; Survival analysis","score_opus":0.02536864398055786,"score_gpt":0.2831186031077861,"score_spread":0.2577499591272282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095670170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950942,0.00018059366,0.00000543652,0.0005739481,0.000019374207,0.0037955535,0.000039865034,0.00007577452,0.00021528166],"genre_scores_gemma":[0.998667,0.000012120318,0.0004725814,0.00005628717,0.000103263636,0.00052084203,0.000017034785,0.000032625645,0.00011825461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978609,0.0003906923,0.00026331912,0.0005651913,0.0005455796,0.00037428722],"domain_scores_gemma":[0.9989506,0.00027103073,0.000048145135,0.00024109898,0.00007536911,0.00041375242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050514215,0.00021296032,0.0004885851,0.00012437868,0.000069984984,0.0000260268,0.00008289519,0.00007487146,0.00005713271],"category_scores_gemma":[0.001933791,0.00018441863,0.00006113673,0.00032701984,0.00007234579,0.00007332968,0.00008138244,0.00033015897,0.000026345586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009750178,0.003216326,0.9697453,0.000031408126,0.00032284312,0.0037585348,0.001413906,5.992978e-7,0.011320981,0.000002806774,0.000019686384,0.00041744002],"study_design_scores_gemma":[0.035620864,0.0030910338,0.9568772,0.0000358583,0.00009041824,0.000016587312,0.00062339683,0.0001907993,0.0032756217,0.000005277819,0.000028393919,0.00014460462],"about_ca_topic_score_codex":0.0005784326,"about_ca_topic_score_gemma":0.000517064,"teacher_disagreement_score":0.025870688,"about_ca_system_score_codex":0.000096569915,"about_ca_system_score_gemma":0.00018486091,"threshold_uncertainty_score":0.75203735},"labels":[],"label_agreement":null},{"id":"W3095745908","doi":"10.1182/blood-2020-141319","title":"Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Bortezomib; Regimen; Internal medicine; Peripheral neuropathy; Dexamethasone; Oncology; Multiple myeloma; Chemotherapy regimen; Physical therapy; Cancer","score_opus":0.017770722428880992,"score_gpt":0.23925960712658134,"score_spread":0.22148888469770034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095745908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99848527,0.0003910061,0.000029928296,0.00020535808,0.00001240226,0.00068228855,0.000020747566,0.00008485952,0.00008811389],"genre_scores_gemma":[0.99802834,0.000084657884,0.0010866581,0.0004104646,0.00006345736,0.000055373202,0.000093339106,0.000046054887,0.00013163562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984186,0.00022730921,0.0002493076,0.0004796661,0.00028183684,0.00034324767],"domain_scores_gemma":[0.9989979,0.0002553421,0.0000690856,0.00016955468,0.00008686547,0.0004212407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017190857,0.00023414366,0.00035812083,0.00009743113,0.00009366453,0.000035493955,0.000041095904,0.00008816875,0.000044769895],"category_scores_gemma":[0.0009502786,0.00016145085,0.000027561166,0.00030024347,0.00008007114,0.00009373058,0.000046706868,0.00027902177,0.0000042913343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004156581,0.00090771145,0.96379584,0.00009527988,0.00014798847,0.00071380124,0.00041835062,0.0000017440289,0.0016919285,5.072435e-7,0.000027781844,0.02804249],"study_design_scores_gemma":[0.03661398,0.007381916,0.950153,0.00013017542,0.00013418101,0.000050515944,0.00014206591,0.0044121863,0.00047008795,5.020574e-7,0.00033770467,0.0001737185],"about_ca_topic_score_codex":0.00015834253,"about_ca_topic_score_gemma":0.00011310502,"teacher_disagreement_score":0.032457396,"about_ca_system_score_codex":0.000036626647,"about_ca_system_score_gemma":0.00007623706,"threshold_uncertainty_score":0.65837747},"labels":[],"label_agreement":null},{"id":"W3095935119","doi":"10.1182/blood-2020-139358","title":"Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Internal medicine; Regimen; Daratumumab; Oncology; Population; Multiple myeloma; Refractory (planetary science); Dosing; Dexamethasone; Carfilzomib; Gastroenterology","score_opus":0.0510870203777942,"score_gpt":0.28953908191901306,"score_spread":0.23845206154121887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095935119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98967147,0.00015071155,0.00039254798,0.00066546473,0.000026114441,0.00163658,0.000069986294,0.00010452398,0.007282617],"genre_scores_gemma":[0.9829758,0.0000040703126,0.01525267,0.0010951924,0.00006848098,0.00019048687,0.00022261323,0.00006253069,0.00012818007],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9974507,0.00012203549,0.0003705767,0.0006552951,0.00079680275,0.0006045622],"domain_scores_gemma":[0.99853027,0.00008987903,0.0000742007,0.000450123,0.0001433493,0.00071216864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020363976,0.00028198984,0.00044622415,0.00020511117,0.000082630366,0.00003015378,0.00018252911,0.00012897424,0.000020608752],"category_scores_gemma":[0.0007446379,0.00024689763,0.00012024328,0.00042561014,0.00003665295,0.00009762606,0.000105384344,0.00034721743,0.00010950977],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00899555,0.027053896,0.90087754,0.0006480045,0.0005886084,0.00045461982,0.0043282034,0.01547847,0.015061174,0.000026126918,0.0025337532,0.023954045],"study_design_scores_gemma":[0.06717273,0.00157764,0.18410656,0.00017274747,0.00019107759,0.0000024632889,0.000096476106,0.7395496,0.0063626007,0.00001872612,0.00037548348,0.0003739181],"about_ca_topic_score_codex":0.0001070414,"about_ca_topic_score_gemma":0.000014234352,"teacher_disagreement_score":0.7240711,"about_ca_system_score_codex":0.00015245996,"about_ca_system_score_gemma":0.00024437215,"threshold_uncertainty_score":0.99999833},"labels":[],"label_agreement":null},{"id":"W3096049589","doi":"10.1182/blood-2020-141029","title":"Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Pomalidomide; Carfilzomib; Medicine; Lenalidomide; Internal medicine; Cohort; Population; Refractory (planetary science); Regimen; Oncology; Dexamethasone; Surgery","score_opus":0.06429584796946747,"score_gpt":0.3207606016718996,"score_spread":0.25646475370243216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096049589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328035,0.0011113359,0.00008090464,0.0007551741,0.00014225392,0.0032820592,0.00013847918,0.00022225278,0.0009872073],"genre_scores_gemma":[0.9947301,0.000086542146,0.003149007,0.00055774435,0.00033344762,0.0003825246,0.00015668634,0.00012671806,0.00047722168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952743,0.00049379776,0.0008865161,0.001192521,0.0010293622,0.0011235189],"domain_scores_gemma":[0.9973552,0.00035288776,0.0001992667,0.00086420315,0.0002056709,0.0010227662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046011427,0.00062124344,0.0012213713,0.00036326237,0.0001804078,0.00008681075,0.00040134735,0.00023105509,0.00020990445],"category_scores_gemma":[0.0015856207,0.0005366636,0.00030282114,0.00075529504,0.00014225628,0.00026602967,0.00033269895,0.0009395151,0.0004320392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083136745,0.022959769,0.9328772,0.00023996331,0.0013419767,0.010436678,0.0040101856,0.000016280535,0.014964823,0.0000050335384,0.000528035,0.0043063816],"study_design_scores_gemma":[0.3273273,0.0041883066,0.64432096,0.00028279284,0.0005310238,0.00025215646,0.0026409526,0.0033249096,0.013503082,0.000004737688,0.0028215735,0.00080221257],"about_ca_topic_score_codex":0.0010012793,"about_ca_topic_score_gemma":0.0012542024,"teacher_disagreement_score":0.31901363,"about_ca_system_score_codex":0.0003117721,"about_ca_system_score_gemma":0.00040023265,"threshold_uncertainty_score":0.9997085},"labels":[],"label_agreement":null},{"id":"W3096085400","doi":"10.1182/blood-2020-142115","title":"Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Autologous stem-cell transplantation; Daratumumab; Medicine; Multiple myeloma; Stem cell; Transplantation; Bortezomib; Internal medicine; Hematopoietic stem cell transplantation; Oncology; Biology","score_opus":0.016397252140872773,"score_gpt":0.24665487965510838,"score_spread":0.23025762751423562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096085400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977132,0.00019343915,0.00005148538,0.00004857743,0.000035586887,0.0011486782,0.00017311375,0.00006919014,0.0005666918],"genre_scores_gemma":[0.9993719,0.00010083328,0.00014215942,0.000026277938,0.000027391989,0.00004104451,0.0001822833,0.00003130036,0.000076837976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840754,0.000119512966,0.00033423147,0.00038507706,0.00040949817,0.00034413024],"domain_scores_gemma":[0.9989922,0.00017303866,0.00013807324,0.0001926066,0.00010181745,0.00040228784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054546825,0.00025405045,0.00040901618,0.00012803415,0.0001741802,0.000023837918,0.00006663873,0.00010326066,0.00001647122],"category_scores_gemma":[0.000005988175,0.00020204384,0.00015165424,0.00022003922,0.000060811693,0.00007028195,0.00002785634,0.00019180807,0.000014102421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020547411,0.004109279,0.9725937,0.00049779227,0.00047263023,0.00021451882,0.0021499724,0.000054282355,0.016005827,0.000001959658,0.00012630259,0.0017189878],"study_design_scores_gemma":[0.024683489,0.007851668,0.8151063,0.0001715989,0.00029527443,0.000017828641,0.0001557045,0.0014002114,0.15014333,0.0000012032776,0.00000675144,0.0001667003],"about_ca_topic_score_codex":0.00012691342,"about_ca_topic_score_gemma":0.000035883877,"teacher_disagreement_score":0.15748747,"about_ca_system_score_codex":0.00012515624,"about_ca_system_score_gemma":0.00011670286,"threshold_uncertainty_score":0.8239109},"labels":[],"label_agreement":null},{"id":"W3096107683","doi":"10.1182/blood-2020-138391","title":"Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Medicine; Dexamethasone; Carfilzomib; Internal medicine; Multiple myeloma; Proteasome inhibitor; Oncology; Ixazomib; Refractory (planetary science); Regimen; Pharmacology; Hazard ratio; Gastroenterology; Confidence interval; Biology","score_opus":0.027538245513581347,"score_gpt":0.2955877824111594,"score_spread":0.26804953689757804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096107683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907836,0.0015436347,0.000008700971,0.00075645465,0.000007633768,0.0067568896,0.00009969126,0.000027194037,0.000016218466],"genre_scores_gemma":[0.9985504,0.00022416259,0.0006879993,0.000037093192,0.000043833967,0.00033449774,0.000057326484,0.000048634087,0.000016063726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608123,0.0011495103,0.00077376823,0.0008433673,0.0007242895,0.00042784275],"domain_scores_gemma":[0.99346733,0.005082542,0.00041699715,0.0006339465,0.00009195736,0.0003072075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009790768,0.0005257288,0.0016491935,0.0002673009,0.0001238935,0.00003397471,0.00015315384,0.00013959147,0.000013335384],"category_scores_gemma":[0.00093250227,0.00023748721,0.0000873856,0.0013081564,0.00038666307,0.00008449215,0.00010282166,0.00052322046,8.081385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059498195,0.0060559288,0.90557617,0.00012959601,0.0032714193,0.00026058307,0.005528474,0.000025169868,0.00401187,7.945424e-7,0.000004235657,0.015637588],"study_design_scores_gemma":[0.079508,0.050250154,0.8493633,0.00041595986,0.003163818,0.000010059644,0.002330482,0.0015472502,0.013182924,4.9804095e-7,0.000017488048,0.00021001628],"about_ca_topic_score_codex":0.005330353,"about_ca_topic_score_gemma":0.006550235,"teacher_disagreement_score":0.056212798,"about_ca_system_score_codex":0.00010931844,"about_ca_system_score_gemma":0.00017803459,"threshold_uncertainty_score":0.9684447},"labels":[],"label_agreement":null},{"id":"W3096307008","doi":"10.1182/blood-2020-137574","title":"Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Carfilzomib; Refractory (planetary science); Internal medicine; Oncology; Biology","score_opus":0.047951407480157825,"score_gpt":0.3135839291236633,"score_spread":0.2656325216435055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096307008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929674,0.0018724005,0.00000694659,0.0019702776,0.000011211659,0.002663484,0.0004240875,0.000032284493,0.00005190259],"genre_scores_gemma":[0.99796563,0.0005518916,0.0011587004,0.00010164825,0.000058732676,0.000035436093,0.00005302633,0.000045639466,0.000029262192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698895,0.0006308032,0.0007218223,0.00067154766,0.00060382474,0.0003830581],"domain_scores_gemma":[0.99190545,0.0065841135,0.00039278835,0.0006716825,0.00015752645,0.00028845543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008402291,0.00039588302,0.00095724943,0.00009580565,0.0001577718,0.0000356423,0.00020492803,0.00010956225,0.000018284893],"category_scores_gemma":[0.0027929773,0.00018781566,0.000077411525,0.0004652584,0.0004363903,0.00008840761,0.00014000054,0.0005426381,0.000001239646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11378057,0.0050990866,0.8273756,0.000075896634,0.0023000373,0.00021452464,0.017738668,0.000013436148,0.019309023,0.0000028407217,0.00006986037,0.0140204765],"study_design_scores_gemma":[0.07569774,0.010909635,0.90505785,0.00032763183,0.0004327971,0.00001969299,0.0045315945,0.00089643634,0.001899915,0.0000025363179,0.000049116843,0.00017504628],"about_ca_topic_score_codex":0.0042754603,"about_ca_topic_score_gemma":0.0012263536,"teacher_disagreement_score":0.07768228,"about_ca_system_score_codex":0.000047999667,"about_ca_system_score_gemma":0.00024935472,"threshold_uncertainty_score":0.76589},"labels":[],"label_agreement":null},{"id":"W3096378490","doi":"10.1182/blood-2020-139785","title":"DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Dexamethasone; Bortezomib; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Phases of clinical research; Surgery; Clinical trial","score_opus":0.016220613694295595,"score_gpt":0.25784255581232624,"score_spread":0.24162194211803065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096378490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500996,0.00064531696,0.000016569378,0.00017655834,0.000014431395,0.0039120596,0.00012268391,0.0000309605,0.00007148915],"genre_scores_gemma":[0.99816,0.000108527674,0.0014231123,0.00007380525,0.000030446,0.000068212794,0.0000401348,0.00006607352,0.000029658962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689466,0.00036160127,0.0007097488,0.0007478152,0.0007843964,0.0005017517],"domain_scores_gemma":[0.9975381,0.0008266702,0.00040387938,0.00055688823,0.00017969537,0.00049479184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037146758,0.00045000185,0.001203469,0.00019618809,0.0001344621,0.000025274234,0.00017039465,0.00013345672,0.000019574265],"category_scores_gemma":[0.000678764,0.00028066523,0.000055278033,0.0005489753,0.00043686168,0.00015397544,0.0002621683,0.00045139124,7.724567e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078885466,0.008168006,0.90077776,0.00025453512,0.00095169834,0.00023742767,0.0036438645,0.0000055504966,0.0028371473,0.0000038797025,0.0000074757572,0.004227207],"study_design_scores_gemma":[0.28305608,0.011237146,0.6990346,0.0003350024,0.0006636702,0.000047974496,0.0009440327,0.00012860203,0.0043362384,0.000001561922,0.000013816936,0.00020131383],"about_ca_topic_score_codex":0.0008941816,"about_ca_topic_score_gemma":0.00058097247,"teacher_disagreement_score":0.20417063,"about_ca_system_score_codex":0.000054405147,"about_ca_system_score_gemma":0.00020435987,"threshold_uncertainty_score":0.99996454},"labels":[],"label_agreement":null},{"id":"W3096400445","doi":"10.1182/blood-2020-136415","title":"Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Pomalidomide; Dexamethasone; Internal medicine; Renal function; Multiple myeloma; Adverse effect; Interim analysis; Oncology; Urology; Gastroenterology; Randomized controlled trial","score_opus":0.01947837347230705,"score_gpt":0.2509341816604504,"score_spread":0.23145580818814335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096400445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965606,0.0011630997,0.000055204117,0.00041384037,0.000031237323,0.0013305268,0.00016347652,0.00008559008,0.00019647049],"genre_scores_gemma":[0.99323505,0.00013733719,0.005851699,0.00013763101,0.00007686551,0.00011605513,0.00032739053,0.00006244961,0.000055539236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670535,0.00020857855,0.0004913447,0.0010063533,0.00079337443,0.0007949948],"domain_scores_gemma":[0.99770874,0.0004924753,0.0002049717,0.00047825804,0.0001680974,0.00094746926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002566602,0.0004858974,0.0010955374,0.00045981893,0.00014835392,0.00007123972,0.00014148284,0.00019833844,0.00008028066],"category_scores_gemma":[0.0007612442,0.00038694605,0.00015412066,0.0014600079,0.00023272142,0.00015918267,0.00019687484,0.00046509987,0.0000138743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014405179,0.0014130892,0.97362417,0.00016257397,0.0031709066,0.0006509377,0.0014662079,0.000022356064,0.00096959027,0.0000054043626,0.000033746135,0.004075848],"study_design_scores_gemma":[0.13557974,0.003881922,0.8521402,0.000085000735,0.0024162417,0.000018972873,0.00031366435,0.0032650514,0.0018678413,0.000003766969,0.00006446124,0.00036317788],"about_ca_topic_score_codex":0.0011561981,"about_ca_topic_score_gemma":0.0013909631,"teacher_disagreement_score":0.121484,"about_ca_system_score_codex":0.00017369623,"about_ca_system_score_gemma":0.0001702694,"threshold_uncertainty_score":0.99985826},"labels":[],"label_agreement":null},{"id":"W3096445279","doi":"10.1182/blood-2020-140141","title":"Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary; University of Alberta; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Carfilzomib; Pomalidomide; Thalidomide; Biology","score_opus":0.021725629664099987,"score_gpt":0.2593842463441836,"score_spread":0.23765861668008362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096445279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965042,0.00083184877,0.00018834976,0.0007451417,0.000018956014,0.0014530679,0.00011048767,0.00006507062,0.00008290788],"genre_scores_gemma":[0.9864653,0.00020337557,0.012336833,0.00045307475,0.0001310304,0.00012661955,0.0001523581,0.000046553945,0.00008485589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867463,0.000044877223,0.00020555174,0.00043708112,0.00028751636,0.0003503526],"domain_scores_gemma":[0.99843687,0.00057983765,0.00007321608,0.00018674761,0.00014521446,0.00057813077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008719994,0.00021777315,0.00036632858,0.000060746628,0.000108754815,0.000032832184,0.000054013977,0.00008648659,0.000021740518],"category_scores_gemma":[0.0011225608,0.00015707112,0.000048553902,0.000117849275,0.00009495166,0.00011232479,0.000056808483,0.00015946903,0.000008845517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048335684,0.0013567014,0.9686383,0.00025585337,0.00044854544,0.0001488995,0.00041097158,5.193842e-7,0.0013400865,0.000007351238,0.00040454342,0.022154635],"study_design_scores_gemma":[0.122385815,0.0055576,0.86224866,0.00013380536,0.00047518886,0.00002049024,0.0001290897,0.00058437476,0.0041722157,0.000016943946,0.0040068342,0.00026899524],"about_ca_topic_score_codex":0.00005827097,"about_ca_topic_score_gemma":0.000035347504,"teacher_disagreement_score":0.11755224,"about_ca_system_score_codex":0.000018158646,"about_ca_system_score_gemma":0.0000713254,"threshold_uncertainty_score":0.6405174},"labels":[],"label_agreement":null},{"id":"W3096538903","doi":"10.1182/blood-2020-134847","title":"Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Daratumumab; Internal medicine; Multiple myeloma; Transplantation; Minimal residual disease; Phases of clinical research; Oncology; Surgery; Chemotherapy; Bone marrow","score_opus":0.02812058088858904,"score_gpt":0.2912251193874986,"score_spread":0.2631045384989096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096538903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563944,0.0007976366,0.00009390205,0.00046427225,0.000027038854,0.002477342,0.0003813536,0.00005219838,0.00006681922],"genre_scores_gemma":[0.99797016,0.00020541609,0.00096530153,0.00011613783,0.000039993894,0.00013269059,0.00050013606,0.000053133823,0.000017033406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658984,0.00040356696,0.0006885523,0.0008277571,0.00085457903,0.0006357097],"domain_scores_gemma":[0.9973874,0.0010425451,0.000234166,0.0005814187,0.00019662408,0.000557831],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004305332,0.00047897056,0.0013167475,0.00049391825,0.00016491358,0.00006489645,0.00022836974,0.00012362027,0.00007764026],"category_scores_gemma":[0.0005428122,0.00031662025,0.00014742812,0.0018424478,0.00024868167,0.0001823959,0.00011056387,0.00041448363,0.000005010621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056454457,0.0052130674,0.9220907,0.00010406061,0.0077297552,0.0007693935,0.0031127324,0.00009629427,0.0011802624,0.0000025493914,0.0000555547,0.0031911728],"study_design_scores_gemma":[0.28297403,0.005017978,0.69638664,0.00009038083,0.006791552,0.000008267863,0.0012168387,0.0032901764,0.0038776665,0.0000018505657,0.000044715198,0.00029990484],"about_ca_topic_score_codex":0.0016545617,"about_ca_topic_score_gemma":0.002386719,"teacher_disagreement_score":0.22651958,"about_ca_system_score_codex":0.00006566113,"about_ca_system_score_gemma":0.0001530091,"threshold_uncertainty_score":0.9999286},"labels":[],"label_agreement":null},{"id":"W3096609892","doi":"10.1182/blood-2020-133355","title":"Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; University of Alberta; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Refractory (planetary science); Multiple myeloma; Antibody; Pharmacology; Antigen; Internal medicine; Oncology; Immunology","score_opus":0.01532073475445875,"score_gpt":0.26735117926769025,"score_spread":0.2520304445132315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096609892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609995,0.00075440574,0.000041165895,0.00028092752,0.000069620866,0.0020485758,0.0002766252,0.00007416145,0.00035458483],"genre_scores_gemma":[0.99630654,0.00090693077,0.0013669014,0.00010644873,0.000090156784,0.000021649119,0.0010405603,0.00008251235,0.00007830727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737567,0.0001386653,0.0006470811,0.00065263663,0.0006660891,0.0005198682],"domain_scores_gemma":[0.99845093,0.00022084558,0.00027406486,0.0003465939,0.00021489577,0.0004926884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010808439,0.00040028334,0.000618127,0.00023969599,0.000088988374,0.000031026964,0.00018378586,0.00014663025,0.00007888137],"category_scores_gemma":[0.00012302029,0.0003373576,0.000096871896,0.00041656068,0.00017019021,0.00015808138,0.00014540738,0.00041685754,0.000024794963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040707547,0.008845648,0.85369396,0.0007133004,0.00045978554,0.0014221884,0.0011837698,0.000026665386,0.08342728,0.0000027228295,0.00010937255,0.009407737],"study_design_scores_gemma":[0.06864115,0.007841688,0.8831824,0.000279393,0.00037899596,0.000071960705,0.00010640572,0.0036562127,0.03493107,0.0000015622579,0.0005304038,0.00037873504],"about_ca_topic_score_codex":0.000044053435,"about_ca_topic_score_gemma":0.000016493199,"teacher_disagreement_score":0.048496213,"about_ca_system_score_codex":0.000061324405,"about_ca_system_score_gemma":0.00017234359,"threshold_uncertainty_score":0.99990785},"labels":[],"label_agreement":null},{"id":"W3096616006","doi":"10.1182/blood-2020-141060","title":"Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Juravinski Cancer Centre; Hamilton Health Sciences","funders":"","keywords":"Minimal residual disease; Bone marrow; Flow cytometry; Lysis; Pathology; Staining; Molecular biology; Bovine serum albumin; Chemistry; Biomedical engineering; Medicine; Chromatography; Biology","score_opus":0.07247607809429459,"score_gpt":0.32188583152384864,"score_spread":0.24940975342955407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096616006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7134156,0.00041904554,0.27401218,0.0028295976,0.00017936008,0.0041291416,0.004578383,0.00021418584,0.00022251958],"genre_scores_gemma":[0.81271476,0.000006619688,0.18537627,0.00027552553,0.00046301747,0.00035344186,0.00033880104,0.00004969352,0.00042187996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876785,0.000026245927,0.0001895389,0.0003815747,0.00026147577,0.0003733099],"domain_scores_gemma":[0.9987324,0.00037879907,0.00004984474,0.0001605489,0.00009797288,0.00058047584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011995847,0.00015911124,0.0002471761,0.00007169152,0.00010241255,0.000028123406,0.00007349665,0.00007700831,0.000024189454],"category_scores_gemma":[0.00077384885,0.00013883365,0.0001513184,0.00015709618,0.000023728511,0.000054196953,0.000031684245,0.00008814518,0.00001812661],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005172631,0.002076992,0.00062228733,0.00041900066,0.00035632914,0.00003370683,0.00008463813,0.0000034742945,0.95256037,0.0000038638864,0.0023611009,0.0363056],"study_design_scores_gemma":[0.024501702,0.002832874,0.0016215724,0.00002782384,0.00061245786,0.000014150196,0.00007818294,0.023203727,0.94020945,0.000012261304,0.006721967,0.00016381344],"about_ca_topic_score_codex":0.000012794899,"about_ca_topic_score_gemma":0.0000055906726,"teacher_disagreement_score":0.099299155,"about_ca_system_score_codex":0.000035652127,"about_ca_system_score_gemma":0.00008569522,"threshold_uncertainty_score":0.5661472},"labels":[],"label_agreement":null},{"id":"W3096653635","doi":"10.1182/blood-2020-136613","title":"Development of a Hydrashift 2/4 Isatuximab Assay to Mitigate Interference with Monoclonal Protein Detection on Immunofixation Electrophoresis in Vitro Diagnostic Tests in Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Serum protein electrophoresis; Pomalidomide; Daratumumab; Multiple myeloma; Lenalidomide; Carfilzomib; Immunofixation; Medicine; Monoclonal; Monoclonal antibody; Internal medicine; Immunology; Antibody","score_opus":0.020141626482074026,"score_gpt":0.2516306067253915,"score_spread":0.2314889802433175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096653635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751836,0.000052810068,0.00039030047,0.00036873098,0.000006429138,0.0015619827,0.000009048537,0.00002734945,0.00006496757],"genre_scores_gemma":[0.9911667,0.000005696346,0.008053094,0.00008545186,0.000018640168,0.00060379825,0.000036256664,0.000023314913,0.000007011342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845797,0.00009417152,0.0003549204,0.0003678597,0.00037303145,0.00035206095],"domain_scores_gemma":[0.9992721,0.00021567223,0.000081938335,0.00016706789,0.000071002454,0.00019221769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015548311,0.00019019489,0.0003110314,0.00027534657,0.00003640542,0.00001274871,0.00009498697,0.000082988525,0.000009864847],"category_scores_gemma":[0.0013719853,0.00015591815,0.000033162836,0.0005761336,0.000027538003,0.00005760808,0.00004376172,0.00030189124,0.000034691144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050192056,0.0013267283,0.10468801,0.00009750192,0.00008253176,0.00020144712,0.0008949863,0.000010847927,0.83541405,0.0000010001766,0.0000010468161,0.052262653],"study_design_scores_gemma":[0.005209659,0.0010460315,0.4488418,0.00026808292,0.000012484441,0.000004664829,0.000022666978,0.00035102855,0.54415196,0.0000027813649,0.000008587738,0.00008024272],"about_ca_topic_score_codex":0.00015023435,"about_ca_topic_score_gemma":0.0011615346,"teacher_disagreement_score":0.34415382,"about_ca_system_score_codex":0.0001598083,"about_ca_system_score_gemma":0.00023544305,"threshold_uncertainty_score":0.6358158},"labels":[],"label_agreement":null},{"id":"W3096690841","doi":"10.1182/blood-2020-139182","title":"Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interim analysis; Multiple myeloma; Lenalidomide; Pomalidomide; Oncology; Dosing; Pharmacology; Refractory (planetary science); Cmax; Internal medicine; Adverse effect; Pharmacokinetics; Clinical trial","score_opus":0.04663736924831915,"score_gpt":0.2639642465014611,"score_spread":0.21732687725314195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096690841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960071,0.000032388194,0.000039863728,0.00030139432,0.0000497584,0.003088461,0.00006529585,0.000072564166,0.00034318565],"genre_scores_gemma":[0.99829584,0.00001846366,0.000530287,0.00015845122,0.00005765821,0.0002039359,0.0005457124,0.00007295835,0.00011671183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972911,0.000065558466,0.00049254316,0.0005888129,0.0009459872,0.00061601034],"domain_scores_gemma":[0.99878436,0.00015920539,0.00018059935,0.00034715745,0.00011148985,0.00041718123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001256137,0.00038147974,0.0006192821,0.00029436313,0.00007040268,0.000034850014,0.0001684052,0.00015661103,0.00006369988],"category_scores_gemma":[0.0002417246,0.00026434578,0.0000720597,0.00046338598,0.00006099589,0.0002173817,0.00008579553,0.00051767676,0.000038683724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057772007,0.012614508,0.92505544,0.00011296794,0.00025864135,0.00040685877,0.00047364767,0.0000052162895,0.0002506948,0.000011344248,0.000037088852,0.0030015605],"study_design_scores_gemma":[0.33742857,0.0061369915,0.65468436,0.00022542953,0.0000861603,0.0000073871047,0.00006536421,0.00031816037,0.0007940977,0.0000040994796,0.000060897022,0.00018847233],"about_ca_topic_score_codex":0.00023538021,"about_ca_topic_score_gemma":0.0006960341,"teacher_disagreement_score":0.2796566,"about_ca_system_score_codex":0.00022071105,"about_ca_system_score_gemma":0.00014561508,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W3096699547","doi":"10.1182/blood-2020-139008","title":"Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University Health Network; University of Toronto; PROTO Manufacturing (Canada); Ottawa Hospital; Joseph Brant Hospital; University of Ottawa","funders":"","keywords":"Medicine; Thematic analysis; Multiple myeloma; Family medicine; Referral; Cohort; Internal medicine; Qualitative research; Gerontology; Oncology","score_opus":0.05360058509147542,"score_gpt":0.3566460779614236,"score_spread":0.3030454928699482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096699547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636804,0.0002669725,0.026246132,0.000056520308,0.000049521605,0.00905907,0.00044676434,0.00018417877,0.000010480504],"genre_scores_gemma":[0.8977347,0.00003135904,0.09946875,0.000045974288,0.000037043057,0.0023698881,0.00021144477,0.000073350086,0.000027465398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745893,0.00025330458,0.00039250313,0.0008521848,0.00040050322,0.0006425906],"domain_scores_gemma":[0.99662834,0.0020525414,0.000144012,0.00046963786,0.00015139904,0.000554037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021836492,0.00045391975,0.00071808754,0.00014331244,0.000340165,0.00006459212,0.00019226174,0.00012994166,0.000011091279],"category_scores_gemma":[0.00014076495,0.0002990308,0.00022305682,0.00022550416,0.000048512018,0.00017476399,0.00003009957,0.00014338832,0.0000040762266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018533953,0.01661995,0.76226205,0.00048192652,0.0015635798,0.0007256517,0.026367303,0.000192886,0.0041925316,0.0000039240285,0.00001953876,0.16903673],"study_design_scores_gemma":[0.09327202,0.019211795,0.83385104,0.0003210776,0.0015253907,0.000032316424,0.008167498,0.0036929948,0.039482586,0.000004505442,0.00006815116,0.00037064086],"about_ca_topic_score_codex":0.00020593728,"about_ca_topic_score_gemma":0.00069954264,"teacher_disagreement_score":0.1686661,"about_ca_system_score_codex":0.000099705925,"about_ca_system_score_gemma":0.00015043002,"threshold_uncertainty_score":0.9999462},"labels":[],"label_agreement":null},{"id":"W3096841065","doi":"10.1182/blood-2020-142800","title":"Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hamilton Health Sciences; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; University of Ottawa; McGill University Health Centre; London Health Sciences Centre; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; University of Toronto; Western University; University of New Brunswick; Université de Montréal; University of Alberta; Saint John Regional Hospital; BC Cancer Agency; University Health Network; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Pomalidomide; Daratumumab; Carfilzomib; Multiple myeloma; Medicine; Internal medicine; Database; Oncology; Lenalidomide; Family medicine","score_opus":0.15810868312927467,"score_gpt":0.3464041833252228,"score_spread":0.18829550019594815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096841065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415547,0.00057957554,0.000035013465,0.0026042627,0.00004878831,0.0013456845,0.0009781497,0.000028713168,0.00022434992],"genre_scores_gemma":[0.99270684,0.000048286453,0.0053466577,0.00023598105,0.0001986166,0.00010663255,0.0011977378,0.000030644125,0.00012860452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969047,0.0003530434,0.0005159446,0.0006390341,0.0008815687,0.0007057627],"domain_scores_gemma":[0.9975564,0.0005892913,0.00008972051,0.0006054282,0.00027575754,0.0008833935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007539019,0.00022897018,0.00042159684,0.00024079873,0.00036818284,0.00007776584,0.00020789183,0.00015221692,0.00008771617],"category_scores_gemma":[0.0049473043,0.00016341949,0.00009695269,0.0005669883,0.0005060292,0.00019487053,0.00025925378,0.0006610452,0.000027979795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013701576,0.00079567754,0.92716795,0.000095378986,0.00043433244,0.024923386,0.0009081239,0.0000070625374,0.04252945,0.00025649037,0.00083821063,0.0006737818],"study_design_scores_gemma":[0.02476375,0.00032563813,0.95905006,0.00019939728,0.00014846202,0.000442718,0.00034085914,0.0025832583,0.00786088,0.000020062835,0.0040647215,0.0002001818],"about_ca_topic_score_codex":0.5422581,"about_ca_topic_score_gemma":0.557048,"teacher_disagreement_score":0.03466857,"about_ca_system_score_codex":0.00019916406,"about_ca_system_score_gemma":0.001385058,"threshold_uncertainty_score":0.6664053},"labels":[],"label_agreement":null},{"id":"W3097041936","doi":"10.1182/blood-2020-133369","title":"Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Population; Nausea; Depression (economics); Multiple myeloma; Anxiety; Disease; Disease burden; Pediatrics; Intensive care medicine; Emergency medicine; Internal medicine; Psychiatry","score_opus":0.01746510945567214,"score_gpt":0.26505943704276086,"score_spread":0.24759432758708871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097041936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727815,0.000025566358,0.000008401644,0.00017065938,0.000017156504,0.002351635,0.000059249796,0.000057517816,0.000031630185],"genre_scores_gemma":[0.99893093,0.000001749787,0.00038550998,0.00008450475,0.000017017112,0.00015939874,0.0003824856,0.00003272809,0.0000056927506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979778,0.0000760743,0.00054351136,0.0003793079,0.00071263785,0.00031069526],"domain_scores_gemma":[0.9989241,0.00019799382,0.00016335535,0.00030305926,0.00013706669,0.00027447368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004769059,0.00022913842,0.00054513715,0.00019112452,0.000042389063,0.000011305113,0.00008932269,0.000059330916,0.00003207171],"category_scores_gemma":[0.000277336,0.00016206026,0.00007298375,0.00043819906,0.00001717443,0.000067828165,0.000021682277,0.00014312369,0.000006059504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018857081,0.008881943,0.98488694,0.00009698207,0.00045658488,0.00065785716,0.0019767876,0.00027724696,0.0000928629,4.680297e-7,0.000003766314,0.0007828675],"study_design_scores_gemma":[0.07945424,0.002922207,0.915695,0.000106017374,0.00026006036,0.0000012908649,0.00028732768,0.0004987944,0.000633964,8.7401025e-7,0.0000042314055,0.00013597932],"about_ca_topic_score_codex":0.0035859842,"about_ca_topic_score_gemma":0.00076795154,"teacher_disagreement_score":0.07756854,"about_ca_system_score_codex":0.000036890084,"about_ca_system_score_gemma":0.000107850115,"threshold_uncertainty_score":0.66086257},"labels":[],"label_agreement":null},{"id":"W3097320822","doi":"10.1177/1078155220967738","title":"A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting","year":2020,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Oncology","score_opus":0.12117873050926282,"score_gpt":0.5053502990464438,"score_spread":0.384171568537181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097320822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045822704,0.96814173,0.000017362436,0.021643365,0.0005371457,0.005691226,0.00008467496,0.000013539295,0.0038251395],"genre_scores_gemma":[0.00021729675,0.9874665,0.008665419,0.002523039,0.00040020453,0.00031898494,0.000097740005,0.00006436755,0.00024642673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927708,0.002540934,0.0030664585,0.00037253814,0.00077640207,0.0004728956],"domain_scores_gemma":[0.9801883,0.0137889,0.0041300245,0.00041043333,0.0010501671,0.00043219156],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0049248454,0.00043582593,0.0029059926,0.00075579423,0.00013941756,0.000023461027,0.0005271897,0.00018388098,0.00013760611],"category_scores_gemma":[0.023922475,0.0002700464,0.0009971581,0.0014338089,0.000077604345,0.00040308823,0.00013868547,0.0027272047,0.00005541583],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004233257,0.0018793108,0.000112272726,0.040376794,0.0020036788,0.0031353117,0.00056255114,0.0000010084652,0.000047995247,0.00001000574,0.018465815,0.929172],"study_design_scores_gemma":[0.010325019,0.0014545699,0.000072526054,0.06202361,0.0060564056,0.002774776,0.00015793486,0.00005984271,0.000009640596,0.0000019762356,0.9169022,0.00016151629],"about_ca_topic_score_codex":0.000090124995,"about_ca_topic_score_gemma":0.00003435918,"teacher_disagreement_score":0.9290105,"about_ca_system_score_codex":0.0010004162,"about_ca_system_score_gemma":0.0027425217,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W3097439692","doi":"10.1182/blood-2020-133372","title":"Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Saint John Regional Hospital; Université de Montréal; University of New Brunswick; Nova Scotia Health Authority; Hôpital Maisonneuve-Rosemont; University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital; McGill University Health Centre; University of Alberta; McMaster University","funders":"","keywords":"Lenalidomide; Daratumumab; Multiple myeloma; Medicine; Tolerability; Bortezomib; Pomalidomide; Internal medicine; Oncology; Maintenance therapy; Autologous stem-cell transplantation; Database; Adverse effect; Chemotherapy","score_opus":0.06544335901939595,"score_gpt":0.3406583747330585,"score_spread":0.2752150157136625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097439692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917297,0.0002575822,0.0000038002142,0.003029005,0.000029999303,0.0010922131,0.0006927527,0.000020839738,0.0031441483],"genre_scores_gemma":[0.998001,0.00015810606,0.00032651497,0.0004481387,0.00008735735,0.000095509036,0.00079945184,0.000028008973,0.000055904544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972151,0.0002786426,0.00041583672,0.0005050332,0.00079224864,0.0007931612],"domain_scores_gemma":[0.99786377,0.00056668377,0.0000718174,0.0005847397,0.00025588175,0.0006570812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043269305,0.00018748362,0.00037721824,0.00020887279,0.00024612766,0.00003918644,0.00037205243,0.00006184129,0.000098471835],"category_scores_gemma":[0.000912014,0.00013077972,0.00007464165,0.00075652514,0.00026051176,0.00012534045,0.00008210517,0.0005480937,0.00003553362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064332457,0.0012013775,0.9623055,0.00008336644,0.000251624,0.0023732553,0.0129938135,0.0000019134518,0.011311009,0.00078851497,0.00084948185,0.0014068902],"study_design_scores_gemma":[0.026326755,0.0011065346,0.9554859,0.00086530944,0.00007090713,0.00000915427,0.0017317892,0.00013008986,0.012460549,0.000018108502,0.0016108874,0.00018406013],"about_ca_topic_score_codex":0.5082864,"about_ca_topic_score_gemma":0.62004006,"teacher_disagreement_score":0.11175362,"about_ca_system_score_codex":0.00020597823,"about_ca_system_score_gemma":0.0005887124,"threshold_uncertainty_score":0.5333042},"labels":[],"label_agreement":null},{"id":"W3097496716","doi":"10.1182/blood-2020-137303","title":"Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Biology","score_opus":0.15432705662022184,"score_gpt":0.3934805609807746,"score_spread":0.23915350436055277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097496716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887594,0.0072036763,0.000048620102,0.0014766508,0.00006658804,0.0019768523,0.00026169178,0.000106746986,0.00009976655],"genre_scores_gemma":[0.99433756,0.0010848575,0.003453092,0.00038258475,0.00025365013,0.00012044971,0.00017175908,0.000075359356,0.00012070305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616355,0.0005793576,0.00068165665,0.0011880747,0.00071146723,0.00067587855],"domain_scores_gemma":[0.99495965,0.003223041,0.00022387669,0.00067818735,0.00011478108,0.00080046395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006188807,0.0005565203,0.0010556665,0.00017045064,0.00027140518,0.00013504767,0.00022995753,0.00022048257,0.00007439702],"category_scores_gemma":[0.0035227519,0.0003802253,0.00009391615,0.0006767432,0.0003396771,0.00023919345,0.0003058935,0.0008459781,0.000011181914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044109438,0.01084174,0.7483249,0.00019912944,0.0033280817,0.010169836,0.009013978,0.000002364589,0.12266771,0.0000039455244,0.0006104557,0.050728448],"study_design_scores_gemma":[0.16367792,0.011059969,0.807162,0.00017445203,0.001887508,0.000056858076,0.007450085,0.001987674,0.0046924725,0.000011145148,0.0013030757,0.00053682696],"about_ca_topic_score_codex":0.0059163175,"about_ca_topic_score_gemma":0.0051691895,"teacher_disagreement_score":0.11956848,"about_ca_system_score_codex":0.000074597134,"about_ca_system_score_gemma":0.0001960457,"threshold_uncertainty_score":0.999865},"labels":[],"label_agreement":null},{"id":"W3097539251","doi":"10.1182/blood-2020-137161","title":"Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Refractory (planetary science); Multiple myeloma; Pomalidomide; Lenalidomide; Medicine; Carfilzomib; Oncology; Internal medicine; Thalidomide; Biology","score_opus":0.011925850762924567,"score_gpt":0.22431197460194663,"score_spread":0.21238612383902206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097539251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976825,0.00057974714,0.000012693217,0.00013468432,0.00005571987,0.0013686902,0.000025854117,0.000026247517,0.00011383525],"genre_scores_gemma":[0.9991908,0.00002301261,0.00047667607,0.00012884247,0.000033514476,0.000054074444,0.000019051584,0.000036703732,0.000037297606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984085,0.000073051786,0.0002613228,0.00035998598,0.00057529233,0.00032183234],"domain_scores_gemma":[0.9990212,0.00013031563,0.00011494364,0.00040218746,0.00008336752,0.00024799106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008212713,0.00021538386,0.0003484827,0.00007521195,0.0000650185,0.000012303006,0.00014213908,0.000090744965,0.00000846998],"category_scores_gemma":[0.00029551343,0.00013418782,0.00007337712,0.00019816148,0.00010989461,0.000083157385,0.00015753502,0.00031414963,0.000011443947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014167903,0.00981425,0.9646928,0.0003965062,0.00037584547,0.00008164586,0.00046717795,0.0000027699002,0.019997979,0.000010179719,0.000008528508,0.0027355743],"study_design_scores_gemma":[0.08161479,0.0015684131,0.89117926,0.0002312417,0.00012989908,0.0000047615044,0.00003680743,0.00012375764,0.024944166,0.0000017121997,0.00005095425,0.0001142164],"about_ca_topic_score_codex":0.00008148036,"about_ca_topic_score_gemma":0.000024238328,"teacher_disagreement_score":0.080198005,"about_ca_system_score_codex":0.000057611494,"about_ca_system_score_gemma":0.00011850686,"threshold_uncertainty_score":0.5472021},"labels":[],"label_agreement":null},{"id":"W3097644161","doi":"10.1182/blood-2020-137183","title":"Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Dalhousie University; University of Alberta; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Internal medicine; Multiple myeloma; Adverse effect; Refractory (planetary science); Neutropenia; Oncology; Lenalidomide; Proteasome inhibitor; Pharmacology; Cancer research; Gastroenterology; Toxicity; Materials science","score_opus":0.022807597408235573,"score_gpt":0.2645409406002516,"score_spread":0.241733343192016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097644161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966731,0.00019402559,0.0002502807,0.0009030792,0.000013812576,0.001737986,0.000065592,0.000049932296,0.000112196656],"genre_scores_gemma":[0.98846847,0.00003418646,0.010599463,0.00027963053,0.000041849722,0.00017848187,0.0002710876,0.000041821346,0.0000850125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986737,0.0000487267,0.00019944874,0.00040124942,0.00034610069,0.00033082525],"domain_scores_gemma":[0.9989879,0.00025112016,0.000082151935,0.00017873893,0.00018911634,0.00031096887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088828994,0.00019461234,0.00031184845,0.00008824723,0.000055527704,0.000021839855,0.00006599585,0.00007681083,0.000009390557],"category_scores_gemma":[0.00037110693,0.00013732366,0.0000300842,0.00019631271,0.000062177,0.00014020168,0.000031529067,0.00018706548,0.000006645211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004577539,0.0025463488,0.98388445,0.00019318286,0.00025124106,0.000093245275,0.00057538063,0.000003157277,0.00075799087,0.000016137068,0.00010923394,0.0069920756],"study_design_scores_gemma":[0.09388413,0.00861072,0.8918624,0.00017289435,0.0002086029,0.00001128622,0.00015292667,0.0014041378,0.0021846239,0.000012927655,0.0012813773,0.00021396262],"about_ca_topic_score_codex":0.00010700431,"about_ca_topic_score_gemma":0.00017934472,"teacher_disagreement_score":0.09202206,"about_ca_system_score_codex":0.00004767514,"about_ca_system_score_gemma":0.00010697593,"threshold_uncertainty_score":0.5599896},"labels":[],"label_agreement":null},{"id":"W3097738629","doi":"10.1182/blood-2020-137754","title":"Targeted Deep Sequencing As a Clinically Effective Approach to Profile the Mutational Landscape in Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"KRAS; Multiple myeloma; Cancer research; Malignancy; Somatic evolution in cancer; Neuroblastoma RAS viral oncogene homolog; Exome sequencing; Deep sequencing; Mutation; Medicine; Exome; Indel; Biology; Oncology; Gene; Internal medicine; Genetics; Cancer; Single-nucleotide polymorphism; Genotype; Genome","score_opus":0.03417814561777288,"score_gpt":0.3039738596276435,"score_spread":0.2697957140098706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097738629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98947334,0.00012526564,0.00034638285,0.0012054172,0.000018423943,0.0023752798,0.000024983616,0.000060833027,0.006370065],"genre_scores_gemma":[0.9896888,0.000003175625,0.008185802,0.0010790706,0.00016183125,0.0006466731,0.00015302672,0.000022331371,0.000059303813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847966,0.00015580765,0.00026934576,0.00037203246,0.00039399145,0.0003291533],"domain_scores_gemma":[0.99886674,0.00047374243,0.000046487537,0.00018384437,0.00009515117,0.00033405836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025900928,0.00014566552,0.0002588195,0.00006886298,0.00008360703,0.000023578514,0.00012701678,0.0000715633,0.000092653],"category_scores_gemma":[0.0023313381,0.00009448001,0.00008650471,0.00042068964,0.00004055374,0.00004655079,0.000075501994,0.00029147507,0.00031922228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037174702,0.0026189222,0.94252455,0.00024570758,0.0007925815,0.0011407277,0.00875075,0.00033716648,0.01747119,0.00012825991,0.00036098014,0.021911705],"study_design_scores_gemma":[0.02082416,0.002136802,0.9182895,0.00007346018,0.00013468061,0.00014253672,0.0014629827,0.04313691,0.013314929,0.00006582865,0.0001898339,0.00022842361],"about_ca_topic_score_codex":0.00007211742,"about_ca_topic_score_gemma":0.000022834147,"teacher_disagreement_score":0.04279974,"about_ca_system_score_codex":0.000048476937,"about_ca_system_score_gemma":0.0002094276,"threshold_uncertainty_score":0.41030627},"labels":[],"label_agreement":null},{"id":"W3097818908","doi":"10.1182/blood-2020-137154","title":"Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine; Refractory (planetary science); Biology","score_opus":0.08415400050837109,"score_gpt":0.356338819197198,"score_spread":0.27218481868882693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097818908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873526,0.007624484,0.00010177932,0.0008378611,0.0001212056,0.0026928633,0.0010660605,0.00015635336,0.000046802033],"genre_scores_gemma":[0.9909604,0.0028337191,0.0048831776,0.00021086221,0.0003947514,0.00019815602,0.00033146268,0.000117654854,0.000069778216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942542,0.0013196914,0.00097406184,0.0015296843,0.0009887023,0.00093367544],"domain_scores_gemma":[0.992336,0.005017236,0.0004980582,0.0010254694,0.00017220613,0.00095105503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009232667,0.00075256196,0.001341209,0.00024818952,0.00042472256,0.00013554654,0.00038072493,0.00029328399,0.00010597895],"category_scores_gemma":[0.005515448,0.0005213767,0.00015926486,0.00096836616,0.00031569842,0.00020579319,0.00032353625,0.0012455367,0.000035880486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052639358,0.0077853734,0.8782706,0.00007900692,0.0033943355,0.002614034,0.0036313005,0.000019496807,0.02521379,0.0000011214291,0.00032749114,0.026024044],"study_design_scores_gemma":[0.18114296,0.019875597,0.7751572,0.00014862689,0.00408832,0.000039287614,0.0066022114,0.003550847,0.008336186,0.0000145897775,0.0004227355,0.0006214076],"about_ca_topic_score_codex":0.017506098,"about_ca_topic_score_gemma":0.009831154,"teacher_disagreement_score":0.1285036,"about_ca_system_score_codex":0.000119746546,"about_ca_system_score_gemma":0.0003005292,"threshold_uncertainty_score":0.9997238},"labels":[],"label_agreement":null},{"id":"W3097858251","doi":"10.1182/blood-2020-136991","title":"Clonally Expanded Bone Marrow T Cells Show Effector Differentiation and Rarely Recognize Disease-Associated Antigens in Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; Bone marrow; Cytotoxic T cell; Antigen; Multiple myeloma; Immunology; CD8; T cell; Immune system; Cancer research; In vitro","score_opus":0.027021206205120756,"score_gpt":0.25292436395849077,"score_spread":0.22590315775337003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097858251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704546,0.0006439875,0.000015411919,0.00082872226,0.000045989582,0.0010599521,0.00019148529,0.00009470121,0.00007431985],"genre_scores_gemma":[0.9984444,0.00020572031,0.0002847265,0.00020404824,0.00008488762,0.000075366734,0.00050587335,0.000037179034,0.000157793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832946,0.00015182976,0.00027159834,0.0004409582,0.00039066593,0.0004154606],"domain_scores_gemma":[0.9988153,0.00022161425,0.000080327314,0.00017037946,0.00007268614,0.0006397191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001131605,0.0002224231,0.0004105745,0.00010825002,0.00007825593,0.000040965617,0.000062406856,0.00010026735,0.00011345499],"category_scores_gemma":[0.0007704273,0.00019346717,0.00010145456,0.00024301313,0.00004326522,0.00008360857,0.00006677796,0.00020207764,0.000062855885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001156427,0.0012349687,0.84902453,0.00017553034,0.00023221645,0.00070253573,0.00019903702,4.970878e-7,0.14449807,0.000001082446,0.00019043127,0.002584673],"study_design_scores_gemma":[0.021342417,0.00042411804,0.94250625,0.00014361666,0.00019536588,0.000006813643,0.000022246388,0.0018196427,0.03331228,0.000012594934,0.00004480583,0.00016987199],"about_ca_topic_score_codex":0.000051777723,"about_ca_topic_score_gemma":0.00012538605,"teacher_disagreement_score":0.11118578,"about_ca_system_score_codex":0.00004638176,"about_ca_system_score_gemma":0.00008711536,"threshold_uncertainty_score":0.78893626},"labels":[],"label_agreement":null},{"id":"W3097964787","doi":"10.1182/blood-2020-137681","title":"Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Carfilzomib; Oncology; Hazard ratio; Progression-free survival; Clinical endpoint; Minimal residual disease; Interim analysis; Dexamethasone; Bone marrow; Bortezomib; Gastroenterology; Randomized controlled trial; Confidence interval; Chemotherapy","score_opus":0.03920528921607046,"score_gpt":0.3076559750043929,"score_spread":0.26845068578832243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097964787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725324,0.0012946134,0.000069744725,0.00076985394,0.000008081713,0.00045022875,0.000082224135,0.000017972206,0.00005405313],"genre_scores_gemma":[0.9946387,0.00010021918,0.005078818,0.00005443331,0.000012751914,0.000018024055,0.000018956516,0.000021971511,0.00005616402],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980753,0.0004922727,0.00047106316,0.0003729593,0.0003232586,0.0002651379],"domain_scores_gemma":[0.9979671,0.0011421109,0.00013938904,0.000327468,0.00011446872,0.0003094265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005126103,0.00018593167,0.00078399596,0.00046183408,0.00001922242,0.00000909275,0.00008566298,0.000113532624,0.000023202329],"category_scores_gemma":[0.003865474,0.00016113014,0.00010997591,0.0008842009,0.0002140111,0.00003564874,0.00014351493,0.00018219335,0.0000016910963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07806461,0.0009985409,0.4434802,0.00022669914,0.0011779116,0.000478964,0.0029629052,0.000010274871,0.4706061,0.000002971385,0.000011877037,0.0019789464],"study_design_scores_gemma":[0.028812137,0.0026895308,0.8013816,0.000086002205,0.0008525316,0.000030664494,0.000554031,0.0021701525,0.16327167,0.0000035803794,0.00003875564,0.000109382585],"about_ca_topic_score_codex":0.00032023754,"about_ca_topic_score_gemma":0.00029307834,"teacher_disagreement_score":0.35790136,"about_ca_system_score_codex":0.00004475063,"about_ca_system_score_gemma":0.00011812277,"threshold_uncertainty_score":0.6570697},"labels":[],"label_agreement":null},{"id":"W3104212033","doi":"10.1002/jha2.122","title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SAIT Polytechnic; Alberta Cancer Foundation; Vancouver General Hospital; CancerCare Manitoba; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Neutropenia; Tolerability; Refractory (planetary science); Regimen; Gastroenterology; Adverse effect; Cohort; Oncology; Multiple myeloma; Surgery; Bortezomib; Toxicity","score_opus":0.03176295292882655,"score_gpt":0.27793286999841593,"score_spread":0.24616991706958938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104212033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974278,0.00020659689,0.00004063042,0.0007837382,0.000027783586,0.00076451903,0.000026106023,0.00006481279,0.0006580172],"genre_scores_gemma":[0.9948357,0.000032301592,0.0041321404,0.00042695712,0.00006718282,0.000034211083,0.00010706311,0.000036347003,0.00032810454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985608,0.00007026875,0.00022250589,0.00039950496,0.00039924847,0.0003477153],"domain_scores_gemma":[0.999003,0.0001749803,0.000056529014,0.0002345214,0.000089929614,0.00044105193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089694346,0.00019397725,0.0003514251,0.000093760835,0.0000637362,0.000019065015,0.00006897475,0.00008440672,0.00014322164],"category_scores_gemma":[0.0006826576,0.00012464754,0.00003000164,0.0003253036,0.00008217935,0.00012428909,0.00006396156,0.00031336874,0.0000649078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010078714,0.00047910196,0.9552587,0.00008864624,0.00009735021,0.0005501188,0.0006854854,0.0000012092169,0.00026275023,0.000004114684,0.00059258274,0.031901196],"study_design_scores_gemma":[0.024643658,0.0029089195,0.966438,0.00011274326,0.000033590433,0.00000865757,0.00013090647,0.0009950679,0.0005438475,0.0000033225122,0.0040234313,0.00015785373],"about_ca_topic_score_codex":0.00007123077,"about_ca_topic_score_gemma":0.00013236071,"teacher_disagreement_score":0.03174334,"about_ca_system_score_codex":0.00007628464,"about_ca_system_score_gemma":0.00010286626,"threshold_uncertainty_score":0.508298},"labels":[],"label_agreement":null},{"id":"W3105812043","doi":"10.1016/s0140-6736(20)32292-3","title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Cancer Research UK","keywords":"Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Proteasome inhibitor; Clinical endpoint; Internal medicine; Population; Clinical trial; Oncology","score_opus":0.10846902631598958,"score_gpt":0.353852140548447,"score_spread":0.2453831142324574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105812043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667514,0.0012087527,0.000088519475,0.004443195,0.00014427968,0.0063596154,0.000302718,0.000097363525,0.00068040896],"genre_scores_gemma":[0.9899471,0.0005533457,0.006657115,0.0012360443,0.0006296766,0.00047322415,0.00029966724,0.000094237286,0.00010963479],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959959,0.0005423031,0.00068003737,0.0009739275,0.0008000786,0.0010077541],"domain_scores_gemma":[0.9963743,0.001536528,0.00026383865,0.00082491786,0.00019213301,0.00080826547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096873584,0.00058141287,0.0017604117,0.00014255627,0.00026353172,0.0002176424,0.0005331523,0.00018117686,0.00015877072],"category_scores_gemma":[0.0019080142,0.00037429953,0.00007289052,0.0005000588,0.00042145385,0.00036344558,0.00037080716,0.0007768993,0.000048380145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89379793,0.0038519446,0.051902357,0.00013548415,0.0007155323,0.00021796935,0.0013565547,0.0000027670183,0.0010241097,0.000015768574,0.0016065729,0.045372996],"study_design_scores_gemma":[0.92393124,0.018263273,0.04926987,0.00016106518,0.000398572,0.000017991144,0.00033170552,0.0023427808,0.0004937472,0.00001537849,0.004333532,0.0004408313],"about_ca_topic_score_codex":0.000695655,"about_ca_topic_score_gemma":0.00035107203,"teacher_disagreement_score":0.044932168,"about_ca_system_score_codex":0.00013733564,"about_ca_system_score_gemma":0.00028289694,"threshold_uncertainty_score":0.9998709},"labels":[],"label_agreement":null},{"id":"W3106398547","doi":"10.2196/18982","title":"Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study","year":2020,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Multiple myeloma; Physical therapy; Intervention (counseling); Family medicine; Internal medicine; Nursing","score_opus":0.15539753585349717,"score_gpt":0.514011368855484,"score_spread":0.3586138330019869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106398547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917201,0.000163264,0.0017732539,0.00017232393,0.000025923868,0.0060149534,0.00008706458,0.000018599143,0.000024540595],"genre_scores_gemma":[0.99667054,0.000025301382,0.002021057,0.000004211241,0.000031682972,0.0008910113,0.00033109458,0.000020233007,0.0000048498246],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970426,0.00075382245,0.00041456101,0.00028822248,0.0011870213,0.0003137805],"domain_scores_gemma":[0.99759775,0.0005534341,0.0001981627,0.00012425493,0.0012741417,0.00025225742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002272709,0.00013253522,0.0002704065,0.00025684616,0.00021407667,0.000063597065,0.000048538757,0.000030064652,0.000007800271],"category_scores_gemma":[0.0006368031,0.00010299121,0.000032706663,0.00031172976,0.00008948108,0.00066049607,0.00008757005,0.00019974804,0.0000016033321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003663021,0.0014499685,0.3297741,0.00052069494,0.00018906339,5.8982585e-7,0.014745157,0.0000019363968,0.00018324741,0.000007767412,0.00004128389,0.6494232],"study_design_scores_gemma":[0.026700871,0.033732574,0.90461844,0.00018322276,0.000035967783,9.282623e-7,0.02537909,0.00861331,0.0005922154,0.000041070783,0.000027058482,0.00007522455],"about_ca_topic_score_codex":0.000093037444,"about_ca_topic_score_gemma":0.00002838059,"teacher_disagreement_score":0.64934796,"about_ca_system_score_codex":0.00028196766,"about_ca_system_score_gemma":0.0001786903,"threshold_uncertainty_score":0.41998595},"labels":[],"label_agreement":null},{"id":"W3107980856","doi":"10.22239/2317-269x.01557","title":"Thalidomide surveillance and pharmacovigilance in Brazil – an overview","year":2021,"lang":"en","type":"article","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Thalidomide; Pharmacovigilance; Medicine; Context (archaeology); Medical prescription; Intensive care medicine; Pediatrics; Drug; Pharmacology; Immunology","score_opus":0.07794836048380609,"score_gpt":0.42275385416755257,"score_spread":0.34480549368374647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107980856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816371,0.007662866,0.000009861703,0.0013753783,0.000028235156,0.00016926133,0.000010679438,0.00002966365,0.009076934],"genre_scores_gemma":[0.991194,0.0048949057,0.0007582835,0.0009643429,0.000036546804,0.000013775641,0.000046596906,0.000009181829,0.0020823702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992047,0.000079206715,0.00011245465,0.00023414197,0.00015814095,0.00021138009],"domain_scores_gemma":[0.99949914,0.00006541423,0.000012768363,0.00018478063,0.000047952,0.00018995831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013952315,0.00008100635,0.00019852468,0.000037243433,0.000022759572,0.000019046982,0.000029689005,0.000026495101,0.000597951],"category_scores_gemma":[0.00008185326,0.00006357867,0.000023163662,0.00015760184,0.000026407008,0.000084852756,0.00003667395,0.00008727281,0.000030222933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017768716,0.00022086668,0.96595544,0.00010385576,0.000033560304,0.0013242086,0.000035595618,6.560602e-7,0.0067690257,0.00028544696,0.00034154268,0.024752125],"study_design_scores_gemma":[0.0052813482,0.00007498829,0.9767469,0.00005088655,0.000005645523,0.00016766062,0.000035913446,0.00070925866,0.010463298,0.00009772407,0.006284298,0.00008206464],"about_ca_topic_score_codex":0.0001916992,"about_ca_topic_score_gemma":0.00073818036,"teacher_disagreement_score":0.02467006,"about_ca_system_score_codex":0.000030881183,"about_ca_system_score_gemma":0.00008763659,"threshold_uncertainty_score":0.6547144},"labels":[],"label_agreement":null},{"id":"W3110265345","doi":"10.1038/d41586-020-03223-2","title":"Outlook: Multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Nature","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Stephen's University","funders":"","keywords":"Multiple myeloma; Computational biology; Medicine; Biology; Internal medicine","score_opus":0.026234478888293788,"score_gpt":0.31586377797635556,"score_spread":0.2896292990880618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110265345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92682743,0.0028898725,0.00010192631,0.043528114,0.00018980834,0.00086963916,0.000069773334,0.00032285755,0.025200572],"genre_scores_gemma":[0.9900615,0.000025800098,0.0019076109,0.0064257467,0.00033509883,0.000012652984,0.00007877364,0.000019217336,0.0011335916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990684,0.000017885835,0.00009296344,0.00023339911,0.00034126575,0.00024611846],"domain_scores_gemma":[0.99927515,0.000048169415,0.000019441371,0.00017736455,0.00007573922,0.00040411344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003369442,0.00011057014,0.00017478911,0.000035501198,0.000049174338,0.000013813788,0.00008266652,0.00051412993,0.0003830582],"category_scores_gemma":[0.000590381,0.00008123691,0.00008876559,0.00017520963,0.000026656853,0.000044572607,0.000045197372,0.0014661602,0.00043575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027222747,0.00046846757,0.7165648,0.00031464474,0.00053786696,0.0028054502,0.0008121147,0.000004344137,0.034209374,0.00047635305,0.13134304,0.109741285],"study_design_scores_gemma":[0.011583549,0.0008807487,0.6373523,0.000072007206,0.00009247476,0.00009126088,0.00015163395,0.005409984,0.036753364,0.000050380637,0.30728048,0.0002818303],"about_ca_topic_score_codex":0.000008222033,"about_ca_topic_score_gemma":0.000005329071,"teacher_disagreement_score":0.17593746,"about_ca_system_score_codex":0.000032439955,"about_ca_system_score_gemma":0.000061428145,"threshold_uncertainty_score":0.63698184},"labels":[],"label_agreement":null},{"id":"W3111063908","doi":"10.1016/s2152-2650(20)30952-6","title":"MM-296: A Real-World Study of Panobinostat, Weekly Bortezomib, and Dexamethasone in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Panobinostat; Bortezomib; Dexamethasone; Context (archaeology); Internal medicine; Multiple myeloma; Population; Retrospective cohort study; Toxicity; Surgery","score_opus":0.04744791081935797,"score_gpt":0.3499770439149999,"score_spread":0.30252913309564194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111063908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962573,0.00013266392,0.000004953332,0.00015556242,0.00009197504,0.0028480785,0.00012290156,0.00009418157,0.0002923588],"genre_scores_gemma":[0.99835193,0.00015791623,0.0005825663,0.00014169673,0.000110116904,0.0001094753,0.00035185897,0.000081147504,0.00011326749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941433,0.0006951278,0.0024466312,0.0010802269,0.00095778797,0.0006769327],"domain_scores_gemma":[0.9957246,0.0015957085,0.0007123086,0.00075546035,0.00037783646,0.0008340817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062006037,0.0005092712,0.0018745591,0.00042432017,0.00008540254,0.00002507417,0.00026630875,0.00031526134,0.000039621347],"category_scores_gemma":[0.0027802994,0.00044773833,0.0002924854,0.0012360706,0.0002990912,0.00023703687,0.0003035279,0.0003656135,0.00001722045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010325013,0.0035387047,0.8204697,0.000245524,0.00039135065,0.00025233155,0.0008148097,0.0000086994005,0.00056651747,0.000007953648,0.0001182867,0.16326115],"study_design_scores_gemma":[0.03768548,0.007246821,0.950153,0.00032774702,0.0002546171,0.000006534741,0.00032607594,0.0027619414,0.0008559973,0.000022903305,0.000057191657,0.000301702],"about_ca_topic_score_codex":0.011356962,"about_ca_topic_score_gemma":0.0023885083,"teacher_disagreement_score":0.16295944,"about_ca_system_score_codex":0.000622122,"about_ca_system_score_gemma":0.0005216243,"threshold_uncertainty_score":0.99979746},"labels":[],"label_agreement":null},{"id":"W3111394247","doi":"10.1182/bloodadvances.2020002827","title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","year":2020,"lang":"en","type":"review","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cilag; National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"Multiple myeloma; Term (time); Negativity effect; Meta-analysis; Oncology; Internal medicine; Survival analysis; Medicine; Psychology; Developmental psychology","score_opus":0.04332111366551855,"score_gpt":0.34186931996023096,"score_spread":0.2985482062947124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111394247","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019626502,0.9770841,0.0000066099683,0.000043909968,0.0000225401,0.002373925,0.00068482757,0.000020857087,0.00013674085],"genre_scores_gemma":[0.18259609,0.8155765,0.0003386547,0.000016056147,0.00002799223,0.0006100949,0.00067594514,0.00006046132,0.00009821387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635726,0.0005841624,0.0008715783,0.00068896456,0.00095167157,0.0005463684],"domain_scores_gemma":[0.99727726,0.0011590053,0.0005451494,0.0007140194,0.00012330404,0.00018129084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036723915,0.00059081713,0.005840371,0.00052362215,0.000054235334,0.000034946002,0.00038492144,0.00013281257,0.00009627027],"category_scores_gemma":[0.0006266502,0.00028100508,0.0014588928,0.001898579,0.00011931533,0.00024780125,0.00017520486,0.0005067838,0.00000857539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001345859,0.0016689237,0.8151978,0.0020902655,0.05345762,0.0001237919,0.00007954464,0.0000018484861,5.3578493e-8,0.000005526409,2.6953123e-7,0.12723972],"study_design_scores_gemma":[0.00521406,0.00043675647,0.8160087,0.000681098,0.15462582,0.000002206287,0.00007253313,0.000009396179,0.000009869166,0.0000106409125,0.022593472,0.0003354893],"about_ca_topic_score_codex":0.00026027055,"about_ca_topic_score_gemma":0.008955328,"teacher_disagreement_score":0.16296959,"about_ca_system_score_codex":0.00006723835,"about_ca_system_score_gemma":0.00021887277,"threshold_uncertainty_score":0.99996424},"labels":[],"label_agreement":null},{"id":"W3111817003","doi":"10.1016/s2152-2650(20)30955-1","title":"MM-347: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary; University of Alberta","funders":"","keywords":"Lenalidomide; Ixazomib; Placebo; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Double blind; Oncology; Pathology","score_opus":0.09393117564019866,"score_gpt":0.36876817165603426,"score_spread":0.2748369960158356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111817003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531873,0.00062049786,0.0033534835,0.0049651517,0.0018588165,0.03313319,0.0018669137,0.0005575851,0.00045705916],"genre_scores_gemma":[0.9765123,0.00034959344,0.0025234872,0.0034544163,0.0033518625,0.009879622,0.002036805,0.00037580085,0.001516116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98765105,0.00107512,0.004389993,0.0026176572,0.0016106064,0.0026555536],"domain_scores_gemma":[0.97368574,0.020288724,0.0014463225,0.0016739042,0.0009353401,0.001969958],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0030816558,0.0016171968,0.0043701474,0.00033943003,0.0010398879,0.00034074386,0.0014914182,0.0013529841,0.00015066654],"category_scores_gemma":[0.0041129473,0.0011588467,0.0031441688,0.0006802246,0.0007125143,0.00041528762,0.00030336017,0.0010389435,0.0004184794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82236993,0.0028258518,0.0017235896,0.00052493275,0.0017955144,0.00041949566,0.00081688137,0.00015599246,0.0005776597,0.00005050803,0.009596532,0.15914309],"study_design_scores_gemma":[0.90772957,0.016002951,0.0059801834,0.00023747858,0.0022094857,0.000046263518,0.00029694175,0.03554045,0.011392415,0.00003274189,0.019404134,0.0011274018],"about_ca_topic_score_codex":0.00031782678,"about_ca_topic_score_gemma":0.00012951059,"teacher_disagreement_score":0.15801568,"about_ca_system_score_codex":0.0014833511,"about_ca_system_score_gemma":0.0038096213,"threshold_uncertainty_score":0.9999435},"labels":[],"label_agreement":null},{"id":"W3112002107","doi":"10.1200/jco.20.01370","title":"Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Biotech; Juno Therapeutics; Pharmacyclics; Kite Pharma; Servier; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Array BioPharma; Legend Biotech; Celgene; Takeda Pharmaceuticals North America; Exelixis; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Medicine; Multiple myeloma; Quality of life (healthcare); Internal medicine; Oncology; Nursing","score_opus":0.1781192389579719,"score_gpt":0.46776651708590544,"score_spread":0.28964727812793356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112002107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97769225,0.00029988334,0.000078194,0.020411734,0.00030136324,0.0010382725,0.00010752688,0.000008219702,0.00006257465],"genre_scores_gemma":[0.9958708,0.00033229977,0.00088947854,0.0024301475,0.00036948992,0.000009892024,0.00007102715,0.000017036296,0.000009815785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930809,0.0013518,0.004231865,0.00025431227,0.00072926795,0.00035185507],"domain_scores_gemma":[0.9874537,0.009049529,0.0020513635,0.00019976884,0.00029260223,0.00095305406],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027686427,0.00017751606,0.0024993464,0.00008254095,0.000051392068,0.000007579994,0.00024958942,0.00028256146,0.00015508296],"category_scores_gemma":[0.010781993,0.00009604891,0.00040434158,0.00029147835,0.00021508375,0.000100701174,0.000034965506,0.0012226257,0.000011212714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39504772,0.0052822703,0.58122766,0.000025225325,0.00048813078,0.00028087033,0.0005630466,0.000008931457,0.000019866111,0.0000044237017,0.0010406091,0.016011247],"study_design_scores_gemma":[0.41825312,0.020502998,0.5602042,0.000101899546,0.00008857637,0.0000029981754,0.00008736006,0.00013760704,0.000015498877,0.000017915974,0.0005348409,0.000052970812],"about_ca_topic_score_codex":0.001872112,"about_ca_topic_score_gemma":0.00095103844,"teacher_disagreement_score":0.023205373,"about_ca_system_score_codex":0.00011677904,"about_ca_system_score_gemma":0.0023565853,"threshold_uncertainty_score":0.9975506},"labels":[],"label_agreement":null},{"id":"W3112014241","doi":"10.1182/blood.v130.suppl_1.5530.5530","title":"Chemosensitive Disease Better Predicts Outcome Than Age Following Autologous Heamatopoietic Stem Cell Transplantation in Elderly Patients with Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Internal medicine; Surgery; Pediatrics","score_opus":0.01620754916367078,"score_gpt":0.26184550030829207,"score_spread":0.24563795114462128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112014241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978238,0.00004185378,0.000026654849,0.00021910373,0.000065499684,0.0011938807,0.00010158976,0.00006153381,0.0004661069],"genre_scores_gemma":[0.99884206,0.000006810092,0.00045417738,0.0000724251,0.000035286877,0.00008247968,0.0002679059,0.00003871838,0.00020016215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982899,0.00006262496,0.00026589687,0.00040801344,0.0004983744,0.00047520403],"domain_scores_gemma":[0.9988503,0.00008294606,0.00011292313,0.0005319858,0.000054807657,0.00036704697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008929562,0.00024232481,0.00037470742,0.00011304838,0.0002201183,0.00006844115,0.00013373715,0.000083894665,0.0000066473453],"category_scores_gemma":[0.000051644383,0.00018466418,0.00012089099,0.000059463502,0.00007504386,0.00019768131,0.000033530887,0.0002007591,0.00003105996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010412873,0.0013965637,0.98487955,0.00024445445,0.00014817817,0.007953634,0.0005796457,0.000001146108,0.00032766943,8.065095e-7,0.0000039745955,0.0034231115],"study_design_scores_gemma":[0.029145375,0.0005705873,0.96502686,0.00028219505,0.00034773626,0.000013018857,0.000049191174,0.00008895763,0.0042915945,0.000007195669,0.0000051122533,0.00017218021],"about_ca_topic_score_codex":0.00016294414,"about_ca_topic_score_gemma":0.00021465903,"teacher_disagreement_score":0.028104087,"about_ca_system_score_codex":0.000053592805,"about_ca_system_score_gemma":0.00007199597,"threshold_uncertainty_score":0.7530387},"labels":[],"label_agreement":null},{"id":"W3113174850","doi":"10.1016/j.jgo.2020.12.001","title":"Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper","year":2020,"lang":"en","type":"review","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; McMaster University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Heart Foundation of New Zealand","keywords":"Medicine; Multiple myeloma; Clinical trial; Intensive care medicine; Malignancy; Gerontology; Internal medicine","score_opus":0.13775085277086507,"score_gpt":0.42517748219901014,"score_spread":0.28742662942814506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113174850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016531166,0.98800313,0.00007778631,0.005546731,0.002984619,0.0025326463,0.00022011835,0.00001787886,0.00045177955],"genre_scores_gemma":[0.00014155271,0.9831724,0.008380033,0.00036046578,0.00743713,0.00015030566,0.00024364317,0.0000674913,0.00004695559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99360293,0.0009637485,0.0033897331,0.0006873789,0.00079188735,0.0005642943],"domain_scores_gemma":[0.9942368,0.0015453324,0.0023166956,0.000360237,0.00052769546,0.0010132103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015029509,0.00065169757,0.006060597,0.0004978802,0.00007941659,0.000023731061,0.00057810056,0.00087898015,0.00014681315],"category_scores_gemma":[0.0006567416,0.00044734305,0.0023022757,0.0008891213,0.00014660822,0.00013280018,0.00023020299,0.0019575865,0.000034638433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001007992,0.0010795236,0.0015951653,0.030426115,0.002004469,0.0010322707,0.00040460745,2.578147e-7,0.0000013249197,0.000006728492,0.027907101,0.93453443],"study_design_scores_gemma":[0.008197484,0.0038201744,0.0013126007,0.006211353,0.0055905953,0.0028518385,0.00013919747,0.000009031056,5.248631e-7,0.000003784769,0.97157276,0.00029066027],"about_ca_topic_score_codex":0.00002360086,"about_ca_topic_score_gemma":0.000021295773,"teacher_disagreement_score":0.9436657,"about_ca_system_score_codex":0.0011972823,"about_ca_system_score_gemma":0.0055298917,"threshold_uncertainty_score":0.9997978},"labels":[],"label_agreement":null},{"id":"W3113268117","doi":"10.1016/s2152-2650(20)30930-7","title":"MM-128: Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Carfilzomib; Daratumumab; Medicine; Dexamethasone; Oncology; Subgroup analysis; Multiple myeloma; Internal medicine; Lenalidomide; Meta-analysis","score_opus":0.07079603572095108,"score_gpt":0.3867732350962609,"score_spread":0.31597719937530977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113268117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917008,0.0050376737,0.000012202438,0.00030025744,0.00012715964,0.00237785,0.00034314502,0.000044738696,0.00005617103],"genre_scores_gemma":[0.99473625,0.0031091014,0.0015289378,0.00015556756,0.00009422522,0.000119639575,0.00006129984,0.00008731965,0.000107669366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99384755,0.0011601466,0.0021920297,0.0012260139,0.00094035093,0.00063388323],"domain_scores_gemma":[0.9913845,0.005514107,0.0009886249,0.0010293778,0.00041480034,0.0006685909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013131638,0.0006676476,0.0028711946,0.00031662086,0.00017590214,0.00004058824,0.0004210588,0.00045941916,0.00009786973],"category_scores_gemma":[0.004414188,0.00043493792,0.00046455313,0.0017834621,0.0014869538,0.00017849595,0.00037191712,0.00052337133,0.000001954177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048776224,0.0021488518,0.6060725,0.00019708836,0.0036490185,0.000115824354,0.00283143,0.0000019845236,0.008194574,0.00000518054,0.00006842999,0.32793888],"study_design_scores_gemma":[0.102328114,0.005665871,0.87901956,0.00016532891,0.001602452,0.000019269162,0.0020517947,0.0032719055,0.0051683183,0.0000075982566,0.0003441095,0.00035566016],"about_ca_topic_score_codex":0.002628876,"about_ca_topic_score_gemma":0.0016281161,"teacher_disagreement_score":0.32758325,"about_ca_system_score_codex":0.00027414103,"about_ca_system_score_gemma":0.00096940546,"threshold_uncertainty_score":0.9998102},"labels":[],"label_agreement":null},{"id":"W3113309259","doi":"10.1182/blood-2021-147101","title":"Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; London Health Sciences Centre; Western University; CancerCare Manitoba; Vancouver General Hospital; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Multiple myeloma; Dosing; Dexamethasone; Internal medicine; Refractory (planetary science); Pharmacology; Adverse effect; Oncology; Gastroenterology","score_opus":0.05008346032906371,"score_gpt":0.31301101659526115,"score_spread":0.26292755626619746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113309259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968415,0.000980842,0.000009982709,0.000104588835,0.000020123041,0.0018496359,0.0001034346,0.0000070281967,0.00008285843],"genre_scores_gemma":[0.99814886,0.00032731344,0.0010971229,0.000003166392,0.000016775532,0.00016357454,0.000067974324,0.000017769926,0.00015745302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862885,0.00013699026,0.00045180603,0.00026515225,0.00031720434,0.00020000893],"domain_scores_gemma":[0.9979065,0.0012526468,0.00023519811,0.0003505382,0.00018630797,0.000068784066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028891783,0.00014331247,0.0004853229,0.00013546998,0.000046399015,0.0000053703907,0.000051824965,0.000054426902,0.0000060509133],"category_scores_gemma":[0.00042648794,0.0000892095,0.00006111537,0.0002564047,0.000092016315,0.00003975666,0.000025140649,0.00006832682,2.8727726e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013062018,0.033300225,0.9084042,0.00024267673,0.0014043042,0.00023283972,0.0048230644,0.000010018409,0.021878768,0.000024313353,0.0000096643535,0.016607955],"study_design_scores_gemma":[0.14095911,0.013003657,0.69320625,0.00023679662,0.0005033187,0.000031676627,0.0030921528,0.00017843345,0.14863831,0.0000100657135,0.00006995642,0.00007029803],"about_ca_topic_score_codex":0.00065654854,"about_ca_topic_score_gemma":0.0014282637,"teacher_disagreement_score":0.21519794,"about_ca_system_score_codex":0.00004695028,"about_ca_system_score_gemma":0.00012354147,"threshold_uncertainty_score":0.36378577},"labels":[],"label_agreement":null},{"id":"W3113360743","doi":"10.1136/jitc-2020-sitc2020.0020","title":"20 Quantification of sBCMA in human plasma using a high-throughput mass spectrometry workflow for exploratory, CAP/CLIA or regulated studies","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Chemistry; Chromatography; Mass spectrometry; Peptide; Selected reaction monitoring; Tandem mass spectrometry; Biochemistry","score_opus":0.1380512454315843,"score_gpt":0.3556764921383321,"score_spread":0.21762524670674777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113360743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995715,0.0009142217,0.00019090324,0.0018889754,0.000115482595,0.001032038,0.00006079688,0.000060620765,0.000021935408],"genre_scores_gemma":[0.9826815,0.00011893574,0.01656069,0.000096844065,0.00015804198,0.000055118293,0.00013352,0.000050284605,0.00014503796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978837,0.00008455177,0.00060968794,0.0005483413,0.00042484616,0.0004488707],"domain_scores_gemma":[0.99850357,0.000117909585,0.00025390557,0.0003200735,0.00020788821,0.0005966774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035208245,0.00029143685,0.0007244137,0.0002270476,0.00014308227,0.000038752132,0.000105094434,0.0001685299,0.000012084347],"category_scores_gemma":[0.0010928045,0.00023873625,0.000099879355,0.0005210178,0.00035004155,0.00021451095,0.000037327405,0.00021342517,0.000004509431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001552856,0.00027983604,0.048465937,0.0017945616,0.00082225417,0.00038764617,0.0017035155,0.00035326276,0.9420641,0.00042209,0.0015410866,0.0006128204],"study_design_scores_gemma":[0.012110361,0.0018383004,0.15393046,0.0015444532,0.00046741127,0.00008560426,0.0025047234,0.0081566665,0.8167805,0.0014722954,0.00050628814,0.00060295],"about_ca_topic_score_codex":0.0001342007,"about_ca_topic_score_gemma":0.00008885083,"teacher_disagreement_score":0.12528364,"about_ca_system_score_codex":0.00016484632,"about_ca_system_score_gemma":0.00032305325,"threshold_uncertainty_score":0.97353816},"labels":[],"label_agreement":null},{"id":"W3115671232","doi":"10.3324/haematol.2020.267757","title":"Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care; Amgen; McMaster University; Cancer Care Ontario; Celgene; Sanofi","keywords":"Medicine; Multiple myeloma; Cohort; Internal medicine; Population; Oncology; Environmental health","score_opus":0.021667831886878514,"score_gpt":0.27253379591813964,"score_spread":0.25086596403126116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115671232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490476,0.000041233856,0.000082876504,0.0007678773,0.000020072697,0.0037336443,0.00004778044,0.00015730619,0.00024446694],"genre_scores_gemma":[0.9978071,0.000006935036,0.00081083825,0.00027728963,0.00002961297,0.0004573552,0.0005630514,0.00003056064,0.000017285658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977994,0.00013452131,0.000392155,0.00057225936,0.00063400285,0.00046768205],"domain_scores_gemma":[0.9988239,0.00029715282,0.00008792234,0.00031107356,0.000101759615,0.00037823032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009903809,0.00028065182,0.0007084123,0.0001467041,0.0000963471,0.00002747832,0.00014515928,0.00009856401,0.00018054414],"category_scores_gemma":[0.00030788637,0.00018702637,0.000076112876,0.00045928388,0.000038993705,0.000075613774,0.000027712447,0.00022140946,0.0000991745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030958408,0.0015779402,0.99136883,0.000099237805,0.00014169206,0.002425493,0.00045458303,0.00018217908,0.000010698477,0.000005372495,0.00006702944,0.0005710946],"study_design_scores_gemma":[0.023140438,0.001582328,0.97122663,0.000106738255,0.00009741838,0.00000869273,0.00013420646,0.0033929052,0.000078411496,0.000003967483,0.000038002352,0.00019024443],"about_ca_topic_score_codex":0.0016789472,"about_ca_topic_score_gemma":0.00055881526,"teacher_disagreement_score":0.020142192,"about_ca_system_score_codex":0.00008353753,"about_ca_system_score_gemma":0.000091038215,"threshold_uncertainty_score":0.76267135},"labels":[],"label_agreement":null},{"id":"W3118735017","doi":"10.1016/j.bbmt.2020.06.011","title":"Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","year":2020,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Department of Veterans Affairs","keywords":"Medicine; Minimal residual disease; Multiple myeloma; Clinical trial; Hematology; Oncology; Immune system; Disease; Profiling (computer programming); Bone transplantation; Bone marrow; Immunology; Internal medicine; Surgery","score_opus":0.08440333781862538,"score_gpt":0.3886070230307096,"score_spread":0.3042036852120842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118735017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08677432,0.9088371,0.000010717411,0.00028176038,0.00018103598,0.002118817,0.0017333709,0.000017582552,0.00004531189],"genre_scores_gemma":[0.09087845,0.90665036,0.0003287617,0.000031872518,0.00027824118,0.00006588595,0.0016861187,0.000031156913,0.000049155726],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955881,0.0016790716,0.0015752035,0.0006272376,0.00020416969,0.0003262141],"domain_scores_gemma":[0.99638796,0.0023689694,0.00062936527,0.00026494378,0.000046180896,0.00030258737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014461421,0.00043651476,0.002538358,0.000128916,0.00009350459,0.000012784767,0.00014151065,0.0004726746,0.000009315169],"category_scores_gemma":[0.00030361392,0.00026323067,0.00046272154,0.00014876317,0.00051299465,0.000041464846,0.000042131367,0.0005254832,7.1118177e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019932587,0.0010958643,0.041710895,0.048349533,0.008953875,0.0006466449,0.0003095572,3.560492e-7,0.004338524,0.00049147476,0.00012702534,0.87404364],"study_design_scores_gemma":[0.11225646,0.025210502,0.21663114,0.31615034,0.28136018,0.0035526368,0.00027480154,0.00010384495,0.0079593435,0.00092838716,0.031695105,0.0038772642],"about_ca_topic_score_codex":0.000021042946,"about_ca_topic_score_gemma":0.000016862696,"teacher_disagreement_score":0.8701664,"about_ca_system_score_codex":0.000006292457,"about_ca_system_score_gemma":0.0002548045,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W3119550966","doi":"10.1016/j.kint.2020.11.010","title":"Management of acute kidney injury in symptomatic multiple myeloma","year":2021,"lang":"en","type":"review","venue":"Kidney International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Multiple myeloma; Acute kidney injury; Medicine; Intensive care medicine; Kidney disease; Kidney; Internal medicine","score_opus":0.03583569146158748,"score_gpt":0.3783480890400921,"score_spread":0.3425123975785046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119550966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019327023,0.9587411,0.00007014868,0.0011856236,0.0016437824,0.0036062729,0.006537202,0.00010033239,0.027922269],"genre_scores_gemma":[0.00031166992,0.9815778,0.003345833,0.00018533284,0.00013562189,0.00041518564,0.008497805,0.000061621045,0.0054691234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971628,0.000115718554,0.0009356626,0.0005197169,0.00090431777,0.00036174938],"domain_scores_gemma":[0.998314,0.0000768581,0.00030100066,0.0005287305,0.00016942964,0.0006099511],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019705835,0.00040277772,0.0014861585,0.00069391076,0.000025277073,0.00003195408,0.00041591996,0.0002128318,0.0015498862],"category_scores_gemma":[0.00038314075,0.0003336026,0.00061016326,0.0004409329,0.000066300556,0.000083231076,0.00032997286,0.00037551482,0.00023985903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010316923,0.0010863828,0.0028326535,0.024071297,0.012929913,0.003438477,0.000046661604,6.169215e-8,0.0000054342263,0.0006837235,0.024966765,0.92983544],"study_design_scores_gemma":[0.0025471996,0.0000899221,0.0012020342,0.060094737,0.0013824813,0.00017705023,0.000009309292,0.00012534129,0.000026496651,0.000016602702,0.9340898,0.00023902227],"about_ca_topic_score_codex":0.00003611768,"about_ca_topic_score_gemma":7.810555e-7,"teacher_disagreement_score":0.9295964,"about_ca_system_score_codex":0.00056170503,"about_ca_system_score_gemma":0.00092072674,"threshold_uncertainty_score":0.9999116},"labels":[],"label_agreement":null},{"id":"W3119909233","doi":"10.1016/j.nut.2021.111141","title":"Adipose tissue radiodensity: A new prognostic biomarker in people with multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Nutrition","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Radiodensity; Adipose tissue; Proinflammatory cytokine; Medicine; Hazard ratio; Internal medicine; Biomarker; Confidence interval; Oncology; Radiology; Inflammation; Biology","score_opus":0.02504447198340892,"score_gpt":0.2906324703308023,"score_spread":0.2655879983473934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119909233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402297,0.0015943333,0.00031226026,0.0021829584,0.000039500006,0.001078669,0.000017198381,0.00006570642,0.0006864083],"genre_scores_gemma":[0.9921542,0.00015305825,0.0058831447,0.00010179203,0.000084660256,0.00012624897,0.00045540105,0.00002388198,0.0010176213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878854,0.000067874236,0.00016316304,0.00032498938,0.00032615123,0.0003292857],"domain_scores_gemma":[0.99919707,0.00011023402,0.000029864992,0.00024765878,0.00013872514,0.00027646357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006598229,0.00014010865,0.00026874495,0.00016272966,0.00004946697,0.00003180381,0.0000365289,0.000084309184,0.00020239524],"category_scores_gemma":[0.00026988046,0.00011938932,0.00004305947,0.00055479724,0.000029561703,0.00010315534,0.000024884179,0.00014196728,0.00011087561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002328103,0.002683222,0.84460324,0.00046930878,0.00018112046,0.0063254205,0.00029493234,0.000001228975,0.05056854,0.000026458323,0.002814501,0.089703895],"study_design_scores_gemma":[0.015043959,0.0004886119,0.95151573,0.00058039435,0.000072805444,0.00080475723,0.000098591096,0.0007592489,0.026593914,0.000057185258,0.0038515877,0.00013321487],"about_ca_topic_score_codex":0.0004756848,"about_ca_topic_score_gemma":0.002711976,"teacher_disagreement_score":0.106912464,"about_ca_system_score_codex":0.00014901029,"about_ca_system_score_gemma":0.00022540551,"threshold_uncertainty_score":0.4868555},"labels":[],"label_agreement":null},{"id":"W3121285120","doi":"10.3390/curroncol28010063","title":"Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Adverse effect; Disease; Internal medicine; Anemia; Oncology; Thalidomide; Drug; Malignancy; Pharmacology","score_opus":0.140054248443033,"score_gpt":0.47209528389630734,"score_spread":0.33204103545327435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121285120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052387005,0.9915021,0.0000052191767,0.00028376072,0.000448126,0.0065369876,0.0003249562,0.000045148274,0.00032979934],"genre_scores_gemma":[0.00006712352,0.9959943,0.00029289725,0.0001550639,0.00024482064,0.0008860641,0.0020385925,0.000077764,0.00024337109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958412,0.0010978432,0.0009734835,0.0009548414,0.00048734638,0.00064526364],"domain_scores_gemma":[0.9941755,0.0030903115,0.00040969744,0.0007946211,0.00035732053,0.0011725789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021108305,0.00071368675,0.0051369285,0.0003577969,0.00007865613,0.000013260896,0.00022303368,0.00019857379,0.00006764478],"category_scores_gemma":[0.0019451099,0.00052250165,0.00070743554,0.0005505115,0.00018006345,0.000031893076,0.0004609272,0.0006447135,0.00015575465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016206047,0.0010175006,0.00017637412,0.33240107,0.00033321374,0.0007490774,0.000027117143,2.0220712e-8,0.0000015777581,0.000007338347,0.004151193,0.6609734],"study_design_scores_gemma":[0.003854479,0.0006247053,0.0016211306,0.24649568,0.0037679765,0.00016164932,0.0000063269504,0.0000019530726,0.000004853636,0.0000012419649,0.74320334,0.00025668228],"about_ca_topic_score_codex":0.000021647977,"about_ca_topic_score_gemma":0.000008363283,"teacher_disagreement_score":0.7390521,"about_ca_system_score_codex":0.0004789314,"about_ca_system_score_gemma":0.0012704626,"threshold_uncertainty_score":0.99972266},"labels":[],"label_agreement":null},{"id":"W3122371497","doi":"10.20944/preprints201803.0151.v1","title":"Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model","year":2018,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates","keywords":"3D cell culture; Cell culture; Bortezomib; STAT3; Multiple myeloma; Cancer research; Spheroid; Chemistry; Bone marrow; Molecular biology; Biology; Cell biology; Immunology; Phosphorylation","score_opus":0.12053394244446355,"score_gpt":0.36239797049266714,"score_spread":0.2418640280482036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122371497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922772,0.00008022016,0.00012723453,0.00018877804,0.00014989215,0.0025255575,0.00018011792,0.000057753463,0.004413265],"genre_scores_gemma":[0.9939714,0.00008071139,0.004682779,0.000046476784,0.000047209393,0.00028070994,0.0003424983,0.000039296276,0.0005089324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654216,0.00018124719,0.0009543005,0.0011042232,0.00068201264,0.00053603126],"domain_scores_gemma":[0.9976219,0.00013701805,0.00045210574,0.0010352816,0.0005067263,0.0002469812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005831175,0.00045482616,0.001025297,0.00067846506,0.000045695124,0.000009486443,0.00025152267,0.0005477303,0.00061350997],"category_scores_gemma":[0.000629194,0.00042172094,0.00019052108,0.00036864608,0.00048520413,0.00013074455,0.00089309004,0.0010868295,0.00020359925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030718972,0.0010886613,0.8320164,0.00056108955,0.00036396857,0.00020814544,0.0007122004,0.0031105487,0.15768489,0.00010916216,0.000056477304,0.0010165512],"study_design_scores_gemma":[0.0060475348,0.00009094913,0.60245144,0.0022081013,0.00006923063,0.00002388912,0.00007508935,0.030287681,0.35485014,0.0034935414,0.000028704322,0.00037368108],"about_ca_topic_score_codex":0.0016848858,"about_ca_topic_score_gemma":0.0006938128,"teacher_disagreement_score":0.22956493,"about_ca_system_score_codex":0.000660268,"about_ca_system_score_gemma":0.0012900048,"threshold_uncertainty_score":0.99982345},"labels":[],"label_agreement":null},{"id":"W3122660020","doi":"10.1016/j.stem.2020.12.017","title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","year":2021,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; NIH Clinical Center; National Cancer Institute; National Institutes of Health; Moores Cancer Center, UC San Diego Health; National Aeronautics and Space Administration; Georgia Clinical and Translational Science Alliance; Ionis Pharmaceuticals; University of California, San Diego; University of Toronto","keywords":"IRF4; Cancer research; Multiple myeloma; Progenitor cell; Biology; Stem cell; Haematopoiesis; Immunology; Cell biology; Transcription factor; Genetics","score_opus":0.01718121206281325,"score_gpt":0.27328527020990895,"score_spread":0.2561040581470957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122660020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465663,0.0006309602,0.00054834364,0.00004790808,0.000107085914,0.00082422927,0.00004295085,0.00005457108,0.013087328],"genre_scores_gemma":[0.98894304,0.00022292905,0.0005786432,0.000034453486,0.00011774511,0.000041854386,0.00059671176,0.000053181175,0.009411464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977056,0.00024459185,0.0005018537,0.0005479604,0.0005177128,0.000482307],"domain_scores_gemma":[0.9986743,0.000046485697,0.0002463684,0.0004542959,0.00031188835,0.00026666498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001973171,0.000262115,0.0004118597,0.00014999774,0.00020674504,0.000031939184,0.00006079484,0.00015142783,0.00018015846],"category_scores_gemma":[0.000007771377,0.00024825166,0.00018794052,0.00035216418,0.00005701393,0.00015134408,0.0000861342,0.00019595608,0.00015555248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016768755,0.0014473553,0.0061239777,0.00071812596,0.000043695465,0.0004319893,0.00037419118,0.00004076609,0.9870332,0.000014472826,0.0003586477,0.0032458755],"study_design_scores_gemma":[0.0037404753,0.0006015944,0.022546655,0.00017630056,0.00012308113,0.00003445877,0.0002108232,0.00092137494,0.97128475,0.00007623726,0.00008838979,0.00019587907],"about_ca_topic_score_codex":0.0001173756,"about_ca_topic_score_gemma":0.000041518164,"teacher_disagreement_score":0.016422676,"about_ca_system_score_codex":0.00023036284,"about_ca_system_score_gemma":0.00013910739,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W3124926129","doi":"10.20944/preprints201901.0114.v1","title":"Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma","year":2019,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates","keywords":"CD38; Chemistry; IC50; STAT3; Cell culture; Monoclonal antibody; Cancer research; Pharmacology; Antibody; Molecular biology; Phosphorylation; In vitro; Medicine; Biochemistry; Biology; Cell biology; Immunology; Stem cell; Genetics","score_opus":0.11477090053505494,"score_gpt":0.37344201649407827,"score_spread":0.2586711159590233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124926129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934055,0.00021404002,0.000013697407,0.0012902315,0.0004698795,0.003168547,0.00009365623,0.00009160544,0.0012528341],"genre_scores_gemma":[0.99853784,0.00021446854,0.000055048225,0.00022096268,0.00020471757,0.00022937979,0.00014947489,0.00007143634,0.00031666982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967938,0.0002907776,0.0006482767,0.00090073206,0.00081595837,0.0005504746],"domain_scores_gemma":[0.99685454,0.00032323168,0.0004212648,0.0018351095,0.0003363169,0.00022951528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006168882,0.00043656075,0.0006999788,0.00019631021,0.00013748143,0.000034779805,0.00039849602,0.00026297625,0.00014609053],"category_scores_gemma":[0.00051984866,0.00030099397,0.00031182973,0.00018103287,0.00017821553,0.00005441257,0.0007334215,0.00092919724,0.000433811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000790435,0.0007012774,0.4959808,0.0004290212,0.0007221854,0.00004180109,0.0013986103,0.0005726465,0.4832841,0.000049972954,0.000012945769,0.016016224],"study_design_scores_gemma":[0.0020107885,0.00016951584,0.5420453,0.00038353028,0.00012662644,0.0000032819285,0.00016855281,0.000745356,0.45400056,0.00007462332,0.00010343382,0.00016843557],"about_ca_topic_score_codex":0.00047400908,"about_ca_topic_score_gemma":0.00005165421,"teacher_disagreement_score":0.0460645,"about_ca_system_score_codex":0.00032823964,"about_ca_system_score_gemma":0.00069183164,"threshold_uncertainty_score":0.9999442},"labels":[],"label_agreement":null},{"id":"W3125260594","doi":"10.1200/jco.20.01814","title":"Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Daratumumab; Medicine; Oncology; Minimal residual disease; Multiple myeloma; Refractory (planetary science); Internal medicine; Negativity effect; Lenalidomide; Bone marrow","score_opus":0.13877459397116443,"score_gpt":0.4711845921469824,"score_spread":0.33240999817581796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125260594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689776,0.0006520543,0.000016142336,0.0019363079,0.000054076183,0.00028005283,0.000019409981,0.000001951794,0.00014221849],"genre_scores_gemma":[0.9979156,0.00022493045,0.0016111959,0.000041166313,0.000056018307,0.0000054436578,0.000017525843,0.000008170684,0.00011990508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956367,0.0016751753,0.0013800545,0.00022164374,0.00092017715,0.0001662525],"domain_scores_gemma":[0.9930081,0.0032501642,0.0012440586,0.00019431135,0.0019420449,0.00036134443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050231367,0.00011065176,0.001289009,0.0004516549,0.00003045866,0.000004894283,0.000047495203,0.00016826103,0.000053861233],"category_scores_gemma":[0.024058683,0.00007375343,0.00016124517,0.0005512577,0.00030097135,0.0001128235,0.000045904155,0.00040680097,1.7922794e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03993668,0.0045857695,0.89653206,0.0000917535,0.0025124783,0.0017943559,0.00030741643,0.00004413444,0.0008201652,0.00003294025,0.000063267355,0.053278957],"study_design_scores_gemma":[0.031880833,0.009530177,0.9467479,0.00011429909,0.00418534,0.00004851562,0.00062594685,0.0064490507,0.00024469278,0.000062656676,0.000054891563,0.00005569425],"about_ca_topic_score_codex":0.00007445036,"about_ca_topic_score_gemma":0.0015100981,"teacher_disagreement_score":0.053223263,"about_ca_system_score_codex":0.00024936083,"about_ca_system_score_gemma":0.003911435,"threshold_uncertainty_score":0.9841621},"labels":[],"label_agreement":null},{"id":"W3125598993","doi":"10.1097/ijg.0000000000001698","title":"Netarsudil-related Eyelid Wound Dehiscence","year":2021,"lang":"en","type":"article","venue":"Journal of Glaucoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Bimatoprost; Eyelid; Basal cell carcinoma; Wound dehiscence; Surgery; Dehiscence; Basal cell; Mohs surgery; Granulation tissue; Ophthalmology; Wound healing; Intraocular pressure; Internal medicine; Ocular hypertension","score_opus":0.020388953961754087,"score_gpt":0.30700464458951493,"score_spread":0.2866156906277608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125598993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99044013,0.0030314664,0.00006741817,0.0023521604,0.0002476502,0.00008380267,0.0000023561522,0.000009877903,0.0037651584],"genre_scores_gemma":[0.99337685,0.00044499637,0.002837799,0.00021746551,0.00017191774,9.86759e-7,0.0000070663828,0.000014007157,0.0029289222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986378,0.000071201815,0.00040525902,0.00011510001,0.00051501475,0.00025562302],"domain_scores_gemma":[0.9987547,0.00009045873,0.00016747527,0.00020155087,0.0004409468,0.00034489424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020590556,0.00010537899,0.00032248267,0.00011112487,0.000058465823,0.000029460323,0.000092304275,0.000068074834,0.0008806007],"category_scores_gemma":[0.00036866489,0.0000773333,0.00020059879,0.00024320616,0.000049515438,0.00011482504,0.000037000387,0.00036293524,0.0001290772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000532614,0.0005499138,0.9341267,0.000048892784,0.00064725435,0.017532215,0.00012345039,3.6906746e-7,0.017983036,0.00010399161,0.0040438985,0.024307692],"study_design_scores_gemma":[0.0045294613,0.00055990246,0.9642679,0.00019904542,0.00013339349,0.0073015243,0.000087858825,0.00015312475,0.009984261,0.0002970639,0.012408589,0.00007787501],"about_ca_topic_score_codex":0.000013863391,"about_ca_topic_score_gemma":0.00001108315,"teacher_disagreement_score":0.030141229,"about_ca_system_score_codex":0.00011716663,"about_ca_system_score_gemma":0.0004041341,"threshold_uncertainty_score":0.964196},"labels":[],"label_agreement":null},{"id":"W3126084169","doi":"10.1007/s00277-021-04420-3","title":"Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”","year":2021,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality","keywords":"Carfilzomib; Medicine; Multiple myeloma; Internal medicine; Comorbidity; Hazard ratio; Hematology; Adverse effect; Dialysis; Proportional hazards model; Kidney disease; Intensive care medicine; Epidemiology; Oncology; Proteasome inhibitor; Confidence interval","score_opus":0.060605959715778736,"score_gpt":0.34046886891887235,"score_spread":0.2798629092030936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126084169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971816,0.00034628593,6.708845e-7,0.0009309425,0.000024843153,0.00029878272,0.000038950642,0.0000146567745,0.0011632941],"genre_scores_gemma":[0.99929523,0.0001149123,0.00008107747,0.00015036704,0.000010008892,0.000020564961,0.00023520361,0.000012644055,0.000079998055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998458,0.00025500948,0.0003288706,0.00025839976,0.00028850447,0.00041120817],"domain_scores_gemma":[0.9988111,0.0005367001,0.000116001815,0.00023425053,0.00018028342,0.000121618745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016933547,0.0001520455,0.00048102142,0.00017333505,0.00006957933,0.000012486628,0.00008716215,0.00011299984,0.000050228606],"category_scores_gemma":[0.0008917269,0.0001029758,0.000093927476,0.00035427586,0.00015052498,0.00006880644,0.00007527953,0.00022727314,0.0000028427132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013030121,0.00043260073,0.9960415,0.000051446663,0.00016286087,0.00038253682,0.00071929104,2.9026185e-7,0.0004282775,0.00019003423,0.00059689424,0.0008639857],"study_design_scores_gemma":[0.0025981688,0.00017219786,0.9785021,0.00011195518,0.000023529477,0.000017210894,0.00078870077,0.00007095407,0.017408997,0.00007671905,0.00015482996,0.00007464608],"about_ca_topic_score_codex":0.00056952547,"about_ca_topic_score_gemma":0.006845857,"teacher_disagreement_score":0.01753939,"about_ca_system_score_codex":0.000014639667,"about_ca_system_score_gemma":0.000076873155,"threshold_uncertainty_score":0.41992313},"labels":[],"label_agreement":null},{"id":"W3126347994","doi":"10.1007/s40801-020-00226-3","title":"Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study","year":2021,"lang":"en","type":"article","venue":"Drugs - Real World Outcomes","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Daratumumab; Medicine; Regimen; Adverse effect; Internal medicine; Emergency medicine; Multiple myeloma","score_opus":0.11842715844150209,"score_gpt":0.40153267830723555,"score_spread":0.28310551986573346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126347994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96948916,0.000059914855,0.0000018260308,0.0015849554,0.00005969627,0.0010714522,0.00013810396,0.000043751825,0.027551156],"genre_scores_gemma":[0.99300134,0.00024443338,0.00058518176,0.00012280256,0.000023537232,0.00006767518,0.00065264426,0.000023747443,0.0052786544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751467,0.0006189688,0.00064299535,0.00032530975,0.00058382325,0.0003142491],"domain_scores_gemma":[0.9978647,0.0008339465,0.0001826909,0.00060102553,0.00031897257,0.00019863517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006407697,0.00022876653,0.00069866504,0.00041308234,0.00029473373,0.00002972817,0.000114738395,0.000050355473,0.0002066504],"category_scores_gemma":[0.0007417823,0.00019595376,0.00010501339,0.0012300293,0.00011865189,0.00012618721,0.00026926037,0.00048537558,0.0000040932528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077599165,0.0018083408,0.98797774,0.00009226677,0.0002474753,0.000121490506,0.003892128,9.5181974e-7,0.000114210125,0.0010381213,0.00012253823,0.0038087382],"study_design_scores_gemma":[0.0077971397,0.00030270463,0.98718464,0.00017683963,0.00008171565,0.000004519577,0.0033651898,0.00020243446,0.00020321782,0.00023580658,0.00031620805,0.00012958741],"about_ca_topic_score_codex":0.0044657495,"about_ca_topic_score_gemma":0.043633834,"teacher_disagreement_score":0.039168082,"about_ca_system_score_codex":0.00035133085,"about_ca_system_score_gemma":0.0003711764,"threshold_uncertainty_score":0.97381735},"labels":[],"label_agreement":null},{"id":"W3126942294","doi":"10.4103/tjo.tjo_81_20","title":"Optic nerve head plasmacytoma as a manifestation of multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Taiwan Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Plasmacytoma; Optic nerve; Multiple myeloma; Extramedullary plasmacytoma; Orbit (dynamics); Presentation (obstetrics); Pathology; Disease; Radiology; Anatomy; Internal medicine","score_opus":0.04638589656100285,"score_gpt":0.35706020354933277,"score_spread":0.31067430698832993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126942294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370956,0.00061547616,0.000035834168,0.0007762365,0.0001980088,0.00016558121,0.000012457439,0.0000063930725,0.0044804714],"genre_scores_gemma":[0.99273765,0.000014293433,0.006148186,0.0000181847,0.000119029086,0.000004587176,0.00002586259,0.00002317916,0.00090905186],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99818337,0.00021359263,0.00064246135,0.00018007733,0.0004505247,0.00032996974],"domain_scores_gemma":[0.9980277,0.00024363288,0.00038443392,0.0002482691,0.0007770837,0.000318901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000278628,0.00015708194,0.000574263,0.00025265542,0.000049910348,0.000011443194,0.00012384923,0.00010848901,0.0010333802],"category_scores_gemma":[0.0010120848,0.00012991036,0.00023047622,0.00024573045,0.000127533,0.00011405051,0.000055075125,0.00030440706,0.00006158084],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006086107,0.0017818029,0.40459487,0.00033852397,0.0011693117,0.49473217,0.0006630264,0.00006827283,0.08375529,0.00041916958,0.00019266215,0.0061987718],"study_design_scores_gemma":[0.008153005,0.004565177,0.3979363,0.00020318192,0.00014580388,0.5385308,0.00059855,0.00030267122,0.048883606,0.00050059083,0.00007388231,0.00010641348],"about_ca_topic_score_codex":0.000035054938,"about_ca_topic_score_gemma":0.0000021836186,"teacher_disagreement_score":0.04379862,"about_ca_system_score_codex":0.00010217947,"about_ca_system_score_gemma":0.0006663534,"threshold_uncertainty_score":0.99987984},"labels":[],"label_agreement":null},{"id":"W3127156187","doi":"10.1111/ejh.13596","title":"The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; University of Saskatchewan; Dalhousie University; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; Institute of Cancer Research; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Occupational Cancer Research Centre; Ottawa Hospital; Canadian Institutes of Health Research; McGill University; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Internal medicine; Oncology; Cohort; Maintenance therapy; Thalidomide; Chemotherapy; Surgery","score_opus":0.01508152340516909,"score_gpt":0.2850994780564227,"score_spread":0.2700179546512536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127156187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974634,0.0003550513,0.000093891824,0.00065744726,0.000047277277,0.00017897996,0.000020069394,0.000003982709,0.0011798793],"genre_scores_gemma":[0.9989625,0.00029112241,0.0004042481,0.00010146874,0.00003180327,0.0000012507091,0.000011263564,0.000028680362,0.00016762757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826086,0.00043372758,0.0005657643,0.00014321707,0.0002725597,0.00032389406],"domain_scores_gemma":[0.9986514,0.00029800658,0.00030963327,0.00024349744,0.000342461,0.00015501077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045112724,0.00015481892,0.00054848345,0.00013465255,0.000045013807,0.00001052715,0.00014688552,0.0000241043,0.00011401614],"category_scores_gemma":[0.0002194884,0.00007557406,0.00018272043,0.00016980268,0.000118795964,0.000046667883,0.000015407666,0.00031734945,0.000014710229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025071261,0.0015836448,0.9228576,0.00009240667,0.00096716225,0.033343278,0.0005662972,0.00013289141,0.0038152682,0.000057008227,0.0011599853,0.010353198],"study_design_scores_gemma":[0.025271146,0.004065743,0.9495854,0.0005484215,0.00002900002,0.0042923763,0.00007510444,0.000099083045,0.015356697,0.000023184664,0.0005666384,0.00008719917],"about_ca_topic_score_codex":0.000010186448,"about_ca_topic_score_gemma":0.000048640602,"teacher_disagreement_score":0.029050903,"about_ca_system_score_codex":0.000066423054,"about_ca_system_score_gemma":0.00020192203,"threshold_uncertainty_score":0.3081821},"labels":[],"label_agreement":null},{"id":"W3127479238","doi":"10.1111/bjh.17350","title":"Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; Hôpital Maisonneuve-Rosemont; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; CancerCare Manitoba; Ottawa Regional Cancer Foundation; Ottawa Hospital; Saskatchewan Cancer Agency; Alberta Cancer Foundation; Canadian Institutes of Health Research; Université de Montréal; University of Saskatchewan; University of Alberta; McGill University","funders":"","keywords":"Bortezomib; Lenalidomide; Multiple myeloma; Dexamethasone; Medicine; Regimen; Melphalan; Prednisone; Internal medicine; Oncology; Thalidomide; Cyclophosphamide; Chemotherapy","score_opus":0.09525598580510063,"score_gpt":0.36691124114013407,"score_spread":0.27165525533503343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127479238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98073786,0.011019836,0.0009202962,0.005207242,0.00013136929,0.0011143732,0.00071674754,0.000009557179,0.00014271872],"genre_scores_gemma":[0.9835927,0.003717204,0.011620672,0.00010580002,0.00013580777,0.0001231357,0.00036305079,0.00003184246,0.00030978382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971425,0.00034143924,0.00080171437,0.0003961841,0.0006674325,0.0006507307],"domain_scores_gemma":[0.9944469,0.0033970855,0.00032349574,0.00045797564,0.0009010407,0.00047350844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012099583,0.00023748568,0.0010482991,0.00024674792,0.00077328767,0.00008496416,0.0002046212,0.000107709224,0.000044871456],"category_scores_gemma":[0.0011471722,0.00013793125,0.00022825977,0.00031339496,0.00072173297,0.00013620812,0.000036567184,0.00043735828,0.0000013983688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056494502,0.0008633297,0.6600329,0.00013226681,0.0038521516,0.31454322,0.0010432042,0.000031306914,0.0010446083,0.00055356376,0.00113,0.011123983],"study_design_scores_gemma":[0.035756126,0.0015332444,0.66406524,0.0013304088,0.0009926294,0.28249326,0.0018231755,0.0010497863,0.0033604822,0.00012871304,0.007222545,0.00024438786],"about_ca_topic_score_codex":0.26605496,"about_ca_topic_score_gemma":0.854928,"teacher_disagreement_score":0.588873,"about_ca_system_score_codex":0.000443416,"about_ca_system_score_gemma":0.0027835304,"threshold_uncertainty_score":0.7388325},"labels":[],"label_agreement":null},{"id":"W3128184630","doi":"10.1017/cjn.2021.20","title":"The Importance of Being Significant: “Monoclonal Gammopathies of Neurological Significance”","year":2021,"lang":"en","type":"letter","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Content (measure theory); Monoclonal; Medicine; Monoclonal antibody; Psychology; Neuroscience; Immunology; Antibody; Mathematics","score_opus":0.05208481952817656,"score_gpt":0.2952812488328111,"score_spread":0.24319642930463453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128184630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.853107,0.0037179508,0.000007787999,0.14053594,0.00078964385,0.00037538027,0.000059968745,0.000011398801,0.001394982],"genre_scores_gemma":[0.94235355,0.0022290626,0.0012520291,0.052891597,0.001112851,0.00001015025,0.000004623604,0.00003187984,0.000114247494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9899159,0.002193027,0.0022869436,0.00092675816,0.002429023,0.0022483678],"domain_scores_gemma":[0.9901393,0.003341594,0.0026637812,0.00045016754,0.0016379177,0.0017672415],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.005450784,0.0006597109,0.001627708,0.0011007553,0.002410591,0.00049045635,0.003002843,0.0007233898,0.00023855381],"category_scores_gemma":[0.0074955565,0.0003691363,0.00088937365,0.0017948309,0.018123211,0.00044325087,0.00016923586,0.0052153985,0.0000018760727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037904992,0.00007159125,0.90714395,0.00008795292,0.00013249915,0.06791258,0.00016935145,0.0002479822,0.00010903835,0.0002389647,0.020404583,0.0031024772],"study_design_scores_gemma":[0.0024451208,0.2922599,0.46287483,0.00080628745,0.0007931135,0.107282996,0.00066714064,0.0014764352,0.0015191922,0.025509585,0.10284551,0.0015199012],"about_ca_topic_score_codex":0.00087338226,"about_ca_topic_score_gemma":0.012280352,"teacher_disagreement_score":0.44426912,"about_ca_system_score_codex":0.00023533453,"about_ca_system_score_gemma":0.010961173,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W3129944430","doi":"10.1007/s00277-021-04405-2","title":"Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study","year":2021,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Internal medicine; Cohort; Gastroenterology; Population; Multiple myeloma; Hazard ratio; Confidence interval; Bortezomib","score_opus":0.0680167143978006,"score_gpt":0.3963128372205184,"score_spread":0.3282961228227178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129944430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737173,0.00039433784,0.0000037451616,0.00036279304,0.000038504288,0.0011363047,0.00009079179,0.000015041889,0.0005867409],"genre_scores_gemma":[0.999576,0.000021644666,0.0001162175,0.00004814261,0.000006491119,0.000042191,0.00010900613,0.000021220976,0.000059120837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977378,0.00039630086,0.00056895294,0.00037606468,0.0004977087,0.00042313346],"domain_scores_gemma":[0.9981985,0.00021423605,0.00023076871,0.00066665467,0.00054543075,0.00014442285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013122748,0.00020989604,0.00093669747,0.00018163375,0.00008449949,0.000009086058,0.00016532585,0.00010403372,0.000071291666],"category_scores_gemma":[0.0005293528,0.00014082607,0.00013607559,0.0007718714,0.00022283233,0.000059507944,0.00012698953,0.00024776915,0.0000039914376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031411736,0.011214227,0.97902656,0.00014811043,0.00065268954,0.0021949664,0.00047593567,0.0000026988373,0.0018695288,0.000018048775,0.0000625021,0.0011935646],"study_design_scores_gemma":[0.016006859,0.0044496474,0.89799017,0.00017085383,0.00013884084,0.00027842517,0.00062009937,0.000084765124,0.08011381,0.000016369524,0.000015770345,0.00011437693],"about_ca_topic_score_codex":0.0011006832,"about_ca_topic_score_gemma":0.004329491,"teacher_disagreement_score":0.081036374,"about_ca_system_score_codex":0.00002287641,"about_ca_system_score_gemma":0.00027001422,"threshold_uncertainty_score":0.57427204},"labels":[],"label_agreement":null},{"id":"W3130635418","doi":"10.1111/bcp.14792","title":"Repurposing of thalidomide and its derivatives for the treatment of SARS‐coV‐2 infections: Hints on molecular action","year":2021,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada); Hospital for Sick Children","funders":"","keywords":"Thalidomide; Drug repositioning; Lenalidomide; Pneumonia; Immunology; Angiogenesis; Repurposing; Medicine; Immune system; Transcriptome; Drug; Pharmacology; Biology; Cancer research; Multiple myeloma; Internal medicine","score_opus":0.21429986587665045,"score_gpt":0.5288995026849976,"score_spread":0.3145996368083472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130635418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878164,0.010038716,0.00022373015,0.0009576957,0.00045338125,0.0004198599,0.000020192896,0.0000027628791,0.000067244655],"genre_scores_gemma":[0.97118914,0.027737305,0.0004924993,0.00025827077,0.00024864593,0.000016804124,0.000003900146,0.000009638578,0.00004380021],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984962,0.0003339752,0.0007420815,0.0001303426,0.00016719662,0.00013023996],"domain_scores_gemma":[0.9968637,0.0020148137,0.00044937286,0.00006563946,0.0005099475,0.00009652246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044319578,0.000076675184,0.0005153955,0.000056637415,0.000059411675,0.000007703478,0.000041634627,0.00007437149,0.000047157937],"category_scores_gemma":[0.0014496672,0.000057963138,0.00028354354,0.00008305862,0.00013735829,0.00005246505,0.000015251342,0.00017996428,5.4546376e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068645617,0.008998577,0.01186771,0.00019601051,0.004493279,0.0021827526,0.00012521997,0.000060558,0.29361796,0.000040920837,0.0011526567,0.6703998],"study_design_scores_gemma":[0.022733413,0.009188873,0.08170592,0.0002819542,0.0011056816,0.0026724301,0.00009328028,0.00043723063,0.8748833,0.00022996697,0.0066011203,0.00006686248],"about_ca_topic_score_codex":0.000019900788,"about_ca_topic_score_gemma":0.000010258572,"teacher_disagreement_score":0.6703329,"about_ca_system_score_codex":0.000038894363,"about_ca_system_score_gemma":0.00019624358,"threshold_uncertainty_score":0.23636682},"labels":[],"label_agreement":null},{"id":"W3131490660","doi":"10.1016/j.leukres.2021.106542","title":"Association of insurance disparities and survival in adults with multiple myeloma: A non-concurrent cohort study","year":2021,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health","funders":"","keywords":"Medicine; Hazard ratio; Medicaid; Marital status; Socioeconomic status; Residence; Confidence interval; Demography; Epidemiology; Cohort; Internal medicine; Environmental health; Population; Health care","score_opus":0.027287999753992848,"score_gpt":0.33705095681831604,"score_spread":0.3097629570643232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131490660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963507,0.0003439708,0.000004713922,0.0003136014,0.000034924466,0.0014993419,0.000042627456,0.000012871739,0.0013972382],"genre_scores_gemma":[0.99758005,0.00036915534,0.000087849374,0.0000064473475,0.000043237495,0.00029849712,0.000062840685,0.00002021811,0.0015317161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662554,0.00044101605,0.00029793792,0.00045324973,0.0016109606,0.00057129853],"domain_scores_gemma":[0.9977601,0.00084577175,0.000060991246,0.0003311,0.0007999632,0.00020203847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013630881,0.00014199421,0.00047056784,0.0002378561,0.00009573716,0.00003613162,0.00008993181,0.000089754816,0.000026151256],"category_scores_gemma":[0.0013881164,0.00011290169,0.000035745034,0.00072144956,0.00013087873,0.0001027364,0.00015323132,0.0006140097,0.000010192443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013621633,0.0009454933,0.9909431,0.000371909,0.00024592623,0.00063845527,0.00079412194,0.0000033591762,0.00036264225,0.000013128181,0.00016830658,0.004151445],"study_design_scores_gemma":[0.015845312,0.0008165664,0.9781571,0.00039038365,0.000017868506,0.000010974738,0.0015304934,0.0010809727,0.0020113944,0.000008246565,0.000040285096,0.00009040388],"about_ca_topic_score_codex":0.005111469,"about_ca_topic_score_gemma":0.012030039,"teacher_disagreement_score":0.014483149,"about_ca_system_score_codex":0.0011105167,"about_ca_system_score_gemma":0.0008572183,"threshold_uncertainty_score":0.7727046},"labels":[],"label_agreement":null},{"id":"W3131492282","doi":"10.1016/j.clnu.2021.02.010","title":"Visceral adipose tissue glucose uptake is linked to prognosis in multiple myeloma patients: An exploratory study","year":2021,"lang":"en","type":"article","venue":"Clinical Nutrition","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Medicine; Hazard ratio; Adipose tissue; Confidence interval; Internal medicine; Standardized uptake value; Multiple myeloma; Leptin; Gastroenterology; Body mass index; Obesity; Positron emission tomography; Nuclear medicine","score_opus":0.1004739811137804,"score_gpt":0.4037816679290408,"score_spread":0.3033076868152604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131492282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948657,0.00024925562,0.000013576809,0.0012326743,0.00020992185,0.0032119772,0.00008249087,0.00008348951,0.00005091288],"genre_scores_gemma":[0.9943043,0.00017706714,0.0026334217,0.00091769104,0.00036805667,0.00085372245,0.00062133867,0.000041220028,0.00008315871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968225,0.0004987841,0.0009014639,0.00079005916,0.00053501833,0.00045220536],"domain_scores_gemma":[0.99784684,0.00026719188,0.000078433266,0.00051495485,0.00052000105,0.0007725779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045485876,0.00022592275,0.0005662688,0.00018525659,0.000095125026,0.000052683507,0.00012155867,0.00020047385,0.00022301075],"category_scores_gemma":[0.0016309423,0.0002119773,0.00014317497,0.00053260656,0.00006111472,0.00024412689,0.00011838049,0.00041217252,0.0003471458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002516991,0.053868163,0.8117795,0.000101856334,0.00012710017,0.0010517846,0.0008627864,3.2266198e-7,0.0013114432,0.000002022731,0.0013259638,0.12705208],"study_design_scores_gemma":[0.027073395,0.0088268295,0.9550139,0.0002859533,0.000079623984,0.0000053713047,0.0010164719,0.00019237524,0.0038629845,0.00006215217,0.0033778553,0.00020313793],"about_ca_topic_score_codex":0.00003619159,"about_ca_topic_score_gemma":0.0006341304,"teacher_disagreement_score":0.14323437,"about_ca_system_score_codex":0.00015215122,"about_ca_system_score_gemma":0.00013574069,"threshold_uncertainty_score":0.8644183},"labels":[],"label_agreement":null},{"id":"W3132405511","doi":"10.1038/s41375-021-01180-x","title":"Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Multiple myeloma; Medicine; Internal medicine; Serum protein electrophoresis; Hematology; Surrogate endpoint; Gastroenterology; Oncology; Immunology; Monoclonal; Antibody; Monoclonal antibody","score_opus":0.04591227923151518,"score_gpt":0.34574227588327006,"score_spread":0.29982999665175486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132405511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769366,0.00018961314,0.000059877224,0.0007273112,0.000073925316,0.0008725617,0.00010775686,0.000059583665,0.00021570324],"genre_scores_gemma":[0.985571,0.000021481957,0.0121015,0.000088775945,0.000039870498,0.00025602843,0.00008974345,0.000046390534,0.0017851943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976919,0.00019624359,0.0002926757,0.0005423151,0.00071554957,0.0005612897],"domain_scores_gemma":[0.9982188,0.0004105863,0.00007976395,0.00048563327,0.000338661,0.0004665914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023758967,0.0002500962,0.0003520754,0.00017094522,0.00013262474,0.000055903496,0.000094869756,0.00007113893,0.00005331407],"category_scores_gemma":[0.0011354457,0.00019667778,0.00007289181,0.00048814938,0.0000837843,0.00023299929,0.000105545194,0.00037035032,0.00003431782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007911904,0.00052601,0.9816992,0.00018285602,0.00012538028,0.0034879926,0.0006196494,0.00018248291,0.0026902205,0.00002043813,0.00006903504,0.0024848317],"study_design_scores_gemma":[0.01007102,0.000619126,0.97713625,0.00079875294,0.000048251866,0.000008902932,0.0009436369,0.0030178686,0.006852902,0.000025710688,0.00028461477,0.00019297047],"about_ca_topic_score_codex":0.00027991983,"about_ca_topic_score_gemma":0.00009222766,"teacher_disagreement_score":0.012122653,"about_ca_system_score_codex":0.0016512689,"about_ca_system_score_gemma":0.0024852774,"threshold_uncertainty_score":0.8020287},"labels":[],"label_agreement":null},{"id":"W3133701599","doi":"10.1002/ajh.26147","title":"Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the <scp>MCRN</scp>‐003/<scp>MYX</scp>.1 single arm phase <scp>II</scp> trial","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa; Western University; Saint John Regional Hospital; Hôtel-Dieu de Québec; Hotel Dieu Hospital; Princess Margaret Cancer Centre; Micropharma (Canada); University of Alberta; University of New Brunswick; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Amgen Canada; Amgen","keywords":"Carfilzomib; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Regimen; Clinical endpoint; Internal medicine; Cyclophosphamide; Adverse effect; Gastroenterology; Phases of clinical research; Metastatic breast cancer; Thalidomide; Progression-free survival; Refractory (planetary science); Oncology; Neutropenia; Toxicity; Chemotherapy; Clinical trial; Cancer; Breast cancer","score_opus":0.04164704233889885,"score_gpt":0.3148523281370852,"score_spread":0.27320528579818637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133701599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846366,0.011469126,0.00006681659,0.0013554344,0.00043575317,0.0010657408,0.00030438343,0.000024858817,0.00064126716],"genre_scores_gemma":[0.9919819,0.0033747603,0.0029662277,0.00039160516,0.0004712583,0.00007696561,0.00014996645,0.000070750255,0.0005165175],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99376214,0.0014763048,0.0018617627,0.000749988,0.0010573551,0.0010924549],"domain_scores_gemma":[0.9757234,0.020479225,0.0017794553,0.0009794667,0.00045590548,0.00058258086],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010345171,0.00063840405,0.0023041486,0.00034794334,0.00032024243,0.00006387773,0.00051499554,0.00025121396,0.000012687938],"category_scores_gemma":[0.011681371,0.00038958102,0.0005578533,0.0009050035,0.0012757679,0.0001878218,0.00014811526,0.0009886397,0.000014903144],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068102114,0.10758278,0.25121787,0.00037832028,0.014771211,0.08258182,0.13479853,0.00022490868,0.063463286,0.00041439213,0.04352061,0.23294415],"study_design_scores_gemma":[0.5232677,0.09627019,0.1087203,0.00084649026,0.002200758,0.012673602,0.08238831,0.0005710273,0.08669425,0.0005618817,0.085579425,0.00022607998],"about_ca_topic_score_codex":0.0012618338,"about_ca_topic_score_gemma":0.0004732263,"teacher_disagreement_score":0.45516557,"about_ca_system_score_codex":0.00044320588,"about_ca_system_score_gemma":0.001177446,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W3133800890","doi":"10.3324/haematol.2020.261842","title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study","year":2021,"lang":"en","type":"letter","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Erasmus Universitair Medisch Centrum Rotterdam; Vrije Universiteit Amsterdam; Servier; Sorbonne Université; Institut National de la Santé et de la Recherche Médicale; Amsterdam University Medical Centers; Sanofi; Université de Lille; Assistance publique-Hôpitaux de Paris; Celgene; Bristol-Myers Squibb; Amgen","keywords":"Daratumumab; Bortezomib; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Thalidomide; Transplantation; Autologous stem-cell transplantation; Oncology","score_opus":0.058757850347967176,"score_gpt":0.3123871978541202,"score_spread":0.25362934750615307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133800890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803773,0.0010745855,0.000020884983,0.012749469,0.00014477855,0.004645033,0.0002734208,0.000056063545,0.0006584595],"genre_scores_gemma":[0.98516303,0.0013827214,0.00017579304,0.010379746,0.00011887979,0.0009343297,0.0016218042,0.00006674968,0.00015695575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99479294,0.00110686,0.0010181578,0.0011527318,0.000989456,0.00093984534],"domain_scores_gemma":[0.9958767,0.0028467868,0.0002705938,0.00072395446,0.000111800204,0.00017012884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006239017,0.00069635303,0.0015772622,0.0005219103,0.00019750177,0.00014127209,0.00035588548,0.0007485051,0.00009513376],"category_scores_gemma":[0.00018598513,0.00046514758,0.00018362771,0.00064303575,0.00011429661,0.00016059751,0.000052863827,0.0021824653,0.000022411969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004182697,0.007114302,0.7358901,0.0022109775,0.00026695727,0.20556268,0.01280804,0.0000040102227,0.00023554897,9.771697e-7,0.018304793,0.013418899],"study_design_scores_gemma":[0.11127736,0.005418793,0.8604924,0.004040285,0.00096151506,0.0018366216,0.0063819927,0.0003271652,0.00298305,0.000018018114,0.004863256,0.001399524],"about_ca_topic_score_codex":0.0018810434,"about_ca_topic_score_gemma":0.0039153444,"teacher_disagreement_score":0.20372605,"about_ca_system_score_codex":0.00015259738,"about_ca_system_score_gemma":0.00016233248,"threshold_uncertainty_score":0.99978},"labels":[],"label_agreement":null},{"id":"W3134103265","doi":"10.1016/s1470-2045(20)30756-7","title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genesis Pharma; Genentech; National Natural Science Foundation of China; Takeda Pharmaceutical Company; AbbVie; Sanofi; Roche; Novartis; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Clinical trial; Internal medicine; Oncology; Clinical Practice; Family medicine","score_opus":0.17899591068222734,"score_gpt":0.42305126285013306,"score_spread":0.24405535216790572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134103265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000760783,0.9882635,0.000012327691,0.0060020844,0.00063957914,0.0011937597,0.00035016707,0.00003343875,0.0027443501],"genre_scores_gemma":[0.0021533018,0.9914218,0.0014924805,0.00019053121,0.0013745723,0.0004163248,0.0023097112,0.000040080446,0.0006011995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758023,0.00082756125,0.0005605863,0.00042493746,0.00026859422,0.0003380796],"domain_scores_gemma":[0.99403936,0.004572052,0.00043107365,0.000769733,0.00008159036,0.000106219944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038044646,0.00032275298,0.0019084828,0.000085454725,0.00017077544,0.000030475647,0.0003648667,0.0002728726,0.00032547614],"category_scores_gemma":[0.00042180243,0.00015809477,0.00033294308,0.00018890495,0.00022220919,0.000032189335,0.00021049076,0.0004664057,0.000034634137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022197714,0.00047700628,0.0016189959,0.0002075456,0.0019594657,0.00020049898,0.00029530647,4.7248236e-8,0.000008401273,0.00017677166,0.0027163127,0.99211764],"study_design_scores_gemma":[0.0040140557,0.0005904422,0.0021487512,0.0019947905,0.0010125437,0.00020881958,0.00015059135,0.000022846403,0.0000034139596,0.000033671855,0.98970723,0.00011286181],"about_ca_topic_score_codex":0.00027566933,"about_ca_topic_score_gemma":0.0004389192,"teacher_disagreement_score":0.9920048,"about_ca_system_score_codex":0.0006861472,"about_ca_system_score_gemma":0.00043929016,"threshold_uncertainty_score":0.64469177},"labels":[],"label_agreement":null},{"id":"W3134398991","doi":"10.1016/j.clml.2021.02.012","title":"Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Population; Oncology; Transplantation; Salvage therapy; Surgery; Chemotherapy","score_opus":0.04923739033260672,"score_gpt":0.33478305367199535,"score_spread":0.28554566333938863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134398991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553007,0.00041879556,0.0003929518,0.00008437891,0.0008642893,0.00067257695,0.0005661472,0.00038373575,0.0010870822],"genre_scores_gemma":[0.981855,0.00029741132,0.011966382,0.00027327458,0.00048783195,0.00007295181,0.004619138,0.00011672749,0.0003113154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99359024,0.0011098156,0.001787346,0.001520937,0.0011369985,0.00085466437],"domain_scores_gemma":[0.995142,0.0017203694,0.0005312848,0.0013159529,0.00024568307,0.0010447446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010404496,0.00055287156,0.0013280004,0.00013562824,0.00045361675,0.0001419298,0.00030807417,0.0006884914,0.00021720506],"category_scores_gemma":[0.0007881343,0.00053860404,0.00070697593,0.0004913692,0.00017345908,0.00042424453,0.000061734354,0.00064269226,0.00042823577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012049486,0.00073984737,0.7849559,0.000095388634,0.0007269215,0.002911178,0.0003924288,0.00007131685,0.0018894607,0.00010670275,0.00003277641,0.2068731],"study_design_scores_gemma":[0.013493322,0.000620172,0.9643766,0.0002626242,0.0010561616,0.00007654921,0.00037022712,0.002241593,0.016477086,0.00046241487,0.000059533,0.0005036884],"about_ca_topic_score_codex":0.0054458296,"about_ca_topic_score_gemma":0.0015048217,"teacher_disagreement_score":0.20636941,"about_ca_system_score_codex":0.0008134932,"about_ca_system_score_gemma":0.0012994399,"threshold_uncertainty_score":0.99970657},"labels":[],"label_agreement":null},{"id":"W3134403963","doi":"10.2217/fon-2020-1269","title":"Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Oncology; Refractory (planetary science); Carfilzomib; Internal medicine; Pomalidomide","score_opus":0.050819269986887,"score_gpt":0.3395705788726691,"score_spread":0.2887513088857821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134403963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944088,0.00025460214,0.00018870113,0.0013416512,0.00024667082,0.0018178455,0.000016628252,0.000040121227,0.0016849855],"genre_scores_gemma":[0.9942689,0.000056104494,0.0040055728,0.00022516944,0.00014254703,0.00024943193,0.00018240945,0.000037810805,0.0008320652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976762,0.00047868316,0.00038043846,0.0005365901,0.00041486748,0.0005131978],"domain_scores_gemma":[0.99880254,0.00038210413,0.00010495365,0.00036309476,0.00015566176,0.0001916246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044944594,0.00023794212,0.00057282107,0.00034670596,0.000065737404,0.000013901847,0.000113635295,0.0002548287,0.00018913565],"category_scores_gemma":[0.00027177672,0.00019208969,0.00004728402,0.00061331387,0.000056192992,0.000077305776,0.00008051984,0.0006279177,0.000052383628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052652573,0.022218524,0.9288791,0.000055422537,0.00021824839,0.014245482,0.0019888857,0.000042076448,0.0029344184,0.000053116488,0.00068273017,0.02341676],"study_design_scores_gemma":[0.056275494,0.005217661,0.9297489,0.000083056344,0.000055345736,0.00027255568,0.0029008547,0.00056630274,0.0007360177,0.000014280929,0.00396691,0.00016262503],"about_ca_topic_score_codex":0.00033762134,"about_ca_topic_score_gemma":0.0072991704,"teacher_disagreement_score":0.05101024,"about_ca_system_score_codex":0.0008829897,"about_ca_system_score_gemma":0.00071223977,"threshold_uncertainty_score":0.783319},"labels":[],"label_agreement":null},{"id":"W3135532585","doi":"10.1002/ijc.33547","title":"Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients","year":2021,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Cancer Council Victoria; National Health and Medical Research Council; Mayo Clinic; Medical Research Council; Canadian Institutes of Health Research; Università di Pisa; Wellcome Trust; VicHealth; Deutsches Krebsforschungszentrum; University of Utah; Utah State University; Huntsman Cancer Institute; Utah Department of Health","keywords":"Multiple myeloma; Quantitative trait locus; Biology; Trait; Gene; Genetics; Survival analysis; Oncology; Outcome (game theory); Expression quantitative trait loci; Internal medicine; Medicine; Immunology; Genotype; Single-nucleotide polymorphism","score_opus":0.05539650152486222,"score_gpt":0.3745659952550232,"score_spread":0.319169493730161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135532585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980579,0.00066974334,0.00024677825,0.00022530927,0.00028501503,0.00009741031,0.00029771897,0.0000036458027,0.000116487485],"genre_scores_gemma":[0.99864346,0.000101117046,0.0009743074,0.000023320026,0.00008686123,0.0000044932785,0.000050079947,0.00001349237,0.00010289978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794835,0.00008080718,0.0005451416,0.00010699231,0.0011949477,0.00012377172],"domain_scores_gemma":[0.9953057,0.00027673537,0.0008829164,0.000071655464,0.003365535,0.00009746433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015931633,0.000098466684,0.00037202216,0.00013533646,0.000022298796,0.000008800225,0.0001223061,0.000045846067,0.00016236707],"category_scores_gemma":[0.0010932136,0.00006854697,0.00013823064,0.00011351707,0.000060295995,0.00012836885,0.000038658924,0.00014880598,4.4418707e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020846925,0.0006020815,0.97595376,0.000039665072,0.0015271326,0.00018990893,0.00029044916,0.00019188409,0.014466049,0.000009136277,0.00004510169,0.004600127],"study_design_scores_gemma":[0.007872379,0.0004157235,0.9221871,0.0010756074,0.0000933335,0.000011417945,0.00042524992,0.00031633623,0.06747377,0.000014257333,0.000064426735,0.00005043418],"about_ca_topic_score_codex":0.00008423454,"about_ca_topic_score_gemma":0.00024190599,"teacher_disagreement_score":0.05376671,"about_ca_system_score_codex":0.0001806438,"about_ca_system_score_gemma":0.00025862863,"threshold_uncertainty_score":0.27952644},"labels":[],"label_agreement":null},{"id":"W3135629194","doi":"10.1038/s41408-021-00440-4","title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Mayo Clinic","keywords":"Immune system; Immunology; Multiple myeloma; Immunosurveillance; Tumor microenvironment; Immunotherapy; Cancer research; Biology; Immunosuppression; Stem cell; Medicine; Cell biology","score_opus":0.012191571370281424,"score_gpt":0.2555898192621097,"score_spread":0.2433982478918283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135629194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751148,0.02385271,0.000042669715,0.00039912845,0.00012096394,0.00021917891,0.000154337,0.000010692664,0.00008550807],"genre_scores_gemma":[0.98721594,0.011359299,0.00070443226,0.000030950334,0.00009306135,0.000024487279,0.0000857273,0.000028007777,0.0004580763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830085,0.000119761695,0.00050874613,0.00026082012,0.0004181954,0.00039163628],"domain_scores_gemma":[0.9989477,0.000118204676,0.00024080717,0.0002516411,0.000114140385,0.00032750162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015956305,0.00020014543,0.0004004584,0.00008038612,0.00016538097,0.00003714647,0.000086793676,0.00008360778,0.0006701334],"category_scores_gemma":[0.00009437727,0.00014923711,0.00014417204,0.00009342269,0.00007985606,0.000076570206,0.00010469471,0.000355958,0.000006551217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029288686,0.0005303116,0.48333603,0.000122285,0.00028022638,0.0009164657,0.000097786055,0.0000017169898,0.50988036,3.6398586e-7,0.000039638424,0.004501917],"study_design_scores_gemma":[0.0077328244,0.00025479897,0.5453913,0.0005469645,0.00020574947,0.0008999454,0.00020657452,0.000065430344,0.44439563,0.000004105393,0.00020880827,0.00008786649],"about_ca_topic_score_codex":0.00018118176,"about_ca_topic_score_gemma":0.00003677315,"teacher_disagreement_score":0.06548475,"about_ca_system_score_codex":0.00007483569,"about_ca_system_score_gemma":0.00025302518,"threshold_uncertainty_score":0.73374903},"labels":[],"label_agreement":null},{"id":"W3136388199","doi":"10.1182/blood.2020008787","title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary; University of Alberta","funders":"","keywords":"Ixazomib; Medicine; Lenalidomide; Hazard ratio; Placebo; Internal medicine; Multiple myeloma; Adverse effect; Clinical endpoint; Surgery; Randomized controlled trial; Confidence interval; Carfilzomib","score_opus":0.021123076286984066,"score_gpt":0.27062624192890355,"score_spread":0.2495031656419195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136388199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970469,0.0006334715,0.0004647876,0.00024051667,0.000035774006,0.001066404,0.0002520036,0.000055078977,0.00020506038],"genre_scores_gemma":[0.9789285,0.00016395886,0.019473778,0.00015167215,0.00007090304,0.00019757789,0.00059082167,0.000044107623,0.00037868344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985001,0.000050995422,0.0002128745,0.00043160457,0.00033169298,0.0004727094],"domain_scores_gemma":[0.9986538,0.00040664192,0.00004855136,0.00028214327,0.00024882847,0.0003599802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009970992,0.00022026949,0.00041411145,0.000086606575,0.000118725366,0.000042241514,0.000057913618,0.000086190164,0.000057772882],"category_scores_gemma":[0.000308391,0.00016284845,0.00008783885,0.00018460504,0.000064344145,0.00009704436,0.000027620295,0.00012057627,0.000012313244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033140334,0.00232666,0.97936463,0.0002143165,0.00062268676,0.00062907825,0.0001527171,0.0000013574146,0.0023202705,0.000018175191,0.00019140243,0.010844654],"study_design_scores_gemma":[0.13989183,0.0012787242,0.78780675,0.00022609126,0.00065310835,0.000100721634,0.00006892713,0.00019707554,0.06816222,0.00003203751,0.0013202298,0.00026229175],"about_ca_topic_score_codex":0.00012245025,"about_ca_topic_score_gemma":0.0003249873,"teacher_disagreement_score":0.19155791,"about_ca_system_score_codex":0.000023164373,"about_ca_system_score_gemma":0.00015905398,"threshold_uncertainty_score":0.6640767},"labels":[],"label_agreement":null},{"id":"W3137319952","doi":"10.1002/ajh.26172","title":"Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Alberta Cancer Foundation; University of Calgary; University of Alberta","funders":"Karyopharm Therapeutics","keywords":"Tolerability; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Carfilzomib; Oncology; Internal medicine; Adverse effect","score_opus":0.023214654556878978,"score_gpt":0.32930533429055875,"score_spread":0.30609067973367976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137319952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967924,0.0018555162,0.000013687668,0.0008959214,0.000013059313,0.0003694946,0.000008116464,0.0000034742734,0.00004835897],"genre_scores_gemma":[0.9985263,0.0005768738,0.0007997329,0.000052315154,0.000011877678,0.0000066338084,0.0000035147966,0.000011336941,0.000011432458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799734,0.0007827668,0.00057089963,0.00021082589,0.00020996493,0.0002281962],"domain_scores_gemma":[0.9951016,0.0039467155,0.00039411994,0.00023104834,0.00014443933,0.00018210622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072111853,0.00016205158,0.001214104,0.00013346074,0.000030456216,0.0000060506723,0.00006305062,0.000055513676,0.000017469729],"category_scores_gemma":[0.0026791054,0.00009487796,0.00007375898,0.0002563318,0.0007810068,0.000033647957,0.000053578726,0.0002915149,3.4085775e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004915869,0.0005040457,0.86431015,0.0002472522,0.0003344104,0.00136004,0.0005490846,0.0000021069945,0.008612954,0.000030765597,0.000022366792,0.119110964],"study_design_scores_gemma":[0.011746477,0.012548207,0.91667163,0.00049832655,0.00019569304,0.0028820455,0.0004514508,0.00034969175,0.054488417,0.00003316982,0.00004167071,0.00009320028],"about_ca_topic_score_codex":0.0002459893,"about_ca_topic_score_gemma":0.00008211922,"teacher_disagreement_score":0.119017765,"about_ca_system_score_codex":0.000028340773,"about_ca_system_score_gemma":0.0001013635,"threshold_uncertainty_score":0.3869011},"labels":[],"label_agreement":null},{"id":"W3138534794","doi":"10.1111/bjh.17338","title":"Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","year":2021,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Hotel Dieu Hospital","funders":"Instituto de Salud Carlos III","keywords":"Medicine; Bortezomib; Multiple myeloma; Lenalidomide; Thalidomide; Regimen; Autologous stem-cell transplantation; Internal medicine; Oncology; Etoposide; Melphalan; Cyclophosphamide; Population; Dexamethasone; Surgery; Chemotherapy","score_opus":0.12401649811821401,"score_gpt":0.4253183885157965,"score_spread":0.3013018903975825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138534794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004858223,0.99643123,0.000020072031,0.001086645,0.00016836902,0.0014765419,0.00016414517,0.000012844991,0.00015431587],"genre_scores_gemma":[0.0007932255,0.99513525,0.0027731718,0.00036174105,0.000128211,0.0003332378,0.00036172973,0.000053684773,0.0000597743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633473,0.00084992195,0.0015096425,0.00045606686,0.00043260946,0.00041700914],"domain_scores_gemma":[0.99681395,0.0013214701,0.00061629957,0.00030845706,0.00030467397,0.0006351327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003107299,0.00043626383,0.0040077176,0.00038162307,0.0001495867,0.0000734603,0.000087239074,0.0002067433,0.00040007464],"category_scores_gemma":[0.0015688757,0.0003709089,0.0005141315,0.0002028997,0.00015547346,0.000091404094,0.00005857335,0.00061207975,0.00002234749],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004059198,0.0010727146,0.00019667427,0.009461509,0.0005657996,0.32021093,0.00001289273,1.4951743e-7,2.0117741e-7,0.00016533447,0.0034600676,0.66481316],"study_design_scores_gemma":[0.004462852,0.00074610277,0.0005530049,0.18956396,0.0013696237,0.38345036,0.000021179641,0.0000045577794,0.0000023881184,0.00011360381,0.4194423,0.0002700649],"about_ca_topic_score_codex":0.000069119786,"about_ca_topic_score_gemma":0.00021211563,"teacher_disagreement_score":0.6645431,"about_ca_system_score_codex":0.0005480591,"about_ca_system_score_gemma":0.0023673584,"threshold_uncertainty_score":0.9998743},"labels":[],"label_agreement":null},{"id":"W3141356097","doi":"10.1016/j.leukres.2021.106576","title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis","year":2021,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Sanofi","keywords":"Pomalidomide; Dexamethasone; Lenalidomide; Refractory (planetary science); Medicine; Internal medicine; Multiple myeloma; Oncology; Materials science","score_opus":0.04205705449643045,"score_gpt":0.34249226574410163,"score_spread":0.3004352112476712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141356097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666727,0.0013507901,0.00003525655,0.00019582456,0.000024033367,0.0013648196,0.00010298051,0.000027461645,0.00023158638],"genre_scores_gemma":[0.993113,0.00091213017,0.004741771,0.000035133293,0.000052470252,0.0001672144,0.00024666416,0.000056994162,0.0006746384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570745,0.00058185676,0.0005524186,0.0009815231,0.0010941754,0.0010825932],"domain_scores_gemma":[0.99593544,0.0014952874,0.00011324107,0.0008167066,0.00079438457,0.00084496354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075756066,0.00035322923,0.001072006,0.0014122338,0.00019095349,0.000085270665,0.00013112037,0.00020913655,0.000058103953],"category_scores_gemma":[0.0020828529,0.00026774663,0.00012108367,0.0023037214,0.0002908281,0.00022806077,0.00032658712,0.00061377126,0.000009863313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00919365,0.00088867475,0.9371414,0.00017883499,0.0012845995,0.0003809171,0.0011540727,0.000039733623,0.007850556,0.000009160494,0.000024571062,0.04185381],"study_design_scores_gemma":[0.029601384,0.0036312663,0.9577522,0.00024515743,0.00031641455,0.0000090945,0.0016292507,0.0013382244,0.00472013,0.000009364609,0.0005168607,0.00023062994],"about_ca_topic_score_codex":0.0065315203,"about_ca_topic_score_gemma":0.0032091453,"teacher_disagreement_score":0.041623183,"about_ca_system_score_codex":0.0034956532,"about_ca_system_score_gemma":0.001787447,"threshold_uncertainty_score":0.99997747},"labels":[],"label_agreement":null},{"id":"W3141971605","doi":"10.4021/jh38w","title":"Do Plasma Cells Affect Hemoglobin and Red Blood Cell Counts in Patients With and Without Myeloma?","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Hemoglobin; Affect (linguistics); Red blood cell; Plasma cell; Immunology; Internal medicine; Psychology; Communication","score_opus":0.010630604557802018,"score_gpt":0.26653245368332024,"score_spread":0.2559018491255182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141971605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781245,0.0008751354,0.0000024160834,0.00006812635,0.000056070152,0.00016588128,0.0000028334255,0.0000027703722,0.0010143322],"genre_scores_gemma":[0.9987014,0.00007943791,0.00106818,0.00002479997,0.000025966801,0.0000017036155,0.0000016319709,0.00000999918,0.0000868829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992994,0.00004795357,0.00017631802,0.00007790406,0.00017636073,0.00022207979],"domain_scores_gemma":[0.999497,0.000056616744,0.000114017574,0.00007526392,0.000057686066,0.0001993914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014104514,0.00009003792,0.00032146784,0.00013035232,0.000018782917,0.000006728332,0.000028569388,0.00006291284,0.000045397945],"category_scores_gemma":[0.00003227639,0.0000571683,0.000019463121,0.000054320713,0.000054486747,0.00007181995,0.000019813056,0.0001581476,0.000010035749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077106326,0.0004190199,0.99698687,0.000083380735,0.000078842895,0.00013182628,0.00008370995,7.445518e-8,0.00035774504,0.000015049123,0.0003555973,0.00071682123],"study_design_scores_gemma":[0.016228156,0.0013762321,0.96939886,0.00015596802,0.0001197311,0.0018464853,0.000042245592,0.000012074852,0.010252914,0.00001576478,0.00047009595,0.000081490616],"about_ca_topic_score_codex":0.0000027761832,"about_ca_topic_score_gemma":0.0000021935189,"teacher_disagreement_score":0.027588028,"about_ca_system_score_codex":0.000020073447,"about_ca_system_score_gemma":0.000037612117,"threshold_uncertainty_score":0.23312557},"labels":[],"label_agreement":null},{"id":"W3143050484","doi":"10.4021/jmc1470w","title":"A Multiple Myeloma Patient Presenting with Multiple Hepatic Masses","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasmacytoma; Plasma cell neoplasm; Multiple myeloma; Common bile duct; Plasma cell; Porta hepatis; Radiology; Pathology; Biopsy; Jaundice; Common hepatic duct; Left Hepatic Duct; Internal medicine","score_opus":0.030436060364253743,"score_gpt":0.30921792270410864,"score_spread":0.2787818623398549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143050484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423134,0.000638863,0.00022173714,0.0040505715,0.000104886225,0.0004977406,0.000005354178,0.000022654485,0.00022687201],"genre_scores_gemma":[0.99406713,0.00017452886,0.0048629665,0.0003563694,0.00032316506,0.000035172357,0.000008326133,0.000027500608,0.00014485852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612796,0.00012546263,0.000617245,0.00017715545,0.0024994728,0.00045268456],"domain_scores_gemma":[0.99649394,0.0013315323,0.00030985803,0.00022214817,0.0005051809,0.0011373687],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031709776,0.00019447306,0.0005034693,0.00020191722,0.00009819134,0.000059615053,0.00017402194,0.00011206625,0.0015976143],"category_scores_gemma":[0.0057972283,0.0001092509,0.0001674385,0.00019300077,0.00015199676,0.00023822446,0.0000868424,0.0004963096,0.00007612073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007296382,0.0010622042,0.9259891,0.00020493333,0.00039800085,0.0126043195,0.00022065072,0.000004987647,0.00050545734,0.0000026996258,0.007144529,0.051133472],"study_design_scores_gemma":[0.021926105,0.008564576,0.89097995,0.0021172736,0.00033631365,0.030546917,0.0020686488,0.018300137,0.011062554,0.00005715707,0.013632172,0.00040822456],"about_ca_topic_score_codex":0.000650244,"about_ca_topic_score_gemma":0.00010234151,"teacher_disagreement_score":0.050725248,"about_ca_system_score_codex":0.000093381626,"about_ca_system_score_gemma":0.00042653608,"threshold_uncertainty_score":0.9993151},"labels":[],"label_agreement":null},{"id":"W3143896911","doi":"10.14740/jmc1979w","title":"Mania in a Patient With Multiple Myeloma After Using Bortezomib","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Regimen; Mania; Thalidomide; Dexamethasone; Internal medicine; Adverse effect; Carfilzomib; Proteasome inhibitor; Oncology; Vincristine; Autologous stem-cell transplantation; Lenalidomide; Surgery; Gastroenterology; Chemotherapy; Cyclophosphamide; Bipolar disorder","score_opus":0.028156310400136518,"score_gpt":0.31785850544863403,"score_spread":0.28970219504849754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143896911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761695,0.00040737135,0.00034347022,0.0013107158,0.000064099666,0.00014512343,0.0000028338952,0.000005148186,0.0001042872],"genre_scores_gemma":[0.99647933,0.000055397377,0.002697469,0.0004901066,0.00023804349,0.0000054350944,0.000001873889,0.000015127415,0.000017204298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761087,0.00010351015,0.0004084454,0.00011697093,0.0014832562,0.0002769751],"domain_scores_gemma":[0.99866885,0.00030810706,0.00013708601,0.00013241947,0.00013850832,0.0006150055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043353863,0.000118686374,0.0003560714,0.00020807431,0.000026074662,0.000015247963,0.00007918965,0.000086907836,0.00041026162],"category_scores_gemma":[0.0013441049,0.00006840534,0.0000832516,0.00013900766,0.00008439419,0.00008199071,0.000037280905,0.0003750519,0.000008423159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071652774,0.001129186,0.78173256,0.00014040065,0.0001724369,0.103320256,0.00025958286,0.000012092949,0.00030107386,0.0000067102583,0.00059465435,0.105165765],"study_design_scores_gemma":[0.025844853,0.009020174,0.86070704,0.003391655,0.00019059498,0.07275104,0.000571219,0.014803467,0.0018941112,0.00003356221,0.010524715,0.00026758434],"about_ca_topic_score_codex":0.00019136694,"about_ca_topic_score_gemma":0.00022365357,"teacher_disagreement_score":0.104898185,"about_ca_system_score_codex":0.000120532575,"about_ca_system_score_gemma":0.00029235962,"threshold_uncertainty_score":0.4492077},"labels":[],"label_agreement":null},{"id":"W3146113670","doi":"10.3390/ijms22083840","title":"Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Shriners Hospitals for Children - Canada","funders":"Deutsche Forschungsgemeinschaft; Celgene","keywords":"Bone resorption; Osteoclast; Anabolism; Bone disease; Multiple myeloma; Medicine; Cancer research; Bone remodeling; Chemistry; Internal medicine; Osteoporosis; Receptor","score_opus":0.019134607438967922,"score_gpt":0.3262100709929568,"score_spread":0.30707546355398885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146113670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897108,0.0019347274,0.0027132758,0.005204857,0.00024332758,0.0001133374,0.000024121024,0.0000031514962,0.00005241337],"genre_scores_gemma":[0.99802005,0.00022302079,0.0012485732,0.00026905004,0.000068604466,0.000005079489,0.000014900435,0.0000060279385,0.00014466411],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997718,0.0001122871,0.00046866955,0.0001890268,0.0013499912,0.00016205509],"domain_scores_gemma":[0.99893475,0.0000622993,0.00028645687,0.000101207595,0.00046068654,0.0001546125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005051408,0.00009429013,0.00019332334,0.00017508313,0.000052494655,0.00005204775,0.0001861687,0.00003576355,0.000050626444],"category_scores_gemma":[0.0005038701,0.00006653279,0.00015408685,0.00028333373,0.00015078804,0.00021195928,0.00006802965,0.00015950823,0.0000022488919],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005389142,0.0017349035,0.0010512297,0.000012749957,0.000107637105,0.00058064295,0.000082892155,0.000007504986,0.9783419,0.00019866487,0.00032148618,0.017021505],"study_design_scores_gemma":[0.0058871023,0.00032310962,0.0041002952,0.00031586943,0.000040468152,0.00024434848,0.00012919158,0.00050518254,0.98761433,0.00061908504,0.00016003147,0.00006099892],"about_ca_topic_score_codex":0.00003953339,"about_ca_topic_score_gemma":0.000009269533,"teacher_disagreement_score":0.016960505,"about_ca_system_score_codex":0.00013592935,"about_ca_system_score_gemma":0.0003609713,"threshold_uncertainty_score":0.27131283},"labels":[],"label_agreement":null},{"id":"W3153567302","doi":"10.3390/cancers13081969","title":"Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ontario Genomics; University of British Columbia; University of Manitoba; Jewish General Hospital; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Cancer Research Society","keywords":"Multiple myeloma; Monoclonal gammopathy of undetermined significance; Malignancy; Telomere; Medicine; Chromosome instability; Oncology; Disease; Genome instability; Bone marrow; Internal medicine; Pathology; Monoclonal; Immunology; Biology; Antibody; Chromosome; Monoclonal antibody; Genetics","score_opus":0.01877940194868354,"score_gpt":0.2808491830078113,"score_spread":0.26206978105912776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153567302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407506,0.0023993468,0.00006182883,0.00045258575,0.000080601676,0.0003124692,0.000022414893,0.00003624008,0.0025594388],"genre_scores_gemma":[0.9974933,0.00016469878,0.00082834606,0.0001693508,0.000059339774,0.00008915105,0.00007514365,0.000025455238,0.0010952167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989027,0.00004166935,0.00012324356,0.00031223937,0.00025664677,0.0003634951],"domain_scores_gemma":[0.99928355,0.00010041825,0.000039211754,0.0002682856,0.000099395096,0.00020911888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003786588,0.00014759749,0.00026042774,0.000101218335,0.000057078763,0.000015725991,0.000058851892,0.0000672031,0.00025259404],"category_scores_gemma":[0.00014694419,0.00010702568,0.000050046292,0.00039778632,0.00010337762,0.000040624785,0.000032083768,0.00026440498,0.000032396623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015555151,0.00008146656,0.8972376,0.00017441061,0.00021812304,0.008476696,0.00050462125,0.0019167485,0.004569122,0.000029250741,0.0002495779,0.084986895],"study_design_scores_gemma":[0.018736573,0.0005942742,0.9021682,0.0019515265,0.00009164426,0.0008795307,0.001206326,0.0024965142,0.063479565,0.00012210412,0.007849707,0.00042399907],"about_ca_topic_score_codex":0.00031005344,"about_ca_topic_score_gemma":0.0014818779,"teacher_disagreement_score":0.0845629,"about_ca_system_score_codex":0.00069036696,"about_ca_system_score_gemma":0.0011768672,"threshold_uncertainty_score":0.43643805},"labels":[],"label_agreement":null},{"id":"W3154559926","doi":"10.1186/s13045-021-01071-9","title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cilag; Jazz Pharmaceuticals; Janssen Pharmaceuticals; Celgene; Karyopharm Therapeutics; Gilead Sciences; Bristol-Myers Squibb; Spectrum Pharmaceuticals; Amgen","keywords":"Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Peripheral neuropathy; Adverse effect; Lenalidomide; Proteasome inhibitor; Thalidomide; Hematology; Oncology; Gastroenterology; Surgery; Endocrinology","score_opus":0.025295061423108424,"score_gpt":0.3534062134124607,"score_spread":0.32811115198935226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154559926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9474654,0.00627711,0.000004316137,0.04402304,0.0002735599,0.0014980492,0.00003353384,0.000014948083,0.00041004573],"genre_scores_gemma":[0.94207776,0.0048875837,0.0064619654,0.042254098,0.0014875276,0.0002997958,0.0005115938,0.00027476225,0.001744924],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99438006,0.0020559637,0.001613728,0.0005727087,0.00057399424,0.00080354634],"domain_scores_gemma":[0.99115455,0.0062134997,0.0013881752,0.0004860498,0.0004583648,0.00029938028],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009997818,0.0006313744,0.004348439,0.0011311386,0.000053278658,0.000011172319,0.00021894978,0.0017648421,0.00011821426],"category_scores_gemma":[0.0026704788,0.00043241004,0.00047280433,0.0003895414,0.0003305004,0.00006578541,0.00009906137,0.0025434324,0.000016119138],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019694401,0.0031400113,0.54164386,0.0028126661,0.006673386,0.23806395,0.0003173641,0.0000028955255,0.0024743376,0.000004593547,0.073171206,0.112001345],"study_design_scores_gemma":[0.20699131,0.22441292,0.18067312,0.009183095,0.010342361,0.15382007,0.00016325628,0.0003599979,0.07805308,0.000071552415,0.13454427,0.0013849837],"about_ca_topic_score_codex":0.0001319233,"about_ca_topic_score_gemma":0.00008714064,"teacher_disagreement_score":0.36097074,"about_ca_system_score_codex":0.000723478,"about_ca_system_score_gemma":0.0010120024,"threshold_uncertainty_score":0.9998128},"labels":[],"label_agreement":null},{"id":"W3158259440","doi":"10.1016/s0140-6736(21)00274-9","title":"Multiple myeloma triplet therapies: baseline characteristics and control groups","year":2021,"lang":"en","type":"letter","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Internal medicine; Regimen; Clinical trial; Oncology; Carfilzomib","score_opus":0.041034848780461146,"score_gpt":0.2905877666967366,"score_spread":0.24955291791627543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158259440","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023308158,0.0041584466,0.00025010502,0.9675651,0.00034751784,0.0013639617,0.0022159708,0.00012605455,0.00066468446],"genre_scores_gemma":[0.23409228,0.002660797,0.0004894876,0.73051625,0.021717235,0.0002372753,0.004609084,0.00012570427,0.005551902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974589,0.00042677586,0.0003569951,0.0004810705,0.0005574071,0.00071888656],"domain_scores_gemma":[0.9972387,0.0011575957,0.00016400676,0.0011169116,0.00018225088,0.00014053153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049722794,0.00041284604,0.0013856171,0.000086786255,0.00016225099,0.00012755104,0.0002778336,0.00039605744,0.0004759566],"category_scores_gemma":[0.00082439766,0.00024428195,0.00017387998,0.00013004393,0.00019772824,0.00004194103,0.00009148518,0.0016934046,0.000090051195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011730752,0.00009382775,0.028219055,0.000561835,0.0012389198,0.0036786173,0.00021189246,4.6493966e-8,0.0005292249,0.000008727682,0.9500748,0.014209999],"study_design_scores_gemma":[0.011974989,0.00020626406,0.073454686,0.00028912263,0.00032022246,0.00026442434,0.00003598835,0.0006313612,0.00006808015,0.00004484324,0.9124567,0.00025334925],"about_ca_topic_score_codex":0.00006271915,"about_ca_topic_score_gemma":0.000015600557,"teacher_disagreement_score":0.23704886,"about_ca_system_score_codex":0.00007292239,"about_ca_system_score_gemma":0.00012981595,"threshold_uncertainty_score":0.9961529},"labels":[],"label_agreement":null},{"id":"W3158356424","doi":"10.1016/j.clml.2021.04.013","title":"Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Institute of Cancer Research; Cancer Research UK; Myeloma UK; National Cancer Research Institute; Celgene; University of Leeds; National Institute for Health and Care Research; Melanoma Research Alliance; Amgen; University of Birmingham; Cancer Research Institute","keywords":"Multiple myeloma; Dyscrasia; Lenalidomide; Incidence (geometry); Internal medicine; Disease; Cancer; Medicine; Oncology; Clinical trial; Plasma cell dyscrasia; Immunology; Plasma cell","score_opus":0.11725789145464567,"score_gpt":0.3878514811505375,"score_spread":0.27059358969589187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158356424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908182,0.00021374175,0.000014616779,0.0020462638,0.0019260253,0.002455954,0.0009064908,0.0001351403,0.0014835864],"genre_scores_gemma":[0.99023926,0.0005807599,0.0010614484,0.0032595994,0.0013445016,0.00033344372,0.0021457153,0.00009556273,0.00093973445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9841821,0.0044760327,0.005523608,0.002622364,0.001428898,0.001766968],"domain_scores_gemma":[0.9709875,0.024241727,0.00085266633,0.0025292425,0.0004163885,0.0009725033],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003977279,0.0009728278,0.0032794364,0.00037764042,0.00027657003,0.0001625264,0.0012647784,0.0015410297,0.00020257973],"category_scores_gemma":[0.034803845,0.0006582863,0.0013629089,0.0010528322,0.0011530627,0.00024383377,0.0006948339,0.0016805287,0.00063492445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039547086,0.0034269406,0.68225485,0.000020300906,0.00038140945,0.001970397,0.00026226742,5.416754e-7,0.00003650388,0.00004297067,0.00070996,0.27134678],"study_design_scores_gemma":[0.19529606,0.0022118594,0.7980563,0.0001946929,0.00013080965,0.000024192137,0.0004087301,0.00064317085,0.00019986129,0.00036762093,0.0019487615,0.0005179556],"about_ca_topic_score_codex":0.0038379286,"about_ca_topic_score_gemma":0.0032197724,"teacher_disagreement_score":0.2708288,"about_ca_system_score_codex":0.0010150113,"about_ca_system_score_gemma":0.0027107238,"threshold_uncertainty_score":0.9997552},"labels":[],"label_agreement":null},{"id":"W3161580798","doi":"10.1016/j.clml.2021.05.002","title":"Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Institute of Aging; Juravinski Cancer Centre","funders":"Takeda Canada; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Janssen Pharmaceuticals; Celgene; Sanofi; Roche; Amgen","keywords":"Medicine; Multiple myeloma; Population; Cohort; Internal medicine; Odds ratio; Environmental health","score_opus":0.02771372705732486,"score_gpt":0.3153239903634349,"score_spread":0.28761026330611006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161580798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995666,0.00010242363,0.000051320007,0.00002528141,0.0003119635,0.0035279521,0.00015092635,0.00007152239,0.00009256115],"genre_scores_gemma":[0.9980767,0.000013461268,0.0006780428,0.000079330086,0.000029301005,0.00029502512,0.0006642961,0.00007447059,0.000089396235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940194,0.0005020176,0.0028776636,0.00096516486,0.0009852763,0.0006505078],"domain_scores_gemma":[0.99364895,0.0035966786,0.0008594131,0.0009414033,0.0005677082,0.00038585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056616246,0.00045092162,0.0018897477,0.0003242834,0.00010073034,0.000014834325,0.0002076196,0.00037279777,0.000029854564],"category_scores_gemma":[0.0010235385,0.00039187775,0.00063317356,0.0005073211,0.00013352171,0.00009680994,0.000067999186,0.00022844312,0.000004999182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034720344,0.008238063,0.9094995,0.0004394235,0.000812233,0.00039327255,0.000310362,0.00016764272,0.00010414178,0.000004375472,0.000014249285,0.076544695],"study_design_scores_gemma":[0.04951668,0.004227237,0.9406328,0.0002973447,0.00048619378,0.000009037233,0.00032272414,0.0022736015,0.0019263262,0.000011085425,0.000009218462,0.00028775018],"about_ca_topic_score_codex":0.0006946363,"about_ca_topic_score_gemma":0.00080774806,"teacher_disagreement_score":0.076256946,"about_ca_system_score_codex":0.0008972327,"about_ca_system_score_gemma":0.0019665454,"threshold_uncertainty_score":0.9998533},"labels":[],"label_agreement":null},{"id":"W3162491641","doi":"10.14740/wjon1384","title":"Pulmonary Vein Thrombosis in a Patient With Multiple Myeloma on Treatment With Lenalidomide","year":2021,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Lenalidomide; Pulmonary embolism; Radiology; Thrombosis; Multiple myeloma; Venous thrombosis; Dexamethasone; Deep vein; Surgery; Internal medicine","score_opus":0.036316949114161605,"score_gpt":0.3284735684193207,"score_spread":0.29215661930515907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162491641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845948,0.00054800196,0.0000154431,0.0038806645,0.00007066031,0.00034324877,0.0000070080896,0.0000077846,0.010532349],"genre_scores_gemma":[0.9945814,0.0003121946,0.0037548495,0.0003664454,0.000100146404,0.000036261095,0.0000132784,0.000025567559,0.0008098336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983057,0.0002151002,0.00042645386,0.00023328554,0.00043999476,0.00037948947],"domain_scores_gemma":[0.9985657,0.00040154834,0.00024665333,0.00022696896,0.00025290647,0.00030624607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013808589,0.0002131373,0.00072150526,0.00041891346,0.00005246722,0.000012772915,0.000064583925,0.00005875364,0.00021896075],"category_scores_gemma":[0.00007232635,0.000117557276,0.00011873986,0.00045072963,0.000091513306,0.000073619485,0.00002407862,0.0003362884,0.000018852656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024423195,0.009053246,0.4896856,0.00003906519,0.001189418,0.16218229,0.0007171377,0.00018558081,0.005078631,0.000034843088,0.00029600709,0.307115],"study_design_scores_gemma":[0.05442353,0.08279958,0.73393196,0.0013253494,0.00045071595,0.02881119,0.0014160943,0.0002895571,0.028419452,0.000052420095,0.06773054,0.0003495831],"about_ca_topic_score_codex":0.00010523102,"about_ca_topic_score_gemma":0.0027492184,"teacher_disagreement_score":0.3067654,"about_ca_system_score_codex":0.0012779072,"about_ca_system_score_gemma":0.0010425682,"threshold_uncertainty_score":0.47938466},"labels":[],"label_agreement":null},{"id":"W3164363592","doi":"10.3390/curroncol28030188","title":"Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Multiple myeloma; Hazard ratio; Internal medicine; Retrospective cohort study; Proportional hazards model; Cohort; Population; Risk stratification; Gastroenterology; Oncology; Confidence interval","score_opus":0.1470503368057117,"score_gpt":0.42715540387107803,"score_spread":0.2801050670653663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164363592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267256,0.00057784456,0.00020330517,0.00011760464,0.00033024914,0.001466129,0.00007574386,0.000039731684,0.0045168],"genre_scores_gemma":[0.9966507,0.000100219564,0.00212466,0.00003603544,0.0001316955,0.00011746653,0.00009233442,0.00003893799,0.000707972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997389,0.00031150816,0.00068709254,0.00063010055,0.0004641205,0.0005181447],"domain_scores_gemma":[0.998264,0.0002951866,0.0002856079,0.00045109785,0.00046949566,0.000234592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004239349,0.00024380497,0.0008269913,0.00020986653,0.00006623118,0.000010771294,0.00013113064,0.00013489895,0.00024268034],"category_scores_gemma":[0.0019756625,0.0002185001,0.00011853559,0.00052149076,0.00008911519,0.00007849912,0.0002140021,0.00059594616,0.000042364096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004404826,0.005876303,0.9235843,0.00005627879,0.0002496628,0.00020526527,0.0010464112,0.000056192086,0.00021239361,0.0000048134657,0.00066609506,0.06760179],"study_design_scores_gemma":[0.013353543,0.0025204108,0.9757393,0.00018990063,0.00018850272,0.0000103749335,0.0004276746,0.0064281533,0.00015139388,0.0002084616,0.000625244,0.00015702561],"about_ca_topic_score_codex":0.0002819071,"about_ca_topic_score_gemma":0.00095241255,"teacher_disagreement_score":0.06744477,"about_ca_system_score_codex":0.0007402083,"about_ca_system_score_gemma":0.0009361255,"threshold_uncertainty_score":0.89101756},"labels":[],"label_agreement":null},{"id":"W3165234271","doi":"10.1111/bjh.17541","title":"Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Amgen","keywords":"Lenalidomide; Daratumumab; Carfilzomib; Medicine; Multiple myeloma; Bortezomib; Oncology; Internal medicine; Dexamethasone; Proteasome inhibitor; Ixazomib","score_opus":0.039036589010301034,"score_gpt":0.33193391277954026,"score_spread":0.2928973237692392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165234271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603329,0.022710253,0.0000028205736,0.014806256,0.00030325569,0.0014005848,0.0004033336,0.0000055691035,0.000035086283],"genre_scores_gemma":[0.98959315,0.0051633473,0.00042116997,0.0034530957,0.0003055373,0.000040081897,0.00012805172,0.00006687974,0.0008287138],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951295,0.0011786821,0.0019657756,0.0004370962,0.0008218101,0.00046712518],"domain_scores_gemma":[0.9955363,0.0013797339,0.001659673,0.00050256704,0.00076753896,0.00015417427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081532245,0.00034934506,0.0026028755,0.00034905548,0.00009118201,0.000025362688,0.00036116698,0.0005843626,0.0000616063],"category_scores_gemma":[0.0029614286,0.00024328295,0.00028948832,0.00037429002,0.00043098113,0.00007177692,0.00013141315,0.002250977,4.152996e-7],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047303036,0.009468746,0.023058176,0.0011615963,0.003698523,0.4254831,0.0017923099,0.0000011288824,0.0054116785,3.2734206e-7,0.40869537,0.07392598],"study_design_scores_gemma":[0.5735141,0.016860403,0.045666877,0.009343752,0.0011917704,0.2576673,0.0024692726,0.00006616149,0.018244436,0.00001962395,0.074151136,0.0008051654],"about_ca_topic_score_codex":0.0025102214,"about_ca_topic_score_gemma":0.0024993003,"teacher_disagreement_score":0.5262111,"about_ca_system_score_codex":0.00011052682,"about_ca_system_score_gemma":0.00094214326,"threshold_uncertainty_score":0.9920791},"labels":[],"label_agreement":null},{"id":"W3165381538","doi":"10.1002/ajh.26261","title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Alberta Cancer Foundation; University of Calgary; University of Alberta","funders":"Karyopharm Therapeutics","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Gastroenterology; Population; Oncology","score_opus":0.017818009130890246,"score_gpt":0.31031762290113085,"score_spread":0.2924996137702406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165381538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984193,0.01374705,0.00019298906,0.0013415406,0.000075847835,0.00033465595,0.000034037173,0.000018222729,0.00006263567],"genre_scores_gemma":[0.9811829,0.006374138,0.012075261,0.0001773847,0.000030271329,0.000018489234,0.00002456016,0.00004365812,0.00007336652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706435,0.0005904759,0.0008677013,0.00045878967,0.00037168484,0.00064702245],"domain_scores_gemma":[0.99632055,0.0018253137,0.00060350785,0.0003413658,0.0002858062,0.00062348763],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004941077,0.00034679993,0.0016679168,0.0003348171,0.00008287324,0.000028345654,0.00011625038,0.00012408782,0.000058179066],"category_scores_gemma":[0.0023631516,0.00027242073,0.00015763514,0.0005034755,0.00056451216,0.000099276884,0.00009964686,0.0005650275,0.0000062964623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002766934,0.0005180883,0.9236912,0.000047299254,0.0008927444,0.0031871893,0.00026171535,0.000002248416,0.0021220397,0.0000087833,0.00021523125,0.0662865],"study_design_scores_gemma":[0.041708723,0.0056099016,0.9244523,0.00021171584,0.0008254822,0.011075004,0.0021991339,0.0006031403,0.011869359,0.00005589396,0.00097106316,0.00041830362],"about_ca_topic_score_codex":0.0006621837,"about_ca_topic_score_gemma":0.000457062,"teacher_disagreement_score":0.06586819,"about_ca_system_score_codex":0.00011811221,"about_ca_system_score_gemma":0.00029494977,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W3165778820","doi":"10.1111/ejh.13671","title":"A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Victoria Hospital; Hôtel-Dieu de Québec; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University of Toronto; Université Laval; University of Alberta; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Regimen; Multiple myeloma; Carfilzomib; Internal medicine; Dexamethasone; Lenalidomide","score_opus":0.12795554083561045,"score_gpt":0.42214811278364356,"score_spread":0.2941925719480331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165778820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470484,0.0037441477,0.00020079785,0.00041044055,0.00022544904,0.0005062039,0.00002672342,0.000008554976,0.00017282802],"genre_scores_gemma":[0.9896874,0.0009150643,0.009061975,0.0000909983,0.00009596906,0.000006331846,0.00002449195,0.000035252284,0.00008254896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931428,0.0036697385,0.0018992167,0.00043033418,0.00047591524,0.00038199386],"domain_scores_gemma":[0.99550724,0.0020836212,0.0009807877,0.00034265837,0.0006142487,0.0004714548],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038691165,0.00024268797,0.0019398591,0.000680537,0.00006606757,0.000022641489,0.00012676368,0.000103543905,0.00009722214],"category_scores_gemma":[0.010332461,0.0001969872,0.00031862681,0.000707122,0.00036703114,0.00010311443,0.00015368321,0.00075162726,0.0000050053886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24971129,0.005821688,0.4396066,0.00022977288,0.010747606,0.11731894,0.0026659516,0.00004123279,0.012063703,0.00006959752,0.00027184613,0.16145176],"study_design_scores_gemma":[0.36474222,0.014278094,0.6052328,0.00045636823,0.0036790424,0.004665073,0.0015114126,0.0033599054,0.0014904991,0.000041852716,0.00029010195,0.00025268036],"about_ca_topic_score_codex":0.000053858614,"about_ca_topic_score_gemma":0.000090461224,"teacher_disagreement_score":0.16562615,"about_ca_system_score_codex":0.0000838398,"about_ca_system_score_gemma":0.00042616946,"threshold_uncertainty_score":0.9980039},"labels":[],"label_agreement":null},{"id":"W3166150115","doi":"10.1200/jco.2021.39.15_suppl.8038","title":"Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Dalhousie University; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba","funders":"Karyopharm Therapeutics","keywords":"Carfilzomib; Medicine; Regimen; Dexamethasone; Bortezomib; Pharmacology; Internal medicine; Refractory (planetary science); Oncology; Multiple myeloma; Cancer research; Biology","score_opus":0.13274553903255915,"score_gpt":0.4615143807599671,"score_spread":0.32876884172740795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166150115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916672,0.0019363791,0.00005495115,0.003657397,0.0007769444,0.00029871287,0.000024478,0.00001055997,0.0015733913],"genre_scores_gemma":[0.9811821,0.0020858794,0.013891842,0.0014314062,0.0007278405,0.000008797193,0.000028507015,0.000031449294,0.00061216776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99479896,0.0010889348,0.0024985136,0.00041852563,0.00067839824,0.00051669584],"domain_scores_gemma":[0.9908957,0.0055993637,0.0010751126,0.0003202211,0.0011509694,0.00095867406],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025963392,0.00024530813,0.001964506,0.00023378713,0.000058576756,0.000020066946,0.00016468341,0.000527501,0.00020967999],"category_scores_gemma":[0.021931818,0.00018518677,0.00041551184,0.00031218532,0.00027245493,0.00020545613,0.00016869589,0.0017252348,0.000032242013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043353327,0.0032692992,0.7413558,0.000048456684,0.0003457621,0.0046277875,0.000119639575,0.000007996944,0.0005763941,0.000007743778,0.0012442764,0.24406154],"study_design_scores_gemma":[0.03492581,0.00616327,0.9218796,0.00017268845,0.0001770206,0.00036955712,0.00026759438,0.00041739523,0.00046853343,0.0000593714,0.03494815,0.00015102369],"about_ca_topic_score_codex":0.00015368099,"about_ca_topic_score_gemma":0.0006963051,"teacher_disagreement_score":0.24391052,"about_ca_system_score_codex":0.000363271,"about_ca_system_score_gemma":0.0025642135,"threshold_uncertainty_score":0.98630685},"labels":[],"label_agreement":null},{"id":"W3166204225","doi":"10.1200/jco.21.00972","title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Ixazomib; Lenalidomide; Medicine; Placebo; Hazard ratio; Internal medicine; Multiple myeloma; Population; Surgery; Gastroenterology; Oncology; Confidence interval; Pathology; Carfilzomib","score_opus":0.14823605115153535,"score_gpt":0.462971200887676,"score_spread":0.3147351497361407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166204225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981609,0.00014001221,0.000044573284,0.00072620634,0.00033564423,0.00041767018,0.000035074496,0.0000020256448,0.00013788861],"genre_scores_gemma":[0.99688953,0.00029689152,0.0022188344,0.00015681345,0.00019068124,0.0000042010543,0.000018194734,0.000013004103,0.00021182871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944776,0.0014339517,0.0027367272,0.00024817677,0.0008426626,0.00026083997],"domain_scores_gemma":[0.98967916,0.006441834,0.0022414003,0.00035370202,0.0009557259,0.00032815433],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00292947,0.00016728512,0.0025329334,0.00030788605,0.000032546875,0.0000064656333,0.00016427267,0.00028528518,0.00020216979],"category_scores_gemma":[0.014915794,0.00008698896,0.0006206932,0.0006436207,0.00032769403,0.0001147451,0.000104184925,0.00085856445,4.6945115e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44135475,0.009230348,0.5186693,0.000025568965,0.0029222053,0.00047425507,0.00006246507,0.000027118658,0.00018183097,0.0000054003567,0.00006720159,0.02697953],"study_design_scores_gemma":[0.36201298,0.018283915,0.61704856,0.00009320774,0.0014918505,0.000013878384,0.000057180514,0.0003131523,0.00020917463,0.000008931021,0.00041360105,0.000053572316],"about_ca_topic_score_codex":0.00012811767,"about_ca_topic_score_gemma":0.00090786093,"teacher_disagreement_score":0.09837925,"about_ca_system_score_codex":0.00012582324,"about_ca_system_score_gemma":0.0021612337,"threshold_uncertainty_score":0.993382},"labels":[],"label_agreement":null},{"id":"W3167608264","doi":"10.1200/jco.2021.39.15_suppl.8011","title":"Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Carfilzomib; Minimal residual disease; Lenalidomide; Dexamethasone; Oncology; Internal medicine; Multiple myeloma; Autologous stem-cell transplantation; Interim analysis; Clinical endpoint; Phases of clinical research; Chemotherapy; Clinical trial; Bone marrow","score_opus":0.2087677462614769,"score_gpt":0.5099627723187464,"score_spread":0.30119502605726955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167608264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471503,0.0012019896,0.0008001952,0.0016437834,0.00035953353,0.00083713565,0.0003051087,0.000006139051,0.00013107705],"genre_scores_gemma":[0.9813506,0.00084342225,0.016652502,0.00022342023,0.00063772214,0.000040141473,0.000072041425,0.00002703658,0.0001530935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99360317,0.0011934697,0.0036368738,0.0004402748,0.0007112582,0.00041497042],"domain_scores_gemma":[0.9782372,0.016065378,0.0025136876,0.00039066348,0.0016909211,0.001102156],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0030453622,0.00026323347,0.003729413,0.0005555825,0.00005435766,0.000013655264,0.00020025858,0.00034425803,0.00017374686],"category_scores_gemma":[0.040665735,0.00019834176,0.0016320249,0.0005767398,0.00058339763,0.00014115259,0.0001485272,0.0006028387,0.0000013196125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7772789,0.013217377,0.04713023,0.00013489297,0.012959293,0.0032847456,0.00021319145,0.000025985966,0.0023793506,0.000046976787,0.0007134347,0.14261565],"study_design_scores_gemma":[0.575037,0.076985694,0.32130787,0.00025995547,0.0139548145,0.00008618522,0.0007520597,0.0045920955,0.0039793113,0.00016173709,0.0026572733,0.00022598155],"about_ca_topic_score_codex":0.000108367036,"about_ca_topic_score_gemma":0.0003607871,"teacher_disagreement_score":0.27417764,"about_ca_system_score_codex":0.00017112953,"about_ca_system_score_gemma":0.0038391212,"threshold_uncertainty_score":0.96741515},"labels":[],"label_agreement":null},{"id":"W3168041049","doi":"10.1200/jco.2021.39.15_suppl.8033","title":"Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Ophthalmology; Common Terminology Criteria for Adverse Events; Visual acuity; Adverse effect; Internal medicine","score_opus":0.1078112055969082,"score_gpt":0.4274042842452491,"score_spread":0.3195930786483409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168041049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979922,0.00020148327,0.000054421555,0.00061753055,0.0003722944,0.00049570395,0.0000225534,0.000018764102,0.00022504675],"genre_scores_gemma":[0.9955232,0.00014492533,0.003131628,0.0002047418,0.0003984409,0.00000905959,0.00011082233,0.00004385901,0.00043329506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943036,0.0014654541,0.0023462342,0.00048663456,0.00084312214,0.00055497524],"domain_scores_gemma":[0.9848486,0.011983999,0.001140056,0.00028901288,0.0009174589,0.0008208257],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024862865,0.0002921837,0.0018117436,0.00032927314,0.00014367363,0.00003229078,0.00016067772,0.0007070774,0.00014422389],"category_scores_gemma":[0.030055191,0.0001994952,0.00022001025,0.0005969752,0.00026824558,0.00028243935,0.0001455178,0.0023782789,0.000024078325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01441171,0.0030490602,0.90869856,0.000054426273,0.00048208062,0.003154547,0.0001208293,0.0000021951728,0.000028931947,0.0000035187634,0.00018017217,0.069813944],"study_design_scores_gemma":[0.042698544,0.018575525,0.9361685,0.0004750052,0.00044339974,0.0002616157,0.00012612794,0.00009536437,0.00007470608,0.000023361063,0.00087441487,0.0001834193],"about_ca_topic_score_codex":0.000060673676,"about_ca_topic_score_gemma":0.00041019788,"teacher_disagreement_score":0.069630526,"about_ca_system_score_codex":0.0004856483,"about_ca_system_score_gemma":0.0025410154,"threshold_uncertainty_score":0.9999233},"labels":[],"label_agreement":null},{"id":"W3168326299","doi":"10.1038/s41408-021-00507-2","title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; bluebird bio; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Surgery","score_opus":0.036563343465977595,"score_gpt":0.3583077447515886,"score_spread":0.321744401285611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168326299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936924,0.0042434167,0.00000852203,0.00077435124,0.00008255966,0.00021988947,0.000024382725,0.000014069175,0.0009403945],"genre_scores_gemma":[0.99477863,0.0016589296,0.0020991727,0.00008966745,0.000100281635,0.000024322042,0.000010511892,0.0000303965,0.001208088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814993,0.00012084565,0.00050896924,0.00026802073,0.00056740054,0.00038481786],"domain_scores_gemma":[0.99871224,0.00018100586,0.00022943971,0.00025697352,0.00025141754,0.00036891422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021158783,0.00019372084,0.00067175337,0.00025602127,0.00009736461,0.00003143166,0.00008159413,0.00006583794,0.00022129131],"category_scores_gemma":[0.00014429084,0.00013953331,0.000085221145,0.0003510096,0.000089191075,0.000092414404,0.0000517582,0.0005275256,0.0000028511074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010551172,0.0011495367,0.96326804,0.00009685605,0.0006124,0.001561552,0.00047205872,0.0000257563,0.017528096,0.000007221895,0.00016288062,0.014060508],"study_design_scores_gemma":[0.017686306,0.0005745741,0.93548083,0.00045585932,0.00021062752,0.00027119162,0.00043550486,0.00018188165,0.04403504,0.000015433647,0.0005212486,0.0001314877],"about_ca_topic_score_codex":0.00095676346,"about_ca_topic_score_gemma":0.008316752,"teacher_disagreement_score":0.027787171,"about_ca_system_score_codex":0.00015236049,"about_ca_system_score_gemma":0.00060495164,"threshold_uncertainty_score":0.5690003},"labels":[],"label_agreement":null},{"id":"W3168451900","doi":"10.3390/cimb43010026","title":"Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism","year":2021,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Viability assay; Trypan blue; Cell culture; In vitro; 3D cell culture; Staining; Bone marrow; Cell growth; Molecular biology; Biology; Chemistry; Immunology; Medicine; Pathology; Biochemistry","score_opus":0.027092150576085442,"score_gpt":0.3630246285741934,"score_spread":0.33593247799810794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168451900","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041491077,0.9910916,0.00041923788,0.00007213564,0.00060333294,0.0031581363,0.0004516437,0.000024214709,0.00003059803],"genre_scores_gemma":[0.0014647596,0.98870337,0.005853951,0.00002825489,0.00010004601,0.00043812193,0.0032667797,0.00006908914,0.00007564098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953813,0.0010860983,0.0012883216,0.0010635172,0.00046289063,0.00071786187],"domain_scores_gemma":[0.99781007,0.00025122103,0.00046948012,0.0010611726,0.00022147321,0.00018657114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006936518,0.0006774118,0.0030496977,0.0003943023,0.00004732936,0.00001671597,0.00040612565,0.0006432941,0.00013093911],"category_scores_gemma":[0.00027797304,0.0004282357,0.000668505,0.0005579075,0.0003806789,0.000030874453,0.0005506557,0.0013156034,0.000024369285],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024967964,0.00088293536,0.0001236253,0.010678034,0.00052961026,0.0007901024,0.000057311783,3.9855138e-7,0.056547027,0.00022678086,0.00006652168,0.92984796],"study_design_scores_gemma":[0.02065041,0.0036312456,0.00075434597,0.047720592,0.0048511527,0.0031068574,0.00017166689,0.0005891695,0.11322416,0.016051142,0.7850853,0.0041639414],"about_ca_topic_score_codex":0.00018835012,"about_ca_topic_score_gemma":0.000060464597,"teacher_disagreement_score":0.92568403,"about_ca_system_score_codex":0.000462027,"about_ca_system_score_gemma":0.0007777465,"threshold_uncertainty_score":0.99981695},"labels":[],"label_agreement":null},{"id":"W3168673883","doi":"10.1200/jco.2021.39.15_suppl.e20020","title":"Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of British Columbia; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Karyopharm Therapeutics","keywords":"Daratumumab; Medicine; Pomalidomide; Carfilzomib; Lenalidomide; Bortezomib; Refractory (planetary science); Internal medicine; Regimen; Multiple myeloma; Population; Dexamethasone; Oncology; Gastroenterology; Pharmacology; Biology","score_opus":0.07674062404312741,"score_gpt":0.41199405177640797,"score_spread":0.33525342773328054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168673883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962288,0.00038950887,0.000043966815,0.0019878228,0.00013496805,0.0005052838,0.000013867129,0.00001684227,0.0006789367],"genre_scores_gemma":[0.9874304,0.00039541794,0.010892461,0.0005445713,0.0002891819,0.000009532572,0.000059298935,0.000037741716,0.0003413735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568874,0.00064673915,0.0019407066,0.00040123853,0.00075062725,0.0005719716],"domain_scores_gemma":[0.99422324,0.0020501183,0.0011983631,0.0003143041,0.0015563702,0.0006575984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013245636,0.0002792548,0.0020525858,0.00023114737,0.0000728591,0.000022977856,0.0001492769,0.00030676523,0.00011267306],"category_scores_gemma":[0.0035049596,0.00016551602,0.0002826245,0.0003491144,0.00027593007,0.00019430477,0.000072762734,0.0011124666,0.00001804235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02510832,0.004563085,0.93338054,0.000044112734,0.001100503,0.010276398,0.00010125675,0.000032423177,0.00008141634,0.000007477849,0.00033867973,0.024965798],"study_design_scores_gemma":[0.05464182,0.02382001,0.9169223,0.0005145796,0.00031394506,0.0005435205,0.00018289959,0.00020813377,0.00030010892,0.00000944588,0.0023868906,0.00015636104],"about_ca_topic_score_codex":0.00006550204,"about_ca_topic_score_gemma":0.0003584121,"teacher_disagreement_score":0.0295335,"about_ca_system_score_codex":0.0002641353,"about_ca_system_score_gemma":0.0024860674,"threshold_uncertainty_score":0.6749547},"labels":[],"label_agreement":null},{"id":"W3168849811","doi":"10.1111/bjh.17448","title":"Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Merck","keywords":"Carfilzomib; Medicine; Pembrolizumab; Dexamethasone; Daratumumab; Multiple myeloma; Cohort; Oncology; Refractory (planetary science); Lenalidomide; Internal medicine; Cancer; Immunotherapy; Materials science","score_opus":0.030762873772526903,"score_gpt":0.31395151268870836,"score_spread":0.28318863891618146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168849811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765977,0.0034620552,0.00006618955,0.015991561,0.00043955498,0.0031024304,0.00029413402,0.000015735674,0.000030587158],"genre_scores_gemma":[0.98706484,0.0008159484,0.0017776102,0.0078604175,0.0005912812,0.0002088027,0.00024637277,0.00016254303,0.0012722146],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99573165,0.0007764337,0.0012908772,0.00055302813,0.0009836562,0.0006643376],"domain_scores_gemma":[0.9945433,0.0019792977,0.001296182,0.00061446783,0.001294879,0.0002718343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006031342,0.00045919587,0.0027649684,0.00029966774,0.00020466092,0.000060671442,0.00038581598,0.0006193231,0.00012545905],"category_scores_gemma":[0.0029381812,0.00031042146,0.0004055174,0.00028748915,0.0005312653,0.000113267095,0.00016120727,0.0022451452,0.0000014653468],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050909676,0.0074489894,0.058232352,0.0031235362,0.009287623,0.61068994,0.00044218468,0.0000020817586,0.00045684748,0.0000020260338,0.24532773,0.014077],"study_design_scores_gemma":[0.2621207,0.03364827,0.0816758,0.006509176,0.0049390956,0.5883959,0.0009373393,0.00015859862,0.0014592715,0.00003898035,0.019353695,0.000763164],"about_ca_topic_score_codex":0.0002851253,"about_ca_topic_score_gemma":0.0005678608,"teacher_disagreement_score":0.22597404,"about_ca_system_score_codex":0.00016668465,"about_ca_system_score_gemma":0.0013023448,"threshold_uncertainty_score":0.9999348},"labels":[],"label_agreement":null},{"id":"W3169117957","doi":"10.1016/j.ctarc.2021.100414","title":"Practical management and assessment of primary plasma cell leukemia in the novel agent era","year":2021,"lang":"en","type":"review","venue":"Cancer Treatment and Research Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Plasma cell leukemia; Malignancy; Medicine; Multiple myeloma; Leukemia; Clinical trial; Oncology; Internal medicine","score_opus":0.40737040633907273,"score_gpt":0.5537650122771408,"score_spread":0.14639460593806808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169117957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002715572,0.9785258,0.000006521229,0.0014599224,0.000017372824,0.0031696171,0.00012570423,0.0000074218715,0.016416082],"genre_scores_gemma":[0.00094616215,0.98355335,0.009688688,0.000018325833,0.000028288985,0.0035572604,0.00064379355,0.00002806285,0.0015360386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710226,0.0009665694,0.000461984,0.00041822705,0.0006357256,0.0004152186],"domain_scores_gemma":[0.9960623,0.0017505216,0.00012466157,0.0016941706,0.00016834601,0.00020002833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086478196,0.00028296642,0.0010299807,0.00038820994,0.00031491052,0.00008020649,0.00036372748,0.00014511368,0.000036755926],"category_scores_gemma":[0.000044799548,0.00016292803,0.00017643232,0.00060574606,0.00051116076,0.0000570641,0.0007312514,0.0009770871,0.0000036064469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030539963,0.0022234372,0.00074364984,0.008081502,0.0011768899,0.00016643935,0.0003198403,3.0439455e-7,0.0000033248248,0.0016707338,0.0007123739,0.984871],"study_design_scores_gemma":[0.002842023,0.00042550295,0.0036120156,0.005862879,0.0010352248,0.00007873578,0.0005137069,0.00020494433,0.0000036047618,0.000009585639,0.98527795,0.00013380045],"about_ca_topic_score_codex":0.00094621745,"about_ca_topic_score_gemma":0.00035380773,"teacher_disagreement_score":0.98473716,"about_ca_system_score_codex":0.002898639,"about_ca_system_score_gemma":0.0035830685,"threshold_uncertainty_score":0.75798404},"labels":[],"label_agreement":null},{"id":"W3169299949","doi":"10.1200/jco.2021.39.15_suppl.8034","title":"Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"Sanofi","keywords":"Medicine; Carfilzomib; Regimen; Refractory (planetary science); Lenalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Gastroenterology; Urology; Oncology; Surgery; Randomized controlled trial","score_opus":0.08195935304219472,"score_gpt":0.4289977155027925,"score_spread":0.34703836246059777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169299949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782705,0.0008610723,0.0000561019,0.000661559,0.00010602031,0.00038729075,0.00002104994,0.000004156865,0.00007567647],"genre_scores_gemma":[0.9835597,0.0011279564,0.014903929,0.00017513715,0.00010735731,0.000008080119,0.00001979903,0.000017202654,0.00008083986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680626,0.00052217644,0.0016242468,0.00033993216,0.00036029922,0.00034707194],"domain_scores_gemma":[0.9940254,0.003286851,0.0010484619,0.00024587405,0.0006730689,0.0007203348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010088361,0.00019518804,0.002278244,0.00043538184,0.00003754763,0.000012653415,0.00006363237,0.00023525501,0.000025638536],"category_scores_gemma":[0.006712435,0.00012427804,0.00024642452,0.00053348165,0.00016132128,0.00012196068,0.00008560377,0.00045103754,0.0000012132675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018256107,0.0024709578,0.84659874,0.000037184138,0.0019713917,0.0006101493,0.0002851686,0.000024699862,0.00021826525,0.0000016869758,0.00001486892,0.12951078],"study_design_scores_gemma":[0.050657813,0.023409834,0.9226357,0.00012124293,0.0011138447,0.00003282473,0.0005185232,0.0002596274,0.00018629998,0.000006274644,0.0009648065,0.00009322536],"about_ca_topic_score_codex":0.00028275247,"about_ca_topic_score_gemma":0.0014803862,"teacher_disagreement_score":0.12941755,"about_ca_system_score_codex":0.00051854824,"about_ca_system_score_gemma":0.0016061997,"threshold_uncertainty_score":0.80358964},"labels":[],"label_agreement":null},{"id":"W3169873720","doi":"10.1016/j.jtct.2021.05.027","title":"The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma","year":2021,"lang":"en","type":"review","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Hematology; Oncology; Immunology; Flow cytometry; Immune system; Internal medicine; Computational biology; Bone marrow; Biology","score_opus":0.07644627137797783,"score_gpt":0.3392379421358628,"score_spread":0.26279167075788495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169873720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05095963,0.94686055,0.00003092605,0.00017190317,0.00007468183,0.0016657532,0.0000870197,0.000037385562,0.00011217462],"genre_scores_gemma":[0.01911796,0.97844005,0.00033397047,0.000041001145,0.00014657657,0.0002757632,0.0012460013,0.00006544577,0.0003332612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997574,0.00041464518,0.00062180514,0.00059341185,0.00037141284,0.00042473766],"domain_scores_gemma":[0.9979114,0.0012774937,0.00015204489,0.00031865074,0.000059032278,0.00028137298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037616814,0.00045525233,0.00090898626,0.00015816822,0.00027323334,0.00012565692,0.00011912478,0.00017707862,0.000021273738],"category_scores_gemma":[0.00012985956,0.0002952123,0.00018508047,0.0003287233,0.00013804405,0.00006393506,0.000022383845,0.0005540664,0.00000877682],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00162559,0.00018541016,0.0016525022,0.0040105665,0.00028136815,0.0019708513,0.0003098543,5.5767913e-7,0.00028581943,0.000037636637,0.000007019947,0.98963284],"study_design_scores_gemma":[0.08819164,0.0054784766,0.14074695,0.29401016,0.0064299507,0.0026962005,0.0038942948,0.0042658793,0.0073664165,0.000215853,0.4405524,0.006151748],"about_ca_topic_score_codex":0.000024563173,"about_ca_topic_score_gemma":0.000030755484,"teacher_disagreement_score":0.98348105,"about_ca_system_score_codex":0.000059812173,"about_ca_system_score_gemma":0.0002237294,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W3170038569","doi":"10.1016/s0140-6736(21)00592-4","title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Sanofi Genzyme; Sanofi","keywords":"Carfilzomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Population; Oncology; Lenalidomide","score_opus":0.10551337317480322,"score_gpt":0.388914458078011,"score_spread":0.2834010849032078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170038569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792315,0.0018672684,0.000021799533,0.0038308993,0.00016141187,0.0035106274,0.000087813154,0.00004833114,0.0025486767],"genre_scores_gemma":[0.99162406,0.0005879515,0.004332611,0.0007990187,0.00046374023,0.00038290175,0.00012849418,0.000038131406,0.0016430828],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99747694,0.0005652061,0.00042180918,0.0004990904,0.00038220853,0.00065476506],"domain_scores_gemma":[0.9974505,0.0012112005,0.00010394966,0.0008442442,0.00011138053,0.0002787456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009220915,0.00025088375,0.0010792797,0.00008397359,0.00015105649,0.0001309667,0.00031026686,0.00011110469,0.00024435853],"category_scores_gemma":[0.0030296037,0.00016556127,0.00006833759,0.00039111928,0.00014611207,0.00010150526,0.00029804205,0.00044332602,0.000056469005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90725964,0.0051599685,0.011628476,0.00015376805,0.0005360754,0.0022182507,0.0012392361,0.0000021958185,0.02032816,0.00008958502,0.0038073126,0.047577314],"study_design_scores_gemma":[0.9757557,0.0007544903,0.0083507,0.000159048,0.00013643484,0.000087634784,0.00027218516,0.0049967966,0.0055750366,0.00010114119,0.003631604,0.00017925893],"about_ca_topic_score_codex":0.0003825265,"about_ca_topic_score_gemma":0.00053765863,"teacher_disagreement_score":0.06849601,"about_ca_system_score_codex":0.000112426635,"about_ca_system_score_gemma":0.00026034523,"threshold_uncertainty_score":0.67513925},"labels":[],"label_agreement":null},{"id":"W3170783707","doi":"10.1200/jco.2021.39.15_suppl.8018","title":"Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Vancouver General Hospital; CancerCare Manitoba; University of Calgary; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Pomalidomide; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Dexamethasone; Regimen; Phases of clinical research; Gastroenterology; Bortezomib; Multiple myeloma; Pharmacology; Oncology; Toxicity","score_opus":0.1983294157969046,"score_gpt":0.5080308278211916,"score_spread":0.30970141202428697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170783707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863587,0.0018607122,0.00002502078,0.009617768,0.0006550084,0.00029175586,0.000014229751,0.000012872105,0.0011639151],"genre_scores_gemma":[0.97525764,0.0026096518,0.018296862,0.0018910978,0.00056212937,0.000009096458,0.000028558541,0.000031479893,0.0013135135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99424034,0.0016793465,0.002691731,0.00039576684,0.0005053383,0.00048747985],"domain_scores_gemma":[0.98959047,0.0073453044,0.0011127973,0.00033411043,0.000582267,0.0010350636],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004333866,0.00022905493,0.0020328257,0.00024114201,0.00006862838,0.000015813042,0.0001362459,0.00056475867,0.0006668476],"category_scores_gemma":[0.024689345,0.00017190084,0.0004275104,0.00029198834,0.00020700754,0.00013578495,0.00018938445,0.0016270418,0.000040397466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043351125,0.010223562,0.36777782,0.00005309755,0.0007082611,0.026208222,0.000120810946,0.0000025187232,0.005509203,0.00001139591,0.00526326,0.5407707],"study_design_scores_gemma":[0.20400056,0.02046238,0.63918436,0.00024499124,0.00035846763,0.0033715956,0.00025039917,0.001153582,0.0018706719,0.00023562773,0.12862763,0.00023971025],"about_ca_topic_score_codex":0.000053181713,"about_ca_topic_score_gemma":0.0007175257,"teacher_disagreement_score":0.54053104,"about_ca_system_score_codex":0.0004739951,"about_ca_system_score_gemma":0.0017901206,"threshold_uncertainty_score":0.9835261},"labels":[],"label_agreement":null},{"id":"W3170905114","doi":"10.1111/ejh.13678","title":"Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; University of Alberta; Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; CancerCare Manitoba; Ottawa Hospital; Institute of Cancer Research; McGill University; Canadian Institutes of Health Research","funders":"Celgene","keywords":"Lenalidomide; Daratumumab; Medicine; Salvage therapy; Bortezomib; Pomalidomide; Multiple myeloma; Carfilzomib; Internal medicine; Oncology; Autologous stem-cell transplantation; Ixazomib; Combination therapy; Dexamethasone; Maintenance therapy; Surgery; Chemotherapy","score_opus":0.02875396049537949,"score_gpt":0.2991474922586249,"score_spread":0.27039353176324543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170905114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984997,0.00021540784,0.00003003181,0.0006358388,0.000093009854,0.00039076974,0.000041769017,0.0000021127494,0.00009139447],"genre_scores_gemma":[0.99934846,0.000059105267,0.0004095039,0.00006566074,0.000023184813,0.0000049627033,0.0000069874654,0.000019510717,0.00006260138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984748,0.00038985387,0.0005654922,0.00016620223,0.00018374572,0.00021991842],"domain_scores_gemma":[0.99886787,0.00022031377,0.00024773736,0.00016849225,0.00033428275,0.00016130132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022319079,0.00013485391,0.00079865917,0.00013809654,0.000030337002,0.000005806932,0.000063733074,0.000013632501,0.000028821214],"category_scores_gemma":[0.0005718581,0.000092988645,0.00008709077,0.000072106996,0.000026430218,0.000034500248,0.00004116573,0.0001153877,8.714029e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088885543,0.00065989804,0.9599955,0.00004964736,0.0005805545,0.033875115,0.0007392696,0.000004122501,0.00034364962,0.000008252398,0.000033329114,0.00282177],"study_design_scores_gemma":[0.018389387,0.0037365647,0.96891934,0.00007662228,0.00010495109,0.0036738547,0.0035986959,0.00003420302,0.0013313927,0.0000057806155,0.00007033756,0.00005889408],"about_ca_topic_score_codex":0.07418959,"about_ca_topic_score_gemma":0.5697692,"teacher_disagreement_score":0.4955796,"about_ca_system_score_codex":0.00038535913,"about_ca_system_score_gemma":0.000685526,"threshold_uncertainty_score":0.9319755},"labels":[],"label_agreement":null},{"id":"W3171123541","doi":"10.1016/j.jval.2021.04.096","title":"PCN4 Carfilzomib in Combination with Dexamethasone (Kd) Versus Pomalidomide in Combination with Bortezomib and Dexamethasone (PVd): A Matching Adjusted Indirect Treatment Comparison (MAIC)","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Carfilzomib; Hazard ratio; Internal medicine; Oncology; Multiple myeloma; Dexamethasone; Surgery; Confidence interval","score_opus":0.08798981438038964,"score_gpt":0.35239230713077546,"score_spread":0.26440249275038585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171123541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993173,0.0022659204,0.00012906887,0.0018624365,0.00007692998,0.0021643057,0.000020338615,0.000053280848,0.0002547133],"genre_scores_gemma":[0.99008733,0.0007096245,0.008394918,0.00008374603,0.000020714004,0.00025281607,0.0003151866,0.00005326611,0.000082369465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609715,0.0010308891,0.00073507626,0.0007137349,0.0006577363,0.00076540007],"domain_scores_gemma":[0.99789715,0.0009605906,0.0002584116,0.0003819878,0.00013645041,0.00036543602],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009817695,0.0003718785,0.0010906685,0.0007880368,0.00010925211,0.00005316077,0.00007467464,0.00015154287,0.000020088946],"category_scores_gemma":[0.00027491534,0.00030396794,0.000043848595,0.0014093621,0.00009540826,0.00020114637,0.000046657788,0.00050557905,0.0000043953532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010392202,0.0040479396,0.94367677,0.000489998,0.00018321909,0.0013408968,0.0048762164,0.0013660945,0.00023733953,0.00028504452,0.000009303069,0.033094976],"study_design_scores_gemma":[0.09851008,0.007206776,0.866489,0.0016263023,0.000068674926,0.00013818814,0.0029333758,0.020385321,0.0021388966,0.00014043627,0.00006030641,0.00030262535],"about_ca_topic_score_codex":0.040564775,"about_ca_topic_score_gemma":0.037723485,"teacher_disagreement_score":0.088117875,"about_ca_system_score_codex":0.0024969256,"about_ca_system_score_gemma":0.0011724951,"threshold_uncertainty_score":0.99994123},"labels":[],"label_agreement":null},{"id":"W3171140567","doi":"10.14740/jh844","title":"Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma","year":2021,"lang":"en","type":"review","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Venetoclax; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Leukemia; Biology; Chronic lymphocytic leukemia","score_opus":0.05440442137144052,"score_gpt":0.37576931989419465,"score_spread":0.3213648985227541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171140567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02861962,0.9706045,7.3162425e-7,0.000046492492,0.000051649506,0.00051778,0.00001595124,0.0000013209011,0.00014194963],"genre_scores_gemma":[0.018629858,0.98083586,0.00036575834,0.000006129545,0.00005365166,0.00002266828,0.000022109314,0.000019416906,0.000044569904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977554,0.0004571896,0.0011123897,0.00015472685,0.00030916443,0.0002111033],"domain_scores_gemma":[0.9973256,0.0011107033,0.0009776189,0.00032476598,0.00015680667,0.000104496015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029105938,0.00022539828,0.0028793411,0.0003734401,0.0000180615,0.000003912387,0.0001343624,0.00024868335,0.000038088627],"category_scores_gemma":[0.00032729923,0.00011756999,0.0005127898,0.00020095434,0.00012359285,0.000028000866,0.00002388385,0.00032178962,0.000002121424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040772773,0.0018216609,0.006601897,0.0074560978,0.0016929461,0.0035571796,0.0007812144,3.0218985e-7,0.00005902561,0.00014338204,0.00012900516,0.9773496],"study_design_scores_gemma":[0.007966493,0.006563652,0.003360526,0.017414028,0.0020425685,0.019384747,0.0007052351,0.000013582434,0.00035085162,0.00007069879,0.9419635,0.00016414681],"about_ca_topic_score_codex":0.000046601974,"about_ca_topic_score_gemma":0.000034862856,"teacher_disagreement_score":0.9771854,"about_ca_system_score_codex":0.00020838696,"about_ca_system_score_gemma":0.00083523104,"threshold_uncertainty_score":0.4794365},"labels":[],"label_agreement":null},{"id":"W3171144462","doi":"10.3390/curroncol28030193","title":"Possible Therapeutic Potential of Disulfiram for Multiple Myeloma","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Ministerstvo Zdravotnictví Ceské Republiky","keywords":"Disulfiram; Medicine; Multiple myeloma; Disease; Cancer; Oncology; Internal medicine; Cancer research; Pharmacology","score_opus":0.26830778777933767,"score_gpt":0.5095518848602719,"score_spread":0.24124409708093425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171144462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008174739,0.9943709,0.0004552051,0.000051322135,0.0012850079,0.0031049908,0.00037216497,0.000034844197,0.00024384013],"genre_scores_gemma":[0.000384985,0.994488,0.00075407134,0.000010962953,0.0005140161,0.0009322431,0.0024248664,0.00007343548,0.0004173925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997405,0.0002879126,0.0008022223,0.0005845983,0.0003287717,0.0005915266],"domain_scores_gemma":[0.99769396,0.00071684556,0.00040853018,0.0005537161,0.00033793368,0.0002890483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023525248,0.0004316875,0.00298641,0.00028305931,0.000079759004,0.000014978335,0.000231805,0.00043836187,0.0002190415],"category_scores_gemma":[0.00039298716,0.00031214952,0.001289814,0.00029922463,0.0001673558,0.00003217413,0.00014664736,0.00047963858,0.00005195453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000155015,0.0017297185,0.000248529,0.022068739,0.001031603,0.00010393989,0.000021276212,8.674595e-8,0.0000064178566,0.000081780054,0.00092008285,0.9736328],"study_design_scores_gemma":[0.003866713,0.001233151,0.00017906775,0.006430495,0.0025862302,0.00020755881,0.000021369708,0.00010135442,0.00001498861,0.000029152347,0.98511994,0.00021000313],"about_ca_topic_score_codex":0.0000066776397,"about_ca_topic_score_gemma":0.000008879527,"teacher_disagreement_score":0.9841998,"about_ca_system_score_codex":0.00040345557,"about_ca_system_score_gemma":0.0019508674,"threshold_uncertainty_score":0.99993306},"labels":[],"label_agreement":null},{"id":"W3171496624","doi":"10.1182/blood.v130.suppl_1.1859.1859","title":"The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Multiple myeloma; Cohort; Medicine; Bortezomib; Oncology; Hematologic Neoplasms; Expanded access; Lenalidomide; Daratumumab; Internal medicine; Intensive care medicine; Cancer","score_opus":0.10446215210696526,"score_gpt":0.4018126330277292,"score_spread":0.29735048092076394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171496624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405164,0.000021761361,0.0000024371116,0.0007299052,0.000050442086,0.001724627,0.000023977427,0.000028796025,0.0033664475],"genre_scores_gemma":[0.9974289,0.000046164238,0.00023436699,0.000044208722,0.00004355434,0.0006960311,0.000010368407,0.000033099503,0.0014632993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998045,0.000054755496,0.00026327214,0.0004913664,0.00048871886,0.0006568415],"domain_scores_gemma":[0.99808717,0.00029383003,0.00009903653,0.0011709797,0.00006389469,0.0002850832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022257656,0.00030885075,0.0005283118,0.00023569331,0.0003223193,0.0002562314,0.00037982294,0.00004794188,0.0000323036],"category_scores_gemma":[0.0003585641,0.0001491088,0.00009062003,0.00017838742,0.00011009008,0.00022113977,0.00013506527,0.0001452312,0.00003064643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017095373,0.0016748073,0.9926752,0.0000074682193,0.00028035263,0.0007251606,0.0006563321,0.000008574696,0.0003340361,0.000007925649,0.000012013735,0.0019086276],"study_design_scores_gemma":[0.017846009,0.0011029523,0.97614795,0.00019515354,0.000043573094,0.000014467261,0.000118085314,0.00015799451,0.0041745813,0.0000026179243,0.00004262565,0.00015397227],"about_ca_topic_score_codex":0.020242833,"about_ca_topic_score_gemma":0.035865635,"teacher_disagreement_score":0.016527195,"about_ca_system_score_codex":0.0004322593,"about_ca_system_score_gemma":0.00014356569,"threshold_uncertainty_score":0.98628145},"labels":[],"label_agreement":null},{"id":"W3172419753","doi":"10.1200/jco.2021.39.15_suppl.e20005","title":"Testing Mayo Clinic’s new 20/20/20 risk stratification model in another cohort of smoldering myeloma patients: A retrospective study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Notre-Dame; Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Multiple myeloma; Hazard ratio; Internal medicine; Retrospective cohort study; Asymptomatic; Cohort; Population; Clinical endpoint; Proportional hazards model; Oncology; Gastroenterology; Confidence interval; Clinical trial","score_opus":0.16988610431133744,"score_gpt":0.46645491912553005,"score_spread":0.2965688148141926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172419753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931635,0.00013481072,0.00042371877,0.0008107875,0.00026646652,0.00064744893,0.000018375262,0.000008888296,0.0045259837],"genre_scores_gemma":[0.9833675,0.00014879911,0.015171693,0.00017930573,0.00033936507,0.000009785433,0.000011798856,0.000026585281,0.00074517966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945479,0.00082973513,0.0031912583,0.00037964204,0.00072906516,0.0003223874],"domain_scores_gemma":[0.9934729,0.0020448647,0.0023201846,0.0003639639,0.0014071749,0.00039096686],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032602488,0.00018257594,0.0016414345,0.00018847894,0.00004685802,0.000013620932,0.00016816249,0.0003089451,0.00017537303],"category_scores_gemma":[0.018408855,0.00014268799,0.00033253172,0.0004035089,0.00012349391,0.00016064936,0.000085379346,0.0012946635,0.000013746291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024250573,0.0069597387,0.91611516,0.000019528208,0.00062064745,0.00055976806,0.00024322065,0.00018513121,0.0003087379,0.000007478656,0.0004607022,0.07209483],"study_design_scores_gemma":[0.017277353,0.011119029,0.96607816,0.00016272851,0.0003325647,0.000035260404,0.0003237061,0.0036276544,0.000102623846,0.0006877215,0.00015628304,0.00009690465],"about_ca_topic_score_codex":0.00015679403,"about_ca_topic_score_gemma":0.00072527333,"teacher_disagreement_score":0.07199792,"about_ca_system_score_codex":0.00038917354,"about_ca_system_score_gemma":0.003192129,"threshold_uncertainty_score":0.9898595},"labels":[],"label_agreement":null},{"id":"W3173193747","doi":"10.1038/s41409-021-01371-1","title":"Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Multiple myeloma; Salvage therapy; Internal medicine; Autologous stem-cell transplantation; Transplantation; Surgery; Stem cell; Multivariate analysis; Oncology; Chemotherapy","score_opus":0.008386388017164494,"score_gpt":0.22479694030904826,"score_spread":0.21641055229188377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173193747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99797857,0.00023414726,0.00015449384,0.0001474804,0.00004008642,0.0006664423,0.00038474234,0.000043864402,0.00035018806],"genre_scores_gemma":[0.99697965,0.000103398284,0.0009865966,0.00011862891,0.0000071471613,0.00009788903,0.0009953178,0.000030744886,0.00068060384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848765,0.00009840407,0.00031249566,0.00039990322,0.0003525942,0.0003489305],"domain_scores_gemma":[0.99935824,0.00012677748,0.000051036684,0.00019508341,0.0000827867,0.00018605613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008082919,0.00022713555,0.0003716279,0.00015437105,0.0000554915,0.000023668468,0.00003223009,0.00011547229,0.00012646221],"category_scores_gemma":[0.0000044658327,0.0001772846,0.000057713383,0.00016706376,0.00004668831,0.00014003365,0.0000060776565,0.00018752733,0.000015539292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008717872,0.00047255037,0.9799233,0.00045809252,0.000106483305,0.0033294274,0.0012556139,0.0000042619868,0.0016501225,0.0000036099466,0.00000772869,0.0040709306],"study_design_scores_gemma":[0.022415236,0.00041052877,0.9697797,0.00014323708,0.00015646826,0.00011538303,0.000073922056,0.00015806351,0.006532108,0.000005128708,0.00002841629,0.00018186586],"about_ca_topic_score_codex":0.000067496185,"about_ca_topic_score_gemma":0.0019113058,"teacher_disagreement_score":0.013697363,"about_ca_system_score_codex":0.0000614961,"about_ca_system_score_gemma":0.000091881906,"threshold_uncertainty_score":0.72294563},"labels":[],"label_agreement":null},{"id":"W3174618187","doi":"10.1158/1078-0432.ccr-21-0649","title":"A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Princess Margaret Cancer Centre; D2L (Canada)","funders":"Canadian Cancer Society Research Institute","keywords":"Multiple myeloma; Cancer; Ideal (ethics); Myeloma protein; Immunopathology","score_opus":0.12011536654454748,"score_gpt":0.46543167783069944,"score_spread":0.345316311286152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174618187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920556,0.00030123748,0.00019749509,0.0042122905,0.00009173364,0.0022118418,0.00011355158,0.000042521482,0.000773711],"genre_scores_gemma":[0.98377854,0.000035143985,0.01129912,0.00031935654,0.00030069,0.0008535219,0.00010985902,0.00006692368,0.0032368647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99343455,0.001255954,0.0006014627,0.0010248367,0.0024337557,0.0012494276],"domain_scores_gemma":[0.99504745,0.0014702616,0.000060467602,0.00080821756,0.0013838252,0.0012297806],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022510446,0.00025538716,0.0007173229,0.0005141523,0.00015423016,0.000083820974,0.00027971278,0.00020486143,0.0017141058],"category_scores_gemma":[0.0065036304,0.00019510329,0.0001960417,0.0021267328,0.00034251998,0.000080297235,0.00017592443,0.0013876371,0.00033332527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013956516,0.0021334304,0.9618356,0.00012864919,0.00018869508,0.0010393977,0.00004129931,0.0000046825135,0.0031414293,0.000015845784,0.000667971,0.016846472],"study_design_scores_gemma":[0.025864793,0.002625791,0.9598389,0.00053310575,0.000021682956,0.0000012788763,0.00009984325,0.00043310135,0.008196706,0.000030872096,0.0021408633,0.00021305673],"about_ca_topic_score_codex":0.00061108154,"about_ca_topic_score_gemma":0.0006600302,"teacher_disagreement_score":0.016633416,"about_ca_system_score_codex":0.00086680066,"about_ca_system_score_gemma":0.00150345,"threshold_uncertainty_score":0.99919844},"labels":[],"label_agreement":null},{"id":"W3175478791","doi":"10.1038/s41408-021-00505-4","title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Internal medicine; Medicine; Gastroenterology; Biomarker; Cohort; Hematology; Oncology; Monoclonal; Immunology; Monoclonal antibody; Antibody; Biology","score_opus":0.029876526239525292,"score_gpt":0.31746582814420443,"score_spread":0.28758930190467913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175478791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955742,0.0025719388,0.0000074302893,0.0010199089,0.0001970689,0.00017983848,0.000056654353,0.000013447445,0.00037953086],"genre_scores_gemma":[0.99759454,0.00080630055,0.00044173733,0.00021127486,0.0001466016,0.000021361988,0.0000062844742,0.00002067389,0.0007512193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859476,0.000061866915,0.00028028726,0.00021292071,0.00044128674,0.000408892],"domain_scores_gemma":[0.9992318,0.00004408708,0.00006945259,0.00014233624,0.00015647546,0.0003558205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012356359,0.00014736361,0.00031792195,0.00012721088,0.00010511529,0.00006241941,0.000058536643,0.00006059515,0.00042760302],"category_scores_gemma":[0.00015608134,0.000115117466,0.00007288078,0.00015197044,0.0000313832,0.0001298135,0.0000724587,0.00035995725,0.000005101486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007774375,0.0003831401,0.940128,0.000052178653,0.00033743255,0.0016441197,0.00015259156,0.000002861881,0.0004948398,0.0000024916399,0.00007598004,0.05664859],"study_design_scores_gemma":[0.011971124,0.00022956434,0.98158723,0.0002966593,0.000099275094,0.0004888129,0.00007738059,0.000041624124,0.0047626826,0.000037286292,0.0003124171,0.000095945456],"about_ca_topic_score_codex":0.000075014024,"about_ca_topic_score_gemma":0.00019923283,"teacher_disagreement_score":0.056552645,"about_ca_system_score_codex":0.00011982142,"about_ca_system_score_gemma":0.00033597625,"threshold_uncertainty_score":0.4694354},"labels":[],"label_agreement":null},{"id":"W3175859892","doi":"10.1158/1538-7445.am2021-ct154","title":"Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer","score_opus":0.13706679409820502,"score_gpt":0.4601622671213244,"score_spread":0.32309547302311936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175859892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990368,0.0007647213,0.0000026184864,0.0006153974,0.00012233588,0.004800177,0.0012491039,0.000041912575,0.0020356996],"genre_scores_gemma":[0.9945806,0.00036514335,0.0005108765,0.00011483533,0.00009751288,0.0013022663,0.00088808144,0.00008982125,0.0020508473],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938168,0.00042496074,0.00069859345,0.001426616,0.0021813011,0.0014517166],"domain_scores_gemma":[0.9959849,0.00046468276,0.00012818718,0.0012943482,0.0014352406,0.0006926332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007870778,0.00039188148,0.00079447665,0.00036972846,0.00028129126,0.00026248785,0.0006197578,0.00013485472,0.00081096333],"category_scores_gemma":[0.0010505652,0.00030525058,0.00005595929,0.001219045,0.00022730872,0.0004747117,0.00068665546,0.001071115,0.00022298636],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30162537,0.093463965,0.324179,0.00049882126,0.0019848829,0.021606648,0.011216349,0.000098976,0.01943347,0.000012314339,0.0050735185,0.22080669],"study_design_scores_gemma":[0.51393944,0.0066164606,0.4555894,0.0015885639,0.00006944954,0.000004635704,0.004226418,0.00042830218,0.014121704,0.000018456823,0.0029382613,0.00045887884],"about_ca_topic_score_codex":0.011905979,"about_ca_topic_score_gemma":0.0058752187,"teacher_disagreement_score":0.2203478,"about_ca_system_score_codex":0.0019961628,"about_ca_system_score_gemma":0.002213851,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W3176714232","doi":"10.1002/ajh.26282","title":"Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone","year":2021,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary; University of Alberta","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Multiple myeloma; Internal medicine; Dexamethasone; Family medicine; Library science; Gerontology","score_opus":0.011060448868156745,"score_gpt":0.24692227025848532,"score_spread":0.23586182139032857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176714232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98215383,0.002385633,0.000066481814,0.014722058,0.000049528833,0.0005474845,0.000018180997,0.000023247041,0.00003356615],"genre_scores_gemma":[0.9698151,0.0007062731,0.0014810602,0.02714143,0.00025857068,0.000040439998,0.00028158017,0.000115542665,0.00016001027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963158,0.0010881562,0.0008511874,0.0005652929,0.0004799463,0.00069963664],"domain_scores_gemma":[0.99711156,0.0008327333,0.0008429149,0.0002991592,0.00056772854,0.0003459017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003383594,0.00052194216,0.0019758523,0.0005787641,0.00008716638,0.000048728987,0.000105483916,0.00027347292,0.000048448117],"category_scores_gemma":[0.0007470364,0.00037341335,0.00013445214,0.00049240753,0.0005478206,0.00010839633,0.00006153553,0.0016163689,0.0000014471682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019273999,0.00027855168,0.9343681,0.00020943569,0.00078603317,0.01938028,0.00021339474,0.0000015442106,0.0000353859,3.3952244e-7,0.0048412425,0.037958343],"study_design_scores_gemma":[0.02781411,0.029923001,0.88987815,0.0024173113,0.0011724725,0.032525446,0.0006013999,0.0009314333,0.00015268219,0.000004174452,0.013760135,0.00081970094],"about_ca_topic_score_codex":0.00039231352,"about_ca_topic_score_gemma":0.00012348285,"teacher_disagreement_score":0.044489916,"about_ca_system_score_codex":0.00017369456,"about_ca_system_score_gemma":0.00027938944,"threshold_uncertainty_score":0.9998718},"labels":[],"label_agreement":null},{"id":"W3177947173","doi":"10.1186/s12885-021-08527-8","title":"The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences","year":2021,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Takeda (Canada); Queen's University; St. Michael's Hospital","funders":"Takeda Canada","keywords":"Qualitative research; Psychosocial; Medicine; Work (physics); Context (archaeology); Nursing; Grounded theory; Psychology; Psychiatry","score_opus":0.07002699977256978,"score_gpt":0.42097255509661746,"score_spread":0.3509455553240477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177947173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99118334,0.007440623,0.000056153265,0.00016117995,0.000031491363,0.0010547369,0.000034025838,0.0000053044455,0.000033125045],"genre_scores_gemma":[0.99811465,0.00039063336,0.0004639663,0.0000055006353,0.000007112047,0.000890402,0.0000055661344,0.000007898828,0.00011430256],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99924827,0.00007285593,0.00020534034,0.00020922702,0.00013285347,0.00013142875],"domain_scores_gemma":[0.9985391,0.0009464383,0.00009661149,0.00015914779,0.00020219671,0.000056531313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006607416,0.0000849107,0.00019971112,0.0000414776,0.00014031779,0.000010570667,0.000030201183,0.00002251467,0.000010807226],"category_scores_gemma":[0.0001881214,0.000052127365,0.000038168084,0.0001762139,0.00006673235,0.00003237521,0.000042665695,0.00002044461,1.6958619e-7],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023091517,0.00080195133,0.30413523,0.0000981308,0.00061941467,0.000008347698,0.46360606,0.000022341,0.0005455427,0.00014194625,0.000077688215,0.22763422],"study_design_scores_gemma":[0.0093153315,0.0015713522,0.4854073,0.00034794438,0.00018441067,0.000006830106,0.49888015,0.0006631209,0.0030735394,0.00022113777,0.00022500758,0.00010385957],"about_ca_topic_score_codex":0.0001153089,"about_ca_topic_score_gemma":0.00089406525,"teacher_disagreement_score":0.22753036,"about_ca_system_score_codex":0.00006382027,"about_ca_system_score_gemma":0.00009563682,"threshold_uncertainty_score":0.21256922},"labels":[],"label_agreement":null},{"id":"W3178434074","doi":"10.1080/03007995.2021.1953456","title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Hazard ratio; Multiple myeloma; Gastroenterology; Refractory (planetary science); Progression-free survival; Odds ratio; Oncology; Overall survival","score_opus":0.2050472340995364,"score_gpt":0.46977746952371724,"score_spread":0.26473023542418084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178434074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917193,0.0042024646,0.00016325341,0.00050282764,0.00027891863,0.0029498853,0.00015950477,0.0000114238255,0.000012389224],"genre_scores_gemma":[0.99539787,0.0028757611,0.0004329055,0.0000060016005,0.00006511723,0.00055859546,0.0005824478,0.000026101872,0.000055219385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996559,0.00024309993,0.00066581875,0.00045960827,0.0014359915,0.0006364497],"domain_scores_gemma":[0.9922118,0.006357835,0.00013023854,0.00037995662,0.0004992413,0.00042090006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007912538,0.0002209476,0.0008094054,0.00033109402,0.00012092298,0.000016141814,0.00016779918,0.00014883124,0.000051500938],"category_scores_gemma":[0.0036465041,0.0001223709,0.000120232864,0.00054836366,0.00028430004,0.0000622359,0.000084615756,0.0003462015,0.0000013823719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031196259,0.010077615,0.60848796,0.0008177844,0.00029562478,0.00002654265,0.001526386,0.00001096164,0.00021221506,0.000032104806,0.00011956068,0.347197],"study_design_scores_gemma":[0.069179155,0.009169256,0.9081406,0.00081449153,0.00004291833,9.3996226e-7,0.00063576736,0.003191961,0.0041971006,0.000019473462,0.0044860924,0.00012223813],"about_ca_topic_score_codex":0.00028621365,"about_ca_topic_score_gemma":0.001845181,"teacher_disagreement_score":0.34707475,"about_ca_system_score_codex":0.00029616748,"about_ca_system_score_gemma":0.00091966096,"threshold_uncertainty_score":0.49901405},"labels":[],"label_agreement":null},{"id":"W3178434373","doi":"10.1021/acs.jproteome.0c01022","title":"Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients","year":2021,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Mass spectrometry; Peptide sequence; Protein sequencing; Blood proteins; Biology; Molecular biology; Chromatography; Chemistry; Biochemistry; Gene","score_opus":0.06277754053042331,"score_gpt":0.3410959802994921,"score_spread":0.2783184397690688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178434373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970089,0.00041296898,0.00007921079,0.00067996734,0.000013780685,0.0014732641,0.000024775714,0.000002564672,0.00030455866],"genre_scores_gemma":[0.98773915,0.00012797191,0.011919678,0.000009118029,0.00007429467,0.000030051066,0.0000050327462,0.000019966277,0.00007473119],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99551964,0.0009924738,0.00071685214,0.00023636952,0.0020283123,0.00050636893],"domain_scores_gemma":[0.99564636,0.0009834406,0.00034909797,0.00027932337,0.0025470078,0.00019476874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030357295,0.00015083751,0.0005780507,0.00082862796,0.0000924494,0.000040348554,0.0001852975,0.000084765765,0.000017716151],"category_scores_gemma":[0.0058714845,0.00009783759,0.00015059489,0.0011293591,0.00027938728,0.0002065774,0.000103529615,0.001015956,0.000001490345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010934856,0.00077900826,0.13458253,0.0007574189,0.00035744233,0.0045165047,0.0020867037,0.0000029788225,0.85361594,0.000054373264,0.0000053530193,0.0021482555],"study_design_scores_gemma":[0.006114157,0.0028447595,0.17309602,0.0015397256,0.000052013012,0.0005347874,0.0038936192,0.00012366172,0.8113835,0.00034136805,0.000005099973,0.00007127962],"about_ca_topic_score_codex":0.00018301408,"about_ca_topic_score_gemma":0.0000747115,"teacher_disagreement_score":0.042232428,"about_ca_system_score_codex":0.00025210358,"about_ca_system_score_gemma":0.0011038973,"threshold_uncertainty_score":0.70291394},"labels":[],"label_agreement":null},{"id":"W3180213695","doi":"10.18103/mra.v9i7.2452","title":"Randomized Controlled Trials versus Single Cohort Studies in Relapse Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Medical Research Archives","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"Janssen Canada","keywords":"Medicine; Randomized controlled trial; Refractory (planetary science); Internal medicine; Multiple myeloma; Cohort; Demographics; Gold standard (test)","score_opus":0.24236813094815166,"score_gpt":0.4839909464215107,"score_spread":0.24162281547335904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180213695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88729554,0.055458833,0.0001664888,0.010101235,0.000846838,0.008295372,0.000033919026,0.00013615582,0.037665606],"genre_scores_gemma":[0.9562732,0.03249171,0.0011381689,0.00011989266,0.0005333239,0.0021009212,0.00014663192,0.000051495612,0.0071446556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97471,0.016482573,0.0019248915,0.00087495445,0.004582793,0.0014248071],"domain_scores_gemma":[0.6830315,0.31065705,0.00042395815,0.0016123436,0.001171042,0.0031040935],"candidate_categories":["metaresearch","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.027331894,0.00036474573,0.0055058645,0.0009457907,0.00025601854,0.00006613216,0.0003246668,0.00022006327,0.0014803972],"category_scores_gemma":[0.61203194,0.00022121142,0.0010881166,0.0007344947,0.0027312709,0.000110312285,0.00051793654,0.0018117448,0.00016821628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.874226,0.0028725483,0.009811643,0.0002888325,0.0071629384,0.013847334,0.0012611002,0.0000013145487,0.004862978,0.0004028494,0.0017532149,0.08350929],"study_design_scores_gemma":[0.97705597,0.0010832627,0.005864479,0.0014474367,0.00028633734,0.00007405856,0.0016649059,0.0023073556,0.0035656914,0.0013849573,0.0050411504,0.0002243828],"about_ca_topic_score_codex":0.0001441109,"about_ca_topic_score_gemma":0.00043765001,"teacher_disagreement_score":0.58470005,"about_ca_system_score_codex":0.00031904125,"about_ca_system_score_gemma":0.0021325503,"threshold_uncertainty_score":0.9999827},"labels":[],"label_agreement":null},{"id":"W3180549397","doi":"10.1182/blood.2020010439","title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute","keywords":"Daratumumab; Medicine; Internal medicine; Lenalidomide; Bortezomib; Minimal residual disease; Multiple myeloma; Oncology; Melphalan; Prednisone; Population; Gastroenterology; Surgery; Leukemia","score_opus":0.014807023198906767,"score_gpt":0.2988162049552055,"score_spread":0.28400918175629875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180549397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605256,0.002288159,0.0000011937707,0.0007002026,0.0000066831412,0.0006469514,0.00007296672,0.000008362184,0.00022293458],"genre_scores_gemma":[0.9992536,0.000258973,0.00021712367,0.000018430334,0.000030803178,0.0000525497,0.000048666632,0.000013367997,0.00010651464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867946,0.0002493257,0.00024022783,0.00027888533,0.00022764795,0.00032445087],"domain_scores_gemma":[0.99863356,0.0007154205,0.000050122573,0.0002792266,0.00006940143,0.00025228193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002490391,0.00015115397,0.00038590207,0.00012247497,0.000045745048,0.000023933735,0.000048107326,0.00005045557,0.000027027152],"category_scores_gemma":[0.002163854,0.0000975403,0.00006671547,0.00029492495,0.00023082067,0.000080496095,0.0001498808,0.00017392018,0.0000010221352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062750145,0.0016332885,0.98212874,0.00011073133,0.00015673849,0.004044597,0.0006361705,0.00000242538,0.0017601342,0.00004491631,0.000035965128,0.003171296],"study_design_scores_gemma":[0.06550181,0.00026596815,0.9304801,0.0001059388,0.00007184108,0.000036981055,0.0004097093,0.0006434949,0.0022270887,0.00017846002,0.000002701795,0.00007589754],"about_ca_topic_score_codex":0.0018365269,"about_ca_topic_score_gemma":0.0016748643,"teacher_disagreement_score":0.059226792,"about_ca_system_score_codex":0.00004308676,"about_ca_system_score_gemma":0.00035140506,"threshold_uncertainty_score":0.39775783},"labels":[],"label_agreement":null},{"id":"W3181852980","doi":"10.3390/ijms22147470","title":"Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Diagnostic biomarker; Malignancy; Medicine; Disease; Molecular biomarkers; Biomarker; Bioinformatics; Biomarker discovery; Bone marrow; Computational biology; Diagnostic accuracy; Pathology; Internal medicine; Proteomics; Biology","score_opus":0.22345119301783442,"score_gpt":0.397275601223619,"score_spread":0.17382440820578457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181852980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031541653,0.96291757,0.0031633496,0.0010712883,0.00032413783,0.0009359646,0.00002996272,0.0000028874679,0.000013179913],"genre_scores_gemma":[0.23026107,0.7664152,0.0030081621,0.00007029121,0.00007680805,0.00011931618,0.000030254936,0.000015573856,0.0000033478923],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9975451,0.00027718634,0.00066270103,0.00031906282,0.0009501814,0.0002457591],"domain_scores_gemma":[0.99860907,0.0005551507,0.00037030256,0.00010156383,0.00025600084,0.00010793564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009906726,0.00020708032,0.00061022467,0.00087507314,0.00008119178,0.00037881665,0.00033794917,0.00010896463,0.000011651711],"category_scores_gemma":[0.0012255224,0.00013356181,0.00038696342,0.00049519766,0.00020625557,0.000296286,0.00009836353,0.00023342631,4.426733e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017924879,0.0007386719,0.018313667,0.0009099227,0.0028652821,0.007751441,0.00021109617,0.00023420797,0.0012832682,0.0008492238,0.00013190316,0.96653205],"study_design_scores_gemma":[0.07834647,0.012668471,0.029973034,0.35930285,0.016506406,0.030471958,0.014365171,0.11011658,0.021209737,0.0040656207,0.3152314,0.007742281],"about_ca_topic_score_codex":0.00008261761,"about_ca_topic_score_gemma":0.0000909205,"teacher_disagreement_score":0.95878977,"about_ca_system_score_codex":0.0004661388,"about_ca_system_score_gemma":0.000603199,"threshold_uncertainty_score":0.5446493},"labels":[],"label_agreement":null},{"id":"W3183441818","doi":"10.1002/cncr.33809","title":"Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karyopharm Therapeutics; Pharmacyclics; Genentech; Celgene; Daiichi Sankyo Europe; Amgen Canada; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Bristol-Myers Squibb; Regeneron Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Term (time); Oncology; Internal medicine; Surgery","score_opus":0.03730700392493223,"score_gpt":0.29672583371819394,"score_spread":0.2594188297932617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183441818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996698,0.00047825478,0.000005033477,0.000286436,0.00023101771,0.0017857266,0.00021200176,0.000048430447,0.00025510424],"genre_scores_gemma":[0.9957178,0.000027114971,0.0001579826,0.0002472142,0.00010153805,0.00038709556,0.00024829933,0.00007349906,0.0030394553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712056,0.00021365438,0.00033871408,0.0006688652,0.0010949731,0.0005632341],"domain_scores_gemma":[0.99821,0.00033356974,0.0001273397,0.00077927805,0.00029355602,0.00025621615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014098268,0.00036619513,0.000585193,0.00007814112,0.00015326575,0.000059338134,0.00017206956,0.000087380526,0.00061409484],"category_scores_gemma":[0.00024748995,0.00018060944,0.0000863843,0.00034466016,0.00011011891,0.0001403514,0.000113193324,0.00039821575,0.000032461954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008315724,0.003925099,0.96867126,0.000022838798,0.0009920744,0.001529729,0.002113636,0.000005900234,0.00014293604,2.7616568e-7,0.00033768534,0.013942814],"study_design_scores_gemma":[0.049058508,0.0020235036,0.9456023,0.00030475497,0.00032534124,0.0000056737276,0.0016649972,0.000020743322,0.00049128046,8.7992885e-7,0.00026929635,0.00023269339],"about_ca_topic_score_codex":0.0023968692,"about_ca_topic_score_gemma":0.04196536,"teacher_disagreement_score":0.040742785,"about_ca_system_score_codex":0.00064369035,"about_ca_system_score_gemma":0.0005221502,"threshold_uncertainty_score":0.97551626},"labels":[],"label_agreement":null},{"id":"W3183895493","doi":"10.1080/13696998.2021.1962664","title":"The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"Amgen","keywords":"Latin Americans; Medicine; Demography; Environmental health; Socioeconomics","score_opus":0.032495212423711964,"score_gpt":0.3590363809811568,"score_spread":0.32654116855744486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183895493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040024925,0.95616937,0.0000038547087,0.0028929648,0.00026759418,0.00048141862,0.000029578463,0.0000029035075,0.0001273709],"genre_scores_gemma":[0.0024212655,0.9968193,0.00009756645,0.00006128546,0.00022214568,0.000010874578,0.000023864559,0.000035653527,0.0003080077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965266,0.0003171474,0.0019043206,0.00022435408,0.0006589841,0.0003685962],"domain_scores_gemma":[0.9959886,0.0013669828,0.0016388567,0.00026775384,0.00015329765,0.0005845181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020639342,0.00026758012,0.0026081796,0.0002475952,0.000057509074,0.000023562265,0.00036598038,0.00031370053,0.00023954322],"category_scores_gemma":[0.0020011389,0.00016927574,0.00051972346,0.00022378787,0.00040864432,0.00005365668,0.00016239869,0.0011404203,0.000012643421],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090709626,0.00016215527,0.0028557885,0.0021310025,0.0019041819,0.0006765242,0.00008819439,0.0000025467625,6.837194e-8,0.00013080762,0.00074565946,0.99121237],"study_design_scores_gemma":[0.0037429656,0.0005642025,0.0013701303,0.012861728,0.00063494674,0.001083122,0.00018380271,0.0003429521,6.9167515e-7,0.00007602264,0.97898626,0.00015314511],"about_ca_topic_score_codex":0.00017833564,"about_ca_topic_score_gemma":0.00007379048,"teacher_disagreement_score":0.99105924,"about_ca_system_score_codex":0.0003468633,"about_ca_system_score_gemma":0.0026119826,"threshold_uncertainty_score":0.69028646},"labels":[],"label_agreement":null},{"id":"W3185145180","doi":"10.1007/s00277-021-04591-z","title":"N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution","year":2021,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Internal medicine; Multivariate analysis; Natriuretic peptide; Brain natriuretic peptide; Hematology; Univariate analysis; Cardiology; Cohort; Multiple myeloma; Gastroenterology; Academic institution; Heart failure; Oncology","score_opus":0.03998587440098521,"score_gpt":0.31988444559654516,"score_spread":0.27989857119555994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185145180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964108,0.0003729072,0.000082138904,0.0016332445,0.000048265654,0.0006696295,0.00002830383,0.000031730047,0.00072299485],"genre_scores_gemma":[0.9965052,0.0000078398325,0.0025771544,0.00021042117,0.000020358535,0.00006745434,0.0004845154,0.000019966887,0.00010707094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803036,0.00012474704,0.00057741546,0.00042691486,0.00042164468,0.00041893986],"domain_scores_gemma":[0.99856496,0.00024976826,0.0002216487,0.00045860454,0.00033860482,0.0001664005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013239718,0.00019439813,0.0006545636,0.00020998508,0.000044758734,0.000010441914,0.00008014716,0.00013564934,0.000069160254],"category_scores_gemma":[0.001461841,0.0001548175,0.00009071818,0.00031287395,0.000179121,0.00011370646,0.000067938454,0.00018076981,0.000023351346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010531023,0.0023042872,0.9799362,0.0003212624,0.00022215344,0.011689127,0.00020378153,0.0000030749138,0.0012998229,0.00010045519,0.00036022894,0.002506517],"study_design_scores_gemma":[0.008687652,0.0010999641,0.93467855,0.00084596156,0.000060778468,0.0017012528,0.0001054946,0.00029380657,0.05182695,0.00030219945,0.00021004422,0.0001873142],"about_ca_topic_score_codex":0.000190373,"about_ca_topic_score_gemma":0.00028399646,"teacher_disagreement_score":0.050527126,"about_ca_system_score_codex":0.000038565846,"about_ca_system_score_gemma":0.00034127964,"threshold_uncertainty_score":0.6313275},"labels":[],"label_agreement":null},{"id":"W3185171385","doi":"10.1182/blood.2021011101","title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute","keywords":"Internal medicine; Medicine; Hazard ratio; Oncology; Multiple myeloma; Daratumumab; Proportional hazards model; Progression-free survival; Minimal residual disease; Confidence interval; Overall survival; Lenalidomide; Bone marrow","score_opus":0.01710911962369718,"score_gpt":0.28758062782116406,"score_spread":0.2704715081974669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185171385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980157,0.0009749745,0.0000036715346,0.00025592663,0.000009890909,0.00030620367,0.00018694204,0.000008323685,0.00023836433],"genre_scores_gemma":[0.99880433,0.000049456252,0.0007955035,0.000013938798,0.000014226355,0.00001992733,0.00013952352,0.000010175378,0.00015292123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987135,0.00014164842,0.0002910135,0.0002640973,0.00036197787,0.0002277781],"domain_scores_gemma":[0.999009,0.0002423502,0.00008077678,0.00028838948,0.00012364514,0.00025581603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013527882,0.00011807803,0.00051277527,0.00031589903,0.000023254284,0.0000064293727,0.000044974364,0.000045145298,0.00006529909],"category_scores_gemma":[0.0008820281,0.00010398996,0.00011008368,0.0008721659,0.00011812404,0.000042011983,0.000077409684,0.00008944741,0.0000013445024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076528423,0.003312694,0.9852631,0.00024035224,0.0017307496,0.0014609663,0.00018749235,0.0000045725633,0.0062344833,0.00009315185,0.00001070733,0.00069642055],"study_design_scores_gemma":[0.008033663,0.00038040947,0.9760093,0.00010062483,0.002903684,0.0000108338345,0.00009656452,0.0006250362,0.011729736,0.000037840095,0.000003312263,0.00006897511],"about_ca_topic_score_codex":0.00031831703,"about_ca_topic_score_gemma":0.00030917098,"teacher_disagreement_score":0.009253805,"about_ca_system_score_codex":0.000019647603,"about_ca_system_score_gemma":0.00029481988,"threshold_uncertainty_score":0.42405874},"labels":[],"label_agreement":null},{"id":"W3185822896","doi":"10.1021/acs.jmedchem.1c00506","title":"Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of New Brunswick; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Government of Ontario","keywords":"Chemistry; Kinase; G protein-coupled receptor kinase; IC50; Small molecule; Drug discovery; Pharmacology; Receptor; In vitro; Biochemistry; Biology; G protein-coupled receptor","score_opus":0.024760412819241115,"score_gpt":0.2789612372945284,"score_spread":0.25420082447528725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185822896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536264,0.0018857026,0.0003110004,0.0016466348,0.00007956628,0.00066431874,0.00003440933,0.0000022783806,0.000013442971],"genre_scores_gemma":[0.9974544,0.0011180897,0.00080428354,0.000014545649,0.00027818812,0.00004673978,0.000012906287,0.000015424792,0.00025543134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983728,0.000070025584,0.0006592841,0.00013240137,0.00060011144,0.00016541003],"domain_scores_gemma":[0.99748874,0.00061990344,0.0007531266,0.00025047356,0.0007461159,0.00014164069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039740387,0.00015909542,0.0005306022,0.000040010298,0.000060031558,0.000005189216,0.00011025761,0.00008877111,0.000061035214],"category_scores_gemma":[0.0015783573,0.00007924437,0.00022130364,0.00014568525,0.00020138768,0.000038119233,0.000025381029,0.000113608105,1.9137805e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026881262,0.00085320993,0.005655612,0.00069557835,0.00046112077,0.000045806763,0.00029888249,0.0000027984172,0.967493,9.437448e-7,0.000021011654,0.021783903],"study_design_scores_gemma":[0.0042432174,0.0011076961,0.019355752,0.0010736395,0.00042931564,0.00023515376,0.0005531326,0.00038842275,0.9723227,0.000009131373,0.00022948881,0.000052356892],"about_ca_topic_score_codex":0.000023526938,"about_ca_topic_score_gemma":0.0000012074971,"teacher_disagreement_score":0.021731548,"about_ca_system_score_codex":0.000106427855,"about_ca_system_score_gemma":0.0004944402,"threshold_uncertainty_score":0.32314917},"labels":[],"label_agreement":null},{"id":"W3186399416","doi":"10.1158/1078-0432.ccr-21-1059","title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; bluebird bio; Agios Pharmaceuticals; TG Therapeutics; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; Legend Biotech; Celgene; AstraZeneca; Pfizer; Amgen; GlaxoSmithKline; Multiple Myeloma Research Foundation; Foundation for the National Institutes of Health","keywords":"Multiple myeloma; Medicine; Drug; Residual; Intensive care medicine; Minimal residual disease; Disease; Internal medicine; Pharmacology; Computer science","score_opus":0.3248483922535994,"score_gpt":0.5827453539241509,"score_spread":0.25789696167055154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186399416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719969,0.0107671125,0.000074691576,0.014391378,0.00011943626,0.0019122825,0.0000937548,0.000026996722,0.0006174454],"genre_scores_gemma":[0.98524547,0.0065317904,0.0016784678,0.00021579709,0.0014840866,0.0006501324,0.00036266205,0.000031255902,0.0038003575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641347,0.0006180136,0.0008038203,0.00087824365,0.0007480093,0.0005384649],"domain_scores_gemma":[0.9953081,0.0021922784,0.00007417328,0.0005612312,0.0007591938,0.0011050323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024195304,0.00013319963,0.00042333704,0.00011726174,0.00013937584,0.00005617395,0.00013114802,0.0001696991,0.00007933344],"category_scores_gemma":[0.005974604,0.000118026575,0.00015847896,0.00037323716,0.00038409347,0.00008653885,0.00015169177,0.0007685636,0.000026705191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005545774,0.0004558039,0.68972415,0.00029566349,0.00005406955,0.00020060438,0.000107031316,8.493309e-7,0.00006792024,0.00021159273,0.014954755,0.28838181],"study_design_scores_gemma":[0.009513898,0.0006751573,0.9515816,0.00019128797,0.000050679246,0.000003167418,0.00033455514,0.00040967495,0.0002849308,0.00064231077,0.036196545,0.000116219104],"about_ca_topic_score_codex":0.00076015474,"about_ca_topic_score_gemma":0.0026055297,"teacher_disagreement_score":0.2882656,"about_ca_system_score_codex":0.00019970206,"about_ca_system_score_gemma":0.003840469,"threshold_uncertainty_score":0.715259},"labels":[],"label_agreement":null},{"id":"W3188660209","doi":"10.1007/s40273-021-01068-9","title":"Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Pomalidomide; Progression-free survival; Chemotherapy","score_opus":0.08245124933852116,"score_gpt":0.3953296840196429,"score_spread":0.31287843468112175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188660209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915673,0.0003514643,0.00012610774,0.00071879,0.00033339727,0.004433547,0.0019004075,0.000054213007,0.0005147599],"genre_scores_gemma":[0.99487686,0.00034061534,0.0003872311,0.0004410406,0.00031070746,0.00041678993,0.0030483482,0.000063661784,0.00011476781],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962172,0.0010775645,0.0010171506,0.00080693915,0.0003058228,0.0005753124],"domain_scores_gemma":[0.9924096,0.00592417,0.00032996753,0.00080675574,0.0001874407,0.0003420647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001608948,0.00040091752,0.0010514626,0.00019248092,0.000099116514,0.000042344047,0.00024698468,0.00015515383,0.000291371],"category_scores_gemma":[0.0017421355,0.0003124073,0.00031760585,0.00037743498,0.000123561,0.000116030846,0.000076796125,0.00051598717,0.00005569553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85496753,0.0073966794,0.020161487,0.00015219524,0.0009463904,0.00074097636,0.00042391132,0.0018543209,0.046679463,0.000008047439,0.0010590958,0.065609924],"study_design_scores_gemma":[0.5924601,0.0013332866,0.014232071,0.00028693248,0.0002898108,0.0000082299875,0.00009371576,0.091205575,0.297426,0.0000104996825,0.002398255,0.00025552878],"about_ca_topic_score_codex":0.0015885428,"about_ca_topic_score_gemma":0.00029004784,"teacher_disagreement_score":0.2625074,"about_ca_system_score_codex":0.00052791194,"about_ca_system_score_gemma":0.0006536098,"threshold_uncertainty_score":0.9999328},"labels":[],"label_agreement":null},{"id":"W3188942243","doi":"10.1016/j.clml.2021.07.028","title":"Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","year":2021,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; London Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba; Memorial University of Newfoundland; University of Manitoba; Centre hospitalier universitaire de Québec; Université de Montréal; Western University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Guideline; Multiple myeloma; Medicine; Family medicine; Intensive care medicine; Disease; Internal medicine; Pathology","score_opus":0.17558033125824968,"score_gpt":0.460361134728241,"score_spread":0.2847808034699913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188942243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01604137,0.9408071,0.000021622858,0.0059402655,0.0010728678,0.013634699,0.004011052,0.00005281182,0.01841821],"genre_scores_gemma":[0.21930152,0.7688244,0.002625461,0.00026710643,0.0004512679,0.0011552143,0.005787055,0.00023633144,0.001351617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9834907,0.0049788323,0.005423488,0.0015548127,0.002559693,0.001992445],"domain_scores_gemma":[0.98078716,0.00773704,0.002039811,0.002892099,0.0053688926,0.0011750265],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.008365914,0.0008370556,0.003343023,0.0007012377,0.0014951988,0.0000884948,0.0014476548,0.0008449783,0.00023364242],"category_scores_gemma":[0.0028971361,0.0005765242,0.00094838836,0.0035004823,0.004619808,0.0000869416,0.0012248013,0.0019308917,0.000021041118],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00025093823,0.0002543645,0.0023236973,0.0066519217,0.0022682329,0.00051278534,0.00016651998,0.0000036860185,0.0000019025065,0.005651086,0.030010385,0.9519045],"study_design_scores_gemma":[0.003272462,0.0008607512,0.300193,0.013731155,0.0017247434,0.00062643446,0.003610684,0.00016454149,0.000017329852,0.0002823294,0.67497474,0.0005418013],"about_ca_topic_score_codex":0.519768,"about_ca_topic_score_gemma":0.77155876,"teacher_disagreement_score":0.95136267,"about_ca_system_score_codex":0.0060640243,"about_ca_system_score_gemma":0.03588663,"threshold_uncertainty_score":0.99980474},"labels":[],"label_agreement":null},{"id":"W3189402043","doi":"10.1016/j.soncn.2021.151173","title":"Multidisciplinary Professional Roles Addressing Needs in Multiple Myeloma: An Innovative ‘Virtual’ Pharmacist Surveillance Clinic","year":2021,"lang":"en","type":"review","venue":"Seminars in Oncology Nursing","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Pharmacist; Multiple myeloma; Pharmacy; Family medicine; Health care; MEDLINE; Nursing; Intensive care medicine; Internal medicine","score_opus":0.1613863639507363,"score_gpt":0.5065066837180954,"score_spread":0.3451203197673591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189402043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017718675,0.97354233,0.000011277945,0.00017685934,0.0010654539,0.0024190608,0.000089919195,0.00008664096,0.004889808],"genre_scores_gemma":[0.011800109,0.97783846,0.0030624014,0.00004519641,0.0003868052,0.0005535698,0.0019764246,0.00024194294,0.004095081],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99338794,0.0022198935,0.0015747076,0.0011311393,0.0005452965,0.0011410286],"domain_scores_gemma":[0.99597293,0.002118347,0.00065967796,0.00064099603,0.0002278244,0.0003802138],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015446419,0.0007982621,0.00362155,0.0019227148,0.00021949079,0.00003318515,0.00037067244,0.0010832924,0.00033370263],"category_scores_gemma":[0.0010445191,0.00069609145,0.0003013528,0.0029425814,0.00067405606,0.00019269667,0.00027245822,0.0024222005,0.000081097576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006163845,0.004004671,0.027508382,0.0018596125,0.00018630447,0.0048678126,0.0022117582,0.0000023819869,0.000030378114,0.0000072432454,0.00066109316,0.958044],"study_design_scores_gemma":[0.025538279,0.0035156047,0.020164143,0.39800006,0.0005991406,0.0022742318,0.012491182,0.0029351613,0.00007866273,0.00003578462,0.53209656,0.0022711784],"about_ca_topic_score_codex":0.000019356396,"about_ca_topic_score_gemma":0.00015559155,"teacher_disagreement_score":0.9557728,"about_ca_system_score_codex":0.0033480537,"about_ca_system_score_gemma":0.0037165747,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W3191410965","doi":"10.5858/arpa.2020-0794-cp","title":"Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies","year":2021,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Amyloidosis; Monoclonal; AL amyloidosis; Immunoglobulin light chain; Monoclonal antibody; Paraproteinemias; Guideline; Monoclonal gammopathy","score_opus":0.02005146834752879,"score_gpt":0.31160365745078683,"score_spread":0.29155218910325803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191410965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028623,0.0074929837,0.0001358572,0.0007195013,0.00013443582,0.00020798927,0.00018348769,0.000025191355,0.000814339],"genre_scores_gemma":[0.9954753,0.00233082,0.0016605306,0.00022108124,0.0001562557,0.00005227634,0.000051783853,0.000020014022,0.00003193008],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983394,0.0003489066,0.00044180654,0.00033065767,0.0002873955,0.00025179744],"domain_scores_gemma":[0.9982754,0.0006615352,0.00016806462,0.00033413587,0.00033550936,0.0002253642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000261927,0.00017651745,0.00061356195,0.00028952336,0.000060731873,0.000002061927,0.00006455066,0.000099181525,0.00012611334],"category_scores_gemma":[0.0014027845,0.0001442662,0.000055261567,0.00038247922,0.0013915471,0.00006207516,0.0000840815,0.00024850963,0.000003040013],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083211483,0.00042026784,0.35147384,0.0004405156,0.0002329225,0.0035233628,0.0016136979,6.3574254e-7,0.6146675,0.00028145063,0.0000811041,0.026432605],"study_design_scores_gemma":[0.0045410288,0.0016797394,0.5220276,0.000356266,0.00019701952,0.00022515096,0.0007869139,0.000038976952,0.4688321,0.00040048148,0.0008130484,0.000101694706],"about_ca_topic_score_codex":0.000031752174,"about_ca_topic_score_gemma":0.000053582713,"teacher_disagreement_score":0.17055374,"about_ca_system_score_codex":0.000015756663,"about_ca_system_score_gemma":0.00036040373,"threshold_uncertainty_score":0.5883005},"labels":[],"label_agreement":null},{"id":"W3192759045","doi":"10.1200/jco.21.00443","title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Venetoclax; Multiple myeloma; Refractory (planetary science); Phases of clinical research; Clinical trial; Salvage therapy; Chemotherapy","score_opus":0.10622742260560453,"score_gpt":0.45977177651391904,"score_spread":0.3535443539083145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192759045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818987,0.00019669732,0.000048462636,0.00016057072,0.00008599974,0.0011774137,0.000011953502,0.000008538277,0.00012049532],"genre_scores_gemma":[0.989296,0.00015598895,0.009924413,0.00013712498,0.000102017315,0.000024127761,0.000010702199,0.000046879926,0.00030271334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957233,0.0008045769,0.0016928099,0.000492239,0.0008830748,0.00040397243],"domain_scores_gemma":[0.99447584,0.001948453,0.0014463677,0.00039187924,0.0010130185,0.0007244303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012755677,0.000313621,0.0025105446,0.00024473158,0.00007358801,0.000020669255,0.00012280307,0.00027625015,0.000048053756],"category_scores_gemma":[0.0028704284,0.00015266147,0.00007211429,0.00039607566,0.0004928951,0.00023221844,0.00008731379,0.0011100838,8.078525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24264602,0.010082498,0.71600497,0.00007090203,0.00094258203,0.0040733204,0.0004988404,0.00000918637,0.00002318649,6.689024e-7,0.00003014729,0.025617678],"study_design_scores_gemma":[0.21731596,0.16506208,0.6142454,0.00039431592,0.00049957825,0.0005189454,0.0011018737,0.00025398625,0.000043090706,0.0000015048257,0.00043389943,0.00012936097],"about_ca_topic_score_codex":0.00016096431,"about_ca_topic_score_gemma":0.008085179,"teacher_disagreement_score":0.15497959,"about_ca_system_score_codex":0.0003511173,"about_ca_system_score_gemma":0.00541614,"threshold_uncertainty_score":0.96079993},"labels":[],"label_agreement":null},{"id":"W3197669971","doi":"10.1111/ejh.13706","title":"Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Lenalidomide; Pomalidomide; Internal medicine; Hazard ratio; Bortezomib; Multiple myeloma; Dexamethasone; Clinical endpoint; Creatinine; Renal function; Gastroenterology; Progression-free survival; Surgery; Randomized controlled trial; Chemotherapy; Confidence interval","score_opus":0.03265644451244482,"score_gpt":0.3192080389079468,"score_spread":0.286551594395502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197669971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419415,0.0033152404,0.00014027274,0.0014119279,0.00009866694,0.00013448768,0.000032181826,0.000007889644,0.00066520297],"genre_scores_gemma":[0.9926258,0.0031020977,0.0035463818,0.00012708118,0.000059133607,0.0000013924338,0.000047895344,0.000040765506,0.00044950293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562824,0.0015397561,0.0018089133,0.00032587908,0.00033442082,0.00036276816],"domain_scores_gemma":[0.99707574,0.0008234382,0.00084845384,0.00036531844,0.00044569082,0.00044137868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016955105,0.00022585774,0.0016476163,0.0003160799,0.000058060137,0.000016795075,0.00015199087,0.000099742545,0.00027036952],"category_scores_gemma":[0.0029595895,0.00018088489,0.00030946863,0.00035581423,0.00031135682,0.0000793456,0.00017497006,0.0005082658,0.000025257557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046930574,0.0010027778,0.8631529,0.00019527525,0.0013769798,0.11815859,0.00022405497,0.0000032667901,0.0036838264,0.000021322645,0.002613608,0.004874352],"study_design_scores_gemma":[0.02837826,0.0019164197,0.90888506,0.00070926454,0.0010751109,0.044147477,0.00021243528,0.00051615504,0.011144832,0.000017121183,0.002716179,0.00028165974],"about_ca_topic_score_codex":0.00001590708,"about_ca_topic_score_gemma":0.00003493002,"teacher_disagreement_score":0.07401111,"about_ca_system_score_codex":0.00008407571,"about_ca_system_score_gemma":0.00016079466,"threshold_uncertainty_score":0.73762715},"labels":[],"label_agreement":null},{"id":"W3198317060","doi":"10.1503/cmaj.202824","title":"Managing multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Medical Association; University of Alberta","funders":"","keywords":"Multiple myeloma; Incidence (geometry); Medicine; Proteasome; Internal medicine; Oncology; Biology","score_opus":0.014781539848913068,"score_gpt":0.27799982431770043,"score_spread":0.26321828446878737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198317060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6866264,0.0016142701,0.00040644396,0.24845588,0.0014547587,0.0002987827,0.000050842726,0.00007044035,0.06102219],"genre_scores_gemma":[0.98171777,0.00037702217,0.0006693401,0.010181589,0.0013493717,0.000006339552,0.000048534537,0.000020000749,0.0056300154],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973909,0.00012685066,0.00026416636,0.00015414726,0.0014831325,0.00058075314],"domain_scores_gemma":[0.99603987,0.00016336628,0.00007068525,0.00011986098,0.000550883,0.0030553578],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065475923,0.00009436615,0.00020322789,0.00015823024,0.00026338254,0.00008573352,0.00008531047,0.00021047561,0.008817252],"category_scores_gemma":[0.004395678,0.000084561245,0.00012499919,0.00025920774,0.000020972062,0.00007958688,0.000018384435,0.0007734033,0.0005533782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025785022,0.000081751576,0.63599557,0.00001752407,0.00041015007,0.026208594,0.00011900558,0.0000013137931,0.00011572183,0.00009329004,0.07501972,0.26191157],"study_design_scores_gemma":[0.004789099,0.000073382995,0.47631755,0.0001505831,0.00005166308,0.004964545,0.00042844235,0.0016420732,0.00046845162,0.00022469582,0.5107421,0.00014740902],"about_ca_topic_score_codex":0.0011624584,"about_ca_topic_score_gemma":0.024249017,"teacher_disagreement_score":0.43572238,"about_ca_system_score_codex":0.0012869483,"about_ca_system_score_gemma":0.00487941,"threshold_uncertainty_score":0.9935559},"labels":[],"label_agreement":null},{"id":"W3198710304","doi":"10.1186/s12885-021-08453-9","title":"Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study","year":2021,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"National Center for Advancing Translational Sciences; Karyopharm Therapeutics","keywords":"Medicine; Multiple myeloma; Clinical endpoint; Confidence interval; Internal medicine; Minimal clinically important difference; Quality of life (healthcare); Refractory (planetary science); Oncology; Post-hoc analysis; Clinical trial; Randomized controlled trial","score_opus":0.14441074090325215,"score_gpt":0.42869664444645394,"score_spread":0.2842859035432018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198710304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942917,0.0020538128,0.000012853053,0.00011113537,0.00007573018,0.0014018519,0.0019552135,0.000017674445,0.000079995814],"genre_scores_gemma":[0.9981777,0.00017465898,0.0005021692,0.000040987656,0.00012363354,0.00019571355,0.00056326675,0.00002863984,0.00019320428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996899,0.00046679197,0.00088845316,0.0005491858,0.0008715038,0.00032507753],"domain_scores_gemma":[0.996915,0.0009356449,0.00040945836,0.00095872843,0.00055256346,0.00022864007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022817195,0.0002767579,0.00087501085,0.000110277404,0.00006366637,0.000011378446,0.00013102006,0.000074709744,0.00016613246],"category_scores_gemma":[0.0010815738,0.00015841005,0.00016825771,0.0005076076,0.00012015755,0.000082559236,0.000056410485,0.00012852355,0.0000053953804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0243641,0.01464076,0.9426525,0.000053618292,0.0010642279,0.000043516342,0.002150354,0.00005642981,0.0015510268,5.019902e-7,0.00012445527,0.013298491],"study_design_scores_gemma":[0.07211033,0.0025948968,0.9176095,0.00012342523,0.00022403071,2.7242865e-7,0.0020974455,0.00013287427,0.004639985,0.0000012411289,0.0003349286,0.00013102546],"about_ca_topic_score_codex":0.03375228,"about_ca_topic_score_gemma":0.061170094,"teacher_disagreement_score":0.047746234,"about_ca_system_score_codex":0.0004113566,"about_ca_system_score_gemma":0.0010831847,"threshold_uncertainty_score":0.97268206},"labels":[],"label_agreement":null},{"id":"W3198880734","doi":"10.1038/s41408-021-00544-x","title":"A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Singapore General Hospital; National University of Singapore; Onyx Pharmaceuticals; Duke-NUS Medical School","keywords":"Carfilzomib; Dexamethasone; Medicine; Cyclophosphamide; Internal medicine; Phase (matter); Oncology; Intensive care medicine; Chemotherapy; Lenalidomide; Chemistry","score_opus":0.025987748150059484,"score_gpt":0.3327062772657641,"score_spread":0.30671852911570463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198880734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93938464,0.03434584,0.0000506293,0.02147835,0.00021483348,0.0028952814,0.0015526783,0.000026652084,0.000051118765],"genre_scores_gemma":[0.8770474,0.07297055,0.007260112,0.017582871,0.0082250135,0.002336751,0.0015786767,0.00042262816,0.012575988],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99657625,0.00023176441,0.00063245714,0.00072384346,0.0009903202,0.00084537547],"domain_scores_gemma":[0.99769443,0.0003152429,0.00054761244,0.00048453663,0.00049863296,0.00045951782],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022776228,0.00069438503,0.0016797052,0.00033523605,0.00030309724,0.0001031129,0.00017055053,0.00039931247,0.00021043574],"category_scores_gemma":[0.000061615254,0.00044548078,0.0002980271,0.00020796589,0.00010939648,0.000088832785,0.000029296905,0.0015530124,0.0000012488899],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08208594,0.052751888,0.23514593,0.004235024,0.11319391,0.16578408,0.010305162,0.00009008663,0.0040003164,0.000006381589,0.23007151,0.102329776],"study_design_scores_gemma":[0.59979177,0.15074788,0.023255737,0.0044796295,0.044611927,0.013345097,0.0022258959,0.00002576282,0.046909872,0.00009647275,0.11284496,0.00166501],"about_ca_topic_score_codex":0.011120502,"about_ca_topic_score_gemma":0.001611044,"teacher_disagreement_score":0.5177058,"about_ca_system_score_codex":0.00030009644,"about_ca_system_score_gemma":0.0013018001,"threshold_uncertainty_score":0.99979967},"labels":[],"label_agreement":null},{"id":"W3199545669","doi":"10.1016/j.jmoldx.2021.08.011","title":"DMG26","year":2021,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Beatrice Hunter Cancer Research Institute; McMaster University; Nova Scotia Health Authority; Dalhousie University","funders":"Beatrice Hunter Cancer Research Institute","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Plasma cell leukemia; Oncology; Internal medicine; Biology; Exon; Cohort; Medicine; Gene; Cancer research; Pathology; Genetics","score_opus":0.017863874553320978,"score_gpt":0.31499907156661144,"score_spread":0.29713519701329044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199545669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785939,0.0101412935,0.0046710824,0.0029676948,0.0002281916,0.00009930224,0.000006574885,0.0000072273524,0.003284753],"genre_scores_gemma":[0.98638105,0.0023889292,0.010218581,0.0006325807,0.0001399715,0.0000011754067,0.000008370176,0.000014866838,0.00021448352],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990432,0.00004650286,0.0002319995,0.000071312126,0.00044651542,0.00016043127],"domain_scores_gemma":[0.9987384,0.00018355728,0.00008964896,0.00015975573,0.00056215,0.00026646646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107644555,0.00007152883,0.00021050741,0.00007418489,0.000021439373,0.000018496321,0.00005313222,0.000044285,0.00015904345],"category_scores_gemma":[0.0029300675,0.000056326448,0.00016301309,0.00013469892,0.000025093868,0.000031526542,0.0000313809,0.0002021731,0.000037178175],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005672196,0.0034537385,0.2848023,0.00024080373,0.0022290794,0.39963317,0.00017867173,0.00011026959,0.18469396,0.0017233716,0.030409183,0.09195823],"study_design_scores_gemma":[0.009977485,0.0017108882,0.19400401,0.00061803026,0.0007200836,0.012133499,0.00014274959,0.000116494746,0.72974914,0.0014425934,0.04917299,0.00021202804],"about_ca_topic_score_codex":0.000001592724,"about_ca_topic_score_gemma":9.2232443e-7,"teacher_disagreement_score":0.54505515,"about_ca_system_score_codex":0.00005156672,"about_ca_system_score_gemma":0.00034975386,"threshold_uncertainty_score":0.3507776},"labels":[],"label_agreement":null},{"id":"W3200434719","doi":"10.1182/blood.v130.suppl_1.4377.4377","title":"Targeting of Marcks By MiR-34a Overcomes Drug Resistance in Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"MARCKS; Bortezomib; Cancer research; Drug resistance; Carfilzomib; microRNA; Multiple myeloma; Cell culture; Downregulation and upregulation; Lenalidomide; Biology; Medicine; Chemistry; Protein kinase C; Immunology; Kinase; Cell biology; Genetics; Gene","score_opus":0.019584759188848597,"score_gpt":0.2907585840408525,"score_spread":0.27117382485200386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200434719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919578,0.001822054,0.0000050827334,0.0005948619,0.000038293132,0.00040149209,0.000061018778,0.000021459862,0.0050979597],"genre_scores_gemma":[0.9931653,0.0001040617,0.0027896794,0.000024163952,0.00004402105,0.000034128403,0.000050626262,0.000021130514,0.0037668792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987153,0.00004529227,0.00026393106,0.0002644315,0.0003471867,0.00036389177],"domain_scores_gemma":[0.99893004,0.0001345498,0.00014448195,0.00057575,0.00006506327,0.00015009435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022197088,0.00013795636,0.00032617647,0.000080060025,0.00014883057,0.00002674014,0.00021412806,0.000059169153,0.000077972836],"category_scores_gemma":[0.0009041314,0.0001171973,0.000073787356,0.00005886882,0.00012037979,0.00010910331,0.000101259255,0.00016088902,0.00002457558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042927434,0.0011053585,0.9338768,0.00021111719,0.00013096395,0.00029467358,0.00022282447,1.3863973e-7,0.058685165,0.00002964626,0.0041273627,0.000886642],"study_design_scores_gemma":[0.014933726,0.00007706285,0.88576746,0.00030715094,0.000047637375,0.0000052803202,0.00008338486,0.00006660582,0.09423204,0.00009072574,0.0042473986,0.00014152903],"about_ca_topic_score_codex":0.00059865817,"about_ca_topic_score_gemma":0.00054277433,"teacher_disagreement_score":0.048109375,"about_ca_system_score_codex":0.000035354864,"about_ca_system_score_gemma":0.000062148,"threshold_uncertainty_score":0.47791672},"labels":[],"label_agreement":null},{"id":"W3200717490","doi":"10.1016/s1470-2045(21)00428-9","title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Autologous stem-cell transplantation; Multiple myeloma; Thalidomide; Bortezomib; Internal medicine; Interim analysis; Clinical endpoint; Oncology; Dexamethasone; Progression-free survival; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.09038015065881295,"score_gpt":0.36434493194217504,"score_spread":0.2739647812833621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200717490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906867,0.00027936356,0.00028399224,0.0007157178,0.000061728875,0.007519964,0.0001278016,0.00006202256,0.0002627059],"genre_scores_gemma":[0.98382056,0.00038335545,0.01273556,0.00029385605,0.00008512032,0.0015381661,0.00036465665,0.00008590891,0.0006928387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962273,0.000889503,0.0005113083,0.0009859313,0.00050401676,0.0008819085],"domain_scores_gemma":[0.997197,0.0011165026,0.00032434054,0.00075986004,0.0001998675,0.0004024636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058858254,0.0005926057,0.0020221989,0.00011617722,0.000371983,0.00015227718,0.00025533384,0.00018231475,0.000024851184],"category_scores_gemma":[0.00008036115,0.00024892218,0.00003153806,0.0005005665,0.0003753719,0.00041926434,0.00007502619,0.00041298431,0.0000016752708],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7595892,0.0058511896,0.19359444,0.000088910914,0.00073917623,0.0084710745,0.0015217954,0.000011413997,0.00026236585,0.000006455414,0.000022590166,0.02984139],"study_design_scores_gemma":[0.834258,0.09204221,0.06804283,0.0005210339,0.00077151676,0.0006332262,0.00082763884,0.0013258464,0.00066568435,0.0000026904336,0.0005335549,0.00037575015],"about_ca_topic_score_codex":0.0008505758,"about_ca_topic_score_gemma":0.0252912,"teacher_disagreement_score":0.12555161,"about_ca_system_score_codex":0.00040118015,"about_ca_system_score_gemma":0.0013496823,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W3200752197","doi":"10.1182/bloodadvances.2021005327","title":"Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Multiple myeloma; Tumor necrosis factor alpha; Bone marrow; Cancer research; Medicine; Intravasation; Interleukin 6; Inflammation; Immunology; Biology; Metastasis; Internal medicine; Cancer","score_opus":0.009523889715419667,"score_gpt":0.3072454667300081,"score_spread":0.2977215770145884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200752197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987521,0.011192478,0.00012254892,0.00024342454,0.00004618689,0.0003787622,0.000046775738,0.000030248948,0.00041860895],"genre_scores_gemma":[0.99249345,0.0010516287,0.00403775,0.000009981988,0.00005959536,0.000035840134,0.000045801735,0.000016820466,0.0022491054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888587,0.000041147625,0.00021086965,0.00028596527,0.00034612668,0.00023000564],"domain_scores_gemma":[0.9992236,0.00014988403,0.00007791457,0.00021659695,0.0001743657,0.00015765516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070071364,0.00013280351,0.00026305008,0.00006864114,0.00006723539,0.000020466754,0.000049576443,0.000045437562,0.000094522715],"category_scores_gemma":[0.00038399294,0.000108728505,0.000043306496,0.00016387927,0.00008722218,0.00017044407,0.00005980803,0.000081827566,0.0000127020885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017189706,0.00051194587,0.17447253,0.0003917227,0.00017313525,0.00084042316,0.00049908395,8.2902017e-7,0.5974786,0.00003358573,0.000025396084,0.22540085],"study_design_scores_gemma":[0.0013432634,0.00036716388,0.36451206,0.00017889458,0.00007403,0.00008843143,0.00009957449,0.000030987325,0.63237685,0.00010830775,0.00075174065,0.00006867462],"about_ca_topic_score_codex":0.000058756006,"about_ca_topic_score_gemma":0.00007626359,"teacher_disagreement_score":0.22533217,"about_ca_system_score_codex":0.000014261962,"about_ca_system_score_gemma":0.000042067346,"threshold_uncertainty_score":0.443382},"labels":[],"label_agreement":null},{"id":"W3200833309","doi":"10.1101/2021.09.20.461083","title":"Identification of topoisomerase as a precision-medicine target in chromatin reader SP140-driven Crohn’s disease","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Harvard Stem Cell Institute; National Institutes of Health; Broad Institute; Massachusetts General Hospital","keywords":"Chromatin; Biology; Immune system; Bromodomain; Genome instability; Topoisomerase; Cell biology; Cancer research; Computational biology; DNA damage; Immunology; Genetics; DNA; Histone","score_opus":0.019913539470299817,"score_gpt":0.28672869667024664,"score_spread":0.2668151571999468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200833309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284023,0.0030378632,0.00032073946,0.0009947943,0.00041996987,0.0019903835,0.00026269123,0.00011749378,0.000015816127],"genre_scores_gemma":[0.99574673,0.0007336363,0.0024645515,0.000113625814,0.00029687703,0.00047754459,0.000013764147,0.000107567445,0.000045693534],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956933,0.00027453902,0.0012100532,0.0011733284,0.0010718498,0.0005769319],"domain_scores_gemma":[0.99571157,0.00016489324,0.0005749036,0.0019013953,0.0008627946,0.00078444334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063746807,0.0005404905,0.0010766465,0.000727357,0.000079192774,0.00007873349,0.00037822753,0.0003704062,0.0005769507],"category_scores_gemma":[0.0026138292,0.0005008563,0.00022030604,0.0008029114,0.00024282771,0.00017354338,0.00039906756,0.0007420148,0.00008247649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088668417,0.0018070705,0.18088058,0.002957731,0.0005280685,0.004863215,0.00011531486,0.00010131405,0.80731064,0.00009340086,0.00042877803,0.000027196036],"study_design_scores_gemma":[0.002796679,0.00011478469,0.88622624,0.0031607084,0.00020456017,9.177909e-8,0.000024491868,0.0017606204,0.10516496,0.000005812365,0.0001809325,0.00036013807],"about_ca_topic_score_codex":0.0004039067,"about_ca_topic_score_gemma":0.000008769152,"teacher_disagreement_score":0.70534563,"about_ca_system_score_codex":0.0005431148,"about_ca_system_score_gemma":0.0016547476,"threshold_uncertainty_score":0.9997443},"labels":[],"label_agreement":null},{"id":"W3202325939","doi":"","title":"Renal extramedullary plasmacytoma in a dog.","year":2021,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Virtual Materials Group (Canada)","funders":"","keywords":"Medicine; Plasmacytoma; Extramedullary plasmacytoma; Histopathology; Multiple myeloma; Nephrectomy; Presentation (obstetrics); Kidney; Radiology; Cyst; Surgery; Pathology; Internal medicine","score_opus":0.03927455838271005,"score_gpt":0.2928203089746113,"score_spread":0.25354575059190126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202325939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783096,0.0006522275,0.000008305739,0.0017819075,0.00006319563,0.0005557905,0.000008092017,0.00003792017,0.018582989],"genre_scores_gemma":[0.9937176,0.00008997553,0.00048706314,0.00023212358,0.00008565679,0.0009786827,0.00004911833,0.0000129292175,0.004346816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886316,0.00004704442,0.00014486717,0.00022382352,0.00027304215,0.00044803505],"domain_scores_gemma":[0.99936014,0.00006689073,0.000016458469,0.0002207744,0.00004657777,0.00028913983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013110887,0.00008545945,0.00017409919,0.00010379338,0.000022920996,0.000018541275,0.000044268174,0.0000537551,0.00017079207],"category_scores_gemma":[0.00035526164,0.00007225616,0.000059208596,0.00027609043,0.0000310105,0.000046301855,0.000045859553,0.00016824175,0.000061034338],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047025734,0.0007019898,0.44862247,0.00007007366,0.00014232965,0.015504342,0.00007580619,0.0000016197165,0.00066304964,0.0000860293,0.0016845077,0.53197753],"study_design_scores_gemma":[0.0039787455,0.000026008684,0.9770535,0.000022049759,0.0000144789465,0.00032361006,0.000028055894,0.00007837849,0.01108209,0.00008507252,0.007244805,0.00006316132],"about_ca_topic_score_codex":0.000045803226,"about_ca_topic_score_gemma":0.00010007451,"teacher_disagreement_score":0.53191435,"about_ca_system_score_codex":0.00011501031,"about_ca_system_score_gemma":0.00012019715,"threshold_uncertainty_score":0.29465207},"labels":[],"label_agreement":null},{"id":"W3203238634","doi":"10.7759/cureus.18334","title":"The Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma: A Systematic Review of the Literature","year":2021,"lang":"en","type":"review","venue":"Cureus","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Systematic review; Oncology; Stem cell; Disease; Critical appraisal; Cochrane Library; Internal medicine; Hematopoietic stem cell transplantation; Lenalidomide; Intensive care medicine; MEDLINE; Meta-analysis; Pathology; Alternative medicine","score_opus":0.030799860478918317,"score_gpt":0.3188337664525465,"score_spread":0.2880339059736282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203238634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052788768,0.9949272,7.794783e-7,0.000021132075,0.00006854345,0.0044443514,0.00018535115,0.0000058530586,0.00029397378],"genre_scores_gemma":[0.0011085403,0.9976329,0.00002751042,0.000014975566,0.000024874938,0.0005074655,0.0002534752,0.000030408652,0.00039980418],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9970851,0.0008634453,0.0010538844,0.00025519673,0.0005054174,0.00023697899],"domain_scores_gemma":[0.99758434,0.0006503498,0.0005801435,0.0009131768,0.00019908167,0.00007287858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005205372,0.00028937974,0.0022036964,0.00006126675,0.00005192354,0.00001458683,0.00036091602,0.00019183228,0.000015550528],"category_scores_gemma":[0.0002347747,0.0001259493,0.0007569334,0.00055922044,0.000057138768,0.000028620041,0.00005202283,0.00035713124,0.000008807411],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011281255,0.00013133741,0.0000827882,0.9538618,0.00032447596,0.00006265402,0.00018257012,5.2395855e-8,0.000009701303,0.000023143164,0.000021794704,0.04528841],"study_design_scores_gemma":[0.0004946261,0.000055665925,0.000054648637,0.97321117,0.002559659,0.00014060982,0.000079598205,0.000003997486,0.0001346261,0.0000034319985,0.023167923,0.000094065865],"about_ca_topic_score_codex":0.000021241472,"about_ca_topic_score_gemma":0.00004696505,"teacher_disagreement_score":0.045194346,"about_ca_system_score_codex":0.00012654433,"about_ca_system_score_gemma":0.00041951452,"threshold_uncertainty_score":0.5136063},"labels":[],"label_agreement":null},{"id":"W3203356756","doi":"10.1002/14651858.cd014739","title":"Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents","year":2021,"lang":"en","type":"review","venue":"Cochrane Database of Systematic Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Antithrombotic; Ambulatory; Medicine; Multiple myeloma; Internal medicine; Oncology; Intensive care medicine","score_opus":0.12902968909029408,"score_gpt":0.39547611034081126,"score_spread":0.2664464212505172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203356756","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003293296,0.96516985,0.0002156776,0.000002920214,0.00025847458,0.032698132,0.0012454365,0.00003906418,0.000041135463],"genre_scores_gemma":[0.00013598334,0.9807588,0.0036104354,0.000027480599,0.00010669449,0.0044064564,0.010553432,0.00020774057,0.00019301145],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920703,0.0014075923,0.0035294378,0.0010811962,0.0012256693,0.0006857998],"domain_scores_gemma":[0.99114615,0.0015556286,0.002728823,0.0033315122,0.0008400837,0.0003977884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022010303,0.0011275668,0.011969901,0.0004237552,0.00016015042,0.000061765844,0.0005704225,0.00026960627,0.00020387943],"category_scores_gemma":[0.0036317236,0.0006520261,0.0017489046,0.0006232109,0.00015015253,0.0002210214,0.00016268827,0.00039207534,0.00015664914],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007941295,0.0008587025,0.00059468416,0.9085358,0.0022067367,0.00006465167,0.000040196883,9.1413625e-8,0.0000041278668,0.000005842775,0.00084099045,0.086768776],"study_design_scores_gemma":[0.0047529973,0.00051271595,0.0006418383,0.90801495,0.0041396767,0.000079988204,0.000019912844,0.00002481097,0.000006892531,2.8817473e-7,0.08128405,0.0005218638],"about_ca_topic_score_codex":0.000022177364,"about_ca_topic_score_gemma":0.000005801527,"teacher_disagreement_score":0.086246915,"about_ca_system_score_codex":0.0003233957,"about_ca_system_score_gemma":0.00071553787,"threshold_uncertainty_score":0.9995931},"labels":[],"label_agreement":null},{"id":"W3203613081","doi":"10.1038/s41409-021-01455-y","title":"Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis","year":2021,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Maintenance therapy; Multiple myeloma; Pomalidomide; Internal medicine; Lenalidomide; Bortezomib; Univariate analysis; Transplantation; Salvage therapy; Surgery; Hematopoietic cell; Oncology; Hematopoietic stem cell transplantation; Multivariate analysis; Chemotherapy; Stem cell; Haematopoiesis","score_opus":0.015663942061117025,"score_gpt":0.2704659876102498,"score_spread":0.25480204554913277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203613081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663506,0.0011203734,0.02921673,0.00045217268,0.000081561826,0.0011380233,0.0008136764,0.000097197626,0.00072963047],"genre_scores_gemma":[0.9849511,0.0016815371,0.006238214,0.0002914096,0.000049673577,0.0006064665,0.0037875264,0.000041771575,0.0023523036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980158,0.000107752116,0.00043884158,0.00056963915,0.00037759895,0.0004903501],"domain_scores_gemma":[0.9988692,0.00024854162,0.00009790975,0.00032522174,0.00024715197,0.00021198741],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017657418,0.00027644922,0.0005143221,0.00028561437,0.0001277712,0.000048019352,0.00006328189,0.0001533307,0.00066179683],"category_scores_gemma":[0.000022262757,0.0002464209,0.00042528755,0.0005665487,0.000055693206,0.00014760508,0.0000041378144,0.00014609858,0.00003611624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038512565,0.0025052223,0.51503044,0.007294284,0.004341121,0.012012927,0.0076983944,0.00021921495,0.37385547,0.00015847615,0.00046223687,0.03790964],"study_design_scores_gemma":[0.014650808,0.0003423103,0.7936973,0.00012059042,0.0017442472,0.00055165234,0.00012762887,0.0016595862,0.18622664,0.00009941713,0.00046175445,0.0003180598],"about_ca_topic_score_codex":0.00004658822,"about_ca_topic_score_gemma":0.0010131798,"teacher_disagreement_score":0.27866688,"about_ca_system_score_codex":0.00007871479,"about_ca_system_score_gemma":0.00016097483,"threshold_uncertainty_score":0.9999988},"labels":[],"label_agreement":null},{"id":"W3203807700","doi":"10.1016/j.annonc.2021.08.1043","title":"521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi; Meso Scale Diagnostics; Novartis; AstraZeneca; Amgen","keywords":"Medicine; Dosing; Carcinoembryonic antigen; Conjugate; Pharmacology; Toxicity; Limiting; Monoclonal antibody; Maximum tolerated dose; Pharmacokinetics; Antibody; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.06641753308482397,"score_gpt":0.41423351638436795,"score_spread":0.347815983299544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203807700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983463,0.00014783982,0.000032730255,0.00020176715,0.00005326505,0.0008000464,0.000026129406,0.0000058555615,0.00038604584],"genre_scores_gemma":[0.99893165,0.00008666843,0.0007725132,0.00003765909,0.00001920116,0.00002846915,0.000078796635,0.000016908507,0.000028166249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980517,0.00026706886,0.00062213023,0.00029473065,0.00047362628,0.00029071665],"domain_scores_gemma":[0.9981526,0.00022152366,0.00039562766,0.0002812188,0.00083500764,0.000113989874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016818078,0.00017273481,0.00087093574,0.00026378586,0.000024337161,0.0000029244281,0.0000826555,0.000057717993,0.00004811399],"category_scores_gemma":[0.00029303695,0.00013002797,0.00006830848,0.00030463559,0.00012899585,0.000090870366,0.00008338605,0.0001649418,0.0000016768752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060467827,0.016670585,0.89348364,0.00013163846,0.00049582525,0.00020793181,0.0012906431,0.0002815296,0.00806227,0.00006994353,0.000005918064,0.07325332],"study_design_scores_gemma":[0.02897086,0.01915619,0.85575706,0.00033379137,0.00006295467,0.0000046032924,0.0009342156,0.00036095298,0.09421666,0.00011213168,0.000006818113,0.0000837822],"about_ca_topic_score_codex":0.0002808763,"about_ca_topic_score_gemma":0.0006951456,"teacher_disagreement_score":0.086154394,"about_ca_system_score_codex":0.00009585539,"about_ca_system_score_gemma":0.0002087379,"threshold_uncertainty_score":0.5302387},"labels":[],"label_agreement":null},{"id":"W3205120821","doi":"10.1002/cyto.b.21142","title":"Feasibility study: Phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma","year":2013,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"","keywords":"Flow cytometry; Bone marrow; Multiplex; Multiple myeloma; Pathology; Cancer research; Medicine; Molecular biology; Cell biology; Biology; Chemistry; Immunology; Bioinformatics","score_opus":0.09101338906528827,"score_gpt":0.34731392552616885,"score_spread":0.2563005364608806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205120821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991044,0.0010153183,0.0018954552,0.0000992774,0.00055083854,0.0034403882,0.00147518,0.00023512467,0.0002444569],"genre_scores_gemma":[0.9889416,0.00016445661,0.0062207193,0.00021384234,0.0004958116,0.00027144654,0.003257808,0.00013055772,0.00030376457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890576,0.00075284584,0.0031229395,0.0023481292,0.0033398168,0.00137864],"domain_scores_gemma":[0.9865515,0.0061028427,0.0010232362,0.0026656142,0.001957708,0.0016990821],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002338288,0.00094146596,0.0035507455,0.003962524,0.00037073586,0.0001769696,0.0005445629,0.0005900506,0.011651859],"category_scores_gemma":[0.007729959,0.0007210166,0.0014749065,0.013220964,0.0007936671,0.0005806575,0.00049133296,0.001322671,0.00062155165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057225097,0.014609053,0.94147265,0.00009821117,0.01089847,0.000097616685,0.000069938105,0.000026526437,0.00044522705,0.000001420685,0.0010346146,0.02552374],"study_design_scores_gemma":[0.02018451,0.0032764731,0.9691641,0.00012684564,0.0031711482,0.000003484608,0.00056883466,0.0014377469,0.0009791255,0.00001839579,0.00042359086,0.0006457456],"about_ca_topic_score_codex":0.0006402604,"about_ca_topic_score_gemma":0.000106201216,"teacher_disagreement_score":0.027691428,"about_ca_system_score_codex":0.0005037943,"about_ca_system_score_gemma":0.00033917825,"threshold_uncertainty_score":0.9995241},"labels":[],"label_agreement":null},{"id":"W3206192616","doi":"10.1016/s1470-2045(21)00466-6","title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development; Strong","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Multiple myeloma; Open label; Oncology; Internal medicine; Clinical trial","score_opus":0.1690328158794252,"score_gpt":0.4209981267549274,"score_spread":0.2519653108755022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206192616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810101,0.00358643,0.00006402154,0.008128872,0.0007079591,0.0034926683,0.00054713985,0.000059617854,0.0024032337],"genre_scores_gemma":[0.9827963,0.0046700197,0.008669512,0.0008095608,0.0011595339,0.0005538255,0.00071942556,0.00006826246,0.0005535481],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935451,0.0027051952,0.0009985137,0.0011393331,0.0005496701,0.0010621852],"domain_scores_gemma":[0.9813802,0.01647637,0.00035857223,0.001048259,0.00019567471,0.00054090365],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003170471,0.000505158,0.0024419134,0.00016878592,0.0002814279,0.00018459623,0.00045128525,0.00036702515,0.00017062025],"category_scores_gemma":[0.01127028,0.00037238872,0.000109346445,0.0004326808,0.00053354603,0.00025622075,0.0007122263,0.0009255859,0.00003159534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93391407,0.0028194739,0.0022844174,0.000043215205,0.0009489874,0.0049927155,0.00086213247,0.000005408286,0.009313075,0.000087704764,0.0019265203,0.04280226],"study_design_scores_gemma":[0.96850747,0.0042041773,0.011134474,0.00015632295,0.00037906857,0.00012944045,0.0004142696,0.001354532,0.0031805688,0.0003169373,0.009865488,0.0003572745],"about_ca_topic_score_codex":0.0062952917,"about_ca_topic_score_gemma":0.013044057,"teacher_disagreement_score":0.04244498,"about_ca_system_score_codex":0.00036697576,"about_ca_system_score_gemma":0.00075241824,"threshold_uncertainty_score":0.9998728},"labels":[],"label_agreement":null},{"id":"W3207101086","doi":"10.1016/j.jmoldx.2021.09.006","title":"Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients","year":2021,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea; National Research Foundation","keywords":"Minimal residual disease; Multiple myeloma; Multiplex; DNA sequencing; Gene; Biology; Internal medicine; Polymerase chain reaction; Medicine; Molecular biology; Genetics; Bone marrow","score_opus":0.0651338782560594,"score_gpt":0.29693568364079664,"score_spread":0.23180180538473724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207101086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9413825,0.00055791816,0.05705628,0.000105193845,0.00007184901,0.00072524534,0.00009337123,0.0000063344387,0.0000012595316],"genre_scores_gemma":[0.9672441,0.00009067243,0.032080274,0.00008200767,0.00016575656,0.000030427287,0.00027289835,0.000030615312,0.0000032572048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978869,0.00023180763,0.00062868017,0.00030579302,0.0005992137,0.00034763195],"domain_scores_gemma":[0.9973003,0.00048931735,0.00035834577,0.00022926147,0.0012244547,0.000398312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003559677,0.00020115166,0.00046057653,0.00035785185,0.00010547362,0.00007457355,0.00007013305,0.000081686376,0.000005206496],"category_scores_gemma":[0.0063314885,0.00016696591,0.00024745564,0.0006292908,0.00004780495,0.00014583698,0.00003286642,0.00022346115,4.1928456e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017791231,0.0009125437,0.49955624,0.00010420791,0.0011782001,0.0025699835,0.00007126929,0.01264198,0.47712433,0.0000029704117,0.0000047780263,0.004054365],"study_design_scores_gemma":[0.00670121,0.0012284259,0.46323407,0.00017447176,0.0030840102,0.000055371416,0.00007580622,0.22197239,0.30325285,0.00003082672,0.000006175167,0.000184405],"about_ca_topic_score_codex":0.000077185505,"about_ca_topic_score_gemma":0.00014074639,"teacher_disagreement_score":0.20933041,"about_ca_system_score_codex":0.0005340222,"about_ca_system_score_gemma":0.0009370698,"threshold_uncertainty_score":0.75798404},"labels":[],"label_agreement":null},{"id":"W3207809849","doi":"10.3324/haematol.2021.279229","title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","year":2021,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Sanofi Genzyme; Sanofi","keywords":"Carfilzomib; Medicine; Renal function; Hazard ratio; Internal medicine; Dexamethasone; Multiple myeloma; Population; Confidence interval; Adverse effect; Urology; Gastroenterology; Subgroup analysis; Creatinine; Oncology; Lenalidomide","score_opus":0.022369191073017495,"score_gpt":0.27161218656555364,"score_spread":0.24924299549253615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207809849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582475,0.001972103,0.0000886084,0.0003572,0.000055272532,0.001032208,0.00009887227,0.0000876637,0.000483312],"genre_scores_gemma":[0.9880774,0.00028420374,0.010690842,0.00010063938,0.000024212759,0.0001662462,0.00042489954,0.000042207237,0.00018936323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628687,0.00037872736,0.0005707848,0.0011333574,0.0007339402,0.0008963292],"domain_scores_gemma":[0.99722403,0.0009347415,0.00024394618,0.0006913054,0.00029404432,0.0006119109],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003439175,0.0005074542,0.0015386239,0.0005170396,0.00021369563,0.00008237551,0.00012950397,0.00029099995,0.00024546523],"category_scores_gemma":[0.0012468067,0.00037171433,0.0001833654,0.0015488239,0.00035747388,0.00013840769,0.00026647944,0.0004763449,0.000017230086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01214035,0.0010497029,0.9744168,0.00018902069,0.0019392279,0.004226624,0.000630496,0.000020577008,0.00034182682,0.00005092124,0.00007075074,0.0049237097],"study_design_scores_gemma":[0.055158187,0.001832708,0.93622667,0.00015207769,0.0011166938,0.00023041041,0.0005604396,0.0024368612,0.0017383621,0.000029801047,0.00011588056,0.00040193307],"about_ca_topic_score_codex":0.00074637093,"about_ca_topic_score_gemma":0.00289621,"teacher_disagreement_score":0.04301784,"about_ca_system_score_codex":0.0002993964,"about_ca_system_score_gemma":0.00021577346,"threshold_uncertainty_score":0.99987346},"labels":[],"label_agreement":null},{"id":"W3207994228","doi":"10.1182/blood-2021-148813","title":"Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; CD38; Pomalidomide; Refractory (planetary science); Multiple myeloma; Oncology; Tumor lysis syndrome; Immunology; Gastroenterology; Lenalidomide; Chemotherapy; Stem cell; Biology","score_opus":0.018257228312412603,"score_gpt":0.2827512217054763,"score_spread":0.2644939933930637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207994228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530125,0.00038931242,0.000031646643,0.00016128777,0.00008909092,0.001517201,0.00058461906,0.00007138457,0.0018542088],"genre_scores_gemma":[0.99336827,0.00003101457,0.0026109135,0.0000764017,0.00008918376,0.00017126331,0.002065565,0.000059205006,0.0015281689],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764603,0.00007878225,0.00043199165,0.00064307655,0.0005552321,0.00064487895],"domain_scores_gemma":[0.9982329,0.0003005201,0.000115336356,0.00063665636,0.0003687042,0.00034588337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012812152,0.00028532688,0.00049369456,0.00016807002,0.00012817417,0.000037729675,0.00011097518,0.00014964203,0.00003272809],"category_scores_gemma":[0.00087574695,0.00022852562,0.00012065857,0.00033551984,0.00007236052,0.00012229891,0.00006044539,0.0003005945,0.000043373337],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22783764,0.20520785,0.42178017,0.0011043431,0.0032028188,0.04124743,0.002113993,0.000027832875,0.009380238,0.000094690666,0.003402464,0.08460053],"study_design_scores_gemma":[0.78034925,0.017906496,0.16787803,0.00047526127,0.0004409889,0.00037730212,0.00017906615,0.0006322814,0.023882259,0.000027517126,0.0072832513,0.0005683149],"about_ca_topic_score_codex":0.00006319197,"about_ca_topic_score_gemma":0.0003543056,"teacher_disagreement_score":0.5525116,"about_ca_system_score_codex":0.00019171748,"about_ca_system_score_gemma":0.00047040067,"threshold_uncertainty_score":0.93190044},"labels":[],"label_agreement":null},{"id":"W3208273355","doi":"10.1111/bjh.17946","title":"The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of New Brunswick; Princess Margaret Cancer Centre; Essar Steel Algoma (Canada); Saint John Regional Hospital; Vancouver General Hospital; Université de Moncton; Horizon Health Network","funders":"","keywords":"Multiple myeloma; Medicine; General partnership; Alliance; Quality of life (healthcare); Disease; Intensive care medicine; Internal medicine; Political science; Nursing","score_opus":0.03986587115633533,"score_gpt":0.33406215830674396,"score_spread":0.29419628715040863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208273355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5793024,0.08671689,4.3297067e-7,0.3326671,0.0003529705,0.00044156206,0.00015113183,0.0000019607892,0.00036558628],"genre_scores_gemma":[0.9441172,0.03596138,0.0012810801,0.014921855,0.0026074767,0.0000271041,0.00016245547,0.00007836941,0.0008431126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951712,0.00125671,0.0013076493,0.0003075885,0.0012543824,0.000702475],"domain_scores_gemma":[0.99514544,0.0020130123,0.00082471065,0.00032976817,0.0015055314,0.00018152867],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020001407,0.00018906714,0.001317468,0.00019303821,0.00011952244,0.000034963494,0.00031133523,0.00043796207,0.000013770555],"category_scores_gemma":[0.0022445293,0.00015609669,0.00013981044,0.0003284049,0.00044951646,0.00005556317,0.00014572659,0.0037020063,3.916744e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092246506,0.00007910882,0.021309221,0.0014181271,0.0004371486,0.33569616,0.00022281401,3.430205e-7,0.000019446177,0.000012977743,0.5796018,0.060280353],"study_design_scores_gemma":[0.015900655,0.0012383696,0.11191802,0.012997476,0.00024290397,0.31452164,0.0060653803,0.00003418548,0.0014256309,0.0009182178,0.5342951,0.00044243474],"about_ca_topic_score_codex":0.2172512,"about_ca_topic_score_gemma":0.7094859,"teacher_disagreement_score":0.49223468,"about_ca_system_score_codex":0.00029022893,"about_ca_system_score_gemma":0.006240364,"threshold_uncertainty_score":0.99939334},"labels":[],"label_agreement":null},{"id":"W3208716659","doi":"10.14309/01.ajg.0000779816.47457.f8","title":"S1571 Isolated Melanoma to Pancreas in the Context of Myeloproliferative Neoplasm: A Rare Occurrence","year":2021,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Melanoma; Biopsy; Pathology; Pancreas; Abdominal pain; Internal medicine; Gastroenterology; Radiology","score_opus":0.01782386864103607,"score_gpt":0.30052466033519276,"score_spread":0.2827007916941567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208716659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874886,0.00012970033,0.00027046943,0.01174783,0.000049857495,0.00021451146,0.00003298007,0.000002520221,0.000063494044],"genre_scores_gemma":[0.99593484,0.00009300445,0.00041020702,0.0034659943,0.000051959498,0.000010940052,0.0000070106776,0.0000066265256,0.000019432686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979208,0.0008406552,0.00045161715,0.00013384197,0.00030640652,0.00034667997],"domain_scores_gemma":[0.9985305,0.00030009935,0.0003775199,0.00027727222,0.0003594282,0.00015516738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043943262,0.0001304785,0.0006757152,0.00014213227,0.000040438612,0.000010482602,0.00028039285,0.00001796849,0.000045756617],"category_scores_gemma":[0.00033395877,0.000067440764,0.00013252118,0.00036547042,0.00032415614,0.000033496286,0.00006501024,0.00039077218,0.000009413249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04610234,0.00053631375,0.9198285,0.000017539638,0.0007093432,0.0026002103,0.0059647695,0.00001708312,0.0035572196,0.000024860952,0.0011326976,0.019509165],"study_design_scores_gemma":[0.007087897,0.038857438,0.9237653,0.00021263344,0.00017611131,0.014083472,0.013525768,0.00014417803,0.0015973093,0.000057808702,0.00041506637,0.00007701853],"about_ca_topic_score_codex":0.00009043673,"about_ca_topic_score_gemma":0.00018774687,"teacher_disagreement_score":0.039014444,"about_ca_system_score_codex":0.00005062049,"about_ca_system_score_gemma":0.00019040598,"threshold_uncertainty_score":0.27501544},"labels":[],"label_agreement":null},{"id":"W3208868326","doi":"10.1503/cmaj.202824-f","title":"Prise en charge du myélome multiple","year":2021,"lang":"fr","type":"letter","venue":"Canadian Medical Association Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Humanities; Philosophy","score_opus":0.014254227692034122,"score_gpt":0.26078339510388204,"score_spread":0.2465291674118479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208868326","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017764052,0.0068063396,0.000056050114,0.95604247,0.009875914,0.0007123381,0.0008004992,0.00003643736,0.007905877],"genre_scores_gemma":[0.050869044,0.012284183,0.00046831247,0.65358317,0.16566819,0.000130726,0.0031225681,0.0003084223,0.11356537],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876044,0.001818345,0.001268803,0.0006528602,0.005716121,0.0029394815],"domain_scores_gemma":[0.9858244,0.0021187179,0.0006010662,0.00040969244,0.0015821934,0.009463953],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0036442294,0.0006420292,0.0012252785,0.0007081212,0.00080132723,0.0004679945,0.00064320414,0.0037340887,0.11376951],"category_scores_gemma":[0.028469034,0.0006019129,0.0007083726,0.0005612439,0.00014101712,0.0002266222,0.00009482446,0.010076776,0.008315934],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000021039661,0.00013190697,0.21962516,0.00013047032,0.0014971306,0.07386377,0.00033492025,4.871658e-7,0.000009685295,0.000023633896,0.6690314,0.03533043],"study_design_scores_gemma":[0.005816459,0.00016546529,0.056105435,0.0012857884,0.00028035004,0.003995767,0.00020526268,0.001018794,0.000017438211,0.000016267904,0.93065375,0.00043920113],"about_ca_topic_score_codex":0.014947059,"about_ca_topic_score_gemma":0.030223154,"teacher_disagreement_score":0.3024593,"about_ca_system_score_codex":0.014274454,"about_ca_system_score_gemma":0.025593525,"threshold_uncertainty_score":0.9996432},"labels":[],"label_agreement":null},{"id":"W3208940288","doi":"10.1038/s41467-021-26598-w","title":"Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; McGill University; University Health Network","funders":"Canadian Institutes of Health Research; Ministry of Colleges and Universities; National Cancer Institute; Ontario Institute for Cancer Research; Government of Canada; University of Toronto; Princess Margaret Hospital Foundation; Princess Margaret Cancer Foundation","keywords":"Multiple myeloma; Computational biology; Biology; Cancer research; Immunology","score_opus":0.04881635500619205,"score_gpt":0.35018255779363605,"score_spread":0.30136620278744397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208940288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915374,0.0045183403,0.00041743586,0.000980283,0.000008430324,0.00044813656,0.00008947972,0.00006952389,0.001931],"genre_scores_gemma":[0.9797779,0.00012144617,0.015578902,0.000037321315,0.0000040796676,0.00009651551,0.003473822,0.000022146405,0.00088787725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984197,0.00016035198,0.0002641249,0.00027062363,0.0006351423,0.00025006515],"domain_scores_gemma":[0.9969316,0.00014046772,0.00016728071,0.0015462826,0.0010613336,0.00015304735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015868775,0.00015608182,0.00038988277,0.000270671,0.0001635037,0.000044730594,0.00034048062,0.00021244543,0.000019800493],"category_scores_gemma":[0.00030232032,0.00012205399,0.00022465359,0.001689614,0.00021263424,0.000078939804,0.00024765194,0.0006124614,0.0000023927705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005136131,0.014616243,0.75442004,0.00012334742,0.010440384,0.00026216244,0.000517543,0.0003628985,0.21111636,0.0014908535,0.00019301494,0.0059435167],"study_design_scores_gemma":[0.008430572,0.0011792998,0.50386,0.0007728187,0.011818911,0.00004868625,0.0005589945,0.14688599,0.32525447,0.00015500389,0.0003618631,0.00067339017],"about_ca_topic_score_codex":0.000015445949,"about_ca_topic_score_gemma":0.00096404855,"teacher_disagreement_score":0.25056005,"about_ca_system_score_codex":0.00012109303,"about_ca_system_score_gemma":0.0002612619,"threshold_uncertainty_score":0.49772173},"labels":[],"label_agreement":null},{"id":"W3210721043","doi":"10.1182/blood-2021-148723","title":"Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Oncology; Phases of clinical research; Gastroenterology; Lenalidomide; Multiple myeloma; Clinical trial","score_opus":0.02074947527204619,"score_gpt":0.2892408066175379,"score_spread":0.26849133134549175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210721043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938685,0.0003660919,0.000038783444,0.00008065574,0.000040435498,0.0044029406,0.0010944394,0.00002971264,0.00007838631],"genre_scores_gemma":[0.9961232,0.000058738988,0.0011532567,0.000009185178,0.00003110018,0.0005226559,0.001858338,0.000041868596,0.00020167933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979928,0.00010977428,0.00043665376,0.0005318698,0.00059040554,0.0003384962],"domain_scores_gemma":[0.9976244,0.00092570996,0.00017912907,0.0007003288,0.00043372973,0.00013671695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103320745,0.00026793475,0.000494991,0.0001109105,0.0001367389,0.00002559407,0.0000924775,0.00007117535,0.0000142117215],"category_scores_gemma":[0.00029465804,0.00015047195,0.00007954482,0.00029488426,0.00008696126,0.00007271906,0.000021973485,0.00012872461,0.0000032487974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053675175,0.22522143,0.69415474,0.000037894377,0.001876526,0.0021098587,0.0029977309,0.000009666199,0.00048708363,0.0000025980344,0.000014139261,0.019413171],"study_design_scores_gemma":[0.38194686,0.03328628,0.57596433,0.000096690106,0.0008538632,0.000016520265,0.001059219,0.00048662728,0.0057569803,0.000003789598,0.00037724373,0.0001516135],"about_ca_topic_score_codex":0.00088285335,"about_ca_topic_score_gemma":0.0032184813,"teacher_disagreement_score":0.3282717,"about_ca_system_score_codex":0.00017574622,"about_ca_system_score_gemma":0.00022998455,"threshold_uncertainty_score":0.6136068},"labels":[],"label_agreement":null},{"id":"W3211377756","doi":"10.1182/blood-2021-152662","title":"DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Tolerability; Medicine; Multiple myeloma; Oncology; Refractory (planetary science); Interim analysis; Lenalidomide; Phases of clinical research; Internal medicine; Pharmacology; Clinical trial; Adverse effect","score_opus":0.014788209068084217,"score_gpt":0.2600192719463961,"score_spread":0.2452310628783119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211377756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968034,0.0003814697,0.0000033998078,0.00006460855,0.00006244647,0.002337773,0.000018695322,0.000040178977,0.00028802562],"genre_scores_gemma":[0.9989854,0.00003641921,0.00027276267,0.00007031999,0.000028419698,0.0001595343,0.00022155906,0.00005507264,0.00017053005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748766,0.00040703962,0.0004178079,0.00046307617,0.00080924545,0.00041517123],"domain_scores_gemma":[0.9980313,0.00068838877,0.000211824,0.0006150502,0.00025703662,0.00019635334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027507835,0.00027671093,0.0004956125,0.00016273539,0.00017342308,0.000037925638,0.00015984161,0.00010942578,0.000024427072],"category_scores_gemma":[0.00057558174,0.00018505834,0.000074870215,0.0005186693,0.00013317833,0.0001067674,0.00007443291,0.00041708694,0.000016106931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005753497,0.014191268,0.97072506,0.00021999048,0.0003292296,0.00028488852,0.0012855345,0.000018051029,0.010292517,0.000008275158,0.00002359624,0.0020462328],"study_design_scores_gemma":[0.06791941,0.0037496744,0.8130503,0.0002664508,0.00013270268,0.00000597792,0.00033279927,0.00017521533,0.11419514,0.0000094483885,0.000016474216,0.00014639401],"about_ca_topic_score_codex":0.00032957364,"about_ca_topic_score_gemma":0.000112585214,"teacher_disagreement_score":0.15767476,"about_ca_system_score_codex":0.00012102508,"about_ca_system_score_gemma":0.00041570063,"threshold_uncertainty_score":0.754646},"labels":[],"label_agreement":null},{"id":"W3211521877","doi":"10.1182/blood-2021-148062","title":"Rivaroxaban for Improvement in Thromboembolism Outcomes in Patients with Multiple Myeloma on Lenalidomide-Based Therapy: The Rithmm Feasibility Pilot Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Victoria Hospital; Health Sciences Centre; Ottawa Hospital; PROTO Manufacturing (Canada); Dalhousie University; University of Ottawa; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Rivaroxaban; Lenalidomide; Internal medicine; Surgery; Randomized controlled trial; Randomization; Adverse effect; Multiple myeloma; Warfarin; Atrial fibrillation","score_opus":0.04579526784693528,"score_gpt":0.3123710177476709,"score_spread":0.2665757499007356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211521877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926375,0.00005234563,0.000011035154,0.0010361301,0.00009100475,0.005945788,0.00011809002,0.00002640319,0.00008168021],"genre_scores_gemma":[0.9976913,0.000007808586,0.0005249656,0.000591604,0.00006594328,0.0008506482,0.00016921057,0.000034664674,0.00006390212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978393,0.00017447161,0.00039567117,0.00051085214,0.00058474287,0.00049499475],"domain_scores_gemma":[0.99834687,0.0005789314,0.000088708126,0.000649667,0.0002020439,0.00013376142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003916985,0.00026096366,0.0005723304,0.000121803845,0.000092204034,0.000036162095,0.00013444824,0.00006538362,0.00004188912],"category_scores_gemma":[0.0006898971,0.00014502114,0.00013995614,0.00024607955,0.00007169167,0.000054101336,0.000038018396,0.00023678015,0.000006103742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06579451,0.022240631,0.9052373,0.00004020077,0.0002538146,0.000050405022,0.00008919825,0.000004716029,0.0005422865,0.000014461275,0.000015109096,0.005717359],"study_design_scores_gemma":[0.34175438,0.0054563535,0.6398189,0.000053327436,0.00003731042,4.0698131e-7,0.000029951489,0.000039665912,0.012629096,0.000049902163,0.000031981122,0.000098748096],"about_ca_topic_score_codex":0.000360188,"about_ca_topic_score_gemma":0.0010910921,"teacher_disagreement_score":0.27595985,"about_ca_system_score_codex":0.00015818863,"about_ca_system_score_gemma":0.00031689662,"threshold_uncertainty_score":0.59137905},"labels":[],"label_agreement":null},{"id":"W3211565834","doi":"10.1038/s41375-021-01454-4","title":"Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"AL amyloidosis; Amyloidosis; Medicine; Multiple myeloma; Internal medicine; Monoclonal gammopathy of undetermined significance; Family history; Gastroenterology; Hazard ratio; Cohort; Family aggregation; Disease; Immunology; Immunoglobulin light chain; Confidence interval; Monoclonal; Antibody","score_opus":0.014922197300437649,"score_gpt":0.23336242953106298,"score_spread":0.21844023223062534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211565834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495107,0.0018246843,0.000011504946,0.00010321071,0.000103711325,0.00042070157,0.000057781814,0.000032716678,0.0024945973],"genre_scores_gemma":[0.9946823,0.0003643421,0.00024287614,0.00013482485,0.000014365589,0.000044886925,0.00011106014,0.00003625224,0.0043690754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984216,0.00011589988,0.0003012247,0.0003993417,0.0003739212,0.00038801783],"domain_scores_gemma":[0.9990085,0.00026219155,0.00011798957,0.00029616058,0.0001230722,0.00019212265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015296061,0.0002078606,0.00051148765,0.00012947053,0.000030614643,0.000008645517,0.00007178977,0.00013473455,0.00003536818],"category_scores_gemma":[0.00020158905,0.0001756086,0.00007346794,0.00022548644,0.00011562002,0.00006555199,0.00006029969,0.00026209163,0.000007767031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009741166,0.0003690323,0.7833795,0.00033845386,0.00031065318,0.00033042015,0.0010622042,0.0000062431004,0.20675468,0.0000029267887,0.0013718352,0.0050999443],"study_design_scores_gemma":[0.028121898,0.00066758686,0.9326645,0.00059642707,0.00014614587,0.000038718703,0.0013370177,0.015025227,0.019201396,0.00000561737,0.0018555357,0.00033991394],"about_ca_topic_score_codex":0.0031780007,"about_ca_topic_score_gemma":0.0028159479,"teacher_disagreement_score":0.18755329,"about_ca_system_score_codex":0.0023737699,"about_ca_system_score_gemma":0.0012556826,"threshold_uncertainty_score":0.71611106},"labels":[],"label_agreement":null},{"id":"W3211611146","doi":"10.1111/ejh.13726","title":"Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains","year":2021,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Oncology; Medicine; Cohort; Multiple myeloma; Bortezomib; Internal medicine; Immunoglobulin light chain; Dexamethasone; Cyclophosphamide; Clearance; Melphalan; Complete response; Kinetics; Immunology; Chemotherapy; Urology; Antibody","score_opus":0.023104294104956746,"score_gpt":0.3006644771747745,"score_spread":0.2775601830698178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211611146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864155,0.0044233035,0.0003748586,0.008261135,0.000050459996,0.00014748506,0.000017042157,0.000004322713,0.00030586994],"genre_scores_gemma":[0.9940423,0.0005150483,0.004823859,0.00020463413,0.000027863969,0.0000015424175,0.000004218953,0.000021837828,0.00035874554],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982441,0.000679032,0.00050785835,0.0001657525,0.00018812252,0.00021514685],"domain_scores_gemma":[0.99889463,0.00037603415,0.00017389026,0.00016517154,0.00015370593,0.00023654172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058948575,0.00013130243,0.000545901,0.00022577507,0.000032322947,0.000014280071,0.000073162744,0.000030393103,0.000088762215],"category_scores_gemma":[0.0005379189,0.00009930691,0.000047721605,0.00012888436,0.000096436364,0.00004312924,0.000094403455,0.00020739983,0.000002611523],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00777744,0.0015743817,0.33948365,0.00045262836,0.0005316048,0.058255114,0.0044992683,0.000009040294,0.57269156,0.00011383632,0.003757003,0.010854464],"study_design_scores_gemma":[0.01329717,0.005007253,0.8747924,0.00046749253,0.0000642461,0.012408616,0.0011300517,0.00012671578,0.069246165,0.00002314135,0.023272334,0.0001644045],"about_ca_topic_score_codex":0.000002999914,"about_ca_topic_score_gemma":0.00006280763,"teacher_disagreement_score":0.5353088,"about_ca_system_score_codex":0.000029341125,"about_ca_system_score_gemma":0.000058372934,"threshold_uncertainty_score":0.40496182},"labels":[],"label_agreement":null},{"id":"W3211648211","doi":"10.1182/blood-2021-150092","title":"Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Medicine; Monoclonal; AL amyloidosis; Pathology; Flow cytometry; Phenotype; Internal medicine; Gastroenterology; Immunology; Monoclonal antibody; Immunoglobulin light chain; Biology; Antibody; Genetics","score_opus":0.04212614470195446,"score_gpt":0.3117220646237578,"score_spread":0.2695959199218033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211648211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986306,0.00018643631,0.000002039899,0.000072416085,0.00002722792,0.00057060167,0.000017379285,0.000006356237,0.00048697044],"genre_scores_gemma":[0.9991575,0.00005246487,0.0006119586,0.000042855165,0.000020410342,0.000040071154,0.000015287784,0.000008787024,0.000050698687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998941,0.00016222039,0.00023034458,0.00021551803,0.00030904662,0.00014187029],"domain_scores_gemma":[0.999384,0.00013864563,0.00006046363,0.00021863611,0.00012509462,0.00007320175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015482807,0.00008260299,0.00021249775,0.0000318337,0.000035866433,0.000007983961,0.000044730547,0.000035425837,0.00001753434],"category_scores_gemma":[0.00023654534,0.000049895905,0.00003664664,0.00018424587,0.000092188915,0.000029127446,0.000058204936,0.00015225164,0.0000036690146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044447667,0.0072997776,0.9890457,0.000037627655,0.00014373423,0.00013756055,0.00019975181,2.1169052e-7,0.0000918682,0.000025676409,0.000008913482,0.0025647306],"study_design_scores_gemma":[0.014514232,0.0013755758,0.9828593,0.000088588364,0.0001424775,0.00000912587,0.00026911253,0.000012811916,0.0006118516,0.00005881857,0.000011700499,0.00004636373],"about_ca_topic_score_codex":0.00009008415,"about_ca_topic_score_gemma":0.0005354768,"teacher_disagreement_score":0.014069756,"about_ca_system_score_codex":0.000014092829,"about_ca_system_score_gemma":0.00015382581,"threshold_uncertainty_score":0.20346959},"labels":[],"label_agreement":null},{"id":"W3211914517","doi":"10.1182/blood-2021-146012","title":"Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Venetoclax; Multiple myeloma; Medicine; Refractory (planetary science); Lenalidomide; Immunology; Cancer research; Oncology; Biology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.008048729171041265,"score_gpt":0.21969716987758914,"score_spread":0.21164844070654787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211914517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975905,0.0014533611,0.0000015461244,0.00004330948,0.000012473342,0.0007693216,0.000015058929,0.0000058848495,0.00010859185],"genre_scores_gemma":[0.9990497,0.00028468197,0.00048375945,0.0000031303991,0.000005027961,0.000024330267,0.000044435204,0.000018600613,0.00008633871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886376,0.0001721098,0.0002500406,0.00028833892,0.0002432171,0.0001825537],"domain_scores_gemma":[0.9991673,0.00012467061,0.00016842372,0.00024158545,0.0002337499,0.00006426331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108831715,0.00014610526,0.0003207541,0.00014685017,0.000059486178,0.000011292295,0.000032289397,0.000082747014,0.0000028878815],"category_scores_gemma":[0.0001451143,0.000096468146,0.000018327504,0.00033318918,0.0002025464,0.0001113132,0.000054274817,0.00015770977,4.8485113e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00219871,0.0019548752,0.8164322,0.00029123452,0.000105815736,0.00011950783,0.0011001909,0.00000407583,0.17221758,0.0000033165456,0.0000027535698,0.0055697686],"study_design_scores_gemma":[0.033983994,0.0012239836,0.5583424,0.0004941959,0.00009480129,0.000047434492,0.0006882889,0.000118109994,0.40492254,0.000005572279,0.0000065148993,0.00007217081],"about_ca_topic_score_codex":0.0005035888,"about_ca_topic_score_gemma":0.00021735551,"teacher_disagreement_score":0.2580898,"about_ca_system_score_codex":0.000074662246,"about_ca_system_score_gemma":0.00017917271,"threshold_uncertainty_score":0.39338568},"labels":[],"label_agreement":null},{"id":"W3211931509","doi":"10.1182/blood-2021-147551","title":"Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Enhancer; BRD4; Bromodomain; Cancer research; Bortezomib; Biology; Ixazomib; Transcription factor; Multiple myeloma; Chromatin; Acetylation; Carfilzomib; Genetics; Immunology; Gene","score_opus":0.0265716416777689,"score_gpt":0.30919431805025294,"score_spread":0.28262267637248406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211931509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98874134,0.00047799115,0.000060842616,0.00083127676,0.00006705147,0.00034721603,0.00002158942,0.00008573776,0.009366941],"genre_scores_gemma":[0.98967916,0.00004898353,0.003642297,0.00024342042,0.00021773661,0.00007332737,0.000078606165,0.00002824785,0.0059882044],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861836,0.00004302274,0.00017673367,0.00038287838,0.00031665564,0.00046235],"domain_scores_gemma":[0.9989189,0.00011423811,0.000018483683,0.00040642405,0.00011461963,0.00042732846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059917504,0.00015890454,0.00026820792,0.00008105108,0.000109448985,0.000035979865,0.000069903144,0.00006106171,0.0004971387],"category_scores_gemma":[0.00052626117,0.00013326416,0.00011657652,0.00029238174,0.000024399904,0.00005411043,0.00008400996,0.00012657876,0.00042767107],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020460448,0.0016356151,0.6746509,0.00018848827,0.00031293157,0.004091407,0.00061825337,0.000002845724,0.26318425,0.000037774076,0.00043041806,0.054642476],"study_design_scores_gemma":[0.010657884,0.00044002046,0.35100338,0.00014083312,0.00018325435,0.00029801,0.00033458628,0.00007851774,0.63357276,0.00001549329,0.003080058,0.00019523092],"about_ca_topic_score_codex":0.00012220789,"about_ca_topic_score_gemma":0.0001295854,"teacher_disagreement_score":0.37038848,"about_ca_system_score_codex":0.00007034781,"about_ca_system_score_gemma":0.00015562733,"threshold_uncertainty_score":0.5496989},"labels":[],"label_agreement":null},{"id":"W3212141300","doi":"10.1182/blood-2021-152681","title":"Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Lenalidomide; Carfilzomib; Internal medicine; Surgery","score_opus":0.01438412536529552,"score_gpt":0.2536311524582137,"score_spread":0.2392470270929182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212141300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966953,0.0002696565,0.000011308355,0.00023718868,0.00006590642,0.0009920346,0.000086083666,0.00009314794,0.0015493722],"genre_scores_gemma":[0.99619323,0.000042747866,0.0017184115,0.000099650795,0.000038587055,0.0001597455,0.0009940731,0.000063208696,0.00069037103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726146,0.00014538075,0.0005855063,0.0006460316,0.0007614862,0.0006001219],"domain_scores_gemma":[0.99792135,0.00014558173,0.00018966314,0.00089675485,0.00044958974,0.00039703635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012506825,0.00028736697,0.0004173365,0.0002357777,0.00015582073,0.000040054118,0.000113768794,0.00013572178,0.00011418513],"category_scores_gemma":[0.00081368425,0.00024073872,0.00010274277,0.00057589164,0.00006949015,0.00012714652,0.00009296163,0.00034585063,0.000038403556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035420162,0.0055455663,0.9797015,0.000052782372,0.00057096715,0.0016483532,0.00036151736,0.000011139405,0.0017491303,0.000008035473,0.00010460476,0.009892194],"study_design_scores_gemma":[0.025466066,0.0006732952,0.9656538,0.00029707173,0.00024469945,0.000083637446,0.00014531735,0.0001123636,0.006459698,0.000008514666,0.0006140124,0.0002415466],"about_ca_topic_score_codex":0.000557137,"about_ca_topic_score_gemma":0.00065329164,"teacher_disagreement_score":0.025111863,"about_ca_system_score_codex":0.00021444049,"about_ca_system_score_gemma":0.00047327075,"threshold_uncertainty_score":0.981704},"labels":[],"label_agreement":null},{"id":"W3212241519","doi":"10.1182/blood-2021-150641","title":"Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Bromodomain; BRD4; Multiple myeloma; Cancer research; BET inhibitor; Enhancer; Biology; Medicine; Molecular biology; Internal medicine; Gene; Gene expression; Genetics; Epigenetics","score_opus":0.02636046732419182,"score_gpt":0.3021907183115276,"score_spread":0.27583025098733577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212241519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974653,0.00015422027,0.000026103342,0.0015982132,0.000021401123,0.0005850542,0.000031553103,0.000012499805,0.00010564069],"genre_scores_gemma":[0.9975479,0.000031587806,0.001976495,0.000026495783,0.00002673213,0.00013663381,0.00013656623,0.000012307392,0.00010528268],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989077,0.00014379846,0.0002936838,0.00024692246,0.0002194731,0.00018845999],"domain_scores_gemma":[0.9991618,0.0003143472,0.000046884492,0.00021341395,0.00014223221,0.00012132908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026067818,0.000087278975,0.00020271781,0.00024627385,0.00003720515,0.00000951257,0.00003465102,0.00006349514,0.000018583081],"category_scores_gemma":[0.0012360614,0.000087018125,0.000027453172,0.0004329046,0.000026367446,0.00007329813,0.0000612377,0.00009380848,0.0000057411717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030194916,0.0008685266,0.46792975,0.000040735697,0.0000195765,0.000028920715,0.0009397426,0.00000857688,0.52678216,0.000034776174,0.000009495279,0.0030357821],"study_design_scores_gemma":[0.0071184775,0.00017014431,0.79128575,0.00011194111,0.000017255725,0.000008826321,0.00018296542,0.00043943102,0.20052902,0.000052626765,0.000030848438,0.00005271181],"about_ca_topic_score_codex":0.00010204969,"about_ca_topic_score_gemma":0.0005357967,"teacher_disagreement_score":0.32625315,"about_ca_system_score_codex":0.00009970056,"about_ca_system_score_gemma":0.00013773234,"threshold_uncertainty_score":0.35484964},"labels":[],"label_agreement":null},{"id":"W3212303742","doi":"10.1182/blood-2021-147915","title":"Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Antibody; Medicine; Antigen; Refractory (planetary science); Immunology; Cancer research; Biology","score_opus":0.029544945508862545,"score_gpt":0.3206302640846435,"score_spread":0.29108531857578096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212303742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996113,0.00074882247,0.000008042829,0.00009511943,0.00010321732,0.0012215957,0.00053436594,0.00007061695,0.0011052351],"genre_scores_gemma":[0.994771,0.00017265497,0.0009014893,0.000019712603,0.00009649407,0.00003363093,0.00342106,0.000043939734,0.0005400109],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971511,0.000261263,0.00081038603,0.0007047147,0.0006495962,0.00042293489],"domain_scores_gemma":[0.99810994,0.00024584265,0.00023577503,0.00089991937,0.00028539484,0.00022315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000236333,0.00027397132,0.0005858411,0.00031305625,0.000081814476,0.000039561164,0.00014968673,0.00016776989,0.00016482733],"category_scores_gemma":[0.00046076084,0.00024490632,0.00010454314,0.00073292083,0.00005718199,0.000121531164,0.00010607151,0.0003711099,0.00007146078],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077177836,0.061554685,0.3038848,0.00007246125,0.00046429213,0.0070072063,0.0019231638,0.000005597519,0.6137159,0.0000020666532,0.000286415,0.0033656291],"study_design_scores_gemma":[0.1519756,0.0020570313,0.64296037,0.0001796753,0.00018623372,0.000030983312,0.0022072522,0.00039208366,0.19905126,0.000009737687,0.0007233645,0.00022640412],"about_ca_topic_score_codex":0.0013053243,"about_ca_topic_score_gemma":0.0008968497,"teacher_disagreement_score":0.41466463,"about_ca_system_score_codex":0.00007223009,"about_ca_system_score_gemma":0.00025364975,"threshold_uncertainty_score":0.99869895},"labels":[],"label_agreement":null},{"id":"W3212319088","doi":"10.1016/s2152-2650(21)02339-9","title":"P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interim analysis; Cohort; Oncology; Refractory (planetary science); Dosing; Internal medicine; Multiple myeloma; Biomarker; Adverse effect; Combination therapy; Lenalidomide; Interim; Clinical trial","score_opus":0.04562237161427093,"score_gpt":0.3188402669338923,"score_spread":0.2732178953196214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212319088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440205,0.00013022784,0.000052774307,0.0002629986,0.00042754723,0.0033222297,0.00017324493,0.00014105605,0.0010878551],"genre_scores_gemma":[0.99396026,0.00014694428,0.0011416026,0.00043178455,0.00019320312,0.0003787154,0.0020679631,0.00017849015,0.0015010209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924358,0.0004309376,0.0021355627,0.0017381905,0.0017959165,0.0014635584],"domain_scores_gemma":[0.99468166,0.0018206943,0.0006451351,0.0013444063,0.0005634544,0.00094465783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007574814,0.0009202043,0.00193895,0.00057165214,0.0002061197,0.00011273336,0.00044153884,0.0007593475,0.00020609696],"category_scores_gemma":[0.0018427613,0.00068833015,0.0003765152,0.0011144066,0.00042757698,0.00048410127,0.0003445284,0.0011000752,0.00013977368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09544959,0.010754054,0.74471766,0.00011322995,0.00044858328,0.002089906,0.0002085987,0.000014600059,0.00006048957,0.00006550713,0.00024938677,0.1458284],"study_design_scores_gemma":[0.2966602,0.005279678,0.69447106,0.0008109246,0.00013402429,0.000053509913,0.00015268975,0.0009901015,0.0003752371,0.000042413263,0.00050976145,0.0005203692],"about_ca_topic_score_codex":0.00063504744,"about_ca_topic_score_gemma":0.0022010047,"teacher_disagreement_score":0.20121063,"about_ca_system_score_codex":0.003571287,"about_ca_system_score_gemma":0.0020986896,"threshold_uncertainty_score":0.9995568},"labels":[],"label_agreement":null},{"id":"W3212530786","doi":"10.1182/blood-2021-151466","title":"Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Interquartile range; Multiple myeloma; Regimen; Stage (stratigraphy); Internal medicine; Referral; Family medicine","score_opus":0.06384833249801761,"score_gpt":0.33749987252539126,"score_spread":0.2736515400273737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212530786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876257,0.00071386155,0.000009212709,0.00021285411,0.00004803583,0.00035026713,0.000037227383,0.00004512893,0.010957698],"genre_scores_gemma":[0.9954192,0.00023658753,0.001112718,0.0000744481,0.00008435101,0.00017321469,0.00016510632,0.000019931318,0.0027144433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986873,0.000054444245,0.00023388497,0.0003839639,0.00022883025,0.00041152656],"domain_scores_gemma":[0.99924,0.00005855806,0.000030705,0.0003840246,0.00007589453,0.00021085794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038697828,0.0001854854,0.00030265396,0.00009242546,0.000054513803,0.00004433704,0.000057206595,0.00007299195,0.0009009437],"category_scores_gemma":[0.000078839614,0.00014348989,0.000093957475,0.00020796931,0.000053145246,0.0001264813,0.000048127764,0.000117761396,0.000091556285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079469144,0.018216237,0.8535497,0.00017248026,0.00047827404,0.016415767,0.0040510856,0.000004938095,0.084952585,0.00014452085,0.00009557973,0.02112414],"study_design_scores_gemma":[0.06241369,0.0018260382,0.5646829,0.00023598842,0.00010081558,0.0008649455,0.0036687683,0.00033196402,0.35424182,0.00008900428,0.0111913225,0.00035273458],"about_ca_topic_score_codex":0.00011484294,"about_ca_topic_score_gemma":0.001733968,"teacher_disagreement_score":0.2888668,"about_ca_system_score_codex":0.00010017081,"about_ca_system_score_gemma":0.00026594766,"threshold_uncertainty_score":0.98647016},"labels":[],"label_agreement":null},{"id":"W3212592260","doi":"10.1182/blood-2021-152993","title":"Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Biology; Cancer research; Gene expression profiling; Multiple myeloma; Epigenomics; Epigenetics; Chromatin; Venetoclax; Epigenetic therapy; Chromosomal translocation; Molecular biology; Gene; Genetics; Gene expression; DNA methylation; Leukemia; Immunology","score_opus":0.02714428134344178,"score_gpt":0.2679746298240504,"score_spread":0.24083034848060864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212592260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902779,0.008412225,0.000060380982,0.00014599698,0.000014320023,0.00013983516,0.00010799592,0.000012477472,0.0008289103],"genre_scores_gemma":[0.9973598,0.0004947079,0.0010205619,0.000023371551,0.000014748661,0.000008256567,0.0002034602,0.000009975981,0.0008651163],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990593,0.000055146917,0.00019006191,0.00025612905,0.00025743336,0.00018190373],"domain_scores_gemma":[0.9993865,0.000056114375,0.000034483073,0.00014073636,0.00019196587,0.00019021964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006550114,0.00011034921,0.00031020105,0.00019600838,0.000041302723,0.000014812055,0.000031033775,0.000064079446,0.00033821558],"category_scores_gemma":[0.000079662794,0.00009236393,0.000087010536,0.00048593112,0.000042043834,0.00003565799,0.000022139082,0.00007858183,0.0000039431047],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010565657,0.0022406874,0.3625466,0.0001673465,0.0017386915,0.00039120845,0.0003154747,0.0000022683193,0.6269579,0.000101144025,0.000007348625,0.0054256674],"study_design_scores_gemma":[0.0047011613,0.00029223942,0.7071154,0.000040915027,0.0026511012,0.0000641715,0.00013546935,0.0005377638,0.28424305,0.000039227853,0.00009533273,0.000084168016],"about_ca_topic_score_codex":0.00006933364,"about_ca_topic_score_gemma":0.00036428004,"teacher_disagreement_score":0.3445688,"about_ca_system_score_codex":0.000012625033,"about_ca_system_score_gemma":0.00009871884,"threshold_uncertainty_score":0.37664917},"labels":[],"label_agreement":null},{"id":"W3212668607","doi":"10.1182/blood-2021-151249","title":"Prognostic Factors for Early (&amp;lt;2 years) and Late (&amp;gt;5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Cohort; Multivariate analysis; Odds ratio; Multiple myeloma; Oncology","score_opus":0.039429567468611794,"score_gpt":0.285232250251891,"score_spread":0.24580268278327919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212668607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963904,0.0023903616,0.000007663701,0.000052392938,0.00003578822,0.00084264914,0.00014995062,0.000029361494,0.0001014014],"genre_scores_gemma":[0.9959451,0.00017312227,0.0027109883,0.000013706798,0.000056351008,0.00010601643,0.00018360406,0.00004042335,0.00077069266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865896,0.00005578508,0.00022558607,0.00035938868,0.00028794928,0.00041230902],"domain_scores_gemma":[0.99903965,0.0002792693,0.00006520062,0.000301547,0.000098487726,0.00021583811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109150074,0.00016951202,0.00036439495,0.00016839273,0.00003475476,0.000021918702,0.00006944601,0.00011894389,0.000058778194],"category_scores_gemma":[0.0007136713,0.00015990142,0.00008463249,0.00022574503,0.0000755108,0.000042286956,0.000085623666,0.00013254791,0.00002287059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018587125,0.0008571799,0.86212677,0.00013038274,0.00020366142,0.00013878843,0.001091046,9.965389e-7,0.12914304,0.000009563835,0.000009490285,0.0061032115],"study_design_scores_gemma":[0.007850732,0.0004500307,0.96611893,0.00016298008,0.00017236696,0.000033134347,0.00009222799,0.000031786938,0.023954622,0.00006689731,0.0009312253,0.00013504976],"about_ca_topic_score_codex":0.00012464137,"about_ca_topic_score_gemma":0.0010032115,"teacher_disagreement_score":0.10518842,"about_ca_system_score_codex":0.000023738266,"about_ca_system_score_gemma":0.0001022491,"threshold_uncertainty_score":0.6520591},"labels":[],"label_agreement":null},{"id":"W3212782606","doi":"10.1182/blood-2021-150998","title":"Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Alberta; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Dalhousie University; University of Calgary; Institute of Cancer Research; Vancouver General Hospital; CancerCare Manitoba","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Bortezomib; Pomalidomide; Oncology; Chimeric antigen receptor; Pharmacology; Immunotherapy; Cancer","score_opus":0.009864349185879324,"score_gpt":0.24097564005758013,"score_spread":0.2311112908717008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212782606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813116,0.0002864086,0.000021109287,0.00020580483,0.000029699282,0.00095469627,0.00006187834,0.00004578345,0.0002634655],"genre_scores_gemma":[0.9938487,0.000036495254,0.0045975097,0.00009633037,0.00004984524,0.00013120571,0.00066233246,0.000035835325,0.0005417667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849623,0.00007471723,0.00023186018,0.00041891675,0.00039092012,0.00038732513],"domain_scores_gemma":[0.9990688,0.00005827986,0.00006006558,0.00042212056,0.00019594989,0.00019480879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000474413,0.00022630523,0.00031773373,0.00013117188,0.000056867346,0.00003198164,0.00004163111,0.0000851348,0.00011780203],"category_scores_gemma":[0.000052259737,0.00015959021,0.000078227604,0.00027126382,0.00003093801,0.00007961457,0.000021570584,0.00010223684,0.000076774726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014857583,0.007972372,0.9843405,0.00006401716,0.00014248122,0.0016695706,0.00011322746,0.000009522475,0.0024921596,4.4938253e-7,0.000020669611,0.001689264],"study_design_scores_gemma":[0.040740557,0.0010206955,0.87534946,0.00011170966,0.00011284648,0.000011431125,0.000027007238,0.0002618924,0.08193168,6.725468e-7,0.00029251585,0.0001395556],"about_ca_topic_score_codex":0.000072107476,"about_ca_topic_score_gemma":0.00019928139,"teacher_disagreement_score":0.10899107,"about_ca_system_score_codex":0.0001172992,"about_ca_system_score_gemma":0.00030069303,"threshold_uncertainty_score":0.65079004},"labels":[],"label_agreement":null},{"id":"W3212884449","doi":"10.1016/s2152-2650(21)02100-5","title":"OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; McGill University Health Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Internal medicine; Minimal residual disease; Pharmacokinetics; Multiple myeloma; Oncology; Gastroenterology; Pharmacodynamics; Neutropenia; Pharmacology; Toxicity; Chimeric antigen receptor; Bone marrow; Immunotherapy; Cancer","score_opus":0.038156058875315195,"score_gpt":0.32254077801467923,"score_spread":0.28438471913936403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212884449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926033,0.00070150103,0.00029928135,0.00016671128,0.0005156944,0.0043972824,0.0002848147,0.00021434457,0.0008170665],"genre_scores_gemma":[0.9864747,0.00040341192,0.008127131,0.00027320994,0.00034043688,0.00044300986,0.0016961792,0.00022976416,0.002012168],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9919453,0.00094376685,0.0023505352,0.0018847362,0.00161782,0.0012578082],"domain_scores_gemma":[0.99215776,0.0024732684,0.00091573177,0.0018225968,0.0016979078,0.00093271176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008962682,0.0008569445,0.0018421533,0.00041771238,0.00050623924,0.00012861758,0.0005224665,0.00059156993,0.00033563268],"category_scores_gemma":[0.0035852902,0.0006675845,0.0005682467,0.0011768718,0.00036706924,0.00041003054,0.0003017973,0.00070228876,0.0001249913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057110205,0.023690885,0.41267657,0.0009506349,0.0019715792,0.0043813465,0.0011944808,0.000027018672,0.012115473,0.000024398996,0.005078759,0.48077863],"study_design_scores_gemma":[0.07675521,0.013611869,0.8891897,0.000412468,0.00047194815,0.00007645214,0.0015566392,0.0026974801,0.01063495,0.00002078339,0.0038834566,0.0006890178],"about_ca_topic_score_codex":0.00024127967,"about_ca_topic_score_gemma":0.00030677303,"teacher_disagreement_score":0.4800896,"about_ca_system_score_codex":0.0010862611,"about_ca_system_score_gemma":0.0024538094,"threshold_uncertainty_score":0.9995775},"labels":[],"label_agreement":null},{"id":"W3212917465","doi":"10.1182/blood-2021-153011","title":"Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Transplantation; Medicine; Oncology; Monosomy; Internal medicine; Autologous stem-cell transplantation; Chromosome abnormality; Biology; Karyotype; Genetics; Chromosome","score_opus":0.00946990536767246,"score_gpt":0.26121099036784434,"score_spread":0.2517410850001719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212917465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990053,0.00030634343,0.000013967254,0.000024360981,0.0000051190623,0.00019577227,0.000088100365,0.000006382773,0.00035461513],"genre_scores_gemma":[0.99904716,0.0001621591,0.00063740055,0.0000056186095,0.000010730373,0.0000048712745,0.000084462474,0.000008643574,0.00003897559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934036,0.000026290136,0.00013476606,0.0001212369,0.00024378828,0.00013357011],"domain_scores_gemma":[0.9994894,0.00006331319,0.00004743271,0.00013014923,0.00015851398,0.000111191104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038183003,0.000077997654,0.0002254866,0.00003142884,0.000016683663,0.0000027748004,0.000018666122,0.000036501417,0.00008220199],"category_scores_gemma":[0.00005679565,0.00005070324,0.000053654072,0.00010704434,0.000043912463,0.000027390312,0.000008854656,0.00005094771,0.0000010437922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054940826,0.0015175453,0.9758673,0.000106251966,0.0005012574,0.0001156529,0.000109798384,4.0049778e-7,0.01899834,0.0000067734095,0.000007183994,0.0022201468],"study_design_scores_gemma":[0.012950798,0.0015467274,0.9340412,0.00014358827,0.0002069154,0.00004162682,0.000011424337,0.000008746647,0.050994307,0.000011485189,0.0000027291148,0.000040461302],"about_ca_topic_score_codex":0.00008303213,"about_ca_topic_score_gemma":0.000019691908,"teacher_disagreement_score":0.04182605,"about_ca_system_score_codex":0.0000122433285,"about_ca_system_score_gemma":0.000104673156,"threshold_uncertainty_score":0.2067618},"labels":[],"label_agreement":null},{"id":"W3213172814","doi":"10.1182/blood-2021-144421","title":"Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Dexamethasone; Daratumumab; Multiple myeloma; Medicine; Internal medicine; Oncology","score_opus":0.02593192923513089,"score_gpt":0.2995565192646997,"score_spread":0.27362459002956885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213172814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952647,0.0010951967,0.000016359558,0.0003459345,0.000032514265,0.0029241315,0.00026808365,0.000018433093,0.000034664492],"genre_scores_gemma":[0.9981577,0.00039269996,0.0009236453,0.00004634532,0.00001431174,0.00013260712,0.00026576195,0.00003816919,0.000028765644],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99626935,0.00068663,0.0012073418,0.0005907758,0.0006612038,0.00058471883],"domain_scores_gemma":[0.99745584,0.0009146331,0.0005036565,0.00050075573,0.00026397425,0.0003611396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080192555,0.00035884744,0.0012498309,0.00025257916,0.000082729144,0.00002225117,0.00011276101,0.00013658618,0.000026269798],"category_scores_gemma":[0.0009775985,0.00023020283,0.00008797729,0.000882601,0.00025883777,0.00012489127,0.000083632876,0.00033880374,3.9893806e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30237272,0.00609792,0.68332106,0.0005839685,0.00074455957,0.00022993213,0.0005148988,0.000014683623,0.0027611514,0.000018785571,0.0000049272135,0.0033353928],"study_design_scores_gemma":[0.6125498,0.0044004177,0.36108133,0.00050072744,0.0002088451,0.000007917443,0.00045986183,0.0001247632,0.02047491,0.000010272399,0.000004291721,0.00017689826],"about_ca_topic_score_codex":0.007712873,"about_ca_topic_score_gemma":0.007823517,"teacher_disagreement_score":0.32223973,"about_ca_system_score_codex":0.00011407259,"about_ca_system_score_gemma":0.00072436355,"threshold_uncertainty_score":0.9988949},"labels":[],"label_agreement":null},{"id":"W3213271749","doi":"10.1038/s41571-021-00581-2","title":"Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Oncology; Internal medicine; Intensive care medicine; Bortezomib","score_opus":0.2276479383870076,"score_gpt":0.5494101196842723,"score_spread":0.32176218129726475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213271749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007837666,0.9899261,0.0000045889437,0.0017184522,0.00084543106,0.0037823897,0.00015558071,0.00003390598,0.0034552019],"genre_scores_gemma":[0.000057706646,0.9866425,0.007408564,0.0013684558,0.0011086786,0.00059099804,0.0019375266,0.00010020605,0.00078541087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98812723,0.005119283,0.003757374,0.001733512,0.00050968636,0.00075291854],"domain_scores_gemma":[0.9871443,0.0089089265,0.0016462874,0.0011692973,0.00018461376,0.000946601],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00352613,0.00087771827,0.0114801815,0.0003098401,0.00012741495,0.000056106914,0.00039856212,0.004487783,0.00028703804],"category_scores_gemma":[0.016757028,0.0005801553,0.0015033274,0.0008743506,0.0003682159,0.00007233983,0.00057976076,0.009434083,0.00026377136],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007613151,0.0009814701,0.0015979818,0.0052127372,0.00046231798,0.008429874,0.000017546601,1.7354601e-8,3.4211462e-7,0.00015405499,0.004648356,0.9784192],"study_design_scores_gemma":[0.004729626,0.00092946633,0.002140632,0.026762707,0.0017519916,0.00026576652,0.000018839997,0.000006881211,1.2468374e-7,0.000073699055,0.9629204,0.00039983666],"about_ca_topic_score_codex":0.00020989143,"about_ca_topic_score_gemma":0.0018739686,"teacher_disagreement_score":0.97801936,"about_ca_system_score_codex":0.0007313381,"about_ca_system_score_gemma":0.0034176994,"threshold_uncertainty_score":0.99966496},"labels":[],"label_agreement":null},{"id":"W3213312927","doi":"10.1182/blood-2021-150232","title":"Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; CancerCare Manitoba; Vancouver General Hospital; McGill University Health Centre","funders":"","keywords":"Pomalidomide; Medicine; Carfilzomib; Internal medicine; Regimen; Population; Oncology; Refractory (planetary science); Multiple myeloma; Adverse effect; Dexamethasone; Daratumumab; Pharmacology; Gastroenterology; Bortezomib; Biology","score_opus":0.012462478136754619,"score_gpt":0.25182255970764145,"score_spread":0.23936008157088684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213312927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979626,0.0005521036,0.0000068215213,0.00008483118,0.0000070328347,0.00094016345,0.000054438347,0.000039034152,0.00035298397],"genre_scores_gemma":[0.994965,0.00015600477,0.0043182382,0.000024561936,0.000019090267,0.000023162269,0.0003299226,0.000038215196,0.00012580925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822503,0.00009140242,0.0003468141,0.00046178818,0.00042449575,0.00045044927],"domain_scores_gemma":[0.9988268,0.00018106599,0.00012343115,0.00035194893,0.00030071137,0.00021603318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011485624,0.00026306827,0.00062650733,0.00015272517,0.00007606721,0.000019339932,0.000059880902,0.00007813478,0.000034515233],"category_scores_gemma":[0.00019487948,0.0001804098,0.00004543295,0.000346179,0.00012919065,0.00009691502,0.000066752655,0.00018509034,0.0000034229795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00609724,0.0027460144,0.98563457,0.00015848603,0.00070583785,0.0008775119,0.00035016882,0.000010658652,0.0012101162,0.000008802689,0.0000070587084,0.002193517],"study_design_scores_gemma":[0.06469554,0.002301884,0.92146426,0.00075195497,0.0002630893,0.00008467884,0.00012827161,0.00010777848,0.010007951,0.0000015108548,0.000024159088,0.00016889414],"about_ca_topic_score_codex":0.00017163488,"about_ca_topic_score_gemma":0.00018745603,"teacher_disagreement_score":0.0641703,"about_ca_system_score_codex":0.00003896124,"about_ca_system_score_gemma":0.00019470979,"threshold_uncertainty_score":0.7356898},"labels":[],"label_agreement":null},{"id":"W3213323870","doi":"10.1186/s12885-021-08881-7","title":"Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study","year":2021,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Weill Cornell Medical College; Janssen Scientific Affairs","keywords":"Daratumumab; Medicine; Internal medicine; Surgical oncology; Multiple myeloma; Oncology; Bortezomib","score_opus":0.052386753905377385,"score_gpt":0.37895811123165873,"score_spread":0.32657135732628134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213323870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912543,0.0059161093,0.000009468924,0.000023237038,0.000039005496,0.0023419803,0.00036625672,0.000012926793,0.00003670227],"genre_scores_gemma":[0.9890986,0.00985257,0.000054965003,0.000016189933,0.000033543212,0.0006967751,0.00015658553,0.000026667187,0.00006408907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984764,0.00025412365,0.00031382655,0.00034429476,0.00036772323,0.00024366147],"domain_scores_gemma":[0.9987757,0.0003046002,0.0001670062,0.00033873104,0.0002993695,0.00011458516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010732194,0.0002233258,0.0007569815,0.000048477898,0.00006493986,0.000009159262,0.000042986452,0.000026292026,0.00005874134],"category_scores_gemma":[0.000065806984,0.00013346504,0.000086176246,0.00020382612,0.000051396495,0.00004627872,0.000055811302,0.000067494606,5.444754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023044497,0.0026646797,0.9659859,0.003674603,0.00059020764,0.000037163885,0.00047465696,9.896264e-7,0.00024189103,9.0979046e-7,0.0000017459289,0.024022821],"study_design_scores_gemma":[0.017704438,0.0021043604,0.9643625,0.0039757034,0.00015545335,0.0000019452991,0.00014936837,0.000027004919,0.011382717,7.025754e-7,0.000033540742,0.00010223384],"about_ca_topic_score_codex":0.0022737386,"about_ca_topic_score_gemma":0.010324383,"teacher_disagreement_score":0.023920586,"about_ca_system_score_codex":0.00015265349,"about_ca_system_score_gemma":0.00014953343,"threshold_uncertainty_score":0.5761248},"labels":[],"label_agreement":null},{"id":"W3213371026","doi":"10.1182/blood-2021-148481","title":"Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary; University of Alberta","funders":"","keywords":"Lenalidomide; Ixazomib; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Oncology; Placebo; Carfilzomib; Pathology","score_opus":0.02882644790991139,"score_gpt":0.30070417148720346,"score_spread":0.27187772357729206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213371026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295574,0.00021560662,0.000012550785,0.0009802933,0.000046509384,0.005164556,0.0005031154,0.00009472994,0.000026866132],"genre_scores_gemma":[0.9965182,0.00008097919,0.0012432601,0.00022234351,0.000058292557,0.0007804013,0.00024492628,0.00014413612,0.0007074774],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99005646,0.004887244,0.0013685641,0.0011483534,0.001339367,0.0012000266],"domain_scores_gemma":[0.9844116,0.012506636,0.00078752,0.0011117688,0.00065618154,0.0005262745],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035526203,0.0008421966,0.002069815,0.00076533284,0.00017535427,0.00013554073,0.0003567727,0.00039360547,0.00007395315],"category_scores_gemma":[0.021931907,0.0004993214,0.00024155606,0.0017940195,0.0003610202,0.0003116948,0.00015433051,0.0008608738,0.0000075475423],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5018038,0.009988661,0.47404832,0.000055128017,0.00094546535,0.0051873713,0.001188835,0.0000073905867,0.005880845,2.8697428e-7,0.000016757927,0.00087714306],"study_design_scores_gemma":[0.42503142,0.011066663,0.545157,0.0005688977,0.00049646123,0.000048260616,0.0006992069,0.00022148012,0.016356854,0.0000022027707,0.000014987139,0.0003365605],"about_ca_topic_score_codex":0.0017528164,"about_ca_topic_score_gemma":0.008991157,"teacher_disagreement_score":0.07677237,"about_ca_system_score_codex":0.00028694826,"about_ca_system_score_gemma":0.0009953439,"threshold_uncertainty_score":0.99974585},"labels":[],"label_agreement":null},{"id":"W3213542315","doi":"10.1016/s2152-2650(21)02075-9","title":"OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Daratumumab; Dexamethasone; Clinical endpoint; Hazard ratio; Interim analysis; Surgery; Gastroenterology; Oncology; Confidence interval; Randomized controlled trial","score_opus":0.04464540784505627,"score_gpt":0.3670065401425495,"score_spread":0.32236113229749325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213542315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928766,0.0014368818,0.00010366181,0.00081305124,0.00035493987,0.0030619996,0.00046056838,0.00019324533,0.0006990819],"genre_scores_gemma":[0.99259645,0.001376936,0.0019386987,0.00014193344,0.0003646988,0.0006170393,0.0018004538,0.00014091963,0.0010228686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992019,0.0013466579,0.0019063607,0.001932169,0.0014962621,0.0012995775],"domain_scores_gemma":[0.9933295,0.0031187837,0.00039542373,0.001530306,0.00037644623,0.0012495117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013014423,0.00095265836,0.0021029292,0.00026059663,0.0003594107,0.00022036719,0.0003603329,0.00048144892,0.00017675293],"category_scores_gemma":[0.0015982949,0.00070865103,0.00032601636,0.0007325123,0.00043040342,0.0004128635,0.00020628843,0.00051770784,0.000064929234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02744276,0.017492661,0.64784217,0.00012942035,0.0011217681,0.017065298,0.00048038116,0.000006859257,0.0021410908,0.000037530186,0.0008187165,0.28542134],"study_design_scores_gemma":[0.21696638,0.007873899,0.76640797,0.00037412698,0.00044913747,0.00028971996,0.0006348404,0.0015230165,0.003213789,0.00004794003,0.0015893637,0.0006298261],"about_ca_topic_score_codex":0.0019517548,"about_ca_topic_score_gemma":0.0049751224,"teacher_disagreement_score":0.2847915,"about_ca_system_score_codex":0.0014484419,"about_ca_system_score_gemma":0.0019242539,"threshold_uncertainty_score":0.99953645},"labels":[],"label_agreement":null},{"id":"W3213621180","doi":"10.1182/blood-2021-153315","title":"DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Tolerability; Cohort; Bortezomib; Regimen; Internal medicine; Oncology; Adverse effect; Surgery","score_opus":0.012040937761254046,"score_gpt":0.2802904466225992,"score_spread":0.2682495088613452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213621180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713784,0.0004067904,0.000009319237,0.000017741226,0.000023193448,0.0014820604,0.00069080695,0.000021381422,0.00021085393],"genre_scores_gemma":[0.9986928,0.000051909257,0.00054640585,0.000008114898,0.00001780997,0.00006377363,0.00055145286,0.000032344364,0.000035401186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797314,0.00010618762,0.0004413355,0.00036306967,0.0007580451,0.0003582476],"domain_scores_gemma":[0.9987321,0.00014065982,0.00011234954,0.00042870542,0.0003940539,0.00019212277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007842982,0.00021354725,0.00073933374,0.00019719201,0.000039060033,0.0000083769,0.00010140814,0.0000684799,0.00006836274],"category_scores_gemma":[0.00010535349,0.00016601382,0.000077588884,0.000416336,0.000047308866,0.00005959937,0.000038797963,0.00016088922,0.0000030879853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016773773,0.017309327,0.95345074,0.00041288242,0.00050562725,0.0019730723,0.0048151626,0.000015400281,0.0006864861,0.0000015488802,0.000009679333,0.004046274],"study_design_scores_gemma":[0.23624381,0.012855011,0.68460906,0.00041484038,0.00037281826,0.000011392654,0.0032230609,0.000018599658,0.062103596,9.4499035e-7,0.000016431502,0.00013040818],"about_ca_topic_score_codex":0.0006735928,"about_ca_topic_score_gemma":0.0033324638,"teacher_disagreement_score":0.26884168,"about_ca_system_score_codex":0.000071192,"about_ca_system_score_gemma":0.00038241316,"threshold_uncertainty_score":0.6769847},"labels":[],"label_agreement":null},{"id":"W3213704960","doi":"10.1182/blood-2021-153994","title":"Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Pomalidomide; Bortezomib; Panobinostat; Multiple myeloma; Dexamethasone; Ixazomib; Proteasome inhibitor; Carfilzomib; Pharmacology; Medicine; Chemistry; Immunology; Cancer research; Internal medicine; Biochemistry","score_opus":0.030104273116348328,"score_gpt":0.34843880240225616,"score_spread":0.31833452928590783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213704960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799424,0.00082209456,0.000011911617,0.00009493989,0.000060725382,0.0008395306,0.000005591257,0.000016967833,0.00015399157],"genre_scores_gemma":[0.9975653,0.00038052088,0.0016375753,0.000052438358,0.000041045558,0.00004863635,0.000038336668,0.000022176822,0.00021393615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795204,0.00038828404,0.00069210975,0.00040129496,0.00028748022,0.0002787686],"domain_scores_gemma":[0.997834,0.0013993249,0.00011067652,0.00035630417,0.00011010052,0.00018956837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005651803,0.0001531117,0.0006369161,0.00013340598,0.000025029016,0.000011487241,0.00006433516,0.00016651743,0.00001561922],"category_scores_gemma":[0.0021885172,0.00011249857,0.00008484419,0.00027444417,0.00019881861,0.00007758985,0.00007960821,0.00034621096,0.000005641306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031193728,0.017735992,0.9644657,0.0002552535,0.00029551555,0.0027549306,0.00009323286,2.2484033e-7,0.00075685297,0.000017914732,0.000009547282,0.010495495],"study_design_scores_gemma":[0.12999749,0.0022017325,0.86012137,0.00045087782,0.00011262849,0.00008600572,0.000038804013,0.0003534887,0.006499219,0.000023012286,0.000023736531,0.0000916442],"about_ca_topic_score_codex":0.00019913334,"about_ca_topic_score_gemma":0.000987944,"teacher_disagreement_score":0.12687811,"about_ca_system_score_codex":0.000027842496,"about_ca_system_score_gemma":0.00035709675,"threshold_uncertainty_score":0.45875585},"labels":[],"label_agreement":null},{"id":"W3213759191","doi":"10.1182/blood-2021-149339","title":"Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Plasma cell leukemia; Internal medicine; Creatinine; Lenalidomide; Gastroenterology; Surgery; Oncology","score_opus":0.03303626481738194,"score_gpt":0.3652707919915378,"score_spread":0.33223452717415586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213759191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886394,0.00012053258,0.000003699526,0.00018989679,0.000059531787,0.000508552,0.0000088691095,0.000041093776,0.00020391827],"genre_scores_gemma":[0.9933036,0.000007337766,0.0060529183,0.0000921774,0.00003453965,0.000047903653,0.00015133491,0.000023279154,0.00028693693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984105,0.00007709676,0.00031532062,0.00037056103,0.00047750588,0.00034897312],"domain_scores_gemma":[0.9990742,0.00021974008,0.000043630578,0.00031590762,0.00008738298,0.000259106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012716587,0.000149041,0.00039137996,0.00006324928,0.0000418378,0.000016967728,0.00006236506,0.0001096906,0.00006586629],"category_scores_gemma":[0.0011360539,0.00008566886,0.00013268279,0.0002385848,0.000042072683,0.000054736254,0.00008487794,0.0002223855,0.000034076387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088002475,0.0063548815,0.9809606,0.00003437716,0.00029762083,0.0018597597,0.00002409209,3.26698e-8,0.0002167545,8.764813e-7,0.0000448234,0.009326179],"study_design_scores_gemma":[0.03984331,0.00072389585,0.9524542,0.00024116109,0.000102932914,0.0000086570735,0.0000241663,0.000013106041,0.0063956752,0.0000021059084,0.00009104481,0.000099719546],"about_ca_topic_score_codex":0.00000986586,"about_ca_topic_score_gemma":0.000034576915,"teacher_disagreement_score":0.038963284,"about_ca_system_score_codex":0.000029231498,"about_ca_system_score_gemma":0.00019934657,"threshold_uncertainty_score":0.34934744},"labels":[],"label_agreement":null},{"id":"W3214037196","doi":"10.1182/blood-2021-146043","title":"Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Dexamethasone; Venetoclax; Oncology; Multiple myeloma; Bortezomib; Lenalidomide; Proteasome inhibitor; Phases of clinical research; Gastroenterology; Clinical trial; Surgery; Leukemia; Chronic lymphocytic leukemia","score_opus":0.015627071897642265,"score_gpt":0.27519022754206174,"score_spread":0.25956315564441945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214037196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303013,0.0037734872,0.000018420787,0.00003855419,0.00003869148,0.0028226052,0.00021529432,0.000021505522,0.000041332285],"genre_scores_gemma":[0.9979449,0.00044726822,0.0010954635,0.000021685995,0.000029929208,0.000081276456,0.0002908325,0.00005016793,0.000038470385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694073,0.0004385578,0.0006586008,0.0007876411,0.0007677328,0.0004067531],"domain_scores_gemma":[0.99704075,0.0013113994,0.00027997504,0.0007952367,0.00027336486,0.00029928007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003851453,0.00037756367,0.0010593014,0.00015475924,0.00017410557,0.000027578883,0.0001242112,0.00016609795,0.00002055906],"category_scores_gemma":[0.000810874,0.00026460362,0.000052608622,0.000403931,0.00033463884,0.00015730837,0.00029073394,0.0004238464,6.690453e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031504884,0.008031583,0.94229746,0.00014139937,0.00094352616,0.0005133662,0.003812664,0.000015172586,0.001795299,0.0000017923342,0.000014052038,0.010928788],"study_design_scores_gemma":[0.15979885,0.009073777,0.8249985,0.0004595233,0.00076330674,0.00003582446,0.00128483,0.000671547,0.0026907194,0.0000028346042,0.00002859294,0.00019169901],"about_ca_topic_score_codex":0.0017183597,"about_ca_topic_score_gemma":0.0010165923,"teacher_disagreement_score":0.12829396,"about_ca_system_score_codex":0.00015931403,"about_ca_system_score_gemma":0.00047150688,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W3214062012","doi":"10.1182/blood-2021-146862","title":"Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Population; Emergency department; Nausea; Depression (economics); Health care; Emergency medicine; Family medicine; Psychiatry; Internal medicine; Environmental health","score_opus":0.02539162776975244,"score_gpt":0.29463116859813493,"score_spread":0.2692395408283825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214062012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970284,0.00022186578,0.000051641404,0.000113748225,0.000018190583,0.0021410747,0.00031299164,0.00005886592,0.00005323809],"genre_scores_gemma":[0.9953329,0.000012683702,0.0003678481,0.00006876298,0.00002666688,0.00015089393,0.0039610686,0.00004056779,0.000038595772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976373,0.00013847057,0.00037341402,0.00047702354,0.0010031934,0.00037062756],"domain_scores_gemma":[0.99822295,0.0001594282,0.00018719034,0.00040936522,0.000756126,0.00026496916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000814625,0.00024150312,0.00056867476,0.00014058479,0.00016137061,0.000023397297,0.000074723175,0.00006697346,0.000073361916],"category_scores_gemma":[0.00011952543,0.00017784182,0.00006142797,0.0006170354,0.000029781198,0.00006463779,0.00001627174,0.00013010087,0.0000027252056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008967343,0.006653625,0.9882754,0.00017361974,0.0011956297,0.00029569745,0.0019190962,0.00010566367,0.000005410501,7.291434e-7,0.000019105131,0.00045926718],"study_design_scores_gemma":[0.050740533,0.0033002575,0.9432206,0.0004974349,0.00054094795,0.0000048339602,0.00064112793,0.00022704684,0.000670088,2.7055543e-7,0.0000047460917,0.00015210846],"about_ca_topic_score_codex":0.0033495945,"about_ca_topic_score_gemma":0.0053992346,"teacher_disagreement_score":0.0498438,"about_ca_system_score_codex":0.00014921789,"about_ca_system_score_gemma":0.00061038154,"threshold_uncertainty_score":0.72521794},"labels":[],"label_agreement":null},{"id":"W3214324911","doi":"10.1182/blood-2021-146324","title":"Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Royal Victoria Hospital; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Bortezomib; Dexamethasone; Internal medicine; Medicine; Oncology; Cytogenetics; Progression-free survival; Chemotherapy; Biology; Chromosome","score_opus":0.014842797403253912,"score_gpt":0.2671911534404253,"score_spread":0.25234835603717143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214324911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780285,0.0011907718,0.000012264154,0.0000671946,0.000010026288,0.0006414595,0.000032939166,0.00002786382,0.00021459737],"genre_scores_gemma":[0.99622744,0.00043416666,0.0029057467,0.000038316684,0.000017900406,0.00006427699,0.000035459085,0.000028738294,0.0002479594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866855,0.00014839445,0.0002211723,0.00035327443,0.00030645198,0.00030217014],"domain_scores_gemma":[0.99864465,0.0006885723,0.000070626695,0.00030303904,0.00009349582,0.0001996145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009753786,0.00019929738,0.0005160163,0.00015183022,0.00003825238,0.000010005581,0.000042996493,0.00008105906,0.000019037963],"category_scores_gemma":[0.00072768325,0.00013670752,0.00006134886,0.00028755883,0.0000704749,0.000025472831,0.00003688525,0.00017162955,0.000009563966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070139364,0.0028883568,0.9631732,0.00019698584,0.0005640006,0.0020167523,0.00008472498,0.0000036059353,0.022114431,0.0000039268766,0.0000036937831,0.008248906],"study_design_scores_gemma":[0.024104236,0.0011278058,0.6796918,0.00016370529,0.00028580625,0.000053380303,0.00003370677,0.000101653284,0.29434052,0.0000063716943,0.000009183674,0.00008186812],"about_ca_topic_score_codex":0.00037796004,"about_ca_topic_score_gemma":0.00035363558,"teacher_disagreement_score":0.28348145,"about_ca_system_score_codex":0.000024566252,"about_ca_system_score_gemma":0.00009386428,"threshold_uncertainty_score":0.5574771},"labels":[],"label_agreement":null},{"id":"W3214338991","doi":"10.1182/blood-2021-147812","title":"CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University","funders":"","keywords":"Bortezomib; Cereblon; Dexamethasone; Medicine; Lenalidomide; Multiple myeloma; Refractory (planetary science); Internal medicine; Pharmacology; Oncology; Ubiquitin ligase; Chemistry; Biology; Ubiquitin","score_opus":0.023712702083550627,"score_gpt":0.2703067045698111,"score_spread":0.24659400248626046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214338991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944698,0.0005903112,0.000038775892,0.00033411724,0.00006264417,0.0037313243,0.0005675172,0.000075916985,0.00012959719],"genre_scores_gemma":[0.9964216,0.0001048161,0.0013285964,0.00012490254,0.00007065949,0.0003247876,0.0013022325,0.000110391615,0.00021204689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955766,0.0003472218,0.00082790415,0.0012996675,0.0011751,0.0007734604],"domain_scores_gemma":[0.99692285,0.00070928334,0.0003474444,0.0011843434,0.00037051432,0.00046558172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049329264,0.00058814534,0.0008111961,0.00031996347,0.00021405594,0.00009772792,0.0002403095,0.00020959131,0.00001340668],"category_scores_gemma":[0.00092061615,0.00040671366,0.00008687798,0.0008687071,0.00015316645,0.00036013348,0.00022564322,0.0007814026,0.00001323216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023932353,0.22525088,0.73107076,0.000068903224,0.0008128268,0.003089254,0.0027741313,0.000011483701,0.001363835,0.0000034991647,0.000077603196,0.011544498],"study_design_scores_gemma":[0.36096483,0.009996623,0.6218192,0.00042357857,0.0003756635,0.00004632153,0.0011146137,0.0014038477,0.0034943246,0.0000065927766,0.00005821668,0.0002961775],"about_ca_topic_score_codex":0.0027338893,"about_ca_topic_score_gemma":0.0032691383,"teacher_disagreement_score":0.33703247,"about_ca_system_score_codex":0.00025771974,"about_ca_system_score_gemma":0.00037984253,"threshold_uncertainty_score":0.9998385},"labels":[],"label_agreement":null},{"id":"W3214392141","doi":"10.1182/blood-2021-152984","title":"Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Carfilzomib; Multiple myeloma; Internal medicine; Refractory (planetary science); Bortezomib; Population; Clinical endpoint; Oncology; Proteasome inhibitor; Phases of clinical research; Lenalidomide; Clinical trial","score_opus":0.031146593383131953,"score_gpt":0.3333311392751745,"score_spread":0.3021845458920425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214392141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931392,0.00019410762,0.000009726312,0.00004540465,0.000071168884,0.0060631996,0.00011312105,0.000035011893,0.000329081],"genre_scores_gemma":[0.9947298,0.00006001678,0.0035224834,0.000062730374,0.000032375912,0.00043959075,0.0005046574,0.00007051909,0.00057782966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99644655,0.0005905516,0.00079398975,0.00075918186,0.0008530077,0.0005566955],"domain_scores_gemma":[0.99735725,0.00043252524,0.00025449638,0.0010305527,0.00049628154,0.00042891013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043986947,0.0003679268,0.0013331833,0.00026170208,0.00009872074,0.0000565541,0.0003505582,0.0001198284,0.0003649103],"category_scores_gemma":[0.0010711778,0.00025150733,0.00005828713,0.0005301825,0.00014202303,0.00038526498,0.00025012047,0.00034894716,0.000020384166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42394158,0.24980548,0.30478355,0.00016830512,0.0012521148,0.0034591407,0.0018005654,0.0000012392288,0.0029231668,0.000001356425,0.000049544124,0.011813966],"study_design_scores_gemma":[0.76807076,0.018424151,0.20800488,0.0002660356,0.000513362,0.000011437606,0.0009144933,0.0004563252,0.003084079,0.0000013881229,0.000041531337,0.00021155468],"about_ca_topic_score_codex":0.0011548373,"about_ca_topic_score_gemma":0.0022857503,"teacher_disagreement_score":0.3441292,"about_ca_system_score_codex":0.0000785723,"about_ca_system_score_gemma":0.00036317777,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W3214401861","doi":"10.1182/blood-2021-151242","title":"Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Blockade; Cancer research; Immune checkpoint; Bone marrow; Immune system; T cell; Immunology; Medicine; Biology; Receptor; Internal medicine","score_opus":0.020697118025805348,"score_gpt":0.28825409320888573,"score_spread":0.26755697518308036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214401861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993799,0.00042683794,0.000013984614,0.00035651863,0.000016586095,0.0010816498,0.00003475566,0.000013837926,0.004256887],"genre_scores_gemma":[0.99635684,0.00007804841,0.0015057501,0.000089931185,0.00003247268,0.00017636648,0.000054545148,0.000019740324,0.001686301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983567,0.00018343078,0.000286659,0.0003323057,0.00047089037,0.00036999257],"domain_scores_gemma":[0.99912894,0.0001718443,0.000076269185,0.0003034358,0.00014059701,0.00017890467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020179313,0.00019254832,0.00034432704,0.00023059215,0.000053971384,0.00001961463,0.000077305966,0.00003345002,0.000028141185],"category_scores_gemma":[0.000028456885,0.000114839095,0.00008537079,0.0007350388,0.000033489894,0.00003245925,0.000038686063,0.00012767705,0.000023978168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006082646,0.0236891,0.28316846,0.0002876135,0.00082383724,0.0035855246,0.016708786,0.0000737775,0.66332215,0.000024789064,0.00020465361,0.002028662],"study_design_scores_gemma":[0.01695625,0.0038948983,0.05120818,0.000142371,0.00014503679,0.00006114774,0.0012270976,0.000017126571,0.9257636,0.00001699691,0.00045846563,0.00010885205],"about_ca_topic_score_codex":0.00029777896,"about_ca_topic_score_gemma":0.0004745714,"teacher_disagreement_score":0.26244143,"about_ca_system_score_codex":0.00019256104,"about_ca_system_score_gemma":0.00039854628,"threshold_uncertainty_score":0.46830022},"labels":[],"label_agreement":null},{"id":"W3214512886","doi":"10.1182/blood-2021-153876","title":"Outcomes of Maintenance Treatment Post Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients: A Canadian Single Center Experience","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Internal medicine; Autologous stem-cell transplantation; Cohort; Maintenance therapy; Oncology; Transplantation; Proportional hazards model; Single Center; Retrospective cohort study; Univariate analysis; Surgery; Multivariate analysis; Chemotherapy","score_opus":0.017718298065217963,"score_gpt":0.25433554100460515,"score_spread":0.23661724293938718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214512886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978886,0.00013735205,0.000008134302,0.00021631298,0.00006100317,0.0005854732,0.00037605446,0.0000181283,0.000708904],"genre_scores_gemma":[0.998427,0.0001081585,0.00046617133,0.00014111039,0.0000089782825,0.0001073756,0.00037825477,0.000018296569,0.00034470763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986524,0.000067017434,0.0002988705,0.00030878372,0.00022895042,0.00044399334],"domain_scores_gemma":[0.9990966,0.000120306955,0.00006137896,0.00026191503,0.0001655985,0.00029421676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000027774508,0.00017578047,0.00034252138,0.00015618026,0.000045608336,0.000012442382,0.00006592581,0.00007157424,0.000057646248],"category_scores_gemma":[0.00006691494,0.00013981156,0.0000980445,0.00018473092,0.00004426964,0.000074299365,0.000011276144,0.00006628648,0.000016470798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022551572,0.004700026,0.976708,0.00006939268,0.000084901665,0.0029247918,0.0030592172,0.0000025157158,0.002914129,0.000002803654,0.0000077401355,0.009300988],"study_design_scores_gemma":[0.023229932,0.0007445257,0.91212267,0.00009895268,0.000056147863,0.000034131455,0.00072141807,0.00003088305,0.06275365,0.0000012668075,0.00010361327,0.00010282974],"about_ca_topic_score_codex":0.037527114,"about_ca_topic_score_gemma":0.17373371,"teacher_disagreement_score":0.1362066,"about_ca_system_score_codex":0.0002652939,"about_ca_system_score_gemma":0.00030585047,"threshold_uncertainty_score":0.9688821},"labels":[],"label_agreement":null},{"id":"W3214582472","doi":"10.1182/blood-2021-148673","title":"Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Unfolded protein response; XBP1; Downregulation and upregulation; Mitochondrion; Biology; Cancer research; Apoptosis; Gene signature; Molecular biology; Gene; Cell biology; Gene expression; Endoplasmic reticulum; Genetics; RNA","score_opus":0.044417988746988955,"score_gpt":0.3174616241647744,"score_spread":0.2730436354177855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214582472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937247,0.002987324,0.0004436232,0.00050984527,0.00002450742,0.0018214153,0.00026483653,0.00007126187,0.0001524952],"genre_scores_gemma":[0.98610383,0.0001913861,0.011767998,0.00006836431,0.00021717855,0.0006751533,0.000100571386,0.00005927462,0.0008162242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981643,0.000067316614,0.00025050036,0.0005869546,0.00041159548,0.00051934057],"domain_scores_gemma":[0.99843884,0.0003522085,0.00012031198,0.00038750982,0.0002185524,0.00048258548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015719596,0.00026624196,0.00035591642,0.000082099825,0.00036219694,0.00009676888,0.0000698305,0.00007269267,0.000019856096],"category_scores_gemma":[0.00067171984,0.0001980339,0.0000927009,0.0002445068,0.00009432432,0.00013981813,0.00008077635,0.0001952959,0.0000056157946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011698232,0.006253389,0.8166516,0.002307452,0.0031364637,0.003185138,0.00079138455,0.00001235379,0.13385111,0.0006990848,0.000048125665,0.021365708],"study_design_scores_gemma":[0.04788559,0.0015459094,0.8309837,0.0013850218,0.0018185854,0.00017448403,0.0009567577,0.00072698924,0.11262777,0.00083516847,0.0004698268,0.00059022126],"about_ca_topic_score_codex":0.00011553115,"about_ca_topic_score_gemma":0.00023405587,"teacher_disagreement_score":0.03618736,"about_ca_system_score_codex":0.00005337206,"about_ca_system_score_gemma":0.0004051,"threshold_uncertainty_score":0.8075588},"labels":[],"label_agreement":null},{"id":"W3214826832","doi":"10.1182/blood-2021-153632","title":"A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; CancerCare Manitoba","funders":"","keywords":"Lenalidomide; Autologous stem-cell transplantation; Multiple myeloma; Melphalan; Medicine; Internal medicine; Maintenance therapy; Transplantation; Oncology; Bortezomib; Surgery; Chemotherapy","score_opus":0.06499604698242274,"score_gpt":0.3708422051237642,"score_spread":0.3058461581413415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214826832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955017,0.00041279505,0.00005563594,0.00020784678,0.000054286873,0.003125276,0.00051294774,0.000025999127,0.00010353668],"genre_scores_gemma":[0.9939552,0.00045227268,0.0045012813,0.00007684902,0.0000285573,0.00046897313,0.00016988508,0.000036650923,0.00031032707],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99776626,0.00018185878,0.00049379887,0.0006386545,0.00042788993,0.00049151876],"domain_scores_gemma":[0.9987816,0.00011686295,0.00009393003,0.00044601553,0.00019464247,0.00036694366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002162399,0.00028117406,0.00072443334,0.00022723427,0.00008548702,0.000058055248,0.00016042787,0.000081204416,0.000026456322],"category_scores_gemma":[0.00028169111,0.00023319258,0.00005273211,0.00046677195,0.00004203218,0.00018450644,0.00015301294,0.00018306117,0.00000948482],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017880937,0.27707458,0.58068377,0.0001918219,0.0015779866,0.008915512,0.0056077745,0.0000026558575,0.053015497,0.00000641004,0.00015860584,0.05488443],"study_design_scores_gemma":[0.7534544,0.009617736,0.15262759,0.0006816875,0.00039679295,0.0002241053,0.0025092755,0.00014399405,0.0798116,0.000008423883,0.00026264746,0.00026174402],"about_ca_topic_score_codex":0.0023208533,"about_ca_topic_score_gemma":0.005508215,"teacher_disagreement_score":0.7355735,"about_ca_system_score_codex":0.00012426054,"about_ca_system_score_gemma":0.00022461703,"threshold_uncertainty_score":0.9509317},"labels":[],"label_agreement":null},{"id":"W3214859407","doi":"10.1016/j.ctarc.2021.100494","title":"Aging-associated immune system changes in multiple myeloma: The dark side of the moon.","year":2021,"lang":"en","type":"review","venue":"Cancer Treatment and Research Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Immunosenescence; Immunosurveillance; Immune system; Disease; Immunology; Medicine; Immunotherapy; Bone marrow; Senescence; Internal medicine","score_opus":0.24505326140434658,"score_gpt":0.465090804440809,"score_spread":0.22003754303646245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214859407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007970477,0.9909037,1.3493134e-7,0.0030914543,0.000058950918,0.0034797161,0.00031897952,0.000022708491,0.0013273156],"genre_scores_gemma":[0.05388077,0.93937343,0.000031965694,0.0000063427356,0.000045232413,0.003981098,0.00041510502,0.00004578182,0.0022202597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954359,0.0024828417,0.0005420502,0.0003796075,0.0005884328,0.00057115586],"domain_scores_gemma":[0.99354357,0.0025812788,0.0002484538,0.003031858,0.00043899755,0.000155839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010121079,0.00033660638,0.0013811627,0.00032400244,0.0008611291,0.00006297942,0.0009628355,0.00020887192,0.000022355558],"category_scores_gemma":[0.00053655426,0.00015994058,0.00038777126,0.0014899268,0.0008732068,0.00003470176,0.0010435195,0.00092773564,0.000008815675],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003213251,0.0011055932,0.00476921,0.004769083,0.002459462,0.00004078591,0.0008089981,6.0997263e-7,0.00002034523,0.00037349365,0.00021675619,0.98540354],"study_design_scores_gemma":[0.004393663,0.0003851006,0.011715174,0.06141781,0.0016876329,0.000063673986,0.0018397892,0.00017335948,0.0001813107,0.000015342182,0.9178211,0.00030603752],"about_ca_topic_score_codex":0.0052956413,"about_ca_topic_score_gemma":0.010851009,"teacher_disagreement_score":0.98509747,"about_ca_system_score_codex":0.0020236606,"about_ca_system_score_gemma":0.0016713145,"threshold_uncertainty_score":0.80054605},"labels":[],"label_agreement":null},{"id":"W3215143226","doi":"10.1038/s41416-021-01608-2","title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Royal Victoria Hospital; Dalhousie University; University of Toronto; University of Alberta; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba","funders":"Karyopharm Therapeutics; American Society of Clinical Oncology","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Dexamethasone; Adverse effect; Internal medicine; Nausea; Multiple myeloma; Oncology; Gastroenterology; Lenalidomide","score_opus":0.016647814103603182,"score_gpt":0.30554761793782803,"score_spread":0.28889980383422487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215143226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757092,0.022956323,0.00002694238,0.00035313232,0.00027156327,0.0002465914,0.00011002813,0.0000074773957,0.00031874957],"genre_scores_gemma":[0.9860635,0.010569012,0.002015567,0.00027196165,0.00031060493,0.000020172674,0.000028309662,0.00003506498,0.00068580953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793714,0.00012000595,0.00058572623,0.00028609473,0.00064701226,0.000424013],"domain_scores_gemma":[0.99813133,0.00018141004,0.0002442844,0.00015492168,0.0008485847,0.0004394434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027093707,0.00017753975,0.0005921116,0.00015666561,0.00007630673,0.00006831884,0.00009920318,0.00011527138,0.00024639774],"category_scores_gemma":[0.00087915827,0.0001822383,0.00013588207,0.00029357706,0.00008703311,0.00025524388,0.000072791925,0.0005822914,0.0000054135803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058401056,0.0005143417,0.64103436,0.0000961518,0.00019871692,0.005169254,0.00014633813,0.000013027212,0.0038507392,4.289733e-7,0.0010124764,0.34738013],"study_design_scores_gemma":[0.017153706,0.00035712266,0.96762806,0.0013849292,0.00008522591,0.0011173937,0.00018367854,0.00021316315,0.0041159466,0.000011295459,0.007586127,0.0001633646],"about_ca_topic_score_codex":0.0023389412,"about_ca_topic_score_gemma":0.004822416,"teacher_disagreement_score":0.34721678,"about_ca_system_score_codex":0.00035685487,"about_ca_system_score_gemma":0.0006757067,"threshold_uncertainty_score":0.74314624},"labels":[],"label_agreement":null},{"id":"W3215543426","doi":"10.1038/s41409-021-01532-2","title":"Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study","year":2021,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Bortezomib; Minimal residual disease; Multiple myeloma; Prospective cohort study; Oncology; Transplantation; Surgery; Bone marrow","score_opus":0.015076073740852848,"score_gpt":0.29242407272908183,"score_spread":0.277347998988229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215543426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953291,0.0001725116,0.0005019868,0.00033128884,0.00025275958,0.0022471524,0.00090514333,0.00012664136,0.00013344643],"genre_scores_gemma":[0.99316067,0.00135601,0.0007251168,0.00011059833,0.000030169522,0.00043401457,0.0030170975,0.000063742424,0.001102587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963383,0.0004108445,0.00085794495,0.0008023979,0.0008192374,0.0007712861],"domain_scores_gemma":[0.99860424,0.00031364328,0.00019160124,0.00039801135,0.00017285283,0.0003196409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037381347,0.00045280586,0.00089668686,0.00027340464,0.00028919915,0.000049119626,0.000131367,0.00019128624,0.0001768203],"category_scores_gemma":[0.00023371857,0.00035576773,0.00019035446,0.00053939986,0.00005478398,0.00021437585,0.00002052329,0.00038529944,0.0000174994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062961224,0.007814202,0.9450229,0.00014915313,0.0004700609,0.011235213,0.003310964,0.00000988916,0.0072901314,0.0000034817463,0.00026795396,0.018129975],"study_design_scores_gemma":[0.081493944,0.0034675575,0.9098798,0.00027494613,0.00061826524,0.00011377359,0.0004805152,0.00017637617,0.0031089177,0.000012662262,0.000034857392,0.0003383923],"about_ca_topic_score_codex":0.0014891407,"about_ca_topic_score_gemma":0.013501426,"teacher_disagreement_score":0.075197816,"about_ca_system_score_codex":0.0002762092,"about_ca_system_score_gemma":0.00028554667,"threshold_uncertainty_score":0.99988943},"labels":[],"label_agreement":null},{"id":"W3215615180","doi":"10.1182/blood-2021-154506","title":"Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Bone marrow; Minimal residual disease; Maintenance therapy; Immune system; Oncology; Internal medicine; Hematology; Immunology; Chemotherapy","score_opus":0.005425268742964134,"score_gpt":0.2016910275470722,"score_spread":0.19626575880410804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215615180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998873,0.00008020358,0.000016943843,0.0002102978,0.000009330739,0.00066270045,0.000044829365,0.0000109096545,0.000091768256],"genre_scores_gemma":[0.9990387,0.00001784848,0.0002094154,0.00003560335,0.000006714867,0.000032354852,0.00009111925,0.000021819595,0.0005464089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986582,0.00010918682,0.00023236763,0.00023690163,0.0004399821,0.00032336454],"domain_scores_gemma":[0.9992046,0.000056914596,0.00015276979,0.00034471697,0.00017130213,0.00006973139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008823238,0.00014646922,0.00027924732,0.000051133127,0.000078590834,0.000009987436,0.00007212614,0.000046181045,0.00003834186],"category_scores_gemma":[0.0002785599,0.000087943954,0.000054332268,0.00035480483,0.000088163644,0.00007544272,0.000081730934,0.00013410034,0.000001948092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011138425,0.0023161967,0.9860864,0.00007816363,0.00032345878,0.00014550997,0.00025688423,0.000022651877,0.009524251,0.0000027266449,0.0000035860155,0.00012628919],"study_design_scores_gemma":[0.026529921,0.00019887423,0.7496247,0.00035390182,0.0000772171,0.000007711089,0.00010217284,0.000049987015,0.22297984,0.0000019813472,0.0000045416723,0.00006910906],"about_ca_topic_score_codex":0.00013183174,"about_ca_topic_score_gemma":0.0003472193,"teacher_disagreement_score":0.2364617,"about_ca_system_score_codex":0.00016835143,"about_ca_system_score_gemma":0.00011678019,"threshold_uncertainty_score":0.35862502},"labels":[],"label_agreement":null},{"id":"W3215969161","doi":"10.1038/s41598-021-02433-6","title":"Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Frailty Index; Charlson comorbidity index; Multiple myeloma; Comorbidity; Population","score_opus":0.07240353791995933,"score_gpt":0.36888889929670604,"score_spread":0.2964853613767467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215969161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979675,0.000018297207,0.00035153772,0.00006201379,0.0005125493,0.0007242702,0.0000039533184,0.000012943686,0.00034697782],"genre_scores_gemma":[0.9739972,3.962283e-7,0.024830636,0.000008919221,0.000017594293,0.00001691666,0.00031146713,0.000013931575,0.0008029839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678284,0.00006757151,0.0011002745,0.0006351214,0.0011169047,0.0002972953],"domain_scores_gemma":[0.9980075,0.000046770234,0.00034362136,0.0006687033,0.00054650137,0.00038691907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007838839,0.00013552832,0.00044172443,0.00028680282,0.00006444009,0.000031122046,0.000068927584,0.00008625415,0.0000815033],"category_scores_gemma":[0.0010615687,0.00010701123,0.000079062345,0.0008882492,0.00007134727,0.00010706557,0.000084095394,0.00013053851,0.000006097489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002617443,0.0009058958,0.8801947,0.0000578518,0.00006071602,0.00037630307,0.0004183607,0.000008640557,0.0011874952,0.0000017060624,0.000162346,0.11636421],"study_design_scores_gemma":[0.0022925513,0.00020568812,0.98639935,0.00028996708,0.000016359974,0.00001954344,0.000114900526,0.000041211122,0.009335715,0.00005230156,0.0011395073,0.000092885755],"about_ca_topic_score_codex":0.0002463944,"about_ca_topic_score_gemma":0.0022582188,"teacher_disagreement_score":0.116271324,"about_ca_system_score_codex":0.00010712161,"about_ca_system_score_gemma":0.0014214457,"threshold_uncertainty_score":0.4363791},"labels":[],"label_agreement":null},{"id":"W3216382063","doi":"10.1182/blood-2021-153897","title":"Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Fleurimont; University Health Network; Moncton Hospital; CancerCare Manitoba","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Oncology; Dexamethasone; Proteasome inhibitor; Minimal residual disease; Cyclophosphamide; Immunology; Melphalan; Internal medicine; Population; Cancer research; Chemotherapy; Leukemia","score_opus":0.035969974717345116,"score_gpt":0.34137627923060127,"score_spread":0.3054063045132561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216382063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935661,0.0007057579,0.000037562037,0.00048637105,0.000063808744,0.004516602,0.0003468139,0.000045531917,0.00023144751],"genre_scores_gemma":[0.99426436,0.0005556987,0.0034286946,0.0002754436,0.000045618814,0.0004096676,0.00045364414,0.00006032262,0.00050655083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711007,0.0001490004,0.00056093506,0.00088740775,0.0005326245,0.00075999234],"domain_scores_gemma":[0.99804026,0.0002306929,0.000081418395,0.0006107216,0.00025053916,0.00078634155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022177832,0.00039490798,0.00081577216,0.00021252452,0.00015084425,0.00011853738,0.00026129518,0.00011507627,0.00022620117],"category_scores_gemma":[0.00048440462,0.00034445742,0.000062802595,0.0006763717,0.000039627826,0.0001867842,0.00028308237,0.00027943187,0.00006437155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044616633,0.06437721,0.890186,0.00014930985,0.00060600805,0.008948866,0.003026092,0.000004670858,0.001423781,0.0000019692004,0.00019553935,0.02661888],"study_design_scores_gemma":[0.31729668,0.003667019,0.668075,0.00044520348,0.00039805044,0.000046634883,0.00056898827,0.00029965807,0.00847708,0.000004546385,0.00037235208,0.0003487432],"about_ca_topic_score_codex":0.0022364159,"about_ca_topic_score_gemma":0.00621513,"teacher_disagreement_score":0.312835,"about_ca_system_score_codex":0.00009920028,"about_ca_system_score_gemma":0.00028095065,"threshold_uncertainty_score":0.99990076},"labels":[],"label_agreement":null},{"id":"W3216439638","doi":"10.1182/blood-2021-145096","title":"Patient, Caregiver, and Healthcare Provider Priorities for Future Multiple Myeloma Research: Results of a James Lind Alliance Priority Setting Partnership","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Université de Moncton; Horizon Health Network; Princess Margaret Cancer Centre; Saint John Regional Hospital","funders":"","keywords":"General partnership; Multiple myeloma; Medicine; Alliance; Health care; Family medicine; Nursing; Political science; Internal medicine","score_opus":0.07891637162729005,"score_gpt":0.36732426042606214,"score_spread":0.2884078887987721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216439638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755025,0.015731407,0.0000029408586,0.0061650155,0.00009667461,0.0017616313,0.0004502358,0.00004129521,0.00024833187],"genre_scores_gemma":[0.99203175,0.0008121336,0.0054412833,0.0000866476,0.00044959268,0.00018428797,0.00017197683,0.000031055082,0.0007912587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974133,0.00028319948,0.0004052363,0.00057606597,0.00066186796,0.0006603403],"domain_scores_gemma":[0.9967462,0.0007263029,0.0001271067,0.00047374438,0.0015653817,0.00036125994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005150279,0.0001902617,0.0004097018,0.000089389665,0.00027160588,0.00004431089,0.000074772644,0.0001682167,0.0000046008354],"category_scores_gemma":[0.0036190103,0.00016463784,0.000108522894,0.0002764746,0.00018483275,0.00010753331,0.00013433774,0.0003822465,0.000002164038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007748736,0.0024783385,0.7228158,0.009632291,0.0010438048,0.0013102784,0.03456279,7.23955e-7,0.0057351007,0.00040374874,0.006086075,0.2081823],"study_design_scores_gemma":[0.08320334,0.0072509027,0.47730216,0.003495056,0.00040549936,0.0003195278,0.06579724,0.00029485903,0.26363808,0.00081802683,0.09666849,0.0008068349],"about_ca_topic_score_codex":0.0003180882,"about_ca_topic_score_gemma":0.00081168156,"teacher_disagreement_score":0.25790298,"about_ca_system_score_codex":0.0000667408,"about_ca_system_score_gemma":0.0009303278,"threshold_uncertainty_score":0.6713736},"labels":[],"label_agreement":null},{"id":"W3216448276","doi":"10.1038/s41408-021-00569-2","title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Risk stratification; Medicine; Stratification (seeds); Internal medicine; Oncology; Intensive care medicine; Biology","score_opus":0.043779452069503774,"score_gpt":0.3397416861487298,"score_spread":0.295962234079226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216448276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995727,0.0023338522,0.00022312604,0.0006316091,0.00015200583,0.00046051093,0.00005194127,0.000018441122,0.00040148592],"genre_scores_gemma":[0.99657923,0.0011059876,0.0017322164,0.000045196903,0.0003214645,0.00014019213,0.000029186222,0.00002050784,0.000026012045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.00018417306,0.00041885837,0.00024002542,0.00053442473,0.0003108637],"domain_scores_gemma":[0.9982791,0.00038229013,0.0003082115,0.00030633048,0.00052639813,0.00019765118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044002337,0.00015040342,0.0002782915,0.000060781713,0.00035709233,0.00019344762,0.00012663317,0.00006119163,0.00052404474],"category_scores_gemma":[0.0009731088,0.000100796715,0.00012582794,0.00024003877,0.000096296135,0.00016023376,0.000049956507,0.0004116236,0.0000040639525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016153169,0.0005507601,0.8711827,0.00011182756,0.0005342002,0.00013215175,0.00025997718,0.000023946328,0.042922262,0.000009552728,0.000059096597,0.08405202],"study_design_scores_gemma":[0.0026567583,0.00010181792,0.8588909,0.00026364622,0.0004309007,0.00018344262,0.00051164767,0.0003358012,0.13641906,0.00006859662,0.00006229543,0.00007516524],"about_ca_topic_score_codex":0.0002618844,"about_ca_topic_score_gemma":0.00036432443,"teacher_disagreement_score":0.0934968,"about_ca_system_score_codex":0.000052796084,"about_ca_system_score_gemma":0.0009537202,"threshold_uncertainty_score":0.5737922},"labels":[],"label_agreement":null},{"id":"W3216450604","doi":"","title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","year":2021,"lang":"en","type":"article","venue":"UCL Discovery (University College London)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Clinical trial; Oncology; Internal medicine; Clinical Practice; Intensive care medicine; Family medicine","score_opus":0.026431096345622376,"score_gpt":0.25123568045764794,"score_spread":0.22480458411202556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216450604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884061,0.0005425353,0.00021616941,0.0058253035,0.0002561217,0.00040867453,0.0014872224,0.00003197062,0.002825893],"genre_scores_gemma":[0.98469335,0.0012794464,0.0018291947,0.00009722842,0.000098304045,0.000004366979,0.00096396473,0.00001588044,0.011018273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877197,0.00012695849,0.0001697662,0.00038365534,0.0003241395,0.00022353433],"domain_scores_gemma":[0.99854547,0.00069320295,0.00010927007,0.00039747014,0.00011152124,0.00014307178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059069953,0.000172931,0.00029915498,0.00011881782,0.00030494077,0.000035357418,0.0001540443,0.00008279848,0.00032205888],"category_scores_gemma":[0.00011445304,0.0001422891,0.00016659066,0.00031858185,0.00013407953,0.00037310718,0.00018282662,0.00013331286,0.000017915509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071204165,0.004232749,0.8631075,0.00004684048,0.0036995537,0.0057079494,0.0024834268,0.0000064290166,0.02046065,0.0076946756,0.00753783,0.07790197],"study_design_scores_gemma":[0.020668019,0.00068117084,0.82814914,0.00021130535,0.0004066124,0.00012019843,0.008983159,0.0018090393,0.0023924499,0.00013214575,0.13617337,0.0002733703],"about_ca_topic_score_codex":0.0006560055,"about_ca_topic_score_gemma":0.0015113788,"teacher_disagreement_score":0.12863553,"about_ca_system_score_codex":0.00041658923,"about_ca_system_score_gemma":0.0002037487,"threshold_uncertainty_score":0.5802381},"labels":[],"label_agreement":null},{"id":"W3216453369","doi":"10.1182/blood-2021-153321","title":"Outcomes of Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Multiple myeloma; Single Center; Internal medicine; Autologous stem-cell transplantation; Oncology; Hematopoietic stem cell transplantation; Transplantation; Progression-free survival; Stem cell; Melphalan; Surgery; Overall survival","score_opus":0.018170437707012013,"score_gpt":0.25553659653085803,"score_spread":0.237366158823846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216453369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99851555,0.00030319847,0.000018358274,0.000059681817,0.00006347514,0.00037096493,0.00007885765,0.000028317809,0.00056161283],"genre_scores_gemma":[0.9990908,0.00006552359,0.00046325513,0.000045902198,0.000009653522,0.000054190234,0.00005587976,0.00001773364,0.00019706151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984932,0.00009596723,0.00036937193,0.00030477124,0.00038821032,0.0003484592],"domain_scores_gemma":[0.99923515,0.000106769025,0.00008881596,0.00031835318,0.00009646842,0.00015443069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056715628,0.0001631097,0.00045635074,0.00009386778,0.00003484707,0.0000099760855,0.00008631103,0.000082375,0.000095508934],"category_scores_gemma":[0.00004127793,0.00012678906,0.00010567496,0.00019950488,0.0000596741,0.00005019046,0.000038613256,0.00014087823,0.00001919203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009021958,0.007285254,0.98513466,0.0001299202,0.000115642826,0.0010768588,0.0019463362,4.6743722e-7,0.0020925186,0.000010811932,0.0000071565714,0.0021101376],"study_design_scores_gemma":[0.016698817,0.00051069056,0.8854802,0.00015479304,0.00010015666,0.00006277318,0.00032503792,0.0000118087755,0.09651632,0.000013247903,0.00002283623,0.00010330605],"about_ca_topic_score_codex":0.00008862587,"about_ca_topic_score_gemma":0.00009639075,"teacher_disagreement_score":0.099654466,"about_ca_system_score_codex":0.0000469629,"about_ca_system_score_gemma":0.00007999158,"threshold_uncertainty_score":0.5170308},"labels":[],"label_agreement":null},{"id":"W3216633465","doi":"10.1182/blood-2021-151862","title":"Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Bortezomib; CD34; Autologous stem-cell transplantation; Lenalidomide; Cyclophosphamide; Transplantation; Internal medicine; Vincristine; Leukapheresis; Oncology; Urology; Stem cell; Dexamethasone; Surgery; Chemotherapy; Biology","score_opus":0.020934222514732197,"score_gpt":0.2829169357886185,"score_spread":0.2619827132738863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216633465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983875,0.00012012657,0.000020085692,0.00022252205,0.000042271295,0.00079722895,0.00014459944,0.00003475038,0.00023092037],"genre_scores_gemma":[0.9982478,0.000062539155,0.00088055804,0.00003086519,0.000020011174,0.00013020127,0.00015575797,0.000023690272,0.0004485648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893594,0.000058602487,0.00014866261,0.00031273847,0.00020814396,0.00033588862],"domain_scores_gemma":[0.9991994,0.00037240624,0.000022872959,0.000176096,0.00006140797,0.00016783086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008883084,0.00017340561,0.0003894861,0.00011758361,0.00007786352,0.000017598759,0.000030338482,0.00007819465,0.000034636978],"category_scores_gemma":[0.000074407246,0.000112624795,0.00007984756,0.00017141247,0.000041304294,0.000035177574,0.000008777888,0.00011878715,0.0000038946782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023194118,0.0020411287,0.984174,0.000115606395,0.00027489298,0.0009257696,0.00020786023,0.000010398518,0.009193376,0.000008355949,0.000017475895,0.0007117293],"study_design_scores_gemma":[0.02998788,0.0023606115,0.90877205,0.000056693945,0.00013657717,0.00013539569,0.00014550041,0.00024405473,0.05802634,0.000010823942,0.000013330428,0.00011075658],"about_ca_topic_score_codex":0.0005445339,"about_ca_topic_score_gemma":0.0012411688,"teacher_disagreement_score":0.07540196,"about_ca_system_score_codex":0.00006642724,"about_ca_system_score_gemma":0.00018981431,"threshold_uncertainty_score":0.4592706},"labels":[],"label_agreement":null},{"id":"W3216815214","doi":"10.1182/blood-2021-149270","title":"Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Regimen; Internal medicine; Multiple myeloma; Dexamethasone; Oncology; Salvage therapy; Retrospective cohort study; Cohort; Surrogate endpoint; Venetoclax; Progression-free survival; Refractory (planetary science); Surgery; Chemotherapy; Leukemia","score_opus":0.011944329175700243,"score_gpt":0.27463708178375534,"score_spread":0.2626927526080551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216815214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679667,0.00010641366,0.00002397089,0.000027248585,0.000031839932,0.0009980579,0.00009684631,0.000026738086,0.0018921976],"genre_scores_gemma":[0.997366,0.000020623922,0.001860919,0.0000150605565,0.000023746668,0.00008113404,0.000374346,0.00003570831,0.00022242541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813324,0.0002886114,0.00025890442,0.00041297896,0.0005102314,0.000396046],"domain_scores_gemma":[0.9983233,0.0005771301,0.000083932835,0.00039999388,0.0004070174,0.00020862829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021848956,0.00020514622,0.0005715333,0.00021816882,0.000041523243,0.000011071109,0.000072649236,0.00007372654,0.000047758844],"category_scores_gemma":[0.00035602154,0.0001624432,0.0000845164,0.00065928017,0.000086574095,0.00008155251,0.0000746608,0.0001814305,0.000011569737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033633893,0.0039166072,0.9856574,0.00026358754,0.00046750632,0.00089300325,0.00011366621,0.000006065203,0.003837191,0.000039525217,0.000004954525,0.0014371303],"study_design_scores_gemma":[0.041371126,0.000775299,0.8285725,0.00059514935,0.00016004703,0.000010955152,0.00003255835,0.000034149783,0.12830894,0.000010574134,0.000008410225,0.00012027179],"about_ca_topic_score_codex":0.0013026786,"about_ca_topic_score_gemma":0.0019064917,"teacher_disagreement_score":0.15708484,"about_ca_system_score_codex":0.0001664534,"about_ca_system_score_gemma":0.00034293838,"threshold_uncertainty_score":0.66242415},"labels":[],"label_agreement":null},{"id":"W3216969145","doi":"10.1182/blood-2021-149602","title":"Outcomes of Single Versus Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Autologous stem-cell transplantation; Proportional hazards model; Hematopoietic stem cell transplantation; Univariate analysis; Single Center; Transplantation; Surgery; Multivariate analysis","score_opus":0.026690148592107228,"score_gpt":0.26347976866733197,"score_spread":0.23678962007522475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216969145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982412,0.0003190592,0.000014264318,0.00005457092,0.00014906818,0.0003769542,0.00008268648,0.000035666195,0.0007265212],"genre_scores_gemma":[0.9991886,0.00004394128,0.00046535843,0.00002787091,0.000013738552,0.00004716936,0.00007047489,0.000022063303,0.000120755285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982997,0.00010465309,0.0003949438,0.0003511819,0.0004424038,0.00040707836],"domain_scores_gemma":[0.99909693,0.00018376001,0.00008080518,0.00035330452,0.000111552894,0.00017365151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056399072,0.0001921654,0.0004881748,0.0001050097,0.00004357224,0.000014118927,0.00009965612,0.000097477365,0.00009098474],"category_scores_gemma":[0.00006850792,0.0001564743,0.00012054371,0.00023319185,0.000075194795,0.00006350522,0.00004672332,0.0001450861,0.000020274894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039676038,0.010739115,0.97665524,0.00012231195,0.00017046068,0.0010668834,0.0020917985,8.235988e-7,0.006609433,0.000008676812,0.00000763129,0.0021308546],"study_design_scores_gemma":[0.041727755,0.0016499608,0.743643,0.00019591476,0.00018463277,0.000047924306,0.00072471733,0.000012675468,0.21159472,0.000006940233,0.000047337293,0.00016444083],"about_ca_topic_score_codex":0.00008904478,"about_ca_topic_score_gemma":0.00015695782,"teacher_disagreement_score":0.23301226,"about_ca_system_score_codex":0.00008578299,"about_ca_system_score_gemma":0.00008481119,"threshold_uncertainty_score":0.63808364},"labels":[],"label_agreement":null},{"id":"W3217253848","doi":"10.1038/s41375-021-01488-8","title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Subgroup analysis; Medicine; Multiple myeloma; Internal medicine; Oncology; Confidence interval","score_opus":0.029499066880206554,"score_gpt":0.2957577830302103,"score_spread":0.26625871615000374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217253848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996885,0.0010953884,0.00020591501,0.00015550104,0.00004568303,0.0006090533,0.00030853218,0.000040308576,0.0006546335],"genre_scores_gemma":[0.99726176,0.00026296687,0.0011154413,0.00011926483,0.00002798164,0.00019342366,0.00055403094,0.000029551255,0.0004355481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766004,0.00019929736,0.0004844182,0.0005016976,0.0006387177,0.000515848],"domain_scores_gemma":[0.9985328,0.0005775244,0.00011654671,0.00045287848,0.000050843573,0.0002694109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040251645,0.00024190544,0.0008673473,0.000876104,0.00015206153,0.000017675076,0.00017054104,0.00008966988,0.0004535361],"category_scores_gemma":[0.00018175365,0.000221211,0.00021444388,0.0016756596,0.00010846607,0.000089311776,0.00011907154,0.00045278465,0.000007015833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006140099,0.0003888481,0.9638229,0.00017139365,0.0018120175,0.002133659,0.0017420232,0.0029399742,0.0128643,0.000066455155,0.0003370663,0.007581266],"study_design_scores_gemma":[0.027565207,0.00040220842,0.9169525,0.00005635664,0.0009995826,0.00005566775,0.0004889116,0.0469231,0.005579523,0.00003733637,0.0007000328,0.00023956198],"about_ca_topic_score_codex":0.008497382,"about_ca_topic_score_gemma":0.0039557195,"teacher_disagreement_score":0.046870388,"about_ca_system_score_codex":0.0009340288,"about_ca_system_score_gemma":0.00037313884,"threshold_uncertainty_score":0.9981051},"labels":[],"label_agreement":null},{"id":"W3217295000","doi":"10.1182/blood-2021-148191","title":"Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; Dalhousie University; McGill University Health Centre; Princess Margaret Cancer Centre; University of Calgary; CancerCare Manitoba; Ottawa Hospital; Hôpital Maisonneuve-Rosemont; Western University; University of Alberta; Université de Montréal; London Health Sciences Centre; McMaster University","funders":"","keywords":"Lenalidomide; Tolerability; Medicine; Multiple myeloma; Dosing; Ixazomib; Internal medicine; Hazard ratio; Oncology; Surgery; Adverse effect; Carfilzomib; Confidence interval","score_opus":0.04791665323441076,"score_gpt":0.31545289136587984,"score_spread":0.2675362381314691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217295000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953153,0.0007444171,0.000053073203,0.0013945677,0.00006442846,0.0011437123,0.0009910464,0.00003185533,0.00026159832],"genre_scores_gemma":[0.9900253,0.00010173473,0.0058788816,0.00019948739,0.0000879162,0.00016175292,0.003371707,0.000036007725,0.00013724774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966865,0.00026685352,0.00042253925,0.000730993,0.0010442656,0.00084886025],"domain_scores_gemma":[0.99741167,0.0008173966,0.0000622123,0.0006881624,0.00034407506,0.00067647285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059148716,0.00029084223,0.0004585485,0.00028522327,0.0006322252,0.00013226707,0.00016824684,0.00012585394,0.00006789003],"category_scores_gemma":[0.0013414572,0.00018199057,0.00007662648,0.0005411609,0.0002889577,0.00021779563,0.000096397234,0.0005983066,0.00002279738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058158865,0.0016477202,0.97084415,0.000045413213,0.00035904473,0.023908282,0.00038390496,0.000003607218,0.0009009832,0.000028888337,0.000105154584,0.0011912419],"study_design_scores_gemma":[0.038787,0.00012509465,0.9569894,0.0004121196,0.00012890226,0.00028773223,0.0001860547,0.0001919105,0.002031964,0.000013860599,0.00065474916,0.0001912182],"about_ca_topic_score_codex":0.31743425,"about_ca_topic_score_gemma":0.83500886,"teacher_disagreement_score":0.5175746,"about_ca_system_score_codex":0.00025390062,"about_ca_system_score_gemma":0.0015749261,"threshold_uncertainty_score":0.74213606},"labels":[],"label_agreement":null},{"id":"W3217436200","doi":"10.1182/blood-2021-150519","title":"Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary; McGill University Health Centre","funders":"","keywords":"Medicine; Multiple myeloma; Cytokine release syndrome; Lenalidomide; Adverse effect; Common Terminology Criteria for Adverse Events; Neutropenia; Internal medicine; Pomalidomide; Oncology; Febrile neutropenia; Toxicity; Pharmacology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.016623479650106996,"score_gpt":0.24550516732316358,"score_spread":0.22888168767305658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217436200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320936,0.00110987,0.00030700854,0.00032187512,0.00017072436,0.0019516159,0.0018676581,0.00015845086,0.0009034101],"genre_scores_gemma":[0.96212745,0.0002354204,0.024410442,0.000113559596,0.0001960486,0.00017529126,0.010730627,0.0001058429,0.0019053302],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99677336,0.00019174698,0.0005799361,0.00096563535,0.00079517014,0.0006941513],"domain_scores_gemma":[0.99724054,0.00061679195,0.00023882174,0.0008552275,0.0006570287,0.0003915685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017477405,0.00040431265,0.0005353927,0.0002010567,0.0003221769,0.00010227864,0.00016644895,0.0002076494,0.00020452403],"category_scores_gemma":[0.0012203179,0.00030722131,0.00015452951,0.00048110023,0.00007006651,0.00024238738,0.000081836806,0.00040835247,0.00007867114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14032814,0.045759894,0.31997746,0.0012507866,0.00463257,0.010843493,0.003851858,0.000028747296,0.40852427,0.000030010737,0.01779716,0.04697561],"study_design_scores_gemma":[0.17264958,0.003647199,0.60860133,0.00049032026,0.00062763446,0.000036624497,0.00057775964,0.0011804076,0.20311259,0.000024766165,0.008330801,0.0007210064],"about_ca_topic_score_codex":0.00022444232,"about_ca_topic_score_gemma":0.00020953269,"teacher_disagreement_score":0.28862384,"about_ca_system_score_codex":0.00011107754,"about_ca_system_score_gemma":0.00041152368,"threshold_uncertainty_score":0.999938},"labels":[],"label_agreement":null},{"id":"W3217592658","doi":"10.1182/blood-2021-154190","title":"Outcomes after First Rescue Treatment in Patients with Relapsed or Refractory Multiple Myeloma in Colombia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Lenalidomide; Carfilzomib; Medicine; Multiple myeloma; Internal medicine; Bortezomib; Clinical endpoint; Refractory (planetary science); Propensity score matching; Pomalidomide; Oncology; Gastroenterology; Surgery; Clinical trial","score_opus":0.01632419019254333,"score_gpt":0.26656195274061373,"score_spread":0.2502377625480704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217592658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805117,0.00018187922,3.3228022e-7,0.00028135692,0.000038552756,0.0010243772,0.00005733469,0.000031226402,0.0003337684],"genre_scores_gemma":[0.9958002,0.000061757615,0.00082540896,0.00009509002,0.00001957056,0.0004238699,0.00017608475,0.00003737008,0.0025606363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982648,0.000093473296,0.00031454486,0.00045269667,0.00039682508,0.00047764668],"domain_scores_gemma":[0.99894583,0.00021100162,0.00004069067,0.0004889867,0.000095706055,0.00021776168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006681258,0.00024497646,0.00048571645,0.00018720947,0.000044450604,0.000019740473,0.000059639202,0.00011537841,0.00030570565],"category_scores_gemma":[0.00033862886,0.00015431688,0.00007494921,0.00035604328,0.000045284825,0.00009155976,0.000050374823,0.0001790058,0.00006358557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005490351,0.011108935,0.9743257,0.00005471508,0.00020653986,0.0060937153,0.00035239442,0.0000014378008,0.000032319003,5.036318e-7,0.000040183695,0.0022931693],"study_design_scores_gemma":[0.07007924,0.0019847364,0.92536104,0.00020836575,0.00007940754,0.00001219932,0.00007457776,0.000014760832,0.0010363554,0.000001194981,0.0009990023,0.00014914818],"about_ca_topic_score_codex":0.0006600513,"about_ca_topic_score_gemma":0.036846876,"teacher_disagreement_score":0.06458888,"about_ca_system_score_codex":0.00033129382,"about_ca_system_score_gemma":0.0002975193,"threshold_uncertainty_score":0.98072815},"labels":[],"label_agreement":null},{"id":"W3217731526","doi":"10.1182/blood-2021-149785","title":"M-Protein Sequencing and Monitoring in Serum of LC-Only Multiple Myeloma Patients","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Waterloo","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Serum protein electrophoresis; Internal medicine; Thalidomide; Lenalidomide; Bone marrow; Bortezomib; Antibody; Immunofixation; Gastroenterology; Immunology; Monoclonal; Monoclonal antibody","score_opus":0.026081212424968744,"score_gpt":0.27765190012104674,"score_spread":0.251570687696078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217731526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863076,0.00048968074,0.0000022147744,0.00004667071,0.000029559647,0.00030644095,0.000019509309,0.000015416637,0.0004597484],"genre_scores_gemma":[0.9973723,0.000040500785,0.0022842106,0.0000074442983,0.00004158922,0.00001927841,0.000017746372,0.000014806389,0.00020212364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990205,0.000044200307,0.00020257238,0.00021911843,0.00026096802,0.00025259668],"domain_scores_gemma":[0.99945897,0.000052049858,0.00004127648,0.00019547985,0.00011691229,0.00013532884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007684191,0.000101442216,0.0002232126,0.00009080092,0.000032136897,0.000009834502,0.00003600822,0.000056463872,0.000020849731],"category_scores_gemma":[0.0003744528,0.00009210069,0.000037423113,0.00018430264,0.000029027027,0.00006340739,0.00007359266,0.00012272738,0.0000059293484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056765566,0.0004967926,0.9194033,0.0001483985,0.00006722464,0.00038795717,0.00017131033,4.6487352e-7,0.0669575,0.0000061452483,9.207801e-7,0.012303217],"study_design_scores_gemma":[0.0068500587,0.00014215184,0.6849056,0.00025941804,0.000021789307,0.00002074929,0.00014095184,0.00003707265,0.30754796,0.000013150358,0.0000116770725,0.000049471124],"about_ca_topic_score_codex":0.00019025353,"about_ca_topic_score_gemma":0.00008049837,"teacher_disagreement_score":0.24059045,"about_ca_system_score_codex":0.00005262807,"about_ca_system_score_gemma":0.00016188351,"threshold_uncertainty_score":0.3755757},"labels":[],"label_agreement":null},{"id":"W3217766765","doi":"10.1182/blood-2021-148718","title":"Identification of Previously Unrecognized Multiple Myeloma Risk Subgroups with a Novel Biological Disease Stratifier","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Terry Fox Research Institute","funders":"","keywords":"Oncology; Internal medicine; Hazard ratio; Multiple myeloma; Disease; Framingham Risk Score; Proportional hazards model; Medicine; Cytogenetics; Survival analysis; Bioinformatics; Biology; Confidence interval; Genetics; Gene","score_opus":0.030892080059636375,"score_gpt":0.28432168439028077,"score_spread":0.2534296043306444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217766765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731153,0.00062241685,0.0007896754,0.00010579815,0.00002289754,0.00067085394,0.00029663846,0.00004464543,0.00013552108],"genre_scores_gemma":[0.99659646,0.0001969384,0.002302009,0.00002061525,0.00005072784,0.00010440017,0.00037028518,0.000017471208,0.0003411185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985907,0.0000943383,0.00032082392,0.00038590212,0.00033418328,0.00027406806],"domain_scores_gemma":[0.9986271,0.00016404087,0.0001438656,0.00043786623,0.0002973765,0.0003297464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017183702,0.00014923606,0.00029247784,0.000060032668,0.00006967059,0.000023747278,0.0000724001,0.00006548543,0.00012954614],"category_scores_gemma":[0.0010039296,0.000101491416,0.00011041066,0.00025477272,0.000102807004,0.0000606217,0.000038716877,0.00013796113,0.000025308387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013990902,0.004986592,0.8552704,0.00013712521,0.00056154456,0.00040378052,0.00011657633,0.0000019967597,0.13269703,0.0000399147,0.000014244211,0.0043717134],"study_design_scores_gemma":[0.013643042,0.00037960976,0.8824568,0.00009200929,0.00043737373,0.00005721564,0.000079536454,0.0003369061,0.102316566,0.00004033826,0.000051242503,0.0001093685],"about_ca_topic_score_codex":0.000045197987,"about_ca_topic_score_gemma":0.000070196154,"teacher_disagreement_score":0.030380458,"about_ca_system_score_codex":0.000019740086,"about_ca_system_score_gemma":0.00026034465,"threshold_uncertainty_score":0.41386998},"labels":[],"label_agreement":null},{"id":"W322081330","doi":"10.1007/978-1-60327-969-7_102","title":"Multiple Myeloma Surveillance Counterpoint: Canada","year":2012,"lang":"en","type":"book-chapter","venue":"Humana Press eBooks","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Multiple myeloma; Counterpoint; Medicine; Bone marrow; Cancer; Monoclonal; Plasma cell neoplasm; Plasma cell; Internal medicine; Oncology; Pathology; Monoclonal antibody; Immunology; Antibody; Psychology","score_opus":0.05857236900967779,"score_gpt":0.2768801817691555,"score_spread":0.21830781275947772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W322081330","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004211834,0.01523677,0.000007224121,0.000038567814,0.00038295117,0.0013290606,0.0005807112,0.00012409041,0.9818794],"genre_scores_gemma":[0.19294883,0.000621506,0.00007284402,0.00024285435,0.00072392495,0.000089610796,0.0004943548,0.00017411566,0.80463195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970528,0.000034678204,0.00047450545,0.00059529924,0.0010430759,0.00079966476],"domain_scores_gemma":[0.99766254,0.00017227531,0.00022999683,0.0010400435,0.00024092823,0.0006541996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014440993,0.00061960897,0.00086124294,0.00012073357,0.00017573348,0.00004380085,0.00027065878,0.0003132556,0.00079818995],"category_scores_gemma":[0.000050913106,0.0005467787,0.00022060565,0.0000050495178,0.00017557718,0.000037875703,0.0001960496,0.0006456325,0.00011074728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032944006,0.00033906207,0.004230621,0.0035891235,0.007474064,0.009024982,0.00068226916,0.000003439715,0.00018243658,0.07297314,0.18168104,0.71652544],"study_design_scores_gemma":[0.0023341684,0.00011851953,0.004027681,0.00034475667,0.00014645561,0.00009284524,0.0000037420737,0.00006576026,0.0002382246,0.00010530226,0.9920385,0.00048403832],"about_ca_topic_score_codex":0.2567574,"about_ca_topic_score_gemma":0.5510885,"teacher_disagreement_score":0.81035745,"about_ca_system_score_codex":0.00060189655,"about_ca_system_score_gemma":0.00067882234,"threshold_uncertainty_score":0.9996984},"labels":[],"label_agreement":null},{"id":"W394742526","doi":"10.1182/blood.v122.21.3185.3185","title":"Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Dexamethasone; Multiple myeloma; Medicine; Randomized controlled trial; Internal medicine; Oncology; Nuclear medicine; Lenalidomide","score_opus":0.03229036244339042,"score_gpt":0.33606534210989253,"score_spread":0.30377497966650213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W394742526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907331,0.0029865012,0.00004107862,0.00021189779,0.000037570295,0.0053325766,0.00024376942,0.00002560674,0.00038789818],"genre_scores_gemma":[0.9918555,0.0013030367,0.006201087,0.000020527606,0.000046192978,0.00023234358,0.00013099468,0.000030188065,0.00018014737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99627674,0.0008152549,0.0015819375,0.00046937575,0.00043044094,0.0004262795],"domain_scores_gemma":[0.9929197,0.005536377,0.0005327511,0.00045781187,0.00019239704,0.00036096445],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0024230897,0.000293939,0.0024999166,0.00031911823,0.00004599535,0.000016884173,0.00009667044,0.0001444992,0.00008287022],"category_scores_gemma":[0.017911674,0.00021196505,0.0001973171,0.00029107594,0.00035768998,0.00014793093,0.00009940491,0.00019551069,0.000006454696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7428012,0.005461927,0.006049109,0.0004995804,0.0012765531,0.00017100635,0.00091876806,0.000011648658,0.18053952,0.00002328028,0.0000469481,0.062200487],"study_design_scores_gemma":[0.8584936,0.0008717014,0.03946551,0.00047384828,0.00043256805,0.000031859636,0.0001190461,0.00083071063,0.09903938,0.000049462393,0.000041474337,0.00015078773],"about_ca_topic_score_codex":0.0010223213,"about_ca_topic_score_gemma":0.00006542104,"teacher_disagreement_score":0.115692474,"about_ca_system_score_codex":0.00003884347,"about_ca_system_score_gemma":0.00015042257,"threshold_uncertainty_score":0.99036086},"labels":[],"label_agreement":null},{"id":"W4200048325","doi":"10.3390/cells10123464","title":"The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Cells","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bortezomib; Cell culture; Downregulation and upregulation; Flow cytometry; Apoptosis; Blot; Autophagy; Molecular biology; Programmed cell death; Cancer research; Chemistry; Biology; Multiple myeloma; Immunology; Biochemistry","score_opus":0.012029000831436005,"score_gpt":0.2614269696367979,"score_spread":0.24939796880536189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200048325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838466,0.005253211,0.000003842542,0.0003137756,0.00007808334,0.00035411466,0.000036485035,0.000023053633,0.005552754],"genre_scores_gemma":[0.99639595,0.00048418134,0.00026712616,0.000045239452,0.000035818142,0.000032009455,0.00006131736,0.00001740143,0.0026609416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871796,0.00008690977,0.00028370155,0.00022575463,0.00032102477,0.00036464774],"domain_scores_gemma":[0.9988497,0.00039987444,0.000056149052,0.00041325347,0.00012160273,0.00015945434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018286744,0.00011253019,0.00024796807,0.00006384761,0.000067342466,0.000014255225,0.00009749338,0.00006875241,0.00019328504],"category_scores_gemma":[0.00039083595,0.00007634043,0.00007987971,0.0002813723,0.0000949847,0.000031985677,0.00006788707,0.0001574803,0.00014073805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007835642,0.0005026476,0.049512085,0.000055447927,0.00011508406,0.00083145365,0.00032592408,0.0000029883226,0.92476,0.0001720571,0.00024329346,0.022695465],"study_design_scores_gemma":[0.003265604,0.00014784775,0.2808211,0.00006265897,0.000016911854,0.000009833805,0.0005018203,0.0021498378,0.69320107,0.00006782141,0.019683583,0.00007191479],"about_ca_topic_score_codex":0.0001661029,"about_ca_topic_score_gemma":0.00024176895,"teacher_disagreement_score":0.23155893,"about_ca_system_score_codex":0.000078705416,"about_ca_system_score_gemma":0.00024538132,"threshold_uncertainty_score":0.31130725},"labels":[],"label_agreement":null},{"id":"W4200108738","doi":"10.1182/blood-2021-147983","title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Cytokine release syndrome; Internal medicine; Lenalidomide; Adverse effect; Refractory (planetary science); Cohort; Oncology; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.017965553631843066,"score_gpt":0.3122577428817261,"score_spread":0.29429218924988304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200108738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962528,0.00007216958,0.00002169809,0.0001696907,0.00003611124,0.0024708877,0.0005772583,0.00012840335,0.00027103137],"genre_scores_gemma":[0.99627215,0.000044333727,0.001749263,0.00013336577,0.000054413085,0.00007359966,0.0012595035,0.00007221553,0.00034114558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653995,0.0004198769,0.0006638351,0.001148455,0.0006407333,0.00058714754],"domain_scores_gemma":[0.9975415,0.00045254876,0.00019263169,0.0009087772,0.0003229264,0.0005816542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043590984,0.0003932346,0.0007857021,0.00019938116,0.00016295566,0.00010013552,0.0001462918,0.00015460757,0.000057607147],"category_scores_gemma":[0.000649726,0.00032226523,0.00006320516,0.00047976425,0.00006117364,0.00034996623,0.00012841877,0.00042469412,0.000011600257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063705415,0.03008841,0.86541176,0.000016762304,0.0008368787,0.0012355659,0.0017880191,0.0000050754497,0.0043860083,3.099906e-7,0.000036392466,0.032489378],"study_design_scores_gemma":[0.15905684,0.008520484,0.82524437,0.000204257,0.00019216214,0.000003074061,0.0003982301,0.00020184412,0.005730233,0.000002419813,0.00018301193,0.00026306833],"about_ca_topic_score_codex":0.0025825123,"about_ca_topic_score_gemma":0.0045171296,"teacher_disagreement_score":0.09535142,"about_ca_system_score_codex":0.00012176931,"about_ca_system_score_gemma":0.00017846658,"threshold_uncertainty_score":0.99992293},"labels":[],"label_agreement":null},{"id":"W4200312704","doi":"10.1182/blood-2021-146940","title":"Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Daratumumab; Dexamethasone; Internal medicine; Carfilzomib; Oncology; Phases of clinical research; Renal function; Bortezomib; Urology; Toxicity","score_opus":0.020433083204420964,"score_gpt":0.2753407263694819,"score_spread":0.254907643165061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200312704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975758,0.00038439306,0.00007863599,0.0001375406,0.00002321521,0.0015506615,0.00019314462,0.000025753183,0.00003086244],"genre_scores_gemma":[0.99854064,0.000034962286,0.0008026973,0.00010602596,0.000046017067,0.000085732296,0.00034184323,0.000030901152,0.000011191027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782586,0.0003440748,0.0004231692,0.0005108129,0.0005413571,0.0003547004],"domain_scores_gemma":[0.9976202,0.0014957027,0.0001340216,0.0004048431,0.00013080265,0.00021441383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003217496,0.00026349552,0.0004964313,0.00013133186,0.00013559652,0.00004461119,0.000066114226,0.00006649544,0.000029747907],"category_scores_gemma":[0.00055574364,0.0001684833,0.00006033659,0.00034106002,0.000088983266,0.0000956619,0.000033200853,0.00024981587,0.0000017612509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036018573,0.01176266,0.93423384,0.000052081086,0.0004740708,0.0007266877,0.0008425527,0.000047771326,0.007153678,0.0000011587908,0.00001548246,0.008671467],"study_design_scores_gemma":[0.22319175,0.0030052683,0.7589551,0.00038181792,0.00045592876,0.0000045385004,0.00031523342,0.0010979053,0.012454671,0.0000055676164,0.000007651869,0.00012453126],"about_ca_topic_score_codex":0.0010835232,"about_ca_topic_score_gemma":0.0016517158,"teacher_disagreement_score":0.18717317,"about_ca_system_score_codex":0.000032788226,"about_ca_system_score_gemma":0.00014638064,"threshold_uncertainty_score":0.68705493},"labels":[],"label_agreement":null},{"id":"W4200328156","doi":"10.1016/s2152-2650(21)01578-0","title":"Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Bispecific antibody; Refractory (planetary science); Medicine; CD3; Antigen; Antibody; Multiple myeloma; Daratumumab; Immunology; Monoclonal antibody; Materials science; CD8","score_opus":0.03499639870044778,"score_gpt":0.33360450492688143,"score_spread":0.29860810622643363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200328156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919504,0.00083989097,0.00015654767,0.00021042673,0.0006395339,0.004891253,0.0004752986,0.00021650369,0.0006201817],"genre_scores_gemma":[0.9884838,0.00043327684,0.005332775,0.00027545978,0.00041301586,0.00029899622,0.0029178625,0.00023424749,0.0016105875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915864,0.00093542127,0.0025163195,0.0019635695,0.0016538847,0.0013443945],"domain_scores_gemma":[0.9916145,0.0027599768,0.0009870277,0.0019634224,0.0017245766,0.000950498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009856998,0.00091569865,0.0020185048,0.00046649456,0.0005479834,0.00015559173,0.00055586756,0.0006195679,0.00033596868],"category_scores_gemma":[0.002938611,0.0007013663,0.00062272936,0.0011111726,0.0003942661,0.00052770623,0.00036074006,0.0007281981,0.00013073892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041396003,0.0134903,0.67762434,0.00067623437,0.0012432922,0.002493041,0.00083944073,0.000006527218,0.0070761847,0.000009520892,0.0014646677,0.2536804],"study_design_scores_gemma":[0.07421188,0.013305246,0.90045583,0.0005434686,0.0004948585,0.00010171238,0.0012757146,0.0010584794,0.0038875262,0.00001750187,0.003949184,0.0006985776],"about_ca_topic_score_codex":0.00027842613,"about_ca_topic_score_gemma":0.00031398295,"teacher_disagreement_score":0.25298184,"about_ca_system_score_codex":0.0009476902,"about_ca_system_score_gemma":0.0024911223,"threshold_uncertainty_score":0.9995437},"labels":[],"label_agreement":null},{"id":"W4200384131","doi":"10.1182/hematology.2021000231","title":"Treatment of older adult or frail patients with multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institute on Aging; H. Lundbeck A/S","keywords":"Multiple myeloma; Lenalidomide; Medicine; Carfilzomib; Oncology; Internal medicine; Cancer research","score_opus":0.020556722094367676,"score_gpt":0.29581544475657257,"score_spread":0.2752587226622049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200384131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975263,0.0002687947,0.000065178254,0.00042479413,0.000047904243,0.0005061342,0.00003913704,0.000032035183,0.0010897538],"genre_scores_gemma":[0.9945536,0.00006653808,0.003295207,0.00008357313,0.000019918965,0.00009352249,0.00021563718,0.000023360828,0.0016486183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884135,0.00005214382,0.00023219496,0.00029828853,0.00024571395,0.00033032577],"domain_scores_gemma":[0.9987674,0.00017416416,0.000069943904,0.00038457342,0.00041500918,0.0001889209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000011787883,0.00016754757,0.000524234,0.00007620859,0.000044105174,0.000004122821,0.00003942434,0.000095348325,0.0007770817],"category_scores_gemma":[0.00018737634,0.0000970551,0.00008013232,0.00017786204,0.00009596764,0.000031418484,0.000025416264,0.00005371876,0.00008731834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001987914,0.0029367832,0.98121166,0.00014774881,0.00042621559,0.0018929306,0.00026764016,2.3797962e-7,0.00015068795,0.00022692645,0.00022965755,0.0105216205],"study_design_scores_gemma":[0.027941607,0.0029948135,0.9179298,0.000119982695,0.0001295431,0.00067908765,0.00018549786,0.00009897938,0.048043825,0.000014310895,0.0017328437,0.00012969159],"about_ca_topic_score_codex":0.000069511894,"about_ca_topic_score_gemma":0.00025767676,"teacher_disagreement_score":0.06328182,"about_ca_system_score_codex":0.00006813483,"about_ca_system_score_gemma":0.0002346046,"threshold_uncertainty_score":0.85085},"labels":[],"label_agreement":null},{"id":"W4200413879","doi":"10.1182/hematology.2021000304","title":"Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies","year":2021,"lang":"en","type":"article","venue":"Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Risk stratification; Medicine; Clinical trial; Dilemma; Intensive care medicine; Bone marrow; Oncology; Internal medicine; Epistemology","score_opus":0.03873260786322305,"score_gpt":0.3333129025542195,"score_spread":0.29458029469099645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200413879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907446,0.005675486,0.00016965723,0.0007192601,0.00009203016,0.0002850266,0.000009560196,0.00007319007,0.0022312014],"genre_scores_gemma":[0.996006,0.00055159203,0.002847888,0.000060234634,0.00005330995,0.00009814854,0.000059604306,0.00002061347,0.0003026221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989176,0.000066739216,0.00018577522,0.00033579662,0.000114412825,0.00037970836],"domain_scores_gemma":[0.9987285,0.00068383384,0.00003007902,0.00025769873,0.00008889798,0.0002109501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038827457,0.00016969141,0.00040067686,0.00007292415,0.00010626886,0.000048760914,0.000029513692,0.00008590262,0.000449627],"category_scores_gemma":[0.00069201953,0.00013833464,0.000058984013,0.00009231703,0.0000879015,0.000090812486,0.00006435228,0.00007971988,0.000053749176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022307095,0.0009187288,0.9232874,0.00045085783,0.0005980724,0.021871567,0.00093986955,0.0000022054085,0.022677515,0.002775857,0.0004476765,0.025807165],"study_design_scores_gemma":[0.011644013,0.00097193994,0.88548064,0.00035722123,0.00022745569,0.011227515,0.0026250796,0.0029427193,0.080264986,0.00075308036,0.0031459306,0.0003593907],"about_ca_topic_score_codex":0.00011798428,"about_ca_topic_score_gemma":0.00025522348,"teacher_disagreement_score":0.05758747,"about_ca_system_score_codex":0.00007273125,"about_ca_system_score_gemma":0.0001817217,"threshold_uncertainty_score":0.5641123},"labels":[],"label_agreement":null},{"id":"W4200451397","doi":"10.3390/cancers14010113","title":"Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Immune system; Clinical trial; Medicine; Drug development; Bone marrow; Cancer research; Immunology; Drug; Pharmacology; Internal medicine","score_opus":0.05196716915942231,"score_gpt":0.34732233286036185,"score_spread":0.29535516370093956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200451397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021663,0.99494016,0.0000037527254,0.000042172112,0.00028467746,0.0019687368,0.000049551563,0.00004024959,0.00050442095],"genre_scores_gemma":[0.0029344698,0.99484944,0.00033439384,0.00001915385,0.00036440554,0.00049918384,0.00033572974,0.00007287099,0.00059036847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976133,0.00014773705,0.00063991966,0.0006864331,0.00036375163,0.00054885005],"domain_scores_gemma":[0.99884385,0.00013602758,0.00018589567,0.00036454093,0.00008793609,0.00038173064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020774701,0.0004471694,0.0019324729,0.0003918188,0.000079665355,0.00005215496,0.00010231504,0.00030671226,0.00014699352],"category_scores_gemma":[0.000580585,0.0003471181,0.00038403107,0.0004890632,0.00014187716,0.00006574378,0.00015618432,0.0005973231,0.000024397075],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080946695,0.000045355857,0.00031803877,0.010450211,0.00040187838,0.0017522182,0.000070885464,0.0000025006725,0.000010503906,0.0000036773229,0.00041541667,0.98644835],"study_design_scores_gemma":[0.006522179,0.00020153148,0.0002899954,0.04020158,0.00082126516,0.00037270208,0.00016765595,0.00016738515,0.000098100245,0.000004504468,0.9506445,0.0005086279],"about_ca_topic_score_codex":0.0006798323,"about_ca_topic_score_gemma":0.00020963643,"teacher_disagreement_score":0.98593974,"about_ca_system_score_codex":0.0026993782,"about_ca_system_score_gemma":0.002923029,"threshold_uncertainty_score":0.9998981},"labels":[],"label_agreement":null},{"id":"W4200573460","doi":"10.1186/s12885-021-09015-9","title":"Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study","year":2021,"lang":"en","type":"erratum","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Daratumumab; Surgical oncology; Medicine; Chart; Multiple myeloma; Oncology; Medical physics; Internal medicine; Statistics","score_opus":0.04476410368227295,"score_gpt":0.3744249979711227,"score_spread":0.32966089428884976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200573460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775575,0.012094511,0.000012956744,0.000017628121,0.0025992878,0.006437161,0.0010824408,0.00002466451,0.00017389691],"genre_scores_gemma":[0.95800734,0.03281021,0.00002889831,0.000027307833,0.00030715344,0.002510323,0.0017416003,0.0000895746,0.004477593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972422,0.00042704624,0.00055925787,0.0006893614,0.0006987307,0.00038338182],"domain_scores_gemma":[0.99779546,0.0004398576,0.00043626688,0.00055625907,0.0005648385,0.00020729261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018957026,0.00052435056,0.0017097797,0.00016370452,0.000103477694,0.000020816733,0.00008789713,0.0001007691,0.00007696973],"category_scores_gemma":[0.0001782165,0.00033298903,0.00018218759,0.00037322182,0.000055959423,0.00004924619,0.00010316538,0.0002885154,9.1434237e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003671093,0.0027710441,0.94659376,0.00966509,0.0012301452,0.00002957875,0.0005717036,0.0000017551954,0.000024393827,8.5819764e-8,0.0012440833,0.034197256],"study_design_scores_gemma":[0.010943886,0.004776857,0.9500595,0.031368308,0.0004109622,0.000002007686,0.0001493814,0.000037127462,0.0009585262,1.478905e-7,0.0010595558,0.0002337962],"about_ca_topic_score_codex":0.01019842,"about_ca_topic_score_gemma":0.05687911,"teacher_disagreement_score":0.046680693,"about_ca_system_score_codex":0.00055180414,"about_ca_system_score_gemma":0.00043713048,"threshold_uncertainty_score":0.9999122},"labels":[],"label_agreement":null},{"id":"W4200605356","doi":"10.1002/ajh.26434","title":"Efficacy and tolerability of <scp>once‐weekly</scp> selinexor, bortezomib, and dexamethasone in comparison with standard <scp>twice‐weekly</scp> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <scp>BOSTON</scp> study","year":2021,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Population; Pharmacology; Nephrotoxicity; Renal function; Tolerability; Oncology; Kidney; Adverse effect","score_opus":0.01931272400488909,"score_gpt":0.29232031986818535,"score_spread":0.27300759586329626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200605356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98151726,0.010592007,0.00038629846,0.0040840995,0.00004820311,0.0030027584,0.00029717237,0.00003923164,0.000033002136],"genre_scores_gemma":[0.98949575,0.0014304611,0.005966009,0.0021020307,0.00022037387,0.00015282138,0.00039944387,0.00016451461,0.00006857338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881267,0.0033649052,0.0030686858,0.0018375996,0.00187885,0.0017232725],"domain_scores_gemma":[0.9769798,0.016416868,0.003424283,0.0013668234,0.00096414285,0.000848076],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023840694,0.0014479562,0.007811993,0.0016677537,0.00022425951,0.00016908164,0.0006157887,0.0006331663,0.000016341619],"category_scores_gemma":[0.0037208123,0.00094727764,0.00040998132,0.0031544862,0.0024706558,0.0002823892,0.000352716,0.0039339457,0.000001328868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00197108,0.002696073,0.9592174,0.00032374606,0.010279067,0.008896335,0.00897672,0.000063327316,0.000240999,0.0000010659697,0.0032292213,0.0041049058],"study_design_scores_gemma":[0.0319764,0.02199393,0.9106079,0.0013326268,0.006533222,0.002831516,0.021370683,0.0007717282,0.00074904534,0.00001448886,0.0016160528,0.00020241221],"about_ca_topic_score_codex":0.0065779993,"about_ca_topic_score_gemma":0.0068899444,"teacher_disagreement_score":0.048609562,"about_ca_system_score_codex":0.0005265865,"about_ca_system_score_gemma":0.0009764071,"threshold_uncertainty_score":0.999827},"labels":[],"label_agreement":null},{"id":"W4205852291","doi":"10.1002/jha2.359","title":"Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Bortezomib; Multiple myeloma; Internal medicine; Dexamethasone; Oncology; Neutropenia; Carfilzomib; Chemotherapy","score_opus":0.02396165785600094,"score_gpt":0.26758377684002865,"score_spread":0.24362211898402772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205852291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446195,0.0008167095,0.000034746787,0.00091402326,0.0002488094,0.0024871028,0.00032003093,0.00013491373,0.000581703],"genre_scores_gemma":[0.9935288,0.00006406438,0.0018768541,0.00045538688,0.00014162034,0.0007892123,0.0013856803,0.000115730065,0.0016426552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953925,0.0005634747,0.0008130772,0.0010572426,0.0013163243,0.0008573533],"domain_scores_gemma":[0.9959265,0.0018637902,0.00037091208,0.0012219958,0.00017128907,0.00044552976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075959053,0.00052902364,0.00087190274,0.00023745763,0.00067983754,0.00007416709,0.00035735298,0.00013968593,0.0006466001],"category_scores_gemma":[0.0014210768,0.00033420196,0.00014313599,0.00069840514,0.00031960904,0.00021476373,0.0005028975,0.0010763636,0.000035621808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026308661,0.002149511,0.94059294,0.000046415204,0.0005152994,0.0076170517,0.0013833798,0.000015488378,0.0008470218,0.000012885923,0.0035037783,0.01700756],"study_design_scores_gemma":[0.04709154,0.0034467264,0.9254222,0.00015705795,0.00014716141,0.00037666605,0.0014771447,0.0012221123,0.0006740832,0.00003468842,0.019529779,0.00042085245],"about_ca_topic_score_codex":0.0036501864,"about_ca_topic_score_gemma":0.0075917137,"teacher_disagreement_score":0.02078288,"about_ca_system_score_codex":0.00055249454,"about_ca_system_score_gemma":0.00032760427,"threshold_uncertainty_score":0.999911},"labels":[],"label_agreement":null},{"id":"W4206125294","doi":"10.3390/cells11010130","title":"Risk Stratification and Treatment in Smoldering Multiple Myeloma","year":2021,"lang":"en","type":"review","venue":"Cells","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Saint-Boniface; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Risk stratification; Multiple myeloma; Clinical trial; Asymptomatic; Medicine; Stratification (seeds); Oncology; Internal medicine; Bioinformatics; Computational biology; Biology","score_opus":0.08031506957518032,"score_gpt":0.3633376079332018,"score_spread":0.2830225383580215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206125294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002135537,0.9955853,0.0000075653857,0.000009045228,0.000060234914,0.0015848266,0.000074706106,0.00002234313,0.00052043976],"genre_scores_gemma":[0.0012360873,0.99563146,0.00065675273,0.0000030141,0.00007633219,0.00029979838,0.00054157997,0.00004022579,0.0015147772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850774,0.00016622881,0.0003763092,0.0004890932,0.00016976483,0.00029087637],"domain_scores_gemma":[0.9989452,0.00027056615,0.0001287761,0.00042022727,0.000031489963,0.00020379263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010652991,0.0003157091,0.0011718811,0.00019207211,0.000050644416,0.000041398434,0.000050404098,0.00019060259,0.00010230677],"category_scores_gemma":[0.000079753234,0.00023026376,0.00020754508,0.00020780654,0.000037546124,0.000032674237,0.00003699733,0.00022888367,0.0001091426],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009730532,0.00024499485,0.0012053446,0.0024464768,0.00022548242,0.00042670846,0.00006189929,2.8882562e-7,0.000017041679,0.0000030291123,0.000027367729,0.99533165],"study_design_scores_gemma":[0.002381059,0.0002788403,0.002635631,0.007913872,0.0008370775,0.000081368235,0.000057876987,0.00011293953,0.00035887377,0.0000034030074,0.98506314,0.0002759404],"about_ca_topic_score_codex":0.00031040973,"about_ca_topic_score_gemma":0.00014696569,"teacher_disagreement_score":0.9950557,"about_ca_system_score_codex":0.0003641671,"about_ca_system_score_gemma":0.00030976417,"threshold_uncertainty_score":0.9389883},"labels":[],"label_agreement":null},{"id":"W4206364523","doi":"10.1182/blood.v126.23.5492.5492","title":"Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Bortezomib; Cyclophosphamide; Melphalan; Internal medicine; Single Center; Lenalidomide; Median follow-up; Dexamethasone; Transplantation; Urology; Oncology; Multiple myeloma; Chemotherapy","score_opus":0.043573851624621004,"score_gpt":0.3019730353361254,"score_spread":0.2583991837115044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206364523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961463,0.0009889835,0.00012946647,0.00026841147,0.00006651504,0.000603738,0.00003305132,0.00008871172,0.0016747946],"genre_scores_gemma":[0.9941238,0.00007995606,0.003879183,0.00014697888,0.000075408745,0.00014301973,0.00015649007,0.000035665616,0.0013594712],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984165,0.000062591724,0.00020754614,0.00042705092,0.00047414014,0.00041216964],"domain_scores_gemma":[0.99890137,0.00006429158,0.000094504896,0.00030213376,0.00015579785,0.0004819218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001417057,0.00021269322,0.00030747382,0.00008967196,0.00012000399,0.00006368667,0.000063899475,0.00009193678,0.000071628085],"category_scores_gemma":[0.00029783385,0.00014891452,0.000035099067,0.00026226,0.00016118269,0.00026398184,0.00004579884,0.00017055249,0.000018810593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006007529,0.006067872,0.9069163,0.000118785814,0.001107523,0.001940982,0.003397681,0.0000012838548,0.057744894,0.000037044323,0.008231028,0.008429061],"study_design_scores_gemma":[0.23707362,0.024978861,0.2021718,0.002004675,0.0015378857,0.007015968,0.011089034,0.00025519895,0.48173574,0.00018217682,0.029983124,0.001971917],"about_ca_topic_score_codex":0.00030040933,"about_ca_topic_score_gemma":0.000047240268,"teacher_disagreement_score":0.7047445,"about_ca_system_score_codex":0.00008867912,"about_ca_system_score_gemma":0.00014999139,"threshold_uncertainty_score":0.6072558},"labels":[],"label_agreement":null},{"id":"W4206490155","doi":"10.1038/s41408-021-00600-6","title":"Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal","keywords":"Multiple myeloma; Immunoglobulin light chain; Medicine; Antibody; Immunoglobulin A; Internal medicine; Myeloma protein; Immunology; Immunoglobulin G; Oncology","score_opus":0.03656930127434755,"score_gpt":0.31523575146382365,"score_spread":0.2786664501894761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206490155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6928144,0.011278521,0.000009864594,0.28812444,0.0033964193,0.0020922548,0.00034290075,0.00011476909,0.0018264034],"genre_scores_gemma":[0.91079426,0.00812568,0.00089011533,0.03775839,0.020643188,0.0024361312,0.002003609,0.0004825435,0.016866082],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.995324,0.00043582323,0.0010437346,0.0006272152,0.0015530513,0.00101615],"domain_scores_gemma":[0.99827576,0.00007944279,0.00054410007,0.00068075064,0.00012901898,0.00029096016],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052077154,0.00059777376,0.0010390562,0.0009849792,0.00043034108,0.0001877432,0.00037655502,0.000514124,0.001486953],"category_scores_gemma":[0.00015635442,0.00050146336,0.0006220834,0.000528702,0.000032036376,0.0003412735,0.00013044104,0.0034235884,0.000028752887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036236076,0.002936594,0.45894474,0.00068451394,0.012009639,0.08631444,0.0034711065,0.00010141381,0.0029512388,0.000004522106,0.39117333,0.03778484],"study_design_scores_gemma":[0.08791029,0.013791889,0.2818684,0.0036008663,0.0056908904,0.00929865,0.0006224698,0.00010044637,0.005144285,0.0003760395,0.5896712,0.0019245838],"about_ca_topic_score_codex":0.0025817011,"about_ca_topic_score_gemma":0.00010434432,"teacher_disagreement_score":0.25036603,"about_ca_system_score_codex":0.0038724283,"about_ca_system_score_gemma":0.0013269036,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W4210295699","doi":"10.1016/j.clinbiochem.2022.01.007","title":"To skim or splice? Comparing the quantification of M-proteins using two peak-integration protocols across multiple electrophoresis platforms","year":2022,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Serum protein electrophoresis; Chemistry; Chromatography; Analytical Chemistry (journal); Medicine; Monoclonal; Immunology; Monoclonal antibody","score_opus":0.20685561931479338,"score_gpt":0.491252099073745,"score_spread":0.28439647975895166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210295699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914446,0.000034123183,0.0008069851,0.00022286914,0.000034651483,0.0072818715,0.00006311134,0.000032881104,0.00007892224],"genre_scores_gemma":[0.99348325,0.0000063232364,0.0019606166,0.00008673872,0.00014267703,0.0038237534,0.00015110722,0.000021371392,0.00032418745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979697,0.00006225646,0.000682247,0.00042878886,0.0005027379,0.00035429295],"domain_scores_gemma":[0.99835485,0.00033697742,0.0002347648,0.00069709204,0.00016609949,0.00021023933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088425656,0.00015576954,0.00037576462,0.000030109828,0.0003606144,0.00002404617,0.00028972834,0.000073421455,0.00013145916],"category_scores_gemma":[0.0017437825,0.00009721022,0.00018020507,0.00037513865,0.00014261401,0.000033783144,0.0002400749,0.00046944004,0.000013534339],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006206995,0.0011462633,0.15141644,0.00015327337,0.00013872655,0.000024972906,0.00016450115,0.00009236979,0.83336294,0.000010983968,0.00026291612,0.007019618],"study_design_scores_gemma":[0.0044728653,0.00085248123,0.05390507,0.00015040436,0.000045963046,0.000040640858,0.00080897385,0.015680775,0.9234609,0.000021066357,0.00040859336,0.00015229455],"about_ca_topic_score_codex":0.00018448613,"about_ca_topic_score_gemma":0.000048862825,"teacher_disagreement_score":0.097511366,"about_ca_system_score_codex":0.00019830828,"about_ca_system_score_gemma":0.00027325103,"threshold_uncertainty_score":0.39641178},"labels":[],"label_agreement":null},{"id":"W4210500075","doi":"10.24908/pocus.v7ikidney.15342","title":"POCUS Allows for Rapid Elucidation of Acute Kidney Injury in a Patient with Progressive Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"POCUS Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Proteinuria; Urinalysis; Pyuria; Urology; Tumor lysis syndrome; Internal medicine; Surgery; Kidney; Urine; Chemotherapy","score_opus":0.014753141822073199,"score_gpt":0.2977501641753203,"score_spread":0.2829970223532471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210500075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960272,0.00022124602,0.00021586719,0.0011642836,0.000113650356,0.001545256,0.00037715945,0.000014970369,0.0003204184],"genre_scores_gemma":[0.9942062,0.00004774685,0.0047663124,0.00016287804,0.00007186346,0.00042736935,0.0001675336,0.000029619536,0.00012050435],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981797,0.00012938963,0.00040177986,0.00021098397,0.0006721682,0.00040603318],"domain_scores_gemma":[0.9988604,0.00005847597,0.0002972555,0.00018522286,0.00023564098,0.00036301193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030688278,0.00015507637,0.00032010773,0.00034618156,0.00020607897,0.000021753534,0.000113583345,0.000036058693,0.00043548644],"category_scores_gemma":[0.00022251146,0.00011225491,0.00012221228,0.00027945146,0.000049852144,0.00012351079,0.00007239125,0.000384928,0.0000033442345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051400974,0.0047593806,0.38072,0.0002375241,0.0027254026,0.0064430963,0.0038974958,0.00006233532,0.036069266,0.00005093836,0.011471282,0.5021623],"study_design_scores_gemma":[0.14682609,0.09023589,0.4452393,0.0015729404,0.0016634176,0.022132825,0.003433975,0.012197533,0.20227064,0.0009865187,0.07187023,0.0015706441],"about_ca_topic_score_codex":0.000031068,"about_ca_topic_score_gemma":0.0000037970376,"teacher_disagreement_score":0.50059164,"about_ca_system_score_codex":0.00028965183,"about_ca_system_score_gemma":0.00051756884,"threshold_uncertainty_score":0.4768271},"labels":[],"label_agreement":null},{"id":"W4210632919","doi":"10.1016/s2352-3026(21)00283-0","title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Context (archaeology); Vaccination; Disease; Immunology; Internal medicine","score_opus":0.33242502555324743,"score_gpt":0.45737459681764064,"score_spread":0.12494957126439321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210632919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036051192,0.96915674,0.00029464645,0.020279791,0.0013076636,0.0045389025,0.00027922352,0.00009303721,0.0004448932],"genre_scores_gemma":[0.0014979952,0.9883793,0.0025674463,0.00029040573,0.000609828,0.0024088074,0.003916624,0.00004345016,0.0002861588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767226,0.00048536208,0.0008561758,0.00044861773,0.00021994385,0.00031762666],"domain_scores_gemma":[0.9957097,0.0031127725,0.0005177567,0.00053044973,0.000078273224,0.000051027808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011754418,0.0002557464,0.0014323365,0.0001545739,0.0002676166,0.000039573748,0.00023928806,0.00016292222,0.00017162203],"category_scores_gemma":[0.0026312727,0.00014846004,0.00023710355,0.00021827068,0.000116687894,0.000027830809,0.00025578652,0.0005204139,0.0000090636095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025359407,0.00012376717,0.012614837,0.0008994149,0.00065257243,0.0005417993,0.00008501957,6.21205e-7,9.2623657e-7,0.00038271796,0.016377106,0.96806765],"study_design_scores_gemma":[0.002093728,0.00006568331,0.0025096976,0.0020574215,0.00043732152,0.005335067,0.00005446137,0.00025722614,5.2846457e-7,0.0007861315,0.9862812,0.00012149284],"about_ca_topic_score_codex":0.00056899275,"about_ca_topic_score_gemma":0.0018694199,"teacher_disagreement_score":0.9699041,"about_ca_system_score_codex":0.00018849784,"about_ca_system_score_gemma":0.00018836222,"threshold_uncertainty_score":0.60540247},"labels":[],"label_agreement":null},{"id":"W4210777755","doi":"10.1111/ejh.13750","title":"Allogeneic hematopoietic stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma","year":2022,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Oncology; Monosomy; Population; Cohort; Gastroenterology; Karyotype; Chromosome; Biology","score_opus":0.017251799663774423,"score_gpt":0.23133553108340002,"score_spread":0.2140837314196256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210777755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997443,0.0012467866,0.00021029144,0.00029956698,0.00010023393,0.00043889807,0.000009801002,0.000019099965,0.00023231935],"genre_scores_gemma":[0.99840283,0.000120194636,0.0011354631,0.00017913924,0.000008629555,0.000020605246,0.000026806687,0.00004418271,0.00006216959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730414,0.0009048762,0.0007225812,0.00022712022,0.000459098,0.0003821642],"domain_scores_gemma":[0.9990525,0.0001171007,0.0003687589,0.00017894572,0.00014886404,0.00013382458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004950573,0.00021120164,0.0005833591,0.00039627653,0.00011114528,0.000012564301,0.00018561613,0.00003147032,0.00017355781],"category_scores_gemma":[0.000015891,0.00014923801,0.00010629221,0.0002936511,0.000081108934,0.00008977993,0.000054779422,0.00039308902,0.000029534947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005522918,0.00063904363,0.93872184,0.00018692853,0.00018429065,0.049988855,0.00216399,0.00008280753,0.00045292,0.00002877049,0.000036475594,0.0019911416],"study_design_scores_gemma":[0.01696757,0.0023666453,0.9633984,0.00018921749,0.000059754253,0.013059819,0.00053714385,0.00001668306,0.002933991,0.000020201467,0.00025662457,0.00019393617],"about_ca_topic_score_codex":0.0000024068418,"about_ca_topic_score_gemma":0.0000041700123,"teacher_disagreement_score":0.036929034,"about_ca_system_score_codex":0.00011846909,"about_ca_system_score_gemma":0.00014283622,"threshold_uncertainty_score":0.608575},"labels":[],"label_agreement":null},{"id":"W4210793676","doi":"10.1177/15330338211065252","title":"The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Technology in Cancer Research & Treatment","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Science and Technology Project of Nantong City","keywords":"Cyclin D1; Internal medicine; Medicine; Oncology; Multiple myeloma; Hazard ratio; Meta-analysis; Subgroup analysis; Confidence interval; Transplantation; Cell cycle; Cancer","score_opus":0.25229791697989584,"score_gpt":0.48833806613281133,"score_spread":0.2360401491529155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210793676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002005067,0.98019964,1.3328159e-7,0.0014411806,0.000010386372,0.017771373,0.00026954358,0.00004385486,0.00006336806],"genre_scores_gemma":[0.0026598978,0.9188616,0.000051921023,0.000010058226,0.0000059719287,0.077561274,0.00011036576,0.000054345433,0.00068451866],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933624,0.0018724632,0.0016226958,0.0009813939,0.0011013529,0.0010596927],"domain_scores_gemma":[0.99381477,0.0036295461,0.00046142584,0.0017474216,0.00016712728,0.00017969789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025827258,0.00060920976,0.008593228,0.0032132063,0.00023741838,0.000025174584,0.00063716073,0.00034572228,0.00034266073],"category_scores_gemma":[0.0020918872,0.00031139783,0.0013247653,0.0063076722,0.00065075886,0.000035575013,0.0005147327,0.0013486649,0.000020846894],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104851,0.0018961129,0.003974459,0.57386684,0.24691673,0.0010817912,0.000101750586,0.0000013313264,9.5237056e-7,0.00014999283,0.000029969864,0.1718752],"study_design_scores_gemma":[0.0026391307,0.0021653494,0.00024528505,0.046418015,0.867397,0.00016616672,0.00048541022,0.000051648218,0.00001274412,0.0003492956,0.07961567,0.00045429086],"about_ca_topic_score_codex":0.0032059867,"about_ca_topic_score_gemma":0.006084845,"teacher_disagreement_score":0.62048024,"about_ca_system_score_codex":0.0027172577,"about_ca_system_score_gemma":0.0011241636,"threshold_uncertainty_score":0.99993384},"labels":[],"label_agreement":null},{"id":"W4210829474","doi":"10.1080/10428194.2022.2030477","title":"Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; McGill University Health Centre","funders":"Bristol-Myers Squibb","keywords":"Lenalidomide; Pomalidomide; Medicine; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Neutropenia; Oncology; Chemotherapy","score_opus":0.0279549313468648,"score_gpt":0.29230793487169454,"score_spread":0.26435300352482977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210829474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888212,0.0030914901,0.0000117325335,0.0008193678,0.00015896771,0.004154951,0.00276483,0.000086845204,0.000090629655],"genre_scores_gemma":[0.99436253,0.00035739236,0.00033325484,0.00062736555,0.00008790385,0.00047038274,0.0035600946,0.000100772064,0.000100302415],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927048,0.0014707758,0.0021514532,0.001420283,0.0012227192,0.0010299886],"domain_scores_gemma":[0.9946489,0.0023128493,0.0009215742,0.0010264519,0.00016533316,0.0009248963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015005997,0.000839101,0.0019670543,0.00037696926,0.0006697026,0.00009472527,0.0002636059,0.00027986075,0.00007924176],"category_scores_gemma":[0.00064623076,0.00058037555,0.00021729682,0.00079771515,0.0006577847,0.00019868264,0.0003168712,0.00029210048,0.0000047657604],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6483105,0.0031502428,0.24767824,0.00007994943,0.0008481949,0.00031140778,0.0017002438,0.00006808348,0.00010318302,0.000016749156,0.0002287462,0.09750451],"study_design_scores_gemma":[0.4422309,0.0041977866,0.5500743,0.000102835686,0.00015021783,0.00002318271,0.00027094633,0.0017670353,0.00023859896,0.000011896002,0.0006099444,0.00032236482],"about_ca_topic_score_codex":0.040500063,"about_ca_topic_score_gemma":0.0019201568,"teacher_disagreement_score":0.30239606,"about_ca_system_score_codex":0.005500226,"about_ca_system_score_gemma":0.004575421,"threshold_uncertainty_score":0.9996648},"labels":[],"label_agreement":null},{"id":"W4210858405","doi":"10.3390/curroncol29020077","title":"An Individualized Exercise Intervention for People with Multiple Myeloma—Study Protocol of a Randomized Waitlist-Controlled Trial","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Physical therapy; Randomized controlled trial; Cardiorespiratory fitness; Population; Quality of life (healthcare); Attendance; Adverse effect; Internal medicine","score_opus":0.07304345562877779,"score_gpt":0.4463367663670824,"score_spread":0.37329331073830463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210858405","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50638556,0.000059240447,0.00047606113,0.000058040074,0.00028668178,0.4925383,0.000060451457,0.000048595335,0.00008704948],"genre_scores_gemma":[0.4858097,0.000001924572,0.00050665013,0.0000038886187,0.00006739587,0.5133248,0.0002020046,0.000019832592,0.00006381362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996129,0.0014932185,0.0009327604,0.00044964545,0.00061184296,0.00038352885],"domain_scores_gemma":[0.9977112,0.0008109875,0.00058184215,0.00039097352,0.0002958257,0.00020919104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022684333,0.00024220583,0.0022771885,0.0003411823,0.00020688269,0.00001607197,0.00020556666,0.000059180107,0.0006001883],"category_scores_gemma":[0.00075911026,0.00016359241,0.00050076476,0.0002292671,0.00010975222,0.000074183554,0.00012009394,0.00027477584,0.0000035919734],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89852774,0.03152178,0.01775191,0.00026192123,0.00069854455,0.000021781576,0.0018282126,0.000008730944,0.000048284484,0.000015854837,0.0001744857,0.049140733],"study_design_scores_gemma":[0.95173657,0.036367174,0.002670858,0.000056843106,0.00084972807,0.000012939714,0.0014500854,0.003407216,0.00008061101,0.00003489879,0.0031997792,0.00013330835],"about_ca_topic_score_codex":0.000119981414,"about_ca_topic_score_gemma":0.00020171756,"teacher_disagreement_score":0.0532088,"about_ca_system_score_codex":0.00025895378,"about_ca_system_score_gemma":0.00045536252,"threshold_uncertainty_score":0.6671105},"labels":[],"label_agreement":null},{"id":"W4210895175","doi":"10.3389/fonc.2022.820768","title":"Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Multiple myeloma; Gene expression profiling; Medicine; Risk stratification; Bone marrow; Oncology; Profiling (computer programming); Bioinformatics; Gene expression; Internal medicine; Gene; Cancer research; Computational biology; Biology; Genetics","score_opus":0.10201212435762731,"score_gpt":0.37529063596216805,"score_spread":0.27327851160454075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210895175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014430155,0.9934746,0.000064972046,0.000047915346,0.0006617988,0.0031940674,0.000180154,0.000027070988,0.0009064126],"genre_scores_gemma":[0.0011590873,0.977825,0.017979164,0.000010507141,0.00009796658,0.0019504698,0.00077802624,0.00006677497,0.00013303329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99575657,0.001488771,0.0010714218,0.00065723865,0.00038952206,0.00063648296],"domain_scores_gemma":[0.9969817,0.001474725,0.0006705295,0.00070702296,0.000021036949,0.00014500588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007596615,0.00046251566,0.0028590965,0.00078799005,0.00014053927,0.000006890174,0.00032418847,0.00043165387,0.00012688602],"category_scores_gemma":[0.0008686923,0.00028709363,0.0004344515,0.0006842012,0.00017118282,0.00003411336,0.00020208667,0.0010145381,0.000008942965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072929676,0.00091820216,0.021595392,0.0010608798,0.0003696289,0.00097106554,0.0004960761,0.000017801176,0.000004386508,0.0000072608104,0.00039810635,0.9734319],"study_design_scores_gemma":[0.007886624,0.0014926444,0.0010917988,0.0022354631,0.0006266981,0.00012367507,0.0006183872,0.0004136295,0.00010251699,0.000063944084,0.9850887,0.00025590725],"about_ca_topic_score_codex":0.00045039738,"about_ca_topic_score_gemma":0.00016756814,"teacher_disagreement_score":0.9846906,"about_ca_system_score_codex":0.003136046,"about_ca_system_score_gemma":0.0013494062,"threshold_uncertainty_score":0.9999581},"labels":[],"label_agreement":null},{"id":"W4211191410","doi":"10.1016/s0140-6736(21)00135-5","title":"Multiple myeloma","year":2021,"lang":"en","type":"review","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":852,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Janssen Pharmaceuticals; Bayer; Celgene; Takeda Canada; Novartis; Cancer Research UK; Roche Products; Servier; Amgen","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.15414648916733306,"score_gpt":0.4120173834667758,"score_spread":0.25787089429944277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211191410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007756957,0.99000835,0.000004231089,0.00048353613,0.00012474426,0.0008940094,0.0001262533,0.00006871065,0.008282419],"genre_scores_gemma":[0.000024784173,0.9917258,0.0003552937,0.00017549259,0.0017695727,0.00019914452,0.0006275608,0.00005172441,0.005070596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984104,0.00021603548,0.0002664415,0.00030689454,0.0003354328,0.0004648091],"domain_scores_gemma":[0.99806505,0.00040014123,0.000096029136,0.0012279253,0.000056424047,0.00015444981],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022813,0.00028131314,0.0023493918,0.000060876457,0.00009269226,0.00004393532,0.00031672456,0.0001514792,0.00044012401],"category_scores_gemma":[0.00043038483,0.00013806087,0.0004956599,0.0002654216,0.00006984918,0.000018245875,0.00015367116,0.00055267866,0.0010053501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002393031,0.0000626552,0.00013813318,0.006160517,0.00060903677,0.0004818695,0.000015146481,1.6894807e-8,2.292718e-7,0.00007818003,0.025352538,0.96707773],"study_design_scores_gemma":[0.0011523004,0.00004568283,0.00020185331,0.008403315,0.00063206314,0.00033340554,0.0000065458,0.0000062547037,0.000001877031,0.000008431105,0.98908955,0.00011869604],"about_ca_topic_score_codex":0.000025935135,"about_ca_topic_score_gemma":0.000011818462,"teacher_disagreement_score":0.96695906,"about_ca_system_score_codex":0.00010520551,"about_ca_system_score_gemma":0.00034290593,"threshold_uncertainty_score":0.9997725},"labels":[],"label_agreement":null},{"id":"W4211204703","doi":"10.1002/9781119398929.ch7","title":"PLASMA CELL NEOPLASMS","year":2019,"lang":"en","type":"other","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Multiple myeloma; Plasma Cell Myeloma; Bone marrow; Medicine; Plasma cell; Pathology; Biopsy; Bone pain; Plasma cell neoplasm; Hypercalcaemia; clone (Java method); Trephine; Plasmacytoma; Internal medicine; Biology; Calcium","score_opus":0.01847725702033875,"score_gpt":0.2869098953680951,"score_spread":0.2684326383477563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211204703","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025501664,0.00027841306,0.000014685487,0.000119218224,0.00018292472,0.0007713096,0.000036872676,0.0001910986,0.99815047],"genre_scores_gemma":[0.0016980428,0.00019905028,0.0017742158,0.00010555289,0.00019629349,0.000020877844,0.0001570267,0.00037963327,0.99546933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990548,0.000012349527,0.000087297216,0.00026628483,0.00030080936,0.00027847514],"domain_scores_gemma":[0.99928176,0.000029231542,0.000039894272,0.00042874055,0.000015136629,0.00020520814],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000022161532,0.00019313101,0.00032075006,0.00019677589,0.000010013092,0.000010448079,0.00007042663,0.00023004218,0.02695007],"category_scores_gemma":[0.000012746095,0.00013054987,0.00009765084,0.000059437712,0.000023705239,0.0000078612475,0.000040100917,0.00016924195,0.033993363],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000629504,0.00015035734,0.0017374532,0.00024986215,0.00015412949,0.00018138214,0.000005779454,4.2354557e-8,0.00008649015,0.000033189426,0.99259156,0.0047467775],"study_design_scores_gemma":[0.0035169586,0.00021440102,0.00022439899,0.000114363516,0.000050449384,0.000020955693,0.000010894369,0.00006768405,0.0012834298,0.000001705296,0.994378,0.0001167663],"about_ca_topic_score_codex":0.0004976397,"about_ca_topic_score_gemma":0.00008940816,"teacher_disagreement_score":0.007043294,"about_ca_system_score_codex":0.00005094658,"about_ca_system_score_gemma":0.00015468845,"threshold_uncertainty_score":0.9739394},"labels":[],"label_agreement":null},{"id":"W4212910932","doi":"10.1007/s43678-022-00270-8","title":"Just the facts: how to diagnose and manage patients with multiple myeloma in the emergency department?","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Emergency Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Emergency department; Multiple myeloma; Medical emergency; Emergency medicine; MEDLINE; Internal medicine; Nursing","score_opus":0.057579257317164866,"score_gpt":0.31823642323988816,"score_spread":0.2606571659227233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212910932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669845,0.0020139387,0.000009944112,0.028119413,0.0010321286,0.001055361,0.00006965463,0.0000032173457,0.0007118317],"genre_scores_gemma":[0.99811745,0.00038035834,0.000028339007,0.00052756636,0.00026567513,0.00009302728,0.000044975524,0.00002331426,0.0005193103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977627,0.00023131665,0.00047530144,0.00020215013,0.0008089848,0.00051957206],"domain_scores_gemma":[0.9982405,0.000118781805,0.00018735204,0.00033843206,0.000214162,0.0009008055],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007216738,0.00020079185,0.00032759787,0.0004337965,0.0004385256,0.00000861943,0.0003610516,0.000026157097,0.0027701822],"category_scores_gemma":[0.0009059948,0.00009868036,0.000068450085,0.0008056621,0.00008750089,0.000098314245,0.000040317256,0.0004653239,0.000004035876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025323563,0.00011478783,0.93328875,0.000025543093,0.00014384529,0.0008164471,0.0033701623,0.000008453652,0.0000095983005,0.000022857666,0.056041405,0.0059048855],"study_design_scores_gemma":[0.00328458,0.0023548158,0.9034488,0.00007007232,0.0001224668,0.000050860766,0.004653395,0.00002066687,0.0000030481885,0.000029235933,0.08586227,0.00009974717],"about_ca_topic_score_codex":0.005101786,"about_ca_topic_score_gemma":0.055474207,"teacher_disagreement_score":0.05037242,"about_ca_system_score_codex":0.00021149873,"about_ca_system_score_gemma":0.00026552344,"threshold_uncertainty_score":0.9981414},"labels":[],"label_agreement":null},{"id":"W4213271638","doi":"10.3389/fonc.2022.826342","title":"Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; Juravinski Cancer Centre; Institute of Cancer Research; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital; McGill University; University of Saskatchewan; Université de Montréal; University of Alberta","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Multiple myeloma; Internal medicine; Regimen; Pomalidomide; Bortezomib; Oncology; Cohort; Population; Surgery","score_opus":0.011788867705269511,"score_gpt":0.29113106051374915,"score_spread":0.27934219280847966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213271638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952792,0.00010516585,0.0003739594,0.00013195814,0.00022234007,0.0012430105,0.0000532245,0.000032799195,0.0025583676],"genre_scores_gemma":[0.99181455,0.000008923095,0.0072612893,0.000066039145,0.00003139383,0.0002724761,0.00022556892,0.000032012387,0.00028774244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974093,0.00035863186,0.0004291556,0.000560153,0.0006558765,0.00058691134],"domain_scores_gemma":[0.9986687,0.00020156206,0.00035207506,0.0004319941,0.00017422975,0.00017145925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041874388,0.00022477654,0.00097258633,0.0009399073,0.0002345323,0.000010008498,0.00017541088,0.00009390032,0.000080401915],"category_scores_gemma":[0.00045203714,0.00018121934,0.00017675872,0.0013222657,0.00032952247,0.000073894575,0.00013135026,0.00060730125,0.000001601555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019307612,0.0017368852,0.95871913,0.000017325941,0.0017116972,0.00056443724,0.00087507744,0.0005498612,0.000017298562,0.000021008307,0.0009428249,0.015536843],"study_design_scores_gemma":[0.02483475,0.006658866,0.96289116,0.00007563485,0.0003928674,0.0000058994733,0.0011959776,0.0030655703,0.00012262902,0.00002425019,0.00058216986,0.0001502153],"about_ca_topic_score_codex":0.00019073098,"about_ca_topic_score_gemma":0.00017403708,"teacher_disagreement_score":0.015386628,"about_ca_system_score_codex":0.0022880994,"about_ca_system_score_gemma":0.0002498942,"threshold_uncertainty_score":0.73899096},"labels":[],"label_agreement":null},{"id":"W4213288074","doi":"10.3324/haematol.2021.280394","title":"All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Ixazomib; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine; Carfilzomib","score_opus":0.058924197317112646,"score_gpt":0.32786834550963384,"score_spread":0.2689441481925212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213288074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957966,0.00023064959,0.000007978013,0.000839302,0.000056476158,0.002516938,0.00043218088,0.000021422791,0.000098458506],"genre_scores_gemma":[0.9988616,0.00010208335,0.00027187937,0.00007119231,0.0000054144252,0.0003006077,0.00028232916,0.000014583773,0.00009032393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971604,0.0006455932,0.0007598133,0.00039306786,0.00069349766,0.00034766784],"domain_scores_gemma":[0.99836123,0.0006707043,0.0003234639,0.00040165902,0.0001266321,0.00011630888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006931567,0.00021171925,0.00074868184,0.0002409477,0.00020277993,0.000008608947,0.00022581314,0.000069539296,0.00007813863],"category_scores_gemma":[0.0008096501,0.00014208975,0.00011763868,0.00045751344,0.00013677285,0.00008410025,0.00021688586,0.00029762957,0.00000203776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02094723,0.023151621,0.94324124,0.00014636923,0.0002589659,0.00046193702,0.0032504182,0.00004024061,0.0012212411,0.00006090254,0.0018674232,0.005352408],"study_design_scores_gemma":[0.16476963,0.009673762,0.8175144,0.00010989954,0.00016127052,0.00005887848,0.0010668365,0.0012501172,0.0045760176,0.00011728555,0.0005364351,0.00016545503],"about_ca_topic_score_codex":0.0017012588,"about_ca_topic_score_gemma":0.00058932125,"teacher_disagreement_score":0.1438224,"about_ca_system_score_codex":0.00007374536,"about_ca_system_score_gemma":0.000080723825,"threshold_uncertainty_score":0.57942516},"labels":[],"label_agreement":null},{"id":"W4213391082","doi":"10.1016/j.jcjo.2022.01.022","title":"Hypertensive uveitis in a patient with uveal plasmacytoma","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plasmacytoma; Uveitis; Multiple myeloma; Biopsy; Work-up; Pathology; Internal medicine; Ophthalmology","score_opus":0.026436216650159886,"score_gpt":0.27314259004086533,"score_spread":0.24670637339070545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213391082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99007905,0.0003870402,5.823796e-7,0.000973537,0.00015153235,0.00018977592,0.0000355011,0.0000012271024,0.008181787],"genre_scores_gemma":[0.99923044,0.0000013399745,0.00027138693,0.00013140333,0.00003324339,0.000017939925,0.000010044143,0.000015052208,0.00028914987],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989012,0.000118558004,0.00023633732,0.00011966895,0.00022790559,0.00039634897],"domain_scores_gemma":[0.99884844,0.00006205148,0.000101448335,0.000117691605,0.0001562577,0.00071408646],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000106001695,0.000094194555,0.00031347774,0.0005583038,0.00010966377,0.00000706569,0.00009944038,0.000033158267,0.0024025282],"category_scores_gemma":[0.00010659559,0.00007537563,0.000057178833,0.00024073749,0.00008850629,0.000037902908,0.000018911707,0.00041837784,0.000008683405],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006900931,0.00007358418,0.2919553,0.0000061941837,0.00009741102,0.7048853,0.0003573244,0.00007186324,0.000037433376,0.000017015302,0.0005193361,0.0012891722],"study_design_scores_gemma":[0.0030068946,0.006218554,0.1827339,0.000024230585,0.00001996272,0.80572325,0.00080648775,0.000038711707,0.000086816035,0.00003999362,0.0012378572,0.00006337031],"about_ca_topic_score_codex":0.008287986,"about_ca_topic_score_gemma":0.001145024,"teacher_disagreement_score":0.10922139,"about_ca_system_score_codex":0.00053145713,"about_ca_system_score_gemma":0.0023230226,"threshold_uncertainty_score":0.9985094},"labels":[],"label_agreement":null},{"id":"W4214497236","doi":"10.14740/jh971","title":"Consensus Statement: Importance of Timely Access to Multiple Myeloma Diagnosis and Treatment in Central America and the Caribbean","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Consensus conference; Disease; Caribbean region; Intensive care medicine; Family medicine; Political science; Pathology; Latin Americans; Immunology","score_opus":0.037025982800864776,"score_gpt":0.33823887895764093,"score_spread":0.30121289615677616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214497236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871171,0.0024679038,0.0000057461593,0.009662341,0.00004333232,0.0006055007,0.00003937667,0.0000023148139,0.000056378998],"genre_scores_gemma":[0.9985282,0.0006552211,0.0004543031,0.00023597122,0.000012920492,0.00007941355,0.0000041032736,0.000008237087,0.000021674521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869645,0.00019826906,0.0004982149,0.00012805802,0.00022449555,0.0002545089],"domain_scores_gemma":[0.9987649,0.0005852168,0.0002853434,0.0001234364,0.000060014147,0.00018109185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016461464,0.00010454309,0.0005686408,0.00017662614,0.0000702337,0.0000096777185,0.00008586567,0.000019550567,0.00008765438],"category_scores_gemma":[0.00023654121,0.000063185274,0.0000619089,0.00015347543,0.00017351704,0.000031372398,0.0001140261,0.00014331822,4.6594158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003684972,0.00041171157,0.98426527,0.000034217,0.0002871821,0.0015471705,0.001137414,0.00002670387,0.00014308844,0.00007421652,0.00063363503,0.0077544106],"study_design_scores_gemma":[0.022128988,0.002858209,0.9627432,0.000054145145,0.00014184248,0.0029624968,0.001807055,0.00054074527,0.0022394042,0.00014703415,0.0042867283,0.00009014073],"about_ca_topic_score_codex":0.00045573112,"about_ca_topic_score_gemma":0.0003207821,"teacher_disagreement_score":0.021522067,"about_ca_system_score_codex":0.00013850017,"about_ca_system_score_gemma":0.0001373924,"threshold_uncertainty_score":0.2576621},"labels":[],"label_agreement":null},{"id":"W4214820605","doi":"10.3390/curroncol29030132","title":"Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Juravinski Cancer Centre; Ottawa Hospital; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; McGill University; Saint John Regional Hospital; BC Cancer Agency; University of Alberta; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Carfilzomib; Medicine; Daratumumab; Multiple myeloma; Internal medicine; Lenalidomide; Database; Oncology","score_opus":0.30481293179745444,"score_gpt":0.4521881507513063,"score_spread":0.14737521895385186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214820605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992327,0.0018280472,0.000005942715,0.0023581716,0.00048202247,0.00165976,0.00089512696,0.00001944861,0.00042451624],"genre_scores_gemma":[0.9964453,0.000119762626,0.0004491383,0.00008921337,0.00017558802,0.00052813615,0.0018925699,0.000031486103,0.00026882227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955082,0.001474684,0.0005991266,0.00065295084,0.0008648408,0.00090022857],"domain_scores_gemma":[0.99674106,0.0014911075,0.00015481164,0.0008052588,0.0002482718,0.00055951416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002093378,0.00020168521,0.000523773,0.00054851157,0.00058955693,0.00003556085,0.00027733485,0.000115557654,0.00041163157],"category_scores_gemma":[0.0027319198,0.00016039633,0.00009322549,0.00067129376,0.0005182139,0.00010630802,0.0007248802,0.001355081,0.000013198359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030741116,0.0010871199,0.942744,0.00007199273,0.00019597457,0.014071993,0.0013809425,0.00000777568,0.0039943373,0.00035394364,0.012742469,0.02027535],"study_design_scores_gemma":[0.012166727,0.0009455022,0.73174995,0.00008383952,0.00008605619,0.0007582962,0.001354299,0.0015205584,0.00028816613,0.00014368398,0.2507178,0.00018513182],"about_ca_topic_score_codex":0.4462129,"about_ca_topic_score_gemma":0.6202363,"teacher_disagreement_score":0.23797531,"about_ca_system_score_codex":0.001803205,"about_ca_system_score_gemma":0.002212806,"threshold_uncertainty_score":0.65407723},"labels":[],"label_agreement":null},{"id":"W4220811291","doi":"10.3390/cancers14061592","title":"Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Mdm2; Bortezomib; Chromatin immunoprecipitation; Cancer research; Transfection; Molecular biology; Oncogene; Biology; Cell culture; Viability assay; XIAP; Cell cycle; Apoptosis; Chemistry; Multiple myeloma; Gene expression; Gene; Programmed cell death; Immunology; Genetics; Caspase; Promoter","score_opus":0.027182417952151813,"score_gpt":0.30772504640572373,"score_spread":0.2805426284535719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220811291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501276,0.00094866555,0.000021471835,0.0009381863,0.00018656232,0.0007498959,0.00008749823,0.000063662825,0.001991284],"genre_scores_gemma":[0.991723,0.00003183895,0.0023682779,0.0006459241,0.00009834115,0.00044825458,0.00010761549,0.00003412083,0.004542632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819964,0.00011450524,0.00022359972,0.00043045942,0.0005042852,0.0005275203],"domain_scores_gemma":[0.9990908,0.00008535256,0.000043104752,0.0003541476,0.000046679477,0.0003799098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002913071,0.00014843229,0.00025729378,0.00020659165,0.00023314351,0.000016586364,0.00017453356,0.00002389606,0.00072007184],"category_scores_gemma":[0.00022792,0.00014933993,0.000055874538,0.00053740415,0.000039320665,0.00009691293,0.00012531425,0.00029117576,0.00004113432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008647837,0.0004448455,0.869528,0.00030719713,0.00021931394,0.0028143744,0.014080874,0.0076492336,0.026892783,0.00020450226,0.050814174,0.018396856],"study_design_scores_gemma":[0.01749671,0.0010791579,0.65893906,0.00026290843,0.000047404195,0.000027543047,0.007336662,0.010177362,0.0054228264,0.00023835909,0.29806364,0.00090835954],"about_ca_topic_score_codex":0.0028969669,"about_ca_topic_score_gemma":0.0029990878,"teacher_disagreement_score":0.24724945,"about_ca_system_score_codex":0.0037186423,"about_ca_system_score_gemma":0.0005138525,"threshold_uncertainty_score":0.97241205},"labels":[],"label_agreement":null},{"id":"W4220862006","doi":"10.3324/haematol.2021.279459","title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"National Cancer Institute; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Celgene; Pharmacyclics; Sanofi; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Neutropenia; Gastroenterology; Population; Adverse effect; Multiple myeloma; Lenalidomide; Chemotherapy","score_opus":0.037694526573671436,"score_gpt":0.31148603190424057,"score_spread":0.2737915053305691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220862006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974696,0.000026263828,0.0000035957082,0.000020394193,0.00007376283,0.0020484412,0.00014229609,0.000018278515,0.00019739292],"genre_scores_gemma":[0.99950475,0.0000045441116,0.000103256396,0.000011496578,0.0000041880294,0.00017405332,0.000108028384,0.000014127921,0.000075542914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997495,0.00032209707,0.000561426,0.00038645076,0.00089269795,0.0003423423],"domain_scores_gemma":[0.99829286,0.00035736238,0.00035929526,0.00070724264,0.00017322096,0.00011003738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020369538,0.0001985645,0.0010236052,0.00032062846,0.00024197219,0.0000070700844,0.00027860733,0.000063948675,0.0004377549],"category_scores_gemma":[0.0003313803,0.000118867254,0.00014225299,0.0016381578,0.0001557151,0.000037003832,0.00023397643,0.00039985945,0.000001637048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11794135,0.021281365,0.8516452,0.0000576022,0.0019550864,0.0025547384,0.0018295253,0.0001305477,0.000106771804,0.0000037102802,0.000032378568,0.0024617482],"study_design_scores_gemma":[0.06654081,0.031568225,0.8972174,0.000027508988,0.0010141924,0.00004301181,0.0021414573,0.0011402372,0.0001409694,0.0000012873268,0.00003708933,0.00012782504],"about_ca_topic_score_codex":0.0013194359,"about_ca_topic_score_gemma":0.0037372494,"teacher_disagreement_score":0.051400546,"about_ca_system_score_codex":0.00022271214,"about_ca_system_score_gemma":0.00021882443,"threshold_uncertainty_score":0.48472658},"labels":[],"label_agreement":null},{"id":"W4220913590","doi":"10.1093/oncolo/oyac067","title":"Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Daratumumab; Medicine; Internal medicine; Multiple myeloma; Hazard ratio; Oncology; Cohort; Bortezomib; Autologous stem-cell transplantation; Progression-free survival; Proportional hazards model; Surgery; Confidence interval; Chemotherapy","score_opus":0.026222690483483503,"score_gpt":0.32028486441752685,"score_spread":0.2940621739340433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220913590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994851,0.00083093025,0.000013191349,0.00200686,0.0001330172,0.0013392377,0.00029240176,0.00005027758,0.00048306835],"genre_scores_gemma":[0.9978752,0.0003566621,0.0008029458,0.000060902665,0.000045163404,0.00043166333,0.00007424505,0.00002544629,0.0003277488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718666,0.0010503824,0.00037387188,0.00034852966,0.00060251466,0.00043802845],"domain_scores_gemma":[0.9966531,0.0023526938,0.00016746807,0.00061467703,0.00005111034,0.00016094097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016299294,0.00020188943,0.00046839443,0.00018160255,0.00034380675,0.000016965998,0.00035837392,0.00007350394,0.0000610209],"category_scores_gemma":[0.0014811711,0.000127091,0.00007924777,0.00038787766,0.0003881629,0.000051983992,0.0003095696,0.0005322572,0.0000043943837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06560424,0.0016369123,0.84451306,0.00010176535,0.00018253927,0.0018695651,0.0013087335,0.000049982435,0.011540014,0.0000830918,0.00080339034,0.0723067],"study_design_scores_gemma":[0.019626029,0.003314084,0.97123283,0.00005404718,0.00007547799,0.00006864482,0.0007962496,0.0006804372,0.003002944,0.00016318019,0.0008572314,0.00012882691],"about_ca_topic_score_codex":0.0042178836,"about_ca_topic_score_gemma":0.0043488652,"teacher_disagreement_score":0.12671979,"about_ca_system_score_codex":0.0002018243,"about_ca_system_score_gemma":0.00029728646,"threshold_uncertainty_score":0.6376207},"labels":[],"label_agreement":null},{"id":"W4220949248","doi":"10.1182/bloodadvances.2021006201","title":"Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Confidence interval; Internal medicine; Family history; Population; Monoclonal gammopathy of undetermined significance; Poisson regression; Demography; Gastroenterology; Monoclonal; Immunology; Antibody; Monoclonal antibody","score_opus":0.026839556569976844,"score_gpt":0.30851307704213116,"score_spread":0.2816735204721543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220949248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93286544,0.059304163,0.0069530876,0.00006572113,0.00007018421,0.0004062491,0.00022101245,0.000034184774,0.00007995138],"genre_scores_gemma":[0.93619573,0.0016592895,0.06163094,0.00006241465,0.00003996973,0.000035502995,0.000015957627,0.00001959275,0.0003405799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981757,0.00050699065,0.00020068295,0.00036797224,0.00046862746,0.00028005012],"domain_scores_gemma":[0.9990592,0.00038189552,0.00013422656,0.00022490269,0.000051745865,0.00014805223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070647564,0.00014784816,0.00035065267,0.000099383215,0.00019475266,0.000004402914,0.000059078473,0.000027107479,0.00004472423],"category_scores_gemma":[0.0002253254,0.00013709442,0.000058858626,0.00012815557,0.000115413306,0.00014236741,0.00014255813,0.00024782654,4.9370385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025432054,0.0016628789,0.50280845,0.0012054312,0.0006592208,0.0006997054,0.0010465623,0.000682232,0.32305735,0.000096039905,0.00033840755,0.1652005],"study_design_scores_gemma":[0.028280186,0.006057213,0.7722418,0.0007423335,0.0024057773,0.0011498987,0.002623405,0.040981274,0.12536046,0.0003391362,0.018661465,0.0011570957],"about_ca_topic_score_codex":0.001140039,"about_ca_topic_score_gemma":0.000014120447,"teacher_disagreement_score":0.26943332,"about_ca_system_score_codex":0.0001156628,"about_ca_system_score_gemma":0.00007763027,"threshold_uncertainty_score":0.55905485},"labels":[],"label_agreement":null},{"id":"W4221000304","doi":"10.1038/s41375-022-01529-w","title":"Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Asymptomatic; Multiple myeloma; Proteinuria; AL amyloidosis; Excretion; Gastroenterology; Medicine; Immunoglobulin light chain; Internal medicine; Urine; Amyloidosis; Retrospective cohort study; Urology; Kidney; Antibody; Immunology","score_opus":0.014563577989093355,"score_gpt":0.2679453236427972,"score_spread":0.25338174565370386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221000304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66725963,0.0023992702,0.00019272952,0.29217204,0.00064365094,0.028140958,0.0014004605,0.0010530371,0.0067381975],"genre_scores_gemma":[0.6353172,0.00057569076,0.039110184,0.16010459,0.016866699,0.058625594,0.025028577,0.0021753495,0.062196102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99408793,0.0005955855,0.0007352233,0.0011575292,0.0022153656,0.0012083679],"domain_scores_gemma":[0.997154,0.0003309022,0.0004885608,0.0015643289,0.0001239472,0.00033827804],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043627236,0.0008013726,0.0010880207,0.0006957891,0.00028317445,0.00009310965,0.00059572066,0.000796016,0.0010056804],"category_scores_gemma":[0.0006407275,0.0005783242,0.00022304052,0.00067316054,0.00014108683,0.00016113621,0.00037839875,0.004284298,0.00011715171],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005763685,0.0007391553,0.17266776,0.0026112695,0.0014167365,0.03816192,0.001441152,0.00008402794,0.0004378795,0.0000060196166,0.7543495,0.022320896],"study_design_scores_gemma":[0.075270265,0.011743111,0.20261012,0.007828083,0.00098809,0.0014699362,0.00020654748,0.036860157,0.004467823,0.0003292748,0.6557234,0.0025032158],"about_ca_topic_score_codex":0.0010273863,"about_ca_topic_score_gemma":0.00039463566,"teacher_disagreement_score":0.13206744,"about_ca_system_score_codex":0.0029966163,"about_ca_system_score_gemma":0.0019779585,"threshold_uncertainty_score":0.99990755},"labels":[],"label_agreement":null},{"id":"W4221035698","doi":"10.1016/j.clml.2022.03.002","title":"Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; McGill University; Juravinski Cancer Centre","funders":"Janssen Pharmaceuticals","keywords":"Medicine; Multiple myeloma; Bortezomib; Lenalidomide; Cohort; Internal medicine; Retrospective cohort study; Oncology; Autologous stem-cell transplantation; Database","score_opus":0.05144154557177737,"score_gpt":0.3483073221873166,"score_spread":0.2968657766155392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221035698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774237,0.00066248403,0.0000266266,0.0007907833,0.00047895228,0.0019727156,0.017673489,0.00006961026,0.00090161496],"genre_scores_gemma":[0.98825234,0.00041277095,0.00044595497,0.0004117786,0.00020014503,0.0003454787,0.009458439,0.00009623941,0.0003768634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98921174,0.002430528,0.0017870971,0.0016844259,0.00302934,0.0018568751],"domain_scores_gemma":[0.9882721,0.006673693,0.0004405797,0.0018910896,0.0005947568,0.0021278276],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003175808,0.0006465176,0.0018574195,0.00062927743,0.0016074721,0.00015575546,0.0008816173,0.00036343624,0.0009781143],"category_scores_gemma":[0.0035760615,0.00049329933,0.00070089026,0.0019627414,0.0012933916,0.00025349358,0.00053264975,0.001354561,0.0000525679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029080831,0.0010705232,0.932501,0.000028214534,0.003534869,0.0006549067,0.00050708686,0.000005050842,0.00016117342,0.00012950425,0.0067261276,0.05177347],"study_design_scores_gemma":[0.016433338,0.0015481564,0.9745608,0.00004612862,0.0009547348,0.000006758093,0.0009250251,0.0012864171,0.00012308142,0.000111679845,0.0035699385,0.00043396148],"about_ca_topic_score_codex":0.39644977,"about_ca_topic_score_gemma":0.37879753,"teacher_disagreement_score":0.051339507,"about_ca_system_score_codex":0.0036164222,"about_ca_system_score_gemma":0.003051506,"threshold_uncertainty_score":0.99993515},"labels":[],"label_agreement":null},{"id":"W4221091625","doi":"10.1016/s0735-1097(22)02937-0","title":"EARLY CARDIOVASCULAR RISK AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Stem cell; Hematopoietic stem cell; Oncology; Hematopoietic stem cell transplantation; Haematopoiesis; Internal medicine; Cardiology; Transplantation","score_opus":0.012499504415732972,"score_gpt":0.24620561356784698,"score_spread":0.233706109152114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221091625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382764,0.0024641391,0.0010323506,0.0003920174,0.00031403248,0.0007452785,0.0010881537,0.000008321514,0.00012804863],"genre_scores_gemma":[0.9984587,0.0002113379,0.0007461327,0.00006975397,0.00016387022,0.00011509282,0.0000028335335,0.000030485853,0.00020181728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744344,0.00079722103,0.0005461042,0.00020505062,0.00062695413,0.0003812218],"domain_scores_gemma":[0.9980434,0.0004608095,0.00058868126,0.000522712,0.00021687907,0.00016751439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078868197,0.00017925334,0.0013954495,0.00019104886,0.00018006894,0.0000032597452,0.00034322057,0.000041192296,0.000013655133],"category_scores_gemma":[0.000065786706,0.00011691196,0.0018795553,0.00030985015,0.0003222927,0.000029674704,0.00010851178,0.00044253303,0.0000017053904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032274093,0.0004826857,0.91617787,0.0003511894,0.0142684,0.007943131,0.000929759,0.005729833,0.0043297433,0.000026740314,0.004351295,0.013135261],"study_design_scores_gemma":[0.017191939,0.012269186,0.90269405,0.00008441543,0.0041436125,0.017008128,0.0026152923,0.0004916642,0.005713245,0.00015127433,0.037277993,0.0003592006],"about_ca_topic_score_codex":0.000042012343,"about_ca_topic_score_gemma":0.00000239894,"teacher_disagreement_score":0.032926697,"about_ca_system_score_codex":0.00018020999,"about_ca_system_score_gemma":0.00031004686,"threshold_uncertainty_score":0.47675312},"labels":[],"label_agreement":null},{"id":"W4223543763","doi":"10.1002/cncr.34211","title":"Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials","year":2022,"lang":"en","type":"review","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Randomized controlled trial; Confidence interval; Multiple myeloma; Transplantation; Oncology; Cytogenetics; Meta-analysis","score_opus":0.0880408065243122,"score_gpt":0.39816612461136963,"score_spread":0.31012531808705746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223543763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.070896514,0.90765095,0.000046263045,0.000005821385,0.00007428066,0.013219567,0.008035005,0.000014702644,0.000056876663],"genre_scores_gemma":[0.09927544,0.89279425,0.00008865696,0.00000459983,0.00002938612,0.0052693114,0.002418166,0.00005827201,0.00006191203],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9896181,0.005735392,0.0025650703,0.00057818525,0.0011076701,0.0003955514],"domain_scores_gemma":[0.98156,0.014662009,0.00278344,0.0005425604,0.00026110592,0.00019089883],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002801543,0.0006580285,0.029915258,0.0016250005,0.000045258836,0.0000123967275,0.00018340899,0.00022503982,0.0016858522],"category_scores_gemma":[0.0030978315,0.0003287819,0.009119425,0.00094014016,0.00013793222,0.000031828884,0.000022118236,0.00038755185,0.0000014000733],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33147764,0.00073531776,0.031650994,0.0021966281,0.5149249,0.00007475356,0.00015207147,0.0011349038,1.7261449e-7,0.0000016807642,0.000005227594,0.1176457],"study_design_scores_gemma":[0.43136263,0.0010940729,0.035070527,0.0009114642,0.5309288,4.881524e-7,0.000006907285,0.000263028,0.0000045264437,0.0000012564241,0.00016497653,0.00019131677],"about_ca_topic_score_codex":0.007678744,"about_ca_topic_score_gemma":0.0014804676,"teacher_disagreement_score":0.11745439,"about_ca_system_score_codex":0.0005029958,"about_ca_system_score_gemma":0.0009759318,"threshold_uncertainty_score":0.99991643},"labels":[],"label_agreement":null},{"id":"W4223576903","doi":"10.1038/s41375-022-01569-2","title":"Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100","year":2022,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Multiple myeloma; Proteinuria; Asymptomatic; Medicine; Immunoglobulin light chain; Monoclonal; Internal medicine; Oncology; Immunology; Monoclonal antibody; Antibody; Kidney","score_opus":0.01198347319694225,"score_gpt":0.27003634590276215,"score_spread":0.2580528727058199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223576903","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52443534,0.022767175,0.0009668991,0.006882411,0.08134389,0.082335636,0.003029873,0.0043548634,0.2738839],"genre_scores_gemma":[0.2251716,0.00096090836,0.0058453325,0.00026389383,0.005831695,0.01859767,0.01007484,0.00071014813,0.7325439],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9945009,0.0005015582,0.0007678391,0.0011647209,0.002067653,0.000997349],"domain_scores_gemma":[0.9970393,0.00023815292,0.00057983224,0.0014265702,0.00018108085,0.0005350332],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004927062,0.00080114155,0.001132671,0.0007158385,0.00040939127,0.00009977367,0.0005009586,0.00068922166,0.0012508379],"category_scores_gemma":[0.0012083213,0.0006019121,0.00022519211,0.0009459222,0.00013602326,0.00017901199,0.00037032133,0.003511567,0.00009789961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046908613,0.00088659604,0.078986324,0.0010751148,0.0008034173,0.004247237,0.0010474244,0.00010571907,0.00010344295,0.0000054300494,0.8755022,0.032546226],"study_design_scores_gemma":[0.045321923,0.009957089,0.4042388,0.010842724,0.0007819967,0.0012941923,0.00048675772,0.14976726,0.0016892077,0.00012114644,0.37369674,0.0018021354],"about_ca_topic_score_codex":0.0014905457,"about_ca_topic_score_gemma":0.0022573953,"teacher_disagreement_score":0.5018054,"about_ca_system_score_codex":0.0040393663,"about_ca_system_score_gemma":0.0040407395,"threshold_uncertainty_score":0.99978393},"labels":[],"label_agreement":null},{"id":"W4224085202","doi":"10.1111/bjh.18172","title":"Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; McGill University; Saint John Regional Hospital; BC Cancer Agency; Canadian Institutes of Health Research; Juravinski Cancer Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Pomalidomide; Multiple myeloma; Bortezomib; Internal medicine; Retrospective cohort study; Cohort; Progression-free survival; Oncology; Overall survival","score_opus":0.055654552876401295,"score_gpt":0.35681313966272865,"score_spread":0.30115858678632734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224085202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274665,0.0028492066,0.0000019715296,0.0013958385,0.00013792618,0.0019203352,0.00065096124,0.0000032098355,0.0002938771],"genre_scores_gemma":[0.9991133,0.00029044336,0.00014691752,0.000055183704,0.00004882308,0.00019135224,0.00009224747,0.000020199728,0.000041491105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948514,0.0020101846,0.00083264586,0.00028864786,0.0014937463,0.0005233721],"domain_scores_gemma":[0.9971171,0.0013164517,0.00033240693,0.00057917106,0.0004466415,0.00020820944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024658262,0.00016272046,0.0011015877,0.00042308235,0.00053233263,0.00002919317,0.0005653022,0.00005976447,0.00025976947],"category_scores_gemma":[0.0011072232,0.000106864994,0.00020351075,0.0006213412,0.00039520397,0.00007986287,0.000118879754,0.00082393404,0.000003129196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007849081,0.003810249,0.9272573,0.000011974785,0.0009418902,0.060902692,0.002661051,0.000002090771,0.000052979583,0.000086017426,0.0009978806,0.0024909652],"study_design_scores_gemma":[0.008539368,0.004050561,0.96393645,0.00006315901,0.00014936745,0.013440281,0.0089852875,0.000032576914,0.0000839311,0.00013955962,0.0005119842,0.00006749499],"about_ca_topic_score_codex":0.4378802,"about_ca_topic_score_gemma":0.7330236,"teacher_disagreement_score":0.29514337,"about_ca_system_score_codex":0.0009076223,"about_ca_system_score_gemma":0.00074584363,"threshold_uncertainty_score":0.565863},"labels":[],"label_agreement":null},{"id":"W4224216547","doi":"10.3390/curroncol29050242","title":"Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; National Center for Advancing Translational Sciences; Leukemia and Lymphoma Society","keywords":"Bone marrow; Multiple myeloma; Plasma cell; Plasma cell leukemia; Pathology; Monoclonal gammopathy of undetermined significance; Malignancy; Plasma cell neoplasm; Medicine; Circulating tumor cell; Cancer research; Biology; Monoclonal; Cancer; Antibody; Immunology; Monoclonal antibody; Metastasis; Internal medicine; Plasmacytoma","score_opus":0.09271894927963167,"score_gpt":0.3368746487033278,"score_spread":0.2441556994236961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224216547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601126,0.0014326117,0.00035496557,0.00011735848,0.00044567155,0.001166198,0.0001329071,0.000036325906,0.0003027191],"genre_scores_gemma":[0.99566376,0.000052730284,0.003713573,0.000030867093,0.00008356658,0.0002672431,0.00013484643,0.000025929623,0.000027486167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982746,0.00018404433,0.00042695476,0.00040599247,0.00032526703,0.00038309122],"domain_scores_gemma":[0.998966,0.00018952365,0.0001919781,0.00029522626,0.000125551,0.0002317132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018531375,0.0001796581,0.00037981194,0.00025943067,0.00022178113,0.000009242102,0.000116472474,0.00005270524,0.000091367394],"category_scores_gemma":[0.0001727602,0.0001715109,0.00007926214,0.0002203998,0.00004816548,0.000033665165,0.0004579609,0.00025495925,0.000008405346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010391806,0.001504642,0.069526374,0.00033262442,0.000058166177,0.00010334123,0.001008723,0.00027148813,0.61295384,0.0000049987625,0.00010370834,0.31309292],"study_design_scores_gemma":[0.020035928,0.017522955,0.03131067,0.00012512834,0.00037635872,0.0005448512,0.005565293,0.016477812,0.8697059,0.00009496693,0.037627656,0.0006124435],"about_ca_topic_score_codex":0.00006101714,"about_ca_topic_score_gemma":0.000027230939,"teacher_disagreement_score":0.31248048,"about_ca_system_score_codex":0.0006359692,"about_ca_system_score_gemma":0.00016555261,"threshold_uncertainty_score":0.69940114},"labels":[],"label_agreement":null},{"id":"W4224219848","doi":"10.1038/s41409-022-01659-w","title":"Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis","year":2022,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Multiple myeloma; Stem cell; Autologous stem-cell transplantation; Amyloidosis; Surgery; Pathology; Internal medicine","score_opus":0.01354871891833673,"score_gpt":0.24144987681646002,"score_spread":0.2279011578981233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224219848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90421593,0.0008126057,0.000017609545,0.09116709,0.00020670294,0.0018692132,0.0014095602,0.0000613212,0.00023995334],"genre_scores_gemma":[0.97726846,0.00038712294,0.00021756755,0.018646514,0.00009786462,0.0005280063,0.0015992925,0.0000746181,0.00118054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969458,0.0004171899,0.0005979636,0.00063817564,0.0008321341,0.00056875293],"domain_scores_gemma":[0.9987784,0.0003366692,0.00024145859,0.0004751174,0.000067569184,0.000100806625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019847843,0.00043670778,0.00073591684,0.00040540192,0.00014209774,0.000031262654,0.00020996618,0.00048862334,0.00021625945],"category_scores_gemma":[0.000014201328,0.0003323761,0.00022215238,0.00033896434,0.00020880066,0.00009895514,0.00006404206,0.0014286723,0.000009241615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066243224,0.000501427,0.88270783,0.007238264,0.00045100623,0.018824456,0.0024092086,0.000027045518,0.005165907,0.0000038418657,0.06716233,0.008884337],"study_design_scores_gemma":[0.008903384,0.00060398004,0.95042264,0.00056048186,0.00067932345,0.0011637191,0.00013081012,0.00037640656,0.0048414897,0.000016856964,0.031791195,0.0005097307],"about_ca_topic_score_codex":0.00096818124,"about_ca_topic_score_gemma":0.0011854742,"teacher_disagreement_score":0.07305253,"about_ca_system_score_codex":0.00018544763,"about_ca_system_score_gemma":0.00018922343,"threshold_uncertainty_score":0.9999128},"labels":[],"label_agreement":null},{"id":"W4224283527","doi":"10.51731/cjht.2022.305","title":"Isatuximab (Sarclisa)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Carfilzomib; Medicine; Family medicine; Multiple myeloma; Political science; Internal medicine; Health care; Bortezomib","score_opus":0.05283725872536472,"score_gpt":0.3347017299084163,"score_spread":0.2818644711830516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224283527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72224593,0.11120322,0.00008449247,0.16340224,0.0006024585,0.00067096384,0.00010069427,0.00015664642,0.0015333608],"genre_scores_gemma":[0.9982133,0.00018796753,0.00072316494,0.000618385,0.000008249562,0.000012345941,0.0000059144895,0.000011221633,0.00021943761],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872655,0.00006809808,0.0003321464,0.000097211625,0.00028982118,0.00048619587],"domain_scores_gemma":[0.9992176,0.000036305577,0.0002522509,0.0002164629,0.00009500373,0.00018237196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052882894,0.00008011253,0.00029849206,0.0007635191,0.000463773,0.000013470341,0.00023354233,0.00003931087,0.0002525015],"category_scores_gemma":[0.00045686626,0.00006695807,0.000080749596,0.0003471885,0.000132865,0.00004549941,0.00004061917,0.00064510095,0.000010467596],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009767093,0.000084674495,0.05691331,0.0000745473,0.000107544096,0.002696044,0.00024452293,0.000009246911,0.000039984734,0.0006661849,0.019582711,0.91948354],"study_design_scores_gemma":[0.0038968655,0.0037985553,0.07671001,0.00010534087,0.000023767152,0.005456534,0.0091517605,0.000042120253,0.00039541596,0.0034218817,0.89685214,0.00014562535],"about_ca_topic_score_codex":0.003690203,"about_ca_topic_score_gemma":0.00085067516,"teacher_disagreement_score":0.9193379,"about_ca_system_score_codex":0.0009832465,"about_ca_system_score_gemma":0.004799847,"threshold_uncertainty_score":0.8514722},"labels":[],"label_agreement":null},{"id":"W4225273169","doi":"10.1016/j.clml.2022.03.014","title":"Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Weill Cornell Medical College; Janssen Scientific Affairs","keywords":"Medicine; Daratumumab; Multiple myeloma; Chart; Oncology; Internal medicine; Bortezomib; Statistics","score_opus":0.03021988995951118,"score_gpt":0.32775632858393355,"score_spread":0.29753643862442236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225273169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321294,0.0003394789,0.0000020111122,0.00028746814,0.00017694785,0.0048163054,0.0004972688,0.0001417689,0.0005257872],"genre_scores_gemma":[0.99392605,0.0023236144,0.00018563202,0.0009677736,0.00012083463,0.00094961515,0.00087442296,0.00012286077,0.00052921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99400896,0.00081641186,0.0017192661,0.001411611,0.0011592817,0.000884453],"domain_scores_gemma":[0.9961061,0.00088268466,0.00072401296,0.0010371488,0.00026850184,0.0009815868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006669191,0.0007719619,0.001928165,0.00026083682,0.0007072816,0.00010251201,0.00020089511,0.00011161777,0.00022677999],"category_scores_gemma":[0.00063190906,0.0005645856,0.00026477006,0.00040797488,0.0004076069,0.0002206457,0.0006583599,0.000450773,0.00003086911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011607883,0.0022054915,0.7238695,0.00036725454,0.0006452617,0.00082975696,0.0004727371,3.2866186e-7,6.279111e-7,0.0000020466646,0.00018463626,0.27026156],"study_design_scores_gemma":[0.01983767,0.0088358335,0.96719897,0.00082858204,0.00060691696,0.000034366236,0.00054096116,0.0003604376,0.0000044110025,0.0000028985653,0.0012275117,0.00052143284],"about_ca_topic_score_codex":0.0012521818,"about_ca_topic_score_gemma":0.0008287088,"teacher_disagreement_score":0.26974013,"about_ca_system_score_codex":0.0014059605,"about_ca_system_score_gemma":0.0004475953,"threshold_uncertainty_score":0.9996806},"labels":[],"label_agreement":null},{"id":"W4225709908","doi":"10.1016/j.gastha.2022.02.028","title":"Extramedullary Myeloma to the Liver Following Bispecific Antigen T-Cell Treatment for Refractory Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Gastro Hep Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Radiology; Chemotherapy; Nuclear medicine; Pathology; Internal medicine","score_opus":0.03485735860081758,"score_gpt":0.30973041855005723,"score_spread":0.27487305994923966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225709908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738088,0.01742527,0.0023770775,0.0010572008,0.00063793786,0.003519807,0.0003515218,0.00013535372,0.0006870024],"genre_scores_gemma":[0.97859985,0.0012177125,0.014532297,0.0002925607,0.00031582435,0.001928855,0.00024734455,0.000068395,0.0027971861],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734354,0.00013721875,0.00033325807,0.00063921674,0.00068831915,0.00085845374],"domain_scores_gemma":[0.998385,0.00040724681,0.00010218575,0.0006492709,0.00006474646,0.000391524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026000116,0.00034259236,0.0004331997,0.00018612739,0.0009212788,0.00004600494,0.00029471423,0.000040949268,0.00026219297],"category_scores_gemma":[0.000112367954,0.00023720451,0.000403751,0.00031982682,0.000058384445,0.00016380532,0.000157614,0.00022218833,0.00009912717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050523006,0.0021857177,0.13753217,0.00011061165,0.0005681092,0.0012615694,0.0015446043,0.0012877815,0.00899984,0.00002427303,0.0038950515,0.83753794],"study_design_scores_gemma":[0.007750033,0.005582779,0.065138,0.000048580725,0.00013187354,0.00009893006,0.0023060048,0.0022663372,0.0054796855,0.000026418676,0.91086084,0.00031050423],"about_ca_topic_score_codex":0.000104743434,"about_ca_topic_score_gemma":0.00018030792,"teacher_disagreement_score":0.9069658,"about_ca_system_score_codex":0.00060040323,"about_ca_system_score_gemma":0.00017404351,"threshold_uncertainty_score":0.9672919},"labels":[],"label_agreement":null},{"id":"W4226145115","doi":"10.1177/2050313x221091602","title":"Adenopathy and extensive skin patch overlying plasmacytoma syndrome—the clue to early diagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes: A case series and literature review","year":2022,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital; Université Laval","funders":"","keywords":"Organomegaly; Medicine; Polyneuropathy; Monoclonal gammopathy; Dermatology; Plasmacytoma; Pathology; Multiple myeloma; Monoclonal; Internal medicine; Monoclonal antibody; Immunology","score_opus":0.018010367844300778,"score_gpt":0.30328056648023594,"score_spread":0.28527019863593517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226145115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256481,0.06673338,0.000002390456,0.0038793625,0.00012890225,0.003215509,0.00030214,0.000024990855,0.00006521307],"genre_scores_gemma":[0.9695066,0.027085729,0.00022140033,0.0015008582,0.00007518634,0.0012502313,0.0000591207,0.00006433208,0.00023654013],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99567765,0.00060806714,0.00081502064,0.0010200443,0.0012507555,0.000628465],"domain_scores_gemma":[0.9968967,0.00049590535,0.00034231003,0.00074911123,0.00019867923,0.00131732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015255513,0.00044269656,0.0010728053,0.00022848826,0.0006326741,0.00018602634,0.00016020755,0.000101394406,0.0004801282],"category_scores_gemma":[0.0021456096,0.00032396868,0.00009236529,0.00070939393,0.00031073138,0.00025884798,0.0020870082,0.0008095331,0.0000019316346],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003467721,0.00021934176,0.032526605,0.0011744951,0.00012700236,0.87812144,0.001883346,6.463253e-8,0.000055967706,0.0000054681946,0.00031099978,0.085228495],"study_design_scores_gemma":[0.0016168699,0.0029509747,0.020829609,0.003111226,0.0002906632,0.96641976,0.0014095022,0.000019897569,0.0003664184,0.000021165426,0.0026869099,0.000277035],"about_ca_topic_score_codex":0.0021135642,"about_ca_topic_score_gemma":0.0006568766,"teacher_disagreement_score":0.08829829,"about_ca_system_score_codex":0.0000921564,"about_ca_system_score_gemma":0.00030987666,"threshold_uncertainty_score":0.99992126},"labels":[],"label_agreement":null},{"id":"W4226210798","doi":"10.1182/bloodadvances.2022007082","title":"Outcomes after biochemical or clinical progression in patients with multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Medicine; Internal medicine; MEDLINE; Oncology; Biology; Biochemistry","score_opus":0.019565612470503726,"score_gpt":0.35470788578300794,"score_spread":0.33514227331250424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226210798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980305,0.0006267793,0.0000019224585,0.00020640275,0.000074027914,0.0008678463,0.00004682937,0.000041856998,0.00010384242],"genre_scores_gemma":[0.9952812,0.00003192462,0.0035323799,0.00015877592,0.000037829872,0.0005198323,0.00009931247,0.000021735848,0.00031699898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982554,0.00009458898,0.00031031825,0.00037965033,0.0006135126,0.00034656114],"domain_scores_gemma":[0.99924433,0.00018945534,0.00007178722,0.00025501568,0.00004851289,0.00019091519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013405156,0.00015815151,0.00034149078,0.0000987797,0.00008125588,0.000008987783,0.00010095081,0.00003885745,0.0003042665],"category_scores_gemma":[0.00027172684,0.00008963742,0.000071528426,0.00023137403,0.00009416359,0.00010217432,0.0001532467,0.00028707538,0.00001392896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009537991,0.0039380337,0.9549847,0.000038597937,0.00008513916,0.00044325064,0.000032842374,0.0000010794367,0.000014558927,8.7409705e-7,0.0000440543,0.030878868],"study_design_scores_gemma":[0.019005798,0.0022772632,0.975018,0.00006600631,0.000042467633,0.000009516044,0.000051012925,0.000019708732,0.0003567507,0.0000058731835,0.0030304957,0.000117062555],"about_ca_topic_score_codex":0.000007988019,"about_ca_topic_score_gemma":0.00003254399,"teacher_disagreement_score":0.030761806,"about_ca_system_score_codex":0.000044846394,"about_ca_system_score_gemma":0.000087727654,"threshold_uncertainty_score":0.3655308},"labels":[],"label_agreement":null},{"id":"W4229444575","doi":"10.1002/jha2.455","title":"Transcriptional profiles define drug refractory disease in myeloma","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Multiple myeloma; Lenalidomide; Medicine; Internal medicine; Refractory (planetary science); Oncology; Drug resistance; Disease; Gene expression profiling; Drug; Carfilzomib; Gene; Gene expression; Cancer research; Biology; Pharmacology; Genetics","score_opus":0.02663950204685158,"score_gpt":0.2924291734670066,"score_spread":0.265789671420155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229444575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924955,0.0014695763,0.000004824456,0.0025802697,0.0000980594,0.0005048346,0.00015629629,0.000050894043,0.0026397572],"genre_scores_gemma":[0.993683,0.000024365305,0.00023988329,0.00023063809,0.00008064978,0.00036882886,0.00041465467,0.000019490699,0.00493851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986788,0.00009736319,0.0001625183,0.00024520795,0.00053368305,0.0002824161],"domain_scores_gemma":[0.99942744,0.000046465455,0.000023684475,0.00020973891,0.00002520038,0.0002674982],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015255589,0.00010751789,0.00015897687,0.00016727502,0.00012783849,0.000007818426,0.00008313421,0.000014294608,0.0025886288],"category_scores_gemma":[0.00006036606,0.000095667245,0.00008310926,0.00020551568,0.000043136457,0.000059849594,0.000052941232,0.00027457712,0.0000885996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045982124,0.00304814,0.94370776,0.00018378298,0.00013101024,0.0051524187,0.0011662085,0.00004850584,0.0061060567,0.0020727809,0.009041899,0.024743216],"study_design_scores_gemma":[0.003512118,0.00017407583,0.95708215,0.00002609308,0.000022015673,0.000023041546,0.00017753632,0.00038699628,0.00024508685,0.00031609525,0.037934132,0.00010064972],"about_ca_topic_score_codex":0.00011759518,"about_ca_topic_score_gemma":0.000033468194,"teacher_disagreement_score":0.028892234,"about_ca_system_score_codex":0.00024107027,"about_ca_system_score_gemma":0.0002378683,"threshold_uncertainty_score":0.99832314},"labels":[],"label_agreement":null},{"id":"W4229458082","doi":"10.1016/s2352-3026(22)00103-x","title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Celgene; European Hematology Association; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Transplantation; Autologous stem-cell transplantation; Oncology; Surgery; Clinical trial","score_opus":0.062251826724128344,"score_gpt":0.36570004295411734,"score_spread":0.303448216229989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229458082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876368,0.000116440155,0.000917935,0.0007316548,0.00009920194,0.009351031,0.0010370439,0.000034169978,0.000075719356],"genre_scores_gemma":[0.9876275,0.000085032094,0.0063994676,0.00036624324,0.00007536919,0.0037379735,0.0016275225,0.00003574935,0.000045156834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979463,0.000460124,0.0004129523,0.00039467425,0.00033958192,0.00044633696],"domain_scores_gemma":[0.99776506,0.0012696362,0.00021123285,0.00040370872,0.00014036905,0.00021001158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052120164,0.00020398157,0.00096575957,0.00015027235,0.00028748866,0.000028771157,0.00028083852,0.000052271003,0.00014227707],"category_scores_gemma":[0.00039865746,0.00013741493,0.000038583934,0.00020643073,0.00010484798,0.00014073924,0.00010436786,0.00016484245,0.0000041275557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9679289,0.0044972724,0.008685218,0.00024214505,0.00032077602,0.00017968466,0.0012853366,0.000043844102,0.000739986,0.00026143633,0.0008559143,0.01495949],"study_design_scores_gemma":[0.9783733,0.011007799,0.005724841,0.0000679585,0.00036568617,0.00014423582,0.00033614112,0.0011239373,0.0015984407,0.00008632469,0.000997043,0.00017429666],"about_ca_topic_score_codex":0.00039574175,"about_ca_topic_score_gemma":0.00025982675,"teacher_disagreement_score":0.014785194,"about_ca_system_score_codex":0.00007542881,"about_ca_system_score_gemma":0.00012272975,"threshold_uncertainty_score":0.5603618},"labels":[],"label_agreement":null},{"id":"W4232139787","doi":"10.1182/blood.v114.22.1872.1872","title":"Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Hazard ratio; Venous thrombosis; Thrombosis; Internal medicine; Multiple myeloma; Population; Confidence interval; Gastroenterology; Proportional hazards model; Monoclonal; Immunology; Monoclonal antibody; Antibody","score_opus":0.025100910829319766,"score_gpt":0.29583229384803705,"score_spread":0.2707313830187173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232139787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893814,0.00011964296,0.0000045412116,0.00008934835,0.000014239162,0.0007611834,0.000025056623,0.000015741263,0.000032127027],"genre_scores_gemma":[0.9991489,0.000008699686,0.0007172676,0.000024219147,0.000034968663,0.000020534317,0.000031125815,0.000008364274,0.000005904535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999117,0.00005017244,0.00021568249,0.00023472113,0.00019724488,0.00018517663],"domain_scores_gemma":[0.99954814,0.00010021918,0.000053761403,0.00015438462,0.00003113068,0.00011234879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009191554,0.00011601861,0.0003081857,0.00011803379,0.000037099577,0.000012212294,0.00003251415,0.000042843327,0.000008745917],"category_scores_gemma":[0.00010047888,0.000100270896,0.000026279022,0.00011268512,0.00002890517,0.000040463732,0.000012035203,0.00006644164,6.935326e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005944097,0.0042291363,0.97179306,0.00003872433,0.000049043658,0.00012899762,0.00024082782,0.000002600514,0.019413935,0.0000028807976,9.846544e-7,0.0035054188],"study_design_scores_gemma":[0.016845357,0.0023679414,0.9763127,0.00005179008,0.00007604495,0.000009009588,0.000060540646,0.0006775909,0.0034859763,0.000036336354,0.0000011760827,0.00007551995],"about_ca_topic_score_codex":0.00042405937,"about_ca_topic_score_gemma":0.00021416105,"teacher_disagreement_score":0.016250947,"about_ca_system_score_codex":0.000021944239,"about_ca_system_score_gemma":0.000054346063,"threshold_uncertainty_score":0.40889284},"labels":[],"label_agreement":null},{"id":"W4232494473","doi":"10.1182/blood-2019-123486","title":"Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Carfilzomib; Dexamethasone; Internal medicine; Multiple myeloma; Oncology; Adverse effect; Surgery; Proteasome inhibitor; Bortezomib","score_opus":0.01949929881675953,"score_gpt":0.2947767710423797,"score_spread":0.27527747222562016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232494473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745331,0.00050847785,0.000016396354,0.000048019443,0.00009581352,0.02340521,0.0002885876,0.00013780926,0.0009666113],"genre_scores_gemma":[0.99509317,0.00006253172,0.0016412863,0.000025869394,0.00006192833,0.0013880497,0.0007133156,0.00022864933,0.00078517414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913419,0.0013703721,0.0014410949,0.0018112316,0.0024326083,0.0016028103],"domain_scores_gemma":[0.9942243,0.0011887323,0.0006351713,0.0019892275,0.0009906366,0.000971907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001110621,0.001232797,0.0041326312,0.0009157853,0.00023110691,0.000085755724,0.00045764164,0.00029415963,0.00017693164],"category_scores_gemma":[0.00080314884,0.0008474671,0.0002963539,0.0013419623,0.0002954292,0.00022700634,0.00021793284,0.00077078934,0.00008816875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68312174,0.027629625,0.26895112,0.00020070079,0.0062652514,0.002882044,0.005498656,0.0003033338,0.00038228737,0.0000016132647,0.000015946618,0.004747695],"study_design_scores_gemma":[0.8153775,0.078510925,0.093327366,0.00063724665,0.0036057157,0.00012484605,0.0012403807,0.001052104,0.0053715534,0.0000014718635,0.0000140067095,0.0007369197],"about_ca_topic_score_codex":0.006182041,"about_ca_topic_score_gemma":0.0031986271,"teacher_disagreement_score":0.17562376,"about_ca_system_score_codex":0.0009997616,"about_ca_system_score_gemma":0.0005931224,"threshold_uncertainty_score":0.99939764},"labels":[],"label_agreement":null},{"id":"W4232774961","doi":"10.1182/blood-2019-124457","title":"A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Thunder Bay Regional Health Sciences Centre; Ottawa Hospital; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; University of New Brunswick; Dalhousie University; University of Ottawa; McGill University Health Centre; Juravinski Cancer Centre; Saint John Regional Hospital; BC Cancer Agency","funders":"","keywords":"Pomalidomide; Daratumumab; Medicine; Dexamethasone; Lenalidomide; Internal medicine; Cyclophosphamide; Oncology; Multiple myeloma; Regimen; Pharmacology; Surgery; Chemotherapy","score_opus":0.024975060637187456,"score_gpt":0.31624395299566677,"score_spread":0.2912688923584793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232774961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989546,0.00026204964,0.0000021845628,0.000031943207,0.000021759508,0.00985498,0.0000370145,0.000028188158,0.00021587721],"genre_scores_gemma":[0.9957566,0.000049014827,0.002974819,0.00003642411,0.000010444354,0.0003394208,0.000061421415,0.00006275243,0.00070908834],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973315,0.00037147125,0.00054397946,0.0006812264,0.0006160106,0.00045578546],"domain_scores_gemma":[0.9980898,0.0004817639,0.00028601012,0.00059599895,0.00020278918,0.00034362622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006313726,0.00038757827,0.0016415906,0.0002399396,0.00011165502,0.00005441564,0.00017873352,0.00009997804,0.000050500985],"category_scores_gemma":[0.00044772105,0.00022430351,0.00002871069,0.00038396486,0.00023341956,0.00032821068,0.00027190865,0.00030477438,0.000003972956],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42259437,0.02227667,0.55106616,0.0000926739,0.0007146995,0.00022451562,0.00087561,3.7399053e-7,0.00042285118,0.0000011014118,0.0000046642735,0.0017262908],"study_design_scores_gemma":[0.6619869,0.023746831,0.31205252,0.00039077326,0.00040102427,0.000021259199,0.00047941878,0.00013229901,0.0005838235,0.0000021720825,0.00001034832,0.0001926695],"about_ca_topic_score_codex":0.0014732714,"about_ca_topic_score_gemma":0.0012998428,"teacher_disagreement_score":0.23939249,"about_ca_system_score_codex":0.000045375557,"about_ca_system_score_gemma":0.000206607,"threshold_uncertainty_score":0.9146832},"labels":[],"label_agreement":null},{"id":"W4233274781","doi":"10.21203/rs.3.rs-92579/v1","title":"The Work of Managing Multiple Myeloma and its Implications for Treatment-related Decision Making: A Qualitative Study of Patient and Caregiver Experiences.","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Ottawa Hospital; Queen's University","funders":"","keywords":"Multiple myeloma; Qualitative research; Work (physics); Psychology; Medicine; Sociology; Internal medicine; Engineering; Social science","score_opus":0.13372034672098312,"score_gpt":0.4793909619943605,"score_spread":0.3456706152733774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233274781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858185,0.005203539,0.000058280966,0.0010072879,0.000032133088,0.007616009,0.0001805749,0.000018433439,0.00006525956],"genre_scores_gemma":[0.9953984,0.00091930735,0.00039320916,0.000002938228,0.000018096249,0.00312012,0.00006405762,0.00003231938,0.000051541927],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.996958,0.0005820715,0.0005404733,0.00068529573,0.0007859945,0.00044813115],"domain_scores_gemma":[0.9937421,0.004262759,0.0002206152,0.00057330116,0.00093733094,0.0002639054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006118402,0.0002513383,0.0005971922,0.00030911862,0.0004224558,0.000056106852,0.00019804352,0.00013280488,0.000008623533],"category_scores_gemma":[0.001681948,0.00016061013,0.00012311943,0.00048132785,0.000313528,0.000045095767,0.00074796536,0.00030256197,0.0000012874212],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063476544,0.0017910311,0.047171187,0.0012220526,0.0015424166,0.000051137682,0.7594763,0.000025574069,0.00020235141,0.00029430605,0.00020845384,0.1816675],"study_design_scores_gemma":[0.010632617,0.010198565,0.18997823,0.0023986595,0.0001969472,0.0000077268405,0.77974564,0.0028454715,0.0007463147,0.0027854154,0.00019796827,0.00026644784],"about_ca_topic_score_codex":0.00020172294,"about_ca_topic_score_gemma":0.00011839835,"teacher_disagreement_score":0.18140106,"about_ca_system_score_codex":0.00022211451,"about_ca_system_score_gemma":0.00025934368,"threshold_uncertainty_score":0.65494907},"labels":[],"label_agreement":null},{"id":"W4235159110","doi":"10.1182/blood.v126.23.1842.1842","title":"Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience","year":2015,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Regimen; Multiple myeloma; Internal medicine; Cyclophosphamide; Dexamethasone; Gastroenterology; Progression-free survival; Bortezomib; Progressive disease; Surgery; Median follow-up; Oncology; Chemotherapy","score_opus":0.027547759311993568,"score_gpt":0.3001757576348941,"score_spread":0.2726279983229006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235159110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12441259,0.87139285,0.000001198271,0.000008483192,0.000029630113,0.0035086626,0.000421646,0.000012316272,0.00021263419],"genre_scores_gemma":[0.036358822,0.96237904,0.00034223782,0.000042391912,0.00002460712,0.00024731713,0.00048490553,0.000053644257,0.0000670564],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973255,0.0001890608,0.000826981,0.00054165255,0.0007871168,0.0003297292],"domain_scores_gemma":[0.997995,0.00018372164,0.0005592126,0.00052500004,0.00040139342,0.0003356421],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020649929,0.00039512035,0.002162524,0.00027575565,0.000023006416,0.000006858261,0.000115844,0.00015258705,0.00004644587],"category_scores_gemma":[0.0010847892,0.00027068824,0.00015701981,0.00046174784,0.00010584554,0.000078915145,0.000082404185,0.00026567042,0.000011462869],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032514136,0.012103329,0.2585778,0.12615061,0.0010436509,0.0003198665,0.00073355355,1.5545744e-7,0.000021878206,0.0000067246883,0.00042538406,0.5973656],"study_design_scores_gemma":[0.033466753,0.012231437,0.17451955,0.7060346,0.002364433,0.000040008188,0.000084739535,8.58005e-7,0.00030608193,0.0000053033714,0.0702541,0.0006921199],"about_ca_topic_score_codex":0.000045292232,"about_ca_topic_score_gemma":0.00003468999,"teacher_disagreement_score":0.5966735,"about_ca_system_score_codex":0.00028518194,"about_ca_system_score_gemma":0.00023634102,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W4235426531","doi":"10.1182/blood.v106.11.355.355","title":"CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Stromal cell; Multiple myeloma; Bone marrow; CD28; Cancer research; Plasma cell; CD86; Biology; Monoclonal gammopathy of undetermined significance; CD80; T cell; Immunology; Medicine; CD40; Monoclonal; Antibody; In vitro; Cytotoxic T cell; Monoclonal antibody; Immune system","score_opus":0.018141114981176713,"score_gpt":0.265237578060888,"score_spread":0.24709646307971128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235426531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681216,0.0002845836,0.000050980496,0.00027053268,0.00001683399,0.0004700993,0.000015543576,0.00003470028,0.0020445548],"genre_scores_gemma":[0.996896,0.00006066759,0.002017686,0.000021656047,0.00011134041,0.00002246316,0.00015262424,0.000012738523,0.00070481264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992054,0.00003861541,0.00018214573,0.00015949075,0.00025792167,0.00015644287],"domain_scores_gemma":[0.9994659,0.00008401372,0.000057579233,0.0001603166,0.00010729993,0.0001249267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001180419,0.000086946566,0.00016430859,0.00009053564,0.000040013263,0.000008665239,0.000025756493,0.0000622693,0.000070098125],"category_scores_gemma":[0.00016953427,0.00007179603,0.00003053838,0.000111097055,0.000036081015,0.00007933135,0.000018818439,0.00006295326,0.00003252663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029175964,0.0013015515,0.8252137,0.00013096642,0.00008987326,0.000010728585,0.00022560102,0.0000046902674,0.16027664,0.000024030047,0.00010172889,0.012328773],"study_design_scores_gemma":[0.009126138,0.00025663665,0.7494239,0.000026749345,0.00006411939,0.000011758962,0.00002435119,0.0027612657,0.2377971,0.000010584777,0.00043958533,0.000057791298],"about_ca_topic_score_codex":0.000030484347,"about_ca_topic_score_gemma":0.00005902869,"teacher_disagreement_score":0.07752045,"about_ca_system_score_codex":0.000016148491,"about_ca_system_score_gemma":0.000047606944,"threshold_uncertainty_score":0.2927757},"labels":[],"label_agreement":null},{"id":"W4236199686","doi":"10.1182/blood.v126.23.29.29","title":"Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Refractory (planetary science); Gastroenterology; Multiple myeloma; Surgery; Lenalidomide","score_opus":0.04897654935328532,"score_gpt":0.3399102040956416,"score_spread":0.2909336547423563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236199686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778897,0.000171981,0.00000582926,0.00004004892,0.000050799754,0.0011849094,0.000030109404,0.000051113675,0.0006762363],"genre_scores_gemma":[0.99733526,0.000038094713,0.0019812253,0.000038933347,0.00004711816,0.00003042829,0.00013741729,0.000043056833,0.00034845292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979554,0.000185811,0.00054334325,0.00038596182,0.0005738113,0.00035571874],"domain_scores_gemma":[0.9982973,0.00030361905,0.00015401856,0.0005636663,0.00026428042,0.00041713478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027518952,0.00020868264,0.00056546816,0.0001747901,0.000029000152,0.000009071362,0.000120135504,0.00015780525,0.000043712003],"category_scores_gemma":[0.00088496617,0.00013046074,0.00008476452,0.00036306508,0.00012671214,0.000092639435,0.00003366587,0.0002944822,0.000033244396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03270309,0.012504809,0.94181645,0.00003023905,0.00035750592,0.00021176609,0.00020326408,0.0000014516241,0.00008204334,0.000001233363,0.00013278819,0.011955381],"study_design_scores_gemma":[0.1419888,0.008922378,0.8471423,0.00018433364,0.000084114145,0.0000055991604,0.000030114707,0.0000545769,0.0011564788,0.000002224694,0.00031446866,0.00011461923],"about_ca_topic_score_codex":0.0001763469,"about_ca_topic_score_gemma":0.0001216683,"teacher_disagreement_score":0.10928571,"about_ca_system_score_codex":0.00007601104,"about_ca_system_score_gemma":0.0003612371,"threshold_uncertainty_score":0.53200346},"labels":[],"label_agreement":null},{"id":"W4244042359","doi":"10.14694/edbook_am.2013.33.e307","title":"Update on the Initial Therapy of Multiple Myeloma","year":2013,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Thalidomide; Bortezomib; Multiple myeloma; Medicine; Regimen; Oncology; Melphalan; Internal medicine; Maintenance therapy; Dexamethasone; Population; Pharmacology; Chemotherapy","score_opus":0.28856113041625625,"score_gpt":0.5530178974308779,"score_spread":0.2644567670146217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244042359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016793545,0.9646738,0.000005955359,0.023496525,0.0003487158,0.0028328716,0.0001414998,0.000018014518,0.0068032295],"genre_scores_gemma":[0.0006385838,0.98450226,0.0033076194,0.006420902,0.0008508056,0.0005745993,0.0003297121,0.00004362798,0.0033318761],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959895,0.0008528472,0.0018039857,0.00046465368,0.00056069036,0.00032832453],"domain_scores_gemma":[0.97806114,0.01862074,0.0019340281,0.0006474762,0.00044170534,0.00029489986],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000952076,0.00034642217,0.0031805488,0.00006165235,0.00008392565,0.000005523721,0.0004024892,0.0003700707,0.0026880882],"category_scores_gemma":[0.0016389751,0.00019261555,0.0023129417,0.00026817783,0.0030674266,0.000039878298,0.00008915894,0.0009954132,0.00035477962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018662903,0.0022503622,0.00084674254,0.00045886866,0.0018353096,0.000001598654,0.00006358878,6.673601e-8,6.8577117e-7,0.00029709097,0.06765921,0.9263998],"study_design_scores_gemma":[0.0013897205,0.002581197,0.005865179,0.0008562891,0.00027750092,0.000012006096,0.000115144765,0.000008584956,0.000005229313,0.00007614184,0.9886787,0.00013431814],"about_ca_topic_score_codex":0.00014147215,"about_ca_topic_score_gemma":0.0000020444054,"teacher_disagreement_score":0.92626554,"about_ca_system_score_codex":0.0001995519,"about_ca_system_score_gemma":0.007036849,"threshold_uncertainty_score":0.99964565},"labels":[],"label_agreement":null},{"id":"W4244878561","doi":"10.1182/blood.v116.21.5028.5028","title":"Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Refractory (planetary science); Internal medicine; Concomitant; Gastroenterology; Thalidomide; Toxicity; Pharmacology; Oncology; Surgery","score_opus":0.032615279134119865,"score_gpt":0.3107651264905731,"score_spread":0.2781498473564532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244878561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954043,0.0007247439,0.0000711225,0.0005072416,0.00015060716,0.0020883842,0.00015443878,0.00018938837,0.0007097747],"genre_scores_gemma":[0.9775634,0.0002877863,0.018204667,0.00017957407,0.0003059558,0.0003718869,0.00019439665,0.00009231184,0.0028000532],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99771976,0.00007658917,0.0004268121,0.00065093004,0.00040669023,0.0007192431],"domain_scores_gemma":[0.99740726,0.0009283907,0.00013364929,0.0006402952,0.00022244852,0.00066798483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039171474,0.00035849446,0.0006045515,0.00020995091,0.00021206817,0.00004830021,0.00014510218,0.00032170507,0.00024787168],"category_scores_gemma":[0.002557799,0.00025934045,0.0001619998,0.00023681502,0.00018749973,0.00015888899,0.000076644355,0.0005544307,0.000042712072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014480059,0.004722615,0.38776577,0.00059677305,0.0016975624,0.0009297542,0.00041909143,3.180826e-7,0.519355,0.00009268679,0.0023811883,0.067559175],"study_design_scores_gemma":[0.1026903,0.004557763,0.57972497,0.00030173117,0.0011998047,0.00084939605,0.00015313714,0.0007919515,0.29108524,0.00012574026,0.01784633,0.0006736297],"about_ca_topic_score_codex":0.0001963568,"about_ca_topic_score_gemma":0.00041797553,"teacher_disagreement_score":0.22826979,"about_ca_system_score_codex":0.000042953165,"about_ca_system_score_gemma":0.00026509142,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W4245008980","doi":"10.1182/blood.v108.11.3484.3484","title":"Targeting Aurora Kinases as Therapy in Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Aurora inhibitor; Mitosis; Kinase; Aurora kinase; Cytokinesis; Cancer research; Cell biology; Cell cycle; Aurora B kinase; Apoptosis; Biology; Bortezomib; Multiple myeloma; Cell; Immunology; Cell division; Genetics","score_opus":0.024780395922784103,"score_gpt":0.29110681245467035,"score_spread":0.26632641653188627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245008980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189454,0.001490359,0.000004347852,0.00022697405,0.000029030378,0.00048704608,0.0000081151165,0.00007400219,0.005785561],"genre_scores_gemma":[0.9974038,0.00013712015,0.001066594,0.000097678116,0.00018124127,0.00006601823,0.000104660525,0.000025846932,0.0009170631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988164,0.000047787576,0.00020310444,0.00025270498,0.00028085947,0.0003991483],"domain_scores_gemma":[0.9994846,0.0001099311,0.000036317568,0.00020793326,0.000049619655,0.00011158739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011148915,0.00014185737,0.00020987345,0.00013754077,0.000065875414,0.000020565369,0.000069167036,0.00006230756,0.00020530591],"category_scores_gemma":[0.00020033849,0.00011212675,0.000065967535,0.0002109643,0.00004154033,0.000059049453,0.000026906897,0.0001366333,0.00019830087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029736702,0.0024530275,0.93726003,0.000023392786,0.000065299355,0.0013308433,0.000055685818,0.0000067649007,0.048646916,0.00004925471,0.00042416604,0.009387271],"study_design_scores_gemma":[0.020526266,0.0006374891,0.8818869,0.000068276,0.000024177265,0.00006124721,0.0000724548,0.00021162507,0.09198676,0.00018884016,0.004176177,0.0001597767],"about_ca_topic_score_codex":0.0022296624,"about_ca_topic_score_gemma":0.00013879982,"teacher_disagreement_score":0.0553731,"about_ca_system_score_codex":0.000033379314,"about_ca_system_score_gemma":0.00007617164,"threshold_uncertainty_score":0.4572396},"labels":[],"label_agreement":null},{"id":"W4246230746","doi":"10.1182/blood.v104.11.4884.4884","title":"P53 Gene Deletion Detected by Fluorescence In Situ Hybridization Is an Adverse Prognostic Factor for Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Biology; Internal medicine; Cancer research; Oncology; Pathology; Immunology; Medicine; Chromosome; Gene; Genetics","score_opus":0.011556524683610868,"score_gpt":0.23739732105117745,"score_spread":0.22584079636756657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246230746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942933,0.000054662913,0.0028835698,0.000023073255,0.00002908181,0.002316062,0.0003079914,0.00008489,0.0000074162713],"genre_scores_gemma":[0.9902693,0.000019314572,0.008088981,0.000019757888,0.00001614471,0.00021620773,0.0013175434,0.000035765734,0.000016985268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986038,0.000042383806,0.00024367288,0.00038443485,0.00035364242,0.0003720517],"domain_scores_gemma":[0.9993487,0.000072443516,0.000075419804,0.00017630268,0.0001378432,0.00018926548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045368743,0.00019298538,0.00021650874,0.00013308466,0.00010379307,0.00001648047,0.00006983743,0.00008496071,0.0000053715767],"category_scores_gemma":[0.00004714137,0.00016196595,0.0000611952,0.00021424064,0.000023593779,0.00020528847,0.0000070393326,0.00009334569,0.000008376259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010745822,0.0029663297,0.8745719,0.00019653459,0.00010746971,0.00019364263,0.00096137746,0.000039320963,0.11353188,4.365973e-7,0.0000024717542,0.006354035],"study_design_scores_gemma":[0.02509787,0.0014656171,0.66313535,0.0001055028,0.0001564518,0.000009508122,0.00003867402,0.00024942757,0.30960238,0.0000019811457,0.000003187202,0.00013403498],"about_ca_topic_score_codex":0.00008123772,"about_ca_topic_score_gemma":0.0001328032,"teacher_disagreement_score":0.21143657,"about_ca_system_score_codex":0.00010689339,"about_ca_system_score_gemma":0.00012321357,"threshold_uncertainty_score":0.66047794},"labels":[],"label_agreement":null},{"id":"W4246587232","doi":"10.4161/cbt.4.7.1973","title":"Velcade Prolongs Survival in Relapsed Myeloma","year":2005,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dexamethasone; Multiple myeloma; Bortezomib; Clinical trial; Internal medicine; Progressive disease; Oncology; Surgery; Disease","score_opus":0.04865251567876211,"score_gpt":0.37168111725043074,"score_spread":0.3230286015716686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246587232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464113,0.0064650793,0.000006293618,0.0068357633,0.000146987,0.00056627806,0.000017757828,0.000050510665,0.0012702005],"genre_scores_gemma":[0.99365556,0.0032664393,0.0002804821,0.0011361166,0.0003780852,0.00027985254,0.00004383756,0.000020764992,0.0009388301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886745,0.00009813324,0.00018477737,0.00030936094,0.00010247444,0.00043780313],"domain_scores_gemma":[0.9994891,0.000057704587,0.000039762446,0.00023239836,0.000046289322,0.00013472188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016453472,0.00014916107,0.0002964455,0.000117946314,0.000041761294,0.0000049974346,0.00010511627,0.00016420867,0.00061064],"category_scores_gemma":[0.000027537495,0.00010736214,0.00006579585,0.00017662733,0.00013420256,0.000028891818,0.000018649043,0.00024459392,0.000100545105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019433865,0.00022662268,0.59021115,0.000006778973,0.00015437139,0.000041145366,0.00027917433,0.000002645896,0.03150111,0.000104056744,0.00028553038,0.375244],"study_design_scores_gemma":[0.012615909,0.00081166567,0.87574226,0.000037673075,0.000010322726,0.000015231653,0.00003493865,0.00011388991,0.01592234,0.00013874313,0.09440774,0.00014930953],"about_ca_topic_score_codex":0.00027699216,"about_ca_topic_score_gemma":0.0003379864,"teacher_disagreement_score":0.37509468,"about_ca_system_score_codex":0.00018869808,"about_ca_system_score_gemma":0.0001765302,"threshold_uncertainty_score":0.668608},"labels":[],"label_agreement":null},{"id":"W4246939828","doi":"10.1385/1592599168","title":"Multiple Myeloma","year":2005,"lang":"en","type":"book","venue":"Humana Press eBooks","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Southampton; Universiteit Antwerpen; Tenovus; University of Alberta; University of Arkansas for Medical Sciences; Johns Hopkins University","keywords":"Multiple myeloma; Computer science; Medicine; Internal medicine","score_opus":0.08409999340653478,"score_gpt":0.3226709856854385,"score_spread":0.23857099227890372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246939828","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016149982,0.008351292,0.000011956773,0.000028853296,0.00014569655,0.0016273331,0.00012975365,0.00027034234,0.98927325],"genre_scores_gemma":[0.0044062827,0.0004869321,0.0005298857,0.00021474513,0.0016474888,0.00022349118,0.0006251419,0.00017878306,0.99168724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972525,0.000047793084,0.000446072,0.0007032022,0.000849944,0.0007004749],"domain_scores_gemma":[0.9979226,0.00012783462,0.0001710501,0.0010877398,0.00016778441,0.0005230003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010822694,0.0005655456,0.0008023295,0.0002521562,0.00016589243,0.000065640204,0.00029185507,0.00048621558,0.00057337957],"category_scores_gemma":[0.00006622115,0.000490599,0.00038244287,0.000008729217,0.00021442308,0.000041164647,0.00022080367,0.0007857584,0.00055395253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081852806,0.00026553983,0.000056678356,0.000911404,0.0017460024,0.0023349863,0.00034228695,0.0000014871129,0.00006733417,0.006234048,0.2739178,0.7133039],"study_design_scores_gemma":[0.0039552967,0.0002730331,0.00071415777,0.00047443472,0.00032738468,0.00007829755,0.0000031709542,0.00012194595,0.0006078995,0.00022564163,0.99283004,0.00038869813],"about_ca_topic_score_codex":0.00013289595,"about_ca_topic_score_gemma":0.00016680843,"teacher_disagreement_score":0.71891224,"about_ca_system_score_codex":0.00043289224,"about_ca_system_score_gemma":0.00045261142,"threshold_uncertainty_score":0.99975455},"labels":[],"label_agreement":null},{"id":"W4247169223","doi":"10.1097/jom.0b013e31826647b5","title":"Multiple Myeloma","year":2012,"lang":"en","type":"letter","venue":"Journal of Occupational and Environmental Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Incidence (geometry); Odds ratio; Internal medicine; Confidence interval; Etiology; Epidemiology; Population; Immunology; Oncology; Environmental health; Demography","score_opus":0.045255568859152565,"score_gpt":0.3088081437570076,"score_spread":0.26355257489785505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247169223","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40238917,0.015493794,0.0001400104,0.57844543,0.0011936998,0.0008028399,0.00031376697,0.000018812505,0.0012025038],"genre_scores_gemma":[0.8030033,0.0018194118,0.00106461,0.17467119,0.014595561,0.000011934941,0.0015422228,0.0000605022,0.0032312716],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9977085,0.000057241305,0.0005685162,0.00017007448,0.0011798736,0.0003157782],"domain_scores_gemma":[0.9987881,0.00026776618,0.0004043477,0.00015991055,0.00003604143,0.00034379706],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022298521,0.0002739211,0.00062950293,0.00028778258,0.000070810995,0.0000068129766,0.000087538225,0.000293098,0.0013812179],"category_scores_gemma":[0.00014218471,0.00017236774,0.00014493041,0.000052766707,0.0003185429,0.00012373309,0.000049666414,0.0011079693,0.000043821306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012402121,0.00023709744,0.31470704,0.00020335385,0.0006063701,0.0020585828,0.00013227253,4.503438e-7,0.0012721524,0.0000016906965,0.66243035,0.01711044],"study_design_scores_gemma":[0.0040056184,0.0010412092,0.5299663,0.00031689994,0.0003539986,0.003220715,0.0000582187,0.000026749565,0.0000855092,0.000019865174,0.46078357,0.000121345045],"about_ca_topic_score_codex":0.000014925642,"about_ca_topic_score_gemma":5.364211e-7,"teacher_disagreement_score":0.40377423,"about_ca_system_score_codex":0.00019952434,"about_ca_system_score_gemma":0.0000657992,"threshold_uncertainty_score":0.9995316},"labels":[],"label_agreement":null},{"id":"W4247424005","doi":"10.22541/au.159231486.62956838","title":"Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada); SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Thalidomide; Repurposing; Lenalidomide; Drug repositioning; Medicine; Pneumonia; Immunology; Angiogenesis; Immune system; Inflammation; Pharmacology; Cancer research; Biology; Multiple myeloma; Drug; Internal medicine","score_opus":0.19112690121913922,"score_gpt":0.4308300542973206,"score_spread":0.23970315307818135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247424005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902895,0.0023095452,0.002189622,0.0010386473,0.00008998892,0.0033160443,0.000074055955,0.000029000159,0.0006635993],"genre_scores_gemma":[0.9952021,0.0029997176,0.0011360238,0.00006211501,0.00004405106,0.00039013245,0.00006459804,0.000022627295,0.00007858669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989837,0.000063101455,0.00027677728,0.00031975508,0.00021801393,0.00013868698],"domain_scores_gemma":[0.99893546,0.0003568761,0.00018797327,0.00030476562,0.00016154458,0.000053364573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007393788,0.00020458226,0.00044887493,0.0001138102,0.000057615667,0.000012455433,0.00004946404,0.000108405366,0.0000096629155],"category_scores_gemma":[0.0002978448,0.00011976735,0.00020254214,0.000075910764,0.00006651798,0.000024651305,0.0000620877,0.000113660266,0.0000016175989],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005477437,0.00429925,0.0048583956,0.0029413255,0.0073609035,0.00006126204,0.002213684,0.00014050807,0.83296436,0.0016499548,0.00014518572,0.13788773],"study_design_scores_gemma":[0.003067977,0.0027256047,0.0051138084,0.00024131875,0.0005299841,0.000009084126,0.00011702255,0.0026337686,0.98443973,0.0005571174,0.0004844609,0.00008013252],"about_ca_topic_score_codex":0.00033052766,"about_ca_topic_score_gemma":0.00002383705,"teacher_disagreement_score":0.15147537,"about_ca_system_score_codex":0.00012062727,"about_ca_system_score_gemma":0.00010366972,"threshold_uncertainty_score":0.4883971},"labels":[],"label_agreement":null},{"id":"W4247934501","doi":"10.1182/blood.v110.11.1183.1183","title":"Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Pharmacology; Oncology; Cancer research; Immunology","score_opus":0.029475049843357706,"score_gpt":0.3257205409892322,"score_spread":0.2962454911458745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247934501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997566,0.0002363843,0.000017277942,0.000113092145,0.000025150865,0.0014399949,0.0000807571,0.000020605037,0.00050077116],"genre_scores_gemma":[0.99760854,0.00020278625,0.001530616,0.000015018989,0.000033562508,0.000049204005,0.00042350258,0.000027209355,0.00010954162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776167,0.00018189885,0.0007279025,0.0003757367,0.00055617717,0.00039659417],"domain_scores_gemma":[0.99837863,0.0005402686,0.00025069088,0.00057171664,0.00013031156,0.00012837071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006584591,0.0002332666,0.00050308526,0.00041974138,0.000037434605,0.000008787854,0.000161499,0.00012226804,0.000014787678],"category_scores_gemma":[0.00020991809,0.00013499426,0.00007857027,0.0004733877,0.00013306769,0.00013935704,0.000019753423,0.00016695373,0.00000253529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05584644,0.045015506,0.84052265,0.00014590904,0.00029267158,0.0029775898,0.0058648693,0.000011764112,0.032881424,0.000025210644,0.000017609977,0.016398365],"study_design_scores_gemma":[0.056425635,0.029827096,0.8539813,0.0002752647,0.00010640543,0.00010432609,0.0009784289,0.00040552343,0.05766362,0.000009791892,0.00010905412,0.00011356069],"about_ca_topic_score_codex":0.0017414829,"about_ca_topic_score_gemma":0.0028330765,"teacher_disagreement_score":0.024782196,"about_ca_system_score_codex":0.0001518773,"about_ca_system_score_gemma":0.0001872412,"threshold_uncertainty_score":0.5504906},"labels":[],"label_agreement":null},{"id":"W4249236223","doi":"10.1182/blood.v106.11.360.360","title":"Analysis of Clonotypic Switch Junctions Reveals Multiple Myeloma Originates from a Single Class Switch Event with Ongoing Mutation in the Isotype Switched Progeny.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Isotype; Immunoglobulin class switching; Immunoglobulin D; Immunology; Antibody; Biology; Bone marrow; Immunoglobulin gene; Multiple myeloma; B cell; Monoclonal antibody","score_opus":0.021040794752231962,"score_gpt":0.2858491353832564,"score_spread":0.26480834063102443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249236223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694073,0.0004756918,0.00035529898,0.0007909188,0.000020827216,0.00097538176,0.000039200302,0.00004336228,0.00035857104],"genre_scores_gemma":[0.99557555,0.000023544284,0.003547729,0.00009073028,0.00009192255,0.00018659257,0.00031495554,0.00002525026,0.00014370518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980876,0.00012784412,0.00045054333,0.00039264586,0.00056723144,0.00037416967],"domain_scores_gemma":[0.99863243,0.00034859363,0.00018510046,0.000507862,0.00020236938,0.00012364148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030986778,0.00021465785,0.0004909525,0.00045056493,0.000098420176,0.00003231633,0.0001475478,0.000095976844,0.00008207932],"category_scores_gemma":[0.00024370856,0.00013726002,0.00016868216,0.0015922163,0.000053836666,0.00012721494,0.000027357986,0.00022214293,0.00003072328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007043189,0.0042035063,0.9520971,0.00004716519,0.003084988,0.00012938808,0.0016066243,0.00032981395,0.026952893,0.000025033138,0.000023879227,0.010795248],"study_design_scores_gemma":[0.008588606,0.0007937466,0.95174533,0.0001326646,0.0030074336,0.00002951065,0.00066844415,0.007921306,0.026556782,0.000048709295,0.0003375478,0.00016990051],"about_ca_topic_score_codex":0.0010289631,"about_ca_topic_score_gemma":0.0058596386,"teacher_disagreement_score":0.0106253475,"about_ca_system_score_codex":0.00013219289,"about_ca_system_score_gemma":0.00014739376,"threshold_uncertainty_score":0.5597301},"labels":[],"label_agreement":null},{"id":"W4249539749","doi":"10.1182/blood.v114.22.1874.1874","title":"Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Regimen; Thalidomide; Internal medicine; Prednisone; Multiple myeloma; Cyclophosphamide; Gastroenterology; Bortezomib; Surgery; Dexamethasone; Chemotherapy","score_opus":0.023131485574558845,"score_gpt":0.29655952899943766,"score_spread":0.2734280434248788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249539749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436855,0.0019798852,0.000016108064,0.000146105,0.000029910647,0.0032226641,0.00016669853,0.000016229273,0.00005387072],"genre_scores_gemma":[0.9967862,0.0011485487,0.001578881,0.000019790514,0.00004487511,0.00012599361,0.00009675427,0.000018482358,0.0001805031],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99879956,0.000040759187,0.0003346218,0.00026942085,0.0002973431,0.0002582973],"domain_scores_gemma":[0.9988639,0.00032397642,0.0001791584,0.0003204385,0.00014682896,0.00016572124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114943665,0.00020175429,0.00049268216,0.00007308417,0.00012128387,0.00000760464,0.000052214924,0.0000704384,0.000008739578],"category_scores_gemma":[0.0001702728,0.000110262365,0.00008918615,0.00009814765,0.00015013063,0.00006494861,0.0000133813555,0.000056177545,3.136492e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47500697,0.08437022,0.15003377,0.00019856394,0.0021356328,0.00004331358,0.0012050751,0.000001975375,0.0045203664,0.000023879811,0.00011240962,0.28234783],"study_design_scores_gemma":[0.65663064,0.10001162,0.22124,0.00008265265,0.00086710294,0.000005119871,0.000046548805,0.00009856763,0.019791445,0.000025270312,0.001090512,0.00011052138],"about_ca_topic_score_codex":0.00009709848,"about_ca_topic_score_gemma":0.000026424583,"teacher_disagreement_score":0.2822373,"about_ca_system_score_codex":0.000028761167,"about_ca_system_score_gemma":0.00007418667,"threshold_uncertainty_score":0.44963688},"labels":[],"label_agreement":null},{"id":"W4249570029","doi":"10.35493/medu.36.6","title":"Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"The Meducator","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.023312465298688544,"score_gpt":0.3092068058461208,"score_spread":0.2858943405474323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249570029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98193234,0.0002750331,0.000003287152,0.003632378,0.00028714485,0.000650609,0.000005165251,0.000046707755,0.013167343],"genre_scores_gemma":[0.98041904,0.000016088048,0.00031335838,0.0004669733,0.00017477975,0.000049216997,0.000017144319,0.000018390641,0.018525006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914706,0.000038182065,0.00009844956,0.00016231772,0.0002679467,0.00028606277],"domain_scores_gemma":[0.9990726,0.00016050643,0.00002337112,0.0005120186,0.00004142655,0.00019009189],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013912749,0.00009539022,0.00015080678,0.00004677667,0.00006159401,0.000013682583,0.00012455472,0.000031854426,0.0017737541],"category_scores_gemma":[0.00016036909,0.000050818526,0.00007783627,0.00012367415,0.000051745013,0.000032655847,0.000043724394,0.00013878872,0.006656629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056529033,0.00049112254,0.9339732,0.00008216472,0.00025862953,0.00004390978,0.00097055314,6.372654e-7,0.023991795,0.00041569164,0.009660326,0.029546674],"study_design_scores_gemma":[0.003157352,0.0002799827,0.90960187,0.00004539768,0.00004714115,0.00010148256,0.0006401301,0.0002544141,0.018306736,0.00009569977,0.067356296,0.000113516486],"about_ca_topic_score_codex":0.00008352364,"about_ca_topic_score_gemma":0.000007783736,"teacher_disagreement_score":0.057695966,"about_ca_system_score_codex":0.00006003608,"about_ca_system_score_gemma":0.00015951814,"threshold_uncertainty_score":0.9991388},"labels":[],"label_agreement":null},{"id":"W4250653753","doi":"10.1182/blood.v116.21.1937.1937","title":"Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Bortezomib; Dexamethasone; Regimen; Multiple myeloma; Internal medicine; Melphalan; Phases of clinical research; Urology; Gastroenterology; Surgery; Pharmacology; Chemotherapy","score_opus":0.03389884462609319,"score_gpt":0.32003217873439055,"score_spread":0.28613333410829733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250653753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650824,0.00032822453,0.0000061765104,0.00037770483,0.00017184563,0.0018374741,0.0002238087,0.000060707265,0.00048579552],"genre_scores_gemma":[0.9954135,0.000112682785,0.0033971977,0.000043291064,0.00032006504,0.000115798364,0.0002209114,0.000042263688,0.00033432475],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971887,0.0001407179,0.0008418122,0.0006102053,0.00057410327,0.00064444455],"domain_scores_gemma":[0.99771816,0.0007768003,0.00023369852,0.00059491926,0.0001872586,0.0004891889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006164332,0.0003358576,0.00079265516,0.0003894223,0.0001193052,0.0000280281,0.00016463314,0.0002810416,0.00010172587],"category_scores_gemma":[0.0035444496,0.0002791268,0.00015663431,0.0004421234,0.00023334428,0.00014713721,0.0001348242,0.0006470368,0.0000147189985],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35037988,0.031001873,0.08103216,0.00017183041,0.0007299582,0.0033762483,0.0010961768,0.0000018577708,0.45719245,0.000028142718,0.00043882476,0.0745506],"study_design_scores_gemma":[0.7246669,0.007547994,0.10070963,0.00014408138,0.000261677,0.0001502214,0.00007225135,0.00051878026,0.16501337,0.000026544461,0.00065244944,0.00023609166],"about_ca_topic_score_codex":0.0016232113,"about_ca_topic_score_gemma":0.0016315021,"teacher_disagreement_score":0.37428704,"about_ca_system_score_codex":0.000027898152,"about_ca_system_score_gemma":0.0002924726,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W4251531700","doi":"10.4161/cbt.6.12.5509","title":"Drug combination effective against multiple myeloma: NEJM study shows lenalidomide-dexamethasone slows disease","year":2007,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Dexamethasone; Interim analysis; Internal medicine; Placebo; Oncology; Cancer; Clinical trial; Alternative medicine; Pathology","score_opus":0.03038858199074687,"score_gpt":0.3595932897851773,"score_spread":0.32920470779443045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251531700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884793,0.0055268505,0.00025784716,0.000620873,0.00040985472,0.0042163422,0.000076739445,0.00013422706,0.0002779665],"genre_scores_gemma":[0.9959787,0.00096836465,0.00012912945,0.0008994637,0.00033019105,0.00093605596,0.00019962486,0.000050012302,0.00050844986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766785,0.00039571722,0.00034462838,0.0006459287,0.00027620778,0.00066967035],"domain_scores_gemma":[0.9979689,0.000662416,0.0001282675,0.000495721,0.0002471149,0.0004975784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081414235,0.00034130522,0.0005462722,0.00024219441,0.00021275728,0.000018980629,0.0001753112,0.000120691715,0.00018185929],"category_scores_gemma":[0.00020912584,0.00025176015,0.00017804785,0.00031646847,0.00024130131,0.000087469496,0.000053097054,0.00033034183,0.000053429383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008187329,0.0017817556,0.71791774,0.000017446366,0.00070759637,0.0001767011,0.0007176486,0.000003742025,0.02394193,0.000021049289,0.00020439141,0.24632269],"study_design_scores_gemma":[0.029748987,0.0015037647,0.9512169,0.000049018705,0.000086057786,0.000003321164,0.000461175,0.00020675678,0.013256758,0.00012055004,0.0030920228,0.00025472758],"about_ca_topic_score_codex":0.00054582715,"about_ca_topic_score_gemma":0.0005151736,"teacher_disagreement_score":0.24606797,"about_ca_system_score_codex":0.00042088976,"about_ca_system_score_gemma":0.00018032306,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W4252188521","doi":"10.1182/blood.v126.23.1845.1845","title":"Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"","keywords":"Dexamethasone; Bortezomib; Lenalidomide; Medicine; Regimen; Multiple myeloma; Cyclophosphamide; Internal medicine; Gastroenterology; Oncology; Chemotherapy; Surgery","score_opus":0.04759866484761019,"score_gpt":0.3205993776655472,"score_spread":0.27300071281793703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252188521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874771,0.007314674,0.0012674563,0.00055769866,0.000065391105,0.0028734263,0.00023933803,0.000037663005,0.00016723991],"genre_scores_gemma":[0.980319,0.0020408619,0.016597629,0.00008616106,0.00009796933,0.00047777928,0.00007237705,0.000042827727,0.00026538476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981853,0.000057575257,0.00038805295,0.00046614776,0.00038122004,0.00052172143],"domain_scores_gemma":[0.9974986,0.0010307768,0.000096406875,0.00047397966,0.00019980677,0.0007004684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003389395,0.00031910214,0.00072076713,0.00013933185,0.00013232228,0.000036552494,0.00011054639,0.000095146155,0.000009936813],"category_scores_gemma":[0.00025350053,0.00020168305,0.0001187793,0.00020870283,0.00016313855,0.000063515705,0.000041416377,0.000083825405,0.000008046454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012418394,0.0049009137,0.8732375,0.00033599386,0.0028371885,0.00026539396,0.0038223872,0.000039904,0.033905905,0.000037968246,0.000572469,0.06762602],"study_design_scores_gemma":[0.109480366,0.008463508,0.61589384,0.00030864167,0.0020743092,0.00030075843,0.00093720964,0.004172158,0.2502522,0.00011156444,0.007525189,0.00048028017],"about_ca_topic_score_codex":0.0015906711,"about_ca_topic_score_gemma":0.0004349561,"teacher_disagreement_score":0.25734365,"about_ca_system_score_codex":0.00006307881,"about_ca_system_score_gemma":0.00015782261,"threshold_uncertainty_score":0.8224397},"labels":[],"label_agreement":null},{"id":"W4252341638","doi":"10.1182/blood-2019-123483","title":"Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Internal medicine; Dexamethasone; Multiple myeloma; Oncology; Surgery; Gastroenterology","score_opus":0.05240809702567301,"score_gpt":0.3185706646804925,"score_spread":0.2661625676548195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252341638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461114,0.0014469125,0.000005105305,0.00016849142,0.00023091669,0.0030507054,0.00010318909,0.00003292764,0.0003505997],"genre_scores_gemma":[0.9975173,0.00022835603,0.0011462927,0.00003005297,0.00006635707,0.00008946538,0.000021120819,0.00007370367,0.0008273414],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962082,0.00055353093,0.00086093077,0.0007596103,0.0009640249,0.0006537234],"domain_scores_gemma":[0.99621,0.0016932734,0.0004192838,0.0011163936,0.00020728656,0.000353782],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008965972,0.00045416062,0.001337815,0.00039696856,0.000121458565,0.000027589129,0.00028938503,0.00022664378,0.00013429842],"category_scores_gemma":[0.0023721883,0.00030743645,0.00017367322,0.00067395193,0.0003038381,0.00016136434,0.00032747717,0.0005729333,0.000013284951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1559577,0.013412484,0.6605051,0.00076579984,0.0033043881,0.00085219456,0.0051568816,0.000013087554,0.14663677,0.00001899046,0.00016604153,0.013210578],"study_design_scores_gemma":[0.63302904,0.011936267,0.29245844,0.0006326541,0.0011311892,0.00013384997,0.005166612,0.00046898067,0.054393474,0.000020963966,0.00019328058,0.00043523608],"about_ca_topic_score_codex":0.0019510086,"about_ca_topic_score_gemma":0.0026820179,"teacher_disagreement_score":0.47707134,"about_ca_system_score_codex":0.0001381416,"about_ca_system_score_gemma":0.00038152045,"threshold_uncertainty_score":0.9999378},"labels":[],"label_agreement":null},{"id":"W4253375275","doi":"10.22374/cjgim.v9i3.17","title":"Scrotal and Orbital Involvement in Extramedullary De-differentiated Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of General Internal Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Paracentesis; Erythema; Bortezomib; Plasmacytoma; Cyclophosphamide; Internal medicine; Surgery; Gastroenterology; Ascites; Chemotherapy","score_opus":0.02455333387066062,"score_gpt":0.2835927377976791,"score_spread":0.25903940392701846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253375275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426216,0.0015237497,0.00031487338,0.0024324057,0.0003197769,0.00017890317,0.000006055736,0.0000046645796,0.00095743773],"genre_scores_gemma":[0.9969773,0.000059154998,0.000877552,0.0007127864,0.0007373112,0.0000045752486,0.000015702215,0.000021863816,0.0005936995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984007,0.00009153232,0.0005360317,0.00016560708,0.00031850554,0.0004876644],"domain_scores_gemma":[0.997996,0.00008617622,0.00014655599,0.00013696599,0.00018941263,0.0014449317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005082121,0.00018235289,0.00046015927,0.00070286455,0.000052669984,0.000026980213,0.00014083138,0.000084094274,0.00032743262],"category_scores_gemma":[0.0008111258,0.00013179512,0.00007218781,0.0001509838,0.00023838352,0.00009633508,0.000021221269,0.00043532526,0.0000064111455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005497759,0.000077036755,0.9519417,0.0000747616,0.00019669792,0.004668131,0.0005470794,0.0000077641635,0.014196383,0.00010711344,0.003213372,0.024420138],"study_design_scores_gemma":[0.010707536,0.0024039145,0.9698264,0.0012045479,0.0000811534,0.0038398611,0.00026316667,0.0058945613,0.0024074826,0.0003214241,0.0028963373,0.0001536397],"about_ca_topic_score_codex":0.03720415,"about_ca_topic_score_gemma":0.042225376,"teacher_disagreement_score":0.0242665,"about_ca_system_score_codex":0.00035308884,"about_ca_system_score_gemma":0.00048175338,"threshold_uncertainty_score":0.9752515},"labels":[],"label_agreement":null},{"id":"W4253587619","doi":"10.1182/blood.v114.22.3851.3851","title":"A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Proteasome inhibitor; Multiple myeloma; Internal medicine; Pharmacology; Refractory (planetary science); Lenalidomide; Oncology; Biology","score_opus":0.0980473417023826,"score_gpt":0.3940497644056899,"score_spread":0.2960024227033073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253587619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971488,0.00032240094,0.0000045165543,0.00031262432,0.000047418795,0.00097210787,0.000007290561,0.000022961785,0.0011618697],"genre_scores_gemma":[0.99907917,0.000051324183,0.0005804757,0.00007475232,0.00011076269,0.000022566292,0.000021010095,0.0000076058213,0.00005231861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869204,0.00016197824,0.00046232803,0.00021485462,0.00026090821,0.00020789405],"domain_scores_gemma":[0.99851567,0.00090016186,0.00013267795,0.0002434807,0.00008480683,0.00012321059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006953325,0.00010504256,0.00029770637,0.00009463276,0.000054993558,0.000010835313,0.00006777535,0.00009012511,0.000009801663],"category_scores_gemma":[0.0034727415,0.00006999552,0.00006491074,0.0002008475,0.000093565584,0.00004452783,0.000023516632,0.00028138465,0.0000049770283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029421804,0.037396837,0.5073126,0.00004821188,0.00018011441,0.0003018124,0.00029508193,5.182943e-7,0.01114439,0.00009298013,0.00011037157,0.41369528],"study_design_scores_gemma":[0.37879324,0.009216456,0.60925275,0.000080948565,0.00009696203,0.00002506696,0.0000438851,0.00094475405,0.0012072925,0.000109209046,0.00016712061,0.000062317726],"about_ca_topic_score_codex":0.000056405708,"about_ca_topic_score_gemma":0.000016843333,"teacher_disagreement_score":0.41363296,"about_ca_system_score_codex":0.000017606037,"about_ca_system_score_gemma":0.00010817252,"threshold_uncertainty_score":0.41574466},"labels":[],"label_agreement":null},{"id":"W4253607854","doi":"10.1182/blood.v116.21.3055.3055","title":"Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Regimen; Thalidomide; Gastroenterology; Cyclophosphamide; Prednisone; Multiple myeloma; Dexamethasone; Bortezomib; Surgery; Chemotherapy","score_opus":0.02025790824414703,"score_gpt":0.29203620686852483,"score_spread":0.2717782986243778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253607854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995658,0.000682666,0.000009145874,0.00008760235,0.000072992974,0.003204707,0.00022675094,0.000015014196,0.000043160697],"genre_scores_gemma":[0.9967702,0.00050556834,0.0021013436,0.000009170239,0.00006137231,0.00024629376,0.00009287829,0.00002669273,0.00018648038],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99884284,0.000033153992,0.00031766258,0.00026926183,0.00028734977,0.0002497222],"domain_scores_gemma":[0.9986442,0.00045204788,0.00018285468,0.00037023734,0.0001704767,0.00018019971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001351644,0.00019646338,0.0004579285,0.00006999521,0.00012984857,0.000008161756,0.00005843705,0.00008864251,0.000017736558],"category_scores_gemma":[0.00025933745,0.000106137515,0.00008583133,0.00008326733,0.0002483961,0.0000631581,0.000023726523,0.00009291355,4.2213287e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36478195,0.06619918,0.39223465,0.00027980856,0.0024367608,0.000032491327,0.001114137,5.4107403e-7,0.018335931,0.000026423848,0.00007857947,0.15447956],"study_design_scores_gemma":[0.69013,0.057268623,0.20754941,0.000053636362,0.0008837602,0.000007216835,0.00004726085,0.00010563769,0.041669473,0.000015957869,0.0021517144,0.00011730159],"about_ca_topic_score_codex":0.00019366089,"about_ca_topic_score_gemma":0.00014010668,"teacher_disagreement_score":0.32534808,"about_ca_system_score_codex":0.000015497682,"about_ca_system_score_gemma":0.00008742043,"threshold_uncertainty_score":0.43281624},"labels":[],"label_agreement":null},{"id":"W4253648635","doi":"10.1182/blood.v104.11.641.641","title":"CHIR258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Treatment of t(4;14) Multiple Myeloma.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Fibroblast growth factor receptor 3; Tyrosine kinase; Cancer research; Biology; Tyrosine-kinase inhibitor; Receptor tyrosine kinase; Chromosomal translocation; Fibroblast growth factor receptor; Multiple myeloma; Fibroblast growth factor; Cell culture; Molecular biology; Receptor; Kinase; Signal transduction; Cell biology; Immunology; Cancer; Biochemistry; Genetics","score_opus":0.04047147652059239,"score_gpt":0.3035838897335806,"score_spread":0.26311241321298817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253648635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965263,0.004313178,0.0015968253,0.00068927475,0.00014468329,0.0030512174,0.0003999151,0.00007859801,0.000073682684],"genre_scores_gemma":[0.9791322,0.00033454507,0.018890016,0.000056308774,0.00024162621,0.00054918503,0.00018283006,0.0000475917,0.00056572753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847794,0.000016164422,0.00034506485,0.00035132008,0.00033193175,0.00047760233],"domain_scores_gemma":[0.99868125,0.00023403703,0.00010227411,0.0005385451,0.00020150229,0.00024238358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009707617,0.00027202713,0.00041753938,0.00011467385,0.0001705783,0.0000164455,0.00011380021,0.00009931123,0.000026330492],"category_scores_gemma":[0.00028654587,0.00016171033,0.00029932827,0.00022732027,0.0001302867,0.000050948376,0.00002671807,0.00008238737,0.000023992143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005266793,0.08822895,0.12224101,0.00042614347,0.004230313,0.00033244182,0.0024432053,0.000152816,0.7238896,0.00024961843,0.00017293937,0.052366186],"study_design_scores_gemma":[0.11613083,0.0045528295,0.17594443,0.00012584962,0.0006979649,0.0000565852,0.00012205142,0.00072366185,0.69633573,0.000019715062,0.0050915848,0.00019876462],"about_ca_topic_score_codex":0.00045820937,"about_ca_topic_score_gemma":0.00024945577,"teacher_disagreement_score":0.110864036,"about_ca_system_score_codex":0.00012615444,"about_ca_system_score_gemma":0.00019127282,"threshold_uncertainty_score":0.6594356},"labels":[],"label_agreement":null},{"id":"W4255006273","doi":"10.1182/blood.v122.21.5315.5315","title":"Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Melphalan; Bortezomib; Multiple myeloma; Thalidomide; Internal medicine; Autologous stem-cell transplantation; Oncology; Chemotherapy; Surgery; Chemotherapy regimen; Cancer","score_opus":0.02963862632873042,"score_gpt":0.3127204609648486,"score_spread":0.2830818346361182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255006273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980167,0.00028226763,9.22669e-7,0.00024751615,0.0000498825,0.00067272456,0.000022215718,0.000017598151,0.00069014117],"genre_scores_gemma":[0.99823606,0.000055970522,0.00015952658,0.00007976354,0.000046105066,0.0001625607,0.00001000033,0.00001600339,0.0012340036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988049,0.0000436436,0.00024152297,0.0002110127,0.0003646472,0.00033426133],"domain_scores_gemma":[0.9992989,0.0000984954,0.000060562346,0.00033876408,0.00007322009,0.00013011195],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006830566,0.000118535856,0.00022693822,0.000067424386,0.00003321983,0.000016351105,0.00016433412,0.00005443753,0.0021692805],"category_scores_gemma":[0.0001704499,0.000075458265,0.000062470805,0.00019580997,0.00011336048,0.000087758286,0.00009126312,0.0001348032,0.0001125618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049830225,0.0004926047,0.9921436,0.000040835817,0.00006328491,0.000059107086,0.0008243996,0.0000015569575,0.0014498322,0.000009875477,0.000249425,0.00461567],"study_design_scores_gemma":[0.004838915,0.000057743273,0.98788714,0.00007183616,0.000022141368,0.000005345318,0.0003100673,0.000119577635,0.0052649495,0.000006734688,0.0013442663,0.00007128765],"about_ca_topic_score_codex":0.0032309708,"about_ca_topic_score_gemma":0.001421743,"teacher_disagreement_score":0.0047890847,"about_ca_system_score_codex":0.000041829935,"about_ca_system_score_gemma":0.000055434124,"threshold_uncertainty_score":0.9987429},"labels":[],"label_agreement":null},{"id":"W4256185211","doi":"10.1182/blood.v112.11.3328.3328","title":"Outcome of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Melphalan; Immunoglobulin D; Medicine; Hematopoietic stem cell transplantation; Multiple myeloma; Internal medicine; Transplantation; Gastroenterology; Median follow-up; Regimen; Surgery; Chemotherapy; Oncology; Immunology; Antibody; B cell","score_opus":0.019329556537412567,"score_gpt":0.24809924023309732,"score_spread":0.22876968369568476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256185211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978002,0.00018711241,0.000032212607,0.000018753592,0.000021290047,0.0013246351,0.000078271194,0.00005954325,0.00047799034],"genre_scores_gemma":[0.9990718,0.00003935563,0.0005232586,0.000013103085,0.000013988611,0.000046759676,0.000024598947,0.000034075558,0.0002330801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982692,0.000068794136,0.00034239166,0.0004011489,0.00055363175,0.00036480968],"domain_scores_gemma":[0.99903506,0.00015854393,0.00011295398,0.00033753936,0.00013330605,0.00022260948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007839954,0.00023421178,0.00056699006,0.00013710881,0.00014157775,0.0000081543185,0.00008093401,0.00007252944,0.000020768548],"category_scores_gemma":[0.000036028883,0.0001674701,0.00006538549,0.00019253985,0.00013457901,0.00007413773,0.000037844795,0.00017896325,0.000009937601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007505248,0.006190298,0.9889666,0.0002802475,0.00041443674,0.000858974,0.0022086592,6.899607e-7,0.0001491033,0.00000408372,0.000005406149,0.00017102173],"study_design_scores_gemma":[0.031917177,0.0041156,0.959414,0.00009828463,0.00030159607,0.00013052303,0.00058259163,0.00002039191,0.0032662381,0.000004865806,0.0000025698087,0.0001461634],"about_ca_topic_score_codex":0.00010140468,"about_ca_topic_score_gemma":0.00014893635,"teacher_disagreement_score":0.031166654,"about_ca_system_score_codex":0.000050713832,"about_ca_system_score_gemma":0.00008415642,"threshold_uncertainty_score":0.68292326},"labels":[],"label_agreement":null},{"id":"W4280629311","doi":"10.3390/ijms23105688","title":"The Role of DNA Repair in Genomic Instability of Multiple Myeloma","year":2022,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Genome instability; DNA repair; DNA damage; Cancer research; genomic DNA; Biology; DNA; Multiple myeloma; Genetics; Immunology","score_opus":0.04865831095478523,"score_gpt":0.37200122739383756,"score_spread":0.32334291643905233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280629311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07025148,0.9285406,0.000006085458,0.00007161015,0.00022210547,0.0003138753,0.000046473942,0.0000026259556,0.0005451601],"genre_scores_gemma":[0.13365705,0.8656204,0.0006312624,0.000009740833,0.0000383625,0.00001273143,0.0000066460802,0.000009005575,0.000014817786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682236,0.0002947603,0.0010176694,0.0001817945,0.001514753,0.0001686543],"domain_scores_gemma":[0.997895,0.00060136267,0.00094105967,0.00020188907,0.00028084923,0.00007983551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017293493,0.000137322,0.0006894387,0.00048447022,0.00005223551,0.0000148480785,0.00092058204,0.000050628816,0.00007298671],"category_scores_gemma":[0.00116919,0.000080766724,0.0006649429,0.00035301666,0.00038889144,0.00007015322,0.00022621507,0.00031816322,0.0000013702586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016211635,0.0003278172,0.006567223,0.00036373147,0.0006048271,0.00034803318,0.00009443317,0.000018006396,0.000460858,0.00019470401,0.000008440946,0.9908498],"study_design_scores_gemma":[0.0019739221,0.001279942,0.008944025,0.004134747,0.00028841326,0.00096967,0.00057519024,0.00035649788,0.001524287,0.00072505634,0.979039,0.00018920907],"about_ca_topic_score_codex":0.00010095387,"about_ca_topic_score_gemma":0.00002858226,"teacher_disagreement_score":0.9906606,"about_ca_system_score_codex":0.00028848913,"about_ca_system_score_gemma":0.0013974025,"threshold_uncertainty_score":0.32935715},"labels":[],"label_agreement":null},{"id":"W4281251623","doi":"10.1016/j.jval.2022.04.003","title":"Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids","year":2022,"lang":"en","type":"review","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Multiple myeloma; Decision aids; Medicine; Intensive care medicine; Management science; Alternative medicine; Internal medicine; Engineering; Pathology","score_opus":0.12025877929423238,"score_gpt":0.41947872882124226,"score_spread":0.29921994952700987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281251623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021014797,0.9698287,0.000025428952,0.000008240443,0.00017450325,0.0084692985,0.00044913817,0.000012210509,0.00001764703],"genre_scores_gemma":[0.01588538,0.979368,0.0037358627,0.00002078436,0.000013524328,0.00064479123,0.0002684487,0.000053286058,0.000009963236],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99184835,0.001437313,0.003735792,0.000946315,0.0014935132,0.00053874694],"domain_scores_gemma":[0.98960465,0.0071637086,0.0015340226,0.0012208782,0.0001476796,0.00032904022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014325267,0.0006344355,0.00490667,0.0013748817,0.000080080084,0.000018339499,0.00026011874,0.0002571894,0.000032897013],"category_scores_gemma":[0.0062702578,0.00039454957,0.0005203004,0.0017982273,0.000068702575,0.00009154075,0.00025446402,0.00047786717,0.0000022926436],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047651058,0.0004224071,0.0006262757,0.4190887,0.000047287762,0.0002478169,0.002850323,0.0000082366605,1.3495831e-7,0.000002841659,0.000017518523,0.5762119],"study_design_scores_gemma":[0.0033098874,0.0030287325,0.0008534158,0.9689981,0.000146965,0.00016811499,0.00041628207,0.00017411259,0.000002210747,0.000013647008,0.022677146,0.00021138857],"about_ca_topic_score_codex":0.0012171522,"about_ca_topic_score_gemma":0.00009753236,"teacher_disagreement_score":0.5760006,"about_ca_system_score_codex":0.0021519891,"about_ca_system_score_gemma":0.00092770223,"threshold_uncertainty_score":0.99985063},"labels":[],"label_agreement":null},{"id":"W4281628749","doi":"10.1056/nejmoa2204925","title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Knight Cancer Institute, Oregon Health and Science University; Houston Methodist Research Institute; Massachusetts General Hospital; Houston Methodist Hospital; Takeda Oncology; Winship Cancer Institute; State University of New York Upstate Medical University; Moffitt Cancer Center; Ohio State University; Barbara Ann Karmanos Cancer Institute; Comprehensive Cancer Center, City of Hope; Medical Center, University of Pittsburgh; Syracuse University; University of Pittsburgh; Memorial Sloan-Kettering Cancer Center; University of Washington; Roswell Park Cancer Institute; University of Pennsylvania; Celgene; U.S. Department of Veterans Affairs; Wayne State University; Takeda Pharmaceuticals North America; Emory University; Bristol-Myers Squibb; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Lenalidomide; Transplantation; Melphalan; Hazard ratio; Autologous stem-cell transplantation; Surgery; Internal medicine; Bortezomib; Dexamethasone; Hematopoietic stem cell transplantation; Clinical endpoint; Randomized controlled trial; Confidence interval","score_opus":0.02580289369441924,"score_gpt":0.32334621539751024,"score_spread":0.297543321703091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281628749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795615,0.0054771816,0.00010024525,0.013796721,0.0001713255,0.00028112024,0.0000045729403,0.0000064513315,0.00060086674],"genre_scores_gemma":[0.9940548,0.004212196,0.00041764873,0.0003481645,0.0005062225,0.0000073437986,0.000014644184,0.0000110026,0.00042798076],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99856836,0.00014583365,0.00036828002,0.00011286898,0.00061357935,0.00019106142],"domain_scores_gemma":[0.99929756,0.00013530966,0.00014747574,0.00008528371,0.000079140715,0.00025522194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008760025,0.00010164849,0.00033326625,0.00028874195,0.00006902849,0.000004826917,0.000071862676,0.000022432476,0.0004210029],"category_scores_gemma":[0.00013972828,0.00005997307,0.00003440355,0.00022758117,0.00006689609,0.00005867445,0.000013999568,0.00038067705,6.6409683e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01382034,0.00023664044,0.18769214,0.000059013077,0.00009437541,0.004817662,0.0026061842,0.000010643187,0.0044292468,0.000055429467,0.003247712,0.7829306],"study_design_scores_gemma":[0.3072765,0.009817421,0.5894858,0.0007267945,0.00008484125,0.012661655,0.00072225626,0.0001827075,0.0007984733,0.00062393607,0.07750122,0.00011839073],"about_ca_topic_score_codex":0.00008401515,"about_ca_topic_score_gemma":0.000026353015,"teacher_disagreement_score":0.78281224,"about_ca_system_score_codex":0.00006701552,"about_ca_system_score_gemma":0.0001743892,"threshold_uncertainty_score":0.46096864},"labels":[],"label_agreement":null},{"id":"W4281649126","doi":"10.1200/jco.2022.40.16_suppl.e20006","title":"Preliminary efficacy of optimal pharmacotherapy and patient views in multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Internal medicine; Hazard ratio; Population; Oncology; Randomized controlled trial; Clinical endpoint; Progression-free survival; Randomization; Clinical trial; Transplantation; Intensive care medicine; Confidence interval; Chemotherapy; Environmental health","score_opus":0.1814915426467222,"score_gpt":0.4981602613134877,"score_spread":0.3166687186667655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281649126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480844,0.0022670636,0.000008299477,0.0017714337,0.00033676584,0.00042108953,0.00001108414,0.0000030199037,0.0003728077],"genre_scores_gemma":[0.99505013,0.0010726439,0.0028910015,0.00076314213,0.00011147573,0.000023850804,0.000004023803,0.000012965082,0.00007076993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964357,0.0009730592,0.0017302209,0.0001592432,0.00049116724,0.00021059444],"domain_scores_gemma":[0.9956934,0.002803952,0.0009809257,0.00012744681,0.000096354524,0.00029795073],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019212362,0.00009835481,0.001011529,0.0002052715,0.00006589209,0.000002061104,0.00012753787,0.000070648006,0.0010339734],"category_scores_gemma":[0.001373165,0.00007376285,0.00027404306,0.00015345406,0.00014607549,0.000049859114,0.00016889638,0.0010195303,0.0000017818622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054864574,0.009622677,0.24714635,0.000025286896,0.00034217114,0.0025015706,0.00062248536,0.0003744568,0.0012718705,0.0000064470364,0.0018576006,0.68136454],"study_design_scores_gemma":[0.04570084,0.07303377,0.722273,0.000029779816,0.00010724084,0.000715218,0.00047780157,0.0014758739,0.00037454767,0.000018483332,0.15571363,0.00007980347],"about_ca_topic_score_codex":0.000027851305,"about_ca_topic_score_gemma":0.000005500669,"teacher_disagreement_score":0.6812847,"about_ca_system_score_codex":0.00017170014,"about_ca_system_score_gemma":0.0007010154,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W4281650201","doi":"10.1200/jco.2022.40.16_suppl.tps8072","title":"MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Pomalidomide; Internal medicine; Oncology; Multiple myeloma; Bortezomib; Dexamethasone; Progressive disease; Surgery; Chemotherapy","score_opus":0.11914582969451691,"score_gpt":0.4442931853155352,"score_spread":0.32514735562101826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281650201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444544,0.0014881584,0.00001977985,0.0003267968,0.00060560176,0.0027406747,0.00008144046,0.00001378096,0.0002783044],"genre_scores_gemma":[0.9954488,0.00035894196,0.0036186313,0.00013852972,0.00014305605,0.00010290365,0.00003102494,0.00006323838,0.00009483481],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9887942,0.0038394236,0.0044572335,0.00069220085,0.0016214107,0.00059549813],"domain_scores_gemma":[0.97490424,0.018014126,0.004311004,0.0006769769,0.00088215864,0.0012114812],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006609535,0.0004926937,0.005187209,0.0008044469,0.00021827171,0.000022324315,0.00038515287,0.00037402913,0.00012568146],"category_scores_gemma":[0.031407945,0.000334289,0.00034948808,0.0007804399,0.0014437778,0.00035090002,0.00044127996,0.0024761374,0.000001036991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6359456,0.016594823,0.32285327,0.00012300262,0.001798941,0.0012897312,0.0006529168,0.00003070142,0.000081907056,0.00001224446,0.0001716019,0.020445252],"study_design_scores_gemma":[0.61969554,0.08413864,0.29205018,0.00014925905,0.0009876516,0.00009128895,0.0012717004,0.00036196611,0.00005623272,0.000017387792,0.00097484316,0.00020529548],"about_ca_topic_score_codex":0.0006226274,"about_ca_topic_score_gemma":0.0009936396,"teacher_disagreement_score":0.06754382,"about_ca_system_score_codex":0.0005287801,"about_ca_system_score_gemma":0.0027566033,"threshold_uncertainty_score":0.9999109},"labels":[],"label_agreement":null},{"id":"W4281719370","doi":"10.1200/jco.2022.40.16_suppl.8018","title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Multiple myeloma; Clinical endpoint; Oncology; Expanded access; Lenalidomide; Phases of clinical research; Discontinuation; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","score_opus":0.05975955941285862,"score_gpt":0.4140060801500837,"score_spread":0.3542465207372251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975726,0.00007463875,0.000017628885,0.0005721012,0.00024695165,0.0010047883,0.000032910444,0.000007964018,0.0004703894],"genre_scores_gemma":[0.9984331,0.0001589993,0.0009294316,0.00014584856,0.00015052542,0.00001271894,0.000011107725,0.000032381333,0.00012589479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99321586,0.0022631509,0.0025489486,0.0004146686,0.0011586598,0.00039869265],"domain_scores_gemma":[0.9915149,0.0049279383,0.0021610183,0.0003663288,0.00043557127,0.0005942208],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004489812,0.00023621232,0.0023171855,0.00028504996,0.00011211524,0.0000064600295,0.00022761503,0.00022471805,0.00015558777],"category_scores_gemma":[0.0028056542,0.00014907215,0.00026705014,0.00029566415,0.00042563214,0.00016033342,0.00025275006,0.0025384964,0.0000028046652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18854704,0.022765588,0.67729247,0.00002082777,0.00083796226,0.0014558672,0.00010712352,0.000012929795,0.0000043622676,0.000002202035,0.000067586654,0.10888604],"study_design_scores_gemma":[0.11014687,0.12489001,0.7624912,0.00005924289,0.00030900675,0.00015033182,0.0002678551,0.00008330217,0.0000050516096,0.0000050595945,0.0014887671,0.00010329968],"about_ca_topic_score_codex":0.00017597665,"about_ca_topic_score_gemma":0.00065304665,"teacher_disagreement_score":0.10878274,"about_ca_system_score_codex":0.00037209498,"about_ca_system_score_gemma":0.001976896,"threshold_uncertainty_score":0.9997627},"labels":[],"label_agreement":null},{"id":"W4281777449","doi":"10.1200/jco.2022.40.16_suppl.8014","title":"Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Neutropenia; Cytokine release syndrome; Adverse effect; Oncology; Common Terminology Criteria for Adverse Events; Transplantation; Minimal residual disease; Autologous stem-cell transplantation; Gastroenterology; Immunology; Immunotherapy; Chemotherapy; Chimeric antigen receptor; Bone marrow; Cancer","score_opus":0.06754253009766986,"score_gpt":0.3958977306044321,"score_spread":0.32835520050676226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281777449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937786,0.00047899416,0.00007503088,0.0019313924,0.0011929447,0.0011758767,0.0005544817,0.000036220652,0.0007764583],"genre_scores_gemma":[0.97495556,0.00023070432,0.02111966,0.0007998321,0.0005747684,0.000057625766,0.0006224843,0.000067576235,0.0015717647],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99417526,0.0010306252,0.0028289529,0.00047360756,0.0009640586,0.0005274809],"domain_scores_gemma":[0.98722535,0.008249236,0.0026570167,0.0004443064,0.0008770287,0.0005470486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029023564,0.0002661035,0.0016184417,0.0002495841,0.00028694762,0.00001851531,0.0003447316,0.00029733288,0.00084238435],"category_scores_gemma":[0.008290224,0.00017190473,0.000473822,0.00032011876,0.00015493274,0.00017357623,0.00012317304,0.0017255292,0.000012136631],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.559218,0.014392212,0.12686425,0.000029442828,0.0018151947,0.0021950146,0.00039946564,0.000033945515,0.0012566934,0.0000012101385,0.025348553,0.26844603],"study_design_scores_gemma":[0.2150896,0.09577497,0.4328789,0.00007582008,0.00040242725,0.00008112062,0.00041990567,0.0007185724,0.00023764157,0.00003940917,0.25403607,0.00024556808],"about_ca_topic_score_codex":0.00024466167,"about_ca_topic_score_gemma":0.000109744535,"teacher_disagreement_score":0.3441284,"about_ca_system_score_codex":0.0004989445,"about_ca_system_score_gemma":0.0021276732,"threshold_uncertainty_score":0.99247706},"labels":[],"label_agreement":null},{"id":"W4281828145","doi":"10.1016/j.jdcr.2022.05.019","title":"A case of relapsed systemic multiple myeloma mimicking adenopathy and extensive skin patch overlying a plasmacytoma","year":2022,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et Services Sociaux de la Gaspésie; Centre hospitalier de l'Université Laval","funders":"","keywords":"POEMS syndrome; Medicine; Organomegaly; Multiple myeloma; Monoclonal gammopathy; Polyneuropathy; Pathology; Plasmacytoma; Dermatology; Monoclonal; Internal medicine; Immunology; Monoclonal antibody; Antibody","score_opus":0.02635756310879638,"score_gpt":0.28969879126128145,"score_spread":0.26334122815248506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281828145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645996,0.0014605768,0.000042436546,0.000048068086,0.00020046048,0.0013936261,0.00008731565,0.000078376186,0.00022917004],"genre_scores_gemma":[0.9983259,0.000030555086,0.00088785676,0.000042371597,0.00006176139,0.0003015764,0.000054783657,0.00005811936,0.00023711183],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972241,0.00021375754,0.0007912489,0.0006651494,0.0006147799,0.0004909942],"domain_scores_gemma":[0.997828,0.00035467412,0.0005080231,0.00069225515,0.0002352307,0.00038178364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000576399,0.00027882034,0.0006471162,0.00031350445,0.0004521325,0.000026498905,0.000034963567,0.000087372144,0.000103629725],"category_scores_gemma":[0.00064674893,0.0002590089,0.00017122398,0.00034814732,0.00007210977,0.000101846126,0.0002723579,0.00040063245,0.0000029441817],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064614264,0.00021452403,0.08171931,0.00041482094,0.0002411509,0.89074683,0.0018208699,0.000017284943,0.009736496,0.0000052487067,0.00011395822,0.014323381],"study_design_scores_gemma":[0.0037093533,0.0007521043,0.006033974,0.00022155719,0.00020711147,0.9744224,0.005349145,0.0029560577,0.0059594586,0.000016849439,0.00016442548,0.00020759004],"about_ca_topic_score_codex":0.0032092724,"about_ca_topic_score_gemma":0.00021684924,"teacher_disagreement_score":0.08367556,"about_ca_system_score_codex":0.00032269387,"about_ca_system_score_gemma":0.00024880882,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4281874725","doi":"10.1200/jco.2022.40.16_suppl.tps8071","title":"TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; CD47; Multiple myeloma; In vivo; Neutropenia; Pharmacodynamics; Pharmacology; Blockade; Bone marrow; Bortezomib; Phagocytosis; Cancer research; Oncology; Internal medicine; Immunology; Pharmacokinetics; Receptor; Chemotherapy; Biology","score_opus":0.13319477364459895,"score_gpt":0.4655549709589065,"score_spread":0.33236019731430755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281874725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972829,0.0002387028,0.00005651826,0.000781678,0.00041120246,0.0010650002,0.00001844419,0.000009059338,0.0001364548],"genre_scores_gemma":[0.9957013,0.00017111014,0.0036801053,0.00018639516,0.00013533451,0.000041426978,0.00003260583,0.000019364334,0.000032368913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953866,0.00085466914,0.0022455934,0.00030022764,0.0008563684,0.0003565258],"domain_scores_gemma":[0.9950117,0.002298571,0.0017804683,0.0002121903,0.0003227826,0.0003742879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025489137,0.00018685729,0.0016188121,0.000332093,0.00012112375,0.000006768724,0.00014769792,0.00019963978,0.00011325021],"category_scores_gemma":[0.0045418614,0.00012824763,0.00022080618,0.00032442316,0.00019697825,0.00018170539,0.00019467415,0.000934219,0.000001816554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.373129,0.015173314,0.46205267,0.00006094352,0.00022435538,0.00079867407,0.00019853737,0.00005506885,0.0006167235,0.000016146509,0.000120773955,0.14755379],"study_design_scores_gemma":[0.4077615,0.083269045,0.5058681,0.00014546466,0.00013411345,0.000105238025,0.00027338945,0.00059136376,0.00016263813,0.000090419584,0.0014874882,0.000111256246],"about_ca_topic_score_codex":0.00002915356,"about_ca_topic_score_gemma":0.000044758086,"teacher_disagreement_score":0.14744253,"about_ca_system_score_codex":0.00033071605,"about_ca_system_score_gemma":0.0009424575,"threshold_uncertainty_score":0.54373604},"labels":[],"label_agreement":null},{"id":"W4281935189","doi":"10.1200/jco.2022.40.16_suppl.8044","title":"Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Dexamethasone; Population; Nausea; Clinical endpoint; Multiple myeloma; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.05480611066813929,"score_gpt":0.39481319436516243,"score_spread":0.34000708369702315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281935189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563724,0.00025086888,0.00005151655,0.0019524988,0.000093948816,0.0018354511,0.00016002872,0.000007577795,0.000010865561],"genre_scores_gemma":[0.9974216,0.00007325534,0.0021240686,0.00017911757,0.000019015188,0.0000667029,0.000028608629,0.000031166917,0.00005644664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99154115,0.0035225519,0.0027381333,0.00052342785,0.0012708587,0.0004038591],"domain_scores_gemma":[0.98327667,0.012960281,0.0022203191,0.00045532477,0.0005728264,0.0005145839],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00528479,0.00033370152,0.0027054923,0.0009780955,0.00016588673,0.00001957852,0.00019618333,0.0001669853,0.000064198146],"category_scores_gemma":[0.008399831,0.00020162005,0.0002500113,0.0013575909,0.00046920005,0.00018338575,0.0001687218,0.00081055536,5.077954e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4440934,0.0036782825,0.5397373,0.000019269388,0.0029348896,0.0009188411,0.0010905531,0.0002604185,0.00091424224,3.173352e-7,0.000038560476,0.0063139386],"study_design_scores_gemma":[0.16615923,0.04812436,0.7806393,0.000090239446,0.0025429898,0.00009251839,0.0010112288,0.00070243335,0.00035007676,0.00000242433,0.00013455561,0.00015063553],"about_ca_topic_score_codex":0.00044097655,"about_ca_topic_score_gemma":0.001751245,"teacher_disagreement_score":0.27793416,"about_ca_system_score_codex":0.00028995224,"about_ca_system_score_gemma":0.0010776336,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W4281945717","doi":"10.1200/jco.2022.40.16_suppl.tps8069","title":"CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pomalidomide; Medicine; Daratumumab; Tolerability; Multiple myeloma; Lenalidomide; Carfilzomib; Internal medicine; Pharmacodynamics; Bortezomib; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Phases of clinical research; Clinical trial; Adverse effect","score_opus":0.16850953554944664,"score_gpt":0.5046144150094214,"score_spread":0.33610487945997475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281945717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656504,0.00009754175,0.00001820165,0.001360018,0.00048647771,0.0013282015,0.000029618512,0.0000045030647,0.00011040309],"genre_scores_gemma":[0.99790233,0.000106973246,0.001285049,0.00028014262,0.00026093906,0.00002925862,0.000009235481,0.000021721944,0.00010431717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994516,0.0022033348,0.0017803073,0.00025200247,0.000923197,0.00032515536],"domain_scores_gemma":[0.98995763,0.0071055503,0.0019779971,0.00023616789,0.00041638233,0.00030628877],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054449015,0.00016577981,0.0012068208,0.0001785363,0.00013444186,0.0000072895996,0.00017405275,0.00011825418,0.00020704584],"category_scores_gemma":[0.009000472,0.000090812435,0.00019650221,0.0001911436,0.0002520912,0.00011601314,0.00018985108,0.0016284273,8.7098306e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.602926,0.0070713954,0.17717513,0.000018168934,0.00040514092,0.00038353406,0.0002699851,0.000024592697,0.00025811716,6.502056e-7,0.000082578365,0.21138468],"study_design_scores_gemma":[0.4509566,0.17638488,0.3670392,0.000073287716,0.0003018399,0.00003483235,0.00029972984,0.002488247,0.00006729016,0.0000035283674,0.002277843,0.00007269457],"about_ca_topic_score_codex":0.00007224733,"about_ca_topic_score_gemma":0.00008472172,"teacher_disagreement_score":0.21131198,"about_ca_system_score_codex":0.00036303516,"about_ca_system_score_gemma":0.0014853858,"threshold_uncertainty_score":0.99934715},"labels":[],"label_agreement":null},{"id":"W4281960949","doi":"10.1158/2643-3230.bcd-21-0205","title":"Perspectives on the Risk-Stratified Treatment of Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Multiple myeloma; Risk stratification; Stratification (seeds); Medicine; Oncology; Intensive care medicine; Internal medicine; Biology","score_opus":0.03138852994115597,"score_gpt":0.3023293460820964,"score_spread":0.2709408161409404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281960949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918018,0.0029945492,0.0000044336334,0.0011095159,0.00008198945,0.00087227824,0.0007386371,0.000023969811,0.002372856],"genre_scores_gemma":[0.9949984,0.0011012075,0.00004770668,0.000056946992,0.00013078128,0.0009922135,0.000036726833,0.000022051394,0.0026139994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998594,0.00015655848,0.00017208734,0.00031629077,0.0004979481,0.00026310777],"domain_scores_gemma":[0.9990251,0.00027497715,0.00011346103,0.00046093203,0.000041041287,0.00008446669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009336937,0.00016821898,0.0002648861,0.00007729669,0.0002916797,0.000021559421,0.0001092488,0.000018023034,0.000675603],"category_scores_gemma":[0.000065800275,0.00009874236,0.00020573265,0.0001951823,0.00010153959,0.00005985503,0.0000493024,0.00014696103,0.000008067416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00866562,0.014851547,0.8981817,0.00007856623,0.0055769407,0.00043266048,0.009771618,0.00087738363,0.022636663,0.003386903,0.0011932104,0.03434719],"study_design_scores_gemma":[0.036594283,0.014401285,0.7295085,0.000111743655,0.0015353775,0.00007160208,0.02753326,0.00084816717,0.18292594,0.00030553073,0.0057007954,0.00046347824],"about_ca_topic_score_codex":0.0027063314,"about_ca_topic_score_gemma":0.0002799091,"teacher_disagreement_score":0.16867316,"about_ca_system_score_codex":0.00029349016,"about_ca_system_score_gemma":0.0002926361,"threshold_uncertainty_score":0.73973787},"labels":[],"label_agreement":null},{"id":"W4282033105","doi":"10.1056/nejmoa2203478","title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; Hotel Dieu Hospital","funders":"Janssen Research and Development; Winship Cancer Institute; School of Medicine, Stanford University; Cancer Center Amsterdam; Centro de Investigación Biomédica en Red de Cáncer; Eberhard Karls Universität Tübingen; National Cancer Institute; Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona; Emory University; Universidad de Navarra; University College London; Memorial Sloan-Kettering Cancer Center; Perelman School of Medicine, University of Pennsylvania; Universitat de Barcelona; Vrije Universiteit Amsterdam; University of Pennsylvania; University of California, San Francisco; Comprehensive Cancer Center, City of Hope; National Institute for Health and Care Research; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Refractory (planetary science); Antibody; Cancer research; Antigen; Medicine; CD3; Immunology; Biology; CD8","score_opus":0.04050119126847216,"score_gpt":0.323883615450082,"score_spread":0.2833824241816098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282033105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98568785,0.0021856069,0.000046422843,0.00932956,0.0005216325,0.000327437,0.000007906572,0.00001641134,0.0018771479],"genre_scores_gemma":[0.99347395,0.00026307756,0.000662741,0.00049924117,0.0014572738,0.000008588028,0.000017912393,0.00002522557,0.0035920078],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746895,0.00024253636,0.0006775157,0.00017069114,0.0011071047,0.00033320463],"domain_scores_gemma":[0.9982544,0.00059027097,0.00027954995,0.00023843828,0.00012832906,0.00050899544],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012729372,0.0001631977,0.0006014087,0.00058864476,0.00009855788,0.0000054842335,0.00017984974,0.000045512483,0.0027885481],"category_scores_gemma":[0.0020218669,0.00009790993,0.00008570418,0.00045723666,0.00008033443,0.00006286137,0.000065213906,0.00097057386,0.000007861531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050359316,0.0012467382,0.22755092,0.00010233073,0.00035835383,0.030010592,0.0028084402,0.00009432174,0.012170886,0.00004021882,0.029618742,0.6456391],"study_design_scores_gemma":[0.37430236,0.017837463,0.22134323,0.00049406535,0.00016436295,0.009463115,0.0015798867,0.0004402173,0.00041573736,0.00022491471,0.37355027,0.00018437757],"about_ca_topic_score_codex":0.00034701457,"about_ca_topic_score_gemma":0.00018590601,"teacher_disagreement_score":0.64545476,"about_ca_system_score_codex":0.00035996435,"about_ca_system_score_gemma":0.0006219462,"threshold_uncertainty_score":0.99812305},"labels":[],"label_agreement":null},{"id":"W4282838554","doi":"10.1158/1055-9965.epi-22-0043","title":"Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?","year":2022,"lang":"en","type":"review","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"National Cancer Institute","keywords":"Multiple myeloma; Medicine; Internal medicine; Oncology","score_opus":0.08076212401473437,"score_gpt":0.37985687382812044,"score_spread":0.2990947498133861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282838554","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012440234,0.9778089,0.00012740072,0.000079635516,0.001196641,0.0056514596,0.0024760459,0.00011632409,0.000103389306],"genre_scores_gemma":[0.0026787373,0.9861551,0.0011021395,0.000034238834,0.0002516865,0.0022890351,0.0064645726,0.00015855841,0.0008659615],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9909605,0.0038517106,0.0019372978,0.0014582598,0.0006957964,0.0010964809],"domain_scores_gemma":[0.99270004,0.002957047,0.0024479935,0.0011783511,0.00020841676,0.00050814485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021065874,0.0009425435,0.004182932,0.00062579213,0.00027032607,0.000009142273,0.0004657392,0.0006555898,0.0018460704],"category_scores_gemma":[0.0024565752,0.0005370175,0.0015467335,0.0005872565,0.00051459006,0.00014470023,0.00033412388,0.0009803066,0.000023136517],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019398392,0.0004224658,0.46823856,0.0056403913,0.006014415,0.000022489497,0.000014114988,0.0000011718015,2.9983707e-7,0.0000059596036,0.00059915765,0.5171011],"study_design_scores_gemma":[0.008335495,0.0019111942,0.61227846,0.010227195,0.0066578374,0.000014109098,0.000020873147,0.00005958221,0.0000023935183,0.00022050455,0.35961774,0.0006546325],"about_ca_topic_score_codex":0.0010383776,"about_ca_topic_score_gemma":0.0005832736,"teacher_disagreement_score":0.5164465,"about_ca_system_score_codex":0.0011154342,"about_ca_system_score_gemma":0.0013033637,"threshold_uncertainty_score":0.9997081},"labels":[],"label_agreement":null},{"id":"W4282934260","doi":"10.1007/s12105-022-01465-2","title":"Intrathyroidal Plasmacytoma with Pleomorphic Multilobated Bizarre Cells: A Rare Primary Clinicopathological Presentation Mimicking Anaplastic Carcinoma of Thyroid","year":2022,"lang":"en","type":"article","venue":"Head and Neck Pathology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre","funders":"","keywords":"Plasmacytoma; Medicine; Pathology; Thyroid; Multiple myeloma; Neck mass; Anaplastic carcinoma; Thyroid carcinoma; Malignancy; Immunohistochemistry; Dysphagia; Carcinoma; Radiology; Internal medicine","score_opus":0.03014979279836589,"score_gpt":0.29129048049074757,"score_spread":0.2611406876923817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282934260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760276,0.00080684037,0.000057462315,0.00018103728,0.0000763166,0.0007501508,0.00018507433,0.00005524626,0.00028511378],"genre_scores_gemma":[0.99727136,0.000099596,0.0017752681,0.00019362484,0.000050866296,0.00014018008,0.00036179397,0.000027398723,0.0000799281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792403,0.00037184948,0.00038962968,0.0005185371,0.0003588559,0.00043709337],"domain_scores_gemma":[0.99899274,0.00027542165,0.00016092393,0.00026222022,0.0000968327,0.00021184409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021579745,0.00022370796,0.00055649894,0.00021482444,0.00023111995,0.000010711632,0.00009909401,0.00010695605,0.0001117973],"category_scores_gemma":[0.00009560297,0.00017220541,0.00007123646,0.0002808687,0.0002773433,0.000059103797,0.00018643448,0.0004445325,0.0000069274256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012274013,0.0012488451,0.7997564,0.00020624921,0.00006858189,0.01402174,0.0009154024,0.00006348976,0.16665159,0.000039759347,0.00021970444,0.0045342185],"study_design_scores_gemma":[0.014964797,0.01547895,0.94851756,0.000055773653,0.00011651465,0.0054120678,0.00065308216,0.0022704557,0.012195042,0.000020083588,0.00011028283,0.00020537655],"about_ca_topic_score_codex":0.000049767248,"about_ca_topic_score_gemma":0.000043709344,"teacher_disagreement_score":0.15445656,"about_ca_system_score_codex":0.00007718587,"about_ca_system_score_gemma":0.00018395232,"threshold_uncertainty_score":0.7022333},"labels":[],"label_agreement":null},{"id":"W4283326517","doi":"10.1097/01.hs9.0000843644.02496.66","title":"S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Adverse effect; Phases of clinical research; Refractory (planetary science); Clinical trial; Bortezomib","score_opus":0.035882064541854906,"score_gpt":0.30806208928966367,"score_spread":0.2721800247478088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594774,0.004302337,0.01629328,0.00137496,0.00014632907,0.01257668,0.0021231838,0.00015876241,0.0035470573],"genre_scores_gemma":[0.9863131,0.000051200375,0.007209936,0.00006382853,0.000019517756,0.0022187172,0.002371971,0.000041227322,0.0017105003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981762,0.00010280743,0.000437453,0.00042693855,0.0004878434,0.0003687232],"domain_scores_gemma":[0.99844694,0.0004522394,0.00020691054,0.0006553283,0.0001571002,0.00008149917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026883246,0.00025787207,0.00044065338,0.00014150668,0.00031258966,0.000016577535,0.00015752073,0.000070295784,0.0000999096],"category_scores_gemma":[0.000070374204,0.00016385355,0.00014171009,0.00056772586,0.00011606377,0.000058413356,0.00002350733,0.00020259732,0.0000012511608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41441232,0.27269512,0.02081575,0.0008676185,0.0033938268,0.00039174707,0.0052648555,0.007186006,0.039482847,0.00073570677,0.0050135534,0.22974063],"study_design_scores_gemma":[0.6621848,0.03387045,0.011810321,0.00015065918,0.0003189195,0.000041047166,0.0035969731,0.1698995,0.02093859,0.000021359232,0.096690394,0.00047703995],"about_ca_topic_score_codex":0.00046499597,"about_ca_topic_score_gemma":0.00014239346,"teacher_disagreement_score":0.24777243,"about_ca_system_score_codex":0.0005956608,"about_ca_system_score_gemma":0.0003923757,"threshold_uncertainty_score":0.66817534},"labels":[],"label_agreement":null},{"id":"W4283366934","doi":"10.1097/01.hs9.0000846464.96684.8e","title":"P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Population; Oncology; Surgery; Gastroenterology","score_opus":0.04771458878182294,"score_gpt":0.29972435333488623,"score_spread":0.2520097645530633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283366934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553263,0.0005092161,0.00006569038,0.00004506653,0.000083322346,0.0025987981,0.00020464198,0.00010272927,0.00085787824],"genre_scores_gemma":[0.99496496,0.0000066812654,0.0033854048,0.000024373498,0.000028609324,0.00024120597,0.0007729717,0.00011589891,0.00045986997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995891,0.00036750332,0.0008709146,0.0007240781,0.0013610226,0.00078551145],"domain_scores_gemma":[0.99795604,0.0002768709,0.0005695308,0.00070562295,0.00016711008,0.00032479977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019786728,0.0005493379,0.0014442985,0.0003327665,0.00032863682,0.000027262044,0.00021256169,0.00013250714,0.0006103208],"category_scores_gemma":[0.000054980675,0.0004085505,0.00014582401,0.0008622001,0.0001423161,0.00014810117,0.00014064925,0.00065122853,0.000012511197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02000734,0.00935955,0.9539988,0.00020828731,0.00057647005,0.0002970979,0.0025052642,0.0012067464,0.0011762124,0.000005512453,0.00011236045,0.010546348],"study_design_scores_gemma":[0.06342581,0.012013094,0.9031653,0.0004189739,0.00031548485,0.00003904624,0.0056681386,0.006202848,0.007653547,0.0000036291797,0.00062123,0.00047294344],"about_ca_topic_score_codex":0.0016167994,"about_ca_topic_score_gemma":0.0022826449,"teacher_disagreement_score":0.050833553,"about_ca_system_score_codex":0.0015620872,"about_ca_system_score_gemma":0.00045398026,"threshold_uncertainty_score":0.9998366},"labels":[],"label_agreement":null},{"id":"W4283372513","doi":"10.1097/01.hs9.0000846600.20422.ca","title":"P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Daratumumab; Clinical endpoint; Oncology; Dexamethasone; Subgroup analysis; Clinical trial; Confidence interval","score_opus":0.03893365579631453,"score_gpt":0.3151773999234155,"score_spread":0.27624374412710095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283372513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780923,0.0006210727,0.0000013395743,0.00007351314,0.00003284597,0.0013127199,0.00008331791,0.000018060216,0.000047880327],"genre_scores_gemma":[0.9979948,0.00012074468,0.00039269228,0.000044727087,0.000008749406,0.0004662855,0.00010917953,0.000041452608,0.0008214161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976995,0.00028670233,0.00048170754,0.00046946743,0.000676742,0.00038587878],"domain_scores_gemma":[0.9989246,0.00030190678,0.00017886343,0.0003322744,0.00014590163,0.000116430034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025373013,0.00027163592,0.00080271106,0.0006186325,0.00008451623,0.000012742934,0.00008436303,0.000081366576,0.00055258797],"category_scores_gemma":[0.00017661699,0.00015890587,0.0000492956,0.002033508,0.00016057931,0.00017746168,0.00009143478,0.0004169952,0.0000017994273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11461328,0.0023701887,0.870625,0.00011090418,0.00087751716,0.0023701326,0.0043442366,0.000039439732,0.000042871354,0.0000016709531,0.000022950406,0.004581781],"study_design_scores_gemma":[0.047901273,0.010258331,0.93845105,0.00024269149,0.00015273898,0.000009108149,0.0022354682,0.00042740983,0.000069182606,0.0000026958405,0.000061738305,0.0001883166],"about_ca_topic_score_codex":0.0013368166,"about_ca_topic_score_gemma":0.034317892,"teacher_disagreement_score":0.067826025,"about_ca_system_score_codex":0.00046458395,"about_ca_system_score_gemma":0.00022064544,"threshold_uncertainty_score":0.9833033},"labels":[],"label_agreement":null},{"id":"W4283374492","doi":"10.3390/curroncol29070355","title":"Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Daratumumab; Multiple myeloma; Bortezomib; Disease; Refractory (planetary science); Oncology; Immunology; Internal medicine; Immunotherapy; Immune system","score_opus":0.34996530861628683,"score_gpt":0.54482977370429,"score_spread":0.19486446508800315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283374492","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000893252,0.9934042,0.000016469852,0.00004717446,0.0015978988,0.003369155,0.00014518574,0.000031401316,0.0012991764],"genre_scores_gemma":[0.00009822667,0.99790436,0.00025796692,0.000011870862,0.00016390861,0.00077728735,0.00064518757,0.000052861753,0.00008833408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946591,0.0012719359,0.0021950358,0.0007306082,0.00066901743,0.00047427308],"domain_scores_gemma":[0.9964061,0.0010048065,0.0014321447,0.00072693254,0.00016415313,0.00026587842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014425322,0.00053337374,0.0043044556,0.00037648794,0.00008121508,0.000009738301,0.00034425218,0.0001999944,0.00064974016],"category_scores_gemma":[0.00033613903,0.0003915436,0.0009692314,0.00044896052,0.0004092083,0.00008524703,0.0005285329,0.0011795537,0.000010474749],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109209264,0.0016108975,0.00034970252,0.29197323,0.0011036735,0.00007021747,0.000041303017,7.713713e-9,1.01042914e-7,0.00020646474,0.0011228641,0.7034123],"study_design_scores_gemma":[0.0028011955,0.0012307062,0.00046977453,0.0969039,0.002648644,0.00004411674,0.00024046695,0.0000059319495,1.3705139e-7,0.000019163028,0.8954239,0.00021208274],"about_ca_topic_score_codex":0.000006742421,"about_ca_topic_score_gemma":0.0000041285443,"teacher_disagreement_score":0.894301,"about_ca_system_score_codex":0.00035912928,"about_ca_system_score_gemma":0.0012043471,"threshold_uncertainty_score":0.9998537},"labels":[],"label_agreement":null},{"id":"W4283376400","doi":"10.1097/01.hs9.0000846460.44039.3d","title":"P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Cytokine release syndrome; Adverse effect; Common Terminology Criteria for Adverse Events; Minimal residual disease; Oncology; Transplantation; Immunology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor; Bone marrow","score_opus":0.024270762174428962,"score_gpt":0.29195613847621205,"score_spread":0.2676853763017831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283376400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310726,0.00035631197,0.000029234341,0.00011501529,0.00012828792,0.0044516833,0.0013913565,0.000105371815,0.00031550042],"genre_scores_gemma":[0.9939693,0.000013268601,0.0019014465,0.000083573,0.00007355678,0.0005652192,0.0021009187,0.000097749034,0.0011949707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693966,0.0003270453,0.00067252765,0.00062845345,0.000932083,0.0005002048],"domain_scores_gemma":[0.9968104,0.0013466165,0.0004536983,0.0009177988,0.00031424733,0.00015724865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043358526,0.00031474337,0.0005516502,0.00007482824,0.00065605174,0.00002565924,0.0002927734,0.00006777125,0.0008522149],"category_scores_gemma":[0.00067621924,0.00019196792,0.00012468481,0.00053882273,0.000061485,0.00010939658,0.00014055464,0.00045845006,0.0000061067817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45754027,0.053554524,0.31159493,0.00021044088,0.0042707184,0.00070140464,0.023575034,0.00016301444,0.026404629,0.0000020518858,0.016390815,0.10559218],"study_design_scores_gemma":[0.6372588,0.06074689,0.20051762,0.0004088886,0.0007511685,0.000019828407,0.05046181,0.005997847,0.015656695,0.000013738936,0.027202904,0.00096378836],"about_ca_topic_score_codex":0.0020164181,"about_ca_topic_score_gemma":0.00056602363,"teacher_disagreement_score":0.17971855,"about_ca_system_score_codex":0.00023417806,"about_ca_system_score_gemma":0.0002624526,"threshold_uncertainty_score":0.9331155},"labels":[],"label_agreement":null},{"id":"W4283379818","doi":"10.1097/01.hs9.0000846628.17113.b2","title":"P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Adverse effect; Multiple myeloma; Oncology; Clinical endpoint; Expanded access; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","score_opus":0.016813890652781462,"score_gpt":0.28782187908842116,"score_spread":0.2710079884356397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283379818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964956,0.0000976825,0.000010575568,0.00006443842,0.000038436363,0.002197683,0.000099607205,0.000039346083,0.0009566416],"genre_scores_gemma":[0.9987395,0.000023669985,0.0003736412,0.00002638934,0.000024173782,0.000102431826,0.00008338465,0.000054863525,0.00057196984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970652,0.0004254332,0.00048246526,0.0006189609,0.0009556427,0.00045233234],"domain_scores_gemma":[0.99840117,0.00038310874,0.00023221258,0.0005749241,0.00011861813,0.00028997287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004019303,0.00028747896,0.0007580748,0.0001082681,0.00018430203,0.000010564129,0.00013038916,0.00007838065,0.00044824422],"category_scores_gemma":[0.00013646738,0.00020682634,0.00007487523,0.0003676546,0.00016986903,0.00012523726,0.00024489453,0.0007286842,0.0000073531055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052591935,0.010114823,0.91262335,0.00008854349,0.00041369925,0.0004795118,0.00037091377,0.000013230294,0.000021813154,0.0000037637587,0.000051096176,0.023227343],"study_design_scores_gemma":[0.06026847,0.014181216,0.9236943,0.000085604384,0.00012844517,0.00003337016,0.0009114629,0.00016357772,0.00006623075,0.0000018641696,0.0002771905,0.00018824272],"about_ca_topic_score_codex":0.00077054196,"about_ca_topic_score_gemma":0.0016477793,"teacher_disagreement_score":0.0230391,"about_ca_system_score_codex":0.00024893146,"about_ca_system_score_gemma":0.00028534757,"threshold_uncertainty_score":0.84341335},"labels":[],"label_agreement":null},{"id":"W4283389183","doi":"10.1097/01.hs9.0000850912.43010.d3","title":"PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Internal medicine; Pomalidomide; Oncology; Multiple myeloma; Bortezomib; Dexamethasone","score_opus":0.02841387785979811,"score_gpt":0.30961096755874207,"score_spread":0.28119708969894397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283389183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922508,0.00031335565,0.000012709469,0.000048539652,0.00019588691,0.0052192267,0.00012260664,0.00006786044,0.0017690175],"genre_scores_gemma":[0.9965668,0.000013577358,0.0003943522,0.000026561636,0.00003627165,0.0010024356,0.00026046878,0.00007451996,0.0016250187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622476,0.00049725734,0.00070373697,0.0006175664,0.0013877695,0.0005689154],"domain_scores_gemma":[0.9977758,0.0006861808,0.00028792096,0.00078360067,0.00018252834,0.00028395426],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041274284,0.00037291524,0.0012153994,0.00021086111,0.00023822379,0.000019160074,0.00023933887,0.00008073249,0.0025031844],"category_scores_gemma":[0.0006118084,0.00025991508,0.000151971,0.0007252203,0.00015331937,0.00013977922,0.00024876496,0.00063191063,0.000030417867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8765176,0.016928723,0.09455125,0.00015941441,0.00078115077,0.0016269602,0.0017683933,0.00010016957,0.000040235085,0.000010459752,0.00043099406,0.0070846668],"study_design_scores_gemma":[0.9414495,0.018409014,0.03135681,0.00010317585,0.00026497286,0.000014393411,0.006240982,0.0006990132,0.00012624187,0.0000034404738,0.0010571704,0.00027524252],"about_ca_topic_score_codex":0.0007190753,"about_ca_topic_score_gemma":0.001064816,"teacher_disagreement_score":0.06493196,"about_ca_system_score_codex":0.00064038654,"about_ca_system_score_gemma":0.00043348892,"threshold_uncertainty_score":0.9999853},"labels":[],"label_agreement":null},{"id":"W4283397661","doi":"10.1097/01.hs9.0000846624.61314.38","title":"P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Cohort; Adverse effect; Internal medicine; Pharmacology; Combination therapy; Oncology; Gastroenterology","score_opus":0.006609456375418366,"score_gpt":0.23269093646809835,"score_spread":0.22608148009267998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950479,0.00018492607,0.000012144838,0.000029715367,0.00006727211,0.0043685073,0.0000600582,0.00004861875,0.00018081686],"genre_scores_gemma":[0.9980695,0.0000071274585,0.00030215955,0.000024803287,0.00001754376,0.00080470403,0.00041006194,0.000077453515,0.00028659188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659127,0.00043581234,0.00052055507,0.00061652734,0.001260766,0.00057509844],"domain_scores_gemma":[0.99830824,0.00048149395,0.0002549675,0.0005516753,0.00014608518,0.0002575299],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028753994,0.00037173938,0.00068998284,0.00032954232,0.00012630419,0.00001720314,0.00016330185,0.00007713188,0.00020761442],"category_scores_gemma":[0.00028809006,0.00029125382,0.000061369254,0.0008590673,0.000107980835,0.00016243824,0.0001562217,0.00060721056,0.000014358116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013993072,0.018698249,0.95598984,0.0007602749,0.00019119155,0.0034376243,0.0014512936,0.00015699181,0.00049239816,0.000009965351,0.00006601573,0.0047531105],"study_design_scores_gemma":[0.08179709,0.014659424,0.89886445,0.00063910795,0.00009614293,0.00001238061,0.0016335764,0.00053360756,0.0014538585,0.0000066937855,0.000035715075,0.00026793394],"about_ca_topic_score_codex":0.0010046192,"about_ca_topic_score_gemma":0.0021459935,"teacher_disagreement_score":0.06780402,"about_ca_system_score_codex":0.00063489605,"about_ca_system_score_gemma":0.0003117771,"threshold_uncertainty_score":0.999954},"labels":[],"label_agreement":null},{"id":"W4283579103","doi":"10.14740/jh1007","title":"Conventional Karyotyping and Fluorescence <i>In Situ</i> Hybridization for Detection of Chromosomal Abnormalities in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Karyotype; Fluorescence in situ hybridization; Fish <Actinopterygii>; Biology; Multiple myeloma; Pathology; Chromosome; Cytogenetics; Medicine; Genetics; Immunology; Gene; Fishery","score_opus":0.02252028173870626,"score_gpt":0.28443492111638313,"score_spread":0.2619146393776769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283579103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806684,0.0007608811,0.00057404966,0.0002236499,0.00008885589,0.00024810462,0.000009165659,0.0000024462208,0.000026006646],"genre_scores_gemma":[0.9987807,0.000048017002,0.0010700843,0.000019740053,0.00002411392,0.000025638543,0.000010843094,0.0000062488916,0.000014599892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905986,0.00009258992,0.00042739132,0.000085325875,0.00018527672,0.00014957308],"domain_scores_gemma":[0.99936694,0.00022631891,0.00021248603,0.000048369493,0.00009790265,0.000047981062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033399015,0.000059763828,0.00029306984,0.00031672328,0.000052706822,0.000002982234,0.00004130802,0.000029001381,0.00002371005],"category_scores_gemma":[0.0002572337,0.0000556643,0.000057691886,0.00012166171,0.000054432323,0.000087853135,0.000033133794,0.00015769909,2.4883704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043365927,0.0006541389,0.826438,0.00047979833,0.00009521433,0.00061491504,0.0004011782,0.00010799659,0.16144398,0.00070777175,0.00004782176,0.004672564],"study_design_scores_gemma":[0.020756071,0.00302272,0.6863409,0.00030154226,0.000051986695,0.011518035,0.0013967548,0.008226069,0.26711047,0.0008272722,0.0003170312,0.00013111305],"about_ca_topic_score_codex":0.000027613607,"about_ca_topic_score_gemma":0.000075036616,"teacher_disagreement_score":0.14009708,"about_ca_system_score_codex":0.00009184134,"about_ca_system_score_gemma":0.00011027894,"threshold_uncertainty_score":0.22699241},"labels":[],"label_agreement":null},{"id":"W4283698909","doi":"10.1038/s41408-022-00695-5","title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"National Cancer Institute; National Institutes of Health","keywords":"Multiple myeloma; Medicine; Clinical trial; Carfilzomib; Lenalidomide; Refractory (planetary science); Transplantation; Oncology; Salvage therapy; Intensive care medicine; Internal medicine; Chemotherapy; Biology","score_opus":0.15640130480209158,"score_gpt":0.3700564653846089,"score_spread":0.21365516058251732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283698909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019931601,0.97593766,7.1132143e-7,0.00082015217,0.0003620702,0.0017498486,0.00079271465,0.00001083422,0.0003944277],"genre_scores_gemma":[0.015874475,0.9825934,0.00015749465,0.000045907786,0.00019392632,0.0004976376,0.00008775459,0.000060189657,0.000489223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625784,0.0010528942,0.0011908389,0.00030724984,0.00073912315,0.0004520392],"domain_scores_gemma":[0.996027,0.0019466614,0.0010204953,0.0006635043,0.00013384449,0.0002085231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006493866,0.0004650629,0.0015944418,0.00038062464,0.0004078117,0.000037731526,0.00038884455,0.00015729835,0.00027276287],"category_scores_gemma":[0.00027278988,0.0002537756,0.0006162358,0.00034559448,0.00028278268,0.000056961984,0.00012353118,0.00096210354,0.0000010425496],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018431786,0.0017786167,0.007603991,0.0030273837,0.0019027671,0.00040264268,0.0015235096,0.0000031948523,0.000013388925,0.000016207145,0.00084389694,0.9827001],"study_design_scores_gemma":[0.0075289933,0.0011296353,0.004109029,0.0058809705,0.0022708927,0.001362787,0.0018332681,0.000019280335,0.000040890256,0.000008032944,0.9756024,0.00021382974],"about_ca_topic_score_codex":0.00066525507,"about_ca_topic_score_gemma":0.00066794665,"teacher_disagreement_score":0.98248625,"about_ca_system_score_codex":0.00051417586,"about_ca_system_score_gemma":0.0014145372,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W4283745047","doi":"10.1038/s41467-022-31430-0","title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Multiple Myeloma Research Foundation; National Cancer Institute; Prostate Cancer Foundation; Howard Hughes Medical Institute","keywords":"Multiple myeloma; Lenalidomide; Drug resistance; Disease; Biology; Medicine; Malignancy; Oncology; Bioinformatics; Cancer research; Immunology; Internal medicine; Genetics","score_opus":0.023879256028986173,"score_gpt":0.3149509845224097,"score_spread":0.29107172849342355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283745047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89309025,0.08524843,0.00011587718,0.01678083,0.00016491166,0.00150717,0.00021026548,0.00008860481,0.0027936602],"genre_scores_gemma":[0.98690563,0.0016879721,0.010006074,0.0001499717,0.000008392485,0.0001964229,0.00007974818,0.000015923377,0.0009498337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987578,0.00035575381,0.00020506709,0.00016168198,0.00034973264,0.00016995799],"domain_scores_gemma":[0.9971047,0.0007763407,0.00010728975,0.0017936081,0.00012261751,0.000095418385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003233093,0.00009134016,0.00014754695,0.00006164317,0.0010153669,0.0000121897365,0.0005321884,0.00005944817,0.00001373295],"category_scores_gemma":[0.00038094007,0.00006848784,0.000064213455,0.00021832011,0.0001937414,0.000026798692,0.0005888662,0.00083672075,0.0000024256483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008258075,0.0076215975,0.49295595,0.00050807983,0.0033336612,0.00021030409,0.004347209,0.000035420337,0.2182926,0.10508177,0.05957707,0.09977829],"study_design_scores_gemma":[0.0045703114,0.00028273364,0.6872023,0.00005297801,0.00013988782,0.000061480634,0.00071747066,0.0011208518,0.008910454,0.0025048088,0.29422182,0.00021493083],"about_ca_topic_score_codex":0.00003259645,"about_ca_topic_score_gemma":0.0016584018,"teacher_disagreement_score":0.23464476,"about_ca_system_score_codex":0.0000983661,"about_ca_system_score_gemma":0.00009347653,"threshold_uncertainty_score":0.7809484},"labels":[],"label_agreement":null},{"id":"W4285409427","doi":"10.2196/39068","title":"Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review","year":2022,"lang":"en","type":"review","venue":"JMIR Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; PsycINFO; Nausea; Social media; Quality of life (healthcare); Patient satisfaction; Qualitative research; MEDLINE; Patient experience; Tolerability; Family medicine; Health care; Clinical psychology; Physical therapy; Adverse effect; Nursing; Surgery; Internal medicine","score_opus":0.21885742817115617,"score_gpt":0.48620719294253484,"score_spread":0.2673497647713787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285409427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054896092,0.99152017,2.1051675e-7,0.0009207399,0.00021792635,0.006109357,0.00032284728,0.000027957978,0.00082591607],"genre_scores_gemma":[0.00004656367,0.9807521,0.000024622337,0.0009848234,0.00017559585,0.016697703,0.00048860547,0.000078701334,0.00075130304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962451,0.001095091,0.0008450293,0.0005191833,0.000749531,0.00054607674],"domain_scores_gemma":[0.9979003,0.00073621114,0.0004831914,0.00061133486,0.00006389534,0.00020504912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006270394,0.00045016815,0.001946574,0.0002063304,0.00017285127,0.000025021227,0.00026951253,0.0001127713,0.0034539774],"category_scores_gemma":[0.0004273623,0.00025297207,0.0006119154,0.00072535354,0.00007714759,0.00006874115,0.00021723536,0.0012008518,0.00013097729],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046215206,0.00018007477,0.00004838618,0.040167518,0.0003277856,0.0002532922,0.001753064,2.4139041e-8,4.2630614e-7,0.0000042974607,0.004490702,0.9527282],"study_design_scores_gemma":[0.0007046208,0.00014536435,0.0002021391,0.06717871,0.00034447253,0.000060055412,0.0003190497,0.000002228036,5.807718e-7,0.000001916099,0.93082815,0.00021269654],"about_ca_topic_score_codex":0.00032678345,"about_ca_topic_score_gemma":0.00010680086,"teacher_disagreement_score":0.95251554,"about_ca_system_score_codex":0.0013265602,"about_ca_system_score_gemma":0.0009177004,"threshold_uncertainty_score":0.99999225},"labels":[],"label_agreement":null},{"id":"W4286294091","doi":"10.1200/jco.2022.40.16_suppl.tps8074","title":"MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Pfizer","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Combination therapy; Oncology; Clinical endpoint; Pomalidomide; Phases of clinical research; Multiple myeloma; Regimen; Dexamethasone; Refractory (planetary science); Pharmacology; Clinical trial","score_opus":0.07689841356222658,"score_gpt":0.45274538678816556,"score_spread":0.37584697322593896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959984,0.00018396512,0.000010656574,0.0003991855,0.00012793201,0.0031430863,0.000010774084,0.0000038337425,0.00012219793],"genre_scores_gemma":[0.99793947,0.00016687986,0.0014775791,0.00019192572,0.00002369375,0.00010008281,0.000027081585,0.000025558405,0.000047721307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994004,0.0027330858,0.0019568058,0.0003089414,0.0007519504,0.0002452236],"domain_scores_gemma":[0.99543285,0.0022005863,0.001462216,0.00025074717,0.0003506564,0.00030293377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003763626,0.00018022416,0.0020479704,0.00041778845,0.00007215465,0.000015546275,0.0002666494,0.0001103216,0.00010967871],"category_scores_gemma":[0.0014627952,0.00011629911,0.000053120635,0.00028170642,0.00022335017,0.00034401796,0.00012620026,0.0010885061,7.5654066e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5178946,0.09012409,0.3430912,0.000010323963,0.000302938,0.00077707716,0.00052341376,0.00001543254,0.000022368025,0.0000031304714,0.000014079049,0.047221348],"study_design_scores_gemma":[0.5051446,0.14540757,0.34775,0.00004179633,0.000094867006,0.000018263196,0.00055394357,0.00076688325,0.00000484614,0.000013554821,0.00014649854,0.000057182424],"about_ca_topic_score_codex":0.0005202483,"about_ca_topic_score_gemma":0.0009462654,"teacher_disagreement_score":0.05528348,"about_ca_system_score_codex":0.00024232762,"about_ca_system_score_gemma":0.00069212145,"threshold_uncertainty_score":0.474254},"labels":[],"label_agreement":null},{"id":"W4286295042","doi":"10.1200/jco.2022.40.16_suppl.8033","title":"Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cohort; Visual analogue scale; Quality of life (healthcare); Refractory (planetary science); Progressive disease; Clinical trial; Oncology; Surgery; Disease","score_opus":0.09080855741906677,"score_gpt":0.42029281233436727,"score_spread":0.32948425491530053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964775,0.00030363706,0.00000860383,0.0013423305,0.00022824146,0.0013433292,0.00005000228,0.000017599694,0.00022877699],"genre_scores_gemma":[0.99820846,0.00014211648,0.001003278,0.00027201403,0.000031332504,0.000024966244,0.00018273511,0.000040798215,0.00009431597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98987937,0.0022623257,0.005559757,0.00043405598,0.001352036,0.00051244185],"domain_scores_gemma":[0.990678,0.0020316658,0.0056692953,0.00043078273,0.0006276569,0.0005626129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003170366,0.0002954164,0.002976374,0.0007231391,0.0000987286,0.000010087859,0.00019633022,0.0002890289,0.00012967488],"category_scores_gemma":[0.0028984975,0.00019334904,0.0003021545,0.0008252551,0.00023766397,0.00020581242,0.00009399425,0.00182206,0.0000039933657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07320663,0.01720519,0.89457136,0.00007964105,0.00052325457,0.0011687323,0.0002817068,0.000088889785,0.00013319454,0.000002948045,0.00010439395,0.0126340585],"study_design_scores_gemma":[0.07359406,0.03461929,0.8903295,0.00013926536,0.000060843162,0.0000427788,0.00042011222,0.000086479085,0.000027408376,0.000008524666,0.0005202105,0.00015155431],"about_ca_topic_score_codex":0.0014960028,"about_ca_topic_score_gemma":0.0010935812,"teacher_disagreement_score":0.0174141,"about_ca_system_score_codex":0.00079690624,"about_ca_system_score_gemma":0.0029493987,"threshold_uncertainty_score":0.7916045},"labels":[],"label_agreement":null},{"id":"W4286296271","doi":"10.1200/jco.2022.40.16_suppl.e20028","title":"Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Dexamethasone; Oncology; Daratumumab; TEC; Gastroenterology; Surgery; Lenalidomide","score_opus":0.18829153612612937,"score_gpt":0.43592106167785666,"score_spread":0.2476295255517273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941525,0.0010972902,0.00022675983,0.0007836182,0.0012798407,0.001994255,0.0002533785,0.000018699408,0.00019364944],"genre_scores_gemma":[0.9930531,0.00058028236,0.005271495,0.000113061156,0.00034232595,0.00017340426,0.000090927766,0.0000583527,0.00031708408],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9930616,0.0012692426,0.003419186,0.00040194156,0.001321708,0.0005263384],"domain_scores_gemma":[0.97742283,0.016468583,0.0040051835,0.00056280335,0.0010698506,0.00047077466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002579539,0.00036080435,0.0029267855,0.00034394386,0.0002101248,0.000009668381,0.00040627952,0.0003173026,0.00026213564],"category_scores_gemma":[0.003499673,0.00020994544,0.0009793807,0.00043800546,0.00043148192,0.000105601706,0.000103411345,0.0011066347,0.000004018505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34912884,0.03556789,0.3130005,0.00012948272,0.005062305,0.00033873957,0.0015153935,0.00026523898,0.00038957837,0.000013770231,0.0010210121,0.29356727],"study_design_scores_gemma":[0.20363455,0.22698642,0.48360127,0.00010431886,0.002195933,0.000051722815,0.0024302942,0.0016672806,0.0012055449,0.000030691728,0.07785342,0.00023856948],"about_ca_topic_score_codex":0.00016920689,"about_ca_topic_score_gemma":0.00037365,"teacher_disagreement_score":0.2933287,"about_ca_system_score_codex":0.0009474826,"about_ca_system_score_gemma":0.001894584,"threshold_uncertainty_score":0.8561327},"labels":[],"label_agreement":null},{"id":"W4286298030","doi":"10.1200/jco.2022.40.16_suppl.8035","title":"Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Population; Oncology; Refractory (planetary science); Clinical trial; Surgery","score_opus":0.17223124497874664,"score_gpt":0.426324916349482,"score_spread":0.25409367137073535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365824,0.00094361394,0.00007679367,0.00082966994,0.0012472572,0.0025141253,0.00037352488,0.000019694524,0.00033707844],"genre_scores_gemma":[0.99551326,0.000836769,0.0022917558,0.00007452577,0.00030243254,0.00022696081,0.00016968684,0.00006294223,0.0005216627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327326,0.0011368787,0.0033493072,0.00044253873,0.0012090667,0.0005889617],"domain_scores_gemma":[0.98217714,0.012089566,0.003967002,0.0006021883,0.0006822002,0.00048188958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015460555,0.0004347385,0.0030760812,0.00036425263,0.00029065777,0.000011322091,0.0003952026,0.00030728534,0.0002564233],"category_scores_gemma":[0.0012737304,0.00024446694,0.0011541191,0.0003648454,0.0003961546,0.000097597695,0.00009144895,0.00076812523,0.000005094439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2723545,0.046711743,0.34102386,0.00008915726,0.0065708295,0.00043142232,0.0016036463,0.0001987346,0.00030819976,0.000022443359,0.00082034257,0.3298651],"study_design_scores_gemma":[0.21071772,0.29753247,0.41464013,0.00008080389,0.0023778167,0.000069895555,0.0020815053,0.00071839406,0.0018210952,0.000022194741,0.06972818,0.0002098048],"about_ca_topic_score_codex":0.00030096935,"about_ca_topic_score_gemma":0.0007600621,"teacher_disagreement_score":0.32965532,"about_ca_system_score_codex":0.0018319489,"about_ca_system_score_gemma":0.00207096,"threshold_uncertainty_score":0.9969072},"labels":[],"label_agreement":null},{"id":"W4286298426","doi":"10.1200/jco.2022.40.16_suppl.8052","title":"Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Daratumumab; Clinical endpoint; Oncology; Dexamethasone; Subgroup analysis; Clinical trial; Confidence interval","score_opus":0.15148787291625726,"score_gpt":0.45750047916652814,"score_spread":0.3060126062502709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675494,0.0007748758,0.000010934652,0.00077076466,0.00026018434,0.00133846,0.000060137238,0.0000070118526,0.000022705643],"genre_scores_gemma":[0.99729264,0.0006836387,0.0011625604,0.00036264086,0.00006815281,0.00013495627,0.00001741909,0.00004296543,0.00023500614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99215215,0.0029263096,0.0027013542,0.00050587876,0.0011960819,0.00051823055],"domain_scores_gemma":[0.9905915,0.0060846615,0.0020450035,0.0004245914,0.0005357735,0.00031843325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004083091,0.0003559451,0.0029422801,0.0012551305,0.00011560828,0.000015844089,0.00028219048,0.00028176626,0.00019473046],"category_scores_gemma":[0.005838659,0.00017648311,0.000280105,0.0022052424,0.00062899635,0.00026259778,0.00020353572,0.0021025632,8.3663446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40631077,0.0070972615,0.547127,0.000039401446,0.0023440244,0.005880752,0.0020480312,0.00020992891,0.000043051707,0.0000010184386,0.000029294935,0.028869454],"study_design_scores_gemma":[0.19120851,0.060782462,0.7439207,0.00025731997,0.0007435882,0.00011399035,0.0011758575,0.0013443754,0.00003703608,0.000007866589,0.00024295,0.00016533061],"about_ca_topic_score_codex":0.0007609,"about_ca_topic_score_gemma":0.020784708,"teacher_disagreement_score":0.21510226,"about_ca_system_score_codex":0.0015722193,"about_ca_system_score_gemma":0.0028973792,"threshold_uncertainty_score":0.9970834},"labels":[],"label_agreement":null},{"id":"W4286298719","doi":"10.1200/jco.2022.40.16_suppl.8019","title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Cohort; Adverse effect; Internal medicine; Gastroenterology; Pharmacology; Oncology; Surgery","score_opus":0.029723395850542424,"score_gpt":0.36360403092387455,"score_spread":0.33388063507333215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975255,0.0001092986,0.000013841218,0.0002201313,0.00030850878,0.0017076614,0.000016724583,0.000008130992,0.000090214264],"genre_scores_gemma":[0.99898285,0.000035989084,0.00057866913,0.000104252314,0.00007979467,0.00007876335,0.00004338922,0.000036508238,0.00005976591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940366,0.0018113981,0.0021269703,0.0003510711,0.001255896,0.0004180354],"domain_scores_gemma":[0.9923871,0.004762371,0.0017291093,0.00029699056,0.00040266773,0.00042171727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024045643,0.00024586543,0.0016968023,0.00062299863,0.00006606964,0.00000764593,0.00021744803,0.00016632784,0.000065024615],"category_scores_gemma":[0.0042310227,0.0001677975,0.00016979456,0.0005385939,0.00021892959,0.00016049232,0.00013996492,0.0017039932,0.0000044802932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07024161,0.042485222,0.85136116,0.00016026828,0.00037708378,0.009438407,0.0003990303,0.00010804703,0.000094266594,0.0000048153024,0.00007841049,0.025251705],"study_design_scores_gemma":[0.12665096,0.105347864,0.76651174,0.0003148128,0.00017819967,0.00003878289,0.00041324325,0.0001890648,0.00008347263,0.0000124288545,0.00014681392,0.00011259333],"about_ca_topic_score_codex":0.00020670175,"about_ca_topic_score_gemma":0.0008144578,"teacher_disagreement_score":0.08484937,"about_ca_system_score_codex":0.0007320188,"about_ca_system_score_gemma":0.001636939,"threshold_uncertainty_score":0.7403097},"labels":[],"label_agreement":null},{"id":"W4286696362","doi":"10.30699/mmlj17.2.1.20","title":"Serum Free Light-chain Assay for the Diagnosis, Management, and Prognosis of Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Modern Medical Laboratory Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Immunoglobulin light chain; Medicine; Heavy chain; Monoclonal; Intensive care medicine; Medical physics; Immunology; Antibody; Monoclonal antibody","score_opus":0.018179460585872127,"score_gpt":0.286256297560263,"score_spread":0.2680768369743909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286696362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96392494,0.008911649,0.0052793045,0.017834414,0.00044098182,0.0027245288,0.00023480286,0.000048822927,0.00060055335],"genre_scores_gemma":[0.9951157,0.001426277,0.002002308,0.0005764193,0.00024051635,0.00021692197,0.00000835255,0.000036479298,0.00037703983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974977,0.00015749052,0.00041471925,0.00026891218,0.0012071094,0.00045409682],"domain_scores_gemma":[0.9977909,0.000726908,0.00015479157,0.0003997338,0.00030070747,0.00062695885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014855543,0.00019159188,0.00038160995,0.000133886,0.00019548167,0.000046328303,0.00032535044,0.00014739414,0.00040852543],"category_scores_gemma":[0.00120074,0.00011191266,0.0001246425,0.00019119316,0.00013404108,0.00010869865,0.00016196271,0.00045773975,0.000014423375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061922,0.00055903126,0.8670329,0.00043921065,0.0010209732,0.00028134714,0.0002318328,0.0000028913862,0.00051623106,0.00025859202,0.009451455,0.119586356],"study_design_scores_gemma":[0.037875097,0.0020846233,0.8210123,0.0015833767,0.0007300542,0.0003403158,0.00076684833,0.03764728,0.0106030945,0.0018772526,0.08498928,0.00049043563],"about_ca_topic_score_codex":0.0000068227937,"about_ca_topic_score_gemma":0.000025652334,"teacher_disagreement_score":0.11909592,"about_ca_system_score_codex":0.00006168888,"about_ca_system_score_gemma":0.0002336079,"threshold_uncertainty_score":0.45636657},"labels":[],"label_agreement":null},{"id":"W4288046493","doi":"10.1038/s41408-022-00706-5","title":"Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Pharmacyclics; Amgen; U.S. Department of Health and Human Services","keywords":"Haematopoiesis; Distribution (mathematics); Biology; Race (biology); Immunology; Plasma cell; Plasma cell neoplasm; Hematology; Internal medicine; Cancer research; Medicine; Stem cell; Genetics; Plasmacytoma; Antibody; Multiple myeloma","score_opus":0.009441518617760419,"score_gpt":0.23951033742045671,"score_spread":0.2300688188026963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288046493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872798,0.00014627991,0.000007502659,0.008866182,0.00012466546,0.00057418447,0.0029435789,0.000007980196,0.000049856182],"genre_scores_gemma":[0.9941812,0.00012076661,0.00009563884,0.0030804388,0.00023794408,0.00006664068,0.0016100626,0.00006779111,0.0005395297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961863,0.00020374387,0.0006459227,0.00034916433,0.002040516,0.0005743287],"domain_scores_gemma":[0.99788254,0.00010273513,0.0011047357,0.00025415214,0.00049293647,0.00016289107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020942303,0.00036744156,0.0009417682,0.0003125668,0.000119585726,0.000025407555,0.00022061417,0.0003117224,0.00083045574],"category_scores_gemma":[0.000049938822,0.0002659169,0.00019164039,0.0003803426,0.00013263003,0.000100461104,0.000080233985,0.0022137403,0.000001228458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01438048,0.0032143642,0.9110579,0.0010421363,0.0039190613,0.005495282,0.00042622548,0.00010063942,0.00022154847,2.9837548e-7,0.058495052,0.0016470321],"study_design_scores_gemma":[0.076628625,0.009988057,0.87352294,0.0031887735,0.0031336502,0.00054925715,0.00009472234,0.00014613656,0.02718364,0.000009025267,0.0048488965,0.00070630293],"about_ca_topic_score_codex":0.00030261674,"about_ca_topic_score_gemma":0.000066962115,"teacher_disagreement_score":0.062248144,"about_ca_system_score_codex":0.0005516484,"about_ca_system_score_gemma":0.0010777264,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W4289223990","doi":"10.1080/2162402x.2022.2104070","title":"Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis","year":2022,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Worldwide Cancer Research; Versus Arthritis; Medical Research Scotland","keywords":"Osteoclast; RANKL; Cancer research; Multiple myeloma; Immune system; Epigenetics; Regulator; Biology; Bone marrow; Cell biology; Signal transduction; Receptor; Immunology; Genetics; Gene; Activator (genetics)","score_opus":0.014935925523961703,"score_gpt":0.2768729583328667,"score_spread":0.26193703280890496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289223990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98610693,0.0019490897,0.00008093119,0.0075513828,0.0002966931,0.0011186567,0.00013880555,0.00010274473,0.0026547827],"genre_scores_gemma":[0.98974365,0.000044196106,0.0010480807,0.0009634672,0.00017095222,0.0006509125,0.00037591442,0.00005618729,0.006946634],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754083,0.0004432547,0.00027976953,0.0004879206,0.00048823628,0.0007599655],"domain_scores_gemma":[0.99875015,0.00026348798,0.00008245787,0.00066564436,0.000070208065,0.00016803158],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022643051,0.00024661564,0.0004168236,0.00017626733,0.0009025157,0.0000163696,0.0004050787,0.00009078317,0.0058506145],"category_scores_gemma":[0.00018628057,0.00017504922,0.00015480992,0.00036398254,0.00020017092,0.00002669387,0.0011788914,0.0005570512,0.00046875316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008719921,0.0008115268,0.04630608,0.00009538402,0.0016182436,0.002566173,0.0046046143,0.0045959977,0.7597667,0.000072378614,0.018842787,0.15200016],"study_design_scores_gemma":[0.011087447,0.004851082,0.15074569,0.00003844455,0.00025561015,0.0029902551,0.001813015,0.0006969993,0.023143394,0.0000341147,0.8037715,0.0005724675],"about_ca_topic_score_codex":0.0002233408,"about_ca_topic_score_gemma":0.00008659309,"teacher_disagreement_score":0.7849287,"about_ca_system_score_codex":0.00056435046,"about_ca_system_score_gemma":0.00018137465,"threshold_uncertainty_score":0.9950582},"labels":[],"label_agreement":null},{"id":"W4289836925","doi":"10.1038/s41408-022-00710-9","title":"Venetoclax ex vivo functional profiling predicts improved progression-free survival","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Winship Cancer Institute; Emory University; Multiple Myeloma Research Foundation; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; American Cancer Society","keywords":"Ex vivo; Venetoclax; Profiling (computer programming); In vivo; Medicine; Oncology; Computational biology; Internal medicine; Biology; Bioinformatics; Cancer research; Leukemia; Computer science; Genetics","score_opus":0.038656709197645085,"score_gpt":0.31966684938514667,"score_spread":0.2810101401875016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289836925","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058219515,0.049962275,0.00020231004,0.83560044,0.024566092,0.010098733,0.005514004,0.0007350681,0.015101539],"genre_scores_gemma":[0.022029612,0.014147959,0.013482368,0.4959159,0.30070797,0.009464448,0.009879764,0.00215522,0.13221677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942407,0.00029962359,0.00067638874,0.00069893524,0.0029170949,0.0011672662],"domain_scores_gemma":[0.9975192,0.00016969227,0.00052511034,0.000739531,0.0004911493,0.00055533194],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057226693,0.00056680833,0.00080580654,0.00040438783,0.000621208,0.00017966364,0.00053638965,0.00052308483,0.011006197],"category_scores_gemma":[0.00032369333,0.00044210785,0.00048682807,0.00029632443,0.000118616765,0.00016110782,0.00036915526,0.0060402644,0.00002198037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018714718,0.00034418883,0.017995656,0.0006273415,0.0034448022,0.01144202,0.000048824346,0.00002000494,0.0017105236,0.0000024303108,0.9558996,0.00659315],"study_design_scores_gemma":[0.022408891,0.0028352924,0.004814675,0.0011416163,0.0019549006,0.0055483254,0.00006128559,0.00042915344,0.0029348747,0.00016022666,0.95700413,0.00070660753],"about_ca_topic_score_codex":0.00012839,"about_ca_topic_score_gemma":0.000018843326,"teacher_disagreement_score":0.33968458,"about_ca_system_score_codex":0.0012707385,"about_ca_system_score_gemma":0.0050245654,"threshold_uncertainty_score":0.99980307},"labels":[],"label_agreement":null},{"id":"W4290879625","doi":"10.1200/jco.21.02815","title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Internal medicine; Dexamethasone; Refractory (planetary science); Clinical endpoint; Multiple myeloma; Hazard ratio; Ixazomib; Progression-free survival; Oncology; Surgery; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval; Carfilzomib","score_opus":0.1882167091889099,"score_gpt":0.47928399839735003,"score_spread":0.29106728920844016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290879625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869807,0.0019355224,0.0011242939,0.006026139,0.001510273,0.0019524888,0.00017691094,0.000013726747,0.00027995804],"genre_scores_gemma":[0.99100643,0.00060313405,0.004650307,0.000981144,0.0015953518,0.00020816892,0.00011821889,0.00002992227,0.00080731564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907555,0.0043209083,0.0030426255,0.0004268579,0.0009838325,0.00047028932],"domain_scores_gemma":[0.9489982,0.04722657,0.00234612,0.00040729548,0.00038263603,0.00063918106],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012984682,0.00026539652,0.0039391206,0.00027349973,0.00047454354,0.000027498,0.0003421758,0.0002685036,0.00082764967],"category_scores_gemma":[0.026242776,0.00015884108,0.002274047,0.00031160068,0.00045706925,0.000109317705,0.00028921195,0.00161665,0.0000032800865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9234996,0.006278227,0.004796439,0.000007569386,0.011854666,0.0007670277,0.0002603142,0.000058569633,0.000078319244,0.00008482899,0.0017828438,0.05053162],"study_design_scores_gemma":[0.90216947,0.03599601,0.01720917,0.0000141603105,0.006775934,0.0000821421,0.0002956259,0.004156029,0.000012458861,0.00040059316,0.032752052,0.00013637052],"about_ca_topic_score_codex":0.0005421002,"about_ca_topic_score_gemma":0.00017816278,"teacher_disagreement_score":0.050395247,"about_ca_system_score_codex":0.0005049942,"about_ca_system_score_gemma":0.0023905158,"threshold_uncertainty_score":0.9819596},"labels":[],"label_agreement":null},{"id":"W4290879690","doi":"10.1200/go.22.00119","title":"Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies","year":2022,"lang":"en","type":"review","venue":"JCO Global Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Hospital","funders":"National Cancer Institute","keywords":"Clinical trial; Medicine; Clinical endpoint; Clinical research; Multiple myeloma; Family medicine; Internal medicine","score_opus":0.18021940368035794,"score_gpt":0.501218724591833,"score_spread":0.3209993209114751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290879690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013800103,0.97585523,0.000005129215,0.00084148056,0.0003671586,0.0035267104,0.0004173077,0.000018010873,0.005168896],"genre_scores_gemma":[0.009964511,0.9882186,0.00012999718,0.00020899903,0.00020470253,0.0009658996,0.0002633538,0.000012275321,0.000031640953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729776,0.000783791,0.0006711976,0.0003748162,0.00048488498,0.0003875336],"domain_scores_gemma":[0.9985093,0.0006214137,0.0003563983,0.0003505643,0.000045031215,0.000117313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006692216,0.00028222342,0.0015769863,0.00006525075,0.00007459194,0.000029541383,0.00037136386,0.00022617064,0.00019834685],"category_scores_gemma":[0.00037425803,0.00016824114,0.00026143607,0.0007043339,0.00018134502,0.00006767514,0.0002560438,0.0003961888,0.0000056880863],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046525607,0.001505733,0.0018627767,0.0012909651,0.0003729663,0.00019239675,0.00011793224,4.0062903e-7,4.0927972e-8,0.0006380069,0.00064271555,0.9887235],"study_design_scores_gemma":[0.029969515,0.0017969997,0.01272339,0.0005427247,0.00069376343,0.00016494235,0.00010135647,0.000011693961,5.87474e-8,0.00011057512,0.953756,0.00012901358],"about_ca_topic_score_codex":0.00088808604,"about_ca_topic_score_gemma":0.0010362333,"teacher_disagreement_score":0.9885945,"about_ca_system_score_codex":0.001023053,"about_ca_system_score_gemma":0.0011933933,"threshold_uncertainty_score":0.68606746},"labels":[],"label_agreement":null},{"id":"W4292411599","doi":"10.1016/j.esmoop.2022.100562","title":"Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; PharmaMar; Servier; Astellas Pharma; Eisai; Incyte; Seagen; Gilead Sciences; Ipsen; BeiGene; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Adverse effect; Tolerability; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.049488667941219096,"score_gpt":0.38240333920553315,"score_spread":0.33291467126431407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292411599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858233,0.000024781999,0.0000016438554,0.00041584938,0.00008967653,0.009768686,0.0010946033,0.000032156488,0.0027493392],"genre_scores_gemma":[0.9928691,0.0000038950884,0.0011995119,0.000301548,0.000025781661,0.0014663573,0.0022676103,0.000059450773,0.001806793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967564,0.00030698304,0.00056743925,0.0008980584,0.0008562973,0.00061482465],"domain_scores_gemma":[0.9983233,0.00010583836,0.00019603547,0.0009360426,0.00012434705,0.0003144237],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038250306,0.0003092305,0.0007382605,0.00017116246,0.00045795873,0.00015969426,0.00106901,0.00003390767,0.00095532526],"category_scores_gemma":[0.0002179458,0.0002425758,0.000029312449,0.00042521392,0.000050484356,0.00052732386,0.0032570846,0.00047905606,0.00007372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42935508,0.14919533,0.3347297,0.000027044644,0.0012021692,0.0054607242,0.01286879,0.00012132314,0.00008097537,0.0000062004046,0.003895324,0.06305736],"study_design_scores_gemma":[0.574192,0.028301252,0.38989156,0.00017771781,0.00008293458,0.000003788053,0.0021624654,0.0011297942,0.00019807281,0.0000125034485,0.003517066,0.00033086012],"about_ca_topic_score_codex":0.017718546,"about_ca_topic_score_gemma":0.0023712679,"teacher_disagreement_score":0.14483692,"about_ca_system_score_codex":0.00071395806,"about_ca_system_score_gemma":0.00039482405,"threshold_uncertainty_score":0.9999579},"labels":[],"label_agreement":null},{"id":"W4292497528","doi":"10.58931/cht.2022.119","title":"To transplant or not to transplant in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Transplantation; Autologous stem-cell transplantation; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Stem cell; Surgery; Chemotherapy","score_opus":0.038293469552183476,"score_gpt":0.2977335464162181,"score_spread":0.2594400768640346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292497528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98016155,0.000086579355,0.000042343177,0.015967593,0.00019589397,0.00149381,0.00092463486,0.000043856606,0.0010837364],"genre_scores_gemma":[0.99051994,0.000009511258,0.0004983043,0.0062728203,0.00002895344,0.00061466714,0.00018902725,0.00003771208,0.0018290381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976926,0.00012947175,0.00032873603,0.0005018005,0.00030121472,0.0010462033],"domain_scores_gemma":[0.9974685,0.00019055339,0.000020327923,0.0003879692,0.000032735654,0.0018999304],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021432329,0.00022008497,0.0005162527,0.0009073303,0.00024233466,0.000010003662,0.00024100936,0.0000964124,0.0026003015],"category_scores_gemma":[0.00013094024,0.00019433175,0.00008162297,0.000605926,0.00003978326,0.000029869998,0.00003105867,0.00035796702,0.0003701957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105674155,0.0005397587,0.84603363,0.00025064687,0.00030721867,0.09672796,0.010622182,0.0001854344,0.0036027322,0.0012734426,0.017626142,0.012263415],"study_design_scores_gemma":[0.014179418,0.0029884872,0.7846777,0.0003270315,0.00011632518,0.0101815965,0.001361471,0.00090007903,0.013804138,0.00003956883,0.17047566,0.00094853196],"about_ca_topic_score_codex":0.06564486,"about_ca_topic_score_gemma":0.6256551,"teacher_disagreement_score":0.56001025,"about_ca_system_score_codex":0.0006797626,"about_ca_system_score_gemma":0.0011102475,"threshold_uncertainty_score":0.99831146},"labels":[],"label_agreement":null},{"id":"W4292674947","doi":"10.1016/j.cell.2022.06.048","title":"Epigenetic reader SP140 loss of function drives Crohn’s disease due to uncontrolled macrophage topoisomerases","year":2022,"lang":"en","type":"article","venue":"Cell","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Harvard Stem Cell Institute; National Institutes of Health; Canada Foundation for Innovation; University of California Berkeley; University of Massachusetts Medical School; Massachusetts Institute of Technology; National Institute of Diabetes and Digestive and Kidney Diseases; Kenneth Rainin Foundation; Massachusetts General Hospital","keywords":"Biology; Epigenetics; Immune system; Chromatin; Loss function; Bromodomain; Genetics; Cancer research; Cell biology; Gene; Phenotype","score_opus":0.01453923271229509,"score_gpt":0.268478244606234,"score_spread":0.2539390118939389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292674947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950414,0.0015376614,0.00018211329,0.0005441063,0.00016679779,0.00089962326,0.000112687165,0.000029916519,0.0014857505],"genre_scores_gemma":[0.9885177,0.000035560195,0.00015953768,0.00026988902,0.00008410878,0.00021557814,0.00010555187,0.000022940118,0.010589114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987194,0.00010431356,0.00020766242,0.00027146455,0.00040859883,0.0002885894],"domain_scores_gemma":[0.9990182,0.000083989406,0.00005311408,0.00034873193,0.00006673596,0.0004292324],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000090240654,0.0001302311,0.0002791457,0.00014985967,0.00013602423,0.000009460268,0.00008843544,0.000020658736,0.0027963296],"category_scores_gemma":[0.00008098127,0.0001104455,0.00012525561,0.00021337086,0.00004709029,0.000027246995,0.00010328549,0.000120533536,0.00013226381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07164071,0.0122740315,0.5379457,0.001982161,0.0014423917,0.035696816,0.0028707937,0.002930345,0.24213521,0.00016322106,0.019699698,0.07121893],"study_design_scores_gemma":[0.0101704085,0.0014434742,0.9592909,0.00003146019,0.00023379628,0.000020687987,0.0004469815,0.0003475546,0.02023625,0.0001560895,0.0074402867,0.00018208809],"about_ca_topic_score_codex":0.0001130963,"about_ca_topic_score_gemma":0.000010539647,"teacher_disagreement_score":0.42134523,"about_ca_system_score_codex":0.00010841774,"about_ca_system_score_gemma":0.000134999,"threshold_uncertainty_score":0.99811524},"labels":[],"label_agreement":null},{"id":"W4293107714","doi":"10.1016/s2152-2650(22)00591-2","title":"P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Attrition; Internal medicine; Medicine; Oncology; Myeloma protein; Dentistry","score_opus":0.13385913341498837,"score_gpt":0.41054080873491755,"score_spread":0.27668167531992915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293107714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876787,0.0014604424,0.000016440143,0.002574705,0.00039779072,0.0028392277,0.0006060021,0.00019951804,0.0042271623],"genre_scores_gemma":[0.98917514,0.0004868077,0.00093260803,0.00069255853,0.0005583586,0.0020911752,0.002772897,0.0001592767,0.00313116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98714805,0.0029884244,0.0022639153,0.0023291947,0.00231869,0.002951715],"domain_scores_gemma":[0.9913259,0.0029734091,0.0003244885,0.002046466,0.00050760014,0.0028221428],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004341008,0.00085420616,0.0021722221,0.0037301423,0.0017039619,0.00019454092,0.00086951075,0.00058905367,0.0023051412],"category_scores_gemma":[0.0022497925,0.0008001614,0.0014497496,0.00662555,0.0008165044,0.00030272215,0.000591691,0.0013291256,0.0007661972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035124084,0.0021460825,0.627881,0.000056647765,0.0020638409,0.007860613,0.0003366396,0.00009381325,0.00039461252,0.00026104317,0.0025720343,0.3528213],"study_design_scores_gemma":[0.017415253,0.003975259,0.92616695,0.00008263263,0.00059747626,0.00023759365,0.00088843366,0.010728055,0.00032636017,0.0002970555,0.038645755,0.0006391598],"about_ca_topic_score_codex":0.18323658,"about_ca_topic_score_gemma":0.2706521,"teacher_disagreement_score":0.35218212,"about_ca_system_score_codex":0.01987467,"about_ca_system_score_gemma":0.0060187606,"threshold_uncertainty_score":0.9996162},"labels":[],"label_agreement":null},{"id":"W4293147782","doi":"10.1055/s-0042-1747713","title":"Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR","year":2022,"lang":"en","type":"article","venue":"Pneumologie","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Exacerbation; Corticosteroid; Computer science; Medicine; Intensive care medicine; Internal medicine","score_opus":0.042552601879859916,"score_gpt":0.341194797656071,"score_spread":0.2986421957762111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293147782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839604,0.00008058854,7.816533e-7,0.00022188961,0.00010561104,0.0007367321,0.000030049558,0.00004340331,0.0003849151],"genre_scores_gemma":[0.999117,0.000011932771,0.000030639305,0.000064742606,0.0000058832634,0.0001675751,0.00010987387,0.000015546544,0.00047680366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998519,0.00036539632,0.0002469066,0.00023195024,0.00036730335,0.00026944635],"domain_scores_gemma":[0.99891394,0.0006163737,0.000069384034,0.0002813472,0.000023778548,0.000095199364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034843836,0.00011948832,0.00030358278,0.00016168057,0.000056026045,0.0000066447183,0.00008939429,0.000045025638,0.0003639774],"category_scores_gemma":[0.00076451077,0.00009242966,0.00007320241,0.00023470623,0.000052321033,0.000046591133,0.00010629751,0.0003166543,0.00005193993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031064446,0.00068476505,0.94910866,0.00007306398,0.00010209995,0.0012580716,0.0000786028,0.00016151124,0.017291173,0.00003876011,0.00014999778,0.027946828],"study_design_scores_gemma":[0.010483827,0.013259973,0.94592893,0.00006785162,0.000057274217,0.00010432403,0.000043902568,0.0009880377,0.02857985,0.000055617198,0.00030022187,0.00013019436],"about_ca_topic_score_codex":0.00021797542,"about_ca_topic_score_gemma":0.000010652688,"teacher_disagreement_score":0.027816633,"about_ca_system_score_codex":0.00026543275,"about_ca_system_score_gemma":0.00007082303,"threshold_uncertainty_score":0.3985297},"labels":[],"label_agreement":null},{"id":"W4293524905","doi":"10.3390/curroncol29090490","title":"Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathology; Plasma cell; Dermatology; Bioinformatics; Biology","score_opus":0.2410850786478531,"score_gpt":0.519466017772785,"score_spread":0.2783809391249319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293524905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986415,0.0004330873,0.00003165403,0.00092479034,0.0008177681,0.0004408633,0.000059113714,0.00002425203,0.010853425],"genre_scores_gemma":[0.9977631,0.0002300815,0.0005814712,0.00005380224,0.000109884415,0.00012948403,0.00013140039,0.000011349066,0.000989418],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985765,0.0002687263,0.0003778854,0.00022826031,0.00029722185,0.00025138212],"domain_scores_gemma":[0.99904823,0.0002909898,0.00012304723,0.00021232438,0.00008524916,0.00024015104],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002595419,0.00009045962,0.00029036822,0.00013582828,0.0001587007,0.000002516244,0.00011112786,0.00004802637,0.0015910657],"category_scores_gemma":[0.00021296527,0.00008147155,0.00013964767,0.00015937121,0.00012475415,0.000020677835,0.00016848366,0.00047165903,0.00021001759],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036358547,0.011990134,0.4563472,0.00021678183,0.00018637652,0.002318057,0.0003843454,0.000020827241,0.0009666369,0.0011600074,0.02403031,0.49874347],"study_design_scores_gemma":[0.012766423,0.01613299,0.34653798,0.00003775434,0.00023544437,0.0011990326,0.00094624463,0.001128502,0.00061124575,0.00029975674,0.6199594,0.00014522256],"about_ca_topic_score_codex":0.000030330037,"about_ca_topic_score_gemma":0.000017133623,"teacher_disagreement_score":0.5959291,"about_ca_system_score_codex":0.00021245165,"about_ca_system_score_gemma":0.0009173175,"threshold_uncertainty_score":0.99932164},"labels":[],"label_agreement":null},{"id":"W4293915832","doi":"10.1002/jha2.559","title":"Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont; McGill University; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; Canadian Apheresis Group; University of Saskatchewan; Université de Montréal; University of Alberta; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; Ottawa Regional Cancer Foundation","funders":"Amgen Canada; Amgen","keywords":"Carfilzomib; Multiple myeloma; Medicine; Oncology; Internal medicine; Database; Lenalidomide; Computer science","score_opus":0.052499326878677435,"score_gpt":0.3199260177462836,"score_spread":0.2674266908676062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293915832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336505,0.0001299586,0.000018185021,0.0015948405,0.00013780098,0.0018472067,0.0025632316,0.000032532767,0.00031116552],"genre_scores_gemma":[0.99319047,0.000007963306,0.0009413877,0.00026782407,0.00006235055,0.00050418364,0.0043294453,0.000040100716,0.0006562843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960116,0.00043606854,0.00038335822,0.0007301342,0.001605493,0.00083333795],"domain_scores_gemma":[0.99777234,0.00049751526,0.00008156636,0.0008631435,0.00017695683,0.00060848345],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0010331881,0.00027345802,0.00039841022,0.00037391478,0.0013271221,0.00007260857,0.00028645954,0.00007165273,0.00039961882],"category_scores_gemma":[0.00088896166,0.00017330912,0.00006692684,0.00048328916,0.0003056406,0.00017886094,0.000425964,0.0010291316,0.000027625045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008044472,0.000612072,0.9878769,0.000017378612,0.0001818617,0.006457503,0.00070500036,0.000007106439,0.00003930272,0.000031573592,0.0005851942,0.0026816488],"study_design_scores_gemma":[0.012621853,0.0003925939,0.981256,0.00006556398,0.000031036467,0.00008118135,0.00057063927,0.0004893298,0.000024606647,0.000009668699,0.0042780773,0.00017944294],"about_ca_topic_score_codex":0.5354039,"about_ca_topic_score_gemma":0.78391504,"teacher_disagreement_score":0.24851114,"about_ca_system_score_codex":0.001145855,"about_ca_system_score_gemma":0.0009044919,"threshold_uncertainty_score":0.999973},"labels":[],"label_agreement":null},{"id":"W4294843065","doi":"10.1177/10781552221103551","title":"Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Lenalidomide; Adverse effect; Multiple myeloma; Internal medicine; Expanded access; Oncology","score_opus":0.03477357326497679,"score_gpt":0.37979663970437233,"score_spread":0.3450230664393955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294843065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98564506,0.00077098055,0.000121009114,0.010655876,0.00027219136,0.00064558,0.00014578356,0.000011942579,0.0017315567],"genre_scores_gemma":[0.98594254,0.00016488614,0.0084876,0.004900597,0.00014871075,0.000034299832,0.000045731405,0.000031414605,0.00024423745],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752086,0.0005014581,0.00048064496,0.00027852374,0.0008741985,0.00034432398],"domain_scores_gemma":[0.9969188,0.0012527046,0.00063085445,0.00018381707,0.00042645182,0.00058739714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006385954,0.00019017611,0.00046803502,0.00020085827,0.0003587621,0.00003813457,0.00017870973,0.000038138136,0.0007757361],"category_scores_gemma":[0.0010370234,0.00014567649,0.00006572437,0.00022782742,0.00003778702,0.0006420666,0.0002090322,0.0010709424,0.000023033825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09820741,0.006539627,0.5287045,0.000030285204,0.002803932,0.0031325587,0.003163865,0.000026330905,0.016309973,0.0000020723962,0.08760268,0.2534767],"study_design_scores_gemma":[0.044751137,0.0067843217,0.10189048,0.00003667298,0.0006681828,0.0010126097,0.0006582679,0.0004018695,0.00177651,0.000008053744,0.84184706,0.00016480501],"about_ca_topic_score_codex":0.0002546825,"about_ca_topic_score_gemma":0.000013533855,"teacher_disagreement_score":0.7542444,"about_ca_system_score_codex":0.00056285696,"about_ca_system_score_gemma":0.00049716874,"threshold_uncertainty_score":0.8493767},"labels":[],"label_agreement":null},{"id":"W4296180542","doi":"10.1016/j.jcjo.2022.08.011","title":"Paraproteinemic keratopathy: recognizing the ocular significance","year":2022,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; Western University","funders":"","keywords":"Ophthalmology; Medicine; Dermatology","score_opus":0.054143933742375756,"score_gpt":0.30072579662020144,"score_spread":0.24658186287782569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296180542","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26059824,0.012228907,0.000005719555,0.70626897,0.0019688988,0.0013932451,0.00021031457,0.000007932033,0.01731779],"genre_scores_gemma":[0.8755833,0.00006128915,0.0003176577,0.10447961,0.004984105,0.00013846676,0.0002951533,0.00014650573,0.0139939375],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974242,0.00049413607,0.00053864194,0.0002819507,0.00047060128,0.0007904758],"domain_scores_gemma":[0.99793535,0.00025210352,0.0004330835,0.00048977847,0.00031053173,0.0005791371],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000576267,0.00028617692,0.00067690836,0.0005361639,0.00033730757,0.000039249262,0.00053628307,0.00039396877,0.009732106],"category_scores_gemma":[0.00053219066,0.00019970261,0.00035102575,0.0002833133,0.00026579507,0.000048687394,0.000031744552,0.004040369,0.00006553846],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010684527,0.000013281208,0.020125464,0.00007193662,0.00043883806,0.66267097,0.00008028119,0.0000037753268,0.00004242915,0.000003338673,0.3159211,0.0005217258],"study_design_scores_gemma":[0.0009116087,0.0011477185,0.0047094696,0.00010055406,0.00016936057,0.4183708,0.000060127102,0.000005461167,0.000078445184,0.0001291047,0.57415223,0.00016510337],"about_ca_topic_score_codex":0.0049726428,"about_ca_topic_score_gemma":0.000054397162,"teacher_disagreement_score":0.61498505,"about_ca_system_score_codex":0.0006375334,"about_ca_system_score_gemma":0.005564387,"threshold_uncertainty_score":0.99825734},"labels":[],"label_agreement":null},{"id":"W4296529456","doi":"10.1016/s2152-2650(22)01102-8","title":"Poster: MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to ALL-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Lenalidomide; Dexamethasone; Ixazomib; Induction therapy; Bortezomib; Medicine; Oncology; Internal medicine; Multiple myeloma; Chemotherapy","score_opus":0.07614721502983941,"score_gpt":0.37314232684239695,"score_spread":0.29699511181255756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894147,0.00014467219,0.000058718044,0.0006961605,0.0004785555,0.008792196,0.00033537784,0.00003755406,0.000042089574],"genre_scores_gemma":[0.9942513,0.000025289615,0.00025386707,0.0016595504,0.00007476382,0.0031495367,0.00049917103,0.000078203906,0.00000829217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98714834,0.0070960843,0.0019316243,0.0011029362,0.0019787154,0.0007423084],"domain_scores_gemma":[0.99402857,0.0029986075,0.00061731297,0.00095093175,0.0009879691,0.0004165813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004390095,0.0005923063,0.0018024016,0.00068174425,0.00013830149,0.000035033914,0.00047783335,0.00029263212,0.000150277],"category_scores_gemma":[0.0013762722,0.00047635057,0.00063399336,0.0014669717,0.000258119,0.00019922016,0.0001318288,0.0005596173,0.000012851742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13604142,0.0039009273,0.7018035,0.00009329829,0.00034665837,0.000053506858,0.0021345532,0.0036363967,0.005935052,0.0000019489746,0.00010065358,0.14595208],"study_design_scores_gemma":[0.08913777,0.0067544435,0.8608533,0.00070714415,0.00010847389,0.000003236691,0.00023365031,0.010025857,0.031676438,0.000032465556,0.00011582386,0.00035140166],"about_ca_topic_score_codex":0.0014302955,"about_ca_topic_score_gemma":0.0006844632,"teacher_disagreement_score":0.1590498,"about_ca_system_score_codex":0.00306751,"about_ca_system_score_gemma":0.0017593172,"threshold_uncertainty_score":0.9997688},"labels":[],"label_agreement":null},{"id":"W4296530176","doi":"10.1016/s2152-2650(22)01456-2","title":"MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Anemia; Phases of clinical research; Fibrosis; Extramedullary hematopoiesis; Surgery; Bone marrow; Clinical trial; Haematopoiesis; Stem cell","score_opus":0.050845993663231476,"score_gpt":0.3320740202494757,"score_spread":0.28122802658624424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296530176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98708814,0.000073686824,0.000006587828,0.0016392539,0.00026212406,0.007661905,0.0027161215,0.00024561505,0.00030657285],"genre_scores_gemma":[0.9896997,0.000010049644,0.0021902039,0.0013390447,0.0005465692,0.0013678046,0.003433396,0.0002984722,0.0011147371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872471,0.0027319398,0.0020314034,0.0028713457,0.00326745,0.0018507474],"domain_scores_gemma":[0.9874219,0.005441955,0.00063042546,0.0044843983,0.0005084155,0.0015129221],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028172699,0.0011628337,0.0018822122,0.00042143578,0.0009630996,0.00024324899,0.0020188878,0.0002644894,0.00056112383],"category_scores_gemma":[0.0018633275,0.0006869888,0.0002037592,0.0018358737,0.00077827036,0.0005341234,0.0028239738,0.0013199046,0.00022499815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38051194,0.006233795,0.58944845,0.00004169438,0.0006506159,0.0047319434,0.00069571426,0.00002454472,0.000021879665,0.000006356866,0.0032474333,0.014385619],"study_design_scores_gemma":[0.06947618,0.07887579,0.84329087,0.0005303151,0.0005193849,0.00018485762,0.0033045157,0.00030682652,0.000057266727,0.0000075991825,0.002640174,0.00080625725],"about_ca_topic_score_codex":0.0018602333,"about_ca_topic_score_gemma":0.001197379,"teacher_disagreement_score":0.31103575,"about_ca_system_score_codex":0.0020491632,"about_ca_system_score_gemma":0.0043673147,"threshold_uncertainty_score":0.99955815},"labels":[],"label_agreement":null},{"id":"W4296532123","doi":"10.1016/s2152-2650(22)01095-3","title":"Poster: MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Carfilzomib; Dexamethasone; Multiple myeloma; Psychology; Medicine; Internal medicine; Bortezomib","score_opus":0.04094230007902169,"score_gpt":0.3441232329738066,"score_spread":0.30318093289478487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962655,0.0010662619,0.000025972364,0.00039811246,0.00015020861,0.0011607215,0.00036990317,0.000077062265,0.00048627492],"genre_scores_gemma":[0.99630195,0.00013192924,0.0019265622,0.0002507376,0.000056233726,0.0001474085,0.00044342777,0.00008078587,0.0006609852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99195987,0.0022180665,0.0024885526,0.0012011844,0.0012502973,0.00088203343],"domain_scores_gemma":[0.9925643,0.004174593,0.0007926699,0.0014276676,0.0003462572,0.00069451873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034452002,0.0005187737,0.0025375308,0.0013109988,0.00019273408,0.000022137638,0.000497855,0.00038645588,0.00037906182],"category_scores_gemma":[0.0043502045,0.00048253225,0.00083170435,0.0029807864,0.0007692325,0.000118838914,0.00080748287,0.0006498717,0.000020124085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06670621,0.0015282911,0.8183306,0.000147647,0.0025267703,0.0016411447,0.0005955393,0.00014259748,0.0070674033,0.00002689885,0.00036053368,0.10092639],"study_design_scores_gemma":[0.0394988,0.002704774,0.9413657,0.000083503015,0.0010393524,0.00016255816,0.0005052926,0.009481134,0.0042239157,0.000038767826,0.0005414187,0.0003547446],"about_ca_topic_score_codex":0.0017856981,"about_ca_topic_score_gemma":0.0005177116,"teacher_disagreement_score":0.12303517,"about_ca_system_score_codex":0.0017906772,"about_ca_system_score_gemma":0.0022512781,"threshold_uncertainty_score":0.99976265},"labels":[],"label_agreement":null},{"id":"W4296781602","doi":"10.1111/jvim.16540","title":"Spurious laboratory results associated with immunoglobulin M gammopathy in a dog with multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Journal of Veterinary Internal Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Paraproteinemia; Azotemia; Serum protein electrophoresis; Pathology; Multiple myeloma; Plasma cell dyscrasia; Serology; Gastroenterology; Internal medicine; Immunology; Antibody; Monoclonal; Monoclonal antibody","score_opus":0.02604723539582103,"score_gpt":0.31126853793103126,"score_spread":0.2852213025352102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296781602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952754,0.0011577256,0.00004364004,0.002025215,0.00024468522,0.00039181046,0.00007592606,0.000021595633,0.00076401344],"genre_scores_gemma":[0.99829006,0.00009886772,0.0004211222,0.0003417052,0.00023410139,0.000031549058,0.000038854323,0.000045100296,0.0004986103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964949,0.00036436346,0.0009292046,0.0002791381,0.0014682879,0.00046413217],"domain_scores_gemma":[0.9978018,0.00039099195,0.00072467775,0.00031113173,0.00039817576,0.00037323716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011848533,0.00028832475,0.0008104386,0.00065424753,0.00011068873,0.000014414002,0.0003116724,0.000053826134,0.0002522981],"category_scores_gemma":[0.0008768504,0.0001774984,0.000091955495,0.0006665304,0.00020573851,0.00015862737,0.0001315382,0.0011730889,0.0000043290884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19747767,0.0034086264,0.4661587,0.00013299756,0.0019258757,0.28201687,0.0037418208,0.0002516522,0.03142575,0.000003823709,0.002698708,0.01075751],"study_design_scores_gemma":[0.06973166,0.12568699,0.7593793,0.003506955,0.00020545404,0.029654665,0.0022024107,0.00043007362,0.00072557793,0.000010185773,0.008187511,0.00027920437],"about_ca_topic_score_codex":0.00027273488,"about_ca_topic_score_gemma":0.00006094616,"teacher_disagreement_score":0.2932206,"about_ca_system_score_codex":0.0008394184,"about_ca_system_score_gemma":0.00040526476,"threshold_uncertainty_score":0.72381747},"labels":[],"label_agreement":null},{"id":"W4296965640","doi":"10.1016/s2152-2650(22)01601-9","title":"MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Medicine; Internal medicine; Carfilzomib; Clinical endpoint; Multiple myeloma; Dexamethasone; Oncology; Nuclear medicine; Gastroenterology; Surgery; Randomized controlled trial; Lenalidomide","score_opus":0.04308698812435666,"score_gpt":0.34772240567931995,"score_spread":0.30463541755496326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964775,0.0010529527,0.000049100046,0.00032984104,0.0001438684,0.0010978675,0.000312562,0.00007720428,0.0004591484],"genre_scores_gemma":[0.99517393,0.00014558388,0.0030911195,0.00020006415,0.0000579487,0.00016287604,0.00038751445,0.000077442965,0.00070352637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99209934,0.002156624,0.0024337685,0.001182929,0.0012589077,0.0008684526],"domain_scores_gemma":[0.99242896,0.004382256,0.00077328744,0.0013973056,0.00033095296,0.00068723474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036658908,0.00050142885,0.002525553,0.0012864544,0.00019533403,0.000019602803,0.00048361922,0.00038011334,0.00041743365],"category_scores_gemma":[0.0051110126,0.0004673914,0.000819737,0.0032265722,0.00080895936,0.000109554945,0.00073575607,0.0006574007,0.000019323475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062495414,0.0016673872,0.80434203,0.0001506163,0.0027009335,0.0015983239,0.0005549884,0.00029935507,0.0068557677,0.0000475344,0.00048454653,0.1188031],"study_design_scores_gemma":[0.03845872,0.0022547957,0.93516356,0.00007442767,0.0010147309,0.00011975177,0.00058628793,0.017597534,0.0036273326,0.000052293202,0.00070900336,0.00034155592],"about_ca_topic_score_codex":0.0018500054,"about_ca_topic_score_gemma":0.00051850866,"teacher_disagreement_score":0.13082154,"about_ca_system_score_codex":0.0018337689,"about_ca_system_score_gemma":0.002408908,"threshold_uncertainty_score":0.9997778},"labels":[],"label_agreement":null},{"id":"W4297100560","doi":"10.1002/jha2.574","title":"Aberrant expression of cytokeratin in plasma cell neoplasms: A pitfall for diagnostic errors","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Cytokeratin; Pathology; Expression (computer science); Plasma cell; Medicine; Immunohistochemistry; Computer science","score_opus":0.025660107102862133,"score_gpt":0.2948468456899351,"score_spread":0.2691867385870729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297100560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972395,0.00022731502,0.000053942487,0.00031427282,0.00008479106,0.0011203404,0.0001096041,0.000020637817,0.0008296137],"genre_scores_gemma":[0.9954309,0.000021006617,0.0019023033,0.000053560874,0.000029489762,0.00070846285,0.00012171854,0.000022711756,0.0017098524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877363,0.00007633874,0.00025850962,0.00023520691,0.0003516438,0.00030467618],"domain_scores_gemma":[0.9989052,0.00063676544,0.000069106056,0.00022603231,0.000035369587,0.00012755583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018459804,0.00011794832,0.00026840676,0.0001553878,0.00009367448,0.0000048173465,0.00009650722,0.000034267636,0.000397384],"category_scores_gemma":[0.0003652729,0.000099897115,0.000074790034,0.00015785395,0.000030823558,0.000036467947,0.000101453166,0.00018376565,0.000015499967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009809833,0.008279364,0.41131616,0.0015731388,0.00016574428,0.0023992343,0.011019354,0.002362713,0.5005832,0.000122026475,0.03350326,0.018866016],"study_design_scores_gemma":[0.04416183,0.006919086,0.10900723,0.00039207196,0.0001264017,0.000119451586,0.004916467,0.021185683,0.79140884,0.00016546473,0.021111792,0.00048566362],"about_ca_topic_score_codex":0.00023045269,"about_ca_topic_score_gemma":0.00011780838,"teacher_disagreement_score":0.30230892,"about_ca_system_score_codex":0.00013618787,"about_ca_system_score_gemma":0.00014355278,"threshold_uncertainty_score":0.43510762},"labels":[],"label_agreement":null},{"id":"W4297237848","doi":"10.1002/cam4.5245","title":"Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; Dalhousie University; McGill University; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; Canadian Apheresis Group; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation; Université de Montréal; University of Saskatchewan; University of Alberta; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Celgene","keywords":"Lenalidomide; Multiple myeloma; Medicine; Dosing; Dexamethasone; Internal medicine; Oncology","score_opus":0.10841482058669892,"score_gpt":0.3831136186323534,"score_spread":0.27469879804565445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297237848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677704,0.0005962361,9.617883e-7,0.023195375,0.00020988475,0.0019164844,0.005167602,0.000031609376,0.0011114747],"genre_scores_gemma":[0.9892132,0.00036670122,0.00019146912,0.0015758378,0.0003377301,0.0003815242,0.0074166786,0.000058372894,0.00045844074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950245,0.0005983963,0.00049986626,0.0010463025,0.0018869387,0.0009439835],"domain_scores_gemma":[0.9943671,0.002684381,0.00013753228,0.0018508913,0.00017261684,0.00078743364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019493458,0.00031251967,0.0006214691,0.0006532216,0.0008937663,0.000044064884,0.0006469924,0.000042217365,0.00021788952],"category_scores_gemma":[0.0023027074,0.00018453559,0.000025969533,0.0011838757,0.00063654257,0.00016643245,0.0005488796,0.0011928543,0.000009038355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008060821,0.00028444093,0.94540936,0.000025188618,0.00019675205,0.0011132372,0.0012987668,0.000010948902,0.00007015118,0.00003259099,0.018026695,0.025471035],"study_design_scores_gemma":[0.036308836,0.0012339858,0.9458649,0.00055534585,0.0000763578,0.0000035666658,0.0012546882,0.0005969441,0.00002957926,0.000013465416,0.013889831,0.00017248718],"about_ca_topic_score_codex":0.8874051,"about_ca_topic_score_gemma":0.9598052,"teacher_disagreement_score":0.07240012,"about_ca_system_score_codex":0.0016189608,"about_ca_system_score_gemma":0.00090139493,"threshold_uncertainty_score":0.7525143},"labels":[],"label_agreement":null},{"id":"W4297884240","doi":"10.21203/rs.3.rs-2058259/v1","title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Minimal residual disease; Residual; Multiple myeloma; Medicine; Oncology; Internal medicine; Computer science; Algorithm; Bone marrow","score_opus":0.12988744024299945,"score_gpt":0.3920470768077536,"score_spread":0.26215963656475416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297884240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936128,0.0011766553,0.000010104849,0.0002650816,0.00004290409,0.0019844405,0.0025759784,0.00002845274,0.0003035714],"genre_scores_gemma":[0.98179305,0.0013943507,0.00037611023,0.000012853686,0.00006914522,0.0005040456,0.015536592,0.000043363947,0.00027050124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99409974,0.0011057402,0.00068448205,0.00097442645,0.002345486,0.0007901534],"domain_scores_gemma":[0.99741644,0.00031034884,0.00013028846,0.00074952946,0.0007156626,0.0006777124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013745506,0.00033806922,0.0008832338,0.0034221848,0.00021204424,0.00011166063,0.00026461165,0.0001425541,0.0007174844],"category_scores_gemma":[0.0007372743,0.00029574838,0.00025295062,0.0020681405,0.00021687962,0.00011638223,0.00054916024,0.0014830322,0.000004679492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033678722,0.0008625774,0.978932,0.0017103597,0.0015488697,0.0018304795,0.0014419275,0.00082157686,0.0030875236,0.000033276217,0.00025803296,0.006105489],"study_design_scores_gemma":[0.0028252813,0.00082330866,0.9320327,0.0007910844,0.0006378879,0.0000037779753,0.0010297523,0.060677435,0.0008124174,0.00004130723,0.000079640085,0.00024541316],"about_ca_topic_score_codex":0.007516657,"about_ca_topic_score_gemma":0.0028469567,"teacher_disagreement_score":0.059855856,"about_ca_system_score_codex":0.0013646698,"about_ca_system_score_gemma":0.0020424589,"threshold_uncertainty_score":0.99994946},"labels":[],"label_agreement":null},{"id":"W4298143191","doi":"10.1002/jha2.572","title":"Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Alberta; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Dalhousie University; University of Calgary; Institute of Cancer Research; Vancouver General Hospital; CancerCare Manitoba","funders":"Karyopharm Therapeutics","keywords":"Multiple myeloma; Chimeric antigen receptor; Medicine; Antigen; Oncology; Antibody; Immunology; Internal medicine; T cell; Pharmacology; Immune system","score_opus":0.011667212519135682,"score_gpt":0.24987602520445354,"score_spread":0.23820881268531785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298143191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973065,0.00013149362,0.000020936306,0.00033187872,0.000067756904,0.001674494,0.00011521135,0.000060102917,0.00029159896],"genre_scores_gemma":[0.99580204,0.000009338503,0.0016373257,0.00016272931,0.000047990376,0.00047392235,0.0007609081,0.000042538675,0.0010632032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821013,0.00011512031,0.0002413008,0.0004151129,0.0005935395,0.00042477134],"domain_scores_gemma":[0.9991976,0.00006363229,0.00007860477,0.0004029491,0.000078772006,0.00017845706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093771916,0.00023195827,0.00030837578,0.00023333228,0.00015919782,0.000021777709,0.0000749423,0.000044013403,0.0004981385],"category_scores_gemma":[0.000025059286,0.00016798571,0.00007672946,0.0003218192,0.00003520254,0.000085527965,0.000052906544,0.00017107325,0.000068075235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005323317,0.002370871,0.9856981,0.000031243653,0.000071062685,0.0007505745,0.00043445476,0.00014390044,0.0003394907,7.3788885e-7,0.00019555431,0.0046407124],"study_design_scores_gemma":[0.01894547,0.0022730504,0.9694644,0.00003255617,0.00003895896,0.0000075047,0.00010239008,0.0025247647,0.0034049384,0.0000010512458,0.0030387687,0.00016612255],"about_ca_topic_score_codex":0.00021572788,"about_ca_topic_score_gemma":0.00013519752,"teacher_disagreement_score":0.016233658,"about_ca_system_score_codex":0.00057214976,"about_ca_system_score_gemma":0.0002020838,"threshold_uncertainty_score":0.6850259},"labels":[],"label_agreement":null},{"id":"W4304893106","doi":"10.1016/j.gore.2022.101087","title":"Extramedullary plasmacytoma of the uterine cervix arising in an asymptomatic 46-year-old female","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Plasmacytoma; Asymptomatic; Plasma cell neoplasm; Biopsy; Multiple myeloma; Colposcopy; Plasma cell; Serum protein electrophoresis; Pathology; Extramedullary plasmacytoma; Radiology; Cytopathology; Bone marrow; Cancer; Internal medicine; Cervical cancer; Antibody; Cytology","score_opus":0.03483329269085153,"score_gpt":0.35170371313074295,"score_spread":0.31687042043989144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304893106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936455,0.00014953912,0.0000034115587,0.00073003746,0.0005459969,0.0011598952,0.0000140723905,0.000059728703,0.0036918167],"genre_scores_gemma":[0.9970317,0.00002305881,0.0011683669,0.00039914314,0.000040592906,0.00033849495,0.000056449288,0.000022327826,0.0009198809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723494,0.0005382346,0.0007489467,0.00047052983,0.00049372436,0.0005136411],"domain_scores_gemma":[0.9981045,0.00040436664,0.00044666682,0.0007923899,0.00007430558,0.00017778107],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010238701,0.00019186137,0.0006135629,0.0002027276,0.00022308002,0.000009624976,0.00021388452,0.00015263983,0.0020521719],"category_scores_gemma":[0.0007007741,0.00013734285,0.00014407354,0.0004612151,0.00019345662,0.00007466218,0.00048948475,0.0005698827,0.000007520513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023534796,0.0019682746,0.96955454,0.00008196512,0.00009025303,0.014287991,0.00046079664,0.0001886546,0.0016505329,0.00002581119,0.00022369169,0.011232156],"study_design_scores_gemma":[0.0024694777,0.003283234,0.9814077,0.00002491656,0.000061856794,0.0049977945,0.00079873693,0.0005306327,0.0011256908,0.0004509424,0.0047364053,0.000112590365],"about_ca_topic_score_codex":0.00019212335,"about_ca_topic_score_gemma":0.00036356982,"teacher_disagreement_score":0.011853198,"about_ca_system_score_codex":0.000834773,"about_ca_system_score_gemma":0.0006580601,"threshold_uncertainty_score":0.99886006},"labels":[],"label_agreement":null},{"id":"W4306670021","doi":"10.1177/20552076221129066","title":"Feasibility of a tailored and virtually supported home exercise program for people with multiple myeloma using a novel eHealth application","year":2022,"lang":"en","type":"article","venue":"Digital Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Government of Alberta","keywords":"eHealth; Aerobic exercise; Psychological intervention; Physical therapy; Medicine; Flexibility (engineering); Quality of life (healthcare); Psychology; Health care; Nursing","score_opus":0.042780462690172404,"score_gpt":0.3559123845854651,"score_spread":0.3131319218952927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306670021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494846,0.00015289527,0.0057175616,0.0003956698,0.00001550485,0.0076836646,0.0009695352,0.00007926661,0.00003745081],"genre_scores_gemma":[0.991777,0.000012978411,0.005726345,0.00006952462,0.000015456424,0.0011093027,0.0012187558,0.000033707936,0.000036928002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982882,0.000024595556,0.00037172032,0.00042104808,0.00043148917,0.00046294878],"domain_scores_gemma":[0.9987717,0.000098665005,0.00021406246,0.0003207511,0.00015816015,0.00043662256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026803312,0.00015850592,0.00048700836,0.00013062367,0.0002524253,0.000027118233,0.000070229864,0.000030281562,0.0000080545715],"category_scores_gemma":[0.00006157025,0.00013325611,0.00006159905,0.00037594166,0.00008080904,0.00013704832,0.000080736216,0.00012628184,6.1043966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062381052,0.004215945,0.64049995,0.0017464207,0.00007202627,0.000004844597,0.0007844109,0.0000194588,0.00047023373,0.00006678313,0.000030719155,0.3458511],"study_design_scores_gemma":[0.015768215,0.009240097,0.92742944,0.00012287454,0.00004302405,0.00013192603,0.0012855246,0.045216616,0.0000888315,0.00009997828,0.00037433722,0.00019911402],"about_ca_topic_score_codex":0.0007082257,"about_ca_topic_score_gemma":0.00017659087,"teacher_disagreement_score":0.34565198,"about_ca_system_score_codex":0.00034672904,"about_ca_system_score_gemma":0.00096319057,"threshold_uncertainty_score":0.5434027},"labels":[],"label_agreement":null},{"id":"W4306867613","doi":"10.3324/haematol.2021.280051","title":"Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study","year":2022,"lang":"en","type":"letter","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Institut National Du Cancer; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; CHIST-ERA; Labex Iron","keywords":"Positron emission tomography; Medicine; Multiple myeloma; Cassiopeia A; Positron Emission Tomography-Computed Tomography; Nuclear medicine; Radiology; Tomography; Internal medicine; Physics; Astronomy","score_opus":0.02303871682484634,"score_gpt":0.27348528004051986,"score_spread":0.25044656321567355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306867613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743818,0.0011040708,0.00001295829,0.015040889,0.000342272,0.007643162,0.0010834063,0.00015405781,0.00023736546],"genre_scores_gemma":[0.98400635,0.00010416055,0.00050040084,0.008757079,0.00018268137,0.0015031049,0.0047680144,0.000104479856,0.00007372461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99295396,0.0014788234,0.0012562699,0.0013289773,0.0018618312,0.0011201614],"domain_scores_gemma":[0.99531436,0.0023797825,0.00055167684,0.0012659022,0.00020669833,0.0002815728],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00034476697,0.0008899554,0.0019837567,0.0009722918,0.00039024054,0.000062460385,0.0008917398,0.0007096481,0.00048413567],"category_scores_gemma":[0.00039189516,0.000539908,0.00065272365,0.0014399844,0.00023249547,0.00009077832,0.00037699897,0.0026314345,0.000018453318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021983709,0.004272716,0.91225713,0.0003938533,0.0008874005,0.02258588,0.0010452258,0.0000080002965,0.00007749658,0.0000014526175,0.05492657,0.0013459242],"study_design_scores_gemma":[0.013192368,0.0042563407,0.97165054,0.001070215,0.0007374226,0.00013057025,0.00037356964,0.00031444526,0.00048934843,0.000054894233,0.0071694027,0.0005608968],"about_ca_topic_score_codex":0.0051047057,"about_ca_topic_score_gemma":0.0003130796,"teacher_disagreement_score":0.059393417,"about_ca_system_score_codex":0.00016271211,"about_ca_system_score_gemma":0.00021823705,"threshold_uncertainty_score":0.99970526},"labels":[],"label_agreement":null},{"id":"W4307092490","doi":"10.1080/03007995.2022.2139052","title":"Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Hazard ratio; Odds ratio; Gastroenterology; Oncology","score_opus":0.18304367590100745,"score_gpt":0.4477553956450189,"score_spread":0.2647117197440115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307092490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165624,0.0018550801,0.000058293663,0.00058857084,0.0003122557,0.004273504,0.001231142,0.000016406932,0.000008509775],"genre_scores_gemma":[0.9945164,0.00089643925,0.00027878457,0.0000067683563,0.000055882192,0.0010231817,0.0031547153,0.000029261,0.000038616545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956946,0.0003895918,0.0008558386,0.0005517186,0.0018636297,0.0006446659],"domain_scores_gemma":[0.9912316,0.00743786,0.00021201762,0.00043788232,0.00028616583,0.00039446005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011968303,0.00023779745,0.00081763795,0.0004609436,0.00022542193,0.000014051389,0.00026901314,0.00010972445,0.00007789764],"category_scores_gemma":[0.003258067,0.00013750499,0.00011155646,0.00063764857,0.0002599413,0.00005917312,0.00015689415,0.000496209,0.0000010276417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19800723,0.015264408,0.48216674,0.00030428177,0.00049661903,0.000027392258,0.003840631,0.000080858255,0.00019496906,0.000014097557,0.00058980583,0.29901296],"study_design_scores_gemma":[0.119675756,0.015395923,0.8441696,0.00033799096,0.000047105692,4.51263e-7,0.00091334985,0.0099848425,0.0009929177,0.00001740929,0.008325906,0.000138751],"about_ca_topic_score_codex":0.00159808,"about_ca_topic_score_gemma":0.0017208124,"teacher_disagreement_score":0.36200285,"about_ca_system_score_codex":0.00048045174,"about_ca_system_score_gemma":0.0007163063,"threshold_uncertainty_score":0.5607291},"labels":[],"label_agreement":null},{"id":"W4307101073","doi":"10.14740/wjon1521","title":"Extramedullary Multiple Myeloma: A Patient-Focused Review of the Pathogenesis of Bone Marrow Escape","year":2022,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Bortezomib; Bone marrow; Pathology; Internal medicine","score_opus":0.06536201156746348,"score_gpt":0.36145154678934543,"score_spread":0.29608953522188197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307101073","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002506835,0.9956168,0.0000018262203,0.00044757262,0.0005667133,0.0017650694,0.00014310048,0.000005707711,0.0012025377],"genre_scores_gemma":[0.00035301925,0.9971517,0.0014611494,0.00023656433,0.00015946208,0.00010543282,0.000047881043,0.00006768791,0.00041713062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99352735,0.0017490935,0.0028044344,0.00028971437,0.0011929435,0.0004364742],"domain_scores_gemma":[0.99248934,0.0015651998,0.0044303862,0.0007637142,0.0004386773,0.0003126641],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013990666,0.0004311595,0.0049530803,0.0007455509,0.00008842851,0.0000042046577,0.00053712353,0.00020287708,0.0022032822],"category_scores_gemma":[0.001898773,0.00025025316,0.0023287763,0.0012416297,0.00024485303,0.00004754092,0.0003428631,0.0012223489,0.000008548393],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032729728,0.0010933956,0.00048044807,0.06322198,0.0011155562,0.0013186232,0.00004001036,2.1958557e-7,0.000032585966,0.000006846242,0.003840723,0.9285223],"study_design_scores_gemma":[0.0023521772,0.0019984187,0.0005627251,0.06532439,0.003232571,0.002772302,0.000022846974,0.0000013648297,0.000014786966,0.0000066192433,0.92356783,0.00014399076],"about_ca_topic_score_codex":0.000018120596,"about_ca_topic_score_gemma":0.00004088953,"teacher_disagreement_score":0.92837834,"about_ca_system_score_codex":0.0007624505,"about_ca_system_score_gemma":0.003230508,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W4307154696","doi":"10.1016/j.clml.2022.10.005","title":"Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Alberta Cancer Foundation","funders":"","keywords":"Bortezomib; Discontinuation; Medicine; Cumulative dose; Multiple myeloma; Dexamethasone; Internal medicine; Cyclophosphamide; Cumulative incidence; Gastroenterology; Oncology; Surgery; Cohort; Chemotherapy","score_opus":0.04323960663855163,"score_gpt":0.3505000595739032,"score_spread":0.30726045293535154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307154696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514085,0.0006820857,0.0000110214305,0.0005555893,0.00006118391,0.0024255414,0.00017858928,0.00007408286,0.0008710264],"genre_scores_gemma":[0.99520594,0.0015786784,0.0015825673,0.00026212327,0.000064295964,0.0005014157,0.00019088839,0.000082868435,0.00053119974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529815,0.00082108617,0.0011632615,0.0009662955,0.0009523707,0.00079884275],"domain_scores_gemma":[0.99283975,0.0052486802,0.00037121848,0.00091232825,0.00011334407,0.000514661],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010025045,0.0006335143,0.0016007657,0.0003480361,0.00043824696,0.000047753743,0.00027494656,0.0001435579,0.000048102116],"category_scores_gemma":[0.00023321046,0.00036237584,0.00023604133,0.0009077091,0.00083118,0.0001432724,0.00010024755,0.00047409383,0.000005073734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014401881,0.0030557043,0.8003471,0.000078210185,0.00076306035,0.0019593656,0.001984899,0.000046514906,0.000075034855,0.0000932856,0.000035412922,0.17715952],"study_design_scores_gemma":[0.049131583,0.009416515,0.93716824,0.0001500379,0.0004652034,0.00034494797,0.0008228827,0.000935603,0.0002940011,0.000052101266,0.000859942,0.00035892637],"about_ca_topic_score_codex":0.0052784653,"about_ca_topic_score_gemma":0.0020277237,"teacher_disagreement_score":0.1768006,"about_ca_system_score_codex":0.00080182025,"about_ca_system_score_gemma":0.00086287386,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W4307277614","doi":"10.21203/rs.3.rs-2184702/v1","title":"An APOBEC/Inflammation-based classifier improves the stratification of multiple myeloma patients and identifies novel risk subgroups","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Deutsche Forschungsgemeinschaft; Multiple Myeloma Research Foundation; Leukemia and Lymphoma Society of Canada; Michael Smith Health Research BC; Simon Fraser University; International Myeloma Society","keywords":"Risk stratification; Multiple myeloma; Internal medicine; Oncology; Medicine; Framingham Risk Score; Disease; Inflammation; APOBEC; Bioinformatics; Biology","score_opus":0.057070037378344374,"score_gpt":0.37429677326260014,"score_spread":0.31722673588425576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307277614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927173,0.00029195784,0.00027293223,0.00056666665,0.00012167207,0.004431928,0.0012324963,0.000057729598,0.00030732082],"genre_scores_gemma":[0.9935453,0.00031140327,0.0005864375,0.000009542208,0.00014810936,0.0013159305,0.0037341542,0.00006254095,0.00028656577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99420923,0.0010053333,0.00066022767,0.00087536144,0.0026105102,0.00063934264],"domain_scores_gemma":[0.994816,0.0013900183,0.00038075395,0.0015486635,0.0014950696,0.0003694613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00198335,0.00033855584,0.00048721753,0.00061812357,0.0007872312,0.00024160153,0.0005286378,0.00026772675,0.00026055827],"category_scores_gemma":[0.0023058653,0.00024364333,0.00019639358,0.00046773974,0.0005814459,0.00017389814,0.0006032141,0.0018452737,0.000012768476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026917607,0.0031931635,0.845945,0.003538129,0.0006601231,0.000028991419,0.0024263633,0.00038853908,0.05701669,0.00027943862,0.00038384233,0.08344797],"study_design_scores_gemma":[0.0034519404,0.0011279621,0.9420189,0.00023801331,0.00007207352,0.0000011730795,0.0016522147,0.031225283,0.019314863,0.0003277725,0.00036454515,0.00020525244],"about_ca_topic_score_codex":0.0023431117,"about_ca_topic_score_gemma":0.0007650629,"teacher_disagreement_score":0.09607392,"about_ca_system_score_codex":0.00036774724,"about_ca_system_score_gemma":0.0008646281,"threshold_uncertainty_score":0.9935487},"labels":[],"label_agreement":null},{"id":"W4307753391","doi":"10.1097/pai.0000000000001069","title":"Dual Expression of Immunoglobulin Light Chains in Plasma Cell Myeloma: A Case Report and Literature Review","year":2022,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; Prince Albert Grand Council; Saskatchewan Health Authority; University of Saskatchewan","funders":"","keywords":"Immunoglobulin light chain; Plasma cell; Immunohistochemistry; Bone marrow; Pathology; Plasma Cell Myeloma; Antibody; Plasma cell neoplasm; CD20; Multiple myeloma; Medicine; Monoclonal; Molecular biology; Chemistry; Biology; Plasmacytoma; Monoclonal antibody; Immunology","score_opus":0.01598478229294595,"score_gpt":0.31585601776434663,"score_spread":0.29987123547140065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307753391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009090878,0.9849278,0.000005800753,0.00006105346,0.000078543075,0.0026078462,0.00014708242,0.000038010916,0.0030429894],"genre_scores_gemma":[0.0033265636,0.98939294,0.0007472059,0.000087025655,0.00003768394,0.0018551617,0.0035755236,0.00013094531,0.00084694737],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99574965,0.00022992978,0.0016042566,0.0012492329,0.00051429245,0.0006526129],"domain_scores_gemma":[0.99681556,0.00013115307,0.00095103314,0.0017670068,0.000086600914,0.00024867227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048850855,0.00085854915,0.0032429288,0.00031675244,0.00011800614,0.000016083384,0.00029950027,0.0007284865,0.00045021882],"category_scores_gemma":[0.00021738924,0.0007641211,0.0005892822,0.00073764817,0.00022247742,0.000027406855,0.0006570757,0.0017643879,0.000012751517],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001804696,0.00045952812,9.451572e-7,0.07446748,0.00022026931,0.5766171,0.00007293725,8.049879e-8,0.29601318,0.0000048001334,0.0005799068,0.051383313],"study_design_scores_gemma":[0.0031361282,0.0002476033,0.0000017321382,0.031346984,0.0013728796,0.6635981,0.000044387292,9.2565483e-7,0.028011747,0.0000042088404,0.27155575,0.00067952136],"about_ca_topic_score_codex":0.000028612056,"about_ca_topic_score_gemma":6.8040535e-8,"teacher_disagreement_score":0.27097586,"about_ca_system_score_codex":0.0005886383,"about_ca_system_score_gemma":0.0006749196,"threshold_uncertainty_score":0.99948096},"labels":[],"label_agreement":null},{"id":"W4307972632","doi":"10.1111/bjh.18536","title":"The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population","year":2022,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Pharmaceutical Company; Celgene; Bristol-Myers Squibb Canada; Gilead Sciences; AbbVie; Sanofi; Janssen Research and Development; Novartis; Amgen","keywords":"Multiple myeloma; Staging system; Medicine; Progression-free survival; Overall survival; Oncology; Internal medicine; Population; Cancer; Environmental health","score_opus":0.07219630896276948,"score_gpt":0.3477075047314594,"score_spread":0.27551119576868993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307972632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9295179,0.0008641505,4.5601948e-7,0.068118006,0.00034739135,0.0005509449,0.0005316413,0.000005548904,0.00006390895],"genre_scores_gemma":[0.9947334,0.0008981512,0.00049893314,0.0007617749,0.000487182,0.000006388536,0.0009443248,0.000034706263,0.0016351655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968781,0.000669221,0.00107171,0.00035176985,0.00072839274,0.00030082208],"domain_scores_gemma":[0.99785304,0.0005667866,0.00086869317,0.00049204077,0.0001121014,0.000107361375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012735449,0.00017900857,0.000734344,0.0002991969,0.00013350355,0.00013217096,0.0006252248,0.00014866877,0.000025956697],"category_scores_gemma":[0.000598614,0.00012674069,0.000054151355,0.00014891484,0.00016203825,0.0002558668,0.000469781,0.0014369296,1.2107294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022063006,0.000103907434,0.7759554,0.0005903713,0.00019983709,0.029708654,0.00020775794,0.0000031115446,0.000023921579,0.00003185951,0.16598846,0.024980418],"study_design_scores_gemma":[0.009325655,0.00031597793,0.9296601,0.004017378,0.00006467565,0.020669786,0.00040834743,0.00036263288,0.000019567478,0.00014043489,0.034858245,0.00015720425],"about_ca_topic_score_codex":0.0061626933,"about_ca_topic_score_gemma":0.057979163,"teacher_disagreement_score":0.15370469,"about_ca_system_score_codex":0.00015123952,"about_ca_system_score_gemma":0.00021053095,"threshold_uncertainty_score":0.9592103},"labels":[],"label_agreement":null},{"id":"W4308154018","doi":"10.1016/j.jtct.2022.10.022","title":"Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal","keywords":"Medicine; Multiple myeloma; Incidence (geometry); Bortezomib; Internal medicine; Gastroenterology; Graft-versus-host disease; Clinical endpoint; Immunosuppression; Transplantation; Tacrolimus; Retrospective cohort study; Discontinuation; Surgery; Clinical trial","score_opus":0.011641333878656637,"score_gpt":0.25310032472843347,"score_spread":0.24145899084977684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308154018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727905,0.0012988785,0.00018646632,0.00010504702,0.000026389896,0.00079383026,0.00022924741,0.000010903635,0.000070173715],"genre_scores_gemma":[0.9887835,0.010031355,0.00016717306,0.00010831922,0.000007343897,0.00017475625,0.0006877466,0.000013370185,0.000026482183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863344,0.00018980545,0.00035087738,0.000297172,0.00030154496,0.00022715158],"domain_scores_gemma":[0.9995781,0.00009501691,0.00007066467,0.00011961574,0.000034055214,0.00010250126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024987911,0.00014272892,0.00023590679,0.00019841858,0.00005370579,0.000008105894,0.000050947354,0.000048248756,0.00008729215],"category_scores_gemma":[0.00000910609,0.00013132064,0.000036540776,0.00021890234,0.00006360802,0.00009312138,0.0000061992528,0.00015688971,8.191355e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020841049,0.0007636768,0.89118385,0.00031672753,0.000040052684,0.0014202346,0.004467795,0.000056964112,0.013375414,0.000012203247,0.0000027671294,0.06751924],"study_design_scores_gemma":[0.02841034,0.0007237532,0.9589335,0.0000857742,0.000023104425,0.000028732595,0.000101616904,0.0006620535,0.010842405,0.000031817624,0.000042288495,0.00011464139],"about_ca_topic_score_codex":0.000778591,"about_ca_topic_score_gemma":0.0010115748,"teacher_disagreement_score":0.0677496,"about_ca_system_score_codex":0.00009849021,"about_ca_system_score_gemma":0.00009146017,"threshold_uncertainty_score":0.53551},"labels":[],"label_agreement":null},{"id":"W4308364989","doi":"10.26508/lsa.202201543","title":"Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing","year":2022,"lang":"en","type":"article","venue":"Life Science Alliance","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Calgary; University Health Network; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Somatic hypermutation; Biology; Chromosomal translocation; Multiple myeloma; Immunoglobulin heavy chain; Antibody; Immunoglobulin gene; Gene rearrangement; Concordance; Bone marrow; DNA sequencing; Immunoglobulin light chain; Molecular biology; Gene; Cancer research; Genetics; B cell; Immunology","score_opus":0.03509366537565328,"score_gpt":0.3035197939090226,"score_spread":0.26842612853336933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308364989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920226,0.0030687645,0.0011885468,0.0017422788,0.00014441251,0.00065328175,0.00001342621,0.00006861834,0.001098074],"genre_scores_gemma":[0.9959472,0.00029231363,0.0025201775,0.0005753869,0.00004351681,0.00013919189,0.000013530851,0.000009749392,0.00045892122],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981869,0.00005015157,0.0001714601,0.00042208642,0.00079854735,0.00037087896],"domain_scores_gemma":[0.99937874,0.000021152204,0.000058104204,0.00026533575,0.000094530216,0.00018213465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045077398,0.00011160258,0.0001464374,0.00006516591,0.0007657474,0.000043849483,0.00012898073,0.000024015799,0.00012961557],"category_scores_gemma":[0.00014672797,0.00010038333,0.000033921962,0.00081597693,0.00025852528,0.00031548672,0.00006985368,0.00021709458,0.00001841428],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047907242,0.00012801876,0.007181579,0.00006793533,0.000058663296,0.000085848296,0.0039834627,0.00031670486,0.9489689,0.00016202174,0.0002079116,0.038359907],"study_design_scores_gemma":[0.009557188,0.0022647195,0.5251028,0.00023806602,0.00011727469,0.0006815614,0.01164704,0.028286764,0.39203095,0.000784915,0.028446248,0.0008424709],"about_ca_topic_score_codex":0.00041984348,"about_ca_topic_score_gemma":0.00003540532,"teacher_disagreement_score":0.55693793,"about_ca_system_score_codex":0.0004460914,"about_ca_system_score_gemma":0.00041428368,"threshold_uncertainty_score":0.58895874},"labels":[],"label_agreement":null},{"id":"W4308721350","doi":"10.3390/curroncol29110670","title":"Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Thalidomide; Multiple myeloma; Lenalidomide; Dexamethasone; Bortezomib; Internal medicine; Autologous stem-cell transplantation; Cyclophosphamide; Oncology; Transplantation; Hematology; Surgery; Chemotherapy","score_opus":0.14608055190135216,"score_gpt":0.4197039970769977,"score_spread":0.2736234451756455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308721350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963288,0.0017113346,0.000019182862,0.0004327127,0.0003370955,0.000863404,0.0001111667,0.000031871274,0.00016445684],"genre_scores_gemma":[0.9985671,0.00061745115,0.00015379816,0.000094471085,0.000028228542,0.00022268918,0.00027231933,0.000018461717,0.000025481771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980276,0.0006345444,0.00026263107,0.00034037128,0.00033531574,0.00039953718],"domain_scores_gemma":[0.9990706,0.0004704188,0.000058078847,0.00016811627,0.000046843474,0.00018598682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004878679,0.00015378337,0.0003109088,0.00027081673,0.00019159912,0.000016785749,0.00008612417,0.000056399316,0.0001599958],"category_scores_gemma":[0.00010637105,0.00013098026,0.00005189528,0.0001934038,0.00008288903,0.00008856113,0.00005961578,0.00046900503,0.000006714787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017197499,0.0022087176,0.8205911,0.00005161267,0.00004052303,0.0004688756,0.0010579185,0.0000035446528,0.0030415813,0.0000053969093,0.00006414961,0.1552691],"study_design_scores_gemma":[0.016262943,0.0032298563,0.9594985,0.000055000524,0.000018595842,0.000117802796,0.00020285457,0.0008009528,0.00044948817,0.000013852558,0.019232336,0.000117774376],"about_ca_topic_score_codex":0.000044442346,"about_ca_topic_score_gemma":0.000020196245,"teacher_disagreement_score":0.15515132,"about_ca_system_score_codex":0.0003928091,"about_ca_system_score_gemma":0.00026104163,"threshold_uncertainty_score":0.534122},"labels":[],"label_agreement":null},{"id":"W4308866990","doi":"10.3390/curroncol29110672","title":"Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Stromal cell; Medicine; Bone marrow; Drug resistance; Mitochondrion; Cancer research; Mechanism (biology); Cancer cell; Drug; Cell biology; Cancer; Pharmacology; Biology; Immunology; Microbiology; Internal medicine","score_opus":0.25446690412747835,"score_gpt":0.4696698750430471,"score_spread":0.21520297091556873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308866990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016923211,0.99109936,0.000137558,0.00009687054,0.0015599983,0.0062768725,0.00057668966,0.000022143819,0.00006128631],"genre_scores_gemma":[0.00003585022,0.99311197,0.00024640484,0.0000053694375,0.00078006,0.0043572113,0.0011184112,0.000055068613,0.00028963125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786574,0.0002808052,0.00063527067,0.00049540383,0.00026124538,0.00046152246],"domain_scores_gemma":[0.99617463,0.003067197,0.00015440775,0.00034524096,0.000067813344,0.00019068063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016443247,0.00040639171,0.0019638955,0.00017146723,0.0002188267,0.000009651653,0.00015426206,0.00020020072,0.0003075994],"category_scores_gemma":[0.00027395258,0.00022718705,0.0007086578,0.00015896311,0.00018158855,0.000019307663,0.00005014582,0.00030481207,0.0000071278578],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048743395,0.0014534998,0.00016031068,0.0063284175,0.00094219425,0.000027109072,0.00031148965,2.5989368e-7,0.000004236535,0.000019290635,0.0009849799,0.98928076],"study_design_scores_gemma":[0.006669346,0.0041700406,0.000030462228,0.00059730123,0.0026898915,0.00006763151,0.00008437008,0.00013082243,0.0000052971704,0.0000039300194,0.9854,0.0001509152],"about_ca_topic_score_codex":0.00004325927,"about_ca_topic_score_gemma":0.00003439349,"teacher_disagreement_score":0.98912984,"about_ca_system_score_codex":0.00064189255,"about_ca_system_score_gemma":0.00070787757,"threshold_uncertainty_score":0.9264419},"labels":[],"label_agreement":null},{"id":"W4309686345","doi":"10.3390/curroncol29110705","title":"Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Context (archaeology); Multiple myeloma; Tumor microenvironment; Bone marrow; Transplantation; Immune system; Immunology; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.1855494720203959,"score_gpt":0.43130409492103444,"score_spread":0.24575462290063854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309686345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019103495,0.9931627,6.8207794e-7,0.0002794507,0.00046064015,0.003134241,0.00014567406,0.000008825299,0.0008974296],"genre_scores_gemma":[0.004147162,0.9937934,0.000034130695,0.000061551626,0.00012658142,0.0012406552,0.00032686602,0.000036266014,0.00023334839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965141,0.0013368508,0.0007789586,0.00041422134,0.0004993528,0.00045652126],"domain_scores_gemma":[0.9972404,0.0014135493,0.000489445,0.00074728054,0.0000174546,0.000091869355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060976436,0.0003498513,0.001628608,0.00017618082,0.00013834586,0.0000073375704,0.00047347447,0.00015995288,0.0005581258],"category_scores_gemma":[0.0004650593,0.00017396284,0.00064602285,0.00034913962,0.00025123483,0.000017505505,0.000365269,0.0011090225,0.00004281371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006928381,0.0013118542,0.004902455,0.0039845943,0.00015228777,0.00013940793,0.00045010977,9.944094e-8,0.0000034090785,0.000014916683,0.0010447542,0.98792684],"study_design_scores_gemma":[0.002399436,0.0004556692,0.0021563603,0.0022779906,0.0005455395,0.00027910783,0.00048466815,0.000013425925,0.000003818108,0.0000034983605,0.9912644,0.00011607146],"about_ca_topic_score_codex":0.00007375752,"about_ca_topic_score_gemma":0.00014587103,"teacher_disagreement_score":0.99021965,"about_ca_system_score_codex":0.001131577,"about_ca_system_score_gemma":0.00053553167,"threshold_uncertainty_score":0.7093999},"labels":[],"label_agreement":null},{"id":"W4309706624","doi":"10.1007/s11899-022-00682-4","title":"The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma","year":2022,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Oncology; Nausea; Internal medicine; Vomiting","score_opus":0.07597734830097738,"score_gpt":0.36046075590868615,"score_spread":0.28448340760770874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309706624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016471748,0.99380666,0.0000013206025,0.000022432147,0.00035322658,0.0029780515,0.00005598223,0.00005559811,0.0010795732],"genre_scores_gemma":[0.0051393537,0.9929131,0.000093425835,0.000003594452,0.000051113595,0.0010583829,0.00046774672,0.000057539728,0.00021571711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952843,0.0003873654,0.0019604748,0.0008957885,0.0007572944,0.0007147867],"domain_scores_gemma":[0.9964181,0.0009466522,0.0012406273,0.001049397,0.0000893392,0.00025588527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009166665,0.00060703186,0.0026799499,0.00032241273,0.00023547403,0.000029500085,0.00024522227,0.00024015062,0.00022394296],"category_scores_gemma":[0.0013235821,0.00035784327,0.00051695755,0.0005369662,0.00020838856,0.000048056223,0.0005012256,0.0008138148,0.000012024891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047858884,0.0004577383,0.03752048,0.014029526,0.00022721833,0.0040760273,0.00004410506,5.0778077e-8,0.0000012329097,0.0001805152,0.0002187066,0.94319654],"study_design_scores_gemma":[0.0007005832,0.00015070081,0.00066550827,0.009146392,0.0004643027,0.010001452,0.000077345045,0.000021731352,0.000029119095,0.00044285328,0.9780016,0.00029840338],"about_ca_topic_score_codex":0.00005876393,"about_ca_topic_score_gemma":0.000027122152,"teacher_disagreement_score":0.9777829,"about_ca_system_score_codex":0.0001796397,"about_ca_system_score_gemma":0.00056874927,"threshold_uncertainty_score":0.99988735},"labels":[],"label_agreement":null},{"id":"W4310019125","doi":"10.1016/j.clml.2022.11.007","title":"Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Overall survival; Cohort; Multiple myeloma; Salvage therapy; Oncology; Internal medicine; Progression-free survival; Surgery; Chemotherapy","score_opus":0.05518662296403471,"score_gpt":0.3486581173803121,"score_spread":0.2934714944162774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310019125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888701,0.0023232743,0.00037366312,0.0018182963,0.00080633856,0.0034357554,0.00078068185,0.0004776658,0.0011142605],"genre_scores_gemma":[0.985921,0.0010727007,0.0037603485,0.0021416498,0.00047946675,0.0018845516,0.0010585891,0.00020139542,0.0034803015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99362004,0.00062644115,0.0017397841,0.0016076724,0.0010174972,0.0013885492],"domain_scores_gemma":[0.99439055,0.0025628107,0.0004880464,0.0013949139,0.0002070865,0.0009565928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011483425,0.00078001345,0.0015935851,0.0002580289,0.00103601,0.00007679612,0.00056132453,0.00037749344,0.00024908248],"category_scores_gemma":[0.0006668406,0.00063087355,0.001158571,0.00040459906,0.00040088163,0.00017958449,0.00013716696,0.00055827526,0.00013205194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023888601,0.0024244443,0.027462067,0.00010037358,0.0014747094,0.0039806785,0.0012747142,0.00019577843,0.003821022,0.0006304883,0.0009484466,0.9337987],"study_design_scores_gemma":[0.058972962,0.020955354,0.834141,0.00018181629,0.00046864178,0.0020516797,0.0002607315,0.027965628,0.003792045,0.0013155096,0.048828162,0.0010664571],"about_ca_topic_score_codex":0.00036976486,"about_ca_topic_score_gemma":0.000113360205,"teacher_disagreement_score":0.9327322,"about_ca_system_score_codex":0.00331177,"about_ca_system_score_gemma":0.002822324,"threshold_uncertainty_score":0.99961424},"labels":[],"label_agreement":null},{"id":"W4310096327","doi":"10.1182/blood-2022-169920","title":"IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Cancer research; Multiple myeloma; Downregulation and upregulation; IRF4; Biology; Transcription factor; Coactivator; Pomalidomide; Lenalidomide; Immunology; Genetics","score_opus":0.018763215678207542,"score_gpt":0.2670754296227389,"score_spread":0.24831221394453135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428684,0.00018681097,0.000027575137,0.002539602,0.000041409494,0.0012006768,0.00007656648,0.000059400343,0.0015811373],"genre_scores_gemma":[0.9969972,0.000012717762,0.00052352983,0.00042125612,0.000083217434,0.0008789997,0.00011275469,0.00003535989,0.0009349915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815434,0.00014292212,0.00021652848,0.0003642067,0.00065576326,0.0004662583],"domain_scores_gemma":[0.9990572,0.00015547087,0.000042744647,0.0004630106,0.00005175384,0.00022986843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025748753,0.00017813192,0.00024920012,0.00018380833,0.00028752818,0.00002656214,0.00012866026,0.00003513893,0.00041516533],"category_scores_gemma":[0.0001661509,0.00011336879,0.00007095503,0.00062353566,0.00006472311,0.00006061233,0.00019685013,0.00033304884,0.00008383268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037116192,0.006082892,0.94246155,0.00012985861,0.00050487195,0.004813776,0.0027732581,0.00026001167,0.020800106,0.00022645047,0.0016225406,0.016613076],"study_design_scores_gemma":[0.023870513,0.0032116638,0.9415669,0.00014321087,0.00016736935,0.0006060081,0.0017603753,0.000500245,0.021856338,0.0000749406,0.0059206523,0.00032179814],"about_ca_topic_score_codex":0.000619129,"about_ca_topic_score_gemma":0.0006322074,"teacher_disagreement_score":0.020158894,"about_ca_system_score_codex":0.00014404165,"about_ca_system_score_gemma":0.00012475782,"threshold_uncertainty_score":0.46230453},"labels":[],"label_agreement":null},{"id":"W4310098617","doi":"10.1182/blood-2022-158520","title":"Clinician and Patient Perspectives on Treatment Decision-Making in Multiple Myeloma: A Qualitative Survey","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Qualitative research; Pomalidomide; Intensive care medicine; Lenalidomide; Family medicine; Oncology; Internal medicine; Sociology","score_opus":0.07068498751265276,"score_gpt":0.3975614782808181,"score_spread":0.3268764907681654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310098617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973251,0.0010252227,0.000005955744,0.00013632754,0.000037259644,0.0007870662,0.00019623735,0.000023094088,0.00046368543],"genre_scores_gemma":[0.99849147,0.000099977806,0.00094770326,0.00007552113,0.000018526758,0.0002549274,0.00004154845,0.000020812742,0.00004951659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980015,0.0005855883,0.00026354686,0.00043894767,0.0004147367,0.00029564605],"domain_scores_gemma":[0.99713606,0.0023593926,0.00006826096,0.00024580234,0.00005574296,0.00013474462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041351444,0.00017133681,0.00032755092,0.00024564128,0.00020273004,0.000015501812,0.00005156059,0.000031719057,0.0001144668],"category_scores_gemma":[0.0011987038,0.00013136162,0.000073513984,0.00026506186,0.000057219415,0.000032585187,0.00009693058,0.00018444723,0.00001459679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005356321,0.012888536,0.7554437,0.000013214123,0.00046326075,0.0013004029,0.09111024,0.00002117348,0.000086965956,0.00006446516,0.00006146417,0.13319026],"study_design_scores_gemma":[0.015155101,0.0073938617,0.9241223,0.00008083769,0.000042631287,0.000039634586,0.05231199,0.00021126184,0.00015792319,0.00013119822,0.00021022087,0.0001430939],"about_ca_topic_score_codex":0.00078573776,"about_ca_topic_score_gemma":0.0010363241,"teacher_disagreement_score":0.16867854,"about_ca_system_score_codex":0.0003344241,"about_ca_system_score_gemma":0.00010910498,"threshold_uncertainty_score":0.5356772},"labels":[],"label_agreement":null},{"id":"W4310107076","doi":"10.1182/blood-2022-163555","title":"Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Multiple myeloma; Medicine; Dexamethasone; Subgroup analysis; Internal medicine; Oncology; Pomalidomide; Pediatrics; Confidence interval","score_opus":0.01224282486809824,"score_gpt":0.24186484019343388,"score_spread":0.22962201532533563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310107076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777067,0.00047878435,0.00006854575,0.00008140369,0.00002293025,0.0009942751,0.00025170002,0.000051639116,0.00028006276],"genre_scores_gemma":[0.9969773,0.000070130875,0.0013425932,0.00007695935,0.000024571515,0.00028233283,0.0009892544,0.000037933336,0.00019887922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763685,0.00017742651,0.00032300316,0.00055656803,0.00073640095,0.0005697272],"domain_scores_gemma":[0.9988898,0.00025112665,0.000082213395,0.00040608054,0.00005275108,0.00031803318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023438799,0.00026931698,0.00065639557,0.0006176472,0.00022168609,0.000037504447,0.00013587456,0.000058264057,0.00018313447],"category_scores_gemma":[0.00007835679,0.00021834891,0.00012242868,0.0012356,0.00007858682,0.00009949313,0.00009083025,0.0003554949,0.000007356393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005111634,0.0024286048,0.985772,0.000062712395,0.0015260739,0.0030512933,0.00058671634,0.00013013094,0.00024049166,0.0000061927058,0.00003340209,0.0010507432],"study_design_scores_gemma":[0.07922591,0.0009762256,0.9166861,0.000035051653,0.0013374827,0.000026731597,0.0001408377,0.0005975667,0.0006406026,0.000006865492,0.00011110757,0.00021548865],"about_ca_topic_score_codex":0.0017775021,"about_ca_topic_score_gemma":0.002420732,"teacher_disagreement_score":0.07411428,"about_ca_system_score_codex":0.00014670003,"about_ca_system_score_gemma":0.00010676678,"threshold_uncertainty_score":0.890401},"labels":[],"label_agreement":null},{"id":"W4310108940","doi":"10.1182/blood-2022-163661","title":"Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Regina Qu'Appelle Health Region; Spinal Cord Injury BC; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Saint John Regional Hospital; London Health Sciences Centre; McMaster University; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; Hôpital Maisonneuve-Rosemont; University Health Network; CancerCare Manitoba; Ottawa Hospital; McGill University Health Centre; McGill University; Western University; University of Toronto; Terry Fox Research Institute; Jewish General Hospital","funders":"","keywords":"Medicine; Salvage therapy; Multiple myeloma; Transplantation; Oncology; Maintenance therapy; Surgery; Autologous stem-cell transplantation; Stem cell; Internal medicine; Chemotherapy","score_opus":0.016496195716723453,"score_gpt":0.27702304449750464,"score_spread":0.2605268487807812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310108940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979412,0.00067737716,0.000011252713,0.000045264787,0.000027283691,0.00066044397,0.00017167104,0.000029847044,0.00043566254],"genre_scores_gemma":[0.99891126,0.00017195087,0.00021969723,0.000030248233,0.000012973565,0.00023380002,0.00007061324,0.000022366337,0.00032711157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988022,0.00013026364,0.00023431788,0.00022220793,0.0003023409,0.0003087058],"domain_scores_gemma":[0.9994794,0.000093660485,0.000065971515,0.00023337838,0.00003339238,0.00009417666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014310726,0.00012945195,0.00025575244,0.00016554426,0.000043756165,0.000004435294,0.000081622995,0.000041751442,0.0002632969],"category_scores_gemma":[0.000009722645,0.00010027662,0.00014406334,0.00023499908,0.000032591055,0.000031875465,0.000020333695,0.00020571947,0.00001029385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005447323,0.0026244195,0.94305056,0.00008039229,0.00015243421,0.0020875006,0.0012636324,0.000047498197,0.035478294,0.0000019596303,0.000032443768,0.009733527],"study_design_scores_gemma":[0.021792099,0.0018451768,0.95842224,0.000029360028,0.000035153054,0.00012294363,0.00010020099,0.00023335173,0.01729917,0.000007486331,0.000029889365,0.00008290728],"about_ca_topic_score_codex":0.00035128588,"about_ca_topic_score_gemma":0.00004801203,"teacher_disagreement_score":0.018179124,"about_ca_system_score_codex":0.00010187223,"about_ca_system_score_gemma":0.00012670363,"threshold_uncertainty_score":0.40891618},"labels":[],"label_agreement":null},{"id":"W4310109030","doi":"10.1182/blood-2022-170869","title":"Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Multiple myeloma; Medicine; Stem cell; Meta-analysis; Oncology; Internal medicine; Lenalidomide; Autologous stem-cell transplantation; Transplantation; Biology; Genetics","score_opus":0.022916815207145575,"score_gpt":0.24100253934347954,"score_spread":0.21808572413633395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310109030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966723,0.0008960527,0.000058621557,0.00024924762,0.000027286751,0.0012186663,0.0005476407,0.00005912329,0.00027110724],"genre_scores_gemma":[0.99690545,0.000015184046,0.00094970246,0.00027913353,0.000019691048,0.0005683559,0.0005318012,0.000035028606,0.0006956613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974008,0.0002615904,0.00036440959,0.00053471664,0.0007351146,0.00070336444],"domain_scores_gemma":[0.9987693,0.00024747846,0.00012380058,0.00050755724,0.000100982776,0.000250917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023947337,0.0002721363,0.0010315898,0.0002707291,0.00018947381,0.000018384382,0.00019001825,0.000051116334,0.00042137754],"category_scores_gemma":[0.000017338505,0.00018725084,0.00050661026,0.0010460753,0.000045731766,0.0000539478,0.000074606316,0.00034713806,0.000019948322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023889402,0.0046363706,0.94724596,0.00004078592,0.039738372,0.002875581,0.00042885347,0.0019178648,0.000025500469,0.0000058355913,0.000101381265,0.0005945701],"study_design_scores_gemma":[0.027539348,0.001793872,0.90731347,0.0000073930482,0.06193005,0.000016858752,0.00014009522,0.0006599199,0.00018814705,0.000003933383,0.00017558591,0.0002313122],"about_ca_topic_score_codex":0.00069324847,"about_ca_topic_score_gemma":0.0010194721,"teacher_disagreement_score":0.039932463,"about_ca_system_score_codex":0.00009675654,"about_ca_system_score_gemma":0.00011909504,"threshold_uncertainty_score":0.7635868},"labels":[],"label_agreement":null},{"id":"W4310109045","doi":"10.1182/blood-2022-166429","title":"Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Venetoclax; Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Dexamethasone; Population; Proportional hazards model; Bortezomib; Gastroenterology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.00957636951548764,"score_gpt":0.24524580708338173,"score_spread":0.2356694375678941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310109045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998013,0.00026703725,0.000007830451,0.00006902752,0.000035620593,0.0011935979,0.00026597513,0.000026313108,0.000121585246],"genre_scores_gemma":[0.99803275,0.0000133837775,0.0008161516,0.000047549765,0.00001042507,0.0002506607,0.00042195417,0.000038182767,0.0003689395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972409,0.00054187933,0.00042899314,0.00052700087,0.00081703387,0.00044418022],"domain_scores_gemma":[0.9982775,0.00051959127,0.00020412718,0.00052689546,0.00017964852,0.00029223747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004952346,0.00026499465,0.0006952569,0.00068659446,0.00014731874,0.000016460324,0.00012512364,0.0000794157,0.0002765506],"category_scores_gemma":[0.0003483058,0.00022381062,0.0001378008,0.0008471974,0.00014284273,0.00011057832,0.00019243744,0.00033260346,0.0000030216347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03897159,0.0062030028,0.94661796,0.00004188202,0.001746247,0.0016044952,0.0015434643,0.000037930156,0.0020959764,0.0000028586494,0.000042015738,0.0010925691],"study_design_scores_gemma":[0.045018606,0.011015272,0.93897057,0.000048563004,0.0009968108,0.000032242962,0.00027274562,0.00024344682,0.0030930906,0.0000079463025,0.00010525945,0.00019544244],"about_ca_topic_score_codex":0.0006937385,"about_ca_topic_score_gemma":0.00068954483,"teacher_disagreement_score":0.0076473895,"about_ca_system_score_codex":0.0002446312,"about_ca_system_score_gemma":0.00032096184,"threshold_uncertainty_score":0.91267323},"labels":[],"label_agreement":null},{"id":"W4310127434","doi":"10.1182/blood-2022-157547","title":"Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary; Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto","funders":"","keywords":"Multiple myeloma; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Oncology; Pomalidomide; Bortezomib","score_opus":0.01930820697504737,"score_gpt":0.285848960289887,"score_spread":0.2665407533148396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310127434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975877,0.00019706633,0.0000031215534,0.000025551928,0.00005767581,0.0018403159,0.00019345182,0.0000569716,0.000038153998],"genre_scores_gemma":[0.99797857,0.000010899494,0.00023087507,0.000042023672,0.000038754337,0.0013518401,0.00015740115,0.000041122992,0.00014849189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766624,0.00031206294,0.00030701002,0.00049879553,0.0008429815,0.00037293305],"domain_scores_gemma":[0.9990123,0.00017082601,0.00009214771,0.0004818436,0.000078310695,0.00016457387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014758421,0.00021398223,0.0002727851,0.00023802833,0.00018994739,0.000037523478,0.00012886884,0.000040575727,0.0004894407],"category_scores_gemma":[0.00015076382,0.00017210834,0.000049769547,0.0003057387,0.000044927227,0.00021812563,0.000106758176,0.00033724197,0.000017870507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03346476,0.020226194,0.9322739,0.0000046877108,0.00017124534,0.0008101949,0.008321201,8.5981526e-7,0.0018153607,2.2295735e-7,0.000006027485,0.002905313],"study_design_scores_gemma":[0.09287037,0.009731471,0.8923929,0.000028164428,0.00003586821,0.0000029072833,0.0018982898,0.000014250118,0.0027519239,0.0000016092627,0.0001174327,0.00015485502],"about_ca_topic_score_codex":0.00067991135,"about_ca_topic_score_gemma":0.0001180346,"teacher_disagreement_score":0.05940561,"about_ca_system_score_codex":0.0001446846,"about_ca_system_score_gemma":0.00011817595,"threshold_uncertainty_score":0.7018375},"labels":[],"label_agreement":null},{"id":"W4310159991","doi":"10.1182/blood-2022-163335","title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Multiple myeloma; Internal medicine; Oncology; Thalidomide; Ixazomib; Carfilzomib","score_opus":0.02020970116908737,"score_gpt":0.2842972444813167,"score_spread":0.26408754331222933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310159991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952568,0.0008568089,0.000033335575,0.0001806237,0.00006337638,0.0027424837,0.00075710734,0.000043276785,0.00006620757],"genre_scores_gemma":[0.99796635,0.00012474778,0.0007243212,0.000059832786,0.000022963452,0.00035086708,0.0006267216,0.000057822857,0.00006638006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958934,0.0006711142,0.0007045735,0.00085192773,0.0011875001,0.0006914686],"domain_scores_gemma":[0.99749583,0.00089592306,0.00028702494,0.00078593293,0.00016284808,0.00037242624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006447351,0.00046810287,0.0012830163,0.00081459375,0.0003608049,0.000047528,0.00028656423,0.000090534704,0.00016063606],"category_scores_gemma":[0.00033338892,0.00033254063,0.00017753454,0.0023647244,0.0002322043,0.0001556339,0.00025705487,0.0005404562,0.0000018530591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042680915,0.010179412,0.933577,0.00006963941,0.0064335554,0.0008176289,0.002020613,0.00028374942,0.0017511363,0.0000025354386,0.00005293132,0.0021308977],"study_design_scores_gemma":[0.2959157,0.0035424212,0.687155,0.000067187255,0.005799994,0.000026929614,0.0013844237,0.0019952997,0.003742445,0.0000034969032,0.00006151812,0.00030558795],"about_ca_topic_score_codex":0.0035405734,"about_ca_topic_score_gemma":0.005329538,"teacher_disagreement_score":0.25323477,"about_ca_system_score_codex":0.00016992896,"about_ca_system_score_gemma":0.00021443063,"threshold_uncertainty_score":0.9999127},"labels":[],"label_agreement":null},{"id":"W4310161009","doi":"10.1182/blood-2022-167113","title":"Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Chromosome abnormality; Internal medicine; Oncology; Medicine; Biology; Genetics; Chromosome; Karyotype; Gene","score_opus":0.03853193098052319,"score_gpt":0.28129435749673903,"score_spread":0.24276242651621585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310161009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977732,0.00020552157,0.0000016659305,0.00010849978,0.00010867966,0.00056072866,0.0005182944,0.00004739307,0.00067605526],"genre_scores_gemma":[0.99872994,0.000021478016,0.00013583894,0.000042604337,0.000100966165,0.00020012069,0.00020298133,0.000027317012,0.0005387575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978929,0.00019475255,0.00032932445,0.00029873577,0.00089256803,0.00039172982],"domain_scores_gemma":[0.99910194,0.00010969568,0.00010226872,0.00039706432,0.000068279,0.00022074617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032716576,0.00015352227,0.00038911245,0.00022866635,0.0001054195,0.000010488793,0.00017933539,0.00005255429,0.0006521868],"category_scores_gemma":[0.00015263222,0.00014210874,0.00008618916,0.00022652787,0.00006728807,0.00010207824,0.00020145567,0.0002953246,0.000011004696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007724877,0.0040720147,0.98483896,0.00013837471,0.00018414544,0.0010117892,0.00083807996,0.000018935496,0.0074494667,0.000056064662,0.000022676133,0.0005970017],"study_design_scores_gemma":[0.014578216,0.0011804047,0.9627558,0.0000410853,0.000055805835,0.00009475804,0.001671585,0.00026960226,0.018954363,0.000021664464,0.00025830124,0.00011838593],"about_ca_topic_score_codex":0.00080503896,"about_ca_topic_score_gemma":0.00053455966,"teacher_disagreement_score":0.022083135,"about_ca_system_score_codex":0.00010073901,"about_ca_system_score_gemma":0.00017074386,"threshold_uncertainty_score":0.7140988},"labels":[],"label_agreement":null},{"id":"W4310161038","doi":"10.1182/blood-2022-158011","title":"Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; University of Calgary; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Daratumumab; Tolerability; Refractory (planetary science); Regimen; Dexamethasone; Internal medicine; Population; Multiple myeloma; Oncology; Proteasome inhibitor; Pharmacology; Adverse effect; Biology","score_opus":0.027351468814737673,"score_gpt":0.28865458530026,"score_spread":0.26130311648552235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310161038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405533,0.0025228157,0.000009333407,0.00062526006,0.00009449456,0.0007700266,0.00011246255,0.00007274126,0.001737563],"genre_scores_gemma":[0.9949548,0.00019266395,0.001861119,0.00022217522,0.00010527403,0.00026116899,0.0001257892,0.000040213126,0.0022367563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997919,0.00022038055,0.00031843345,0.0004847385,0.0005455548,0.00051184575],"domain_scores_gemma":[0.99886835,0.00030089653,0.00008031027,0.00039320262,0.00005573473,0.00030152657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042001472,0.00020562886,0.00040504834,0.00025879458,0.00019202226,0.000020777848,0.00013260041,0.000073743475,0.00029162073],"category_scores_gemma":[0.0005249149,0.00019140932,0.000078255245,0.00041775813,0.00007291386,0.00008868548,0.0002347682,0.00055592204,0.000022487944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019162195,0.0046699694,0.9123683,0.00014653963,0.0003523208,0.0026770346,0.0008091926,0.000015414895,0.04055422,0.000051458697,0.0014006452,0.03503867],"study_design_scores_gemma":[0.067067765,0.0026436185,0.8698538,0.00009653485,0.00022483217,0.0006007832,0.0015724576,0.0030885243,0.010681234,0.000073564166,0.043619268,0.0004776116],"about_ca_topic_score_codex":0.0007724348,"about_ca_topic_score_gemma":0.0003392973,"teacher_disagreement_score":0.06515154,"about_ca_system_score_codex":0.00016952933,"about_ca_system_score_gemma":0.00020639948,"threshold_uncertainty_score":0.7805445},"labels":[],"label_agreement":null},{"id":"W4310161266","doi":"10.1182/blood-2022-166854","title":"Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Cancer; Internal medicine; Open label; Oncology; Clinical trial","score_opus":0.04226042840478516,"score_gpt":0.35336905738708646,"score_spread":0.3111086289823013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310161266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222475,0.000072478455,0.0000060332004,0.00004432503,0.000018971385,0.006898784,0.00060191046,0.000019835947,0.00011291517],"genre_scores_gemma":[0.99553794,0.000008590148,0.0010888702,0.00003501882,0.000010361278,0.002351149,0.00050561514,0.00005716435,0.00040531528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982556,0.00013503923,0.00025895986,0.00044767125,0.00058353256,0.0003192154],"domain_scores_gemma":[0.99910784,0.0000595566,0.00014476737,0.0003955083,0.00015489967,0.00013742963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013692306,0.00020540872,0.00041881634,0.00019648849,0.00016097557,0.00002596316,0.00023146218,0.000029462797,0.00016954863],"category_scores_gemma":[0.000020087955,0.00015022107,0.000018332767,0.0003496832,0.000038042315,0.0001733053,0.00011446975,0.00011008876,0.0000016395028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009009761,0.20513634,0.77296835,0.0000490982,0.00071677,0.00006403363,0.00064727233,0.000011777514,0.00087777455,0.0000054331595,0.000018868155,0.010494548],"study_design_scores_gemma":[0.41931334,0.07102186,0.506275,0.000049634258,0.00039214146,0.000004174851,0.0005569679,0.0003524065,0.0017489804,0.0000045944744,0.00012879902,0.00015210005],"about_ca_topic_score_codex":0.002161132,"about_ca_topic_score_gemma":0.0011156626,"teacher_disagreement_score":0.4103036,"about_ca_system_score_codex":0.00010401931,"about_ca_system_score_gemma":0.00012398775,"threshold_uncertainty_score":0.6125837},"labels":[],"label_agreement":null},{"id":"W4310167620","doi":"10.1182/blood-2022-169721","title":"Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Receptor; Cancer research; Lenalidomide; Internal medicine; Oncology; Immunology","score_opus":0.01622887686775603,"score_gpt":0.2632041443761236,"score_spread":0.24697526750836757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310167620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612105,0.0002874633,0.0000033473304,0.00009778427,0.00008521424,0.0006769634,0.00009952816,0.000023412049,0.0026052373],"genre_scores_gemma":[0.998005,0.000028650604,0.00046872,0.00005248513,0.000041886622,0.00023858859,0.00010837532,0.0000259744,0.0010303365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985762,0.00012330752,0.0002520727,0.0002832788,0.00044666967,0.00031843048],"domain_scores_gemma":[0.9991696,0.00029100876,0.00009465167,0.00029924183,0.000035806897,0.00010972925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015713427,0.00013409593,0.0003082851,0.00020725015,0.000066211935,0.00000814331,0.00011617443,0.000026013913,0.00019904533],"category_scores_gemma":[0.00026881872,0.00012021119,0.00010561929,0.00035595318,0.00004860073,0.00010064415,0.00014636634,0.0002675523,0.000018713936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014893208,0.0070039704,0.93334883,0.00009208775,0.00013848422,0.0017413138,0.0007535709,0.000012790845,0.052874528,0.000014085665,0.00039617243,0.0021348356],"study_design_scores_gemma":[0.03136158,0.0016099102,0.6142286,0.000060801944,0.00009993245,0.000056752026,0.0017570187,0.000116237454,0.3491779,0.000035046123,0.0013150093,0.00018119275],"about_ca_topic_score_codex":0.001048442,"about_ca_topic_score_gemma":0.00011788059,"teacher_disagreement_score":0.3191202,"about_ca_system_score_codex":0.00011746247,"about_ca_system_score_gemma":0.00018529917,"threshold_uncertainty_score":0.490207},"labels":[],"label_agreement":null},{"id":"W4311027234","doi":"10.1111/bjh.18568","title":"Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis","year":2022,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Queen's University","funders":"","keywords":"Surrogate endpoint; Medicine; Confidence interval; Hazard ratio; Internal medicine; Progression-free survival; Clinical endpoint; Multiple myeloma; Oncology; Clinical trial; Proportional hazards model; Pearson product-moment correlation coefficient; Overall survival; Statistics; Mathematics","score_opus":0.07511153867178022,"score_gpt":0.38234383984500037,"score_spread":0.30723230117322015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311027234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017082538,0.9764308,0.00006785241,0.00048251523,0.0003681081,0.0040486236,0.0013879229,0.00002434948,0.00010731418],"genre_scores_gemma":[0.00065881805,0.994707,0.0014772005,0.00017693073,0.00027350397,0.0004021113,0.0011067807,0.0001120105,0.0010856718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871503,0.005213629,0.0045499303,0.0008059021,0.0012007717,0.0010794296],"domain_scores_gemma":[0.9891696,0.0065710363,0.0020016478,0.00060923456,0.0002625691,0.0013859379],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0063952873,0.00065662747,0.01368169,0.0031162545,0.00014270503,0.0000963881,0.00072023954,0.00040858833,0.020983303],"category_scores_gemma":[0.014191195,0.00060215715,0.003758385,0.001758094,0.00010057155,0.00011747689,0.0003421308,0.0013356949,0.0009740976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005801916,0.0010000523,0.00019442906,0.0010685924,0.013087318,0.16332234,0.00008935899,0.00002643933,0.000004015356,6.972259e-7,0.015350761,0.8000541],"study_design_scores_gemma":[0.04460682,0.00055820553,0.0005270035,0.009500762,0.011384364,0.045830145,0.000045341043,0.000054423017,0.000010543608,0.000014924217,0.886947,0.00052049273],"about_ca_topic_score_codex":0.0013702442,"about_ca_topic_score_gemma":0.001494833,"teacher_disagreement_score":0.8715962,"about_ca_system_score_codex":0.0007676554,"about_ca_system_score_gemma":0.001417958,"threshold_uncertainty_score":0.9998038},"labels":[],"label_agreement":null},{"id":"W4311587513","doi":"10.1038/s41408-022-00757-8","title":"Second- and third-line treatment strategies in multiple myeloma: a referral-center experience","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Referral; Medicine; Center (category theory); Internal medicine; Oncology; Family medicine; Intensive care medicine","score_opus":0.0614510644982715,"score_gpt":0.3488668860152637,"score_spread":0.28741582151699224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311587513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331445,0.0038417843,0.0000053976305,0.0006400531,0.00014171918,0.0003465732,0.00006428406,0.00001966685,0.0016260635],"genre_scores_gemma":[0.9961751,0.0016116748,0.00026561358,0.00012409802,0.00016848007,0.0003506329,0.000014483878,0.000019972602,0.001269941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985149,0.00010485075,0.00028685288,0.0002681159,0.0003982848,0.00042700977],"domain_scores_gemma":[0.9993683,0.00004004571,0.00008663828,0.00016818674,0.000048545957,0.0002882988],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013362025,0.00018163696,0.00029837093,0.0001838109,0.00032036836,0.00007250077,0.00009101289,0.000032894182,0.0017392498],"category_scores_gemma":[0.00002017459,0.00013708526,0.000078152654,0.00016840486,0.000064783584,0.00017927558,0.00008366433,0.00039942947,0.0000034033333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028192939,0.003512837,0.9102622,0.00007340785,0.00056442514,0.0057020066,0.007846161,0.00011598031,0.013704076,0.000047495894,0.00052036095,0.054831706],"study_design_scores_gemma":[0.093997106,0.008403483,0.79830617,0.0002964429,0.00026401057,0.012464612,0.016902309,0.0016478417,0.012385196,0.00027670318,0.05442435,0.00063177047],"about_ca_topic_score_codex":0.00038316773,"about_ca_topic_score_gemma":0.0010918243,"teacher_disagreement_score":0.111956075,"about_ca_system_score_codex":0.0003808146,"about_ca_system_score_gemma":0.00041999342,"threshold_uncertainty_score":0.9991733},"labels":[],"label_agreement":null},{"id":"W4311624411","doi":"10.3390/curroncol29120749","title":"Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Epigenetics; Chromatin remodeling; Multiple myeloma; Cancer research; Chromatin; Bone marrow; Tumor progression; Biology; Immune system; Medicine; Cancer; Bioinformatics; Computational biology; Immunology; Gene; Tumor cells; Genetics","score_opus":0.21998668852243997,"score_gpt":0.4499656839527758,"score_spread":0.22997899543033584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311624411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024200391,0.9726615,0.000024788531,0.000045462282,0.00020267603,0.0024246625,0.00018471974,0.00003499359,0.00022082483],"genre_scores_gemma":[0.0026960818,0.9943655,0.00057447405,0.000020387346,0.00014438783,0.00077469164,0.001301506,0.00008513108,0.00003779858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966683,0.0005106089,0.00087731914,0.0008352116,0.00040710616,0.0007014614],"domain_scores_gemma":[0.9983202,0.0005094223,0.00030614983,0.00047985135,0.00001690334,0.00036745617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041440065,0.0005180995,0.0023341675,0.0004485228,0.00013272645,0.000022256525,0.00021198469,0.00020932558,0.00037059942],"category_scores_gemma":[0.00028316816,0.0004460415,0.0003312019,0.00025845718,0.00018822686,0.000038129514,0.0005527336,0.0011644483,0.000066764704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004457468,0.00051439815,0.0039001007,0.008206981,0.00016006904,0.0011372624,0.00006619302,0.0000011774115,0.00001240062,0.0000022045715,0.00006198576,0.98589265],"study_design_scores_gemma":[0.0031260166,0.0005529724,0.0017091451,0.0033393574,0.0005449673,0.0003398716,0.000032250686,0.000182478,0.0000073752276,0.000010097774,0.9898581,0.00029739767],"about_ca_topic_score_codex":0.000036612797,"about_ca_topic_score_gemma":0.000013267536,"teacher_disagreement_score":0.9897961,"about_ca_system_score_codex":0.0018017179,"about_ca_system_score_gemma":0.00058241043,"threshold_uncertainty_score":0.99979913},"labels":[],"label_agreement":null},{"id":"W4311663966","doi":"10.1182/hematology.2022000334","title":"Antibodies and bispecifics for multiple myeloma: effective effector therapy","year":2022,"lang":"en","type":"review","venue":"Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Antibody; Monoclonal antibody; Medicine; Antigen; Multiple myeloma; clone (Java method); Cancer research; Immunotherapy; Immunology; Bispecific antibody; Immune system; Biology","score_opus":0.0949432377112657,"score_gpt":0.4019331827898597,"score_spread":0.306989945078594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311663966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004970721,0.9907136,0.00003730862,0.00003650465,0.00026525575,0.0078095538,0.00028674584,0.000086832675,0.00026715102],"genre_scores_gemma":[0.00021345646,0.9926153,0.0006184297,0.000032530355,0.00012623786,0.005097946,0.000922932,0.000105814426,0.00026734377],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778664,0.0003546292,0.00040303965,0.00068231777,0.00021633029,0.0005570385],"domain_scores_gemma":[0.9947576,0.004345039,0.00019241215,0.00043910046,0.000056447992,0.0002094141],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002512436,0.00050616544,0.0028270292,0.0003462384,0.00023115084,0.000018985329,0.00012706315,0.00032108894,0.00022788614],"category_scores_gemma":[0.0006225107,0.00035097334,0.00052952796,0.00019804391,0.0001827497,0.000028196235,0.0001378853,0.00043275097,0.00006156563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040914636,0.00026787966,0.0013719697,0.023868313,0.0012931251,0.0003930272,0.000049216924,6.8428174e-9,0.0000025692152,0.00028856247,0.0011711438,0.97088504],"study_design_scores_gemma":[0.0040834295,0.0011351048,0.0003822282,0.0014444292,0.0004591801,0.0015967702,0.000018250124,0.000014505275,0.000034452605,0.000030786847,0.990548,0.00025284855],"about_ca_topic_score_codex":0.000016415896,"about_ca_topic_score_gemma":0.000008608692,"teacher_disagreement_score":0.98937684,"about_ca_system_score_codex":0.00014061171,"about_ca_system_score_gemma":0.00017727373,"threshold_uncertainty_score":0.9998942},"labels":[],"label_agreement":null},{"id":"W4311849859","doi":"10.3389/fonc.2022.1061417","title":"Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; Moncton Hospital; Hamilton Health Sciences; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre; Positive Living North","funders":"Janssen Canada","keywords":"Medicine; Multiple myeloma; Adverse effect; Health care; Quality of life (healthcare); Dosing; Intensive care medicine; Perspective (graphical); Quality (philosophy); Nursing; Internal medicine","score_opus":0.1217677207842939,"score_gpt":0.39822275766384363,"score_spread":0.27645503687954975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311849859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573974,0.0006125991,0.0000112633425,0.03936357,0.00031031427,0.0018165578,0.000055800065,0.000004750388,0.0004277276],"genre_scores_gemma":[0.99170125,0.00012242413,0.003159023,0.004571198,0.000016243544,0.0003465384,0.00002015955,0.000013548332,0.000049600425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654007,0.0020585582,0.00047996733,0.000341813,0.00024129797,0.00033829105],"domain_scores_gemma":[0.997851,0.0015052402,0.0001264832,0.00027993345,0.000056264027,0.00018104435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009329418,0.00011730402,0.0004183135,0.0005444595,0.00006149353,0.0000063440657,0.000094613744,0.000093348,0.000043848748],"category_scores_gemma":[0.0032142545,0.00008759057,0.000049302333,0.000287353,0.00012865842,0.000053716965,0.00006937163,0.00080691575,0.0000014219528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055566747,0.001621277,0.8221335,0.000030347504,0.000036026846,0.0008759947,0.0051331306,0.00012673692,0.0000020853797,0.000048139795,0.0044056517,0.16003047],"study_design_scores_gemma":[0.0096028345,0.013172604,0.8197133,0.00014452779,0.000014812352,0.000021096144,0.033796243,0.021587092,0.000011144452,0.000039961953,0.10177389,0.0001225263],"about_ca_topic_score_codex":0.07897613,"about_ca_topic_score_gemma":0.24931534,"teacher_disagreement_score":0.1703392,"about_ca_system_score_codex":0.0025736217,"about_ca_system_score_gemma":0.000980047,"threshold_uncertainty_score":0.92715704},"labels":[],"label_agreement":null},{"id":"W4311870820","doi":"10.5348/100116z10gi2022cr","title":"A case of incidental multiple Myeloma presenting with pathologically proven large frontal skull plasmacytoma and review of therapeutic targets: Case report","year":2022,"lang":"en","type":"article","venue":"Journal of Case Reports and Images in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Multiple myeloma; Plasmacytoma; Medicine; Radiology; Lenalidomide; Skeletal survey; Plasma cell; Magnetic resonance imaging; Internal medicine","score_opus":0.02127635905644106,"score_gpt":0.3417416440208804,"score_spread":0.3204652849644394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311870820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776066,0.021028448,0.000029925479,0.00020403597,0.00006802861,0.0007691564,0.000044169024,0.0000044731587,0.00024514837],"genre_scores_gemma":[0.9951135,0.0017793555,0.0028559517,0.00008840649,0.000039865616,0.000036937512,0.00001118322,0.000016528062,0.000058281243],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9974037,0.0003256439,0.0013650627,0.00026479244,0.00036537214,0.00027545428],"domain_scores_gemma":[0.99725753,0.00031653568,0.0016874002,0.00022592391,0.00031461875,0.000197984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002001394,0.00016948591,0.00092489587,0.00022105586,0.00012753878,0.000008561526,0.000032307533,0.00006306038,0.000116263254],"category_scores_gemma":[0.00097525056,0.000113187605,0.00011898577,0.00014384396,0.00021104483,0.00013889815,0.00021649127,0.00046999802,4.8297334e-8],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080843514,0.0008598153,0.18511187,0.00090369687,0.00019775599,0.80164814,0.00038478654,0.0000011799173,0.0010168608,0.0000014223888,0.000096213735,0.008969851],"study_design_scores_gemma":[0.003941264,0.004016519,0.016121924,0.0004055746,0.0002830836,0.9714597,0.0018308931,0.00012033125,0.00069029024,0.000018863395,0.0010200525,0.00009152151],"about_ca_topic_score_codex":0.00028444975,"about_ca_topic_score_gemma":0.0002366713,"teacher_disagreement_score":0.16981156,"about_ca_system_score_codex":0.0001769781,"about_ca_system_score_gemma":0.00044626705,"threshold_uncertainty_score":0.46156564},"labels":[],"label_agreement":null},{"id":"W4312095146","doi":"10.3324/haematol.2022.280482","title":"Adjusted comparison of outcomes between patients from CARTITUDE-1 &lt;i&gt;versus&lt;/i&gt; multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"Legend Biotech","keywords":"Medicine; Hazard ratio; Internal medicine; Multiple myeloma; Confidence interval; Dexamethasone; Gastroenterology; Pomalidomide; Cyclophosphamide; Proportional hazards model; Oncology; Bortezomib; Chemotherapy","score_opus":0.03679352061212361,"score_gpt":0.35022404532614887,"score_spread":0.31343052471402527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312095146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088466,0.00014086496,0.000009480077,0.00021860051,0.00016711757,0.007690969,0.0007523683,0.000059703645,0.000076264005],"genre_scores_gemma":[0.99625534,0.0000069362177,0.0019112544,0.00003146726,0.000047572063,0.00044779302,0.0012417379,0.000039199014,0.00001869057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945953,0.0011145098,0.0013166727,0.0007892742,0.0017956469,0.00038858832],"domain_scores_gemma":[0.99439585,0.0027196025,0.0010420061,0.0007428356,0.0008628663,0.00023681992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005800922,0.000385671,0.0013822288,0.0002001933,0.00045573333,0.000028008108,0.00033260245,0.000113771435,0.000060695536],"category_scores_gemma":[0.001739421,0.0002524744,0.0001435416,0.0005125401,0.00024215142,0.00022174587,0.0006175081,0.0005083961,0.000006824445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005973786,0.0134562105,0.9723786,0.00004284441,0.0013468444,0.000023582854,0.0030041141,0.000022169344,0.00024533027,0.000017410533,0.00011910269,0.003370019],"study_design_scores_gemma":[0.028607383,0.0069975606,0.96155,0.00010377848,0.0004432816,6.275961e-7,0.0015083536,0.00006796819,0.00032719635,0.0000053634426,0.00016429267,0.0002241858],"about_ca_topic_score_codex":0.0010659691,"about_ca_topic_score_gemma":0.00057846995,"teacher_disagreement_score":0.022633597,"about_ca_system_score_codex":0.00019429476,"about_ca_system_score_gemma":0.00013795715,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W4312114807","doi":"10.1038/s41408-022-00769-4","title":"Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Flatiron Health","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Chromosomal translocation; Internal medicine; Oncology; CD38; Daratumumab; Hematology; Bortezomib; Stem cell; Biology","score_opus":0.01845025648032841,"score_gpt":0.2758553600145342,"score_spread":0.2574051035342058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620049,0.0050264625,0.000009963637,0.030919697,0.00038678467,0.0013981111,0.000116508876,0.000022009173,0.00011556411],"genre_scores_gemma":[0.9739771,0.0061532296,0.00035991555,0.0166445,0.0014864003,0.00029592653,0.0005095027,0.00017342837,0.00040001053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628526,0.00037051868,0.0006622282,0.0004209566,0.0016481869,0.00061286293],"domain_scores_gemma":[0.99838895,0.0001628154,0.0005580843,0.00035867016,0.00035971223,0.00017175946],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035122377,0.000385023,0.00076853944,0.00059232523,0.00015825217,0.000039346574,0.0002579966,0.0002967744,0.0010636657],"category_scores_gemma":[0.00009168472,0.00028597013,0.00018584251,0.00043528999,0.000087117995,0.00015896244,0.000026119162,0.0028743052,0.0000026691164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014690938,0.0015112573,0.94150305,0.00034984894,0.001220836,0.0013814761,0.0004672407,0.00003751969,0.000119522534,4.464633e-7,0.020864213,0.03107547],"study_design_scores_gemma":[0.025403839,0.003631566,0.9302943,0.0021770652,0.00042023204,0.00017491053,0.000032029857,0.0000157422,0.0004048653,0.000011062245,0.03711301,0.00032138097],"about_ca_topic_score_codex":0.00033290542,"about_ca_topic_score_gemma":0.000059404625,"teacher_disagreement_score":0.03075409,"about_ca_system_score_codex":0.00042733038,"about_ca_system_score_gemma":0.0012709264,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W4312269342","doi":"10.1166/jbn.2022.3380","title":"Clinical Significance of Circulating Clonal Plasma Cells Detected by a Novel Microfluidic Chip in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Journal of Biomedical Nanotechnology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Microfluidic chip; Microfluidics; Minimal residual disease; Flow cytometry; Bone marrow; Multiple myeloma; Biomarker; Medicine; Biology; Pathology; Immunology; Materials science; Nanotechnology; Biochemistry","score_opus":0.03129925112652226,"score_gpt":0.30995542224662975,"score_spread":0.2786561711201075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312269342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944002,0.0011029001,0.0017515409,0.0018843359,0.00032422107,0.00038959295,0.00011177705,0.000026764683,0.00000866871],"genre_scores_gemma":[0.9949406,0.00019523493,0.0045634727,0.00010549576,0.00008966103,0.000021964886,0.00002554055,0.00002576248,0.000032298092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962614,0.00022789594,0.0016644668,0.00032594363,0.0009866091,0.00053366646],"domain_scores_gemma":[0.997728,0.00079384627,0.00071572163,0.00027833,0.00015200808,0.0003320742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012768143,0.00019303757,0.00089447154,0.00087318616,0.00009897611,0.0000049420264,0.00042787715,0.00038157316,0.00021084631],"category_scores_gemma":[0.0017037346,0.00016200943,0.0002896726,0.001042387,0.00071709946,0.000044358014,0.00024833975,0.0017240215,0.0000054466987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015956067,0.0024283936,0.04341461,0.00005922634,0.00021864205,0.0011533608,0.000043916745,0.0000026698242,0.89149415,0.0000072434696,0.0010702015,0.05851196],"study_design_scores_gemma":[0.055732843,0.014747186,0.09966841,0.00040597434,0.0002092374,0.0059004007,0.00075626094,0.006798646,0.7845321,0.0001766276,0.03058324,0.0004890564],"about_ca_topic_score_codex":0.00006960206,"about_ca_topic_score_gemma":0.000004637437,"teacher_disagreement_score":0.10696205,"about_ca_system_score_codex":0.0002840703,"about_ca_system_score_gemma":0.0005966632,"threshold_uncertainty_score":0.74901116},"labels":[],"label_agreement":null},{"id":"W4313379762","doi":"10.1053/j.ajkd.2022.11.008","title":"The Association Between the Urine Protein-to-Albumin Gap and the Diagnosis of Multiple Myeloma: A Population-Based Retrospective Cohort Study","year":2022,"lang":"en","type":"letter","venue":"American Journal of Kidney Diseases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital; University of Ottawa","funders":"National Kidney Foundation","keywords":"Medicine; Multiple myeloma; Retrospective cohort study; Albumin; Urine; Myeloma protein; Cohort; Internal medicine; Population; Environmental health","score_opus":0.012861551538356542,"score_gpt":0.28571751848230886,"score_spread":0.2728559669439523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313379762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.623407,0.0003484699,0.0000050581407,0.3713035,0.000086908796,0.003930128,0.0008770861,0.000011505049,0.000030328016],"genre_scores_gemma":[0.96925247,0.000099817975,0.000038635182,0.02815873,0.0010302188,0.0009169583,0.00021846678,0.000050113813,0.00023456346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947449,0.0015663423,0.0007643612,0.00030304375,0.002224169,0.000397187],"domain_scores_gemma":[0.992119,0.0044074287,0.0018287192,0.00056435016,0.0005708476,0.0005096341],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012207999,0.0003109865,0.0011214793,0.00021487418,0.0005611235,0.00008243634,0.00043289104,0.000056464338,0.00007982549],"category_scores_gemma":[0.0167742,0.00014359124,0.00042008585,0.00057225884,0.00039397145,0.00005558438,0.00013671005,0.0011808935,0.0000020650277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016423974,0.00032341096,0.91010857,0.00003695259,0.002889162,0.00013308805,0.00015293567,0.000003245931,9.1445787e-7,0.0000010851576,0.082677335,0.0020309153],"study_design_scores_gemma":[0.0048021916,0.002500599,0.97812116,0.00015251871,0.002220627,0.000007686215,0.0004075954,0.000017601757,0.000010738747,0.00003875919,0.011591208,0.00012932859],"about_ca_topic_score_codex":0.001992435,"about_ca_topic_score_gemma":0.000025594572,"teacher_disagreement_score":0.34584546,"about_ca_system_score_codex":0.00081390666,"about_ca_system_score_gemma":0.00083158223,"threshold_uncertainty_score":0.99150795},"labels":[],"label_agreement":null},{"id":"W4313431583","doi":"10.1080/10428194.2022.2148221","title":"Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Tapering; Refractory (planetary science); Open label; Multicenter study; Multiple myeloma; Phases of clinical research; Oncology; Internal medicine; Clinical trial; Computer science; Materials science; Lenalidomide","score_opus":0.03396421959788129,"score_gpt":0.2982158978671249,"score_spread":0.26425167826924356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313431583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933383,0.00021398833,0.000006306635,0.00004600783,0.0002545108,0.0049948096,0.000164437,0.00014966595,0.0008319985],"genre_scores_gemma":[0.99634457,0.0002047512,0.00052173744,0.00025085328,0.000072234,0.0005441949,0.00022507878,0.00017031743,0.0016662452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99404114,0.0005178357,0.0012971307,0.0014325009,0.0013872389,0.001324161],"domain_scores_gemma":[0.9963074,0.0006683979,0.00055062474,0.0015953984,0.00028117563,0.0005970092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062447187,0.00082483713,0.0013442149,0.000459373,0.0006456805,0.00019899046,0.00085522386,0.00031853045,0.000057656478],"category_scores_gemma":[0.00058814604,0.0005367182,0.00013537731,0.0016842432,0.00037557783,0.0004864995,0.00096165104,0.0003653296,0.000037238173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054644316,0.015369718,0.6856972,0.0005368809,0.00091979885,0.0021506855,0.0052911914,0.000020684372,0.0018204667,0.0000042413194,0.0008087374,0.2327361],"study_design_scores_gemma":[0.24091116,0.007553521,0.73250747,0.0009203774,0.00028028956,0.00022583338,0.0024218978,0.011889957,0.0011049118,0.0000033600857,0.0015566073,0.0006246278],"about_ca_topic_score_codex":0.0017643409,"about_ca_topic_score_gemma":0.00048312172,"teacher_disagreement_score":0.23211147,"about_ca_system_score_codex":0.004114084,"about_ca_system_score_gemma":0.0019584675,"threshold_uncertainty_score":0.99970895},"labels":[],"label_agreement":null},{"id":"W4313544410","doi":"10.1200/jco.22.00940","title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute","keywords":"Lenalidomide; Medicine; Daratumumab; Dexamethasone; Multiple myeloma; Oncology; Internal medicine","score_opus":0.23679982054285367,"score_gpt":0.5162298201272686,"score_spread":0.27942999958441495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313544410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124056,0.0004914388,0.000054795066,0.0026254563,0.00045704184,0.0033086387,0.000013565074,0.000025674159,0.0017828072],"genre_scores_gemma":[0.9931166,0.0021940656,0.002720736,0.00031880723,0.00046856637,0.000115477575,0.000024133855,0.000041160034,0.0010004308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99214506,0.0028008681,0.0032500182,0.00045060253,0.00071467826,0.000638762],"domain_scores_gemma":[0.98306644,0.0136859,0.0015772721,0.00032042532,0.00040122974,0.00094870426],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0126693165,0.0003116644,0.004753676,0.0004554769,0.00009220602,0.000062504776,0.0003195423,0.000419507,0.00012788107],"category_scores_gemma":[0.017121222,0.00018573318,0.00033213967,0.00054623734,0.00057854387,0.000297921,0.00021359477,0.001266217,0.000025196927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90187144,0.00721743,0.016499402,0.000028871336,0.0014749041,0.007961342,0.00014124018,0.0000038139453,0.00012119129,0.000047250403,0.0008535204,0.06377956],"study_design_scores_gemma":[0.930879,0.04567247,0.017915182,0.00024806126,0.0005063513,0.00037577908,0.00008826867,0.0013952181,0.00004844574,0.00013796966,0.0025715488,0.0001617244],"about_ca_topic_score_codex":0.0004416663,"about_ca_topic_score_gemma":0.00073038123,"teacher_disagreement_score":0.06361784,"about_ca_system_score_codex":0.00020576469,"about_ca_system_score_gemma":0.0018449848,"threshold_uncertainty_score":0.991158},"labels":[],"label_agreement":null},{"id":"W4313545228","doi":"10.1038/s41408-022-00779-2","title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Ottawa Hospital; McMaster University","funders":"National Institute on Aging; National Cancer Institute; Hamilton Health Sciences Foundation; Cancer Research UK; Hamilton Health Sciences","keywords":"Medicine; Clinical trial; Population; Randomized controlled trial; Frailty syndrome; Multiple myeloma; Psychological intervention; Gerontology; MEDLINE; Internal medicine; Frailty Index","score_opus":0.19399017801219695,"score_gpt":0.4970273322898045,"score_spread":0.3030371542776076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313545228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084381364,0.9913276,4.016144e-7,0.00023698418,0.00022980398,0.0072485246,0.000093641014,0.000009924113,0.000009303258],"genre_scores_gemma":[0.00022243682,0.9975991,0.000033703105,0.000050445946,0.00016308046,0.0013913496,0.0000068287595,0.000050598097,0.00048244026],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9877411,0.0048513785,0.0057000895,0.0004126519,0.0008006751,0.0004940892],"domain_scores_gemma":[0.9860284,0.010469551,0.00245843,0.0005463484,0.00017688479,0.00032042395],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017819408,0.00041509248,0.008143899,0.00032366565,0.00008030222,0.00004464582,0.00036955497,0.0002516518,0.000045553446],"category_scores_gemma":[0.032275226,0.00019529316,0.0011846878,0.00054445484,0.00012614623,0.000060114915,0.000120616074,0.0013397292,0.000014833169],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073885516,0.00027198522,0.02931353,0.77077824,0.0014882473,0.0003720619,0.00003868036,1.5667815e-8,1.2328672e-8,0.0000010324104,0.00012136883,0.19754092],"study_design_scores_gemma":[0.0068169194,0.00016836521,0.029930122,0.95323753,0.00703031,0.00036042833,0.00002637007,0.0000061283145,1.3559794e-7,0.000004861085,0.002266748,0.00015209209],"about_ca_topic_score_codex":0.000112888214,"about_ca_topic_score_gemma":0.00042509337,"teacher_disagreement_score":0.19738883,"about_ca_system_score_codex":0.00015654934,"about_ca_system_score_gemma":0.0011844456,"threshold_uncertainty_score":0.97587633},"labels":[],"label_agreement":null},{"id":"W4315880837","doi":"10.1101/mcs.a006249","title":"Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression","year":2023,"lang":"en","type":"article","venue":"Molecular Case Studies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Janssen Research and Development; Ministry of Colleges and Universities; Multiple Myeloma Research Foundation; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Hospital Foundation; Princess Margaret Cancer Foundation","keywords":"Multiple myeloma; Cancer research; Targeted therapy; Medicine; Oncology; Biology; Cancer; Internal medicine","score_opus":0.08477564211597191,"score_gpt":0.41738790103084517,"score_spread":0.3326122589148732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315880837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941497,0.0021856385,0.00023856224,0.0008213432,0.00015833658,0.0020896764,0.000046125835,0.0001768855,0.00013373622],"genre_scores_gemma":[0.9849069,0.000076090226,0.014014158,0.0001997374,0.00007017113,0.00029092134,0.000037446665,0.00007405492,0.00033053046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99640244,0.0006527371,0.0008044106,0.0006872636,0.00077908963,0.00067407143],"domain_scores_gemma":[0.99741477,0.00071225385,0.00017172538,0.0006733488,0.0005611165,0.00046678638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001505948,0.00033800263,0.0007814348,0.00044110234,0.00017351877,0.000020392872,0.000112438625,0.00014639753,0.000006669674],"category_scores_gemma":[0.006759951,0.0002715992,0.0003430341,0.00091286143,0.00022600476,0.000049097114,0.00046438983,0.00026510208,0.00013349661],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047676284,0.0006594085,0.034849033,0.0004479312,0.0005295342,0.10329064,0.000478181,0.00001610946,0.8417586,0.000006879277,0.0005532122,0.012642851],"study_design_scores_gemma":[0.0062039136,0.0043038214,0.008604509,0.00073420233,0.00023419208,0.0007153935,0.0011612456,0.00026423135,0.9768472,0.00003770146,0.00056759274,0.00032601543],"about_ca_topic_score_codex":0.0000097586235,"about_ca_topic_score_gemma":0.0000046041246,"teacher_disagreement_score":0.1350886,"about_ca_system_score_codex":0.00012460432,"about_ca_system_score_gemma":0.00012728156,"threshold_uncertainty_score":0.9999736},"labels":[],"label_agreement":null},{"id":"W4317702565","doi":"10.1016/j.jcpo.2023.100407","title":"Subgroups and precision in myeloma","year":2023,"lang":"en","type":"letter","venue":"Journal of Cancer Policy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.04031091324552851,"score_gpt":0.39150086252491695,"score_spread":0.35118994927938846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317702565","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11084452,0.0046742917,0.000002599506,0.8827566,0.00035272958,0.00035424824,0.000059736263,0.00001291025,0.00094235165],"genre_scores_gemma":[0.15474968,0.05817832,0.0007889627,0.66801745,0.07442593,0.00012660022,0.00012366258,0.00041755044,0.043171827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981406,0.000075589385,0.0004858795,0.00016915635,0.00072839967,0.0004003957],"domain_scores_gemma":[0.99897313,0.00019793978,0.00029266483,0.00017906526,0.00016450335,0.00019269038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023839244,0.00019585808,0.0006256462,0.0012562395,0.000025297732,0.000032564913,0.00012219913,0.00033228402,0.00008196401],"category_scores_gemma":[0.00034823292,0.00013833896,0.00015098204,0.00038990777,0.000058475034,0.00008144408,0.000059171427,0.0015481153,0.000023149087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049247127,0.000041825806,0.031039247,0.00035735362,0.00031937705,0.008747234,0.00016281464,0.0000015536891,0.000113537964,0.0000039167962,0.84280926,0.11591141],"study_design_scores_gemma":[0.0045196144,0.00061288796,0.34966633,0.0017242505,0.000111555455,0.0006238965,0.0000140233105,0.000025561114,0.00015125734,0.00041337352,0.64199466,0.00014262105],"about_ca_topic_score_codex":0.0020463606,"about_ca_topic_score_gemma":0.00022072301,"teacher_disagreement_score":0.31862706,"about_ca_system_score_codex":0.0005736825,"about_ca_system_score_gemma":0.000985083,"threshold_uncertainty_score":0.6725877},"labels":[],"label_agreement":null},{"id":"W4318054850","doi":"10.3390/curroncol30020123","title":"Multisite Quality Improvement Initiative to Identify and Address Racial Disparities and Deficiencies in Delivering Equitable, Patient-Centered Care for Multiple Myeloma—Exploring the Differences between Academic and Community Oncology Centers","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Celgene; AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Family medicine; Quality management; Documentation; Nursing; Intervention (counseling); Health care","score_opus":0.4163179202061643,"score_gpt":0.49006488900188605,"score_spread":0.07374696879572173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318054850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949234,0.0017043758,0.00007040784,0.00044424087,0.00031154425,0.0020104265,0.00047393082,0.000040627277,0.0000210297],"genre_scores_gemma":[0.99693036,0.0017022437,0.00009125233,0.000069004534,0.00006392808,0.00093584164,0.00019011747,0.000014984003,0.0000022490522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764526,0.0006141607,0.00046616246,0.00036871785,0.00022893367,0.00067677355],"domain_scores_gemma":[0.9966789,0.0026457629,0.0001324523,0.00017228501,0.00011674438,0.00025386323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006528786,0.00022661741,0.00058407214,0.0002607261,0.00065900903,0.000040657746,0.00014970222,0.00011159902,0.0000014870624],"category_scores_gemma":[0.0010237293,0.00017182813,0.000045700654,0.00020319707,0.00036798674,0.00017240857,0.0009048767,0.00069592457,0.0000013559759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005270471,0.00015324507,0.6667207,0.0004044028,0.00005737784,0.0000074006502,0.027920263,0.0000011168007,0.0012637915,0.000011396448,0.000009143042,0.30292413],"study_design_scores_gemma":[0.005630383,0.002051387,0.94863695,0.0002555065,0.000062363986,0.0000034655097,0.04164207,0.0002599445,0.0006948599,0.000043144202,0.0005733488,0.00014659761],"about_ca_topic_score_codex":0.0013865174,"about_ca_topic_score_gemma":0.0045631696,"teacher_disagreement_score":0.30277753,"about_ca_system_score_codex":0.0003341212,"about_ca_system_score_gemma":0.00007401714,"threshold_uncertainty_score":0.70069474},"labels":[],"label_agreement":null},{"id":"W4318200489","doi":"10.3389/fonc.2022.974038","title":"Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Toronto; University Health Network; PROTO Manufacturing (Canada); University of Ottawa; Joseph Brant Hospital","funders":"Hamilton Health Sciences Foundation; Hamilton Health Sciences; American Society of Hematology","keywords":"Medicine; Multiple myeloma; Family medicine; Thematic analysis; Quality of life (healthcare); Internal medicine; Gerontology; Oncology; Qualitative research; Nursing","score_opus":0.034556613711278,"score_gpt":0.3772522729611184,"score_spread":0.3426956592498404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318200489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8667176,0.0001647246,0.12909682,0.00012021443,0.0002570705,0.0029621222,0.0005097268,0.0001045735,0.00006717535],"genre_scores_gemma":[0.9209147,0.00005439868,0.07653022,0.000060375827,0.000037747624,0.0013531301,0.0008257601,0.000046566252,0.00017710093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975156,0.00024899672,0.00045775532,0.0006949255,0.00029134014,0.00079136563],"domain_scores_gemma":[0.9942714,0.0048063,0.00015565933,0.00032428929,0.00016736826,0.00027496726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005080327,0.00028775173,0.0010387802,0.0010657331,0.00015658991,0.000016466889,0.00018324006,0.00026761048,0.000014162757],"category_scores_gemma":[0.00029795058,0.00021243891,0.00026873918,0.0010397678,0.00012301975,0.0001050953,0.000022647399,0.00018797303,0.0000045511015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03806798,0.0017034593,0.5553806,0.00037895303,0.0024645226,0.0010067299,0.09795817,0.00091843534,0.00004527364,0.000014774456,0.004494981,0.29756615],"study_design_scores_gemma":[0.0630904,0.011603947,0.61953247,0.00041933748,0.0018552538,0.000017109942,0.14649276,0.1535923,0.0004869944,0.00030687926,0.001973907,0.00062864163],"about_ca_topic_score_codex":0.0001769599,"about_ca_topic_score_gemma":0.002729251,"teacher_disagreement_score":0.2969375,"about_ca_system_score_codex":0.00045578927,"about_ca_system_score_gemma":0.00030176912,"threshold_uncertainty_score":0.86630076},"labels":[],"label_agreement":null},{"id":"W4319073050","doi":"10.1016/j.clml.2023.01.016","title":"First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; McMaster University; Juravinski Cancer Centre; University of Saskatchewan; Université de Montréal; Memorial University of Newfoundland; CancerCare Manitoba; Centre hospitalier universitaire de Québec; University of Manitoba; Western University; Hôpital Maisonneuve-Rosemont","funders":"Hamilton Health Sciences Foundation; Dalhousie University; Hamilton Health Sciences; Sierra Oncology; GlaxoSmithKline","keywords":"Medicine; Multiple myeloma; Guideline; Oncology; Internal medicine; Family medicine; Intensive care medicine; Pathology","score_opus":0.24478193990965672,"score_gpt":0.4566497579962298,"score_spread":0.2118678180865731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319073050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0086768605,0.9512155,0.000026924808,0.008365247,0.0018806157,0.011592459,0.016417941,0.00048018087,0.0013442363],"genre_scores_gemma":[0.013315197,0.95872724,0.001949448,0.00033966446,0.0024206329,0.0020296995,0.018915255,0.0004637306,0.0018391245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9831254,0.0028915298,0.006691647,0.002576828,0.0019942569,0.0027203213],"domain_scores_gemma":[0.9610498,0.029730055,0.0013377853,0.0035739176,0.0013529384,0.0029555333],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0038582955,0.0017651119,0.006401496,0.0012964648,0.0015583382,0.00022982754,0.0015207678,0.0021682803,0.0006261348],"category_scores_gemma":[0.0076944176,0.0011799751,0.0029070403,0.0027543982,0.0021074316,0.00010777519,0.0003689656,0.001623808,0.002114804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00087710103,0.0013022207,0.005538519,0.0018752565,0.003976131,0.004899592,0.00020742233,0.0000050122526,0.0000017266498,0.00010967707,0.041173678,0.9400337],"study_design_scores_gemma":[0.01436002,0.002150838,0.056480348,0.0116669675,0.0028682395,0.00026076107,0.0001536692,0.00072543515,0.000009815627,0.00017645113,0.91024846,0.0008990224],"about_ca_topic_score_codex":0.3218518,"about_ca_topic_score_gemma":0.58076227,"teacher_disagreement_score":0.93913466,"about_ca_system_score_codex":0.0078736385,"about_ca_system_score_gemma":0.019463884,"threshold_uncertainty_score":0.9997415},"labels":[],"label_agreement":null},{"id":"W4319161971","doi":"10.1038/s41408-023-00791-0","title":"Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"European Regional Development Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Shota Rustaveli National Science Foundation; Ostravská Univerzita v Ostravě; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"RNA splicing; Biology; Alternative splicing; Transcriptome; Gene; RNA; Computational biology; Disease; Cancer research; Bioinformatics; Genetics; Gene expression; Messenger RNA; Medicine; Internal medicine","score_opus":0.029960230637768478,"score_gpt":0.33604121860853825,"score_spread":0.30608098797076977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319161971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930531,0.002321849,0.00025549703,0.0036288854,0.00007394131,0.0004232722,0.00016298637,0.000022865257,0.00005764176],"genre_scores_gemma":[0.9984325,0.0009213231,0.00011105624,0.00010901026,0.00003753118,0.00007201122,0.000047464036,0.000018514364,0.00025057272],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987897,0.00007846112,0.00037583662,0.00016581484,0.00033991298,0.00025023313],"domain_scores_gemma":[0.9993418,0.00004311396,0.00008848263,0.00013975581,0.00012011917,0.00026671847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022425322,0.00011598803,0.00019386139,0.00025747073,0.00008323875,0.00007009327,0.00007453442,0.00004190062,0.000072157294],"category_scores_gemma":[0.00002410162,0.000093503346,0.00005998065,0.0004420394,0.000047835412,0.00013164444,0.000006955078,0.00018418895,0.0000063064817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013651596,0.0007630129,0.06133994,0.00019180652,0.0006704531,0.00030623516,0.0026920724,0.0014041456,0.9194706,0.00009759153,0.00048268557,0.01121627],"study_design_scores_gemma":[0.011880198,0.00058599084,0.87555516,0.0004734511,0.0004576859,0.00004599308,0.00079482957,0.011149569,0.09753076,0.00081568706,0.00048665973,0.00022400536],"about_ca_topic_score_codex":0.000080900776,"about_ca_topic_score_gemma":0.00008431125,"teacher_disagreement_score":0.8219399,"about_ca_system_score_codex":0.000045626162,"about_ca_system_score_gemma":0.0003789288,"threshold_uncertainty_score":0.38129556},"labels":[],"label_agreement":null},{"id":"W4319812120","doi":"10.1177/11206721231155974","title":"Ocular complications of plasma cell dyscrasias","year":2023,"lang":"en","type":"review","venue":"European Journal of Ophthalmology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Dyscrasia; Plasma cell; Multiple myeloma; POEMS syndrome; Monoclonal gammopathy of undetermined significance; Organomegaly; Polyneuropathy; Amyloidosis; Pathology; Macroglobulinemia; Cryoglobulinemia; Monoclonal; Plasma cell dyscrasia; Dermatology; Waldenstrom macroglobulinemia; Internal medicine; Immunology; Lymphoma; Monoclonal antibody; Antibody","score_opus":0.18933072758208666,"score_gpt":0.415875165327599,"score_spread":0.22654443774551233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319812120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016431242,0.9570081,0.000018831293,0.00006142008,0.00022040273,0.00049904565,0.00006147405,0.000012092309,0.04047547],"genre_scores_gemma":[0.003540547,0.99194133,0.0013946969,0.0000049951373,0.00022297748,0.0000055152527,0.00008637021,0.00012630013,0.002677239],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675936,0.001064489,0.0012867326,0.00022384005,0.00035976426,0.00030582672],"domain_scores_gemma":[0.99730486,0.00037490248,0.0012166809,0.00047788478,0.00030296098,0.00032271066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007968173,0.00028622837,0.0018502787,0.0006106411,0.00004700749,0.000009517909,0.0004403226,0.00009059531,0.0002604524],"category_scores_gemma":[0.00031939853,0.00020188568,0.00081919983,0.00036393057,0.00015265222,0.00002995761,0.00013777353,0.0006817969,0.00096997194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030137817,0.0018406048,0.0007491311,0.03557172,0.0048773526,0.26944232,0.00014352033,0.0000051920715,0.00006868419,0.00010452216,0.004524195,0.6823714],"study_design_scores_gemma":[0.0022906046,0.0025599801,0.0026889713,0.009790527,0.001626751,0.15272404,0.000025736534,0.0000042877027,0.000018817072,0.000014407001,0.82805884,0.00019704997],"about_ca_topic_score_codex":0.0000026758937,"about_ca_topic_score_gemma":3.2673604e-8,"teacher_disagreement_score":0.8235346,"about_ca_system_score_codex":0.00009581189,"about_ca_system_score_gemma":0.0004608931,"threshold_uncertainty_score":0.9998079},"labels":[],"label_agreement":null},{"id":"W4319826851","doi":"10.1182/bloodadvances.2022008866","title":"Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb; Amgen","keywords":"Daratumumab; Medicine; Carfilzomib; Pomalidomide; Internal medicine; Multiple myeloma; Confidence interval; Dexamethasone; Oncology; Lenalidomide","score_opus":0.02775344379533928,"score_gpt":0.34334252232052176,"score_spread":0.3155890785251825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319826851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621564,0.0021328852,0.000003016712,0.000055065986,0.000015921223,0.0012331734,0.000019622017,0.000054282635,0.00027041766],"genre_scores_gemma":[0.99782765,0.00036022937,0.0012742539,0.000009339629,0.000020975365,0.00013273841,0.000018462008,0.000024563948,0.000331763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985923,0.00008417332,0.00025553445,0.00039503173,0.00033089658,0.0003420431],"domain_scores_gemma":[0.9992011,0.00021840962,0.000084014006,0.0002425263,0.00007087497,0.00018303774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002108506,0.00018526235,0.00048810738,0.0002833979,0.00008008533,0.000015525336,0.000054353866,0.00004180362,0.0000061292985],"category_scores_gemma":[0.0002766274,0.00013115375,0.000019172398,0.00054669037,0.00014920671,0.00013867747,0.00007147765,0.00014343418,0.000002611403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004021394,0.0028351403,0.96983576,0.00017543536,0.00022865107,0.00074596435,0.0011559778,0.000006427289,0.0043371324,0.0000104404,0.00000483722,0.01664282],"study_design_scores_gemma":[0.13812682,0.0103703225,0.8345631,0.00022701395,0.00021159122,0.00012207046,0.0057034274,0.0005660468,0.0097192,0.000033629032,0.00016368469,0.00019309651],"about_ca_topic_score_codex":0.00030048325,"about_ca_topic_score_gemma":0.0009690843,"teacher_disagreement_score":0.13527268,"about_ca_system_score_codex":0.000013261141,"about_ca_system_score_gemma":0.00004413587,"threshold_uncertainty_score":0.53482944},"labels":[],"label_agreement":null},{"id":"W4320917309","doi":"10.3390/curroncol30020179","title":"Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Aging","keywords":"Medicine; Multiple myeloma; Chimeric antigen receptor; Lenalidomide; Disease; Oncology; Autologous stem-cell transplantation; Daratumumab; Intensive care medicine; Immunology; Internal medicine; Bioinformatics; Immunotherapy; Cancer","score_opus":0.3083256481737203,"score_gpt":0.49193268162779874,"score_spread":0.18360703345407842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320917309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044181687,0.99322206,0.0000011566173,0.00015879663,0.0011231446,0.004126484,0.00017121558,0.00008392167,0.00067143043],"genre_scores_gemma":[0.000043569937,0.99680686,0.00022342938,0.000067266694,0.00029830902,0.0006551558,0.00063687575,0.0001202257,0.0011482808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99332845,0.0015155479,0.0026967207,0.0011051139,0.0005668367,0.00078731804],"domain_scores_gemma":[0.9940683,0.0031149487,0.0010871222,0.0009809855,0.00027935856,0.00046924988],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022354075,0.00070778315,0.0056194607,0.0006951853,0.00006976509,0.000014136981,0.00037167614,0.0008343791,0.00046917592],"category_scores_gemma":[0.0040980354,0.00051662064,0.0008981628,0.0007958985,0.00053616025,0.00009904416,0.00039463208,0.00199677,0.0008622389],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021637639,0.0016823139,0.005867972,0.16303992,0.00068719394,0.00042681987,0.00006576644,4.797673e-9,5.3098637e-7,0.0000073663864,0.011511094,0.81649464],"study_design_scores_gemma":[0.0043461565,0.0014133827,0.0016516102,0.19008109,0.0010935289,0.00014271136,0.000025460817,0.000018320483,1.7870926e-7,0.000008666999,0.80094165,0.0002772174],"about_ca_topic_score_codex":0.000062535226,"about_ca_topic_score_gemma":0.00019161664,"teacher_disagreement_score":0.8162174,"about_ca_system_score_codex":0.0007190825,"about_ca_system_score_gemma":0.0022465861,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W4321764716","doi":"10.1182/bloodadvances.2022009138","title":"Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; U.S. Navy; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; Medac; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; National Center for Advancing Translational Sciences; HistoGenetics; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences","keywords":"Multiple myeloma; Medicine; Malignancy; Transplantation; Oncology; Bone transplantation; Internal medicine; Surgery","score_opus":0.017427921747345126,"score_gpt":0.32756835125500866,"score_spread":0.3101404295076635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321764716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734795,0.00064815325,0.000015577152,0.000060108807,0.000027890377,0.0003998401,0.0006949395,0.000058845326,0.0007466724],"genre_scores_gemma":[0.9977611,0.00054732984,0.00056758744,0.00002363905,0.0000136786,0.000033769305,0.00062756997,0.000015537078,0.00040979916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862283,0.000053371277,0.0003661319,0.00026899905,0.00039541844,0.00029324397],"domain_scores_gemma":[0.99890864,0.00038016314,0.00016910252,0.00028926987,0.00013392532,0.000118878044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010497697,0.00017678848,0.00067289826,0.00059839664,0.000040106213,0.0000044607473,0.000090813,0.000059790746,0.00015789301],"category_scores_gemma":[0.00013219967,0.00012192122,0.0004443497,0.0008970322,0.000073578136,0.00011391743,0.000015671647,0.00008234362,0.000020034475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000948178,0.0007306786,0.95452857,0.00043062266,0.003415285,0.00027122578,0.00021990272,0.00013589546,0.027755588,0.000009758714,0.000009815645,0.011544471],"study_design_scores_gemma":[0.004416711,0.0014280103,0.9696146,0.0000726921,0.0010216646,0.000011566256,0.00004394111,0.000075193355,0.023189247,0.000028048455,0.000007709424,0.00009056256],"about_ca_topic_score_codex":0.00014247272,"about_ca_topic_score_gemma":0.00022927063,"teacher_disagreement_score":0.015086077,"about_ca_system_score_codex":0.000030301891,"about_ca_system_score_gemma":0.00009796939,"threshold_uncertainty_score":0.49718028},"labels":[],"label_agreement":null},{"id":"W4321850941","doi":"10.14740/jh1085","title":"Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Neutropenia; Pomalidomide; Internal medicine; Leukopenia; Multiple myeloma; Gastroenterology; Lymphocytopenia; Dexamethasone; Lenalidomide; Toxicity","score_opus":0.0279992848918228,"score_gpt":0.3025471789313544,"score_spread":0.2745478940395316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321850941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725235,0.00032007345,0.00003733634,0.0014419171,0.00008844286,0.00076467264,0.000013926774,0.000026761249,0.00005450484],"genre_scores_gemma":[0.997209,0.00011168948,0.002325948,0.00019855164,0.000020616659,0.000031244963,0.000013609883,0.000028921157,0.00006042884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742573,0.00029597987,0.00065413344,0.00042614885,0.0005823924,0.0006155979],"domain_scores_gemma":[0.99721766,0.0011966431,0.0004141975,0.00026479684,0.0002707543,0.0006359359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052579003,0.00030980032,0.0013042333,0.0007768122,0.00010884306,0.000010174093,0.00013975363,0.00028089262,0.00003216265],"category_scores_gemma":[0.0022591043,0.00019889609,0.00009979665,0.00047362287,0.00021336232,0.0001773743,0.00019869566,0.0006028375,0.00003945179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015067139,0.0006225254,0.97494286,0.0001321392,0.00019103919,0.007705778,0.0002582587,0.0000027421117,0.00013778305,0.00004250367,0.00047344825,0.00042379333],"study_design_scores_gemma":[0.019464398,0.0027686718,0.9713478,0.00058325706,0.000065089,0.0038029219,0.00071686716,0.000059091028,0.00072246185,0.00014215846,0.00014684408,0.00018041482],"about_ca_topic_score_codex":0.000010354921,"about_ca_topic_score_gemma":0.000050392646,"teacher_disagreement_score":0.0043972596,"about_ca_system_score_codex":0.00010249365,"about_ca_system_score_gemma":0.00010876173,"threshold_uncertainty_score":0.8110747},"labels":[],"label_agreement":null},{"id":"W4322619117","doi":"10.7759/cureus.35592","title":"Solitary Plasmacytoma of the Jugular Foramen: A Case Report and Review of the Differential Diagnosis","year":2023,"lang":"en","type":"article","venue":"Cureus","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Plasmacytoma; Differential diagnosis; Jugular foramen; Plasma cell; Paraganglioma; Plasma cell neoplasm; Radiology; Foramen; Presentation (obstetrics); Pathology; Multiple myeloma; Anatomy; Skull; Internal medicine; Bone marrow","score_opus":0.03942549839304486,"score_gpt":0.3386451821588372,"score_spread":0.29921968376579233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322619117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98854095,0.008439397,0.0000012582293,0.0017623951,0.0001103894,0.00076499925,0.00005524335,0.000013371265,0.0003119868],"genre_scores_gemma":[0.9911255,0.0082385745,0.000025287665,0.00008694,0.000036086032,0.000087555134,0.000015614409,0.000010222422,0.00037417814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990875,0.00006656851,0.00024595528,0.00013879355,0.0003041776,0.00015696396],"domain_scores_gemma":[0.99908525,0.00011717994,0.000103741826,0.0005451182,0.00007252594,0.00007616282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015515802,0.00008494801,0.00024851112,0.000021901362,0.00006581646,0.0000031372358,0.000090904905,0.000034445507,0.00009772257],"category_scores_gemma":[0.0007040382,0.000040244297,0.00014297421,0.00021221055,0.00012690514,0.000021564209,0.00019539706,0.00009180105,0.0000032870973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025584167,0.0008736917,0.8716914,0.015042943,0.001348903,0.048175387,0.0006086783,6.926269e-7,0.0017234132,0.00022486877,0.038806036,0.021248166],"study_design_scores_gemma":[0.006438291,0.00079803343,0.87875354,0.015454582,0.0015809864,0.04199569,0.00042865818,0.00056557794,0.04397679,0.000609057,0.009113518,0.00028524862],"about_ca_topic_score_codex":0.00034284987,"about_ca_topic_score_gemma":0.00007059645,"teacher_disagreement_score":0.04225338,"about_ca_system_score_codex":0.000027429542,"about_ca_system_score_gemma":0.00007758179,"threshold_uncertainty_score":0.16411148},"labels":[],"label_agreement":null},{"id":"W4323035289","doi":"10.1002/cam4.5753","title":"Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study","year":2023,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Sanofi","keywords":"Daratumumab; Multiple myeloma; Internal medicine; Medicine; Lenalidomide","score_opus":0.02986163340831269,"score_gpt":0.340492628545331,"score_spread":0.3106309951370183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323035289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955263,0.00024049956,0.000008627059,0.00091576204,0.000102613274,0.002685731,0.000021983413,0.00009262013,0.00040584814],"genre_scores_gemma":[0.9982049,0.00007560499,0.00003829747,0.00012869178,0.00007214044,0.00065981573,0.0003521456,0.00005202763,0.00041637078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975355,0.0000950366,0.00037435038,0.00051489857,0.00093310024,0.0005470727],"domain_scores_gemma":[0.99885494,0.0001813489,0.00010636324,0.00040327018,0.00020126766,0.00025282777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000317221,0.00027154884,0.00059503963,0.00075211393,0.000060349383,0.0000073281926,0.00010685089,0.00007128649,0.00014354593],"category_scores_gemma":[0.00024927355,0.00017084154,0.000021397544,0.001631443,0.0001575532,0.00015102165,0.000040725132,0.0004173816,0.000031313146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010726798,0.0062599457,0.950808,0.00009812845,0.00012460495,0.00091004453,0.0023179832,0.00001321149,0.00010149165,0.0000028235568,0.00047112367,0.02816585],"study_design_scores_gemma":[0.19387501,0.011312965,0.79168916,0.00068397494,0.0000651701,0.0000025512759,0.0013003233,0.0005714216,0.000049635826,0.000005293272,0.0003070012,0.00013751125],"about_ca_topic_score_codex":0.001289711,"about_ca_topic_score_gemma":0.0018187262,"teacher_disagreement_score":0.18314822,"about_ca_system_score_codex":0.0006154424,"about_ca_system_score_gemma":0.000248527,"threshold_uncertainty_score":0.6966716},"labels":[],"label_agreement":null},{"id":"W4323048982","doi":"10.1016/j.mednuc.2023.01.022","title":"Résultats préliminaires de l’étude exploratoire de phase 2 utilisant la TEP au 68GaPentixaFor pour le bilan initial des patients atteints de myélome multiple (MM) symptomatiques","year":2023,"lang":"fr","type":"article","venue":"Médecine Nucléaire","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Nuclear medicine; Gynecology","score_opus":0.05128467821125682,"score_gpt":0.36111140506672756,"score_spread":0.30982672685547075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323048982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897354,0.0020384532,0.0005954522,0.0027748789,0.0004868013,0.001797621,0.000680153,0.0006446499,0.001246585],"genre_scores_gemma":[0.98833,0.0012077446,0.0030635772,0.00033114696,0.0011716707,0.0005700245,0.00094243215,0.00030252204,0.0040808823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925017,0.0010716416,0.0010261383,0.0010565787,0.0010586103,0.0032853815],"domain_scores_gemma":[0.99515885,0.0012866852,0.0003033657,0.0008796358,0.00047697852,0.0018944696],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013144369,0.0009514315,0.0010772063,0.0006954643,0.00093044055,0.00022838051,0.0006285655,0.00054386124,0.0004818447],"category_scores_gemma":[0.004086939,0.000899318,0.0004495388,0.0011384871,0.0008594359,0.0007109483,0.0004791641,0.0007784559,0.0013042496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022106052,0.010185289,0.611789,0.0016770586,0.0010256605,0.006330672,0.011504295,0.00006523057,0.009155186,0.00012314807,0.012846602,0.33308724],"study_design_scores_gemma":[0.04718844,0.0026559145,0.8606427,0.0044811624,0.00054121536,0.00035381236,0.004640675,0.04177707,0.030993784,0.0015287023,0.004242137,0.0009544007],"about_ca_topic_score_codex":0.0052882484,"about_ca_topic_score_gemma":0.0016605234,"teacher_disagreement_score":0.33213285,"about_ca_system_score_codex":0.0022476686,"about_ca_system_score_gemma":0.0030555872,"threshold_uncertainty_score":0.99947333},"labels":[],"label_agreement":null},{"id":"W4323316666","doi":"10.1038/s41408-023-00794-x","title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Minimal residual disease; Oncology; Positron emission tomography; Internal medicine; Negativity effect; Multiple myeloma; Nuclear medicine; Bone marrow","score_opus":0.06746045659604068,"score_gpt":0.32278984922358334,"score_spread":0.2553293926275427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323316666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998437,0.00079775415,0.000006992328,0.00024337375,0.00004914901,0.00018876759,0.00022829327,0.000013189122,0.000035488156],"genre_scores_gemma":[0.9970877,0.0021285585,0.0001882843,0.000034058867,0.00010591566,0.00002470856,0.00033156833,0.000013237781,0.000085925756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985669,0.000093936294,0.00036912202,0.0002058229,0.00045947498,0.00030469435],"domain_scores_gemma":[0.99922884,0.00003600304,0.000102400525,0.00011220988,0.00016787255,0.00035265382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023217611,0.00012871671,0.0003330978,0.0008558999,0.0000879535,0.000043854867,0.000057961493,0.00003113658,0.00012210083],"category_scores_gemma":[0.00007515523,0.00009957818,0.000094685165,0.00108753,0.000043031123,0.00013346941,0.00001594582,0.00020101525,0.0000018687954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079275883,0.00018491701,0.9686492,0.000059971062,0.0012903096,0.0010641093,0.00053867325,0.00028453633,0.018087376,0.0000027119097,0.00018765572,0.008857792],"study_design_scores_gemma":[0.004869115,0.0002810815,0.97027904,0.0002444084,0.0016487746,0.000033704364,0.00019740696,0.017826667,0.0044984976,0.00000784436,0.000019539708,0.000093948904],"about_ca_topic_score_codex":0.0009922031,"about_ca_topic_score_gemma":0.0017329709,"teacher_disagreement_score":0.017542131,"about_ca_system_score_codex":0.00016206631,"about_ca_system_score_gemma":0.0005452043,"threshold_uncertainty_score":0.40606803},"labels":[],"label_agreement":null},{"id":"W4323362510","doi":"10.1038/s41408-023-00805-x","title":"Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS","year":2023,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development; National Cancer Institute; Amgen","keywords":"Daratumumab; Carfilzomib; Pleiades; Dexamethasone; Medicine; Oncology; Multiple myeloma; Internal medicine; Refractory (planetary science); Lenalidomide; Biology; Computer science","score_opus":0.07917735754631587,"score_gpt":0.36156698615345484,"score_spread":0.28238962860713895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323362510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94081724,0.018289672,0.000004858237,0.039520435,0.00023313043,0.00046914333,0.00046692742,0.000028869203,0.00016969992],"genre_scores_gemma":[0.8321374,0.08873775,0.0040298114,0.04311846,0.0076966956,0.0004522682,0.0009682054,0.0005058956,0.022353536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968763,0.00025672143,0.00074282475,0.00054270064,0.00090778444,0.0006736441],"domain_scores_gemma":[0.9981012,0.00055057363,0.00045599035,0.00035456894,0.0002181554,0.00031955025],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005088415,0.00041243577,0.0015209848,0.0018511718,0.00013400469,0.00007563999,0.0001659823,0.0005599114,0.00037673555],"category_scores_gemma":[0.00040984165,0.0002978799,0.000250078,0.0012231515,0.00023766008,0.00008749229,0.000114400595,0.0027562745,0.0000029691853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007214236,0.00089284935,0.56504095,0.0026909958,0.045001786,0.077855915,0.0014667996,0.000031826024,0.0021914095,0.0000034899501,0.21788225,0.07972752],"study_design_scores_gemma":[0.032154214,0.0029485452,0.89170146,0.002780171,0.020685136,0.0023418292,0.00028029742,0.00055718835,0.00056134386,0.000058341353,0.04513438,0.0007971118],"about_ca_topic_score_codex":0.0013536594,"about_ca_topic_score_gemma":0.0018117349,"teacher_disagreement_score":0.3266605,"about_ca_system_score_codex":0.0002400365,"about_ca_system_score_gemma":0.000786429,"threshold_uncertainty_score":0.9999473},"labels":[],"label_agreement":null},{"id":"W4324311114","doi":"10.1182/bloodadvances.2022008345","title":"The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Jewish General Hospital; University of Ottawa; McGill University","funders":"National Cancer Institute; National Institutes of Health; Emory University; Terry Fox Foundation; National Institute of Diabetes and Digestive and Kidney Diseases; McGill University; Jewish General Hospital; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Carfilzomib; Proteasome; Bortezomib; Multiple myeloma; Pharmacology; Proteasome inhibitor; Cancer research; Biology; Medicine; Cell biology; Immunology","score_opus":0.02877557707826679,"score_gpt":0.30573534269820646,"score_spread":0.2769597656199397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324311114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942981,0.0019118375,0.0000025476675,0.0014142854,0.0002431608,0.0017624479,0.000049760554,0.00006997929,0.00024787092],"genre_scores_gemma":[0.9980066,0.0006376317,0.00028045854,0.000024106816,0.0002572657,0.00025362245,0.000053094114,0.00002371653,0.00046352757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823993,0.00012342088,0.00035906836,0.0002701144,0.0005209874,0.00048645772],"domain_scores_gemma":[0.9984619,0.00081916875,0.000114319446,0.0003996715,0.00009049962,0.00011444208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022721669,0.00017148568,0.0002803381,0.00011585393,0.00028005202,0.000030280651,0.00023051273,0.000048249323,0.000019172267],"category_scores_gemma":[0.0010550108,0.00008641188,0.00013308367,0.00064897735,0.00032517101,0.00010030246,0.00011233633,0.00019874233,0.00003986862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028756566,0.0010548052,0.7115827,0.00025085476,0.00064517296,0.00037320337,0.0011729397,0.00023976772,0.16624697,0.00022732081,0.00092891575,0.11440165],"study_design_scores_gemma":[0.011737444,0.00041635623,0.8959161,0.00019444227,0.00008476351,0.000014472257,0.0007826619,0.0006056386,0.06983122,0.00050237385,0.019758124,0.00015637421],"about_ca_topic_score_codex":0.00016225154,"about_ca_topic_score_gemma":0.00031921366,"teacher_disagreement_score":0.18433338,"about_ca_system_score_codex":0.00002220239,"about_ca_system_score_gemma":0.00008414343,"threshold_uncertainty_score":0.3523774},"labels":[],"label_agreement":null},{"id":"W4327700855","doi":"10.1200/jco.22.01916","title":"Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Multiple myeloma; Internal medicine; Hazard ratio; AL amyloidosis; Gastroenterology; Clinical significance; Bone marrow; Phenotype; Pathology; Monoclonal; Oncology; Immunology; Monoclonal antibody; Immunoglobulin light chain; Antibody; Confidence interval; Biology","score_opus":0.12955596645445286,"score_gpt":0.4218574056104702,"score_spread":0.29230143915601736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327700855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977895,0.000100998994,0.00002034731,0.0008269827,0.00039763158,0.00047666408,0.00002888083,0.0000060258567,0.0003529573],"genre_scores_gemma":[0.9964261,0.00046148157,0.0026864687,0.00016542872,0.00017510305,0.000009156184,0.00000905331,0.000017152512,0.000050066425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952896,0.00079001696,0.0026598484,0.00025153704,0.0007197766,0.00028921428],"domain_scores_gemma":[0.9930457,0.0039393995,0.0018624577,0.0002506511,0.00061010435,0.00029170688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030052052,0.00016157058,0.001440887,0.00020050869,0.000034984285,0.0000049138102,0.00019944085,0.0002759065,0.000027988619],"category_scores_gemma":[0.00359317,0.00009291173,0.00034951733,0.00042381947,0.0008222551,0.000095249285,0.000093054485,0.0008431611,0.00000514689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014095467,0.0022446867,0.9410581,0.000074043885,0.00026663448,0.00018267144,0.00006018353,0.000010584655,0.0000970036,0.00006492468,0.00017421826,0.041671496],"study_design_scores_gemma":[0.015713843,0.013580545,0.9689107,0.00022551273,0.00018884437,0.000016672459,0.00007715897,0.00020237225,0.00010178686,0.0006816189,0.00022518364,0.00007576434],"about_ca_topic_score_codex":0.000048974107,"about_ca_topic_score_gemma":0.00009642533,"teacher_disagreement_score":0.04159573,"about_ca_system_score_codex":0.00008449071,"about_ca_system_score_gemma":0.0015376738,"threshold_uncertainty_score":0.43016195},"labels":[],"label_agreement":null},{"id":"W4327719861","doi":"10.1016/j.clml.2023.03.005","title":"Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Johnson and Johnson","keywords":"Medicine; Quality of life (healthcare); Checklist; Health related quality of life; Disease; Physical therapy; Internal medicine","score_opus":0.18961982451733672,"score_gpt":0.4915562219223763,"score_spread":0.3019363974050396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327719861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13883767,0.85121953,3.8866042e-7,0.00015828772,0.00009080231,0.008744018,0.0008777665,0.00006142461,0.000010122425],"genre_scores_gemma":[0.030287197,0.9677854,0.00011221296,0.00009055389,0.000071738206,0.0006203897,0.00075086625,0.00015223546,0.00012936346],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9788632,0.008338377,0.009581162,0.00117183,0.0013027313,0.00074272713],"domain_scores_gemma":[0.97769785,0.0127803795,0.0053382833,0.002070589,0.00060692633,0.0015059792],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009143701,0.0010082993,0.012823683,0.0008597129,0.00006675674,0.000019634997,0.00050832843,0.0008807974,0.000027548878],"category_scores_gemma":[0.0407509,0.0006073262,0.0028677604,0.0022809969,0.0006195996,0.00008679869,0.00026849736,0.0008618168,0.000030548577],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01195806,0.0012615356,0.004962021,0.5118785,0.0013833715,0.00028945875,0.00006325673,2.992424e-7,0.0000012246934,0.0000099717545,0.0001901582,0.46800217],"study_design_scores_gemma":[0.0073062195,0.0034002522,0.36571816,0.62226206,0.00048904656,0.000035372625,0.0000074355216,0.000046249268,6.2220806e-7,0.0000168701,0.00044219248,0.00027553047],"about_ca_topic_score_codex":0.00023637222,"about_ca_topic_score_gemma":0.000017133414,"teacher_disagreement_score":0.46772662,"about_ca_system_score_codex":0.0012302827,"about_ca_system_score_gemma":0.010142616,"threshold_uncertainty_score":0.9996378},"labels":[],"label_agreement":null},{"id":"W4327859571","doi":"10.21203/rs.3.rs-2657360/v1","title":"Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Terry Fox Foundation; Glenmark Pharmaceuticals; American Society of Hematology; Comprehensive Cancer Center, City of Hope; Rising Tide Foundation; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Celgene; Leukemia and Lymphoma Society; Genentech; Deutsche Krebshilfe; Amgen; U.S. Food and Drug Administration; Multiple Myeloma Research Foundation","keywords":"Antigen; Chimeric antigen receptor; Multiple myeloma; Missense mutation; T-cell receptor; Cancer research; Biology; T cell; Immunology; Mutation; Genetics; Gene; Immune system","score_opus":0.0745172393073209,"score_gpt":0.377754997091955,"score_spread":0.3032377577846341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327859571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001163,0.0023144388,0.00014450338,0.001318352,0.00018157084,0.005220346,0.0005322501,0.00016467572,0.0001122137],"genre_scores_gemma":[0.9928982,0.002556995,0.0026832474,0.000041250503,0.00012320622,0.00060299673,0.00044892612,0.00017883042,0.0004663213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993184,0.0007338768,0.0008815826,0.0013482303,0.0022527478,0.0015995811],"domain_scores_gemma":[0.9959537,0.00084816635,0.00016396986,0.001354201,0.0009781745,0.00070182694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023184451,0.0005807863,0.0015137262,0.0030302557,0.0002260015,0.00013723527,0.00058456435,0.00042242688,0.00025305065],"category_scores_gemma":[0.0024092267,0.0005121903,0.00026319147,0.0016878222,0.0003649185,0.00010594739,0.0022412825,0.001854726,0.00026628806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038729098,0.0022069113,0.70310575,0.0089285765,0.0016970494,0.0056844545,0.0034914599,0.00020013604,0.23238763,0.0005650632,0.0011631775,0.036696892],"study_design_scores_gemma":[0.0046513504,0.0010726262,0.92569005,0.00341463,0.000024176088,0.000029880719,0.001256694,0.0013595774,0.06078105,0.0009952124,0.00031360108,0.00041116797],"about_ca_topic_score_codex":0.0035696172,"about_ca_topic_score_gemma":0.00050331996,"teacher_disagreement_score":0.22258429,"about_ca_system_score_codex":0.00038494082,"about_ca_system_score_gemma":0.00087398395,"threshold_uncertainty_score":0.999733},"labels":[],"label_agreement":null},{"id":"W4353014868","doi":"10.1038/s41408-023-00804-y","title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Seagen; bluebird bio; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Lenalidomide; Medicine; Daratumumab; Multiple myeloma; Intensive care medicine; Clinical trial; Bortezomib; Oncology; Internal medicine","score_opus":0.5237619651572638,"score_gpt":0.5617298454699142,"score_spread":0.037967880312650415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353014868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004328791,0.98872674,0.0004943975,0.00021363089,0.000947942,0.005093975,0.00015646189,0.000034767592,0.0000033245979],"genre_scores_gemma":[0.007573978,0.9852162,0.00209846,0.000013877008,0.0013715214,0.003528339,0.000044366643,0.00014134239,0.000011901717],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99469084,0.0004915609,0.00232096,0.00079030194,0.00073200325,0.00097433716],"domain_scores_gemma":[0.9892424,0.008736896,0.00082511344,0.0004978161,0.000372445,0.00032534002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003604755,0.00061183947,0.0027551595,0.0008492319,0.00014249633,0.00014480308,0.00049888727,0.00038332865,0.000028642775],"category_scores_gemma":[0.002863365,0.00042897137,0.0014067205,0.00045914002,0.00008962937,0.00020010436,0.00006895098,0.0014817794,0.00000838586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021792976,0.0009812287,0.0039279996,0.010844643,0.0006646424,0.00035139042,0.00007515578,0.000028481412,9.100099e-7,0.000010536655,0.0000320117,0.9809037],"study_design_scores_gemma":[0.055851694,0.005631359,0.029365204,0.64092755,0.002113986,0.00026789473,0.00025643763,0.0014207003,0.000014752781,0.0010926841,0.26175648,0.0013012433],"about_ca_topic_score_codex":0.00008283874,"about_ca_topic_score_gemma":0.0011781387,"teacher_disagreement_score":0.97960246,"about_ca_system_score_codex":0.00061616296,"about_ca_system_score_gemma":0.0048748897,"threshold_uncertainty_score":0.9998162},"labels":[],"label_agreement":null},{"id":"W4353050819","doi":"10.1016/j.clml.2023.03.009","title":"Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Institute of Cancer Research","funders":"Cilag; EUSA Pharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Context (archaeology); Immune system; Multiple myeloma; Vaccination; Medicine; Session (web analytics); Immunology; Biology; Computer science","score_opus":0.12128700098053999,"score_gpt":0.4174896918128727,"score_spread":0.29620269083233275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353050819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022969466,0.96378535,0.00008982113,0.0016058355,0.0028167379,0.004877838,0.0018678328,0.0005095938,0.001477497],"genre_scores_gemma":[0.0071421764,0.97838783,0.0013579999,0.00023232629,0.0020060667,0.0009388242,0.006075255,0.00020013502,0.0036594088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910606,0.00076856837,0.003918073,0.0020339263,0.0011501955,0.0010686188],"domain_scores_gemma":[0.9869392,0.008863563,0.0012994091,0.0017788016,0.00044855246,0.0006704564],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002716403,0.0010673876,0.0033833869,0.0003746988,0.0004966385,0.00022183084,0.0009566059,0.0015624091,0.00018998227],"category_scores_gemma":[0.009666223,0.0007601678,0.002057027,0.001309619,0.00078329915,0.00036692232,0.0010434432,0.0017061367,0.0006358414],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029150752,0.00038637547,0.009170085,0.0008542753,0.0021599499,0.0037996625,0.00017085303,9.67678e-7,8.2544017e-7,0.00007544328,0.007146655,0.9759434],"study_design_scores_gemma":[0.005716957,0.00011661531,0.43265495,0.008735182,0.0009923952,0.0015916873,0.00026284106,0.0006285964,0.0000011903433,0.00015414915,0.5485382,0.00060726935],"about_ca_topic_score_codex":0.0007877584,"about_ca_topic_score_gemma":0.0005342882,"teacher_disagreement_score":0.97533613,"about_ca_system_score_codex":0.0028429595,"about_ca_system_score_gemma":0.004758349,"threshold_uncertainty_score":0.99973375},"labels":[],"label_agreement":null},{"id":"W4360798156","doi":"10.1016/j.clml.2023.03.006","title":"A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; Queen's University; McGill University; Université Laval; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Refractory (planetary science); Dosing; Phases of clinical research; Clinical trial; Surgery; Anesthesia; Internal medicine; Bortezomib","score_opus":0.0861937956303593,"score_gpt":0.4005179872177594,"score_spread":0.3143241915874001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360798156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605674,0.00004341617,0.0000010524753,0.00004088382,0.000108695305,0.0033207815,0.000097756354,0.00009170201,0.00023898388],"genre_scores_gemma":[0.9983792,0.0000764243,0.00040268633,0.00007361744,0.00004338079,0.00014747251,0.00055029086,0.00007961211,0.00024737246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951842,0.00071567745,0.0017382973,0.0010162996,0.00070113037,0.0006444054],"domain_scores_gemma":[0.99619347,0.00090222125,0.0006023762,0.0011300722,0.0005390207,0.0006328689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001364148,0.0004431921,0.0014774811,0.0005177895,0.00022145374,0.000045541954,0.0004916488,0.00033079527,0.000042513297],"category_scores_gemma":[0.0017024939,0.0003387437,0.00007616064,0.0014887581,0.00039202318,0.0005127756,0.00078385964,0.00039216,0.000020940442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043434463,0.038870975,0.49518707,0.000100746765,0.00034741155,0.00060309615,0.00066902593,0.0000033750853,0.0019922499,0.0000053383965,0.0001670324,0.41861922],"study_design_scores_gemma":[0.21503976,0.04591823,0.73438764,0.0002915095,0.00009951882,0.0000050482895,0.0003307211,0.002910679,0.00067514315,0.00001672723,0.00009638022,0.00022864004],"about_ca_topic_score_codex":0.000907859,"about_ca_topic_score_gemma":0.00044386444,"teacher_disagreement_score":0.41839057,"about_ca_system_score_codex":0.0003688744,"about_ca_system_score_gemma":0.0009162947,"threshold_uncertainty_score":0.9999065},"labels":[],"label_agreement":null},{"id":"W4361010875","doi":"10.3390/cells12071011","title":"Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Cells","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Bone and Joint Health Institute; University of Calgary","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Angiogenesis; Monoclonal gammopathy of undetermined significance; Peroxisome proliferator-activated receptor; Cancer research; Multiple myeloma; Receptor; Rosiglitazone; Neovascularization; Endocrinology; Biology; Internal medicine; Chemistry; Medicine; Monoclonal; Immunology; Monoclonal antibody","score_opus":0.01896607820526747,"score_gpt":0.25769991699332123,"score_spread":0.23873383878805376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361010875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982216,0.00020945167,0.0000021637609,0.00017330213,0.00003601127,0.00084113126,0.00005863042,0.00008795834,0.0003697464],"genre_scores_gemma":[0.9986637,0.00007063544,0.00013446585,0.000030654097,0.00004022912,0.00010542522,0.00014295339,0.000041045954,0.00077088387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848366,0.00012198275,0.00025491166,0.00026616149,0.0004203746,0.0004528876],"domain_scores_gemma":[0.9989822,0.00033326622,0.00009224953,0.00030350118,0.00014723085,0.00014156576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030000397,0.0001701584,0.0003272986,0.00021969638,0.00008269801,0.00001469801,0.00012309753,0.00009716757,0.00011332233],"category_scores_gemma":[0.00030328854,0.00010510342,0.00008383598,0.0011230016,0.00008549887,0.0000536686,0.000050834995,0.00015635359,0.00017233535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051003764,0.00025704125,0.38096124,0.00002974755,0.00022896672,0.00005341381,0.00052992214,0.00005417255,0.6137843,0.0000034831444,0.00013957502,0.0034480712],"study_design_scores_gemma":[0.0026410269,0.00026433088,0.24177858,0.0001591775,0.000031271415,0.0000022396712,0.00064305164,0.0020241558,0.75160545,0.000009149676,0.00074225885,0.000099335186],"about_ca_topic_score_codex":0.0001938529,"about_ca_topic_score_gemma":0.00006927802,"teacher_disagreement_score":0.13918266,"about_ca_system_score_codex":0.00012303088,"about_ca_system_score_gemma":0.00014824313,"threshold_uncertainty_score":0.4285993},"labels":[],"label_agreement":null},{"id":"W4361207696","doi":"10.3390/cells12071030","title":"Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma","year":2023,"lang":"en","type":"review","venue":"Cells","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Leukemia and Lymphoma Society of Canada; Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Microvesicles; microRNA; Tumor microenvironment; Crosstalk; Epigenetics; Multiple myeloma; Biology; Cancer research; Exosome; Bone marrow; Phenotype; Tumor progression; Immunology; Gene; Genetics; Tumor cells","score_opus":0.08893258433723726,"score_gpt":0.3530334594701028,"score_spread":0.2641008751328655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361207696","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021591024,0.99431336,9.460369e-7,0.000036963796,0.00010343726,0.0025429097,0.00014536815,0.000020073092,0.00067782647],"genre_scores_gemma":[0.0006327662,0.99593735,0.00016747668,0.000034092332,0.00010695681,0.0003096957,0.00021313605,0.00006714642,0.0025313632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978522,0.00022850474,0.00060440967,0.00037814587,0.000489631,0.0004470736],"domain_scores_gemma":[0.9983961,0.0005650805,0.00020103045,0.0006917185,0.000015129688,0.00013094305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030458503,0.00033372967,0.0013184422,0.00024187138,0.000034734694,0.000012578828,0.00033258594,0.00013051338,0.00017808378],"category_scores_gemma":[0.0000954683,0.00019140862,0.00047983532,0.0003427893,0.0001184354,0.00001848267,0.00012544238,0.00041386407,0.0017627589],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011063965,0.0012816025,0.00097313593,0.048535664,0.0007080782,0.004819032,0.0003044713,7.053408e-7,0.0003057846,0.000008828278,0.003623931,0.93932813],"study_design_scores_gemma":[0.0014175104,0.00020479548,0.0020393445,0.009423956,0.0004069156,0.0001059346,0.00007331994,0.0000089989135,0.00034292994,0.0000039265665,0.98580503,0.00016732974],"about_ca_topic_score_codex":0.00009245126,"about_ca_topic_score_gemma":0.000024379744,"teacher_disagreement_score":0.98218113,"about_ca_system_score_codex":0.00016757082,"about_ca_system_score_gemma":0.00017810377,"threshold_uncertainty_score":0.9990145},"labels":[],"label_agreement":null},{"id":"W4361817374","doi":"10.1158/1078-0432.c.6519120.v1","title":"Data from Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Insulin-like growth factor; Receptor; Growth factor; Chemistry; Growth inhibition; Apoptosis; In vitro; In vivo; Cancer research; Cell growth; Pharmacology; Biology; Biochemistry","score_opus":0.07671238866365945,"score_gpt":0.3194578745302829,"score_spread":0.24274548586662345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97277474,0.00010303236,0.004974042,0.0015418967,0.0007601689,0.0015249614,0.01814728,0.00011012295,0.000063761676],"genre_scores_gemma":[0.9800271,0.0006475637,0.003409188,0.00010052887,0.00022482211,0.000047727,0.014857895,0.00007951675,0.00060568703],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973443,0.00015583396,0.00039923284,0.0009791998,0.0007838259,0.00033759486],"domain_scores_gemma":[0.997276,0.00016136096,0.00030774792,0.001779727,0.00022699374,0.0002481787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019737592,0.00039179326,0.00066885795,0.00011849274,0.00008180635,0.000064418724,0.0005473478,0.00039619306,0.00027405925],"category_scores_gemma":[0.00069026,0.0002650771,0.00012382388,0.00023921253,0.00015093782,0.00017076363,0.0032545282,0.0007534626,0.00004660526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005893594,0.00073536125,0.08806484,0.00055034045,0.0010071681,0.000036629368,0.00015686009,9.3378804e-7,0.90084356,0.000015734744,0.0005813529,0.0074178725],"study_design_scores_gemma":[0.0021806012,0.00009727066,0.7805962,0.00046039757,0.00011883804,0.0000028236805,0.000016226337,0.0029397937,0.21225226,0.000056032735,0.0010379594,0.00024158203],"about_ca_topic_score_codex":0.0017964713,"about_ca_topic_score_gemma":0.000057388796,"teacher_disagreement_score":0.6925314,"about_ca_system_score_codex":0.00010166204,"about_ca_system_score_gemma":0.00033425348,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W4361943709","doi":"10.1158/1078-0432.c.6519120","title":"Data from Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Insulin-like growth factor; Receptor; Growth factor; Apoptosis; Chemistry; Growth inhibition; In vitro; In vivo; Cancer research; Pharmacology; Biology; Biochemistry","score_opus":0.07671238866365945,"score_gpt":0.3194578745302829,"score_spread":0.24274548586662345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361943709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97277474,0.00010303236,0.004974042,0.0015418967,0.0007601689,0.0015249614,0.01814728,0.00011012295,0.000063761676],"genre_scores_gemma":[0.9800271,0.0006475637,0.003409188,0.00010052887,0.00022482211,0.000047727,0.014857895,0.00007951675,0.00060568703],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973443,0.00015583396,0.00039923284,0.0009791998,0.0007838259,0.00033759486],"domain_scores_gemma":[0.997276,0.00016136096,0.00030774792,0.001779727,0.00022699374,0.0002481787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019737592,0.00039179326,0.00066885795,0.00011849274,0.00008180635,0.000064418724,0.0005473478,0.00039619306,0.00027405925],"category_scores_gemma":[0.00069026,0.0002650771,0.00012382388,0.00023921253,0.00015093782,0.00017076363,0.0032545282,0.0007534626,0.00004660526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005893594,0.00073536125,0.08806484,0.00055034045,0.0010071681,0.000036629368,0.00015686009,9.3378804e-7,0.90084356,0.000015734744,0.0005813529,0.0074178725],"study_design_scores_gemma":[0.0021806012,0.00009727066,0.7805962,0.00046039757,0.00011883804,0.0000028236805,0.000016226337,0.0029397937,0.21225226,0.000056032735,0.0010379594,0.00024158203],"about_ca_topic_score_codex":0.0017964713,"about_ca_topic_score_gemma":0.000057388796,"teacher_disagreement_score":0.6925314,"about_ca_system_score_codex":0.00010166204,"about_ca_system_score_gemma":0.00033425348,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W4362525470","doi":"10.1158/2326-6066.c.6550931","title":"Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft; Deutschen Konsortium für Translationale Krebsforschung; European Commission","keywords":"Bone marrow; Multiple myeloma; Antigen; Immune system; Biology; Immunology; T cell; Cancer research; Molecular biology","score_opus":0.09122586825149427,"score_gpt":0.3373108190329897,"score_spread":0.24608495078149545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362525470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983167,0.0032853568,0.00009874276,0.0004654777,0.00025543824,0.0020855688,0.009843123,0.00013181444,0.0006674602],"genre_scores_gemma":[0.9532267,0.0042402907,0.020314373,0.00002303353,0.0001475253,0.00012070805,0.01785,0.0001002716,0.003977097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647003,0.00014930232,0.00086448673,0.001298732,0.00059830904,0.000619159],"domain_scores_gemma":[0.9965871,0.0005730618,0.0002611795,0.0021154513,0.00012619389,0.00033702218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003051037,0.00057788583,0.0014998672,0.00043163705,0.000057403882,0.000046694986,0.0004260972,0.00039632773,0.00061524584],"category_scores_gemma":[0.00027635568,0.0004512765,0.00018001525,0.00020131502,0.00017862406,0.0001008073,0.0017516878,0.00044826354,0.00014069329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003940861,0.0030323078,0.76875144,0.0008652085,0.0037894344,0.0019490243,0.0009444785,0.000057207006,0.19974679,0.0000140155,0.0014826239,0.015426592],"study_design_scores_gemma":[0.015588332,0.00058595964,0.8747335,0.00075091096,0.00034896322,0.0000108363565,0.00039353102,0.01437049,0.09120266,0.000600515,0.00088824844,0.0005260327],"about_ca_topic_score_codex":0.021811897,"about_ca_topic_score_gemma":0.006350592,"teacher_disagreement_score":0.10854413,"about_ca_system_score_codex":0.00018351585,"about_ca_system_score_gemma":0.00047543203,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W4362533024","doi":"10.1158/2326-6066.22545401","title":"Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft; Deutschen Konsortium für Translationale Krebsforschung; European Commission","keywords":"Bone marrow; Multiple myeloma; Phenotype; Immune system; Antigen; Cancer research; Immunology; Medicine; Biology; Gene; Genetics","score_opus":0.07722117408837974,"score_gpt":0.33467992610708075,"score_spread":0.257458752018701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362533024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9535788,0.0018908797,0.000061242325,0.00080059795,0.0002610831,0.0025304738,0.040561322,0.00008352883,0.00023205417],"genre_scores_gemma":[0.8865341,0.003917136,0.025544934,0.000038453763,0.00015557301,0.00015244399,0.08164418,0.000101293976,0.0019118753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960929,0.00016612322,0.0009927579,0.0013784065,0.00066837866,0.00070143247],"domain_scores_gemma":[0.9966478,0.00054295536,0.00026555208,0.0020870927,0.000106529085,0.00035008776],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033362664,0.00062986097,0.0014977938,0.00046802917,0.00006683214,0.000045526493,0.00046061457,0.00032278767,0.0027147366],"category_scores_gemma":[0.00013967979,0.0005064616,0.00018948049,0.0001931377,0.00017581326,0.00009653608,0.0021583966,0.0004434565,0.00007000181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031480805,0.0023990315,0.86171305,0.00063946575,0.0033653025,0.0014774702,0.00079074915,0.000029672447,0.11554485,0.000006863958,0.0028976211,0.007987845],"study_design_scores_gemma":[0.023503492,0.00089669175,0.81194353,0.0007451564,0.0005632943,0.000013556647,0.00087366503,0.010928274,0.14725582,0.0005919216,0.0020018704,0.00068270543],"about_ca_topic_score_codex":0.06556462,"about_ca_topic_score_gemma":0.016236814,"teacher_disagreement_score":0.067044705,"about_ca_system_score_codex":0.00023777148,"about_ca_system_score_gemma":0.00046658044,"threshold_uncertainty_score":0.9997387},"labels":[],"label_agreement":null},{"id":"W4362547165","doi":"10.1158/2326-6066.c.6550931.v1","title":"Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft; Deutschen Konsortium für Translationale Krebsforschung; European Commission","keywords":"Bone marrow; Multiple myeloma; Antigen; Immune system; Biology; Immunology; Cancer research; T cell","score_opus":0.09122586825149427,"score_gpt":0.3373108190329897,"score_spread":0.24608495078149545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362547165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983167,0.0032853568,0.00009874276,0.0004654777,0.00025543824,0.0020855688,0.009843123,0.00013181444,0.0006674602],"genre_scores_gemma":[0.9532267,0.0042402907,0.020314373,0.00002303353,0.0001475253,0.00012070805,0.01785,0.0001002716,0.003977097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647003,0.00014930232,0.00086448673,0.001298732,0.00059830904,0.000619159],"domain_scores_gemma":[0.9965871,0.0005730618,0.0002611795,0.0021154513,0.00012619389,0.00033702218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003051037,0.00057788583,0.0014998672,0.00043163705,0.000057403882,0.000046694986,0.0004260972,0.00039632773,0.00061524584],"category_scores_gemma":[0.00027635568,0.0004512765,0.00018001525,0.00020131502,0.00017862406,0.0001008073,0.0017516878,0.00044826354,0.00014069329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003940861,0.0030323078,0.76875144,0.0008652085,0.0037894344,0.0019490243,0.0009444785,0.000057207006,0.19974679,0.0000140155,0.0014826239,0.015426592],"study_design_scores_gemma":[0.015588332,0.00058595964,0.8747335,0.00075091096,0.00034896322,0.0000108363565,0.00039353102,0.01437049,0.09120266,0.000600515,0.00088824844,0.0005260327],"about_ca_topic_score_codex":0.021811897,"about_ca_topic_score_gemma":0.006350592,"teacher_disagreement_score":0.10854413,"about_ca_system_score_codex":0.00018351585,"about_ca_system_score_gemma":0.00047543203,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W4362607805","doi":"10.1016/j.jbc.2023.104675","title":"The ubiquitin ligase HERC4 suppresses MafA transcriptional activity triggered by GSK3β in myeloma by atypical K63-linked polyubiquitination","year":2023,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Natural Science Foundation of China; National Key Research and Development Program of China; Priority Academic Program Development of Jiangsu Higher Education Institutions; Guangzhou Medical University","keywords":"Ubiquitin ligase; Ubiquitin; Phosphorylation; GSK-3; Biology; GSK3B; Transcription factor; Downregulation and upregulation; Cell biology; Glycogen synthase; Transcriptional regulation; Biochemistry; Gene","score_opus":0.04144106375019958,"score_gpt":0.32159269445066474,"score_spread":0.28015163070046517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362607805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922758,0.0010034259,0.000019932428,0.006055865,0.00005207405,0.00018167084,0.00012730913,0.000030860374,0.00025310752],"genre_scores_gemma":[0.9976413,0.00090112403,0.000048482943,0.00007926491,0.00020377207,0.00002151016,0.00016728295,0.000011389342,0.00092585775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981919,0.00014558478,0.00049451477,0.00022151152,0.0005073903,0.00043910975],"domain_scores_gemma":[0.9985693,0.0006523111,0.00019105773,0.00014204888,0.00014092376,0.0003043409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065369473,0.00018174948,0.00038997564,0.00004665371,0.00012343917,0.000043417385,0.00020460575,0.0002735989,0.0002751661],"category_scores_gemma":[0.0009966436,0.00010403404,0.00021796029,0.00026100103,0.0002071847,0.00008238855,0.00004142398,0.00065213826,0.000016903216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003412062,0.0006168257,0.008401707,0.000051049698,0.00010223703,0.0002584102,0.000024514335,7.1198684e-7,0.96633315,0.000005605787,0.008672413,0.012121307],"study_design_scores_gemma":[0.0054068933,0.0006203398,0.23002674,0.00012184184,0.000036506997,0.00023119793,0.0001922432,0.0001544705,0.75549257,0.00022453313,0.0073373937,0.00015526771],"about_ca_topic_score_codex":0.00000766166,"about_ca_topic_score_gemma":0.0000019100423,"teacher_disagreement_score":0.22162503,"about_ca_system_score_codex":0.00016258041,"about_ca_system_score_gemma":0.00014050734,"threshold_uncertainty_score":0.4242385},"labels":[],"label_agreement":null},{"id":"W4362657670","doi":"10.1002/cncr.34778","title":"Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Daiichi Sankyo Company; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; Hamilton Health Sciences Foundation; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; TG Therapeutics; bluebird bio; Medac; Prothena; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; National Center for Advancing Translational Sciences; HistoGenetics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Amgen; Omeros Corporation; Sanofi Genzyme; Hamilton Health Sciences; GlaxoSmithKline; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Lenalidomide; Bortezomib; Medicine; Multiple myeloma; Internal medicine; Maintenance therapy; Oncology; Autologous stem-cell transplantation; Surgery; Chemotherapy","score_opus":0.03776128518566816,"score_gpt":0.3495376191272088,"score_spread":0.31177633394154064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362657670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980783,0.00007056349,0.000008643623,0.00011061947,0.000110284964,0.0006796973,0.00080817327,0.000040478262,0.000093230774],"genre_scores_gemma":[0.9990875,0.00023541345,0.0001250686,0.000036967904,0.000028485802,0.000107970125,0.00015201229,0.000035527097,0.00019106035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861455,0.00004661721,0.00023054503,0.00024966293,0.00049783615,0.00036077073],"domain_scores_gemma":[0.9986428,0.0003325968,0.00018635885,0.00040519334,0.00027227568,0.00016074738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008649216,0.00019490106,0.0004673588,0.000177707,0.0000396926,0.0000044003637,0.000096616954,0.00005335438,0.0002308903],"category_scores_gemma":[0.00022926313,0.00011012757,0.00019019205,0.0003592193,0.000113371585,0.00004276807,0.00001696885,0.00012211884,0.000022288312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026513554,0.00041252837,0.9525455,0.000035532717,0.000960804,0.000021561935,0.00006482496,0.00037622548,0.00035092933,0.00000454858,0.0006672587,0.01804668],"study_design_scores_gemma":[0.041939035,0.0029216213,0.94777894,0.0001146347,0.000052674703,8.1517186e-8,0.000013964162,0.00037184067,0.0066208155,0.000004543381,0.000087223794,0.00009463616],"about_ca_topic_score_codex":0.0026157256,"about_ca_topic_score_gemma":0.0001535413,"teacher_disagreement_score":0.017952045,"about_ca_system_score_codex":0.00023095976,"about_ca_system_score_gemma":0.0002750465,"threshold_uncertainty_score":0.4490872},"labels":[],"label_agreement":null},{"id":"W4365811103","doi":"10.1007/s44228-023-00036-8","title":"Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)","year":2023,"lang":"en","type":"review","venue":"Clinical Hematology International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Hematology; Multiple myeloma; Medicine; Round table; Internal medicine; Immune thrombocytopenia; Clinical immunology; Oncology; Immunology; Computer science","score_opus":0.22146585949380115,"score_gpt":0.5320369763188361,"score_spread":0.3105711168250349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365811103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008144777,0.96565694,0.0006168763,0.010457112,0.013830172,0.0042190533,0.003385034,0.0002285202,0.0007918207],"genre_scores_gemma":[0.0005650803,0.97983384,0.0011803912,0.0011109497,0.0023069805,0.0023855504,0.009316232,0.000180628,0.0031203548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989587,0.00071224966,0.005030145,0.0021085122,0.0013744499,0.0011876456],"domain_scores_gemma":[0.98286223,0.013362836,0.0017547029,0.00069958455,0.0007896075,0.0005310288],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0034111259,0.000988679,0.00375617,0.0005055213,0.00022344079,0.00014299866,0.002757089,0.0017114085,0.0005776337],"category_scores_gemma":[0.009414199,0.00070894347,0.0029016873,0.00051138236,0.0012369261,0.000423524,0.0012954946,0.0035957454,0.00085548824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013421496,0.0032401443,0.050078716,0.0027136777,0.005804919,0.00035405369,0.000046316545,0.0000012162403,6.867099e-7,0.004586056,0.1450968,0.78673524],"study_design_scores_gemma":[0.0077122543,0.00031804788,0.0012840724,0.0038992723,0.0005178003,0.0014881229,0.00006359037,0.0025496692,0.0000033411625,0.00093810534,0.9806808,0.0005449118],"about_ca_topic_score_codex":0.000027326138,"about_ca_topic_score_gemma":0.00011558925,"teacher_disagreement_score":0.835584,"about_ca_system_score_codex":0.00067957374,"about_ca_system_score_gemma":0.0011374371,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W4366975166","doi":"10.3390/curroncol30050334","title":"Management of Multiple Myeloma: A Review for General Practitioners in Oncology","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen's University","funders":"BeiGene; Celgene; Gilead Sciences; Sanofi; Pfizer","keywords":"Medicine; Multiple myeloma; Life expectancy; Malignancy; Survivorship curve; Disease; Oncology; Hematologic malignancy; Internal medicine; Intensive care medicine; Chemotherapy; Bone marrow; Cancer; Population","score_opus":0.37414392418028714,"score_gpt":0.5579176109901451,"score_spread":0.183773686809858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366975166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000144522855,0.987916,0.000036914706,0.0003480581,0.00086884137,0.009042443,0.00024664722,0.00004978535,0.0014768937],"genre_scores_gemma":[0.0000019483905,0.98621976,0.0026796085,0.00004108908,0.0002305113,0.007119616,0.0027315363,0.00007666467,0.00089927815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99652874,0.0004633947,0.0013647669,0.0006655597,0.00032657367,0.0006509442],"domain_scores_gemma":[0.99732214,0.0010169847,0.00073201925,0.00049931055,0.00018581089,0.00024370692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008943771,0.00043328555,0.0036305399,0.00058755354,0.000041931846,0.0000042243687,0.0002487318,0.0003843673,0.000096502925],"category_scores_gemma":[0.0004928569,0.00033994747,0.0007615057,0.00071665976,0.00012800489,0.00004154461,0.00020984239,0.00058181805,0.00021024814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012329282,0.0012167718,0.000044399603,0.23289259,0.00069957395,0.00051495736,0.0000141162345,1.0206073e-7,1.3203679e-7,0.00019037277,0.007714624,0.75658906],"study_design_scores_gemma":[0.0041540223,0.0009829024,0.00009980044,0.08251409,0.002204241,0.00010996511,0.00002317499,0.000031275446,3.5878477e-7,0.000032695712,0.90965396,0.00019349797],"about_ca_topic_score_codex":0.000020688167,"about_ca_topic_score_gemma":0.000059131457,"teacher_disagreement_score":0.90193933,"about_ca_system_score_codex":0.0017162301,"about_ca_system_score_gemma":0.0012985314,"threshold_uncertainty_score":0.9999052},"labels":[],"label_agreement":null},{"id":"W4366991230","doi":"10.1007/s00520-023-07762-y","title":"Exploring participant perceptions of a virtually supported home exercise program for people with multiple myeloma using a novel eHealth application: a qualitative study","year":2023,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Government of Alberta","keywords":"eHealth; Usability; Flexibility (engineering); Qualitative research; Applied psychology; Medicine; Medical education; Nursing research; Inclusion (mineral); Perception; Psychology; Nursing; Computer science; Health care; Human–computer interaction; Social psychology","score_opus":0.2228053641827075,"score_gpt":0.47302193433164036,"score_spread":0.25021657014893284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366991230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895422,0.000096904296,0.0005896716,0.00014748635,0.000051242972,0.00871442,0.000727104,0.00011894065,0.000012038359],"genre_scores_gemma":[0.9691086,0.000100126905,0.0023831439,0.000012809836,0.000048596474,0.027800133,0.0004526846,0.000058421,0.000035493573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758196,0.00008079082,0.00057249115,0.0005673991,0.0005259572,0.0006714137],"domain_scores_gemma":[0.99805874,0.0002463472,0.00020753892,0.00034702953,0.00085926126,0.00028110066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037167387,0.00024556014,0.0006949694,0.00038838538,0.00012680492,0.000014614329,0.000096752265,0.000051917465,0.000059142218],"category_scores_gemma":[0.00014134972,0.00020057503,0.00011320146,0.0012855818,0.00011699823,0.00020949368,0.00005850333,0.0001620085,0.0000065644485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039157365,0.002351915,0.6345976,0.0009477862,0.00037090995,0.000051022147,0.32782325,0.00020889835,0.003543228,0.000014033984,0.00001678028,0.026158806],"study_design_scores_gemma":[0.00694121,0.0028897754,0.5848034,0.0003781756,0.00021413593,0.0000034977452,0.4013556,0.002601371,0.0006150519,0.000006118387,0.000025280844,0.0001663714],"about_ca_topic_score_codex":0.0033938403,"about_ca_topic_score_gemma":0.009024955,"teacher_disagreement_score":0.073532335,"about_ca_system_score_codex":0.00048839493,"about_ca_system_score_gemma":0.0010296433,"threshold_uncertainty_score":0.8179212},"labels":[],"label_agreement":null},{"id":"W4367300469","doi":"10.1038/s41408-023-00840-8","title":"An atlas of the bone marrow bone proteome in patients with dysproteinemias","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Bone marrow; Atlas (anatomy); Medicine; Bone marrow transplantation; MEDLINE; Pathology; Internal medicine; Bioinformatics; Biology; Anatomy","score_opus":0.013879807561555286,"score_gpt":0.2832907785892708,"score_spread":0.26941097102771555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367300469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977928,0.00026377465,0.0000016069879,0.00085058867,0.000057782698,0.00087576534,0.0000268794,0.000015228954,0.00011559131],"genre_scores_gemma":[0.9989283,0.00008419501,0.00022091981,0.00004061118,0.00012916904,0.00010348,0.00001013364,0.000023578714,0.0004596202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984116,0.00007885135,0.00026538043,0.00015656199,0.0007277672,0.0003598438],"domain_scores_gemma":[0.9991756,0.000014416433,0.00014888716,0.00026722005,0.00017774399,0.0002161097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023908533,0.00012197076,0.00025585695,0.00017845139,0.00009059738,0.000019162233,0.00012038376,0.000048130856,0.00016560355],"category_scores_gemma":[0.000062760715,0.00006588291,0.000061056926,0.00056354015,0.00006656014,0.00009898728,0.000037274905,0.00037928345,0.000008886029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011886252,0.0006757597,0.9835508,0.00006953305,0.0001343071,0.00029021854,0.00015305544,0.000032964854,0.006197957,0.0000023942055,0.0002394508,0.007464961],"study_design_scores_gemma":[0.013439851,0.0011949331,0.9721574,0.00046487857,0.00007337637,0.00007416755,0.00004062542,0.00004476419,0.012267846,0.000029312903,0.00013925237,0.00007357663],"about_ca_topic_score_codex":0.0002805315,"about_ca_topic_score_gemma":0.00022023219,"teacher_disagreement_score":0.012251225,"about_ca_system_score_codex":0.00009162777,"about_ca_system_score_gemma":0.0003528484,"threshold_uncertainty_score":0.2686627},"labels":[],"label_agreement":null},{"id":"W4367853972","doi":"10.3390/curroncol30050348","title":"Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Immune system; Immunosuppression; Antibody; Cancer research; Immunology","score_opus":0.3033825310285444,"score_gpt":0.49542334391819903,"score_spread":0.19204081288965463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367853972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007646635,0.98933125,0.000007790757,0.000035104127,0.00043339137,0.0022946538,0.00014656658,0.00004143913,0.000063187195],"genre_scores_gemma":[0.0020932537,0.9961766,0.00007937106,0.0000012002317,0.00013700724,0.0005019333,0.00079240155,0.000049054386,0.00016918842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975602,0.0002770545,0.000985614,0.0005297596,0.00022829312,0.00041905793],"domain_scores_gemma":[0.9983694,0.000603488,0.0004237261,0.0003246499,0.00008729851,0.00019144538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028107833,0.0003399074,0.0019906997,0.0005985243,0.000050589024,0.00000973128,0.00009716708,0.00026038825,0.000029035167],"category_scores_gemma":[0.0005432507,0.0002479045,0.00027408206,0.0004344727,0.0001340825,0.000031115684,0.00009729436,0.00029364033,0.00011708061],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005588735,0.0007647569,0.0033789475,0.011728005,0.00026693675,0.00023637917,0.00016124368,1.2282467e-7,0.00003250133,0.000013247943,0.000074623946,0.98328733],"study_design_scores_gemma":[0.003155514,0.0007911125,0.003357081,0.0074085854,0.000767588,0.00008842577,0.000088305525,0.00022931992,0.000041507697,0.000016822516,0.98385674,0.00019900131],"about_ca_topic_score_codex":0.00007712678,"about_ca_topic_score_gemma":0.000116445044,"teacher_disagreement_score":0.9837821,"about_ca_system_score_codex":0.0007825236,"about_ca_system_score_gemma":0.0006335155,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4367856478","doi":"10.5737/23688076332215","title":"Psychosocial and supportive care needs of individuals with advanced myeloma","year":2023,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"University Health Network","keywords":"Psychosocial; Social support; Coping (psychology); Qualitative research; Medicine; Psychological intervention; Population; Multiple myeloma; Psychology; Clinical psychology; Nursing; Psychotherapist; Psychiatry","score_opus":0.022364657110185465,"score_gpt":0.35577029921373676,"score_spread":0.3334056421035513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367856478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482877,0.0008209644,0.000011671022,0.006196664,0.00020814492,0.00027532375,0.000057935245,0.00001624633,0.007584301],"genre_scores_gemma":[0.99840486,0.00017847691,0.0008073952,0.00015842196,0.00014559888,0.000008215481,0.000044502805,0.000019593619,0.0002329175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989156,0.00007058148,0.00019043955,0.00010966201,0.00020537524,0.0005083066],"domain_scores_gemma":[0.9985175,0.000063455416,0.00010625167,0.00009301408,0.00021902232,0.001000715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001533962,0.00011028723,0.0003046229,0.0007723618,0.00022976173,0.000015949965,0.00006292546,0.00012255955,0.00009353409],"category_scores_gemma":[0.000086814216,0.00008958232,0.00004443456,0.0004553509,0.00031072568,0.00006583461,0.000005891818,0.0003240689,0.000011244341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005667049,0.0000702992,0.28164956,0.000037749378,0.00031399043,0.001963308,0.017117176,0.000002697518,0.00032653668,0.000083024286,0.009053306,0.68881565],"study_design_scores_gemma":[0.007845816,0.004268391,0.9397955,0.00085636403,0.00017659225,0.0023388416,0.03189575,0.00001701699,0.0003803313,0.0002172666,0.012066999,0.00014112184],"about_ca_topic_score_codex":0.00050029065,"about_ca_topic_score_gemma":0.0039359173,"teacher_disagreement_score":0.6886745,"about_ca_system_score_codex":0.0012362419,"about_ca_system_score_gemma":0.003961285,"threshold_uncertainty_score":0.702715},"labels":[],"label_agreement":null},{"id":"W4367857211","doi":"10.5737/23688076332223","title":"Besoins en soins psychosociaux et de soutien des personnes atteintes d’un myélome de stade avancé","year":2023,"lang":"fr","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Canadian Nurses Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Humanities; Political science; Medicine; Art","score_opus":0.06074514059652595,"score_gpt":0.4062770885940362,"score_spread":0.34553194799751025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367857211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79534686,0.024943579,0.0008526207,0.14937572,0.0043764473,0.00055895513,0.0003773946,0.00010867607,0.024059745],"genre_scores_gemma":[0.9662776,0.0079435,0.005542732,0.0027033966,0.004170472,0.000032522257,0.00008433328,0.00014484071,0.013100598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99405026,0.0013278498,0.00047542763,0.0004152635,0.0003927992,0.0033384194],"domain_scores_gemma":[0.9940598,0.0007732608,0.00017292917,0.00027257073,0.00023902669,0.0044824206],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019659624,0.0003978106,0.0006273105,0.0011015915,0.0013704611,0.00017951829,0.00038545352,0.0006392296,0.0021332325],"category_scores_gemma":[0.0014418685,0.00041493346,0.00031373935,0.00063634804,0.0011011519,0.00024210593,0.000028359864,0.001895804,0.0011515712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003588021,0.0006950741,0.17960425,0.00014401072,0.0012673076,0.026672915,0.08591255,0.000098041695,0.0011961882,0.0011478105,0.18001191,0.52289116],"study_design_scores_gemma":[0.009744157,0.0039923354,0.6619082,0.0068783485,0.0008729089,0.020911923,0.05548701,0.005549438,0.0003383367,0.010392339,0.22317074,0.00075425854],"about_ca_topic_score_codex":0.037152376,"about_ca_topic_score_gemma":0.16078028,"teacher_disagreement_score":0.52213687,"about_ca_system_score_codex":0.028060304,"about_ca_system_score_gemma":0.029947659,"threshold_uncertainty_score":0.9999296},"labels":[],"label_agreement":null},{"id":"W4368368315","doi":"10.7759/cureus.38512","title":"Solitary Extramedullary Plasmacytoma of the Head and Neck: A Report of Three Cases Treated With Curative Radiotherapy and a Review of the Dose-Control Relationship","year":2023,"lang":"en","type":"review","venue":"Cureus","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plasmacytoma; Radiation therapy; Multiple myeloma; External beam radiotherapy; Head and neck; Radiology; Malignancy; Extramedullary plasmacytoma; Surgery; Pathology; Internal medicine; Brachytherapy","score_opus":0.11217294078659441,"score_gpt":0.3925250467670272,"score_spread":0.2803521059804328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368368315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010848229,0.9844325,0.0000029559592,0.00026696303,0.000026064014,0.003979837,0.00027234343,0.000013476221,0.00015759976],"genre_scores_gemma":[0.00543316,0.99383104,0.0001420188,0.00002735777,0.00002915001,0.00019280887,0.000057616257,0.000043343196,0.00024348922],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979151,0.00035841134,0.00078940147,0.00031064183,0.000430025,0.0001964029],"domain_scores_gemma":[0.99688655,0.0012073232,0.0007997323,0.0008196218,0.00018251855,0.00010423876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003583411,0.0003119725,0.0018144305,0.000077815785,0.00007496263,0.0000047345734,0.00015274284,0.00014329892,0.00001829169],"category_scores_gemma":[0.0011858273,0.00013226179,0.0003238443,0.00050436344,0.00045219075,0.0000447105,0.000056087094,0.0003159432,4.5846116e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014451455,0.0008873523,0.3040021,0.37688458,0.011396428,0.0029450834,0.0005095656,5.3012553e-7,0.000013252195,0.00030520326,0.0015800807,0.30003065],"study_design_scores_gemma":[0.010103597,0.002880885,0.20800374,0.6937494,0.009956204,0.016536104,0.000088121415,0.000058244557,0.000030117864,0.00013524345,0.057972975,0.0004853213],"about_ca_topic_score_codex":0.0004716676,"about_ca_topic_score_gemma":0.00033370973,"teacher_disagreement_score":0.31686488,"about_ca_system_score_codex":0.00009929234,"about_ca_system_score_gemma":0.00076677423,"threshold_uncertainty_score":0.53934795},"labels":[],"label_agreement":null},{"id":"W4368617821","doi":"10.14740/jh1097","title":"Hyperammonemic Encephalopathy: A Rare Presentation of Relapsed Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Hyperammonemia; Medicine; Encephalopathy; Multiple myeloma; Chemotherapy; Pediatrics; Differential diagnosis; Internal medicine; Gastroenterology; Pathology","score_opus":0.033437223202671264,"score_gpt":0.3292276421570165,"score_spread":0.2957904189543452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368617821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976098,0.00061537855,0.00009364069,0.00094232336,0.00016087899,0.00022114694,0.0000066537104,0.000020419717,0.00032979305],"genre_scores_gemma":[0.99802035,0.00021373488,0.0013607068,0.00003083811,0.00006496737,0.000007872783,0.000019657737,0.000014603097,0.0002672432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986288,0.00009370648,0.0005404481,0.000110309,0.00038155852,0.00024519692],"domain_scores_gemma":[0.9986652,0.00037096487,0.00032295182,0.0001641798,0.00031516323,0.00016154756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025046908,0.00009638037,0.0004852107,0.00041389657,0.000036521873,0.0000046355276,0.00010149053,0.00009237638,0.00008785934],"category_scores_gemma":[0.0010050501,0.00007161454,0.00015306944,0.00034281684,0.000079712285,0.00009331691,0.000035376004,0.00020417615,0.000069349364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026043302,0.00043154656,0.8953872,0.00034581634,0.00042504477,0.005469981,0.00093868596,0.000026461903,0.0777637,0.00026128493,0.0048321187,0.011513888],"study_design_scores_gemma":[0.019210152,0.0025590863,0.81089175,0.00049013586,0.00021826995,0.012643113,0.0017631961,0.0027513034,0.14695367,0.0009330044,0.0014128702,0.00017342687],"about_ca_topic_score_codex":0.000017822837,"about_ca_topic_score_gemma":0.0000071631553,"teacher_disagreement_score":0.08449537,"about_ca_system_score_codex":0.000040175037,"about_ca_system_score_gemma":0.00018638762,"threshold_uncertainty_score":0.2920356},"labels":[],"label_agreement":null},{"id":"W4376106087","doi":"10.1097/01.hs9.0000936160.56974.35","title":"P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Centre Hospitalier Universitaire de Toulouse; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Alberta; University of Wolverhampton; National Institute for Health and Care Research; Massachusetts General Hospital; St Vincent's Hospital Melbourne; Université de Lille","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Biomarker; Progression-free survival; Overall survival","score_opus":0.04316716519591803,"score_gpt":0.31308169024064814,"score_spread":0.2699145250447301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376106087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951099,0.00011350133,0.00007791439,0.0004056326,0.0000985913,0.0024584476,0.0008654835,0.00020147732,0.0006690389],"genre_scores_gemma":[0.9910961,0.0000120505065,0.0050633876,0.0000440384,0.00006483552,0.0008844487,0.0016340527,0.00014677797,0.0010543164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963982,0.00012848662,0.0007400971,0.0008491234,0.0007917781,0.0010923106],"domain_scores_gemma":[0.99786866,0.00046365932,0.0002509131,0.00055550085,0.00044314034,0.0004181114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027418602,0.00054118683,0.00097163545,0.0005765201,0.00017606809,0.000057792542,0.00022219312,0.00023753499,0.00023776738],"category_scores_gemma":[0.0004057451,0.0004417939,0.0002803633,0.0015764199,0.00017842434,0.00029590988,0.00016078616,0.0001961081,0.000029555513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006979205,0.0011634592,0.9480844,0.00049807946,0.00051480613,0.0002507892,0.0008717967,0.0000050964154,0.0031920185,0.0000148390745,0.0015849512,0.036840536],"study_design_scores_gemma":[0.022133669,0.0023145003,0.9580553,0.0008119846,0.00010988804,0.0000068731615,0.00038846946,0.0040963655,0.011294956,0.000022524226,0.00035849516,0.00040693392],"about_ca_topic_score_codex":0.0010241485,"about_ca_topic_score_gemma":0.0016550518,"teacher_disagreement_score":0.0364336,"about_ca_system_score_codex":0.00020431414,"about_ca_system_score_gemma":0.00013137414,"threshold_uncertainty_score":0.99980336},"labels":[],"label_agreement":null},{"id":"W4377220744","doi":"10.2217/fon-2023-0082","title":"Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Amgen","keywords":"Daratumumab; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Oncology; Internal medicine","score_opus":0.024376566490560227,"score_gpt":0.32797371336154324,"score_spread":0.303597146870983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377220744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939441,0.0012538293,0.00001624127,0.0010530018,0.00012184683,0.0032981036,0.00015612972,0.000016667305,0.00014009503],"genre_scores_gemma":[0.9978033,0.0004156,0.00056497403,0.00002892717,0.00014101714,0.00047865335,0.00005334997,0.000023024853,0.00049116684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987539,0.00019724974,0.00028154763,0.00023067005,0.00026929582,0.0002673249],"domain_scores_gemma":[0.99692357,0.002231654,0.00019341217,0.00046602168,0.00010493519,0.00008042692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022949926,0.0001678639,0.0006382651,0.000102877406,0.00010647952,0.0000033925212,0.00013520259,0.00009624257,0.000019587682],"category_scores_gemma":[0.00018984143,0.00007616087,0.00010328377,0.00037247507,0.00016350669,0.000021152855,0.000059219903,0.00009765826,0.0000011322797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045117978,0.007860994,0.72531956,0.00059297145,0.003962869,0.0005655336,0.06872821,0.00017570282,0.010404812,0.00009304813,0.0036170415,0.1335613],"study_design_scores_gemma":[0.058518704,0.018063286,0.8706998,0.00006882336,0.00058873516,0.00003857748,0.040440712,0.00080611475,0.00673832,0.0000071151503,0.0039382004,0.00009156302],"about_ca_topic_score_codex":0.0016327479,"about_ca_topic_score_gemma":0.0164672,"teacher_disagreement_score":0.1453803,"about_ca_system_score_codex":0.0001300547,"about_ca_system_score_gemma":0.00023667434,"threshold_uncertainty_score":0.9189085},"labels":[],"label_agreement":null},{"id":"W4377287471","doi":"10.1038/s41408-023-00851-5","title":"Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Phenotype; Biology; Multiple myeloma; Mass cytometry; Malignancy; Genetic heterogeneity; Meta-analysis; Cancer research; Oncology; Internal medicine; Immunology; Genetics; Medicine; Gene","score_opus":0.03962556086710801,"score_gpt":0.30440145318038375,"score_spread":0.26477589231327575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377287471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834085,0.00026018888,0.000048664806,0.0007486134,0.00006806394,0.0002952804,0.0001187646,0.00004878721,0.00007080773],"genre_scores_gemma":[0.99818426,0.00063519477,0.00014356062,0.00014387134,0.00008077159,0.000023845218,0.000029123483,0.000023482677,0.0007358872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982929,0.00012521462,0.00022994449,0.00023767712,0.00059524586,0.0005189767],"domain_scores_gemma":[0.9990247,0.00022495854,0.00011870972,0.00013301642,0.00013229312,0.0003663517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041698225,0.00018158913,0.0004062393,0.00040104613,0.00040656445,0.00003627366,0.00010963577,0.00009005057,0.00013187346],"category_scores_gemma":[0.0002614178,0.00013097428,0.00007101008,0.00051840575,0.00005759148,0.00012534572,0.00017725542,0.0004887525,0.0000071509176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040066804,0.00023158093,0.9926725,0.000043440345,0.0007705469,0.0024947047,0.00032022526,0.0000063078805,0.0008857884,0.0000032281546,0.00009005369,0.002080974],"study_design_scores_gemma":[0.011488044,0.00033066794,0.9865989,0.00033306325,0.00014898802,0.00012016838,0.00016237766,0.00013102553,0.00045206537,0.00009103842,0.000011430594,0.0001322032],"about_ca_topic_score_codex":0.00051990215,"about_ca_topic_score_gemma":0.001019095,"teacher_disagreement_score":0.011087376,"about_ca_system_score_codex":0.00023646711,"about_ca_system_score_gemma":0.00015691161,"threshold_uncertainty_score":0.5340976},"labels":[],"label_agreement":null},{"id":"W4377695552","doi":"10.1016/j.leukres.2023.107324","title":"Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Confidence interval; Incidence (geometry); Meta-analysis; Randomized controlled trial; Odds ratio; Adverse effect; Oncology; Clinical endpoint; Clinical trial; Gastroenterology","score_opus":0.13460659739632136,"score_gpt":0.3991285932244679,"score_spread":0.26452199582814656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377695552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063716145,0.9831647,0.0000018669734,0.000036212077,0.000008658401,0.00973092,0.00052223465,0.000038172664,0.00012557222],"genre_scores_gemma":[0.00295854,0.9914063,0.00046889056,0.000037430935,0.000014016232,0.001842442,0.00067640265,0.000115764065,0.002480165],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909501,0.001961658,0.0020221572,0.0012003882,0.0027523013,0.0011133755],"domain_scores_gemma":[0.99322164,0.0030651353,0.00072529423,0.0015300288,0.0010436856,0.0004142074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044283005,0.0007372467,0.012342162,0.0026142213,0.00015976088,0.00007959507,0.0005979474,0.00033668833,0.00021734192],"category_scores_gemma":[0.0032121907,0.00043815243,0.0013888752,0.0052293083,0.00044102408,0.00020707832,0.00065576873,0.0013554773,0.000084167084],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006273744,0.00015714594,0.010557732,0.9065628,0.080999635,0.00034999178,0.00007134302,6.6632157e-7,9.793869e-7,0.0000035768526,0.00010265043,0.0011307292],"study_design_scores_gemma":[0.002717566,0.00072995416,0.079334795,0.39141655,0.5239489,0.00006580384,0.00007033155,0.000052534626,0.0000054701336,0.000009424979,0.0008814238,0.0007672596],"about_ca_topic_score_codex":0.0005460616,"about_ca_topic_score_gemma":0.0005356126,"teacher_disagreement_score":0.51514626,"about_ca_system_score_codex":0.0015024652,"about_ca_system_score_gemma":0.0020905803,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W4377826847","doi":"10.1016/j.clml.2023.05.008","title":"Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"CSL Behring","keywords":"Hypogammaglobulinemia; Medicine; Intensive care medicine; Immunodeficiency; Primary immunodeficiency; Disease; Antibody; Immunology; Pediatrics; Internal medicine; Immune system","score_opus":0.19724998876862215,"score_gpt":0.46812037936177925,"score_spread":0.2708703905931571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377826847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003192463,0.9806221,0.00014920076,0.00021645312,0.0011117341,0.008930524,0.0014991707,0.00028027,0.0039980817],"genre_scores_gemma":[0.0007464446,0.982544,0.0062822984,0.00007814054,0.0003003439,0.0015090365,0.0051657185,0.00025479958,0.0031191856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919742,0.00047333204,0.004067482,0.0015701579,0.0006941343,0.001220717],"domain_scores_gemma":[0.9925576,0.0039930083,0.0010495816,0.0015343464,0.0002514151,0.00061408896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019015872,0.0008931955,0.0044087167,0.00095127255,0.00018859124,0.0000464842,0.0007678388,0.0009696437,0.00016769607],"category_scores_gemma":[0.0011473281,0.00075093005,0.0021961452,0.0015853386,0.00040524013,0.00013687239,0.00054770336,0.00068814115,0.00063304347],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033031777,0.0008304743,0.0010025514,0.036726825,0.001141284,0.00069046987,0.00002079127,3.361545e-7,7.191757e-7,0.0003453465,0.0029023064,0.95600855],"study_design_scores_gemma":[0.01060294,0.0009206325,0.11693723,0.032718796,0.0017501282,0.000112874295,0.000102503735,0.00022492281,0.0000041645744,0.00024870824,0.83568317,0.00069393124],"about_ca_topic_score_codex":0.00010202865,"about_ca_topic_score_gemma":0.000058096422,"teacher_disagreement_score":0.95531464,"about_ca_system_score_codex":0.0016759138,"about_ca_system_score_gemma":0.0029349376,"threshold_uncertainty_score":0.9994942},"labels":[],"label_agreement":null},{"id":"W4377968636","doi":"10.1093/jsxmed/qdad061.106","title":"(110) Characterizing Sexuality and Assessing Predictors of Sexual Satisfaction in Patients with Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"The Journal of Sexual Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Sexual function; Human sexuality; Medicine; Clinical psychology; Distress; Population; Sexual dysfunction; Psychology; Internal medicine","score_opus":0.0351960055579056,"score_gpt":0.3199693987066257,"score_spread":0.28477339314872013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377968636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982574,0.00011016857,0.000031625434,0.0009850152,0.00017590144,0.0003830578,0.000012254945,0.000017734617,0.000026845446],"genre_scores_gemma":[0.99938124,0.000059569902,0.00010278041,0.00006180808,0.0002779588,0.0000029403943,0.00003065906,0.000022394552,0.00006066864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771225,0.0002181966,0.0006498177,0.0001543205,0.00096294185,0.00030244395],"domain_scores_gemma":[0.9982386,0.00058729236,0.00045868527,0.00021864437,0.00027329684,0.00022343961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001428783,0.00017816319,0.00055567274,0.00040350977,0.00008372412,0.000009759875,0.000089646535,0.00006614932,0.000024888257],"category_scores_gemma":[0.0007664967,0.00009288272,0.000008318329,0.00051358563,0.00027569695,0.00027628063,0.000053590036,0.0004166016,0.0000022171307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020367582,0.00014855523,0.91297996,0.00022049021,0.00020451506,0.00006570745,0.0019354785,0.000006378279,0.049933627,7.8461414e-7,0.00010627292,0.032361466],"study_design_scores_gemma":[0.008859046,0.007494145,0.9792798,0.000438109,0.0002057835,0.000081482765,0.0028932896,0.00018133991,0.00046446975,0.0000063105817,0.000024977597,0.00007121454],"about_ca_topic_score_codex":0.0003786122,"about_ca_topic_score_gemma":0.00008495367,"teacher_disagreement_score":0.06629986,"about_ca_system_score_codex":0.00010115848,"about_ca_system_score_gemma":0.00010963423,"threshold_uncertainty_score":0.37876475},"labels":[],"label_agreement":null},{"id":"W4378087170","doi":"10.3390/curroncol30060396","title":"Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal","keywords":"Medicine; Multiple myeloma; Retrospective cohort study; Pediatrics; Presentation (obstetrics); Young adult; MEDLINE; Disease; Internal medicine; Surgery","score_opus":0.22608022292323962,"score_gpt":0.5120943656532443,"score_spread":0.2860141427300047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378087170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017286306,0.9927242,0.000002914908,0.000046710305,0.00040816294,0.0061530815,0.00023851445,0.0000433087,0.00036584237],"genre_scores_gemma":[0.0000048935062,0.9969201,0.00005786026,0.000021901962,0.000034288423,0.0014534219,0.0010656405,0.000044913828,0.00039696207],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99725753,0.00045693308,0.0012571559,0.00034466604,0.0003848354,0.00029888938],"domain_scores_gemma":[0.9975367,0.00083202904,0.0007001741,0.00043904982,0.00027810765,0.00021389723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037847678,0.0003387631,0.0041959444,0.0003360993,0.000045991084,0.000006856093,0.00013756922,0.00015941462,0.000047360994],"category_scores_gemma":[0.0023571635,0.00021186634,0.000459672,0.0003317147,0.00009652012,0.00003201181,0.00013768351,0.00031856206,0.00023033537],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003071491,0.00032891266,0.0012173277,0.7816472,0.0006188242,0.00006630289,0.000022256389,3.3301017e-10,2.0502877e-9,0.000039133138,0.00052629056,0.21553065],"study_design_scores_gemma":[0.00090347824,0.0003716456,0.0013043383,0.87401474,0.0073366226,0.00013303527,0.000015173906,0.0000014172149,1.0434438e-8,0.000008495492,0.11577517,0.00013589376],"about_ca_topic_score_codex":0.000007820052,"about_ca_topic_score_gemma":0.000010335578,"teacher_disagreement_score":0.21539477,"about_ca_system_score_codex":0.0003296717,"about_ca_system_score_gemma":0.00047574253,"threshold_uncertainty_score":0.86396587},"labels":[],"label_agreement":null},{"id":"W4378188863","doi":"10.1038/s41408-023-00856-0","title":"Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Minimal residual disease; Medicine; Multiple myeloma; Oncology; Internal medicine; Residual; Medical physics; Bone marrow; Computer science; Algorithm","score_opus":0.05230070476117005,"score_gpt":0.3153324173812251,"score_spread":0.26303171262005504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378188863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890475,0.004253596,0.000009387696,0.00021258822,0.0046945703,0.00043651118,0.00096781674,0.000026116184,0.00035189072],"genre_scores_gemma":[0.94468755,0.024314104,0.00014620839,0.00006843282,0.00206763,0.000113642214,0.0056784004,0.00009148629,0.022832545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972494,0.00018795845,0.0007439988,0.00044766662,0.0009131828,0.00045777668],"domain_scores_gemma":[0.9983651,0.00006273481,0.00036747835,0.00021923128,0.000442206,0.0005432606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029066802,0.00033889976,0.00088149455,0.001665076,0.00015607658,0.00010301339,0.00011647911,0.00016927983,0.00027880445],"category_scores_gemma":[0.00018506624,0.0002766414,0.0002461311,0.0013355382,0.000077914825,0.00015317471,0.000029701307,0.0010903169,0.000002485373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027662267,0.00070098555,0.7185475,0.0005559849,0.009861562,0.004697767,0.00093699654,0.00036652372,0.0015729287,0.0000010816213,0.2453716,0.014620836],"study_design_scores_gemma":[0.008238513,0.0009890574,0.9389329,0.003550756,0.012835092,0.00021252508,0.00035158635,0.032186586,0.0007489844,0.000004793,0.0015076497,0.00044158625],"about_ca_topic_score_codex":0.0031777222,"about_ca_topic_score_gemma":0.010418064,"teacher_disagreement_score":0.24386394,"about_ca_system_score_codex":0.0005934019,"about_ca_system_score_gemma":0.0025623117,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W4378516543","doi":"10.3390/ijms24108500","title":"Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization","year":2023,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Regional Development Fund; Instituto de Salud Carlos III; Fundação para a Ciência e a Tecnologia; National Cancer Institute; National Institutes of Health; CRIS Cancer Foundation; Consejería de Transformación Económica, Industria, Conocimiento y Universidades; Bundesministerium für Bildung und Forschung; Fondation contre le Cancer; European Commission","keywords":"Biology; Single-nucleotide polymorphism; Immunology; Peripheral blood mononuclear cell; SNP; Molecular biology; Cancer research; Genetics; Gene; Genotype","score_opus":0.12827986302433092,"score_gpt":0.3914769512419404,"score_spread":0.26319708821760945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378516543","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05500871,0.9378238,0.0040511433,0.0003190122,0.00062251603,0.0012200606,0.0009088149,0.000021036434,0.000024928057],"genre_scores_gemma":[0.17253606,0.8207158,0.0039446233,0.00011149086,0.00018341957,0.0001708045,0.0018731622,0.00007928869,0.0003853849],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99621844,0.00020971619,0.0012866991,0.00043706383,0.0016117044,0.00023638489],"domain_scores_gemma":[0.9966394,0.0005361306,0.0015150824,0.00018829212,0.00093040406,0.00019070678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002381203,0.00028697928,0.0019867993,0.0017418333,0.00010031207,0.00008150738,0.00035012033,0.00015961964,0.00018320777],"category_scores_gemma":[0.0009395091,0.00018665566,0.0021399083,0.0010878491,0.00030167925,0.0001800314,0.000114734525,0.00017288304,0.0000048114784],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008567372,0.00088575407,0.007150197,0.0015722173,0.8192059,0.0009878528,0.00014772435,0.00011044955,0.0047083218,0.0008721445,0.000024431962,0.16347826],"study_design_scores_gemma":[0.009907273,0.0034180337,0.08421271,0.003788329,0.84949166,0.0025574735,0.00019099504,0.021575214,0.0031404505,0.0015028708,0.018849881,0.0013651152],"about_ca_topic_score_codex":0.000052950116,"about_ca_topic_score_gemma":0.000059023278,"teacher_disagreement_score":0.16211314,"about_ca_system_score_codex":0.00012029201,"about_ca_system_score_gemma":0.0007961337,"threshold_uncertainty_score":0.76115966},"labels":[],"label_agreement":null},{"id":"W4379013481","doi":"10.1016/j.critrevonc.2023.104041","title":"Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma","year":2023,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cumming School of Medicine, University of Calgary; Bristol-Myers Squibb","keywords":"Pomalidomide; Lenalidomide; Medicine; Multiple myeloma; Thalidomide; Combination therapy; Drug; Mechanism of action; Pharmacology; Immunology","score_opus":0.2681742536432019,"score_gpt":0.4716844319718877,"score_spread":0.2035101783286858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379013481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004344773,0.99110556,0.001486356,0.0015034643,0.00023700533,0.005150558,0.000065378656,0.00007784274,0.00033036532],"genre_scores_gemma":[0.0031662653,0.9831571,0.00751247,0.00036854442,0.00003064271,0.0052193366,0.0003431627,0.0001258603,0.0000766008],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9915647,0.0027513872,0.0027693454,0.001137776,0.0005818622,0.0011949474],"domain_scores_gemma":[0.9816528,0.015873581,0.0005507341,0.0011038316,0.0003189206,0.0005001323],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002060611,0.00080830004,0.007778289,0.0016181278,0.00008125526,0.000014222503,0.0005652342,0.0011363849,0.000293718],"category_scores_gemma":[0.024775665,0.00057349965,0.0007837069,0.0019702334,0.0009491987,0.00008963077,0.00017142225,0.0013550723,0.00044956472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056726794,0.0054065944,0.0010278067,0.13514891,0.000306481,0.010785824,0.000026364032,0.0000033230394,0.000008467805,0.043982815,0.0005189958,0.8022171],"study_design_scores_gemma":[0.014760199,0.006762377,0.00044812515,0.6099537,0.0027604366,0.0011853154,0.00007413516,0.0017889504,0.00019369897,0.002228354,0.3585394,0.0013053223],"about_ca_topic_score_codex":0.00009647398,"about_ca_topic_score_gemma":0.0007207271,"teacher_disagreement_score":0.80091184,"about_ca_system_score_codex":0.0011282951,"about_ca_system_score_gemma":0.003311715,"threshold_uncertainty_score":0.99967164},"labels":[],"label_agreement":null},{"id":"W4379280656","doi":"10.1200/jco.2023.41.16_suppl.e18827","title":"Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Internal medicine; Refractory (planetary science); Pediatrics","score_opus":0.25324802302955485,"score_gpt":0.49543075120540486,"score_spread":0.24218272817585001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850658,0.00044590904,0.000001607467,0.013014066,0.00030609244,0.0008634046,0.00012945961,0.000011556681,0.00016205727],"genre_scores_gemma":[0.9586276,0.03070074,0.00004800964,0.0021914549,0.000328354,0.000033273398,0.00013679029,0.000029283683,0.007904543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953271,0.0010297021,0.002245559,0.0002523848,0.0007711276,0.00037413702],"domain_scores_gemma":[0.9915496,0.0054025073,0.0014166514,0.00034281623,0.00080827693,0.0004801374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025902733,0.0002137147,0.001534698,0.0001377544,0.00010597645,0.0000115167895,0.00021089741,0.00009494144,0.000064490065],"category_scores_gemma":[0.003292321,0.00011665646,0.00023735,0.00048134784,0.00017286933,0.000075063836,0.000120662095,0.0005723304,0.0000096471085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002136736,0.0017235171,0.9546652,0.00015903449,0.0010172334,0.002197881,0.00020932018,0.000005553072,0.000012074615,0.0000052297964,0.0041436246,0.03372462],"study_design_scores_gemma":[0.009568566,0.008468467,0.7906363,0.00032796132,0.00026768039,0.00007496735,0.00019407539,0.00018187985,0.00000763557,0.000004504313,0.19020069,0.00006726966],"about_ca_topic_score_codex":0.08494602,"about_ca_topic_score_gemma":0.43415868,"teacher_disagreement_score":0.34921265,"about_ca_system_score_codex":0.00038796783,"about_ca_system_score_gemma":0.002677015,"threshold_uncertainty_score":0.9211474},"labels":[],"label_agreement":null},{"id":"W4379280659","doi":"10.1200/jco.2023.41.16_suppl.e18826","title":"Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Refractory (planetary science); Salvage therapy; Internal medicine; Retrospective cohort study; Pediatrics; Chemotherapy","score_opus":0.11932301477636917,"score_gpt":0.45885474674368393,"score_spread":0.3395317319673148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946492,0.00003828896,0.0000019868805,0.0036279948,0.0004288349,0.0007427915,0.00014218499,0.00001673943,0.0003520009],"genre_scores_gemma":[0.98892146,0.0021302414,0.000029339752,0.00037856834,0.00036715993,0.000019490994,0.000041663614,0.000033922934,0.008078133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955846,0.00097579404,0.0018951742,0.00031267936,0.00075247267,0.0004792777],"domain_scores_gemma":[0.99287456,0.0040663993,0.0013403401,0.00038536207,0.0007591536,0.0005742035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002323,0.00024411596,0.001580443,0.00022597246,0.00013289796,0.000017484053,0.00021471868,0.00013443835,0.00004489901],"category_scores_gemma":[0.002534276,0.00013535564,0.00024058734,0.00050839916,0.00026172597,0.00007306425,0.00014737595,0.00077818864,0.000009308672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005353052,0.0022716646,0.96735233,0.000023720795,0.0014903942,0.004043062,0.00090013543,0.000007566037,0.000036904923,0.0000047794288,0.0013748377,0.017141556],"study_design_scores_gemma":[0.017382624,0.02156514,0.91643333,0.000070410715,0.00025179298,0.00007868076,0.0011044416,0.00025934857,0.00005392351,0.000010724304,0.04269873,0.0000908598],"about_ca_topic_score_codex":0.2064951,"about_ca_topic_score_gemma":0.71375257,"teacher_disagreement_score":0.50725746,"about_ca_system_score_codex":0.0007708222,"about_ca_system_score_gemma":0.0021643636,"threshold_uncertainty_score":0.7987889},"labels":[],"label_agreement":null},{"id":"W4379281001","doi":"10.1200/jco.2023.41.16_suppl.e20046","title":"Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Observational study; Adverse effect; Incidence (geometry); Refractory (planetary science); Retrospective cohort study; Surgery","score_opus":0.3787009502811558,"score_gpt":0.5351315061661807,"score_spread":0.15643055588502486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872912,0.00008875233,0.00006258351,0.008436314,0.0013604683,0.0013324807,0.00005546206,0.00005902907,0.0013136825],"genre_scores_gemma":[0.98617464,0.0006135346,0.0051320638,0.00097391725,0.0019766123,0.00008321634,0.0001260173,0.000053178774,0.0048668445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944221,0.00068562577,0.002978766,0.00039423298,0.00092506525,0.0005942113],"domain_scores_gemma":[0.98670244,0.009735378,0.001481771,0.00037157102,0.0009330505,0.0007758069],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0057050143,0.00024581983,0.0017740693,0.00040619055,0.00015429524,0.000020599875,0.00031806252,0.0003389146,0.00027808693],"category_scores_gemma":[0.0113565475,0.00017719826,0.0007562687,0.000569892,0.00016889564,0.00019819922,0.00013802618,0.0011928151,0.0002587195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017221918,0.006429733,0.8396711,0.000047062167,0.0013592206,0.0027559905,0.000104091414,0.000013415381,0.0001564669,0.0001253711,0.041586313,0.090529315],"study_design_scores_gemma":[0.035379104,0.018450798,0.8392665,0.00006857452,0.00034638733,0.00009329512,0.00026309924,0.0007111841,0.00003574746,0.00033677818,0.10492488,0.00012369105],"about_ca_topic_score_codex":0.00009318796,"about_ca_topic_score_gemma":0.00085104,"teacher_disagreement_score":0.09040562,"about_ca_system_score_codex":0.0003476082,"about_ca_system_score_gemma":0.0024761755,"threshold_uncertainty_score":0.9969712},"labels":[],"label_agreement":null},{"id":"W4379281020","doi":"10.1200/jco.2023.41.16_suppl.8002","title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Neutropenia; Oncology; Multiple myeloma; Lenalidomide; Regimen; Alemtuzumab; Bortezomib; Chemotherapy; Transplantation","score_opus":0.05943540418970244,"score_gpt":0.37962879687662415,"score_spread":0.3201933926869217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948539,0.00015970114,0.000004793378,0.0030100746,0.00028688967,0.0012040217,0.0000649962,0.000041857933,0.00037375887],"genre_scores_gemma":[0.99728155,0.0003369054,0.0012424698,0.00027720613,0.0004878254,0.000023613911,0.00005958938,0.00005264884,0.00023817888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943528,0.0009526147,0.0024178403,0.0005753377,0.001114361,0.0005870154],"domain_scores_gemma":[0.98041064,0.016358651,0.0015281809,0.00046856265,0.00066228095,0.0005716605],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037603183,0.00032721454,0.0015796975,0.0002371165,0.00020910992,0.000038855138,0.00030601234,0.00033644994,0.00003182086],"category_scores_gemma":[0.02044264,0.00016898505,0.00018036134,0.0005695823,0.0004127256,0.00019227879,0.00017472035,0.0018902902,0.000033568278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07728489,0.005409875,0.845004,0.00001940861,0.0007781324,0.009455337,0.0010791878,0.00013355071,0.000014714351,6.5348337e-7,0.0014664163,0.059353817],"study_design_scores_gemma":[0.080609515,0.042727478,0.8620149,0.00029496357,0.00024472622,0.00007951787,0.0015765314,0.0012217053,0.000009510492,0.000014835355,0.011041498,0.00016480916],"about_ca_topic_score_codex":0.00073550915,"about_ca_topic_score_gemma":0.005015454,"teacher_disagreement_score":0.05918901,"about_ca_system_score_codex":0.00030826734,"about_ca_system_score_gemma":0.0007816147,"threshold_uncertainty_score":0.9878086},"labels":[],"label_agreement":null},{"id":"W4379281186","doi":"10.1200/jco.2023.41.16_suppl.tps8070","title":"A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Carfilzomib; Internal medicine; Dexamethasone; Lenalidomide; Clinical endpoint; Multiple myeloma; Oncology; Cmax; Pharmacokinetics; Pharmacology; Urology; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.19663143277498835,"score_gpt":0.5185551004945744,"score_spread":0.3219236677195861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382716,0.0018645144,0.000023097577,0.0008905776,0.0008307326,0.0019929253,0.000035405385,0.000032079057,0.0005035247],"genre_scores_gemma":[0.9927043,0.0033902046,0.0028641245,0.00012340477,0.00039156343,0.00007560094,0.0000144411,0.00005802677,0.00037837544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98942095,0.0038216945,0.004325649,0.0006581307,0.0010397318,0.00073385454],"domain_scores_gemma":[0.960503,0.034914177,0.0023440984,0.0004923318,0.0006516109,0.0010948117],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013259349,0.00044482597,0.005361778,0.0010197129,0.00010286662,0.000028451635,0.00029437497,0.0005415946,0.00010838577],"category_scores_gemma":[0.041050423,0.00031951768,0.0005848542,0.0008245414,0.00093977683,0.00024271778,0.00030892904,0.0019288802,0.000012677298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68825024,0.011540555,0.17851602,0.000133746,0.0025805277,0.00578746,0.0011979359,0.000038681028,0.0011011356,0.000022039796,0.0002612717,0.11057038],"study_design_scores_gemma":[0.849849,0.033758447,0.108029075,0.00019128989,0.0010448322,0.00014104877,0.0023336823,0.0027903316,0.00024305226,0.0000806128,0.0013050459,0.00023357614],"about_ca_topic_score_codex":0.0011197168,"about_ca_topic_score_gemma":0.0022626866,"teacher_disagreement_score":0.16159876,"about_ca_system_score_codex":0.0002598548,"about_ca_system_score_gemma":0.0013092879,"threshold_uncertainty_score":0.9999257},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4379281462","doi":"10.1200/jco.2023.41.16_suppl.8045","title":"Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Multiple myeloma; CD38; Plasma cell; Internal medicine; Oncology; Cohort; Proteasome inhibitor; Immunology; Biology; Stem cell; Genetics","score_opus":0.13802688268702376,"score_gpt":0.535442610703193,"score_spread":0.3974157280161692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534667,0.00019697673,0.000022992186,0.0037497396,0.00014389127,0.00037544878,0.000014253329,0.0000041852845,0.00014584759],"genre_scores_gemma":[0.9959163,0.0005488328,0.0022809897,0.00032395206,0.00007950225,0.000011461628,0.000002011007,0.000010086569,0.0008268569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641293,0.00070786645,0.0019312825,0.00023314748,0.00043568073,0.00027909037],"domain_scores_gemma":[0.99587625,0.0024872588,0.00050784537,0.00023994358,0.00025088995,0.000637814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061820643,0.00010462455,0.0015299161,0.0010376502,0.000020495792,0.0000073436636,0.00015650652,0.00016353844,0.000083008665],"category_scores_gemma":[0.0082977675,0.00007755284,0.00027376588,0.0010309292,0.000087941524,0.000043633758,0.0001253118,0.00035311832,0.000047413483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030753687,0.0004190416,0.92990744,0.000025818743,0.0006345685,0.0035264683,0.000109025794,0.000016821059,0.0014899715,0.0000021527449,0.0011780341,0.03193695],"study_design_scores_gemma":[0.0051399185,0.0051864316,0.9853614,0.000085974236,0.00045219657,0.000033585035,0.00007473639,0.0000919209,0.0001159263,0.000050989474,0.0033504833,0.000056412657],"about_ca_topic_score_codex":0.00007388076,"about_ca_topic_score_gemma":0.0018705145,"teacher_disagreement_score":0.055453967,"about_ca_system_score_codex":0.0001767736,"about_ca_system_score_gemma":0.0006380477,"threshold_uncertainty_score":0.9933802},"labels":[],"label_agreement":null},{"id":"W4379281518","doi":"10.1200/jco.2023.41.16_suppl.8011","title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Clinical endpoint; Surrogate endpoint; Multiple myeloma; Cytokine release syndrome; Oncology; Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Chimeric antigen receptor","score_opus":0.07838029115917072,"score_gpt":0.41537985051176585,"score_spread":0.3369995593525951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704427,0.00020871476,0.000044409575,0.00047867995,0.0010707421,0.00065092486,0.00005595996,0.000023769826,0.0004225326],"genre_scores_gemma":[0.9966487,0.00083464634,0.0013379119,0.00010002825,0.00037611846,0.0000073114857,0.0002614367,0.000042896572,0.000390914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951499,0.00053343584,0.0024994148,0.00037502678,0.0009740793,0.00046811442],"domain_scores_gemma":[0.99407184,0.0025070328,0.0018401713,0.00041271566,0.0006882363,0.0004799981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014435194,0.00025103163,0.001696288,0.00054993713,0.000054411827,0.000017545131,0.00026880243,0.0005066718,0.00016898388],"category_scores_gemma":[0.0023312503,0.00017219911,0.00042108746,0.0005489982,0.00025431308,0.00025600783,0.0001008651,0.001141838,0.00009939013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030841261,0.004291613,0.9198414,0.00006843426,0.0003943139,0.0019952166,0.0001256578,0.0000044668886,0.00169667,0.0000019242798,0.0008141277,0.039924897],"study_design_scores_gemma":[0.055182,0.011829036,0.93041927,0.00035704867,0.00014343818,0.000016349892,0.00008126938,0.00009735605,0.00042017407,0.000028118144,0.0012906833,0.0001352876],"about_ca_topic_score_codex":0.00010848404,"about_ca_topic_score_gemma":0.0003932946,"teacher_disagreement_score":0.03978961,"about_ca_system_score_codex":0.00023984937,"about_ca_system_score_gemma":0.0011100221,"threshold_uncertainty_score":0.7022076},"labels":[],"label_agreement":null},{"id":"W4379281877","doi":"10.1200/jco.2023.41.16_suppl.e24078","title":"Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Pomalidomide; Multiple myeloma; Oncology; Confidence interval; Surgery; Lenalidomide","score_opus":0.22361293536407767,"score_gpt":0.47960702118392706,"score_spread":0.2559940858198494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01065131,0.9859321,0.000004882479,0.00019374512,0.00008058087,0.0029276535,0.00013167043,0.000009186953,0.000068830115],"genre_scores_gemma":[0.0038553302,0.993486,0.0017524627,0.00029469442,0.000060649243,0.00009509914,0.000065349945,0.000052486772,0.0003379647],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98703176,0.0026483329,0.008131044,0.00055096357,0.0011684184,0.00046945832],"domain_scores_gemma":[0.9787992,0.010340545,0.008700927,0.00060364185,0.0010755922,0.0004800784],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008043545,0.000580146,0.03012343,0.0010296876,0.000047623224,0.000020169662,0.0004284584,0.00056489976,0.0001345806],"category_scores_gemma":[0.012626962,0.00030140957,0.0037584766,0.0011969957,0.00038182925,0.00020305235,0.00026115775,0.0014763385,0.00001567428],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043005624,0.0012991133,0.060393013,0.71941465,0.20578198,0.0014097934,0.00003123216,0.0000011061352,1.411981e-7,0.0000023422479,0.00017741416,0.011059168],"study_design_scores_gemma":[0.003883936,0.004052444,0.21345267,0.113898285,0.6614224,0.00023901636,0.00001691517,0.0000058472297,2.5598996e-7,0.00000814933,0.0027406488,0.00027946898],"about_ca_topic_score_codex":0.000030023744,"about_ca_topic_score_gemma":0.00025745403,"teacher_disagreement_score":0.6055164,"about_ca_system_score_codex":0.0002804044,"about_ca_system_score_gemma":0.00236797,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W4379282038","doi":"10.1200/jco.2023.41.16_suppl.8039","title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Discontinuation; Refractory (planetary science); Adverse effect; Gastroenterology; Surgery","score_opus":0.09237953159947176,"score_gpt":0.4317053603468726,"score_spread":0.33932582874740086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938338,0.00027632818,0.00014808562,0.0027552936,0.000912913,0.0017976784,0.00008360992,0.000028128092,0.00016415794],"genre_scores_gemma":[0.99509645,0.0010571242,0.0020876555,0.00023116697,0.0006813903,0.000040428193,0.00026836703,0.000037878337,0.00049953215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962096,0.0006003872,0.0016377519,0.0004104688,0.00075731735,0.0003844754],"domain_scores_gemma":[0.99243647,0.0049059563,0.0012062656,0.000346471,0.0006832333,0.00042162207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018370964,0.00024306879,0.0010413995,0.00018529635,0.00021169172,0.000055937202,0.00021164078,0.00030999153,0.00006234679],"category_scores_gemma":[0.0030219564,0.00013872908,0.00028648748,0.00029298416,0.00020790703,0.00025257815,0.00006791418,0.0007277912,0.000033773253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050446704,0.0069446363,0.75045127,0.000038936545,0.0007558214,0.000931644,0.00045998822,0.0000017187275,0.0008792615,0.000006982981,0.0070668412,0.18201621],"study_design_scores_gemma":[0.048601594,0.049902912,0.8835539,0.00007548386,0.0003303911,0.00003612927,0.00086626125,0.00046846663,0.0000960589,0.000084789266,0.015860518,0.00012349893],"about_ca_topic_score_codex":0.00008634424,"about_ca_topic_score_gemma":0.00058681733,"teacher_disagreement_score":0.18189271,"about_ca_system_score_codex":0.000108763896,"about_ca_system_score_gemma":0.0009963186,"threshold_uncertainty_score":0.5657208},"labels":[],"label_agreement":null},{"id":"W4379283210","doi":"10.1200/jco.2023.41.16_suppl.tps5627","title":"ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Karyopharm Therapeutics","keywords":"Medicine; Clinical endpoint; Internal medicine; Placebo; Oncology; Phases of clinical research; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Maintenance therapy; Cancer; Clinical trial; Gastroenterology; Surgery; Pathology","score_opus":0.1379598362240812,"score_gpt":0.478609204240197,"score_spread":0.3406493680161158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97929496,0.0011984936,0.00010034759,0.0007785433,0.002615209,0.015903383,0.00004974731,0.000016564698,0.00004277051],"genre_scores_gemma":[0.9881173,0.007081414,0.0014059254,0.00023857385,0.0013513449,0.0014221701,0.0000507445,0.000060651677,0.00027188775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909288,0.0016187571,0.0051809424,0.0005072604,0.0010361279,0.0007280703],"domain_scores_gemma":[0.9791275,0.01466526,0.0033774297,0.0004126295,0.0018478287,0.00056934264],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0087968465,0.0004282275,0.005525438,0.00088412187,0.000049478414,0.000020388718,0.00031360166,0.00044448467,0.00011422285],"category_scores_gemma":[0.013838844,0.0002157027,0.0013850536,0.0007437564,0.0002987184,0.00016432916,0.000049465885,0.00097548484,0.000011520528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84561485,0.012729783,0.015899558,0.00007937435,0.0021157956,0.00062822335,0.00019630858,0.000017899263,0.000044662924,0.000002900912,0.00024424426,0.122426406],"study_design_scores_gemma":[0.90702575,0.08536949,0.0030726665,0.00044099626,0.00041518052,0.00003998023,0.0001264442,0.00065737026,0.000060492323,0.0000128350475,0.0026006815,0.00017809992],"about_ca_topic_score_codex":0.000034918907,"about_ca_topic_score_gemma":0.00007472235,"teacher_disagreement_score":0.12224831,"about_ca_system_score_codex":0.00029720762,"about_ca_system_score_gemma":0.0022783566,"threshold_uncertainty_score":0.99446803},"labels":[],"label_agreement":null},{"id":"W4379283423","doi":"10.1200/jco.2023.41.16_suppl.6618","title":"An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"Pfizer","keywords":"Cohort; Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Biology","score_opus":0.11470470744722208,"score_gpt":0.47846226075161813,"score_spread":0.3637575533043961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939804,0.00031171524,0.000076040575,0.0022873832,0.00097174,0.00083058863,0.00013097342,0.000044955264,0.0013662018],"genre_scores_gemma":[0.9950652,0.00054141664,0.0016051438,0.0004245054,0.00077148224,0.000024296009,0.000043060936,0.000058644575,0.0014662115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98656446,0.006641359,0.004387647,0.00058958173,0.0010618859,0.00075507007],"domain_scores_gemma":[0.96866393,0.026229734,0.0027951028,0.0005914114,0.0006484522,0.0010713966],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011919174,0.0003811547,0.0038220836,0.0012275057,0.00007489618,0.000024604045,0.0005138004,0.0006418975,0.00039937612],"category_scores_gemma":[0.01721082,0.00029721583,0.00072451413,0.00072460755,0.00052305905,0.00030958737,0.0001023173,0.0024469325,0.000110456545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2373404,0.0039997,0.66808724,0.000027943843,0.0007285242,0.0056438246,0.0005402581,0.000075966884,0.0105770575,0.000009426583,0.0012508897,0.07171875],"study_design_scores_gemma":[0.05394179,0.025728246,0.9062606,0.00029342694,0.00030914435,0.000048302096,0.00042400789,0.0066867354,0.0015040139,0.00027576322,0.004323692,0.00020428191],"about_ca_topic_score_codex":0.00094307004,"about_ca_topic_score_gemma":0.0033315748,"teacher_disagreement_score":0.23817334,"about_ca_system_score_codex":0.00078912254,"about_ca_system_score_gemma":0.0029979763,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W4379341100","doi":"10.1200/jco.2023.41.16_suppl.e20021","title":"Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Neutropenia; KRAS; Oncology; Adverse effect; Minimal residual disease; Gastroenterology; Bone marrow; Immunology; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.09913919666111909,"score_gpt":0.471155325907031,"score_spread":0.37201612924591193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926976,0.00021622537,0.0000835742,0.0051687527,0.00058856636,0.0010602025,0.00003141438,0.000014433041,0.00013926366],"genre_scores_gemma":[0.98749447,0.0006609143,0.010102964,0.0006731036,0.00019457725,0.00006364655,0.0000339718,0.000030669416,0.0007457057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737763,0.00024172696,0.0014237306,0.00024495987,0.0003268205,0.00038509932],"domain_scores_gemma":[0.98813677,0.010326133,0.00061804237,0.0001608695,0.00038239703,0.00037580312],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020810906,0.00015521856,0.0012473318,0.00030713357,0.000051880506,0.000012644192,0.00012456575,0.00035863864,0.000018181501],"category_scores_gemma":[0.037686918,0.00009581021,0.00037126226,0.00017024754,0.00010109253,0.00011162551,0.00005845121,0.00053270475,0.000004578758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02095516,0.0014400115,0.60061663,0.00012064573,0.00033892976,0.0007554113,0.00007410798,0.000004479032,0.00015636941,0.000015771504,0.0060449736,0.36947754],"study_design_scores_gemma":[0.047296897,0.019735415,0.91547966,0.00010844542,0.00012016759,0.000036337315,0.00007786017,0.0004938449,0.00004443015,0.00022656698,0.016295893,0.000084476866],"about_ca_topic_score_codex":0.000018219056,"about_ca_topic_score_gemma":0.00018290395,"teacher_disagreement_score":0.36939305,"about_ca_system_score_codex":0.00012758045,"about_ca_system_score_gemma":0.000561133,"threshold_uncertainty_score":0.97041905},"labels":[],"label_agreement":null},{"id":"W4379345488","doi":"10.1200/jco.2023.41.16_suppl.8044","title":"Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine; Cohort; Internal medicine; Cytokine release syndrome; Immunology; Gastroenterology; Pharmacology; Immune system; T cell","score_opus":0.07945615037243428,"score_gpt":0.44949109181036945,"score_spread":0.37003494143793514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768674,0.00010645847,0.000033403943,0.0017854944,0.000070083675,0.00019965647,0.000048954986,0.000008004182,0.00006120504],"genre_scores_gemma":[0.99839246,0.00070771505,0.00021374004,0.000048096397,0.000031085237,0.000004296284,0.000030099238,0.000010250695,0.0005622402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962539,0.00079038925,0.0020378332,0.00016434614,0.00058435206,0.00016914777],"domain_scores_gemma":[0.9920379,0.0045939977,0.0020041652,0.00021164729,0.00086317986,0.0002891239],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006159478,0.00009475403,0.0016171891,0.0007541595,0.000024056546,0.000004222372,0.000094318864,0.0002004428,0.00006676865],"category_scores_gemma":[0.0160767,0.00006252635,0.00031222717,0.0012971291,0.00031106983,0.00006639541,0.000038776983,0.00032236957,0.000004131103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022913475,0.0012631741,0.95122945,0.000034259614,0.007082343,0.0022644412,0.000043070024,0.00005206297,0.0053984565,0.000007618102,0.000323471,0.009388152],"study_design_scores_gemma":[0.0066133747,0.01135537,0.9756781,0.00008555431,0.0040439237,0.00014651731,0.00005366166,0.0013434669,0.00042855548,0.000027784365,0.00017948152,0.000044214554],"about_ca_topic_score_codex":0.00003086348,"about_ca_topic_score_gemma":0.000047941645,"teacher_disagreement_score":0.024448618,"about_ca_system_score_codex":0.00007409434,"about_ca_system_score_gemma":0.00066856766,"threshold_uncertainty_score":0.9922113},"labels":[],"label_agreement":null},{"id":"W4379345749","doi":"10.1200/jco.2023.41.16_suppl.e20017","title":"Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Discontinuation; Multiple myeloma; Refractory (planetary science); Lenalidomide; Cohort; Gastroenterology; Oncology; Surgery","score_opus":0.04056370450328561,"score_gpt":0.37855677151527556,"score_spread":0.33799306701198994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983305,0.00023965124,0.00004333789,0.0005949691,0.00017687354,0.00039423237,0.000109333196,0.000011887843,0.000099220735],"genre_scores_gemma":[0.99535453,0.0014779906,0.002720106,0.00008762975,0.00015454814,0.000004540335,0.0001103357,0.00002130783,0.0000689983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956208,0.00077611185,0.0022091425,0.00032901193,0.00071560766,0.0003493457],"domain_scores_gemma":[0.990647,0.006595145,0.0015078374,0.00032927224,0.00038955803,0.0005311453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001954303,0.00019009219,0.0020750288,0.000705445,0.000044440185,0.000007804078,0.00016901431,0.00035656197,0.00018574044],"category_scores_gemma":[0.005564525,0.00012463007,0.00034602924,0.00096570957,0.00028937706,0.00013820798,0.000097610544,0.0010675956,0.000019599483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04386494,0.0026707714,0.8084025,0.000016886928,0.0025189053,0.0007455263,0.00008962613,0.000047015863,0.00001997636,0.0000034905456,0.00017870948,0.14144164],"study_design_scores_gemma":[0.077296875,0.016806096,0.90268004,0.000095623145,0.0014857096,0.000004706792,0.00005756904,0.00038184295,0.000014846197,0.000047182017,0.0010368144,0.00009271566],"about_ca_topic_score_codex":0.0009801162,"about_ca_topic_score_gemma":0.0011356748,"teacher_disagreement_score":0.14134893,"about_ca_system_score_codex":0.00014423642,"about_ca_system_score_gemma":0.00053052884,"threshold_uncertainty_score":0.66616577},"labels":[],"label_agreement":null},{"id":"W4379346404","doi":"10.1200/jco.2023.41.16_suppl.8018","title":"A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Interim analysis; Tolerability; Bortezomib; Multiple myeloma; Adverse effect; Internal medicine; Dexamethasone; Clinical endpoint; Gastroenterology; Surgery; Clinical trial","score_opus":0.11451876890469877,"score_gpt":0.5070437614309877,"score_spread":0.392524992526289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989249,0.00006302443,0.0000233155,0.00023156898,0.000068082394,0.0005705619,0.000049735354,0.00000422563,0.00006456146],"genre_scores_gemma":[0.99912983,0.00013098854,0.0006139458,0.000016098644,0.000028733024,0.000010931713,0.000046902027,0.000012023343,0.000010563344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552655,0.00087490096,0.0025454308,0.0001952379,0.00064756174,0.00021034294],"domain_scores_gemma":[0.99460745,0.0026402103,0.0015459183,0.00023794179,0.0007512958,0.00021717692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002455086,0.00012367677,0.0024321,0.0014119735,0.000011898565,0.0000027246201,0.00016615418,0.0001649326,0.000039622897],"category_scores_gemma":[0.0032443656,0.00008595412,0.00026680462,0.0014685636,0.00015124511,0.00009719373,0.00005721247,0.00048672545,6.892457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06449442,0.025173433,0.8257967,0.000077588185,0.0015836505,0.002107207,0.0037289513,0.00022438393,0.00023379983,0.0000037463099,0.000016772607,0.07655932],"study_design_scores_gemma":[0.09923573,0.14658196,0.74187255,0.0001580465,0.0007532401,0.0000065663185,0.009443718,0.0014877351,0.000380205,0.000008059128,0.000027448248,0.00004471748],"about_ca_topic_score_codex":0.00073046907,"about_ca_topic_score_gemma":0.0174624,"teacher_disagreement_score":0.12140854,"about_ca_system_score_codex":0.0002334479,"about_ca_system_score_gemma":0.0008236618,"threshold_uncertainty_score":0.9744429},"labels":[],"label_agreement":null},{"id":"W4379379925","doi":"10.1016/j.clml.2023.06.001","title":"Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Dalhousie University; Vancouver General Hospital; CancerCare Manitoba; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Ontario Institute for Cancer Research","funders":"Karyopharm Therapeutics","keywords":"Medicine; Multiple myeloma; Monoclonal antibody; CD38; Oncology; Antibody; Virology; Internal medicine; Cancer research; Immunology","score_opus":0.03189090537878026,"score_gpt":0.3160870044201881,"score_spread":0.28419609904140786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379379925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506134,0.00011290351,0.000028265726,0.00056347577,0.00011489092,0.0027379263,0.0001869195,0.0006457876,0.00054852176],"genre_scores_gemma":[0.9928654,0.00013328172,0.0024452189,0.00047619623,0.00022495055,0.00027070538,0.002170024,0.00020004813,0.0012142075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99304193,0.0004807996,0.001581595,0.0016396984,0.0014703977,0.0017855869],"domain_scores_gemma":[0.99487525,0.0016011957,0.00045012034,0.0013719281,0.0006069279,0.001094572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092658435,0.00089852634,0.0018535368,0.0007500914,0.00028013714,0.000098194345,0.00043831853,0.0005152999,0.00010231802],"category_scores_gemma":[0.0013699392,0.00061718596,0.00040866787,0.0020795478,0.00074430765,0.00027567608,0.00017633005,0.00057473604,0.0005977307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013397425,0.0015861151,0.90901536,0.00017293188,0.00058334565,0.0035012357,0.00006450459,0.000121425735,0.00007306,0.000010304373,0.0018511772,0.069623135],"study_design_scores_gemma":[0.05978403,0.0044983327,0.9250703,0.0007848711,0.00023973158,0.00005155162,0.00005385312,0.0068575316,0.00068473734,0.000010512703,0.0013079942,0.0006565754],"about_ca_topic_score_codex":0.0004179299,"about_ca_topic_score_gemma":0.0002488627,"teacher_disagreement_score":0.06896656,"about_ca_system_score_codex":0.0011023898,"about_ca_system_score_gemma":0.0020185197,"threshold_uncertainty_score":0.99962795},"labels":[],"label_agreement":null},{"id":"W4379984958","doi":"10.1200/jco.2023.41.16_suppl.e20006","title":"Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Pomalidomide; Medicine; Lenalidomide; Dexamethasone; Refractory (planetary science); Internal medicine; Bortezomib; Daratumumab; Multiple myeloma; Gastroenterology; Cohort","score_opus":0.10937720769085078,"score_gpt":0.44787935980253124,"score_spread":0.33850215211168044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379984958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993642,0.0003901257,0.000019902,0.005230756,0.00009729755,0.0004980768,0.000006967523,0.000009115581,0.00010577226],"genre_scores_gemma":[0.99194354,0.0031672684,0.0043833954,0.00019417795,0.0000980297,0.0000074924424,0.000007493705,0.000018162382,0.0001804439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664074,0.0007326222,0.00170654,0.00026493607,0.00036682675,0.0002883444],"domain_scores_gemma":[0.9881298,0.0103085935,0.0008017379,0.00014975258,0.00023217141,0.00037797235],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003854199,0.00015224084,0.0013682331,0.0004051783,0.00003480437,0.0000076045617,0.00008033291,0.00030465916,0.000017768001],"category_scores_gemma":[0.012282264,0.0000991892,0.00006936771,0.00038333112,0.0003513213,0.00011896457,0.00008163974,0.00090093137,0.0000026187122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12160219,0.0021568034,0.6773887,0.00011396693,0.00020511192,0.003130073,0.0002959412,0.000012682896,0.0011466407,0.000014971502,0.00012606927,0.1938068],"study_design_scores_gemma":[0.08576725,0.018385189,0.89107734,0.00045231124,0.0000797482,0.000274441,0.00023964896,0.0022848197,0.000070422975,0.000060805793,0.001228529,0.000079512625],"about_ca_topic_score_codex":0.00014538951,"about_ca_topic_score_gemma":0.00094459864,"teacher_disagreement_score":0.21368857,"about_ca_system_score_codex":0.00013432889,"about_ca_system_score_gemma":0.0007275289,"threshold_uncertainty_score":0.9960377},"labels":[],"label_agreement":null},{"id":"W4380051195","doi":"10.34172/npj.2023.10604","title":"Association between type 2 diabetes mellitus and multiple myeloma: Fact or fiction","year":2023,"lang":"en","type":"article","venue":"Journal of Nephropharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Medicine; Multiple myeloma; Insulin resistance; Internal medicine; Hyperinsulinemia; Type 2 Diabetes Mellitus; Diabetes mellitus; Endocrinology; Immunology; Cancer research","score_opus":0.046008225687406375,"score_gpt":0.35819195540962284,"score_spread":0.3121837297222165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380051195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966078,0.0005704062,0.00000527114,0.0020698877,0.00042010937,0.00020215078,0.000013658691,0.000031617594,0.00007913783],"genre_scores_gemma":[0.9952605,0.002737955,0.00016667918,0.00016575435,0.0006388317,0.0000030588901,0.000019686446,0.000015832162,0.0009917269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878615,0.0001331478,0.00032747933,0.00011573065,0.00031433656,0.00032317813],"domain_scores_gemma":[0.9984324,0.0007360681,0.00025217014,0.000059667258,0.00028091867,0.00023876748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004116345,0.000107083884,0.00036181862,0.00029732526,0.000086771164,0.00001649342,0.000054895067,0.00011671717,0.0002725333],"category_scores_gemma":[0.0005993141,0.00007442214,0.00007389969,0.00035475582,0.00003541529,0.00011755667,0.000038070044,0.0002987867,0.00008677778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014645384,0.00017468017,0.8341443,0.00007635599,0.0018022304,0.0006150154,0.0001364109,0.000012227393,0.08702533,6.8188933e-7,0.038222443,0.036325805],"study_design_scores_gemma":[0.007839838,0.0019252119,0.94595546,0.00002907076,0.0004901279,0.000057332432,0.000057149748,0.0009233667,0.010440059,0.000021979635,0.03218365,0.00007675364],"about_ca_topic_score_codex":0.000007943336,"about_ca_topic_score_gemma":0.0000026516352,"teacher_disagreement_score":0.111811176,"about_ca_system_score_codex":0.00023121202,"about_ca_system_score_gemma":0.00013274813,"threshold_uncertainty_score":0.30348468},"labels":[],"label_agreement":null},{"id":"W4380082616","doi":"10.3390/curroncol30060423","title":"The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Turkish; Internal medicine; Oncology; Overall survival; Gerontology; Intensive care medicine","score_opus":0.04530402144845281,"score_gpt":0.3476902998304198,"score_spread":0.302386278381967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380082616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758416,0.0007313814,8.1291165e-7,0.00007154238,0.00030557544,0.00091105513,0.00004211807,0.00002017856,0.00033317594],"genre_scores_gemma":[0.9990332,0.000612609,0.00001756122,0.000020493277,0.000037614387,0.00008551871,0.00009257765,0.000011624191,0.0000888073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988152,0.000158976,0.00020165152,0.0002610236,0.00024949427,0.00031364904],"domain_scores_gemma":[0.9983988,0.0011375847,0.00008314048,0.00018557913,0.00006934374,0.00012554854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021937279,0.00013992577,0.0003576847,0.000121478966,0.000072451105,0.000009836685,0.000054606582,0.00006894294,0.000007464624],"category_scores_gemma":[0.00035915538,0.00008413997,0.000029022285,0.00019033573,0.00019028882,0.000041736996,0.00010084369,0.0001875695,0.0000041892426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008738868,0.00046587712,0.9526728,0.0005256001,0.00007649068,0.000059867914,0.00015598764,2.6289348e-7,0.00027178077,0.00002948711,0.00029517058,0.04457282],"study_design_scores_gemma":[0.009605021,0.0017332505,0.9863216,0.000100269266,0.00003221353,0.0000027526628,0.000026233158,0.000053240477,0.00019087407,0.000050356874,0.0018118676,0.000072279145],"about_ca_topic_score_codex":0.000037611873,"about_ca_topic_score_gemma":0.00038171565,"teacher_disagreement_score":0.04450054,"about_ca_system_score_codex":0.00010448163,"about_ca_system_score_gemma":0.00010772428,"threshold_uncertainty_score":0.34311283},"labels":[],"label_agreement":null},{"id":"W4381158392","doi":"10.1002/ajh.26990","title":"A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (<scp>CARAMEL</scp>)","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Carfilzomib; Medicine; Melphalan; Multiple myeloma; Autologous stem-cell transplantation; Clinical endpoint; Internal medicine; Transplantation; Urology; Cohort; Oncology; Adverse effect; Surgery; Lenalidomide; Clinical trial","score_opus":0.028734602147727665,"score_gpt":0.3382647170175598,"score_spread":0.3095301148698321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381158392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931231,0.00035607113,0.005327923,0.00024240317,0.000064255764,0.0006403586,0.0001800819,0.00002223976,0.000043550062],"genre_scores_gemma":[0.99400693,0.0001734168,0.005434628,0.000048319667,0.00003996321,0.00007590642,0.00010222362,0.000024567144,0.00009405451],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986932,0.00007720963,0.0005081489,0.00016960572,0.00017462591,0.00037715974],"domain_scores_gemma":[0.99689275,0.0019704015,0.00051861315,0.00010434,0.00030663918,0.00020726645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027627795,0.00013922516,0.00076249725,0.0003577418,0.00008682295,0.00000848491,0.00007539701,0.00005857789,0.000002835304],"category_scores_gemma":[0.00023341803,0.00011400629,0.00016899603,0.00022011205,0.00025900945,0.000070549046,0.000011317741,0.00011658634,0.0000022343186],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018686974,0.004294836,0.34846827,0.008574952,0.0051247412,0.007310084,0.020847145,0.00013729473,0.20347303,0.0033194846,0.007683621,0.37207955],"study_design_scores_gemma":[0.12672253,0.056901563,0.11747826,0.00075518084,0.002125394,0.020619985,0.03337185,0.012890739,0.6251783,0.0011363679,0.002479091,0.00034073467],"about_ca_topic_score_codex":0.000024645691,"about_ca_topic_score_gemma":0.0000068439904,"teacher_disagreement_score":0.42170528,"about_ca_system_score_codex":0.000029463992,"about_ca_system_score_gemma":0.0001446618,"threshold_uncertainty_score":0.46490416},"labels":[],"label_agreement":null},{"id":"W4382023394","doi":"10.3390/curroncol30070455","title":"Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Cancer research; Medicine; CD163; Angiogenesis; Immune system; Bone marrow; Cytotoxic T cell; Immunology; Multiple myeloma; Immunotherapy; Tumor progression; CD68; Bortezomib; Stromal cell; Tumor-associated macrophage; Macrophage; In vitro; Biology; Cancer; Internal medicine; Immunohistochemistry","score_opus":0.17396190480960147,"score_gpt":0.47445777131145916,"score_spread":0.30049586650185767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382023394","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0088012125,0.9877059,0.000004463931,0.00023726054,0.00030708322,0.0023438171,0.00047779092,0.00007362847,0.000048861293],"genre_scores_gemma":[0.039775282,0.95652944,0.000020846219,0.000022135564,0.00012237873,0.0014418245,0.0019575644,0.000062645595,0.000067855726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701655,0.0006847916,0.00072008825,0.00071607507,0.00013663182,0.0007258607],"domain_scores_gemma":[0.998298,0.0006405761,0.00024379937,0.00036783936,0.00007052821,0.00037924922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031263544,0.00040802697,0.001826381,0.0007845955,0.00007762228,0.00001650038,0.0001986919,0.00031052547,0.000044783646],"category_scores_gemma":[0.0006115587,0.0003248002,0.00024463542,0.0006798366,0.00021438298,0.000033784752,0.00022549128,0.00079496164,0.00015035749],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010684942,0.0013588924,0.05813987,0.0028041718,0.0002085594,0.00046388237,0.000054349915,2.6335678e-7,0.000004916742,0.000062631414,0.0000478083,0.9367478],"study_design_scores_gemma":[0.0069705886,0.00050743326,0.41125,0.00435687,0.00088843075,0.000083248684,0.000040985873,0.00030758017,3.6400087e-7,0.00084466505,0.5743376,0.0004122255],"about_ca_topic_score_codex":0.00010724695,"about_ca_topic_score_gemma":0.0003985699,"teacher_disagreement_score":0.93633556,"about_ca_system_score_codex":0.0008384274,"about_ca_system_score_gemma":0.00097407243,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4382288286","doi":"10.1016/j.jgo.2023.101560","title":"A pilot study of adherence to lenalidomide among older patients with multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; Alvin J. Siteman Cancer Center","keywords":"Medicine; Lenalidomide; Multiple myeloma; Scopus; Internal medicine; Retrospective cohort study; MEDLINE; Oncology; Family medicine","score_opus":0.0388946228521673,"score_gpt":0.34285944195722656,"score_spread":0.30396481910505924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382288286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981038,0.000029476269,0.0000357844,0.00013799766,0.000250397,0.0011631353,0.000008244152,0.000016542836,0.00025463264],"genre_scores_gemma":[0.9984383,0.000021283558,0.0010096399,0.000037456088,0.00016331738,0.00003576756,0.00000530961,0.00002340228,0.00026552827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784917,0.0001943107,0.0006805039,0.00019629262,0.00071342307,0.00036629243],"domain_scores_gemma":[0.99774516,0.00047212854,0.000500505,0.00022563296,0.0006517183,0.00040484156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048227905,0.00015903353,0.0007132468,0.0007082761,0.0000567788,0.000009570028,0.00017620364,0.000045165936,0.00011508089],"category_scores_gemma":[0.0006570873,0.00010335077,0.000079612,0.0008878311,0.00005244076,0.0001012581,0.000090243004,0.00026571983,0.000056812372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010310707,0.005833078,0.9617336,0.00004718478,0.000470736,0.0010076812,0.00072969514,0.000044261455,0.00079360855,6.9516784e-7,0.0019355388,0.017093211],"study_design_scores_gemma":[0.025854997,0.10574136,0.86704665,0.00006932453,0.00017346907,0.000044236163,0.0005978614,0.000028608447,0.00017170678,0.000004074629,0.00019241057,0.00007531562],"about_ca_topic_score_codex":0.0002563773,"about_ca_topic_score_gemma":0.00038276543,"teacher_disagreement_score":0.099908285,"about_ca_system_score_codex":0.00021864782,"about_ca_system_score_gemma":0.00040220178,"threshold_uncertainty_score":0.42145222},"labels":[],"label_agreement":null},{"id":"W4382313481","doi":"10.1097/01.hs9.0000936256.84340.a7","title":"P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; CD8; Antibody; Oncology; Immunology; Immune system; Gastroenterology","score_opus":0.037613535713238215,"score_gpt":0.32640413410390967,"score_spread":0.28879059839067145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382313481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450886,0.00038103678,0.00008022794,0.000058996022,0.000086495136,0.0012887986,0.000101393394,0.00012319387,0.003371009],"genre_scores_gemma":[0.9951442,0.00015832657,0.0010861786,0.000017891487,0.000040969033,0.00005146698,0.0011669596,0.0000648959,0.0022691202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974112,0.0001247457,0.00053464115,0.0005384249,0.0008381842,0.0005528073],"domain_scores_gemma":[0.9983654,0.0002621375,0.0002678969,0.00056326104,0.00031794762,0.00022333146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016275443,0.00032989503,0.0006175046,0.00038419612,0.00010422438,0.00002581015,0.00013806857,0.00018815153,0.00036286234],"category_scores_gemma":[0.00020361406,0.0002478919,0.0001364133,0.0014263205,0.00015518427,0.00024538412,0.00008031372,0.0003666532,0.00029063819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034602857,0.0013740049,0.9763292,0.00028134394,0.00020469353,0.00033468477,0.00048102593,0.00006701166,0.013397673,0.000011645847,0.0008663634,0.0031920744],"study_design_scores_gemma":[0.013063308,0.0011029361,0.9717628,0.00043814635,0.00006711905,0.0000044107483,0.0007448841,0.0012487852,0.010778749,0.000016580103,0.00054091116,0.0002313772],"about_ca_topic_score_codex":0.00036615532,"about_ca_topic_score_gemma":0.00025302073,"teacher_disagreement_score":0.009603022,"about_ca_system_score_codex":0.00018052585,"about_ca_system_score_gemma":0.0001918269,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4382513940","doi":"10.1097/01.hs9.0000936124.56965.24","title":"B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Medicine; Lenalidomide; Regimen; Internal medicine; Dexamethasone; Ixazomib; Oncology; Multiple myeloma; Carfilzomib; Clinical endpoint; Randomized controlled trial","score_opus":0.02313725160101678,"score_gpt":0.3011518509707363,"score_spread":0.27801459936971956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382513940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848542,0.00045757418,0.000018946665,0.0002990963,0.00035293674,0.012166675,0.00008244991,0.00021792806,0.0015501868],"genre_scores_gemma":[0.994318,0.00019875797,0.0005777427,0.00005275162,0.000120947574,0.0014338956,0.00035817263,0.00009065207,0.0028490855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583715,0.00055803964,0.0009262025,0.00072436867,0.0011395742,0.00081467914],"domain_scores_gemma":[0.9962434,0.0020319389,0.00031891002,0.00058868196,0.0002701795,0.00054684887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010950343,0.00048577174,0.002399844,0.0003100264,0.00017010687,0.000055262157,0.00011725679,0.00023017683,0.00038159374],"category_scores_gemma":[0.003268078,0.00032741748,0.00032851804,0.0006686717,0.00024011222,0.00017943137,0.000080693055,0.0004259892,0.00009036094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98494405,0.0016169092,0.0053737145,0.00008310036,0.0011257187,0.0006809466,0.00033861244,0.000003499,0.0005490213,0.000015312811,0.0012035741,0.004065562],"study_design_scores_gemma":[0.98419577,0.008152865,0.003724379,0.00022158539,0.00039159504,0.0000030389997,0.00024479875,0.0012657518,0.00060844334,0.000016725015,0.00086785166,0.00030719137],"about_ca_topic_score_codex":0.00006657931,"about_ca_topic_score_gemma":0.00017952768,"teacher_disagreement_score":0.01073278,"about_ca_system_score_codex":0.00032670196,"about_ca_system_score_gemma":0.00038801413,"threshold_uncertainty_score":0.9999178},"labels":[],"label_agreement":null},{"id":"W4383197462","doi":"10.1038/s41408-023-00866-y","title":"Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Clinical decision making; Immune system; Intensive care medicine; Oncology; Immunology; Internal medicine","score_opus":0.27779533924331146,"score_gpt":0.4866892149139586,"score_spread":0.20889387567064716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383197462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10733599,0.78543466,0.0029901473,0.003307803,0.092206575,0.008099594,0.00035328654,0.00014739526,0.00012453932],"genre_scores_gemma":[0.42044914,0.5607273,0.001971666,0.00007509478,0.010945028,0.0037018578,0.00018772787,0.00026143205,0.0016807378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951816,0.0003273894,0.001704656,0.000840469,0.0009478365,0.0009980195],"domain_scores_gemma":[0.9923173,0.0054879696,0.00069577346,0.0004834421,0.0006898732,0.00032563703],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002754862,0.00055910135,0.0014018746,0.00084894244,0.00021542847,0.00018360178,0.00042199733,0.00055409176,0.000055534387],"category_scores_gemma":[0.003984046,0.00044530275,0.0007881585,0.00041512973,0.000109419714,0.00024181065,0.00006132204,0.0026041663,0.000006580154],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016182339,0.0020770119,0.05221006,0.0010568701,0.0007941279,0.00067446684,0.00033226996,0.00039348422,0.00002402638,0.000005790427,0.03630991,0.88993967],"study_design_scores_gemma":[0.08179574,0.01018839,0.7085099,0.09498421,0.00072652573,0.0002689895,0.0010188088,0.02588466,0.00023392252,0.0012685779,0.07376065,0.0013596218],"about_ca_topic_score_codex":0.00025815683,"about_ca_topic_score_gemma":0.006146518,"teacher_disagreement_score":0.88858,"about_ca_system_score_codex":0.00073327514,"about_ca_system_score_gemma":0.00528563,"threshold_uncertainty_score":0.99979985},"labels":[],"label_agreement":null},{"id":"W4383561158","doi":"10.14740/jh1137","title":"Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Autologous stem-cell transplantation; Chromosome; Clinical endpoint; Population; Multivariate analysis; Transplantation; Overall survival; Clinical trial; Biology; Genetics; Gene","score_opus":0.031661476735574366,"score_gpt":0.31006599514096245,"score_spread":0.2784045184053881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982592,0.00015805228,0.000039482093,0.00073811435,0.0002593138,0.00036244295,0.000024136358,0.000016569142,0.00014272192],"genre_scores_gemma":[0.9990642,0.00018375686,0.0004749996,0.000042404015,0.00006769956,0.000013441253,0.00006458851,0.00001908557,0.00006980435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808747,0.0001355584,0.00076320086,0.0001574326,0.0005131029,0.00034326268],"domain_scores_gemma":[0.99832106,0.0005359353,0.0004132266,0.00019349814,0.00032945434,0.00020685133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032653706,0.000131262,0.0006422755,0.00054339855,0.000027724736,0.0000060113275,0.00013751158,0.00012253836,0.00006689641],"category_scores_gemma":[0.0015346196,0.000102661936,0.00013386506,0.00035231357,0.000072014736,0.000115772884,0.00004925126,0.00023809505,0.000052423075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013246178,0.000915072,0.9884784,0.00016736062,0.00015865086,0.0010583544,0.00023785337,0.000017768236,0.0036273457,0.0001210038,0.0013452597,0.00254832],"study_design_scores_gemma":[0.014500624,0.000962704,0.97731847,0.00020445859,0.000033753426,0.00018979973,0.000087131106,0.00062078837,0.005583556,0.00017378425,0.00025842202,0.00006648695],"about_ca_topic_score_codex":0.000074329226,"about_ca_topic_score_gemma":0.00005938585,"teacher_disagreement_score":0.013176006,"about_ca_system_score_codex":0.000101854814,"about_ca_system_score_gemma":0.00017855251,"threshold_uncertainty_score":0.41864324},"labels":[],"label_agreement":null},{"id":"W4384108168","doi":"10.21203/rs.3.rs-3117230/v1","title":"Isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; University Hospital","funders":"","keywords":"Pomalidomide; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Lenalidomide; Biology","score_opus":0.09119818203104472,"score_gpt":0.3774056283804285,"score_spread":0.2862074463493838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384108168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898821,0.0011095272,0.000105727915,0.0010705588,0.00022621591,0.0056269956,0.0011141445,0.0002889319,0.0005758039],"genre_scores_gemma":[0.9862631,0.0011128826,0.0030575774,0.000048106995,0.00029535254,0.0010108027,0.0044507445,0.00031506256,0.0034463787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98394674,0.0029300752,0.0014167001,0.0031056534,0.0057453434,0.002855506],"domain_scores_gemma":[0.9883496,0.004792649,0.00045999492,0.0028097404,0.0019711216,0.0016168567],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0053286944,0.0012484236,0.003202752,0.005365766,0.00046016934,0.00040861737,0.0007934681,0.001218912,0.0004112934],"category_scores_gemma":[0.007031473,0.001035249,0.0007181147,0.0039401185,0.000945032,0.0003438818,0.0024708642,0.0056559006,0.00023296036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025675226,0.0029689958,0.95734745,0.0018355632,0.004315223,0.0021671597,0.00052030507,0.00022759648,0.00010064962,0.000034133805,0.00075636565,0.004051354],"study_design_scores_gemma":[0.037818354,0.0030016066,0.9515784,0.0016946896,0.0007523584,0.000007756272,0.00030892383,0.0031843886,0.000116766554,0.00021440744,0.0004692334,0.0008531518],"about_ca_topic_score_codex":0.010976572,"about_ca_topic_score_gemma":0.0040449016,"teacher_disagreement_score":0.012143127,"about_ca_system_score_codex":0.0019425577,"about_ca_system_score_gemma":0.0014610805,"threshold_uncertainty_score":0.99920976},"labels":[],"label_agreement":null},{"id":"W4384119997","doi":"10.3324/haematol.2023.282905","title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McMaster University; Ottawa Hospital","funders":"Hamilton Health Sciences; Sanofi; Pfizer; Prothena; Amgen","keywords":"Medicine; Multiple myeloma; Internal medicine; Retrospective cohort study; Cause of death; Population; Cancer; Cohort; Oncology; Disease; Surgery","score_opus":0.07943408511965692,"score_gpt":0.3647558882724021,"score_spread":0.28532180315274513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384119997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958253,0.000098904704,0.000008562551,0.0002897292,0.00009741935,0.0026999472,0.000050531507,0.00030040857,0.0006292306],"genre_scores_gemma":[0.99816376,0.000052654184,0.000119709315,0.000042285967,0.000036208523,0.0011732639,0.00023028658,0.000022207965,0.00015961024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773484,0.00015966268,0.00037506252,0.00059650274,0.0006360313,0.00049789017],"domain_scores_gemma":[0.99892956,0.00019778758,0.000084393374,0.0005006283,0.00010997564,0.00017764534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040930422,0.00020957261,0.00068188837,0.000290425,0.00014689434,0.000022552858,0.0001136711,0.00010206156,0.00042127335],"category_scores_gemma":[0.00042089264,0.00015966615,0.000101229954,0.0010408753,0.000059614817,0.000052294705,0.000059542926,0.0002412543,0.00024331755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031265544,0.00092125224,0.9948796,0.00003785629,0.00013107735,0.00258563,0.00010361527,0.000043561075,0.00005205401,0.000052494568,0.000327087,0.00055308547],"study_design_scores_gemma":[0.0039483607,0.00029983872,0.99257636,0.000050502695,0.000035224268,0.000010709735,0.0001898125,0.0024458545,0.00014448412,0.00011216402,0.000048261874,0.00013842699],"about_ca_topic_score_codex":0.0047329636,"about_ca_topic_score_gemma":0.003832639,"teacher_disagreement_score":0.003635705,"about_ca_system_score_codex":0.0004248552,"about_ca_system_score_gemma":0.00008750646,"threshold_uncertainty_score":0.7154857},"labels":[],"label_agreement":null},{"id":"W4384134175","doi":"10.58931/cht.2023.2233","title":"Evolving role of novel therapies in myeloma: T-cell engagers and antibody-drug conjugates","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Carfilzomib; Multiple myeloma; Pomalidomide; Thalidomide; Bortezomib; Internal medicine; Population; Oncology; Ixazomib; Proteasome inhibitor; Immunology","score_opus":0.017696681872267157,"score_gpt":0.2869579039078653,"score_spread":0.26926122203559816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909782,0.0038118053,0.000001241607,0.0014015266,0.00004116835,0.0003120884,0.00004174233,0.000029954928,0.0033822993],"genre_scores_gemma":[0.9988254,0.00023433943,0.00023109702,0.00011365599,0.0000122124975,0.000023594825,0.000064432475,0.00001995428,0.00047537178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890715,0.00005475786,0.00020154416,0.0002339802,0.00010543014,0.0004971614],"domain_scores_gemma":[0.99905723,0.00027071245,0.000038518767,0.0001944539,0.000054870434,0.0003842242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021785662,0.00012888611,0.00036407117,0.00055347173,0.00007884483,0.000008675344,0.00007328742,0.00009743306,0.00012464325],"category_scores_gemma":[0.00021095529,0.00011532441,0.000039289804,0.0003190129,0.0001733121,0.000051359253,0.000026397569,0.00018767196,0.00004060467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003912618,0.000068876914,0.9703825,0.00018537327,0.00008036402,0.0006807821,0.0018676154,0.0000015416277,0.023871249,0.00082625786,0.00085320795,0.0011431036],"study_design_scores_gemma":[0.0062690945,0.00013438328,0.9550142,0.00026315078,0.00004036331,0.00027283592,0.005375712,0.0025891736,0.027255751,0.00033560116,0.0021988442,0.0002508634],"about_ca_topic_score_codex":0.033034522,"about_ca_topic_score_gemma":0.057196148,"teacher_disagreement_score":0.024161626,"about_ca_system_score_codex":0.0000714397,"about_ca_system_score_gemma":0.00037613543,"threshold_uncertainty_score":0.9734046},"labels":[],"label_agreement":null},{"id":"W4384383301","doi":"10.58931/cht.2023.2121","title":"Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Northern British Columbia; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Multiple myeloma; Malignancy; Hematologic malignancy; Anemia; Bone marrow transplant; Bone marrow; Internal medicine; Pediatrics; Bone marrow transplantation","score_opus":0.020733173375689404,"score_gpt":0.26435175282128953,"score_spread":0.24361857944560011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384383301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225485,0.0004601368,0.000009413592,0.0025790958,0.00017875188,0.0007744424,0.0002598055,0.00003716061,0.0034463163],"genre_scores_gemma":[0.9976285,0.00024539337,0.0003118293,0.00026278442,0.000019138006,0.00012939703,0.00038634025,0.00002997368,0.0009866442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800754,0.000053594536,0.00041258603,0.00034853458,0.00026341554,0.00091434317],"domain_scores_gemma":[0.99854445,0.0001973473,0.000051409344,0.00037725942,0.00005372283,0.00077578175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013453093,0.00019939439,0.00054244703,0.00055449986,0.00005841059,0.0000044587678,0.00017420358,0.000106822314,0.0003563268],"category_scores_gemma":[0.000069892405,0.000188142,0.00006858765,0.00063262036,0.000057931564,0.000033625565,0.000025066418,0.0001848924,0.00013085398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021145462,0.00005666887,0.9494259,0.00037907035,0.00023424532,0.03079315,0.00016436698,0.000044113523,0.000055713917,0.00032938193,0.012743459,0.0055624926],"study_design_scores_gemma":[0.008544594,0.00008410551,0.97774315,0.00044242907,0.00006441051,0.00019253745,0.00072969147,0.0021507475,0.0029139954,0.000062731604,0.00683772,0.00023390388],"about_ca_topic_score_codex":0.9884949,"about_ca_topic_score_gemma":0.9993431,"teacher_disagreement_score":0.030600613,"about_ca_system_score_codex":0.0007612708,"about_ca_system_score_gemma":0.002398343,"threshold_uncertainty_score":0.76722085},"labels":[],"label_agreement":null},{"id":"W4384460914","doi":"10.58931/cht.2023.2s0736","title":"Navigating challenging treatment decisions in relapsed and refractory multiple myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; London Health Sciences Centre; Western University","funders":"University of British Columbia; University of Ottawa; University of Alberta; University of Calgary","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Refractory (planetary science); Oncology; Clinical trial; Internal medicine","score_opus":0.0474630905079517,"score_gpt":0.3348810642120623,"score_spread":0.2874179737041106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384460914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331635,0.0012614152,0.0000024679769,0.0035985336,0.00009420525,0.00054184033,0.000033813052,0.00008504187,0.0010663115],"genre_scores_gemma":[0.99817705,0.00061778683,0.0003054584,0.00014895314,0.00003236697,0.00014431664,0.00012003733,0.000034200762,0.00041983338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828804,0.000078197714,0.00027909045,0.00041399116,0.00014215772,0.0007985525],"domain_scores_gemma":[0.99798006,0.0006919945,0.00003861511,0.00033484367,0.000040094863,0.00091441727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017218945,0.00019879334,0.00042828216,0.00038090523,0.00021494919,0.000012921611,0.000068576686,0.0001924982,0.000082689054],"category_scores_gemma":[0.0008364534,0.00017357396,0.00006225815,0.00042225266,0.00009473482,0.000042906904,0.000032795597,0.00030597716,0.00026365655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012884331,0.00012594761,0.81397593,0.00004572935,0.00016251035,0.01425962,0.001960976,0.000012588111,0.00046598288,0.00044382046,0.00063892815,0.16777913],"study_design_scores_gemma":[0.013423395,0.00079913094,0.95259243,0.001028579,0.000063174324,0.0014313197,0.0024012334,0.009233185,0.0015821166,0.00035469647,0.01663008,0.0004606286],"about_ca_topic_score_codex":0.03078578,"about_ca_topic_score_gemma":0.21402101,"teacher_disagreement_score":0.18323523,"about_ca_system_score_codex":0.0005629311,"about_ca_system_score_gemma":0.0004316032,"threshold_uncertainty_score":0.9756683},"labels":[],"label_agreement":null},{"id":"W4384461310","doi":"10.58931/cht.2023.2s0326","title":"A review of the mechanism of action, safety, and efficacy of selinexor in multiple myeloma","year":2023,"lang":"en","type":"review","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Carfilzomib; Bortezomib; Pomalidomide; Multiple myeloma; Medicine; Dexamethasone; Oncology; Pharmacology; Mechanism of action; Drug; Internal medicine; Chemistry","score_opus":0.09048699920866078,"score_gpt":0.37222517905179714,"score_spread":0.28173817984313637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384461310","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014003468,0.9965173,0.0000017052864,0.00044555077,0.0001004743,0.002288055,0.00032047223,0.00000774736,0.00017863617],"genre_scores_gemma":[0.001020465,0.99830747,0.00006968198,0.000085097396,0.000016231532,0.00008510219,0.000114516864,0.0000403563,0.00026109992],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977543,0.0003081057,0.0010847577,0.00030745787,0.00018720939,0.0003581965],"domain_scores_gemma":[0.9976913,0.00073691935,0.00047338658,0.00062863337,0.00015739336,0.00031241015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043118533,0.00025902689,0.0026387307,0.00052646955,0.000036803736,0.0000012949193,0.00022792545,0.0003192289,0.000102053826],"category_scores_gemma":[0.0022183175,0.00016941252,0.0003396046,0.00075849314,0.00020511392,0.000016083894,0.00007959555,0.00033097644,0.000016025067],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064688946,0.00013909118,0.0014350693,0.552295,0.0009259502,0.0002593638,0.000080726226,7.244544e-8,0.0000037120196,0.0023331952,0.0018937015,0.44056943],"study_design_scores_gemma":[0.0027470773,0.00017491844,0.0019336289,0.41208902,0.0013227895,0.0009804032,0.000035847042,0.000016607648,0.000114413684,0.00009718392,0.5802378,0.0002502794],"about_ca_topic_score_codex":0.015240162,"about_ca_topic_score_gemma":0.06602297,"teacher_disagreement_score":0.5783441,"about_ca_system_score_codex":0.00018802864,"about_ca_system_score_gemma":0.0023138216,"threshold_uncertainty_score":0.99131745},"labels":[],"label_agreement":null},{"id":"W4384463934","doi":"10.58931/cht.2022.1213","title":"Multiple myeloma management: What comes after lenalidomide-based therapy?","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Monoclonal antibody; Quality of life (healthcare); Oncology; Internal medicine; Pharmacology; Antibody; Immunology","score_opus":0.02060857983614805,"score_gpt":0.2658410217929562,"score_spread":0.24523244195680816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643451,0.012453,0.000029109355,0.015087296,0.00056647445,0.0019408899,0.00016593485,0.00012156978,0.0052906233],"genre_scores_gemma":[0.9886563,0.00020760151,0.00035907442,0.006839509,0.000032899043,0.0011312156,0.00025688877,0.00004708319,0.0024694281],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979569,0.00018317038,0.0002497823,0.00044056374,0.0003314724,0.0008381485],"domain_scores_gemma":[0.9983502,0.00014634886,0.000049011196,0.0005746738,0.00005446024,0.0008253096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018863623,0.00023355595,0.00041146192,0.0006001543,0.00038468727,0.000048996008,0.00021155336,0.00008366313,0.006720698],"category_scores_gemma":[0.000038755526,0.00021604646,0.0001605989,0.00032450067,0.00013499068,0.00011385398,0.00007118497,0.00029752633,0.00027925006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002864008,0.00051060336,0.87198514,0.00028888194,0.0010946804,0.034113925,0.00048258252,0.000034206445,0.00006260577,0.0014583649,0.019758673,0.06734635],"study_design_scores_gemma":[0.025347121,0.0008243899,0.27419537,0.00017602163,0.00014899367,0.001532337,0.0018500545,0.001203547,0.002629025,0.00039774567,0.6909735,0.0007218573],"about_ca_topic_score_codex":0.0069661653,"about_ca_topic_score_gemma":0.022961048,"teacher_disagreement_score":0.6712149,"about_ca_system_score_codex":0.00051840616,"about_ca_system_score_gemma":0.00048314309,"threshold_uncertainty_score":0.99964654},"labels":[],"label_agreement":null},{"id":"W4384923381","doi":"10.1038/s41408-023-00883-x","title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; McGill University; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Juravinski Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"Janssen Canada","keywords":"Attrition; Medicine; Multiple myeloma; Internal medicine; Cohort; Surgery; Oncology","score_opus":0.12362651348174936,"score_gpt":0.38956669331827093,"score_spread":0.2659401798365216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384923381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069774,0.0022180795,0.000010776447,0.0041998117,0.00016282,0.0004940004,0.00011103071,0.00006215362,0.0020436086],"genre_scores_gemma":[0.9958534,0.0016702767,0.0004884461,0.00012903662,0.0005243628,0.00020102304,0.00017614524,0.000047706413,0.00090957247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956457,0.00039775632,0.0005468483,0.0004937816,0.0013300903,0.0015858478],"domain_scores_gemma":[0.9975043,0.00026253017,0.0000990274,0.00038497866,0.00040429496,0.0013448688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002118209,0.000230642,0.0005477298,0.0044987584,0.0007008989,0.00016877585,0.00025145325,0.00018157624,0.0008113692],"category_scores_gemma":[0.0006892188,0.00020828059,0.00029057593,0.0060352134,0.0001199153,0.00019337276,0.000080319296,0.0012731386,0.00018854985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047814514,0.00026282316,0.94640064,0.00006488319,0.001870691,0.00804945,0.0006078631,0.00012145137,0.0029172443,0.000045955512,0.003770166,0.035410687],"study_design_scores_gemma":[0.0076541714,0.00043368535,0.9816019,0.00038240472,0.00047198628,0.0003616082,0.000820023,0.003239325,0.0006871642,0.00015894476,0.0039778207,0.00021099776],"about_ca_topic_score_codex":0.13823693,"about_ca_topic_score_gemma":0.5454202,"teacher_disagreement_score":0.40718332,"about_ca_system_score_codex":0.0011259221,"about_ca_system_score_gemma":0.001401066,"threshold_uncertainty_score":0.8883924},"labels":[],"label_agreement":null},{"id":"W4384937145","doi":"10.1016/j.jgo.2023.101592","title":"Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital; University of Ottawa; McMaster University","funders":"Institut canadien d'information sur la santé; Ministry of Health -Singapore; Hamilton Health Sciences Foundation; Institute for Clinical Evaluative Sciences; Alliance for Lupus Research","keywords":"Medicine; Multiple myeloma; Scopus; Clinical trial; Internal medicine; Population; Risk stratification; Malignancy; Cancer; Oncology; MEDLINE","score_opus":0.024472498468960137,"score_gpt":0.33592353481028947,"score_spread":0.3114510363413293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384937145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99762636,0.00052220497,0.0007544592,0.0004184878,0.00013850548,0.00031333807,0.00006600399,0.00002207649,0.00013856756],"genre_scores_gemma":[0.9953653,0.00073043595,0.0033750483,0.000017950775,0.00026231463,0.00001997915,0.000052995885,0.000021975742,0.00015395628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795485,0.000231439,0.00070087,0.0002013915,0.00056329917,0.00034817276],"domain_scores_gemma":[0.99733174,0.00066895137,0.0009542092,0.00025036943,0.00049395004,0.00030075602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058040535,0.00016299004,0.00091522647,0.0015219249,0.00009479463,0.000010870117,0.00013346713,0.0001395134,0.00026072309],"category_scores_gemma":[0.00028573335,0.00010901674,0.00038946624,0.0024795765,0.0000617314,0.000072607094,0.000023306622,0.00030398325,0.000010644439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027468046,0.0004092081,0.9757568,0.000036635985,0.0031473048,0.0009201098,0.00010876834,0.0060852515,0.0003383168,0.0000039597744,0.00033241205,0.01011443],"study_design_scores_gemma":[0.007704978,0.0020853241,0.9812072,0.000028659673,0.002625778,0.000039085528,0.00010982086,0.0050623794,0.00027261535,0.000014633042,0.00076196267,0.00008759428],"about_ca_topic_score_codex":0.0024985662,"about_ca_topic_score_gemma":0.0019094974,"teacher_disagreement_score":0.010026836,"about_ca_system_score_codex":0.00046875814,"about_ca_system_score_gemma":0.00069987244,"threshold_uncertainty_score":0.44455737},"labels":[],"label_agreement":null},{"id":"W4385351176","doi":"10.14740/wjnu441","title":"A Rare Case of Testicular Plasmacytoma as First Presentation in a Monorchid Patient Without Previous History of Multiple Myeloma: Diagnosis, Management and Review of Literature","year":2023,"lang":"en","type":"article","venue":"World Journal of Nephrology and Urology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Plasmacytoma; Presentation (obstetrics); Asymptomatic; Hematologist; Case presentation; Rare disease; Extramedullary plasmacytoma; Disease; Surgery; Pathology; Internal medicine","score_opus":0.015786870688351582,"score_gpt":0.2859702274245367,"score_spread":0.2701833567361851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385351176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8837347,0.114458375,0.0000028130562,0.0010601988,0.00005085,0.00056585163,0.0000126935365,0.000003850981,0.00011067564],"genre_scores_gemma":[0.9502375,0.048767824,0.00041281176,0.00037520973,0.000019606694,0.00004497012,0.00001459002,0.000009166396,0.00011831765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862975,0.00024000285,0.0006305183,0.00016319207,0.00015094713,0.00018556925],"domain_scores_gemma":[0.99864805,0.0004833885,0.00044725678,0.00014814209,0.00016228821,0.00011086529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028227948,0.00012781954,0.00062817265,0.0006209951,0.000020472427,0.0000014056698,0.000054921158,0.000076190365,0.00003694803],"category_scores_gemma":[0.00032314533,0.00009904023,0.00007716022,0.00028695137,0.00022849473,0.000054408127,0.00007585876,0.00023510323,8.744839e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005946454,0.00084041024,0.9240538,0.008914734,0.00078334304,0.029320592,0.0021896637,0.000038232516,0.00039417314,0.000108830616,0.0062781526,0.021131651],"study_design_scores_gemma":[0.020735163,0.011516503,0.89788634,0.007652397,0.0013966691,0.026216803,0.00019140104,0.0017687634,0.00053933304,0.00047397288,0.03138996,0.0002327075],"about_ca_topic_score_codex":0.000058457055,"about_ca_topic_score_gemma":0.00017450926,"teacher_disagreement_score":0.06650281,"about_ca_system_score_codex":0.000046343463,"about_ca_system_score_gemma":0.00007183032,"threshold_uncertainty_score":0.40387434},"labels":[],"label_agreement":null},{"id":"W4385380477","doi":"10.1186/s40900-023-00476-9","title":"How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership","year":2023,"lang":"en","type":"article","venue":"Research Involvement and Engagement","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of New Brunswick; Princess Margaret Cancer Centre; Horizon Health Network; Vitalité Health Network; Saint John Regional Hospital; Vancouver General Hospital","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Canadian Cancer Society; Fondation de la recherche en santé du Nouveau-Brunswick","keywords":"General partnership; Multiple myeloma; Medicine; Political science; Internal medicine","score_opus":0.37298746373698044,"score_gpt":0.43646380890465586,"score_spread":0.06347634516767542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385380477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9230398,0.0012472362,0.0000015752088,0.07100037,0.00007318593,0.003825942,0.00011164363,0.000072672185,0.000627576],"genre_scores_gemma":[0.99389154,0.001595922,0.00018384361,0.0003376256,0.00026938785,0.0017341705,0.00043881257,0.000053348263,0.0014953335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99170697,0.001971693,0.00038367743,0.0009898735,0.0025155314,0.0024322397],"domain_scores_gemma":[0.9952182,0.0025690396,0.00004440686,0.0006918318,0.00038281153,0.001093719],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.009889213,0.00033125438,0.00039550348,0.0018126465,0.0018086722,0.00048520608,0.00028793848,0.00015188256,0.00009100972],"category_scores_gemma":[0.0023914769,0.0002445768,0.00007768955,0.0027268322,0.0005528676,0.00030057487,0.0010201464,0.002116663,0.0000741846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036885348,0.00026231568,0.80827427,0.00022324458,0.00021482258,0.00093772536,0.013005085,3.2748488e-7,0.0012321611,0.0010491854,0.009391898,0.16504014],"study_design_scores_gemma":[0.0037029271,0.00060018373,0.88405293,0.00060639466,0.000023463519,0.0000026027772,0.021587802,0.0028874488,0.0010308177,0.00055346114,0.08469833,0.00025366267],"about_ca_topic_score_codex":0.07117718,"about_ca_topic_score_gemma":0.27034172,"teacher_disagreement_score":0.19916455,"about_ca_system_score_codex":0.00088287616,"about_ca_system_score_gemma":0.00043978126,"threshold_uncertainty_score":0.99949086},"labels":[],"label_agreement":null},{"id":"W4385552858","doi":"10.1002/jha2.759","title":"Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial","year":2023,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Calgary; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of British Columbia; BC Cancer Agency","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Lenalidomide; Internal medicine; Complete response; Placebo; Multiple myeloma; Dexamethasone; Post-hoc analysis; Gastroenterology; Progression-free survival; Thalidomide; Surgery; Overall survival; Chemotherapy; Pathology","score_opus":0.030003690192812987,"score_gpt":0.2978154897159701,"score_spread":0.26781179952315715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385552858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965136,0.000018211225,6.969553e-7,0.0006709124,0.00005557852,0.0025817202,0.00008469367,0.00005072897,0.000023868419],"genre_scores_gemma":[0.9991111,0.000006566853,0.00008759796,0.00004834989,0.000016747985,0.00023557928,0.00007547467,0.00003696867,0.00038159432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970546,0.0010421186,0.00039571623,0.00034952036,0.0006523426,0.00050574174],"domain_scores_gemma":[0.99423134,0.0048877764,0.00019634278,0.00039791054,0.00013632707,0.00015031088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014231985,0.00025232256,0.0006084186,0.00043285737,0.000072457646,0.000029279163,0.00014457645,0.00011671666,0.000009378527],"category_scores_gemma":[0.0065987054,0.00014252483,0.00006840944,0.00088749576,0.00011703308,0.00010315763,0.000061955274,0.00029714225,0.0000080621785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46863195,0.000505375,0.5282649,0.000007852471,0.00015469987,0.0005405589,0.0012810946,0.000007084752,0.000096630945,2.144101e-7,0.0000148561485,0.00049478246],"study_design_scores_gemma":[0.29391575,0.0062318016,0.69867027,0.000110087385,0.00003959106,5.658294e-7,0.00051332085,0.00027341518,0.00013281338,0.0000011459648,0.00000791714,0.00010331004],"about_ca_topic_score_codex":0.0006096145,"about_ca_topic_score_gemma":0.003998822,"teacher_disagreement_score":0.1747162,"about_ca_system_score_codex":0.0001393255,"about_ca_system_score_gemma":0.00020187385,"threshold_uncertainty_score":0.78997433},"labels":[],"label_agreement":null},{"id":"W4385644723","doi":"10.1097/01.hs9.0000967696.13096.54","title":"S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Refractory (planetary science); Adverse effect; Gastroenterology; Multiple myeloma; Surgery","score_opus":0.018638708852403377,"score_gpt":0.2789849677210768,"score_spread":0.2603462588686734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467987,0.0006296995,0.00038736945,0.00031085368,0.00024055826,0.0024017175,0.000516365,0.00022480689,0.0006087891],"genre_scores_gemma":[0.98351,0.00036466127,0.0046679643,0.000044528108,0.00015813728,0.00020993003,0.0072226045,0.000087952554,0.0037342007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762464,0.00006556839,0.00038997762,0.0007259314,0.00062644796,0.000567454],"domain_scores_gemma":[0.9984278,0.00029140883,0.00016979844,0.0004949869,0.00026627397,0.0003497025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012293969,0.00036146396,0.00044391953,0.0001480263,0.0002727044,0.000100399135,0.000105904175,0.00021389539,0.00029880396],"category_scores_gemma":[0.00015740184,0.0002887423,0.00011599673,0.0004003114,0.00009719472,0.00032105183,0.000052912863,0.00021444591,0.00016980885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03383932,0.0036841864,0.79389757,0.0011319113,0.0007827071,0.0008333362,0.0012096833,0.0000046574587,0.05526668,0.00009625209,0.022972297,0.086281374],"study_design_scores_gemma":[0.028596416,0.0036686605,0.94943756,0.00022890342,0.00014123443,0.000010630433,0.0005482322,0.0018384872,0.006166654,0.000115166615,0.0088619795,0.0003860859],"about_ca_topic_score_codex":0.00018015389,"about_ca_topic_score_gemma":0.0003896834,"teacher_disagreement_score":0.15553996,"about_ca_system_score_codex":0.00009150258,"about_ca_system_score_gemma":0.0001943432,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W4385655058","doi":"10.1097/01.hs9.0000975232.20009.f4","title":"PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Observational study; Adverse effect; Retrospective cohort study; Refractory (planetary science); Incidence (geometry); Oncology; Surgery","score_opus":0.12397344370946108,"score_gpt":0.3756518300853904,"score_spread":0.2516783863759293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908705,0.00018992968,0.00006950706,0.0011971593,0.00024820978,0.003315756,0.00025655143,0.00048174453,0.003370666],"genre_scores_gemma":[0.9512653,0.00008931775,0.0030730679,0.00019164068,0.0003752256,0.0009871578,0.0015468155,0.00009626967,0.042375255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742746,0.00008634538,0.0004586713,0.00061041897,0.00069654244,0.0007205471],"domain_scores_gemma":[0.99812835,0.0005766341,0.000116359246,0.00059197226,0.00023067127,0.00035601837],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00039364284,0.00030296345,0.0004877826,0.00018342897,0.00027661372,0.00003996839,0.00017486917,0.00010410622,0.0010303289],"category_scores_gemma":[0.00044445388,0.00025626872,0.00019987948,0.00074698887,0.000055986053,0.00015437437,0.00012951667,0.00027182745,0.0013061624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019584734,0.0017204203,0.9184111,0.00022498066,0.00053539715,0.0007002222,0.00028116713,0.000011032202,0.0013871968,0.0003000755,0.060398426,0.014071512],"study_design_scores_gemma":[0.014910008,0.0009734753,0.9407736,0.0000997488,0.00012705624,0.000015350213,0.00069546944,0.0023297616,0.0006845318,0.00017818612,0.038955055,0.0002577683],"about_ca_topic_score_codex":0.0005110424,"about_ca_topic_score_gemma":0.002445891,"teacher_disagreement_score":0.039605226,"about_ca_system_score_codex":0.00020938856,"about_ca_system_score_gemma":0.0002594031,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4385655501","doi":"10.1097/01.hs9.0000975184.86472.15","title":"PB2100: REAL-WORLD TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A RETROSPECTIVE CHART STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Retrospective cohort study; Salvage therapy; Pediatrics; Chemotherapy","score_opus":0.03435706065089352,"score_gpt":0.3202322981013255,"score_spread":0.285875237450432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958447,0.000074848045,0.0000016232984,0.0005552102,0.00009349898,0.001873168,0.0006018725,0.00011076294,0.00084432156],"genre_scores_gemma":[0.94732267,0.0005015464,0.0000103795,0.000101634105,0.0000799342,0.00019129501,0.00040093533,0.00007222146,0.0513194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733925,0.0002196236,0.00045377534,0.0005629572,0.0007420452,0.00068233063],"domain_scores_gemma":[0.9980423,0.00038262343,0.0001861732,0.0007505851,0.0002861119,0.0003522429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026235447,0.00037890198,0.00063326716,0.00011388382,0.00027247652,0.000041662064,0.00016347304,0.000059493348,0.0001463923],"category_scores_gemma":[0.00015572686,0.0002409757,0.00008760373,0.00083263573,0.00012939132,0.00007095705,0.00017213373,0.00025715833,0.00003429684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074183615,0.0007223742,0.9890602,0.00009310657,0.000718026,0.0012465473,0.003246824,0.000007503467,0.00017637752,0.000008914387,0.0013183551,0.0026598999],"study_design_scores_gemma":[0.007626676,0.0019080245,0.97094905,0.000114620845,0.000116645686,0.000019007499,0.0043359455,0.0005317193,0.0008713182,0.0000048694787,0.013335291,0.00018681842],"about_ca_topic_score_codex":0.66332346,"about_ca_topic_score_gemma":0.92150384,"teacher_disagreement_score":0.25818038,"about_ca_system_score_codex":0.0006786986,"about_ca_system_score_gemma":0.00039930837,"threshold_uncertainty_score":0.98267037},"labels":[],"label_agreement":null},{"id":"W4385666962","doi":"10.1097/01.hs9.0000970384.26808.c7","title":"P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Adverse effect; Gastroenterology; Bortezomib; Oncology; Refractory (planetary science); Surgery; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.014217060108590156,"score_gpt":0.2678927841424802,"score_spread":0.25367572403389005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378407,0.0047374694,0.000011257593,0.00011311024,0.000020066243,0.0010294728,0.00012046308,0.00009069875,0.000093409355],"genre_scores_gemma":[0.9957077,0.001858642,0.0015252023,0.000018866363,0.000016450127,0.000037665242,0.0004837737,0.000029415838,0.0003222737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836224,0.00012091219,0.00036449308,0.00044354433,0.00041529175,0.00029352188],"domain_scores_gemma":[0.99875927,0.00046143893,0.00014145758,0.00031889117,0.00017918626,0.00013977158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000126863,0.00023554917,0.00065364473,0.00024967708,0.000093775016,0.00001815511,0.000056606306,0.000103587765,0.00012422321],"category_scores_gemma":[0.00020221468,0.00016867157,0.000058773057,0.0009757742,0.0001272523,0.00012247577,0.00006990873,0.0001612607,0.00001063284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069458587,0.00061344105,0.9488086,0.00019893995,0.0025787149,0.000083476516,0.0025815768,0.000008553862,0.001481342,0.0000016042587,0.000106182015,0.03659172],"study_design_scores_gemma":[0.021634163,0.00067787746,0.9737742,0.00021706334,0.00052668195,6.617315e-7,0.0012066237,0.001126974,0.00059523684,0.000010340236,0.00008054343,0.00014966933],"about_ca_topic_score_codex":0.0004615384,"about_ca_topic_score_gemma":0.00093179767,"teacher_disagreement_score":0.036442053,"about_ca_system_score_codex":0.0000641222,"about_ca_system_score_gemma":0.000049578306,"threshold_uncertainty_score":0.6878227},"labels":[],"label_agreement":null},{"id":"W4385666975","doi":"10.1097/01.hs9.0000970432.75766.0c","title":"P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Thames Valley Children's Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Cohort; Dexamethasone; Regimen; Clinical endpoint; Oncology; Gastroenterology; Surgery; Clinical trial","score_opus":0.04037242643722707,"score_gpt":0.3232737664310684,"score_spread":0.28290133999384137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704844,0.00016817395,0.000005036905,0.000101123886,0.00005661228,0.0022303155,0.0001877083,0.000047872196,0.00015469184],"genre_scores_gemma":[0.9967673,0.00004658035,0.00025091946,0.000036666304,0.000029441897,0.0003238341,0.0001750162,0.000049322425,0.0023209425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969926,0.0003897519,0.00055348704,0.00063997996,0.0008716537,0.0005525325],"domain_scores_gemma":[0.9979831,0.0005787938,0.00019503816,0.00082356343,0.00015959168,0.000259903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031839794,0.00039666728,0.0010191427,0.0003403176,0.00012256374,0.00002990771,0.00013594862,0.00011108198,0.00045516307],"category_scores_gemma":[0.0003219693,0.00021410915,0.00021875554,0.0016885428,0.00015244457,0.00013193641,0.00012665414,0.00023468497,0.000016857235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036388088,0.005544786,0.94656456,0.00006617572,0.002968498,0.00071941444,0.00096703845,0.00004303933,0.00018299493,0.0000019532238,0.000075360156,0.0064780707],"study_design_scores_gemma":[0.07309336,0.004729921,0.91839284,0.00012503995,0.0012990482,0.000003332415,0.0006686478,0.00092950574,0.00034202883,0.000003085717,0.00021661747,0.00019656777],"about_ca_topic_score_codex":0.0013668411,"about_ca_topic_score_gemma":0.009905138,"teacher_disagreement_score":0.036705274,"about_ca_system_score_codex":0.0002983145,"about_ca_system_score_gemma":0.0002050506,"threshold_uncertainty_score":0.8731118},"labels":[],"label_agreement":null},{"id":"W4385667237","doi":"10.1097/01.hs9.0000970732.34300.9d","title":"P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Cohort; Multiple myeloma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Biology","score_opus":0.05037156805333891,"score_gpt":0.351355052474519,"score_spread":0.30098348442118006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913613,0.00064334756,0.000037148176,0.00027042924,0.00038047362,0.0016843155,0.0004465435,0.00025822865,0.0049181986],"genre_scores_gemma":[0.9909835,0.00012674175,0.0007864056,0.000055246142,0.00019285276,0.00022237893,0.00038120447,0.000113599075,0.00713811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946198,0.0014515572,0.0009844718,0.0009620593,0.0009893597,0.0009927414],"domain_scores_gemma":[0.9938906,0.0038547695,0.00038821273,0.0010070761,0.0002248387,0.0006344974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013088123,0.0005426613,0.0014264038,0.0005936663,0.00014108396,0.000047251877,0.00035487543,0.00029568275,0.0012231605],"category_scores_gemma":[0.001660206,0.00049609656,0.00027050744,0.0010839131,0.00026123013,0.00029744982,0.00012477295,0.00081717456,0.00035315714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23096272,0.0020810487,0.62882483,0.0001823008,0.00086822495,0.0035871,0.0033564244,0.00014439692,0.091972224,0.000048204118,0.0019691605,0.03600337],"study_design_scores_gemma":[0.04492596,0.0026896123,0.91425335,0.00041097417,0.00016315788,0.00000700385,0.0018423892,0.012110053,0.02169172,0.0000972769,0.0014044079,0.00040409353],"about_ca_topic_score_codex":0.0048554097,"about_ca_topic_score_gemma":0.012869494,"teacher_disagreement_score":0.28542852,"about_ca_system_score_codex":0.0007402142,"about_ca_system_score_gemma":0.00059622875,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W4385667566","doi":"10.1097/01.hs9.0000970804.07945.f9","title":"P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics; University of Manitoba","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Disease; Regimen; Cancer","score_opus":0.022002173980866648,"score_gpt":0.27496340337460623,"score_spread":0.2529612293937396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996731,0.00030452802,0.0000075234993,0.00008980492,0.00013493876,0.0014809372,0.00018159447,0.00014867933,0.00092101935],"genre_scores_gemma":[0.99605125,0.000081002625,0.00249752,0.000028617618,0.000068080815,0.00017984388,0.0004280084,0.000056476336,0.0006091976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974404,0.00009859903,0.0005226408,0.00047971783,0.0008360634,0.0006225974],"domain_scores_gemma":[0.9982896,0.0005395237,0.0001657254,0.00047283663,0.00021214002,0.0003201939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002747478,0.0002599546,0.0004949899,0.00020512313,0.00009482294,0.000009872074,0.00012772703,0.00017585055,0.0002891244],"category_scores_gemma":[0.0016697623,0.00021148742,0.0001557618,0.00085025653,0.000097593795,0.00011930579,0.00015441314,0.00037678052,0.00035970012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010592127,0.00076938514,0.9775614,0.00024688724,0.00015798584,0.00052983535,0.0001500584,0.00020343615,0.0006220151,0.00001732035,0.0014766519,0.017205793],"study_design_scores_gemma":[0.014359891,0.0005510616,0.966392,0.0004540241,0.00005480767,0.000005922777,0.00013176903,0.011396321,0.006188388,0.00013677035,0.00016391414,0.00016517886],"about_ca_topic_score_codex":0.00071500096,"about_ca_topic_score_gemma":0.0009964942,"teacher_disagreement_score":0.017040614,"about_ca_system_score_codex":0.00012258209,"about_ca_system_score_gemma":0.00020306943,"threshold_uncertainty_score":0.8624207},"labels":[],"label_agreement":null},{"id":"W4385697375","doi":"10.1097/01.hs9.0000970688.75458.a8","title":"P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Toronto; Jewish General Hospital; Institute of Cancer Research","funders":"","keywords":"Medicine; Tocilizumab; Internal medicine; Multiple myeloma; Cytokine release syndrome; Incidence (geometry); Refractory (planetary science); Gastroenterology; Immunotherapy; Chimeric antigen receptor; Rheumatoid arthritis; Cancer","score_opus":0.0166835084563772,"score_gpt":0.2672355611624662,"score_spread":0.25055205270608905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955505,0.0003695276,0.0000031871791,0.00037788527,0.000064654465,0.0025855992,0.00018029021,0.000115911644,0.00075241097],"genre_scores_gemma":[0.99553573,0.00025220402,0.00029839875,0.000030892006,0.0000352496,0.00039362305,0.000264826,0.000068163674,0.0031209127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968769,0.0002009176,0.00056198833,0.00064848736,0.0010045232,0.0007071741],"domain_scores_gemma":[0.9977109,0.0005651791,0.00024714976,0.0008813705,0.00028139932,0.00031399867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021705434,0.0004046474,0.00068364304,0.00017779,0.0001546689,0.000024009574,0.00024841353,0.00015605708,0.0002652045],"category_scores_gemma":[0.0005169633,0.0002414689,0.0001409625,0.0010344437,0.00024995164,0.00019975573,0.00010943449,0.00033091314,0.0001520325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012263175,0.0028266995,0.9154882,0.00035231007,0.00065813476,0.002431333,0.0023370404,0.00017376317,0.0021568951,0.000020255828,0.0012738018,0.060018413],"study_design_scores_gemma":[0.014364492,0.005440374,0.9648847,0.0008661529,0.000105362116,0.000037793016,0.0008801854,0.00040831452,0.012184744,0.000030422287,0.000549207,0.00024826857],"about_ca_topic_score_codex":0.0011979813,"about_ca_topic_score_gemma":0.0008057551,"teacher_disagreement_score":0.059770145,"about_ca_system_score_codex":0.0005508354,"about_ca_system_score_gemma":0.0004025091,"threshold_uncertainty_score":0.98468155},"labels":[],"label_agreement":null},{"id":"W4385698049","doi":"10.1097/01.hs9.0000970532.16622.f0","title":"P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Multiple myeloma; Refractory (planetary science); Lenalidomide; Oncology; Cohort; Surgery; Gastroenterology","score_opus":0.009288876697198186,"score_gpt":0.24197565072692845,"score_spread":0.23268677402973026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976119,0.00051428756,0.00003439896,0.00008240326,0.000029298393,0.00078666396,0.0005432122,0.00009059201,0.00030726494],"genre_scores_gemma":[0.99594516,0.0004938379,0.0015376621,0.000016985923,0.000028814438,0.000044039614,0.001435454,0.00004616555,0.00045189218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790674,0.00013032563,0.00041919557,0.00053332077,0.00057797786,0.00043244803],"domain_scores_gemma":[0.9983556,0.0005709111,0.00015755503,0.0005479992,0.00009003988,0.00027788992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013717574,0.0002525139,0.00069104636,0.00032057497,0.0000761159,0.000015783267,0.00010600038,0.0001401551,0.0007836631],"category_scores_gemma":[0.00026486625,0.00019081337,0.00010401038,0.0016000683,0.0001226198,0.00012962813,0.000104540006,0.0002938635,0.00007299202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004229281,0.0007544457,0.9677392,0.00008185288,0.0010473003,0.00023496946,0.0002920104,0.00005107536,0.00010466179,0.000009339447,0.00020237915,0.025253482],"study_design_scores_gemma":[0.028468985,0.0007725245,0.9680615,0.00014466081,0.0006140922,8.039967e-7,0.00018908837,0.0010216064,0.00022958212,0.000023688846,0.00030823544,0.0001652524],"about_ca_topic_score_codex":0.0042753066,"about_ca_topic_score_gemma":0.0029332773,"teacher_disagreement_score":0.02508823,"about_ca_system_score_codex":0.00007723496,"about_ca_system_score_gemma":0.00007208542,"threshold_uncertainty_score":0.8580562},"labels":[],"label_agreement":null},{"id":"W4385698349","doi":"10.1097/01.hs9.0000970456.81043.cc","title":"P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Refractory (planetary science); Medicine; Internal medicine; Cohort; Dexamethasone; Oncology; Multiple myeloma; Lenalidomide; Gastroenterology","score_opus":0.031120390621193254,"score_gpt":0.29201849263677154,"score_spread":0.2608981020155783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972405,0.00060758466,0.000013489831,0.00014267625,0.000055763834,0.0012869227,0.00010602911,0.00015883823,0.000388207],"genre_scores_gemma":[0.9964465,0.00009438125,0.0018896238,0.000040867802,0.00003744915,0.00011976454,0.00045428288,0.0000825207,0.0008346394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972353,0.00016132827,0.0005999523,0.00056764565,0.0007847112,0.0006510679],"domain_scores_gemma":[0.998345,0.00041726974,0.00022170029,0.0004964657,0.00018477252,0.0003347488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002755146,0.00036863363,0.0010447894,0.00028404492,0.00007336807,0.000019744217,0.00012153071,0.00023473531,0.0003064231],"category_scores_gemma":[0.00033899513,0.00028776893,0.00008585954,0.00094233727,0.00016265568,0.00014074522,0.00013578091,0.00049264857,0.00012840156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083406605,0.001339218,0.97318465,0.00054555584,0.00025207383,0.00026063976,0.00080422184,0.00001650717,0.00056376006,0.0000036534905,0.00060431974,0.014084747],"study_design_scores_gemma":[0.019996306,0.0018238071,0.96949047,0.000586449,0.00010434824,0.000011103011,0.00068309775,0.0015813713,0.0051100687,0.00000784304,0.0003484254,0.00025670923],"about_ca_topic_score_codex":0.00043687585,"about_ca_topic_score_gemma":0.0006631769,"teacher_disagreement_score":0.013828038,"about_ca_system_score_codex":0.00014401056,"about_ca_system_score_gemma":0.00013451163,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W4385704654","doi":"10.1097/01.hs9.0000970536.69350.bb","title":"P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine; Cytokine release syndrome; Internal medicine; Cohort; Multiple myeloma; Immunology; Gastroenterology; Immunotherapy; Immune system","score_opus":0.016902216350578165,"score_gpt":0.2862964662391734,"score_spread":0.2693942498885952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876654,0.00016539996,0.000024761926,0.00022003124,0.000008070205,0.00042828755,0.00019642575,0.00005331454,0.00013719023],"genre_scores_gemma":[0.99589616,0.0001036731,0.000104881365,0.0000079927395,0.000003942821,0.000046187273,0.00035970818,0.000018499359,0.003458955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986024,0.00011886361,0.0003462898,0.0002567651,0.00047531,0.00020035688],"domain_scores_gemma":[0.99879634,0.00028651874,0.00018831452,0.00035494185,0.00023762058,0.00013624484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004825046,0.00011994781,0.00050655904,0.00033861096,0.00003818292,0.000007988434,0.00005280594,0.000069436755,0.00022589006],"category_scores_gemma":[0.00072834606,0.00009240864,0.00009094017,0.0021236588,0.00012095484,0.000052174033,0.000034725745,0.00007114431,0.000012989658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032837733,0.00030493355,0.93362457,0.00017399288,0.0036506394,0.00070133235,0.00014740892,0.000052046507,0.0567447,0.000019766094,0.00019360002,0.0011032452],"study_design_scores_gemma":[0.0019650857,0.0005910146,0.9850429,0.00012998759,0.0016238401,0.000030375486,0.00013316784,0.0031028313,0.0072715036,0.000012252803,0.000024984676,0.00007202659],"about_ca_topic_score_codex":0.00017526488,"about_ca_topic_score_gemma":0.00011497187,"teacher_disagreement_score":0.051418368,"about_ca_system_score_codex":0.000046065496,"about_ca_system_score_gemma":0.000081851744,"threshold_uncertainty_score":0.37683153},"labels":[],"label_agreement":null},{"id":"W4385707163","doi":"10.1097/01.hs9.0000970568.75232.84","title":"P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Internal medicine; Medicine; Carfilzomib; Multiple myeloma; Oncology; Subgroup analysis; Gastroenterology; Confidence interval; Bortezomib","score_opus":0.04083135418477333,"score_gpt":0.32573524028162926,"score_spread":0.2849038860968559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280405,0.00013290127,0.00001253906,0.00058562483,0.00010215499,0.004564856,0.001025523,0.00032421935,0.00044815443],"genre_scores_gemma":[0.99283296,0.000029884292,0.0007610305,0.00017535244,0.000072010065,0.0003599621,0.0036519263,0.00014443918,0.0019724236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490994,0.00038714748,0.00077369524,0.0011447503,0.0015315393,0.0012528971],"domain_scores_gemma":[0.99614584,0.0011783297,0.000271821,0.0015467231,0.00031843473,0.00053882384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042680925,0.00065039657,0.0010066798,0.00018297353,0.0002650494,0.000097766766,0.00035224017,0.00016816588,0.000451959],"category_scores_gemma":[0.0008458278,0.0003545077,0.00012731645,0.0015457348,0.00022452264,0.00021081803,0.00020964377,0.00069848984,0.0004420437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022899587,0.006116389,0.9520742,0.00004279644,0.0011037086,0.0022666282,0.0028642928,0.000019557372,0.00008263786,0.0000014060597,0.0014657482,0.011062994],"study_design_scores_gemma":[0.14138396,0.003375246,0.85046834,0.00029924806,0.00021599518,0.0000052514642,0.0030543269,0.000340656,0.00028980398,0.000005232458,0.00020937076,0.00035256892],"about_ca_topic_score_codex":0.0028078896,"about_ca_topic_score_gemma":0.00977791,"teacher_disagreement_score":0.11848438,"about_ca_system_score_codex":0.00030657655,"about_ca_system_score_gemma":0.00029062174,"threshold_uncertainty_score":0.9998907},"labels":[],"label_agreement":null},{"id":"W4385707295","doi":"10.1097/01.hs9.0000970420.62475.d0","title":"P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Multiple myeloma; Daratumumab; Cytokine release syndrome; Oncology; Bortezomib; Refractory (planetary science); Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Chimeric antigen receptor","score_opus":0.019967407386132292,"score_gpt":0.2765928248278406,"score_spread":0.2566254174417083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960107,0.0004617136,0.000046721732,0.00006765494,0.00023942707,0.0015307115,0.00021929818,0.00015860304,0.0012651383],"genre_scores_gemma":[0.9934517,0.00020488464,0.000739126,0.000023324188,0.00008454984,0.00006704694,0.0029438867,0.00009451175,0.0023909486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970549,0.000105019215,0.000576996,0.0006640239,0.00094531185,0.00065376336],"domain_scores_gemma":[0.9982257,0.00021446504,0.00024728334,0.0007833213,0.0002445047,0.00028470944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014492848,0.0003815315,0.00065158936,0.00027882514,0.000104139785,0.000040199473,0.00019929145,0.0002400882,0.00059788505],"category_scores_gemma":[0.00013770674,0.0003025954,0.00015584973,0.0008873714,0.00012392922,0.0002589116,0.00011186968,0.00037053248,0.00041326942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046617035,0.0012298551,0.9696454,0.00031263076,0.00016889536,0.00057708635,0.00038061288,0.000004172569,0.01402189,0.000004032561,0.00079882785,0.008194899],"study_design_scores_gemma":[0.023399018,0.0008250996,0.9647265,0.000648917,0.000056585348,0.0000033746664,0.00023572422,0.0001690668,0.009324816,0.000013361632,0.00032779918,0.000269727],"about_ca_topic_score_codex":0.00052830204,"about_ca_topic_score_gemma":0.0009489454,"teacher_disagreement_score":0.018737314,"about_ca_system_score_codex":0.00019116339,"about_ca_system_score_gemma":0.000194049,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4385707424","doi":"10.1097/01.hs9.0000970528.04188.9f","title":"P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; CD38; Medicine; Plasma cell; Internal medicine; Oncology; Bortezomib; Exome sequencing; Cohort; Immunology; Bone marrow; Biology; Gene; Phenotype; Genetics; Stem cell","score_opus":0.028456850265645473,"score_gpt":0.3646396066653157,"score_spread":0.3361827563996702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977299,0.00040679894,0.000017130038,0.00046955704,0.000020242966,0.00095893606,0.000060112514,0.000030621417,0.00030670807],"genre_scores_gemma":[0.9928094,0.00010045752,0.0010998828,0.00006735509,0.000012364066,0.00010569394,0.000019128842,0.000021398053,0.005764325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833906,0.00011664483,0.00035867083,0.00041758368,0.00038501574,0.00038300146],"domain_scores_gemma":[0.99891376,0.00015713109,0.00004788547,0.00045880608,0.00007114924,0.00035123972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160889,0.00015261752,0.0005159822,0.0005055248,0.000037803646,0.000017345323,0.00010445347,0.00006308335,0.00029237004],"category_scores_gemma":[0.00038809847,0.00013408302,0.00008669719,0.0018361429,0.00003561353,0.00003860252,0.0001405611,0.0000900694,0.00017443708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004798303,0.00010472413,0.9749496,0.00015015135,0.00029212172,0.0011401672,0.00046556393,0.0000203656,0.012669365,0.0000044814788,0.0014374712,0.0039677024],"study_design_scores_gemma":[0.001668936,0.0002551222,0.99419826,0.00015046462,0.00016908595,0.0000064893825,0.00023885882,0.00020677896,0.0023498205,0.0000220964,0.0006269099,0.0001071517],"about_ca_topic_score_codex":0.00044878724,"about_ca_topic_score_gemma":0.0052104513,"teacher_disagreement_score":0.019248702,"about_ca_system_score_codex":0.00013411447,"about_ca_system_score_gemma":0.00008924604,"threshold_uncertainty_score":0.5467747},"labels":[],"label_agreement":null},{"id":"W4385727291","doi":"10.1097/01.hs9.0000970360.06967.6b","title":"P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Interim analysis; Bortezomib; Internal medicine; Adverse effect; Tolerability; Clinical endpoint; Dexamethasone; Gastroenterology; Oncology; Surgery; Clinical trial","score_opus":0.028782846873924205,"score_gpt":0.35307287331456155,"score_spread":0.32429002644063737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385727291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998267,0.000113983806,0.000017591896,0.00002418101,0.000010310655,0.0012230992,0.00017364282,0.00002334013,0.00014682797],"genre_scores_gemma":[0.9990831,0.000019552534,0.00029188246,0.000002543463,0.000004379718,0.00009217301,0.00043424478,0.000021828226,0.000050319883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981942,0.00015431034,0.0005328862,0.0002967747,0.0005737672,0.0002480308],"domain_scores_gemma":[0.99885917,0.0001911506,0.00018673716,0.00039710547,0.00025964747,0.000106208645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002316916,0.0001605059,0.0008804169,0.0007011952,0.000017787941,0.000004851443,0.000107647036,0.00006417835,0.00015628908],"category_scores_gemma":[0.00017726963,0.0001292798,0.00008402515,0.0024218692,0.00006293457,0.000084659965,0.00005427338,0.00013124805,0.0000021971769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0107706655,0.006240403,0.9505344,0.00034611777,0.0007415608,0.00060979964,0.01495239,0.0002949185,0.0015184424,0.0000066065772,0.0000146325265,0.013970083],"study_design_scores_gemma":[0.052216582,0.0153069,0.86137044,0.0003332386,0.0004091465,0.000001396012,0.055130128,0.0043657613,0.010756152,0.0000038402686,0.0000056640515,0.00010073617],"about_ca_topic_score_codex":0.0044854726,"about_ca_topic_score_gemma":0.059213456,"teacher_disagreement_score":0.08916392,"about_ca_system_score_codex":0.00017846022,"about_ca_system_score_gemma":0.00013573546,"threshold_uncertainty_score":0.95795345},"labels":[],"label_agreement":null},{"id":"W4385791443","doi":"10.1111/ejh.14082","title":"Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; University of British Columbia; Memorial University of Newfoundland; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Dalhousie University; Saskatchewan Cancer Agency; Ottawa Hospital; CancerCare Manitoba; McGill University; London Health Sciences Centre; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of Calgary; BC Cancer Agency; McGill University Health Centre; Jewish General Hospital; Alberta Cancer Foundation; Canadian Institutes of Health Research; Juravinski Cancer Centre; Université de Montréal; Western University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Daratumumab; Carfilzomib; Medicine; Multiple myeloma; Oncology; Internal medicine; Lenalidomide","score_opus":0.10225996986042807,"score_gpt":0.3763843437896896,"score_spread":0.27412437392926153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385791443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470747,0.00045960062,0.00009234618,0.0021928304,0.00012761241,0.00077988376,0.00019703533,0.000032999324,0.0014102119],"genre_scores_gemma":[0.9967102,0.00003342704,0.002171934,0.0001307538,0.00007417643,0.000046811285,0.00025605335,0.00008368097,0.0004929711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992513,0.0029960037,0.0016376497,0.0005584438,0.00097170786,0.0013231748],"domain_scores_gemma":[0.9957939,0.0009597884,0.00044232627,0.001028693,0.000652678,0.0011226203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038687398,0.00039151084,0.0016856705,0.0064843344,0.0001812789,0.00003530846,0.00043165186,0.00011491338,0.00029020972],"category_scores_gemma":[0.001611784,0.00030261264,0.0006270285,0.0034844,0.00040188347,0.000115573726,0.00011316729,0.0007491862,0.00023590788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054376014,0.0007329026,0.7330555,0.00020119139,0.0013787831,0.25550565,0.00043986147,0.00021995317,0.0013467005,0.000064361724,0.0008603157,0.0007571739],"study_design_scores_gemma":[0.029962428,0.0035142004,0.94977486,0.0003961649,0.0009555331,0.0012481699,0.0007771081,0.006543698,0.002988061,0.0000133859485,0.0034772062,0.00034919367],"about_ca_topic_score_codex":0.0110142855,"about_ca_topic_score_gemma":0.06912245,"teacher_disagreement_score":0.2542575,"about_ca_system_score_codex":0.0007811518,"about_ca_system_score_gemma":0.0009526169,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4385797799","doi":"10.1016/j.clml.2023.07.014","title":"The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Stem cell; Cohort; Internal medicine; CD34; Confounding; Oncology; Overall survival; Surgery; Biology","score_opus":0.14981611638150955,"score_gpt":0.441903336462083,"score_spread":0.2920872200805735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385797799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17749746,0.79518104,0.000054698852,0.00024078222,0.0032671313,0.017888198,0.0029500204,0.0005804085,0.0023402635],"genre_scores_gemma":[0.050730873,0.9428297,0.00015681681,0.000027207607,0.000392044,0.0013653666,0.00082479144,0.00026743667,0.0034057267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9921139,0.000996556,0.00336008,0.0012718154,0.0008669341,0.0013906965],"domain_scores_gemma":[0.97406054,0.022701126,0.0010012514,0.0013763185,0.00024027623,0.00062047254],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022276298,0.0010993788,0.0056041563,0.0006157937,0.00035849086,0.00006456711,0.0007458583,0.0015725303,0.000030738844],"category_scores_gemma":[0.0041488716,0.0006296251,0.004486712,0.001094651,0.0004898243,0.00006404783,0.00014180398,0.0009662747,0.00026141392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003064892,0.0010121042,0.023902303,0.0051404317,0.002001177,0.00054886343,0.000045423396,0.0000071174013,0.0000018487173,0.000030431296,0.001437507,0.9628079],"study_design_scores_gemma":[0.01691085,0.006542316,0.90357435,0.008994675,0.0015201794,0.00012913793,0.000042046773,0.0014863285,0.000021073518,0.00011428512,0.0598226,0.00084213977],"about_ca_topic_score_codex":0.0011768364,"about_ca_topic_score_gemma":0.000678292,"teacher_disagreement_score":0.96196574,"about_ca_system_score_codex":0.0030082143,"about_ca_system_score_gemma":0.005601541,"threshold_uncertainty_score":0.9997236},"labels":[],"label_agreement":null},{"id":"W4385839624","doi":"10.1038/s41591-023-02528-9","title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Genentech; Cilag; Astellas Pharma; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Adaptive Biotechnologies; Karyopharm Therapeutics; AstraZeneca España; Sanofi; Legend Biotech; Celgene; Amgen; Pfizer","keywords":"Medicine; Neutropenia; Dosing; Internal medicine; Adverse effect; Clinical endpoint; Multiple myeloma; Anemia; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Lenalidomide; Clinical trial; Surgery; Cancer; Chemotherapy; Immunotherapy; Chimeric antigen receptor","score_opus":0.044406126423372855,"score_gpt":0.39405858362650675,"score_spread":0.34965245720313387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385839624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97351557,0.0020608916,0.000004676975,0.013287325,0.0013210507,0.0027296615,0.00016838594,0.0003956866,0.0065167574],"genre_scores_gemma":[0.9815276,0.00069081306,0.00028564816,0.0006876926,0.0014530225,0.0001716763,0.0015344404,0.0000671523,0.013581922],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99594927,0.00020224895,0.0008383038,0.00078162167,0.0013637476,0.0008648054],"domain_scores_gemma":[0.9970019,0.0012474367,0.00015678872,0.00084136816,0.00018380872,0.0005687275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001254242,0.00038763092,0.000877186,0.0010871406,0.00011240529,0.000012176951,0.0002512403,0.00066041347,0.0007267564],"category_scores_gemma":[0.011599,0.00024304293,0.0001227824,0.002092904,0.00022889601,0.000092177506,0.00009013349,0.0018964541,0.0003617248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68698514,0.002437099,0.0019275163,0.0002741806,0.00024804077,0.021144165,0.00097297446,0.000002454734,0.0105044525,0.00004959271,0.13176315,0.14369123],"study_design_scores_gemma":[0.81483597,0.013955573,0.046745308,0.0007670383,0.00013564657,0.00013024488,0.0004333279,0.0017807382,0.0014611889,0.00006706626,0.11937481,0.00031308128],"about_ca_topic_score_codex":0.00028840132,"about_ca_topic_score_gemma":0.0004567606,"teacher_disagreement_score":0.14337814,"about_ca_system_score_codex":0.000274236,"about_ca_system_score_gemma":0.00033479338,"threshold_uncertainty_score":0.9967267},"labels":[],"label_agreement":null},{"id":"W4385851839","doi":"10.3324/haematol.2023.283073","title":"Isatuximab plus carfilzomib and dexamethasone in patients with early &lt;i&gt;versus&lt;/i&gt; late relapsed multiple myeloma: IKEMA subgroup analysis","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Sanofi","keywords":"Carfilzomib; Multiple myeloma; Subgroup analysis; Dexamethasone; Oncology; Internal medicine; Medicine; Lenalidomide; Meta-analysis","score_opus":0.024619686835252442,"score_gpt":0.2661916376063397,"score_spread":0.24157195077108723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385851839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963289,0.0003387727,0.000033497217,0.0002792605,0.00008901201,0.0012824469,0.00008074958,0.00024962405,0.0013177593],"genre_scores_gemma":[0.99610597,0.000151445,0.0016825629,0.000046678168,0.000020686624,0.00019983729,0.00042713512,0.000049683716,0.0013159915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645364,0.00023955482,0.00052294193,0.0009163342,0.00085552846,0.0010120085],"domain_scores_gemma":[0.99765456,0.0007157367,0.00022668704,0.0007107554,0.00019982817,0.0004924415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037454872,0.0004528501,0.0013249241,0.0009695379,0.00020968635,0.0000618236,0.00020030314,0.000284527,0.00021494502],"category_scores_gemma":[0.00086646754,0.00032028754,0.00020833436,0.0027499462,0.0002870525,0.00017883301,0.00021714483,0.00035354175,0.00024461854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009098525,0.00057343376,0.9826903,0.000120815144,0.0016041563,0.0022375192,0.00057280174,0.00004537847,0.0003540913,0.00011285521,0.00041623903,0.002173927],"study_design_scores_gemma":[0.03318387,0.0014435239,0.9602155,0.00008315224,0.0006208605,0.000014897765,0.00006664313,0.0034901132,0.00015719121,0.000032085805,0.00036656615,0.00032558068],"about_ca_topic_score_codex":0.00023380145,"about_ca_topic_score_gemma":0.00149624,"teacher_disagreement_score":0.024085341,"about_ca_system_score_codex":0.00022274851,"about_ca_system_score_gemma":0.00010276519,"threshold_uncertainty_score":0.9999249},"labels":[],"label_agreement":null},{"id":"W4386005974","doi":"","title":"Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immune checkpoint; Immune system; Immunology; Immunotherapy","score_opus":0.3934830169263524,"score_gpt":0.6010278940586667,"score_spread":0.20754487713231434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386005974","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049890812,0.98728824,0.00001702964,0.00028902627,0.00018681136,0.010020194,0.0002904321,0.000041358515,0.0018170263],"genre_scores_gemma":[0.0007644476,0.9970043,0.00014203631,0.00015162658,0.00013974316,0.0011569111,0.00028785432,0.00016197276,0.00019112689],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99088734,0.0012179652,0.0050076605,0.00080846046,0.0015320946,0.0005464837],"domain_scores_gemma":[0.99037415,0.0011782013,0.0051312977,0.0017987895,0.0007405435,0.0007770357],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017074652,0.0008880417,0.009781225,0.0011692612,0.00016418195,0.0003438513,0.0032064524,0.0002336951,0.0031815348],"category_scores_gemma":[0.0039597745,0.00063318777,0.0022974461,0.002350617,0.0002030067,0.00059993175,0.0014744282,0.0011598316,0.0001962094],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053218693,0.0006863295,0.0005631285,0.93650055,0.0026276193,0.00038657934,0.000021426724,1.7102457e-7,0.00048048652,0.000011192853,0.005232957,0.05343635],"study_design_scores_gemma":[0.00077566446,0.000055339755,0.0020102107,0.8989513,0.007131039,0.00077894214,0.000009488481,0.0000077074565,0.00020892557,0.000076129276,0.08951696,0.00047832646],"about_ca_topic_score_codex":0.00032801263,"about_ca_topic_score_gemma":0.0000025977147,"teacher_disagreement_score":0.084284,"about_ca_system_score_codex":0.00035446335,"about_ca_system_score_gemma":0.0010628548,"threshold_uncertainty_score":0.9996119},"labels":[],"label_agreement":null},{"id":"W4386024051","doi":"10.1097/01.hs9.0000967672.15362.d7","title":"S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Regimen; Expanded access","score_opus":0.014696673516677618,"score_gpt":0.24480891604604155,"score_spread":0.23011224252936394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944704,0.00035525966,0.0000040324967,0.00052668614,0.00006877521,0.002956595,0.00026839596,0.0002853915,0.0010644476],"genre_scores_gemma":[0.9967368,0.00008898172,0.0006457355,0.000077570905,0.00012799418,0.00022727017,0.0006658407,0.00012268,0.0013071216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960447,0.00022310927,0.00062870426,0.0010801993,0.001150272,0.00087304285],"domain_scores_gemma":[0.9963909,0.0018363069,0.000234145,0.00091282686,0.00025902165,0.0003668171],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046293778,0.00053069164,0.0006695639,0.00012650175,0.00044748583,0.00009587134,0.0002492635,0.0001730388,0.000107813175],"category_scores_gemma":[0.0016700076,0.00031260354,0.00007173914,0.000952916,0.00022738277,0.00020149363,0.00021510561,0.00070714054,0.00013798253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01782329,0.0021231573,0.95226103,0.000097942735,0.0004675698,0.0040194225,0.004471352,0.0001773256,0.00012515996,0.0000014746919,0.002158739,0.016273526],"study_design_scores_gemma":[0.053766362,0.005357316,0.9232613,0.0007437002,0.00015593416,0.000029246465,0.0075006126,0.0031098046,0.00026640686,0.000009145233,0.005312648,0.0004875083],"about_ca_topic_score_codex":0.003953477,"about_ca_topic_score_gemma":0.013843854,"teacher_disagreement_score":0.035943072,"about_ca_system_score_codex":0.00027202288,"about_ca_system_score_gemma":0.00015174321,"threshold_uncertainty_score":0.9999326},"labels":[],"label_agreement":null},{"id":"W4386041116","doi":"","title":"Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics","year":2020,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Cytogenetics; Refractory (planetary science); Internal medicine; Oncology; Biology; Genetics","score_opus":0.1438549890008277,"score_gpt":0.4387859976716153,"score_spread":0.2949310086707876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386041116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411607,0.0028735753,0.00021567421,0.0002333781,0.00008292073,0.0019982483,0.00022425286,0.00004917927,0.00020668512],"genre_scores_gemma":[0.9945575,0.0028961117,0.0017399054,0.00022707261,0.00013161852,0.000081540675,0.00018745849,0.00013097656,0.00004779688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99510384,0.00041855205,0.0010408273,0.00091516704,0.0016603915,0.0008612197],"domain_scores_gemma":[0.99654645,0.00041835225,0.00091937615,0.0005603149,0.0004018544,0.0011536538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006574157,0.0006443042,0.0012734961,0.00076503225,0.000330734,0.00047144867,0.0008758353,0.0001704315,0.0010281879],"category_scores_gemma":[0.00041046512,0.00046769457,0.00012788572,0.0010427717,0.00025381387,0.0009687964,0.0009920532,0.0008899219,0.000013872678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012488435,0.002113527,0.9468823,0.00020644652,0.00080063345,0.00068640383,0.0005206299,0.00013473768,0.009827368,0.0000021959631,0.0008047679,0.025532553],"study_design_scores_gemma":[0.018170612,0.0014713578,0.964566,0.0010592474,0.0003010458,0.00003292001,0.000121113786,0.00028833453,0.012933505,0.000037136106,0.0005123548,0.000506386],"about_ca_topic_score_codex":0.0020512734,"about_ca_topic_score_gemma":0.0006191035,"teacher_disagreement_score":0.025026167,"about_ca_system_score_codex":0.00048359952,"about_ca_system_score_gemma":0.0002882944,"threshold_uncertainty_score":0.999885},"labels":[],"label_agreement":null},{"id":"W4386052329","doi":"10.1097/01.hs9.0000970512.51896.93","title":"P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Internal medicine; Multiple myeloma; Lenalidomide; Dexamethasone; Adverse effect; Oncology; Gastroenterology","score_opus":0.10469259072811767,"score_gpt":0.41219825223623924,"score_spread":0.3075056615081216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893883,0.0014747715,0.00008161266,0.002338929,0.00020704576,0.0027663198,0.00087660295,0.00023360139,0.002632851],"genre_scores_gemma":[0.9804574,0.00096787384,0.003581372,0.00040179896,0.0005263924,0.0005622405,0.0013416256,0.00008581524,0.012075459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99798006,0.00009340203,0.0003978259,0.0006213905,0.00036788176,0.0005394193],"domain_scores_gemma":[0.9980077,0.00085462077,0.00010071064,0.0005367277,0.000106096915,0.00039414715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036911035,0.0002760583,0.0005594388,0.00009059879,0.00012917696,0.00006266641,0.000114824004,0.00015690297,0.0005705675],"category_scores_gemma":[0.0010358538,0.00021230093,0.0001783676,0.00029984393,0.000098944976,0.000096079486,0.00007628425,0.00020390374,0.00027528233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46400905,0.0022935271,0.000702156,0.000151414,0.0012320937,0.0010377351,0.0020378565,5.991328e-7,0.038727347,0.000085766704,0.06764376,0.4220787],"study_design_scores_gemma":[0.82021606,0.011248103,0.0036937026,0.00032450026,0.00017024619,0.000037720998,0.001787453,0.0014262593,0.035611268,0.0010728467,0.12396225,0.00044958925],"about_ca_topic_score_codex":0.0008749697,"about_ca_topic_score_gemma":0.00009959506,"teacher_disagreement_score":0.42162913,"about_ca_system_score_codex":0.00007538156,"about_ca_system_score_gemma":0.0001741117,"threshold_uncertainty_score":0.8657381},"labels":[],"label_agreement":null},{"id":"W4386052515","doi":"10.1097/01.hs9.0000970592.64148.2c","title":"P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Population; Logistic regression; Multiple myeloma; Inverse probability weighting; Internal medicine; Relative risk; Propensity score matching; Confidence interval; Environmental health","score_opus":0.12420305222523104,"score_gpt":0.4449858585240313,"score_spread":0.32078280629880024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224126,0.0006862694,0.00007531207,0.0008932059,0.00007878327,0.0021097693,0.00009415439,0.00012075327,0.0037005164],"genre_scores_gemma":[0.9955618,0.00028381537,0.0024318406,0.000046781774,0.00014614257,0.00017590153,0.00015337166,0.000036331283,0.001164017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973436,0.0006144152,0.0005262269,0.0005015723,0.0007218535,0.00029232854],"domain_scores_gemma":[0.996821,0.001757217,0.0002727024,0.0006521479,0.00031297395,0.00018399586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057003467,0.00024303261,0.00083968445,0.00007325499,0.00017183344,0.000046360565,0.00013246218,0.0000668406,0.0002678418],"category_scores_gemma":[0.00043973816,0.00013676347,0.00013945789,0.0006564416,0.00033926193,0.00013012241,0.0001253754,0.0003725239,0.00005436533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008988771,0.0012610668,0.9784128,0.000023985878,0.004264537,0.00020149934,0.002898769,0.000019648165,0.00029092262,0.0001693399,0.001492491,0.0019761727],"study_design_scores_gemma":[0.03203022,0.0009510101,0.94038475,0.00012645514,0.0012040146,0.0000028232967,0.023179784,0.0010437864,0.0006177767,0.000104729384,0.00023032917,0.00012434213],"about_ca_topic_score_codex":0.021733519,"about_ca_topic_score_gemma":0.021993171,"teacher_disagreement_score":0.03802807,"about_ca_system_score_codex":0.00006524436,"about_ca_system_score_gemma":0.00016055614,"threshold_uncertainty_score":0.9958529},"labels":[],"label_agreement":null},{"id":"W4386074452","doi":"10.1097/01.hs9.0000970600.40043.b8","title":"P924: TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Pediatrics","score_opus":0.0849770091517209,"score_gpt":0.35531216676179295,"score_spread":0.27033515761007204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938963,0.0009090441,9.518878e-7,0.0019676804,0.00006510081,0.0021671336,0.0005381789,0.00007066639,0.00038493026],"genre_scores_gemma":[0.94034815,0.008534027,0.000019574143,0.0006586087,0.000072044284,0.00032204887,0.0013866293,0.00006066477,0.04859827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755967,0.00023097932,0.0005360613,0.0004298563,0.0007380804,0.0005053492],"domain_scores_gemma":[0.99807566,0.0005137555,0.00019525575,0.0006339857,0.0002973741,0.00028396185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033425342,0.00031526553,0.0006020257,0.0000652025,0.00020523445,0.000025315541,0.00015456564,0.000039802904,0.00019716118],"category_scores_gemma":[0.00020570183,0.00019685771,0.00008398454,0.00075405533,0.000080086225,0.00007054484,0.0001331945,0.00018108638,0.00003286461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027780706,0.0005574554,0.98647904,0.00069837604,0.0004929728,0.0005864354,0.000696496,0.0000056049516,0.00006319829,0.000009828792,0.0048244274,0.0053083827],"study_design_scores_gemma":[0.004358725,0.0007590537,0.91766167,0.0007305217,0.00013714499,0.000015440717,0.0007663649,0.00029794715,0.00012866981,0.000002642877,0.07499481,0.00014699029],"about_ca_topic_score_codex":0.39241314,"about_ca_topic_score_gemma":0.7832732,"teacher_disagreement_score":0.3908601,"about_ca_system_score_codex":0.00031973497,"about_ca_system_score_gemma":0.0005045729,"threshold_uncertainty_score":0.80276245},"labels":[],"label_agreement":null},{"id":"W4386074681","doi":"10.1097/01.hs9.0000970832.89903.8f","title":"P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Refractory (planetary science); Bortezomib; Internal medicine; Gastroenterology; Oncology","score_opus":0.029152733148670517,"score_gpt":0.30257578674165714,"score_spread":0.27342305359298663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754983,0.00075872336,0.000015704882,0.00047598634,0.0000143952775,0.00093705714,0.00002750947,0.000030569496,0.00019020712],"genre_scores_gemma":[0.9957427,0.0007161667,0.0028051955,0.000020199832,0.000013751086,0.000038054655,0.000047561913,0.00002904798,0.0005873321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984756,0.00013572167,0.0004259776,0.0003502127,0.00031898078,0.00029348192],"domain_scores_gemma":[0.9983729,0.0009856769,0.00013891839,0.00024268938,0.00009676376,0.00016305788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042207117,0.00018307366,0.00055162964,0.00018789066,0.00003791312,0.000007642125,0.000051233314,0.00012121943,0.00004118807],"category_scores_gemma":[0.0008731886,0.0001366574,0.000023651104,0.00055799703,0.00018347113,0.00009192094,0.00007471309,0.00022174645,0.0000030860604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036008187,0.0012074689,0.8495439,0.0013804499,0.00016663462,0.00080854783,0.001816017,0.00003058249,0.034147505,0.00006193488,0.00010892123,0.07471982],"study_design_scores_gemma":[0.03968877,0.0017166116,0.9461095,0.0010847453,0.00003554824,0.00004228012,0.0008873795,0.0055742217,0.0045568766,0.000024946996,0.00014984635,0.0001293029],"about_ca_topic_score_codex":0.0007494027,"about_ca_topic_score_gemma":0.0017277085,"teacher_disagreement_score":0.09656554,"about_ca_system_score_codex":0.00007103496,"about_ca_system_score_gemma":0.0001247949,"threshold_uncertainty_score":0.5572727},"labels":[],"label_agreement":null},{"id":"W4386101150","doi":"10.1097/01.hs9.0000975152.94267.34","title":"PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Confidence interval; Observational study; MEDLINE; Oncology; Malignancy; Multivariate analysis; Clinical trial; Refractory (planetary science); Intensive care medicine","score_opus":0.03682725364071148,"score_gpt":0.31982114756770513,"score_spread":0.28299389392699364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386101150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6229025,0.35136864,0.00016566274,0.0009565694,0.0005262025,0.020145714,0.0006190187,0.0007272528,0.0025884672],"genre_scores_gemma":[0.9646528,0.022926057,0.001288401,0.00017986678,0.0001247172,0.0013046911,0.0012283784,0.000101009806,0.008194072],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99797904,0.00010221559,0.00057668047,0.00034897582,0.00053404464,0.0004590471],"domain_scores_gemma":[0.9973895,0.0011909235,0.0002051519,0.00057366624,0.00037286684,0.00026787567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033321974,0.0002661146,0.0008887909,0.00011372772,0.00008141246,0.000018073066,0.00013705925,0.00014385257,0.0001784552],"category_scores_gemma":[0.0050835637,0.00017814524,0.00035261104,0.0007278178,0.000049503455,0.00009944198,0.000051761876,0.00019609256,0.00016211746],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002119892,0.00037593732,0.039536662,0.94276834,0.0004708833,0.00029963837,0.00049213704,6.3884437e-7,0.0013642428,0.000084973515,0.013130765,0.001263775],"study_design_scores_gemma":[0.007987758,0.002047181,0.06378498,0.91250145,0.00096150395,0.00014160837,0.0010315656,0.0010307584,0.0050253505,0.00008992395,0.0048812237,0.0005167144],"about_ca_topic_score_codex":0.0000063754674,"about_ca_topic_score_gemma":0.000007490466,"teacher_disagreement_score":0.34175032,"about_ca_system_score_codex":0.00007986255,"about_ca_system_score_gemma":0.00012924896,"threshold_uncertainty_score":0.7264553},"labels":[],"label_agreement":null},{"id":"W4386152079","doi":"10.1002/cncr.34987","title":"Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Seagen; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Pharmacyclics; Genentech; Legend Biotech; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Adverse effect; Clinical endpoint; Anemia; Gastroenterology; Quality of life (healthcare); Clinical trial; Surgery","score_opus":0.04513348790059476,"score_gpt":0.30608748209505837,"score_spread":0.26095399419446363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386152079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982076,0.00010328427,0.00000249719,0.00016924973,0.00015950264,0.00089646643,0.00015005603,0.000026897034,0.0002844219],"genre_scores_gemma":[0.99835503,0.00003790052,0.00003352353,0.000046598205,0.000060020247,0.00013836395,0.00016744625,0.000020811758,0.001140308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983875,0.00008518219,0.00028341828,0.00028568914,0.0006136952,0.00034447803],"domain_scores_gemma":[0.9991101,0.00014079521,0.00012123052,0.00039606678,0.00011512003,0.000116677955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013960683,0.00014690819,0.00040289966,0.00036317736,0.000059566628,0.000008613955,0.00012340286,0.00006971059,0.0002392188],"category_scores_gemma":[0.00019384382,0.000087384156,0.0001688078,0.0016903975,0.00009218366,0.000047814257,0.000067419016,0.00018841497,0.000020289153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02254727,0.00081497745,0.9630261,0.000033625387,0.00096058997,0.000037230042,0.00019430128,0.00013054669,0.00029969882,0.0000021270623,0.00043833742,0.011515216],"study_design_scores_gemma":[0.061895736,0.00067965675,0.93468225,0.00010449905,0.00051279686,2.7623713e-7,0.000044410506,0.0004802072,0.0008074551,0.0000017692411,0.00070879376,0.000082130464],"about_ca_topic_score_codex":0.00061834906,"about_ca_topic_score_gemma":0.0014241972,"teacher_disagreement_score":0.039348464,"about_ca_system_score_codex":0.00033017938,"about_ca_system_score_gemma":0.000184508,"threshold_uncertainty_score":0.35634223},"labels":[],"label_agreement":null},{"id":"W4386202664","doi":"10.1038/s41408-023-00888-6","title":"Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; McGill University; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; Juravinski Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Medicine; Attrition; Internal medicine; Oncology; Family medicine","score_opus":0.09519958533312171,"score_gpt":0.37304994375816725,"score_spread":0.2778503584250455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386202664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25908455,0.18880905,0.00016640336,0.04400514,0.23161167,0.014449402,0.006604274,0.0014801921,0.2537893],"genre_scores_gemma":[0.59013224,0.03190238,0.00059807155,0.0003883135,0.016720021,0.0013643635,0.005096579,0.00052497385,0.35327306],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9919568,0.0007981759,0.0011295844,0.0010904756,0.0026758432,0.0023491764],"domain_scores_gemma":[0.9952602,0.00045408733,0.0003733462,0.0007617282,0.0010849356,0.0020656951],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002527209,0.0006289103,0.001509213,0.008450868,0.0012039565,0.00040495122,0.000510176,0.0010329353,0.0016004395],"category_scores_gemma":[0.0017262569,0.0005977854,0.0007726727,0.006943825,0.00021770172,0.00021916571,0.00015162153,0.0072371275,0.0002343679],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00064378243,0.0003924074,0.1610242,0.0002442856,0.005821531,0.013539818,0.00039980205,0.000052138035,0.0000706664,0.000005708879,0.7906758,0.027129857],"study_design_scores_gemma":[0.011105534,0.0013393357,0.7303987,0.005448794,0.0035451355,0.00187918,0.0011820549,0.0049350755,0.00008343828,0.00009178252,0.23911184,0.0008791103],"about_ca_topic_score_codex":0.34100294,"about_ca_topic_score_gemma":0.88146967,"teacher_disagreement_score":0.5693745,"about_ca_system_score_codex":0.004245675,"about_ca_system_score_gemma":0.0070222365,"threshold_uncertainty_score":0.9996474},"labels":[],"label_agreement":null},{"id":"W4386219363","doi":"10.3390/curroncol30090573","title":"SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; American Society of Hematology","keywords":"Medicine; Multiple myeloma; Clinical trial; Malignancy; Oncology; Bioinformatics; Intensive care medicine; Internal medicine; Biology","score_opus":0.367567180830054,"score_gpt":0.5224180796068416,"score_spread":0.1548508987767876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386219363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009889697,0.99148,0.0000046807795,0.000070328875,0.00095215556,0.0051087085,0.00010144035,0.0001735044,0.0011202372],"genre_scores_gemma":[0.00013378628,0.99349636,0.00028434535,0.000019891899,0.00029360747,0.0022139212,0.0014477271,0.00018194775,0.0019284085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958075,0.0006060179,0.0010838761,0.00094093126,0.0004679487,0.001093692],"domain_scores_gemma":[0.99770653,0.00077164953,0.00038044207,0.0006912608,0.0000899959,0.0003601014],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038576053,0.0007606281,0.0032690517,0.0009968049,0.000116952644,0.00003234496,0.0003063964,0.00059514475,0.00030347804],"category_scores_gemma":[0.00047299804,0.00056878536,0.00072780665,0.0008823758,0.00015689174,0.00006606157,0.00019914834,0.0010650182,0.0032366852],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024293535,0.001920198,0.0018854347,0.010754403,0.0011958602,0.0014982915,0.00015592318,1.1832688e-7,0.0000029057842,0.000012423329,0.00022354757,0.98210794],"study_design_scores_gemma":[0.0070800595,0.0011863343,0.0009819139,0.015564014,0.0010452914,0.00032732543,0.000032808905,0.00007491736,0.0000037885209,0.000087905246,0.9732476,0.00036807836],"about_ca_topic_score_codex":0.0001115793,"about_ca_topic_score_gemma":0.000065763365,"teacher_disagreement_score":0.9817399,"about_ca_system_score_codex":0.002557664,"about_ca_system_score_gemma":0.0022118238,"threshold_uncertainty_score":0.99967635},"labels":[],"label_agreement":null},{"id":"W4386270668","doi":"10.1016/s2152-2650(23)00826-1","title":"POSTER: MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)- Directed Therapies: Pooled Analysis From MagnetisMM Studies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Safety profile; Internal medicine; Adverse effect; Biology","score_opus":0.02350944719620967,"score_gpt":0.31043864061616494,"score_spread":0.28692919341995526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445474,0.0030488768,0.000007650706,0.00022218528,0.00011181689,0.0015637476,0.00029000366,0.00018959929,0.00011138457],"genre_scores_gemma":[0.9932554,0.004099981,0.0009516068,0.00011782451,0.00008167425,0.000056510875,0.0011281668,0.00007213674,0.00023670238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954052,0.000536386,0.001480319,0.0011283346,0.0007988259,0.00065093994],"domain_scores_gemma":[0.9947768,0.003072633,0.00048945437,0.0008028805,0.00040633217,0.000451914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006390612,0.00053352595,0.0017183962,0.00067838986,0.0001963314,0.00005231131,0.00020864885,0.00038369946,0.00005807963],"category_scores_gemma":[0.0013528205,0.0003986337,0.00024458545,0.00154992,0.0005943908,0.00026028376,0.00026598756,0.0003378327,0.000037815742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014504762,0.0007083429,0.68348664,0.00011299608,0.0028414037,0.0001868739,0.0007657928,0.000003160685,0.0004069715,0.0000018901897,0.00009183591,0.2968893],"study_design_scores_gemma":[0.045602597,0.0019291932,0.94846046,0.0003406929,0.0011332261,0.0000033608626,0.00034712773,0.001273229,0.00032642303,0.000026146912,0.00019995085,0.00035757976],"about_ca_topic_score_codex":0.0005534695,"about_ca_topic_score_gemma":0.00041230154,"teacher_disagreement_score":0.29653174,"about_ca_system_score_codex":0.0004185355,"about_ca_system_score_gemma":0.00036740073,"threshold_uncertainty_score":0.9998466},"labels":[],"label_agreement":null},{"id":"W4386270699","doi":"10.1016/s2152-2650(23)01449-0","title":"MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Materials science; Metallurgy","score_opus":0.027328453517233554,"score_gpt":0.3056269084531221,"score_spread":0.27829845493588856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567837,0.00026269702,0.000023654822,0.00031857035,0.0004289757,0.002187773,0.0004057687,0.00035427063,0.0003399185],"genre_scores_gemma":[0.99518245,0.00077491865,0.0012634576,0.00019167794,0.00018999408,0.00023879828,0.0013167732,0.00018721954,0.00065468496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902851,0.0011729097,0.00253472,0.0022334557,0.0019028425,0.0018709825],"domain_scores_gemma":[0.9914634,0.004049616,0.0007809286,0.0018324149,0.0004462291,0.0014273904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024346204,0.00097341335,0.0026565103,0.001987782,0.00030845683,0.00012642935,0.00051268924,0.0008773095,0.00013592016],"category_scores_gemma":[0.004804746,0.000819314,0.0006285254,0.0049888515,0.0006893787,0.00043740348,0.00043538652,0.0011124717,0.00026957982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055893112,0.0010504378,0.8021967,0.00008187265,0.0018566973,0.002193887,0.00028791634,0.000055152817,0.00013360397,0.00001828254,0.0005512289,0.13568111],"study_design_scores_gemma":[0.12196802,0.0057332213,0.86572856,0.00023648563,0.0009337266,0.000007205397,0.00022175361,0.0030893344,0.00032934712,0.000057506844,0.0009927565,0.00070205407],"about_ca_topic_score_codex":0.0017724517,"about_ca_topic_score_gemma":0.0051811575,"teacher_disagreement_score":0.13497904,"about_ca_system_score_codex":0.0033658072,"about_ca_system_score_gemma":0.001524824,"threshold_uncertainty_score":0.99942577},"labels":[],"label_agreement":null},{"id":"W4386270891","doi":"10.1016/s2152-2650(23)00857-1","title":"POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Antibody; Medicine; Refractory (planetary science); Bispecific antibody; Antigen; Cancer research; Virology; Immunology; Materials science; Monoclonal antibody","score_opus":0.03199682874755631,"score_gpt":0.3220475571111516,"score_spread":0.2900507283635953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946215,0.0003719043,0.000021649012,0.00016692898,0.0008751867,0.0022904933,0.00047411243,0.00031559085,0.0008626472],"genre_scores_gemma":[0.9912631,0.00057754974,0.0006182293,0.00015504251,0.00033673184,0.00010422099,0.0053580864,0.00020167558,0.0013853532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924378,0.00053523557,0.0023397307,0.0016578044,0.001692932,0.0013365435],"domain_scores_gemma":[0.99420685,0.0016767017,0.00084263267,0.00184211,0.00058225193,0.0008494516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008115043,0.00081811915,0.0017711811,0.0008147031,0.00021993366,0.00010568639,0.00064559764,0.0008289699,0.00021908252],"category_scores_gemma":[0.0011314482,0.0006704538,0.0005963391,0.0015516847,0.00060498115,0.0004957821,0.0004106535,0.00073095656,0.0008870357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016964773,0.0017222771,0.8553568,0.00023195297,0.00036478788,0.001521417,0.00021827675,0.0000027490291,0.0033135985,0.00000536988,0.00078220194,0.119515814],"study_design_scores_gemma":[0.050092112,0.0026345262,0.94161123,0.0009838691,0.00016281173,0.00001715214,0.000089044064,0.00034861622,0.002809874,0.000034480938,0.0006153207,0.00060095027],"about_ca_topic_score_codex":0.0006756799,"about_ca_topic_score_gemma":0.00045834953,"teacher_disagreement_score":0.118914865,"about_ca_system_score_codex":0.0011921509,"about_ca_system_score_gemma":0.0013212119,"threshold_uncertainty_score":0.99989086},"labels":[],"label_agreement":null},{"id":"W4386270978","doi":"10.1016/s2152-2650(23)00864-9","title":"POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"TEC; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Materials science; Geology; Metallurgy","score_opus":0.022460602139336257,"score_gpt":0.28669273690375563,"score_spread":0.26423213476441937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295175,0.00027964954,0.0000030014771,0.0008657625,0.00026884684,0.00397028,0.0005629083,0.0004945914,0.00060323806],"genre_scores_gemma":[0.99594235,0.00017877146,0.00048553816,0.00037563953,0.00042267068,0.00025664188,0.0014389537,0.00022494429,0.000674484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99140424,0.00082312996,0.002163959,0.0022442173,0.0018160325,0.0015483972],"domain_scores_gemma":[0.9866208,0.009347589,0.0006834288,0.0018739621,0.00053262163,0.00094161654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018008199,0.0009898738,0.0016184733,0.00035214855,0.000713039,0.00021137294,0.0006760509,0.0005446322,0.000049191494],"category_scores_gemma":[0.0075291777,0.00061477744,0.00026327226,0.0014721256,0.00087692245,0.00037100454,0.0006176921,0.001120548,0.0002945891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038198933,0.0020897372,0.8071797,0.000057296482,0.00069300213,0.0049537797,0.0012935513,0.000041536117,0.000033380868,0.0000016043417,0.0012185617,0.14423893],"study_design_scores_gemma":[0.07196919,0.007858971,0.9115982,0.0006617952,0.00026738466,0.0000480194,0.0011160261,0.0020607389,0.000063789936,0.000015449375,0.0036732124,0.00066719565],"about_ca_topic_score_codex":0.0030375111,"about_ca_topic_score_gemma":0.0039801844,"teacher_disagreement_score":0.14357173,"about_ca_system_score_codex":0.0012226513,"about_ca_system_score_gemma":0.00089429534,"threshold_uncertainty_score":0.99963033},"labels":[],"label_agreement":null},{"id":"W4386271025","doi":"10.1016/s2152-2650(23)00863-7","title":"POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Alberta Health Services; University of Calgary; McGill University; Institute of Cancer Research; McGill University Health Centre","funders":"","keywords":"Dexamethasone; Medicine; Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Phase (matter); Materials science; Chemistry; Composite material","score_opus":0.08768596957785604,"score_gpt":0.38017107697080915,"score_spread":0.2924851073929531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98769337,0.00070730405,0.0000068507634,0.0027919696,0.0019936443,0.004097102,0.0010218094,0.00030474467,0.0013832102],"genre_scores_gemma":[0.9920034,0.00061750214,0.00038472711,0.0009920239,0.0014969094,0.00030612742,0.0011967379,0.00018275398,0.002819827],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98800516,0.0024226317,0.003895477,0.0018873351,0.002142604,0.0016468178],"domain_scores_gemma":[0.9761642,0.017761514,0.0012162507,0.003518293,0.00040225353,0.00093746587],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004450195,0.0009257845,0.0022070408,0.00038515803,0.0004905802,0.00010015597,0.0015575635,0.0010948326,0.00015827818],"category_scores_gemma":[0.02131494,0.0005642071,0.0013087073,0.0019846412,0.0013162823,0.00026449445,0.0010676142,0.0014961162,0.00086235924],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33021864,0.007844941,0.025867954,0.00009599286,0.0009699994,0.001971543,0.001291354,0.000039281407,0.004261592,0.000029461924,0.012686728,0.6147225],"study_design_scores_gemma":[0.42807335,0.0023834396,0.5524653,0.0005652939,0.00027235554,0.000042009247,0.00028570657,0.0042238208,0.002237172,0.0001657596,0.008869586,0.0004162219],"about_ca_topic_score_codex":0.0049220426,"about_ca_topic_score_gemma":0.0014517793,"teacher_disagreement_score":0.6143063,"about_ca_system_score_codex":0.0023128306,"about_ca_system_score_gemma":0.004484211,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W4386271028","doi":"10.1016/s2152-2650(23)01446-5","title":"MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Pomalidomide; Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Refractory (planetary science); Oncology; Materials science","score_opus":0.07187944943131912,"score_gpt":0.405540219406015,"score_spread":0.33366076997469585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879542,0.0024257845,0.000039411043,0.00029274463,0.00073657616,0.0069310493,0.00019232472,0.00043235757,0.000995543],"genre_scores_gemma":[0.99186987,0.0028840855,0.0018773641,0.0002045179,0.00041334215,0.0009533378,0.00029484066,0.00026292625,0.0012397182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.985494,0.0030613863,0.0047557238,0.0027313586,0.0018765766,0.0020809236],"domain_scores_gemma":[0.97186977,0.022097785,0.0014313147,0.0020836482,0.0005517325,0.001965727],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0081800185,0.0014205768,0.0059431177,0.0015598139,0.0004127841,0.00017022593,0.00071589055,0.0009538191,0.00021656975],"category_scores_gemma":[0.018323045,0.0012233075,0.0009046718,0.0023595658,0.0021742745,0.0005423089,0.0010118228,0.0013168921,0.00010600923],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49929574,0.0055524097,0.20031954,0.00033244642,0.0026545604,0.005116345,0.0011752613,0.000030245157,0.0021886835,0.00010104363,0.0004736973,0.28276002],"study_design_scores_gemma":[0.5799948,0.0042377827,0.40035823,0.00034677758,0.0008683267,0.00008974438,0.0014892289,0.010424832,0.0008363249,0.00010161571,0.00051978877,0.0007325352],"about_ca_topic_score_codex":0.0048318366,"about_ca_topic_score_gemma":0.002169132,"teacher_disagreement_score":0.28202748,"about_ca_system_score_codex":0.0010673346,"about_ca_system_score_gemma":0.0016962303,"threshold_uncertainty_score":0.99985445},"labels":[],"label_agreement":null},{"id":"W4386271084","doi":"10.1016/s2152-2650(23)01409-x","title":"MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"Universidad de Navarra; Janssen Research and Development; Memorial Sloan-Kettering Cancer Center","keywords":"Daratumumab; Multiple myeloma; Medicine; Oncology; Internal medicine; Lenalidomide","score_opus":0.03261970465901573,"score_gpt":0.3211507475403363,"score_spread":0.2885310428813206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895535,0.00015804794,0.000008766242,0.0005837497,0.0006314872,0.002376755,0.00042883042,0.00076988613,0.00548899],"genre_scores_gemma":[0.98831356,0.00020327441,0.00073712284,0.00047998645,0.00039659065,0.00022326605,0.005146464,0.00022968961,0.004270048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99066603,0.0007160197,0.0026630107,0.0020988819,0.0018322411,0.0020238017],"domain_scores_gemma":[0.99325716,0.001942032,0.00062587217,0.0021281736,0.0005906779,0.0014560912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016235386,0.0009597037,0.001866729,0.0009270037,0.0003789156,0.00012067908,0.000699763,0.00095971354,0.00017784465],"category_scores_gemma":[0.0043116305,0.0007564749,0.00056917075,0.002854919,0.00073712587,0.0005143378,0.0004530823,0.0011437357,0.0031714987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038246647,0.0023012215,0.5652796,0.00009582041,0.00058800896,0.003481397,0.00015115287,0.00002005983,0.00012030137,0.00003328648,0.015043503,0.37463897],"study_design_scores_gemma":[0.092448354,0.0036758508,0.8797369,0.00041763895,0.00014689323,0.00003945113,0.00008347397,0.0017386036,0.00036752882,0.000044643966,0.020604419,0.00069622765],"about_ca_topic_score_codex":0.00042679653,"about_ca_topic_score_gemma":0.00029743777,"teacher_disagreement_score":0.37394276,"about_ca_system_score_codex":0.0022655304,"about_ca_system_score_gemma":0.0022839925,"threshold_uncertainty_score":0.99948865},"labels":[],"label_agreement":null},{"id":"W4386271141","doi":"10.1016/s2152-2650(23)01447-7","title":"MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Oncology; Internal medicine; Cancer research; Materials science","score_opus":0.02495679098042566,"score_gpt":0.3137765315023438,"score_spread":0.28881974052191817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946059,0.0030036552,0.000013482627,0.0001937194,0.00010994996,0.0015202636,0.0002443417,0.0002048846,0.00010381717],"genre_scores_gemma":[0.9923335,0.0044693905,0.0016080919,0.00010261305,0.00008789858,0.0000612623,0.0010156576,0.00007083121,0.00025079696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540836,0.00052318134,0.001471932,0.0011304151,0.00081264856,0.00065348187],"domain_scores_gemma":[0.9946632,0.0031909866,0.00048695147,0.00079588196,0.0004089537,0.000454073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006843034,0.0005267489,0.0017259116,0.000688314,0.00020390429,0.000048483183,0.00020594007,0.00039642633,0.000066104796],"category_scores_gemma":[0.001547957,0.00039581064,0.00024221915,0.0016959478,0.0006259212,0.0002472635,0.00024044003,0.00035018136,0.000039665403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01318626,0.000726824,0.661899,0.00011292104,0.0029512218,0.00017686693,0.00069839414,0.0000061974415,0.00035830724,0.0000029800929,0.00013269801,0.31974834],"study_design_scores_gemma":[0.045983985,0.0016916252,0.94708616,0.0003169998,0.0011223721,0.0000027102571,0.0004204479,0.0024535225,0.0002768558,0.000035599864,0.0002563503,0.00035335627],"about_ca_topic_score_codex":0.0005700039,"about_ca_topic_score_gemma":0.00042425597,"teacher_disagreement_score":0.319395,"about_ca_system_score_codex":0.00043332708,"about_ca_system_score_gemma":0.00040898015,"threshold_uncertainty_score":0.9998494},"labels":[],"label_agreement":null},{"id":"W4386271142","doi":"10.1016/s2152-2650(23)00834-0","title":"POSTER: MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-Up","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Refractory (planetary science); Observational study; Medicine; Multinational corporation; Multiple myeloma; Internal medicine; Materials science; Political science; Metallurgy","score_opus":0.0589811832027855,"score_gpt":0.3656391311726682,"score_spread":0.3066579479698827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955944,0.00014050792,0.000011379322,0.00005913872,0.0002268678,0.0026086834,0.0010022824,0.00009681909,0.00025995093],"genre_scores_gemma":[0.9965139,0.00010445272,0.0002386721,0.00002458025,0.0001037298,0.00026311187,0.0024421285,0.00006749751,0.0002419254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99291456,0.00053165155,0.002028247,0.0010762275,0.0028120177,0.0006372806],"domain_scores_gemma":[0.99368817,0.001338159,0.00081928476,0.0009814717,0.0026519778,0.0005209681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010051631,0.00048931263,0.0016435881,0.0009161027,0.00019680115,0.000023667484,0.00035700388,0.00027555946,0.00016240921],"category_scores_gemma":[0.0027732519,0.000403906,0.00057231257,0.0027711526,0.00036492595,0.00024320766,0.0003809805,0.00038352798,0.00004152915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023745414,0.0039921133,0.93267304,0.00027394205,0.0017377669,0.000095578,0.00094567065,0.00014575427,0.000013090295,0.000026189931,0.00030305295,0.036048368],"study_design_scores_gemma":[0.06433529,0.006835633,0.9256072,0.00031188794,0.00066120946,0.0000015694268,0.0006263089,0.0010353837,0.000056280205,0.0000110340325,0.00021251189,0.00030567014],"about_ca_topic_score_codex":0.0004198352,"about_ca_topic_score_gemma":0.0017941231,"teacher_disagreement_score":0.040589876,"about_ca_system_score_codex":0.0029520153,"about_ca_system_score_gemma":0.0023653773,"threshold_uncertainty_score":0.9998413},"labels":[],"label_agreement":null},{"id":"W4386271167","doi":"10.1016/s2152-2650(23)01445-3","title":"MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Hôpital du Sacré-Cœur de Montréal; Thames Valley Children's Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"","keywords":"Pomalidomide; Daratumumab; Lenalidomide; Multiple myeloma; Dexamethasone; Medicine; Oncology; Refractory (planetary science); Internal medicine; Materials science","score_opus":0.05760666670056215,"score_gpt":0.3624146327548958,"score_spread":0.3048079660543337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955311,0.00015758911,0.000005998613,0.00020956549,0.00025864775,0.0031890448,0.00037094322,0.00012142277,0.00015573138],"genre_scores_gemma":[0.99630034,0.00016085042,0.0003255473,0.00018217358,0.00014220263,0.000472412,0.00039917865,0.0001123991,0.0019048912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99218166,0.0013751587,0.0021185533,0.0015849776,0.0015766377,0.0011630299],"domain_scores_gemma":[0.99313736,0.0031989187,0.0006599502,0.001849815,0.00037764345,0.0007763094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015185239,0.0008508543,0.0025770455,0.0009158517,0.00037074042,0.000068996094,0.0004560677,0.0004251486,0.00024021641],"category_scores_gemma":[0.0022758378,0.000498886,0.00078637054,0.002855821,0.00071538327,0.00027220353,0.0005403978,0.0004989827,0.000047671183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071971856,0.008604333,0.7906348,0.000054464574,0.004410414,0.0013518217,0.0005704846,0.00003201402,0.00007573533,0.0000046696127,0.00014668466,0.12214272],"study_design_scores_gemma":[0.12666033,0.014041745,0.8529,0.00019857583,0.0024091238,0.000011109714,0.00025841882,0.0022904938,0.00014157477,0.000010898594,0.00064579246,0.0004319297],"about_ca_topic_score_codex":0.001534857,"about_ca_topic_score_gemma":0.004061507,"teacher_disagreement_score":0.121710785,"about_ca_system_score_codex":0.001622732,"about_ca_system_score_gemma":0.0013956764,"threshold_uncertainty_score":0.99974626},"labels":[],"label_agreement":null},{"id":"W4386271181","doi":"10.1016/s2152-2650(23)01403-9","title":"MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Stem cell; Oncology; Business; Medicine; Internal medicine; Biology; Cell biology","score_opus":0.03288966119194654,"score_gpt":0.3410242301994113,"score_spread":0.3081345690074648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693596,0.0008719023,0.000004758479,0.00047526107,0.00012500696,0.0013574874,0.00006450662,0.00010850244,0.000056614354],"genre_scores_gemma":[0.99844927,0.0006785274,0.000027281065,0.00014282438,0.00007664079,0.0002591733,0.000045594352,0.000047681857,0.00027302792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966423,0.0005074182,0.00079309224,0.0008316211,0.0004626092,0.0007629693],"domain_scores_gemma":[0.99805784,0.00097407325,0.00013949076,0.00040324932,0.00004707314,0.0003782977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005607279,0.00047431493,0.0011142206,0.00039494305,0.0000999359,0.0001556178,0.0001563102,0.00032057607,0.000016275908],"category_scores_gemma":[0.000092684844,0.0003400973,0.00017131258,0.00047351845,0.00028450318,0.00019963365,0.00008845504,0.00036883214,0.000013820746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016222117,0.0003788898,0.7661805,0.00014963152,0.00008498752,0.0025826688,0.0023843637,0.00000366798,0.00014525009,0.0000060134576,0.00000792885,0.22645389],"study_design_scores_gemma":[0.013491915,0.0015491326,0.9818747,0.00015938641,0.00009417743,0.000048815797,0.0016595153,0.0005753124,0.00007638552,0.00014397547,0.000029536352,0.00029714097],"about_ca_topic_score_codex":0.00074446783,"about_ca_topic_score_gemma":0.0023500165,"teacher_disagreement_score":0.22615674,"about_ca_system_score_codex":0.00037734254,"about_ca_system_score_gemma":0.00056520524,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W4386271204","doi":"10.1016/s2152-2650(23)00836-4","title":"POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Bortezomib; Multiple myeloma; Medicine; Oncology; Internal medicine","score_opus":0.04014677747190292,"score_gpt":0.3526198703852113,"score_spread":0.3124730929133084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041164,0.002015442,0.000008004207,0.00093667983,0.00024729033,0.005715408,0.00025136548,0.00018402578,0.00023012073],"genre_scores_gemma":[0.99068135,0.006591231,0.00035010983,0.00033724462,0.000103997525,0.00068560266,0.0010210812,0.000107339525,0.0001220224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99272984,0.0010750187,0.0023133727,0.0012524521,0.0016486405,0.0009806725],"domain_scores_gemma":[0.99385065,0.0028977327,0.0006338417,0.0013411626,0.0005361366,0.00074046577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026230016,0.0006638556,0.0022940412,0.0005346954,0.00018703243,0.0000547742,0.00051209505,0.00033155363,0.000044569235],"category_scores_gemma":[0.0043530934,0.0004916859,0.00030499065,0.0016284655,0.00040903332,0.00031821575,0.0003145223,0.00049075566,0.000058299913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014260626,0.0035437858,0.78752905,0.0010620597,0.0003851214,0.0016348681,0.0002926089,0.0000011435949,0.00006496698,0.00001165804,0.001092746,0.19012135],"study_design_scores_gemma":[0.096716814,0.0070916815,0.88958025,0.004373348,0.00035223004,0.000047475693,0.00016997752,0.00045355665,0.00034239626,0.000032836608,0.00042147364,0.00041797708],"about_ca_topic_score_codex":0.0006022219,"about_ca_topic_score_gemma":0.0007577896,"teacher_disagreement_score":0.18970338,"about_ca_system_score_codex":0.00051217474,"about_ca_system_score_gemma":0.0008603271,"threshold_uncertainty_score":0.9997535},"labels":[],"label_agreement":null},{"id":"W4386277272","doi":"10.1016/s2152-2650(23)00909-6","title":"POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Randomized controlled trial; Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Materials science","score_opus":0.032151055754009526,"score_gpt":0.3358029235009634,"score_spread":0.3036518677469539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97832817,0.0004548769,0.000015930575,0.0005623353,0.0014814833,0.016994257,0.00021670318,0.0005307838,0.0014154715],"genre_scores_gemma":[0.9925664,0.00061455497,0.00042654388,0.00041118558,0.00052575994,0.0017209018,0.0010598534,0.00024878315,0.0024259817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98659235,0.0024404754,0.0044469093,0.0021708412,0.0023650106,0.0019843988],"domain_scores_gemma":[0.9821796,0.012132915,0.0013995764,0.0017328011,0.0007005057,0.0018545999],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005164002,0.001299883,0.006725107,0.0010465127,0.00044077873,0.00019137812,0.00053757237,0.00069513643,0.00023055584],"category_scores_gemma":[0.013764187,0.00094726763,0.0014364629,0.0013828846,0.0012489684,0.00046432833,0.00041359017,0.0010108547,0.00030919848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88143855,0.0027161026,0.015892584,0.000091682836,0.0025012852,0.0029656047,0.00024233191,0.000002662456,0.0002823134,0.000021792344,0.0016555309,0.09218955],"study_design_scores_gemma":[0.82440794,0.015239035,0.15434211,0.00038451032,0.00096595084,0.000026885997,0.00012745461,0.0015928567,0.0004460868,0.00004223953,0.0016509633,0.00077394396],"about_ca_topic_score_codex":0.0002250728,"about_ca_topic_score_gemma":0.00018803753,"teacher_disagreement_score":0.13844953,"about_ca_system_score_codex":0.0023048199,"about_ca_system_score_gemma":0.002964078,"threshold_uncertainty_score":0.99997526},"labels":[],"label_agreement":null},{"id":"W4386277702","doi":"10.1016/s2152-2650(23)00861-3","title":"POSTER: MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Pomalidomide; Lenalidomide; Daratumumab; Dexamethasone; Multiple myeloma; Medicine; Oncology; Refractory (planetary science); Internal medicine; Materials science","score_opus":0.05485545763940222,"score_gpt":0.35894997089294606,"score_spread":0.30409451325354386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530196,0.00016199495,0.0000035157389,0.00024693267,0.00026599286,0.0033069397,0.00042788853,0.000119915145,0.00016484696],"genre_scores_gemma":[0.9965195,0.0001460039,0.00022059138,0.00022137891,0.00013600527,0.00042645438,0.00044604158,0.00011560885,0.0017684283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920986,0.0014128746,0.002160495,0.0015968415,0.0015599803,0.0011711753],"domain_scores_gemma":[0.9932211,0.0030608734,0.0006747399,0.0018729887,0.00039113357,0.00077916926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014479834,0.00086920464,0.002581896,0.0009339036,0.0003622675,0.00007531608,0.00046621016,0.00042827326,0.00022089148],"category_scores_gemma":[0.001971266,0.00051121204,0.0007951843,0.002658635,0.0006829584,0.00028874353,0.00058693846,0.00049325824,0.00004832617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07964312,0.008225664,0.7935904,0.00005664036,0.004339946,0.0014476588,0.00063678896,0.000018058132,0.00008577036,0.0000030570104,0.00011871837,0.111834146],"study_design_scores_gemma":[0.12678827,0.016056083,0.8518221,0.00021498544,0.0024167285,0.000014810701,0.00022774127,0.0013429333,0.00016568147,0.000008448912,0.0005012068,0.0004410187],"about_ca_topic_score_codex":0.0014816023,"about_ca_topic_score_gemma":0.0039317408,"teacher_disagreement_score":0.11139313,"about_ca_system_score_codex":0.0015842635,"about_ca_system_score_gemma":0.0013162341,"threshold_uncertainty_score":0.9997339},"labels":[],"label_agreement":null},{"id":"W4386277771","doi":"10.1016/s2152-2650(23)01412-x","title":"MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; McGill University Health Centre","funders":"lékařská fakulta Univerzity Karlovy; University of California, San Francisco; Erasmus Universitair Medisch Centrum Rotterdam; Université de Toulouse; Centre Hospitalier Universitaire de Toulouse; Ankara Universitesi; Univerzita Karlova v Praze; Department of Medicine, University of California, San Francisco; Sanofi","keywords":"Multiple myeloma; TEC; Medicine; Oncology; Internal medicine; Refractory (planetary science); Biology; Geology","score_opus":0.023300873658625102,"score_gpt":0.2885946003179734,"score_spread":0.2652937266593483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932947,0.0002740207,0.000005257755,0.0007454705,0.00026156552,0.003844068,0.0004887628,0.0005099948,0.00057611964],"genre_scores_gemma":[0.9957728,0.00019864131,0.00073642284,0.00031098526,0.00044872044,0.0002850364,0.0013052548,0.00022084867,0.00072131393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99144155,0.0007990589,0.002126757,0.0022419896,0.0018440244,0.0015466426],"domain_scores_gemma":[0.98610955,0.009903481,0.00066997064,0.0018566157,0.0005171232,0.00094324903],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019019414,0.00097336434,0.0016125714,0.00034330992,0.00073687226,0.00019629598,0.00066545064,0.00054296764,0.00005303282],"category_scores_gemma":[0.00881024,0.0006029911,0.0002583598,0.0015809141,0.0009247057,0.00035189715,0.0005688756,0.0011461112,0.0002973119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03421566,0.0021750415,0.79645747,0.00005534198,0.0006975746,0.0047033424,0.0011680394,0.00007634975,0.000029280107,0.0000025021002,0.0015652763,0.15885416],"study_design_scores_gemma":[0.071395285,0.0067832046,0.9104522,0.00061541086,0.0002611756,0.000036259575,0.0012934059,0.0035783383,0.000053538362,0.000020260262,0.004854313,0.0006566431],"about_ca_topic_score_codex":0.0031773816,"about_ca_topic_score_gemma":0.004121331,"teacher_disagreement_score":0.1581975,"about_ca_system_score_codex":0.001252091,"about_ca_system_score_gemma":0.0009475153,"threshold_uncertainty_score":0.99964213},"labels":[],"label_agreement":null},{"id":"W4386281969","doi":"10.1016/s2152-2650(23)01441-6","title":"MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Dexamethasone; Multiple myeloma; Medicine; Phase (matter); Oncology; Nuclear medicine; Internal medicine; Physics","score_opus":0.09324318455389913,"score_gpt":0.3844113765912489,"score_spread":0.2911681920373498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386281969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838335,0.0007011617,0.0000122236215,0.002409818,0.0019822896,0.0039654598,0.00088972226,0.00031323475,0.00134273],"genre_scores_gemma":[0.9915801,0.00069941714,0.0005855711,0.00082345883,0.0016171818,0.000343344,0.00108193,0.00017947514,0.0030895174],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9880624,0.0023742893,0.0038519334,0.0018823332,0.0021825037,0.0016465435],"domain_scores_gemma":[0.9749905,0.018970147,0.0012012701,0.003509293,0.00038964255,0.00093915546],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047482513,0.0009090533,0.0022053162,0.00037492425,0.0005062608,0.00009192666,0.0015466702,0.0010993707,0.00017310467],"category_scores_gemma":[0.025375815,0.0005526282,0.0013049814,0.0021446187,0.0013973309,0.00024901668,0.0009864819,0.0015369438,0.00087932247],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29739887,0.008072751,0.019565878,0.00009082137,0.0009530351,0.0017995673,0.0011316843,0.000071539136,0.003785063,0.000046436355,0.016360572,0.65072376],"study_design_scores_gemma":[0.44054124,0.0020606834,0.5337717,0.0005366284,0.0002715668,0.000032018543,0.00033359908,0.0076453686,0.0019896384,0.00022958209,0.01217124,0.00041677774],"about_ca_topic_score_codex":0.005190808,"about_ca_topic_score_gemma":0.0014918792,"teacher_disagreement_score":0.650307,"about_ca_system_score_codex":0.0023911349,"about_ca_system_score_gemma":0.004848642,"threshold_uncertainty_score":0.9998986},"labels":[],"label_agreement":null},{"id":"W4386282091","doi":"10.1016/s2152-2650(23)00860-1","title":"POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Bispecific antibody; Multiple myeloma; Antibody; Oncology; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.03282828537900095,"score_gpt":0.33006032396092655,"score_spread":0.2972320385819256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075794,0.00039607772,0.000069472204,0.0007178351,0.00078197545,0.0059668464,0.00071630167,0.00034160647,0.00025195454],"genre_scores_gemma":[0.9909208,0.00046137386,0.00079905044,0.00031317899,0.00057904504,0.00042846389,0.005082165,0.00016590212,0.00125003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939264,0.0005648201,0.0015464155,0.001643284,0.0012760392,0.0010430386],"domain_scores_gemma":[0.9934824,0.0032215852,0.0005662115,0.0014339751,0.0005746428,0.0007211768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096922944,0.0007469411,0.0011160929,0.00027823646,0.0007289384,0.0002918627,0.00048445663,0.00049644534,0.000089816785],"category_scores_gemma":[0.0013622487,0.0005105411,0.00039958348,0.0007828577,0.0004615885,0.00047325538,0.00026538095,0.0004731344,0.00028873864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02269827,0.002602237,0.7110248,0.00009569942,0.0006029751,0.00051087845,0.00054089795,6.81197e-7,0.0011804239,0.000012360586,0.003768411,0.25696233],"study_design_scores_gemma":[0.05019143,0.010093541,0.9317835,0.00019074896,0.00039130397,0.000023278446,0.00074901077,0.001018099,0.000424512,0.000085297586,0.004528919,0.000520345],"about_ca_topic_score_codex":0.00042308384,"about_ca_topic_score_gemma":0.0005897651,"teacher_disagreement_score":0.25644198,"about_ca_system_score_codex":0.000460732,"about_ca_system_score_gemma":0.001108751,"threshold_uncertainty_score":0.99973464},"labels":[],"label_agreement":null},{"id":"W4386282116","doi":"10.1016/s2152-2650(23)01461-1","title":"MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Observational study; Multiple myeloma; Refractory (planetary science); Medicine; Internal medicine; Oncology; Physics; Astrobiology","score_opus":0.1904529076169951,"score_gpt":0.4317338980922159,"score_spread":0.2412809904752208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898298,0.00009084447,0.000052206222,0.0015372828,0.00093309715,0.0047275717,0.000455947,0.0009515815,0.0014216932],"genre_scores_gemma":[0.96448004,0.00048575952,0.0036706624,0.0010388535,0.0014239919,0.0014222657,0.0026096087,0.00024413886,0.024624683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920517,0.0005935734,0.0024282862,0.0018079258,0.0014660978,0.001652419],"domain_scores_gemma":[0.98941886,0.006455243,0.0005634321,0.0016742466,0.0006338372,0.0012543792],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025120475,0.00078989106,0.0017333948,0.00064941857,0.00063027994,0.00012291566,0.0006905618,0.00052088685,0.00048517482],"category_scores_gemma":[0.0065200017,0.0006204975,0.00083755783,0.0018449551,0.00040080654,0.00034597042,0.00048230798,0.00061723,0.0023505213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016592665,0.0024511537,0.6203492,0.00018438094,0.0011145178,0.0026721149,0.00015441971,0.000006828414,0.00030783282,0.00021279673,0.036938705,0.31901535],"study_design_scores_gemma":[0.03709439,0.003625223,0.9026406,0.00020145587,0.0003625898,0.00006403958,0.00029978054,0.0052298596,0.00020118665,0.00022821914,0.04947998,0.0005726864],"about_ca_topic_score_codex":0.00071232923,"about_ca_topic_score_gemma":0.0016149196,"teacher_disagreement_score":0.31844264,"about_ca_system_score_codex":0.0017645056,"about_ca_system_score_gemma":0.003206423,"threshold_uncertainty_score":0.9996246},"labels":[],"label_agreement":null},{"id":"W4386282130","doi":"10.1016/s2152-2650(23)01510-0","title":"CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Randomized controlled trial; Medicine; Refractory (planetary science); Internal medicine; Multiple myeloma; Oncology; Materials science","score_opus":0.033422919757554743,"score_gpt":0.33872499839986336,"score_spread":0.3053020786423086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787888,0.0004483084,0.000027873375,0.00048183728,0.0014656341,0.016684635,0.00018632488,0.00054730335,0.0013692684],"genre_scores_gemma":[0.9919861,0.0006907526,0.00064168026,0.00034155138,0.0005588734,0.0019439231,0.00096046634,0.00024475466,0.0026318745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866553,0.0023907952,0.0043977876,0.0021663308,0.0024045536,0.0019852112],"domain_scores_gemma":[0.98150474,0.012850675,0.0013810011,0.0017142125,0.0006814973,0.0018678885],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0054921424,0.0012804057,0.006785988,0.001030023,0.0004525356,0.00017748613,0.0005275499,0.00069375505,0.00025148308],"category_scores_gemma":[0.016139481,0.0009323487,0.001430947,0.0014795049,0.0013195567,0.00044111192,0.00038023092,0.0010320221,0.0003122542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87713534,0.002785897,0.012235999,0.000087801534,0.002502746,0.0027622487,0.000212383,0.000004632082,0.00024783798,0.000033999884,0.0020795907,0.09991152],"study_design_scores_gemma":[0.8444864,0.01361289,0.13415217,0.00036580215,0.0009767639,0.000020821613,0.00014780206,0.0028049909,0.00039169475,0.000057035413,0.002202072,0.0007815335],"about_ca_topic_score_codex":0.00022952766,"about_ca_topic_score_gemma":0.00018880707,"teacher_disagreement_score":0.12191618,"about_ca_system_score_codex":0.0023716022,"about_ca_system_score_gemma":0.0031663638,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4386282140","doi":"10.1016/s2152-2650(23)00802-9","title":"POSTER: MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Stem cell; Medicine; Business; Internal medicine; Oncology; Biology; Cell biology","score_opus":0.03137610605555136,"score_gpt":0.3378752403231444,"score_spread":0.30649913426759307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674326,0.0008845035,0.0000026987218,0.00056427956,0.00013056447,0.0014290251,0.000077135555,0.000107621476,0.000060902807],"genre_scores_gemma":[0.9985336,0.00060317124,0.000018471676,0.00017718601,0.000073839044,0.00023378697,0.000052802054,0.00004977479,0.00025734626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965656,0.00052881247,0.00082087825,0.000845865,0.00046451614,0.0007743559],"domain_scores_gemma":[0.99806225,0.0009419675,0.00014578586,0.0004164822,0.00005016319,0.0003833435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053869036,0.0004898159,0.0011292312,0.00040783238,0.00009927956,0.00017013012,0.00016260077,0.00032514895,0.000015344353],"category_scores_gemma":[0.00008206194,0.00035160987,0.00017672566,0.00044789934,0.0002742627,0.00021393376,0.00009878017,0.00036639886,0.000014238586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001948551,0.00038029125,0.7800603,0.0001581237,0.00008909216,0.0028060637,0.0027053321,0.0000020764417,0.00016882425,0.0000038973058,0.0000066510165,0.21167079],"study_design_scores_gemma":[0.013892485,0.0018493928,0.98162806,0.0001752317,0.00009851363,0.00006591133,0.0014311856,0.0003302294,0.000091618975,0.00010697853,0.000023430537,0.00030696203],"about_ca_topic_score_codex":0.0007223046,"about_ca_topic_score_gemma":0.0022905562,"teacher_disagreement_score":0.21136382,"about_ca_system_score_codex":0.00037383134,"about_ca_system_score_gemma":0.00053712196,"threshold_uncertainty_score":0.9998936},"labels":[],"label_agreement":null},{"id":"W4386282157","doi":"10.1016/s2152-2650(23)00805-4","title":"POSTER: MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Lenalidomide; Oncology; Materials science; Metallurgy","score_opus":0.03119223362108285,"score_gpt":0.3182786297286981,"score_spread":0.2870863961076152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905385,0.00016521869,0.0000046575487,0.0006966472,0.00065207103,0.00249294,0.00050833105,0.000744097,0.005682175],"genre_scores_gemma":[0.98834074,0.00018393806,0.0004558477,0.00059408747,0.00037606386,0.00020182268,0.0056893225,0.00023649709,0.0039216797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99054366,0.0007495902,0.0027308506,0.0021210709,0.0018171379,0.0020377096],"domain_scores_gemma":[0.9932374,0.0018722083,0.0006475559,0.002167265,0.00061476347,0.001460837],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015428548,0.0009878905,0.0018879385,0.0009485693,0.0003720449,0.00013329413,0.0007202338,0.00096737704,0.0001637726],"category_scores_gemma":[0.0036821251,0.00077909866,0.0005818126,0.0026365109,0.0007044904,0.00054831355,0.0005033632,0.0011283772,0.0030877795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042358205,0.0021714012,0.6104069,0.00009803716,0.00057968963,0.0036446408,0.00017142044,0.000010035418,0.00013502318,0.000019427398,0.011075379,0.32932985],"study_design_scores_gemma":[0.093630284,0.0043910416,0.88399106,0.00046095264,0.00015447101,0.000054485245,0.00007322592,0.00093518855,0.00044708286,0.000033249053,0.015111032,0.0007178937],"about_ca_topic_score_codex":0.00042331303,"about_ca_topic_score_gemma":0.00029907192,"teacher_disagreement_score":0.32861197,"about_ca_system_score_codex":0.0022140683,"about_ca_system_score_gemma":0.0021469397,"threshold_uncertainty_score":0.999466},"labels":[],"label_agreement":null},{"id":"W4386282331","doi":"10.1016/s2152-2650(23)01457-x","title":"MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lenalidomide; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine; Progression-free survival; Overall survival","score_opus":0.041909718688102546,"score_gpt":0.3558880232178257,"score_spread":0.31397830452972314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907518,0.002012803,0.000014119696,0.0008053872,0.00024087782,0.005550214,0.00021672869,0.00018844104,0.00021963175],"genre_scores_gemma":[0.9895882,0.007569188,0.0005311815,0.00027935865,0.00010914686,0.000767542,0.0009212835,0.000104972016,0.00012913843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927809,0.0010459129,0.002277042,0.0012454668,0.0016743001,0.0009763267],"domain_scores_gemma":[0.993752,0.0030380294,0.00062182674,0.0013262661,0.00052119297,0.00074070983],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027797234,0.0006508339,0.002294925,0.0005243967,0.0001909147,0.000050135804,0.0005033623,0.0003295672,0.000048081452],"category_scores_gemma":[0.005089349,0.0004819394,0.00030007894,0.0017508856,0.0004285944,0.00030133856,0.00028881224,0.00049874326,0.000057988582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01249652,0.0036699965,0.7731265,0.0010476185,0.0003819532,0.0015270001,0.00025869973,0.0000020183,0.000057205492,0.000018319506,0.0013886584,0.20602551],"study_design_scores_gemma":[0.09639259,0.0061297817,0.89066267,0.00415884,0.00034583514,0.000036077556,0.00019487488,0.0007827331,0.00029423766,0.000043526557,0.0005476222,0.00041123197],"about_ca_topic_score_codex":0.00061996584,"about_ca_topic_score_gemma":0.0007720758,"teacher_disagreement_score":0.20561427,"about_ca_system_score_codex":0.00052098226,"about_ca_system_score_gemma":0.0009116121,"threshold_uncertainty_score":0.99976325},"labels":[],"label_agreement":null},{"id":"W4386324983","doi":"10.1038/s41591-023-02491-5","title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute; Terry Fox Foundation; Glenmark Pharmaceuticals; University of Calgary; Comprehensive Cancer Center, City of Hope; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Celgene; Genentech; Deutsche Krebshilfe; Rising Tide Foundation; Pfizer; Amgen; Health Research Board; Multiple Myeloma Research Foundation","keywords":"Chimeric antigen receptor; Antigen; Cancer research; Multiple myeloma; Missense mutation; Immunology; Immunotherapy; Biology; Medicine; Mutation; Genetics; Gene; Immune system","score_opus":0.02830774918335869,"score_gpt":0.32496247235533104,"score_spread":0.29665472317197233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386324983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989061,0.0046512824,0.000115602714,0.0040969783,0.0004144274,0.00089814793,0.00009867289,0.00018122878,0.00048267044],"genre_scores_gemma":[0.994606,0.0010817165,0.0016250849,0.00044973052,0.00019185808,0.000051535942,0.0007131754,0.000054358417,0.0012265344],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974644,0.00010475885,0.0005181276,0.0004452272,0.0009260125,0.0005414294],"domain_scores_gemma":[0.9983456,0.0006024348,0.00012621208,0.00053274096,0.00017583594,0.00021715077],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044932266,0.00029274847,0.0008200467,0.00071063475,0.000064519736,0.0000058031155,0.00022664989,0.0004087228,0.001826041],"category_scores_gemma":[0.0014649524,0.00018133498,0.0001054342,0.00143412,0.00017480362,0.000071750736,0.00007663744,0.00074323505,0.0001268434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054659117,0.0005174924,0.1449366,0.00023969154,0.00093207136,0.0024232233,0.0022758322,0.0000054852976,0.7960194,0.00025272582,0.005273002,0.04165855],"study_design_scores_gemma":[0.017067185,0.0010551767,0.86911464,0.0008539617,0.00007185581,0.000023386141,0.0011113392,0.0016176737,0.10445416,0.0009967677,0.003433769,0.00020006951],"about_ca_topic_score_codex":0.0009069367,"about_ca_topic_score_gemma":0.00037355308,"teacher_disagreement_score":0.7241781,"about_ca_system_score_codex":0.00009163521,"about_ca_system_score_gemma":0.0001458891,"threshold_uncertainty_score":0.99908644},"labels":[],"label_agreement":null},{"id":"W4386331411","doi":"10.1016/s2152-2650(23)01443-x","title":"MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Antigen; Bispecific antibody; CD3; Immunology; Cancer research; Monoclonal antibody; CD8","score_opus":0.034242861841062316,"score_gpt":0.33296083776315466,"score_spread":0.29871797592209237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386331411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106705,0.00039063167,0.0001243737,0.0006188416,0.0007710246,0.0058100796,0.0006269722,0.0003520636,0.00023898548],"genre_scores_gemma":[0.990724,0.000516738,0.0012131172,0.00026062073,0.00061821594,0.0004792313,0.004677144,0.00016301466,0.0013479106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939626,0.00054770935,0.001517371,0.0016394221,0.0012927752,0.0010401532],"domain_scores_gemma":[0.9933517,0.003391741,0.0005551723,0.0014191042,0.0005602139,0.00072206726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010190564,0.000734168,0.0011104079,0.00027089097,0.00075521995,0.00027248738,0.0004766774,0.00049548625,0.000097268916],"category_scores_gemma":[0.0015771368,0.0005011043,0.00039480656,0.0008355056,0.0004845855,0.00045018722,0.00024372741,0.00048097532,0.00029163327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020807007,0.00279065,0.67840743,0.00009582618,0.00062483613,0.00048893807,0.0005004374,0.0000012320156,0.0011057811,0.000020004549,0.0050235623,0.2901343],"study_design_scores_gemma":[0.049660522,0.008760346,0.93139046,0.0001759676,0.00038460878,0.000017598983,0.0008650362,0.0017481864,0.0003646195,0.00011328282,0.0060070944,0.00051225873],"about_ca_topic_score_codex":0.00043489164,"about_ca_topic_score_gemma":0.00059884303,"teacher_disagreement_score":0.28962207,"about_ca_system_score_codex":0.00046859874,"about_ca_system_score_gemma":0.0011782119,"threshold_uncertainty_score":0.99974406},"labels":[],"label_agreement":null},{"id":"W4386332461","doi":"10.1038/s43018-023-00625-9","title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Agence Nationale de la Recherche","keywords":"Epigenetics; Gene silencing; Multiple myeloma; Biology; Cancer research; Allele; Enhancer; Gene; Immunotherapy; Genetics; Gene expression; Immunology; Immune system","score_opus":0.02193617940110326,"score_gpt":0.3180440978058537,"score_spread":0.2961079184047504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881041,0.0052238335,0.000023644187,0.003626969,0.00023707816,0.0015996202,0.00040682376,0.00027471012,0.0005032222],"genre_scores_gemma":[0.98078996,0.00086917594,0.0018042863,0.0014973562,0.00014270032,0.0007405645,0.0004333946,0.00007156956,0.013651021],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997537,0.00014695786,0.00032883728,0.0006382996,0.0006637225,0.000685173],"domain_scores_gemma":[0.9985199,0.00039403702,0.000079583035,0.0004053604,0.00023001112,0.00037113542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001877569,0.00028047766,0.00040235443,0.0004298715,0.000112302856,0.000023917946,0.00016609501,0.00039684377,0.0008363233],"category_scores_gemma":[0.0012159419,0.00022347699,0.00006806606,0.0022654573,0.000043399352,0.00006997323,0.000060650513,0.0005231497,0.00022350803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00643604,0.0005111254,0.20130141,0.00041991132,0.00023179154,0.0008541771,0.0017531795,0.000058255322,0.49018833,0.0000014459258,0.28690746,0.01133686],"study_design_scores_gemma":[0.0072169397,0.00022917458,0.6783866,0.00029232792,0.00003394123,0.0000025182,0.0001099768,0.0019824705,0.23591268,0.000021076294,0.075485125,0.00032714463],"about_ca_topic_score_codex":0.0002420312,"about_ca_topic_score_gemma":0.0012306218,"teacher_disagreement_score":0.47708523,"about_ca_system_score_codex":0.0006011342,"about_ca_system_score_gemma":0.00036617924,"threshold_uncertainty_score":0.91571534},"labels":[],"label_agreement":null},{"id":"W4386372296","doi":"10.3390/cancers15174359","title":"Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Discontinuation; Multiple myeloma; Internal medicine; Retrospective cohort study; Stage (stratigraphy); Gastroenterology; Surgery","score_opus":0.05767866378436156,"score_gpt":0.3191786430423781,"score_spread":0.26149997925801655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386372296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975216,0.00010326446,0.0000054500515,0.0000776465,0.00012234502,0.00040699117,0.000052588242,0.000041050316,0.0016690936],"genre_scores_gemma":[0.99784493,0.00005479336,0.00052174705,0.00015790836,0.000020008649,0.000066583365,0.00012522782,0.000017102453,0.0011917134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989234,0.000020286161,0.00027331672,0.00018785395,0.0002682117,0.0003269074],"domain_scores_gemma":[0.9995127,0.00008768975,0.00005283787,0.000167567,0.000081932274,0.0000973277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010475006,0.00010413678,0.0002763233,0.00023784285,0.000031887772,0.0000044062504,0.00007060863,0.000047820045,0.00009356056],"category_scores_gemma":[0.00019373614,0.000089900335,0.000054456596,0.00046559807,0.00006216258,0.000061365754,0.000057119243,0.00008779235,0.00006609389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016109142,0.000017279748,0.9883561,0.00033675996,0.00004291233,0.00006979293,0.00023861564,0.000018068436,0.0014267634,0.000013399789,0.00059687364,0.008722302],"study_design_scores_gemma":[0.0035862247,0.00009137653,0.989719,0.00015182816,0.000006445763,0.0000011180872,0.000115195595,0.00016089488,0.004402468,0.000016950271,0.0016686834,0.00007986474],"about_ca_topic_score_codex":0.00027099808,"about_ca_topic_score_gemma":0.0004571343,"teacher_disagreement_score":0.008642437,"about_ca_system_score_codex":0.0012036617,"about_ca_system_score_gemma":0.0004484431,"threshold_uncertainty_score":0.36660293},"labels":[],"label_agreement":null},{"id":"W4386390606","doi":"10.1038/s41467-023-40966-8","title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Office of Research Infrastructure Programs, National Institutes of Health; National Cancer Institute; National Institutes of Health; Celgene; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Multiple Myeloma Research Foundation; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center","keywords":"Minimal residual disease; Lenalidomide; Immune system; Multiple myeloma; Medicine; Bone marrow; Negativity effect; Mass cytometry; Immunology; Oncology; Biology; Phenotype; Gene; Psychology","score_opus":0.016122629544052636,"score_gpt":0.30223908035740726,"score_spread":0.28611645081335463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386390606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634284,0.00059847056,0.0000046182436,0.0009932104,0.000029359333,0.0008150833,0.00005329253,0.000078208905,0.0010849263],"genre_scores_gemma":[0.997104,0.00012368345,0.001535781,0.000029505121,0.0000060159286,0.00007803893,0.0008667922,0.000020947235,0.00023523839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894047,0.000120990735,0.00022496068,0.00015917575,0.00029884238,0.0002555889],"domain_scores_gemma":[0.9974886,0.0006271758,0.00008664255,0.0013753044,0.0003367672,0.00008549218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016340564,0.00012312803,0.00025006966,0.00030313895,0.000121497644,0.000008494553,0.00035858285,0.00016263704,0.000018807737],"category_scores_gemma":[0.0008051709,0.000094380965,0.000051192706,0.0011504069,0.00017326641,0.000088246954,0.0002457403,0.0007276968,0.000037067097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005827558,0.00066897576,0.993403,0.000032866017,0.00009936435,0.0000058994247,0.00023139619,0.0000071701024,0.00013861642,0.000522099,0.00019520489,0.004112652],"study_design_scores_gemma":[0.005089695,0.00022984613,0.9923609,0.000094453695,0.000026737724,7.7123445e-7,0.0001793322,0.0012739078,0.00020195557,0.000080780665,0.00038455366,0.00007705086],"about_ca_topic_score_codex":0.00012120971,"about_ca_topic_score_gemma":0.0006855244,"teacher_disagreement_score":0.004506939,"about_ca_system_score_codex":0.00011048787,"about_ca_system_score_gemma":0.00012618389,"threshold_uncertainty_score":0.3848744},"labels":[],"label_agreement":null},{"id":"W4386441220","doi":"10.1038/s41408-023-00905-8","title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Saint John Regional Hospital; McGill University; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; University of British Columbia; Institute of Cancer Research; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre; McMaster University; Western University; Hôpital Maisonneuve-Rosemont; Université Laval","funders":"","keywords":"Multiple myeloma; Medicine; Transplantation; Stem cell; Autologous stem-cell transplantation; Oncology; Internal medicine; Biology; Genetics","score_opus":0.07226150521320708,"score_gpt":0.361496175435274,"score_spread":0.28923467022206695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386441220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913163,0.0008417762,0.0000043414416,0.0033387153,0.00024921223,0.0009214923,0.0014883603,0.000038896214,0.0018009008],"genre_scores_gemma":[0.99310285,0.0039814515,0.00036996868,0.00005504863,0.00040791603,0.00016296907,0.00085331406,0.00004269097,0.0010237707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957677,0.00057946006,0.0008742921,0.00048096635,0.0013205037,0.0009770717],"domain_scores_gemma":[0.9968132,0.0012172626,0.00026035673,0.00062808715,0.0003628975,0.0007182022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024948157,0.00021771196,0.00043494254,0.00089774764,0.00046851233,0.000079937316,0.00034625668,0.00012446965,0.0000911001],"category_scores_gemma":[0.00036042393,0.0001564806,0.0001264015,0.0016202182,0.00017027534,0.00016736028,0.000053799176,0.0011435904,0.000032810163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046880245,0.00052094454,0.8375113,0.00017923983,0.00043148105,0.09630194,0.0037170972,0.000090687114,0.009278611,0.000014429396,0.014269887,0.03299635],"study_design_scores_gemma":[0.015877385,0.00026879483,0.9706919,0.0006558993,0.00015311044,0.0005185917,0.00075982563,0.00045833923,0.008594894,0.0000410356,0.0018380105,0.00014220671],"about_ca_topic_score_codex":0.7319516,"about_ca_topic_score_gemma":0.9515372,"teacher_disagreement_score":0.21958561,"about_ca_system_score_codex":0.00062106695,"about_ca_system_score_gemma":0.0027787434,"threshold_uncertainty_score":0.6381094},"labels":[],"label_agreement":null},{"id":"W4386536904","doi":"10.21203/rs.3.rs-3194726/v1","title":"Prognostic Factors in 448 Newly Diagnosed Multiple Myeloma Receiving Bortezomib-based Induction: Impact of ASCT, Transplant Refusal and High-Risk MM","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Bortezomib; Medicine; Induction therapy; Oncology; Internal medicine; Chemotherapy","score_opus":0.08297973707033078,"score_gpt":0.3935928345410184,"score_spread":0.3106130974706876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386536904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918064,0.00059453724,0.00006358614,0.0003427758,0.00017614527,0.0048185987,0.0019813767,0.00016863704,0.000047927577],"genre_scores_gemma":[0.99409133,0.0018252549,0.00045082066,0.0000029405753,0.0002190957,0.0007757636,0.0023437575,0.00015623301,0.00013480037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992356,0.0013896114,0.0009072622,0.0013390486,0.0022781193,0.0017299437],"domain_scores_gemma":[0.9924093,0.0044102683,0.0002632858,0.0011273304,0.00072118785,0.0010686663],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024576276,0.00065554515,0.0013197701,0.0022390564,0.00025236935,0.00012326063,0.0003842721,0.0007469409,0.00017741464],"category_scores_gemma":[0.0076289056,0.00051110954,0.00045034153,0.0013017392,0.0003813471,0.00013555955,0.00043134284,0.003556446,0.0000349895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028024304,0.0009292743,0.9793129,0.0026790858,0.0006310446,0.0018122012,0.0009928927,0.00052761304,0.0008446496,0.000003485289,0.00017792947,0.009286479],"study_design_scores_gemma":[0.008235705,0.0024172748,0.976154,0.0048040994,0.00011509221,0.0000142005465,0.000407327,0.005346733,0.0020042607,0.0001300041,0.000017699791,0.00035358462],"about_ca_topic_score_codex":0.050759662,"about_ca_topic_score_gemma":0.0057234997,"teacher_disagreement_score":0.04503616,"about_ca_system_score_codex":0.001242296,"about_ca_system_score_gemma":0.002489674,"threshold_uncertainty_score":0.99973404},"labels":[],"label_agreement":null},{"id":"W4386541517","doi":"10.1038/s43018-023-00646-4","title":"Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","year":2023,"lang":"en","type":"erratum","venue":"Nature Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Epigenetics; Cancer research; Multiple myeloma; Resistance (ecology); Genetics; Biology; Computational biology; Molecular biology; Immunology; Gene","score_opus":0.024694899632233105,"score_gpt":0.3243231660114614,"score_spread":0.2996282663792283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386541517","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23428537,0.31393984,0.0004960671,0.06182488,0.27968943,0.046022557,0.02290176,0.0067052245,0.034134857],"genre_scores_gemma":[0.0847122,0.003349037,0.0013799358,0.0016789876,0.001971015,0.002470272,0.0050989655,0.0003537946,0.8989858],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494296,0.00034749467,0.0007322205,0.0014650548,0.0014215672,0.0010907162],"domain_scores_gemma":[0.9969011,0.0006411463,0.0003168352,0.00083046133,0.0006513991,0.0006590419],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00029633672,0.00078368536,0.0011407718,0.0009295741,0.00022671888,0.00006527836,0.00035119298,0.0023059456,0.0016783426],"category_scores_gemma":[0.00324633,0.00065817626,0.00019566528,0.0029265906,0.00008450898,0.000086704065,0.00011927208,0.0029822495,0.0002814516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033897562,0.0002957324,0.005042285,0.0005874088,0.0002872717,0.0005785084,0.0005449473,0.000010612581,0.0058352123,1.1740859e-7,0.97960025,0.0038278762],"study_design_scores_gemma":[0.0050686067,0.0003929954,0.12219967,0.0018515165,0.00014728594,0.000008013562,0.00010628474,0.0018270727,0.015656788,0.000008103049,0.85201377,0.0007198826],"about_ca_topic_score_codex":0.00078200345,"about_ca_topic_score_gemma":0.0068934583,"teacher_disagreement_score":0.86485094,"about_ca_system_score_codex":0.0022817021,"about_ca_system_score_gemma":0.0018884497,"threshold_uncertainty_score":0.99958694},"labels":[],"label_agreement":null},{"id":"W4386697187","doi":"10.1016/j.clml.2023.09.003","title":"Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs; Regeneron Pharmaceuticals; Celgene; Array BioPharma; Alnylam Pharmaceuticals; National Comprehensive Cancer Network; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hazard ratio; Medicine; Lenalidomide; Daratumumab; Internal medicine; Multiple myeloma; Oncology; Progression-free survival; Population; Proportional hazards model; Confidence interval; Chemotherapy","score_opus":0.04650279661337501,"score_gpt":0.3550013715950573,"score_spread":0.30849857498168226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386697187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248034,0.0013187458,0.000013594519,0.00041825324,0.00020939103,0.0050476626,0.00016751286,0.00014978406,0.00019472823],"genre_scores_gemma":[0.9942983,0.0032066605,0.0007611868,0.00009994588,0.00007418916,0.00060518784,0.0008008574,0.00009355098,0.00006015471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940795,0.0007215474,0.001606645,0.0010941427,0.0016576017,0.0008406036],"domain_scores_gemma":[0.9941743,0.0030633828,0.0005182357,0.0011448442,0.00046782562,0.0006314272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018977713,0.0005837235,0.0018980701,0.00041538567,0.00016755848,0.000040306335,0.0003949497,0.0002500666,0.000028727742],"category_scores_gemma":[0.0029839375,0.0003986854,0.00019007218,0.0015986427,0.0004093767,0.00025863477,0.00020068603,0.00042805288,0.000031722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037617467,0.0032973462,0.8019742,0.0007443742,0.0005207388,0.0014612051,0.00019194237,0.0000034309537,0.00002141338,0.000014078666,0.0004735424,0.15368031],"study_design_scores_gemma":[0.1669475,0.00805724,0.820308,0.0030012024,0.00039355847,0.000016993308,0.0001746323,0.0004256027,0.00013789414,0.000012495901,0.00018355055,0.00034127844],"about_ca_topic_score_codex":0.00048482508,"about_ca_topic_score_gemma":0.0011273886,"teacher_disagreement_score":0.15333903,"about_ca_system_score_codex":0.00045905414,"about_ca_system_score_gemma":0.0009132182,"threshold_uncertainty_score":0.9998465},"labels":[],"label_agreement":null},{"id":"W4386884209","doi":"10.1182/blood.2023020276","title":"Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Epigenetics; Venetoclax; Biology; Chromatin; Transcriptome; Genetics; Computational biology; Cancer research; Molecular biology; Gene; Gene expression; Leukemia","score_opus":0.03871333577447593,"score_gpt":0.2750702087617518,"score_spread":0.23635687298727587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386884209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969965,0.0019676387,0.000037403286,0.00013355864,0.000020086656,0.00031144757,0.0001928493,0.000050736966,0.00028977878],"genre_scores_gemma":[0.9978971,0.00042133316,0.00047017867,0.000014420336,0.000018125109,0.000022982767,0.00034160013,0.000016848126,0.00079740124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879944,0.000053779782,0.00024202511,0.00030251392,0.00033085106,0.00027139258],"domain_scores_gemma":[0.99929035,0.0001403241,0.000046352645,0.00015939151,0.00013221764,0.00023134462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012661745,0.00014661795,0.0003616618,0.000522104,0.0000613608,0.000014980486,0.00005204772,0.00008204515,0.00012668518],"category_scores_gemma":[0.0001567514,0.00011988195,0.00010321617,0.00093777466,0.00006103307,0.000046221692,0.000031250645,0.000094554205,0.000017215782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016922901,0.0011453269,0.65623087,0.00015670713,0.0013762063,0.00016309426,0.0003853421,0.000007649625,0.33537295,0.000035723213,0.000015377458,0.0049415366],"study_design_scores_gemma":[0.007126272,0.00041980768,0.9195621,0.00004456676,0.001962979,0.000022314625,0.00015435695,0.0057020597,0.064779714,0.000030250314,0.00008526951,0.0001103213],"about_ca_topic_score_codex":0.00015170168,"about_ca_topic_score_gemma":0.0004512479,"teacher_disagreement_score":0.27059326,"about_ca_system_score_codex":0.000014486364,"about_ca_system_score_gemma":0.000055083554,"threshold_uncertainty_score":0.48886442},"labels":[],"label_agreement":null},{"id":"W4386959308","doi":"10.1016/j.jtct.2023.09.014","title":"Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Takeda Pharmaceuticals U.S.A.; Bristol-Myers Squibb; Multiple Myeloma Research Foundation","keywords":"Medicine; Pomalidomide; Multiple myeloma; Maintenance therapy; Dexamethasone; Salvage therapy; Internal medicine; Melphalan; Transplantation; Autologous stem-cell transplantation; Surgery; Progression-free survival; Oncology; Lenalidomide; Chemotherapy","score_opus":0.028147437791671493,"score_gpt":0.31771735857515937,"score_spread":0.28956992078348787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386959308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919061,0.00044951326,0.0032136664,0.00015014091,0.00010027035,0.0033319967,0.000601411,0.00009016796,0.00015670434],"genre_scores_gemma":[0.9946147,0.0021000314,0.0013815637,0.000050248484,0.000039875133,0.00029072945,0.0010439667,0.000032016338,0.00044683],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99848497,0.00010043088,0.00044352506,0.00040637556,0.00023446226,0.00033022527],"domain_scores_gemma":[0.9990057,0.00049194286,0.00012554391,0.00013683297,0.00009461474,0.00014540621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040524767,0.00021301249,0.00045515923,0.00018815849,0.00013078966,0.000024888739,0.000045908073,0.000109331064,0.000014652099],"category_scores_gemma":[0.000059356105,0.00017444795,0.00014674789,0.00018008216,0.00009670135,0.0001171417,0.0000035253618,0.00010665781,0.0000031045208],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62592477,0.0008402424,0.0073868674,0.0008154629,0.00081544043,0.0007314847,0.008077582,0.0000042110178,0.30601382,0.000091098016,0.000043950073,0.049255036],"study_design_scores_gemma":[0.66604656,0.0042355764,0.046379343,0.00021470775,0.0002895692,0.00007492648,0.00053547724,0.0034741312,0.27800196,0.000104967345,0.00039584597,0.0002469237],"about_ca_topic_score_codex":0.000071740746,"about_ca_topic_score_gemma":0.0000592087,"teacher_disagreement_score":0.04900811,"about_ca_system_score_codex":0.000026641219,"about_ca_system_score_gemma":0.000049780396,"threshold_uncertainty_score":0.7113781},"labels":[],"label_agreement":null},{"id":"W4386996034","doi":"10.3390/cancers15194687","title":"Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Canada Research Chairs; Génome Québec","keywords":"Computational biology; Genome; Biology; Evolutionary biology; Genetics; Gene","score_opus":0.06998939143119869,"score_gpt":0.32965865595169125,"score_spread":0.25966926452049255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386996034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012667,0.000464815,0.000039822542,0.0009361003,0.00005117973,0.0003794417,0.000026269165,0.000044481236,0.007931207],"genre_scores_gemma":[0.9977389,0.00022552226,0.0005530272,0.00015213428,0.00011836303,0.000046313817,0.00004571964,0.000013812684,0.0011062023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999117,0.000026521717,0.00015596095,0.0001492737,0.00025998682,0.00029123347],"domain_scores_gemma":[0.999416,0.000094681476,0.00003346819,0.0002643735,0.000054791395,0.00013671498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011802462,0.00007883712,0.00018880895,0.000085534855,0.00006317101,0.0000075131916,0.00010248436,0.000031084754,0.00035113547],"category_scores_gemma":[0.00007793431,0.00005031187,0.00006721832,0.0003654207,0.000110760084,0.00001274929,0.00004954531,0.00008497251,0.00016853091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010613434,0.00010041971,0.522051,0.0012261407,0.0018653176,0.0014938066,0.0032020737,0.0015873552,0.31373736,0.00088563416,0.04494027,0.10784927],"study_design_scores_gemma":[0.001160987,0.00012321207,0.9883504,0.000046185247,0.000028132396,0.000020570598,0.0003528019,0.0025476555,0.00041879035,0.000053641026,0.0068437285,0.00005391101],"about_ca_topic_score_codex":0.000053324944,"about_ca_topic_score_gemma":0.000009248418,"teacher_disagreement_score":0.46629938,"about_ca_system_score_codex":0.0001890103,"about_ca_system_score_gemma":0.00021080568,"threshold_uncertainty_score":0.3844687},"labels":[],"label_agreement":null},{"id":"W4387003616","doi":"10.1016/s2152-2650(23)01901-8","title":"P-283 Systematic literature review of prognostic factors for relapsed/refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Refractory (planetary science); Internal medicine; Medicine; Oncology; Biology","score_opus":0.056644533830111865,"score_gpt":0.3672240830086483,"score_spread":0.3105795491785364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93724906,0.050103787,0.00006961709,0.00058653025,0.00094459864,0.009212158,0.0005135044,0.0006061664,0.0007145526],"genre_scores_gemma":[0.9550336,0.03583748,0.0011752832,0.00073121535,0.00049323804,0.0012190675,0.0020037664,0.00018614563,0.0033201803],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9933759,0.00058457983,0.00273539,0.0010777991,0.0011303569,0.0010959483],"domain_scores_gemma":[0.9866694,0.009116989,0.00084343227,0.0015197269,0.0009204376,0.00092998246],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020769306,0.00067093037,0.0026492747,0.0004220127,0.00020927656,0.000057718167,0.00053480215,0.00063525647,0.00008185038],"category_scores_gemma":[0.033250332,0.0004813521,0.001487682,0.001527837,0.0003565863,0.00023466418,0.00022776327,0.000451817,0.00045146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022300652,0.0014398841,0.20706497,0.6427859,0.002127748,0.0016786583,0.0003929241,0.0000017750191,0.00077360135,0.00026219804,0.026269069,0.11497322],"study_design_scores_gemma":[0.008602387,0.001987361,0.7949315,0.1877872,0.0008247754,0.00013395464,0.00011293279,0.0011757225,0.00053014903,0.00009939948,0.0033653146,0.000449359],"about_ca_topic_score_codex":0.000016233149,"about_ca_topic_score_gemma":0.0000075427906,"teacher_disagreement_score":0.5878665,"about_ca_system_score_codex":0.0006891901,"about_ca_system_score_gemma":0.0012809597,"threshold_uncertainty_score":0.9997638},"labels":[],"label_agreement":null},{"id":"W4387003657","doi":"10.1016/s2152-2650(23)01797-4","title":"P-179 Altered lipid metabolism in IMiD/CELMoD resistant multiple myeloma confers novel and targetable vulnerabilities","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Multiple myeloma; Metabolism; Lipid metabolism; Chemistry; Cancer research; Biology; Biochemistry; Medicine; Internal medicine","score_opus":0.06091220127442547,"score_gpt":0.34551812921428204,"score_spread":0.28460592793985656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924578,0.000856645,0.000040024366,0.0012922062,0.00078365125,0.0014664344,0.00024811973,0.00043016486,0.0024249747],"genre_scores_gemma":[0.9910737,0.000990933,0.00248012,0.0005904105,0.00087861076,0.0003266827,0.0004003972,0.00014114512,0.003117949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933775,0.00045380733,0.0019129623,0.001574801,0.0009814501,0.0016994812],"domain_scores_gemma":[0.99426013,0.0026922785,0.00028725227,0.0012331149,0.00029659667,0.0012306318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002053584,0.00071229186,0.0018391509,0.0006283537,0.0003266335,0.00014805044,0.00040994308,0.00059343106,0.00020193576],"category_scores_gemma":[0.0046965056,0.00061011914,0.0005006075,0.0010927307,0.0009175547,0.00035214267,0.0004969533,0.0006648684,0.0004511938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0145260785,0.0021263347,0.48915312,0.00091376493,0.0014311766,0.0026037171,0.0010658308,0.00008544266,0.031025525,0.0027141436,0.007922901,0.44643196],"study_design_scores_gemma":[0.02208123,0.00058709056,0.93825763,0.00025282003,0.00013503004,0.00009639598,0.00045928865,0.012688379,0.0019446241,0.00040427299,0.022549234,0.0005439938],"about_ca_topic_score_codex":0.0014307223,"about_ca_topic_score_gemma":0.00049045513,"teacher_disagreement_score":0.44910452,"about_ca_system_score_codex":0.0008738875,"about_ca_system_score_gemma":0.0016098457,"threshold_uncertainty_score":0.99963504},"labels":[],"label_agreement":null},{"id":"W4387003693","doi":"10.1016/s2152-2650(23)01900-6","title":"P-282 Ranking importance of prognostic factors for relapsed/refractory multiple myeloma (RRMM): international physician panel consensus following a systematic review of the literature","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Medicine; Ranking (information retrieval); Oncology; Family medicine; Internal medicine; Computer science; Information retrieval","score_opus":0.10684521102053852,"score_gpt":0.39988145775982925,"score_spread":0.29303624673929074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011909872,0.9721272,0.000007971509,0.000083662926,0.0015881793,0.0127730025,0.0012289687,0.0001344321,0.0001467156],"genre_scores_gemma":[0.01492522,0.9795723,0.00040744324,0.0002761882,0.0005073021,0.0014645812,0.0017750786,0.00029155845,0.00078033353],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9894715,0.001129889,0.0056411917,0.0012694345,0.0016256871,0.0008623119],"domain_scores_gemma":[0.9779867,0.014388996,0.004332592,0.0020386968,0.0008331383,0.00041987246],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022789014,0.0011254553,0.008002356,0.00035776748,0.00019378726,0.00005713636,0.0013301218,0.00096383085,0.000014885548],"category_scores_gemma":[0.03628364,0.00067867263,0.006561903,0.001317519,0.0004439028,0.00011078242,0.00044482455,0.0008962637,0.000040295603],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020625489,0.00039881194,0.0048370874,0.81646365,0.0052210665,0.00034182446,0.00008890979,1.2407699e-7,0.0000055645296,0.000035461802,0.00051072385,0.17189054],"study_design_scores_gemma":[0.0046841507,0.0004434299,0.020075265,0.9526088,0.008859766,0.00011897762,0.0000612037,0.00007044833,0.000013710239,0.000059515816,0.012446825,0.00055788533],"about_ca_topic_score_codex":0.000021709398,"about_ca_topic_score_gemma":0.000013350809,"teacher_disagreement_score":0.17133266,"about_ca_system_score_codex":0.0013174078,"about_ca_system_score_gemma":0.003496606,"threshold_uncertainty_score":0.99956644},"labels":[],"label_agreement":null},{"id":"W4387003704","doi":"10.1016/s2152-2650(23)01968-7","title":"P-350 Single cell analysis identifies new insights into the development of venetoclax resistant in multiple myeloma patients","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Multiple myeloma; Medicine; Immunology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.054993687948832415,"score_gpt":0.33175393006872256,"score_spread":0.27676024211989014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970694,0.00041591545,0.000038040154,0.00017943152,0.00025223612,0.0009485112,0.00001259096,0.00012360215,0.00096026936],"genre_scores_gemma":[0.9942264,0.00012717456,0.0016503824,0.00011998948,0.0001529809,0.000097929034,0.0004484104,0.000062446066,0.0031143127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99430555,0.00040276046,0.0022719603,0.0009480587,0.0012403205,0.0008313776],"domain_scores_gemma":[0.99569285,0.0016901405,0.00048669832,0.0011672466,0.00032965865,0.0006333975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009667265,0.0004506109,0.0012249824,0.0008901508,0.00029850626,0.00006175217,0.00059247564,0.00035358217,0.000082336446],"category_scores_gemma":[0.001592363,0.00032119048,0.0006417065,0.0034365007,0.00039727223,0.00015912084,0.00049426325,0.00031322066,0.0004924726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00256937,0.0009267189,0.562149,0.00020867329,0.001383792,0.00032030826,0.0051492215,0.000084960186,0.004767571,0.000019785344,0.001205185,0.42121542],"study_design_scores_gemma":[0.0081692515,0.00048020823,0.97000146,0.00016864631,0.00034816688,0.0000010856717,0.00049481756,0.0022545925,0.012862605,0.00023294665,0.0046912297,0.00029499814],"about_ca_topic_score_codex":0.0019743724,"about_ca_topic_score_gemma":0.006048848,"teacher_disagreement_score":0.4209204,"about_ca_system_score_codex":0.0020290376,"about_ca_system_score_gemma":0.0028741914,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W4387003741","doi":"10.1016/s2152-2650(23)01902-x","title":"P-284 Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Lenalidomide; Carfilzomib; Multiple myeloma; Dexamethasone; Medicine; Oncology; Internal medicine; Chemotherapy","score_opus":0.06025833011488428,"score_gpt":0.3517906386139641,"score_spread":0.2915323084990798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908691,0.000069936264,0.0000032760763,0.0015674153,0.0004556781,0.0045588,0.000071949326,0.00016843074,0.0022354366],"genre_scores_gemma":[0.99716663,0.0002794758,0.00018989446,0.00064004236,0.00028663917,0.0004676433,0.00023142663,0.00013530307,0.0006029318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919328,0.0017782826,0.0020078097,0.0013150378,0.001776998,0.001189056],"domain_scores_gemma":[0.9918111,0.0048988177,0.0007421378,0.0017382503,0.00032647586,0.00048322522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030507392,0.0007429232,0.0014827416,0.0005827895,0.0005098193,0.00011829839,0.0008945177,0.00041268268,0.000041866657],"category_scores_gemma":[0.0036169442,0.00046930872,0.0005667738,0.0023630618,0.00078302185,0.0001945361,0.00042309097,0.0008335112,0.00009137095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028972118,0.002236497,0.68058753,0.000057886828,0.00026815923,0.00016137323,0.0011457383,0.0000067687442,0.00012430166,0.00007810041,0.0006380998,0.3117983],"study_design_scores_gemma":[0.0392221,0.0019278947,0.95202655,0.00046156204,0.00016346974,0.000013039363,0.0010661118,0.002383509,0.0011419079,0.00020413719,0.0009845922,0.00040512826],"about_ca_topic_score_codex":0.001988479,"about_ca_topic_score_gemma":0.0041861283,"teacher_disagreement_score":0.31139317,"about_ca_system_score_codex":0.0009549922,"about_ca_system_score_gemma":0.0005770409,"threshold_uncertainty_score":0.9997759},"labels":[],"label_agreement":null},{"id":"W4387003746","doi":"10.1016/s2152-2650(23)01822-0","title":"P-204 Targeting TENT5C-associated regulation of antibody synthesis against multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Antibody; Cancer research; Medicine; Immunology","score_opus":0.04588058022428575,"score_gpt":0.35794465009087356,"score_spread":0.3120640698665878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440384,0.00018550773,0.000047399873,0.00047416345,0.0004328805,0.0010010124,0.00014888289,0.00059971365,0.0027066146],"genre_scores_gemma":[0.9945935,0.00054560165,0.001054547,0.00019070265,0.00042256684,0.0001066833,0.0014507684,0.00013065644,0.0015049839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396306,0.00057358085,0.002039677,0.001026537,0.0012199727,0.0011771722],"domain_scores_gemma":[0.99306995,0.0039139804,0.00071280095,0.000973687,0.00057601597,0.00075357425],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021196692,0.0005154765,0.001449269,0.0004823556,0.0003094302,0.000050092498,0.0003970389,0.000646229,0.0001911452],"category_scores_gemma":[0.017068285,0.0004505737,0.0008531516,0.0015676594,0.00048458413,0.00022627387,0.00031317936,0.00035256537,0.0010134717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012477987,0.00068373955,0.5064601,0.00019678542,0.0008273451,0.000560217,0.00010182874,0.000046327485,0.03945436,0.0000494889,0.004502617,0.44586942],"study_design_scores_gemma":[0.0067713982,0.0004326976,0.95223075,0.00059051585,0.00020713039,0.000018407209,0.00015504402,0.024611104,0.012819453,0.000112296104,0.0016788099,0.00037238724],"about_ca_topic_score_codex":0.0001858035,"about_ca_topic_score_gemma":0.0000244732,"teacher_disagreement_score":0.44577068,"about_ca_system_score_codex":0.0010092611,"about_ca_system_score_gemma":0.0010373511,"threshold_uncertainty_score":0.9997946},"labels":[],"label_agreement":null},{"id":"W4387003753","doi":"10.1016/s2152-2650(23)01908-0","title":"P-290 Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Memorial University of Newfoundland; University of Ottawa; McGill University; Princess Margaret Cancer Centre; Vancouver General Hospital; Micropharma (Canada); Nova Scotia Health Authority; Alberta Health Services; BC Cancer Agency; McMaster University; London Health Sciences Centre; Western University","funders":"","keywords":"Refractory (planetary science); Medicine; Term (time); Multiple myeloma; Phase (matter); Oncology; Internal medicine; Materials science; Physics; Metallurgy","score_opus":0.04524721464682365,"score_gpt":0.35010331379787735,"score_spread":0.3048560991510537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934437,0.00007400265,0.000011228508,0.00008858895,0.00023844714,0.0045250338,0.00047667418,0.0005479808,0.00059428695],"genre_scores_gemma":[0.99225765,0.00007151442,0.00028283277,0.00010151388,0.00015295928,0.00034810728,0.0038649335,0.00024585062,0.0026746446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905058,0.0008430862,0.002886906,0.002088142,0.0019940687,0.0016820092],"domain_scores_gemma":[0.99330914,0.0013695444,0.0009807313,0.002261638,0.0008452699,0.0012336699],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013961963,0.0010694914,0.0024025263,0.0010266205,0.00025701945,0.000075187825,0.0006655844,0.0006280326,0.00011201247],"category_scores_gemma":[0.001594294,0.000773123,0.00045273305,0.0027400744,0.00072114955,0.00041482586,0.00037135938,0.00077180023,0.00038689197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088204235,0.014704966,0.72751063,0.00012135259,0.001253481,0.0054072374,0.00036760897,0.000010647556,0.0002329515,0.0000019747438,0.0007781858,0.1614067],"study_design_scores_gemma":[0.25926402,0.019231997,0.71801186,0.0005728315,0.00041856978,0.000025211571,0.00015360334,0.00081363105,0.00076318206,0.0000034723362,0.00018187714,0.00055973075],"about_ca_topic_score_codex":0.0008519493,"about_ca_topic_score_gemma":0.0011572272,"teacher_disagreement_score":0.17105977,"about_ca_system_score_codex":0.0015832694,"about_ca_system_score_gemma":0.0019878258,"threshold_uncertainty_score":0.99947196},"labels":[],"label_agreement":null},{"id":"W4387003780","doi":"10.1016/s2152-2650(23)01884-0","title":"P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Refractory (planetary science); Cancer research; Medicine; Internal medicine; Materials science","score_opus":0.06391069332254784,"score_gpt":0.36361574012151027,"score_spread":0.2997050467989624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306166,0.00024171708,0.000044907858,0.00034816115,0.0011143076,0.0020191183,0.00018550962,0.0004127595,0.0025718533],"genre_scores_gemma":[0.98777944,0.0018673058,0.00060111657,0.0003375825,0.0009538843,0.00022283584,0.0012345151,0.00018602457,0.006817317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9900057,0.0015817807,0.004030774,0.0016724572,0.0012974131,0.0014118839],"domain_scores_gemma":[0.9906513,0.005122084,0.00093475386,0.0017548789,0.000410251,0.0011267008],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003946286,0.00072068215,0.0021886106,0.00084681594,0.00020303998,0.00005937327,0.00064056495,0.001211772,0.00051078096],"category_scores_gemma":[0.006331859,0.0006483749,0.0011042049,0.0019164495,0.0007681027,0.00028913934,0.00042526895,0.0013078958,0.0020366972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058463197,0.0025186385,0.5541511,0.00026559478,0.00027185894,0.0014471076,0.0002773884,0.0000056181702,0.019702017,0.000027095015,0.0023499238,0.41313735],"study_design_scores_gemma":[0.026487827,0.0020109774,0.94708025,0.0004041589,0.00013520037,0.00004307815,0.00010208582,0.0046204645,0.0040124767,0.0000635879,0.014531239,0.0005086493],"about_ca_topic_score_codex":0.00018129937,"about_ca_topic_score_gemma":0.000060996925,"teacher_disagreement_score":0.41262868,"about_ca_system_score_codex":0.00096376624,"about_ca_system_score_gemma":0.0020282099,"threshold_uncertainty_score":0.9995968},"labels":[],"label_agreement":null},{"id":"W4387003819","doi":"10.1016/s2152-2650(23)01939-0","title":"P-321 Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Saskatchewan Cancer Agency; Memorial University of Newfoundland; McGill University; Princess Margaret Cancer Centre; Vancouver General Hospital; Micropharma (Canada); Nova Scotia Health Authority; Saint John Regional Hospital; Alberta Health Services; BC Cancer Agency; Canadiana.org; Western University; University of British Columbia; McMaster University; London Health Sciences Centre","funders":"","keywords":"Multiple myeloma; Medicine; Database; National database; Internal medicine; Oncology; Computer science","score_opus":0.19534024444972697,"score_gpt":0.47128722238003096,"score_spread":0.275946977930304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890481,0.000058501122,0.0000101307805,0.0031090912,0.0006346208,0.0028472077,0.00037916042,0.00023892058,0.0036742715],"genre_scores_gemma":[0.9923793,0.00010124011,0.0019034847,0.0010104682,0.00070304325,0.00030755895,0.0017843711,0.00018787735,0.0016226354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9856909,0.0024303228,0.0031326658,0.0019213074,0.0041217306,0.0027030704],"domain_scores_gemma":[0.98709,0.0065498482,0.00051431975,0.0019659996,0.0015220935,0.0023577556],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009815804,0.00079340546,0.002065813,0.0017814306,0.001199486,0.00029452436,0.0011784432,0.00071777427,0.00023784679],"category_scores_gemma":[0.006573708,0.00054502505,0.00059873227,0.004269814,0.0016429097,0.00043361456,0.00075865525,0.0019685873,0.001050578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021701844,0.0012484012,0.92864627,0.0000789744,0.0004913715,0.0014275333,0.00015060481,0.000021022324,0.000015094899,0.00073116797,0.008395382,0.05662401],"study_design_scores_gemma":[0.016647615,0.0008941911,0.9653737,0.00041908075,0.00012359006,0.000028619255,0.00027142762,0.008289782,0.000021570486,0.00027728634,0.0071080825,0.00054508244],"about_ca_topic_score_codex":0.117068626,"about_ca_topic_score_gemma":0.5669636,"teacher_disagreement_score":0.449895,"about_ca_system_score_codex":0.0063161203,"about_ca_system_score_gemma":0.009878502,"threshold_uncertainty_score":0.99972725},"labels":[],"label_agreement":null},{"id":"W4387003971","doi":"10.1016/s2152-2650(23)01733-0","title":"P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lenalidomide; Daratumumab; Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Oncology; Internal medicine","score_opus":0.081715692748588,"score_gpt":0.40215142749487637,"score_spread":0.3204357347462884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1905687,0.7915834,0.000007900098,0.00016886836,0.00036477981,0.016215151,0.0007534403,0.00020723042,0.00013053996],"genre_scores_gemma":[0.030879017,0.96274024,0.00042669944,0.000121357836,0.00018689851,0.0025868916,0.002601131,0.00029480807,0.00016296357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98702806,0.0024501604,0.004941972,0.0021054503,0.0022313292,0.0012430528],"domain_scores_gemma":[0.9878596,0.0063883434,0.0018874585,0.0022063467,0.00064832385,0.0010099424],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003895683,0.0014608755,0.008705326,0.00090212026,0.00019393908,0.000078056015,0.0009280711,0.0008874708,0.0000403331],"category_scores_gemma":[0.007697619,0.0010106483,0.0010201108,0.002287124,0.0005474934,0.00026945525,0.0005025396,0.0011524518,0.00007981807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005067479,0.0046861414,0.15647942,0.03630191,0.0014474645,0.002378472,0.00009901244,1.875392e-7,2.403437e-7,0.000011407414,0.0009842647,0.792544],"study_design_scores_gemma":[0.088226,0.007647293,0.71315795,0.14768247,0.00377521,0.00012898426,0.00007401127,0.00009312541,0.000003610547,0.000021763472,0.038143642,0.0010459261],"about_ca_topic_score_codex":0.00059015176,"about_ca_topic_score_gemma":0.00089111226,"teacher_disagreement_score":0.79149806,"about_ca_system_score_codex":0.0012277542,"about_ca_system_score_gemma":0.0030521767,"threshold_uncertainty_score":0.9998141},"labels":[],"label_agreement":null},{"id":"W4387004140","doi":"10.1016/s2152-2650(23)01640-3","title":"P-022 Development of trogocytosis resistant CAR-NK for multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; University of Ottawa; Ottawa Hospital","funders":"University of Texas MD Anderson Cancer Center; Université de Liège; University of Arkansas for Medical Sciences","keywords":"Multiple myeloma; Biology; Immunology","score_opus":0.08841249716564327,"score_gpt":0.37913653795428,"score_spread":0.29072404078863673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387004140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947048,0.0002892552,0.0002738061,0.00042665825,0.00044526547,0.0019750742,0.00022124282,0.0003963914,0.0012675063],"genre_scores_gemma":[0.9768526,0.0001945243,0.017712427,0.00022822038,0.00043257384,0.00068684085,0.0007230003,0.00013789372,0.0030319518],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99404573,0.00021624196,0.0022409973,0.0011245122,0.0010665864,0.0013059119],"domain_scores_gemma":[0.99414015,0.002774334,0.00045062153,0.0011333071,0.0005338606,0.00096773787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017036122,0.00053988275,0.0014937222,0.00043986263,0.0003906311,0.000041792613,0.0004871622,0.0004912053,0.00012368627],"category_scores_gemma":[0.0039191456,0.00045976893,0.0008990723,0.0009794513,0.00043057266,0.00012755839,0.0003455776,0.00025899586,0.0005820033],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008801049,0.000713553,0.091038145,0.00070267566,0.0011746711,0.0004381625,0.00037989064,0.0000056120475,0.012121829,0.00020248536,0.007905005,0.87651694],"study_design_scores_gemma":[0.015831165,0.0012543354,0.9059233,0.00033216868,0.00019510962,0.000030523366,0.00024145425,0.002306968,0.025890734,0.000161543,0.047418326,0.00041434835],"about_ca_topic_score_codex":0.00009765379,"about_ca_topic_score_gemma":0.0001245704,"teacher_disagreement_score":0.87610257,"about_ca_system_score_codex":0.0013122397,"about_ca_system_score_gemma":0.0032224776,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W4387045592","doi":"10.1136/spcare-2023-004524","title":"Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study","year":2023,"lang":"en","type":"article","venue":"BMJ Supportive & Palliative Care","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Palliative care; Retrospective cohort study; Multiple myeloma; Emergency medicine; Observational study; Cardiopulmonary resuscitation; Internal medicine; Resuscitation; Nursing","score_opus":0.08589943413845574,"score_gpt":0.405811739844759,"score_spread":0.31991230570630325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387045592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819748,0.00078871136,0.00001888935,0.00014893929,0.0004153853,0.01060008,0.0012850746,0.0003802618,0.004387902],"genre_scores_gemma":[0.99281955,0.00010157925,0.00021022052,0.000047582358,0.00020259706,0.0032730713,0.0029042845,0.00011789246,0.00032325095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930056,0.00063844054,0.0010000302,0.0018270463,0.0019839252,0.0015449926],"domain_scores_gemma":[0.99460524,0.00076937326,0.0003817468,0.0008681714,0.002698555,0.00067692227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003292506,0.0008728367,0.0017614674,0.0006568652,0.0004182424,0.000080494145,0.0003769576,0.00039716237,0.00032371393],"category_scores_gemma":[0.0029297697,0.00073619385,0.00047338996,0.001798744,0.0004045549,0.0002236795,0.00045362394,0.0010612322,0.00071534363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047944863,0.00050532055,0.9078377,0.00027958376,0.0009757571,0.009707171,0.074153535,0.0000140614575,0.000036697755,0.00003901931,0.00031441535,0.0013422628],"study_design_scores_gemma":[0.016981306,0.0052216244,0.7352231,0.00024036302,0.00022730592,0.0000025122445,0.24072433,0.00007815081,0.00069407834,0.0000141904275,0.00008808173,0.00050494075],"about_ca_topic_score_codex":0.0010258693,"about_ca_topic_score_gemma":0.005446955,"teacher_disagreement_score":0.17261457,"about_ca_system_score_codex":0.0033846342,"about_ca_system_score_gemma":0.0007656309,"threshold_uncertainty_score":0.9995089},"labels":[],"label_agreement":null},{"id":"W4387114589","doi":"10.1158/2643-3230.bcd-23-0062","title":"Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Institute of Cancer Research","funders":"National Cancer Institute","keywords":"Downregulation and upregulation; Cancer research; Enhancer; IRF4; In vivo; Transcription factor; Biology; Chemistry; Genetics; Gene","score_opus":0.044221167269561594,"score_gpt":0.33359791446182685,"score_spread":0.28937674719226525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387114589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953435,0.0012739813,0.00002505513,0.0014224319,0.00023881966,0.0006334041,0.00040541164,0.00013170076,0.0005256791],"genre_scores_gemma":[0.9952889,0.0007325292,0.0000983471,0.00013148379,0.00016226668,0.00059452286,0.00038021576,0.000040973613,0.0025707718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794585,0.000077143406,0.00032432715,0.00047547935,0.0005770605,0.00060012605],"domain_scores_gemma":[0.99921644,0.00017800977,0.00004575715,0.0003038592,0.00006595012,0.00019000322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019280509,0.00022742435,0.00034842006,0.0003024166,0.00016966203,0.00007474018,0.00012681237,0.000057822934,0.00015444779],"category_scores_gemma":[0.00009044002,0.00020157221,0.00019480257,0.0006783214,0.00009814616,0.0004907589,0.00006874639,0.00024031481,0.00008516451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031464064,0.0011885082,0.9527699,0.000186656,0.0003456812,0.00027966502,0.0004930739,0.000202785,0.03834287,0.00031745582,0.000387396,0.0051713674],"study_design_scores_gemma":[0.012910861,0.000090228925,0.95674783,0.00025801832,0.00010654683,0.000017429596,0.00025971726,0.0015224223,0.027124342,0.00015040029,0.0005887441,0.00022348104],"about_ca_topic_score_codex":0.0019511316,"about_ca_topic_score_gemma":0.005963243,"teacher_disagreement_score":0.01259622,"about_ca_system_score_codex":0.00021595827,"about_ca_system_score_gemma":0.00027149369,"threshold_uncertainty_score":0.8219876},"labels":[],"label_agreement":null},{"id":"W4387117764","doi":"10.1016/j.asjsur.2023.09.075","title":"Toothache as an initial symptom of extramedullary plasmacytoma in the maxillary sinus: A case report","year":2023,"lang":"en","type":"article","venue":"Asian Journal of Surgery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Science Foundation of Hunan Province","keywords":"Medicine; Toothache; Extramedullary plasmacytoma; Maxillary sinus; Plasmacytoma; Dentistry; Radiology; Dermatology; Multiple myeloma; Internal medicine","score_opus":0.0822348205696149,"score_gpt":0.3719519361595764,"score_spread":0.2897171155899615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387117764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957175,0.0002184629,0.0000037988318,0.0018712757,0.00019013886,0.00019001075,0.000010978905,0.0000147506125,0.0017830669],"genre_scores_gemma":[0.9992611,0.00010597721,0.00013700344,0.00011677181,0.0002400494,0.0000068835266,0.00003256396,0.000023156443,0.00007652179],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99760705,0.00028057944,0.00084946357,0.00015517052,0.0007531476,0.00035461618],"domain_scores_gemma":[0.9981828,0.0006334002,0.00036629193,0.00035162756,0.00017912264,0.000286806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002070198,0.00014689751,0.0005006358,0.00068136555,0.000057581026,0.000027004133,0.00012358848,0.000092351,0.00010808273],"category_scores_gemma":[0.0012451006,0.00009559275,0.00027390916,0.000681687,0.000115177085,0.00023134686,0.00002963731,0.0004005904,0.000021795631],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071893504,0.00033287416,0.11621349,0.00005957816,0.00016844594,0.8496535,0.0009903146,0.0000015890176,0.00018319685,0.0000070028836,0.0012986561,0.030372456],"study_design_scores_gemma":[0.0012056808,0.00043878064,0.18517208,0.00027281613,0.00006314587,0.806756,0.0043032295,0.00003729579,0.001073239,0.0001308562,0.00046776872,0.00007908188],"about_ca_topic_score_codex":0.000115146315,"about_ca_topic_score_gemma":0.000025739217,"teacher_disagreement_score":0.06895858,"about_ca_system_score_codex":0.000055902263,"about_ca_system_score_gemma":0.0008293947,"threshold_uncertainty_score":0.38981593},"labels":[],"label_agreement":null},{"id":"W4387128075","doi":"10.1158/2643-3230.bcd-23-0049","title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Narodowa Agencja Wymiany Akademickiej","keywords":"Hypogammaglobulinemia; Medicine; Antibody; Multiple myeloma; Internal medicine; Immunology; Confidence interval; Cumulative incidence; Incidence (geometry); Gastroenterology; Cohort","score_opus":0.0270653576593723,"score_gpt":0.27648295835949677,"score_spread":0.24941760070012448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387128075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805343,0.00010712042,0.0000025158515,0.00007416754,0.00007669328,0.0010219356,0.0003925502,0.00013798317,0.00013358743],"genre_scores_gemma":[0.9971852,0.00059441983,0.000031254796,0.0000091827405,0.00004577125,0.00022034544,0.0007192419,0.00005648801,0.0011381509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816424,0.00008040921,0.0003098487,0.0004398945,0.00051478285,0.00049081614],"domain_scores_gemma":[0.9990049,0.000116102136,0.00017415085,0.00032800942,0.000249987,0.00012687885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081102626,0.00026593395,0.0004957226,0.0005120155,0.00012286681,0.000058634592,0.000064871696,0.00008289293,0.000018231021],"category_scores_gemma":[0.00014432248,0.00018685107,0.00007799949,0.0016090343,0.00017144754,0.00055141834,0.000042166823,0.0001887869,0.000008547866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010895083,0.002096078,0.98762715,0.00008258561,0.0009415888,0.00018334671,0.00017475788,0.00033387612,0.006028975,0.0000039359606,0.00014740367,0.0012907721],"study_design_scores_gemma":[0.015193175,0.0013878638,0.96481305,0.000805215,0.000279046,0.000018682415,0.00013647086,0.00014432603,0.016993545,0.000002205523,0.000031903553,0.00019453364],"about_ca_topic_score_codex":0.005815551,"about_ca_topic_score_gemma":0.005707067,"teacher_disagreement_score":0.022814138,"about_ca_system_score_codex":0.00021509772,"about_ca_system_score_gemma":0.0002495296,"threshold_uncertainty_score":0.8791413},"labels":[],"label_agreement":null},{"id":"W4387228414","doi":"10.5858/arpa.2023-0035-cp","title":"PCNEO, a New Proficiency Testing Program for Flow Cytometric Analysis of Plasma Cell Neoplasms From the College of American Pathologists Diagnostic Immunology and Flow Cytometry Committee","year":2023,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Flow cytometry; Context (archaeology); Medicine; Plasma Cell Myeloma; Pathology; CD38; Multiple myeloma; Plasma cell; Immunology; Internal medicine; Biology","score_opus":0.02761073261650262,"score_gpt":0.3183403195049698,"score_spread":0.29072958688846723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387228414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922534,0.0019430544,0.0007164971,0.0007393119,0.00008963738,0.0015665968,0.0025077271,0.00007391726,0.00010984304],"genre_scores_gemma":[0.9666056,0.0006256356,0.031897727,0.00007551003,0.00006894134,0.0001938603,0.0004562949,0.000030599458,0.000045828005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727005,0.00043508408,0.00081673136,0.00053572556,0.0003958546,0.0005465539],"domain_scores_gemma":[0.9809545,0.017237095,0.0005963312,0.00068650604,0.0003037423,0.00022176783],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.0006713786,0.0002923271,0.0014930414,0.0018950654,0.00011199906,0.0000025746397,0.00033785583,0.000108829576,0.000020732332],"category_scores_gemma":[0.01224062,0.00019156293,0.00015934835,0.00779244,0.0030960455,0.00003538234,0.00019843529,0.00030079266,0.0000024254025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009695531,0.0006995312,0.78454214,0.00026375699,0.0013728279,0.0007091698,0.0024715199,0.000075634794,0.11298391,0.000027757398,0.00032982542,0.09555435],"study_design_scores_gemma":[0.005496518,0.0072056684,0.95928764,0.00018467983,0.0018615669,0.000029176377,0.0018526545,0.0149732595,0.008727738,0.00012250684,0.00012460367,0.00013401291],"about_ca_topic_score_codex":0.00039389898,"about_ca_topic_score_gemma":0.00010930829,"teacher_disagreement_score":0.17474546,"about_ca_system_score_codex":0.000027235204,"about_ca_system_score_gemma":0.00042524133,"threshold_uncertainty_score":0.999617},"labels":[],"label_agreement":null},{"id":"W4387241722","doi":"10.1158/0008-5472.can-23-2629","title":"A Landmark Paper That Introduced Proteasome Inhibition in Myeloma","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Bortezomib; Proteasome; Proteasome inhibitor; Thalidomide; Medicine; Ubiquitin; Cancer research; Cancer; Disease; Immunology; Biology; Internal medicine; Cell biology; Genetics","score_opus":0.12636119859493644,"score_gpt":0.4338443846064408,"score_spread":0.3074831860115044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387241722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860445,0.00035192058,0.0000012427314,0.009176268,0.000062195795,0.0016398741,0.000023432174,0.00009871003,0.0026018126],"genre_scores_gemma":[0.9907721,0.0007673658,0.00003087044,0.00009682968,0.00031169024,0.002002674,0.000110208486,0.00003460271,0.0058736526],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971851,0.00023529382,0.00016365096,0.0004365562,0.00108965,0.00088975794],"domain_scores_gemma":[0.9989524,0.0001602004,0.000018130115,0.00038152715,0.00019782376,0.0002899326],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011602454,0.00012207904,0.00023171844,0.00076262763,0.0001248009,0.000044665376,0.000081371254,0.0000955345,0.001001903],"category_scores_gemma":[0.00047607033,0.00009589495,0.000055666496,0.0016762521,0.00013058778,0.0001473055,0.00014738504,0.0006094355,0.00106367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004155173,0.0005427126,0.40735027,0.0008007681,0.00018713367,0.0049136016,0.0012394554,0.0000143932775,0.4304599,0.0002878638,0.039030783,0.11101795],"study_design_scores_gemma":[0.0070329495,0.00045513033,0.88293874,0.000585981,0.000008439414,0.000032588065,0.00039530807,0.00023310645,0.092031285,0.0007207284,0.015391474,0.00017425485],"about_ca_topic_score_codex":0.0010805561,"about_ca_topic_score_gemma":0.000615565,"teacher_disagreement_score":0.47558847,"about_ca_system_score_codex":0.00052260596,"about_ca_system_score_gemma":0.00042091776,"threshold_uncertainty_score":0.9999113},"labels":[],"label_agreement":null},{"id":"W4387252273","doi":"10.1038/s41591-023-02589-w","title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network; University of Calgary; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"National Cancer Institute; SkylineDx; Genentech; MEI Pharma; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Gilead Sciences; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Clinical endpoint; Adverse effect; Cumulative incidence; Progression-free survival; Surgery; Oncology; Clinical trial; Chemotherapy; Cancer; Immunotherapy; Cohort","score_opus":0.04272326740296717,"score_gpt":0.3915068327786259,"score_spread":0.34878356537565874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387252273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653992,0.003147211,0.0000055589826,0.02389512,0.0011453519,0.002744914,0.00004475445,0.00024595967,0.0033719451],"genre_scores_gemma":[0.9862692,0.0006265287,0.00010087924,0.0012060663,0.0013506778,0.00023647193,0.00042273322,0.0000522245,0.00973525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686503,0.00021262842,0.0005246753,0.000515195,0.0011842693,0.0006981811],"domain_scores_gemma":[0.99729633,0.0013550624,0.000104799146,0.0007699443,0.00013147035,0.00034236853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010981356,0.0003069104,0.0006295063,0.0005765903,0.00015089226,0.0000123332875,0.0002891204,0.0004419834,0.0013127628],"category_scores_gemma":[0.006092535,0.00014923309,0.000111537694,0.0017604947,0.00028428738,0.00006404908,0.000086235756,0.0018547712,0.0002925895],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45104694,0.0030989198,0.0073779724,0.00036493162,0.00049715186,0.018304536,0.0020722651,0.0000036375848,0.015239971,0.0002259386,0.21116042,0.2906073],"study_design_scores_gemma":[0.70910245,0.011309295,0.083943546,0.0005901398,0.00020630556,0.00018524792,0.0009866558,0.0024034716,0.0011555151,0.00013314333,0.18968235,0.00030190346],"about_ca_topic_score_codex":0.00022879952,"about_ca_topic_score_gemma":0.00042235854,"teacher_disagreement_score":0.2903054,"about_ca_system_score_codex":0.00018419222,"about_ca_system_score_gemma":0.00026336237,"threshold_uncertainty_score":0.9996002},"labels":[],"label_agreement":null},{"id":"W4387744424","doi":"10.21203/rs.3.rs-3449333/v1","title":"Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunoglobulin light chain; Multiple myeloma; Residual; Monoclonal; Mass spectrometry; Progression-free survival; Cancer research; Monoclonal antibody; Chemistry; Oncology; Medicine; Internal medicine; Overall survival; Computer science; Chromatography; Immunology; Algorithm; Antibody","score_opus":0.03772934333849392,"score_gpt":0.3506400183519398,"score_spread":0.3129106750134459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387744424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841119,0.0011957373,0.00031092658,0.0046217777,0.00021038612,0.0054963636,0.0029132718,0.0001083198,0.0010313264],"genre_scores_gemma":[0.9953337,0.00048642102,0.0007456127,0.0000059835475,0.00025185655,0.0006438696,0.00084262545,0.00013796923,0.001552011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98978835,0.001420323,0.00074113166,0.001016824,0.00588439,0.0011489561],"domain_scores_gemma":[0.99238664,0.002307452,0.0005131204,0.0020321717,0.0022950121,0.00046561233],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027038946,0.000531883,0.001075616,0.0011651367,0.00034221055,0.0000991314,0.0011841793,0.00059032947,0.00011328221],"category_scores_gemma":[0.0048139542,0.0003280418,0.0002771196,0.0015527199,0.0007737752,0.00014141883,0.0022015455,0.0030096096,0.000029685663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020828294,0.0031092458,0.89455014,0.006772022,0.0040238495,0.000520794,0.0026188053,0.000031520856,0.029969648,0.00017620198,0.017916251,0.01948324],"study_design_scores_gemma":[0.011237908,0.008585194,0.82665884,0.0042415955,0.000149665,0.000007082851,0.0015996236,0.00070672785,0.14390185,0.0023756349,0.000140218,0.00039565694],"about_ca_topic_score_codex":0.0014867578,"about_ca_topic_score_gemma":0.00072277314,"teacher_disagreement_score":0.113932215,"about_ca_system_score_codex":0.00063193345,"about_ca_system_score_gemma":0.0007159734,"threshold_uncertainty_score":0.99991715},"labels":[],"label_agreement":null},{"id":"W4388204457","doi":"10.14740/jh1148","title":"The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Transplantation; Renal function; Internal medicine; Kidney disease; Urology; Surgery; Creatinine; Autologous stem-cell transplantation","score_opus":0.019168864602323192,"score_gpt":0.30104148501169986,"score_spread":0.28187262040937666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388204457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991642,0.00013164026,0.000108813816,0.00016339394,0.000040463518,0.00027258543,0.000012007273,0.000009834812,0.000097055105],"genre_scores_gemma":[0.99954164,0.00017321104,0.00018977516,0.0000054391794,0.000012855188,0.000008213907,0.000028297925,0.000012050117,0.000028495211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986659,0.00013403728,0.0004961258,0.00009636137,0.0003092852,0.0002982638],"domain_scores_gemma":[0.9985632,0.0006841105,0.00036938448,0.00010278276,0.00016760862,0.00011291378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028425298,0.00011040447,0.0003734695,0.00029311722,0.00008528547,0.00000897471,0.00007761051,0.00005890535,0.000013030331],"category_scores_gemma":[0.000051138308,0.000058940495,0.00011858444,0.00024460244,0.00007691971,0.0000764231,0.0000119359,0.00019771582,0.0000071837144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00298995,0.00033667352,0.990386,0.00014215609,0.0002809464,0.001675045,0.00069763843,0.00054036686,0.00092505204,0.000023458837,0.00015207194,0.0018506355],"study_design_scores_gemma":[0.01047217,0.0039165635,0.9750413,0.0003021056,0.000055126802,0.0015188754,0.0004758441,0.00093584677,0.007161442,0.00006403851,0.0000035794242,0.00005316633],"about_ca_topic_score_codex":0.000043847995,"about_ca_topic_score_gemma":0.00012387687,"teacher_disagreement_score":0.015344764,"about_ca_system_score_codex":0.00014491906,"about_ca_system_score_gemma":0.00029440995,"threshold_uncertainty_score":0.24035236},"labels":[],"label_agreement":null},{"id":"W4388287988","doi":"10.3390/curroncol30110705","title":"Multiple Myeloma in 2023 Ways: From Trials to Real Life","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Multiple myeloma; Chimeric antigen receptor; Disease; Malignancy; Intensive care medicine; Hematologic malignancy; Bioinformatics; Immunology; Internal medicine; Immunotherapy; Cancer","score_opus":0.6375273539588502,"score_gpt":0.5646858573344412,"score_spread":0.07284149662440897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388287988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047569652,0.9882941,0.000020113064,0.0003175888,0.0027537274,0.005486081,0.0013025617,0.00015231529,0.0011977894],"genre_scores_gemma":[0.000032301137,0.9904637,0.0002733471,0.000040258918,0.0019186218,0.0025297345,0.0038332331,0.00012184336,0.0007869967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99391615,0.0014397551,0.0020301344,0.0010746949,0.0005622012,0.0009770346],"domain_scores_gemma":[0.99170023,0.00577809,0.00049953384,0.000782895,0.00012034758,0.0011189138],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017275624,0.00065713766,0.006545711,0.0010984618,0.00006220102,0.00002871012,0.00041247052,0.0007343742,0.00061087724],"category_scores_gemma":[0.011579575,0.00048082566,0.000925309,0.0010488476,0.0000810295,0.00003978223,0.00040944616,0.001119158,0.008161736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004084966,0.00079494674,0.0013310225,0.005393517,0.00071453874,0.0008944057,0.00008790463,2.0575784e-7,0.0000010809694,0.00002291997,0.02076083,0.9695901],"study_design_scores_gemma":[0.005427109,0.0006168173,0.0024753485,0.012318802,0.0009503125,0.00001430466,0.000039099647,0.00002867648,6.142047e-7,0.000046597575,0.9777557,0.00032659853],"about_ca_topic_score_codex":0.0012639363,"about_ca_topic_score_gemma":0.0014187768,"teacher_disagreement_score":0.96926355,"about_ca_system_score_codex":0.0014789877,"about_ca_system_score_gemma":0.002591516,"threshold_uncertainty_score":0.9997643},"labels":[],"label_agreement":null},{"id":"W4388424902","doi":"10.1136/bcr-2023-256250","title":"Diffuse myelomatous infiltration of the pancreas","year":2023,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Infiltration (HVAC); Medicine; Jaundice; Multiple myeloma; Immunoglobulin light chain; Gastroenterology; Obstructive jaundice; Internal medicine; Nuclear medicine; Pathology; Immunology; Antibody; Geography","score_opus":0.04092745895740157,"score_gpt":0.34685154025408316,"score_spread":0.3059240812966816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388424902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519867,0.000038413134,0.000005179423,0.00039707677,0.00012188057,0.0008442533,0.000005555623,0.00007829772,0.0033106836],"genre_scores_gemma":[0.9978148,0.000020945934,0.000069105656,0.000033080985,0.00007084309,0.00007894248,0.00003442972,0.000013963712,0.0018638843],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9988669,0.00004435123,0.0003290072,0.00016400892,0.0004033264,0.00019238578],"domain_scores_gemma":[0.9989747,0.0000702501,0.00015460115,0.00058342237,0.000094783805,0.00012223287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028090746,0.00008420056,0.00017940666,0.000079220765,0.000076924356,0.000008655364,0.00001922387,0.00004804747,0.000062309526],"category_scores_gemma":[0.0007460283,0.000050820403,0.00011003182,0.000359038,0.000053077798,0.00003802124,0.000050805334,0.000076773846,0.000043259093],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008913711,0.00021131364,0.24719675,0.00013907217,0.00013385617,0.7316786,0.00016812605,0.0000042715706,0.005258247,0.00004274807,0.0028512601,0.012226604],"study_design_scores_gemma":[0.0010575625,0.00009002755,0.4617223,0.00011255484,0.00007672629,0.52184474,0.00011604435,0.00035925081,0.012785078,0.00014807383,0.0016142591,0.000073375275],"about_ca_topic_score_codex":0.0004425686,"about_ca_topic_score_gemma":0.00005974478,"teacher_disagreement_score":0.21452557,"about_ca_system_score_codex":0.000036180314,"about_ca_system_score_gemma":0.0001777485,"threshold_uncertainty_score":0.20723958},"labels":[],"label_agreement":null},{"id":"W4388451947","doi":"10.1158/2643-3230.bcd-23-0061","title":"ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Paula and Rodger Riney Foundation; American Society of Hematology; Multiple Myeloma Research Foundation","keywords":"Transcription factor; Enhancer; Chromatin immunoprecipitation; Chromatin; Biology; Cancer research; Genetics; Promoter; Gene expression; Gene","score_opus":0.02987792591273875,"score_gpt":0.29229910765021666,"score_spread":0.2624211817374779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388451947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542445,0.0011411546,0.000025604395,0.0010289173,0.000096481715,0.0006484086,0.000808925,0.000057890495,0.00076818117],"genre_scores_gemma":[0.99589497,0.0014443152,0.0002347372,0.00010148699,0.00011021753,0.00033126323,0.00016672425,0.000028937506,0.0016873621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977257,0.0000949977,0.00045090538,0.00058829715,0.0005676212,0.00057245704],"domain_scores_gemma":[0.9992239,0.000253361,0.00006817845,0.0002226972,0.00003461154,0.00019723758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002759975,0.00021799299,0.00034212056,0.00031362384,0.000081850696,0.000047958485,0.00009797024,0.000090797745,0.00002497481],"category_scores_gemma":[0.00022834988,0.00018762721,0.00006507147,0.00044918284,0.000096784446,0.00029910723,0.000077385615,0.0003036951,0.000013967172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014917314,0.0012088189,0.74307615,0.00046007716,0.00013773027,0.0027192365,0.0011502692,0.0004416995,0.23303053,0.00028046453,0.0008277077,0.001749981],"study_design_scores_gemma":[0.026762951,0.00013753366,0.94753355,0.0009870176,0.00003942362,0.000013533197,0.00024943933,0.00040400785,0.022938397,0.00022859307,0.00050340965,0.00020212668],"about_ca_topic_score_codex":0.0014292797,"about_ca_topic_score_gemma":0.025466343,"teacher_disagreement_score":0.21009214,"about_ca_system_score_codex":0.00021979846,"about_ca_system_score_gemma":0.000248325,"threshold_uncertainty_score":0.99231637},"labels":[],"label_agreement":null},{"id":"W4388495570","doi":"10.1038/s41408-023-00939-y","title":"MRD negativity: considerations for older adults with multiple myeloma","year":2023,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University","funders":"National Cancer Institute; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Multiple myeloma; Medicine; Negativity effect; Internal medicine; Oncology; Gerontology; Psychology; Developmental psychology","score_opus":0.02538720888301478,"score_gpt":0.3279142641090423,"score_spread":0.3025270552260275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495570","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015125225,0.0034393065,0.0003244129,0.0029003879,0.9679655,0.004324877,0.0054089325,0.00024903307,0.0002623251],"genre_scores_gemma":[0.022248624,0.0026111347,0.004204366,0.000100382764,0.9623008,0.001754439,0.00075455895,0.00029289423,0.0057328152],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965194,0.00009263302,0.0005101488,0.00057457224,0.0014613201,0.000841949],"domain_scores_gemma":[0.9938381,0.0031513376,0.00038503527,0.00038515325,0.001545577,0.0006948437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032960868,0.00047936666,0.0008503522,0.00032621907,0.00056939694,0.00023093485,0.00014309054,0.0004979454,0.00036410344],"category_scores_gemma":[0.0038372735,0.0003461621,0.00030914944,0.00022767752,0.00011447922,0.00015125441,0.000052698346,0.0015039563,0.000038283986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023340434,0.00046687332,0.002401364,0.0005667927,0.002793715,0.0014911448,0.00033650603,0.0000076335555,0.000036855647,0.0000022033269,0.9811,0.008462839],"study_design_scores_gemma":[0.1310802,0.004872656,0.01378616,0.011632796,0.0053696577,0.0010689825,0.00051815604,0.00050033093,0.0024761911,0.00026266996,0.82708865,0.0013435393],"about_ca_topic_score_codex":0.0004911015,"about_ca_topic_score_gemma":0.003150523,"teacher_disagreement_score":0.15401137,"about_ca_system_score_codex":0.00029704583,"about_ca_system_score_gemma":0.0039922534,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W4388666218","doi":"10.1016/j.clml.2023.11.001","title":"Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Post-hoc analysis; Physical therapy; Internal medicine; Refractory (planetary science); Health related quality of life; Clinical trial; Multiple myeloma; Minimal clinically important difference; Disease; Randomized controlled trial","score_opus":0.1184171867158281,"score_gpt":0.41028812813908366,"score_spread":0.29187094142325554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388666218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246264,0.00073171454,0.0000012825354,0.0017200983,0.0004075347,0.0036875436,0.0005292386,0.00032309812,0.00013686091],"genre_scores_gemma":[0.99726623,0.00029269533,0.00015883624,0.00048176813,0.00016183176,0.00022558276,0.0007946275,0.00009570244,0.0005227097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98862696,0.0016835083,0.005794048,0.0015705206,0.001273219,0.001051722],"domain_scores_gemma":[0.9872255,0.007525782,0.0018716065,0.0019996248,0.00032502192,0.0010525025],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049098376,0.00060931826,0.0022066897,0.00032323,0.00043957596,0.000050103212,0.00044142824,0.0005394671,0.0000467615],"category_scores_gemma":[0.022266679,0.00039744386,0.00038405703,0.001500555,0.0007288795,0.00016692112,0.00066069624,0.0008105974,0.00006286306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035599835,0.0059652384,0.384251,0.00009519726,0.001046945,0.0012519951,0.0023172863,0.0000027194358,0.00078491593,0.000007978719,0.0014599757,0.56721693],"study_design_scores_gemma":[0.10316209,0.010593485,0.8812061,0.00032626995,0.00012236067,0.000022961576,0.0021105383,0.0014640776,0.000093343035,0.00007063673,0.00050425535,0.0003238698],"about_ca_topic_score_codex":0.015323601,"about_ca_topic_score_gemma":0.0024349438,"teacher_disagreement_score":0.56689304,"about_ca_system_score_codex":0.000909878,"about_ca_system_score_gemma":0.0030666357,"threshold_uncertainty_score":0.99984777},"labels":[],"label_agreement":null},{"id":"W4388738295","doi":"10.1097/01.hs9.0000936192.21618.f2","title":"P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Scientific Affairs; Centre Hospitalier Universitaire de Toulouse; Universitätsklinikum Hamburg-Eppendorf; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Texas MD Anderson Cancer Center; Ankara Universitesi; University of Oxford; Université de Lille; Cancer Research Institute","keywords":"Medicine; Lenalidomide; Daratumumab; Quality of life (healthcare); Internal medicine; Multiple myeloma; Population; Dexamethasone; Subgroup analysis; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.04459092877840427,"score_gpt":0.3177322132499836,"score_spread":0.2731412844715793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388738295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994999,0.00041817265,0.00031708396,0.00016594496,0.000022695298,0.0029749526,0.0009332409,0.00009094234,0.00007798779],"genre_scores_gemma":[0.995138,0.0001385375,0.00196356,0.00003210735,0.000020268144,0.00025926423,0.0021385401,0.00005410365,0.00025560657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996879,0.0002466097,0.0009996236,0.0005611717,0.00072947965,0.0005841571],"domain_scores_gemma":[0.996874,0.0012709831,0.0005170922,0.00048523184,0.00035331046,0.0004993964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005387943,0.000341278,0.0017098802,0.00035309058,0.0001303532,0.000015528185,0.00010539834,0.00016092439,0.00012513495],"category_scores_gemma":[0.00045954026,0.00022918366,0.0002576125,0.001965638,0.00019191342,0.000102139566,0.000023458402,0.00016760458,0.0000039701777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18911205,0.00094851607,0.8008282,0.0007590398,0.004805098,0.000036335656,0.00051051134,0.00011286479,0.00028613137,0.000020184092,0.00019405028,0.0023870093],"study_design_scores_gemma":[0.21342877,0.003802303,0.7780473,0.00027439464,0.0011505701,0.000001520208,0.00029256186,0.0016382916,0.0011235214,0.000007599348,0.000029582554,0.0002035848],"about_ca_topic_score_codex":0.005208494,"about_ca_topic_score_gemma":0.0044871406,"teacher_disagreement_score":0.024316717,"about_ca_system_score_codex":0.00007940551,"about_ca_system_score_gemma":0.00031260867,"threshold_uncertainty_score":0.93458384},"labels":[],"label_agreement":null},{"id":"W4388738310","doi":"10.1097/01.hs9.0000936164.84357.ed","title":"P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Multiple myeloma; Clinical endpoint; Dexamethasone; Surgery; Phases of clinical research; Minimal residual disease; Progression-free survival; Oncology; Gastroenterology; Chemotherapy; Randomized controlled trial; Bone marrow","score_opus":0.02799922324280263,"score_gpt":0.3080481877675247,"score_spread":0.28004896452472205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388738310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558747,0.0006758022,0.00006517743,0.00027253374,0.00007434004,0.0027088167,0.0003834384,0.000093118615,0.00013930582],"genre_scores_gemma":[0.99761534,0.0002895649,0.0008342122,0.000048671835,0.000030238438,0.00021155493,0.0006370769,0.00007398318,0.00025935125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602634,0.00041838884,0.0007556024,0.00091463537,0.0010467661,0.0008382613],"domain_scores_gemma":[0.99704987,0.0011539116,0.00026187766,0.00085044996,0.00022770702,0.0004562094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005611796,0.0005459,0.0014518038,0.0005686247,0.00022620079,0.000059962415,0.00024232015,0.00017493956,0.00020367008],"category_scores_gemma":[0.00048167552,0.00036626525,0.00019417336,0.003455868,0.00029144916,0.00021004208,0.00016663423,0.00044236146,0.000014450251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037945464,0.0024248464,0.94372183,0.00017780063,0.004412899,0.00093155116,0.0020547167,0.00036000446,0.0013031383,0.000004092806,0.00036605517,0.006297625],"study_design_scores_gemma":[0.18018366,0.0018530127,0.80132425,0.000264258,0.0027852398,0.000011901548,0.0022913683,0.0075712465,0.0032346393,0.0000070611627,0.00010239414,0.0003709447],"about_ca_topic_score_codex":0.0033518788,"about_ca_topic_score_gemma":0.013679701,"teacher_disagreement_score":0.14239754,"about_ca_system_score_codex":0.0001873896,"about_ca_system_score_gemma":0.00019369983,"threshold_uncertainty_score":0.99987894},"labels":[],"label_agreement":null},{"id":"W4388833789","doi":"10.1097/01.cot.0000996488.11406.21","title":"Immunoglobulin May Prevent Infections in Patients With Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Antibody; Immunology; Medicine; Immunoglobulin G","score_opus":0.01652046280345482,"score_gpt":0.3171043257003723,"score_spread":0.30058386289691746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388833789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98571426,0.00003845819,0.0000045798547,0.0009166688,0.00007988533,0.0008198129,0.000020515947,0.00012293475,0.012282898],"genre_scores_gemma":[0.98815507,0.00003581725,0.00045552594,0.00006584498,0.00003312895,0.00020826282,0.00027013727,0.00002089394,0.010755307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887794,0.000092601476,0.00018635951,0.00024128283,0.00021148648,0.0003903547],"domain_scores_gemma":[0.99930227,0.00020745437,0.000045295095,0.0002336089,0.00007672026,0.00013465798],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014028727,0.00012976611,0.00027219145,0.0002762504,0.00008102022,0.0000074067507,0.00006242746,0.00010957947,0.00048558478],"category_scores_gemma":[0.00018450609,0.000095163865,0.000049874212,0.00049667427,0.0000878146,0.00005997959,0.000068104404,0.00019832562,0.0012231482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072861597,0.0016855915,0.9668125,0.0000188729,0.00015017149,0.00015357009,0.000111319205,0.000019948073,0.000055081524,0.000018292032,0.0040236595,0.026222391],"study_design_scores_gemma":[0.009131751,0.0024131215,0.970717,0.00004828602,0.000030124544,0.000010711384,0.00004500907,0.00016925775,0.00021262064,0.000025440151,0.017112058,0.000084637715],"about_ca_topic_score_codex":0.00017568124,"about_ca_topic_score_gemma":0.00026189338,"teacher_disagreement_score":0.026137754,"about_ca_system_score_codex":0.00028631688,"about_ca_system_score_gemma":0.00022503785,"threshold_uncertainty_score":0.9995545},"labels":[],"label_agreement":null},{"id":"W4389044694","doi":"10.1016/j.clml.2023.11.008","title":"Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Progression-free survival; Fluorescence in situ hybridization; Oncology; Autologous stem-cell transplantation; Gastroenterology; Overall survival; Surgery; Biology","score_opus":0.06304123243416956,"score_gpt":0.39384388262424075,"score_spread":0.33080265019007116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389044694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997107,0.0010784351,0.000005385509,0.000084873376,0.00013303399,0.0011378529,0.00006296201,0.0001153243,0.0002750847],"genre_scores_gemma":[0.997473,0.0013631687,0.00054106384,0.000038961647,0.0001092581,0.00008296668,0.0002144129,0.00006193091,0.000115231174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964701,0.00027116644,0.0012413533,0.00062963116,0.00074422295,0.00064355705],"domain_scores_gemma":[0.99674696,0.0014421743,0.00030899915,0.00062149024,0.00011958639,0.0007607875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010164719,0.00034088676,0.0010812761,0.00043661956,0.00008148983,0.000016755694,0.0002053935,0.00025204738,0.000036511337],"category_scores_gemma":[0.0015565963,0.00024959113,0.00070858776,0.0008221623,0.00039333678,0.00017810632,0.00018546179,0.000219667,0.000019635667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038579872,0.00037637964,0.60358155,0.00014865745,0.00028877263,0.00044968593,0.00011111325,0.000006563131,0.0024488675,0.0000020943876,0.00016170474,0.38856664],"study_design_scores_gemma":[0.014263704,0.0019029832,0.9761865,0.0008568393,0.00007755468,0.000010110149,0.000037910406,0.005360574,0.0009884737,0.00006379622,0.00006709192,0.00018446104],"about_ca_topic_score_codex":0.0001797484,"about_ca_topic_score_gemma":0.0000086235805,"teacher_disagreement_score":0.3883822,"about_ca_system_score_codex":0.0005301854,"about_ca_system_score_gemma":0.0013807911,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W4389219865","doi":"10.1182/blood-2023-174993","title":"Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Western University; Alberta Health; Ottawa Hospital; Alberta Health Services; London Health Sciences Centre; McMaster University; Vancouver General Hospital; Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Pomalidomide; Tolerability; Adverse effect; Multiple myeloma; Internal medicine; Contact lens; Refractory (planetary science); Surgery; Ophthalmology","score_opus":0.04989332451591136,"score_gpt":0.31242170032171873,"score_spread":0.26252837580580735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389219865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946577,0.000056194436,0.0000069532634,0.000011365021,0.000049756134,0.0051518157,0.000026321788,0.00002083539,0.000019037116],"genre_scores_gemma":[0.9996308,0.00001408744,0.00015529415,0.0000031927293,0.000026947882,0.00012239527,0.0000118363705,0.000020782663,0.0000146287975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980201,0.00047781147,0.00044267884,0.00029869904,0.00048272,0.0002779674],"domain_scores_gemma":[0.9989441,0.00032707505,0.0002455949,0.0002797195,0.00013102118,0.00007250586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005533245,0.00015759228,0.00046180518,0.00021934109,0.00008948016,0.000009331678,0.0000854148,0.000083003986,0.0000050364993],"category_scores_gemma":[0.0017961346,0.0001138464,0.00010570783,0.00050140236,0.00005711109,0.00008026676,0.0001437785,0.00017735816,0.0000011344658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011214303,0.004837376,0.9184421,0.00014045446,0.00033617433,0.000040331583,0.00084538426,0.0000040220316,0.060506973,8.602823e-7,0.0000012199116,0.0036308025],"study_design_scores_gemma":[0.11351975,0.002853689,0.7620845,0.00032924747,0.00017340358,0.0000070398173,0.00047522035,0.00021026356,0.120260604,0.00001759687,3.8017515e-7,0.00006828779],"about_ca_topic_score_codex":0.0014447885,"about_ca_topic_score_gemma":0.0008926753,"teacher_disagreement_score":0.15635759,"about_ca_system_score_codex":0.000062073996,"about_ca_system_score_gemma":0.00009626164,"threshold_uncertainty_score":0.46425214},"labels":[],"label_agreement":null},{"id":"W4389221151","doi":"10.1182/blood-2023-182166","title":"Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Dosing; Cytokine release syndrome; Pharmacokinetics; Population; Internal medicine; Cytokine; Refractory (planetary science); Multiple myeloma; Pharmacology; Disease; Coronavirus disease 2019 (COVID-19); Biology","score_opus":0.15590576573555845,"score_gpt":0.4188750820112462,"score_spread":0.26296931627568776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389221151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99842757,0.000020968308,0.000096019256,0.0005944023,0.000055573077,0.0005279445,0.00006910593,0.00017217512,0.0000362262],"genre_scores_gemma":[0.9975574,0.000019516267,0.00089295255,0.000037237347,0.00003682697,0.0000437526,0.0012703256,0.00002984783,0.00011212041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886465,0.00009531189,0.00027625513,0.00028494117,0.00017992803,0.00029889547],"domain_scores_gemma":[0.9990087,0.00044284898,0.000080374586,0.00016902007,0.000060142254,0.00023889683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005185372,0.00011421823,0.00025423043,0.0001476054,0.0002077416,0.000037744903,0.00004018855,0.00007196294,0.000010524121],"category_scores_gemma":[0.0012685844,0.00008831517,0.00008345536,0.00025867898,0.000030702624,0.0001597325,0.000031452702,0.00015424783,0.0000040413142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023173251,0.0008594565,0.9871219,0.00004524152,0.0007860308,0.00033818695,0.00028450566,0.0000011130916,0.0011179774,0.000010898118,0.00008560346,0.0091173835],"study_design_scores_gemma":[0.017067106,0.0023037824,0.9757251,0.0005737038,0.0005482885,0.000031595668,0.0006850038,0.0021077895,0.0006200047,0.00005746262,0.0001279384,0.00015220011],"about_ca_topic_score_codex":0.000046179593,"about_ca_topic_score_gemma":0.00009738146,"teacher_disagreement_score":0.016835373,"about_ca_system_score_codex":0.000040562303,"about_ca_system_score_gemma":0.00005220262,"threshold_uncertainty_score":0.36013883},"labels":[],"label_agreement":null},{"id":"W4389221196","doi":"10.1182/blood-2023-189506","title":"Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University Medical Centre; University of British Columbia; Institute for Clinical Evaluative Sciences; Population Health Research Institute; McMaster University; Sunnybrook Health Science Centre; Health Sciences Centre; Eli Lilly (Canada); Ottawa Hospital","funders":"","keywords":"Medicine; Daratumumab; Carfilzomib; Pomalidomide; Regimen; Lenalidomide; Internal medicine; Population; Bortezomib; Multiple myeloma; Adverse effect; Oncology; Cohort; Chemotherapy regimen; Randomized controlled trial; Cancer","score_opus":0.22804327444964337,"score_gpt":0.519525203350662,"score_spread":0.29148192890101865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389221196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078375,0.000025178295,0.0000017166582,0.000058396927,0.0001150563,0.0088765565,0.000054969132,0.000015743988,0.00006865674],"genre_scores_gemma":[0.9988751,0.00000570447,0.000047300848,0.000003677075,0.000038073733,0.0008652749,0.00013040655,0.000015588135,0.000018868708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958056,0.0022049628,0.0010067485,0.0002748383,0.00047197778,0.00023584075],"domain_scores_gemma":[0.98214996,0.016960163,0.00027927288,0.00048987154,0.00006864251,0.000052100044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049270666,0.00014118127,0.0009958155,0.00022734852,0.00005187591,0.000006015292,0.00017187861,0.000063606356,0.000004742138],"category_scores_gemma":[0.0064175897,0.000075431555,0.00028852248,0.00086131936,0.000052657284,0.00001875536,0.00003525716,0.00014651951,0.0000028645782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071524926,0.01664601,0.9726929,0.00008064837,0.0006569521,0.000016721426,0.00023144693,0.00010117468,0.00013127844,0.000007811536,0.000009160613,0.0022734248],"study_design_scores_gemma":[0.09042368,0.0017676818,0.9041624,0.00012914588,0.00059536425,1.396023e-7,0.0002111984,0.001126681,0.0015262933,0.0000069636653,0.0000025275674,0.000047893693],"about_ca_topic_score_codex":0.0030110807,"about_ca_topic_score_gemma":0.004493751,"teacher_disagreement_score":0.08327119,"about_ca_system_score_codex":0.0000700279,"about_ca_system_score_gemma":0.00012943656,"threshold_uncertainty_score":0.7682918},"labels":[],"label_agreement":null},{"id":"W4389222038","doi":"10.1182/blood-2023-174479","title":"Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Ascentage Pharma; Omeros Corporation; Exelixis; Actinium Pharmaceuticals; Amgen; Takeda Pharmaceuticals U.S.A.; Janssen Biotech; Adaptive Biotechnologies; Karyopharm Therapeutics; Genentech; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine; Proportional hazards model; Transplantation; Retrospective cohort study; Log-rank test; Incidence (geometry); Hematopoietic stem cell transplantation; Progression-free survival; Survival analysis; Overall survival","score_opus":0.037447988666117725,"score_gpt":0.3160839845619128,"score_spread":0.2786359958957951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671984,0.0009373458,0.000016671122,0.0004665932,0.00012088797,0.0007164648,0.0006603578,0.00011830201,0.00024352323],"genre_scores_gemma":[0.99451476,0.00021279311,0.00014269704,0.000112605274,0.00005866954,0.0007931067,0.00026013906,0.00004695975,0.0038582503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826056,0.000031644962,0.00026393455,0.0004284894,0.0003161947,0.0006991723],"domain_scores_gemma":[0.9992896,0.00015321419,0.000044426502,0.00026614647,0.000028099883,0.00021854343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009576587,0.00025179502,0.00043205614,0.00034534026,0.000070834096,0.000016973217,0.00009417325,0.00013726437,0.00026512067],"category_scores_gemma":[0.000008274727,0.00018355233,0.00021645949,0.00023506786,0.000041936426,0.0000621025,0.000044269716,0.00013166192,0.00005792494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001476663,0.00075450254,0.9765822,0.00017361532,0.00027731634,0.0007892577,0.00069151056,0.0000032086978,0.0013589006,0.0000012903837,0.0010401182,0.016851394],"study_design_scores_gemma":[0.023233183,0.0002845484,0.9653095,0.00010291069,0.00015622399,0.000018197616,0.00005366939,0.00082173955,0.008823747,0.000005796393,0.0010155048,0.00017500178],"about_ca_topic_score_codex":0.00038599095,"about_ca_topic_score_gemma":0.011552676,"teacher_disagreement_score":0.02175652,"about_ca_system_score_codex":0.00014661814,"about_ca_system_score_gemma":0.00004531321,"threshold_uncertainty_score":0.7485047},"labels":[],"label_agreement":null},{"id":"W4389222230","doi":"10.1182/blood-2023-174443","title":"Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Lenalidomide; Multiple myeloma; Regimen; Dexamethasone; Oncology; Gastroenterology","score_opus":0.03654031272279376,"score_gpt":0.2834137563408927,"score_spread":0.24687344361809896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993594,0.0004467691,0.0000050270573,0.0005898354,0.00023883111,0.0032933897,0.0006523281,0.00022389363,0.00095596036],"genre_scores_gemma":[0.9952554,0.00032761914,0.00081085553,0.00014440154,0.00032730983,0.0003418315,0.0011091374,0.000114424714,0.0015690118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952472,0.00045287155,0.00084851054,0.0011130277,0.0012949605,0.0010434487],"domain_scores_gemma":[0.995152,0.002689025,0.00028601201,0.0011847636,0.00018397348,0.00050422596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076106936,0.00056306843,0.0009309096,0.00034051048,0.0003617984,0.00011008556,0.0003668446,0.00030302862,0.00006779472],"category_scores_gemma":[0.00354324,0.00033210567,0.00014221028,0.0010534477,0.00029833987,0.00025416273,0.00028148206,0.00084979757,0.00023323034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6932215,0.015481913,0.22708116,0.00013950735,0.002238206,0.0041292603,0.0037105482,0.000015800437,0.0006122647,0.00001621613,0.0055145468,0.047839087],"study_design_scores_gemma":[0.60651594,0.0044524567,0.38292772,0.000331712,0.00031654516,0.000025061878,0.00038330452,0.0004293427,0.0011027717,0.000023798873,0.0031362495,0.00035508574],"about_ca_topic_score_codex":0.0023838547,"about_ca_topic_score_gemma":0.0035103953,"teacher_disagreement_score":0.15584655,"about_ca_system_score_codex":0.00028908916,"about_ca_system_score_gemma":0.0006209975,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W4389231113","doi":"10.1182/blood-2023-190978","title":"Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Population; Medicine; Oncology; Internal medicine; Melphalan; Transplantation; Hematopoietic stem cell transplantation; Multiple myeloma","score_opus":0.01949208219430457,"score_gpt":0.2713037724180636,"score_spread":0.251811690223759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572986,0.000016262002,0.000034467143,0.000051516985,0.00003703922,0.0022712247,0.001778968,0.00006504039,0.000015646843],"genre_scores_gemma":[0.99634326,0.0000133863205,0.00015921856,0.0000020237499,0.000029921459,0.0001867043,0.0031959906,0.000031000032,0.000038529426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742883,0.00018794478,0.0009165133,0.0005504062,0.00054619944,0.00037009164],"domain_scores_gemma":[0.9990036,0.00016300191,0.00024536118,0.00034448918,0.000102130965,0.00014145681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026872466,0.00024654993,0.00061082054,0.0005298925,0.00006828473,0.000016338056,0.00013758287,0.00012992728,0.000027704496],"category_scores_gemma":[0.000028715693,0.00022504745,0.00009966947,0.000616029,0.000062785686,0.00018013633,0.000033871103,0.00021437921,0.000012162442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039665797,0.006413532,0.9047965,0.00023715601,0.00015118059,0.0018968207,0.011123896,0.00014722279,0.07096517,0.0000015509371,2.2564015e-7,0.00030016343],"study_design_scores_gemma":[0.02206641,0.0013865217,0.9343815,0.0004172024,0.00021900733,0.000061847575,0.00027301215,0.009322761,0.03168879,0.000025131672,8.3105135e-8,0.00015774767],"about_ca_topic_score_codex":0.0017116999,"about_ca_topic_score_gemma":0.0023859094,"teacher_disagreement_score":0.039276384,"about_ca_system_score_codex":0.00007022431,"about_ca_system_score_gemma":0.00010226602,"threshold_uncertainty_score":0.91771686},"labels":[],"label_agreement":null},{"id":"W4389231399","doi":"10.1182/blood-2023-180271","title":"Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Randomized controlled trial; Population; Clinical trial; Multiple myeloma; Oncology","score_opus":0.30456954541512404,"score_gpt":0.5285760360045559,"score_spread":0.2240064905894319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000071089045,0.9664808,0.0000026752307,0.0046369424,0.00017063641,0.028211422,0.00023285288,0.00009778391,0.00009580927],"genre_scores_gemma":[0.000069442605,0.9876944,0.00010093723,0.00040646648,0.00020323461,0.004146784,0.00044030516,0.00014433493,0.0067941113],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9798421,0.012106234,0.00492187,0.0011721388,0.0011531808,0.0008044306],"domain_scores_gemma":[0.9710481,0.022482764,0.003498486,0.0018851858,0.0002371307,0.000848319],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031254318,0.0010476662,0.0299386,0.00064872316,0.00006667172,0.00017943697,0.00031435952,0.000688449,0.0001399848],"category_scores_gemma":[0.1629101,0.00046981074,0.00562952,0.0008267906,0.0001842362,0.00009415052,0.00018928769,0.0010261704,0.00015539667],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012481386,0.0005960381,0.0003504704,0.943911,0.019888729,0.004207066,0.000048056005,5.717029e-10,4.9048374e-8,0.0000014549764,0.003001167,0.026747812],"study_design_scores_gemma":[0.15845439,0.00023148097,0.00006714196,0.77378774,0.057309695,0.0006893481,0.000057265137,0.0000076396145,1.9831694e-7,0.000009718551,0.008965744,0.00041966792],"about_ca_topic_score_codex":0.00006177529,"about_ca_topic_score_gemma":0.00004612948,"teacher_disagreement_score":0.1701233,"about_ca_system_score_codex":0.00015853248,"about_ca_system_score_gemma":0.0010291967,"threshold_uncertainty_score":0.99977535},"labels":[],"label_agreement":null},{"id":"W4389231477","doi":"10.1182/blood-2023-187233","title":"Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Population; Internal medicine; Dexamethasone; Multiple myeloma; Cohort; Bortezomib; Surgery; Oncology","score_opus":0.06021314301611849,"score_gpt":0.33121567867743484,"score_spread":0.2710025356613164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958496,0.0011612923,0.000048009137,0.00022814522,0.000013803937,0.002072576,0.00044602566,0.00007248572,0.000108071144],"genre_scores_gemma":[0.99395365,0.00060057396,0.004212721,0.00003441923,0.00005418846,0.00016362632,0.00043091472,0.0000661515,0.00048375074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971515,0.00016435218,0.0006896059,0.000757347,0.00053698494,0.0007002234],"domain_scores_gemma":[0.9977583,0.00088244723,0.00015626304,0.0004009664,0.00012646746,0.0006755467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033793628,0.0004936953,0.0014109769,0.0005890147,0.0001280274,0.00005585416,0.000101389705,0.000149794,0.000057905927],"category_scores_gemma":[0.00025278778,0.00033476038,0.00006424441,0.00055087934,0.0001609789,0.00018055129,0.00010414018,0.00021294488,0.00003442661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007745376,0.0017786548,0.9686507,0.00022517367,0.00073659356,0.00027064234,0.0010594203,0.000011828198,0.002465611,0.0000015511563,0.00006319277,0.016991233],"study_design_scores_gemma":[0.06335505,0.0053971843,0.91235876,0.00052054465,0.0006904571,0.000034610857,0.00015674475,0.0009360187,0.016013378,0.0000102241975,0.00019921981,0.0003277916],"about_ca_topic_score_codex":0.0015077709,"about_ca_topic_score_gemma":0.0010140406,"teacher_disagreement_score":0.056291953,"about_ca_system_score_codex":0.000082059654,"about_ca_system_score_gemma":0.00012941647,"threshold_uncertainty_score":0.9999104},"labels":[],"label_agreement":null},{"id":"W4389231707","doi":"10.1182/blood-2023-180766","title":"Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Ven; Minimal residual disease; Lenalidomide; Multiple myeloma; Bortezomib; Dexamethasone; Venetoclax; Gastroenterology; Oncology; Phases of clinical research; Refractory (planetary science); Progressive disease; Bone marrow; Clinical trial; Chemotherapy; Leukemia","score_opus":0.03273877375204344,"score_gpt":0.3312713720477828,"score_spread":0.29853259829573936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976361,0.00013415157,0.0000022166244,0.000046675337,0.000009925621,0.0020225605,0.00009366021,0.000036360347,0.000018373412],"genre_scores_gemma":[0.99906486,0.000020238165,0.00023527796,0.000006651736,0.0000070423416,0.00017639097,0.00040229218,0.00003378874,0.000053478998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735194,0.00054149685,0.00045816883,0.0005162895,0.00069524604,0.00043686814],"domain_scores_gemma":[0.99855417,0.0005159946,0.00015843568,0.0003682093,0.0001687208,0.00023449628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048104752,0.00025423063,0.0005715591,0.0010197804,0.00006273225,0.000019985328,0.00008857975,0.000074096475,0.000011663444],"category_scores_gemma":[0.0010558175,0.00019582047,0.000024725545,0.0016718152,0.00013229383,0.00024298781,0.00007082292,0.00026863258,0.00000289867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034468945,0.016520748,0.9442577,0.00009006512,0.00017662636,0.001419217,0.00070827635,0.00005659595,0.0012729013,0.0000010691666,0.00000859019,0.0010192838],"study_design_scores_gemma":[0.12515864,0.0057147867,0.8643922,0.00024268226,0.00015277838,0.0000021867281,0.00049181754,0.00094026176,0.002741005,0.0000054059415,0.0000022601077,0.00015595842],"about_ca_topic_score_codex":0.0014863973,"about_ca_topic_score_gemma":0.006919091,"teacher_disagreement_score":0.09068969,"about_ca_system_score_codex":0.00015496017,"about_ca_system_score_gemma":0.00032930556,"threshold_uncertainty_score":0.79853266},"labels":[],"label_agreement":null},{"id":"W4389231950","doi":"10.1182/blood-2023-179153","title":"Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McMaster University","funders":"","keywords":"Medicine; Transplantation; Multiple myeloma; Cumulative incidence; Internal medicine; Population; Oncology; Proportional hazards model","score_opus":0.02358846687678407,"score_gpt":0.3044549000679961,"score_spread":0.280866433191212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964177,0.00010825523,0.000057319474,0.00006721728,0.000060392642,0.0026015237,0.00058656174,0.000055477,0.000045547546],"genre_scores_gemma":[0.998199,0.00015018477,0.00043549502,0.000026617434,0.0000428239,0.00020052835,0.00090038223,0.000025143347,0.00001983278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828345,0.00015791679,0.0004373845,0.00035084123,0.00034895388,0.0004214865],"domain_scores_gemma":[0.9980346,0.0014502992,0.00011489295,0.00023123441,0.000042320404,0.00012665648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020576305,0.00022682661,0.00040546065,0.0000880801,0.00010529408,0.000024361794,0.00010022621,0.00007752542,0.000008111083],"category_scores_gemma":[0.00013501308,0.0001573701,0.00013492249,0.00034108586,0.000037325048,0.000058804944,0.000014357789,0.00012180932,0.0000065186823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002251626,0.0027976914,0.9900443,0.00020949105,0.00036678297,0.0007065118,0.0017735172,0.00036572624,0.00022454784,0.0000033904673,0.000034306555,0.0012221364],"study_design_scores_gemma":[0.046935406,0.0021675224,0.9489201,0.00019796424,0.0006502962,0.000008216907,0.00023560035,0.0002696398,0.0004027661,0.00009335791,5.732027e-7,0.00011860917],"about_ca_topic_score_codex":0.0013726329,"about_ca_topic_score_gemma":0.0065957922,"teacher_disagreement_score":0.044683777,"about_ca_system_score_codex":0.00006019554,"about_ca_system_score_gemma":0.000072069124,"threshold_uncertainty_score":0.6417367},"labels":[],"label_agreement":null},{"id":"W4389232113","doi":"10.1182/blood-2023-178881","title":"Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Daratumumab; Medicine; Bone marrow; Multiple myeloma; Dexamethasone; Cereblon; Biomarker; Peripheral blood mononuclear cell; Antibody-dependent cell-mediated cytotoxicity; Oncology; Internal medicine; Immunology; Bortezomib; Antibody; Monoclonal antibody; Biology","score_opus":0.1846643830559381,"score_gpt":0.4401408400866205,"score_spread":0.25547645703068245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850446,0.00013562218,0.000085403575,0.00038963632,0.00001297643,0.00068418507,0.000010878688,0.000019054916,0.00015779967],"genre_scores_gemma":[0.98397106,0.000056498084,0.0157337,0.000022706361,0.00000777814,0.00006713896,0.00009110685,0.000011374057,0.00003865718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840873,0.00008451922,0.000627863,0.0002856928,0.00036369328,0.00022947631],"domain_scores_gemma":[0.9987319,0.00080011017,0.000065758206,0.00013053599,0.00007521288,0.00019645489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082968705,0.00012591714,0.00039444095,0.0004536177,0.000051242798,0.000011312461,0.000044647753,0.000095550735,0.000008192806],"category_scores_gemma":[0.000691053,0.00009606444,0.00003181734,0.0007129433,0.00011930934,0.000084245374,0.000049580405,0.00014576105,0.0000062963572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017928411,0.0020649242,0.9187104,0.000073632946,0.00019206348,0.000068726884,0.00048196266,0.0000021426242,0.0006161682,0.000012234343,0.000005992069,0.07597892],"study_design_scores_gemma":[0.047318447,0.00047845012,0.9478981,0.0001816751,0.000048596907,0.000012207015,0.00011128825,0.0017091845,0.002060051,0.000028581588,0.000063417625,0.00009003386],"about_ca_topic_score_codex":0.00007252211,"about_ca_topic_score_gemma":0.0014951584,"teacher_disagreement_score":0.07588889,"about_ca_system_score_codex":0.000016647675,"about_ca_system_score_gemma":0.00017270017,"threshold_uncertainty_score":0.3917394},"labels":[],"label_agreement":null},{"id":"W4389232625","doi":"10.1182/blood-2023-181765","title":"Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Daratumumab; Gastroenterology; Multiple myeloma; Oncology; Lenalidomide; Adverse effect","score_opus":0.01957714151402078,"score_gpt":0.2954745439370473,"score_spread":0.2758974024230265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792075,0.00005356704,0.000009249774,0.000014062745,0.000029919624,0.0015884445,0.00035029763,0.000025251726,0.000008432694],"genre_scores_gemma":[0.99950695,0.00014840673,0.00011613365,0.0000054096245,0.000013440405,0.00004830999,0.00010553932,0.000025010257,0.000030828225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815,0.00019716738,0.00044978206,0.00035274224,0.00053816667,0.00031214982],"domain_scores_gemma":[0.99871397,0.00029972562,0.00025669765,0.0005169776,0.00009096632,0.00012163586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002362536,0.0002041075,0.0006195716,0.0004835316,0.00009972572,0.000010861687,0.00015173291,0.00005129147,0.000035383644],"category_scores_gemma":[0.0002743747,0.00011582407,0.000100294295,0.0016060511,0.00012238884,0.000054373537,0.000109914414,0.0002180662,0.0000019093557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015581756,0.007963132,0.94629574,0.000036482666,0.0037723028,0.00007274457,0.0013697947,0.000093679526,0.00013265779,3.594491e-7,0.0000040043556,0.02467732],"study_design_scores_gemma":[0.11215796,0.003832716,0.8792159,0.00009152539,0.001666245,7.84597e-7,0.00035454132,0.0009230576,0.0016596596,0.0000010298749,0.0000046115606,0.00009198213],"about_ca_topic_score_codex":0.0012306,"about_ca_topic_score_gemma":0.0016729777,"teacher_disagreement_score":0.096576214,"about_ca_system_score_codex":0.000037985363,"about_ca_system_score_gemma":0.00007269518,"threshold_uncertainty_score":0.47231683},"labels":[],"label_agreement":null},{"id":"W4389233288","doi":"10.1182/blood-2023-173362","title":"Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Jewish General Hospital; McGill University; Hôtel-Dieu de Québec; Hôpital Charles-Le Moyne; Université Laval; Université de Montréal; Concordia University; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"","keywords":"Plasma cell leukemia; Medicine; Multiple myeloma; Plasma cell dyscrasia; Internal medicine; Incidence (geometry); Gastroenterology; Bortezomib; Cohort; Retrospective cohort study; Surgery; Immunology; Immunoglobulin light chain; Antibody","score_opus":0.042708375587919865,"score_gpt":0.3053376740174409,"score_spread":0.26262929842952104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830198,0.00017875334,0.000010103916,0.0001563166,0.00008692281,0.0006989692,0.00015196558,0.00029249018,0.0154046295],"genre_scores_gemma":[0.95486164,0.00015141413,0.0011035565,0.00015956459,0.00012903161,0.00016016774,0.0005403726,0.00006527688,0.04282897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998106,0.000043342796,0.00029930464,0.0004296933,0.00047340847,0.0006482769],"domain_scores_gemma":[0.9989055,0.00013151302,0.000057003723,0.00044771843,0.000042492014,0.00041577037],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000103820035,0.0002645909,0.00041153387,0.00021176634,0.00013676388,0.00003153198,0.00012929577,0.00013405312,0.00031431305],"category_scores_gemma":[0.000058363425,0.00018257156,0.0001638089,0.00031944312,0.00005391291,0.00010792425,0.00013576342,0.00026509946,0.0015404592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018726229,0.0032511575,0.89609975,0.00081434695,0.0013109378,0.013536864,0.0004994693,0.000008958482,0.016552905,0.0000068681416,0.0020513395,0.06399478],"study_design_scores_gemma":[0.04357845,0.0015260219,0.9302136,0.0000679073,0.0007068826,0.0002647242,0.00007625242,0.0013385942,0.020090275,0.00006384953,0.0017517182,0.00032175667],"about_ca_topic_score_codex":0.00005989207,"about_ca_topic_score_gemma":0.000022718958,"teacher_disagreement_score":0.06367302,"about_ca_system_score_codex":0.00027165338,"about_ca_system_score_gemma":0.00050385174,"threshold_uncertainty_score":0.99923694},"labels":[],"label_agreement":null},{"id":"W4389234575","doi":"10.1182/blood-2023-173550","title":"Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bone marrow; Internal medicine; CD8; Cytopenia; Oncology; Immune system; Gastroenterology; Multiple myeloma; Flow cytometry; Immunology","score_opus":0.04014223672840837,"score_gpt":0.31468856441477894,"score_spread":0.27454632768637055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995596,0.000110448884,0.0000041496855,0.00006656188,0.000010310005,0.003858901,0.0001565,0.000037048947,0.00016009505],"genre_scores_gemma":[0.99890655,0.00004370457,0.00021731583,0.000009256273,0.000011995903,0.0003327642,0.0001589515,0.000046273442,0.00027316532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974308,0.00034201224,0.0003567345,0.00052579027,0.0009555343,0.00038912322],"domain_scores_gemma":[0.9979166,0.00087394053,0.0002491889,0.00062290626,0.00019057601,0.0001468172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003054687,0.0003616253,0.0005844406,0.0004897341,0.000113963266,0.000015844767,0.00012243095,0.000078287434,0.000011882248],"category_scores_gemma":[0.000147648,0.00017025248,0.00004356438,0.0008955184,0.00027631517,0.00011834786,0.00003920097,0.0002712733,0.0000046094647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07020444,0.029824145,0.8865384,0.00008603588,0.00089398597,0.0015636892,0.0086771855,0.000010761379,0.0001698412,0.000009781995,0.000020731308,0.0020009947],"study_design_scores_gemma":[0.110294625,0.089190684,0.78770655,0.0004377842,0.00043434888,0.000023342334,0.010546815,0.000037533937,0.0011572626,0.0000028023915,0.000020993371,0.00014725843],"about_ca_topic_score_codex":0.00029777712,"about_ca_topic_score_gemma":0.0007689611,"teacher_disagreement_score":0.098831855,"about_ca_system_score_codex":0.00009084968,"about_ca_system_score_gemma":0.00022650899,"threshold_uncertainty_score":0.6942694},"labels":[],"label_agreement":null},{"id":"W4389234604","doi":"10.1182/blood-2023-182330","title":"Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical trial; Phases of clinical research; Oncology; Carfilzomib; Lenalidomide; Bortezomib","score_opus":0.0844195497930193,"score_gpt":0.4021215023683741,"score_spread":0.3177019525753548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727565,0.0003092122,0.0000012277991,0.00008468292,0.00007549887,0.0019623472,0.00016886937,0.00007131287,0.00005118908],"genre_scores_gemma":[0.9989123,0.000086085565,0.00014890918,0.000032343894,0.000036394875,0.00018534595,0.00041929472,0.00004124689,0.00013812841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974899,0.00033118343,0.0006248273,0.00045947082,0.0007031186,0.00039145778],"domain_scores_gemma":[0.99791604,0.001011675,0.00016742838,0.0006789998,0.00006224277,0.00016360673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028726796,0.00029768422,0.00077900925,0.0001838044,0.000108109,0.000023632972,0.00017245719,0.00007553818,0.000047893944],"category_scores_gemma":[0.000257536,0.00015231033,0.00033513957,0.00048556615,0.00010163172,0.00011629098,0.00007130245,0.00018438192,0.00003665101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015985803,0.027783139,0.95420307,0.0000059949552,0.005772359,0.00048196292,0.0014237973,0.000001898346,0.00030514144,4.3138155e-7,0.0000133807025,0.008410244],"study_design_scores_gemma":[0.09930592,0.0058595627,0.8913148,0.00005660722,0.00081880734,4.9568143e-7,0.0016389728,0.000031792228,0.0008139592,0.0000059545846,0.000034119534,0.00011899283],"about_ca_topic_score_codex":0.0020736477,"about_ca_topic_score_gemma":0.0009254428,"teacher_disagreement_score":0.097707346,"about_ca_system_score_codex":0.000091343936,"about_ca_system_score_gemma":0.000100729354,"threshold_uncertainty_score":0.6211035},"labels":[],"label_agreement":null},{"id":"W4389234664","doi":"10.1182/blood-2023-190426","title":"Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Institute for Clinical Evaluative Sciences; Population Health Research Institute; McMaster University; Ottawa Hospital","funders":"","keywords":"Medicine; Pomalidomide; Daratumumab; Lenalidomide; Population; Regimen; Multiple myeloma; Internal medicine; Health care; Clinical trial; Oncology","score_opus":0.036318336607746644,"score_gpt":0.2969344160111481,"score_spread":0.2606160794034015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950722,0.000025024372,0.000011675388,0.0001386511,0.000024180108,0.004348325,0.00014405293,0.00019701512,0.000038911134],"genre_scores_gemma":[0.9958893,0.000010934592,0.00006123019,0.000031333013,0.000037851816,0.0005737974,0.0031247209,0.000048841695,0.00022198926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807346,0.0001545091,0.00027597707,0.00050351874,0.00059862743,0.0003939023],"domain_scores_gemma":[0.99892163,0.00012912921,0.00009548556,0.0004048498,0.00012776729,0.0003211437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010765552,0.0002412038,0.00036516602,0.00024866324,0.00022271609,0.000036103873,0.000049388545,0.00007327466,0.000018374561],"category_scores_gemma":[0.00010259295,0.00017371736,0.000050555434,0.00040646098,0.000029035233,0.00006679337,0.000028476194,0.00008803642,0.000012103091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065609446,0.0034368583,0.991245,0.000072049756,0.00032130716,0.00016437074,0.00031557606,0.000009677555,0.000007943064,7.770828e-7,0.000013780521,0.0037566212],"study_design_scores_gemma":[0.036924373,0.0036937762,0.9565179,0.0000714738,0.00024945298,0.0000022773131,0.00033750225,0.0017925529,0.00023353481,9.106486e-7,0.00003838938,0.00013786858],"about_ca_topic_score_codex":0.0032505577,"about_ca_topic_score_gemma":0.0028244255,"teacher_disagreement_score":0.03626828,"about_ca_system_score_codex":0.0001468152,"about_ca_system_score_gemma":0.0000799021,"threshold_uncertainty_score":0.7083988},"labels":[],"label_agreement":null},{"id":"W4389235299","doi":"10.1182/blood-2023-181138","title":"Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; London Health Sciences Centre; Jewish General Hospital; Université de Montréal; University of Saskatchewan; Memorial University of Newfoundland; Concordia University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; McGill University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Bortezomib; Regimen; Internal medicine; Autologous stem-cell transplantation; Oncology; Transplantation; Retrospective cohort study; Database; Surgery","score_opus":0.06968017449943593,"score_gpt":0.3416757621476033,"score_spread":0.2719955876481674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937818,0.00013198334,0.0000032472637,0.0006475477,0.000055456585,0.0015165415,0.0030172574,0.000052986285,0.00079319556],"genre_scores_gemma":[0.9902235,0.00006144967,0.0015972372,0.00004058164,0.0000975953,0.00022259346,0.005695392,0.000034678076,0.0020269202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973946,0.00014117944,0.00038459612,0.0005670499,0.0008398287,0.00067274726],"domain_scores_gemma":[0.99754107,0.0006241002,0.00009301452,0.00078071584,0.000325111,0.0006360052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004770329,0.00027045293,0.00044738085,0.00043958004,0.0005474256,0.000044200377,0.00015235016,0.00007879739,0.00015613761],"category_scores_gemma":[0.00053489493,0.00014764165,0.00008358905,0.0006944095,0.00041546297,0.0001159224,0.00013204379,0.00027566607,0.00004927957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044470854,0.0015052176,0.9914499,0.000033429696,0.0009191144,0.0023284375,0.0002575453,7.76013e-7,0.0002316131,0.000044938533,0.0003214702,0.0024628702],"study_design_scores_gemma":[0.017827826,0.000558393,0.97764933,0.00008555796,0.00016742075,0.00002547256,0.000101162885,0.00016309066,0.00080294133,0.0000108677295,0.0024784408,0.00012950339],"about_ca_topic_score_codex":0.29259682,"about_ca_topic_score_gemma":0.89277387,"teacher_disagreement_score":0.60017705,"about_ca_system_score_codex":0.00027859118,"about_ca_system_score_gemma":0.0009066656,"threshold_uncertainty_score":0.71211386},"labels":[],"label_agreement":null},{"id":"W4389243001","doi":"10.1182/blood-2023-190720","title":"Multiple Myeloma B Cells and Pre-Plasma Cells Are Important Reservoirs for Myeloma Relapse Following Plasma Cell-Directed Therapy and Prevent Cure with Standard Therapies","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Daratumumab; Carfilzomib; Lenalidomide; Bortezomib; Plasma cell; Multiple myeloma; Plasma Cell Myeloma; CD20; Cancer research; clone (Java method); Plasma cell neoplasm; Plasma cell leukemia; CD38; Medicine; Biology; Stem cell; Immunology; Lymphoma; CD34; Plasmacytoma","score_opus":0.019349774552108956,"score_gpt":0.2675097893738075,"score_spread":0.24816001482169853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933336,0.0017658925,0.000009694923,0.00039607886,0.00013110127,0.0033625597,0.00050159666,0.000381666,0.00011784937],"genre_scores_gemma":[0.98684055,0.004840071,0.0051376047,0.000037904927,0.00012391775,0.00059569813,0.0001657656,0.00014029014,0.0021182108],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707395,0.00011932041,0.0004570837,0.0008135753,0.00069306174,0.0008429964],"domain_scores_gemma":[0.9979707,0.0005798661,0.00021138646,0.0005269578,0.00022275237,0.0004883366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042250156,0.0004923886,0.0007208999,0.00025316648,0.0003858414,0.000113280745,0.00014488769,0.00020431084,0.000019505422],"category_scores_gemma":[0.00014671244,0.0003460804,0.00017465974,0.0004280744,0.00013029233,0.0001645532,0.00009694659,0.00028237057,0.000008587399],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024666289,0.0033811058,0.5779912,0.0017812934,0.0057185763,0.0035295456,0.013092429,0.000032108426,0.3418832,0.000012598249,0.0056338524,0.022277782],"study_design_scores_gemma":[0.062432557,0.006010021,0.12332111,0.00074893323,0.00056511257,0.00008134676,0.0024668078,0.002708319,0.7861039,0.0000663185,0.014752865,0.00074271084],"about_ca_topic_score_codex":0.000066956345,"about_ca_topic_score_gemma":0.0002210212,"teacher_disagreement_score":0.4546701,"about_ca_system_score_codex":0.00006785148,"about_ca_system_score_gemma":0.00018569457,"threshold_uncertainty_score":0.99989915},"labels":[],"label_agreement":null},{"id":"W4389243140","doi":"10.1182/blood-2023-190168","title":"Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ottawa Hospital; Princess Margaret Cancer Centre; Dalhousie University; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Lenalidomide; Medicine; Melphalan; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Oncology","score_opus":0.12265492500038555,"score_gpt":0.4250328955985352,"score_spread":0.30237797059814964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915225,0.00071295066,0.0000049221217,0.0008965554,0.00015777406,0.006376328,0.00016145926,0.000029384035,0.00013812013],"genre_scores_gemma":[0.99578893,0.0018804012,0.0014805649,0.00004066673,0.000119762655,0.00027636086,0.00009326268,0.00005132501,0.00026873642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961481,0.00049412606,0.0010385826,0.000840845,0.0007097626,0.0007685924],"domain_scores_gemma":[0.9974053,0.00084062363,0.00025078413,0.0006877491,0.00027870142,0.0005368588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026308738,0.00028642046,0.000913646,0.00040687236,0.00021066987,0.00004854105,0.0003238173,0.00026960354,0.000017722365],"category_scores_gemma":[0.0021145276,0.00021735879,0.00009782739,0.0013679751,0.00056111073,0.00017972992,0.00015819677,0.00069052796,0.000004187811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041859746,0.013290364,0.8914714,0.00018040034,0.0005254655,0.0019323517,0.001893661,0.0000015198137,0.0069336393,0.000036254558,0.00023189388,0.041643314],"study_design_scores_gemma":[0.33989263,0.0015471585,0.6494601,0.00030000816,0.000081753955,0.000099683944,0.00021255323,0.00033035397,0.007710368,0.00004415991,0.00018199974,0.0001392429],"about_ca_topic_score_codex":0.065366365,"about_ca_topic_score_gemma":0.06414156,"teacher_disagreement_score":0.29803288,"about_ca_system_score_codex":0.00012398697,"about_ca_system_score_gemma":0.0009444476,"threshold_uncertainty_score":0.9529354},"labels":[],"label_agreement":null},{"id":"W4389243189","doi":"10.1182/blood-2023-190200","title":"Efficacy of Maintenance Therapies By Prognostic Subgroups in Post-Transplant Newly Diagnosed Multiple Myeloma Patients: A Systematic Review and Network Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Lenalidomide; Ixazomib; Internal medicine; Daratumumab; Medicine; Multiple myeloma; Oncology; Carfilzomib; Pomalidomide; Hazard ratio; Progression-free survival; Transplantation; Confidence interval; Overall survival","score_opus":0.05455623364378186,"score_gpt":0.32165691286035386,"score_spread":0.267100679216572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068271795,0.98546624,0.0000054881752,0.000048289832,0.000016801885,0.012655064,0.0010627237,0.000053729305,0.000008933831],"genre_scores_gemma":[0.0027702574,0.99092144,0.00014988142,0.00007607686,0.000020125737,0.0034417494,0.0023736777,0.00009573403,0.00015106204],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99504,0.00093590206,0.0019102615,0.00075780664,0.00067699834,0.0006790149],"domain_scores_gemma":[0.9944661,0.0033142925,0.00083838287,0.0008697984,0.00023826961,0.00027315598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008310573,0.0007287746,0.010870611,0.00043828454,0.000056191962,0.000030116536,0.00030016666,0.00022120695,0.000048480364],"category_scores_gemma":[0.0021581617,0.0004220715,0.0023317086,0.0019283795,0.000098443714,0.000055509747,0.00008062305,0.0003779403,0.000034641278],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004871346,0.001520424,0.0048349784,0.74188274,0.24866998,0.00032605376,0.00008069596,2.634006e-7,9.744857e-8,0.0000028576333,0.000071918636,0.0025613],"study_design_scores_gemma":[0.004414177,0.00038475718,0.0041526463,0.20817049,0.7818703,0.000026302869,0.0000106318475,0.000004637431,3.187809e-7,0.0000016188063,0.0006434339,0.0003206791],"about_ca_topic_score_codex":0.0002583334,"about_ca_topic_score_gemma":0.0003074577,"teacher_disagreement_score":0.5337122,"about_ca_system_score_codex":0.000056992092,"about_ca_system_score_gemma":0.00014681887,"threshold_uncertainty_score":0.9998231},"labels":[],"label_agreement":null},{"id":"W4389243215","doi":"10.1182/blood-2023-182130","title":"Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Adverse effect; Clinical endpoint; Pomalidomide; Minimal residual disease; Gastroenterology; Phases of clinical research; Lenalidomide; Oncology; Clinical trial; Surgery; Leukemia","score_opus":0.04387892977143066,"score_gpt":0.3515561858806986,"score_spread":0.30767725610926794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965307,0.0006225085,0.0000022627064,0.000373173,0.000047958147,0.0021630796,0.00004941542,0.00003653459,0.00017435227],"genre_scores_gemma":[0.9980386,0.0011701966,0.00010446814,0.000055036016,0.000086554275,0.00013203504,0.0001058708,0.000026670547,0.00028055254],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99826515,0.00022612177,0.00043782833,0.00031329316,0.00038923923,0.00036835816],"domain_scores_gemma":[0.99852854,0.0008246251,0.00007941237,0.00042493857,0.000028960165,0.00011350304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005357148,0.00017397436,0.0004015831,0.00032533408,0.000047886693,0.000014171573,0.00015073485,0.00011231001,0.000131671],"category_scores_gemma":[0.00052201963,0.00010891446,0.000066235596,0.0005985237,0.00009834417,0.00005202779,0.000040341674,0.00027193702,0.000021046098],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45879522,0.017085921,0.25750884,0.00029980548,0.0003799202,0.0063854964,0.0031905218,0.0000027718977,0.01641192,0.000016715254,0.00019306925,0.23972978],"study_design_scores_gemma":[0.42693233,0.0031016902,0.5680142,0.0001233624,0.000043807697,0.00002717352,0.00009216834,0.00011456821,0.0012929704,0.0000065956365,0.00017219037,0.000078902565],"about_ca_topic_score_codex":0.00017645948,"about_ca_topic_score_gemma":0.0004537404,"teacher_disagreement_score":0.3105054,"about_ca_system_score_codex":0.00003378441,"about_ca_system_score_gemma":0.00012984542,"threshold_uncertainty_score":0.44414026},"labels":[],"label_agreement":null},{"id":"W4389243235","doi":"10.1182/blood-2023-180829","title":"Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Population; Internal medicine; Multiple myeloma; Bortezomib; Oncology; Clinical trial","score_opus":0.25152029933865633,"score_gpt":0.43487470191905686,"score_spread":0.18335440258040053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72119373,0.27233765,0.00006498829,0.0011522984,0.000030633448,0.0045520933,0.0005819917,0.0000682655,0.000018321693],"genre_scores_gemma":[0.84902126,0.14305782,0.0055871652,0.0002622281,0.00005519963,0.0013471583,0.00041691083,0.000046189354,0.00020607017],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99528134,0.0008048812,0.0016643556,0.0010646979,0.00058738975,0.0005973372],"domain_scores_gemma":[0.98267823,0.014839317,0.0006223846,0.0007160672,0.0004185219,0.0007254982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020510626,0.0006526624,0.0049994504,0.00054030825,0.000261033,0.00011101149,0.00015661048,0.00020428613,0.000027113641],"category_scores_gemma":[0.005200119,0.00043681415,0.00093539624,0.0016304649,0.00037359446,0.00027048387,0.00009393985,0.0002899889,0.0000066111556],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013155593,0.003821166,0.1376488,0.17462745,0.65843165,0.001997677,0.0062318086,0.00008628236,0.0018608505,0.00015579493,0.0005579339,0.0014249703],"study_design_scores_gemma":[0.067994386,0.0059375605,0.02726994,0.018563347,0.86581135,0.00022782257,0.00043588504,0.007369365,0.005497045,0.00006625732,0.00006805257,0.00075898133],"about_ca_topic_score_codex":0.00033392216,"about_ca_topic_score_gemma":0.00081129174,"teacher_disagreement_score":0.2073797,"about_ca_system_score_codex":0.000050247403,"about_ca_system_score_gemma":0.00015178465,"threshold_uncertainty_score":0.9998084},"labels":[],"label_agreement":null},{"id":"W4389243281","doi":"10.1182/blood-2023-180061","title":"The 3D- Telomere Profiling Assay Identifies High Risk Smoldering Multiple Myeloma Patients with High Precision","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Manitoba; Ontario Genomics","funders":"","keywords":"Telomere; Multiple myeloma; Medicine; Oncology; Internal medicine; Genotyping; Asymptomatic; Bioinformatics; Genotype; Biology; Genetics; Gene","score_opus":0.014425750659531056,"score_gpt":0.2576301301874951,"score_spread":0.24320437952796403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977043,0.00014040506,0.000032082553,0.00011841293,0.0001864391,0.0012750893,0.00008978231,0.00025209557,0.00020139264],"genre_scores_gemma":[0.9963824,0.00017314266,0.001685408,0.00001091018,0.00012782867,0.00021172692,0.00028002914,0.00005957533,0.0010689598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753934,0.0001414294,0.0003018309,0.00045045762,0.0009300282,0.0006369043],"domain_scores_gemma":[0.99808156,0.0007389606,0.00013116717,0.00059640827,0.00023269732,0.00021921191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045909043,0.00024427945,0.0002849039,0.00016265322,0.0006369619,0.000120812634,0.00019173186,0.000089611174,0.000031899806],"category_scores_gemma":[0.0010741235,0.00013907805,0.00007920587,0.0005258215,0.00009668604,0.00014157397,0.00018127266,0.00029989937,0.00029202158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005199429,0.00052374124,0.95827323,0.000067536355,0.0005223486,0.00015953496,0.000111686466,0.000021100259,0.00097772,0.000018017125,0.00016483026,0.038640287],"study_design_scores_gemma":[0.010478683,0.00048771233,0.9550199,0.00017110564,0.00020391552,0.000007470582,0.00012373511,0.00036357754,0.032657288,0.00010090366,0.00022445607,0.0001612555],"about_ca_topic_score_codex":0.00039289624,"about_ca_topic_score_gemma":0.0001452651,"teacher_disagreement_score":0.03847903,"about_ca_system_score_codex":0.000051144805,"about_ca_system_score_gemma":0.000075926204,"threshold_uncertainty_score":0.56714386},"labels":[],"label_agreement":null},{"id":"W4389243948","doi":"10.1182/blood-2023-186559","title":"A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont; Pfizer (Canada)","funders":"","keywords":"Medicine; Internal medicine; Propensity score matching; Multiple myeloma; Cohort; Clinical trial; Logistic regression; Oncology","score_opus":0.035783399633189335,"score_gpt":0.2824382959831082,"score_spread":0.24665489634991888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806964,0.00007987471,2.9981535e-7,0.000018057937,0.000094945615,0.0012858168,0.00021453852,0.000018590377,0.00021821876],"genre_scores_gemma":[0.99962693,0.000011368982,0.000035669127,0.000004958455,0.000019298148,0.000054756376,0.0001621327,0.00003017625,0.0000546794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980406,0.00013049896,0.00048294215,0.00026912687,0.00070904463,0.00036775702],"domain_scores_gemma":[0.9980908,0.000776911,0.00036540572,0.00050510274,0.00013642738,0.00012534321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006683424,0.00022816316,0.0007454915,0.00019707176,0.000047493126,0.0000032786272,0.00018444312,0.000059530063,0.00001149045],"category_scores_gemma":[0.00020327362,0.0001452071,0.00011900414,0.000828082,0.00010532897,0.000053775006,0.000061090665,0.00016248744,0.000001786953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026828647,0.0038151995,0.98379517,0.00015176661,0.00082599785,0.000023994058,0.00076532987,0.00011360193,0.0018056163,0.0000013120978,0.000032160253,0.0059870123],"study_design_scores_gemma":[0.0563532,0.0016701459,0.8901133,0.00028101576,0.0002580025,2.2433196e-7,0.00061752147,0.000311255,0.050270535,5.086978e-7,0.000028172224,0.00009611892],"about_ca_topic_score_codex":0.5032157,"about_ca_topic_score_gemma":0.67796266,"teacher_disagreement_score":0.174747,"about_ca_system_score_codex":0.00043903186,"about_ca_system_score_gemma":0.0009299147,"threshold_uncertainty_score":0.5921374},"labels":[],"label_agreement":null},{"id":"W4389244018","doi":"10.1182/blood-2023-182700","title":"Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Melphalan; Multiple myeloma; Autologous stem-cell transplantation; Oncology; Internal medicine; Univariate analysis; Transplantation; Hematopoietic stem cell transplantation; Proportional hazards model; Survival analysis; Multivariate analysis; Progression-free survival; Surgery; Chemotherapy","score_opus":0.04297853181349259,"score_gpt":0.33417248971475394,"score_spread":0.29119395790126135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389244018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846953,0.0001897227,0.000030237668,0.000007582611,0.000068329435,0.00073074055,0.000102122656,0.00008462842,0.00031712806],"genre_scores_gemma":[0.9992786,0.000086811604,0.00007455129,0.0000042349184,0.000018567887,0.000027208489,0.0002978651,0.000037515976,0.00017462285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819326,0.000108902794,0.0005058877,0.00027054056,0.0004953978,0.00042602076],"domain_scores_gemma":[0.99900067,0.00025968958,0.00017672384,0.00030488346,0.00009876345,0.00015929414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019482823,0.00021179186,0.0005048441,0.0002622937,0.000059271188,0.000012013602,0.00012220438,0.000110798144,0.000036195375],"category_scores_gemma":[0.000034668177,0.00016292978,0.00039162647,0.00037930484,0.000038173996,0.000106105275,0.00002318025,0.0001413863,0.00003132269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003468329,0.0010592059,0.95036197,0.00053963077,0.00072761264,0.00027165675,0.00046901047,0.000031558175,0.020544402,7.977695e-7,0.0000027098042,0.025644606],"study_design_scores_gemma":[0.011385571,0.0013857519,0.9511998,0.00016694926,0.00041038805,0.000012349571,0.000056554494,0.0002200841,0.035044584,0.000004685255,2.3643032e-7,0.00011300198],"about_ca_topic_score_codex":0.00022392144,"about_ca_topic_score_gemma":0.00005355112,"teacher_disagreement_score":0.025531605,"about_ca_system_score_codex":0.000059551865,"about_ca_system_score_gemma":0.00010857267,"threshold_uncertainty_score":0.6644083},"labels":[],"label_agreement":null},{"id":"W4389246672","doi":"10.1182/blood-2023-185151","title":"Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Expanded access; Multiple myeloma; Carfilzomib; Bortezomib; Family medicine; Internal medicine; Oncology","score_opus":0.033736136938265264,"score_gpt":0.3546823641972789,"score_spread":0.3209462272590136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371827,0.00020725731,0.00004601803,0.003666424,0.00004394322,0.0016816851,0.00015729207,0.00013682996,0.0003422786],"genre_scores_gemma":[0.9984883,0.00020225292,0.00020647439,0.0004451137,0.00005313397,0.00038599697,0.000044172113,0.000020454645,0.00015406468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859107,0.000041887506,0.00019398694,0.00040423297,0.0003870337,0.00038179845],"domain_scores_gemma":[0.99860454,0.000108117034,0.000023497789,0.0003107847,0.00006163592,0.00089141063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018228882,0.00017490266,0.00027131068,0.00018229529,0.00022660584,0.00014356589,0.0002334276,0.000056050387,0.00007608313],"category_scores_gemma":[0.00027015657,0.00014077769,0.00003199384,0.0006968022,0.000069478534,0.00014821,0.00015495431,0.00008102172,0.000033638014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036953914,0.00037078818,0.98246527,0.00005615907,0.0005570112,0.00021884558,0.0027700257,0.0000014591069,0.001279878,0.000009880901,0.00034592036,0.011555229],"study_design_scores_gemma":[0.007773055,0.00044664202,0.9882266,0.000067993955,0.00016863455,0.00004521817,0.00082733796,0.000048013546,0.0015939992,0.000029447112,0.0006394561,0.00013360316],"about_ca_topic_score_codex":0.00042831045,"about_ca_topic_score_gemma":0.00080050406,"teacher_disagreement_score":0.0114216255,"about_ca_system_score_codex":0.000031947926,"about_ca_system_score_gemma":0.0001132092,"threshold_uncertainty_score":0.57407475},"labels":[],"label_agreement":null},{"id":"W4389246785","doi":"10.1182/blood-2023-191338","title":"Global Burden and Trends of Multiple Myeloma in High-Income North America Countries between 1990-2019, with Projections of Deaths to 2040: A Benchmarking Analysis for the Global Burden of Disease Study 2019","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Disease burden; Incidence (geometry); Epidemiology; Confidence interval; Demography; Burden of disease; Global health; Years of potential life lost; Mortality rate; Public health; Disease; Gerontology; Environmental health; Population; Life expectancy; Surgery; Internal medicine; Pathology","score_opus":0.017176183056148625,"score_gpt":0.307566981431898,"score_spread":0.2903907983757493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944136,0.00019196876,0.00011153939,0.0003003467,0.000013599583,0.0014706951,0.0034466302,0.000022125882,0.000029454533],"genre_scores_gemma":[0.9987066,0.00004814178,0.0005495703,0.0000033049478,0.000087365814,0.00019252712,0.00032687673,0.000011036479,0.00007461035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983068,0.00006996797,0.00040340284,0.0003377901,0.0005506021,0.0003314533],"domain_scores_gemma":[0.99867594,0.0003350605,0.0001695302,0.0004156176,0.00019653911,0.00020732092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001768787,0.00018528388,0.0006645829,0.00040337598,0.00008601143,0.000013868755,0.00015628044,0.000034482,0.00001240759],"category_scores_gemma":[0.00015835963,0.00012122426,0.00013061309,0.003287119,0.00014278566,0.000050771036,0.0001275933,0.000054586726,0.0000015252389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016158896,0.00047121377,0.9860071,0.00010970975,0.0036839682,0.000036662408,0.0006038431,0.00085836696,0.000006993645,0.000005698181,0.000028945824,0.0065716137],"study_design_scores_gemma":[0.0073702848,0.0022985102,0.98494244,0.00007403401,0.00336513,0.0000014203629,0.0008116302,0.00095154025,0.000016733684,0.000007170226,0.000063820866,0.000097295844],"about_ca_topic_score_codex":0.027516726,"about_ca_topic_score_gemma":0.009060035,"teacher_disagreement_score":0.018456692,"about_ca_system_score_codex":0.000073339295,"about_ca_system_score_gemma":0.00016422947,"threshold_uncertainty_score":0.97895914},"labels":[],"label_agreement":null},{"id":"W4389246989","doi":"10.1182/blood-2023-178933","title":"Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Regimen; Interim analysis; Clinical endpoint; Oncology; Progression-free survival; Population; Multiple myeloma; Neutropenia; Clinical trial; Chemotherapy","score_opus":0.020853644306228745,"score_gpt":0.2679152240224768,"score_spread":0.24706157971624806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678516,0.00024296627,0.000012279099,0.00021482009,0.00010716601,0.0011821584,0.00062073115,0.0002590189,0.00057571975],"genre_scores_gemma":[0.9942927,0.00018002912,0.0009600923,0.00006362063,0.00006337003,0.00009631961,0.0034614168,0.000087065455,0.0007954205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610716,0.00023582367,0.0006336318,0.0009987027,0.001157008,0.00086766534],"domain_scores_gemma":[0.9975021,0.0004652486,0.00022268998,0.0009098304,0.0002738983,0.0006262479],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035395892,0.00046650576,0.0009733374,0.0010318424,0.00018189508,0.00007054945,0.00019721687,0.00024121227,0.00024762098],"category_scores_gemma":[0.000543047,0.00038191024,0.00018801684,0.002470158,0.00014396495,0.0002150704,0.0001562254,0.00043022592,0.00013710839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025276426,0.00202216,0.95345455,0.000042754396,0.005166941,0.0014364679,0.00055625295,0.000014488285,0.006507204,0.000003461512,0.00097652077,0.0045427503],"study_design_scores_gemma":[0.12745303,0.0035322527,0.851451,0.00009553281,0.0018465107,0.000002650399,0.00029081348,0.0007594134,0.01288841,0.000010544699,0.001289629,0.0003802343],"about_ca_topic_score_codex":0.00082267245,"about_ca_topic_score_gemma":0.0021098629,"teacher_disagreement_score":0.1021766,"about_ca_system_score_codex":0.0002857882,"about_ca_system_score_gemma":0.00023978352,"threshold_uncertainty_score":0.99986327},"labels":[],"label_agreement":null},{"id":"W4389247119","doi":"10.1182/blood-2023-188080","title":"The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Biology; Chimeric antigen receptor; Antigen; Cancer research; NFAT; Molecular biology; T cell; Immunology; Gene; Immune system; Genetics; Transcription factor","score_opus":0.03253788870408592,"score_gpt":0.3233113030359155,"score_spread":0.29077341433182957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975076,0.00086202373,9.081051e-7,0.00032499962,0.000036816567,0.0005390009,0.000027107386,0.000054711163,0.00064685725],"genre_scores_gemma":[0.99784786,0.0010866466,0.000060480048,0.000017267332,0.000041456453,0.00005031777,0.000029904457,0.000029163535,0.0008369188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867743,0.000083821054,0.00024217245,0.00022672926,0.00029840454,0.00047141907],"domain_scores_gemma":[0.9989076,0.0004872486,0.00006038927,0.0003736339,0.000051209016,0.0001198992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034007223,0.00016971584,0.00030672495,0.00020511985,0.0001358694,0.000030523166,0.00010946713,0.00007076307,0.000055378117],"category_scores_gemma":[0.0003153688,0.00010078914,0.00012111495,0.0003804851,0.00013892284,0.00005052195,0.00006691757,0.00016575542,0.00009422731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009598672,0.0011106784,0.91837347,0.000065270666,0.0006954124,0.00028907336,0.0007499097,0.000024481982,0.050825212,0.00004964984,0.0005918456,0.026265105],"study_design_scores_gemma":[0.011029657,0.0010395647,0.9657683,0.00012686265,0.000024467003,0.00002597101,0.000244884,0.0012326025,0.020126937,0.00010289259,0.00018535012,0.00009254879],"about_ca_topic_score_codex":0.0010374181,"about_ca_topic_score_gemma":0.0001501083,"teacher_disagreement_score":0.047394767,"about_ca_system_score_codex":0.000038310285,"about_ca_system_score_gemma":0.00009450946,"threshold_uncertainty_score":0.41100618},"labels":[],"label_agreement":null},{"id":"W4389247396","doi":"10.1182/blood-2023-189229","title":"Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology","score_opus":0.04818474863862107,"score_gpt":0.32692956793264843,"score_spread":0.2787448192940274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971584,0.00003281394,0.000003030012,0.0001520696,0.00015156346,0.001647519,0.00014348273,0.00019280246,0.0005182815],"genre_scores_gemma":[0.9948384,0.0012245455,0.00029877207,0.000045043227,0.00010722586,0.00012270075,0.0007705165,0.000052493997,0.002540279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976755,0.00016511738,0.00056957995,0.0006201171,0.00044341598,0.0005262632],"domain_scores_gemma":[0.9983435,0.00048201624,0.00015331137,0.00042228162,0.000093516275,0.0005053197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020332799,0.00033658592,0.0006132814,0.00029625703,0.00018276963,0.00007314309,0.0000743416,0.00014741231,0.00003751087],"category_scores_gemma":[0.00021356675,0.0002481533,0.00017147913,0.0002583757,0.00010707202,0.00014679549,0.00010036261,0.00015947569,0.00006304196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046562267,0.00223315,0.9851858,0.00006828679,0.0004525965,0.00026490784,0.00023346783,1.06522506e-7,0.0006823028,0.0000019756853,0.00014000102,0.010271765],"study_design_scores_gemma":[0.038244337,0.0015208845,0.95280993,0.00006160059,0.00025158032,0.0000038496223,0.00012927725,0.00051734503,0.0061167106,0.0000060194257,0.00013806326,0.00020039218],"about_ca_topic_score_codex":0.0010539696,"about_ca_topic_score_gemma":0.0018227495,"teacher_disagreement_score":0.037778713,"about_ca_system_score_codex":0.00007075609,"about_ca_system_score_gemma":0.00006330669,"threshold_uncertainty_score":0.9999971},"labels":[],"label_agreement":null},{"id":"W4389247399","doi":"10.1182/blood-2023-184607","title":"High Prevalence of Iron Deficiency Among Daratumumab-Treated Newly Diagnosed Multiple Myeloma Patients","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Iron deficiency; Internal medicine; Ferritin; Lenalidomide; Anemia; Gastroenterology; AL amyloidosis; Surgery; Immunology; Antibody","score_opus":0.016002078237881568,"score_gpt":0.2633972735357814,"score_spread":0.24739519529789983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977481,0.00016392692,0.0000038213066,0.00003153166,0.00007883415,0.0009930956,0.00017507316,0.00018339288,0.0006222656],"genre_scores_gemma":[0.9981039,0.00019358839,0.00026192723,0.000011486807,0.000040681003,0.000113506074,0.00032528493,0.000035982175,0.00091361953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979369,0.0000726679,0.000355881,0.00042334868,0.00066744065,0.00054374733],"domain_scores_gemma":[0.99866134,0.00022887345,0.00012251828,0.00051009207,0.00019946574,0.00027771515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012297262,0.00021813592,0.00033564362,0.00024698628,0.00011828195,0.000014687232,0.00017756497,0.00010657795,0.00012684878],"category_scores_gemma":[0.000725041,0.00017717933,0.00011639989,0.00068856525,0.00014445827,0.000112763366,0.000111901405,0.00014827825,0.00024727578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023326294,0.0022295513,0.99011254,0.0005093829,0.00006887289,0.0003062363,0.00015929119,0.000008206497,0.0022682075,0.00000992289,0.0002759791,0.0038185443],"study_design_scores_gemma":[0.015239656,0.0009272144,0.9576875,0.00018500618,0.00018760811,0.0000036017839,0.00003278551,0.00016926043,0.02540347,0.000012909799,0.000018741057,0.00013227688],"about_ca_topic_score_codex":0.00067815016,"about_ca_topic_score_gemma":0.00006607108,"teacher_disagreement_score":0.032425072,"about_ca_system_score_codex":0.000043340107,"about_ca_system_score_gemma":0.00006663826,"threshold_uncertainty_score":0.7225163},"labels":[],"label_agreement":null},{"id":"W4389247523","doi":"10.1182/blood-2023-174338","title":"Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Concordia University; McGill University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; University of British Columbia; Dalhousie University; CancerCare Manitoba; Ottawa Hospital; Saint John Regional Hospital; BC Cancer Agency; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Regeneron Pharmaceuticals; Celgene; Gilead Sciences; Amgen","keywords":"Medicine; Multiple myeloma; Young adult; Internal medicine; Disease; Pediatrics; Retrospective cohort study; Surgery","score_opus":0.011093121874601448,"score_gpt":0.23194306101365342,"score_spread":0.22084993913905196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99895096,0.00006314746,0.0000011565929,0.000067083485,0.000008447405,0.0005712715,0.0002847668,0.000025624742,0.000027556547],"genre_scores_gemma":[0.99934995,0.00007391798,0.00006271937,0.000022176258,0.0000065905333,0.00008573897,0.00028585154,0.000024790319,0.000088282926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989826,0.000027735092,0.00015923417,0.00020246688,0.00035811614,0.0002698165],"domain_scores_gemma":[0.9993179,0.0001241619,0.000056498535,0.00019854987,0.000081437036,0.00022144844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028712127,0.00015356566,0.00031459203,0.00010426131,0.000035373807,0.000008663986,0.000043613054,0.000020163485,0.000008149471],"category_scores_gemma":[0.000096724274,0.00009373608,0.000017613624,0.00020210799,0.00004972907,0.000042706884,0.000023844643,0.00006670617,0.0000014424411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008360581,0.0006294777,0.9933467,0.00008834781,0.00031912027,0.0011644209,0.00028507778,0.0000014992555,0.00007405018,7.650379e-7,0.000006091791,0.0032484028],"study_design_scores_gemma":[0.015405056,0.0003302343,0.9830124,0.000114563336,0.00011135187,0.0000028437614,0.00013312616,0.0005379356,0.000256108,0.0000022700956,0.000003831887,0.00009028169],"about_ca_topic_score_codex":0.2560264,"about_ca_topic_score_gemma":0.47872338,"teacher_disagreement_score":0.222697,"about_ca_system_score_codex":0.00005979372,"about_ca_system_score_gemma":0.00034092015,"threshold_uncertainty_score":0.74892783},"labels":[],"label_agreement":null},{"id":"W4389247674","doi":"10.1182/blood-2023-186997","title":"Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Pomalidomide; Lenalidomide; Multiple myeloma; Internal medicine; Adverse effect; Dexamethasone; Neutropenia; Pharmacology; Daratumumab; Oncology; Toxicity","score_opus":0.01756551560532309,"score_gpt":0.2862399001126101,"score_spread":0.268674384507287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622333,0.000044713506,0.000001994139,0.00013010745,0.000022832519,0.0021159155,0.0009975177,0.000049477607,0.00041409172],"genre_scores_gemma":[0.9985299,0.000036273017,0.00016925515,0.000010267674,0.00001193496,0.000060119728,0.001080561,0.000023175848,0.00007850542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976927,0.00021822767,0.0006824569,0.0005148993,0.00053158007,0.00036010589],"domain_scores_gemma":[0.99837023,0.0006284001,0.00013047933,0.0005314883,0.00015254598,0.00018683646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004690717,0.00020014143,0.0005446531,0.00032460282,0.00007322032,0.000010802656,0.00009529129,0.00008272004,0.000026548349],"category_scores_gemma":[0.00087946316,0.0001599292,0.000043451793,0.0006725894,0.00009934958,0.00013203445,0.00010068846,0.00027314096,0.00001333624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01839457,0.033127528,0.9392228,0.000036957492,0.00018017023,0.00024365501,0.0014800269,0.000005680835,0.00010413044,0.0000033606996,0.000011854141,0.007189235],"study_design_scores_gemma":[0.21107762,0.0029663357,0.7847464,0.00011015266,0.00007038177,8.718692e-7,0.00041154068,0.000299059,0.00015433521,0.000019299701,0.000041615665,0.000102366095],"about_ca_topic_score_codex":0.0016748564,"about_ca_topic_score_gemma":0.00185825,"teacher_disagreement_score":0.19268304,"about_ca_system_score_codex":0.00011044663,"about_ca_system_score_gemma":0.00012232391,"threshold_uncertainty_score":0.6521723},"labels":[],"label_agreement":null},{"id":"W4389247802","doi":"10.1182/blood-2023-189567","title":"A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Bone marrow; RNA; Gene signature; Gene expression; Biology; Gene; Transcriptome; Molecular biology; Cancer research; Internal medicine; Computational biology; Oncology; Medicine; Immunology; Genetics","score_opus":0.03507370313292706,"score_gpt":0.2737519082806611,"score_spread":0.23867820514773402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802744,0.00003729294,0.0001248029,0.00066267647,0.000064838685,0.0007321807,0.00004956282,0.00011327337,0.00018790532],"genre_scores_gemma":[0.9990762,0.000043096345,0.00018473931,0.000032190153,0.00008811318,0.00020309896,0.00009920429,0.000021789114,0.0002515986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988042,0.00012366,0.00019396457,0.00023011003,0.00040990324,0.00023814575],"domain_scores_gemma":[0.9987437,0.0005275004,0.0001027135,0.0004350583,0.00009712337,0.00009388694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002785615,0.000119481556,0.00017242772,0.0001836829,0.00012886758,0.000011954122,0.00008368845,0.00007119257,0.000041670173],"category_scores_gemma":[0.00070586277,0.00007542613,0.00009803841,0.00048978714,0.00006284075,0.000030060233,0.000018942708,0.00014199638,0.00019492889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010000947,0.0014720089,0.7768869,0.000110619934,0.0002340805,0.00005925884,0.000113761715,0.000013847837,0.19416082,0.00008282338,0.0001355507,0.025730243],"study_design_scores_gemma":[0.0046783327,0.0006216987,0.81433153,0.00004008666,0.00011862372,0.0000038590206,0.000107036416,0.009061519,0.17082796,0.000032568492,0.000121114455,0.000055692824],"about_ca_topic_score_codex":0.00040472526,"about_ca_topic_score_gemma":0.00013159351,"teacher_disagreement_score":0.03744463,"about_ca_system_score_codex":0.000030521172,"about_ca_system_score_gemma":0.000051380626,"threshold_uncertainty_score":0.30757883},"labels":[],"label_agreement":null},{"id":"W4389247812","doi":"10.1182/blood-2023-181468","title":"Genetic Variations in Multiple Myeloma with Extramedullary Disease","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Multiple myeloma; Medicine; Pathology; Exome sequencing; Equidae; Internal medicine; Biology; Gene; Genetics; Mutation","score_opus":0.025483248948040903,"score_gpt":0.27897756674187624,"score_spread":0.25349431779383536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801695,0.00019798201,0.000066076245,0.00051422167,0.000019247327,0.00054280803,0.00003382542,0.00011888002,0.0004900111],"genre_scores_gemma":[0.99667454,0.00007281941,0.0022096313,0.00005260184,0.000063542044,0.00018696794,0.00011466387,0.000023618568,0.0006015893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900687,0.00003328332,0.00012534224,0.00022678179,0.0002818063,0.00032590234],"domain_scores_gemma":[0.9992375,0.00009946887,0.00001880547,0.00028257008,0.000036815774,0.00032487983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057010435,0.000102780345,0.00013522586,0.00020329937,0.000058554713,0.000014630798,0.000055881857,0.00003304379,0.00008375364],"category_scores_gemma":[0.00019118989,0.00007863651,0.00003737647,0.00052590726,0.000037628328,0.000037204394,0.000031363306,0.00010032384,0.00029625528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023262396,0.0009006245,0.9903781,0.00005490339,0.00010007442,0.0037206064,0.000087646,0.00002371951,0.00062153715,0.000028575292,0.000091413225,0.0037601942],"study_design_scores_gemma":[0.007804182,0.00016885888,0.988518,0.00006853263,0.00008767776,0.000032739557,0.000030219886,0.0026768877,0.00025334937,0.000075314674,0.00020430419,0.000079949954],"about_ca_topic_score_codex":0.000084438885,"about_ca_topic_score_gemma":0.00012186024,"teacher_disagreement_score":0.007571558,"about_ca_system_score_codex":0.000024367435,"about_ca_system_score_gemma":0.00017549636,"threshold_uncertainty_score":0.38078612},"labels":[],"label_agreement":null},{"id":"W4389258287","doi":"10.1182/blood-2023-189700","title":"Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Expanded access; Oncology; Progressive disease; Disease","score_opus":0.019623837999790585,"score_gpt":0.3005322399943265,"score_spread":0.28090840199453593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389258287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588071,0.000013745416,0.0000024741703,0.00007310073,0.000026929827,0.03991296,0.00015726648,0.000100984995,0.000905418],"genre_scores_gemma":[0.9748326,0.000028868919,0.00024724414,0.000048943366,0.000036646496,0.02389776,0.00041523288,0.000072601106,0.00042010096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965168,0.00022258172,0.00078142545,0.0006716482,0.0009893812,0.0008181414],"domain_scores_gemma":[0.9981072,0.00029156674,0.000332517,0.00073976204,0.00019134583,0.00033763368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002712166,0.00038592992,0.0008533841,0.00092018367,0.000065151806,0.000024174546,0.00034789494,0.00011339353,0.00011492231],"category_scores_gemma":[0.0004756242,0.00029640712,0.00010790142,0.0022315641,0.00022557328,0.0003090699,0.00019114099,0.00054307724,0.00003440344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011815922,0.005869856,0.9584856,0.0002615593,0.00016949324,0.0005403378,0.0002665406,0.00001096236,0.0001896768,0.000001056156,0.0001933782,0.022195585],"study_design_scores_gemma":[0.08057574,0.0034388588,0.913191,0.00028428063,0.000050994993,0.000004141172,0.000095630974,0.00014761934,0.00060312264,0.0000025764525,0.0013532751,0.0002527119],"about_ca_topic_score_codex":0.0013126305,"about_ca_topic_score_gemma":0.0063809096,"teacher_disagreement_score":0.06875982,"about_ca_system_score_codex":0.0002227668,"about_ca_system_score_gemma":0.00040854045,"threshold_uncertainty_score":0.9999488},"labels":[],"label_agreement":null},{"id":"W4389259127","doi":"10.1182/blood-2023-182164","title":"Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Daratumumab; Carfilzomib; Internal medicine; Oncology; Multiple myeloma; Population; Bortezomib; Refractory (planetary science)","score_opus":0.10312788611521921,"score_gpt":0.3503873702330216,"score_spread":0.24725948411780235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972911,0.00039475053,0.000010580105,0.0000362165,0.000017909382,0.0020751148,0.00011044154,0.0000380937,0.000025785579],"genre_scores_gemma":[0.9965418,0.00009144337,0.0030253236,0.000007359732,0.000014149132,0.00006434773,0.00020204607,0.000033992084,0.000019513645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979674,0.0002304285,0.00051161915,0.0003368132,0.0006192143,0.0003345295],"domain_scores_gemma":[0.99767244,0.0011271776,0.0004236592,0.00043240678,0.00023946875,0.00010483153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017414012,0.00030084638,0.000988063,0.00033758066,0.00006961756,0.000008746078,0.00011115075,0.000088074645,0.0000083584555],"category_scores_gemma":[0.000080843034,0.00015430195,0.0000765213,0.00080911943,0.00022058323,0.000054123542,0.00001831002,0.0001368576,9.750572e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09366257,0.02366632,0.8459424,0.00031394322,0.0020885952,0.00021908374,0.013119001,0.00072896277,0.014519452,0.0000021302444,0.000008793108,0.0057287468],"study_design_scores_gemma":[0.12637813,0.016817247,0.78945583,0.00039453516,0.00037842593,0.0000042117026,0.001213406,0.0027122402,0.06247079,5.250637e-7,0.00003160493,0.00014307261],"about_ca_topic_score_codex":0.00047516832,"about_ca_topic_score_gemma":0.00039670855,"teacher_disagreement_score":0.0564866,"about_ca_system_score_codex":0.000087891334,"about_ca_system_score_gemma":0.0003751146,"threshold_uncertainty_score":0.6292251},"labels":[],"label_agreement":null},{"id":"W4389259576","doi":"10.1182/blood-2023-190255","title":"Skp2 Inhibition Diminishes Essential Cell Survival Markers c-Maf and c-Myc, Enhancing Therapeutic Efficacy Against Drug Resistant Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Gene knockdown; Multiple myeloma; Cancer research; Malignancy; Medicine; Cell culture; Biology; Internal medicine; Oncology; Genetics","score_opus":0.017133143004395484,"score_gpt":0.26930654494173956,"score_spread":0.25217340193734405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958855,0.00044885837,0.000016880289,0.00045322586,0.00014341841,0.0007615512,0.00004623541,0.00023618036,0.0020081347],"genre_scores_gemma":[0.99746245,0.0003712473,0.00024192203,0.000067585075,0.00024423015,0.000062518106,0.0002994733,0.00005949473,0.0011910752],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99778724,0.00016219517,0.00033765085,0.0005141974,0.00057661626,0.00062210084],"domain_scores_gemma":[0.9986113,0.00053603726,0.00008338141,0.00035522378,0.00008118718,0.0003329257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040683494,0.00026894058,0.00036687232,0.00022737875,0.00026144847,0.0000775575,0.000076807635,0.00009864389,0.00005196024],"category_scores_gemma":[0.0001804668,0.00023014842,0.00013044829,0.00039229964,0.000121872195,0.00010401794,0.00011510954,0.00022741532,0.00014818112],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025289007,0.002200274,0.0737027,0.0006247742,0.00068101246,0.0020618313,0.0013240589,0.00000477893,0.90038717,0.000021543778,0.0006941053,0.015768878],"study_design_scores_gemma":[0.022902537,0.00047421898,0.50810534,0.00031390565,0.00034925214,0.00002436122,0.0012209676,0.00052952854,0.4649692,0.000038063306,0.0007091635,0.00036349974],"about_ca_topic_score_codex":0.00010339732,"about_ca_topic_score_gemma":0.000166337,"teacher_disagreement_score":0.43541795,"about_ca_system_score_codex":0.000044933484,"about_ca_system_score_gemma":0.000116662944,"threshold_uncertainty_score":0.938518},"labels":[],"label_agreement":null},{"id":"W4389297506","doi":"10.1182/bloodadvances.2023010579","title":"Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Daratumumab; Internal medicine; Medicine; Lenalidomide; Hazard ratio; Oncology; Population; Dexamethasone; Subgroup analysis; Confidence interval","score_opus":0.016520869720489155,"score_gpt":0.2990142377944913,"score_spread":0.28249336807400216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389297506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981756,0.00057175895,0.000013054978,0.00005590514,0.000019967116,0.00076333893,0.0002951118,0.000038260605,0.00006695937],"genre_scores_gemma":[0.9974475,0.00023859889,0.0013313764,0.000027216849,0.000031064646,0.00021075811,0.00016127923,0.000026758615,0.0005254776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988584,0.00002601742,0.0001724842,0.00029686556,0.00034991634,0.0002963432],"domain_scores_gemma":[0.99926513,0.00012749978,0.000087396766,0.00021304117,0.0001597141,0.00014722743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059952472,0.00016664564,0.00040719917,0.00032195006,0.00007595629,0.000017286015,0.000049801092,0.000039721093,0.00004671914],"category_scores_gemma":[0.00004077271,0.000090262605,0.00006415382,0.0008552527,0.00012639714,0.00018105368,0.00002110958,0.00006566496,0.0000031016702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022090558,0.00047191177,0.95317507,0.00009118172,0.0029252388,0.0002407322,0.0004114091,0.0000047395465,0.00010557723,0.0000049335936,0.000007039708,0.020471605],"study_design_scores_gemma":[0.014011189,0.0065166242,0.976761,0.000087761604,0.0010491004,0.0000042477654,0.00007218758,0.00007710017,0.0008344942,0.000007917561,0.00045740083,0.00012098276],"about_ca_topic_score_codex":0.000056864872,"about_ca_topic_score_gemma":0.00044498284,"teacher_disagreement_score":0.023585921,"about_ca_system_score_codex":0.000012410259,"about_ca_system_score_gemma":0.000058672333,"threshold_uncertainty_score":0.36808023},"labels":[],"label_agreement":null},{"id":"W4389485135","doi":"10.1038/s41408-023-00946-z","title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institutes of Health Research; University of British Columbia; Memorial University of Newfoundland; McGill University; McGill University Health Centre; London Health Sciences Centre; Western University; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Juravinski Cancer Centre; Jewish General Hospital; Alberta Cancer Foundation; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Dalhousie University","funders":"Pfizer Canada; Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Cohort; Lenalidomide; Salvage therapy; Bortezomib; Daratumumab; Oncology; Surgery; Chemotherapy","score_opus":0.15252260014164173,"score_gpt":0.41818446379962954,"score_spread":0.26566186365798783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389485135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904856,0.00021311252,0.0000103052835,0.0017638505,0.00035802845,0.001165748,0.0054716696,0.00005894187,0.00047273136],"genre_scores_gemma":[0.9895496,0.0006098894,0.0008733786,0.00009728034,0.0005214644,0.00007257071,0.0076443544,0.000074200965,0.00055731233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940037,0.0004406902,0.0008287602,0.0008696633,0.002645453,0.0012117024],"domain_scores_gemma":[0.995263,0.0007539026,0.00044863828,0.0016832238,0.0008294244,0.0010218408],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0019844389,0.00042024258,0.00078609993,0.0010668987,0.001646564,0.00016667838,0.00090646686,0.000116603354,0.00014274142],"category_scores_gemma":[0.0015437055,0.0002441274,0.00014864632,0.0017060041,0.00055039144,0.0004756939,0.00044382663,0.0014763513,0.000039537656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001460702,0.0012163753,0.97857827,0.00003505008,0.0016791564,0.006504037,0.00014081615,0.000014104964,0.0014771625,0.000019197843,0.0049171015,0.003958015],"study_design_scores_gemma":[0.01627404,0.00057299924,0.97424334,0.0006375653,0.00031789287,0.00012448104,0.00016809454,0.0007349847,0.0005484893,0.0000057940338,0.0061369278,0.00023541684],"about_ca_topic_score_codex":0.41972598,"about_ca_topic_score_gemma":0.7097068,"teacher_disagreement_score":0.28998083,"about_ca_system_score_codex":0.0009565397,"about_ca_system_score_gemma":0.0031229823,"threshold_uncertainty_score":0.99965316},"labels":[],"label_agreement":null},{"id":"W4389489108","doi":"10.1182/hematology.2023000433","title":"Current use of bispecific antibodies to treat multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Sanofi; Pfizer; Amgen","keywords":"Bispecific antibody; Immune system; Immunotherapy; Multiple myeloma; Antigen; Chimeric antigen receptor; Medicine; Cancer research; Antibody; Immunology; Monoclonal antibody","score_opus":0.11467163592271526,"score_gpt":0.3760434748807849,"score_spread":0.2613718389580696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389489108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759406,0.00048389123,0.000059617385,0.0007104468,0.00015155315,0.00051863753,0.000051617408,0.00013196147,0.00029822742],"genre_scores_gemma":[0.99763614,0.00038627165,0.00084911863,0.000033866272,0.000036271307,0.0000612816,0.00011085795,0.000022351305,0.0008638452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987451,0.00004972959,0.0002634812,0.0002853453,0.00022686785,0.0004295145],"domain_scores_gemma":[0.9988807,0.00034531776,0.0000442225,0.00037803932,0.000112052105,0.00023967115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006613233,0.00014381144,0.00046658175,0.0004289472,0.000051805077,0.00000784629,0.00007079655,0.000065003595,0.00013202347],"category_scores_gemma":[0.0005195224,0.00011100307,0.0001010401,0.00047971559,0.00009502646,0.00004568101,0.00010099497,0.00009585371,0.0012091043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005876359,0.00036179274,0.9391611,0.000395747,0.00009289719,0.0006749798,0.00030843727,0.0000041820012,0.008335821,0.0010272076,0.021944225,0.027105946],"study_design_scores_gemma":[0.0034017633,0.00049257535,0.8964924,0.00023026166,0.000054704615,0.00027155146,0.00014663445,0.0006693401,0.06514256,0.000087553264,0.03284141,0.00016921441],"about_ca_topic_score_codex":0.00007143738,"about_ca_topic_score_gemma":0.00004853517,"teacher_disagreement_score":0.056806736,"about_ca_system_score_codex":0.000032522545,"about_ca_system_score_gemma":0.000053325733,"threshold_uncertainty_score":0.9995686},"labels":[],"label_agreement":null},{"id":"W4390005460","doi":"10.1111/ejh.14143","title":"Determinants of durable humoral and T cell immunity in myeloma patients following <scp>COVID</scp>‐19 vaccination","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute for Health and Care Research; Janssen UK; Cancer Research UK; Myeloma UK; European Hematology Association","keywords":"Vaccination; Medicine; Antibody; Immunology; Immune system; Multiple myeloma; Immunity; Coronavirus disease 2019 (COVID-19); Internal medicine; Disease","score_opus":0.028763906509255335,"score_gpt":0.3075254082450133,"score_spread":0.278761501735758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390005460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979065,0.0002536719,0.000011420617,0.000040852527,0.00013122786,0.00018535716,0.000004120895,0.000011903578,0.0014549532],"genre_scores_gemma":[0.9992669,0.00012532553,0.00031618826,0.000032536027,0.000017295357,0.0000012774036,0.00001051299,0.000023277262,0.00020668386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805415,0.0006153633,0.0006201843,0.00013172388,0.00026991157,0.00030865832],"domain_scores_gemma":[0.9988168,0.00031361752,0.00035812036,0.0001574275,0.0001341641,0.00021986222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009886314,0.00012403549,0.00051926484,0.00052562833,0.000069102876,0.000010749241,0.00013805005,0.000035291876,0.000014478015],"category_scores_gemma":[0.0013665961,0.0001006084,0.000103354476,0.0003033046,0.000038546976,0.00013164002,0.000108904605,0.00025556813,0.00003632331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011784151,0.00023921809,0.9779439,0.00020341788,0.000046371937,0.014790296,0.00090891944,0.000004485323,0.001288621,0.0000037608506,0.00038955378,0.004063605],"study_design_scores_gemma":[0.006830346,0.0009100591,0.98783,0.00014327344,0.000040884,0.0009081116,0.00044041604,0.00015519024,0.002489822,0.00004097498,0.00017688857,0.00003406271],"about_ca_topic_score_codex":0.000020355183,"about_ca_topic_score_gemma":0.000012921977,"teacher_disagreement_score":0.0138821835,"about_ca_system_score_codex":0.000049660866,"about_ca_system_score_gemma":0.000090901274,"threshold_uncertainty_score":0.41026914},"labels":[],"label_agreement":null},{"id":"W4390029779","doi":"10.1016/j.clml.2023.12.009","title":"Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; Centers for Disease Control and Prevention; National Institutes of Health; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; TG Therapeutics; Medac; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; BeiGene; National Center for Advancing Translational Sciences; HistoGenetics; Comprehensive Cancer Center, University of California, Davis; Mallinckrodt Pharmaceuticals; Astellas Pharma US; University of Southern California; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Incyte; Pfizer; National Center for Chronic Disease Prevention and Health Promotion; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Amgen","keywords":"Medicine; Hazard ratio; Population; Proportional hazards model; Hematopoietic cell; Transplantation; Medicaid; Confidence interval; Oncology; Internal medicine; Haematopoiesis; Stem cell; Health care","score_opus":0.057046776532737556,"score_gpt":0.36223962794040304,"score_spread":0.3051928514076655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390029779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720025,0.00006224121,0.00007724702,0.00009649151,0.00014087989,0.0017854217,0.000064036445,0.00025061905,0.00032282944],"genre_scores_gemma":[0.9977121,0.00004345302,0.00039900528,0.000089233145,0.000074071904,0.00014741029,0.0010367417,0.00006477047,0.0004332624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596053,0.00046436235,0.0014908029,0.0007252774,0.00077844475,0.00058059045],"domain_scores_gemma":[0.99690956,0.0016754186,0.00030393084,0.0006314118,0.00015705098,0.0003226143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089254556,0.00033598606,0.0009358625,0.00055560295,0.00010849352,0.000022662967,0.00020468836,0.00033292768,0.00020113235],"category_scores_gemma":[0.00086298044,0.00030330676,0.00030316503,0.0012699354,0.00011755424,0.00012758591,0.000054257725,0.00021055603,0.00046860913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022212018,0.0016673383,0.9132595,0.0003078336,0.00008409874,0.000943062,0.0002583203,0.00024431595,0.0005424176,0.000010295903,0.0001405675,0.080321066],"study_design_scores_gemma":[0.017635254,0.0011296596,0.93868893,0.00018046636,0.00014196744,0.000017043712,0.00009540695,0.040569678,0.0012193469,0.000071005656,0.000028991279,0.00022227215],"about_ca_topic_score_codex":0.00063695794,"about_ca_topic_score_gemma":0.00023486889,"teacher_disagreement_score":0.08009879,"about_ca_system_score_codex":0.0005743956,"about_ca_system_score_gemma":0.0007635927,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4390126634","doi":"10.1016/j.jval.2023.09.028","title":"P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Matching (statistics); Class (philosophy); Refractory (planetary science); Oncology; Internal medicine; Computer science; Physics; Artificial intelligence; Pathology","score_opus":0.0862507112215568,"score_gpt":0.3333338324338619,"score_spread":0.24708312121230508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390126634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899552,0.0010720136,0.00005297252,0.0006417471,0.00019834713,0.007018472,0.0009004887,0.00010603122,0.000054770262],"genre_scores_gemma":[0.9951578,0.0012353049,0.0010861031,0.000037298243,0.00006352133,0.00070529705,0.0011182608,0.00008904743,0.00050738885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602056,0.0004202155,0.0012300084,0.00059801125,0.0008209179,0.0009102934],"domain_scores_gemma":[0.99576056,0.0022330706,0.00067319645,0.00079397444,0.00019372442,0.0003454769],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052814826,0.00047165458,0.0014380363,0.000600076,0.0002305885,0.000014821,0.00019301673,0.00016002635,0.00003313523],"category_scores_gemma":[0.00020073228,0.00028227712,0.00027470654,0.0008973883,0.00015579385,0.00007133747,0.00003554076,0.00019381633,0.000018195322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02125068,0.0099415295,0.8899534,0.0009750807,0.00094324746,0.000056496687,0.006951593,0.001063443,0.00024280522,0.000036043122,0.0003326525,0.06825307],"study_design_scores_gemma":[0.056039855,0.026320186,0.8956702,0.00055853504,0.00019718245,0.000004471894,0.0011836019,0.011245957,0.004521023,0.00002383133,0.0040073707,0.00022781959],"about_ca_topic_score_codex":0.00926929,"about_ca_topic_score_gemma":0.0016057913,"teacher_disagreement_score":0.068025246,"about_ca_system_score_codex":0.0015369862,"about_ca_system_score_gemma":0.00078245334,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W4390128515","doi":"10.1016/j.jval.2023.09.163","title":"CO91 Association Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Progression-free survival; Multiple myeloma; Medicine; Refractory (planetary science); Oncology; Internal medicine; Overall survival; Biology","score_opus":0.04410244819865129,"score_gpt":0.3251122891990199,"score_spread":0.28100984100036863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390128515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957103,0.00018061724,0.0000042465535,0.0016690961,0.00019991113,0.0017471057,0.0001709454,0.00011075994,0.00020699692],"genre_scores_gemma":[0.9981733,0.00026693864,0.00038447074,0.000067019624,0.00012838826,0.00008689255,0.00057407987,0.0000540405,0.00026485964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588907,0.00068859884,0.00059978815,0.0005402825,0.0013546827,0.0009275764],"domain_scores_gemma":[0.99736595,0.0013392792,0.00025923533,0.0004425382,0.00013006492,0.00046290996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018934513,0.00025115057,0.0006553519,0.0004677009,0.0001367015,0.00003046774,0.0001418491,0.00019483601,0.000018925113],"category_scores_gemma":[0.0016994033,0.00020867553,0.000048431342,0.0006855737,0.000051829407,0.00017460066,0.00014613708,0.0005649082,0.00004657302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009747305,0.00050913217,0.98165,0.0003048906,0.00008650479,0.00005983053,0.0004341929,0.000044118693,0.0000056204785,0.000022211952,0.00034301972,0.015565746],"study_design_scores_gemma":[0.020097237,0.001390053,0.9757905,0.00060111226,0.000014108242,5.4759835e-7,0.00007423317,0.0012365386,0.000012163661,0.00011602907,0.0005002077,0.00016726206],"about_ca_topic_score_codex":0.00517991,"about_ca_topic_score_gemma":0.0010379413,"teacher_disagreement_score":0.019122507,"about_ca_system_score_codex":0.0011827366,"about_ca_system_score_gemma":0.00046475104,"threshold_uncertainty_score":0.8509541},"labels":[],"label_agreement":null},{"id":"W4390128716","doi":"10.1016/j.jval.2023.09.165","title":"CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Dexamethasone; Medicine; Matching (statistics); Refractory (planetary science); Class (philosophy); Oncology; Multiple myeloma; Internal medicine; Computer science; Physics; Pathology; Artificial intelligence","score_opus":0.13386070313518275,"score_gpt":0.35811897525514064,"score_spread":0.22425827211995789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390128716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999006,0.0017118666,0.00007987288,0.0004378322,0.0003142543,0.0064852084,0.0008383066,0.000102964135,0.00003964636],"genre_scores_gemma":[0.9943807,0.001417316,0.0019363327,0.000021982161,0.00007379396,0.00090452394,0.00092066365,0.0000843759,0.00026031444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615794,0.00043692536,0.0011555005,0.00058242073,0.00082228717,0.00084492535],"domain_scores_gemma":[0.9942151,0.0037225243,0.00062541146,0.0007961257,0.0002948609,0.0003459844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057343295,0.00045632356,0.0013696315,0.00054329867,0.00018120211,0.00001304648,0.0001660161,0.00016137378,0.000032322303],"category_scores_gemma":[0.00042774098,0.00027607597,0.0002445412,0.0011408824,0.00017290674,0.00007070981,0.00003141487,0.00019227208,0.000014477351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087187834,0.015420521,0.73063815,0.0012448817,0.0019505313,0.00008043183,0.010290065,0.002494907,0.00025630806,0.00003349543,0.00030096882,0.15010192],"study_design_scores_gemma":[0.12102344,0.04443377,0.80020857,0.0005512268,0.00033295024,0.0000024287424,0.0020362814,0.023096938,0.003509397,0.000018527422,0.0044937143,0.0002927396],"about_ca_topic_score_codex":0.0078318985,"about_ca_topic_score_gemma":0.0016377647,"teacher_disagreement_score":0.14980918,"about_ca_system_score_codex":0.001597283,"about_ca_system_score_gemma":0.00093835767,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W4390340497","doi":"10.14740/jh1201","title":"Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lenalidomide; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Oncology; Population; Induction chemotherapy; Transplantation; Chemotherapy; Surgery","score_opus":0.016254359001987035,"score_gpt":0.29760942072255336,"score_spread":0.28135506172056635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390340497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992502,0.00011661312,0.000018393783,0.00015879117,0.000038934653,0.0003814679,0.000014906326,0.000009499487,0.000011238681],"genre_scores_gemma":[0.9988926,0.0006125806,0.00034988852,0.000027805561,0.000009505145,0.000025202675,0.00000965707,0.000016798538,0.000055960085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987902,0.00009076374,0.00041680218,0.00017360864,0.00024959492,0.0002790257],"domain_scores_gemma":[0.999109,0.00025355542,0.00026775277,0.00012272752,0.00010685724,0.00014010318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012082623,0.00016032539,0.00052734837,0.00045943723,0.00002980163,0.000007784546,0.000045905726,0.000076710596,0.000009172734],"category_scores_gemma":[0.000026958067,0.00010184251,0.00005391058,0.00022959331,0.00011969287,0.00011073773,0.000010704498,0.00017079536,9.854477e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009226569,0.0002947164,0.9834744,0.0001353763,0.00010823314,0.001296682,0.0021185244,0.00002031744,0.00018102281,0.00000894641,0.00001414527,0.0031211223],"study_design_scores_gemma":[0.016644826,0.0019677903,0.9783827,0.00024527492,0.000035109206,0.00033999843,0.00024411987,0.00005082317,0.00199502,0.00001449086,0.0000012495459,0.00007861046],"about_ca_topic_score_codex":0.00032156165,"about_ca_topic_score_gemma":0.0002940818,"teacher_disagreement_score":0.0074182576,"about_ca_system_score_codex":0.00010042769,"about_ca_system_score_gemma":0.00008385318,"threshold_uncertainty_score":0.4153017},"labels":[],"label_agreement":null},{"id":"W4390500319","doi":"10.1016/j.hoc.2023.12.007","title":"Management of Newly Diagnosed Multiple Myeloma Today, and in the Future","year":2024,"lang":"en","type":"review","venue":"Hematology/Oncology Clinics of North America","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Chimeric antigen receptor; Monoclonal antibody; CD38; Antibody; Oncology; Bispecific antibody; Internal medicine; Immunology; Immunotherapy; Cancer; Biology; Stem cell","score_opus":0.04841792103483246,"score_gpt":0.40457217099634657,"score_spread":0.3561542499615141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390500319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00575348,0.98978055,0.0000065806016,0.00058764435,0.00031250567,0.0026939865,0.00015830214,0.000028449496,0.00067852787],"genre_scores_gemma":[0.00440848,0.99179506,0.0024727564,0.00016331761,0.00010134136,0.00055875804,0.00034999364,0.000053773794,0.000096522665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612516,0.00058866607,0.0016709277,0.0007055396,0.0003673678,0.0005423293],"domain_scores_gemma":[0.9953961,0.00263468,0.00083318073,0.0008554784,0.00009872813,0.00018185165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004825088,0.0005229003,0.003943761,0.00047115347,0.00004768859,0.000006791712,0.00046567095,0.0005484216,0.000033423275],"category_scores_gemma":[0.00024752686,0.00031359636,0.000618925,0.0008739494,0.00078461535,0.000030872652,0.00035385793,0.0010987632,0.00007699066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032175652,0.0009045948,0.02078039,0.028216515,0.001499189,0.006558313,0.00014854314,2.1359095e-7,1.0794429e-8,0.00009975,0.00150648,0.93996423],"study_design_scores_gemma":[0.002985443,0.0014138989,0.012434754,0.0058423714,0.0033356498,0.00077267806,0.0005159272,0.00002921112,1.9136067e-7,0.000046901743,0.97238904,0.000233948],"about_ca_topic_score_codex":0.000041772753,"about_ca_topic_score_gemma":0.00032321998,"teacher_disagreement_score":0.97088253,"about_ca_system_score_codex":0.00009406632,"about_ca_system_score_gemma":0.00053133175,"threshold_uncertainty_score":0.99993163},"labels":[],"label_agreement":null},{"id":"W4390588040","doi":"10.1038/s41591-023-02703-y","title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Apheresis Group; Juravinski Cancer Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"Genentech; McMaster University; Gilead Sciences; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; London Health Sciences Centre; Amgen; Pfizer; Dalhousie University; Hamilton Health Sciences; GlaxoSmithKline","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Multiple myeloma; Neutropenia; Adverse effect; Dexamethasone; Refractory (planetary science); Oncology; Febrile neutropenia; Gastroenterology; Toxicity","score_opus":0.026166730936901177,"score_gpt":0.3845048810255943,"score_spread":0.35833815008869313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390588040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511301,0.038659226,0.00003978231,0.0054236427,0.0007483008,0.0015252352,0.000037981765,0.00016100677,0.0022747205],"genre_scores_gemma":[0.99458414,0.0009994762,0.00067012955,0.0005468551,0.0012988802,0.00010062382,0.00021080847,0.000054697557,0.0015343598],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974359,0.00014322865,0.0004757206,0.0006534806,0.00074706087,0.0005445778],"domain_scores_gemma":[0.99793345,0.001084647,0.000054477954,0.0003774945,0.000086413085,0.00046351654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082231953,0.00032850602,0.00072392984,0.0007019089,0.000063083855,0.000027482454,0.00010692312,0.00045000663,0.0004102038],"category_scores_gemma":[0.002620131,0.00021812937,0.00008980578,0.0006793654,0.0002419877,0.00012867806,0.000067666864,0.0017036829,0.000046215006],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26774806,0.0038719063,0.033817448,0.001920824,0.0012623017,0.035057567,0.0024873174,5.4036445e-7,0.08345271,0.00082474784,0.02363107,0.5459255],"study_design_scores_gemma":[0.7925029,0.012232104,0.06285076,0.0038744134,0.00062922476,0.0016524533,0.0005768489,0.0040214737,0.0077003585,0.0003838771,0.11296187,0.00061374035],"about_ca_topic_score_codex":0.00025860817,"about_ca_topic_score_gemma":0.00015940877,"teacher_disagreement_score":0.54531175,"about_ca_system_score_codex":0.00021534464,"about_ca_system_score_gemma":0.00019719309,"threshold_uncertainty_score":0.88950574},"labels":[],"label_agreement":null},{"id":"W4390706597","doi":"10.1182/blood.2023022499","title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Terry Fox Foundation; Sanofi; Pfizer; Amgen; Multiple Myeloma Research Foundation","keywords":"Multiple myeloma; Bispecific antibody; Antibody; Medicine; Immunology; Chimeric antigen receptor; Antigen; Cancer research; Immune system; Oncology; Monoclonal antibody; Immunotherapy","score_opus":0.028554548486618637,"score_gpt":0.296561545064348,"score_spread":0.26800699657772936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810118,0.012833659,0.0002354394,0.0010247173,0.00015849003,0.00089315383,0.00007048772,0.00024611954,0.003526097],"genre_scores_gemma":[0.9860754,0.0017829824,0.008620118,0.000030403933,0.00011603446,0.000030369503,0.00006359678,0.000045256653,0.0032358386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998226,0.000065725406,0.00033536972,0.00052173086,0.00035607285,0.00049513363],"domain_scores_gemma":[0.9990306,0.0004348615,0.00003108895,0.0002557688,0.000045372064,0.00020232932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003167104,0.0002223632,0.00037270033,0.00026969114,0.00013253305,0.000081607555,0.00008461164,0.00009544644,0.00013241565],"category_scores_gemma":[0.00046315457,0.0001596578,0.00007127146,0.00040915716,0.000085135005,0.00010298263,0.000097644865,0.00026411162,0.00009736548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016693708,0.00993414,0.42926922,0.007897045,0.0035802794,0.06663737,0.0063808644,0.0000100112,0.3324331,0.01674854,0.005700393,0.10471534],"study_design_scores_gemma":[0.050249327,0.0013439697,0.8129109,0.0046716984,0.00058635615,0.0005857451,0.001415066,0.0022378915,0.08502311,0.0020118305,0.03781887,0.0011452201],"about_ca_topic_score_codex":0.000060994156,"about_ca_topic_score_gemma":0.00039275156,"teacher_disagreement_score":0.3836417,"about_ca_system_score_codex":0.00006165458,"about_ca_system_score_gemma":0.00011500753,"threshold_uncertainty_score":0.6510656},"labels":[],"label_agreement":null},{"id":"W4390848187","doi":"10.1016/j.jgo.2023.101689","title":"Impact of age, comorbidity, and polypharmacy on receipt of systemic therapy in advanced cancers: A retrospective population-based study","year":2024,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg; University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Comorbidity; Medicine; Polypharmacy; Internal medicine; Cancer; Retrospective cohort study; Cancer registry; Lung cancer; Population; Odds ratio; Logistic regression; Breast cancer; Oncology","score_opus":0.03785853534255882,"score_gpt":0.42999089856973394,"score_spread":0.3921323632271751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390848187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996178,0.0026999475,0.0000050793033,0.00011337594,0.0002158775,0.0006771804,0.000020737012,0.0000049406253,0.000084891704],"genre_scores_gemma":[0.9985652,0.0011277321,0.00013975393,0.000009554514,0.000113494556,0.000009734403,0.0000035329801,0.000012613933,0.000018406252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859923,0.0002426589,0.0005595962,0.00013520534,0.00030784903,0.00015545939],"domain_scores_gemma":[0.9989062,0.00034794424,0.0003434164,0.00010752046,0.0001842048,0.00011073993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004851341,0.0001132203,0.00068585767,0.0006886049,0.00001561093,0.0000049906357,0.000062424624,0.00005887332,0.000041898802],"category_scores_gemma":[0.00016913736,0.000074860334,0.00013845686,0.00047992155,0.000026903315,0.000063293744,0.0000123060445,0.0002836753,0.0000011789774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079881605,0.0011924756,0.9571486,0.00010330516,0.00052596943,0.0011446624,0.00048647553,0.00019358718,0.0058602444,0.0000033387996,0.000059169943,0.025294019],"study_design_scores_gemma":[0.012049627,0.02426979,0.9624993,0.00026364462,0.00008495132,0.00013776489,0.00018350703,0.00022174044,0.00020500777,0.000031680087,0.000008199193,0.0000447937],"about_ca_topic_score_codex":0.0023945,"about_ca_topic_score_gemma":0.00014245331,"teacher_disagreement_score":0.025249224,"about_ca_system_score_codex":0.0016827172,"about_ca_system_score_gemma":0.0010628396,"threshold_uncertainty_score":0.4400247},"labels":[],"label_agreement":null},{"id":"W4390893554","doi":"10.1038/s41408-024-00978-z","title":"Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?","year":2024,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Chromosomal translocation; Multiple myeloma; Medicine; Internal medicine; Biology; Genetics; Gene","score_opus":0.0379314257076081,"score_gpt":0.3384788602232021,"score_spread":0.300547434515594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390893554","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03736697,0.026905343,0.000016801394,0.0026436916,0.9293454,0.0016851397,0.0010211084,0.000044423527,0.000971075],"genre_scores_gemma":[0.14935613,0.018573077,0.00011473661,0.00010067259,0.8184863,0.00028961795,0.00016751456,0.00016257542,0.012749404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996712,0.00015346361,0.000729791,0.00036706822,0.001527064,0.0005105704],"domain_scores_gemma":[0.9983236,0.00031368213,0.00028775304,0.0003996606,0.000424355,0.00025090357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004140596,0.00034165775,0.00067171635,0.00029143228,0.00011211664,0.00007374204,0.00032242425,0.00049203995,0.00068394095],"category_scores_gemma":[0.0006757487,0.00019009996,0.00034938025,0.0004551336,0.000118054966,0.00009111718,0.00005906421,0.0020646364,0.00002580422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015814641,0.0005279706,0.004266554,0.0010420304,0.0010437126,0.0006671952,0.0005633704,0.0000069642856,0.00028353187,0.000001425148,0.9761222,0.01389359],"study_design_scores_gemma":[0.020024544,0.0006933916,0.004360099,0.009854401,0.0018341109,0.00037027482,0.00025678592,0.000070295755,0.0065310285,0.000053773776,0.95558417,0.00036712005],"about_ca_topic_score_codex":0.0006103505,"about_ca_topic_score_gemma":0.004490749,"teacher_disagreement_score":0.111989155,"about_ca_system_score_codex":0.00050025835,"about_ca_system_score_gemma":0.0031144752,"threshold_uncertainty_score":0.8969933},"labels":[],"label_agreement":null},{"id":"W4390912491","doi":"10.3390/curroncol31010034","title":"Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Karyopharm Therapeutics","keywords":"Medicine; Hazard ratio; Internal medicine; Limiting; Refractory (planetary science); Proportional hazards model; Incidence (geometry); Multiple myeloma; Oncology; Confidence interval","score_opus":0.11821370558203202,"score_gpt":0.4690541109099745,"score_spread":0.3508404053279425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390912491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464136,0.0024515803,0.000009980157,0.00012974505,0.00032517684,0.0015888178,0.0000458557,0.00008528814,0.00072216324],"genre_scores_gemma":[0.9979075,0.00028633635,0.0010921103,0.000004289549,0.000118758144,0.00023466759,0.00020919746,0.00003458682,0.00011251487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982073,0.00016825425,0.0003836608,0.00041487179,0.00036785097,0.0004581165],"domain_scores_gemma":[0.9984187,0.0005750003,0.00023710266,0.0002788437,0.00025373755,0.00023660193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024814508,0.00021662062,0.0004580112,0.00037840067,0.00003389478,0.000023217557,0.00010191773,0.00013063349,0.00012550759],"category_scores_gemma":[0.0011225787,0.0001400937,0.0001257177,0.0004889297,0.00012593577,0.00022346339,0.00006144886,0.0005735986,0.00007336353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016659951,0.0059949276,0.5820408,0.00024589995,0.00019017253,0.000107859996,0.00023241165,0.0000020435969,0.00006362268,0.0000017360725,0.00029311713,0.4091614],"study_design_scores_gemma":[0.008124979,0.014023764,0.9529537,0.00082485384,0.00012507079,0.000018454215,0.00006754641,0.0016036342,0.000033286226,0.000004880936,0.022089532,0.0001302966],"about_ca_topic_score_codex":0.00027990437,"about_ca_topic_score_gemma":0.00026775704,"teacher_disagreement_score":0.4090311,"about_ca_system_score_codex":0.0006882395,"about_ca_system_score_gemma":0.0008647138,"threshold_uncertainty_score":0.57128555},"labels":[],"label_agreement":null},{"id":"W4391165908","doi":"10.2139/ssrn.4703031","title":"The EMMY Longitudinal, Cohort Study: Real-World Data to Describe Multiple Myeloma Management and Outcomes as More Therapeutic Options Emerge","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; Longitudinal data; Cohort; Medicine; Longitudinal study; Statistics; Computer science; Mathematics; Internal medicine; Data mining","score_opus":0.07671516482433405,"score_gpt":0.3954360838218167,"score_spread":0.31872091899748267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391165908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657998,0.013947512,0.00020577117,0.012663074,0.00058740226,0.005565149,0.00011555441,0.00013874214,0.0009769646],"genre_scores_gemma":[0.93666,0.041446477,0.00028390196,0.00011466168,0.00028514536,0.00042882038,0.00018084036,0.000111832174,0.020488312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99379206,0.00026188573,0.0007063203,0.0011904672,0.0012868575,0.0027624005],"domain_scores_gemma":[0.9967761,0.00022330733,0.00020920316,0.0021064428,0.00018820983,0.00049672666],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003123729,0.0006162439,0.0008070672,0.00056854077,0.0007854432,0.00047698338,0.0010956145,0.000099793855,0.00003258211],"category_scores_gemma":[0.00015672397,0.00038471553,0.00024275074,0.00046237666,0.00015944817,0.00009388258,0.0032639054,0.004405827,0.00011025256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063199154,0.00065342226,0.918779,0.000110639805,0.01618175,0.000583824,0.0002358619,0.000014082612,0.000007711022,0.005282634,0.0011161902,0.056402884],"study_design_scores_gemma":[0.0020984882,0.00086458126,0.96818185,0.00022117271,0.0023430614,0.00034753897,0.0034880356,0.00048579398,0.000003036841,0.018331077,0.0032725057,0.00036284048],"about_ca_topic_score_codex":0.0026777762,"about_ca_topic_score_gemma":0.03932612,"teacher_disagreement_score":0.056040045,"about_ca_system_score_codex":0.001885147,"about_ca_system_score_gemma":0.0017333619,"threshold_uncertainty_score":0.99986047},"labels":[],"label_agreement":null},{"id":"W4391226400","doi":"10.1038/s41408-024-00985-0","title":"Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Multiple myeloma; Randomized controlled trial; Clinical trial; Medicine; Internal medicine; MEDLINE; Chromosome; Oncology; Bioinformatics; Genetics; Biology; Gene","score_opus":0.2498751381734825,"score_gpt":0.5259056938982104,"score_spread":0.2760305557247279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391226400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014248881,0.9844013,0.000010842209,0.0004526198,0.0007766882,0.014077291,0.00012542614,0.000028962077,0.00011261539],"genre_scores_gemma":[0.00005766147,0.9909722,0.00018171727,0.00018419228,0.0012528586,0.0064397804,0.00010446403,0.00009832655,0.0007087559],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9756777,0.014086286,0.008060386,0.0006330384,0.00088707136,0.00065550016],"domain_scores_gemma":[0.99012125,0.006677711,0.0017994137,0.0006092347,0.00018651709,0.00060590444],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.028237958,0.00069565646,0.018070359,0.0010056276,0.00008070608,0.00017477934,0.00035015255,0.00040511883,0.00043022924],"category_scores_gemma":[0.029640833,0.0003800133,0.0038757077,0.0010039706,0.00011222762,0.00012043274,0.0000932968,0.002876106,0.00022497622],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001810766,0.0006301514,0.000035145826,0.862177,0.005232189,0.0042386204,0.00004208757,2.3689746e-7,1.1900205e-7,0.000008213907,0.00087760185,0.12494786],"study_design_scores_gemma":[0.10241557,0.00012016974,0.000003683737,0.84418935,0.03386434,0.0024918593,0.000008553457,0.00011480475,1.9600273e-7,0.00002217768,0.016514765,0.0002545563],"about_ca_topic_score_codex":0.00012195432,"about_ca_topic_score_gemma":0.0002972154,"teacher_disagreement_score":0.124693304,"about_ca_system_score_codex":0.00067074667,"about_ca_system_score_gemma":0.0035409613,"threshold_uncertainty_score":0.9998652},"labels":[],"label_agreement":null},{"id":"W4391286250","doi":"10.14740/jmc4188","title":"Early Detection and Diagnostic Approach Through Automated Hematological Analysis for Plasma Cell Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasma cell leukemia; Multiple myeloma; Hematology; Hematology analyzer; Context (archaeology); Bone marrow; Leukemia; Bone marrow aspirate; Internal medicine; Oncology; Pathology","score_opus":0.047398995824697136,"score_gpt":0.3490893142042082,"score_spread":0.30169031837951105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391286250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857191,0.0027711014,0.010170598,0.00081329007,0.00009728074,0.00022366706,0.000012178794,0.00006782617,0.00012496507],"genre_scores_gemma":[0.9959315,0.00071920844,0.002980891,0.00006323941,0.00021218984,0.000019514217,0.000010382008,0.000011088635,0.000051956442],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99831086,0.00006731619,0.0003730364,0.00016833187,0.000862826,0.00021761001],"domain_scores_gemma":[0.9970012,0.0023196437,0.00007642556,0.00007892649,0.00010375615,0.0004201051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000446801,0.000116123134,0.00044077812,0.00022508707,0.000061380604,0.00005577657,0.00006731083,0.00017092696,0.000103372346],"category_scores_gemma":[0.0028817914,0.00006831877,0.00024920606,0.00036799494,0.00010184827,0.0000988724,0.00002804253,0.00034374828,0.000005576087],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013386181,0.0067401645,0.271235,0.013212938,0.029347382,0.19443636,0.0034981002,0.0003436639,0.0038846037,0.00068066485,0.03952433,0.4237106],"study_design_scores_gemma":[0.012243712,0.00747577,0.14197817,0.0009015266,0.00627359,0.03446821,0.0006888011,0.7818565,0.0077984906,0.00024889293,0.005745615,0.00032076795],"about_ca_topic_score_codex":0.000078169534,"about_ca_topic_score_gemma":0.000009641068,"teacher_disagreement_score":0.7815128,"about_ca_system_score_codex":0.00013431227,"about_ca_system_score_gemma":0.00027929424,"threshold_uncertainty_score":0.34499815},"labels":[],"label_agreement":null},{"id":"W4391482982","doi":"10.1038/s41408-023-00966-9","title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Medicine; Multiple myeloma; Chimeric antigen receptor; Clinical trial; Adverse effect; Pharmacodynamics; Malignancy; Cytokine release syndrome; Immunotherapy; Oncology; Antigen; Internal medicine; Pharmacokinetics; Immunology; Immune system","score_opus":0.1028294294267789,"score_gpt":0.44232088335920794,"score_spread":0.339491453932429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391482982","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010501579,0.99203265,0.0000379109,0.0008708197,0.00051164365,0.005485606,0.000873187,0.000020009307,0.0001576984],"genre_scores_gemma":[0.000014088634,0.9906043,0.00095795054,0.00009301802,0.0013076076,0.0034388797,0.00011604677,0.000101739344,0.0033664152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972479,0.00011752817,0.0010102696,0.00044276717,0.0006345751,0.00054698077],"domain_scores_gemma":[0.99760187,0.0005389023,0.00061680004,0.00048128772,0.0003826179,0.00037851708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036784515,0.0006285414,0.0027251013,0.0002102364,0.00024398329,0.000055648794,0.00027307638,0.00017707243,0.00041058954],"category_scores_gemma":[0.000284605,0.0002835387,0.0021214536,0.00042406435,0.00010797977,0.000049837494,0.000039400526,0.0005503907,0.00004056393],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017071828,0.0013034765,0.000015133601,0.059114933,0.013379338,0.0002989864,0.00039066625,2.6888438e-7,0.000003343152,0.000012666069,0.0078105046,0.91749996],"study_design_scores_gemma":[0.0043320837,0.0025744655,0.0000046552254,0.102295816,0.023674417,0.0022678988,0.00006244255,0.000014816416,0.000023592804,0.00001586631,0.8645443,0.00018970105],"about_ca_topic_score_codex":0.00012397979,"about_ca_topic_score_gemma":0.000046046134,"teacher_disagreement_score":0.91731024,"about_ca_system_score_codex":0.0005604199,"about_ca_system_score_gemma":0.003166091,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W4391559535","doi":"10.1200/jco.2024.42.36_suppl.439572","title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Bortezomib; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Refractory (planetary science); Oncology","score_opus":0.10140309870037255,"score_gpt":0.4550800140791745,"score_spread":0.3536769153788019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391559535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842729,0.008237328,0.00007109807,0.0037606312,0.0008356554,0.0021894423,0.00012445367,0.00002897157,0.0004795351],"genre_scores_gemma":[0.9910036,0.0048944284,0.002615417,0.00030952753,0.0007310001,0.000046749297,0.000043486558,0.000060514645,0.0002952988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98780525,0.0041747354,0.0055093938,0.0008319723,0.0010511714,0.00062745047],"domain_scores_gemma":[0.944094,0.052012797,0.0020071089,0.0006420592,0.00042561934,0.00081841985],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014534551,0.00048699282,0.0046953796,0.0004829061,0.00012282962,0.00006744163,0.00037016798,0.00068350893,0.000103731974],"category_scores_gemma":[0.025919916,0.00028957112,0.0006144313,0.0005043353,0.0010670071,0.0002500966,0.0002860665,0.0030294894,0.000010385677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65896964,0.012258375,0.07144131,0.00007776551,0.00409737,0.0069773453,0.0032586798,0.000004716668,0.0006226208,0.000030599887,0.0018186137,0.24044296],"study_design_scores_gemma":[0.7091485,0.022805428,0.25431165,0.0006185431,0.0018848091,0.00048202358,0.0019594983,0.0037738562,0.0001734527,0.00022170976,0.0043730163,0.00024750523],"about_ca_topic_score_codex":0.0027423229,"about_ca_topic_score_gemma":0.0026767813,"teacher_disagreement_score":0.24019545,"about_ca_system_score_codex":0.0002185998,"about_ca_system_score_gemma":0.0014128004,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W4391812167","doi":"10.1016/j.clml.2024.02.006","title":"Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Cohort; Population; Health care; Oncology; Internal medicine; Environmental health","score_opus":0.04032604097197609,"score_gpt":0.3367106443747134,"score_spread":0.2963846034027373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391812167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921109,0.0005003498,0.00009792021,0.000496427,0.00025507552,0.005734732,0.00017988558,0.00044885167,0.00017585818],"genre_scores_gemma":[0.99514246,0.000067210196,0.00018319637,0.00020772892,0.0003808295,0.00070708833,0.0025517438,0.00015918036,0.0006005381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943018,0.0006573487,0.0013572064,0.0016438547,0.0011984123,0.00084135495],"domain_scores_gemma":[0.9960223,0.0013153922,0.00026005154,0.001041446,0.00031964178,0.0010411874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053420506,0.0006957724,0.0012101731,0.00037575644,0.00037903804,0.00021866194,0.0001952523,0.0003970048,0.00007084877],"category_scores_gemma":[0.00054087676,0.0005035833,0.00030366643,0.00064530026,0.00025813078,0.00023560178,0.00010765425,0.00031091552,0.00007023323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015478305,0.00096299633,0.6474535,0.00014221745,0.0005727006,0.0005151661,0.00020477771,0.000010914348,0.0000030907179,0.0000046197856,0.00011239986,0.3484698],"study_design_scores_gemma":[0.02517659,0.006107931,0.9380313,0.00045071324,0.000514976,0.00001987376,0.00021923316,0.027375821,0.000036623223,0.000007839915,0.0016339055,0.00042519454],"about_ca_topic_score_codex":0.0037336282,"about_ca_topic_score_gemma":0.0008853411,"teacher_disagreement_score":0.34804457,"about_ca_system_score_codex":0.002627233,"about_ca_system_score_gemma":0.0010892919,"threshold_uncertainty_score":0.99974155},"labels":[],"label_agreement":null},{"id":"W4391999506","doi":"10.1016/j.clinbiochem.2024.110730","title":"Laboratory reflex testing strategy for the early identification of primary care patients with multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Securities Institute Research Foundation","keywords":"Interquartile range; Serum protein electrophoresis; Medicine; Multiple myeloma; Macroglobulinemia; Immunofixation; Waldenstrom macroglobulinemia; Internal medicine; Monoclonal; Gastroenterology; Immunology; Monoclonal antibody; Antibody; Lymphoma","score_opus":0.06750989915983437,"score_gpt":0.3802737250576918,"score_spread":0.31276382589785745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391999506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968,0.0014730776,0.000067683766,0.00007478768,0.00008224503,0.000671229,0.0004150329,0.000056519326,0.00035943137],"genre_scores_gemma":[0.9980741,0.000020076284,0.00080498034,0.000032172382,0.00018708504,0.000091547954,0.0004838067,0.000024823517,0.00028136407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986418,0.000026771855,0.00047506255,0.00036811648,0.0002932479,0.00019501384],"domain_scores_gemma":[0.9973817,0.0013302591,0.000108986555,0.00042825018,0.00061530725,0.00013551516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027794656,0.0001254029,0.00022086325,0.000023132727,0.000073777715,0.000038046393,0.00012359307,0.0001283094,0.000007950107],"category_scores_gemma":[0.0012440777,0.00007516904,0.00010533971,0.00022051936,0.00021572143,0.000045823643,0.000037513055,0.0002287674,0.000011564717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010857983,0.00040930818,0.7811647,0.0023582275,0.0003658907,0.000022071334,0.00006173982,0.0000019325366,0.039213717,0.00000482106,0.0004052065,0.17490658],"study_design_scores_gemma":[0.0025549254,0.00067590707,0.9269403,0.00038245023,0.00016739934,0.0000013018796,0.000114416034,0.00027469837,0.06846436,0.000008390094,0.0003208861,0.000094939904],"about_ca_topic_score_codex":0.0000109862085,"about_ca_topic_score_gemma":0.0000013520583,"teacher_disagreement_score":0.17481165,"about_ca_system_score_codex":0.00008215314,"about_ca_system_score_gemma":0.00045832642,"threshold_uncertainty_score":0.30653045},"labels":[],"label_agreement":null},{"id":"W4392106791","doi":"10.1111/ejh.14180","title":"The <scp>EASEMENT</scp> study: <scp>A</scp> multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"Takeda Pharmaceuticals International","keywords":"Medicine; Observational study; Patient satisfaction; Family medicine; Cross-sectional study; Quality of life (healthcare); Internal medicine; Surgery; Nursing","score_opus":0.11404974343214659,"score_gpt":0.3636238877025933,"score_spread":0.24957414427044672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392106791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963675,0.0009393761,0.000023103032,0.00012675356,0.00017146888,0.0022676026,0.00005324476,0.00002610743,0.00002480313],"genre_scores_gemma":[0.9989353,0.0000742999,0.00062893867,0.00007433838,0.00004843969,0.000049392816,0.000023778364,0.000048265225,0.000117246454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99313706,0.0033243804,0.0015184407,0.0004735443,0.0010528195,0.0004937477],"domain_scores_gemma":[0.9938631,0.003907731,0.00063531334,0.0003245526,0.00088872993,0.00038056087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021587103,0.0003354295,0.00077134545,0.00038369565,0.00033661365,0.00019731911,0.0001615875,0.000038515853,0.000010471016],"category_scores_gemma":[0.0049686152,0.00018733599,0.00008980225,0.00042184643,0.00012875615,0.00029499555,0.00013085973,0.0003825689,0.0000063238213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032075846,0.001975145,0.96895474,0.00010018157,0.0014087305,0.0007449372,0.014386189,0.00015819422,0.000012432491,0.000007065498,0.00012326744,0.008921524],"study_design_scores_gemma":[0.012004558,0.019658342,0.95114386,0.0002573536,0.000098566445,0.00010714133,0.01614752,0.00010759522,0.000013771371,0.0000054424727,0.0004083389,0.000047483958],"about_ca_topic_score_codex":0.00087917555,"about_ca_topic_score_gemma":0.005688709,"teacher_disagreement_score":0.017810863,"about_ca_system_score_codex":0.00030564232,"about_ca_system_score_gemma":0.00048244648,"threshold_uncertainty_score":0.76393396},"labels":[],"label_agreement":null},{"id":"W4392108250","doi":"10.15173/m.v1i36.2329","title":"Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"The Meducator","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.023312465298688544,"score_gpt":0.3092068058461208,"score_spread":0.2858943405474323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392108250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98193234,0.0002750331,0.000003287152,0.003632378,0.00028714485,0.000650609,0.000005165251,0.000046707755,0.013167343],"genre_scores_gemma":[0.98041904,0.000016088048,0.00031335838,0.0004669733,0.00017477975,0.000049216997,0.000017144319,0.000018390641,0.018525006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914706,0.000038182065,0.00009844956,0.00016231772,0.0002679467,0.00028606277],"domain_scores_gemma":[0.9990726,0.00016050643,0.00002337112,0.0005120186,0.00004142655,0.00019009189],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013912749,0.00009539022,0.00015080678,0.00004677667,0.00006159401,0.000013682583,0.00012455472,0.000031854426,0.0017737541],"category_scores_gemma":[0.00016036909,0.000050818526,0.00007783627,0.00012367415,0.000051745013,0.000032655847,0.000043724394,0.00013878872,0.006656629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056529033,0.00049112254,0.9339732,0.00008216472,0.00025862953,0.00004390978,0.00097055314,6.372654e-7,0.023991795,0.00041569164,0.009660326,0.029546674],"study_design_scores_gemma":[0.003157352,0.0002799827,0.90960187,0.00004539768,0.00004714115,0.00010148256,0.0006401301,0.0002544141,0.018306736,0.00009569977,0.067356296,0.000113516486],"about_ca_topic_score_codex":0.00008352364,"about_ca_topic_score_gemma":0.000007783736,"teacher_disagreement_score":0.057695966,"about_ca_system_score_codex":0.00006003608,"about_ca_system_score_gemma":0.00015951814,"threshold_uncertainty_score":0.9991388},"labels":[],"label_agreement":null},{"id":"W4392130094","doi":"10.1007/s12325-024-02797-x","title":"Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cilag; Janssen Research and Development; Genentech; Chugai Pharmaceutical; EUSA Pharma; Servier; Incyte; bluebird bio; Regeneron Pharmaceuticals; Universidad de Salamanca; Adaptive Biotechnologies; Karyopharm Therapeutics; Legend Biotech; Celgene; Cerecor; Janssen Pharmaceuticals; Yale University; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Relative risk; Refractory (planetary science); Proportional hazards model; Multiple myeloma; Gastroenterology; Surgery","score_opus":0.059782962332057994,"score_gpt":0.3848374014435362,"score_spread":0.3250544391114782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392130094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9449859,0.052532155,0.000008048418,0.00018822389,0.000117019496,0.0020451625,0.000021540525,0.000015724308,0.00008622957],"genre_scores_gemma":[0.9861005,0.013318349,0.00012720822,0.000035375044,0.000018407487,0.0002843039,0.000079793936,0.00001571504,0.000020323956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834204,0.00024854802,0.0003823622,0.00035043366,0.00040043108,0.0002761854],"domain_scores_gemma":[0.99892354,0.00064695237,0.00008481569,0.00023348765,0.00005973771,0.000051462535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021869525,0.00023987677,0.0005084845,0.00030186897,0.000035023586,0.000014106856,0.00009216594,0.00004044091,0.000009061792],"category_scores_gemma":[0.000057330566,0.00013204134,0.00004789922,0.00046484097,0.00020344171,0.0002767511,0.000024607705,0.00027335488,0.0000038709986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070873084,0.0042885346,0.73410875,0.0001554095,0.00025539947,0.000069380025,0.010082665,0.00005214618,0.00008236702,0.000029858824,0.000025904368,0.24376225],"study_design_scores_gemma":[0.034481443,0.0036294793,0.9559836,0.0009613497,0.000023462107,0.0000022896304,0.0010606209,0.00037726745,0.0008776481,0.00009086363,0.0023871919,0.00012480865],"about_ca_topic_score_codex":0.000043220556,"about_ca_topic_score_gemma":0.00025586103,"teacher_disagreement_score":0.24363744,"about_ca_system_score_codex":0.0003073049,"about_ca_system_score_gemma":0.00004908887,"threshold_uncertainty_score":0.538449},"labels":[],"label_agreement":null},{"id":"W4392170506","doi":"10.2147/jbm.s434055","title":"Presentation and Outcome of Patients with Multiple Myeloma (MM), Single Centre Experience from Windsor Essex Regional Cancer Centre","year":2024,"lang":"en","type":"article","venue":"Journal of Blood Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Windsor; Windsor Regional Hospital; Western University","funders":"","keywords":"Medicine; Multiple myeloma; Lenalidomide; Bortezomib; Melphalan; Internal medicine; Regimen; Cyclophosphamide; Surgery; Oncology; Progressive disease; Cancer; Thalidomide; Disease; Chemotherapy","score_opus":0.031550029914985483,"score_gpt":0.3205771289599939,"score_spread":0.28902709904500845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392170506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896749,0.0058276737,0.000038136106,0.003810475,0.00020842419,0.00031086445,0.00005482977,0.000012108509,0.00006258333],"genre_scores_gemma":[0.99786085,0.00031381194,0.0007899057,0.00010173971,0.00040745785,0.0000036942774,0.000058441878,0.000023112189,0.00044096797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979631,0.000047723413,0.0005589512,0.00021619398,0.000978987,0.00023508277],"domain_scores_gemma":[0.99853003,0.00027604957,0.00026760707,0.00014951949,0.00042171523,0.00035509848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008916696,0.0001758765,0.0004907032,0.00021707022,0.00003890453,0.000014678827,0.00007968939,0.000059261925,0.0003401686],"category_scores_gemma":[0.00026384337,0.000102429454,0.00006796505,0.00021822621,0.00020069488,0.00020265942,0.00002730362,0.00022741425,0.0000017225458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015059292,0.0006644401,0.9733936,0.00025565756,0.0007214802,0.00044113665,0.0032773819,0.000003098101,0.009105605,0.0000050635144,0.0009016241,0.009724974],"study_design_scores_gemma":[0.015893519,0.0014950612,0.96619976,0.0029976568,0.00089848647,0.00006208079,0.001749756,0.0002446344,0.008513227,0.000018841172,0.001815114,0.00011186643],"about_ca_topic_score_codex":0.00034961686,"about_ca_topic_score_gemma":0.00011374905,"teacher_disagreement_score":0.014387589,"about_ca_system_score_codex":0.000059811144,"about_ca_system_score_gemma":0.00011749334,"threshold_uncertainty_score":0.4176952},"labels":[],"label_agreement":null},{"id":"W4392238297","doi":"10.2217/fon-2023-0995","title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"Pfizer","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; World class; Class (philosophy); Internal medicine; Artificial intelligence; Computer science","score_opus":0.0196711530789508,"score_gpt":0.3296302245845405,"score_spread":0.3099590715055897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392238297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95517814,0.003213439,0.00003220577,0.011424921,0.0009060602,0.002857768,0.00010887538,0.00023971937,0.026038848],"genre_scores_gemma":[0.9948702,0.0003654046,0.0008387739,0.00038271816,0.0006558069,0.00029580478,0.00024831004,0.00006197516,0.002281037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972169,0.0003430007,0.0005307441,0.00069337117,0.00041429795,0.000801732],"domain_scores_gemma":[0.9981497,0.00090766145,0.000075839656,0.00044994737,0.00007333779,0.00034352063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037914907,0.00035543874,0.00096315355,0.00092958054,0.000047346446,0.000032489792,0.00018412819,0.00028843252,0.0005384365],"category_scores_gemma":[0.00014309361,0.00024980423,0.0001147856,0.0009831,0.00016592971,0.00011916614,0.000045519824,0.0010493689,0.00018359082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04982404,0.008360238,0.55060476,0.0009088621,0.0010983117,0.069695875,0.0035566257,0.000117298834,0.0068293572,0.0013840019,0.02030766,0.28731295],"study_design_scores_gemma":[0.042724237,0.0023184875,0.7577024,0.00031565432,0.00008354282,0.00016580327,0.00038683097,0.00421878,0.00009711898,0.00001902524,0.191737,0.00023112254],"about_ca_topic_score_codex":0.0013906247,"about_ca_topic_score_gemma":0.03644539,"teacher_disagreement_score":0.28708184,"about_ca_system_score_codex":0.0011857869,"about_ca_system_score_gemma":0.0007598401,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W4392284795","doi":"10.1097/01.cot.0001009928.12155.28","title":"Multiple Myeloma Treatments Fair Worse in the Real World","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.037025884488258096,"score_gpt":0.37010177827643886,"score_spread":0.33307589378818075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392284795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66431576,0.0013103543,0.000005844185,0.008115668,0.0002584174,0.001127426,0.000028506618,0.00017546344,0.32466254],"genre_scores_gemma":[0.93422174,0.00023126781,0.00062332314,0.00029501307,0.00017614003,0.00027668977,0.00010036315,0.00002291959,0.06405254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998549,0.00019063143,0.00021975163,0.0003394294,0.0002597656,0.00044146075],"domain_scores_gemma":[0.9987757,0.0007277977,0.000023607565,0.0003151468,0.000025287203,0.00013246691],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028188873,0.00017798546,0.00030186825,0.0003169991,0.00007884477,0.000033608005,0.00013698515,0.000105887695,0.0008680778],"category_scores_gemma":[0.000091794696,0.000102231315,0.00011747537,0.0005135285,0.00013055495,0.000078379846,0.00004825094,0.0003134901,0.0012982679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011989019,0.002028828,0.53572077,0.000096871554,0.0007906863,0.016230855,0.0022838805,0.0000035897303,0.00075226766,0.0014719348,0.051317226,0.3881042],"study_design_scores_gemma":[0.0053725946,0.0013747311,0.78386784,0.00015923918,0.0001895947,0.00019037364,0.00047150502,0.0019529315,0.0004701505,0.00044437393,0.20535329,0.00015338406],"about_ca_topic_score_codex":0.0006456421,"about_ca_topic_score_gemma":0.002077057,"teacher_disagreement_score":0.38795084,"about_ca_system_score_codex":0.00041119722,"about_ca_system_score_gemma":0.0002927353,"threshold_uncertainty_score":0.99947935},"labels":[],"label_agreement":null},{"id":"W4392287332","doi":"10.3324/haematol.2023.283713","title":"Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; University of Calgary","funders":"Loxo Oncology; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Genentech; Celgene; BeiGene; Sanofi; Pfizer; Amgen","keywords":"Lenalidomide; Medicine; Internal medicine; Hazard ratio; Ixazomib; Population; Confidence interval; Dexamethasone; Surgery; Oncology; Carfilzomib","score_opus":0.08382698583699201,"score_gpt":0.375925104901556,"score_spread":0.292098119064564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392287332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948803,0.00038359663,0.0003013675,0.0012647306,0.000032634634,0.002934552,0.000034623703,0.000025595564,0.00014260202],"genre_scores_gemma":[0.99588835,0.000056515943,0.0030951723,0.00018214394,0.00003413131,0.00067259744,0.000024741688,0.000014491708,0.000031849904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982961,0.00020668952,0.0004950778,0.00035833675,0.00034108033,0.0003027607],"domain_scores_gemma":[0.99823713,0.001329036,0.00007030746,0.00021263826,0.00007180753,0.000079072226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001551687,0.0001636229,0.0004918752,0.00014820196,0.000040297637,0.000040072187,0.00010192933,0.000054823744,0.000044803255],"category_scores_gemma":[0.0005700201,0.00008507315,0.000058247268,0.0001854445,0.000058331676,0.000059604645,0.000054586137,0.00019028166,0.0000019391982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025170164,0.004669628,0.8702243,0.0015428264,0.0009850748,0.0041138,0.016199011,0.00008268981,0.007099533,0.0028084358,0.00034782974,0.0667567],"study_design_scores_gemma":[0.02940264,0.029914184,0.89971256,0.0021164576,0.00036450598,0.00027860492,0.027495204,0.0041387547,0.0042523514,0.0013880343,0.00042272758,0.0005139713],"about_ca_topic_score_codex":0.00034397686,"about_ca_topic_score_gemma":0.0014815506,"teacher_disagreement_score":0.06624273,"about_ca_system_score_codex":0.000056343728,"about_ca_system_score_gemma":0.000071449846,"threshold_uncertainty_score":0.34691826},"labels":[],"label_agreement":null},{"id":"W4392296400","doi":"10.1097/01.cot.0001009844.75140.19","title":"Tactics of Multiple Myeloma in Evading Targeted Immunotherapies","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Computational biology; Cancer research; Computer science; Medicine; Internal medicine; Biology","score_opus":0.02780771361232466,"score_gpt":0.3515694154215863,"score_spread":0.32376170180926167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392296400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961356,0.010389155,0.00005073011,0.0016474138,0.00024316434,0.00048804056,0.000021423584,0.00009833061,0.025705736],"genre_scores_gemma":[0.99105567,0.00032529293,0.003257483,0.000053050582,0.000051107407,0.000038307193,0.000030095183,0.0000212262,0.0051677674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990957,0.00007383886,0.00023290487,0.0001861364,0.00015280247,0.00025866457],"domain_scores_gemma":[0.9991952,0.000492292,0.000033078322,0.00016229034,0.00004773245,0.00006939461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020095216,0.00010720616,0.00031358236,0.00028298213,0.000026137093,0.000009029983,0.00006064676,0.00012140262,0.0007918443],"category_scores_gemma":[0.00023668242,0.000084001724,0.00007723773,0.00025875864,0.00011053327,0.0000678511,0.00003300232,0.00020965848,0.0001552477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023106285,0.0014768791,0.3833031,0.0006082089,0.0015527072,0.003384558,0.0036899154,0.000018642659,0.23216039,0.001126062,0.0069370572,0.36343184],"study_design_scores_gemma":[0.01415834,0.0044657183,0.64192766,0.00095429603,0.00023410663,0.0004087485,0.0013121448,0.03164392,0.10283673,0.001028384,0.20060968,0.00042028978],"about_ca_topic_score_codex":0.00015436142,"about_ca_topic_score_gemma":0.000059370377,"teacher_disagreement_score":0.36301157,"about_ca_system_score_codex":0.0002075866,"about_ca_system_score_gemma":0.0002900481,"threshold_uncertainty_score":0.86701393},"labels":[],"label_agreement":null},{"id":"W4392297809","doi":"10.1111/bjh.19346","title":"Impact of elranatamab on quality of life: Patient‐reported outcomes from <scp>MagnetisMM</scp>‐3","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"Pfizer","keywords":"Medicine; Multiple myeloma; Quality of life (healthcare); Disease; Internal medicine; Physical therapy","score_opus":0.046974038907692715,"score_gpt":0.36968905573581284,"score_spread":0.32271501682812015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392297809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98803395,0.01030645,0.00004128046,0.0001902485,0.00026692773,0.00023391501,0.000267865,0.000016884058,0.0006424577],"genre_scores_gemma":[0.9986951,0.0005836099,0.0004728128,0.000047362908,0.00004737552,0.0000038944327,0.000043738917,0.000024850351,0.00008125883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708563,0.00027327324,0.0014296309,0.00021452103,0.0006781351,0.0003188078],"domain_scores_gemma":[0.9971133,0.0012224538,0.0006460915,0.00025216397,0.0004146498,0.0003513238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037208275,0.00017307627,0.0013947297,0.00032545385,0.00003032671,0.000023312392,0.00014355638,0.00014998633,0.00042969987],"category_scores_gemma":[0.0037705372,0.00014049886,0.0006301893,0.00021538901,0.00017572886,0.00011231178,0.000047431597,0.0004343619,0.000015710259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007967893,0.0016734451,0.84387904,0.00048573167,0.0051822457,0.087456144,0.00035271587,0.000008055746,0.0021717288,0.000098134464,0.010515747,0.04738021],"study_design_scores_gemma":[0.004998672,0.0022674722,0.9694501,0.00088433176,0.0002137603,0.019828124,0.00015853724,0.000042601754,0.0015371621,0.00041630768,0.00015053943,0.00005238146],"about_ca_topic_score_codex":0.0028406754,"about_ca_topic_score_gemma":0.00008847147,"teacher_disagreement_score":0.12557106,"about_ca_system_score_codex":0.000076971904,"about_ca_system_score_gemma":0.0005408267,"threshold_uncertainty_score":0.5729377},"labels":[],"label_agreement":null},{"id":"W4392384615","doi":"10.1158/2643-3249.bcdsymp24-p19","title":"Abstract P19: Mitohormetic Regulation in Multiple Myeloma: Exploiting Mitochondrial Stress Responses for Therapeutic Gain","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Multiple myeloma; Stress (linguistics); Medicine; Psychology; Internal medicine; Linguistics","score_opus":0.04870299445471482,"score_gpt":0.34121024415855455,"score_spread":0.29250724970383973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392384615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707867,0.008432628,0.0005618713,0.0010237033,0.00055506924,0.0015987589,0.00042770372,0.0001014745,0.000220127],"genre_scores_gemma":[0.99521935,0.00036402114,0.00058855326,0.000067526795,0.0009040306,0.0011203209,0.00018168129,0.00006436695,0.0014901594],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981039,0.000067894216,0.0003719472,0.000528192,0.0004061357,0.00052188715],"domain_scores_gemma":[0.99866384,0.00079389167,0.000058328733,0.00029228968,0.000059543832,0.00013213043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017994676,0.00023976623,0.00032432165,0.00030988935,0.000095492665,0.00018355728,0.0000970423,0.000093793664,0.00007850964],"category_scores_gemma":[0.00021725993,0.000197659,0.00019151154,0.00028998667,0.00006605362,0.00043599517,0.000033206114,0.00021275245,0.000015045465],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015364932,0.0019738607,0.19382258,0.0033088168,0.0019283226,0.0010039345,0.0013536355,0.0007508323,0.6017194,0.0005142757,0.0012532166,0.17700619],"study_design_scores_gemma":[0.028598202,0.00092224375,0.62240577,0.004961993,0.000827041,0.000059418642,0.0008858352,0.011412797,0.3252295,0.0012233946,0.00273753,0.0007363004],"about_ca_topic_score_codex":0.00081227056,"about_ca_topic_score_gemma":0.0011407083,"teacher_disagreement_score":0.42858317,"about_ca_system_score_codex":0.00023463542,"about_ca_system_score_gemma":0.0004826684,"threshold_uncertainty_score":0.80603004},"labels":[],"label_agreement":null},{"id":"W4392388763","doi":"10.1182/blood.2024023880","title":"Smoldering multiple myeloma: taking the narrow over the wide path?","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Path (computing); Lenalidomide; Medicine; Daratumumab; Internal medicine; Computer science","score_opus":0.0685273946874271,"score_gpt":0.35706952220406923,"score_spread":0.2885421275166421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392388763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054923404,0.99451166,0.0000027616452,0.00021433954,0.00029433647,0.0021214413,0.0000715535,0.00013605256,0.0020986157],"genre_scores_gemma":[0.008465702,0.98773164,0.00008986718,0.00012367484,0.0007388065,0.0006636399,0.00012350197,0.0001527565,0.0019104155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741375,0.00020708836,0.0004930158,0.0005641452,0.0006785956,0.00064342667],"domain_scores_gemma":[0.9976215,0.0008515231,0.0002194045,0.0010702661,0.000049026108,0.00018831031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040895838,0.0005498254,0.0010957213,0.00013805793,0.0003052832,0.00016119558,0.00045924998,0.00023023115,0.00020714133],"category_scores_gemma":[0.00072254386,0.0002265407,0.0008544141,0.00047201663,0.00013378344,0.000044567685,0.00030400697,0.0011182833,0.0005897198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017910665,0.00038706028,0.000984827,0.01676473,0.002957721,0.0023824777,0.00025025458,1.8706183e-7,0.000003754193,0.000050552815,0.003833,0.9723675],"study_design_scores_gemma":[0.0015336694,0.00009730364,0.0013060614,0.013237709,0.0059221624,0.0006446152,0.000038032304,0.0000372596,0.000009138277,0.000018544511,0.9769089,0.0002465932],"about_ca_topic_score_codex":0.00014847427,"about_ca_topic_score_gemma":0.000042417516,"teacher_disagreement_score":0.9730759,"about_ca_system_score_codex":0.00011063203,"about_ca_system_score_gemma":0.00038611933,"threshold_uncertainty_score":0.92380613},"labels":[],"label_agreement":null},{"id":"W4392446787","doi":"10.1159/000536675","title":"Isolated Non-Secretory Extramedullary Relapse of Multiple Myeloma Responded Completely to Localized Radiotherapy","year":2024,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Western University","funders":"","keywords":"Medicine; Multiple myeloma; Radiation therapy; Immunofixation; Biopsy; Systemic therapy; Chemotherapy; Systemic disease; Pelvis; Pathology; Radiology; Oncology; Internal medicine; Monoclonal; Disease; Antibody; Monoclonal antibody; Immunology; Cancer","score_opus":0.0363504540477133,"score_gpt":0.37125608079931427,"score_spread":0.33490562675160096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392446787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957217,0.0034969153,0.001989216,0.00069437,0.0006483653,0.0016740138,0.000021328178,0.00012027823,0.0017833181],"genre_scores_gemma":[0.99068075,0.00023983026,0.007059362,0.00029886857,0.00012145285,0.00018025482,0.00007608815,0.0000651145,0.0012782932],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99715364,0.00026002052,0.0010208813,0.00066458527,0.00035245944,0.0005484205],"domain_scores_gemma":[0.9976328,0.0008819348,0.00014778765,0.0006940956,0.00015990094,0.0004834764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009096769,0.00026539824,0.00088109606,0.00077942346,0.000053863645,0.000016126307,0.0000647021,0.0003451101,0.00049492955],"category_scores_gemma":[0.0008823512,0.00022737368,0.00018978174,0.0007494687,0.00021359726,0.00006874741,0.000074335854,0.00049024815,0.00003157438],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005287829,0.00058640883,0.014895951,0.00031129448,0.00036114187,0.848478,0.001084846,0.000027565506,0.047023475,0.00002886132,0.002253321,0.0796613],"study_design_scores_gemma":[0.013770973,0.009763281,0.030782385,0.0013578705,0.00021719266,0.5825306,0.0006694933,0.044737205,0.010627628,0.00018553791,0.3047066,0.0006511966],"about_ca_topic_score_codex":0.00057753804,"about_ca_topic_score_gemma":0.00030903151,"teacher_disagreement_score":0.30245328,"about_ca_system_score_codex":0.000933894,"about_ca_system_score_gemma":0.0011183697,"threshold_uncertainty_score":0.92720294},"labels":[],"label_agreement":null},{"id":"W4392516550","doi":"10.1038/s41408-024-01018-6","title":"Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Narrative; Medicine; Narrative review; Internal medicine; Bioinformatics; Intensive care medicine; Biology; Literature; Art","score_opus":0.0883671284899405,"score_gpt":0.4293044025224052,"score_spread":0.3409372740324647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392516550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000052306846,0.9917516,0.00006289764,0.00068468746,0.0019718213,0.004771955,0.00047081106,0.000023866163,0.00025710269],"genre_scores_gemma":[0.000012187111,0.9857229,0.0005036454,0.00007879555,0.0018002978,0.0032704503,0.00010451876,0.00008924974,0.008417966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974402,0.00011766825,0.00094772654,0.0004299778,0.0005889396,0.00047544486],"domain_scores_gemma":[0.9975682,0.00062714855,0.000612282,0.00042538022,0.00043047866,0.00033651758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033031366,0.00058453815,0.0024202322,0.000205065,0.000291466,0.000057199337,0.0002183756,0.00017557786,0.00048096947],"category_scores_gemma":[0.00033086663,0.0002740512,0.0019111073,0.00047903098,0.00010025657,0.000052319658,0.000031854725,0.0006028512,0.000038814364],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018728069,0.0011614419,0.000016949394,0.033640835,0.010608515,0.00021263995,0.00035754955,5.3890795e-7,0.0000017360198,0.0000046251953,0.029084235,0.9247236],"study_design_scores_gemma":[0.0036121467,0.0027819064,0.000006051461,0.10130933,0.020615032,0.0040038424,0.00008523,0.00004167333,0.000024122255,0.0000073399956,0.8673317,0.00018162395],"about_ca_topic_score_codex":0.00014675861,"about_ca_topic_score_gemma":0.000066098175,"teacher_disagreement_score":0.924542,"about_ca_system_score_codex":0.0006562976,"about_ca_system_score_gemma":0.003081047,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W4392612040","doi":"10.1016/j.jgo.2024.101735","title":"A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"Hamilton Health Sciences","keywords":"Medicine; Randomized controlled trial; Multiple myeloma; Chemotherapy; Oncology; Internal medicine; Physical therapy","score_opus":0.012965772138725875,"score_gpt":0.33034965839093544,"score_spread":0.3173838862522096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392612040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884852,0.0008310163,0.00064782216,0.0015545698,0.0009833215,0.006994195,0.000007454016,0.000029433679,0.00046695946],"genre_scores_gemma":[0.98525614,0.00017904297,0.012508916,0.00018607675,0.0009756064,0.0003897407,0.000003984821,0.000035893005,0.00046460837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99668443,0.0007283055,0.0012492003,0.0003209607,0.00054806063,0.00046902883],"domain_scores_gemma":[0.9970508,0.0017962398,0.0004154682,0.00018778861,0.00023037799,0.0003193185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024641815,0.00028354756,0.0025502422,0.0007922471,0.0000526067,0.000059784983,0.00016495051,0.00015078747,0.00017271937],"category_scores_gemma":[0.0026619425,0.00015525866,0.00042922635,0.00039975636,0.00007152089,0.00014993762,0.000033731503,0.0008522855,0.000015327074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8934463,0.0010359614,0.00047309583,0.00008108717,0.0009998711,0.002091109,0.00074730697,0.000008360432,0.0023955638,0.000026754811,0.0002962322,0.09839835],"study_design_scores_gemma":[0.9636292,0.030285498,0.0018421878,0.00026603162,0.00035111938,0.0005618064,0.00011824867,0.0015747485,0.00013541969,0.00008613671,0.0010023663,0.00014723754],"about_ca_topic_score_codex":0.00017613001,"about_ca_topic_score_gemma":0.00014757043,"teacher_disagreement_score":0.09825111,"about_ca_system_score_codex":0.00058228424,"about_ca_system_score_gemma":0.001527486,"threshold_uncertainty_score":0.63312644},"labels":[],"label_agreement":null},{"id":"W4392614927","doi":"10.1038/s41375-024-02210-0","title":"Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier","year":2024,"lang":"en","type":"letter","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Simon Fraser University; Terry Fox Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; National Cancer Institute; BC Cancer Foundation; University of British Columbia; Deutsche Forschungsgemeinschaft; Michael Smith Health Research BC; Leukemia and Lymphoma Society of Canada; Simon Fraser University; Cancer Prevention and Research Institute of Texas","keywords":"APOBEC; Multiple myeloma; Classifier (UML); Inflammation; Medicine; Biology; Internal medicine; Genetics; Computer science; Genome; Gene; Artificial intelligence","score_opus":0.026128593397258114,"score_gpt":0.2744422811506523,"score_spread":0.24831368775339416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392614927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5254866,0.00089479133,0.00089686626,0.4439023,0.0013851057,0.004865153,0.0017103315,0.0021476855,0.01871115],"genre_scores_gemma":[0.6609839,0.00016785489,0.027901368,0.22024591,0.017856197,0.0015564825,0.029546233,0.001125199,0.040616825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958999,0.00021040002,0.0005169767,0.001128729,0.0012918314,0.00095212675],"domain_scores_gemma":[0.997328,0.00052206806,0.00025699518,0.0012927796,0.00022100189,0.00037916965],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023268192,0.00071638194,0.0008263228,0.00053056434,0.00023708641,0.00020811953,0.00028292462,0.0010546175,0.00051975244],"category_scores_gemma":[0.00027042784,0.00051529217,0.00024809252,0.00040369635,0.00019137317,0.0001397571,0.000067715344,0.0035836326,0.0012700368],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019973402,0.00009078314,0.028528016,0.0016160267,0.0017660983,0.024035655,0.00022762877,0.00021412483,0.00023407,0.000037760252,0.8957528,0.04549968],"study_design_scores_gemma":[0.011821913,0.0022201652,0.032451402,0.0020533476,0.0011441227,0.00020883993,0.000057145575,0.03335653,0.0023451142,0.00022257271,0.9129964,0.0011224179],"about_ca_topic_score_codex":0.002498828,"about_ca_topic_score_gemma":0.0004609844,"teacher_disagreement_score":0.2236564,"about_ca_system_score_codex":0.0017016352,"about_ca_system_score_gemma":0.0019502911,"threshold_uncertainty_score":0.9997299},"labels":[],"label_agreement":null},{"id":"W4393069992","doi":"10.1111/jvim.17051","title":"Descriptive analysis and prognostic factors in cats with myeloma-related disorders: A multicenter retrospective study of 50 cases","year":2024,"lang":"en","type":"article","venue":"Journal of Veterinary Internal Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Medicine; Prednisolone; CATS; Plasmacytosis; Melphalan; Cyclophosphamide; Internal medicine; Gastroenterology; Chlorambucil; Multiple myeloma; Hazard ratio; Chemotherapy; Surgery; Confidence interval","score_opus":0.03810174324415783,"score_gpt":0.34866242467787834,"score_spread":0.3105606814337205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393069992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748707,0.0013601739,0.00012681582,0.0002381545,0.00013932478,0.0005427272,0.000009957095,0.0000105573345,0.00008522453],"genre_scores_gemma":[0.99946505,0.00020767843,0.00014676966,0.000006991217,0.000054955774,0.000009623937,0.000004857621,0.000020924761,0.00008316179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805135,0.00014249206,0.0006992746,0.00025260443,0.00062799006,0.00022629682],"domain_scores_gemma":[0.9988566,0.00030109394,0.00024719525,0.00014263322,0.00021786736,0.00023458274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028929743,0.00022729051,0.00083532924,0.0013972287,0.000024996956,0.000016256388,0.0000980198,0.000048372673,0.00010348872],"category_scores_gemma":[0.00043789245,0.00012520768,0.00011778399,0.00076463073,0.0002016883,0.00019264517,0.0000523821,0.00048671194,8.6129035e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056670923,0.0013776288,0.95193577,0.0001671873,0.0057742205,0.017540334,0.013238175,0.000004786002,0.0020108907,0.000001610876,0.000012850903,0.0022694434],"study_design_scores_gemma":[0.006716102,0.055868644,0.9184596,0.002656473,0.0018821489,0.0022683535,0.011404742,0.0005267781,0.000102918966,0.000012414481,0.000015406917,0.000086419845],"about_ca_topic_score_codex":0.0018250623,"about_ca_topic_score_gemma":0.0006319147,"teacher_disagreement_score":0.054491013,"about_ca_system_score_codex":0.00023753308,"about_ca_system_score_gemma":0.000065484055,"threshold_uncertainty_score":0.5105821},"labels":[],"label_agreement":null},{"id":"W4393256071","doi":"10.1182/blood.2023023487","title":"<i>TP53</i> function over forms in multiple myeloma","year":2024,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Lenalidomide; Medicine; Internal medicine","score_opus":0.02448921042199161,"score_gpt":0.2753981944926289,"score_spread":0.25090898407063733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393256071","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45109332,0.009086139,0.00004914806,0.48377478,0.0021904316,0.005796232,0.0007809359,0.0009168713,0.046312157],"genre_scores_gemma":[0.45508775,0.00033143724,0.00040235164,0.48035234,0.0087942155,0.00093581673,0.0060101408,0.00043423564,0.04765172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754995,0.00004355311,0.00035570728,0.0006386184,0.0007105723,0.000701572],"domain_scores_gemma":[0.9990667,0.00012866013,0.00006131877,0.00054805254,0.000052188756,0.00014308459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011754679,0.00039418985,0.0005327992,0.00048696034,0.000046898833,0.0000612126,0.00012076951,0.0007416104,0.00041173666],"category_scores_gemma":[0.00010571511,0.0002937369,0.00026898354,0.0003320418,0.000052693096,0.000087632696,0.00010049674,0.0019534675,0.001356238],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002836787,0.00064012816,0.06259956,0.0012777061,0.0008749618,0.016729796,0.000052527932,1.8334782e-7,0.0006084005,0.000008051609,0.9108486,0.006076382],"study_design_scores_gemma":[0.011015296,0.00062491273,0.06037229,0.0007378567,0.00066799583,0.00024354075,0.000008597954,0.00008315637,0.0008630306,0.0002622202,0.92477787,0.0003432233],"about_ca_topic_score_codex":0.00028596274,"about_ca_topic_score_gemma":0.00014148105,"teacher_disagreement_score":0.016486255,"about_ca_system_score_codex":0.00015164285,"about_ca_system_score_gemma":0.0001844705,"threshold_uncertainty_score":0.9999515},"labels":[],"label_agreement":null},{"id":"W4394202558","doi":"10.6084/m9.figshare.19217187","title":"Comprehensive bioinformatics analysis reveals the hub genes and pathways associated with multiple myeloma","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Computational biology; Gene; Pathway analysis; Bioinformatics; Biology; Genetics; Immunology; Gene expression","score_opus":0.06668546517322381,"score_gpt":0.2972517180787416,"score_spread":0.2305662529055178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394202558","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009804025,0.0013030035,1.0731652e-7,0.000058434605,0.000016131295,0.0011955552,0.99634933,0.000048061265,0.00004897067],"genre_scores_gemma":[0.0007942532,0.00016782944,0.000046269608,0.00032157043,0.000049139606,0.0006774397,0.99774706,0.000028714885,0.00016770593],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977787,0.00016720982,0.00035790002,0.00036624834,0.00087054475,0.00045935874],"domain_scores_gemma":[0.997203,0.0010111432,0.00037110064,0.0008388783,0.00031435676,0.0002615539],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008052155,0.0004007387,0.00079173344,0.00034539055,0.00041727515,0.000102625636,0.0003057147,0.00019825154,0.21052383],"category_scores_gemma":[0.0014736587,0.00023846758,0.00022003097,0.00089864223,0.000037618884,0.00006867485,0.00044000903,0.0006058623,0.00023162412],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010674951,0.00011089322,0.0010860958,0.0005541442,0.004451259,0.00044503476,0.000072038645,0.000011805486,0.0000019990377,4.788143e-8,0.99212414,0.0010357948],"study_design_scores_gemma":[0.0018911227,0.00041606597,0.05275143,0.0007494428,0.0015861968,0.000048906204,0.00022028043,0.00086587894,0.000012057327,9.009978e-7,0.941173,0.00028471928],"about_ca_topic_score_codex":0.00011079059,"about_ca_topic_score_gemma":0.00033964004,"teacher_disagreement_score":0.2102922,"about_ca_system_score_codex":0.00016427838,"about_ca_system_score_gemma":0.00020858808,"threshold_uncertainty_score":0.97244257},"labels":[],"label_agreement":null},{"id":"W4394620048","doi":"10.20935/acadonco6185","title":"The experience and needs of myeloma patients: exploring race and ethnicity","year":2024,"lang":"en","type":"article","venue":"Academia oncology.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ethnic group; Race (biology); Multiple myeloma; Medicine; Sociology; Gender studies; Anthropology; Internal medicine","score_opus":0.06585038946801049,"score_gpt":0.3776727523053644,"score_spread":0.31182236283735393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394620048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003756,0.0056590503,0.000010303818,0.002448821,0.00011621347,0.00029101188,0.0000043676646,0.000033100117,0.0013995445],"genre_scores_gemma":[0.99200004,0.006988933,0.00014832386,0.00012960516,0.00006115257,0.000108803186,0.0000030957005,0.000010259362,0.00054977596],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916965,0.00006342527,0.00019016967,0.00015663913,0.00018287245,0.00023722158],"domain_scores_gemma":[0.99903387,0.0006046767,0.000033100667,0.00012293953,0.000047333524,0.00015808144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002577014,0.00009507895,0.00019603503,0.00007958211,0.00011347752,0.000013158126,0.00006750576,0.00019482967,0.000013815618],"category_scores_gemma":[0.00040780683,0.000057251862,0.00002714963,0.00019442392,0.00035318473,0.0001374277,0.00013138683,0.00058500975,0.000007145741],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003893465,0.00007408934,0.3230189,0.00013946013,0.00014037584,0.000058333502,0.01175283,1.3137542e-7,0.0026325204,0.0014326347,0.00095196586,0.6594094],"study_design_scores_gemma":[0.002388125,0.0012263719,0.858459,0.00022539466,0.00008209464,0.00006824452,0.00436023,0.00038406317,0.0070615904,0.00020929155,0.12541744,0.000118184034],"about_ca_topic_score_codex":0.00004375737,"about_ca_topic_score_gemma":0.000003876694,"teacher_disagreement_score":0.6592912,"about_ca_system_score_codex":0.00008729866,"about_ca_system_score_gemma":0.00008110835,"threshold_uncertainty_score":0.25416088},"labels":[],"label_agreement":null},{"id":"W4394872755","doi":"10.1002/cncr.35319","title":"Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"Seagen; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Multiple myeloma; Internal medicine; Adverse effect; Refractory (planetary science); Oncology; Progressive disease; Immunotherapy; Gastroenterology; Cancer; Disease","score_opus":0.014513265457485035,"score_gpt":0.2882694146390943,"score_spread":0.27375614918160923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394872755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726844,0.0011515706,0.000013488277,0.00013205768,0.000042875265,0.00073693943,0.000096727905,0.000036833324,0.0005210463],"genre_scores_gemma":[0.99806994,0.00027846554,0.00028156536,0.000030198884,0.000035744626,0.000049859464,0.00006969272,0.000037539096,0.0011469933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883217,0.000034060442,0.00020012059,0.00032516252,0.00033494376,0.00027357307],"domain_scores_gemma":[0.9993224,0.00018195843,0.000042992702,0.00021782814,0.00007834171,0.00015644517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000628142,0.0001630134,0.0003138546,0.00015554272,0.00003264024,0.000012626805,0.000047624708,0.00006147184,0.00022305494],"category_scores_gemma":[0.000067573696,0.000090498426,0.000025652591,0.00028927473,0.00011381308,0.00008804044,0.00002871044,0.0002123947,0.0000086051305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047694404,0.0003965752,0.8765436,0.00042354607,0.00029250074,0.00036489952,0.00041203207,0.000009821429,0.00014826159,0.000012394733,0.00013362651,0.07356838],"study_design_scores_gemma":[0.028334586,0.0018844163,0.9653305,0.0012473955,0.00007957717,0.000013579717,0.00003753984,0.00029126182,0.00047003108,0.0000010867408,0.0021979574,0.00011210322],"about_ca_topic_score_codex":0.00033631112,"about_ca_topic_score_gemma":0.0005665935,"teacher_disagreement_score":0.088786915,"about_ca_system_score_codex":0.00022005901,"about_ca_system_score_gemma":0.00032825378,"threshold_uncertainty_score":0.36904186},"labels":[],"label_agreement":null},{"id":"W4394909371","doi":"10.1093/oncolo/oyae041","title":"A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Alberta; Ottawa Hospital; University of Ottawa; University of Calgary; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"Ontario Ministry of Health and Long-Term Care; Hamilton Health Sciences","keywords":"Medicine; Proportional hazards model; Internal medicine; Multiple myeloma; Population; Retrospective cohort study; Emergency medicine; Oncology; Intensive care medicine","score_opus":0.04688907369917945,"score_gpt":0.3251112198427596,"score_spread":0.27822214614358015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394909371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902345,0.000096005206,0.0036220031,0.0011033234,0.00016855574,0.0032562325,0.00024861534,0.0002528472,0.0010179488],"genre_scores_gemma":[0.99407506,0.0000074767268,0.003945705,0.00011383667,0.00005174517,0.00072743313,0.00045588275,0.000050312097,0.00057255273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982129,0.00005905797,0.00037324106,0.00039433409,0.0004963984,0.00046412076],"domain_scores_gemma":[0.9983214,0.00086086575,0.00010312837,0.00033670213,0.00020392655,0.00017395114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000264044,0.0002580386,0.00039571055,0.000100198224,0.00023121794,0.000071602895,0.00012995115,0.00008538326,0.000011973206],"category_scores_gemma":[0.00045647292,0.0001280299,0.00013703624,0.00024191457,0.00018184283,0.000098618846,0.00004238247,0.00021887793,0.000023058972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019753457,0.0006746552,0.982657,0.00022393723,0.0005685032,0.00024978747,0.0003523704,0.00025710964,0.00015079915,0.00018429541,0.00033898672,0.012367215],"study_design_scores_gemma":[0.01399315,0.004157172,0.7901895,0.00046241962,0.00086473196,0.000051893014,0.00022325726,0.18781404,0.0005580794,0.00058614614,0.0006766342,0.00042298672],"about_ca_topic_score_codex":0.0001596703,"about_ca_topic_score_gemma":0.00029627047,"teacher_disagreement_score":0.1924675,"about_ca_system_score_codex":0.00016983887,"about_ca_system_score_gemma":0.0003890508,"threshold_uncertainty_score":0.5220908},"labels":[],"label_agreement":null},{"id":"W4395033839","doi":"10.1097/mph.0000000000002859","title":"Unveiling the Uncommon: A Unique Case of ALPS-like Syndrome Complicated by Plasma Cell Disorder","year":2024,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Multiple myeloma; Context (archaeology); Medicine; Autoimmunity; Plasma Cell Myeloma; Evans syndrome; Disease; Plasma cell; Rare disease; Immunology; Monoclonal; Immune system; Pediatrics; Pathology; Monoclonal antibody; Antibody; Biology","score_opus":0.023559067677000948,"score_gpt":0.3417840537540865,"score_spread":0.31822498607708555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395033839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97728646,0.015114403,0.00041066683,0.0049896557,0.00045145024,0.00047488225,0.000039316474,0.000034397002,0.0011987905],"genre_scores_gemma":[0.99676996,0.0014601152,0.0010330324,0.0001378761,0.00017121558,0.000022485676,0.000016563701,0.000035398138,0.00035333572],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99744785,0.00042986532,0.0010724971,0.00025490046,0.00031856966,0.00047629827],"domain_scores_gemma":[0.99660504,0.0019430976,0.00048568103,0.00030548323,0.0003031272,0.00035759722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008617672,0.00024236774,0.001011766,0.00046849906,0.00011016408,0.000016819255,0.0002619033,0.00034667697,0.00022770774],"category_scores_gemma":[0.00021935866,0.00014668064,0.00029806167,0.0007313135,0.00022566275,0.00008880011,0.00011116268,0.001062297,0.00007607976],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031747865,0.0073857494,0.14012472,0.0035225255,0.003468268,0.53871244,0.0028317964,0.00008695674,0.004453967,0.0009079438,0.2738775,0.021453364],"study_design_scores_gemma":[0.014088579,0.010786344,0.0021406815,0.00017937056,0.002645307,0.8354437,0.0024271274,0.0055936407,0.0032873785,0.0005754092,0.12239386,0.0004386115],"about_ca_topic_score_codex":0.00012553767,"about_ca_topic_score_gemma":0.00005331205,"teacher_disagreement_score":0.29673126,"about_ca_system_score_codex":0.00029296422,"about_ca_system_score_gemma":0.0012665492,"threshold_uncertainty_score":0.5981463},"labels":[],"label_agreement":null},{"id":"W4395038612","doi":"10.1186/s40364-024-00592-y","title":"Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes","year":2024,"lang":"en","type":"article","venue":"Biomarker Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Bone and Joint Health Institute; University of Calgary","funders":"Associazione Italiana per la Ricerca sul Cancro; Massachusetts General Hospital","keywords":"PI3K/AKT/mTOR pathway; CD28; Gene silencing; Monoclonal gammopathy of undetermined significance; Cancer research; Transfection; MAPK/ERK pathway; Molecular biology; Downregulation and upregulation; CD8; CD80; Multiple myeloma; Cell biology; Biology; Chemistry; Cytotoxic T cell; Immune system; Signal transduction; Cell culture; CD40; In vitro; Immunology; Antibody; Monoclonal antibody; Monoclonal; Gene","score_opus":0.06248834702139504,"score_gpt":0.3488840983327582,"score_spread":0.28639575131136313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395038612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96964407,0.026603902,0.000029591747,0.00063357444,0.000085973996,0.002043377,0.0002531046,0.000032021704,0.0006744095],"genre_scores_gemma":[0.99600774,0.0016925888,0.0010159294,0.000004115748,0.000085743006,0.0001383635,0.000063035666,0.000041618987,0.0009508922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962183,0.00067198614,0.0006599378,0.0005564772,0.0012664456,0.00062681455],"domain_scores_gemma":[0.9950469,0.003506875,0.00008404191,0.0007489758,0.00037867404,0.00023450643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029513778,0.00020188984,0.0004913623,0.0004562147,0.00015398835,0.000066354696,0.00026713102,0.00012651052,0.00012248379],"category_scores_gemma":[0.001628888,0.0001238942,0.00017821134,0.00075165,0.0009583677,0.00007329256,0.00036206417,0.0003602202,0.000044889235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006924881,0.00019462827,0.005229108,0.0008737714,0.0005843751,0.0002095756,0.0012616742,0.0000017009646,0.8815908,0.00002517528,0.00017750371,0.102926806],"study_design_scores_gemma":[0.008381301,0.00033898387,0.16775417,0.0015748196,0.00006536812,0.000017690221,0.00068477466,0.018955475,0.80146575,0.00013317187,0.00050219445,0.00012627694],"about_ca_topic_score_codex":0.004694899,"about_ca_topic_score_gemma":0.000068414076,"teacher_disagreement_score":0.16252507,"about_ca_system_score_codex":0.00008412272,"about_ca_system_score_gemma":0.00031290433,"threshold_uncertainty_score":0.70973146},"labels":[],"label_agreement":null},{"id":"W4395068649","doi":"10.1182/blood.2023022823","title":"Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Multiple myeloma; Immune system; Correlation; Hematologic Neoplasms; Medicine; Immunology; Pomalidomide; Oncology; Transplantation; Internal medicine; Biology; Lenalidomide; Mathematics","score_opus":0.018647312058973273,"score_gpt":0.29985646662594817,"score_spread":0.2812091545669749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395068649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670166,0.0006111986,0.000018259221,0.0004265572,0.000041553045,0.0018676982,0.00001595771,0.000032778167,0.00028431663],"genre_scores_gemma":[0.99910283,0.0000073564097,0.00015329935,0.000020741607,0.000021357408,0.0002391102,0.000017156224,0.000024307883,0.00041384684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830955,0.00033143902,0.00034635494,0.00028438977,0.000477121,0.0002511417],"domain_scores_gemma":[0.9986532,0.0007400759,0.00003862009,0.00044251853,0.000054536915,0.00007105402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096862786,0.00014344559,0.00026359415,0.00043335382,0.00003289259,0.000023394005,0.00013053275,0.000060937942,0.0000255408],"category_scores_gemma":[0.000549095,0.00008723853,0.00004500034,0.00087000063,0.000043295266,0.00006345994,0.000042865908,0.0003196619,0.00003765287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0137216365,0.0071659144,0.9495501,0.00014767505,0.00017993379,0.0041672667,0.009070623,0.0000703627,0.010299922,0.000018497563,0.000025089508,0.0055829827],"study_design_scores_gemma":[0.014477835,0.0032399748,0.9770087,0.00045271334,0.00007591466,0.00006379274,0.0027304366,0.0003882625,0.0012902318,0.0000072607045,0.00017871897,0.00008617999],"about_ca_topic_score_codex":0.00054221624,"about_ca_topic_score_gemma":0.0009042208,"teacher_disagreement_score":0.027458582,"about_ca_system_score_codex":0.000081703874,"about_ca_system_score_gemma":0.00017652899,"threshold_uncertainty_score":0.3557484},"labels":[],"label_agreement":null},{"id":"W4395070968","doi":"10.2196/49861","title":"Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi","keywords":"Medicine; Multiple myeloma; Medical record; Retrospective cohort study; Epidemiology; Disease; Intensive care medicine; Internal medicine","score_opus":0.3396823257617645,"score_gpt":0.5569063068653292,"score_spread":0.21722398110356467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395070968","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06377721,0.000003866796,0.0000016212808,0.0023497592,0.0000038714757,0.9320105,0.00019971296,0.000059092825,0.0015944032],"genre_scores_gemma":[0.21155973,0.000007266206,0.00004568164,0.000041059597,0.00013741899,0.78556436,0.0000541802,0.000054549328,0.0025357548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942706,0.0016178358,0.00057861686,0.0010680739,0.0016130354,0.0008517968],"domain_scores_gemma":[0.99599504,0.0017598971,0.00015853038,0.0015477082,0.00031670454,0.00022214356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005069397,0.00034525013,0.00053464004,0.00062986906,0.0003745738,0.00026272854,0.0007298797,0.00008373307,0.000053529668],"category_scores_gemma":[0.0005166704,0.00018143492,0.00008678664,0.0015460986,0.0006003764,0.00023619478,0.00044655736,0.0011138127,0.0000056090075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025192307,0.0056068054,0.917263,0.0013262166,0.00059546786,0.0026969865,0.0017448596,2.5545887e-7,0.001858924,0.00016809396,0.03119482,0.012352289],"study_design_scores_gemma":[0.01620277,0.009284646,0.9451273,0.006044582,0.000021872247,0.000057495847,0.00065959117,0.0022827291,0.00094634446,0.00055685575,0.018589752,0.00022605908],"about_ca_topic_score_codex":0.0012659013,"about_ca_topic_score_gemma":0.0017595697,"teacher_disagreement_score":0.14778252,"about_ca_system_score_codex":0.00041919987,"about_ca_system_score_gemma":0.00036584405,"threshold_uncertainty_score":0.73987013},"labels":[],"label_agreement":null},{"id":"W4395701643","doi":"10.1016/j.jval.2024.04.017","title":"Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Multilevel model; Meta-analysis; Event (particle physics); Randomized controlled trial; Meta-regression; Multiple myeloma; Regression; Computer science; Aggregate (composite); Regression analysis; Medicine; Statistics; Internal medicine; Machine learning; Mathematics","score_opus":0.1678395498886775,"score_gpt":0.442002677789358,"score_spread":0.2741631279006805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395701643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98749435,0.0021981855,0.00023940716,0.0015722027,0.00022925746,0.00801177,0.00009628394,0.00011952423,0.00003899792],"genre_scores_gemma":[0.9906426,0.000026130756,0.006068659,0.00027654183,0.00014084157,0.0014788507,0.00005987077,0.00007771682,0.0012287721],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9957259,0.00058090803,0.0010933197,0.0007581794,0.0005268733,0.0013147979],"domain_scores_gemma":[0.9969573,0.001847039,0.00012517419,0.0004916342,0.000066230365,0.0005126265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036104412,0.00036073293,0.0010499775,0.00058637455,0.00021238388,0.000040717936,0.00011471014,0.00009251432,0.00016142095],"category_scores_gemma":[0.0007865891,0.00024243491,0.000270268,0.0006000158,0.000017925764,0.00007895765,0.0001575044,0.00045217518,0.00011075793],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021264462,0.005596024,0.70294964,0.002710466,0.0028205945,0.026926491,0.011698991,0.0076342695,0.00018655781,0.000030557756,0.003646469,0.23367348],"study_design_scores_gemma":[0.033546455,0.00753838,0.30194193,0.0034214386,0.0006215436,0.0007007298,0.004027157,0.6225834,0.00007000762,0.000113450325,0.024658885,0.00077660655],"about_ca_topic_score_codex":0.014581014,"about_ca_topic_score_gemma":0.0026494076,"teacher_disagreement_score":0.6149491,"about_ca_system_score_codex":0.0009062608,"about_ca_system_score_gemma":0.00056955667,"threshold_uncertainty_score":0.99198097},"labels":[],"label_agreement":null},{"id":"W4396237652","doi":"10.21203/rs.3.rs-4253193/v1","title":"Reduced Intensity transplantation vs chemotherapy. A prospective, pseudorandomized study in 50-70 year old AML patients","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Université Laval; Hôpital Maisonneuve-Rosemont","funders":"NordForsk; Vetenskapsrådet; Swedish Cancer Foundation","keywords":"Medicine; Internal medicine; Transplantation; Chemotherapy; Prospective cohort study; Sibling; Gastroenterology; Surgery","score_opus":0.04374601609310403,"score_gpt":0.3945642646719188,"score_spread":0.3508182485788148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396237652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813182,0.0002487972,0.00000431998,0.0007433314,0.000218818,0.015449938,0.00024388665,0.00014443605,0.0016282827],"genre_scores_gemma":[0.9943199,0.00078467,0.00019103411,0.00002578431,0.0001990494,0.0021624735,0.0006993791,0.00011807592,0.0014996144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935378,0.00089087704,0.00066094,0.0013683186,0.0025461365,0.0009959505],"domain_scores_gemma":[0.99703455,0.00032041085,0.000088597575,0.00092652754,0.0011899823,0.00043994345],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002104085,0.00047927516,0.0011891149,0.0014556054,0.0001399804,0.00019055992,0.00032173443,0.00038364079,0.00026383993],"category_scores_gemma":[0.000748868,0.00038378997,0.0003287652,0.0008885575,0.00016990684,0.00007065399,0.0005499872,0.0033558058,0.000348903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1088315,0.00734179,0.8634675,0.004387576,0.0011085654,0.0018342495,0.0073741404,0.000006857313,0.00063507474,0.000022875785,0.0009452224,0.004044644],"study_design_scores_gemma":[0.061772294,0.002405016,0.9291868,0.002558795,0.000121054516,0.00000949714,0.000884936,0.0003351654,0.0014848422,0.0009146022,0.0000358139,0.0002911561],"about_ca_topic_score_codex":0.0027831309,"about_ca_topic_score_gemma":0.00045069432,"teacher_disagreement_score":0.06571932,"about_ca_system_score_codex":0.0013378959,"about_ca_system_score_gemma":0.00077270705,"threshold_uncertainty_score":0.9998614},"labels":[],"label_agreement":null},{"id":"W4396534346","doi":"10.1002/jha2.894","title":"Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Memorial University of Newfoundland; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; University of Saskatchewan; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; Juravinski Cancer Centre; McGill University; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Spinal Cord Injury BC; Canadian Apheresis Group; Jewish General Hospital","funders":"","keywords":"Lenalidomide; Bortezomib; Medicine; Multiple myeloma; Internal medicine; Dexamethasone; Melphalan; Oncology; Prednisone; Maintenance therapy; Progression-free survival; Cyclophosphamide; Surgery; Chemotherapy","score_opus":0.10700761405325468,"score_gpt":0.41025824185256915,"score_spread":0.30325062779931444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396534346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948145,0.0004812614,0.000031026586,0.0042811134,0.00030010135,0.0027320234,0.0009624684,0.000044651926,0.0016858936],"genre_scores_gemma":[0.99514747,0.00006825295,0.0013693265,0.000092298425,0.00011883938,0.00035319742,0.0025169717,0.000045935303,0.0002876897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99456215,0.00069187995,0.00069415895,0.0007272193,0.0024233973,0.0009011679],"domain_scores_gemma":[0.9955149,0.0025036824,0.000117716256,0.0011946883,0.00031349188,0.00035552046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030882508,0.00034313867,0.0005122915,0.00076872983,0.00048499057,0.0001442992,0.0006282635,0.00012242021,0.00006986636],"category_scores_gemma":[0.002324804,0.00017265708,0.00012415924,0.0015886602,0.00041300192,0.00047469654,0.0001995689,0.0011514494,0.000024074294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001955252,0.0007964225,0.97523236,0.00012990985,0.00031142723,0.013461253,0.0027936564,0.000003799794,0.000052480285,0.00025894254,0.00046524726,0.0045392285],"study_design_scores_gemma":[0.009211554,0.00021276031,0.98680913,0.0014671407,0.00008526132,0.00006236307,0.00042317953,0.00035495765,0.000091269016,0.00002874087,0.0010763876,0.00017725538],"about_ca_topic_score_codex":0.35928726,"about_ca_topic_score_gemma":0.90612507,"teacher_disagreement_score":0.5468378,"about_ca_system_score_codex":0.000749705,"about_ca_system_score_gemma":0.0016595487,"threshold_uncertainty_score":0.70407516},"labels":[],"label_agreement":null},{"id":"W4396604922","doi":"10.1200/jco.23.00934","title":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Adaptive Biotechnologies; Astellas Pharma; bluebird bio; Kiadis Pharma; Omeros Corporation; Pfizer; Incyte; Jazz Pharmaceuticals; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Celgene; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; GlaxoSmithKline; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US; National Institute of Allergy and Infectious Diseases; Roswell Park Cancer Institute","keywords":"Medicine; Minimal residual disease; Internal medicine; Multiple myeloma; Oncology; Hazard ratio; Lenalidomide; Hematopoietic stem cell transplantation; Transplantation; Progression-free survival; Surgery; Gastroenterology; Bone marrow; Overall survival; Confidence interval","score_opus":0.0611446475342914,"score_gpt":0.39033018106175177,"score_spread":0.3291855335274604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396604922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609596,0.0012437695,0.000051833576,0.0018231216,0.00025533486,0.00029065466,0.000069859845,0.000015910453,0.00015354595],"genre_scores_gemma":[0.99733496,0.0014062227,0.00051454996,0.00018096941,0.0002007718,0.000013400016,0.000026152504,0.000025286712,0.0002977021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719167,0.00052421994,0.0011195346,0.00028440615,0.00045557308,0.00042460934],"domain_scores_gemma":[0.9960326,0.0026278386,0.00039811543,0.00011692636,0.00018011124,0.0006444279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146547,0.0001733397,0.00094966416,0.00017923806,0.0000264393,0.000028713797,0.00006988452,0.00021935666,0.00007396641],"category_scores_gemma":[0.001617452,0.00011312459,0.00018504562,0.000119110264,0.00023503405,0.00014205271,0.000025123294,0.00079893786,0.000012209826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036903337,0.0010795349,0.9051391,0.00025688566,0.00033274206,0.051360797,0.00017365979,0.000006288849,0.00003859977,0.000008446679,0.00016091848,0.004539697],"study_design_scores_gemma":[0.018988676,0.0037738609,0.9750339,0.0010024763,0.0004121663,0.00023941255,0.000067405526,0.00017733255,0.000030633026,0.00005678138,0.00010983502,0.0001075265],"about_ca_topic_score_codex":0.000024619116,"about_ca_topic_score_gemma":0.0006436762,"teacher_disagreement_score":0.0698948,"about_ca_system_score_codex":0.00022350696,"about_ca_system_score_gemma":0.0011880734,"threshold_uncertainty_score":0.46130866},"labels":[],"label_agreement":null},{"id":"W4396716301","doi":"10.14740/wjon1780","title":"Multiple Myeloma: A Review of the Literature and a Case Report Highlighting the Immunocompromised State of Myeloma Patients","year":2024,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Incidence (geometry); Malignancy; Intensive care medicine; Population; Hematological malignancy; Immune system; Pediatrics; Internal medicine; Immunology; Environmental health","score_opus":0.03445061647076343,"score_gpt":0.3720964710453962,"score_spread":0.3376458545746328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396716301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024378754,0.99359924,6.0635193e-7,0.0007574178,0.0004985607,0.002137622,0.000104439765,0.0000055169203,0.00045869703],"genre_scores_gemma":[0.0033703158,0.9947402,0.0003672514,0.000093895665,0.00016638552,0.00005418374,0.000036527075,0.000048342332,0.0011229083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539155,0.0008605186,0.00250547,0.0002936774,0.0006181609,0.00033061186],"domain_scores_gemma":[0.9939488,0.00094397203,0.0033831117,0.0006431918,0.00089196576,0.00018892834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016382926,0.00041179385,0.0030706294,0.00043570684,0.000103161816,0.000022935155,0.0003469729,0.00015099432,0.000030504056],"category_scores_gemma":[0.0013277866,0.0001705509,0.0011143511,0.0010054203,0.0002788483,0.0000614226,0.0003107393,0.0014947978,0.0000032625378],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022251923,0.00035427697,0.00024468536,0.094989,0.0018752438,0.04683145,0.0002913088,3.9073715e-8,0.000005673547,0.0000073115725,0.0021981357,0.8529804],"study_design_scores_gemma":[0.0019713924,0.0007183168,0.00047105938,0.19782144,0.003402973,0.10054315,0.00001027603,0.000001974049,0.000008301154,0.00001789674,0.6949309,0.000102286],"about_ca_topic_score_codex":0.000022379396,"about_ca_topic_score_gemma":0.00004524901,"teacher_disagreement_score":0.8528781,"about_ca_system_score_codex":0.0003203434,"about_ca_system_score_gemma":0.0013864135,"threshold_uncertainty_score":0.69548637},"labels":[],"label_agreement":null},{"id":"W4396752788","doi":"10.2139/ssrn.4815741","title":"Pomalidomide Use and Kidney Outcomes in Patients with Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Manitoba; University of Toronto; Lawson Health Research Institute; McMaster University","funders":"","keywords":"Pomalidomide; Medicine; Multiple myeloma; Cohort; Kidney disease; Internal medicine; Refractory (planetary science); Oncology; Population; Lenalidomide; Environmental health","score_opus":0.012940827104156363,"score_gpt":0.289666139931329,"score_spread":0.27672531282717266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396752788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930075,0.0016222307,0.00001718515,0.000781648,0.00019384037,0.0040031527,0.00026594332,0.000082079394,0.000026465814],"genre_scores_gemma":[0.9953781,0.0015374379,0.00011650314,0.0001283066,0.00015413265,0.00025860328,0.0009819,0.00014911176,0.001295922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99437505,0.00037881793,0.0007887266,0.0010775835,0.0011849983,0.0021948216],"domain_scores_gemma":[0.9969158,0.00026655837,0.00034639158,0.0006970759,0.00022932098,0.0015448211],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001035974,0.0007346963,0.0011235793,0.0010944452,0.0002262384,0.00029204856,0.00019434106,0.00020180686,0.000036887814],"category_scores_gemma":[0.0010897825,0.0005364544,0.00018709636,0.00031423738,0.00010947777,0.00021032491,0.00035525835,0.0046598325,0.000007891292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041347817,0.0016390983,0.9890224,0.00037951084,0.0023335142,0.0003619993,0.000068488,0.00003264476,0.000003735681,0.00008532912,0.000057906163,0.0018806396],"study_design_scores_gemma":[0.02194868,0.0018531092,0.9714999,0.0011564231,0.0009658613,0.000021065784,0.000050410512,0.0009085349,0.0000017674635,0.001077048,0.00006217467,0.00045502002],"about_ca_topic_score_codex":0.005505489,"about_ca_topic_score_gemma":0.014941443,"teacher_disagreement_score":0.017813899,"about_ca_system_score_codex":0.005547602,"about_ca_system_score_gemma":0.01135543,"threshold_uncertainty_score":0.9997087},"labels":[],"label_agreement":null},{"id":"W4396925099","doi":"10.1002/ajh.27364","title":"Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Ontario Genomics","funders":"","keywords":"Oncology; Internal medicine; Medicine; Biomarker; Multiple myeloma; Risk stratification; Cohort; Predictive value; Correlation; Proportional hazards model; Biology; Genetics","score_opus":0.0180515829767489,"score_gpt":0.3237621007054432,"score_spread":0.3057105177286943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396925099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949246,0.0037125822,0.00043046943,0.0003973596,0.00014022707,0.00029160047,0.000010136147,0.000020414935,0.00007260768],"genre_scores_gemma":[0.9825934,0.00010916937,0.017167274,0.00001712976,0.000064133375,0.000011994244,0.000005525544,0.000024943736,0.0000064035594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982067,0.00011129836,0.0006720704,0.00020900965,0.00045214265,0.00034878418],"domain_scores_gemma":[0.9986061,0.0004889609,0.0003605552,0.00016630303,0.00016557108,0.00021255201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041890552,0.00015783303,0.00072240963,0.0005405814,0.0000341007,0.000008499518,0.00010571738,0.000060773775,0.000039497685],"category_scores_gemma":[0.00048933027,0.00010763733,0.00016554547,0.0004536263,0.00031249406,0.000095726384,0.00006154774,0.0005120545,0.00000925107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011994906,0.00030457077,0.8683021,0.00025610015,0.0004009183,0.0036252148,0.0001771544,0.000053755346,0.004119697,0.00010856525,0.000070198665,0.12138222],"study_design_scores_gemma":[0.009140256,0.00951068,0.8138686,0.006693964,0.0004125495,0.021253668,0.0010182154,0.043019254,0.09348066,0.0009648715,0.00026979894,0.00036752975],"about_ca_topic_score_codex":0.00009760696,"about_ca_topic_score_gemma":0.000038926173,"teacher_disagreement_score":0.12101469,"about_ca_system_score_codex":0.000079865786,"about_ca_system_score_gemma":0.00035881792,"threshold_uncertainty_score":0.4389323},"labels":[],"label_agreement":null},{"id":"W4396976433","doi":"10.3390/diagnostics14101030","title":"The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Diagnostics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Meta-analysis; Medicine; Oncology; Intensive care medicine; Internal medicine","score_opus":0.09719415840238789,"score_gpt":0.3463820449157358,"score_spread":0.24918788651334794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396976433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017065671,0.9846293,0.000075096665,0.00006633411,0.00006550117,0.010010968,0.005078699,0.000023358065,0.000033711185],"genre_scores_gemma":[0.001717939,0.9955154,0.00009154314,0.000025578403,0.000018429984,0.0012892953,0.0011038348,0.00006361408,0.00017436857],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99687713,0.00032960184,0.0013842431,0.00053124496,0.00048738578,0.00039036764],"domain_scores_gemma":[0.9858634,0.01266938,0.00043020144,0.00058752036,0.00018533821,0.00026417122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056225655,0.0005836735,0.0061953506,0.00019429463,0.00014313783,0.00005373572,0.00018135653,0.00018921011,0.000009088058],"category_scores_gemma":[0.0006897768,0.0002816411,0.0017958398,0.00046076346,0.00012057565,0.00002785038,0.000040237017,0.00026174472,0.00000775964],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015040465,0.0003209065,0.000029754841,0.84907335,0.1418319,0.00005672969,0.00010800267,1.4259419e-7,4.254701e-8,0.000020202513,0.00010453876,0.008304019],"study_design_scores_gemma":[0.0023053312,0.00065354083,0.000019193449,0.061996847,0.919804,0.000013602643,0.000013832166,0.000026657903,0.0000020628772,0.0000013505046,0.014941209,0.00022238806],"about_ca_topic_score_codex":0.00001071184,"about_ca_topic_score_gemma":0.000045648576,"teacher_disagreement_score":0.7870765,"about_ca_system_score_codex":0.000091690104,"about_ca_system_score_gemma":0.00011303872,"threshold_uncertainty_score":0.9999636},"labels":[],"label_agreement":null},{"id":"W4396990448","doi":"10.1681/asn.20223311s1639a","title":"The Urine Protein-Albumin Gap as a Predictor of Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Urine; Albumin; Myeloma protein; Medicine; Internal medicine","score_opus":0.021904244381743,"score_gpt":0.29940247352238764,"score_spread":0.27749822914064465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396990448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98272014,0.00049565244,0.000022099633,0.016057642,0.000065444925,0.00049403746,0.00002618421,0.0000056483022,0.00011317966],"genre_scores_gemma":[0.9958266,0.00019349037,0.0015789813,0.001445237,0.00016416177,0.00003261481,0.0000018007543,0.000018474484,0.0007386171],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997828,0.00036708193,0.0005499957,0.00012389754,0.00080756244,0.0003234406],"domain_scores_gemma":[0.99746037,0.0004280213,0.0013146921,0.0004064048,0.0002557692,0.00013477451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066392764,0.00012959528,0.0005557155,0.000049124596,0.00026655363,0.000004501189,0.0005066264,0.000030007168,0.000108787746],"category_scores_gemma":[0.0002974156,0.00007023267,0.0006915654,0.00037953432,0.0011832714,0.000033549895,0.00033692492,0.0005695763,0.0000019762567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013746648,0.0018155081,0.116437495,0.0001350912,0.0044218996,0.000112765134,0.0023217124,0.0001026977,0.771836,0.000103193226,0.0643785,0.024588484],"study_design_scores_gemma":[0.011121627,0.01617653,0.8081674,0.000078080615,0.0003893709,0.0020282522,0.006246875,0.0012926584,0.019515665,0.0006919321,0.1341265,0.00016509778],"about_ca_topic_score_codex":0.0002647632,"about_ca_topic_score_gemma":0.000008766558,"teacher_disagreement_score":0.75232035,"about_ca_system_score_codex":0.00014483373,"about_ca_system_score_gemma":0.00045012592,"threshold_uncertainty_score":0.43598127},"labels":[],"label_agreement":null},{"id":"W4397012677","doi":"10.3389/fonc.2024.1352281","title":"Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Pomalidomide; Dexamethasone; Multiple myeloma; Medicine; Refractory (planetary science); Internal medicine; Oncology; Lenalidomide; Pharmacology; Biology","score_opus":0.0288569035527572,"score_gpt":0.33310364049492613,"score_spread":0.3042467369421689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397012677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895913,0.00721346,0.0002292777,0.0011324694,0.00032130562,0.0008904722,0.00003181632,0.000035031448,0.0005548831],"genre_scores_gemma":[0.9633365,0.002555542,0.03338547,0.000050696195,0.00006280888,0.000058297675,0.000027430371,0.000032500386,0.00049071613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982554,0.00023247207,0.0003925051,0.000510828,0.00020201119,0.00040684],"domain_scores_gemma":[0.99794763,0.0014810194,0.00007398447,0.00021919505,0.00004633328,0.00023181525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004787585,0.00021615469,0.00070515316,0.00043174706,0.000043295157,0.000013226828,0.00006973341,0.00023376667,0.000021063644],"category_scores_gemma":[0.00093610864,0.00015817894,0.000027901628,0.00035437665,0.00043721465,0.00008898809,0.00008886417,0.00046356133,0.0000021224603],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17705163,0.0008337072,0.32435113,0.00056877534,0.0006119592,0.005578292,0.0022197498,0.000015144374,0.003267522,0.00003633387,0.0016660825,0.48379967],"study_design_scores_gemma":[0.11061414,0.011529643,0.83005244,0.0010252343,0.00023544098,0.00033248126,0.0023299402,0.018994454,0.0005892417,0.000052507203,0.023893517,0.00035098477],"about_ca_topic_score_codex":0.0003675704,"about_ca_topic_score_gemma":0.0010230903,"teacher_disagreement_score":0.50570124,"about_ca_system_score_codex":0.00039035923,"about_ca_system_score_gemma":0.00039324778,"threshold_uncertainty_score":0.645035},"labels":[],"label_agreement":null},{"id":"W4397047590","doi":"10.1080/14712598.2024.2357382","title":"Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Daratumumab; CD38; Monoclonal antibody; Multiple myeloma; Antibody; Cancer research; Medicine; Immunology; Biology; Genetics; Stem cell","score_opus":0.16356094872052226,"score_gpt":0.4215744358332648,"score_spread":0.2580134871127425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397047590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008333947,0.995262,0.0000021771616,0.00056188204,0.00017066635,0.0028125313,0.00020997327,0.00003203741,0.00011533281],"genre_scores_gemma":[0.0026646568,0.9952346,0.00026652342,0.00028256662,0.00018386333,0.00040946124,0.0008894615,0.00003802891,0.000030847543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722457,0.0005348479,0.0008311721,0.0006254221,0.00047045856,0.0003135047],"domain_scores_gemma":[0.99829215,0.00036866235,0.00038405374,0.0007033641,0.00014864682,0.00010310517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035217154,0.00052234286,0.0021847708,0.0002223899,0.000047041412,0.000015964783,0.0003399781,0.0003839317,0.00010476707],"category_scores_gemma":[0.00024816892,0.00020189788,0.00068155635,0.0009064527,0.00028154333,0.000032151638,0.000076905526,0.0005970018,0.000019153546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060264923,0.0016067673,0.00085541885,0.022044217,0.00071698095,0.00005019059,0.00020291547,1.4038899e-7,0.0003859384,0.00028910945,0.00083819666,0.97240746],"study_design_scores_gemma":[0.0011819367,0.0016072881,0.0019341401,0.2589287,0.000010752873,0.00007674311,0.000013071564,0.000004835844,0.0003051593,0.000025603747,0.7356923,0.00021947327],"about_ca_topic_score_codex":0.000012556034,"about_ca_topic_score_gemma":5.3910304e-7,"teacher_disagreement_score":0.972188,"about_ca_system_score_codex":0.00010621221,"about_ca_system_score_gemma":0.0002054628,"threshold_uncertainty_score":0.8233157},"labels":[],"label_agreement":null},{"id":"W4397049853","doi":"10.1016/j.clml.2024.05.014","title":"Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bristol-Myers Squibb","keywords":"Pomalidomide; Medicine; Nivolumab; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Lenalidomide; Materials science; Immunotherapy; Cancer","score_opus":0.06850739743317062,"score_gpt":0.38812460186264236,"score_spread":0.3196172044294717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397049853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969877,0.00375495,0.00003115508,0.0010609785,0.00035518128,0.0036504504,0.00095734093,0.00017195762,0.00031921908],"genre_scores_gemma":[0.9948529,0.0013884107,0.00075626705,0.0000901802,0.0003470876,0.0003473398,0.0007034793,0.000089669855,0.0014246713],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956782,0.00044140883,0.0015474205,0.0012213319,0.0005513371,0.00056030357],"domain_scores_gemma":[0.9907767,0.007149264,0.00033775604,0.0010003276,0.000246719,0.00048922526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011228813,0.00049987825,0.0011668521,0.00016445293,0.00030683514,0.00012578489,0.00019021111,0.00032756515,0.00002063505],"category_scores_gemma":[0.0024483937,0.000330417,0.00035419024,0.00029643034,0.0005753094,0.00020550136,0.00014163746,0.00017818881,0.000030227895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029605925,0.005488791,0.029239805,0.00016088509,0.0021781828,0.00081007346,0.00239511,7.989228e-7,0.0019268331,0.00016072995,0.002518328,0.9255145],"study_design_scores_gemma":[0.12383962,0.015438027,0.8346671,0.00035822924,0.00091521686,0.000073144736,0.00077175564,0.009498199,0.0015737558,0.0003600509,0.012186826,0.00031807474],"about_ca_topic_score_codex":0.0014410448,"about_ca_topic_score_gemma":0.00023728948,"teacher_disagreement_score":0.92519647,"about_ca_system_score_codex":0.0009654802,"about_ca_system_score_gemma":0.0008022673,"threshold_uncertainty_score":0.99991477},"labels":[],"label_agreement":null},{"id":"W4399373340","doi":"10.2139/ssrn.4850456","title":"A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Disease Biomarkers and Delays Progression to Myeloma","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Multiple myeloma; Plasma cell; Disease; Medicine; Intervention (counseling); Plasma Cell Myeloma; Dietary fiber; Cancer research; Oncology; Internal medicine; Chemistry; Food science; Psychiatry","score_opus":0.00898442464586947,"score_gpt":0.2978177738021862,"score_spread":0.28883334915631675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399373340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744089,0.019561209,0.00019439998,0.0029718797,0.0003778765,0.0022149442,0.000053463707,0.00006491502,0.00015239927],"genre_scores_gemma":[0.98889524,0.007383239,0.00072997774,0.000017170896,0.0002041606,0.00036093823,0.00024462954,0.00008681385,0.0020778216],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956509,0.00021801861,0.0006158832,0.0007924474,0.00060593546,0.0021168534],"domain_scores_gemma":[0.99862856,0.000053267886,0.00021400762,0.00033044978,0.000090406174,0.00068330165],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00096593896,0.00048107677,0.0005127519,0.00088188273,0.00012650175,0.00015779713,0.00021370518,0.00023411958,0.000053893116],"category_scores_gemma":[0.00011475353,0.00038643187,0.00043159918,0.00029161826,0.00008378866,0.00011638913,0.0006783499,0.003401974,0.00009422123],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010758868,0.0017714052,0.02046955,0.0025584728,0.0022116173,0.00047184748,0.00026194745,0.000029201528,0.001401581,0.00033328403,0.000317199,0.959415],"study_design_scores_gemma":[0.044249095,0.01754983,0.4524672,0.025218923,0.0042845397,0.0009671611,0.0024217349,0.01038118,0.0031347752,0.4344917,0.0019086145,0.0029252355],"about_ca_topic_score_codex":0.00027668115,"about_ca_topic_score_gemma":0.0015994076,"teacher_disagreement_score":0.9564898,"about_ca_system_score_codex":0.0020318143,"about_ca_system_score_gemma":0.0020664085,"threshold_uncertainty_score":0.99985874},"labels":[],"label_agreement":null},{"id":"W4399419913","doi":"10.1016/j.jtct.2024.06.001","title":"Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; National Institutes of Health; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Paula and Rodger Riney Foundation; University of Texas MD Anderson Cancer Center; Leukemia and Lymphoma Society","keywords":"Lenalidomide; Medicine; Multiple myeloma; Carfilzomib; Internal medicine; Bortezomib; Oncology; Transplantation; Autologous stem-cell transplantation; Hematopoietic stem cell transplantation; Surgery","score_opus":0.02872631718296677,"score_gpt":0.3155118879821562,"score_spread":0.2867855707991894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399419913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98840564,0.0054577896,0.0045143166,0.00050752243,0.00009517375,0.000581912,0.00020407683,0.00009241166,0.00014113491],"genre_scores_gemma":[0.9962214,0.0018057304,0.0005486957,0.00012655872,0.000034654604,0.00026310363,0.00049495493,0.00003132995,0.0004735608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989325,0.000031774063,0.00022863735,0.00032067197,0.00019076945,0.00029565502],"domain_scores_gemma":[0.99958867,0.00014204078,0.000014518144,0.00011600187,0.000015924992,0.00012285514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001162692,0.00019880205,0.00027170047,0.0003189467,0.000047428257,0.000040723502,0.00004168866,0.00010584072,0.00023656733],"category_scores_gemma":[0.0000021051176,0.00014078243,0.0001481344,0.0001409121,0.000048304013,0.00009234183,0.000001765883,0.00012433031,0.000009873205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056401063,0.00024438003,0.7191893,0.00039904466,0.00034189827,0.0011027935,0.0026404213,0.0000032552346,0.013273216,0.00021554802,0.00002618862,0.25692388],"study_design_scores_gemma":[0.00878679,0.0003276086,0.9736255,0.00014768764,0.00008794105,0.00006055045,0.000027001564,0.0048384196,0.010638886,0.00015225812,0.0011416376,0.0001657397],"about_ca_topic_score_codex":0.00012757769,"about_ca_topic_score_gemma":0.0007833746,"teacher_disagreement_score":0.25675815,"about_ca_system_score_codex":0.000033180837,"about_ca_system_score_gemma":0.000030592724,"threshold_uncertainty_score":0.5740941},"labels":[],"label_agreement":null},{"id":"W4399452320","doi":"10.1200/jco.2024.42.17_suppl.lba105","title":"Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Bortezomib; Multiple myeloma; Interim analysis; Refractory (planetary science); Randomized controlled trial; Oncology; Gastroenterology","score_opus":0.11373483014546089,"score_gpt":0.45582014480989064,"score_spread":0.34208531466442976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475945,0.007331258,0.000074548465,0.004182009,0.00078128563,0.0023684306,0.00014124226,0.000029100367,0.00033267774],"genre_scores_gemma":[0.990634,0.0040245648,0.0037055772,0.00040202247,0.00082309375,0.000050605177,0.00003315015,0.00006350077,0.00026345687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98703784,0.005020711,0.005458715,0.00080101896,0.0010424836,0.0006392483],"domain_scores_gemma":[0.9283427,0.067724034,0.0020401892,0.0006211759,0.00041197066,0.0008599406],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01584676,0.0004855344,0.005021927,0.0004959754,0.00011223192,0.00006805893,0.00037058746,0.0006423584,0.000094692994],"category_scores_gemma":[0.043648828,0.00028893937,0.00066058943,0.0004504235,0.0010214234,0.00022934872,0.00030286284,0.0025879156,0.00001138623],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80217046,0.0065137143,0.058753144,0.000091626,0.003584513,0.009148266,0.0034059393,0.000020753057,0.00094047084,0.000021284122,0.0009686872,0.11438114],"study_design_scores_gemma":[0.7716349,0.019440204,0.1946801,0.0006796718,0.0019046841,0.00072055496,0.0023706316,0.0058926074,0.00024306463,0.0002584519,0.0019267745,0.00024837485],"about_ca_topic_score_codex":0.0031088358,"about_ca_topic_score_gemma":0.002343222,"teacher_disagreement_score":0.13592695,"about_ca_system_score_codex":0.00041773,"about_ca_system_score_gemma":0.002192859,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W4399480640","doi":"10.1200/jco.2024.42.16_suppl.7510","title":"Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Internal medicine; Venetoclax; Multiple myeloma; Refractory (planetary science); Oncology; Subgroup analysis; Lenalidomide; Leukemia; Meta-analysis","score_opus":0.09263894720094318,"score_gpt":0.45702555486786345,"score_spread":0.36438660766692027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946558,0.0009373179,0.00027450407,0.0006244797,0.0008965288,0.0020763953,0.000112867536,0.000040491203,0.00038162855],"genre_scores_gemma":[0.9959259,0.00019561472,0.0026997454,0.00018112348,0.00042438947,0.000046919256,0.000110222114,0.00010101049,0.00031509664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98823416,0.002873164,0.0049683307,0.0010277006,0.0019332612,0.0009633712],"domain_scores_gemma":[0.9817894,0.01235655,0.0023474537,0.00084062293,0.0014658588,0.0012001148],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071057254,0.0006480201,0.0046838024,0.0020618774,0.00009502899,0.00005204715,0.0005278807,0.0007555827,0.00036598937],"category_scores_gemma":[0.01006902,0.00044808374,0.001417157,0.0027171767,0.00067245547,0.00041517243,0.00021707594,0.0022117519,0.000035794666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063120805,0.03330049,0.77584714,0.00010159713,0.011490466,0.007800741,0.0005841346,0.00008326853,0.0003957744,0.000012727037,0.0004548823,0.106807984],"study_design_scores_gemma":[0.113173984,0.050696034,0.8269398,0.000460949,0.0043453765,0.00010104331,0.00035576927,0.0013076095,0.00025077167,0.000018163826,0.0020254725,0.00032502777],"about_ca_topic_score_codex":0.0014255715,"about_ca_topic_score_gemma":0.0038905647,"teacher_disagreement_score":0.10648295,"about_ca_system_score_codex":0.0015318018,"about_ca_system_score_gemma":0.0037410362,"threshold_uncertainty_score":0.9997971},"labels":[],"label_agreement":null},{"id":"W4399480665","doi":"10.1200/jco.2024.42.16_suppl.7561","title":"Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Regeneron Pharmaceuticals","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.13113638108570327,"score_gpt":0.46271516226638715,"score_spread":0.33157878118068385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612594,0.0006172811,0.000011803397,0.00029060655,0.0005221002,0.0013939897,0.00010870331,0.0000110548945,0.0009185293],"genre_scores_gemma":[0.99774003,0.0013519094,0.00048351218,0.00004411246,0.00011120711,0.000045436656,0.00015946725,0.000028094355,0.000036216577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993088,0.0030808705,0.002228238,0.0003421853,0.00086918066,0.00039154597],"domain_scores_gemma":[0.9765097,0.021013005,0.0009992038,0.0003156969,0.00088855065,0.00027388157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026433382,0.00030415584,0.0024247842,0.00082725787,0.00004069046,0.000014645716,0.00024196098,0.00027592128,0.00003431491],"category_scores_gemma":[0.001808551,0.0001648728,0.00042048073,0.0009770327,0.0004300994,0.00014439385,0.000046994097,0.0011236451,0.0000052199703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3134641,0.008380882,0.632693,0.00043659314,0.0017455432,0.002161555,0.0041747047,0.00026048138,0.00009583484,0.00005678464,0.00014677772,0.03638377],"study_design_scores_gemma":[0.09924277,0.12994425,0.75785196,0.0013687868,0.00039490947,0.000012206603,0.00236688,0.00069601485,0.001102412,0.000037150137,0.006852258,0.00013039073],"about_ca_topic_score_codex":0.0007550226,"about_ca_topic_score_gemma":0.0069922414,"teacher_disagreement_score":0.21422133,"about_ca_system_score_codex":0.0015513565,"about_ca_system_score_gemma":0.0023830722,"threshold_uncertainty_score":0.6723318},"labels":[],"label_agreement":null},{"id":"W4399480666","doi":"10.1200/jco.2024.42.16_suppl.7539","title":"Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Dexamethasone; Pharmacokinetics; Multiple myeloma; Refractory (planetary science); Internal medicine; Oncology; Pharmacology","score_opus":0.1267504707767002,"score_gpt":0.5154475091146857,"score_spread":0.3886970383379855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954051,0.0009127018,0.00006983246,0.0018924365,0.0006030125,0.0005756407,0.000025070522,0.000017318695,0.00049890304],"genre_scores_gemma":[0.99300045,0.0022110068,0.0035512832,0.00033564505,0.0005787604,0.000008661306,0.0000061877818,0.000043274118,0.0002647105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99370307,0.0010779683,0.0034585036,0.0004345147,0.00082343176,0.00050249],"domain_scores_gemma":[0.9829674,0.014269499,0.0010996967,0.0003155554,0.0003407216,0.0010071743],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005131432,0.00032581773,0.0026441677,0.00047848778,0.000031318108,0.000018863166,0.00019730227,0.00048435363,0.00016753926],"category_scores_gemma":[0.006324714,0.00018054705,0.0010239843,0.00028471067,0.0005468399,0.000115527575,0.00010137884,0.00248566,0.000019877407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043933917,0.0052131903,0.7690523,0.00007727486,0.003152112,0.007943518,0.000108904074,0.0001220875,0.00014460292,0.000008509811,0.0009571094,0.16928646],"study_design_scores_gemma":[0.04900552,0.071211725,0.87227,0.00052562536,0.00062403764,0.00059690484,0.000044319182,0.0032465216,0.00007150253,0.000047798592,0.0022151321,0.00014094835],"about_ca_topic_score_codex":0.00013941406,"about_ca_topic_score_gemma":0.00018361422,"teacher_disagreement_score":0.16914551,"about_ca_system_score_codex":0.0007813532,"about_ca_system_score_gemma":0.0044769812,"threshold_uncertainty_score":0.99981564},"labels":[],"label_agreement":null},{"id":"W4399480809","doi":"10.1200/jco.2024.42.16_suppl.7543","title":"Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Oncology; Internal medicine; Refractory (planetary science)","score_opus":0.07123496320944629,"score_gpt":0.4203326377822693,"score_spread":0.34909767457282304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922084,0.0024657205,0.00007327607,0.0012401153,0.0007481786,0.0030222218,0.00004558746,0.000041751628,0.00015475639],"genre_scores_gemma":[0.99593437,0.0006488502,0.0024860676,0.00040826068,0.00026054907,0.00007217691,0.000058512767,0.000071169095,0.00006005158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906409,0.0025988559,0.0041120118,0.00080234394,0.0011993706,0.0006465286],"domain_scores_gemma":[0.9744759,0.021699328,0.0018783563,0.00058134476,0.0005158425,0.00084920635],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060090814,0.00054298266,0.004504709,0.00038957328,0.00018295443,0.0001193309,0.00024670686,0.00042791804,0.00007263185],"category_scores_gemma":[0.0116838515,0.0002913569,0.00047548802,0.00039063668,0.00078962825,0.00038907691,0.0002572721,0.0025560253,0.000008313301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21973291,0.007864022,0.6727525,0.000031815383,0.003439778,0.0027979293,0.00084845634,0.0000020470216,0.000016721264,0.0000034206084,0.00020459536,0.092305824],"study_design_scores_gemma":[0.3644601,0.013845827,0.61758965,0.00028026657,0.0013282355,0.00010945186,0.0005682628,0.0009239017,0.000012340301,0.00004129671,0.0006603783,0.0001802802],"about_ca_topic_score_codex":0.0009366515,"about_ca_topic_score_gemma":0.0010397554,"teacher_disagreement_score":0.14472719,"about_ca_system_score_codex":0.00025939563,"about_ca_system_score_gemma":0.00096403016,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4399480854","doi":"10.1200/jco.2024.42.16_suppl.7503","title":"DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","score_opus":0.1691857205432594,"score_gpt":0.5092422431011188,"score_spread":0.34005652255785934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845105,0.0108908,0.00021335013,0.0019014312,0.0010297701,0.0009205645,0.00017271625,0.000031833213,0.00032902733],"genre_scores_gemma":[0.9806215,0.00776106,0.009844337,0.00028924027,0.0011035871,0.000024883166,0.000094090516,0.000067920846,0.00019338573],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99151003,0.0017246299,0.0042893975,0.00081751903,0.0009672471,0.00069116213],"domain_scores_gemma":[0.98310536,0.013271521,0.0015939443,0.0005074933,0.00037696867,0.0011446985],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005366312,0.00049295014,0.003771832,0.0008700588,0.00007845908,0.0000665723,0.00029610883,0.0009551209,0.00035294224],"category_scores_gemma":[0.009993125,0.00036407643,0.0006931391,0.0006159278,0.0008122119,0.00035763264,0.00022296318,0.0026282393,0.00001957095],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37296587,0.011471316,0.14926246,0.00022826192,0.0038251826,0.011937746,0.0004503911,0.0000030816036,0.0071890964,0.000050586303,0.0025172571,0.44009876],"study_design_scores_gemma":[0.4894261,0.056137186,0.41937762,0.0010302888,0.0027220894,0.0010283426,0.00049759983,0.0047621126,0.0024387245,0.00057975017,0.021483436,0.00051673775],"about_ca_topic_score_codex":0.0009785894,"about_ca_topic_score_gemma":0.0010847118,"teacher_disagreement_score":0.43958202,"about_ca_system_score_codex":0.00029575243,"about_ca_system_score_gemma":0.0018985779,"threshold_uncertainty_score":0.99988115},"labels":[],"label_agreement":null},{"id":"W4399480918","doi":"10.1200/jco.2024.42.16_suppl.tps7577","title":"MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. Everett Chalmers Regional Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine","score_opus":0.1305628271357605,"score_gpt":0.48819228077042975,"score_spread":0.35762945363466925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966803,0.00015074038,0.000016196549,0.00071347447,0.00022227026,0.0017985973,0.0000121446965,0.000007996108,0.00039823275],"genre_scores_gemma":[0.9972396,0.00010425091,0.0021136506,0.00013345762,0.00006886051,0.00003790104,0.000016285596,0.000032707365,0.00025331826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954138,0.0008428753,0.0022844402,0.00034675476,0.00079063367,0.00032149692],"domain_scores_gemma":[0.99496645,0.00305409,0.0008628389,0.00027914133,0.0004924588,0.00034500417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025330745,0.00020189524,0.001626071,0.0005374909,0.00002878093,0.00002573231,0.00028438785,0.00023742601,0.0001635013],"category_scores_gemma":[0.0029094936,0.00011388027,0.00007346065,0.0005589233,0.00017207224,0.0003586289,0.000105492756,0.0013031694,0.000012335642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15100618,0.13308398,0.49303237,0.00008530091,0.0005380453,0.008358173,0.00042371984,0.000003837679,0.000022169757,0.000008103332,0.00027792918,0.2131602],"study_design_scores_gemma":[0.3117968,0.1649495,0.520891,0.00046951976,0.00015017971,0.000040742376,0.00028333254,0.00051577884,0.000009161712,0.00001885453,0.0007999494,0.0000751615],"about_ca_topic_score_codex":0.0003042035,"about_ca_topic_score_gemma":0.0024918178,"teacher_disagreement_score":0.21308504,"about_ca_system_score_codex":0.00039690323,"about_ca_system_score_gemma":0.0021101928,"threshold_uncertainty_score":0.5661695},"labels":[],"label_agreement":null},{"id":"W4399676872","doi":"10.1002/ajh.27419","title":"Still high risk? A review of translocation t(14;16) in multiple myeloma","year":2024,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Multiple myeloma; Presentation (obstetrics); Chromosomal translocation; Medicine; Biomarker; Disease; Internal medicine; Oncology; Intensive care medicine; Bioinformatics; Biology; Surgery; Genetics; Gene","score_opus":0.04152078225076134,"score_gpt":0.379898403241376,"score_spread":0.3383776209906147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399676872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066570676,0.99770117,0.00009059861,0.0003767274,0.00016353144,0.0008670028,0.00006406268,0.000010129964,0.00006108297],"genre_scores_gemma":[0.009814759,0.9884546,0.0013669685,0.00007193363,0.00007794231,0.000053312564,0.00006254382,0.000059586968,0.00003835344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99601036,0.00071034447,0.0020995531,0.00031023388,0.00048736436,0.00038216152],"domain_scores_gemma":[0.9963855,0.0006742009,0.0019649079,0.00039961914,0.0003117485,0.0002640254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077582075,0.00039668352,0.00540632,0.00091744115,0.000014279041,0.000005611964,0.00026578346,0.00014890189,0.00011721635],"category_scores_gemma":[0.0010960366,0.0002539042,0.00093224447,0.0010246524,0.0003557757,0.00005038598,0.000039286308,0.0010881631,0.00006734828],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001286378,0.00024434747,0.00046787164,0.09929793,0.0010147532,0.0012555125,0.00006152049,1.08081565e-7,3.3180282e-7,0.0000464816,0.0005822224,0.8969003],"study_design_scores_gemma":[0.0023166365,0.0026457738,0.00025731855,0.47210598,0.0054801856,0.01593024,0.00008230756,0.000010738183,0.00001613546,0.000083661,0.500776,0.0002949951],"about_ca_topic_score_codex":0.00029725622,"about_ca_topic_score_gemma":0.000058558202,"teacher_disagreement_score":0.8966053,"about_ca_system_score_codex":0.00027473381,"about_ca_system_score_gemma":0.00110194,"threshold_uncertainty_score":0.9999913},"labels":[],"label_agreement":null},{"id":"W4399700467","doi":"10.1016/j.jval.2024.03.183","title":"CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Middlesex London Health Unit","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Medicine; Clinical endpoint; Residual; Oncology; Primary (astronomy); Clinical trial; Internal medicine; Mathematics; Algorithm; Bone marrow","score_opus":0.23198385353040846,"score_gpt":0.47397725614956016,"score_spread":0.2419934026191517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399700467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98150206,0.010163212,0.000022920687,0.005394757,0.00036853776,0.0019875094,0.0001652344,0.000064912754,0.0003308356],"genre_scores_gemma":[0.99464226,0.0016915228,0.0022354247,0.00056776014,0.00036890467,0.00012756378,0.000115703275,0.0000427398,0.00020811592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934932,0.0022138024,0.0021931278,0.0006622203,0.0007427568,0.0006949014],"domain_scores_gemma":[0.99375457,0.0047651273,0.00021120776,0.0004603891,0.000051452203,0.0007572436],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0082957465,0.00023236059,0.0012379906,0.0004879812,0.000048497175,0.00002707706,0.00015758358,0.00013354149,0.00014273968],"category_scores_gemma":[0.00951879,0.00019009212,0.00029287493,0.0005611054,0.00014404826,0.00018381815,0.0001111934,0.000637242,0.0000669976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017215066,0.0023674709,0.7745917,0.006070623,0.000248112,0.005650208,0.001204858,0.0001426215,0.0007144957,0.0010626273,0.0015978777,0.18913436],"study_design_scores_gemma":[0.009219126,0.0012468742,0.9735578,0.0030484048,0.00004208566,0.000022837592,0.00021527761,0.0098685855,0.00037398885,0.00054138945,0.0016952488,0.00016843133],"about_ca_topic_score_codex":0.0030082376,"about_ca_topic_score_gemma":0.00012681725,"teacher_disagreement_score":0.19896607,"about_ca_system_score_codex":0.00054529175,"about_ca_system_score_gemma":0.0030171112,"threshold_uncertainty_score":0.9988245},"labels":[],"label_agreement":null},{"id":"W4399703344","doi":"10.1016/s1470-2045(24)00282-1","title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Adaptive Biotechnologies; Celgene; National Cancer Institute; Yale University; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Multiple myeloma; Thalidomide; Internal medicine; Oncology; Regimen; Dexamethasone; Surgery","score_opus":0.0623832820278561,"score_gpt":0.36822774319097507,"score_spread":0.305844461163119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399703344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869073,0.0019880654,0.00025378037,0.0026389307,0.00033856888,0.0074006855,0.00016138829,0.000054142834,0.00025713354],"genre_scores_gemma":[0.9943497,0.00158835,0.0004895514,0.00023653576,0.00017460174,0.0012018875,0.000085951506,0.000045970013,0.0018274491],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969811,0.00079213054,0.00067119236,0.0005378831,0.00040070215,0.0006170209],"domain_scores_gemma":[0.9955883,0.0033891401,0.00023751133,0.00050249224,0.00010108108,0.00018144486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012949853,0.00037054578,0.0018839425,0.00012320672,0.00018631335,0.000066297056,0.00024090035,0.00020626457,0.00005124391],"category_scores_gemma":[0.0010517421,0.00015208226,0.0001420259,0.00045965295,0.0004519856,0.00015201698,0.00006086949,0.0005065661,0.000002251417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9247387,0.0006937059,0.0543547,0.00028481957,0.00076640403,0.0013551902,0.0012338979,0.000002128327,0.008326411,0.000024472083,0.0012713359,0.0069482154],"study_design_scores_gemma":[0.95915574,0.005008695,0.027023438,0.0007041636,0.00071426167,0.00036354564,0.00017576941,0.0037982573,0.0020341508,0.000017222434,0.00080273935,0.0002020009],"about_ca_topic_score_codex":0.0005026074,"about_ca_topic_score_gemma":0.008249467,"teacher_disagreement_score":0.034417037,"about_ca_system_score_codex":0.00017877718,"about_ca_system_score_gemma":0.00066351506,"threshold_uncertainty_score":0.6201734},"labels":[],"label_agreement":null},{"id":"W4399882982","doi":"10.21203/rs.3.rs-4470765/v1","title":"Quality of Life in High-Risk Myeloma Patients Treated with Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Quality of life (healthcare); Multiple myeloma; Internal medicine; Transplantation; Bortezomib; Hematopoietic stem cell transplantation; Psychological intervention; Neuropsychology; Oncology; Graft-versus-host disease; Physical therapy; Cognition; Psychiatry","score_opus":0.0328742678098364,"score_gpt":0.3517492612738257,"score_spread":0.31887499346398934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399882982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988324,0.0018931326,0.000036780017,0.00028074716,0.000053879445,0.0040035,0.002874322,0.00007799532,0.00089638506],"genre_scores_gemma":[0.9911319,0.0026691568,0.00029169797,0.000013477283,0.000040763116,0.0007711617,0.003983657,0.00011182106,0.0009863636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927961,0.0012553544,0.0010193399,0.0011868054,0.0026311595,0.001111197],"domain_scores_gemma":[0.9965384,0.00056772627,0.0002746162,0.0010065223,0.00096561987,0.000647122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015765094,0.0005163556,0.0012448179,0.0008843767,0.00010147195,0.00006848872,0.00035492226,0.00048466583,0.0001269345],"category_scores_gemma":[0.00052564166,0.0003793768,0.000281802,0.0009621892,0.0002544311,0.000057281533,0.00033095246,0.002149552,0.00009153945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007053064,0.0019715754,0.9713464,0.013421007,0.0004665004,0.0005922383,0.00057484856,0.000035138775,0.0012067438,0.000033147764,0.0015340744,0.0017652768],"study_design_scores_gemma":[0.012913822,0.0018786949,0.973418,0.0035852655,0.0001492427,0.0000044020085,0.00026579064,0.0001511409,0.006883981,0.00033974068,0.000042886866,0.00036705952],"about_ca_topic_score_codex":0.011820055,"about_ca_topic_score_gemma":0.0014226016,"teacher_disagreement_score":0.010397453,"about_ca_system_score_codex":0.0006690199,"about_ca_system_score_gemma":0.0011354351,"threshold_uncertainty_score":0.99986583},"labels":[],"label_agreement":null},{"id":"W4399940368","doi":"10.1038/s41598-024-65590-4","title":"Multiple myeloma incidence and mortality trends in the United States, 1999–2020","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Demography; Pacific islanders; Medicine; Incidence (geometry); Population; Epidemiology; Mortality rate; American Community Survey; Ethnic group; Census; Internal medicine; Environmental health","score_opus":0.038789230362160185,"score_gpt":0.3453120540072073,"score_spread":0.3065228236450471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399940368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958626,0.0011940686,0.000015153559,0.0009047993,0.0008651231,0.00034550796,0.000012995201,0.00007348826,0.0007262366],"genre_scores_gemma":[0.99610245,0.000053916563,0.000112367634,0.000075181575,0.0000493809,0.000049444436,0.0007373401,0.0000121733765,0.0028077306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976931,0.00009669226,0.0003675318,0.0006884591,0.000790561,0.00036363062],"domain_scores_gemma":[0.9988281,0.00014009404,0.00005179482,0.0007155289,0.00007337798,0.00019108644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017418741,0.00014196143,0.00018231386,0.00048372938,0.00017292984,0.0003644898,0.00008788656,0.000048987316,0.00013801224],"category_scores_gemma":[0.0002969113,0.0000857388,0.00006705166,0.002009673,0.0003189308,0.0001428602,0.000076711454,0.0002309255,0.000023084332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057936093,0.00023863693,0.88916945,0.00017061584,0.00010629803,0.045687515,0.0027410835,0.000020971205,0.002070311,0.000053728585,0.023461878,0.036221582],"study_design_scores_gemma":[0.0004875936,0.00009657692,0.9158194,0.00017401722,0.000055772547,0.0020089785,0.0003817703,0.01428538,0.0009602635,0.0015608639,0.06403427,0.00013513198],"about_ca_topic_score_codex":0.0021038728,"about_ca_topic_score_gemma":0.0009919824,"teacher_disagreement_score":0.043678537,"about_ca_system_score_codex":0.0000754953,"about_ca_system_score_gemma":0.00013130666,"threshold_uncertainty_score":0.35147837},"labels":[],"label_agreement":null},{"id":"W4400094382","doi":"10.1038/s41572-024-00529-7","title":"Multiple myeloma","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Disease Primers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":257,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.064750900655604,"score_gpt":0.4241585985592794,"score_spread":0.3594076979036754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400094382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.153219e-7,0.98965096,0.000002510949,0.00015534763,0.00062619906,0.007011816,0.00040749495,0.00022696276,0.0019180956],"genre_scores_gemma":[0.000007381706,0.9894373,0.00071356806,0.000267509,0.00071719143,0.0013168977,0.0025026877,0.00022761807,0.004809889],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956021,0.00039503365,0.0010640634,0.0012916707,0.0008425937,0.0008045757],"domain_scores_gemma":[0.9961327,0.00019657174,0.00030735126,0.0014845011,0.00010419448,0.0017747079],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042914724,0.0011425208,0.0040167463,0.0005810638,0.00010281636,0.000092637434,0.00041272974,0.00089106394,0.00044500793],"category_scores_gemma":[0.0014997231,0.00067067926,0.003552802,0.0010417633,0.00011938849,0.00008545062,0.00024454747,0.0029384042,0.008713472],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058161186,0.00018727111,0.00002834329,0.13999717,0.0010268656,0.001258461,0.0000042118627,3.822915e-9,1.415302e-7,0.000045794535,0.02933089,0.8280627],"study_design_scores_gemma":[0.0005249284,0.00005303903,0.000056369154,0.07396978,0.014484365,0.000091408256,0.0000011718038,0.000006782236,3.298049e-7,0.000013751649,0.91033256,0.00046548332],"about_ca_topic_score_codex":0.0000053539206,"about_ca_topic_score_gemma":0.0000021118656,"teacher_disagreement_score":0.8810017,"about_ca_system_score_codex":0.0006123671,"about_ca_system_score_gemma":0.001639051,"threshold_uncertainty_score":0.9995744},"labels":[],"label_agreement":null},{"id":"W4400103959","doi":"10.14740/jh1256","title":"Steady-State Versus Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma: A Single-Center Study to Analyze Efficacy and Safety","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Mobilization; Chemotherapy; Single Center; Oncology; Stem cell; Internal medicine; Cancer research; Biology","score_opus":0.03572092129485953,"score_gpt":0.3242911383531945,"score_spread":0.28857021705833497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400103959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677444,0.00075631856,0.00056823343,0.00077283115,0.0001766617,0.0008381165,0.0000069031107,0.000017514665,0.00008896383],"genre_scores_gemma":[0.9991874,0.000036232523,0.00055008027,0.000072672934,0.000032184453,0.000009922284,0.0000049714185,0.000025116067,0.000081426864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985051,0.0001561388,0.0005451139,0.00022963963,0.00028773758,0.0002762449],"domain_scores_gemma":[0.9989097,0.00047491494,0.00010352319,0.00015639403,0.000122011625,0.00023347311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003411805,0.00015705187,0.00050714856,0.0005537923,0.000035149485,0.00003217781,0.00007317286,0.000051353687,0.00003908238],"category_scores_gemma":[0.00007930786,0.00011649306,0.00007777646,0.00035470314,0.000038033057,0.000074784715,0.00002964486,0.00023465445,0.000017435477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045879982,0.012996378,0.87042135,0.00076337165,0.00096631335,0.01015305,0.0062770867,0.00046413695,0.007917962,0.000017678864,0.0004994271,0.04364324],"study_design_scores_gemma":[0.33414078,0.049512897,0.5303133,0.0027366572,0.0007452439,0.0036045944,0.009375585,0.028851511,0.033404067,0.00004259024,0.0063299104,0.0009428339],"about_ca_topic_score_codex":0.0000143594725,"about_ca_topic_score_gemma":0.00013238579,"teacher_disagreement_score":0.34010804,"about_ca_system_score_codex":0.0001978572,"about_ca_system_score_gemma":0.00015210333,"threshold_uncertainty_score":0.47504488},"labels":[],"label_agreement":null},{"id":"W4400103971","doi":"10.14740/jh1248","title":"Non-Secretory Multiple Myeloma Associated With High-Risk Phenotype and Complex Cytogenetics Including t(8;22)","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Allegheny Health Network","keywords":"Multiple myeloma; Cytogenetics; Plasma cell dyscrasia; Chromosomal translocation; Dyscrasia; Medicine; Phenotype; Pathology; Gastroenterology; Internal medicine; Oncology; Immunology; Chromosome; Immunoglobulin light chain; Gene; Plasma cell; Biology; Genetics; Antibody","score_opus":0.04093604836193709,"score_gpt":0.31704681664960715,"score_spread":0.27611076828767006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400103971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962332,0.0021213263,0.0005803049,0.00044467935,0.0001748475,0.00019228368,0.000015817044,0.000026311709,0.00021118484],"genre_scores_gemma":[0.9956012,0.00028569094,0.003778655,0.000056413755,0.00012014755,0.00000406421,0.000016721502,0.00003384342,0.00010329577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986256,0.00009750306,0.00040480978,0.00018479022,0.00035727522,0.00033007382],"domain_scores_gemma":[0.99857545,0.0005593356,0.00021498927,0.00013790766,0.00023436038,0.00027796865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032289274,0.00017324656,0.0005953404,0.00028478156,0.000108586595,0.000031709256,0.000082555016,0.00012555458,0.000110058165],"category_scores_gemma":[0.00042366883,0.00011557114,0.00008560534,0.00019649422,0.0001543486,0.000072908355,0.00006404438,0.00045422744,0.000018353496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010274611,0.00019721127,0.98101133,0.00021582589,0.0015220295,0.006176034,0.00029566765,0.00000940525,0.003953511,0.00020769837,0.0013149264,0.004068869],"study_design_scores_gemma":[0.00688581,0.002647397,0.97294337,0.0007324374,0.00052386057,0.0069158715,0.00015543797,0.0046438067,0.0029871988,0.0003916602,0.000996388,0.00017677067],"about_ca_topic_score_codex":0.000037610065,"about_ca_topic_score_gemma":0.00005167206,"teacher_disagreement_score":0.008067999,"about_ca_system_score_codex":0.00012494842,"about_ca_system_score_gemma":0.00023158589,"threshold_uncertainty_score":0.47128546},"labels":[],"label_agreement":null},{"id":"W4400259216","doi":"10.1038/s41375-024-02306-7","title":"Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100","year":2024,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Proteinuria; Multiple myeloma; Asymptomatic; Immunoglobulin light chain; Medicine; Internal medicine; Monoclonal; Oncology; Immunology; Monoclonal antibody; Antibody; Kidney","score_opus":0.011684794658361837,"score_gpt":0.27594138818056174,"score_spread":0.2642565935221999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400259216","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4013916,0.054438643,0.0013198706,0.010202954,0.10848762,0.08060063,0.0027088746,0.0065694107,0.3342804],"genre_scores_gemma":[0.1952702,0.0009089788,0.004756168,0.00014740111,0.0072642495,0.008318246,0.004384335,0.00062334037,0.7783271],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950846,0.000283411,0.0007660465,0.001230796,0.0016632153,0.00097194046],"domain_scores_gemma":[0.99739933,0.00019411976,0.00037053225,0.0012716929,0.00020764997,0.0005566583],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00040885198,0.0008589092,0.0011133349,0.000778256,0.00020075189,0.00017259442,0.00039416715,0.0009941661,0.00026460877],"category_scores_gemma":[0.0009908357,0.0005927012,0.00023999858,0.00094093214,0.00015053467,0.00017529217,0.00025777504,0.0034243865,0.0004046572],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026227538,0.00049707585,0.027151696,0.0023567993,0.00095928623,0.005370275,0.00092175335,0.000032168526,0.00012255741,0.000008088566,0.9259337,0.034023844],"study_design_scores_gemma":[0.038925752,0.0093027875,0.23032935,0.055271596,0.0016216128,0.0018264333,0.0003611762,0.31618485,0.004101199,0.0004119527,0.33932132,0.0023420006],"about_ca_topic_score_codex":0.0010518989,"about_ca_topic_score_gemma":0.0028111718,"teacher_disagreement_score":0.5866124,"about_ca_system_score_codex":0.0029300004,"about_ca_system_score_gemma":0.0039400877,"threshold_uncertainty_score":0.99965245},"labels":[],"label_agreement":null},{"id":"W4400345395","doi":"10.1016/j.jtct.2024.06.030","title":"Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Memorial University of Newfoundland; University of Alberta; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation; Juravinski Cancer Centre; Institute of Cancer Research; Saint John Regional Hospital; BC Cancer Agency; University of Calgary; Princess Margaret Cancer Centre; University of British Columbia; Alberta Cancer Foundation; McGill University","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Internal medicine; Oncology; Bortezomib; Regimen; Maintenance therapy; Cyclophosphamide; Cohort; Surgery; Chemotherapy","score_opus":0.03335916754604702,"score_gpt":0.2918436707820194,"score_spread":0.2584845032359724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400345395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908985,0.0008234343,0.00011593502,0.003001268,0.00018332253,0.0015447121,0.0040673367,0.000059100974,0.0011150534],"genre_scores_gemma":[0.9681422,0.024823356,0.00013737947,0.00033771293,0.000120986784,0.00013856556,0.0056992653,0.000038915103,0.0005616357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966589,0.00068764226,0.0004773406,0.00064589485,0.00088983536,0.000640347],"domain_scores_gemma":[0.9980509,0.0010540861,0.000065258406,0.00046137086,0.00011675701,0.00025157796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013902003,0.0002830608,0.00026999685,0.0003493622,0.0006220265,0.00022427397,0.00026798103,0.0001361322,0.000054959964],"category_scores_gemma":[0.000010634964,0.0001478386,0.000084966,0.0006122147,0.00019058431,0.00019200683,0.000007400393,0.0008167627,0.000042477095],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025028603,0.0011805466,0.3448961,0.000934967,0.00084429374,0.011114915,0.07673422,0.000044466924,0.019487917,0.008116768,0.0011606285,0.51045656],"study_design_scores_gemma":[0.00896657,0.00042334225,0.97246206,0.00038739742,0.00012513115,0.000019307627,0.00074391847,0.0007010739,0.013913974,0.0004299261,0.0016036842,0.00022363343],"about_ca_topic_score_codex":0.30135328,"about_ca_topic_score_gemma":0.65967524,"teacher_disagreement_score":0.6275659,"about_ca_system_score_codex":0.00020316405,"about_ca_system_score_gemma":0.00022448102,"threshold_uncertainty_score":0.70329905},"labels":[],"label_agreement":null},{"id":"W4400643471","doi":"10.1016/j.clml.2024.07.007","title":"Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; St. Michael's Hospital; Seven Oaks General Hospital; University of Manitoba; Ottawa Hospital; McMaster University; St. Boniface Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Government of Ontario; Amgen","keywords":"Pomalidomide; Medicine; Internal medicine; Kidney disease; Cohort; Renal function; Multiple myeloma; Population; Oncology; Lenalidomide; Environmental health","score_opus":0.023755765837815017,"score_gpt":0.32616980036152243,"score_spread":0.3024140345237074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400643471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942223,0.00031638265,0.000008784987,0.0005197609,0.00030455535,0.0038861972,0.0003653293,0.00028413054,0.000092555965],"genre_scores_gemma":[0.9956552,0.00015890377,0.0004680393,0.0007123951,0.00018553488,0.0003899313,0.0012248254,0.00015438219,0.0010508205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943966,0.0005442463,0.0013956694,0.0016704636,0.0010994066,0.0008935991],"domain_scores_gemma":[0.99333876,0.0024191812,0.00021557735,0.0010825485,0.00020381853,0.002740095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079414254,0.00071443233,0.0013907126,0.000656834,0.00022692133,0.00028655078,0.00019844729,0.00026532647,0.00010489705],"category_scores_gemma":[0.0043902206,0.0005305845,0.0002479761,0.0006861728,0.00039456272,0.0005615963,0.00020948942,0.00053512206,0.00005100926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056516505,0.0019041761,0.9464383,0.00035544994,0.0007887862,0.0016095478,0.000049213177,0.0000050065205,0.000006656083,0.000028896968,0.000561141,0.042601183],"study_design_scores_gemma":[0.034436066,0.0020240308,0.9557923,0.00097572635,0.0005328954,0.000006974128,0.000014557777,0.0044681886,0.000005616137,0.000021456994,0.0012010472,0.0005211183],"about_ca_topic_score_codex":0.003351737,"about_ca_topic_score_gemma":0.0013261539,"teacher_disagreement_score":0.042080063,"about_ca_system_score_codex":0.002425383,"about_ca_system_score_gemma":0.0032792462,"threshold_uncertainty_score":0.99971455},"labels":[],"label_agreement":null},{"id":"W4400658880","doi":"10.1186/s40814-024-01524-1","title":"A multidisciplinary group-based survivorship intervention for those living with multiple myeloma: a feasibility study","year":2024,"lang":"en","type":"article","venue":"Pilot and Feasibility Studies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Survivorship curve; Medicine; Intervention (counseling); Psychological intervention; Multiple myeloma; Quality of life (healthcare); Multidisciplinary approach; Cancer survivorship; Physical therapy; Randomized controlled trial; Qualitative research; Family medicine; Gerontology; Cancer; Nursing; Surgery; Internal medicine","score_opus":0.24901031874075633,"score_gpt":0.4408235075671122,"score_spread":0.19181318882635587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400658880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857185,0.005686277,0.0009669392,0.00029258188,0.00012042395,0.006710606,0.000058181107,0.00030297294,0.00014355803],"genre_scores_gemma":[0.99615747,0.000042118238,0.0017796919,0.000012249463,0.000089325426,0.0010969739,0.0000278478,0.00006113857,0.0007331889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760914,0.00025872258,0.0003798,0.0009539388,0.00035252544,0.00044587775],"domain_scores_gemma":[0.99747163,0.001565812,0.00005834434,0.00047053245,0.000209643,0.00022403062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014415948,0.00034797005,0.0005999811,0.0001858551,0.00031513508,0.000077836514,0.00007691113,0.000047094123,0.000022987704],"category_scores_gemma":[0.0013510444,0.00022765614,0.0001725257,0.00028728336,0.00029541488,0.00014732526,0.00017401845,0.00019364235,0.000010225597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046026343,0.0065636546,0.97606176,0.0024363708,0.0009070684,0.00007730198,0.0021051052,7.5050787e-7,0.00018422666,0.000022949976,0.00004969512,0.006988485],"study_design_scores_gemma":[0.009030154,0.012217842,0.9672618,0.0010419644,0.00030305347,0.000010980716,0.00633205,0.0033030624,0.000067904744,0.0001902759,0.00001985719,0.00022104019],"about_ca_topic_score_codex":0.00037446615,"about_ca_topic_score_gemma":0.009159064,"teacher_disagreement_score":0.010439006,"about_ca_system_score_codex":0.00024232343,"about_ca_system_score_gemma":0.000062480234,"threshold_uncertainty_score":0.9283548},"labels":[],"label_agreement":null},{"id":"W4400898001","doi":"10.46989/001c.121371","title":"The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge","year":2024,"lang":"en","type":"article","venue":"Clinical Hematology International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Longitudinal study; Cohort; Medical record; Longitudinal data; Intensive care medicine; Internal medicine; Demography; Pathology","score_opus":0.20297133141172918,"score_gpt":0.5076096884930626,"score_spread":0.30463835708133347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400898001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96600825,0.00057303335,0.00019175312,0.027896779,0.0011341462,0.0018088928,0.00009363656,0.00012879372,0.0021647222],"genre_scores_gemma":[0.98791623,0.00091863674,0.0010310435,0.00052803796,0.00012571935,0.00029799974,0.0002184108,0.000025719175,0.008938222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761283,0.00014293328,0.0006495041,0.00076347525,0.000508446,0.0003227889],"domain_scores_gemma":[0.9969618,0.0017220449,0.000060977636,0.0008722128,0.00011905658,0.0002639549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092202844,0.00019366869,0.00042217117,0.00019869926,0.00020070789,0.00010347787,0.0005277153,0.000056505218,0.0001713256],"category_scores_gemma":[0.0006169674,0.00012078507,0.00011457349,0.00021714861,0.00032793434,0.00010242508,0.00076090376,0.00032729647,0.00031615733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033372923,0.00071789505,0.9615046,0.00002363458,0.0035428947,0.00094785035,0.000048432823,4.2073003e-7,0.0000010250736,0.010712971,0.007341484,0.014825083],"study_design_scores_gemma":[0.0013978501,0.00027740223,0.97341686,0.00006144665,0.00027260403,0.0001104797,0.0002783365,0.0022986524,0.0000027366882,0.0004575182,0.021326527,0.000099574245],"about_ca_topic_score_codex":0.00021431249,"about_ca_topic_score_gemma":0.0013990836,"teacher_disagreement_score":0.027368741,"about_ca_system_score_codex":0.00007432261,"about_ca_system_score_gemma":0.00006509947,"threshold_uncertainty_score":0.49254724},"labels":[],"label_agreement":null},{"id":"W4400982166","doi":"10.1002/hem3.136","title":"Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Pfizer","keywords":"Multiple myeloma; Term (time); Refractory (planetary science); Medicine; Oncology; Internal medicine; Biology; Physics","score_opus":0.016703976176522393,"score_gpt":0.27470621404530243,"score_spread":0.25800223786878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400982166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584854,0.0017411968,0.000014688821,0.00019117654,0.00009945828,0.0015143016,0.00018094503,0.00004132011,0.00036835024],"genre_scores_gemma":[0.9986615,0.00014826829,0.00024621887,0.000023788512,0.000044938737,0.000046678808,0.00019352172,0.00004016571,0.00059491146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998279,0.00015079348,0.0003200021,0.000417925,0.00054297823,0.00028935514],"domain_scores_gemma":[0.99875635,0.0005034528,0.000052239648,0.00047316318,0.00007299529,0.00014178985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018788606,0.00021290111,0.0003832835,0.000049259175,0.00006320614,0.00003125143,0.00011424381,0.00007267409,0.0008802231],"category_scores_gemma":[0.00013832418,0.00011045395,0.000042978547,0.00027638255,0.000110301626,0.00012268854,0.00009910022,0.00030878687,0.000033953656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081788385,0.0011022183,0.9503298,0.00013270634,0.00034482486,0.0007379151,0.00062982825,6.3070945e-7,0.000032386,0.0000073130036,0.00017349275,0.038330045],"study_design_scores_gemma":[0.017042112,0.0016952277,0.9794263,0.00043548347,0.00011764493,0.000004011418,0.00063971773,0.00007843113,0.000053067502,0.0000062799927,0.0003865188,0.00011516371],"about_ca_topic_score_codex":0.00082957785,"about_ca_topic_score_gemma":0.004976191,"teacher_disagreement_score":0.03821488,"about_ca_system_score_codex":0.00008090527,"about_ca_system_score_gemma":0.00013026601,"threshold_uncertainty_score":0.9637826},"labels":[],"label_agreement":null},{"id":"W4401163065","doi":"10.1056/nejme2406799","title":"A Belantamab Mafodotin Revival in Multiple Myeloma Therapy","year":2024,"lang":"en","type":"editorial","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.0333031131878232,"score_gpt":0.33848832633772147,"score_spread":0.30518521314989827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401163065","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042360198,0.072604425,0.00003741168,0.01166977,0.86932355,0.001237712,0.0001027232,0.000060143822,0.0026040736],"genre_scores_gemma":[0.03621212,0.02476104,0.00040236604,0.0001304454,0.93274975,0.000009412978,0.00025100983,0.00011734773,0.005366491],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994813,0.0002674622,0.0013615242,0.00042062034,0.0025442885,0.000593078],"domain_scores_gemma":[0.99568725,0.0020561414,0.0005055416,0.00041012827,0.00050431554,0.000836653],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020387433,0.00054155505,0.0019119746,0.0011453041,0.00004471233,0.000034230514,0.00034428635,0.00057824096,0.000565463],"category_scores_gemma":[0.0052214446,0.00031683577,0.000313141,0.00047732762,0.00015840179,0.00009079589,0.000065199834,0.0032621592,0.00007555498],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076837605,0.00019644012,0.0028539312,0.00037129392,0.0006248396,0.01291057,0.00052908197,0.0000010080797,0.00037352627,0.0000035860955,0.7823875,0.19206445],"study_design_scores_gemma":[0.13602346,0.0047042677,0.0022922019,0.007070372,0.0003208613,0.0011870236,0.00006576472,0.00003259124,0.00009572921,0.00018081692,0.8478305,0.0001964313],"about_ca_topic_score_codex":0.00069057435,"about_ca_topic_score_gemma":0.00025521492,"teacher_disagreement_score":0.19186802,"about_ca_system_score_codex":0.00039795708,"about_ca_system_score_gemma":0.0018170727,"threshold_uncertainty_score":0.99992836},"labels":[],"label_agreement":null},{"id":"W4401327466","doi":"10.1200/jco.2024.42.16_suppl.7540","title":"Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Biotech","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology","score_opus":0.09953379128334754,"score_gpt":0.45577106812228896,"score_spread":0.3562372768389414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401327466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467546,0.00084962766,0.000047344947,0.001418279,0.0018228051,0.00083150563,0.00005255365,0.000011160206,0.00029125073],"genre_scores_gemma":[0.9977676,0.0003300343,0.00049740344,0.00021200013,0.0008976225,0.000013362968,0.000034783505,0.000028918921,0.00021825854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995622,0.0006627658,0.002296542,0.00027643424,0.00082763477,0.0003146363],"domain_scores_gemma":[0.99056506,0.0074177403,0.00091471814,0.00035888408,0.0003702144,0.0003733872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002044789,0.00019227217,0.0014081864,0.00018796399,0.000035887315,0.000019747436,0.00026596314,0.00035231348,0.00019548272],"category_scores_gemma":[0.0058575096,0.00009702878,0.00051135314,0.00025495727,0.00031154836,0.0001706397,0.00007067474,0.0015167276,0.00002612371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26898852,0.0067045945,0.50101066,0.000029386334,0.00075450033,0.0016281389,0.00009756653,6.1772437e-7,0.000035467983,0.000004141637,0.0006273751,0.22011906],"study_design_scores_gemma":[0.31747782,0.0359708,0.64201546,0.0004438693,0.00032548435,0.000016776947,0.000031749634,0.000041705254,0.000039373033,0.00003581602,0.0035364297,0.00006473728],"about_ca_topic_score_codex":0.000085684944,"about_ca_topic_score_gemma":0.0003167716,"teacher_disagreement_score":0.22005431,"about_ca_system_score_codex":0.00023428773,"about_ca_system_score_gemma":0.0018233821,"threshold_uncertainty_score":0.7012409},"labels":[],"label_agreement":null},{"id":"W4401352977","doi":"10.3390/curroncol31080331","title":"Monoclonal Gammopathy of Undetermined Significance and Associated Cardiovascular Outcomes in a Hospital Setting—A Fresh Perspective","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Perspective (graphical); Monoclonal gammopathy; Multiple myeloma; Pathology; Internal medicine; Intensive care medicine; Monoclonal; Monoclonal antibody; Immunology; Antibody; Artificial intelligence","score_opus":0.05239628993256391,"score_gpt":0.3930421367737118,"score_spread":0.3406458468411479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401352977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832683,0.014206336,0.00002933689,0.000897286,0.0003555529,0.0006151999,0.00007963488,0.00003879909,0.0005095206],"genre_scores_gemma":[0.9991674,0.0004157286,0.00014027183,0.0000076034466,0.00005989313,0.00009139454,0.000030720257,0.000014450538,0.00007256416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987209,0.0001388647,0.00023069202,0.00035159633,0.000273678,0.0002843042],"domain_scores_gemma":[0.9992683,0.00028794113,0.000041535226,0.00016126987,0.00011958717,0.00012138965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002973904,0.0001410302,0.0005684767,0.0001993775,0.00002229172,0.000010614998,0.00005465924,0.000092335635,0.000028281602],"category_scores_gemma":[0.0005640893,0.00011299216,0.00020586628,0.00019771759,0.00014312245,0.00004647147,0.000057475554,0.00028362114,0.000008752976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022546241,0.0019880172,0.9160875,0.0002916173,0.0016830685,0.001505433,0.0026664366,0.0000031597917,0.00039455903,0.0003179494,0.0004903061,0.074346505],"study_design_scores_gemma":[0.005966568,0.0022890233,0.9830363,0.00032275115,0.0003149196,0.000038606122,0.0011856672,0.002360825,0.0004041229,0.00049898296,0.0034017803,0.00018047386],"about_ca_topic_score_codex":0.00020132406,"about_ca_topic_score_gemma":0.000089784895,"teacher_disagreement_score":0.07416604,"about_ca_system_score_codex":0.00064145395,"about_ca_system_score_gemma":0.0003330149,"threshold_uncertainty_score":0.46076867},"labels":[],"label_agreement":null},{"id":"W4401433011","doi":"10.1016/j.clml.2024.07.014","title":"Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Surrey Place Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"EMD Serono; Pharmacyclics; Genentech; Incyte; bluebird bio; Celgene; Teva Pharmaceutical Industries; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Pomalidomide; Lenalidomide; Medicine; Daratumumab; Internal medicine; Dexamethasone; Multiple myeloma; Cohort; Clinical endpoint; Adverse effect; Oncology; Refractory (planetary science); Discontinuation; Surgery; Clinical trial","score_opus":0.0919602946311303,"score_gpt":0.3804131323060837,"score_spread":0.2884528376749534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401433011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603565,0.003461683,0.00010975771,0.0010012054,0.002365324,0.0013947122,0.0003406185,0.00063079165,0.004660274],"genre_scores_gemma":[0.9837461,0.0008782845,0.0038092101,0.0006535429,0.0019521574,0.00022153133,0.00072946533,0.0002439723,0.0077657164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99072117,0.0010947256,0.0025748212,0.0023280154,0.0015639726,0.0017173113],"domain_scores_gemma":[0.98726064,0.009025374,0.00029710575,0.0017288345,0.000250022,0.001438049],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002001753,0.0010022075,0.0022104252,0.00060465594,0.00024960688,0.00026777972,0.00068614684,0.0011825596,0.0016865218],"category_scores_gemma":[0.0067702946,0.0007823812,0.0010185059,0.0010957472,0.0007056861,0.00042366883,0.00045424106,0.0016213806,0.0026259313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026724543,0.0019510258,0.18438572,0.0003502895,0.0013236639,0.030176822,0.00032228814,0.0000118177095,0.0026309167,0.00034895973,0.008572973,0.743201],"study_design_scores_gemma":[0.031683017,0.001992642,0.90499765,0.0012468009,0.00026824995,0.0002411241,0.00011904799,0.009522045,0.0007608713,0.00058719993,0.047789782,0.00079155405],"about_ca_topic_score_codex":0.0028836858,"about_ca_topic_score_gemma":0.0013240159,"teacher_disagreement_score":0.7424094,"about_ca_system_score_codex":0.0032168273,"about_ca_system_score_gemma":0.003912265,"threshold_uncertainty_score":0.9994627},"labels":[],"label_agreement":null},{"id":"W4401514025","doi":"10.1200/jco.2024.42.23_suppl.174","title":"Autologous bone marrow transplant in standard-risk newly diagnosed multiple myeloma: A systematic review.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Bone marrow transplant; Oncology; Internal medicine; Bone marrow transplantation; Surgery","score_opus":0.07149453237243764,"score_gpt":0.4441682284034876,"score_spread":0.37267369603104994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401514025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81391865,0.1619698,0.000566374,0.017312875,0.0018885066,0.0030318405,0.00011678294,0.00007438926,0.0011207534],"genre_scores_gemma":[0.93946,0.056838725,0.0021590076,0.0008491576,0.00035698697,0.0000510222,0.000009845398,0.000029180484,0.00024611258],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99294245,0.0016063806,0.0039648125,0.0003006546,0.0007471163,0.00043860116],"domain_scores_gemma":[0.98866105,0.00914486,0.0009706584,0.00030245096,0.00028128715,0.0006397178],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00769986,0.00022510026,0.0036283778,0.00032381393,0.00003724078,0.000020678825,0.00019092833,0.00036738967,0.00015625033],"category_scores_gemma":[0.01942521,0.0001352688,0.000896849,0.00033614205,0.00015854137,0.00012384301,0.000032907268,0.0017747544,0.000106551284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023701593,0.005551257,0.25058475,0.2153566,0.004608183,0.31298155,0.00065020245,0.00001921592,0.00014396606,0.00013102719,0.017508991,0.16876267],"study_design_scores_gemma":[0.072172455,0.04703226,0.47906882,0.34962824,0.009229518,0.0160699,0.0002960572,0.005768196,0.00012349749,0.000610921,0.019377489,0.00062267063],"about_ca_topic_score_codex":0.00006813952,"about_ca_topic_score_gemma":0.00032785136,"teacher_disagreement_score":0.29691163,"about_ca_system_score_codex":0.0004021227,"about_ca_system_score_gemma":0.0021431283,"threshold_uncertainty_score":0.98883456},"labels":[],"label_agreement":null},{"id":"W4401520882","doi":"10.1080/03007995.2024.2391112","title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison","year":2024,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Multiple myeloma; Oncology; Surgery","score_opus":0.17942306898730398,"score_gpt":0.4459208483556996,"score_spread":0.26649777936839564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401520882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428655,0.012563553,0.000026508242,0.00013690928,0.00008593297,0.0027415836,0.00008441922,0.000026493251,0.000048063994],"genre_scores_gemma":[0.9907763,0.008327022,0.00014726212,0.0000025481534,0.00006626513,0.0001897406,0.00043502255,0.000026009848,0.000029801009],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99553156,0.00059578544,0.0006701515,0.00048106324,0.002198841,0.0005225886],"domain_scores_gemma":[0.99549216,0.0031042828,0.00016469463,0.00040293537,0.00044131247,0.00039461875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076104316,0.00029499398,0.0009522032,0.00050455955,0.00009189051,0.00002384731,0.00021960524,0.00013314097,0.000074868876],"category_scores_gemma":[0.00049947546,0.00013429199,0.00008998289,0.0011166744,0.0006675346,0.000090260306,0.00005069581,0.0005061351,0.0000032676949],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11390783,0.019563675,0.3019154,0.0017163426,0.0011795688,0.000136247,0.0125085255,0.000007647376,0.00066743005,0.00002043216,0.0002137778,0.5481631],"study_design_scores_gemma":[0.051250536,0.04669496,0.88195825,0.0042510647,0.00008973317,0.0000063183684,0.00095631724,0.0030089354,0.0085664075,0.000005279396,0.0030309018,0.00018127574],"about_ca_topic_score_codex":0.00038947826,"about_ca_topic_score_gemma":0.0003070976,"teacher_disagreement_score":0.58004284,"about_ca_system_score_codex":0.00017864315,"about_ca_system_score_gemma":0.00089838007,"threshold_uncertainty_score":0.54762685},"labels":[],"label_agreement":null},{"id":"W4401525609","doi":"10.1016/j.clml.2024.08.003","title":"Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Global Risk Institute in Financial Services","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Overall survival; Surgery; Gastroenterology","score_opus":0.05868525513036327,"score_gpt":0.36450511369899596,"score_spread":0.3058198585686327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401525609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844219,0.00055729324,0.000015373938,0.00009863053,0.0011889458,0.003452897,0.00020395244,0.0004716748,0.009589344],"genre_scores_gemma":[0.9952196,0.000180256,0.00031532807,0.00012368536,0.0006298066,0.00066276686,0.0010303663,0.00019103102,0.0016471628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99290663,0.001111592,0.0014494035,0.0019764467,0.001162044,0.0013938595],"domain_scores_gemma":[0.9891576,0.007918239,0.00031531378,0.0012855056,0.0003489042,0.00097440445],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063124235,0.0010848928,0.0022450672,0.00071322493,0.00025916306,0.00017072698,0.00039647418,0.0004925983,0.00009855047],"category_scores_gemma":[0.0007103024,0.00080481207,0.00073636585,0.0017139182,0.00069360976,0.0006161081,0.00016514264,0.0007612024,0.0007796866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04701209,0.0043296586,0.5360645,0.00030882598,0.0022015243,0.0017243,0.0002836688,0.000022369177,0.00026053577,0.00017301926,0.0005214654,0.40709803],"study_design_scores_gemma":[0.08631408,0.0093626855,0.888059,0.0011439438,0.00044429462,0.000007295813,0.00007095633,0.0025582984,0.0014494887,0.000030395773,0.009876674,0.0006828383],"about_ca_topic_score_codex":0.0012130341,"about_ca_topic_score_gemma":0.0016436036,"teacher_disagreement_score":0.4064152,"about_ca_system_score_codex":0.0072374986,"about_ca_system_score_gemma":0.0022841492,"threshold_uncertainty_score":0.99999833},"labels":[],"label_agreement":null},{"id":"W4401550727","doi":"10.1080/15321819.2024.2388614","title":"Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Journal of Immunoassay and Immunochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Bortezomib; CD34; Dexamethasone; Medicine; Multiple myeloma; Proteasome inhibitor; Internal medicine; Progenitor cell; Oncology; Population; Flow cytometry; Biomarker; Immunology; Cancer research; Stem cell; Biology","score_opus":0.02183238892424652,"score_gpt":0.32304035158262456,"score_spread":0.301207962658378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401550727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992543,0.006801469,0.000004070147,0.00010339836,0.00006526219,0.00040510207,0.000027082728,0.0000074062364,0.000043207776],"genre_scores_gemma":[0.9983446,0.000962711,0.00050714577,0.0000093027265,0.000069060945,0.000022500511,0.0000047389594,0.00002483748,0.000055079086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838746,0.0001329157,0.0006398408,0.00021572364,0.000335249,0.00028878654],"domain_scores_gemma":[0.99900943,0.00038287687,0.00015488645,0.00018422713,0.00011380726,0.00015479936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008197534,0.00020972422,0.00046314378,0.00034445903,0.000042402095,0.000053715994,0.00009570236,0.00012675536,0.000028546245],"category_scores_gemma":[0.00046657637,0.00014640512,0.00017181542,0.00025343316,0.00006433094,0.00013109967,0.00004930602,0.0004774666,0.0000014475359],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016532311,0.00043474126,0.112970255,0.00013477127,0.0001898783,0.00047986713,0.0008445286,0.000007188937,0.83728534,1.2475219e-7,0.000021851278,0.031099157],"study_design_scores_gemma":[0.004659536,0.0016990782,0.33665842,0.0018973792,0.000013471822,0.0002715119,0.00023644634,0.00013363862,0.65429467,0.0000047737167,0.000040917865,0.00009015797],"about_ca_topic_score_codex":0.000068577865,"about_ca_topic_score_gemma":9.576884e-7,"teacher_disagreement_score":0.22368816,"about_ca_system_score_codex":0.00022819049,"about_ca_system_score_gemma":0.00034484183,"threshold_uncertainty_score":0.5970228},"labels":[],"label_agreement":null},{"id":"W4401610295","doi":"10.1182/blood.2024025269","title":"Role and timing of chromosome deletions in multiple myeloma","year":2024,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; Chromosome abnormality; Genetics; Biology; Lenalidomide; Chromosome; Medicine; Karyotype; Immunology; Gene","score_opus":0.030481328256618447,"score_gpt":0.2861796986766263,"score_spread":0.25569837042000787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401610295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86846703,0.00842268,0.0000025564286,0.11730158,0.00009704244,0.0011906262,0.0003692041,0.00008633113,0.0040629352],"genre_scores_gemma":[0.96921283,0.0004702462,0.001521102,0.022256035,0.0013588946,0.00022375345,0.0010006796,0.00012262759,0.003833818],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869865,0.000037931317,0.00026374325,0.00034557012,0.00031705236,0.00033704846],"domain_scores_gemma":[0.9993888,0.00014728874,0.000048043432,0.0002837753,0.000045071753,0.00008700771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006935955,0.00020186194,0.00043483265,0.00037493484,0.000028197263,0.000017484283,0.00007091623,0.0003321363,0.00011450566],"category_scores_gemma":[0.00011507029,0.00016936842,0.00009735998,0.00018560556,0.000081083555,0.00002973935,0.00008769865,0.00084336416,0.00007732565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036434704,0.00410267,0.33535677,0.01473207,0.005265892,0.05136047,0.001862772,0.0000018066131,0.053751856,0.000030196446,0.49290836,0.0402628],"study_design_scores_gemma":[0.0376479,0.002248697,0.32725927,0.008848954,0.0031750815,0.0028497027,0.00021988917,0.0023990837,0.03110535,0.0006500198,0.58221567,0.0013803575],"about_ca_topic_score_codex":0.00023841439,"about_ca_topic_score_gemma":0.00007136191,"teacher_disagreement_score":0.1007458,"about_ca_system_score_codex":0.000040072817,"about_ca_system_score_gemma":0.00011532211,"threshold_uncertainty_score":0.69066435},"labels":[],"label_agreement":null},{"id":"W4401701543","doi":"10.1002/ajh.27451","title":"Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (<scp>WBMT</scp>)","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McMaster University","funders":"Medac; JCR Pharmaceuticals; National Cancer Institute; Prothena; Hamilton Health Sciences; Celgene; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Medicine; Multiple myeloma; Internal medicine; Cumulative incidence; Transplantation; Lenalidomide; Hematopoietic stem cell transplantation; Clinical endpoint; Oncology; Multivariate analysis; Surgery; Clinical trial","score_opus":0.011718091949148926,"score_gpt":0.28239324345271366,"score_spread":0.27067515150356475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401701543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943803,0.0011087081,0.0027665223,0.00026165607,0.00013851614,0.0011380339,0.00018943343,0.000009817132,0.0000070318274],"genre_scores_gemma":[0.99686176,0.0003784636,0.0025863699,0.00003539568,0.00003121516,0.000055767418,0.000014720603,0.000018897754,0.000017419676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850684,0.00013792352,0.0006812816,0.00019134271,0.00021429991,0.0002682798],"domain_scores_gemma":[0.9968312,0.002290169,0.00047796618,0.0001256374,0.00015225117,0.0001227717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024930053,0.0001755128,0.0008847637,0.00011079067,0.00006616353,0.0000132512705,0.00009411545,0.000052676536,9.332868e-7],"category_scores_gemma":[0.00010205354,0.00011432529,0.000152271,0.00021795544,0.00022400192,0.000054379,0.000011974312,0.00011238934,1.3753638e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013387598,0.0006476363,0.9766855,0.0018925497,0.00092461176,0.00043124423,0.0035555044,0.000017579297,0.00057697046,0.00014260675,0.0000596971,0.013727323],"study_design_scores_gemma":[0.011436496,0.005490214,0.96962154,0.00042571002,0.0022514747,0.0036178892,0.0034038462,0.0006528302,0.002827836,0.00017340906,0.000025868654,0.00007290673],"about_ca_topic_score_codex":0.00005095119,"about_ca_topic_score_gemma":0.00012148137,"teacher_disagreement_score":0.013654416,"about_ca_system_score_codex":0.000021253421,"about_ca_system_score_gemma":0.000121106175,"threshold_uncertainty_score":0.466205},"labels":[],"label_agreement":null},{"id":"W4401702221","doi":"10.1038/s41588-024-01853-0","title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","year":2024,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Alberta Cancer Foundation; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"Principia Biopharma; Legend Biotech; Pharmacyclics; Kite Pharma; Genentech; EMD Serono; MorphoSys; Seagen; BeiGene; SkylineDx; Moderna; Pfizer; Incyte; Astex Pharmaceuticals; Baxalta; TG Therapeutics; Daewoong Pharmaceutical Company; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; CSL Behring; Swedish Orphan Biovitrum; Novo Nordisk; Teva Pharmaceutical Industries; Array BioPharma; National Cancer Institute; Gilead Sciences; Sanofi; Amgen; Vifor Pharma; Multiple Myeloma Research Foundation","keywords":"Biology; Multiple myeloma; Gene expression profiling; Computational biology; Profiling (computer programming); Expression (computer science); Genetics; Gene expression; Gene; Immunology; Computer science","score_opus":0.017007049811199958,"score_gpt":0.3285415472476464,"score_spread":0.31153449743644646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401702221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761217,0.022541067,0.000109898734,0.00014991497,0.00021236685,0.00039273585,0.000040581945,0.000051928215,0.00037979934],"genre_scores_gemma":[0.98529077,0.00064350147,0.013530044,0.000054984775,0.000074733805,0.000015345344,0.00008167687,0.000028655555,0.00028031727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890965,0.00003818285,0.0001827401,0.00029592754,0.00036798674,0.00020550397],"domain_scores_gemma":[0.99927485,0.00012167367,0.000032313084,0.00024163071,0.00020605394,0.00012347274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056063123,0.00014807105,0.00022925303,0.00009036782,0.000042348045,0.000031657237,0.000059617556,0.00023013719,0.0000395449],"category_scores_gemma":[0.00011246508,0.000112790534,0.00006747633,0.00016744471,0.00008780498,0.000032390264,0.00008689319,0.00036219644,0.000020179545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030168993,0.00006787705,0.13675265,0.00092095725,0.00018259243,0.00039282086,0.000150513,0.0000072017233,0.8546999,0.000060273,0.0005130525,0.0059504556],"study_design_scores_gemma":[0.0010611479,0.000095994765,0.07997501,0.0003412354,0.000071777016,0.0000615872,0.00006328243,0.0013573322,0.9140811,0.00016699423,0.002629117,0.00009542859],"about_ca_topic_score_codex":0.0000073841097,"about_ca_topic_score_gemma":0.0000025361173,"teacher_disagreement_score":0.059381172,"about_ca_system_score_codex":0.000024559722,"about_ca_system_score_gemma":0.00006578458,"threshold_uncertainty_score":0.45994642},"labels":[],"label_agreement":null},{"id":"W4401749349","doi":"10.1182/blood.2023023616","title":"Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Multiple myeloma; Febrile neutropenia; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Anemia; Toxicity; Oncology; Surgery; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.00809974756133244,"score_gpt":0.24497383491490463,"score_spread":0.23687408735357218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401749349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949444,0.003909386,0.0000055939936,0.00007424271,0.000028258442,0.00062069285,0.00004223705,0.00004510658,0.00033009142],"genre_scores_gemma":[0.99869746,0.00015395548,0.00085156935,0.000017512893,0.0000336737,0.000041957093,0.00005567309,0.000031636842,0.00011655726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886405,0.000047222286,0.00023935827,0.00028332314,0.0003047044,0.00026130857],"domain_scores_gemma":[0.9993931,0.00021004787,0.00003458535,0.00019116503,0.000059486156,0.000111583395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012271601,0.00015519801,0.00025489263,0.00016875353,0.000032079886,0.000019827481,0.000042724067,0.000066114946,0.00006935282],"category_scores_gemma":[0.00013348952,0.0001033714,0.00003974093,0.00019182875,0.000090542366,0.00009679887,0.000041480722,0.0002012225,0.000011711454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004462829,0.0015288604,0.97114104,0.00027591517,0.00032926325,0.00023614803,0.0008049144,3.966404e-7,0.0007319778,0.000007689204,0.000015794722,0.020465184],"study_design_scores_gemma":[0.021962957,0.00092564255,0.97433674,0.0005735082,0.00008377354,0.000004656575,0.00006803353,0.00003333114,0.0010257511,0.0000066297694,0.0008790258,0.00009994874],"about_ca_topic_score_codex":0.00005572859,"about_ca_topic_score_gemma":0.000028550645,"teacher_disagreement_score":0.020365234,"about_ca_system_score_codex":0.000034125427,"about_ca_system_score_gemma":0.00006304639,"threshold_uncertainty_score":0.42153633},"labels":[],"label_agreement":null},{"id":"W4401770046","doi":"10.3324/haematol.2024.285768","title":"Comparing the clinical trial efficacy &lt;i&gt;versus&lt;/i&gt; real-world effectiveness of treatments for multiple myeloma: a population-based study","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta; McMaster University; University of Toronto; Sunnybrook Health Science Centre; Eli Lilly (Canada); BC Cancer Agency; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Medicine; Clinical trial; Population; Oncology; World population; Internal medicine; Environmental health","score_opus":0.1593452859384943,"score_gpt":0.4341329201977882,"score_spread":0.27478763425929387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401770046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98828566,0.00031963346,0.00015497662,0.00012820229,0.0006384709,0.009375618,0.000058022655,0.00021411998,0.0008253042],"genre_scores_gemma":[0.99723876,0.000020045285,0.00061424525,0.000010356092,0.00015685227,0.0013968906,0.00032465282,0.000045004534,0.0001931802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996289,0.0009894191,0.0009015405,0.0007288491,0.00058175763,0.0005094254],"domain_scores_gemma":[0.98630613,0.012435497,0.00018728517,0.00069290696,0.00015101706,0.00022713386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015084064,0.0003579529,0.0012855687,0.00024531316,0.00027342862,0.0000581286,0.0002455977,0.00014585216,0.00005247073],"category_scores_gemma":[0.0018905138,0.00020595013,0.0006078653,0.0005102338,0.00014672441,0.000064687345,0.00009479378,0.00023417278,0.000048652026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24015258,0.00929944,0.73695374,0.0006271754,0.0032106566,0.0007103721,0.00014071683,0.00007332429,0.00037775934,0.0015976036,0.0002467401,0.0066099046],"study_design_scores_gemma":[0.14927909,0.006464555,0.83541334,0.00033843715,0.0009919256,0.000009975921,0.00003189729,0.006507274,0.00029135955,0.00007046665,0.00043192226,0.00016976782],"about_ca_topic_score_codex":0.00018477488,"about_ca_topic_score_gemma":0.0006979421,"teacher_disagreement_score":0.0984596,"about_ca_system_score_codex":0.00021589713,"about_ca_system_score_gemma":0.00022688443,"threshold_uncertainty_score":0.83984023},"labels":[],"label_agreement":null},{"id":"W4401875426","doi":"10.1016/s2152-2650(24)01697-5","title":"MM-520 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Refractory (planetary science)","score_opus":0.047108712013716955,"score_gpt":0.33103404425382993,"score_spread":0.28392533224011296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881013,0.0021866695,0.000032075277,0.0011202303,0.0013979968,0.004463019,0.0011990753,0.0004016748,0.0010979439],"genre_scores_gemma":[0.99043554,0.00088736304,0.0018614166,0.00088927697,0.0016813362,0.00042248482,0.0014261025,0.00027283,0.0021236702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98926836,0.0012541028,0.0031141134,0.0027197201,0.0019130643,0.0017306526],"domain_scores_gemma":[0.9813689,0.0138865765,0.00058870047,0.002287719,0.000385673,0.0014824063],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024143558,0.001212867,0.0023618694,0.00041417227,0.00042785448,0.00037115024,0.0008169337,0.0010899771,0.00020214134],"category_scores_gemma":[0.009956139,0.0007263069,0.00064693054,0.0012553129,0.0012670122,0.0005890659,0.0005866654,0.0017173991,0.0004016781],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38423082,0.0029405246,0.1422918,0.00013530512,0.001606265,0.0039544576,0.00070026855,0.0000074926975,0.00004439372,0.000034515197,0.008309819,0.45574433],"study_design_scores_gemma":[0.32423002,0.0041254247,0.64956343,0.0008728502,0.00047977705,0.00005051685,0.00017716021,0.0027283435,0.00011336301,0.00007296554,0.016959857,0.00062632485],"about_ca_topic_score_codex":0.0038957985,"about_ca_topic_score_gemma":0.002619043,"teacher_disagreement_score":0.5072716,"about_ca_system_score_codex":0.0027725757,"about_ca_system_score_gemma":0.004629256,"threshold_uncertainty_score":0.9995188},"labels":[],"label_agreement":null},{"id":"W4401875916","doi":"10.1016/s2152-2650(24)01666-5","title":"MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Term (time); Nuclear medicine","score_opus":0.038792346269578074,"score_gpt":0.34768720031977113,"score_spread":0.30889485405019307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922091,0.0013538918,0.000048737606,0.0003310694,0.0015495302,0.0032218292,0.00049058336,0.0002170445,0.0005782281],"genre_scores_gemma":[0.9959531,0.00026772934,0.00035419542,0.00027916828,0.00086847664,0.0002606337,0.0009428202,0.00016638504,0.0009075167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9930501,0.0006384892,0.00220912,0.0014516271,0.0015918949,0.001058742],"domain_scores_gemma":[0.991971,0.0047189854,0.00043284392,0.0018056207,0.00033114266,0.0007404111],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011004137,0.0007382979,0.0015817311,0.0003173935,0.00018324832,0.0001397813,0.0007121529,0.0006646117,0.000327313],"category_scores_gemma":[0.0027118311,0.00046607325,0.00078723003,0.0009109021,0.00085224234,0.0003668419,0.00030994322,0.0009782412,0.0003471051],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12599504,0.0027896087,0.42012748,0.00011893091,0.0007254521,0.0012077302,0.00016238251,6.917883e-7,0.00010318104,0.000018892588,0.00081395736,0.44793665],"study_design_scores_gemma":[0.26726723,0.005768121,0.72245204,0.0011486028,0.00035472304,0.000014358066,0.00004347713,0.00031934734,0.00032761693,0.00005502197,0.0019019799,0.00034750596],"about_ca_topic_score_codex":0.00064616726,"about_ca_topic_score_gemma":0.00047786746,"teacher_disagreement_score":0.44758916,"about_ca_system_score_codex":0.0013689701,"about_ca_system_score_gemma":0.0024630865,"threshold_uncertainty_score":0.9997791},"labels":[],"label_agreement":null},{"id":"W4401876389","doi":"10.1016/s2152-2650(24)01687-2","title":"MM-488 Iberdomide, Bortezomib, and Dexamethasone (IberVd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology","score_opus":0.051436834759031554,"score_gpt":0.34713429406455604,"score_spread":0.2956974593055245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262477,0.0054137143,0.000055827462,0.0034536303,0.0014887967,0.0032556062,0.0013404165,0.00043874513,0.0019284725],"genre_scores_gemma":[0.9859865,0.004639914,0.0016791354,0.0011952682,0.00251541,0.00044359165,0.0016029769,0.00019432808,0.0017428998],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9905125,0.0011266005,0.0030394983,0.0023460551,0.001307862,0.0016675193],"domain_scores_gemma":[0.9753534,0.021015912,0.00033026902,0.0017656024,0.00019112458,0.0013436978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030066231,0.0010000239,0.0020102048,0.000388518,0.0003432938,0.0004002748,0.00075673667,0.0010073257,0.00016936802],"category_scores_gemma":[0.006581052,0.0006978812,0.0008154366,0.0011290812,0.0009028708,0.00042326466,0.00033020505,0.0013386435,0.0007053178],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15216272,0.0035832482,0.042371847,0.00016915907,0.0012207344,0.013017447,0.0009397108,0.0000066565012,0.0003088489,0.00011385489,0.014563219,0.77154255],"study_design_scores_gemma":[0.36067364,0.0014108343,0.6027284,0.0010507726,0.0004886258,0.00022589993,0.00014693274,0.007690426,0.00046722568,0.0005223298,0.023960494,0.0006344115],"about_ca_topic_score_codex":0.009167991,"about_ca_topic_score_gemma":0.003308463,"teacher_disagreement_score":0.7709082,"about_ca_system_score_codex":0.0010632949,"about_ca_system_score_gemma":0.002154143,"threshold_uncertainty_score":0.99954724},"labels":[],"label_agreement":null},{"id":"W4401876575","doi":"10.1016/s2152-2650(24)00986-8","title":"Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","score_opus":0.03394083343133087,"score_gpt":0.3328008750787567,"score_spread":0.29886004164742586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888236,0.0028282765,0.000076691664,0.00037912448,0.00054393726,0.0065737115,0.00017716094,0.00032597294,0.00027152596],"genre_scores_gemma":[0.99589133,0.00035639037,0.0015892612,0.0003747016,0.000205771,0.0005298817,0.00064447057,0.00020901927,0.00019919808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98947865,0.0021100168,0.0031545325,0.0023300264,0.0016122271,0.0013145335],"domain_scores_gemma":[0.9819982,0.014193653,0.00073788833,0.0016184094,0.00033041308,0.0011214239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030503268,0.0012014891,0.0038196023,0.00046351823,0.00043565786,0.0004065997,0.0004159775,0.0005690195,0.000110007146],"category_scores_gemma":[0.0059059495,0.0007491076,0.0005345138,0.0008625312,0.0014139483,0.0005284685,0.0006156,0.0014410956,0.000059222308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.110139824,0.0032262246,0.6473425,0.00006760318,0.0026889383,0.0020194196,0.00097147067,0.0000015523142,0.000023120352,0.000013320103,0.00021628111,0.23328973],"study_design_scores_gemma":[0.32991853,0.0028945198,0.66004163,0.0005343046,0.0011639021,0.00006477379,0.0004277605,0.004010949,0.000052876032,0.000043433116,0.0003226384,0.000524705],"about_ca_topic_score_codex":0.0037248828,"about_ca_topic_score_gemma":0.00092613604,"teacher_disagreement_score":0.23276502,"about_ca_system_score_codex":0.00093169033,"about_ca_system_score_gemma":0.00095827854,"threshold_uncertainty_score":0.999496},"labels":[],"label_agreement":null},{"id":"W4401876795","doi":"10.1016/s2152-2650(24)00983-2","title":"Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Lenalidomide; Oncology; Internal medicine","score_opus":0.04655856962218402,"score_gpt":0.33104658670500936,"score_spread":0.28448801708282534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889141,0.0020711448,0.000030103554,0.0010403186,0.0012841607,0.0042016055,0.0010663528,0.00037113173,0.0010211165],"genre_scores_gemma":[0.99113625,0.0008159341,0.0017888101,0.00081753824,0.001528224,0.00038786596,0.0012928841,0.00024668858,0.0019858165],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9900705,0.0011465172,0.0028913005,0.0025292572,0.0017675862,0.0015948064],"domain_scores_gemma":[0.98218596,0.013447168,0.0005310816,0.0021323443,0.00035242856,0.0013510444],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022770658,0.0011098023,0.002175515,0.00038203484,0.0003904868,0.00034297013,0.0007387791,0.0009960701,0.00017851923],"category_scores_gemma":[0.009345072,0.00065517204,0.0005880336,0.0011699068,0.0011833103,0.00054548326,0.0005362136,0.0015779196,0.00036369334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3810925,0.002685713,0.13657303,0.000116484414,0.0014235348,0.0035593242,0.0006151418,0.0000057668467,0.000038224687,0.00003201125,0.006995948,0.46686232],"study_design_scores_gemma":[0.32405818,0.0038844782,0.65197927,0.0008060382,0.00042954244,0.00004543613,0.00015787157,0.0022998767,0.000093335606,0.000067358604,0.015618609,0.000560041],"about_ca_topic_score_codex":0.003515396,"about_ca_topic_score_gemma":0.002519679,"teacher_disagreement_score":0.5154062,"about_ca_system_score_codex":0.002576218,"about_ca_system_score_gemma":0.0043726317,"threshold_uncertainty_score":0.99959},"labels":[],"label_agreement":null},{"id":"W4401877238","doi":"10.1016/s2152-2650(24)01664-1","title":"MM-328 Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Subgroup analysis; Internal medicine; Oncology; Multiple myeloma; Confidence interval","score_opus":0.01636859731662604,"score_gpt":0.3111379459528655,"score_spread":0.29476934863623944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941262,0.0013160821,0.00006926872,0.00017454544,0.00014625565,0.003118975,0.0007761386,0.00016265314,0.00010985232],"genre_scores_gemma":[0.99722975,0.00030204226,0.0008483137,0.00011931774,0.00020999061,0.00016197895,0.0008114869,0.00012565055,0.00019145511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933157,0.0009641958,0.0016932047,0.0017013504,0.0014732507,0.0008522739],"domain_scores_gemma":[0.9905562,0.0061770794,0.00048687513,0.00176946,0.00032141779,0.0006889879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012307051,0.00076806644,0.0019136159,0.0005409928,0.00027730296,0.00015205808,0.0004974505,0.00042243514,0.00010178685],"category_scores_gemma":[0.0015714429,0.00043381864,0.00040696986,0.0022812614,0.0008812223,0.00028224217,0.00028043232,0.0010745286,0.00003979857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0351788,0.004708793,0.693038,0.000066522196,0.0051886123,0.0010693789,0.0006730351,0.000016545198,0.000019393447,0.000013874574,0.00014477823,0.25988227],"study_design_scores_gemma":[0.08725791,0.009952937,0.8963099,0.00057950075,0.0037017106,0.000013456032,0.0005087683,0.0006607558,0.000055260145,0.000022631595,0.0005142543,0.00042293576],"about_ca_topic_score_codex":0.005104135,"about_ca_topic_score_gemma":0.0038662897,"teacher_disagreement_score":0.25945935,"about_ca_system_score_codex":0.0009057547,"about_ca_system_score_gemma":0.0011184966,"threshold_uncertainty_score":0.99981135},"labels":[],"label_agreement":null},{"id":"W4401877385","doi":"10.1016/s2152-2650(24)01700-2","title":"MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Dexamethasone; Bortezomib; Internal medicine; Oncology; Refractory (planetary science); Multiple myeloma","score_opus":0.034740617643537634,"score_gpt":0.33254429824586,"score_spread":0.2978036806023224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883651,0.0029885906,0.00008195206,0.0003933984,0.000580172,0.0067671817,0.00019814605,0.00034261832,0.00028283702],"genre_scores_gemma":[0.99570405,0.00037939774,0.0016248812,0.00037974672,0.00021806348,0.00055927376,0.0007047198,0.00022250078,0.00020733787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988971,0.0022028913,0.0032999103,0.0024384283,0.0017009272,0.0013868328],"domain_scores_gemma":[0.98164207,0.014341344,0.000789098,0.0017067454,0.0003509653,0.0011697778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031217127,0.0012675165,0.0039906455,0.0004886826,0.00046108235,0.0004265966,0.0004723344,0.00060428184,0.00011551367],"category_scores_gemma":[0.006124524,0.00079610193,0.00056671666,0.0009057606,0.0014441746,0.0005545033,0.00064523047,0.0015127904,0.00006350062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11313674,0.0034246875,0.64315534,0.000072456416,0.0028408105,0.0021325669,0.0010070902,0.0000017099778,0.000025267625,0.000013645463,0.0002315602,0.23395815],"study_design_scores_gemma":[0.33328763,0.0030341565,0.656314,0.000548305,0.001239349,0.000070289774,0.00045141557,0.0040521338,0.00006129912,0.000045296445,0.00034159442,0.00055452844],"about_ca_topic_score_codex":0.0038128344,"about_ca_topic_score_gemma":0.00096065615,"teacher_disagreement_score":0.23340362,"about_ca_system_score_codex":0.0010184282,"about_ca_system_score_gemma":0.0010386225,"threshold_uncertainty_score":0.999449},"labels":[],"label_agreement":null},{"id":"W4401877498","doi":"10.1016/s2152-2650(24)00991-1","title":"DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Daratumumab; Dexamethasone; Bortezomib; Oncology; Internal medicine; Multiple myeloma","score_opus":0.07079501631935992,"score_gpt":0.40671953953289164,"score_spread":0.3359245232135317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98072284,0.013687532,0.00019789096,0.00048000584,0.0007931683,0.0024619282,0.0008357722,0.00029951314,0.00052135973],"genre_scores_gemma":[0.9859717,0.004829235,0.0058057667,0.00029830332,0.0008880737,0.00024314043,0.0011798955,0.0002286433,0.0005552339],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98965555,0.0013139651,0.0034521963,0.0026389358,0.0014109777,0.001528361],"domain_scores_gemma":[0.9879098,0.007869787,0.0006761809,0.0016432377,0.00027937657,0.0016216394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026102504,0.0012055619,0.0033739277,0.0010440461,0.00023719882,0.00025997218,0.0005485807,0.0012888698,0.00041344474],"category_scores_gemma":[0.004585422,0.0010343924,0.0008181513,0.0014408472,0.0015330584,0.0005423299,0.0006089098,0.0014766958,0.00014220529],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15030953,0.004139854,0.10596964,0.0004953791,0.0024979764,0.0060471306,0.00049496925,0.00000235901,0.009714229,0.00012797769,0.0020024416,0.71819854],"study_design_scores_gemma":[0.2508529,0.006600271,0.7138761,0.0012323834,0.001376198,0.00033709873,0.00029716885,0.011834532,0.0061937496,0.00040595527,0.0060198857,0.0009737567],"about_ca_topic_score_codex":0.0040731835,"about_ca_topic_score_gemma":0.0010381963,"teacher_disagreement_score":0.7172248,"about_ca_system_score_codex":0.0010852448,"about_ca_system_score_gemma":0.0020172822,"threshold_uncertainty_score":0.99921066},"labels":[],"label_agreement":null},{"id":"W4401942365","doi":"10.1182/blood.2024024582","title":"Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Pharmacyclics; Chugai Pharmaceutical; BeiGene; Regeneron Pharmaceuticals; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; National Cancer Research Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Progression-free survival; Confidence interval; Interim analysis; Multiple myeloma; Lenalidomide; Refractory (planetary science); Gastroenterology; Tolerability; Surgery; Randomized controlled trial; Adverse effect; Overall survival","score_opus":0.041943455543660677,"score_gpt":0.33497596063706037,"score_spread":0.2930325050933997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401942365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902637,0.0051809414,0.000022082819,0.0008055049,0.0001396628,0.0008517615,0.00015514418,0.00025040147,0.002330777],"genre_scores_gemma":[0.9951707,0.0005172903,0.0009660068,0.000095260686,0.000115011324,0.00007319721,0.00031452908,0.000065073524,0.0026829108],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974685,0.00015963565,0.00048139875,0.0006843258,0.0006047097,0.00060144404],"domain_scores_gemma":[0.9985826,0.0003295021,0.00006391661,0.0005023582,0.000109815075,0.0004118225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036612395,0.00032303977,0.0006090975,0.00059872435,0.000098125,0.000097372795,0.000110133915,0.00019757403,0.0002199675],"category_scores_gemma":[0.00054120587,0.00025648065,0.00014409839,0.0007119494,0.00013058893,0.00019359584,0.00008816187,0.000511412,0.00010270496],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011580863,0.005313729,0.44615307,0.0011848573,0.004660109,0.025050078,0.0018684183,0.0000053451486,0.46223244,0.00024412453,0.01986975,0.021837195],"study_design_scores_gemma":[0.122939184,0.006444091,0.54989743,0.0017850391,0.0021262104,0.0006739582,0.00084436237,0.004215505,0.25156677,0.00030847106,0.057943363,0.0012556171],"about_ca_topic_score_codex":0.00020981557,"about_ca_topic_score_gemma":0.0002539459,"teacher_disagreement_score":0.21066567,"about_ca_system_score_codex":0.00017368101,"about_ca_system_score_gemma":0.0003248295,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W4401976889","doi":"10.26685/urncst.599","title":"Rising Biomarkers in the Diagnosis of Multiple Myeloma: A Narrative Review","year":2024,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Multiple myeloma; Narrative; Medicine; Narrative review; Internal medicine; Intensive care medicine; Literature; Art","score_opus":0.15910507090599035,"score_gpt":0.5122142933703718,"score_spread":0.3531092224643815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401976889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005133001,0.9591006,2.8037678e-7,0.03381799,0.00013571615,0.0016179516,0.000008496697,0.000014680539,0.0001712945],"genre_scores_gemma":[0.06670554,0.9328195,0.00014371632,0.000066745575,0.00007048312,0.00012426158,0.0000056020854,0.000015172175,0.000049011956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99368685,0.0011814771,0.0014954717,0.0008469933,0.001731497,0.0010576902],"domain_scores_gemma":[0.9949501,0.0033081435,0.00031930773,0.00042567,0.000620711,0.00037606154],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016090605,0.00036295538,0.0018078916,0.0027088954,0.0004973713,0.00016402782,0.00084387086,0.0004579568,0.000008711422],"category_scores_gemma":[0.0107880235,0.00017174637,0.0003046093,0.008340953,0.005508368,0.0002223237,0.00063317985,0.0063197715,0.000015964944],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005186759,0.00030324337,0.0066210367,0.0067663966,0.00027578895,0.0014656287,0.000040632833,3.7559555e-9,0.0000016800177,0.0002635689,0.0013791384,0.982831],"study_design_scores_gemma":[0.007119314,0.0050632237,0.0050306288,0.43147027,0.0017298826,0.013156161,0.003287467,0.00046430444,0.000013865544,0.038010165,0.49364135,0.0010133687],"about_ca_topic_score_codex":0.000092105474,"about_ca_topic_score_gemma":0.00017372821,"teacher_disagreement_score":0.98181766,"about_ca_system_score_codex":0.00039793263,"about_ca_system_score_gemma":0.0018345874,"threshold_uncertainty_score":0.9975445},"labels":[],"label_agreement":null},{"id":"W4402103762","doi":"10.1016/j.jaad.2024.07.195","title":"53225 Gammopathic Dermopathy of MGUS: Unraveling the Mysterious Gamut of Unrelated Scenarios","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Gamut; Dermatology; Artificial intelligence","score_opus":0.02304565812086819,"score_gpt":0.34025031215895263,"score_spread":0.31720465403808445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97374874,0.0068904296,0.00015657043,0.018620277,0.00014686222,0.00028150977,0.000015611333,0.000010266698,0.00012972509],"genre_scores_gemma":[0.99775875,0.001196039,0.0004936744,0.00040535288,0.000059844642,0.0000031885725,8.81566e-7,0.00002586842,0.00005642618],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972158,0.00050545816,0.0011725482,0.00015179018,0.0006247468,0.00032963097],"domain_scores_gemma":[0.9974265,0.0006687902,0.0013533961,0.0002351755,0.00017646604,0.00013964073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047866834,0.0001851692,0.0010268415,0.00035619497,0.000054956443,0.0000075941657,0.00050867454,0.00012042715,0.000025372325],"category_scores_gemma":[0.00049237924,0.00009476712,0.00045699376,0.00067800796,0.0010999892,0.000070152026,0.00014152993,0.0010047854,0.000007010649],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070586167,0.0013343085,0.34174722,0.003934731,0.00886543,0.0032308563,0.0075844503,0.00043372423,0.53600913,0.0013309405,0.005055348,0.08341524],"study_design_scores_gemma":[0.009558056,0.00315555,0.4475717,0.008308518,0.0034565253,0.11033098,0.004258734,0.0129469,0.39257035,0.002708655,0.004590823,0.00054319034],"about_ca_topic_score_codex":0.000060331073,"about_ca_topic_score_gemma":0.0000016504703,"teacher_disagreement_score":0.14343877,"about_ca_system_score_codex":0.0000685015,"about_ca_system_score_gemma":0.0004503229,"threshold_uncertainty_score":0.43653488},"labels":[],"label_agreement":null},{"id":"W4402112448","doi":"10.14740/jh1267","title":"Optic Disc Infiltration as a Sign of Multiple Myeloma Recurrence","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Infiltration (HVAC); Sign (mathematics); Pathology; Radiology; Internal medicine; Mathematics","score_opus":0.03082361547534723,"score_gpt":0.34816612614466164,"score_spread":0.3173425106693144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402112448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930158,0.0032888018,0.0007770542,0.0013955415,0.00026602345,0.00018708188,0.000004916553,0.000012158777,0.0010525979],"genre_scores_gemma":[0.99704415,0.00016460086,0.0025328668,0.000023257637,0.00007736817,0.000004900241,0.000005326726,0.000010216208,0.00013732676],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887097,0.00006790207,0.00047490242,0.000107690015,0.00029824043,0.00018027872],"domain_scores_gemma":[0.99899846,0.00038052507,0.00015419094,0.00012510321,0.00019099464,0.00015074541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022859454,0.000093193885,0.0003887719,0.00026682232,0.000022867045,0.000013070835,0.00007889012,0.000073748015,0.00015996875],"category_scores_gemma":[0.00077475305,0.00006275152,0.00014210865,0.00018455119,0.00008548427,0.00012751775,0.000020117404,0.0002507796,0.000068050154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006538946,0.0030245162,0.6172429,0.005042895,0.0037767203,0.030695746,0.0036842546,0.00005128889,0.12900203,0.035476096,0.009810928,0.1556537],"study_design_scores_gemma":[0.02415129,0.025323467,0.31628072,0.010371152,0.0015676257,0.17855729,0.0028688025,0.022376822,0.3880005,0.01514914,0.014490247,0.00086293963],"about_ca_topic_score_codex":0.000013677113,"about_ca_topic_score_gemma":0.000006519167,"teacher_disagreement_score":0.30096215,"about_ca_system_score_codex":0.000047327176,"about_ca_system_score_gemma":0.0003382562,"threshold_uncertainty_score":0.25589326},"labels":[],"label_agreement":null},{"id":"W4402169337","doi":"10.1080/03007995.2024.2391553","title":"Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Propensity score matching; Refractory (planetary science); Oncology","score_opus":0.07985771078524738,"score_gpt":0.405961925221136,"score_spread":0.3261042144358886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402169337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218155,0.015641522,0.00008215671,0.00056500774,0.00023593192,0.0010879086,0.00008056494,0.000051215546,0.0000741579],"genre_scores_gemma":[0.99484867,0.004133097,0.00020545475,0.000011956962,0.0001408394,0.00009462433,0.000473613,0.000038061287,0.00005369565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99518687,0.0004211935,0.00055075577,0.00064785493,0.0024475716,0.00074578193],"domain_scores_gemma":[0.9969019,0.001521684,0.00006365729,0.00028328897,0.00026008635,0.00096937997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014762593,0.0002636975,0.00069465867,0.0007730198,0.00010683063,0.000059058333,0.00014513599,0.00022636657,0.00017791653],"category_scores_gemma":[0.001609611,0.00018032263,0.000054407534,0.00075108686,0.0005749772,0.00016560407,0.00025027437,0.0016982855,0.00002477957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066435398,0.0016922947,0.72424567,0.0017606836,0.000110118155,0.000107915715,0.00066860707,2.6480848e-7,0.000034273027,0.0000506608,0.0005178478,0.26416814],"study_design_scores_gemma":[0.011540626,0.0044151875,0.9698623,0.005350013,0.000025300513,0.000016731807,0.00021020275,0.003640547,0.00029504017,0.000091316084,0.0043691825,0.00018356639],"about_ca_topic_score_codex":0.00029842023,"about_ca_topic_score_gemma":0.00017163585,"teacher_disagreement_score":0.2639846,"about_ca_system_score_codex":0.00015605753,"about_ca_system_score_gemma":0.0004887955,"threshold_uncertainty_score":0.73783},"labels":[],"label_agreement":null},{"id":"W4402171124","doi":"10.1002/cam4.70192","title":"Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Jewish General Hospital; Hôpital de l'Enfant-Jésus; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Hôpital Charles-Le Moyne; Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Université de Sherbrooke","keywords":"Medicine; Plasma cell leukemia; Internal medicine; Multiple myeloma; Gastroenterology; Retrospective cohort study; Incidence (geometry); Population; Bone marrow","score_opus":0.019430853827525265,"score_gpt":0.3054342369176595,"score_spread":0.28600338309013423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402171124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050325,0.004509792,0.00002043743,0.00022096786,0.00015411366,0.0016143107,0.000116026225,0.0000599426,0.0028011862],"genre_scores_gemma":[0.9969085,0.00028793345,0.00011361545,0.00014595897,0.000118315955,0.00020260211,0.00009545101,0.000049323353,0.0020783346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812514,0.000040952924,0.00034498426,0.0005096301,0.00066758273,0.0003117139],"domain_scores_gemma":[0.99907625,0.00007930542,0.0000818475,0.0002912276,0.00017582774,0.00029556055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010344124,0.00027691043,0.00066088943,0.00024282302,0.00006055584,0.0000108019,0.000067435845,0.00006118576,0.0002381073],"category_scores_gemma":[0.00003851678,0.0001624508,0.00004038632,0.00029605467,0.00018548583,0.00011485191,0.00005295588,0.00028581498,0.0000063174234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017959949,0.0007604537,0.9405287,0.0007922086,0.0010178036,0.00043234575,0.002883144,0.0000024104877,0.00060850824,0.0000035654186,0.0005571596,0.05061773],"study_design_scores_gemma":[0.02799709,0.008859282,0.9598783,0.0006567073,0.0008584673,0.0000126431405,0.00046972148,0.0005720695,0.00026822233,0.000018226305,0.00027129645,0.00013796963],"about_ca_topic_score_codex":0.00086398295,"about_ca_topic_score_gemma":0.00014863309,"teacher_disagreement_score":0.05047976,"about_ca_system_score_codex":0.001176407,"about_ca_system_score_gemma":0.00040032357,"threshold_uncertainty_score":0.66245514},"labels":[],"label_agreement":null},{"id":"W4402238211","doi":"10.3390/curroncol31090382","title":"Case Report of Concomitant Diagnosis of Locally Advanced Intrahepatic Cholangiocarcinoma and Solitary Plasmacytoma of T11 Vertebra: Impact on Diagnostic and Clinical Management","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Intrahepatic Cholangiocarcinoma; Medicine; Concomitant; Plasmacytoma; Gemcitabine; Radiation therapy; Pathology; Radiology; Oncology; Cancer; Multiple myeloma; Internal medicine","score_opus":0.08241961265236848,"score_gpt":0.45003329318529256,"score_spread":0.3676136805329241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402238211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894137,0.008807713,0.00003037495,0.00014794734,0.0003287714,0.0008958909,0.000098499695,0.00001627629,0.0002608524],"genre_scores_gemma":[0.99368066,0.00579921,0.0003093965,0.0000111050185,0.000045597448,0.00008439533,0.000044353896,0.000016468524,0.000008806199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823844,0.00014438598,0.0007775101,0.00036785577,0.00022657625,0.00024522268],"domain_scores_gemma":[0.99654603,0.0026412844,0.00016692776,0.00028505357,0.0000997177,0.00026098784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004070529,0.00017950972,0.0007585169,0.00022427372,0.000021155605,0.000004083591,0.000054613418,0.00009292365,0.000039694878],"category_scores_gemma":[0.0008850584,0.00012823511,0.00015838747,0.00014581431,0.0003734359,0.00004616383,0.00011608182,0.00023295076,0.000003383653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011996083,0.001356533,0.6099325,0.0014408962,0.0007408556,0.06325307,0.00012324305,0.0000016848513,0.000016529779,0.000106615735,0.00035809647,0.32147038],"study_design_scores_gemma":[0.007909002,0.012527655,0.9613131,0.0015702053,0.0009118402,0.011233667,0.00018223251,0.0029251822,0.0007254248,0.00014681803,0.00041996661,0.00013487626],"about_ca_topic_score_codex":0.00008920085,"about_ca_topic_score_gemma":0.00003724661,"teacher_disagreement_score":0.35138065,"about_ca_system_score_codex":0.00013756916,"about_ca_system_score_gemma":0.00019075187,"threshold_uncertainty_score":0.52292764},"labels":[],"label_agreement":null},{"id":"W4402326482","doi":"10.1093/oncolo/oyae219","title":"Evaluating early intervention in smoldering myeloma clinical trials: a systematic review","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Clinical endpoint; Clinical trial; Internal medicine; Randomized controlled trial; Oncology; Surgery","score_opus":0.6741545513710383,"score_gpt":0.6617437026961426,"score_spread":0.012410848674895725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402326482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026127835,0.98487216,0.000009165765,0.00026689007,0.00043243155,0.013712836,0.000020708463,0.000082615195,0.0005770433],"genre_scores_gemma":[0.000092364244,0.9937468,0.00014719041,0.000087209046,0.00031996417,0.0035886585,0.00009374207,0.00006395543,0.0018600944],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9816496,0.012214715,0.0044748164,0.00059093424,0.00064062985,0.0004293088],"domain_scores_gemma":[0.99165076,0.0057616,0.0013509917,0.00097032334,0.00009319756,0.00017312611],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.044349987,0.00046971906,0.007834544,0.00023530444,0.00006655734,0.00009088065,0.0004424587,0.00034577434,0.00011562894],"category_scores_gemma":[0.036324527,0.00021038807,0.0026017404,0.0006149003,0.0001534713,0.00004181052,0.00030075927,0.0014622657,0.0012119575],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025410416,0.0001268604,0.0000071750537,0.5309517,0.00068831816,0.00031770472,0.000010355696,1.8028631e-8,1.8113345e-8,0.000010265635,0.00023066222,0.46763152],"study_design_scores_gemma":[0.0011151682,0.0010141404,0.0000470895,0.9552773,0.020917585,0.0002452443,0.0000220005,0.00009276655,3.9839723e-8,0.000033784614,0.021071956,0.00016290953],"about_ca_topic_score_codex":0.00015527624,"about_ca_topic_score_gemma":0.000069668255,"teacher_disagreement_score":0.4674686,"about_ca_system_score_codex":0.0008365676,"about_ca_system_score_gemma":0.0005319379,"threshold_uncertainty_score":0.9995657},"labels":[],"label_agreement":null},{"id":"W4402415968","doi":"10.1002/ajh.27473","title":"Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma","year":2024,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quadruplets; Multiple myeloma; Medicine; MEDLINE; Oncology; Internal medicine; Biology; Pregnancy; Genetics","score_opus":0.01985682815134042,"score_gpt":0.3086462158474822,"score_spread":0.28878938769614176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402415968","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3700257,0.005773669,0.00012985467,0.62184566,0.0007524019,0.00067385583,0.00010712858,0.000054699885,0.0006370639],"genre_scores_gemma":[0.85147405,0.0015915589,0.0020086265,0.14229862,0.0015592166,0.00005235919,0.00019447702,0.00016189202,0.0006592163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964778,0.0002970115,0.0011731099,0.00044748833,0.00070994004,0.0008946731],"domain_scores_gemma":[0.99738616,0.0011433329,0.00057424995,0.00040407316,0.00018497695,0.00030718168],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000275731,0.00048202515,0.0022184332,0.0014171726,0.00003455211,0.000030736162,0.00034639842,0.0004051733,0.00019183781],"category_scores_gemma":[0.00028232535,0.00035945696,0.0005345558,0.00059299875,0.0004252019,0.00007381505,0.00004502874,0.003226552,0.00024701297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011224626,0.00028990768,0.100419775,0.0007073958,0.0011012265,0.3143193,0.00064223696,0.000004449783,0.00009428384,0.000011579215,0.5684956,0.012791792],"study_design_scores_gemma":[0.022139682,0.007984447,0.04053721,0.0064232983,0.0014329675,0.13310985,0.0007221127,0.0004386415,0.0011902712,0.00044962822,0.78432375,0.0012481619],"about_ca_topic_score_codex":0.00065193005,"about_ca_topic_score_gemma":0.00015896648,"teacher_disagreement_score":0.48144835,"about_ca_system_score_codex":0.0002240534,"about_ca_system_score_gemma":0.00067697227,"threshold_uncertainty_score":0.99988574},"labels":[],"label_agreement":null},{"id":"W4402460449","doi":"10.1038/s41408-024-01135-2","title":"Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org; Juravinski Cancer Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Dexamethasone; Subgroup analysis; Multiple myeloma; Internal medicine; Oncology; Medicine; Refractory (planetary science); Lenalidomide; Meta-analysis; Biology","score_opus":0.03603070339032477,"score_gpt":0.32597029922849974,"score_spread":0.28993959583817497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402460449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98095304,0.0152379675,0.00030114446,0.0009207117,0.00075134786,0.0013771524,0.00033806943,0.000033524117,0.000087020686],"genre_scores_gemma":[0.99511147,0.0016301451,0.001049253,0.000097338874,0.0007046917,0.00020871195,0.000036965837,0.000048963568,0.0011124805],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974869,0.00022848086,0.00068462885,0.00040790395,0.0006784113,0.00051366445],"domain_scores_gemma":[0.9979992,0.0007908572,0.0002639176,0.0003603675,0.00022816927,0.00035749562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008681583,0.000266584,0.0007979748,0.0005495988,0.0002469046,0.00011485314,0.00020153717,0.00015858372,0.00023300221],"category_scores_gemma":[0.00060512393,0.00016641559,0.000731747,0.0009758079,0.00015765123,0.00014979702,0.000073440744,0.000569396,0.0000020326563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1970439,0.0044303015,0.41679642,0.001348752,0.07229119,0.0012466726,0.002915252,0.000080455764,0.13990076,0.00021721107,0.009287714,0.15444139],"study_design_scores_gemma":[0.4907873,0.007213315,0.3637565,0.0013802032,0.039868437,0.0010574425,0.00087495026,0.018512944,0.05880657,0.00022690388,0.016753545,0.0007618788],"about_ca_topic_score_codex":0.00024549078,"about_ca_topic_score_gemma":0.00044550293,"teacher_disagreement_score":0.2937434,"about_ca_system_score_codex":0.00018706101,"about_ca_system_score_gemma":0.0006243604,"threshold_uncertainty_score":0.6786231},"labels":[],"label_agreement":null},{"id":"W4402488118","doi":"10.51731/cjht.2024.972","title":"Teclistamab (Tecvayli)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Vial; Medicine; Refractory (planetary science); Drug; Multiple myeloma; Subcutaneous injection; Monoclonal antibody; Internal medicine; Pharmacology; Family medicine; Oncology; Antibody; Health care; Immunology; Chemistry; Political science","score_opus":0.045761241313877425,"score_gpt":0.3538396592666456,"score_spread":0.3080784179527682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402488118","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21838942,0.5776585,0.0005601576,0.19811782,0.00092383823,0.00066242414,0.00006503029,0.0005114429,0.0031114141],"genre_scores_gemma":[0.9976639,0.000941583,0.0008215489,0.00019357607,0.000017614142,0.0000048941138,0.0000033220497,0.000014866515,0.00033868145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988535,0.000024439803,0.00035384597,0.00011434116,0.00018939507,0.0004644832],"domain_scores_gemma":[0.99937546,0.000050427083,0.0000707576,0.00019226214,0.00011366352,0.00019742125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040560486,0.00009672453,0.00028644106,0.0009803622,0.00012494976,0.00005502339,0.00015190608,0.00009974893,0.000083418505],"category_scores_gemma":[0.0005235945,0.0000684026,0.000095519856,0.00039864896,0.00016436393,0.00008354256,0.000011724358,0.0005112158,0.000057047506],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020283143,0.000014657395,0.0047671627,0.0002758866,0.000106009415,0.0039534476,0.00008564744,5.056058e-7,0.000044227258,0.0012878397,0.0114310235,0.97801334],"study_design_scores_gemma":[0.0010525666,0.001339245,0.020937735,0.0013292922,0.000032650016,0.0035780491,0.0014703983,0.000075646094,0.0010871929,0.0038889225,0.9650908,0.00011748838],"about_ca_topic_score_codex":0.0026675793,"about_ca_topic_score_gemma":0.0012641195,"teacher_disagreement_score":0.9778958,"about_ca_system_score_codex":0.0006161206,"about_ca_system_score_gemma":0.0052055735,"threshold_uncertainty_score":0.92344636},"labels":[],"label_agreement":null},{"id":"W4402567816","doi":"10.1080/14796694.2024.2394323","title":"A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Biotech; Sanofi Pasteur; AbbVie Biotherapeutics; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Janssen Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Daratumumab; Lenalidomide; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology","score_opus":0.02224847335936487,"score_gpt":0.34278931138209917,"score_spread":0.3205408380227343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402567816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047977,0.004876629,0.000028333596,0.00089909433,0.00028487443,0.0022977828,0.00015383259,0.000034828125,0.00094485324],"genre_scores_gemma":[0.9968593,0.00009970229,0.001612619,0.000083399245,0.0003764706,0.0002536442,0.00004867583,0.00003265077,0.0006335332],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985046,0.00022975272,0.00036197223,0.00034599192,0.00025277093,0.00030495643],"domain_scores_gemma":[0.99769104,0.0016336212,0.000118317235,0.0003404442,0.000093597846,0.00012297537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035094723,0.00019064723,0.00062451133,0.00015457935,0.00010407125,0.0000121582625,0.00012419185,0.00014260074,0.00003384109],"category_scores_gemma":[0.0006386247,0.00011708863,0.00014836735,0.00026782142,0.0001369537,0.000048210393,0.00010337085,0.0002586831,0.0000015498032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027934136,0.0059631676,0.21094537,0.0032385457,0.0047382927,0.003954205,0.084728874,0.000035788507,0.05972803,0.00039248032,0.011782153,0.58655894],"study_design_scores_gemma":[0.15667337,0.028178426,0.57291985,0.0013813501,0.002570009,0.0006461361,0.1644422,0.013623684,0.021023137,0.000071543654,0.037799597,0.00067070447],"about_ca_topic_score_codex":0.0009620241,"about_ca_topic_score_gemma":0.0029270975,"teacher_disagreement_score":0.58588827,"about_ca_system_score_codex":0.00019227913,"about_ca_system_score_gemma":0.00036244828,"threshold_uncertainty_score":0.4774736},"labels":[],"label_agreement":null},{"id":"W4402824750","doi":"10.1182/blood.2024026212","title":"Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Multiple Myeloma Research Foundation","keywords":"Chimeric antigen receptor; Medicine; Multiple myeloma; Antigen; Cytotoxic T cell; Immunology; T cell; Internal medicine; Cancer research; Oncology; Biology; In vitro; Immune system","score_opus":0.026364824498237616,"score_gpt":0.3097894521498539,"score_spread":0.2834246276516163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402824750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969079,0.0005549715,0.000008038863,0.00005181728,0.00012123692,0.0006684538,0.00004601264,0.00005649885,0.0015851007],"genre_scores_gemma":[0.99866414,0.00009256453,0.000370099,0.000012861134,0.00008684559,0.000033134016,0.000059461938,0.00005137869,0.00062951935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829894,0.00006644644,0.00030922735,0.00044605028,0.00036230293,0.0005170148],"domain_scores_gemma":[0.99875826,0.00045189328,0.000045731562,0.0002853929,0.00006234085,0.0003963675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002611448,0.0002640764,0.00040437625,0.00041413167,0.00007266249,0.000041485375,0.00009435303,0.00010693846,0.000087971675],"category_scores_gemma":[0.00033370024,0.00019357628,0.00014473786,0.00043178807,0.000034465866,0.00009865375,0.00007867791,0.00038087668,0.00006121232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035775718,0.0015245286,0.8014616,0.00048167064,0.0001482564,0.00044231027,0.0015576788,0.00002153664,0.19224076,7.36277e-7,0.00022621617,0.0015369748],"study_design_scores_gemma":[0.007965202,0.0018527593,0.6776281,0.0003713935,0.00009061594,0.0000087745475,0.0003424909,0.0006044429,0.31050414,0.0000046401774,0.00039680264,0.00023066024],"about_ca_topic_score_codex":0.0013662683,"about_ca_topic_score_gemma":0.00004282761,"teacher_disagreement_score":0.123833485,"about_ca_system_score_codex":0.00011994843,"about_ca_system_score_gemma":0.00016369227,"threshold_uncertainty_score":0.7893812},"labels":[],"label_agreement":null},{"id":"W4402867103","doi":"10.1016/j.cancergen.2024.08.011","title":"9. Best practices for testing and reporting of FISH studies in multiple myeloma: Recommendations from the CGC working group","year":2024,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fish <Actinopterygii>; Multiple myeloma; Group (periodic table); Internal medicine; Biology; Fishery; Medicine; Chemistry","score_opus":0.4630757048226476,"score_gpt":0.4853282062555848,"score_spread":0.02225250143293722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402867103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623325,0.033138458,0.000067574576,0.0033623981,0.00025112415,0.0006255512,0.00007847713,0.000018943056,0.00012497326],"genre_scores_gemma":[0.97953403,0.005025231,0.014643492,0.000097538694,0.00027920763,0.0002359018,0.000030194069,0.000017758102,0.00013663968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989784,0.000032687014,0.00047819063,0.0002218236,0.00011915203,0.0001697953],"domain_scores_gemma":[0.99634403,0.0029309362,0.00041785318,0.00014515864,0.00011810111,0.000043897177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003859317,0.000087454435,0.00021151334,0.000045913373,0.00009956994,0.000032134514,0.0000445299,0.00003277089,0.0000062580293],"category_scores_gemma":[0.0066688596,0.000060111,0.00003169621,0.0002030305,0.00007777185,0.00004041811,0.00006274075,0.00012491814,4.6964442e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046065605,0.000041933516,0.6369196,0.00023298187,0.00023506078,0.000031291722,0.0010738074,0.000015209199,0.0021343012,0.000003870304,0.0005929329,0.35867295],"study_design_scores_gemma":[0.00418726,0.000675482,0.84392095,0.008665515,0.00081620214,0.000048412167,0.01105732,0.047849443,0.00955059,0.0006956873,0.072203636,0.00032949165],"about_ca_topic_score_codex":0.0016090067,"about_ca_topic_score_gemma":0.005048962,"teacher_disagreement_score":0.35834345,"about_ca_system_score_codex":0.000088503264,"about_ca_system_score_gemma":0.000102697406,"threshold_uncertainty_score":0.798373},"labels":[],"label_agreement":null},{"id":"W4402975451","doi":"10.1182/bloodadvances.2024014139","title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ottawa Hospital; Impact; McMaster University","funders":"","keywords":"Meta-analysis; Multiple myeloma; Medicine; Oncology; MEDLINE; Internal medicine; Biology","score_opus":0.057377145620243784,"score_gpt":0.36597223175094773,"score_spread":0.30859508613070397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402975451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027959104,0.98251164,0.00003014928,0.00010237999,0.000024747666,0.015483518,0.0017193884,0.00008084182,0.000044513155],"genre_scores_gemma":[0.000024652394,0.98251647,0.0030308454,0.00011791758,0.000037606384,0.010546381,0.0016449217,0.000107826585,0.0019733792],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964083,0.00025708816,0.0011098481,0.0010297231,0.00066586625,0.00052921474],"domain_scores_gemma":[0.9965346,0.0012356729,0.0006450319,0.000938198,0.0002757698,0.00037074115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003500285,0.0008652921,0.01094601,0.00046120584,0.00011333166,0.00007867415,0.00021208602,0.00014575373,0.00005604946],"category_scores_gemma":[0.00094609475,0.00041391057,0.0026719724,0.0010636507,0.000089288296,0.00014080864,0.00008465229,0.00027388605,0.00004793104],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023306524,0.00033854568,0.00004873515,0.72070545,0.2746194,0.00011249847,0.0000110181945,8.7894975e-8,2.9090879e-9,0.000008078495,0.00013729859,0.003995579],"study_design_scores_gemma":[0.0016545809,0.0004985481,0.000006019707,0.07264208,0.82727104,0.00002997735,0.000007826005,0.0000034859152,1.5886219e-7,0.0000047845597,0.09756,0.0003214993],"about_ca_topic_score_codex":0.000022735623,"about_ca_topic_score_gemma":0.00010110165,"teacher_disagreement_score":0.64806336,"about_ca_system_score_codex":0.00006472776,"about_ca_system_score_gemma":0.00017582333,"threshold_uncertainty_score":0.99983126},"labels":[],"label_agreement":null},{"id":"W4403103653","doi":"10.1080/10428194.2024.2408646","title":"Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Clinical trial; Medicine; Medical physics; Intensive care medicine; Computer science; Internal medicine","score_opus":0.41103464638971776,"score_gpt":0.51015466070124,"score_spread":0.09912001431152229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403103653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039771316,0.98573595,0.00021817465,0.00011247212,0.0009332559,0.006821199,0.00043546018,0.00036257564,0.0014037498],"genre_scores_gemma":[0.004268828,0.98150223,0.004596579,0.000107295535,0.0018477521,0.003592128,0.0009878121,0.00036314063,0.0027342474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98875254,0.002096132,0.0035412658,0.0025326863,0.0012971077,0.0017802737],"domain_scores_gemma":[0.98412573,0.011927564,0.00082472793,0.0011286505,0.0006761705,0.0013171651],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.009052021,0.0014371123,0.0053796195,0.0014641975,0.0011851321,0.0013892171,0.00041853543,0.0015947709,0.000021416932],"category_scores_gemma":[0.0061419215,0.0010596428,0.0016427138,0.0010794685,0.0009197072,0.00047761257,0.00059768005,0.0008578997,0.0000855517],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007922026,0.00024731897,0.000045004694,0.024964543,0.002416093,0.0003937758,0.0003607814,0.0000011567279,0.000025399992,0.00042129296,0.006193474,0.964139],"study_design_scores_gemma":[0.01756994,0.0017023036,0.00043385368,0.02441633,0.0056620836,0.00089900015,0.0015740402,0.0052147293,0.000034357872,0.0005500107,0.94086313,0.0010802215],"about_ca_topic_score_codex":0.000719095,"about_ca_topic_score_gemma":0.00015318824,"teacher_disagreement_score":0.9630587,"about_ca_system_score_codex":0.0076721744,"about_ca_system_score_gemma":0.016539948,"threshold_uncertainty_score":0.9998379},"labels":[],"label_agreement":null},{"id":"W4403159483","doi":"10.1038/s41409-024-02428-7","title":"Transplant in myeloma: individualized approaches needed depending on context, access and biology","year":2024,"lang":"en","type":"review","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Multiple myeloma; MEDLINE; Hematopoietic cell; Intensive care medicine; Immunology; Oncology; Computational biology; Stem cell; Haematopoiesis; Genetics; Biology","score_opus":0.2231139613264283,"score_gpt":0.4140143833311895,"score_spread":0.1909004220047612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403159483","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032085844,0.9904988,0.000089261346,0.0001420715,0.00014986664,0.0026543413,0.0009691523,0.00010041351,0.0021874995],"genre_scores_gemma":[0.054457817,0.9387536,0.00012906796,0.000049343016,0.000077436176,0.0005564731,0.005677722,0.00007985626,0.00021870296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743867,0.00031163095,0.00073191064,0.0007676832,0.00026796263,0.00048214014],"domain_scores_gemma":[0.9990217,0.00033394207,0.00013406394,0.00023199315,0.000016609853,0.00026167888],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036864818,0.0005749748,0.0017178034,0.0011530649,0.000068274865,0.000101993,0.00014800587,0.00047058152,0.00005960456],"category_scores_gemma":[0.000029470066,0.00041398918,0.00028212368,0.0004372072,0.000091188864,0.00011820148,0.000021940006,0.00067404116,0.000071335395],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009209675,0.00020204457,0.0009231021,0.049930554,0.000643526,0.0018595668,0.0005220762,2.628077e-7,0.0000143944,0.0007562095,0.000049984337,0.9441773],"study_design_scores_gemma":[0.059951283,0.003914684,0.012267301,0.30403063,0.04138125,0.014015139,0.0006364376,0.0005869097,0.0004936063,0.0010720403,0.5565775,0.005073212],"about_ca_topic_score_codex":0.00026581498,"about_ca_topic_score_gemma":0.00040322624,"teacher_disagreement_score":0.9391041,"about_ca_system_score_codex":0.00018678421,"about_ca_system_score_gemma":0.00026022943,"threshold_uncertainty_score":0.9998312},"labels":[],"label_agreement":null},{"id":"W4403348875","doi":"10.1016/j.bneo.2024.100045","title":"Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Irene Levi Sala Care Archaeological Foundation; Center for Individualized Medicine, Mayo Clinic; Gairdner Foundation; Mayo Clinic","keywords":"Germline; Multiple myeloma; Prospective cohort study; Oncology; Medicine; Center (category theory); Cohort; Internal medicine; Genetics; Biology; Gene","score_opus":0.00790845023562135,"score_gpt":0.25317451658200646,"score_spread":0.24526606634638512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403348875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961589,0.00047118886,0.000031445637,0.00005334181,0.000084955995,0.0021536893,0.00020167913,0.00007534774,0.0007694588],"genre_scores_gemma":[0.9975088,0.000051777024,0.0016221604,0.000024659654,0.000057039335,0.00020679961,0.00017563831,0.000052996675,0.00030010357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980713,0.000054477714,0.00036387437,0.0005210569,0.0005440921,0.00044515936],"domain_scores_gemma":[0.9990552,0.00015252353,0.00006197459,0.00034671303,0.00017314997,0.00021043066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001319741,0.00024957274,0.00043871877,0.00029935827,0.00003392204,0.00001864691,0.000090557056,0.00010173042,0.00013143812],"category_scores_gemma":[0.00018251527,0.00017700745,0.0001002947,0.0004941814,0.00007815096,0.00012683324,0.000061345636,0.0002694568,0.00007266879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002121302,0.0025260467,0.9857882,0.00029238025,0.0007807297,0.0012685817,0.00038200276,0.0000028658762,0.002214886,0.000019115214,0.000026230962,0.004577604],"study_design_scores_gemma":[0.014459143,0.0012471477,0.9763521,0.00050435826,0.00029086843,0.00004144119,0.000024785044,0.0014505074,0.005383475,0.000018071038,0.00007982716,0.00014827566],"about_ca_topic_score_codex":0.00013034641,"about_ca_topic_score_gemma":0.00025585032,"teacher_disagreement_score":0.012337841,"about_ca_system_score_codex":0.0001011903,"about_ca_system_score_gemma":0.00021408267,"threshold_uncertainty_score":0.7218154},"labels":[],"label_agreement":null},{"id":"W4403400873","doi":"10.1038/s41408-024-01159-8","title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Universitätsklinikum Heidelberg; Deutsches Krebsforschungszentrum","keywords":"Multiple myeloma; Cohort; Medicine; Internal medicine; Oncology","score_opus":0.029946250782767674,"score_gpt":0.3128324942580536,"score_spread":0.2828862434752859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403400873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804072,0.0050485437,0.0000074279833,0.01234202,0.00025513154,0.0013351346,0.0003979257,0.000017020919,0.00018962962],"genre_scores_gemma":[0.9942265,0.0004246033,0.0002478406,0.0035576855,0.0007519439,0.00015585725,0.00026459162,0.00009614361,0.00027483585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709255,0.00010090672,0.00073610706,0.00035477028,0.0012760336,0.0004396538],"domain_scores_gemma":[0.9986089,0.000076890916,0.0005135379,0.00029261815,0.00033991307,0.00016812532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018497987,0.00033759908,0.0008892141,0.00053191575,0.000035307385,0.000027520182,0.0001741508,0.00030303266,0.000137381],"category_scores_gemma":[0.00004752568,0.0002213729,0.0001913985,0.00021251471,0.00006464535,0.00009338868,0.000081481776,0.0018492667,0.000002299605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008269203,0.0005515513,0.96180385,0.0021956698,0.001688983,0.005243325,0.00015433592,0.0000015034831,0.00010278038,9.7180354e-8,0.020799236,0.006631768],"study_design_scores_gemma":[0.0148830535,0.0017040386,0.95058084,0.020307094,0.0005722685,0.00021882146,0.000032101587,0.00002796517,0.003353487,0.00000504152,0.008061556,0.00025376247],"about_ca_topic_score_codex":0.00061489205,"about_ca_topic_score_gemma":0.000080041624,"teacher_disagreement_score":0.018111423,"about_ca_system_score_codex":0.00017334733,"about_ca_system_score_gemma":0.0008474801,"threshold_uncertainty_score":0.9027325},"labels":[],"label_agreement":null},{"id":"W4403458741","doi":"10.1038/s41408-024-01164-x","title":"Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Huntsman Cancer Institute; McMaster University; University of Arkansas for Medical Sciences; Hamilton Health Sciences","keywords":"Multiple myeloma; Retrospective cohort study; Medicine; MEDLINE; Internal medicine; Pediatrics; Oncology; Political science","score_opus":0.05742110478828666,"score_gpt":0.38477372673609556,"score_spread":0.3273526219478089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403458741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95922065,0.0028455104,0.000072895666,0.023916453,0.0009980231,0.0099750515,0.0023961768,0.00008833668,0.0004868838],"genre_scores_gemma":[0.98038435,0.0018681171,0.00021424983,0.004488904,0.0057105767,0.002186655,0.00097203674,0.00019347413,0.0039816555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681205,0.00015167946,0.0006420426,0.000615402,0.0011976083,0.0005812015],"domain_scores_gemma":[0.9978915,0.0003640765,0.0004256543,0.0004184931,0.0006573267,0.00024297195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026745707,0.00055856846,0.0011545306,0.0006477602,0.00017989097,0.00011608952,0.00015366993,0.00033391136,0.00026682927],"category_scores_gemma":[0.00041848954,0.00036135444,0.0008465695,0.00033218993,0.000058203226,0.0000806459,0.000028336199,0.0010829878,0.000013732135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015283101,0.002886474,0.78172225,0.00018924009,0.014431364,0.007045533,0.00051355694,0.000030968684,0.000069866896,9.2041176e-7,0.1856011,0.0059804013],"study_design_scores_gemma":[0.025062352,0.016665267,0.9426377,0.0007800623,0.004350903,0.00021411867,0.000051376945,0.00019732387,0.00046652008,0.00006113737,0.0092199985,0.000293236],"about_ca_topic_score_codex":0.0015630478,"about_ca_topic_score_gemma":0.00052430044,"teacher_disagreement_score":0.17638111,"about_ca_system_score_codex":0.002726486,"about_ca_system_score_gemma":0.0013013761,"threshold_uncertainty_score":0.99988383},"labels":[],"label_agreement":null},{"id":"W4403464661","doi":"10.1016/j.jtct.2024.10.008","title":"A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Multiple myeloma; Cord blood; Transplantation; Internal medicine; CD34; Hematopoietic stem cell transplantation; Gastroenterology; Oncology; Surgery; Immunology; Stem cell; Biology","score_opus":0.021304694824276976,"score_gpt":0.2703610820459259,"score_spread":0.24905638722164894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478126,0.0020357054,0.000622967,0.00003418846,0.00007580792,0.0021575834,0.00021599035,0.000047606532,0.000028903154],"genre_scores_gemma":[0.9910656,0.008054048,0.0001466457,0.000024267369,0.00001976905,0.00017820812,0.00040398535,0.00003631587,0.00007113705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984985,0.000120276825,0.00039048638,0.00040938397,0.00030566147,0.00027566895],"domain_scores_gemma":[0.9994116,0.00018470903,0.000058610658,0.00014314767,0.00005002095,0.00015195837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019265624,0.00024024954,0.0004016706,0.00022285218,0.00008314765,0.000030814623,0.00005605529,0.00005794676,0.000028034983],"category_scores_gemma":[0.000003144724,0.00018591246,0.000055658045,0.00017759042,0.000055596036,0.000066886096,0.0000023934706,0.0001500287,0.0000019131019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012843061,0.007972536,0.7486913,0.0020900883,0.00087669713,0.00061076635,0.012028027,0.000007368877,0.19327989,0.0001353526,0.00000621284,0.021458698],"study_design_scores_gemma":[0.06614607,0.026537541,0.7080974,0.00044306248,0.0008448743,0.00005758514,0.0004932524,0.0002216295,0.19647054,0.0003261084,0.00002116512,0.00034078624],"about_ca_topic_score_codex":0.0005397493,"about_ca_topic_score_gemma":0.00027308657,"teacher_disagreement_score":0.053303007,"about_ca_system_score_codex":0.00001651107,"about_ca_system_score_gemma":0.00004675887,"threshold_uncertainty_score":0.75812906},"labels":[],"label_agreement":null},{"id":"W4403497627","doi":"10.3324/haematol.2024.285893","title":"Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Observational study; Multiple myeloma; Refractory (planetary science); Medicine; Internal medicine; Oncology; Intensive care medicine; Astrobiology; Biology","score_opus":0.19924721023739833,"score_gpt":0.41256001151294147,"score_spread":0.21331280127554314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403497627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207413,0.00027559113,0.000087424,0.0034432064,0.000077524455,0.0034159203,0.000090628295,0.00017630191,0.0003592547],"genre_scores_gemma":[0.9934561,0.00029607533,0.0015190538,0.0005792185,0.000060502654,0.0013428832,0.0007698351,0.00003467993,0.001941639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980211,0.00026807107,0.00042720413,0.00043780953,0.0004206101,0.00042519925],"domain_scores_gemma":[0.99664444,0.002717934,0.00006163255,0.00037949576,0.00009876669,0.0000977185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006023097,0.00023145854,0.00042965042,0.0003953395,0.00015451421,0.00007283851,0.00020185126,0.00008442884,0.00022261383],"category_scores_gemma":[0.0004329758,0.0001171417,0.0001090444,0.0009329893,0.00007419769,0.00008250963,0.00003629847,0.0003085896,0.000057343186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012184064,0.0043069255,0.9469666,0.0004549855,0.0006772958,0.0074372487,0.0049782605,0.000023049932,0.00024968205,0.0020280005,0.014011571,0.0066823103],"study_design_scores_gemma":[0.010846894,0.0031581922,0.9343159,0.0002547098,0.0001015995,0.00016952617,0.0030313241,0.014641964,0.00017921938,0.0006893588,0.032384884,0.00022643329],"about_ca_topic_score_codex":0.0013267301,"about_ca_topic_score_gemma":0.0029073954,"teacher_disagreement_score":0.01837331,"about_ca_system_score_codex":0.00013021388,"about_ca_system_score_gemma":0.00016600285,"threshold_uncertainty_score":0.47769},"labels":[],"label_agreement":null},{"id":"W4403523923","doi":"10.1002/9781394244843.ch7","title":"PLASMA CELL NEOPLASMS AND RELATED CONDITIONS","year":2024,"lang":"en","type":"other","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Computational biology; Computer science; Biology","score_opus":0.014402054289936649,"score_gpt":0.29922515553649703,"score_spread":0.2848231012465604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403523923","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008527049,0.0015841954,0.0000012746192,0.00033262672,0.00015356895,0.00047061505,0.000169352,0.0002994287,0.99613625],"genre_scores_gemma":[0.012833254,0.00047690384,0.00037107483,0.000037787813,0.000062074534,0.000033007986,0.00036690236,0.0002985094,0.9855205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992773,0.000011962605,0.00009899217,0.000267249,0.00016058524,0.00018393146],"domain_scores_gemma":[0.99953395,0.000026642061,0.000022547298,0.00018820092,0.0000109953035,0.00021763619],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000022175249,0.0001616988,0.00022509065,0.0002555676,0.000016782104,0.000019989242,0.000026012745,0.00021822675,0.027587518],"category_scores_gemma":[0.000013872683,0.00011325023,0.000056878955,0.00008985678,0.00006737187,0.000008987184,0.000035763507,0.00022658372,0.010506043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016192402,0.00007666366,0.00020403344,0.00033296744,0.00036186457,0.00093599805,0.000022327646,1.4102582e-8,0.00009768917,0.0003115062,0.99700445,0.00063630287],"study_design_scores_gemma":[0.0028505614,0.00021791506,0.00031315544,0.00045304294,0.000288299,0.00027095078,0.000044183784,0.00013661412,0.00042161913,0.00026992694,0.9945787,0.0001550034],"about_ca_topic_score_codex":0.00020885721,"about_ca_topic_score_gemma":0.000080188,"teacher_disagreement_score":0.017081473,"about_ca_system_score_codex":0.000031471754,"about_ca_system_score_gemma":0.00006863654,"threshold_uncertainty_score":0.9902644},"labels":[],"label_agreement":null},{"id":"W4403568842","doi":"10.1016/j.htct.2024.09.865","title":"LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES","year":2024,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Subgroup analysis; Refractory (planetary science); Multiple myeloma; Internal medicine; Term (time); Oncology; Meta-analysis","score_opus":0.015667412912132736,"score_gpt":0.2839526485226636,"score_spread":0.26828523561053086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403568842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850141,0.013111368,0.00023666165,0.00021621783,0.000095881325,0.0011188458,0.00014646431,0.000027048764,0.00003341627],"genre_scores_gemma":[0.99180824,0.007568393,0.00007251022,0.000041401363,0.000017650162,0.0000648476,0.00029136357,0.000026181635,0.00010939481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984012,0.0001850424,0.00046525156,0.00037539267,0.000340721,0.0002323523],"domain_scores_gemma":[0.9988503,0.00054297806,0.00009264184,0.00034382698,0.00007964145,0.00009065445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001739416,0.00023225865,0.0007379177,0.00023773039,0.000060468963,0.000014055441,0.0001091508,0.00016472077,0.00024264077],"category_scores_gemma":[0.000015359221,0.0001262943,0.00020915346,0.0005039014,0.00024085098,0.00006584151,0.000011799213,0.00023159193,0.0000016774989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11597108,0.0039727637,0.8303033,0.00013664545,0.0015623529,0.000060522012,0.0017093488,2.4160738e-7,0.013386103,0.000009888407,0.000046218545,0.032841545],"study_design_scores_gemma":[0.42416778,0.0070612156,0.51887876,0.0003526932,0.0008290058,0.0000053597096,0.00039916002,0.00024448844,0.047424525,0.000035371664,0.0003416661,0.00025994782],"about_ca_topic_score_codex":0.00038971673,"about_ca_topic_score_gemma":0.00051696796,"teacher_disagreement_score":0.31142452,"about_ca_system_score_codex":0.000017174954,"about_ca_system_score_gemma":0.00006116956,"threshold_uncertainty_score":0.5150132},"labels":[],"label_agreement":null},{"id":"W4403576148","doi":"10.1002/vms3.70084","title":"Cryoglobulinemia Associated With Multiple Myeloma in a Dog Presenting With Epistaxis and Skin Lesions","year":2024,"lang":"en","type":"article","venue":"Veterinary Medicine and Science","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cryoglobulin; Medicine; Pathology; Multiple myeloma; Serum protein electrophoresis; Cryoglobulinemia; Plasmacytoma; Lymphoproliferative disorders; Pancytopenia; Cryoprecipitate; Plasmacytosis; Bone marrow; Lymphoma; Monoclonal; Internal medicine; Immunology; Antibody","score_opus":0.054653554748715756,"score_gpt":0.3484385553914717,"score_spread":0.293785000642756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403576148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541974,0.0010946462,0.00005775005,0.0016355334,0.000031504842,0.0003903166,0.00000687012,0.000053686228,0.0013099714],"genre_scores_gemma":[0.998413,0.00017233155,0.00080136425,0.00007354117,0.000045483837,0.000034306624,0.00001090664,0.000013137108,0.00043592532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831593,0.00004126426,0.00017488039,0.00050381996,0.000541173,0.0004229256],"domain_scores_gemma":[0.9991115,0.0002724314,0.00002933948,0.00018057854,0.00007632779,0.00032982012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000535923,0.00016323352,0.00026496378,0.0003886898,0.00018835386,0.000053023712,0.000081454666,0.000038426377,0.000027303038],"category_scores_gemma":[0.0005315158,0.00009088579,0.000012903191,0.0010453467,0.0011358437,0.00022893565,0.000098965094,0.00021211753,0.0000021901042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011901663,0.00033005702,0.8557946,0.0006672274,0.00014988321,0.022696719,0.005208571,0.0000057113534,0.04200009,0.00014771216,0.0003169269,0.071492344],"study_design_scores_gemma":[0.0031509118,0.0039688493,0.97622293,0.0018303809,0.000039327944,0.0015289063,0.00060704665,0.011576764,0.00026595307,0.000025229254,0.00064939127,0.00013430745],"about_ca_topic_score_codex":0.00039541072,"about_ca_topic_score_gemma":0.000115400755,"teacher_disagreement_score":0.12042833,"about_ca_system_score_codex":0.00007385472,"about_ca_system_score_gemma":0.00021808589,"threshold_uncertainty_score":0.41850635},"labels":[],"label_agreement":null},{"id":"W4403584947","doi":"10.1038/s41408-024-01160-1","title":"Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Coronavirus disease 2019 (COVID-19); Multiple myeloma; Refractory (planetary science); Medicine; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Internal medicine; Phase (matter); Oncology; Intensive care medicine; Virology; Biology; Disease; Chemistry","score_opus":0.03408087033670494,"score_gpt":0.3724803498232491,"score_spread":0.3383994794865442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403584947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676768,0.0006327638,0.0000014438211,0.028251734,0.00012299452,0.0026985528,0.00049948785,0.000020212297,0.00009597883],"genre_scores_gemma":[0.98081714,0.00009278271,0.000036736343,0.01770369,0.00047087407,0.00030802633,0.00015559825,0.0001160819,0.00029904314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534166,0.00048323817,0.0007463024,0.0005726408,0.0020892348,0.0007669343],"domain_scores_gemma":[0.9977944,0.00050640793,0.00046764352,0.0007011928,0.00020412171,0.00032627274],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00053228723,0.00063593907,0.0011188536,0.0010809436,0.000109908055,0.00010632729,0.00042174428,0.00028549277,0.0002073765],"category_scores_gemma":[0.00027825177,0.00029030355,0.00026613407,0.0006609421,0.0001395866,0.00012407769,0.000050044095,0.0045088083,0.000009372673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0093539,0.009429099,0.9179559,0.0003179071,0.0027086248,0.022449782,0.0015918459,0.00003566791,0.000003063696,1.448997e-7,0.034332797,0.0018212702],"study_design_scores_gemma":[0.10184975,0.024460273,0.8657621,0.0012698105,0.00086207554,0.00023195069,0.00039037858,0.000006727745,0.000006131594,0.0000055484807,0.004845718,0.00030950303],"about_ca_topic_score_codex":0.002532637,"about_ca_topic_score_gemma":0.0017845043,"teacher_disagreement_score":0.09249585,"about_ca_system_score_codex":0.0013444407,"about_ca_system_score_gemma":0.0025105672,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W4403597409","doi":"10.58931/cht.2022.1s1130","title":"Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM)","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Charles-Le Moyne; Saskatchewan Cancer Agency; Saint John Regional Hospital; Capital District Health Authority; Southlake Regional Health Center; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Multiple myeloma; Adverse effect; Lenalidomide; Intensive care medicine; Internal medicine","score_opus":0.04678523042382879,"score_gpt":0.36160123150018186,"score_spread":0.3148160010763531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403597409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984885,0.0012215785,0.00068973115,0.0066992487,0.0012934508,0.0034107994,0.00032051143,0.00007855591,0.0014011743],"genre_scores_gemma":[0.9780716,0.00005765807,0.015667725,0.0012017942,0.00003928431,0.0009338586,0.000264191,0.000059179118,0.0037047118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973016,0.00013835836,0.0008561434,0.00061924173,0.00036278574,0.00072187517],"domain_scores_gemma":[0.9973246,0.0005135261,0.00021405194,0.0008455023,0.00013732906,0.00096498843],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062645547,0.00023675668,0.00069364597,0.00039182525,0.00030095628,0.00000210784,0.00026855816,0.00023644105,0.0010678688],"category_scores_gemma":[0.0006962313,0.00022766569,0.00029402104,0.0003505025,0.000117737836,0.00004371013,0.0001332564,0.00045352988,0.000065277614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038927253,0.0028050048,0.90830314,0.0004086868,0.0047583818,0.015455706,0.0027797532,0.000042595253,0.0003003843,0.011512981,0.02810463,0.021636039],"study_design_scores_gemma":[0.023811802,0.0030973672,0.5022166,0.00058824423,0.00032833774,0.0027624008,0.0047567408,0.00047153467,0.000584647,0.0017442683,0.45885172,0.00078633527],"about_ca_topic_score_codex":0.0032913222,"about_ca_topic_score_gemma":0.0032737702,"teacher_disagreement_score":0.43074712,"about_ca_system_score_codex":0.000493746,"about_ca_system_score_gemma":0.0006299669,"threshold_uncertainty_score":0.99984527},"labels":[],"label_agreement":null},{"id":"W4403622133","doi":"10.58931/cht.2024.3254","title":"High-Risk Myeloma: Definitions and Treatments","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.028396329164918483,"score_gpt":0.2820652679824287,"score_spread":0.25366893881751024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97733694,0.006605837,0.000021732872,0.0050988076,0.0002444427,0.00044237392,0.00040313398,0.000120233366,0.009726523],"genre_scores_gemma":[0.99617136,0.00059941213,0.0007884962,0.00026123004,0.000049689937,0.00009737699,0.0001961879,0.000025962601,0.0018102919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998922,0.000045798635,0.00014534246,0.00032072063,0.00009499187,0.0004711419],"domain_scores_gemma":[0.99867696,0.00014565435,0.000013990306,0.00022353228,0.00003296687,0.0009069197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060575025,0.00015213276,0.00026622647,0.00037439706,0.00018120478,0.000032871118,0.000041069572,0.00013383891,0.0006479517],"category_scores_gemma":[0.00011020682,0.0001238476,0.00005959248,0.00018923784,0.0001341012,0.000054410084,0.000015338821,0.00019291969,0.00081666233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114759285,0.00024254262,0.64330006,0.00047479136,0.00263678,0.034737773,0.0006522128,7.935276e-7,0.00012629204,0.1815047,0.04544034,0.09076894],"study_design_scores_gemma":[0.008731923,0.0012689708,0.8642239,0.00066178304,0.001507822,0.014177578,0.00031726528,0.0007935735,0.0027048257,0.020002607,0.084888205,0.00072154566],"about_ca_topic_score_codex":0.050043542,"about_ca_topic_score_gemma":0.07718511,"teacher_disagreement_score":0.22092383,"about_ca_system_score_codex":0.00022125719,"about_ca_system_score_gemma":0.00057896,"threshold_uncertainty_score":0.9999613},"labels":[],"label_agreement":null},{"id":"W4403622172","doi":"10.58931/cht.2023.2340","title":"Monoclonal gammopathy of clinical and undetermined significance","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Monoclonal gammopathy; Paraproteinemias; Medicine; Monoclonal; Immunology; Monoclonal antibody; Antibody","score_opus":0.07689407381640198,"score_gpt":0.3801003601665178,"score_spread":0.3032062863501158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944186,0.00022974481,0.0000046315113,0.0024120763,0.00010666789,0.0002707053,0.000050268816,0.000030232633,0.002477071],"genre_scores_gemma":[0.9979911,0.000085499625,0.0002794274,0.00021861216,0.000042593878,0.000026920712,0.00004160109,0.000012500845,0.0013017826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890095,0.00006578159,0.0003103403,0.00024008725,0.00010656117,0.000376281],"domain_scores_gemma":[0.9986212,0.00026451092,0.00004619372,0.00022253918,0.00005838804,0.00078713265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002449414,0.00009156034,0.00041721412,0.00023300872,0.00004729912,0.0000036860458,0.000061555416,0.00013292233,0.00015564205],"category_scores_gemma":[0.00048598534,0.00007951424,0.000066250504,0.00020453363,0.00029489934,0.000021436683,0.000021266913,0.00013765787,0.00013796196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010887519,0.000029305691,0.9818003,0.00008337538,0.00009020059,0.0023222885,0.00005599853,2.0458364e-7,0.00011104777,0.0014648915,0.004551287,0.009382226],"study_design_scores_gemma":[0.002466071,0.0003024716,0.9876843,0.000060882256,0.000037640126,0.0003951129,0.00007958306,0.00086157135,0.0012923254,0.00043391564,0.006284257,0.0001018607],"about_ca_topic_score_codex":0.0084656,"about_ca_topic_score_gemma":0.02434612,"teacher_disagreement_score":0.015880521,"about_ca_system_score_codex":0.000027897839,"about_ca_system_score_gemma":0.0007645337,"threshold_uncertainty_score":0.9981371},"labels":[],"label_agreement":null},{"id":"W4403629204","doi":"10.1182/blood.2024025415","title":"Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Internal medicine; Asymptomatic; Cumulative incidence; Cohort; Incidence (geometry); Population; Gastroenterology; Oncology; Immunology; Monoclonal; Antibody; Monoclonal antibody","score_opus":0.0332881193770181,"score_gpt":0.400594317533617,"score_spread":0.36730619815659893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403629204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928395,0.0024704621,0.0038972108,0.000012584409,0.00003421036,0.00040902576,0.00013448465,0.000015937374,0.00018658361],"genre_scores_gemma":[0.9885578,0.00008220558,0.011239353,5.379116e-7,0.000017004886,0.000023041825,0.000019819652,0.000012036121,0.000048198322],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988011,0.00011729561,0.00041285474,0.00016842569,0.00037676186,0.00012355375],"domain_scores_gemma":[0.9991613,0.00022482206,0.00023247213,0.00019019947,0.00012274597,0.000068468966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026508133,0.00009161828,0.00041535683,0.00012452222,0.000012845031,0.0000021147164,0.00005740568,0.00006374921,0.000025204678],"category_scores_gemma":[0.00015082874,0.00006815944,0.00011684824,0.00022887526,0.00008279404,0.000029818859,0.000024647312,0.00011219092,0.0000012085301],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057730684,0.0015680579,0.1398849,0.00093205046,0.00035264948,0.000009493535,0.00019400568,0.0000034644004,0.7493066,0.0000070520714,0.000025093774,0.107139304],"study_design_scores_gemma":[0.0022132604,0.0019172691,0.03674325,0.0004058392,0.00036522752,0.000008025782,0.00006384484,0.0047701765,0.95339257,0.000047116715,0.00003283003,0.000040583163],"about_ca_topic_score_codex":0.00023628645,"about_ca_topic_score_gemma":0.000011697093,"teacher_disagreement_score":0.20408596,"about_ca_system_score_codex":0.00001532515,"about_ca_system_score_gemma":0.00008300459,"threshold_uncertainty_score":0.2779461},"labels":[],"label_agreement":null},{"id":"W4403634972","doi":"10.1016/j.jtct.2024.10.011","title":"Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Hematopoietic stem cell transplantation; Stem cell; Autologous stem-cell transplantation; Transplantation; Oncology; Internal medicine; Biology; Genetics","score_opus":0.013130217495050202,"score_gpt":0.25231359619047644,"score_spread":0.23918337869542625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403634972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952452,0.00043714105,0.002701776,0.00009706034,0.000032443775,0.00107294,0.000072184266,0.000072918134,0.0002683381],"genre_scores_gemma":[0.9959495,0.002350481,0.0006551773,0.000030635754,0.000008047522,0.000076205564,0.0006842022,0.000036303147,0.00020941786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986503,0.00008642151,0.00030748188,0.00032149893,0.00039225142,0.00024200666],"domain_scores_gemma":[0.999471,0.00014758261,0.000059673665,0.00014535224,0.000060126647,0.000116284675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099484,0.00022700014,0.00035198004,0.00029439028,0.000048999493,0.0000259506,0.000045374287,0.00006854298,0.000038914335],"category_scores_gemma":[6.6219394e-7,0.00014870832,0.000054378248,0.00026724103,0.00006912238,0.00013034463,0.0000015840427,0.00013759757,0.0000064922683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008924519,0.0006295527,0.9562074,0.0011935297,0.00021473672,0.00078282173,0.004871222,0.00006664811,0.0038124588,0.000084129875,0.0000032634414,0.023209749],"study_design_scores_gemma":[0.018772723,0.0012036213,0.937961,0.0003893421,0.00014552989,0.000016276164,0.00015993675,0.0006323549,0.0405119,0.000010598887,0.000025618363,0.00017109547],"about_ca_topic_score_codex":0.00044456264,"about_ca_topic_score_gemma":0.00071193837,"teacher_disagreement_score":0.03669944,"about_ca_system_score_codex":0.000049046375,"about_ca_system_score_gemma":0.00007196154,"threshold_uncertainty_score":0.6064149},"labels":[],"label_agreement":null},{"id":"W4403667780","doi":"10.1016/j.clml.2024.10.012","title":"First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium","year":2024,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Manitoba; Juravinski Cancer Centre; McMaster University; Saskatchewan Science Centre; London Health Sciences Centre; Université de Montréal; Western University; GLS Industries (Canada); Hôpital Maisonneuve-Rosemont; Ottawa Hospital; Saskatchewan Cancer Agency; Windsor Regional Hospital; CancerCare Manitoba; Centre hospitalier universitaire de Québec; Memorial University of Newfoundland","funders":"Hamilton Health Sciences; Celgene; Leukemia and Lymphoma Society; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Guideline; Multiple myeloma; Family medicine; Intensive care medicine; Internal medicine; Oncology; Pathology","score_opus":0.10348786416042127,"score_gpt":0.40949220947574555,"score_spread":0.3060043453153243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403667780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051029003,0.9680882,0.000029692554,0.0019735165,0.0016396234,0.0048374105,0.016814895,0.0003048188,0.0012089524],"genre_scores_gemma":[0.0074551874,0.96604943,0.0038621894,0.00029713064,0.001521846,0.00089484465,0.017598616,0.000345097,0.0019756365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98874986,0.0006906391,0.0059038154,0.00220023,0.00082574284,0.0016296874],"domain_scores_gemma":[0.98691696,0.006309625,0.0010456459,0.0022021427,0.00051920244,0.0030064047],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00071629474,0.0017450971,0.006823131,0.0010747226,0.00033897324,0.00012269018,0.00064422016,0.0017503119,0.0009921388],"category_scores_gemma":[0.0018025493,0.0012918152,0.003431792,0.0010877337,0.00070604344,0.000074826996,0.00014206312,0.00073921756,0.0019897516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005402428,0.0011243797,0.0015864212,0.003252901,0.0050637354,0.007952751,0.00010142289,0.0000028629715,0.0000013252512,0.00003248039,0.02288116,0.95746034],"study_design_scores_gemma":[0.01215169,0.0020141832,0.007506548,0.016373541,0.00956165,0.00045444627,0.000040626397,0.0010311884,0.00001702348,0.000080390644,0.94982797,0.0009407289],"about_ca_topic_score_codex":0.14327218,"about_ca_topic_score_gemma":0.14709015,"teacher_disagreement_score":0.9565196,"about_ca_system_score_codex":0.0057021896,"about_ca_system_score_gemma":0.017803488,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W4403707232","doi":"10.1016/j.bneo.2024.100050","title":"Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary","keywords":"Multiple myeloma; In vivo; In vitro; Pharmacology; Medicine; Chemistry; Biology; Internal medicine; Biochemistry; Biotechnology","score_opus":0.0566284165187802,"score_gpt":0.36746191264710704,"score_spread":0.31083349612832684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403707232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909134,0.006853788,6.724472e-7,0.00043538402,0.00012807889,0.0010649688,0.000027902504,0.000068359266,0.0005074501],"genre_scores_gemma":[0.9978122,0.0006939607,0.0006204667,0.000052433035,0.00014192762,0.0003221662,0.000011147657,0.000033877615,0.00031179347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793506,0.00016898103,0.00047274563,0.00059805735,0.00029914832,0.0005260327],"domain_scores_gemma":[0.9983977,0.001170173,0.000029102739,0.00018319736,0.00004322765,0.00017658141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036203186,0.00024101962,0.0005671982,0.00057027134,0.00003360392,0.00003233723,0.00006275238,0.00016259965,0.000015615651],"category_scores_gemma":[0.0010452133,0.00020048846,0.00007152806,0.00072263385,0.00015025116,0.00014011795,0.000115979376,0.00059391995,0.000028603823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039518448,0.0016522729,0.9144342,0.00062558224,0.00045257254,0.0083594015,0.0041559963,0.0000031259058,0.04828639,0.000014345265,0.00044021054,0.017624078],"study_design_scores_gemma":[0.031547777,0.001589673,0.7344831,0.0023200545,0.0001760737,0.000659106,0.0018470212,0.0040366547,0.22140649,0.00039696388,0.0010586674,0.0004783848],"about_ca_topic_score_codex":0.00032007578,"about_ca_topic_score_gemma":0.0041423035,"teacher_disagreement_score":0.17995104,"about_ca_system_score_codex":0.0001928032,"about_ca_system_score_gemma":0.00024539075,"threshold_uncertainty_score":0.8175682},"labels":[],"label_agreement":null},{"id":"W4403732996","doi":"10.3390/labmed1010004","title":"Comparison of Two Different Integration Methods for Quantifying Monoclonal Proteins on Agarose Gel and Capillary Zone Electrophoresis Instruments","year":2024,"lang":"en","type":"article","venue":"LabMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Vancouver Coastal Health; BC Cancer Agency; Saint John Regional Hospital; Vancouver General Hospital; Horizon Health Network","funders":"","keywords":"Capillary electrophoresis; Agarose; Chromatography; Agarose gel electrophoresis; Chemistry; Monoclonal antibody; Capillary action; Electrophoresis; Biology; Materials science; Biochemistry; DNA; Genetics; Antibody","score_opus":0.11461003300782563,"score_gpt":0.47250725635782514,"score_spread":0.3578972233499995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403732996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849326,0.0016208158,0.011427662,0.00037904776,0.000087240085,0.0014110192,0.000026049893,0.00004146268,0.00007411081],"genre_scores_gemma":[0.9661245,0.00018114282,0.032922488,0.000023418103,0.000050110277,0.00031190252,0.00013455046,0.00002279145,0.00022913814],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989021,0.00009649486,0.0002520289,0.00026852562,0.00022622205,0.00025462155],"domain_scores_gemma":[0.99939203,0.00021444919,0.000047570404,0.00015421667,0.000058454505,0.00013325019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018528526,0.00015307117,0.0003567883,0.0001727018,0.0000622018,0.00003225161,0.00004354712,0.00005701549,0.000016216623],"category_scores_gemma":[0.00014158849,0.00010472053,0.000078396915,0.0001282537,0.000045568093,0.000042215903,0.000028912833,0.00016758536,0.0000031239367],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014614408,0.00044931562,0.028655197,0.0004666621,0.0003619572,0.000012414107,0.00034746891,7.9549733e-7,0.41124555,0.0012230506,0.00008593612,0.55569017],"study_design_scores_gemma":[0.0036365653,0.0018525925,0.07853677,0.00042257019,0.00014564014,0.000009878513,0.00007798378,0.050064832,0.864265,0.00047397608,0.00039606952,0.00011808724],"about_ca_topic_score_codex":0.00012696644,"about_ca_topic_score_gemma":0.00007917554,"teacher_disagreement_score":0.5555721,"about_ca_system_score_codex":0.000117464566,"about_ca_system_score_gemma":0.000054017302,"threshold_uncertainty_score":0.42703792},"labels":[],"label_agreement":null},{"id":"W4403947139","doi":"10.1038/s41408-024-01165-w","title":"Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society; U.S. Department of Health and Human Services","keywords":"CD34; Medicine; Plerixafor; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Autologous stem-cell transplantation; Melphalan; Haematopoiesis; Propensity score matching; Internal medicine; Urology; Stem cell; Surgery; Oncology; CXCR4; Biology","score_opus":0.019294930824064492,"score_gpt":0.27803633748950685,"score_spread":0.2587414066654424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403947139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203694,0.0057915403,0.00022834695,0.00022323224,0.00041905075,0.00054634496,0.000053352975,0.000070162096,0.0006310442],"genre_scores_gemma":[0.995681,0.0024173907,0.0009515415,0.000059078968,0.00016916957,0.00007012001,0.00004184501,0.000051456285,0.00055842154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978208,0.000117086165,0.0005096524,0.0003509558,0.0006007439,0.00060077955],"domain_scores_gemma":[0.999084,0.00017681914,0.000102316844,0.0001663201,0.00010002881,0.0003705264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019977445,0.00025961708,0.00035598752,0.00035907756,0.0001493545,0.0001324482,0.00012592779,0.0001261982,0.0002134588],"category_scores_gemma":[0.000013880321,0.00021108423,0.0001604639,0.0002820941,0.000041794567,0.00023075854,0.0000255818,0.0006345571,0.00006562789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029370214,0.003487937,0.8785305,0.0042042728,0.0007461516,0.015104879,0.009463738,0.0022698583,0.01260415,0.000012101878,0.0010054498,0.069633946],"study_design_scores_gemma":[0.07286444,0.003425251,0.80462134,0.0043139467,0.0013220104,0.0020807844,0.0013461577,0.012650302,0.0954818,0.000059653757,0.00095853576,0.0008757472],"about_ca_topic_score_codex":0.00014001604,"about_ca_topic_score_gemma":0.00027933792,"teacher_disagreement_score":0.08287765,"about_ca_system_score_codex":0.0003807123,"about_ca_system_score_gemma":0.00075140805,"threshold_uncertainty_score":0.8607765},"labels":[],"label_agreement":null},{"id":"W4403973714","doi":"10.1002/cam4.70308","title":"Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone ( <scp>DRd</scp> ) Versus Bortezomib, Lenalidomide, and Dexamethasone ( <scp>VRd</scp> ) Among Transplant‐Ineligible Patients With Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; Janssen Scientific Affairs; National Comprehensive Cancer Network","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Multiple myeloma; Medicine; Carfilzomib; Bortezomib; Internal medicine; Pharmacology","score_opus":0.07142107851143867,"score_gpt":0.3604306037266603,"score_spread":0.2890095252152216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403973714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752427,0.018576404,0.0005831399,0.00039348463,0.00027770502,0.0029473242,0.00079247076,0.00019241247,0.0009943795],"genre_scores_gemma":[0.9885794,0.002608157,0.0019505717,0.000119804434,0.0006971375,0.0004491433,0.00084949593,0.00017669237,0.004569578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99463946,0.0002223511,0.0011779201,0.0014057376,0.001317728,0.0012368087],"domain_scores_gemma":[0.99275607,0.004159334,0.00030430453,0.0007354171,0.00040270278,0.0016421961],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005228173,0.0010140237,0.0025351795,0.00077897444,0.00025275096,0.000092954586,0.00025754923,0.0002951235,0.0002265595],"category_scores_gemma":[0.0011568811,0.00064287294,0.0001659758,0.0008864362,0.00068382017,0.00037025777,0.000116285366,0.00056478963,0.000060059225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050867996,0.00065165554,0.9360367,0.0009973812,0.003308638,0.0004369317,0.004233787,0.000057496098,0.0023267968,0.0000044072967,0.0064700763,0.040389303],"study_design_scores_gemma":[0.076885924,0.01640205,0.8550094,0.004805908,0.004060941,0.00004428575,0.0008785333,0.0036859673,0.016994884,0.000013133806,0.0209094,0.000309594],"about_ca_topic_score_codex":0.003409301,"about_ca_topic_score_gemma":0.0012211327,"teacher_disagreement_score":0.08102735,"about_ca_system_score_codex":0.0006437333,"about_ca_system_score_gemma":0.00044217572,"threshold_uncertainty_score":0.99960226},"labels":[],"label_agreement":null},{"id":"W4404068977","doi":"10.1002/cam4.70332","title":"Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; McGill University; Juravinski Cancer Centre; Ottawa Regional Cancer Foundation; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; University of British Columbia; Saint John Regional Hospital; BC Cancer Agency; Dalhousie University; Canadian Apheresis Group; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal; Regeneron Pharmaceuticals; Hamilton Health Sciences; Gilead Sciences; Sanofi; Celgene; AstraZeneca; Hamilton Health Sciences Foundation; Pfizer; Amgen","keywords":"Medicine; Multiple myeloma; Internal medicine; Population; Maintenance therapy; Autologous stem-cell transplantation; Surgery; Lenalidomide; Oncology; Chemotherapy","score_opus":0.05289500299435463,"score_gpt":0.3714900261942705,"score_spread":0.3185950231999159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404068977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039304,0.0044127214,0.000011205619,0.0018866587,0.00012769349,0.0019589718,0.0008362216,0.000052826163,0.00032066187],"genre_scores_gemma":[0.9970993,0.0006755326,0.000028096265,0.00012156875,0.00017518026,0.0003752035,0.0006417533,0.00006329592,0.0008201023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971269,0.00014965177,0.00036415036,0.00059360854,0.0011302835,0.0006354179],"domain_scores_gemma":[0.997463,0.00018784929,0.00005089911,0.0005769651,0.00043877497,0.0012824954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004353952,0.00029792194,0.0006196373,0.000686755,0.00016486163,0.000033037915,0.00014085507,0.00005397323,0.0002889631],"category_scores_gemma":[0.00027737796,0.0001764554,0.00003917986,0.0006332841,0.00047154503,0.0001327652,0.00006324743,0.00036590133,0.000008195754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013267896,0.00044093526,0.94890946,0.00047655296,0.000885908,0.0017340885,0.003092709,7.9745604e-8,0.00023906963,0.000031776228,0.0005206241,0.042341992],"study_design_scores_gemma":[0.0059041763,0.0022772965,0.98770463,0.0012543174,0.00038638862,0.000008622188,0.00094848766,0.0006859321,0.000021241944,0.000016453476,0.00064399844,0.00014843114],"about_ca_topic_score_codex":0.081895836,"about_ca_topic_score_gemma":0.04822435,"teacher_disagreement_score":0.04219356,"about_ca_system_score_codex":0.0004382278,"about_ca_system_score_gemma":0.00071743154,"threshold_uncertainty_score":0.9691431},"labels":[],"label_agreement":null},{"id":"W4404162914","doi":"10.5737/23688076344539","title":"The experiences of living with multiple myeloma and a palliative approach to care: A grounded theory study","year":2024,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Grounded theory; Multiple myeloma; Palliative care; Medicine; Nursing; Sociology; Qualitative research; Gerontology; Psychology; Internal medicine; Anthropology","score_opus":0.029916416209311243,"score_gpt":0.3423654989252281,"score_spread":0.31244908271591687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404162914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653775,0.005634023,0.00050254446,0.00082411896,0.0002641036,0.0007507491,0.0000035835103,0.000012507164,0.0054706223],"genre_scores_gemma":[0.99836653,0.00004605582,0.0011278272,0.000063339394,0.000120761324,0.00008253191,9.784118e-7,0.000016496162,0.00017549617],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99869835,0.0002697934,0.00017948996,0.00020844565,0.00022964345,0.00041430056],"domain_scores_gemma":[0.99812263,0.0008215304,0.000042468968,0.00012789424,0.0001411104,0.0007443452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004974872,0.00012206115,0.00023230941,0.0002645011,0.00055983214,0.00010950057,0.00010809392,0.00005519062,0.000015575266],"category_scores_gemma":[0.00046294922,0.000069299036,0.00003773558,0.00025279121,0.00036535348,0.00006423712,0.000012562933,0.00033860255,0.0000020304242],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006866467,0.00033670772,0.045943007,0.000040228035,0.00060366845,0.0010982855,0.6354829,0.0000037641246,0.000044915654,0.0004811995,0.0006614706,0.31461722],"study_design_scores_gemma":[0.0011472689,0.004809174,0.24299201,0.0014871313,0.00015506982,0.0012396149,0.7465071,0.0005561942,0.000025199946,0.00009076536,0.00087980676,0.00011064745],"about_ca_topic_score_codex":0.001382945,"about_ca_topic_score_gemma":0.015915308,"teacher_disagreement_score":0.31450656,"about_ca_system_score_codex":0.0015601141,"about_ca_system_score_gemma":0.002701232,"threshold_uncertainty_score":0.8881116},"labels":[],"label_agreement":null},{"id":"W4404162993","doi":"10.5737/23688076344550","title":"Myélome multiple et approche palliative des soins : étude théorique ancrée dans la pratique","year":2024,"lang":"fr","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine","score_opus":0.042849034159412616,"score_gpt":0.3810065454756031,"score_spread":0.3381575113161905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404162993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26602,0.22884844,0.03719575,0.25198275,0.014237455,0.0031248769,0.0010686999,0.00029010678,0.19723193],"genre_scores_gemma":[0.96795565,0.008914021,0.0077434005,0.000953554,0.0025109581,0.00007197126,0.00008215661,0.0001378295,0.011630486],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99501467,0.0015290055,0.0005843796,0.00055605563,0.0003987099,0.0019171931],"domain_scores_gemma":[0.99439174,0.0013450485,0.00013859064,0.00024085093,0.00032595938,0.0035578148],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015950666,0.00047923703,0.0006584606,0.0008125713,0.0007405203,0.0003876436,0.0002984588,0.0008296598,0.00055682636],"category_scores_gemma":[0.0013520401,0.00044053316,0.00028364532,0.0006073477,0.001527034,0.00044450618,0.000027072845,0.003098419,0.00028928244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005785548,0.0015013949,0.033818047,0.00072625885,0.002935451,0.100723006,0.10289346,0.00022047943,0.003499117,0.024857024,0.091726065,0.63652116],"study_design_scores_gemma":[0.008337103,0.0052612843,0.21500646,0.026580978,0.0011406206,0.03171164,0.02509359,0.026078552,0.0008941227,0.0141855655,0.64465195,0.0010581098],"about_ca_topic_score_codex":0.0144281285,"about_ca_topic_score_gemma":0.26116592,"teacher_disagreement_score":0.7019356,"about_ca_system_score_codex":0.026031671,"about_ca_system_score_gemma":0.048530918,"threshold_uncertainty_score":0.9998046},"labels":[],"label_agreement":null},{"id":"W4404222964","doi":"10.1038/s41408-024-01177-6","title":"Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Lenalidomide; Multiple myeloma; Dexamethasone; Bortezomib; Medicine; Internal medicine; Hematology; Induction therapy; Oncology; Chemotherapy","score_opus":0.021626995701039278,"score_gpt":0.3043724535718073,"score_spread":0.28274545787076805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404222964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464184,0.0027032918,0.000021912983,0.00092125114,0.00018097476,0.00059609814,0.00082370016,0.000029288582,0.000081620914],"genre_scores_gemma":[0.99755895,0.0010886953,0.00033040074,0.000057902507,0.00067971344,0.00003770877,0.000113187714,0.00004007874,0.0000933844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978561,0.00016552235,0.000455937,0.0003901831,0.0007379845,0.00039431313],"domain_scores_gemma":[0.9979769,0.00079675147,0.0002630264,0.00035468687,0.00023901758,0.00036963949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035246788,0.00027000133,0.0003927349,0.000147183,0.00018896264,0.00012931175,0.00012461861,0.00010177415,0.00013794762],"category_scores_gemma":[0.00051160203,0.00013968717,0.00018040545,0.00028084603,0.00015809477,0.0001811749,0.000037148446,0.0007082469,0.0000051228817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028960468,0.0012943756,0.8733343,0.00006576656,0.004673527,0.0009251055,0.001220849,0.00015122084,0.0034475748,0.0000055042024,0.004661634,0.081259705],"study_design_scores_gemma":[0.03720107,0.0041144677,0.9512272,0.0016476162,0.0005611938,0.00019703081,0.00013297076,0.00022624519,0.004250805,0.00003657783,0.00024675744,0.00015806718],"about_ca_topic_score_codex":0.0034874214,"about_ca_topic_score_gemma":0.00028518328,"teacher_disagreement_score":0.08110164,"about_ca_system_score_codex":0.00025978073,"about_ca_system_score_gemma":0.0006140468,"threshold_uncertainty_score":0.56962776},"labels":[],"label_agreement":null},{"id":"W4404360795","doi":"10.3324/haematol.2024.285916","title":"Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute","keywords":"Pomalidomide; Ixazomib; Dexamethasone; Multiple myeloma; Medicine; Oncology; Lenalidomide; Internal medicine; Refractory (planetary science); Cytogenetics; Carfilzomib; Biology; Genetics; Chromosome","score_opus":0.035197362417903034,"score_gpt":0.30476384999350237,"score_spread":0.2695664875755993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404360795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944193,0.001736152,0.000027497359,0.0008684463,0.00009064757,0.0024911151,0.00004483988,0.0001699865,0.0001520518],"genre_scores_gemma":[0.99570566,0.00092644343,0.0020382807,0.00010970596,0.00006353668,0.00048716847,0.000032530952,0.000051599658,0.0005850964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972513,0.0005510281,0.00045097608,0.00071656227,0.00046614904,0.0005640099],"domain_scores_gemma":[0.9973757,0.0015463169,0.00011408272,0.0006538162,0.000061746105,0.00024829587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006523854,0.00036016415,0.00078500825,0.00023101528,0.0001846735,0.0001044829,0.00018289867,0.0001567107,0.00036594618],"category_scores_gemma":[0.00079149054,0.00016663935,0.00007521283,0.0003872492,0.0002536564,0.000079384525,0.00015021524,0.0005892309,0.00018195288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016056303,0.001533753,0.93645996,0.00023024641,0.0008234708,0.017815601,0.0015245384,0.000002162682,0.0032232627,0.00005387198,0.00039140208,0.021885408],"study_design_scores_gemma":[0.014745299,0.004348467,0.97380924,0.0002914389,0.00027723968,0.0010833426,0.0011569415,0.0006528215,0.002040903,0.00006047198,0.001275274,0.0002585388],"about_ca_topic_score_codex":0.00067270035,"about_ca_topic_score_gemma":0.0010564035,"teacher_disagreement_score":0.037349284,"about_ca_system_score_codex":0.00009291124,"about_ca_system_score_gemma":0.0001581342,"threshold_uncertainty_score":0.67953557},"labels":[],"label_agreement":null},{"id":"W4404590966","doi":"10.3390/curroncol31110535","title":"A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Jazz Pharmaceuticals; Gilead Sciences; Sanofi; Amgen; Pfizer; Vertex Pharmaceuticals","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Stem cell; Oncology; Internal medicine","score_opus":0.12156147556254786,"score_gpt":0.42413521734486276,"score_spread":0.3025737417823149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404590966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778997,0.016845105,0.00006880516,0.0001598486,0.0005945516,0.0040451875,0.00014579268,0.00005419228,0.00018683939],"genre_scores_gemma":[0.9972669,0.001037944,0.00036141928,0.000026256437,0.000036058053,0.0007476925,0.00014462759,0.00004494601,0.0003341462],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970982,0.00042270625,0.0007628999,0.00074362534,0.00037389674,0.0005986896],"domain_scores_gemma":[0.998366,0.00069486885,0.0001132657,0.00037141962,0.000057056,0.00039736807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067323074,0.0003478405,0.0010305723,0.00040255423,0.00015261865,0.0000372291,0.0002686351,0.00017145975,0.000043866166],"category_scores_gemma":[0.00007651939,0.00028001142,0.00011869474,0.00045123088,0.00008915218,0.000121159785,0.00030777243,0.00040043623,0.000011679987],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016726589,0.09652172,0.1315739,0.0007840199,0.0013892609,0.004737086,0.014496382,0.0000065041527,0.24421024,0.0000123040545,0.0018214157,0.48772055],"study_design_scores_gemma":[0.8383845,0.064431794,0.013421699,0.002276466,0.0023143324,0.0002476292,0.006070362,0.021554502,0.023542548,0.000033141885,0.026645025,0.0010780165],"about_ca_topic_score_codex":0.00046852464,"about_ca_topic_score_gemma":0.0010467612,"teacher_disagreement_score":0.8216579,"about_ca_system_score_codex":0.00058073574,"about_ca_system_score_gemma":0.0006235429,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W4404633978","doi":"10.1016/j.clml.2024.11.009","title":"Let's Agree to Disagree: Reflections From the Smoldering Multiple Myeloma Session at the International Myeloma Society Study Summit","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Summit; Multiple myeloma; Session (web analytics); Oncology; Internal medicine; Cartography; Advertising","score_opus":0.09523749738024062,"score_gpt":0.4045810270794931,"score_spread":0.3093435296992525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404633978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97702956,0.00092970213,0.00033742876,0.013208266,0.0026559278,0.0024123762,0.00027382918,0.00047745963,0.0026754204],"genre_scores_gemma":[0.981672,0.00022814146,0.0010561093,0.0030104308,0.0029733926,0.0005034954,0.0002974113,0.0001452943,0.010113712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9935374,0.00052331656,0.001431405,0.001687927,0.001790876,0.0010290489],"domain_scores_gemma":[0.9914074,0.0054083453,0.00019945158,0.0018680488,0.00029330634,0.00082348124],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016232532,0.0006844963,0.00081420527,0.00012726794,0.0012656703,0.00053721224,0.0012370528,0.00039525193,0.0011509303],"category_scores_gemma":[0.0021652915,0.00039057177,0.0011611222,0.00097095186,0.0005504752,0.00030172337,0.0016634776,0.00093397737,0.0020214224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014174036,0.0007604286,0.28238222,0.000033794928,0.002177118,0.00097062474,0.0016544166,0.000031953485,0.0021799328,0.00003726469,0.06975727,0.63859755],"study_design_scores_gemma":[0.004460732,0.00071517396,0.85486346,0.0003468584,0.00036912644,0.000094864896,0.0018437825,0.0056905705,0.0010053808,0.000105013976,0.13012011,0.00038491713],"about_ca_topic_score_codex":0.0015429859,"about_ca_topic_score_gemma":0.0041086776,"teacher_disagreement_score":0.6382126,"about_ca_system_score_codex":0.0030245294,"about_ca_system_score_gemma":0.0011102688,"threshold_uncertainty_score":0.9998546},"labels":[],"label_agreement":null},{"id":"W4404672934","doi":"10.1097/01.cot.0001095668.90597.ea","title":"TRIMM-2 Study Shows Efficacy in R/R Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.051462670732438646,"score_gpt":0.38252459011935364,"score_spread":0.331061919386915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404672934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588565,0.0013242315,0.000006130395,0.0013578736,0.00022345857,0.0013902618,0.0000105301415,0.00016556436,0.03666543],"genre_scores_gemma":[0.9770527,0.00003941759,0.00041187461,0.00009626391,0.00014394072,0.00018006553,0.000034055545,0.000028571116,0.022013132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984853,0.00016939266,0.00027086536,0.0004169894,0.0002410636,0.00041635655],"domain_scores_gemma":[0.99877346,0.0007083718,0.000019921741,0.00027655653,0.000034361656,0.00018732864],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034142926,0.00016898217,0.0004156793,0.00034536503,0.000055285156,0.00002562347,0.000101046055,0.0001312284,0.0013392358],"category_scores_gemma":[0.00033785685,0.00012678953,0.00009650291,0.00034735785,0.00008626407,0.0000681606,0.00007722592,0.00035794673,0.0013999537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018615784,0.00970739,0.48149008,0.00010187597,0.00071336515,0.017974004,0.0021902926,0.0000065899653,0.0030673381,0.00012235797,0.017319607,0.46544555],"study_design_scores_gemma":[0.016073328,0.005196183,0.88663,0.000116243835,0.00015011821,0.0001940723,0.0008089278,0.0031113888,0.0010845176,0.000054374952,0.0863871,0.0001937783],"about_ca_topic_score_codex":0.0001870007,"about_ca_topic_score_gemma":0.00039165016,"teacher_disagreement_score":0.46525174,"about_ca_system_score_codex":0.00032980464,"about_ca_system_score_gemma":0.00039509434,"threshold_uncertainty_score":0.99957365},"labels":[],"label_agreement":null},{"id":"W4404727058","doi":"10.1016/j.ajem.2024.11.073","title":"An emergency medicine review: Multiple myeloma and its complications","year":2024,"lang":"en","type":"review","venue":"The American Journal of Emergency Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"U.S. Army; Defense Health Agency; U.S. Department of Defense","keywords":"Multiple myeloma; Medicine; Intensive care medicine; Internal medicine","score_opus":0.16213366626834178,"score_gpt":0.48132217494685053,"score_spread":0.3191885086785088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404727058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020451038,0.9863764,0.000043596192,0.008709156,0.0017798519,0.0016697148,0.00005671933,0.000043825643,0.0011162026],"genre_scores_gemma":[0.00060775445,0.9937317,0.00007567056,0.00020830287,0.0030729894,0.00011228248,0.00015514142,0.00013870807,0.0018974879],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932285,0.00076946954,0.003410433,0.00059722504,0.001372863,0.0006215075],"domain_scores_gemma":[0.99362373,0.00040235324,0.0026892908,0.0011513251,0.000991778,0.0011415287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002040003,0.00084892596,0.004702841,0.00076927163,0.00022170824,0.000003989539,0.000870052,0.000098052195,0.0031625917],"category_scores_gemma":[0.0022291432,0.00038684972,0.0007349688,0.0021846232,0.0006510192,0.00013306973,0.00012960717,0.0014334468,0.0001411156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014936004,0.00029518994,0.00024578755,0.03445069,0.0027837798,0.0001985259,0.00039775204,1.2688025e-7,0.00006576618,0.00009074216,0.16120927,0.800113],"study_design_scores_gemma":[0.00084822293,0.005255846,0.00086295913,0.08012516,0.013613637,0.0016805239,0.00026028111,0.00005431468,5.8093553e-7,0.00008246034,0.89689434,0.0003216622],"about_ca_topic_score_codex":0.000112481546,"about_ca_topic_score_gemma":0.000017221062,"teacher_disagreement_score":0.79979134,"about_ca_system_score_codex":0.00016081858,"about_ca_system_score_gemma":0.00040083152,"threshold_uncertainty_score":0.9998583},"labels":[],"label_agreement":null},{"id":"W4405034776","doi":"10.1182/blood-2024-207816","title":"A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Antibody-drug conjugate; Medicine; Multiple myeloma; Refractory (planetary science); Phases of clinical research; Lenalidomide; Conjugate; Internal medicine; Pomalidomide; Oncology; Drug; Antibody; Pharmacology; Monoclonal antibody; Immunology; Clinical trial; Biology","score_opus":0.016775214664985792,"score_gpt":0.30284185576448125,"score_spread":0.2860666410994955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965797,0.000628507,0.00001550557,0.000053318527,0.00010020209,0.0020860764,0.00014662024,0.00010745392,0.0002826156],"genre_scores_gemma":[0.99849194,0.000022896116,0.00066438684,0.00002339681,0.00007119629,0.000103124745,0.00028163375,0.00007219963,0.00026920933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973773,0.00008975796,0.000560069,0.000621352,0.00079023023,0.00056131993],"domain_scores_gemma":[0.99878013,0.00020031702,0.00011535232,0.00044613314,0.00018808096,0.00026997062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030520564,0.0003264953,0.00057895517,0.00042246358,0.00011620553,0.000033331773,0.00014667677,0.00008145682,0.00007046502],"category_scores_gemma":[0.00028127263,0.00023980826,0.000095739146,0.00058453315,0.00008427885,0.0002066948,0.00013785799,0.00044183986,0.000032139782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039910707,0.09602137,0.86342686,0.00045394833,0.0011648575,0.0012718043,0.003918873,0.0000054117963,0.023957077,0.000007934034,0.000124295,0.0056564976],"study_design_scores_gemma":[0.31418508,0.034454238,0.6304281,0.0017501729,0.0007718642,0.00002972989,0.0017953019,0.001719619,0.013221024,0.0000070534975,0.0010472136,0.00059059705],"about_ca_topic_score_codex":0.00058266445,"about_ca_topic_score_gemma":0.00019794806,"teacher_disagreement_score":0.31019402,"about_ca_system_score_codex":0.00007846314,"about_ca_system_score_gemma":0.00021658966,"threshold_uncertainty_score":0.9779097},"labels":[],"label_agreement":null},{"id":"W4405035355","doi":"10.1182/blood-2024-199752","title":"Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pomalidomide; Dexamethasone; Bortezomib; Multiple myeloma; Medicine; Lenalidomide; Internal medicine; Refractory (planetary science); Oncology; Biology","score_opus":0.04045807147465276,"score_gpt":0.35374473819284347,"score_spread":0.3132866667181907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405035355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842233,0.002624765,0.000052351603,0.00013082587,0.00015519254,0.0076155984,0.0006369135,0.00027505215,0.0000869704],"genre_scores_gemma":[0.9910215,0.0011181674,0.0058530723,0.0000736803,0.00019321575,0.000481008,0.00058693823,0.00037826292,0.00029413626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99004066,0.0011855526,0.0027670383,0.002269113,0.0021481244,0.0015895198],"domain_scores_gemma":[0.99366075,0.001956489,0.0010381839,0.0016390826,0.0007547375,0.000950753],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016752818,0.0015223945,0.0034692022,0.0019394453,0.00034554253,0.00024133424,0.00068803923,0.0005381762,0.00023791002],"category_scores_gemma":[0.0015897956,0.0010613202,0.00039964454,0.0021995166,0.00070124894,0.0013502093,0.00048814094,0.0011359561,0.0000096038675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13893709,0.043296095,0.68234533,0.0011094551,0.0040821224,0.0039369636,0.003320194,0.000031818192,0.1075673,0.0000128902575,0.000027106045,0.015333645],"study_design_scores_gemma":[0.2751056,0.03492979,0.5833788,0.0026636522,0.0015028999,0.0003774353,0.0025929306,0.0016770785,0.09638129,0.00002391145,0.00014347928,0.0012231295],"about_ca_topic_score_codex":0.0024435667,"about_ca_topic_score_gemma":0.0013021817,"teacher_disagreement_score":0.13616852,"about_ca_system_score_codex":0.0004454283,"about_ca_system_score_gemma":0.0011983848,"threshold_uncertainty_score":0.99975246},"labels":[],"label_agreement":null},{"id":"W4405038457","doi":"10.1182/blood-2024-201543","title":"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University of Alberta","funders":"","keywords":"Daratumumab; Bortezomib; Dexamethasone; Medicine; Internal medicine; Oncology; Multiple myeloma; Minimal residual disease; Refractory (planetary science); Carfilzomib; Bone marrow; Biology","score_opus":0.014830320408139985,"score_gpt":0.26912738377670514,"score_spread":0.25429706336856517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933867,0.0014812517,0.000019447256,0.0005226212,0.000036887515,0.0028905466,0.0014914793,0.00013535921,0.00003573229],"genre_scores_gemma":[0.9962233,0.00013503886,0.0011284976,0.00008027448,0.0000853779,0.0002320307,0.0016414621,0.00009554919,0.00037851895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957092,0.000594235,0.0006217848,0.001286553,0.0010376084,0.0007506317],"domain_scores_gemma":[0.9947548,0.003353522,0.00019600666,0.0008434532,0.00011626725,0.0007359722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044463243,0.0006693065,0.0012983856,0.00041247928,0.0002668058,0.00023400149,0.00019615267,0.0002078598,0.00008180035],"category_scores_gemma":[0.0011920988,0.00035615324,0.0001620408,0.0012484103,0.00044214158,0.00028981696,0.00014379447,0.0006897487,0.0000071567583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20124668,0.0028569251,0.78472435,0.000056575635,0.00480669,0.0012131865,0.0004374972,0.0000020168607,0.00007422928,0.0000013323888,0.00018813585,0.0043924055],"study_design_scores_gemma":[0.20935702,0.0034828957,0.78045326,0.00023028089,0.0050951866,0.000008349369,0.00013808542,0.0005121701,0.0002750124,0.000002413418,0.000099502075,0.00034580549],"about_ca_topic_score_codex":0.0034803809,"about_ca_topic_score_gemma":0.0034639603,"teacher_disagreement_score":0.008110356,"about_ca_system_score_codex":0.00016627552,"about_ca_system_score_gemma":0.00044666493,"threshold_uncertainty_score":0.999889},"labels":[],"label_agreement":null},{"id":"W4405038598","doi":"10.1182/blood-2024-209131","title":"Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Hypogammaglobulinemia; Multiple myeloma; Medicine; Incidence (geometry); Internal medicine; Gastroenterology; Pediatrics; Immunology; Antibody","score_opus":0.007209675090959893,"score_gpt":0.23586235475856795,"score_spread":0.22865267966760805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986185,0.00025512706,0.0000058758246,0.00002729191,0.0000057968473,0.0007127884,0.000107627464,0.000028684086,0.00023832428],"genre_scores_gemma":[0.9984416,0.000045379762,0.001285312,0.0000032951864,0.000006918816,0.000037379155,0.00006738937,0.000015410538,0.00009731476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914056,0.000035127676,0.0001883192,0.00024000296,0.00022944935,0.00016654971],"domain_scores_gemma":[0.9994677,0.00012440536,0.000048191163,0.00015094965,0.00010377281,0.00010501648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000073414434,0.00012601666,0.00026913724,0.00017324396,0.000027172051,0.000008960892,0.00002666188,0.00005595633,0.00001800339],"category_scores_gemma":[0.00009599546,0.000083468345,0.00001750503,0.00034755695,0.00013718306,0.00008922351,0.000036105976,0.00013407103,0.0000016416808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010079356,0.0011419888,0.993236,0.0004221556,0.00018828327,0.000121185374,0.0001531908,7.0150395e-7,0.0007111909,0.0000053327462,0.0000074852805,0.0030045193],"study_design_scores_gemma":[0.0135498885,0.002320549,0.9729781,0.0006099434,0.00016238194,0.00007255149,0.000034919678,0.00027164197,0.009911215,0.0000041645217,0.000008796095,0.000075859854],"about_ca_topic_score_codex":0.000641593,"about_ca_topic_score_gemma":0.00044176003,"teacher_disagreement_score":0.020257942,"about_ca_system_score_codex":0.00002138588,"about_ca_system_score_gemma":0.00009627882,"threshold_uncertainty_score":0.34037405},"labels":[],"label_agreement":null},{"id":"W4405038601","doi":"10.1182/blood-2024-198797","title":"Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Windsor Regional Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Gerontology; Internal medicine","score_opus":0.021203817859159913,"score_gpt":0.27429770396881803,"score_spread":0.2530938861096581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973252,0.0005271832,0.00003985892,0.000024678919,0.000032420754,0.0005651388,0.00019413729,0.000061590006,0.0012298152],"genre_scores_gemma":[0.9986747,0.0000268608,0.00080999266,0.000009952825,0.000038871134,0.000043920645,0.0002687262,0.000029931376,0.000097068354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986359,0.00005709241,0.00020628399,0.0003272278,0.00045649768,0.00031699447],"domain_scores_gemma":[0.9993416,0.0001076789,0.000029760824,0.00023316912,0.00010696947,0.000180831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106169966,0.00017373658,0.00029296902,0.00023665781,0.00003775268,0.000020566933,0.000075920834,0.00008046617,0.00005597688],"category_scores_gemma":[0.00006756233,0.00012098651,0.000055767356,0.00033592485,0.000051562198,0.00014460973,0.000014013845,0.000227165,0.000011343164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097145647,0.002162454,0.9770136,0.0002493687,0.0003972952,0.00034738914,0.0012761803,0.0000057732013,0.002661712,0.000015926838,0.000014587657,0.014884282],"study_design_scores_gemma":[0.014833256,0.0018193504,0.94556016,0.0010444862,0.00019500797,0.000016737811,0.00012192786,0.00077253877,0.035387766,0.000015544361,0.00008681433,0.00014639116],"about_ca_topic_score_codex":0.00049540086,"about_ca_topic_score_gemma":0.0009994097,"teacher_disagreement_score":0.032726053,"about_ca_system_score_codex":0.00003774159,"about_ca_system_score_gemma":0.00017092383,"threshold_uncertainty_score":0.49336866},"labels":[],"label_agreement":null},{"id":"W4405038610","doi":"10.1182/blood-2024-208192","title":"MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Dosing; Multiple myeloma; Refractory (planetary science); Term (time); Internal medicine; Intensive care medicine; Oncology; Surgery","score_opus":0.015081073140971075,"score_gpt":0.26859676719311715,"score_spread":0.2535156940521461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621606,0.0027868028,0.000013028622,0.00005309695,0.000025228992,0.00073261146,0.00009206564,0.000020687348,0.00006043488],"genre_scores_gemma":[0.9984105,0.0005844888,0.00079708756,0.000009416561,0.000014143367,0.0000120182,0.00010165033,0.000026362704,0.00004429258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877876,0.000053793774,0.00031540237,0.00030726485,0.00031506686,0.00022968833],"domain_scores_gemma":[0.99931586,0.0001760661,0.00006503466,0.00023564747,0.00006361304,0.00014378053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011832253,0.00015851767,0.000354944,0.00020523909,0.000029338868,0.000015314996,0.000051038653,0.00007253649,0.0000363704],"category_scores_gemma":[0.000093094626,0.000105777195,0.000026960613,0.00019871084,0.00014306852,0.000102675505,0.00005945527,0.00016762562,0.0000017982096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050222077,0.0015060933,0.91367656,0.000951183,0.00028749445,0.00046529085,0.0002333786,4.3221425e-7,0.0021140883,0.000015014041,0.000004069699,0.07572417],"study_design_scores_gemma":[0.03323149,0.0017929765,0.9591389,0.0013692398,0.00017872946,0.000023890001,0.000026225403,0.00004848355,0.0040685777,0.0000036601268,0.000021393544,0.00009645738],"about_ca_topic_score_codex":0.00012843659,"about_ca_topic_score_gemma":0.00016292093,"teacher_disagreement_score":0.075627714,"about_ca_system_score_codex":0.00003245796,"about_ca_system_score_gemma":0.00009012977,"threshold_uncertainty_score":0.43134686},"labels":[],"label_agreement":null},{"id":"W4405038614","doi":"10.1182/blood-2024-209661","title":"Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Residual; Minimal residual disease; Internal medicine; Peripheral; Disease; Pomalidomide; Oncology; Lenalidomide; Bone marrow","score_opus":0.03498846860530305,"score_gpt":0.30830685385841694,"score_spread":0.2733183852531139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437207,0.000849982,0.000006519067,0.001496565,0.00005838516,0.0022633485,0.00051523576,0.00016487791,0.00027300164],"genre_scores_gemma":[0.9950386,0.00012940106,0.0008152681,0.000099948855,0.00014444794,0.0007259314,0.00031983794,0.00008692773,0.0026395873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687356,0.0003508082,0.00034134008,0.0008728794,0.0008321192,0.0007292699],"domain_scores_gemma":[0.9969217,0.00060877466,0.00003660724,0.00059318775,0.00012251824,0.0017171862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027140934,0.00041909318,0.0004479227,0.00048872706,0.00015098664,0.00017664928,0.00010609821,0.000055520697,0.00008981936],"category_scores_gemma":[0.00070923445,0.00030006794,0.00008283888,0.0005461768,0.00009731295,0.00022005117,0.00008472969,0.00018895726,0.000041517666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053792726,0.0035785064,0.9262921,0.00018007128,0.00041467787,0.010998246,0.00043365388,0.000037934293,0.0001839636,0.000026313006,0.00036226402,0.0036995083],"study_design_scores_gemma":[0.024217613,0.002402608,0.9703934,0.00065517926,0.00046427257,0.0000057957404,0.00006885332,0.0002653877,0.00042250307,0.00001735107,0.0007840886,0.00030293915],"about_ca_topic_score_codex":0.0011215797,"about_ca_topic_score_gemma":0.0022795112,"teacher_disagreement_score":0.044101276,"about_ca_system_score_codex":0.0004364194,"about_ca_system_score_gemma":0.00089873,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W4405038949","doi":"10.1182/blood-2024-208740","title":"Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Health Sciences Centre; University Health Network; University of Toronto; University of New Brunswick; Princess Margaret Cancer Centre; Vancouver General Hospital; Saint John Regional Hospital; BC Cancer Agency","funders":"","keywords":"Multiple myeloma; Cell-free fetal DNA; Biology; Genome; Whole genome sequencing; DNA sequencing; DNA; Computational biology; Genetics; Cancer research; Gene; Immunology","score_opus":0.027899975355678914,"score_gpt":0.273542996899855,"score_spread":0.24564302154417608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566346,0.0008899511,0.00058900384,0.00020583982,0.00012590537,0.0012940097,0.00012903547,0.000109482164,0.0009932818],"genre_scores_gemma":[0.9961491,0.000052959178,0.0019498658,0.00004313223,0.00026480324,0.00036965247,0.000111587804,0.000046434085,0.0010124262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866974,0.000025177133,0.00022283885,0.00039383344,0.0002410914,0.0004473416],"domain_scores_gemma":[0.9991213,0.00025472385,0.000026923319,0.00035005438,0.000065691354,0.00018129028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016897432,0.00017017372,0.00023345066,0.0002800858,0.000086087006,0.000048265098,0.00010846236,0.00010369196,0.000026568061],"category_scores_gemma":[0.00032809546,0.00014776645,0.00013135432,0.00028614549,0.00003285899,0.00010859056,0.00006230433,0.00019178269,0.00015069472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021376998,0.00039224495,0.008062376,0.0008236303,0.00018771122,0.0010485837,0.0005870786,0.000008464669,0.98203456,0.0000049520736,0.00012327815,0.006513335],"study_design_scores_gemma":[0.017003173,0.0011453258,0.046763945,0.0003755952,0.00021734061,0.00014304795,0.00039494262,0.0050909873,0.9263268,0.00023658012,0.0020527788,0.00024948872],"about_ca_topic_score_codex":0.00019567244,"about_ca_topic_score_gemma":0.0006206614,"teacher_disagreement_score":0.05570778,"about_ca_system_score_codex":0.0002416842,"about_ca_system_score_gemma":0.0002691095,"threshold_uncertainty_score":0.60257405},"labels":[],"label_agreement":null},{"id":"W4405039028","doi":"10.1182/blood-2024-206247","title":"Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; Vancouver General Hospital; BC Cancer Agency; Saint John Regional Hospital; Hôpital Maisonneuve-Rosemont; Concordia University; McGill University; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University","funders":"","keywords":"Melphalan; Medicine; Busulfan; Lenalidomide; Multiple myeloma; Maintenance therapy; Plerixafor; Surgery; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.03033523071453066,"score_gpt":0.28672348037757434,"score_spread":0.2563882496630437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993026,0.00019785257,0.000014000229,0.0007189408,0.0001619762,0.0045434586,0.0010885716,0.00003453282,0.00021462854],"genre_scores_gemma":[0.9970407,0.000031043855,0.0012776853,0.000020190331,0.0002197633,0.00047341775,0.00055479794,0.00006194469,0.00032049572],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99691284,0.00018035634,0.00057686487,0.00060116954,0.00096771197,0.0007610467],"domain_scores_gemma":[0.99712044,0.0006980856,0.00020161821,0.0005170509,0.0010309193,0.00043189042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008009356,0.00028653888,0.00058078393,0.00041675218,0.00040079278,0.00009312245,0.00020435278,0.00016257007,0.0000155321],"category_scores_gemma":[0.00086542545,0.00017439509,0.00009036277,0.0006648685,0.00059199746,0.00016656879,0.00006002368,0.00046782885,0.0000030573226],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69595444,0.011257794,0.21913381,0.0019585846,0.005328239,0.0016550539,0.0034785548,0.00002865545,0.0041677677,0.0028737497,0.0033724145,0.050790943],"study_design_scores_gemma":[0.48500258,0.012032509,0.49043792,0.0014647035,0.0004414394,0.00010424657,0.00034201858,0.000077450386,0.008404714,0.000121562545,0.0013045965,0.00026626905],"about_ca_topic_score_codex":0.076488696,"about_ca_topic_score_gemma":0.13431811,"teacher_disagreement_score":0.2713041,"about_ca_system_score_codex":0.00020846742,"about_ca_system_score_gemma":0.001171634,"threshold_uncertainty_score":0.92966104},"labels":[],"label_agreement":null},{"id":"W4405039089","doi":"10.1182/blood-2024-211173","title":"Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Terry Fox Research Institute","funders":"","keywords":"APOBEC; Mutagenesis; Biology; Genetics; Replication (statistics); Mutation; Virology; Genome; Gene","score_opus":0.04264487445024339,"score_gpt":0.31857309672138456,"score_spread":0.27592822227114117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469775,0.0022780222,0.0000075750963,0.000511366,0.000059843274,0.0004748391,0.000042552994,0.00013977961,0.0017882505],"genre_scores_gemma":[0.9979575,0.00020114596,0.00054859224,0.000037212565,0.00013900017,0.00016171024,0.00013500548,0.000027880791,0.00079191127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998766,0.000040583895,0.00019610445,0.0004487947,0.00027112872,0.00027739455],"domain_scores_gemma":[0.9991584,0.00012482463,0.000019083778,0.0005096312,0.00004024736,0.00014780392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001488462,0.00012752392,0.00017999337,0.00023034532,0.000045350043,0.00004315378,0.00008738747,0.0000845121,0.00010546779],"category_scores_gemma":[0.00027386766,0.00010288579,0.000067550136,0.0003631215,0.00003464616,0.00009263019,0.000043691936,0.00015502446,0.00021191179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012522847,0.0016739065,0.6189173,0.00031427311,0.00025411503,0.0012236492,0.00038857735,0.0000017786895,0.0895203,0.000064520864,0.00016792952,0.28734845],"study_design_scores_gemma":[0.0034398234,0.00019780877,0.70402277,0.00029666143,0.00007860518,0.00009773887,0.00012574067,0.00061061647,0.28842255,0.000037846265,0.0025436971,0.00012611563],"about_ca_topic_score_codex":0.00046302192,"about_ca_topic_score_gemma":0.00021886178,"teacher_disagreement_score":0.28722236,"about_ca_system_score_codex":0.000059079353,"about_ca_system_score_gemma":0.000115225106,"threshold_uncertainty_score":0.41955608},"labels":[],"label_agreement":null},{"id":"W4405039227","doi":"10.1182/blood-2024-199282","title":"Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Dexamethasone; Bortezomib; Medicine; Multiple myeloma; Internal medicine; Oncology; Lenalidomide; Refractory (planetary science); Biology","score_opus":0.02230919046572011,"score_gpt":0.2789554290237184,"score_spread":0.2566462385579983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325186,0.0034844668,0.000040690305,0.00013002112,0.000045905417,0.0025917909,0.00031186166,0.00006749111,0.00007589832],"genre_scores_gemma":[0.9949342,0.001144276,0.002812014,0.000070997536,0.000052764204,0.00016531354,0.00055467495,0.000119283715,0.00014647654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950653,0.0005267716,0.0012083078,0.001240106,0.0010257075,0.00093382347],"domain_scores_gemma":[0.9968845,0.0013082718,0.00035917663,0.0006627947,0.00029359927,0.00049162953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001009062,0.00069191103,0.0019506565,0.0018979253,0.00012748923,0.00010107836,0.00020884411,0.0003354918,0.00005455212],"category_scores_gemma":[0.0009596871,0.00054464187,0.00021699665,0.0016677752,0.00030182116,0.00039200552,0.00024188995,0.0007619023,0.000004578372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024407998,0.002505896,0.95845634,0.00034149285,0.0027881055,0.00047402916,0.0020263062,0.000045724675,0.0007164843,0.0000032354565,0.000015735553,0.008218669],"study_design_scores_gemma":[0.11600112,0.002621156,0.871223,0.0009759662,0.001026911,0.000015252847,0.00022802377,0.003225644,0.0041982564,0.000013863615,0.00003113887,0.00043966653],"about_ca_topic_score_codex":0.0024749502,"about_ca_topic_score_gemma":0.0024523248,"teacher_disagreement_score":0.091593124,"about_ca_system_score_codex":0.0004600408,"about_ca_system_score_gemma":0.0003440151,"threshold_uncertainty_score":0.9997005},"labels":[],"label_agreement":null},{"id":"W4405039231","doi":"10.1182/blood-2024-208803","title":"Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Multiple myeloma; Medicine; Clinical decision making; Family medicine; Internal medicine","score_opus":0.07321582580118782,"score_gpt":0.3994079923189591,"score_spread":0.3261921665177713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951722,0.0010343811,0.0000138387895,0.00006959044,0.0002883029,0.0005454755,0.000049676128,0.00006343715,0.0027631118],"genre_scores_gemma":[0.99886423,0.0001280948,0.00067857414,0.00009383404,0.00007271295,0.00006105001,0.000039921535,0.000020393345,0.00004116389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796224,0.00019349011,0.00048416268,0.00045956703,0.00056197605,0.00033857065],"domain_scores_gemma":[0.9977058,0.001693305,0.000038568884,0.00030522502,0.00006465911,0.00019241644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046084786,0.00015725904,0.0003006951,0.00022961742,0.000039874285,0.000050267667,0.00007586542,0.00010073482,0.00016661617],"category_scores_gemma":[0.0014665991,0.000107455664,0.000110441084,0.00033647617,0.000045188986,0.00004909748,0.00008308664,0.00034176125,0.0003449921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006269734,0.0023018697,0.5027193,0.000036349764,0.00015494012,0.001434734,0.00021446969,0.000002153417,0.000014762501,0.000021268848,0.00044723097,0.49202594],"study_design_scores_gemma":[0.0025599115,0.0036190446,0.99040216,0.0013694309,0.00004478904,0.00003220699,0.000053444484,0.00027383902,0.00030466085,0.0002615995,0.00096179877,0.00011713298],"about_ca_topic_score_codex":0.00013808918,"about_ca_topic_score_gemma":0.0004527181,"teacher_disagreement_score":0.49190882,"about_ca_system_score_codex":0.000057622437,"about_ca_system_score_gemma":0.00020463305,"threshold_uncertainty_score":0.44342905},"labels":[],"label_agreement":null},{"id":"W4405039302","doi":"10.1182/blood-2024-200071","title":"Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McMaster University","funders":"","keywords":"Multiple myeloma; Medicine; Transplantation; Internal medicine; Oncology; Bone marrow transplantation; Hematologic Neoplasms","score_opus":0.022009571042101998,"score_gpt":0.2868463553171174,"score_spread":0.2648367842750154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619174,0.0007765354,0.000104156024,0.0002036633,0.00017036343,0.0022007516,0.00015742065,0.000059617345,0.000135755],"genre_scores_gemma":[0.99785006,0.00003808467,0.0013644618,0.000018507148,0.00014998042,0.0001607447,0.00007897926,0.000022904216,0.00031629152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868006,0.000095065036,0.00029369496,0.00031423804,0.0003641212,0.0002527964],"domain_scores_gemma":[0.99928856,0.00020076324,0.0000645819,0.0002520622,0.00008176147,0.00011229412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030545314,0.00015737556,0.00022368415,0.000050908096,0.00012189852,0.00005065005,0.00008594475,0.00006370109,0.000010522669],"category_scores_gemma":[0.00012570301,0.00010540305,0.00009923651,0.00035403296,0.000058615577,0.00009817907,0.000027354507,0.00012583585,0.0000037097695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007985271,0.0010038429,0.9898908,0.00044933203,0.0008297657,0.0001463634,0.001079507,0.000028463708,0.0036464424,0.00016883336,0.00008399591,0.0018740849],"study_design_scores_gemma":[0.015080103,0.001339103,0.9541455,0.00062085316,0.0021805274,0.00014423503,0.00016977896,0.0005322399,0.025174942,0.00044099404,0.000036186488,0.00013553954],"about_ca_topic_score_codex":0.00019392054,"about_ca_topic_score_gemma":0.00045783722,"teacher_disagreement_score":0.035745345,"about_ca_system_score_codex":0.000024220362,"about_ca_system_score_gemma":0.00010347832,"threshold_uncertainty_score":0.42982116},"labels":[],"label_agreement":null},{"id":"W4405039376","doi":"10.1182/blood-2024-211410","title":"Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Astellas Pharma; Incyte; Mallinckrodt Pharmaceuticals; Jazz Pharmaceuticals; Springworks Therapeutics; Regeneron Pharmaceuticals; Swedish Orphan Biovitrum; Therakos; Alexion Pharmaceuticals; Gilead Sciences; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Multiple myeloma; Refractory (planetary science); Lenalidomide; Medicine; Daratumumab; Dynamics (music); Cancer research; Hematologic Neoplasms; Internal medicine; Oncology; Biology; Cancer; Psychology","score_opus":0.02366276717185334,"score_gpt":0.27922762802130685,"score_spread":0.2555648608494535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951455,0.00051300845,0.0007042749,0.0004787738,0.00006119137,0.0017805615,0.0007423503,0.00025045252,0.0003239015],"genre_scores_gemma":[0.9900907,0.000022273882,0.0024965026,0.000078284946,0.000050364688,0.0002564748,0.00085636775,0.0001033433,0.006045664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801,0.000049550163,0.0003159654,0.0006090688,0.0004395928,0.0005758632],"domain_scores_gemma":[0.9981605,0.0007717724,0.0001019049,0.0004128061,0.0001965837,0.00035645068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019412013,0.00037504424,0.00064349425,0.00014802643,0.00018037883,0.00010549942,0.00010844125,0.00014556054,0.000050627084],"category_scores_gemma":[0.0004596158,0.00021639922,0.00011113563,0.00027140084,0.00014709479,0.00011991671,0.000054736116,0.00029381382,0.000011858009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090707615,0.005326979,0.95033944,0.0012994807,0.008357258,0.0034328315,0.00091914815,0.0000010423607,0.012253601,0.000052737207,0.0008816123,0.00806513],"study_design_scores_gemma":[0.12647791,0.014350993,0.7228636,0.0017725495,0.004376518,0.00027867558,0.00079486443,0.10921545,0.016282067,0.00007491076,0.0022606868,0.0012517598],"about_ca_topic_score_codex":0.000205885,"about_ca_topic_score_gemma":0.0013568964,"teacher_disagreement_score":0.2274758,"about_ca_system_score_codex":0.00017874883,"about_ca_system_score_gemma":0.0003082525,"threshold_uncertainty_score":0.8824504},"labels":[],"label_agreement":null},{"id":"W4405039791","doi":"10.1182/blood-2024-209905","title":"A National UK Survey of Multiple Myeloma Patient Led Research Priorities: Embedding PROMs, Patient Characteristics and Patient Perspectives","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Family medicine; Internal medicine","score_opus":0.05425260997543508,"score_gpt":0.3610040198404346,"score_spread":0.30675140986499955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936717,0.0036288947,0.0000063153107,0.00012375737,0.00009279039,0.0012286581,0.00065599906,0.00004883858,0.00054304756],"genre_scores_gemma":[0.9984705,0.00026934218,0.000719756,0.000013052748,0.00005828778,0.00017586237,0.00017817231,0.000035414854,0.00007965163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969577,0.0002948188,0.00044220182,0.00049431116,0.0013545334,0.00045640703],"domain_scores_gemma":[0.9972917,0.0008951444,0.00007342715,0.00023290084,0.0012562874,0.0002505838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005078074,0.0001999073,0.00035603024,0.00040693456,0.00015843906,0.00007664955,0.00006863447,0.00009317252,0.00009997344],"category_scores_gemma":[0.0026797345,0.00016207561,0.00007489547,0.00042773422,0.00022094339,0.000087242595,0.0001731875,0.00035722525,0.000019477544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022033353,0.0068616606,0.80602396,0.002103538,0.002151169,0.0011929604,0.049367316,0.000003090309,0.011384694,0.0005369333,0.0011428669,0.11702846],"study_design_scores_gemma":[0.0038047226,0.0043193744,0.9711299,0.0010000985,0.00008060673,0.00012211184,0.0049544116,0.003447626,0.010028586,0.00008032941,0.0007694566,0.0002627885],"about_ca_topic_score_codex":0.0006093306,"about_ca_topic_score_gemma":0.00007387144,"teacher_disagreement_score":0.16510591,"about_ca_system_score_codex":0.0001937684,"about_ca_system_score_gemma":0.00058601703,"threshold_uncertainty_score":0.66092515},"labels":[],"label_agreement":null},{"id":"W4405039792","doi":"10.1182/blood-2024-203735","title":"Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Pharmacyclics; Bausch Health; Biogen; AstraZeneca","keywords":"Medicine; Multiple myeloma; Lenalidomide; Medical record; Refractory (planetary science); Chart; Pediatrics; Internal medicine; Oncology","score_opus":0.02605670403598028,"score_gpt":0.30621008701527036,"score_spread":0.2801533829792901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562675,0.0014924188,0.0000010453545,0.00016217545,0.000050783037,0.002382145,0.00019216567,0.00007101292,0.000021518725],"genre_scores_gemma":[0.99409413,0.0050870725,0.00003504531,0.00012958692,0.000032320087,0.00022856165,0.00026577673,0.000052273237,0.00007521962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976487,0.00019301324,0.00049546524,0.0005500444,0.0007114278,0.0004013274],"domain_scores_gemma":[0.9986893,0.00024298727,0.00011975995,0.0003970392,0.00011956809,0.0004313765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017161435,0.00033349896,0.000759281,0.00016322041,0.000065020606,0.000029515868,0.00006178098,0.000090132904,0.00015845831],"category_scores_gemma":[0.0002974173,0.00018683818,0.00006137633,0.00014152941,0.00007145313,0.00011258141,0.000047421592,0.00026436982,0.00000980204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014481161,0.008132139,0.88964593,0.0005821584,0.001149412,0.0008007915,0.0004381131,2.2775717e-9,0.000012791697,0.0000018775944,0.000009068553,0.097779624],"study_design_scores_gemma":[0.013273229,0.04133663,0.9419291,0.0019766104,0.0006813707,0.000022667587,0.00006441817,0.000017084603,0.000113521724,0.0000010210846,0.00041532738,0.00016902137],"about_ca_topic_score_codex":0.00034429663,"about_ca_topic_score_gemma":0.00038716933,"teacher_disagreement_score":0.0976106,"about_ca_system_score_codex":0.00009764693,"about_ca_system_score_gemma":0.00024016907,"threshold_uncertainty_score":0.761904},"labels":[],"label_agreement":null},{"id":"W4405039835","doi":"10.1182/blood-2024-210518","title":"Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Pomalidomide; Refractory (planetary science); Internal medicine; Oncology; Term (time); Lenalidomide; Pediatrics","score_opus":0.0387345179316094,"score_gpt":0.31291491762960755,"score_spread":0.2741803996979981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775845,0.01787923,0.00021179928,0.0006170557,0.00050409493,0.0019110503,0.00021561167,0.0001890336,0.0008876487],"genre_scores_gemma":[0.99238235,0.0032893643,0.0010230764,0.00017776414,0.0005590473,0.00035880227,0.00045789892,0.0001194618,0.0016322408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997779,0.00013496885,0.00050142105,0.0005192027,0.0005271146,0.00053825945],"domain_scores_gemma":[0.99684864,0.0018602172,0.00012804112,0.000911135,0.000100895435,0.00015107397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003896939,0.00034102538,0.0005360744,0.00018275705,0.00021438295,0.00010070969,0.00035906603,0.00014260251,0.00022158076],"category_scores_gemma":[0.000105633895,0.00021773501,0.0004725012,0.00039678378,0.0001728148,0.00010982337,0.000065191336,0.00041096515,0.00003118219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046965163,0.0018602709,0.73767924,0.00015396772,0.0032524136,0.0002471511,0.00114366,2.0949253e-7,0.054104265,0.00021691801,0.0012642666,0.19538113],"study_design_scores_gemma":[0.038186193,0.0012278688,0.92190146,0.00095391704,0.00034832975,0.000016446718,0.00011075759,0.00012232023,0.02069812,0.00032318415,0.015826149,0.0002852443],"about_ca_topic_score_codex":0.0011288789,"about_ca_topic_score_gemma":0.0012059081,"teacher_disagreement_score":0.1950959,"about_ca_system_score_codex":0.00009704448,"about_ca_system_score_gemma":0.00015010436,"threshold_uncertainty_score":0.88789755},"labels":[],"label_agreement":null},{"id":"W4405040200","doi":"10.1182/blood-2024-209251","title":"Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Alberta Health Services; University of Alberta; University of Calgary","funders":"","keywords":"Incidence (geometry); Multiple myeloma; Medicine; Population; Internal medicine; Environmental health","score_opus":0.025518910987700167,"score_gpt":0.322855379856127,"score_spread":0.29733646886842685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804574,0.0012289375,0.00007981959,0.00007589559,0.00003965491,0.0003884611,0.000010021751,0.000053976873,0.000077505334],"genre_scores_gemma":[0.9976614,0.00019863508,0.0017170799,0.000012122866,0.00007703544,0.000029746587,0.000008546631,0.000012580009,0.00028281502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907225,0.000053035954,0.00026252447,0.00021012589,0.00024234313,0.00015973543],"domain_scores_gemma":[0.99934417,0.00026655575,0.00004246158,0.0002073949,0.00004840622,0.000090988535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023092575,0.000084785184,0.00013011973,0.00005420357,0.0000538328,0.000024562061,0.000065283,0.000050746283,0.000023976025],"category_scores_gemma":[0.0005410916,0.000053524174,0.000051601386,0.00013426592,0.00008816153,0.00007659817,0.000065237975,0.0001372242,0.000004939988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000622081,0.00008489342,0.9700941,0.0003640659,0.00009965849,0.000085727515,0.00011609564,0.0000025234153,0.015317324,0.000014369325,0.0000048030265,0.013754229],"study_design_scores_gemma":[0.0011551599,0.00022807927,0.98220414,0.00030595998,0.00013765134,0.00006605698,0.00001056661,0.0064825206,0.009308635,0.000045420486,0.00000793467,0.00004786332],"about_ca_topic_score_codex":0.00032046498,"about_ca_topic_score_gemma":0.000068010326,"teacher_disagreement_score":0.013706366,"about_ca_system_score_codex":0.000012643446,"about_ca_system_score_gemma":0.000037232152,"threshold_uncertainty_score":0.21826525},"labels":[],"label_agreement":null},{"id":"W4405040476","doi":"10.1182/blood-2024-212136","title":"Survival Following Quadruplet and Triple Therapy in Transplant in-Eligible Multiple Myeloma - a Meta-Analysis of Recent Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Meta-analysis; Medicine; Clinical trial; Oncology; Internal medicine","score_opus":0.3302126182422315,"score_gpt":0.47250223191591906,"score_spread":0.14228961367368753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98180467,0.01604049,0.000030291896,0.0005924209,0.00012766047,0.000998021,0.00015135424,0.000029239614,0.00022583251],"genre_scores_gemma":[0.9914842,0.0076746508,0.0004024848,0.00004037203,0.00004265555,0.00012194848,0.00011690826,0.000021392261,0.00009534213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629784,0.0010647917,0.0013198138,0.0005004392,0.0004740305,0.00034308806],"domain_scores_gemma":[0.99669564,0.0026676916,0.000089492256,0.00031663504,0.00003773787,0.00019278383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005980991,0.00020958256,0.002547659,0.00080652273,0.000021944308,0.00003243047,0.00008708241,0.00013621156,0.00029819214],"category_scores_gemma":[0.0010449222,0.00013615731,0.0015277533,0.0013269077,0.000044635202,0.00006827303,0.000021609992,0.0002684522,0.0000055986043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021117465,0.0032700808,0.74599457,0.00013673137,0.218624,0.001863653,0.0008053306,0.00000855849,0.003936973,0.000045636723,0.000025129284,0.023177564],"study_design_scores_gemma":[0.05777579,0.0017978105,0.71971846,0.00014702657,0.20093277,0.000018919956,0.0002875335,0.0054089935,0.011227526,0.00012656058,0.0021392412,0.00041939452],"about_ca_topic_score_codex":0.0009283266,"about_ca_topic_score_gemma":0.0017596835,"teacher_disagreement_score":0.055664044,"about_ca_system_score_codex":0.000024982504,"about_ca_system_score_gemma":0.0001586908,"threshold_uncertainty_score":0.5552334},"labels":[],"label_agreement":null},{"id":"W4405040542","doi":"10.1182/blood-2024-205709","title":"Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Internal medicine; Oncology","score_opus":0.009863182357684179,"score_gpt":0.27595382173681715,"score_spread":0.26609063937913296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98807997,0.00214537,0.00024462014,0.00023583583,0.000097761644,0.0027308178,0.0063537243,0.00005371083,0.00005821519],"genre_scores_gemma":[0.9962778,0.0014040688,0.0005302355,0.000021967287,0.00005463191,0.00044911954,0.0011686429,0.000026244357,0.00006729211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734265,0.00029443917,0.00056072517,0.00071254175,0.00059579563,0.0004938606],"domain_scores_gemma":[0.99851644,0.0006256615,0.000120986566,0.00038707542,0.00007962809,0.00027023503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033967427,0.00034782136,0.0006298018,0.000108657274,0.00010923833,0.000075905264,0.00014403368,0.00008193335,0.000014032606],"category_scores_gemma":[0.000036522622,0.00023858456,0.0001852405,0.00063482736,0.00012178009,0.00013205419,0.000037115093,0.0001343754,5.872502e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011668245,0.00202997,0.979508,0.0012835516,0.001347191,0.0016604551,0.0010751397,0.000024778572,0.00014091161,0.00006817312,0.0000149913485,0.0011786058],"study_design_scores_gemma":[0.023004139,0.00066669716,0.9674666,0.0007289074,0.006898134,0.0000065263166,0.00014194135,0.00048666194,0.00018174307,0.00020311312,0.0000055765477,0.00020998878],"about_ca_topic_score_codex":0.0023680555,"about_ca_topic_score_gemma":0.046967972,"teacher_disagreement_score":0.044599917,"about_ca_system_score_codex":0.00008511742,"about_ca_system_score_gemma":0.00010253576,"threshold_uncertainty_score":0.9729196},"labels":[],"label_agreement":null},{"id":"W4405040632","doi":"10.1182/blood-2024-211167","title":"Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Pomalidomide; Population; Internal medicine; Carfilzomib; Oncology; Lenalidomide","score_opus":0.019905287953075213,"score_gpt":0.2882926644433249,"score_spread":0.2683873764902497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685276,0.00031525054,0.0000075020407,0.0003119846,0.0000150726055,0.0022201487,0.00013525125,0.000071954775,0.00007005242],"genre_scores_gemma":[0.9975949,0.00002290523,0.0015125632,0.00002042596,0.000017638004,0.00018723385,0.00028004675,0.00004925507,0.00031503357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775934,0.00012595838,0.0005367943,0.0005031776,0.0007642351,0.000310479],"domain_scores_gemma":[0.9982668,0.0004652882,0.00020488136,0.0006355594,0.00028168762,0.00014578673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016117441,0.0002906988,0.00062883407,0.00024715072,0.000045038607,0.000028900628,0.00011799782,0.00006337165,0.00003568933],"category_scores_gemma":[0.00018048761,0.00013777817,0.00006541017,0.000960161,0.00011619804,0.00015398356,0.00003415338,0.00017723646,0.0000028123065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008188119,0.0011900176,0.98451465,0.00013742401,0.0013469582,0.0011037685,0.0008434179,0.000012403761,0.0012818655,0.000005018154,0.000012876726,0.001363492],"study_design_scores_gemma":[0.010307254,0.003917901,0.9744459,0.0022570523,0.0005279786,0.000033376502,0.00010285804,0.000043231656,0.008210321,0.0000033730998,0.0000047991707,0.00014598375],"about_ca_topic_score_codex":0.025616294,"about_ca_topic_score_gemma":0.017132021,"teacher_disagreement_score":0.010068769,"about_ca_system_score_codex":0.00009438679,"about_ca_system_score_gemma":0.00027106074,"threshold_uncertainty_score":0.9808722},"labels":[],"label_agreement":null},{"id":"W4405040781","doi":"10.1182/blood-2024-198119","title":"Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pomalidomide; Multiple myeloma; Randomized controlled trial; Internal medicine; Refractory (planetary science); Oncology; Lenalidomide; Nuclear medicine; Materials science","score_opus":0.03050820499688557,"score_gpt":0.3314219374434796,"score_spread":0.30091373244659403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916597,0.0022856107,0.00050123385,0.00020624026,0.0002396646,0.002804119,0.00005012201,0.000098614924,0.0021546977],"genre_scores_gemma":[0.9955579,0.00047520598,0.0026162213,0.00001906941,0.00019038786,0.00028153928,0.00019699908,0.000039101655,0.000623556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998092,0.0002430705,0.000566411,0.0003461902,0.00044553305,0.00030679253],"domain_scores_gemma":[0.9986479,0.0006873024,0.000080064616,0.000325752,0.00007763717,0.00018131832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006246241,0.00019253195,0.00070357195,0.0003955903,0.000031300508,0.000024919396,0.000082737606,0.0001374912,0.00027030008],"category_scores_gemma":[0.0012509829,0.00014600712,0.000263244,0.00037660645,0.00010575649,0.00010225003,0.00003842849,0.00024832442,0.00004017789],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9618903,0.010025437,0.00053149153,0.00030751823,0.00086644327,0.0010554394,0.00043485878,0.00037489095,0.0047657695,0.00008105594,0.00012323407,0.01954361],"study_design_scores_gemma":[0.93158865,0.0011548258,0.000164431,0.00026191399,0.00034274516,0.000022005692,0.000025467736,0.06025638,0.0058157975,0.00005667881,0.00020004761,0.00011107914],"about_ca_topic_score_codex":0.00015566206,"about_ca_topic_score_gemma":0.000020361424,"teacher_disagreement_score":0.05988149,"about_ca_system_score_codex":0.00006135291,"about_ca_system_score_gemma":0.00025901775,"threshold_uncertainty_score":0.5953998},"labels":[],"label_agreement":null},{"id":"W4405040856","doi":"10.1182/blood-2024-200956","title":"Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; McMaster University; McMaster University Medical Centre; Ottawa Hospital","funders":"Celgene; Gilead Sciences; Bristol-Myers Squibb; Juno Therapeutics; Amgen","keywords":"Multiple myeloma; Medicine; Cohort; Hematologic Neoplasms; Oncology; Population; Internal medicine; Demography; Cancer; Family medicine; Environmental health","score_opus":0.006318723466510849,"score_gpt":0.22504646639636453,"score_spread":0.21872774292985367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985687,0.00007532469,0.000003139433,0.000020135802,0.00003204016,0.0005496066,0.0002043091,0.000018274384,0.000528434],"genre_scores_gemma":[0.9980312,0.0000011036536,0.00022760822,0.00002629559,0.0000080175705,0.00006798657,0.0014207343,0.000017077062,0.00019995129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998704,0.000026918635,0.00023657258,0.00028429297,0.0005022018,0.00024600583],"domain_scores_gemma":[0.9993806,0.00009950139,0.00004464315,0.0002321534,0.000083950144,0.00015917396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006562073,0.00013153774,0.00036322538,0.0003997944,0.000028165205,0.000012532361,0.000051208604,0.00004334316,0.0005827487],"category_scores_gemma":[0.000046533874,0.00010173536,0.00007921307,0.0007768423,0.00002816264,0.00005248621,0.000012962759,0.00018546684,0.0000013667986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021543948,0.00028954874,0.99571013,0.000076978606,0.0026394555,0.00024123059,0.00008134667,0.0003337537,0.000008052243,0.0000013540887,0.00006249162,0.0003402259],"study_design_scores_gemma":[0.0055616377,0.00015614071,0.9895747,0.00013572737,0.0012982703,4.6588275e-7,0.000024601397,0.002963642,0.00013647586,6.8279394e-7,0.000056043737,0.00009164505],"about_ca_topic_score_codex":0.99579346,"about_ca_topic_score_gemma":0.99956,"teacher_disagreement_score":0.0061354553,"about_ca_system_score_codex":0.00089153234,"about_ca_system_score_gemma":0.002617345,"threshold_uncertainty_score":0.6380689},"labels":[],"label_agreement":null},{"id":"W4405040905","doi":"10.1182/blood-2024-209286","title":"Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Proteome; Disease; Medicine; Oncology; Computational biology; Biology; Internal medicine; Immunology; Cancer research; Antibody; Bioinformatics; Monoclonal; Monoclonal antibody","score_opus":0.011688222118667293,"score_gpt":0.27525359962219054,"score_spread":0.26356537750352327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176913,0.0003035617,0.000041416308,0.00010575936,0.000042954696,0.004475947,0.0032429153,0.000014456543,0.0000038661137],"genre_scores_gemma":[0.9991352,0.00008253772,0.00014596862,0.0000015876033,0.000021844233,0.000362061,0.0001844104,0.00001182368,0.000054556232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899876,0.000076234566,0.0003424779,0.00021073736,0.0002790382,0.0000927409],"domain_scores_gemma":[0.99913025,0.000059517868,0.00024474296,0.00018140288,0.0002854493,0.000098644334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091429974,0.00009677048,0.00020145898,0.0001437962,0.000041543517,0.000007671751,0.00004478193,0.000062706524,0.000004759332],"category_scores_gemma":[0.000276187,0.000065224325,0.000049699862,0.0002325508,0.00009614474,0.00009671619,0.00005194465,0.00009925879,6.420982e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006305438,0.00050495344,0.063032515,0.0024955783,0.0001780722,0.0000018071412,0.00042443402,0.0000017486572,0.9306529,0.00001891707,0.0000023796185,0.0020561258],"study_design_scores_gemma":[0.0013316702,0.00035785904,0.49260417,0.0006296115,0.00018370975,0.000002638407,0.000016164404,0.0025871156,0.50224423,0.000017231274,0.0000034764637,0.000022113069],"about_ca_topic_score_codex":0.000008071925,"about_ca_topic_score_gemma":0.0000011793189,"teacher_disagreement_score":0.42957166,"about_ca_system_score_codex":0.000011310659,"about_ca_system_score_gemma":0.00008959679,"threshold_uncertainty_score":0.26597705},"labels":[],"label_agreement":null},{"id":"W4405040983","doi":"10.1182/blood-2024-201712","title":"Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Daratumumab; Lenalidomide; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Oncology","score_opus":0.02329557136254877,"score_gpt":0.2876899346676038,"score_spread":0.264394363305055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490083,0.003940836,0.000008557247,0.00020453865,0.00003436663,0.0052217087,0.005441646,0.00012162986,0.00012585863],"genre_scores_gemma":[0.968284,0.025957799,0.000602914,0.00006229806,0.00009323109,0.0005214586,0.003735034,0.000104661136,0.00063856464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660844,0.0002504192,0.00083455665,0.0011344648,0.0005941427,0.00057797914],"domain_scores_gemma":[0.99751973,0.0007811164,0.00023785312,0.0007204369,0.000192856,0.0005479954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001761429,0.0007450905,0.001482118,0.00029884846,0.0001331251,0.0000876522,0.00009450111,0.0000879134,0.000068433175],"category_scores_gemma":[0.00009909822,0.00043868454,0.00012580233,0.00028228766,0.00011878157,0.00018274668,0.000036973677,0.00018128581,0.000018469555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021109095,0.011031554,0.93738216,0.00065753056,0.00459772,0.0034684502,0.0017401212,3.115869e-7,0.0002312334,7.975657e-7,0.00001988964,0.01976115],"study_design_scores_gemma":[0.12156966,0.015674174,0.8457799,0.006299213,0.0055322545,0.00003779966,0.0001434162,0.00018799418,0.0039874557,6.5675385e-7,0.00040772549,0.00037972987],"about_ca_topic_score_codex":0.020949436,"about_ca_topic_score_gemma":0.0091604395,"teacher_disagreement_score":0.100460574,"about_ca_system_score_codex":0.00016823942,"about_ca_system_score_gemma":0.00016096456,"threshold_uncertainty_score":0.99980646},"labels":[],"label_agreement":null},{"id":"W4405041593","doi":"10.1182/blood-2024-193994","title":"Identification of Novel Protein Biomarkers in Bone Marrow Interstitial Fluid Links Coagulation Cascade Proteins to Survival Outcomes in Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Multiple myeloma; Bone marrow; Medicine; Coagulation; Immunology; Myeloma protein; Cancer research; Pathology; Internal medicine","score_opus":0.0350872227502858,"score_gpt":0.3147350536602894,"score_spread":0.2796478309100036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994802,0.00018358452,0.0007614798,0.00094334234,0.000117020536,0.0029553052,0.000093297596,0.00005392138,0.00009006135],"genre_scores_gemma":[0.9975907,0.0000046917958,0.0015004214,0.00001201726,0.000052071955,0.00045432005,0.00009454492,0.000029692921,0.00026149684],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982088,0.00007046153,0.0005842828,0.0003883555,0.00044222604,0.00030586138],"domain_scores_gemma":[0.9993624,0.000095231066,0.000057839254,0.0002745857,0.00007154223,0.00013837893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004661272,0.00017048941,0.0003554269,0.0007046456,0.00002479468,0.00003433875,0.00008955419,0.00016642301,0.000024420371],"category_scores_gemma":[0.0006560746,0.00014973812,0.00009153728,0.0005933004,0.000051459003,0.00012763678,0.00006066386,0.00024304877,0.000033442913],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061408675,0.0016972233,0.1742585,0.00038754006,0.00021897689,0.00025035444,0.00044000635,0.000013727997,0.81738114,0.00006013201,0.000008813135,0.004669525],"study_design_scores_gemma":[0.008856736,0.00038029996,0.68443274,0.00072605535,0.000051997213,0.000017168011,0.00013156497,0.007915523,0.29728124,0.000018568855,0.000038603983,0.00014948475],"about_ca_topic_score_codex":0.001254645,"about_ca_topic_score_gemma":0.0018908719,"teacher_disagreement_score":0.5200999,"about_ca_system_score_codex":0.00015142102,"about_ca_system_score_gemma":0.00013856849,"threshold_uncertainty_score":0.6106143},"labels":[],"label_agreement":null},{"id":"W4405041821","doi":"10.1182/blood-2024-206054","title":"Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pharmacodynamics; Pharmacokinetics; Medicine; Cytokine; Pharmacology; Internal medicine","score_opus":0.018916802492688196,"score_gpt":0.3205301772789801,"score_spread":0.3016133747862919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993597,0.00042778396,0.00043284084,0.00010219945,0.00012849597,0.0041334555,0.0010413765,0.00011540396,0.000021453998],"genre_scores_gemma":[0.9914057,0.000068729474,0.0062428466,0.00004003989,0.00006086074,0.00059828104,0.0003163758,0.00010003447,0.0011670975],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99710554,0.00021985458,0.00065395323,0.0007946318,0.0006005318,0.0006255148],"domain_scores_gemma":[0.9981327,0.0006127152,0.00014030152,0.00033191137,0.00030487086,0.00047749162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041260518,0.0004166632,0.0006572863,0.00072920683,0.00010131674,0.000041134906,0.00012690769,0.00013846815,0.00013880392],"category_scores_gemma":[0.0005390746,0.00030197427,0.00012839398,0.0008662124,0.00008933806,0.00023423709,0.00008579165,0.00034934265,0.000016056461],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.321142,0.006193185,0.12018566,0.0022015953,0.0026259143,0.001272144,0.0006791241,0.00015415122,0.48710817,0.000003200672,0.00029346385,0.058141414],"study_design_scores_gemma":[0.09378386,0.021814398,0.77276355,0.0009012223,0.0014229442,0.00015300578,0.00015126841,0.025472341,0.08208549,0.000001484412,0.000901008,0.0005494098],"about_ca_topic_score_codex":0.00016025032,"about_ca_topic_score_gemma":0.00006330507,"teacher_disagreement_score":0.65257794,"about_ca_system_score_codex":0.00021628442,"about_ca_system_score_gemma":0.0004221974,"threshold_uncertainty_score":0.99994326},"labels":[],"label_agreement":null},{"id":"W4405041836","doi":"10.1182/blood-2024-212294","title":"Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Antigen; Immunology; Immunotherapy; Daratumumab; Medicine; Biology; Virology; Cancer research; Bortezomib; Immune system","score_opus":0.025718262907941953,"score_gpt":0.2762986199602764,"score_spread":0.25058035705233445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882662,0.0068692653,0.0000133939575,0.000099490186,0.00003426829,0.00046402751,0.000008009596,0.00022138329,0.0040239417],"genre_scores_gemma":[0.9963025,0.00024721734,0.0016030967,0.000018733312,0.00007755984,0.000059072005,0.00003785025,0.000054838518,0.0015991316],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873763,0.000045056247,0.00019854888,0.00034988683,0.0002560058,0.00041287259],"domain_scores_gemma":[0.9994223,0.00016214022,0.00002493111,0.00024285175,0.000038807982,0.00010895932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014235733,0.00018670245,0.00025554406,0.00027700543,0.00007722456,0.00005957806,0.00006497384,0.000069027315,0.00011802224],"category_scores_gemma":[0.00005263919,0.0001331792,0.00007439324,0.00047991812,0.000046280635,0.00009418252,0.00002524146,0.00023282239,0.00010272274],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006351073,0.0012515711,0.7385151,0.0003558391,0.00067955366,0.004306406,0.0011447822,0.000004496849,0.21703072,0.000005944694,0.00004979258,0.036020715],"study_design_scores_gemma":[0.0260287,0.0015913215,0.4071975,0.0019974904,0.0003786354,0.000636218,0.00076023646,0.00491895,0.5545263,0.0000146580405,0.0014754863,0.00047444596],"about_ca_topic_score_codex":0.00043764638,"about_ca_topic_score_gemma":0.00012917563,"teacher_disagreement_score":0.33749563,"about_ca_system_score_codex":0.000057714373,"about_ca_system_score_gemma":0.00011120495,"threshold_uncertainty_score":0.54308903},"labels":[],"label_agreement":null},{"id":"W4405041848","doi":"10.1182/blood-2024-208086","title":"Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Vancouver General Hospital; CancerCare Manitoba; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Pomalidomide; Multiple myeloma; Dexamethasone; Lenalidomide; Medicine; Internal medicine; Oncology; Carfilzomib; Refractory (planetary science)","score_opus":0.02489133715367356,"score_gpt":0.29655424616642034,"score_spread":0.2716629090127468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945692,0.0029332708,0.00006671242,0.000072005096,0.000028661312,0.0018738161,0.00034676533,0.000035941674,0.00007365424],"genre_scores_gemma":[0.9902482,0.0007059624,0.00826123,0.000008240719,0.000043140728,0.00008934382,0.0001702686,0.000039147737,0.0004344511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876773,0.00004490305,0.00033140535,0.0003528122,0.0002572197,0.00024589704],"domain_scores_gemma":[0.9983738,0.0009414069,0.00008367285,0.00025350033,0.00014573295,0.00020186653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010838858,0.000207712,0.0005168609,0.00014871937,0.00004833815,0.000011611501,0.0000354564,0.000085165055,0.000028708137],"category_scores_gemma":[0.00030805168,0.00012125111,0.00006633557,0.00016203213,0.00013090862,0.00006419748,0.000025870082,0.00005125201,0.0000014829611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06473139,0.010741234,0.69765407,0.0020049459,0.0038290517,0.00024481726,0.0011595878,0.0000014324921,0.009046682,0.00004846723,0.000085123174,0.2104532],"study_design_scores_gemma":[0.12725282,0.019409515,0.8210239,0.00065997813,0.0012856984,0.000037731093,0.00008680095,0.0003759634,0.026518872,0.000012651999,0.0031410626,0.00019500947],"about_ca_topic_score_codex":0.00007323855,"about_ca_topic_score_gemma":0.000044664997,"teacher_disagreement_score":0.21025819,"about_ca_system_score_codex":0.000041428804,"about_ca_system_score_gemma":0.00014535092,"threshold_uncertainty_score":0.49444768},"labels":[],"label_agreement":null},{"id":"W4405042012","doi":"10.1182/blood-2024-209597","title":"Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carfilzomib; Multiple myeloma; Lenalidomide; Medicine; Oncology; Internal medicine; Dexamethasone","score_opus":0.03124142184940028,"score_gpt":0.3292639495267669,"score_spread":0.29802252767736664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921571,0.00626367,0.0000017587762,0.00014276583,0.000046760146,0.00095737557,0.000039327122,0.00005177733,0.0003394889],"genre_scores_gemma":[0.99860704,0.00023462414,0.00047198814,0.000016430147,0.00005028169,0.000065244065,0.000017709172,0.000030686668,0.0005060117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856955,0.00009725293,0.00030363168,0.0004306018,0.00031128828,0.00028765984],"domain_scores_gemma":[0.99911326,0.00029429302,0.00003894244,0.000287074,0.000047279656,0.00021912581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002705152,0.00018339332,0.00042064875,0.00030815313,0.00006366258,0.000021235648,0.000052619565,0.00008863658,0.00003264472],"category_scores_gemma":[0.00031117233,0.00014732667,0.000040127255,0.0002862571,0.000094256466,0.00007722078,0.00011562273,0.000285255,0.000005480038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003909307,0.062473454,0.5619498,0.0010773283,0.001687819,0.0059778984,0.012104534,5.627464e-7,0.13586783,0.00003237222,0.00029324964,0.21462585],"study_design_scores_gemma":[0.27815467,0.045383833,0.64046013,0.00093734387,0.0010440839,0.00036258064,0.00489311,0.0021067446,0.024250502,0.000077967816,0.0018401868,0.000488858],"about_ca_topic_score_codex":0.0005959252,"about_ca_topic_score_gemma":0.00034987123,"teacher_disagreement_score":0.27424535,"about_ca_system_score_codex":0.00003533264,"about_ca_system_score_gemma":0.00009552145,"threshold_uncertainty_score":0.6007808},"labels":[],"label_agreement":null},{"id":"W4405042087","doi":"10.1182/blood-2024-206912","title":"A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Bispecific antibody; Medicine; Multiple myeloma; Refractory (planetary science); Antibody; Antigen; Cancer research; Internal medicine; Immunology; Monoclonal antibody; Materials science","score_opus":0.022120398361263754,"score_gpt":0.3101483756464769,"score_spread":0.2880279772852131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650365,0.00035925827,0.00008322834,0.000022352417,0.000082864695,0.0025846078,0.0000618011,0.000093164075,0.00020904529],"genre_scores_gemma":[0.99785656,0.000048012902,0.0012126392,0.000008584145,0.00005484814,0.000073419156,0.00029817093,0.00007117106,0.00037661372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975973,0.00012279967,0.00043767705,0.00057807774,0.0008355029,0.00042866362],"domain_scores_gemma":[0.99884284,0.00015003268,0.00013007293,0.000495299,0.000188343,0.0001934405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016598316,0.0003032221,0.0004849581,0.00049251295,0.00008760546,0.000067618894,0.00011029654,0.00009417582,0.000054530406],"category_scores_gemma":[0.000065432076,0.00018578494,0.00005369889,0.0008078715,0.000072051356,0.0002586417,0.0000448893,0.00032977524,0.000025608651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0277725,0.07310085,0.862276,0.00062321586,0.00085044646,0.0025693804,0.0033527217,0.0000023173843,0.015207483,0.000002241383,0.00008328265,0.014159547],"study_design_scores_gemma":[0.1985461,0.028030887,0.7602881,0.0013275143,0.00040379452,0.0000339335,0.0017319695,0.0009803148,0.008080762,9.725567e-7,0.00025794763,0.00031768225],"about_ca_topic_score_codex":0.00030002865,"about_ca_topic_score_gemma":0.0004093427,"teacher_disagreement_score":0.17077361,"about_ca_system_score_codex":0.000095283576,"about_ca_system_score_gemma":0.00026036793,"threshold_uncertainty_score":0.757609},"labels":[],"label_agreement":null},{"id":"W4405042184","doi":"10.1182/blood-2024-194386","title":"Infectious Risk in Multiple Myeloma Patients Undergoing Treatment with Teclistamab","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple myeloma; Medicine; Lenalidomide; Internal medicine; Oncology","score_opus":0.014774548582116501,"score_gpt":0.26589547331245583,"score_spread":0.2511209247303393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950219,0.00075082155,0.000028822242,0.00005763866,0.000056063036,0.0008049034,0.000047510308,0.00016983224,0.0030625346],"genre_scores_gemma":[0.9983549,0.0003548102,0.00042611334,0.000015176076,0.00006517303,0.00015901668,0.00009030437,0.000041292205,0.0004932103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987145,0.00005311966,0.00018456505,0.00037571907,0.00029099156,0.000381102],"domain_scores_gemma":[0.9992521,0.0002348621,0.000029687302,0.00025792085,0.000044847115,0.00018059507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006343118,0.00020538304,0.00024454604,0.00026321944,0.000080799975,0.000054501877,0.000039225262,0.00006584757,0.000050945262],"category_scores_gemma":[0.000113762304,0.0001348975,0.000077269025,0.0003548775,0.000042523316,0.000090516216,0.000025077006,0.00017041064,0.00015301334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026846977,0.002658897,0.95209366,0.0001056369,0.00049493625,0.0011992533,0.00024945888,0.0000049395862,0.000099983845,0.000015053211,0.000019756173,0.04278994],"study_design_scores_gemma":[0.036305632,0.0057680397,0.9514596,0.00044275486,0.00035077412,0.000091501555,0.00006599679,0.0006468001,0.0031872229,0.00005539195,0.0014356448,0.000190679],"about_ca_topic_score_codex":0.00081135734,"about_ca_topic_score_gemma":0.0027390644,"teacher_disagreement_score":0.04259926,"about_ca_system_score_codex":0.00028415787,"about_ca_system_score_gemma":0.00022305532,"threshold_uncertainty_score":0.55009604},"labels":[],"label_agreement":null},{"id":"W4405042203","doi":"10.1182/blood-2024-210717","title":"Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Windsor Regional Hospital","funders":"","keywords":"Multiple myeloma; Hematologic Neoplasms; Medicine; Internal medicine; Oncology; Prospective cohort study; Transplantation","score_opus":0.029332789454426987,"score_gpt":0.3191707154345213,"score_spread":0.28983792598009434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660987,0.000574436,0.000019231631,0.000078371,0.000020194297,0.0011786375,0.0012915278,0.000046732282,0.00018099547],"genre_scores_gemma":[0.99878395,0.00003257234,0.0002978547,0.0000038119995,0.000028715614,0.00013778279,0.00058658567,0.000014585596,0.00011415617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849826,0.00007426477,0.0003687687,0.00048667577,0.00035078655,0.00022121565],"domain_scores_gemma":[0.99902564,0.00044107594,0.000042051513,0.00026726015,0.000089240784,0.00013471946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017089046,0.00015376623,0.00042920338,0.0005913328,0.00004882946,0.00003058729,0.00005828541,0.000043964825,0.000031177944],"category_scores_gemma":[0.0002453407,0.00011858068,0.00011755457,0.00087810535,0.000062691215,0.00007309021,0.00003053869,0.00017122466,0.0000063388684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019262766,0.0032099332,0.97270983,0.000046450263,0.0065044714,0.001164127,0.009778842,0.000010896588,0.003618104,0.000008433013,0.0000010005683,0.0010216312],"study_design_scores_gemma":[0.0130747445,0.0008258707,0.9762176,0.0001467214,0.0038691163,0.000015580285,0.0007691268,0.0017479879,0.003215314,0.000024904328,9.685784e-7,0.000092050184],"about_ca_topic_score_codex":0.0063938512,"about_ca_topic_score_gemma":0.009419555,"teacher_disagreement_score":0.011148469,"about_ca_system_score_codex":0.000038466747,"about_ca_system_score_gemma":0.00009814661,"threshold_uncertainty_score":0.9665633},"labels":[],"label_agreement":null},{"id":"W4405042301","doi":"10.1182/blood-2024-207919","title":"Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Daratumumab; Oncology; Internal medicine; Carfilzomib; Refractory (planetary science); Lenalidomide; Pomalidomide; Immunotherapy; Immunology; Cancer","score_opus":0.018682784518157174,"score_gpt":0.27276798593326435,"score_spread":0.25408520141510715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993694,0.003767703,0.000049878123,0.00019982057,0.0004170179,0.0010492523,0.0002522351,0.00024284644,0.0003272679],"genre_scores_gemma":[0.99215907,0.00016407903,0.003976927,0.00011166189,0.00011656903,0.00021867752,0.00012708349,0.00010170473,0.0030242282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767417,0.000091822454,0.0005330783,0.0005126463,0.00066996337,0.0005183186],"domain_scores_gemma":[0.99854344,0.00034334944,0.0000882143,0.0005317276,0.00025510674,0.00023816265],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017411976,0.00036154257,0.0005611498,0.00038146303,0.00008239879,0.00006081737,0.00016856121,0.00017204734,0.0005678001],"category_scores_gemma":[0.0003974516,0.00024523685,0.0002448136,0.0004533795,0.00008317408,0.00017712761,0.00009687499,0.00028535508,0.00009464353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035940025,0.004362766,0.6824549,0.00043656048,0.00232553,0.00027651634,0.0041839075,0.0000011735867,0.2884002,0.0000024967603,0.00026918147,0.013692783],"study_design_scores_gemma":[0.01418385,0.0020199132,0.9117163,0.00046652454,0.00024690817,0.0000125173065,0.0001903139,0.000027621065,0.06843493,0.000005092272,0.002423239,0.00027278299],"about_ca_topic_score_codex":0.00016877434,"about_ca_topic_score_gemma":0.00010216624,"teacher_disagreement_score":0.22926143,"about_ca_system_score_codex":0.000088524364,"about_ca_system_score_gemma":0.00019520262,"threshold_uncertainty_score":1},"labels":[],"label_agreement":null},{"id":"W4405042663","doi":"10.1182/blood-2024-198408","title":"Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"","keywords":"Carfilzomib; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Lenalidomide; Internal medicine; Refractory (planetary science); Oncology; Pomalidomide","score_opus":0.026743721818984715,"score_gpt":0.2772049587992465,"score_spread":0.2504612369802618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212396,0.0015395548,0.000010262229,0.0006085334,0.0003304841,0.003258352,0.0011832488,0.0002094477,0.0007361312],"genre_scores_gemma":[0.99459535,0.00034014965,0.0010595695,0.000183596,0.00045236238,0.0002638376,0.0016698213,0.00012349944,0.0013118422],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955873,0.00039460213,0.0008934844,0.0011972252,0.0010445219,0.0008828591],"domain_scores_gemma":[0.996261,0.0018169087,0.00018750224,0.0010299851,0.00017861773,0.0005259584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006413568,0.00058284693,0.0008972604,0.00029473423,0.00020770497,0.00018100276,0.00030383468,0.00031804107,0.00014316074],"category_scores_gemma":[0.0016629449,0.00032972964,0.00015573027,0.00078253925,0.00026964414,0.00029631238,0.0002003975,0.00093876664,0.000111155954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67195255,0.017881397,0.22498642,0.00024660278,0.005080357,0.0077969776,0.0041170754,0.000009327397,0.0012445711,0.000029448096,0.010530481,0.056124795],"study_design_scores_gemma":[0.7412782,0.0050220694,0.23750913,0.0007382789,0.0009753378,0.000057682628,0.00036762588,0.0011238245,0.0022887965,0.000028470777,0.010070282,0.0005403059],"about_ca_topic_score_codex":0.003985859,"about_ca_topic_score_gemma":0.0041326294,"teacher_disagreement_score":0.06932564,"about_ca_system_score_codex":0.0002995626,"about_ca_system_score_gemma":0.0007687695,"threshold_uncertainty_score":0.9999155},"labels":[],"label_agreement":null},{"id":"W4405042667","doi":"10.1182/blood-2024-200877","title":"Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Discontinuation; Internal medicine; Clinical trial; Comorbidity; Database; Oncology","score_opus":0.046269374636048514,"score_gpt":0.3783891061889204,"score_spread":0.3321197315528719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691314,0.00002030423,0.000035617762,0.00018127241,0.000016898799,0.0006292628,0.00009237565,0.000041672258,0.002069456],"genre_scores_gemma":[0.99795586,0.000018315786,0.00029456127,0.000017384908,0.000034464796,0.00008670668,0.0011652549,0.000012936809,0.00041453983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985845,0.00012595682,0.00024988785,0.0002981168,0.0005842908,0.00015724407],"domain_scores_gemma":[0.9991754,0.00014748353,0.000044757267,0.00048359504,0.00008198932,0.00006674684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034309993,0.00012799502,0.0002722833,0.00072135107,0.000037126167,0.00006225592,0.00016344663,0.000021545973,0.00018403205],"category_scores_gemma":[0.00005872775,0.00006927518,0.0000732576,0.0013836622,0.00004512449,0.00020691172,0.00003105898,0.00013224299,0.000011847861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002948967,0.00396074,0.9877203,0.00002374563,0.0033190532,0.0008991007,0.0006133725,0.0000028508314,0.00021352559,0.00020318896,0.000004741039,0.0027444996],"study_design_scores_gemma":[0.004575455,0.00062917947,0.9912239,0.000029206916,0.0016488966,0.000009680338,0.0005919381,0.000810592,0.00035571767,0.000009084558,0.00005406263,0.000062308485],"about_ca_topic_score_codex":0.0039437143,"about_ca_topic_score_gemma":0.01231273,"teacher_disagreement_score":0.0083690155,"about_ca_system_score_codex":0.000052901458,"about_ca_system_score_gemma":0.000070723836,"threshold_uncertainty_score":0.6870792},"labels":[],"label_agreement":null},{"id":"W4405042676","doi":"10.1182/blood-2024-205524","title":"Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; London Health Sciences Centre; McMaster University; Population Health Research Institute","funders":"","keywords":"Multiple myeloma; Medicine; Prospective cohort study; Categorization; Hematologic Neoplasms; Cohort; Internal medicine; Cohort study; Oncology; Cancer; Computer science; Artificial intelligence","score_opus":0.009789723285105986,"score_gpt":0.26951941573971544,"score_spread":0.2597296924546095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354434,0.00005468311,0.000020226713,0.000008826359,0.000055806002,0.0032839351,0.00008982388,0.00014605619,0.0027962737],"genre_scores_gemma":[0.9968675,0.0000068661184,0.00017313001,0.0000029685852,0.000079868005,0.0002928051,0.0002749634,0.000050522438,0.0022514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819136,0.000058898233,0.00027530116,0.00046076826,0.00072349375,0.00029017596],"domain_scores_gemma":[0.9990735,0.00011300676,0.000069493755,0.00033198146,0.00025346773,0.00015854446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012250758,0.0002228842,0.00039813272,0.00023610429,0.00007569519,0.000038879785,0.00007133513,0.00005571965,0.00018229835],"category_scores_gemma":[0.00011115227,0.0001547943,0.000069476926,0.0006739037,0.000107555265,0.00018608448,0.000042097072,0.00017537383,0.000038746817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048747298,0.004340446,0.9917915,0.000116355375,0.0015011092,0.00014348909,0.00082818244,0.0000012472238,0.00025273056,0.000036726287,0.000067532215,0.00043322792],"study_design_scores_gemma":[0.009467124,0.0017186803,0.9849618,0.00012246291,0.00059353845,0.0000019245697,0.000060519273,0.00017892165,0.0027117098,0.000020900006,0.000022949398,0.00013946126],"about_ca_topic_score_codex":0.001809119,"about_ca_topic_score_gemma":0.0013001477,"teacher_disagreement_score":0.00897965,"about_ca_system_score_codex":0.00011697072,"about_ca_system_score_gemma":0.00015901348,"threshold_uncertainty_score":0.6312328},"labels":[],"label_agreement":null},{"id":"W4405042905","doi":"10.1182/blood-2024-200300","title":"Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"Kite Pharma; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Genentech; Celgene; Bristol-Myers Squibb; GlaxoSmithKline; Servier; Amgen","keywords":"Daratumumab; Pomalidomide; Medicine; Multiple myeloma; Lenalidomide; Internal medicine; Refractory (planetary science); Oncology; Pharmacodynamics; Biology; Pharmacokinetics","score_opus":0.00999610232743083,"score_gpt":0.26660087542740096,"score_spread":0.25660477309997015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528134,0.0029187873,0.000010435116,0.000056678935,0.000021398624,0.0012162717,0.00018805216,0.000078405814,0.00022865678],"genre_scores_gemma":[0.99837196,0.00013107335,0.00052653777,0.000016694667,0.00001513616,0.000069737536,0.00011482421,0.000059991104,0.0006940579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981654,0.00020116096,0.00030482866,0.00053136173,0.0004298638,0.0003673821],"domain_scores_gemma":[0.99865246,0.0006637151,0.00008742794,0.0002492904,0.00011233631,0.00023478358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001841202,0.0003282475,0.0005131935,0.0004451085,0.000078423196,0.00004252987,0.0000658189,0.00013160282,0.000037603815],"category_scores_gemma":[0.00022545441,0.0001937695,0.00003852903,0.00046277817,0.0003196061,0.00022039177,0.000056600074,0.00041758962,0.000003238219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19093141,0.0021443507,0.7862298,0.0005769811,0.001264785,0.003670497,0.0011073707,0.000014137694,0.010110455,0.000013327201,0.000041213,0.0038956723],"study_design_scores_gemma":[0.07033332,0.0068244194,0.9145055,0.0010582899,0.00042206605,0.00011618772,0.00018107475,0.0017641798,0.004451728,0.0000041852873,0.000099646975,0.00023943977],"about_ca_topic_score_codex":0.00014123536,"about_ca_topic_score_gemma":0.00015568256,"teacher_disagreement_score":0.12827566,"about_ca_system_score_codex":0.000106493244,"about_ca_system_score_gemma":0.00030427772,"threshold_uncertainty_score":0.7901691},"labels":[],"label_agreement":null},{"id":"W4405043055","doi":"10.1182/blood-2024-203723","title":"The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Lenalidomide; Carfilzomib; Hematologic Neoplasms; Internal medicine; Oncology; Cancer; Biology","score_opus":0.008222179153024665,"score_gpt":0.24464309202882356,"score_spread":0.2364209128757989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942557,0.0007150799,0.0000016383526,0.00016373632,0.00016381765,0.004414461,0.00011489149,0.00010375623,0.00006689713],"genre_scores_gemma":[0.99916095,0.000034863377,0.00006677911,0.000040042924,0.000019796931,0.0002122423,0.00028048403,0.0000479493,0.00013692245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760544,0.0004081226,0.0004452428,0.00048117712,0.00073417515,0.0003258293],"domain_scores_gemma":[0.99777603,0.0012506255,0.000120384,0.0006066952,0.000116600444,0.00012965561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025883532,0.00030920943,0.00043946813,0.0001560919,0.00015899673,0.00008201972,0.00014073988,0.00008273296,0.00002851776],"category_scores_gemma":[0.00035366783,0.00014145092,0.0000767736,0.0004268263,0.0000646411,0.000095703464,0.00006289956,0.0002827052,0.000015623587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009023601,0.0019115189,0.9625814,0.000029045785,0.001213487,0.00017466732,0.002736905,7.321523e-7,0.0024208466,5.6281385e-7,0.00014533945,0.0197619],"study_design_scores_gemma":[0.035687942,0.010685872,0.9433567,0.00016930056,0.00027355872,0.000001549672,0.0005325906,0.000088073575,0.008933757,0.0000026874966,0.00012974803,0.00013820783],"about_ca_topic_score_codex":0.0006317992,"about_ca_topic_score_gemma":0.00055357546,"teacher_disagreement_score":0.026664343,"about_ca_system_score_codex":0.0000518758,"about_ca_system_score_gemma":0.000060079685,"threshold_uncertainty_score":0.57682014},"labels":[],"label_agreement":null},{"id":"W4405043193","doi":"10.1182/blood-2024-200336","title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Internal medicine; Oncology; Refractory (planetary science); Lenalidomide; Biology","score_opus":0.022583204831675897,"score_gpt":0.31777974230081707,"score_spread":0.29519653746914115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929832,0.0042085648,0.0000247204,0.00041687634,0.00016977383,0.00162318,0.00030877767,0.00007945659,0.00018544424],"genre_scores_gemma":[0.9976397,0.00074711535,0.0007504699,0.000047515045,0.00009204212,0.00005790174,0.0001993722,0.000059586262,0.0004063088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965558,0.00044064238,0.0007931987,0.00090135646,0.00069514214,0.0006138693],"domain_scores_gemma":[0.99713564,0.0014657516,0.00018740683,0.0006951606,0.000100994075,0.0004150663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000915581,0.00048172942,0.0013866712,0.00068964215,0.00015878509,0.0001101849,0.00017135145,0.00026519987,0.00007213666],"category_scores_gemma":[0.0011271125,0.00032767677,0.00028402923,0.0011696737,0.00039073554,0.00016462244,0.00025960946,0.00066189276,0.0000042429874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022113765,0.004939555,0.94278806,0.00023345363,0.0064333705,0.00061300845,0.0006127617,0.0000019829452,0.00726657,0.00005904825,0.00008174208,0.014856671],"study_design_scores_gemma":[0.19743282,0.0013205595,0.7921179,0.00013104659,0.003455541,0.00006930914,0.00010141194,0.0013343955,0.0034810298,0.00002700819,0.00025892988,0.00027004772],"about_ca_topic_score_codex":0.0014096391,"about_ca_topic_score_gemma":0.0010424458,"teacher_disagreement_score":0.17531905,"about_ca_system_score_codex":0.000071090435,"about_ca_system_score_gemma":0.00018995834,"threshold_uncertainty_score":0.9999175},"labels":[],"label_agreement":null},{"id":"W4405043414","doi":"10.1182/blood-2024-200871","title":"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Daratumumab; Bortezomib; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Transplantation; Thalidomide; Surgery","score_opus":0.04351882518375011,"score_gpt":0.3480125436039243,"score_spread":0.3044937184201742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882868,0.0006128072,0.000020720492,0.00017136542,0.000061725215,0.008111983,0.0027041018,0.000021562288,0.000008924329],"genre_scores_gemma":[0.9975583,0.00023508846,0.0001607356,0.000044596236,0.000066144,0.0010189294,0.00086782844,0.00003898005,0.000009414253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99647486,0.0006160585,0.00095308135,0.0006078159,0.0008898579,0.00045830946],"domain_scores_gemma":[0.9946383,0.0044499543,0.00016633484,0.00041206533,0.00010993598,0.00022340822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008759662,0.00038076137,0.001668167,0.000851369,0.00008401935,0.000058290338,0.00018662114,0.00009453759,0.000035963163],"category_scores_gemma":[0.0005002346,0.00021598434,0.00029502745,0.000997934,0.00021380313,0.00013059608,0.00001577344,0.00023623607,6.4632536e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8858252,0.024259893,0.068585895,0.00019774138,0.0074702348,0.0016554547,0.010353567,0.000015588626,0.00015663312,0.0000019738445,0.000011213971,0.0014665764],"study_design_scores_gemma":[0.88576615,0.024554944,0.07612025,0.00026763155,0.0079669,0.000003148707,0.00068240217,0.0013227306,0.0031046602,0.0000035186438,0.0000067269834,0.00020095675],"about_ca_topic_score_codex":0.0018935682,"about_ca_topic_score_gemma":0.0028901251,"teacher_disagreement_score":0.009671165,"about_ca_system_score_codex":0.0000296812,"about_ca_system_score_gemma":0.00042035672,"threshold_uncertainty_score":0.8807586},"labels":[],"label_agreement":null},{"id":"W4405043418","doi":"10.1182/blood-2024-201057","title":"Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Oncology; Lenalidomide","score_opus":0.019061961283635,"score_gpt":0.29999737200296356,"score_spread":0.28093541071932854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937691,0.00021516312,0.000002470725,0.0000100472025,0.00019837606,0.0055784346,0.000091149035,0.000033867458,0.00010140554],"genre_scores_gemma":[0.9994268,0.000029368091,0.00014538509,8.572786e-7,0.000048889902,0.00026263643,0.000019616842,0.00003856394,0.000027921913],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975701,0.0004098155,0.0005494851,0.0004189158,0.0007803213,0.00027137971],"domain_scores_gemma":[0.9982477,0.0007718629,0.00019608105,0.00056711846,0.00013381867,0.00008345446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042099835,0.00023598455,0.00077338214,0.00022827736,0.00007342125,0.000018255792,0.00016244085,0.000049462382,0.0000033573797],"category_scores_gemma":[0.00036353729,0.00013584488,0.00010920961,0.00050337194,0.000086542816,0.0001082763,0.000094004245,0.0003148521,0.0000012574735],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4389732,0.03753435,0.5031608,0.000072691466,0.003060435,0.00011749112,0.006568664,0.000021760521,0.0006148207,4.407024e-7,0.0000015042411,0.009873886],"study_design_scores_gemma":[0.53803927,0.0065137167,0.44473147,0.00018392026,0.00048207358,4.3710102e-7,0.0011139495,0.00004887324,0.008817843,0.0000011546449,9.670011e-7,0.00006633285],"about_ca_topic_score_codex":0.001697201,"about_ca_topic_score_gemma":0.0001830218,"teacher_disagreement_score":0.09906607,"about_ca_system_score_codex":0.00010614725,"about_ca_system_score_gemma":0.000117852614,"threshold_uncertainty_score":0.5539593},"labels":[],"label_agreement":null},{"id":"W4405043607","doi":"10.1182/blood-2024-202098","title":"Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Multiple myeloma; Medicine; Lenalidomide; Internal medicine; Oncology","score_opus":0.04614598840469218,"score_gpt":0.3359464436156041,"score_spread":0.2898004552109119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716675,0.00038697405,0.0002631794,0.0010968993,0.000051569623,0.0007764659,0.00003607344,0.000027938684,0.00019415807],"genre_scores_gemma":[0.9984824,0.000008722833,0.0010542899,0.000024315967,0.000056216486,0.00011573905,0.000036339356,0.000011851649,0.00021010563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992945,0.00008038904,0.00018292366,0.00011426,0.00017026575,0.00015761967],"domain_scores_gemma":[0.9990091,0.00073588965,0.000025308524,0.00013168473,0.000058098518,0.00003996135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048478282,0.00006400248,0.00011701778,0.00012499129,0.000037816353,0.000017400782,0.000046413086,0.00003792588,0.00002415999],"category_scores_gemma":[0.00082714343,0.000041698757,0.00006580798,0.00016141337,0.00003944687,0.000043316566,0.000019095864,0.000082076665,0.000010617625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015004958,0.0016002876,0.058338676,0.0016132105,0.00078625954,0.00051474123,0.005406176,0.000027090175,0.82344306,0.00096630154,0.00037141202,0.09192785],"study_design_scores_gemma":[0.024061035,0.0018362184,0.41854072,0.0008130818,0.00031604382,0.00013370535,0.0012787508,0.046950813,0.5034312,0.00030810956,0.002169577,0.00016078686],"about_ca_topic_score_codex":0.00007079551,"about_ca_topic_score_gemma":0.000024652,"teacher_disagreement_score":0.360202,"about_ca_system_score_codex":0.000026423437,"about_ca_system_score_gemma":0.000110378445,"threshold_uncertainty_score":0.17004259},"labels":[],"label_agreement":null},{"id":"W4405043889","doi":"10.1182/blood-2024-199542","title":"Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; University of Calgary; Princess Margaret Cancer Centre","funders":"Juno Therapeutics; Genentech; City of Hope; Pharmacyclics; Gilead Sciences; Kite Pharma; Regeneron Pharmaceuticals; University of Pennsylvania; Bristol-Myers Squibb; AstraZeneca; Celgene; Amgen","keywords":"Medicine; Multiple myeloma; Pomalidomide; Regimen; Lenalidomide; Oncology; Internal medicine; Refractory (planetary science); Phases of clinical research; Clinical trial; Intensive care medicine; Biology","score_opus":0.0287834125894258,"score_gpt":0.3350266829619709,"score_spread":0.3062432703725451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576914,0.00051776815,0.0000064612364,0.0002249558,0.000029348203,0.0029388166,0.00031331848,0.00007684825,0.00012331114],"genre_scores_gemma":[0.9987734,0.00030387973,0.00028795408,0.000021213933,0.000019602956,0.00008372639,0.00038706794,0.000028550303,0.00009458125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828696,0.00011719643,0.0004285059,0.0005619127,0.00031074902,0.00029466767],"domain_scores_gemma":[0.9981527,0.0010865229,0.00012732814,0.00030174936,0.00016467586,0.00016702263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006214506,0.00024709353,0.00042034214,0.00015043022,0.00024693395,0.000120288874,0.000060983806,0.00008366681,0.0000015850511],"category_scores_gemma":[0.0005442947,0.00015382851,0.000023904287,0.00022700483,0.00016680988,0.00047180464,0.00009663508,0.00026404797,6.70472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037647113,0.0066758464,0.8749575,0.00017384553,0.001935671,0.00017673637,0.005079702,0.0000013007518,0.00022312446,0.000012736859,0.00002229787,0.07309414],"study_design_scores_gemma":[0.09357252,0.009562814,0.8916389,0.00036080688,0.00045970076,0.0000044056333,0.0020428614,0.0017181177,0.00038202762,0.00004941826,0.00005058025,0.00015786174],"about_ca_topic_score_codex":0.0004855164,"about_ca_topic_score_gemma":0.000988281,"teacher_disagreement_score":0.072936274,"about_ca_system_score_codex":0.000064257234,"about_ca_system_score_gemma":0.00007518618,"threshold_uncertainty_score":0.6272945},"labels":[],"label_agreement":null},{"id":"W4405044004","doi":"10.1182/blood-2024-198403","title":"Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Pomalidomide; Multiple myeloma; Internal medicine; Oncology; Refractory (planetary science); Biology","score_opus":0.06561095051632172,"score_gpt":0.33243927684294644,"score_spread":0.26682832632662473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816326,0.0013594859,0.00041095025,0.004907645,0.00085228466,0.006014259,0.0032682118,0.00023322944,0.0013213392],"genre_scores_gemma":[0.9881632,0.000082313534,0.00401045,0.00016728658,0.00057899224,0.0009865178,0.0013627367,0.00007569193,0.0045728493],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99748653,0.00009860901,0.0006727069,0.00067124853,0.0005303833,0.00054051593],"domain_scores_gemma":[0.99361944,0.0052389214,0.000101226586,0.00070440135,0.00011416669,0.0002218555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006454143,0.00029178208,0.00044095115,0.00021180474,0.00019854218,0.000091557224,0.00025669602,0.00021974856,0.000055640958],"category_scores_gemma":[0.0051342337,0.00018150822,0.00022758517,0.0004555956,0.000111255504,0.00016921254,0.0001061806,0.0005019914,0.00006192133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8328183,0.046641607,0.0036336542,0.00050482416,0.0038708693,0.0021283568,0.0064816047,0.000024716128,0.046865474,0.0013718111,0.019223584,0.036435198],"study_design_scores_gemma":[0.87331265,0.008403696,0.04966585,0.0010350607,0.0009006599,0.00009203582,0.0005317995,0.008755777,0.009207849,0.00027772874,0.047367096,0.00044979656],"about_ca_topic_score_codex":0.0011028865,"about_ca_topic_score_gemma":0.0009760071,"teacher_disagreement_score":0.046032198,"about_ca_system_score_codex":0.00021047649,"about_ca_system_score_gemma":0.0008683738,"threshold_uncertainty_score":0.74016905},"labels":[],"label_agreement":null},{"id":"W4405044345","doi":"10.1182/blood-2024-211949","title":"COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Saint John Regional Hospital; Alberta Health Services; Western University; Juravinski Cancer Centre; St. Michael's Hospital; Jewish General Hospital; Toronto General Hospital; McMaster University; Queen's University; University of Alberta; University of Ottawa; McGill University; University Health Network; Ottawa Hospital; Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Immunology; Dyscrasia; Medicine; Humoral immunity; Plasma cell; Coronavirus disease 2019 (COVID-19); Virology; Immunity; Cellular immunity; Convalescent plasma; Immune system; Antibody; Internal medicine","score_opus":0.02129312880879864,"score_gpt":0.28676161734710426,"score_spread":0.2654684885383056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961991,0.0020165194,0.000004736909,0.00042475332,0.000020802894,0.0011180999,0.000015913783,0.000064493506,0.00013562571],"genre_scores_gemma":[0.99866545,0.00043839362,0.00048925047,0.00010286068,0.000020018848,0.00009479391,0.00006318924,0.000034823654,0.00009122258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984598,0.00013087154,0.00023817805,0.000384504,0.00034776804,0.0004388827],"domain_scores_gemma":[0.9991172,0.00015361395,0.000042713375,0.00029349249,0.000049977152,0.00034298742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002559296,0.00023690445,0.00033818532,0.0002457008,0.00007148557,0.000089174326,0.000079011654,0.000067596426,0.00002515149],"category_scores_gemma":[0.0001160357,0.00014479118,0.000030598258,0.00041588172,0.000062544525,0.00018737014,0.000046009744,0.00034081726,0.0000054345983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022638512,0.0023429045,0.9858273,0.00030427522,0.00018061021,0.0012692368,0.0013635722,0.0000029472087,0.0037747598,0.000009387269,0.00002038053,0.002640721],"study_design_scores_gemma":[0.028137146,0.0028046789,0.9571987,0.0003844265,0.00007360987,0.000032537693,0.0002709709,0.00014762869,0.010638032,0.000018520823,0.00012121938,0.00017254573],"about_ca_topic_score_codex":0.001453707,"about_ca_topic_score_gemma":0.0009118077,"teacher_disagreement_score":0.02862867,"about_ca_system_score_codex":0.0001282659,"about_ca_system_score_gemma":0.0004431335,"threshold_uncertainty_score":0.5904413},"labels":[],"label_agreement":null},{"id":"W4405044372","doi":"10.1182/blood-2024-201056","title":"Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; CD38; Antibody; Mechanism (biology); Medicine; Immunology; Cancer research; Biology; Genetics; Stem cell; Physics","score_opus":0.03242307861881754,"score_gpt":0.3096346920862939,"score_spread":0.27721161346747636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914371,0.00475871,0.0003103012,0.0014387675,0.00029228168,0.0009541046,0.00019174405,0.00008259142,0.0005344232],"genre_scores_gemma":[0.99678934,0.00079414534,0.0012555202,0.00005511298,0.000099770325,0.00007872813,0.000044113734,0.00003070934,0.0008525502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798894,0.00006657313,0.00041343822,0.0004929303,0.0005825934,0.00045552367],"domain_scores_gemma":[0.9991264,0.00006512835,0.00004808121,0.00037269227,0.00014658076,0.00024113066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000248931,0.00021895814,0.00043594572,0.00042913036,0.000051195184,0.000023899716,0.00012525557,0.00009958431,0.00013608277],"category_scores_gemma":[0.0002537533,0.00018559954,0.00015411054,0.00058002333,0.00006099862,0.00007711129,0.00010450077,0.00018128891,0.00015031685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004832237,0.012675831,0.5354384,0.0094882585,0.003705109,0.007964331,0.010857873,0.000011374421,0.35309574,0.011663512,0.010829014,0.039438307],"study_design_scores_gemma":[0.012866649,0.0013953601,0.5805745,0.003583144,0.00034245732,0.00008118917,0.00037990455,0.0017754352,0.39187902,0.0013364024,0.0052802004,0.0005057304],"about_ca_topic_score_codex":0.0003660486,"about_ca_topic_score_gemma":0.00046733973,"teacher_disagreement_score":0.045136094,"about_ca_system_score_codex":0.00017164867,"about_ca_system_score_gemma":0.0002727757,"threshold_uncertainty_score":0.756853},"labels":[],"label_agreement":null},{"id":"W4405044540","doi":"10.1182/blood-2024-202224","title":"A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Pharmacyclics; Genentech; Seagen; Alexion Pharmaceuticals; Prothena; SkylineDx; Springworks Therapeutics; Regeneron Pharmaceuticals; Bristol-Myers Squibb; CSL Behring; Memorial Sloan-Kettering Cancer Center; Legend Biotech; Celgene; Omeros Corporation; Array BioPharma; Gilead Sciences; Seres Therapeutics; Amgen","keywords":"Multiple myeloma; Disease; Plasma cell; Medicine; Oncology; Internal medicine","score_opus":0.010503309799121391,"score_gpt":0.29497132270508253,"score_spread":0.28446801290596113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522024,0.0026164132,0.00001738278,0.0005736629,0.00007216611,0.0012129254,0.000053147665,0.000045664303,0.00018842176],"genre_scores_gemma":[0.9971232,0.00016152977,0.0016515695,0.000005977632,0.000027906832,0.00021569335,0.000112445035,0.000023700517,0.00067802385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988542,0.00006366124,0.00025534947,0.0003420862,0.00024319117,0.00024148542],"domain_scores_gemma":[0.9994271,0.00005787784,0.00003781641,0.00016769044,0.000028557428,0.00028095677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012697649,0.00014794308,0.0001951357,0.00031891145,0.000028285904,0.000026155214,0.000053049123,0.000051947925,0.00006169224],"category_scores_gemma":[0.00005429749,0.00011448381,0.000119383345,0.0002781072,0.0000597406,0.00011135795,0.00008374866,0.00009828015,0.00003566543],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068105496,0.008790653,0.20269987,0.005939774,0.001155451,0.00087597355,0.00045941726,0.0000023492526,0.037526533,0.000037478287,0.00056603557,0.7351359],"study_design_scores_gemma":[0.014319184,0.0033192027,0.9299237,0.0035737737,0.0006492867,0.000017141372,0.00011698461,0.0009183024,0.045913376,0.0002423201,0.00075579423,0.00025093785],"about_ca_topic_score_codex":0.000108160675,"about_ca_topic_score_gemma":0.00006736399,"teacher_disagreement_score":0.734885,"about_ca_system_score_codex":0.00003681555,"about_ca_system_score_gemma":0.00006491791,"threshold_uncertainty_score":0.4668514},"labels":[],"label_agreement":null},{"id":"W4405044949","doi":"10.1182/blood-2024-201288","title":"Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cart; Multiple myeloma; Refractory (planetary science); Oncology; Lenalidomide; Internal medicine; Cancer research; Immunology; Immunotherapy; Biology; Cancer","score_opus":0.010942681774476,"score_gpt":0.2501756502306125,"score_spread":0.2392329684561365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958104,0.002424332,0.0000037740394,0.000047113,0.00009073153,0.001027051,0.000114880684,0.000057033198,0.00042472407],"genre_scores_gemma":[0.99688095,0.00023779334,0.0018821798,0.000025491974,0.000048920156,0.00005904368,0.00005602586,0.00006352527,0.00074605324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824065,0.00006947522,0.00035383506,0.00046890855,0.00042317522,0.00044398187],"domain_scores_gemma":[0.99908674,0.00011019022,0.00007293539,0.0004322937,0.00009151543,0.00020634916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012698259,0.00024107646,0.00044673032,0.00032537707,0.00005142447,0.000024860357,0.00014548615,0.00008268848,0.00007695026],"category_scores_gemma":[0.00006922211,0.00017902386,0.00008169509,0.00045995877,0.000074568365,0.00010593355,0.00005569498,0.00018586473,0.00013968372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009419044,0.0016951405,0.9575127,0.00028880907,0.00017309627,0.00016948878,0.00066990167,8.206327e-7,0.032416575,0.0000011722033,0.00015231936,0.005978107],"study_design_scores_gemma":[0.008262395,0.0011562856,0.9460136,0.000581311,0.000055265715,0.0000028355048,0.000080737926,0.00001748892,0.04192884,0.000002324166,0.0017358144,0.00016305172],"about_ca_topic_score_codex":0.00008432093,"about_ca_topic_score_gemma":0.00018119418,"teacher_disagreement_score":0.011499017,"about_ca_system_score_codex":0.00007716191,"about_ca_system_score_gemma":0.00017075114,"threshold_uncertainty_score":0.7300381},"labels":[],"label_agreement":null},{"id":"W4405044954","doi":"10.1182/blood-2024-205608","title":"Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; TEC; Lenalidomide; Internal medicine; Oncology; Multiple myeloma; Cohort; Autologous stem-cell transplantation; Surgery","score_opus":0.02588443696714383,"score_gpt":0.2991773898175876,"score_spread":0.2732929528504438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928761,0.0013446284,0.000025651754,0.0004971494,0.00014425525,0.0047204955,0.00020618102,0.00006153053,0.00012401793],"genre_scores_gemma":[0.998327,0.0007161581,0.00019175446,0.00002157518,0.00004621793,0.0003235936,0.0002791123,0.000040155923,0.000054436532],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969659,0.00046418415,0.000828597,0.00067014934,0.0006216187,0.00044954597],"domain_scores_gemma":[0.99718034,0.0020982102,0.00014885468,0.00040794854,0.00005689195,0.00010772583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008588829,0.00032405448,0.0006869995,0.00034308725,0.000081149825,0.000054762033,0.00016788304,0.00014327042,0.0000061720375],"category_scores_gemma":[0.00019436194,0.00022155143,0.00009130604,0.0006692757,0.000082899074,0.0002128663,0.00002961755,0.00043771535,0.0000046914747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78614026,0.025269065,0.06792052,0.00020714318,0.0009301263,0.017234182,0.024336226,0.00007377493,0.008175013,0.000015447495,0.00001445356,0.06968376],"study_design_scores_gemma":[0.76231664,0.009650543,0.21050034,0.00077812356,0.00024131208,0.000025357826,0.003798409,0.0007962509,0.011626707,0.00002146809,0.00003697649,0.00020786648],"about_ca_topic_score_codex":0.011829871,"about_ca_topic_score_gemma":0.01705805,"teacher_disagreement_score":0.14257982,"about_ca_system_score_codex":0.00016629744,"about_ca_system_score_gemma":0.00022503723,"threshold_uncertainty_score":0.99475044},"labels":[],"label_agreement":null},{"id":"W4405045412","doi":"10.1182/blood-2024-198669","title":"Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Tolerability; Medicine; Lenalidomide; Multiple myeloma; Interim analysis; Adverse effect; Clinical endpoint; Internal medicine; Bortezomib; Data monitoring committee; Oncology; Surgery; Urology; Clinical trial","score_opus":0.015078072237765125,"score_gpt":0.315646823370327,"score_spread":0.3005687511325619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759805,0.0005687232,0.000059006135,0.00003988215,0.00001620592,0.0012135342,0.00035727813,0.00003600377,0.000111292924],"genre_scores_gemma":[0.9987849,0.00006994023,0.00021544273,0.000002829992,0.0000073352344,0.000082052924,0.0007936388,0.000022533959,0.000021339154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834573,0.00011215772,0.00047975453,0.0003391808,0.0004693914,0.0002538061],"domain_scores_gemma":[0.9993027,0.00013141776,0.000068363326,0.0002672015,0.00013488345,0.00009547548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017615687,0.00018002243,0.0006833072,0.0011467001,0.00001743313,0.000014984043,0.00009560405,0.000063408384,0.000049968614],"category_scores_gemma":[0.00003984686,0.00013789149,0.00008963986,0.0017275296,0.00004059878,0.00008182939,0.000023004317,0.00018228384,0.0000022137112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096452525,0.018142799,0.94688535,0.00052503566,0.0020985967,0.0030888817,0.011472682,0.000056078417,0.0032293196,0.0000077531895,0.000007416293,0.0048408327],"study_design_scores_gemma":[0.23035222,0.028194722,0.6196019,0.0012295351,0.0034596084,0.00002796904,0.011569088,0.0032078768,0.10206154,0.000006939168,0.000022402128,0.0002661902],"about_ca_topic_score_codex":0.002737595,"about_ca_topic_score_gemma":0.017071715,"teacher_disagreement_score":0.32728344,"about_ca_system_score_codex":0.0001072192,"about_ca_system_score_gemma":0.00014644394,"threshold_uncertainty_score":0.9526417},"labels":[],"label_agreement":null},{"id":"W4405046844","doi":"10.1182/blood-2024-206096","title":"R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Sierra Oncology; Incyte; Swedish Orphan Biovitrum; Astex Pharmaceuticals; Jazz Pharmaceuticals; MorphoSys; Celgene; Bristol-Myers Squibb; Helsinn; Servier; Amgen","keywords":"Medicine; Internal medicine; Refractory (planetary science); Myelodysplastic syndromes; Lenalidomide; Oncology; Gastroenterology; Bone marrow; Biology; Multiple myeloma","score_opus":0.015385067720385746,"score_gpt":0.28987608832230516,"score_spread":0.27449102060191943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405046844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473363,0.00035464962,0.000006510435,0.000062418854,0.00042103173,0.0020293894,0.0017717874,0.00019018498,0.00043038302],"genre_scores_gemma":[0.998099,0.00002432849,0.00018198199,0.000024322726,0.000272525,0.00016590148,0.0008932056,0.00009091319,0.00024777264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963131,0.00024072919,0.00061295036,0.0009815881,0.0011688985,0.0006827182],"domain_scores_gemma":[0.9980524,0.0005786654,0.00011546828,0.0006494073,0.0001263313,0.00047768775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030401195,0.00044079803,0.0006098823,0.00051256287,0.000114671646,0.00010472967,0.00013636767,0.00017087952,0.00014066602],"category_scores_gemma":[0.00065747753,0.00032803713,0.000110373985,0.00063848024,0.000110265166,0.00026593645,0.00012849442,0.0008844957,0.00037756574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047086302,0.15938653,0.6663831,0.00023955252,0.004226818,0.09832168,0.004239003,0.0000058918613,0.00029993214,0.0000052693317,0.0009851772,0.018820776],"study_design_scores_gemma":[0.26078954,0.03537998,0.69950086,0.0011902191,0.0012126748,0.000101413294,0.00031255197,0.00016781369,0.0003027684,0.000023343815,0.00055444165,0.00046438377],"about_ca_topic_score_codex":0.0010494963,"about_ca_topic_score_gemma":0.0004020443,"teacher_disagreement_score":0.21370323,"about_ca_system_score_codex":0.0001766953,"about_ca_system_score_gemma":0.000448358,"threshold_uncertainty_score":0.99991715},"labels":[],"label_agreement":null},{"id":"W4405047439","doi":"10.1182/blood-2024-211833","title":"BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Computer science; Immunology","score_opus":0.020111423298800016,"score_gpt":0.25240620912103845,"score_spread":0.23229478582223845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864666,0.0064518373,0.0004906468,0.00053783477,0.00013237828,0.00069255556,0.000057990615,0.00010216074,0.0050680176],"genre_scores_gemma":[0.97945845,0.000105914034,0.012502344,0.000073865915,0.00014442869,0.00010140651,0.000051957257,0.00004107443,0.0075205727],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818146,0.00009808018,0.0002538112,0.0005557277,0.00041439454,0.0004965272],"domain_scores_gemma":[0.998961,0.0003109381,0.00002174714,0.0002939386,0.000049174247,0.00036324907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044392672,0.00020999844,0.00028409902,0.0003126279,0.000121637124,0.000074233234,0.00007164079,0.00010840397,0.00027159785],"category_scores_gemma":[0.00018255202,0.00018561492,0.000061102306,0.00054847717,0.00005583095,0.00010892232,0.00006193188,0.00033882124,0.00018608026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014085437,0.0026987412,0.3308734,0.0014476109,0.00045876292,0.009959168,0.0012733192,0.000031048497,0.64225036,0.0015754653,0.0045216163,0.0035019466],"study_design_scores_gemma":[0.019633774,0.00051032123,0.8699499,0.0010068926,0.00022281717,0.00023246084,0.0005128404,0.0007102065,0.05746017,0.00082115486,0.048351124,0.00058838225],"about_ca_topic_score_codex":0.00007539359,"about_ca_topic_score_gemma":0.000073592884,"teacher_disagreement_score":0.5847902,"about_ca_system_score_codex":0.0000773421,"about_ca_system_score_gemma":0.00017114558,"threshold_uncertainty_score":0.7569156},"labels":[],"label_agreement":null},{"id":"W4405047455","doi":"10.1182/blood-2024-208842","title":"Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Lenalidomide; CD38; Multiple myeloma; Cancer research; Immune system; Immunology; Medicine; Internal medicine; Biology; Oncology; CD34; Stem cell","score_opus":0.012634975666536784,"score_gpt":0.27417086489991216,"score_spread":0.2615358892333754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896472,0.008109884,0.000010298598,0.00084122893,0.00006236575,0.00060968427,0.000054364777,0.000055537286,0.0006094516],"genre_scores_gemma":[0.997249,0.000058718986,0.001985035,0.000057043864,0.000036639893,0.0001054941,0.000021617236,0.000027675418,0.0004587863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998794,0.00005642447,0.00027395802,0.00029218107,0.00031093784,0.00027245205],"domain_scores_gemma":[0.99920595,0.0002673387,0.000027342756,0.0002772964,0.000049229537,0.00017284494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021377853,0.00014526822,0.0003109062,0.000291134,0.000036808,0.000020517125,0.000073861374,0.000049612136,0.000052394553],"category_scores_gemma":[0.0003303598,0.00011390515,0.00006141823,0.00043954668,0.00007984118,0.00003985044,0.000035656587,0.00015428364,0.000018604262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045145345,0.0026687435,0.7282325,0.0023426241,0.0008428406,0.0044191843,0.0036802527,0.0000049042424,0.24177982,0.00039415568,0.00084760395,0.010272827],"study_design_scores_gemma":[0.014741171,0.0007285393,0.8122514,0.0012176399,0.00010429271,0.00002102651,0.00030479283,0.0005410471,0.16744496,0.00007538342,0.0023787546,0.00019102296],"about_ca_topic_score_codex":0.00007873829,"about_ca_topic_score_gemma":0.000339515,"teacher_disagreement_score":0.084018864,"about_ca_system_score_codex":0.00003906212,"about_ca_system_score_gemma":0.00014383093,"threshold_uncertainty_score":0.46449172},"labels":[],"label_agreement":null},{"id":"W4405049365","doi":"10.1182/blood-2024-203809","title":"Health Care Utilization for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma: Experience from a Canadian Center","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Center (category theory); Refractory (planetary science); Lenalidomide; Family medicine; Pediatrics; Internal medicine","score_opus":0.025417387844696333,"score_gpt":0.2923889276660677,"score_spread":0.2669715398213714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465555,0.0022435684,0.000058779646,0.0002924488,0.00011997193,0.0015111271,0.0008827589,0.00006413622,0.00017167693],"genre_scores_gemma":[0.99589145,0.000068744215,0.0013315695,0.00016836119,0.00006528963,0.00019805318,0.0021101774,0.000036420774,0.00012990809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987795,0.00003498643,0.000172671,0.00039343376,0.00023780874,0.0003816533],"domain_scores_gemma":[0.99903417,0.000083442304,0.00003262242,0.00021688725,0.00011610454,0.00051677093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036040594,0.00015135997,0.00021496059,0.00014660008,0.00015378626,0.00004897734,0.000047852016,0.000069337126,0.000027781425],"category_scores_gemma":[0.00010573066,0.00011469025,0.000039073286,0.0001352117,0.00004363688,0.00011328103,0.000015226641,0.00010358607,0.0000072300177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001021123,0.00080357125,0.9474514,0.00034556637,0.00027280688,0.000118251424,0.008408983,1.3401889e-7,0.00020697218,0.00001540502,0.0008055126,0.040550265],"study_design_scores_gemma":[0.042540133,0.0032915426,0.90731055,0.0006775774,0.00013241387,0.0000108261365,0.0018750918,0.00070159393,0.0016585945,0.000008317194,0.041504193,0.00028915727],"about_ca_topic_score_codex":0.01438241,"about_ca_topic_score_gemma":0.04960447,"teacher_disagreement_score":0.04151901,"about_ca_system_score_codex":0.00021993577,"about_ca_system_score_gemma":0.00051386224,"threshold_uncertainty_score":0.9921809},"labels":[],"label_agreement":null},{"id":"W4405049845","doi":"10.1182/blood-2024-204683","title":"Thromboembolism in Multiple Myeloma: A Single Centre Retrospective Review","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Multiple myeloma; Medicine; Retrospective cohort study; Lenalidomide; Internal medicine; Oncology","score_opus":0.029048022117262234,"score_gpt":0.2999584004392421,"score_spread":0.27091037832197984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8685477,0.11029457,0.000007955871,0.003143313,0.00018462988,0.0016471959,0.000065016815,0.00026923936,0.015840396],"genre_scores_gemma":[0.9946678,0.0034311118,0.00044580468,0.00021828942,0.00014340658,0.00004968345,0.00006214524,0.000032796783,0.00094891083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998616,0.000051516177,0.00022265983,0.00038587052,0.00033683976,0.00038712946],"domain_scores_gemma":[0.99937266,0.000080952515,0.000020317557,0.0002883585,0.000060368104,0.00017732484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001461671,0.00015557268,0.00041177348,0.00013464253,0.000035125642,0.000029091329,0.00006814094,0.00006522606,0.00034362357],"category_scores_gemma":[0.0003751909,0.00012533189,0.00012552805,0.00047191905,0.00004535601,0.00008509846,0.000050165974,0.0002567911,0.00046254395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002486544,0.012312541,0.7842908,0.013424474,0.0020128032,0.019422974,0.001590238,3.9285223e-7,0.03352036,0.0014168302,0.016090447,0.1156695],"study_design_scores_gemma":[0.010355593,0.0005955696,0.9435956,0.01530927,0.0006063915,0.0003226669,0.000089675945,0.0002642892,0.013197268,0.0004342411,0.014874804,0.00035462293],"about_ca_topic_score_codex":0.00008820138,"about_ca_topic_score_gemma":0.00013591003,"teacher_disagreement_score":0.15930481,"about_ca_system_score_codex":0.0001481004,"about_ca_system_score_gemma":0.00010679263,"threshold_uncertainty_score":0.59452206},"labels":[],"label_agreement":null},{"id":"W4405049933","doi":"10.1182/blood-2024-198626","title":"Unmet Needs in Multiple Myeloma and Potential Solutions: A Systemic Literature Review","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Lenalidomide; Medicine; Ixazomib; Intensive care medicine; Internal medicine; Carfilzomib","score_opus":0.020357993317921805,"score_gpt":0.2861096032675662,"score_spread":0.26575160994964436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049933","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4163024,0.5814747,0.000022287362,0.0007731235,0.00007777091,0.0008170586,0.000052452135,0.00007818424,0.0004020247],"genre_scores_gemma":[0.9394192,0.059159495,0.00028045668,0.00010497296,0.00011252207,0.000113289105,0.00009876023,0.000017828286,0.00069346523],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99897987,0.00006828063,0.00020846976,0.000230492,0.00022011135,0.00029277772],"domain_scores_gemma":[0.99952495,0.000058772366,0.000016033191,0.00020205855,0.000043909633,0.00015426548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020738653,0.00012718396,0.0002635629,0.000275857,0.00004761158,0.000059526457,0.000045882218,0.00007758651,0.000033520624],"category_scores_gemma":[0.00016728175,0.00009809797,0.00007740727,0.0006093725,0.000033605214,0.00009163257,0.000053063228,0.00023282961,0.00006544077],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008575749,0.008321143,0.25614938,0.18200085,0.004418514,0.115348384,0.0040328447,0.0000046212062,0.073168255,0.002632318,0.0128045,0.3402616],"study_design_scores_gemma":[0.05412608,0.002435596,0.36815563,0.44322413,0.0040194746,0.09323124,0.00059886393,0.007796055,0.0038402872,0.00053248595,0.020458184,0.001581979],"about_ca_topic_score_codex":0.000019993855,"about_ca_topic_score_gemma":0.0000068145596,"teacher_disagreement_score":0.5231168,"about_ca_system_score_codex":0.000037582704,"about_ca_system_score_gemma":0.000080753474,"threshold_uncertainty_score":0.4000319},"labels":[],"label_agreement":null},{"id":"W4405050034","doi":"10.1182/blood-2024-198804","title":"Efficacy and Safety of Teclistamab in Relapsed or Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Lenalidomide; Oncology; Meta-analysis; Pomalidomide; Biology","score_opus":0.09983939720085885,"score_gpt":0.3863450865801625,"score_spread":0.28650568937930365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038062826,0.9925053,8.957459e-7,0.000056710793,0.000008751944,0.0068876115,0.0003626105,0.000032305405,0.00010771531],"genre_scores_gemma":[0.0005363094,0.99636084,0.0002764635,0.000029561379,0.000012962049,0.00089890364,0.00019821037,0.00006214828,0.0016245873],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960492,0.00062698673,0.0017593862,0.00073967734,0.00049396907,0.00033077362],"domain_scores_gemma":[0.99696344,0.0012093531,0.0005219693,0.0009499113,0.000090272304,0.00026502437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009911547,0.0005958036,0.011901553,0.00081764103,0.000036392285,0.000027210692,0.00015288251,0.0002630481,0.00013583072],"category_scores_gemma":[0.0020437797,0.00029957938,0.0015377689,0.0014938045,0.00010078515,0.000034892833,0.00016416487,0.00053677993,0.000029334988],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006120592,0.00054317515,0.000011451889,0.7929166,0.20311143,0.0005794209,0.000026212503,7.4325293e-9,2.1221138e-7,0.000004577572,0.000021075644,0.0027246543],"study_design_scores_gemma":[0.002986831,0.00023735686,0.000047226702,0.13140851,0.8584382,0.00021978808,0.000008040123,0.0000029813204,4.5772381e-7,0.0000010908835,0.006453958,0.0001955574],"about_ca_topic_score_codex":0.00006830322,"about_ca_topic_score_gemma":0.00009917084,"teacher_disagreement_score":0.6615081,"about_ca_system_score_codex":0.00007994656,"about_ca_system_score_gemma":0.00028300728,"threshold_uncertainty_score":0.99994564},"labels":[],"label_agreement":null},{"id":"W4405050191","doi":"10.1182/blood-2024-208861","title":"ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Carfilzomib; Internal medicine; Oncology; Pomalidomide","score_opus":0.08088941607811272,"score_gpt":0.36705118882494575,"score_spread":0.286161772746833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98477733,0.0042197797,0.0019096443,0.0010901443,0.0003924382,0.003931235,0.00016644964,0.00031958634,0.0031934015],"genre_scores_gemma":[0.9592967,0.00046346342,0.03605807,0.00027892707,0.0014485802,0.0007682056,0.000310261,0.00011870062,0.0012571159],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99638695,0.0003012361,0.00094493263,0.001034769,0.00059438316,0.00073772337],"domain_scores_gemma":[0.9948543,0.0035846548,0.00016146658,0.00057103275,0.00014376169,0.0006848065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017020886,0.00042799863,0.0009709176,0.00022524827,0.0001952528,0.00022358076,0.00019195538,0.0003542842,0.00004325459],"category_scores_gemma":[0.00396638,0.0003333834,0.00043533836,0.00040507384,0.0002844791,0.00020180586,0.00005110395,0.0006653644,0.00006538982],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07105529,0.022015367,0.22154345,0.005034733,0.009198316,0.0043099574,0.0019067116,0.000007899679,0.036140103,0.0018081134,0.018811712,0.60816836],"study_design_scores_gemma":[0.8552817,0.014379601,0.06175693,0.0015830687,0.0039834003,0.0008944706,0.00095496344,0.004584218,0.032644458,0.0019296381,0.020388624,0.0016189187],"about_ca_topic_score_codex":0.0001143175,"about_ca_topic_score_gemma":0.000027091819,"teacher_disagreement_score":0.7842264,"about_ca_system_score_codex":0.00006259527,"about_ca_system_score_gemma":0.00047552394,"threshold_uncertainty_score":0.99991184},"labels":[],"label_agreement":null},{"id":"W4405050384","doi":"10.1182/blood-2024-200679","title":"Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Medicine; Lenalidomide; Oncology; Pomalidomide; Internal medicine; Refractory (planetary science); Biology","score_opus":0.04334734194192181,"score_gpt":0.34909795020215906,"score_spread":0.30575060826023726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775807,0.018947322,0.000061510924,0.000023369785,0.00031761866,0.0014372609,0.00048202224,0.000094300995,0.0010558546],"genre_scores_gemma":[0.99749225,0.001213225,0.00040905186,0.0000019417898,0.000073950076,0.00018293831,0.00052293896,0.00004505625,0.000058646092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664646,0.00062445505,0.0006992399,0.0006541768,0.00088317855,0.0004924948],"domain_scores_gemma":[0.99656206,0.0020274718,0.00018282262,0.00059992657,0.0003993228,0.00022841067],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056845794,0.0004005346,0.0015611998,0.0012779745,0.00006975623,0.000032453732,0.00020457906,0.00013747497,0.00009092087],"category_scores_gemma":[0.00023675855,0.00032280415,0.0005607607,0.002213974,0.00022393104,0.00015010654,0.00008658665,0.00049939484,0.000015531697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06448428,0.0071855863,0.81774443,0.0062866653,0.021466173,0.0008361573,0.0173226,0.000094389965,0.03517088,0.00067079597,0.000086486354,0.028651541],"study_design_scores_gemma":[0.057230495,0.005180107,0.76984537,0.0020761178,0.0034553779,0.0000037459606,0.002408351,0.001081134,0.15717603,0.000048792084,0.0010656811,0.00042882512],"about_ca_topic_score_codex":0.0004854912,"about_ca_topic_score_gemma":0.0027566107,"teacher_disagreement_score":0.12200516,"about_ca_system_score_codex":0.00042261276,"about_ca_system_score_gemma":0.0005042393,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4405051237","doi":"10.1182/blood-2024-208502","title":"Long Term Survivors (&amp;gt;15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Term (time); Pediatrics; Internal medicine; Intensive care medicine; Gerontology","score_opus":0.02803883137723486,"score_gpt":0.2907828724479438,"score_spread":0.262744041070709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975076,0.0013576223,0.000019131832,0.00006757922,0.00013228953,0.0003868958,0.00017961326,0.000064380605,0.00028493043],"genre_scores_gemma":[0.9985907,0.0002889726,0.00034932708,0.000010881722,0.00015859376,0.000023349034,0.00016858804,0.000027946095,0.00038162898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885297,0.00003898749,0.00023740876,0.00027408483,0.0003352112,0.00026135342],"domain_scores_gemma":[0.999248,0.00015332608,0.000042805084,0.00027809397,0.000066494504,0.00021126588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104961204,0.00013718862,0.00028243486,0.00012147896,0.000033566594,0.000032319516,0.000056646408,0.00007477661,0.00012529595],"category_scores_gemma":[0.00021800726,0.00011793357,0.000074373944,0.00013452016,0.00008486323,0.000054424552,0.00009162403,0.00015091898,0.000073604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014784656,0.00073452253,0.8409956,0.00067577313,0.0004639657,0.0012301196,0.0008503558,1.9564823e-7,0.020138664,0.0000148094205,0.00010775396,0.13464037],"study_design_scores_gemma":[0.0020290606,0.0002880259,0.9907157,0.00027579512,0.00018044157,0.000097098215,0.000024107048,0.00014192992,0.0048885467,0.00000707013,0.0012455031,0.000106727704],"about_ca_topic_score_codex":0.00033254345,"about_ca_topic_score_gemma":0.000112394,"teacher_disagreement_score":0.14972006,"about_ca_system_score_codex":0.000023707022,"about_ca_system_score_gemma":0.0000663316,"threshold_uncertainty_score":0.48091912},"labels":[],"label_agreement":null},{"id":"W4405051387","doi":"10.1182/blood-2024-212070","title":"Detection of M-Protein in Transplant-Ineligible Multiple Myeloma Patients on Daratumumab Using Liquid Chromatography Quadruple Time of Flight Mass Spectrometry","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Chromatography; Mass spectrometry; Chemistry; Multiple myeloma; Liquid chromatography–mass spectrometry; Medicine; Immunology","score_opus":0.012684650673471744,"score_gpt":0.2592106278680797,"score_spread":0.24652597719460795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771243,0.0006495291,0.00013283415,0.000014739926,0.00005703076,0.00076442497,0.00012451383,0.0000576605,0.00048682422],"genre_scores_gemma":[0.9985601,0.00003884924,0.0011701648,0.0000037949694,0.000042550368,0.000029577723,0.000076755445,0.000037335274,0.000040894545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983274,0.00006626932,0.00042318425,0.00033911644,0.00049884315,0.0003452245],"domain_scores_gemma":[0.9993753,0.0000788535,0.00007396519,0.0002785279,0.00007001435,0.00012336957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013984783,0.00020234848,0.00041755856,0.0009986142,0.000038284852,0.0000119498645,0.00008651557,0.00011746033,0.000068005385],"category_scores_gemma":[0.00005517122,0.00017059433,0.00018339408,0.0010058117,0.000056055247,0.000088478555,0.000016939324,0.00020393591,0.000032712705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016482798,0.0017645054,0.05234557,0.0006856314,0.00032906677,0.00018490365,0.0001777988,0.0000046619984,0.9422133,0.000011009481,0.000002456508,0.0006328153],"study_design_scores_gemma":[0.006940589,0.0024390137,0.06271881,0.0011140711,0.00012927651,0.00001749783,0.0000190465,0.0018752066,0.9245817,0.000018124592,0.00002034537,0.0001262848],"about_ca_topic_score_codex":0.0002858664,"about_ca_topic_score_gemma":0.000037901453,"teacher_disagreement_score":0.017631564,"about_ca_system_score_codex":0.00006670154,"about_ca_system_score_gemma":0.00007671628,"threshold_uncertainty_score":0.6956635},"labels":[],"label_agreement":null},{"id":"W4405053172","doi":"10.1182/blood-2024-205517","title":"Clinical Outcomes for Patients with Triple Class Exposed Relapsed and Refractory Multiple Myeloma in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Cohort; Population; Lenalidomide; Oncology; Environmental health","score_opus":0.022235365477753177,"score_gpt":0.29816021716723295,"score_spread":0.2759248516894798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405053172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748874,0.00019566408,0.000004521895,0.0004885235,0.00017313437,0.0012289574,0.00009066495,0.00002789827,0.00030186962],"genre_scores_gemma":[0.99678135,0.000030159474,0.0007280075,0.00014695089,0.0000526605,0.00014324862,0.00017978663,0.000036661404,0.00190119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985142,0.00005456838,0.00035253086,0.00040377915,0.00031752267,0.00035741067],"domain_scores_gemma":[0.9980852,0.0012806301,0.000039542992,0.00024582233,0.00006763884,0.0002811741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014662169,0.00017578945,0.00038997032,0.000101633224,0.000048887854,0.000024318302,0.000058727346,0.000095747484,0.00001989485],"category_scores_gemma":[0.0008156484,0.00011806992,0.000072896415,0.00013006828,0.000051086467,0.000072769886,0.000029140941,0.00022299035,0.0000056917947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090682675,0.0011307149,0.987703,0.00013003945,0.00036528122,0.00021540448,0.000059947906,9.845805e-8,0.000017104601,0.000013320692,0.00083711464,0.008621136],"study_design_scores_gemma":[0.031394947,0.0012447607,0.95601314,0.00014138424,0.00013115497,0.0000052516302,0.000032797594,0.0002574699,0.000103868995,0.000009086003,0.010538041,0.00012807881],"about_ca_topic_score_codex":0.106312566,"about_ca_topic_score_gemma":0.5927781,"teacher_disagreement_score":0.4864655,"about_ca_system_score_codex":0.0000984521,"about_ca_system_score_gemma":0.00062244857,"threshold_uncertainty_score":0.8996386},"labels":[],"label_agreement":null},{"id":"W4405053344","doi":"10.1182/blood-2024-206645","title":"Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Medicine; Pomalidomide; Meta-analysis; Internal medicine; Lenalidomide; Oncology; Intensive care medicine","score_opus":0.09550213315032745,"score_gpt":0.36283175536153517,"score_spread":0.2673296222112077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405053344","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16510905,0.82708514,0.00048311029,0.001610597,0.000017983662,0.0049862103,0.00018083422,0.00009212962,0.00043492837],"genre_scores_gemma":[0.9791551,0.01882062,0.0008938266,0.00017092116,0.000004065306,0.00032189293,0.00009324485,0.000014932066,0.0005253739],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99879235,0.00009542559,0.0004441481,0.00024042002,0.00027274597,0.00015492152],"domain_scores_gemma":[0.9993577,0.00019536886,0.000063433625,0.00023360732,0.00007989582,0.000069994036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027217457,0.00014026408,0.0013164842,0.000315408,0.00002229546,0.000018996245,0.000040394872,0.0000393944,0.00010224383],"category_scores_gemma":[0.00022109128,0.000087638466,0.00026016912,0.00079500483,0.000026336116,0.00006790218,0.000023611146,0.00004434837,0.000016664666],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003050083,0.00053963065,0.04051055,0.5685346,0.38901007,0.00043774734,0.00041522068,0.0000011372678,0.000045224257,0.00037162352,0.000025385021,0.00007828345],"study_design_scores_gemma":[0.0018945097,0.00012227766,0.015629245,0.0070968284,0.9725872,0.00004888546,0.0000417529,0.0005667976,0.0018272507,0.000017516379,0.000048700764,0.00011900202],"about_ca_topic_score_codex":0.000088845445,"about_ca_topic_score_gemma":0.00008498868,"teacher_disagreement_score":0.8140461,"about_ca_system_score_codex":0.000047850408,"about_ca_system_score_gemma":0.00008337475,"threshold_uncertainty_score":0.35737932},"labels":[],"label_agreement":null},{"id":"W4405054898","doi":"10.1182/blood-2024-200922","title":"An Investigation of Potential Treatment Effect Modifiers in Multiple Myeloma from Published Randomized Controlled Trials","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Randomized controlled trial; Medicine; Pomalidomide; Oncology; Internal medicine; Lenalidomide","score_opus":0.028807039254962724,"score_gpt":0.31619278271171614,"score_spread":0.2873857434567534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405054898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910395,0.0023666327,0.00009999427,0.00029408434,0.00019478562,0.005635712,0.000105304745,0.00009378916,0.00017020688],"genre_scores_gemma":[0.99695945,0.00013823238,0.000712391,0.000014219582,0.00021387704,0.0011247881,0.00069108687,0.000028789762,0.00011719476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955061,0.002227993,0.0010667205,0.0004333076,0.0004744444,0.0002914162],"domain_scores_gemma":[0.994868,0.0042338893,0.00017894447,0.00035687108,0.000077162345,0.00028513104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030827788,0.00028150604,0.003329787,0.00049454044,0.0000354115,0.0001086163,0.000083105566,0.00015129846,0.00019182244],"category_scores_gemma":[0.0041329097,0.00015259776,0.00086615153,0.00025711817,0.00012438068,0.00021133888,0.000015262545,0.00013634274,0.000018774988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61992866,0.0026046117,0.076243415,0.00025208807,0.013154321,0.0013099712,0.0013506522,0.00007114957,0.26341733,0.00008232953,0.00006797349,0.021517511],"study_design_scores_gemma":[0.85007066,0.0013302085,0.017722309,0.00024136773,0.0028908583,0.00000891806,0.0000404517,0.028874438,0.09833158,0.00037267213,0.00000385465,0.00011267949],"about_ca_topic_score_codex":0.002301253,"about_ca_topic_score_gemma":0.00009345726,"teacher_disagreement_score":0.23014203,"about_ca_system_score_codex":0.000101270314,"about_ca_system_score_gemma":0.00027074717,"threshold_uncertainty_score":0.6222756},"labels":[],"label_agreement":null},{"id":"W4405105877","doi":"10.1016/j.clml.2024.12.006","title":"Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Cancer Institute","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal gammopathy; Oncology; Internal medicine; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.052160912604549046,"score_gpt":0.3816797154227979,"score_spread":0.32951880281824886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405105877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06424026,0.91500103,0.000017930115,0.000054481025,0.00025995678,0.016706415,0.003485127,0.00015795897,0.00007684121],"genre_scores_gemma":[0.026987849,0.96380776,0.0012935129,0.00013759409,0.0003121401,0.0022929043,0.0046234364,0.00027382775,0.00027095556],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9905029,0.0009683872,0.0046563316,0.0014570984,0.0015697592,0.00084553263],"domain_scores_gemma":[0.9920915,0.0021893897,0.0024262196,0.0012789337,0.0007163001,0.001297658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011087315,0.0011371981,0.008409742,0.00043188623,0.00016266514,0.000101541475,0.00043053337,0.0007578029,0.000018042037],"category_scores_gemma":[0.0049942564,0.00071104884,0.001146602,0.0009738328,0.0003839219,0.00012899406,0.00046770228,0.0007004428,0.00016890888],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012202247,0.00034355032,0.031462397,0.36783966,0.001453394,0.00023041903,0.000034154888,9.781257e-9,1.362581e-7,0.0000024443837,0.00030255716,0.59820926],"study_design_scores_gemma":[0.0018145243,0.0021553785,0.41923454,0.5587955,0.012561878,0.000027995899,0.0000057503235,0.000022382701,0.0000019147692,0.000003847913,0.004797974,0.00057828426],"about_ca_topic_score_codex":0.000037977457,"about_ca_topic_score_gemma":0.000009662012,"teacher_disagreement_score":0.597631,"about_ca_system_score_codex":0.0017828856,"about_ca_system_score_gemma":0.002272857,"threshold_uncertainty_score":0.9995341},"labels":[],"label_agreement":null},{"id":"W4405177404","doi":"10.1182/blood.2024025897","title":"Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Daratumumab; Multiple myeloma; Medicine; Oncology; Internal medicine; Lenalidomide","score_opus":0.019100284888633426,"score_gpt":0.2904791316358852,"score_spread":0.27137884674725177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405177404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973594,0.0018466148,0.00004213873,0.000029392591,0.00004188467,0.0003167162,0.00016095524,0.000023422688,0.00017946474],"genre_scores_gemma":[0.9986915,0.0005779797,0.000514701,0.0000032556763,0.000026268646,0.000013523955,0.00011270844,0.000014826489,0.00004522493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987671,0.000057172634,0.000384369,0.00028547968,0.0002663369,0.00023953589],"domain_scores_gemma":[0.9992113,0.00031008144,0.00006445672,0.0002480609,0.000040589843,0.00012551881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017914726,0.00013573999,0.0005013164,0.0006410834,0.00002633568,0.000011597193,0.00006806878,0.00006458322,0.00006777592],"category_scores_gemma":[0.00024394252,0.00010945681,0.00012562398,0.00082050555,0.0000988102,0.00005300919,0.000082355364,0.00019165731,0.000004290552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012120777,0.0012630117,0.94557893,0.0003798308,0.0038353093,0.0005100003,0.00065824366,0.000038146754,0.0051984205,0.000041397187,0.000008069571,0.04127656],"study_design_scores_gemma":[0.011641334,0.00038742338,0.96871537,0.00031040685,0.001839458,0.000012499552,0.00008144113,0.0036637676,0.013224104,0.000009559589,0.000038538616,0.00007608955],"about_ca_topic_score_codex":0.00089675264,"about_ca_topic_score_gemma":0.00046707902,"teacher_disagreement_score":0.04120047,"about_ca_system_score_codex":0.000035497153,"about_ca_system_score_gemma":0.00006315884,"threshold_uncertainty_score":0.44635192},"labels":[],"label_agreement":null},{"id":"W4405184123","doi":"10.1016/j.lpm.2024.104264","title":"Kidney disease in multiple myeloma","year":2024,"lang":"en","type":"review","venue":"La Presse Médicale","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Multiple myeloma; Medicine; Kidney; Internal medicine","score_opus":0.06299915709602795,"score_gpt":0.37689456342724453,"score_spread":0.3138954063312166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405184123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024719933,0.99241227,0.000004707364,0.00020953339,0.00015312589,0.0018470981,0.00061803847,0.00015731606,0.0045731645],"genre_scores_gemma":[0.00021772385,0.9828441,0.00019162547,0.00008979736,0.00028131274,0.0009590624,0.0011062515,0.00013220683,0.0141778765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971553,0.00028726406,0.00057424774,0.0007799844,0.0005986198,0.0006045624],"domain_scores_gemma":[0.9970836,0.00037096234,0.000077659344,0.0007986509,0.000032845124,0.0016362484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022728993,0.0005219016,0.0015757716,0.00042829246,0.000046703444,0.0000826879,0.00027066364,0.00036209024,0.0005956064],"category_scores_gemma":[0.0011943771,0.00035085843,0.0006480313,0.00047853417,0.00016816607,0.000058472302,0.0002999303,0.0010205903,0.0017497109],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013817563,0.0007839666,0.0011857784,0.06988468,0.000485494,0.012442661,0.000034749704,1.363717e-7,5.360443e-7,0.000077715915,0.022543235,0.89242285],"study_design_scores_gemma":[0.0013044041,0.000047883233,0.00048570032,0.037033588,0.0014522774,0.00006374503,0.000002030202,0.00016306895,9.4190773e-7,0.000048633312,0.95913595,0.00026177734],"about_ca_topic_score_codex":0.00007697029,"about_ca_topic_score_gemma":0.000009251895,"teacher_disagreement_score":0.9365927,"about_ca_system_score_codex":0.00019003132,"about_ca_system_score_gemma":0.0012495756,"threshold_uncertainty_score":0.9998943},"labels":[],"label_agreement":null},{"id":"W4405316354","doi":"10.1016/j.lpm.2024.104266","title":"Treatment of elderly and frail myeloma patients","year":2024,"lang":"es","type":"review","venue":"La Presse Médicale","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Disease; Immunotherapy; Population; Multiple myeloma; Intensive care medicine; Cancer; Gerontology; Internal medicine","score_opus":0.03928767510549993,"score_gpt":0.35215481480283967,"score_spread":0.31286713969733976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405316354","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012997714,0.9755171,0.00000274861,0.00014096069,0.00024007526,0.0023993207,0.0009687256,0.00006361402,0.0076697543],"genre_scores_gemma":[0.017587915,0.9668924,0.00016460191,0.000009873122,0.0002882814,0.00042977315,0.00061492244,0.000121687466,0.013890516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625725,0.00039962624,0.0008986225,0.00091842026,0.00086446496,0.0006616124],"domain_scores_gemma":[0.9974285,0.0006367287,0.0002608618,0.0007945218,0.00014323228,0.0007361541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013594932,0.00080665364,0.00234432,0.00031950476,0.000093267394,0.000105412626,0.00021634872,0.00059389265,0.00054267875],"category_scores_gemma":[0.00021440107,0.0005094031,0.00059897173,0.000304964,0.00047661393,0.00007291426,0.00021948239,0.00040837761,0.00052957557],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001633362,0.002592541,0.007994416,0.027981102,0.00254048,0.00078505225,0.00027228578,2.5774842e-8,0.0000052000764,0.00015408327,0.001810904,0.9557006],"study_design_scores_gemma":[0.0044921692,0.0042019635,0.008386062,0.0139697185,0.005028097,0.00005974216,0.000020469684,0.000030834355,0.000058576865,0.00005008849,0.9633544,0.00034786414],"about_ca_topic_score_codex":0.00018103176,"about_ca_topic_score_gemma":0.0000059144677,"teacher_disagreement_score":0.9615435,"about_ca_system_score_codex":0.00020077817,"about_ca_system_score_gemma":0.0004380887,"threshold_uncertainty_score":0.9997358},"labels":[],"label_agreement":null},{"id":"W4405537000","doi":"10.1182/blood.2024025690","title":"Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Eye Institute; Pfizer; National Heart, Lung, and Blood Institute; Genentech; National Institutes of Health; Regeneron Pharmaceuticals; National Cancer Institute; Emory University; Amgen; Georgia Institute of Technology; Cancer Prevention and Research Institute of Texas; GlaxoSmithKline","keywords":"Heme; Biochemistry; Hemin; Biology; Globin; Chemistry; Cancer research; Enzyme; Hemoglobin","score_opus":0.03149116940997665,"score_gpt":0.2897438552208521,"score_spread":0.25825268581087546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405537000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830041,0.013918305,0.000022341463,0.00077622203,0.00003847139,0.00064241985,0.00003426453,0.00012320244,0.0014406671],"genre_scores_gemma":[0.99095213,0.00033001194,0.0076798433,0.00003599313,0.00012581074,0.00010094124,0.000025169118,0.00003838803,0.00071173086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985698,0.000051843574,0.00023963538,0.00044370143,0.00029493286,0.00040011437],"domain_scores_gemma":[0.9992448,0.00029703474,0.000024602474,0.00025423543,0.000035975074,0.00014335375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017696542,0.0001878783,0.0002909901,0.00014186041,0.00007158305,0.00006094356,0.00007215504,0.000081672464,0.00008335709],"category_scores_gemma":[0.0003278176,0.00015081266,0.00006583252,0.0003305378,0.00007965763,0.000121237324,0.00005981757,0.00018668034,0.000050945848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019327312,0.003048183,0.41883096,0.006063876,0.0023491362,0.017356925,0.0050412985,0.0000052543446,0.5107247,0.0016301685,0.00069026445,0.032326482],"study_design_scores_gemma":[0.011894546,0.00069797883,0.1533757,0.0037569045,0.00041710722,0.00023629038,0.00026290247,0.0013446423,0.8151835,0.0023286494,0.009937133,0.0005645993],"about_ca_topic_score_codex":0.00013425655,"about_ca_topic_score_gemma":0.0002604911,"teacher_disagreement_score":0.30445883,"about_ca_system_score_codex":0.00008559061,"about_ca_system_score_gemma":0.00013557462,"threshold_uncertainty_score":0.6149962},"labels":[],"label_agreement":null},{"id":"W4405590089","doi":"10.2196/64905","title":"Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Prehabilitation; Physical therapy; Cardiorespiratory fitness; Randomized controlled trial; Aerobic exercise; Multiple myeloma; Clinical trial; Strength training; Internal medicine","score_opus":0.103946106249413,"score_gpt":0.4703609447546926,"score_spread":0.36641483850527956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405590089","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03370516,0.0000031210068,0.00037511086,0.0002227823,0.000014621154,0.9651462,0.00012424424,0.00017209543,0.00023666136],"genre_scores_gemma":[0.10018866,3.5036976e-7,0.0067427782,0.000012921375,0.00014588727,0.8921997,0.00011983355,0.000104359955,0.00048551062],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99336725,0.0013123915,0.0011767512,0.0010811386,0.0016595272,0.0014029149],"domain_scores_gemma":[0.99164045,0.006168232,0.00011793025,0.0005636089,0.00082024717,0.0006895097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004857715,0.00046636112,0.0017821541,0.0010739479,0.00020849299,0.00028879129,0.00028282488,0.00017188431,0.00013767638],"category_scores_gemma":[0.0053139897,0.00028941632,0.0003964635,0.00095751253,0.00024623063,0.00032607475,0.000074849595,0.00075586716,0.000029166215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9681411,0.0069790776,0.0010511857,0.0033751305,0.00022325847,0.0003265229,0.0028457479,0.000008584687,0.0009488332,0.00005015962,0.00031016875,0.015740253],"study_design_scores_gemma":[0.94311637,0.03136499,0.0025705004,0.009811805,0.000024915444,0.0000034485683,0.00016529046,0.008088397,0.0007364345,0.0001395455,0.003698744,0.00027958816],"about_ca_topic_score_codex":0.00011098076,"about_ca_topic_score_gemma":0.00013609667,"teacher_disagreement_score":0.072946504,"about_ca_system_score_codex":0.00044738522,"about_ca_system_score_gemma":0.0012914665,"threshold_uncertainty_score":0.9999558},"labels":[],"label_agreement":null},{"id":"W4405729475","doi":"10.1101/2024.12.17.628799","title":"CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Nationales Centrum für Tumorerkrankungen Heidelberg; Deutsches Krebsforschungszentrum; Deutsche Forschungsgemeinschaft; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Tow Foundation","keywords":"CD38; Mechanism (biology); Multiple myeloma; Antibody; Cancer research; Resistance (ecology); Medicine; Genetics; Biology; Immunology; Physics; Stem cell","score_opus":0.029202729816238046,"score_gpt":0.282488027503105,"score_spread":0.2532852976868669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405729475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892674,0.0042853407,0.00012696326,0.0014778151,0.0008951214,0.0025170732,0.0011372053,0.00025637835,0.00003671548],"genre_scores_gemma":[0.99166906,0.0014576531,0.005769342,0.00017105033,0.00028473974,0.0003925063,0.0000021979745,0.00018674872,0.00006670437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99515694,0.00016228597,0.00102514,0.0016201228,0.0010321009,0.0010033798],"domain_scores_gemma":[0.99648786,0.00013289777,0.0003067957,0.0017466466,0.0006834677,0.0006423259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000670362,0.00080008246,0.0014478043,0.0012310804,0.000098177516,0.000117533935,0.00052897434,0.00055606896,0.00007959034],"category_scores_gemma":[0.0007329519,0.0007684061,0.00035662163,0.0012058954,0.000164304,0.000074433374,0.001183301,0.0011758741,0.00027569645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001645289,0.0017994909,0.08845768,0.010895222,0.0015792812,0.0039709182,0.00028437047,0.000014235603,0.886996,0.0017456097,0.002560574,0.000051335006],"study_design_scores_gemma":[0.0032480985,0.000326582,0.33774486,0.008659628,0.00027264428,1.2757002e-7,0.000015422604,0.0005867987,0.6452332,0.000046157227,0.0029106261,0.00095585454],"about_ca_topic_score_codex":0.0002488398,"about_ca_topic_score_gemma":0.00010949775,"teacher_disagreement_score":0.24928717,"about_ca_system_score_codex":0.0006336032,"about_ca_system_score_gemma":0.0010951107,"threshold_uncertainty_score":0.9994767},"labels":[],"label_agreement":null},{"id":"W4405749694","doi":"10.1016/j.jval.2024.10.3470","title":"PCR228 Clinical and Socioeconomic Burden of Multiple Myeloma in the Czech Republic: A Cross-Sectional Study on 190 Patients","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Czech; Socioeconomic status; Multiple myeloma; Cross-sectional study; Medicine; Environmental health; Internal medicine; Pathology","score_opus":0.12557055603808595,"score_gpt":0.4393535523587843,"score_spread":0.3137829963206984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405749694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659055,0.00029447625,9.711658e-7,0.0011143076,0.00019699946,0.0015858512,0.000042174088,0.000018840676,0.00015584847],"genre_scores_gemma":[0.9993421,0.00010501121,0.00006543267,0.00015113298,0.00013654555,0.000083497966,0.000030363515,0.000015375921,0.000070578455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976051,0.0005264327,0.0007974383,0.00040983863,0.00035946557,0.00030171307],"domain_scores_gemma":[0.99828994,0.0011751866,0.000077239325,0.0002762604,0.000043178417,0.00013817102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025559512,0.000116710704,0.00031922915,0.00025902304,0.00006374,0.000044018736,0.0000999855,0.00008209725,0.000031099295],"category_scores_gemma":[0.00055952027,0.00007894145,0.000071682894,0.00017878262,0.000113232345,0.000064902895,0.00005074617,0.00046992803,0.000034386543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045143333,0.0012311253,0.9858984,0.00017731373,0.000052204818,0.000047978658,0.0018956743,0.00004736495,0.0000012666156,0.00008856112,0.00009856391,0.010010142],"study_design_scores_gemma":[0.0052907076,0.0024713883,0.9847607,0.000119629585,0.000004007091,0.0000073666456,0.0004133836,0.0064777914,0.0000024198866,0.00012649315,0.0002766541,0.000049437607],"about_ca_topic_score_codex":0.0076003936,"about_ca_topic_score_gemma":0.00019443671,"teacher_disagreement_score":0.0099607045,"about_ca_system_score_codex":0.00023292744,"about_ca_system_score_gemma":0.00039848068,"threshold_uncertainty_score":0.99900806},"labels":[],"label_agreement":null},{"id":"W4405750302","doi":"10.1016/j.jval.2024.10.2386","title":"MSR152 A Literature Review to Identify Prognostic Factors and Treatment Effect Modifiers in Population-Adjusted Indirect Comparisons for Multiple Myeloma","year":2024,"lang":"en","type":"review","venue":"Value in Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Medicine; Oncology; Internal medicine","score_opus":0.17357693465477037,"score_gpt":0.46261786494067525,"score_spread":0.2890409302859049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405750302","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009493742,0.9647504,0.000003541808,0.00031750067,0.00022099967,0.024450157,0.00068391085,0.00007148135,0.00000824063],"genre_scores_gemma":[0.006532806,0.98480064,0.0004280699,0.000065286935,0.000086111846,0.0042878273,0.003581513,0.00010734564,0.00011037436],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955379,0.0009774407,0.0012879214,0.0009771533,0.0003967074,0.00082289334],"domain_scores_gemma":[0.99672586,0.001834777,0.00025475197,0.00047247278,0.000051503193,0.0006606366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090337335,0.00079603837,0.004005459,0.001318878,0.00009362803,0.0000814557,0.00012696779,0.00032108408,0.00000510258],"category_scores_gemma":[0.0015570221,0.00048578653,0.0005015598,0.0016038577,0.000025922767,0.00006206965,0.000066034416,0.0006210262,0.000025471109],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012635118,0.0003258098,0.07343017,0.3772317,0.00040193176,0.0002689507,0.00039818577,0.000005898341,8.379065e-8,0.000009501577,0.0006504873,0.5471509],"study_design_scores_gemma":[0.0037450627,0.0032462035,0.068992056,0.7302063,0.0016370834,0.00012936335,0.000018561093,0.0010245448,7.969962e-7,0.0000096968415,0.19045413,0.00053622224],"about_ca_topic_score_codex":0.003965123,"about_ca_topic_score_gemma":0.0011575258,"teacher_disagreement_score":0.5466147,"about_ca_system_score_codex":0.0020829325,"about_ca_system_score_gemma":0.00068079756,"threshold_uncertainty_score":0.9997594},"labels":[],"label_agreement":null},{"id":"W4405758735","doi":"10.35509/01239015.986","title":"Multiple myeloma in Latin America: Are we moving at the same pace as other regions?","year":2023,"lang":"en","type":"article","venue":"Revista Colombiana de Cancerología","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.04915883263022831,"score_gpt":0.3279692906218432,"score_spread":0.2788104579916149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405758735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96632326,0.0031287533,0.000023225348,0.027807985,0.000052466523,0.0011717379,0.000071385104,0.00016784419,0.0012533576],"genre_scores_gemma":[0.975509,0.0029135782,0.000112305956,0.002776507,0.000116354655,0.0004409427,0.00005236203,0.000061098515,0.018017845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764293,0.00030825188,0.00032286457,0.0004991249,0.00038096623,0.0008458341],"domain_scores_gemma":[0.99815875,0.00063765765,0.00017244129,0.0006740582,0.00007029243,0.00028680652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004093703,0.00024761347,0.0005100844,0.00019029058,0.0002265333,0.00005056955,0.00021943421,0.00014105786,0.0004972767],"category_scores_gemma":[0.0009953785,0.0001824038,0.00015061781,0.0010564682,0.00025560745,0.000053537206,0.00017643864,0.00038977532,0.00065796013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012899488,0.00013694864,0.9042313,0.0002355189,0.00022816168,0.0014453102,0.0008218532,0.00014425424,0.0023032313,0.00018939232,0.063452,0.025522081],"study_design_scores_gemma":[0.0032665979,0.00033177444,0.7138396,0.00040102398,0.000055810295,0.000059386224,0.000785601,0.0036061148,0.0003100502,0.00009871966,0.27703974,0.00020557699],"about_ca_topic_score_codex":0.0033687414,"about_ca_topic_score_gemma":0.0064380732,"teacher_disagreement_score":0.21358775,"about_ca_system_score_codex":0.0011096016,"about_ca_system_score_gemma":0.000292167,"threshold_uncertainty_score":0.84569657},"labels":[],"label_agreement":null},{"id":"W4405758757","doi":"10.35509/01239015.989","title":"From hope to reality: the road to cure from multiple myeloma centers of excellence","year":2023,"lang":"en","type":"article","venue":"Revista Colombiana de Cancerología","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Art","score_opus":0.040909811750054696,"score_gpt":0.33164896528321947,"score_spread":0.29073915353316476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405758757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759017,0.0007797747,0.00018895543,0.019860005,0.00013966185,0.001541257,0.0011736513,0.00011037503,0.00030458518],"genre_scores_gemma":[0.9949624,0.0006850348,0.0005016523,0.0021398496,0.00025611234,0.00029650007,0.00028810665,0.000039920204,0.0008304189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752796,0.00023905099,0.0004127563,0.0006021153,0.0005198184,0.00069830386],"domain_scores_gemma":[0.99767035,0.00046453805,0.00011432734,0.0009708791,0.00015385609,0.0006260621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040221546,0.0002451359,0.0005900038,0.00014530495,0.00013222144,0.00004726605,0.00045229314,0.00012609133,0.0003101366],"category_scores_gemma":[0.0008502542,0.000184748,0.0001644444,0.0008363547,0.00011874754,0.000046103676,0.0002501062,0.00025352367,0.0003904695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061047473,0.00035566807,0.49733034,0.00025160096,0.0011668882,0.0008648029,0.0037435053,0.00025623766,0.06461287,0.00006633122,0.2463133,0.17893372],"study_design_scores_gemma":[0.0024888283,0.00066145917,0.87543046,0.00042415672,0.0001388651,0.0000041091184,0.00045722848,0.001396056,0.0034336539,0.00006711609,0.11529641,0.00020165369],"about_ca_topic_score_codex":0.03429858,"about_ca_topic_score_gemma":0.0029921713,"teacher_disagreement_score":0.37810016,"about_ca_system_score_codex":0.00043269014,"about_ca_system_score_gemma":0.00030612445,"threshold_uncertainty_score":0.9721321},"labels":[],"label_agreement":null},{"id":"W4405774805","doi":"10.1016/j.clinbiochem.2024.110870","title":"Enhanced detection and Characterization of M-proteins in multiple myeloma patients using An Agilent AssayMAP Bravo liquid handling system coupled to an LC-QTOF","year":2024,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; London Health Sciences Centre; Western University","funders":"London Health Sciences Centre","keywords":"Chromatography; Multiple myeloma; Characterization (materials science); Chemistry; Medicine; Materials science; Nanotechnology; Internal medicine","score_opus":0.04831530289516255,"score_gpt":0.35729717832218794,"score_spread":0.3089818754270254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405774805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695086,0.00006425012,0.0019250932,0.000025746427,0.00015769963,0.0007367776,0.000056630208,0.00006937809,0.000013581243],"genre_scores_gemma":[0.99890643,0.000022708677,0.00047456648,0.000022932778,0.00019101016,0.000042316093,0.00028926486,0.000027948432,0.00002284848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981533,0.000093327275,0.0006534799,0.0005625841,0.00028751962,0.0002497452],"domain_scores_gemma":[0.9988903,0.0001189933,0.00010371833,0.00032247623,0.00017158741,0.00039296923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043117217,0.00016932379,0.00037792727,0.000105070976,0.0000558239,0.00003739772,0.00007161053,0.0002327689,0.000011403317],"category_scores_gemma":[0.00059208786,0.00015271497,0.00007327372,0.00022978829,0.00007021622,0.00011973589,0.00006277758,0.0002336876,0.0000056253393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013839083,0.00059364166,0.016586712,0.0007747103,0.000055796587,0.000026344353,0.0000871378,0.0000033896972,0.9646199,5.03279e-7,2.0404536e-7,0.015867766],"study_design_scores_gemma":[0.002330902,0.0014147479,0.08973705,0.0011579896,0.000049786187,0.000006010197,0.00008986189,0.048009437,0.85706633,6.600674e-7,0.0000072757325,0.00012996681],"about_ca_topic_score_codex":0.000088383684,"about_ca_topic_score_gemma":0.000025872405,"teacher_disagreement_score":0.10755357,"about_ca_system_score_codex":0.00016509819,"about_ca_system_score_gemma":0.00011923312,"threshold_uncertainty_score":0.6227536},"labels":[],"label_agreement":null},{"id":"W4405941401","doi":"10.1016/j.jtct.2024.12.023","title":"Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Paula and Rodger Riney Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","keywords":"Medicine; Multiple myeloma; Hematopoietic stem cell transplantation; Oncology; Stem cell; Transplantation; Internal medicine; Biology","score_opus":0.01573033053922362,"score_gpt":0.26431313494168557,"score_spread":0.24858280440246194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405941401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854524,0.002955592,0.009611449,0.0001053647,0.00011367242,0.0007835546,0.00044993105,0.00010195867,0.00042604367],"genre_scores_gemma":[0.9847122,0.013877215,0.000320862,0.000040791696,0.000014310602,0.00003584177,0.00052701397,0.000037423,0.00043436597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998437,0.00012414112,0.00038085814,0.00033695073,0.00046008104,0.00026097067],"domain_scores_gemma":[0.9993205,0.00019459482,0.000073403404,0.00017197189,0.00007872686,0.00016080089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015089783,0.0002390417,0.00040109458,0.00018269214,0.0001021025,0.000037381233,0.00005947529,0.00011150587,0.000092279435],"category_scores_gemma":[0.0000024207452,0.00017897556,0.00014526724,0.00014336688,0.00007929789,0.000119541415,0.0000031924433,0.00016539023,0.000019690591],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006460696,0.00072931475,0.7949983,0.0035524408,0.0008958652,0.00063581835,0.01465428,0.00003214367,0.016288942,0.00032059025,0.00005798141,0.16137363],"study_design_scores_gemma":[0.017117184,0.0015570124,0.7233472,0.0003555043,0.00044881387,0.000051429553,0.000424905,0.0015446781,0.25422126,0.00017077956,0.00044790676,0.00031334997],"about_ca_topic_score_codex":0.000091066766,"about_ca_topic_score_gemma":0.00003556596,"teacher_disagreement_score":0.23793232,"about_ca_system_score_codex":0.000044629225,"about_ca_system_score_gemma":0.00007678152,"threshold_uncertainty_score":0.7298412},"labels":[],"label_agreement":null},{"id":"W4406091238","doi":"10.58931/cht.2024.3360","title":"Minimal Residual Disease in Myeloma in 2024: Where We are Today","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Capital District Health Authority","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Residual; Disease; Medicine; Computer science; Internal medicine; Algorithm; Bone marrow","score_opus":0.02206489221781091,"score_gpt":0.29813870958593974,"score_spread":0.27607381736812886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88646746,0.04641793,0.0000010579472,0.059032828,0.0004459361,0.00085924135,0.00025219156,0.00007049587,0.006452858],"genre_scores_gemma":[0.99067324,0.0003638574,0.000088383706,0.0003848501,0.000103368584,0.00015763291,0.00007856824,0.000041484254,0.008108626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780184,0.00012317757,0.00034201064,0.00056706334,0.00021324055,0.0009526876],"domain_scores_gemma":[0.99794537,0.000193388,0.000023801143,0.00038268918,0.000036741403,0.0014180309],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017235667,0.00023860401,0.00046824437,0.0010614111,0.00005450391,0.000035913195,0.00014218717,0.00021787854,0.0020338001],"category_scores_gemma":[0.0003082289,0.00021608153,0.000085714026,0.0005774297,0.00013481159,0.00009508393,0.000038670285,0.00049660704,0.0007392312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026280983,0.00009553742,0.83092445,0.000730495,0.00010139182,0.107881516,0.00038950564,0.0000024879632,0.000023381606,0.0019774642,0.053709384,0.0039015803],"study_design_scores_gemma":[0.0027569905,0.00015497518,0.9083628,0.0026237941,0.0000831181,0.0005732418,0.00050878467,0.0008045097,0.00018554484,0.0007020799,0.082890764,0.0003533654],"about_ca_topic_score_codex":0.028279306,"about_ca_topic_score_gemma":0.6550902,"teacher_disagreement_score":0.6268109,"about_ca_system_score_codex":0.00053022965,"about_ca_system_score_gemma":0.0020742263,"threshold_uncertainty_score":0.9988785},"labels":[],"label_agreement":null},{"id":"W4406213558","doi":"10.1182/blood.2024027362","title":"Doubling down on GPRC5D in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Doubling time; Lenalidomide; Medicine; Internal medicine; Biology; Genetics","score_opus":0.031297875336970093,"score_gpt":0.3166248728459736,"score_spread":0.28532699750900353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406213558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96969664,0.0002678946,0.0000130992885,0.0008167164,0.00006528347,0.00045982195,0.000007048121,0.000057178502,0.028616304],"genre_scores_gemma":[0.9966636,0.000037120004,0.0005894806,0.00027163868,0.00005381042,0.00006609964,0.000029395887,0.000010639256,0.0022782441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990074,0.000030589406,0.00017079493,0.00025491646,0.00021718828,0.00031912085],"domain_scores_gemma":[0.99938756,0.00014743075,0.000018734796,0.00029382008,0.000039020393,0.00011342601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011552182,0.00011695359,0.0002047178,0.00031569874,0.000056957786,0.000019406507,0.000076165845,0.00007029264,0.000086338376],"category_scores_gemma":[0.00031300733,0.00009365146,0.00006353652,0.0003494309,0.000029008797,0.000035454796,0.00004401992,0.00019906499,0.00016715155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000791082,0.0028911454,0.95787597,0.00010746581,0.00021654014,0.000806246,0.00009283773,0.0000065958397,0.0067644226,0.0005473,0.00042701713,0.029473359],"study_design_scores_gemma":[0.028562702,0.0003815246,0.90946764,0.00040507596,0.00006569965,0.000016811819,0.000063837266,0.00044454186,0.056826927,0.00014297041,0.0035068807,0.00011541842],"about_ca_topic_score_codex":0.00017776225,"about_ca_topic_score_gemma":0.00013413084,"teacher_disagreement_score":0.050062504,"about_ca_system_score_codex":0.00005654085,"about_ca_system_score_gemma":0.00010585374,"threshold_uncertainty_score":0.38189957},"labels":[],"label_agreement":null},{"id":"W4406385834","doi":"10.1038/s41375-024-02506-1","title":"Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Medicine","score_opus":0.020560870229512286,"score_gpt":0.309989620882545,"score_spread":0.2894287506530327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406385834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607694,0.00029317682,0.000046535017,0.00013150927,0.000056264253,0.001188686,0.000053804906,0.000021553695,0.002131515],"genre_scores_gemma":[0.9980233,0.000022352098,0.00020158674,0.000045401197,0.000011025628,0.0000646563,0.000053596563,0.000014462914,0.0015636393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978103,0.0002892367,0.00063125737,0.00037989658,0.0005363675,0.00035296503],"domain_scores_gemma":[0.99817234,0.00046384547,0.00017641882,0.0009037959,0.00018928813,0.000094337534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041362236,0.00021437736,0.0009546377,0.00082852406,0.000066074994,0.000010939508,0.00027994264,0.00011289603,0.000099285],"category_scores_gemma":[0.000659854,0.00014096026,0.00030126,0.0039043634,0.00015882737,0.000052282237,0.00017023562,0.0002934512,0.000006068367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021205125,0.00077362155,0.9845655,0.00010189519,0.0035407213,0.000109867724,0.000999302,0.0006346124,0.0048855375,0.00006800556,0.00010655568,0.002093853],"study_design_scores_gemma":[0.016211636,0.00024016308,0.9573375,0.00013653006,0.0015996216,0.0000022741276,0.0008822295,0.01202286,0.011414456,0.000022543714,0.000044049084,0.000086119726],"about_ca_topic_score_codex":0.009750238,"about_ca_topic_score_gemma":0.006822551,"teacher_disagreement_score":0.027228,"about_ca_system_score_codex":0.0009368224,"about_ca_system_score_gemma":0.000574016,"threshold_uncertainty_score":0.99684393},"labels":[],"label_agreement":null},{"id":"W4406452669","doi":"10.1016/s1155-1984(24)47567-5","title":"10.1016/s1155-1984(24)47567-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.014543959915957907,"score_gpt":0.24005800088227816,"score_spread":0.22551404096632024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406452669","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042902417,0.000112204994,3.1212912e-7,0.0006312794,0.0000011981133,0.00048092275,0.000026685213,0.0001249522,0.9943322],"genre_scores_gemma":[0.002106871,0.0000010698926,0.0002856257,0.000069560134,0.00015482969,0.00005107975,0.000079450445,0.000030949253,0.9972206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876875,0.00003480153,0.00015702007,0.0002654467,0.00034575968,0.00042820125],"domain_scores_gemma":[0.99899334,0.000049415903,0.00001510982,0.0003906925,0.000057128476,0.00049430056],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009357726,0.00015343951,0.00023431207,0.000106120395,0.00007385719,0.000024081774,0.00011035086,0.00006156512,0.9985876],"category_scores_gemma":[0.00007622581,0.00012495836,0.00008478851,0.00020786053,0.00003769185,0.000056207515,0.00003400492,0.00013877182,0.9976957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006984587,0.00021262234,0.000006395931,0.000014593559,0.0000834659,0.00015839672,0.000012265574,0.0000027787783,0.00011661273,4.3160716e-7,0.27555057,0.7231434],"study_design_scores_gemma":[0.0018317129,0.00059401075,0.00085891446,0.00003844849,0.00003733986,0.00005022377,8.91675e-7,0.00016919147,0.0004330158,0.000004148368,0.9958669,0.000115187606],"about_ca_topic_score_codex":0.0000863243,"about_ca_topic_score_gemma":4.4237117e-7,"teacher_disagreement_score":0.7230282,"about_ca_system_score_codex":0.00008201458,"about_ca_system_score_gemma":0.00006876813,"threshold_uncertainty_score":0.5095654},"labels":[],"label_agreement":null},{"id":"W4406507290","doi":"10.1016/s0246-0521(19)30395-x","title":"10.1016/s0246-0521(19)30395-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.016092838939454027,"score_gpt":0.25063244133008555,"score_spread":0.23453960239063154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406507290","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018429608,0.00012989879,3.9379796e-7,0.0007518428,8.0803807e-7,0.00048264064,0.000025469495,0.00013073422,0.99663526],"genre_scores_gemma":[0.0016868886,0.0000014015048,0.0003185649,0.000079742276,0.00014658281,0.00004540787,0.000077330726,0.000030248377,0.99761385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873334,0.00003692452,0.00015606046,0.0002700864,0.00036642826,0.00043718467],"domain_scores_gemma":[0.99883294,0.00005880082,0.000014589581,0.00038803133,0.000056890585,0.00064874924],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000109707114,0.00015144784,0.00022676385,0.00011187695,0.00007972663,0.000025576815,0.00011217104,0.000061811676,0.99886924],"category_scores_gemma":[0.00011591927,0.00012153825,0.000084584746,0.00022289214,0.000039300416,0.000055760243,0.00003521369,0.00013556043,0.99759793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005833625,0.0001743068,0.0000055254986,0.0000138662235,0.0000703921,0.0001542693,0.000011038699,0.000002193094,0.000075952674,2.1420985e-7,0.49356028,0.5053486],"study_design_scores_gemma":[0.0018757106,0.0005746068,0.0008376371,0.000036651523,0.000035009085,0.000053921467,0.0000010419011,0.00017930717,0.0003299981,0.00000535587,0.9959578,0.00011297043],"about_ca_topic_score_codex":0.00012001335,"about_ca_topic_score_gemma":4.3233794e-7,"teacher_disagreement_score":0.5052356,"about_ca_system_score_codex":0.00009691334,"about_ca_system_score_gemma":0.0000860776,"threshold_uncertainty_score":0.4956186},"labels":[],"label_agreement":null},{"id":"W4406530449","doi":"10.1016/0024-7804(96)85744-7","title":"10.1016/0024-7804(96)85744-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Thalidomide; Medicine; Internal medicine; Multiple myeloma","score_opus":0.013377876225124458,"score_gpt":0.24042107678080896,"score_spread":0.2270432005556845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406530449","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004016102,0.000106509804,3.6391648e-7,0.0007321227,9.610956e-7,0.00046024247,0.000026197566,0.00012454954,0.99453294],"genre_scores_gemma":[0.0027435953,0.0000010572228,0.00026846313,0.00006259703,0.00015715892,0.000048824983,0.000070194605,0.000030183908,0.9966179],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877465,0.0000342544,0.00015534254,0.00026349173,0.0003496633,0.00042259318],"domain_scores_gemma":[0.9990045,0.000048338377,0.000014480563,0.00038191304,0.000059542457,0.0004912542],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000092350485,0.00015252015,0.00023081499,0.00010377753,0.00007158965,0.000024130435,0.00010778998,0.000062188104,0.99872637],"category_scores_gemma":[0.00007648978,0.00012350579,0.00008519616,0.0002061535,0.00003755562,0.000053810923,0.00003354116,0.00013335471,0.99755657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000645965,0.00020984611,0.000011091801,0.000014573557,0.00008775512,0.00017609213,0.000011500487,0.000002220651,0.000094974115,6.0620533e-7,0.23531713,0.7634283],"study_design_scores_gemma":[0.0017574326,0.000584879,0.000823294,0.00003930438,0.00003670106,0.000052132033,8.9520904e-7,0.00024513088,0.00041541876,0.0000046369064,0.9959266,0.000113583184],"about_ca_topic_score_codex":0.000079627935,"about_ca_topic_score_gemma":3.0696415e-7,"teacher_disagreement_score":0.76331466,"about_ca_system_score_codex":0.00007934473,"about_ca_system_score_gemma":0.000063739295,"threshold_uncertainty_score":0.50364196},"labels":[],"label_agreement":null},{"id":"W4406548729","doi":"10.1016/s1155-1984(23)47049-5","title":"10.1016/s1155-1984(23)47049-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.013305307686065925,"score_gpt":0.24145853096059047,"score_spread":0.22815322327452456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406548729","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005140665,0.000113211194,3.3818262e-7,0.00057258323,8.96391e-7,0.00047131992,0.000027834585,0.00012463212,0.9935485],"genre_scores_gemma":[0.0025572684,0.0000011050927,0.00026402035,0.00006453884,0.00015074939,0.000049261547,0.000102111015,0.000030842697,0.9967801],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882466,0.000035434357,0.00015643984,0.0002646886,0.00029310884,0.0004257011],"domain_scores_gemma":[0.99899614,0.000048995204,0.000014932647,0.00039087367,0.000057299545,0.0004917515],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009768225,0.00015244451,0.00023495185,0.00010481159,0.00007365883,0.000023881668,0.00010963049,0.000062100065,0.9981242],"category_scores_gemma":[0.00007434139,0.00012450843,0.000087867964,0.0002045445,0.000037133374,0.000056031284,0.000033642333,0.00012907834,0.9983311],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071571826,0.00022160386,0.0000069199436,0.000014915829,0.00009070004,0.00016336031,0.000012538588,0.0000027756626,0.000103325234,5.487259e-7,0.24614146,0.7525261],"study_design_scores_gemma":[0.001804879,0.0005781116,0.0009843125,0.000038310325,0.00003826994,0.000049886912,9.171196e-7,0.00016858056,0.00037455742,0.0000047083417,0.99584293,0.0001145493],"about_ca_topic_score_codex":0.000079279576,"about_ca_topic_score_gemma":4.967581e-7,"teacher_disagreement_score":0.7524116,"about_ca_system_score_codex":0.00008071634,"about_ca_system_score_gemma":0.0000673021,"threshold_uncertainty_score":0.5077306},"labels":[],"label_agreement":null},{"id":"W4406548814","doi":"10.1016/s1155-1984(20)30029-7","title":"10.1016/s1155-1984(20)30029-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psychology","score_opus":0.012611457153224948,"score_gpt":0.23857873636697216,"score_spread":0.2259672792137472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406548814","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039235004,0.00010042472,2.9339716e-7,0.0007178185,7.2755245e-7,0.00046730787,0.00003151131,0.00012446426,0.994634],"genre_scores_gemma":[0.0017798627,8.917129e-7,0.00027102683,0.00006501288,0.00016755227,0.00004960611,0.00009514342,0.00003087574,0.99754006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987709,0.000034196553,0.00015629166,0.00026491712,0.0003434055,0.00043027787],"domain_scores_gemma":[0.9989897,0.000052386713,0.0000150119895,0.00038731183,0.00005897959,0.0004966046],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009325513,0.00015296371,0.00023284425,0.00010574163,0.00007366964,0.000023625593,0.00010999035,0.00006219358,0.99869615],"category_scores_gemma":[0.00007361187,0.00012461765,0.00008466462,0.00020933078,0.000037529648,0.00005488161,0.00003336128,0.00013294298,0.9976349],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067881966,0.00021877475,0.0000067862147,0.0000147522,0.00008568673,0.00016356628,0.000011100263,0.0000037682823,0.00014273089,3.7596567e-7,0.27642667,0.72224694],"study_design_scores_gemma":[0.0018120547,0.00058061734,0.00077339506,0.0000377691,0.000037183643,0.000050845174,8.2387766e-7,0.00020345494,0.00038864737,0.0000037025443,0.995997,0.00011448364],"about_ca_topic_score_codex":0.0000633132,"about_ca_topic_score_gemma":4.843086e-7,"teacher_disagreement_score":0.72213244,"about_ca_system_score_codex":0.000080385325,"about_ca_system_score_gemma":0.00006768769,"threshold_uncertainty_score":0.508176},"labels":[],"label_agreement":null},{"id":"W4406557605","doi":"10.1016/s0246-0319(15)66870-4","title":"10.1016/s0246-0319(15)66870-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Thalidomide; Medicine; Internal medicine; Multiple myeloma","score_opus":0.014075067411008384,"score_gpt":0.2442784452486239,"score_spread":0.23020337783761552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406557605","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012728298,0.00012463961,3.3843946e-7,0.00057289377,9.0925846e-7,0.0004727101,0.000024877201,0.00012326865,0.99740756],"genre_scores_gemma":[0.0026121207,0.0000011220034,0.00025988708,0.000060099097,0.0001564854,0.000051413277,0.000078892954,0.00003141866,0.99674857],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872905,0.00003544,0.00015761294,0.0002692548,0.00036767326,0.00044095537],"domain_scores_gemma":[0.9989692,0.00005236144,0.000014784828,0.00038972954,0.0000614479,0.00051249494],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010294077,0.00015412236,0.00023282194,0.00010970728,0.00007460913,0.000024896837,0.000111781796,0.00006215026,0.99901575],"category_scores_gemma":[0.000085971085,0.00012481479,0.00008595221,0.00021483893,0.0000392206,0.00005642287,0.00003528736,0.00014080801,0.998119],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050611794,0.00016937836,0.0000061863907,0.000012234041,0.000067885834,0.00013121581,0.000009432272,0.000002050089,0.00008635081,8.035277e-8,0.6521509,0.34685814],"study_design_scores_gemma":[0.0017817353,0.00059380225,0.0011040616,0.00004201756,0.000036749785,0.000050604714,9.680922e-7,0.00017448133,0.00040654305,0.000004457734,0.99569,0.00011459968],"about_ca_topic_score_codex":0.00008728436,"about_ca_topic_score_gemma":5.194453e-7,"teacher_disagreement_score":0.34674355,"about_ca_system_score_codex":0.000080413054,"about_ca_system_score_gemma":0.00007185696,"threshold_uncertainty_score":0.50898},"labels":[],"label_agreement":null},{"id":"W4406562665","doi":"10.1016/j.bjorlp.2021.11.002","title":"10.1016/j.bjorlp.2021.11.002","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Art","score_opus":0.012615298353264937,"score_gpt":0.23845320371970533,"score_spread":0.22583790536644038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406562665","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004920449,0.00009345359,3.1587132e-7,0.0007158642,8.8995455e-7,0.0004340883,0.000023103501,0.00007778317,0.99373406],"genre_scores_gemma":[0.0025265913,0.0000010670241,0.0002483951,0.00005030646,0.00018172973,0.00004527287,0.00007479218,0.000028074368,0.99684376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881935,0.000033902026,0.00014919856,0.00025763141,0.0003351262,0.00040479124],"domain_scores_gemma":[0.9990384,0.000047998386,0.000013977389,0.0003737047,0.000057646153,0.00046830223],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000084291976,0.00014528925,0.00022304953,0.00010598243,0.00006903808,0.000023688332,0.000101746606,0.00005685567,0.9992269],"category_scores_gemma":[0.00007252005,0.000118510594,0.00008217758,0.00022004549,0.000034493158,0.00005195596,0.000032562795,0.0001083874,0.99735135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044600133,0.00022869972,0.00001198427,0.000011872251,0.00007065094,0.00017998091,0.000010855844,0.0000026099833,0.00010562316,5.3387294e-7,0.20942043,0.7895107],"study_design_scores_gemma":[0.00175223,0.00046892068,0.0009251717,0.000038312897,0.000035869954,0.000037981757,9.1764474e-7,0.00019483177,0.0003820231,0.000002815774,0.9960528,0.000108111715],"about_ca_topic_score_codex":0.000105060106,"about_ca_topic_score_gemma":8.147614e-7,"teacher_disagreement_score":0.78940266,"about_ca_system_score_codex":0.00007440423,"about_ca_system_score_gemma":0.000060243463,"threshold_uncertainty_score":0.48327217},"labels":[],"label_agreement":null},{"id":"W4406571906","doi":"10.1016/j.abdp.2024.02.019","title":"10.1016/j.abdp.2024.02.019","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psychology","score_opus":0.012891105787258975,"score_gpt":0.24212342469525566,"score_spread":0.2292323189079967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406571906","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038944844,0.000107928296,2.6199382e-7,0.0005687139,0.0000012849315,0.00044711266,0.000024605843,0.00011178402,0.99484384],"genre_scores_gemma":[0.0022319662,0.0000011156393,0.00017275776,0.000061325176,0.00015113766,0.00004285254,0.00005909594,0.000030476771,0.99724925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988575,0.000029991228,0.00014305074,0.00024962024,0.00032854947,0.00039126715],"domain_scores_gemma":[0.99908674,0.00004778086,0.000012922329,0.00035803643,0.00005139718,0.00044312558],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000085686,0.00014113708,0.00021672831,0.000101606245,0.000059008285,0.000022978047,0.00009858174,0.000056756613,0.998995],"category_scores_gemma":[0.00006594266,0.00011417792,0.00008292038,0.00021291131,0.000031019124,0.000049566075,0.000032684013,0.00013152487,0.99756575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040076274,0.00016992475,0.000009369522,0.000014248035,0.00008030225,0.0001395394,0.000010675644,0.0000027572153,0.00006692594,2.8146823e-7,0.28145748,0.71764773],"study_design_scores_gemma":[0.0015561003,0.0005572408,0.0011039489,0.000039089704,0.00003718137,0.000043551525,0.000001003895,0.00020553627,0.0003127761,0.0000028986635,0.99603605,0.00010462826],"about_ca_topic_score_codex":0.00008820926,"about_ca_topic_score_gemma":3.9800713e-7,"teacher_disagreement_score":0.7175431,"about_ca_system_score_codex":0.00005916659,"about_ca_system_score_gemma":0.000065871594,"threshold_uncertainty_score":0.46560404},"labels":[],"label_agreement":null},{"id":"W4406573122","doi":"10.1016/s1879-8551(19)30112-5","title":"10.1016/s1879-8551(19)30112-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.015216086123310017,"score_gpt":0.2453442866982514,"score_spread":0.23012820057494138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406573122","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039056093,0.00012798552,3.908261e-7,0.00069024577,8.5815674e-7,0.00048161222,0.00002617231,0.00012903957,0.9946381],"genre_scores_gemma":[0.002367269,0.000001213401,0.00027704792,0.0000867117,0.00014475545,0.000051885934,0.00007653831,0.000030086125,0.9969645],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987611,0.00003641276,0.00015634953,0.000267143,0.0003532325,0.00042572065],"domain_scores_gemma":[0.9988632,0.000053154385,0.000015160812,0.00038887464,0.000054626715,0.00062494894],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010174715,0.00015278278,0.00023066673,0.00010969245,0.00007958308,0.000023482238,0.000110971225,0.00006239911,0.9987791],"category_scores_gemma":[0.000099171004,0.00012413994,0.000085162515,0.00020722314,0.000039162922,0.00005431126,0.000034100744,0.00013131044,0.9976596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070686155,0.00021309982,0.000008716069,0.00001594093,0.00008457935,0.00018969207,0.000013475762,0.0000032208964,0.000080485835,4.858374e-7,0.28735727,0.7113262],"study_design_scores_gemma":[0.001865487,0.0005677651,0.0010694274,0.000031941105,0.000036898375,0.00006121941,0.00000100477,0.000157219,0.00026595924,0.000004728601,0.9958242,0.000114113165],"about_ca_topic_score_codex":0.00011797366,"about_ca_topic_score_gemma":4.3871813e-7,"teacher_disagreement_score":0.71121204,"about_ca_system_score_codex":0.000092392336,"about_ca_system_score_gemma":0.00008236038,"threshold_uncertainty_score":0.506228},"labels":[],"label_agreement":null},{"id":"W4406574446","doi":"10.1016/s1634-6939(20)30476-2","title":"10.1016/s1634-6939(20)30476-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psychology","score_opus":0.013009505025243598,"score_gpt":0.2401836556297847,"score_spread":0.2271741506045411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406574446","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003419991,0.000109419074,3.4604835e-7,0.0006870053,8.7421563e-7,0.0004672089,0.00002927613,0.00012413991,0.9951617],"genre_scores_gemma":[0.0018743745,9.097237e-7,0.00025944473,0.000065111926,0.00015964152,0.00004946008,0.00009599027,0.000030982486,0.99746406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998758,0.000034577653,0.00015672545,0.00026545697,0.00035280842,0.00043241293],"domain_scores_gemma":[0.99898976,0.000048155573,0.000015062304,0.00038827915,0.000061508574,0.000497223],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009521706,0.0001537639,0.0002335418,0.00010337933,0.000073619376,0.000023784438,0.00011084805,0.00006250675,0.9986286],"category_scores_gemma":[0.000069742426,0.00012489333,0.0000839333,0.00021224727,0.000038208,0.0000570149,0.000033823446,0.0001287559,0.997581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006852536,0.00021610093,0.000006757001,0.000014424042,0.000086509346,0.00016996563,0.000010648991,0.000003410712,0.00014267537,3.3900582e-7,0.2622809,0.736383],"study_design_scores_gemma":[0.0018291665,0.0005905796,0.0007440217,0.000037760245,0.000037958285,0.00005113949,8.110435e-7,0.00020517001,0.00040455122,0.0000039378265,0.99598014,0.00011476667],"about_ca_topic_score_codex":0.000072817675,"about_ca_topic_score_gemma":5.3394524e-7,"teacher_disagreement_score":0.7362682,"about_ca_system_score_codex":0.00007971127,"about_ca_system_score_gemma":0.00006916226,"threshold_uncertainty_score":0.5093002},"labels":[],"label_agreement":null},{"id":"W4406642884","doi":"10.1016/b978-2-294-76306-9.50497-x","title":"10.1016/b978-2-294-76306-9.50497-x","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Geography","score_opus":0.018792685163533128,"score_gpt":0.2348430129709702,"score_spread":0.21605032780743708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406642884","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033056679,0.00056790333,2.1954207e-7,0.0002954514,0.0000030444273,0.0011462875,0.0002505208,0.00019062146,0.9975426],"genre_scores_gemma":[0.00000882717,0.0000059029917,0.00014884154,0.00006970276,0.0005718206,0.00005598385,0.00076364516,0.000176092,0.99819916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997542,0.000020719868,0.0003822076,0.00064795295,0.0007891411,0.0006179828],"domain_scores_gemma":[0.9979788,0.0000899725,0.00008394838,0.0008516016,0.00014694173,0.000848712],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011308942,0.0005563707,0.00079313805,0.00040825352,0.00009815863,0.000042539734,0.00024059377,0.0004018231,0.9987909],"category_scores_gemma":[0.00006019759,0.0004839731,0.00031392043,0.00006207053,0.000098163524,0.000052290212,0.000121033845,0.0005496864,0.9982726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009233707,0.0001019415,1.9826825e-7,0.00006266823,0.00046893812,0.0008140287,0.0000064898904,7.159788e-7,0.000007785803,0.00003089902,0.22288135,0.7747016],"study_design_scores_gemma":[0.0017977926,0.0009064432,0.000017894885,0.00037789604,0.00023971626,0.00012546279,2.1252204e-7,0.000020161067,0.000031062453,0.0001377285,0.9959585,0.0003871475],"about_ca_topic_score_codex":0.000051000065,"about_ca_topic_score_gemma":7.120609e-7,"teacher_disagreement_score":0.77431446,"about_ca_system_score_codex":0.0002522313,"about_ca_system_score_gemma":0.0002481248,"threshold_uncertainty_score":0.99976116},"labels":[],"label_agreement":null},{"id":"W4406667073","doi":"10.1016/b978-0-323-04602-2.50063-1","title":"10.1016/b978-0-323-04602-2.50063-1","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","score_opus":0.018299348647360422,"score_gpt":0.2336662067505439,"score_spread":0.21536685810318346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406667073","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000030610029,0.00056230556,2.1094012e-7,0.00029784327,0.0000031255088,0.0011333011,0.0002552331,0.00018866715,0.99755627],"genre_scores_gemma":[0.0000095460955,0.0000048799347,0.00014788129,0.00006787794,0.00051178783,0.000059446458,0.0008060178,0.00017440699,0.9982182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753815,0.000021942935,0.00038624392,0.00064456265,0.00079286395,0.0006162384],"domain_scores_gemma":[0.9979827,0.00008939143,0.000082845276,0.00086958974,0.00014211376,0.0008333925],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011331847,0.0005526483,0.0007929549,0.000406265,0.000096748394,0.000042345026,0.00023948336,0.00040227608,0.99888045],"category_scores_gemma":[0.000057657464,0.00047534035,0.0003191059,0.000060032966,0.00009685682,0.000049769817,0.00012102206,0.00054972724,0.9982751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009491522,0.000102339436,1.5693601e-7,0.000060859682,0.00046785403,0.00077598006,0.0000065805766,7.815043e-7,0.000009278109,0.00003071881,0.19664644,0.8009499],"study_design_scores_gemma":[0.0017310167,0.0009061176,0.000017276334,0.00036052827,0.00023176183,0.00010906916,1.9240447e-7,0.000019775205,0.000033972276,0.00011238541,0.9960964,0.0003815186],"about_ca_topic_score_codex":0.000056015837,"about_ca_topic_score_gemma":8.2607784e-7,"teacher_disagreement_score":0.80056834,"about_ca_system_score_codex":0.00025733616,"about_ca_system_score_gemma":0.00023380466,"threshold_uncertainty_score":0.9997698},"labels":[],"label_agreement":null},{"id":"W4406669602","doi":"10.1080/10428194.2025.2455485","title":"Are we maintaining minimal residual disease in myeloma?","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Medicine; Oncology; Clinical trial; Disease; Intensive care medicine; Residual; Clinical endpoint; Maintenance therapy; Internal medicine; Chemotherapy; Bone marrow; Computer science","score_opus":0.04017158920676689,"score_gpt":0.3358778949116927,"score_spread":0.2957063057049258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406669602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01150676,0.98079,0.0000068418635,0.00024211605,0.00034458018,0.002904973,0.0005343795,0.0002919961,0.0033783158],"genre_scores_gemma":[0.006681933,0.98134995,0.00038837374,0.0004287042,0.00067836273,0.0011390508,0.0010683278,0.00026596666,0.007999323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99138314,0.0006601166,0.0019967908,0.0024456738,0.0013025017,0.0022118054],"domain_scores_gemma":[0.9939798,0.001307692,0.0009156527,0.0017346161,0.00017663301,0.001885618],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00061224145,0.0019740318,0.0049823066,0.0019784248,0.00042145114,0.0002631363,0.00074522453,0.001314654,0.00014249954],"category_scores_gemma":[0.0009979781,0.0016702703,0.001142879,0.0016869081,0.0005186825,0.00027761806,0.00082427467,0.0006157721,0.0002072126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001281007,0.00034243634,0.0044026584,0.033393897,0.0007716722,0.016882427,0.00013593414,0.0000030120623,8.9241274e-7,0.0002405451,0.0035711154,0.9389744],"study_design_scores_gemma":[0.019760866,0.00030741555,0.03980957,0.08992861,0.0028193018,0.0010567833,0.00029920664,0.00042085885,0.000008234164,0.00018748578,0.8437266,0.001675086],"about_ca_topic_score_codex":0.0007834659,"about_ca_topic_score_gemma":0.00017262642,"teacher_disagreement_score":0.9372993,"about_ca_system_score_codex":0.017496234,"about_ca_system_score_gemma":0.020669097,"threshold_uncertainty_score":0.9999818},"labels":[],"label_agreement":null},{"id":"W4406697420","doi":"10.58931/cht.2025.4s0161","title":"Practical Considerations for Early Relapsed/Refractory Multiple Myeloma in the Canadian Landscape in 2024","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; London Health Sciences Centre; Western University","funders":"","keywords":"Refractory (planetary science); Multiple myeloma; Medicine; Oncology; Intensive care medicine; Internal medicine; Biology; Astrobiology","score_opus":0.04380890724049456,"score_gpt":0.33824928806811133,"score_spread":0.29444038082761675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406697420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.771291,0.0009795588,0.000030286366,0.16428804,0.0005789688,0.0041093226,0.00027572823,0.000030892264,0.058416195],"genre_scores_gemma":[0.99344754,0.000011004515,0.0007243561,0.0036692885,0.000030131318,0.00048887235,0.00007854806,0.00001415936,0.0015361154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833226,0.00016439022,0.0002970121,0.00031291714,0.000117824544,0.0007755989],"domain_scores_gemma":[0.9972651,0.0016762232,0.000028478311,0.00035782164,0.00009768047,0.0005746887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037259882,0.00015316941,0.0003248098,0.0009709852,0.00025641016,0.000046705758,0.00008249059,0.0002807367,0.0003838621],"category_scores_gemma":[0.0034812277,0.00012286037,0.00006438238,0.00038992453,0.00012128342,0.00007480444,0.000010857959,0.00051234785,0.00008216999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010233034,0.000105133826,0.87143046,0.00005288456,0.0000791483,0.0048149005,0.00057609315,0.000001645406,0.000007566965,0.022798723,0.099618725,0.00041239837],"study_design_scores_gemma":[0.0064802365,0.00021026826,0.91783214,0.00015491448,0.00005718444,0.0007284293,0.0007558192,0.001050022,0.00009014154,0.0027506948,0.06969215,0.00019799994],"about_ca_topic_score_codex":0.70729506,"about_ca_topic_score_gemma":0.9987235,"teacher_disagreement_score":0.29142848,"about_ca_system_score_codex":0.00063535414,"about_ca_system_score_gemma":0.006884544,"threshold_uncertainty_score":0.9987455},"labels":[],"label_agreement":null},{"id":"W4406771622","doi":"10.1016/j.clml.2025.01.010","title":"Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada","year":2025,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Manitoba; William Osler Health System; Saskatchewan Science Centre; London Health Sciences Centre; University of Alberta; University of Saskatchewan; University of Ottawa; Kingston Health Sciences Centre; McGill University; McGill University Health Centre; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; Western University; University of Toronto; Queen's University; McMaster University","funders":"Janssen Research and Development; Johnson and Johnson; Hamilton Health Sciences","keywords":"Medicine; Multiple myeloma; Minimal residual disease; Residual; Clinical trial; Clinical Practice; Disease; Oncology; Internal medicine; Intensive care medicine; Family medicine; Bone marrow; Algorithm","score_opus":0.1723257882737399,"score_gpt":0.4460666182586723,"score_spread":0.2737408299849324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406771622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12040743,0.86534613,0.000010617928,0.00036712998,0.0014329812,0.0107613,0.0013728825,0.00009270599,0.00020878563],"genre_scores_gemma":[0.010876432,0.970508,0.011867022,0.0008555251,0.002138095,0.0016151015,0.0012756239,0.00020860632,0.00065558625],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98581594,0.0025125348,0.0064057102,0.0026079833,0.0010341048,0.0016236951],"domain_scores_gemma":[0.9276499,0.066687614,0.0016944105,0.001628369,0.0005610853,0.0017786087],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0038358264,0.0012970028,0.0059653986,0.00054027356,0.00020293774,0.00016102905,0.0006916364,0.0012906635,0.00001840758],"category_scores_gemma":[0.21111107,0.001084789,0.00096626894,0.0012751552,0.00051219907,0.00038428014,0.00074083725,0.0018564084,0.000012341977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04283283,0.00057064305,0.14145985,0.0076173404,0.0004098174,0.0047567347,0.000007360498,0.000001978941,4.212327e-8,0.000015070204,0.0038590692,0.79846925],"study_design_scores_gemma":[0.08497954,0.0009552906,0.608646,0.016706176,0.0013121299,0.00012978847,0.00003147496,0.000642432,1.482807e-7,0.00002066006,0.28591058,0.0006657879],"about_ca_topic_score_codex":0.13908432,"about_ca_topic_score_gemma":0.20421498,"teacher_disagreement_score":0.79780346,"about_ca_system_score_codex":0.006002825,"about_ca_system_score_gemma":0.06526137,"threshold_uncertainty_score":0.9999782},"labels":[],"label_agreement":null},{"id":"W4407094971","doi":"10.14740/jh1380","title":"Allogeneic Stem Cell Transplantation for High/Ultra High-Risk Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Medicine; Stem cell; Transplantation; Oncology; Immunology; Internal medicine; Biology; Genetics","score_opus":0.01658550299123056,"score_gpt":0.2956754711297462,"score_spread":0.2790899681385156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407094971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855278,0.0012186223,0.010921377,0.0012233964,0.0003661175,0.00048506018,0.000052514133,0.000015488391,0.00018958708],"genre_scores_gemma":[0.9923993,0.0006984505,0.006106188,0.00012776586,0.0000765818,0.000026197433,0.000033174078,0.000015787164,0.0005166072],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864155,0.0001051134,0.000564335,0.00016618386,0.0002121633,0.0003106542],"domain_scores_gemma":[0.9984528,0.0006509438,0.0003025267,0.00016268464,0.00027478617,0.0001562924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002537929,0.00014791869,0.0005727766,0.0003245626,0.000093885756,0.000011170354,0.00011879851,0.00014537715,0.000037469785],"category_scores_gemma":[0.000094137424,0.00010905899,0.00019190725,0.00013463733,0.000052291438,0.0000689172,0.000008407214,0.00023543541,0.000014747234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01603852,0.001963923,0.808684,0.0027542794,0.0024368926,0.0032283359,0.0005806168,0.00010024746,0.07276905,0.0043889214,0.006519919,0.08053532],"study_design_scores_gemma":[0.031673033,0.0026302994,0.34646523,0.00035624238,0.0011147398,0.0026669072,0.0003098496,0.00023680176,0.6106853,0.0017116592,0.001954735,0.00019521492],"about_ca_topic_score_codex":0.000051634357,"about_ca_topic_score_gemma":0.000044686323,"teacher_disagreement_score":0.53791624,"about_ca_system_score_codex":0.00007785654,"about_ca_system_score_gemma":0.00021872473,"threshold_uncertainty_score":0.44472963},"labels":[],"label_agreement":null},{"id":"W4407099959","doi":"10.3390/cancers17030489","title":"A Prognostic Symptom Model Incorporating Patient-Reported Symptoms for Transplant-Ineligible Patients with Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Public Health Ontario; Hamilton Health Sciences; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"Leukemia and Lymphoma Society of Canada; Hamilton Health Sciences","keywords":"Medicine; Depression (economics); Cohort; Logistic regression; Internal medicine; Population; Multivariate analysis; Retrospective cohort study; Physical therapy","score_opus":0.015785714437839757,"score_gpt":0.27604282661819945,"score_spread":0.2602571121803597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407099959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885314,0.0001257033,0.006629823,0.00010126744,0.00010375676,0.0032047373,0.00020350303,0.00012841025,0.00097138115],"genre_scores_gemma":[0.99394923,0.000009846645,0.00359004,0.00022643535,0.000026933578,0.0011495625,0.0006095734,0.000040291277,0.00039810993],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99824363,0.000019740659,0.00036579784,0.0004746615,0.00038067825,0.00051551935],"domain_scores_gemma":[0.99874264,0.00015742023,0.00013940918,0.0003272049,0.00038399032,0.00024935752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006353306,0.00026362127,0.00037379717,0.00021034137,0.00018540188,0.000030596966,0.0000931815,0.00009095933,0.000008601389],"category_scores_gemma":[0.00019008525,0.00019893197,0.00010199544,0.0003720607,0.00009270536,0.00011290526,0.00002388936,0.00014171646,0.00000390758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003081452,0.00017861837,0.97674596,0.0003572447,0.0006584755,0.000042296284,0.00023392664,0.0024492422,0.00035796812,0.000070455055,0.00043220355,0.015392147],"study_design_scores_gemma":[0.048389755,0.0031002192,0.4185267,0.002584259,0.0011520828,0.00001603597,0.00019513926,0.51763105,0.0067596943,0.0002981735,0.0006204297,0.0007264346],"about_ca_topic_score_codex":0.00019281912,"about_ca_topic_score_gemma":0.000118816475,"teacher_disagreement_score":0.55821925,"about_ca_system_score_codex":0.0008682025,"about_ca_system_score_gemma":0.0015147253,"threshold_uncertainty_score":0.81122106},"labels":[],"label_agreement":null},{"id":"W4407120774","doi":"","title":"Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)","year":2020,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Medicine; Multiple myeloma; Oncology; Internal medicine; Refractory (planetary science); Cancer; Immunotherapy; Biology","score_opus":0.21065060110088143,"score_gpt":0.5302432956176063,"score_spread":0.3195926945167249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407120774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964365,0.0007278815,0.00006482112,0.00022030083,0.000050796232,0.0019049235,0.00006394126,0.000018877863,0.0005119699],"genre_scores_gemma":[0.9979185,0.0012310715,0.0005393958,0.000080005586,0.000036669484,0.000033976732,0.00007074549,0.00005946397,0.000030180476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99548286,0.00081514916,0.0012126893,0.00065901474,0.0013554014,0.0004749005],"domain_scores_gemma":[0.9965326,0.0010708593,0.0010283269,0.00039403618,0.00047838848,0.0004957777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015489729,0.00037252408,0.0013713086,0.00065503037,0.00011595911,0.00013425568,0.0005862844,0.0001713645,0.0005510901],"category_scores_gemma":[0.0015983054,0.00028201728,0.00010830963,0.0010323469,0.0002528319,0.0012960306,0.00046575052,0.00094280887,0.0000036711863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03932625,0.00263011,0.8854484,0.00023196191,0.0003189872,0.00012896067,0.00025377274,0.000045359287,0.0023021882,0.0000036258998,0.00007452173,0.06923586],"study_design_scores_gemma":[0.038735755,0.001165808,0.95466393,0.0011357622,0.00012690295,0.000008836047,0.0000697269,0.0017630743,0.001999386,0.000033469427,0.00003750353,0.00025981522],"about_ca_topic_score_codex":0.0013128228,"about_ca_topic_score_gemma":0.00055173825,"teacher_disagreement_score":0.06921556,"about_ca_system_score_codex":0.0002578756,"about_ca_system_score_gemma":0.0004364718,"threshold_uncertainty_score":0.9999632},"labels":[],"label_agreement":null},{"id":"W4407150890","doi":"10.1038/s41591-024-03485-7","title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Daratumumab; Multiple myeloma; Lenalidomide; Internal medicine; Hazard ratio; Bortezomib; Clinical endpoint; Transplantation; Surgery; Oncology; Confidence interval; Clinical trial","score_opus":0.030951679959523193,"score_gpt":0.3699476036177096,"score_spread":0.3389959236581864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407150890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8901005,0.03393024,0.0129882535,0.033988267,0.0022733484,0.023551224,0.0008200839,0.00033487115,0.0020132333],"genre_scores_gemma":[0.9857726,0.0038901577,0.0012557382,0.0028077664,0.000989143,0.0016867951,0.0009878611,0.00006484074,0.0025451046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959057,0.0004494016,0.0010409169,0.0008444616,0.00085891545,0.00090057927],"domain_scores_gemma":[0.9903121,0.007984816,0.00020925158,0.00070008344,0.00029453723,0.0004991995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019279422,0.0006533087,0.0023195655,0.00047615689,0.00046842152,0.000052051146,0.00034250793,0.0005457548,0.00014038857],"category_scores_gemma":[0.005550656,0.00032239247,0.00042556378,0.0007093492,0.00074016955,0.00011676572,0.00003593934,0.0012419315,0.0000044397366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9661973,0.00065067055,0.00023540006,0.0005326163,0.0016858507,0.0006859354,0.0011038305,0.0000023186674,0.0028587948,0.0002283773,0.008222703,0.017596167],"study_design_scores_gemma":[0.96827537,0.0021576933,0.0005773299,0.0011045107,0.002750717,0.00017615587,0.0002820952,0.004183343,0.0050494405,0.00020037651,0.014952742,0.00029021208],"about_ca_topic_score_codex":0.00058403827,"about_ca_topic_score_gemma":0.00054423907,"teacher_disagreement_score":0.09567211,"about_ca_system_score_codex":0.00016096972,"about_ca_system_score_gemma":0.0006089568,"threshold_uncertainty_score":0.9999228},"labels":[],"label_agreement":null},{"id":"W4407238709","doi":"10.1038/s41408-025-01212-0","title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Seagen","keywords":"Medicine; Pomalidomide; Context (archaeology); Clinical trial; Multiple myeloma; Oncology; Internal medicine; Dexamethasone; Daratumumab; Clinical endpoint; Lenalidomide","score_opus":0.1447630802165594,"score_gpt":0.4704130007054941,"score_spread":0.3256499204889347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407238709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045396267,0.99263245,0.0000019255929,0.00042875332,0.0006016591,0.0013514686,0.00006047624,0.000011693315,0.00037194762],"genre_scores_gemma":[0.0017319605,0.9928059,0.00069812103,0.00003466702,0.00035965905,0.00027686992,0.00003276673,0.0000570069,0.004003032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937308,0.0011721277,0.0029077253,0.0004964756,0.0008644149,0.00082845625],"domain_scores_gemma":[0.99505097,0.0026792772,0.0011132351,0.0005109513,0.00021525646,0.00043030837],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030024627,0.00051332795,0.0026695856,0.0007359808,0.00023538178,0.000058217633,0.0005978227,0.00039719814,0.00014953167],"category_scores_gemma":[0.0020421504,0.00027982876,0.00062562304,0.00081309123,0.0001523794,0.00005914558,0.00021169023,0.0033448322,0.000015273448],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009117957,0.0015526469,0.01656853,0.0055264416,0.001315471,0.0021643606,0.00015248022,6.907772e-7,6.662158e-7,0.0000046285904,0.0016203879,0.9701819],"study_design_scores_gemma":[0.015978567,0.00034140592,0.02065032,0.08997665,0.0011325554,0.00079009606,0.00015577543,0.0000054000707,0.00002036719,0.000009825637,0.8706116,0.0003274255],"about_ca_topic_score_codex":0.00029329053,"about_ca_topic_score_gemma":0.0076496303,"teacher_disagreement_score":0.9698545,"about_ca_system_score_codex":0.0008774726,"about_ca_system_score_gemma":0.013981007,"threshold_uncertainty_score":0.99996537},"labels":[],"label_agreement":null},{"id":"W4407242015","doi":"10.1001/jamanetworkopen.2024.58585","title":"Cumulative Excess Body Mass Index and MGUS Progression to Myeloma","year":2025,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Body mass index; Internal medicine; Cohort; Multiple myeloma; Cumulative incidence; Obesity; Cohort study; Risk factor; Gastroenterology; Immunology; Antibody; Monoclonal; Monoclonal antibody","score_opus":0.028153666108074148,"score_gpt":0.3884566531460423,"score_spread":0.36030298703796815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407242015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8845872,0.0013505422,0.0011206182,0.009552337,0.00024423798,0.0053636655,0.000015732361,0.00008483917,0.09768079],"genre_scores_gemma":[0.98623717,0.0000857857,0.0038489082,0.0009177426,0.00022661331,0.00030479959,0.00004787748,0.000018997403,0.0083121015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847347,0.00012811138,0.00022346886,0.00041394023,0.00029605822,0.00046496908],"domain_scores_gemma":[0.998955,0.00016366654,0.000053762746,0.0003533749,0.0001204827,0.00035370706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040713017,0.00017647704,0.00035736963,0.00010485393,0.00020214013,0.00024129814,0.00025277698,0.00011871323,0.0001358689],"category_scores_gemma":[0.00017192506,0.00013097034,0.00003762906,0.0005170492,0.000053331518,0.00019463703,0.0006334725,0.0002313225,0.00005482882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004066482,0.00014981718,0.78117406,0.00008905359,0.00028950928,0.00028017684,0.00011184108,0.000057460675,0.00017124272,0.00054862397,0.017524969,0.19553678],"study_design_scores_gemma":[0.00558039,0.00041452414,0.9690949,0.0012532802,0.000046283185,0.000009398025,0.00007145811,0.0044053704,0.0004455368,0.0009824085,0.017559703,0.00013675098],"about_ca_topic_score_codex":0.00017463694,"about_ca_topic_score_gemma":0.00004357245,"teacher_disagreement_score":0.19540003,"about_ca_system_score_codex":0.00009658292,"about_ca_system_score_gemma":0.0001415151,"threshold_uncertainty_score":0.5340815},"labels":[],"label_agreement":null},{"id":"W4407480694","doi":"10.1038/s41591-025-03581-2","title":"Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","year":2025,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Bortezomib; Medicine; Multiple myeloma; Internal medicine; Oncology","score_opus":0.03630016595111352,"score_gpt":0.3699775401689008,"score_spread":0.33367737421778726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407480694","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030954555,0.3159459,0.026099153,0.12689288,0.3120868,0.14358142,0.014414188,0.0022906782,0.027734436],"genre_scores_gemma":[0.25080603,0.035833426,0.0018731037,0.005711626,0.026053965,0.010715285,0.034798298,0.00054350897,0.6336648],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99191964,0.0009623659,0.0019680695,0.0017576833,0.0019199962,0.0014722324],"domain_scores_gemma":[0.98515624,0.01117122,0.00069995265,0.0013068726,0.0007107727,0.00095492264],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0028657606,0.0016066056,0.0055182767,0.0010077886,0.0008397034,0.00011651717,0.00065314426,0.0025647911,0.0003677975],"category_scores_gemma":[0.012229973,0.000843215,0.001052136,0.001079825,0.0010906158,0.00014689042,0.00007092202,0.005537202,0.000007960445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5399997,0.00047812206,0.000011423591,0.0010583651,0.0022233184,0.0009838426,0.0007499411,0.0000011164642,0.000082542014,0.000016747614,0.44423985,0.0101550305],"study_design_scores_gemma":[0.70232,0.0031581281,0.00006542981,0.0039689387,0.0065810033,0.0004789376,0.00023412335,0.005039481,0.00038409952,0.000043951477,0.2771769,0.0005490066],"about_ca_topic_score_codex":0.001232639,"about_ca_topic_score_gemma":0.0015604862,"teacher_disagreement_score":0.6059303,"about_ca_system_score_codex":0.00046308822,"about_ca_system_score_gemma":0.0025172916,"threshold_uncertainty_score":0.9996682},"labels":[],"label_agreement":null},{"id":"W4407570874","doi":"10.1111/ejh.14392","title":"Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: <scp>MAIA</scp> Final Analysis of Patient‐Reported Outcomes","year":2025,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; Johnson and Johnson; Janssen Scientific Affairs; National Cancer Institute; Kite Pharma; Celgene; Amgen","keywords":"Daratumumab; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Quality of life (healthcare)","score_opus":0.030771107431434543,"score_gpt":0.3157290462354384,"score_spread":0.2849579388040039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407570874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691474,0.0014303733,0.00019171313,0.00046240442,0.000031785192,0.0006415845,0.00002927006,0.00001116151,0.00028695638],"genre_scores_gemma":[0.9986505,0.00029474925,0.0007934521,0.00009599601,0.0000035209325,0.000007611026,0.000050453826,0.000022218363,0.000081490965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941708,0.0015188013,0.0030650313,0.00033155992,0.0004371447,0.0004767031],"domain_scores_gemma":[0.995832,0.0014897627,0.0016672985,0.0003299735,0.00038772123,0.00029319187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017796025,0.00028882333,0.0024899235,0.002121496,0.000045730732,0.0000105993195,0.00015519165,0.00007493292,0.000015479869],"category_scores_gemma":[0.0023896804,0.0002049662,0.00025164383,0.0017048933,0.00021925196,0.0000921,0.000062692205,0.00038239258,5.0498215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050229845,0.0011428111,0.9746801,0.00055825,0.003913911,0.00951668,0.0012577518,0.0003080421,0.00088589825,0.000043578577,0.000049259226,0.0026207224],"study_design_scores_gemma":[0.036005463,0.0019412081,0.9569077,0.0005323432,0.00056329963,0.00024178404,0.0013558489,0.00052861596,0.0018153604,0.000017848928,0.000017726077,0.0000727847],"about_ca_topic_score_codex":0.0014686149,"about_ca_topic_score_gemma":0.0014479307,"teacher_disagreement_score":0.030982478,"about_ca_system_score_codex":0.00011828399,"about_ca_system_score_gemma":0.00046844909,"threshold_uncertainty_score":0.8358279},"labels":[],"label_agreement":null},{"id":"W4407597886","doi":"10.1016/j.jgo.2025.102199","title":"Updates on myeloma in older adults: Conference summary from the 2024 International Myeloma Society annual meeting","year":2025,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Family medicine; Gerontology; Internal medicine","score_opus":0.012524014455307193,"score_gpt":0.3253223171240399,"score_spread":0.3127983026687327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407597886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662981,0.0017041098,0.000062273044,0.01981997,0.0014910925,0.00036679604,0.00007683672,0.000010828793,0.010170007],"genre_scores_gemma":[0.99250513,0.0019418742,0.0018556045,0.0013824765,0.00086086115,0.000014956396,0.000035679783,0.00001139479,0.0013920368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982487,0.0002039491,0.0006303405,0.00021318138,0.00041573003,0.00028808182],"domain_scores_gemma":[0.9978953,0.0010994411,0.00030899816,0.00016939073,0.00041047682,0.00011642135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055837526,0.0001568364,0.00044255043,0.00022759731,0.00007431417,0.00003067712,0.00032308305,0.000155572,0.0004586073],"category_scores_gemma":[0.0005713073,0.00009814514,0.00021779016,0.0003442688,0.000091456925,0.00011570728,0.00012791004,0.0006871119,0.000025979447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009145575,0.0019793296,0.2500187,0.00006709284,0.0016215896,0.001981696,0.0030033188,0.000023557152,0.00085766293,0.00020208718,0.18385033,0.5472491],"study_design_scores_gemma":[0.013695749,0.0012617314,0.939689,0.0009946316,0.00016785572,0.0001646934,0.003853966,0.00087045383,0.0004072032,0.00039522015,0.038373373,0.00012614638],"about_ca_topic_score_codex":0.00013599294,"about_ca_topic_score_gemma":0.00009655116,"teacher_disagreement_score":0.68967026,"about_ca_system_score_codex":0.00056320487,"about_ca_system_score_gemma":0.0009811781,"threshold_uncertainty_score":0.50214285},"labels":[],"label_agreement":null},{"id":"W4407987841","doi":"10.1016/j.clml.2025.01.022","title":"Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Tolerability; Multiple myeloma; Adverse effect; Oncology; Internal medicine","score_opus":0.018595504712545678,"score_gpt":0.3097689885473519,"score_spread":0.29117348383480623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407987841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048483,0.0003146132,0.000039441748,0.0003377246,0.00017256576,0.0017793576,0.00011352219,0.00008946177,0.0066685053],"genre_scores_gemma":[0.9958919,0.0003964372,0.0021296137,0.00028818683,0.00008268045,0.000064695596,0.00021035205,0.000050397804,0.0008857196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949758,0.00042905723,0.0019533627,0.0011207238,0.00067819585,0.0008428375],"domain_scores_gemma":[0.99545974,0.0020291544,0.00035293718,0.0011764666,0.0004149181,0.00056677987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010401077,0.0005071916,0.00177906,0.00044466066,0.00014629491,0.000034497283,0.00030310018,0.0003702141,0.00015260572],"category_scores_gemma":[0.0017838592,0.00039840836,0.000253138,0.00095495576,0.000924986,0.00015872827,0.00029960545,0.00047293192,0.00003333526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009047791,0.0013455781,0.5616549,0.00020280131,0.00023518899,0.00010100363,0.000054986518,0.0000019152487,0.000020038458,0.00013480039,0.00015874878,0.42704225],"study_design_scores_gemma":[0.036604803,0.001991185,0.9568657,0.00059984956,0.00014742422,0.0000069442967,0.00004328682,0.0007220739,0.00036208486,0.00016393408,0.0021922712,0.0003004263],"about_ca_topic_score_codex":0.0014833879,"about_ca_topic_score_gemma":0.0009125109,"teacher_disagreement_score":0.4267418,"about_ca_system_score_codex":0.001439239,"about_ca_system_score_gemma":0.0017496403,"threshold_uncertainty_score":0.99984676},"labels":[],"label_agreement":null},{"id":"W4407992657","doi":"10.1016/j.clml.2025.02.011","title":"Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Memorial University of Newfoundland; Saint John Regional Hospital; Université de Montréal; University of Saskatchewan; Dalhousie University; Juravinski Cancer Centre; University of British Columbia; McGill University; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; Queen Elizabeth II Health Sciences Centre; University of Alberta; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Janssen Canada; Johnson and Johnson","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology","score_opus":0.06408015381037947,"score_gpt":0.38643911078947374,"score_spread":0.3223589569790943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407992657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929991,0.0006622597,0.000050068065,0.00092084566,0.00026392489,0.0019938485,0.0004970637,0.00009981121,0.0025130857],"genre_scores_gemma":[0.99367434,0.0011624034,0.00060228753,0.0005656259,0.00013915788,0.00025496475,0.00074767356,0.000084308944,0.0027692176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928088,0.0009266536,0.0019388578,0.0015541812,0.0011290162,0.0016424548],"domain_scores_gemma":[0.99152744,0.004057975,0.00033715568,0.0016245185,0.00079600094,0.0016569128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013066,0.00074835616,0.0022464755,0.0020767862,0.00057668786,0.00012584303,0.00050144264,0.00064851186,0.0003925736],"category_scores_gemma":[0.0021197265,0.000580931,0.001053202,0.0021444608,0.0007278094,0.00021141558,0.00032427625,0.00049818686,0.000072734794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012220456,0.0009325647,0.6392568,0.00010332552,0.0046658255,0.00024810364,0.00014865735,0.0000017480676,0.00005082508,0.00011881954,0.00016253564,0.35308874],"study_design_scores_gemma":[0.022708368,0.003283414,0.96736825,0.00019360546,0.0007548347,0.00001174709,0.0002505068,0.0014676623,0.0006001987,0.00017440565,0.002795665,0.00039133587],"about_ca_topic_score_codex":0.062265653,"about_ca_topic_score_gemma":0.23362878,"teacher_disagreement_score":0.3526974,"about_ca_system_score_codex":0.0033478916,"about_ca_system_score_gemma":0.0035449069,"threshold_uncertainty_score":0.9996642},"labels":[],"label_agreement":null},{"id":"W4408053851","doi":"10.1182/blood.2024026455","title":"The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Vrije Universiteit Amsterdam","keywords":"Daratumumab; Bone marrow; Multiple myeloma; Medicine; Immunology; Granzyme; Antibody; Cytotoxic T cell; Bortezomib; Immune system; Cancer research; Oncology; Biology; Perforin; CD8","score_opus":0.008667859743753462,"score_gpt":0.23548157536982306,"score_spread":0.2268137156260696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408053851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311936,0.00036221923,0.000016484326,0.00027096446,0.000020622709,0.0028014865,0.000069817565,0.00008992049,0.0032491426],"genre_scores_gemma":[0.9968382,0.000031634932,0.000594093,0.00008776763,0.000018961513,0.0004659211,0.00023477229,0.00003587325,0.0016927564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803925,0.00015635767,0.00024602722,0.0004390355,0.00056385953,0.0005554573],"domain_scores_gemma":[0.9986358,0.00027858227,0.00009284907,0.0006067811,0.0002069726,0.0001789658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001588363,0.0002953018,0.00036310023,0.000172949,0.00025422432,0.00005109236,0.0001409781,0.0000920244,0.00003104439],"category_scores_gemma":[0.000102940976,0.0001529025,0.000056622725,0.00064888474,0.00018147941,0.00008488348,0.000033111726,0.00028983376,0.000016280599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009461454,0.005497319,0.9762416,0.00008013883,0.00027076763,0.0001691566,0.000052161962,0.000004751077,0.00077156204,0.000004113148,0.00020647248,0.0072405394],"study_design_scores_gemma":[0.074123554,0.0027159704,0.8719914,0.00025324855,0.00008711885,0.000002126108,0.000029260613,0.0005007728,0.04981663,0.0000040321415,0.0003378794,0.00013798433],"about_ca_topic_score_codex":0.00032384176,"about_ca_topic_score_gemma":0.0006003442,"teacher_disagreement_score":0.10425014,"about_ca_system_score_codex":0.00008799368,"about_ca_system_score_gemma":0.00035327632,"threshold_uncertainty_score":0.6235183},"labels":[],"label_agreement":null},{"id":"W4408061910","doi":"10.1038/s41375-024-02505-2","title":"Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Daratumumab; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Oncology","score_opus":0.027483650340193993,"score_gpt":0.3332355615420652,"score_spread":0.3057519112018712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408061910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757744,0.0010551305,0.00033010892,0.0012066131,0.00022402145,0.0009938244,0.000042515858,0.00013088512,0.00843949],"genre_scores_gemma":[0.98941517,0.00045133565,0.00071910897,0.0006339554,0.000068653084,0.00018283034,0.00019347949,0.000036031368,0.008299418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975387,0.00011125948,0.00051944004,0.0005708805,0.00046803014,0.00079172506],"domain_scores_gemma":[0.9984557,0.0004690181,0.00006406425,0.0006337464,0.00007220742,0.00030525224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026137434,0.00036313388,0.0007647659,0.0005447933,0.00010878959,0.00005802381,0.00024911732,0.00021717075,0.00028236752],"category_scores_gemma":[0.000239728,0.0002890663,0.00021885312,0.0006941754,0.00011133701,0.00014315863,0.00006706042,0.00051317335,0.00023967288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011602978,0.00031497312,0.9717307,0.00029947516,0.00030380787,0.0040667127,0.00021031147,0.000014823516,0.0020024052,0.00021922028,0.0011636289,0.018513653],"study_design_scores_gemma":[0.022680793,0.00013856102,0.9691707,0.00058539934,0.00012626589,0.0000422482,0.000039683386,0.00023053317,0.006182788,0.00014287647,0.000440468,0.00021967503],"about_ca_topic_score_codex":0.0013328978,"about_ca_topic_score_gemma":0.0013640187,"teacher_disagreement_score":0.021520495,"about_ca_system_score_codex":0.0009877445,"about_ca_system_score_gemma":0.0006594089,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W4408070992","doi":"10.1016/j.mednuc.2025.01.153","title":"Détermination du temps de captation optimal du 68Ga-PentixaFor lors du bilan initial des myélomes multiples. Étude ancillaire au protocole PentiMyelo","year":2025,"lang":"fr","type":"article","venue":"Médecine Nucléaire","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Physics","score_opus":0.02139533334152404,"score_gpt":0.3366565519049197,"score_spread":0.3152612185633957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408070992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97098124,0.0016875118,0.0025488958,0.0064527327,0.0013485693,0.0123198,0.00018900822,0.0002602185,0.0042119958],"genre_scores_gemma":[0.98345107,0.00063484977,0.0036209496,0.00032026792,0.0020998844,0.0037746257,0.0005679243,0.00013061834,0.005399814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946415,0.00051763136,0.0010693498,0.0010417558,0.0009944908,0.0017352703],"domain_scores_gemma":[0.99694735,0.00040001905,0.0003309025,0.00071046816,0.00083161594,0.0007796688],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001185558,0.0008069419,0.00093032484,0.0007788465,0.0011064138,0.00025945544,0.00047579885,0.00036926667,0.0011347437],"category_scores_gemma":[0.0021149307,0.0007608027,0.00041669776,0.0010097877,0.0008116045,0.00080219243,0.00033630666,0.00055798615,0.000496694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020629643,0.0033740245,0.7833736,0.0023314077,0.0007437123,0.0024795386,0.0036830243,0.000495238,0.0017180567,0.0007504101,0.0053061326,0.19368187],"study_design_scores_gemma":[0.022637885,0.0012513296,0.89468545,0.0029028533,0.000523959,0.00041445368,0.002307763,0.05599365,0.0056034722,0.00027151883,0.012788205,0.0006194601],"about_ca_topic_score_codex":0.0033242637,"about_ca_topic_score_gemma":0.0028100323,"teacher_disagreement_score":0.19306241,"about_ca_system_score_codex":0.0028627058,"about_ca_system_score_gemma":0.0018192981,"threshold_uncertainty_score":0.99977833},"labels":[],"label_agreement":null},{"id":"W4408660014","doi":"10.1038/s41375-025-02552-3","title":"Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Multiple myeloma; Medicine; Immunotherapy; Foundation (evidence); Gerontology; Internal medicine; Oncology; Database; Cancer; History; Computer science","score_opus":0.020780248770691657,"score_gpt":0.33998575072949977,"score_spread":0.3192055019588081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408660014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940555,0.000026097481,0.0007717055,0.00009644676,0.000032107262,0.00048019466,0.00016194083,0.00004399662,0.004331981],"genre_scores_gemma":[0.99141616,0.0000983336,0.0019025556,0.00006202065,0.000018946124,0.000045106095,0.0029787794,0.000017792401,0.0034603253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844545,0.00006870354,0.00043870934,0.000346585,0.000490699,0.0002098707],"domain_scores_gemma":[0.99857545,0.000118602504,0.00019533935,0.00071531953,0.0002991429,0.000096162774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001519476,0.00019161022,0.0005495323,0.00083284214,0.000048859667,0.000020284422,0.0001996917,0.0000624024,0.0004588889],"category_scores_gemma":[0.000061236926,0.00013780117,0.00015483655,0.001125202,0.00012962747,0.00021795103,0.000041062638,0.0001346976,0.0000050242675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035537076,0.00046953195,0.9678479,0.00009000441,0.0038661654,0.00009194964,0.00021321888,0.000016161934,0.003834951,0.00039717308,0.00003499258,0.019584259],"study_design_scores_gemma":[0.008628018,0.0002262025,0.97574914,0.0001692838,0.00048730712,0.0000017747818,0.000091646405,0.0018997475,0.012511995,0.000013831917,0.00012525158,0.0000957918],"about_ca_topic_score_codex":0.010513048,"about_ca_topic_score_gemma":0.004102645,"teacher_disagreement_score":0.019488467,"about_ca_system_score_codex":0.0004416955,"about_ca_system_score_gemma":0.00024688538,"threshold_uncertainty_score":0.99607605},"labels":[],"label_agreement":null},{"id":"W4408660209","doi":"10.3390/curroncol32030182","title":"Extramedullary Multiple Myeloma: Challenges and Opportunities","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; National Institutes of Health","keywords":"Multiple myeloma; Medicine; Bone marrow; Population; Cancer research; Pathology; Bioinformatics; Immunology; Biology","score_opus":0.4624507365339048,"score_gpt":0.49517783536690063,"score_spread":0.03272709883299585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408660209","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010626126,0.9884844,0.0000046247737,0.0003758655,0.0008085958,0.0016391568,0.00011607761,0.000086742955,0.008473913],"genre_scores_gemma":[0.000015395235,0.99669,0.00014551097,0.000029988063,0.00034043228,0.00068517047,0.00067530526,0.0000406825,0.0013775369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764323,0.00039240715,0.00054315536,0.0006242434,0.00025536903,0.0005415912],"domain_scores_gemma":[0.9975452,0.0012284223,0.00019195989,0.0004648156,0.00011935166,0.0004502742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025534545,0.0005091609,0.0024856662,0.00052725966,0.00008910067,0.00001575789,0.00016750791,0.0005080323,0.00009157015],"category_scores_gemma":[0.0004551204,0.00037879267,0.0003612196,0.000096406126,0.00026799948,0.000044482735,0.00028394663,0.0007767186,0.00006010623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046600217,0.00055198587,0.000030262267,0.065057136,0.00040367778,0.0005866962,0.00006800701,1.5611938e-9,2.5971682e-8,0.00034257397,0.0014730192,0.93144],"study_design_scores_gemma":[0.0016359212,0.00048673467,0.00012564652,0.018130403,0.0012383093,0.0004160054,0.00009037252,0.000006053774,1.6150854e-7,0.000040929604,0.97760046,0.00022900972],"about_ca_topic_score_codex":0.0000035276234,"about_ca_topic_score_gemma":0.000017955756,"teacher_disagreement_score":0.97612745,"about_ca_system_score_codex":0.0003853796,"about_ca_system_score_gemma":0.0017956027,"threshold_uncertainty_score":0.9998664},"labels":[],"label_agreement":null},{"id":"W4408675643","doi":"10.3324/haematol.2024.287200","title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Lenalidomide; Hazard ratio; Internal medicine; Multiple myeloma; Confidence interval; Adverse effect; Odds ratio; Bortezomib","score_opus":0.03638377731833328,"score_gpt":0.32255061909428157,"score_spread":0.2861668417759483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408675643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328667,0.000559432,0.0012674645,0.00089093554,0.000116187504,0.0031115483,0.00030028546,0.000047614667,0.00041988282],"genre_scores_gemma":[0.9964183,0.00017781656,0.0020510461,0.00038136917,0.000022027056,0.00046550608,0.00021314477,0.000014386655,0.00025640344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979196,0.00016921738,0.00061611313,0.00048901344,0.00035828305,0.00044774325],"domain_scores_gemma":[0.99715894,0.0017270948,0.00020967993,0.00053342636,0.00022410291,0.00014677865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030855287,0.00026369665,0.0012244566,0.0003689747,0.00019721489,0.00002816693,0.00021280923,0.0001693566,0.000054733748],"category_scores_gemma":[0.0019330234,0.00015617465,0.0005468627,0.0010784211,0.00022440038,0.0000616667,0.00008714057,0.00017304474,0.0000023774874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13977677,0.0023780281,0.8350849,0.00076334225,0.0064409515,0.000097392505,0.00043043017,0.000025187319,0.0008918807,0.00070270355,0.002263496,0.011144928],"study_design_scores_gemma":[0.24765043,0.0011146137,0.72799426,0.00023298927,0.004602249,0.000009601648,0.000146458,0.006024304,0.009885661,0.00021466627,0.0018881952,0.00023658943],"about_ca_topic_score_codex":0.00055345986,"about_ca_topic_score_gemma":0.00040587448,"teacher_disagreement_score":0.10787366,"about_ca_system_score_codex":0.00006196275,"about_ca_system_score_gemma":0.00016008329,"threshold_uncertainty_score":0.63686174},"labels":[],"label_agreement":null},{"id":"W4408781448","doi":"10.1182/blood.2024027620","title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Celgene; National Cancer Institute; Kite Pharma; Yale University; Sanofi; Servier; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Daratumumab; Medicine; Internal medicine; Bortezomib; Minimal residual disease; Multiple myeloma; Thalidomide; Oncology; Surgery; Gastroenterology; Bone marrow","score_opus":0.028714405923374372,"score_gpt":0.3321263116093556,"score_spread":0.3034119056859812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408781448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820449,0.0021105867,0.00012278355,0.0041875695,0.00025040246,0.0026377311,0.0010269696,0.00018547408,0.0074335863],"genre_scores_gemma":[0.9822316,0.00012238038,0.0056526274,0.00032170885,0.00040709827,0.0006746593,0.00071104034,0.00005284357,0.009826005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997129,0.00013270472,0.00058921374,0.0008125694,0.00053325156,0.0008032622],"domain_scores_gemma":[0.99692404,0.0010267966,0.0001619892,0.00086960936,0.0002680569,0.0007495099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042627906,0.0003608267,0.00059864274,0.0003098459,0.00030078104,0.000083394865,0.00023909868,0.00015956972,0.00005897658],"category_scores_gemma":[0.0047943513,0.00029743245,0.00026035774,0.00044003027,0.00015885911,0.00012209643,0.0001405436,0.00026343775,0.00006794062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13918172,0.027089419,0.4607629,0.0029987404,0.0077698594,0.024194978,0.0010282367,0.000018766941,0.026289841,0.002758053,0.21312931,0.09477819],"study_design_scores_gemma":[0.13015404,0.0014320719,0.8185326,0.0006392383,0.0017888652,0.000044403114,0.00018797896,0.00027412848,0.026336215,0.00033808936,0.01981499,0.00045739493],"about_ca_topic_score_codex":0.00021824538,"about_ca_topic_score_gemma":0.00012289741,"teacher_disagreement_score":0.3577697,"about_ca_system_score_codex":0.000100707475,"about_ca_system_score_gemma":0.00079997967,"threshold_uncertainty_score":0.9999478},"labels":[],"label_agreement":null},{"id":"W4408845871","doi":"10.1111/trf.18188","title":"Exchange transfusion and pre‐filter apheresis dilution for hyperviscosity syndrome refractory to conventional therapeutic plasma exchange in a patient with <scp>IgA</scp> multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Transfusion","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Hyperviscosity syndrome; Apheresis; Medicine; Hyperviscosity; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Complication; Surgery; Intensive care medicine; Blood viscosity; Internal medicine; Immunology; Monoclonal; Platelet; Monoclonal antibody; Antibody","score_opus":0.023101539445313797,"score_gpt":0.27414080437733984,"score_spread":0.25103926493202605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408845871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891513,0.00091341214,0.0043040942,0.000653768,0.00009880101,0.0043169674,0.00013339915,0.00006722618,0.00036105784],"genre_scores_gemma":[0.99596244,0.00091754884,0.0008997986,0.00023621297,0.000026054218,0.00096372317,0.00016966843,0.00003629645,0.0007882677],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99800515,0.00012352206,0.00032135553,0.0006093436,0.00044483054,0.0004957674],"domain_scores_gemma":[0.9989539,0.00035579113,0.000042750715,0.00027334937,0.000116468655,0.0002577384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021617104,0.00030012248,0.00042785943,0.00042352546,0.0002076394,0.000027649821,0.000085311,0.00017567523,0.00007586166],"category_scores_gemma":[0.000053633066,0.0002331818,0.00012106901,0.00040415084,0.00007200954,0.0001507074,0.000034392582,0.00021433918,0.000008713325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019270511,0.0053136335,0.23590185,0.0044743996,0.0007402591,0.00067037577,0.009719656,0.00003635144,0.12816659,0.000090452704,0.00063452363,0.59498143],"study_design_scores_gemma":[0.022435343,0.0052026627,0.94405663,0.0013927643,0.0002348835,0.00015014336,0.00052014046,0.0030468283,0.015287567,0.000066613546,0.007415501,0.00019092743],"about_ca_topic_score_codex":0.0007189576,"about_ca_topic_score_gemma":0.0034861653,"teacher_disagreement_score":0.7081548,"about_ca_system_score_codex":0.00019879066,"about_ca_system_score_gemma":0.00009081437,"threshold_uncertainty_score":0.95088774},"labels":[],"label_agreement":null},{"id":"W4408868147","doi":"10.1038/s41408-025-01243-7","title":"Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","year":2025,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Drug development; Internal medicine; Drug; Oncology; Intensive care medicine; Pharmacology; Biology","score_opus":0.07078477127089412,"score_gpt":0.39924263271318067,"score_spread":0.32845786144228656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408868147","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6386059,0.10944432,0.000058363894,0.025631702,0.15597369,0.0077887424,0.000546404,0.00016730776,0.06178355],"genre_scores_gemma":[0.27842954,0.065032825,0.0011367544,0.0005378402,0.005213002,0.00041641938,0.00024447707,0.00015835912,0.6488308],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99471194,0.0007805533,0.0020638984,0.00054632575,0.0011252776,0.00077203644],"domain_scores_gemma":[0.99676746,0.001037894,0.00092041545,0.000510342,0.00037950402,0.0003843763],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021526646,0.00047694184,0.0014073559,0.00081872445,0.00024591983,0.000057568137,0.0005164901,0.00059311447,0.0005975986],"category_scores_gemma":[0.001890017,0.0002950639,0.00035359175,0.0007762765,0.00017481612,0.000075834236,0.0001902,0.0065594246,0.000012763315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038954609,0.0027539188,0.1804667,0.000371717,0.0013155254,0.0030067214,0.0007858222,0.0000121173725,0.00001688793,0.0000016425182,0.7183467,0.08902675],"study_design_scores_gemma":[0.026371108,0.0006579021,0.6022682,0.012612891,0.0005377702,0.0010547661,0.0008057959,0.0002246173,0.00038332547,0.000012817884,0.3546867,0.00038407993],"about_ca_topic_score_codex":0.0014060055,"about_ca_topic_score_gemma":0.031019574,"teacher_disagreement_score":0.5870473,"about_ca_system_score_codex":0.000994016,"about_ca_system_score_gemma":0.01331059,"threshold_uncertainty_score":0.9999502},"labels":[],"label_agreement":null},{"id":"W4408889678","doi":"10.1158/1078-0432.ccr-24-3475","title":"Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Minimal residual disease; Clinical trial; Medicine; Oncology; Residual; Disease; Multiple myeloma; Selection (genetic algorithm); Internal medicine; Computer science; Machine learning; Algorithm; Leukemia","score_opus":0.23244624773717434,"score_gpt":0.53304227182326,"score_spread":0.30059602408608566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408889678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97219163,0.0018719719,0.00025656354,0.022368005,0.00016416526,0.002450449,0.00003816508,0.00003647483,0.00062260317],"genre_scores_gemma":[0.99256456,0.0034479967,0.00032860957,0.0006054629,0.00012211903,0.0005370104,0.000019903093,0.000022830596,0.0023515094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677086,0.00061492337,0.0004386987,0.00072471803,0.0006751076,0.0007756796],"domain_scores_gemma":[0.997543,0.0010707108,0.00002456586,0.00039455283,0.00023256455,0.00073463476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012565373,0.00022307219,0.000660926,0.000553908,0.00017699486,0.000063606094,0.00014195888,0.00017560343,0.000048003003],"category_scores_gemma":[0.0015817853,0.00015807376,0.000097144926,0.00068346807,0.0003606326,0.00006276767,0.00025416512,0.00063325616,0.000022313232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006643204,0.0012345568,0.7803825,0.0005230555,0.0010179711,0.00105327,0.0008539659,0.0002961912,0.00083541434,0.000407364,0.0013582151,0.20539427],"study_design_scores_gemma":[0.031038156,0.008101167,0.8878427,0.0020596774,0.00019032984,0.0000080668915,0.00119781,0.062151577,0.0027229474,0.0027425236,0.0015672882,0.0003777636],"about_ca_topic_score_codex":0.0028498715,"about_ca_topic_score_gemma":0.0056648003,"teacher_disagreement_score":0.20501651,"about_ca_system_score_codex":0.000841248,"about_ca_system_score_gemma":0.0009078353,"threshold_uncertainty_score":0.64460605},"labels":[],"label_agreement":null},{"id":"W4408985065","doi":"10.1016/j.clml.2025.03.014","title":"Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Legend Biotech; Johnson and Johnson","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine","score_opus":0.03591341014526184,"score_gpt":0.3351751832576492,"score_spread":0.2992617731123874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408985065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922399,0.0026086955,0.000033084183,0.002421618,0.00031195022,0.002029722,0.00018077009,0.00006411726,0.000110170295],"genre_scores_gemma":[0.9967914,0.0005796901,0.0005154764,0.0011446186,0.00007388844,0.00021415917,0.00032134543,0.000043493954,0.00031588762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958559,0.0005965682,0.0014121097,0.0008297593,0.00074355816,0.0005620905],"domain_scores_gemma":[0.9929666,0.004834912,0.00037017668,0.0010331125,0.00032929666,0.0004659127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062657904,0.0004800607,0.0012867677,0.00021188185,0.00016844587,0.000034559467,0.0003088486,0.00024938173,0.000031047035],"category_scores_gemma":[0.0041851536,0.00028961536,0.00028952418,0.00044130848,0.0007970576,0.00017386397,0.00032970062,0.00040072657,0.000015931213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007590243,0.0012441449,0.7642829,0.00010731363,0.0010951677,0.00015171723,0.00019740923,0.000003667568,0.000033648317,0.000035408815,0.00045818827,0.22480018],"study_design_scores_gemma":[0.03682359,0.0007862451,0.9587267,0.00070654036,0.00045305898,9.0555284e-7,0.00040370494,0.00066716236,0.00015427207,0.00026978867,0.00077216944,0.00023586111],"about_ca_topic_score_codex":0.00034993608,"about_ca_topic_score_gemma":0.00022113005,"teacher_disagreement_score":0.22456431,"about_ca_system_score_codex":0.00091044005,"about_ca_system_score_gemma":0.0008613139,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W4409045855","doi":"10.3390/curroncol32040204","title":"Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China","keywords":"Multiple myeloma; Medicine; Myeloid leukemia; Myeloid; Malignancy; Internal medicine; Oncology; Disease; Leukemia; Incidence (geometry); Bioinformatics; Immunology; Biology","score_opus":0.19674044904098312,"score_gpt":0.4909625340265438,"score_spread":0.2942220849855607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409045855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019441942,0.9768583,0.0003810962,0.000097395605,0.0005820527,0.0022879909,0.00018305091,0.000035579018,0.00013258851],"genre_scores_gemma":[0.004491684,0.9929388,0.0016045296,0.00015040838,0.000098831,0.0002658155,0.00027502628,0.000043547116,0.0001313599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966039,0.0006007109,0.0009131737,0.0010785015,0.00026222935,0.00054144877],"domain_scores_gemma":[0.99575067,0.0029577133,0.00016525321,0.00040235755,0.000058411326,0.00066561025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045809065,0.00055486616,0.0031197227,0.00048773954,0.000060546798,0.000030642826,0.00013816364,0.0005910056,0.000028354716],"category_scores_gemma":[0.0017894595,0.00041875467,0.00022324518,0.00022312705,0.00017709567,0.000032933232,0.0005875199,0.00067839737,0.000027209246],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010163305,0.0004575754,0.02493811,0.0058679115,0.00047911672,0.0005792961,0.00011625662,8.34177e-8,0.0000018953332,0.000071137445,0.00012787707,0.9672591],"study_design_scores_gemma":[0.025669781,0.0021617983,0.109562024,0.01319969,0.0042679636,0.00035874895,0.00012179318,0.00035719696,0.000008150532,0.001842156,0.8412421,0.0012086208],"about_ca_topic_score_codex":0.000092882365,"about_ca_topic_score_gemma":0.00009893871,"teacher_disagreement_score":0.9660505,"about_ca_system_score_codex":0.0004928095,"about_ca_system_score_gemma":0.0010128727,"threshold_uncertainty_score":0.99982643},"labels":[],"label_agreement":null},{"id":"W4409137118","doi":"10.2139/ssrn.5201850","title":"A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 Trial","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Daratumumab; Lenalidomide; Regimen; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine","score_opus":0.018183811027336457,"score_gpt":0.3012463703878101,"score_spread":0.28306255936047364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409137118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989181,0.0038660234,0.0009052586,0.0011037629,0.0001735943,0.0041119815,0.00006252717,0.000042237436,0.0005536036],"genre_scores_gemma":[0.99390095,0.002789809,0.00089538464,0.00009208035,0.0003710657,0.00037695674,0.00017976802,0.00007255237,0.0013214457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99393517,0.0004626568,0.00069451256,0.00086541503,0.0011242344,0.0029179917],"domain_scores_gemma":[0.99730206,0.000621464,0.00053014705,0.00080781156,0.0003426815,0.00039586713],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016979469,0.0007171448,0.0011550252,0.0005426098,0.00039654702,0.00020609373,0.00047887143,0.00033534187,0.0000309852],"category_scores_gemma":[0.0006599342,0.0004071437,0.00019406449,0.0004058556,0.0002747564,0.0001615229,0.00035101402,0.006914772,0.0000094145735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5630673,0.0060315104,0.32110727,0.00030570265,0.006652402,0.0008912638,0.0009957782,0.00026980042,0.000025365669,0.0005350443,0.00028108648,0.09983742],"study_design_scores_gemma":[0.91139966,0.014805397,0.06189937,0.0021756038,0.001343655,0.0005070612,0.0010402594,0.0011277304,0.00017932255,0.003384661,0.0012289921,0.00090828276],"about_ca_topic_score_codex":0.0016624249,"about_ca_topic_score_gemma":0.012347855,"teacher_disagreement_score":0.34833232,"about_ca_system_score_codex":0.0020194093,"about_ca_system_score_gemma":0.008383019,"threshold_uncertainty_score":0.99983805},"labels":[],"label_agreement":null},{"id":"W4409147719","doi":"10.1038/s41408-025-01259-z","title":"Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Cilag; Pharmacyclics; Genentech; National Institutes of Health; National Cancer Institute; University College London; National Institute for Health and Care Research; Ascentage Pharma; SkylineDx; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Celgene; Swedish Orphan Biovitrum; Array BioPharma; Kite Pharma; Gilead Sciences; BeiGene; Sanofi; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Progression-free survival; Dosing; Oncology; Surgery; Gastroenterology; Chemotherapy","score_opus":0.08100113878727644,"score_gpt":0.40975673512727917,"score_spread":0.32875559634000273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409147719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934024,0.0023129603,0.00011329048,0.0002970374,0.0006704638,0.0022101484,0.00005779663,0.0000158794,0.0009200007],"genre_scores_gemma":[0.99566066,0.001938519,0.000708055,0.000021319342,0.00048700577,0.0005446722,0.000035432695,0.000024017712,0.0005802874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750084,0.00023052825,0.0006405111,0.00028320096,0.0010556682,0.00028923393],"domain_scores_gemma":[0.99776256,0.00044372148,0.00040707263,0.0004175686,0.00083196524,0.00013709054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010582731,0.00020373038,0.0004173775,0.000403373,0.0002363999,0.000042631305,0.00025114475,0.000058019166,0.00018239846],"category_scores_gemma":[0.00021293291,0.00013109721,0.0002319584,0.0003291208,0.000083685634,0.00014450196,0.000030472569,0.00018816507,6.802862e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033112364,0.0062040607,0.58950347,0.000033985394,0.0032966486,0.00002870785,0.00094333466,0.000101809535,0.003220721,0.000057977948,0.00008154528,0.39321652],"study_design_scores_gemma":[0.03883728,0.004177864,0.9391941,0.0003457119,0.0026113733,0.000025470566,0.0011555183,0.0043596756,0.0061153723,0.00011406916,0.0029539834,0.00010960142],"about_ca_topic_score_codex":0.00088508095,"about_ca_topic_score_gemma":0.0032397727,"teacher_disagreement_score":0.39310694,"about_ca_system_score_codex":0.0006985452,"about_ca_system_score_gemma":0.00073592516,"threshold_uncertainty_score":0.5345989},"labels":[],"label_agreement":null},{"id":"W4409195656","doi":"10.1016/j.clml.2025.03.013","title":"Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Regeneron Pharmaceuticals","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine; Ranking (information retrieval); Intensive care medicine; Family medicine; Machine learning","score_opus":0.04914085767088743,"score_gpt":0.36332775307073184,"score_spread":0.3141868953998444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409195656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93892103,0.04994071,0.00015749363,0.0015978676,0.0013452941,0.0065135937,0.00015957153,0.00013839628,0.0012260249],"genre_scores_gemma":[0.9922391,0.002766448,0.0008073196,0.002005039,0.00024850023,0.00064003124,0.00035599162,0.00005846796,0.000879075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952239,0.00046927278,0.002142175,0.0007745322,0.0007740703,0.0006160611],"domain_scores_gemma":[0.9878342,0.009420556,0.00081264914,0.0010717179,0.0006045379,0.0002562989],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015751759,0.0004901281,0.0017556599,0.00018720965,0.00025969322,0.0000720699,0.00060161366,0.00032191997,0.000012623358],"category_scores_gemma":[0.019615347,0.00030834976,0.0014204425,0.0006753455,0.0003079831,0.00012409844,0.0001845966,0.00043108506,0.000017581275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026943514,0.0015335779,0.7644492,0.10704339,0.0066304,0.0010360545,0.00047925417,0.0000037635045,0.0009242398,0.0010425069,0.0065558534,0.10760744],"study_design_scores_gemma":[0.01168346,0.0004937485,0.8515609,0.12947693,0.0016653716,0.00006208044,0.00026992825,0.0019314444,0.00033314351,0.0003000732,0.0018743462,0.0003485699],"about_ca_topic_score_codex":0.00001447305,"about_ca_topic_score_gemma":0.000016954167,"teacher_disagreement_score":0.10725887,"about_ca_system_score_codex":0.00076571055,"about_ca_system_score_gemma":0.0011427087,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W4409210334","doi":"10.3390/cancers17071235","title":"Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"National Cancer Institute; Janssen Scientific Affairs","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Systematic review; Oncology; Internal medicine; MEDLINE; Biology","score_opus":0.06320102485982723,"score_gpt":0.40182482433069416,"score_spread":0.33862379947086696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409210334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050900377,0.98550904,0.0000012992765,0.00002566153,0.00018535745,0.013188976,0.00014821475,0.000072285824,0.00081827614],"genre_scores_gemma":[0.00013329284,0.9909665,0.00038196406,0.00012753684,0.00008006588,0.0038642618,0.0007371054,0.00009246103,0.0036168345],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9945968,0.0009312708,0.0014517916,0.0010356173,0.0012645869,0.0007199609],"domain_scores_gemma":[0.9951496,0.001713252,0.0008521262,0.0013898844,0.0005504527,0.00034466182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009753463,0.00082967995,0.0043975427,0.000871526,0.00010833969,0.00006922965,0.0003993561,0.00028270463,0.00006540037],"category_scores_gemma":[0.0046602003,0.00052406965,0.0005113522,0.002735656,0.00009105963,0.0002277102,0.00012513432,0.001239271,0.000052448995],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00022207599,0.000073732015,0.0021971797,0.8384339,0.00044116686,0.0002781937,0.000042600022,8.5153556e-7,4.491449e-8,0.0000027515434,0.00081743865,0.15749006],"study_design_scores_gemma":[0.0029616759,0.00051542633,0.0013081607,0.9687743,0.002957787,0.000011676163,0.000007729188,0.00002335204,1.2183693e-7,7.215646e-7,0.023054384,0.0003846258],"about_ca_topic_score_codex":0.00025031008,"about_ca_topic_score_gemma":0.00052545837,"teacher_disagreement_score":0.15710543,"about_ca_system_score_codex":0.009433838,"about_ca_system_score_gemma":0.0062586004,"threshold_uncertainty_score":0.9997211},"labels":[],"label_agreement":null},{"id":"W4409335490","doi":"10.1002/hon.70061","title":"Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis","year":2025,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Scientific Affairs","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Hazard ratio; Multiple myeloma; Oncology; Meta-analysis; Bortezomib; Randomized controlled trial; Cochrane Library; Dexamethasone; Surgery; Confidence interval","score_opus":0.097623608691779,"score_gpt":0.40854111592677966,"score_spread":0.31091750723500067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409335490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032332595,0.99000984,0.0000653164,0.0008809641,0.00007043367,0.0078249965,0.0003565943,0.0000924919,0.0003760125],"genre_scores_gemma":[0.0013785736,0.99003386,0.0034181152,0.00065857446,0.000035060864,0.0035103213,0.0005789283,0.000058793077,0.00032774732],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99081373,0.0031912911,0.0024498336,0.0019052214,0.0005410327,0.0010989176],"domain_scores_gemma":[0.9803923,0.01683003,0.0008059369,0.0009155258,0.0002218518,0.00083439663],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019419006,0.0014201727,0.020209398,0.0014597457,0.00019328197,0.00012359432,0.0003320688,0.0014290089,0.00013945914],"category_scores_gemma":[0.0046103173,0.0008634537,0.0016612293,0.0027835106,0.0005294067,0.0001587136,0.00033120665,0.0016536162,0.00001545881],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017526828,0.00081836106,0.00054201856,0.87723434,0.089133315,0.012636212,0.00011819227,3.3728188e-7,8.1218036e-7,0.0002622547,0.0003152749,0.0171862],"study_design_scores_gemma":[0.021954421,0.0013606371,0.00023621485,0.13774495,0.80097276,0.00536236,0.000061229584,0.000086689055,0.0000037638736,0.00005841917,0.031034587,0.0011239713],"about_ca_topic_score_codex":0.00013468978,"about_ca_topic_score_gemma":0.00060462696,"teacher_disagreement_score":0.7394894,"about_ca_system_score_codex":0.0002851251,"about_ca_system_score_gemma":0.00049909734,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4409419708","doi":"10.21203/rs.3.rs-6306816/v1","title":"Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"National Cancer Institute; National Institutes of Health; Rising Tide Foundation; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Bristol-Myers Squibb; Tow Foundation; Regeneron Pharmaceuticals; Moffitt Cancer Center; Karyopharm Therapeutics; Florida Department of Health; Celgene; University of South Florida; Amgen; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Foundation","keywords":"Epigenetics; Carcinogenesis; Multiple myeloma; Malignancy; Cancer research; Epigenetic therapy; Biology; Bioinformatics; DNA methylation; Computational biology; Immunology; Genetics; Gene; Gene expression","score_opus":0.10277268425088477,"score_gpt":0.4023976770324844,"score_spread":0.29962499278159965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409419708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96906376,0.023752023,0.0001890178,0.00063510844,0.000092358074,0.004523614,0.00055424904,0.00008954487,0.0011003461],"genre_scores_gemma":[0.97596246,0.013256637,0.005354248,0.00003171517,0.00012550909,0.0012383314,0.00021551663,0.000060918377,0.0037546519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396306,0.0009830791,0.00059621746,0.0014901063,0.0015712964,0.0013962223],"domain_scores_gemma":[0.9957441,0.0016977538,0.00009006798,0.0010099934,0.0007719079,0.00068619166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097085134,0.00053924427,0.0009933327,0.0015644053,0.00033585323,0.00013186371,0.00042475952,0.0005795652,0.00010534386],"category_scores_gemma":[0.0023613765,0.0004774665,0.0002173683,0.00083542865,0.00057115837,0.000059016806,0.0012272651,0.001984724,0.00003824085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036133532,0.0011421727,0.9595666,0.0047579175,0.00039779497,0.0012967056,0.0014206446,0.000075142016,0.0026123342,0.00006805617,0.00031674368,0.024732547],"study_design_scores_gemma":[0.0077296495,0.00035572724,0.97573423,0.0031399827,0.000026266462,0.0000053745944,0.000322274,0.0048557376,0.005861801,0.00031965284,0.0013082349,0.00034109008],"about_ca_topic_score_codex":0.0025172995,"about_ca_topic_score_gemma":0.007764354,"teacher_disagreement_score":0.024391456,"about_ca_system_score_codex":0.00094262976,"about_ca_system_score_gemma":0.0017383399,"threshold_uncertainty_score":0.9997677},"labels":[],"label_agreement":null},{"id":"W4409624317","doi":"10.1158/1538-7445.am2025-902","title":"Abstract 902: Examining the impact of chromosome 1q-located gamma secretase subunits in the resistance to BCMA-targeted therapies in multiple myeloma patients","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Gamma secretase; Multiple myeloma; Cancer research; Medicine; Chromosome; Genetics; Internal medicine; Oncology; Biology; Gene","score_opus":0.09377439422504756,"score_gpt":0.4112129885647848,"score_spread":0.3174385943397372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409624317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926132,0.0023349049,0.0000013027925,0.0013349061,0.000039661198,0.0024627112,0.00014373758,0.000016640231,0.0010529549],"genre_scores_gemma":[0.9980671,0.00033916943,0.00002452693,0.00009027603,0.00004093456,0.00081477495,0.000090972746,0.000027354827,0.0005049014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636924,0.0006781384,0.000473585,0.00044374133,0.0010963018,0.0009390013],"domain_scores_gemma":[0.9968794,0.0014796079,0.00007065134,0.0007958923,0.00059475086,0.00017969223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017269468,0.00023201574,0.00040951665,0.0007878087,0.0002080429,0.000060421604,0.00060917437,0.00010647275,0.00022839315],"category_scores_gemma":[0.0017997883,0.0001275567,0.00009333331,0.0031325337,0.00030343473,0.00011152921,0.00014871955,0.0008787241,0.000024068278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00456488,0.0007381968,0.92287487,0.0002424694,0.00025697565,0.00018928053,0.004901,0.00010020927,0.045882303,0.000018375256,0.0021235354,0.018107923],"study_design_scores_gemma":[0.004610725,0.00039562507,0.97953176,0.000764118,0.000007823297,8.1359525e-7,0.001162911,0.00013174527,0.01288401,0.000058810612,0.00035203263,0.00009960611],"about_ca_topic_score_codex":0.0091487365,"about_ca_topic_score_gemma":0.008133047,"teacher_disagreement_score":0.05665693,"about_ca_system_score_codex":0.00083981897,"about_ca_system_score_gemma":0.0008287695,"threshold_uncertainty_score":0.9974494},"labels":[],"label_agreement":null},{"id":"W4409624717","doi":"10.1158/1538-7445.am2025-3250","title":"Abstract 3250: Tumor-independent monitoring of minimal residual disease in multiple myeloma using cfDNA fragmentomics","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of British Columbia; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre; University of Toronto; University of New Brunswick; Dalhousie University; Vancouver General Hospital; Saint John Regional Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Medicine; Residual; Oncology; Internal medicine; Cancer research; Mathematics; Algorithm; Bone marrow","score_opus":0.12105039476548349,"score_gpt":0.4411958385278112,"score_spread":0.3201454437623277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409624717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953619,0.002391162,0.000008814444,0.0003671088,0.0001517969,0.0010344209,0.000067837704,0.000019617555,0.00059732643],"genre_scores_gemma":[0.99803245,0.00032145748,0.0004881538,0.000014160066,0.0001868385,0.00020377403,0.000017246744,0.00003049216,0.0007054312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996661,0.00014970082,0.00045718622,0.00051524997,0.0013211742,0.0008956693],"domain_scores_gemma":[0.99818105,0.0003857154,0.00006335761,0.00051905477,0.0003956613,0.0004551877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085525383,0.00019157409,0.00038898495,0.00092728174,0.00015922762,0.000045853936,0.00027026827,0.000088418936,0.00018607354],"category_scores_gemma":[0.00078590965,0.00017701183,0.00010090754,0.00084433245,0.00024242616,0.00012554337,0.00026654586,0.00071751926,0.000017352424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037468025,0.00052672584,0.88055426,0.0006570744,0.00013559045,0.0009079515,0.00015179018,0.0001197315,0.10550393,0.000027392556,0.00012864947,0.0075400905],"study_design_scores_gemma":[0.004316947,0.00009724944,0.87752116,0.0012957625,0.000025781206,0.000002165465,0.00038573984,0.0012402193,0.11478169,0.00008143923,0.00014503679,0.0001068122],"about_ca_topic_score_codex":0.0046695573,"about_ca_topic_score_gemma":0.00020092567,"teacher_disagreement_score":0.009277762,"about_ca_system_score_codex":0.0012660054,"about_ca_system_score_gemma":0.0019376128,"threshold_uncertainty_score":0.7218333},"labels":[],"label_agreement":null},{"id":"W4409785682","doi":"10.1182/blood.2024027873","title":"A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Active Biotech; Regeneron Pharmaceuticals; BeiGene; Sanofi; Genentech; Celgene; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Neutropenia; Adverse effect; Internal medicine; Refractory (planetary science); Multiple myeloma; Febrile neutropenia; Gastroenterology; Phases of clinical research; Progressive disease; Surgery; Clinical trial; Toxicity; Chemotherapy","score_opus":0.02022512990478543,"score_gpt":0.3084402270575456,"score_spread":0.28821509715276017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409785682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105173,0.00022623737,0.00015827357,0.000051490304,0.000060941504,0.0072663375,0.00006178976,0.000046224075,0.0010769955],"genre_scores_gemma":[0.9965349,0.0000117750815,0.001056672,0.000055553377,0.00002585759,0.0009800888,0.00014042435,0.000029398529,0.0011653746],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998267,0.00013915119,0.00042610947,0.00037241814,0.00046123736,0.00033407792],"domain_scores_gemma":[0.9982872,0.0006271608,0.00015282705,0.0004517452,0.00032608878,0.00015495597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000223604,0.00022269267,0.0007957654,0.00023998137,0.00009649025,0.00001545552,0.000104712286,0.000068144676,0.000048463102],"category_scores_gemma":[0.00114219,0.00015064109,0.00017798792,0.00023327005,0.00008826355,0.00006328031,0.000053995012,0.0001163041,0.000008595394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52458066,0.278753,0.15642883,0.00041786567,0.0060718735,0.00016839332,0.0013776672,0.0000030659378,0.0032296516,0.0000329906,0.00025493375,0.028681051],"study_design_scores_gemma":[0.9583481,0.017132351,0.015408722,0.0002160188,0.0014201985,0.000002525307,0.00029704702,0.0002215424,0.006420392,0.000035779187,0.00036808,0.00012925614],"about_ca_topic_score_codex":0.00018476791,"about_ca_topic_score_gemma":0.0000572056,"teacher_disagreement_score":0.4337674,"about_ca_system_score_codex":0.000058031797,"about_ca_system_score_gemma":0.00016367168,"threshold_uncertainty_score":0.61429656},"labels":[],"label_agreement":null},{"id":"W4409804269","doi":"10.1016/j.healun.2025.02.716","title":"Successful Management of Antibody Mediated Rejection with Daratumumab in a Critically Ill Child with Severe Intracranial Bleeding","year":2025,"lang":"en","type":"article","venue":"The Journal of Heart and Lung Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton; Stollery Children's Hospital","funders":"","keywords":"Critically ill; Daratumumab; Medicine; Intensive care medicine; Antibody; Immunology; Monoclonal antibody","score_opus":0.006251880383860497,"score_gpt":0.29220179075135516,"score_spread":0.2859499103674947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409804269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941535,0.00032339615,0.002520007,0.0018286413,0.000024406667,0.0002854003,0.000004512696,0.0000042925913,0.0008558343],"genre_scores_gemma":[0.9970243,0.0015404584,0.0013199454,0.00006277282,0.000017069378,0.0000019619324,0.000012202876,0.0000049080204,0.000016364327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992897,0.000058398633,0.00021753013,0.00006428334,0.0002548348,0.00011526691],"domain_scores_gemma":[0.99956906,0.00008409662,0.00005182341,0.00005148812,0.00019905891,0.000044459415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002912811,0.0000728428,0.00017934105,0.00017108326,0.000068848014,0.000010236393,0.000032431333,0.000027134673,0.000007687896],"category_scores_gemma":[0.000008399297,0.000039160233,0.000018756005,0.0002283683,0.000054361935,0.000117217285,0.0000031059026,0.00018264569,2.0948853e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07853074,0.0008313695,0.8712286,0.0046799537,0.0016510286,0.0021600467,0.0029293709,0.00025850005,0.031909514,0.00048060523,0.00004301182,0.0052973093],"study_design_scores_gemma":[0.010507693,0.0012037792,0.975471,0.0043638023,0.0007630924,0.0030190784,0.0010582954,0.0010228078,0.0024876932,0.000030456567,0.000013157493,0.0000590983],"about_ca_topic_score_codex":0.00007616986,"about_ca_topic_score_gemma":0.00008542282,"teacher_disagreement_score":0.1042425,"about_ca_system_score_codex":0.000027270695,"about_ca_system_score_gemma":0.000042704134,"threshold_uncertainty_score":0.1596908},"labels":[],"label_agreement":null},{"id":"W4409831630","doi":"10.14740/jh2031","title":"Aggressive Extramedullary Multiple Myeloma Presenting as Small Bowel Obstruction","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Defense Health Agency; U.S. Department of Defense","keywords":"Medicine; Multiple myeloma; Bowel obstruction; Dermatology; Pathology; Surgery; Internal medicine","score_opus":0.021319587260636107,"score_gpt":0.32200464751690744,"score_spread":0.30068506025627134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409831630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065083,0.00337062,0.00053071865,0.001993329,0.00052678224,0.00025948812,0.0000018820575,0.000018976722,0.0026473426],"genre_scores_gemma":[0.992139,0.00023085889,0.0060829776,0.00017420635,0.00013210683,0.000008614292,0.0000059038985,0.000013597293,0.0012127404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854296,0.000106831045,0.00057610654,0.00016766562,0.0002632392,0.00034322048],"domain_scores_gemma":[0.99833345,0.00036403676,0.00052797986,0.00020731753,0.0003681047,0.00019910143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001911935,0.00014415236,0.0004951497,0.0004022845,0.0001003214,0.00002016554,0.00013592932,0.00015459575,0.00011627031],"category_scores_gemma":[0.002150573,0.0001096809,0.00020503753,0.00018650235,0.000105272535,0.00008900384,0.000069636,0.00042904427,0.00003287072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022753861,0.0006486323,0.9156886,0.00047699388,0.001326665,0.016684048,0.00029771752,0.00001189822,0.0073989853,0.0013836642,0.003569964,0.050237454],"study_design_scores_gemma":[0.022721117,0.001605047,0.7135905,0.0022801359,0.00071691006,0.09671594,0.0016432959,0.0018050647,0.1382883,0.007432638,0.012833844,0.00036718498],"about_ca_topic_score_codex":0.000028255929,"about_ca_topic_score_gemma":0.000015451033,"teacher_disagreement_score":0.20209809,"about_ca_system_score_codex":0.000091505106,"about_ca_system_score_gemma":0.00034880213,"threshold_uncertainty_score":0.4472657},"labels":[],"label_agreement":null},{"id":"W4410036009","doi":"10.3390/curroncol32050268","title":"Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Karyopharm Therapeutics","keywords":"Daratumumab; Medicine; Regimen; Pomalidomide; Carfilzomib; Multiple myeloma; Oncology; Internal medicine; Bortezomib; Clinical trial; Refractory (planetary science)","score_opus":0.05683108286331712,"score_gpt":0.37247414036209187,"score_spread":0.31564305749877475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410036009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962688,0.00015062965,0.00012440409,0.00033232916,0.00014000748,0.0016158771,0.00017682415,0.00008015476,0.0011109663],"genre_scores_gemma":[0.9974792,0.00014489815,0.00056183833,0.000040034243,0.00003217815,0.00027789708,0.00073417864,0.00003692269,0.0006928499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977981,0.0002498112,0.0004890288,0.00057306833,0.00037478458,0.0005151936],"domain_scores_gemma":[0.9978593,0.00078190904,0.0002688023,0.00047352657,0.00033183445,0.00028464213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015796883,0.00041087318,0.0011227009,0.0005186457,0.00011239676,0.0000135704295,0.000097928336,0.00011676702,0.00004996574],"category_scores_gemma":[0.00012913946,0.00024896068,0.0001048365,0.00037515245,0.0002043269,0.00007004786,0.00004869434,0.00024420428,0.0000038896114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012577249,0.0038283828,0.91183364,0.00016695182,0.0008705907,0.000108453,0.00014988246,0.0000037812142,0.000026696785,0.000025994346,0.000058351074,0.07035],"study_design_scores_gemma":[0.054196075,0.009610478,0.9295801,0.0003202005,0.0005024638,0.0000018311721,0.00014719911,0.00042539925,0.00039847783,0.0000025855531,0.004629841,0.00018533575],"about_ca_topic_score_codex":0.0015101881,"about_ca_topic_score_gemma":0.004464287,"teacher_disagreement_score":0.07016466,"about_ca_system_score_codex":0.00077984284,"about_ca_system_score_gemma":0.00064671395,"threshold_uncertainty_score":0.99999624},"labels":[],"label_agreement":null},{"id":"W4410197384","doi":"10.1016/j.clml.2025.05.006","title":"Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"Janssen Canada; Johnson and Johnson","keywords":"Medicine; Multiple myeloma; Confidence interval; Attrition; Health care; Internal medicine; Emergency medicine","score_opus":0.019803092311802772,"score_gpt":0.3308765082936681,"score_spread":0.31107341598186533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410197384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378234,0.00006822948,0.000037589125,0.00057775766,0.00033268888,0.0049915835,0.00009437277,0.000029756266,0.000085705666],"genre_scores_gemma":[0.99526995,0.000013008941,0.002430726,0.00076415436,0.000075302174,0.00059773086,0.0001975415,0.000049521874,0.0006020346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957503,0.0003245229,0.0017865106,0.0009229364,0.0006041163,0.0006115985],"domain_scores_gemma":[0.9954793,0.0021896583,0.00032727534,0.00079852546,0.0005221899,0.00068309094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083519256,0.00040220915,0.0013137133,0.00026320288,0.00012781253,0.000031232103,0.00025545724,0.00032631902,0.000009522691],"category_scores_gemma":[0.0040165656,0.0003119584,0.00023297833,0.00039010413,0.00025613522,0.0001668026,0.00018151026,0.00025998274,0.00000450922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051445384,0.0015000948,0.69885105,0.00016720209,0.00028318228,0.000034410707,0.00006257741,0.0000025730442,0.000021079626,0.000053970267,0.00020337167,0.29367596],"study_design_scores_gemma":[0.03798883,0.004471367,0.9546806,0.0004504721,0.00011315495,0.000002836293,0.00006393548,0.00052633986,0.00019360104,0.00005602711,0.0011841013,0.00026872457],"about_ca_topic_score_codex":0.07526652,"about_ca_topic_score_gemma":0.20461984,"teacher_disagreement_score":0.29340723,"about_ca_system_score_codex":0.0011908244,"about_ca_system_score_gemma":0.00406297,"threshold_uncertainty_score":0.99993324},"labels":[],"label_agreement":null},{"id":"W4410214356","doi":"10.1016/j.clinbiochem.2025.110941","title":"Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory’s experience: Unsatisfactory assay reproducibility","year":2025,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; London Health Sciences Centre; Western University","funders":"","keywords":"Reproducibility; Enzyme; Immunology; Antigen; Chemistry; Molecular biology; Medicine; Chromatography; Biochemistry; Biology","score_opus":0.06622016257871215,"score_gpt":0.37663203634715675,"score_spread":0.3104118737684446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410214356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947335,0.0025150066,0.000086934444,0.00057132525,0.0001690744,0.00061108527,0.00009414593,0.000038478458,0.0011804496],"genre_scores_gemma":[0.9983598,0.0003096201,0.0004910612,0.000121084726,0.000063227555,0.000052981773,0.00010266368,0.0000121751345,0.00048737702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963041,0.00034451144,0.00120449,0.0010949062,0.00070625596,0.00034574035],"domain_scores_gemma":[0.9972422,0.00033441646,0.00021780778,0.0015576219,0.00044827897,0.00019966392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045345305,0.00021586647,0.00059388875,0.000060901417,0.000056822708,0.00001902074,0.00019500044,0.00033457507,0.00014518519],"category_scores_gemma":[0.0065861405,0.00019658587,0.0001646307,0.00034412526,0.00023624982,0.000058925107,0.00012165122,0.0005310755,0.000008323509],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041186687,0.001464181,0.47649992,0.00027160795,0.000099367506,0.000011112321,0.00005054892,3.3533826e-7,0.51549494,0.0000013695411,0.0007977691,0.0048969886],"study_design_scores_gemma":[0.0019722432,0.00007518066,0.37844935,0.00024422078,0.000027432088,4.365907e-7,0.00012955558,0.00005126054,0.6187098,0.000009587218,0.00023825077,0.000092664784],"about_ca_topic_score_codex":0.00007467626,"about_ca_topic_score_gemma":0.000011086693,"teacher_disagreement_score":0.10321489,"about_ca_system_score_codex":0.00039079614,"about_ca_system_score_gemma":0.0006982011,"threshold_uncertainty_score":0.80165386},"labels":[],"label_agreement":null},{"id":"W4410266714","doi":"10.1002/jha2.70045","title":"A Single‐Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q Abnormalities","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Abnormality; Internal medicine; Multiple myeloma; Cohort; Oncology; Cancer; Gastroenterology","score_opus":0.03853036811070795,"score_gpt":0.31961650582521733,"score_spread":0.2810861377145094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410266714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278283,0.000057317233,0.00010887383,0.0003343547,0.00012490914,0.0037248305,0.00019979318,0.00008066601,0.0025864255],"genre_scores_gemma":[0.98979354,0.0000037130517,0.00076637394,0.00018884477,0.00007522358,0.00069372926,0.00036508185,0.000030277342,0.008083216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857503,0.000049123355,0.00023477431,0.00038701316,0.0003300638,0.0004239992],"domain_scores_gemma":[0.999009,0.00019417284,0.000049833572,0.00041614549,0.0001723605,0.00015846461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006152761,0.0002649773,0.0003893334,0.0001835286,0.00015067577,0.000033473265,0.00007599924,0.00004829893,0.00004707344],"category_scores_gemma":[0.000103541024,0.00016585723,0.00010916889,0.00012860482,0.0000481302,0.000062464715,0.000034227673,0.00007537644,0.000037882746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007679021,0.014218936,0.9467573,0.000047970723,0.0008935191,0.00007123094,0.00078092807,0.00000214412,0.000033125267,0.000022680015,0.0008283085,0.028664825],"study_design_scores_gemma":[0.054185383,0.01622125,0.9146286,0.0001731324,0.0001899595,0.0000025936733,0.00089394447,0.000128252,0.0019749636,0.0000120000905,0.01143027,0.00015963157],"about_ca_topic_score_codex":0.00016117557,"about_ca_topic_score_gemma":0.00035107273,"teacher_disagreement_score":0.046506364,"about_ca_system_score_codex":0.00039170505,"about_ca_system_score_gemma":0.000084438136,"threshold_uncertainty_score":0.6763461},"labels":[],"label_agreement":null},{"id":"W4410290330","doi":"10.21203/rs.3.rs-6556935/v1","title":"Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment : diagnostic and prognostic impact","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Institut National Du Cancer; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Multiple myeloma; Medicine; Radiology; Nuclear medicine; PET-CT; Positron emission tomography; Internal medicine","score_opus":0.05728324813926567,"score_gpt":0.44155350886112144,"score_spread":0.38427026072185577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410290330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97896606,0.00475034,0.0006189186,0.0010234186,0.00021296518,0.0124105085,0.0010775526,0.00023785223,0.0007023601],"genre_scores_gemma":[0.98620415,0.0031295926,0.0050187344,0.000024828285,0.00017594024,0.002610343,0.0013140304,0.0001323274,0.0013900521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9898122,0.0013901216,0.0010978922,0.00219171,0.0028420156,0.0026660808],"domain_scores_gemma":[0.9759775,0.01935301,0.00020705546,0.0017651023,0.0012297583,0.0014676214],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022434453,0.0010500287,0.0017084356,0.004246709,0.00042825378,0.0005108072,0.0006978277,0.00052946445,0.00016386902],"category_scores_gemma":[0.03016819,0.0008868938,0.0004599592,0.0025522062,0.00047046092,0.00016779733,0.0029559385,0.0050794613,0.000109267494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006940432,0.0032229505,0.9425723,0.0062285946,0.00077371125,0.016996771,0.00027111178,0.0043925634,0.0003419763,0.000014797589,0.0002678489,0.024223354],"study_design_scores_gemma":[0.007457673,0.0014024006,0.75445056,0.0062582768,0.00012316731,0.00014634099,0.00033765275,0.22870183,0.00018107372,0.000091223366,0.0003036603,0.00054614345],"about_ca_topic_score_codex":0.0051851654,"about_ca_topic_score_gemma":0.0009510004,"teacher_disagreement_score":0.22430927,"about_ca_system_score_codex":0.0029811612,"about_ca_system_score_gemma":0.0031472968,"threshold_uncertainty_score":0.9993582},"labels":[],"label_agreement":null},{"id":"W4410429348","doi":"10.1038/s41409-025-02626-x","title":"Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients","year":2025,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Multiple myeloma; Transplantation; Immunopathology; Minimal residual disease; Oncology; Internal medicine; Surgery; Bone marrow","score_opus":0.015297808761671106,"score_gpt":0.2569560206941432,"score_spread":0.24165821193247208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410429348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766853,0.0008959806,0.00019301243,0.01751023,0.00019595002,0.0028639594,0.0014410785,0.000068775065,0.0001457573],"genre_scores_gemma":[0.98165816,0.0011576995,0.0002495422,0.0062774313,0.00012337015,0.0003628761,0.009777556,0.00006445099,0.0003289111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964028,0.0003739539,0.0008071853,0.0007511908,0.0009983707,0.0006664697],"domain_scores_gemma":[0.99857825,0.0005626366,0.00018295426,0.00034169081,0.000106642015,0.00022784526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022679557,0.00052105583,0.0009300145,0.000674203,0.00008591386,0.00003366325,0.00013815225,0.00048366634,0.0000280784],"category_scores_gemma":[0.0001497573,0.000475917,0.00023524431,0.00026795937,0.00006618891,0.000107493885,0.000015894728,0.00074585516,0.000004644817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014344229,0.00037615822,0.97156584,0.005903241,0.00038635996,0.015034168,0.00039101476,0.000024797477,0.00037643974,0.000005345187,0.0017010862,0.0028011107],"study_design_scores_gemma":[0.0119361,0.00042885175,0.9795969,0.005000483,0.0017550285,0.000040120434,0.000012355286,0.00014771301,0.0003765804,0.000051683637,0.00029327997,0.0003608887],"about_ca_topic_score_codex":0.00077644555,"about_ca_topic_score_gemma":0.00038260486,"teacher_disagreement_score":0.014994048,"about_ca_system_score_codex":0.00015543109,"about_ca_system_score_gemma":0.0003925967,"threshold_uncertainty_score":0.9997693},"labels":[],"label_agreement":null},{"id":"W4410452393","doi":"10.1016/j.jtct.2025.05.008","title":"Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Paula and Rodger Riney Foundation; American Honda Motor; University of Texas MD Anderson Cancer Center; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Oncology; Surgery; Internal medicine","score_opus":0.01285890529037351,"score_gpt":0.27360771933720934,"score_spread":0.2607488140468358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410452393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926875,0.00021822799,0.00561958,0.0001271906,0.000032079675,0.00073494366,0.000047623605,0.00004641878,0.0004863947],"genre_scores_gemma":[0.9972296,0.0011289464,0.000834807,0.0001166295,0.000005004585,0.000029855973,0.00042464063,0.000015123645,0.00021539447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990142,0.00005572629,0.00026394194,0.00022082118,0.00025063026,0.00019468299],"domain_scores_gemma":[0.9994741,0.00015660998,0.000069582675,0.00013040961,0.000086600274,0.00008270045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068559195,0.00016647424,0.00031285224,0.00017710884,0.000103677216,0.000013008959,0.00004621891,0.00006285106,0.000029763842],"category_scores_gemma":[0.000007357676,0.000117482734,0.000059993286,0.00014934396,0.000078985475,0.00008009667,0.0000021571784,0.000086167674,0.0000028901263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004687188,0.00041994438,0.95908976,0.0005359055,0.00037585874,0.0000814671,0.0010448756,0.000012736231,0.008620939,0.0001451354,0.0000021950798,0.024984019],"study_design_scores_gemma":[0.01768438,0.00050801795,0.9019084,0.00019936783,0.00012076598,0.000009040446,0.00007944045,0.00018294598,0.07916267,0.00003265005,0.000015321433,0.00009701309],"about_ca_topic_score_codex":0.00005977717,"about_ca_topic_score_gemma":0.000073068935,"teacher_disagreement_score":0.07054173,"about_ca_system_score_codex":0.000021514921,"about_ca_system_score_gemma":0.00009308516,"threshold_uncertainty_score":0.47908068},"labels":[],"label_agreement":null},{"id":"W4410598538","doi":"10.51731/cjht.2025.1130","title":"Daratumumab (Darzalex SC)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; Psychology; Medicine; Internal medicine; Multiple myeloma","score_opus":0.035072396872024375,"score_gpt":0.354769225012068,"score_spread":0.31969682814004363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410598538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39484134,0.28771183,0.00081699615,0.29639366,0.0010658136,0.0011814749,0.000052332965,0.0002891547,0.017647378],"genre_scores_gemma":[0.99725825,0.0005725385,0.0009953217,0.00051288935,0.0000065949366,0.000004715018,0.0000029702198,0.000006756181,0.00063996954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988507,0.00003348932,0.00038280303,0.000105739564,0.00015111954,0.00047616693],"domain_scores_gemma":[0.9992077,0.000041562856,0.0001367685,0.0002552089,0.00020192104,0.00015684539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034622813,0.00009703788,0.00034910368,0.0010797587,0.00025440863,0.000024532606,0.00020609934,0.000108531895,0.000038583836],"category_scores_gemma":[0.0008727453,0.00007373232,0.000077838245,0.0004625019,0.00019680965,0.000058557645,0.00001844732,0.0004488134,0.000015561938],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005627479,0.000033011907,0.05171574,0.0001371157,0.00013007227,0.00083714415,0.000047400372,0.0000010030446,0.000029598823,0.0018576831,0.017594561,0.9275604],"study_design_scores_gemma":[0.0038737503,0.0013650857,0.23973586,0.0013737199,0.000044107055,0.00082322885,0.0021174313,0.000031989213,0.0020493928,0.0055905385,0.74285346,0.00014144518],"about_ca_topic_score_codex":0.003368817,"about_ca_topic_score_gemma":0.0032043068,"teacher_disagreement_score":0.92741895,"about_ca_system_score_codex":0.00063717633,"about_ca_system_score_gemma":0.006285821,"threshold_uncertainty_score":0.9993476},"labels":[],"label_agreement":null},{"id":"W4410644984","doi":"10.51731/cjht.2025.1132","title":"Pemigatinib (Pemazyre)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.03601682565298907,"score_gpt":0.3585972738525122,"score_spread":0.32258044819952314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410644984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5082622,0.15914978,0.0007177377,0.32056275,0.0006880754,0.0009265955,0.000032735075,0.00021872918,0.009441411],"genre_scores_gemma":[0.99681246,0.00045529363,0.0015385858,0.0006335745,0.00000586368,0.000004959602,0.000002367434,0.0000058692476,0.0005410034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894613,0.00003233477,0.00038345705,0.000090887,0.00013342974,0.0004137424],"domain_scores_gemma":[0.99925447,0.000057008736,0.0001415822,0.00021684906,0.00018973558,0.00014034745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038051401,0.000084691885,0.0003235747,0.00083741866,0.00016654491,0.000018237737,0.00017541165,0.000096090014,0.000038564518],"category_scores_gemma":[0.0011751584,0.00006365301,0.000073584044,0.00039239778,0.00017079414,0.00004490332,0.000014455672,0.0003945661,0.000012128962],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003554375,0.000025641368,0.08676213,0.00016494516,0.000107369575,0.000525122,0.00006347073,8.248557e-7,0.00003401282,0.0014895529,0.013145177,0.8976462],"study_design_scores_gemma":[0.004650006,0.0016330832,0.31651807,0.0020743313,0.000055814966,0.00094191014,0.004428106,0.000040563675,0.004027571,0.011803502,0.6536544,0.0001726652],"about_ca_topic_score_codex":0.003297409,"about_ca_topic_score_gemma":0.002172777,"teacher_disagreement_score":0.8974736,"about_ca_system_score_codex":0.00046200148,"about_ca_system_score_gemma":0.0058395597,"threshold_uncertainty_score":0.9997964},"labels":[],"label_agreement":null},{"id":"W4410707587","doi":"10.1016/j.blre.2025.101305","title":"Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies","year":2025,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Université de Sherbrooke","keywords":"Pathophysiology; Multiple myeloma; Medicine; Disease; Bone disease; Intensive care medicine; Pathology; Internal medicine; Osteoporosis","score_opus":0.0549185626342033,"score_gpt":0.3809709815167961,"score_spread":0.3260524188825928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410707587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035165765,0.99185264,0.000018163768,0.00018421066,0.000283088,0.0063329386,0.0004807732,0.000103457554,0.0007095513],"genre_scores_gemma":[0.0000036338379,0.9873946,0.0028917538,0.00062323676,0.00085777347,0.0022694245,0.0017410227,0.00009387925,0.0041247127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551725,0.0008274707,0.0013620197,0.0011722745,0.00038176074,0.0007392018],"domain_scores_gemma":[0.99648255,0.00055258337,0.0004300895,0.0016116131,0.00010913929,0.00081400963],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004187316,0.0008940257,0.005309843,0.00039132766,0.00015592815,0.00005109974,0.00040816682,0.00030834958,0.00050659425],"category_scores_gemma":[0.0015245687,0.00056603824,0.0016626175,0.0007174394,0.00006924072,0.000044260363,0.00034120915,0.00060726225,0.0018323032],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047598736,0.0003845935,0.00005116175,0.045560222,0.000848158,0.000599641,0.00003883377,1.4088351e-8,0.0000081863445,0.000012825241,0.0031305708,0.9493182],"study_design_scores_gemma":[0.00081770966,0.00016358827,0.00015631753,0.09176434,0.004879997,0.000014550543,0.0000039478637,8.4457025e-7,0.0000021021835,0.00003461608,0.9018011,0.00036087818],"about_ca_topic_score_codex":0.000037763566,"about_ca_topic_score_gemma":0.000004828018,"teacher_disagreement_score":0.9489573,"about_ca_system_score_codex":0.00010989624,"about_ca_system_score_gemma":0.00073646446,"threshold_uncertainty_score":0.9996791},"labels":[],"label_agreement":null},{"id":"W4410795567","doi":"10.1200/jco.2025.43.16_suppl.7516","title":"Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Johnson and Johnson","keywords":"Lenalidomide; Medicine; Daratumumab; Bortezomib; Multiple myeloma; Dexamethasone; Subgroup analysis; Oncology; Internal medicine; Confidence interval","score_opus":0.05493743037109683,"score_gpt":0.432347701128864,"score_spread":0.3774102707577672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973591,0.00023003406,0.00011061051,0.00061160274,0.00015514357,0.0012836849,0.000055920875,0.000004295452,0.00018963181],"genre_scores_gemma":[0.9982558,0.00035334393,0.0006527396,0.00056142564,0.00004699036,0.000029786626,0.00006376745,0.0000138861315,0.000022245342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99423975,0.0013476871,0.002795211,0.00037365893,0.00082459615,0.00041907927],"domain_scores_gemma":[0.9914871,0.006202956,0.0010999396,0.00036929143,0.0005488661,0.00029184282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003066099,0.0002586112,0.0025447642,0.0011064293,0.00005630367,0.0000183713,0.00030656176,0.00022898972,0.000029582234],"category_scores_gemma":[0.0035811907,0.00014803886,0.00036516527,0.0015274741,0.0002561314,0.00016117161,0.000057464214,0.0009960681,0.0000010941841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062412694,0.023271853,0.86250114,0.000040994106,0.0026360073,0.0009437215,0.0007860351,0.0000700116,0.000004177486,0.0000038246485,0.00016391865,0.04716559],"study_design_scores_gemma":[0.17176147,0.018006958,0.80670863,0.00013694499,0.0018968207,0.000003864847,0.00041147176,0.00065022527,0.000012401878,0.00001250583,0.00030733552,0.00009133844],"about_ca_topic_score_codex":0.0011496528,"about_ca_topic_score_gemma":0.007180542,"teacher_disagreement_score":0.109348774,"about_ca_system_score_codex":0.00024076519,"about_ca_system_score_gemma":0.0008479057,"threshold_uncertainty_score":0.60368496},"labels":[],"label_agreement":null},{"id":"W4410795580","doi":"10.1200/jco.2025.43.16_suppl.7515","title":"Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Oncology; Bortezomib; Multiple myeloma; Internal medicine; Lenalidomide; Refractory (planetary science)","score_opus":0.061370792376647235,"score_gpt":0.39533056254890103,"score_spread":0.3339597701722538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322,0.0007576331,0.000083817715,0.0037001332,0.00013483687,0.00177057,0.00015380325,0.000023109238,0.00015614445],"genre_scores_gemma":[0.9912167,0.0007529371,0.006297298,0.0007674202,0.00030304817,0.00006118324,0.00010023263,0.000046129706,0.00045502227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99140733,0.0032726303,0.0027507886,0.00086858275,0.0010054418,0.00069520215],"domain_scores_gemma":[0.9725695,0.02298172,0.0019750835,0.000690419,0.00062704907,0.0011561848],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037685644,0.00054371497,0.0035787506,0.0006706948,0.00020408718,0.00007772632,0.00031894236,0.00053097226,0.00010191615],"category_scores_gemma":[0.017108008,0.0002827989,0.00040940213,0.0012405257,0.0010025253,0.00030852674,0.00020907426,0.0017260464,0.0000032448559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43590084,0.002804661,0.5323374,0.000026765389,0.0034011672,0.0021210269,0.00009516499,0.000009547165,0.000021461741,0.00000301306,0.00024828335,0.023030628],"study_design_scores_gemma":[0.26733506,0.021600768,0.70457464,0.00030683493,0.0046588355,0.000033739663,0.00024111824,0.000494696,0.00006095724,0.000027281645,0.00046416273,0.00020186052],"about_ca_topic_score_codex":0.0020356635,"about_ca_topic_score_gemma":0.007945062,"teacher_disagreement_score":0.17223725,"about_ca_system_score_codex":0.00049639534,"about_ca_system_score_gemma":0.0031762235,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W4410803893","doi":"10.1200/jco.2025.43.16_suppl.e19504","title":"Tocilizumab prophylaxis for outpatient administration of teclistamab in relapsed/refractory multiple myeloma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Tocilizumab; Multiple myeloma; Refractory (planetary science); Internal medicine; Oncology; Rheumatoid arthritis","score_opus":0.11591799416245513,"score_gpt":0.4818491829674907,"score_spread":0.36593118880503556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938344,0.00039115053,0.00032739106,0.0019962713,0.000625673,0.00091596204,0.000016676746,0.0000051525035,0.0018873352],"genre_scores_gemma":[0.99303955,0.00012464973,0.005830792,0.00019213083,0.0001742729,0.00003442924,0.000010117602,0.000009193754,0.00058487064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99637365,0.0003228213,0.0025350123,0.00018883025,0.00034750273,0.0002321976],"domain_scores_gemma":[0.9939123,0.0037905958,0.0011378721,0.00020601036,0.0007343025,0.00021892699],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021079143,0.000118905664,0.0011967241,0.00030115116,0.000028106107,0.0000047292356,0.00013524292,0.00041693228,0.000034576482],"category_scores_gemma":[0.018227614,0.00008516095,0.00044522726,0.00020110719,0.00016974795,0.00006390751,0.000037187,0.00073099,0.0000034860216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07527791,0.010481208,0.33517146,0.00031502705,0.00046510925,0.0004947909,0.00011175941,0.000010406504,0.0007321002,0.00021168597,0.0014082394,0.5753203],"study_design_scores_gemma":[0.049219824,0.081519514,0.837229,0.00036264415,0.00016946689,0.000045794717,0.00023289646,0.0005315699,0.0017172426,0.0006387132,0.028245702,0.000087613276],"about_ca_topic_score_codex":0.000032729477,"about_ca_topic_score_gemma":0.00027473917,"teacher_disagreement_score":0.5752327,"about_ca_system_score_codex":0.00034413967,"about_ca_system_score_gemma":0.0035723646,"threshold_uncertainty_score":0.99004227},"labels":[],"label_agreement":null},{"id":"W4410809758","doi":"10.1200/jco.2025.43.16_suppl.7532","title":"Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology","score_opus":0.10576998602998161,"score_gpt":0.44522419343433833,"score_spread":0.3394542074043567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723227,0.0015040693,0.00009084178,0.021600889,0.001021964,0.0011739264,0.00014113366,0.000020987443,0.0021234793],"genre_scores_gemma":[0.9870145,0.0052591544,0.00308315,0.0027371647,0.00085423765,0.00002959486,0.00013646432,0.000025745861,0.00085998815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99281895,0.001664528,0.0038434106,0.00050672924,0.00058275566,0.00058363157],"domain_scores_gemma":[0.96983206,0.027461326,0.0012100923,0.0004673304,0.00039282648,0.00063635106],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005794081,0.0003102572,0.0022925704,0.00030806972,0.000108646906,0.000041097406,0.00037388652,0.0006615951,0.00008750536],"category_scores_gemma":[0.01813648,0.00018604069,0.00047402922,0.0005025229,0.0003900294,0.00016562367,0.00010747924,0.0018840223,0.000027566077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5048602,0.015137386,0.17876767,0.00002748697,0.0016322996,0.00564099,0.0002658583,0.000007995601,0.00018017822,0.00002905321,0.023250768,0.2702001],"study_design_scores_gemma":[0.5426465,0.004834322,0.41044274,0.00029244018,0.00048488198,0.00007447872,0.00012285406,0.0007254308,0.00016775254,0.00036450263,0.039718434,0.00012562424],"about_ca_topic_score_codex":0.0022115035,"about_ca_topic_score_gemma":0.004006943,"teacher_disagreement_score":0.2700745,"about_ca_system_score_codex":0.00020733752,"about_ca_system_score_gemma":0.0019286883,"threshold_uncertainty_score":0.9901342},"labels":[],"label_agreement":null},{"id":"W4410809877","doi":"10.1200/jco.2025.43.16_suppl.7529","title":"Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Johnson and Johnson","keywords":"Medicine; Lenalidomide; Daratumumab; Bortezomib; Multiple myeloma; Dexamethasone; Oncology; Internal medicine","score_opus":0.10313142747771947,"score_gpt":0.46795437639282544,"score_spread":0.36482294891510597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98926383,0.0029052028,0.0017983452,0.0029262132,0.00088585005,0.0012957215,0.00010609797,0.000027311433,0.00079141965],"genre_scores_gemma":[0.9880449,0.0068872403,0.0030097899,0.0010369907,0.0005859886,0.000054414093,0.000100377125,0.000035110344,0.00024518275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99151593,0.0015812713,0.004490997,0.0007199755,0.0008077018,0.00088408997],"domain_scores_gemma":[0.98781663,0.008943037,0.0012164753,0.0005186345,0.00040907785,0.0010961667],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043341443,0.00048517264,0.0043358007,0.0014253941,0.00012854871,0.00005455532,0.00040545786,0.0007395522,0.0001550958],"category_scores_gemma":[0.0046979114,0.00036867824,0.0012985736,0.0013026064,0.000429461,0.00020482167,0.00006789174,0.0017662339,0.000012582269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45702335,0.008240245,0.43280593,0.00012535577,0.005120351,0.009561783,0.00021681724,0.000060136696,0.0009131385,0.000021106247,0.00077234703,0.085139446],"study_design_scores_gemma":[0.5269048,0.019140324,0.43663287,0.00036406887,0.005206477,0.00030386014,0.0001157694,0.002579545,0.0007742299,0.0001575576,0.007514096,0.00030638615],"about_ca_topic_score_codex":0.00052652886,"about_ca_topic_score_gemma":0.0027889623,"teacher_disagreement_score":0.084833056,"about_ca_system_score_codex":0.00029385617,"about_ca_system_score_gemma":0.0021465104,"threshold_uncertainty_score":0.9998765},"labels":[],"label_agreement":null},{"id":"W4410809998","doi":"10.1200/jco.2025.43.16_suppl.7546","title":"DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Subgroup analysis; Oncology; Refractory (planetary science); Confidence interval","score_opus":0.036353756517859694,"score_gpt":0.38051493281884136,"score_spread":0.34416117630098164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554837,0.0019721386,0.000067622015,0.00036669703,0.00022201838,0.0016221436,0.000047245045,0.000012977033,0.00014079029],"genre_scores_gemma":[0.99377555,0.0017828596,0.003898715,0.00018072505,0.00010479369,0.000041617375,0.000034667133,0.000044053424,0.00013704548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914981,0.0022798516,0.0035630125,0.0008750723,0.0010488709,0.0007350997],"domain_scores_gemma":[0.9894195,0.00631729,0.0022703118,0.00065698486,0.000599961,0.00073591986],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0040643634,0.0005211301,0.0044846176,0.0018760022,0.0001125461,0.00003350752,0.0003438334,0.00074333424,0.000036964204],"category_scores_gemma":[0.005666169,0.00037826307,0.0003694568,0.0017370794,0.0005501574,0.00017489551,0.00029504354,0.0025667895,0.0000019554009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06274589,0.009832769,0.8519999,0.000094958814,0.004247834,0.0017320284,0.0006963502,0.0001967057,0.000039808376,0.0000048343795,0.000096600015,0.068312354],"study_design_scores_gemma":[0.13179353,0.0330212,0.8295118,0.0002691753,0.0030576654,0.00006225154,0.000981145,0.00087184925,0.00005432992,0.000032747448,0.00011498576,0.00022929335],"about_ca_topic_score_codex":0.00478175,"about_ca_topic_score_gemma":0.030440861,"teacher_disagreement_score":0.06904764,"about_ca_system_score_codex":0.00079693075,"about_ca_system_score_gemma":0.001749705,"threshold_uncertainty_score":0.9998669},"labels":[],"label_agreement":null},{"id":"W4410810019","doi":"10.1200/jco.2025.43.16_suppl.7527","title":"Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Oncology; Refractory (planetary science); Antigen; Internal medicine; Cancer research; Immunology","score_opus":0.0469796783495657,"score_gpt":0.4166866793760618,"score_spread":0.3697070010264961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970774,0.00044551358,0.000103211816,0.0005181365,0.0003422779,0.0006599442,0.000009870312,0.0000062660556,0.0008373973],"genre_scores_gemma":[0.9966113,0.0015125162,0.0013938727,0.0001429736,0.00010962749,0.000002627055,0.00004106264,0.000014940604,0.00017110464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966238,0.0004409587,0.0019414091,0.00025954563,0.00045736824,0.00027688534],"domain_scores_gemma":[0.9958365,0.0020357359,0.0011187735,0.00023982243,0.00048322996,0.00028596973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011504642,0.00017324592,0.0012804763,0.0003863181,0.000045923505,0.000010331566,0.00013506295,0.00033165776,0.000045686513],"category_scores_gemma":[0.001631473,0.00011474724,0.00018283767,0.00027252737,0.00026566224,0.00015807798,0.000071623836,0.00087194436,0.000005990271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04692067,0.006185464,0.85982937,0.00010045029,0.000326318,0.00038788514,0.00005484615,0.0000026829143,0.0006484648,0.0000059446993,0.00012573988,0.08541217],"study_design_scores_gemma":[0.06272291,0.011740258,0.9235076,0.0004712615,0.00013729931,0.000018389464,0.000032285057,0.000049946728,0.00019559887,0.0000075946255,0.0010387856,0.0000780994],"about_ca_topic_score_codex":0.00002111815,"about_ca_topic_score_gemma":0.00007877563,"teacher_disagreement_score":0.08533406,"about_ca_system_score_codex":0.00017108985,"about_ca_system_score_gemma":0.0008660182,"threshold_uncertainty_score":0.46792567},"labels":[],"label_agreement":null},{"id":"W4410810024","doi":"10.1200/jco.2025.43.16_suppl.7533","title":"DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Bortezomib; Oncology; Internal medicine; Lenalidomide; Multiple myeloma; Subgroup analysis; Refractory (planetary science); Meta-analysis","score_opus":0.03328689332769362,"score_gpt":0.37548436703091237,"score_spread":0.34219747370321874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613625,0.001484651,0.00005691131,0.00040748855,0.00017828263,0.0015979202,0.000039610324,0.0000112193475,0.000087685716],"genre_scores_gemma":[0.99315494,0.0010191534,0.005311622,0.0001969239,0.000095306495,0.000035456633,0.000023942368,0.00003978614,0.00012285417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99161386,0.0025112238,0.0034880256,0.0007689686,0.0009431481,0.0006747948],"domain_scores_gemma":[0.9876579,0.008325924,0.0022118287,0.00057106244,0.0005520457,0.0006812065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044946275,0.00047068886,0.0044142464,0.001873284,0.00008590858,0.000028637594,0.00030071728,0.0006523481,0.000037102614],"category_scores_gemma":[0.007935167,0.0003382562,0.00036412614,0.0015236887,0.0004937584,0.00015325604,0.0002699194,0.0020670916,0.000001528376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09316261,0.007733576,0.8580487,0.00008435565,0.003972064,0.0017906599,0.00051732373,0.00022218884,0.00006129667,0.0000054446523,0.000045698285,0.03435612],"study_design_scores_gemma":[0.15294373,0.024424477,0.81785583,0.00024984832,0.0029300088,0.000052292096,0.0007206454,0.00045252885,0.00008101324,0.00004232414,0.00004527487,0.00020203294],"about_ca_topic_score_codex":0.004626268,"about_ca_topic_score_gemma":0.020929076,"teacher_disagreement_score":0.059781127,"about_ca_system_score_codex":0.0006969197,"about_ca_system_score_gemma":0.0015078173,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W4410810680","doi":"10.1200/jco.2025.43.16_suppl.2643","title":"JAK inhibitor for the treatment of steroid refractory and life-threatening immune-related adverse events secondary to immune checkpoint inhibitors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Adverse effect; Immune system; Refractory (planetary science); Immune checkpoint; Oncology; Pharmacology; Internal medicine; Immunology; Immunotherapy","score_opus":0.07114671738270015,"score_gpt":0.4380272972597141,"score_spread":0.36688057987701395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830961,0.0072067087,0.000079825724,0.0067337756,0.0013271158,0.0010843936,0.000015728454,0.000007675166,0.00044865493],"genre_scores_gemma":[0.9932297,0.0032743798,0.0015528514,0.0002741034,0.0003956993,0.00003959576,0.0000073826604,0.000018512737,0.0012077936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995741,0.00030406777,0.0031385857,0.00022775255,0.00028584016,0.00030277064],"domain_scores_gemma":[0.99431235,0.0032494916,0.0012603396,0.00028840892,0.00045593944,0.00043348465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021960954,0.00019912564,0.001560703,0.00023532202,0.00010130229,0.0000048187367,0.00013961946,0.00032169354,0.00006732609],"category_scores_gemma":[0.0032126154,0.00011232518,0.00083330984,0.00016904189,0.0002012054,0.00008884645,0.00008237758,0.00054984767,0.0000073852893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042445492,0.008305828,0.09496179,0.00020515319,0.006811367,0.00037102838,0.0008244486,0.000024765855,0.012558047,0.000027602211,0.00082744996,0.832637],"study_design_scores_gemma":[0.05640624,0.054682165,0.8065917,0.00065063016,0.0012615595,0.000097998134,0.00072044926,0.0001677697,0.0075969365,0.00019011802,0.07149317,0.00014128927],"about_ca_topic_score_codex":0.00006251622,"about_ca_topic_score_gemma":0.000020644706,"teacher_disagreement_score":0.83249575,"about_ca_system_score_codex":0.00031382107,"about_ca_system_score_gemma":0.0016998273,"threshold_uncertainty_score":0.4580488},"labels":[],"label_agreement":null},{"id":"W4410811627","doi":"10.1200/jco.2025.43.16_suppl.tps7563","title":"QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Lenalidomide; Oncology; Internal medicine; Phases of clinical research; Cancer research; Toxicity","score_opus":0.11608095900723578,"score_gpt":0.493371956361664,"score_spread":0.37729099735442817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617296,0.00027795782,0.000066369925,0.0010428973,0.00033908754,0.0019677677,0.0000106775715,0.000007957168,0.00011434913],"genre_scores_gemma":[0.9975474,0.00019556282,0.001632407,0.00025658507,0.000100501195,0.00002273212,0.000006546938,0.000020610445,0.00021766314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942335,0.0016909123,0.0027076586,0.00036254976,0.0006664956,0.0003389156],"domain_scores_gemma":[0.9879456,0.009246494,0.0014694949,0.0003412895,0.00066499156,0.0003321343],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0042285346,0.0002355733,0.0016212965,0.00029155528,0.00010028213,0.000018009861,0.0001876945,0.00022361467,0.000046696652],"category_scores_gemma":[0.0155384205,0.00012205654,0.00016119292,0.0003007065,0.00041182624,0.00013314735,0.00014931339,0.0010522145,0.0000011999056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20938405,0.018781893,0.52289283,0.00007286015,0.0009294224,0.00040517034,0.0005897734,0.000005139394,0.0007581997,0.0000020233028,0.00008369364,0.24609494],"study_design_scores_gemma":[0.20822537,0.07195294,0.7153419,0.0003838375,0.0004965358,0.000017089831,0.0008849834,0.0021201866,0.000090152775,0.0000056404365,0.0004019515,0.00007939734],"about_ca_topic_score_codex":0.000092099224,"about_ca_topic_score_gemma":0.00043492985,"teacher_disagreement_score":0.24601553,"about_ca_system_score_codex":0.00018243676,"about_ca_system_score_gemma":0.0013536178,"threshold_uncertainty_score":0.9927541},"labels":[],"label_agreement":null},{"id":"W4410812803","doi":"10.1200/jco.2025.43.16_suppl.tps7568","title":"MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Lenalidomide; Oncology; Internal medicine; Metallurgy","score_opus":0.0720768217424995,"score_gpt":0.4572068126716047,"score_spread":0.38512999092910516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951718,0.00054934266,0.000016267375,0.00080805965,0.00031490743,0.002915748,0.000015028748,0.000016530248,0.00019235194],"genre_scores_gemma":[0.99512804,0.0016379637,0.0021676326,0.00035433503,0.00009524703,0.000045921417,0.00001013257,0.000026347887,0.00053436804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930637,0.002302309,0.0031644222,0.00038782833,0.00069749705,0.00038426247],"domain_scores_gemma":[0.9863914,0.010350618,0.001664605,0.00036143247,0.0008154477,0.00041646542],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003527222,0.0002858185,0.0038071852,0.00057462294,0.00006455153,0.000013776824,0.00021633106,0.00036167816,0.00025835808],"category_scores_gemma":[0.015760262,0.0001443641,0.00028497647,0.000522118,0.00036677133,0.00015537863,0.00008395717,0.0011046454,0.0000028299862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5238009,0.023315234,0.27850464,0.00004280126,0.0011966748,0.0012717522,0.0001962976,7.8641665e-7,0.000039351136,7.1206193e-7,0.00018840378,0.17144242],"study_design_scores_gemma":[0.47916746,0.06289148,0.4558275,0.00020340252,0.00030844653,0.000021304617,0.00015263881,0.00015114757,0.000030491663,0.0000062466543,0.0011691046,0.00007074632],"about_ca_topic_score_codex":0.00014898131,"about_ca_topic_score_gemma":0.00059029774,"teacher_disagreement_score":0.17732286,"about_ca_system_score_codex":0.00015145654,"about_ca_system_score_gemma":0.0021219759,"threshold_uncertainty_score":0.9925304},"labels":[],"label_agreement":null},{"id":"W4410812818","doi":"10.1200/jco.2025.43.16_suppl.tps7567","title":"Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Daratumumab; Multiple myeloma; Internal medicine; Oncology; Phases of clinical research; Toxicity","score_opus":0.11298973716068444,"score_gpt":0.4503265996954301,"score_spread":0.33733686253474565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858464,0.0026183247,0.0022518106,0.0034897686,0.00047279597,0.0022242314,0.000042156138,0.000017437946,0.0002988491],"genre_scores_gemma":[0.9889196,0.0029232416,0.006663598,0.0006165545,0.00024978144,0.000055999335,0.000009575396,0.000042374344,0.00051927735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907565,0.0032515954,0.003721471,0.0006514469,0.0008713685,0.0007476342],"domain_scores_gemma":[0.97829294,0.018334515,0.0015914699,0.00056421146,0.0005077753,0.00070910994],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071733035,0.0004911536,0.0035902807,0.00065017043,0.00016872498,0.00004387109,0.0004980301,0.0005957781,0.00010132254],"category_scores_gemma":[0.011569635,0.00031856738,0.00047036304,0.0007113614,0.0007902058,0.00021336829,0.00023637855,0.0019360378,0.000005861351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2270916,0.010361214,0.62770784,0.00032010177,0.0027315908,0.0061713434,0.001288418,0.00033686176,0.0027888026,0.000030313295,0.0017408615,0.11943105],"study_design_scores_gemma":[0.36018503,0.021503843,0.6002108,0.0012859748,0.001967942,0.0009971443,0.0011511437,0.0070388853,0.0032546583,0.00025636298,0.0017716319,0.00037657432],"about_ca_topic_score_codex":0.001085155,"about_ca_topic_score_gemma":0.0020709166,"teacher_disagreement_score":0.13309343,"about_ca_system_score_codex":0.00043515355,"about_ca_system_score_gemma":0.0031963459,"threshold_uncertainty_score":0.9999266},"labels":[],"label_agreement":null},{"id":"W4410929433","doi":"10.1002/jha2.70071","title":"A Comparative Study of the Outcomes of Surgically Versus Non‐Surgically Treated Spinal Disease in Patients With Multiple Myeloma: Northern Ireland's Experience","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Medicine; Cohort; Multiple myeloma; Retrospective cohort study; Surgery; Cohort study; Malignancy; Bone marrow; Back pain; Internal medicine; Pathology","score_opus":0.025385542065117252,"score_gpt":0.3274377467584394,"score_spread":0.30205220469332217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410929433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976503,0.00003125927,0.000003233858,0.00006752476,0.000045945806,0.00167302,0.000027969496,0.000012383749,0.00048834324],"genre_scores_gemma":[0.9995641,0.0000017900819,0.000031089512,0.000007895132,0.000004179569,0.000117752046,0.000019356636,0.000008564564,0.0002452414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983861,0.00012339736,0.00036895837,0.0002907959,0.00058156,0.00024918202],"domain_scores_gemma":[0.9988303,0.00021019945,0.00012349569,0.00044227467,0.00024762226,0.00014606556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069094436,0.00019382269,0.00058288424,0.00012185253,0.000064226566,0.000007056243,0.00018443937,0.000035791956,0.000027673],"category_scores_gemma":[0.00016036378,0.000101425234,0.00009687759,0.0005193018,0.00018464462,0.000050595732,0.00010360409,0.00014180804,0.000003660208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027444722,0.0053829937,0.9640289,0.000028807097,0.00040251896,0.00009680526,0.0018475802,0.000041879568,0.000014787626,0.0000043291184,0.000003827867,0.00070284214],"study_design_scores_gemma":[0.037215248,0.0021098007,0.95895267,0.00014519694,0.0001019705,1.8866278e-7,0.0009734012,0.00023239007,0.00017682862,0.000001162839,0.000011749862,0.000079374164],"about_ca_topic_score_codex":0.0010186451,"about_ca_topic_score_gemma":0.0023679892,"teacher_disagreement_score":0.009770527,"about_ca_system_score_codex":0.000092595576,"about_ca_system_score_gemma":0.00016127342,"threshold_uncertainty_score":0.41360012},"labels":[],"label_agreement":null},{"id":"W4410998031","doi":"10.1200/jco-25-00744","title":"Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Pomalidomide; Adverse effect; Dexamethasone; Refractory (planetary science); Internal medicine; Clinical endpoint; Multiple myeloma; Gastroenterology; Randomized controlled trial; Lenalidomide","score_opus":0.08940169969264583,"score_gpt":0.4717100872894226,"score_spread":0.38230838759677677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410998031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921832,0.0015361508,0.00004065148,0.0016448915,0.0015924276,0.0012825117,0.000027968199,0.000025176105,0.0016670285],"genre_scores_gemma":[0.99656266,0.00063504453,0.000897312,0.0007462781,0.00041314086,0.000028573208,0.000013615508,0.000039270613,0.0006641019],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935336,0.0013745143,0.003026,0.00060586724,0.00075918576,0.00070083386],"domain_scores_gemma":[0.9845207,0.012669823,0.0011415259,0.00048014018,0.00038448922,0.0008033363],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032671492,0.00040327414,0.0029205903,0.0006172514,0.00011688091,0.00003239529,0.00032210536,0.0006435789,0.000111211186],"category_scores_gemma":[0.014504259,0.0003083621,0.0003956411,0.0004416684,0.00041947974,0.00011588416,0.00016503953,0.0026964021,0.000028103039],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45560154,0.063294806,0.08344736,0.00007848171,0.0028224674,0.02936272,0.0006558117,0.000011873323,0.0015617713,0.00003629867,0.004886474,0.3582404],"study_design_scores_gemma":[0.6055309,0.21193823,0.1620993,0.0003037691,0.0010470386,0.0007876914,0.0017782616,0.0011666801,0.00036659927,0.000092526716,0.014502641,0.0003863584],"about_ca_topic_score_codex":0.00039521971,"about_ca_topic_score_gemma":0.00046406075,"teacher_disagreement_score":0.35785404,"about_ca_system_score_codex":0.0011539615,"about_ca_system_score_gemma":0.0027193432,"threshold_uncertainty_score":0.9999368},"labels":[],"label_agreement":null},{"id":"W4411033373","doi":"10.1186/s12885-025-14420-5","title":"Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Surgical oncology; Multiple myeloma; Meta-analysis; Hepatitis B virus; Hepatitis C virus; Virology; Hepatitis virus; Internal medicine; Immunology; Oncology; Virus","score_opus":0.08898396000653565,"score_gpt":0.39993942823765294,"score_spread":0.3109554682311173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411033373","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000794266,0.99477756,0.000052200492,0.000012213218,0.000014834189,0.0040385034,0.0009609766,0.00001485924,0.000049405306],"genre_scores_gemma":[0.000087690416,0.9962094,0.00019792105,0.00002793325,0.000014139829,0.0022130758,0.00008210756,0.000019098232,0.0011486374],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99786615,0.00051044795,0.00072746724,0.00045695098,0.0002602435,0.00017871702],"domain_scores_gemma":[0.99801713,0.00071410695,0.00054381834,0.0004290557,0.00013238203,0.00016353384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004308066,0.0003568203,0.0067985696,0.00040021003,0.000065287924,0.000022568858,0.000042409974,0.00013856299,0.00014292626],"category_scores_gemma":[0.0009190166,0.00021351302,0.0009842981,0.000650445,0.00008027567,0.000044718818,0.00009114457,0.00018708479,0.0000026125067],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007322813,0.000030536798,0.011950195,0.83442193,0.13805917,0.000006042671,0.000008792687,8.784268e-8,3.6347604e-8,0.0000017723991,0.00004917875,0.01546495],"study_design_scores_gemma":[0.0004232532,0.00005554013,0.0026706418,0.06867967,0.92347085,0.00002324584,0.0000011780986,0.000029483044,6.2461834e-7,0.0000020049526,0.004506089,0.00013740962],"about_ca_topic_score_codex":0.015027804,"about_ca_topic_score_gemma":0.015842456,"teacher_disagreement_score":0.7854117,"about_ca_system_score_codex":0.000098102864,"about_ca_system_score_gemma":0.00022826374,"threshold_uncertainty_score":0.9915312},"labels":[],"label_agreement":null},{"id":"W4411085883","doi":"10.1002/jha2.70072","title":"Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; Gilead Sciences","keywords":"Daratumumab; Medicine; Pomalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Refractory (planetary science); Neutropenia; Adverse effect; Oncology; Phases of clinical research; Clinical trial; Lenalidomide; Toxicity","score_opus":0.03366329470104022,"score_gpt":0.33531640225832565,"score_spread":0.3016531075572854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411085883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964804,0.000052666477,0.000022742859,0.00006731442,0.00003982752,0.0017246044,0.000116158975,0.00002125481,0.0014750126],"genre_scores_gemma":[0.9983552,0.0000043774107,0.0005832279,0.000014817924,0.000006052886,0.000078563746,0.00016468712,0.000015004505,0.00077807176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982998,0.00011346203,0.00053218566,0.00030961703,0.00047931113,0.00026565773],"domain_scores_gemma":[0.99864733,0.00024220409,0.000168405,0.00046438698,0.00037429528,0.00010339941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017964414,0.00016867844,0.000446063,0.00048822956,0.00005165511,0.0000056981817,0.00012338629,0.00006346606,0.000021724556],"category_scores_gemma":[0.00058984454,0.00012966356,0.000056226927,0.000585277,0.00009860447,0.00009431852,0.000070695474,0.00022138613,0.000006287177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016791813,0.07841675,0.8858926,0.000118587624,0.0003071936,0.000116367504,0.0014556447,0.000008138668,0.00025289593,0.000022382164,0.00021011636,0.016407466],"study_design_scores_gemma":[0.1879635,0.0070953807,0.80219424,0.00021769079,0.00007366581,6.79344e-7,0.00062484556,0.00060286775,0.0010549519,0.000008523335,0.00008967487,0.00007398545],"about_ca_topic_score_codex":0.0005432422,"about_ca_topic_score_gemma":0.00056444283,"teacher_disagreement_score":0.1711717,"about_ca_system_score_codex":0.00012480271,"about_ca_system_score_gemma":0.00017504537,"threshold_uncertainty_score":0.5287527},"labels":[],"label_agreement":null},{"id":"W4411141147","doi":"10.1200/jco-24-01893","title":"International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Context (archaeology); Oncology; Internal medicine; Risk stratification; Clinical trial; Fluorescence in situ hybridization; Clinical Practice; Intensive care medicine; Family medicine; Gene; Genetics","score_opus":0.15608531305572798,"score_gpt":0.4504290073324454,"score_spread":0.2943436942767174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411141147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8897257,0.00009350798,0.0010606633,0.077173874,0.0046407734,0.00044290567,0.0000881713,0.000022570961,0.026751831],"genre_scores_gemma":[0.97200507,0.0013519735,0.022796324,0.0022952843,0.0010401749,0.000020307954,0.00007272179,0.000017788467,0.000400375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955817,0.00072193,0.0023530428,0.00028883418,0.0007627902,0.0002917256],"domain_scores_gemma":[0.984352,0.012211592,0.0019928594,0.00029642796,0.00092039676,0.0002267329],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0032487717,0.0002017553,0.0009292981,0.00028320588,0.00017164186,0.00003035129,0.00044919358,0.00035373043,0.0005816977],"category_scores_gemma":[0.011127154,0.00013336325,0.0008769102,0.0002703995,0.00040058797,0.00008046382,0.00015630038,0.0013935495,0.000037070662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010241136,0.0041099936,0.2745163,0.000024940988,0.005179019,0.0003998569,0.00015584053,0.000026788732,0.00050332927,0.013132003,0.03633294,0.6553778],"study_design_scores_gemma":[0.02104641,0.0045188335,0.83682424,0.0005625498,0.00051308953,0.00030804623,0.00058548094,0.0021002488,0.00048574706,0.0065885102,0.1263048,0.00016202744],"about_ca_topic_score_codex":0.000059048332,"about_ca_topic_score_gemma":0.00006835454,"teacher_disagreement_score":0.6552158,"about_ca_system_score_codex":0.0003862687,"about_ca_system_score_gemma":0.0008201433,"threshold_uncertainty_score":0.9972025},"labels":[],"label_agreement":null},{"id":"W4411141965","doi":"10.1182/blood.2024027949","title":"Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Oncology; Clinical trial; Monoclonal gammopathy of undetermined significance; Surrogate endpoint; Progression-free survival; Disease; Serum protein electrophoresis; Monoclonal; Antibody; Immunology; Chemotherapy; Monoclonal antibody","score_opus":0.036461286842071255,"score_gpt":0.3341772016959929,"score_spread":0.2977159148539217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411141965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967574,0.00011558333,0.00038997416,0.001286669,0.000032765263,0.0009162622,0.000019555202,0.000013055214,0.00046872417],"genre_scores_gemma":[0.998093,0.0000051236,0.0013143097,0.00006406001,0.000019207735,0.00012467711,0.00002680969,0.000005566054,0.00034726574],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99932337,0.00009673884,0.00019789881,0.000099505916,0.00013030226,0.0001521893],"domain_scores_gemma":[0.9989808,0.0006876595,0.000045337576,0.00016241557,0.00009500165,0.00002876039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043587494,0.000060563816,0.00013641796,0.00013734895,0.000054067565,0.000007821077,0.000057852274,0.000040117862,0.000011707141],"category_scores_gemma":[0.0015332161,0.00004180526,0.00005560872,0.00018017077,0.000043385062,0.000027702055,0.00002563614,0.00006716773,0.0000026728403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026624547,0.0025155675,0.3429022,0.0007682579,0.00064927054,0.00008422533,0.001944818,0.000027952568,0.5678051,0.0010761933,0.00030177203,0.055300087],"study_design_scores_gemma":[0.023121554,0.00049086683,0.66525006,0.00022092935,0.00012089674,0.00000913075,0.0006008167,0.0048954682,0.30463725,0.00016131722,0.00043865808,0.000053059764],"about_ca_topic_score_codex":0.00009484739,"about_ca_topic_score_gemma":0.00004116054,"teacher_disagreement_score":0.32234782,"about_ca_system_score_codex":0.000026441006,"about_ca_system_score_gemma":0.0001273578,"threshold_uncertainty_score":0.18355137},"labels":[],"label_agreement":null},{"id":"W4411152766","doi":"10.1038/s41588-025-02251-w","title":"Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","year":2025,"lang":"en","type":"erratum","venue":"Nature Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Alberta Cancer Foundation; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Gene expression profiling; Multiple myeloma; Profiling (computer programming); Computational biology; Expression (computer science); Genetics; Gene expression; Gene; Immunology; Computer science","score_opus":0.017310649407687406,"score_gpt":0.33100820473314657,"score_spread":0.3136975553254592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411152766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.778389,0.12596196,0.00048199474,0.0011596441,0.06493483,0.005206852,0.0008986032,0.0003157605,0.022651363],"genre_scores_gemma":[0.6233317,0.004965473,0.020714926,0.00029634003,0.0013550349,0.00015023972,0.004080047,0.00016164545,0.34494457],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976087,0.00012258164,0.00044769762,0.0006551758,0.00078671594,0.00037908173],"domain_scores_gemma":[0.9977695,0.0001975807,0.00025031992,0.0006372018,0.0009342301,0.00021118321],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0000934798,0.00043518108,0.0008042783,0.00025655713,0.00012834703,0.0000418279,0.00016665416,0.0015799514,0.00006899925],"category_scores_gemma":[0.00060607766,0.0003695106,0.00018266465,0.00032036265,0.00016374372,0.000029860406,0.00024716483,0.0018977699,0.00001140775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015449239,0.0003115706,0.06488267,0.0038300317,0.00096136937,0.00051398185,0.00017209405,0.0000125452425,0.07004972,0.00001436591,0.84971267,0.007994051],"study_design_scores_gemma":[0.0042442176,0.00037626698,0.08502155,0.0038216992,0.0007403746,0.00014032329,0.00020209244,0.0017094413,0.70806676,0.00011185203,0.19499762,0.000567822],"about_ca_topic_score_codex":0.000027499442,"about_ca_topic_score_gemma":0.000020949288,"teacher_disagreement_score":0.65471506,"about_ca_system_score_codex":0.000094361734,"about_ca_system_score_gemma":0.0004428436,"threshold_uncertainty_score":0.99987566},"labels":[],"label_agreement":null},{"id":"W4411170038","doi":"10.1182/blood.2024028107","title":"Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute","keywords":"Multiple myeloma; Antibody; Antigen; Immunology; Mechanism (biology); CD38; Medicine; Virology; Biology; Cancer research; Genetics","score_opus":0.023945573857095715,"score_gpt":0.3022157461441357,"score_spread":0.27827017228704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411170038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298805,0.0008009139,0.00009787158,0.0012556033,0.000054579727,0.0008202983,0.00005479588,0.000040722225,0.0038871497],"genre_scores_gemma":[0.99342394,0.00039132067,0.0034795608,0.00027591607,0.00002778477,0.00004250922,0.000018434,0.000017324455,0.0023232289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850774,0.000049717157,0.0003419343,0.0003713245,0.00032696605,0.0004023302],"domain_scores_gemma":[0.999091,0.000098997116,0.000052499752,0.0004537182,0.00016184161,0.00014191719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016855107,0.00017407512,0.00047084945,0.00047152923,0.000062075305,0.000013888386,0.00015453485,0.000090057154,0.00007505945],"category_scores_gemma":[0.00041736595,0.0001533494,0.00009253529,0.00078691996,0.000049142505,0.000046986144,0.000113200505,0.00012062835,0.00005131643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005853684,0.002092007,0.7761155,0.00048590204,0.000483032,0.00042721137,0.00072812015,8.3871674e-7,0.21463744,0.0008812132,0.0012555411,0.0023078234],"study_design_scores_gemma":[0.007013317,0.00016477128,0.58297527,0.00054670026,0.00005691443,0.0000043792265,0.00013034171,0.000050990493,0.40764531,0.00026337072,0.0010395296,0.00010910917],"about_ca_topic_score_codex":0.00022558826,"about_ca_topic_score_gemma":0.00049627695,"teacher_disagreement_score":0.19314024,"about_ca_system_score_codex":0.000034061144,"about_ca_system_score_gemma":0.00017988145,"threshold_uncertainty_score":0.62534076},"labels":[],"label_agreement":null},{"id":"W4411396441","doi":"10.1038/s41408-025-01286-w","title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Fluorescence in situ hybridization; Risk stratification; Medicine; Multiple myeloma; Internal medicine; Oncology; Family medicine; Biology; Genetics; Chromosome","score_opus":0.22496739292696086,"score_gpt":0.42518130795705555,"score_spread":0.2002139150300947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411396441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016043724,0.97814393,0.00035056242,0.00015607689,0.00038961935,0.003924116,0.0009129801,0.000006885908,0.00007211558],"genre_scores_gemma":[0.017245343,0.96210796,0.019134857,0.00000832643,0.000490132,0.0007006652,0.000036891146,0.000045100584,0.00023070544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941688,0.00013268454,0.004523449,0.00042074252,0.0004200436,0.00033423348],"domain_scores_gemma":[0.98103607,0.0031642541,0.013447181,0.00058411254,0.0016626898,0.00010568687],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026435188,0.0003150222,0.0015878441,0.00014954251,0.0003095179,0.000030543142,0.00028024116,0.00017489374,0.000001966292],"category_scores_gemma":[0.018174509,0.00017323764,0.00059136236,0.0003488248,0.00014754444,0.000027175094,0.00009591373,0.0004189348,2.3161816e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043795008,0.00016044085,0.026544878,0.020251328,0.0019411381,0.000029731615,0.00012190242,0.00022881698,0.00096482737,0.0000023671673,0.0002779542,0.9490387],"study_design_scores_gemma":[0.057677742,0.0027664867,0.04089666,0.35416308,0.10215403,0.01066899,0.0015305704,0.018021826,0.051884916,0.00035532055,0.35792476,0.0019556272],"about_ca_topic_score_codex":0.000721275,"about_ca_topic_score_gemma":0.00061179773,"teacher_disagreement_score":0.94708306,"about_ca_system_score_codex":0.00014869827,"about_ca_system_score_gemma":0.0036526674,"threshold_uncertainty_score":0.99009585},"labels":[],"label_agreement":null},{"id":"W4411657865","doi":"10.51847/2ij3giq","title":"10.51847/2iJ3GIq","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Yield (engineering); Cell culture; Cell biology; Biology; Immunology; Materials science; Genetics","score_opus":0.014633798942824489,"score_gpt":0.2524637933862924,"score_spread":0.2378299944434679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411657865","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01245868,0.00006106591,1.711516e-7,0.0005263467,8.944233e-7,0.0003208188,0.000012304693,0.00008534452,0.98653436],"genre_scores_gemma":[0.0073767602,9.362642e-7,0.00023352531,0.000086460765,0.00009373482,0.000029472378,0.000043188717,0.000017907241,0.992118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991901,0.000019883122,0.00009759968,0.00017226982,0.00023556559,0.00028456093],"domain_scores_gemma":[0.99931246,0.000029061777,0.000007716464,0.00026236175,0.000037014786,0.00035140224],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000060362232,0.000094479416,0.00015039307,0.00006703632,0.000045890596,0.0000140893435,0.00006572875,0.000037339603,0.9968688],"category_scores_gemma":[0.00004672767,0.00007553329,0.000053105134,0.00014265791,0.00002164442,0.00003399316,0.000018863713,0.00007261996,0.99270445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005179398,0.00014640976,0.000014791565,0.000008189304,0.00005362897,0.00012812372,0.0000072575267,0.0000019052922,0.00012520794,5.8270535e-7,0.024096569,0.9748994],"study_design_scores_gemma":[0.0012755491,0.00045599238,0.0021519572,0.000021907945,0.000021673768,0.000034339133,4.231762e-7,0.00014184383,0.00014395919,0.0000010597195,0.9956818,0.000069450194],"about_ca_topic_score_codex":0.000050699015,"about_ca_topic_score_gemma":1.4228172e-7,"teacher_disagreement_score":0.97483,"about_ca_system_score_codex":0.000048220547,"about_ca_system_score_gemma":0.00004217024,"threshold_uncertainty_score":0.30801582},"labels":[],"label_agreement":null},{"id":"W4411907834","doi":"10.1186/s12885-025-14490-5","title":"Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians","year":2025,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GLS Industries (Canada); Ottawa Hospital","funders":"","keywords":"Medicine; Surgical oncology; Multiple myeloma; Refractory (planetary science); Oncology; Family medicine; Internal medicine; Intensive care medicine","score_opus":0.0364796505248754,"score_gpt":0.29296103516194594,"score_spread":0.25648138463707054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411907834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668556,0.00041989592,0.0000036856995,0.0007378932,0.00018642684,0.0015516633,0.00011279079,0.000022370567,0.000279736],"genre_scores_gemma":[0.9965332,0.0005499823,0.00016365202,0.00061581563,0.000035492038,0.0013439561,0.00013359511,0.00003375016,0.0005905482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984737,0.000043010255,0.00017900635,0.00048656375,0.00027800197,0.00053969235],"domain_scores_gemma":[0.99906063,0.0000760639,0.000043873923,0.00031115123,0.0000947257,0.0004135277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023664184,0.00025810208,0.00031308216,0.00036991024,0.00012747213,0.00005923492,0.00006985903,0.000043966153,0.000026710104],"category_scores_gemma":[0.000039710787,0.00020759706,0.000042322237,0.00037504957,0.000052488787,0.00031869035,0.000037137128,0.000098674755,0.000008780061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010259359,0.0002648242,0.9351524,0.000062211286,0.00014176214,0.000027972572,0.0036944472,0.0000421785,0.00008406159,0.0000016595965,0.00031677933,0.059185766],"study_design_scores_gemma":[0.013361307,0.000700449,0.9706902,0.0010838921,0.000055854252,2.288721e-7,0.0025914651,0.000081122475,0.001382538,3.5754388e-7,0.00985668,0.00019589174],"about_ca_topic_score_codex":0.42637652,"about_ca_topic_score_gemma":0.6729797,"teacher_disagreement_score":0.24660322,"about_ca_system_score_codex":0.002607487,"about_ca_system_score_gemma":0.0004010741,"threshold_uncertainty_score":0.84655625},"labels":[],"label_agreement":null},{"id":"W4412097337","doi":"10.12659/ajcr.946709","title":"Unusual Presentation of Multiple Myeloma as a Liver Tumor at Initial Diagnosis: A Case Report","year":2025,"lang":"en","type":"article","venue":"American Journal of Case Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Presentation (obstetrics); General surgery; Radiology; Internal medicine","score_opus":0.022003460267792,"score_gpt":0.35995349987607456,"score_spread":0.33795003960828257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412097337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970494,0.00059554423,0.0001121544,0.00024554264,0.00019144895,0.0004761634,0.000011982154,0.000014676788,0.0013031021],"genre_scores_gemma":[0.99775463,0.00006463819,0.0013340075,0.00011372822,0.00013888911,0.000045318124,0.00001421549,0.000021293927,0.00051329273],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972663,0.0001675116,0.0013145416,0.0002752421,0.0006768843,0.00029953566],"domain_scores_gemma":[0.99620116,0.0004659037,0.0017155772,0.00041741526,0.0007899963,0.0004099785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005499617,0.00019441886,0.00070413697,0.0005971088,0.000110010624,0.000018071793,0.000038078862,0.000039690094,0.00012296907],"category_scores_gemma":[0.0024340318,0.00015571006,0.0003151281,0.0006117284,0.0003294613,0.00015808879,0.00008525207,0.00024377668,0.0000037722632],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012959386,0.00047692718,0.18565528,0.00007499019,0.0006229805,0.7775559,0.00027923536,0.0000070804736,0.00037139587,0.0000026985524,0.000733098,0.03292449],"study_design_scores_gemma":[0.0019610047,0.0017507325,0.026471023,0.00030125206,0.0004819056,0.9450231,0.0011674631,0.000094386545,0.021495083,0.000018865463,0.0011355923,0.00009959935],"about_ca_topic_score_codex":0.0028654383,"about_ca_topic_score_gemma":0.00025339675,"teacher_disagreement_score":0.1674672,"about_ca_system_score_codex":0.00025649072,"about_ca_system_score_gemma":0.00092916534,"threshold_uncertainty_score":0.6349672},"labels":[],"label_agreement":null},{"id":"W4412162065","doi":"10.1182/blood.2025028865","title":"Silence of the myeloma clones: GPRC5D epigenetic regulation","year":2025,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Epigenetics; Biology; Cancer research; Medicine; Genetics; Immunology; Gene","score_opus":0.018503326395002823,"score_gpt":0.2751283451659038,"score_spread":0.25662501877090094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412162065","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2512476,0.0046803528,0.000089806585,0.7142122,0.0008834833,0.004552927,0.00037663692,0.00013771995,0.023819275],"genre_scores_gemma":[0.7620527,0.00051494734,0.0012431345,0.15401156,0.003144544,0.00029843085,0.00090257777,0.0001029372,0.077729136],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9983462,0.000111140194,0.00029239454,0.00031662616,0.0006333915,0.00030022394],"domain_scores_gemma":[0.99863243,0.00016272205,0.00014454429,0.0008597134,0.00015075096,0.00004980915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000775748,0.00020582514,0.00037260275,0.00013374165,0.00006796784,0.00001098735,0.00023894625,0.0003763655,0.00018005472],"category_scores_gemma":[0.00021916162,0.00013138543,0.00021862965,0.0002648298,0.000116498035,0.000017886874,0.00010430903,0.0006137216,0.000036500634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016804054,0.0010492095,0.10152445,0.003985826,0.0018833849,0.0007053276,0.0002115263,0.0000029265057,0.0059622903,0.000038850947,0.8643114,0.020156765],"study_design_scores_gemma":[0.007947364,0.00052921346,0.6714846,0.0031501604,0.0019953083,0.0001352141,0.00002671583,0.000060472,0.08624444,0.000515273,0.22755156,0.0003596897],"about_ca_topic_score_codex":0.000090152105,"about_ca_topic_score_gemma":0.0000061189485,"teacher_disagreement_score":0.6367598,"about_ca_system_score_codex":0.000040561707,"about_ca_system_score_gemma":0.00032877148,"threshold_uncertainty_score":0.53577423},"labels":[],"label_agreement":null},{"id":"W4412394230","doi":"10.1080/13543784.2025.2532446","title":"Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; Juno Therapeutics; Incyte; BeiGene; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; GlaxoSmithKline; Johns Hopkins University; Amgen; Pfizer; Legend Biotech; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Multiple myeloma; Current (fluid); Medicine; Intensive care medicine; Immunology; Engineering","score_opus":0.11858936609891704,"score_gpt":0.4678993425352598,"score_spread":0.34930997643634276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412394230","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004283419,0.99228823,0.000024254352,0.0017311315,0.002071742,0.0030577888,0.0005925051,0.000033981476,0.00019605717],"genre_scores_gemma":[0.0000039185693,0.9915379,0.001258321,0.00009199565,0.0024314132,0.0026464208,0.0015896682,0.000029341614,0.0004110144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784106,0.00020139583,0.0007586474,0.0005427533,0.0004136245,0.00024249252],"domain_scores_gemma":[0.9950331,0.003846404,0.00028382332,0.00041101137,0.00017687619,0.0002487786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018723389,0.00040108527,0.0012141838,0.00021509544,0.00027286055,0.000020916506,0.00012329766,0.0002024429,0.000022832353],"category_scores_gemma":[0.00046262195,0.00022165789,0.0006882091,0.00026390937,0.00036895688,0.000055639382,0.00003272118,0.00023282661,0.000009407769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013482275,0.0008597694,0.000105940046,0.0033242896,0.00046338834,6.479767e-7,0.0001694938,2.0575453e-7,5.3515606e-8,0.0010230874,0.002661234,0.9912571],"study_design_scores_gemma":[0.002770239,0.0007736812,0.000343631,0.0054143146,0.00014265541,0.000006658874,0.0000621627,0.00008775344,0.0000041561316,0.000101520076,0.99014175,0.00015147164],"about_ca_topic_score_codex":0.000015781674,"about_ca_topic_score_gemma":0.00000318591,"teacher_disagreement_score":0.9911056,"about_ca_system_score_codex":0.00020433009,"about_ca_system_score_gemma":0.0009227757,"threshold_uncertainty_score":0.90389466},"labels":[],"label_agreement":null},{"id":"W4412435012","doi":"10.1016/j.clml.2025.07.003","title":"Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Cross-sectional study; Family medicine; Internal medicine; Oncology; Pathology","score_opus":0.06866963713237662,"score_gpt":0.423243187999214,"score_spread":0.3545735508668374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412435012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96682495,0.00021758256,0.00012330474,0.00081588357,0.00031164297,0.0015367195,0.00022585128,0.000080292746,0.029863756],"genre_scores_gemma":[0.9926663,0.00056561164,0.0021922947,0.0016810575,0.00015194778,0.00036002684,0.00079392083,0.000037895185,0.0015509594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939271,0.0011019635,0.0017984258,0.00091307756,0.0015505959,0.00070884434],"domain_scores_gemma":[0.98532754,0.012521395,0.00036256644,0.0007971393,0.0007190429,0.0002722941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046543134,0.0004060537,0.0007857613,0.0005213825,0.00023507515,0.00010286318,0.0006051619,0.00031483165,0.000094895615],"category_scores_gemma":[0.0028741716,0.00031116788,0.00046717515,0.0016724734,0.0005117113,0.00022423537,0.00011227668,0.00048070555,0.000104957544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010180529,0.002173243,0.9532412,0.0002964045,0.00076048943,0.001145561,0.000047002675,0.00016902508,0.000033854434,0.0010351177,0.001698332,0.029219184],"study_design_scores_gemma":[0.023766037,0.00029391673,0.9668975,0.0003724136,0.00015022137,0.000030107787,0.000040156505,0.0031483122,0.00022734095,0.00021956164,0.0046267016,0.00022773776],"about_ca_topic_score_codex":0.004222122,"about_ca_topic_score_gemma":0.0017711164,"teacher_disagreement_score":0.028991446,"about_ca_system_score_codex":0.0012310462,"about_ca_system_score_gemma":0.0030135876,"threshold_uncertainty_score":0.999934},"labels":[],"label_agreement":null},{"id":"W4412461070","doi":"10.1016/s2352-3026(25)00163-2","title":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Open label; Refractory (planetary science); Surgery; Clinical trial","score_opus":0.04989390241174046,"score_gpt":0.35109203108008247,"score_spread":0.301198128668342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346037,0.00054905424,0.000046146997,0.0016166653,0.00026304074,0.012960102,0.0003327264,0.000097105265,0.00067477446],"genre_scores_gemma":[0.994009,0.00020260924,0.003149669,0.00039609207,0.000051294388,0.0011976371,0.0006536496,0.0000643585,0.00027564826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994837,0.0010758913,0.0013610024,0.0011578284,0.00060549,0.0009628121],"domain_scores_gemma":[0.98991174,0.007330055,0.00081206986,0.0013103791,0.00028920436,0.00034658203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010291507,0.00067732035,0.004008747,0.0003529364,0.0003236693,0.000120425975,0.00037106412,0.00032167198,0.00004475755],"category_scores_gemma":[0.0055939187,0.0003518,0.00007654741,0.0005478144,0.00062855793,0.00024675176,0.00032732764,0.0007851985,0.0000055226888],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8356673,0.0034797236,0.14834078,0.00006133103,0.0025939287,0.0017828433,0.00045302333,9.4937764e-7,0.00006924748,0.00002779799,0.00039459314,0.0071285],"study_design_scores_gemma":[0.8712431,0.009048402,0.11677016,0.0003323621,0.0010524865,0.00008337036,0.00024404719,0.0004213665,0.00019095556,0.000033800217,0.00024337924,0.0003365417],"about_ca_topic_score_codex":0.0014762575,"about_ca_topic_score_gemma":0.0027422276,"teacher_disagreement_score":0.035575837,"about_ca_system_score_codex":0.00015378714,"about_ca_system_score_gemma":0.0005086482,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W4412461073","doi":"10.1016/s1470-2045(25)00330-4","title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Refractory (planetary science); Open label; Oncology; Internal medicine; Lenalidomide; Clinical trial; Materials science","score_opus":0.06159927844167269,"score_gpt":0.3929654672770072,"score_spread":0.33136618883533453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178505,0.00023878436,0.000117552896,0.0013586206,0.00018043171,0.0041641598,0.00057086075,0.00005434376,0.0015302026],"genre_scores_gemma":[0.9944672,0.00021527501,0.0020424337,0.000695979,0.0001323575,0.0003157905,0.001541142,0.000022841516,0.00056700886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963621,0.0012442744,0.00062108843,0.0006858523,0.00040847488,0.0006782258],"domain_scores_gemma":[0.99684864,0.0016929308,0.0002729357,0.00079962215,0.00015113101,0.00023472728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010723833,0.0003467461,0.0020203425,0.00023962738,0.00016180471,0.00007260547,0.00046157732,0.00025234735,0.00030392758],"category_scores_gemma":[0.0009394904,0.00019930319,0.00008029799,0.0010774626,0.0002407948,0.00013670343,0.0003351606,0.0004978556,0.000014873494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7358918,0.0035875104,0.24205993,0.000018147986,0.0034290026,0.00035610693,0.00012000491,0.0000053950366,0.000078920566,0.000025151729,0.001219666,0.013208312],"study_design_scores_gemma":[0.6651188,0.0041963933,0.32561967,0.00005115441,0.001261053,0.0000032393425,0.00006594802,0.0013052643,0.000026989142,0.000044372755,0.0021613927,0.0001457097],"about_ca_topic_score_codex":0.0054829596,"about_ca_topic_score_gemma":0.011305032,"teacher_disagreement_score":0.08355974,"about_ca_system_score_codex":0.000785464,"about_ca_system_score_gemma":0.0008241126,"threshold_uncertainty_score":0.82886314},"labels":[],"label_agreement":null},{"id":"W4412620910","doi":"10.1200/op-25-00322","title":"Patient Preferences on Clinical Decision Making in Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Multiple myeloma; Medicine; Toxicity; Dyscrasia; Internal medicine; Progression-free survival; Bortezomib; Oncology; Drug; Maintenance therapy; Chemotherapy; Plasma cell; Pharmacology","score_opus":0.11210540083162775,"score_gpt":0.49822999267785695,"score_spread":0.3861245918462292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412620910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9011236,0.00022157276,0.0001738016,0.004970863,0.00056316686,0.0008716457,0.0000042715074,0.000045850335,0.092025235],"genre_scores_gemma":[0.9809855,0.00026298512,0.0146999005,0.0035592671,0.00006515988,0.00009966827,0.000010629119,0.000009531791,0.00030735522],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976318,0.0006725154,0.0005745698,0.0004426683,0.00033130043,0.00034715136],"domain_scores_gemma":[0.98635525,0.012809907,0.0001837934,0.00036377084,0.00016024084,0.00012705004],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009847969,0.0001461358,0.00041344506,0.00028807356,0.00009976605,0.000020062062,0.00011016919,0.00026602592,0.00011294956],"category_scores_gemma":[0.019054161,0.000111874666,0.000087152526,0.0003335238,0.00010078786,0.00015921274,0.0001408049,0.0007419541,0.00028378257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010568154,0.0027597314,0.29037225,0.000015340556,0.0001265827,0.0009480008,0.000115119496,0.000007460995,0.000027319862,0.0001985578,0.002440937,0.69242054],"study_design_scores_gemma":[0.007837551,0.005054117,0.77052575,0.00037465885,0.000092778755,0.000060061957,0.0005944618,0.0008793246,0.00011613406,0.00042569046,0.21393988,0.00009959283],"about_ca_topic_score_codex":0.00009044483,"about_ca_topic_score_gemma":0.00033595384,"teacher_disagreement_score":0.69232094,"about_ca_system_score_codex":0.0004077784,"about_ca_system_score_gemma":0.0005561508,"threshold_uncertainty_score":0.98920876},"labels":[],"label_agreement":null},{"id":"W4412690814","doi":"10.1002/ajh.70015","title":"Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events","year":2025,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"GlaxoSmithKline","keywords":"Medicine; MEDLINE; Intensive care medicine; Political science","score_opus":0.09633654355105074,"score_gpt":0.501464673043311,"score_spread":0.40512812949226024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412690814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009524878,0.9952842,0.00019303613,0.00069564197,0.00037535775,0.00093520444,0.00004043039,0.000013730605,0.0015098874],"genre_scores_gemma":[0.0018113761,0.9920053,0.005478928,0.00011396609,0.00006241823,0.000021332731,0.000036971334,0.000035093293,0.00043463238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99495065,0.0012527046,0.0022807652,0.00035391963,0.0007025361,0.00045943356],"domain_scores_gemma":[0.9940991,0.0017613843,0.003007798,0.0004940165,0.00030819382,0.0003295399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011432341,0.00037191203,0.0049527725,0.00046365638,0.000038052814,0.0000049026903,0.00031475807,0.00022697737,0.000072360934],"category_scores_gemma":[0.0013918659,0.00025475406,0.0012933469,0.0005453284,0.00034525158,0.00003156748,0.00013947897,0.001064243,0.000056403274],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088744995,0.0026876081,0.006129207,0.011275694,0.011856448,0.01444992,0.0000071540576,1.1900597e-7,4.7085e-8,0.0007955924,0.0038989794,0.94801176],"study_design_scores_gemma":[0.012761263,0.021325065,0.0062237913,0.21050291,0.019153032,0.022977937,0.00023173697,0.000008616215,0.00000987165,0.0001704286,0.7059115,0.00072386063],"about_ca_topic_score_codex":0.000009533071,"about_ca_topic_score_gemma":9.940991e-7,"teacher_disagreement_score":0.9472879,"about_ca_system_score_codex":0.00021385876,"about_ca_system_score_gemma":0.0009339495,"threshold_uncertainty_score":0.99999046},"labels":[],"label_agreement":null},{"id":"W4412779709","doi":"10.3324/haematol.2025.288041","title":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McMaster University","funders":"Sanofi","keywords":"Medicine; Multiple myeloma; Internal medicine; Hematopoietic cell; Cumulative incidence; Transplantation; Incidence (geometry); Population; Hematopoietic stem cell transplantation; Surgery; Gastroenterology; Haematopoiesis; Stem cell","score_opus":0.0236028157870531,"score_gpt":0.32334170441655197,"score_spread":0.2997388886294989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412779709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970847,0.00024133068,0.000021589029,0.00008328126,0.00004693481,0.0008663342,0.00004473942,0.0000249315,0.0015861691],"genre_scores_gemma":[0.9993726,0.00026849087,0.00006174396,0.000022261278,0.0000038490557,0.00015057839,0.000053997042,0.000007726442,0.00005873557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865323,0.00018788746,0.00033677262,0.0002692085,0.00023970768,0.00031320273],"domain_scores_gemma":[0.998711,0.0007761116,0.00007959563,0.00027979026,0.000057655896,0.00009586623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001727048,0.0001774408,0.00044515263,0.000112200985,0.00007932227,0.000019425426,0.000092368515,0.00010761528,0.000024198214],"category_scores_gemma":[0.00024096521,0.00009847137,0.000109514505,0.00019984337,0.0001653873,0.000037702266,0.000032616455,0.00015554758,0.000006820358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025029636,0.0007641087,0.99185884,0.00029601288,0.00008078734,0.0013087734,0.0002745624,0.0000076041715,0.000079860976,0.00006738119,0.00003742855,0.002721649],"study_design_scores_gemma":[0.0053588287,0.0004935961,0.99159354,0.00015669464,0.000040840103,0.000010857947,0.00008036205,0.00017670357,0.0017659916,0.00024332319,0.0000050704725,0.00007420935],"about_ca_topic_score_codex":0.0006644673,"about_ca_topic_score_gemma":0.000530174,"teacher_disagreement_score":0.0028558648,"about_ca_system_score_codex":0.000057252968,"about_ca_system_score_gemma":0.000060523584,"threshold_uncertainty_score":0.40155458},"labels":[],"label_agreement":null},{"id":"W4412891869","doi":"10.1016/j.jtct.2025.07.023","title":"Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Paula and Rodger Riney Foundation; University of Texas MD Anderson Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society","keywords":"Medicine; Multiple myeloma; Internal medicine; Hazard ratio; Concomitant; Propensity score matching; Hematopoietic stem cell transplantation; Single Center; Oncology; Retrospective cohort study; Progression-free survival; Transplantation; Overall survival; Proportional hazards model; Surgery; Gastroenterology; Confidence interval","score_opus":0.010592422072602824,"score_gpt":0.2443225478716972,"score_spread":0.23373012579909436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412891869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907857,0.000368683,0.007506577,0.00008241556,0.000027897488,0.00075900165,0.0000539865,0.000041803938,0.00037390293],"genre_scores_gemma":[0.99821997,0.00042708445,0.00055306475,0.00007883213,0.0000032873338,0.000036569993,0.00037757662,0.000016693384,0.0002869051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990225,0.000054738466,0.00020470242,0.00022904798,0.00029018216,0.00019882873],"domain_scores_gemma":[0.9995745,0.00008004145,0.000054813823,0.000142099,0.00006280672,0.000085778294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064298365,0.00017927011,0.00031534382,0.00013928965,0.00008846943,0.0000116817755,0.000045198467,0.00006480609,0.000015351046],"category_scores_gemma":[6.2492484e-7,0.00011140901,0.00006972895,0.00014738382,0.00005324246,0.00006712754,0.0000016926473,0.00009009394,0.0000018616463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006418266,0.0004551303,0.96357954,0.00026811508,0.0004440637,0.00013355605,0.0010225938,0.0000087515455,0.0076180995,0.000031548698,0.0000015385837,0.020018827],"study_design_scores_gemma":[0.02022878,0.0008654661,0.8861991,0.00015009608,0.00020771594,0.0000047861413,0.00010840944,0.00014599082,0.09191103,0.0000050992508,0.000060341692,0.00011316097],"about_ca_topic_score_codex":0.000058912825,"about_ca_topic_score_gemma":0.00003849128,"teacher_disagreement_score":0.08429293,"about_ca_system_score_codex":0.00001884603,"about_ca_system_score_gemma":0.00005455337,"threshold_uncertainty_score":0.45431277},"labels":[],"label_agreement":null},{"id":"W4413055524","doi":"10.1038/s43018-025-01006-0","title":"SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Circulating tumor cell; Multiple myeloma; Malignancy; Bone marrow; Computational biology; Cancer research; Biology; RNA-Seq; Transcriptome; Medicine; Pathology; Internal medicine; Immunology; Gene; Metastasis; Cancer; Gene expression; Genetics","score_opus":0.026646576898140453,"score_gpt":0.305176710401668,"score_spread":0.27853013350352757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413055524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730597,0.024317361,0.000009612171,0.00018112725,0.00019680204,0.0011218876,0.00010530337,0.00002873596,0.000979451],"genre_scores_gemma":[0.99815,0.0002370598,0.00088157284,0.00020962485,0.00004672677,0.000084149775,0.000029556646,0.000022945082,0.00033836736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862784,0.0000610646,0.00029941983,0.0003854038,0.00025779646,0.00036849664],"domain_scores_gemma":[0.9992163,0.00020488286,0.000085917054,0.00016753933,0.00021229139,0.00011304777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081636426,0.00020292819,0.0004363591,0.00026779808,0.000056140252,0.000013341263,0.00008304141,0.00019979278,0.000030883766],"category_scores_gemma":[0.00012072326,0.00017438715,0.000077829034,0.0003839702,0.00006226579,0.00007627539,0.000035756297,0.0005697717,0.0000016744896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064390904,0.00024822843,0.0962075,0.0016834134,0.00011646629,0.00010201431,0.00040688072,0.00009638107,0.8960987,0.00005463701,0.0000653117,0.0042765564],"study_design_scores_gemma":[0.0063975616,0.00012519388,0.06935931,0.0010664703,0.00007732127,0.000006882366,0.00033507464,0.0052952515,0.9166592,0.000036552872,0.00049888593,0.0001422904],"about_ca_topic_score_codex":0.00016160682,"about_ca_topic_score_gemma":0.00025873745,"teacher_disagreement_score":0.026848191,"about_ca_system_score_codex":0.00021320349,"about_ca_system_score_gemma":0.00024259934,"threshold_uncertainty_score":0.7111302},"labels":[],"label_agreement":null},{"id":"W4413103009","doi":"10.57264/cer-2024-0180","title":"Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Oncology; Population; Progression-free survival; Refractory (planetary science); Randomized controlled trial; Overall survival","score_opus":0.08580465074146751,"score_gpt":0.439554261778722,"score_spread":0.35374961103725444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413103009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590707,0.0014644252,0.00019410717,0.00005376091,0.00006382834,0.0022119798,0.000010781182,0.000005801661,0.00008826004],"genre_scores_gemma":[0.99915266,0.00048421317,0.000063457876,0.0000014657772,0.000020288015,0.00013901843,0.000006904191,0.000011727214,0.00012027713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99595696,0.0022645087,0.0005726569,0.00029286725,0.0005747471,0.00033825537],"domain_scores_gemma":[0.98605853,0.012653226,0.00021137566,0.00020275918,0.0006506755,0.00022343884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021379767,0.00022087802,0.0009570255,0.0012463711,0.00012625949,0.00004454127,0.00010343671,0.00010687436,0.0000075391977],"category_scores_gemma":[0.002873271,0.00013150058,0.00010186278,0.0007703018,0.000397933,0.00020476781,0.00006159808,0.0004825346,0.0000014851104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017653294,0.000982404,0.8792899,0.00065665797,0.00058778346,0.00025313228,0.0012033494,0.000060182538,0.086347915,0.00003604338,0.000017006467,0.012912338],"study_design_scores_gemma":[0.014556328,0.009022584,0.86624134,0.0009930973,0.000076977856,0.000021953818,0.0005930096,0.0017522277,0.106551245,0.00008352272,0.000036284455,0.00007140604],"about_ca_topic_score_codex":0.00022804952,"about_ca_topic_score_gemma":0.0001031674,"teacher_disagreement_score":0.02020333,"about_ca_system_score_codex":0.000723801,"about_ca_system_score_gemma":0.0005858571,"threshold_uncertainty_score":0.5362438},"labels":[],"label_agreement":null},{"id":"W4413260191","doi":"10.2139/ssrn.5379364","title":"Real-World Outcomes in Myeloma Patients with T (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Princess Margaret Cancer Centre; McMaster University; London Health Sciences Centre; CancerCare Manitoba; Vancouver General Hospital","funders":"","keywords":"Multiple myeloma; Database; Medicine; Internal medicine; Computer science","score_opus":0.11041373714093715,"score_gpt":0.44959884668376254,"score_spread":0.3391851095428254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413260191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98853785,0.00055421103,0.0001460715,0.0051011927,0.0003958488,0.0025889361,0.00028864047,0.000033270917,0.0023539565],"genre_scores_gemma":[0.99455655,0.0007389306,0.0011354423,0.0001990486,0.00039056948,0.00011093428,0.0007400534,0.00006615141,0.0020623193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98862934,0.0015294704,0.001356981,0.0008997935,0.0031031352,0.0044812635],"domain_scores_gemma":[0.9955531,0.00082211697,0.00043454033,0.0008992708,0.0014915789,0.0007994004],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010168371,0.00055238296,0.0012193464,0.0020963324,0.0009101783,0.00026272467,0.00093265506,0.00041444032,0.00006853933],"category_scores_gemma":[0.0011636429,0.0003595921,0.00032653048,0.0010804604,0.00034536287,0.00016420189,0.0006101496,0.014300951,0.000022450404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012885256,0.0010088241,0.98567843,0.00008354028,0.0013353393,0.0001477145,0.00013505874,0.000066056746,0.0000029666833,0.005321759,0.0004816632,0.0044501293],"study_design_scores_gemma":[0.008703579,0.0006680043,0.9748778,0.0009137222,0.00020809392,0.000054130433,0.0005747204,0.0024319403,0.0000061636156,0.010510654,0.00068105786,0.00037014947],"about_ca_topic_score_codex":0.26925328,"about_ca_topic_score_gemma":0.96528095,"teacher_disagreement_score":0.69602764,"about_ca_system_score_codex":0.016541941,"about_ca_system_score_gemma":0.053012185,"threshold_uncertainty_score":0.9998856},"labels":[],"label_agreement":null},{"id":"W4413316408","doi":"10.1182/bloodadvances.2025017214","title":"Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Ontario Institute for Cancer Research","funders":"Astellas Pharma; International Myeloma Society; Celgene; BeiGene; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Multiple myeloma; Medicine; Internal medicine; Odds ratio; Confidence interval; Population; Disease; Stage (stratigraphy); Bone marrow; Biology; Environmental health","score_opus":0.03007711981643215,"score_gpt":0.38988789659169804,"score_spread":0.3598107767752659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413316408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907638,0.0060952483,0.000020475045,0.00016011714,0.000033514956,0.001958857,0.00003852324,0.000018831093,0.0009106284],"genre_scores_gemma":[0.9982887,0.00065891654,0.00027282172,0.000013141367,0.000018464098,0.00038867295,0.000033781154,0.0000052031182,0.00032031376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983903,0.00024772406,0.00030859772,0.00042946805,0.0004172774,0.00020661556],"domain_scores_gemma":[0.9989076,0.00028560657,0.00009383669,0.00029071435,0.00027232696,0.0001498896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059870526,0.00013349057,0.00041979618,0.0006401236,0.000052942272,0.0000057719303,0.00007446724,0.00002680685,0.000040800904],"category_scores_gemma":[0.0015991847,0.00010116484,0.000057948724,0.0012197868,0.00015740306,0.00009890332,0.000059816437,0.00008473375,9.2917355e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048330083,0.0017316935,0.98683584,0.00018775855,0.0006878037,0.000026509713,0.00020918183,0.00003285833,0.00015254383,0.00011029541,0.0000027647393,0.0095394375],"study_design_scores_gemma":[0.008648551,0.00032798637,0.9842708,0.00012620431,0.003245625,2.962872e-7,0.0002569235,0.0016930011,0.0004865881,0.0008595809,0.000017860933,0.00006657708],"about_ca_topic_score_codex":0.00056781573,"about_ca_topic_score_gemma":0.008478567,"teacher_disagreement_score":0.00947286,"about_ca_system_score_codex":0.00007294746,"about_ca_system_score_gemma":0.00023309776,"threshold_uncertainty_score":0.4731239},"labels":[],"label_agreement":null},{"id":"W4413412436","doi":"10.51731/cjht.2025.1197","title":"Daratumumab (Darzalex SC)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Multiple myeloma; Lenalidomide","score_opus":0.035072396872024375,"score_gpt":0.354769225012068,"score_spread":0.31969682814004363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413412436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39484134,0.28771183,0.00081699615,0.29639366,0.0010658136,0.0011814749,0.000052332965,0.0002891547,0.017647378],"genre_scores_gemma":[0.99725825,0.0005725385,0.0009953217,0.00051288935,0.0000065949366,0.000004715018,0.0000029702198,0.000006756181,0.00063996954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988507,0.00003348932,0.00038280303,0.000105739564,0.00015111954,0.00047616693],"domain_scores_gemma":[0.9992077,0.000041562856,0.0001367685,0.0002552089,0.00020192104,0.00015684539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034622813,0.00009703788,0.00034910368,0.0010797587,0.00025440863,0.000024532606,0.00020609934,0.000108531895,0.000038583836],"category_scores_gemma":[0.0008727453,0.00007373232,0.000077838245,0.0004625019,0.00019680965,0.000058557645,0.00001844732,0.0004488134,0.000015561938],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005627479,0.000033011907,0.05171574,0.0001371157,0.00013007227,0.00083714415,0.000047400372,0.0000010030446,0.000029598823,0.0018576831,0.017594561,0.9275604],"study_design_scores_gemma":[0.0038737503,0.0013650857,0.23973586,0.0013737199,0.000044107055,0.00082322885,0.0021174313,0.000031989213,0.0020493928,0.0055905385,0.74285346,0.00014144518],"about_ca_topic_score_codex":0.003368817,"about_ca_topic_score_gemma":0.0032043068,"teacher_disagreement_score":0.92741895,"about_ca_system_score_codex":0.00063717633,"about_ca_system_score_gemma":0.006285821,"threshold_uncertainty_score":0.9993476},"labels":[],"label_agreement":null},{"id":"W4413684526","doi":"10.51731/cjht.2025.1205","title":"Pemigatinib (Pemazyre)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.03601682565298907,"score_gpt":0.3585972738525122,"score_spread":0.32258044819952314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413684526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5082622,0.15914978,0.0007177377,0.32056275,0.0006880754,0.0009265955,0.000032735075,0.00021872918,0.009441411],"genre_scores_gemma":[0.99681246,0.00045529363,0.0015385858,0.0006335745,0.00000586368,0.000004959602,0.000002367434,0.0000058692476,0.0005410034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894613,0.00003233477,0.00038345705,0.000090887,0.00013342974,0.0004137424],"domain_scores_gemma":[0.99925447,0.000057008736,0.0001415822,0.00021684906,0.00018973558,0.00014034745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038051401,0.000084691885,0.0003235747,0.00083741866,0.00016654491,0.000018237737,0.00017541165,0.000096090014,0.000038564518],"category_scores_gemma":[0.0011751584,0.00006365301,0.000073584044,0.00039239778,0.00017079414,0.00004490332,0.000014455672,0.0003945661,0.000012128962],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003554375,0.000025641368,0.08676213,0.00016494516,0.000107369575,0.000525122,0.00006347073,8.248557e-7,0.00003401282,0.0014895529,0.013145177,0.8976462],"study_design_scores_gemma":[0.004650006,0.0016330832,0.31651807,0.0020743313,0.000055814966,0.00094191014,0.004428106,0.000040563675,0.004027571,0.011803502,0.6536544,0.0001726652],"about_ca_topic_score_codex":0.003297409,"about_ca_topic_score_gemma":0.002172777,"teacher_disagreement_score":0.8974736,"about_ca_system_score_codex":0.00046200148,"about_ca_system_score_gemma":0.0058395597,"threshold_uncertainty_score":0.9997964},"labels":[],"label_agreement":null},{"id":"W4413749345","doi":"10.64628/aam.twfw3fmw3","title":"We need answers to the thalidomide tragedy – to ensure drug safety today","year":2018,"lang":"en","type":"article","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tragedy (event); Thalidomide; Drug; Engineering ethics; Business; Medicine; Engineering; Pharmacology; Art; Literature; Multiple myeloma; Internal medicine","score_opus":0.023607338774195692,"score_gpt":0.3152285685134283,"score_spread":0.2916212297392326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413749345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69881815,0.00011145398,0.0009923407,0.17603792,0.0003273816,0.0024569763,0.000050235278,0.0001576713,0.12104785],"genre_scores_gemma":[0.940641,0.00002518947,0.0019936382,0.004095584,0.00040482453,0.000054416043,0.000015118661,0.000022988439,0.05274725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984442,0.000095311756,0.00019080515,0.00030635952,0.00046878742,0.0004945443],"domain_scores_gemma":[0.9985059,0.00015993704,0.000017667158,0.0005744092,0.00012894443,0.0006131771],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004040429,0.00016879376,0.00023409916,0.000110488916,0.00019929178,0.00003346732,0.00018760687,0.000045269175,0.0019846016],"category_scores_gemma":[0.0002869681,0.000088518034,0.000095076924,0.00037100018,0.00006160105,0.00004322508,0.00008347992,0.00014950929,0.003002601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00840972,0.0006616048,0.03987262,0.00006976239,0.00083530234,0.0004010651,0.016590795,0.000017136814,0.016747693,0.0011722347,0.6836233,0.23159875],"study_design_scores_gemma":[0.006766715,0.0015353475,0.18714876,0.0001369035,0.000099746474,0.00006704901,0.0044677095,0.00021505922,0.045898438,0.000073504096,0.75327164,0.0003191097],"about_ca_topic_score_codex":0.0008014509,"about_ca_topic_score_gemma":0.0013317344,"teacher_disagreement_score":0.24182282,"about_ca_system_score_codex":0.00009931665,"about_ca_system_score_gemma":0.00009066076,"threshold_uncertainty_score":0.9989277},"labels":[],"label_agreement":null},{"id":"W4413774531","doi":"10.1016/s2152-2650(25)01319-9","title":"POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine","score_opus":0.03154759248529704,"score_gpt":0.3419932738643108,"score_spread":0.31044568137901374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956823,0.0021049783,0.000009349326,0.00026880353,0.00065464806,0.005921235,0.00018282705,0.00017788207,0.0011120411],"genre_scores_gemma":[0.9960469,0.0009279602,0.00040044394,0.00054420874,0.00013869027,0.00043116193,0.0006596011,0.00018224727,0.00066880346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98736066,0.0021330703,0.0044506546,0.0023988092,0.0017486144,0.0019081966],"domain_scores_gemma":[0.990207,0.0048161224,0.0010009005,0.002444514,0.0005728665,0.00095855247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027561784,0.0012435417,0.0034488568,0.0013039848,0.00024487195,0.00008924453,0.0010927165,0.00111878,0.00013352779],"category_scores_gemma":[0.0045856778,0.0011096273,0.00072492,0.0023117736,0.00071570213,0.0003211243,0.0005879972,0.001591507,0.00010727387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021331651,0.02486284,0.66873854,0.00011274596,0.00073076715,0.0006781802,0.00047611207,0.000007651508,0.0007693848,0.000010316706,0.0009427719,0.28133902],"study_design_scores_gemma":[0.13626346,0.008354738,0.84940886,0.00073799316,0.00019729369,0.000016706686,0.00036066998,0.00033035144,0.0024490268,0.00002696406,0.0011729737,0.0006809732],"about_ca_topic_score_codex":0.0039015908,"about_ca_topic_score_gemma":0.0016844305,"teacher_disagreement_score":0.28065807,"about_ca_system_score_codex":0.0034278007,"about_ca_system_score_gemma":0.0020929214,"threshold_uncertainty_score":0.9991354},"labels":[],"label_agreement":null},{"id":"W4413781006","doi":"10.1016/s2152-2650(25)02676-x","title":"MM-1049: DREAMM-7 Study of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","score_opus":0.032112283500004626,"score_gpt":0.3444139536119541,"score_spread":0.3123016701119495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413781006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896647,0.0021236434,0.000016882273,0.00024164851,0.0006511168,0.005872199,0.00017101086,0.00018639624,0.0010724453],"genre_scores_gemma":[0.9956485,0.0010478954,0.00064959185,0.00045283602,0.00014620184,0.00049515284,0.0006223327,0.00018593777,0.0007515627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872224,0.002114792,0.0044581974,0.0024454033,0.0018073855,0.0019518345],"domain_scores_gemma":[0.99009156,0.0048992615,0.0010034619,0.002476332,0.00055557786,0.00097378535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028958712,0.0012552231,0.0035071028,0.0013058772,0.00025258044,0.0000855127,0.001107462,0.0011488751,0.00015468516],"category_scores_gemma":[0.0050954744,0.0011241039,0.00073161855,0.0024823176,0.00074394536,0.0003080089,0.0005627778,0.0016599549,0.000114054514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01999973,0.026461357,0.65385056,0.00011433788,0.00074784004,0.0006807007,0.00040882846,0.000013140288,0.0006859356,0.000016350865,0.0011515566,0.29586968],"study_design_scores_gemma":[0.14196256,0.007288923,0.84450346,0.00070113695,0.00020067174,0.000014306545,0.0004311558,0.00057368114,0.0021379287,0.000036773898,0.0014631922,0.00068624644],"about_ca_topic_score_codex":0.0039633536,"about_ca_topic_score_gemma":0.0016575878,"teacher_disagreement_score":0.29518342,"about_ca_system_score_codex":0.0036971495,"about_ca_system_score_gemma":0.002266757,"threshold_uncertainty_score":0.9991209},"labels":[],"label_agreement":null},{"id":"W4413782928","doi":"10.1016/s2152-2650(25)01341-2","title":"POSTER: MM-1193 Daratumumab-Bortezomib-Lenalidomide-Dexamethasone vs Contemporary Treatment Alternatives in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Results of a Systematic Literature Review and Network Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Multiple myeloma; Meta-analysis; Bortezomib; Dexamethasone; Oncology; Internal medicine","score_opus":0.06223099620461319,"score_gpt":0.3533510164860563,"score_spread":0.2911200202814431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413782928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.777352,0.21097018,0.00007574604,0.0012996923,0.00012879254,0.007805399,0.0012519973,0.00010698791,0.0010092439],"genre_scores_gemma":[0.96974444,0.02474806,0.0012328865,0.0012128666,0.00006976951,0.0008304926,0.001316433,0.00006160979,0.00078346033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912125,0.0017880184,0.0037084457,0.0015415784,0.0009115975,0.0008378932],"domain_scores_gemma":[0.99056035,0.005384195,0.0011787497,0.0015921044,0.0006552258,0.0006293566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018375404,0.0009560757,0.007356987,0.0007331714,0.00015643261,0.00010507645,0.00042984812,0.0003742359,0.000026142223],"category_scores_gemma":[0.0018486364,0.00058615184,0.0017640841,0.0026496886,0.00042316277,0.00031237342,0.00013757328,0.0003954221,0.000011790498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03077061,0.0029990843,0.7657105,0.0334127,0.15423854,0.002911233,0.00055514666,0.000058346355,0.000009935952,0.00004358424,0.0011061557,0.008184199],"study_design_scores_gemma":[0.053302366,0.0023071324,0.83166194,0.0214877,0.08977027,0.000033642853,0.000035513614,0.00053607294,0.00014282746,0.000027749511,0.00022206256,0.00047270194],"about_ca_topic_score_codex":0.00080995524,"about_ca_topic_score_gemma":0.0006157334,"teacher_disagreement_score":0.19239245,"about_ca_system_score_codex":0.00065423764,"about_ca_system_score_gemma":0.0009628986,"threshold_uncertainty_score":0.999659},"labels":[],"label_agreement":null},{"id":"W4413783339","doi":"10.1016/s2152-2650(25)02742-9","title":"MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Internal medicine; Oncology; Subgroup analysis; Bortezomib; Multiple myeloma; Refractory (planetary science); Lenalidomide; Confidence interval","score_opus":0.016639519967585864,"score_gpt":0.2954803109364394,"score_spread":0.2788407909688535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944503,0.0014147576,0.000059004156,0.000081378086,0.00013556758,0.0034051747,0.00021233456,0.00009479502,0.00014674566],"genre_scores_gemma":[0.995603,0.00066807005,0.0024948646,0.00015573506,0.000077275596,0.00031579178,0.00025287713,0.00011050201,0.0003218486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903714,0.0019400113,0.0030624494,0.002010322,0.0012351864,0.0013806302],"domain_scores_gemma":[0.9907943,0.005501446,0.00093760435,0.0015299615,0.00041132234,0.0008253789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025031331,0.0010133344,0.003797684,0.0020780494,0.00024404266,0.000103872495,0.00047674493,0.0007137938,0.00005338032],"category_scores_gemma":[0.0032811053,0.0008546402,0.0003886916,0.0027787453,0.0010133977,0.00028794006,0.00064554403,0.0009603726,0.000010523132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037870962,0.0033762932,0.89529216,0.000276613,0.0032470564,0.0009823664,0.0010038269,0.0001791019,0.000047816,0.000027256696,0.000026242193,0.05767031],"study_design_scores_gemma":[0.12540549,0.005207187,0.86120063,0.0004783576,0.002364562,0.000026914751,0.0015013398,0.002896156,0.00023146006,0.00006288235,0.000022050353,0.00060299685],"about_ca_topic_score_codex":0.022632437,"about_ca_topic_score_gemma":0.015988251,"teacher_disagreement_score":0.08753453,"about_ca_system_score_codex":0.0021360046,"about_ca_system_score_gemma":0.0015251713,"threshold_uncertainty_score":0.9993904},"labels":[],"label_agreement":null},{"id":"W4413788439","doi":"10.1016/s2152-2650(25)02630-8","title":"MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Daratumumab; Multiple myeloma; Oncology; Internal medicine; Bortezomib","score_opus":0.03567797545871287,"score_gpt":0.36619478685123347,"score_spread":0.3305168113925206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413788439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954293,0.00015841996,0.000043372605,0.000041229836,0.00079125864,0.0028586504,0.00008018153,0.00012613232,0.00047146372],"genre_scores_gemma":[0.9980184,0.00012819955,0.0009891208,0.000033010972,0.00020581766,0.0002740272,0.00009315024,0.00009550568,0.00016276444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99462676,0.0005178319,0.0016190283,0.0012685336,0.0010197839,0.0009480665],"domain_scores_gemma":[0.99527526,0.0018886165,0.0005448252,0.0013543738,0.00043325956,0.0005036627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005598867,0.00065175944,0.0015800835,0.00058046106,0.0002601397,0.000054644115,0.00047950866,0.0003870875,0.00003869069],"category_scores_gemma":[0.0013629145,0.00053694536,0.00029359089,0.0011346019,0.00033386174,0.00029602513,0.00026688178,0.0006817828,0.00003176298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047016848,0.005810477,0.5494621,0.00004775044,0.0010616728,0.0002309636,0.00030272568,0.00003003942,0.000090461865,0.0000064346423,0.000024123065,0.39591646],"study_design_scores_gemma":[0.17989084,0.009994275,0.80439025,0.00042083632,0.0002835387,0.0000017762364,0.0006875706,0.0005095584,0.0033560588,0.000019114015,0.000117871525,0.00032827625],"about_ca_topic_score_codex":0.0020330593,"about_ca_topic_score_gemma":0.00035193612,"teacher_disagreement_score":0.3955882,"about_ca_system_score_codex":0.0018728712,"about_ca_system_score_gemma":0.0010004039,"threshold_uncertainty_score":0.99970824},"labels":[],"label_agreement":null},{"id":"W4413791120","doi":"10.1016/s2152-2650(25)00902-4","title":"POSTER: MPN-780 Safety and Efficacy of Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis (MF) and Other Advanced Myeloid Neoplasms: A Phase 1 Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Bromodomain; Refractory (planetary science); Myeloid; Phases of clinical research; Internal medicine; Cancer research; Oncology; Clinical trial; Epigenetics; Bone marrow; Gene","score_opus":0.020424472641104884,"score_gpt":0.3417641464352782,"score_spread":0.32133967379417333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591345,0.0005161412,0.000011851543,0.00010422071,0.000106186344,0.0027969792,0.00013274155,0.00006182899,0.00035659835],"genre_scores_gemma":[0.9976605,0.00023309713,0.0010949402,0.0002833783,0.00006292332,0.00009030928,0.000058935693,0.000072921845,0.0004430047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526435,0.0005363227,0.0016440066,0.0012462673,0.00062749645,0.0006815314],"domain_scores_gemma":[0.9957482,0.002258765,0.00039444515,0.000763517,0.00019230375,0.00064273115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008026042,0.00059697416,0.0015601651,0.00042911456,0.00018553137,0.000060642764,0.00019038575,0.0003782527,0.000040364448],"category_scores_gemma":[0.0011886322,0.00043190332,0.00012563409,0.000582911,0.00085220387,0.00027299524,0.0004251101,0.00043025962,0.0000058238784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06604556,0.0032817489,0.5016228,0.00020404201,0.00030407077,0.0003262535,0.00033452344,2.516786e-7,0.00028562755,0.0000076072256,0.000028021565,0.42755952],"study_design_scores_gemma":[0.12960778,0.014463123,0.8528604,0.0010969214,0.00027497945,0.000051372685,0.00031162615,0.00010001336,0.0002499142,0.00002421902,0.00062412454,0.00033551556],"about_ca_topic_score_codex":0.00019884539,"about_ca_topic_score_gemma":0.0001856223,"teacher_disagreement_score":0.427224,"about_ca_system_score_codex":0.0005547718,"about_ca_system_score_gemma":0.0009479985,"threshold_uncertainty_score":0.99981326},"labels":[],"label_agreement":null},{"id":"W4413791590","doi":"10.1016/s2152-2650(25)02640-0","title":"MM-771: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-ineligible (TIE) Patients in the Phase 3 CEPHEUS Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Oncology; Internal medicine; Subgroup analysis; Confidence interval","score_opus":0.02306697003661301,"score_gpt":0.3389365604046721,"score_spread":0.3158695903680591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454534,0.00031845222,0.000094452575,0.00012970816,0.0001416207,0.0040263645,0.00034266402,0.000054191492,0.00034721766],"genre_scores_gemma":[0.997306,0.00023208548,0.0004164904,0.00050282327,0.00004755393,0.00035081737,0.0010057144,0.000058913258,0.00007964072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925272,0.0011701793,0.0024778193,0.0014158005,0.00134217,0.0010668372],"domain_scores_gemma":[0.9931501,0.004033851,0.0005110685,0.0013903565,0.00043266604,0.00048193557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016484438,0.0007409437,0.0025100166,0.0014419106,0.0002023218,0.000091210226,0.00064994855,0.0003618447,0.000043784723],"category_scores_gemma":[0.0017998741,0.00050587463,0.00048253266,0.0038422698,0.000560849,0.00028592718,0.000189592,0.0006344015,0.00001079718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027912974,0.010513813,0.8167167,0.00012039352,0.0022064464,0.000663475,0.0011935044,0.000050774295,0.0000096443455,0.000013084613,0.00013950071,0.14045973],"study_design_scores_gemma":[0.15762566,0.003764964,0.8317453,0.00035039007,0.0018525089,0.0000029205814,0.00062736176,0.003454031,0.00006753813,0.000017668131,0.0001313732,0.0003602234],"about_ca_topic_score_codex":0.0054184184,"about_ca_topic_score_gemma":0.0076310937,"teacher_disagreement_score":0.1400995,"about_ca_system_score_codex":0.0010431554,"about_ca_system_score_gemma":0.0010614478,"threshold_uncertainty_score":0.9997393},"labels":[],"label_agreement":null},{"id":"W4413791744","doi":"10.1016/s2152-2650(25)02669-2","title":"MM-1034: Characterization of Ophthalmic Examination Findings and Impact on Reading and Driving in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Reading (process); Characterization (materials science); Ophthalmology; Internal medicine; Optics; Metallurgy; Linguistics","score_opus":0.014288166023179479,"score_gpt":0.2982431722143342,"score_spread":0.2839550061911547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817914,0.00003232494,0.00002190016,0.000047512207,0.000041338437,0.0011485809,0.000043283133,0.000054993634,0.00043090043],"genre_scores_gemma":[0.99861866,0.00010130402,0.00024708096,0.000055689092,0.00003302791,0.00004947301,0.0005104327,0.000053251824,0.00033109583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971744,0.00027507744,0.00082337315,0.00076659943,0.00047100356,0.0004895817],"domain_scores_gemma":[0.99769205,0.001052844,0.00031000047,0.00042509774,0.00021147798,0.00030852447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005250559,0.0004207734,0.00087911787,0.0005878878,0.00013193605,0.000049928938,0.00011301559,0.00031181597,0.000019677875],"category_scores_gemma":[0.0006844445,0.00029396339,0.0000867967,0.00060396345,0.000305986,0.00029448557,0.000092044764,0.0003081096,0.0000061256565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005771991,0.0006941614,0.79905456,0.000112184745,0.00022331136,0.00013076742,0.00009882064,0.000001587309,0.0023423433,0.000015892507,0.0000067959418,0.19154757],"study_design_scores_gemma":[0.023396395,0.0042595337,0.9665361,0.0017927362,0.00013574703,0.000033286626,0.000040037,0.0012146538,0.002324119,0.0000063009234,0.000016710408,0.00024435722],"about_ca_topic_score_codex":0.00016967177,"about_ca_topic_score_gemma":0.000030841227,"teacher_disagreement_score":0.19130322,"about_ca_system_score_codex":0.0009082552,"about_ca_system_score_gemma":0.00039525205,"threshold_uncertainty_score":0.99995124},"labels":[],"label_agreement":null},{"id":"W4413796318","doi":"10.3324/haematol.2025.288203","title":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chimeric antigen receptor; TIGIT; Antigen; Immunology; B cell; Antibody; Multiple myeloma; T cell; CD19; Medicine; Cancer research; Immune system","score_opus":0.02896208532303257,"score_gpt":0.2932672466752372,"score_spread":0.2643051613522046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413796318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462706,0.0005261386,0.0002027224,0.0010135495,0.00027901545,0.0014198549,0.000024444982,0.00014885045,0.0017583924],"genre_scores_gemma":[0.9944666,0.00033463753,0.0006796157,0.0001559091,0.000035475343,0.00019805152,0.00014760841,0.000017563201,0.003964561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799454,0.00018283924,0.00056086556,0.00047480606,0.0003135935,0.00047335634],"domain_scores_gemma":[0.9989107,0.00029414578,0.00013948666,0.00043693208,0.00011071916,0.00010801968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027350808,0.0002562637,0.0006296906,0.00034449826,0.00016488382,0.0000441518,0.00015218156,0.00026394136,0.00019098139],"category_scores_gemma":[0.00045384647,0.00014830598,0.00010363831,0.000491126,0.00008138117,0.00012112587,0.0001057461,0.00032836024,0.00025406925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014685499,0.001611891,0.78511184,0.0020790882,0.0002633966,0.0058431,0.00039625115,0.000010539326,0.17580946,0.0004940497,0.0006278716,0.013067009],"study_design_scores_gemma":[0.010669184,0.00038570893,0.74866885,0.000978767,0.00006607575,0.0008695123,0.0007026712,0.0012749702,0.23560941,0.00007806339,0.0004520221,0.00024473792],"about_ca_topic_score_codex":0.0003585089,"about_ca_topic_score_gemma":0.00023061225,"teacher_disagreement_score":0.05979996,"about_ca_system_score_codex":0.00019875668,"about_ca_system_score_gemma":0.00017300026,"threshold_uncertainty_score":0.60477424},"labels":[],"label_agreement":null},{"id":"W4413807594","doi":"10.1038/s41408-025-01352-3","title":"Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Saskatchewan Cancer Agency; McMaster University; Ottawa Hospital; Institute of Cancer Research; Saskatoon Medical Imaging; University of Alberta; University of Calgary; University of Ottawa","funders":"Janssen Pharmaceuticals","keywords":"Multiple myeloma; Incidence (geometry); Medicine; Retrospective cohort study; Observational study; Population; Cohort; Cohort study; Internal medicine; Environmental health","score_opus":0.0452434986231261,"score_gpt":0.35435939692169266,"score_spread":0.30911589829856656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413807594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698056,0.0012385376,0.000029870927,0.026610652,0.0003428713,0.0017915354,0.00012137874,0.000022325847,0.00003720898],"genre_scores_gemma":[0.9800651,0.0006785174,0.0016225108,0.013345532,0.0023027542,0.000276465,0.00004781951,0.00003592811,0.0016253545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627787,0.00036530185,0.001083808,0.00051343907,0.0014076883,0.00035190332],"domain_scores_gemma":[0.99732745,0.0004372698,0.0008471834,0.0004389961,0.0008106791,0.00013843944],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00094352564,0.00031995255,0.00069620897,0.00017787052,0.000323628,0.000082198036,0.00030774352,0.00027453623,0.00011521006],"category_scores_gemma":[0.0013758219,0.00021528346,0.00017015978,0.00030529496,0.00014841567,0.00012220067,0.00016297626,0.002359144,7.296732e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037474174,0.00019334875,0.99049765,0.00034712334,0.0018226834,0.00067198643,0.00017792886,0.000020986054,0.00009846708,0.0000013160675,0.0050452733,0.0007485229],"study_design_scores_gemma":[0.0039144563,0.0007982923,0.9915464,0.001006313,0.0013213636,0.0004838679,0.000028529616,0.0004304156,0.000101628655,0.000074758966,0.00012822016,0.00016575865],"about_ca_topic_score_codex":0.0010823647,"about_ca_topic_score_gemma":0.0002979737,"teacher_disagreement_score":0.01326512,"about_ca_system_score_codex":0.00027833553,"about_ca_system_score_gemma":0.00091274356,"threshold_uncertainty_score":0.9999425},"labels":[],"label_agreement":null},{"id":"W4413810249","doi":"10.1016/s2152-2650(25)01335-7","title":"POSTER: MM-1157 Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Class (philosophy); Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Artificial intelligence; Composite material","score_opus":0.029116074895706334,"score_gpt":0.35439127306206136,"score_spread":0.32527519816635503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266595,0.0006518014,0.0000058194387,0.00017964125,0.0003122098,0.005813948,0.000050673847,0.00007634895,0.00024361923],"genre_scores_gemma":[0.99846864,0.0001210685,0.00031747884,0.00011689405,0.0000911803,0.00041063063,0.00014222352,0.00006671648,0.00026517478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938171,0.00085679215,0.002340413,0.0013470597,0.0008267473,0.00081189367],"domain_scores_gemma":[0.9961539,0.0015197513,0.00053771917,0.0009451471,0.00030458806,0.0005388825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011233463,0.000602158,0.0018571309,0.0008137044,0.00012139299,0.00006837029,0.00028810205,0.00046679593,0.000023737288],"category_scores_gemma":[0.0020335738,0.00048103192,0.00017680075,0.00092159293,0.0007233721,0.00027549276,0.00032713247,0.0005598669,0.000006401962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14972822,0.011582101,0.5805512,0.00017658113,0.00032833955,0.00057249103,0.00043858064,4.7590592e-7,0.00017713915,0.000006569385,0.00006505098,0.25637323],"study_design_scores_gemma":[0.35426885,0.012584185,0.63061965,0.000547321,0.0001538362,0.000007751304,0.0004307142,0.00064812845,0.00034221832,0.000014902564,0.00013803848,0.00024442544],"about_ca_topic_score_codex":0.0006433622,"about_ca_topic_score_gemma":0.0009961546,"teacher_disagreement_score":0.25612882,"about_ca_system_score_codex":0.00074974867,"about_ca_system_score_gemma":0.0012709216,"threshold_uncertainty_score":0.99976414},"labels":[],"label_agreement":null},{"id":"W4413810439","doi":"10.1016/s2152-2650(25)02692-8","title":"MM-1157: Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Class (philosophy); Oncology; Lenalidomide; Internal medicine; Artificial intelligence","score_opus":0.030155378113087584,"score_gpt":0.3578107111767318,"score_spread":0.3276553330636442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289024,0.000645256,0.000010373964,0.00015116221,0.00030635102,0.005641951,0.00004258799,0.0000771936,0.00023487843],"genre_scores_gemma":[0.99826086,0.00013463268,0.0004827432,0.00009568002,0.00009582213,0.0004587542,0.00012519662,0.000064684624,0.00028162682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938888,0.0008309844,0.0023021451,0.0013393839,0.00083282194,0.000805871],"domain_scores_gemma":[0.99613094,0.0015837764,0.0005255521,0.000929515,0.0002939659,0.00053621817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011827418,0.0005891582,0.0018535447,0.00080134807,0.00012325191,0.00006278297,0.0002810979,0.00046506905,0.000025393096],"category_scores_gemma":[0.0023634199,0.00047086418,0.00017254152,0.0009872965,0.00075577555,0.00026005643,0.0002991736,0.00056968216,0.0000061935657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13907579,0.01233656,0.5694959,0.00017375301,0.0003290663,0.0005335047,0.0003856397,8.542357e-7,0.00015579007,0.000010774332,0.00008250377,0.27741984],"study_design_scores_gemma":[0.35725245,0.010904841,0.6288286,0.00051038107,0.00014960085,0.0000057433535,0.00048800028,0.0011306504,0.0002893862,0.000019853407,0.00018147881,0.00023903538],"about_ca_topic_score_codex":0.0006666122,"about_ca_topic_score_gemma":0.001020119,"teacher_disagreement_score":0.2771808,"about_ca_system_score_codex":0.0007650258,"about_ca_system_score_gemma":0.0013641319,"threshold_uncertainty_score":0.9997743},"labels":[],"label_agreement":null},{"id":"W4413826493","doi":"10.1002/ajh.70042","title":"Real‐World Outcomes of Transplant Ineligible Older Adults With Multiple Myeloma Treated With Novel Regimens: A Population‐Based Retrospective Cohort Study","year":2025,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; Hamilton Health Sciences","keywords":"Multiple myeloma; Retrospective cohort study; Medicine; Cohort; Population; Cohort study; Internal medicine; Oncology; Environmental health","score_opus":0.011374241173232678,"score_gpt":0.29021689182726296,"score_spread":0.2788426506540303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413826493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96815044,0.00005985128,0.00025606825,0.028638836,0.00005300612,0.002323551,0.00022452507,0.000038504437,0.00025522316],"genre_scores_gemma":[0.9880691,0.000036047375,0.0036899918,0.0069955382,0.00009862188,0.00011459654,0.00036869186,0.000081858656,0.000545517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961999,0.00026888328,0.0011538339,0.00059250684,0.0011852405,0.0005996449],"domain_scores_gemma":[0.9956626,0.00066713657,0.0017816894,0.00067898945,0.001005038,0.00020452478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022665597,0.00061328546,0.0035659177,0.001534325,0.00007908911,0.000013853557,0.00027268942,0.00018596354,0.00005090587],"category_scores_gemma":[0.00011814987,0.000365611,0.00029184576,0.001067301,0.0003896112,0.000074347794,0.000024397246,0.0013602751,0.0000016541541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009575782,0.0015457454,0.9702199,0.00030905113,0.0059686624,0.006833249,0.00026970296,0.000008613745,0.0000093252975,0.000004707306,0.0050564148,0.00019886003],"study_design_scores_gemma":[0.019417122,0.008053839,0.9659829,0.0021450173,0.0019125843,0.001464815,0.0003447949,0.000049853053,0.000187639,0.0000019009839,0.00014852289,0.00029099043],"about_ca_topic_score_codex":0.0075229187,"about_ca_topic_score_gemma":0.0013493211,"teacher_disagreement_score":0.021643298,"about_ca_system_score_codex":0.00039908214,"about_ca_system_score_gemma":0.0006653697,"threshold_uncertainty_score":0.9998796},"labels":[],"label_agreement":null},{"id":"W4413976388","doi":"10.1158/2643-3230.bcd-25-0005","title":"Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"National Cancer Institute; National Institutes of Health","keywords":"Chimeric antigen receptor; CAR T-cell therapy; Multiple myeloma; Antigen; Immunology; Immunotherapy; Digital polymerase chain reaction; Medicine; Biology; Oncology; Cancer research; Genetics; Immune system; Polymerase chain reaction; Gene","score_opus":0.019038993411813976,"score_gpt":0.2854513872654947,"score_spread":0.2664123938536807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413976388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889231,0.0074153,0.000044570188,0.00020070633,0.00006561691,0.0006709806,0.000045009983,0.00006606491,0.0025686645],"genre_scores_gemma":[0.9942748,0.0011583167,0.00039220988,0.000118425254,0.000077419194,0.00021478413,0.000041505227,0.000039468203,0.0036830585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853903,0.000051107887,0.00025768214,0.0004224199,0.00022726732,0.0005024867],"domain_scores_gemma":[0.999352,0.000114200484,0.00007089815,0.00033066695,0.000052010553,0.00008024081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009892373,0.00024389327,0.00039470583,0.0002792755,0.0001312255,0.000070622555,0.00011552069,0.000062200146,0.000056272933],"category_scores_gemma":[0.000024803974,0.00018713118,0.00008491758,0.00045710686,0.00009197955,0.00020686624,0.00005900498,0.00020332784,0.000009535683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015093657,0.0004621715,0.9082658,0.00014996373,0.00058609794,0.00038880613,0.00027912244,0.00010582508,0.07695552,0.00000713824,0.00002911801,0.011261063],"study_design_scores_gemma":[0.016746506,0.00021891027,0.77884024,0.0008062438,0.00016921337,0.000020888543,0.00030815924,0.00035310627,0.20194583,0.000010075408,0.00036947225,0.00021135136],"about_ca_topic_score_codex":0.00738468,"about_ca_topic_score_gemma":0.0020054183,"teacher_disagreement_score":0.12942557,"about_ca_system_score_codex":0.00024186025,"about_ca_system_score_gemma":0.00044553346,"threshold_uncertainty_score":0.99922526},"labels":[],"label_agreement":null},{"id":"W4414001194","doi":"10.1016/j.jnma.2025.08.088","title":"Racial Differences in Metabolic Changes during Induction Therapy for Newly Diagnosed Myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of the National Medical Association","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Multiple myeloma; Medicine; Induction therapy; Internal medicine; Chemotherapy","score_opus":0.03542553774599676,"score_gpt":0.350184577525065,"score_spread":0.3147590397790682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414001194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95756274,0.00040578892,0.00003646017,0.04099486,0.000510781,0.00034071345,0.000007023755,0.0000046571486,0.00013697261],"genre_scores_gemma":[0.9971557,0.00051573926,0.00011322115,0.00061259465,0.00084825093,0.000040029867,0.00000377676,0.000004326244,0.000706318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770236,0.0001393302,0.00032214058,0.00008165333,0.001603269,0.00015123683],"domain_scores_gemma":[0.9983474,0.0006522951,0.00030666677,0.000034915465,0.0005864236,0.00007231294],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012068144,0.00007162387,0.00024113499,0.00026755536,0.00009579649,0.000018374267,0.000117887605,0.00015042226,0.000054955424],"category_scores_gemma":[0.008968013,0.000042466403,0.00012392907,0.00033561443,0.0000209174,0.000082882405,0.000019559679,0.00031483805,0.0000014342712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015322942,0.0008605094,0.86652124,0.00004626595,0.0007642459,0.0000127503035,0.00040384545,0.0000057096104,0.0037975751,0.0005628212,0.0021392375,0.1233535],"study_design_scores_gemma":[0.0074112853,0.00011894789,0.98669124,0.00014881445,0.000029572984,0.000007645694,0.00003690752,0.00020164633,0.0026582873,0.0010518287,0.0016123828,0.00003147296],"about_ca_topic_score_codex":0.000013166876,"about_ca_topic_score_gemma":0.00007575295,"teacher_disagreement_score":0.12332203,"about_ca_system_score_codex":0.0005430637,"about_ca_system_score_gemma":0.00049167295,"threshold_uncertainty_score":0.9993799},"labels":[],"label_agreement":null},{"id":"W4414002743","doi":"10.1111/bjh.70041","title":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the <scp>UK</scp> Myeloma Research Alliance Frailty Group","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Guideline; Quality of life (healthcare); Gerontology; Polypharmacy; Population; Multiple myeloma; Cancer; Disease; Intensive care medicine; Internal medicine; Pathology; Environmental health","score_opus":0.04191771513113096,"score_gpt":0.3634831112193089,"score_spread":0.3215653960881779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414002743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946325,0.0027251714,0.00013281654,0.000469386,0.00011099941,0.0008197509,0.00005326072,0.0000066208363,0.0010494861],"genre_scores_gemma":[0.9941121,0.0011455223,0.004200055,0.0000756114,0.000039924445,0.000039319915,0.000012945766,0.000022896233,0.00035167538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967589,0.0004914199,0.0009858143,0.00031463406,0.0009524892,0.00049673783],"domain_scores_gemma":[0.99624395,0.00141351,0.00052158325,0.0003788812,0.0012252975,0.00021676191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007099443,0.00021262706,0.0009888391,0.00028436558,0.00019195235,0.000027978329,0.00025656965,0.00014875246,0.000034258475],"category_scores_gemma":[0.0015521422,0.00014703731,0.0001837393,0.00041864195,0.0005135075,0.0000787669,0.00014036211,0.00044406028,0.0000014817605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025729835,0.0027943237,0.9414559,0.00021164339,0.0008139024,0.0026341628,0.00021098639,0.0000073915226,0.0007037929,0.00020781622,0.002671009,0.048031762],"study_design_scores_gemma":[0.008314933,0.0048247096,0.9760822,0.0029772702,0.0001438087,0.0034346117,0.0004319831,0.00014012815,0.0021608965,0.000112673275,0.0013314456,0.00004534959],"about_ca_topic_score_codex":0.0004570354,"about_ca_topic_score_gemma":0.00079349877,"teacher_disagreement_score":0.04798641,"about_ca_system_score_codex":0.0002469285,"about_ca_system_score_gemma":0.0005206648,"threshold_uncertainty_score":0.59960073},"labels":[],"label_agreement":null},{"id":"W4414003234","doi":"10.2147/ott.s398118","title":"The Role of CELMoD Agents in Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Pharmaceuticals; Kite Pharma; Genentech; Servier; Regeneron Pharmaceuticals; Adaptive Biotechnologies; Karyopharm Therapeutics; BeiGene; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; TG Therapeutics; Amgen; Pfizer","keywords":"Multiple myeloma; Medicine; Computer science; Computational biology; Internal medicine; Biology","score_opus":0.0251265564514516,"score_gpt":0.32038975439380807,"score_spread":0.29526319794235645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414003234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732622,0.015810732,0.0000040733826,0.0005854549,0.000046650173,0.00039741493,0.0000060254324,0.000009709364,0.009877778],"genre_scores_gemma":[0.9917832,0.006845953,0.00013159943,0.00010048449,0.000017005861,0.000034297987,0.000007195172,0.0000070018314,0.001073247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993204,0.00003860145,0.0001572371,0.00014012275,0.00013762325,0.00020603267],"domain_scores_gemma":[0.9995481,0.00013349883,0.00002934942,0.00018652598,0.000040488812,0.0000620801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013595917,0.00008850624,0.00017843874,0.000075101874,0.00009479061,0.000012192795,0.000063788335,0.000041279673,0.000029290462],"category_scores_gemma":[0.000043096465,0.000050516748,0.000047022913,0.00013467229,0.00007993603,0.000025990377,0.000027757307,0.00008939145,0.000003905053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074468885,0.00023181201,0.59820384,0.000011323859,0.000103746264,0.000013829975,0.00013210303,4.07316e-7,0.0048349686,0.000563455,0.00009421381,0.3950656],"study_design_scores_gemma":[0.005297759,0.00023079314,0.8690926,0.000055591852,0.0000060004068,0.000002292511,0.00015217619,0.0012435128,0.01667019,0.0016610639,0.105540186,0.000047859055],"about_ca_topic_score_codex":0.0002993433,"about_ca_topic_score_gemma":0.00010697696,"teacher_disagreement_score":0.39501774,"about_ca_system_score_codex":0.000026303538,"about_ca_system_score_gemma":0.000061201084,"threshold_uncertainty_score":0.20600131},"labels":[],"label_agreement":null},{"id":"W4414057587","doi":"10.58931/cht.2025.4s0570","title":"Expert Discussion: Building Unique Networks and Partnerships to Bring Novel Therapies to Remote Patients","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Ottawa Hospital","funders":"McMaster University; University of Ottawa","keywords":"MEDLINE; Raising (metalworking); Patient care; Patient privacy; Best practice; Key (lock)","score_opus":0.033866605633873156,"score_gpt":0.32028929606258716,"score_spread":0.286422690428714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414057587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91028666,0.0011246218,0.006975475,0.076606624,0.00035579078,0.0015631433,0.000019466734,0.000069415255,0.0029987788],"genre_scores_gemma":[0.9879495,0.000028429191,0.0034881583,0.0065115807,0.00004066719,0.000027837299,0.000018987048,0.000018837763,0.0019160294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987076,0.000049129114,0.00018342692,0.00035700848,0.00010024642,0.0006025937],"domain_scores_gemma":[0.99837106,0.00009085307,0.000019024063,0.00029396833,0.00007665949,0.0011484356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011397051,0.00016610275,0.00031801773,0.00037733352,0.00016177034,0.000026808262,0.00010186878,0.00013454501,0.000048895792],"category_scores_gemma":[0.00029227484,0.000117318945,0.00003824239,0.00030702693,0.000052534877,0.00003755426,0.00006997142,0.00016398566,0.000017674189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005422426,0.00015585494,0.78301847,0.00014434467,0.0005106018,0.0006654036,0.0023455508,0.000037023026,0.00069729146,0.010501658,0.033705425,0.16767614],"study_design_scores_gemma":[0.008061311,0.0007262657,0.5069097,0.0026083216,0.0000914951,0.00024927527,0.0010830357,0.0029516132,0.0043860916,0.00055241055,0.4715301,0.0008503435],"about_ca_topic_score_codex":0.010789582,"about_ca_topic_score_gemma":0.05298516,"teacher_disagreement_score":0.4378247,"about_ca_system_score_codex":0.00024117272,"about_ca_system_score_gemma":0.00025329826,"threshold_uncertainty_score":0.99579763},"labels":[],"label_agreement":null},{"id":"W4414194885","doi":"10.1016/j.clml.2026.04.016","title":"Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"Alexion Pharmaceuticals; Celgene; Sanofi","keywords":"Daratumumab; Multiple myeloma; Monoclonal antibody; Clinical trial; Antibody; Randomized controlled trial; Immunopathology; Cancer","score_opus":0.09720225098659022,"score_gpt":0.3758695564124113,"score_spread":0.2786673054258211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414194885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438304,0.0020260024,0.00031786194,0.00070310896,0.00021194185,0.0012960144,0.00035563685,0.0001359748,0.0005704001],"genre_scores_gemma":[0.9874272,0.0012904364,0.007513815,0.00060002826,0.000100665864,0.00021814,0.00030308941,0.00005683536,0.0024898425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99289405,0.0010695053,0.0027075391,0.0013894673,0.0009212227,0.0010181986],"domain_scores_gemma":[0.9880085,0.008303432,0.000666083,0.0019145822,0.0005034466,0.0006039732],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014870173,0.00067977904,0.0043569864,0.0013887412,0.00017287733,0.00008709308,0.0004989298,0.00060607865,0.00034844145],"category_scores_gemma":[0.010074805,0.00052078534,0.0035759106,0.0030066113,0.0007347048,0.00031073263,0.00042368908,0.00056767755,0.00013551241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024970144,0.0012998605,0.7741462,0.000120201716,0.08435127,0.0010752595,0.00006890541,0.00016442905,0.00011493803,0.0002257918,0.0012387119,0.13469742],"study_design_scores_gemma":[0.011838006,0.00044450568,0.9125097,0.000065718996,0.067115836,0.00000832691,0.00006048386,0.004583342,0.0012767856,0.0002753483,0.0014878738,0.00033407204],"about_ca_topic_score_codex":0.011114146,"about_ca_topic_score_gemma":0.003515911,"teacher_disagreement_score":0.13836351,"about_ca_system_score_codex":0.00076356006,"about_ca_system_score_gemma":0.0014133235,"threshold_uncertainty_score":0.9997244},"labels":[],"label_agreement":null},{"id":"W4414228279","doi":"10.1158/2643-3230.bcd-25-0280","title":"Perspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; Immunotherapy; MEDLINE; Clinical Practice; Daratumumab; Cancer","score_opus":0.026186199949584318,"score_gpt":0.329213792396261,"score_spread":0.30302759244667665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414228279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9190212,0.0630238,0.000007912458,0.0056796586,0.00009310431,0.00053730165,0.000040468145,0.000050254668,0.011546313],"genre_scores_gemma":[0.9429249,0.051886786,0.00007547711,0.00014109597,0.00015934267,0.00034344257,0.000010426117,0.000017174816,0.004441311],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988917,0.000039093527,0.00012458896,0.00045250435,0.00018296047,0.00030914287],"domain_scores_gemma":[0.99938303,0.00012168279,0.0000309333,0.0002977811,0.000038047743,0.00012850182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004377633,0.00020814699,0.0002971054,0.00016866617,0.00010971781,0.000047575304,0.000048782196,0.000042616757,0.000046376077],"category_scores_gemma":[0.000047927053,0.00015121308,0.00009246697,0.00012406944,0.00007451271,0.000121718054,0.00003947225,0.00008943005,0.000007494595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027494214,0.0049503255,0.16527644,0.00043288758,0.0049907975,0.001005787,0.006149672,0.000027453703,0.004308423,0.012278095,0.0005826379,0.79724807],"study_design_scores_gemma":[0.045549396,0.0037980506,0.89730704,0.0015090217,0.0013295116,0.00003221584,0.012684153,0.00011524782,0.02772329,0.000532066,0.008932874,0.00048713817],"about_ca_topic_score_codex":0.00089560536,"about_ca_topic_score_gemma":0.00051056995,"teacher_disagreement_score":0.7967609,"about_ca_system_score_codex":0.00021982632,"about_ca_system_score_gemma":0.0002193314,"threshold_uncertainty_score":0.61662906},"labels":[],"label_agreement":null},{"id":"W4414287350","doi":"10.14740/wjon2611","title":"IgM Myeloma: A Comprehensive Overview and Practical Approach to Chemotherapeutic Management","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Bone marrow; Hyperviscosity syndrome; Plasma cell; Clinical Practice; Monoclonal antibody; Hyperviscosity; Bortezomib","score_opus":0.08202821175955467,"score_gpt":0.4244419834350345,"score_spread":0.3424137716754798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414287350","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31027415,0.022340601,0.0071936296,0.13495593,0.00087583927,0.0036208632,0.0000069906614,0.000053548287,0.52067846],"genre_scores_gemma":[0.90424824,0.0022447656,0.07514034,0.010521205,0.0001517015,0.000032226264,0.0000031294126,0.00001828339,0.007640083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989352,0.00011704006,0.00032271128,0.00015427974,0.00023039822,0.00024034263],"domain_scores_gemma":[0.9991248,0.00020880108,0.000110258465,0.00014281592,0.00016459524,0.00024872794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002347356,0.00011417358,0.000470186,0.00045102963,0.000049685164,0.0000152084,0.000059943846,0.000046592624,0.00005854874],"category_scores_gemma":[0.000048049238,0.000083763494,0.000082207946,0.00036272954,0.00007360233,0.00004472724,0.00009235193,0.00029169777,0.000015641026],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060894266,0.0037395484,0.010551313,0.0009141182,0.0036027206,0.0034619598,0.00035222844,0.000007718054,0.0010458638,0.017004367,0.032464452,0.9207663],"study_design_scores_gemma":[0.009170545,0.0014970568,0.20066586,0.0002631066,0.00046795764,0.0020464659,0.0003093741,0.00012357213,0.00017646467,0.00053727865,0.7846552,0.000087105844],"about_ca_topic_score_codex":0.0000056958816,"about_ca_topic_score_gemma":0.000009802416,"teacher_disagreement_score":0.92067915,"about_ca_system_score_codex":0.00025591443,"about_ca_system_score_gemma":0.00021016374,"threshold_uncertainty_score":0.34157762},"labels":[],"label_agreement":null},{"id":"W4414294998","doi":"10.14740/jmc4334","title":"Radiotherapy for Isolated Breast Myeloid Sarcoma","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Myeloid sarcoma; Myeloid leukemia; Radiation therapy; Myeloid; Chemotherapy; Sarcoma; Hematopoietic cell","score_opus":0.028254485769883816,"score_gpt":0.37139132635670064,"score_spread":0.3431368405868168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414294998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7958182,0.012660242,0.021177674,0.1681397,0.0007188689,0.0008017836,0.00005366668,0.000039192662,0.0005906629],"genre_scores_gemma":[0.99229175,0.0014790224,0.0025044612,0.001998281,0.00056973286,0.000009088654,0.000009225928,0.000013762508,0.0011246513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984148,0.00005273451,0.0003910501,0.0000968588,0.0008081588,0.00023636056],"domain_scores_gemma":[0.998449,0.0005998566,0.00010190403,0.00011984594,0.0002659687,0.00046341156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052281865,0.00010066532,0.00037196657,0.00021963812,0.000059563135,0.000018693187,0.00014232537,0.00011969632,0.0007025616],"category_scores_gemma":[0.0010643295,0.00006340106,0.00021623727,0.00017396518,0.00008441664,0.000052784766,0.000019466454,0.00028436357,0.0000037970533],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015104416,0.0019565204,0.042504296,0.00045845722,0.0020772398,0.009514421,0.000086157066,0.0000016601983,0.002645878,0.00039580668,0.13779557,0.78745955],"study_design_scores_gemma":[0.117060505,0.016972201,0.25645003,0.0057743154,0.0010151466,0.122452565,0.00064507406,0.012896177,0.0057757706,0.0015080008,0.45892823,0.000522006],"about_ca_topic_score_codex":0.000033778553,"about_ca_topic_score_gemma":0.000006552102,"teacher_disagreement_score":0.7869376,"about_ca_system_score_codex":0.00011801649,"about_ca_system_score_gemma":0.0007040857,"threshold_uncertainty_score":0.7692557},"labels":[],"label_agreement":null},{"id":"W4414303437","doi":"10.1016/s2152-2650(25)03661-4","title":"Clinical Utility of Quantitative, Mass Spectrometry-Based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-Canadian Real-World Cohort Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cohort study; Cohort; Prognostic model; MEDLINE","score_opus":0.05968875976820813,"score_gpt":0.3989852415055754,"score_spread":0.33929648173736726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414303437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861304,0.00006523879,0.0053248885,0.00015127158,0.00031487085,0.006187594,0.00005818795,0.00013850752,0.0016290124],"genre_scores_gemma":[0.9659869,0.000081137056,0.032236744,0.000058809663,0.00013341615,0.0011559204,0.00011219886,0.000060484163,0.0001743917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933982,0.0009846184,0.0026712795,0.0013604554,0.0006705053,0.00091497635],"domain_scores_gemma":[0.9929586,0.0043442203,0.00047497326,0.0010400529,0.00063878414,0.0005433491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004704035,0.0005157881,0.0018178594,0.0019577206,0.0001604091,0.00006896017,0.00036706115,0.0005064992,0.00002195492],"category_scores_gemma":[0.0068633794,0.00043944592,0.0004069124,0.0027165588,0.00047315544,0.00026915243,0.00007388552,0.00077813986,0.000007839567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008561113,0.0015684224,0.74560404,0.00012673321,0.00025159967,0.00018942852,0.000041164207,0.000002921661,0.0006256102,0.000037563204,0.000028115504,0.24296331],"study_design_scores_gemma":[0.016332394,0.0037993542,0.95726573,0.0008070852,0.00018868227,0.000002747337,0.0004644633,0.010985623,0.009565698,0.00017959277,0.000101992184,0.0003066565],"about_ca_topic_score_codex":0.074034974,"about_ca_topic_score_gemma":0.32069334,"teacher_disagreement_score":0.24665835,"about_ca_system_score_codex":0.0030902755,"about_ca_system_score_gemma":0.0038897754,"threshold_uncertainty_score":0.99980575},"labels":[],"label_agreement":null},{"id":"W4414398065","doi":"10.1182/blood.2025029360","title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Bone and Joint Health Institute; University of Calgary; Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Servier; Onyx Pharmaceuticals; Prothena; Regeneron Pharmaceuticals; Genentech; Celgene; Adaptive Biotechnologies; Kite Pharma; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Daratumumab; Multiple myeloma; Adverse effect; Refractory (planetary science); Clinical endpoint; Proteasome inhibitor; Phases of clinical research; Cohort","score_opus":0.04932490908800263,"score_gpt":0.3540793614770588,"score_spread":0.3047544523890562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414398065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897628,0.002229829,0.000033146913,0.00070370216,0.00009429347,0.0060899025,0.000050559207,0.000024959783,0.0010108273],"genre_scores_gemma":[0.99485165,0.00029597155,0.00020029575,0.00006559009,0.000067477944,0.0015069911,0.000035365843,0.000017026725,0.0029596272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850166,0.00017144691,0.00036839003,0.00029790515,0.00033456218,0.00032605988],"domain_scores_gemma":[0.9972933,0.001724225,0.00007937981,0.0007599058,0.00008749422,0.000055691908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032438114,0.00020080918,0.00042809398,0.00015565882,0.00017627336,0.000021509799,0.00022500676,0.000071286435,0.000026794381],"category_scores_gemma":[0.0004545439,0.0000862579,0.00017209734,0.00041042257,0.00008312948,0.000038017133,0.000028130904,0.00013187763,0.0000070264805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05453869,0.14494322,0.52395296,0.00056994177,0.009209589,0.00200853,0.02278477,0.000023716157,0.0050440365,0.00032890218,0.0026393158,0.2339563],"study_design_scores_gemma":[0.18140343,0.01918762,0.7579329,0.00015114495,0.0016820449,0.000034326433,0.00854242,0.0008694595,0.008940676,0.00004592561,0.021030204,0.00017982139],"about_ca_topic_score_codex":0.0005159782,"about_ca_topic_score_gemma":0.0012621529,"teacher_disagreement_score":0.23397994,"about_ca_system_score_codex":0.0001499637,"about_ca_system_score_gemma":0.00036225817,"threshold_uncertainty_score":0.3517495},"labels":[],"label_agreement":null},{"id":"W4414420388","doi":"10.1002/hem3.70224","title":"The impact of reduced dosing frequency of elranatamab on patient‐reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM‐3","year":2025,"lang":"en","type":"letter","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Pfizer","keywords":"Dosing; Refractory (planetary science); Incidence (geometry); Multiple myeloma; Clinical trial; Quality of life (healthcare)","score_opus":0.021111578107003495,"score_gpt":0.29165523703766494,"score_spread":0.27054365893066146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414420388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98518986,0.00031789034,9.325278e-7,0.007437275,0.00018693165,0.0025357774,0.0021528248,0.000044567438,0.0021339483],"genre_scores_gemma":[0.9903608,0.000069722715,0.0008079605,0.0019882293,0.00010961767,0.00010813446,0.003919007,0.000104153776,0.0025323858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516577,0.0003147478,0.0015578448,0.00083594705,0.0014079739,0.0007177436],"domain_scores_gemma":[0.9941827,0.0022053618,0.0011857634,0.0017699806,0.0005031433,0.00015303676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017387743,0.0006710241,0.0014613037,0.00028081,0.000109652756,0.000025244884,0.0003212187,0.00069601636,0.0002463037],"category_scores_gemma":[0.0025824183,0.00034571206,0.0003926644,0.0005417718,0.00022041523,0.000100365614,0.00009670502,0.0016404216,0.000008792497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04071152,0.0027520387,0.7753924,0.0005287348,0.003756553,0.003217705,0.0005694043,0.000013203629,0.00046045677,0.0000010907552,0.14695986,0.025637044],"study_design_scores_gemma":[0.034437638,0.0054580183,0.9535386,0.0031979815,0.00027866568,0.0000044709295,0.00010132075,0.000031487773,0.0010826428,0.000028304737,0.0014644546,0.0003764429],"about_ca_topic_score_codex":0.010371778,"about_ca_topic_score_gemma":0.0005854767,"teacher_disagreement_score":0.17814618,"about_ca_system_score_codex":0.0006199263,"about_ca_system_score_gemma":0.0010347987,"threshold_uncertainty_score":0.9998995},"labels":[],"label_agreement":null},{"id":"W4414449058","doi":"10.1002/jha2.70145","title":"Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Johnson and Johnson","keywords":"Multiple myeloma; Clinical trial; MEDLINE; Disease; Incidence (geometry)","score_opus":0.035874759921380936,"score_gpt":0.3299574661307874,"score_spread":0.29408270620940646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414449058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962967,0.000037513564,0.000020506264,0.0009975382,0.00012671496,0.001939813,0.00012841566,0.000097023585,0.0003557543],"genre_scores_gemma":[0.9940276,0.00027011105,0.0003305052,0.00038317352,0.000034743185,0.00012427646,0.00060041796,0.000037493603,0.0041916873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773526,0.00027066638,0.00056371436,0.00056484056,0.00041134175,0.0004541571],"domain_scores_gemma":[0.99763936,0.0010904275,0.00016845265,0.00056852546,0.0001627369,0.0003705189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027105803,0.000387251,0.0006532221,0.00032160923,0.00028382955,0.000088987705,0.00011716782,0.000103070124,0.00003024592],"category_scores_gemma":[0.00026287115,0.00019935786,0.00011363034,0.00042171814,0.00038048756,0.000095945885,0.00011128586,0.00028357515,0.0000074601435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017394089,0.0008239284,0.98507607,0.000047412694,0.0011730111,0.00011106758,0.00054785324,0.0000027523768,0.0000074001996,0.000039221388,0.00019865234,0.010233234],"study_design_scores_gemma":[0.02388203,0.0016786833,0.9702647,0.00016392802,0.00033279444,0.0000022263257,0.0005217855,0.0019769543,0.00035107136,0.000026370657,0.0006225987,0.00017688476],"about_ca_topic_score_codex":0.0062362347,"about_ca_topic_score_gemma":0.0138572315,"teacher_disagreement_score":0.02214262,"about_ca_system_score_codex":0.00016457644,"about_ca_system_score_gemma":0.0001239386,"threshold_uncertainty_score":0.94273627},"labels":[],"label_agreement":null},{"id":"W4414567861","doi":"10.1016/j.blre.2025.101339","title":"Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists","year":2025,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of New Brunswick","funders":"","keywords":"Immunotherapy; Clinical trial; Multiple myeloma; Population; Cell therapy; Disease; Refractory (planetary science); Cytokine release syndrome; CAR T-cell therapy","score_opus":0.19025716891468455,"score_gpt":0.4526536092552804,"score_spread":0.26239644034059584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414567861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016134421,0.9813918,0.00008030464,0.00009518897,0.00018860212,0.011839432,0.00010768788,0.00008028731,0.0062005864],"genre_scores_gemma":[0.00002597295,0.97355914,0.015119595,0.00022252485,0.00008112251,0.0026463533,0.00043326442,0.0000648437,0.007847197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926163,0.0029267634,0.0023578464,0.0007242892,0.00072676543,0.00064804085],"domain_scores_gemma":[0.9928933,0.0023031945,0.00094099384,0.0030768618,0.00026412352,0.00052157015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030324708,0.0008364329,0.0053490857,0.0006196429,0.00019577611,0.000025397036,0.000978985,0.00042272086,0.0001947359],"category_scores_gemma":[0.0043734154,0.0005676447,0.0016432295,0.0012941287,0.00013836627,0.00009250468,0.00059896446,0.0011936738,0.00048195955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010235081,0.0015905248,0.00007190566,0.22252178,0.0008906451,0.00035859534,0.000014160327,1.3870435e-7,0.0000025179163,0.000010161681,0.006635304,0.76780194],"study_design_scores_gemma":[0.00190852,0.0007985664,0.00016830834,0.29001626,0.005089983,0.00001603959,0.000010362981,7.6662167e-7,0.000013614964,0.0000011108303,0.7017246,0.00025184953],"about_ca_topic_score_codex":0.00025453253,"about_ca_topic_score_gemma":0.00005754685,"teacher_disagreement_score":0.76755005,"about_ca_system_score_codex":0.0005817457,"about_ca_system_score_gemma":0.0011047841,"threshold_uncertainty_score":0.9996775},"labels":[],"label_agreement":null},{"id":"W4414611697","doi":"10.1080/10428194.2025.2560085","title":"The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Incidence (geometry); Confidence interval; Pharmacovigilance; Clinical trial; Clinical endpoint; Cohort; Adverse effect; Cohort study; Malignancy","score_opus":0.012847556902866512,"score_gpt":0.2676493473679365,"score_spread":0.25480179046507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414611697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006314638,0.9782868,0.0000079029105,0.000013890512,0.00023097402,0.013324419,0.00069519866,0.0001267236,0.0009994595],"genre_scores_gemma":[0.0028683108,0.9870268,0.00040239628,0.00016528534,0.0000711706,0.0044609415,0.0008645285,0.000162627,0.003977941],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9925967,0.0011882186,0.002871868,0.0012215027,0.00091244135,0.0012092929],"domain_scores_gemma":[0.9889817,0.0066638784,0.001871094,0.0016204393,0.00050736853,0.00035549156],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015194746,0.0013387923,0.006569613,0.0006066034,0.000500998,0.00011991886,0.0007419175,0.00070799724,0.000014823363],"category_scores_gemma":[0.0031141865,0.00082417484,0.0014254056,0.0011630529,0.00035094153,0.00016911366,0.00035220155,0.00030279468,0.000016320731],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00027143594,0.00023167659,0.0013609428,0.61046463,0.0010971031,0.00003276054,0.000114445145,7.730095e-8,0.0000017747844,0.000011033546,0.00085674296,0.38555738],"study_design_scores_gemma":[0.023418363,0.0006318298,0.021323288,0.85505694,0.008852867,0.0001059973,0.000113065864,0.00014437735,0.000031990097,0.000050458355,0.08918639,0.0010844169],"about_ca_topic_score_codex":0.00033340263,"about_ca_topic_score_gemma":0.00022213007,"teacher_disagreement_score":0.38447297,"about_ca_system_score_codex":0.0072198603,"about_ca_system_score_gemma":0.006845184,"threshold_uncertainty_score":0.99993634},"labels":[],"label_agreement":null},{"id":"W4414780017","doi":"10.1080/10428194.2025.2561117","title":"Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Carfilzomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Interim analysis; Panobinostat; Clinical trial","score_opus":0.013305664650567555,"score_gpt":0.26235908081363185,"score_spread":0.24905341616306428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414780017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98270607,0.008587664,0.000015049684,0.00008191979,0.0003878083,0.0052895024,0.00022080448,0.0002717166,0.002439474],"genre_scores_gemma":[0.992098,0.0028777353,0.00093723193,0.00016667465,0.00012795877,0.0007144428,0.0004116467,0.00021587429,0.002450442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919309,0.00082440843,0.0013641878,0.002705934,0.0012402476,0.0019342989],"domain_scores_gemma":[0.9944228,0.0017825828,0.0004717652,0.0016648093,0.0004207644,0.0012372901],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00055485277,0.0017449195,0.0026970722,0.0011254081,0.0010622431,0.000354097,0.00042101223,0.0008150401,0.000039157665],"category_scores_gemma":[0.00075334054,0.0014293445,0.00023713455,0.0014039251,0.0009129966,0.00059839594,0.00049674924,0.0005586532,0.000021953787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076206535,0.0026530128,0.58523417,0.00048176732,0.002553259,0.0041294917,0.004507605,0.000037064674,0.00032572425,0.000035704186,0.0002465966,0.3235891],"study_design_scores_gemma":[0.24602672,0.011110204,0.73143876,0.0007766054,0.00120779,0.00043248924,0.0020461576,0.0029420902,0.0006362747,0.000026551137,0.0022227475,0.0011335972],"about_ca_topic_score_codex":0.008632018,"about_ca_topic_score_gemma":0.004537893,"teacher_disagreement_score":0.3224555,"about_ca_system_score_codex":0.014165737,"about_ca_system_score_gemma":0.003599119,"threshold_uncertainty_score":0.99952966},"labels":[],"label_agreement":null},{"id":"W4414800255","doi":"10.1093/neuonc/noaf193.522","title":"P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Randomized controlled trial; Clinical endpoint; Discontinuation; Quality of life (healthcare); Radiation therapy; Placebo; Chemoradiotherapy; Maintenance therapy","score_opus":0.04164772387309838,"score_gpt":0.42070722184840514,"score_spread":0.37905949797530675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414800255","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39446858,0.00012512883,0.00054506934,0.0056018177,0.0002553333,0.5986131,0.000029481209,0.00009752487,0.00026397314],"genre_scores_gemma":[0.4789835,0.000045168148,0.00012411087,0.0004986884,0.0001722179,0.5191782,0.000012685818,0.000050141985,0.0009352863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934706,0.0016686816,0.0017064983,0.0012279016,0.00067098974,0.0012553463],"domain_scores_gemma":[0.9922075,0.005641051,0.0004664063,0.0010663519,0.00027900646,0.00033963725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022470988,0.0008143572,0.0036328395,0.00059937785,0.00036732436,0.00008489755,0.00042824884,0.00024506813,0.00021245418],"category_scores_gemma":[0.00186679,0.0004566312,0.00071366044,0.0006815606,0.00031359438,0.00010801563,0.00013597576,0.00064427854,0.00003271249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92789096,0.037043262,0.011516718,0.00007031089,0.0024320884,0.00424211,0.0017557794,0.000038563237,0.0011457299,0.000018893139,0.0004417844,0.0134038],"study_design_scores_gemma":[0.938738,0.037885442,0.0009585603,0.00007057254,0.0010936278,0.00013674378,0.001379541,0.004240812,0.0014715148,0.00008078924,0.013682808,0.00026161276],"about_ca_topic_score_codex":0.0004629676,"about_ca_topic_score_gemma":0.0033907655,"teacher_disagreement_score":0.08451491,"about_ca_system_score_codex":0.0014558553,"about_ca_system_score_gemma":0.0013346813,"threshold_uncertainty_score":0.9997885},"labels":[],"label_agreement":null},{"id":"W4414853478","doi":"10.1038/s41408-025-01356-z","title":"Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Pomalidomide; Dexamethasone; Cyclophosphamide; Multiple myeloma; Clinical endpoint; Adverse effect; Lenalidomide; Refractory (planetary science)","score_opus":0.04355623544536998,"score_gpt":0.38981062880104506,"score_spread":0.3462543933556751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414853478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98387414,0.007318167,0.00009138195,0.00037687298,0.0013019416,0.00598088,0.00003091979,0.00008497597,0.00094072893],"genre_scores_gemma":[0.9932522,0.0016269548,0.0022977125,0.00012764859,0.00072840025,0.0008498986,0.000021499096,0.000116001494,0.0009796537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9900514,0.003301663,0.002491976,0.0010720225,0.0016320137,0.0014509427],"domain_scores_gemma":[0.99424726,0.0018587108,0.0010240452,0.0012247898,0.00064993225,0.0009952612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004929173,0.0008295342,0.003239621,0.0011013501,0.0004506057,0.0001524061,0.000672837,0.00029308765,0.0006725574],"category_scores_gemma":[0.0029768306,0.00062020094,0.0004761021,0.0022367719,0.00030731875,0.0004966995,0.00024617527,0.0017858412,0.000008762616],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7000724,0.03456113,0.1938758,0.00011841056,0.007928003,0.0089582205,0.0029698939,0.0002581147,0.0006862185,0.000019602658,0.00034195036,0.05021028],"study_design_scores_gemma":[0.8266015,0.014617301,0.14312066,0.0007786341,0.0035326155,0.00021558594,0.009039669,0.00023784625,0.0010841842,0.00008475559,0.0002086838,0.0004785533],"about_ca_topic_score_codex":0.003149262,"about_ca_topic_score_gemma":0.0064960453,"teacher_disagreement_score":0.12652913,"about_ca_system_score_codex":0.00074648333,"about_ca_system_score_gemma":0.002055837,"threshold_uncertainty_score":0.9996249},"labels":[],"label_agreement":null},{"id":"W4414901463","doi":"10.1371/journal.pgen.1011848","title":"Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma","year":2025,"lang":"en","type":"article","venue":"PLoS Genetics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Pharmaceuticals; Janssen Research and Development; Vlaamse regering; European Commission; Agentschap Innoveren en Ondernemen; Multiple Myeloma Research Foundation","keywords":"Monoclonal gammopathy of undetermined significance; Tumor microenvironment; Multiple myeloma; CD8; Immune system; Bone marrow; Population; Pathogenesis; Plasma cell","score_opus":0.017519630743770116,"score_gpt":0.284325659607385,"score_spread":0.2668060288636149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414901463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423826,0.0020499236,0.000003510118,0.002152105,0.000026964413,0.0013463489,0.00001097699,0.000016136883,0.00015579385],"genre_scores_gemma":[0.9973433,0.00017287763,0.0014589712,0.00054536876,0.00003928729,0.00021830587,0.000011516256,0.00001463039,0.00019576862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989646,0.000059393453,0.00014676024,0.00025358007,0.0002518073,0.00032387176],"domain_scores_gemma":[0.9994706,0.00006600791,0.000025907864,0.00032075198,0.000018131776,0.00009861745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008563007,0.00013909025,0.00017478083,0.00013711181,0.00009701933,0.000027358687,0.00011532467,0.000025763327,0.000021218533],"category_scores_gemma":[0.00008377496,0.00009281018,0.000022562084,0.0001703863,0.0000528971,0.000011725768,0.00015760619,0.00013358187,0.000029844054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054948404,0.00061930506,0.5690353,0.00028956422,0.0000796332,0.00027908216,0.00065119343,0.0000040033096,0.41699252,0.0000059700074,0.00006429127,0.011429677],"study_design_scores_gemma":[0.0019198979,0.00026480202,0.71434677,0.0002711707,0.000034562145,0.000020098767,0.0001855835,0.0004892573,0.2817026,0.000012332175,0.0006825621,0.00007037688],"about_ca_topic_score_codex":0.000009881645,"about_ca_topic_score_gemma":0.00008936789,"teacher_disagreement_score":0.14531146,"about_ca_system_score_codex":0.00008651567,"about_ca_system_score_gemma":0.000029960442,"threshold_uncertainty_score":0.37846893},"labels":[],"label_agreement":null},{"id":"W4414948966","doi":"10.1080/14796694.2025.2557174","title":"A plain language summary of LocoMMotion – an observational study of treatments used for pretreated multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Legend Biotech","keywords":"Observational study; Multiple myeloma; Plain language; MEDLINE; English language","score_opus":0.0831085566720721,"score_gpt":0.41474552715769386,"score_spread":0.33163697048562174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955462,0.00015310259,0.00007229079,0.00034195394,0.00012847787,0.0027239656,0.00019670033,0.000031278145,0.00080603786],"genre_scores_gemma":[0.99491334,0.000009558833,0.0021791302,0.00004996961,0.00010044061,0.0003564555,0.0012286649,0.000014363341,0.0011481023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987814,0.00018725867,0.0003552672,0.00026045495,0.00020413705,0.00021152447],"domain_scores_gemma":[0.99887,0.00036305396,0.0001432356,0.00031788315,0.00021450224,0.000091312366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016947798,0.00014815747,0.00050910277,0.00023193765,0.000058233512,0.0000030405815,0.00009856655,0.0001651352,0.00005366079],"category_scores_gemma":[0.00015799809,0.00011585485,0.00008918902,0.00027991226,0.00005005306,0.000060953975,0.000035452733,0.000095091375,0.0000015734576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063776146,0.01251497,0.91259795,0.00024392162,0.0012746776,0.000086319764,0.0022267366,0.000009343566,0.023444582,0.0001877007,0.0009015215,0.04013463],"study_design_scores_gemma":[0.029111076,0.010649798,0.9455347,0.000069476846,0.00031141884,0.0000057414236,0.0032389902,0.0008994399,0.008628451,0.00003077202,0.0014484836,0.00007164414],"about_ca_topic_score_codex":0.00039711504,"about_ca_topic_score_gemma":0.0015102156,"teacher_disagreement_score":0.040062986,"about_ca_system_score_codex":0.00021570554,"about_ca_system_score_gemma":0.0002869438,"threshold_uncertainty_score":0.47244236},"labels":[],"label_agreement":null},{"id":"W4414948984","doi":"10.1080/14796694.2025.2560134","title":"A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency; University of Alberta; Alberta Cancer Foundation","funders":"National Cancer Institute","keywords":"Daratumumab; Multiple myeloma; Dexamethasone; Plain language; Stem cell","score_opus":0.014462611549110644,"score_gpt":0.2932345295906881,"score_spread":0.2787719180415774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192405,0.0008310231,0.00015509306,0.0013361049,0.00014210152,0.0047807917,0.00047098097,0.000025462004,0.00033439387],"genre_scores_gemma":[0.99677306,0.00007974856,0.0012524194,0.00029221454,0.00008890227,0.0007127119,0.000052154184,0.000028060487,0.0007207374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981323,0.00032609262,0.0004126421,0.00044744485,0.00030174246,0.0003798084],"domain_scores_gemma":[0.9976134,0.0012765591,0.00022422774,0.00049097935,0.00021732533,0.00017753031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022048003,0.00025927235,0.0010814095,0.00021389485,0.00012522168,0.000008521554,0.00020116381,0.00016352414,0.000012961154],"category_scores_gemma":[0.00013435478,0.00016023936,0.00010268658,0.0005144462,0.00008921418,0.00003566396,0.0000806998,0.00025648778,6.763008e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18558495,0.009122577,0.5667663,0.0027148896,0.0029876265,0.0015993629,0.13983168,0.0001140339,0.039787654,0.00005209642,0.008267012,0.04317177],"study_design_scores_gemma":[0.08989153,0.010324757,0.78336203,0.00079552364,0.00072995643,0.00004666246,0.08082809,0.00033663752,0.03147106,0.0000025684396,0.0019687081,0.00024246272],"about_ca_topic_score_codex":0.0011808139,"about_ca_topic_score_gemma":0.02978376,"teacher_disagreement_score":0.2165957,"about_ca_system_score_codex":0.00020274059,"about_ca_system_score_gemma":0.0004470019,"threshold_uncertainty_score":0.98792017},"labels":[],"label_agreement":null},{"id":"W4414960061","doi":"10.46989/001c.144582","title":"Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Clinical Hematology International","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Pomalidomide; Overall survival; Transplantation; Clinical trial; Autologous stem-cell transplantation; Developing country; Ixazomib; Lenalidomide","score_opus":0.22432945688594108,"score_gpt":0.5196438872827304,"score_spread":0.2953144303967893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414960061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000080541895,0.9940955,0.000056183744,0.001916622,0.000074522126,0.0033216611,0.00030481405,0.000016643558,0.00020599761],"genre_scores_gemma":[0.000089117595,0.99473566,0.0010340743,0.00056098134,0.000008390633,0.001428912,0.00041413482,0.000015724778,0.0017130091],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949238,0.00062972965,0.0032326404,0.00061720563,0.00034988095,0.00024680042],"domain_scores_gemma":[0.99076307,0.007361692,0.00092100416,0.0005635986,0.00026051575,0.00013015041],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0007051175,0.00045682935,0.015604915,0.00077705143,0.000025415786,0.000011181082,0.00027355077,0.00036171384,0.0002633183],"category_scores_gemma":[0.004141122,0.0002567371,0.0033506313,0.00048117235,0.00018769197,0.00003515154,0.00015386175,0.00025260352,0.000039241673],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019358784,0.0003553539,0.012878671,0.60339886,0.38070878,0.00023138085,0.000007574104,2.4082615e-8,2.594689e-10,0.0011229935,0.00003606231,0.0012409303],"study_design_scores_gemma":[0.0014680689,0.00013208442,0.0007306988,0.060591303,0.9144519,0.00020468366,0.000005655158,0.00002204993,1.6956304e-7,0.000021852757,0.022171896,0.00019966354],"about_ca_topic_score_codex":0.000037847345,"about_ca_topic_score_gemma":0.00009377666,"teacher_disagreement_score":0.5428076,"about_ca_system_score_codex":0.00024531884,"about_ca_system_score_gemma":0.0006693002,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W4414987375","doi":"10.1182/blood.2025030399","title":"Mel200 or BuMel conditioning in myeloma: is there a winner?","year":2025,"lang":"en","type":"letter","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Conditioning; Central air conditioning; Quality (philosophy); MEDLINE","score_opus":0.02818191209263476,"score_gpt":0.31031070148034307,"score_spread":0.2821287893877083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414987375","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06875969,0.0037808972,0.000013392165,0.8635499,0.00033119248,0.0028102773,0.0009901914,0.00024871138,0.05951575],"genre_scores_gemma":[0.07806649,0.000674229,0.001304989,0.6957999,0.0037403582,0.00076362427,0.003929359,0.00017471868,0.21554635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978594,0.00009271522,0.00033884513,0.0005417236,0.00054370816,0.00062361785],"domain_scores_gemma":[0.99892336,0.00022709915,0.000084637824,0.00055536855,0.000098176635,0.00011136745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009769989,0.0003538692,0.00064998824,0.00042835358,0.00007970029,0.00004784492,0.00018444858,0.0006341732,0.002311252],"category_scores_gemma":[0.00018150911,0.00025806692,0.00017233446,0.00036521693,0.0000688727,0.00005190795,0.000086801345,0.0014901303,0.00030167552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001863477,0.0005866672,0.018449213,0.00091452384,0.0010258404,0.0278827,0.00012858277,6.451546e-8,0.000057797297,0.000008214309,0.9484338,0.0023262487],"study_design_scores_gemma":[0.02430099,0.00065078074,0.04106163,0.0032572532,0.0008951217,0.00044151983,0.00008062652,0.00002743382,0.0029771763,0.00017282215,0.9256069,0.000527736],"about_ca_topic_score_codex":0.00038846847,"about_ca_topic_score_gemma":0.00008378908,"teacher_disagreement_score":0.16775003,"about_ca_system_score_codex":0.00012261058,"about_ca_system_score_gemma":0.0005903267,"threshold_uncertainty_score":0.9999872},"labels":[],"label_agreement":null},{"id":"W4415132558","doi":"10.1002/hem3.70216","title":"European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Kite Pharma; EUSA Pharma; Servier; Adaptive Biotechnologies; Regeneron Pharmaceuticals; BeiGene; European Commission; Sanofi; PharmaMar; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Ministero della Salute; Pfizer; GlaxoSmithKline","keywords":"Multiple myeloma; Risk stratification; Workflow; Genetic testing; DNA sequencing; Statement (logic); MEDLINE","score_opus":0.17092217404667132,"score_gpt":0.3226412180158104,"score_spread":0.1517190439691391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415132558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990625,0.00027446606,0.0046632765,0.0008374476,0.00011185089,0.0033657143,0.00006506892,0.000040129897,0.00073577143],"genre_scores_gemma":[0.9877605,0.000042138203,0.010891326,0.00014900697,0.00010346479,0.0002364279,0.00029306713,0.000026653273,0.00049742154],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99826276,0.00026248713,0.0005758539,0.00029675412,0.0003049568,0.00029718998],"domain_scores_gemma":[0.9973829,0.0015197636,0.000244825,0.0004635141,0.00030257695,0.000086452674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040612186,0.00018074109,0.00028733915,0.00004980539,0.00014939578,0.000038016464,0.00009165908,0.000052864496,0.000055071956],"category_scores_gemma":[0.0012910154,0.0001258986,0.00011136811,0.00026671684,0.00010106348,0.000060505507,0.00003245809,0.00011063546,0.000007139252],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057846415,0.0023274114,0.16685426,0.0024427758,0.0020220336,0.00022299016,0.0013581099,0.011781956,0.44497573,0.022902751,0.055558015,0.2837693],"study_design_scores_gemma":[0.020242916,0.0049299723,0.45001265,0.0037359293,0.0008020823,0.00001767351,0.0024631014,0.2916213,0.21438468,0.0005916696,0.010572113,0.0006259024],"about_ca_topic_score_codex":0.00016130008,"about_ca_topic_score_gemma":0.00040376963,"teacher_disagreement_score":0.2831584,"about_ca_system_score_codex":0.00013484011,"about_ca_system_score_gemma":0.00020917314,"threshold_uncertainty_score":0.5133996},"labels":[],"label_agreement":null},{"id":"W4415144101","doi":"10.1186/s41687-025-00943-9","title":"Joint modeling of progression-free survival and patient-reported outcomes to evaluate the association between disease progression and symptoms among patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Patient-Reported Outcomes","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Bristol-Myers Squibb","keywords":"Hazard ratio; Disease; Multiple myeloma; Joint pain; Proportional hazards model; Clinical trial; Quality of life (healthcare)","score_opus":0.02355747816106897,"score_gpt":0.3196514778869421,"score_spread":0.29609399972587314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415144101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566096,0.00033005275,0.0001017595,0.0011063236,0.00033545244,0.0023126088,0.000046416593,0.000035019384,0.00007139685],"genre_scores_gemma":[0.99873054,0.000025684592,0.00088621315,0.000090806796,0.000028585124,0.0000697938,0.000052595366,0.000043431806,0.000072346294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939586,0.00032682632,0.0020465918,0.00046208245,0.00268154,0.00052435795],"domain_scores_gemma":[0.99396646,0.000696569,0.002103164,0.0006937199,0.0018410125,0.0006990763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009216415,0.0004501691,0.0012013663,0.000589843,0.00028394753,0.000075548654,0.00017841494,0.00016313013,0.000009173882],"category_scores_gemma":[0.007096997,0.00023722599,0.00027662722,0.00043187925,0.00013877428,0.00037024906,0.0003186754,0.00051640533,6.7916693e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019888736,0.00088458776,0.9523995,0.000125707,0.0027689985,0.00016934167,0.0005685123,0.00007398458,0.00005158213,0.0000036425881,0.00006304878,0.04090221],"study_design_scores_gemma":[0.013402593,0.0020760468,0.9801101,0.0012468129,0.0014437693,0.000007781234,0.00027953117,0.0008828543,0.00020678979,0.00009164065,0.00003804905,0.0002140092],"about_ca_topic_score_codex":0.000073947616,"about_ca_topic_score_gemma":0.000026830232,"teacher_disagreement_score":0.040688198,"about_ca_system_score_codex":0.00035628746,"about_ca_system_score_gemma":0.00042100417,"threshold_uncertainty_score":0.9673795},"labels":[],"label_agreement":null},{"id":"W4415335434","doi":"10.2196/75586","title":"Assessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database","year":2025,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Longitudinal study; Duration (music); Longitudinal data; Disease; Patient data; Data collection","score_opus":0.14684922726251248,"score_gpt":0.4706662021991212,"score_spread":0.3238169749366087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415335434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901935,0.00006022172,0.0008478592,0.000037843096,0.00008842356,0.0028379702,0.0058808015,0.000015445721,0.00003795777],"genre_scores_gemma":[0.98883164,0.00005825893,0.0013459132,0.00000938845,0.000038753085,0.0000762568,0.009598588,0.000023140157,0.000018082548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969418,0.00017367853,0.0005642189,0.0008354934,0.0011903151,0.00029446074],"domain_scores_gemma":[0.99743015,0.00022169115,0.00024622155,0.0017405443,0.0001829946,0.0001783777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024260566,0.0002705718,0.0006518436,0.00036175945,0.000076978955,0.000019150559,0.00040802665,0.00007786719,0.00017908553],"category_scores_gemma":[0.000072756295,0.00018246825,0.000034908193,0.00050440605,0.0001207845,0.00058838207,0.0006645338,0.00020868689,2.5876815e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022512253,0.0042182286,0.98827195,0.00008439593,0.0010172334,0.000057952482,0.00020120603,0.00006669849,0.0003449308,0.000001133509,0.000047975573,0.0034370662],"study_design_scores_gemma":[0.010196606,0.00094265473,0.8573938,0.00093542296,0.0004112346,2.7928976e-7,0.00038247055,0.12927017,0.0003516054,0.0000012619007,0.000012992546,0.00010149048],"about_ca_topic_score_codex":0.06299145,"about_ca_topic_score_gemma":0.05495948,"teacher_disagreement_score":0.13087814,"about_ca_system_score_codex":0.0011723175,"about_ca_system_score_gemma":0.0015018045,"threshold_uncertainty_score":0.96228504},"labels":[],"label_agreement":null},{"id":"W4415479117","doi":"10.1159/000548964","title":"Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab","year":2025,"lang":"en","type":"article","venue":"Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple myeloma; Antibody; Incidence (geometry); Humoral immunity; Immunity; Immune system; Immunopathology; Antibody response","score_opus":0.012311747550952237,"score_gpt":0.28677185182580334,"score_spread":0.2744601042748511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415479117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985595,0.00005942216,0.000069980895,0.00020362047,0.000041909243,0.0014118747,0.000010626699,0.000065891254,0.008280718],"genre_scores_gemma":[0.997631,0.00003565826,0.0008119935,0.00008834124,0.00001937207,0.0002826889,0.00015878948,0.00001933504,0.0009527813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986914,0.00011898113,0.00023802198,0.00034643,0.00020031692,0.0004048686],"domain_scores_gemma":[0.9992313,0.00011315949,0.00007062717,0.00027066478,0.00020763028,0.00010661192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009473897,0.00019151902,0.0004091773,0.00036293504,0.00009041329,0.000013620797,0.000060115282,0.00017340972,0.000061191655],"category_scores_gemma":[0.0001483617,0.0001254092,0.000033973745,0.000683441,0.00015450927,0.000060102153,0.000037182006,0.00031233896,0.000041857224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007894043,0.0029665239,0.8585022,0.00007131411,0.0001886623,0.00049424643,0.00009606625,0.000008024204,0.00038952977,0.000018168896,0.000056700374,0.12931448],"study_design_scores_gemma":[0.020234615,0.016750017,0.9574709,0.00015247274,0.000055964327,0.000043933076,0.000038305247,0.00010524906,0.0018616354,0.000010415221,0.0031684905,0.00010798214],"about_ca_topic_score_codex":0.0028898572,"about_ca_topic_score_gemma":0.004335001,"teacher_disagreement_score":0.12920651,"about_ca_system_score_codex":0.0008782867,"about_ca_system_score_gemma":0.00048611013,"threshold_uncertainty_score":0.51140386},"labels":[],"label_agreement":null},{"id":"W4415521520","doi":"10.1038/s41408-025-01387-6","title":"35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Multiple myeloma; French; Autologous stem-cell transplantation; Clinical trial; Transplantation; Stem cell; Standard of care","score_opus":0.09186293333158163,"score_gpt":0.3964676674332405,"score_spread":0.3046047341016589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415521520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06411092,0.9337437,0.000020072956,0.00013409904,0.00070940546,0.001094013,0.000113478476,0.000013480454,0.000060805192],"genre_scores_gemma":[0.028049618,0.9705441,0.000072689305,0.00006779767,0.00076324673,0.00019582987,0.000011709256,0.000032893073,0.0002620992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970588,0.00069576304,0.0010312174,0.0003238495,0.00055514765,0.00033520412],"domain_scores_gemma":[0.997688,0.0010583184,0.00070923864,0.00026332674,0.00008552182,0.00019562458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082517543,0.00034420562,0.0019316244,0.00029637647,0.0001558918,0.000044892968,0.00029175877,0.00027256925,0.00014252498],"category_scores_gemma":[0.000067848094,0.0001969632,0.00043338886,0.00036015027,0.00013509186,0.00006888466,0.000031786112,0.0011569039,0.000003779308],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074057205,0.00013695458,0.00013775149,0.0037176602,0.00082659425,0.0004592585,0.0013630276,8.6551586e-7,0.00009490107,0.0000039282995,0.00012425888,0.9923942],"study_design_scores_gemma":[0.08740859,0.0072469665,0.027859043,0.30593267,0.015172134,0.011406353,0.0018877198,0.000016749527,0.007863862,0.00013967154,0.5331065,0.0019597448],"about_ca_topic_score_codex":0.00009822428,"about_ca_topic_score_gemma":0.000006089143,"teacher_disagreement_score":0.99043447,"about_ca_system_score_codex":0.00011746835,"about_ca_system_score_gemma":0.00097408576,"threshold_uncertainty_score":0.8031926},"labels":[],"label_agreement":null},{"id":"W4415590751","doi":"10.1101/2025.10.24.25338566","title":"Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple Myeloma","year":2025,"lang":"","type":"preprint","venue":"medRxiv","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre; University of New Brunswick; Vancouver General Hospital; Saint John Regional Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Whole genome sequencing; DNA sequencing; Bone marrow; Genome; Personalized medicine; Liquid biopsy","score_opus":0.03806121162642923,"score_gpt":0.29309185052100734,"score_spread":0.2550306388945781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415590751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97817916,0.002157777,0.0018018411,0.0009703986,0.0012902563,0.009985418,0.0046452754,0.00012368664,0.0008462016],"genre_scores_gemma":[0.9830546,0.00080281403,0.002603067,0.0001453181,0.0012726177,0.0041552503,0.0016095522,0.00016467026,0.006192155],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99079305,0.0005919639,0.0018825834,0.0028968242,0.0014494098,0.0023861742],"domain_scores_gemma":[0.9916159,0.0023131866,0.00063411804,0.0029772418,0.0007247017,0.0017348474],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014787103,0.0014382311,0.0018534436,0.0016847489,0.00065212615,0.00018656685,0.0013761442,0.0008761442,0.00015999188],"category_scores_gemma":[0.007761522,0.0014624083,0.0009007345,0.00087444106,0.000397582,0.00026165287,0.001922661,0.0017913062,0.00022700516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024978088,0.0027723399,0.45911664,0.019108597,0.001695678,0.005744269,0.0039881077,0.0014208074,0.46581444,0.0000104442715,0.0004483715,0.014902194],"study_design_scores_gemma":[0.033048723,0.0015575406,0.7463423,0.003898081,0.0011703406,0.0000179253,0.001444626,0.025731683,0.18316744,0.00050355756,0.001607912,0.001509859],"about_ca_topic_score_codex":0.0010744308,"about_ca_topic_score_gemma":0.0030086774,"teacher_disagreement_score":0.28722566,"about_ca_system_score_codex":0.0030622012,"about_ca_system_score_gemma":0.0052537066,"threshold_uncertainty_score":0.99983674},"labels":[],"label_agreement":null},{"id":"W4415596352","doi":"10.1158/2643-3230.bcd-25-0130","title":"CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Conquer Cancer Foundation; Marcus Foundation; Tanoto Foundation; Johns Hopkins University; Paula and Rodger Riney Foundation; Multiple Myeloma Research Foundation; American Society of Clinical Oncology; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society; National Institutes of Health","keywords":"Multiple myeloma; Downregulation and upregulation; Cytotoxicity; Cell culture; Tumor cells","score_opus":0.012603208836699872,"score_gpt":0.27011183621648716,"score_spread":0.2575086273797873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415596352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941562,0.002915794,0.00046358933,0.00021693626,0.0003868405,0.00089275534,0.00035250228,0.00004805755,0.00056734536],"genre_scores_gemma":[0.9958402,0.001528184,0.0005608578,0.00007502122,0.00019404369,0.0001880496,0.00010578654,0.00003187784,0.0014759611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979973,0.000117176096,0.00037790163,0.0005883963,0.00038570602,0.0005335539],"domain_scores_gemma":[0.99907386,0.00022698387,0.00010866429,0.0003507129,0.00007860079,0.00016118895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002560073,0.00027581782,0.00048211668,0.00023761987,0.00012416119,0.000090823574,0.00009793295,0.0001170275,0.000023227567],"category_scores_gemma":[0.00009330242,0.00023808166,0.00009918234,0.0003278208,0.000083123734,0.00051279913,0.00014235075,0.0002894152,0.000004520316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001556893,0.00065637013,0.8487105,0.0005581473,0.00070635305,0.0001409604,0.0003096135,0.0038895663,0.11754551,0.0005312779,0.00013524728,0.025259584],"study_design_scores_gemma":[0.028320067,0.00031374136,0.84834343,0.0006103837,0.0005222128,0.0000032263886,0.00030669285,0.03943871,0.08001441,0.0015182376,0.0001651749,0.00044372943],"about_ca_topic_score_codex":0.019009478,"about_ca_topic_score_gemma":0.0029857552,"teacher_disagreement_score":0.037531096,"about_ca_system_score_codex":0.00023685984,"about_ca_system_score_gemma":0.00030266654,"threshold_uncertainty_score":0.987523},"labels":[],"label_agreement":null},{"id":"W4415631913","doi":"10.1155/crh/8425047","title":"A Case Report Supporting the Use of Teclistamab in Multiple Myeloma With CNS Involvement","year":2025,"lang":"en","type":"article","venue":"Case Reports in Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital; BC Cancer Agency; Island Health","funders":"","keywords":"Multiple myeloma; Central nervous system; Disease; Immunotherapy; Antibody; Chemotherapy; Serology","score_opus":0.07610605424225281,"score_gpt":0.3491953492542578,"score_spread":0.273089295012005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415631913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970605,0.00023936553,0.00013403696,0.00046787277,0.000083455576,0.0015164346,0.0000064231294,0.0000284969,0.00046340722],"genre_scores_gemma":[0.9973873,0.000009490641,0.0017495407,0.00009804738,0.000009374137,0.00030830374,0.000040372743,0.000018921392,0.00037864904],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9971833,0.00013269218,0.0013986792,0.00052450394,0.0002531219,0.00050768285],"domain_scores_gemma":[0.9975123,0.0006656971,0.0004928897,0.0010178225,0.00019089958,0.0001204235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007920181,0.00021089247,0.000689515,0.0004564239,0.00008790159,0.000014660649,0.000038964838,0.00013599853,0.000038807957],"category_scores_gemma":[0.0027902133,0.00013595393,0.00008696029,0.00063551695,0.00028180444,0.00008010889,0.00012918476,0.0003365771,9.896571e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020043363,0.0002999224,0.44967303,0.00021022726,0.00007947556,0.5481129,0.00021454837,0.000018743496,0.00005287109,0.00011960104,0.000075218304,0.0009430137],"study_design_scores_gemma":[0.002192469,0.00014651903,0.019352576,0.00035559435,0.00006903765,0.9712007,0.0010488181,0.0011423175,0.0036512078,0.00007444442,0.0006649328,0.00010139893],"about_ca_topic_score_codex":0.005374576,"about_ca_topic_score_gemma":0.013101949,"teacher_disagreement_score":0.43032044,"about_ca_system_score_codex":0.00019477843,"about_ca_system_score_gemma":0.00057630864,"threshold_uncertainty_score":0.8124787},"labels":[],"label_agreement":null},{"id":"W4415665455","doi":"10.51731/cjht.2025.1272","title":"Belantamab Mafodotin, Pomalidomide, Dexamethasone","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pomalidomide; Dexamethasone; Regimen; Multiple myeloma; Refractory (planetary science); Combination therapy","score_opus":0.03492998391048633,"score_gpt":0.34642810840904276,"score_spread":0.3114981244985564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415665455","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15544926,0.6821288,0.0007555485,0.15482873,0.0021790247,0.0014152995,0.00015755468,0.00012829877,0.0029575196],"genre_scores_gemma":[0.9821482,0.0132214185,0.0017485445,0.0010722036,0.000037875205,0.000014707064,0.000009476566,0.000035810197,0.0017118058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99477434,0.00036099204,0.001893605,0.0004190848,0.0005169522,0.002035016],"domain_scores_gemma":[0.99635226,0.00045912268,0.0009731781,0.0008165048,0.0007596879,0.0006392567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002218038,0.00046217543,0.0015723206,0.0038501183,0.0008071329,0.00013247856,0.00095339323,0.00058188284,0.00028380338],"category_scores_gemma":[0.0058772108,0.00039341114,0.00033760775,0.0017223734,0.00096302415,0.00019378454,0.000107733824,0.0019541879,0.00008345246],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002940325,0.00013557858,0.09739064,0.0008386064,0.0009139415,0.0032456848,0.0001812711,0.0000041934236,0.000040321193,0.0018585187,0.01735954,0.8777377],"study_design_scores_gemma":[0.022298919,0.006889278,0.30592227,0.014887298,0.0006882119,0.0032146864,0.021098292,0.00017687623,0.0062102964,0.011632358,0.6061002,0.00088133005],"about_ca_topic_score_codex":0.024211774,"about_ca_topic_score_gemma":0.0108548375,"teacher_disagreement_score":0.8768563,"about_ca_system_score_codex":0.0028236338,"about_ca_system_score_gemma":0.029116826,"threshold_uncertainty_score":0.99985176},"labels":[],"label_agreement":null},{"id":"W4415667920","doi":"10.1038/s41598-025-21719-7","title":"Targeting of SKP2 to combat drug resistance in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Multiple myeloma; Drug resistance; SKP2; Drug; Bortezomib; Malignancy; Proteasome; Lenalidomide","score_opus":0.017859317943769357,"score_gpt":0.30452798719729995,"score_spread":0.2866686692535306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415667920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891489,0.0006387062,0.00010053798,0.00083721953,0.0012742963,0.0008694783,0.0000036458155,0.000034359266,0.0070928326],"genre_scores_gemma":[0.9607062,0.0000039346087,0.00406322,0.0000419706,0.000014189582,0.000048224898,0.000050143197,0.000008970299,0.035063166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781805,0.00005070358,0.00058870093,0.00060162164,0.0005588236,0.00038210684],"domain_scores_gemma":[0.99862546,0.000103204315,0.00012229606,0.0007320172,0.0002395,0.00017750685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001219369,0.00011827001,0.00031117137,0.00051645684,0.00013356842,0.000045701912,0.00009677152,0.00003934318,0.000067244146],"category_scores_gemma":[0.0015997874,0.00010082099,0.00007562074,0.0012244149,0.00015180236,0.000067396875,0.000111021065,0.00011769781,0.0000210669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037450696,0.0005167818,0.8048489,0.00037025035,0.00006164017,0.0025173912,0.00083104114,0.000037187514,0.11497796,0.00013413503,0.07094938,0.004380808],"study_design_scores_gemma":[0.00319585,0.000064989414,0.61425203,0.0016644648,0.00004425628,0.000038564962,0.00053513783,0.0006118043,0.26657507,0.0038274804,0.10889339,0.00029696384],"about_ca_topic_score_codex":0.0001543742,"about_ca_topic_score_gemma":0.0006156883,"teacher_disagreement_score":0.19059688,"about_ca_system_score_codex":0.00013405783,"about_ca_system_score_gemma":0.0003002934,"threshold_uncertainty_score":0.41113603},"labels":[],"label_agreement":null},{"id":"W4415668960","doi":"10.1016/j.htct.2025.104824","title":"DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Multiple myeloma; Clinical endpoint; Daratumumab; Subgroup analysis; Post-hoc analysis; Population; Overall survival; Phases of clinical research; Confidence interval","score_opus":0.012867494538952943,"score_gpt":0.28694795537164447,"score_spread":0.27408046083269155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415668960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587417,0.001041974,0.00017337434,0.00015598118,0.00002817849,0.0025183442,0.000060464892,0.0000150971,0.00013240041],"genre_scores_gemma":[0.99653035,0.0026652103,0.00009778239,0.0002841901,0.0000029655757,0.00016888443,0.00021309196,0.000016880735,0.000020654381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773335,0.0004023847,0.00058034033,0.00052633416,0.00037380066,0.00038377923],"domain_scores_gemma":[0.9987802,0.00054637116,0.00009300415,0.00036184874,0.000101128986,0.00011743274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033325056,0.00030675056,0.0010323199,0.0008505853,0.00011444789,0.000018715129,0.00013601706,0.00012947439,0.000047091926],"category_scores_gemma":[0.000026221143,0.0001898554,0.000100510355,0.0013062102,0.00016869414,0.00007930569,0.000015587662,0.00028815656,5.5992365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024486758,0.010118702,0.94823223,0.0001036965,0.000670897,0.00015400784,0.0056211953,0.000007973127,0.00019176696,0.0000121395005,0.00001767383,0.010382939],"study_design_scores_gemma":[0.13875322,0.0024205965,0.8553948,0.00008714384,0.00039926506,0.00000277475,0.0009816581,0.00054251676,0.0012115762,0.000009129555,0.000057319645,0.00014002471],"about_ca_topic_score_codex":0.0020162528,"about_ca_topic_score_gemma":0.005827567,"teacher_disagreement_score":0.11426646,"about_ca_system_score_codex":0.00003867547,"about_ca_system_score_gemma":0.00007382718,"threshold_uncertainty_score":0.7742079},"labels":[],"label_agreement":null},{"id":"W4415669720","doi":"10.1016/j.htct.2025.104870","title":"UPDATED RESULTS OF SONROTOCLAX + DEXAMETHASONE, AN ALL-ORAL TREATMENT, IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"","keywords":"Discontinuation; Multiple myeloma; Cohort; Adverse effect; Refractory (planetary science); Dexamethasone; Cohort study; Retrospective cohort study","score_opus":0.01810491532816009,"score_gpt":0.2925487832883246,"score_spread":0.2744438679601645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415669720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559206,0.0003772178,0.00006645774,0.00025189325,0.000038576054,0.0025324177,0.00008086053,0.000042190877,0.0010183428],"genre_scores_gemma":[0.9966024,0.0012214426,0.0007852799,0.00018121702,0.000004873838,0.00016234093,0.000552334,0.000026162365,0.00046394017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981295,0.0002939718,0.0004281881,0.0005358932,0.0002180158,0.00039443054],"domain_scores_gemma":[0.9989882,0.00020425137,0.000094731826,0.00037555041,0.00013712577,0.0002001553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015101177,0.00030421492,0.0006960185,0.00033539982,0.00008678745,0.000009595924,0.00008368751,0.00024310437,0.00008530804],"category_scores_gemma":[0.00001728458,0.00020674092,0.00008102009,0.0003035354,0.00020025129,0.00010611217,0.000012849946,0.00019878699,0.0000035618034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046509523,0.006389788,0.9062664,0.000060298633,0.0003288246,0.00013877565,0.0012575557,0.000001982371,0.006171736,0.000060584287,0.00008228303,0.032732256],"study_design_scores_gemma":[0.11223222,0.007842262,0.7905933,0.00016353234,0.000084727006,0.000014340993,0.0002582868,0.00021740326,0.08638997,0.000033395107,0.001958801,0.00021175017],"about_ca_topic_score_codex":0.0009938173,"about_ca_topic_score_gemma":0.001530758,"teacher_disagreement_score":0.11567308,"about_ca_system_score_codex":0.00008174169,"about_ca_system_score_gemma":0.00015685674,"threshold_uncertainty_score":0.843065},"labels":[],"label_agreement":null},{"id":"W4415671112","doi":"10.1016/j.htct.2025.104836","title":"HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRANSPLANT-INELIGIBLE OR TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) IN THE PHASE 3 CEPHEUS TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Multiple myeloma; Quality of life (healthcare); Bortezomib; Population; Clinical trial; Phases of clinical research","score_opus":0.03849506143546937,"score_gpt":0.33214157402619215,"score_spread":0.2936465125907228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415671112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290967,0.0017773561,0.00012615343,0.001517205,0.00006832102,0.0032907808,0.00008561868,0.000028563394,0.00019634588],"genre_scores_gemma":[0.99334943,0.00561529,0.00007286935,0.0005105884,0.0000061360397,0.00018077648,0.00019878602,0.00001753367,0.000048607944],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715424,0.0006777421,0.00096586696,0.00041269846,0.00033273632,0.00045672673],"domain_scores_gemma":[0.9987032,0.0006555301,0.00012114964,0.0003013781,0.000048074,0.00017067566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005414277,0.00027548484,0.001094505,0.00031931401,0.00010356093,0.000009631737,0.00014090097,0.00021045882,0.000107482054],"category_scores_gemma":[0.000034543664,0.00015468404,0.00011025907,0.0005603545,0.00015061919,0.0000526488,0.0000044170656,0.0003532512,0.00000160027],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4213,0.0074469494,0.551681,0.00042829005,0.00013086319,0.00014167186,0.004399902,0.0000020598827,0.0005359391,0.000055478427,0.000036444646,0.013841415],"study_design_scores_gemma":[0.54122686,0.0038883947,0.45197403,0.00035207576,0.000030370533,0.0000138563055,0.0004237334,0.00009934162,0.0017092001,0.000035278805,0.00009354497,0.0001533148],"about_ca_topic_score_codex":0.002591788,"about_ca_topic_score_gemma":0.0042311368,"teacher_disagreement_score":0.11992685,"about_ca_system_score_codex":0.000028413831,"about_ca_system_score_gemma":0.00032406746,"threshold_uncertainty_score":0.6307832},"labels":[],"label_agreement":null},{"id":"W4415728297","doi":"10.2196/81225","title":"Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)","year":2025,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Massive open online course; Descriptive research; Data collection; MEDLINE; Patient education; Descriptive statistics; Continuing medical education","score_opus":0.0360283249277008,"score_gpt":0.3699870251638291,"score_spread":0.3339587002361283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415728297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547,0.00023052501,0.00017274254,0.000112169946,0.000091793176,0.011592561,0.0018631564,0.000023048584,0.00044398836],"genre_scores_gemma":[0.9951511,0.000032810978,0.001163947,0.000017306911,0.000020953988,0.0014238444,0.0018129813,0.00004954565,0.0003275187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578357,0.0005982167,0.0007837369,0.0007485169,0.0012761207,0.0008098307],"domain_scores_gemma":[0.9927266,0.0010792649,0.00067622133,0.00050236407,0.0047271685,0.00028834734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044768295,0.00045665092,0.0009093639,0.0005895973,0.0004553222,0.00011538754,0.0003539371,0.00018176697,0.00001654999],"category_scores_gemma":[0.00078582444,0.00034011822,0.00007849922,0.00096656446,0.00042065876,0.0010782592,0.00067643507,0.00051098247,0.000001945765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048492523,0.021182789,0.85902107,0.0007190697,0.0012029867,0.0000030396163,0.07267782,9.08767e-7,0.000097927616,0.000014052116,0.0023155787,0.037915498],"study_design_scores_gemma":[0.03562944,0.014971238,0.8986418,0.0014270747,0.00016188671,6.1755776e-7,0.047040753,0.00070492603,0.00073033705,0.00002917538,0.00039902786,0.00026370323],"about_ca_topic_score_codex":0.0021109714,"about_ca_topic_score_gemma":0.0038203401,"teacher_disagreement_score":0.039620746,"about_ca_system_score_codex":0.0011372159,"about_ca_system_score_gemma":0.0007242181,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W4415739231","doi":"10.51731/cjht.2025.1278","title":"Belantamab Mafodotin (Blenrep), Bortezomib, Dexamethasone","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dexamethasone; Bortezomib; Multiple myeloma; Refractory (planetary science); Drug","score_opus":0.034661680369379236,"score_gpt":0.3464443294400952,"score_spread":0.31178264907071596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415739231","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13062948,0.69158405,0.0011765587,0.16820796,0.0025635678,0.0017846694,0.0001993812,0.00017527718,0.0036790585],"genre_scores_gemma":[0.97866935,0.016420646,0.002138383,0.0009377852,0.000040849984,0.00001783987,0.00001255482,0.00004014506,0.0017224657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437463,0.00035262998,0.0020170745,0.0004827521,0.0005696299,0.0022032808],"domain_scores_gemma":[0.99615306,0.00042871787,0.0010374178,0.0009446645,0.00073377456,0.00070235715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023291602,0.00050421496,0.0016467506,0.0038164787,0.0008512955,0.00013532239,0.0010006342,0.0006355167,0.00028756438],"category_scores_gemma":[0.0050772736,0.00043409242,0.00034874774,0.0017924759,0.00095942814,0.00020809821,0.00011411198,0.0021947366,0.0000866706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024698168,0.00012530216,0.07667623,0.00085738866,0.0009168677,0.003125607,0.0002003895,0.00000468444,0.000041429557,0.0015751213,0.015547537,0.90068245],"study_design_scores_gemma":[0.02052365,0.007862079,0.34124866,0.015762415,0.0007925316,0.0030169804,0.025285304,0.00022131363,0.006101716,0.016190607,0.561981,0.0010137166],"about_ca_topic_score_codex":0.026443634,"about_ca_topic_score_gemma":0.012556538,"teacher_disagreement_score":0.89966875,"about_ca_system_score_codex":0.0031423366,"about_ca_system_score_gemma":0.034135956,"threshold_uncertainty_score":0.9998111},"labels":[],"label_agreement":null},{"id":"W4415897690","doi":"10.1016/j.clml.2025.10.019","title":"Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Memorial University of Newfoundland; Jewish General Hospital; Saint John Regional Hospital; Juravinski Cancer Centre; McGill University; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Saskatchewan; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation","funders":"AbbVie","keywords":"Multiple myeloma; National database; MEDLINE; Outcomes research; Benchmark (surveying)","score_opus":0.13771947700868384,"score_gpt":0.46515680384845237,"score_spread":0.32743732683976856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415897690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335916,0.000112764705,0.000034300912,0.0034981656,0.0006622091,0.0029577715,0.0002418096,0.00012120191,0.009012621],"genre_scores_gemma":[0.9910212,0.000068431946,0.0036127667,0.001657309,0.00041615506,0.0002651459,0.00082727545,0.000112503134,0.0020191765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98742867,0.0023802735,0.003140488,0.0018123805,0.003055525,0.0021826557],"domain_scores_gemma":[0.98812866,0.0060317214,0.00045824994,0.0019510478,0.0017077057,0.0017226202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0076879244,0.00075423793,0.0020617102,0.0016447528,0.0011401746,0.0002915095,0.0011757792,0.00071658153,0.00018597928],"category_scores_gemma":[0.006221239,0.00051557814,0.0005583323,0.0030939472,0.0017123608,0.0003766617,0.00068461546,0.0019929083,0.00024463923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028492433,0.001820551,0.92174584,0.00009591008,0.00062796206,0.0005915657,0.000082122024,0.000010811463,0.000013899282,0.0020610238,0.0057940925,0.06430696],"study_design_scores_gemma":[0.01865108,0.0006907564,0.96588045,0.00064935745,0.0001724895,0.000015672298,0.00018164306,0.004759135,0.000032702166,0.0004127907,0.008097379,0.00045657065],"about_ca_topic_score_codex":0.13523707,"about_ca_topic_score_gemma":0.60101926,"teacher_disagreement_score":0.46578217,"about_ca_system_score_codex":0.008144209,"about_ca_system_score_gemma":0.014360493,"threshold_uncertainty_score":0.9997296},"labels":[],"label_agreement":null},{"id":"W4415900084","doi":"10.1016/s2352-3026(25)00256-x","title":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Dexamethasone; Multiple myeloma; Refractory (planetary science); Randomized controlled trial; Phases of clinical research","score_opus":0.047484709287832494,"score_gpt":0.3549491914005954,"score_spread":0.3074644821127629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814653,0.0006274901,0.000056478497,0.0016150783,0.00022552453,0.015231529,0.00006332678,0.00009788091,0.0006173983],"genre_scores_gemma":[0.9937383,0.00017874133,0.0030558119,0.000555857,0.000042872496,0.0018150868,0.00015697465,0.00007108098,0.0003852549],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950137,0.001161521,0.0012119291,0.0009887227,0.0005799817,0.0010441062],"domain_scores_gemma":[0.9914764,0.006064899,0.00071145303,0.0010895744,0.00030342326,0.00035426064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011470208,0.0006845467,0.004232742,0.00044111922,0.00029961125,0.00011988487,0.00035725386,0.00030016754,0.000068672714],"category_scores_gemma":[0.0046221237,0.0003519372,0.000088008775,0.0006168304,0.0006647369,0.0002552596,0.00033770635,0.0006803943,0.0000057032535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7096312,0.002913233,0.27817872,0.000110626745,0.0021440962,0.0016098982,0.00021052899,7.759107e-7,0.00007186587,0.00007082801,0.00020503376,0.0048532034],"study_design_scores_gemma":[0.8807054,0.009898067,0.10654588,0.00029943947,0.0010688638,0.0002443864,0.00021362257,0.00027079455,0.00022583352,0.000037204987,0.00014651052,0.00034397474],"about_ca_topic_score_codex":0.0006360518,"about_ca_topic_score_gemma":0.0013252241,"teacher_disagreement_score":0.17163283,"about_ca_system_score_codex":0.00015406712,"about_ca_system_score_gemma":0.00050749636,"threshold_uncertainty_score":0.99989325},"labels":[],"label_agreement":null},{"id":"W4415940025","doi":"10.1016/j.annonc.2025.08.1923","title":"1289P Prognostic value of FDG PET/CT in multiple myeloma patients at the time of initial diagnosis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Value (mathematics); Overall survival; Infiltration (HVAC); Bone marrow; Predictive value of tests","score_opus":0.06354901922538532,"score_gpt":0.4090645909389949,"score_spread":0.3455155717136096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180967,0.00032566575,0.0000010987045,0.0019175793,0.000067452675,0.0009673179,0.00010510466,0.000006801791,0.004799341],"genre_scores_gemma":[0.99877423,0.00021542361,0.0001151221,0.00029487401,0.000015609008,0.00014948816,0.000080606565,0.000009997596,0.00034464308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984074,0.0002635801,0.000536977,0.00020032279,0.00028788592,0.0003038384],"domain_scores_gemma":[0.9972437,0.001840499,0.00021177075,0.00029176104,0.00033470744,0.000077568686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003318085,0.00012709151,0.00057528284,0.00024470262,0.00003580283,0.0000016237422,0.00015984473,0.000035808935,0.00016101931],"category_scores_gemma":[0.0023947074,0.00008807141,0.0001410344,0.00032804723,0.00033226894,0.00003628557,0.00018236238,0.00013592145,0.000024047908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015182743,0.002831695,0.94424754,0.00019792859,0.0002846412,0.0002321866,0.00014777402,0.00000995765,0.0005337442,0.00005327964,0.002914627,0.047028363],"study_design_scores_gemma":[0.005927821,0.0036434436,0.94071096,0.00024349566,0.00006393056,0.000014119618,0.000051943774,0.00026590927,0.046786282,0.0001294899,0.002106428,0.00005614851],"about_ca_topic_score_codex":0.00060173805,"about_ca_topic_score_gemma":0.00029336495,"teacher_disagreement_score":0.04697221,"about_ca_system_score_codex":0.00006859242,"about_ca_system_score_gemma":0.00031242732,"threshold_uncertainty_score":0.35914478},"labels":[],"label_agreement":null},{"id":"W4415942115","doi":"10.1016/j.annonc.2025.08.2705","title":"2084eTiP A phase III study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard of care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Università degli Studi di Perugia; Istituto Oncologico Veneto; Sapienza Università di Roma; Università degli Studi di Padova","keywords":"Standard of care; Chemotherapy; Chemotherapy regimen; Immunotherapy; Immune checkpoint; Clinical trial","score_opus":0.058893868294680976,"score_gpt":0.4324994319029268,"score_spread":0.3736055636082458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908854,0.002169968,0.0000053084177,0.002094514,0.00018039801,0.0051665865,0.000068771464,0.000023481418,0.0012024423],"genre_scores_gemma":[0.9984674,0.0004403227,0.000499367,0.00006079207,0.000039837632,0.00032043108,0.00006654898,0.00003400786,0.0000713009],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962277,0.00038065965,0.0015132963,0.00054913573,0.000720847,0.0006083553],"domain_scores_gemma":[0.99733233,0.00033962072,0.0006200471,0.00061028963,0.0009532182,0.00014451859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007314429,0.00036948523,0.0020031887,0.00074940093,0.000047706264,0.0000072879106,0.00026682008,0.00025806346,0.000056662906],"category_scores_gemma":[0.00037736824,0.000288196,0.00018246408,0.0011256109,0.00051102997,0.000112209585,0.00010302018,0.00044153936,8.2442995e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8657895,0.014360773,0.004110852,0.00058281,0.0007803953,0.00057005015,0.0055458266,0.000020580032,0.058521718,0.00008629647,0.000038804155,0.04959241],"study_design_scores_gemma":[0.51478416,0.15111768,0.009398299,0.0011566284,0.00012000374,0.0000036451952,0.00673386,0.000027637747,0.31606787,0.000035444747,0.0003727762,0.00018202046],"about_ca_topic_score_codex":0.00094364194,"about_ca_topic_score_gemma":0.002444865,"teacher_disagreement_score":0.35100535,"about_ca_system_score_codex":0.00040206403,"about_ca_system_score_gemma":0.0017111233,"threshold_uncertainty_score":0.999957},"labels":[],"label_agreement":null},{"id":"W4416055381","doi":"10.1093/jnci/djaf326","title":"Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials","year":2025,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Drug; Randomized controlled trial; Clinical trial; MEDLINE; Clinical endpoint","score_opus":0.06882719695673326,"score_gpt":0.42199613556585563,"score_spread":0.35316893860912235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416055381","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18459922,0.7182293,0.0017690224,0.023264015,0.008746511,0.030613318,0.00017715749,0.000029814442,0.032571644],"genre_scores_gemma":[0.9606712,0.026673999,0.007083458,0.0016823699,0.0003217652,0.0005078638,0.000010329478,0.000015414447,0.0030336252],"study_design_codex":"systematic_review","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949575,0.0009957359,0.0026680247,0.00008346765,0.0011776384,0.00011759837],"domain_scores_gemma":[0.99281794,0.002503006,0.0027348534,0.00011037406,0.0017669928,0.000066823726],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010533162,0.000116448384,0.0040456178,0.0003324745,0.00005013602,0.0000068604863,0.0002412821,0.000051119736,0.00008554389],"category_scores_gemma":[0.027642744,0.00005912679,0.0009827408,0.00031457632,0.00014526011,0.0000906529,0.000047975518,0.00019771284,0.0000013729353],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41530457,0.0016652152,0.0006228476,0.47808018,0.061727885,0.00014879456,0.0016196383,0.0012282521,0.004830544,0.008362884,0.0143427225,0.012066488],"study_design_scores_gemma":[0.5918235,0.00011281934,0.001084922,0.38831615,0.007358,0.00011929058,0.000055634075,0.0002671045,0.007034812,0.00048446946,0.0032134422,0.00012983501],"about_ca_topic_score_codex":0.000021659993,"about_ca_topic_score_gemma":0.000013476243,"teacher_disagreement_score":0.77607197,"about_ca_system_score_codex":0.00060991466,"about_ca_system_score_gemma":0.0044765105,"threshold_uncertainty_score":0.98054785},"labels":[],"label_agreement":null},{"id":"W4416306788","doi":"10.1111/bjh.70257","title":"Return to employment outcomes in patients with multiple myeloma","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; MEDLINE; Immunopathology; Hematology","score_opus":0.010825367374835684,"score_gpt":0.2904119371044533,"score_spread":0.2795865697296176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416306788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969502,0.00030840977,0.00011365371,0.0016513737,0.00012825437,0.0004921723,0.0000113162305,0.000009004064,0.00033559656],"genre_scores_gemma":[0.9967885,0.000027347169,0.002196411,0.00051224366,0.000012247569,0.000015272206,0.0000077849845,0.000012642487,0.00042753184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985901,0.0000846762,0.0004936245,0.00016370189,0.00033396613,0.0003339002],"domain_scores_gemma":[0.9990871,0.00013507614,0.00011675558,0.00014637216,0.00029933522,0.00021533835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016400058,0.000118438875,0.00069780136,0.00039633477,0.000044952503,0.000022344613,0.00012494836,0.00007129314,0.00005476657],"category_scores_gemma":[0.00060985493,0.000096719275,0.00008680992,0.00024412079,0.00005278926,0.000072632894,0.000056510788,0.00027210708,0.000012688737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013804211,0.00083865836,0.95619434,0.000042621698,0.0002580443,0.019768074,0.00004239178,0.0000023157522,0.000014474766,0.000018683395,0.0014408389,0.019999154],"study_design_scores_gemma":[0.012368281,0.00092592917,0.9800936,0.00070198724,0.000042749773,0.004628433,0.00004421145,0.0000076831075,0.00028420705,0.000046939833,0.0007842277,0.000071767645],"about_ca_topic_score_codex":0.00017121117,"about_ca_topic_score_gemma":0.00072308106,"teacher_disagreement_score":0.02389926,"about_ca_system_score_codex":0.00013120867,"about_ca_system_score_gemma":0.00016556385,"threshold_uncertainty_score":0.39440978},"labels":[],"label_agreement":null},{"id":"W4416307752","doi":"10.1080/14796694.2025.2589058","title":"Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Johnson and Johnson","keywords":"Multiple myeloma; Resource use; Health care; Healthcare system; MEDLINE; Clinical trial","score_opus":0.03811956074926689,"score_gpt":0.3619815659137525,"score_spread":0.32386200516448566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416307752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989886,0.00038513154,0.0000064196734,0.006531528,0.0004031889,0.0014122825,0.000044014632,0.00005867096,0.0012598921],"genre_scores_gemma":[0.99256206,0.00014553312,0.0016374064,0.0028219265,0.00015166262,0.00010389326,0.00022138018,0.000028702052,0.0023274298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997489,0.00054326,0.00057901937,0.00057783583,0.00029230324,0.00051857904],"domain_scores_gemma":[0.99749035,0.0013845298,0.00013820946,0.0004672174,0.0001580703,0.00036162377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034266236,0.00025467624,0.00083330274,0.00032768003,0.000106411106,0.000017730705,0.00011016604,0.00047607083,0.000031667634],"category_scores_gemma":[0.0010126695,0.00017421828,0.00009958805,0.0003119976,0.00019573029,0.00010173568,0.00010907053,0.0008164844,0.0000143916695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007514615,0.0013539589,0.90703344,0.00007951605,0.00018844572,0.00034786633,0.00015611139,1.702361e-7,0.000008610948,0.00007708558,0.0031428628,0.08009733],"study_design_scores_gemma":[0.03242726,0.002733876,0.8157341,0.00010106949,0.000046671947,0.0000065190397,0.00025572407,0.000025616453,0.000007453936,0.000010031707,0.14854394,0.000107765],"about_ca_topic_score_codex":0.00023203681,"about_ca_topic_score_gemma":0.003810499,"teacher_disagreement_score":0.14540108,"about_ca_system_score_codex":0.00038695408,"about_ca_system_score_gemma":0.0004938769,"threshold_uncertainty_score":0.7104415},"labels":[],"label_agreement":null},{"id":"W4416401078","doi":"10.1186/s12978-025-02182-z","title":"Reproductive autonomy of women living with multiple myeloma participating in a pregnancy prevention program","year":2025,"lang":"en","type":"article","venue":"Reproductive Health","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; McMaster University; Ottawa Hospital; University of Alberta; Centre for Global Health Research","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Reproductive medicine; Pregnancy; Socioeconomic status; Autonomy; Reproductive health; Family planning; Qualitative research; Public health","score_opus":0.041685107587265055,"score_gpt":0.38785009994579084,"score_spread":0.34616499235852577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416401078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030334,0.0012274783,0.000315201,0.0013119109,0.00006075321,0.004720314,0.000005058925,0.0000941734,0.0019617542],"genre_scores_gemma":[0.98337805,0.000055987595,0.009545288,0.000026792619,0.00006903627,0.0047954535,0.000013836235,0.000024557943,0.002090966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968371,0.0003465199,0.00059490325,0.001083895,0.0003150143,0.0008225931],"domain_scores_gemma":[0.9981231,0.00015246344,0.00029840178,0.00090988225,0.00031089454,0.00020523365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012501813,0.00020833459,0.000646461,0.00034413202,0.00011422919,0.000012428701,0.000079703255,0.00005349731,0.000049486072],"category_scores_gemma":[0.0021471924,0.00016966184,0.00006373045,0.0010175651,0.0001464992,0.00017059546,0.00008562048,0.00028202042,0.000008678866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007767742,0.0028529111,0.68342614,0.0011983656,0.00026993226,0.000012843311,0.0077386755,0.000041605937,0.00027892253,0.0001127433,0.000028106359,0.30326298],"study_design_scores_gemma":[0.0028790724,0.003224425,0.98171675,0.0045069098,0.000024036255,0.000013941293,0.0019289479,0.00045742153,0.0046035782,0.00014049726,0.00037797456,0.00012646166],"about_ca_topic_score_codex":0.00079843844,"about_ca_topic_score_gemma":0.00015175108,"teacher_disagreement_score":0.30313653,"about_ca_system_score_codex":0.0017300309,"about_ca_system_score_gemma":0.0020293968,"threshold_uncertainty_score":0.6918609},"labels":[],"label_agreement":null},{"id":"W4416735535","doi":"10.1186/s12911-025-03229-8","title":"Patients and healthcare professionals’ perspectives on the implementation of shared decision making in multiple myeloma: a multinational qualitative study","year":2025,"lang":"en","type":"article","venue":"BMC Medical Informatics and Decision Making","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Fonds Wetenschappelijk Onderzoek","keywords":"Qualitative research; Focus group; Health care; Health informatics; Multidisciplinary approach; Focus (optics); Multinational corporation","score_opus":0.06442199078142519,"score_gpt":0.47927586618254275,"score_spread":0.41485387540111757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416735535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767984,0.00017284154,0.010252619,0.00018070618,0.000049591355,0.0015287052,0.000035332578,0.000009224932,0.00009112133],"genre_scores_gemma":[0.9698666,0.000038981896,0.029641084,0.00031224525,0.0000106577,0.00009785319,0.00002170628,0.000006572905,0.0000043140044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99715984,0.00021869902,0.0008581975,0.00019815896,0.0013503823,0.00021471795],"domain_scores_gemma":[0.9916943,0.007459969,0.00022523718,0.00017248299,0.00033718138,0.00011083767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015425065,0.00015312516,0.00032194966,0.0004267657,0.00021920826,0.000041408963,0.000106167645,0.000084796826,0.00008926394],"category_scores_gemma":[0.0036110054,0.0000913755,0.00004530508,0.00035435767,0.00009632484,0.00014270579,0.00024929736,0.00025394387,0.0000023354219],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018337744,0.00095144246,0.41793567,0.0002725466,0.00006617148,0.000007548407,0.08877649,0.000004904986,9.963692e-7,0.0016629469,0.00018219046,0.4883053],"study_design_scores_gemma":[0.0072187055,0.00041686784,0.6275008,0.0023603102,0.0000128192205,0.0000019703764,0.3191959,0.041912403,0.0000040152268,0.0013018139,0.000007025402,0.00006736365],"about_ca_topic_score_codex":0.00003876102,"about_ca_topic_score_gemma":0.00041218547,"teacher_disagreement_score":0.48823795,"about_ca_system_score_codex":0.00011481417,"about_ca_system_score_gemma":0.00029575854,"threshold_uncertainty_score":0.43229714},"labels":[],"label_agreement":null},{"id":"W4416775922","doi":"10.1007/s12325-025-03409-y","title":"Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Johnson and Johnson; Universidad de Salamanca; Regeneron Pharmaceuticals; Genentech; Celgene; Adaptive Biotechnologies; Karyopharm Therapeutics; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Identifier; Rheumatology; MEDLINE; Comparative effectiveness research; Identification (biology)","score_opus":0.058499155964655956,"score_gpt":0.41023446096345717,"score_spread":0.35173530499880123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416775922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982555,0.0044082557,0.000034789544,0.00019187013,0.000092667506,0.0021280309,0.00009433205,0.00002471855,0.0031997596],"genre_scores_gemma":[0.99162,0.0067109233,0.0005513925,0.00008521463,0.000020227337,0.00016564876,0.00031960037,0.000021483225,0.0005055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743474,0.0003178221,0.00103417,0.00045121196,0.00038873858,0.0003733125],"domain_scores_gemma":[0.99782777,0.000827697,0.0004984981,0.0005845866,0.00016974338,0.00009170019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016401095,0.00036134347,0.0014130234,0.0008327211,0.00003834938,0.000005716258,0.00021165807,0.00008331401,0.00007311311],"category_scores_gemma":[0.000065796055,0.00028201702,0.00024651355,0.0013708427,0.00027906956,0.00025165212,0.00004431285,0.00020375903,0.0000037268412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025545077,0.0208816,0.71152127,0.0002992401,0.0020138712,0.0000460018,0.0020053117,0.002054109,0.15736087,0.00021356963,0.00019614589,0.07786294],"study_design_scores_gemma":[0.037844107,0.0027555143,0.48719892,0.00044754127,0.000070789596,3.7448916e-7,0.00034145545,0.0010674151,0.46711028,0.00007416663,0.0029418238,0.00014764264],"about_ca_topic_score_codex":0.0029757398,"about_ca_topic_score_gemma":0.003234748,"teacher_disagreement_score":0.3097494,"about_ca_system_score_codex":0.00083516975,"about_ca_system_score_gemma":0.00022728025,"threshold_uncertainty_score":0.9999632},"labels":[],"label_agreement":null},{"id":"W4416853882","doi":"10.1016/j.clml.2025.10.026","title":"Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Memorial University of Newfoundland; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; Dalhousie University; McGill University; University of British Columbia; University of Alberta; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; Saint John Regional Hospital; BC Cancer Agency; Vancouver General Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Jewish General Hospital; Alberta Cancer Foundation; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Real world evidence; Multiple myeloma; Real world data; Stem cell; Autologous stem-cell transplantation; Transplantation","score_opus":0.12446060375010545,"score_gpt":0.38362339408857327,"score_spread":0.2591627903384678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416853882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883349,0.001213644,0.000058016412,0.006210091,0.0002972697,0.0025202779,0.0004185185,0.00006309624,0.0008842169],"genre_scores_gemma":[0.9922846,0.0024204198,0.00141699,0.0010256767,0.00009877155,0.0002780496,0.00023324505,0.000050121853,0.002192138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918983,0.0029076915,0.0017457291,0.0011546878,0.0010793175,0.0012142783],"domain_scores_gemma":[0.96878797,0.02817779,0.0002993237,0.0017293086,0.00038464763,0.0006209676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0048304354,0.0004679318,0.0012401587,0.00055417046,0.00062706135,0.0001648592,0.00082321436,0.0003997833,0.00003513828],"category_scores_gemma":[0.0045026285,0.00027771838,0.00034399328,0.0014558347,0.0024078924,0.00031611073,0.00031194455,0.0011860083,0.000050181552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00821734,0.00020854668,0.81029606,0.00018646101,0.000246127,0.0013514583,0.00060616544,0.000008025408,0.00027728188,0.0009826109,0.00224031,0.17537959],"study_design_scores_gemma":[0.017653914,0.00022962004,0.97319555,0.0014141989,0.00020194254,0.000022871262,0.00028667084,0.0047302824,0.00040661756,0.00024157266,0.0013922108,0.0002245716],"about_ca_topic_score_codex":0.45276958,"about_ca_topic_score_gemma":0.7162903,"teacher_disagreement_score":0.26352072,"about_ca_system_score_codex":0.0018667663,"about_ca_system_score_gemma":0.0035213141,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W4416904525","doi":"10.2196/85053","title":"Establishing Barriers to and Enablers of Nurse-Enabled Subcutaneous Therapy Self-Administration Programs for Patients With Myeloma: Protocol for a Qualitative Descriptive Study","year":2025,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Blueprint; Protocol (science); Qualitative research; Descriptive research; Health care; Quality (philosophy); Quality of life (healthcare); Research design","score_opus":0.16684884253426255,"score_gpt":0.5395604755778772,"score_spread":0.37271163304361465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416904525","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11266558,6.902668e-7,0.00017438423,0.00023519665,0.000002972424,0.88649267,0.000058141894,0.00006363055,0.00030671127],"genre_scores_gemma":[0.120778054,7.042713e-8,0.006159448,0.000017180797,0.00002417094,0.87236935,0.000041735508,0.000045410554,0.00056456844],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9960028,0.00066723925,0.000515443,0.00075143145,0.0011354892,0.00092757447],"domain_scores_gemma":[0.9949444,0.00094315596,0.00014673511,0.00046576603,0.0028704645,0.00062948756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019891209,0.0003067362,0.0005554287,0.0005392351,0.000469796,0.00026231667,0.00024676873,0.000119977994,0.000016811528],"category_scores_gemma":[0.0016400099,0.00021459971,0.000083631756,0.0009677514,0.00021883934,0.00029999527,0.00007043765,0.00031033182,0.0000011624312],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4865166,0.036164727,0.28086364,0.009425213,0.0020981343,0.00011246227,0.09358697,0.000001976446,0.0015552394,0.0006803894,0.004764249,0.08423042],"study_design_scores_gemma":[0.21934447,0.5019659,0.049040493,0.0097049475,0.00007602105,0.000010551156,0.13406797,0.0003957113,0.015310078,0.0012864382,0.06787898,0.00091848016],"about_ca_topic_score_codex":0.00007534745,"about_ca_topic_score_gemma":0.00008717198,"teacher_disagreement_score":0.46580115,"about_ca_system_score_codex":0.00042993113,"about_ca_system_score_gemma":0.0019705635,"threshold_uncertainty_score":0.87511224},"labels":[],"label_agreement":null},{"id":"W4416995933","doi":"10.1158/2159-8290.cd-25-1101","title":"A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model","year":2025,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"NextGenerationEU; National Cancer Institute; National Heart, Lung, and Blood Institute; American Society of Hematology; Tow Foundation; Paula and Rodger Riney Foundation; Fondazione AIRC per la ricerca sul cancro ETS; Allen Foundation; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; International Myeloma Society","keywords":"Multiple myeloma; Immune system; Clinical trial; Body mass index; Microbiome; Immunity; Weight loss; Diabetes mellitus; Disease","score_opus":0.07918418177968839,"score_gpt":0.40540674631108853,"score_spread":0.32622256453140014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416995933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679197,0.0019741547,0.00081264455,0.005710965,0.0004844695,0.0019758171,0.0017854187,0.000034686404,0.00042987106],"genre_scores_gemma":[0.9938118,0.0024736722,0.00034596393,0.0004001969,0.0003348987,0.00046836105,0.0006821566,0.00001804173,0.0014649425],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976595,0.00030019524,0.0007373985,0.0006440741,0.0003173262,0.0003415089],"domain_scores_gemma":[0.9972807,0.0019066159,0.00013952292,0.00049845397,0.000036650694,0.00013806198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054394966,0.00020745776,0.0005068533,0.00008414427,0.00008711193,0.00007021915,0.00015982748,0.00016374537,0.000023796727],"category_scores_gemma":[0.0007214487,0.00013634734,0.00020205633,0.00020410852,0.00028125165,0.00017510801,0.000105884654,0.00044284723,0.000009808971],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7055131,0.002817986,0.12931861,0.000115461844,0.00062990765,0.00004708661,0.00011861067,0.0010180644,0.000028547533,0.000261673,0.011866495,0.14826445],"study_design_scores_gemma":[0.44620985,0.0024568245,0.4846855,0.0019320701,0.00048283205,5.7867726e-7,0.00010102247,0.057165798,0.00023705115,0.003162442,0.003253657,0.00031236664],"about_ca_topic_score_codex":0.0026958636,"about_ca_topic_score_gemma":0.0041779606,"teacher_disagreement_score":0.3553669,"about_ca_system_score_codex":0.00016464437,"about_ca_system_score_gemma":0.0007672783,"threshold_uncertainty_score":0.55600834},"labels":[],"label_agreement":null},{"id":"W4417001876","doi":"10.1182/blood-2025-8120","title":"Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Multiple myeloma; Carfilzomib; Bortezomib; Guideline; Daratumumab; Cancer; Thalidomide; Transplantation; Ixazomib","score_opus":0.17238568986395333,"score_gpt":0.40849723795789805,"score_spread":0.23611154809394472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972219,0.00047939856,0.00008194759,0.0011984353,0.000029797313,0.000667186,0.000040658688,0.000017912433,0.00026278893],"genre_scores_gemma":[0.9981207,0.0006509781,0.00065275107,0.00036717852,0.000021019354,0.000039480645,0.000036211553,0.000010715931,0.00010094494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871624,0.00022562277,0.0003310584,0.0002351424,0.00025264523,0.00023928021],"domain_scores_gemma":[0.9984284,0.0009914944,0.00009307721,0.00031357317,0.00010315121,0.000070293165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032574087,0.00013981723,0.00034173534,0.0001435038,0.00010016203,0.000038996,0.00007846227,0.00006708616,0.000024737545],"category_scores_gemma":[0.00087363855,0.00008929845,0.00006315485,0.00032367586,0.00013082949,0.0001366016,0.000073232826,0.00017463627,0.0000023625726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018347634,0.0014738786,0.9840841,0.00009338291,0.000294393,0.00006641253,0.0004963152,0.000005537587,0.0019101443,0.000033408163,0.00007023042,0.011288666],"study_design_scores_gemma":[0.0121554155,0.00013519502,0.97550505,0.00019346784,0.000037488524,0.000005036432,0.00018149811,0.0007900639,0.010118645,0.000056276807,0.00075466075,0.000067212095],"about_ca_topic_score_codex":0.0008748169,"about_ca_topic_score_gemma":0.00031479978,"teacher_disagreement_score":0.011971939,"about_ca_system_score_codex":0.000025876148,"about_ca_system_score_gemma":0.00010879427,"threshold_uncertainty_score":0.36414853},"labels":[],"label_agreement":null},{"id":"W4417001881","doi":"10.1182/blood-2025-100","title":"Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. Everett Chalmers Regional Hospital; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Refractory (planetary science); Regimen; Multiple myeloma; Phases of clinical research; Bone marrow; Neutropenia; Bortezomib; Lenalidomide; Proteasome inhibitor; Progressive disease","score_opus":0.012640389278778093,"score_gpt":0.275946361885988,"score_spread":0.2633059726072099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964321,0.00014778391,0.000009845825,0.0003276126,0.00003077644,0.0024449248,0.00021895628,0.00001566487,0.0003722872],"genre_scores_gemma":[0.9986968,0.000060392795,0.00045988584,0.000037237816,0.00001793724,0.00004930452,0.00048553623,0.000015454998,0.00017743072],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983541,0.00019330642,0.00047035152,0.0003553316,0.00038867843,0.0002382495],"domain_scores_gemma":[0.9979972,0.0012782369,0.00014073208,0.00040291212,0.00009901403,0.000081864746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002875196,0.00017187445,0.0004019444,0.0001793144,0.00005626361,0.000013642131,0.00009927222,0.00008786725,0.000024219658],"category_scores_gemma":[0.001181455,0.00009398063,0.000027123051,0.00040458186,0.00012313804,0.0000842886,0.00004597926,0.00026124215,0.0000023456073],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71271354,0.019310351,0.24033058,0.000041039104,0.00025935253,0.00015948892,0.00051539444,0.0000023259174,0.000104171624,0.000013305481,0.000051379026,0.026499096],"study_design_scores_gemma":[0.48994708,0.0037629928,0.505293,0.0002871253,0.00009288458,6.2414296e-7,0.000054681575,0.00006832223,0.00034154498,0.0000057977013,0.00009287707,0.00005307569],"about_ca_topic_score_codex":0.0013203309,"about_ca_topic_score_gemma":0.0013982567,"teacher_disagreement_score":0.2649624,"about_ca_system_score_codex":0.000070763665,"about_ca_system_score_gemma":0.00021595284,"threshold_uncertainty_score":0.38324186},"labels":[],"label_agreement":null},{"id":"W4417001889","doi":"10.1182/blood-2025-94","title":"Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Cyclophosphamide; Cytogenetics; Population; Dexamethasone; Minimal residual disease; Progression-free survival; Chemotherapy","score_opus":0.015546457846614998,"score_gpt":0.29866513852176224,"score_spread":0.2831186806751472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927738,0.0017145518,0.000108638866,0.00031697602,0.00011690921,0.0013165544,0.0001690526,0.00016729027,0.0033162346],"genre_scores_gemma":[0.9939573,0.0003127265,0.0027644804,0.000045115,0.00007885829,0.00021261741,0.00015862174,0.000051367166,0.0024189549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972023,0.00012276061,0.0004215995,0.0006409813,0.0009193965,0.00069300085],"domain_scores_gemma":[0.99795717,0.00029558488,0.0001326064,0.0010856781,0.00020369876,0.00032526528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039012486,0.00034361487,0.00059815403,0.00038402734,0.00017422254,0.000049323786,0.00029553732,0.00019963247,0.00012165799],"category_scores_gemma":[0.00068613974,0.0002507383,0.00011498452,0.00058081053,0.0001327223,0.00012501903,0.00021029131,0.0005613349,0.00002960182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004021891,0.0023143962,0.94630754,0.00021145986,0.0005344735,0.0019309453,0.000102819526,0.000003570007,0.001602007,0.00003568028,0.000120010336,0.042815223],"study_design_scores_gemma":[0.046008054,0.0013710302,0.93739563,0.0009603464,0.00025584718,0.00003124576,0.00004789454,0.00007854561,0.013166783,0.00006674089,0.00039737238,0.00022050123],"about_ca_topic_score_codex":0.00020311345,"about_ca_topic_score_gemma":0.0017167275,"teacher_disagreement_score":0.042594723,"about_ca_system_score_codex":0.00020917234,"about_ca_system_score_gemma":0.0005078316,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4417001913","doi":"10.1182/blood-2025-2253","title":"A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Daratumumab; Multiple myeloma; Lenalidomide; Adverse effect; Regimen; Pomalidomide; Bortezomib; Bristol-Myers; Hematology","score_opus":0.04015539964167918,"score_gpt":0.3531118143982857,"score_spread":0.3129564147566065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543065,0.00042664827,0.000028912595,0.00025675175,0.000070399125,0.0035699944,0.000014057256,0.000008987969,0.00019361441],"genre_scores_gemma":[0.99849135,0.00049938547,0.0003937723,0.00006673959,0.000022348715,0.00041769617,0.00007776523,0.000010790819,0.00002018467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998268,0.00035718238,0.0005720999,0.00029259728,0.0002709745,0.00023914673],"domain_scores_gemma":[0.998346,0.0011770864,0.0001203039,0.00022290146,0.000087458175,0.00004630837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093310507,0.00013799882,0.00044221562,0.00034245866,0.00004048773,0.00001932479,0.0000698046,0.00011077543,0.000003822208],"category_scores_gemma":[0.0017617071,0.00009763548,0.00006638567,0.00053255033,0.00006660932,0.00010702697,0.000035677804,0.00024616867,5.862481e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024992473,0.005246821,0.932617,0.0002506063,0.00005924218,0.00003065173,0.0001689515,0.0000021244648,0.000012836934,0.00005444944,0.000027013484,0.036537796],"study_design_scores_gemma":[0.29649752,0.0025160024,0.6997446,0.00054581044,0.000059995902,0.0000014470166,0.000031304393,0.00030351672,0.0001138224,0.00007964381,0.000052046737,0.00005427324],"about_ca_topic_score_codex":0.0011756964,"about_ca_topic_score_gemma":0.007858567,"teacher_disagreement_score":0.27150506,"about_ca_system_score_codex":0.00005925757,"about_ca_system_score_gemma":0.00013155729,"threshold_uncertainty_score":0.43852645},"labels":[],"label_agreement":null},{"id":"W4417002078","doi":"10.1182/blood-2025-2250","title":"Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Transplantation; Bone marrow; Flow cytometry; Surrogate endpoint; Monoclonal gammopathy of undetermined significance; Autologous stem-cell transplantation","score_opus":0.009968163287180221,"score_gpt":0.25441198149699135,"score_spread":0.24444381820981112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973586,0.00013058235,0.00076098996,0.000103223785,0.000081179634,0.0011746171,0.000057763224,0.00006916093,0.0002638831],"genre_scores_gemma":[0.9955484,0.000012888612,0.003886312,0.00008780784,0.00010114767,0.0000529791,0.00011008296,0.000034410965,0.00016593025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981204,0.0001362838,0.0002588479,0.0004962401,0.0004518409,0.0005363892],"domain_scores_gemma":[0.9989707,0.0001403632,0.00006677618,0.0003565445,0.0001582305,0.00030742126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009742569,0.0002615667,0.00034864346,0.00044099594,0.00014304864,0.000042247666,0.00006985602,0.000092617884,0.000029261273],"category_scores_gemma":[0.000348579,0.00021914323,0.00008146139,0.00067966955,0.00007946107,0.0001351764,0.00005254272,0.000286078,0.000012075959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006462409,0.0018173405,0.984148,0.000086501124,0.00032909756,0.0009241126,0.0000797934,0.00004174679,0.0032687853,0.000006286799,0.000005808598,0.0028300695],"study_design_scores_gemma":[0.032736793,0.0005977057,0.95017815,0.00024463082,0.00025659436,0.000004853143,0.000104444305,0.0012693243,0.014392307,0.000023729273,0.000012474254,0.00017897668],"about_ca_topic_score_codex":0.00039306236,"about_ca_topic_score_gemma":0.00047145277,"teacher_disagreement_score":0.03396988,"about_ca_system_score_codex":0.00033799603,"about_ca_system_score_gemma":0.0002787198,"threshold_uncertainty_score":0.89364016},"labels":[],"label_agreement":null},{"id":"W4417002079","doi":"10.1182/blood-2025-2238","title":"Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Isotype; Immunoglobulin light chain; Kappa; Multiple myeloma; Monoclonal; Monoclonal antibody; Bone marrow; Minimal residual disease","score_opus":0.15392628887993035,"score_gpt":0.4986896564270345,"score_spread":0.3447633675471041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726174,0.00072826346,0.02253834,0.0008179062,0.00015317279,0.0029906556,0.0000454021,0.00002451887,0.000084374005],"genre_scores_gemma":[0.79561037,0.000008928612,0.20375124,0.000025426038,0.0003146829,0.00021305427,0.000029076013,0.000015323281,0.00003192715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974479,0.00042361408,0.0008137682,0.00055641617,0.0003557576,0.00040252737],"domain_scores_gemma":[0.9952922,0.0037652082,0.00011684757,0.00043791998,0.0001290155,0.00025884467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000750857,0.00023192227,0.0009069958,0.0002997767,0.00011532158,0.000036317255,0.00019224506,0.00014287264,0.000015860945],"category_scores_gemma":[0.0022378773,0.00015891899,0.00023591393,0.00057432224,0.00015927461,0.00004311243,0.00009192077,0.000436235,0.0000043588007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025698131,0.0037284412,0.9511695,0.000073013,0.00072456006,0.00003397216,0.000053775675,0.000009554749,0.006776171,0.000091537484,0.000014635861,0.011626688],"study_design_scores_gemma":[0.14486401,0.0025129772,0.79404306,0.00027090524,0.00052717346,0.0000012244222,0.000055059987,0.019775787,0.037343293,0.00036929044,0.000109130946,0.0001280598],"about_ca_topic_score_codex":0.00066633575,"about_ca_topic_score_gemma":0.00037401056,"teacher_disagreement_score":0.18121289,"about_ca_system_score_codex":0.00007660652,"about_ca_system_score_gemma":0.00028665244,"threshold_uncertainty_score":0.6480528},"labels":[],"label_agreement":null},{"id":"W4417002342","doi":"10.1182/blood-2025-5823","title":"Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Clinical Global Impression; Visual analogue scale; Global health; Multiple myeloma; Bortezomib; Hazard ratio; Scale (ratio)","score_opus":0.06096495421358535,"score_gpt":0.32421268082549365,"score_spread":0.2632477266119083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464244,0.0028871186,0.000016793889,0.00019657178,0.00014800279,0.0011941763,0.0005779962,0.000025110015,0.00031179603],"genre_scores_gemma":[0.9988853,0.00015564279,0.0006922951,0.000121104196,0.000020404867,0.00003825807,0.000070635324,0.000010705721,0.000005692964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979413,0.00012595279,0.00057095336,0.00040748232,0.000612603,0.000341679],"domain_scores_gemma":[0.99865323,0.00010657514,0.000340129,0.0004928424,0.00019916499,0.00020807657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007921679,0.0002630177,0.0005375083,0.00006376139,0.00013515541,0.000022417193,0.00008771623,0.00014222853,0.000027473281],"category_scores_gemma":[0.00020283768,0.00016172027,0.000110666406,0.00024485897,0.00016994169,0.00010163669,0.00053425436,0.00012134012,4.98399e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055879966,0.0013315653,0.84564465,0.00012077707,0.00055460475,0.0000735149,0.00062279153,5.46457e-7,0.005206505,0.000010832864,0.00006139638,0.14581403],"study_design_scores_gemma":[0.007196246,0.00078765576,0.96373206,0.0007144788,0.0005905275,0.00003954446,0.0006329234,0.00038701112,0.025463682,0.00022195661,0.00009494186,0.0001389523],"about_ca_topic_score_codex":0.0064771087,"about_ca_topic_score_gemma":0.00010395524,"teacher_disagreement_score":0.14567508,"about_ca_system_score_codex":0.000083739855,"about_ca_system_score_gemma":0.00011345887,"threshold_uncertainty_score":0.9791494},"labels":[],"label_agreement":null},{"id":"W4417002349","doi":"10.1182/blood-2025-5820","title":"Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Subgroup analysis; Clinical endpoint; Hazard ratio; Dexamethasone; Adverse effect; Multiple myeloma; Clinical trial; Randomized controlled trial","score_opus":0.00996949051566891,"score_gpt":0.2462573102883356,"score_spread":0.2362878197726667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554193,0.0008795993,0.0005619561,0.00051656313,0.00009266064,0.0007141602,0.00019881931,0.00016751362,0.0013267949],"genre_scores_gemma":[0.9896258,0.00032961596,0.0022760688,0.00017360483,0.00008930873,0.00012683273,0.0005942887,0.000042788073,0.00674168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972505,0.00015286579,0.0004429543,0.00079858577,0.000716201,0.000638874],"domain_scores_gemma":[0.99786764,0.0006348415,0.00016686606,0.00072714343,0.00019639364,0.00040710304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002829505,0.00043579933,0.0008606086,0.00079574296,0.00035571482,0.000071289185,0.00014024622,0.00020815773,0.00031691903],"category_scores_gemma":[0.00033729844,0.00031167158,0.00027068902,0.001061737,0.00020516272,0.00015098062,0.0001338587,0.0005056223,0.00007663734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014136536,0.002007383,0.977438,0.00010244863,0.01033243,0.00041042783,0.00007526258,0.0000104508335,0.00056063524,0.00017606672,0.000408178,0.0070650647],"study_design_scores_gemma":[0.026067624,0.00071360293,0.96326286,0.00008842337,0.0061578564,0.00005677688,0.00013425683,0.00021049991,0.0024262972,0.000071102935,0.00054448145,0.0002662438],"about_ca_topic_score_codex":0.0020520964,"about_ca_topic_score_gemma":0.0018707702,"teacher_disagreement_score":0.02465397,"about_ca_system_score_codex":0.00010901888,"about_ca_system_score_gemma":0.00022888422,"threshold_uncertainty_score":0.99993354},"labels":[],"label_agreement":null},{"id":"W4417002382","doi":"10.1182/blood-2025-5840","title":"Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Visual acuity; Multiple myeloma; Clinical endpoint; Dexamethasone; Dosing; Proportional hazards model; Hazard ratio; Logistic regression","score_opus":0.015564423951555112,"score_gpt":0.29107672760683256,"score_spread":0.27551230365527746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066174,0.00023244826,0.00014454625,0.00020529963,0.000010768937,0.008569856,0.00007876789,0.000017920966,0.00007865061],"genre_scores_gemma":[0.997569,0.0003272077,0.00065146846,0.000031839765,0.0000071807535,0.0011379914,0.00020910945,0.000023640756,0.00004255341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998158,0.0002059823,0.0003765935,0.00048711983,0.00040425605,0.00036805202],"domain_scores_gemma":[0.9988874,0.0005223812,0.00011189621,0.00031590334,0.00007077781,0.00009163564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031258498,0.0003030975,0.0005028574,0.00047907702,0.00009721612,0.000019322355,0.00009414225,0.000058845966,0.0000017624261],"category_scores_gemma":[0.00007184878,0.00018251583,0.00004440413,0.00045397444,0.00006310593,0.000083720355,0.000023873534,0.00011559225,6.1277956e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026655491,0.048699804,0.90014535,0.00025971778,0.00091368286,0.00033201682,0.0015062755,0.000014918764,0.00011560015,0.000046494843,0.000007385829,0.02130326],"study_design_scores_gemma":[0.30201682,0.013969622,0.6796248,0.00060732494,0.00070599024,0.000009618603,0.0005108446,0.00036986617,0.0020243349,0.000028638395,0.00001286071,0.00011928035],"about_ca_topic_score_codex":0.0010988673,"about_ca_topic_score_gemma":0.0021471537,"teacher_disagreement_score":0.27536133,"about_ca_system_score_codex":0.00010905417,"about_ca_system_score_gemma":0.00005153628,"threshold_uncertainty_score":0.74427795},"labels":[],"label_agreement":null},{"id":"W4417004835","doi":"10.1182/blood-2025-5697","title":"Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Biomarker; Pomalidomide; Pharmacodynamics; Multiple myeloma; Bone marrow; Clinical trial; Whole blood","score_opus":0.033714665266651574,"score_gpt":0.36313672704094896,"score_spread":0.3294220617742974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715084,0.0009152122,0.0000047719564,0.00035615073,0.00009405799,0.0010887058,0.00016224942,0.000020765183,0.00020726353],"genre_scores_gemma":[0.9987603,0.0008474285,0.00010281851,0.00004823709,0.000048596597,0.000046331952,0.000031773972,0.000012592611,0.00010194333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983093,0.00043097424,0.00036232005,0.00037061202,0.00027436632,0.0002523861],"domain_scores_gemma":[0.9980074,0.0013154186,0.00009863296,0.00040776265,0.00005377023,0.000116987445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067545404,0.00015790133,0.00045016894,0.000108891276,0.00006823806,0.000014612356,0.00013578878,0.000082276325,0.000031107957],"category_scores_gemma":[0.0004153069,0.00010054614,0.00008085274,0.00028116722,0.000120135366,0.000052492753,0.00016684589,0.0003286021,0.0000089750765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014106021,0.019634025,0.9163762,0.00001891931,0.0013442629,0.00007194449,0.00006369013,2.7466055e-7,0.00071288546,0.000009902913,0.000054758457,0.06030259],"study_design_scores_gemma":[0.0768889,0.00039395125,0.9199889,0.00007575854,0.0007804826,0.0000020652913,0.000087358865,0.0003855722,0.0012531992,0.00005687711,0.000022246184,0.00006474441],"about_ca_topic_score_codex":0.012406488,"about_ca_topic_score_gemma":0.007016862,"teacher_disagreement_score":0.07547829,"about_ca_system_score_codex":0.000028541914,"about_ca_system_score_gemma":0.00008527671,"threshold_uncertainty_score":0.99417},"labels":[],"label_agreement":null},{"id":"W4417004958","doi":"10.1182/blood-2025-1030","title":"Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Antigen; Mutation; Bone marrow; Flow cytometry; T cell; Chimeric antigen receptor; Multiple myeloma; Immune system","score_opus":0.019741545579833257,"score_gpt":0.29060074867316643,"score_spread":0.27085920309333317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847394,0.0005383394,0.00007996976,0.00024493606,0.00012627986,0.0006587184,0.000028246068,0.00010368766,0.013480424],"genre_scores_gemma":[0.9922581,0.00013890442,0.0007453287,0.00019941929,0.00006452712,0.000046811685,0.000066882996,0.000028399625,0.00645167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824405,0.000104297906,0.00021778882,0.00040421216,0.0005374025,0.00049227977],"domain_scores_gemma":[0.9990721,0.000094841336,0.00005326753,0.00039920118,0.000118052034,0.0002625667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018503265,0.0002252335,0.00034392762,0.00020703809,0.00019964455,0.000040258168,0.00014504213,0.00010442343,0.00041013994],"category_scores_gemma":[0.000054232765,0.00015490886,0.00009505822,0.00027671808,0.00012214614,0.00006861519,0.00008542598,0.00035968778,0.00012136912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003191052,0.009552703,0.88911265,0.0006445727,0.0024356602,0.01359306,0.00029357136,0.0000064425294,0.070857376,0.00047324251,0.0016620527,0.008177645],"study_design_scores_gemma":[0.04287973,0.0014355207,0.53654736,0.00027959055,0.00047579466,0.00036729887,0.00029112864,0.00007823766,0.41391703,0.000046920883,0.0033528272,0.0003285482],"about_ca_topic_score_codex":0.0001341757,"about_ca_topic_score_gemma":0.000039644325,"teacher_disagreement_score":0.35256526,"about_ca_system_score_codex":0.0000669469,"about_ca_system_score_gemma":0.00063421245,"threshold_uncertainty_score":0.63170004},"labels":[],"label_agreement":null},{"id":"W4417005305","doi":"10.1182/blood-2025-7565","title":"Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dexamethasone; Induction therapy; Multiple myeloma; Neutropenia; Adverse effect; Meta-analysis; Induction chemotherapy; Minimal residual disease; Randomized controlled trial","score_opus":0.05244011514780706,"score_gpt":0.32639834790211963,"score_spread":0.2739582327543126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8294305,0.15150666,0.00038946405,0.0074228854,0.00010565776,0.00995028,0.0003841066,0.00021747865,0.00059292215],"genre_scores_gemma":[0.99484795,0.002543392,0.000538086,0.00046849676,0.000013091365,0.0008816471,0.00026731184,0.000020142794,0.00041987162],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99751747,0.00036669665,0.00071934384,0.00055363047,0.00041985486,0.0004230097],"domain_scores_gemma":[0.9981925,0.0006629004,0.00015657656,0.00067167514,0.00011501921,0.00020131822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061339757,0.00032445134,0.0025986505,0.0007979193,0.00008843894,0.00003764525,0.0001266106,0.00012546657,0.000097602475],"category_scores_gemma":[0.00074838096,0.00023300156,0.0006565505,0.0017515392,0.000054815984,0.00008738422,0.00002435154,0.00023610928,0.000019498217],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023772698,0.00806476,0.12665135,0.37329188,0.4832592,0.0029152946,0.00044140412,0.00008640497,0.0017401341,0.00012338578,0.00095135585,0.00009758301],"study_design_scores_gemma":[0.040421188,0.00036137702,0.02716712,0.003806278,0.9236042,0.000027518561,0.00009673101,0.0006750183,0.0034600375,0.000007951538,0.000045549135,0.0003270142],"about_ca_topic_score_codex":0.00070050027,"about_ca_topic_score_gemma":0.00076550024,"teacher_disagreement_score":0.44034502,"about_ca_system_score_codex":0.00006954979,"about_ca_system_score_gemma":0.00016343854,"threshold_uncertainty_score":0.95015275},"labels":[],"label_agreement":null},{"id":"W4417006557","doi":"10.1182/blood-2025-7490","title":"Priming of bone marrow stromal cells with the epigenetic modifier decitabine overcomes stroma-mediated resistance to bortezomib in multiple myeloma cells.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Bortezomib; Bone marrow; Multiple myeloma; Stromal cell; Priming (agriculture); Cancer cell","score_opus":0.013338281209722866,"score_gpt":0.2520764960907462,"score_spread":0.23873821488102337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555683,0.0009878945,0.00014100842,0.0007453074,0.00004298387,0.0013324749,0.00009403524,0.000031601317,0.001067838],"genre_scores_gemma":[0.992121,0.000067641355,0.004888093,0.00011391788,0.00002936929,0.00013335024,0.000034761564,0.000030165045,0.0025817472],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979736,0.00009754983,0.00041462068,0.00042465737,0.00052600895,0.00056357105],"domain_scores_gemma":[0.99850184,0.0004272856,0.000099880024,0.00062255387,0.00013644299,0.00021202404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024045735,0.0002519621,0.0005168259,0.00030431157,0.000086159795,0.000022379516,0.00019257271,0.00008866464,0.00003774803],"category_scores_gemma":[0.00018739994,0.00016883199,0.00008821935,0.00069843,0.00012006179,0.000049208815,0.00010354966,0.00023345157,0.000016391125],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035229868,0.0024679098,0.3089872,0.00045343614,0.00060208177,0.00072487385,0.000616086,0.0001409445,0.6796651,0.000047267113,0.0008713698,0.0019007473],"study_design_scores_gemma":[0.013487397,0.00050494814,0.6529232,0.00047155656,0.0001817682,0.000005265478,0.00028047693,0.00023924277,0.33121806,0.000013380444,0.00051825505,0.00015643123],"about_ca_topic_score_codex":0.00023491262,"about_ca_topic_score_gemma":0.001134996,"teacher_disagreement_score":0.34844705,"about_ca_system_score_codex":0.00008504714,"about_ca_system_score_gemma":0.00029726245,"threshold_uncertainty_score":0.68847686},"labels":[],"label_agreement":null},{"id":"W4417007141","doi":"10.1182/blood-2025-2204","title":"Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Multiple myeloma; Cytokine release syndrome; Cytokine; Proinflammatory cytokine; Biomarker; Dexamethasone; Immune system; Flow cytometry; Pharmacodynamics","score_opus":0.02138638260249365,"score_gpt":0.2825917297231733,"score_spread":0.26120534712067967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967088,0.00016984693,0.0000843408,0.000096720585,0.00003284142,0.0021771782,0.00020571526,0.0000337432,0.0004908208],"genre_scores_gemma":[0.9974515,0.000034703065,0.001250518,0.000029888963,0.000008796852,0.00012498492,0.000102999315,0.000035940837,0.0009606562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976813,0.00022432697,0.00038522083,0.0006046224,0.0006292697,0.00047524355],"domain_scores_gemma":[0.9986553,0.00021339393,0.00016234559,0.00039506136,0.00025558512,0.00031830042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021026078,0.00035113355,0.0006244527,0.00061700365,0.000114712275,0.000015573592,0.000099838384,0.0001253012,0.00006288216],"category_scores_gemma":[0.00014453789,0.0002466796,0.000091879025,0.0005282982,0.00019384298,0.00016833765,0.000109853114,0.00024219572,0.000008111039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10309881,0.0059707887,0.7240543,0.00029394496,0.0010303449,0.0007314564,0.00043667748,0.000030339634,0.15964858,4.6667336e-7,0.000060359365,0.0046439585],"study_design_scores_gemma":[0.04854276,0.0038884925,0.8094165,0.00025615783,0.0004658915,0.000017846382,0.00008475062,0.00014300057,0.13693835,1.922249e-7,0.000060592753,0.00018550096],"about_ca_topic_score_codex":0.0001163338,"about_ca_topic_score_gemma":0.0001169363,"teacher_disagreement_score":0.085362196,"about_ca_system_score_codex":0.00014947854,"about_ca_system_score_gemma":0.00036172496,"threshold_uncertainty_score":0.99999857},"labels":[],"label_agreement":null},{"id":"W4417007176","doi":"10.1182/blood-2025-2217","title":"Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Ontario Genomics","funders":"","keywords":"Minimal residual disease; Circulating tumor cell; Liquid biopsy; Immunophenotyping; Bone marrow; Biopsy; Multiple myeloma; Disease","score_opus":0.034749612833538474,"score_gpt":0.3303466241274335,"score_spread":0.29559701129389504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979593,0.0004154669,0.00029026967,0.000102846134,0.000020380066,0.0005190667,0.000089471396,0.000017214896,0.000585952],"genre_scores_gemma":[0.8210199,0.0000035205426,0.17883123,0.000030679697,0.000025023131,0.000027627844,0.000008833886,0.000012349841,0.000040823124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998686,0.00006516681,0.0004177276,0.00030384917,0.00023589615,0.000291325],"domain_scores_gemma":[0.9988523,0.000507764,0.00009580711,0.00021085548,0.00014789528,0.00018536515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036379177,0.00014485067,0.0003948427,0.0003460986,0.000043246007,0.000009744986,0.000068153844,0.00003632169,0.000006112976],"category_scores_gemma":[0.0017196679,0.000129107,0.000040751827,0.00055724476,0.000058378435,0.000041758944,0.00013222026,0.000115995244,0.0000012745242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006482512,0.0005252604,0.22110839,0.0006840404,0.000108010645,0.00015482161,0.00018094844,0.00003177245,0.77377015,0.000037784666,0.0000014239648,0.0027491546],"study_design_scores_gemma":[0.004252459,0.0003661799,0.33582225,0.00074225024,0.00016036908,0.000020703512,0.00020372422,0.001146107,0.65718156,0.000014419161,0.0000024645424,0.00008750985],"about_ca_topic_score_codex":0.00027971744,"about_ca_topic_score_gemma":0.000011946593,"teacher_disagreement_score":0.17854096,"about_ca_system_score_codex":0.000021271604,"about_ca_system_score_gemma":0.00025541347,"threshold_uncertainty_score":0.526483},"labels":[],"label_agreement":null},{"id":"W4417008999","doi":"10.1182/blood-2025-4598","title":"Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Multiple myeloma; Lenalidomide; Immunotherapy; Cart; Expanded access; Progression-free survival; Retrospective cohort study","score_opus":0.02916013662651603,"score_gpt":0.3099720713084753,"score_spread":0.2808119346819593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417008999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523926,0.0004583733,0.0007826873,0.0001823387,0.00010137775,0.00046954074,0.00006463735,0.00009544052,0.002606359],"genre_scores_gemma":[0.99308324,0.00040984328,0.0046177777,0.00009726283,0.00012424406,0.00005292581,0.0011247688,0.000030023988,0.0004599038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797773,0.00011980783,0.00030950006,0.0006007838,0.0005931884,0.0003989636],"domain_scores_gemma":[0.99883777,0.000114213406,0.000058242276,0.0006411441,0.00011782684,0.00023077958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034262048,0.00026126095,0.00046406846,0.0005816542,0.00017910301,0.00011166914,0.00018471493,0.0000901184,0.0001256722],"category_scores_gemma":[0.000053404998,0.00020539755,0.00011522049,0.00081201625,0.00011903318,0.00023401425,0.00009893769,0.00022774635,0.000005761505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017893047,0.0013332793,0.9385193,0.00002140138,0.0074745785,0.0009434441,0.0001605427,0.0000019984802,0.01771931,0.00021208612,0.000013034592,0.031811725],"study_design_scores_gemma":[0.010418095,0.00047219027,0.981038,0.00011417706,0.0009150391,0.000051613242,0.00019607207,0.00057558244,0.005500622,0.000012415762,0.00050913077,0.00019711323],"about_ca_topic_score_codex":0.00014294106,"about_ca_topic_score_gemma":0.0003319514,"teacher_disagreement_score":0.042518653,"about_ca_system_score_codex":0.0000526009,"about_ca_system_score_gemma":0.000098611265,"threshold_uncertainty_score":0.8375869},"labels":[],"label_agreement":null},{"id":"W4417009446","doi":"10.1182/blood-2025-2792","title":"The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Multiple myeloma; Proportional hazards model; Poisson regression; Cancer; Incidence (geometry); Cohort study; Cohort; Survival analysis; Relative survival","score_opus":0.028052626219121427,"score_gpt":0.34211614534862733,"score_spread":0.3140635191295059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992412,0.000070234375,0.000002383899,0.00007397824,0.00007196766,0.0067542302,0.00027738092,0.000020336944,0.00031753656],"genre_scores_gemma":[0.9988593,0.000032585715,0.000036481313,0.000035599554,0.000042413525,0.0006085234,0.000104959705,0.000021152027,0.00025901664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998026,0.0002603706,0.00041706895,0.000432448,0.00049174053,0.00037233724],"domain_scores_gemma":[0.9963041,0.0027336306,0.00010609276,0.00065991783,0.000086469074,0.000109771434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050608674,0.00026408042,0.00054160954,0.00013047276,0.00022285104,0.000047363756,0.00020552023,0.000054233446,0.000011629644],"category_scores_gemma":[0.0007800922,0.0001244123,0.00014847355,0.00030751698,0.00007899791,0.00005418377,0.00014574312,0.0002423067,0.0000019995339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025830863,0.013368284,0.97410846,0.000011459647,0.0022148555,0.000022643273,0.0010182043,0.0000012320664,0.000025084923,0.000008256371,0.00009564688,0.0065427986],"study_design_scores_gemma":[0.05043144,0.0038425645,0.9444739,0.00005042234,0.00031311382,1.9082661e-7,0.00053750776,0.00007571098,0.000029183027,0.00007364986,0.00008007327,0.00009219595],"about_ca_topic_score_codex":0.024771564,"about_ca_topic_score_gemma":0.056674752,"teacher_disagreement_score":0.047848355,"about_ca_system_score_codex":0.00010478613,"about_ca_system_score_gemma":0.000070343965,"threshold_uncertainty_score":0.9817226},"labels":[],"label_agreement":null},{"id":"W4417009454","doi":"10.1182/blood-2025-2798","title":"Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Newfoundland and Labrador Centre for Applied Health Research; St. John’s Health Sciences Centre; Jewish General Hospital; BC Cancer Agency; Saint John Regional Hospital; Hôpital Maisonneuve-Rosemont; Dr. Georges-L.-Dumont University Hospital Centre; Juravinski Cancer Centre; Institute of Cancer Research; McGill University; Ottawa Hospital; CancerCare Manitoba; Occupational Cancer Research Centre; Saskatchewan Cancer Agency; University of Saskatchewan; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Bortezomib; Regimen; Context (archaeology); Retrospective cohort study; Observational study; Chemotherapy regimen; Clinical trial","score_opus":0.01380753445270157,"score_gpt":0.27822076164989135,"score_spread":0.2644132271971898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317235,0.000072820985,0.00005603016,0.00031649406,0.000022291204,0.0009712906,0.00003594088,0.000073681265,0.0052790893],"genre_scores_gemma":[0.99575144,0.0001342092,0.0014892069,0.00007949965,0.000022350094,0.00023796382,0.00013962577,0.000024688512,0.0021209922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842525,0.000028151911,0.00023958478,0.00042799432,0.00039435423,0.00048468378],"domain_scores_gemma":[0.9990927,0.00013406566,0.000046426372,0.00042884168,0.00010726653,0.0001907138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055234643,0.00022778193,0.0003423499,0.000332509,0.00009588273,0.000019534762,0.00011640075,0.000053450523,0.00004578107],"category_scores_gemma":[0.00004593442,0.00014987226,0.000038640614,0.0007399858,0.000092376926,0.0000945068,0.00002683677,0.0001733377,0.000016484406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023718548,0.0023074243,0.9932328,0.00014229811,0.00017204898,0.00049692224,0.0004567271,0.0000110155515,0.00014774388,0.000033484193,0.000067159366,0.0005605088],"study_design_scores_gemma":[0.03251808,0.00078111456,0.95576483,0.00084747805,0.00010991351,0.0000096324975,0.0000563639,0.000088436806,0.009234227,0.0000073852834,0.00042869506,0.00015387201],"about_ca_topic_score_codex":0.0013011054,"about_ca_topic_score_gemma":0.011964691,"teacher_disagreement_score":0.037468012,"about_ca_system_score_codex":0.00007267817,"about_ca_system_score_gemma":0.0001771129,"threshold_uncertainty_score":0.6676578},"labels":[],"label_agreement":null},{"id":"W4417009494","doi":"10.1182/blood-2025-4058","title":"Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Refractory (planetary science); Multiple myeloma; Phases of clinical research; Bone marrow; Bortezomib; Progressive disease; Logistic regression","score_opus":0.014471959261729653,"score_gpt":0.2906162230157695,"score_spread":0.27614426375403983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963391,0.0003224516,0.0000040343193,0.0002253505,0.000032640946,0.002207657,0.00047548872,0.000025214307,0.0003680643],"genre_scores_gemma":[0.9987454,0.00008739877,0.00037213427,0.000041912335,0.00001813279,0.000034377816,0.00030321997,0.000017821447,0.00037961805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818933,0.00019282442,0.00046152808,0.00043735266,0.00043766544,0.00028127627],"domain_scores_gemma":[0.9977741,0.0012528673,0.00011808483,0.00062303455,0.00010881611,0.00012308868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002450305,0.0002006724,0.00041185072,0.00013367514,0.00009596967,0.000016576314,0.00014185657,0.00006846261,0.000029451321],"category_scores_gemma":[0.0011519965,0.00010974646,0.00003575489,0.00038470625,0.00012598297,0.00007378379,0.00010038026,0.00025757813,0.0000045702504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07691248,0.03369005,0.85244226,0.000037591668,0.0005873574,0.0003090083,0.0014361053,9.968392e-7,0.0001221072,0.0000022148026,0.000119524346,0.03434029],"study_design_scores_gemma":[0.28463137,0.0040250705,0.7097787,0.00018244745,0.00024201647,9.79986e-7,0.00046047464,0.000032823194,0.00027157992,0.0000019986162,0.00030222256,0.00007028314],"about_ca_topic_score_codex":0.0012781327,"about_ca_topic_score_gemma":0.0013818162,"teacher_disagreement_score":0.20771891,"about_ca_system_score_codex":0.00004490425,"about_ca_system_score_gemma":0.00016326329,"threshold_uncertainty_score":0.44753307},"labels":[],"label_agreement":null},{"id":"W4417009510","doi":"10.1182/blood-2025-4039","title":"Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Lenalidomide; Multiple myeloma; Maintenance therapy; Thalidomide; Randomized controlled trial; Nausea; Dexamethasone; Autologous stem-cell transplantation","score_opus":0.012472698615939415,"score_gpt":0.27401167501488016,"score_spread":0.26153897639894075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991568,0.00068777957,0.00023090727,0.00035483533,0.000097990174,0.0060350928,0.0008714851,0.000024743507,0.00012914639],"genre_scores_gemma":[0.9973394,0.00064852764,0.0006949639,0.00013576285,0.000028983939,0.00044754945,0.00042884884,0.000025740586,0.0002501889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99760246,0.00034263247,0.00073373155,0.00042767572,0.0004982892,0.00039522935],"domain_scores_gemma":[0.99568594,0.0028309878,0.00038478512,0.0005026561,0.00044277357,0.00015283287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052209076,0.00030839918,0.001641178,0.0003120472,0.00010508927,0.00001639874,0.00019602085,0.00011768324,0.0000125921],"category_scores_gemma":[0.00034939245,0.00016713935,0.0005822072,0.00055059383,0.00027189965,0.000058230165,0.00003442691,0.00014649385,5.449566e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.945599,0.0068782447,0.027725719,0.00025622552,0.010083702,0.00004036763,0.00037738157,0.000016517919,0.0031452083,0.000013338965,0.000036270038,0.0058279852],"study_design_scores_gemma":[0.935953,0.003654137,0.02611027,0.00018982662,0.0071433596,0.0000021722105,0.000072675764,0.00063927716,0.026044281,0.000008944205,0.00004222664,0.00013978514],"about_ca_topic_score_codex":0.00051140285,"about_ca_topic_score_gemma":0.00017911458,"teacher_disagreement_score":0.022899073,"about_ca_system_score_codex":0.00004485104,"about_ca_system_score_gemma":0.00038061567,"threshold_uncertainty_score":0.6815745},"labels":[],"label_agreement":null},{"id":"W4417010065","doi":"10.1182/blood-2025-7540","title":"Safety and efficacy of the use of anabolic bone agents in patients with underlying plasma cell dyscrasias: A case series.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Multiple myeloma; Osteoporosis; Plasma cell dyscrasia; Monoclonal gammopathy of undetermined significance; Dyscrasia; Adverse effect; Population; Occult; Retrospective cohort study; Cancer","score_opus":0.03887787072356657,"score_gpt":0.2868829622134642,"score_spread":0.24800509148989763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889505,0.00008289711,0.000002911509,0.00005671497,0.0000120455,0.0006844574,0.000043671134,0.0000054255647,0.00021681956],"genre_scores_gemma":[0.99929833,0.000035807556,0.0003503452,0.000020305053,0.0000021785079,0.0000068104764,0.000010292292,0.000008340714,0.00026760067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924463,0.000051388757,0.00020837739,0.00014591088,0.00018869452,0.00016097455],"domain_scores_gemma":[0.9994587,0.00010025766,0.000068003734,0.0002567285,0.000061703075,0.000054660894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048164293,0.00009397111,0.0002318891,0.00011289353,0.00004277995,0.0000062231957,0.000038734583,0.00003841395,0.000008383046],"category_scores_gemma":[0.00013856412,0.000058282854,0.000030203568,0.00030739015,0.000085781154,0.00005546208,0.00006649944,0.00009135428,4.5801252e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015515261,0.0021121558,0.9912059,0.00020750366,0.00017128329,0.0003875677,0.00029122637,0.000009372406,0.0002154273,0.00001831605,0.000013140565,0.0038166163],"study_design_scores_gemma":[0.024375027,0.0003764532,0.97086376,0.00030679425,0.0001497136,0.000053787277,0.00008015078,0.000054113912,0.0036024349,0.0000026014761,0.00009222339,0.000042937078],"about_ca_topic_score_codex":0.0003686219,"about_ca_topic_score_gemma":0.0002756251,"teacher_disagreement_score":0.0228235,"about_ca_system_score_codex":0.000025281975,"about_ca_system_score_gemma":0.00009628066,"threshold_uncertainty_score":0.23767059},"labels":[],"label_agreement":null},{"id":"W4417011959","doi":"10.1182/blood-2025-2168","title":"Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Monoclonal gammopathy of undetermined significance; Proteome; Bone marrow; Disease; Plasma cell; Plasma cell neoplasm; Myeloma protein; Waldenstrom macroglobulinemia","score_opus":0.008905233685841098,"score_gpt":0.27248066089474854,"score_spread":0.2635754272089074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996966,0.00023417271,0.000019058447,0.00009462096,0.00002034506,0.0022147056,0.0004297841,0.00000695999,0.0000143310335],"genre_scores_gemma":[0.9993832,0.0000831717,0.00017706424,0.0000014376625,0.000006566637,0.00013641824,0.00011417125,0.000006030022,0.00009195712],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99917984,0.0000749138,0.0003134786,0.00013866725,0.0002112012,0.00008188454],"domain_scores_gemma":[0.9990681,0.0001125462,0.00035830302,0.0001614902,0.00026482277,0.000034776273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011329125,0.00007588477,0.00021513655,0.00012262576,0.000041163385,0.0000035711935,0.000050709754,0.00007401855,0.00000449086],"category_scores_gemma":[0.0006830006,0.00005011144,0.0000328336,0.00025565582,0.00011949301,0.00005499714,0.000046560664,0.00007897996,1.8910949e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017496591,0.00069346296,0.30032623,0.000963379,0.00013974617,6.814667e-7,0.00017101364,3.2275122e-7,0.6958,0.000087340566,0.0000011329305,0.0016417402],"study_design_scores_gemma":[0.0020771676,0.00017690205,0.5014239,0.0004720387,0.00016604709,0.000001930597,0.000014695132,0.00027471117,0.49534276,0.000032692118,0.0000010746478,0.000016060636],"about_ca_topic_score_codex":0.000012351561,"about_ca_topic_score_gemma":0.0000056801,"teacher_disagreement_score":0.2010977,"about_ca_system_score_codex":0.000005234647,"about_ca_system_score_gemma":0.000073237476,"threshold_uncertainty_score":0.20434853},"labels":[],"label_agreement":null},{"id":"W4417012482","doi":"10.1182/blood-2025-2265","title":"Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Bortezomib; Multiple myeloma; Negativity effect; Interim analysis; Daratumumab; Dexamethasone; Minimal residual disease; Clinical endpoint","score_opus":0.012509134671503164,"score_gpt":0.27078280630996493,"score_spread":0.25827367163846177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419993,0.00011896292,0.000006553995,0.0011666298,0.00005615478,0.0028053022,0.00008661785,0.000048607555,0.0015112482],"genre_scores_gemma":[0.99777573,0.00001120791,0.00017641415,0.00021145857,0.0001260037,0.0002980842,0.00024091003,0.00002357316,0.0011365906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761105,0.00038491105,0.00032112605,0.0004472847,0.0006967355,0.00053886714],"domain_scores_gemma":[0.9982004,0.0006786923,0.00008491586,0.00063632184,0.00014734357,0.0002522831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032486542,0.00026037035,0.00037686073,0.00021736087,0.0001781253,0.000050368144,0.000216543,0.000095392315,0.000029712817],"category_scores_gemma":[0.001697441,0.00015667881,0.00010236698,0.0004758772,0.00015116575,0.00013500635,0.00008956573,0.00039829087,0.000013052702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12352339,0.008845587,0.8626352,0.00009488498,0.0002744305,0.00055724086,0.00031026747,6.230489e-7,0.00004888988,0.00006439235,0.00059340673,0.0030516856],"study_design_scores_gemma":[0.2136214,0.0016514878,0.7833115,0.00012512675,0.00022812201,0.0000011677299,0.00020785164,0.0000320536,0.00018660507,0.000037966933,0.00048084187,0.00011589704],"about_ca_topic_score_codex":0.00018617648,"about_ca_topic_score_gemma":0.00028837437,"teacher_disagreement_score":0.09009799,"about_ca_system_score_codex":0.00009604406,"about_ca_system_score_gemma":0.0005641602,"threshold_uncertainty_score":0.6389176},"labels":[],"label_agreement":null},{"id":"W4417012485","doi":"10.1182/blood-2025-2269","title":"Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Refractory (planetary science); Clinical endpoint; Dosing; Progressive disease; Adverse effect; Multiple myeloma; Mallinckrodt; Proteasome inhibitor; Phases of clinical research","score_opus":0.018483087045418116,"score_gpt":0.2914891864335762,"score_spread":0.27300609938815806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996504,0.00026690715,0.00004020934,0.00025463547,0.00004211228,0.0017992991,0.00033487962,0.00007624351,0.0006816795],"genre_scores_gemma":[0.9951806,0.00009422666,0.0012980514,0.00009975357,0.000031249245,0.0003299052,0.0008454271,0.000028803073,0.0020919556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977681,0.00013322911,0.00038446972,0.0007532068,0.0005139304,0.00044704438],"domain_scores_gemma":[0.9986628,0.00012899286,0.0001239141,0.0006865752,0.00020504081,0.00019263037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088954366,0.00033576455,0.0007151356,0.0008343014,0.00009461876,0.000039095932,0.00012146328,0.00016658289,0.00048745202],"category_scores_gemma":[0.0002170887,0.00022302897,0.00017262618,0.0015947417,0.00007319818,0.00013745372,0.000055625667,0.0002552128,0.000036481117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010320918,0.0067051593,0.96432465,0.000029063662,0.0046722046,0.00028722544,0.00050806237,0.0000011620139,0.00022057365,0.0000021968601,0.000068787514,0.012860015],"study_design_scores_gemma":[0.05869128,0.004392213,0.9314468,0.00019164897,0.002408008,0.0000014185625,0.000104055274,0.00031351167,0.0021178683,0.000016630926,0.00014335872,0.00017318757],"about_ca_topic_score_codex":0.0023788828,"about_ca_topic_score_gemma":0.0067580873,"teacher_disagreement_score":0.04837036,"about_ca_system_score_codex":0.00071580237,"about_ca_system_score_gemma":0.00026657674,"threshold_uncertainty_score":0.90948576},"labels":[],"label_agreement":null},{"id":"W4417012491","doi":"10.1182/blood-2025-2267","title":"Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Multiple myeloma; Pooled analysis; Subgroup analysis; Post-hoc analysis; Phases of clinical research; Thalidomide; Dexamethasone; Bortezomib","score_opus":0.029862564288176782,"score_gpt":0.35612464121876275,"score_spread":0.32626207693058595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782366,0.0005895719,0.000008150865,0.000037347152,0.000017483006,0.001299966,0.00016659927,0.000010110767,0.000047119327],"genre_scores_gemma":[0.9988222,0.0002447072,0.0006461379,0.000025645266,0.0000052830205,0.000063213134,0.00013891992,0.00001287173,0.00004103322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983475,0.00012048061,0.0005525341,0.00038022632,0.00032011388,0.00027913987],"domain_scores_gemma":[0.9986734,0.000533406,0.00014721716,0.00027919016,0.00024655,0.00012022895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014527008,0.00021825338,0.0010041381,0.00073472253,0.000040284118,0.000008880314,0.00006774172,0.00007582445,0.000015524982],"category_scores_gemma":[0.000986206,0.00014797454,0.000052873733,0.0010525623,0.00019824899,0.000089628105,0.00009500943,0.00012037984,2.9871993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012555883,0.011494824,0.949067,0.00030995585,0.0036487211,0.000060825376,0.0013010778,0.0000018135172,0.0002751079,0.0000011240147,0.000009069011,0.02127462],"study_design_scores_gemma":[0.15521473,0.0025345208,0.83795136,0.00052395783,0.0017269956,3.8782898e-7,0.00030493498,0.0002472586,0.0013895053,0.0000029211208,0.00000732554,0.000096122945],"about_ca_topic_score_codex":0.00055253616,"about_ca_topic_score_gemma":0.0023212251,"teacher_disagreement_score":0.14265884,"about_ca_system_score_codex":0.000042045274,"about_ca_system_score_gemma":0.00007998817,"threshold_uncertainty_score":0.60342264},"labels":[],"label_agreement":null},{"id":"W4417012576","doi":"10.1182/blood-2025-2283","title":"Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Hotel Dieu Hospital","funders":"","keywords":"Daratumumab; Multiple myeloma; Lenalidomide; Bortezomib; Incidence (geometry); Disease; Proteasome inhibitor; Cohort; Overall survival","score_opus":0.008197257128600513,"score_gpt":0.25031424681673087,"score_spread":0.24211698968813036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961578,0.00008387294,0.000001914655,0.0001765654,0.000005375287,0.0032233195,0.00013332657,0.000009000306,0.00020879164],"genre_scores_gemma":[0.99957436,0.000027721098,0.00006526308,0.000013047395,0.0000056639956,0.00017199661,0.00009181149,0.000019682593,0.000030466634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980188,0.00039624827,0.00038912115,0.0003181753,0.00057172973,0.00030591607],"domain_scores_gemma":[0.9986311,0.0005199595,0.00020559698,0.0004556214,0.00012213638,0.000065590735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037834447,0.00024890114,0.0005484425,0.00046958192,0.00005222649,0.000017607732,0.00015203272,0.000059113867,0.000014081885],"category_scores_gemma":[0.0003410871,0.00011127364,0.000051073854,0.0009643907,0.0001850453,0.00008343098,0.000029690775,0.00035167692,8.067646e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119599774,0.0044635907,0.8738511,0.00007333276,0.0003692782,0.0004088358,0.00025792414,0.00005985603,0.00008737192,0.000017399967,0.00000701352,0.0008045031],"study_design_scores_gemma":[0.24457504,0.013016254,0.7404166,0.00060809,0.00019246842,0.000020265496,0.00013644565,0.0002885588,0.0006534779,0.000011829939,0.0000012440429,0.00007975611],"about_ca_topic_score_codex":0.006089556,"about_ca_topic_score_gemma":0.0020429133,"teacher_disagreement_score":0.13343455,"about_ca_system_score_codex":0.00009533053,"about_ca_system_score_gemma":0.00019775447,"threshold_uncertainty_score":0.92056274},"labels":[],"label_agreement":null},{"id":"W4417013233","doi":"10.1182/blood-2025-7498","title":"Artificial intelligence for predicting transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: A systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Discriminative model; Multiple myeloma; Monoclonal gammopathy; Feature selection; Transformation (genetics)","score_opus":0.07449027410429242,"score_gpt":0.35039119347410735,"score_spread":0.2759009193698149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7035126,0.054108985,0.2114614,0.0026152616,0.000041458326,0.026510758,0.0012595737,0.00008546188,0.000404502],"genre_scores_gemma":[0.9948615,0.00013859599,0.0041326135,0.00006087658,0.0000045186794,0.00071063964,0.000029505545,0.0000057565935,0.000055981487],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9985512,0.000072864415,0.0008049545,0.00019561886,0.00022546173,0.0001499198],"domain_scores_gemma":[0.9988434,0.00041944993,0.00017608255,0.00024571683,0.00023083168,0.00008454217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050792814,0.000121090736,0.0013544005,0.0002479247,0.000035720397,0.0000070276387,0.000075198426,0.000035671885,0.00001371864],"category_scores_gemma":[0.00084422354,0.00008657149,0.00042695363,0.00058316585,0.000034069508,0.000045934696,0.00001656931,0.00004428216,8.2683533e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091120566,0.0022330864,0.006716893,0.758558,0.21176602,0.000015269437,0.0014313284,0.000083868385,0.015475982,0.0009108017,0.000010142803,0.0018874599],"study_design_scores_gemma":[0.000986223,0.00071952125,0.0019685072,0.0035703366,0.79539275,0.000007674771,0.0002751496,0.008793754,0.18791142,0.00023977192,0.0000014701212,0.00013342395],"about_ca_topic_score_codex":0.00005544984,"about_ca_topic_score_gemma":0.00006424726,"teacher_disagreement_score":0.7549876,"about_ca_system_score_codex":0.000015562158,"about_ca_system_score_gemma":0.00006410498,"threshold_uncertainty_score":0.3530283},"labels":[],"label_agreement":null},{"id":"W4417013308","doi":"10.1182/blood-2025-372","title":"Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Alberta Cancer Foundation","funders":"","keywords":"Daratumumab; Multiple myeloma; Clinical endpoint; Lenalidomide; Asymptomatic; Data monitoring committee; Surrogate endpoint; Progression-free survival; Pomalidomide","score_opus":0.01578562255723771,"score_gpt":0.2875565832478632,"score_spread":0.2717709606906255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973871,0.00022244775,0.00009323285,0.00014029606,0.00022302059,0.0014811342,0.00021581745,0.000060499824,0.00017645999],"genre_scores_gemma":[0.99630857,0.00019712854,0.002840158,0.000025812291,0.00007459749,0.00023154264,0.00016930849,0.000047415047,0.00010546314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781805,0.00017729116,0.0003666571,0.0006857449,0.00047798676,0.00047427186],"domain_scores_gemma":[0.99851775,0.00039090388,0.00015846705,0.00059588195,0.00011330773,0.00022367899],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012854747,0.0003780172,0.0005241981,0.00023962249,0.00023082938,0.00008683778,0.00014749875,0.00013209452,0.000027796677],"category_scores_gemma":[0.00027400735,0.0003083099,0.00007039006,0.00037672397,0.000093245646,0.00011951943,0.00005258085,0.0003743991,0.0000112611615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007817452,0.001327188,0.97825193,0.00006789099,0.000608798,0.00015550545,0.00028477103,0.0001159048,0.00077932404,0.0000025339818,0.000029137444,0.010559534],"study_design_scores_gemma":[0.06307705,0.0014158125,0.9204879,0.00019858286,0.00025951458,7.2892215e-7,0.000145557,0.00087332644,0.013281132,0.000013917416,0.000023154413,0.00022335513],"about_ca_topic_score_codex":0.0012310838,"about_ca_topic_score_gemma":0.00035621773,"teacher_disagreement_score":0.057764094,"about_ca_system_score_codex":0.00022378092,"about_ca_system_score_gemma":0.00016393757,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W4417013416","doi":"10.1182/blood-2025-2264","title":"Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Clinical endpoint; Hazard ratio; Randomization; Multiple myeloma; Intention-to-treat analysis; Randomized controlled trial","score_opus":0.0169290117943093,"score_gpt":0.3025473535185282,"score_spread":0.2856183417242189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977824,0.00030994,0.0000035473033,0.000098477496,0.000020334119,0.0016272597,0.00007288522,0.000016690445,0.00006842858],"genre_scores_gemma":[0.99866426,0.000033133725,0.00012624197,0.000027692122,0.000004893496,0.000061885105,0.000037262038,0.000015356603,0.0010292804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986562,0.0002161927,0.00026835618,0.00032159055,0.0002896396,0.0002480014],"domain_scores_gemma":[0.99900407,0.00038069522,0.00007929756,0.0003608651,0.0000689507,0.00010609788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013953247,0.00019163058,0.0005078622,0.00017636173,0.000079131045,0.000022650593,0.00008687994,0.000055503187,0.00001864421],"category_scores_gemma":[0.00033802004,0.00010081224,0.000040952655,0.00026095114,0.000103211576,0.000054117074,0.00010686465,0.00012924272,0.0000010380276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011209982,0.005129097,0.9789064,0.000046916084,0.00094812125,0.00019249383,0.0004793686,1.6795788e-7,0.00053064286,0.0000010185001,0.0000028562467,0.0025529303],"study_design_scores_gemma":[0.13870682,0.0015670414,0.85191447,0.00018336502,0.0005691175,0.0000061134724,0.00023303235,0.000018876555,0.0067208568,0.000004760732,6.6261896e-7,0.000074914955],"about_ca_topic_score_codex":0.002119703,"about_ca_topic_score_gemma":0.0022781254,"teacher_disagreement_score":0.12749684,"about_ca_system_score_codex":0.000042454172,"about_ca_system_score_gemma":0.00009137394,"threshold_uncertainty_score":0.4111004},"labels":[],"label_agreement":null},{"id":"W4417014418","doi":"10.1182/blood-2025-5773","title":"Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ontario Institute for Cancer Research; Windsor Regional Hospital; Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Toxicity; Multiple myeloma; Clinical trial; Prospective cohort study; Comorbidity; Hematopoietic stem cell transplantation; Performance status; Stem cell","score_opus":0.015005603728760511,"score_gpt":0.27564382316848773,"score_spread":0.2606382194397272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958013,0.00021344396,0.000059182545,0.00014483223,0.000018345012,0.000801231,0.00013837594,0.000043013584,0.002780219],"genre_scores_gemma":[0.9986818,0.000045240562,0.00071961246,0.000058880225,0.000013896918,0.000088142646,0.00018464726,0.000010939383,0.00019685198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901164,0.000035250094,0.00016801173,0.00027308936,0.00023724337,0.0002747628],"domain_scores_gemma":[0.9994658,0.000112912036,0.000023674998,0.00019403287,0.000057388963,0.00014618879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064306485,0.0001344327,0.00021405533,0.00019677225,0.00008069029,0.000021280212,0.000053042506,0.000065935084,0.000028950231],"category_scores_gemma":[0.000093505834,0.00009922499,0.000029727267,0.0002782812,0.000066642926,0.00007070086,0.000021018483,0.00014935878,0.000007213933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045482238,0.0016794213,0.9933231,0.000104502695,0.0001757079,0.000073225834,0.00021546279,0.0000023797822,0.00061974727,0.000026085614,0.000026593221,0.003298966],"study_design_scores_gemma":[0.021506967,0.00037619102,0.96918166,0.00025559336,0.00012377763,0.0000066316907,0.000031693682,0.00013448483,0.00816793,0.00006226038,0.0000734082,0.000079376136],"about_ca_topic_score_codex":0.00017668723,"about_ca_topic_score_gemma":0.00036203663,"teacher_disagreement_score":0.0241414,"about_ca_system_score_codex":0.00002680806,"about_ca_system_score_gemma":0.00010298526,"threshold_uncertainty_score":0.40462777},"labels":[],"label_agreement":null},{"id":"W4417014954","doi":"10.1182/blood-2025-7547","title":"An open-label rollover study to assess the long-term safety of ixazomib","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ixazomib; Adverse effect; Common Terminology Criteria for Adverse Events; Proteasome inhibitor; Clinical endpoint","score_opus":0.07319296200780288,"score_gpt":0.4131517652719811,"score_spread":0.3399588032641782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990603,0.000094086994,0.00005759845,0.0004520565,0.000049652022,0.0023279558,0.000022503107,0.000017879207,0.0063752616],"genre_scores_gemma":[0.99695647,0.0000123464415,0.00028180704,0.00022752244,0.00003328838,0.00008104643,0.000017751747,0.000011644757,0.0023781364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988923,0.00012409779,0.00020818667,0.00024997123,0.00030231476,0.0002231083],"domain_scores_gemma":[0.99888474,0.00010829716,0.000034351346,0.0007123678,0.000110478075,0.00014975901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034025987,0.0001118371,0.00027554805,0.00007891831,0.00009358711,0.00005184014,0.00041368156,0.000028289081,0.00010762114],"category_scores_gemma":[0.00013205953,0.00006724637,0.000025897327,0.0002869308,0.000029788971,0.00008168258,0.00027667554,0.00011253497,0.000033596458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011475068,0.02098774,0.9641935,0.000039043032,0.0008168294,0.00015716667,0.00027247024,7.837755e-7,0.004843426,0.00010728621,0.00017340627,0.0072608036],"study_design_scores_gemma":[0.022215158,0.002064803,0.96791124,0.00007275327,0.00028980302,0.000005700588,0.00019764928,0.000016565982,0.0070788073,0.000014018471,0.000077904595,0.00005561124],"about_ca_topic_score_codex":0.00022834894,"about_ca_topic_score_gemma":0.00030472016,"teacher_disagreement_score":0.021067651,"about_ca_system_score_codex":0.000029455392,"about_ca_system_score_gemma":0.00016975337,"threshold_uncertainty_score":0.27422273},"labels":[],"label_agreement":null},{"id":"W4417015358","doi":"10.1182/blood-2025-8236","title":"ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"AL amyloidosis; Immunoglobulin light chain; Multiple myeloma; Population; Minimal residual disease; Amyloidosis; Bone marrow; Monoclonal; Refractory (planetary science); CD19","score_opus":0.04004829720196012,"score_gpt":0.3470153644016904,"score_spread":0.30696706719973027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574125,0.0006259454,0.0000030328436,0.0004982326,0.00004145657,0.0019432012,0.000020805383,0.000048006605,0.001078071],"genre_scores_gemma":[0.9972391,0.00029632886,0.00013211834,0.0001857045,0.000025316927,0.00034986515,0.000017354734,0.000032185584,0.0017220424],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99778813,0.00022535033,0.00044224726,0.00046538992,0.0005118208,0.00056704896],"domain_scores_gemma":[0.9987175,0.00016356225,0.000104325685,0.00064908876,0.00012422755,0.00024133852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003123252,0.000259008,0.00062333216,0.00037757706,0.00006859823,0.000016277621,0.00015148269,0.00009035628,0.0001066209],"category_scores_gemma":[0.00015341678,0.00016733537,0.0000707882,0.0007420147,0.00005728642,0.00007703587,0.000059799764,0.00030101978,0.00001297193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015978688,0.14159165,0.7484496,0.00026382835,0.0015833562,0.002635511,0.005360623,0.000001300287,0.07365419,0.0000054284774,0.00046444996,0.010011337],"study_design_scores_gemma":[0.39450097,0.03775652,0.27449444,0.00077739044,0.0010412019,0.000019339368,0.0055033215,0.00018994456,0.28281754,0.000015326079,0.0024175164,0.00046648172],"about_ca_topic_score_codex":0.0009793337,"about_ca_topic_score_gemma":0.0010332642,"teacher_disagreement_score":0.4739552,"about_ca_system_score_codex":0.00007691121,"about_ca_system_score_gemma":0.00037209335,"threshold_uncertainty_score":0.6823738},"labels":[],"label_agreement":null},{"id":"W4417016321","doi":"10.1182/blood-2025-8246","title":"Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Tolerability; Multiple myeloma; Phases of clinical research; Pharmacokinetics; Pharmacodynamics; Bortezomib; Drug","score_opus":0.019260332922885086,"score_gpt":0.3344037877665396,"score_spread":0.3151434548436545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894705,0.00008877837,0.000005036676,0.00025593888,0.00004672752,0.009890156,0.000016259846,0.000034798442,0.00019184897],"genre_scores_gemma":[0.9979209,0.000004092535,0.00045905958,0.0000445897,0.000015619882,0.0012909562,0.0001123096,0.000029428853,0.00012308851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973212,0.0003352048,0.00049804547,0.0005602854,0.0007963834,0.0004888964],"domain_scores_gemma":[0.9989562,0.00016834577,0.000091008274,0.00043623423,0.00017788443,0.00017033887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006036414,0.00026352922,0.00054995046,0.00101348,0.000046907513,0.00003093797,0.0001427034,0.000071984025,0.000020047737],"category_scores_gemma":[0.0005099282,0.00018965831,0.000034336215,0.0012269347,0.00005347884,0.00016402974,0.0000695365,0.00035526266,0.000013309026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16456665,0.092414536,0.73098344,0.00004899709,0.00021467594,0.00048503434,0.0007618449,0.0000052114965,0.00001926033,0.0000028450659,0.000016951635,0.010480552],"study_design_scores_gemma":[0.47073305,0.012835951,0.51531184,0.0003266653,0.000091619186,7.567849e-7,0.0002474824,0.00013182608,0.00019873292,0.0000062203558,0.00001703601,0.0000988466],"about_ca_topic_score_codex":0.000556641,"about_ca_topic_score_gemma":0.005765033,"teacher_disagreement_score":0.30616638,"about_ca_system_score_codex":0.00029899122,"about_ca_system_score_gemma":0.0003536565,"threshold_uncertainty_score":0.7734041},"labels":[],"label_agreement":null},{"id":"W4417016748","doi":"10.1182/blood-2025-7596","title":"Real-world outcomes of teclistamab for multiple myeloma in Canada: Multi-institutional report from the Canadian myeloma research group (CMRG) database","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Dr. Georges-L.-Dumont University Hospital Centre; St. John’s Health Sciences Centre; William Osler Health System; Ontario Institute for Cancer Research; McGill University; Jewish General Hospital; Newfoundland and Labrador Centre for Applied Health Research; Dalhousie University; Juravinski Cancer Centre; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; University of Alberta; CancerCare Manitoba; Ottawa Hospital; Occupational Cancer Research Centre; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; Saint John Regional Hospital; BC Cancer Agency","funders":"","keywords":"Multiple myeloma; Observational study; Clinical trial; Overall survival; Retrospective cohort study; Outcomes research; Melphalan; Lenalidomide","score_opus":0.07502390516473915,"score_gpt":0.365392429111874,"score_spread":0.2903685239471348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856145,0.00043151123,0.0000564442,0.00446457,0.00021868262,0.0026941616,0.0031352027,0.000024034596,0.0033609078],"genre_scores_gemma":[0.9914446,0.000033866745,0.004268491,0.00018497872,0.000076274766,0.0004535914,0.001883504,0.000023076289,0.0016316582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968984,0.000160759,0.000648111,0.0005657293,0.0008931179,0.0008338466],"domain_scores_gemma":[0.99659777,0.00147004,0.000095547715,0.0009957058,0.0004237431,0.00041719596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010069015,0.00023857909,0.0005346379,0.00053462974,0.00046659057,0.000031834476,0.00037357208,0.000090317924,0.000063097534],"category_scores_gemma":[0.0033964987,0.00016325674,0.00012394831,0.0008381377,0.0002583595,0.000085980006,0.00015324737,0.00046989464,0.0000058318506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003105183,0.0006326789,0.9894519,0.0000885908,0.000490535,0.0023045647,0.00005576555,0.0000027729677,0.00092662184,0.0009269119,0.0028745336,0.0019346079],"study_design_scores_gemma":[0.0109288925,0.000050630457,0.97773206,0.00022917466,0.00010424223,0.000020122563,0.00022126497,0.0005562868,0.0027478538,0.000074766525,0.0072123716,0.00012235242],"about_ca_topic_score_codex":0.99921083,"about_ca_topic_score_gemma":0.9999685,"teacher_disagreement_score":0.013645398,"about_ca_system_score_codex":0.0018104551,"about_ca_system_score_gemma":0.015455854,"threshold_uncertainty_score":0.9901256},"labels":[],"label_agreement":null},{"id":"W4417017886","doi":"10.1182/blood-2025-698","title":"Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Health; Alberta Health Services","funders":"","keywords":"Multiple myeloma; Cohort; Phases of clinical research; Plasmacytoma; Progressive disease; Cancer; Soft tissue; Bone marrow","score_opus":0.009697505005120908,"score_gpt":0.26703960228675483,"score_spread":0.25734209728163393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472666,0.0010429008,0.000006131849,0.00020511796,0.00003193141,0.0030413114,0.0007015902,0.000048284743,0.00019606708],"genre_scores_gemma":[0.99839,0.000094959316,0.00032565155,0.000038875092,0.000018927114,0.000081759405,0.0008004321,0.00003046593,0.00021893665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776435,0.00022561508,0.00047301766,0.0006442672,0.0005482126,0.00034452972],"domain_scores_gemma":[0.9980463,0.0006409187,0.00015388834,0.00072051707,0.00016723225,0.00027115224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024438367,0.0003023541,0.00051520026,0.00016654634,0.00014281207,0.00003178864,0.00013002007,0.00007792737,0.000012751827],"category_scores_gemma":[0.00071666733,0.00017507987,0.00003754,0.0004492394,0.00025814015,0.00011227222,0.00011153137,0.0003188007,0.000001030889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14205314,0.014905061,0.8229028,0.000049943363,0.0010797807,0.00043292544,0.00058900786,8.8551553e-7,0.00021534658,0.0000041008425,0.00008732119,0.017679662],"study_design_scores_gemma":[0.23984034,0.0028364686,0.75541925,0.00042143013,0.0006078296,0.0000022373636,0.00029807966,0.00005102977,0.00024753116,0.000006663143,0.00014254541,0.00012656857],"about_ca_topic_score_codex":0.0004533737,"about_ca_topic_score_gemma":0.0005131194,"teacher_disagreement_score":0.097787194,"about_ca_system_score_codex":0.000047514714,"about_ca_system_score_gemma":0.00021383731,"threshold_uncertainty_score":0.713955},"labels":[],"label_agreement":null},{"id":"W4417017894","doi":"10.1182/blood-2025-701","title":"Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; Alberta Health Services; McGill University","funders":"","keywords":"Multiple myeloma; Phases of clinical research; Regimen; Safety profile; Adverse effect; Plasmacytoma; Progressive disease","score_opus":0.010249553946417508,"score_gpt":0.2699321107751611,"score_spread":0.2596825568287436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972557,0.00025086908,0.000010441121,0.000036570254,0.00003343109,0.00096366444,0.0009194758,0.000022252552,0.000507599],"genre_scores_gemma":[0.99668676,0.00006103921,0.0024016863,0.000008622249,0.00001441698,0.000016648535,0.00067727314,0.000026769974,0.00010677822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796736,0.00012215835,0.0006238046,0.00044369508,0.0005596652,0.00028331426],"domain_scores_gemma":[0.99825686,0.00038792464,0.0002858002,0.00062241475,0.00024247749,0.00020453855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020872935,0.00021694324,0.00070849195,0.00035531857,0.00002861469,0.000005472292,0.00013021434,0.0001243896,0.000016552982],"category_scores_gemma":[0.0006667051,0.00016180209,0.000060160386,0.00045772392,0.00027053026,0.00011361256,0.000055707445,0.00020868442,6.9332947e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1552176,0.028628703,0.73789275,0.00027546386,0.0013534575,0.00024794062,0.0015974041,0.0000016457087,0.0067179636,0.000017877312,0.00002827186,0.068020925],"study_design_scores_gemma":[0.23791921,0.0047907117,0.7395124,0.0006820926,0.00026819232,0.0000014117396,0.000137014,0.00004032634,0.016482359,0.000012126173,0.000054039767,0.00010015525],"about_ca_topic_score_codex":0.0012573273,"about_ca_topic_score_gemma":0.0009839172,"teacher_disagreement_score":0.08270161,"about_ca_system_score_codex":0.0000464573,"about_ca_system_score_gemma":0.0002777711,"threshold_uncertainty_score":0.65980977},"labels":[],"label_agreement":null},{"id":"W4417018218","doi":"10.1182/blood-2025-3998","title":"Tracking peripheral residual disease in myeloma: Clonotypic sequencing and mass spectrometry in the teclistamab era","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Monoclonal; Minimal residual disease; Monoclonal antibody; Immunofixation; Serum protein electrophoresis; clone (Java method); Selected reaction monitoring; Multiple myeloma","score_opus":0.019750617200870017,"score_gpt":0.29717043670788545,"score_spread":0.27741981950701544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328375,0.0024728884,0.000019628449,0.001576152,0.000022345048,0.00048370377,0.000010326484,0.000021352756,0.002109855],"genre_scores_gemma":[0.99842227,0.00009278347,0.00091489824,0.00020001187,0.00006409082,0.000053975575,0.000018542225,0.000010209306,0.00022321193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881214,0.00011557029,0.00020220912,0.0002754519,0.00024159595,0.00035302856],"domain_scores_gemma":[0.9994607,0.00013800024,0.000022274226,0.00025605396,0.000021428119,0.00010151903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029550798,0.00013040857,0.00020504706,0.0002869826,0.00007074588,0.00005625776,0.00009668524,0.000050370913,0.000028047552],"category_scores_gemma":[0.00028907266,0.00009260535,0.00003888865,0.00049126253,0.00006247513,0.00007628028,0.000035880315,0.00035125317,0.0000030762726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004165214,0.00043567887,0.9877881,0.00014640202,0.00006322533,0.0024230818,0.00044065018,0.0000029319363,0.005018781,0.0004026996,0.000020674146,0.0028412961],"study_design_scores_gemma":[0.007147231,0.0001025935,0.989663,0.00019720948,0.000068707355,0.00002208717,0.00048024172,0.00019608522,0.0013350452,0.0006634384,0.000048331327,0.00007601262],"about_ca_topic_score_codex":0.00022938884,"about_ca_topic_score_gemma":0.00023749548,"teacher_disagreement_score":0.0067307097,"about_ca_system_score_codex":0.00015361814,"about_ca_system_score_gemma":0.00025963908,"threshold_uncertainty_score":0.37763366},"labels":[],"label_agreement":null},{"id":"W4417019670","doi":"10.1182/blood-2025-4588","title":"Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Multiple myeloma; Refractory (planetary science); Immunotherapy; Progression-free survival; Progressive disease; Hematology; Phases of clinical research; Pembrolizumab","score_opus":0.016038977654783414,"score_gpt":0.3084764834002524,"score_spread":0.292437505745469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710953,0.0003443183,0.0004970872,0.000058189984,0.000053688982,0.0011146757,0.00031770742,0.000039995884,0.0004647926],"genre_scores_gemma":[0.9883179,0.00079204503,0.0079000555,0.000024706707,0.00004721521,0.00005235719,0.0026611215,0.000028377977,0.00017620866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828863,0.000076737204,0.00040593513,0.00054914545,0.00038163277,0.0002979053],"domain_scores_gemma":[0.998518,0.00043276238,0.0001646666,0.00052646233,0.00019108418,0.0001670257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024141952,0.00023270413,0.00050897815,0.0008090042,0.00015860714,0.000045122382,0.00014612645,0.000069076,0.000031671752],"category_scores_gemma":[0.00012847078,0.00018281167,0.00008977446,0.0007315835,0.00015148146,0.00020739289,0.00007740699,0.00016173246,5.417091e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012457121,0.0031960395,0.9439934,0.00008488061,0.00406701,0.000035562996,0.00014029485,0.0000010442162,0.0053704414,0.00015851874,0.000009572879,0.030486109],"study_design_scores_gemma":[0.045194585,0.00085128826,0.9506449,0.00025271732,0.0008725871,0.0000021462897,0.00005408341,0.0005152327,0.00060066243,0.000007705672,0.00085709203,0.00014701678],"about_ca_topic_score_codex":0.00021875561,"about_ca_topic_score_gemma":0.00041535287,"teacher_disagreement_score":0.032737464,"about_ca_system_score_codex":0.000057020883,"about_ca_system_score_gemma":0.00006522353,"threshold_uncertainty_score":0.74548435},"labels":[],"label_agreement":null},{"id":"W4417019768","doi":"10.1182/blood-2025-2302","title":"Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Lenalidomide; Multiple myeloma; Clinical trial; Refractory (planetary science); Phases of clinical research; Pomalidomide; Adverse effect; Standard of care","score_opus":0.015609160564724936,"score_gpt":0.31740208740408565,"score_spread":0.3017929268393607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948764,0.00030388575,0.000003353278,0.00003536578,0.0000810607,0.004489898,0.00010407351,0.000018089755,0.000087912726],"genre_scores_gemma":[0.9990277,0.000015479465,0.00054966164,0.000007295196,0.00001732224,0.00027328442,0.000067575755,0.000021451762,0.00002021831],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979224,0.0001654006,0.00060161133,0.00041708793,0.0005823249,0.00031114946],"domain_scores_gemma":[0.9987184,0.00018793101,0.00015084984,0.0003951236,0.00039489177,0.00015283341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001592474,0.00021590825,0.00071819045,0.0005383058,0.00003172365,0.000010969011,0.000106407206,0.0000820858,0.000009082409],"category_scores_gemma":[0.00059458945,0.00017174639,0.00005113647,0.00049524906,0.000086981745,0.00007068844,0.000087125416,0.00018082872,6.3336853e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5369012,0.015895478,0.43074644,0.00031565013,0.0003835782,0.00017454832,0.0027618574,0.0000029778691,0.0013575889,0.0000021578317,0.0000087437,0.011449788],"study_design_scores_gemma":[0.74603504,0.05223576,0.16316293,0.0008076784,0.00023815082,4.52713e-7,0.0038687352,0.000021599373,0.03348468,9.75483e-7,0.000020608983,0.00012340894],"about_ca_topic_score_codex":0.00031370798,"about_ca_topic_score_gemma":0.0034186041,"teacher_disagreement_score":0.2675835,"about_ca_system_score_codex":0.0001285348,"about_ca_system_score_gemma":0.0003184021,"threshold_uncertainty_score":0.70036143},"labels":[],"label_agreement":null},{"id":"W4417021048","doi":"10.1182/blood-2025-5780","title":"Low skeletal muscle mass and cancer cachexia among patients with multiple myeloma undergoing CAR-T cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Simon Fraser University","funders":"","keywords":"Multiple myeloma; Cachexia; Cancer; Lymphoma; Skeletal muscle; Diffuse large B-cell lymphoma; Chimeric antigen receptor; Rituximab","score_opus":0.008883666690951208,"score_gpt":0.2497956715004315,"score_spread":0.2409120048094803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963,0.001204588,0.000040421495,0.00009422169,0.000048672737,0.0007823422,0.000035996625,0.00005143453,0.0014423147],"genre_scores_gemma":[0.9975697,0.00038003188,0.00050070207,0.00009184847,0.00004115864,0.000113414295,0.000055879493,0.000028193916,0.0012190868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879557,0.000039454204,0.0001466395,0.0003471728,0.0002915097,0.0003796445],"domain_scores_gemma":[0.9992843,0.00011048442,0.000047854446,0.00025837077,0.00010489256,0.00019409366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004862323,0.00019751553,0.00024567716,0.00011064945,0.00013545407,0.000033149154,0.00006802165,0.00007682783,0.000055586515],"category_scores_gemma":[0.000037355545,0.00014214385,0.000052024498,0.00019171165,0.000097241405,0.00008567745,0.00003916147,0.0001591493,0.000006371908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018280026,0.0010030189,0.97360754,0.00014572442,0.00034149754,0.000064595966,0.000112676724,0.0000030898466,0.0032417965,0.000002917522,0.00005351218,0.02124085],"study_design_scores_gemma":[0.024784673,0.00042379732,0.9527444,0.00019379568,0.000113485155,9.895865e-7,0.000069137284,0.00012629597,0.02112901,0.00000836661,0.0002763722,0.00012965947],"about_ca_topic_score_codex":0.0007565913,"about_ca_topic_score_gemma":0.00057644874,"teacher_disagreement_score":0.024601873,"about_ca_system_score_codex":0.000060756607,"about_ca_system_score_gemma":0.00018881529,"threshold_uncertainty_score":0.5796458},"labels":[],"label_agreement":null},{"id":"W4417021106","doi":"10.1182/blood-2025-5794","title":"Tumor flare pain reaction during teclistamab step-up dosing with tocilizumab prophylaxis: An underrecognized toxicity in the outpatient setting","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dosing; Tocilizumab; Acetaminophen; Toxicity; Adverse effect; Pegfilgrastim; Bone pain; Neutropenia","score_opus":0.017129156851388126,"score_gpt":0.2838537990957559,"score_spread":0.2667246422443678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705875,0.00012259993,0.00013569318,0.0003007418,0.000039647413,0.0015493236,0.0000098505325,0.00007421944,0.00070914737],"genre_scores_gemma":[0.99856067,0.0000050699505,0.00079220126,0.00013883805,0.000051238494,0.00020233801,0.000057561618,0.000017834,0.00017427887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811953,0.00042622,0.00026341708,0.0003677183,0.00043128795,0.00039179396],"domain_scores_gemma":[0.99918264,0.00016217312,0.000079639896,0.0003843761,0.00009725284,0.00009392007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006784199,0.00018315972,0.00024282387,0.00018846325,0.00022796424,0.00006813867,0.00011223024,0.00006574461,0.00000985981],"category_scores_gemma":[0.00047331004,0.000114373484,0.00005376598,0.00042833106,0.000043478718,0.00012999933,0.00003975748,0.00038515372,0.0000045686447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009660625,0.010346432,0.6435395,0.0020811947,0.00084189686,0.0026938014,0.0053740414,0.0000083617615,0.05569816,0.00007242554,0.00006848869,0.2696151],"study_design_scores_gemma":[0.0435466,0.0038028539,0.8943554,0.0017775028,0.00028925476,0.00021166526,0.010678853,0.001166596,0.043645438,0.00007850768,0.00010364478,0.00034366318],"about_ca_topic_score_codex":0.0004164334,"about_ca_topic_score_gemma":0.0009612289,"teacher_disagreement_score":0.26927143,"about_ca_system_score_codex":0.00021760428,"about_ca_system_score_gemma":0.00021267832,"threshold_uncertainty_score":0.46640152},"labels":[],"label_agreement":null},{"id":"W4417021249","doi":"10.1182/blood-2025-5785","title":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung","keywords":"Multiple myeloma; Malignancy; Carfilzomib; Proteasome inhibitor; Bortezomib; Hematologic malignancy; Proteasome; Immunohistochemistry; Antibody","score_opus":0.016163841067426375,"score_gpt":0.3010828026486136,"score_spread":0.28491896158118724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934771,0.002145684,0.00007590772,0.00091687264,0.000080806814,0.00033192185,0.000013831609,0.000023934283,0.0029339627],"genre_scores_gemma":[0.9967978,0.00014651522,0.00025441332,0.00007219726,0.00006580719,0.000036654237,0.00001109096,0.000007823453,0.0026077116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912024,0.00005354465,0.00017404443,0.00018245462,0.0002397496,0.00022999423],"domain_scores_gemma":[0.99933517,0.00011904026,0.00003461683,0.00027339376,0.000105745006,0.0001320063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015428803,0.00009871319,0.00017113241,0.00010835653,0.00012903832,0.000018517345,0.000079820646,0.000055567307,0.000020009324],"category_scores_gemma":[0.00024542323,0.00006430843,0.000056903504,0.00019094464,0.00012318388,0.000042391912,0.000092780174,0.00010121607,0.0000189947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014463965,0.0017548958,0.8224489,0.0003851222,0.001449768,0.00018325588,0.0005043283,0.0000013345996,0.10974258,0.004336405,0.0019103779,0.055836614],"study_design_scores_gemma":[0.0067192125,0.00070005516,0.93741566,0.00020825949,0.00026787035,0.00002704146,0.00028126317,0.00005278998,0.04585218,0.00048806253,0.007888422,0.00009917184],"about_ca_topic_score_codex":0.00031122947,"about_ca_topic_score_gemma":0.0001661013,"teacher_disagreement_score":0.11496676,"about_ca_system_score_codex":0.00005997711,"about_ca_system_score_gemma":0.00018438818,"threshold_uncertainty_score":0.26224214},"labels":[],"label_agreement":null},{"id":"W4417042055","doi":"10.1182/blood-2025-lba-6","title":"Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Lenalidomide; Multiple myeloma; Bortezomib; Dexamethasone; Refractory (planetary science); Dosing; Regimen","score_opus":0.0275454128551027,"score_gpt":0.31831427676072543,"score_spread":0.29076886390562273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417042055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930545,0.00053268013,0.000010551306,0.000049152248,0.00006052794,0.005012631,0.00020411758,0.000037759444,0.0010380789],"genre_scores_gemma":[0.99732435,0.000048477443,0.0018137174,0.000018254563,0.000017470302,0.00025175817,0.000115638046,0.000059263126,0.00035108736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956862,0.00063771725,0.0013918406,0.0007730449,0.0010059044,0.0005052929],"domain_scores_gemma":[0.99507815,0.0020781222,0.00083793816,0.0010673156,0.0005771769,0.00036129527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079377653,0.00050347345,0.0021545903,0.00071303797,0.000089793175,0.000018371915,0.00024866738,0.00019824777,0.000014836645],"category_scores_gemma":[0.0052356212,0.00032454642,0.00011276567,0.0011083167,0.00072815246,0.00018873745,0.0001389671,0.00044835842,9.767657e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8112195,0.023628285,0.15624586,0.00055278925,0.0027460894,0.00028128113,0.0014711353,0.00000897226,0.0018703104,0.00001018585,0.00006039149,0.0019051977],"study_design_scores_gemma":[0.84573793,0.020633837,0.11435081,0.001136952,0.0014114159,0.000006452607,0.00095509744,0.0001506449,0.015314954,0.0000037654115,0.00005603363,0.00024210317],"about_ca_topic_score_codex":0.0024673236,"about_ca_topic_score_gemma":0.0035344572,"teacher_disagreement_score":0.04189505,"about_ca_system_score_codex":0.00015069479,"about_ca_system_score_gemma":0.00095911487,"threshold_uncertainty_score":0.99992067},"labels":[],"label_agreement":null},{"id":"W4417050716","doi":"10.1038/s41409-025-02771-3","title":"Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","keywords":"Salvage therapy; Multiple myeloma; Hematopoietic stem cell transplantation; Hematopoietic cell; Transplantation; Retrospective cohort study; Overall survival; Cohort","score_opus":0.021724001656311873,"score_gpt":0.2929218022564447,"score_spread":0.2711978006001328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417050716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95932734,0.00029059735,0.033575732,0.00045678523,0.00014767717,0.002461704,0.0015415421,0.00013511645,0.0020635084],"genre_scores_gemma":[0.9895274,0.00053797924,0.004913598,0.00007261095,0.000022330927,0.00024291081,0.0020586425,0.000028173345,0.0025963718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981283,0.00007131867,0.0006948937,0.00040502497,0.0003345045,0.00036597933],"domain_scores_gemma":[0.99860895,0.0006553911,0.0001573442,0.0002766043,0.00017558548,0.00012613104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026642333,0.00023658933,0.00045936852,0.0003196885,0.000116826755,0.00001553071,0.000090715075,0.00017058522,0.00001999706],"category_scores_gemma":[0.000035761186,0.00019370735,0.00017562564,0.00033209292,0.00006759193,0.000105104264,0.0000052215637,0.00012267574,0.000011255466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28988206,0.0026377365,0.0189236,0.027828764,0.0011598136,0.0022357085,0.009034049,0.00033120453,0.5351121,0.00095400517,0.002138391,0.10976256],"study_design_scores_gemma":[0.058700237,0.00234116,0.13510889,0.0011024529,0.0016483016,0.00038339596,0.0005447981,0.005929819,0.7931575,0.00023852522,0.0004323484,0.0004125602],"about_ca_topic_score_codex":0.0001645038,"about_ca_topic_score_gemma":0.00039704813,"teacher_disagreement_score":0.2580454,"about_ca_system_score_codex":0.00007717127,"about_ca_system_score_gemma":0.00023685739,"threshold_uncertainty_score":0.7899157},"labels":[],"label_agreement":null},{"id":"W4417098399","doi":"10.1056/nejmoa2514752","title":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Health Services","funders":"Johnson and Johnson","keywords":"Multiple myeloma; Incidence (geometry); Adverse effect; Extramedullary plasmacytoma; Dual (grammatical number)","score_opus":0.013093493199606145,"score_gpt":0.29566795492209363,"score_spread":0.2825744617224875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417098399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97860855,0.007760278,0.0007688541,0.0086699,0.00013933479,0.00021667025,0.0000031106456,0.000009412546,0.0038238834],"genre_scores_gemma":[0.9942559,0.0007244522,0.0032328498,0.00018693323,0.0007034785,0.0000011489724,0.000007728217,0.000011641185,0.0008758692],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99853337,0.000068838075,0.0005078229,0.0001295338,0.00054480694,0.00021563935],"domain_scores_gemma":[0.99867326,0.0002996958,0.00024049902,0.00013840191,0.00031108392,0.00033704477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063259783,0.0001495375,0.0005986091,0.00034056426,0.000044503307,0.0000068891363,0.000065607084,0.000058267055,0.000116675765],"category_scores_gemma":[0.0007363748,0.00008200264,0.000048042606,0.0002583581,0.00023098716,0.00007173658,0.000026880292,0.00034695904,6.165191e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015898267,0.0004383465,0.3120006,0.00079282885,0.0016442935,0.0052635004,0.0014203059,0.0000105425615,0.034858946,0.0005587954,0.016862791,0.6102508],"study_design_scores_gemma":[0.35709465,0.015583741,0.5349337,0.007204755,0.0015588503,0.0096913865,0.0020088123,0.00026423528,0.016600557,0.0012680044,0.053503815,0.00028751846],"about_ca_topic_score_codex":0.00012486217,"about_ca_topic_score_gemma":0.000021103258,"teacher_disagreement_score":0.60996324,"about_ca_system_score_codex":0.000040228322,"about_ca_system_score_gemma":0.00039580834,"threshold_uncertainty_score":0.33439705},"labels":[],"label_agreement":null},{"id":"W4417129987","doi":"10.58931/cht.2025.4379","title":"Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Place Centre","funders":"","keywords":"Multiple myeloma; Toxicity; Chimeric antigen receptor; Drug; Disease; Monoclonal antibody; Adverse effect; Bortezomib","score_opus":0.020146227947620308,"score_gpt":0.2911424927427976,"score_spread":0.27099626479517724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.904814,0.030118331,0.00049648975,0.025055863,0.00073013647,0.0027769972,0.001779699,0.00007192554,0.034156535],"genre_scores_gemma":[0.99004745,0.0014908459,0.00048504779,0.0017952871,0.000066736844,0.00011945349,0.0001089019,0.00005105888,0.005835218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961388,0.00026869055,0.0008860912,0.0008610096,0.0003118535,0.0015335386],"domain_scores_gemma":[0.9961408,0.001039549,0.00021183929,0.00091649825,0.00033364454,0.0013576939],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044470854,0.00062104524,0.0016255294,0.0021883298,0.00032630196,0.000042785385,0.00035179476,0.0007228559,0.0008932915],"category_scores_gemma":[0.0006150158,0.00056506577,0.00026793272,0.0011068721,0.0010033128,0.00008175422,0.000098842065,0.00065489113,0.00004728091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027277903,0.0019162922,0.5102362,0.0026329167,0.021764388,0.0040527596,0.0050509367,0.000018884422,0.0020788151,0.39464715,0.011975841,0.042898025],"study_design_scores_gemma":[0.060278803,0.007563096,0.68924725,0.008753551,0.0065202834,0.002459925,0.011144228,0.007134311,0.1353273,0.008814398,0.059442528,0.0033143593],"about_ca_topic_score_codex":0.06865375,"about_ca_topic_score_gemma":0.22235088,"teacher_disagreement_score":0.38583276,"about_ca_system_score_codex":0.0005442561,"about_ca_system_score_gemma":0.0036054777,"threshold_uncertainty_score":0.9996801},"labels":[],"label_agreement":null},{"id":"W4417156840","doi":"10.1056/nejmoa2514663","title":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"Johnson and Johnson","keywords":"Daratumumab; Multiple myeloma; Refractory (planetary science); Progression-free survival; Overall survival; Chemoimmunotherapy; Clinical trial","score_opus":0.03293884961373357,"score_gpt":0.3410807698555924,"score_spread":0.3081419202418588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417156840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657171,0.005583017,0.00044411118,0.014901729,0.0009584811,0.0005721845,0.000005508254,0.000030027479,0.011787841],"genre_scores_gemma":[0.9882622,0.00067185523,0.0010132802,0.00050371775,0.0011953755,0.0000046009773,0.000013170479,0.000019022717,0.00831678],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99771285,0.00015379682,0.00083820574,0.00020910811,0.0007083199,0.00037770683],"domain_scores_gemma":[0.9979612,0.0007603527,0.00024444456,0.00030986842,0.00025841244,0.00046570334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009157004,0.00021809163,0.00083113805,0.0008301496,0.00006595996,0.000011473553,0.00018708268,0.00012525487,0.0004232903],"category_scores_gemma":[0.003782571,0.00012382408,0.00009710435,0.0006066831,0.00013789853,0.00008958881,0.000040676347,0.000825081,0.000011643139],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060676936,0.00077183923,0.12384389,0.00032261235,0.00065361056,0.015661098,0.0015719206,0.000033928074,0.008360716,0.00016215493,0.0372269,0.75071436],"study_design_scores_gemma":[0.49846762,0.0067903986,0.2752916,0.004019465,0.00030501047,0.001992402,0.0007080568,0.0007526717,0.001251812,0.00040786798,0.20981637,0.00019674901],"about_ca_topic_score_codex":0.00038256022,"about_ca_topic_score_gemma":0.00062370935,"teacher_disagreement_score":0.75051767,"about_ca_system_score_codex":0.0004236089,"about_ca_system_score_gemma":0.0011814456,"threshold_uncertainty_score":0.50494},"labels":[],"label_agreement":null},{"id":"W4417274379","doi":"10.1200/jco-25-00924","title":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Primary (astronomy); Clinical endpoint; Phase (matter); Phases of clinical research; Point (geometry)","score_opus":0.09756831229007881,"score_gpt":0.4690346421725317,"score_spread":0.3714663298824529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417274379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847846,0.0011257164,0.0000777572,0.003045213,0.002342031,0.0029531321,0.000043862554,0.000012612081,0.005615102],"genre_scores_gemma":[0.99570024,0.00051611743,0.0018323091,0.0004883935,0.00039847946,0.000054634842,0.000014704411,0.000029627292,0.00096547825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9868849,0.0054402403,0.0055086445,0.0005176721,0.0010831954,0.0005653449],"domain_scores_gemma":[0.9543906,0.039839696,0.003400337,0.0007851141,0.0011028474,0.0004814021],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014801703,0.00035856362,0.0046340963,0.0005625144,0.000098861376,0.000014385676,0.0005619433,0.0005889144,0.000051657382],"category_scores_gemma":[0.05965873,0.00021840484,0.0012139198,0.00084903836,0.00097432535,0.00016797027,0.00032328218,0.002321336,0.0000070864858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8493048,0.016063169,0.05885642,0.000051771818,0.0031091429,0.0018586088,0.00046786212,0.00004245406,0.00069501565,0.000038616694,0.0013081406,0.06820402],"study_design_scores_gemma":[0.75492656,0.015585951,0.2241701,0.0003917071,0.0011869264,0.000051844843,0.000513364,0.0002194707,0.00057934626,0.000086134656,0.002159379,0.00012919388],"about_ca_topic_score_codex":0.0013712341,"about_ca_topic_score_gemma":0.0016034183,"teacher_disagreement_score":0.16531369,"about_ca_system_score_codex":0.0013331077,"about_ca_system_score_gemma":0.0069428086,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W4417474681","doi":"10.1182/bloodadvances.2025018655","title":"Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; McMaster University","funders":"","keywords":"Multiple myeloma; Overall survival; MEDLINE; Survival analysis; Retrospective cohort study; Immunopathology","score_opus":0.01934420190524761,"score_gpt":0.3338939976282746,"score_spread":0.314549795723027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417474681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412537,0.0014839807,0.000006613101,0.0003176353,0.000033059627,0.0014099756,0.000030320445,0.000032742653,0.0025602982],"genre_scores_gemma":[0.993708,0.00028066384,0.005174676,0.000037051996,0.00002057432,0.00013919704,0.000052442912,0.00001604763,0.0005713026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986137,0.00006880135,0.00028643582,0.00031979688,0.00041326508,0.00029797442],"domain_scores_gemma":[0.9988856,0.00040757156,0.0000841517,0.00033736124,0.00012307768,0.00016224073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009657022,0.0001787031,0.00048077424,0.00026166358,0.000057248435,0.000018665432,0.0001330647,0.000037434926,0.000042825526],"category_scores_gemma":[0.00025513227,0.000119774806,0.000031831147,0.0005123204,0.00009094091,0.00014086734,0.000084167186,0.00011020856,0.000007981294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027116567,0.0017243882,0.8115157,0.000072762894,0.0001000221,0.00002531167,0.00012288906,0.0000083570885,0.0004941266,0.000017942504,0.00009401324,0.18311282],"study_design_scores_gemma":[0.02116198,0.0016819686,0.9671761,0.0005488285,0.000030222398,3.073822e-7,0.00009458334,0.00013206895,0.0072702244,0.000035783614,0.0017604902,0.000107436244],"about_ca_topic_score_codex":0.00028385207,"about_ca_topic_score_gemma":0.0014091852,"teacher_disagreement_score":0.18300538,"about_ca_system_score_codex":0.000027595377,"about_ca_system_score_gemma":0.00008203167,"threshold_uncertainty_score":0.4884275},"labels":[],"label_agreement":null},{"id":"W4417488439","doi":"10.1016/j.jtct.2025.12.986","title":"Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Paula and Rodger Riney Foundation; University of Texas MD Anderson Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society","keywords":"Propensity score matching; Population; MEDLINE; Component (thermodynamics); Antibody","score_opus":0.030963235935494594,"score_gpt":0.2910458129717718,"score_spread":0.2600825770362772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417488439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489,0.00055820856,0.0024061184,0.00064522773,0.000032557487,0.0008064074,0.00007496293,0.000050521932,0.0005360151],"genre_scores_gemma":[0.9958456,0.002162579,0.00022868904,0.00038969974,0.000006787625,0.00004993037,0.0006286338,0.00001090735,0.00067717105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987933,0.00009697019,0.00028438272,0.00032322473,0.0002368085,0.00026531192],"domain_scores_gemma":[0.9994689,0.000099650206,0.000035174955,0.00020623153,0.0000687494,0.000121284196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001743617,0.00019271462,0.00048202596,0.00047148133,0.00008808898,0.000030292014,0.00006583067,0.00008965394,0.00008075092],"category_scores_gemma":[0.000008146148,0.00014213605,0.00015241522,0.0004967965,0.000060237857,0.00007808463,0.0000044584353,0.00014989286,0.000010692996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027397238,0.00040172497,0.9349203,0.00013598015,0.0010010647,0.00034776522,0.000943278,0.000010873594,0.05303516,0.00007911535,0.0000014337475,0.006383561],"study_design_scores_gemma":[0.008752802,0.00014244235,0.9392295,0.00006502715,0.00035975396,0.0000088209335,0.00007186351,0.0006328687,0.050535604,0.000030857303,0.000048597125,0.000121898986],"about_ca_topic_score_codex":0.00082381483,"about_ca_topic_score_gemma":0.001134128,"teacher_disagreement_score":0.006261662,"about_ca_system_score_codex":0.000033628166,"about_ca_system_score_gemma":0.0000655762,"threshold_uncertainty_score":0.579614},"labels":[],"label_agreement":null},{"id":"W4417530843","doi":"10.1016/j.esmorc.2025.100061","title":"JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TO DRIVE CIC-REARRANGED SARCOMAS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Barrie Urology Group","funders":"","keywords":"Sarcoma; Mutation; Cancer; Cell culture","score_opus":0.017030919063464094,"score_gpt":0.3220248881436876,"score_spread":0.3049939690802235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9232122,0.0014863176,0.0003112583,0.010209763,0.00031562327,0.0022706306,0.00033438829,0.00022518903,0.06163465],"genre_scores_gemma":[0.9810452,0.00015425045,0.0011199375,0.0020967037,0.00013602649,0.0003449961,0.00022226475,0.000037125617,0.014843523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982013,0.0000693301,0.0002097589,0.0005014595,0.00042608695,0.000592052],"domain_scores_gemma":[0.99857527,0.00012335123,0.000037963033,0.00053864636,0.00022915906,0.000495624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000099729354,0.00027017965,0.00041904856,0.00025803185,0.0002803946,0.000051197123,0.00016767521,0.000093568364,0.0011620341],"category_scores_gemma":[0.000148192,0.00019441922,0.00008989074,0.0005629986,0.00011927037,0.00008562741,0.00007386673,0.00029284114,0.00025317742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007611084,0.00079838565,0.6251092,0.00051309273,0.0024670379,0.004554381,0.004907195,0.00016199582,0.025936155,0.0010357823,0.18730007,0.13960561],"study_design_scores_gemma":[0.018925859,0.002567171,0.44860992,0.001769794,0.00027469516,0.000083708495,0.002785155,0.00034208078,0.10904993,0.000104575454,0.41471308,0.0007740361],"about_ca_topic_score_codex":0.0015966612,"about_ca_topic_score_gemma":0.0017906319,"teacher_disagreement_score":0.22741301,"about_ca_system_score_codex":0.0006551251,"about_ca_system_score_gemma":0.0011863591,"threshold_uncertainty_score":0.99975103},"labels":[],"label_agreement":null},{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","score_opus":0.020862588265296064,"score_gpt":0.3186337084991464,"score_spread":0.29777112023385033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923073,0.003454718,0.0001618804,0.00041918203,0.0002789595,0.0026199226,0.0002563859,0.000048503287,0.00045311838],"genre_scores_gemma":[0.9962707,0.002144868,0.00024289379,0.00007572161,0.00006874132,0.00023010254,0.00046545573,0.000041156803,0.0004603279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972021,0.00016551315,0.0009092599,0.0006014639,0.0005316135,0.0005900539],"domain_scores_gemma":[0.99826777,0.00037477366,0.00028173733,0.0006653774,0.00018912113,0.00022124781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030384213,0.00036926905,0.0012564593,0.00054361246,0.00009838916,0.000016294907,0.00023366322,0.0001940184,0.00028782338],"category_scores_gemma":[0.00049889873,0.00034097725,0.0001951836,0.0008102265,0.0003451445,0.00013814955,0.00016473343,0.00042373192,0.000003887915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3631703,0.005538309,0.49363843,0.0026923865,0.0030989298,0.0013143682,0.0009471375,0.00015132099,0.024985597,0.00043146173,0.0007882977,0.103243485],"study_design_scores_gemma":[0.46504638,0.005032033,0.50306463,0.0021554634,0.00043863716,0.000025008709,0.00029379575,0.0033505755,0.01866685,0.00026739726,0.0012675071,0.00039168974],"about_ca_topic_score_codex":0.009569853,"about_ca_topic_score_gemma":0.00587643,"teacher_disagreement_score":0.10285179,"about_ca_system_score_codex":0.00081694004,"about_ca_system_score_gemma":0.00071328133,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W596674826","doi":"10.1200/jco.2009.27.15_suppl.8504","title":"Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Lenalidomide; Internal medicine; Thalidomide; Bortezomib; Proteasome inhibitor; Phases of clinical research; Multiple myeloma; Gastroenterology; Surgery; Chemotherapy","score_opus":0.23576606908328196,"score_gpt":0.48849202840508077,"score_spread":0.2527259593217988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W596674826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975131,0.000113557224,0.0000020425139,0.00037220938,0.00014051651,0.0010818049,0.000043840224,0.0000039889255,0.0007289476],"genre_scores_gemma":[0.99685514,0.00011799233,0.0026156676,0.000117712705,0.00011932088,0.0000056093954,0.000023333572,0.000018418239,0.00012681469],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99365854,0.0010365159,0.0037350021,0.00037375174,0.00082405825,0.00037210545],"domain_scores_gemma":[0.99308264,0.0017484141,0.0031556499,0.00045028527,0.0009952704,0.00056773925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030801357,0.00023146052,0.0023646802,0.00033300745,0.000056429755,0.000007892653,0.00035413017,0.0003083807,0.000029825896],"category_scores_gemma":[0.0067929677,0.0001564783,0.000105487416,0.00031554225,0.0003284912,0.00032065457,0.00015832351,0.00088264944,7.619392e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24118166,0.25720984,0.22824082,0.00005193545,0.00057241105,0.0012539448,0.00081621466,0.000007872921,0.0015487672,0.0000047086082,0.00044744962,0.26866436],"study_design_scores_gemma":[0.19620213,0.38892224,0.41267988,0.0002223719,0.0001896272,0.000028359094,0.00033706153,0.00006721777,0.00044660526,0.000020918387,0.0008083248,0.00007525703],"about_ca_topic_score_codex":0.000267876,"about_ca_topic_score_gemma":0.00055785745,"teacher_disagreement_score":0.2685891,"about_ca_system_score_codex":0.00014975251,"about_ca_system_score_gemma":0.0009457582,"threshold_uncertainty_score":0.81323075},"labels":[],"label_agreement":null},{"id":"W6892811757","doi":"10.5281/zenodo.12680934","title":"Novel Method Development and Validation for The Quantitative Estimation of Lenalidomide in Api Form and Marketed Capsule Dosage Form by Using RP-HPLC","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Analyte; Lenalidomide; Dosage form; Correlation coefficient; Phosphate buffered saline; Coefficient of variation; Capsule; Linear correlation","score_opus":0.07816002247834583,"score_gpt":0.3441402015852711,"score_spread":0.2659801791069253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6892811757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57062185,0.00096421165,0.4224991,0.0009093192,0.00004546266,0.0025075127,0.00038835625,0.0001617812,0.0019024276],"genre_scores_gemma":[0.9373916,0.00016169956,0.060439195,0.00002436888,0.000020477853,9.584375e-7,0.001239952,0.00038608117,0.00033567185],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989137,0.0000981466,0.00025587273,0.00025939694,0.0002562822,0.00021657848],"domain_scores_gemma":[0.99932504,0.0001824205,0.00006152088,0.0001326654,0.00020727122,0.000091072834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011495911,0.00010790294,0.0001554557,0.00022887754,0.0005027707,0.00021703716,0.00010762244,0.00004200702,0.00020687512],"category_scores_gemma":[0.00076037855,0.00008280913,0.000025397527,0.00033008616,0.00008851194,0.00023110314,0.00019855013,0.00012166431,0.000022924534],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010407529,0.0002669167,0.000036212303,0.0012583195,0.00039823563,0.000014317391,0.0069881384,0.00012875334,0.16162847,0.0032248937,0.003547999,0.821467],"study_design_scores_gemma":[0.008641118,0.001082618,0.008897693,0.00082691683,0.00021806321,0.00042870405,0.0023990318,0.75340503,0.09665562,0.00066086237,0.12639555,0.0003887848],"about_ca_topic_score_codex":0.00007975797,"about_ca_topic_score_gemma":0.0000013992309,"teacher_disagreement_score":0.8210782,"about_ca_system_score_codex":0.00016928512,"about_ca_system_score_gemma":0.000015732865,"threshold_uncertainty_score":0.38669565},"labels":[],"label_agreement":null},{"id":"W6901577819","doi":"10.60692/hkf9x-bqz69","title":"Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Tolerability; Dexamethasone; Multiple myeloma; Incidence (geometry); Peripheral neuropathy; Post-hoc analysis; Subgroup analysis","score_opus":0.044299079906682325,"score_gpt":0.2831438360510245,"score_spread":0.23884475614434217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901577819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998108,0.00005798061,0.000038610582,0.00006424747,0.00001684126,0.0013138278,0.00008283654,0.000023712742,0.00029388984],"genre_scores_gemma":[0.99969846,0.0000055793084,0.00012194706,0.000020579944,0.000010317272,0.000060653118,0.000037972393,0.0000075083412,0.000036975885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842864,0.00033624473,0.0005813804,0.00018505413,0.0002758662,0.00019279479],"domain_scores_gemma":[0.99884063,0.00036636897,0.00019191288,0.0003401773,0.0001354566,0.00012547079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007588289,0.00017789417,0.00056063937,0.00013883195,0.000052021496,0.000033308585,0.000042920445,0.00009597189,0.000007779279],"category_scores_gemma":[0.0006245648,0.000104534825,0.00004484333,0.00021677655,0.00011371772,0.0001327842,0.000060420036,0.0001259046,0.0000046418236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017295383,0.000024178633,0.97209907,0.001846022,0.00011439549,0.000039042796,0.011113448,0.0000040376685,0.0001588165,0.000009778762,0.00000483868,0.012856836],"study_design_scores_gemma":[0.010204834,0.00097406446,0.96669275,0.0007263686,0.000073118594,0.000061568935,0.001309256,0.0033156902,0.016548492,3.2223465e-7,0.000012851473,0.000080711696],"about_ca_topic_score_codex":0.00010181285,"about_ca_topic_score_gemma":0.000005632865,"teacher_disagreement_score":0.016389675,"about_ca_system_score_codex":0.000055083427,"about_ca_system_score_gemma":0.000039689952,"threshold_uncertainty_score":0.42628065},"labels":[],"label_agreement":null},{"id":"W6901661491","doi":"10.60692/6p7zw-yqd58","title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dexamethasone; Multiple myeloma; Bortezomib; Peripheral neuropathy; Adverse effect; Incidence (geometry); Proteasome inhibitor","score_opus":0.026628372774061854,"score_gpt":0.27198430275947943,"score_spread":0.24535592998541758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901661491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969199,0.000036674202,0.00006251545,0.00002155953,0.00004681922,0.0015304898,0.00010273551,0.000076417244,0.0012029281],"genre_scores_gemma":[0.99895436,0.0000029263797,0.00040939669,0.000029267363,0.000021383286,0.00019276339,0.00013618884,0.000016828508,0.00023686123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810696,0.0002543303,0.00065034645,0.00024390698,0.00040618403,0.00033827397],"domain_scores_gemma":[0.99884593,0.00011623807,0.00020107742,0.00040964704,0.00021176705,0.00021532191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038518079,0.0002664289,0.0006369834,0.00036550005,0.000058643633,0.00004259673,0.000053171952,0.00013563385,0.000018646437],"category_scores_gemma":[0.0003151027,0.00018532436,0.00009414781,0.00043245303,0.000035711404,0.00022295256,0.000043662294,0.00011705539,0.00013134118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002263249,0.000035057335,0.9687751,0.0012339378,0.00024561418,0.0001707972,0.004602395,0.000007912611,0.00007398585,0.0000027943515,0.0000073984497,0.02258179],"study_design_scores_gemma":[0.024071943,0.0020808103,0.91865045,0.001027402,0.00017753865,0.00020783502,0.0008577187,0.0043784236,0.048363976,1.0567956e-7,0.00002731232,0.00015646164],"about_ca_topic_score_codex":0.00006404421,"about_ca_topic_score_gemma":0.000002189185,"teacher_disagreement_score":0.050124597,"about_ca_system_score_codex":0.00024022794,"about_ca_system_score_gemma":0.00008591803,"threshold_uncertainty_score":0.7557308},"labels":[],"label_agreement":null},{"id":"W6901695264","doi":"10.60692/pzc3t-dpj46","title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Multiple myeloma; Cytogenetics; Dexamethasone; Bortezomib; Chemotherapy; Randomized controlled trial","score_opus":0.038244366831529264,"score_gpt":0.26559906713475473,"score_spread":0.22735470030322547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901695264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632174,0.0004630171,0.0006677507,0.00011584181,0.000112502756,0.0013198752,0.0004100206,0.00015084168,0.00043843943],"genre_scores_gemma":[0.99701446,0.000066982306,0.0019946655,0.00008443686,0.000030690397,0.00019939769,0.00030481824,0.000033869306,0.00027068832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971503,0.00028554132,0.000942997,0.00046299765,0.00053377927,0.00062437926],"domain_scores_gemma":[0.99817264,0.0001787991,0.0003138579,0.0005607997,0.0002835682,0.0004903223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005468265,0.00042895894,0.0008430314,0.00037696972,0.00016617631,0.00017750396,0.000090618894,0.00024361956,0.00003272527],"category_scores_gemma":[0.00059429166,0.0003420048,0.0001083124,0.00046812274,0.00009319018,0.0004265037,0.00012790081,0.0002818466,0.00010602777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011598931,0.00003120601,0.98435926,0.0004073686,0.0003784343,0.00012337467,0.006052464,0.0000062707077,0.00004178461,0.0000031303898,0.00006651937,0.0073702605],"study_design_scores_gemma":[0.03202148,0.00037573764,0.9519815,0.00027009833,0.00028560823,0.00022538498,0.0056949602,0.0058965585,0.0026129566,5.0350553e-7,0.0002894012,0.0003458322],"about_ca_topic_score_codex":0.00031698582,"about_ca_topic_score_gemma":0.000035087152,"teacher_disagreement_score":0.032377817,"about_ca_system_score_codex":0.00026534745,"about_ca_system_score_gemma":0.00013095968,"threshold_uncertainty_score":0.9999032},"labels":[],"label_agreement":null},{"id":"W6902008308","doi":"10.6084/m9.figshare.23804868","title":"Additional file 1 of How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Horizon Health Network","funders":"","keywords":"General partnership; Multiple myeloma; MEDLINE; Data collection; Expanded access","score_opus":0.2196840931329428,"score_gpt":0.3827225993931137,"score_spread":0.1630385062601709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902008308","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039675724,0.00010811505,5.571051e-9,0.0046515376,0.000012919013,0.0010763253,0.95377135,0.00004524701,0.0006587572],"genre_scores_gemma":[0.45398945,0.0000027083584,0.00007060084,0.00011266831,0.00011000764,0.0022840376,0.54279274,0.00002093903,0.0006168604],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9974858,0.00023117241,0.00020740094,0.000445511,0.00079806306,0.00083206483],"domain_scores_gemma":[0.99279904,0.0060759964,0.00006681375,0.00035495454,0.0002699245,0.000433246],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018136881,0.00018596876,0.00026314508,0.0005650523,0.00030392318,0.00006114819,0.00016444718,0.00013358884,0.668276],"category_scores_gemma":[0.015627341,0.00014475845,0.00007891327,0.0015041156,0.000065091626,0.00015135945,0.00023869834,0.0006089997,0.0008188713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006929097,0.000053085278,0.022398382,0.000083633044,0.000046694164,0.00037717138,0.0012682265,5.999239e-8,0.00001804749,0.0000038632415,0.94737804,0.02830353],"study_design_scores_gemma":[0.0006534272,0.00007933299,0.63024604,0.0024774077,0.0000041759868,0.0000044114995,0.0006470382,0.0006110443,0.00008825061,0.000013633339,0.36508793,0.00008733644],"about_ca_topic_score_codex":0.008154116,"about_ca_topic_score_gemma":0.15537015,"teacher_disagreement_score":0.6674571,"about_ca_system_score_codex":0.000224198,"about_ca_system_score_gemma":0.00049686397,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W6902225571","doi":"10.6084/m9.figshare.19074995.v1","title":"Novel biomarkers and protein-protein interaction in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Disease; Hematological malignancy; Malignancy; Cancer; Adept; Autoantibody; Antibody","score_opus":0.0695307571560249,"score_gpt":0.31400551487240624,"score_spread":0.24447475771638133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902225571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93731314,0.00029146305,0.0000016587513,0.00057442574,0.000029639614,0.0028706843,0.056669682,0.000085689986,0.002163598],"genre_scores_gemma":[0.97004926,5.262738e-7,0.00037987158,0.000056722216,0.000028653287,0.002306261,0.02634008,0.00002077253,0.0008178649],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990071,0.00004730419,0.00014508332,0.0002679202,0.00028191064,0.00025066946],"domain_scores_gemma":[0.99954677,0.000057705493,0.000048069454,0.000175407,0.00003706315,0.00013497437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000058112026,0.00011463335,0.00014366674,0.00019603068,0.00012731848,0.000021614722,0.00006627626,0.00003447847,0.05238642],"category_scores_gemma":[0.0007951549,0.00010787459,0.000042054045,0.00023987498,0.00000723173,0.000094563824,0.00019972706,0.0002556917,0.00019253827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009363729,0.004119482,0.046110015,0.0025951841,0.0008048006,0.003999476,0.0013870643,0.00004410605,0.5826178,0.000034145287,0.08496681,0.26395735],"study_design_scores_gemma":[0.026237262,0.002145674,0.65957284,0.00432157,0.000026818914,0.00068262045,0.0014659469,0.01769669,0.055687197,0.00004010424,0.23140304,0.0007202586],"about_ca_topic_score_codex":0.0002111446,"about_ca_topic_score_gemma":0.00008990932,"teacher_disagreement_score":0.6134628,"about_ca_system_score_codex":0.00020500143,"about_ca_system_score_gemma":0.00007632044,"threshold_uncertainty_score":0.94847983},"labels":[],"label_agreement":null},{"id":"W6908493131","doi":"10.25949/27274056","title":"Communicating primary school enrolment information to parents from non-English-speaking backgrounds","year":2021,"lang":"en","type":"dissertation","venue":"Macquarie University","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metropolitan area; Educational attainment; Diversity (politics); Thematic analysis; Population; Demographics; Quarter (Canadian coin); Immigration","score_opus":0.015264872638476165,"score_gpt":0.266636377698844,"score_spread":0.2513715050603679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908493131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87534434,0.0001311795,0.00020046062,0.00010663759,0.00037397753,0.0009224526,0.00022885438,0.00009753816,0.122594535],"genre_scores_gemma":[0.9397952,0.00015595558,0.004469345,0.00033073468,0.00014835937,0.000005894994,0.04906234,0.00003213996,0.006000016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820375,0.00010683298,0.0002989106,0.0003433626,0.0006729482,0.000374184],"domain_scores_gemma":[0.99780047,0.00011235641,0.00020969613,0.00077570515,0.00059889315,0.00050289574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013029283,0.0003031149,0.0004904514,0.00033890278,0.000469785,0.00017404956,0.00036930476,0.0002781859,0.0007018687],"category_scores_gemma":[0.00022702437,0.00033776835,0.00017734466,0.0003640123,0.000029507411,0.000478574,0.00026638363,0.00063596806,0.00029836412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018594496,0.002895801,0.5111179,0.0037919125,0.006716316,0.002641645,0.13030262,0.00016971352,0.004248443,0.00021590429,0.014787076,0.30451822],"study_design_scores_gemma":[0.0087453155,0.0004085904,0.7786335,0.00209062,0.0006225203,0.0000039268434,0.055872932,0.0005848511,0.0010583044,0.000011848951,0.15121259,0.0007550015],"about_ca_topic_score_codex":0.0064487783,"about_ca_topic_score_gemma":0.0011049191,"teacher_disagreement_score":0.3037632,"about_ca_system_score_codex":0.001420665,"about_ca_system_score_gemma":0.0007429997,"threshold_uncertainty_score":0.99990743},"labels":[],"label_agreement":null},{"id":"W6920510199","doi":"10.60692/dzn99-h7p42","title":"Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Tolerability; Dexamethasone; Multiple myeloma; Incidence (geometry); Peripheral neuropathy; Post-hoc analysis; Subgroup analysis","score_opus":0.044299079906682325,"score_gpt":0.2831438360510245,"score_spread":0.23884475614434217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920510199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998108,0.00005798061,0.000038610582,0.00006424747,0.00001684126,0.0013138278,0.00008283654,0.000023712742,0.00029388984],"genre_scores_gemma":[0.99969846,0.0000055793084,0.00012194706,0.000020579944,0.000010317272,0.000060653118,0.000037972393,0.0000075083412,0.000036975885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842864,0.00033624473,0.0005813804,0.00018505413,0.0002758662,0.00019279479],"domain_scores_gemma":[0.99884063,0.00036636897,0.00019191288,0.0003401773,0.0001354566,0.00012547079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007588289,0.00017789417,0.00056063937,0.00013883195,0.000052021496,0.000033308585,0.000042920445,0.00009597189,0.000007779279],"category_scores_gemma":[0.0006245648,0.000104534825,0.00004484333,0.00021677655,0.00011371772,0.0001327842,0.000060420036,0.0001259046,0.0000046418236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017295383,0.000024178633,0.97209907,0.001846022,0.00011439549,0.000039042796,0.011113448,0.0000040376685,0.0001588165,0.000009778762,0.00000483868,0.012856836],"study_design_scores_gemma":[0.010204834,0.00097406446,0.96669275,0.0007263686,0.000073118594,0.000061568935,0.001309256,0.0033156902,0.016548492,3.2223465e-7,0.000012851473,0.000080711696],"about_ca_topic_score_codex":0.00010181285,"about_ca_topic_score_gemma":0.000005632865,"teacher_disagreement_score":0.016389675,"about_ca_system_score_codex":0.000055083427,"about_ca_system_score_gemma":0.000039689952,"threshold_uncertainty_score":0.42628065},"labels":[],"label_agreement":null},{"id":"W6920640607","doi":"10.6084/m9.figshare.19074995","title":"Novel biomarkers and protein-protein interaction in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Disease; Hematological malignancy; Malignancy; Cancer; Adept; Autoantibody; Antibody","score_opus":0.0695307571560249,"score_gpt":0.31400551487240624,"score_spread":0.24447475771638133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920640607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93731314,0.00029146305,0.0000016587513,0.00057442574,0.000029639614,0.0028706843,0.056669682,0.000085689986,0.002163598],"genre_scores_gemma":[0.97004926,5.262738e-7,0.00037987158,0.000056722216,0.000028653287,0.002306261,0.02634008,0.00002077253,0.0008178649],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990071,0.00004730419,0.00014508332,0.0002679202,0.00028191064,0.00025066946],"domain_scores_gemma":[0.99954677,0.000057705493,0.000048069454,0.000175407,0.00003706315,0.00013497437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000058112026,0.00011463335,0.00014366674,0.00019603068,0.00012731848,0.000021614722,0.00006627626,0.00003447847,0.05238642],"category_scores_gemma":[0.0007951549,0.00010787459,0.000042054045,0.00023987498,0.00000723173,0.000094563824,0.00019972706,0.0002556917,0.00019253827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009363729,0.004119482,0.046110015,0.0025951841,0.0008048006,0.003999476,0.0013870643,0.00004410605,0.5826178,0.000034145287,0.08496681,0.26395735],"study_design_scores_gemma":[0.026237262,0.002145674,0.65957284,0.00432157,0.000026818914,0.00068262045,0.0014659469,0.01769669,0.055687197,0.00004010424,0.23140304,0.0007202586],"about_ca_topic_score_codex":0.0002111446,"about_ca_topic_score_gemma":0.00008990932,"teacher_disagreement_score":0.6134628,"about_ca_system_score_codex":0.00020500143,"about_ca_system_score_gemma":0.00007632044,"threshold_uncertainty_score":0.94847983},"labels":[],"label_agreement":null},{"id":"W6920756720","doi":"10.6084/m9.figshare.14411788","title":"Additional file 1 of Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Dexamethasone; Clinical trial; Expanded access; Pembrolizumab","score_opus":0.03146068060177912,"score_gpt":0.33160100979109985,"score_spread":0.30014032918932076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920756720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9045453,0.00009371664,2.3941408e-7,0.000024802197,0.0000066375487,0.001189302,0.09011643,0.0000014717405,0.0040220837],"genre_scores_gemma":[0.9098028,0.00004478588,0.018084517,0.000015583388,0.00002874048,0.0006832903,0.06363899,0.000032807424,0.00766846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998619,0.00018181249,0.00031777957,0.00036771415,0.00027670735,0.00023699088],"domain_scores_gemma":[0.9965145,0.0027875775,0.00011814336,0.00028843968,0.00012555529,0.00016578179],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012804335,0.00017911804,0.00057881116,0.000122564,0.000031036965,0.000015473594,0.00008409507,0.00008472097,0.28871825],"category_scores_gemma":[0.0023669896,0.00013446674,0.000072010596,0.00031458726,0.00007262224,0.00007170841,0.000095633455,0.00010286587,0.00010680248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055529713,0.002545776,0.10620595,0.00016453608,0.0007633811,0.0011837087,0.00018195088,0.0000023482041,0.0065458417,3.625955e-7,0.037259184,0.839594],"study_design_scores_gemma":[0.024720924,0.005785035,0.760949,0.0019823904,0.00021037542,0.00010922149,0.000067023815,0.00076315756,0.18656246,0.0000033570896,0.018657822,0.00018920461],"about_ca_topic_score_codex":0.00017810904,"about_ca_topic_score_gemma":0.00020714711,"teacher_disagreement_score":0.83940476,"about_ca_system_score_codex":0.00007882123,"about_ca_system_score_gemma":0.00024385312,"threshold_uncertainty_score":0.71193194},"labels":[],"label_agreement":null},{"id":"W6920836587","doi":"10.6084/m9.figshare.14795168.v1","title":"Additional file 1 of SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Apoptosis; Cell culture; Cell; In vitro; Cell growth; Cell cycle; Signal transduction","score_opus":0.030856674313110618,"score_gpt":0.28045712825441166,"score_spread":0.24960045394130104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920836587","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030701756,0.00049394165,1.0765379e-7,0.00010801413,0.00000759064,0.00023857469,0.99293417,0.000016439017,0.003131009],"genre_scores_gemma":[0.2631373,0.000003240337,0.00052097643,0.000082359526,0.000028345856,0.000425803,0.7336172,0.000014166913,0.0021706126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989728,0.000059383343,0.00017546947,0.00024880175,0.00030334183,0.000240258],"domain_scores_gemma":[0.9987533,0.0007081251,0.000050589297,0.00017862233,0.00016015263,0.00014919613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000018522605,0.00011992298,0.00020780429,0.00010022716,0.000042248164,0.0000165626,0.000049461054,0.00006278711,0.9890974],"category_scores_gemma":[0.002274086,0.00010412166,0.0000797413,0.00020468389,0.000018390014,0.00005365952,0.000080583595,0.000109304136,0.00076166913],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030364093,0.0002462082,0.00022718031,0.00017727712,0.000107631415,0.0012238931,0.000034937668,2.787098e-7,0.0014440924,0.0000011265703,0.99051255,0.0057211597],"study_design_scores_gemma":[0.0026738402,0.00010734154,0.4562381,0.0022706063,0.000013041903,0.00012768451,0.0001116277,0.0012026614,0.0032180212,0.000059762315,0.5338446,0.00013271064],"about_ca_topic_score_codex":0.000032072763,"about_ca_topic_score_gemma":0.00007783672,"teacher_disagreement_score":0.9883358,"about_ca_system_score_codex":0.00004096677,"about_ca_system_score_gemma":0.0003093075,"threshold_uncertainty_score":0.978997},"labels":[],"label_agreement":null},{"id":"W6921073946","doi":"10.6084/m9.figshare.23060818","title":"A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal College of Physicians and Surgeons of Canada; Ottawa Hospital; Queen's University","funders":"","keywords":"Carfilzomib; Thalidomide; Tolerability; Bortezomib; Adverse effect; Proteasome inhibitor; AL amyloidosis; Multiple myeloma","score_opus":0.028152330019933332,"score_gpt":0.2938618571517955,"score_spread":0.2657095271318622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921073946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938071,0.00013162187,2.2570963e-7,0.000032299315,0.0000070136525,0.002630728,0.0032745874,0.000038489747,0.00007794215],"genre_scores_gemma":[0.98168236,0.0000071215513,0.00001907569,0.0000056393883,0.000008174739,0.0005810112,0.017582577,0.000028545433,0.00008550273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843866,0.00016194768,0.00031680343,0.0003133075,0.0004923184,0.00027694457],"domain_scores_gemma":[0.9991262,0.00017819977,0.00015596488,0.00025594654,0.00018381771,0.00009990238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015630698,0.00017609526,0.00038632567,0.00050751516,0.000040692154,0.000017759001,0.00006677199,0.00007989943,0.00044145677],"category_scores_gemma":[0.00040701515,0.00012796269,0.000020369998,0.0008875445,0.000009901293,0.00016468835,0.00005577045,0.00019822289,0.000040685543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075331875,0.011910201,0.9694859,0.00089371635,0.00019005431,0.0003749164,0.0034827762,0.000026079362,0.00030228318,0.0000010938687,0.00051509734,0.0052846926],"study_design_scores_gemma":[0.09378523,0.0064153224,0.8946166,0.00313289,0.000029289067,0.0000045690194,0.0010659527,0.00054060266,0.0002648799,0.0000013088423,0.000026766138,0.00011656755],"about_ca_topic_score_codex":0.00032802546,"about_ca_topic_score_gemma":0.00021601182,"teacher_disagreement_score":0.08625204,"about_ca_system_score_codex":0.00020462695,"about_ca_system_score_gemma":0.000077162586,"threshold_uncertainty_score":0.5218167},"labels":[],"label_agreement":null},{"id":"W6921197150","doi":"10.6084/m9.figshare.26613068.v1","title":"Additional file 2 of CircRNAs in diagnosis, prognosis, and clinicopathological features of multiple myeloma; a systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Quality (philosophy); Scale (ratio); Quality assessment; Data quality","score_opus":0.0988369399562844,"score_gpt":0.3572743739040848,"score_spread":0.2584374339478004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921197150","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006454077,0.12806469,3.3420587e-8,0.00014094693,0.0000012422101,0.0011651034,0.8704376,0.000015131564,0.000110681],"genre_scores_gemma":[0.10482934,0.0011961185,0.00057347654,0.00017375096,0.000014009479,0.015320882,0.8773177,0.000016495038,0.00055818603],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99866,0.00014727218,0.00046403302,0.00029737965,0.0002848845,0.00014638802],"domain_scores_gemma":[0.99532765,0.004129517,0.00012228734,0.00019171998,0.00011724012,0.00011160639],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001100596,0.00014494918,0.0014554872,0.00021574658,0.0000171438,0.000015556869,0.00006136238,0.00007706407,0.86867595],"category_scores_gemma":[0.011574528,0.00008913839,0.00042709915,0.000499443,0.000027852826,0.000053071664,0.00007735273,0.0001486707,0.00006373832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011065603,0.00016245921,0.00058443286,0.215137,0.00884466,0.00019450462,0.000021542071,8.4492015e-8,8.4231135e-7,0.000001447535,0.7748942,0.0001477725],"study_design_scores_gemma":[0.0011164977,0.0008132856,0.51766276,0.23340672,0.22447798,0.00027305156,0.00006639391,0.00036420854,0.00015081998,0.000030164489,0.021247612,0.00039052317],"about_ca_topic_score_codex":0.000008576725,"about_ca_topic_score_gemma":0.00003677683,"teacher_disagreement_score":0.8686122,"about_ca_system_score_codex":0.000015664764,"about_ca_system_score_gemma":0.000059402868,"threshold_uncertainty_score":0.9967514},"labels":[],"label_agreement":null},{"id":"W6921304496","doi":"10.6084/m9.figshare.23060818.v1","title":"A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal College of Physicians and Surgeons of Canada; Ottawa Hospital; Queen's University","funders":"","keywords":"Carfilzomib; Thalidomide; Tolerability; Bortezomib; Adverse effect; Proteasome inhibitor; AL amyloidosis; Multiple myeloma","score_opus":0.028152330019933332,"score_gpt":0.2938618571517955,"score_spread":0.2657095271318622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921304496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938071,0.00013162187,2.2570963e-7,0.000032299315,0.0000070136525,0.002630728,0.0032745874,0.000038489747,0.00007794215],"genre_scores_gemma":[0.98168236,0.0000071215513,0.00001907569,0.0000056393883,0.000008174739,0.0005810112,0.017582577,0.000028545433,0.00008550273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843866,0.00016194768,0.00031680343,0.0003133075,0.0004923184,0.00027694457],"domain_scores_gemma":[0.9991262,0.00017819977,0.00015596488,0.00025594654,0.00018381771,0.00009990238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015630698,0.00017609526,0.00038632567,0.00050751516,0.000040692154,0.000017759001,0.00006677199,0.00007989943,0.00044145677],"category_scores_gemma":[0.00040701515,0.00012796269,0.000020369998,0.0008875445,0.000009901293,0.00016468835,0.00005577045,0.00019822289,0.000040685543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075331875,0.011910201,0.9694859,0.00089371635,0.00019005431,0.0003749164,0.0034827762,0.000026079362,0.00030228318,0.0000010938687,0.00051509734,0.0052846926],"study_design_scores_gemma":[0.09378523,0.0064153224,0.8946166,0.00313289,0.000029289067,0.0000045690194,0.0010659527,0.00054060266,0.0002648799,0.0000013088423,0.000026766138,0.00011656755],"about_ca_topic_score_codex":0.00032802546,"about_ca_topic_score_gemma":0.00021601182,"teacher_disagreement_score":0.08625204,"about_ca_system_score_codex":0.00020462695,"about_ca_system_score_gemma":0.000077162586,"threshold_uncertainty_score":0.5218167},"labels":[],"label_agreement":null},{"id":"W6922017842","doi":"10.7939/r3-e91k-km59","title":"Detection and characterization of circulating clonal cells in human multiple myeloma","year":2000,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Cell culture; Antibody; Immune system; DNA","score_opus":0.004910831212409741,"score_gpt":0.18498273764892623,"score_spread":0.1800719064365165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6922017842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833192,0.00008684751,0.0000021975482,0.000058616424,0.00005866685,0.00034952478,0.0002130282,0.000004021093,0.015907882],"genre_scores_gemma":[0.9953876,0.00017980268,0.00008733143,0.000042325726,0.000034004228,0.000014422998,0.0004499762,0.000023936404,0.0037805752],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99815893,0.000044228873,0.00035232818,0.00023740463,0.0010033337,0.00020375311],"domain_scores_gemma":[0.9994258,0.00008981938,0.00019614185,0.0001136339,0.000001110878,0.00017346749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000008589253,0.00018086308,0.0003459331,0.00007462892,0.00008717816,0.00000895885,0.00005080606,0.000059242004,0.000038482733],"category_scores_gemma":[0.0000033728684,0.00018101367,0.000026492384,0.00007478598,0.000032909575,0.00013621946,0.000020109017,0.00016702319,1.1473215e-9],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017097475,0.000050543298,0.07151215,0.0008246205,0.00008145867,0.000106450214,0.000120196215,0.0000034228033,0.88788825,0.00011823424,0.0000019986835,0.03758294],"study_design_scores_gemma":[0.00075324747,0.00008271094,0.60870314,0.0003133526,0.00002149321,0.000004322519,0.00037689053,0.0010066725,0.3884768,0.000023969817,0.00014728043,0.00009013869],"about_ca_topic_score_codex":0.004737021,"about_ca_topic_score_gemma":0.0633391,"teacher_disagreement_score":0.537191,"about_ca_system_score_codex":0.000013807522,"about_ca_system_score_gemma":0.0007542431,"threshold_uncertainty_score":0.9537525},"labels":[],"label_agreement":null},{"id":"W6929857522","doi":"10.5281/zenodo.10094858","title":"FIGURE 187 in Revision of the metallic species of Lasioglossum (Dialictus) in Canada (Hymenoptera, Halictidae, Halictini) 2591","year":2010,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metal; Scale (ratio); Proterozoic; Overprinting","score_opus":0.025985364941686417,"score_gpt":0.24902948783043383,"score_spread":0.22304412288874742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929857522","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060324788,0.00075726985,0.000008686202,0.0007561142,0.00020544261,0.002070209,0.0009217531,0.000114515584,0.9348412],"genre_scores_gemma":[0.78760386,0.0010357795,0.00019700281,0.00010161114,0.00018828391,2.3637436e-7,0.0017108414,0.0035326823,0.20562974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974851,0.0003683915,0.0004910621,0.00040791123,0.0008413451,0.00040621497],"domain_scores_gemma":[0.9983709,0.0000504008,0.0003016488,0.0008555827,0.00025175314,0.0001697219],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040209838,0.0002428424,0.0005419754,0.00055352127,0.00017188789,0.000056833618,0.00079468574,0.00017194416,0.039998733],"category_scores_gemma":[0.001049784,0.00018735953,0.00009688275,0.00083185337,0.00019652069,0.00004995772,0.0006831265,0.00067169225,0.0003432616],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052397227,0.0008830448,0.005021879,0.001630283,0.00044558916,0.00023609707,0.00093665667,0.000009902265,0.008775129,0.0012021142,0.90758616,0.072749175],"study_design_scores_gemma":[0.0015112672,0.0001425554,0.016896412,0.00082846126,0.00003136027,0.000024192868,0.00013274385,0.000026000554,0.0016222626,0.000007341443,0.97864455,0.00013282768],"about_ca_topic_score_codex":0.22055456,"about_ca_topic_score_gemma":0.056565482,"teacher_disagreement_score":0.7292115,"about_ca_system_score_codex":0.00040245347,"about_ca_system_score_gemma":0.000100126344,"threshold_uncertainty_score":0.96087885},"labels":[],"label_agreement":null},{"id":"W6938930385","doi":"10.60692/2615m-ty652","title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dexamethasone; Multiple myeloma; Bortezomib; Peripheral neuropathy; Adverse effect; Incidence (geometry); Proteasome inhibitor","score_opus":0.026628372774061854,"score_gpt":0.27198430275947943,"score_spread":0.24535592998541758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6938930385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969199,0.000036674202,0.00006251545,0.00002155953,0.00004681922,0.0015304898,0.00010273551,0.000076417244,0.0012029281],"genre_scores_gemma":[0.99895436,0.0000029263797,0.00040939669,0.000029267363,0.000021383286,0.00019276339,0.00013618884,0.000016828508,0.00023686123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810696,0.0002543303,0.00065034645,0.00024390698,0.00040618403,0.00033827397],"domain_scores_gemma":[0.99884593,0.00011623807,0.00020107742,0.00040964704,0.00021176705,0.00021532191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038518079,0.0002664289,0.0006369834,0.00036550005,0.000058643633,0.00004259673,0.000053171952,0.00013563385,0.000018646437],"category_scores_gemma":[0.0003151027,0.00018532436,0.00009414781,0.00043245303,0.000035711404,0.00022295256,0.000043662294,0.00011705539,0.00013134118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002263249,0.000035057335,0.9687751,0.0012339378,0.00024561418,0.0001707972,0.004602395,0.000007912611,0.00007398585,0.0000027943515,0.0000073984497,0.02258179],"study_design_scores_gemma":[0.024071943,0.0020808103,0.91865045,0.001027402,0.00017753865,0.00020783502,0.0008577187,0.0043784236,0.048363976,1.0567956e-7,0.00002731232,0.00015646164],"about_ca_topic_score_codex":0.00006404421,"about_ca_topic_score_gemma":0.000002189185,"teacher_disagreement_score":0.050124597,"about_ca_system_score_codex":0.00024022794,"about_ca_system_score_gemma":0.00008591803,"threshold_uncertainty_score":0.7557308},"labels":[],"label_agreement":null},{"id":"W6939543046","doi":"10.6084/m9.figshare.26613068","title":"Additional file 2 of CircRNAs in diagnosis, prognosis, and clinicopathological features of multiple myeloma; a systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Quality (philosophy); Scale (ratio); Quality assessment; Data quality","score_opus":0.0988369399562844,"score_gpt":0.3572743739040848,"score_spread":0.2584374339478004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939543046","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006454077,0.12806469,3.3420587e-8,0.00014094693,0.0000012422101,0.0011651034,0.8704376,0.000015131564,0.000110681],"genre_scores_gemma":[0.10482934,0.0011961185,0.00057347654,0.00017375096,0.000014009479,0.015320882,0.8773177,0.000016495038,0.00055818603],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99866,0.00014727218,0.00046403302,0.00029737965,0.0002848845,0.00014638802],"domain_scores_gemma":[0.99532765,0.004129517,0.00012228734,0.00019171998,0.00011724012,0.00011160639],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001100596,0.00014494918,0.0014554872,0.00021574658,0.0000171438,0.000015556869,0.00006136238,0.00007706407,0.86867595],"category_scores_gemma":[0.011574528,0.00008913839,0.00042709915,0.000499443,0.000027852826,0.000053071664,0.00007735273,0.0001486707,0.00006373832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011065603,0.00016245921,0.00058443286,0.215137,0.00884466,0.00019450462,0.000021542071,8.4492015e-8,8.4231135e-7,0.000001447535,0.7748942,0.0001477725],"study_design_scores_gemma":[0.0011164977,0.0008132856,0.51766276,0.23340672,0.22447798,0.00027305156,0.00006639391,0.00036420854,0.00015081998,0.000030164489,0.021247612,0.00039052317],"about_ca_topic_score_codex":0.000008576725,"about_ca_topic_score_gemma":0.00003677683,"teacher_disagreement_score":0.8686122,"about_ca_system_score_codex":0.000015664764,"about_ca_system_score_gemma":0.000059402868,"threshold_uncertainty_score":0.9967514},"labels":[],"label_agreement":null},{"id":"W6958274895","doi":"10.6084/m9.figshare.14411788.v1","title":"Additional file 1 of Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Dexamethasone; Clinical trial; Expanded access; Pembrolizumab","score_opus":0.026767192926073033,"score_gpt":0.294442554671933,"score_spread":0.26767536174585993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958274895","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16257188,0.00019385562,1.487168e-8,0.000010462401,0.0000031682082,0.0006582419,0.8356552,0.00001657688,0.0008905967],"genre_scores_gemma":[0.18907292,0.000008910483,0.0006676438,0.000016757183,0.000023583212,0.0011321391,0.8079903,0.00002182408,0.0010659146],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99871916,0.00013391124,0.00027147532,0.0003138621,0.00031105944,0.0002505236],"domain_scores_gemma":[0.99515295,0.004112499,0.00011422073,0.00026067052,0.00019346477,0.00016620067],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000032152595,0.00019037079,0.00049198023,0.00013905806,0.000027148417,0.000006591367,0.00004902682,0.00010267108,0.8573208],"category_scores_gemma":[0.010848392,0.00014677021,0.000101870486,0.0003385985,0.000017450198,0.00004630088,0.000053071795,0.0001207575,0.00025012513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014667809,0.001035662,0.015796714,0.0009379483,0.00039851014,0.00089630374,0.000053522137,0.000001937242,0.00081274036,1.5917054e-7,0.8999606,0.078639165],"study_design_scores_gemma":[0.013147097,0.0036399763,0.8877159,0.011382843,0.00008510952,0.000088123015,0.000017402632,0.00090533344,0.054084897,0.0000020691589,0.02875499,0.00017625681],"about_ca_topic_score_codex":0.00003776899,"about_ca_topic_score_gemma":0.00005402074,"teacher_disagreement_score":0.8719192,"about_ca_system_score_codex":0.00008141353,"about_ca_system_score_gemma":0.00018970249,"threshold_uncertainty_score":0.9974837},"labels":[],"label_agreement":null},{"id":"W6958294491","doi":"10.60692/fqdb0-5js45","title":"Ocular complications of plasma cell dyscrasias","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dyscrasia; Plasma cell; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal gammopathy; Monoclonal; Asymptomatic","score_opus":0.06216668557987582,"score_gpt":0.2731703634208842,"score_spread":0.21100367784100837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958294491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97517866,0.0000017806796,0.0012775093,0.00010756758,0.00006226048,0.0006169054,0.00015821522,0.00022436903,0.022372752],"genre_scores_gemma":[0.99881566,2.8602648e-7,0.00031372003,0.000026130923,0.000017557986,0.00008933985,0.00018752605,0.000007701023,0.0005420856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989661,0.00002498236,0.00038436847,0.00008569425,0.000343304,0.0001955623],"domain_scores_gemma":[0.99919134,0.000009814459,0.00013309841,0.0003471668,0.00018799337,0.00013058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014189648,0.000095065625,0.00019110355,0.0003440571,0.00007397142,0.000023969087,0.000074628275,0.000055796834,0.000026480664],"category_scores_gemma":[0.000020178668,0.000073492825,0.00007654784,0.00039139672,0.000026742115,0.00016264293,0.00003725403,0.0000558066,0.0043330677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023796057,0.0000197212,0.9603191,0.0025117118,0.0002260245,0.000035284636,0.032803413,0.00010552903,0.00014411884,0.0004241107,0.0013120252,0.0018609886],"study_design_scores_gemma":[0.005001533,0.00016077659,0.9483647,0.00024548048,0.00006359104,0.00007043385,0.010643088,0.020280596,0.013020755,0.000001022329,0.0020129636,0.00013509688],"about_ca_topic_score_codex":0.000009996625,"about_ca_topic_score_gemma":6.222183e-8,"teacher_disagreement_score":0.023637014,"about_ca_system_score_codex":0.000077179946,"about_ca_system_score_gemma":0.00005423493,"threshold_uncertainty_score":0.9964422},"labels":[],"label_agreement":null},{"id":"W6958525381","doi":"10.6084/m9.figshare.23804868.v1","title":"Additional file 1 of How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Horizon Health Network","funders":"","keywords":"General partnership; Multiple myeloma; MEDLINE; Data collection; Expanded access","score_opus":0.2196840931329428,"score_gpt":0.3827225993931137,"score_spread":0.1630385062601709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958525381","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039675724,0.00010811505,5.571051e-9,0.0046515376,0.000012919013,0.0010763253,0.95377135,0.00004524701,0.0006587572],"genre_scores_gemma":[0.45398945,0.0000027083584,0.00007060084,0.00011266831,0.00011000764,0.0022840376,0.54279274,0.00002093903,0.0006168604],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9974858,0.00023117241,0.00020740094,0.000445511,0.00079806306,0.00083206483],"domain_scores_gemma":[0.99279904,0.0060759964,0.00006681375,0.00035495454,0.0002699245,0.000433246],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018136881,0.00018596876,0.00026314508,0.0005650523,0.00030392318,0.00006114819,0.00016444718,0.00013358884,0.668276],"category_scores_gemma":[0.015627341,0.00014475845,0.00007891327,0.0015041156,0.000065091626,0.00015135945,0.00023869834,0.0006089997,0.0008188713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006929097,0.000053085278,0.022398382,0.000083633044,0.000046694164,0.00037717138,0.0012682265,5.999239e-8,0.00001804749,0.0000038632415,0.94737804,0.02830353],"study_design_scores_gemma":[0.0006534272,0.00007933299,0.63024604,0.0024774077,0.0000041759868,0.0000044114995,0.0006470382,0.0006110443,0.00008825061,0.000013633339,0.36508793,0.00008733644],"about_ca_topic_score_codex":0.008154116,"about_ca_topic_score_gemma":0.15537015,"teacher_disagreement_score":0.6674571,"about_ca_system_score_codex":0.000224198,"about_ca_system_score_gemma":0.00049686397,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W6976857210","doi":"10.60692/y9g0g-w1n51","title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Multiple myeloma; Cytogenetics; Dexamethasone; Bortezomib; Chemotherapy; Randomized controlled trial","score_opus":0.038244366831529264,"score_gpt":0.26559906713475473,"score_spread":0.22735470030322547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976857210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632174,0.0004630171,0.0006677507,0.00011584181,0.000112502756,0.0013198752,0.0004100206,0.00015084168,0.00043843943],"genre_scores_gemma":[0.99701446,0.000066982306,0.0019946655,0.00008443686,0.000030690397,0.00019939769,0.00030481824,0.000033869306,0.00027068832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971503,0.00028554132,0.000942997,0.00046299765,0.00053377927,0.00062437926],"domain_scores_gemma":[0.99817264,0.0001787991,0.0003138579,0.0005607997,0.0002835682,0.0004903223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005468265,0.00042895894,0.0008430314,0.00037696972,0.00016617631,0.00017750396,0.000090618894,0.00024361956,0.00003272527],"category_scores_gemma":[0.00059429166,0.0003420048,0.0001083124,0.00046812274,0.00009319018,0.0004265037,0.00012790081,0.0002818466,0.00010602777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011598931,0.00003120601,0.98435926,0.0004073686,0.0003784343,0.00012337467,0.006052464,0.0000062707077,0.00004178461,0.0000031303898,0.00006651937,0.0073702605],"study_design_scores_gemma":[0.03202148,0.00037573764,0.9519815,0.00027009833,0.00028560823,0.00022538498,0.0056949602,0.0058965585,0.0026129566,5.0350553e-7,0.0002894012,0.0003458322],"about_ca_topic_score_codex":0.00031698582,"about_ca_topic_score_gemma":0.000035087152,"teacher_disagreement_score":0.032377817,"about_ca_system_score_codex":0.00026534745,"about_ca_system_score_gemma":0.00013095968,"threshold_uncertainty_score":0.9999032},"labels":[],"label_agreement":null},{"id":"W6976920734","doi":"10.6084/m9.figshare.14795168","title":"Additional file 1 of SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Apoptosis; Cell culture; Cell; In vitro; Cell growth; Cell cycle; Signal transduction","score_opus":0.030856674313110618,"score_gpt":0.28045712825441166,"score_spread":0.24960045394130104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976920734","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030701756,0.00049394165,1.0765379e-7,0.00010801413,0.00000759064,0.00023857469,0.99293417,0.000016439017,0.003131009],"genre_scores_gemma":[0.2631373,0.000003240337,0.00052097643,0.000082359526,0.000028345856,0.000425803,0.7336172,0.000014166913,0.0021706126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989728,0.000059383343,0.00017546947,0.00024880175,0.00030334183,0.000240258],"domain_scores_gemma":[0.9987533,0.0007081251,0.000050589297,0.00017862233,0.00016015263,0.00014919613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000018522605,0.00011992298,0.00020780429,0.00010022716,0.000042248164,0.0000165626,0.000049461054,0.00006278711,0.9890974],"category_scores_gemma":[0.002274086,0.00010412166,0.0000797413,0.00020468389,0.000018390014,0.00005365952,0.000080583595,0.000109304136,0.00076166913],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030364093,0.0002462082,0.00022718031,0.00017727712,0.000107631415,0.0012238931,0.000034937668,2.787098e-7,0.0014440924,0.0000011265703,0.99051255,0.0057211597],"study_design_scores_gemma":[0.0026738402,0.00010734154,0.4562381,0.0022706063,0.000013041903,0.00012768451,0.0001116277,0.0012026614,0.0032180212,0.000059762315,0.5338446,0.00013271064],"about_ca_topic_score_codex":0.000032072763,"about_ca_topic_score_gemma":0.00007783672,"teacher_disagreement_score":0.9883358,"about_ca_system_score_codex":0.00004096677,"about_ca_system_score_gemma":0.0003093075,"threshold_uncertainty_score":0.978997},"labels":[],"label_agreement":null},{"id":"W6977008058","doi":"10.60692/rnn7n-d9c43","title":"Ocular complications of plasma cell dyscrasias","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dyscrasia; Plasma cell; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal gammopathy; Monoclonal; Asymptomatic","score_opus":0.06216668557987582,"score_gpt":0.2731703634208842,"score_spread":0.21100367784100837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977008058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97517866,0.0000017806796,0.0012775093,0.00010756758,0.00006226048,0.0006169054,0.00015821522,0.00022436903,0.022372752],"genre_scores_gemma":[0.99881566,2.8602648e-7,0.00031372003,0.000026130923,0.000017557986,0.00008933985,0.00018752605,0.000007701023,0.0005420856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989661,0.00002498236,0.00038436847,0.00008569425,0.000343304,0.0001955623],"domain_scores_gemma":[0.99919134,0.000009814459,0.00013309841,0.0003471668,0.00018799337,0.00013058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014189648,0.000095065625,0.00019110355,0.0003440571,0.00007397142,0.000023969087,0.000074628275,0.000055796834,0.000026480664],"category_scores_gemma":[0.000020178668,0.000073492825,0.00007654784,0.00039139672,0.000026742115,0.00016264293,0.00003725403,0.0000558066,0.0043330677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023796057,0.0000197212,0.9603191,0.0025117118,0.0002260245,0.000035284636,0.032803413,0.00010552903,0.00014411884,0.0004241107,0.0013120252,0.0018609886],"study_design_scores_gemma":[0.005001533,0.00016077659,0.9483647,0.00024548048,0.00006359104,0.00007043385,0.010643088,0.020280596,0.013020755,0.000001022329,0.0020129636,0.00013509688],"about_ca_topic_score_codex":0.000009996625,"about_ca_topic_score_gemma":6.222183e-8,"teacher_disagreement_score":0.023637014,"about_ca_system_score_codex":0.000077179946,"about_ca_system_score_gemma":0.00005423493,"threshold_uncertainty_score":0.9964422},"labels":[],"label_agreement":null},{"id":"W6980848371","doi":"","title":"Critical Care Outreach Team Nurses' Roles in End-of-Life Discussions","year":2024,"lang":"en","type":"article","venue":"Scholarship@Western (Western University)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thematic analysis; Outreach; MEDLINE; Health care; Workload; Program evaluation","score_opus":0.09931036915165839,"score_gpt":0.39857288954028497,"score_spread":0.29926252038862655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980848371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951318,0.0013994813,0.00006323434,0.0007842348,0.00024053712,0.00046751133,0.00015232069,0.00015403748,0.0016068717],"genre_scores_gemma":[0.9954703,0.000077200944,0.0000631818,0.00005534836,0.000086221546,0.000004174381,0.000116368195,0.000047242433,0.004079999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976888,0.00023804474,0.00029816647,0.00060544687,0.000583921,0.0005856471],"domain_scores_gemma":[0.99838054,0.00027007094,0.00003763236,0.00050403626,0.00016014169,0.0006475883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001651436,0.00029669318,0.00047106773,0.0009714279,0.00011217916,0.00012889993,0.0003213685,0.00021441297,0.00011940476],"category_scores_gemma":[0.00026850967,0.00024973418,0.00022811095,0.0006640106,0.00026185182,0.0008104081,0.00023000284,0.0007557117,0.00023114878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036480516,0.00036317515,0.9872365,0.00048726026,0.00011559418,0.0024239137,0.0013365876,0.0000032083394,0.0005847793,0.00027282975,0.0000021021756,0.0068092365],"study_design_scores_gemma":[0.002418113,0.00037211445,0.9876678,0.0013555638,0.00019054061,0.000057775233,0.0036955224,0.0000032624728,0.0017129326,0.000052568437,0.0022203103,0.0002534858],"about_ca_topic_score_codex":0.000025993613,"about_ca_topic_score_gemma":0.0019948618,"teacher_disagreement_score":0.0065557505,"about_ca_system_score_codex":0.00039205584,"about_ca_system_score_gemma":0.0004446481,"threshold_uncertainty_score":0.99999547},"labels":[],"label_agreement":null},{"id":"W6981375002","doi":"","title":"Effets de stéroïdes et d'antiestrogènes non-stéroïdiens sur l'activité du SNC du rongeur, implication des récepteurs aminergiques et glutamatergiques","year":2000,"lang":"fr","type":"other","venue":"Library and Archives Canada (Government of Canada)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Action (physics); Identification (biology); Diabetes mellitus","score_opus":0.004527496962314812,"score_gpt":0.1887722620835192,"score_spread":0.18424476512120438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981375002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.604861,0.003863064,0.00027999846,0.0028785889,0.00026924151,0.001203741,0.0020988516,0.00006533718,0.38448015],"genre_scores_gemma":[0.88087386,0.022455102,0.002757357,0.00076430716,0.00036575165,0.00013317751,0.0003859764,0.00028719008,0.09197727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942943,0.0006704863,0.00069142896,0.0008567933,0.0020891665,0.0013978179],"domain_scores_gemma":[0.9965989,0.0011277401,0.0004293476,0.00060617964,0.0000060429084,0.0012317867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007675503,0.0009679585,0.0011041145,0.00016678116,0.00041661898,0.00013745102,0.00047636483,0.00021294472,0.0010819407],"category_scores_gemma":[0.000044413966,0.00086671894,0.00016937849,0.00015688705,0.00073303946,0.0007842503,0.00026467518,0.0005417937,1.7483916e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003418948,0.00089515676,0.8273664,0.00302546,0.0017631972,0.0013325647,0.0012962492,0.00013668672,0.027416883,0.00913059,0.006936557,0.117281325],"study_design_scores_gemma":[0.002315615,0.0007514852,0.79257864,0.002117172,0.00023943234,0.00011674477,0.0012687491,0.0010800947,0.08329721,0.00043286796,0.115036994,0.0007650115],"about_ca_topic_score_codex":0.059001934,"about_ca_topic_score_gemma":0.15325785,"teacher_disagreement_score":0.29250288,"about_ca_system_score_codex":0.0001497764,"about_ca_system_score_gemma":0.004222234,"threshold_uncertainty_score":0.9998312},"labels":[],"label_agreement":null},{"id":"W6981636620","doi":"","title":"Étude d'expressions identitaires en Fransaskoisie : les Rendez-vous de la Francophonie 2018 à 2020","year":2023,"lang":"fr","type":"other","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Identity (music); Perspective (graphical); Context (archaeology); Period (music)","score_opus":0.014985273177443857,"score_gpt":0.31851615000721745,"score_spread":0.3035308768297736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981636620","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019103713,0.036789414,0.0028921939,0.0028257193,0.0040271957,0.002704991,0.0008130695,0.0017989061,0.9290448],"genre_scores_gemma":[0.17843854,0.019407887,0.003466243,0.00014056695,0.003000348,0.00033742553,0.00012478033,0.0011196214,0.79396456],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99492437,0.0007679867,0.0006184085,0.000999306,0.0011107308,0.0015791748],"domain_scores_gemma":[0.9952245,0.0022942922,0.00016997768,0.0010423112,0.00009443726,0.0011745081],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006246496,0.0008184307,0.0010256405,0.00044665363,0.00035263627,0.00013320695,0.0006041398,0.001316113,0.11005909],"category_scores_gemma":[0.0015389097,0.00065441075,0.00050988735,0.00055526616,0.00056456996,0.00011494387,0.00033432647,0.0012890217,0.01999895],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048447956,0.0017669791,0.11982667,0.0013332576,0.0045671794,0.014624144,0.0025804616,0.000033207794,0.0049508014,0.0009333411,0.5699599,0.27893957],"study_design_scores_gemma":[0.0070625297,0.0006034087,0.44592175,0.004965778,0.0006794363,0.00019535192,0.0018118045,0.0005595416,0.0016948659,0.0005229277,0.5350636,0.0009189659],"about_ca_topic_score_codex":0.03271687,"about_ca_topic_score_gemma":0.018805316,"teacher_disagreement_score":0.32609507,"about_ca_system_score_codex":0.00067579024,"about_ca_system_score_gemma":0.0007813147,"threshold_uncertainty_score":0.9999804},"labels":[],"label_agreement":null},{"id":"W6983018224","doi":"","title":"Le bortezomib après l’allogreffe diminue l’incidence et la sévérité de la maladie du greffon contre l’hôte chronique chez les patients avec un myélome multiple","year":2022,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal","keywords":"Hematopoietic cell; Transplantation; Connective tissue disease","score_opus":0.005961094242453934,"score_gpt":0.20759825772738594,"score_spread":0.201637163484932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6983018224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569319,0.011757763,0.00017230265,0.00045700002,0.00081307953,0.0015759943,0.0006474665,0.00018298079,0.02746152],"genre_scores_gemma":[0.96516615,0.0033003078,0.00063012645,0.00014064634,0.00026955217,0.00030308045,0.004313963,0.000118805096,0.025757365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99358344,0.0017759516,0.0007280225,0.0012049406,0.0014796916,0.0012279702],"domain_scores_gemma":[0.99576896,0.0013260263,0.0006479549,0.0006664092,0.0005146621,0.0010759917],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00092342496,0.00092950417,0.0009658785,0.0005553507,0.0076128305,0.00013433157,0.0007139067,0.0009442002,0.00036319255],"category_scores_gemma":[0.0007893943,0.0010593135,0.0006459141,0.00046061323,0.00092791626,0.0005242475,0.0004909124,0.0016413631,0.000057474128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0057163225,0.0031160917,0.88265854,0.0008185994,0.0020675864,0.030947195,0.033208013,0.0014211049,0.00862106,0.0152671095,0.00035831818,0.015800053],"study_design_scores_gemma":[0.013086395,0.00067965116,0.91592455,0.00091644377,0.0007904936,0.0017130228,0.011232908,0.004883338,0.006674051,0.000118086136,0.043062054,0.0009190337],"about_ca_topic_score_codex":0.1195119,"about_ca_topic_score_gemma":0.017960165,"teacher_disagreement_score":0.10155174,"about_ca_system_score_codex":0.009980524,"about_ca_system_score_gemma":0.006579325,"threshold_uncertainty_score":0.9999595},"labels":[],"label_agreement":null},{"id":"W7005853841","doi":"","title":"Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma","year":2005,"lang":"en","type":"article","venue":"NPARC","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Microfluidics; Template; Single-cell analysis; Polymerase chain reaction; Cell","score_opus":0.021823311675798332,"score_gpt":0.251636834026135,"score_spread":0.2298135223503367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7005853841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806124,0.000524394,0.00019856692,0.00048603234,0.000044685698,0.0004906253,0.00004219088,0.00004292807,0.000109338944],"genre_scores_gemma":[0.97944343,0.00009471324,0.02023355,0.000023507562,0.00008727983,0.000010431831,0.000025183315,0.000022836872,0.000059037477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988569,0.000043398937,0.00024636165,0.00036369078,0.00018145698,0.0003081747],"domain_scores_gemma":[0.9993297,0.00010760012,0.000087786,0.00023910319,0.00015379307,0.000082058075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008658612,0.00015541942,0.00031397378,0.0002803902,0.0000656008,0.000009890333,0.000046647674,0.00014499344,0.000015783768],"category_scores_gemma":[0.00021850054,0.00014259797,0.000025591555,0.0003510714,0.000185473,0.00009229723,0.000057871668,0.00018840052,0.000011746033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037522832,0.00036087635,0.047608893,0.00006979181,0.000038027174,0.00008377365,0.00020296352,0.0000059105178,0.9104878,0.0000025799059,0.000009785648,0.04075441],"study_design_scores_gemma":[0.0030601516,0.00027689236,0.052144136,0.00015820848,0.00002728225,0.000046158235,0.0001370457,0.00236011,0.94144166,0.000112343085,0.00013394094,0.00010210007],"about_ca_topic_score_codex":0.0005556682,"about_ca_topic_score_gemma":0.0002280382,"teacher_disagreement_score":0.040652312,"about_ca_system_score_codex":0.00017699062,"about_ca_system_score_gemma":0.00006721098,"threshold_uncertainty_score":0.58149767},"labels":[],"label_agreement":null},{"id":"W7010248366","doi":"","title":"HIGH-DOSE WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA – EXPLORING THE FINANCIAL COST AND RARE SIDE-EFFECTS","year":2021,"lang":"en","type":"dissertation","venue":"QSpace (Queen's University Library)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"MorphoSys; Celgene; Gilead Sciences; Amgen","keywords":"Carfilzomib; Multiple myeloma; Clinical trial; Dexamethasone; Cyclophosphamide; Clinical endpoint; Refractory (planetary science); Cancer","score_opus":0.010362651284581649,"score_gpt":0.20919420948357603,"score_spread":0.1988315581989944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7010248366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510527,0.0008186923,0.0000021544329,0.001538415,0.0000896711,0.0021012146,0.000102250146,0.000027996515,0.0002143496],"genre_scores_gemma":[0.98519593,0.007030417,0.0005181206,0.000034822744,0.000036734396,0.000044344273,0.0013728589,0.00004587715,0.0057209167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982385,0.0002974597,0.00017767005,0.00054577977,0.00039400317,0.00034658553],"domain_scores_gemma":[0.9982151,0.00090069755,0.00018379216,0.00040506874,0.00008503078,0.0002103496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004718651,0.00040456906,0.00064107194,0.00026051508,0.00024295581,0.00005130688,0.00012576123,0.00019163014,0.000012318088],"category_scores_gemma":[0.00014388199,0.00025965876,0.00007679301,0.00041701083,0.00017615926,0.00048855867,0.00006993647,0.00035584858,8.3158113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014017453,0.0015003193,0.91482204,0.0009407058,0.0005834184,0.0026540388,0.010319551,0.000005120941,0.000030731284,0.00009414637,0.0007180634,0.05431441],"study_design_scores_gemma":[0.011954122,0.0018130093,0.9762641,0.0005057944,0.00027538906,0.0000012319821,0.0046938546,0.000004905472,0.0012092324,0.00000957827,0.0030464828,0.0002223104],"about_ca_topic_score_codex":0.0053965696,"about_ca_topic_score_gemma":0.0014353684,"teacher_disagreement_score":0.061442047,"about_ca_system_score_codex":0.00013699662,"about_ca_system_score_gemma":0.0002650401,"threshold_uncertainty_score":0.9999856},"labels":[],"label_agreement":null},{"id":"W7034066292","doi":"","title":"Social Enterprise Law: A Multijurisdictional Comparative Review","year":2023,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Social enterprise; Social business; Corporation; Shareholder; Social entrepreneurship; Social economy; Free enterprise; State (computer science); Subsidy; Certification","score_opus":0.056444056057256387,"score_gpt":0.37011138393382575,"score_spread":0.31366732787656937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7034066292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61671174,0.02605099,0.0000948511,0.02799904,0.00096421805,0.0074155955,0.00080107374,0.0022024855,0.31776002],"genre_scores_gemma":[0.9860154,0.0015797929,0.0003716356,0.0032647639,0.0004964842,0.00031141855,0.00055682624,0.00003146668,0.007372253],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808204,0.00013261964,0.00030684593,0.00036173934,0.0006410182,0.00047571887],"domain_scores_gemma":[0.99897814,0.00010960146,0.00006680111,0.00026887748,0.00015627524,0.00042033097],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025217445,0.00020556245,0.00047997228,0.00007307043,0.00034080123,0.0000354384,0.00012363965,0.00007887708,0.0013385842],"category_scores_gemma":[0.00008226553,0.00017034746,0.00022798263,0.00036564842,0.00017689912,0.00014214432,0.00009666207,0.00034969967,0.0070960317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024064393,0.002544205,0.050182156,0.0038742013,0.0026835497,0.0028681457,0.0015977388,0.000007932032,0.0032642223,0.078906715,0.8420365,0.009628211],"study_design_scores_gemma":[0.010458201,0.00057366275,0.112017564,0.0023674248,0.00031174463,0.00010613141,0.00016173758,0.0005701753,0.0015098533,0.0011056295,0.8703129,0.00050491875],"about_ca_topic_score_codex":0.0006171581,"about_ca_topic_score_gemma":0.00029113446,"teacher_disagreement_score":0.36930364,"about_ca_system_score_codex":0.0001523714,"about_ca_system_score_gemma":0.00011598066,"threshold_uncertainty_score":0.9995743},"labels":[],"label_agreement":null},{"id":"W7083302324","doi":"10.1109/tie.2025.3603055","title":"Systematic Health Monitoring and Management for UAV Hydrogen Energy Systems via a Hybrid Excitation Operator","year":2025,"lang":"en","type":"article","venue":"IEEE Transactions on Industrial Electronics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"General Motors (Canada)","funders":"National Natural Science Foundation of China","keywords":"Fault detection and isolation; State of health; Condition monitoring; Feature extraction; Fuzzy logic; Fault (geology); Remotely operated underwater vehicle","score_opus":0.03438470363715025,"score_gpt":0.31636442329519443,"score_spread":0.2819797196580442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7083302324","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09827937,0.0070346124,0.88207626,0.0010887041,0.0016419226,0.009369065,0.00009890034,0.00021709107,0.00019406827],"genre_scores_gemma":[0.9948185,0.0012822762,0.0001610831,0.000051551673,0.000104886545,0.0017479152,0.000019288358,0.000025589841,0.0017889087],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839795,0.0001279009,0.00043268243,0.00031384197,0.00027146967,0.00045615618],"domain_scores_gemma":[0.9992581,0.00015516879,0.00008237287,0.00024322502,0.000081027865,0.00018007579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003116849,0.00019008097,0.00043863023,0.00032713872,0.0003078123,0.000059910708,0.00006736201,0.00009742406,0.0000025590364],"category_scores_gemma":[0.000013827223,0.00016960775,0.000097559554,0.00028097932,0.000021526,0.00007023568,0.000001370492,0.00022623898,0.0000031568857],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0221927,0.0085638305,0.00057927583,0.11469522,0.038910296,0.0003404936,0.0010222031,0.028411109,0.013578473,0.017519386,0.0047336044,0.7494534],"study_design_scores_gemma":[0.14744577,0.026672741,0.00025770528,0.06805981,0.008053316,0.0006562317,0.0029417237,0.3485121,0.37536946,0.0015177638,0.017743744,0.0027696288],"about_ca_topic_score_codex":0.00020823527,"about_ca_topic_score_gemma":0.00002356145,"teacher_disagreement_score":0.89653915,"about_ca_system_score_codex":0.00085713057,"about_ca_system_score_gemma":0.00036339177,"threshold_uncertainty_score":0.6916404},"labels":[],"label_agreement":null},{"id":"W7084574625","doi":"10.1386/public_00245_1","title":"Pulsating Abundance","year":2025,"lang":"en","type":"article","venue":"Public","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Ephemera; Queer; Feeling; Modernity; Diaspora; Colonialism; Temporality; Photography","score_opus":0.03895993679046997,"score_gpt":0.3549889728242578,"score_spread":0.31602903603378785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084574625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70585585,0.00074346043,0.00048960035,0.02062434,0.00011931718,0.00034307194,0.000004069823,0.00012121905,0.27169907],"genre_scores_gemma":[0.9848935,0.000015725906,0.0008369688,0.0005551633,0.000036803875,0.000034495413,0.000018207631,0.000004448548,0.01360469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994419,0.000014308158,0.00007736221,0.00011927673,0.00012971066,0.00021741714],"domain_scores_gemma":[0.9996095,0.00004123875,0.000012029884,0.00017202986,0.00006535954,0.000099895915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008850091,0.000048512455,0.00008872418,0.00011072733,0.00006670651,0.00003519355,0.000050003368,0.000023443486,0.00021601934],"category_scores_gemma":[0.00040323756,0.00003821966,0.0000333541,0.00026329682,0.000025246985,0.0000601123,0.000033981825,0.00008152149,0.0001357325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004631751,0.00020340167,0.69073343,0.00009000267,0.00013841185,0.000053539225,0.000034249188,1.8134197e-7,0.0012192368,0.00988556,0.005547243,0.29204842],"study_design_scores_gemma":[0.002490487,0.00007295633,0.85460204,0.000073211326,0.000018252744,0.000014119479,0.00004874711,0.001028679,0.002084745,0.0007749915,0.13872641,0.0000653535],"about_ca_topic_score_codex":0.000039834886,"about_ca_topic_score_gemma":0.000012139364,"teacher_disagreement_score":0.29198307,"about_ca_system_score_codex":0.00006226476,"about_ca_system_score_gemma":0.0001320761,"threshold_uncertainty_score":0.23652603},"labels":[],"label_agreement":null},{"id":"W7093121128","doi":"","title":"DP114 | ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Subgroup analysis; Adverse effect; Hazard ratio; Clinical endpoint; Multiple myeloma; Common Terminology Criteria for Adverse Events","score_opus":0.09302658097092445,"score_gpt":0.49240532249358043,"score_spread":0.39937874152265596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093121128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893956,0.0068753827,0.00031532918,0.00025683918,0.000096072035,0.0015010348,0.00017386042,0.00004052823,0.0013453119],"genre_scores_gemma":[0.99123085,0.0069515165,0.00069554464,0.00037694135,0.000042762393,0.00013396172,0.00019605791,0.0000544783,0.00031788164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957404,0.00036343062,0.0011328743,0.00084200123,0.0011266895,0.00079459016],"domain_scores_gemma":[0.99687374,0.0009221159,0.0004926689,0.00068512646,0.00041895823,0.00060742354],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009626587,0.00055190147,0.0018864343,0.0034334299,0.00021785685,0.00062163407,0.0010071311,0.00016216795,0.0015285154],"category_scores_gemma":[0.00039903246,0.00042503708,0.00028910436,0.004111595,0.0002284818,0.0013067675,0.0003586575,0.00060094666,0.0000075714297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008209407,0.0015266382,0.96563834,0.0002552411,0.003639697,0.0005413985,0.0001618734,0.0000697844,0.0018756303,0.000013186488,0.0018455491,0.016223256],"study_design_scores_gemma":[0.020455536,0.000097143966,0.9698212,0.0009353048,0.001506201,0.000008428813,0.00006304842,0.00033570713,0.0057985634,0.00018436178,0.00042314336,0.00037131915],"about_ca_topic_score_codex":0.005225271,"about_ca_topic_score_gemma":0.001639162,"teacher_disagreement_score":0.015851935,"about_ca_system_score_codex":0.0002567302,"about_ca_system_score_gemma":0.00035978094,"threshold_uncertainty_score":0.9998202},"labels":[],"label_agreement":null},{"id":"W7093121815","doi":"","title":"C002 | SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NDMM: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Daratumumab; Minimal residual disease; Lenalidomide; Multiple myeloma; Clinical endpoint; Clinical trial; Confidence interval","score_opus":0.12078357911660595,"score_gpt":0.5252448282280195,"score_spread":0.40446124911141357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093121815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266934,0.0020225025,0.0001326828,0.0005291705,0.000060149716,0.0032336197,0.00059992657,0.000016152493,0.00073647505],"genre_scores_gemma":[0.9977321,0.0011814072,0.00018001774,0.0001730047,0.00004177867,0.00020840007,0.00024343512,0.000041470415,0.00019840192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940249,0.0012736858,0.0013909013,0.00079850847,0.001684173,0.0008278715],"domain_scores_gemma":[0.9956018,0.001613646,0.0008057375,0.0009142063,0.00064031326,0.00042429802],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021280332,0.0005455958,0.0020342774,0.0027963852,0.00021960352,0.000375354,0.001422744,0.00010803797,0.0006851191],"category_scores_gemma":[0.001118617,0.00033489318,0.0003395578,0.005066356,0.000457756,0.00092578284,0.00019328468,0.00080141047,0.0000011724405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34998503,0.0044028093,0.6362698,0.00021520525,0.0023078043,0.0026499033,0.0005860761,0.0002533829,0.0007074645,0.000021942447,0.0006024189,0.0019981747],"study_design_scores_gemma":[0.131198,0.0007118316,0.86069477,0.0013314484,0.002706029,0.000016518452,0.00080869964,0.00054120383,0.0013853217,0.00014308446,0.00009755473,0.00036553357],"about_ca_topic_score_codex":0.0047695045,"about_ca_topic_score_gemma":0.0024358004,"teacher_disagreement_score":0.22442497,"about_ca_system_score_codex":0.00036727838,"about_ca_system_score_gemma":0.0010910796,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W7093123001","doi":"","title":"C003 | MODELING LONG-TERM PROGRESSION-FREE SURVIVAL IN TRANSPLANT-ELIGIBLE AND TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; University of Calgary","funders":"","keywords":"Cohort; Population; Multiple myeloma; Randomized controlled trial; Overall survival; Dexamethasone","score_opus":0.14531548056820925,"score_gpt":0.5000742940997444,"score_spread":0.3547588135315351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093123001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699709,0.025478764,0.0009690057,0.00031080443,0.00009134828,0.002102305,0.00018680262,0.00006363094,0.0008264389],"genre_scores_gemma":[0.962956,0.035423283,0.00085665943,0.00010669986,0.000052483523,0.00021749502,0.000140695,0.00007402366,0.00017267285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958234,0.00036582752,0.0010674351,0.00092208013,0.0009675733,0.00085367134],"domain_scores_gemma":[0.9971249,0.00091207825,0.00031200377,0.0006817785,0.00030428972,0.0006649614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010698478,0.00063845643,0.0016206366,0.0015781941,0.0003367673,0.00070024014,0.00095533347,0.00021115359,0.0002996848],"category_scores_gemma":[0.0003125417,0.0004754822,0.00014229387,0.0013725319,0.00026346778,0.0012725033,0.0003160859,0.0006804337,0.0000018857697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013479489,0.00086141203,0.9447596,0.0007063723,0.00077440665,0.0021462594,0.00023623098,0.0001627971,0.016639933,0.000010683162,0.00028476905,0.019938031],"study_design_scores_gemma":[0.027006505,0.00012369028,0.93826866,0.005651727,0.00044713987,0.00014672459,0.00007365162,0.00501539,0.02251134,0.00022590662,0.00004385521,0.0004854079],"about_ca_topic_score_codex":0.0044296887,"about_ca_topic_score_gemma":0.0027300091,"teacher_disagreement_score":0.019452624,"about_ca_system_score_codex":0.00013559774,"about_ca_system_score_gemma":0.00037207972,"threshold_uncertainty_score":0.9997697},"labels":[],"label_agreement":null},{"id":"W7097751074","doi":"","title":"Review Article Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus","year":2012,"lang":"en","type":"article","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Multiple myeloma; Neutropenia; Thalidomide; Adverse effect","score_opus":0.4493966654863895,"score_gpt":0.3733754041573754,"score_spread":0.0760212613290141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097751074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9233885,0.004684445,0.000058737987,0.06655115,0.000045786364,0.0026890258,0.00003091284,0.000020667938,0.002530776],"genre_scores_gemma":[0.98834103,0.00022179994,0.008002008,0.0028929552,0.000039116763,0.000094791736,0.000009618457,0.000011521089,0.00038713834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870515,0.00016159321,0.00026033903,0.00013877379,0.00021459567,0.00051955134],"domain_scores_gemma":[0.9982806,0.00055503147,0.000032268348,0.0003551223,0.000053212032,0.00072375976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051638973,0.00010132736,0.0002582032,0.0001001082,0.000042681302,0.000009918447,0.000049212886,0.000039692455,0.00020410997],"category_scores_gemma":[0.003319684,0.00005777117,0.000059256585,0.0003041696,0.00006649959,0.00007754802,0.00003582267,0.00014877238,0.00021766567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065264077,0.0009320281,0.9182272,0.0005629266,0.0001922443,0.00016941136,0.0004912059,0.000010836757,0.0005075529,0.0012461232,0.053796638,0.023211215],"study_design_scores_gemma":[0.004160204,0.00022786635,0.7879322,0.0009820799,0.00015649789,0.00036078892,0.00037026985,0.0028727967,0.0043864097,0.000009860256,0.19833215,0.00020888764],"about_ca_topic_score_codex":0.08278688,"about_ca_topic_score_gemma":0.1447943,"teacher_disagreement_score":0.14453551,"about_ca_system_score_codex":0.00012972292,"about_ca_system_score_gemma":0.00028670154,"threshold_uncertainty_score":0.92332095},"labels":[],"label_agreement":null},{"id":"W7100232175","doi":"","title":"News | Spheres of Influence ALBERTA’S OIL SANDS","year":2013,"lang":"en","type":"article","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oil sands; Government (linguistics); Petroleum industry; Population; Petroleum; Commission; Fossil fuel","score_opus":0.016501325223916525,"score_gpt":0.2935573492490486,"score_spread":0.2770560240251321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100232175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8448532,0.00007179058,0.000004843636,0.0005487158,0.000010617351,0.0001025735,9.122728e-7,0.000013465626,0.15439387],"genre_scores_gemma":[0.952803,0.000050954128,0.0013721526,0.00020855533,0.00002023107,0.000028057933,0.0000070562046,0.0000070658766,0.045502886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993496,0.000012520645,0.00013950345,0.00011485442,0.00019556799,0.00018794308],"domain_scores_gemma":[0.99938726,0.000077946286,0.000024716463,0.00022712674,0.00010186601,0.00018108728],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000176099,0.000072943716,0.00015634134,0.000035421475,0.00001679213,0.000008846985,0.000055135242,0.00003516428,0.008865266],"category_scores_gemma":[0.00016660756,0.000045911653,0.00004602769,0.00008708049,0.000051416966,0.00008705421,0.000029901135,0.000052599466,0.00085723284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009291157,0.0002206804,0.8449279,0.000093584524,0.00011449799,0.000015267513,0.00008107243,0.000002157023,0.017005244,0.00020213108,0.00989355,0.12735097],"study_design_scores_gemma":[0.0040443875,0.00050745695,0.95039994,0.000096712414,0.000032533397,0.000023898045,0.00031441203,0.00035653025,0.036450952,0.00014247035,0.007515733,0.00011496782],"about_ca_topic_score_codex":0.051666543,"about_ca_topic_score_gemma":0.0024974737,"teacher_disagreement_score":0.12723601,"about_ca_system_score_codex":0.000016746746,"about_ca_system_score_gemma":0.000065822314,"threshold_uncertainty_score":0.9999207},"labels":[],"label_agreement":null},{"id":"W7101048736","doi":"","title":"ACKNOWLEDGEMENTS Many thanks to the members of the Ecology Action Centre’s Food Action Committee","year":2007,"lang":"en","type":"article","venue":"","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova scotia; Action (physics); Procurement; Food systems; Food supply","score_opus":0.05809733476219259,"score_gpt":0.3542242255144593,"score_spread":0.2961268907522667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7101048736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707166,0.000019596337,0.0002960035,0.0034234186,0.00090769597,0.0010408538,0.0000059651848,0.000027460766,0.023562437],"genre_scores_gemma":[0.983502,0.000017141709,0.00015931632,0.00042458693,0.00015174512,0.000016061478,0.000008488343,0.000010588367,0.015710091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989554,0.000074099895,0.00018065686,0.00015583893,0.00031762314,0.00031633975],"domain_scores_gemma":[0.9991231,0.00012269776,0.000059074926,0.00037630324,0.00019019043,0.00012860763],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000321443,0.00010093765,0.00013754457,0.00007950964,0.0001333068,0.000007804292,0.00014099307,0.00006749281,0.0025445432],"category_scores_gemma":[0.00021273129,0.00004966053,0.000091160684,0.00023069982,0.00005098769,0.000042633754,0.00010025826,0.00016029995,0.0005508617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016888228,0.0014285488,0.6956151,0.00012979888,0.0010975623,0.000014240986,0.00138549,0.000016082397,0.0071040737,0.00032767002,0.12487689,0.16631569],"study_design_scores_gemma":[0.0020445676,0.0004770787,0.8845975,0.000023125891,0.00007987595,0.000008815724,0.0015233842,0.0001222827,0.067326225,0.000033333316,0.043705754,0.000058070924],"about_ca_topic_score_codex":0.00007475031,"about_ca_topic_score_gemma":0.010494735,"teacher_disagreement_score":0.18898235,"about_ca_system_score_codex":0.00018772653,"about_ca_system_score_gemma":0.000045424462,"threshold_uncertainty_score":0.99836725},"labels":[],"label_agreement":null},{"id":"W7104549544","doi":"10.2139/ssrn.5711639","title":"European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma","year":2025,"lang":"","type":"preprint","venue":"SSRN Electronic Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Multiple myeloma; Adverse effect; Hematology; Safety profile; Disease; Chimeric antigen receptor; Clinical trial; Incidence (geometry)","score_opus":0.03997918005517454,"score_gpt":0.34891147546999485,"score_spread":0.3089322954148203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104549544","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051079754,0.08126207,0.3101813,0.1017163,0.032036338,0.07176385,0.0055715265,0.0019382379,0.34445062],"genre_scores_gemma":[0.5349576,0.22917598,0.0070514395,0.0011682408,0.0028754545,0.0011977911,0.0016679502,0.0003618921,0.22154368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98559284,0.0014090296,0.002071969,0.0018365802,0.001360198,0.00772941],"domain_scores_gemma":[0.9941354,0.0013050258,0.0011142377,0.0018371835,0.00069841923,0.00090977916],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005833299,0.0013871932,0.0014323741,0.0015281659,0.0017581072,0.0003427002,0.0014894435,0.0005111356,0.0009246823],"category_scores_gemma":[0.0014892435,0.0011206138,0.0012260973,0.000578152,0.00018527849,0.0002369123,0.0008363182,0.009769622,0.0004019344],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02565692,0.004367234,0.00037253823,0.00069555634,0.011747126,0.00056848757,0.00070298486,0.0000529542,0.0001483046,0.011398475,0.015895266,0.92839414],"study_design_scores_gemma":[0.089036345,0.021263273,0.0038957063,0.011547219,0.00282822,0.00092912454,0.018633695,0.002825619,0.0005980011,0.02263047,0.823088,0.0027243674],"about_ca_topic_score_codex":0.0001272608,"about_ca_topic_score_gemma":0.0008749573,"teacher_disagreement_score":0.9256698,"about_ca_system_score_codex":0.0105043445,"about_ca_system_score_gemma":0.00873771,"threshold_uncertainty_score":0.9999886},"labels":[],"label_agreement":null},{"id":"W7105996157","doi":"10.6084/m9.figshare.30646580.v1","title":"Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Health care; Confidence interval; Healthcare system; Bortezomib; Emergency department","score_opus":0.08124463587078833,"score_gpt":0.35262831559140245,"score_spread":0.2713836797206141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7105996157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.818413,0.002987734,6.1114434e-7,0.0011301402,0.0002783634,0.005729513,0.17055947,0.00012617465,0.00077497074],"genre_scores_gemma":[0.9142222,0.00011784256,0.00015637487,0.001315699,0.00009912597,0.0005289241,0.07873901,0.00009807256,0.004722783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99338204,0.0010382074,0.0015835367,0.0015414025,0.0010482895,0.0014065459],"domain_scores_gemma":[0.9913325,0.005197628,0.0004422037,0.0013182171,0.0005806929,0.0011287839],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034211707,0.0008039371,0.0015604824,0.0007205732,0.0003313108,0.00019009344,0.00038554193,0.000760094,0.009748058],"category_scores_gemma":[0.019815518,0.00063548423,0.00029840448,0.0008960011,0.00012415956,0.0004714932,0.0005379125,0.0017633811,0.00047651562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005780935,0.0020855607,0.8949114,0.0012313289,0.0005155582,0.00054588035,0.00024920353,0.0000011203205,0.0000012403056,0.000003157471,0.043723732,0.05095088],"study_design_scores_gemma":[0.04500228,0.0020135385,0.86727756,0.011555568,0.000090675705,0.0000024957642,0.0002216502,0.00039561925,0.00001822475,0.0000034604705,0.07299224,0.00042665837],"about_ca_topic_score_codex":0.00036409727,"about_ca_topic_score_gemma":0.0019408658,"teacher_disagreement_score":0.09580915,"about_ca_system_score_codex":0.0005638618,"about_ca_system_score_gemma":0.0010303583,"threshold_uncertainty_score":0.99960965},"labels":[],"label_agreement":null},{"id":"W7106025286","doi":"10.6084/m9.figshare.30646580","title":"Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Health care; Confidence interval; Healthcare system; Bortezomib; Emergency department","score_opus":0.08124463587078833,"score_gpt":0.35262831559140245,"score_spread":0.2713836797206141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7106025286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.818413,0.002987734,6.1114434e-7,0.0011301402,0.0002783634,0.005729513,0.17055947,0.00012617465,0.00077497074],"genre_scores_gemma":[0.9142222,0.00011784256,0.00015637487,0.001315699,0.00009912597,0.0005289241,0.07873901,0.00009807256,0.004722783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99338204,0.0010382074,0.0015835367,0.0015414025,0.0010482895,0.0014065459],"domain_scores_gemma":[0.9913325,0.005197628,0.0004422037,0.0013182171,0.0005806929,0.0011287839],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034211707,0.0008039371,0.0015604824,0.0007205732,0.0003313108,0.00019009344,0.00038554193,0.000760094,0.009748058],"category_scores_gemma":[0.019815518,0.00063548423,0.00029840448,0.0008960011,0.00012415956,0.0004714932,0.0005379125,0.0017633811,0.00047651562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005780935,0.0020855607,0.8949114,0.0012313289,0.0005155582,0.00054588035,0.00024920353,0.0000011203205,0.0000012403056,0.000003157471,0.043723732,0.05095088],"study_design_scores_gemma":[0.04500228,0.0020135385,0.86727756,0.011555568,0.000090675705,0.0000024957642,0.0002216502,0.00039561925,0.00001822475,0.0000034604705,0.07299224,0.00042665837],"about_ca_topic_score_codex":0.00036409727,"about_ca_topic_score_gemma":0.0019408658,"teacher_disagreement_score":0.09580915,"about_ca_system_score_codex":0.0005638618,"about_ca_system_score_gemma":0.0010303583,"threshold_uncertainty_score":0.99960965},"labels":[],"label_agreement":null},{"id":"W7108441195","doi":"10.1182/blood-2025-252","title":"Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation; McMaster University","funders":"","keywords":"Pomalidomide; Multiple myeloma; Biomarker; Dexamethasone; Randomized controlled trial; Clinical endpoint; Lenalidomide; Minimal residual disease","score_opus":0.017667836661984015,"score_gpt":0.2774876403507092,"score_spread":0.2598198036887252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108441195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960336,0.0017485282,0.0000053513954,0.00013735352,0.000022315291,0.0012358079,0.00049054663,0.000065504515,0.00026095856],"genre_scores_gemma":[0.9971988,0.00006760611,0.0014088255,0.000095269235,0.000020106716,0.00011915081,0.00037549066,0.00005344908,0.00066128623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750674,0.0001814447,0.00039916034,0.00082161854,0.00052639126,0.0005646563],"domain_scores_gemma":[0.99816227,0.0005349609,0.00014288138,0.0005157607,0.00014661512,0.0004975309],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001039138,0.00046416768,0.00080459693,0.00044496157,0.00016261973,0.00007102591,0.000109156244,0.00010620374,0.00003649863],"category_scores_gemma":[0.00032086388,0.00031041392,0.0000652598,0.00048249384,0.00034097218,0.00019045369,0.00011000408,0.0002647258,0.00000528464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031204306,0.003524694,0.9600773,0.0001679467,0.0009045724,0.0014147033,0.000086163,0.0000021623748,0.0006749962,0.0000014098998,0.00006101814,0.0018807318],"study_design_scores_gemma":[0.09033097,0.001140831,0.90364534,0.00039476407,0.0009084385,0.0000051165266,0.00015639637,0.0001597866,0.0029253757,0.00000682042,0.000038370912,0.00028781107],"about_ca_topic_score_codex":0.0019442519,"about_ca_topic_score_gemma":0.00081478106,"teacher_disagreement_score":0.059126668,"about_ca_system_score_codex":0.000100296355,"about_ca_system_score_gemma":0.00032600356,"threshold_uncertainty_score":0.9999348},"labels":[],"label_agreement":null},{"id":"W7108444082","doi":"10.1182/blood-2025-2288","title":"A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; Multiple myeloma; Dexamethasone; Monoclonal antibody; Monoclonal; Phases of clinical research; Antibody; Clinical trial","score_opus":0.04428676901334626,"score_gpt":0.3690392358046509,"score_spread":0.32475246679130465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108444082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670226,0.0010615517,0.00009860258,0.0001806221,0.00003340929,0.011654074,0.00013270673,0.000018862886,0.000117890944],"genre_scores_gemma":[0.99612856,0.0001867174,0.0028322106,0.00011160857,0.000011926116,0.0005696259,0.000083680316,0.000026971413,0.00004871151],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997107,0.0006526153,0.0006921743,0.00063359475,0.00049044116,0.00042414776],"domain_scores_gemma":[0.99651414,0.002459219,0.0001532162,0.00042235843,0.00019127164,0.00025979354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010936017,0.00034893368,0.0011868296,0.00027051353,0.00025437918,0.000103456274,0.00020072062,0.00006689525,0.000008366691],"category_scores_gemma":[0.0010565885,0.00021454254,0.00003602491,0.00044968355,0.00024465343,0.0001468793,0.00024893542,0.0002713527,0.0000011542631],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39092278,0.023024049,0.56489897,0.00018013568,0.0011770498,0.000099430494,0.0035843612,0.0000069716375,0.0011278334,0.0000060546618,0.000017991795,0.0149543695],"study_design_scores_gemma":[0.6838287,0.0029751223,0.3078618,0.0007246942,0.0007399374,0.0000059773856,0.00053074665,0.0025963243,0.0005842415,0.0000035138514,0.000008474728,0.00014041807],"about_ca_topic_score_codex":0.0014232325,"about_ca_topic_score_gemma":0.0011831895,"teacher_disagreement_score":0.29290596,"about_ca_system_score_codex":0.00003357053,"about_ca_system_score_gemma":0.000101764104,"threshold_uncertainty_score":0.87487906},"labels":[],"label_agreement":null},{"id":"W7108453570","doi":"10.1182/blood-2025-250","title":"Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Panobinostat; Phases of clinical research; Clinical endpoint; Cereblon; Pharmacodynamics; Proteasome inhibitor; Clinical trial; Carfilzomib; Ubiquitin ligase","score_opus":0.04703664611367812,"score_gpt":0.37922288353181416,"score_spread":0.332186237418136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108453570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967214,0.00027935955,0.000004849345,0.00020994795,0.00014792045,0.0017353725,0.00003691048,0.000047433754,0.00081683055],"genre_scores_gemma":[0.99916345,0.00007484343,0.00023145271,0.00003278748,0.00006212501,0.0001570489,0.00002176822,0.000024233708,0.0002323161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971701,0.00039533083,0.0008288403,0.0006148107,0.00045081825,0.0005401258],"domain_scores_gemma":[0.9978942,0.0010063682,0.00015281411,0.00059304264,0.000107463784,0.00024605743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007107621,0.00028288402,0.0008719297,0.00048838754,0.00007004778,0.00001763731,0.00017852668,0.00023266532,0.00004363002],"category_scores_gemma":[0.0012870603,0.00024418332,0.00016552526,0.0007156694,0.00015944461,0.000113431546,0.00014544754,0.0007193019,0.000022064556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003470308,0.092888206,0.8726115,0.0001337054,0.00037346437,0.0011100798,0.00024068271,0.0000025820473,0.002424625,0.000005046185,0.00012135394,0.026618425],"study_design_scores_gemma":[0.12737127,0.0059019495,0.8551342,0.00034985313,0.00019093289,0.000009464096,0.00055968104,0.0010627151,0.009020049,0.000020384554,0.00021446652,0.00016503678],"about_ca_topic_score_codex":0.001470118,"about_ca_topic_score_gemma":0.008953293,"teacher_disagreement_score":0.12390096,"about_ca_system_score_codex":0.00012204984,"about_ca_system_score_gemma":0.00040409437,"threshold_uncertainty_score":0.9957506},"labels":[],"label_agreement":null},{"id":"W7108455829","doi":"10.1182/blood-2025-3988","title":"Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Bortezomib; Lenalidomide; Multiple myeloma; Dexamethasone; Regimen; Thalidomide; Pomalidomide; Performance status; Carfilzomib","score_opus":0.026256291101218618,"score_gpt":0.32518897360278337,"score_spread":0.29893268250156474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108455829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420667,0.00033042885,0.0000054115108,0.000078454024,0.000044943074,0.004890343,0.000044666973,0.0000922517,0.0003068515],"genre_scores_gemma":[0.99854,0.00008477126,0.00028614845,0.000016531214,0.000056084486,0.0003926734,0.00013780803,0.000047698923,0.0004383009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976454,0.00012913553,0.00047042212,0.00067961,0.00042794927,0.00064747606],"domain_scores_gemma":[0.9984214,0.0004488578,0.00014054075,0.0005493428,0.00014546074,0.00029442488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016400547,0.00047204373,0.00075195805,0.00060827646,0.0002201117,0.00007144708,0.00009818421,0.000089718924,0.00001651762],"category_scores_gemma":[0.00047916183,0.00031300177,0.00008785548,0.00087544345,0.000082184306,0.000184253,0.00011863831,0.00027259366,0.0000040902455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011326916,0.014614793,0.97686464,0.00013354511,0.0010307969,0.00024533315,0.0008646246,0.0000033100719,0.00080692157,0.0000017252742,0.000002323317,0.00429928],"study_design_scores_gemma":[0.052706927,0.0056958925,0.9351079,0.00051775906,0.00034036397,0.000006097285,0.00032157457,0.000144276,0.0048372922,0.0000030729777,0.000092352835,0.00022652654],"about_ca_topic_score_codex":0.01738804,"about_ca_topic_score_gemma":0.020261172,"teacher_disagreement_score":0.051574234,"about_ca_system_score_codex":0.00039517228,"about_ca_system_score_gemma":0.00021571374,"threshold_uncertainty_score":0.9999322},"labels":[],"label_agreement":null},{"id":"W7108456461","doi":"10.1182/blood-2025-8151","title":"Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada); Hotel Dieu Hospital","funders":"","keywords":"Interim analysis; Adverse effect; Dosing; Interim; Observational study; Mallinckrodt; Multiple myeloma","score_opus":0.020402476598391978,"score_gpt":0.31573424057809496,"score_spread":0.29533176397970295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108456461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962002,0.00007612823,0.000019167494,0.00012918403,0.0001620262,0.0013788817,0.00020014255,0.000035443685,0.0017988392],"genre_scores_gemma":[0.99810654,0.000034734567,0.00008240038,0.000054070697,0.0000243563,0.00007431935,0.00012809574,0.000021613982,0.0014738732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727637,0.0003597133,0.00080692215,0.0005360377,0.00061793556,0.00040304047],"domain_scores_gemma":[0.9979787,0.00036626018,0.00023202418,0.0010903116,0.00021220626,0.00012048875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039669062,0.00024881217,0.00063172344,0.0009522256,0.000102240156,0.000024368142,0.00030777048,0.000085682856,0.000033919885],"category_scores_gemma":[0.00073166477,0.00017096318,0.00027987795,0.0020363447,0.0000763643,0.00007195624,0.00027119185,0.00039887114,0.0000071532845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016716737,0.00818728,0.97720504,0.00008652972,0.0023521634,0.00007311869,0.00072050176,0.0000046719906,0.00036108057,0.000006102421,0.00010779577,0.009224038],"study_design_scores_gemma":[0.03842734,0.00059442676,0.95566475,0.00036772757,0.0014828547,5.943933e-7,0.0007477072,0.00032270336,0.002174681,0.0000029795194,0.00010017554,0.00011402477],"about_ca_topic_score_codex":0.008402142,"about_ca_topic_score_gemma":0.023865145,"teacher_disagreement_score":0.03675567,"about_ca_system_score_codex":0.00019120376,"about_ca_system_score_gemma":0.00013621499,"threshold_uncertainty_score":0.998201},"labels":[],"label_agreement":null},{"id":"W7108466202","doi":"10.1182/blood-2025-495","title":"Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrow-derived mutations in newly diagnosed multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Alberta Cancer Foundation; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Toronto; University of New Brunswick; Dalhousie University; Vancouver General Hospital; Saint John Regional Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Germline; Deep sequencing; DNA sequencing; Somatic cell; Copy number analysis; Whole genome sequencing; Structural variation; Bone marrow","score_opus":0.016730283328497627,"score_gpt":0.260427158636545,"score_spread":0.24369687530804734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108466202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990977,0.0005954288,0.0001244196,0.00053270505,0.00006853081,0.001051969,0.0002475656,0.00006132993,0.006341077],"genre_scores_gemma":[0.99449664,0.00012751626,0.0037304878,0.00013393286,0.00003640807,0.00014398145,0.00044410204,0.000031112388,0.00085581123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813116,0.00009931808,0.0005030933,0.00040800826,0.0003603779,0.0004980351],"domain_scores_gemma":[0.99839705,0.00048416518,0.00012227702,0.0006380594,0.00014540055,0.00021302397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018254304,0.00023261673,0.0004789238,0.00047471226,0.00009436257,0.000022253655,0.00020448146,0.00012856243,0.000095824056],"category_scores_gemma":[0.001255523,0.0002239331,0.00013218609,0.000773744,0.00011104408,0.00011471047,0.00007057869,0.00024847235,0.000037178823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034177894,0.0013323167,0.10547581,0.0002900758,0.0002482677,0.0009048241,0.00079537166,0.00009567556,0.88836616,0.000013787807,0.000077131204,0.002058805],"study_design_scores_gemma":[0.048701167,0.0004893162,0.3804505,0.0003950977,0.00032614009,0.00003330295,0.0019352719,0.00060384086,0.5662706,0.00020783841,0.00030514481,0.00028179493],"about_ca_topic_score_codex":0.0010760451,"about_ca_topic_score_gemma":0.0012136608,"teacher_disagreement_score":0.32209554,"about_ca_system_score_codex":0.0002178395,"about_ca_system_score_gemma":0.00045288666,"threshold_uncertainty_score":0.91317266},"labels":[],"label_agreement":null},{"id":"W7108476913","doi":"10.1182/blood-2025-494","title":"Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Circulating tumor cell; Minimal residual disease; Bone marrow; Multiple myeloma; Immunophenotyping; Clinical trial; Flow cytometry","score_opus":0.01174581384605436,"score_gpt":0.2997749837798987,"score_spread":0.2880291699338443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108476913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955622,0.00010836138,0.00068060216,0.00006137771,0.000040901385,0.002272062,0.00074163853,0.000027208975,0.0005056263],"genre_scores_gemma":[0.9853182,0.000027285798,0.013971936,0.000018591447,0.000010172055,0.00022142082,0.00028681624,0.000029359015,0.00011621189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979901,0.00012416986,0.00047708745,0.00042004458,0.0006154343,0.00037316504],"domain_scores_gemma":[0.9981331,0.00041314977,0.00029974678,0.00043550695,0.00045750762,0.0002609937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031683617,0.00023485979,0.00055852806,0.00019970145,0.0001431455,0.000021117017,0.00010366227,0.000047892845,0.000015545422],"category_scores_gemma":[0.0003121634,0.00018391783,0.00010295804,0.00022711638,0.00011461264,0.00008277663,0.00008706194,0.00015884696,3.9586695e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009418573,0.004117114,0.9842847,0.0012241069,0.00086828775,0.00003558511,0.00003587708,0.00006201114,0.0065184273,0.00006566444,0.000024641162,0.0018217145],"study_design_scores_gemma":[0.032056432,0.0015608569,0.93789434,0.00049075496,0.00092149683,0.0000010970938,0.000087934255,0.020307368,0.006449605,0.000085693915,0.000009571978,0.0001348732],"about_ca_topic_score_codex":0.00016727316,"about_ca_topic_score_gemma":0.000060886243,"teacher_disagreement_score":0.0463904,"about_ca_system_score_codex":0.000112467096,"about_ca_system_score_gemma":0.00055443944,"threshold_uncertainty_score":0.7499952},"labels":[],"label_agreement":null},{"id":"W7108604932","doi":"10.1182/blood-2025-2262","title":"Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dexamethasone; Daratumumab; Clinical endpoint; Multiple myeloma; Bortezomib; Phases of clinical research; Intention-to-treat analysis; Randomized controlled trial; Randomization","score_opus":0.026574681224570032,"score_gpt":0.322453296623898,"score_spread":0.29587861539932797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108604932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895744,0.0063093044,0.00004648013,0.0003569962,0.000110754896,0.003064481,0.00020554113,0.00006933934,0.0002627479],"genre_scores_gemma":[0.997658,0.0006153029,0.0006288658,0.00013884292,0.00008027565,0.00019064735,0.00016558838,0.00006233329,0.00046012356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599105,0.00064780086,0.00086502626,0.0010242328,0.00073216273,0.00073971465],"domain_scores_gemma":[0.99584746,0.002239009,0.00026725276,0.0011211693,0.00014791025,0.00037721056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008572986,0.0005370396,0.001206618,0.00050723733,0.00026797576,0.00007875998,0.00032947407,0.00027777388,0.0000654629],"category_scores_gemma":[0.0013156228,0.00040625926,0.00012072038,0.0007168525,0.0004079042,0.0001552954,0.00038098078,0.0008358159,0.0000072091193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0176419,0.008185408,0.9396495,0.00017793037,0.0016872137,0.0016077177,0.0037065293,0.0000030884426,0.008456986,0.000010899366,0.00012397715,0.018748837],"study_design_scores_gemma":[0.14283322,0.0028192198,0.84475344,0.0004535517,0.00090473704,0.00006920961,0.0027347037,0.000441128,0.004630887,0.000025836303,0.000058489386,0.00027555795],"about_ca_topic_score_codex":0.004316983,"about_ca_topic_score_gemma":0.0060506384,"teacher_disagreement_score":0.12519132,"about_ca_system_score_codex":0.00022480873,"about_ca_system_score_gemma":0.00050444575,"threshold_uncertainty_score":0.99983895},"labels":[],"label_agreement":null},{"id":"W7108643524","doi":"10.1182/blood-2025-2163","title":"Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Transcriptome; Bone marrow; Gene expression profiling; Disease; Beta-2 microglobulin; Chromothripsis","score_opus":0.01795868949242272,"score_gpt":0.2700083733081279,"score_spread":0.25204968381570514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108643524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963381,0.00080510776,0.00059221644,0.00011884255,0.00014515668,0.0013385884,0.00013001433,0.000057822832,0.00047415134],"genre_scores_gemma":[0.9982189,0.00012791643,0.00073625694,0.0000407981,0.000048588343,0.00014581364,0.00004894133,0.000024285619,0.00060850143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983273,0.0001611663,0.00040982568,0.00040928012,0.00032964587,0.00036274365],"domain_scores_gemma":[0.99910223,0.00015056106,0.00010261875,0.0003609449,0.00011875147,0.00016487083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012083525,0.00021584719,0.0003914739,0.0002567539,0.00008679918,0.000022024537,0.000106242616,0.000102638005,0.000030847863],"category_scores_gemma":[0.00016804515,0.00018800065,0.00014913155,0.00044549047,0.0000952473,0.00013939329,0.000034827284,0.00025323627,0.000031854626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018894918,0.0053150505,0.21523315,0.00044917324,0.00026775777,0.00023716471,0.00056864246,0.00001774329,0.7740466,0.000020265297,0.00003495569,0.0019200244],"study_design_scores_gemma":[0.014692248,0.00038148786,0.29016793,0.00016189246,0.00031077518,0.0000016922473,0.000089529494,0.00025807394,0.6935981,0.00019326915,0.000050785424,0.00009420544],"about_ca_topic_score_codex":0.0011598144,"about_ca_topic_score_gemma":0.0004531882,"teacher_disagreement_score":0.08044847,"about_ca_system_score_codex":0.00010689655,"about_ca_system_score_gemma":0.00017410131,"threshold_uncertainty_score":0.76664436},"labels":[],"label_agreement":null},{"id":"W7108662280","doi":"10.1182/blood-2025-2187","title":"Light-chain MGUS defined as per the revised definition of the istopmm study: Experience from the university of calgary MGUS clinic","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal gammopathy; Confidence interval; Lymphoproliferative disorders; Population; Waldenstrom macroglobulinemia; Prospective cohort study","score_opus":0.031228438704084212,"score_gpt":0.2915604792796188,"score_spread":0.2603320405755346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108662280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864479,0.0010147176,0.00001564098,0.0015096776,0.000060018727,0.0008992232,0.000015493028,0.0000127443145,0.010024615],"genre_scores_gemma":[0.9986294,0.0001346521,0.0001528398,0.00018597014,0.000019093977,0.000010671805,0.000008371123,0.00000570726,0.0008533275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988448,0.0002978268,0.00019546042,0.0001932588,0.0003227483,0.00014592924],"domain_scores_gemma":[0.99859023,0.0004959664,0.00009931054,0.00066948147,0.00010059932,0.000044429133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024033246,0.000098940014,0.00021786573,0.000027940761,0.00022169524,0.0000062570916,0.00030518774,0.000048878486,0.0002537217],"category_scores_gemma":[0.00044305934,0.000048233625,0.0001380797,0.00022828889,0.00016015154,0.000022692851,0.0001567647,0.00017255715,0.000033039043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016854916,0.0043522464,0.9653197,0.000083201194,0.0011217976,0.000120631434,0.011563996,2.2144204e-7,0.0092969015,0.0015117949,0.0011832777,0.0037607304],"study_design_scores_gemma":[0.008158661,0.0004421173,0.9752008,0.00021592253,0.0006142286,0.0000049996456,0.0087871365,0.0000165616,0.0051213093,0.00048297454,0.0008923996,0.00006293563],"about_ca_topic_score_codex":0.0027449785,"about_ca_topic_score_gemma":0.00031337797,"teacher_disagreement_score":0.012181496,"about_ca_system_score_codex":0.000036870384,"about_ca_system_score_gemma":0.00020553087,"threshold_uncertainty_score":0.41496047},"labels":[],"label_agreement":null},{"id":"W7108684918","doi":"10.1182/blood-2025-6341","title":"Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Discontinuation; Multiple myeloma; Observational study; Population; Retrospective cohort study; Melphalan; Charlson comorbidity index; Lenalidomide","score_opus":0.023729353248533203,"score_gpt":0.2908707777886225,"score_spread":0.2671414245400893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108684918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376243,0.00009851128,0.000004236736,0.0006387718,0.00001565237,0.0013491741,0.00017119572,0.000051574134,0.0039084707],"genre_scores_gemma":[0.9970521,0.00018406492,0.00015071049,0.00022737685,0.0000071422487,0.00013769329,0.0013593759,0.000019930161,0.0008616227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848264,0.00015734535,0.00037671925,0.0002694222,0.00037947073,0.00033442312],"domain_scores_gemma":[0.9985386,0.0006960587,0.00009199863,0.00042623165,0.00014426807,0.000102827405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014197733,0.00022599245,0.0004743919,0.0005757999,0.00006172853,0.000015666232,0.00016058494,0.00005748512,0.000013488297],"category_scores_gemma":[0.00009527397,0.00012517764,0.000079924255,0.0011074616,0.00009832893,0.000059177997,0.000019733172,0.00017099705,0.000005068462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001872578,0.0034422805,0.9918074,0.000119176104,0.00060373126,0.00051072426,0.0006872402,0.000006229923,0.000114757044,0.000041601772,0.0005327129,0.00026159242],"study_design_scores_gemma":[0.03888459,0.00063167757,0.95276517,0.00033925023,0.0002018008,0.0000025493346,0.00025594386,0.00012292432,0.006322515,0.000016482587,0.00035412377,0.000102979546],"about_ca_topic_score_codex":0.015540947,"about_ca_topic_score_gemma":0.0038149261,"teacher_disagreement_score":0.039042216,"about_ca_system_score_codex":0.000036337526,"about_ca_system_score_gemma":0.00013403609,"threshold_uncertainty_score":0.99101466},"labels":[],"label_agreement":null},{"id":"W7116920300","doi":"10.1097/rlu.0000000000006270","title":"Prognostic Value of [18F]FDG PET/CT in Multiple Myeloma Patients at the Time of Initial Diagnosis","year":2025,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital","funders":"","keywords":"Multiple myeloma; Value (mathematics); Bone marrow; Overall survival; Predictive value of tests","score_opus":0.04695590156072009,"score_gpt":0.39698503238596894,"score_spread":0.35002913082524884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116920300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052036,0.00026535572,0.0000011291705,0.0045281583,0.00022173123,0.0012297827,0.000037954203,0.00002449155,0.003171026],"genre_scores_gemma":[0.997861,0.000269987,0.0001281883,0.001002024,0.000101443606,0.000043382784,0.000085807755,0.000028023262,0.0004801403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970851,0.00035013125,0.0012328577,0.0003755467,0.00060938695,0.00034699446],"domain_scores_gemma":[0.9942111,0.0045246547,0.00023699692,0.00057499023,0.00023229436,0.00021998624],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088089734,0.00019794505,0.00089940656,0.00020124609,0.000070131755,0.000003055553,0.0002494689,0.000040464736,0.0011642887],"category_scores_gemma":[0.014991552,0.00011791148,0.00020695619,0.00048907695,0.0011126518,0.000038260543,0.000270365,0.0004021004,0.0001473868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017510277,0.001948733,0.9672413,0.0002152386,0.00023495963,0.00034728568,0.00009700393,0.0000015910366,0.00010397492,0.00006544213,0.008283301,0.019710133],"study_design_scores_gemma":[0.013974424,0.002419965,0.97632545,0.0012912829,0.00023347925,0.000015968311,0.00009864729,0.0012586643,0.0002729797,0.000076194185,0.00395332,0.000079612895],"about_ca_topic_score_codex":0.00028809317,"about_ca_topic_score_gemma":0.00004721707,"teacher_disagreement_score":0.019630522,"about_ca_system_score_codex":0.000090642214,"about_ca_system_score_gemma":0.00011839549,"threshold_uncertainty_score":0.99974877},"labels":[],"label_agreement":null},{"id":"W7117577240","doi":"10.14740/jh2142","title":"Efficacy and Safety of Daratumumab, Lenalidomide and Dexamethasone Therapy in the First Relapse of Multiple Myeloma Patients – Real World Data from Hungary","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Real world data; Multiple myeloma; Lenalidomide; Dexamethasone; Real world evidence","score_opus":0.04450856082807372,"score_gpt":0.3420874789510913,"score_spread":0.2975789181230176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117577240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946874,0.003145742,0.00002154523,0.0013628522,0.00005545115,0.00037712566,0.000050431743,0.0000021350318,0.00029733838],"genre_scores_gemma":[0.99575037,0.0026309101,0.0014375935,0.00009641284,0.000018619001,0.0000027723245,0.00003679017,0.000007638906,0.000018869658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844474,0.00023411102,0.00070491456,0.00018101791,0.00026078688,0.00017445826],"domain_scores_gemma":[0.99669605,0.0022561313,0.00040556022,0.0004378934,0.0001323005,0.00007207775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057849387,0.00012371523,0.000726603,0.00030922415,0.000049709764,0.000006605288,0.00024954847,0.000064500775,0.0000143020925],"category_scores_gemma":[0.0008225983,0.00007455898,0.000049094713,0.00025044818,0.00027386693,0.0000918097,0.0001772682,0.0003075367,4.807641e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014012809,0.0008549271,0.964782,0.00009344862,0.00043211566,0.00018106289,0.0004178101,6.7383183e-7,0.00040809117,0.000107406995,0.00076601346,0.017943637],"study_design_scores_gemma":[0.024266671,0.00070772157,0.9713122,0.0004477356,0.000082859995,0.00008463334,0.00016653677,0.00012734912,0.0019541527,0.00018730226,0.00061656244,0.000046241574],"about_ca_topic_score_codex":0.0004915673,"about_ca_topic_score_gemma":0.0014114586,"teacher_disagreement_score":0.017897397,"about_ca_system_score_codex":0.000025958318,"about_ca_system_score_gemma":0.00010015284,"threshold_uncertainty_score":0.3040427},"labels":[],"label_agreement":null},{"id":"W7117741172","doi":"10.3390/curroncol33010016","title":"Emerging Real-World Treatment Patterns and Clinical Outcomes of Multiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Study in the Private Healthcare Sector","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Bortezomib; Disease; Health care; Attrition; Cumulative incidence; Drug","score_opus":0.1585021123012549,"score_gpt":0.49399518600899606,"score_spread":0.3354930737077412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117741172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923188,0.0012667384,0.0000037653792,0.0038474007,0.00029260057,0.0021539573,0.000039186943,0.000010963242,0.000066598215],"genre_scores_gemma":[0.99699324,0.0025191235,0.000030807772,0.00013252073,0.000060024406,0.00017973871,0.00004843642,0.000008715402,0.000027413975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997603,0.0009110716,0.00062250433,0.0003942288,0.00018958289,0.00027960163],"domain_scores_gemma":[0.99734056,0.002032067,0.00012312805,0.00036924647,0.000040667623,0.00009432003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037638872,0.00018730455,0.0006516817,0.00019722893,0.00008212105,0.000012499775,0.00012871642,0.00006927913,0.000011023384],"category_scores_gemma":[0.00025164365,0.00009501346,0.00007570136,0.00026770748,0.00011831547,0.00003251011,0.000144393,0.00032992478,0.0000014507551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042097934,0.0028027215,0.9035902,0.00005035275,0.0002033498,0.000103695835,0.002786045,1.7812881e-7,0.000006030247,0.00008625221,0.000030336383,0.08991984],"study_design_scores_gemma":[0.010645726,0.0012000204,0.9839952,0.00013603775,0.00009213949,0.0000016694177,0.0017569538,0.00020159327,0.000016165362,0.00011809667,0.0017751205,0.00006130449],"about_ca_topic_score_codex":0.010224125,"about_ca_topic_score_gemma":0.16287303,"teacher_disagreement_score":0.15264891,"about_ca_system_score_codex":0.0002120756,"about_ca_system_score_gemma":0.0001533504,"threshold_uncertainty_score":0.99636686},"labels":[],"label_agreement":null},{"id":"W7119277531","doi":"","title":"COMPARISON OF SINGLE, TANDEM, AND SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA AT SASKATCHEWAN CANCER AGENCY: A RETROSPECTIVE POPULATION-BASED STUDY","year":2025,"lang":"en","type":"article","venue":"University Library (University of Saskatchewan)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Autologous stem-cell transplantation; Cancer; Transplantation; Retrospective cohort study; Hematopoietic stem cell transplantation; Clinical trial; Malignancy; Standard of care","score_opus":0.010017340634458194,"score_gpt":0.21828688574856644,"score_spread":0.20826954511410825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7119277531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99797773,0.00004673832,0.000092063536,0.00008764062,0.000022080172,0.0010074821,0.00034797107,0.000044241177,0.00037403152],"genre_scores_gemma":[0.99571747,0.00000571181,0.0008265931,0.000011349204,0.000002562839,2.9492213e-7,0.00024780782,0.000011063182,0.003177181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988175,0.000125512,0.00016788498,0.00038345423,0.00028951198,0.00021613858],"domain_scores_gemma":[0.99926424,0.00011161917,0.00018734451,0.00021259669,0.00009581021,0.00012841096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004347949,0.00018315381,0.0005306334,0.0005026185,0.00017399044,0.000006291126,0.00014189955,0.00011686265,0.00013512713],"category_scores_gemma":[0.000002134005,0.0002038351,0.00007138514,0.0005927918,0.00013216818,0.0004174134,0.000086726766,0.00016188061,0.0000015973046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005357616,0.0017364635,0.967914,0.00029924183,0.00020607524,0.00012404488,0.022648634,0.0000631991,0.00027329777,0.0000014200019,0.000022363238,0.0013536575],"study_design_scores_gemma":[0.013813842,0.0010867629,0.9266015,0.00017274571,0.0002215206,3.0363984e-7,0.056252334,0.0002897639,0.0014076433,0.000004624357,0.000011252562,0.00013767039],"about_ca_topic_score_codex":0.0059955856,"about_ca_topic_score_gemma":0.046513025,"teacher_disagreement_score":0.041312452,"about_ca_system_score_codex":0.00035235728,"about_ca_system_score_gemma":0.00036606521,"threshold_uncertainty_score":0.97088563},"labels":[],"label_agreement":null},{"id":"W7133075194","doi":"","title":"Segregation, Capture and Recovery of Circulating Clonal Plasma Cells in Peripheral Blood of MM patients using Micropillar-integrated Microfluidic Device and its Cinical Applicability","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bone marrow; Microfluidics; Minimal residual disease; Multiple myeloma; Circulating tumor cell; Peripheral blood; Biomarker","score_opus":0.0245210705341026,"score_gpt":0.32959984790649616,"score_spread":0.30507877737239353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133075194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98773545,0.009333886,0.000008865697,0.000027165852,0.00016767727,0.00220803,0.0004361488,0.000010311101,0.00007248021],"genre_scores_gemma":[0.99549794,0.0017474402,0.00068090647,0.00001618057,0.000029337227,0.000050117033,0.0016713893,0.00006860927,0.00023809922],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9957085,0.0005694802,0.0013164997,0.0010062824,0.00081656064,0.00058265997],"domain_scores_gemma":[0.99713904,0.0005561496,0.0008692042,0.00036871264,0.0007466933,0.00032022037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005375616,0.0006009321,0.001351588,0.00035802484,0.00020273188,0.000030317295,0.00015857827,0.0004568427,0.00040083006],"category_scores_gemma":[0.0005808411,0.0005957869,0.00017562698,0.00071130384,0.00019775161,0.00011689807,0.00014995356,0.0009488033,9.880835e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033788003,0.0015137611,0.4468876,0.004051479,0.00062670984,0.00007180574,0.0074440227,0.0000504169,0.5319307,0.0000064267265,0.000011233562,0.0040270677],"study_design_scores_gemma":[0.028304955,0.00251982,0.5461992,0.0034956587,0.0016625634,0.00012422614,0.024429185,0.017589783,0.37440345,0.000030579165,0.0001108572,0.0011297138],"about_ca_topic_score_codex":0.005150618,"about_ca_topic_score_gemma":0.0003972633,"teacher_disagreement_score":0.15752722,"about_ca_system_score_codex":0.00038753715,"about_ca_system_score_gemma":0.0008413426,"threshold_uncertainty_score":0.99964935},"labels":[],"label_agreement":null},{"id":"W7133082987","doi":"","title":"Outcome prediction in newly diagnosed multiple myeloma: a comparison meta-analysis between ISS and R-ISS in 8536 patients","year":2021,"lang":"en","type":"article","venue":"Repositorio Institucional Universidad El Bosque","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Data extraction; Risk stratification; Multiple myeloma; MEDLINE; Clinical trial; Risk assessment; Randomized controlled trial","score_opus":0.053746796753542554,"score_gpt":0.32034979698106425,"score_spread":0.2666030002275217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133082987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964244,0.00046033063,0.00013218146,0.0004140848,0.00014491557,0.00059094775,0.0001641614,0.000040640454,0.0016283393],"genre_scores_gemma":[0.99765295,0.000029163828,0.00079293776,0.000045276083,0.000106392756,0.00003316444,0.00067087536,0.000018405071,0.00065084494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972758,0.00021805371,0.0006867995,0.0006846613,0.00071957277,0.0004150944],"domain_scores_gemma":[0.99846554,0.00036413642,0.00013993485,0.00038493134,0.00027765625,0.00036780268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020974224,0.00029574652,0.0012183429,0.0007731524,0.00015029966,0.00005458016,0.000114301925,0.00021806675,0.0000598302],"category_scores_gemma":[0.00036173133,0.00027305263,0.00044867984,0.0013025341,0.00007078219,0.00031116893,0.00014459263,0.00044214592,0.000015089291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026789933,0.00083681336,0.9851606,0.000053798165,0.010804839,0.0014282082,0.00034179742,0.00040618345,0.00012218894,0.00013590106,0.00008357126,0.00035823687],"study_design_scores_gemma":[0.007575794,0.00016947219,0.9771823,0.00003092332,0.010674081,0.000015667374,0.00022391863,0.0012927174,0.0007173998,0.000012971025,0.0019150658,0.00018968598],"about_ca_topic_score_codex":0.002345043,"about_ca_topic_score_gemma":0.0030309695,"teacher_disagreement_score":0.00797826,"about_ca_system_score_codex":0.0007496131,"about_ca_system_score_gemma":0.0002594885,"threshold_uncertainty_score":0.99997216},"labels":[],"label_agreement":null},{"id":"W7139181973","doi":"","title":"Pomalidomide Use Outcomes in Patients with Relapse/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study","year":2025,"lang":"","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kidney disease; Renal function; Multiple myeloma; Adverse effect; Pomalidomide; Cohort study; Kidney; Cohort","score_opus":0.012767963625870307,"score_gpt":0.2779282741520384,"score_spread":0.2651603105261681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7139181973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037737,0.0004062467,0.0000102549275,0.00015229359,0.00021980329,0.0071887397,0.00065683504,0.00006341475,0.0009250354],"genre_scores_gemma":[0.9735906,0.00043348517,0.00029406493,0.000018725621,0.000023597724,0.000022931148,0.0064721988,0.00006732375,0.019077081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953295,0.00053059607,0.00052597915,0.0013605581,0.0014567182,0.0007966308],"domain_scores_gemma":[0.99565876,0.00068669865,0.0007417181,0.0011526692,0.0005809059,0.0011792309],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027912375,0.0008582898,0.0017753377,0.0007229369,0.00049017044,0.000057394704,0.00037645432,0.00030724378,0.0031095443],"category_scores_gemma":[0.00064059923,0.00089937064,0.0002765286,0.0003916559,0.00016413153,0.00096923375,0.00016197808,0.0005196525,0.000010149382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023135364,0.005190312,0.9602216,0.0010730714,0.0020312404,0.00033348694,0.0022493477,0.00005128524,0.000007853937,0.000009919819,0.000049431033,0.0056471233],"study_design_scores_gemma":[0.041474484,0.0019802728,0.9467041,0.0018573496,0.0019267942,1.0321419e-7,0.003812192,0.0015923579,0.000002641055,7.1898444e-7,0.00003705047,0.0006119239],"about_ca_topic_score_codex":0.6727727,"about_ca_topic_score_gemma":0.79551506,"teacher_disagreement_score":0.12274236,"about_ca_system_score_codex":0.0046702814,"about_ca_system_score_gemma":0.0021679979,"threshold_uncertainty_score":0.9993457},"labels":[],"label_agreement":null},{"id":"W7155880826","doi":"10.5281/zenodo.19822547","title":"Longitudinal single-cell analysis of a myeloma mouse model","year":2021,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Multiple myeloma; Disease; Phenotype; In vitro; Mechanism (biology); Mutation","score_opus":0.06744689566557097,"score_gpt":0.2799390395041374,"score_spread":0.21249214383856643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7155880826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74892443,0.0023598613,0.020341134,0.0011378642,0.000147191,0.0015626678,0.0048856554,0.00065149233,0.21998972],"genre_scores_gemma":[0.9768293,0.0007449532,0.0010941067,0.00006527864,0.00011134092,8.289359e-8,0.0071021,0.0016771726,0.012375674],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9946146,0.0007927435,0.00087638164,0.0011646581,0.001484921,0.0010666716],"domain_scores_gemma":[0.9940267,0.00009618647,0.00034610066,0.0014995486,0.0031386304,0.0008928308],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00083311804,0.00041994033,0.0009049227,0.0013119627,0.0017791794,0.0006763062,0.00096965756,0.0002057447,0.040092804],"category_scores_gemma":[0.0016938379,0.00045120082,0.00052490435,0.0040489603,0.0004682433,0.0003071614,0.0021167044,0.00059805386,0.004050437],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041680117,0.020130463,0.001587898,0.0026732045,0.022297991,0.0021559424,0.007978135,0.01028633,0.6219083,0.0035109853,0.058307935,0.2449948],"study_design_scores_gemma":[0.019127872,0.0053721806,0.018261528,0.0005860915,0.012542349,0.00047189306,0.0041113505,0.4048044,0.23058036,0.00015815986,0.30206135,0.0019224698],"about_ca_topic_score_codex":0.000046593497,"about_ca_topic_score_gemma":0.000003328255,"teacher_disagreement_score":0.39451808,"about_ca_system_score_codex":0.00057874713,"about_ca_system_score_gemma":0.000061060186,"threshold_uncertainty_score":0.99979395},"labels":[],"label_agreement":null},{"id":"W7156358482","doi":"10.5281/zenodo.19822548","title":"Longitudinal single-cell analysis of a myeloma mouse model","year":2021,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Multiple myeloma; Disease; Phenotype; In vitro; Mechanism (biology); Mutation","score_opus":0.06744689566557097,"score_gpt":0.2799390395041374,"score_spread":0.21249214383856643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7156358482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74892443,0.0023598613,0.020341134,0.0011378642,0.000147191,0.0015626678,0.0048856554,0.00065149233,0.21998972],"genre_scores_gemma":[0.9768293,0.0007449532,0.0010941067,0.00006527864,0.00011134092,8.289359e-8,0.0071021,0.0016771726,0.012375674],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9946146,0.0007927435,0.00087638164,0.0011646581,0.001484921,0.0010666716],"domain_scores_gemma":[0.9940267,0.00009618647,0.00034610066,0.0014995486,0.0031386304,0.0008928308],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00083311804,0.00041994033,0.0009049227,0.0013119627,0.0017791794,0.0006763062,0.00096965756,0.0002057447,0.040092804],"category_scores_gemma":[0.0016938379,0.00045120082,0.00052490435,0.0040489603,0.0004682433,0.0003071614,0.0021167044,0.00059805386,0.004050437],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041680117,0.020130463,0.001587898,0.0026732045,0.022297991,0.0021559424,0.007978135,0.01028633,0.6219083,0.0035109853,0.058307935,0.2449948],"study_design_scores_gemma":[0.019127872,0.0053721806,0.018261528,0.0005860915,0.012542349,0.00047189306,0.0041113505,0.4048044,0.23058036,0.00015815986,0.30206135,0.0019224698],"about_ca_topic_score_codex":0.000046593497,"about_ca_topic_score_gemma":0.000003328255,"teacher_disagreement_score":0.39451808,"about_ca_system_score_codex":0.00057874713,"about_ca_system_score_gemma":0.000061060186,"threshold_uncertainty_score":0.99979395},"labels":[],"label_agreement":null},{"id":"W802914929","doi":"10.1182/blood.v124.21.5704.5704","title":"A Systematic Literature Review on the Epidemiological Burden in Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Epidemiology; MEDLINE; Incidence (geometry); Multiple myeloma; Systematic review; Family medicine; Demography; Internal medicine","score_opus":0.041439539561852465,"score_gpt":0.3162305012531897,"score_spread":0.2747909616913372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W802914929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8183595,0.14499393,0.00002689802,0.020687327,0.00007856225,0.00695036,0.0000200822,0.0001337976,0.008749573],"genre_scores_gemma":[0.98926896,0.007184679,0.00024305862,0.002285151,0.00013684176,0.00042883254,0.000028637403,0.000012918994,0.0004109463],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99810356,0.00072592,0.00035111816,0.0002458564,0.00027429004,0.00029922897],"domain_scores_gemma":[0.997472,0.0017427002,0.00007265249,0.0005236351,0.000051613275,0.00013741519],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012598571,0.00016034754,0.0006042896,0.00006116292,0.000053838037,0.000016001797,0.00014084208,0.00008370958,0.00006163656],"category_scores_gemma":[0.010669913,0.00006971707,0.00013771273,0.00024774254,0.000038384707,0.000021786625,0.00003905231,0.00031067024,0.00028046896],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011255771,0.008042857,0.32725513,0.6101536,0.0023596953,0.005639193,0.0014370593,0.000008929752,0.0034547348,0.011844224,0.012660463,0.016018517],"study_design_scores_gemma":[0.016605565,0.0024267633,0.26247102,0.7090012,0.0007205995,0.0009346183,0.00008993569,0.0030371204,0.0009380534,0.00065865915,0.0026450425,0.00047142798],"about_ca_topic_score_codex":0.000011756066,"about_ca_topic_score_gemma":0.000006983551,"teacher_disagreement_score":0.17090946,"about_ca_system_score_codex":0.000025000363,"about_ca_system_score_gemma":0.000018182835,"threshold_uncertainty_score":0.9976636},"labels":[],"label_agreement":null},{"id":"W8239046","doi":"10.1182/blood.v95.3.1056.003k26_1056_1065","title":"Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice","year":2000,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"","keywords":"Bone marrow; Progenitor cell; Multiple myeloma; Immunology; Medicine; Homing (biology); Stem cell; Pathology; Biology; Cell biology","score_opus":0.01016805378354015,"score_gpt":0.24858711608381864,"score_spread":0.23841906230027848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W8239046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662143,0.0010102022,3.6976157e-8,0.000102563914,0.0000058340916,0.001820726,0.00013090903,0.000008099277,0.0003001886],"genre_scores_gemma":[0.999093,0.00009671695,0.00039733568,0.000030411908,0.000029704928,0.00016913273,0.00012079792,0.000019281566,0.000043646753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785566,0.00023413828,0.00045852107,0.00028621955,0.00083923654,0.0003262303],"domain_scores_gemma":[0.9989532,0.00017508953,0.0002459353,0.00039912728,0.00010727698,0.00011936213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002584055,0.00021585835,0.00043874604,0.00016930947,0.000057824498,0.000010033816,0.00021280866,0.000051884697,0.00006436585],"category_scores_gemma":[0.000069510344,0.00010787898,0.000071294984,0.00039125807,0.00023857532,0.000058842328,0.000046339155,0.00014878635,0.0000013026357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003970411,0.01705586,0.9693484,0.00057137053,0.00047056618,0.0008430983,0.002413495,4.5172828e-7,0.0021230336,0.000010781169,0.000013164327,0.0031793735],"study_design_scores_gemma":[0.019888671,0.0028920604,0.9649182,0.0004139152,0.000549971,0.000045164143,0.00025311598,0.0000029809069,0.010901411,0.000012135754,0.000019897225,0.00010246455],"about_ca_topic_score_codex":0.00013920045,"about_ca_topic_score_gemma":0.00015098216,"teacher_disagreement_score":0.015918259,"about_ca_system_score_codex":0.000025476616,"about_ca_system_score_gemma":0.00021152622,"threshold_uncertainty_score":0.4399177},"labels":[],"label_agreement":null},{"id":"W84591217","doi":"10.1182/blood.v122.21.2.2","title":"Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Thalidomide; Internal medicine; Melphalan; Clinical endpoint; Adverse effect; Surgery; Dexamethasone; Phases of clinical research; Oncology; Gastroenterology; Randomized controlled trial; Clinical trial","score_opus":0.04326538170802355,"score_gpt":0.30895721281488925,"score_spread":0.2656918311068657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W84591217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187547,0.00010121459,0.00013653039,0.00023882653,0.00025688024,0.005795672,0.00143256,0.000025420155,0.00013744863],"genre_scores_gemma":[0.9967542,0.000090516034,0.0015166228,0.00003579596,0.00015304209,0.0005542404,0.00079627155,0.00004141755,0.000057865822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705666,0.00023188742,0.0011180649,0.00041575948,0.0007473865,0.00043025086],"domain_scores_gemma":[0.9968377,0.0015499347,0.00052046304,0.00044598692,0.00043267946,0.00021325203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051783706,0.0002884059,0.00068461464,0.00024371935,0.00009653287,0.000030326051,0.00020523932,0.0001753016,0.000036506382],"category_scores_gemma":[0.00089879,0.00021167986,0.00022763842,0.00037145786,0.0001586065,0.00028591958,0.000041446132,0.00019987364,0.000009660803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82942325,0.007699247,0.12538041,0.0013935044,0.00055627147,0.000053999254,0.0035535211,0.00012235086,0.01875228,0.000013271895,0.00087088044,0.01218101],"study_design_scores_gemma":[0.58954185,0.005327838,0.037707247,0.00030670638,0.0003188695,0.0000015237913,0.00016141872,0.00037821426,0.36599678,0.00003146922,0.00008189421,0.00014617573],"about_ca_topic_score_codex":0.0018580665,"about_ca_topic_score_gemma":0.0014196604,"teacher_disagreement_score":0.3472445,"about_ca_system_score_codex":0.0001298974,"about_ca_system_score_gemma":0.0003270338,"threshold_uncertainty_score":0.8632054},"labels":[],"label_agreement":null},{"id":"W950248854","doi":"10.1182/blood.v122.21.5541.5541","title":"Pre-Transplant Remission Status and Peripheral Blood Stem Cell Graft Contribute To Long-Term Outcome After Myeloablative Sibling-Donor Allogeneic Transplant For Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Proportional hazards model; Graft-versus-host disease; Single Center; Oncology; Retrospective cohort study; Cohort; Cumulative incidence; Surgery","score_opus":0.019077501586503575,"score_gpt":0.2809743732923201,"score_spread":0.26189687170581655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W950248854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909845,0.0016264631,0.0009622134,0.00031202132,0.00008263339,0.0047856527,0.0010880011,0.00011095085,0.000047590118],"genre_scores_gemma":[0.9938611,0.000320758,0.0021618952,0.00021496863,0.00013568296,0.0013074345,0.00041831715,0.000081501545,0.0014983546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681485,0.000096287426,0.0006062271,0.0007928859,0.00048288688,0.0012068538],"domain_scores_gemma":[0.9976484,0.000284809,0.00010700693,0.00044412728,0.00024290908,0.0012727071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018359747,0.00050844037,0.0007288926,0.00021676102,0.00021150698,0.00010578947,0.00015182159,0.00021911954,0.00019992099],"category_scores_gemma":[0.00004168497,0.0003814571,0.00023044385,0.00016773271,0.00008001572,0.00018737605,0.000055213073,0.0002545264,0.000037411213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002821647,0.0013894561,0.9327618,0.00080264243,0.00057870976,0.00048802415,0.0010992344,0.0000037895215,0.05726132,0.000001737167,0.000017978426,0.002773677],"study_design_scores_gemma":[0.026188187,0.001946676,0.87870455,0.0003178485,0.0010726172,0.000101712874,0.00005038996,0.0001931088,0.0909139,0.000007084907,0.00009781068,0.00040608714],"about_ca_topic_score_codex":0.00020504424,"about_ca_topic_score_gemma":0.00021943919,"teacher_disagreement_score":0.054057207,"about_ca_system_score_codex":0.00007114208,"about_ca_system_score_gemma":0.00012246514,"threshold_uncertainty_score":0.99986374},"labels":[],"label_agreement":null}]}